<SEC-DOCUMENT>0000318154-23-000017.txt : 20230209
<SEC-HEADER>0000318154-23-000017.hdr.sgml : 20230209
<ACCEPTANCE-DATETIME>20230209162631
ACCESSION NUMBER:		0000318154-23-000017
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		150
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230209
DATE AS OF CHANGE:		20230209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		23606604

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>amgn-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:4e826620-fc5c-4c14-9c2e-3ba20b6aa99d,g:1e6ee203-6cba-438e-aedd-ef42aa695ae1,d:f8055099d1994bb494875d41c341f00d--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20221231" xmlns:currency="http://xbrl.sec.gov/currency/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amgn-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF80L2ZyYWc6MmQxZWFiNzJiY2NlNDVhNDgwZDRmMjkxYWE1NGVhY2QvdGFibGU6ZjRlYzhkMjI2OTQzNGU3ZGI5OGU5MmRkOWI2YmUzMjQvdGFibGVyYW5nZTpmNGVjOGQyMjY5NDM0ZTdkYjk4ZTkyZGQ5YjZiZTMyNF8wLTEtMS0xLTE4ODk3NA_bece68e4-0a14-4c98-b3e5-285dd84e21be">0000318154</ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF80L2ZyYWc6MmQxZWFiNzJiY2NlNDVhNDgwZDRmMjkxYWE1NGVhY2QvdGFibGU6ZjRlYzhkMjI2OTQzNGU3ZGI5OGU5MmRkOWI2YmUzMjQvdGFibGVyYW5nZTpmNGVjOGQyMjY5NDM0ZTdkYjk4ZTkyZGQ5YjZiZTMyNF8xLTEtMS0xLTE4ODk3NA_710c3551-0f1c-4d48-83d0-050366542de6">false</ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF80L2ZyYWc6MmQxZWFiNzJiY2NlNDVhNDgwZDRmMjkxYWE1NGVhY2QvdGFibGU6ZjRlYzhkMjI2OTQzNGU3ZGI5OGU5MmRkOWI2YmUzMjQvdGFibGVyYW5nZTpmNGVjOGQyMjY5NDM0ZTdkYjk4ZTkyZGQ5YjZiZTMyNF8yLTEtMS0xLTE4ODk3NA_34e3061b-2298-47dd-9668-a263063e36fb">2022</ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF80L2ZyYWc6MmQxZWFiNzJiY2NlNDVhNDgwZDRmMjkxYWE1NGVhY2QvdGFibGU6ZjRlYzhkMjI2OTQzNGU3ZGI5OGU5MmRkOWI2YmUzMjQvdGFibGVyYW5nZTpmNGVjOGQyMjY5NDM0ZTdkYjk4ZTkyZGQ5YjZiZTMyNF8zLTEtMS0xLTE4ODk3NA_7703955a-6a9c-4e47-a50c-d528e180f1a8">FY</ix:nonNumeric><ix:nonNumeric contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_359201fb-5c99-405a-ab38-b09b1a0810df">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_e337db26-bca6-43a8-9a70-6927970d6b3a">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_8eb856b2-2130-4703-a4b4-acc8ce46190d">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_cfef6f7b-b5d4-400a-8a9d-e47d21f5486b">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_8acdce6f-01bc-4f81-be80-17993b14c4ca">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_f528949b-9261-49f0-9348-a8f3a32624b2">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amgn-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia583ee59c26e4591a6c760c2f5aa05d2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i580757a974aa4b85b143f5523fc7aa91_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa76a93f17df45cd9d66d36fd211676b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3dd260e9045c46d1bd6dbbdbd6942bb1_I20230206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2f333186d8da4378bcf0c5a3e6baf0f9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b25c75934844f82a32f7a76cdbe5042_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8db07843e5b426fbe44e0590a500e74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id25b0832750a4204ac083f11c97f8288_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2457cd740816456db1f50da03ba631dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50cbcfb77ce746588d1956f2435637ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i129c92e214904c7e8aec016ec2d5e387_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2798874e9ac48be975005deb320dde9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0567102b4dbd4cabaf51e541f2a41652_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2edf981fef6d4fa4973e8992576dab4c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5f2c87a3f74cd797cc6268b82470bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb02e3f6128454a820a56e2cfbb6e3f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice20f9c10bef48889e1c07a014676f7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic10864dfaff048eca24b894294bae77d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeb157cdc95045539f3bb40881b31817_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56dda630a2e4ae3bbca72a1ff1cf2ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief1a47791c7f42599aacea53954586bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5998f096c32498584f7ddcb1b102049_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a339f1adc784aaa9ffccfd08a332107_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59da9a82507b4a00bb722da4afa5b3c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2470640538814b629fcb492196758669_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f7304b1f329421f82c9e6191840585b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e70878840254d839c51604f86fab42a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a40b865ed594f40bd48caac4049fc3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f0e0839efe462786cfb45f06b6105b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b88900199d7479494b9b92a28082482_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46710aa460c94e759e4be58d5b0aa1cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9214e72c6081443dbdd4956e36759200_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5cc146400d04167a6eb49d6a45c2634_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0604e8ad2a44749afd263c7e0c52319_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib964505bb2264c0e858b211061796b49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee236cd90d724c118c6bd2bd1de4571e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0d3563966d49f2afdae70577b5770d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if935497be7004087ab59197b95cf4c00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6677b10603d44f784a36a5a29714649_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec4b231199d0442bb9d2420b71dfb984_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i349ee45aa1e94ce9adf98a1fa8b76e0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>amgn:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i74c70cd97a504fa799571d2da1e07298_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib368433c7847450cbea77bf019f238ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5514fe5c6f934d69accc89f4f6207683_I20221212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i779f44ca9ddf42f9bd2fc86981e1cdd2_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>amgn:product</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>amgn:program</xbrli:measure></xbrli:unit><xbrli:context id="ic722736e5ec247d6afb3eb14a1913c36_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18e6e75e0234bfb8fa9c069b0ac7278_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="traunche"><xbrli:measure>amgn:traunche</xbrli:measure></xbrli:unit><xbrli:context id="i547c2ec2000946a09fe9312e8ebfb63a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amgn:BridgeCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ad27c707bf4fc9a91323e63aadb826_D20221222-20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1304d3c33395494bb59cbeb2cb292045_I20221020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-20</xbrli:startDate><xbrli:endDate>2022-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df31b4fae07412cbb1789e8d483f2f0_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife9b8122096240a5b48fd15f27ecd4ba_I20221020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd98af0751824e778fbc9d7d6daabf74_D20221020-20221020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-20</xbrli:startDate><xbrli:endDate>2022-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ad51334f6c74fc69c9126bdca69dd80_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i483da69e647945579f570280de6d2535_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c3e817eb2db4040b29557e7f0a8bdae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878b1937a0c64c239da6ad0a2e1748ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ea65e5beec49d492a8c189bb7ff681_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a560be5e64148d1b01ab70221c57257_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amgn:MoleculeTypeAxis">amgn:AMG340Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b93dbb92ca4fad905e8f7074369960_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c94a0244a24346bbce7f236220492d_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id61a508e81d74e23babeb5ae04b7c428_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2622610117f541b3981af6c597b45012_D20210416-20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f833d40beb6488f852b2cd047fd2af3_I20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a449b4d91a4aa9837f80b68d94b3de_D20221102-20221102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa290da793e84fbbbc403ed0500e088d_I20221102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a81370a9864611897507a5c90c9308_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherGeneralExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54d95ce0934d41258b8bb4e3c9ae99ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fcbf93e9fd941c2b5eb2795960a999c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d8239300c734a85ac79f2e26ba5280f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf51567a953d41b99c4b4d59745e4ee4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ef981e3c2740e0b2d606ba990e403a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08fe0ca98dba40f1916b2858ece00d3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d9b8bbe1fe042b38d3911eaa570829e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia96d969e20ba48c5865d66cf127544fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if847c1f2b53649958a0e412c568c260c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabbccaadaa0e479bb555d47033b24d0d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d0ac761b5e4c64a58d335767cf2473_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9b224ccf76a440c8fff126d491a4b0b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81533ef907a44709b3be7b02daabe41e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dfacc540ca4410bad949df3bf9e3989_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70dda4219ab244b7b55afbcb42b4096d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c3af95c457646d89f7ccabdfe96ed78_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e858062804243e7a95db1099336e60c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea6afbe5b0948f38ad7891711ec6fdd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eea70a9f89a460c81ea5589813c4763_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1d0ac70f39f475ba99cef136b4e6db2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad2d33f98f144869b7feb640d3176c4e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e4a13b30ff4c109a876c1c9aaf2a6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1efdd0c80b64aa48ebe629be932cb59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b509ea03164c7aa49578a912572c8f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i931aa36bec5b4419a4286d8ee93da365_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d05f99fee60403f9ca2a1f93a62cf48_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e026f4c1ba44496a8bb17b973a51cba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8037f0f06384716a6e33c023dafa910_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ed14a4244f540049b8d29da49b4c3c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1effa3ff3a54202849eece7ac796687_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14decb65256d4431b54b68596dcf53cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55dd93e8acf407da56339a95d05c26d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90e5f5a81c64fd8a2d5eca216f1ac96_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d2433db185474e8f07acef38f88309_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife44f12d898a40c2b26d2899e1f87c7b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72c4cccf0ed4d4e98361bdf264e1ab8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4672ebffc2642038eb7bc351335c563_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8989af1d9ee941ccbf1d38df278cc651_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ecec34e1ba548dfae54d6428a2be0ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72818ade50a84197b7066c09d32fe4b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e998945c35c44b78153987bfb0988e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife184a05fefe4459858a75cd03edbb4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa50e2701f6349c2976473694523273c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c662b22fd6d4f538341070c6658378a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90e2b230dc243709b1d0eea15c4120d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i130d478f5c344266ad4bd4b7ab54798f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d627f909504f5bb6aec2303812401b_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b642d2cd344106b2a9b43195affb7d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e495b2d1a824af7811048f9f9bc9a17_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic905e297ec6e4217a0a0992727261a16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4824dabd1ef04421b159a085c221b393_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac4f0dce8ef748aeae685b9a10378f08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25bdbcb88c32403d8e379e2f8730b5ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie12cb06ca50647f08c8d0f02d992ddb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab84e501cf364e47a226c6765f0a1320_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f569aa2b2b469081ca5099662ae431_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48d68f0d45e34ce3afe76b0c1819f0f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1dd3fc9f8784e4c8374d245b0c7fb71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id28a9a6d2501418081e48da0d0dc78ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia79c2d0bccb749ce9727366fb1126ceb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i257e9c51364e4d82b08262ef2ac191a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic120030329c6425dad6cd6f3e198f509_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf507146d984867ac54d44e61ad8dc6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c25cc3cd16f40dc875390afe7993316_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04869452639e49c4889ecd6ea51662ad_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d869ac7f27a4395b24b5b634039d37e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab122339be0b431f90bca45e37234133_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260c1936cd204104b9c849ec4c5f1086_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib16b3709a01e464fbb530033aa9546a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39749dabb5124d4da5d2ebbe0c7f9bab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1734816467749ce9071cf1a91e0ea7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1885db8f4e54fc68d9a604c36caefc1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e97be903941430ba5c15572221083c5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862040fed4914d45b07c1986dde77ca1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafe19cf36dad4281bb45cf16884ba782_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic31ee96f0c344214b71935816f6d82bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if976b4b2b7594c2d9f40e64ea67f3e83_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2089ffa1cd467083ed4a1db7f715e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b4597ba3cb4f84aa35b4d25bfb8261_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb3f737b3494a4cbc9bc33b832a55ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bdc8fa194f44dfd99072ad9bcca3737_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f5bd2a8d54048c38e2e840cbd09500d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ab76d96eac4989a331ad1292e4f071_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2876569878e64fa28cfa8f94277c4955_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6814d750caec49fc9617453d49cd87de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f8b506414e4400f94126bb294f8de27_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab191a59b38e4a6aa145b09f8bd9d253_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca7535ce0ea49c7b96444b2409cf8d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93535a2cb1d74743ba6ebf13264af448_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1164b97eced64b058786a55ff9fb37e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02da5611affd4bb39c32bd0b8b1af6b4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93f46843ff741beafe6a37517e53dd2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie830411e990944a58b257c504ac9bd03_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e7e76085a9842b38a2bd7b388f5d89a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ea6966e44b490499ae329249bdde9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08293a2d22a847e882c434fc87376ede_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1d34a61daa04c4abac9d3a4af47df32_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d2558e049e14f7fad9ba2b4954fbece_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47dc3c579513437d88fef139e4772cdb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dddf5cfe0e94fa19b1688a79d7445ae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib65a6afa486142c9a0bed18deeea04c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c5766aba06f4d61bfab9fcffab156e5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic65873c515ce4f70aec863e02db39e0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e69273cff94b48bc90019f3c462804_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i419f6f8b71f643678f664afe333ad342_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9009ee1e369c449292e70d4d067b1184_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cee17c29ea542229fc4893cb3183b4d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4df96a522844448bf9e3616baca9df9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37ac076bb994281907bc729c8f6d935_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d14a8530ad947f7b3fa2aefa3363fda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6053e1fe314de1b2bb31df2e6ce976_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4871c35ef74d7e8c872893b4cdaebc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf92b1997d60491abc1e2f5b65cf03a4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63498908586e409e90d8f39594556f93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie377953c909f44678464f43ddbf57467_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c5ae9adf5244a858af6f315eef250b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64d8fc93c0f84588aacc70e98160df80_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>amgn:customer</xbrli:measure></xbrli:unit><xbrli:context id="ic492dbf72e134124ace0523e8918ae54_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3be857e2d3446f6a9576880dc95fdbf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ced2b08bd74e91807733d80569e8f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce35b441d394680be0e8bc1af6382e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04ebce1b8e1b4437b11925ff3b848025_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660bbb9450f640a2b53f5e591fae8ed1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if75d92c2783d458a8be680eb71b21a63_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf450c77c4449a8b3ecf57bc98e144a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1681e5dde84590a71f0e996bf9146f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i821d0160b8fd46f592bae9bed6edeeca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d0dbb92b9046b892ae095e67db26c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac17b1564825474f83ed71156fbe3405_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07973e812ee241aea2269d4041a67153_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i219ff676680c41029ce9c7eaf92b5b3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb195f7ff9c4f059c27b617ec488e62_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeed4f08e59e4fb882fab3526d452c25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2088886061214180b8eaf2c7c870e341_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5361cc7c39a4e2aba0e4628230f4a9e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c95759e9f834fff8e2ab6b9325f2188_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154b8bdaf9ab475f99a1f2846362c79c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de81be8345e48fb922b906166ab900a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb430bb605c14773b903da59d06a7e70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8471d8b9c83641319a4f6ddfcd0f18c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4e89011fbe4e4cbcf5dd5272b78ecc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a84fb02f834393b706d526a6e58884_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc64ba5f13184705bbcea61dca732af0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb268048ef47498c93e842c4884d3b1a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:ExpirationInTaxYearsBetween2023And2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c663e71979d4887b26c8be64eb736f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b423717f36c40579ed83c7a713b6b0c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3470fa30c75149af83b41d392e448110_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2022And2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13c5612dc4a5450684e24434f6a3ec86_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofnotices"><xbrli:measure>amgn:numberOfNotices</xbrli:measure></xbrli:unit><xbrli:context id="ic981a166a2b44b269c7a5073481bc3dc_I20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94eb03241527483ebaf961e48ef6e18d_I20221219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>amgn:Case</xbrli:measure></xbrli:unit><xbrli:context id="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ad848ccc9e43da99f1f90d2e7be305_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b14ed1cf56b40588d947c7c195dba31_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397d9bb426e14efc97584ac20babda5c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6ac0af9e05484e9ff74b916399b3b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61880ef9cc974d208e701a854ba365f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b5fe9d56b04cc0b750c143fe63a442_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id68f71c0e79f414eb9a0f7738f203cb6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69081709322243d7bbce5ac32eca556d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d993f3e9e94186b4be512af2ce0c7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67856dd9461b467aa245cba68be2243c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e07e3056c344299b9420e74a38ebf5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24211ce70c914e6bbc5c138c04403948_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e2a1eff2f0448ba9a98ef6babf5bf8a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i550d1116353a45e988ecb42fddd2ea71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if22b1ca6b4224e409cb1dcbe7350db6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0717c9df57574deba2c7ff65d7c5e0b5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief89781cb0e44c878c87fc5562d3ca89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ecf58c2e31f47edb3c517d8ed16b4ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3587bfdb4d8c43eca1da9c2f79b27ab9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356368409a2d4829afb562f99d59b84a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:UCBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2325b63848cb4d779d17a0fb7049c3ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:UCBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceb527e7ec734f6e818dc3d2674e17fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:UCBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i077a1aab04d044379338908da753b2fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad6cab3b37664965858bb4a82cbba6fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if044214b0e1f473786d143875c57f645_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e19f3c8340e4982bd712b7b9ac5d3e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d8484c53c2490ab0ee83876aa635bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2285c8c0ccac4adbb106cc9bee4bbb49_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:KyowaKirinCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i612eb99920494bc69ea0f16bc1bccb20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:KyowaKirinCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i824e9eea42274a06994918fdb9b1899f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba24b9313e764100a95332b21228b55d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb5ac9be58f43fbb615c494dcccf380_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i213219e02daf455db4856867bb8edfc1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf926a8c4ff481397c62e643795c0d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea6cee4c27ca4399a8a02d26694846a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95cead4d37bb4601864dc9667b4457bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i736ffca3dc1842b084f709c4fe9809b1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8c6fe835b2741e1b409f5f32f417ec2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e65698c0cb74a14bfeefadc59b77d5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa1b51ec520940e1b313db6b89b5a604_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bb10a68da424589a4aa8d60cbb4b509_I20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6db31ce9c8264445a32e5e5e66606b87_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ba36de5fe841cbac0c77bb92159e4e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i742aa0979b534c78a1fbaaeec95b8732_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d78be49a55146f8aea0014dec6caca1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f9fd669564646ed90c1f923fcf22115_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd010ea395424e80984bb752c13cc1f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4568cf82cca34f0fa0f23589a150184f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i547718310bf54e6390c23b1af397545a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5225514442b04c37a257024814d81c9f_D20210930-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba147b39322644f2a1a03599c2a39483_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48de6ba3d9f0465e9462933890029a6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01ad554978334ac88cec9913e0cc5884_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia353ede4e8b345c0b2974e1070e1fe2e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89fb6287a84346aabe16f3d5d6175fe4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e93272860d242648586e251f19acc41_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0661190d8893467dbcd83a57c4222013_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0012e716a1434d35ac79af91c9e382bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c4b1eddbef0462d9ae3e1a3e2db2e8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910730fc1f734dcb85a4bd843a18a53a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68fa55908a0746a48abeb3eeff056228_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie659e94abdcd4ea3973f9174b5bd64ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf57870a9f4462796cf71eb1204b562_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc1644aa9a14b298eb0dda7bc0c7d85_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7adefe057e4125a56fb1a162b59975_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e514d61eb942da9c90cf58cce3e55c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b15e7cf27494cc1bd340423025d53ed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6ca69fcdd8a42a6b7a9ac5979fa620c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b79fbf871a84da7a223e2f58e7878f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:FixedEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i604a564a01bb466c93664f563428196a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibea9550cddf5409f89486fce84d29e92_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc07e2aaa249436e81ba3ffc71d13fb1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b7a507438942a2aaf4c1748fe959cd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff279f49fa7b4713b3a0452ae164a793_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a78eea27ce4a75b4576bdbeb318deb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16e4fdfd9b274a029d3f820b2f8ec447_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b95da36271405f854a5fa63ee0cc73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754ee2be39904612a8009537c4174025_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3acd696e90a462fa8d84de0529809d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07936c549f844514b26e4db0ad2a21fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e5aca0dc80d4c96b4e71d7909172c62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3d3bede71c84c74a83e0be4081f5b18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e0adc328161459b89b9bc11ba4f1e97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i417d0ad23573423c9d2dd34c69b3960f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b45a76886284dc78290674a5dee3ee5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed7681dee014e09849b2353f1235d03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided57f427b2f48c68511bb6a663847ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i509e8b79cd3447cdbd36db889a772260_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib88e57fb4e5e4aea802f1aeacd840bee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3d84b8dde9b4ef58d9a8a439a7b1fed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:AbandonedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib87a5903e27546d7be1b99e84a2bd998_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i63458e59bdcd46bcbc8cde633cc0a217_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cbb8923ef5d4b82912c6157f84c6bef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i114486aa96344ee5b788b817b4b17d96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a39813c072d4e5eb904fe1d28cd03c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1b495696b94d78b5dbd6696d16bd3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dae08b71e7d4ab88b6e9e253336b859_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9444cb9457a24d94834f8ec64291471e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i914ec06154d64420b43f2721a1ae01b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4d0b0eb1fb4567ad07ac7b398eda3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6e2d495694d4d3cb2e097b25c5a10e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ice6da97a847948f08a2ba11d9378169d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99921d01b0e541bf8d50ea58272c554b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b3e11f5be94ce49f2f3b9b0ecde667_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d9211ecea36437580bc7b0a70919e0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="ic3f7dc76afa046759c07651d4147c51a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5597930bfb1b45bc98481de8f6393843_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab97f27b4cdb45eea26aa79814ee24f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i315cb82b31f04ff097bb4573859346f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996fa0fbb28a4ae5a66025a540485a05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d6933a21774133aab412e2e354668c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A165NotesDue20281652028NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42913198da614e1b811abab5b612e355_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A165NotesDue20281652028NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2abdf31bab164b7c95baa1ed9ef98248_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20293002029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A405NotesDue20294052029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i385a16395bf64c2bb403ca851a184d2a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0953d601cec9484fbc9df96f00426496_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf7b55ef9cb1473085781b63a83bbdac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51217f4e8bed4990907c44f9d502ade2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11702be5618f4b6b84417ab7311bb910_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i343cbda319a14a27951c64ddae810439_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4de45cdb4364327a92140dc1f1c7cfb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i240a1929b4d74306bb09ea03fed64c41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21348edb6cd5466a9ef24edd6a2d0938_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A335NotesDue20323352032NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51940b5cb1b241febc825ae180ec3de7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A420NotesDue20334202033NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5f965633bd497bae6b284f87fd754a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i197c2b86499f4c749103e68bdb36f3f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aff41f7e3e648c9be7ca6b79abca8e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f2e4ca4f8004d6c9bfebd3720cee531_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c17dea73c8477a803ae09e22dccbbc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia00b4eabc3a7467ea3ebd7138b1b2a74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23363383d2174b2d8ab38bf2003a6ce8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b887f6d478f455aa05ed3a9d50ab8b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a2c9ab1d0d74042b5625c4d3863fc9a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c2234b75d747f78a8f666e6a4bd7a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b1952961fcf4393b06b95f66a0599ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d652ba10ed148fcb905cf1d5cc7e9a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7ae3396aeb042e386de28c02ab1deee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0332f21f1314de4ae95621b6ac2c956_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799db871194f4747ab9f6118c675a2f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2da62baf08ef4c5b91a5152a82a01c53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ceee26f1075435e9fdfdd7a75a72ab5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e818249c4f49d79e8872325e9ce099_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieadcf920bf8f4c5f9aa97d54a77a11ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie22ac487559948448b70189d26074a44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c399705808348afac4fb0a614c63170_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbe3e6b61a09400e97634eebf130e74a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9e2fac888b644c6bcecbe5803617340_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i459df9e4545545c5acca6667f316af22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61dde3927cd046c3ae459081902d8719_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a53c4efbbc3497fb791219ac49e571d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91a9673685984fa4a4d87c723a4b99b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fbb4c180e604823bf8fe6193c622eaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ea14090c5d46a68fa6c66a684d6252_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec66496c6a840d998963fb080719768_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25202f83ea744eccb99587dd65d7f169_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A420NotesDue20524202052NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4875NotesDue205348752053NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0c22ebe78346a996c2daeeeab201b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f1ab566422f43e9ae7b52770249ed7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2a31746bf0d474c8f6cacbba8fbb650_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A440NotesDue20624402062NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f3097471304363bf528a0d267e397a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A440NotesDue20624402062NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefc3b8cff79b4b5a9d37b0a3cfa13a59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dcd01e084f04f7da2597aedeba26b9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ae65b7af0f742268bed15aafd3a152c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015b4b460a304d11a76423022adf7fb4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i850e2cf58a7341ba9d67a7b5bb83feaa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ca5e3f8d5e4e19a9336ace84b8e4de_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdf49fbaa3564bfeb07fa6eab5ff9453_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f60bbed45a476b84f32d5cd638fa27_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id071e59acfce43278b6718d99d9ada1d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02f6daf07f04020881c0917e7205beb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc8d9408f58940f5aea794a5984b2b6d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53bd2b17ef4e40b9ab31b350fb9bcca0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb1ef0f568a470293b1b4b19ff1eb25_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbc703b5ac5464b934f026814c76b10_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A405NotesDue20294052029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63aa0c69ac4d42fea8344496f99d3fb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A440NotesDue20624402062NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0f3163a47a477abfa471e4f31bc4ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i994c0f07cba345b594aa2dcc8f01ae2a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae7d08a8c95844f89b4bc95827153edc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ebe21c56f7b49eab0d1f2b569ab2d69_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dedfbd2aadc42a4b92b844cb973cf5c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4875NotesDue205348752053NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d2edc811fbf442281992e3f83c386d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97e03c380118450bb96b17ea6c0975ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20293002029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5abe004e1f64a0cb9c9056890639151_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cbd26680ac94508aca54119b9a2b4f1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe3f9f94b8740cb8f007f2610521598_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa82e45553c4fe38c964335a7502e78_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fd31a2352f045398f3a8eb8645c3d22_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife0fd2905ff54a6ea2da3ac299266202_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66b14e567be349d2b9d238dd8fa3d12d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i093e46e46f254549afa8c5b85e22d6ec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadf162d5956f4e0c8eeaf73fec25a6ee_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64bd322d7bdc4336bdcaa7f9c771196d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A335NotesDue20323352032NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf447a9235a4172905a462133a6ffff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A200NotesDue20322002032NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90390b22ae74a819b9f25f7e52c8cd4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A280NotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6372321cb54979aa35bc0ab3e56ae0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A165NotesDue20281652028NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic385067cc0a541f7acc94e65e1d25159_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35ba09ad3416417584b285ae9e364e4d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A420NotesDue20334202033NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304fcc0c170d49fab4f536fb9d368d1e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i198527cafdc44eeca16fc7290ab43d35_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide32c761d0db4322ac4858a8059cfa8b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A420NotesDue20524202052NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie30a691e9b49416cb63804f9bee95ad0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie930e646dcf5443abd63824803a610e3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie48acc0ed4094a3d91842dd5e715d92e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id185478a58284d89b9439c8843eb6f89_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc43e58b90c442fa9e2c3b2c14137433_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9924ee115de34d74a2b634b1cb90e492_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A200NotesDue20322002032NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if564b13b89634481901bd164eb63c59f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A280NotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e59b900a4ba40609f70a3f1ebf4fb65_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ecab054ef954f2bbe765d19ba69cf36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec7e0e38fad401c881d41f4c40df8d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie507238fe5a046649c456d858ed9e23a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8bc2063ee0d4b268efa59bb040e751e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56bdffad54214969af59aa30ffe7fdc8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53fed3d90cd3422f8495f0171cae0423_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a71b99759f43bb8745b086512815bf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ffa41fba39e4ab794adaacf3e2fa171_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaca4dae277dc4dd99ebb82e55a868dd1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1347de6bb8044d39a48f67625521dccc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da1b9cbb0984b97a73d42d2db8533a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847ad6943c6948fca81b24ff5d689fe3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i561a96f4dc354ad3a90b2b25b980a842_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8e02d4a00804cc4a01eff072b7e2f66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766094e09bca49dd9585d02df2f31831_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9de4610aa6c4469ea8f2b7e53baf43e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2efa7dc8599f4cbf803535c380f5c0a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a2a77b537d4549980bc9ee3c342a33_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbb916e5bc874443803468bda0e734e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd7c6ea10ec4560aebf2e8cf2cdf029_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37fbc3aef92b4fe7a7795bdf6c1c7572_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9da66eabb244ebc99d3f74da210e1ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0351400ea14a1a92d887dfc66b4eaa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebdc2a05aee049ac9929bbe48b8b70e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida12280bfa6149bf8c7594c904e394c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ec7f5fc463475eb5b87f53220a55e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80e1ce0caa3742e5b52a143ca346a03e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75d223f0739043aa95bb0cff432d8e57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96413bd0bc84b608c7ceb7cbe2da49e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86ae682dbc94b06a43ad27eff012f5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib98c19b2205645dc87dc300e20564cd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad19f1af440047f5bd2d2a7b58c2704c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i745dd63e9cdd4959af07252f017a9eaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ed264795f2f4426adc19343d029ad1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98780303768142868e91c1f5e2254492_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e055314ebc4ed0b56423ed298d665f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95a65fbba5eb437390241efe7cc1bc36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97cf13585e1c40fb990546d925c79ac7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia87de4924b5449ffaf2a569727731d96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3596be95666d43788e785254aa341628_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9992852da66444809770265c95298e01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bd0602a17242c7afbd9f2891132c95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c05fd05200c4fd89c9d750167797479_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e90624438bb44448c8bd5de6bd2ea2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie97d7b079fd244fc9390520981dfe82c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1572a102df9d4c8ea6c80c299b0c59c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1716ecbde7da4b99b7645064d92f04e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf0e44d0cbd340d5ba7c2e8a3f4793ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0783150b28c641c7902d993a142cb45c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id967fc79551b44ac97ef5042140ac816_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6d15fd3bd7a46d697fa1cb5eb430566_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff0e1c427c4f46afbcaa4a68bfb4d2e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7d6ca660c7746d3b61378810b89801d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b59b91df70443e68676c97eacce25d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40fd98a8110c4ff289fab753a7c5a2ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ee57e5a8a3245a6a3cb9a15be5df829_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic29bd0cf7cf0435990f458b78cd7e2dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8320821864644efe8f0edb105edca9e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0947ed7f05cf44148673b8fdbbb01f40_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a4586b2c0174806b7f34ea5bd75a188_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5fea782081e4895be4943c726463c8b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd293d73d43e4b46885dca2ec515d496_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233084f1697843b28ef19302f4ca18c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i983918d489184fe48f8103d3daedddca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525ba3ed8d5d45f998cd0b44ccdf96d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6df68bf77edd43e0967eb97c5820dae5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id934c9ad45d24abcaed4f914bd53414a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93560032f3de4bcfb44d52d784c56eb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if925782f8a6e48fb9707082d9722b522_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddb555093f204b73ad69194c448331d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f4b32aef48940438e79c7f4fdd934dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07692f763cdc46eb807c9eab3a20b027_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626e02e818cb4ed494a4840a11c2d6c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8e42823293746a6bb668e39faa8573a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i230ad1456faf4cd5ae3a81c4e040d168_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e784458a35492fbec6c0e6c982a3f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90e35bf522a340e79908048767761c5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f393109a944495bbe43538e525fdba7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4039b3cb11c419c948393d621712209_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ebc1d1a288841db9bff22881bf98a61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e2726b4b0146ca9ec8b95c68183d50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2421a70ae11841d09f5ec2cee484630d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0717808e41b45288577472d48ad1319_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewal_option"><xbrli:measure>amgn:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="i400cdd89c79b4ce0a15e3ad45f90a859_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">amgn:SecuredOvernightFinancingRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e7270e76304c008e4095e3dcaa84f5_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsPurchasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib35744505c1e440c82abbaf57f20fe46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieafdc665523f4a6289df98ee45f3ca5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic520f1877b1b468fb3b71c4ec23d7a05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amgn:BridgeCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1639085198472380ac8baa83001db0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc00ec3fc9549debfc91c2a92aa5314_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e695d739c9d4986a787a639a8e8a77b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81249a29133467eabb1d34b6bdc5483_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50725a0076ed4b89ba38bcbbbfecd2a2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a53ed11f70c43369915dd0d29dbb42a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4136b215dbf24da08247954154d63658_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0caaabac894eaaaa6744f8d15302de_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8267ea8792a8481e880966120cbb1033_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa03d6422826451ab8c9411225c3e9c9_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78ea81b8276943f0b89ca47f8b931e80_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79222ac692e1477aba781d2ff3a5f7c5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cb79e8187a746398d43e3bd13cc6898_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77bd16e1aee146a682056d066f6539d3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae1609cedcdb41f08bdbbf907cf65e3c_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09775729f39c42a3a86f1013c58734d4_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d9c119784043f18fc9dc9683bc2ff7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3de1e54db16b45a680ea17867c15ae9a_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib07ee9684f834ac189f302e8ce8f8377_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d05f148289f4f8ebcab61f83ce94ee7_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0375ffbe4dcf4bdaaf2abf150f3bca4e_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f2c6f9b7a7a46e09d3931f0d8199da3_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1351e1c5d58d4b228b689baa94a08823_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc68e5fe01f4338a8c7676f9e5e9152_D20201231-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1a7ea27d4e4ea893aefca7f2ae9dd4_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffab2bf10a0b4ec490ac20e7b6b5f6fb_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c44917d50b84030bdfa5f48afb2fd94_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17bd2c1e1f6646129c19ffebbe131aa9_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f99105a26404ad389de99b212cfe895_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i213496b5cf4a425b96468749b0447825_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i547af651cb9446b18cc108538306f5ab_D20230301-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9817fa1cfe3409a975c7a8b3cdefd06_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e32313a221f41ad8ccd356225fd8eb0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i561b1b87095d42118b9170aa94c6c7ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1631e26b0d454c06bcc4b0fc4c38dcdc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15d8369eda74b4090810b1af2596778_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b691b97c86241478dd9d32f77155dd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe3a213cdc9d4969b1391eef5c1c503f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie255fb9441af4696b7b5537c9d7d9ffb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46d39b7cc594460ca05a08fe50fe2af5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8ce4697430147afaaf15b34b37a2893_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad7d8f86bf24966a05f5ef686ce8c79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07bf0adb842e42abaf0c52d80659a7f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d505608dcf4454bc0a6caf5d45ad79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6ba3418eed04a19b1d923ff8948405e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6baac2693814ca29a0d4ae5530452b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic696a300be6d4aa6a52c2fbcdfb34389_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia94576e55ab04deaaea5f1b0f981f32a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47cab96086794a69b3747cf784732a9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id21f25ed89f74791850385e82bcb5291_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a54ab8f414d41e9bfaf147b535c4239_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i074ac2af68414c0bbc7a1a601dca087a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97279c89cb3b4d598cc35eb7287e230f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90308d5f52fe46da90947c1f214b73db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica9d03894dc947b0b0664666c999e8d2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c7085eb7de24bdf9364ff05d2d06c22_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cee74d142364011bb64569b6e7ff8a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5592ef4a3504edaab5252ca41492cdb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae23449150e54375b157ac5b160edbd9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idee57457aa704a5588746800b8bd3c58_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ea2249a07045cea77ac843dd3ee186_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6bae6c3e9ff45c4bc483aa371e79620_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc245132cc174af6870e31cfd882e769_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdafbb775bf94addace467b7558c90c5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6b34d2b5b6f4beba907bb845e7cc2b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic916478fec014452ac32d62171a7e5fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fec4c1d74cc4014b5be9b695eda82a9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521f9300ea9e4c53a353c3a3895f2a5e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a53f0a87704f59a5cb2cfabcd59979_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562b0243b6ba47edb88a24870e0e2a7d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec76a0aa8be34cacb8193aae6cd1f062_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4567fe1b74d4ed5aa5d569e9dbeb8fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbc2fff9b80c4cfd94f8bf10fa1a0426_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0eab2c4927424ea7412f20ed53a84a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb3d055e549b4d20aa3bd79921592b07_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia228ad665d09441a9861fb9c7e5b0516_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia50199fde02748f9bf98f5cdedf79621_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d6aeb558db04b82be74458c91784748_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd7ca4767784bd68bc0e5d0a9794960_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eac0bf72e7643508c5232330c7c0e0d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b0a668cee2e4193b99588a3b62eedff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22598ba91ebc4a90903405b80f9b2b90_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30ecd41cf6e44462b19bf11b5f28af8f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e803186d99e4d92800d0f91df12c1ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf69cca5e514b7aa23adb1152babe9a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44e12214117d468cadd851f609eafd23_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04cf9d5f14444094b92bcc0d9ae9c6c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1185eef083e41a98369064a5c024e6a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc1f370e2ad42c6b4c013b49ed46649_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d9b4ff9d7f46de8ab75bad1566254f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195a5331519a4c8ebc478f4e698c9bf0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7ba0f3fb224e79ab0fe6a5fbf238e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i153762966e424fa9acf2972130ddc1c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib555b80a3d9d4e2e9c78009dab8a9f54_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a24aee5c964365b0dc96473c06f9c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i681c12cca8b24893906caf0cabe34abd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcd8de791a54d38a00b14d46bd0e184_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ed68b118d34472994cc95aaa8e8a6c9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba7a6ebd1caa4564bcbb05dd9ae6251a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5402fe697c814ce7b466859cedc94d30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c0de5b5539746a0b7f92ee5f134419e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a10914bc11449188ce8ebe9ba6d1e7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac87a69358fc4fd589fb827383a29399_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8495c3e692f14eecb7e49b36322c3b37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id189833f84714d86b873bc1305ea1122_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569bb5a225ac490892da958f5708abba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2668497e150b43a791a72f0c8455c08e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2d5b99ab33b4e739ed1626b9b36b488_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d74df6c17364a8aabc1122e2efe6f4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42fe4d733a7f4f13bb7813256bad4ea3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idabb4b707739487e85cf95efbce18ef9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i797ddf4c639f495e92b203d4350e1885_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i577871f373d34ff481985f5ec576c5a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i132049d557004a2b9c5a3e2500f496fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id70719b622e54833ae9798bf9ddc0a57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cba56b2736f4a09aa520371c0cb29ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4da8e4a0b6f4526bfb950095170ff2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifce18bab23fc49839c5ff35eebbc64f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if69c6f84cc55499992a9a2e32132005e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb904ccb9024b858913d7acf42062d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccad64003d424270be4e3bf87201a726_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id946d775421d4962835fc013c2dd949a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia240f27fa9af4af381d9cd9b830cdc68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53e3c3e57bfa41579e675e5dacc3bd0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib665f9cde8cf48c5b5fc22d5eab5ff32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d24cfe7dee24743a1c19c57c666aad9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9866c2a563d74089bd190f1596f41fc2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c2ad38235c0444d8eb13ded4145682a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7dfd23ab294cfdaa4374b169b9c14d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbbed003175d41bfa117df6296bf5c46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92535cf54c5042858d8b357cb40f0d14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied47fb81a807413c89dca88a7846b5c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c83ac6e195467b945c631bdc59e85c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia46cd94f860647c4b3b4f6dd2d098fff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i944c4da8f51949d7bd4524a5221b53f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic575aff5abc14a04a5d1c46f2b053e12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a5af4745b754c7b874785b32bb24b00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5962db8b8248e8a56de2423329a813_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dddebd646fe4e9aae847684ea09146c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82707d8217c743548ff4520578c0f7cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18586610d42b4565923516e609315ed0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a279bb1582744739e5f9088fe666593_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb35b6ee6b4c481cbd643d0e1261cc8e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i141bfbb6d4734cb1906b822194473416_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i000c813b74c349b6be351b38fd528099_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36cf59fd6e684e63bd2fb4dcb7870271_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12701a294ac24a63ac70115c6686c71c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0e2e65349e4185a303be08740aed7e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc93e8ad61544af5aef6ae040ba31401_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i893dec2695f241eea7e09febe91d6056_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4403c288e6734e15b800b88b0a641274_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d8039e3232a4ce3b5bcb3dfbf62c725_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia924eeb3bb7543ed8daaa1f3364c31e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e3f19a1ae64901bda8ca62eb6abcfd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia013b3bfbdf74724934c7921f702d9ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e86b4b83c1402e9dbc2c712ea987c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95699e6c8574452f9e3e864d40b1dc25_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a18b2800d894d86bd5f131724792cfa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i224736ead83447e6a2b3bbfb08ecf30d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60cabd0b1a14cb189936f2de2a378c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0921f2d8651244eab61f2a275f079822_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916dce6d88664036bb8c4c3bcd21707a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61f2865a5c7548b6986efb37a72d32f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35dca8996f6e45938deded2944b3efba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10bea2bc73284b47b799ca78b75b4e06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d1709057914d44afb932729cfecfcf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235e4ed48f85437d8644836bbc43ca87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55a872aceca74648a5734c2e9893a09e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc2cebe6a0c248f594910077166c27c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie19c8a33e809469baa28577670a15fd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c2d36bbe6a4d419b04a238a8121559_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForeignCurrencyAndCrossCurrencySwapsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0070fbcf9e5043e28c33ca586f2f12d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a3731a49f5b4c0ab1587258bbb6fa81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6300669025b46f7b380270aefda2eb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1b4d3bc8dd644d09c1cfa7a23a15d73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27ace983c9a64dc7b4239aea83dc7b02_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd95f2130b1849c0a6ac303164815eac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaef37d1d19a34b4abe782126c5137fe0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54e75f2069df4597912a649d3b21612f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f3b2c5c4c594281bf2350f890860495_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40227117f78447a9ad9ae92218498e28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2944af81b1f24f5e8934a081989872fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49d6cb8ea64d45f092c9ccbe06efae29_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i629346f484274f9ea377c96a9845eb29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id334802554e34a95a80f6c8df61e0238_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378d88e1dff64d65904267fc06da9175_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09e8414ca5604a31a388ddd2badf96b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i824bdb4659bd41509979bb787b6de333_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6523296eb7b74ed7b7ff7acdfe444319_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf6a2a3c143432ea3c1e2d1ca761a0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8c2b20543e445bb5dea750ab9c396a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36b86d79154149259fd101e1fe5655b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2958a5f5fff1421995cfbfcd99f50244_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>amgn:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i2c106f85af6b497789bb2d2c5d8a09e5_D20210928-20210928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-28</xbrli:startDate><xbrli:endDate>2021-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>amgn:patent</xbrli:measure></xbrli:unit><xbrli:context id="ia142d93a85b941c08264cf95a13ea31d_D20211012-20211012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-12</xbrli:startDate><xbrli:endDate>2021-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i726c606382b04686ab59e3bf5cf547f4_D20141001-20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice91453cc6994225aeb0216b9be20795_D20160201-20160228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-01</xbrli:startDate><xbrli:endDate>2016-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba99da398a24a8da5609feecbdda3b2_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c422a12ee04646bd081c628e80d370_D20221129-20221129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:JanssenBiotechIncVsAmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="numberofplaintiffs"><xbrli:measure>amgn:numberOfPlaintiffs</xbrli:measure></xbrli:unit><xbrli:unit id="numberofclaims"><xbrli:measure>amgn:numberOfClaims</xbrli:measure></xbrli:unit><xbrli:context id="if7c1ec63c1ec45feb8a564cb6250b077_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee18063ebe5b4821977151cc6f74a5c1_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="states"><xbrli:measure>amgn:States</xbrli:measure></xbrli:unit><xbrli:context id="ieb8da649b50d456aabccb1d09b37ed81_I20220527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:RegeneronPharmaceuticalsIncAntitrustActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="argument"><xbrli:measure>amgn:argument</xbrli:measure></xbrli:unit><xbrli:context id="ib9fd3c9e12f348fda85ef0818a380f80_D20210505-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:ChemoCentryxIncSecuritiesMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-05</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>amgn:installment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="if8055099d1994bb494875d41c341f00d_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDEw_08b7dff7-007b-49ab-8dfc-6f44d0f9fe52">10-K</ix:nonNumeric> </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:5.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6YjkxOTZiYmYyNjQ3NDgwZWIxY2Y3ODAwMjFhMWIyNzUvdGFibGVyYW5nZTpiOTE5NmJiZjI2NDc0ODBlYjFjZjc4MDAyMWExYjI3NV8wLTAtMS0xLTE4ODk3NA_68e8b9fd-ab30-4ba1-bce3-90e98463289f">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV81NDk3NTU4MTc3MDk_661c9155-fdac-4274-afbe-601d5ce8d873"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV81NDk3NTU4MTc3MDk_27833414-9b5e-4056-936b-eb4e40c29a52">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:5.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6OGRhYWFjMWRhZDE3NGI2YTlkY2E2Zjg1YjFmODcwYzUvdGFibGVyYW5nZTo4ZGFhYWMxZGFkMTc0YjZhOWRjYTZmODViMWY4NzBjNV8wLTAtMS0xLTE4ODk3NA_a38e4830-5ff6-4139-aa12-e87663bb56b6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDEx_87d078f1-dd4f-49ee-91d2-5b7c937454b6">001-37702</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDEy_a42c4fd6-e4cd-458a-8451-165c71f5e3aa">Amgen Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8wLTAtMS0xLTE4ODk3NA_b3188651-deb9-4952-8d3a-1bab63bf76aa">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8wLTItMS0xLTE4ODk3NA_87bce937-bc98-46dc-acf9-c40d38734207">95-3540776</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8yLTAtMS0xLTE4ODk3NA_e1c99252-4dba-401d-8059-e98c071ec9e5">One Amgen Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8yLTItMS0xLTE4ODk3NA_d9883055-6405-41ae-9711-45104b013598">91320-1799</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8zLTAtMS0xLTE4ODk3NA_3e09113f-52b4-4d53-bc83-8a7efba124fe">Thousand Oaks</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF80LTAtMS0xLTE4ODk3NA_983fa38d-8611-444e-a4bf-0e6866a8cde7">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA0_42dcaee8-88c7-49fd-93fc-a22f83fd89db">805</ix:nonNumeric>) <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA1_641c215e-9208-4af9-b8dc-ac2cf8661972">447-1000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol (s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia583ee59c26e4591a6c760c2f5aa05d2_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18xLTAtMS0xLTE4ODk3NA_301fb877-fd52-480e-8a5d-a61a9f09c872">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia583ee59c26e4591a6c760c2f5aa05d2_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18xLTEtMS0xLTE4ODk3NA_63f1340f-3d44-4a0a-ac61-8be92e1b4476">AMGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia583ee59c26e4591a6c760c2f5aa05d2_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18xLTItMS0xLTE4ODk3NA_2b0bf425-ee0b-4352-a58d-15147d8d9ae4">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i580757a974aa4b85b143f5523fc7aa91_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18yLTAtMS0xLTE4ODk3NA_e890454d-ad2e-4173-a937-04524572f79a">2.00% Senior Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i580757a974aa4b85b143f5523fc7aa91_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18yLTEtMS0xLTE4ODk3NA_afde0713-10c0-4e12-a13a-30500f88e72d">AMGN26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i580757a974aa4b85b143f5523fc7aa91_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18yLTItMS0xLTE4ODk3NA_30d578c9-faa2-4b77-b881-92ce0d40995a">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> None</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDEz_fd3d7624-7adf-4e15-bd11-e84b1d521452">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA2_5c902bce-5783-43f5-ba2d-1ce0f5fc4873">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or Section&#160;15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDE0_d3ff00f8-79a6-4650-9b10-7507e0709fa0">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA3_4831ed18-aab3-4a36-957d-9a7a3098b2e7">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:1pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6MTZhYmZhM2QxM2JjNDBjOGJhOTA1MTdhODYyZDZiNTMvdGFibGVyYW5nZToxNmFiZmEzZDEzYmM0MGM4YmE5MDUxN2E4NjJkNmI1M18wLTAtMS0xLTE4ODk3NA_0b10fb45-5603-42e2-8698-4e0df6e2d0bd">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6MTZhYmZhM2QxM2JjNDBjOGJhOTA1MTdhODYyZDZiNTMvdGFibGVyYW5nZToxNmFiZmEzZDEzYmM0MGM4YmE5MDUxN2E4NjJkNmI1M18xLTMtMS0xLTE4ODk3NA_f3438740-3263-48f5-90a5-15b775cbb8d1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6MTZhYmZhM2QxM2JjNDBjOGJhOTA1MTdhODYyZDZiNTMvdGFibGVyYW5nZToxNmFiZmEzZDEzYmM0MGM4YmE5MDUxN2E4NjJkNmI1M18xLTQtMS0xLTE4ODk3NA_df42ca0b-1688-4f5f-af55-380f00c9d921">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.     </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDE1_5d35a10e-d75a-49cf-87ac-66c7066f9cee">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:2pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA4_22e82ac3-da7b-4293-8c5d-89be875ff43f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approximate aggregate market value of voting and non-voting stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="usd" contextRef="ifa76a93f17df45cd9d66d36fd211676b_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8yNjAw_bd516064-efb0-4833-bab0-5cb4fc8865b1">129,940,091,621</ix:nonFraction> as of June&#160;30, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(A)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(A)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.41pt">Excludes 818,128 shares of common stock held by directors and executive officers, and any stockholders whose ownership exceeds ten percent of the shares outstanding, at June&#160;30, 2022. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3dd260e9045c46d1bd6dbbdbd6942bb1_I20230206" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zMTA2_7ca0e629-24bd-4104-8863-076d57af6c3d">533,976,238</ix:nonFraction></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Number of shares of common stock outstanding as of February 6, 2023)</span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA5_317d3ad1-2a2b-44fd-8555-dad1ce446cad" escape="true"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified portions of the registrant&#8217;s Proxy Statement with respect to the 2023 Annual Meeting of Stockholders to be held May 19, 2023, are incorporated by reference into Part&#160;III of this annual report.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_10">DEFINED TERMS AND PRODUCTS</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_10">ii</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_19">Significant Developments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_22">Marketing, Distribution and Selected Marketed Products</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_25">Reimbursement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_28">Manufacturing, Distribution and Raw Materials</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_28">11</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_31">Government Regulation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_31">13</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_34">Research and Development and Selected Product Candidates</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_34">16</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_37">Business Relationships</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_37">22</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_40">Human Capital Resources</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_40">23</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_43">Information about our Executive Officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_43">26</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_46">Geographic Area Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_46">27</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_49">Investor Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_49">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_52">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_52">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_55">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_55">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_58">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_58">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_61">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_61">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_64">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_64">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_67">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_67">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_70">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_70">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_73">RESERVED</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_73">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_76">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_76">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_106">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_106">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_109">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_109">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_112">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_112">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_115">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_115">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_124">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_124">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_127">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_127">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_130">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_130">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_136">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_136">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_139">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_139">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_148">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_148">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_151">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_151">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_154">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_154">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_157">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_157">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_160">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_160">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_163">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_163">90</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Terms and Products </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined terms</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use several terms in this Form 10-K, including but not limited to those that are finance, regulation and disease-state related as well as names of other companies, which are given below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended 2009 Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2009 Equity Incentive Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANDA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abbreviated New Drug Application</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accumulated other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASCVD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">atherosclerotic cardiovascular disease</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated Share Repurchase</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca plc</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bergamo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorio Quimico Farmaceutico Bergamo Ltda</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">bispecific T-cell engager</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BPCIA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics Price Competition and Innovation Act of 2009</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CCPA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Consumer Privacy Act of 2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celgene</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celgene Corporation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CGRP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">calcitonin gene-related peptide</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ChemoCentryx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ChemoCentryx, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">chemotherapy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">anticancer medicines</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHMP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Committee for Medicinal Products for Human Use</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COSO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Committee of Sponsoring Organizations of the Treadway Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">coronavirus disease 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cardiovascular</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DLL3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">delta-like ligand 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DOJ</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Justice</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eczac&#305;ba&#351;&#305;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EIS Eczac&#305;ba&#351;&#305; &#304;la&#231;, S&#305;nai ve Finansal Yat&#305;r&#305;mlar Sanayi ve Ticaret A.&#350;.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Medicines Agency</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">earnings per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESG</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">environmental, social and governance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Union</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FCPA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Foreign Corrupt Practices Act</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDCA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Food, Drug, and Cosmetic Act</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitch Ratings, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime Therapeutics, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FTC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Trade Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. generally accepted accounting principles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GDPR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Data Protection Regulation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GEJ</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">gastroesophageal junction</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gensenta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gensenta &#304;la&#231; Sanayi ve Ticaret A.&#350;.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HHS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health &amp; Human Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Horizon</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Horizon Therapeutics plc</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">interleukin</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IND</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigational New Drug Application</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in-process research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflation Reduction Act</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal Revenue Service</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">K-A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirin-Amgen, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KKC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyowa Kirin Co., Ltd.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRAS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirsten rat sarcoma viral oncogene</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDL-C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">low-density lipoprotein cholesterol</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">London Interbank Offered Rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lp(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lipoprotein(a)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MD&amp;A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">management&#8217;s discussion and analysis</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moody&#8217;s</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moody&#8217;s Investors Service, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRD</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">minimal residual disease</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neumora</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neumora Therapeutics, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net operating loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Pharma AG</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-small cell lung cancer</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OECD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organisation for Economic Co-operation and Development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OIG</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office of Inspector General</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OLE</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">open label extension</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">objective response rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PBM</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pharmacy benefit manager</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PCSK9</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proprotein convertase subtilisin/kexin type 9</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PDE4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">phosphodiesterase 4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PFS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">progression-free survival</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PNH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">paroxysmal nocturnal hemoglobinuria</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit Sharing Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Profit Sharing Plan for Employees in Ireland</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RANKL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">receptor activator of nuclear factor kappa-B ligand</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RAR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Agent Report</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REMS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">risk evaluation and mitigation strategy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">right-of-use</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">rest of world</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s Financial Services LLC</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Securities and Exchange Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">siRNA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">small interfering RNA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOFR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secured Overnight Financing Rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teneobio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teneobio, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Treasury</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USPTO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Patent and Trademark Office</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UTB</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">unrecognized tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are given below.</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acapatamab</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acapatamab (formerly AMG 160)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (erenumab-aooe)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(adalimumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (adalimumab-atto)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (darbepoetin alfa)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AutoTouch</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AutoTouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVSOLA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVSOLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (infliximab-axxq)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (blinatumomab)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corlanor</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corlanor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (ivabradine)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Efavaleukin alfa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Efavaleukin alfa (formerly AMG 592)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emirodatamab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emirodatamab (formerly AMG 427)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (etanercept)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL Mini</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL Mini</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (epoetin alfa)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (romosozumab-aqqg)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMLYGIC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (talimogene laherparepvec)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (trastuzumab-anns)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (carfilzomib)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS/LUMYKRAS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> / LUMYKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (sotorasib)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (bevacizumab-awwb)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (pegfilgrastim)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filgrastim)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (romiplostim)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olpasiran (formerly AMG 890)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onpro</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onpro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordesekimab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordesekimab (formerly AMG 714)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (apremilast)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (etelcalcetide)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (evolocumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIABNI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rituximab-arrx)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rocatinlimab </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rocatinlimab (formerly AMG 451)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rozibafusp alfa</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rozibafusp alfa (formerly AMG 570)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar/Mimpara</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/Mimpara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (cinacalcet)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SureClick</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SureClick</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarlatamab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarlatamab (formerly AMG 757)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAVNEOS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAVNEOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (avacopan)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(tezepelumab-ekko)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (panitumumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products referenced in this report that are not included in the above list are trademarks of their respective owners. They are Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cosentyx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Fulphila</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Herceptin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HUMIRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, POMALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/IMNOVID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PROMACTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/REVOLADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RINVOQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Rituxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MabThera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Skyrizi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SOLIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Taltz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Teribone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tremfya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, UDENYCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Xeljanz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="if8055099d1994bb494875d41c341f00d_16"></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BUSINESS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people&#8217;s lives. A biotechnology pioneer, Amgen has grown to be one of the world&#8217;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. We have a presence in approximately 100 countries worldwide. Amgen operates in one business segment: human therapeutics.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_19"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Developments </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of significant developments affecting our business that have occurred and that we have reported since the filing of our Annual Report on Form 10-K for the year ended December 31, 2021. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposed acquisition of Horizon Therapeutics plc</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">On December 12, 2022, we announced that we entered into a transaction agreement under which Amgen will acquire all shares of Horizon for $116.50 per share in cash for a transaction equity value of approximately $27.8 billion. In connection with the proposed acquisition of Horizon, in December 2022 we entered into a bridge credit agreement and a term loan credit agreement with an aggregate principal amount of $28.5&#160;billion. Horizon is a global biotechnology company headquartered in Dublin, Ireland and is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Horizon has 12 marketed medicines and a pipeline with more than 20 development programs. The closing of this transaction is contingent upon satisfaction of certain regulatory (including FTC review) and other customary closing conditions.</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">On January 30, 2023, the Company and Horizon each received a request for additional information and documentary materials (Second Request) from the FTC in connection with the FTC&#8217;s review of the Company&#8217;s proposed acquisition of Horizon. The effect of the Second Request is to extend the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, until 30 days after the Company and Horizon have substantially complied with the Second Request, unless that period is extended voluntarily by the Company and Horizon or terminated sooner by the FTC.</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ChemoCentryx, Inc.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">On October 20, 2022, we completed our acquisition of ChemoCentryx for $52.00 per share in cash totaling approximately $3.8&#160;billion, net of cash acquired.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products/Pipeline</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cardiometabolic</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In 2022, we presented results from the Repatha FOURIER-OLE studies, two open label extension (OLE) studies (with 6,635 patients) to the Phase 3 FOURIER cardiovascular (CV) outcomes trial. FOURIER-OLE was designed to assess the long-term safety and tolerability of Repatha in adults with clinically evident atherosclerotic cardiovascular disease (ASCVD). In these studies, an exploratory analysis demonstrated that earlier initiation of Repatha resulted in a lower risk of cardiovascular outcomes as defined by the composite endpoint of cardiovascular death, myocardial infarction (MI) and stroke, and the incidence of serious adverse events did not increase over time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Olpasiran</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In November 2022, we presented positive end-of-treatment results from the Phase 2 OCEAN(a)-DOSE study evaluating olpasiran in adult patients with lipoprotein(a), or Lp(a), levels over 150 nmol/L and a history of ASCVD. Olpasiran is a small interfering RNA (siRNA) designed to lower the body&#8217;s production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of CV events. In the double-blind placebo-controlled treatment period, olpasiran was administered up to 225 mg subcutaneously every 12 weeks to patients with a median baseline Lp(a) of approximately 260 nmol/L. Patients who received a 75 mg or higher dose every 12 weeks had a 95% or greater reduction in Lp(a) compared to placebo at week 36. Overall, the rates of adverse events were similar in the olpasiran and placebo arms.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflammation</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEZSPIRE</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In September 2022, the EC approved TEZSPIRE in the EU as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The approval follows the recommendation by the CHMP of the EMA in July 2022.</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 654</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In April 2022, we announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA (ustekinumab) in adult patients with moderate-to-severe plaque psoriasis. The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and STELARA.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology/Hematology</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUMAKRAS/LUMYKRAS</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In April 2022, we announced long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C&#8211;mutated advanced non-small cell lung cancer (NSCLC) who received LUMAKRAS/LUMYKRAS. In 174 heavily pre-treated patients (172 with baseline measurable lesion(s)), LUMAKRAS/LUMYKRAS demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate of 83.7% and median duration of response (DOR) of 12.3 months. The results also showed median progression-free survival (PFS) of 6.3 months and overall survival of 12.5 months, with 32.5% of patients still alive at two years. No new safety signals for LUMAKRAS/LUMYKRAS were identified with the long-term follow-up.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In September 2022, we announced results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral LUMAKRAS/LUMYKRAS led to significantly superior PFS (primary endpoint) and a significantly higher ORR (a key secondary endpoint) in patients with KRAS G12C&#8211;mutated NSCLC, compared with intravenous chemotherapy, docetaxel. LUMAKRAS/LUMYKRAS significantly improved PFS compared to docetaxel in heavily pre-treated patients. The proportion of patients with PFS at one year was 25% for LUMAKRAS/LUMYKRAS versus 10% for docetaxel. LUMAKRAS/LUMYKRAS demonstrated a significantly higher ORR than docetaxel with double the response rates in the LUMAKRAS/LUMYKRAS arm (28% versus 13%, respectively).</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 959</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In August 2022, we announced positive top-line results from the DAHLIA study, a randomized, double-blind, active-controlled, two-period crossover Phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). The study met its primary endpoints, demonstrating no clinically meaningful differences between ABP 959 and SOLIRIS. The safety and immunogenicity profile of ABP 959 was comparable to that of SOLIRIS.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New manufacturing facility</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In March 2022, we broke ground to build a drug substance plant in North Carolina that will increase our manufacturing network capacity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing, Distribution and Selected Marketed Products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The largest concentration of our sales and marketing forces is based in the United States and Europe. In recent years, we have expanded the commercialization and marketing of our products into other geographic territories, including Japan, China and other parts of Asia; Latin America; and the Middle East. This expansion has occurred, and is expected to continue to occur, by establishing our own affiliates, by acquiring existing third-party businesses or product rights or by collaborating with third parties. See Business Relationships for our significant alliances. Whether we use our own sales and marketing forces or a third party&#8217;s services varies across these markets. Such use typically depends on several factors, including the nature of entry into the new market, the size of an opportunity and operational capabilities. Together with our collaborators, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, substantially all of our sales are to pharmaceutical wholesale distributors, which are the principal means of distributing our products to healthcare providers. We also market certain products through direct-to-consumer channels, including print, television and online media. For further discussion, see Government Regulation&#8212;Regulation in the United States&#8212;Regulation of Product Marketing and Promotion. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. In the Asia Pacific region, we also sell our products in partnership with other companies, including Astellas Pharma Inc., BeiGene, KKC, Takeda Pharmaceutical Company Limited and Daiichi Sankyo Co., Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product sales to three large wholesalers, McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2022, 2021 and 2020. On a combined basis, these wholesalers accounted for 82%, 82% and 83% of worldwide gross revenues for 2022, 2021 and 2020, respectively. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are marketed around the world, with the United States as our largest market. The following chart shows our product sales by principal product, and the table below (dollar amounts in millions) shows product sales by geography for the years 2022, 2021 and 2020.</span></div><div style="margin-bottom:8pt;text-align:center"><img src="amgn-20221231_g1.jpg" alt="amgn-20221231_g1.jpg" style="height:550px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Sales by Geography:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market ENBREL, a tumor necrosis factor blocker, in the United States and Canada. ENBREL was launched in 1998 and is used primarily in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prolia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Prolia in many countries around the world. Prolia contains the same active ingredient as XGEVA but is approved for different indications, patient populations, dose and frequency of administration. Prolia was launched in the United States and Europe in 2010. In the United States, it is used primarily in the indication for the treatment of postmenopausal women with osteoporosis at high risk of fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or in patients who have failed or are intolerant to other available osteoporosis therapy. In Europe, Prolia is used primarily for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Otezla, a small molecule that inhibits phosphodiesterase 4 (PDE4), in many countries around the world. Otezla was acquired from Bristol Myers Squibb Company in November 2019 after their acquisition of Celgene. Otezla is an oral therapy approved for the treatment of adults with plaque psoriasis across all severities (United States and Japan) and moderate-to-severe plaque psoriasis (other global markets including Europe), for adults with active psoriatic arthritis and for adults with oral ulcers associated with Beh&#231;et&#8217;s disease.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XGEVA</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market XGEVA in many countries around the world. XGEVA was launched in 2010 and is used primarily in the indication for prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in patients with bone metastases from solid tumors and multiple myeloma.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aranesp</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Aranesp primarily in the United States and Europe. Aranesp was launched in 2001 and is indicated to treat a lower-than-normal number of red blood cells (anemia) caused by chronic kidney disease (CKD) in both patients on dialysis and patients not on dialysis. Aranesp is also indicated for the treatment of anemia due to concomitant myelosuppressive chemotherapy in certain patients with nonmyeloid malignancies and when chemotherapy will be used for at least two months after starting Aranesp.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nplate</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Nplate in many countries around the world. Nplate was launched in 2008 and is indicated to treat thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Repatha, a PCSK9 inhibitor, in many countries around the world. Repatha was launched in 2015 and is indicated to reduce the risks of myocardial infarction, stroke and coronary revascularization in adults with established CV disease. Repatha is also indicated to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market KYPROLIS primarily in the United States and Europe. KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was launched in 2012 and is indicated in combination with (i) dexamethasone, (ii) lenalidomide plus dexamethasone and (iii) DARZALEX plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. It is also approved as a single agent for patients with relapsed or refractory multiple myeloma who have received one or more previous therapies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neulasta</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the United States and Europe. Neulasta was launched in 2002 and is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count in patients with certain types of cancer (nonmyeloid) who receive anticancer medicines (chemotherapy) that can cause fever and a low blood cell count. In 2015, the Neulasta Onpro kit became available in the United States. The Neulasta Onpro kit provides physicians the opportunity to initiate administration of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the same day as chemotherapy, with drug delivery of the recommended dose of Neulasta at home the day after chemotherapy, thereby saving the patient a trip back to the doctor.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EVENITY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Together with our collaboration partners, we market EVENITY in many countries around the world. EVENITY was launched in the United States and Japan in 2019. In the United States, it is used in the indication for the treatment of osteoporosis in postmenopausal women at high risk for fracture. In Japan, EVENITY is used primarily in the indication for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Marketed Products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also market a number of other products in various markets worldwide, including MVASI, Vectibix, BLINCYTO, EPOGEN, AMGEVITA, Aimovig, Parsabiv, KANJINTI, LUMAKRAS/LUMYKRAS, TEZSPIRE, NEUPOGEN, Sensipar/Mimpara and TAVNEOS.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists our outstanding material patents for the indicated product by territory, general subject matter and latest expiry date. Certain of the European patents are subjects of&#160;supplemental protection certificates that provide additional protection for the products in certain European countries beyond the dates listed in the table. See footnotes to the patent table below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more patents with the same or earlier expiry dates may fall under the same general subject matter and are not listed separately.</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">General subject matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(etanercept)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment using aqueous formulations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/8/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulations and methods of preparing formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/19/2037</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fusion protein and pharmaceutical compositions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/22/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DNA encoding fusion protein and methods of making fusion protein</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/24/2029</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nucleic acids encoding RANKL antibodies and methods of producing RANKL antibodies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/30/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RANKL antibodies, including sequences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/19/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RANKL antibodies, including sequences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/25/2022</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(apremilast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions and compounds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/16/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystalline form</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/9/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/29/2034</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions, compounds and methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/20/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (darbepoetin alfa)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Glycosylation analogs of erythropoietin proteins</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2024</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(romiplostim)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Polynucleotides encoding fusion protein</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/25/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/12/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thrombopoietic compounds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/22/2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/20/2027</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(evolocumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/25/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/8/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/22/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/10/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/3/2033</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (carfilzomib)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions and compounds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/7/2027</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of making</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/8/2033</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions, compounds and methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/7/2025</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">General subject matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(romosozumab-aqqg)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/25/2026</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/9/2033</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation and methods of using formulation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/11/2031</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/28/2026</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/18/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation and methods of using formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/11/2031</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (blinatumomab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical compositions and bifunctional polypeptides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/6/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/28/2027</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bifunctional polypeptides</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/26/2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/6/2029</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (erenumab-aooe)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CGRP receptor antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/17/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/22/2036</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions and pharmaceutical formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/1/2039</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CGRP receptor antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/18/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/10/2035</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(etelcalcetide)</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compound and pharmaceutical composition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/7/2031</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/27/2034</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of making</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/9/2035</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compound and pharmaceutical composition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/29/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/27/2034</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LUMAKRAS&#174; /LUMYKRAS&#8482; (sotorasib)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compounds and pharmaceutical compositions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/21/2038</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystalline form, pharmaceutical compositions and methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/20/2040</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/11/2040</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compounds, pharmaceutical compositions and methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/21/2038</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TEZSPIRE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(tezepelumab-ekko)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Polypeptides</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/3/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/23/2038</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TAVNEOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (avacopan)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compounds and pharmaceutical compositions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/3/2031</span></td></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A European patent with this subject matter may also be entitled to supplemental protection in one or more countries in Europe, and the length of any such extension will vary by country. For example, supplementary protection certificates have been issued related to the indicated products for patents in at least the following countries:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">denosumab &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2025</span></div><div style="margin-bottom:8pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">apremilast &#8212; France, Germany, Italy, Spain and the United Kingdom expiring in 2028</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">carfilzomib &#8212; France, Germany, Italy, Spain and the United Kingdom expiring in 2030</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">evolocumab &#8212; France, Spain and the United Kingdom, expiring in 2030</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">romiplostim &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2024</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">romosozumab &#8212; France, Italy, Spain and the United Kingdom, expiring in 2031</span></div><div style="margin-bottom:8pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">blinatumomab &#8212; France, Germany, Italy and Spain, expiring in 2029</span></div><div style="margin-bottom:8pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">erenumab &#8212; France, Italy, Spain and the United Kingdom, expiring in 2033</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">etelcalcetide &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2031</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">U.S. Patent No. 10,092,541 was held invalid by the New Jersey District Court. We disagree with the court&#8217;s holding and we are in the process of appealing this judgment. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements, Amgen Inc. v. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A patent with this subject matter may be entitled to patent term extension in the United States.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. A number of our marketed products are indicated for disease areas in which other products or treatments are currently available or are being pursued by our competitors through R&amp;D activities. Additionally, some competitor-marketed products target the same genetic pathways as our recently launched marketed products or are currently in development. This competition could impact the pricing and market share of our products. We continue to pursue ways of increasing the value of our medicines through innovations during their life cycles, which can include expanding the disease areas for which our products are indicated and finding new methods to make the delivery of our medicines easier and less costly. Such activities can offer important opportunities for differentiation. For example, we market the Neulasta Onpro kit, which provides physicians the opportunity to initiate administration of the recommended dose of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the same day as chemotherapy, with drug delivery at home the day after chemotherapy, thereby saving the patient a trip back to the doctor. We plan to continue pursuing innovation efforts to strengthen our competitive position. Such position may be based on, among other things, safety, efficacy, reliability, availability, patient convenience, delivery devices, price, reimbursement, access to and timing of market entry and patent position and expiration.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the existing patents on our principal products have expired, and we face new and increasing competition, including from biosimilars and generics. A biosimilar is another version of a biological product for which marketing approval is sought or has been obtained based on a demonstration that it is &#8220;highly similar&#8221; to the original reference product. We have experienced adverse effects from biosimilar competition on our originator product sales. Companies have launched biosimilar versions of EPOGEN, NEUPOGEN and Neulasta and have approved biosimilars for ENBREL. Once multiple biosimilar versions of one of our originator products have launched, competition has intensified rapidly, resulting in greater net price declines for both reference and biosimilar products and a greater effect on product sales. See also Government Regulation&#8212;Regulation in the United States&#8212;Approval of Biosimilars. Although competitor biosimilars compete on price, we believe many patients, providers and payers will continue to place high value on the reputation, supply reliability and safety of our products. As additional biosimilar competitors come to market, we will continue to leverage our global experience to distinguish against both branded and biosimilar competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have our own biosimilar products both in the United States and outside of U.S. markets that are competing against branded and biosimilar versions of our competitors&#8217; products. In 2019, Amgen launched MVASI, a biosimilar to Avastin, and KANJINTI, a biosimilar to Herceptin; and in 2018, Amgen launched AMGEVITA, a biosimilar to HUMIRA in markets outside the United States. We have also received FDA approval of AMJEVITA, a biosimilar to HUMIRA for the U.S. market, which launched in January 2023. In 2020, we launched AVSOLA, a biosimilar to Remicade;</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and in 2021 we launched RIABNI, a biosimilar to Rituxan. We expect additional biosimilar competition against both our branded and biosimilar products in the future across markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although most of our products are biologics, some are small molecule products. Because the FDA approval process permits generic manufacturers to rely on the safety and efficacy data of the innovator product rather than having to conduct their own costly and time-consuming clinical trials, generic manufacturers can often develop and market their competing versions of our small molecule products at much lower prices. For example, following loss of exclusivity of patents directed to cinacalcet, the active ingredient in our small molecule calcimimetic Sensipar, we lost a significant share of the market and corresponding revenues in a very short period of time. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The introduction of new products, the development of new processes or technologies by competitors or the emergence of new information about existing products may result in (i) increased competition for our marketed products, even for those protected by patents and/or (ii) reductions in the prices we receive from selling our products. In addition, the development of new treatment options or standards of care may reduce the use of our products or may limit the utility and application of ongoing clinical trials of our product candidates. (As used in this document, the term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may include prospective clinical trials, observational studies, registries and other studies.) See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products face substantial competition and our product candidates are also likely to face substantial competition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our significant competitors and is not exhaustive.</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Competitor-marketed product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Competitors</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HUMIRA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xeljanz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RINVOQ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S., Europe &amp; Asia Pacific</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alendronate, raloxifene and zoledronate generics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HUMIRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cosentyx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skyrizi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methotrexate generics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoledronate generics</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epoetin alfa biosimilars</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROMACTA/REVOLADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S., Europe &amp; Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRALUENT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals, Inc.<br/>Sanofi</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VELCADE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Millennium Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POMALYST/IMNOVID</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celgene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UDENYCA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coherus BioSciences, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fulphila</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mylan Institutional Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filgrastim biosimilars</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alendronate, raloxifene and zoledronate generics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teribone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Approved biosimilars available in Europe and Canada.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A subsidiary of Johnson &amp; Johnson.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">PROCRIT competes with Aranesp in supportive cancer care and predialysis settings.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">REVLIMID also includes generics.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A subsidiary of Takeda Pharmaceutical Company Limited.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A subsidiary of Bristol Myers Squibb Company.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Other biosimilars under regulatory review in the United States and Europe.</span></div><div style="text-align:justify;text-indent:4.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_25"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products are dependent on the availability and extent of coverage and reimbursement from third-party payers. In many markets around the world, these payers, including government health systems, private health insurers and other organizations, remain focused on reducing the cost of healthcare; and their efforts have intensified as a result of rising healthcare costs, economic pressures and broader challenges generated by the COVID-19 pandemic. Drugs remain heavily scrutinized for cost containment. As a result, payers are becoming more restrictive regarding the use of biopharmaceutical products and are scrutinizing the prices of these products while requiring a higher level of clinical evidence to support the benefits such products bring to patients and the broader healthcare system.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These pressures become intensified when our products become subject to competition, including from biosimilars.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, healthcare providers and other entities such as pharmacies and PBMs are reimbursed for covered services and products they deliver through both private-payer and government healthcare programs such as Medicare and Medicaid. We provide negotiated rebates to healthcare providers, private payers, government payers and PBMs. In addition, we are required to (i) provide rebates or discounts on our products that are reimbursed through certain government programs, including Medicare and Medicaid, and (ii) provide discounts to qualifying healthcare providers under the federal 340B Drug Pricing Program. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both private and some government payers use formularies to manage access to and utilization of drugs. A drug&#8217;s inclusion and favorable positioning on a formulary are essential to ensure patients have access to a particular drug. Even when access is available, some patients abandon their prescriptions for economic reasons. Payers continue to institute cost reduction and containment measures that lower drug utilization and/or spending altogether and/or shift a greater portion of the costs to patients. Such measures include, but are not limited to, more-limited benefit plan designs, higher patient co-pays or coinsurance obligations, limitations on patients&#8217; use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs), stricter utilization management criteria before a patient may get access to a drug, higher-tier formulary placement that increases the level of patient out-of-pocket costs and formulary exclusion, which effectively encourages patients and providers to seek alternative treatments or pay 100% of the cost of a drug. The use of such measures by PBMs and insurers has continued to intensify and has thereby limited Amgen product usage and sales. Furthermore, during the past few years, many PBMs and insurers have consolidated, resulting in a smaller number of PBMs and insurers overseeing a large portion of total covered lives in the United States. As a result, PBMs and insurers have greater market power and negotiating leverage to mandate stricter utilization criteria and/or exclude drugs from their formularies in favor of competitor drugs or alternative treatments. In highly competitive treatment markets such as the markets for ENBREL, Otezla, Repatha and Aimovig, PBMs are also able to exert negotiating leverage by requiring incremental rebates from manufacturers in order for them to gain and/or maintain their formulary position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to market actions taken by private and government payers in the United States, policy makers in both of the major U.S. political parties have supported policies to lower drug costs. See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2022, the Inflation Reduction Act (IRA) was enacted and includes provisions requiring that (1) beginning in 2026, mandatory price setting be introduced in Medicare for certain drugs paid for under Parts B and D, whereby manufacturers must accept a price established by the government or face penalties on all U.S. sales (starting with 10 drugs in 2026, adding 15 in 2027 and 2028, and adding 20 in 2029 and subsequent years such that by 2031 approximately 100 drugs could be subject to such set prices); (2) starting in 2024, Medicare Part D be redesigned to cap beneficiary out-of-pocket costs and, beginning January 1, 2025, Federal reinsurance be reduced in the catastrophic phase (resulting in a shift and increase of such costs to Part D plans and manufacturers, including by requiring manufacturer discounts on certain drugs); and (3) beginning October 1, 2022, manufacturers now owe rebates on drugs reimbursed under Medicare Part D if price increases outpace inflation, and beginning January 1, 2023, now owe rebates on drugs reimbursed under Medicare Part B if price increases outpace inflation. Although the IRA has passed, the environment remains dynamic, and the Administration and Congress are continuing to consider drug pricing reforms.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other potential policies cover a wide range of areas, including allowing the importation of drugs from other countries; increasing transparency in drug pricing; and using third-party value assessments to determine drug prices. The Infrastructure Investment and Jobs Act, signed into law on November 15, 2021, requires manufacturers of certain Part B&#8211;covered drugs packaged in single-use containers to give refunds to the government starting in 2023 for discarded amounts. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries other than the United States, government-sponsored healthcare systems are the primary payers for drugs and biologics. With increasing budgetary constraints and/or difficulty in understanding the value of medicines, governments and payers in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls, price referencing, therapeutic-reference pricing, increases in mandates, incentives for generic substitution and biosimilar usage and government-mandated price cuts. In this regard, many countries have health technology assessment organizations that use formal economic metrics such as cost-effectiveness to determine prices, coverage and reimbursement of new therapies; and these organizations are expanding in both established and emerging markets. Many countries also limit coverage to populations narrower than those specified on our product labels or impose volume caps to limit utilization. We expect that countries will continue taking aggressive actions to seek to reduce expenditures on drugs and biologics. Similarly, fiscal constraints may also affect the extent to which countries are willing to approve new and innovative therapies and/or allow access to new technologies. The EU is currently undergoing a review and possible revision of its pharmaceutical legislation, now scheduled to end in the first half of 2023, with implementation by 2025 or 2026. It is likely that this review will lead to proposals that will reduce intellectual property protection for new products, as well as change the reimbursement and regulatory landscape in ways that are difficult to predict at this point.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dynamics and developments discussed above create pressures on the pricing and potential usage of our products and on the industry. Given the diverse interests in play between payers, biopharmaceutical manufacturers, policy makers, healthcare providers and independent organizations, if and whether the parties involved can achieve alignment on the matters discussed above remain unclear, and the outcome of any such alignment is difficult to predict. We remain focused on pricing our products responsibly and delivering breakthrough treatments for unmet medical needs. Amgen is committed to working with the entire healthcare community to ensure continued innovation and to facilitate patient access to needed medicines. We do this by:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investing billions of dollars annually in R&amp;D;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing our medicines to reflect the value they provide;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partnering with payers to share risk and accountability for health outcomes;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing patient support and education programs; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">helping patients in financial need access our medicines; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">working with policy makers, patients and other stakeholders to establish a sustainable healthcare system with access to affordable care and in which patients and their healthcare professionals are the primary decision makers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guidelines and recommendations published by various organizations can reduce the use of our products.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_28"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing, Distribution and Raw Materials</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are a leader in the manufacture of biologics and that our manufacturing capabilities represent a competitive advantage. The products we manufacture consist of both biologics and small molecule drugs. The majority of our products are biologics that are produced in living cells and that are inherently complex due to naturally occurring molecular variations. Highly specialized knowledge and extensive process and product characterization are required to transform laboratory-scale processes into reproducible commercial manufacturing processes. Further, our expertise in the manufacture of biologics positions us well for leadership in the global biosimilars market. For additional information regarding manufacturing facilities, see Item&#160;2. Properties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been innovating our manufacturing facilities designed to extend our manufacturing advantage by optimizing our manufacturing network and/or by mitigating risks while continuing to ensure adequate supply of our products. For example, our licensed next-generation biomanufacturing plants operating in Singapore and West Greenwich, Rhode Island, incorporate multiple innovative technologies into a single facility. Next-generation biomanufacturing plants require smaller manufacturing footprints and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions. Within such plants, the equipment is portable and smaller, which provides greater flexibility and speed in the manufacture of different medicines simultaneously. This enables Amgen to respond to changing demands for its medicines with increased agility. The Singapore site also has a plant that has been approved by several agencies, including the FDA and EMA, to produce small molecule drugs for commercial manufacturing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal manufacturing network has commercial production capabilities for bulk manufacturing, formulation, fill, finish, tableting and device assembly. These activities are performed within the United States and its territory in our Puerto Rico, Rhode Island and California facilities as well as internationally in our Ireland, Netherlands and Singapore facilities. In addition, we use third-party contract manufacturers to supplement the capacity or capability of our commercial manufacturing network.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support our clinical trials, we manufacture product candidates primarily at our California facilities. We also use third-party contract manufacturers to supplement the capacity or capability of our overall clinical manufacturing network.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1A. Risk Factors&#160;for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate distribution centers in Puerto Rico, Kentucky, California and the Netherlands for worldwide distribution of the majority of our commercial and clinical products. We also use third-party distributors to supplement distribution of our products worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the manufacturing and distribution activities noted above, each of our manufacturing locations includes key manufacturing support functions such as quality control, process development, engineering, procurement, production scheduling and warehousing. Certain of those manufacturing and distribution activities are highly regulated by the FDA as well as international regulatory agencies. See Government Regulation&#8212;Regulation in the United States&#8212;Regulation of Manufacturing Standards.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Initiatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, we have been expanding capacity and advancing new innovations with multiple ongoing projects.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next-generation biomanufacturing plant at our West Greenwich, Rhode Island, campus, the first of its kind in the United States, has been approved by the FDA and EMA. This plant expands our capacity to manufacture certain products for U.S. and global markets, as we receive regulatory approval in those markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we broke ground for our newest biomanufacturing plant located in New Albany, Ohio. This final product assembly and packaging plant will support the growing demand for Amgen&#8217;s medicines in the United States and will use state-of-the-art technologies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we broke ground for our new multi-product drug substance manufacturing facility in Holly Springs, North Carolina. The new plant will support both traditional stainless steel-fed batch manufacturing and next-generation single-use technologies, allowing flexibility in the production of multiple products in one plant.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen continues to embed environmental sustainability into the upfront design, development and execution of our new facilities. The new facilities under construction in North Carolina and Ohio contain many examples of environmental advances, including on-site photovoltaic renewable energy generation at both sites. We expect our North Carolina facility&#8217;s carbon, waste and water footprints to be substantially lower than those at a traditional drug substance manufacturing plant, and we expect lower footprints per unit produced as well at our Ohio facility compared with existing similar facilities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Raw Materials and Medical Devices</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain raw materials, medical devices (including companion diagnostics) and components necessary for the commercial and/or clinical manufacturing of our products are provided by and are the proprietary products of unaffiliated third-party suppliers, certain of which may be our only sources for such materials. We currently attempt to manage the risk associated with such suppliers by means of inventory management, relationship management and evaluation of alternative sources when feasible. We also monitor the financial condition of certain suppliers and their ability to supply our needs. See Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on third-party suppliers for certain of our raw materials, medical devices and components.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform various procedures to help authenticate the sources of raw materials, including intermediary materials used in the manufacture of our products; the procedures include verification of country of origin and are incorporated into the manufacturing processes we and our third-party contract manufacturers perform.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To better ensure supply, Amgen has a risk mitigation strategy that uses a combination of methods, including multiple sources or backup inventory of critical raw materials. In response to the COVID-19 pandemic and as part of our ongoing business continuity efforts, we continue to closely monitor our inventory levels and have taken additional measures to mitigate against raw material supply interruption. See Item&#160;1A. Risk Factors&#160;for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation by government authorities in the United States and other countries is a significant factor in the production and marketing of our products and our ongoing R&amp;D activities. To clinically test, manufacture and market products for therapeutic use, we must satisfy mandatory procedures and safety and effectiveness standards established by various regulatory bodies. Compliance with these standards is complex, and failure to comply with any of these standards can result in significant implications. See Item 1A. Risk Factors for a discussion of factors, including global regulatory implications, that can adversely impact our development and marketing of commercial products.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation in the United States</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Public Health Service Act; the FDCA; and the regulations promulgated thereunder as well as other federal and state statutes and regulations govern, among other things, the production, research, development, testing, manufacture, quality control, labeling, storage, record keeping, approval, advertising, promotion and distribution of our products in addition to the reporting of certain payments and other transfers of value to healthcare professionals and teaching hospitals.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development and Product Approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug development in our industry is complex, challenging and risky, and failure rates are high. Product development cycles are typically very long&#8212;approximately 10 to 15 years from discovery to market. A potential new medicine must undergo many years of preclinical and clinical testing to establish its safety and efficacy for use in humans at appropriate dosing levels and with an acceptable risk&#8211;benefit profile. We continue to work toward reducing cycle times by applying our expertise in human genetics and innovation in technology, clinical trials and real-world evidence.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After laboratory analysis and preclinical testing in animals, we file an IND with the FDA to begin human testing. Typically, we undertake an FDA-designated three-phase human clinical testing program.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In phase 1, we conduct small clinical trials to investigate the safety and proper dose ranges of our product candidates in a small number of human subjects.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In phase 2, we conduct clinical trials to investigate side-effect profiles and the efficacy of our product candidates in a patient population larger than phase 1 but still relatively small, who have the disease or condition under study.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In phase&#160;3, we conduct clinical trials to investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA monitors the progress of each trial conducted under an IND and may, at its discretion, reevaluate, alter, suspend or terminate the testing based on data accumulated to that point and the FDA&#8217;s risk&#8211;benefit assessment with regard to the patients enrolled in the trial. The results of preclinical and clinical trials are submitted to the FDA in the form of either a Biologics License Application for biologic products or a New Drug Application for small molecule products. We are not permitted to market or promote a new product until the FDA has approved our marketing application.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act authorized the FDA to approve biosimilars via a separate, abbreviated pathway. The pathway allows sponsors of a biosimilar to seek and obtain regulatory approval based in part on the nonclinical-trial and clinical-trial data of an originator product to which the biosimilar has been demonstrated to be &#8220;highly similar&#8221; and to have no clinically meaningful differences with regard to safety, purity and potency. The relevance of demonstrating &#8220;similarity&#8221; is that in many cases, biosimilars can be brought to market without conducting the full suite of clinical trials typically required of originators, because risk&#8211;benefit has previously been established. To preserve incentives for future innovation, the law establishes a period of exclusivity for originators&#8217; products, which in general prohibits biosimilars from gaining FDA approval based in part on reliance on or reference to the originator&#8217;s data in their application to the FDA for 12 years after initial FDA approval of the originator product. The law does not change the duration of patents granted on biologic products. As part of the implementation of the abbreviated approval pathway for biosimilars, the FDA released a number of guidance documents, some of which remain in draft form. See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Product Marketing and Promotion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA regulates the marketing and promotion of drug products. Our product promotions for approved product indications must comply with the statutory standards of the FDCA and the FDA&#8217;s implemented regulations and guidance. The FDA&#8217;s review of marketing and promotional activities encompasses but is not limited to direct-to-consumer advertising, healthcare-provider-directed advertising and promotion, sales representative communications to healthcare professionals, promotional programming and promotional activities involving electronic media. The FDA may also review industry-sponsored scientific and educational activities that make representations regarding product safety or efficacy in a promotional context. The FDA may take enforcement action against a company for promoting unapproved uses of a product or for other violations of the FDA&#8217;s advertising and labeling laws and regulations. Enforcement action may include product seizures, injunctions, civil or criminal penalties or regulatory letters, which may require corrective advertising or other corrective communications to healthcare professionals. Failure to comply with the FDA&#8217;s regulations also can result in adverse publicity or increased scrutiny of company activities by the U.S. Congress or other legislators. Additionally, as described below, such failure may lead to additional liability under U.S. healthcare fraud and abuse laws.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Manufacturing Standards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA regulates and inspects the equipment, facilities, laboratories and processes used in the manufacturing and testing of products prior to granting approval to market products. If after receiving approval from the FDA we make a material change in manufacturing equipment, location or process, additional regulatory review may be required. We also must adhere to current Good Manufacturing Practice regulations and product-specific regulations enforced by the FDA through its facilities inspection program. The FDA conducts regular, periodic visits to reinspect our equipment, facilities, laboratories and processes following an initial approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Combination Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Combination products are defined by the FDA as products composed of two or more regulated components (e.g., a biologic and/or drug and a device). Biologics/drugs and devices each have their own regulatory requirements, and combination products may have additional requirements. A number of our marketed products meet this definition and are regulated under this framework, and we expect that a number of our pipeline product candidates will be evaluated for regulatory approval under this framework as well.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation outside the United States</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In EU countries as well as in the United Kingdom, Switzerland, Canada, Australia and Japan, regulatory requirements and approval processes are similar in principle to those in the United States.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, there are currently two potential tracks for seeking marketing approval for a product not authorized in any EU member state: a decentralized procedure and a centralized procedure. In the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">decentralized procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, identical applications for marketing authorization are submitted simultaneously to the national regulatory agencies. Regulatory review is led by one member state (the reference-member state), and its assessment&#8212;based on safety, quality and efficacy&#8212;is reviewed and approved (assuming there are no concerns that the product poses a serious risk to public health) by the other member states from which the applicant is seeking approval (the concerned-member states). The decentralized procedure leads to a series of single national approvals in all relevant countries. In the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">centralized procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is required of all products derived from biotechnology, a company submits a single Marketing Authorisation Application to the EMA, which conducts an evaluation of the dossier, drawing upon its scientific resources across Europe. If the drug product is proven to fulfill requirements for quality, safety and efficacy, the EMA&#8217;s CHMP adopts a positive opinion, which is transmitted to the EC for final decision on granting of the marketing authorization. Even though the EC generally follows the CHMP&#8217;s opinion, it is not bound to do so. Subsequent commercialization is enabled by country-by-country reimbursement approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, biosimilars are approved under a specialized pathway of the centralized procedure. As with the U.S. pathway, an applicant seeks and obtains regulatory approval for a biosimilar once the data exclusivity period for the original reference product has expired, relying in part on the data submitted for the originator product together with data evidencing that the biosimilar is &#8220;highly similar&#8221; with regard to quality, safety and efficacy to the original reference product authorized in the European Economic Area. See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other countries such as those in Latin America and the Middle East have review processes and data requirements similar to those of the EU and in some cases can rely on prior marketing approval from U.S. or EU regulatory authorities. The regulatory process in these countries may include manufacturing/testing facility inspections, testing of drug product upon importation and other domestic requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Asia Pacific, a number of countries such as China, Japan, South Korea and Taiwan may require local clinical-trial data for bridging purposes as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. In most of the Asian markets, registration timelines depend on marketing approval in the United States or the EU. In some markets in Asia, such as China, Indonesia and Thailand, regulatory timelines can be less predictable. The regulatory process may also include manufacturing/testing facility inspections, testing of drug product upon importation and other domestic requirements. Countries such as Australia and Japan have more-mature systems that would allow for submissions under more-competitive time frames. With regard to biosimilars, several of these countries have pathways to register biosimilars (e.g., Australia, India, Singapore, South Korea and Taiwan), and biosimilar products are already present on the markets (e.g., Australia and South Korea).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, such as Japan and those in the EU, medical devices may be subject to regulatory regimes whereby manufacturers must establish that their medical devices conform to essential requirements set out in the law for the particular device category. For example, in the EU, with limited exceptions, medical devices placed on the market must bear the Conformit&#233; Europ&#233;enne marking to indicate their conformity with legal requirements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Postapproval Phase</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After approval, we continue to monitor adverse events and product complaints reported following the use of our products through routine postmarketing surveillance and studies when applicable. We report such events to the appropriate regulatory agencies as required by local regulations for individual cases and aggregate reports. We proactively monitor (according to good pharmacovigilance practices) and ensure the implementation of signal detection, assessment and the communication of adverse events that may be associated with the use of our products. We also proactively monitor product complaints through our quality systems, which includes assessing our drug delivery devices for device complaints, adverse events and malfunctions. We may also be required by regulatory agencies to conduct further clinical trials on our marketed products as a condition of their approval or to provide additional information on safety and efficacy. Health regulators, including the FDA, have authority to mandate labeling changes to products at any point in a product&#8217;s life cycle based on new safety information or as part of an evolving label change to a particular class of products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health regulators, including the FDA, also have authority both before and after approval to require that a company implement a risk management program for a product to ensure that the benefits of the drug outweigh the risks. Each risk management program is unique and varies depending on the specific factors required. In the United States, such a risk management program is known as a REMS, and we currently have REMSs for Prolia, Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and BLINCYTO.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Regulation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various laws pertaining to healthcare fraud and abuse, including antikickback laws and false-claims laws. Antikickback laws make it illegal to solicit, offer, receive or pay any remuneration in exchange for or to induce the referral of business, including the purchase or prescribing of a particular drug that is reimbursed by a state or federal program. False-claims laws prohibit knowingly and willingly presenting or causing to be presented for payment to third-party payers (including Medicare and Medicaid) any claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as by the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid). Liability under false-claims laws may also arise when violation of certain laws or regulations related to the underlying product (e.g., a violation regarding improper promotional activity or unlawful payments) contributes to the submission of a false claim.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2019, we entered into a settlement agreement with the DOJ and the OIG of the HHS to settle certain allegations related to our support of independent charitable organizations that provide patients with financial assistance to access medicines. Additionally, we entered into a corporate integrity agreement that requires us to both maintain a corporate compliance program and undertake a set of defined corporate integrity obligations for a period of five years. Due to the breadth of the statutory provisions and the absence of guidance in the form of regulations or court decisions addressing some of our practices, it is possible that in the future, our practices might be further challenged under antikickback or similar laws. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA arguably includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anticorruption laws and/or regulations. Failure by our employees, agents, contractors, vendors, licensees, partners or collaborators to comply with the FCPA and other anticorruption laws and/or regulations could result in significant civil or criminal penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations globally with regard to privacy and data protection. These laws and regulations involve the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environments regarding privacy and data protection are continually evolving and developing because these issues are subjects of increasing amounts of attention in countries globally. For example, we are subject to the EU&#8217;s GDPR, which became effective on May 25, 2018; the CCPA, which became effective on January 1, 2020; the California Privacy Rights Act of 2020, which amended the CCPA and became effective on January 1, 2023; and China&#8217;s Personal Information Protection Law, which became effective on November 1, 2021. Other jurisdictions where we operate have enacted or proposed similar legislation and/or regulations.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, Virginia, Colorado, Utah and Connecticut have all subsequently passed similar consumer privacy laws, which went into effect in Virginia as of January 1, 2023, and will go into effect in Colorado, Utah and Connecticut later in 2023. Failure to comply with these laws could result in significant penalties.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been and will continue to be subject to various other U.S. and foreign laws, rules and regulations, including provisions of the IRA. See Reimbursement section above.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_34"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development and Selected Product Candidates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our R&amp;D on novel human therapeutics for the treatment of serious illness. We capitalize on our strengths in human genetics, novel biology and protein engineering. We leverage our biologic expertise and seek to choose the optimal modality for a drug target and disease. And we use cutting-edge science and technology to study subtle biological mechanisms in search of therapies that will improve the lives of those who suffer from diseases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discovery research programs may therefore yield targets that lead to the development of human therapeutics delivered as large molecules, small molecules, other combination modalities or new modalities. We have reshaped our portfolio and have increasingly focused our efforts on human genetics when possible to enhance the likelihood of success.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since early 2021, efforts have been under way to control the COVID-19 pandemic. However, uncertainty remains as to the efficacy of these activities with respect to the ongoing trajectory of the pandemic. Challenges to vaccination efforts, new variants and other causes of virus spread may require governments to change restrictions and/or shutdown requirements in various geographies. As a result, we expect to see continued volatility for at least the duration of the pandemic as governments respond to current local conditions. With regard to our clinical trial activities, we are continuously monitoring COVID-19 infection rates, including changes from new variants; we are working to mitigate effects on future study enrollment in our clinical trials; and we are evaluating the impact in all relevant countries. We remain focused on supporting our active clinical sites in their providing care for patients and in our providing investigational drug supply.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, our R&amp;D expenses were $4.4 billion, $4.8 billion and $4.2 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have major R&amp;D centers in Thousand Oaks and San Francisco, California; Iceland; and the United Kingdom, as well as smaller research centers and development facilities globally. See Item&#160;2. Properties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial activities are conducted by both our internal staff and third-party contract clinical trial service providers. To increase the number and diversity of patients available for enrollment in our clinical trials, we have opened clinical sites and will continue opening clinical sites and enrolling patients in a number of geographic locations. See Government Regulation&#8212;Regulation in the United States&#8212;Clinical Development and Product Approval for a discussion of government regulation over clinical development. Also see Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors are actively engaged in R&amp;D in areas in which we have products or in which we are developing product candidates or new indications for existing products. For example, we compete with other clinical trials for eligible patients, which may limit the number of available patients who meet the criteria for certain clinical trials. The competitive marketplace for our product candidates is greatly dependent on the timing of entry into the market. Early entry may have important advantages in gaining product acceptance, thereby contributing to a product&#8217;s eventual success and profitability. Accordingly, we expect that in some cases, the relative speed with which we can develop products, complete clinical testing, receive regulatory approval and supply commercial quantities of a product to the market will be important to our competitive position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to product candidates and marketed products generated from our internal R&amp;D efforts, we acquire companies, acquire and license certain product and R&amp;D technology rights and establish R&amp;D arrangements with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D capabilities, product pipeline and marketed product base. In pursuing these R&amp;D arrangements and licensing or acquisition activities, we face competition from other pharmaceutical and biotechnology companies that also seek to license or acquire technologies, product candidates or marketed products from those entities performing the R&amp;D.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a selection of certain of our product candidates by phase of development in our therapeutic areas of focus as of January&#160;31, 2023, unless otherwise indicated. Additional product candidate information can be found on our website at www.amgen.com. (The website address is not intended to function as a hyperlink, and the information contained on our website is not intended to be a part of this filing.) The information in this section does not include other, nonregistrational clinical trials that we may conduct for purposes other than for submission to regulatory agencies for their approval of a new product indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may conduct nonregistrational clinical trials for various reasons, including to evaluate real-world outcomes or to collect additional safety information with regard to the use of products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investigational indication</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 3 programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interchangeability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bemarituzumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">GEJ adenocarcinoma</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ph-negative B-cell precursor acute lymphoblastic leukemia</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Male osteoporosis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weekly dosing for relapsed multiple myeloma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS/LUMYKRAS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advanced colorectal cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chemotherapy-induced thrombocytopenia</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genital psoriasis; Palmoplantar pustulosis </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rocatinlimab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic rhinosinusitis with nasal polyps; Eosinophilic esophagitis; Severe asthma</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 654</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational biosimilar to STELARA (ustekinumab)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 938</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational biosimilar to EYLEA (aflibercept)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 959</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational biosimilar to SOLIRIS (eculizumab)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 2 programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Efavaleukin alfa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Systemic lupus erythematosus; Ulcerative colitis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS/LUMYKRAS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">NSCLC monotherapy; Other solid tumors with KRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> mutations</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordesekimab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Celiac disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rozibafusp alfa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarlatamab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Small cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic obstructive pulmonary disease; Chronic spontaneous urticaria</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Obesity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 1 programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acapatamab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bemarituzumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSCLC and other tumors</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emirodatamab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acute myeloid leukemia</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latikafusp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarlatamab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuroendocrine prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asthma</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 119</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Small-cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 176</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hematologic malignancies</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 193</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 199</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 340</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 404</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 509</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMG 609</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 651</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colorectal cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 786</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Obesity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 794</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 994</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical trials investigate side-effect profiles and efficacy of product candidates in a larger patient population than phase 1, but still relatively small, who have the disease or condition under study.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical trials investigate the safety and proper dose ranges of product candidates in a small number of human subjects.</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Product Candidate Program Changes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 8, 2022, we had 13 phase 3 programs. As of January 31, 2023, we have 18 phase 3 programs, as five programs initiated phase 3 studies. These changes are set forth in the following table.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investigational indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LUMAKRAS/LUMYKRAS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advanced colorectal cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Initiated phase 3 study</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Olpasiran</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cardiovascular disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Initiated phase 3 study</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Otezla</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Palmoplantar pustulosis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Initiated phase 3 study</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rocatinlimab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Atopic dermatitis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Initiated phase 3 study</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TEZSPIRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Eosinophilic esophagitis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Initiated phase 3 study</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Product Candidate Patent Information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes our composition-of-matter patents that have been issued thus far for our product candidates in phase 3 development that have yet to be approved for any indication in the United States or the EU. Patents for products already approved for one or more indications in the United States or the EU but that are currently undergoing phase 3 clinical trials for additional indications have been previously described. See Marketing, Distribution and Selected Marketed Products&#8212;Patents.</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">General subject matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;expiration*</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bemarituzumab</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Olpasiran</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compounds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compounds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rocatinlimab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Patent expiration estimates are based on issued patents, which may be challenged, invalidated or circumvented by competitors. The estimates do not include any term adjustments, extensions or supplemental protection certificates that may be obtained in the future and thereby extend these dates. Corresponding patent applications are pending in other jurisdictions. Additional patents may be filed or issued and may provide additional exclusivity for the product candidate or its use.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phases 3 and 2 Program Descriptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides additional information about selected product candidates that have advanced into human clinical trials.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMJEVITA</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMJEVITA is a biosimilar to HUMIRA, which is a monoclonal antibody that inhibits binding of tumor necrosis factor (TNF) alpha to cell surface TNF receptor / TNF-alpha.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bemarituzumab</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced gastroesophageal junction (GEJ) adenocarcinoma.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLINCYTO</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BLINCYTO is an anti-CD19 x anti-CD3 BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> molecule. It is being investigated in newly diagnosed adults aged 40 and older with Ph negative B-Cell precursor acute lymphoblastic leukemia (ALL).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efavaleukin alfa</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efavaleukin alfa is an interleukin (IL)-2 mutein Fc fusion protein. It is being investigated for the treatment of systemic lupus erythematosus and ulcerative colitis.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EVENITY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being evaluated as a treatment for male osteoporosis. EVENITY is being developed in collaboration with UCB.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KYPROLIS is a small molecule proteasome inhibitor. It is being investigated for weekly dosing in combinations with lenalidomide and dexamethasone for relapsed multiple myeloma.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUMAKRAS/LUMYKRAS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMAKRAS/LUMYKRAS is a KRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> small molecule inhibitor. It is being investigated as treatment for a variety of solid tumors, including NSCLC, colorectal cancer and other solid tumor cancers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with&#160;KRAS&#160;G12C&#8211;mutated advanced pancreatic cancer who received LUMAKRAS/LUMYKRAS.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with&#160;KRAS&#160;G12C&#8211;mutated advanced NSCLC who received LUMAKRAS/LUMYKRAS.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS/LUMYKRAS met its primary endpoint of PFS, demonstrating statistical significance and superiority over standard-of-care chemotherapy, intravenous docetaxel. The first randomized clinical trial for a KRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;inhibitor assessed the efficacy and safety of LUMAKRAS/LUMYKRAS in 345 previously treated patients with&#160;KRAS&#160;G12C&#8211;mutated NSCLC who had received at minimum, prior platinum-based doublet chemotherapy and checkpoint inhibitor therapy.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral LUMAKRAS/LUMYKRAS led to significantly superior PFS (primary endpoint) and a significantly higher ORR (a key secondary endpoint) in patients with&#160;KRAS&#160;G12C&#8211;mutated NSCLC, compared with intravenous chemotherapy, docetaxel.&#160;We also announced updated data from its Phase 1b CodeBreaK 101 study, one of the most comprehensive global clinical development programs in patients with&#160;KRAS&#160;G12C&#8211;mutated colorectal cancer. These data show that combining LUMAKRAS/LUMYKRAS with Vectibix,&#160;Amgen's monoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody, demonstrated encouraging efficacy and safety.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nplate</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nplate is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of chemotherapy-induced thrombocytopenia (CIT).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Olpasiran</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Olpasiran is an siRNA that lowers Lp(a). It is being investigated in phase 3 for the treatment of ASCVD.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we announced positive end-of-treatment data from the Phase 2 OCEAN(a)-DOSE study evaluating olpasiran in adult patients with Lp(a) levels over 150 nmol/L and a history of ASCVD. The study was designed to assess safety, tolerability and optimal dose of olpasiran in adults with established ASCVD to reduce Lp(a).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ordesekimab</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordesekimab is a monoclonal antibody that inhibits the action of IL-15. It is being investigated for the treatment of celiac disease and is being developed in collaboration with Provention Bio, Inc.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla is a small molecule that inhibits PDE4. It is being investigated in phase 3 studies for the treatment of patients with moderate-to-severe genital psoriasis. It is also being investigated in a phase 2 study for treatment of palmoplantar pustulosis.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we announced results from two significant Phase 3 clinical studies of oral Otezla, demonstrating efficacy in pediatric patients with moderate-to-severe plaque psoriasis and in adults with moderate-to-severe genital psoriasis.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a human monoclonal antibody that inhibits PCSK9. It is being investigated as a treatment for ASCVD in high-risk patients with high LDL-C without prior heart attack or stroke.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we presented results from the Repatha OLE studies to the Phase 3 FOURIER CV outcomes trial. The studies were designed to assess the long-term safety and tolerability of Repatha in adults with clinically evident ASCVD. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rocatinlimab</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rocatinlimab is a monoclonal antibody that inhibits OX-40. It is being investigated for the treatment of moderate-to-severe atopic dermatitis. Rocatinlimab is being developed in collaboration with KKC.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rozibafusp alfa </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rozibafusp alfa is a novel antibody-peptide conjugate that simultaneously blocks the B-cell activating factor (BAFF) and inducible costimulatory ligand (ICOSL) activity. It is being investigated as a treatment for systemic lupus erythematosus.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tarlatamab</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarlatamab is a half-life extended (HLE) anti- DLL3 x anti-CD3 BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> molecule. It is being investigated for the treatment of small cell lung cancer.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEZSPIRE</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TEZSPIRE is a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin. It is being evaluated in phase 3 studies as a treatment for severe asthma and chronic rhinosinusitis with nasal polyps. It is also being investigated in phase 2 studies as a treatment for chronic obstructive pulmonary disease and chronic spontaneous urticaria. TEZSPIRE is being developed jointly in collaboration with AstraZeneca.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we announced results from a pooled post hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials that showed TEZSPIRE demonstrated reductions in the annualized asthma exacerbation rate (AAER) across biomarker subgroups of patients with severe asthma.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 3 study of TEZSPIRE in patients with eosinophilic esophagitis has started.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 133</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG 133 is a gastric inhibitory polypeptide receptor (GIPR) antagonist and glucagon-like peptide 1 (GLP-1) receptor agonist. It is being investigated for the treatment of obesity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 654</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABP 654, a biosimilar candidate to STELARA, is a monoclonal antibody that inhibits IL-12 and IL-23. It is being investigated in a phase 3 study for biosimilarity to STELARA. The reference-product primary conditions are psoriasis, psoriatic arthritis and Crohn&#8217;s disease.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA in adult patients with moderate-to-severe plaque psoriasis. The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and STELARA.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 938</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABP 938, a biosimilar candidate to EYLEA, is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein. It is being investigated in a phase 3 study for biosimilarity to EYLEA. The reference-product primary conditions are wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 959</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABP 959, a biosimilar candidate to SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5. It is being investigated in a phase 3 study for biosimilarity to SOLIRIS. The reference-product primary conditions are PNH and atypical hemolytic uremic syndrome (aHUS).</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced positive top-line results from the DAHLIA study, a randomized, double-blind, active-controlled, two-period crossover Phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS, compared with SOLIRIS in adult patients with PNH.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_37"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Relationships</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D capabilities, product pipeline and marketed-product base. These arrangements generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalties and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we generally require counterparties to execute confidentiality agreements upon commencement of a business relationship with us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we acquired an equity stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. For additional information regarding our equity investment in BeiGene, see Part IV&#8212;Note 9, Investments, to the Consolidated Financial Statements. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash and development services of up to $1.25 billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca plc</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with AstraZeneca for the development and commercialization of TEZSPIRE. Under our collaboration, both companies share global costs, profits and losses equally after payment by AstraZeneca of a mid-single-digit royalty to Amgen. AstraZeneca leads global development, and both Amgen and AstraZeneca jointly commercialize TEZSPIRE in North America. In North America, Amgen, as the principal, recognizes product sales of TEZSPIRE in the United States, and AstraZeneca, as the principal, recognizes product sales of TEZSPIRE in Canada. AstraZeneca leads commercialization for TEZSPIRE outside North America. Amgen manufactures and supplies TEZSPIRE worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UCB</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with UCB for the development and commercialization of EVENITY. Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe and China (excluding Hong Kong). Amgen, as the principal, leads commercialization for EVENITY and recognizes product sales in all other territories, including the United States. Global development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial information about our significant collaborative arrangements, see Part IV&#8212;Note 8, Collaborations, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen&#8217;s approach to human capital resource management starts with our mission to serve patients. We strive to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. The way we approach our business is guided by our Amgen Values:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#0063c3;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amgen Values</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Be Science-Based</span></div></td><td colspan="3" style="border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compete Intensely and Win</span></div></td><td colspan="3" style="border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Create Value for Patients, Staff and Stockholders</span></div></td><td colspan="3" style="border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Be Ethical</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trust and Respect Each Other</span></div></td><td colspan="3" style="border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ensure Quality</span></div></td><td colspan="3" style="border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Work in Teams</span></div></td><td colspan="3" style="border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Collaborate, Communicate and Be Accountable</span></div></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our staff are also guided by the Company&#8217;s Code of Conduct, which is designed to help every person who does business on our behalf worldwide (including all staff, management, consultants, contract workers and temporary workers) to understand what is expected of them.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry exists in a complex regulatory and reimbursement environment. The unique demands of our industry, together with the challenges of running an enterprise focused on the discovery, development, manufacture and commercialization of innovative medicines, requires a highly engaged and committed workforce.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Amgen had approximately 25,200 staff members in over 50 countries, and we have had relatively low global turnover rates compared to available industry information. We also supplement our workforce with independent contractors, contingent workers and temporary workers, as needed. Outside of the United States, some of our employees are represented by unions or works councils. We consider our staff relations to be good, supported by regular assessments of staff engagement surveys on a wide range of topics (including flexible work environments, diversity, inclusion and belonging, and maintaining a culture of compliance). We discuss the results of these surveys with our workforce and our Board of Directors. Reflecting our staff members&#8217; desire to retain flexibility to work virtually as COVID-19 related restrictions eased and sites became more accessible, we implemented a flexible workspace initiative that enables many employees to work together with their manager to determine the location that best enables their work at hand, supporting virtual work as well as coming on site.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation, Benefits and Development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to employee compensation and benefits is designed to deliver cash, equity and benefit programs that are competitive with those offered by leading companies in the biotechnology and pharmaceutical industries, and to attract, motivate and retain talent with a focus on encouraging performance, promoting accountability and adherence to Company values and alignment with the interests of the Company&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our base pay program aims to compensate staff members relative to the value of the contributions of their role, which takes into account the skills, knowledge and abilities required to perform each position, as well as the experience brought to the job. We also provide annual incentive programs to reward our staff in alignment with achievement of Company-wide goals that are established annually and designed to drive aspects of our strategic priorities that support and advance our strategy across our Company. The majority of our staff members are also eligible for the grant of equity awards under our long-term incentive program that are designed to align the interests of our staff members with those of our shareholders. For senior level staff, a significant proportion of equity award value is based on company performance.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All staff also participate in a regular performance measurement process through which staff receive performance and development feedback, and pay is aligned to performance. The Amgen Values and leadership behaviors are an integral part of the performance assessments of our staff members, and these evaluations serve as an important information tool and basis for compensation decisions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support the development of our staff, we provide a variety of programs, including leadership development programs, classroom-based and virtual instructor-led courses, and self-paced learning options as well as mentoring, networking and coaching opportunities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit programs are also generally broad-based, promote health and overall well-being and emphasize saving for retirement. All regular U.S. staff members are eligible to participate in the same core health and welfare and retirement savings plans. Other U.S. employee benefits include medical plans, dental plans, adoption assistance, paid parental leave programs, access to childcare, employee assistance programs, employee stock purchase plan, flexible spending accounts, life, long-term care and business travel accident insurance, short and long-term disability benefits, wellness benefits and work-life resources and referrals. Comparable programs and benefits are available globally, with the same health and well-being intent, consistent with statutory requirements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation and Management Development Committee provides oversight of our compensation plans, policies and programs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safety and Wellness and Our Response to the Evolving COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Creating a safe and healthy workplace for our staff is an important priority at Amgen. Our goal is to have a world class safety record through safety leadership, risk management practices and integrating safety throughout our business processes. To foster our safety culture, we implement a comprehensive safety program and reinforce desired safety behaviors, driving to understand and mitigate the root cause of safety incidents and manage and control variability. We use leading indicators to assess the effectiveness of our safety programs and make course corrections as needed. Additionally, we perform formal executive management review of functional safety performance for Operations, Global Commercial Operations and R&amp;D on a quarterly basis with a focus on identifying early signals and taking action to drive continuous improvement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, in response to the evolving requirements of the COVID-19 pandemic, to continue to maintain staff safety while enabling greater flexibility for Amgen sites and enhance efficiencies, we began shifting to a decentralized model for COVID-19 decision-making, empowering our local teams to adjust COVID-19 safety guidance for their individual sites or regions (such as the use of masks and other personal protective equipment, occupancy limits, and temperature check and testing, based on local regulations and risk assessments of local epidemiology criteria). We will continue to learn and adapt this approach as needed for the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Corporate Responsibility and Compliance Committee provides general oversight of our safety programs and initiatives, while our Board of Directors, as a whole, has overseen our specific responses to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Inclusion and Belonging</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that a diverse and inclusive culture fosters innovation, which supports our ability to serve patients. Further, we also believe our global presence is strengthened by having a workforce that reflects the diversity of the patients we serve. It is with these beliefs in mind that we have continued to strengthen and grow our culture of diversity, inclusion and belonging. Our Diversity, Inclusion and Belonging Council is led by our executive leadership and is responsible for overseeing our strategy to further a diverse and inclusive workplace. We offer a variety of diversity, inclusion and belonging training and learning programs and have continued to launch enhanced tools and resources that guide staff on the role they play in creating diversity, inclusion and belonging throughout the organization. Further, we continue to incorporate diversity, inclusion and belonging considerations into our business operations, including clinical trial design, procurement and site selection.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of Amgen&#8217;s Employee Resource Groups is sponsored by senior executive leadership. Our Employee Resource Groups promote leadership, development and belonging for members while also working to impact our business by leading business initiatives and providing diverse perspectives and experience. In 2022, Amgen launched its newest global Employee Resource Group called Recognition of Indigenous Peoples, Values and Environmental Resources, or RIVER, to share and continue the traditions, values and culture of Indigenous people.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#0063c3;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Global Employee Resource Groups</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Asian Association (AAA)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Black Employee Network (ABEN)</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ability Bettered through Leadership and Education (ABLE), a resource group for those with disabilities, visible and invisible, including those conditions also experienced by the patients that Amgen serves</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Early Career Professionals (AECP)</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen International Network (AIN)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Latin Employee Network (ALEN)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen LGBTQ and Allies Network (PRIDE)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen South Asian Network (ASAN)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Veterans Employees Network (AVEN)</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Recognition of Indigenous Peoples, Values and Environmental Resources (RIVER)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women Empowered to be Exceptional (WE2)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women in STEM Enrichment (WISE)</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on the successful adoption of our 2021 ESG goal under our annual incentive plan, we are driving leadership ownership and accountability for diversity, inclusion and belonging deeper in the organization with an enhanced ESG goal for 2022 designed to advance our progress on key ESG initiatives, including by expanding the number of leaders accountable for establishing, documenting and executing on diversity, inclusion and belonging action plans.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, women comprised over 52% of our global workforce, and ethnic minorities accounted for approximately 52% of our U.S. and Puerto Rico-based workforce. In areas of underrepresentation, we develop plans with a goal of bringing our representation in line with availability. We engage in outreach efforts to attract, retain and advance more women and minorities in our workforce. For example, we have worked to enhance our diverse candidate recruiting pool by developing relationships with organizations that can serve as a source of diverse candidates, such as the National Black MBA Association and Society of Women in Engineering, as well as historically black colleges and universities. In 2021, a fellowship program between Amgen and Howard University was established to expand the talent pool and diversify ranks in research and development. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are a founding member of OneTen, a coalition of the world&#8217;s largest, best-known companies, that aims to hire one million Black Americans (with a specific focus on those without four-year college degrees) into good-paying, family-sustaining jobs over the next ten years. Amgen is taking a leadership role in the greater Los Angeles region, where the company is headquartered, to help expand the coalition of OneTen organizations that share our desire to offer opportunities to diverse talent, and we developed an in-house apprenticeship program in support of our OneTen commitment. Other examples of actions that we are taking in this area include increased investment and participation in the Healthcare Businesswomen&#8217;s Association (a global organization focused on development and business networking for women in healthcare) and the UCLA Anderson School of Management leadership advancement programs for women and underrepresented talent.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2021 Consolidated EEO-1 Report can be viewed on our website at www.amgen.com (the website address is not intended to function as a hyperlink, and the information contained in our website is not intended to be a part of this filing).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022, our Compensation and Management Development Committee oversaw our labor and employment policies, programs and initiatives, including those relating to diversity, inclusion and belonging.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about Our Executive Officers</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The executive officers of the Company as of February&#160;9, 2023, are set forth below. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Robert A. Bradway, age 60, has served as a director of the Company since 2011 and Chairman of the Board of Directors since 2013. Mr. Bradway has been the Company&#8217;s President since 2010 and Chief Executive Officer since 2012. From 2010 to 2012, Mr. Bradway served as the Company&#8217;s President and Chief Operating Officer. Mr. Bradway joined the Company in 2006 as Vice President, Operations Strategy, and served as Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior to joining the Company, Mr. Bradway was a Managing Director at Morgan Stanley in London, where, beginning in 2001, he had responsibility for the firm&#8217;s banking department and corporate finance activities in Europe. Mr. Bradway has been a director of The Boeing Company, an aerospace company and manufacturer of commercial airplanes, defense, space and securities systems, since 2016. He has served on the board of trustees of the University of Southern California since 2014. From 2011 to 2017, Mr. Bradway was a director of Norfolk Southern Corporation, a transportation company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Murdo Gordon, age 56, became Executive Vice President, Global Commercial Operations, in 2018. Prior to joining the Company, Mr. Gordon was Chief Commercial Officer at Bristol Myers Squibb Company (BMS), a pharmaceutical company, from 2016 to 2018. Mr. Gordon served as Head of Worldwide Markets at BMS from 2015 to 2016. Prior to this, Mr. Gordon served in a variety of leadership roles at BMS for more than 25 years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Jonathan P. Graham, age 62, became Executive Vice President, General Counsel and Secretary in 2019. Mr. Graham joined the Company in 2015. From 2015 to 2019, Mr. Graham was Senior Vice President, General Counsel and Secretary. Prior to joining Amgen, from 2006 to 2015, Mr. Graham was Senior Vice President and General Counsel at Danaher Corporation. From 2004 to 2006, Mr. Graham was Vice President, Litigation and Legal Policy, at General Electric Company (GE). Prior to GE, Mr. Graham was a partner at Williams &amp; Connolly LLP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Peter H. Griffith, age 64, became Executive Vice President and Chief Financial Officer in 2020. Mr. Griffith joined the Company in 2019 as Executive Vice President, Finance. Prior to joining Amgen, Mr. Griffith was President of Sherwood Canyon Group, LLC, a private equity firm. From 1997 to 2019, Mr. Griffith was a partner at EY, an accounting and professional services firm, and served in a variety of senior leadership roles, with his last position being Global Vice Chair, Corporate Development. Prior to EY, Mr. Griffith was a Managing Director and head of the investment banking division of Wedbush Securities Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Nancy A. Grygiel, age 55, became Senior Vice President and Chief Compliance Officer in 2020. Ms. Grygiel joined the Company in 2015. From 2016 to 2020, Ms. Grygiel was Vice President, Compliance. Prior to joining Amgen, from 2011 to 2015, Ms. Grygiel served as Vice President, Compliance, Corporate &amp; International, at Allergan, Inc. (Allergan). Prior to Allergan, Ms. Grygiel held several management positions at Mylan Pharmaceuticals, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Rachna Khosla, age 50, became Senior Vice President, Business Development, in 2021. Ms. Khosla joined the Company in 2013 as Corporate Development Director. From 2018 to 2021, Ms. Khosla was Vice President, Business Development, and from 2016 to 2018, was Executive Director, Business Development. Prior to joining the Company, Ms. Khosla was a Director at Lazard Ltd. (Lazard) responsible for healthcare mergers and acquisitions. Prior to Lazard, Ms. Khosla had various roles at Credit Suisse Group AG, Sanofi Aventis, Aventis Capital, J.P. Morgan Chase &amp; Co., and Salomon Brothers, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Derek Miller, age 50, became Senior Vice President, Human Resources, in 2022. Mr. Miller joined the Company in 2003 and has held human resources leadership roles supporting each of the Company&#8217;s major business functions. From 2020 to 2022, Mr. Miller was Vice President, Global Total Rewards, and from 2018 to 2020, was Vice President, Human Resources. From 2015 to 2018, Mr. Miller was an Executive Director, Human Resources. Prior to 2015, Mr. Miller served as a Senior Manager in the Human Resources organization, before his promotion to Director, Human Resources, and then to Strategy Director.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. David M. Reese, age 60, became Executive Vice President, R&amp;D, in 2018. Dr. Reese joined the Company in 2005 and has held leadership roles in development, medical sciences and discovery research. Dr. Reese was Senior Vice President, Translational Sciences and Oncology, from 2017 to 2018 and Senior Vice President, Translational Sciences, from 2015 to 2017. Prior to joining Amgen, Dr. Reese was director of Clinical Research at the Breast Cancer International Research Group from 2001 to 2003 and a cofounder, president and chief medical officer of Translational Oncology Research International, a not-for-profit academic clinical research organization, from 2003 to 2005. Dr. Reese previously served on the faculty at the University of California, Los Angeles and the University of California, San Francisco.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Esteban Santos, age 55, became Executive Vice President, Operations, in 2016. Mr. Santos joined the Company in 2007 as Executive Director, Manufacturing Technologies. From 2013 to 2016, Mr. Santos was Senior Vice President, Manufacturing. From 2008 to 2013, Mr. Santos held a number of Vice President roles at the Company in engineering, manufacturing, site operations and drug product. Prior to joining the Company, Mr. Santos served as Site General Manager of Johnson &amp; Johnson&#8217;s (J&amp;J) Cordis operation in Puerto Rico. Prior to J&amp;J, Mr. Santos held several management positions in GE&#8217;s industrial and transportation businesses.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_46"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Area Financial Information</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial information concerning the geographic areas in which we operate, see Part IV&#8212;Note 3, Revenues, and Note 11, Property, plant and equipment, to the Consolidated Financial Statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_49"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Information</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about us is available on our website at www.amgen.com. We make available on our website, free of charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with or furnish it to the U.S. Securities and Exchange Commission (SEC). In addition, we have previously filed registration statements and other documents with the SEC. Any document we file may be inspected without charge at the SEC&#8217;s website at www.sec.gov. (These website addresses are not intended to function as hyperlinks, and the information contained in our website and in the SEC&#8217;s website is not intended to be a part of this filing.)</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_52"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management&#8217;s assumptions. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties our business faces. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Economic Conditions and Operating a Global Business, Including During the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">A breakdown of our information technology systems, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Government Regulations and Third-Party Policies</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Guidelines and recommendations published by various organizations can reduce the use of our products.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our business may be affected by litigation and government investigations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Competition</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our products face substantial competition and our product candidates are also likely to face substantial competition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation. </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Concentration of sales at certain of our wholesaler distributors and consolidation of private payers may negatively affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Research and Development</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may not be able to develop commercial products despite significant investments in R&amp;D.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our current products and products in development cannot be sold without regulatory approval.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Some of our pharmaceutical pipeline and our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sales of our products.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Operations</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We rely on third-party suppliers for certain of our raw materials, medical devices and components.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The effects of global climate change and related natural disasters could negatively affect our business and operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our stock price is volatile.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO ECONOMIC CONDITIONS AND OPERATING A GLOBAL BUSINESS, INCLUDING DURING THE COVID-19 PANDEMIC</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The novel coronavirus identified in late 2019, SARS-CoV-2, which causes the disease known as COVID-19, is an ongoing global pandemic that has resulted in public and governmental efforts to contain or slow the spread of the disease, including widespread shelter-in-place orders, social distancing interventions, quarantines, travel restrictions and various forms of operational shutdowns. The COVID-19 pandemic and the resulting measures implemented in response to the pandemic are adversely affecting, and are expected to continue to adversely affect, our business (including our R&amp;D, clinical trials, operations, manufacturing, supply chains, distribution systems, product development and sales activities), the business activities </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our suppliers, customers, third-party payers and our patients. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">see also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Due to the pandemic and these measures and their effects, we have experienced, and expect to continue to experience, unpredictable reductions in demand for certain of our products, exacerbated by COVID-19 surges resulting in repeated shutdowns and/or disruptions in certain geographies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and local, and international governmental policies and initiatives designed to reduce the transmission of COVID-19 also have resulted in the cancellation or delay of diagnostic, elective, specialty and other procedures and appointments to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. For example, an NPR/Harvard poll in 2021 found that, with hospitals crowded from COVID-19, one in five U.S. households had to delay care for serious illnesses. These measures and challenges will likely continue to varying degrees and have significantly reduced patient access to, and administration of, certain of our drugs. For example, Prolia requires administration by a healthcare provider in doctors&#8217; offices or other healthcare settings that are affected by COVID-19. The U.S. label for Prolia instructs healthcare professionals who discontinue Prolia to transition the patient to an alternative antiresorptive, including oral treatments that do not require administration by a healthcare provider. Further, as a result of COVID-19, oncology patients, in consultation with their doctors, may be selecting therapies that are less immunosuppressive or therapies that do not require administration in a hospital setting, potentially adversely affecting sales of certain of our products. Also, new patients have been, and are expected to continue to be, less likely to be diagnosed and/or to start therapeutics during the pandemic, and these effects, together with the lower treatment rates during the pandemic, have had, and are expected to continue to have, a cumulative negative effect on the commercial performance of our business. The decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact our business. As COVID-19 infection rates ebb and flow, we anticipate there could be periodic backlogs of patients seeking appointments with physicians relating to a variety of medical conditions, and as a result, patients seeking treatment with certain of our products may have to navigate lower provider capacity, and this lower provider capacity could have a continued adverse effect on our sales. Further, the effects of the COVID-19 pandemic may result in long-term shifts in preferences among healthcare professionals and patients toward treatments that do not require administration by healthcare professionals or visits to medical facilities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the pandemic continues, and if conditions worsen or if the duration of the pandemic extends significantly, we expect to experience additional adverse effects on our development, operational and commercial activities, customer purchases and our collections of accounts receivable. It remains uncertain the degree to which these adverse effects would impact our future operational and commercial activities, customer purchases and our collections as conditions begin to improve. There was a resurgence in COVID-19 infections in numerous jurisdictions in 2022, resulting in the reinstatement of stricter restrictions and shutdowns in a number of jurisdictions, including in the United States, Europe and Asia Pacific regions. It is expected that the pandemic will continue to ebb and flow, with different jurisdictions having higher levels of infections than others over the course of the pandemic. New variants of the SARS-CoV-2 virus have emerged, including the delta and omicron variants and its subvariants, and have been shown to be present in many geographies and appear to spread more easily and quickly than other variants. Further, although some studies suggest that antibodies generated with currently authorized vaccines may be effective against these variants, it remains uncertain whether currently available vaccines will retain their efficacy against future variants of the virus. Further, even while vaccine booster shots are available for certain patients, persistent vaccine hesitancy may result in under-vaccinated populations which may prolong the duration of the COVID-19 pandemic and continue to disrupt the availability of healthcare services to the patients we serve. Jurisdictions may implement, continue or reinstate border closures, impose or reimpose prolonged quarantines and further restrict travel and business activity. These measures could significantly affect our ability to support our operations and customers and the ability of our employees to get to their workplaces to discover, study, develop and produce our product candidates and products, disrupt the movement of our products through the supply chain, and further prevent or discourage patients from participating in our clinical trials, seeking healthcare services and the administration of certain of our products. The increased availability of remote working arrangements in response to the COVID-19 pandemic has expanded the pool of companies that can compete for our employees and employment candidates. Further, in connection with the global outbreak and spread of COVID-19 and in an effort to increase the wider availability of needed medical products, we or our suppliers may elect to, or governments may require us or our suppliers to, allocate manufacturing capacity (for example pursuant to the U.S. Defense Production Act) in a way that adversely affects our regular operations, customer relationships and financial results. In the United States, on January 21, 2021, President Biden issued an Executive Order instructing federal agencies to use all available legal authorities, including the Defense Production Act, to improve current and future pandemic response and biological threat preparedness. The rapid reallocation of resources for the treatment and prevention of COVID-19 (including the production of COVID-19 vaccines or related therapies, such as our agreement to contribute to the production of COVID-19 antibody therapies for Lilly) and/or disruptions and shortages in the global supply chain caused by the pandemic, could also result in increased competition for, or reduced availability of, materials or components used in the development, manufacturing, distribution or administration of our products. For example, during the second quarter of 2021, an industry-wide shortage of certain lab kit supplies necessary for some activities that support our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials has developed that we are actively monitoring and managing. We have also experienced challenges in obtaining certain COVID-19-related supplies, including COVID-19 antigen rapid test kits for our staff, as a result of high demand and limited supplies during the omicron variant surge. In addition, unpredictable increases in demand for certain of our products could exceed our capacity to meet such demand, which could adversely affect our financial results and customer relationships.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the volatile global economic conditions stemming from it may precipitate or amplify the other risks described in this &#8220;Risk Factors&#8221; section, which could materially adversely affect our business, operations and financial condition and results. For example, if a natural disaster or other potentially disruptive event occurs concurrently with the COVID-19 pandemic, such disaster or event could deplete our inventory levels and we could experience a disruption to our manufacturing or ability to supply our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapid development and fluidity of the pandemic precludes any prediction as to the ultimate effect of COVID-19 on us. The duration of the measures being taken by the authorities to mitigate against the spread of COVID-19 (including the distribution and/or availability of vaccines and boosters), and the extent to which such measures are effective, if at all, remain highly uncertain. The magnitude and degree of COVID-19&#8217;s adverse effect on our business (including our product development, product sales, operating results and resulting cash flows) and financial condition will be driven by the severity and duration of the pandemic, the pandemic&#8217;s effect on the United States and global economies and the timing, scope and effectiveness of federal, state, local and international governmental responses to the pandemic. If mitigation of the pandemic continues to require further shelter-in-place and shutdown orders and/or restrictions on individual and/or group conduct, any adverse effects of the COVID-19 pandemic will likely grow and could be enduring, and our business and financial position could be materially adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A breakdown of our information technology systems, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve our business objectives, we rely on sophisticated information technology systems, including software, mobile applications, cloud services and network-connected control systems, some of which are managed, hosted, provided or serviced by third parties. Internal or external events that compromise the confidentiality, integrity and availability of our systems and data may significantly interrupt the operation of our business, result in significant costs and/or adversely affect our reputation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology systems are highly integrated into our business, including our R&amp;D efforts, our clinical and commercial manufacturing processes and our product sales and distribution processes. Further, as the majority of our employees work remotely for some portion of their jobs in our hybrid work environment, our reliance on our and third-party information technology systems has increased substantially and is expected to continue to increase. The complexity and interconnected nature of our systems makes them potentially vulnerable to breakdown or other service interruptions. Upgrades or changes to our systems or the software that we use may result in the introduction of new cybersecurity vulnerabilities and risks. In 2022 we identified a number of security vulnerabilities introduced into our information systems as a result of flaws that we subsequently identified in software that we purchased and installed, and these flaws required that we apply emergency patches to certain of our systems. While we did not experience any significant adverse effects as a result of these vulnerabilities, there can be no assurance that we will timely identify and address any future vulnerabilities. Our systems are also subject to frequent perimeter network reconnaissance and scanning, phishing and other cyberattacks. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of harmful and virulent malware, including ransomware or other denials of service, that can be deployed through various means, including the software supply chain, e-mail, malicious websites and/or the use of social engineering. We have also experienced denial of service attacks against our network, and although such attacks did not succeed, there can be no assurance that our efforts to guard against the wide and growing variety of potential attack techniques will be successful in the future. Attacks such as those experienced by governmental entities (including those that approve and/or regulate our products, such as the EMA) and other multi-national companies, including some of our peers, could leave us unable to utilize key business systems or access or protect important data and could have a material adverse effect on our ability to operate our business, including developing, gaining regulatory approval for, manufacturing, selling and/or distributing our products. For example, in 2017, a pharmaceutical company experienced a cyberattack involving virulent malware that significantly disrupted its operations, including its research and sales operations and the production of some of its medicines and vaccines. As a result of the cyberattack, its orders and sales for certain products in certain markets were negatively affected. In late 2020, SolarWinds Corporation, a leading provider of software for monitoring and managing information technology infrastructure, disclosed that it had suffered a cybersecurity incident whereby attackers had inserted malicious code into legitimate software updates for its products that were installed by myriad private and government customers, enabling the attackers to access a backdoor to such systems. In 2022, Okta, Inc., a provider of software that helps companies manage user authentication, disclosed that several hundred of its corporate customers were vulnerable to a security breach that allowed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attackers to access Okta&#8217;s internal network. Although this breach did not have a significant effect on our business, there can be no assurance that a similar future breach would not result in a material adverse effect on our business or results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systems also contain and utilize a high volume of sensitive data, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials and/or personal information belonging to us, our staff, our patients, customers and/or other parties. In some cases, we utilize third-party service providers to process, store, manage or transmit such data, which may increase our risk. Intentional or inadvertent data privacy or security breaches (including cyberattacks) resulting from attacks or lapses by employees, service providers (including providers of information technology-specific services), business partners, nation states (including groups associated with or supported by foreign intelligence agencies), organized crime organizations, &#8220;hacktivists&#8221; or others, create risks that our sensitive data may be exposed to unauthorized persons, our competitors or the public. System vulnerabilities and/or cybersecurity breaches experienced by our third-party service providers have constituted a substantial share of the information security risks that have affected us. For example, in the first half of 2021, a supplier experienced a data breach in which an unauthorized third party acquired access to certain information provided to the supplier in the course of its provision of services to us, including business documents and certain personally identifiable patient information (not including social security or other financial or health insurance information). As required, we promptly notified the applicable state attorneys general and the individuals whose personally identifiable information was affected of this data breach at the supplier. In the third quarter of 2022, another service provider experienced a similar cybersecurity breach in which an attacker exfiltrated certain data (including non-significant Amgen data) from the service provider&#8217;s systems. Although these supplier data breaches have not resulted in material adverse effects on our business, there can be no assurance that a similar future cybersecurity incident would not result in a material adverse effect on our business or results of operations. Further, the timeliness of our awareness of a cybersecurity incident affects our ability to respond to and work to mitigate the severity of such events. For example, in 2020 and 2022, two of our vendors experienced cyberattacks and each initially reported to us that neither event involved our data. However, upon further investigation, they each subsequently informed us that the attackers had accessed limited, non-significant Amgen information. Although neither of these breaches had a significant adverse effect on our business, in the future we may again not receive timely reporting of cybersecurity events and such events could have a material adverse effect on our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyberattackers are also increasingly exploiting vulnerabilities in commercially available software from shared or open-source code. We rely on third party commercial software that may have such vulnerabilities, but as use of open-source code is frequently not disclosed, our ability to fully assess this risk to our systems is limited. For example, in December 2021, a remote code execution vulnerability was discovered in a widely used software library that is used in a variety of commercially available software and services. Although this vulnerability has not resulted in any significant adverse effects on us, there can be no assurances that a similar future vulnerability in the software and services that we use would not result in a material adverse effect on our business or results of operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and global government regulators, our business partners, suppliers with whom we do business, companies that provide us or our partners with business services and companies we have acquired or may acquire face similar risks, and security breaches of their systems or service outages could adversely affect our security, leave us without access to important systems, products, raw materials, components, services or information or expose our confidential data or sensitive personal information. For example, in 2019, two vendors that perform testing and analytical services that we use in developing and manufacturing our products experienced cyberattacks, and in April and September of 2020, vendors that provide us with information technology services and clinical data services, respectively, each experienced ransomware attacks. Although there was no breach of our systems, each of these incidents required us to disconnect our systems from those vendors&#8217; systems. While we were able to reconnect our systems following restoration of these vendors&#8217; capabilities without significantly affecting product availability, a more extended service outage affecting these or other vendors, particularly where such vendor is the single source from which we obtain the services, could have a material adverse effect on our business or results of operations. In addition, we distribute our products in the United States primarily through three pharmaceutical wholesalers, and a security breach that impairs the distribution operations of our wholesalers could significantly impair our ability to deliver our products to healthcare providers and patients.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have experienced system breakdowns, attacks and information security breaches, we do not believe such breakdowns, attacks and breaches have had a material adverse effect on our business or results of operations. We continue to invest in the monitoring, protection and resilience of our critical and/or sensitive data and systems. However, there can be no assurances that our efforts will detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks and/or breaches of our systems that could adversely affect our business and operations and/or result in the loss or exposure of critical, proprietary, private, confidential or otherwise sensitive data, which could result in material financial, legal, business or reputational harm to us or negatively affect our stock price. While we maintain cyber-liability insurance, our insurance is not sufficient to cover us against all losses that could potentially result from a service interruption, breach of our systems or loss of our critical or sensitive data.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally. For example, we are subject to the EU&#8217;s GDPR, which became effective in May 2018, and the CCPA, which became effective in January 2020, both of which provide for substantial penalties for noncompliance. The CCPA was amended in late 2020, to create the California Privacy Rights Act to create opt in requirements for the use of sensitive personal data and the formation of a new dedicated agency for the enforcement of the law, the California Privacy Protection Agency. Virginia, Colorado, Utah and Connecticut have all subsequently passed similar consumer privacy laws, which went into effect in Virginia as of January 1, 2023, and will go into effect in Colorado, Utah and Connecticut later in 2023. Other jurisdictions where we operate have passed, or continue to propose, similar legislation and/or regulations. For example, in China, the Personal Information Protection Law and the Data Security Law, which regulate data processing activities associated with personal and nonpersonal data, are in effect and build upon the existing Cybersecurity Law. Failure to comply with these current and future laws could result in significant penalties and reputational harm and could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue our expansion efforts in emerging markets around the world, through acquisitions and l</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">icensing transactions as well as through the development and introduction, both independently and through collaborations such as our collaboration with BeiGene, of our products in new markets, we face numerous risks to our business. There is no guarantee that our efforts and strategies to expand sales in emerging markets will succeed. Our international business, including in China and emerging market countries, may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability, including issues of geopolitical relations, the imposition of international sanctions in response to certain state actions and/or sovereign debt issues. Further, in 2022 and continuing through early 2023, the Asia Pacific region also experienced a surge of COVID-19 infections. While one country in the region initially responded to the surge by activating strict containment measures, in late 2022 that country abruptly reversed those measures, resulting in a significant COVID-19 outbreak, causing issues such as lack of capacity at hospitals that could lead to a local health emergencies. If relations between the United States and other governments deteriorate, our business and investments in such markets may also be adversely affected. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements including those previously utilized by companies we partner with or acquire in emerging markets. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our expansion efforts in China and emerging markets around the world are dependent upon the establishment of an environment that is predictable, navigable and supportive of biopharmaceutical innovation, sustained access for our products and predictable pricing controls. For example, China continues to strengthen regulations on the collection, use and transmission of Chinese human genetic resources, and has expanded regulations on the conduct of biotechnology R&amp;D activities in China. Between 2020 and 2022, we experienced delays in our applications to the Human Genetic Resources Administration of China that sought approval to conduct clinical trials in China. Our international operations and business may also be subject to less protective intellectual property or other applicable laws, diverse data privacy and protection requirements, changing tax laws and tariffs, trade restrictions or other barriers designed to protect industry in the home country against foreign competition, far-reaching antibribery and anticorruption laws and regulations and/or evolving legal and regulatory environments. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the ongoing armed conflict in Ukraine, the U.S. government, numerous state governments, the EU and other countries in which we conduct business have imposed a wide range of economic sanctions that restrict commerce and business dealings with Russia, certain regions of Ukraine and certain entities and individuals. This conflict may also precipitate or amplify the other risks described herein, including risks relating to cybersecurity, global economic conditions, clinical trials and supply chains, which could adversely affect our business, operations and financial condition and results.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand internationally, we are subject to fluctuations in foreign currency exchange rates relative to the U.S. dollar. While </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we have a program in place that is designed to reduce our exposure to foreign currency exchange rate fluctuations through foreign currency hedging arrangements, our hedging efforts do not completely offset the effect of these fluctuations on our revenues and earnings. Overall, the legal and operational challenges of our international business operations, along with government controls, the challenges of attracting and retaining qualified personnel and obtaining and/or maintaining necessary regulatory or pricing approvals of our products, may result in material adverse effects on our international product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO GOVERNMENT REGULATIONS AND THIRD-PARTY POLICIES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers continue to pursue initiatives to manage drug utilization and contain costs. Further, pressures on healthcare budgets from the pandemic, the economic downturn and inflation continue and are likely to increase across the markets we serve. Payers are increasingly focused on costs, which have resulted, and are expected to continue to result, in lower reimbursement rates for our products or narrower populations for which payers will reimburse. Continued intense public scrutiny of the price of drugs and other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which can have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced and/or signed into law that attempt to lower drug prices. These include legislation promulgated by the IRA that enables the U.S. government to set prices for certain drugs in Medicare, redesigns Medicare Part D benefits to shift a greater portion of the costs to manufacturers and enables the U.S. government to impose penalties if drug prices are increased at a rate faster than inflation. Additional proposals focused on drug pricing continue to be debated, and additional executive orders focused on drug pricing and competition are likely to be adopted and implemented in some form. Government actions or ballot initiatives at the state level also represent a highly active area of policymaking and experimentation, including pursuit of proposals that limit drug reimbursement under state run Medicaid programs based on reference prices or permitting importation of drugs from Canada. Such state policies may also eventually be adopted at the federal level.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict which or how many policy, regulatory, administrative or legislative changes may ultimately be, or effectively estimate the consequences to our business if, enacted and implemented. However, to the extent that payer actions further decrease or modify the coverage or reimbursement available for our products, require that we pay increased rebates or shift other costs to us, limit or affect our decisions regarding the pricing of or otherwise reduce the use of our products, such actions could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Changing U.S. federal coverage and reimbursement policies and practices have affected and are likely to continue to affect access to, pricing of and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our U.S. business relies on reimbursement from federal government healthcare programs and commercial insurance plans regulated by federal and state governments. See Part I, Item 1. Business&#8212;Reimbursement. Our business has been and will continue to be affected by legislative actions changing U.S. federal reimbursement policy. For example, in August 2022, the IRA was enacted and includes provisions requiring that: (1) beginning in 2026, mandatory price setting be introduced in Medicare for certain drugs paid for under Parts B and D, whereby manufacturers must accept a price established by the government or face penalties on all U.S. sales (starting with 10 drugs in 2026, adding 15 in 2027 and 2028, and adding 20 in 2029 and subsequent years such that by 2031 approximately 100 drugs could be subject to such set prices); (2) starting in 2024, Medicare Part D be redesigned to cap beneficiary out-of-pocket costs and, beginning January 1, 2025, Federal reinsurance be reduced in the catastrophic phase (resulting in a shift and increase of such costs to Part D plans and manufacturers, including by requiring manufacturer discounts on certain drugs); and (3) beginning October 1, 2022, manufacturers will owe rebates on drugs reimbursed under Medicare Part D if price increases outpace inflation, and beginning January 1, 2023, will owe rebates on drugs reimbursed under Medicare Part B if price increases outpace inflation. The IRA&#8217;s drug pricing controls and Medicare redesign is likely to have a material adverse effect on our sales (particularly for our products that are more substantially reliant on Medicare reimbursement), our business and our results of operations. However, as the degree of impact from this legislation on our business depends on a number of implementation decisions, the extent of the IRA&#8217;s impact on our sales and, in turn, our business remains unclear. Further, following the passage of the IRA, the environment remains dynamic, and in October 2022, the Administration issued an Executive Order on Lowering Prescription Drug Costs for Americans that calls for the HHS to issue a report within 90 days on Innovation Center models that would lower drug costs and promote access to innovative drug therapies for Medicare and Medicaid beneficiaries. </span><span style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Executive Order follows a 2021 Executive Order that included </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a timeline designed to increase competition in the healthcare sector, including by calling for the FDA to develop prescription drug importation programs and the FTC to apply greater scrutiny of anticompetitive activity. Responses to this order, including by the HHS, which released a report with drug pricing proposals that seek to promote competition, and by the USPTO, which has taken steps to strengthen coordination with the FDA to address impediments to generic drug and biosimilar competition. CMS policy changes and demonstration projects to test new care, delivery and payment models can also significantly affect how drugs, including our products, are covered and reimbursed. In September 2021, HHS released a plan to address drug pricing that included potential future mandatory models that link payment for prescription drugs and biologics to certain factors, including the overall cost of care.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks related to the reporting of pricing data that affects reimbursement of and discounts provided for our products. U.S. government price reporting regulations are complex and may require biopharmaceutical manufacturers to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we may be required to pay additional rebates and provide additional discounts. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Changing reimbursement and pricing actions in various states have negatively affected and may continue to negatively affect access to and have affected and may continue to affect sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, government actions or ballot initiatives can also affect how our products are covered and reimbursed and/or create additional pressure on our pricing decisions. Existing and proposed state pricing laws have added complexity to the pricing of drugs and may already be affecting industry pricing decisions. A number of states have adopted, and many other states are considering, drug importation programs or other pricing actions, including proposals designed to require biopharmaceutical manufacturers to report to the state proprietary pricing information or provide advance notice of certain price increases. For example, a California law requires biopharmaceutical manufacturers to notify health insurers and government health plans at least 60 days before scheduled prescription drug price increases that exceed certain thresholds. Similar laws exist in Oregon and Washington. Additional proposals directed at Medicaid seek to penalize manufacturers for pricing drugs above a certain threshold or limit spending on biopharmaceutical products. States are also seeking to change the way they pay for drugs for patients covered by state programs. New York has established a Medicaid drug spending cap, and Massachusetts implemented a new review and supplemental rebate negotiation process. Six states (Colorado, Maine, New Hampshire, Maryland, Oregon and Washington) have enacted laws that establish Prescription Drug Affordability Boards (PDABs) to study drug prices and identify drugs that pose affordability challenges, and in three states (Colorado, Maryland and Washington) include authority for the state PDAB to set upper payment limits on certain drugs in state regulated plans. Other states may consider implementing similar policies and laws. Additionally, Colorado, Florida, Maine, New Hampshire, New Mexico and Vermont have enacted laws, and several other states have proposed bills, to implement importation of drugs from Canada. The FDA has met with representatives from Colorado, Florida, Maine and New Mexico to discuss those states&#8217; proposed importation programs, and the FDA may be working towards approving such plans. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs. Ultimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;U.S. commercial payer actions have affected and may continue to affect access to and sales of our products </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payers, including healthcare insurers, PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, increasingly seek ways to reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient co-pay or coinsurance obligations and more significant limitations on patients&#8217; use of manufacturer commercial co-pay assistance programs. Further, government regulation of payers may affect these trends. For example, CMS finalized a policy for plan years starting on or after January 1, 2021 that has caused commercial payers to more widely adopt co-pay accumulator adjustment programs. Payers, including PBMs, have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, and to also impose restrictions on access to or usage of our products (such as Step Therapy), require that patients receive the payer&#8217;s prior authorization before covering the product, and/or chosen to exclude certain indications for which our products are approved. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet their utilization criteria, and these requirements have served to limit and may continue to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers (including PBMs that administer Medicare Part D prescription drug plans), and in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list price. However, affordability of patient out-of-pocket co-pay cost has limited and may continue to limit patient use. Further, despite these net and list price reductions, some payers have restricted, and may continue to restrict, patient access and may seek further discounts or rebates or take other actions, such as changing formulary coverage for Repatha, that could reduce our sales of Repatha. These factors have limited, and may continue to limit, patient affordability and use, negatively affecting Repatha sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in the United States, as of the beginning of 2023, the top five integrated health plans and PBMs controlled about 92% of all pharmacy prescriptions. This high degree of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidation among insurers and PBMs and other payers, including through integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers and has resulted in greater price discounts, rebates and service fees realized by those payers from our business. Each of CVS, Express Scripts and United Health Group (among the top five integrated health plans and PBMs), each have Rebate Management Organizations that further increase their leverage to negotiate deeper discounts. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse effect on our product sales, business and results of operations. Policy reforms advanced by Congress or the Administration that refine the role of PBMs in the U.S. marketplace could have downstream implications or consequences for our business and how we interact with these entities. For example, on June 7, 2022, the FTC launched an inquiry into the business practices of PBMs, and the results of such inquiry could have an effect on manufacturer interactions with PBMs, resulting in changes to access for certain medicines. See our &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of sales at certain of our wholesaler distributors and consolidation of private payers may negatively affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is also affected by policies implemented by private healthcare entities that process Medicare claims, including Medicare Administrative Contractors. For example, in the second quarter of 2022, several Medicare Administrative Contractors issued notice, in contravention of TEZSPIRE&#8217;s FDA approved labeling, that TEZSPIRE would be added to their &#8220;self-administered drug&#8221; exclusion lists. Although the Medicare Administrative Contractors subsequently removed TEZSPIRE from their exclusion lists, these exclusions, if reintroduced and/or implemented, would result in Medicare beneficiaries with severe asthma losing access to TEZSPIRE coverage under Medicare Part B and potentially also under Medicare Advantage.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, we expect countries will also continue to take actions to reduce their drug expenditures. See Part I, Item 1. Business&#8212;Reimbursement. Pressures to decrease drug expenditures may further intensify as the COVID-19 pandemic has strained government budgets and as economic conditions continue to worsen in certain regions, including in Europe where high inflation and the energy crisis relating to the Russia&#8211;Ukraine conflict are challenging the economies in that region. International reference pricing has been widely used by many countries outside the United States to control costs based on an external benchmark of a product&#8217;s price in other countries. International reference pricing policies can change quickly and frequently and may not reflect differences in the burden of disease, indications, market structures or affordability differences across countries or regions. Other expenditure control practices, including but not limited to the use of revenue clawbacks, rebates and percentage caps on price increases, are used in various foreign jurisdictions as well. In addition, countries may refuse to reimburse or may restrict the reimbursed population for a product when their national health technology assessments do not consider a medicine to demonstrate sufficient clinical benefit beyond existing therapies or to meet certain cost effectiveness thresholds. For example, despite the EMA&#8217;s approval of Repatha for the treatment of patients with established atherosclerotic disease, prior to 2020, the reimbursement of Repatha in France was limited to a narrower patient population (such as those with homozygous familial hypercholesterolemia (HoFH)) following a national health technology assessment. Many countries decide on reimbursement between potentially competing products through national or regional tenders that often result in one product receiving most or all of the sales in that country or region. Failure to obtain coverage and reimbursement for our products, a deterioration in their existing coverage and reimbursement or a decline in the timeliness or certainty of payment by payers to physicians and other providers has negatively affected, and may further negatively affect, the ability or willingness of healthcare providers to prescribe our products for their patients and otherwise negatively affect the use of our products or the prices we realize for them. Such changes have had, and could in the future have, a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guidelines and recommendations published by various organizations can reduce the use of our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies promulgate regulations and guidelines directly applicable to us and to our products. Professional societies, practice management groups, insurance carriers, physicians&#8217; groups, private health and science foundations and organizations involved in various diseases also publish guidelines and recommendations to healthcare providers, administrators and payers, as well as patient communities. Recommendations by government agencies or other groups and organizations may relate to such matters as usage, dosage, route of administration and use of related therapies. In addition, a growing number of organizations are providing assessments of the value and pricing of biopharmaceutical products, and even organizations whose guidelines have historically been focused on clinical matters have begun to incorporate analyses of the cost effectiveness of various treatments into their treatment guidelines and recommendations. Value assessments may come from private organizations that publish their findings and offer recommendations relating to the products&#8217; reimbursement by government and private payers. Some companies and payers have announced pricing and payment decisions based in part on the assessments of private organizations. In addition, government health technology assessment organizations in many countries make reimbursement recommendations to payers in their jurisdictions based on the clinical effectiveness, cost-effectiveness and service effects of new, emerging and existing medicines and treatments. Such health technology assessment organizations have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommended, and may in the future recommend, reimbursement for certain of our products for a narrower indication than was approved by applicable regulatory agencies or may recommend against reimbursement entirely. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such recommendations or guidelines may affect our reputation, and any recommendations or guidelines that result in decreased use, dosage or reimbursement of our products could have a material adverse effect on our product sales, business and results of operations. In addition, the perception by the investment community or stockholders that such recommendations or guidelines will result in decreased use and dosage of our products could adversely affect the market price of our common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income and other taxes in the United States and other jurisdictions in which we do business. As a result, our provision for income taxes is derived from a combination of applicable tax rates in the various places we operate. Significant judgment is required for determining our provision for income tax.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts, and such tax authorities (including the IRS) are becoming more aggressive in their audits and are particularly focused on such matters. In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#8211;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS administrative appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#8211;2012 that we received in May and July 2021 which seek to increase our U.S. taxable income for the years 2010&#8211;2012. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#8211;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#8211;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#8211;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#8211;2015 and asserts penalties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010&#8211;2012 and 2013&#8211;2015 Notices are without merit. We are contesting the 2010&#8211;2012 and 2013&#8211;2015 Notices through the judicial process. The cases were consolidated on December 19, 2022. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently also under examination by the IRS for the years 2016&#8211;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex tax matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse effect on the results of our operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations, Income Taxes, and Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes and results of operations in the future could be adversely affected by changes to our operating structure, changes in the mix of income and expenses in countries with differing tax rates, changes in the valuation of deferred tax assets and liabilities and changes in applicable tax laws, regulations or administrative interpretations thereof. The 2017 Tax Act is complex and a large volume of regulations and guidance has been issued and could be subject to different interpretations. We could face audit challenges to our application of the 2017 Tax Act. In addition, there are several upcoming provisions in the 2017 Tax Act, including increases in the tax rates on foreign earnings and export income scheduled to take effect at the end of 2025, that could result in an increase in our effective tax rate. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administration and Congress continue to discuss changes to existing tax law that could substantially increase the taxes we pay in the United States. Further, the OECD reached an agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. Some individual countries, including those in the EU, have proposed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legislation to implement the global minimum tax agreement. In other countries such as the United States, however, the implementation of the OECD agreement remains highly uncertain. If enacted, either by all OECD participants or unilaterally by individual countries, the agreement could result in tax increases or double taxation that could affect our United States or foreign tax liabilities. Changes to existing tax law in the United States, the U.S. territory of Puerto Rico or other jurisdictions, including the changes and potential changes discussed above, could result in tax increases where we do business and could have a material adverse effect on the results of our operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are involved in legal proceedings. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. Civil and criminal litigation is inherently unpredictable, and the outcome can result in costly verdicts, fines and penalties, exclusion from federal healthcare programs and/or injunctive relief that affect how we operate our business. Defense of litigation claims can be expensive, time consuming and distracting, and it is possible that we could incur judgments or enter into settlements of claims for monetary damages or change the way we operate our business, which could have a material adverse effect on our product sales, business and results of operations. In addition, product liability is a major risk in testing and marketing biotechnology and pharmaceutical products. We may face substantial product liability exposure in human clinical trials and for products we sell after regulatory approval. Product liability claims, regardless of their merits, could be costly and divert management&#8217;s attention and could adversely affect our reputation and the demand for our products. We and certain of our subsidiaries have previously been named as defendants in product liability actions for certain of our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in government investigations that arise in the ordinary course of our business. In recent years, there has been a trend of increasing government investigations and litigations against companies operating in our industry, both in the United States and around the world. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our business activities outside of the United States are subject to the FCPA and similar antibribery or anticorruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. We cannot ensure that all our employees, agents, contractors, vendors, licensees, partners or collaborators will comply with all applicable laws and regulations. On April 25, 2019, we entered into a settlement agreement with the DOJ and the OIG of the HHS to settle certain allegations relating to our support of independent charitable organizations that provide patients with financial assistance to access their medicines. As a result, we entered into a corporate integrity agreement with the OIG that requires us to maintain a corporate compliance program and to undertake a set of defined corporate integrity obligations for a period of five years. While we expect to fully comply with all of our obligations under the corporate integrity agreement, failure to do so could result in substantial penalties and potential exclusion from government healthcare programs. We may also see new government investigations of or actions against us citing novel theories of recovery. For example, prosecutors are placing greater scrutiny on patient support programs, including commercial copay assistance programs, and further enforcement actions and investigations regarding such programs could limit our ability to provide co-pay assistance to commercial patients. Greater scrutiny has also been placed on sponsorships, speaker programs and other arrangements where healthcare professionals receive remuneration, travel or other value to participate in certain events, and further enforcement actions could limit our ability to participate in such arrangements. Any of these results could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO COMPETITION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products face substantial competition and our product candidates are also likely to face substantial competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. We expect that our products and product candidates will compete with existing drugs, new drugs currently in development, drugs currently approved for other indications that may later be approved for the same indications as those of our products and drugs approved for other indications that are used off-label. Large pharmaceutical companies and generics manufacturers of pharmaceutical products have expanded into, and are expected to continue expanding into, the biotechnology field, and some pharmaceutical companies and generics manufacturers have formed partnerships to pursue biosimilars. With the proliferation of companies pursuing biopharmaceuticals, several of our biosimilar products have entered, and a number of our product candidates may enter, markets with one or more competitors or with competitors soon to arrive. In addition, some of our competitors may have technical, competitive or other advantages over us for the development of technologies and processes or greater experience in particular therapeutic areas, and consolidation among pharmaceutical and biotechnology companies can enhance such advantages. These advantages may make it difficult for us to compete with them successfully to discover, develop and market new products and for our current products to compete with new products or new product indications they may bring to market. As a result, our products have been competing and may continue to compete, and our product candidates may compete, against products or product candidates that offer higher rebates or discounts, lower prices, equivalent or superior efficacy, better safety profiles, easier administration, earlier market availability or other competitive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">features. If we are unable to compete effectively, this could reduce our sales, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and defend patent rights and other intellectual property rights that are important to the commercialization of our products and product candidates. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often involve complex legal, scientific and factual questions. Driven by cost pressures, efforts to limit or weaken patent protection for our industry are increasing. For example, the COVID-19 pandemic has resulted in increased interest in compulsory licenses, march-in rights or other governmental interventions, both in the United States and internationally, related to the procurement of drugs, and the World Trade Organization has agreed to a waiver of COVID-19 vaccine intellectual property protections through the Trade-Related Aspects of Intellectual Property Rights waiver process. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties have challenged and may continue to challenge, invalidate or circumvent our patents and patent applications relating to our products, product candidates and technologies. Challenges to patents may come from potential competitors or from parties other than those who seek to market a potentially-infringing product. In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not infringe our patents. For certain of our product candidates, there are third parties who have patents or pending patent applications that they may claim necessitate payment of a royalty or prevent us from commercializing these product candidates in certain territories. Patent disputes are frequent, costly and can preclude, delay or increase the cost of commercialization of products. We have been in the past, are currently and expect to be in the future, involved in patent litigation. These matters have included, and may in the future include, litigation with manufacturers of products that purport to be biosimilars of certain of our products for patent infringement and for failure to comply with certain provisions of the BPCIA. A determination made by a court, agency or tribunal concerning infringement, validity, enforceability, injunctive or economic remedy, or the right to patent protection, for example, are typically subject to appellate or administrative review. Upon review, such initial determinations may be afforded little or no deference by the reviewing tribunal and may be affirmed, reversed or made the subject of reconsideration through further proceedings. A patent dispute or litigation has not discouraged, and may not in the future discourage, a potential violator from bringing the allegedly infringing product to market prior to a final resolution of the dispute or litigation. The period from inception until resolution of a patent dispute or litigation is subject to the availability and schedule of the court, agency or tribunal before which the dispute or litigation is pending. We have been, and may in the future be, subject to competition during this period and may not be able to recover fully from the losses, damages and harms we incur from infringement by the competitor product even if we prevail. Moreover, if we lose or settle current or future litigations at certain stages or entirely, we could be subject to competition and/or significant liabilities, be required to enter into third-party licenses for the infringed product or technology or be required to cease using the technology or product in dispute. In addition, we cannot guarantee that such licenses will be available on terms acceptable to us, or at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the Hatch&#8211;Waxman Act, our products approved by the FDA under the FDCA have been, and may in the future be, the subject of patent litigation with generics competitors before expiry of the five-year period of data exclusivity provided for under the Hatch-Waxman Act and prior to the expiration of the patents listed for the product. Likewise, our innovative biologic products have been, and may in the future be, the subject of patent litigation prior to the expiration of our patents and, with respect to competitors seeking approval as a biosimilar or interchangeable version of our products, prior to the 12-year exclusivity period provided under the BPCIA. In addition, we have faced, and may in the future face, patent litigation involving claims that the biosimilar product candidates we are working to develop infringe the patents of other companies, including those that manufacture, market or sell the applicable reference products or who are developing or have developed other biosimilar versions of such products. Alternatively, patents held by other entities have contributed, and may in the future contribute, to a decision by us to not pursue all of the same labeled indications as are held by these companies. While we have attempted, and expect to continue to attempt, to challenge the patents held by other companies, our efforts may be unsuccessful. For examples of and information related to our patent litigation, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the existing patents on our products have expired or will soon expire. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Patents. As our patents expire, competitors are able to legally produce and market similar products or technologies, including biosimilars, which has had, and may continue to have, a material adverse effect on our product sales, business and results of operations. In addition, competitors have been, and may continue to be, able to invalidate, design around or otherwise circumvent our patents and sell competing products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics in most of the territories in which we operate, including the United States and Europe, and we expect to face increasing biosimilar and/or generics competition this year and beyond. Expiration or successful challenge of applicable patent rights or expiration of an applicable exclusivity period has accelerated such competition, and we expect to face more litigation regarding the validity and/or scope of our patents. Our products have also experienced greater competition from lower cost biosimilars or generics that come to market when branded products that compete with our products lose their own patent protection. To the extent that governments adopt more permissive regulatory approval standards and competitors are able to obtain broader or expedited marketing approval for biosimilars and generics, the rate of increased competition for our products could accelerate.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, biosimilars are evaluated for marketing authorization pursuant to a set of general and product class-specific guidelines. In addition, in an effort to spur biosimilar utilization and/or increase potential healthcare savings, some EU countries and some Canadian provinces have adopted, or are considering the adoption of, biosimilar uptake measures such as physician prescribing quotas or automatic pharmacy substitution of biosimilars for the corresponding reference products. Some EU countries impose automatic price reductions upon market entry of one or more biosimilar competitors. In September 2022, the EMA and the EU Heads of Medicines&#8217; Agencies (HMA) issued a joint statement providing that biosimilar medicines approved in the EU are &#8220;interchangeable&#8221; with their reference products and other biosimilars of the same reference product. This EMA-HMA statement could further contribute to the prescribing of biosimilars and to greater competition in Europe. While the degree of competitive effects of biosimilar competition differs between EU countries and between products, in the EU the overall use of biosimilars and the rate at which product sales of innovative products are being affected by biosimilar competition is increasing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the BPCIA authorizes the FDA to approve biosimilars via a separate, abbreviated pathway. See Item 1. Business&#8212;Government Regulation&#8212;Regulation in the United States&#8212;Approval of Biosimilars. In the United States, the FDA has approved numerous biosimilars, including biosimilar versions of Neulasta, EPOGEN and ENBREL, and a growing number of companies have announced that they are also developing biosimilar versions of our products. For example, six biosimilar versions of Neulasta are now approved in the United States, and we expect that other biosimilar versions of Neulasta may be marketed or receive approval in the future. Impact to our Neulasta sales has accelerated as additional competitors have launched. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. Manufacturers of biosimilars have attempted, and may in the future attempt, to compete with our products by offering lower list prices, greater discounts or rebates, or contracts that offer longer-term pricing or a broader portfolio of other products. Companies pursuing development of biosimilar versions of our products have challenged and may continue to challenge our patents well in advance of the expiration of our material patents. For examples of and information related to our biosimilars and generics patent litigation, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. biosimilar pathway includes the option for biosimilar products that meet certain criteria to be approved as interchangeable with their reference products. Some companies currently developing or already marketing biosimilars may seek to obtain interchangeable status from the FDA, which could potentially allow pharmacists to substitute those biosimilars for our reference products without prior approval from the prescriber in most states under state law. The FDA approved the first interchangeable biosimilar in 2021 and has subsequently granted interchangeability designations to three additional biosimilars. In 2019, the FDA issued draft guidance that provides that comparative immunogenicity studies will not generally be expected for biosimilar and interchangeable insulin products. This has opened the door for other product-specific guidance development and the removal of the expectation for certain studies, which may contribute to increased biosimilar competition for our innovative products. For example, in August 2022, the FDA designated a monoclonal antibody biosimilar as interchangeable without requiring a switching study to support the interchangeability determination. Further, in September 2022, the FDA indicated that while comparative clinical trials will continue to be a requirement for many biosimilar development programs, the agency is focused on reducing the need for them in the future through a range of statistical, analytical and pharmacologic approaches.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, critics of the 12-year exclusivity period in the biosimilar pathway law will likely continue to seek to shorten the data exclusivity period and/or to encourage the FDA to interpret narrowly the law&#8217;s provisions regarding which new products receive data exclusivity. In 2019, the Administration agreed to remove from the United States-Mexico-Canada Agreement a requirement for at least 10 years of data exclusivity for biologic products. Also, the FDA is considering whether subsequent changes to a licensed biologic would be protected by the remainder of the reference product&#8217;s original 12-year exclusivity period (a concept known in the generic drug context as &#8220;umbrella exclusivity&#8221;). If the FDA were to decide that umbrella exclusivity does not apply to biological reference products or were to make other changes to the exclusivity period, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this could expose us to biosimilar competition at an earlier time. There also have been, and may continue to be, legislative and regulatory efforts to promote competition through policies enabling easier generic and biosimilar approval and commercialization, including efforts to lower standards for demonstrating biosimilarity or interchangeability, limit patents that may be litigated and/or patent settlements, implement preferential reimbursement policies for biosimilars and pass new laws requiring more disclosure in the FDA&#8217;s Orange and Purple Books. For example, in 2021 the FDA sent a letter to the USPTO describing ways to strengthen coordination between the two agencies, offered training to help identify prior art, and seeking USPTO&#8217;s views on practices that extend market exclusivities, whether pharmaceutical patent examiners need additional resources, and the effect of post-grant challenges at the Patent Trial and Appeal Board on drug patents. The USPTO responded in July 2022 with a letter to the FDA stating that it is prepared to create formal mechanisms to collaborate with the FDA on patent issues that may affect the timing of generic and biosimilar entry. In January 2023, the USPTO held a joint listening session with the FDA on USPTO-FDA collaboration efforts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the expiration or loss of patent protection and/or applicable exclusivity for one of our products, we can lose the majority of revenues for that product in a very short period of time. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. Additionally, if one of our products is the subject of an FDA Written Request for pediatric studies and we are unable to adequately complete these studies, we may not obtain the pediatric exclusivity award that extends unexpired regulatory exclusivity for the product (and existing patents for a small molecule product) by an additional six months. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are unable to predict the precise effects of biosimilars and generics on our products, we are currently facing and expect to face greater competition in the United States, Europe and elsewhere as a result of biosimilar and generic competition and, in turn, downward pressure on our product prices and sales. This competition has had, and could increasingly have, a material adverse effect on our product sales, business and results of operations. State laws may also have an impact on our business. For example, California is the first state to have passed legislation, effective on January 1, 2020, against &#8220;pay for delay&#8221; settlements of patent infringement claims filed by manufacturers of generics or biosimilars where anything of value is given in exchange for settlement. Under this law, such settlement agreements are presumptively anticompetitive. The law may result in prolonged litigation and fewer settlements. Other states, including Connecticut, New York, Illinois and Minnesota, may adopt similar laws or a similar law could be adopted at the federal level.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of sales at certain of our wholesaler distributors and consolidation of private payers may negatively affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our distributors, customers and payers have substantial purchasing leverage, due to the volume of our products they purchase or the number of patient lives for which they provide coverage. The substantial majority of our U.S. product sales is made to three pharmaceutical product wholesaler distributors: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc. These distributors, in turn, sell our products to their customers, which include physicians or their clinics, dialysis centers, hospitals and pharmacies. Similarly, as discussed above, there has been significant consolidation in the health insurance industry, including that a small number of PBMs now oversee a substantial percentage of total covered lives in the United States. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three largest PBMs in the United States are now part of major health insurance providers. The growing concentration of purchasing and negotiating power by these entities has, and may continue to, put pressure on our pricing due to their ability to extract price discounts on our products, fees for other services or rebates, negatively affecting our bargaining position, sales and/or profit margins. In addition, decisions by these entities to purchase or cover less or none of our products in favor of competing products could have a material adverse effect on our product sales, business and results of operations due to their purchasing volume. Further, if one of our significant wholesale distributors encounters financial or other difficulties and becomes unable or unwilling to pay us all amounts that such distributor owes us on a timely basis, or at all, it could negatively affect our business and results of operations. In addition, if one of our significant wholesale distributors becomes insolvent or otherwise unable to continue its commercial relationship with us in its present form, it could significantly disrupt our business and adversely affect our product sales, our business and results of operations unless suitable alternatives are timely found or lost sales are absorbed by another distributor.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO RESEARCH AND DEVELOPMENT</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to develop commercial products despite significant investments in R&amp;D.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen invests heavily in R&amp;D. Successful product development in the biotechnology industry is highly uncertain, and very few R&amp;D projects yield approved and commercially viable products. Product candidates, including biosimilar product candidates, or new indications for existing products (collectively, product candidates) that appear promising in the early phases of development have failed to reach the market for a number of reasons, such as:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate did not demonstrate acceptable clinical trial results even though it achieved its primary endpoints and/or demonstrated positive preclinical or early clinical trial results, for reasons that could include changes in the standard of care of medicine or expectations of health authorities;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate was not effective or not more effective than currently available or potentially competitive therapies in treating a specified condition or illness;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate was not cost effective in light of existing or potentially competitive therapeutics;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate had harmful side effects in animals or humans;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the necessary regulatory bodies, such as the FDA or EMA, did not approve the product candidate for an intended use;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reimbursement for the product candidate is limited despite regulatory approval;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate was not economical for us to manufacture and commercialize;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">other parties had or may have had proprietary rights relating to our product candidate, such as patent rights, and did not let us sell it on reasonable terms, or at all;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we and certain of our licensees, partners, contracted organizations or independent investigators failed to effectively conduct clinical development or clinical manufacturing activities; </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the pathway to regulatory approval or reimbursement for product candidates was uncertain or not well-defined;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the biosimilar product candidate failed to demonstrate the requisite biosimilarity to the applicable reference product, or was otherwise determined by a regulatory authority to not meet applicable standards for approval; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a companion diagnostic device that is required with the use of a product candidate is not approved by the necessary regulatory authority.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have spent considerable time, energy and resources developing our expertise in human genetics and acquiring access to libraries of genetic information with the belief that genetics could meaningfully aid our search for new medicines and help guide our R&amp;D decisions and investments. We have focused our R&amp;D strategy on drug targets validated by genetic or other compelling human evidence. However, product candidates based on genetically validated targets remain subject to the uncertainties of the drug development process and may not reach the market for a number of reasons, including the factors listed above.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a product may be sold, we must conduct clinical trials to demonstrate that our product candidates are safe and effective for use in humans. The results of those clinical trials are used as the basis to obtain approval from regulatory authorities such as the FDA and EMA. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are required to conduct clinical trials using an appropriate number of trial sites and patients to support the product label claims. The length of time, number of trial sites and number of patients required for clinical trials vary substantially, and we may spend several years and incur substantial expense in completing certain clinical trials. In addition, we may have difficulty finding a sufficient number of clinical trial sites and/or patients to participate in our clinical trials, particularly if competitors are conducting clinical trials in similar patient populations. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients may withdraw from clinical trials at any time, and privacy laws and/or other restrictions in certain countries may restrict the ability of clinical trial investigators to conduct further follow-up on such patients, which may adversely affect the interpretation of study results. Delays and complications in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planned clinical trials can result in increased development costs, associated delays in regulatory approvals and in product candidates reaching the market and revisions to existing product labels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, to increase the number of patients available for enrollment in our clinical trials, we have opened, and will continue to open, clinical sites and enroll patients in a number of locations where our experience conducting clinical trials is more limited, including India, China, South Korea, the Philippines, Singapore and some Central and South American countries, either through utilization of third-party contract clinical trial providers entirely or in combination with local staff. Conducting clinical trials in locations where we have limited experience requires substantial time and resources to understand the unique regulatory environments of individual countries. For other examples of the risks of conducting clinical trials in China, see also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, we must ensure the timely production, distribution and delivery of the clinical supply of our product candidates to numerous and varied clinical trial sites. Additionally, regional disruptions, including natural and man-made disasters, health emergencies (such as novel viruses or pandemics such as the one we are currently experiencing with COVID-19), or geopolitical conflicts (such as the ongoing armed conflict in Ukraine) have significantly disrupted the timing of clinical trials, and in the future could disrupt the timing, execution and outcome of clinical trials. If we fail to adequately manage the design, execution and diverse regulatory aspects of our clinical trials or to manage the production or distribution of our clinical supply, or such sites experience disruptions as a result of a natural/man-made disaster, health emergency or geopolitical conflict, corresponding regulatory approvals may be delayed or we may fail to gain approval for our product candidates or could lose our ability to market existing products in certain therapeutic areas or altogether. For example, our clinical trials have been adversely affected by the COVID-19 pandemic. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to market and sell our products or product candidates or to obtain approvals in the timeframe needed to execute our product strategies, our business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on independent third-party clinical investigators to recruit patients and conduct clinical trials on our behalf in accordance with applicable study protocols, laws and regulations. Further, we rely on unaffiliated third-party vendors to perform certain aspects of our clinical trial operations. In some circumstances, we enter into co-development arrangements with other pharmaceutical and medical devices companies that provide for the other company to conduct certain clinical trials for the product we are co-developing or to develop a diagnostic test used in screening or monitoring patients in our clinical trials. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our pharmaceutical pipeline and our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sales of our products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may acquire companies that have past or ongoing clinical trials or rights to products or product candidates for which clinical trials have been or are being conducted. These trials may not have been conducted to the same standards as ours; however, once an acquisition has been completed we assume responsibility for the conduct of these trials, including any potential risks and liabilities associated with the past and prospective conduct of those trials. If regulatory authorities determine that we or others, including our licensees or co-development partners, or the independent investigators or vendors selected by us, our co-development partners or by a company we have acquired or from which we have acquired rights to a product or product candidate, have not complied with regulations applicable to the clinical trials, those authorities may refuse or reject some or all of the clinical trial data or take other actions that could delay or otherwise negatively affect our ability to obtain or maintain marketing approval of the product or indication. In addition, delays or failures to develop diagnostic tests for our clinical trials can affect the timely enrollment of such trials and lead to delays or inability to obtain marketing approval. If we were unable to market and sell our products or product candidates, our business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some of our clinical trials utilize drugs manufactured and marketed by other pharmaceutical companies. These drugs may be administered in clinical trials in combination with one of our products or product candidates or in a head-to-head study comparing the products&#8217; or product candidates&#8217; relative efficacy and safety. In the event that any of these vendors or pharmaceutical companies have unforeseen issues that negatively affect the quality of their work product or create a shortage of supply, or if we are otherwise unable to obtain an adequate supply of these other drugs, our ability to complete our applicable clinical trials and/or evaluate clinical results may also be negatively affected. As a result, such quality or supply problems could adversely affect our ability to timely file for, gain or maintain regulatory approvals worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must generally be designed based on the current standard of medical care. However, in certain diseases, such as cancer, the standard of care is evolving rapidly. In some cases, we may design a clinical trial based on the standard of care we anticipate will exist at the time our study is completed. The duration of time needed to complete certain clinical trials may result in the design of such clinical trials being based on standards of medical care that are no longer or that have not become the current standards by the time such trials are completed, limiting the utility and application of such trials. Additionally, the views of regulatory agencies relating to the requirements for accelerated approval may change over time, and trial designs that were sufficient to support accelerated approvals for some oncology products may not be considered sufficient </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for later candidates. We may not obtain favorable clinical trial results and therefore may not be able to obtain regulatory approval for new product candidates or new indications for existing products and/or maintain our current product labels. Participants in clinical trials of our products and product candidates may also suffer adverse medical events or side effects that could, among other factors, delay or terminate clinical trial programs and/or require additional or longer trials to gain approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after a product is on the market, safety concerns may require additional or more extensive clinical trials as part of a risk management plan for our product or for approval of a new indication. Additional clinical trials we initiate, including those required by the FDA, could result in substantial additional expense, and the outcomes could result in further label restrictions or the loss of regulatory approval for an approved indication, each of which could have a material adverse effect on our product sales, business and results of operations. Additionally, any negative results from such trials could materially affect the extent of approvals, the use, reimbursement and sales of our products, our business and results of operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to extensive regulation by numerous state and federal government authorities in the United States, including the FDA, and by foreign regulatory authorities, including the EMA. We are required in the United States and in the other regions and countries in which we, or our partners and affiliates, sell to obtain approval from regulatory authorities before we manufacture, market and sell our products. Once our products are approved, the FDA and other U.S. and ex-U.S. regulatory agencies have substantial authority to require additional testing and reporting, perform inspections, change product labeling or mandate withdrawals of our products. Failure to comply with applicable regulatory requirements may subject us to administrative and/or judicially imposed sanctions or monetary penalties as well as reputational and other harms. The sanctions could include the FDA&#8217;s or ex-U.S. regulatory authorities&#8217; refusals to approve pending applications, delays in obtaining or withdrawals of approvals, delays or suspensions of clinical trials, warning letters, product recalls or seizures, total or partial suspensions of our operations, injunctions, fines, civil penalties and/or criminal prosecutions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approvals have been, and will continue to be, increasingly difficult, time-consuming and costly. Legislative bodies or regulatory agencies could enact new laws or regulations, change existing laws or regulations or change their interpretations of laws or regulations at any time, which could affect our ability to obtain or maintain approval of our products or product candidates. The rate and degree of change in existing laws and regulations and regulatory expectations have accelerated in established markets, and regulatory expectations continue to evolve in emerging markets.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict whether and when any further changes to laws or regulatory policies affecting our business could occur, such as changes to laws or regulations governing manufacturer communications concerning drug products and drug product candidates and whether such changes could have a material adverse effect on our product sales, business and results of operations. Further, we are reliant on regulators having the resources necessary to evaluate and approve our products. In the United States, a partial federal government shutdown halted the work of many federal agencies and their employees from late December 2018 through late January 2019. A subsequent extended shutdown could result in reductions or delays of FDA&#8217;s activities, including with respect to our ongoing clinical programs, our manufacturing of our products and product candidates and our product approvals.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have questioned, and may in the future question, the sufficiency for approval of the endpoints we select for our clinical trials. A number of our products and product candidates have been evaluated in clinical trials using surrogate endpoints that measure an effect that is known to correlate with an ultimate clinical benefit. For example, a therapeutic oncology product candidate may be evaluated for its ability to reduce or eliminate minimal residual disease (MRD), or to extend the length of time during and after the treatment that a patient lives without the disease worsening, measured by PFS. Demonstrating that the product candidate induces MRD-negative responses or produces a statistically significant improvement in PFS does not necessarily mean that the product candidate will show a statistically significant improvement in overall survival or the time that the patients remain alive. In the CV setting, a heart disease therapeutic candidate may be evaluated for its ability to reduce LDL-C levels, as an elevated LDL-C level has been a surrogate endpoint for CV events such as death, heart attack and stroke. The use of surrogate endpoints such as PFS and LDL-C reduction, in the absence of other measures of clinical benefit, may not be sufficient for broad usage or approval even when such results are statistically significant. Regulatory authorities could also add new requirements, such as the completion of enrollment in a confirmatory study or the completion of an outcomes study or a meaningful portion of an outcomes study, as conditions for obtaining approval or obtaining an indication. For example, despite demonstrating that Repatha reduced LDL-C levels in a broad patient population, only after our large phase 3 outcomes study evaluating the ability of Repatha to prevent CV events met certain of its primary composite endpoint and key secondary composite endpoint did the FDA grant a broader approval of Repatha to reduce the risk of certain CV events. There may also be situations in which demonstrating the efficacy and safety of a product candidate may not be sufficient to gain regulatory approval unless superiority to other existing treatment options can be shown. The imposition of additional requirements or our inability to meet them in a timely fashion, or at all, has delayed, and may in the future delay, our clinical development and regulatory filing efforts, delay or prevent us from obtaining regulatory approval for new product candidates or new indications for existing products, or prevent us from maintaining our current product labels.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our products have been approved by U.S. and ex-U.S. regulatory authorities on an accelerated or conditional basis with full approval conditioned upon fulfilling the requirements of regulators. For example, in May 2021, we announced that the FDA approved LUMAKRAS under accelerated approval for the treatment of adult patients with KRAS G12C-mutated local advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. Continued approval for this indication is contingent upon verification and description of clinical benefit in confirmatory trials, including a requirement by the FDA that we complete a post-marketing trial to investigate whether a lower dose will have a similar clinical effect to the results demonstrated in our pre-marketing trial. We have since received the data from such post-marketing trial and intend to submit it to the FDA, as required. Regulatory authorities are placing greater focus on monitoring products originally approved on an accelerated or conditional basis and on whether the sponsors of such products have met the conditions of the accelerated or conditional approvals. If we are unable to fulfill the regulators&#8217; requirements that were conditions of a product&#8217;s accelerated or conditional approval and/or if regulators reevaluate the data or risk-benefit profile of our product, the conditional approval may not result in full approval or may be revoked or not renewed. Alternatively, we may be required to change the product&#8217;s labeled indications or even withdraw the product from the market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities can also impose post-marketing pediatric study requirements. Failure to fulfill such requirements may result in regulatory or enforcement action, including financial penalties or the invalidation of a product&#8217;s marketing authorization.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Safety problems or signals can arise as our products and product candidates are evaluated in clinical trials, including investigator sponsored studies, or as our marketed products are used in clinical practice. We are required continuously to collect and assess adverse events reported to us and to communicate to regulatory agencies these adverse events and safety signals regarding our products. Regulatory agencies periodically perform inspections of our pharmacovigilance processes, including our adverse event reporting. In the United States, for our products with approved REMS (see Item 1. Business&#8212;Government Regulation&#8212;Postapproval Phase), we are required to submit periodic assessment reports to the FDA to demonstrate that the goals of the REMS are being met. REMS and other risk management programs are designed to help ensure that a drug&#8217;s benefits outweigh the risks and vary in the elements they contain. If the FDA is not satisfied with the results of the periodic assessment reports we submit for any of our REMS, the FDA may also modify our REMS or take other regulatory actions, such as implementing revised or restrictive labeling. The drug delivery devices approved for use in combination with our products are also subject to regulatory oversight and review for safety and malfunctions. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory agencies determine that we or other parties (including our clinical trial investigators, those operating our patient support programs or licensees of our products) have not complied with the applicable reporting, other pharmacovigilance or other safety or quality assessment requirements, we may become subject to additional inspections, warning letters or other enforcement actions, including fines, marketing authorization withdrawal and other penalties. Our product candidates and marketed products can also be affected by safety problems or signals occurring with respect to products that are similar to ours or that implicate an entire class of products. Further, as a result of clinical trials, including sub-analyses or meta-analyses of earlier clinical trials (a meta-analysis involves the use of various statistical methods to combine results from previous separate but related studies) performed by us or others, concerns may arise about the sufficiency of the data or studies underlying a product&#8217;s approved label. Such actual or perceived safety problems or concerns can lead to:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">revised or restrictive labeling for our products, or the potential for restrictive labeling that has resulted, and may in the future result, in our decision not to commercialize a product candidate;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">requirement of risk management or minimization activities or other regulatory agency compliance actions related to the promotion and sale of our products;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">post-marketing commitments, mandated post-marketing requirements or pharmacovigilance programs for our approved products;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">product recalls of our approved products;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">required changes to the processes used in the manufacture of our products, which could increase our manufacturing costs and affect the availability of contract manufacturers we may utilize to assist in such manufacturing;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">revocation of approval for our products from the market completely, or within particular therapeutic areas or patient types;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">increased timelines or delays in being approved by the FDA or other regulatory bodies; and/or</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">treatments or product candidates not being approved by regulatory bodies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, after an imbalance in positively adjudicated CV serious adverse events was observed in one of the phase 3 clinical trials for EVENITY but not in another, larger phase 3 study, in April 2019 the FDA approved EVENITY for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of osteoporosis in postmenopausal women at high risk for fracture, along with a post-marketing requirement. The requirement includes a five-year observational feasibility study that could be followed by a comparative safety study or trial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our innovative products, we are working to develop and commercialize biosimilar versions of a number of products currently manufactured, marketed and sold by other pharmaceutical companies. In some markets, there is not yet a legislative or regulatory pathway for the approval of biosimilars. In the United States, the BPCIA provided for such a pathway. Discussions within the FDA and other regulatory authorities, and between regulatory authorities and sponsors, continue as to the evidence needed to demonstrate biosimilarity or interchangeability for specific products. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Delays or uncertainties in the development or implementation of such pathways, or changes in existing regulatory pathways, including degradation of regulatory standards, could result in delays or difficulties in getting our biosimilar products approved by regulatory authorities, subject us to unanticipated development costs or otherwise reduce the value of the investments we have made in the biosimilars area. Further, we cannot predict the extent to which any potential legislative or policy initiatives would affect the biosimilar pathway or have a material adverse effect on our development of biosimilars or on our marketed biosimilars. In addition, if we are unable to bring our biosimilar products to market on a timely basis and secure &#8220;first-to-market&#8221; or other advantageous positions, our future biosimilar sales, business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products and product candidates may be used in combination with a drug delivery device, such as an injector or other delivery system. For example, Neulasta is available as part of the Neulasta Onpro kit, and our AutoTouch reusable autoinjector is used with ENBREL Mini single-dose prefilled cartridges. In addition, some of our products or product candidates, including many of our oncology product candidates and products, including LUMAKRAS/LUMYKRAS and bemarituzumab, may also require the use of a companion or other diagnostic device such as a device that determines whether the patient is eligible to use our drug or that helps ensure its safe and effective use. In some regions, including the United States, regulatory authorities may require contemporaneous approval of the companion diagnostic device and the therapeutic product; in others the regulatory authorities may require a separate study of the companion diagnostic device. Our product candidates or expanded indications of our products used with such devices may not be approved or may be substantially delayed in receiving regulatory approval if development or approval of such devices is delayed, such devices do not also gain or maintain regulatory approval or clearance, or if such devices do not remain commercially available. When approval of the product and device is sought under a single marketing drug application, the increased complexity of the review process may delay receipt of regulatory approval. In addition, some of these devices may be provided by single-source unaffiliated third-party companies. We are dependent on the sustained cooperation and effort of those third-party companies to supply and/or market the devices and, in some cases, to conduct the studies required for approval or clearance by the applicable regulatory agencies. We are also dependent on those third-party companies continuing to meet applicable regulatory or other requirements. Failure to successfully develop, modify, or supply the devices, delays in or failures of the Amgen or third-party studies, or failure of us or the third-party companies to obtain or maintain regulatory approval or clearance of the devices could result in increased development costs; delays in, or failure to obtain or maintain, regulatory approval; and/or associated delays in a product candidate reaching the market or in the addition of new indications for existing products. We are also required to collect and assess user complaints, adverse events and malfunctions regarding our devices, and actual or perceived safety problems or concerns with a device used with our product can lead to regulatory actions and adverse effects on our products. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, regulatory agencies conduct routine monitoring and inspections to identify and evaluate potential issues with our devices. For example, in 2017, the FDA reported on its adverse event reporting system that it was evaluating our Neulasta Onpro kit. Subsequently, we implemented device and labeling enhancements to address product complaints received on this device. We continuously monitor complaints and adverse events and implement additional enhancements as needed. Loss of regulatory approval or clearance of a device that is used with our product may also result in the removal of our product from the market. Further, failure to successfully develop, supply, or gain or maintain approval for these devices could adversely affect sales of the related approved products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our pharmaceutical pipeline and our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sales of our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on alliances with other companies, including pharmaceutical and biotechnology companies, vendors and service providers, for the development of a portion of the products in our pharmaceutical pipeline and for the commercialization and sales of certain of our commercial products. For example, we have collaborations with third parties under which we share development rights, obligations and costs and/or commercial rights and obligations. See Item 1. Business&#8212;Business Relationships.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failures by these parties to meet their contractual, regulatory, or other obligations to us or any disruption in the relationships between us and these third parties, could have a material adverse effect on our pharmaceutical pipeline and business. In addition, our collaborative relationships for R&amp;D and/or commercialization and sales often extend for many years and have given, and may in the future give, rise to disputes regarding the relative rights, obligations and revenues of us and our collaboration partners, including the ownership or prosecution of intellectual property and associated rights and obligations. This could result in the loss of intellectual property rights or protection, delay the development and sale of potential pharmaceutical products, affect the sale and delivery of our commercialized products and lead to lengthy and expensive litigation, administrative proceedings or arbitration. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek innovation through significant investment in both internal R&amp;D and external transactions, including collaborations, partnerships, alliances, licenses, joint ventures, mergers and acquisitions (collectively, acquisition activity). Acquisition activities may be subject to regulatory approvals or other requirements that are not within our control. There can be no assurance that such regulatory or other approvals will be obtained or that all closing conditions required in connection with our acquisition activities will be satisfied or waived, which could result in us being unable to complete the planned acquisition activities. In addition, antitrust scrutiny by regulatory agencies and changes to regulatory approval process in the U.S. and foreign jurisdictions may cause approvals to take longer than anticipated to obtain, not be obtained at all, or contain burdensome conditions, which may jeopardize, delay or reduce the anticipated benefits of acquisitions to us and could impede the execution of our business strategy.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition activities are complex, time consuming and expensive and may result in unanticipated costs, delays or other operational or financial problems related to integrating the acquired company and business with our company, which may divert our management&#8217;s attention from other business issues and opportunities and restrict the full realization of the anticipated benefits of such transactions within the expected timeframe or at all. We may pay substantial amounts of cash, incur debt or issue equity securities to pay for acquisition activities, which could adversely affect our liquidity or result in dilution to our stockholders, respectively. Further, failures or difficulties in integrating or retaining new personnel or in integrating the operations of the businesses, products or assets we acquire (including related technology, commercial operations, compliance programs, manufacturing, distribution and general business operations and procedures and ESG activities) may affect our ability to realize the benefits of the transaction and grow our business and may result in us incurring asset impairment or restructuring charges. These and other challenges may arise in connection with our acquisitions of Otezla, Five Prime, Teneobio, ChemoCentryx, Horizon and/or our collaborations with BeiGene and KKC, or with other acquisition activities, which could have a material adverse effect on our business, results of operations and stock price.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global supply of our products and product candidates for commercial sales and for use in our clinical trials is significantly dependent on the uninterrupted and efficient operation of our manufacturing facilities, in particular those in the U.S. territory of Puerto Rico and Thousand Oaks, California. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently perform a substantial majority of our clinical manufacturing that supports our product candidates at our facility in Thousand Oaks, California. A substantial disruption in our ability to operate our Thousand Oaks manufacturing facility could materially and adversely affect our ability to supply our product candidates for use in our clinical trials, leading to delays in development of our product candidates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we currently perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico. In recent years, Puerto Rico has been affected by a number of natural disasters, including Hurricane Maria (2017), earthquakes (2020) and Hurricane Fiona (2022). These natural disasters have affected, and may continue to affect, public and private properties and Puerto Rico&#8217;s electric grid and communications networks. While the critical manufacturing areas of our commercial manufacturing facility were not significantly affected by these natural disasters, the restoration of electrical service on the island after Hurricane Maria was a slow process, and our facility relied on backup diesel powered generators for some time. We also operated on backup generators for a few weeks after the early 2020 earthquakes in Puerto Rico. In 2021, the baseload power generation units of the Puerto Rico Electric Power Authority malfunctioned due to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lack of adequate maintenance for over a decade, leading to selective outages across the island. In September 2022, Hurricane Fiona caused further damage to the island&#8217;s utility infrastructure which again resulted in widespread power outages and water supply issues. Although these events did not directly have a material effect on our business, they have resulted in disruptions to our third-party suppliers on the island. Further instability of the electric grid could require us to increase our use of our generators or to use them exclusively. In addition, future storms, earthquakes or other natural or man-made disasters or events (including political unrest or labor shortages) could have a more significant effect on our manufacturing operations. The COVID-19 pandemic has also resulted in disruptions to activities on the island. In March 2020, the Governor of Puerto Rico issued Executive Orders requiring the lockdown of businesses and government facilities, imposing restrictions on business operations and a curfew on residents in response to COVID-19. Additionally, during the summer of 2021, a labor dispute arose between the maritime terminal operation company and its employees, represented by the International Longshoremen&#8217;s Association (ILA), which resulted in a strike that delayed cargo movement from the San Juan Port Zone for several days. Hurricanes Maria and Fiona, the 2020 earthquakes, the COVID-19 pandemic and the ILA strike have also placed greater stress on the island&#8217;s already challenged economy. Beginning in 2016, the government of Puerto Rico defaulted on its roughly $72 billion of debt. In response, the U.S. Congress passed the Puerto Rico Oversight, Management, and Economic Stability Act, which established a financial oversight board for Puerto Rico. After years of negotiations with bondholders and other creditors, this financial oversight board reached an agreement with the same, which was confirmed by the U.S. District Court for the District of Puerto Rico effective March 2022. Although our ability to manufacture and supply our products has not, to date, been significantly affected by natural disasters, unreliable electric utility services, strikes, pandemic lockdowns or the island&#8217;s economic challenges, these, or a combination of these challenges, or other issues that create a substantial disruption to our ability to operate our Puerto Rico manufacturing facility or get supplies and manufactured products transported to and from that location, could make it more expensive or difficult for us to operate in Puerto Rico, and could materially and adversely affect our ability to supply our products and affect our product sales. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on third-party suppliers for certain of our raw materials, medical devices and components.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on unaffiliated third-party suppliers for certain raw materials, medical devices and components necessary for the manufacturing of our commercial and clinical products. Certain of those raw materials, medical devices and components are proprietary products of those unaffiliated third-party suppliers and are specifically cited in our drug applications with regulatory agencies so that they must be obtained from that specific sole source or sources and could not be obtained from another supplier unless and until the regulatory agency approved such supplier. For example, we rely on a single source for the SureClick</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">autoinjectors used in the drug delivery of Repatha, ENBREL, Aimovig, AMGEVITA and Aranesp. Also, certain of the raw materials required in the commercial and clinical manufacturing of our products are sourced from other countries and/or derived from biological sources, including mammalian tissues, bovine serum and human serum albumin.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the reasons we may be unable to obtain these raw materials, medical devices and components include:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory requirements or action by regulatory agencies or others;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">adverse financial or other strategic developments at or affecting the supplier, including bankruptcy;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">unexpected demand for or shortage of raw materials, medical devices or components;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to comply with our quality standards which results in quality and product failures, product contamination and/or recall;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a material shortage, contamination, recall and/or restrictions on the use of certain biologically derived substances or other raw materials;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">discovery of previously unknown or undetected imperfections in raw materials, medical devices or components;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">cyberattacks on supplier systems; </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">natural or other disasters, including hurricanes, earthquakes, volcanoes or fires; </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">labor disputes or shortages, including from the effects of health emergencies (such as novel viruses or pandemics such as the one we are currently experiencing with COVID-19) or natural disasters; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">geopolitical conflicts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in prior years we have experienced shortages in certain components necessary for the formulation, fill and finish of certain of our products in our Puerto Rico facility, and we have also experienced shortages related to single use systems and packaging which has caused disruptions to our manufacturing plans. Further quality issues that result in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unexpected additional demand for certain components have resulted in shortages and in the future may lead to shortages of required raw materials or components (such as we have experienced with EPOGEN glass vials). We may experience similar or other shortages in the future resulting in delayed shipments, supply constraints, clinical trial delays, contract disputes and/or stock-outs of our products. These or other similar events could negatively affect our ability to satisfy demand for our products or conduct clinical trials, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing biologic and small molecule human therapeutic products is difficult, complex and highly regulated. We manufacture many of our commercial products and product candidates internally. In addition, we currently use third-party contract manufacturers to produce, or assist in the production of, a number of our products, and we currently use contract manufacturers to produce, or assist in the production of, a number of our late-stage product candidates and drug delivery devices. See Item 1. Business&#8212;Manufacturing, Distribution and Raw Materials&#8212;Manufacturing. Our ability to adequately and timely manufacture and supply our products (and product candidates to support our clinical trials) is dependent on the uninterrupted and efficient operation of our facilities and those of our third-party contract manufacturers, which may be affected by:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">capacity of manufacturing facilities;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">contamination by microorganisms or viruses, or foreign particles from the manufacturing process;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">natural or other disasters, including hurricanes, earthquakes, volcanoes or fires;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">labor disputes or shortages, including the effects of health emergencies (such as novel viruses or pandemics such as the one we are currently experiencing with COVID-19) or natural disasters;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">compliance with regulatory requirements;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in forecasts of future demand;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">timing and actual number of production runs and production success rates and yields;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">updates of manufacturing specifications;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">contractual disputes with our suppliers and contract manufacturers;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">timing and outcome of product quality testing;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">power failures and/or other utility failures;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">cyberattacks on supplier systems;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">breakdown, failure, substandard performance or improper installation or operation of equipment (including our information technology systems and network-connected control systems or those of our contract manufacturers or third-party service providers); </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in the ability of the FDA or foreign regulatory agencies to provide us necessary reviews, inspections and approvals, including as a result of a subsequent extended U.S. federal or other government shutdowns; and/or</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">geopolitical conflicts. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these or other problems affect production in one or more of our facilities or those of our third-party contract manufacturers, or if we do not accurately forecast demand for our products or the amount of our product candidates required in clinical trials, we may be unable to start or increase production in our unaffected facilities to meet demand. If the efficient manufacture and supply of our products or product candidates is interrupted, we may experience delayed shipments, delays in our clinical trials, supply constraints, stock-outs, adverse event trends, contract disputes and/or recalls of our products. From time to time, we have initiated recalls of certain lots of our products. For example, in July 2014 we initiated a voluntary recall of an Aranesp lot distributed in the EU after particles were detected in a quality control sample following distribution of that lot, and in April 2018 we initiated a precautionary recall of two batches of Vectibix distributed in Switzerland after potential crimping defects were discovered in the metal seals on some product vials. If we are at any time unable to provide an uninterrupted supply of our products to patients, we may lose patients and physicians may elect to prescribe competing therapeutics instead of our products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing processes, those of our third-party contract manufacturers and those of certain of our third-party service providers must undergo regulatory approval processes and are subject to continued review by the FDA and other regulatory authorities. It can take longer than five years to build, validate and license another manufacturing plant, and it can take longer than three years to qualify and license a new contract manufacturer or service provider. If we elect or are required to make changes to our manufacturing processes because of new regulatory requirements, new interpretations of existing requirements or other reasons, this could increase our manufacturing costs and result in delayed shipments, delays in our clinical trials, supply constraints, stock-outs, adverse event trends or contract negotiations or disputes. Such manufacturing challenges may also occur if our existing contract manufacturers are unable or unwilling to timely implement such changes, or at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regulatory agencies conduct routine monitoring and inspections of our manufacturing facilities and processes as well as those of our third-party contract manufacturers and service providers. If regulatory authorities determine that we or our third-party contract manufacturers or certain of our third-party service providers have violated regulations, they may mandate corrective actions and/or issue warning letters, or even restrict, suspend or revoke our prior approvals, prohibiting us from manufacturing our products or conducting clinical trials or selling our marketed products until we or the affected third-party contract manufacturers or third-party service providers comply, or indefinitely. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such issues may also delay the approval of product candidates we have submitted for regulatory review, even if such product candidates are not directly related to the products, devices or processes at issue with regulators. Because our third-party contract manufacturers and certain of our third-party service providers are subject to the FDA and foreign regulatory authorities, alternative qualified third-party contract manufacturers and third-party service providers may not be available on a timely basis, or at all. If we or our third-party contract manufacturers or third-party service providers cease or interrupt production or if our third-party contract manufacturers and third-party service providers fail to supply materials, products or services to us, we may experience delayed shipments, delays in our clinical trials, supply constraints, contract disputes, stock-outs and/or recalls of our products. Additionally, we distribute a substantial volume of our commercial products through our primary distribution centers in Louisville, Kentucky for the United States and in Breda, Netherlands for Europe and much of the rest of the world. We also conduct most of the labeling and packaging of our products distributed in Europe and much of the rest of the world in Breda. Our ability to timely supply products is dependent on the uninterrupted and efficient operations of our distribution and logistics centers, our third-party logistics providers and our labeling and packaging facility in Breda. Further, we rely on commercial transportation, including air and sea freight, for the distribution of our products to our customers, which has been negatively affected by the ongoing COVID-19 pandemic and may be negatively affected by natural disasters or geopolitical security threats.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have also been legislative and administrative proposals seeking to incentivize greater drug manufacturing in the United States with the stated goal of improving supply reliability in the United States. For example, on August 6, 2020, the previous Administration issued an Executive Order aimed at boosting domestic production of essential medicines, medical countermeasures, and critical inputs titled &#8220;Executive Order on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States.&#8221; Additionally, one legislative proposal would have prohibited the U.S. Department of Veterans Affairs from purchasing certain drugs that have active pharmaceutical ingredients manufactured outside the United States. While we perform a substantial majority of our commercial manufacturing activities in the United States, including in the U.S. territory of Puerto Rico, and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California, the passage of such legislation could result in foreign governments enacting retaliatory legislation or regulatory actions, which may have an adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work towards operating our business in an environmentally responsible and socially inclusive manner. Stakeholders, including our investors and our employees, have increasingly focused on, and are expected to continue to focus on, our ESG practices. If our ESG practices fail to meet these stakeholders&#8217; expectations and standards, there could be a material adverse effect on our reputation, business and, ultimately, our stock price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ESG report is made available on our website and describes our ESG goals and the progress we have made on the ESG issues deemed most important to our external and internal stakeholders, based on surveys, interviews and certain frameworks for corporate responsibility. Achieving our ESG goals requires long-term investments and broad, coordinated activity, and we may be required to incur additional costs or allocate additional resources towards monitoring, reporting and implementing our ESG practices. Further, we may fail to accurately assess our stakeholders&#8217; ESG priorities, as such priorities have evolved and will continue to evolve. While we have achieved most of our goals set in prior years, whether we can achieve our current and future ESG goals continues to be uncertain and remains subject to numerous risks, including evolving regulatory requirements and social expectations affecting ESG practices, our ability to recruit, develop and retain a diverse workforce, the availability of suppliers and collaboration partners that can meet our ESG goals, the effects of the organic growth of our business and potential </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisitions of other businesses on our ESG performance, and the availability and cost of technologies or resources, such as carbon credits, that support our goals. For example, impacts on the commodity market and supply chains caused by the armed conflict in Ukraine could limit the availability of electric vehicle components, impairing our ability to meet some of our environmental sustainability goals. Any failure or perceived failure to meet our ESG program priorities could result in a material adverse effect on our reputation, business and stock price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The effects of global climate change and related natural disasters could negatively affect our business and operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our operations and facilities, including those essential to our manufacturing, R&amp;D and distribution activities, are in locations that are subject to natural disasters, including droughts, fires, extreme temperatures, hurricanes, tropical storms and/or floods. For example, in 2017 Hurricane Maria caused catastrophic damage, compounded in 2022 by Hurricane Fiona, to the U.S. territory of Puerto Rico, where we perform a substantial majority of our commercial manufacturing activities. Although our site was well-protected and suffered minimal damage, there can be no assurances that we would have similar results in the face of future natural disasters. The severity and frequency of weather-related natural disasters has been amplified, and is expected to continue to be amplified by, global climate change. Such natural disasters have caused, and in the future may cause, damage to and/or disrupt our operations, which may result in a material adverse effect on our product sales, business and results of operations. Our suppliers, vendors and business partners also face similar risks, and any disruption to their operations could have an adverse effect on our supply and manufacturing chain. Further, many of our key facilities are located on islands, including Puerto Rico, Singapore and Ireland, which rely on essential port facilities that may be vulnerable to climate change-related or other natural disasters. Although we have detailed business continuity plans in place and periodic assessments of our natural disaster risk, any natural disaster may also result in prolonged interruption to our critical operational and business activities, and we may be required to incur significant costs to remedy the effects of such natural disasters and fully resume operations, which may result in a material adverse effect on our product sales, business and results of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions. The economic downturn resulting from the COVID-19 pandemic precipitated a global recession, and together with high rates of inflation and energy supply issues experienced in certain regions, have led to regional and/or global macroeconomic challenges, the effects of which may be of an extended duration. In particular, acute rising energy costs may further adversely affect productivity and economic conditions in Europe. Additionally, financial pressures may cause government or other third-party payers to more aggressively seek cost containment measures in healthcare and other settings. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships (including inflation) may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to reduced demand for our products, which could have a material adverse effect on our product sales, business and results of operations. The current inflationary environment related to increased aggregate demand, supply chain constraints and the effects from the armed conflict in Ukraine (including the effects of the sanctions that were implemented in response to the conflict and the resulting impacts on the commodity market and supply chains) have also increased our operating expenses and may continue to affect our operating expenses. Our operational costs, including the cost of energy, materials, labor, distribution and our other operational and facilities costs are subject to market conditions and are being adversely affected by inflationary pressures. Economic conditions may also adversely affect the ability of our distributors, customers and suppliers to obtain the liquidity required to buy inventory or raw materials and to perform their obligations under agreements with us, which could disrupt our operations. Although we monitor our distributors&#8217;, customers&#8217; and suppliers&#8217; financial condition and their liquidity to mitigate our business risks, some of our distributors, customers and suppliers may become insolvent, which could have a material adverse effect on our product sales, business and results of operations. A significant worsening of global economic conditions could </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">precipitate or materially amplify the other risks described herein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a significant portfolio of investments disclosed as cash equivalents and marketable securities on our consolidated balance sheets. The global spread of COVID-19 has also led to disruption and volatility in the global capital markets. We have certain assets, including equity investments, that are exposed to market fluctuations that could, in a sustained </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or recurrent series of market disruptions, result in impairments. The value of our investments may also be adversely affected by interest rate fluctuations, inflation, downgrades in credit ratings, illiquidity in the capital markets and other factors that may result in other-than-temporary declines in the value of our investments. Any of those events could cause us to record impairment charges with respect to our investment portfolio or to realize losses on sales of investments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price is volatile.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price, like that of our peers in the biotechnology and pharmaceutical industries, is volatile. Our revenues and operating results may fluctuate from period to period for a number of reasons. Events such as a delay in product development, changes to our expectations or strategy or even a relatively small revenue shortfall may cause financial results for a period to be below our expectations or projections. As a result, our revenues and operating results and, in turn, our stock price may be subject to significant fluctuations. Announcements or discussions, including via social media channels, of possible restrictive actions by government or private payers that would negatively affect our business or industry if ultimately enacted or adopted may also cause our stock price to fluctuate, whether or not such restrictive actions ever actually occur. Similarly, actual or perceived safety issues with our products or similar products or unexpected clinical trial results can have an immediate and rapid effect on our stock price, whether or not our operating results are materially affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The capital and credit markets may experience extreme volatility and disruption, which may lead to uncertainty and liquidity issues for both borrowers and investors. For example, early in 2020, there were significant disruptions in the commercial paper market and several borrowers were unable to obtain funding at normal rates or maturities, which resulted in a significant increase in draws of corporate credit lines with banks. Similarly, the bond markets experienced extreme volatility in terms of interest rates and credit spreads, with several days without new issuances of corporate bonds. We expect to access the capital markets, from time to time, to supplement our existing funds and cash generated from operations to satisfy our needs for working capital; capital expenditure and debt service requirements; our plans to pay dividends and repurchase stock; and other business initiatives we strategically plan to pursue, including acquisitions (such as our acquisition of Horizon) and licensing activities. In the event of adverse capital and credit market conditions, we may be unable to obtain capital market financing on similar favorable terms, or at all, which could have a material adverse effect on our business and results of operations or our ability to complete business acquisitions. Changes in credit ratings issued by nationally recognized credit-rating agencies could adversely affect our ability to obtain capital market financing and the cost of such financing and have an adverse effect on the market price of our securities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_55"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNRESOLVED STAFF COMMENTS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTIES</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we owned or leased approximately 150 properties. The locations and primary functions of significant properties are summarized in the following tables:</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Administrative</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales &amp; marketing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warehouse</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution center</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thousand Oaks, CA*</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Francisco, CA</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisville, KY</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge, MA</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Juncos, Puerto Rico</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Greenwich, RI</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tampa, FL</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other U.S. cities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate headquarters</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Administrative</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales &amp; marketing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warehouse</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution center</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China </span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iceland</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluded from the information above are (i) undeveloped land and leased properties that have been abandoned and (ii) certain buildings we still own but that are no longer used in our business. There are no material encumbrances on our owned properties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our facilities are suitable for their intended uses and, in conjunction with our third-party contract manufacturing agreements, provide adequate capacity and are sufficient to meet our expected needs. See Item&#160;1A. Risk Factors&#160;for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1. Business&#8212;Manufacturing, Distribution and Raw Materials.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_61"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LEGAL PROCEEDINGS</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the legal proceedings in which we are involved are discussed in Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements and are hereby incorporated by reference.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_64"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MINE SAFETY DISCLOSURES</span></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_70"></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the NASDAQ Global Select Market under the symbol AMGN. As of February 6, 2023, there were approximately 4,838 holders of record of our common stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance graph</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows the value of an investment of $100 on December&#160;31, 2017, in each of Amgen common stock, the Amex Biotech Index, the Amex Pharmaceutical Index and Standard&#160;&amp; Poor&#8217;s 500 Index. All values assume reinvestment of the pretax value of dividends and are calculated as of December&#160;31 of each year. The historical stock price performance of the Company&#8217;s common stock shown in the performance graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-bottom:6pt;text-align:justify"><img src="amgn-20221231_g2.jpg" alt="amgn-20221231_g2.jpg" style="height:500px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen (AMGN)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$115.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$146.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$143.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$145.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$174.94</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amex Biotech (BTK)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$120.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$137.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$132.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127.01</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amex Pharmaceutical (DRG)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$107.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$138.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$170.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$183.88</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s 500 (SPX)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$95.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$125.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$148.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$191.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$156.74</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material in the above performance graph is not soliciting material, is not deemed filed with the SEC and is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made on, before or after the date of this filing and irrespective of any general incorporation language in such filing.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months and year ended December 31, 2022, we had one outstanding stock repurchase program, under which the repurchasing activity was as follows:</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:37.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>number of<br/>shares<br/>purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">price&#160;paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;number<br/>of&#160;shares<br/>purchased as<br/>part&#160;of<br/>publicly<br/>announced<br/>program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum dollar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">value that may</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">yet be purchased</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">under the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - October 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,979,263,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 - November 30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,979,263,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 - December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,979,263,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;1 - December&#160;31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,147,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,147,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Average price paid per share includes related expenses.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">In October 2022, our Board of Directors increased the amount authorized under the stock repurchase program by an additional $2.4 billion.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Includes the impact of ASR agreements entered into with third-party financial institutions under which a total of 24,784,400 shares of common stock were delivered at an average price of approximately $242.09 per share.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022 and 2021, we paid quarterly dividends. We expect to continue to pay quarterly dividends, although the amount and timing of any future dividends are subject to approval by our Board of Directors. Additional information required by this item is incorporated herein by reference to Part IV&#8212;Note 16, Stockholders&#8217; equity, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Authorized for Issuance Under Existing Equity Compensation Plans</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about securities authorized for issuance under existing equity compensation plans is incorporated by reference from Part III, Item 12&#8212;Securities Authorized for Issuance Under Existing Equity Compensation Plans.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_73"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESERVED</span></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following MD&amp;A is intended to assist the reader in understanding Amgen&#8217;s business. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and accompanying notes. Our results of operations discussed in MD&amp;A are presented in conformity with GAAP. Amgen operates in one business segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management&#8217;s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;outlook,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;assume&#8221; and &#8220;continue&#8221; as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Part I, Item 1A. Risk Factors. We have based our forward-looking statements on our management&#8217;s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, EPS, liquidity and capital resources, trends, planned dividends, stock repurchases, collaborations and effects of pandemics. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses. A biotechnology pioneer since 1980, Amgen has grown to be one of the world&#8217;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal products are ENBREL, Prolia, Otezla, XGEVA, Aranesp, Nplate, Repatha, KYPROLIS, Neulasta and EVENITY. We also market a number of other products, including MVASI, Vectibix, BLINCYTO, EPOGEN, AMGEVITA, Aimovig, Parsabiv, KANJINTI, LUMAKRAS/LUMYKRAS, TEZSPIRE, NEUPOGEN, Sensipar/Mimpara and TAVNEOS. For additional information about our products, see Part I, Item&#160;1. Business&#8212;Marketing, Distribution and Selected Marketed Products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy includes integrated activities intended to strengthen our competitive position in the industry. We operate in six commercial areas: inflammation, oncology/hematology, bone health, cardiovascular (CV) disease, nephrology and neuroscience. We conduct discovery research primarily in three therapeutic areas: inflammation, oncology/hematology and general medicine. In 2022, we advanced our innovative pipeline, grew our international business, completed a strategic transaction to augment our marketed product portfolio, announced our intention to acquire Horizon and continued providing uninterrupted supplies of our medicines globally through the third year of the COVID-19 pandemic. We accomplished these objectives while maintaining a strategic and disciplined approach to capital allocation and advancing our ESG efforts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we continued to advance our pipeline, initiating phase 3 clinical trials for a number of programs, including LUMAKRAS/LUMYKRAS for advanced colorectal cancer, olpasiran for CV disease and rocatinlimab for atopic dermatitis. We continued to grow our international business, including achieving key regulatory approvals for TEZSPIRE in the EU and Japan. Our external business development activities for 2022 included the acquisition of ChemoCentryx, adding recently launched TAVNEOS to our inflammation portfolio. We also continued to advance our biosimilar program, with launches in new markets. Our biosimilars are expected to continue launching in new markets throughout 2023, including the U.S. launch of AMJEVITA in January 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, while gradually recovering from the global pandemic and facing increased competition from biosimilars and generics, total product sales increased 2%, primarily driven by volume growth for certain brands, partially offset by declines in net selling prices of certain products and unfavorable changes to foreign currency exchange rates. Product sales increased 3% in the United States, primarily driven by volume growth, partially offset by declines in net selling prices, and increased 1% in ROW, primarily driven by volume growth, partially offset by unfavorable changes to foreign currency exchange rates and declines in net selling prices. Total operating expenses decreased 9% due to both the acquired IPR&amp;D write-off from the Five Prime acquisition and a licensing-related upfront payment to KKC in 2021, partially offset by a loss on a nonstrategic divestiture in 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities totaled $9.7 billion, which supported investment in our business while returning capital to shareholders through the payment of cash dividends and stock repurchases. For 2022, we increased our quarterly cash dividend by 10% to $1.94 per share of common stock. In December 2022, we declared a cash dividend of $2.13 per share of common stock for the first quarter of 2023, an increase of 10% for this period, to be paid in March 2023. We also repurchased 26.1 million shares of our common stock during 2022 at an aggregate cost of $6.3 billion. In 2022, we received net proceeds from the issuance of debt of $6.9 billion and extinguished $0.3 billion of debt. In December 2022, in connection with the proposed acquisition of Horizon, we entered into a bridge credit agreement and a term loan credit agreement which provide for borrowings in the aggregate of $28.5&#160;billion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen&#8217;s approach to and investment in human capital resource management is directed at attracting, motivating, developing and retaining talent to tackle the challenges of running an enterprise focused on the discovery, development and commercialization of innovative medicines. Our compensation, benefits and development programs are designed to encourage performance, promote accountability and adherence to Company values, and align with the interests of the Company&#8217;s shareholders. Further, we believe that a diverse and inclusive culture fosters innovation, which supports our ability to serve patients. We are engaging in activities and setting goals to improve our focus on diversity, inclusion and belonging. For further information on these and other efforts, see Part I, Item 1. Business&#8212;Human Capital Resources.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a long-standing ambition to be environmentally responsible, and we regularly set targets to challenge ourselves to deliver further improvements. We achieved our targets for the 2013&#8211;2020 period while growing revenues, increasing production capacity and expanding to approximately 100 countries over the same period. To continue on our path to greater environmental sustainability, in January 2021 we announced a new set of long-term environmental targets to achieve by 2027, including achieving carbon neutrality, reducing water consumption by 40% and reducing waste disposed by 75%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2022 we issued our first green bonds to finance eligible projects that meet specified criteria to reduce our impact on the environment.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends, to a great extent, on our ability to continue to discover, develop and commercialize innovative products and acquire or collaborate on therapies currently in development by other companies. We must develop new products to achieve revenue growth and to offset revenue losses from when products lose their exclusivity or when competing products are launched. Certain of our products face increasing pressure from competition, including biosimilars and generics. For additional information, including information on the expirations of patents for various products, see Part I, Item&#160;1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Patents, and Part I, Item&#160;1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. We devote considerable resources to R&amp;D activities, but successful product development in the biotechnology industry is highly uncertain. We also face increasing regulatory scrutiny of safety and efficacy both before and after products launch.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rising healthcare costs, uncertain macroeconomic conditions, including higher inflation and rising interest rates, and geopolitical conflicts continue to pose challenges to our business. As a result of public and private healthcare-provider focus, the industry continues to be subject to cost containment measures and significant pricing pressures, including net price declines. Moreover, legislation enacted to reduce healthcare expenditures, including provisions of the IRA, have affected, and are likely to continue to affect, our business. Finally, wholesale and end-user buying patterns can affect our product sales. These buying patterns can cause fluctuations in quarterly product sales but have generally not been significant to date when comparing full-year product performance to the prior year. See Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products, and Part I, Item 1A. Risk Factors for further discussion of certain factors that could impact our future product sales.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the onset of the pandemic in 2020, we have been closely monitoring the pandemic&#8217;s effects on our global operations. We continue to take appropriate steps to minimize risks to our employees, a significant number of whom have continued to work virtually. To date, our remote working arrangements have not significantly affected our ability to maintain critical business operations, and we have not experienced disruptions to or shortages of our supply of medicines.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the course of the pandemic we have experienced changes in demand for some of our products as fluctuations in the frequency of patient visits to doctors&#8217; offices have impacted the provision of treatments to existing patients and reduced diagnoses in new patients. During 2021, there was a gradual recovery in both patient visits and diagnosis rates that approached pre-pandemic levels. In 2022, the pandemic continued to impact the healthcare sector and our business, to varying degrees across our markets. During 2022, with the exception of the Asia Pacific region that was affected by lockdowns during most of the year, we saw greater stability in patient visits and demand patterns even in areas that were facing surges in the virus. Given the evolution of COVID-19 since its onset, including the proliferation of variants, we cannot predict the impact of future virus surges on our business and will continue to closely monitor the impact of COVID-19 on our business and on the healthcare sector more generally.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since early 2021, efforts have been under way to control the COVID-19 pandemic. However, uncertainty remains as to the efficacy of these activities with respect to the ongoing trajectory of the pandemic. Challenges to vaccination efforts, new variants and other causes of virus spread may require governments to change restrictions and/or shutdown requirements in various geographies. As a result, we expect to see continued volatility for at least the duration of the pandemic as governments respond to current local conditions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to our clinical trial activities, we are continuously monitoring COVID-19 infection rates, including changes from new variants; we are working to mitigate effects on future study enrollment in our clinical trials; and we are evaluating the impact in all relevant countries. We remain focused on supporting our active clinical sites in their providing care for patients and in our providing investigational drug supply. For a discussion of the risks the COVID-19 pandemic could present to our results, see Part I, Item 1A. Risk Factors of this Form 10-K.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents reductions against established baselines, taking into account only verified reduction projects and does not take into account changes associated with contraction or expansion of the Company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Carbon neutrality goal refers to Scope 1 and 2.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Financial Information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is an overview of our results of operations (in millions, except percentages and per-share data):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the following discussion of changes in product sales, any reference to volume growth or decline refers to changes in the purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total product sales increased in 2022, primarily driven by volume growth for certain brands, including Repatha, Prolia, EVENITY, Nplate, LUMAKRAS/LUMYKRAS, KYPROLIS, Otezla and TEZSPIRE, partially offset by declines in net selling prices of certain products, including Neulasta, Repatha and MVASI, and unfavorable changes to foreign currency exchange rates. For 2023, we expect that net selling prices will continue to decline at a portfolio level driven by increased competition. Further, the first quarter of a year historically represents the lowest product sales quarter for the year, in part due to plan changes, insurance reverifications and higher co-pay expenses as U.S. patients work through deductibles, particularly for products acquired through pharmacy benefit programs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of uncertain macroeconomic conditions, we expect volatility around foreign currency exchange rates to continue. The impact of unfavorable changes to foreign currency exchange rates will be partially offset by corresponding decreases in our international operating expenses. While not designed to completely address foreign currency changes, our hedging activities also seek to offset, in part, such effects on our net income by hedging our net foreign currency exposure, primarily with respect to product sales denominated in euros.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, our product sales have been affected by reduced demand as a result of the COVID-19 pandemic. In general, the dynamics of the pandemic were most significant on our product sales in the early months of the pandemic, with demand beginning to show some recovery in late 2020. In late 2021 and early 2022, increased infection rates caused by variants of the virus (including Omicron) led to diminished capacity in the healthcare sector and reduced working days for our own sales force, which impacted our business. As of the second quarter of 2022, we saw the effects of these variants recede in most markets, which allowed us to engage in increased field-facing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Provider and patient activity also increased, leading to improvements in demand for our products to pre-pandemic levels. However, the cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which continues to impact our business.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the unpredictable nature of the pandemic, there could be intermittent disruptions in physician&#8211;patient interactions, and as a result, we may experience quarter-to-quarter variability. In addition, other changes in the healthcare ecosystem have the potential to introduce variability into product sales trends. For example, changes in U.S. employment have led to changes to the insured population. Growth in numbers of Medicaid enrollees and uninsured individuals, along with provisions of the IRA, may have a negative impact on product sales. Overall, uncertainty remains around the timing and magnitude of our sales during the COVID-19 pandemic. See Risk Factors in Part I, Item 1A. of this Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues decreased for 2022, driven by lower revenue from COVID-19 antibody material and licensing-related revenues.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses decreased for 2022 due to both the acquired IPR&amp;D write-off related to the bemarituzumab program acquired as part of the Five Prime acquisition and a licensing-related upfront payment to KKC in 2021, partially offset by a loss </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a nonstrategic divestiture in 2022. See Part IV&#8212;Note 2, Acquisitions and divestitures, and Note 8, Collaborations, to the Consolidated Financial Statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_85"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide product sales were as follows (dollar amounts in millions): </span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S.</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,743&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,801&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales of our products will depend in part on the factors discussed in the Overview, Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition, in Part I, Item 1A. Risk Factors, and any additional factors discussed in the individual product sections below. In addition, for a list of our products&#8217; significant competitors, see Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total ENBREL sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL&#160;&#8212;&#160;Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ENBREL</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in ENBREL sales for 2022 was primarily driven by unfavorable changes to estimated sales deductions, lower volume and lower net selling price. For 2023, we expect ENBREL to follow the historical pattern of lower sales in the first quarter relative to subsequent quarters due to the impact of benefit plan changes, insurance reverification and increased co-pay expenses as U.S. patients work through deductibles. In addition, for 2023, we expect further declines in net selling price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in ENBREL sales for 2021 was driven by lower net selling price, volume and unfavorable changes to inventory.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Prolia sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Prolia</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2022 was driven by volume growth and higher net selling price, partially offset by unfavorable changes to foreign currency exchange rates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Prolia sales for 2021 was primarily driven by volume growth.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Otezla sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla&#160;&#8212;&#160;U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla&#160;&#8212;&#160;ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Otezla</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2022 was primarily driven by volume growth, partially offset by lower net selling price. ROW Otezla sales for 2022 were impacted by unfavorable changes to foreign currency exchange rates. For 2023, we expect Otezla to follow the historical pattern of lower sales in the first quarter relative to subsequent quarters due to the impact of benefit plan changes, insurance reverification and increased co-pay expenses as U.S. patients work through deductibles.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2021 was driven by volume growth, partially offset by lower net selling price and unfavorable changes to inventory.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of ongoing litigation related to Otezla, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XGEVA</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total XGEVA sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total XGEVA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global XGEVA sales were relatively unchanged for 2022 as higher net selling price was offset by lower volume as a result of increased competition and unfavorable changes to foreign currency exchange rates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global XGEVA sales for 2021 was primarily driven by volume growth, partially offset by lower net selling price.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aranesp</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Aranesp sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp&#160;&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Aranesp</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global Aranesp sales for 2022 was driven by lower net selling price and unfavorable changes to foreign currency exchange rates, partially offset by favorable changes to estimated sales deductions and volume growth.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global Aranesp sales for 2021 was primarily driven by lower net selling price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aranesp continues to face competition from a long-acting erythropoiesis-stimulating agent (ESA) and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from a biosimilar version of EPOGEN, which will impact net selling price and volume in the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nplate</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Nplate sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate&#160;&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Nplate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Nplate sales for 2022 was driven by volume growth. Nplate sales for 2022 included a $207&#160;million order in the fourth quarter from the U.S. government.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Nplate sales for 2021 was primarily driven by volume growth.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Repatha sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Repatha</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2022 was driven by volume growth, partially offset by lower net selling price and unfavorable changes to foreign currency exchange rates. Volume benefited from contracting changes to support and improve Medicare Part D and commercial patient access and the inclusion of Repatha on China&#8217;s National Reimbursement Drug List as of January 1, 2022, both of which resulted in decreases to the net selling price in 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2021 was driven by volume growth, partially offset by lower net selling price. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of ongoing litigation related to Repatha, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total KYPROLIS sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS&#160;&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total KYPROLIS</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in global KYPROLIS sales for 2022 and 2021 were primarily driven by volume growth.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has reported that it has granted tentative or final approval of ANDAs for generic carfilzomib products filed by a number of companies. The date of approval of those ANDAs for generic carfilzomib products is governed by the Hatch&#8211;Waxman Act and any applicable settlement agreements between us and certain companies that seek to develop generic carfilzomib products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neulasta</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Neulasta sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta &#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neulasta</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in global Neulasta sales for 2022 and 2021 were driven by lower net selling price and volume. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased competition as a result of biosimilar versions of Neulasta has had and will continue to have a significant adverse impact on brand sales, including accelerating net price erosion and lower volume. We also expect other biosimilar versions, including biosimilars that will use an on-body injector that would compete with our Onpro injector, to be approved in the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EVENITY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total EVENITY sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY &#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total EVENITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in global EVENITY sales for 2022 and 2021 were driven by volume growth across our markets. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI &#8212; U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMYKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN &#8212; U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN &#8212; ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar &#8212; U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar/Mimpara &#8212; ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAVNEOS &#8212; U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAVNEOS &#8212; ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other &#8212; ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. &#8212; other products</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,630&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ROW &#8212; other products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM = not meaningful</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Change in excess of 100%</span></div><div style="margin-top:7pt;padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">TAVNEOS was acquired on October 20, 2022 from our acquisition of ChemoCentryx. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Consists of Corlanor, AVSOLA, IMLYGIC and RIABNI, as well as sales by our Gensenta and Bergamo subsidiaries. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM = not meaningful</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Change in excess of 100%</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales decreased to 24.3% of total revenues for 2022, driven by lower COVID-19 antibody shipments and manufacturing costs, partially offset by changes in our product mix.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased to 24.8% of total revenues for 2021, driven by changes in our product mix and higher profit share and royalties, partially offset by lower amortization expense from acquisition-related assets and lower manufacturing costs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company groups all of its R&amp;D activities and related expenditures into three categories: (i)&#160;research and early pipeline, (ii)&#160;later-stage clinical programs and (iii)&#160;marketed products. These categories are described below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and early pipeline </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later-stage clinical programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses incurred in or related to phase 2 and phase 3 clinical programs intended to result in registration of a new product or a new indication for an existing product primarily in the United States or the EU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses incurred in support of the Company&#8217;s marketed products that are authorized to be sold primarily in the United States or the EU. Includes clinical trials designed to gather information on product safety (certain of which may be required by regulatory authorities) and their product characteristics after regulatory approval has been obtained, as well as the costs of obtaining regulatory approval of a product in a new market after approval in either the United States or the EU has been obtained</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense by category was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and early pipeline</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later-stage clinical programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total R&amp;D expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in R&amp;D expense for 2022 was driven by higher business development activity in 2021 included in later-stage clinical programs and research and early pipeline and lower marketed products support, partially offset by higher later-stage clinical programs support and research and early pipeline spend.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&amp;D expense for 2021 was driven by a licensing-related upfront payment to KKC included in later-stage clinical programs and higher spend in research and early pipeline, including other business development activities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Acquired IPR&amp;D expense in 2021 was related to the bemarituzumab program, which was acquired as part of the Five Prime acquisition in 2021. See Part IV&#8212;Note 2, Acquisitions and divestitures, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in SG&amp;A expense for 2022 was primarily driven by higher acquisition-related expenses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in SG&amp;A expense for 2021 was primarily driven by lower spend for marketed products and lower general and administrative expenses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for 2022 primarily consisted of a loss on a nonstrategic divestiture. See Part IV&#8212;Note 2, Acquisitions and divestitures, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for 2021 primarily consisted of expenses related to cost-savings initiatives and a legal judgment.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for 2020 primarily consisted of legal settlement expenses.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_91"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonoperating expenses/income and income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonoperating expenses/income and income taxes were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Interest expense, net, for 2022 was primarily due to higher overall debt outstanding and higher LIBORs on debt for which we effectively pay a variable rate of interest through the use of interest rate swaps.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Interest expense, net, for 2021 was primarily due to net higher costs associated with the early retirement of debt in 2020 and lower LIBORs in 2021 on debt for which we effectively pay a variable rate of interest through the use of interest rate swaps, partially offset by higher overall debt outstanding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (expense) income, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other (expense) income, net, for 2022 was primarily due to higher losses recognized in connection with our BeiGene investment compared with 2021 and losses recognized on our investments in limited partnerships, publicly traded equity securities and other strategic investments.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other (expense) income, net, for 2021 was primarily due to lower losses incurred in connection with our BeiGene investment compared with 2020, partially offset by lower income on our interest-bearing investments in 2021 and other nonrecurring gains recognized in 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_94"></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our effective tax rate for 2022 compared with 2021 was primarily due to the nondeductible IPR&amp;D expense arising from the acquisition of Five Prime in the prior year, partially offset by a nondeductible loss on a nonstrategic divestiture in 2022 and net unfavorable items as compared to the prior year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our effective tax rate for 2021 compared with 2020 was primarily driven by the nondeductible IPR&amp;D expense arising from the acquisition of Five Prime, partially offset by earnings mix and adjustments to prior-year tax liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administration and Congress continue to discuss changes to existing tax law that could substantially increase the taxes we pay to the U.S. government. Further, the OECD recently reached an agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, either by all OECD participants or unilaterally by individual countries, this agreement could result in a tax increase that could affect our U.S. and foreign tax liabilities. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Treasury released final foreign tax credit regulations in December 2021 that eliminated U.S. creditability of the Puerto Rico Excise Tax beginning in 2023, which would have increased our U.S. tax liability. In response, on June 30, 2022, the U.S. territory of Puerto Rico enacted Act 52-2022, which provides for an alternate fixed tax rate on industrial development income that the U.S. Treasury confirmed will be creditable under federal law. As part of this new law, eligible businesses will be subject to incremental income and withholding taxes in lieu of payment of the Puerto Rico Excise Tax. In order to qualify for the alternative fixed tax rate, our current tax grant with the Puerto Rico government was amended in December 2022. We qualify for this alternative fixed tax rate, beginning January 1, 2023 and our tax expense will increase. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#8211;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#8211;2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010&#8211;2012 by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed for the years 2010&#8211;2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#8211;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#8211;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#8211;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#8211;2015 by an amount that would result in additional federal tax of approximately $5.1&#160;billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0&#160;billion. Any additional tax that could be imposed for the years 2013&#8211;2015 would be reduced by up to approximately $2.2&#160;billion of repatriation tax previously accrued on our foreign earnings. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010&#8211;2012 and 2013&#8211;2015 Notices are without merit. We are contesting the 2010&#8211;2012 and 2013&#8211;2015 Notices through the judicial process. The two cases were consolidated in U.S. Tax Court on December 19, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently under examination by the IRS for the years 2016&#8211;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Part II, Item 7. Management&#8217;s Discussion and Analysis or Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates, Income taxes; and Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements for further discussion.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_97"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial data was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our balance of cash, cash equivalents and marketable securities was $9.3 billion at December 31, 2022. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital allocation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including investments in innovation, both internally and externally, strategic transactions (including those that expand our portfolio of products in areas of therapeutic interest), repayment of debt, payment of dividends and stock repurchases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to continue investing in our business while returning capital to stockholders through the payment of cash dividends and stock repurchases, thereby reflecting our confidence in the future cash flows of our business and our desire to optimize our cost of capital. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, availability of financing on acceptable terms, debt service requirements, our credit rating, changes to applicable tax laws or corporate laws, changes to our business model and periodic determination by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Company&#8217;s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include block purchases, tender offers, accelerated share repurchases and market transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors declared quarterly cash dividends of $1.94, $1.76 and $1.60 per share of common stock paid in 2022, 2021 and 2020, respectively, an increase of 10% over the prior year in both 2022 and 2021. In December 2022, the Board of Directors declared a cash dividend of $2.13 per share of common stock for the first quarter of 2023, an increase of 10% for this period, to be paid in March 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also returned capital to stockholders through our stock repurchase program. During 2022, we repurchased $6.3 billion of common stock, including $6.0 billion under ASR agreements and had cash settlements for stock repurchases of $6.4 billion. In 2021, we repurchased and had cash settlements of $5.0 billion of common stock. In 2020, we repurchased and had cash settlements of $3.5 billion of common stock. In October 2022, the Board of Directors increased the amount authorized under our stock repurchase program by $2.4 billion. As of December 31, 2022, $7.0 billion remained available under the stock repurchase program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of December 31, 2022 and 2021. Our accumulated deficit is not anticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our expected continued profitability and strong financial position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure and debt service requirements, our plans to pay dividends and repurchase stock, and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, borrowings through commercial paper and/or syndicated credit facilities, and access to other domestic and foreign debt markets and equity markets. See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help meet our liquidity requirements, we have entered into various financing arrangements. The noncurrent portions of our long-term borrowings as of December 31, 2022 and 2021, were $37.4 billion and $33.2 billion, respectively. The carrying values of our long-term borrowings are net of fair value adjustments for interest rate swaps and unamortized discounts, premiums and offering costs. As of December 31, 2022, S&amp;P, Moody&#8217;s and Fitch assigned credit ratings to our outstanding senior notes of BBB+, Baa1 and BBB+, respectively, which are considered investment grade. Unfavorable changes to these ratings may have an adverse impact on future financings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, we issued debt with aggregate principal amounts of $7.0 billion, $5.0 billion and $9.0 billion, respectively. During 2022, we repurchased portions of our debt at a cost of $0.3 billion. During 2021 and 2020, we repaid/redeemed debt of $4.2 billion and $6.5 billion, respectively. In addition, during 2020, we exchanged $0.7 billion of certain of our outstanding note issuances with $0.9 billion of newly issued notes with a lower interest rate and later maturity date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted a fixed-rate interest coupon for certain of our debt issuances to a floating, LIBOR-based coupon over the lives of the respective notes. These interest rate swap contracts qualify and are designated as fair value hedges. As of both December 31, 2022 and 2021, we had interest rate swap contracts with aggregate notional amount of $6.7 billion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts, which effectively convert the interest payments and principal repayment of the respective notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts qualify and are designated as cash flow hedges. As of both December 31, 2022 and 2021, we had cross-currency swap contracts with aggregate notional amount of $3.4 billion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. During 2022, 2021 and 2020, we did not issue any commercial paper. No commercial paper was outstanding as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.1% of the unused portion of the facility based on our current credit rating. In December 2022, this revolving credit agreement was further amended to replace LIBOR with SOFR as the reference rate, pursuant to provisions contained therein related to determination of successor rates in case of phaseout or unavailability of existing designated reference rates. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) SOFR plus 1.125% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month SOFR plus 1.1%. As of December 31, 2022 and 2021, no amounts were outstanding under this facility.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, in connection with the proposed acquisition of Horizon, we entered into a bridge credit agreement and a term loan credit agreement which provide for borrowings in the aggregate of $28.5&#160;billion. As of December 31, 2022, no amounts have been borrowed under either agreement. See Part IV&#8212;Note 2, Acquisitions and divestitures, to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is anticipated that the U.S. dollar LIBOR rate will be phased out and replaced by 2023. The Alternative Reference Rates Committee, a group of private-market participants convened by the Federal Reserve Board and the Federal Reserve Bank of New York to help ensure a successful transition from U.S. dollar LIBOR to a more robust reference rate, recommends SOFR as the U.S. dollar LIBOR alternative. As such, we expect SOFR to become widely adopted by market participants. We do not expect this change to have a material impact on our consolidated financial statements. See Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depositary shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depositary shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This shelf registration statement expires in February 2023, and our Board has approved a new shelf registration statement to replace it.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement, bridge credit agreement and term loan credit agreement include a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements. We were in compliance with all applicable covenants under these arrangements as of December 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These financing arrangements are more fully discussed in Part IV&#8212;Note 15, Financing arrangements, and Note 18, Derivative instruments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our summarized cash flow activity was as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,044)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities has been and is expected to continue to be our primary recurring source of funds. Cash provided by operating activities increased in 2022 primarily due to the timing of payments for sales incentives and discounts, vendor purchases, liabilities to tax authorities and receipts from corporate partners, partially offset by higher manufacturing activities in the current year. Cash provided by operating activities decreased during 2021 primarily due to the monetization of interest rate swaps that occurred in 2020 and the timing of payments for sales incentives and discounts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during 2022 was primarily due to our $3.8&#160;billion purchase of ChemoCentryx and net cash outflows related to marketable securities of $1.4&#160;billion. Cash provided by investing activities during 2021 was primarily due to net cash inflows related to marketable securities of $4.3 billion, partially offset by cash used in the acquisitions of Teneobio and Five Prime of $2.5 billion. Cash used in investing activities during 2020 was primarily due to our $3.2 billion of purchases of equity method investments, primarily BeiGene, and net cash outflows related to marketable securities of $1.5 billion. Capital expenditures were $936 million, $880 million and $608 million in 2022, 2021 and 2020, respectively. We currently estimate 2023 spending on capital projects to be approximately $925&#160;million. A majority of the increase in expenditures relates to expansion of manufacturing capacity to enable supply of products and product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during 2022 was primarily due to payments to repurchase our common stock of $6.4&#160;billion and dividends paid of $4.2&#160;billion, partially offset by proceeds from the issuance of debt of $6.9&#160;billion. Cash used in financing activities during 2021 was primarily due to payments to repurchase our common stock of $5.0 billion and the payment of dividends of $4.0&#160;billion, partially offset by proceeds from the issuance of debt, net of repayments of $0.8 billion. Cash used in financing activities during 2020 was primarily due to the payment of dividends of $3.8 billion and payments to repurchase our common stock of $3.5 billion, partially offset by proceeds from issuance of debt, net of repayments of $2.5 billion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part IV&#8212;Note 9, Investments; Note 15, Financing arrangements; and Note 16, Stockholders&#8217; equity, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital requirements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have material cash requirements to pay third parties under various contractual obligations discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to pay interest and repay principal under our various financing arrangements, including amounts under interest rate swap and cross-currency swap contracts related to certain of our long-term debt obligations. For information on scheduled debt maturities and payments under derivative contracts associated with our long-term debt obligations, see Part IV&#8212;Note 15, Financing arrangements, and Note 18, Derivative instruments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make payments for operating leases, including rental commitments on abandoned leases and leases that have not yet commenced. For information on these obligations, see Part IV&#8212;Note 13, Leases, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Tax Act, we elected to pay in eight annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. For information on the remaining scheduled repatriation tax installments, see Part IV&#8212;Note 19, Contingencies and commitments&#8212;Commitments&#8212;U.S. repatriation tax, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have purchase obligations of $3.5 billion primarily related to (i) R&amp;D commitments (including those related to clinical trials) for new and existing products, (ii) capital expenditures and (iii) open purchase orders for the acquisition of goods and services in the ordinary course of business. Most of these obligations are expected to be paid within one year, and payment of certain of these amounts may be reduced based on certain future events.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the purchase obligations noted above, we are contractually obligated to pay additional amounts that in the aggregate are significant, upon the achievement of various development, regulatory and commercial milestones for agreements we have entered into with third parties, including contingent consideration incurred in the acquisitions of Teneobio and K-A. These payments are contingent upon the occurrence of various future events, substantially all of which have a high degree of uncertainty of occurring, and any resulting cash requirements are managed through our operational budgeting processes. Except with respect to the fair value of the contingent consideration of approximately $0.3 billion, these obligations are not recorded on our Consolidated Balance Sheets. As of December 31, 2022, the maximum amount that may be payable in the future for agreements we have entered into with third parties is $5.6 billion.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded liabilities for UTBs that, because of their nature, have a high degree of uncertainty regarding the timing of future cash payment and other events that extinguish these liabilities. See Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. Our significant accounting policies are included in Part IV&#8212;Note 1, Summary of significant accounting policies. The following are considered critical to our consolidated financial statements because they require the most difficult, subjective or complex judgments, often because of the need to make estimates about matters that are inherently uncertain.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate. Accruals are also adjusted to reflect actual results. Amounts recorded in Accrued liabilities in the Consolidated Balance Sheets for sales deductions were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, total sales deductions were 51%, 47% and 44% of gross product sales, respectively. The increase in the total sales deductions balance as of December 31, 2022, compared with December 31, 2021, was primarily driven by the impact of higher U.S. chargeback and commercial rebate discount rates and an increase in gross sales, partially offset by timing of payments. Included in the amounts are immaterial net adjustments related to prior-year sales due to changes in estimates. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we use wholesalers as the principal means of distributing our products to healthcare providers such as physicians or their clinics, dialysis centers, hospitals and pharmacies. Products we sell in Europe are distributed principally to hospitals and/or wholesalers depending on the distribution practice in each country where the products are sold. We monitor the inventory levels of our products at our wholesalers by using data from our wholesalers and other third parties, and we believe wholesaler inventories have been maintained at appropriate levels (generally two to three weeks) given end-user demand. Accordingly, historical fluctuations in wholesaler inventory levels have not significantly affected our method of estimating sales deductions and returns.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given year, can be affected by the mix of products sold.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates include primarily amounts paid to payers and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements that vary by product, by payer and by individual payer plans. As we sell products, we estimate the amount of rebate we will pay based on the product sold, contractual terms, estimated patient population, historical experience and wholesaler inventory levels; and we accrue these rebates in the period the related sales are recorded. We then adjust the rebate accruals as more information becomes available and to reflect </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">actual claims experience. Estimating such rebates is complicated, in part because of the time delay between the date of sale and the actual settlement of the liability. We believe the methodology we use to accrue for rebates is reasonable and appropriate given current facts and circumstances, but actual results may differ. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wholesaler chargebacks relate to our contractual agreements to sell products to healthcare providers in the United States at fixed prices that are lower than the prices we charge wholesalers. When healthcare providers purchase our products through wholesalers at these reduced prices, wholesalers charge us for the difference between their purchase prices and the contractual prices between Amgen and the healthcare providers. The provision for chargebacks is based on expected sales by our wholesaler customers to healthcare providers. Accruals for wholesaler chargebacks are less difficult to estimate than rebates are, and they closely approximate actual results because chargeback amounts are fixed at the date of purchase by the healthcare providers and because we generally settle the liability for these deductions within a few weeks.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated by comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. In each of the past three years, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-year sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We believe our estimates for uncertain tax positions are appropriate and sufficient for any assessments that may result from examinations of our tax returns. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items are included in our tax return at different times than they are reflected in the financial statements, and they cause temporary differences between the tax bases of assets and liabilities and their reported amounts. Such temporary differences create deferred tax assets and liabilities. Deferred tax assets are generally items that can be used as tax deductions or credits in tax returns in future years but for which we have already recorded the tax benefit in the consolidated financial statements. We establish valuation allowances against our deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities are either (i)&#160;tax expenses recognized in the consolidated financial statements for which payment has been deferred, (ii)&#160;expenses for which we have already taken a deduction on the tax return but have not yet recognized in the consolidated financial statements or (iii) liabilities for the difference between the book basis and the tax basis of the intangible assets acquired in many business combinations, because future expenses associated with these assets most often will not be tax deductible. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a vertically integrated enterprise with operations in the United States and various foreign jurisdictions. In the jurisdictions where we conduct operations, we are subject to income tax based on the tax laws and principles of such jurisdictions and on the functions, risks and activities performed therein. Our pretax income is therefore attributed to domestic or foreign sources based on the operations performed and risks assumed in each location and the tax laws and principles of the respective taxing jurisdictions. For example, we conduct significant operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes, pertaining to manufacturing, distribution and other related functions to meet our worldwide product demand. Income from our operations in Puerto Rico is subject to tax incentive grants through 2050.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#8211;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#8211;2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010&#8211;2012 by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed for the years 2010&#8211;2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#8211;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#8211;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#8211;2015 that we received in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#8211;2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for the years 2013&#8211;2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued on our foreign earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010&#8211;2012 and 2013&#8211;2015 Notices are without merit. We are contesting the 2010&#8211;2012 and 2013&#8211;2015 Notices through the judicial process. The two cases were consolidated in U.S. Tax Court on December 19, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently under examination by the IRS for the years 2016&#8211;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we have examinations by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not li</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">kely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements. See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations, Income taxes; and Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements for further discussion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to the tax laws, regulations and administrative practices of the United States, the U.S. territory of Puerto Rico, U.S. state jurisdictions and other countries in which we do business. Significant changes in these rules could have a material adverse effect on our results of operations. See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters such as intellectual property disputes, contractual disputes and class action suits that are complex in nature and have outcomes that are difficult to predict. We describe our legal proceedings and other matters that are significant or that we believe could become significant in Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of assets and liabilities in connection with acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired and continue to acquire intangible assets in connection with business combinations and asset acquisitions. These intangible assets consist primarily of technology associated with currently marketed human therapeutic products and IPR&amp;D product candidates. Discounted cash flow models are typically used to determine the fair values of these intangible assets for purposes of allocating consideration paid to the net assets acquired in an acquisition. See Part IV&#8212;Note 2, Acquisitions and divestitures, to the Consolidated Financial Statements. These models require the use of significant estimates and assumptions, including but not limited to:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">determining the timing and expected costs to complete in-process projects, taking into account the stage of completion at the acquisition date;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">projecting the probability and timing of obtaining marketing approval from the FDA and other regulatory agencies for product candidates;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">estimating the timing of and future net cash flows from product sales resulting from completed products and in-process projects; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developing appropriate discount rates to calculate the present values of the cash flows. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions are also required to determine the business combination date fair values of any contingent consideration obligations incurred in connection with business combinations. In addition, we must revalue these obligations each subsequent reporting period until the related contingencies are resolved and record changes in their fair values in earnings. The acquisition date fair values of contingent consideration obligations incurred or assumed in the acquisitions were determined using a combination of valuation techniques. Significant estimates and assumptions required for these valuations included but were not limited to the timing and probability of achieving regulatory milestones, product sales projections under various scenarios and discount rates used to calculate the present value of the required payments. These estimates and assumptions are required to be updated in order to revalue these contingent consideration obligations each reporting period. Accordingly, subsequent changes in underlying facts and circumstances could result in changes in these estimates and assumptions, which could have a material impact on the estimated future fair values of these obligations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the fair values used to record intangible assets acquired and contingent consideration obligations incurred in connection with business combinations and asset acquisitions are based on reasonable estimates and assumptions given the facts and circumstances as of the related valuation dates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the carrying value of our property, plant and equipment and our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such circumstances exist, an estimate of undiscounted future cash flows to be generated by the long-lived asset is compared with the carrying value to determine whether an impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, composed of IPR&amp;D projects acquired in a business combination that have not reached technological feasibility or that lack regulatory approval at the time of acquisition, are reviewed for impairment annually, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable and upon establishment of technological feasibility or regulatory approval. We determine impairment by comparing the fair value of the asset to its carrying value. If the asset&#8217;s carrying value exceeds its fair value, an impairment charge is recorded for the difference, and its carrying value is reduced accordingly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating future cash flows of an IPR&amp;D product candidate for purposes of an impairment analysis requires us to make significant estimates and assumptions regarding the amount and timing of costs to complete the project and the amount, timing and probability of achieving revenues from the completed product similar to how the acquisition date fair value of the project was determined, as described above. There are often major risks and uncertainties associated with IPR&amp;D projects as we are required to obtain regulatory approvals in order to be able to market these products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods which could have a material adverse effect on our results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our estimations of future cash flows used for assessing impairment of long-lived assets are based on reasonable assumptions given the facts and circumstances as of the related dates of the assessments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of equity method investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the carrying value of our equity method investments whenever events or changes in circumstances indicate that the carrying amount of an investment may not be recoverable. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time and the extent to which the fair value is below the carrying value, volatility of the security price, the financial condition of the issuer, changes in technology that may impair the earnings potential of the investment and our intent and ability to retain the investment to allow for a recovery in fair value. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our judgments used in assessing impairment of equity method investments are based on reasonable assumptions given the facts and circumstances as of the related dates of the assessments.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_103"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="text-align:justify;text-indent:24.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part IV&#8212;Note 1, Summary of significant accounting policies, to the Consolidated Financial Statements for a discussion of recently issued accounting pronouncements not yet adopted as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks that may result from changes in interest rates, foreign currency exchange rates and prices of equity instruments as well as changes in general economic conditions in the countries where we conduct business. To reduce certain of these risks, we enter into various types of foreign currency and interest rate derivative hedging transactions as part of our risk management program. We do not use derivatives for speculative trading purposes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discussion that follows, we assumed a hypothetical change in interest rates of 100 basis points from those as of December 31, 2022 and 2021. Except as noted below, we also assumed a hypothetical 20% change in foreign currency exchange rates against the U.S. dollar based on its position relative to other currencies as of December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-rate-sensitive financial instruments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of available-for-sale investments as of December 31, 2022 and 2021, was composed almost entirely of U.S. Treasury securities and money market mutual funds. The fair values of our available-for-sale investments were $4.3 billion and $7.3 billion as of December 31, 2022 and 2021, respectively. Duration is a sensitivity measure that can be used to approximate the change in the value of a security that will result from a 100 basis point change in interest rates. Applying a duration model, a hypothetical 100 basis point increase in interest rates as of December 31, 2022 and 2021, would not have resulted in a material reduction in the fair values of these securities. In addition, a hypothetical 100 basis point decrease in interest rates as of December 31, 2022 and 2021, would not result in a material effect on income in the respective ensuing year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had outstanding debt with a carrying value of $38.9 billion and a fair value of $35.0 billion. As of December 31, 2021, we had outstanding debt with a carrying value of $33.3 billion and a fair value of $37.9 billion. Our outstanding debt was composed of debt with fixed interest rates. Changes in interest rates do not affect interest expense on fixed-rate debt. Changes in interest rates would, however, affect the fair values of fixed-rate debt. A hypothetical 100 basis point decrease in interest rates relative to interest rates as of December 31, 2022 and 2021, would have resulted in an increase of $3.5 billion and $4.5 billion, respectively, in the aggregate fair value of our outstanding debt on these dates. Analysis of the debt does not consider the impact that hypothetical changes in interest rates would have on related interest rate swap contracts and cross-currency swap contracts, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified and were designated for accounting purposes as fair value hedges for certain of our fixed-rate debt. These interest rate swap contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective notes. Interest rate swap contracts with aggregate notional amounts of $6.7 billion were outstanding as of both December 31, 2022 and 2021. A hypothetical 100 basis point increase in interest rates relative to interest rates as of December 31, 2022 and 2021, would have resulted in reductions in fair values of approximately $210</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and $330 million, respectively, on our interest rate swap contracts on these dates. Analysis of the interest rate swap contracts does not consider the impact that hypothetical changes in interest rates would have on the related fair values of debt that these interest-rate-sensitive instruments were designed to offset. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts, which are designated as cash flow hedges, in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. As of December 31, 2022, we had forward interest rate contracts outstanding with an aggregate notional amount of $700&#160;million; there were no outstanding forward interest rate contracts as of December 31, 2021. A hypothetical 100 basis point decrease in interest rates relative to interest rates as of December 31, 2022 would have resulted in a reduction in fair value of approximately $60</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million on our forward interest rate contracts on this date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both December 31, 2022 and 2021, we had outstanding cross-currency swap contracts with aggregate notional amount of $3.4 billion that hedge our foreign-currency-denominated debt and related interest payments. These contracts effectively convert interest payments and principal repayment of this debt to U.S. dollars from euros, pounds sterling and Swiss francs and are designated for accounting purposes as cash flow hedges. A hypothetical 100 basis point adverse movement in interest rates relative to interest rates as of December 31, 2022 and 2021, would have resulted in reductions in the fair values of our cross-currency swap contracts of approximately $90 million and $170 million, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign-currency-sensitive financial instruments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations are affected by fluctuations in the value of the U.S. dollar compared with foreign currencies, predominantly the euro. Increases and decreases in our international product sales from movements in foreign currency exchange rates are partially offset by corresponding increases or decreases in our international operating expenses. Increases and decreases in our foreign-currency-denominated assets from movements in foreign currency exchange rates are partially offset by corresponding increases or decreases in our foreign-currency-denominated liabilities. To further reduce our net exposure to foreign currency exchange rate fluctuations on our results of operations, we enter into foreign currency forward and cross-currency swap contracts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had outstanding euro-, pound-sterling- and Swiss-franc-denominated debt with a principal carrying value and a fair value of $3.0 billion and $2.9 billion, respectively. As of December 31, 2021, we had outstanding euro-, pound-sterling- and Swiss-franc-denominated debt with a principal carrying value and a fair value of $3.2 billion and $3.6 billion, respectively. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2022, would have resulted in an increase in fair value of this debt of approximately $580 million on this date and a reduction in income in the ensuing year of approximately $600 million. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2021, would have resulted in an increase in fair value of this debt of $710 million on this date and a reduction in income in the ensuing year of $640 million. The impact on income from these hypothetical changes in foreign currency exchange rates would be substantially offset by the impact such changes would have on related cross-currency swap contracts, which are in place for the related foreign-currency-denominated debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have cross-currency swap contracts that are designated as cash flow hedges of our debt denominated in euros, pounds sterling and Swiss francs, with aggregate notional amount of $3.4 billion as of both December 31, 2022 and 2021. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates on these dates would have resulted in reductions in the fair values of these contracts of approximately $540 million and $700 million on these dates, respectively. The impact of this hypothetical adverse movement in foreign currency exchange rates on ensuing years&#8217; income from these contracts would be fully offset by corresponding hypothetical changes in the carrying amounts of the related hedged debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward contracts that are designated for accounting purposes as cash flow hedges of certain anticipated foreign currency transactions. As of December 31, 2022, the fair values of these contracts were a $288 million asset and a $76 million liability. As of December 31, 2021, the fair values of these contracts were a $183 million asset and a $39 million liability. As of December 31, 2022, we had primarily euro-based open foreign currency forward contracts with notional amounts of $6.0 billion. As of December 31, 2021, we had primarily euro-based open foreign currency forward contracts with notional amounts of $5.7 billion. With regard to foreign currency forward contracts that were open as of December 31, 2022, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2022, would have resulted in a reduction in fair value of these contracts of approximately $1.1 billion on this date and in the ensuing year, a reduction in income of approximately $590 million. With regard to contracts that were open as of December 31, 2021, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2021, would have resulted in a reduction in fair value of these contracts of approximately $1.1 billion on this date and in the ensuing year, a reduction in income of $390 million. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on anticipated transactions that these foreign-currency-sensitive instruments were designed to offset.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, we had open, short-duration, foreign currency forward contracts that mature in one month or less, that had notional amounts of $0.5 billion and $0.7 billion, respectively, and that hedged fluctuations of certain assets and liabilities denominated in foreign currencies but were not designated as hedges for accounting purposes. These contracts had no material net unrealized gains or losses as of December 31, 2022 and 2021. With regard to these foreign currency forward contracts that were open as of December 31, 2022 and 2021, a hypothetical 5% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates on these dates would not have a material effect on the fair values of these contracts or related income in the respective ensuing years. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on assets and liabilities that these foreign-currency-sensitive instruments were designed to offset.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market-price-sensitive financial instruments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, we were exposed to price risk on equity securities included in our portfolio of investments, which were acquired primarily for the promotion of business and strategic objectives. These investments include publicly and privately held small-capitalization stocks, limited partnerships that invest in early-stage biotechnology companies </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our investment in BeiGene. A 20% decrease in the aggregate value of our equity investment portfolio as of December 31, 2022 and 2021, would result in losses in fair value of approximately $1.1 billion and $1.4 billion, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Counterparty credit risks</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments, including derivatives, are subject to counterparty credit risk, which we consider as part of the overall fair value measurement. Our financial risk management policy limits derivative transactions by requiring that transactions be made only with institutions with minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch; and it places exposure limits on the amount with any individual counterparty. In addition, we have an investment policy that limits investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_109"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to the financial statements and schedule listed in Item&#160;15(a)1 and (a)2 of Part IV and included in this Annual Report on Form 10-K.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_112"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined under the Securities Exchange Act Rule&#160;13a-15(e), that are designed to ensure that information required to be disclosed in Amgen&#8217;s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to Amgen&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgen&#8217;s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, Amgen&#8217;s management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation under the supervision and with the participation of our management, including Amgen&#8217;s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgen&#8217;s disclosure controls and procedures. Based upon their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2022.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determined that as of December 31, 2022, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter then ended that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_118"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP in the United States. However, all internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and reporting.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria set forth by the COSO in Internal Control&#8212;Integrated Framework (2013 framework). Based on our assessment, management believes that the Company maintained effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting has been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as stated in their attestation report appearing below, which expresses an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Amgen Inc. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Amgen Inc.&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Amgen Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and the financial statement schedule listed in the Index at Item&#160;15(a)2 and our report dated February 9, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="text-align:right;text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xMjEvZnJhZzpkMWI2OGVmZmQwZWM0MzcwYTQzYjQzMTUyM2MzMGRjZi90ZXh0cmVnaW9uOmQxYjY4ZWZmZDBlYzQzNzBhNDNiNDMxNTIzYzMwZGNmXzQxNjM_24bd42cc-dda8-4d05-b35e-eb18e4e93a4a">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xMjEvZnJhZzpkMWI2OGVmZmQwZWM0MzcwYTQzYjQzMTUyM2MzMGRjZi90ZXh0cmVnaW9uOmQxYjY4ZWZmZDBlYzQzNzBhNDNiNDMxNTIzYzMwZGNmXzQxNjQ_fc61861c-1121-4049-a9bd-7f18dbaac6de">Los Angeles, California</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February&#160;9, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_124"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER INFORMATION</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_127"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-align:center"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_130"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our Directors is incorporated by reference from the section entitled ITEM&#160;1&#8212;ELECTION OF DIRECTORS in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2022 (the Proxy Statement). Information about the procedures by which stockholders may recommend nominees for the Board of Directors is incorporated by reference from APPENDIX A&#8212;AMGEN INC. BOARD OF DIRECTORS GUIDELINES FOR DIRECTOR QUALIFICATIONS AND EVALUATIONS and OTHER MATTERS&#8212;Stockholder Proposals for the 2024 Annual Meeting in our Proxy Statement. Information about our Audit Committee, members of the committee and our Audit Committee financial experts is incorporated by reference from the section entitled CORPORATE GOVERNANCE&#8212;Audit Committee in our Proxy Statement. Information about our executive officers is contained in the discussion entitled Part I, Item&#160;1. Business&#8212;Information about our Executive Officers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_133"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a Code of Ethics for the Chief Executive Officer and Senior Financial Officers applicable to our principal executive officer, principal financial officer, principal accounting officer or controller and other persons performing similar functions. To view this code of ethics free of charge, please visit our website at www.amgen.com. (The website address is not intended to function as a hyperlink, and the information contained in our website is not intended to be a part of this filing.) We intend to satisfy the disclosure requirements under Item&#160;5.05 of Form 8-K regarding an amendment to or a waiver from a provision of this code of ethics, if any, by posting such information on our website as set forth above.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_136"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXECUTIVE COMPENSATION</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about director and executive compensation is incorporated by reference from the sections entitled COMPENSATION DISCUSSION AND ANALYSIS, EXECUTIVE COMPENSATION TABLES, DIRECTOR COMPENSATION and CORPORATE GOVERNANCE&#8212;Pay Ratio in our Proxy Statement. Information about compensation committee matters is incorporated by reference from the sections entitled CORPORATE GOVERNANCE&#8212;Compensation and Management Development Committee and CORPORATE GOVERNANCE&#8212;Compensation Committee Report in our Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></td></tr></table></div><div id="if8055099d1994bb494875d41c341f00d_142"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Existing Equity Compensation Plans</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information as of December 31, 2022, concerning the shares of our common stock that may be issued under any form of award granted under our equity compensation plans in effect as of December 31, 2022 (including upon the exercise of options, upon the vesting of awards of RSUs or when performance units are earned and related dividend equivalents have been granted).</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:54.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities to be issued upon exercise of outstanding options and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price of outstanding options and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in<br/>column (a))</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by Amgen security holders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2009 Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,255,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 1991 Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,180,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total approved plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,237,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,435,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plan not approved by Amgen security holders:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Profit Sharing Plan for Employees in Ireland</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unapproved plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total all plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,237,811&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.29&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,657,894&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:7pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">The Amended 2009 Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. In accordance with this formula, each option or stock appreciation right counts as one share, while each RSU, performance unit or dividend equivalent counts as 1.9 shares. The number under column (a) represents the actual number of shares issuable under our outstanding awards without giving effect to the fungible share-counting formula. The number under column (c) represents the number of shares available for issuance under this plan based on each such available share counting as one share. Commencing with the grants made in April 2012, RSUs and performance units accrue dividend equivalents that are payable in shares only to the extent and when the underlying RSUs vest or underlying performance units have been earned and the related shares are issued to the grantee. The performance units granted under this plan are earned based on the accomplishment of specified performance goals at the end of their respective three-year performance periods; the number of performance units granted represent target performance, and the maximum number of units that could be earned based on our performance is 200% of the performance units granted in 2020, 2021 and 2022. </span></div><div style="margin-bottom:7pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the number of outstanding awards under column (a) includes (i) 5,322,407 shares issuable upon the exercise of outstanding options with a weighted-average exercise price of $207.29; (ii) 3,173,806 shares issuable upon the vesting of outstanding RSUs (including 307,825 related dividend equivalents); and (iii) 1,739,407 shares subject to outstanding 2020, 2021 and 2022 performance units (including 84,603 related dividend equivalents). The weighted-average exercise price shown in column (b) is for the outstanding options only. The number of available shares under column (c) represents the number of shares that remain available for future issuance under this plan as of December 31, 2022, employing the fungible share formula and presumes the issuance of target shares under the performance units granted in 2020, 2021 and 2022 and related dividend equivalents. The numbers under columns (a) and (c) do not give effect to the additional shares that could be issuable in the event above target performance on the performance goals under these outstanding performance units is achieved. Maximum performance under these goals could result in 200% of target shares being awarded for performance units granted in 2020, 2021 and 2022.</span></div><div style="margin-bottom:7pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">This plan has terminated as to future grants. The number under column (a) with respect to this plan includes 2,191 shares issuable upon the settlement of deferred RSUs (including 519 related dividend equivalents).</span></div><div style="margin-bottom:7pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">The Profit Sharing Plan was approved by the Board of Directors on July 28, 2011. The Profit Sharing Plan permits eligible employees of the Company&#8217;s subsidiaries located in Ireland who participate in the Profit Sharing Plan to apply a portion of their qualifying bonus and salary to the purchase of the Company&#8217;s common stock on the open market at the market price by a third-party trustee as described in the Profit Sharing Plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Directors and Executive Officers and Certain Beneficial Owners</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about security ownership of certain beneficial owners and management is incorporated by reference from the sections entitled SECURITY OWNERSHIP OF DIRECTORS AND EXECUTIVE OFFICERS and SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS in our Proxy Statement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_148"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about certain relationships and related transactions and director independence is incorporated by reference from the sections entitled CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS and CORPORATE GOVERNANCE&#8212;Director Independence in our Proxy Statement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_151"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the fees for professional services rendered by our independent registered public accountants is incorporated by reference from the section entitled AUDIT MATTERS&#8212;Independent Registered Public Accountants in our Proxy Statement.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_157"></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.34pt">Index to Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Consolidated Financial Statements are included herein:</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:81.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page<br/>number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNTcvZnJhZzo5ZTIzZTFmOGQwYWY0MjE2OTJlY2RhN2M1NDJiZDk3MC90YWJsZTpiZWRhOTk1NWU1OTM0Y2Y1YTc1ZWYzMGJlZGUyZGE5ZS90YWJsZXJhbmdlOmJlZGE5OTU1ZTU5MzRjZjVhNzVlZjMwYmVkZTJkYTllXzEtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246ZGE2NzdjNzVmOGJlNGY4NWI1MGEzZmViNzIxM2NkODZfNzE_b6612c4c-9e3a-458c-9346-334daac25957">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_172">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_172">1</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Income for each of the three years in the period ended December 31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_175">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_175">4</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income for each of the three years in the period ended December 31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_178">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_178">5</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_181">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_181">6</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_184">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_184">7</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_187">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_187">8</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_190">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_190">9</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.34pt">Index to Financial Statement Schedules</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Schedule is filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:1pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:81.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page<br/>number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule II. Valuation and Qualifying Accounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8055099d1994bb494875d41c341f00d_253">F-55</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules are omitted because they are not applicable, not required or because the required information is included in the consolidated financial statements or notes thereto.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.34pt">Exhibits</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519228830/d787825dex21.htm">Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519270139/d655928dex101.htm">Amendment No. 1 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on October 17, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a23amendmentno2toapa.htm">Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a24letteragreementv3.htm">Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgen&#8217;s acquisition of Otezla</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519228830/d787825dex22.htm">Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/amgn-ex27_202193021xq3.htm">Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis Advisors LLC.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential)(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2021 on November 3, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522211860/d346334dex21.htm">Agreement and Plan of Merger, dated as of August 3, 2022, among ChemoCentryx, Inc., Amgen Inc. and Carnation Merger Sub, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 4, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522302256/d346985dex21.htm">Transaction Agreement, dated as of December 11, 2022, by and among Amgen Inc., Pillartree Limited and Horizon Therapeutics plc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 12, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522302256/d346985dex22.htm">Appendix 3 to the Rule 2.7 Announcement, dated as of December 12, 2022 (Conditions Appendix).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 12, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000144530513001107/amgn-exh31_2013331xq1.htm">Restated Certificate of Incorporation of Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Restated March 6, 2013.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 on May 3, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516466178/d46204dex31.htm">Amended and Restated Bylaws of Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Amended and Restated February 15, 2016.) (Filed as an exhibit to Form 8-K on February 17, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000318154-97-000008.txt">Form of stock certificate for the common stock, par value $.0001 of the Company.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1997 on May 14, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508040431/dex43.htm">Agreement of Resignation, Appointment and Acceptance dated February 15, 2008.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2007 on February 28, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001006.txt">First Supplemental Indenture, dated February 26, 1997.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on March 14, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001433.txt">8-1/8% Debentures due April 1, 2097.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001433.txt">Officer&#8217;s Certificate of Amgen Inc., dated April 8, 1997, establishing a series of securities entitled &#8220;8 1/8% Debentures due April 1, 2097.&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000104746903026118/a2115639zex-4_1.htm">Indenture, dated August 4, 2003.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form S-3 Registration Statement on August 4, 2003 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000318154-98-000005.txt">Corporate Commercial Paper - Master Note between and among Amgen Inc., as Issuer, Cede &amp; Co., as Nominee of The Depository Trust Company, and Citibank, N.A., as Paying Agent.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March&#160;31, 1998 on May&#160;13, 1998 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312507126045/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 30, 2007, including form of the Company&#8217;s 6.375% Senior Notes due 2037.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 30, 2007 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508121768/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 23, 2008, including form of the Company&#8217;s 6.90% Senior Notes due 2038.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on May 23, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312509007552/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated January 16, 2009, including form of the Company&#8217;s 6.40% Senior Notes due 2039.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on January 16, 2009 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510055545/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated March 12, 2010, including form of the Company&#8217;s 5.75% Senior Notes due 2040.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on March 12, 2010 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510211595/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated September 16, 2010, including form of the Company&#8217;s 4.95% Senior Notes due 2041.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on September 17, 2010 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511178620/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated June 30, 2011, including form of the Company&#8217;s 5.65% Senior Notes due 2042.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on June 30, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511306300/d254287dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated November 10, 2011, including form of the Company&#8217;s 5.15% Senior Notes due 2041.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on November 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511329468/d265264dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated December 5, 2011, including form of the Company&#8217;s 5.50% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 5, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312512234621/d352967dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 15, 2012, including form of the Company&#8217;s 5.375% Senior Notes due 2043.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 15, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312512390074/d410209dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated September 13, 2012, including form of the Company&#8217;s 4.000% Senior Notes due 2029.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on September 13, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312514209848/d732359dex41.htm">Indenture, dated May 22, 2014, between Amgen Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312514209848/d732359dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 22, 2014, including form of the Company&#8217;s 3.625% Senior Notes due 2024.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312515165541/d919213dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated May 1, 2015, including forms of the Company&#8217;s 3.125% Senior Notes due 2025 and 4.400% Senior Notes due 2045.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on May 1, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516476783/d129782dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 25, 2016, including form of the Company&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516476783/d129782dex42.htm"> 2.000% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on February 26, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516495970/d156859dex41.htm">Form of Permanent Global Certificate for the Company&#8217;s 0.410% bonds due 2023.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516495970/d156859dex42.htm">Terms of the Bonds for the Company&#8217;s 0.410% bonds due 2023.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516621372/d203675dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of June 14, 2016, including forms of the Company&#8217;s 4.563% Senior Notes due 2048 and 4.663% Senior Notes due 2051.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on June 14, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516686451/d187158dex43.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 19, 2016, including forms of the Company&#8217;s 2.250% Senior Notes due 2023 and 2.600% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 19, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312517331065/d472956dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of November 2, 2017, including in the form of the Company&#8217;s 3.200% Senior Notes due 2027.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on November 2, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520044757/d894000dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 21, 2020, including forms of the Company&#8217;s 1.900% Senior Notes due 2025, 2.200% Senior Notes due 2027, 2.450% Senior Notes due 2030, 3.150% Senior Notes due 2040 and 3.375% Senior Notes due 2050.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on February 21, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520134934/d925911dex43.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of May 6, 2020, including form of the Company&#8217;s 2.300% Senior Notes due 2031.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 6, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520222579/d60848dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Company&#8217;s 2.770% Senior Notes due 2053.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.) </span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312521240434/d213858dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 9, 2021, including forms of the Company&#8217;s 1.650% Senior Notes due 2028, 2.000% Senior Notes due 2032, 2.800% Senior Notes due 2041 and 3.000% Senior Notes due 2052.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 9, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522048514/d302710dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 22, 2022, including forms of the Company&#8217;s 3.000% Senior Notes due 2029, 3.350% Senior Notes due 2032, 4.200% Senior Notes due 2052 and 4.400% Senior Notes due 2062.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on February 22, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522224115/d280175dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 18, 2022, including forms of the Company&#8217;s 4.050% Senior Notes due 2029, 4.200% Senior Notes due 2033 and 4.875% Senior Notes due 2053.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 18, 2022 and incorporated herein by reference.)</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit434-descriptionofse.htm">Description of Amgen Inc.&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312513145924/d475543ddef14a.htm#toc475543_21">Amgen Inc. Amended and Restated 2009 Equity Incentive Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as Appendix C to the Definitive Proxy Statement on Schedule 14A on April 8, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815415000010/amgn-ex102_2015331xq1.htm">First Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 4, 2015.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2015 on April 27, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000035/amgn-ex103_2016331xq1.htm">Second Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 2, 2016</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2016 on May 2, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit104-formofgrantofst.htm">Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Amended and Restated on December 12, 2022.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit105-formofrestricte.htm">Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Amended and Restated on December 12, 2022.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815418000004/exhibit106performanceaward.htm">Amgen Inc. 2009 Performance Award Program. (As Amended on December 12, 2017.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2017 on February 13, 2018 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit107-formofperforman.htm">Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Amended and Reinstated on December 12, 2022.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/amgn-ex108_20201231xq4.htm">Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on October 21, 2020.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1010-amgenxdirectorrs.htm">Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1010-amgenxdirectorrs.htm"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1011-amgenxdirectorca.htm">Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815414000004/amgn-ex109_20131231x10k.htm">Amgen Inc. Supplemental Retirement Plan. (As Amended and Restated effective October 16, 2013.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000053/amgn-ex1012_2016930xq3.htm">First Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 14, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1014-secondamendmento.htm">Second Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 23, 2019.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-ex1015_20211231xq4.htm">Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.4+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10114-fourthamendme.htm">Fourth Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2022.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000095012311048073/v58996exv10w9.htm">Amended and Restated Amgen Change of Control Severance Plan. (As Amended and Restated effective December 9, 2010 and subsequently amended effective March 2, 2011.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/amgn-ex1017_2022331xq1.htm">Amgen Inc. Executive Incentive Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Amended and Restated effective January 1, 2022.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2022 on April 28, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815414000004/amgn-ex1015_20131231x10k.htm">Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated effective October 16, 2013.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000053/amgn-ex1017_2016930xq3.htm">First Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective October 14, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1021-secondamendmentt.htm">Second Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2020.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-ex1023_20211231xq4.htm">Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-ex1025_20211231xq4.htm">Aircraft Time Sharing Agreement, dated December 3, 2021, by and between Amgen Inc. and Robert A. Bradway.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519312129/d834361dex101.htm">Second Amended and Restated Credit Agreement, dated December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as administrative agent, and JPMorgan Chase Bank, N.A., as syndication agent.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 12, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10161-amendmentno1t.htm">Amendment No. 1 to the Second Amended and Restated Credit Agreement, dated as of December 29, 2022, between Amgen Inc. and Citibank, N.A., as the Administrative Agent and an Issuing Bank.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522302256/d346985dex101.htm">Bridge Credit Agreement, dated as of December 12, 2022, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A. and Bank of America, N.A., as lead arrangers and book runners, and the other banks party thereto.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 12, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522311112/d429654dex101.htm">Term Loan Credit Agreement, dated as of December 22, 2022, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A., Bank of America, N.A., Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, Goldman Sachs Bank USA and Mizuho Bank, Ltd. as documentation agents, and the other banks party thereto.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 22, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312513312834/d573775dex1054.htm">Collaboration and License Agreement between Amgen Inc. and Celltech R&amp;D Limited dated May 10, 2002 (portions of the exhibit have been omitted pursuant to a request for confidential treatment) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&amp;D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K/A for the year ended December 31, 2012 on July 31, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000004/amgn-ex1032_20161231x10k.htm">Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&amp;D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2016 on February 14, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815419000037/amgn-ex282019630xq2.htm">Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1041bridgecollaborati.htm">Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/exhibit1041-firstamendment.htm">First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1042guaranteeagreement.htm">Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520003926/d848812dex991.htm">Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520003926/d848812dex992.htm">Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/a1046restatedamendment.htm">Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/exhibit1046-collaborationa.htm">Collaboration Agreement dated March 30, 2012 by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, a wholly owned subsidiary of AstraZeneca Pharmaceuticals LP</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/exhibit1047-amendmentno1to.htm">Amendment No. 1 to the Collaboration Agreement, dated October 1, 2014, by and among Amgen Inc., AstraZeneca Collaboration Ventures, LLC and AstraZeneca Pharmaceuticals LP</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/amgn-ex10492020630xq2.htm">Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/amgn-ex1050_20201231xq4.htm">Amendment No. 7 to the Collaboration Agreement, dated December 17, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-1051_20211231xq4.htm">Amendment No. 8 to the Collaboration Agreement, dated November 19, 2021, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/amgn-ex1049_2021630xq2.htm">License and Collaboration Agreement, dated June 1, 2021, by and between Amgen Inc. and Kyowa Kirin Co., Ltd. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2021 on August 4, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex21_20221231xq4.htm">Subsidiaries of the Company.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of the Independent Registered Public Accounting Firm. The consent is set forth on page 91 of this Annual Report on the 10-K.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney. The Power of Attorney is set forth on page 92 of this Annual Report on Form 10-K.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex31_20221231xq4.htm">Rule 13a-14(a) Certifications.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex32_20221231xq4.htm">Section 1350 Certifications.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(* = filed herewith)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(** = furnished herewith and not &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(+ = management contract or compensatory plan or arrangement)</span></div><div style="text-align:justify"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_160"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K SUMMARY</span></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEN INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER H. GRIFFITH</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23</span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-3 No. 333-236351) of Amgen Inc.,</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-8 No. 333-159377) pertaining to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, </span></div><div style="padding-left:40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-8 No. 33-39183) pertaining to the Amgen Inc. Amended and Restated Employee Stock Purchase Plan, </span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statements (Form S-8 No. 33-39104, as amended by Form S-8 Nos. 333-144581 and 333-216719) pertaining to the Amgen Retirement and Savings Plan,</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statements (Form S-8 Nos. 33-47605, 333-144580 and 333-216715) pertaining to The Retirement and Savings Plan for Amgen Manufacturing, Limited (formerly known as the Retirement and Savings Plan for Amgen Manufacturing, Inc.), </span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statements (Form S-8 Nos. 333-81284, 333-177868, 333-216723 and 333-260723) pertaining to the Amgen Nonqualified Deferred Compensation Plan, and</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-8 Nos. 333-176240 and 333-260724) pertaining to the Amgen Profit Sharing Plan for Employees in Ireland;</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February 9, 2023, with respect to the consolidated financial statements of Amgen Inc. and the effectiveness of internal control over financial reporting of Amgen Inc. included in this Annual Report (Form 10-K) of Amgen Inc. for the year ended December 31, 2022.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst&#160;&amp; Young LLP</span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Los Angeles, California</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 9, 2023 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 24</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL MEN AND WOMEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert A. Bradway, Peter H. Griffith and Jonathan P. Graham, or any of them, his or her attorney-in-fact, each with the power of substitution and re-substitution, for him or her in any and all capacities, to sign any amendments to this Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ROBERT A. BRADWAY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board, Chief Executive Officer<br/>and President, and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Robert A. Bradway</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;PETER H. GRIFFITH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter H. Griffith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;LINDA H. LOUIE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance and<br/>Chief Accounting Officer<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Linda H. Louie</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;WANDA M. AUSTIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wanda M. Austin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;MICHAEL V. DRAKE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael V. Drake</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;BRIAN J. DRUKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Brian J. Druker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ROBERT A. ECKERT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Robert A. Eckert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;GREG C. GARLAND</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greg C. Garland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;CHARLES M. HOLLEY, JR.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charles M. Holley, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;S. OMAR ISHRAK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">S. Omar Ishrak</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;TYLER JACKS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tyler Jacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ELLEN J. KULLMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ellen J. Kullman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;AMY E. MILES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amy E. Miles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;RONALD D. SUGAR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ronald D. Sugar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;R. SANDERS WILLIAMS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R. Sanders Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Amgen Inc.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Amgen Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and the financial statement schedule listed in the Index at Item&#160;15(a)2 (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 9, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:14.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales deductions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company recorded accrued sales deductions of $6.0 billion. As described in Note 1 to the financial statements under the caption &#8220;Product sales and sales deductions,&#8221; revenues from product sales are recognized net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively sales deductions), which are established at the time of sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the estimation of sales deductions, which are netted against product sales, is complex, requires significant judgment, and the amounts involved are material to the financial statements taken as a whole. Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, and is based on an amount that reflects the consideration to which the Company expects to be entitled, which represents an amount that is net of accruals for estimated sales deductions. The estimated sales deductions are based on current contractual and statutory requirements, market events and trends, internal and external historical data, and forecasted customer buying patterns.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the sales deduction processes. This included testing controls over management&#8217;s review of significant assumptions and inputs used in the estimate of sales deductions, including actual sales, contractual terms, historical experience, wholesaler inventory levels, demand data and estimated patient population. We also tested management&#8217;s controls over the accuracy of forecasting demand activity as well as the completeness and accuracy of the significant components included in the final sales deduction estimates. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test management&#8217;s estimated sales deductions, we obtained management&#8217;s calculations for the respective estimates and performed the following procedures, among others. We tested management&#8217;s estimation process over the determination of sales discount accruals by developing an independent expectation of the estimated accrual balances, including comparing accrual balances recorded by management to those implied by historical payment trends, performing a lookback analysis using actual historical data to evaluate the forecasted amounts, assessing subsequent events to determine whether there was any new information that would require adjustment to the initial accruals, evaluating trends in actual sales and discount accrual balances, comparing cash receipts to product sales, confirming terms and conditions for a sample of contracts, testing a sample of credits issued and payments made throughout the year, and agreeing rates to underlying contract terms.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:14.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized tax benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 6 to the consolidated financial statements, the Company operates in various jurisdictions in which differing interpretations of complex tax laws and regulations create uncertainty and necessitate the use of significant judgment in the determination of the Company&#8217;s unrecognized tax benefits related to allocation of profits among various jurisdictions (&#8220;transfer pricing&#8221;), particularly in the U.S. federal tax jurisdiction where the Company has significant assets and operations. In this regard, the Company uses significant judgment in (1) determining whether a tax position&#8217;s technical merits are more-likely-than-not to be sustained and (2) measuring the amount of tax benefit that qualifies for recognition. As of December 31, 2022, the Company accrued $3.8 billion of gross unrecognized tax benefits including those related to transfer pricing. Auditing the assessment of the technical merits and measurement of the Company&#8217;s unrecognized tax benefits is challenging and can be complex, highly judgmental, and based on interpretations of tax laws and regulations and application of those interpretations to the Company&#8217;s facts and circumstances.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the Company&#8217;s process to assess the technical merits of its tax positions, as well as management&#8217;s process to measure the unrecognized tax benefits of those tax positions, particularly in regard to transfer pricing. This included testing controls over management&#8217;s review of the inputs, calculations, assumptions and methods selected to measure the amount of tax benefits that qualify for recognition. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We involved tax and transfer pricing specialists to assist in assessing the technical merits and measurement of certain of the Company&#8217;s unrecognized tax benefits. Depending on the nature of the specific tax position and, as applicable, developments with the relevant tax authorities, our procedures included obtaining and reviewing the Company&#8217;s correspondence with such tax authorities and evaluating certain third-party advice to support the Company&#8217;s evaluations and recorded positions. We used our knowledge of and experience with how the income tax laws and regulations related to transfer pricing are applied by the relevant tax authorities to evaluate the Company&#8217;s accounting for its unrecognized tax benefits. We evaluated developments in the applicable regulatory environments to assess potential effects on the Company&#8217;s recorded positions. We assessed management&#8217;s consideration of current tax controversy, litigation and tax litigation trends. We analyzed the assumptions and data used by the Company when it determined the amount of tax benefits to recognize, including applicable interest and penalties, and we tested the accuracy of those underlying calculations. We have also evaluated the Company&#8217;s income tax disclosures included in Note 6 in relation to these matters.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzIvZnJhZzozZTQwMDg2ODhiMTQ0ODkwYjkyNmNlZGI1MjY5ZTEwNS90YWJsZTo3ODQxZGIzZTk4YTE0MmMzYjY2YWU5NmYyNDgxNTkxOS90YWJsZXJhbmdlOjc4NDFkYjNlOThhMTQyYzNiNjZhZTk2ZjI0ODE1OTE5XzUtMi0xLTEtMTg4OTc0L3RleHRyZWdpb246Yjk5YWMyNGQ4ODM5NDZmNGI3NDdkODJmODJiNDU1NjlfOQ_11e9a07c-39fd-48c8-8e42-6b2314ec5548">Ernst &amp; Young LLP</ix:nonNumeric></span></div></td></tr></table></div><div style="padding-right:13.5pt;text-align:right"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 1980.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzIvZnJhZzozZTQwMDg2ODhiMTQ0ODkwYjkyNmNlZGI1MjY5ZTEwNS90ZXh0cmVnaW9uOjNlNDAwODY4OGIxNDQ4OTBiOTI2Y2VkYjUyNjllMTA1XzM1Nzk_3d3e955b-94a1-47e9-aff7-95bb73eb010a">Los Angeles, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 9, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2022, 2021 and 2020 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f333186d8da4378bcf0c5a3e6baf0f9_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzItMS0xLTEtMTg4OTc0_b88d2e08-8866-450a-8f6a-a2bba1d4ab51">24,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b25c75934844f82a32f7a76cdbe5042_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzItMy0xLTEtMTg4OTc0_76c0357b-eda9-42d8-946a-8286de91bfb3">24,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8db07843e5b426fbe44e0590a500e74_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzItNS0xLTEtMTg4OTc0_143d2a32-2cb2-4ecb-a3c3-f8547207b50c">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id25b0832750a4204ac083f11c97f8288_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMtMS0xLTEtMTg4OTc0_af9638ba-0c10-4afb-b80a-0f8fac22271b">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2457cd740816456db1f50da03ba631dc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMtMy0xLTEtMTg4OTc0_2028a9de-4f44-4fe9-a70b-3ba9af028f5e">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cbcfb77ce746588d1956f2435637ae_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMtNS0xLTEtMTg4OTc0_58fd98e4-aa96-45e2-9ce1-0ec6759c8f5d">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzQtMS0xLTEtMTg4OTc0_8defa462-223e-4760-a9ba-9338d83fb4e5">26,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzQtMy0xLTEtMTg4OTc0_afa8c79b-7aa1-4ac8-8d87-05a48544bb91">25,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzQtNS0xLTEtMTg4OTc0_0115902a-8ad4-4a07-b449-2579c3bf814a">25,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzctMS0xLTEtMTg4OTc0_148a0ab5-171b-4cd0-b6d0-0d9797c89739">6,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzctMy0xLTEtMTg4OTc0_116bb8b7-b9de-469b-ac5f-9deeff97cee3">6,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzctNS0xLTEtMTg4OTc0_6db25518-87de-40f8-a074-67562c9eb31f">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzgtMS0xLTEtMTg4OTc0_6730120b-e778-4dd9-8303-6ede3bd5b2f3">4,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzgtMy0xLTEtMTg4OTc0_6db62b91-7bf7-43e7-9f53-ac2609b15344">4,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzgtNS0xLTEtMTg4OTc0_acc0de27-a5a0-4b9a-b0ed-f41adb13e765">4,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzktMS0xLTEtMTg4OTc0_1cef4fca-3a17-48e0-810c-080fe515acc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzktMy0xLTEtMTg4OTc0_6081ce12-a859-4faa-a5c1-0fae1af8ed9d">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzktNS0xLTEtMTg4OTc0_041e3fc4-7876-460e-91c3-60cff59c5a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEwLTEtMS0xLTE4ODk3NA_d4f37e9a-3361-4c7d-922c-72a86650a808">5,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEwLTMtMS0xLTE4ODk3NA_906442a8-c4df-4e66-a2b5-7158a7e1f7fc">5,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEwLTUtMS0xLTE4ODk3NA_2e5128de-68b0-4285-ab8d-68328ce9105b">5,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OtherGeneralExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzExLTEtMS0xLTE4ODk3NA_6c725a28-fe30-44c2-9083-f287057b0a73">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OtherGeneralExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzExLTMtMS0xLTE4ODk3NA_06c50921-2af9-42ee-b6d0-8e4d533539ec">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:OtherGeneralExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzExLTUtMS0xLTE4ODk3NA_f45a35ee-4580-418a-8e73-b60c9bef2f5d">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEyLTEtMS0xLTE4ODk3NA_68a9b23b-ad1d-44da-b43b-d4a7d2c19aef">16,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEyLTMtMS0xLTE4ODk3NA_26c79658-ee9e-4035-b898-2de0df5ed9d3">18,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEyLTUtMS0xLTE4ODk3NA_bc7c7bc7-f8e2-408d-b5b6-1de455463e7d">16,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE0LTEtMS0xLTE4ODk3NA_3ea675a1-1811-4be7-a601-b9e6fe0dc9a3">9,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE0LTMtMS0xLTE4ODk3NA_01f7351d-1e61-4205-aa91-a6e0dd9e7ea1">7,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE0LTUtMS0xLTE4ODk3NA_8251dd2b-e344-47ca-8ebd-71503b73b7a9">9,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE3LTEtMS0xLTE4ODk3NA_a4bb8425-3ca9-4565-8a6e-4d35ff5d3def">1,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE3LTMtMS0xLTE4ODk3NA_5612fb69-4126-4a6d-80d6-95cc1381d441">1,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE3LTUtMS0xLTE4ODk3NA_d3097df9-0473-48ea-9c24-5e2e1f4395ba">1,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE4LTEtMS0xLTE4ODk3NA_0c98d736-2551-48c4-b9f8-822dfbdeb146">814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE4LTMtMS0xLTE4ODk3NA_96966e9d-e91d-4f65-925a-887d124523cb">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE4LTUtMS0xLTE4ODk3NA_ad1ca72f-e394-48ee-80d5-c060cce55265">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIwLTEtMS0xLTE4ODk3NA_c8c71de5-1bf2-4252-9e7c-82c72f72eeaa">7,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIwLTMtMS0xLTE4ODk3NA_5ef77341-bfbc-419e-b11f-fb3503c33003">6,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIwLTUtMS0xLTE4ODk3NA_1fae516a-6f7d-4432-9601-201b9d32cece">8,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIyLTEtMS0xLTE4ODk3NA_988b3740-0a07-4e79-8a9f-0daa6863fbcd">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIyLTMtMS0xLTE4ODk3NA_2d24c6be-e5d7-4c02-ac64-10a053310081">808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIyLTUtMS0xLTE4ODk3NA_9c927bf6-0907-4318-bbb2-d16dcde6647a">869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI0LTEtMS0xLTE4ODk3NA_213d2dc1-2f5e-426e-9ba6-061e388599f6">6,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI0LTMtMS0xLTE4ODk3NA_61ce32e9-4638-4a30-87de-0b07151223be">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI0LTUtMS0xLTE4ODk3NA_d9ab75ce-0ee0-48c2-983e-69cb5ea51bfd">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI3LTEtMS0xLTE4ODk3NA_35feb22c-1204-4af8-9f5f-9503070621fe">12.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI3LTMtMS0xLTE4ODk3NA_1b6ba5f3-e813-402a-90aa-f9118a00c17a">10.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI3LTUtMS0xLTE4ODk3NA_b46a717a-10a4-4c64-a027-684fcb8763f4">12.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI4LTEtMS0xLTE4ODk3NA_3afd4988-050a-4898-a6d0-db788fd412fd">12.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI4LTMtMS0xLTE4ODk3NA_6af7e6ff-5f3b-42eb-85c9-92789cb3cc29">10.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI4LTUtMS0xLTE4ODk3NA_17c769c7-0230-4321-bc01-edbbb07cdf92">12.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in the calculation of earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMxLTEtMS0xLTE4ODk3NA_34a28710-b20d-45e7-9e52-acdd7f58aa3c">538</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMxLTMtMS0xLTE4ODk3NA_294d1302-f7a3-4888-83a4-bfabc8e76d76">570</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMxLTUtMS0xLTE4ODk3NA_a7b23b0d-8aac-464a-9cae-7ac2d69963d2">586</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMyLTEtMS0xLTE4ODk3NA_22d96441-142e-4e2e-9dbc-daccd8b44e60">541</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMyLTMtMS0xLTE4ODk3NA_2f156750-e777-411b-b5b6-ae0aeb1da7b9">573</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMyLTUtMS0xLTE4ODk3NA_5f0fff11-1bc1-407b-9090-8fe8c2f0f0d6">590</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2022, 2021 and 2020 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzEtMS0xLTEtMTg4OTc0_14bc04c3-6a37-462c-b2ab-351b35e26065">6,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzEtMy0xLTEtMTg4OTc0_63629072-852c-491d-b372-bf81b967eff6">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzEtNS0xLTEtMTg4OTc0_4ddcd2e2-53bb-43d9-82b5-2f3cd468fc19">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of reclassification adjustments and taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzMtMS0xLTEtMTg4OTc0_7488c5ea-b2ae-4238-9c05-b6a7477485a6">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzMtMy0xLTEtMTg4OTc0_cac4e98a-b3cb-4b11-b887-79605050e7d5">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzMtNS0xLTEtMTg4OTc0_c99c21cf-d920-46d2-bc73-eb2156574271">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzQtMS0xLTEtMTg4OTc0_504cf090-6ea6-49f9-9526-1aecbaa7695d">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzQtMy0xLTEtMTg4OTc0_655ec8ba-f50a-496b-8f63-cdf779c02458">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzQtNS0xLTEtMTg4OTc0_f0877cbd-71bd-4e76-ae21-a578aec3f3b4">438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzUtMS0xLTEtMTg4OTc0_b1095882-9e60-412c-b0f0-c569580b160a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzUtMy0xLTEtMTg4OTc0_cf6db635-39e6-431a-a610-9463d23897e2">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzUtNS0xLTEtMTg4OTc0_f7ad989e-3380-450a-879a-d2ffa3717823">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzYtMS0xLTEtMTg4OTc0_d4ca1a3d-4f43-4a6a-ae7f-bc41befb497a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzYtMy0xLTEtMTg4OTc0_7c92d8d3-9fa7-42d7-977f-e6d180e2e165">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzYtNS0xLTEtMTg4OTc0_0f005909-1a08-4dd4-81d8-10a8a9e84232">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzctMS0xLTEtMTg4OTc0_f2018176-3a4c-4b90-b1f9-9530a26dca2c">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzctMy0xLTEtMTg4OTc0_1952c7f0-aaf1-472d-bce0-2910c1ffdfe7">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzctNS0xLTEtMTg4OTc0_23b5de90-9184-46e0-ac68-b285c139ad60">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzgtMS0xLTEtMTg4OTc0_e69207d7-78b2-4807-a5cd-5705ad527a9e">7,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzgtMy0xLTEtMTg4OTc0_19a79603-13ab-432e-a762-bf02e631a7ff">6,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzgtNS0xLTEtMTg4OTc0_aa0dd0d2-8544-490f-b197-f3d3730c0df1">6,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022 and 2021 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMtMS0xLTEtMTg4OTc0_cecfba4a-191b-4ba5-b642-e4e51d81b679">7,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMtMy0xLTEtMTg4OTc0_5a510c90-74c3-4da9-bdcd-395bb7600fd5">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzQtMS0xLTEtMTg4OTc0_ecd9ddb5-6bfc-4742-9df8-1e9cee3604cf">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzQtMy0xLTEtMTg4OTc0_fd5049fc-5f6f-43b3-a4ce-357e2f42af62">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzUtMS0xLTEtMTg4OTc0_fe86a08a-ccfc-4f4c-b37e-1739252a3392">5,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzUtMy0xLTEtMTg4OTc0_d3b87b84-850a-48b9-87bb-6e72218dc0ca">4,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzYtMS0xLTEtMTg4OTc0_1341956a-c0ff-4e6a-9a32-2630c827d0e9">4,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzYtMy0xLTEtMTg4OTc0_7f9e0516-d87d-497e-9ac7-c274ac5836b7">4,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzctMS0xLTEtMTg4OTc0_67eb7cfc-3ae5-4c06-97ce-234f6ff0d969">2,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzctMy0xLTEtMTg4OTc0_c4817cfa-0a6a-44da-879f-7094e71db6a6">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzgtMS0xLTEtMTg4OTc0_3cd4f76d-1b51-4fc6-ba93-a05a3320bb74">22,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzgtMy0xLTEtMTg4OTc0_98642183-1df4-4e18-aff7-6206010689e7">19,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEwLTEtMS0xLTE4ODk3NA_18490382-bd9e-4b87-a325-968bf3bb5074">5,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEwLTMtMS0xLTE4ODk3NA_be0dd8a4-30bc-4369-b323-9f468662dc83">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzExLTEtMS0xLTE4ODk3NA_43c36c2b-eb23-4b61-aeac-a2bff5a5a1a3">16,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzExLTMtMS0xLTE4ODk3NA_9f91b781-6307-4ede-823a-23ccac6b92b8">15,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEyLTEtMS0xLTE4ODk3NA_4a0ceb39-f71d-4407-bfa7-4efd1867a9cd">15,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEyLTMtMS0xLTE4ODk3NA_1fbd1dbd-e60b-49c1-8e83-4a48dcafb4d1">14,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEzLTEtMS0xLTE4ODk3NA_af74b73f-ce57-4f06-8012-75ca03e91561">5,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEzLTMtMS0xLTE4ODk3NA_3b5b6144-963a-45ec-955e-e1f3a75acc5e">6,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE0LTEtMS0xLTE4ODk3NA_39e422ff-a994-459e-85b2-34105802d8b8">65,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE0LTMtMS0xLTE4ODk3NA_cffda9b5-aa35-4612-86a4-27ecdb8eda76">61,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE4LTEtMS0xLTE4ODk3NA_8eb92059-33a5-461e-a05f-40fd69a84b61">1,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE4LTMtMS0xLTE4ODk3NA_2d8eeb26-81cb-4437-848d-3e9c1757255d">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE5LTEtMS0xLTE4ODk3NA_4da57fc8-51e9-458c-93fd-8ddba766caeb">12,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE5LTMtMS0xLTE4ODk3NA_f26216dc-64a0-4d04-a690-79d33f7acf80">10,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIwLTEtMS0xLTE4ODk3NA_613f37dd-b465-4d06-8028-61679aa84b31">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIwLTMtMS0xLTE4ODk3NA_58031cc3-4833-4725-bf6b-0e86a646924e">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIxLTEtMS0xLTE4ODk3NA_f10e0294-268b-414b-a5c0-95b7f9b7ebb3">15,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIxLTMtMS0xLTE4ODk3NA_c2f36a9f-406f-4684-86e8-d9bf136a2740">12,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIzLTEtMS0xLTE4ODk3NA_44b8140c-29e7-436f-b8f9-3d1ece700b15">37,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIzLTMtMS0xLTE4ODk3NA_adf646e9-d105-4765-84a1-4e552d8953fc">33,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI1LTEtMS0xLTE4ODk3NA_8b7b902f-9b1a-4158-9502-88ca2118582b">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI1LTMtMS0xLTE4ODk3NA_18c5f7b1-9b40-45cd-a978-cf073b83291f">6,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI2LTEtMS0xLTE4ODk3NA_c51a0fc8-9802-4266-98f5-c71402091c1b">2,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI2LTMtMS0xLTE4ODk3NA_8ce59234-9153-4251-b08a-fa09bb18243b">2,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingencies and commitments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI4LTEtMS0xLTE4ODk3NA_efc3b42c-bfb8-4e9d-af6b-75f3e1227ac2"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI4LTMtMS0xLTE4ODk3NA_83777605-1c36-4920-bb77-bbec4dc1f140"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital; $<ix:nonFraction unitRef="usdPerShare" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzQ5_a9847645-e2f1-4c5b-8235-3cfb0652d5c3"><ix:nonFraction unitRef="usdPerShare" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzQ5_efb011d4-7a9d-4952-a039-357975551069">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzcz_a80b8062-7ce4-4157-bf80-aacdc89909fa"><ix:nonFraction unitRef="shares" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzcz_ae4697ea-151d-4eda-b100-e0a15822ad92">2,750.0</ix:nonFraction></ix:nonFraction> shares authorized; outstanding&#8212;<ix:nonFraction unitRef="shares" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzEwNw_a9ef3d00-8550-4225-bb70-5250100aeffe">534.0</ix:nonFraction> shares in 2022 and <ix:nonFraction unitRef="shares" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzEyNw_fe91512e-c3c3-4bce-9ae0-018131a4c940">558.3</ix:nonFraction> shares in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTEtMS0xLTE4ODk3NA_9d06acba-5f87-4202-9cab-8cf93fdd9174">32,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTMtMS0xLTE4ODk3NA_4a43bf52-7227-4895-b0cb-655850e4c089">32,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMyLTEtMS0xLTE4ODk3NA_2d871583-1549-4570-adb2-bfb8cc8537f5">28,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMyLTMtMS0xLTE4ODk3NA_62a75ae3-9d2b-4825-bdf7-5fda73d8fe9c">24,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMzLTEtMS0xLTE4ODk3NA_888cd757-8955-4e89-8e7f-ffd3d2850824">231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMzLTMtMS0xLTE4ODk3NA_e35c7ab1-2c80-4089-a9e8-38bcdf452595">796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzM0LTEtMS0xLTE4ODk3NA_48a7d13e-497e-4239-b3aa-aee50c02771e">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzM0LTMtMS0xLTE4ODk3NA_57cbbaea-22f4-42e8-bf45-42b6e073996a">6,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzM1LTEtMS0xLTE4ODk3NA_86c2e035-0c8a-46ca-9d92-e6a087319bb7">65,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzM1LTMtMS0xLTE4ODk3NA_fa78e202-ee4f-4704-8b05-6f1b113fc01d">61,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2022, 2021 and 2020 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares<br/>of&#160;common<br/>stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>stock and<br/>additional<br/>paid-in&#160;capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>(loss) income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0567102b4dbd4cabaf51e541f2a41652_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtMS0xLTEtMTg4OTc0_2cedbbcc-a60a-44bb-9fea-b8a79c6a8e0b">591.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edf981fef6d4fa4973e8992576dab4c_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtMy0xLTEtMTg4OTc0_742de2c6-2727-477b-9f46-b3a02f38dbe6">31,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc5f2c87a3f74cd797cc6268b82470bc_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtNS0xLTEtMTg4OTc0_f229e73c-2b99-4d74-aeae-4d49903d3966">21,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb02e3f6128454a820a56e2cfbb6e3f_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtNy0xLTEtMTg4OTc0_08136141-dc30-4366-8b7e-ac4d1483fa03">528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtOS0xLTEtMTg4OTc0_d6651a0f-07d7-4239-8f2c-d7cf294652ab">9,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of changes in accounting principles, net of taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice20f9c10bef48889e1c07a014676f7b_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzItNS0xLTEtMTg4OTc0_b43d0fb3-0746-462c-8d83-dd8c178471ac">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10864dfaff048eca24b894294bae77d_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzItNy0xLTEtMTg4OTc0_b0a9f1b1-5d00-4d0c-9bf0-5754d1afb92e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb157cdc95045539f3bb40881b31817_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzItOS0xLTEtMTg4OTc0_9195ebe3-fa6e-48bb-8874-55107f339c41">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56dda630a2e4ae3bbca72a1ff1cf2ef_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzMtNS0xLTEtMTg4OTc0_18bb8a0f-95cf-4047-9822-1c906e0f57e4">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzMtOS0xLTEtMTg4OTc0_7198ade5-a4e8-4d1e-84c3-fca6ec725961">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzQtNy0xLTEtMTg4OTc0_da0a0454-0919-428e-8d12-8e762542be83">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzQtOS0xLTEtMTg4OTc0_987b366c-28fc-4010-a767-ac1359a004a3">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzUtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246NTE2ZDkyNWVkMzRiNDg5M2IzZGY4MTk5NjRhODY3OThfNDA_7819106c-1bda-4ee0-9f59-8b6a614901a4">6.56</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia56dda630a2e4ae3bbca72a1ff1cf2ef_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzUtNS0xLTEtMTg4OTc0_0e60386e-d18d-4914-aeaf-a04bf104f053">3,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzUtOS0xLTEtMTg4OTc0_6cbb7915-590f-4fa4-9b1e-207119ad4029">3,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5998f096c32498584f7ddcb1b102049_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzYtMS0xLTEtMTg4OTc0_f13d3f22-bd91-445c-adfa-d5da5c2841c2">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a339f1adc784aaa9ffccfd08a332107_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzYtMy0xLTEtMTg4OTc0_ead76ca3-2bf9-4671-bae5-02465845855f">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzYtOS0xLTEtMTg4OTc0_894d2af9-5caa-4f88-af1f-01d56818d875">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a339f1adc784aaa9ffccfd08a332107_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzctMy0xLTEtMTg4OTc0_42921a7f-4afb-494a-a922-9f3268640882">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzctOS0xLTEtMTg4OTc0_9a1ea7e7-2083-4ed7-a1a1-53bcfea4b9c6">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a339f1adc784aaa9ffccfd08a332107_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzgtMy0xLTEtMTg4OTc0_e9be383a-cfc3-43e4-b5b4-465677283012">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzgtOS0xLTEtMTg4OTc0_889773a5-40af-4caa-8d4d-3708cc098a22">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia5998f096c32498584f7ddcb1b102049_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzktMS0xLTEtMTg4OTc0_970a80a4-fafb-4531-8505-d422880ea66e">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia56dda630a2e4ae3bbca72a1ff1cf2ef_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzktNS0xLTEtMTg4OTc0_45091064-3b5f-4f2c-9800-5908e66c4957">3,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzktOS0xLTEtMTg4OTc0_c39b5fde-6a76-4529-85cc-50337b4f5c32">3,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59da9a82507b4a00bb722da4afa5b3c1_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTEtMS0xLTE4ODk3NA_dd8088a2-d903-4910-a68a-eb35b2977033">578.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2470640538814b629fcb492196758669_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTMtMS0xLTE4ODk3NA_2220702d-82c5-43ca-8ea2-20e8623d3863">31,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f7304b1f329421f82c9e6191840585b_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTUtMS0xLTE4ODk3NA_00a8ad1c-d43c-4174-a415-ce949d1de94e">21,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e70878840254d839c51604f86fab42a_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTctMS0xLTE4ODk3NA_a5bb9666-3b2d-4c01-90a1-cca4062aeca8">985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTktMS0xLTE4ODk3NA_c21d449d-09b3-4a0a-b505-5d61a7a206f0">9,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f0e0839efe462786cfb45f06b6105b_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEyLTUtMS0xLTE4ODk3NA_5e74b4f4-2292-44b7-9686-3f9bc4d8996d">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEyLTktMS0xLTE4ODk3NA_97660576-93a0-461b-803c-c260f315e2bb">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEzLTctMS0xLTE4ODk3NA_913bd6dd-e516-48ac-bfe4-49e0110808c0">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEzLTktMS0xLTE4ODk3NA_8e17db96-982f-4233-bb9d-1d5b1be1dd0c">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE0LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjZkZWE0NWJlN2YxNzRjMGE5ZTE3MDU2M2M5Y2JhM2Q0XzQw_8242e7b6-9f33-4f03-9454-af39e41a2c71">7.22</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39f0e0839efe462786cfb45f06b6105b_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE0LTUtMS0xLTE4ODk3NA_36e9b521-cd63-4a68-b123-425b47684aea">4,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE0LTktMS0xLTE4ODk3NA_7ec5c876-6477-4859-8459-e6a76d3d3ce3">4,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b88900199d7479494b9b92a28082482_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE1LTEtMS0xLTE4ODk3NA_22a83866-21b2-456c-a870-e687e2066a6a">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46710aa460c94e759e4be58d5b0aa1cf_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE1LTMtMS0xLTE4ODk3NA_07e8e77b-b47e-4014-b8d5-ec2ba1625378">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE1LTktMS0xLTE4ODk3NA_ee524a20-6bd9-41c4-8aa0-cb8626b250ee">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46710aa460c94e759e4be58d5b0aa1cf_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE2LTMtMS0xLTE4ODk3NA_242b88c4-2a40-45c5-912e-0a7d3ea43cfe">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE2LTktMS0xLTE4ODk3NA_9cd3dccb-21db-4d1d-aa2c-680865e82f57">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46710aa460c94e759e4be58d5b0aa1cf_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE3LTMtMS0xLTE4ODk3NA_00179a24-c69c-4760-b6cd-9f9fd7b44494">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE3LTktMS0xLTE4ODk3NA_77e3c574-aa9a-4aa4-a127-0d3adbb0516e">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5b88900199d7479494b9b92a28082482_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE4LTEtMS0xLTE4ODk3NA_2672c628-4b76-45f5-9a9c-239cb9ccd9d0">21.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39f0e0839efe462786cfb45f06b6105b_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE4LTUtMS0xLTE4ODk3NA_29d1712d-6963-4cb3-a6b9-64aa068bc663">4,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE4LTktMS0xLTE4ODk3NA_58fabdb9-f5cb-401c-b170-6d28757788f3">4,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9214e72c6081443dbdd4956e36759200_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTEtMS0xLTE4ODk3NA_325bf93e-fc8f-40a1-9fd9-768bdcd4e6cb">558.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cc146400d04167a6eb49d6a45c2634_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTMtMS0xLTE4ODk3NA_11682dc6-1d81-49b9-bd0f-2d98c889564d">32,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0604e8ad2a44749afd263c7e0c52319_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTUtMS0xLTE4ODk3NA_3997f653-4720-45e3-81cf-2ef27bc1c261">24,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib964505bb2264c0e858b211061796b49_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTctMS0xLTE4ODk3NA_8a655154-2300-4dbe-9d43-97ece48d1cbf">796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTktMS0xLTE4ODk3NA_185dd1fb-fc94-4097-83e4-505011d936dc">6,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee236cd90d724c118c6bd2bd1de4571e_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIxLTUtMS0xLTE5MDU1Mw_b02d48c0-842a-4446-a6c1-43856c8d70dc">6,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIxLTktMS0xLTE4ODk3NA_a6fa37e8-1e70-4ad5-8957-cec2ab9dab8a">6,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIyLTctMS0xLTE5MDU4MQ_6de218cc-dc10-498b-ae51-3ab877d5fe19">565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIyLTktMS0xLTE4ODk3NA_5d9d04e4-35b7-4d9e-9fe3-78f6c00b3c06">565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIzLTAtMS0xLTE5MDc0MC90ZXh0cmVnaW9uOjU3ODJlODZlNjhhYTQ3MWM4NDU3M2FhMjQwNjU2MDkyXzU0OTc1NTgxMzk0MQ_6f718bc1-5ae9-4317-a3f5-10b8762ba9eb">7.95</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee236cd90d724c118c6bd2bd1de4571e_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIzLTUtMS0xLTE5MDU5NQ_934befa9-4502-43ce-9063-98499d8f3e2e">4,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIzLTktMS0xLTE4ODk3NA_ce0c1343-f496-448f-8925-cf8d2470032b">4,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida0d3563966d49f2afdae70577b5770d_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI0LTEtMS0xLTE5MDQ3MA_8d7789e0-66bc-43d7-8aaf-79ac70e67beb">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI0LTMtMS0xLTE5MDYwOQ_2ce5432c-da86-4885-97dc-da0279b88bf7">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI0LTktMS0xLTE4ODk3NA_9351103c-5927-44c0-8216-a2f9debeab37">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI1LTMtMS0xLTE5MDYzMA_b11b6e0f-1cd1-4474-a90f-b61f4d31818c">419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI1LTktMS0xLTE4ODk3NA_610d268e-bb8b-4cbe-8cb7-e20ce8cbbbea">419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI2LTMtMS0xLTE5MDY1MQ_db4b1d27-2b0e-4255-a47f-88e7c42aa209">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI2LTktMS0xLTE4ODk3NA_3156f6f9-bd42-4cc0-81cc-14ecc88373ea">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ida0d3563966d49f2afdae70577b5770d_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI3LTEtMS0xLTE5MDQ5Mg_2cd6794e-fc95-4e2e-a779-aa7acc2a66d3">26.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI3LTMtMS0xLTE5MDY2OQ_a83940ac-a0d1-4d36-a679-bdc987ae20ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee236cd90d724c118c6bd2bd1de4571e_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI3LTUtMS0xLTE5MDY3Nw_9c6651fe-78e4-4564-b25d-ebcf2d231d84">6,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI3LTktMS0xLTE4ODk3NA_a22d0462-ad7f-46fa-85c5-762cfeb62aeb">6,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if935497be7004087ab59197b95cf4c00_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTEtMS0xLTE4ODk3NA_3900bce9-dc98-4b06-84ea-7516a1d92ccd">534.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6677b10603d44f784a36a5a29714649_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTMtMS0xLTE4ODk3NA_ba047496-7dfa-4f75-9f5b-946d493c403f">32,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec4b231199d0442bb9d2420b71dfb984_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTUtMS0xLTE4ODk3NA_abf016dd-937c-43f4-9881-34535c617cfc">28,622</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i349ee45aa1e94ce9adf98a1fa8b76e0e_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTctMS0xLTE4ODk3NA_3a7d3b59-feb8-463c-b09d-9b1ab276102c">231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTktMS0xLTE4ODk3NA_51f0778c-55e2-40f5-9a41-5e4632083a03">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2022, 2021 and 2020 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzItMS0xLTEtMTg4OTc0_5a7f8116-936e-4179-863a-77f4bdebc8a9">6,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzItMy0xLTEtMTg4OTc0_e0de8dee-c631-4d3c-b4eb-f08c706cc19b">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzItNS0xLTEtMTg4OTc0_a249a1dd-9e25-4cf6-b1df-538de3378bfd">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation, amortization and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMtMS0xLTEtMTg4OTc0_c958b437-28ba-4a0b-9c0c-e47f02f3bddf">3,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMtMy0xLTEtMTg4OTc0_b332c581-e06b-4489-8ea2-b329ccb01276">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMtNS0xLTEtMTg4OTc0_2b36d93f-2fa4-45b3-bcc3-9625d5eeedfd">3,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzQtMS0xLTEtMTg4OTc0_b16f2e89-c1e9-4ba8-b0c3-a21ed12c85d0">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzQtMy0xLTEtMTg4OTc0_143c054f-8707-4848-9e7b-f1face2a7939">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzQtNS0xLTEtMTg4OTc0_674e5b92-1837-4dd3-8982-9fdf87b27bca">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzUtMS0xLTEtMTg4OTc0_266ed60b-99d8-4832-9e01-71f405e32a2b">1,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzUtMy0xLTEtMTg4OTc0_5f34f8cb-ceec-4ae3-bf28-c11ca9658df4">453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzUtNS0xLTEtMTg4OTc0_31bb4434-9dd0-447b-98d3-67a4219b76f3">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzYtMS0xLTEtMTg4OTc0_ad0e8935-524d-4a49-a4f5-321f4e2446be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzYtMy0xLTEtMTg4OTc0_d0be7d49-b001-496c-9685-960670c3a387">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzYtNS0xLTEtMTg4OTc0_f5892638-3eb7-44a5-86e4-c7f701e215a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctMS0xLTEtMTkyNTE5_3bd4b73d-b83f-462b-b9ef-32180ac36f4b">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctMy0xLTEtMTk3ODIx_f43b75fa-3d5f-473a-85b5-e42eab64d8a8">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctNS0xLTEtMTk3ODI0_b10d79d8-2a1b-46dd-afbf-376755ab86e9">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on divestiture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzgtMS0xLTEtMTk3ODI3_8109adb8-69ca-47d6-afda-2ffee663399a">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzgtMy0xLTEtMTk3ODMw_d0ab8bbf-5bb3-43a5-b2af-fe2be0cb602d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzgtNS0xLTEtMTk3ODMz_6a5b8fed-bca9-4120-8da5-0584a76fc0fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctMS0xLTEtMTg4OTc0_91e009ed-f24d-4840-8477-0fdb11aa6718">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctMy0xLTEtMTg4OTc0_9a20a2d1-f11e-448f-b5d4-863193943e5c">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctNS0xLTEtMTg4OTc0_21d49397-d381-40ff-96ed-c25b7aee1fc8">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzktMS0xLTEtMTg4OTc0_cee09034-f1db-4913-8247-cc6787cd99d2">746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzktMy0xLTEtMTg4OTc0_2012a595-5c98-4da2-a5af-d774e3e7f112">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzktNS0xLTEtMTg4OTc0_19409d25-66c7-4087-9f81-ea31ed12bd80">427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEwLTEtMS0xLTE4ODk3NA_e0c57850-47ad-4749-a51b-e00e2a37efd3">742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEwLTMtMS0xLTE4ODk3NA_680e1c7f-e2dc-49a8-b778-71012d78cb0b">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEwLTUtMS0xLTE4ODk3NA_9b33b88c-677e-4585-99d4-f325eab2e64a">215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzExLTEtMS0xLTE4ODk3NA_522d6e54-6fb1-4fb7-b839-3476d5f9dea1">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzExLTMtMS0xLTE4ODk3NA_8a4395d6-f7f2-43a3-ab11-f19d7d4140fa">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzExLTUtMS0xLTE4ODk3NA_5bbca096-fbf3-4b1c-9c09-ccc1af371b93">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEyLTEtMS0xLTE4ODk3NA_775e4217-9e05-43a4-8852-49dce4371f6d">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEyLTMtMS0xLTE4ODk3NA_548d61cb-7b30-406d-bf02-a4b8a3df0876">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEyLTUtMS0xLTE4ODk3NA_cbd2b8a5-78da-453c-888a-114bc8112c91">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEzLTEtMS0xLTE4ODk3NA_6cb3721b-9729-4392-ac75-210bfdb2bfdf">647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEzLTMtMS0xLTE4ODk3NA_ebe948d6-b651-4723-a827-c380c7a61609">854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEzLTUtMS0xLTE4ODk3NA_6efb63bd-3294-4388-830d-74efd55b2cf8">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE0LTEtMS0xLTE4ODk3NA_cd85d8c1-901b-4bad-869f-3313bcdda2e0">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE0LTMtMS0xLTE4ODk3NA_e0409fd8-a395-4e26-8adf-65255938cc4b">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE0LTUtMS0xLTE4ODk3NA_0bffb609-a44b-4748-ba60-ad5328a626f0">482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE1LTEtMS0xLTE4ODk3NA_e041c5cf-be9a-4c8e-967d-9092d6a3cb13">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE1LTMtMS0xLTE4ODk3NA_4f7d5a66-4f88-4ab6-90fc-834ea101eaf2">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE1LTUtMS0xLTE4ODk3NA_380d3035-4550-4108-b13d-c9379028ecb7">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE2LTEtMS0xLTE4ODk3NA_aa4c114e-7dee-453e-9452-713f1243a838">9,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE2LTMtMS0xLTE4ODk3NA_9ec479f8-8a68-4a60-a027-1e0c35b893f1">9,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE2LTUtMS0xLTE4ODk3NA_7048885b-2ab1-422f-997b-fbbb05982192">10,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE4LTEtMS0xLTE4ODk3NA_be006b7e-e4fa-4a36-b38a-4da63b402b58">2,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE4LTMtMS0xLTE4ODk3NA_74938be3-acd0-4a4a-b28e-8b923353aca9">8,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE4LTUtMS0xLTE4ODk3NA_b8f4dbee-c844-4ec6-82fa-fde8357e3a3f">8,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE5LTEtMS0xLTE4ODk3NA_8069b860-c52c-4932-96ec-a0b19103f2c7">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE5LTMtMS0xLTE4ODk3NA_79320623-5e84-4b2f-832e-fd0e23d5ac7e">4,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE5LTUtMS0xLTE4ODk3NA_a06ad226-d24f-4168-be68-45784e63d92e">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIwLTEtMS0xLTE4ODk3NA_bedc9138-57ce-4e86-9902-af5e1d9adc03">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIwLTMtMS0xLTE4ODk3NA_46d9b40f-0831-4ac1-8b60-2258e2a38e88">8,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIwLTUtMS0xLTE4ODk3NA_ea8ea44c-e140-4a71-a075-770ef0ea6416">4,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIxLTEtMS0xLTE4ODk3NA_fdea08f2-844a-4a93-b29a-ea898325263d">936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIxLTMtMS0xLTE4ODk3NA_d26b415a-9ae1-4186-a168-f4bbb5e8e339">880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIxLTUtMS0xLTE4ODk3NA_e7a07521-9972-4a31-9301-7032bb4dd9ea">608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIyLTEtMS0xLTE4ODk3NA_e772af49-11f8-4e23-8b90-3b05b7734fbd">3,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI0LTMtMS0xLTE5MjU0Mg_319d6e6a-d83c-4182-aa16-4a6fec621cbe">2,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIyLTUtMS0xLTE4ODk3NA_ec1b749b-4f4f-43d5-90e1-291dd4d9103d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIzLTEtMS0xLTE4ODk3NA_a4f0fa56-6912-48e4-b002-f2b76265092a">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIzLTMtMS0xLTE4ODk3NA_a3eef4a4-3ad6-4bd7-bb14-59f29ad86d6b">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIzLTUtMS0xLTE4ODk3NA_bd8597b6-aab2-450b-969c-0e7d731003e0">3,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from business divestiture, net of divested cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI2LTEtMS0xLTIwMDY3OQ_9f43d9c9-6be9-42ee-ad2f-c466a71502ca">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI2LTMtMS0xLTIwMDY4Ng_1b449f7a-c43d-4eb6-ad49-863fcde5fc9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI2LTUtMS0xLTIwMDY5Mw_4550d430-8348-4908-8a41-519b34f1c0c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI0LTEtMS0xLTE4ODk3NA_3b5ac558-9c74-4266-8bf8-de132f65889b">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI0LTMtMS0xLTE4ODk3NA_abddc3a6-03fe-4a13-831f-396b28f15ab1">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI2LTUtMS0xLTE5MjU2Mw_295ea152-e4fc-4a38-8501-55258e0e8f29">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI1LTEtMS0xLTE4ODk3NA_284451fa-1659-48ff-8de1-246c5bdde0f4">6,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI1LTMtMS0xLTE4ODk3NA_48e24ae1-819c-49e2-a7a6-4c92ac1c458a">733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI1LTUtMS0xLTE4ODk3NA_e485bb12-c130-45ef-9370-c21fd4ffd4bb">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI3LTEtMS0xLTE4ODk3NA_82a38a24-f34e-4bc1-bff4-41881c113f6a">6,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI3LTMtMS0xLTE4ODk3NA_e85ba3d1-e076-487a-8298-89856d8fa1fe">4,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI3LTUtMS0xLTE4ODk3NA_f4d2c818-d33e-4d4e-8477-4e8ef0410c61">8,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMxLTEtMS0xLTIwNzQyOA_a2ae790f-9cc1-4c93-b0ec-f08a64193781">297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMxLTMtMS0xLTIwNzQzNw_5cf243f8-aaa1-463e-af70-0a86ed14f462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMxLTUtMS0xLTIwNzQ0Nw_c0bcd46c-0404-4b57-a93e-36f86e9d07c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI4LTEtMS0xLTE4ODk3NA_b45037e9-f269-4b8e-a323-5c13e473f640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI4LTMtMS0xLTE4ODk3NA_7e8cf7ce-1d8e-4cdc-93e0-0e0e03260e8f">4,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI4LTUtMS0xLTE4ODk3NA_72b6057b-f3d9-4f7c-a6d3-bbe8b6201e6c">6,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI5LTEtMS0xLTE4ODk3NA_abe50959-279f-4f80-b714-0e6295753095">6,360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI5LTMtMS0xLTE4ODk3NA_f637995d-0a73-45ab-a97d-522c4fa4d00e">4,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI5LTUtMS0xLTE4ODk3NA_e4ddaab3-d889-4e90-98f7-35724233104b">3,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMwLTEtMS0xLTE4ODk3NA_654b16c1-1f8c-4aea-b450-9048ad90f887">4,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMwLTMtMS0xLTE4ODk3NA_0b1a1f79-e0ae-4796-bedf-6206d11ff1cc">4,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMwLTUtMS0xLTE4ODk3NA_7514a9fb-9640-4b23-be6b-9380e6754ea4">3,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMyLTEtMS0xLTE4ODk3NA_e3f90a6e-1d4a-4c98-aa5e-652dc05ef092">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMyLTMtMS0xLTE4ODk3NA_442787f6-a3d1-46e2-ac16-466f10e8f226">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMyLTUtMS0xLTE4ODk3NA_865dc528-637d-4113-8fe8-4d9c04ed83a7">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMzLTEtMS0xLTE4ODk3NA_cf216190-12ae-4360-869e-a2b881fd0812">4,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMzLTMtMS0xLTE4ODk3NA_181ec0ab-5b43-4c16-b2f0-948cac129c02">8,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMzLTUtMS0xLTE4ODk3NA_304f2651-7e8f-4781-8534-59b70b7f1506">4,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM0LTEtMS0xLTE4ODk3NA_2990b2e2-6a65-4557-98d2-df5ca8a0d181">360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM0LTMtMS0xLTE4ODk3NA_b0dc24b6-c61f-4a12-bd60-9fa210f3c28f">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM0LTUtMS0xLTE4ODk3NA_c103ef8c-915a-442e-b3e3-0988d08048e2">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM1LTEtMS0xLTE4ODk3NA_f73996dc-08ac-48b7-8633-2b439ed1eccb">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM1LTMtMS0xLTE4ODk3NA_4957027f-9078-4398-82c4-72f76d79f7e8">6,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM1LTUtMS0xLTE4ODk3NA_340ff7d5-25af-4883-b930-450b0bc8681b">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM2LTEtMS0xLTE4ODk3NA_37e9b1ad-9fcf-45d3-8d8a-ea8c4d702e90">7,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM2LTMtMS0xLTE4ODk3NA_7ec44cb3-f150-44ac-a4dd-a51c6f95114f">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM2LTUtMS0xLTE4ODk3NA_409baa12-caa1-4047-9e2a-035c34256ddf">6,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022 </span></div><div id="if8055099d1994bb494875d41c341f00d_193"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjIz_50405b20-4f41-497c-bc6a-0d7a852c882f" continuedAt="i45bcccdb4d474b80bd627673cd54df9c" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i45bcccdb4d474b80bd627673cd54df9c" continuedAt="i28288c9c32ad4b0aa6f2504a340490a0"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:NatureOfOperationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjEx_ea28035f-e7dd-4ac5-8e50-b7afc3f2930c" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in <ix:nonFraction unitRef="segment" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI1Mg_5ad1c97c-fc5b-422e-a15e-d498e588091a">one</ix:nonFraction> business segment: human therapeutics.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjAz_863b5b7b-b957-4625-887d-3e1e23a79294" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTYy_939341b3-3f71-4fef-988b-f458abcf80ea" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTgx_a1fd94cd-c39b-4517-b296-edafe632078b" continuedAt="i00a2db74fb2646ecbc09d84df968037f" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than <ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="2" name="amgn:SalesReturnProvisionsAsPercentageOfProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI5MjA_35cc5f83-7cb6-4f65-834b-47deea1e4a34">1</ix:nonFraction>% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from <ix:nonNumeric contextRef="i74c70cd97a504fa799571d2da1e07298_D20220101-20221231" name="amgn:RevenuePaymentArrangementTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzMyNDg_254c488c-4d66-46f0-80b9-7b6e2919d1c3">30</ix:nonNumeric> to <ix:nonNumeric contextRef="ib368433c7847450cbea77bf019f238ce_D20220101-20221231" name="amgn:RevenuePaymentArrangementTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzMyNTQ_007a974b-0aae-465a-a635-1c8ebff8ad08">120</ix:nonNumeric> days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#8217;s products, primarily in Europe, are excluded from revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;A expense in the Consolidated Statements of Income.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i28288c9c32ad4b0aa6f2504a340490a0" continuedAt="i1d04152d724743c184f9da60cc59843e"><ix:continuation id="i00a2db74fb2646ecbc09d84df968037f"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with multiple-performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into arrangements for the R&amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div></ix:continuation><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjE4_072d1248-93e4-42fb-8a1a-78927e1fe5eb" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#8217; costs; and amortization of acquired technology used in R&amp;D with alternative future uses. R&amp;D expenses also include costs and cost recoveries associated with third-party R&amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTIx_fe921614-00c8-40d4-a2d5-cd8722fb33c5" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzc4NDM_31cf3cc4-5ed1-42e9-b898-c8c6b9c0907a">841</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzc4NDc_92fe5a3f-b5a9-4a23-a0e0-fada9b75764d">843</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzc4NTQ_df1da611-d388-4f16-8084-1ea9e27940d5">962</ix:nonFraction> million during the years ended December 31, 2022, 2021 and 2020, respectively. SG&amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTYz_48a6478e-84df-45bd-a600-238da4490115" continuedAt="i8ebf06b9f91749148be44e1d67e2f4d3" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1d04152d724743c184f9da60cc59843e" continuedAt="ife8eac57c3874760a1e7b375a4c9422c"><ix:continuation id="i8ebf06b9f91749148be44e1d67e2f4d3"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.</span></div></ix:continuation><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTc2_0159afd4-ba79-4a3b-9c72-882f23efdd51" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTY0_cf3cb6ac-6bad-4a1d-9b50-90650e04dc49" continuedAt="i890990e0dd844a6ba6e9f7b8aa38a6ff" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i890990e0dd844a6ba6e9f7b8aa38a6ff">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjA1_f1841258-fde5-40c2-baeb-2a49bc33b1bc" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#8217;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;D projects with no alternative future use are recorded in R&amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions and divestitures, and Note 17, Fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTU4_1252e24a-e6c2-4cbf-8008-43c2233951ad" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ife8eac57c3874760a1e7b375a4c9422c" continuedAt="i4d430e176b5e4d4da390882c2db29900"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MDk5_cc14a39d-6278-408e-bac2-64e92cb341f6" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTkx_6e285d9f-7da4-4c1b-85a8-3e40d32f1e09" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjQy_f6806e48-6128-402e-be6e-ce3252833528" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTQx_06c6e9ee-72e8-47fc-82f5-19b4c6a1a4ee" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#8217; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjQ5_a5796338-3e8c-4561-8fde-160eb1658f70" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#8217; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of IPR&amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4d430e176b5e4d4da390882c2db29900" continuedAt="i58b5ea35ce484632add610ae06138952"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjM4_6aa5d680-a754-436c-b721-6337068723e5" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjAx_ea4786fd-c152-460c-96ab-cd0088612f03" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#8217; earnings are translated into U.S. dollars by using average exchange rates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:EquityInvestmentsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTg4_37caa558-1891-4b36-b284-9139c20fc653" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and nonmarketable equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other (expense) income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other (expense) income, net, in the Consolidated Statements of Income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjQz_71745e77-d2af-4f23-a1ee-98e3bd573706" escape="true"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#8217; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other (expense) income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other (expense) income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other (expense) income, net, in the Consolidated Statements of Income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjA5_89acd864-e516-4eaa-b2fe-ff3344b7fe6a" continuedAt="ic534b49bb86145aab2c841bcbac60f9c" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. The provisions of these standards have not had and are not expected to have a material impact on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i58b5ea35ce484632add610ae06138952"><ix:continuation id="ic534b49bb86145aab2c841bcbac60f9c">In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.</ix:continuation></ix:continuation></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_196"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzEwOTk1MTE3MTY4MzY_2ce9bb1d-a8c7-4191-9aa8-19f20de69d1e" continuedAt="icdc5591ec6214336b73d3ae6a2a31433" escape="true">Acquisitions and divestitures </ix:nonNumeric></span></div><ix:continuation id="icdc5591ec6214336b73d3ae6a2a31433" continuedAt="i4550896f678b43b387454823675e5089"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposed acquisition of Horizon Therapeutics plc</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2022, we announced that we entered into a transaction agreement under which Amgen will acquire all shares of Horizon for $<ix:nonFraction unitRef="usdPerShare" contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTgwNTY_4edadcac-d4d8-4699-8262-358830acef7e">116.50</ix:nonFraction> per share in cash for a transaction equity value of approximately $<ix:nonFraction unitRef="usd" contextRef="i779f44ca9ddf42f9bd2fc86981e1cdd2_D20221201-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTY3NjU_bf737c4e-ca81-43e2-a029-2a327c5225e0">27.8</ix:nonFraction> billion. Horizon is a global biotechnology company headquartered in Dublin, Ireland and is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Horizon has <ix:nonFraction unitRef="product" contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212" decimals="0" name="amgn:ApprovedProducts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkxMDIyMzg_57a29867-3e13-4211-8919-449e8b0e1ccd">12</ix:nonFraction> marketed medicines and a pipeline with more than <ix:nonFraction unitRef="program" contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212" decimals="0" name="amgn:DevelopmentPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkxMDIyNDI_9c72f506-9b62-4ce9-b1b9-988a9461f6fa"><ix:nonFraction unitRef="program" contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212" decimals="0" name="amgn:DevelopmentPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkxMDIyNDI_b814ab8c-1b3f-408d-8363-e9e1f16102c1">20</ix:nonFraction></ix:nonFraction> development programs. The closing of this transaction is contingent upon satisfaction of certain regulatory (including FTC review) and other customary closing conditions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the proposed acquisition of Horizon, Amgen entered into a <ix:nonNumeric contextRef="ic722736e5ec247d6afb3eb14a1913c36_D20221231-20221231" name="amgn:BridgeCreditAgreementMaximumLength" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTkwMjk2OA_d955cbbf-657c-4831-a0cb-556f06c4e91b">364</ix:nonNumeric>-day bridge credit agreement with a syndicated group of banks for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212" decimals="-8" name="amgn:BridgeCreditAgreementInitialAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5MTAyOTE_e56cf7fd-06f9-4b64-9c6f-fd9fb6c446dc">28.5</ix:nonFraction> billion on December 12, 2022. On December 22, 2022, we entered into a term loan credit agreement with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ia18e6e75e0234bfb8fa9c069b0ac7278_I20221222" decimals="-8" name="amgn:TermLoanCreditAgreementTotalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5MTAyNzM_4786b60c-5af2-469d-b1e6-aa8524774b0d">4.0</ix:nonFraction> billion which provides for <ix:nonFraction unitRef="traunche" contextRef="ia18e6e75e0234bfb8fa9c069b0ac7278_I20221222" decimals="0" name="amgn:TermLoanCreditAgreementNumberOfTraunches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTkwMjk3Ng_7c76df90-1b85-420a-afd6-44f4b3cbb6c9">two</ix:nonFraction> equally sized tranches of term loans, one with an 18-month term and one with a three-year term. Accordingly, the bridge credit agreement was reduced by the amount of the term loan credit agreement to $<ix:nonFraction unitRef="usd" contextRef="ia18e6e75e0234bfb8fa9c069b0ac7278_I20221222" decimals="-8" name="amgn:BridgeCreditReducedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5MTAzMTE_fd442c68-07c9-4048-ad21-2b3f26fd1c1c">24.5</ix:nonFraction>&#160;billion. As of December 31, 2022, <ix:nonFraction unitRef="usd" contextRef="i547c2ec2000946a09fe9312e8ebfb63a_I20221231" decimals="INF" name="amgn:BridgeCreditAgreementAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTkxMDA0Nw_6c1cf52c-7bbc-4960-a24e-b9db49fba2f3">no</ix:nonFraction> amounts have been drawn under the bridge credit agreement or the term loan credit agreement. In connection with these credit agreements, Amgen incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ib6ad27c707bf4fc9a91323e63aadb826_D20221222-20221222" decimals="-6" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkxMDIyMTg_cb7120a2-b877-42f6-99c9-5a85370b4827">97</ix:nonFraction> million of financing costs, which was capitalized primarily in Other current assets in our Consolidated Balance Sheets and is being amortized to Interest expense, net, in our Consolidated Statements of Income over the terms of the agreements. Additionally, we have agreed to maintain a cash balance of $<ix:nonFraction unitRef="usd" contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212" decimals="-6" name="us-gaap:CompensatingBalanceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5MTY0MTc_a36cb837-f35f-4b22-932c-6120531428bf">2.96</ix:nonFraction> billion that, together with any borrowings under the bridge credit agreement and term loan credit agreement, represents sources of funds available to finance the acquisition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;30, 2023, the Company and Horizon each received a request for additional information and documentary materials (Second Request) from the FTC in connection with the FTC&#8217;s review of the Company&#8217;s proposed acquisition of Horizon. The effect of the Second Request is to extend the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, until 30 days after the Company and Horizon have substantially complied with the Second Request, unless that period is extended voluntarily by the Company and Horizon or terminated sooner by the FTC.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of ChemoCentryx, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2022, we acquired all the outstanding stock of ChemoCentryx, a publicly traded biotechnology company focused on orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $<ix:nonFraction unitRef="usdPerShare" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc3MDY_96c99eff-abf0-4f06-a905-8ec58ab36763">52.00</ix:nonFraction> per share in cash, representing a total consideration of $<ix:nonFraction unitRef="usd" contextRef="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020" decimals="-8" name="amgn:Businessassetacquisitionconsiderationtransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc1NzM_ab13e323-149c-4e9b-b2d2-a35da1a18b47">3.9</ix:nonFraction>&#160;billion. The acquisition, which was accounted for as a business combination, includes TAVNEOS, an orally administered selective complement 5a receptor inhibitor that was approved by the U.S. FDA in October 2021 as an adjunctive therapy for adults with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis). TAVNEOS is commercialized by us in the United States; for markets outside the United States, TAVNEOS is commercialized by a collaboration partner, and Amgen is entitled to royalties and milestones based off future sales of the product. Upon its acquisition, ChemoCentryx became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2022, the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i5df31b4fae07412cbb1789e8d483f2f0_D20221001-20221231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc1ODc_a8e9979d-a263-473b-9184-120a2814a35e">106</ix:nonFraction>&#160;million of costs directly related to the acquisition of ChemoCentryx, consisting of share-based payments to settle non-vested equity awards attributable to post-combination services, severance and other transaction costs. These costs were included primarily in SG&amp;A expense in the Consolidated Statements of Income.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4550896f678b43b387454823675e5089" continuedAt="i7ca666e222584ed389d8943472533ead"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU5OTIzMzgzODA5OTE1_55b4ae2f-2132-4623-b11b-761e44618e34" continuedAt="i4f506e79038f47049ed534cc0cf9d028" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzEtMi0xLTEtMjIzODk0_6c088ef1-76d8-4ca0-965f-cabfe02542de">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzItMi0xLTEtMjIzODk2_d8c19541-b6aa-4939-b295-2aec824b0262">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzMtMi0xLTEtMjIzODk4_4ae953c0-e436-4198-805d-f745823b0c4c">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; developed-product-technology rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9b8122096240a5b48fd15f27ecd4ba_I20221020" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzQtMi0xLTEtMjIzOTAw_d0dfde78-9a45-46da-a884-ca1e05e7f4cf">3,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzUtMi0xLTEtMjIzOTAy_cb9620ea-5f5e-4a24-8911-1af43e4d7073">667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" sign="-" name="amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzYtMi0xLTEtMjIzOTA0_83c1ab9b-1b5a-403a-a904-48af75962d0d">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzctMi0xLTEtMjIzOTA2_b3c3ddd1-e310-4cd6-a3b2-f670beca812a">516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzgtMi0xLTEtMjIzOTA4_8a7a4b37-cd7c-44a3-8f64-8e2734756570">3,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020" decimals="-8" name="amgn:Businessassetacquisitionconsiderationtransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2MDE_3cf7ecc3-bbaa-45bf-82a0-21280524c9f6">3.9</ix:nonFraction>&#160;billion total consideration consisted of (i) a $<ix:nonFraction unitRef="usd" contextRef="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2MTU_b5f97da4-49bf-4e6a-a374-f1ca62ccbaf7">3.7</ix:nonFraction>&#160;billion cash payment to outstanding common stockholders of ChemoCentryx and (ii) a $<ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="amgn:BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2Mjk_4e9c938c-beec-4307-9d5c-ee6521375814">181</ix:nonFraction>&#160;million cash payment to equity award holders of ChemoCentryx for services rendered prior to the acquisition date of October 20, 2022, under the ChemoCentryx equity award plans.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The developed-product-technology rights acquired relates to TAVNEOS, which is approved in the United States and EU for ANCA-associated vasculitis. The estimated fair values of $<ix:nonFraction unitRef="usd" contextRef="ife9b8122096240a5b48fd15f27ecd4ba_I20221020" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2NDM_0f2d720a-2ffa-4c0e-8af9-a220c95de31d">3.5</ix:nonFraction>&#160;billion were determined by using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The developed-product-technology rights are being amortized on a straight-line basis over a weighted-average period of approximately <ix:nonNumeric contextRef="ifd98af0751824e778fbc9d7d6daabf74_D20221020-20221020" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc3MDI_e8b73310-15c2-4c0e-a56e-d97d20e52c19">11</ix:nonNumeric> years using the straight-line method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the acquired inventory of $<ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2NTc_4633c3e7-9f18-403f-b61c-a0cc0558a0a6">41</ix:nonFraction>&#160;million was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer&#8217;s effort are applied. The inventory fair value adjustment is being amortized as inventory turns over, which we estimate to be approximately <ix:nonNumeric contextRef="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020" name="amgn:BusinessCombinationTurnoverPeriodOfInventoryAcquired" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2OTg_80be080a-130e-480e-8e7e-0cd96a73a5b9">13</ix:nonNumeric> months.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2NzA_502fb546-fe18-493e-8086-4f1a20165001">516</ix:nonFraction>&#160;million was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2ODQ_f3ea1cea-c386-45a5-805f-7bb7e3ad06f1">667</ix:nonFraction>&#160;million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value is primarily attributable to the expected synergies from the TAVNEOS asset.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, liabilities assumed and tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Teneobio, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies, which complement Amgen&#8217;s existing antibody capabilities and bispecific T-cell engager BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen&#8217;s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7ca666e222584ed389d8943472533ead" continuedAt="i19545e3462fe467d951cae017b234279"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustments for the year ended December 31, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $<ix:nonFraction unitRef="usd" contextRef="i8ad51334f6c74fc69c9126bdca69dd80_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTgzMzAwMg_f6271922-f222-4161-8bd1-2cf01ea112fd">22</ix:nonFraction>&#160;million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen&#8217;s results of operations during the year ended December 31, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. <ix:continuation id="i4f506e79038f47049ed534cc0cf9d028" continuedAt="i66af61418e3b4e9690de92193e258599">The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify"><ix:continuation id="i66af61418e3b4e9690de92193e258599"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzEtMi0xLTEtMTg4OTc0_42a785fc-ef8c-45af-b3bd-78cc794bb156">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzItMi0xLTEtMTg4OTc0_edb46b8c-bcc9-40d1-834d-ef6096236bba">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231" decimals="-6" name="amgn:Businessassetacquisitionconsiderationtransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzMtMi0xLTEtMTg4OTc0_e7612624-778e-4baf-bc62-e8a0bd24a8ea">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzUtMi0xLTEtMTg4OTc0_1d91d290-3274-4f72-a9b9-1ede86d1afa5">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c3e817eb2db4040b29557e7f0a8bdae_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzYtMi0xLTEtMTg4OTc0_2743f3a2-1874-4656-b286-4f337cd2f148">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset &#8211; R&amp;D technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878b1937a0c64c239da6ad0a2e1748ac_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzctMi0xLTEtMTg4OTc0_b9d60a7a-ad62-4e87-a35e-cd8525948150">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ea65e5beec49d492a8c189bb7ff681_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzgtMi0xLTEtMTg4OTc0_bc0c7620-0711-4c79-a155-67ebd92a3f6c">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzktMi0xLTEtMTg4OTc0_1fd2a6eb-dd52-45e8-8e05-ce02fc4b49fd">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231" decimals="-6" name="amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzEwLTItMS0xLTE4ODk3NA_13afd39e-9b6e-4e7d-85cf-8b11158e8e78">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzExLTItMS0xLTE4ODk3NA_e1349b48-0219-43b0-9d98-e8ad75d8347b">244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231" decimals="-6" name="amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzEyLTItMS0xLTE4ODk3NA_f2f7f530-7639-410c-b934-67fe7e72a8ba">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration for this transaction comprised of (i) an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzExMjA_bff04dda-a1b2-4324-aa6b-ba893de92c10">993</ix:nonFraction>&#160;million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio&#8217;s former equity holders of up to $<ix:nonFraction unitRef="usd" contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzEyNTk_3975fff5-bfb0-4603-9e35-210e9adc12cf">1.6</ix:nonFraction>&#160;billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $<ix:nonFraction unitRef="usd" contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzE1NTE_77c1db94-c7f3-483e-b453-d9a293102904">299</ix:nonFraction>&#160;million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 17, Fair value measurement, for information regarding the estimated fair value of these obligations as of December 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of acquired IPR&amp;D assets totaled $<ix:nonFraction unitRef="usd" contextRef="i3c3e817eb2db4040b29557e7f0a8bdae_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzIwNDg_bab7ac02-f428-4f2c-8adb-f9cd8a1ad23d">991</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i4a560be5e64148d1b01ab70221c57257_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzIwNjE_aeab4fa0-58f3-4e79-8076-b5e64d2b65a5">784</ix:nonFraction>&#160;million relates to AMG 340, that is in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to <ix:nonFraction unitRef="program" contextRef="ia4b93dbb92ca4fad905e8f7074369960_D20220101-20221231" decimals="INF" name="amgn:NumberOfPreclinicalOncologyPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTkwMjk3Nw_933de7ee-3674-4861-9365-2d31643be738">four</ix:nonFraction> separate preclinical oncology programs. The R&amp;D technology rights of $<ix:nonFraction unitRef="usd" contextRef="ic6c94a0244a24346bbce7f236220492d_D20221231-20221231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzIyNDk_6bcfaa8c-395d-4990-ac00-d694138e17f7">115</ix:nonFraction>&#160;million relate to Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over <ix:nonNumeric contextRef="ic6c94a0244a24346bbce7f236220492d_D20221231-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzIzNjM_3cd46b2a-19eb-4c7f-820e-df32aaf5ff0c">10</ix:nonNumeric> years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $<ix:nonFraction unitRef="usd" contextRef="id61a508e81d74e23babeb5ae04b7c428_D20221231-20221231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI1NDM_9b2d5618-d0f3-4f3c-bfae-6701b7a417fd">41</ix:nonFraction>&#160;million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyMDA_22586a09-66b7-4169-9c90-1d01215cc980">244</ix:nonFraction>&#160;million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzM1MzM_d1e4e3f3-f035-48af-93fb-b4137b30df02">273</ix:nonFraction> million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i19545e3462fe467d951cae017b234279"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Five Prime Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i2622610117f541b3981af6c597b45012_D20210416-20210416" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwODY3OTA_95bff5b4-abfa-4cb4-a7d1-2c95dd969c0e">1.6</ix:nonFraction>&#160;billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a Phase 3 first-in-class program for gastric cancer. Five Prime&#8217;s operations have been included in our consolidated financial statements commencing after the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Five Prime to the bemarituzumab IPR&amp;D program of $<ix:nonFraction unitRef="usd" contextRef="i2622610117f541b3981af6c597b45012_D20210416-20210416" decimals="-8" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzQ3MTA_c65fb556-b33b-43ea-93ab-2f898b6e7e05">1.5</ix:nonFraction>&#160;billion, which was expensed immediately in Acquired IPR&amp;D expense in the Consolidated Statements of Income; deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i7f833d40beb6488f852b2cd047fd2af3_I20210416" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzQ4MzY_dc015225-a45e-4f29-a485-d8d36c219912">177</ix:nonFraction>&#160;million; and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i7f833d40beb6488f852b2cd047fd2af3_I20210416" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzQ4Njk_ca089ef5-1129-4676-93a0-7f0aa58b2ead">47</ix:nonFraction>&#160;million. The acquired IPR&amp;D expense was not tax deductible.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Gensenta &#304;la&#231; Sanayi ve Ticaret A.&#350;.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2022, we sold our shares in Gensenta, a subsidiary in Turkey, to Eczac&#305;ba&#351;&#305; for net cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ia1a449b4d91a4aa9837f80b68d94b3de_D20221102-20221102" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTEwMTU_4264f405-4ed5-4109-b91b-fb9b3c59bfd0">130</ix:nonFraction>&#160;million. The transaction was accounted for as a sale of a business and did not meet the criteria to be classified as discontinued operations. Upon closing of this transaction, net assets related to Gensenta of $<ix:nonFraction unitRef="usd" contextRef="ifa290da793e84fbbbc403ed0500e088d_I20221102" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTY1NTA_da70643b-21b7-4613-b302-8966579feb3e">86</ix:nonFraction> million were divested, and during the year ended December 31, 2022, we recognized a loss on divestiture of $<ix:nonFraction unitRef="usd" contextRef="ie2a81370a9864611897507a5c90c9308_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTEwNDY_05ac0619-6b7a-4abc-b940-680a681a1135">567</ix:nonFraction>&#160;million recorded in Other operating expenses in the Consolidated Statements of Income, primarily due to the reclassification of $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="amgn:ForeignCurrencyTranslationLossOnDivestitureOfABusiness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTEwNjc_2b1701e0-c893-4cbb-a101-13e820af9846">615</ix:nonFraction>&#160;million of cumulative foreign currency translation losses from AOCI into earnings. See Note 16, Stockholders&#8217; equity.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_199"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE5NjE_2d1a5101-7fe2-4a29-a47e-c1cd038d757e" continuedAt="ia129863f7b724f7db34c6941da612446" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="ia129863f7b724f7db34c6941da612446" continuedAt="iad815992cd5b4cbb820bd5a3b6f89ab7"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzI2_6e5b0f96-04b7-45df-b34f-ba9d6b7358b3">one</ix:nonFraction> business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#8217; locations, are presented below. The majority of ROW revenues relates to products sold in Europe. </span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE5NjU_c82f81e5-a4a0-41cb-b5f7-93a479b5a492" continuedAt="i4f4bc9752ca948c2ab586ee6e206318e" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d95ce0934d41258b8bb4e3c9ae99ef_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMi0xLTEtMTg4OTc0_2a61b48d-e40a-42dd-b437-d66d91d46415">4,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcbf93e9fd941c2b5eb2795960a999c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItNC0xLTEtMTg4OTc0_f77b1431-cc46-4951-bf45-2ccd589ca389">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8239300c734a85ac79f2e26ba5280f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItNi0xLTEtMTg4OTc0_855db3ea-9da6-412f-956c-6c3f3b55023d">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf51567a953d41b99c4b4d59745e4ee4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItOC0xLTEtMTg4OTc0_770520ac-6743-4f69-9257-4a363b7a0df7">4,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ef981e3c2740e0b2d606ba990e403a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTAtMS0xLTE4ODk3NA_c3824708-4df5-4987-bfc4-c877ccc05f6c">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08fe0ca98dba40f1916b2858ece00d3b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTItMS0xLTE4ODk3NA_65e199be-5a0c-4784-bf86-27263d643b36">4,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d9b8bbe1fe042b38d3911eaa570829e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTQtMS0xLTE4ODk3NA_e76de8ee-3301-4591-ab45-757c075b023a">4,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96d969e20ba48c5865d66cf127544fd_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTYtMS0xLTE4ODk3NA_ead6580b-4575-45cb-8105-4624a23581bf">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if847c1f2b53649958a0e412c568c260c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTgtMS0xLTE4ODk3NA_a108bf0d-2c0d-4426-a1fd-7f921d30c637">4,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabbccaadaa0e479bb555d47033b24d0d_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMi0xLTEtMTg4OTc0_2164fd53-c94a-40d7-8d13-f03814450b17">2,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d0ac761b5e4c64a58d335767cf2473_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtNC0xLTEtMTg4OTc0_d58fcd2d-566e-4fcb-9660-88d50dea47f7">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b224ccf76a440c8fff126d491a4b0b_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtNi0xLTEtMTg4OTc0_5721f294-6620-4e07-a02b-17666f01bc1b">3,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81533ef907a44709b3be7b02daabe41e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtOC0xLTEtMTg4OTc0_7671baf7-a498-4abe-be89-bb12a1b25e95">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dfacc540ca4410bad949df3bf9e3989_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTAtMS0xLTE4ODk3NA_e223820d-3f50-4972-940c-4df081e2246e">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70dda4219ab244b7b55afbcb42b4096d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTItMS0xLTE4ODk3NA_98af0fb2-5955-4398-b447-9475c7333179">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3af95c457646d89f7ccabdfe96ed78_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTQtMS0xLTE4ODk3NA_cb6969b0-c040-40dc-a73a-e273670ea4e7">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e858062804243e7a95db1099336e60c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTYtMS0xLTE4ODk3NA_dc6595c7-b15e-4f46-84be-71774d98a6db">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea6afbe5b0948f38ad7891711ec6fdd_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTgtMS0xLTE4ODk3NA_8c5ada24-3ae1-41d7-b27d-e1af97c1cb30">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eea70a9f89a460c81ea5589813c4763_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMi0xLTEtMTg4OTc0_b28da0aa-4b34-4ad7-9ae7-d17c7eb0dd7c">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d0ac70f39f475ba99cef136b4e6db2_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtNC0xLTEtMTg4OTc0_1e7de747-4ff8-40e5-abb7-f43c37181f7e">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad2d33f98f144869b7feb640d3176c4e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtNi0xLTEtMTg4OTc0_a47625e1-4a41-4a30-b323-b1bf3438b843">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e4a13b30ff4c109a876c1c9aaf2a6a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtOC0xLTEtMTg4OTc0_6fd2a9c1-3dc1-4870-8e3f-95bb178e0bce">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1efdd0c80b64aa48ebe629be932cb59_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTAtMS0xLTE4ODk3NA_bcef37f7-a2eb-4c75-b6f9-74357bf3f724">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b509ea03164c7aa49578a912572c8f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTItMS0xLTE4ODk3NA_e865377d-bd95-4e5a-a9d2-df18f7de4353">2,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i931aa36bec5b4419a4286d8ee93da365_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTQtMS0xLTE4ODk3NA_50b4bc80-c5bf-4ff0-8bbb-1d306a2eadda">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d05f99fee60403f9ca2a1f93a62cf48_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTYtMS0xLTE4ODk3NA_468f049c-8b48-4873-b6c3-4dda33df3454">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e026f4c1ba44496a8bb17b973a51cba_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTgtMS0xLTE4ODk3NA_3a309d95-4111-40b8-8b2e-c048bb092465">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8037f0f06384716a6e33c023dafa910_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMi0xLTEtMTg4OTc0_d07edc95-f4b2-4b5d-825d-87d2d04dee71">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ed14a4244f540049b8d29da49b4c3c4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtNC0xLTEtMTg4OTc0_d2f5ae01-a7ce-4552-a333-c5a1e055a77e">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1effa3ff3a54202849eece7ac796687_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtNi0xLTEtMTg4OTc0_e662d50e-33ff-49fc-86ae-a439758931ce">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14decb65256d4431b54b68596dcf53cc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtOC0xLTEtMTg4OTc0_90e00bcd-519f-48ab-8dbd-28ffd8a3b283">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55dd93e8acf407da56339a95d05c26d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTAtMS0xLTE4ODk3NA_9a9f82a5-8c69-4607-afb1-066435a61222">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90e5f5a81c64fd8a2d5eca216f1ac96_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTItMS0xLTE4ODk3NA_a19e9877-3144-4fe9-b570-eab78a9664ff">2,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d2433db185474e8f07acef38f88309_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTQtMS0xLTE4ODk3NA_f0146fe3-2fb7-44e1-acd3-469e6f9e0ece">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife44f12d898a40c2b26d2899e1f87c7b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTYtMS0xLTE4ODk3NA_2e366b3a-e08c-415d-ac9c-1f2804360048">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72c4cccf0ed4d4e98361bdf264e1ab8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTgtMS0xLTE4ODk3NA_a0b4f10e-ddd9-43f1-9dc0-4d7d0d4ddc04">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4672ebffc2642038eb7bc351335c563_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMi0xLTEtMjA2MTg5_4acbf141-fa32-4914-b836-6fdc8d468b96">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8989af1d9ee941ccbf1d38df278cc651_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtNC0xLTEtMjA2MTg5_391acc2f-793b-43ff-94aa-70554b470620">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecec34e1ba548dfae54d6428a2be0ef_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtNi0xLTEtMjA2MTg5_62d870e0-c127-4f7f-9f5d-f1d21b9a9c9b">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72818ade50a84197b7066c09d32fe4b8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtOC0xLTEtMjA2MTg5_ced6de49-7b90-46ed-adfb-3ca27379d9b4">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e998945c35c44b78153987bfb0988e0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTAtMS0xLTIwNjE4OQ_6088e5ce-fb76-467e-aa9e-79fa4f084f4b">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife184a05fefe4459858a75cd03edbb4e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTItMS0xLTIwNjE4OQ_dc73fce6-dc6a-46eb-9872-634c5ebe1a1b">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa50e2701f6349c2976473694523273c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTQtMS0xLTIwNjE4OQ_56410f82-8d5a-4a64-bdb3-e2929a9c5d9b">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c662b22fd6d4f538341070c6658378a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTYtMS0xLTIwNjE4OQ_8c3de6fa-8f80-49b3-9b9f-2963a48b2f19">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90e2b230dc243709b1d0eea15c4120d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTgtMS0xLTIwNjE4OQ_b0404e3b-45ae-42a4-89ff-1a97770937c0">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i130d478f5c344266ad4bd4b7ab54798f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMi0xLTEtMjA2MjAx_59846407-2cb0-4fa1-bded-9a279f2c8f70">848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d627f909504f5bb6aec2303812401b_D20221001-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctNC0xLTEtMjA2MjAx_ac8ddd72-a9e0-473d-aefd-ecb5592d6c91">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b642d2cd344106b2a9b43195affb7d_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctNi0xLTEtMjA2MjAx_0d749272-ec73-4e86-91ae-5071a1ce539b">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e495b2d1a824af7811048f9f9bc9a17_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctOC0xLTEtMjA2MjAx_d4891fba-440f-44e0-9c7c-b0debe2e807d">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic905e297ec6e4217a0a0992727261a16_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTAtMS0xLTIwNjIwMQ_f7a9ce6c-0f96-41a3-9db0-41924edc56cc">461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4824dabd1ef04421b159a085c221b393_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTItMS0xLTIwNjIwMQ_e7c70047-7437-4411-9860-2fc25e0a12c9">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac4f0dce8ef748aeae685b9a10378f08_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTQtMS0xLTIwNjIwMQ_3fbec480-c80d-44b2-aafc-2adf9f508846">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bdbcb88c32403d8e379e2f8730b5ee_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTYtMS0xLTIwNjIwMQ_5a996d69-38e0-407b-a033-c97d7b9aa404">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie12cb06ca50647f08c8d0f02d992ddb8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTgtMS0xLTIwNjIwMQ_360c3eee-d7b0-4227-9940-f10d91f7d29b">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab84e501cf364e47a226c6765f0a1320_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMi0xLTEtMjA2MjA2_dd1d7030-674d-4188-bc94-fe3c0a2bff4c">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f569aa2b2b469081ca5099662ae431_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtNC0xLTEtMjA2MjA2_589032db-197e-4502-9ed8-d1d9b3364786">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d68f0d45e34ce3afe76b0c1819f0f5_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtNi0xLTEtMjA2MjA2_a9d52039-6724-4052-b461-f117b00802bf">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1dd3fc9f8784e4c8374d245b0c7fb71_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtOC0xLTEtMjA2MjA2_34cc0c5f-8e8e-49c4-9dcc-7c58afa41867">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28a9a6d2501418081e48da0d0dc78ce_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTAtMS0xLTIwNjIwNg_b7a0023d-e8e0-4fcf-8a40-7b30255e0b04">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79c2d0bccb749ce9727366fb1126ceb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTItMS0xLTIwNjIwNg_8a4944f4-6020-4af6-8720-dff8a390bb2f">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257e9c51364e4d82b08262ef2ac191a3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTQtMS0xLTIwNjIwNg_2a739f3c-ef95-418d-8cf1-566c7f8b0108">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic120030329c6425dad6cd6f3e198f509_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTYtMS0xLTIwNjIwNg_db6b464b-9248-4727-936d-64b6ebce6663">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf507146d984867ac54d44e61ad8dc6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTgtMS0xLTIwNjIwNg_0ad15ba5-dd83-468d-943d-2d72f03f34df">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c25cc3cd16f40dc875390afe7993316_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMi0xLTEtMjA2MjA2_53357124-d1d2-4a0f-8163-65debd1f094b">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04869452639e49c4889ecd6ea51662ad_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktNC0xLTEtMjA2MjA2_02e9b228-b06f-4fe6-9f8b-3e14ef186eae">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d869ac7f27a4395b24b5b634039d37e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktNi0xLTEtMjA2MjA2_05333726-b52c-4a96-94a9-c7ceeeb0ef4e">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab122339be0b431f90bca45e37234133_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktOC0xLTEtMjA2MjA2_73f7a517-6c9e-44f8-9228-e20148886507">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260c1936cd204104b9c849ec4c5f1086_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTAtMS0xLTIwNjIwNg_bac3c57f-4168-4d54-b984-6c81d0ff1382">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib16b3709a01e464fbb530033aa9546a9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTItMS0xLTIwNjIwNg_351fe121-6d09-4185-b784-750648727464">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39749dabb5124d4da5d2ebbe0c7f9bab_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTQtMS0xLTIwNjIwNg_143ee592-e6a4-48c4-ace7-a04db4d5a610">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1734816467749ce9071cf1a91e0ea7d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTYtMS0xLTIwNjIwNg_b4823258-71ce-407f-94a7-478d78e86611">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1885db8f4e54fc68d9a604c36caefc1_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTgtMS0xLTIwNjIwNg_c2b8c1e8-8dee-4162-b4e4-845674814144">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e97be903941430ba5c15572221083c5_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMi0xLTEtMTg4OTc0_6522b1fc-02ff-4a22-861f-7336135dc566">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862040fed4914d45b07c1986dde77ca1_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtNC0xLTEtMTg4OTc0_78bb9bc5-c3a6-4619-9859-69aa21741c66">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe19cf36dad4281bb45cf16884ba782_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtNi0xLTEtMTg4OTc0_171d6b8a-34ac-4ec5-bd58-d6e7234577c1">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic31ee96f0c344214b71935816f6d82bf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtOC0xLTEtMTg4OTc0_185caec6-eb2d-4e98-9c2e-7cbde58d3933">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if976b4b2b7594c2d9f40e64ea67f3e83_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTAtMS0xLTE4ODk3NA_85663666-5fc4-4870-b79b-9e78c21e969f">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2089ffa1cd467083ed4a1db7f715e7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTItMS0xLTE4ODk3NA_e878cc03-3503-41c2-ae51-362c0a66a295">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b4597ba3cb4f84aa35b4d25bfb8261_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTQtMS0xLTE4ODk3NA_32a47f56-9ef0-42f4-87f4-1e30803972ee">2,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb3f737b3494a4cbc9bc33b832a55ee_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTYtMS0xLTE4ODk3NA_14ea657d-3834-43f1-a369-0b2e47d874eb">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bdc8fa194f44dfd99072ad9bcca3737_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTgtMS0xLTE4ODk3NA_5942795c-c911-4a78-98ee-bf4691e3df46">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5bd2a8d54048c38e2e840cbd09500d_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTItMS0xLTIwODU1OA_94e2c266-6971-49e6-a7fb-adc191bb2f68">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ab76d96eac4989a331ad1292e4f071_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTQtMS0xLTIwODU4NA_3cb853ca-7092-4854-80ed-3ab5b9d47b1a">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2876569878e64fa28cfa8f94277c4955_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTYtMS0xLTIwODYyNA_54c00367-e2fb-4208-96b3-4ae5ee6282d0">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6814d750caec49fc9617453d49cd87de_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTgtMS0xLTIwODU5OQ_0aff7f06-ffbd-4a7a-b046-1be2e889bd64">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8b506414e4400f94126bb294f8de27_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTEwLTEtMS0yMDg2MDM_9a84fa2d-7208-40aa-897c-4651e47a92cd">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab191a59b38e4a6aa145b09f8bd9d253_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTEyLTEtMS0yMjM4NDk_62c8d6b0-bd1b-430c-9df8-3b1b6934dce3">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7535ce0ea49c7b96444b2409cf8d0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE0LTEtMS0yMDg2MDg_4604c4f4-f7f1-4734-95c5-06de24fe5dd7">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93535a2cb1d74743ba6ebf13264af448_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE2LTEtMS0yMDg2MTk_55b42b9f-2db3-476c-bded-52215c5fba6e">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164b97eced64b058786a55ff9fb37e5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE4LTEtMS0yMjM4NTU_f01e934a-5a09-4995-85b4-a35d54d2a1cf">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02da5611affd4bb39c32bd0b8b1af6b4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTItMS0xLTE4ODk3NA_f7a09bfa-1c5d-406a-8530-f10c73b2ee9f">3,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia93f46843ff741beafe6a37517e53dd2_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTQtMS0xLTE4ODk3NA_84eb72e5-63ca-4762-945b-8922d385d34c">2,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie830411e990944a58b257c504ac9bd03_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTYtMS0xLTE4ODk3NA_49ec2cbb-68fc-4e91-bb8a-0db54ba590bd">5,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7e76085a9842b38a2bd7b388f5d89a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTgtMS0xLTE4ODk3NA_79ca92b5-ea03-4984-8578-61c9c309ea5b">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ea6966e44b490499ae329249bdde9b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTEwLTEtMS0xODg5NzQ_c93ef6ce-fd5d-490f-a197-f84f8972da26">2,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08293a2d22a847e882c434fc87376ede_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTEyLTEtMS0xODg5NzQ_09654626-2ddb-45cd-953e-befd49aa38c0">5,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d34a61daa04c4abac9d3a4af47df32_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE0LTEtMS0xODg5NzQ_d34be79d-c9f6-4e6b-955c-4a0b42560e0a">3,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d2558e049e14f7fad9ba2b4954fbece_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE2LTEtMS0xODg5NzQ_30536263-d205-4491-9a3c-470789649c34">1,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc3c579513437d88fef139e4772cdb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE4LTEtMS0xODg5NzQ_f2765ecd-1ba7-4500-937e-172109cedffb">5,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dddf5cfe0e94fa19b1688a79d7445ae_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTItMS0xLTE4ODk3NA_6efd882e-f14b-4b42-b1c0-8300911e2db3">17,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib65a6afa486142c9a0bed18deeea04c4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTQtMS0xLTE4ODk3NA_3d18ad00-30e2-4cde-b8bf-7950bc3c015e">7,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f333186d8da4378bcf0c5a3e6baf0f9_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTYtMS0xLTE4ODk3NA_620e5923-7e34-4153-8ba3-0e4be1ac39cb">24,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c5766aba06f4d61bfab9fcffab156e5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTgtMS0xLTE4ODk3NA_e2dea178-c596-47b0-838f-dbbf18b04725">17,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65873c515ce4f70aec863e02db39e0b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTEwLTEtMS0xODg5NzQ_5e189da8-cfa9-4933-9109-13a1cb76c97a">7,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b25c75934844f82a32f7a76cdbe5042_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTEyLTEtMS0xODg5NzQ_fb956c23-8d08-4511-b8d8-266dca135f5a">24,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e69273cff94b48bc90019f3c462804_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTE0LTEtMS0xODg5NzQ_dedf1a1c-ef04-47c8-a9b1-ef9ac6f78c68">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i419f6f8b71f643678f664afe333ad342_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTE2LTEtMS0xODg5NzQ_386463d5-584b-4200-8dfe-13ba386f8b8e">6,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8db07843e5b426fbe44e0590a500e74_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTE4LTEtMS0xODg5NzQ_6a0f5ae4-77d5-4039-819f-9d173addee1e">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9009ee1e369c449292e70d4d067b1184_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTItMS0xLTE4ODk3NA_c745c926-a49f-4acc-80e5-755609a602e9">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cee17c29ea542229fc4893cb3183b4d_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTQtMS0xLTE4ODk3NA_125e8955-544c-4b0b-9d2e-2c6868595042">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id25b0832750a4204ac083f11c97f8288_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTYtMS0xLTE4ODk3NA_9f1ad583-f500-4b05-84e2-904fc046f299">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4df96a522844448bf9e3616baca9df9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTgtMS0xLTE4ODk3NA_be6127c3-095f-4d95-a052-a198f150db7e">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37ac076bb994281907bc729c8f6d935_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTEwLTEtMS0xODg5NzQ_ddd4fe5b-886b-4024-a70e-bc61dfc7e484">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2457cd740816456db1f50da03ba631dc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTEyLTEtMS0xODg5NzQ_9b319c46-6eb7-4e88-acec-e55ade18d688">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d14a8530ad947f7b3fa2aefa3363fda_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTE0LTEtMS0xODg5NzQ_88844f14-4f7d-4eec-b065-93b2f6745b19">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6053e1fe314de1b2bb31df2e6ce976_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTE2LTEtMS0xODg5NzQ_1c1ad2c6-d908-4a8b-8231-0d5b495f626e">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cbcfb77ce746588d1956f2435637ae_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTE4LTEtMS0xODg5NzQ_3293af5c-b4c6-42e2-be3f-904b24b563db">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d4871c35ef74d7e8c872893b4cdaebc_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTItMS0xLTE4ODk3NA_daebf730-5fad-4af2-ab11-660dda1e604d">18,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf92b1997d60491abc1e2f5b65cf03a4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTQtMS0xLTE4ODk3NA_37f1c889-176e-48d4-970e-b544555cc37e">7,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTYtMS0xLTE4ODk3NA_5f09bccb-6759-4bf2-b31b-9a1585d9caf6">26,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63498908586e409e90d8f39594556f93_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTgtMS0xLTE4ODk3NA_088ebdb8-af23-4802-a227-489747343217">18,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie377953c909f44678464f43ddbf57467_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTEwLTEtMS0xODg5NzQ_a848a664-d0a2-496c-b32e-795663867563">7,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTEyLTEtMS0xODg5NzQ_79ef3947-0b5a-46bd-8717-1a9d87d3c383">25,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5ae9adf5244a858af6f315eef250b6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTE0LTEtMS0xODg5NzQ_22a61cb1-77d0-4aa1-8a70-7ece96483495">18,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64d8fc93c0f84588aacc70e98160df80_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTE2LTEtMS0xODg5NzQ_f8063990-68bf-4ea5-b986-64191bfae1ca">6,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTE4LTEtMS0xODg5NzQ_7a7a9733-bffb-4f31-95dc-75548e0d37a0">25,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i4f4bc9752ca948c2ab586ee6e206318e" continuedAt="i89e96ba814644bf3883b72760e45d9f0">(2)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i89e96ba814644bf3883b72760e45d9f0">Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2022, 2021 and 2020.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iad815992cd5b4cbb820bd5a3b6f89ab7"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had product sales to <ix:nonFraction unitRef="customer" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzExODE_0725b331-3a56-40ed-9fed-3a55349477e6"><ix:nonFraction unitRef="customer" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzExODE_42b6e944-b279-4d08-b85a-cb2f320378bb"><ix:nonFraction unitRef="customer" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzExODE_ddba0334-eaf3-4915-a313-1eeb126d4a90">three</ix:nonFraction></ix:nonFraction></ix:nonFraction> customers that individually accounted for more than 10% of total revenues for each of the years ended December 31, 2022, 2021 and 2020. For the year ended December 31, 2022, on a combined basis, these customers accounted for <ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="2" name="amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzEzNzI_e639ba87-c8ce-4e38-8600-91cf4b395541">82</ix:nonFraction>% of total gross revenues as shown in the following table. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE5NjA_3075ee93-4f5e-46e5-bd62-20fb73950840" continuedAt="i9196725c1369405399a0840b5a7ea0dc" escape="true">Certain information with respect to these customers was as follows (dollar amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="i9196725c1369405399a0840b5a7ea0dc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic492dbf72e134124ace0523e8918ae54_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzMtMS0xLTEtMTg4OTc0_adef51a0-468e-4cc3-9888-574b0783ea60">17,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3be857e2d3446f6a9576880dc95fdbf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzMtMy0xLTEtMTg4OTc0_a087388b-c346-466c-a58b-c44289fa8655">15,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ced2b08bd74e91807733d80569e8f2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzMtNS0xLTEtMTg4OTc0_88650fda-b87c-4780-8b2d-266ec9c459ed">13,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic492dbf72e134124ace0523e8918ae54_D20220101-20221231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzQtMS0xLTEtMTg4OTc0_6c9e2c03-43cb-4205-9986-6534109a1647">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3be857e2d3446f6a9576880dc95fdbf_D20210101-20211231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzQtMy0xLTEtMTg4OTc0_9b5ae283-3e96-49de-841f-a3db4ca4bd5b">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3ced2b08bd74e91807733d80569e8f2_D20200101-20201231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzQtNS0xLTEtMTg4OTc0_d667be95-47a0-47b1-a856-af1f53f347d2">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce35b441d394680be0e8bc1af6382e6_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzYtMS0xLTEtMTg4OTc0_6bba0a42-acea-4caf-8f77-dc2f27e45316">15,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ebce1b8e1b4437b11925ff3b848025_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzYtMy0xLTEtMTg4OTc0_a0b20ffb-0d82-4587-8e70-e314afaba89f">14,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660bbb9450f640a2b53f5e591fae8ed1_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzYtNS0xLTEtMTg4OTc0_718d5a07-ddc1-453b-be53-82f8920f399b">14,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ce35b441d394680be0e8bc1af6382e6_D20220101-20221231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzctMS0xLTEtMTg4OTc0_e1fbed9e-5c66-4ff3-a6ba-e28ed28007e0">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04ebce1b8e1b4437b11925ff3b848025_D20210101-20211231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzctMy0xLTEtMTg4OTc0_c18fc0be-ec3d-495f-95e0-fd8e8f7e2a4b">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i660bbb9450f640a2b53f5e591fae8ed1_D20200101-20201231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzctNS0xLTEtMTg4OTc0_ae026990-b82a-4899-be04-c3708de4ded0">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75d92c2783d458a8be680eb71b21a63_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzktMS0xLTEtMTg4OTc0_47af6cdf-618c-4f15-b6b5-001f24e0dc20">8,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf450c77c4449a8b3ecf57bc98e144a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzktMy0xLTEtMTg4OTc0_bcdb19fe-81ef-4444-bd22-9507076953a8">7,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1681e5dde84590a71f0e996bf9146f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzktNS0xLTEtMTg4OTc0_023ab841-f9bf-4b93-a635-ea2babbc31c0">7,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if75d92c2783d458a8be680eb71b21a63_D20220101-20221231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzEwLTEtMS0xLTE4ODk3NA_c92647a8-3b69-4f35-867a-b0d09124c260">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4bf450c77c4449a8b3ecf57bc98e144a_D20210101-20211231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzEwLTMtMS0xLTE4ODk3NA_5cca5bbb-788b-4355-b2b7-5fc2554170df">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd1681e5dde84590a71f0e996bf9146f_D20200101-20201231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzEwLTUtMS0xLTE4ODk3NA_f23a40e3-31ee-401e-bce9-a37058c2f288">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, amounts due from these <ix:nonFraction unitRef="customer" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE1NzE_28a9dd76-37e3-405f-91c7-608a12251bfc"><ix:nonFraction unitRef="customer" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE1NzE_57f874ba-d643-4736-8494-642dad9d5c6b">three</ix:nonFraction></ix:nonFraction> customers each exceeded 10% of gross trade receivables and accounted for <ix:nonFraction unitRef="number" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="2" name="amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE2NDc_126e3bf3-1ddb-409c-91f3-47e5e36574b3">75</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="2" name="amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE2NTQ_d12a10e5-4fd1-4f15-b781-1fbcb3bc6def">73</ix:nonFraction>%, respectively, of net trade receivables on a combined basis. As of December 31, 2022 and 2021, <ix:nonFraction unitRef="number" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="2" name="amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE3MzU_737a22bd-c7d9-43f8-8fae-16fa80cc2a12">26</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="2" name="amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE3NDI_b19e5f94-6469-454d-9db1-9ea4b22dc4ed">27</ix:nonFraction>%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2022 and 2021, was not material.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_202"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzcyOTY_b93f1b3c-9f86-45d9-8cde-821599eeea43" continuedAt="i5c21976922e148efb66abae8f4075318" escape="true">Stock-based compensation</ix:nonNumeric></span></div><ix:continuation id="i5c21976922e148efb66abae8f4075318" continuedAt="ic9553cb6ea9643aba9d1a47859e16a65"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by <ix:nonFraction unitRef="shares" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="INF" name="amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzMyNA_b2afb131-1632-492b-ac68-a0e695ed1633">one</ix:nonFraction> share for each stock option granted and by <ix:nonFraction unitRef="shares" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="INF" name="amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3MA_0670eef8-b528-472d-a0f1-b4fff73b0608"><ix:nonFraction unitRef="shares" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="INF" name="amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3MA_2b613345-dca1-40a4-8e9b-32cf80e585f4">1.9</ix:nonFraction></ix:nonFraction> shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of <ix:nonFraction unitRef="shares" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="INF" name="amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzkxOA_c3eb6539-aa70-480c-85e1-8057570d8add"><ix:nonFraction unitRef="shares" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="INF" name="amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzkxOA_f3706c69-aa57-441e-9b08-4f3e72502ba8">1.9</ix:nonFraction></ix:nonFraction> shares. As of December 31, 2022, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately <ix:nonFraction unitRef="shares" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="INF" name="amgn:AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzEwMjg_a8c594f2-9085-46d3-862f-c7d093087110">15</ix:nonFraction> million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMDI_cac20f5c-a1df-479e-9879-2a027d42b7ec" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzItMS0xLTEtMTg4OTc0_76236c25-a7aa-43f1-aac6-63979ec15a91">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821d0160b8fd46f592bae9bed6edeeca_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzItMy0xLTEtMTg4OTc0_2a93dde2-c079-4baf-84f3-31c669e9ddff">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d0dbb92b9046b892ae095e67db26c1_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzItNS0xLTEtMTg4OTc0_5c992588-9a63-4c36-b4fa-f1678ec7842a">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzMtMS0xLTEtMTg4OTc0_f1a6e05d-1476-4cdc-b89a-6cf8164c72bc">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzMtMy0xLTEtMTg4OTc0_e540ee87-0336-4c84-8853-17be419af81f">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzMtNS0xLTEtMTg4OTc0_76911020-ba8c-491f-b54d-ca627d353bd5">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzQtMS0xLTEtMTg4OTc0_1439ccfe-e316-441f-abec-1de6e1be252a">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzQtMy0xLTEtMTg4OTc0_04990434-8d1f-4322-953b-39fb7eb7b081">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzQtNS0xLTEtMTg4OTc0_8aac31df-efb0-4ec1-be62-762ccceabac0">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzUtMS0xLTEtMTg4OTc0_b40f710f-7da9-4ce8-9ed1-a20000931299">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzUtMy0xLTEtMTg4OTc0_5c40bcbc-68cc-4bf1-8eb7-05b2b22d2b2d">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzUtNS0xLTEtMTg4OTc0_198a78cb-6ff3-4364-95c9-5d098f49d95a">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzYtMS0xLTEtMTg4OTc0_394c854b-f274-4f72-a595-dde2a64183e5">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzYtMy0xLTEtMTg4OTc0_85e46e73-289f-49ff-8a25-9cab55c7ca45">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzYtNS0xLTEtMTg4OTc0_cbeee7ac-9a1e-452b-9275-7d39d21e37a3">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="amgn:StockBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzctMS0xLTEtMTg4OTc0_1af9b405-ec4f-4a7a-878b-c0b2151298b2">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="amgn:StockBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzctMy0xLTEtMTg4OTc0_78bcbe60-6cf0-4783-94e1-a72462c67488">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="amgn:StockBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzctNS0xLTEtMTg4OTc0_70989f65-c465-47e5-bbda-e9d34acce114">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units and stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee&#8217;s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic9553cb6ea9643aba9d1a47859e16a65" continuedAt="i8076a9186c6641d0916c112bbc8865c5"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMTg_f2885e4a-e43a-4d16-a368-8ca641c4424f">RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.</ix:nonNumeric> RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usdPerShare" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI3MDY_74e98047-d53a-47e2-bbdf-a8cf867a71c3">234.47</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i821d0160b8fd46f592bae9bed6edeeca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI3MTA_03470171-5c26-44b2-bed6-07490e4867ff">233.10</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i11d0dbb92b9046b892ae095e67db26c1_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI3MTc_67591b36-4c1c-4f12-b471-a81f4dc5a8ac">235.63</ix:nonFraction>, respectively. </span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMTQ_b7cc32e6-ff97-4b3f-b119-42c390124ecb" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our RSUs:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant&#160;date<br/>fair&#160;value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i219ff676680c41029ce9c7eaf92b5b3b_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzItMS0xLTEtMTg4OTc0_c5f27914-64e5-4557-bc66-341f2e908f7e">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i219ff676680c41029ce9c7eaf92b5b3b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzItMy0xLTEtMTg4OTc0_440f4235-781d-4750-9b2c-f0a5f95c6e9a">217.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzMtMS0xLTEtMTg4OTc0_ce67e9fe-d29f-46d9-ad14-d2e65b96f5e4">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzMtMy0xLTEtMTg4OTc0_3d4486d6-578f-49e2-b9b5-8e8e69636dd8">234.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzQtMS0xLTEtMTg4OTc0_a5f2f3b9-d260-45fb-b34e-1c1f1855f1a5">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzQtMy0xLTEtMTg4OTc0_008dfe1b-3a4e-49af-9d22-59c2a00db5c6">201.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzUtMS0xLTEtMTg4OTc0_7189ad90-6005-42d2-8ffe-6dd471b8e057">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzUtMy0xLTEtMTg4OTc0_7203c48c-b52f-4506-b77f-80fcb5d7bf25">226.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3eb195f7ff9c4f059c27b617ec488e62_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzYtMS0xLTEtMTg4OTc0_b4d1e182-a1f1-49a9-a394-07ef91302550">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3eb195f7ff9c4f059c27b617ec488e62_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzYtMy0xLTEtMTg4OTc0_4e32a8e9-7e3b-47d6-8d95-bed9e1c57834">228.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair values of RSUs that vested during the years ended December 31, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usd" contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI5MTA_8047756c-e615-420d-9d6a-4d86c899a9b1">192</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i821d0160b8fd46f592bae9bed6edeeca_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI5MTQ_4dbdf1ad-af38-4bee-b547-ae120f397d0d">166</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i11d0dbb92b9046b892ae095e67db26c1_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI5MjE_e7de68bc-85bd-41c1-a31e-ab740bbca373">161</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire <ix:nonNumeric contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzMxNDM_040da89d-60cd-40c2-a4ea-04551d34d828">10</ix:nonNumeric> years from the date of grant. We use the Black&#8211;Scholes option valuation model to estimate the grant date fair value of stock options. </span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzcyOTk_5a796b47-bcc2-4d30-91a4-49dbad824d63" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzItMS0xLTEtMTg4OTc0_73d0e737-61e6-49a6-b14a-980648b5407d">230.92</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzItMy0xLTEtMTg4OTc0_ed6d0a13-8b5b-47bb-ad8c-73acfa1aae28">237.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzItNS0xLTEtMTg4OTc0_0ceccaf3-43c7-41d6-9baa-4c0fd902af1f">236.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (average of implied and historical volatility)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzMtMS0xLTEtMTg4OTc0_43f089b0-bd95-4d47-bc12-39160cf451f6">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzMtMy0xLTEtMTg4OTc0_fc1da60b-58d9-4acf-84b8-c614d27110d0">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzMtNS0xLTEtMTg4OTc0_845a8da4-808b-48ca-be65-13334cfae52f">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzQtMS0xLTEtMTg4OTc0_fbe56a39-bd75-46d9-ac54-584645d72f68">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzQtMy0xLTEtMTg4OTc0_79e55dec-3d9b-4d4d-b068-cec82a553ff7">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzQtNS0xLTEtMTg4OTc0_0522bf81-7492-4731-ba04-f224dad52dbe">5.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzUtMS0xLTEtMTg4OTc0_fa20a674-713a-4beb-8177-9b0e43758ca3">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzUtMy0xLTEtMTg4OTc0_0a5a3d7c-31cf-44e6-a069-bcd21917656e">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzUtNS0xLTEtMTg4OTc0_a739b366-ad33-448c-a9b4-ff34f8526eec">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzYtMS0xLTEtMTg4OTc0_b41e77b0-a3fd-4b09-b590-bec910f4b50d">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzYtMy0xLTEtMTg4OTc0_816c8ff7-0e29-4591-8627-7ce444edb310">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzYtNS0xLTEtMTg4OTc0_fbefc269-3cfc-4aa1-a12a-c722b80beaeb">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzctMS0xLTEtMTg4OTc0_876cbaca-b6a9-4b51-bf34-d98a5d9c4b69">42.43</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzctMy0xLTEtMTg4OTc0_da018e23-7c6f-4050-8701-076d2279c2f1">40.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzctNS0xLTEtMTg4OTc0_01dce528-878e-4e30-ad39-b012311fb01c">42.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8076a9186c6641d0916c112bbc8865c5" continuedAt="ic1604a49c5e84a30b11dd1f1ba80d650"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMTA_a09535f9-faef-4ea4-8326-b781f260c793" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our stock options:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise&#160;price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value<br/>(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifeed4f08e59e4fb882fab3526d452c25_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzItMS0xLTEtMTg4OTc0_557c7a6a-520a-4ad7-b422-1e9eb951e5d0">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifeed4f08e59e4fb882fab3526d452c25_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzItMy0xLTEtMTg4OTc0_6ace8647-e873-40c2-ba76-844de9742b4b">197.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzMtMS0xLTEtMTg4OTc0_8566bb32-25e0-45a0-a897-0aca180a9e9b">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzMtMy0xLTEtMTg4OTc0_7ef96be0-52f5-405a-a00b-e57efe8f54dc">230.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzQtMS0xLTEtMTg4OTc0_ea818779-ad96-4ae5-bcf1-7b4af606f2a3">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzQtMy0xLTEtMTg4OTc0_e541dadc-02ad-4cfc-ac33-dbbf32057a4a">167.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzUtMS0xLTEtMTg4OTc0_f1258aec-2e23-42b4-8625-3346472b8233">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzUtMy0xLTEtMTg4OTc0_9f6b47a2-9ceb-455f-99e0-e820127ae596">226.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2088886061214180b8eaf2c7c870e341_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzYtMS0xLTEtMTg4OTc0_68712bef-6f89-4655-85e7-5887e1cd5ae2">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2088886061214180b8eaf2c7c870e341_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzYtMy0xLTEtMTg4OTc0_d7cc21e6-a142-474e-b03b-d0b27a3cecff">207.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzYtNS0xLTEtMTg4OTc0_77302359-71fe-4f34-a5b9-3191c8c0f9a0">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2088886061214180b8eaf2c7c870e341_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzYtNy0xLTEtMTg4OTc0_650fcafa-5034-441a-9d0a-239006a7d163">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2088886061214180b8eaf2c7c870e341_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzctMS0xLTEtMTg4OTc0_6eda6183-028b-4628-9fc6-840148d9e8ce">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2088886061214180b8eaf2c7c870e341_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzctMy0xLTEtMTg4OTc0_cb16344e-d12d-4c7d-8a2d-13b2b801d3ac">206.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzctNS0xLTEtMTg4OTc0_27d3cf5d-b0b8-4c90-95a2-c442993f4fe7">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2088886061214180b8eaf2c7c870e341_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzctNy0xLTEtMTg4OTc0_b1b6f16d-fe71-4832-b648-f8beb60bfa91">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2088886061214180b8eaf2c7c870e341_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzgtMS0xLTEtMTg4OTc0_e6b0380c-d4cb-49af-99c4-eb9fd7fc0517">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2088886061214180b8eaf2c7c870e341_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzgtMy0xLTEtMTg4OTc0_6cebd1dd-30f2-440a-8bb4-6e469412cba2">177.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzgtNS0xLTEtMTg4OTc0_8c4e9997-22cb-43de-895d-7f143895d760">5.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2088886061214180b8eaf2c7c870e341_I20221231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzgtNy0xLTEtMTg4OTc0_b794789b-bd92-46ec-8aa3-80a5f32e451c">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic values of options exercised during the years ended December 31, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usd" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM2MTA_cdbea7e8-2103-410f-95d0-97f17acd50b7">67</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM2MTQ_cf1d4313-3f8a-4239-b888-ec5cbe75bc0e">56</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM2MjE_70848fc6-88a6-472a-b9ba-45d20cb44235">98</ix:nonFraction> million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usd" contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3NTc_bcc7cb67-9c0b-420f-b1db-20edb2824cd8">14</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3NjE_363665df-97fa-4a30-a67a-ed5f9396524a">12</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3Njg_d76d244b-838d-4996-b400-6d7458188932">21</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3OTY_add3bf95-18fd-4861-89fa-4baa0eeee845">362</ix:nonFraction> million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM5NjA_3567477b-4673-4b06-af30-e1c774037e0d">1.7</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzQyNDk_6560ff2c-4f45-450d-b551-b66f91c40ced">three years</ix:nonNumeric>. The performance goals for the units granted during the years ended December 31, 2022, 2021 and 2020, which are accounted for as equity awards, are based on (i) Amgen&#8217;s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen&#8217;s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a <ix:nonFraction unitRef="shares" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="INF" name="amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzUxMTQ_43a0f248-50fb-4b94-afc7-c40ab4e13a92"><ix:nonFraction unitRef="shares" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="INF" name="amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzUxMTQ_584c1dfe-4b7a-4f08-b991-0b3c54b03c8e"><ix:nonFraction unitRef="shares" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="INF" name="amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzUxMTQ_5c0ddc99-3e00-457d-a5e0-ecf9111d3ba5">one</ix:nonFraction></ix:nonFraction></ix:nonFraction>-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a payout simulation model to estimate the grant date fair value of performance units. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMzQ_d3477492-8c3d-48e3-8c56-c981ae5365d8" continuedAt="i9ff22627f25448359dbd95ad387fdb5c" escape="true">The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><ix:continuation id="i9ff22627f25448359dbd95ad387fdb5c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzItMS0xLTEtMTg4OTc0_ee1d050d-2df8-47f0-a000-d6c7398a4949">230.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzItMy0xLTEtMTg4OTc0_fe0f12cb-9398-4d72-b349-26f120876b0e">239.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzItNS0xLTEtMTg4OTc0_dc0723a9-b19f-45af-a217-ac5e6190f091">236.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzMtMS0xLTEtMTg4OTc0_0364d3d0-9729-41e3-91fb-40ecd4d7809d">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzMtMy0xLTEtMTg4OTc0_d8841a9b-0db0-42c9-bcbe-aad60702d177">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzMtNS0xLTEtMTg4OTc0_586064e4-20f2-4357-a7dd-15f1e7a2658b">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzQtMS0xLTEtMTg4OTc0_3e638dfa-238a-4f59-9f86-cf47a7bac7fc">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzQtMy0xLTEtMTg4OTc0_d6ece1b7-88ab-48a6-b825-eb3c712498ac">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzQtNS0xLTEtMTg4OTc0_bec40350-cfb9-4b9c-80f6-843b2900a030">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of units granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzUtMS0xLTEtMTg4OTc0_76d9782c-5b83-4ef6-95f7-ca50e43377ba">247.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzUtMy0xLTEtMTg4OTc0_76829e00-7d7b-406b-b72a-17083b51b04e">254.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzUtNS0xLTEtMTg4OTc0_58cbccbe-fec1-4dc6-9813-e9884a01a32a">249.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic1604a49c5e84a30b11dd1f1ba80d650" continuedAt="i753bdc627ec74d15a6203f780b95afd9"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both December 31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="if5361cc7c39a4e2aba0e4628230f4a9e_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY0Nzg_2aef6d5c-1cd6-463a-8c73-48bebde51bd8">1.6</ix:nonFraction> million performance units were outstanding, with weighted-average grant date fair values per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="if5361cc7c39a4e2aba0e4628230f4a9e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY1ODE_7a7e4eaf-d7ee-4d22-bea3-645639da587c">250.27</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0c95759e9f834fff8e2ab6b9325f2188_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY1ODg_33038872-08f4-4394-90f0-29cf3601b176">229.39</ix:nonFraction> per unit, respectively. During the year ended December 31, 2022, <ix:nonFraction unitRef="shares" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY2NDE_7a9be6b1-aa61-453a-91e1-1475b2c312ec">0.6</ix:nonFraction> million performance units with a weighted-average grant date fair value per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY3MjA_a1870e58-6c58-448e-9a92-f7afd6b25027">247.48</ix:nonFraction> were granted, and <ix:nonFraction unitRef="shares" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY3NDE_133d746d-50c9-4001-a193-f021ffcac15d">0.1</ix:nonFraction> million performance units with a weighted-average grant date fair value per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY4MjA_1f6cdbad-c041-43c1-97d8-ae58168fa577">250.94</ix:nonFraction> were forfeited.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair values of performance units paid during the years ended December 31, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usd" contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY5NDM_ec7584e9-8b2f-464f-a62a-e9ad69a17cd0">150</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY5NDc_f65706dc-77de-46c3-90e5-6db651350ac6">149</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY5NTQ_abc706b2-aa21-4150-8756-d08e60d1e30a">230</ix:nonFraction> million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i753bdc627ec74d15a6203f780b95afd9">As of December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="if5361cc7c39a4e2aba0e4628230f4a9e_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzcxMzE_5335595b-fa0a-4fec-b0bd-a37de8ffeff5">132</ix:nonFraction> million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzcyODE_c02ae515-8f26-4cfa-871f-7ee4f0292ae2">one year</ix:nonNumeric>.</ix:continuation> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_205"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDUvZnJhZzpiMDc4MGExMzNlM2Q0MmJmYmMyMzI4MTlhNTc1ZWVkZi90ZXh0cmVnaW9uOmIwNzgwYTEzM2UzZDQyYmZiYzIzMjgxOWE1NzVlZWRmXzQxMQ_8da1fbb9-26c9-4c50-aec3-13e319adf018" continuedAt="i0a2881271e9c49d9bb2d4686d0d54c12" escape="true">Defined contribution plan</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0a2881271e9c49d9bb2d4686d0d54c12">The Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDUvZnJhZzpiMDc4MGExMzNlM2Q0MmJmYmMyMzI4MTlhNTc1ZWVkZi90ZXh0cmVnaW9uOmIwNzgwYTEzM2UzZDQyYmZiYzIzMjgxOWE1NzVlZWRmXzM1MA_a8129b8e-5131-497d-ba09-020342b0673a">243</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDUvZnJhZzpiMDc4MGExMzNlM2Q0MmJmYmMyMzI4MTlhNTc1ZWVkZi90ZXh0cmVnaW9uOmIwNzgwYTEzM2UzZDQyYmZiYzIzMjgxOWE1NzVlZWRmXzM1NA_3ea84675-880a-493f-959b-c010e80ad144">279</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDUvZnJhZzpiMDc4MGExMzNlM2Q0MmJmYmMyMzI4MTlhNTc1ZWVkZi90ZXh0cmVnaW9uOmIwNzgwYTEzM2UzZDQyYmZiYzIzMjgxOWE1NzVlZWRmXzM2MQ_26cc761e-ba68-4431-ad17-008f97669890">231</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively.</ix:continuation></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_208"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc5MDU_42977328-7134-48e1-b498-60230cb03562" continuedAt="ie84ef56fba50442fb6ea5d5d01562496" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="ie84ef56fba50442fb6ea5d5d01562496" continuedAt="i75d0c8a575014ee687b281240c59e4bd"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc5MTE_eaf0ec6b-cb47-4bb5-b061-4694f9132dfe" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes included the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154b8bdaf9ab475f99a1f2846362c79c_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzItMS0xLTEtMTg4OTc0_f91770e3-0cda-40ae-be94-ad499f211714">3,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de81be8345e48fb922b906166ab900a_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzItMy0xLTEtMTg4OTc0_dcf6e148-f4e7-4cbb-aee0-0d08b4376034">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb430bb605c14773b903da59d06a7e70_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzItNS0xLTEtMTg4OTc0_ee5b4ad8-08f0-4980-b573-457efd94b959">4,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8471d8b9c83641319a4f6ddfcd0f18c3_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzMtMS0xLTEtMTg4OTc0_8dd2f89a-c123-48fa-b579-516bb0310838">4,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice4e89011fbe4e4cbcf5dd5272b78ecc_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzMtMy0xLTEtMTg4OTc0_3c8811ce-a7ae-41dc-88c9-2804d89c9618">4,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a84fb02f834393b706d526a6e58884_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzMtNS0xLTEtMTg4OTc0_dd941eb6-9312-4cd1-934c-15c91ec5b6fe">4,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzQtMS0xLTEtMTg4OTc0_c758da96-803d-4b77-8cbb-f4e489aa4afc">7,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzQtMy0xLTEtMTg4OTc0_aaf31f23-af39-4af6-b0fb-93853ca5077e">6,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzQtNS0xLTEtMTg4OTc0_0f5b2dc0-38ba-41bc-b31a-8cff244f201f">8,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i75d0c8a575014ee687b281240c59e4bd" continuedAt="i3c1bdaea55744307bbb4a5a361e28c4e"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc4OTc_1f9255fa-6116-4cdd-8c12-bec2c1a323f9" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes included the following (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzMtMS0xLTEtMTg4OTc0_9d23b9ab-274b-4850-aa46-fd7c89d884e4">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzMtMy0xLTEtMTg4OTc0_d8a30ed4-7b0d-420a-a249-395a5cfc212c">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzMtNS0xLTEtMTg4OTc0_3fafb78e-a673-42fd-b04a-3ac5d77f1713">921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzQtMS0xLTEtMTg4OTc0_9a5ed9ef-57f2-433b-8b02-08f209c3761e">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzQtMy0xLTEtMTg4OTc0_138b1869-aa79-4ac0-a89d-8b4f2f312eb0">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzQtNS0xLTEtMTg4OTc0_15ca0f56-3b68-405a-a1d0-800822a4a97f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzUtMS0xLTEtMTg4OTc0_b80583b4-7e26-4681-980f-f3f1bdbdcbe9">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzUtMy0xLTEtMTg4OTc0_05e12d1e-132d-4032-8c4e-bc13b1a73c43">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzUtNS0xLTEtMTg4OTc0_2e6f0c0c-b98c-412e-a808-1d5ddbf619af">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzYtMS0xLTEtMTg4OTc0_5dbc03ac-2667-4c56-806c-bd7899f453c0">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzYtMy0xLTEtMTg4OTc0_371ba370-7eab-49df-9eeb-486db8178cd7">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzYtNS0xLTEtMTg4OTc0_e77f9249-7c65-43cb-8861-8fee2759402a">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred benefit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzgtMS0xLTEtMTg4OTc0_993ad3e1-ea9b-4632-99af-e104aa21ab21">1,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzgtMy0xLTEtMTg4OTc0_abb1be8a-13a8-47f5-9390-d09fc8dcdad0">308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzgtNS0xLTEtMTg4OTc0_3467282b-79a7-4db2-ad59-c12c1da8a382">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzktMS0xLTEtMTg4OTc0_ff2603d2-c6fd-4e34-ab29-27271f27c267">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzktMy0xLTEtMTg4OTc0_f0947523-d201-4c0f-8eac-dd48676852d1">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzktNS0xLTEtMTg4OTc0_3bd5fc9f-2757-4dae-ae1e-15111aafc3f8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEwLTEtMS0xLTE4ODk3NA_c364490c-a413-4cf3-a1bb-45c37da5d41b">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEwLTMtMS0xLTE4ODk3NA_aba34f52-00e1-4f7e-b5a1-3e3899324471">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEwLTUtMS0xLTE4ODk3NA_1e8c9fd0-291b-487d-9f52-3a0e4e20717d">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzExLTEtMS0xLTE4ODk3NA_efc394eb-dc79-445a-bbfb-304653a17e91">1,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzExLTMtMS0xLTE4ODk3NA_f9fb7a42-a64d-47aa-a890-8daacbe63d56">434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzExLTUtMS0xLTE4ODk3NA_b75fc6e2-857a-4f38-81e6-b508a69be45f">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEyLTEtMS0xLTE4ODk3NA_7572f4c4-b56b-4468-96fd-214baf6aeef9">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEyLTMtMS0xLTE4ODk3NA_42ae4fb0-8be2-41ac-aa34-f4a87f2d70a1">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEyLTUtMS0xLTE4ODk3NA_24ad72e6-8309-4834-9e48-5b7ce39987fb">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of NOL carryforwards. As of December 31, 2022, we elected to establish deferred taxes with respect to the U.S. minimum tax on the earnings of our foreign subsidiaries for the reversal of temporary items in future years. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc4ODU_590e3bce-bcca-4ab0-abc5-a3f63b93e15f" continuedAt="ic4df3f39df64404ebc7b4978c6770ded" escape="true">Significant components of our deferred tax assets and liabilities were as follows (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><ix:continuation id="ic4df3f39df64404ebc7b4978c6770ded"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzMtMS0xLTEtMTg4OTc0_99b37aaf-e893-46f9-a7c5-5481064f54b4">1,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzMtMy0xLTEtMTg4OTc0_68ef2b0e-32e0-4edf-9585-5fc9ab0cb8c4">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzQtMS0xLTEtMTg4OTc0_a3610fa1-0048-4783-b2b8-74a5a9585bc2">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzQtMy0xLTEtMTg4OTc0_6c30fb45-7b7c-43e8-b91b-1a7e28ffab6c">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzUtMS0xLTEtMjE0NjEz_29bf0063-6420-4850-a352-ff1ba799d30c">515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="amgn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzUtMy0xLTEtMjIzOTM1_9c194541-bca7-4405-8c02-682c5a461b5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzYtMS0xLTEtMjEyMDgw_a09ff7fb-f82c-45b7-b041-63de0942444e">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzYtMy0xLTEtMjEyMDgw_d7dcca90-034b-4dfa-89f3-d1f32933c53b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses capitalized for tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzUtMS0xLTEtMTg4OTc0_a29254e7-9c5f-48c5-838f-9bfda7df001d">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzUtMy0xLTEtMTg4OTc0_dde062c7-c4d5-48ce-871a-8409142b89d6">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:DeferredTaxAssetEarningsOfForeignSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzYtMS0xLTEtMTg4OTc0_15b6b61a-798b-43ef-aa7f-9ee05d7a3599">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="amgn:DeferredTaxAssetEarningsOfForeignSubsidiaries" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzYtMy0xLTEtMTg4OTc0_72fca3b0-f2b7-44fe-8685-db3111e4e7ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzEwLTEtMS0xLTIxMjExMw_ff03510c-48b9-4710-b388-59143d2b26a1">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzEwLTMtMS0xLTIxMjExMw_2cb1069c-2b35-4b3f-afb2-29061d08dfaa">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzgtMS0xLTEtMTg4OTc0_4024510d-9647-40d7-8666-ad0228ba7c74">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzgtMy0xLTEtMTg4OTc0_83f44750-c281-4809-932a-132b8e6ecb72">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzktMS0xLTEtMTg4OTc0_eaae9d01-404c-4401-ac4b-e28f6abc4fe2">3,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzktMy0xLTEtMTg4OTc0_0a8b2f1b-eb26-46f8-9bb0-b134ad263c13">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzEwLTEtMS0xLTE4ODk3NA_685bb2f1-83f1-4106-836e-bd11d0dcd3c2">718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzEwLTMtMS0xLTE4ODk3NA_59764c57-1eae-474e-bd78-9ec60f05a6bf">663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzExLTEtMS0xLTE4ODk3NA_965d5768-9225-4fb6-9795-fe2ab86a0d81">2,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzExLTMtMS0xLTE4ODk3NA_d910bd47-f169-4620-998e-008403b207f4">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE0LTEtMS0xLTE4ODk3NA_276661a4-91ed-447f-8f20-cca9c28d98d7">1,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE0LTMtMS0xLTE4ODk3NA_537de561-9f72-4f5c-b4fa-ef15b491c715">824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE1LTEtMS0xLTE4ODk3NA_59975545-99fb-4cac-be41-6aae7eba4c3c">272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE1LTMtMS0xLTE4ODk3NA_b101c08a-0a7b-42f4-b0d2-b272030cd184">275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE2LTEtMS0xLTE4ODk3NA_973f0aa1-b5fb-4fc7-b50c-4fdb1c28bd93">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE2LTMtMS0xLTE4ODk3NA_a437355f-1a9e-4425-9eee-833525246fea">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE3LTEtMS0xLTE4ODk3NA_cdc8aa3d-1a99-4cea-be1d-05ba45237443">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE3LTMtMS0xLTE4ODk3NA_264d5559-7864-4cc0-9637-e37e4f19f7fb">221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE4LTEtMS0xLTE4ODk3NA_dad88751-034a-4610-845e-d339d6bf1843">1,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE4LTMtMS0xLTE4ODk3NA_b9819218-8438-4dbd-82da-5b39846311ee">1,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE5LTEtMS0xLTE4ODk3NA_630061a5-ed06-4a81-8662-c5450a9a35d4">943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE5LTMtMS0xLTE4ODk3NA_c2cb388f-8be5-44b3-82b0-e7115e19d436">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased in 2022, primarily driven by the Company&#8217;s expectation that certain state R&amp;D credits will expire unused.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3c1bdaea55744307bbb4a5a361e28c4e" continuedAt="ic2832954230e4b88b0d7770ba822123c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="ibc64ba5f13184705bbcea61dca732af0_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzEwMzg_4cbb3463-fad5-4e6a-8061-fa1b53ad17e7">170</ix:nonFraction> million of federal tax credit carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="ibb268048ef47498c93e842c4884d3b1a_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzQ1NjI5NzMyNTYzMjU3_2e289423-ce35-4d46-a3c6-cb2eee16838a">6</ix:nonFraction>&#160;million of those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2042. We had $<ix:nonFraction unitRef="usd" contextRef="i0c663e71979d4887b26c8be64eb736f1_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzEyODQ_15c8278a-3023-4f44-afb2-df2f2691d82c">896</ix:nonFraction> million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="i0c663e71979d4887b26c8be64eb736f1_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE0MTE_0b81f397-766d-4f45-8850-68848f7b0981">813</ix:nonFraction> million of those state tax credit carryforwards. We had $<ix:nonFraction unitRef="usd" contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgzMDAzNQ_bad8f65d-4754-4e0f-bca2-32180a0642c2">51</ix:nonFraction>&#160;million of tax credit carryforwards related to our foreign jurisdictions available to offset future foreign income taxes for which we have provided <ix:nonFraction unitRef="usd" contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardValuationAllowance" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgzMDA1NQ_4a607c58-3730-49d1-b1ac-6d62166ea3fe">no</ix:nonFraction> valuation allowance. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="ibc64ba5f13184705bbcea61dca732af0_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE0NzI_a02cbbe7-a4a7-4366-8004-becdfbd3ca0c">1.3</ix:nonFraction> billion of federal NOL carryforwards available to reduce future federal income taxes and have provided <ix:nonFraction unitRef="usd" contextRef="ibc64ba5f13184705bbcea61dca732af0_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgzMDA2Mw_6a0eafd4-abae-4458-8f3b-a7da238b0dff">no</ix:nonFraction> valuation allowance on those federal NOL carryforwards. Additionally, $<ix:nonFraction unitRef="usd" contextRef="ibc64ba5f13184705bbcea61dca732af0_I20221231" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE3MjE_4f58884e-1871-4d27-b0a1-18241595b465">1.0</ix:nonFraction>&#160;billion of those federal NOL carryforwards have no expiration; the remainder begin to expire between 2023 and 2037. We had $<ix:nonFraction unitRef="usd" contextRef="i0c663e71979d4887b26c8be64eb736f1_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE4MDQ_4cb632f0-0f29-4d8a-8fbc-b62ae887d991">536</ix:nonFraction> million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="i0c663e71979d4887b26c8be64eb736f1_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE5MjQ_a8c8c74c-8354-456f-ad69-b360e38e583f">415</ix:nonFraction>&#160;million of those state NOL carryforwards. We had $<ix:nonFraction unitRef="usd" contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE5Njg_1d9f8466-65c8-484d-b90d-894e0e358ffe">1.9</ix:nonFraction> billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzIwOTI_469f8626-e7c0-4498-b3b1-14ac8135b023">186</ix:nonFraction> million of those foreign NOL carryforwards. For the foreign NOLs with <ix:nonFraction unitRef="usd" contextRef="i3470fa30c75149af83b41d392e448110_I20221231" decimals="0" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzIxNTc_b0f23f3a-ed6c-4498-9f51-209757fc4cdd">no</ix:nonFraction> valuation allowance provided, $<ix:nonFraction unitRef="usd" contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzIxOTA_556b4e76-a064-4e38-bb78-fa4d45692f93">640</ix:nonFraction> million have no expiration; and the remainder will expire between 2023 and 2051.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc5MDg_df0f86a6-467f-4e77-8622-a22e73bcfef2" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the total gross amounts of UTBs were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzItMS0xLTEtMTg4OTc0_22e6cc0f-859d-4644-87f0-61653a4454de">3,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzItMy0xLTEtMTg4OTc0_400b894d-53c0-41f1-a076-549fd7bc1010">3,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzItNS0xLTEtMTg4OTc0_81f4a0e0-02aa-4bcb-9f9d-4ba1b8b42116">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzMtMS0xLTEtMTg4OTc0_afdacee6-370c-4e54-abf0-afc32f45900a">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzMtMy0xLTEtMTg4OTc0_537570b0-0630-4ba1-ab94-8fb375e11ce7">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzMtNS0xLTEtMTg4OTc0_bcfb3637-8425-4800-b1bc-2a0de2bbd119">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzQtMS0xLTEtMTg4OTc0_396bc76d-c98f-428a-b94b-420c052c6aa7">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzQtMy0xLTEtMTg4OTc0_18343b46-072d-4c42-b9fc-534ca4fe1792">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzQtNS0xLTEtMTg4OTc0_36e8b448-9101-4b37-a4af-49093ec622e9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzUtMS0xLTEtMTg4OTc0_5696d294-01bd-4be8-9059-537cb972f12d">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzUtMy0xLTEtMTg4OTc0_15e56f14-d4ac-4422-9c4e-efffb55defd2">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzUtNS0xLTEtMTg4OTc0_1c72b5e0-8c54-4ca3-b613-c6fd980cba5d">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for expiration of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzYtMS0xLTEtMTg4OTc0_53dbff94-d872-48ab-9ba0-4bf8fec6b7e3">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzYtMy0xLTEtMTg4OTc0_513d2cbe-e303-42f5-ab11-7e366d949c5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzYtNS0xLTEtMTg4OTc0_2e657b42-7b42-415c-931d-4f19e3d0e092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzctMS0xLTEtMTg4OTc0_61087d32-96f6-4da9-9fe0-d441b5e5cff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzctMy0xLTEtMTg4OTc0_427dd6ff-2344-44f9-8614-f6cfc5f8a77b">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzctNS0xLTEtMTg4OTc0_8af8f57a-d3ab-4b7c-b38a-79fc44a1a9ce">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzgtMS0xLTEtMTg4OTc0_5edb8904-fa81-46c5-9a26-de0f09e0d737">3,770</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzgtMy0xLTEtMTg4OTc0_eb9b3887-9417-4a73-b5f3-adedd364f914">3,546</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzgtNS0xLTEtMTg4OTc0_f10258ad-a955-49a3-817b-aa7216a9fb25">3,352</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the UTBs as of December 31, 2022, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2022, 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzI3MzY_b365699c-8f03-4cee-9e1b-ebca9586d637">189</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzI3NDA_2c79e442-ee1c-483e-a996-d8a4ef053497">98</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzI3NDc_4649368d-bb55-4c91-8f77-c1c3c1a609a4">116</ix:nonFraction> million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The increase in interest expense for the year ended December 31, 2022, was primarily due to higher interest rates during 2022. As of December 31, 2022 and 2021, accrued interest and penalties associated with UTBs were $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzMxMDM_c5b51f9f-2be7-4b13-8e03-408b717ffc28">1.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzMxMTA_ec56e64a-18dc-48e3-8065-01638b92de36">881</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc4ODE_6b84a09e-3e1e-475d-89e2-9bbda7071022" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzItMS0xLTEtMTg4OTc0_b2b09d87-d31f-4b38-8eba-974950393747">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzItMy0xLTEtMTg4OTc0_e9b2888d-198c-4be6-9f1e-dc5e89a3d616">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzItNS0xLTEtMTg4OTc0_eb2adc16-57ef-4215-866a-34d1e2d8bc70">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzMtMS0xLTEtMTg4OTc0_86df5b3c-a660-451e-809d-1858d797b108">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzMtMy0xLTEtMTg4OTc0_f26935ba-7627-4334-8bae-5d9508501819">7.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzMtNS0xLTEtMTg4OTc0_a02452f9-659d-4cc4-8648-d70da24ca9bd">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzQtMS0xLTEtMTg4OTc0_8f92dede-f103-47b4-8fe6-86c4ff9e4b16">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzQtMy0xLTEtMTg4OTc0_23fcd90b-8371-41b3-befd-3b7837b3137c">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzQtNS0xLTEtMTg4OTc0_3a0b3ef5-883c-4fba-8e41-6437df93e4c2">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzUtMS0xLTEtMTg4OTc0_d3663d6f-c244-47bf-8777-5550e07ff946">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzUtMy0xLTEtMTg4OTc0_7c60332a-b161-4b5b-aaf6-870312a3e5b4">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzUtNS0xLTEtMTg4OTc0_6bed2695-ee8b-49e3-b3fa-b27a72636cbf">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzctMS0xLTEtMTg4OTc0_89554488-2d9c-462d-9642-69cdb4812928">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzctMy0xLTEtMTg4OTc0_719a09a0-ce00-44fb-8503-b8a77945556f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzctNS0xLTEtMTg4OTc0_339c1b51-8d45-4849-9e72-78553401b4cb">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, primarily federal R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzgtMS0xLTEtMTg4OTc0_e262754c-f12f-4d87-be3c-7a4214dcc337">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzgtMy0xLTEtMTg4OTc0_d3141a01-c2f7-415c-90f0-4d4d852d64a1">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzgtNS0xLTEtMTg4OTc0_826cc775-6e52-47f5-8a90-daa6e90f7eda">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzktMS0xLTEtMTg4OTc0_0a2ab19e-daba-4d97-a48c-2d22db70a7c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzktMy0xLTEtMTg4OTc0_a979e94f-603b-499c-8bc0-f5792a108859">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzktNS0xLTEtMTg4OTc0_61d81d1a-da34-456b-9389-f921cf2300c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEwLTEtMS0xLTE4ODk3NA_e2c983df-4204-4ad4-8356-989c7b1d1cb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEwLTMtMS0xLTE4ODk3NA_2ed5dea8-f019-41c9-bacd-8856b4178375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEwLTUtMS0xLTE4ODk3NA_a4e81baa-8045-4cb3-ad3a-a35fc858da6c">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzExLTEtMS0xLTE4ODk3NA_f2bb6937-c89d-4b69-88ff-6087f4dd61e1">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzExLTMtMS0xLTE4ODk3NA_63ae7668-579d-4e8e-9589-ca913cad28bc">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzExLTUtMS0xLTE4ODk3NA_4a9a413c-7732-4734-93ce-2366b3bef4d9">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEyLTEtMS0xLTE4ODk3NA_18af4cc2-ac41-4054-b95d-88001190da3e">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEyLTMtMS0xLTE4ODk3NA_5a0fa111-bbd7-4c10-b0c8-bf3875619d31">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEyLTUtMS0xLTE4ODk3NA_822470a0-18bb-49c4-b584-894f2bb78600">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic2832954230e4b88b0d7770ba822123c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the years ended December 31, 2022, 2021 and 2020, differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company&#8217;s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2050. Additionally, the Company&#8217;s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. territory of Puerto Rico imposes a 4% excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico effective through December 31, 2022. For 2022, we account for the excise tax as a manufacturing cost that is capitalized in Inventories and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid during the years ended December 31, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzQ1NjE_e02017c6-21ae-4c96-a51a-0e6c4cad48e9">2.4</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzQ1NjU_5e4fc14c-7f8e-4f0f-ae9f-c1b4dd9e63ab">1.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzQ1NzI_a8767ee4-6e66-4860-bc52-396ed6efd9ff">1.4</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#8211;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest <ix:nonFraction unitRef="numberofnotices" contextRef="i13c5612dc4a5450684e24434f6a3ec86_I20210531" decimals="INF" name="amgn:NumberOfNoticesOnProposedAdditionalTax" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc5MDY_c0ccaad8-2eb0-4426-a777-0ddae895bad4">two</ix:nonFraction> duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#8211;2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010&#8211;2012 by an amount that would result in additional federal tax of approximately $<ix:nonFraction unitRef="usd" contextRef="i13c5612dc4a5450684e24434f6a3ec86_I20210531" decimals="-8" name="amgn:ProposedAdditionalIncomeTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU5ODk_51f45a0d-798f-4c48-8ed7-dd1c745fd581">3.6</ix:nonFraction>&#160;billion plus interest. Any additional tax that could be imposed for the years 2010&#8211;2012 would be reduced by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i13c5612dc4a5450684e24434f6a3ec86_I20210531" decimals="-6" name="amgn:RepatriationTaxOnProposedAdditionalTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzYwODg_d0b7a4c3-83ff-43fe-b5a7-84a2ed734454">900</ix:nonFraction>&#160;million of repatriation tax previously accrued on our foreign earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#8211;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#8211;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#8211;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#8211;2015 by an amount that would result in additional federal tax of approximately $<ix:nonFraction unitRef="usd" contextRef="ic981a166a2b44b269c7a5073481bc3dc_I20220428" decimals="-8" name="amgn:ProposedAdditionalIncomeTax20132015" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgyOTk3NA_0c56e439-bf6a-4324-b71e-59c636deefec">5.1</ix:nonFraction>&#160;billion, plus interest. In addition, the Notice asserts penalties of approximately $<ix:nonFraction unitRef="usd" contextRef="ic981a166a2b44b269c7a5073481bc3dc_I20220428" decimals="-8" name="amgn:PenaltiesOnProposedAdditionalIncomeTax20132105" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgyOTk4OA_c939af78-6ab4-4bd6-bb98-6af4ca977fc3">2.0</ix:nonFraction>&#160;billion. Any additional tax that could be imposed for the years 2013&#8211;2015 would be reduced by up to approximately $<ix:nonFraction unitRef="usd" contextRef="ic981a166a2b44b269c7a5073481bc3dc_I20220428" decimals="-8" name="amgn:RepatriationTaxOnProposedAdditionalTax20132015" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgzMDAwMg_b4bdd015-ea9b-429d-bc68-1a2e20dee446">2.2</ix:nonFraction>&#160;billion of repatriation tax previously accrued on our foreign earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010&#8211;2012 and 2013&#8211;2015 Notices are without merit. We are contesting the 2010&#8211;2012 and 2013&#8211;2015 Notices through the judicial process. The <ix:nonFraction unitRef="case" contextRef="i94eb03241527483ebaf961e48ef6e18d_I20221219" decimals="INF" name="amgn:NumberOfNoticesConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE0MjkzNjUxMTc3MjI3_44c8e1f2-829f-43ee-b9c9-7f06e5ca3895">two</ix:nonFraction> cases were consolidated in U.S. Tax Court on December 19, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently under examination by the IRS for the years 2016&#8211;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90ZXh0cmVnaW9uOjM3YmVjZDVjMTZmZTRhN2M4ZTkyNTA1NmFmMDQ0MTg3XzczNA_8fa8954a-3dbf-4c58-9960-d49eba1d4d8a" continuedAt="id43d6f16385248ed960e5a71ca363698" escape="true">Earnings per share</ix:nonNumeric></span></div><ix:continuation id="id43d6f16385248ed960e5a71ca363698"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90ZXh0cmVnaW9uOjM3YmVjZDVjMTZmZTRhN2M4ZTkyNTA1NmFmMDQ0MTg3XzczMw_557939d5-d26e-4727-8d17-82759d07378a" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzMtMS0xLTEtMTg4OTc0_14bc04c3-6a37-462c-b2ab-351b35e26065">6,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzMtMy0xLTEtMTg4OTc0_63629072-852c-491d-b372-bf81b967eff6">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzMtNS0xLTEtMTg4OTc0_4ddcd2e2-53bb-43d9-82b5-2f3cd468fc19">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzYtMS0xLTEtMTg4OTc0_34a28710-b20d-45e7-9e52-acdd7f58aa3c">538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzYtMy0xLTEtMTg4OTc0_294d1302-f7a3-4888-83a4-bfabc8e76d76">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzYtNS0xLTEtMTg4OTc0_a7b23b0d-8aac-464a-9cae-7ac2d69963d2">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzctMS0xLTEtMTg4OTc0_8596bd1d-dd3c-4caf-984c-ae313a9fd5d6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzctMy0xLTEtMTg4OTc0_38dc7f4b-395c-4799-b79f-21c5449178b8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzctNS0xLTEtMTg4OTc0_8bccac63-644a-4092-b0e6-a482c043bd35">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzgtMS0xLTEtMTg4OTc0_6c665f2b-812b-4bc0-9f9c-25da653b16d7">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzgtMy0xLTEtMTg4OTc0_f11a24d8-91d2-4f8e-8ad3-ece0e8754282">573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzgtNS0xLTEtMTg4OTc0_f155e408-3be3-4176-b1d8-aed0582de240">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzEwLTEtMS0xLTE4ODk3NA_46cc5025-da01-45b4-b269-822f44adbc6f">12.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzEwLTMtMS0xLTE4ODk3NA_9a731dbe-1917-4e26-ae17-5dc5174913ed">10.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzEwLTUtMS0xLTE4ODk3NA_3dd22796-56ce-483d-ae63-8ab75293c476">12.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzExLTEtMS0xLTE4ODk3NA_6a91dccf-63f0-429e-8320-581ef3f832cb">12.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzExLTMtMS0xLTE4ODk3NA_3d342c26-1202-427b-9d63-0fa123bcf106">10.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzExLTUtMS0xLTE4ODk3NA_78ee5e40-58f4-4f56-9039-246427d13d6e">12.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three years ended December 31, 2022, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_214"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzgzMTY_58a9a7f0-d4ae-4636-adbe-79fda9913d74" continuedAt="ieab1261d39b04ca095891a5656b189b6" escape="true">Collaborations</ix:nonNumeric></span></div><ix:continuation id="ieab1261d39b04ca095891a5656b189b6" continuedAt="id57403ca860840248fcc840e63bcbdcb"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i)&#160;active participants in the activity and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalties and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized under these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we acquired an equity stake in BeiGene for approximately $<ix:nonFraction unitRef="usd" contextRef="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102" decimals="-8" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzE0MTk_09481926-4457-4355-834d-23a5b94fe1f4">2.8</ix:nonFraction>&#160;billion in cash as part of a collaboration to expand our oncology presence in China. For additional information regarding our equity investment in BeiGene, see Note 9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash and development services of up to $<ix:nonFraction unitRef="usd" contextRef="ia5ad848ccc9e43da99f1f90d2e7be305_D20200102-20200102" decimals="INF" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzIxMzM_e1e6899a-8538-4813-a12d-d192a33fbc32">1.25</ix:nonFraction>&#160;billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, net costs recovered from BeiGene for oncology product candidates were $<ix:nonFraction unitRef="usd" contextRef="i0b14ed1cf56b40588d947c7c195dba31_D20220101-20221231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI2Mzc_a3eca7b4-8ae8-4803-988d-5c1a7b0645dd">199</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i397d9bb426e14efc97584ac20babda5c_D20210101-20211231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI2NDQ_32a265c7-bca2-477e-9483-38e4723ed307">220</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5f6ac0af9e05484e9ff74b916399b3b1_D20200101-20201231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwNzc4MjQ_45396b7b-a2a0-4804-ba27-917f8e4b6c2b">225</ix:nonFraction>&#160;million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2022 and 2021, product sales from Amgen to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id57403ca860840248fcc840e63bcbdcb" continuedAt="i5d296e9971b54b96b47c81b5be600322"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BeiGene under the collaboration were $<ix:nonFraction unitRef="usd" contextRef="i61880ef9cc974d208e701a854ba365f7_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwNzc4NzY_0b5bb3cf-8c20-4876-8a27-a06b0902c71f">64</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i48b5fe9d56b04cc0b750c143fe63a442_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI4NDE_9cb367b6-f554-4fc6-be66-eae8777daa5c">72</ix:nonFraction>&#160;million, respectively, and were recorded in Product sales in the Consolidated Statements of Income. During the years ended December 31, 2022 and 2021, profit and loss share expenses related to the initial product-specific commercialization period were $<ix:nonFraction unitRef="usd" contextRef="id68f71c0e79f414eb9a0f7738f203cb6_D20220101-20221231" decimals="-6" name="amgn:ProfitAndLossShareOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMwNDg_d91a0faf-6f69-46c6-b6b0-be027dd83510">53</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i69081709322243d7bbce5ac32eca556d_D20210101-20211231" decimals="-6" name="amgn:ProfitAndLossShareOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwNzc5Mjg_21ed5ef6-2a2c-4573-af09-98ccfc7ade2b">64</ix:nonFraction>&#160;million, respectively, and were recorded in SG&amp;A expense in the Consolidated Statements of Income. Product sales from Amgen to BeiGene and profit and loss share expenses were not material during the year ended December 31, 2020. Amounts owed from BeiGene for product sales were $<ix:nonFraction unitRef="usd" contextRef="ie1d993f3e9e94186b4be512af2ce0c7d_I20221231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMzMTY_f5bd307a-be1e-43a7-9f85-bbed8df22ec5">6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i67856dd9461b467aa245cba68be2243c_I20211231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMzMjM_68b34d31-a491-45ce-bd41-b3b0a77a268a">21</ix:nonFraction>&#160;million as of December 31, 2022 and 2021, respectively, which are included in Trade receivables, net, in the Consolidated Balance Sheets. Net amounts owed from BeiGene for cost recoveries and profit and loss share payments were $<ix:nonFraction unitRef="usd" contextRef="i2e07e3056c344299b9420e74a38ebf5d_I20221231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzM1Mjk_b2344063-4b7f-4791-b042-ad35c5784e5a">47</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i24211ce70c914e6bbc5c138c04403948_I20211231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzM1MzY_c86ca669-4fbf-4a38-8794-03a56a29d5f2">61</ix:nonFraction>&#160;million as of December 31, 2022 and 2021, respectively, which are included in Other current assets in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca plc</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with AstraZeneca for the development and commercialization of TEZSPIRE. Under our collaboration, both companies share global costs, profits and losses equally after payment by AstraZeneca of a mid-single-digit royalty to Amgen. AstraZeneca leads global development, and both Amgen and AstraZeneca jointly commercialize TEZSPIRE in North America. In North America, Amgen, as the principal, recognizes product sales of TEZSPIRE in the United States, and AstraZeneca, as the principal, recognizes product sales of TEZSPIRE in Canada. AstraZeneca leads commercialization for TEZSPIRE outside North America. Amgen manufactures and supplies TEZSPIRE worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, net costs due to AstraZeneca for global development were $<ix:nonFraction unitRef="usd" contextRef="i9e2a1eff2f0448ba9a98ef6babf5bf8a_D20220101-20221231" decimals="-6" name="amgn:DevelopmentCostsDueToCollaborationPartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTcxMTY_a4226bc2-6679-4353-a28c-39366cc8fb83">74</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i550d1116353a45e988ecb42fddd2ea71_D20210101-20211231" decimals="-6" name="amgn:DevelopmentCostsDueToCollaborationPartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMyOTg1MzQ5MTI4MjU_a83b1530-43d0-4189-9a4c-2e249d3fffc3">49</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if22b1ca6b4224e409cb1dcbe7350db6f_D20200101-20201231" decimals="-6" name="amgn:DevelopmentCostsDueToCollaborationPartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMyOTg1MzQ5MTI4Mzg_c93ab582-907d-4586-aeda-ab9933acda49">52</ix:nonFraction>&#160;million, respectively, and were recorded in R&amp;D Expense in the Consolidated Statements of Income. During the years ended December 31, 2022, 2021 and 2020, net costs due to AstraZeneca for global commercialization were $<ix:nonFraction unitRef="usd" contextRef="i0717c9df57574deba2c7ff65d7c5e0b5_D20220101-20221231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTcxMzI_3a46d932-7e4b-4603-98a2-fdb1fa25df04">60</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ief89781cb0e44c878c87fc5562d3ca89_D20210101-20211231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMyOTg1MzQ5MTI5MTI_4672f6c6-7f24-4ead-b8ba-23ffc7aa8e01">39</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7ecf58c2e31f47edb3c517d8ed16b4ca_D20200101-20201231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMyOTg1MzQ5MTI5MjU_d6686812-cd15-480b-8b7b-7984704bdb02">16</ix:nonFraction>&#160;million, respectively, and were recorded in SG&amp;A Expense in the Consolidated Statements of Income. During the year ended December 31, 2022, global profit and loss share expenses were $<ix:nonFraction unitRef="usd" contextRef="i3587bfdb4d8c43eca1da9c2f79b27ab9_D20220101-20221231" decimals="-6" name="amgn:ProfitAndLossShareOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTcxNDg_66fbd1a3-adca-4e92-a2e2-69662bd74de1">119</ix:nonFraction> million and were recorded primarily in Cost of sales in the Consolidated Statements of Income. TEZSPIRE launched in the United States in January 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UCB</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with UCB for the development and commercialization of EVENITY. Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe and China (excluding Hong Kong). Amgen, as the principal, leads commercialization for EVENITY and recognizes product sales in all other territories, including the United States. Global development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, global profit and loss share expenses were $<ix:nonFraction unitRef="usd" contextRef="i356368409a2d4829afb562f99d59b84a_D20220101-20221231" decimals="-6" name="amgn:ProfitAndLossShareOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTc3OTU_8d96816c-8c21-42ce-aed4-b0ccb43fb870">255</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i2325b63848cb4d779d17a0fb7049c3ca_D20210101-20211231" decimals="-6" name="amgn:ProfitAndLossShareOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTgxMzg_6c686010-ccd6-42a2-8f7b-63218ff8b5b1">186</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iceb527e7ec734f6e818dc3d2674e17fc_D20200101-20201231" decimals="-6" name="amgn:ProfitAndLossShareOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTgxNjE_b10ed742-b5cf-4cb8-8774-2bee6a70541c">115</ix:nonFraction> million, respectively, and were recorded primarily in Cost of sales in the Consolidated Statements of Income. Net costs recovered from and due to UCB during the years ended December 31, 2022, 2021 and 2020, were not material.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, we modified the terms of the collaboration. Effective January 1, 2022, in the United States, Novartis no longer collaborates with Amgen, shares Aimovig commercialization costs or is required to pay milestones, and Amgen no longer pays royalties to Novartis on U.S. sales of Aimovig. Novartis continues to hold global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig. Amgen and Novartis share global development expenses, and Novartis pays Amgen double-digit royalties on net sales of the product outside the United States and Japan. Amgen manufactures and supplies Aimovig worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, net costs recovered from Novartis for migraine products were $<ix:nonFraction unitRef="usd" contextRef="i077a1aab04d044379338908da753b2fb_D20220101-20221231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTg0OTk_018914f9-af3c-41c7-bfef-102491044b4c">53</ix:nonFraction>&#160;million and were recorded in R&amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2021 and 2020, net costs recovered from Novartis for migraine products were $<ix:nonFraction unitRef="usd" contextRef="iad6cab3b37664965858bb4a82cbba6fc_D20210101-20211231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzU3Mzc_6188b91c-48d1-48e8-88bc-afa1d81947c3">160</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if044214b0e1f473786d143875c57f645_D20200101-20201231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzU3NDQ_b421ede7-f2f7-452a-97c6-9010ef4075ad">192</ix:nonFraction> million, respectively, and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2021 and 2020, royalties due to Novartis for Aimovig were $<ix:nonFraction unitRef="usd" contextRef="i0e19f3c8340e4982bd712b7b9ac5d3e7_D20210101-20211231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzU5MzM_8e190470-dda5-4232-9e3b-ffec31e75544">116</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id5d8484c53c2490ab0ee83876aa635bf_D20200101-20201231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzU5NDA_74a0c793-215c-435a-b229-4031db19fd90">139</ix:nonFraction> million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2022, 2021 and 2020, royalties due from Novartis for Aimovig were not material.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5d296e9971b54b96b47c81b5be600322"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kyowa Kirin Co., Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, we closed our collaboration and licensing agreement with KKC to jointly develop and commercialize rocatinlimab, an anti-OX40 fully human monoclonal antibody, worldwide, except in Japan. Rocatinlimab is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we lead the global development, manufacture and commercialization of rocatinlimab, except in Japan. KKC will co-promote rocatinlimab with Amgen in the United States and have opt in rights to co-promote rocatinlimab in various other markets outside the United States, including in Europe and Asia.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2285c8c0ccac4adbb106cc9bee4bbb49_D20210701-20210930" decimals="-6" name="amgn:UpFrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzY4MTY_621285c0-2a78-4ca5-8422-90ffbd04c09a">400</ix:nonFraction>&#160;million to KKC that was recognized in R&amp;D expense in the third quarter of 2021. Amgen and KKC share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by KKC will be reimbursed by Amgen. We may also be required to make milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i612eb99920494bc69ea0f16bc1bccb20_I20221231" decimals="-6" name="amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzcxNzk_4812d6f0-b8ac-473b-8fe2-fefc351815fd">850</ix:nonFraction>&#160;million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay KKC significant double-digit royalties on global sales, except in Japan. Net costs recovered from and due to KKC were not material during the years ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_217"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI0MTg5MjU1ODI0ODY0_4b804c80-1754-4b54-bf3f-e22505740a67" continuedAt="i03b7c5d2b39b4f7d857aad999b3b8572" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i03b7c5d2b39b4f7d857aad999b3b8572" continuedAt="i5cc71597437a481bb539342dfb70bffa"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale investments</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyNTk_9a750b4c-139a-47f9-94e7-70c4f97b742d" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.761%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEtMi0xLTEtMTg4OTc0_ff973d4e-7327-4c4c-b3f5-f433aacc6163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEtNC0xLTEtMTg4OTc0_29d0aac1-0ae6-4e9c-b97c-b29024e3f7f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEtNi0xLTEtMTg4OTc0_baa9a9a5-699b-4eb2-8cec-eeeca577d57a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEtOC0xLTEtMTg4OTc0_6f1734f5-a430-4da7-9f7c-66ea363a2093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba24b9313e764100a95332b21228b55d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzItMi0xLTEtMTg4OTc0_8a75894b-5c54-4e13-aea2-9d4df467b332">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba24b9313e764100a95332b21228b55d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzItNC0xLTEtMTg4OTc0_8f1e460f-b1bf-489a-b913-57ef992daeeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba24b9313e764100a95332b21228b55d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzItNi0xLTEtMTg4OTc0_02c72d3b-646a-4d30-a8db-c0157117e2e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba24b9313e764100a95332b21228b55d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzItOC0xLTEtMTg4OTc0_783f6cb2-06aa-4583-8a49-cdd58cdc0737">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzktMi0xLTEtMTg4OTc0_4104fcfe-c6bd-4b4f-bbdb-1146b7efb925">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzktNC0xLTEtMTg4OTc0_f907486a-6802-42db-b2ac-0a3b5564ad3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzktNi0xLTEtMTg4OTc0_ed668e44-4178-4ef3-b08c-6518e8c8b1aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzktOC0xLTEtMTg4OTc0_6f18d04f-5a6e-4700-a612-4cd64e9688c7">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213219e02daf455db4856867bb8edfc1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEwLTItMS0xLTE4ODk3NA_a87f785a-5acf-4334-8af9-95c2281d5c3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213219e02daf455db4856867bb8edfc1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEwLTQtMS0xLTE4ODk3NA_0e374a12-c57d-45ed-adf0-edd2afd0ff7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213219e02daf455db4856867bb8edfc1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEwLTYtMS0xLTE4ODk3NA_6bc50a4b-4ad2-46fb-be24-c9f03835cc38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213219e02daf455db4856867bb8edfc1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEwLTgtMS0xLTE4ODk3NA_e42560d3-a9a7-4213-a2d8-7ae3d83a17ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzExLTItMS0xLTE4ODk3NA_cccbd9a4-7ccb-4ece-adac-f6934b5a0d1a">4,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzExLTQtMS0xLTE4ODk3NA_90e88772-993a-429e-b46d-91d1e5646464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzExLTYtMS0xLTE4ODk3NA_eb26989d-8e6a-433c-b0c5-4a02919675eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzExLTgtMS0xLTE4ODk3NA_1e9ac942-05b2-434c-a75e-c9e932c16b04">4,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEtMi0xLTEtMTg4OTc0_f8d41edc-fa40-4029-990a-083bf47e1c31">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEtNC0xLTEtMTg4OTc0_8185d6fc-3dd6-4423-8cbc-9a6ec995fd74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEtNi0xLTEtMTg4OTc0_136616f1-04ba-4ef5-8002-0b584e0d935b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEtOC0xLTEtMTg4OTc0_bfad817a-7912-48ea-8d16-2d90cc1fb553">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzItMi0xLTEtMTg4OTc0_3e0260cd-2f95-44f9-8bc3-ff6cfac47864">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzItNC0xLTEtMTg4OTc0_f514c066-370a-4933-babe-b7289077e525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzItNi0xLTEtMTg4OTc0_dd8d3482-8b44-4bd5-918f-d99f5d76d86f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzItOC0xLTEtMTg4OTc0_926fa423-be61-417a-bf5e-9c9417b32fb5">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzktMi0xLTEtMTg4OTc0_a76e83bf-d6da-4b48-982b-c58968f16328">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzktNC0xLTEtMTg4OTc0_73d8b5b3-87db-4f46-9b7c-f542c7b51158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzktNi0xLTEtMTg4OTc0_bd02f8ad-a907-4c68-a13f-8020816f4bbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzktOC0xLTEtMTg4OTc0_ca04ebbc-3915-4cd2-b2b7-95a3f51e069b">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEwLTItMS0xLTE4ODk3NA_4acc5cea-6826-405c-bd4f-39bdfb3952e4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEwLTQtMS0xLTE4ODk3NA_2c0b0d39-120f-4994-844e-1b1d59611977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEwLTYtMS0xLTE4ODk3NA_35952b3e-6e14-481d-be51-1d2bba6df07f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEwLTgtMS0xLTE4ODk3NA_6ef4eff1-0130-46cb-87d9-6cd4e1e34f36">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEzLTItMS0xLTE4ODk3NA_d2f94f61-d05b-4ba3-9096-1a314846710e">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEzLTQtMS0xLTE4ODk3NA_53849a56-3175-4db0-9979-d81886f91fae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEzLTYtMS0xLTE4ODk3NA_32ebdb3b-864f-470f-b00b-b53877cf2534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEzLTgtMS0xLTE4ODk3NA_4e650b67-d19d-499e-a8f7-4c62b6d9e4b9">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyODA_ecc17673-4e6a-4781-b3f7-e5d1bb59f356" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736ffca3dc1842b084f709c4fe9809b1_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzItMi0xLTEtMTg4OTc0_cdf0dd76-08b0-4a0b-9f34-efa8c25e2750">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c6fe835b2741e1b409f5f32f417ec2_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzItNC0xLTEtMTg4OTc0_a192722f-619c-4eb1-8849-1679c0ecc3ac">7,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736ffca3dc1842b084f709c4fe9809b1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzMtMi0xLTEtMTg4OTc0_7f8a98da-3519-4c82-a8dc-b779d0ddec02">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c6fe835b2741e1b409f5f32f417ec2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzMtNC0xLTEtMTg4OTc0_d06fd4de-8ac5-4844-8ba7-c83d5265cdb2">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736ffca3dc1842b084f709c4fe9809b1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzUtMi0xLTEtMTg4OTc0_138cbfc4-558a-4b1b-a6b8-ad18623b20db">4,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c6fe835b2741e1b409f5f32f417ec2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzUtNC0xLTEtMTg4OTc0_ff8497e0-c2b4-41a5-a333-67681aa545f7">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents in the above table excludes bank account cash of $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ2Nw_22e1aa27-fbeb-413e-a038-37eaea0f6814">4,970</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ3NA_77950a1c-cd93-4312-bc4a-9332fbaf6357">733</ix:nonFraction> million as of December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All interest-bearing securities as of December 31, 2022 and 2021, mature in one year or less.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values (publicly traded securities) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="i2e65698c0cb74a14bfeefadc59b77d5a_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE1NjE_55960139-0507-4641-9a36-9e1a8c617792">480</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifa1b51ec520940e1b313db6b89b5a604_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE1Njg_727d8a5c-ff69-4295-a273-872c3b249905">611</ix:nonFraction> million as of December 31, 2022 and 2021, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. For the years ended December 31, 2022, 2021 and 2020, net unrealized gains and losses on publicly traded securities were a loss of $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE3ODg_94817880-0c76-4680-abfe-a92c108870ad">165</ix:nonFraction>&#160;million and gains of $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE3OTI_64d9a9dc-0aab-4d31-ba70-e2dee2e444e2">161</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE3OTk_f6fae730-eb2b-4eea-9c37-28709a800bb7">174</ix:nonFraction>&#160;million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2022, 2021 and 2020, were not material. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments of $<ix:nonFraction unitRef="usd" contextRef="i2e65698c0cb74a14bfeefadc59b77d5a_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE5NjQ_3487e0f3-8f5e-4fe8-8ca2-6e36f3065630">233</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifa1b51ec520940e1b313db6b89b5a604_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE5NzE_8f9de7ce-e471-4e68-9dc2-9be20d4fae5e">262</ix:nonFraction> million in equity securities without readily determinable fair values as of December 31, 2022 and 2021, respectively, which are included in Other noncurrent ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ets in the Consolidated Balance Sheets. For the years ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020, gains due to upward adjustments and gains realized upon dispositions of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5cc71597437a481bb539342dfb70bffa" continuedAt="i117152887c5749dd9a8164c4eb06cdf1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these securities were not material. For the year ended December 31, 2021, gains due to upward adjustments were $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzczMzQ_cc1cee86-83b5-4130-9519-325f622e16b9">152</ix:nonFraction>&#160;million, and gains realized on the dispositions of these securities were $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="amgn:EquitySecuritiesRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc0MDE_0eea6c9e-aed0-4310-b964-b45b8250e26c">41</ix:nonFraction>&#160;million. For the year ended December 31, 2022, downward adjustments to the carrying values of these securities were $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE0MjkzNjUxMTcwMjAw_31b61470-9fcc-48f0-9a90-500b9b0818a5">67</ix:nonFraction>&#160;million. For the years ended December 31, 2021 and 2020, downward adjustments were not material. Adjustments were based on observable price transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a <ix:nonFraction unitRef="number" contextRef="i7bb10a68da424589a4aa8d60cbb4b509_I20200102" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3MjE_3e41040a-fe3f-4753-860c-96e4c34babf0">20.5</ix:nonFraction>% ownership interest in BeiGene for $<ix:nonFraction unitRef="usd" contextRef="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102" decimals="-8" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NTg_445eaad5-9eb6-447e-80ed-145f6398d90b">2.8</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NzE_18f1f147-d6ad-41e2-8db7-39dfe436d1ff">2.6</ix:nonFraction>&#160;billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;D. Our equity investment in BeiGene is included in Other noncurrent assets in the Consolidated Balance Sheets.</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our equity investment is accounted for under the equity method of accounting due to our ability to exert significant influence over BeiGene. See Note 1, Summary of significant accounting policies, for factors in concluding our ability to exert significant influence over BeiGene. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sets of BeiGene by approximately $<ix:nonFraction unitRef="usd" contextRef="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102" decimals="-8" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzM0MzM_b126fc9a-7c41-4a59-b263-146a85aaacf5">2.4</ix:nonFraction>&#160;billion. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity method of accounting requires us to identify and allocate amounts to items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Other (expense) income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from <ix:nonNumeric contextRef="i6db31ce9c8264445a32e5e5e66606b87_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQwODI_e648027d-6202-4e60-a4f8-e48e5a68500e">8</ix:nonNumeric> to <ix:nonNumeric contextRef="i55ba36de5fe841cbac0c77bb92159e4e_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQwODg_c278e404-d993-44e0-b199-8097789a9c32">15</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, 2021 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the carrying value of the investment was reduced by our share of BeiGene&#8217;s net losses of $<ix:nonFraction unitRef="usd" contextRef="i742aa0979b534c78a1fbaaeec95b8732_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc0ODk_b9a68351-d90b-488c-a035-2cfed112f6f6">394</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQyMzg_54029add-0879-4168-8a0a-720fb46ede6f">265</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQyNDU_85115fc1-a3f3-4a34-8225-79d5c31979f2">229</ix:nonFraction>&#160;million, respectively, and amortization of the basis difference of $<ix:nonFraction unitRef="usd" contextRef="i742aa0979b534c78a1fbaaeec95b8732_D20220101-20221231" decimals="-6" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc1MTc_36edad5d-5999-4e8f-a6c6-0606f77c41c5">190</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231" decimals="-6" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQzMDc_0ebce7a9-9d4e-4c36-b95c-1f542c281330">172</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231" decimals="-6" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQzMTQ_47b57c63-2592-42cf-a473-489dd9945332">109</ix:nonFraction>&#160;million, respectively. During the years ended December 31, 2021 and 2020, we increased the carrying value by $<ix:nonFraction unitRef="usd" contextRef="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ0MTg_896a7182-87d2-4fa3-bd69-d7658a8165bb">50</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ0MjU_3eadc21e-ef9b-49c6-a38e-e1804e9e14f9">569</ix:nonFraction>&#160;million, respectively, as a result of our purchases of additional shares of BeiGene; we did not purchase additional shares of BeiGene during the year ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, during the years ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, 2021 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the carrying value increased by $<ix:nonFraction unitRef="usd" contextRef="i742aa0979b534c78a1fbaaeec95b8732_D20220101-20221231" decimals="-6" name="amgn:EquityMethodInvestmentChangeInCarryingValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc5NDc_363c1102-9d59-4e96-bc3c-f26143041eaa">11</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231" decimals="-6" name="amgn:EquityMethodInvestmentChangeInCarryingValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ2MDA_0e151062-1f30-47f4-816a-77a56e20e902">265</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231" decimals="-6" name="amgn:EquityMethodInvestmentChangeInCarryingValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ2MDc_c8ef74fb-a150-4ca9-ab08-3297d60891c9">34</ix:nonFraction>&#160;million, respectively, from the impact of other BeiGene ownership transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, our ownership interest in BeiGene was approximately <ix:nonFraction unitRef="number" contextRef="i0d78be49a55146f8aea0014dec6caca1_I20221231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ3NjU_0c728d88-d5bf-42a2-8b44-c6649a664d40">18.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5f9fd669564646ed90c1f923fcf22115_I20211231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ3NzI_f6ef3e48-3a7b-4fbe-b721-5d4a36e76ab0">18.4</ix:nonFraction>%, respectively. As of December 31, 2022 and 2021, the carrying value of our investment in BeiGene was $<ix:nonFraction unitRef="usd" contextRef="idd010ea395424e80984bb752c13cc1f4_I20221231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ4NzI_d6e553a4-4bac-4b11-8439-2f3d7b671f00">2.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ4Nzk_96dd050c-e78c-4663-bfd3-eeb0fb7c700d">2.8</ix:nonFraction> billion, respectively. As of December 31, 2022 and 2021, the fair value of our investment in BeiGene was $<ix:nonFraction unitRef="usd" contextRef="idd010ea395424e80984bb752c13cc1f4_I20221231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ5NzU_0c8c53b9-100c-4ca4-9c8c-b8aaf9628e57">4.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ5ODI_2d3b082b-9b2f-47a1-8d20-7784eb1f6d57">5.1</ix:nonFraction> billion, respectively. We believe that as of December 31, 2022, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 30, 2023, we relinquished our right to appoint a director to BeiGene&#8217;s Board of Directors. We no longer have the ability to exert significant influence over BeiGene and therefore will account for our equity investment at fair value, with changes in fair value recorded in earnings starting in the first quarter of 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neumora Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 30, 2021, we acquired an approximately <ix:nonFraction unitRef="number" contextRef="i4568cf82cca34f0fa0f23589a150184f_I20210930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzUzMzU_f375b483-d6da-45a9-9792-d63efdcf3368">25.9</ix:nonFraction>% ownership interest in Neumora, a privately held company, for $<ix:nonFraction unitRef="usd" contextRef="i547718310bf54e6390c23b1af397545a_I20210930" decimals="-6" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzUzOTk_19c0cfad-b761-44f2-a1e8-3bc868644793">257</ix:nonFraction>&#160;million, which is included in Other noncurrent assets in the Consolidated Balance Sheets, in exchange for a $<ix:nonFraction unitRef="usd" contextRef="i5225514442b04c37a257024814d81c9f_D20210930-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzU1MDI_e558e1cc-a76f-4fff-ac39-fcb5b15b0487">100</ix:nonFraction>&#160;million cash payment and $<ix:nonFraction unitRef="usd" contextRef="i5225514442b04c37a257024814d81c9f_D20210930-20210930" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzU1MjI_e2deb7c1-1d1d-4f77-b74e-a73d7f49ef8c">157</ix:nonFraction>&#160;million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. During the year ended December 31, 2022, we made an additional $<ix:nonFraction unitRef="usd" contextRef="iba147b39322644f2a1a03599c2a39483_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE0MjkzNjUxMTcxNjE3_1b71cfe5-e738-43ef-afee-dc1074d30a2f">10</ix:nonFraction>&#160;million cash investment via participation in Neumora&#8217;s subsequent financing round. As of December 31, 2022 and 2021, our ownership interest in Neumora was approximately <ix:nonFraction unitRef="number" contextRef="i48de6ba3d9f0465e9462933890029a6f_I20221231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzYwNzU_bc9e9d9a-8ee7-402b-81c2-942292dafaf0">24.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i01ad554978334ac88cec9913e0cc5884_I20211231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc5OTc_127600e8-ab8e-42a6-8a5b-24231e3a1702">25.9</ix:nonFraction>%, respectively, and the fair value of our investment was $<ix:nonFraction unitRef="usd" contextRef="ia353ede4e8b345c0b2974e1070e1fe2e_I20221231" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzgwNzY_8d92b862-e4b8-40a5-87b0-ed588f365d6c">335</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i89fb6287a84346aabe16f3d5d6175fe4_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzYxMjA_6d715c91-839f-4f4a-942c-0f00b2e969a8">220</ix:nonFraction>&#160;million, respectively. During the years ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized a net gain of $<ix:nonFraction unitRef="usd" contextRef="i4e93272860d242648586e251f19acc41_D20220101-20221231" decimals="-6" name="amgn:EquityMethodInvestmentChangeInCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzgyNjY_68194625-b552-4b93-aba2-9b58b2d2dd03">105</ix:nonFraction>&#160;million and a net loss of $<ix:nonFraction unitRef="usd" contextRef="i0661190d8893467dbcd83a57c4222013_D20210101-20211231" decimals="-6" sign="-" name="amgn:EquityMethodInvestmentChangeInCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzYxOTY_15c79225-77ec-4adc-a5e9-9803ba714340">37</ix:nonFraction>&#160;million, respectively, for the change in fair values in Other (expense) income, net, in the Consolidated Statements of Income. For information on determination of fair values, see Note 17, Fair value measurement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i117152887c5749dd9a8164c4eb06cdf1"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limited partnerships</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held limited partnership investments of $<ix:nonFraction unitRef="usd" contextRef="i0012e716a1434d35ac79af91c9e382bb_I20221231" decimals="-6" name="us-gaap:AlternativeInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzY0NDk_d0a8a17f-62e3-4d11-bc08-86bc679fe33a">249</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c4b1eddbef0462d9ae3e1a3e2db2e8c_I20211231" decimals="-6" name="us-gaap:AlternativeInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzY0NTY_64737de9-abbd-471d-9fcc-7c0d73e1ab73">573</ix:nonFraction> million as of December 31, 2022 and 2021, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. These investments, which are primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2022, unfunded additional commitments to be made for these investments during the next several years were $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcxMTM_d91c2a6d-e157-4059-9827-b81aa6bcdd27">187</ix:nonFraction>&#160;million. For the years ended December 31, 2022, 2021 and 2020, net gains and losses recognized from our limited partnership investments were a net loss of $<ix:nonFraction unitRef="usd" contextRef="i910730fc1f734dcb85a4bd843a18a53a_D20220101-20221231" decimals="-6" sign="-" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyMTk_89f54358-291a-4bfe-b788-7034bd92d61f">284</ix:nonFraction>&#160;million and net gains of $<ix:nonFraction unitRef="usd" contextRef="i68fa55908a0746a48abeb3eeff056228_D20210101-20211231" decimals="-6" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyMjM_b0cc787e-31da-4f0f-b7ea-c0c9bc5ff03c">143</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie659e94abdcd4ea3973f9174b5bd64ce_D20200101-20201231" decimals="-6" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyMzA_9b640521-4669-407a-9742-9c996bf47db9">241</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_220"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90ZXh0cmVnaW9uOjUzNjUyNWQ3MGY2NjQyN2RiYjdiNDQ5NGRhNGMxOWZlXzgx_9da5b293-e718-4fd7-8b68-19c4bc289121" continuedAt="ie11e4eade894449bb29ccf7eef97400b" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ie11e4eade894449bb29ccf7eef97400b"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90ZXh0cmVnaW9uOjUzNjUyNWQ3MGY2NjQyN2RiYjdiNDQ5NGRhNGMxOWZlXzc1_14d09584-dd53-48d2-99cf-a5aa81518b1d" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzItMS0xLTEtMTg4OTc0_bdba050b-022a-4206-af45-c2d4ffb5f34c">828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzItMy0xLTEtMTg4OTc0_22c83960-03b1-4e54-9d34-9f85eeb57f74">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzMtMS0xLTEtMTg4OTc0_48767ecc-7f71-4bfd-9670-580441636746">3,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzMtMy0xLTEtMTg4OTc0_d32b4045-3434-4e1c-af91-39868a7a98a4">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzQtMS0xLTEtMTg4OTc0_21037099-3e35-4726-9fcb-9bcecffbc708">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzQtMy0xLTEtMTg4OTc0_e73f82cb-8b37-4009-b1c9-cce19abded06">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzUtMS0xLTEtMTg4OTc0_eadd1930-5163-4f49-af03-c961266462d8">4,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzUtMy0xLTEtMTg4OTc0_99400c1a-c8d3-4542-8626-e116d5b75457">4,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzQ0Nw_2f653bbd-001c-449a-9cdb-c527bc3526cb" continuedAt="i8a1b75583f984630823801548dc97a15" escape="true">Property, plant and equipment</ix:nonNumeric></span></div><ix:continuation id="i8a1b75583f984630823801548dc97a15"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzQ0NQ_bd16e012-7f01-411b-ac70-cee1bd4750dd" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;life&#160;(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzItMy0xLTEtMTg4OTc0_14b63e5b-e3d2-41ce-a67e-e4fab6647290">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzItNS0xLTEtMTg4OTc0_c5d0c91d-676b-49de-9fd7-0653fbbb9466">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3bf57870a9f4462796cf71eb1204b562_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzMtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YjM4NTE1YWVhMTQ5NDdhOWE5NGZmZmQ1MjEzYjk2YzNfNA_4dffc267-b5f2-44fa-ab26-cade8707d9b4">10</ix:nonNumeric>-<ix:nonNumeric contextRef="i1cc1644aa9a14b298eb0dda7bc0c7d85_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzMtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YjM4NTE1YWVhMTQ5NDdhOWE5NGZmZmQ1MjEzYjk2YzNfNw_648e637b-593c-458b-9b32-98c83ddc3cc0">40</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzMtMy0xLTEtMTg4OTc0_88c9d8c4-c875-4609-ad2c-5ea882506202">4,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzMtNS0xLTEtMTg4OTc0_82ca5ae2-39fe-4a2c-8e44-c22fdf590fca">4,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e7adefe057e4125a56fb1a162b59975_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzQtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YjkwNTBhZmJlMzAyNDhkZDgyZjhkZDI2ODZhOTEyODBfNA_61bb1a76-4b62-4223-b514-90b07d2edd11">8</ix:nonNumeric>-<ix:nonNumeric contextRef="i13e514d61eb942da9c90cf58cce3e55c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzQtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YjkwNTBhZmJlMzAyNDhkZDgyZjhkZDI2ODZhOTEyODBfNw_93fd6c65-de2f-4f92-968d-a97e169dc298">12</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzQtMy0xLTEtMTg4OTc0_8f481cfe-4738-42eb-811e-6e2ac0b4c17c">3,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzQtNS0xLTEtMTg4OTc0_fca64b95-356f-4141-9d4e-85608f67b006">3,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b15e7cf27494cc1bd340423025d53ed_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzUtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246OWM4YTYyZGQzNTUwNDBjZGJlYmFkZjNkMmJjMWI2ZjJfNA_c2dbfd74-b874-40ca-a138-b5b6da868afb">8</ix:nonNumeric>-<ix:nonNumeric contextRef="ic6ca69fcdd8a42a6b7a9ac5979fa620c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzUtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246OWM4YTYyZGQzNTUwNDBjZGJlYmFkZjNkMmJjMWI2ZjJfNw_b2b51a1e-8157-4949-9bad-278724d26a1f">12</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:LaboratoryEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzUtMy0xLTEtMTg4OTc0_90cd3c45-e3cc-4cca-b967-f861482a764c">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="amgn:LaboratoryEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzUtNS0xLTEtMTg4OTc0_07d159ad-6786-4fbf-86fb-4f9e7c8dd2e1">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b79fbf871a84da7a223e2f58e7878f7_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzYtMS0xLTEtMTg4OTc0_44fcbc47-50aa-44c0-88b3-cda61130ccc5">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:FixedEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzYtMy0xLTEtMTg4OTc0_4cf63e24-06ba-4e47-a421-6381cb917c5d">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="amgn:FixedEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzYtNS0xLTEtMTg4OTc0_4f0196bc-081f-40c2-8d00-f04eccf4a39e">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i604a564a01bb466c93664f563428196a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzctMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YWIxMmM5OWQyNDA3NDdkNmI3NWNkNjUyZWRkYzM3ODZfNA_ea176e6b-9d4f-45f7-af5d-4f1c0c273cce">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ibea9550cddf5409f89486fce84d29e92_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzctMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YWIxMmM5OWQyNDA3NDdkNmI3NWNkNjUyZWRkYzM3ODZfNw_2aef6e1e-ff27-4ec5-9f6c-0d909cfc4518">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzctMy0xLTEtMTg4OTc0_1b691be8-9f37-4bc0-b8e0-2be59819fe16">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzctNS0xLTEtMTg4OTc0_6de18086-f5dd-4b43-b857-0c2775f13fa3">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc07e2aaa249436e81ba3ffc71d13fb1_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzgtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246ZTc3YjAyYzBjNzlmNDk4NGEyMjUxMjMxNzgzODMzYmFfNA_f6fab78c-30c5-4442-9870-d0059718f84b">5</ix:nonNumeric>-<ix:nonNumeric contextRef="ib9b7a507438942a2aaf4c1748fe959cd_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzgtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246ZTc3YjAyYzBjNzlmNDk4NGEyMjUxMjMxNzgzODMzYmFfNw_da0056b0-7aee-48be-901d-34da9ef17799">10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzgtMy0xLTEtMTg4OTc0_431d16b3-1392-4066-9a4f-ac007a1d11fa">929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzgtNS0xLTEtMTg4OTc0_b10d32d4-d174-4e3c-a993-cbc4b65062be">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzktMy0xLTEtMTg4OTc0_90cff908-f55c-4289-981e-cfee4c36764d">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzktNS0xLTEtMTg4OTc0_564fad86-d289-4a3f-9bf6-449519a06e89">987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzEwLTMtMS0xLTE4ODk3NA_e2483b87-028a-4194-bf98-8fa47de43ed4">14,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzEwLTUtMS0xLTE4ODk3NA_945132fd-7d34-4867-8a8a-8013c53043dd">13,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzExLTMtMS0xLTE4ODk3NA_1c6768c0-20fe-4b01-8dea-55b13db0b623">9,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzExLTUtMS0xLTE4ODk3NA_14c434f5-ac7e-4c86-9303-f199d04a5914">8,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzEyLTMtMS0xLTE4ODk3NA_82c9152f-822d-4d31-8bd3-5f032d1eb893">5,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzEyLTUtMS0xLTE4ODk3NA_7bf3b7e8-1597-4789-ad51-b4d00bfeed85">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, we recognized depreciation and amortization expense associated with our property, plant and equipment of $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzI0NA_d20efd57-93d0-4ad4-a476-19a1382dcd0a">661</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzI0OA_da36e69a-14fe-4f12-8a97-95a254f6b4a8">644</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzI1NQ_e1e6e56a-1de0-4570-8506-8c6e61e4d7d3">640</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographic information</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzQzMQ_a8a19aad-c651-4ac8-84ff-62c7931ece79" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff279f49fa7b4713b3a0452ae164a793_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzItMS0xLTEtMTg4OTc0_46c4091c-e424-49d2-bd26-e81c6ddd6a2d">3,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a78eea27ce4a75b4576bdbeb318deb_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzItMy0xLTEtMTg4OTc0_26617782-0977-4b61-81b3-4095de81f852">2,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e4fdfd9b274a029d3f820b2f8ec447_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzMtMS0xLTEtMTg4OTc0_51a7686a-25b0-4a06-8bec-9c6e7099c632">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b95da36271405f854a5fa63ee0cc73_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzMtMy0xLTEtMTg4OTc0_a84b9c66-90f1-46e3-9ead-7edccf64604c">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754ee2be39904612a8009537c4174025_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzQtMS0xLTEtMTg4OTc0_fa3a90b7-76d2-4152-8d33-7a74d63c9497">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3acd696e90a462fa8d84de0529809d6_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzQtMy0xLTEtMTg4OTc0_87c256ff-8914-47c8-b06c-1dc00a52e437">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzUtMS0xLTEtMTg4OTc0_3211b5a6-b741-419c-aee6-a777cdd573b4">5,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzUtMy0xLTEtMTg4OTc0_4ff2b4fa-6a58-490b-9327-f9e93214f1e8">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5ODY_9f9e6a3a-f0bd-4ff3-a157-aeb886969658" continuedAt="iccb79c956c664629bb905f315e9d2d59" escape="true">Goodwill and other intangible assets</ix:nonNumeric></span></div><ix:continuation id="iccb79c956c664629bb905f315e9d2d59" continuedAt="i6fcdc0f8c0ce467eaba815afef4f917b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5Njc_52057781-fb92-4273-ab69-dc9d1d648b45" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzItMS0xLTEtMTg4OTc0_ee9c29e4-94ff-48d6-ab1c-5f8d2c2d7b34">14,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzItMy0xLTEtMTg4OTc0_64af3b90-004c-4e32-b272-1d3c7384fd93">14,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes to goodwill resulting from acquisitions and divestitures, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzMtMS0xLTEtMTg4OTc0_f6fc4ca3-0c15-4611-89e9-c2a7533da6e3">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzMtMy0xLTEtMTg4OTc0_e7b26a28-7755-4e44-afca-c399a4c31259">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzQtMS0xLTEtMTg4OTc0_c60cdbae-b0f3-40e6-9c67-fc2a601c7da6">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzQtMy0xLTEtMTg4OTc0_58bacae6-8350-41a5-80b1-8d3e9602d967">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzUtMS0xLTEtMTg4OTc0_7d48e975-f157-4c4f-a7d5-68ec411c6f6c">15,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzUtMy0xLTEtMTg4OTc0_374c68f1-8fd1-4a6b-9fe9-a267f8e4f7bb">14,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For 2022, the changes to goodwill consist of goodwill resulting from the acquisition of ChemoCentryx, changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other intangible assets</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:ScheduleOfIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5NzM_dfaf32c6-6084-4a83-9906-1012e192ce76" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07936c549f844514b26e4db0ad2a21fc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtMS0xLTEtMTg4OTc0_59ecf769-a738-4570-9b21-4259dfb5366d">29,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07936c549f844514b26e4db0ad2a21fc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtMy0xLTEtMTg4OTc0_134a1180-7063-434d-a8eb-f284645fb11a">15,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07936c549f844514b26e4db0ad2a21fc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtNS0xLTEtMTg4OTc0_1b6d7f4a-fb9a-4195-bdf9-4379b5b7dffc">13,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5aca0dc80d4c96b4e71d7909172c62_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtNy0xLTEtMTg4OTc0_ce479969-f787-4375-a12c-b631754e3cdb">25,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e5aca0dc80d4c96b4e71d7909172c62_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtOS0xLTEtMTg4OTc0_7357db1e-e53b-46dc-9cb5-617af4240731">12,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5aca0dc80d4c96b4e71d7909172c62_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtMTEtMS0xLTE4ODk3NA_b183c9d7-5f69-481f-b147-85c9ceba94d7">12,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d3bede71c84c74a83e0be4081f5b18_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtMS0xLTEtMTg4OTc0_3f3ee585-5c5e-4179-93c8-45c268c9f579">3,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d3bede71c84c74a83e0be4081f5b18_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtMy0xLTEtMTg4OTc0_957cd6e8-e7b3-4533-ac6e-e38e6bd99a24">3,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d3bede71c84c74a83e0be4081f5b18_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtNS0xLTEtMTg4OTc0_908e371b-4b68-4c82-97b5-519e623b8fb8">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0adc328161459b89b9bc11ba4f1e97_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtNy0xLTEtMTg4OTc0_72d1c112-7754-4c39-a13d-98121933a907">3,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e0adc328161459b89b9bc11ba4f1e97_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtOS0xLTEtMTg4OTc0_956d04ab-9245-43db-b06a-0bcc0e9ac1b4">2,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0adc328161459b89b9bc11ba4f1e97_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtMTEtMS0xLTE4ODk3NA_1ba7aa82-fd2b-4eb7-ae4e-8e845cb56ad2">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417d0ad23573423c9d2dd34c69b3960f_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtMS0xLTEtMTg4OTc0_cd73d8b9-37f4-4264-8f0a-1c29b94ccf05">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i417d0ad23573423c9d2dd34c69b3960f_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtMy0xLTEtMTg4OTc0_f2f20405-68cb-42f4-8613-417bb7b96d4b">1,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417d0ad23573423c9d2dd34c69b3960f_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtNS0xLTEtMTg4OTc0_5a511235-815c-482d-83cf-48415f80d938">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b45a76886284dc78290674a5dee3ee5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtNy0xLTEtMTg4OTc0_7604da49-ac5d-40f0-bf69-040e82072d09">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b45a76886284dc78290674a5dee3ee5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtOS0xLTEtMTg4OTc0_6ca182c2-3284-42b9-bfda-aae67a1de769">1,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b45a76886284dc78290674a5dee3ee5_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtMTEtMS0xLTE4ODk3NA_27a3b082-3cfe-4c2d-b88d-6d4bc3fe57ab">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed7681dee014e09849b2353f1235d03_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctMS0xLTEtMTg4OTc0_702b6a0f-de88-4a6e-8b01-8d35d91b19ae">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ed7681dee014e09849b2353f1235d03_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctMy0xLTEtMTg4OTc0_382bbadb-0493-4de6-877b-62120b1b10a4">1,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed7681dee014e09849b2353f1235d03_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctNS0xLTEtMTg4OTc0_31f34cbd-eb59-4f6f-b1e6-137e88b98968">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided57f427b2f48c68511bb6a663847ef_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctNy0xLTEtMTg4OTc0_009144aa-2cde-41af-b0af-18dd4b0c959d">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided57f427b2f48c68511bb6a663847ef_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctOS0xLTEtMTg4OTc0_7a316d65-2686-4d21-9f47-141f66e397f4">1,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided57f427b2f48c68511bb6a663847ef_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctMTEtMS0xLTE4ODk3NA_1900574a-2678-4d4d-a8d5-c062401f4628">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtMS0xLTEtMTg4OTc0_684b4eb9-5217-432f-8b88-07c5222da88a">35,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtMy0xLTEtMTg4OTc0_7decce0e-5669-4288-8e65-144fad97617e">20,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtNS0xLTEtMTg4OTc0_285497b4-6332-4fb9-b4c9-fe0e788fcb11">15,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtNy0xLTEtMTg4OTc0_beafc147-1fb8-401e-a86f-c5b3447a0e66">32,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtOS0xLTEtMTg4OTc0_7735f19d-7343-4e45-b0c8-810c7e167584">17,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtMTEtMS0xLTE4ODk3NA_fe3f5875-4684-475d-8f3d-3ee4433c08e3">14,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509e8b79cd3447cdbd36db889a772260_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzEwLTEtMS0xLTE4ODk3NA_13947819-b2e5-4e18-8963-52e6e3d5a38a">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509e8b79cd3447cdbd36db889a772260_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzEwLTUtMS0xLTE4ODk3NA_3e7760a5-6553-4f1d-a0b6-d35d21144c03">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88e57fb4e5e4aea802f1aeacd840bee_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzEwLTctMS0xLTE4ODk3NA_ff91e167-1029-4cb8-9914-77b025f2a3ca">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88e57fb4e5e4aea802f1aeacd840bee_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzEwLTExLTEtMS0xODg5NzQ_4b0af15b-adda-45a7-a7ff-d010dd7eedba">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTEtMS0xLTE4ODk3NA_28cf6396-0348-448f-b774-6f81dc0926cc">36,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTMtMS0xLTE4ODk3NA_d475fa5c-148e-4698-84f2-bcc32df41eb2">20,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTUtMS0xLTE4ODk3NA_128fbde2-88c5-4b36-a758-27a917fdea14">16,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTctMS0xLTE4ODk3NA_a91f6ba2-898e-4f3a-8413-800ade1e09ec">33,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTktMS0xLTE4ODk3NA_da33081c-149c-41a9-95c4-75c46c09aabc">17,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTExLTEtMS0xODg5NzQ_a8ee4d21-faf7-4634-ba24-b8564cac0c78">15,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses. Developed-product-technology rights include assets acquired with the ChemoCentryx acquisition. IPR&amp;D, R&amp;D technology rights and licensing rights includes assets acquired with the Teneobio acquisition. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&amp;D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;D projects may vary from their estimated fair values. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6fcdc0f8c0ce467eaba815afef4f917b">During the years ended December 31, 2022, 2021 and 2020, we recognized amortization associated with our finite-lived intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI2NTI_ed6db2a0-32ad-49f0-b00f-afafb8495c7c">2.6</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI2NTY_5a471cc2-6172-4414-87f8-56d2d69e31a0">2.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI2NjM_3dbe6ff8-6ee9-49cf-a773-13292249b516">2.8</ix:nonFraction> billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5Mjk_5e0c1586-ecbf-4f27-8380-d188ceb0fa8e">2.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5MzM_a372a51c-d41e-4ad3-9726-9099b6e3bfb4">2.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5Mzc_8587acb3-d008-4c84-858c-cb4e9a675cfd">2.5</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5NDE_0ff9421e-49e8-4353-99a7-2121fd6c91eb">2.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5NDg_3ab5c5f4-e15b-4165-9bb2-88f9de0e67b7">2.1</ix:nonFraction> billion, respectively.</ix:continuation></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_229"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzE4MjE_470f8176-12da-4a4c-8292-983b85020121" continuedAt="i389384c170cf4aceb562e7a39bd01efe" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i389384c170cf4aceb562e7a39bd01efe" continuedAt="i4bfc13f3d79b4cd48e8bf4c977317d2b"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain facilities and equipment related primarily to R&amp;D, administrative and commercial activities. Leases with terms of 12 months or less are expensed as incurred and are not recorded in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most leases include one or more options to renew, with renewal terms that may extend the lease term up to <ix:nonNumeric contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzM4NQ_1e7688ad-b9f9-4e19-8087-1deb14b32c5e">seven years</ix:nonNumeric>. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&amp;D and administrative space.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzE4MjM_face2242-80af-493a-b82d-8bfa9137388a" continuedAt="iff7a4981a95f44d0b5dde9e55978e58c" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_359201fb-5c99-405a-ab38-b09b1a0810df"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_e337db26-bca6-43a8-9a70-6927970d6b3a">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMi0xLTEtMTg4OTc0_5688de39-a8c1-4fbf-8465-f23e50dc12a0">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtNC0xLTEtMTg4OTc0_78a07c84-9e97-440d-b88c-3d2d78c45153">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_8eb856b2-2130-4703-a4b4-acc8ce46190d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_cfef6f7b-b5d4-400a-8a9d-e47d21f5486b">Accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMi0xLTEtMTg4OTc0_5169741c-d1c9-4465-bffe-cbc6de172863">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtNC0xLTEtMTg4OTc0_1d08aa3b-7ae8-4141-bf23-b6eb619f7a23">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_8acdce6f-01bc-4f81-be80-17993b14c4ca"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_f528949b-9261-49f0-9348-a8f3a32624b2">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMi0xLTEtMTg4OTc0_c13257c6-4e6b-4735-9a91-bed927278a54">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtNC0xLTEtMTg4OTc0_b62c2106-d5b6-4f45-88d5-959d5463ce5b">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzctMi0xLTEtMTg4OTc0_d6b9479c-11f7-49b2-b264-eaec0a6754b4">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzctNC0xLTEtMTg4OTc0_f18b4d80-0945-49d2-9834-8d1dee78ca77">670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net lease costs were as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzItMi0xLTEtMTg4OTc0_dd3c7e65-4a4d-4813-af0f-6a0943589dc1">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzItNC0xLTEtMTg4OTc0_16f27dd6-2a1a-4843-ae2d-716991742b85">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzItNi0xLTEtMTg4OTc0_43f10eb1-c880-41fb-8cde-454b142dd280">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzktMi0xLTEtMTg4OTc0_d0d2a840-974e-4a21-87c2-400415a99be6">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzktNC0xLTEtMTg4OTc0_b0b4ac00-16c5-4056-8aad-223c2b58f2ed">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzktNi0xLTEtMTg4OTc0_71b824a5-6d93-44d5-842f-2d21e7fa346f">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzEwLTItMS0xLTE4ODk3NA_165a2da0-1168-4138-89da-8db8f05a34ba">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzEwLTQtMS0xLTE4ODk3NA_39b7c082-b807-41c3-bc11-90adf7252b44">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzEwLTYtMS0xLTE4ODk3NA_37f65b16-c96c-4dec-ac6d-647c76cae491">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2022, 2021 and 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzE4MjQ_32c5dd8c-2c3c-4a17-a3d4-83e8453734df" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2022, were as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzEtMi0xLTEtMTg4OTc0_14b504e4-be65-4a94-a411-0baf339d9444">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzItMi0xLTEtMTg4OTc0_2c6d9d81-fe72-41cf-b62a-0c8e814aa131">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzMtMi0xLTEtMTg4OTc0_e652224a-86b5-466f-84de-f1f4d8ec5f66">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzQtMi0xLTEtMTg4OTc0_2ad77bd1-308a-4267-a462-07b17510818d">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzUtMi0xLTEtMTg4OTc0_7206a561-d874-47f0-85d1-270c3818f0df">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzYtMi0xLTEtMTg4OTc0_5499071f-8274-4443-a2d8-f32d2e0e101a">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzctMi0xLTEtMTg4OTc0_cc91e9db-fb9e-4353-9752-2a08d9c70a12">781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzgtMi0xLTEtMTg4OTc0_0d1c4b72-ce59-4c5a-888e-0d331cfd6892">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzktMi0xLTEtMTg4OTc0_421924ac-1b83-45f3-afab-28ec0e393eeb">695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes future rental commitments for abandoned leases of $<ix:nonFraction unitRef="usd" contextRef="ia3d84b8dde9b4ef58d9a8a439a7b1fed_I20221231" decimals="-6" name="amgn:LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzEzMzI_98b2d9aa-4426-4cc1-a591-e8811fbe0256">90</ix:nonFraction>&#160;million. We expect to receive total future rental income of $<ix:nonFraction unitRef="usd" contextRef="ia3d84b8dde9b4ef58d9a8a439a7b1fed_I20221231" decimals="-6" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzEzODc_f14b90a9-145a-4829-8007-3be3b5404d58">76</ix:nonFraction>&#160;million related to noncancelable subleases for abandoned facilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4bfc13f3d79b4cd48e8bf4c977317d2b"><ix:continuation id="iff7a4981a95f44d0b5dde9e55978e58c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and weighted-average discount rates were as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo2ZjM1NTc2NWRkODI0ZWYyYjQ2OGIyMDRlMjY4ZTUzNi90YWJsZXJhbmdlOjZmMzU1NzY1ZGQ4MjRlZjJiNDY4YjIwNGUyNjhlNTM2XzItNC0xLTEtMTg4OTc0_10c64acd-102d-4681-8813-409244e6ae28">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo2ZjM1NTc2NWRkODI0ZWYyYjQ2OGIyMDRlMjY4ZTUzNi90YWJsZXJhbmdlOjZmMzU1NzY1ZGQ4MjRlZjJiNDY4YjIwNGUyNjhlNTM2XzItNi0xLTEtMTg4OTc0_39ade86f-9724-4985-b804-0c530b24d97b">8.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo2ZjM1NTc2NWRkODI0ZWYyYjQ2OGIyMDRlMjY4ZTUzNi90YWJsZXJhbmdlOjZmMzU1NzY1ZGQ4MjRlZjJiNDY4YjIwNGUyNjhlNTM2XzMtNC0xLTEtMTg4OTc0_f480687d-2e3b-4deb-bae7-1cb3801382b8">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo2ZjM1NTc2NWRkODI0ZWYyYjQ2OGIyMDRlMjY4ZTUzNi90YWJsZXJhbmdlOjZmMzU1NzY1ZGQ4MjRlZjJiNDY4YjIwNGUyNjhlNTM2XzMtNi0xLTEtMTg4OTc0_6802306a-fbd6-4544-ba24-63076f63edd7">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and noncash information related to our leases was as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzMtNC0xLTEtMTg4OTc0_63120ca3-48ae-454d-8b39-72759e0e21c7">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzMtNi0xLTEtMTg4OTc0_5d3be5c3-43d2-45d5-8946-0520114e396f">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzMtOC0xLTEtMTg4OTc0_d7e83567-ec86-449a-8c76-5247054cd8b2">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzctNC0xLTEtMTg4OTc0_69be2a9d-8d69-4dc1-8425-7ada80fa5bc5">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzctNi0xLTEtMTg4OTc0_188ef07b-380d-4807-937c-6fac69fda926">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzctOC0xLTEtMTg4OTc0_8e6883d6-770b-4a7d-8589-5ac453170c8f">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total undiscounted future lease payments for leases that have not yet commenced were not material.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_232"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:AccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90ZXh0cmVnaW9uOjY2MjhjYTAzNTg4ZjQ0YWJhOWM4N2IwYTA1YTA3NDc4XzE1NQ_d8463470-989d-4c36-ad97-8974285e9542" continuedAt="i615eaa5191cf4434a34c44c0e59bb7e5" escape="true">Other current assets and accrued liabilities</ix:nonNumeric></span></div><ix:continuation id="i615eaa5191cf4434a34c44c0e59bb7e5"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90ZXh0cmVnaW9uOjY2MjhjYTAzNTg4ZjQ0YWJhOWM4N2IwYTA1YTA3NDc4XzE1MQ_c2fd68b8-6553-411a-bf3e-52aa691c1c11" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzItMS0xLTEtMTg4OTc0_58e5a2ff-82e5-4cb1-a672-7fa263e9178d">1,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzItMy0xLTEtMTg4OTc0_87772ff3-3fcc-48d1-95a8-9663c7ef0a7f">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate partner receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherReceivablesGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzMtMS0xLTEtMTg4OTc0_8926f157-7579-47d4-8143-47e948e4ce73">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherReceivablesGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzMtMy0xLTEtMTg4OTc0_f42d6bd6-5331-476f-9ef9-3a6b39217fd2">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzQtMS0xLTEtMTg4OTc0_6e775805-33e1-45d7-bb43-05c3bc8f7a7d">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzQtMy0xLTEtMTg4OTc0_581455d7-24ed-438f-892b-be9639308e4a">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzUtMS0xLTEtMTg4OTc0_7eabcc92-ac20-4163-9dd6-f394fc368b84">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzUtMy0xLTEtMTg4OTc0_5a337e77-af5e-4d04-b5e0-0e1c7d940d7c">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzYtMS0xLTEtMTg4OTc0_7b3f151e-e4ed-4e48-86da-6d64f6d8c3ae">2,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzYtMy0xLTEtMTg4OTc0_9e7bd6f2-9fea-49b2-87a4-61c278db2c4c">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90ZXh0cmVnaW9uOjY2MjhjYTAzNTg4ZjQ0YWJhOWM4N2IwYTA1YTA3NDc4XzE0Ng_9946eced-7fe8-44cc-9a9d-565787cf7392" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:AccruedSalesDeductionsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzItMS0xLTEtMTg4OTc0_ff35ff25-d437-426a-b3ec-f0478d565bcb">5,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="amgn:AccruedSalesDeductionsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzItMy0xLTEtMTg4OTc0_13b1354b-d6ab-41b7-8b31-a5d0de5641c3">5,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzMtMS0xLTEtMjA3MTQz_f355e61c-c611-41d1-9db6-7c2cfcd73f56">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzMtMy0xLTEtMjA3MTQz_5ec74d33-9ee8-4fe7-9be7-df359c19a5a3">701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzMtMS0xLTEtMTg4OTc0_60f2f2de-1667-4b92-bb3b-849ea2a31e29">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzMtMy0xLTEtMTg4OTc0_78f838e6-73fb-43fd-98a6-f31d652585ed">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzQtMS0xLTEtMTg4OTc0_e6e8275c-1ad2-4d48-9f2a-4c65709638a5">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzQtMy0xLTEtMTg4OTc0_35a3171b-f018-4410-8fab-61f8125c43a5">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:AccruedSalesReturnReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzYtMS0xLTEtMTg4OTc0_95aa7612-96dc-4504-8da0-d81241ed572c">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="amgn:AccruedSalesReturnReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzYtMy0xLTEtMTg4OTc0_3792b68d-c5c6-46dd-aa6b-0e6f91750d93">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzctMS0xLTEtMTg4OTc0_0d17fb0f-ac47-4b00-88a2-17989724b213">2,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzctMy0xLTEtMTg4OTc0_5ebc0a07-e90f-4833-92a1-e34236b6fe6c">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzgtMS0xLTEtMTg4OTc0_2a8c8410-d37d-4be6-ba9d-3b4a1ca60e8d">12,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzgtMy0xLTEtMTg4OTc0_ce07affe-2237-4d61-a876-48fb09e79a93">10,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI0MTg5MjU1ODMyMjYw_62981de9-04b3-4f00-addd-72d06f07e147" continuedAt="i249a6b55d8524914bb7816b0df962518" escape="true">Financing arrangements</ix:nonNumeric></span></div><ix:continuation id="i249a6b55d8524914bb7816b0df962518" continuedAt="icc8c4e92b2964513bbc2eee10b21db81"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjE0_07cf0ce8-ee0d-4ce0-83db-d4bbe179d7a8" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib87a5903e27546d7be1b99e84a2bd998_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzYtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246MGEyN2MwZGE5ZWRjNGVkMjgwMTU2NzIwNmExYzBkZjlfNA_c9509440-f78a-4374-ad69-93b7a380d446">0.41</ix:nonFraction>% CHF<ix:nonFraction unitRef="chf" contextRef="ib87a5903e27546d7be1b99e84a2bd998_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzYtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246MGEyN2MwZGE5ZWRjNGVkMjgwMTU2NzIwNmExYzBkZjlfNw_787eb427-5526-4706-bcf8-d006bddc27be">700</ix:nonFraction> million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87a5903e27546d7be1b99e84a2bd998_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzYtMS0xLTEtMTg4OTc0_04c8434f-db67-4f9a-a788-d9794d10a9ec">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63458e59bdcd46bcbc8cde633cc0a217_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzYtMy0xLTEtMTg4OTc0_91c3dab6-77fb-43f4-9968-60f870240f16">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3cbb8923ef5d4b82912c6157f84c6bef_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzctMC0xLTEtMTg4OTc0L3RleHRyZWdpb246MDhjMGE2MGY2OGU1NGFlMGJkNGU4ODVkODA1ZDBiOGJfNA_b89d2641-1264-4d65-9bcd-8628dcc93af4">2.25</ix:nonFraction>% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cbb8923ef5d4b82912c6157f84c6bef_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzctMS0xLTEtMTg4OTc0_b3ddabe5-02b3-45fb-9a4e-e98bd022eb8c">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114486aa96344ee5b788b817b4b17d96_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzctMy0xLTEtMTg4OTc0_820eb1f7-3bf7-4eec-be83-0b5ff7005630">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a39813c072d4e5eb904fe1d28cd03c2_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzgtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246NzQ2NzlmYjhhYzc1NDlkOTk0N2YxMjYwOGE3NmUxNTBfNA_0bfebf87-8e9c-40f9-9c4a-0f440ce88e2f">3.625</ix:nonFraction>% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a39813c072d4e5eb904fe1d28cd03c2_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzgtMS0xLTEtMTg4OTc0_dc17ac99-d056-46b7-afba-1cf3ad9297fc">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1b495696b94d78b5dbd6696d16bd3d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzgtMy0xLTEtMTg4OTc0_efca9879-7caa-489b-875a-d1c6b9e844dc">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dae08b71e7d4ab88b6e9e253336b859_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzktMC0xLTEtMTg4OTc0L3RleHRyZWdpb246ZTAyYWU1ODYzY2FmNDVmMzkzNGQ3MGJiM2VhMTE0MzBfNA_df8c5a1e-d906-43c8-9701-b1445c40caab">1.90</ix:nonFraction>% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dae08b71e7d4ab88b6e9e253336b859_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzktMS0xLTEtMTg4OTc0_42b2fd71-671d-4ea1-996d-4e440d7acf61">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9444cb9457a24d94834f8ec64291471e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzktMy0xLTEtMTg4OTc0_83693f34-d0a9-443e-932a-e3f38b1c66b6">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i914ec06154d64420b43f2721a1ae01b6_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEwLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmFmOGQwMTQ0N2I4OTQ2MjA5YzVkNTVkZWI3ZTg5ZjYwXzQ_75d0029b-0425-410a-b178-8ecaf38e6aaa">3.125</ix:nonFraction>% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914ec06154d64420b43f2721a1ae01b6_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEwLTEtMS0xLTE4ODk3NA_d7de417b-87f1-4a26-8c9e-3aa69866eed9">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4d0b0eb1fb4567ad07ac7b398eda3c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEwLTMtMS0xLTE4ODk3NA_8a0229e4-8dfe-4a24-8364-5a1fc9507390">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6e2d495694d4d3cb2e097b25c5a10e6_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzExLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmY5NzNlMzY1NjE4NjQ3ZWZiOTI5YmM4YzQ0YzZmMDE5XzQ_6e2a8881-868a-498d-807f-86f851146d38">2.00</ix:nonFraction>% &#8364;<ix:nonFraction unitRef="eur" contextRef="ib6e2d495694d4d3cb2e097b25c5a10e6_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzExLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmY5NzNlMzY1NjE4NjQ3ZWZiOTI5YmM4YzQ0YzZmMDE5Xzc_cb8da1f0-c7b8-4b47-8d63-66ac837bc2da">750</ix:nonFraction> million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e2d495694d4d3cb2e097b25c5a10e6_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzExLTEtMS0xLTE4ODk3NA_e7c02910-e1ee-498d-89a7-4a514785ea8d">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6da97a847948f08a2ba11d9378169d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzExLTMtMS0xLTE4ODk3NA_ff78cf9b-c9c5-42a2-b62a-37aec01a6ae7">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99921d01b0e541bf8d50ea58272c554b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEyLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjFmNDZlYWMxODRkNTRiZTNiZTFkYjQ0YjQ4NzNmMmRiXzQ_11c5441c-a1b7-4b46-a1c1-c4f9b879c54e">2.60</ix:nonFraction>% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99921d01b0e541bf8d50ea58272c554b_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEyLTEtMS0xLTE4ODk3NA_09db72ee-bd1f-4522-9fd4-779cd90df572">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17b3e11f5be94ce49f2f3b9b0ecde667_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEyLTMtMS0xLTE4ODk3NA_c37e4095-06e1-4b6b-8d8e-937ffc6d155e">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d9211ecea36437580bc7b0a70919e0b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmRkMDgxZTczYTliMTQ2MzU5NGQyOWM3NWY2MWYzODM5XzQ_ab5efd91-18b5-46ff-95cb-3e1087821198">5.50</ix:nonFraction>% &#163;<ix:nonFraction unitRef="gbp" contextRef="i0d9211ecea36437580bc7b0a70919e0b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmRkMDgxZTczYTliMTQ2MzU5NGQyOWM3NWY2MWYzODM5Xzc_b4e18eb2-f784-4ba7-8f9a-671a3339e7a6">475</ix:nonFraction> million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d9211ecea36437580bc7b0a70919e0b_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTEtMS0xLTE4ODk3NA_d8737c30-5a12-4ddc-87e4-753d1bcbe12c">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f7dc76afa046759c07651d4147c51a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTMtMS0xLTE4ODk3NA_5dd06ee3-75bb-4bc2-9b34-4e66e3f741ca">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5597930bfb1b45bc98481de8f6393843_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjk3ZmNhY2Q5N2MzNDQ5Njk5MGJkMGVhNWM4YzY5OWVhXzQ_fd1113b1-a357-42fc-bbfc-5f98fbe86ded">2.20</ix:nonFraction>% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5597930bfb1b45bc98481de8f6393843_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTEtMS0xLTE4ODk3NA_525b8e6c-245c-411e-992f-986564e289cd">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab97f27b4cdb45eea26aa79814ee24f7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTMtMS0xLTE4ODk3NA_67ea9e22-2c9c-495c-988b-f72bf1571867">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i315cb82b31f04ff097bb4573859346f2_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE1LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmRlMWVhOGViNWI2ZTQ1MWI5OWU1YWViN2NhMDBjZjgyXzQ_5d2f4577-ada6-47a0-85ee-41baa56697a3">3.20</ix:nonFraction>% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i315cb82b31f04ff097bb4573859346f2_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE1LTEtMS0xLTE4ODk3NA_014b26a2-7b8d-4162-837b-f7c3c5eaa93d">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996fa0fbb28a4ae5a66025a540485a05_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE1LTMtMS0xLTE4ODk3NA_f6b4b582-caf4-43aa-90c2-6680ad49fd20">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3d6933a21774133aab412e2e354668c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE2LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjdjMjRjZDJhNGM4YjQ2ZWE4YjMzODM4N2M2NjE4ZTRmXzQ_6ad57c91-c256-49b3-a10a-f86148b40bd6">1.65</ix:nonFraction>% notes due in 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d6933a21774133aab412e2e354668c_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE2LTEtMS0xLTE4ODk3NA_07014b9d-7f43-42fd-b6f2-74bda53e65ac">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42913198da614e1b811abab5b612e355_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE2LTMtMS0xLTE4ODk3NA_f873a85a-2086-49e3-ba57-2a716dca46d0">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTAtMS0xLTE5MjY1MS90ZXh0cmVnaW9uOmRjYjZlZThlYTc4MDRiNThhZDY4OGUxOWFjMGQyMDczXzEwOTk1MTE2Mjc4MjU_09cd083f-94e7-4c3b-b247-2515f31c301f">3.00</ix:nonFraction>% notes due 2029 (3.00% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTEtMS0xLTE5MjY1OA_5d2a7c2d-c827-4672-bf8d-17012033e875">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTAtMS0xLTE5MjY1MS90ZXh0cmVnaW9uOjRmYjVjMmE4ZjczMDQwNDdhYzUyOWEzZTkxNjI2NGUxXzEwOTk1MTE2Mjc4MjQ_4386f84a-5ffd-4c9a-a9eb-9f6087e00483">4.05</ix:nonFraction>% notes due 2029 (4.05% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTEtMS0xLTE5MjY1OA_3567b878-d2cf-41a2-8ba2-cd9d791901c4">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i385a16395bf64c2bb403ca851a184d2a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE3LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmYyMDdmYzhmOTFiZDQ1YWRiYmFhMGY1NjRmNjcwNjExXzQ_d69b5cee-cb8c-4ee3-a4d7-451b08af8a90">4.00</ix:nonFraction>% &#163;<ix:nonFraction unitRef="gbp" contextRef="i385a16395bf64c2bb403ca851a184d2a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE3LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmYyMDdmYzhmOTFiZDQ1YWRiYmFhMGY1NjRmNjcwNjExXzc_46152476-ca81-43ce-807e-1631f136efb1">700</ix:nonFraction> million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385a16395bf64c2bb403ca851a184d2a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE3LTEtMS0xLTE4ODk3NA_b581bcbf-df47-45d9-98ba-76909534dfbd">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0953d601cec9484fbc9df96f00426496_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE3LTMtMS0xLTE4ODk3NA_8b58df8a-0c19-4055-804a-cc01729361b8">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf7b55ef9cb1473085781b63a83bbdac_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE4LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmQ5ODkzN2EyMmViNzQyNjhiNThkMTY3MWMwOGRjODFmXzQ_56af8282-f181-47cd-b85a-19197ef60ab6">2.45</ix:nonFraction>% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf7b55ef9cb1473085781b63a83bbdac_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE4LTEtMS0xLTE4ODk3NA_4e95eb3d-3edd-456f-91ed-49229d69b57b">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51217f4e8bed4990907c44f9d502ade2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE4LTMtMS0xLTE4ODk3NA_8db8095e-039c-4c16-ad40-b918731c2eaf">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11702be5618f4b6b84417ab7311bb910_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmI4OWMzZDljNmE3MjQ2ZDFhOTUyOTRjMGRlODI3ZTJmXzQ_6a2df341-8edf-4280-abb9-1232a301630e">2.30</ix:nonFraction>% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11702be5618f4b6b84417ab7311bb910_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTEtMS0xLTE4ODk3NA_8613ca19-f75d-4bb7-9989-ffa863190df0">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343cbda319a14a27951c64ddae810439_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTMtMS0xLTE4ODk3NA_08c2dd26-f75c-4e07-88e3-59393914364b">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4de45cdb4364327a92140dc1f1c7cfb_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmQ1MDIyNTE5MzkxNzRiODc5OWU2Y2U3Yjc1NmY1YjlkXzQ_79c3da43-f239-408c-a455-e955c92dd484">2.00</ix:nonFraction>% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4de45cdb4364327a92140dc1f1c7cfb_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTEtMS0xLTE4ODk3NA_2b99f6eb-9128-4769-96c7-f3c144e50ca1">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240a1929b4d74306bb09ea03fed64c41_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTMtMS0xLTE4ODk3NA_9f621340-c476-490f-8e75-d72a0438e966">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21348edb6cd5466a9ef24edd6a2d0938_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTAtMS0xLTE5MjY5OS90ZXh0cmVnaW9uOjY3YzQxYzZiNTE1MDRkODZhNjk2Yjg4YTcyOGMyNzg5XzEwOTk1MTE2Mjc4MjQ_e13da757-f311-4784-89dc-e89a6b4ad715">3.35</ix:nonFraction>% notes due 2032 (3.35% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21348edb6cd5466a9ef24edd6a2d0938_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTEtMS0xLTE5MjcxMQ_7780c46d-ee56-4f7a-8aa5-3e2f4cafa6ed">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51940b5cb1b241febc825ae180ec3de7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTAtMS0xLTE5MjY5OS90ZXh0cmVnaW9uOjVjMGQ0NWJlZWQxODQwNWE5ZjUwZDIwZjExODA4YTk0XzEwOTk1MTE2Mjc4MjQ_8f1edd98-8246-4739-b094-3c0e97842ea7">4.20</ix:nonFraction>% notes due 2033 (4.20% 2033 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51940b5cb1b241febc825ae180ec3de7_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTEtMS0xLTE5MjcxMQ_e5b44f95-4a67-43a3-a3f6-5677b6058d34">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc5f965633bd497bae6b284f87fd754a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmY2YjFmYTkwMDQ2OTRjZGE4YzM4NGNhNjFiYjUxZjgwXzQ_55f5e763-5b92-4b15-8447-9ab7ca4707c8">6.375</ix:nonFraction>% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5f965633bd497bae6b284f87fd754a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIxLTEtMS0xLTE4ODk3NA_36a2a324-c0c9-4e1c-8f42-f00fd324b92f">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197c2b86499f4c749103e68bdb36f3f4_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIxLTMtMS0xLTE4ODk3NA_76879f57-d811-4099-ba69-afe716134bb8">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4aff41f7e3e648c9be7ca6b79abca8e4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIyLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmE1NTA0MmM5YmM3YTQ4NmJhOTU0OTYzM2U3NzNkODRmXzQ_f89c090b-e959-4262-95ee-67f81a87b4b4">6.90</ix:nonFraction>% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aff41f7e3e648c9be7ca6b79abca8e4_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIyLTEtMS0xLTE4ODk3NA_730575a2-96be-4d76-8f7a-77bae70b6e60">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2e4ca4f8004d6c9bfebd3720cee531_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIyLTMtMS0xLTE4ODk3NA_02caed66-8af2-4c34-a32b-24729480c22c">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c17dea73c8477a803ae09e22dccbbc_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIzLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmI1NTAzMzJkNWE5ZDQ4YTQ5YzFhOTk0YzBiNWY1ZTJjXzQ_81b115e3-5bf9-45ef-b59e-80c6c6bc5e15">6.40</ix:nonFraction>% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c17dea73c8477a803ae09e22dccbbc_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIzLTEtMS0xLTE4ODk3NA_0fd9a2c4-57b5-40cf-9505-2f0d5c78a38b">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00b4eabc3a7467ea3ebd7138b1b2a74_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIzLTMtMS0xLTE4ODk3NA_3388e39d-76c9-4e2f-bc7f-5b56c77c0d3c">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23363383d2174b2d8ab38bf2003a6ce8_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI0LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjM5NjBlZjljNWRmZjQ4ZjhiYmEyMmU3ZTZjNmM0M2MyXzQ_7e1e9965-6a08-4b45-834a-e0c155a8e99b">3.15</ix:nonFraction>% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23363383d2174b2d8ab38bf2003a6ce8_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI0LTEtMS0xLTE4ODk3NA_ba8112f1-35e1-42fe-afac-409ba91368d1">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b887f6d478f455aa05ed3a9d50ab8b1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI0LTMtMS0xLTE4ODk3NA_9d6a1832-76e1-48a9-b9d4-93a49d141f46">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a2c9ab1d0d74042b5625c4d3863fc9a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI1LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmIyOGUwNDgyNTk2YjRkODc4OWViNDk1ZjZjOTAwNWExXzQ_a82bcb58-6f1c-480f-bf1a-5890a1f0cfb8">5.75</ix:nonFraction>% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2c9ab1d0d74042b5625c4d3863fc9a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI1LTEtMS0xLTE4ODk3NA_7f6297ea-f47f-417a-b4e4-5e345329b094">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c2234b75d747f78a8f666e6a4bd7a4_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI1LTMtMS0xLTE4ODk3NA_ad29b884-9495-4575-9e92-05556ae1f2f3">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b1952961fcf4393b06b95f66a0599ae_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI2LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjNzM4YmU1MDRlMzRiOWVhOTUzYmNmYjlmNDI0YThkXzQ_ab4b91d5-07cc-4921-91fe-b644d2ddfbe4">2.80</ix:nonFraction>% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b1952961fcf4393b06b95f66a0599ae_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI2LTEtMS0xLTE4ODk3NA_cc52d900-d99a-4e60-999a-b623d9a8165a">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d652ba10ed148fcb905cf1d5cc7e9a7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI2LTMtMS0xLTE4ODk3NA_0393c4ec-6391-44a3-b3fc-3259807968f5">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7ae3396aeb042e386de28c02ab1deee_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI3LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmYzYjEzZjQwY2VmZDQ2NDY5MDk2YjI3YjRhYTMxMTY2XzQ_cbfcce5c-72cb-46e2-9bc7-2a82b0493325">4.95</ix:nonFraction>% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ae3396aeb042e386de28c02ab1deee_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI3LTEtMS0xLTE4ODk3NA_57f63538-d648-4ceb-8db1-32f99138eec6">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0332f21f1314de4ae95621b6ac2c956_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI3LTMtMS0xLTE4ODk3NA_8a95907c-d2ed-4059-8cab-f85a5e73c7dd">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i799db871194f4747ab9f6118c675a2f7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI4LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjhiNzJlNjljMDY5ZTQxYzY4YjYzZDdjOWM4YWQwZTU5XzQ_54454e6e-60b4-49a0-bc18-cb462ab9beeb">5.15</ix:nonFraction>% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799db871194f4747ab9f6118c675a2f7_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI4LTEtMS0xLTE4ODk3NA_f0b756f3-1ebc-4cf0-a100-3b527c1c4b50">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da62baf08ef4c5b91a5152a82a01c53_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI4LTMtMS0xLTE4ODk3NA_913fd52a-570b-4096-9c9d-e1b3ba6e4a44">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ceee26f1075435e9fdfdd7a75a72ab5_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI5LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjBmYTcyYzllNTc5YTQyZDliZTMwN2M3M2Q4NTZhMzIwXzQ_a53f4216-98f6-4106-865f-d3ebfffc8484">5.65</ix:nonFraction>% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ceee26f1075435e9fdfdd7a75a72ab5_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI5LTEtMS0xLTE4ODk3NA_0fc83a80-8141-4bde-a744-f1e50b2265b2">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e818249c4f49d79e8872325e9ce099_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI5LTMtMS0xLTE4ODk3NA_43b942fa-b204-4f73-a954-b58ac8f8e265">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieadcf920bf8f4c5f9aa97d54a77a11ee_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMwLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmZkMTgxMzFhODM5MTRjMWVhMjk5NWM3N2FkNjdlYWJiXzQ_add70b61-d666-4aa8-a1cc-546fb4be116c">5.375</ix:nonFraction>% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieadcf920bf8f4c5f9aa97d54a77a11ee_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMwLTEtMS0xLTE4ODk3NA_1210d367-b1c3-4ace-844d-7deadca570b9">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie22ac487559948448b70189d26074a44_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMwLTMtMS0xLTE4ODk3NA_d29b12e6-3b4c-48f0-9e32-ec53d568f0a0">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c399705808348afac4fb0a614c63170_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjVkYjdhOGUzNzRmNzQwMmE4ZTFkYjYzMDBiMmEzNjVkXzQ_29cab85e-a8b8-4d75-984c-5de402283cc4">4.40</ix:nonFraction>% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c399705808348afac4fb0a614c63170_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMxLTEtMS0xLTE4ODk3NA_7bd192ac-06e9-4838-8303-b53c623f2440">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe3e6b61a09400e97634eebf130e74a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMxLTMtMS0xLTE4ODk3NA_099aebb4-ebb5-4459-adce-a6af5cc2f06d">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9e2fac888b644c6bcecbe5803617340_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMyLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjQyNjFlMTFiNmJjZDQ5MzJiODkwNzExMzc5ZGQyMGRhXzQ_c04faa3c-cb9a-4c4d-b448-299836526956">4.563</ix:nonFraction>% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e2fac888b644c6bcecbe5803617340_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMyLTEtMS0xLTE4ODk3NA_74744156-4917-4e3d-aeb7-96d635d51c5f">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i459df9e4545545c5acca6667f316af22_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMyLTMtMS0xLTE4ODk3NA_fd4aa8e2-d479-44e9-85be-244f6a553827">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61dde3927cd046c3ae459081902d8719_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMzLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjE0OTBlZjBmZTYzNjQwZDdhYTJjM2UwMDQ2MTM4MGFlXzQ_15370a01-1e70-4bc9-bef9-ab868dfe65e2">3.375</ix:nonFraction>% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61dde3927cd046c3ae459081902d8719_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMzLTEtMS0xLTE4ODk3NA_94dbc1df-5cf9-49d8-a5d8-4470736ddfe2">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a53c4efbbc3497fb791219ac49e571d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMzLTMtMS0xLTE4ODk3NA_7870364b-86f1-4e2c-aeb0-7359fedbd6b4">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a9673685984fa4a4d87c723a4b99b3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM0LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjM2ODJkYjNmYzc5NTRhYWVhYTA5MjBlYzZmMmQ3ODUyXzQ_2cf47544-88f9-4e44-a59c-b2766fccc9c7">4.663</ix:nonFraction>% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a9673685984fa4a4d87c723a4b99b3_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM0LTEtMS0xLTE4ODk3NA_d8e00068-1032-46dc-b225-7a82c5bd10f5">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fbb4c180e604823bf8fe6193c622eaa_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM0LTMtMS0xLTE4ODk3NA_d0966941-4c90-41e8-b563-494654da4af5">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4ea14090c5d46a68fa6c66a684d6252_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM1LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjIzOTQ4NDdiYzk2MzQwMWJiMzYzNWZhNGEyODNkMmI5XzQ_abd3c3fb-2465-4451-8be6-0ed79b7ceb49">3.00</ix:nonFraction>% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ea14090c5d46a68fa6c66a684d6252_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM1LTEtMS0xLTE4ODk3NA_b6c31b38-8b35-458c-9b1e-0fab339b520c">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec66496c6a840d998963fb080719768_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM1LTMtMS0xLTE4ODk3NA_983ff15a-1400-4f42-8548-a776df50ede2">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25202f83ea744eccb99587dd65d7f169_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTAtMS0xLTE5MjcyMi90ZXh0cmVnaW9uOjBjODdlMjgxYTQ3NjQ1ZDA5YWY1N2RmZDVjMWVkYjhlXzEwOTk1MTE2Mjc4MjM_2b7e12bd-f9ba-44f1-a78b-0c7b933e741f">4.20</ix:nonFraction>% notes due 2052 (4.20% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25202f83ea744eccb99587dd65d7f169_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTEtMS0xLTE5MjczOA_3fd11d7b-2996-447b-a54c-bfa43adc641e">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM3LTAtMS0xLTE5MjcyMi90ZXh0cmVnaW9uOmU2Mjc0MTVkZTNhNzQwMjZiY2Y1ZjI4NDU3MWI5NTRhXzEwOTk1MTE2Mjc4Mjc_5a2c3a78-3c94-4dc0-9c55-f116591c4ffd">4.875</ix:nonFraction>% notes due 2053 (4.875% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM3LTEtMS0xLTE5MjczOA_c24d09fe-b320-4d95-a648-2b4f7491ab10">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjlhNDM3ZjZkZjIzNzQyYThhNmNhZTRjMGY0OGRmYTA1XzQ_ff5f999d-97d6-4a15-9cff-dd6a610f85f0">2.77</ix:nonFraction>% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTEtMS0xLTE4ODk3NA_6c5d333b-bee6-49d5-b81e-db7a2e76a1a7">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1ab566422f43e9ae7b52770249ed7b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTMtMS0xLTE4ODk3NA_1a085fa0-7e22-41f4-a506-8a93bdf9e48f">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2a31746bf0d474c8f6cacbba8fbb650_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTAtMS0xLTE5Mjc0Ni90ZXh0cmVnaW9uOjMyMzJmYTVmZWNjNzQzMGJiYWU3YzVlYTE0MjJiZDNkXzEwOTk1MTE2Mjc4MjQ_c941998e-526f-4514-9f98-af9e31f9ea24">4.40</ix:nonFraction>% notes due 2062 (4.40% 2062 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a31746bf0d474c8f6cacbba8fbb650_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTEtMS0xLTE5Mjc2MQ_d6b37a02-20d4-4155-ad09-ca9fc8a33eb5">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f3097471304363bf528a0d267e397a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTMtMS0xLTE5Mjc2NQ_5305bd3a-36ec-41bb-901a-1086145c02ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefc3b8cff79b4b5a9d37b0a3cfa13a59_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM3LTEtMS0xLTE4ODk3NA_00cb72f6-02ce-4bd8-822a-f7c9037bada5">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dcd01e084f04f7da2597aedeba26b9f_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM3LTMtMS0xLTE4ODk3NA_37f4ef63-875b-42a9-b568-0034c146291c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM4LTEtMS0xLTE4ODk3NA_181cc8f2-af44-46e4-aeca-f2e04b0bd4a2">1,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM4LTMtMS0xLTE4ODk3NA_83f2c743-edf2-4f28-870d-56f79a03a506">1,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTEtMS0xLTE4ODk3NA_93952004-aae2-41d7-9266-a69aba3a14fd">437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTMtMS0xLTE4ODk3NA_674988cf-91a9-4ba3-938d-04b6ca79ec33">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQwLTEtMS0xLTE4ODk3NA_ea126d76-50c2-46e9-bd11-05c1109065d3">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQwLTMtMS0xLTE4ODk3NA_dc158c9d-5321-436b-b8e2-7081636850f4">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQxLTEtMS0xLTE4ODk3NA_045fdd2f-ad38-4111-adbc-9185448d4af7">38,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQxLTMtMS0xLTE4ODk3NA_7d86e02a-1a9a-437f-9040-d33e95d91c51">33,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQyLTEtMS0xLTE4ODk3NA_e15c6c91-c04c-42d0-bc79-18f0075988e6">1,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQyLTMtMS0xLTE4ODk3NA_936557db-a8c3-4d16-baee-8382f4c5c053">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQzLTEtMS0xLTE4ODk3NA_52525914-e888-40d8-a52e-444f272f0058">37,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQzLTMtMS0xLTE4ODk3NA_2e062a80-a453-4776-90ce-5f73bc608592">33,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the <ix:nonFraction unitRef="number" contextRef="ia9e2fac888b644c6bcecbe5803617340_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIwNA_f91bfa03-1ca2-481c-9a7a-1dc4c0eadc5d">4.563</ix:nonFraction>% 2048 Notes, the <ix:nonFraction unitRef="number" contextRef="i91a9673685984fa4a4d87c723a4b99b3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIyMw_e39b5371-f116-4307-a7f7-4f449e3d28e3">4.663</ix:nonFraction>% 2051 Notes and the <ix:nonFraction unitRef="number" contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI0NQ_dea0965d-2d48-46ab-9736-46c1384aa9ac">2.77</ix:nonFraction>% 2053 Notes, which have effective interest rates of <ix:nonFraction unitRef="number" contextRef="ia9e2fac888b644c6bcecbe5803617340_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI5OQ_43904324-9443-43b4-a22f-b826b86a7ee5">6.3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i91a9673685984fa4a4d87c723a4b99b3_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzMwMw_cc8405b7-255f-45e3-9b25-c81d9cec10f1">5.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzMxMA_496912d8-cd5d-4bd3-a210-9dbc9dd789bf">5.2</ix:nonFraction>%, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icc8c4e92b2964513bbc2eee10b21db81" continuedAt="i2cfaa61f2e284f7198d3615b8eb4785b"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to <ix:nonFraction unitRef="number" contextRef="i4ae65b7af0f742268bed15aafd3a152c_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_107ac993-9efe-4a54-93a4-72df5ab8791c"><ix:nonFraction unitRef="number" contextRef="i015b4b460a304d11a76423022adf7fb4_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_16b1b076-b68b-4e86-8c43-b2bcbec9eb9d"><ix:nonFraction unitRef="number" contextRef="i850e2cf58a7341ba9d67a7b5bb83feaa_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_17cbdaf2-025c-4e78-99b2-78cb3276973c"><ix:nonFraction unitRef="number" contextRef="i14ca5e3f8d5e4e19a9336ace84b8e4de_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_19dcabf5-e9ab-4fed-b120-d952102009eb"><ix:nonFraction unitRef="number" contextRef="ibdf49fbaa3564bfeb07fa6eab5ff9453_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_2d0aa29f-7f94-4af4-aae5-e51d7bc8e59c"><ix:nonFraction unitRef="number" contextRef="ic1f60bbed45a476b84f32d5cd638fa27_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_31466459-e6f0-424b-8352-0802d1f06834"><ix:nonFraction unitRef="number" contextRef="id071e59acfce43278b6718d99d9ada1d_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_328eac04-d717-4758-936a-29c68b1c2069"><ix:nonFraction unitRef="number" contextRef="if02f6daf07f04020881c0917e7205beb_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_370d5281-b95a-4ffb-8e0a-f0552446e74c"><ix:nonFraction unitRef="number" contextRef="idc8d9408f58940f5aea794a5984b2b6d_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_38071452-67c4-48c3-8088-6512a54c5d3a"><ix:nonFraction unitRef="number" contextRef="i53bd2b17ef4e40b9ab31b350fb9bcca0_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_48310329-ef1d-470c-8f76-568b6af7d36e"><ix:nonFraction unitRef="number" contextRef="ibeb1ef0f568a470293b1b4b19ff1eb25_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_4d88b635-b15e-4c27-992b-d7bd2b617fd6"><ix:nonFraction unitRef="number" contextRef="iafbc703b5ac5464b934f026814c76b10_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_570ad544-608a-43cf-b5ab-8301db2de166"><ix:nonFraction unitRef="number" contextRef="i63aa0c69ac4d42fea8344496f99d3fb8_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_593ec024-c0a6-49d0-bdfc-bcbc3c02dd37"><ix:nonFraction unitRef="number" contextRef="i2c0f3163a47a477abfa471e4f31bc4ab_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_6003789b-320b-4325-bc12-94bf1232460f"><ix:nonFraction unitRef="number" contextRef="i994c0f07cba345b594aa2dcc8f01ae2a_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_61aec0a6-09da-4f6b-9d11-c548a9d0a9cd"><ix:nonFraction unitRef="number" contextRef="iae7d08a8c95844f89b4bc95827153edc_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_750cf224-4123-4bdc-9067-7b13eb04f034"><ix:nonFraction unitRef="number" contextRef="i3ebe21c56f7b49eab0d1f2b569ab2d69_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_7554e0de-c319-4a5f-97c5-62312809d75b"><ix:nonFraction unitRef="number" contextRef="i7dedfbd2aadc42a4b92b844cb973cf5c_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_755cb47b-5476-4e28-b3eb-fdd16e1ee476"><ix:nonFraction unitRef="number" contextRef="i6d2edc811fbf442281992e3f83c386d8_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_7e60a1b6-f43b-4065-ba65-3bbf66c5b39e"><ix:nonFraction unitRef="number" contextRef="i97e03c380118450bb96b17ea6c0975ff_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_8abbcdf6-550f-43f6-9250-44031b043a13"><ix:nonFraction unitRef="number" contextRef="id5abe004e1f64a0cb9c9056890639151_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_8fd77f7d-081d-4d20-96e6-73b9099a6b1a"><ix:nonFraction unitRef="number" contextRef="i4cbd26680ac94508aca54119b9a2b4f1_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_901223c0-12f2-4a3a-a5e7-13c3009b719a"><ix:nonFraction unitRef="number" contextRef="iabe3f9f94b8740cb8f007f2610521598_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_95f0259d-01a5-42e2-93ff-76460d251dc8"><ix:nonFraction unitRef="number" contextRef="ibfa82e45553c4fe38c964335a7502e78_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_9edaaadb-d76f-4a48-9263-36cd8d286428"><ix:nonFraction unitRef="number" contextRef="i7fd31a2352f045398f3a8eb8645c3d22_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_b40c8d0f-79ae-4bec-a97a-f3f159f96517"><ix:nonFraction unitRef="number" contextRef="ife0fd2905ff54a6ea2da3ac299266202_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_bcd67532-c754-4e6f-a452-6c5e8d5ad58c"><ix:nonFraction unitRef="number" contextRef="i66b14e567be349d2b9d238dd8fa3d12d_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_bd6cd962-cf32-4533-954e-65d86fc940d4"><ix:nonFraction unitRef="number" contextRef="i093e46e46f254549afa8c5b85e22d6ec_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_c3e2e67b-27af-4bef-b5a3-66996ce368e3"><ix:nonFraction unitRef="number" contextRef="iadf162d5956f4e0c8eeaf73fec25a6ee_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_c9046d03-fe68-4e1f-8f5c-f5e9d8c1ab3f"><ix:nonFraction unitRef="number" contextRef="i64bd322d7bdc4336bdcaa7f9c771196d_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_cec1ea42-ee38-4fab-8b42-f52629a2e268"><ix:nonFraction unitRef="number" contextRef="i4bf447a9235a4172905a462133a6ffff_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_d179a3e5-ec8b-404c-9b6c-3bb77947b422"><ix:nonFraction unitRef="number" contextRef="ic90390b22ae74a819b9f25f7e52c8cd4_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_d6c51a99-906a-4bba-a943-73571ebca168"><ix:nonFraction unitRef="number" contextRef="i3b6372321cb54979aa35bc0ab3e56ae0_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_dd2526b9-ef56-4dcc-9d1c-2b0526f58dfe"><ix:nonFraction unitRef="number" contextRef="ic385067cc0a541f7acc94e65e1d25159_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_dfa96cf4-a561-4f9b-8699-1093802cc417"><ix:nonFraction unitRef="number" contextRef="i35ba09ad3416417584b285ae9e364e4d_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_e400488e-4399-411f-b640-15912f4cc84a"><ix:nonFraction unitRef="number" contextRef="i304fcc0c170d49fab4f536fb9d368d1e_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_e95acccb-209c-4e73-a334-c9cef640dc7f"><ix:nonFraction unitRef="number" contextRef="i198527cafdc44eeca16fc7290ab43d35_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_f1334941-4570-4ff4-a548-8e1cba9ede60"><ix:nonFraction unitRef="number" contextRef="ide32c761d0db4322ac4858a8059cfa8b_D20220101-20221231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_fd19d26b-91af-4107-b7a6-b66bcd6e0466">101</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes&#8212;except our <ix:nonFraction unitRef="number" contextRef="ie30a691e9b49416cb63804f9bee95ad0_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY4Mw_6850545f-2524-4f0b-999d-1cce525c62b8">0.41</ix:nonFraction>% 2023 Swiss franc Bonds and Other notes due 2097&#8212;may be redeemed at any time at our option&#8212;in whole or in part&#8212;at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from <ix:nonNumeric contextRef="ie930e646dcf5443abd63824803a610e3_D20220101-20221231" name="amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzExNTU_c10e54bd-db4f-48ff-bc00-5f08b72e38c2">one month</ix:nonNumeric> to <ix:nonNumeric contextRef="ie48acc0ed4094a3d91842dd5e715d92e_D20220101-20221231" name="amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzExNjE_4958ed6f-ed27-47cc-99b4-b8536eef884b">six months</ix:nonNumeric> prior to maturity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt issuances</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, we issued debt securities in the following offerings:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2022, we issued $<ix:nonFraction unitRef="usd" contextRef="id185478a58284d89b9439c8843eb6f89_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM0MzM_5e70b591-c08e-460d-b487-0e2c9113994f">7.0</ix:nonFraction>&#160;billion of debt consisting of $<ix:nonFraction unitRef="usd" contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzNzA_48707799-3369-4d7f-b7b2-857b389fecc4">750</ix:nonFraction> million of the <ix:nonFraction unitRef="number" contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzNzY_7f2bbf32-1170-45fa-ae23-e57d37bfb2be">3.00</ix:nonFraction>% 2029 Notes, $<ix:nonFraction unitRef="usd" contextRef="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NTA5_d5f1cbc9-f605-4039-abcd-63b8fbb2dd73">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NTMx_5c0a9f58-de94-4c60-95e5-4f0a5344cba3">4.05</ix:nonFraction>% 2029 Notes, $<ix:nonFraction unitRef="usd" contextRef="i21348edb6cd5466a9ef24edd6a2d0938_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM0NzQ_22197061-7f4a-46e1-a405-925e5c10a25f">1.0</ix:nonFraction> billion of the <ix:nonFraction unitRef="number" contextRef="i21348edb6cd5466a9ef24edd6a2d0938_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzODM_dfed069b-d8ee-49f7-9653-590bb05bc874">3.35</ix:nonFraction>% 2032 Notes, $<ix:nonFraction unitRef="usd" contextRef="i51940b5cb1b241febc825ae180ec3de7_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NTUy_87429013-0820-4ba9-bf49-111ca255c5ed">750</ix:nonFraction>&#160;million of the <ix:nonFraction unitRef="number" contextRef="i51940b5cb1b241febc825ae180ec3de7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NTcz_5ee59f83-cdcc-423f-8991-7fefdad8e835">4.20</ix:nonFraction>% 2033 Notes, $<ix:nonFraction unitRef="usd" contextRef="i25202f83ea744eccb99587dd65d7f169_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM0OTE_82d415f8-f4c6-4aa9-a60e-68d97264b141">1.0</ix:nonFraction> billion of the <ix:nonFraction unitRef="number" contextRef="i25202f83ea744eccb99587dd65d7f169_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzOTA_8345da7f-0ea4-4d0d-9be8-3b555f5393e5">4.20</ix:nonFraction>% 2052 Notes, $<ix:nonFraction unitRef="usd" contextRef="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NjIw_53a14575-27e1-4692-8882-569dbb063239">1.0</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NjQx_13182dc4-41fe-43af-9e60-17383ebd3ba5">4.875</ix:nonFraction>% 2053 Notes and $<ix:nonFraction unitRef="usd" contextRef="if2a31746bf0d474c8f6cacbba8fbb650_I20221231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM1MDg_1281b2af-6129-4ca4-89d1-fa82fff369d8">1.25</ix:nonFraction> billion of the <ix:nonFraction unitRef="number" contextRef="if2a31746bf0d474c8f6cacbba8fbb650_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzOTc_9f3ac81c-8679-415e-ad4d-a79325f4b896">4.40</ix:nonFraction>% 2062 Notes. The <ix:nonFraction unitRef="number" contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM0MjY_6a10f80e-9870-4f4b-b0e2-09827119bce1">3.00</ix:nonFraction>% 2029 Notes were issued to finance eligible projects that meet specified criteria to reduce our impact on the environment.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2021, we issued $<ix:nonFraction unitRef="usd" contextRef="icc43e58b90c442fa9e2c3b2c14137433_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzMjI_44ff124b-467d-47ea-b8bf-7d901b80a22a">5.0</ix:nonFraction>&#160;billion of debt consisting of $<ix:nonFraction unitRef="usd" contextRef="i42913198da614e1b811abab5b612e355_I20211231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzNDc_be9f7b7e-9508-4e3f-8d80-1188ef9d4cf5">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i42913198da614e1b811abab5b612e355_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzNTc_df998893-b672-45ab-94c1-6a7f8221bdcb">1.65</ix:nonFraction>% 2028 Notes, $<ix:nonFraction unitRef="usd" contextRef="i9924ee115de34d74a2b634b1cb90e492_I20211231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzNzI_230fcff1-d5a9-439c-8577-45d53b4c691a">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i9924ee115de34d74a2b634b1cb90e492_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzODI_262f9215-3949-4ada-992d-b74636499b7c">2.00</ix:nonFraction>% 2032 Notes, $<ix:nonFraction unitRef="usd" contextRef="if564b13b89634481901bd164eb63c59f_I20211231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzOTc_a1bb8015-6908-4c64-93e5-bc8660b5c65d">1.15</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="if564b13b89634481901bd164eb63c59f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MDc_46c0aaf5-4bc0-4a51-93e7-d284d55885a6">2.80</ix:nonFraction>% 2041 Notes and $<ix:nonFraction unitRef="usd" contextRef="iaec66496c6a840d998963fb080719768_I20211231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjU_b21ca0f8-a7a7-4f49-8e11-71f2d2946931">1.35</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="iaec66496c6a840d998963fb080719768_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MzU_63e50590-5372-441b-95e5-b84fd6a2c78b">3.00</ix:nonFraction>% 2052 Notes. </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i1e59b900a4ba40609f70a3f1ebf4fb65_I20201231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0NzA_fde6fb7b-0a43-4674-ac03-614533bdfd29">9.0</ix:nonFraction>&#160;billion of debt consisting of $<ix:nonFraction unitRef="usd" contextRef="i1ecab054ef954f2bbe765d19ba69cf36_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0OTU_4346169b-1fa2-4c07-90bf-ee1765c6608e">500</ix:nonFraction>&#160;million of the <ix:nonFraction unitRef="number" contextRef="i1ecab054ef954f2bbe765d19ba69cf36_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1MDU_696af016-1343-4e9c-897f-e2548a09c96e">1.90</ix:nonFraction>% 2025 Notes, $<ix:nonFraction unitRef="usd" contextRef="i1ec7e0e38fad401c881d41f4c40df8d8_I20201231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1MjA_bfe40c11-f253-429d-9c12-c6bab415586b">1.75</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i1ec7e0e38fad401c881d41f4c40df8d8_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1MzA_097bcdf3-b521-4369-959c-abff3068ffeb">2.20</ix:nonFraction>% 2027 Notes, $<ix:nonFraction unitRef="usd" contextRef="ie507238fe5a046649c456d858ed9e23a_I20201231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1NDU_ac694fc1-aefc-4324-883f-e3c8ad6389f5">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="ie507238fe5a046649c456d858ed9e23a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1NTU_104191ec-f8f3-4468-b7fa-6d36f85aa39e">2.45</ix:nonFraction>% 2030 Notes, $<ix:nonFraction unitRef="usd" contextRef="if8bc2063ee0d4b268efa59bb040e751e_I20201231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1NzA_ec1f3f05-e2e0-469b-8879-ba8a1dd98944">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="if8bc2063ee0d4b268efa59bb040e751e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1ODA_1ca65538-5e9a-4131-8ab9-d179579bfb07">2.30</ix:nonFraction>% 2031 Notes, $<ix:nonFraction unitRef="usd" contextRef="i56bdffad54214969af59aa30ffe7fdc8_I20201231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1OTU_32f4ca23-1aed-41b3-85b6-f504de145df7">2.0</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i56bdffad54214969af59aa30ffe7fdc8_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE2MDU_aebb5468-efe0-4070-8db2-9c2aceeb3147">3.15</ix:nonFraction>% 2040 Notes and $<ix:nonFraction unitRef="usd" contextRef="i53fed3d90cd3422f8495f0171cae0423_I20201231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE2MjM_a95ac867-5e2d-4d0f-b5ba-7a3bf9fe4c74">2.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i53fed3d90cd3422f8495f0171cae0423_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE2MzM_86741b72-832f-4cdf-a038-02ba4a47b0a4">3.375</ix:nonFraction>% 2050 Notes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt extinguishment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we repurchased portions of the <ix:nonFraction unitRef="number" contextRef="i5597930bfb1b45bc98481de8f6393843_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODIzNDQ_b2cdedf1-c476-4964-a164-1694ebf559ec">2.20</ix:nonFraction>% 2027 Notes, the <ix:nonFraction unitRef="number" contextRef="ie3d6933a21774133aab412e2e354668c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODIzNTc_dd622ffa-b9a9-47ea-b088-57de54334f3a">1.65</ix:nonFraction>% 2028 Notes, the <ix:nonFraction unitRef="number" contextRef="ia4de45cdb4364327a92140dc1f1c7cfb_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTI5_58229b75-4305-4ad1-9396-5c5d8e5e7365">2.00</ix:nonFraction>% 2032 Notes, the <ix:nonFraction unitRef="number" contextRef="i1b1952961fcf4393b06b95f66a0599ae_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTM3_fb563140-890c-4321-a47f-23628034cd1f">2.80</ix:nonFraction>% 2041 Notes and the <ix:nonFraction unitRef="number" contextRef="ia4ea14090c5d46a68fa6c66a684d6252_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTQ1_4b9723de-e12d-48eb-90c6-07866c3a678f">3.00</ix:nonFraction>% 2052 Notes for an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTUz_ef2d565c-d231-44fe-ab35-7c7f1e77fb7c">297</ix:nonFraction>&#160;million, which resulted in the recognition of a $<ix:nonFraction unitRef="usd" contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTYx_73c64166-9584-4ca4-b247-0c76f2cb8f1c">78</ix:nonFraction>&#160;million gain on extinguishment of debt recorded in Other (expense) income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt repayments/redemptions</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made debt repayments/redemptions during the years ended December 31, 2022, 2021 and 2020, as follows:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2022, <ix:nonFraction unitRef="usd" contextRef="i83a71b99759f43bb8745b086512815bf_D20220101-20221231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjQw_327607e0-8871-449a-a703-b83e9607dde1">no</ix:nonFraction> debt was repaid/redeemed.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2021, we redeemed $<ix:nonFraction unitRef="usd" contextRef="i1ffa41fba39e4ab794adaacf3e2fa171_D20210101-20211231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE4NzA_ae495450-9703-4f25-9537-886618c9492c">4.2</ix:nonFraction>&#160;billion of debt, including the &#8364;<ix:nonFraction unitRef="eur" contextRef="iaca4dae277dc4dd99ebb82e55a868dd1_D20210101-20211231" decimals="-7" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE4OTY_cc9a7441-2ddb-41b6-bfcd-acff186e95bb">1.25</ix:nonFraction>&#160;billion aggregate principal amount ($<ix:nonFraction unitRef="usd" contextRef="iaca4dae277dc4dd99ebb82e55a868dd1_D20210101-20211231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE5Mjc_de8ca1d6-0fb2-48a0-a45a-4e34f465c47c">1.4</ix:nonFraction>&#160;billion upon settlement of the related cross-currency swap) of the <ix:nonFraction unitRef="number" contextRef="i1347de6bb8044d39a48f67625521dccc_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE5ODk_9a57a82b-f187-4872-b18b-eadd22ba114d">1.25</ix:nonFraction>% 2022 euro Notes, the $<ix:nonFraction unitRef="usd" contextRef="i6da1b9cbb0984b97a73d42d2db8533a1_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIwMTM_43389f2c-cc1f-4548-8334-b3cf8585ff5e">500</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i847ad6943c6948fca81b24ff5d689fe3_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIwNTA_8de7a7a3-2a11-43ca-84bc-f413be733cd5">2.70</ix:nonFraction>% 2022 Notes, the $<ix:nonFraction unitRef="usd" contextRef="i561a96f4dc354ad3a90b2b25b980a842_D20210101-20211231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIwNjk_6df437ee-dd41-4aa9-afb9-41d434f0de62">1.5</ix:nonFraction>&#160;billion aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="if8e02d4a00804cc4a01eff072b7e2f66_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIxMDY_7b1b95e3-6779-4db3-bd34-df2cc8a6ac42">2.65</ix:nonFraction>% 2022 Notes and the $<ix:nonFraction unitRef="usd" contextRef="i766094e09bca49dd9585d02df2f31831_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIxMjg_4fbf2e90-d973-430e-acbc-6849aa76402c">750</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i9de4610aa6c4469ea8f2b7e53baf43e4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIxNjU_343afbaf-3c21-4aeb-8e6e-9d3636d3adbd">3.625</ix:nonFraction>% 2022 Notes. In connection with the redemption of these notes, we paid a total of $<ix:nonFraction unitRef="usd" contextRef="i1ffa41fba39e4ab794adaacf3e2fa171_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIyNDk_4d036bde-c324-45de-b576-020cb992f164">24</ix:nonFraction>&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we repaid/redeemed $<ix:nonFraction unitRef="usd" contextRef="i2efa7dc8599f4cbf803535c380f5c0a9_D20200101-20201231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI0NDM_7e9df007-c895-4b85-9a24-43895815155f">6.5</ix:nonFraction>&#160;billion of debt, including the repayment at maturity of the $<ix:nonFraction unitRef="usd" contextRef="i93a2a77b537d4549980bc9ee3c342a33_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI0OTg_187211f1-7071-4c12-a558-cdd1d4c5c69c">300</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="icbb916e5bc874443803468bda0e734e9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI1MzU_ea28f70d-e1c3-418c-b494-6108dd3ae6b5">4.50</ix:nonFraction>% 2020 Notes, the $<ix:nonFraction unitRef="usd" contextRef="iffd7c6ea10ec4560aebf2e8cf2cdf029_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI1NTQ_faa5f834-328f-4379-ba11-fa7c6f6783d9">750</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i37fbc3aef92b4fe7a7795bdf6c1c7572_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI1OTE_09cd5fb4-e83b-4ce3-b0b4-c8ea439fe64a">2.125</ix:nonFraction>% 2020 Notes, the $<ix:nonFraction unitRef="usd" contextRef="id9da66eabb244ebc99d3f74da210e1ab_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI2MTA_d6a7b154-5940-45e2-8497-4e111dfe712f">300</ix:nonFraction>&#160;million Floating Rate Notes due 2020 and the $<ix:nonFraction unitRef="usd" contextRef="i4f0351400ea14a1a92d887dfc66b4eaa_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI2NTA_378e9466-e266-4fc0-bf75-8b6eba721744">700</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="iebdc2a05aee049ac9929bbe48b8b70e0_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI2ODc_9647b409-7647-47b5-8a06-a108294b8c41">2.20</ix:nonFraction>% 2020 Notes. In connection with the redemption of the $<ix:nonFraction unitRef="usd" contextRef="ida12280bfa6149bf8c7594c904e394c3_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDM_65d7733c-7a28-4fb1-abe4-a1c3d9dc20e7">900</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="ic3ec7f5fc463475eb5b87f53220a55e9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3ODA_1bbba8b9-2522-49fc-a7f9-4af8df60b6d9">3.45</ix:nonFraction>% 2020 Notes, the $<ix:nonFraction unitRef="usd" contextRef="i80e1ce0caa3742e5b52a143ca346a03e_D20200101-20201231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3OTk_9eb4392d-fa3f-45ab-ba83-b26815349a1f">1.0</ix:nonFraction>&#160;billion aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="i75d223f0739043aa95bb0cff432d8e57_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI4Mzc_83b2d39c-5d24-4a41-96ac-ec0e231c31d6">4.10</ix:nonFraction>% 2021 Notes, the $<ix:nonFraction unitRef="usd" contextRef="ic96413bd0bc84b608c7ceb7cbe2da49e_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI4NTY_2c16ddcc-4cb9-40d8-9f5f-8787859e9f38">750</ix:nonFraction>&#160;million aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="if86ae682dbc94b06a43ad27eff012f5f_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI4OTQ_d22de948-a3d4-4889-ad1c-9e0fb9f6559c">1.85</ix:nonFraction>% 2021 Notes and the $<ix:nonFraction unitRef="usd" contextRef="ib98c19b2205645dc87dc300e20564cd2_D20200101-20201231" decimals="-7" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI5MTY_9a9b2bd8-4ac2-478a-8508-d2c95f1b6568">1.75</ix:nonFraction>&#160;billion aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="iad19f1af440047f5bd2d2a7b58c2704c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI5NTQ_1c62913f-0873-4968-bd78-eade1616b653">3.875</ix:nonFraction>% 2021 Notes, we paid a total of $<ix:nonFraction unitRef="usd" contextRef="i2efa7dc8599f4cbf803535c380f5c0a9_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI5ODg_647a4b22-0e39-4960-949c-7971d7ee5e9a">96</ix:nonFraction>&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i51217f4e8bed4990907c44f9d502ade2_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQwMTk_bc980012-e5ac-49e4-b230-507ee387cd80">1.0</ix:nonFraction>&#160;billion with respect to the <ix:nonFraction unitRef="number" contextRef="i51217f4e8bed4990907c44f9d502ade2_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQwNDI_cd9eb315-f784-401e-b287-93892f25bf72">2.45</ix:nonFraction>% 2030 Notes and an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i343cbda319a14a27951c64ddae810439_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQwOTI_754e28fb-1f0c-40bf-be54-3f3e7b3fdbf9">500</ix:nonFraction>&#160;million with respect to the <ix:nonFraction unitRef="number" contextRef="i343cbda319a14a27951c64ddae810439_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQxMTU_2d06b708-3bde-4a5b-875d-7d93e0c1f7d9">2.30</ix:nonFraction>% 2031 Notes. In connection with the redemption of the <ix:nonFraction unitRef="number" contextRef="i9de4610aa6c4469ea8f2b7e53baf43e4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQxNzE_f868b001-bc84-4dd8-bf35-4c3f3fb78742">3.625</ix:nonFraction>% 2022 Notes, discussed above, associated interest rate swap contracts with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i745dd63e9cdd4959af07252f017a9eaa_I20211231" decimals="-6" name="amgn:DerivativeNotionalAmountAmountTerminated" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQyODA_bce66df3-f01a-47fd-ab39-fb041d9a33a2">750</ix:nonFraction>&#160;million were terminated.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2cfaa61f2e284f7198d3615b8eb4785b" continuedAt="i421af9f0c46248c08dcb032a741d1da6"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of certain of the notes during the year ended December 31, 2020, discussed above, associated interest rate swap contracts with an aggregate notional value of $<ix:nonFraction unitRef="usd" contextRef="i9ed264795f2f4426adc19343d029ad1b_I20201231" decimals="-7" name="amgn:DerivativeNotionalAmountAmountTerminated" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ0OTI_1dc06677-5d45-45eb-9a1c-2fa39756a67a">3.65</ix:nonFraction>&#160;billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i98780303768142868e91c1f5e2254492_I20201231" decimals="-8" name="amgn:DerivativeNotionalAmountAmountTerminated" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ2ODE_c1174c1b-f2a0-49ce-85c5-13859d333d8f">5.2</ix:nonFraction>&#160;billion that hedged the <ix:nonFraction unitRef="number" contextRef="i42e055314ebc4ed0b56423ed298d665f_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3MDA_4b3842c8-5030-46da-82f2-e1d62fd9610a">3.625</ix:nonFraction>% 2024 Notes, the <ix:nonFraction unitRef="number" contextRef="i95a65fbba5eb437390241efe7cc1bc36_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3MTk_5e2e6301-64f2-4bd4-97b9-c7ef91c83b17">2.60</ix:nonFraction>% 2026 Notes, the <ix:nonFraction unitRef="number" contextRef="i97cf13585e1c40fb990546d925c79ac7_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3Mzg_25c42408-6848-4be5-a36e-909f1facfad9">4.663</ix:nonFraction>% 2051 Notes and portions of the <ix:nonFraction unitRef="number" contextRef="ia87de4924b5449ffaf2a569727731d96_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3NzI_c7428724-1129-4b13-a824-61812b3cb15d">3.625</ix:nonFraction>% 2022 Notes and the <ix:nonFraction unitRef="number" contextRef="i3596be95666d43788e785254aa341628_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3OTQ_d26c6599-3839-4b54-b33b-12dcaaf8d60a">3.125</ix:nonFraction>% 2025 Notes, which resulted in the receipt of $<ix:nonFraction unitRef="usd" contextRef="i9992852da66444809770265c95298e01_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ4NDI_f3f033e5-be66-40be-82b3-aa8ce38c83bb">576</ix:nonFraction> million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $<ix:nonFraction unitRef="usd" contextRef="if8bd0602a17242c7afbd9f2891132c95_I20201231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzUwNDM_4d84ad0a-9680-43a1-a329-82f31ded03d5">5.2</ix:nonFraction> billion principal amount of notes. See Note 18, Derivative instruments.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjEw_a57b7f5b-3b25-45e0-b97d-32e1b8ad776a" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c05fd05200c4fd89c9d750167797479_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246MTMxYmU1MTk3NzlmNGQyYWEyODYzNTkwMjBiNzU3N2JfNA_8d88cea5-ab52-4a17-b2c7-3844ebe1de74">3.625</ix:nonFraction>% 2024 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e90624438bb44448c8bd5de6bd2ea2c_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMi0xLTEtMTg4OTc0_5d58539b-8563-4b06-8345-9166088f9145"><ix:nonFraction unitRef="usd" contextRef="i7c05fd05200c4fd89c9d750167797479_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMi0xLTEtMTg4OTc0_f7901eb2-44bf-44e6-9a28-aa0bb197960b">1,400</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="ie97d7b079fd244fc9390520981dfe82c_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246YTliZDI3MTFjM2UyNDJlMGI0OWQ3YmEwZDIwODlhNDFfMTI_b6b805b9-97f0-4748-989c-a2af146bccfb"><ix:nonFraction unitRef="number" contextRef="i1572a102df9d4c8ea6c80c299b0c59c3_I20221231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246YTliZDI3MTFjM2UyNDJlMGI0OWQ3YmEwZDIwODlhNDFfMTI_ca8644c9-92fb-4bac-8fdf-3579951a6dc7">3.2</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1716ecbde7da4b99b7645064d92f04e6_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246OWRmMWJjYzI2YTZhNDFkMmE0YzcwZjEwY2ZmOGU4NDlfNA_7d3211e0-6c81-4c7f-88f8-aace8a900780">3.125</ix:nonFraction>% 2025 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0e44d0cbd340d5ba7c2e8a3f4793ee_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMi0xLTEtMTg4OTc0_101dc360-1fb8-4904-aaf2-c0655df90d7f"><ix:nonFraction unitRef="usd" contextRef="i1716ecbde7da4b99b7645064d92f04e6_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMi0xLTEtMTg4OTc0_439d2ce4-7131-4e35-ae77-af289e722453">1,000</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i0783150b28c641c7902d993a142cb45c_I20221231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246YTk5OTFiN2I1YjI5NDY2OGJkMDc3MTZjOTcyYjhjMDBfMTI_5e780887-a377-4c90-9453-59baf1089366"><ix:nonFraction unitRef="number" contextRef="id967fc79551b44ac97ef5042140ac816_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246YTk5OTFiN2I1YjI5NDY2OGJkMDc3MTZjOTcyYjhjMDBfMTI_ca2145b6-8eb9-492a-bb5e-b6890dfc76c7">1.8</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6d15fd3bd7a46d697fa1cb5eb430566_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246OWVmZDAwYTdmMzc5NDNiZjgzMWM3MzMyYjYxYmVhMDNfNA_b666ebfa-5206-4bb1-8890-29cd7917e25c">2.60</ix:nonFraction>% 2026 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6d15fd3bd7a46d697fa1cb5eb430566_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMi0xLTEtMTg4OTc0_47f7bf10-ddf5-432c-bee7-8ecdadb11b57"><ix:nonFraction unitRef="usd" contextRef="iff0e1c427c4f46afbcaa4a68bfb4d2e2_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMi0xLTEtMTg4OTc0_635b0c47-6879-4527-8371-22335b873f85">1,250</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="ia7d6ca660c7746d3b61378810b89801d_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246NTJmMDkzYTA1YWJkNDhiYWFhNmJhZjA5MzA2NmVmYjZfMTI_13169e53-8417-4b9f-9ff5-57415894d5c2"><ix:nonFraction unitRef="number" contextRef="i9b59b91df70443e68676c97eacce25d3_I20221231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246NTJmMDkzYTA1YWJkNDhiYWFhNmJhZjA5MzA2NmVmYjZfMTI_3c8577f0-e846-4ee1-8ed4-9647405422c9">1.8</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40fd98a8110c4ff289fab753a7c5a2ca_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246YzdhMDRkNjk1ZjMyNDI5ZmEzODU0OGViMjk0NzZjNjNfNA_b03284d5-8452-4061-83d1-703d2e57c73a">2.45</ix:nonFraction>% 2030 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee57e5a8a3245a6a3cb9a15be5df829_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMi0xLTEtMTg4OTc0_067a1ae7-c168-4e8f-b859-ccdb75abf677"><ix:nonFraction unitRef="usd" contextRef="i40fd98a8110c4ff289fab753a7c5a2ca_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMi0xLTEtMTg4OTc0_e82616e4-5528-4f44-a5e7-b0aa89388f0e">1,000</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="ic29bd0cf7cf0435990f458b78cd7e2dd_I20221231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246MmZjMDNiOGZmNTFjNDI5MDg5N2I1NThjNGU1ZTE0ZjVfMTI_25c4e109-1648-442c-b5d3-e07667fbb807"><ix:nonFraction unitRef="number" contextRef="i8320821864644efe8f0edb105edca9e4_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246MmZjMDNiOGZmNTFjNDI5MDg5N2I1NThjNGU1ZTE0ZjVfMTI_cf07c1d0-3805-4582-971f-ee57ea841808">1.0</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0947ed7f05cf44148673b8fdbbb01f40_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMC0xLTEtMTg4OTc0L3RleHRyZWdpb246NWRiZmE4NmI5YjdjNDRkYzkxNDc1ZTkyNWI1ZTQ2MjVfNA_21390276-e6b3-4fff-82db-1c67c9416c46">2.30</ix:nonFraction>% 2031 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947ed7f05cf44148673b8fdbbb01f40_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMi0xLTEtMTg4OTc0_08f6874a-bda8-4c57-a903-fc0bc0118611"><ix:nonFraction unitRef="usd" contextRef="i1a4586b2c0174806b7f34ea5bd75a188_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMi0xLTEtMTg4OTc0_24a4379a-feb4-4fb8-aa3f-a63adf134440">500</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="ic5fea782081e4895be4943c726463c8b_I20221231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMy0xLTEtMTg4OTc0L3RleHRyZWdpb246ZDc5MWUxN2UzYmIzNDYyMWFlNDg5NGU0ZDI1MzNjNDZfMTI_73cb22d9-794c-4a2c-b226-59319954600f"><ix:nonFraction unitRef="number" contextRef="ifd293d73d43e4b46885dca2ec515d496_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMy0xLTEtMTg4OTc0L3RleHRyZWdpb246ZDc5MWUxN2UzYmIzNDYyMWFlNDg5NGU0ZDI1MzNjNDZfMTI_a78b6f2b-8c04-42b8-8e20-41a7f3a0bcf0">0.8</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i233084f1697843b28ef19302f4ca18c2_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246OWM5ODA2ZmE2Y2MxNGJiMjg0MzJkZjQ0YzFkOTE3N2FfNA_9d661bcd-038d-406e-8b45-5cdda82d5809">4.663</ix:nonFraction>% 2051 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983918d489184fe48f8103d3daedddca_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMi0xLTEtMTg4OTc0_97bb58bf-453c-4020-9961-4ec1ba24a6d1"><ix:nonFraction unitRef="usd" contextRef="i233084f1697843b28ef19302f4ca18c2_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMi0xLTEtMTg4OTc0_cd242d73-6e82-43f4-a3a3-c013de7299f2">1,500</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i525ba3ed8d5d45f998cd0b44ccdf96d7_I20221231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246MzhiNWFjMzViYjIwNDBmMjhiN2E3ZWZkYmIyNWFiMzRfMTE_6403866c-d381-4936-ac76-c21e94d34348"><ix:nonFraction unitRef="number" contextRef="i6df68bf77edd43e0967eb97c5820dae5_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246MzhiNWFjMzViYjIwNDBmMjhiN2E3ZWZkYmIyNWFiMzRfMTE_d7d702a0-30a7-4562-8216-82b4f37d8844">4.1</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id934c9ad45d24abcaed4f914bd53414a_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzktMi0xLTEtMTg4OTc0_014eb2f6-9703-49a5-8147-003bcf27f263"><ix:nonFraction unitRef="usd" contextRef="i93560032f3de4bcfb44d52d784c56eb4_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzktMi0xLTEtMTg4OTc0_85619f11-5a1b-452f-b28e-30eaf776d7ad">6,650</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt exchange</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $<ix:nonFraction unitRef="usd" contextRef="if925782f8a6e48fb9707082d9722b522_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1MTM_73742113-0ea8-4150-a1d6-6ce2bb677136">940</ix:nonFraction>&#160;million principal amount of the newly issued <ix:nonFraction unitRef="number" contextRef="if925782f8a6e48fb9707082d9722b522_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NTM_4d6ab4cf-2e4f-40fd-80eb-43482b4e5b8a">2.77</ix:nonFraction>% 2053 Notes (the Exchange Offer).</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjE4_c3438209-5d75-41aa-88e8-5e59b8cae478" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal amount exchanged</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc5f965633bd497bae6b284f87fd754a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzEtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246M2I5MmJkNTZkMzM0NDExNmE4OWNlMTdlM2ZkYzc5ZGJfNA_aeb7c168-3eb0-45b7-a4d9-485c9b22514d">6.375</ix:nonFraction>% 2037 Notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb555093f204b73ad69194c448331d8_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzEtMS0xLTEtMTg4OTc0_4aa9b7c6-6222-42cd-bbe5-a5afe2d2d228">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4aff41f7e3e648c9be7ca6b79abca8e4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzItMC0xLTEtMTg4OTc0L3RleHRyZWdpb246YjViOTgwMDM0MjBiNDJiODkxOGEwNTEwMjExZGE5ZGRfNA_7ddecfb7-644a-45f1-8c73-f27edc39d044">6.90</ix:nonFraction>% 2038 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4b32aef48940438e79c7f4fdd934dc_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzItMS0xLTEtMTg4OTc0_82b88177-4fec-40d6-a7c6-99668b6dca82">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07692f763cdc46eb807c9eab3a20b027_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzMtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246N2YyMjAyMjE0MGQ3NDQ0MjljMDg5MmNkY2E2MThjOTBfNA_06bd6dfc-40c5-4bad-969b-b0d2ba0e8fb9">6.40</ix:nonFraction>% 2039 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626e02e818cb4ed494a4840a11c2d6c4_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzMtMS0xLTEtMTg4OTc0_54746616-d9e7-4344-a9fa-f68d1b937340">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a2c9ab1d0d74042b5625c4d3863fc9a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzQtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246NmJiYTlhY2NlYThhNGU4MjgzMDY2NGMzNWViYzI5MzRfNA_8b8b2b8e-c927-4a12-a654-5c57374b83ce">5.75</ix:nonFraction>% 2040 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e42823293746a6bb668e39faa8573a_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzQtMS0xLTEtMTg4OTc0_ea0cff8f-a2b8-4e9e-be4a-7be598dd6ed8">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i799db871194f4747ab9f6118c675a2f7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzUtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246N2YzNjhlODRhN2E2NDRjNTljMWNjOWM2NTE4YTA4YTNfNA_374caa35-2ef5-4f15-94f4-1a46626a4663">5.15</ix:nonFraction>% 2041 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230ad1456faf4cd5ae3a81c4e040d168_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzUtMS0xLTEtMTg4OTc0_7e93260a-38dc-4dc7-8d14-c923c1eb7c4c">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ceee26f1075435e9fdfdd7a75a72ab5_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzYtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246ODQwZGZkZmE0NDhmNDExMGFhZTAyNTY2ZjgzMTg2YjNfNA_81ea469d-1fbe-495b-8231-883e0c3118c0">5.65</ix:nonFraction>% 2042 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e784458a35492fbec6c0e6c982a3f6_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzYtMS0xLTEtMTg4OTc0_f91b9d3d-ce36-43f7-bdcc-787f91de7f2b">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieadcf920bf8f4c5f9aa97d54a77a11ee_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzctMC0xLTEtMTg4OTc0L3RleHRyZWdpb246ODQzN2E4OTI5MDE4NGY4NTliNWNiOTgyNjNhOWRlMTdfNA_09fec4c8-757c-4262-94f3-8a969bfd36ab">5.375</ix:nonFraction>% 2043 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e35bf522a340e79908048767761c5f_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzctMS0xLTEtMTg4OTc0_de6e9710-5f38-4404-aa76-79a5c39f446b">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU3NTc_b39bf9ad-5f8d-4478-845d-80be5f060642">2.77</ix:nonFraction>% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the <ix:nonFraction unitRef="number" contextRef="if925782f8a6e48fb9707082d9722b522_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzYwMjQ_39c14ba8-e579-4be7-abe4-2df73b990d9c">2.77</ix:nonFraction>% 2053 Notes. In connection with the Exchange Offer, $<ix:nonFraction unitRef="usd" contextRef="if925782f8a6e48fb9707082d9722b522_I20201231" decimals="-6" name="amgn:DebtExchangeAdditionalCashConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzYwNzg_ed833c9a-b812-4e35-90e8-0cee3c199d67">85</ix:nonFraction> million was paid to holders of the Old Notes (the cash consideration).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $<ix:nonFraction unitRef="usd" contextRef="if925782f8a6e48fb9707082d9722b522_I20201231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzYzMjM_1226ad1a-f3fe-434a-887d-9b8662e5afa3">264</ix:nonFraction> million discount associated with the <ix:nonFraction unitRef="number" contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzYzNTU_d292945c-0af6-4d66-81f4-dfcc9f40d384">2.77</ix:nonFraction>% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i421af9f0c46248c08dcb032a741d1da6" continuedAt="i30686c4aea5940d08fa82f728b286ec5"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cross-currency swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our <ix:nonFraction unitRef="number" contextRef="i3f393109a944495bbe43538e525fdba7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY4MjU_de3b3e13-a596-4a0a-b3ea-b331381f5c62">0.41</ix:nonFraction>% 2023 Swiss franc Bonds, <ix:nonFraction unitRef="number" contextRef="if4039b3cb11c419c948393d621712209_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY4NTI_beb873d7-918c-4c1d-bab0-8157356cf7b6">2.00</ix:nonFraction>% 2026 euro Notes, <ix:nonFraction unitRef="number" contextRef="i0d9211ecea36437580bc7b0a70919e0b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY4NzI_d5fd4be4-c1ac-4c25-ba49-01bba0356ad3">5.50</ix:nonFraction>% 2026 pound sterling Notes and <ix:nonFraction unitRef="number" contextRef="i385a16395bf64c2bb403ca851a184d2a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY5MDU_ed44c33e-7368-45a4-b946-1ff2ee58780a">4.00</ix:nonFraction>% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of the <ix:nonFraction unitRef="number" contextRef="i8ebc1d1a288841db9bff22881bf98a61_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzcyMDg_540926ea-7dac-4215-a4fe-2024a6a58cc6">1.25</ix:nonFraction>% 2022 euro Notes, discussed above, associated cross-currency swap contracts with an aggregate notional amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="i72e2726b4b0146ca9ec8b95c68183d50_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1ODM1_feceb19b-8bce-402c-a276-7e57b100b093">1.25</ix:nonFraction>&#160;billion were terminated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf registration statement and other facilities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we have a commercial paper program that allows us to issue up to $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="INF" name="amgn:MaximumBorrowingCapacityUnderCommercialPaper" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzc0Njk_052b2b1e-c7de-4b0e-b432-9225965e8c9f">2.5</ix:nonFraction> billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2022 and 2021, we had <ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="INF" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU0OTc1NTgzNTAyOA_85a9def5-0242-4208-959a-8ebad48392d7"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="INF" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU0OTc1NTgzNTAyOA_bd05617d-aba2-4f1a-95d3-f95a0c5014a2">no</ix:nonFraction></ix:nonFraction> amounts outstanding under our commercial paper program.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we amended and restated our $<ix:nonFraction unitRef="usd" contextRef="i2421a70ae11841d09f5ec2cee484630d_I20221231" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzc2NzA_f10ab0bf-dc65-45e5-a805-aa0a69fc33a5">2.5</ix:nonFraction> billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $<ix:nonFraction unitRef="usd" contextRef="id0717808e41b45288577472d48ad1319_D20220101-20221231" decimals="-6" name="amgn:AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzc5MTM_c80efee5-5e02-421d-a50b-6d9f9d0516d7">750</ix:nonFraction> million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of <ix:nonNumeric contextRef="id0717808e41b45288577472d48ad1319_D20220101-20221231" name="amgn:LineOfCreditFacilityInitialCommitmentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzgwMjY_09e35c5e-7fee-47bc-af33-edc2bc3c5a9e">five years</ix:nonNumeric>. This term may be extended for up to <ix:nonFraction unitRef="renewal_option" contextRef="id0717808e41b45288577472d48ad1319_D20220101-20221231" decimals="INF" name="amgn:LineofCreditFacilityNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzgwNjY_1bb73270-997d-4fb4-a89f-43110dc3f483">two</ix:nonFraction> additional <ix:nonNumeric contextRef="id0717808e41b45288577472d48ad1319_D20220101-20221231" name="amgn:LineOfCreditFacilityExtensionOfCommitmentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjI3_c899f0a7-313e-4236-a608-c3882cdd3120">one-year</ix:nonNumeric> periods with the agreement of the banks. Annual commitment fees for this agreement are <ix:nonFraction unitRef="number" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="3" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc3NjQ5_07aee1e6-dc00-48fb-9f1c-5aaba40a4138">0.1</ix:nonFraction>% of the unused portion of the facility based on our current credit rating. In December 2022, this revolving credit agreement was further amended to replace LIBOR with SOFR as the reference rate, pursuant to provisions contained therein related to determination of successor rates in case of phaseout or unavailability of existing designated reference rates. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) SOFR plus <ix:nonFraction unitRef="number" contextRef="i400cdd89c79b4ce0a15e3ad45f90a859_D20221201-20221231" decimals="5" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0ODQzNDA2OTkxNjU1_582b25a7-dc8f-4980-ab84-0be8f34b6e35">1.125</ix:nonFraction>% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus <ix:nonFraction unitRef="number" contextRef="id0e7270e76304c008e4095e3dcaa84f5_D20221201-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzg1MjE_6fd7a633-75d2-484a-a80f-262d4ef456a9">0.50</ix:nonFraction>% or (C) <ix:nonNumeric contextRef="i400cdd89c79b4ce0a15e3ad45f90a859_D20221201-20221231" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0ODQzNDA2OTkxNjQ3_93cbf1c2-48a7-463e-b3b9-4fd4804b2fce">one-month SOFR</ix:nonNumeric> plus <ix:nonFraction unitRef="number" contextRef="i400cdd89c79b4ce0a15e3ad45f90a859_D20221201-20221231" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0ODQzNDA2OTkxNjQ5_7105bce0-6f61-4479-a119-ff2885bd4022">1.1</ix:nonFraction>%. As of December 31, 2022 and 2021, <ix:nonFraction unitRef="usd" contextRef="ib35744505c1e440c82abbaf57f20fe46_I20211231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzg3Mzk_7cfe718d-882d-4a39-a85e-f634fe42c7a9"><ix:nonFraction unitRef="usd" contextRef="i2421a70ae11841d09f5ec2cee484630d_I20221231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzg3Mzk_bfffce29-0269-4b3d-b7f3-6726ee1a2ef8">no</ix:nonFraction></ix:nonFraction> amounts were outstanding under this facility.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depositary shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depositary shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023, and our Board has approved a new shelf registration statement to replace it.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, in connection with the proposed acquisition of Horizon, we entered into a bridge credit agreement and a term loan credit agreement which provide for borrowings aggregating $<ix:nonFraction unitRef="usd" contextRef="ieafdc665523f4a6289df98ee45f3ca5b_I20221231" decimals="-8" name="amgn:BridgeCreditAgreementInitialAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU0OTc1NTgzNDI0Mg_795a1839-aef3-4304-ac85-4b26ff07e303">28.5</ix:nonFraction>&#160;billion. As of December 31, 2022, <ix:nonFraction unitRef="usd" contextRef="ic520f1877b1b468fb3b71c4ec23d7a05_I20221231" decimals="INF" name="amgn:BridgeCreditAgreementAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjE1_3e7ef8d2-adcc-418e-a858-3904351d365f">no</ix:nonFraction> amounts have been borrowed under either agreement. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement, bridge credit agreement and term loan agreement include a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements. We were in compliance with all applicable covenants under these arrangements as of December 31, 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual maturities of debt obligations</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjIx_467e392c-cb13-4217-9a9e-5b166ccf71bf" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December 31, 2022, are as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzEtMi0xLTEtMTg4OTc0_f8ddd53d-09f2-404a-8f17-ed5976f4859d">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzItMi0xLTEtMTg4OTc0_3d9a6c9b-04a4-4644-93f4-9e49639d74a4">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzMtMi0xLTEtMTg4OTc0_71a99e30-766c-4429-9a4e-934563a3d2c8">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzQtMi0xLTEtMTg4OTc0_953d44cb-88d9-46e0-82fe-0d79bc5ae70b">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzUtMi0xLTEtMTg4OTc0_d55f67a4-c074-4f78-9a92-dfaabc10439f">2,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzYtMi0xLTEtMTg4OTc0_0a49fbc6-1489-4ede-a889-5e38ae84f8d0">30,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:LongTermDebtMaturitiesRepaymentsOfPrincipalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzctMi0xLTEtMTg4OTc0_4b4a0bc0-9b1f-4800-bc85-219e022b4d79">40,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i30686c4aea5940d08fa82f728b286ec5"><div style="margin-bottom:8pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest costs</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2022, 2021 and 2020, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during each of the years ended December 31, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-8" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjYz_10fa6b2d-2671-4fa0-b322-c5384b07dbdc"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-8" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjYz_44fcf620-64e1-424b-b3e8-998bb2f5d9aa"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-8" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjYz_5d9a832d-3f35-4bab-947c-1321b39e8dfd">1.2</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;billion.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_238"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzIwNDc_a4eac11b-adbb-4f15-983a-255152b9151f" continuedAt="i95dce15b56db4d21b6bfe775c188543e" escape="true">Stockholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="i95dce15b56db4d21b6bfe775c188543e" continuedAt="if78ac56fa5674e7383c646fdbfd15511"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:StockRepurchaseProgramTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzIwMzg_7227f26b-c641-42f5-8763-7c1192787582" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f1639085198472380ac8baa83001db0_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtMS0xLTEtMTg4OTc0_5befe1b1-641e-41d7-8bb8-8142ae1c1cd5">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1639085198472380ac8baa83001db0_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtMy0xLTEtMTg4OTc0_f724855b-aacb-44bc-a5ed-b640c0bbce3b">5,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bc00ec3fc9549debfc91c2a92aa5314_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtNS0xLTEtMTg4OTc0_367d7a59-6a8d-42b3-ac51-c2dd2cad8366">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc00ec3fc9549debfc91c2a92aa5314_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtNy0xLTEtMTg4OTc0_66594f0c-cfc5-4bbb-a21d-ce11e9aaca9f">865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e695d739c9d4986a787a639a8e8a77b_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtOS0xLTEtMTg4OTc0_68263203-fafc-4eab-85b0-f4f55c746882">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e695d739c9d4986a787a639a8e8a77b_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtMTEtMS0xLTE4ODk3NA_f23c5d2e-36d7-4052-b538-ac1aa225214d">933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie81249a29133467eabb1d34b6bdc5483_D20220401-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtMS0xLTEtMTg4OTc0_87d6621e-18ed-477b-a6a6-797d1acc8559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81249a29133467eabb1d34b6bdc5483_D20220401-20220630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtMy0xLTEtMTg4OTc0_f51469ae-2970-4acb-ad4e-40ab962e6a28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50725a0076ed4b89ba38bcbbbfecd2a2_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtNS0xLTEtMTg4OTc0_3abe5961-7cb4-4122-9767-ffed7df2a029">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50725a0076ed4b89ba38bcbbbfecd2a2_D20210401-20210630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtNy0xLTEtMTg4OTc0_27c8a73f-0c57-493b-ab60-b44205f672c1">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a53ed11f70c43369915dd0d29dbb42a_D20200401-20200630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtOS0xLTEtMTg4OTc0_383b8058-1203-4f3b-a3e1-3f08a5a2e329">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a53ed11f70c43369915dd0d29dbb42a_D20200401-20200630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtMTEtMS0xLTE4ODk3NA_103a246c-f1e6-4f35-bc64-c5b7e67f4b80">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4136b215dbf24da08247954154d63658_D20220701-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtMS0xLTEtMTg4OTc0_aa2e2129-7704-4f5e-80ac-b4ca4ccc0e3a">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4136b215dbf24da08247954154d63658_D20220701-20220930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtMy0xLTEtMTg4OTc0_242fb390-2fe7-4a31-9e04-8725cecf0b22">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d0caaabac894eaaaa6744f8d15302de_D20210701-20210930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtNS0xLTEtMTg4OTc0_15938095-3e74-402b-aaaa-11de3b417364">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0caaabac894eaaaa6744f8d15302de_D20210701-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtNy0xLTEtMTg4OTc0_f38b32a9-ffc3-40a4-9232-b0388870aa36">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8267ea8792a8481e880966120cbb1033_D20200701-20200930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtOS0xLTEtMTg4OTc0_a5e0c686-898f-4778-950e-8796d823e78c">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8267ea8792a8481e880966120cbb1033_D20200701-20200930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtMTEtMS0xLTE4ODk3NA_eed042a3-8fe3-4ac4-b428-0c2579cc7ad6">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtMS0xLTEtMTg4OTc0_b791375c-219d-4c4b-b3a5-f169f9d02dbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtMy0xLTEtMTg4OTc0_7cb3b64e-d4e4-4603-b028-45fd6cdb37c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa03d6422826451ab8c9411225c3e9c9_D20211001-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtNS0xLTEtMTg4OTc0_29d22816-d0aa-439f-98f9-741f92853d99">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa03d6422826451ab8c9411225c3e9c9_D20211001-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtNy0xLTEtMTg4OTc0_249cdaf5-e27a-4ecd-8d0f-8b43706ebda8">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78ea81b8276943f0b89ca47f8b931e80_D20201001-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtOS0xLTEtMTg4OTc0_9799947d-1d1e-4dc3-8819-a8f3fcdcbaed">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ea81b8276943f0b89ca47f8b931e80_D20201001-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtMTEtMS0xLTE4ODk3NA_d6fff1ab-ee20-41ec-a765-3b79d8b150d9">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctMS0xLTEtMTg4OTc0_45f8971a-a1d9-488d-9ce3-5debde598c2a">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctMy0xLTEtMTg4OTc0_d0b0de77-4e4b-4d53-ae5c-5b56e52c3ac0">6,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctNS0xLTEtMTg4OTc0_0ad3ed23-b11c-4c67-a425-f2a91c5c869c">21.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctNy0xLTEtMTg4OTc0_302a9f7e-cc93-45d4-b1b5-573a15c5e962">4,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctOS0xLTEtMTg4OTc0_80dfc74e-6e0e-45c4-8c0a-56b138e2dd04">15.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctMTEtMS0xLTE4ODk3NA_a0be91ed-7019-43c3-8d90-2c4cea51f4da">3,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, the Company entered into ASR agreements with third-party financial institutions (Dealers) whereby the Company made payments in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i79222ac692e1477aba781d2ff3a5f7c5_D20220101-20220331" decimals="-8" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMxOTg_739a8a11-7763-4f37-9250-7d89f5a43664">6.0</ix:nonFraction> billion to the Dealers and received and retired an initial <ix:nonFraction unitRef="shares" contextRef="i79222ac692e1477aba781d2ff3a5f7c5_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyMTY_37a39082-e314-4d5c-9e8e-12a88dd2957a">23.3</ix:nonFraction> million shares of the Company&#8217;s common stock from the Dealers. The payments were recorded as reductions to shareholders&#8217; equity, consisting of a $<ix:nonFraction unitRef="usd" contextRef="i1cb79e8187a746398d43e3bd13cc6898_D20220101-20220331" decimals="-8" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyMzY_05fefa9b-2fd5-48ba-943d-cc36174b1d75">5.1</ix:nonFraction> billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $<ix:nonFraction unitRef="usd" contextRef="i77bd16e1aee146a682056d066f6539d3_D20220101-20220331" decimals="-8" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyNTU_af7c73d6-ca03-4011-b5b1-cae19510d931">0.9</ix:nonFraction> billion decrease in additional paid-in capital, which reflects the value of the stock that remained to be delivered by the Dealers. During the third quarter of 2022, an additional <ix:nonFraction unitRef="shares" contextRef="iae1609cedcdb41f08bdbbf907cf65e3c_D20221001-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyNzQ_69d6014a-c36a-4e6a-a0f9-6f5b1f4ce4c9">1.5</ix:nonFraction> million shares of the Company&#8217;s common stock were received from the Dealers which constituted final settlement under the ASR agreements, and accordingly, the $<ix:nonFraction unitRef="usd" contextRef="i09775729f39c42a3a86f1013c58734d4_D20221001-20221231" decimals="-8" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyOTI_7999d8ce-b3fe-4563-a9b3-e34ff22cc15f">0.9</ix:nonFraction> billion decrease in additional paid-in capital recorded in the first quarter was reclassified to accumulated deficit. In total, we repurchased <ix:nonFraction unitRef="shares" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0MjkzNjUxMTY1MDM1_e168981e-d826-4e43-8ff1-43002ffc4ccb">26.1</ix:nonFraction>&#160;million shares of common stock during the year ended December 31, 2022, consisting primarily of the <ix:nonFraction unitRef="shares" contextRef="ia2d9c119784043f18fc9dc9683bc2ff7_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMzMzk_d0e40df2-89f3-4447-a970-614a787071e3">24.8</ix:nonFraction> million shares received under the ASR agreements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $<ix:nonFraction unitRef="usd" contextRef="i3de1e54db16b45a680ea17867c15ae9a_I20221031" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE2Nzg_94cc2567-493c-4400-9b5c-834ea23df594">2.4</ix:nonFraction>&#160;billion. As of December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzM3Mw_89d01815-9d63-4048-9e0f-418fc97675b8">7.0</ix:nonFraction> billion remained available under our stock repurchase program. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors declared quarterly dividends per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib07ee9684f834ac189f302e8ce8f8377_D20211201-20211231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_1c6729dc-7443-43ca-acb6-796b6e36fc22"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d05f148289f4f8ebcab61f83ce94ee7_D20220301-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_42a4a9da-34e1-4284-839a-2fe0b2d70bf6"><ix:nonFraction unitRef="usdPerShare" contextRef="i4136b215dbf24da08247954154d63658_D20220701-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_43a2254a-e666-490d-97b7-595ca0ba9b2b"><ix:nonFraction unitRef="usdPerShare" contextRef="i0375ffbe4dcf4bdaaf2abf150f3bca4e_D20220801-20220831" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_49e437ad-c612-4b53-a994-fe804ba76ea7"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f1639085198472380ac8baa83001db0_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_584fc2c7-1caf-4d91-9e8e-d88142773633"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f2c6f9b7a7a46e09d3931f0d8199da3_D20221001-20221031" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_8662fd96-6777-4fb4-a05d-e572d5f23d3b"><ix:nonFraction unitRef="usdPerShare" contextRef="ie81249a29133467eabb1d34b6bdc5483_D20220401-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_e5fbd2c6-fd6b-4b14-b75a-5ed2d9347bc5"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_ee9114b3-6e19-4339-a1bf-c97e922b3f4c">1.94</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa03d6422826451ab8c9411225c3e9c9_D20211001-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_00b7ae48-f8f3-4fb6-b933-672ddd9d3858"><ix:nonFraction unitRef="usdPerShare" contextRef="i1351e1c5d58d4b228b689baa94a08823_D20211001-20211031" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_2f15d4cc-e6f9-458f-adfe-a05b438c697e"><ix:nonFraction unitRef="usdPerShare" contextRef="i50725a0076ed4b89ba38bcbbbfecd2a2_D20210401-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_3a407176-a8a1-42e8-9bb7-0adc236bcd99"><ix:nonFraction unitRef="usdPerShare" contextRef="idcc68e5fe01f4338a8c7676f9e5e9152_D20201231-20201231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_532dc62b-bdf1-4122-bd92-09ac1bb4efbc"><ix:nonFraction unitRef="usdPerShare" contextRef="i9bc00ec3fc9549debfc91c2a92aa5314_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_6f686a8e-e446-47a3-85be-d68b17e4ea0a"><ix:nonFraction unitRef="usdPerShare" contextRef="idd1a7ea27d4e4ea893aefca7f2ae9dd4_D20210301-20210331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_990d1d51-8771-4695-9ef4-3a2559077484"><ix:nonFraction unitRef="usdPerShare" contextRef="iffab2bf10a0b4ec490ac20e7b6b5f6fb_D20210701-20210731" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_e056550a-ec88-4b8f-81fb-11f15b581c9a"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d0caaabac894eaaaa6744f8d15302de_D20210701-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_f0f1ceb6-05c9-42ef-8b00-4d2b64191b5a">1.76</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i78ea81b8276943f0b89ca47f8b931e80_D20201001-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_37787581-606e-4ee5-8ada-9d5b001f86d8"><ix:nonFraction unitRef="usdPerShare" contextRef="i8267ea8792a8481e880966120cbb1033_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_3f1300c1-ed37-4d0a-b027-6ec9fafd8191"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a53ed11f70c43369915dd0d29dbb42a_D20200401-20200630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_7eb8bab9-3be5-4ebb-ad71-6c6ae0ab4e53"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c44917d50b84030bdfa5f48afb2fd94_D20191201-20191231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_ac410820-9e72-4ae4-9f65-a27976fd78ac"><ix:nonFraction unitRef="usdPerShare" contextRef="i17bd2c1e1f6646129c19ffebbe131aa9_D20200301-20200331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_bb4916c1-e510-4528-bbef-1fe73e181921"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f99105a26404ad389de99b212cfe895_D20200701-20200731" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_d1758898-f3e1-487a-8e1a-80615d00b41b"><ix:nonFraction unitRef="usdPerShare" contextRef="i213496b5cf4a425b96468749b0447825_D20201001-20201031" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_d3d67183-465a-4eec-9709-030e8af6a978"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e695d739c9d4986a787a639a8e8a77b_D20200101-20200331" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_e782405d-4cb5-43d7-a828-dab847e67dd8">1.60</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>, which were paid in each of the four quarters of 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 12, 2022, the Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="i547af651cb9446b18cc108538306f5ab_D20230301-20230331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0MjkzNjUxMTY1MzI1_1baf06ef-73d2-4bc2-94eb-2e29e7aa4f53"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9817fa1cfe3409a975c7a8b3cdefd06_D20221201-20221231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0MjkzNjUxMTY1MzI1_89314c70-5d2e-41ed-acae-8b2fe46e8d57">2.13</ix:nonFraction></ix:nonFraction> per share of common stock, which will be paid in March 2023, to all stockholders of record as of the close of business on February 15, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if78ac56fa5674e7383c646fdbfd15511"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzIwNDg_09f93e6e-bdbe-49e9-80e7-b0326256aec8" escape="true"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e32313a221f41ad8ccd356225fd8eb0_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtMS0xLTEtMTg4OTc0_0e5e5872-3bce-4233-a15a-d29bf79401c0">718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561b1b87095d42118b9170aa94c6c7ea_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtMy0xLTEtMTg4OTc0_9a2a6ff2-24c8-4b44-90ab-f329ee0478d4">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1631e26b0d454c06bcc4b0fc4c38dcdc_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtNS0xLTEtMTg4OTc0_78d8de84-6053-44d1-906d-1d403db71fde">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if15d8369eda74b4090810b1af2596778_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtNy0xLTEtMTg4OTc0_45ee791b-02af-44ac-bc1c-0aec4f93214e">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb02e3f6128454a820a56e2cfbb6e3f_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtOS0xLTEtMTg4OTc0_6d92d80c-3ccb-4047-aa99-c9708ed6ad28">528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b691b97c86241478dd9d32f77155dd2_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzItMS0xLTEtMTg4OTc0_a8a82d0a-b813-43f3-b06e-703e94a345c8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzItOS0xLTEtMTg4OTc0_582aa17c-ef13-41e9-b65c-b405f9431cf9">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe3a213cdc9d4969b1391eef5c1c503f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzMtMy0xLTEtMTg4OTc0_d9c1ff5f-84cd-42b9-83c6-a98dc0ff4e90">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie255fb9441af4696b7b5537c9d7d9ffb_D20200101-20201231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzMtNS0xLTEtMTg4OTc0_7bfaff0c-8dff-4fdc-811e-92cde33f00f1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzMtOS0xLTEtMTg4OTc0_f6acdca6-2b42-4efe-9c1d-afd51369744d">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe3a213cdc9d4969b1391eef5c1c503f_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzQtMy0xLTEtMTg4OTc0_68d746c9-0a91-4abc-a6e3-e74fc53a59dd">501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie255fb9441af4696b7b5537c9d7d9ffb_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzQtNS0xLTEtMTg4OTc0_f16a8502-c4f0-4b8a-babb-0b17e2d77529">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzQtOS0xLTEtMTg4OTc0_bc5d32a8-1058-41a2-bd88-66a6fa7cf96f">534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46d39b7cc594460ca05a08fe50fe2af5_D20200101-20201231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzUtNy0xLTEtMTg4OTc0_2ffb1c44-d539-4c10-8ffa-f611fe288698">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzUtOS0xLTEtMTg4OTc0_9f06a140-ace5-49cd-a198-28fc67c379a2">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b691b97c86241478dd9d32f77155dd2_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzYtMS0xLTEtMTg4OTc0_c66624e9-5c3f-47dd-8358-84b31d4c025a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3a213cdc9d4969b1391eef5c1c503f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzYtMy0xLTEtMTg4OTc0_0dabe21e-13cd-4a25-91cc-92f264f31746">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie255fb9441af4696b7b5537c9d7d9ffb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzYtNS0xLTEtMTg4OTc0_0707a102-6321-44f2-99ce-6c40e6e5d6df">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzYtOS0xLTEtMTg4OTc0_d70aa805-498e-4401-9193-833429a1b2f3">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8ce4697430147afaaf15b34b37a2893_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctMS0xLTEtMTg4OTc0_1767e527-2bf6-4bcd-b232-89ee866aaa04">709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibad7d8f86bf24966a05f5ef686ce8c79_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctMy0xLTEtMTg4OTc0_8e0e20b7-0d14-4a18-ab8b-cb6f5d52477d">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07bf0adb842e42abaf0c52d80659a7f7_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctNS0xLTEtMTg4OTc0_d59f7eec-4413-47a9-8d59-706d020a6585">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03d505608dcf4454bc0a6caf5d45ad79_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctNy0xLTEtMTg4OTc0_80a9b877-3994-4417-86be-b925c482b8fe">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e70878840254d839c51604f86fab42a_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctOS0xLTEtMTg4OTc0_492f13f4-b10d-4ef6-9a61-d3b7c26c86a8">985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6ba3418eed04a19b1d923ff8948405e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzktMS0xLTEtMTg4OTc0_426142c4-6b44-40df-ba8f-04b0388584ef">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzktOS0xLTEtMTg4OTc0_1f8b81bf-e21b-4764-869a-3c087f60c3aa">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6baac2693814ca29a0d4ae5530452b6_D20210101-20211231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEwLTMtMS0xLTE4ODk3NA_a76c9129-c1e1-470a-9510-7b9b77433603">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic696a300be6d4aa6a52c2fbcdfb34389_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEwLTUtMS0xLTE4ODk3NA_0f38a5a0-6caa-4a83-9193-e1b5b059587c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEwLTktMS0xLTE4ODk3NA_16802054-d435-472f-bd93-72762e292562">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6baac2693814ca29a0d4ae5530452b6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzExLTMtMS0xLTE4ODk3NA_c6a390b1-88e9-4e3a-84a1-2b1bfd703e97">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic696a300be6d4aa6a52c2fbcdfb34389_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzExLTUtMS0xLTE4ODk3NA_96588e13-9d64-4f35-8f90-5c756db1f725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzExLTktMS0xLTE4ODk3NA_e4c4c133-11d9-4df0-89cc-e1786b00ff49">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia94576e55ab04deaaea5f1b0f981f32a_D20210101-20211231" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEyLTctMS0xLTE4ODk3NA_fff06662-ab8d-4959-b705-78af0f73045d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEyLTktMS0xLTE4ODk3NA_6e73d691-ae43-40b1-b78e-85e2c9993060">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ba3418eed04a19b1d923ff8948405e_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEzLTEtMS0xLTE4ODk3NA_b517ee54-e7ba-4e03-875b-82c4bf1a4a1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6baac2693814ca29a0d4ae5530452b6_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEzLTMtMS0xLTE4ODk3NA_53b45b90-7c20-4921-8753-22cc984a9cd8">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic696a300be6d4aa6a52c2fbcdfb34389_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEzLTUtMS0xLTE4ODk3NA_c20cf829-0bbb-4be4-ba37-47e0695b98fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEzLTktMS0xLTE4ODk3NA_e1712ec4-f8e5-4640-880d-c1cbb935d0cf">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47cab96086794a69b3747cf784732a9b_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTEtMS0xLTE4ODk3NA_000fdfaa-f852-44df-817b-4ab3c40667ac">844</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21f25ed89f74791850385e82bcb5291_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTMtMS0xLTE4ODk3NA_46a3cdc0-bc9f-4456-b848-672ea843d32e">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a54ab8f414d41e9bfaf147b535c4239_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTUtMS0xLTE4ODk3NA_8b98a14e-912e-421a-b05a-cc5c6fed1872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i074ac2af68414c0bbc7a1a601dca087a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTctMS0xLTE4ODk3NA_e51cda16-5145-476e-ade1-2aca17be8c6d">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib964505bb2264c0e858b211061796b49_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTktMS0xLTE4ODk3NA_19a64fea-b241-4024-a029-5b42e468634d">796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97279c89cb3b4d598cc35eb7287e230f_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE2LTEtMS0xLTE4ODk3NA_2aa917ab-2962-416a-8709-1f49066db56b">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE2LTktMS0xLTE4ODk3NA_47dc265d-4edc-4cff-a690-7155cad8b535">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90308d5f52fe46da90947c1f214b73db_D20220101-20221231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE3LTMtMS0xLTE4ODk3NA_b7b027b4-5e1f-4dd8-a562-f5af891030f8">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9d03894dc947b0b0664666c999e8d2_D20220101-20221231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE3LTUtMS0xLTE4ODk3NA_06cf15af-4793-4eda-b791-7a8ac4fa2bb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE3LTktMS0xLTE4ODk3NA_360ec901-77fc-4750-a3aa-12b6c33806d5">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90308d5f52fe46da90947c1f214b73db_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE4LTMtMS0xLTE4ODk3NA_ef60abc3-8f21-4252-8fa1-c881b1d45c18">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9d03894dc947b0b0664666c999e8d2_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE4LTUtMS0xLTE4ODk3NA_620070d4-e9fd-4354-a7c7-de758e19fd78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE4LTktMS0xLTE4ODk3NA_1d949298-5d73-4d49-9246-55cca4a0042f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7085eb7de24bdf9364ff05d2d06c22_D20220101-20221231" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE5LTctMS0xLTE4ODk3NA_c852ab3c-aae7-4476-b324-7731d58eb91a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE5LTktMS0xLTE4ODk3NA_665238d4-b833-4e8e-ac2d-eb83b5e396f2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97279c89cb3b4d598cc35eb7287e230f_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIwLTEtMS0xLTE4ODk3NA_1b884697-b127-4748-a28c-1abc94b97c55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90308d5f52fe46da90947c1f214b73db_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIwLTMtMS0xLTE4ODk3NA_29cfbc2c-52eb-4ab0-87b9-aaeab3ccb666">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9d03894dc947b0b0664666c999e8d2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIwLTUtMS0xLTE4ODk3NA_7bf89d08-adfb-4ec5-ba8e-22cd8e948d9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIwLTktMS0xLTE4ODk3NA_7ccb023d-e6c4-4b2d-933d-71510fefdf47">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cee74d142364011bb64569b6e7ff8a9_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTEtMS0xLTE4ODk3NA_e1e2bee2-1c45-48c1-9586-8a459ae080eb">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5592ef4a3504edaab5252ca41492cdb_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTMtMS0xLTE4ODk3NA_7808b792-4ff1-43f4-9a04-e94426e4a8f5">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae23449150e54375b157ac5b160edbd9_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTUtMS0xLTE4ODk3NA_b8af49b7-a83a-46c3-9bc3-0596c80b6dde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idee57457aa704a5588746800b8bd3c58_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTctMS0xLTE4ODk3NA_4b566872-41a5-4059-a9f5-a9f22aa08478">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i349ee45aa1e94ce9adf98a1fa8b76e0e_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTktMS0xLTE4ODk3NA_c458622d-e9c8-4e08-b024-2ba06960581d">231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzEzNzU_423d3b74-7e99-40ba-bf84-4c91b9352fb2">19</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzEzOTI_051cc4a9-734b-439d-9150-9a60345894c2">0 million</ix:nonFraction> expense in 2022, a $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0MTI_118d1ebb-6bf7-4c36-b566-6a6aec9a28d8">33</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0Mjk_99fc9319-cda7-45a8-b9b3-57e166dbf6e9">55</ix:nonFraction> million expense in 2021 and a $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0NTI_25690518-bd1b-4bc8-8c1d-de1d711f6e26">14</ix:nonFraction> million benefit and a $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0Njk_8ff36606-623b-412e-8093-64857afdcec4">110</ix:nonFraction> million benefit in 2020, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE3MDE_45f77ff8-12a9-470a-a0fe-4991ee6f4d86">1</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE3MTg_a1667655-70d5-47ac-842b-1487bb3c15b6">7</ix:nonFraction> million benefit in 2020, respectively.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzIwNDQ_80de8e4d-9fad-4463-8eff-3441195b40a0" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ea2249a07045cea77ac843dd3ee186_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzMtMi0xLTEtMTg4OTc0_91b3ecab-edd2-4e84-86f7-b7a7270d694e">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6bae6c3e9ff45c4bc483aa371e79620_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzMtNC0xLTEtMTg4OTc0_ed3cd2e2-fd06-43c3-9d71-78ce749cdfc0">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc245132cc174af6870e31cfd882e769_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzMtNi0xLTEtMTg4OTc0_9fe7442d-12bf-446c-bbb9-f1b3685ebe4b">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdafbb775bf94addace467b7558c90c5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzQtMi0xLTEtMTg4OTc0_44ea5b76-0e9c-41b1-bffe-d0051cd25a79">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6b34d2b5b6f4beba907bb845e7cc2b9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzQtNC0xLTEtMTg4OTc0_3d1e4b81-8207-417f-bf75-2b74e646c482">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic916478fec014452ac32d62171a7e5fd_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzQtNi0xLTEtMTg4OTc0_3b3787a7-d680-4344-8e5c-4da1e9a43495">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fec4c1d74cc4014b5be9b695eda82a9_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzYtMi0xLTEtMTg4OTc0_ff4a9164-6007-4d78-af99-02dbe6fc82c8">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i521f9300ea9e4c53a353c3a3895f2a5e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzYtNC0xLTEtMTg4OTc0_c2d9e344-efe7-4c44-a624-46f316e8bf11">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a53f0a87704f59a5cb2cfabcd59979_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzYtNi0xLTEtMTg4OTc0_5e534776-3821-4d48-9d5e-7c35849ea63c">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fec4c1d74cc4014b5be9b695eda82a9_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzctMi0xLTEtMTg4OTc0_669bf7b9-fdef-4321-8a84-4982f8d59f3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521f9300ea9e4c53a353c3a3895f2a5e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzctNC0xLTEtMTg4OTc0_b97711c0-3857-4256-a7d5-062163d9c87d">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8a53f0a87704f59a5cb2cfabcd59979_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzctNi0xLTEtMTg4OTc0_234bab92-704c-41a6-ae92-53c1de91f882">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fec4c1d74cc4014b5be9b695eda82a9_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzgtMi0xLTEtMTg4OTc0_df204872-b610-49af-b31c-e087df3e3537">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i521f9300ea9e4c53a353c3a3895f2a5e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzgtNC0xLTEtMTg4OTc0_a7008316-468b-485d-83dc-176a7e4595a2">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a53f0a87704f59a5cb2cfabcd59979_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzgtNi0xLTEtMTg4OTc0_debd6ca1-1e8c-4604-afda-abf7950ed40c">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562b0243b6ba47edb88a24870e0e2a7d_D20220101-20221231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEwLTItMS0xLTE4ODk3NA_525a4049-84db-4c6b-9d11-90cf7ac1575e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec76a0aa8be34cacb8193aae6cd1f062_D20210101-20211231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEwLTQtMS0xLTE4ODk3NA_4ba63aad-cede-4736-863b-332c3f0e7e7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4567fe1b74d4ed5aa5d569e9dbeb8fa_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEwLTYtMS0xLTE4ODk3NA_c44b80cf-4866-4a16-85ed-b67b3277e6cd">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562b0243b6ba47edb88a24870e0e2a7d_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzExLTItMS0xLTE4ODk3NA_5ffa0c81-f9e8-4b3a-8f00-734b088abe0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec76a0aa8be34cacb8193aae6cd1f062_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzExLTQtMS0xLTE4ODk3NA_e6ebd3fc-4a16-4dc2-bc05-52100e9487ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4567fe1b74d4ed5aa5d569e9dbeb8fa_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzExLTYtMS0xLTE4ODk3NA_2a7c2658-6c90-4c33-ac14-7c99a8b409e9">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562b0243b6ba47edb88a24870e0e2a7d_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEyLTItMS0xLTE4ODk3NA_491ef811-7b44-40f9-89f2-f57e61eb86da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec76a0aa8be34cacb8193aae6cd1f062_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEyLTQtMS0xLTE4ODk3NA_a3d45d03-adcb-40de-9302-6fa0000e2044">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4567fe1b74d4ed5aa5d569e9dbeb8fa_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEyLTYtMS0xLTE4ODk3NA_000ff9e1-753f-4b0a-9b50-800efd548ef7">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to common stock, our authorized capital includes <ix:nonFraction unitRef="shares" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE4OTg_652627c2-d29e-4e14-8acf-9e6f52dd83ed">5</ix:nonFraction> million shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5Mjg_aff4663d-25d7-41ff-b364-c5241bd6cc0a">0.0001</ix:nonFraction> par value. As of December 31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5NTk_0d397db3-e840-4cd8-ab84-3490aae2e1c2"><ix:nonFraction unitRef="shares" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5NTk_391cfe6d-5dba-4326-832e-aba66d9e9d95"><ix:nonFraction unitRef="shares" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5NTk_4716f66a-5b44-441b-b839-e4b5bcac9bdd"><ix:nonFraction unitRef="shares" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5NTk_5543d2fb-3cfb-4e04-ad31-7abb047f86b0">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock were issued or outstanding.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_241"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzcxMjg_145e0a56-cf77-4cd1-843d-ca0363fefa13" continuedAt="i144a56f2886f4409a6fdc9fd18647f4e" escape="true">Fair value measurement</ix:nonNumeric></span></div><ix:continuation id="i144a56f2886f4409a6fdc9fd18647f4e" continuedAt="if966e920169b4355a7b071208e49b6db"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations for which all significant inputs are observable either directly or indirectly&#8212;other than Level 1 inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzcxMzg_98ae7513-a770-48cc-9fb4-907344440400" continuedAt="ifc02fe94bb8e4922aa6721784ee0d59d" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2022, using:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc2fff9b80c4cfd94f8bf10fa1a0426_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzMtMi0xLTEtMTg4OTc0_22a3d266-75b2-4788-9781-80a4da5da2e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0eab2c4927424ea7412f20ed53a84a_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzMtNC0xLTEtMTg4OTc0_6e1066ea-0809-4504-b3dc-399968b62a85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb3d055e549b4d20aa3bd79921592b07_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzMtNi0xLTEtMTg4OTc0_6dbd0c31-821a-4051-8e2c-e018dcbd7e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzMtOC0xLTEtMTg4OTc0_e3bdf258-598b-4402-96b9-7da372cbd278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia228ad665d09441a9861fb9c7e5b0516_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzQtMi0xLTEtMTg4OTc0_ffde77eb-b226-41d3-856a-e46aaab0c113">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50199fde02748f9bf98f5cdedf79621_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzQtNC0xLTEtMTg4OTc0_1f34cd37-06f4-4034-b993-43a9469253e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d6aeb558db04b82be74458c91784748_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzQtNi0xLTEtMTg4OTc0_da4fb870-bdb6-4562-85cf-a978fad5b870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba24b9313e764100a95332b21228b55d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzQtOC0xLTEtMTg4OTc0_6edaae2d-34b1-40f8-954e-6bed22c3ee91">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd7ca4767784bd68bc0e5d0a9794960_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzExLTItMS0xLTE4ODk3NA_88ed7248-8ecb-4f6f-a6b3-03ee72790267">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eac0bf72e7643508c5232330c7c0e0d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzExLTQtMS0xLTE4ODk3NA_777428c1-5943-4d47-825e-c203c4f74402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0a668cee2e4193b99588a3b62eedff_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzExLTYtMS0xLTE4ODk3NA_a38bc9c5-b767-408f-8857-3e2a41d16efc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzExLTgtMS0xLTE4ODk3NA_726530d0-f492-44fa-98a0-c3102ca0bc0f">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22598ba91ebc4a90903405b80f9b2b90_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEyLTItMS0xLTE4ODk3NA_2c343acf-aca6-4c08-84b4-5755eeb685b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ecd41cf6e44462b19bf11b5f28af8f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEyLTQtMS0xLTE4ODk3NA_af36a83b-bdd2-4b04-83ae-cfcb7cf7ec49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e803186d99e4d92800d0f91df12c1ee_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEyLTYtMS0xLTE4ODk3NA_6a2679da-2118-4305-b978-69268f386c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213219e02daf455db4856867bb8edfc1_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEyLTgtMS0xLTE4ODk3NA_295d5f56-6559-41d4-b33d-b809b947cb03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231" decimals="-6" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTItMS0xLTE5MjQwNA_3af2b584-bc06-48fb-9772-ff029dfcc47a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231" decimals="-6" name="us-gaap:OtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTQtMS0xLTE5MjQwOA_cbaa5dfd-42d0-4b0f-a318-606924b140fd">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e12214117d468cadd851f609eafd23_I20221231" decimals="-6" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTYtMS0xLTE5MjQxMg_07795d78-df9b-45d2-bc80-578309db34cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:OtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTgtMS0xLTE5MjQxNg_7d29d456-d6aa-4b8c-ba52-b995a4aec86f">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTItMS0xLTE4ODk3NA_ebbe4e2d-ff97-42b1-ad26-94e86dd005f9">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTQtMS0xLTE4ODk3NA_308832db-4fda-47e5-87f5-a96d3949f938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e12214117d468cadd851f609eafd23_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTYtMS0xLTE4ODk3NA_73e3a459-b2a3-405b-9b1b-85f52ae60d52">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTgtMS0xLTE4ODk3NA_4057ea23-261c-46b9-9490-fd7afdbbf64f">815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04cf9d5f14444094b92bcc0d9ae9c6c2_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE1LTItMS0xLTE4ODk3NA_86f2ae70-dea1-41fe-8ea5-81af81e781e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1185eef083e41a98369064a5c024e6a_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE1LTQtMS0xLTE4ODk3NA_65865377-dde2-4013-9e60-27c27cce3e07">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc1f370e2ad42c6b4c013b49ed46649_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE1LTYtMS0xLTE4ODk3NA_084e5897-45ac-4e92-b0a1-fcb10bf696ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d9b4ff9d7f46de8ab75bad1566254f_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE1LTgtMS0xLTE4ODk3NA_7f6ac3ed-9d10-42f6-87c5-bee2e60955bd">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195a5331519a4c8ebc478f4e698c9bf0_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE2LTItMS0xLTE4ODk3NA_13408ada-81c5-4025-8fd2-fd9dab3439a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c7ba0f3fb224e79ab0fe6a5fbf238e7_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE2LTQtMS0xLTE4ODk3NA_afa4e4b5-03f2-4ecb-96ce-bfedbd0db0d8">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153762966e424fa9acf2972130ddc1c4_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE2LTYtMS0xLTE4ODk3NA_38fd5e85-5386-47a5-9939-893c552efe09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib555b80a3d9d4e2e9c78009dab8a9f54_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE2LTgtMS0xLTE4ODk3NA_a223ffdb-33a3-4d0b-9892-f459682075ef">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a24aee5c964365b0dc96473c06f9c4_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE3LTItMS0xLTE4ODk3NA_8db7dd4c-4189-496b-9872-7424461734e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681c12cca8b24893906caf0cabe34abd_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE3LTQtMS0xLTE4ODk3NA_8e06ce21-505d-4276-89cf-a272bcf19383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcd8de791a54d38a00b14d46bd0e184_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE3LTYtMS0xLTE4ODk3NA_2cf72ab5-a088-4db7-b0ea-226c0bfe2fb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed68b118d34472994cc95aaa8e8a6c9_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE3LTgtMS0xLTE4ODk3NA_17daabe7-78aa-4717-9e92-b21950310da1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE4LTItMS0xLTE4ODk3NA_ecf44f4c-5d54-4633-92fd-b358f2920422">4,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE4LTQtMS0xLTE4ODk3NA_a2ad289b-1d24-42e4-a7a0-62d1d459a5e8">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e12214117d468cadd851f609eafd23_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE4LTYtMS0xLTE4ODk3NA_741823c2-c646-44b9-a6cd-bfde064154b7">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE4LTgtMS0xLTE4ODk3NA_ad67ce60-a132-4495-9905-33b1536a55bf">5,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04cf9d5f14444094b92bcc0d9ae9c6c2_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIxLTItMS0xLTE4ODk3NA_eeddb609-1282-416f-88ee-fff7191ff07e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1185eef083e41a98369064a5c024e6a_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIxLTQtMS0xLTE4ODk3NA_7251a0de-961b-4253-b2a6-be4a43e2a379">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc1f370e2ad42c6b4c013b49ed46649_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIxLTYtMS0xLTE4ODk3NA_f96bdda7-8c1c-4afd-b977-04d8e1620e2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d9b4ff9d7f46de8ab75bad1566254f_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIxLTgtMS0xLTE4ODk3NA_07a9dd66-b66b-48a0-9ed4-f566dc752015">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195a5331519a4c8ebc478f4e698c9bf0_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIyLTItMS0xLTE4ODk3NA_66258a9c-356f-4da7-9452-0f7ef434fbf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c7ba0f3fb224e79ab0fe6a5fbf238e7_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIyLTQtMS0xLTE4ODk3NA_68357b3e-bfc0-4bb8-9bc5-6999e1769097">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153762966e424fa9acf2972130ddc1c4_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIyLTYtMS0xLTE4ODk3NA_ec013a74-7467-43be-9b28-e57170e755f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib555b80a3d9d4e2e9c78009dab8a9f54_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIyLTgtMS0xLTE4ODk3NA_896d5ecc-6e3b-473a-9b6b-343f6d42d0d5">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a24aee5c964365b0dc96473c06f9c4_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIzLTItMS0xLTE4ODk3NA_bf3ae33f-ef26-40e2-adcc-1af9550e2b0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681c12cca8b24893906caf0cabe34abd_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIzLTQtMS0xLTE4ODk3NA_b8eb492e-b758-4497-9662-ea4563990a68">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcd8de791a54d38a00b14d46bd0e184_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIzLTYtMS0xLTE4ODk3NA_1720c8a3-d27b-459e-8853-1389f7c6283c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed68b118d34472994cc95aaa8e8a6c9_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIzLTgtMS0xLTE4ODk3NA_33f52062-39fa-42de-b8a7-66e6898b917d">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba7a6ebd1caa4564bcbb05dd9ae6251a_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTItMS0xLTIxMDQ3OQ_c551bb2d-275a-4169-b819-57c9e58cd3d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5402fe697c814ce7b466859cedc94d30_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTQtMS0xLTIxMDUwNw_3d755010-e3a1-42a7-908b-b888043dd525">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c0de5b5539746a0b7f92ee5f134419e_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTYtMS0xLTIxMDUxOA_17244a0b-0eee-481a-b373-d3ec383d591e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a10914bc11449188ce8ebe9ba6d1e7a_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTgtMS0xLTIxMDUyNQ_6b6564e3-a206-4be2-bf51-6d61831b0239">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI0LTItMS0xLTE4ODk3NA_11226ee3-7cff-4900-9f13-7e3a2ead470e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI0LTQtMS0xLTE4ODk3NA_239c2ad2-5419-4fe7-aa24-c573a1750dfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e12214117d468cadd851f609eafd23_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI0LTYtMS0xLTE4ODk3NA_4e38d4af-8135-4526-ad08-f64ed076c25a">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI0LTgtMS0xLTE4ODk3NA_ea50e8a9-9163-44fa-b6ec-649ee9fb1466">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTItMS0xLTE4ODk3NA_400cf874-291f-419f-b0bc-b091a580021e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTQtMS0xLTE4ODk3NA_b1e80614-e4dd-4861-bcfb-b3618c7f7f1e">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e12214117d468cadd851f609eafd23_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTYtMS0xLTE4ODk3NA_8e6416ca-894f-48d9-a1fc-1f794e57713d">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTgtMS0xLTE4ODk3NA_efbf5af4-4011-471f-af9b-b5ac30087040">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if966e920169b4355a7b071208e49b6db" continuedAt="i0b6006ad044f4992b5ee71acd196da0d"><div style="margin-bottom:8pt"><ix:continuation id="ifc02fe94bb8e4922aa6721784ee0d59d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac87a69358fc4fd589fb827383a29399_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzMtMi0xLTEtMTg4OTc0_dd86ce9b-6193-476d-af2b-7e0b3a2662f5">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8495c3e692f14eecb7e49b36322c3b37_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzMtNC0xLTEtMTg4OTc0_ffa4e1da-6b73-4904-81db-a69bebfd09dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id189833f84714d86b873bc1305ea1122_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzMtNi0xLTEtMTg4OTc0_2965a2fa-fc41-433c-81d9-0878ebce38e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzMtOC0xLTEtMTg4OTc0_78b038f3-527e-49ba-9039-86704445669b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569bb5a225ac490892da958f5708abba_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzQtMi0xLTEtMTg4OTc0_a54a741a-3f18-48d5-8e87-38e3e6cda1ed">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2668497e150b43a791a72f0c8455c08e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzQtNC0xLTEtMTg4OTc0_5df9a695-5de9-4feb-bb19-d32815028be2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2d5b99ab33b4e739ed1626b9b36b488_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzQtNi0xLTEtMTg4OTc0_79c18015-1da4-4094-be61-a65c2cc83c69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzQtOC0xLTEtMTg4OTc0_098d6fd6-e9db-46e6-b3fe-7a8e4f08bd7b">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d74df6c17364a8aabc1122e2efe6f4e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzExLTItMS0xLTE4ODk3NA_27adce58-87a9-4592-9fec-6b0fb9f899c3">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42fe4d733a7f4f13bb7813256bad4ea3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzExLTQtMS0xLTE4ODk3NA_ee9de920-7ea3-450b-b32b-5d4b889cd7cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabb4b707739487e85cf95efbce18ef9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzExLTYtMS0xLTE4ODk3NA_97e3af27-cf9d-44c4-bd16-695e89bd0d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzExLTgtMS0xLTE4ODk3NA_982e387a-ca37-4c77-929c-01e8efaa0f9f">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ddf4c639f495e92b203d4350e1885_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEyLTItMS0xLTE4ODk3NA_32cd64d7-37d0-486c-83c3-d287a3353f78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577871f373d34ff481985f5ec576c5a9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEyLTQtMS0xLTE4ODk3NA_e4e63241-b7a2-4767-adb7-2d7b1efbc37c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132049d557004a2b9c5a3e2500f496fb_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEyLTYtMS0xLTE4ODk3NA_7048a63c-0703-4a0d-82ca-6ff426f375e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEyLTgtMS0xLTE4ODk3NA_50cfdfc4-bc61-4370-824e-98bc244511f8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231" decimals="-6" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTItMS0xLTE5MjM4MQ_0179398d-6919-4e16-b9e8-fdfada435214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231" decimals="-6" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTQtMS0xLTE5MjM5NA_f2d1ed12-a681-448f-91d6-fea72fb68adc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231" decimals="-6" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTYtMS0xLTE5MjM5MA_553a397f-807a-4812-be1f-1ae045946655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTgtMS0xLTE5MjM5OQ_3bc2e52a-fa0b-4cfc-9f5e-fe62f14b3319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTItMS0xLTE4ODk3NA_58474ea4-8d16-4bc2-a96a-c3403ac567ed">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTQtMS0xLTE4ODk3NA_ccf631a6-27b5-4cb4-a721-97e1cbafede5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTYtMS0xLTE4ODk3NA_86c836b9-68b4-4873-af47-b4abdaf5a7e1">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTgtMS0xLTE4ODk3NA_21dc075c-a461-4477-bc03-ec0e5e6cee3b">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce18bab23fc49839c5ff35eebbc64f5_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE1LTItMS0xLTE4ODk3NA_dc340727-2792-4c43-a0e8-1c73ba803670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69c6f84cc55499992a9a2e32132005e_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE1LTQtMS0xLTE4ODk3NA_ffb70163-abd4-466f-88ab-f5fcd1ec52c2">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb904ccb9024b858913d7acf42062d7_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE1LTYtMS0xLTE4ODk3NA_dbb1ff3f-3c72-4ee2-b583-02d9967df77b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccad64003d424270be4e3bf87201a726_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE1LTgtMS0xLTE4ODk3NA_04354853-f832-4593-b062-c3eaa1616b27">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id946d775421d4962835fc013c2dd949a_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE2LTItMS0xLTE4ODk3NA_e0fcdce9-9842-458b-aa9d-02501880ec24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia240f27fa9af4af381d9cd9b830cdc68_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE2LTQtMS0xLTE4ODk3NA_21f28e22-05e5-41a2-8cf9-d8229044cfee">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53e3c3e57bfa41579e675e5dacc3bd0d_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE2LTYtMS0xLTE4ODk3NA_d7394d5f-e075-4cc7-9b6a-50019bf5aa0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib665f9cde8cf48c5b5fc22d5eab5ff32_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE2LTgtMS0xLTE4ODk3NA_634b4a9a-0fe6-4181-9108-12f11cff0bc7">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d24cfe7dee24743a1c19c57c666aad9_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE3LTItMS0xLTE4ODk3NA_8cacd4de-8960-4095-b2bb-b912c837336b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9866c2a563d74089bd190f1596f41fc2_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE3LTQtMS0xLTE4ODk3NA_3c413c39-5162-4d25-bd21-04572f204663">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2ad38235c0444d8eb13ded4145682a_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE3LTYtMS0xLTE4ODk3NA_1f41cd3b-5fa3-4bfc-bb88-50502483f04b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7dfd23ab294cfdaa4374b169b9c14d_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE3LTgtMS0xLTE4ODk3NA_48873f4b-0077-4b62-9a34-99915cf4cf11">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE4LTItMS0xLTE4ODk3NA_ce9cf546-d1ef-4eb4-ab3f-5f4c18467c71">7,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE4LTQtMS0xLTE4ODk3NA_ece1135a-a5c3-4c3c-b949-59ed98c9e95b">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE4LTYtMS0xLTE4ODk3NA_78e3a768-0ce6-4ac5-8645-3f1d1a928346">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE4LTgtMS0xLTE4ODk3NA_5ca837a0-80b4-407e-8da4-c6c4c0d0d500">8,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce18bab23fc49839c5ff35eebbc64f5_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIxLTItMS0xLTE4ODk3NA_5ab5d891-25c7-4663-b8c8-9b12c990804a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69c6f84cc55499992a9a2e32132005e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIxLTQtMS0xLTE4ODk3NA_435bfe03-c312-46af-854c-65d1b8902c5e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb904ccb9024b858913d7acf42062d7_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIxLTYtMS0xLTE4ODk3NA_cbfebfea-45ad-4f71-afa2-266724e62e6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccad64003d424270be4e3bf87201a726_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIxLTgtMS0xLTE4ODk3NA_9b19ddde-5704-465d-a5a4-3f2f91bba2e5">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id946d775421d4962835fc013c2dd949a_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIyLTItMS0xLTE4ODk3NA_d9a018b0-1e17-4bee-bb4e-0c1c7233fd6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia240f27fa9af4af381d9cd9b830cdc68_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIyLTQtMS0xLTE4ODk3NA_4b73ae1a-79d5-4804-bcdc-d5a3bc250963">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53e3c3e57bfa41579e675e5dacc3bd0d_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIyLTYtMS0xLTE4ODk3NA_b6fafbbe-d289-4d6d-99d4-2ac891417c55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib665f9cde8cf48c5b5fc22d5eab5ff32_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIyLTgtMS0xLTE4ODk3NA_1aca0ec7-e87c-4115-a061-276e07a2e446">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d24cfe7dee24743a1c19c57c666aad9_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIzLTItMS0xLTE4ODk3NA_21400288-aad5-47ad-943b-ba9268017306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9866c2a563d74089bd190f1596f41fc2_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIzLTQtMS0xLTE4ODk3NA_abaf6ce3-c42e-4685-878b-95327023dd23">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2ad38235c0444d8eb13ded4145682a_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIzLTYtMS0xLTE4ODk3NA_e2ba3d80-cca7-49f6-bebd-cc5127844cd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7dfd23ab294cfdaa4374b169b9c14d_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIzLTgtMS0xLTE4ODk3NA_bcc2e2da-cb37-41d4-afdd-4a23ddc59ccd">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbbed003175d41bfa117df6296bf5c46_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTItMS0xLTIxMDU2MQ_61c48ce0-ed73-43e5-b309-05a3c31d2ff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92535cf54c5042858d8b357cb40f0d14_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTQtMS0xLTIxMDU2OQ_09d48f5c-8639-43b3-895c-4be1fafb5007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied47fb81a807413c89dca88a7846b5c4_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTYtMS0xLTIxMDU4MQ_70fbc2cc-1046-45a0-9824-5b33425da09f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c83ac6e195467b945c631bdc59e85c_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTgtMS0xLTIxMDU4OA_f958d3f0-58ac-40e4-9fad-60869382c1c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI0LTItMS0xLTE4ODk3NA_41482491-168d-4617-baae-b3607790b263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI0LTQtMS0xLTE4ODk3NA_cbe88e72-634d-464b-8026-a1c70c16ca34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI0LTYtMS0xLTE4ODk3NA_35784297-8246-486d-bc97-aaaa7224bd85">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI0LTgtMS0xLTE4ODk3NA_e78e3db1-4459-43db-8765-391027a88f12">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTItMS0xLTE4ODk3NA_301658c5-77ab-481c-b7d2-f52b14f2063f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTQtMS0xLTE4ODk3NA_d72aeb1f-4318-43f0-9ff1-24c0618cf5e3">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTYtMS0xLTE4ODk3NA_fdb7f244-8f24-4f8a-8046-ed0812cc026a">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTgtMS0xLTE4ODk3NA_8427767d-347d-4731-8c5f-7339e790d47a">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing and equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. Other investments consist of interest-bearing deposits that are valued at amortized cost, which approximates fair value given their near term maturity. The fair value of equity securities for which the fair value option was elected are initially valued at the transaction price and subsequently valued based on a combination of observable price transactions, when available, market performance and publicly available market information for similar companies that have actively traded equity securities. See Note 9, Investments&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neumora Therapeutics, Inc.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0b6006ad044f4992b5ee71acd196da0d" continuedAt="i4dcd9846af17439189fe8a1d2a405710"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency forward contracts, cross-currency swap contracts and interest rate swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs, as applicable, include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. Certain inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes to these inputs would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzcxMzQ_33c58279-f95b-4347-9b29-a996b554aec8" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzItMi0xLTEtMTg4OTc0_77971dd2-788d-4684-9b96-f2cdf85e5c24">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzItNC0xLTEtMTg4OTc0_f4b8a436-7428-44fe-9b1e-b7d8c3312bae">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzItNi0xLTEtMTg4OTc0_35aad496-f614-4d2c-a1f6-85cd2d206e44">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzMtMi0xLTEtMTg4OTc0_0db950c6-3291-47c8-ad30-90969be3ef82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzMtNC0xLTEtMTg4OTc0_3071ef8d-a383-4b4a-9ae1-0f3639a08be5">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzMtNi0xLTEtMTg4OTc0_26054794-aa14-43fa-b359-bdc6fd455588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzQtMi0xLTEtMTg4OTc0_2d290e72-88d5-4b7e-beb5-89345310e66b">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzQtNC0xLTEtMTg4OTc0_6726cc50-f217-4188-9944-81890d0b6b0f">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzQtNi0xLTEtMTg4OTc0_732afd88-8edc-4f66-920d-832ff5cf6bf0">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzUtMi0xLTEtMTg4OTc0_296f7b02-ae3e-4c10-a539-61387a1b03a4">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzUtNC0xLTEtMTg4OTc0_7eb98a21-30a7-4955-9308-6c101c0fb8ad">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzUtNi0xLTEtMTg4OTc0_b2d8baa2-4b11-42de-92d3-e86f802cbc1e">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzYtMi0xLTEtMTg4OTc0_8d54d590-6189-4665-958d-ebb268370808">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzYtNC0xLTEtMTg4OTc0_2afae797-7f9b-4aad-881c-b4edef273c63">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzYtNi0xLTEtMTg4OTc0_9a9357c4-55d2-4e3c-bb93-679141fb15d3">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Teneobio in 2021, we are obligated to pay its former shareholders up to $<ix:nonFraction unitRef="usd" contextRef="ia46cd94f860647c4b3b4f6dd2d098fff_I20221231" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzU1NDY_f02c861e-b892-4d49-b9c4-ad997f5b6b0b">1.6</ix:nonFraction>&#160;billion upon achieving separate development and regulatory milestones with regard to various R&amp;D programs. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of K-A in 2018, we are obligated to make single-digit royalty payments to Kirin Holdings Company, Limited contingent upon sales of brodalumab.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of BioVex Group Inc. in 2011, we were obligated to pay its former shareholders upon achieving separate sales-related milestones with regard to IMLYGIC if certain sales thresholds were met. During the year ended December 31, 2020, we determined that the likelihood of achieving these milestones was no longer probable, and accordingly, the obligations were written off.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of the fair values of other financial instruments</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2022 and 2021, the aggregate fair values of our borrowings were $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-8" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY1Nzc_931eb32a-3c7d-46b1-a8bf-f1089e66c5ac">35.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-8" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY1ODQ_36e6a429-b6db-4906-8127-38234b42d9ab">37.9</ix:nonFraction> billion, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY2MzE_3c67ee9b-9563-4a68-aeaf-460a01386491">38.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY2Mzg_b0277b32-185c-4e75-81b6-d0f928bc35b7">33.3</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in BeiGene</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2022 and 2021, the fair values were $<ix:nonFraction unitRef="usd" contextRef="idd010ea395424e80984bb752c13cc1f4_I20221231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY3OTg_6c506eb8-706f-4f05-881a-3b70778615ee">4.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY4MDU_b8020be9-ba94-4971-85bf-576e4eab8de5">5.1</ix:nonFraction>&#160;billion, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="idd010ea395424e80984bb752c13cc1f4_I20221231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY4Mzg_96628026-5978-46c9-9481-8e5364918a9b">2.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY4NDU_0c264953-9cf4-4de3-8196-663b8288ba7d">2.8</ix:nonFraction>&#160;billion, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4dcd9846af17439189fe8a1d2a405710">During the years ended December 31, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.</ix:continuation></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_244"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTMy_c7c12b07-3d37-4d74-b1fc-6548e2eb0b6b" continuedAt="ia8421e5be023499c9d3aa6f8df0dbd16" escape="true">Derivative instruments</ix:nonNumeric></span></div><ix:continuation id="ia8421e5be023499c9d3aa6f8df0dbd16" continuedAt="i833bd2cd92474976a0c345e386cd0ab6"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We have designated certain of our derivatives as cash flow and fair value hedges; we also have derivatives not designated as hedges. We do not use derivatives for speculative trading purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. The foreign currency exchange rate fluctuation exposure associated with cash inflows from our international product sales are partially offset by corresponding cash outflows from our international operating expenses. To further reduce this exposure, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEyNjI_4df61dd8-edfb-4e59-96b2-2eda54bfb60e">three years</ix:nonNumeric> into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, 2021 and 2020, we had outstanding foreign currency forward contracts with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i944c4da8f51949d7bd4524a5221b53f5_I20221231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzE1Mjc_eecf7058-6589-4c46-8c56-bf3ede58e46e">6.0</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ic575aff5abc14a04a5d1c46f2b053e12_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzE1MzE_f15dc2f3-7008-4a9b-bdb7-093e5b426fa3">5.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i5a5af4745b754c7b874785b32bb24b00_I20201231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzE1Mzg_b4729360-0524-4038-9926-f8564bc935a1">5.1</ix:nonFraction> billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTUw_011060ed-f98b-4407-b710-c080205e0ad9" continuedAt="ic70d9e6a230a4a48a9ffef9fedb8e4cb" escape="true">The notional amounts and interest rates of our cross-currency swaps as of December 31, 2022, were as follows (notional amounts in millions):</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><ix:continuation id="ic70d9e6a230a4a48a9ffef9fedb8e4cb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="chf" contextRef="i4a5962db8b8248e8a56de2423329a813_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzMtMi0xLTEtMTg4OTc0_16898639-a9b9-4a10-b742-766424081951">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dddebd646fe4e9aae847684ea09146c_I20221231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzMtNC0xLTEtMTg4OTc0_64dbdb8e-0cf9-4851-b6a9-ef4c2c1b2df2">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5962db8b8248e8a56de2423329a813_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzMtNi0xLTEtMTg4OTc0_51b1c0f6-2b61-45a3-ad32-f8f2cda80f4f">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82707d8217c743548ff4520578c0f7cb_I20221231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzMtOC0xLTEtMTg4OTc0_ac33aa50-b0ee-4fc6-8523-c6390b86bc9b">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i18586610d42b4565923516e609315ed0_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzQtMi0xLTEtMTg4OTc0_c227c0ee-08ab-4913-a5e4-5740fe698a27">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a279bb1582744739e5f9088fe666593_I20221231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzQtNC0xLTEtMTg4OTc0_0f772913-4671-4277-9e96-12ff20c8fb36">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18586610d42b4565923516e609315ed0_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzQtNi0xLTEtMTg4OTc0_aa9d4d17-ccfe-4b33-8dff-eb0896e84b20">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb35b6ee6b4c481cbd643d0e1261cc8e_I20221231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzQtOC0xLTEtMTg4OTc0_ecb369b6-a6b7-4357-bc0c-c0f2bc06da73">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="i141bfbb6d4734cb1906b822194473416_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzUtMi0xLTEtMTg4OTc0_371fcae1-9f38-4a7f-b15a-975daad2e9bb">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i000c813b74c349b6be351b38fd528099_I20221231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzUtNC0xLTEtMTg4OTc0_5ae34d46-7e1e-4a33-a36e-91106f6a2d19">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141bfbb6d4734cb1906b822194473416_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzUtNi0xLTEtMTg4OTc0_0c95c8c6-cf39-4e4c-8793-665407e8fb20">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36cf59fd6e684e63bd2fb4dcb7870271_I20221231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzUtOC0xLTEtMTg4OTc0_233f8fe2-6fe7-41ea-8829-1378d331b79b">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="i12701a294ac24a63ac70115c6686c71c_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzYtMi0xLTEtMTg4OTc0_1eafe6b6-93c8-4833-8329-c282e477a10e">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe0e2e65349e4185a303be08740aed7e_I20221231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzYtNC0xLTEtMTg4OTc0_eb6fa74f-51e4-4417-a336-7d51ec9071e9">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12701a294ac24a63ac70115c6686c71c_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzYtNi0xLTEtMTg4OTc0_c5917341-ffd8-4483-826e-c0aae2fb96e8">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc93e8ad61544af5aef6ae040ba31401_I20221231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzYtOC0xLTEtMTg4OTc0_36b2b9e9-4d6b-4c81-9f0f-c957ec30bb07">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. In December 2022, we entered into a forward interest rate contract with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i893dec2695f241eea7e09febe91d6056_I20221231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzE0MjkzNjUxMTc2NDU0_8f42cdba-cef0-4ec3-a97d-98ced8306b16">700</ix:nonFraction>&#160;million. Amounts expected to be recognized during the subsequent 12 months on forward interest rate contracts are not material.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i833bd2cd92474976a0c345e386cd0ab6" continuedAt="i3f9b6effa910453b8a7bd3eacdd8160e"><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTIw_1defcf3b-518d-461b-b36a-8da4e33c36df" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4403c288e6734e15b800b88b0a641274_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzItNC0xLTEtMTg4OTc0_2f1d4445-5c9f-49e5-91cf-41c5cf1e8974">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8039e3232a4ce3b5bcb3dfbf62c725_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzItNi0xLTEtMTg4OTc0_df291280-d024-4084-9f2f-bd7e96f1eba2">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia924eeb3bb7543ed8daaa1f3364c31e9_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzItOC0xLTEtMTg4OTc0_d0617593-2b85-4c51-ab60-806a144d4de0">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e3f19a1ae64901bda8ca62eb6abcfd_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzMtNC0xLTEtMTg4OTc0_0f3a511a-c0d5-4a3a-a6cc-9353fe340ad5">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia013b3bfbdf74724934c7921f702d9ba_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzMtNi0xLTEtMTg4OTc0_25b3dbc8-2392-4f5b-98d3-caba845381dc">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e86b4b83c1402e9dbc2c712ea987c8_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzMtOC0xLTEtMTg4OTc0_2660e211-c49d-4924-a3c7-079cfd506aa0">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95699e6c8574452f9e3e864d40b1dc25_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzQtNC0xLTEtMTg4OTc0_1997d152-fe37-4ad6-ba0e-034b6c5c1ed0">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a18b2800d894d86bd5f131724792cfa_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzQtNi0xLTEtMTg4OTc0_b3482146-8005-4e05-b359-85b85dd7babc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224736ead83447e6a2b3bbfb08ecf30d_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzQtOC0xLTEtMTg4OTc0_feb1c1cf-6495-4d08-8ec4-a7d42238034a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60cabd0b1a14cb189936f2de2a378c3_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzUtNC0xLTEtMTg4OTc0_39cd8b4e-a16e-480d-befb-79f768569405">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0921f2d8651244eab61f2a275f079822_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzUtNi0xLTEtMTg4OTc0_d1a734fa-f21f-4623-bb42-2694e26b5b57">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i916dce6d88664036bb8c4c3bcd21707a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzUtOC0xLTEtMTg4OTc0_34f3e1f1-1d5e-4659-91de-f56571fd4f02">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of both December 31, 2022 and 2021, we had interest rate swap contracts with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i61f2865a5c7548b6986efb37a72d32f6_I20221231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzQ5OTQ_de73349d-97e9-4b4c-876f-5fb0be352af2"><ix:nonFraction unitRef="usd" contextRef="i745dd63e9cdd4959af07252f017a9eaa_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzQ5OTQ_e70dc189-c74c-4649-9111-43f508359d28">6.7</ix:nonFraction></ix:nonFraction>&#160;billion that hedge certain portions of our long-term debt issuances. See Note 15, Financing arrangements, for information on our interest rate swaps.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTUx_7082fb96-13cc-48da-ab8b-444fcacde9df" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35dca8996f6e45938deded2944b3efba_I20221231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzMtMi0xLTEtMTg4OTc0_566c03e3-6e3d-4d0c-b13c-78d4fc859155">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10bea2bc73284b47b799ca78b75b4e06_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzMtNC0xLTEtMTg4OTc0_6a731781-4973-434c-93bf-2ddac26b6dd3">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35dca8996f6e45938deded2944b3efba_I20221231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzMtNi0xLTEtMTg4OTc0_0d12dd6b-14b6-476e-ad78-7703c7c4686c">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10bea2bc73284b47b799ca78b75b4e06_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzMtOC0xLTEtMTg4OTc0_c08918bb-dccc-4b3b-92de-9b4f81985f3b">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d1709057914d44afb932729cfecfcf_I20221231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzQtMi0xLTEtMTg4OTc0_4117fa58-51a9-4d79-a477-bf1ab3144eb7">6,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235e4ed48f85437d8644836bbc43ca87_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzQtNC0xLTEtMTg4OTc0_78fb2e87-d799-4fdb-90b9-a21cd0767455">6,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7d1709057914d44afb932729cfecfcf_I20221231" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzQtNi0xLTEtMTg4OTc0_7cf6b141-cc39-4b38-ba45-d59d0df17afd">519</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235e4ed48f85437d8644836bbc43ca87_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzQtOC0xLTEtMTg4OTc0_895998d3-9209-446e-8731-282624e29356">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt">Current portion of long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i35dca8996f6e45938deded2944b3efba_I20221231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc0MjY_5ffcb1e6-7eaa-49d5-9a40-b8eb32da3bc1">82</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i10bea2bc73284b47b799ca78b75b4e06_I20211231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc0MzM_6a17125e-8542-4bbb-a555-2fd0dcbebd9b">85</ix:nonFraction> million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="ib7d1709057914d44afb932729cfecfcf_I20221231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc1NDk_e84237a1-e8db-4160-8070-6c5ae03f28dd">357</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i235e4ed48f85437d8644836bbc43ca87_I20211231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc1NTY_31246c40-2806-4f99-88e5-1d9bdcebb2be">440</ix:nonFraction> million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt">Current portion of long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i35dca8996f6e45938deded2944b3efba_I20221231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc2OTE_530f42cc-3620-4035-a399-252d34ba0891">82</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i10bea2bc73284b47b799ca78b75b4e06_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc2OTg_e3825ba1-14cb-46a5-ad91-9848d47575a4">85</ix:nonFraction> million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="ib7d1709057914d44afb932729cfecfcf_I20221231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc4MTc_49ad99d1-481c-4b8f-ab9d-e5785c28db73">257</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i235e4ed48f85437d8644836bbc43ca87_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc4MjQ_efdf2612-3387-4ce5-a596-6101debea634">340</ix:nonFraction> million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3f9b6effa910453b8a7bd3eacdd8160e" continuedAt="i5a163308b2464b7aa4a575d61b248787"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of hedging transactions</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTM3_69a0c7e4-e6b5-4028-8ebd-c39b04fc741f" continuedAt="iad3702235f0b47999a7c2f6c1fadd4d5" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f333186d8da4378bcf0c5a3e6baf0f9_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzItMi0xLTEtMTg4OTc0_b88d2e08-8866-450a-8f6a-a2bba1d4ab51">24,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzItNC0xLTEtMTg4OTc0_0c98d736-2551-48c4-b9f8-822dfbdeb146">814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzItNi0xLTEtMTg4OTc0_a4bb8425-3ca9-4565-8a6e-4d35ff5d3def">1,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ea2249a07045cea77ac843dd3ee186_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzUtMi0xLTEtMTg4OTc0_b2f29491-f312-43dd-8ef6-13e796679881">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdafbb775bf94addace467b7558c90c5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzYtNC0xLTEtMTg4OTc0_de79d79c-fbdb-4df2-9c79-398fdfc01390">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a872aceca74648a5734c2e9893a09e_D20220101-20221231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzgtNi0xLTEtMTg4OTc0_e400639d-6a6d-493c-adca-2b26457bf820">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55a872aceca74648a5734c2e9893a09e_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzktNi0xLTEtMTg4OTc0_bbb2cb74-6bb1-4369-a952-bfd26f3cb01a">636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b25c75934844f82a32f7a76cdbe5042_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzItMi0xLTEtMTg4OTc0_82bd3165-eb96-4322-a499-ea71396decc5">24,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzItNC0xLTEtMTg4OTc0_6359cbdf-e8e2-481d-a84e-4fa26663988e">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzItNi0xLTEtMTg4OTc0_25ad4589-43c0-470d-9c07-b5d103530d08">1,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6bae6c3e9ff45c4bc483aa371e79620_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzUtMi0xLTEtMTg4OTc0_4c8202f3-6f93-43e6-8b94-64ff5894750e">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6b34d2b5b6f4beba907bb845e7cc2b9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzYtNC0xLTEtMTg4OTc0_a8b1f90f-3e61-49cd-a59b-2211826840c4">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc2cebe6a0c248f594910077166c27c0_D20210101-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzgtNi0xLTEtMTg4OTc0_177e061a-4b5c-4a33-b265-2287d931d1a8">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc2cebe6a0c248f594910077166c27c0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzktNi0xLTEtMTg4OTc0_de26e579-706c-4ea3-ba3f-c632bec5af45">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8db07843e5b426fbe44e0590a500e74_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzItMi0xLTEtMTg4OTc0_dae66def-b7d4-4d06-ad5c-5a7a4b5f9d82">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzItNC0xLTEtMTg4OTc0_27ade040-9731-45e9-a9ca-8cce509fecff">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzItNi0xLTEtMTg4OTc0_371ede76-2fb5-4b38-b4da-64009437c9e5">1,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc245132cc174af6870e31cfd882e769_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzUtMi0xLTEtMTg4OTc0_92fafadf-df2f-4fe8-b345-60c502919cfa">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic916478fec014452ac32d62171a7e5fd_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzYtNC0xLTEtMTg4OTc0_ff6a82c0-66ad-438f-8d33-2dbea5a00bcc">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19c8a33e809469baa28577670a15fd4_D20200101-20201231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzktNi0xLTEtMTg4OTc0_a1ec7524-91ff-429c-882a-760b2fad2408">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie19c8a33e809469baa28577670a15fd4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzEwLTYtMS0xLTE4ODk3NA_d85bdec8-ea19-4147-a77d-34af75465328">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="iad3702235f0b47999a7c2f6c1fadd4d5" continuedAt="ief170d5989c34ff7af0aa22399dc77d6">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ief170d5989c34ff7af0aa22399dc77d6">&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2022, we expected to reclassify $<ix:nonFraction unitRef="usd" contextRef="ib6c2d36bbe6a4d419b04a238a8121559_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzg3MDM_b31f9009-59ac-4f65-a34c-3799f833d296">159</ix:nonFraction> million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5a163308b2464b7aa4a575d61b248787" continuedAt="i73f8f3550b3b4f2594ec87b7fbced14d"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2022, 2021 and 2020, the total notional amounts of these foreign currency forward contracts were $<ix:nonFraction unitRef="usd" contextRef="i0070fbcf9e5043e28c33ca586f2f12d1_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzkyNTQ_0ccfa04f-97a3-4875-b8ad-047f36550785">517</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6a3731a49f5b4c0ab1587258bbb6fa81_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzkyNTg_7c3fc074-f144-4c72-9f12-d9353ac91dee">680</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6300669025b46f7b380270aefda2eb5_I20201231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzkyNjU_37206cb6-9320-43dc-8159-e79b106f8d34">1.0</ix:nonFraction> billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair values of derivatives</span></div><ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTIx_1b1916d3-6f4f-4943-957f-384c8ec0ee56" escape="true"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b4d3bc8dd644d09c1cfa7a23a15d73_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzMtNC0xLTEtMTg4OTc0_650ed824-c712-4418-b181-9130d0e9f3d4">287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ace983c9a64dc7b4239aea83dc7b02_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzMtOC0xLTEtMTg4OTc0_673d37cb-6b6d-4261-bfe1-6f418f54c5be">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd95f2130b1849c0a6ac303164815eac_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzQtNC0xLTEtMTg4OTc0_a0327358-86ac-4da7-b5f1-3c4a644aabd5">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef37d1d19a34b4abe782126c5137fe0_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzQtOC0xLTEtMTg4OTc0_aecb9e48-9e26-40ec-8854-7585cb6422ba">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54e75f2069df4597912a649d3b21612f_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzUtNC0xLTEtMTg4OTc0_c38d3ca5-d436-4f40-9d44-1797348d715d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3b2c5c4c594281bf2350f890860495_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzUtOC0xLTEtMTg4OTc0_197b77f3-4380-4309-8d9e-0ca7eca16fae">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40227117f78447a9ad9ae92218498e28_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzYtNC0xLTEtMjA2OTA0_ffdf2d9d-bca6-4d6f-8407-13ce20e3ad43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2944af81b1f24f5e8934a081989872fe_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzYtOC0xLTEtMjA2OTM1_8f87391e-7f91-4294-a890-154b04245ca2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49d6cb8ea64d45f092c9ccbe06efae29_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzYtNC0xLTEtMTg4OTc0_6483d215-e4c7-48d3-a0c0-51470f81b7d9">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49d6cb8ea64d45f092c9ccbe06efae29_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzYtOC0xLTEtMTg4OTc0_555acd14-85b5-461f-9738-0b355fff30aa">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzEwLTQtMS0xLTE4ODk3NA_dee0f245-d40a-4639-8a3e-8054245ef761">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzEwLTgtMS0xLTE4ODk3NA_e55ceb19-87c3-44b8-a7da-3ee1b58c0a3d">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629346f484274f9ea377c96a9845eb29_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE1LTQtMS0xLTE4ODk3NA_d353544e-6cbf-4c98-829c-f81c6572c8ae">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id334802554e34a95a80f6c8df61e0238_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE1LTgtMS0xLTE4ODk3NA_452b9662-1c11-4c4e-8ec0-7355d9b976eb">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378d88e1dff64d65904267fc06da9175_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE2LTQtMS0xLTE4ODk3NA_0dde4f87-471a-4b71-9226-ff47470b30ea">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e8414ca5604a31a388ddd2badf96b7_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE2LTgtMS0xLTE4ODk3NA_c50c1595-6a1e-4e72-81ca-5eafd7a2f320">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824bdb4659bd41509979bb787b6de333_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE3LTQtMS0xLTE4ODk3NA_f2956c0c-db69-4511-a470-6d39790a4083">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6523296eb7b74ed7b7ff7acdfe444319_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE3LTgtMS0xLTE4ODk3NA_948fe171-13a2-4882-a8c8-6fa194845df1">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf6a2a3c143432ea3c1e2d1ca761a0d_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE5LTQtMS0xLTIwNjkyNw_95fe94d6-3c90-4082-b4d1-3286507d91a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8c2b20543e445bb5dea750ab9c396a_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE5LTgtMS0xLTIwNjk0Mw_885b00a6-a972-4cd4-a3cb-d84b1c2a614d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36b86d79154149259fd101e1fe5655b4_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE4LTQtMS0xLTE4ODk3NA_4c9d059a-7216-4140-ae5a-0235d70b0d78">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36b86d79154149259fd101e1fe5655b4_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE4LTgtMS0xLTE4ODk3NA_3a247e3d-35b7-43da-b1e1-4cc5fcb1d0ed">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzIyLTQtMS0xLTE4ODk3NA_1db66c98-ed39-40a7-a639-6e6513b4850b">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzIyLTgtMS0xLTE4ODk3NA_4040854c-8afc-4d5d-ba45-fdbb4c3a9a7a">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note 17, Fair value measurement.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i73f8f3550b3b4f2594ec87b7fbced14d"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative contracts that were in liability positions as of December 31, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change-in-control and (ii)&#160;our or the surviving entity&#8217;s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change-in-control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8055099d1994bb494875d41c341f00d_247"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzQ1MjE4_20fe6be8-2b4f-44b0-8f05-9204d4eba957" continuedAt="i8050295cf4274e28ad84dbc1fd7bc5fc" escape="true">Contingencies and commitments </ix:nonNumeric></span></div><ix:continuation id="i8050295cf4274e28ad84dbc1fd7bc5fc" continuedAt="i40682ce104e241179162293d3d7bd3a0"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in June 2018, Celgene filed <ix:nonFraction unitRef="lawsuit" contextRef="i2958a5f5fff1421995cfbfcd99f50244_D20180601-20180630" decimals="INF" name="amgn:GainContingencyNumberofLawsuitsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjE5MA_7feff28d-10a5-4f46-b4ec-36c57e328f50">19</ix:nonFraction> separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC (Amneal); Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited (MSN); Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc. (Sandoz); Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc. (Zydus), each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the &#8217;940 Patent), 7,208,516 (the &#8217;516 Patent), 7,427,638 (the &#8217;638 Patent), 7,659,302 (the &#8217;302 Patent), 7,893,101 (the &#8217;101 Patent), 8,455,536 (the &#8217;536 Patent), 8,802,717 (the &#8217;717 Patent), 9,018,243 (the &#8217;243 Patent) and 9,872,854 (the &#8217;854 Patent), which are listed in the Orange Book for Otezla. Each of these lawsuits was based on each defendant&#8217;s submission of an ANDA seeking FDA approval to market a generic version of Otezla. The New Jersey District Court consolidated these <ix:nonFraction unitRef="lawsuit" contextRef="i2958a5f5fff1421995cfbfcd99f50244_D20180601-20180630" decimals="INF" name="amgn:GainContingencyNumberofLawsuitsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjIyNA_19f7670b-4d6e-4d86-87cc-3e7632fccdb1">19</ix:nonFraction> lawsuits for discovery and case management purposes into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i40682ce104e241179162293d3d7bd3a0" continuedAt="ib2a5c2b35fe64e5fb2b314939a03348f"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, Celgene filed amended complaints against Alkem, Amneal, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz, Actavis, Unichem and Zydus additionally asserting U.S. Patent No. 9,724,330 (the &#8217;330 Patent), which is listed in the Orange Book for Otezla. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN, Pharmascience, Prinston, Sandoz, Actavis, Torrent, Unichem and Zydus additionally asserting U.S. Patent No. 10,092,541 (the &#8217;541 Patent), which is listed in the Orange Book for Otezla. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the &#8217;940, &#8217;302, &#8217;536, &#8217;243 and &#8217;330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the &#8217;283 Patent) and 8,629,173, which are not listed in the Orange Book for Otezla. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz, Shilpa, Actavis, Torrent, Unichem and Zydus filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Amgen&#8217;s acquisition of the patents-in-suit and the new drug application for Otezla, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;854 and &#8217;541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz with respect to the &#8217;717, &#8217;516 and &#8217;854 Patents, leaving the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents asserted by Amgen against Sandoz in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind&#8217;s apremilast product during the term of the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods&#8217; apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal&#8217;s apremilast product during the term of the &#8217;101, &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa&#8217;s apremilast product during the term of the &#8217;638, &#8217;101 and &#8217;854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis&#8217; apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;536, &#8217;717, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On March 24, 2021, based on a joint request by Amgen and Prinston, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Prinston&#8217;s apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 6, 2021, based on a joint request by Amgen and Aurobindo, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Aurobindo&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib2a5c2b35fe64e5fb2b314939a03348f" continuedAt="i41257ff16d26482bb9c7ffc80d92c30b"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, based on a joint request by Amgen and Cipla, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Cipla&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 14, 2021, based on a joint request by Amgen and Torrent, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Torrent&#8217;s apremilast product during the term of the &#8217;101, &#8217;638, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 19, 2021, based on a joint request by Amgen and Alkem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Alkem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 25, 2021, based on a joint request by Amgen and MSN, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of MSN&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 11, 2021, based on a joint request by Amgen and Pharmascience, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience&#8217;s apremilast product during the term of the &#8217;243, &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;536 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the &#8217;638 Patent, claim 6 of the &#8217;536 Patent and claims 2 and 27 of the &#8217;283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the &#8217;101 Patent and claims 2, 19 and 21 of the &#8217;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus&#8217;s ANDA must be after expiration of the <ix:nonFraction unitRef="patent" contextRef="i2c106f85af6b497789bb2d2c5d8a09e5_D20210928-20210928" decimals="INF" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0Mw_39071bc6-00cd-45a5-a668-f43e3632d728">three</ix:nonFraction> infringed patents (the &#8217;638, &#8217;536 and &#8217;283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus&#8217;s generic apremilast products during the term of the <ix:nonFraction unitRef="patent" contextRef="i2c106f85af6b497789bb2d2c5d8a09e5_D20210928-20210928" decimals="INF" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0NA_81049fd2-4d8e-4aa5-8f42-7e2ae06fcdc3">three</ix:nonFraction> infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the &#8217;638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the &#8217;638 Patent, claim 6 of the &#8217;536 Patent and claims 1 and 15 of the &#8217;101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the &#8217;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz&#8217;s ANDA must be after expiration of the <ix:nonFraction unitRef="patent" contextRef="ia142d93a85b941c08264cf95a13ea31d_D20211012-20211012" decimals="INF" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk2MQ_2e9f4b34-26dd-41b7-9f7c-e25921249fd5">three</ix:nonFraction> infringed patents (the &#8217;638, &#8217;536 and &#8217;101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz&#8217;s generic apremilast products during the term of the <ix:nonFraction unitRef="patent" contextRef="ia142d93a85b941c08264cf95a13ea31d_D20211012-20211012" decimals="INF" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk2Mg_9b9ca44f-4ed5-42b4-9326-c6e9254d891e">three</ix:nonFraction> infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the &#8217;638 and &#8217;101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral argument for Amgen&#8217;s, Sandoz&#8217;s and Zydus&#8217; appeals was held on February 8, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Apotex Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 14, 2022, Amgen filed a lawsuit in the New Jersey District Court against Apotex Inc. (Apotex) for infringement of the &#8217;638 Patent, the &#8217;854 Patent and the &#8217;541 Patent. This lawsuit was based on Apotex&#8217;s submission of an ANDA seeking FDA approval to market a generic version of Otezla and seeks an order of the New Jersey District Court making any FDA approval of Apotex&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2022, Apotex filed its answer, disputing infringement and/or validity of the patents-in-suit. Along with its answer, Apotex also filed declaratory judgment counterclaims asserting that the patents-in-suit are not infringed and/or are invalid. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, based on a joint request by Amgen and Apotex, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Apotex&#8217;s apremilast product during the term of the &#8217;638, &#8217;854, and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i41257ff16d26482bb9c7ffc80d92c30b" continuedAt="i570d3e8ac649477e81b3bcd7c6a7a55a"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Sanofi, et al. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, Amgen initiated a series of lawsuits that were consolidated by the U.S. District Court for the District of Delaware (Delaware District Court) in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing <ix:nonFraction unitRef="patent" contextRef="i726c606382b04686ab59e3bf5cf547f4_D20141001-20141031" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0NQ_91f082e6-c749-45e4-a269-9489c3969e1c">seven</ix:nonFraction> of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the &#8217;165 Patent); 8,859,741 (the &#8217;741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to PCSK9. By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron&#8217;s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen&#8217;s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron&#8217;s infringement of Amgen&#8217;s patents is willful.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT infringe certain of Amgen&#8217;s patents, including claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a <ix:nonNumeric contextRef="ice91453cc6994225aeb0216b9be20795_D20160201-20160228" name="amgn:LitigationSettlementLengthofTrial" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzI0MTg5MjU2MDU5NDgz_088ef9c0-4fe5-41eb-8868-c5d35582724b">five-day</ix:nonNumeric> jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron&#8217;s posttrial motions seeking a new trial and for judgment as a matter of law, and granted Amgen&#8217;s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial <ix:nonFraction unitRef="patent" contextRef="ice91453cc6994225aeb0216b9be20795_D20160201-20160228" decimals="INF" name="amgn:GainContingencyNumberOfChallenges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0OA_f87ed247-e643-430a-9da4-641e1078199c">two</ix:nonFraction> of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court&#8217;s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on <ix:nonFraction unitRef="patent" contextRef="ifba99da398a24a8da5609feecbdda3b2_D20180301-20180331" decimals="INF" name="amgn:GainContingencyNumberOfChallenges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0OQ_22e2fe33-23ce-4df5-a4c1-efa65b0c1d14">two</ix:nonFraction> of Sanofi and Regeneron&#8217;s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#8217;s conclusion that the judgment affirming the validity of Amgen&#8217;s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen&#8217;s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron&#8217;s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen&#8217;s claim of willful infringement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2019, a jury of the Delaware District Court again unanimously upheld the validity of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. The jury also found that claims 7 and 15 of the &#8217;165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed posttrial motions seeking to reverse the jury verdict against them or for a new trial, and Amgen filed a motion for a permanent injunction. On August 28, 2019, the Delaware District Court ruled on the posttrial motions, denying Sanofi and Regeneron&#8217;s request for a new trial and their request to reverse the jury verdict that the &#8217;165 Patent and the &#8217;741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court and based on the subsequent hearing, on February 11, 2021 the Federal Circuit Court issued a decision affirming the Delaware District Court&#8217;s ruling. Amgen filed a petition for rehearing en banc which was denied on June 21, 2021. On November 18, 2021, Amgen filed a petition for writ of certiorari with the U.S. Supreme Court seeking review of the invalidation of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent as lacking an enabling disclosure of the invention. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2022, the U.S. Supreme Court granted review on Amgen&#8217;s petition for certiorari on the question of whether the appropriate standard was applied by the lower courts in invalidating claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent as lacking an enabling disclosure of the invention. Amgen filed its opening brief on December 27, 2022. On February 3, 2023, Sanofi and Regeneron filed a brief in response.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral argument before the U.S. Supreme Court is scheduled for March 27, 2023.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i570d3e8ac649477e81b3bcd7c6a7a55a" continuedAt="ie6e46e152ef14ff49b2f1acfc500035d"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes in the International Region</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in Germany, Spain and Japan. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen&#8217;s patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen&#8217;s patent. In November 2018, the EPO confirmed the validity of Amgen&#8217;s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA&#8217;s decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA&#8217;s October 29, 2020 ruling.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, Amgen filed counterclaims alleging that PRALUENT infringes Amgen&#8217;s European Patent No. 2,641,917 (the &#8217;917 Patent). A EPO opposition to the &#8217;917 Patent, filed by Sanofi on February 5, 2021, is pending, and the hearing before the EPO&#8217;s Opposition Division is scheduled for February 21, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP&#8217;004 Patent), seeking infringement damages and injunctive relief. The EP&#8217;004 Patent is currently in opposition proceedings, initiated by Amgen and an anonymous third party, before the EPO. A hearing before the Opposition Division of the EPO was held on June 8 and 9, 2022, and on August 16, 2022, the Opposition Division issued a written decision upholding the validity of the EP&#8217;004 Patent claims at issue, with narrowing amendments. Proceedings before the TBA commenced on August 17, 2022. On November 22, 2022, Amgen filed Grounds of Appeal before the TBA, and on December 30, 2022, Regeneron filed Grounds of Appeal before the TBA. On January 23, 2023, the TBA invited Amgen to file any response to Regeneron&#8217;s Grounds of Appeal by May 23, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.&#8217;s appeals making final the Japanese High Court&#8217;s decisions that PRALUENT infringes Amgen&#8217;s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen&#8217;s Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. On April 15, 2021, the Japanese Patent Office dismissed Regeneron&#8217;s invalidity trials, and in August 2021 Regeneron appealed the decisions to the Japanese High Court. On January 26, 2023, the Japanese High Court found Amgen&#8217;s patent claims invalid for lacking adequate support. The decision is subject to appeal to the Japanese Supreme Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 654 (ustekinumab) Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Biotech, Inc. v. Amgen Inc. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 29, 2022, Janssen filed a lawsuit in the Delaware District Court alleging Amgen&#8217;s infringement of <ix:nonFraction unitRef="patent" contextRef="ib5c422a12ee04646bd081c628e80d370_D20221129-20221129" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1MA_faa6d6b5-a589-44ed-a6ff-284b131b0d3a">two</ix:nonFraction> patents by Amgen&#8217;s submission of an application for FDA licensure of ABP 654, Amgen&#8217;s biosimilar version of Janssen&#8217;s STELARA (ustekinumab) and also seeking declaratory judgment of infringement of the same <ix:nonFraction unitRef="patent" contextRef="ib5c422a12ee04646bd081c628e80d370_D20221129-20221129" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjE5Mw_71948553-5f95-4677-b49d-bbc80e2c5335">two</ix:nonFraction> patents.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Class Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar Antitrust Class Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From February to April 2019, <ix:nonFraction unitRef="numberofplaintiffs" contextRef="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjE4OA_c6229b8a-61ed-44f5-a252-ca7649e0a4ef">four</ix:nonFraction> plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceuticals USA, Inc. (Teva) alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. <ix:nonFraction unitRef="numberofclaims" contextRef="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1MQ_441164a9-6651-4329-afc5-94afa9e0b502">two</ix:nonFraction> of those actions were brought in the Delaware District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 21, 2019) (Local 1500) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cesar Castillo, Inc. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar and alleges that the plaintiffs have overpaid for Sensipar as a result of Amgen&#8217;s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie6e46e152ef14ff49b2f1acfc500035d" continuedAt="i4aa9e6706ea048339303c968b2fd0d80"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lawsuits focus predominantly on the settlement among Amgen, Watson Laboratories, Inc. (Watson) and Teva of the parties&#8217; patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys&#8217; fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the <ix:nonFraction unitRef="lawsuit" contextRef="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430" decimals="INF" name="amgn:LossContingencyNumberOfLawsuitsFiled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1NA_dfd8736d-7dd0-4e1e-bd19-f023cb1824c9">four</ix:nonFraction> lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the <ix:nonFraction unitRef="lawsuit" contextRef="if7c1ec63c1ec45feb8a564cb6250b077_D20180601-20180630" decimals="INF" name="amgn:GainContingencyNumberofLawsuitsFiled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjE5NA_a6ab0462-10d6-4c63-b9c2-0b7ea167397f">four</ix:nonFraction> lawsuits, along with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cipla Ltd. v. Amgen Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consolidated and designated as an MDL in the Delaware District Court. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the <ix:nonFraction unitRef="lawsuit" contextRef="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430" decimals="INF" name="amgn:LossContingencyNumberOfLawsuitsFiled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1NQ_4bbcdd95-3507-46f3-b8f4-f1651771b468">four</ix:nonFraction> class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs&#8217; consolidated class action complaint and the indirect purchaser end payer plaintiffs&#8217; complaint. On December 6, 2019, the plaintiffs responded to Amgen&#8217;s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Delaware District Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge&#8217;s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs&#8217; objections. On November 30, 2020, the District Court adopted the Magistrate Judge&#8217;s recommendation in part and denied it in part, denying Amgen&#8217;s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen&#8217;s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs&#8217; offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court&#8217;s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the plaintiffs in the antitrust class action lawsuit brought on behalf of putative classes of direct or indirect purchasers of Sensipar filed their amended complaints. On March 4, 2021, a stipulation and order regarding the filing of a second amended complaint were filed to add another plaintiff: Teamsters Western Region &amp; Local 177 Health Care Fund. On March 17, 2021, a defendant, MSP Recovery Claims, Series LLC, filed its notice of voluntary dismissal. On March 30, 2021, the remaining defendants, including Amgen, filed their motions to dismiss the second amended complaint.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2021, plaintiffs filed their oppositions to defendants&#8217; (including Amgen&#8217;s) motion to dismiss, and defendants&#8217; reply was filed on May 25, 2021. A hearing on defendants&#8217; motion to dismiss was held in the Delaware District Court on July 13, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2022, the Delaware District Court granted defendants&#8217; (including Amgen&#8217;s) motion to dismiss except as to the reverse payment claim and various state law claims from <ix:nonFraction unitRef="states" contextRef="iee18063ebe5b4821977151cc6f74a5c1_I20220311" decimals="INF" name="amgn:LossContingencyNumberOfStatesInWhichPlaintiffsReside" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1Ng_ed70d1f8-d076-40a7-8fc3-470194b8a908">ten</ix:nonFraction> of the states in which plaintiffs reside. On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal. The plaintiffs did not oppose Amgen&#8217;s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs&#8217; motion on June 10, 2022, and reply briefs were filed on June 24, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. Antitrust Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, Regeneron Pharmaceuticals, Inc. (Regeneron) filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen&#8217;s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payers and PBMs have harmed the sales of its product PRALUENT and focuses on <ix:nonFraction unitRef="argument" contextRef="ieb8da649b50d456aabccb1d09b37ed81_I20220527" decimals="INF" name="amgn:LossContingencyNumberOfPrimaryArguments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1Nw_5bc2b144-0453-49b2-81b3-1ab377cc22fe">two</ix:nonFraction> primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen&#8217;s initial responsive pleading, a motion to dismiss, was filed on August 1, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, Amgen moved to stay the case pending the ultimate decision on the merits of the ongoing patent litigation between Amgen and Regeneron in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Sanofi, et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2023, the Delaware District Court heard oral argument on the motion to stay and the motion to dismiss.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4aa9e6706ea048339303c968b2fd0d80"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Litigation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. &amp; Subsidiaries v. Commissioner of Internal Revenue</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6, Income taxes, for discussion of the IRS tax dispute and the Company&#8217;s petitions in the U.S. Tax Court.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ChemoCentryx, Inc. Securities Matters</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5 and June 8 of 2021, ChemoCentryx and its Chief Executive Officer were named as defendants in <ix:nonFraction unitRef="lawsuit" contextRef="ib9fd3c9e12f348fda85ef0818a380f80_D20210505-20210608" decimals="INF" name="amgn:LossContingencyNumberOfClassActionSuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk2MA_3eab8ab9-4203-4445-b4b4-861db911c3d7">two</ix:nonFraction> putative shareholder class actions filed in the U.S. District Court for the Northern District of California (Northern District Court of California). These cases were consolidated into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Homyk v. ChemoCentryx, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which the plaintiffs allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act in connection with statements regarding the New Drug Application for TAVNEOS and the underlying Phase 3 clinical trial, seeking an award of damages, interest and attorneys&#8217; fees. On March 28, 2022, the plaintiffs filed their consolidated amended complaint, and on May 19, 2022, ChemoCentryx moved to dismiss these claims.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2022, the Board of Directors and certain of ChemoCentryx&#8217;s officers were named as defendants in a putative shareholder derivative action filed in the Northern District Court of California, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Napoli v. Schall,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and on March 11, 2022, the Northern District Court of California stayed the action until judgment is entered in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Homyk v. ChemoCentryx, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action. On December 5, 2022 the plaintiffs in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Napoli</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> filed a Notice of Voluntary Dismissal, and on December 22, 2022, the Court ordered the dismissal of the case.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments &#8211; U.S. repatriation tax</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Tax Act, we elected to pay in <ix:nonFraction unitRef="installment" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="INF" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzQ0OTgy_da54da7f-d2ba-425f-92d5-7bfa630eca26">eight</ix:nonFraction> annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. <ix:nonNumeric contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" name="amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzQ1MjI1_75e97d8a-6633-4b01-9869-3e38838af587" continuedAt="i7bc69aeba6ea4f4bb68fd5de001bf7f3" escape="true">The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2022 (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><ix:continuation id="i7bc69aeba6ea4f4bb68fd5de001bf7f3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90YWJsZTpjODUyZDhiZDYxNWU0MDZkODIzMjMzNDYyMGQ0NjZlZi90YWJsZXJhbmdlOmM4NTJkOGJkNjE1ZTQwNmQ4MjMyMzM0NjIwZDQ2NmVmXzEtMS0xLTEtMTg4OTc0_842dba9b-22f4-4c78-b6f7-66a0d0165318">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90YWJsZTpjODUyZDhiZDYxNWU0MDZkODIzMjMzNDYyMGQ0NjZlZi90YWJsZXJhbmdlOmM4NTJkOGJkNjE1ZTQwNmQ4MjMyMzM0NjIwZDQ2NmVmXzItMS0xLTEtMTg4OTc0_134b8811-cb82-4b8e-ba0d-d5d13e633377">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90YWJsZTpjODUyZDhiZDYxNWU0MDZkODIzMjMzNDYyMGQ0NjZlZi90YWJsZXJhbmdlOmM4NTJkOGJkNjE1ZTQwNmQ4MjMyMzM0NjIwZDQ2NmVmXzMtMS0xLTEtMTg4OTc0_1886529c-647d-4563-b94b-16dfb6bb3511">1,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining U.S. repatriation tax commitments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="amgn:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90YWJsZTpjODUyZDhiZDYxNWU0MDZkODIzMjMzNDYyMGQ0NjZlZi90YWJsZXJhbmdlOmM4NTJkOGJkNjE1ZTQwNmQ4MjMyMzM0NjIwZDQ2NmVmXzUtMS0xLTEtMTg4OTc0_7e0d076f-7bc5-4832-be00-fcffd437b6d5">4,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</span></div></div></div><div id="if8055099d1994bb494875d41c341f00d_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90ZXh0cmVnaW9uOmEyMzIxYjkzODVhNDQ3NTZhOTBhYjc1MDliYzllNjhjXzExMQ_d0757b4b-09e1-46eb-946b-5c0060f862f4" escape="true"><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2022, 2021 and 2020 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at beginning<br/>of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions<br/>charged&#160;to<br/>costs and<br/>expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at end<br/>of period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtMi0xLTEtMTg4OTc0_abeb6f61-5036-4a98-80e6-58828f8bda56">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtNC0xLTEtMTg4OTc0_1a014c76-7936-497b-96f6-152e2836a537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtNi0xLTEtMTg4OTc0_5c40fe9a-4d37-4c57-a6e5-911921231b7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtOC0xLTEtMTg4OTc0_c23725b4-e3fe-463a-8caf-c6fcda0b761a">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtMTAtMS0xLTE4ODk3NA_251294dc-e28a-4a59-80bb-e4344c2b040f">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItMi0xLTEtMTg4OTc0_666023ca-dbfd-4d6c-be22-b2bb74738765">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItNC0xLTEtMTg4OTc0_cefecfe9-7a12-4b3d-890c-86bdec0ea29f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItNi0xLTEtMTg4OTc0_c20b904a-95f7-4c04-b8b8-f4ddc8fdd92b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItOC0xLTEtMTg4OTc0_13a533be-ef24-428c-b781-a3e4b969e40e">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2798874e9ac48be975005deb320dde9_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItMTAtMS0xLTE4ODk3NA_e47633e6-ddc1-497f-a557-787a5ed9254c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtMi0xLTEtMTg4OTc0_e60d19a2-d988-4bda-a782-509355f4e61c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtNC0xLTEtMTg4OTc0_599000b6-88b7-4fa4-892f-dfe910861787">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtNi0xLTEtMTg4OTc0_aa3d5fc4-ca0f-42b1-8963-5cbc17ec10a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtOC0xLTEtMTg4OTc0_149dd638-65c1-4f09-9e43-a76ed73b4cdf">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtMTAtMS0xLTE4ODk3NA_241e5e04-f302-4ad3-b971-cd5c67c4d357">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.34
<SEQUENCE>2
<FILENAME>exhibit434-descriptionofse.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id011ad06a4734d89bbb20c237766376f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 4.34 </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF AMGEN INC.&#8217;S SECURITIES<br>REGISTERED PURSUANT TO SECTION 12 OF THE<br>SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of February 6, 2023, Amgen Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)&#58; (1) our common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;)&#59; and (2) our 2.000% Senior Notes due 2026 (the &#8220;Notes&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF COMMON STOCK</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following description of our capital stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our restated certificate of incorporation, as amended (&#8220;certificate of incorporation&#8221;) and our amended and restated bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K (&#8220;Annual Report&#8221;). The terms &#8220;Amgen&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer solely to Amgen Inc. and not its subsidiaries.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our authorized capital stock includes 2,750,000,000 shares of Common Stock.  Each holder of our Common Stock is entitled to one vote per share on all matters to be voted upon by our stockholders. Upon any liquidation, dissolution or winding up of our business, the holders of our Common Stock are entitled to share equally in all assets available for distribution after payment of all liabilities, subject to the liquidation preference of shares of preferred stock, if any, then outstanding. Our Common Stock has no preemptive or conversion rights. All outstanding shares of common stock are fully paid and non-assessable. Our outstanding shares of common stock are quoted on the Nasdaq Global Select Market under the symbol &#8220;AMGN.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividends</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to preferences that may be applicable to any preferred stock (if any such stock be issued and outstanding), the holders of Common Stock are entitled ratably to receive dividends, if any, declared by our board of directors out of funds legally available for the payment of dividends. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Anti-Takeover Effects of Delaware Law</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">prior to such time, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Section&#160;203, a &#8220;business combination&#8221; includes&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation involving the interested stockholder&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any transaction which results in the issuance or transfer by the corporation or by any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder, subject to limited exceptions&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the corporation which has the effect, directly or indirectly, of increasing the proportionate share of the stock of any class or series, or securities convertible into the stock of any class or series, of the corporation or of any such subsidiary which is owned by the interested stockholder&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation or any direct or indirect majority-owned subsidiary of the corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In general, Section&#160;203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transfer Agent</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The transfer agent and registrar for our Common Stock is the American Stock Transfer&#160;&#38; Trust Company.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF THE NOTES</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following description of our Notes is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the indenture, dated as of May&#160;22, 2014 (the &#8220;Indenture&#8221;), between us and The Bank of New York Mellon Trust Company, N.A., as trustee (the &#8220;Trustee&#8221;), which are incorporated by reference as exhibits to the Annual Report of which this Exhibit 4.34 is a part. The Notes are traded on The Nasdaq Stock Market LLC under the trading symbol of &#8220;AMGN26.&#8221; We encourage you to read the above referenced Indenture for additional information. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We issued &#8364;750,000,000 in aggregate principal amount of 2.000% Senior Notes, maturing February 25, 2026 and bearing interest at a rate of 2.000% per annum, payable annually on February&#160;25 of each year. As of February 6, 2023, &#8364;750,000,000 aggregate principal amount of the Notes was outstanding.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;We may, without notice to or the consent of the holders or beneficial owners of the Notes of any series, create and issue additional Notes and&#47;or notes having the same ranking, interest rate, maturity and other terms as the Notes of that series. Any additional debt securities having such similar terms, together with that series of Notes, could be considered part of the same series of Notes under the Indenture&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that, in the case of any notes represented by global notes, for so long as may be required by the United States Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the procedures of the common depositary, the Euroclear System (&#8220;Euroclear&#8221;) or Clearstream Banking, S.A. (&#8220;Clearstream&#8221;) (or a successor or clearing system), such additional Notes will be represented by one or more separate global notes in accordance with the terms of the Indenture and subject to applicable transfer or other restrictions. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes are redeemable prior to maturity as described below under the headings &#8220;&#8212;Optional Redemption&#8221; and &#8220;&#8212;Redemption Upon Changes in Withholding Taxes.&#8221; The Notes do not have the benefit of any sinking funds. The Notes of each series are issued only in registered form without coupons attached in minimum denominations of &#8364;100,000 and any integral multiple of &#8364;1,000 in excess thereof. Each series of Notes are represented by one or more global securities deposited with, or on behalf of, a common depositary for Euroclear and Clearstream (the &#8220;global notes&#8221;).  </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Definitions </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As used herein, the following terms have the meanings set forth below. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Attributable Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means in connection with a sale and lease-back transaction the lesser of&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the fair market value of the assets subject to such transaction&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the present value (discounted at a rate per annum equal to the average interest borne by all outstanding debt securities issued under the Indenture (which may include debt securities in addition to the Notes) determined on a weighted average basis and compounded semi-annually) of the obligations of the lessee for rental payments during the term of the related lease.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any day on which commercial banks and foreign exchange markets are open for business in New York and London and which is a day on which the Trans-European Automated Real-Time Gross Settlement Express Transfer System (TARGET2) is operating. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Calculation Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an independent financial institution appointed by Amgen, which may include the paying agent, any of the managers or their respective affiliates who agree to serve in such capacity. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Capital Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any Indebtedness represented by a lease obligation of a Person incurred with respect to real property or equipment acquired or leased by such Person and used in its business that is required to be recorded as a capital lease in accordance with GAAP. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Consolidated Net Worth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination, the Stockholders&#8217; Equity of us and our Consolidated Subsidiaries on that date. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Consolidated Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination and with respect to any Person, any Subsidiary of that Person whose financial data is, in accordance with GAAP, reflected in that Person&#8217;s consolidated financial statements. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Credit Facilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, one or more debt facilities (including, without limitation, the revolving credit agreement and the term loan credit agreement, as applicable) or commercial paper facilities, in each case, with banks or other institutional lenders providing for revolving credit loans, term loans, receivables financing (including through the sale of receivables to such lenders or to special purpose entities formed to borrow from such lenders against such receivables) or letters of credit, in each case, as amended, restated, modified, renewed, refunded, replaced (whether upon or after termination or otherwise) or refinanced (including by means of sales of debt securities to institutional investors) in whole or in part from time to time. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exempted Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the sum of the following as of the date of determination&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">our Indebtedness incurred after the first issue date of the Notes and secured by Liens not permitted by the first sentence under &#8220;&#8212;Limitation on Liens&#8221; below&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">our and our Subsidiaries&#8217; Attributable Liens in respect of sale and lease-back transactions entered into after the first issue date of the Notes pursuant to the second paragraph of &#8220;&#8212;Limitation on Sale and Lease-Back Transactions&#8221; below.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means accounting principles generally accepted in the United States set forth in the Accounting Standards Codification of the Financial Accounting Standards Board or in such other documents by such other entity as have been approved by a significant segment of the accounting profession, which are in effect as of the date of determination. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Governmental Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any foreign, federal, state, county or municipal government, or political subdivision thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any governmental or quasi-governmental agency, authority, board, bureau, commission, department, instrumentality or public body&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any court or administrative tribunal&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with respect to any Person, any arbitration tribunal or other nongovernmental authority to whose jurisdiction that Person has consented.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Hedging Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any specified Person, the obligations of such Person under&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">interest rate swap agreements (whether from fixed to floating or from floating to fixed), interest rate cap agreements and interest rate collar agreements&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other agreements or arrangements designed to manage interest rates or interest rate risk&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other agreements or arrangements designed to protect such Person against fluctuations in currency exchange rates or commodity prices.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of any Person means, without duplication, any indebtedness, whether or not contingent, in respect of borrowed money or evidenced by bonds, notes, debentures or similar instruments or letters of credit (or reimbursement agreements with respect thereto) or representing the balance deferred and unpaid of the purchase price of any Property (including pursuant to Capital Leases), except any such balance that constitutes an accrued expense or trade payable, if and to the extent any of the foregoing indebtedness would appear as a liability upon a balance sheet of such Person prepared on a consolidated basis in accordance with GAAP (but does not include </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">contingent liabilities which appear only in a footnote to a balance sheet), and shall also include, to the extent not otherwise included, the guaranty of items which would be included within this definition. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, collectively, all foreign, federal, state and local statutes, treaties, rules, regulations, ordinances, codes and administrative or controlling precedents of any Governmental Agency. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any lien, security interest, charge or encumbrance of any kind (including any conditional sale or other title retention agreement, any lease in the nature thereof, and any agreement to give any security interest). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Make-Whole Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the excess of (1)&#160;the net present value, on the redemption date, of the principal being redeemed or paid and the amount of interest (exclusive of interest accrued to the date of redemption) that would have been payable if such redemption had not been made, over (2)&#160;the aggregate principal amount of the Notes being redeemed or paid. Net present value shall be determined by discounting, on a semi-annual basis, such principal and interest at the Reinvestment Rate (as defined below and as determined on the third Business Day preceding the date such notice of redemption is given) from the respective dates on which such principal and interest would have been payable if such redemption had not been made. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens securing Indebtedness under Credit Facilities&#59;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens on accounts receivable, merchandise inventory, equipment, and patents, trademarks, trade names and other intangibles, securing our Indebtedness&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens on any of our assets, any of our Subsidiaries&#8217; assets, or the assets of any joint venture to which we or any of our Subsidiaries is a party, created solely to secure obligations incurred to finance the refurbishment, improvement or construction of such asset, which obligations are incurred no later than 24 months after completion of such refurbishment, improvement or construction, and all renewals, extensions, refinancings, replacements or refundings of such obligations&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Liens given to secure the payment of the purchase price incurred in connection with the acquisition (including acquisition through merger or consolidation) of Property (including shares of stock), including Capital Lease transactions in connection with any such acquisition, and (b)&#160;Liens existing on Property at the time of acquisition thereof or at the time of acquisition by us or one of our Subsidiaries of any Person then owning such Property whether or not such existing Liens were given to secure the payment of the purchase price of the Property to which they attach&#59; provided that, with respect to clause (a), the Liens shall be given within 24 months after such acquisition and shall attach solely to the Property acquired or purchased and any improvements then or thereafter placed thereon&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens upon specific items of inventory or other goods and proceeds of any Person securing such Person&#8217;s obligations in respect of bankers&#8217; acceptances issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens securing reimbursement obligations with respect to letters of credit that encumber documents and other Property relating to such letters of credit and the products and proceeds thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens on key-man life insurance policies granted to secure our Indebtedness against the cash surrender value thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens encumbering customary initial deposits and margin deposits and other Liens in the ordinary course of business, in each case securing Hedging Obligations and forward contract, option, futures contracts, futures options or similar agreements or arrangements designed to protect us or any of our Subsidiaries from fluctuations in interest rates, currencies or the price of commodities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into by us or any of our Subsidiaries in the ordinary course of business&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pre-existing Liens on assets acquired by us or any of our Subsidiaries after the first issue date of the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens in our favor or the favor of any of our Subsidiaries&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">inchoate Liens incident to construction or maintenance of real property, or Liens incident to construction or maintenance of real property, now or hereafter filed of record for sums not yet delinquent or being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by GAAP shall have been made therefor&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">statutory Liens arising in the ordinary course of business with respect to obligations which are not delinquent or are being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by GAAP shall have been made therefor&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens consisting of pledges or deposits to secure obligations under workers&#8217; compensation laws or similar legislation, including Liens of judgments thereunder which are not currently dischargeable&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens consisting of pledges or deposits of Property to secure performance in connection with operating leases made in the ordinary course of business to which we or any of our Subsidiaries is a party as lessee, provided the aggregate value of all such pledges and deposits in connection with any such lease does not at any time exceed 16&#160;2&#8260;3% of the annual fixed rentals payable under such lease&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens consisting of deposits of Property to secure our statutory obligations or statutory obligations of any of our Subsidiaries in the ordinary course of its business&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens consisting of deposits of Property to secure (or in lieu of) surety, appeal or customs bonds in proceedings to which we or any of our Subsidiaries is a party in the ordinary course of its business, but not in excess of $75,000,000&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">purchase money Liens or purchase money security interests upon or in any Property acquired or held by us or any of our Subsidiaries in the ordinary course of business to secure the purchase price of such Property or to secure indebtedness incurred solely for the purpose of financing the acquisition of such Property&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens on an asset created in connection with the acquisition, construction or development of additions, extensions or improvements to such asset which shall be financed by obligations described in Sections 142, 144(a) or 144(c) of the Code, or by obligations entitled to substantially similar tax benefits under other legislation or regulations in effect from time to time&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liens on Property subject to escrow or similar arrangements established in connection with litigation settlements.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated organization or government or any agency or political subdivision thereof. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any property or asset, whether real, personal or mixed, or tangible or intangible. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reference Bund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Federal Government Bond of Bundesrepublik Deutschland due&#160;February 15, 2026, with ISIN 0001102390. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reference Dealers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means each of the four banks selected by a Calculation Agent which are primary European government security dealers, and their respective successors, or market makers in pricing corporate bond issues. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reinvestment Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means 0.300% plus the average of the four quotations given by the Reference Dealers of the mid-market annual yield to maturity of the Reference Bund at 11&#58; 00 a.m. (Central European time (&#8220;CET&#8221;)) on the fourth Business Day preceding such redemption date and if the Reference Bund is no longer outstanding, a Similar Security will be chosen by the Calculation Agent at 11&#58; 00 a.m. (CET) on the third Business Day in London preceding such redemption date, quoted in writing by the Calculation Agent to us. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Similar Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a reference bond or reference bonds issued by the German Federal Government having an actual or interpolated maturity comparable with the remaining term of the Notes that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Notes. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Stockholders&#8217; Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination, stockholders&#8217; equity as of that date determined in accordance with GAAP&#59; provided that there shall be excluded from Stockholders&#8217; Equity any amount attributable to capital stock that is, directly or indirectly, required to be redeemed or repurchased by the issuer thereof at a specified date or upon the occurrence of specified events or at the election of the holder thereof. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of any specified person means any corporation, association or other business entity of which more than 50% of the total voting power of shares of capital stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of that person or a combination thereof. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paying Agent and Registrar </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Bank of New York Mellon, London Branch, is the principal paying agent for the Notes (the &#8220;principal paying agent&#8221;). The Bank of New York Mellon Trust Company, N.A., is the security registrar for the Notes. Upon notice to the Trustee, we may change any paying agent or security registrar, and we or any of our subsidiaries may act as paying agent or registrar. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes accrue interest at a rate of 2.000% per annum. The Notes accrue interest on their stated principal amounts from the most recent interest payment date on which interest has been paid or duly provided for. Accrued and unpaid interest on the Notes are payable annually in arrears on February&#160;25 of each year. In each case, interest is paid to the holder in whose name a note is registered at the close of business on the day that is one Business Day prior to the relevant interest payment date. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on the Notes is computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the Notes, to but excluding the next scheduled interest payment date. This payment convention is referred to as Actual&#47;Actual (ICMA) as defined in the rulebook of the International Capital Market Association. If any date on which interest, principal or premium is payable on the Notes is not a Business Day, then payment of such amounts payable on such date will be made on the next succeeding day that is a Business Day (and, except as provided under &#8220;&#8212;Payment of Additional Amounts,&#8221; without any interest or other payment in respect of any such delay) with the same force and effect as if made on such interest payment date or maturity date, as the case may be. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any amounts payable on any Notes that are not punctually paid on any payment date will cease to be payable to the person in whose name such Notes are registered on the relevant record date, and such defaulted payment will instead be payable to the person in whose name such Notes are registered on the special record date or other specified date determined in accordance with the Indenture. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ranking </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes are senior unsecured obligations of Amgen. The Notes rank&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equal in right of payment to all of our other existing and future senior unsecured indebtedness&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior in right of payment to all of our existing and future subordinated indebtedness&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">effectively subordinated in right of payment to all of our subsidiaries&#8217; obligations (including secured and unsecured obligations) and subordinated in right of payment to our secured obligations, to the extent of the assets securing such obligations.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes and the Indenture do not limit our ability to incur additional indebtedness. We may incur substantial additional amounts of indebtedness in the future. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Optional Redemption </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes may be redeemed prior to maturity at our option, at any time in whole or from time to time in part. If the Notes are redeemed before November&#160;25, 2025 (three months prior to the maturity date of the Notes), the redemption price will equal the sum of (1)&#160;100% of the principal amount being redeemed, plus accrued and unpaid interest to, but not including, the redemption date, and (2)&#160;the Make-Whole Amount, if any. If the Notes are redeemed on or after November&#160;25, 2025 (three months prior to the maturity date of the Notes), the redemption price will equal 100% of the principal amount being redeemed, plus accrued and unpaid interest to, but not including, the redemption date. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we give notice as provided in the Indenture and funds for the redemption of any Notes called for redemption sufficient to pay the redemption price have been deposited with the principal paying agent on or before 10&#58;00 a.m., London time, on the redemption date, such Notes will cease to bear interest on the date fixed for redemption. Thereafter, the only right of the holders of such Notes will be to receive payment of the redemption price. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon surrender of a note that is redeemed in part, we shall execute and the Trustee shall authenticate for the holder a new note of the same series and the same maturity equal in principal amount to the unredeemed portion of the note surrendered. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes are redeemable prior to maturity as described below under the headings &#8220;&#8212;Optional Redemption&#8221; and &#8220;&#8212;Redemption Upon Changes in Withholding Taxes.&#8221; The Notes do not have the benefit of any sinking funds. The Notes of each series are issued only in registered form without coupons attached in minimum denominations of &#8364;100,000 and any integral multiple of &#8364;1,000 in excess thereof. Each series of Notes are represented by one or more global securities deposited with, or on behalf of, a common depositary for Euroclear and Clearstream (the &#8220;global notes&#8221;). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on the global notes are made through the principal paying agent (as defined herein under the heading &#8220;&#8212;Paying Agent and Registrar&#8221;). Payments on the Notes are made at the specified office or agency of the principal paying agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that all such payments with respect to Notes represented by one or more global notes registered in the name of or held by a nominee of Euroclear or Clearstream, as applicable, will be by wire transfer of immediately available funds to the account specified by the holder or holders thereof. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, at our option, if certificated notes are issued, we may make payments by check mailed to the holder&#8217;s registered address or by wire transfer to the account shown on the register for the certificated notes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If certificated notes are issued, they will be issued only in minimum denominations of &#8364;100,000 principal amount and integral multiples of &#8364;1,000 in excess thereof upon receipt by the applicable registrar of instructions relating thereto and any certificates and other documentation required under the Indenture. It is expected that such instructions will be based upon directions received by Euroclear or Clearstream, as applicable, from the participant which owns the relevant book-entry interests. Certificated notes issued in exchange for book-entry interests will, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">except as provided in the Indenture, be subject to, and will have a legend with respect to the restrictions on transfer summarized below. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the restrictions on transfer referred to above, Notes issued as certificated notes may be transferred or exchanged, in whole or in part, in minimum denominations of &#8364;100,000 principal amount and integral multiples of &#8364;1,000 in excess thereof to persons who take delivery thereof in the form of certificated notes. In connection with any such transfer or exchange, the Indenture requires the transferring or exchanging holder to, among other things, furnish appropriate endorsements and transfer documents, to furnish information regarding the account of the transferee at Euroclear or Clearstream, where appropriate, to furnish certain certificates and opinions, and to pay any tax or other governmental charge in connection with such transfer or exchange. Any such transfer or exchange will otherwise be made without charge to the holder. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, we are not required to register the transfer or exchange of any Notes&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for a period of 15 days prior to any date fixed for the redemption of the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for a period of 15 days immediately prior to the date fixed for selection of Notes to be redeemed in part&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for a period of 15 days prior to the record date with respect to any interest payment date&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">which the holder has tendered (and not withdrawn) for repurchase in connection with a change of control offer.</font></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption Upon Changes in Withholding Taxes </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If (a)&#160;as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated thereunder) of the United States (or any political subdivision or taxing authority thereof or therein having power to tax) (a &#8220;Relevant Taxing Jurisdiction&#8221;), or any change in, or amendment to, the official position regarding the application or interpretation of such laws, regulations or rulings (including by virtue of a holding, judgment or order by a court of competent jurisdiction or a change in published administrative practice), which change or amendment is announced on or after the date of the applicable prospectus supplement, we become or will become obligated to pay additional amounts as described herein under the heading &#8220;&#8212;Payment of Additional Amounts&#8221; or (b)&#160;any act is taken by a Relevant Taxing Jurisdiction on or after the date of the applicable prospectus supplement, whether or not such act is taken with respect to us or any affiliate, that results in a substantial probability that we will or may be required to pay such additional amounts, then we may, at our option, redeem the Notes of any affected series, as a whole but not in part, upon not less than 15 days&#8217; nor more than 60 days&#8217; published notice in accordance with the applicable notice requirement, at 100% of their principal amount, together with interest accrued thereon to the date fixed for redemption&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that we determine, in our business judgment, that the obligation to pay such additional amounts cannot be avoided by the use of reasonable measures available to us (which does not include substitution of the obligor under the Notes). No redemption pursuant to (a)&#160;or (b)&#160;above may be made unless we have received an opinion of independent counsel to the effect that as a result of such change or amendment we will, or that an act taken by a Relevant Taxing Jurisdiction has resulted in a substantial probability that we will, or may, be required to pay the additional amounts described herein under the heading &#8220;&#8212;Payment of Additional Amounts,&#8221; and we shall have delivered to the Trustee a certificate, signed by a duly authorized officer, stating that based on such opinion we are entitled to redeem the Notes pursuant to their terms. </font></div><div style="margin-top:18pt;text-align:justify"><font><br></font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notice of Redemption </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will publish a notice of any redemption of any affected series of Notes described above in accordance with the applicable notice provisions. If fewer than all of the Notes are to be redeemed at any time, the principal paying agent will select the Notes to be redeemed in accordance with the rules of the principal securities exchange, if any, on which the Notes are listed at such time or, if the not Notes are not listed on a securities exchange, in accordance with the rules of Euroclear or Clearstream, or absent any such rules, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, by lot&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that no such partial redemption shall reduce the portion of the principal amount of a note not redeemed to less than &#8364;100,000. The principal paying agent shall not be liable for any selections made by it in accordance with this paragraph. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will give notice of any optional redemption to the registered holders of Notes at least 15 but not more than 60 days before a redemption date. The notice shall identify the Notes to be redeemed and shall state&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the redemption date&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the redemption price&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the name and address of the paying agent&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if any Notes are being redeemed in part, the portion of the principal amount of such notes to be redeemed and that, after the redemption date and upon surrender of such Notes, a new note or notes in principal amount equal to the unredeemed portion of the original note shall be issued in the name of the holder of the Notes thereof upon cancellation of the original note&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that the notes called for redemption must be surrendered to the paying agent to collect the redemption price&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that interest on the Notes called for redemption ceases to accrue on and after the redemption date unless we default in the deposit of the redemption price&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the CUSIP and&#47;or ISIN number of the Notes.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At our request, the Trustee shall give the notice of redemption in our name and at our expense. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment of Additional Amounts </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All payments of principal and interest on the Notes will be made free and clear of and without withholding or deduction for or on account of any present or future tax, assessment or other governmental charge (collectively, &#8220;Taxes&#8221;) imposed by any Relevant Taxing Jurisdiction, unless the withholding of such Taxes is required by law or the official interpretation or administration thereof. We will, subject to the exceptions and limitations set forth below, pay such additional amounts as are necessary in order that the net payment of the principal of and interest on the applicable series of Notes to a holder who is not a U.S. person for U.S. federal income tax purposes, after deduction for any present or future Taxes of any Relevant Taxing Jurisdiction, imposed by withholding with respect to the payment, will not be less than the amount provided in such Notes to be then due and payable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#59; provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that the foregoing obligation to pay additional amounts shall not apply&#58; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld solely by reason of the holder or beneficial owner, or a fiduciary, settlor, beneficiary, member or shareholder of the holder if the holder is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust administered by a fiduciary holder, being considered as&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) &#160;&#160;&#160;&#160;being or having been present or engaged in a trade or business in the United States or having or having had a permanent establishment in the United States&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) &#160;&#160;&#160;&#160;having a current or former relationship with the United States, including a relationship as a citizen or resident thereof&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) &#160;&#160;&#160;&#160;being or having been a foreign or domestic personal holding company, a passive foreign investment company or a controlled foreign corporation with respect to the United States or a corporation that has accumulated earnings to avoid U.S. federal income tax&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) &#160;&#160;&#160;&#160;being or having been a &#8220;10-percent shareholder&#8221; of the obligor under the Notes within the meaning of section 871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or any successor provision&#59; or </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) &#160;&#160;&#160;&#160;being or having been a bank receiving interest described in section 881(c)(3)(A) of the Code or any successor provision&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) &#160;&#160;&#160;&#160;to any holder that is not the sole beneficial owner of the note, or a portion thereof, or that is a fiduciary or partnership, but only to the extent that a beneficiary or settlor with respect to the fiduciary, a beneficial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">owner or member of the partnership would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld solely by reason of the failure to (a)&#160;comply with certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with a Relevant Taxing Jurisdiction of the holder or beneficial owner of such note, if compliance is required by statute or by regulation of the Relevant Taxing Jurisdiction as a precondition to relief or exemption from such Taxes (including the submission of an applicable U.S. Internal Revenue Service (&#8220;IRS&#8221;) Form W-8 (with any required attachments)) or (b)&#160;comply with any informational gathering and reporting requirements or to take any similar action (including entering into any agreement with the IRS), in each case, that are required to obtain the maximum available exemption from withholding by a Relevant Taxing Jurisdiction that is available to payments received by or on behalf of the holder&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4) &#160;&#160;&#160;&#160;to any Taxes that are imposed otherwise than by withholding from the payment&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later&#59; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6) &#160;&#160;&#160;&#160;to any estate, inheritance, gift, sales, excise, transfer, wealth or personal property tax or a similar tax, assessment or governmental charge&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7) &#160;&#160;&#160;&#160;to any Taxes required to be withheld by any paying agent from any payment of principal of or interest on any note, if such payment can be made without such withholding by any other paying agent&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8) &#160;&#160;&#160;&#160;to any Taxes that are imposed or levied by reason of the presentation (where presentation is required in order to receive payment) of such notes for payment on a date more than 30 days after the date on which such payment became due and payable, except to the extent that the holder or beneficial owner thereof would have been entitled to additional amounts had the notes been presented for payment on any date during such 30 day period&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld pursuant to Sections 1471 through 1474 of the Code, as of the issue date (or any amended or successor version of such sections), any U.S. Treasury Regulations promulgated thereunder, any official interpretations thereof, any similar law or regulation adopted pursuant to an intergovernmental agreement between a non-U.S. jurisdiction and the United States with respect to the foregoing or any agreements entered into pursuant to Section&#160;1471(b)(1) of the Code&#59; or </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10) &#160;&#160;&#160;&#160;in the case of any combination of any items (1)&#160;through (9). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The notes are subject in all cases to any tax, fiscal or other law or regulation or administrative or judicial interpretation applicable thereto. Except as specifically provided under this heading &#8220;&#8212;Payment of Additional Amounts,&#8221; we are not required to make any payment with respect to any tax, assessment or governmental charge imposed by any government or a political subdivision or taxing authority thereof or therein. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change of Control Offer </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a change of control triggering event occurs, unless we have exercised our option to redeem the notes as described above, we will be required to make an offer (the &#8220;change of control offer&#8221;) to each holder of the notes to repurchase all or any part (equal to &#8364;100,000 or integral multiples of &#8364;1,000 in excess thereof) of that holder&#8217;s notes on the terms set forth in such notes. In the change of control offer, we will be required to offer payment in cash equal to 101&#160;% of the aggregate principal amount of notes repurchased, plus accrued and unpaid interest, if any, on the notes repurchased to the date of repurchase (the &#8220;change of control payment&#8221;). Within 30 days following any change of control triggering event, a notice will be provided to holders of the notes describing the transaction that constitutes the change of control triggering event and offering to repurchase the notes on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is provided (the &#8220;change of control payment date&#8221;)&#59; provided, however, that in no event will the change of control payment date occur prior to the date 90 days following the first issue date of the notes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On the change of control payment date, we will, to the extent lawful&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accept for payment all notes or portions of notes properly tendered pursuant to the change of control offer&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by 10&#58;00 a.m., London time, deposit with the principal paying agent an amount equal to the change of control payment in respect of all notes or portions of notes properly tendered&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">deliver or cause to be delivered to the Trustee the notes properly accepted together with an officer&#8217;s certificate stating the aggregate principal amount of notes or portions of notes being repurchased.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not repurchase any notes if there has occurred and is continuing on the change of control payment date an event of default under the Indenture, other than a default in the payment of the change of control payment upon a change of control triggering event. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will comply with the requirements of Rule 14e-1 under the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the notes as a result of a change of control triggering event. To the extent that the provisions of any such securities laws or regulations conflict with the change of control offer provisions of the notes, we will comply with those securities laws and regulations and will not be deemed to have breached our obligations under the change of control offer provisions of the notes by virtue of any such conflict. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of the change of control offer provisions of the notes, the following terms will be applicable&#58; </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Beneficial owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall be determined in accordance with Rules 13d-3 and 13d-5 under the Exchange Act or any successor provisions, except that a person will be deemed to have beneficial ownership of all shares that person has the right to acquire irrespective of whether that right is exercisable immediately or only after the passage of time. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change of control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following&#58; (1)&#160;the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any person or group (other than our company or one of our subsidiaries) becomes the beneficial owner, directly or indirectly, of more than 50% of our voting stock or other voting stock into which our voting stock is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares&#59; provided, however, that a person shall not be deemed beneficial owner of, or to own beneficially, (A)&#160;any securities tendered pursuant to a tender or exchange offer made by or on behalf of such person or any of such person&#8217;s affiliates until such tendered securities are accepted for purchase or exchange thereunder, or (B)&#160;any securities if such beneficial ownership (i)&#160;arises solely as a result of a revocable proxy delivered in response to a proxy or consent solicitation made pursuant to the applicable rules and regulations under the Exchange Act, and (ii)&#160;is not also then reportable on Schedule 13D (or any successor schedule) under the Exchange Act&#59; (2)&#160;the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of our assets and the assets of our subsidiaries, taken as a whole, to one or more persons or groups (other than our company or one of our subsidiaries), provided that none of the circumstances in this clause (2)&#160;will be a change of control if the persons that beneficially own our voting stock immediately prior to the transaction own, directly or indirectly, shares with a majority of the total voting power of all outstanding voting securities of the surviving or transferee person that are entitled to vote generally in the election of that person&#8217;s board of directors, managers or trustees immediately after the transaction&#59; (3)&#160;we consolidate with, or merge with or into any person, or any person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">consolidates with, or merges with or into, us, in any such event pursuant to a transaction in which any of our outstanding voting stock or the voting stock of such other person is converted into or exchanged for cash, securities or other property, other than such transaction where the shares of our voting stock outstanding immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the voting stock of the surviving person or any direct or indirect parent company of the surviving person immediately after giving effect to such transaction&#59; or (4)&#160;the adoption of a plan relating to our liquidation or dissolution. Notwithstanding the foregoing, a transaction will not be deemed to involve a change of control under clause (1)&#160;above if (i)&#160;we become a direct or indirect wholly-owned subsidiary of a holding company and (ii)&#160;(A)&#160;the direct or indirect holders of the voting stock of such holding company immediately following that transaction are substantially the same as the holders of our voting stock immediately prior to that transaction or (B)&#160;immediately following that transaction no person (other than a holding company satisfying the requirements of this sentence) is the beneficial owner, directly or indirectly, of more than 50% of the voting stock of such holding company. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change of control triggering event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of both a change of control and a rating event. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Fitch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Fitch, Inc., and its successors. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning given by Section&#160;13(d) and 14(d) of the Exchange Act or any successor provisions and includes any group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the Exchange Act or any successor provision. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Investment grade rating</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a rating equal to or higher than Baa3 (or the equivalent) by Moody&#8217;s, BBB&#8212;(or the equivalent) by S&#38;P and BBB&#8212;(or the equivalent) by Fitch, and the equivalent investment grade credit rating from any additional rating agency or rating agencies selected by us. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Moody&#8217;s Investors Service, Inc., and its successors. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning given by Section&#160;13(d) and 14(d) of the Exchange Act or any successor provisions. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rating agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (1)&#160;each of Fitch, Moody&#8217;s and S&#38;P&#59; and (2)&#160;if any of Fitch, Moody&#8217;s or S&#38;P ceases to rate the notes or fails to make a rating of the notes publicly available for reasons outside of our control, a &#8220;nationally recognized statistical rating organization&#8221; within the meaning of Section&#160;3(a)(62) of the Exchange Act selected by us (as certified by a resolution of our Board of Directors) as a replacement agency for Fitch, Moody&#8217;s or S&#38;P, or all of them, as the case may be. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rating event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the rating on the applicable series of notes is lowered by at least two of the three rating agencies and the notes are rated below an investment grade rating by at least two of the three rating agencies on any day during the period commencing 60 days prior to the first public notice of the occurrence of a change of control or our intention to effect a change of control and ending 60 days following consummation of such change of control (which period will be extended so long as the rating of the applicable series of notes is under publicly announced consideration for a possible downgrade by any of the rating agencies). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Standard&#160;&#38; Poor&#8217;s Rating Services, a division of The McGraw-Hill Companies, Inc., and its successors. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Voting stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; as applied to stock of any person, means shares, interests, participations or other equivalents in the equity interest (however designated) in such person having ordinary voting power for the election of a majority of the directors (or the equivalent) of such person, other than shares, interests, participations or other equivalents having such power only by reason of the occurrence of a contingency. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Covenants </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Limitation on Liens </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not, nor will we permit any of our Subsidiaries to, create or incur any Lien on any of our or their respective Properties, whether now owned or hereafter acquired, or upon any income or profits therefrom, in order to secure any of our Indebtedness, without effectively providing that each series of notes shall be equally and ratably secured until such time as such Indebtedness is no longer secured by such Lien, except&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Liens existing as of the first issue date of the notes&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) Liens granted after the first issue date of the notes on any of our or our Subsidiaries&#8217; Properties securing our Indebtedness created in favor of the holders of the notes&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3) Liens securing our Indebtedness which are incurred to extend, renew or refinance Indebtedness which is secured by Liens permitted to be incurred under the Indenture&#59; provided that those Liens do not extend to or cover any of our or our Subsidiaries&#8217; Property other than the Property securing the Indebtedness being refinanced and that the principal amount of such Indebtedness does not exceed the principal amount of the Indebtedness being refinanced&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4) Liens created in substitution of or as replacements for any Liens permitted by the clauses directly above, provided that, based on a good faith determination of one of our officers, the Property encumbered under any such substitute or replacement Lien is substantially similar in nature to the Property encumbered by the otherwise permitted Lien which is being replaced&#59; and </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5) Permitted Liens. </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, we and any of our Subsidiaries may, without securing any series of notes, create or incur Liens which would otherwise be subject to the restrictions set forth in the preceding paragraph, if after giving effect thereto, Exempted Debt does not exceed the greater of (a)&#160;35% of Consolidated Net Worth calculated as of the date of the creation or incurrence of the Lien or (b)&#160;35% of Consolidated Net Worth calculated as of the first issue date of the notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Limitation on Sale and Lease-Back Transactions </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not, nor will we permit any of our Subsidiaries to, enter into any sale and lease-back transaction for the sale and leasing back of any Property, whether now owned or hereafter acquired, of ours or any of our Subsidiaries, unless&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) such transaction was entered into prior to the first issue date of the notes&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) such transaction was for the sale and leasing back to us of any Property by one of our Subsidiaries&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3) such transaction involves a lease for less than three years&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4) we would be entitled to incur Indebtedness secured by a mortgage on the property to be leased in an amount equal to the Attributable Liens with respect to such sale and lease-back transaction without equally and ratably securing the notes pursuant to the first paragraph of &#8220;&#8212;Limitation on Liens&#8221; above&#59; or </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5) we apply an amount equal to the fair value of the Property sold to the purchase of Property or to the retirement of our or any of our Subsidiaries&#8217; long-term Indebtedness within 120 days of the effective date of any such sale and lease-back transaction. In lieu of applying such amount to such retirement, we may, or may cause any of our Subsidiaries to, deliver debt securities to the Trustee therefor for cancellation, such debt securities to be credited at the cost thereof to us. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, we and any of our Subsidiaries may enter into any sale lease-back transaction which would otherwise be subject to the foregoing restrictions if after giving effect thereto and at the time of determination, Exempted Debt does not exceed the greater of (a)&#160;35% of Consolidated Net Worth calculated as of the closing date of the sale-leaseback transaction or (b)&#160;35% of Consolidated Net Worth calculated as of the first issue date of the notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Events of Default </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event of default means, with respect to each series of notes, any of the following&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">default in the payment of any interest on the notes of that series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the Trustee or with the principal paying agent prior to the expiration of the 30-day period)&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">default in the payment of principal of the notes of that series at their maturity&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">default in the performance or breach of any other covenant or warranty by us in the Indenture (other than defaults pursuant to the previous two bullet points above or pursuant to a covenant or warranty that has been included in the Indenture solely for the benefit of a series of debt securities other than that series of notes), which default continues uncured for a period of 90 days after we receive written notice from the Trustee or we and the Trustee receive written notice from the holders of not less than a majority in principal amount of the outstanding Notes of the affected series as provided in the Indenture&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of our company.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No event of default with respect to the Notes (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of an event of default may constitute an event of default under our bank credit agreements in existence from time to time. In addition, the occurrence of certain events of default or an acceleration under the Indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will provide the Trustee written notice of any default or event of default within 30 days of becoming aware of the occurrence of such default or event of default, which notice will describe in reasonable detail the status of such default or event of default and what action we are taking or propose to take in respect thereof. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an event of default with respect to a series of Notes occurs and is continuing (other than an event of default regarding certain events of bankruptcy, insolvency or reorganization of our company), then the Trustee or the holders of not less than a majority in principal amount of the outstanding Notes of that series may, by a notice in writing to us (and to the Trustee if given by the holders), declare to be due and payable immediately the principal of, and accrued and unpaid interest, if any, on all Notes of that series. In the case of an event of default resulting from certain events of bankruptcy, insolvency or reorganization, the principal of and accrued and unpaid interest, if any, on all outstanding debt securities issued under the Indenture will become and be immediately due and payable without any declaration or other act on the part of the Trustee or any holder of outstanding debt securities, including the Notes. At any time after a declaration of acceleration with respect to a series of Notes has been made, and before a judgment or decree for payment of the money due has been obtained by the Trustee, the holders of a majority in principal amount of the outstanding Notes of that series may, by written notice to us and the Trustee, rescind and annul such acceleration if all events of default, other than the non-payment of accelerated principal and interest, if any, with respect to the Notes of that series, have been cured or waived as provided in the Indenture. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Indenture provides that the Trustee will be under no obligation to exercise any of its rights or powers under the Indenture at the request of any holder of notes, unless the Trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in exercising such right or power. Subject to certain rights of the Trustee, the holders of a majority in principal amount of the outstanding Notes of the affected series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee with respect to the Notes of that series. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No holder of any Note of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the Indenture, or for the appointment of a receiver or Trustee, or for any remedy under the Indenture unless, among other things&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that holder has previously given to the Trustee written notice of a continuing event of default with respect to the Notes of that series&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the holders of at least a majority in principal amount of the outstanding Notes of that series have made written request, and offered reasonable indemnity or security, to the Trustee to institute the proceeding as Trustee, and the Trustee has not received from the holders of a majority in principal amount of the outstanding Notes of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days.</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any other provision in the Indenture, the holder of any Note will have an absolute and unconditional right to receive payment of the principal of, premium and any interest on that Note on or after the due dates expressed in that Note and to institute suit for the enforcement of any such payment. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If any securities are outstanding under the Indenture, the Indenture requires us, within 120 days after the end of each fiscal year, to furnish to the Trustee a statement as to our compliance with the indenture. If a default or event of default occurs and is continuing with respect to notes of any series and if it is known to a responsible officer of the Trustee, the Trustee shall deliver to each holder of the Notes of that series notice of a default or event of default within 90 days after it occurs. The Indenture provides that the Trustee may withhold notice to the holders of the Notes of any default or event of default (except in the case of a default or event of default in payment of principal of or interest on any Note of that series) with respect to Notes of that series if it in good faith determines that withholding notice is in the interest of the holders of those Notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Modification and Waiver </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We and the Trustee may modify and amend the Indenture or Notes of any series without the consent of any holder of Notes&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to cure any ambiguity, defect or inconsistency&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to comply with the covenant described below under the heading &#8220;&#8212;Consolidation, Merger and Sale of Assets&#59;&#8221;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to provide for uncertificated notes in addition to or in place of certificated notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to add guarantees with respect to Notes of any series or secure notes of any series&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to surrender any of our rights or powers under the Indenture&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to add covenants or events of default for the benefit of the holders of Notes of any series&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to comply with the applicable procedures of the applicable depositary&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to make any change that would not adversely affect the rights of any holder of Notes in any material respect&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to provide for the issuance of and establish the form and terms and conditions of additional Notes of any series as permitted by the Indenture&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to effect the appointment of a successor trustee with respect to the Notes and to add to or change any of the provisions of the Indenture to provide for or facilitate administration by more than one trustee&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to comply with requirements of the U.S. Securities and Exchange Commission in order to effect or maintain the qualification of the Indenture under the U.S. Trust Indenture Act of 1939.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may also modify and amend the Indenture with the consent of the holders of at least a majority in principal amount of the outstanding Notes of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected Note then outstanding if that amendment will&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reduce the amount of Notes whose holders must consent to an amendment, supplement or waiver&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reduce the rate of or extend the time for payment of interest (including any additional amounts) on the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reduce the principal of or premium on or change the fixed maturity of the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">waive a default in the payment of the principal of, premium or interest on the notes (except a rescission of acceleration of the notes by the holders of at least a majority in aggregate principal amount of the then outstanding Notes of that series and a waiver of the payment default that resulted from such acceleration)&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">make the principal of or interest on the Notes payable in currency other than that stated in the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">make any change to certain provisions of the Indenture relating to, among other things, the right of holders of the Notes to receive payment of the principal of, premium and interest on the Notes and to institute suit for the enforcement of any such payment and to waivers or amendments&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">waive a redemption payment with respect to the Notes.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding Notes of the affected series may, on behalf of the holders of all the Notes of that series, waive our compliance with provisions of the Indenture. The holders of a majority in principal amount of the outstanding Notes of the affected series may, on behalf of the holders of all the Notes of such series, waive any past default under the Indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any Note of that series&#59; provided, however, that the holders of a majority in principal amount of the outstanding Notes of the affected series may rescind an acceleration and its consequences, including any related payment default that resulted from such acceleration. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No amendment to cure any ambiguity, defect or inconsistency in the Indenture made solely to conform the Indenture to the description of notes contained in the applicable prospectus supplement will be deemed to adversely affect the interests of the holders of the Notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidation, Merger and Sale of Assets </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to, any person, which we refer to as a &#8220;successor person,&#8221; unless&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">we are the surviving corporation or the successor person (if other than Amgen) is organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes, pursuant to a supplemental Indenture, our obligations on the notes and under the Indenture&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing under the Indenture.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, any of our Subsidiaries may consolidate with, merge into or transfer all or part of its properties and assets to us. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defeasance and Covenant Defeasance </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Legal Defeasance </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Indenture provides that we may be discharged from any and all obligations in respect of the Notes (subject to certain exceptions). We will be so discharged upon the deposit with the Trustee, in trust, of money, U.S. government obligations and&#47;or foreign government obligations that, through the payment of interest and principal in accordance with their terms, will provide money, U.S. government obligations or foreign government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on the Notes on the stated maturity of those payments in accordance with the terms of the Indenture and the Notes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This discharge may occur only if, among other things, we have delivered to the Trustee an opinion of counsel stating that we have received from, or there has been published by, the IRS a ruling or, since the date of execution of the Indenture, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the Notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Defeasance of Certain Covenants </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Indenture provides that upon compliance with certain conditions&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">we may omit to comply with the covenant described under the heading &#8220;&#8212;Consolidation, Merger and Sale of Assets&#8221; and certain other covenants set forth in the Indenture, as well as any additional covenants set forth in the applicable prospectus supplement&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any omission to comply with those covenants will not constitute a default or an event of default with respect to the Notes, which we refer to as a &#8220;covenant defeasance.&#8221;</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The conditions include&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">depositing with the Trustee money, U.S. government obligations and&#47;or foreign government obligations that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on the notes on the stated maturity of those payments in accordance with the terms of the Indenture and the Notes&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">delivering to the Trustee an opinion of counsel to the effect that the holders of the Notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred.</font></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Covenant Defeasance and Events of Default </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event we exercise our option to effect covenant defeasance with respect to any series of the Notes and the Notes of that series are declared due and payable because of the occurrence of any event of default, the amount of money, U.S. government obligations and&#47;or foreign government obligations on deposit with the Trustee will be sufficient to pay amounts due on the Notes of that series at the time of their stated maturity but may not be sufficient to pay amounts due on the notes of that series at the time of the acceleration resulting from the event of default. In such a case, we would remain liable for those payments. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Concerning the Trustee</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Bank of New York Mellon Trust Company, N.A. is Trustee under the Indenture.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governing Law </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Indenture and the Notes, including any claim or controversy arising out of or relating to the Indenture or the Notes, are governed by the laws of the State of New York. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>exhibit104-formofgrantofst.htm
<DESCRIPTION>FORM OF GRANT STOCK OPTION AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i378ec3656a004983a2448fca5eca1e92_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Exhibit 10.4</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Award Notice</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank &#38; Trust Co., FSB).  This Award Notice shall be replaced by the equivalent pages on such website.  References to Award Notice in this Agreement shall then refer to the equivalent pages on such website.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#93;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This notice of Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan.  The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement.  Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Type&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan&#58;&#160;&#160;&#160;&#160;Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Price&#58; &#160;&#160;&#160;&#160;$________</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Shares</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covered by Option&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expiration Date&#58;&#160;&#160;&#160;&#160;The &#91;______ (__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#93; anniversary of the Grant Date</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Means the vesting date indicated in the Vesting Schedule</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;&#160;&#160;&#160;&#160;Means the schedule of vesting set forth under Vesting Details </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Details&#58;&#160;&#160;&#160;&#160;Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">IMPORTANT NOTICE REGARDING ACCEPTANCE OF THE AWARD AND THE REQUIREMENT TO OPEN A BROKERAGE ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RESIDENTS OF THE U.S. AND PUERTO RICO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; Please read this Award Notice, the Plan and the Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) carefully.&#160; If you, as a resident of the U.S. or Puerto Rico, do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> wish to receive this Award and&#47;or you do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> consent and agree to the terms and conditions on which this Award is offered, as set forth in the Grant Documents, then you must reject the Award by contacting the Merrill Lynch call center (800) 97AMGEN (800-972-6436) within the U.S., Puerto Rico and Canada or +1 (609) 818-8910 from all other countries (Merrill Lynch will accept the charges for your call) no later than the forty-fifth calendar day following the day on which this Award Notice is made available to you, in which case the Award will be cancelled.&#160; For the purpose of determining the forty-five calendar days, Day 1 will be the day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> following the day on which this Award Notice is made available to you. Your failure to notify the Company of your rejection of the Award within this specified period will constitute your acceptance of the Award and your agreement with all terms and conditions of the Award, as set forth in the Grant Documents.  If you agree to the terms and conditions of your grant and you desire to accept it, then no further action is needed on your part to accept the grant.  However, you must still open a brokerage account as directed by the Company, by 1&#58;00 pm Pacific Time on or before the date that is 11 months after the date of </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.1pt;font-weight:400;line-height:100%;position:relative;top:-4.89pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> This provision is only for use on the form of grant used for the U.S. and Puerto Rico.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">grant.  This step is necessary to process transactions related to your equity grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">If you do not open a brokerage account by this deadline, your grant will be cancelled.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></div></div></div><div id="i378ec3656a004983a2448fca5eca1e92_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GRANT OF STOCK OPTION AGREEMENT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SPECIFIC TERMS OF YOUR STOCK OPTION ARE FOUND IN THE PAGES RELATING TO THE GRANT OF STOCK OPTIONS FOUND ON MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK &#38; TRUST CO., FSB) (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AWARD NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;) WHICH ACCOMPANIES THIS DOCUMENT.  THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS GRANT OF STOCK OPTIONS.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;On the Grant Date, specified in the Award Notice, Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), has granted to you, the grantee named in the Award Notice, under the plan specified in the Award Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to purchase the number of shares of the $0.0001 par value common stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) specified in the Award Notice, pursuant to the terms set forth in this Stock Option Agreement, any additional terms and conditions for your country set forth in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the Award Notice (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Option is not intended to qualify and will not be treated as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986, as amended (together with the regulations and other official guidance promulgated thereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Capitalized terms not defined herein shall have the meanings assigned to such terms in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The terms and conditions of your Option are as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;I.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the terms and conditions of the Plan and this Agreement, on each Vesting Date the Option shall vest with respect to the number of Shares indicated on the Vesting Schedule, provided that you have remained continuously and actively employed with the Company or an Affiliate (as defined in the Plan) through each applicable Vesting Date, unless &#91;(i) your employment has terminated due to your Voluntary Termination (as defined in Section IV(A)(5)) or (ii)&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> you experience a Qualified Termination (as defined in Section IV(B)(4)), or as otherwise determined by the Company in the exercise of its discretion as provided in Section IV(A)(7).  This Option may only be exercised for whole shares of the Common Stock, and the Company shall be under no obligation to issue any fractional Shares to you.  Subject to the limitations contained herein, this Option shall be exercisable with respect to each installment on or after the applicable Vesting Date.  Notwithstanding anything herein to the contrary, the Vesting Schedule may be accelerated (by notice in writing) by the Company in its sole discretion at any time during the term of this Option.  In addition, if not prohibited by local law, vesting may be suspended by the Company in its sole discretion during a leave of absence as provided from time to time according to Company policies and practices&#59; provided, that, in no event shall any such suspension extend the term of this Option beyond the Expiration Date set forth on the Award Notice and in this Agreement.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Section IV(A)(5) of this Agreement is not applicable to awards identified by the Administrator as new hire, retention or promotion grants and the provisions of such section shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">II.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;The per share exercise price of this Option is the Grant Price as defined in the Award Notice, being not less than the Fair Market Value of the Common Stock on the date of grant of this Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;To the extent permitted by applicable statutes and regulations, payment of the exercise price per share is due in full upon exercise of all or any part of each installment which has become exercisable by you by means of (i) cash or a check, (ii) any cashless exercise procedure through the use of a brokerage arrangement approved by the Company, or (iii) any other form of legal consideration that may be acceptable to the Board or the Committee in their discretion. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">(3)&#160;&#160;&#160;&#160;To the extent permitted by applicable statutes and regulations, if, at the time of exercise, the Company&#8217;s Common Stock is publicly traded and quoted regularly in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%;text-decoration:underline">Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">, payment of the exercise price may be made by delivery of already-owned Shares with a Fair Market Value equal to the exercise price of the Shares for which this Option is being exercised.  The already-owned Shares must have been owned by you for the period required to avoid adverse accounting treatment and owned free and clear of any liens, claims, encumbrances or security interests.  Payment may also be made by a combination of cash and already-owned Shares.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the Company reserves the right to restrict the methods of payment of the exercise price if necessary or advisable to comply with applicable law or regulation, as determined by the Company in its sole discretion.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21.03pt">Notwithstanding anything to the contrary contain herein, the Company shall not take any actions that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation, or the rules of any Securities Exchange. The Company, in its sole discretion, may impose any timing or other restrictions with respect to the exercise of this Option arising from compliance with any securities or tax laws or other rules or regulations.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding anything to the contrary contained herein, this Option may not be exercised and no Shares underlying the Option will be issued unless such Shares are then registered under the Securities Act, or, if such Shares are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act, and that the issuance satisfies all other applicable legal requirements.  If the Option cannot be exercised and expires during this period, you will forfeit the Option and no Shares or value will be transferred to you.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;IV.&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;The term of this Option commences on the Grant Date and, unless sooner terminated as set forth below or in the Plan, terminates on the &#91;_______ (__th)&#93; anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  This Option shall terminate prior to the Expiration Date as follows&#58;  three (3) months after the termination of your employment with the Company or an Affiliate (as defined in the Plan) for any reason or for no reason, including if your employment is terminated by the Company or an Affiliate without Cause (as defined below), or in the event of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any other termination of your employment caused directly or indirectly by the Company or an Affiliate, unless&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;such termination of your employment is due to your Permanent and Total Disability (as defined below), in which case the Option shall terminate on the earlier of the Expiration Date or five (5) years after termination of your employment and the vesting of the Option shall be accelerated and the Option shall be fully exercisable, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), as of the day immediately preceding such termination of your employment with respect to the Option, except that if the Option was granted in the calendar year in which such termination occurs, the Option shall be accelerated to vest with respect to a number of Shares equal to the number of Shares subject to the Option multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any portion of the Option (if any) that remains unvested shall automatically expire and terminate on the date of the termination of your active employment due to your Permanent and Total Disability without consideration therefor&#59;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;such termination of your employment is due to your death, in which case the Option shall terminate on the earlier of the Expiration Date or five (5) years after your death and the vesting of the Option shall be accelerated and the Option shall be fully exercisable as of the day immediately preceding your death with respect to the Option, except that if the Option was granted in the calendar year in which your death occurs the Option shall be accelerated to vest with respect to a number of Shares equal to the number of Shares subject to the Option multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any portion of the Option (if any) that remains unvested shall automatically expire and terminate on the date of termination of your active employment due to your death without consideration therefor&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;during any part of such three (3) month period, this Option is not exercisable solely because of the condition set forth in Section III above, in which event this Option shall not terminate until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3) months after the termination of your employment&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;exercise of this Option within three (3) months after termination of your employment with the Company or with an Affiliate would result in liability under Section 16(b) of the Exchange Act, in which case this Option will terminate on the earliest of&#58;  (a) the tenth (10th) day after the last date upon which exercise would result in such liability&#59; (b) six (6) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">months and ten (10) days after the termination of your employment with the Company or an Affiliate&#59; or (c) the Expiration Date&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;&#91;such termination of your employment is due to your voluntary termination (and such voluntary termination is not the result of Permanent and Total Disability (as defined below)) after you are at least sixty five (65) years of age, or after you are at least fifty-five (55) years of age and have been an employee of the Company and&#47;or an Affiliate for at least ten (10) years in the aggregate as determined by the Company in its sole discretion according to Company policies and practices as in effect from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%;text-decoration:underline">Voluntary Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;), in which case this Option shall terminate on the earlier of the Expiration Date or five (5) years after termination of your employment and the unvested portions of this Option will become exercisable pursuant to the Vesting Schedule without regard to your Voluntary Termination of your employment prior to the Vesting Date, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), with respect to the Option&#59; if the Option was granted in the calendar year in which your Voluntary Termination occurs, the Option will become exercisable pursuant to the Vesting Schedule only with respect to a number of Shares equal to the number of Shares subject to the Option multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any portion of the Option (if any) that remains unvested shall automatically expire and terminate on the date of the termination of your active employment due to your Voluntary Termination without consideration therefor&#59; notwithstanding the definition of Voluntary Termination set forth above, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in your jurisdiction that would likely result in the favorable treatment upon Voluntary Termination described above being deemed unlawful and&#47;or discriminatory, then the Committee will not apply the favorable treatment described above&#59;&#93;&#91;Reserved&#93;*</font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:9.1pt;font-weight:400;line-height:111%;position:relative;top:-4.89pt;vertical-align:baseline"> 3</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;such termination of your employment is due to a Qualified Termination, in which case, the Option shall terminate on the earlier of (a) the date that is three (3) months following the date of such Qualified Termination or (b) the Expiration Date, and, to the extent permitted by applicable law, the vesting of the Option shall be accelerated and the Option shall be fully exercisable as of the day immediately prior to the Qualified Termination&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7)&#160;&#160;&#160;&#160;the Company determines, in its sole discretion at any time during the term of this Option, in writing, to otherwise extend the period of time during which this Option will vest and may be exercised after termination of your employment&#59; provided, that, in no event shall any such extension extend the term of this Option beyond the Expiration Date set forth on the Award Notice and in this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Section IV(A)(5) of this Agreement is not applicable to awards identified by the Administrator as new hire, retention or promotion grants and the provisions of such section shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;However, in any and all circumstances and except to the extent the Vesting Schedule has been accelerated by the Company in its sole discretion during the term of this Option or as a result of your Permanent and Total Disability or death as provided in Sections IV(A)(1) or IV(A)(2) above, respectively, &#91;as a result of your Voluntary Termination as provided in Section IV(A)(5) above,&#93;* as a result of a Qualified Termination as provided in Section IV(A)(6) above or as otherwise determined by the Company in the exercise of its discretion as provided in Section IV(A)(7) above, this Option may be exercised following termination of your employment only as to that number of Shares as to which it was exercisable on the date of termination of your employment under the provisions of Section I of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;For purposes of this Option&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">termination of your employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the last date you are either an active employee of the Company or an Affiliate or actively engaged as a Director to the Company or an Affiliate&#59; in the event of termination of your employment (whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive options and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively employed and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, active employment would not include any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any).  Your right, if any, to exercise the Option after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law.  The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of this Agreement (including whether you may still be considered to be providing services while on a leave of absence)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) your conviction of a felony (or similar crime under applicable law, as determined by the Company), or (ii) your engaging in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out your duties, resulting, in either case, in material economic harm to the Company or any Affiliate, unless you believed in good faith that such conduct was in, or not contrary to, the best interests of the Company or any Affiliate.  For purposes of clause (ii) above, no act, or failure to act, on your part shall be deemed &#8220;willful&#8221; unless done, or omitted to be done, by you not in good faith&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term under Section 22(e)(3) of the Code and with such permanent and total disability being certified prior to termination of your employment by (a) the U.S. Social Security Administration, (b) the comparable governmental authority applicable to an Affiliate, (c) such other body having the relevant decision-making power applicable to an Affiliate, or (d) an independent medical advisor appointed by the Company in its sole discretion, as applicable, in any such case&#59; </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Qualified Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;if you are an employee who participates in the Change of Control Plan (as defined below), your termination of employment within two (2) years following a Change of Control (i) by the Company other than for Cause, Disability (as defined below) or as a result of your death, or (ii) by you for Good Reason (as defined in the Change of Control Plan)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;if you are an employee who does not participate in the Change of Control Plan or the Change of Control Plan is no longer in effect, your termination of employment within two (2) years following a Change of Control by the Company other than for Cause, Disability (as defined below) or as a result of your death&#59; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:111%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">(5) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; shall mean the occurrence of any of the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;the acquisition (other than from the Company) by any person, entity or &#8220;group,&#8221; within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (excluding, for this purpose, the Company or any of its Affiliates, or any employee benefit plan of the Company or any of its Affiliates which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either the then outstanding Shares or the combined voting power of the Company&#8217;s then outstanding voting securities entitled to vote generally in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;the consummation by the Company of a reorganization, merger, consolidation, (in each case, with respect to which persons who were the stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own more than fifty percent (50%) of the combined voting power entitled to vote generally in the election of directors of the reorganized, merged or consolidated company&#8217;s then outstanding voting securities) or a liquidation or dissolution of the Company or of the sale of all or substantially all of the assets of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything herein or in any Award Agreement to the contrary, if a Change of Control constitutes a payment event with respect to any Award that is subject to United States income tax and which provides for a deferral of compensation that is subject to Section 409A of the Code, the transaction or event described in subsection (a) or (b), (c) above must also constitute a &#8220;change in control event,&#8221; as defined in U.S. Treasury Regulation &#167;1.409A-3(i)(5), in order to constitute a Change of Control for purposes of payment of such Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(6) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company&#8217;s change of control and severance plan, including the Amgen Inc. Change of Control Severance Plan, as amended and restated, effective as of December 9, 2010 (and any subsequent amendments thereto), or any equivalent plan governing the provision of benefits to eligible employees upon the occurrence of a Change of Control (including resulting from a termination of employment that occurs within a specified time period following a Change of Control), as in effect immediately prior to a Change of Control&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be determined in accordance with the Company&#8217;s long-term disability plan as in effect immediately prior to a Change of Control.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;To the extent specified above, this Option may be exercised by delivering a notice of exercise in person, by mail, via electronic mail or facsimile or by other authorized </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">method designated by the Company, together with the exercise price to the Company Stock Administrator, or to such other person as the Company Stock Administrator may designate, during regular business hours, together with such additional documents as the Company may then require pursuant to Section 7.2(b) of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;Regardless of any action the Company or your actual employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), you acknowledge that the ultimate liability for all Tax Obligations is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or your Employer.  You further acknowledge that the Company and&#47;or your Employer&#58; (a) make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Option grant or the underlying Shares, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends&#59; and (b) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your liability for Tax Obligations or achieve any particular tax result.  Furthermore, if you become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(C)&#160;&#160;&#160;&#160;Prior to any relevant taxable or tax withholding event, as applicable, you shall pay or make adequate arrangements satisfactory to the Company and&#47;or your Employer to satisfy all Tax Obligations.  In this regard, you authorize the Company and&#47;or your Employer, or their respective agents, at their discretion, to satisfy all applicable Tax Obligations by one or a combination of the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;withholding from your wages or other cash compensation paid to you by the Company and&#47;or your Employer&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;withholding from proceeds of the sale of Shares acquired upon exercise of the Option either through your voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;withholding in Shares issuable, or cash payable, upon exercise of the Option, provided that, if such Shares are withheld, the Company and your Employer shall only withhold an amount of Shares with a fair market value not to exceed the Tax Obligations as determined in the discretion of the Company or your Employer, as applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Depending on the withholding method, the Company may withhold or account for Tax Obligations by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates. If the Tax Obligations are satisfied by withholding in Shares, for tax purposes you are deemed to have been issued the full number of Shares subject to the exercised Option, notwithstanding that a number of the Shares is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">held back and not actually issued to you solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(D)&#160;&#160;&#160;&#160;Finally, you shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be or were not satisfied by the means previously described.  You agree to take any further actions and execute any additional documents as may be necessary to effectuate the provisions of this Section V.  Notwithstanding anything to the contrary contained herein, the Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if you fail to comply with your obligations in connection with the Tax Obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;VI.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Option is not transferable, except by will or the laws of descent and distribution, and is exercisable during your life only by you except if you have named a trust created for the benefit of you, your spouse, or members of your immediate family (a &#8220;Trust&#8221;) as beneficiary of this Option, this Option may be exercised by the Trust after your death.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;VII.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any notices provided for in this Option or the Plan shall be given in writing or electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail or equivalent foreign postal service, postage prepaid, addressed to you at such address as is currently maintained in the Company&#8217;s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator.  Such notices may be given using any automated system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, as approved by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;VIII.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Option is subject to all the provisions of the Plan and its provisions are hereby made a part of this Option, including without limitation the provisions of Articles 6 and 7 of the Plan relating to Options, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of this Option and those of the Plan, the provisions of the Plan shall control.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In order for the Company to facilitate your participation in the Plan, the Company and your Employer must collect and use personal data about you.  In accordance with applicable laws, reasonable security measures will be implemented and maintained to protect the security of your personal data&#59; however, you understand that absolute security cannot be guaranteed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and your Employer may hold certain personal information about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor, for the purposes of implementing, administering and managing the Plan (&#8220;personal data&#8221;).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received upon exercise of this Option may be deposited.  You understand that such authorized recipients of your personal data may be located in countries that do not provide the same level of data privacy laws and protections as the country in which your personal data originated.  Transfers of personal data among Company and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on Company&#8217;s BCRs, please visit http&#58;&#47;&#47;www.amgen.com&#47;bcr&#47;.  You acknowledge that the collection, use and transfer of your personal data is necessary to facilitate to your participation in the Plan, as well as to grant you Options or other equity awards and administer or maintain such awards.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You may correct or update your personal data previously provided to Company, by completing the form located at&#160;https&#58;&#47;&#47;preferences.amgen.com.  Subject to applicable law, you may have additional rights, including the right to object and&#47;or request destruction of your personal data.  To exercise these rights, where applicable, please contact your local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;X.&#160;&#160;&#160;&#160;The terms of this Option shall be governed by the laws of the State of Delaware without giving effect to principles of conflicts of laws.  For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Option is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt">Notwithstanding any provision of this Option to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (which constitutes a part of this Agreement), are subject to the laws of any foreign jurisdiction, or relocate to one of the countries included in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Option granted hereunder shall be subject to any additional terms and conditions for your country set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the following additional terms and conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the terms and conditions of this Option, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are deemed modified to the extent necessary or advisable to comply with applicable foreign laws or facilitate the administration to the Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;if applicable, the effectiveness of this Option is conditioned upon its compliance with any applicable foreign laws, regulations, rules or local governmental regulatory exemption and subject to receipt of any required foreign regulatory approvals&#59; and</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">the Company may take any other action before or after the date of this Option that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt"> (A)&#160;&#160;&#160;&#160;In accepting this Option, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;the grant of this Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future awards of options, or benefits in lieu of options even if options have been awarded in the past&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;your participation in the Plan is voluntary&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;the grant of Options, the underlying Shares, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;neither the grant of options nor any provision of this Option, the Plan or the policies adopted pursuant to the Plan confer upon you any right with respect to employment or continuation of current employment and shall not interfere with the ability of your Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7)&#160;&#160;&#160;&#160;in the event that you are not an employee of the Company or any Affiliate, the Option shall not be interpreted to form an employment contract or relationship with the Company or any Affiliate&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8)&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable, and cannot be predicted with certainty&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(9)&#160;&#160;&#160;&#160;if the underlying Shares do not increase in value, this Option will have no value&#59; if you exercise this Option and obtain Shares, the value of those Shares acquired upon exercise may increase or decrease in value, even below the Grant Price per Share&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10)&#160;&#160;&#160;&#160;in consideration of the grant of this Option, no claim or entitlement to compensation or damages arises from forfeiture of options resulting from termination of your employment by the Company or an Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and you irrevocably release the Company and your Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(11)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Options, the underlying Shares, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(12) &#160;&#160;&#160;&#160;except as otherwise provided in this Agreement or the Plan, the Options and the benefits evidenced by this Agreement do not create any entitlement to have the Options or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(13)&#160;&#160;&#160;&#160;the following provisions apply only if you are providing services outside the United States&#58;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;for employment law purposes outside the United States, the Option, underlying Shares, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;neither the Company, your Employer nor any Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Option or of any amounts due to you pursuant to the exercise of the Option or the subsequent sale of any Shares acquired upon exercise of the Option.</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying Shares.  You should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt">If one or more of the provisions of this Option shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Option to be construed so as to foster the intent of this Option and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt">By electing to accept this Agreement, you acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement.  Furthermore, if you have received this Option or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt">This Option is not intended to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Code Section 409A, but rather is intended to be exempt from the application of Code Section 409A.  To the extent that this Option is nevertheless deemed to be subject to Code Section 409A for any reason, this Option shall be interpreted in accordance with Code Section 409A and U.S. Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date.  Notwithstanding any provision herein to the contrary, in the event that following the Grant Date, the Committee (as defined in the Plan) determines that this Option may be or become subject to Code Section 409A, the Committee may adopt such amendments to the Plan and&#47;or this Option or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Plan and&#47;or this Option from the application of Code Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to this Option, or (b) comply with the requirements of Code Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this paragraph shall not create an obligation on the part of the Committee to adopt any such amendment, policy or procedure or take any such other action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt">By electing to accept this Option, you acknowledge receipt of this Option and hereby confirm your understanding that the terms set forth in this Option constitute, subject to the terms of the Plan, which terms shall control in the event of any conflict between the Plan and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Option, the entire agreement and understanding of the parties with respect to the matters contained herein and supersede any and all prior agreements, arrangements and understandings, both oral and written, between the parties concerning the subject matter of this Option.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan (including this Agreement) by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.7pt">The Company reserves the right to impose other requirements on your participation in the Plan, on this Option and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.71pt">This Option and all compensation payable with respect to it shall be subject to recovery by the Company pursuant to&#160;any and all of the Company&#8217;s policies with respect to the recovery of compensation, as they shall be in effect and may be amended from time to time, to the maximum extent permitted by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt">You acknowledge that a waiver by the Company of breach of any provision of this Option shall not operate or be construed as a waiver of any other provision of this Option, or of any subsequent breach by you or any other grantee.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Very truly yours,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AMGEN INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By______________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  Duly authorized on behalf</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  of the Board of Directors</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12</font></div></div></div><div id="i378ec3656a004983a2448fca5eca1e92_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDITIONAL TERMS AND CONDITIONS OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC. 2009 EQUITY INCENTIVE PLAN, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND&#47;OR RESTATED FROM TIME TO TIME</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GRANT OF STOCK OPTION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(BY COUNTRY)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and&#47;or the Agreement to which this Appendix is attached.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix includes additional terms and conditions that govern any Options granted under the Plan if, under applicable law,&#160;you are a resident of, are deemed to be a resident of or are working in one of the countries listed below.&#160; Furthermore, the additional terms and conditions that govern any Options granted hereunder may apply to you if you transfer employment and&#47;or residency to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix also includes notifications relating to exchange control and other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of October 2022.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the Plan because the information may be outdated when you exercise the Options and acquire Shares under the Plan, or when you subsequently sell Shares acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the notifications are general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.  Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL NON-U.S. JURISDICTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision replaces Section II(3)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent permitted by applicable statutes and regulations, payment of the exercise price per Share is due in full in cash or check upon exercise of all or any part of this Option which has become exercisable by you.  Due to legal restrictions outside the U.S., you are not permitted to pay the exercise price by delivery of already-owned Shares of a value equal to the exercise price of the Shares for which this Option is being exercised.  Furthermore, payment may not be made by a combination of cash and already-owned Common Stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section V(C) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Company withholds or accounts for Tax Obligations by considering maximum applicable rates in your jurisdiction(s), in the event of over-withholding, you may receive a refund of any over-withheld amount in cash and will not be entitled to the equivalent amount in Shares, or if not refunded, you may seek a refund from the local tax authorities.  In the event of under-withholding, you may be required to pay any additional Tax Obligations directly to the applicable tax authority or to the Company and&#47;or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Insider Trading Restrictions&#47;Market Abuse Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be subject to insider trading restrictions and&#47;or market abuse laws</font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker&#8217;s country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., Options) or rights linked to the value of Shares during such times as you are considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). &#160;Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information. Furthermore you could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; You are responsible for ensuring your compliance with any applicable restrictions and you should speak with your personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Asset&#47;Account, Tax Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your country of residence may have certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends received, or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside of your country.  You may be required to report such accounts, assets or transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt.  You are responsible for ensuring your compliance with such regulations, and you should speak with your personal legal advisor on this matter. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) &#47; EUROPEAN UNION (&#8220;EU&#8221;) JURISDICTIONS, UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision replaces Section IX of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Please refer to the Fair Processing Notice previously provided by your local human resources representative, which notice governs the collection, use and transfer of your personal data necessary for the Company to facilitate your participation in the Plan.  If you have any questions or concerns regarding the Fair Processing Notice, including questions about your rights afforded thereunder, you should contact your local human resources representative or send an email to </font><font style="color:#002060;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">hrconnect&#64;amgen.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">For purposes of implementing, administering and managing the Plan, Company and your Employer may hold certain personal data about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor (&#8220;personal data&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received upon exercise of this Option may be deposited.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in Argentina, you may be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; The following provision supplements Section XII of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you acknowledge, understand and agree that the grant of the Option is made by the Company (not your Employer) in its sole discretion and that the value of the Option or any Shares acquired under the Plan shall not constitute salary or wages for any purpose under Argentine labor law including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, etc., or (ii) any termination or severance indemnities or similar payments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. &#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither the Option nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; Provided you are not required to purchase foreign currency and remit funds out of Argentina to acquire Shares under the Plan, local exchange control restrictions would not apply.  However, if so required, you personally are responsible for complying with any and all Argentine currency exchange regulations, approvals and reporting requirements.  Exchange control requirements in Argentina are subject to change&#59; you should consult with your personal advisor regarding any obligations you have under the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Argentine resident, you are required to report certain information regarding any Shares you hold as of December 31 each year to the Argentine tax authorities on your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you acquire Shares under the Plan and offer the Shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law.  You should consult with your own legal advisor before making any such offer in Australia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the Options granted under the Plan, such that the Options are intended to be subject to deferred taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers.  If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.  If there is no Australian bank involved in the transfer, you will be required to file the report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; If you are an Austrian resident and you hold Shares acquired under the Plapn outside of Austria, you may be subject to reporting obligations to the Austrian National Bank.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A separate reporting requirement applies when you sell Shares acquired under the Plan or receive a cash dividend paid on such Shares.  In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria.  If the transaction volume of all cash accounts abroad meets or exceeds a specified threshold, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Meldungen SI-Forderungen und&#47;oder SI-Verpflichtungen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BELGIUM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Taxation of the Option.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your tax consequences will vary depending on when you accept the Option.  If you accept the Option in writing within 60 days of the offer date, you will be subject to taxation on the 60th day after the offer date.  If you accept the Option more than 60 days after the offer date, you will be subject to taxation at exercise.  Please refer to the additional materials that will be delivered to you for a more detailed description of the tax consequences of accepting the Option.  You should consult your personal tax advisor prior to accepting the Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Reporting&#59; Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are a Belgian resident, you are required to report any taxable income attributable to the Option granted hereunder on your annual tax return.  You are also required to report any securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) held and bank accounts (including brokerage accounts) opened and maintained outside of Belgium on your annual tax return.  The first time you report the foreign security and&#47;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or bank account on your annual income tax return you will have to provide the National Bank of Belgium Central Contact Point with the account details of any such foreign accounts (including the account number, bank name and country in which such account was opened) in a separate form.  This report, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Kredietcentrales &#47; Centrales des cr&#233;dits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> caption.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Exchange Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;A stock exchange tax applies to transactions executed by a Belgian resident through a non-Belgian financial intermediary, such as a U.S. broker.  The stock exchange tax likely will apply when the Option is exercised and when Shares acquired under the Plan are sold.  It is your responsibility to comply with this tax obligation and you should consult your personal tax advisor for additional details on your obligations with respect to the stock exchange tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Securities Accounts Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;An annual securities accounts tax may be payable if the total value of securities held in a Belgian or foreign securities account (e.g., Shares acquired under the Plan) exceeds a certain threshold on four reference dates within the relevant reporting period (i.e., December 31, March 31, June 30 and September 30).  In such case, the tax will be due on the value of the qualifying securities held in such account.  It is your responsibility to comply with this obligation and you should consult with your personal tax or financial advisor for additional details.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By accepting the Option, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the exercise of the Option, the sale of Shares acquired under the Plan and the payment of dividends on such Shares.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XII of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you acknowledge (i) that you are making an investment decision, (ii) that the Options will be exercisable by you only if the vesting conditions are met and any necessary services are rendered by you during the vesting period set forth in the Vesting Schedule, and (iii) that the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you are resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights on December 31 of each year exceeds US$1,000,000.  If such amount exceeds US$100,000,000, the referenced declaration must be submitted quarterly, in the month following the end of each quarter.  Assets and rights that must be reported include the following&#58; (i) bank deposits&#59; (ii) loans&#59; (iii) financing transactions&#59; (iv) leases&#59; (v) direct investments&#59; (vi) portfolio investments, including Shares acquired under the Plan&#59; (vii) financial derivatives investments&#59; and (viii) other investments, such as real estate.  Please note that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement and must declare at least the assets held abroad that were acquired subsequent to the date of admittance as a resident of Brazil.  Individuals holding assets and rights outside of Brazil valued at less than US$1,000,000 are not required to submit a declaration. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BULGARIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If funds are remitted to purchase Shares abroad, a declaration of the purpose of the remittance must be provided to the local bank that is transferring the funds.  If the funds are remitted to a bank outside the European Union and the amount exceeds a specified amount, documentation evidencing the underlying transaction (for instance a copy of the option agreement) must be provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be required to annually file statistical forms with the Bulgarian National Bank regarding your receivables in bank accounts abroad as well as your securities abroad (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) if the total sum of all such receivables and securities equals or exceeds a specified amount as of the previous calendar year-end.&#160; The reports are due by March 31.  You should contact your bank in Bulgaria for additional information regarding this requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Section IV(B)(1) of the Agreement is amended to read as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date you are either an active employee of the Company or an Affiliate or actively engaged as Director to the Company or an Affiliate&#59; in the event of involuntary termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or unlawful, including for breaching employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive the Option and vest under the Plan, if any, will terminate effective as of the date that is the earlier of&#58; (1) the date you receive written notice of termination of employment from the Company or your Employer, or (2) the date you are no longer actively employed by the Company or your Employer regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law.  Your right, if any, to acquire Shares pursuant to the Option after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Options, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The following provision will apply to you if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">French Language Documents. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A French translation of this document and certain other documents related to this Award will be made available to Participant as soon as reasonably practicable.  Participant understands that, from time to time, additional information related to the Award may be provided in English and such information may not be immediately available in French.  However, upon request, the Company will provide a translation of such information into French as soon as reasonably practicable.  Notwithstanding anything to the contrary in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement, and unless Participant indicates otherwise, the French translation of this document and certain other documents related to the Award will govern Participant&#8217;s participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section IX of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration of the Plan.  You further authorize the Company, your Employer and Merrill Lynch Bank &#38; Trust Co., FSB (or any other stock plan service provider) to disclose and discuss your participation in the Plan with their advisors.  You also authorize the Company and your Employer to record such information and keep it in your file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Nasdaq Global Select Market).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified foreign property, including Shares, Options and other rights to receive Shares of a non-Canadian company held by a Canadian resident employee generally must be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee&#8217;s specified foreign property exceeds C$100,000 at any time during the year.  Thus, such Options must be reported &#8211; generally at nil cost &#8211; if the C$100,000 cost threshold is exceeded because other specified foreign property is held by the employee.  When Shares are acquired, their cost generally is the adjusted cost base (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ACB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Shares.  The ACB ordinarily would equal the fair market value of the Shares at the time of acquisition, but if the employee owns other shares of the same company, this ACB may have to be averaged with the ACB of the other shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following terms apply only to nationals of the People&#8217;s Republic of China (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221;) residing in the PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in the PRC, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To comply with requirements imposed by the State Administration of Foreign Exchange, to the extent that, under Section IV of the Agreement, you may exercise any Option after termination of your employment, you will be permitted to exercise such Option for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">shorter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the period set forth in Section IV of the Agreement and six (6) months from the date of termination of your employment&#59; any unexercised Option shall immediately lapse six (6) months following the termination of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company reserves the right to impose such further restrictions or conditions as may be necessary to comply with changes in applicable local laws in the PRC.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please note that the above provisions will apply to all Options granted to you under the Plan, as well as to any Options granted to you in the past under the Plan.    </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You understand and agree that, pursuant to PRC exchange control requirements, you will be required to repatriate the cash proceeds from the sale of the Shares issued upon the exercise of the Option to China.  You further understand that, under applicable laws, such repatriation of your cash proceeds will need to be effectuated through a special exchange control account established by the Company or any Affiliate, including your Employer, and you hereby consent and agree that any proceeds from the sale of the Shares may be transferred to such special account prior to being delivered to you.  You also understand that the Company will deliver the proceeds to you as soon as possible, but that there may be delays in distributing the funds to you due to exchange control requirements in China.  Proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account.  If the proceeds are paid to you in local currency, the Company is under no obligation to secure any particular currency conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You agree to bear any currency fluctuation risk between the date the Option is exercised and the time that (i) the Tax Obligations are converted to local currency and remitted to the tax authorities, and (ii) net proceeds are converted to local currency and distributed to you. You acknowledge that neither the Company nor any Affiliate will be held liable for any delay in delivering the proceeds to you.  You agree to sign any agreements, forms and&#47;or consents that may be requested by the Company or the Company&#8217;s designated broker to effectuate any of the remittances, transfers, conversions or other processes affecting the proceeds. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The following provision supplements Section XII of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that pursuant to Article 15 of Law 50&#47;1990 (Article 128 of the Colombian Labor Code), the Plan and related benefits do not constitute a component of &#8220;salary&#8221; for any purpose. Therefore, they are considered to be of an extraordinary nature and will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities</font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payroll taxes, social insurance contributions and&#47;or any other labor-related amounts, subject to the limitations provided in Law 1393&#47;2010.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Shares are not and will not be registered with the Colombian registry of publicly traded securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and therefore the Shares may not be offered to the public in Colombia.  Nothing in this document should be construed as the making of a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Investment in assets located abroad (such as Shares acquired under the Plan) does not require prior approval from the Central Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Banco de la Rep&#250;blica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  Nonetheless, such investments are subject to registration before the Central Bank as foreign investments held abroad, regardless of value.  In addition, you must file an annual informative return with the local tax authority detailing assets you hold abroad, which must include the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shares acquired at exercise (every year as long as you keep them). This obligation is only applicable if the assets held abroad exceed the amount of 2,000 Tax Units (approx. US$22.000)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, local banks), which includes the obligation to correctly complete and file the appropriate foreign exchange form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">declaraci&#243;n de cambio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An annual information return may need to be filed with the Colombian Tax Office detailing any assets held abroad (including Shares acquired under the Plan).  If the individual value of any of these assets exceeds a certain threshold, each asset must be described (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, its nature and its value) and the jurisdiction in which it is located must be disclosed.  It is your responsibility to comply with this tax reporting requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CROATIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Croatian residents may be required to report any foreign investments (including Shares acquired under the Plan) to the Croatian National Bank for statistical purposes.  You should be aware that exchange control regulations in Croatia are subject to frequent change and you are solely responsible for ensuring your continued compliance with current Croatian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A Czech resident may be required to notify the Czech National Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CNB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the acquisition of Shares under the Plan or maintenance of a foreign account if (i) he or she maintains foreign direct investments with a value of 2,500,000 K&#269; or more in the aggregate, (ii) he or she maintains other foreign financial assets with a value of 200,000,000 K&#269; or more, or (iii) the Czech resident is specifically requested to do so by the CNB.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DENMARK</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Danish Stock Option Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you acknowledge that you have received an Employer Statement translated into Danish, which is being provided to comply with the Danish Stock Option Act.  To the extent more favorable to you and required to comply with the Stock Option Act, as amended with effect from January 1, 2019.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The requirement to report certain information to the Danish Tax Administration via Form V or K was eliminated effective January 1, 2019.  However, you still must report the foreign bank&#47;brokerage accounts and their deposits, and Shares held in a foreign bank or brokerage account in your tax return under the section on foreign affairs and income. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EGYPT</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you transfer funds into or out of Egypt in connection with the exercise of the Option or the receipt of sale proceeds, you are required to transfer the funds through a registered bank in Egypt.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> There are no specific reporting requirements with respect to foreign assets&#47;accounts. However, please note that you must check your pre-completed tax return to confirm that the ownership of Shares and other securities (foreign or domestic) are correctly reported. If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the grant, you confirm having read and understood the Plan and Agreement which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">En acceptant l&#8217;attribution, vous confirmez avoir lu et compris le Plan et le Contrat, qui ont &#233;t&#233; communiqu&#233;s en langue anglaise.  Vous acceptez les termes de ces documents en connaissance de cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> French residents and non-residents must declare to the Customs Authorities the cash and securities they import or export without the use of a financial institution when the value of such cash or securities exceeds &#8364;10,000.  French residents also must report all foreign bank and brokerage accounts on an annual basis (including accounts opened or closed during the tax year) on Form N&#176; 3916, together with the income tax return.  Failure to comply could trigger significant penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If your acquisition of Shares under the Plan leads to a qualified participation at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year.  A qualified participation is attained only in the unlikely event (i) you own at least 1% of the Company and the value of the Shares acquired exceeds &#8364;150,000 or (ii) you hold Shares exceeding 10% of the Company&#8217;s total Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  In case of payments in connection with securities (including proceeds realized upon the sale of Shares or the receipt of dividends), the report must be made by the 5th day of the month following the month in which the payment was received and must be filed electronically.  The form of report (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Allgemeines Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">can be accessed via the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> website (www.bundesbank.de) and is available in both German and English. In addition, you may be required to report the acquisition or sale of Shares to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if the value of the Shares acquired or sold exceeds &#8364;12,500.   You are responsible for satisfying any applicable reporting obligation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The reporting of foreign assets (including Shares and other investments) is your own obligation and takes place through your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you exercise the Option through a cash exercise, withdraw funds from a bank in Greece and remit those funds out of Greece (in an amount exceeding a specified threshold), you may be required to submit a written application to the bank.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you exercise the Option by way of a cashless method of exercise as described in Section&#160;II(2)(ii) of the Agreement, this application will not be required because no funds will be remitted out of Greece. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Shares received at exercise are accepted as a personal investment.  In the event that Shares are issued in respect of the Options within six (6) months of the Grant Date, you agree that you will not offer to the public or otherwise dispose of the Shares prior to the six (6)-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SECURITIES WARNING&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in doubt about any of the contents of the Agreement, including this Appendix, or the Plan, you should obtain independent professional advice.  The Option and any Shares issued in respect of the Option do not constitute a public offering of securities under Hong Kong law and are available only to members of the Board and Employees.  The Agreement, including this Appendix, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong.  The Option and any documentation related thereto are intended solely for the personal use of each member of the Board and&#47;or Employee and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HUNGARY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ICELAND</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in Iceland, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Approval by the Central Bank of Iceland is no longer required to participate in the Plan, regardless of the value of the Shares acquired under the Plan.  Despite the recent relaxation of the exchange control requirements, you should consult with your personal advisor to ensure compliance with applicable exchange control regulations in&#160;Iceland as such regulations are subject to frequent change.  You are responsible for ensuring compliance with all exchange control laws in&#160;Iceland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in India, you will not be permitted to pay the exercise price for Shares subject to the Option granted hereunder by a cashless &#8220;sell-to-cover&#8221; procedure, under which method a number of Shares with a value sufficient to cover the exercise price, brokerage fees and any applicable Tax Obligations would be sold upon exercise and you would receive only the remaining Shares subject to the exercised Option.  The Company reserves the right to permit this procedure for payment of the exercise price in the future, depending on the development of local law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;If you remit funds out of India to purchase Shares at exercise of the Option granted hereunder, you are responsible for complying with applicable exchange control regulations.  In particular, it will be your obligation to determine whether approval from the Reserve Bank of India is required prior to exercise or whether you have exhausted the investment limit of US$250,000 for the relevant fiscal year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You must repatriate any cash dividends paid on Shares acquired under the Plan to India, as well as any proceeds from the sale of Shares acquired under the Plan within a prescribed period of time (currently, within one hundred and eighty (180) days of receipt of cash dividends, and within ninety (90) days of receipt of sale proceeds), or such other period of time as may be required under applicable regulations.  You will receive a foreign inward remittance certificate (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FIRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from the bank where you deposit the foreign currency, and you must maintain the FIRC as proof of repatriation of funds in the event that the Reserve Bank of India or your Employer requests proof of repatriation.  It is your responsibility to comply with these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You are required to declare foreign bank accounts and any foreign financial assets (including Shares held outside of India) in your annual tax return.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor in this regard.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XII of the Agreement&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you acknowledge that the benefits received under the Plan will not be taken into account for any redundancy or unfair dismissal claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ITALY </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in Italy, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In accepting this Option, you acknowledge that (1)&#160;you have received a copy of the Plan, the Agreement and this Appendix&#59; (2)&#160;you have reviewed the applicable documents in their entirety and fully understand the contents thereof&#59; and (3)&#160;you accept all provisions of the Plan, the Agreement and this Appendix.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the Option granted, you further acknowledge that you have read and specifically and explicitly approve, without limitation, the following Sections of the Option Agreement&#58; Section I, Section IV, Section V, Section X, Section XII, Section XIII, Section XIV, Section XVII and the Data Privacy Notice for All European Economic Area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) &#47; European Union (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Jurisdictions, United Kingdom and Switzerland in this Appendix.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Italian residents who, at any time during the fiscal year, hold foreign financial assets (including cash and Shares) which may generate income taxable in Italy are required to report these assets on their annual tax returns (UNICO Form, RW Schedule) for the year during which the assets are held, or on a special form if no tax return is due.  These reporting obligations will also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Financial Assets Tax.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The fair market value of any Shares held outside of Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is subject to a foreign assets tax at a flat rate.  The fair market value is considered to be the value of the Shares on the Nasdaq Global Select Market on December 31 of the applicable year in which you held the Shares (or when the Shares are acquired during the course of the year, the tax is levied in proportion to the actual days of holding over the calendar year).  No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does not exceed a certain threshold.  You should consult with your personal tax advisor about the foreign financial assets tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you acquire Shares valued at more than &#165;100,000,000 in a single transaction, you must file a Securities Acquisition Report with the Ministry of Finance through the Bank of Japan within 20 days of the purchase of the Shares.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, if you pay more than &#165;30,000,000 in a single transaction for the purchase of Shares when you exercise the Option, you must file a Payment Report with the Ministry of Finance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">through the Bank of Japan by the 20th day of the month following the month in which the payment was made.  The precise reporting requirements vary depending on whether or not the relevant payment is made through a bank in Japan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Payment Report is required independently from a Securities Acquisition Report.  Therefore, if the total amount that you pay upon a one-time transaction for exercising the Option and purchasing Shares exceeds &#165;100,000,000, then you must file both a Payment Report and a Securities Acquisition Report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You will be required to report to the Japanese tax authorities details of any assets held outside of Japan as of December 31st (including any Shares acquired under the Plan) to the extent such assets have a total net fair market value exceeding &#165;50,000,000.  Such report will be due by March 15 each year.  You should consult with your personal tax advisor as to whether the reporting obligation applies to you and whether you will be required to include in the report details of any outstanding Options, Shares or cash that you hold.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare all foreign financial accounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> non-Korean bank accounts, brokerage accounts holding Shares, etc.) to the Korean tax authority and file a report regarding such accounts if the monthly balance of such accounts exceeds a certain threshold.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor to ensure compliance with this requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LITHUANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you (i) hold certain job positions established by the law or (ii) donate to political parties or political campaigners, you must file an Annual Asset Return of the Individual (Family) in Form No. FR0001 with respect to assets held outside of Lithuania (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares).  If you open an account in a foreign financial institution and annual turnover in the account exceeds EUR 15,000, you must file a foreign account report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of the Agreement.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Option granted hereunder, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Option Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.  You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section XII of the Agreement, in which the following is clearly described and established&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in the Plan are offered by Amgen Inc. on a wholly discretionary basis. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. and its Affiliates are not responsible for any decrease in the value of the Option granted and&#47;or Shares issued under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement and Policy Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;In accepting the Option granted hereunder, you expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Shares do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Amgen-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is as a result of a unilateral and discretionary decision of Amgen Inc.&#59; therefore, Amgen Inc. reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time without any liability to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen Inc., its Affiliates, stockholders, officers, agents or legal representatives with respect to any claim that may arise. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Spanish Translation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento del Otorgamiento.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Al aceptar cualquier Opci&#243;n bajo el presente documento, usted reconoce que ha recibido una copia del Plan, que ha revisado el mismo en su totalidad, as&#237; como tambi&#233;n el Acuerdo de Opci&#243;n, incluyendo este Ap&#233;ndice, adem&#225;s que comprende y est&#225; de acuerdo con todas las disposiciones tanto del Plan y del Opci&#243;n, incluyendo este Ap&#233;ndice.  Asimismo, usted reconoce que ha le&#237;do y manifiesta espec&#237;ficamente y expresamente la conformidad con los t&#233;rminos y condiciones establecidos en la Secci&#243;n XII del Acuerdo de Opci&#243;n, en los que se establece y describe claramente que&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan de ninguna manera constituye un derecho adquirido. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan y su participaci&#243;n en el mismo son ofrecidos por Amgen Inc. de forma completamente discrecional. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. y sus Afiliados no son responsables de ninguna disminuci&#243;n en el valor de la opci&#243;n otorgada y&#47;o de las Acciones Comunes emitidas mediante el Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento de la Ley Laboral y Declaraci&#243;n de Pol&#237;tica. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Al aceptar cualquier Opci&#243;n bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la &#250;nica responsable de la administraci&#243;n del Plan y que su participaci&#243;n en el mismo y la adquisici&#243;n de Acciones Comunes no constituyen de ninguna manera una relaci&#243;n laboral entre usted y Amgen </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Inc., debido a que su participaci&#243;n en el Plan es &#250;nicamente una relaci&#243;n comercial y que su &#250;nico empleador es Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-M&#233;xico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Derivado de lo anterior, usted reconoce expresamente que el Plan y los beneficios a su favor que pudieran derivar de la participaci&#243;n en el mismo, no establecen ning&#250;n derecho entre usted y su empleador, Amgen &#8211; M&#233;xico, y no forman parte de las condiciones laborales y&#47;o los beneficios otorgados por Amgen &#8211; M&#233;xico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n del mismo no constituir&#225; un cambio o desmejora de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Asimismo, usted entiende que su participaci&#243;n en el Plan es resultado de la decisi&#243;n unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y&#47;o descontinuar su participaci&#243;n en el Plan en cualquier momento y sin ninguna responsabilidad para usted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Amgen Inc., por cualquier compensaci&#243;n o da&#241;os y perjuicios, en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de toda responsabilidad, como as&#237; tambi&#233;n a sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Options and the Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Options may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and your Employer and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of Amgen-Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="warninglabela.jpg" src="warninglabela.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NORWAY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Norwegian residents may be subject to foreign asset reporting as part of their ordinary tax return. Norwegian banks, financial institutions, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limited companies etc. must report certain information to the Tax Administration. Such information may then be pre-completed in a Norwegian resident&#8217;s tax return. However, if the resident has traded, or is the owner of, financial instruments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares) not pre-completed in the tax return, the Norwegian resident must enter this information in Form RF-1159, which is an appendix to the tax return.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Options will be considered assets and are, therefore, subject to wealth tax. An exemption from wealth tax may be available for non-transferrable awards. However, because the wealth tax regulations and the practice of the tax authorities are not well developed, Norwegian residents should provide the tax authorities with information concerning the Options in the annual tax return even if the Norwegian resident maintains that no wealth tax is payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In general, Norwegian residents should not be subject to any foreign exchange requirements in connection with their acquisition or sale of Shares under the Plan, except normal reporting requirements to the Norwegian Currency Registry. If any transfer of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must file reports with the National Bank of Poland if the aggregate value of Shares and cash held in such foreign accounts exceeds PLN 7,000,000.  If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National Bank of Poland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently &#8364;15,000 (or PLN 15,000 if such transfer of funds is associated with the business activity of a consultant)).  You must store all documents connected with any foreign exchange transactions you engage in for a period of five (5) years from the end of the year when such transactions were made.  Penalties may apply for failure to comply with exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PORTUGAL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent to Receive Information in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Conhecimento da Lingua.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Certain transfers of funds may need to be reported to the National Office for Prevention and Control of Money Laundering on specific forms by the relevant bank or financial institution.  If you deposit proceeds from the sale of Shares or the receipt of dividends in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income.  You should consult with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RUSSIA </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You may be required to repatriate certain cash amounts received with respect to the Option to Russia (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, cash dividends, sale proceeds) as soon as you intend to use those cash amounts for any purpose, including reinvestment.  If the repatriation requirement applies, such funds must initially be credited to you through a foreign currency account at an authorized bank in Russia.  After the funds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.  Under the Directive N 5371-U of the Russian Central Bank (the &#8220;CBR&#8221;), the repatriation requirement may not apply in certain cases with respect to cash amounts received in an account that is considered by the CBR to be a foreign brokerage account.  Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The exchange control rules and regulations in Russia, including temporary restrictions imposed by the Russian government in March 2022, are subject to frequent change.  You should consult with your personal legal advisor to determine the applicability of any repatriation requirements applicable to any Shares or cash received in connection with the Plan and held in an account outside Russia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The Option granted hereunder, the Agreement, including this Appendix, the Plan and all other materials you may receive regarding your participation in the Plan or the Option granted hereunder do not constitute advertising or an offering of securities in Russia.  The issuance of Shares under the Plan has not and will not be registered in Russia&#59; therefore, Shares may not be offered or placed in public circulation in Russia.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In no event will Shares acquired under the Plan be delivered to you in Russia&#59; any and all Shares will be maintained on your behalf in the United States.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are not permitted to sell any Shares acquired under the Plan directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that you must complete and return a Consent to Processing of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) form to the Company.  Further, you understand and agree that if you do not complete and return a Consent form to the Company, the Company will not be able to administer or maintain the Option.  Therefore, you understand that refusing to complete a Consent form or withdrawing your consent may affect your ability to participate in the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Russian residents are required to file the following reports or notifications with the Russian tax authorities, if applicable&#58; (i) annual cash flow reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; (ii) financial asset (including Shares) reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; and (ii) a one-time notification within one (1) month of opening, closing, or changing details of an offshore brokerage account.  You are encouraged to contact your personal tax advisor before remitting your proceeds from participation in the Plan to Russia to ensure compliance with applicable requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Anti-Corruption Legislation Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Individuals holding public office in Russia, as well as their spouses and dependent children, may be prohibited from opening or maintaining a foreign brokerage or bank account and holding any securities, whether acquired directly or indirectly, in a foreign company (including Shares acquired under the Plan).  You should consult with your personal legal advisor to determine whether this restriction applies to your circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby agree that any Shares acquired pursuant to the Option will not be offered for sale in Singapore prior to the six (6)-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or pursuant to, and in accordance with the conditions of, any other applicable provisions of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The grant of the Option is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made with a view to the Option being subsequently offered for sale to any other party.  The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Directors (including alternate, substitute, associate and shadow directors) of a Singapore Affiliate are subject to certain notification requirements under the Singapore Companies Act, regardless of whether they are resident or employed in Singapore. Directors of a Singapore Affiliate must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Options, Shares, etc.) in the Company or any related company within two (2) business days of (i)&#160;its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> when the Shares are sold), or (iii) becoming a director. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVAK REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Slovak Republic residents who carry on business activities as an independent entrepreneur (in Slovakian, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">podnikatel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), must report foreign assets </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(including any Shares) to the National Bank of Slovakia (provided that the value of the foreign assets exceeds an amount of EUR&#160;2,000,000).  These reports must be submitted on a monthly basis by the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of the respective calendar month, as well as on a quarterly basis by the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of the calendar month following the respective calendar quarter, using notification form DEV (NBS) 1-12, which may be found at the National Bank of Slovakia&#8217;s website at </font><font style="color:#002060;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.nbs.sk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVENIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The following provision supplements Section XII of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you consent to participation in the Plan and acknowledge that you have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to grant the Option under the Plan to individuals who may be members of the Board or Employees of the Company or its Affiliates throughout the world.  The decision is a limited decision, which is entered into upon the express assumption and condition that the Option granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the Agreement, including this Appendix.  Consequently, you understand that the Option granted hereunder is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary grant of the Option since the future value of the Option and the underlying Shares is unknown and unpredictable.  In addition, you understand that the Option granted hereunder would not be made but for the assumptions and conditions referred to above&#59; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of an Option or right to an Option shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further, the vesting of the Option is expressly conditioned on your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Option may cease vesting immediately, in whole or in part, effective on the date of your termination of employment (unless otherwise specifically provided in Section IV of the Agreement).  This will be the case, for example, even if (1) you are considered to be unfairly dismissed without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, subject to a &#8220;despido improcedente&#8221;)&#59; (2) you are dismissed for disciplinary or objective reasons or due to a collective dismissal&#59; (3) you terminate service due to a change of work location, duties or any other employment or contractual condition&#59; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate&#59; or (5) your employment terminates for any other reason whatsoever.  Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Options that were not vested on the date of your termination of employment, as described in the Plan and the Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you have read and specifically accept the conditions referred to in Section IV of the Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No &#8220;offer of securities to the public,&#8221; as defined under&#160;Spanish&#160;law,&#160;has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and does not constitute a public offering prospectus. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you acquire Shares under the Plan, you must declare the acquisition to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Direccion General de Comercio e Inversiones </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DGCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If you acquire the Shares through the use of a Spanish financial institution, that institution will automatically make the declaration to the DGCI for you&#59; otherwise, you will be required to make the declaration by filing a D-6 form.  You must declare ownership of any Shares with the DGCI each January while the Shares are owned and must also report, in January, any sale of Shares that occurred in the previous year for which the report is being made, unless the sale proceeds exceed the applicable threshold, in which case the report is due within one (1) month of the sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare electronically to&#160;the Bank of Spain any securities accounts (including brokerage accounts held abroad), as well as the Shares held in such accounts if the&#160;value of the transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax year exceed &#8364;1,000,000.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent that you hold Shares and&#47;or have bank accounts outside of Spain with a value in excess of &#8364;50,000 (for each type of asset) as of December 31 each year, you will be required to report information on such assets in your tax return (tax form 720) for such year.&#160;&#160;After such Shares and&#47;or accounts are initially reported, the reporting obligation will apply for subsequent years only if the value of any previously-reported Shares or accounts increases by more than &#8364;20,000 or if you sell or otherwise dispose of any previously-reported Shares or accounts.  If the value of such Shares and&#47;or accounts as of December 31 does not exceed &#8364;50,000, a summarized form of declaration may be presented.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Authorization to Withhold. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section V of the Agreement&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax Obligations as set forth in the Agreement, in accepting the Options, you authorize the Company to withhold Shares or to sell Shares otherwise issuable to you upon exercise to satisfy Tax Obligations, regardless of whether the Company and&#47;or Employer have an obligation to withhold such Tax Obligations, provided that such withholding would not, in the Company&#8217;s determination, result in adverse accounting consequences to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Neither this document nor any other materials relating to the Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Company or one of its Subsidiaries or (iii) has been or will be filed with, approved or supervised by any Swiss </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may acquire and remit foreign currency (including proceeds from the sale of Shares or the receipt of dividends) up to US$5,000,000 per year without justification.  If the transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.  If the transaction amount is US$500,000 or more in a single transaction, you must also provide supporting documentation to the satisfaction of the remitting bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you receive funds in connection with the Plan (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, dividends or sale proceeds) with a value equal to or greater than US$1,000,000 per transaction, you are required to immediately repatriate such funds to Thailand.  Any foreign currency repatriated to Thailand must be converted to Thai Baht or deposited into a foreign currency deposit account opened with any commercial bank in Thailand acting as the authorized agent within 360 days from the date the funds are repatriated to Thailand.  You are also required to inform the authorized agent of the details of the foreign currency transaction, including your identification information and the purpose of the transaction. The Employee is responsible for ensuring compliance with all exchange control laws in Thailand.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you do not comply with the above obligations, you may be subject to penalties assessed by the Bank of Thailand.  Because exchange control regulations change frequently and without notice, you should consult your legal advisor before selling any Shares (or receiving any other funds in connection with the Plan) to ensure compliance with current regulations.  It is your responsibility to comply with exchange control laws in Thailand, and neither the Company nor your Employer will be liable for any fines or penalties resulting from failure to comply with applicable laws.&#160;&#160;&#160;&#160;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Options under the Plan are granted only to select Board members and Employees of the Company and its Affiliates and are for the purpose of providing equity incentives.  The Plan and the Agreement are intended for distribution only to such Board members and Employees and must not be delivered to, or relied on by, any other person.  You should conduct your own due diligence on the Options offered pursuant to this Agreement.  If you do not understand the contents of the Plan and&#47;or the Agreement, you should consult an authorized financial adviser.  The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section V of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to Section V of the Agreement, you agree that you are liable for all Tax Obligations and hereby covenant to pay all such Tax Obligations as and when requested by the Company or your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and your Employer against any taxes that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you are an executive officer or director within the meaning of Section 13(k) of the Exchange Act, as amended from time to time, you understand that you may not be able to indemnify the Company or your Employer for the amount of income tax not collected from or paid by you, as it may be considered a loan.  In the event that you are an executive officer or director and income tax is not collected from you within ninety (90) days after the end of the tax year in which the Taxable Event occurs, the amount of any uncollected income tax may constitute an additional benefit to you on which additional income tax and national insurance contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may be payable.  You acknowledge that you are responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying your Employer for the amount of any NICs due on this additional benefit, which the Company or your Employer may obtain from you by any of the means set forth in Section V of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the maximum applicable withholding rate is used, any over-withheld amount may be credited to you by the Company or your Employer (with no entitlement to the Common Stock equivalent) or if not so credited, you may seek a refund from the local tax authorities. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are a resident of the United Kingdom between the Grant Date and the vesting of the Option, as a condition of the Option granted hereunder, you agree to accept any liability for secondary Class 1 National Insurance Contributions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which may be payable by the Company or your Employer with respect to the exercise of the Option and issuance of Shares subject to the Option, the assignment or release of the Option for consideration, or the receipt of any other benefit in connection with the Option.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to the foregoing, you agree to make an election (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in the form specified and&#47;or approved for such election by HMRC, that the liability for your Employer NICs payments on any such gains shall be transferred to you to the fullest extent permitted by law. You further agree to execute such other elections as may be required between you and any successor to the Company and&#47;or your Employer. You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section V of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Option, without any liability to the Company or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED STATES</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">TERMS AND CONDITIONS</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provision replaces Section IV(B)(1) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of termination of your employment (whether or not in breach of local labor laws), your right to exercise the Option and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively employed&#59; provided, however, that such right will be extended by any notice period mandated by law (e.g. the Worker Adjustment and Retraining Notification Act (&#8220;WARN Act&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave.  Your right, if any, to exercise the Option after termination of employment will be measured by the date of termination of your active employment&#59; provided, however, that such right will be extended by any notice period mandated by law (e.g. the Worker Adjustment and Retraining Notification Act (&#8220;WARN Act&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave, unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave.  Notwithstanding anything to the contrary herein, in no event shall the term of this Option extend beyond the Expiration Date set forth on the Award Notice and in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>exhibit105-formofrestricte.htm
<DESCRIPTION>FORM OF RESTRICED STOCK UNIT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i583914b2534b40c9ab170c1a518f0727_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.5</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Award Notice</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank &#38; Trust Co., FSB).  This Award Notice shall be replaced by the equivalent pages on such website.  References to Award Notice in this Agreement shall then refer to the equivalent pages on such website.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#93; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This notice of Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan.  The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement.  Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Type&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan&#58;&#160;&#160;&#160;&#160;Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Price&#58; &#160;&#160;&#160;&#160;$________</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Shares&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Units</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Means the vesting date indicated in the Vesting Schedule</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;&#160;&#160;&#160;&#160;Means the schedule of vesting set forth under Vesting Details </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Details&#58;&#160;&#160;&#160;&#160;Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">IMPORTANT NOTICE REGARDING ACCEPTANCE OF THE AWARD AND THE REQUIREMENT TO OPEN A BROKERAGE ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RESIDENTS OF THE U.S. AND PUERTO RICO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160; Please read this Award Notice, the Plan and the Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) carefully.&#160; If you, as a resident of the U.S. or Puerto Rico, do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> wish to receive this Award and&#47;or you do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> consent and agree to the terms and conditions on which this Award is offered, as set forth in the Grant Documents, then you must reject the Award by contacting the Merrill Lynch call center (800) 97AMGEN (800-972-6436) within the U.S., Puerto Rico and Canada or +1 (609) 818-8910 from all other countries (Merrill Lynch will accept the charges for your call) no later than the forty-fifth calendar day following the day on which this Award Notice is made available to you, in which case the Award will be cancelled.&#160; For the purpose of determining the forty-five calendar days, Day 1 will be the day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> following the day on which this Award Notice is made available to you. Your failure to notify the Company of your rejection of the Award within this specified period will constitute your acceptance of the Award and your agreement with all terms and conditions of the Award, as set forth in the Grant Documents.  If you agree to the terms and conditions of your grant and you desire to accept it, then no further action is needed on your part to accept the grant.  However, you must still open a brokerage account as directed by the Company, by 1&#58;00 pm Pacific Time on or before the date that is 11 months after the date of grant.  This step is necessary to process transactions related to your equity grant.  If you do not open a brokerage account by this deadline, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">your grant will be cancelled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">This provision is only for use on the form of grant used for the U.S. and Puerto Rico.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><div id="i583914b2534b40c9ab170c1a518f0727_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SPECIFIC TERMS OF YOUR GRANT OF RESTRICTED STOCK UNITS ARE FOUND IN THE PAGES RELATING TO THE GRANT OF RESTRICTED STOCK UNITS FOUND ON MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK &#38; TRUST CO., FSB) (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AWARD NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;) WHICH ACCOMPANIES THIS DOCUMENT.  THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS RESTRICTED STOCK UNIT AGREEMENT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;On the Grant Date specified in the Award Notice, Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), has granted to you, the grantee named in the Award Notice, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Number of Units with respect to the number of shares of the $0.0001 par value common stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) specified in the Award Notice, on the terms and conditions set forth in this Restricted Stock Unit Agreement, any additional terms and conditions for your country set forth in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the Award Notice (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Units shall constitute Restricted Stock Units under Section 9.5 of the Plan, which is incorporated herein by reference.  Capitalized terms not defined herein shall have the meanings assigned to such terms in the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt;text-decoration:underline">Vesting Schedule and Termination of Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.68pt">General.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, on each Vesting Date, the Number of Units indicated on the Vesting Schedule shall vest, provided that you have remained continuously and actively employed with the Company or an Affiliate (as defined in the Plan) through each applicable Vesting Date, unless (i) &#91;your employment has terminated due to your Voluntary Termination (as defined in paragraph (d) of this Section I below) &#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#91;(ii)&#93; you experience a Qualified Termination (as defined below), or (iii)&#91;(ii)&#93; as otherwise determined by the Company in the exercise of its discretion as provided in paragraph (f) of this Section I.  The Units represent an unfunded, unsecured promise by the Company to deliver Shares.  Only whole Shares shall be issued upon vesting of the Units, and the Company shall be under no obligation to issue any fractional Shares to you.  If your employment with the Company or an Affiliate is terminated for any reason or for no reason, including if your active employment is terminated by the Company or an Affiliate without Cause (as defined below), or in the event of any other termination of your active employment caused directly or indirectly by the Company or an Affiliate, except as otherwise provided in paragraphs (b), (c), &#91;(d), &#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (e) or (f) of this Section I below, your unvested Units shall automatically expire and terminate on the date of termination of your active employment.  Notwithstanding anything herein to the contrary, the Vesting Schedule may be accelerated (by notice in writing) by the Company in its sole discretion at any time that the Units remain outstanding and unvested (in whole or in part).  In addition, if not prohibited by local law, vesting may be suspended by the Company in its sole discretion during a leave of absence as provided from time to time according to Company policies and practices.  </font></div><div><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Paragraph (d) of Section I of this Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Permanent and Total Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding the provisions in paragraph (a) above, if your employment with the Company or an Affiliate terminates due to your Permanent and Total Disability (as defined below), then the vesting of Units granted under this Agreement shall be accelerated, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), to vest as of the day immediately preceding such termination of your employment with respect to all Units granted hereunder, except that if the Units were granted in the calendar year in which such termination occurs, the Units shall be accelerated to vest with respect to a number of Units equal to the number of Units subject to this Agreement multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any Units that remain unvested shall automatically expire and terminate on the date of the termination of your active employment due to your Permanent and Total Disability without consideration therefor.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.68pt">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions in paragraph (a) above, if your employment with the Company or an Affiliate terminates due to your death, then the vesting of Units granted under this Agreement shall be accelerated to vest as of the day immediately preceding your death with respect to all Units granted hereunder, except that if the Units were granted in the calendar year in which your death occurs the Units shall be accelerated to vest with respect to a number of Units equal to the number of Units subject to this Agreement multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any Units that remain unvested shall automatically expire and terminate on the date of the termination of your active employment due to your death without consideration therefor.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">&#91;Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the provisions in paragraph (a) above, if you terminate your employment with the Company or an Affiliate due to your voluntary termination (and such voluntary termination is not the result of Permanent and Total Disability (as defined below)) after you are at least sixty-five (65) years of age, or after you are at least fifty-five (55) years of age and have been an employee of the Company and&#47;or an Affiliate for at least ten (10) years in the aggregate as determined by the Company in its sole discretion according to Company policies and practices as in effect from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Voluntary Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the Units will vest pursuant to the Vesting Schedule without regard to the termination of employment prior to the Vesting Date, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), with respect to all Units granted hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the Units were granted in the calendar year in which the Voluntary Termination occurs, the Units will vest pursuant to the Vesting Schedule provided in the Award Notice, provided, that each tranche of Units scheduled to vest upon each remaining Vesting Date in the Vesting Schedule will vest only with respect to the number of Units in such tranche multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any Units that remain unvested in excess of such number of Units shall automatically expire and terminate on the date of termination of your active employment due to your Voluntary Termination without consideration therefor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in the event of your death following your Voluntary Termination, any Units that remain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">outstanding as of the date of your death will become vested (and the Vesting Date with respect to such Units will occur) as of the day immediately preceding your death.  Notwithstanding the definition of Voluntary Termination set forth above, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in your jurisdiction that would likely result in the favorable treatment upon Voluntary Termination described above being deemed unlawful and&#47;or discriminatory, then the Committee will not apply the favorable treatment described above.&#93;&#91;Reserved&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.68pt">Qualified Termination after a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions in paragraph (a) above, in the event of a Qualified Termination (as defined below), then, to the extent permitted by applicable law, the vesting of Units granted under this Agreement shall be accelerated to vest as of the day immediately prior to the Qualified Termination.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:11.01pt">Continued Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions in paragraph (a) above, the Company may in its sole discretion at any time during the term of this Agreement, in writing, otherwise provide that the Units will vest pursuant to the Vesting Schedule without regard to the termination of employment prior to the Vesting Date, subject to any terms and conditions that the Company may determine.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your active employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date that you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of termination of your employment (whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are working or the terms of your employment agreement, if any), your right to receive Units and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively providing services and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, active employment would not include any period of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">garden leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any).  The Company shall have exclusive discretion to determine when you are no longer actively providing services for purposes of this Agreement (including whether you may still be considered to be providing services while on a leave of absence)&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (i) your conviction of a felony (or similar crime under applicable law, as determined by the Company), or (ii) your engaging in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out your duties, resulting, in either case, in material economic harm to the Company or any Affiliate, unless you believed in good faith that such conduct was in, or not contrary to, the best interests of the Company or any Affiliate.  For purposes of clause (ii) above, no act, or failure to act, on your part shall be deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">willful</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; unless done, or omitted to be done, by you not in good faith&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term under Section 22(e)(3) of the Code and with such permanent and total disability being certified prior to termination of your employment by (i) the U.S. Social Security Administration, (ii) the comparable governmental authority applicable to an Affiliate, (iii) such other body having the </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Paragraph(d) of Section I of this Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relevant decision-making power applicable to an Affiliate, or (iv) an independent medical advisor appointed by the Company in its sole discretion, as applicable, in any such case&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;if you are an employee who participates in the Change of Control Plan (as defined below), your termination of employment within two (2) years following a Change of Control (i) by the Company other than for Cause, Disability (as defined below), or as a result of your death or (ii) by you for Good Reason (as defined in the Change of Control Plan)&#59; or</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;if you are an employee who does not participate in the Change of Control Plan or the Change of Control Plan is no longer in effect, your termination of employment within two (2) years following a Change of Control by the Company other than for Cause, Disability (as defined below), or as a result of your death&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160; the acquisition (other than from the Company) by any person, entity or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (excluding, for this purpose, the Company or any of its Affiliates, or any employee benefit plan of the Company or any of its Affiliates which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either the then-outstanding Shares or the combined voting power of the Company&#8217;s then-outstanding voting securities entitled to vote generally in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160; the consummation by the Company of a reorganization, merger, consolidation, (in each case, with respect to which persons who were the stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own more than fifty percent (50%) of the combined voting power entitled to vote generally in the election of directors of the reorganized, merged or consolidated company&#8217;s then-outstanding voting securities) or a liquidation or dissolution of the Company or of the sale of all or substantially all of the assets of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything herein or in the Agreement to the contrary, if a Change of Control constitutes a payment event with respect to any Unit that is subject to United States income tax and which provides for a deferral of compensation that is subject to Section 409A of the Code, the transaction or event described in subsection (A) or (B) above must also constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">change in control event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; as defined in U.S. Treasury Regulation &#167;&#160;1.409A-3(i)(5), in order to constitute a Change of Control for purposes of payment of such Unit.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company&#8217;s change of control and severance plan, including the Amgen Inc. Change of Control Severance Plan, as amended and restated, effective as of December 9, 2010 (and any subsequent amendments thereto), or equivalent plan governing the provision of benefits to eligible employees upon the occurrence of a Change of Control (including resulting from a termination of employment that occurs within a specified time period following a Change of Control), as in effect immediately prior to a Change of Control&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be determined in accordance with the Company&#8217;s long-term disability plan as in effect immediately prior to a Change of Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Form and Timing of Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to satisfaction of Tax Obligations or similar obligations as provided for in Section III, any vested Units shall be settled by the Company delivering to you a number of Shares equal to the number of such vested Units or in a lump sum in cash with a value equal to the Fair Market Value of the number of Shares subject to the vested Units as of the applicable Vesting Date (without interest thereon), or in a combination of Shares and cash, as determined by the Administrator at any time prior to settlement and in its discretion, as soon as practicable, and in any event within 90 days, after the applicable Vesting Date, which for purposes of this Section II, includes the date of any accelerated vesting, if any (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  &#91;(For the avoidance of doubt, in the event that any Units continue to vest following a Voluntary Termination in accordance with Section 1(d) above, the Vesting Date(s) for purposes of settlement pursuant to this Section II shall be the regularly scheduled Vesting Dates following such termination.)&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding anything to the contrary in the foregoing, in the event that (i) the vesting and settlement of Units is conditioned on your execution and delivery of a release and (ii) the Settlement Period commences in one calendar year and ends in the next calendar year, the Units will be settled in the second calendar year.  Shares issued in respect of a Unit shall be deemed to be issued in consideration of past services actually rendered by you to the Company or an Affiliate or for its benefit for which you have not previously been compensated or for future services to be rendered, as the case may be, which the Company deems to have a value at least equal to the aggregate par value thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.03pt;text-decoration:underline">Tax Withholding&#59; Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or your actual employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Obligations&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, you acknowledge that the ultimate liability for all Tax Obligations is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or your Employer.  You further acknowledge that the Company and&#47;or your Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Units or the underlying Shares, including the grant of the Units, the vesting of Units, the conversion of the Units into Shares or the receipt of an equivalent cash payment, the subsequent sale of any Shares acquired at vesting and the receipt of any Dividends (as defined in Section IV, below) or Dividend Equivalents, and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Units to reduce or eliminate your liability for Tax Obligations or achieve any particular tax result.  Furthermore, if you become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, as applicable, you shall pay, or make adequate arrangements satisfactory to the Company or to your Employer (in their sole discretion) to satisfy all Tax Obligations.  In this regard, you authorize the Company and&#47;or your Employer or their respective agents, at their discretion, to satisfy all applicable Tax Obligations by one or a combination of the following&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;withholding from your wages or other cash compensation paid to you by the Company and&#47;or your Employer&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Paragraph (d) of Section I of this Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;withholding from proceeds of the sale of Shares acquired upon vesting or payment of the Units either through your voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;withholding in Shares issuable, or cash payable, upon vesting or payment of the Units, provided that, if such Shares are withheld, the Company and your Employer shall only withhold an amount of Shares with a fair market value not to exceed the Tax Obligations as determined in the discretion of the Company or your Employer, as applicable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Depending on the withholding method, the Company may withhold or account for Tax Obligations by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates.  If the Tax Obligations are satisfied by withholding in Shares, for tax purposes you are deemed to have been issued the full number of Shares subject to the vested Units, notwithstanding that a number of the Shares is held back and not actually issued to you solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan (any Shares withheld by the Company hereunder shall not be deemed to have been issued by the Company for any purpose under the Plan and shall remain available for issuance thereunder). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be or were not satisfied by the means previously described.&#160; You agree to take any further actions and execute any additional documents as may be necessary to effectuate the provisions of this Section III.  Notwithstanding Section II above, the Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if you fail to comply with your obligations in connection with the Tax Obligations.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Dividend Equivalents</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Crediting and Payment of Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to this Section IV, Dividend Equivalents shall be credited on each Unit granted to you under this Agreement in the manner set forth in the remainder of this Section IV.  If the Company declares one or more dividends or distributions (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on its Common Stock with a record date which occurs during the period commencing on the Grant Date through and including the day immediately preceding the day the shares of Common Stock subject to the Units are issued to you, whether in the form of cash, Common Stock or other property, then on the date such Dividend is paid to the Company&#8217;s stockholders you shall be credited with an amount equal to the amount or fair market value of such Dividend which would have been payable to you if you held a number of shares of Common Stock equal to the number of your Units as of the record date for such Dividend, unless the Units have been forfeited between the record date and payment date for such Dividend.  Any such Dividend Equivalents shall be credited and deemed reinvested in the Common Stock as of the Dividend payment date.  Dividend Equivalents shall be payable in full shares of Common Stock, unless the Administrator determines, at any time prior to payment and in its discretion, that they shall be payable in cash.  Dividend Equivalents payable with respect to fractional shares of Common Stock shall be paid in cash.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise expressly provided in this Section IV, any Dividend Equivalents credited to you shall be subject to all of the provisions of this Agreement which apply to the Units with respect to which they have been credited and shall be payable, if at all, at the time and to the extent that the underlying Unit becomes payable.  Dividend Equivalents shall not be payable on any Units that do not vest, or are forfeited, pursuant to the terms of this Agreement.  Dividend Equivalent rights and any amounts that may become distributable in respect thereof shall be treated separately from the Units and the rights arising in connection therewith for purposes of the designation of time and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">form of payments required by Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No benefit payable under, or interest in, this Agreement or in the Shares that are scheduled to be issued to you hereunder shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge and any such attempted action shall be void and no such benefit or interest shall be, in any manner, liable for, or subject to, your or your beneficiary&#8217;s debts, contracts, liabilities or torts&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, nothing in this Section V shall prevent transfer (i) by will or (ii) by applicable laws of descent and distribution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notices provided for in this Agreement or the Plan shall be given in writing or electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail or equivalent foreign postal service, postage prepaid, addressed to you at such address as is currently maintained in the Company&#8217;s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator.  Such notices may be given using any automated system for the documentation, granting or settlement of Awards, such as a system using an internet website or interactive voice response, as approved by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is subject to all the provisions of the Plan, which provisions are hereby made a part of this Agreement, including without limitation the provisions of Section 9.5 of the Plan relating to Restricted Stock Units, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of this Agreement and those of the Plan, the provisions of the Plan shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms of this Agreement shall be governed by the laws of the State of Delaware without giving effect to principles of conflicts of laws.  For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Agreement is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Code Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The time and form of payment of the Units is intended to comply with the requirements of Section 409A and this Agreement shall be interpreted in accordance with Section 409A.  Accordingly, no acceleration or deferral of any payment shall be permitted if it would cause the payment of the Units to violate Section 409A.  In addition, notwithstanding any provision herein to the contrary, in the event that following the Grant Date, the Committee (as defined in the Plan) determines that it may be necessary or appropriate to do so, the Committee may adopt such amendments to the Plan and&#47;or this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Plan and&#47;or the Units from the application of Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to this Award, or (b) comply with the requirements of Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this paragraph shall not create an obligation on the part of the Committee to adopt any such amendment, policy or procedure or take any such other action.  For purposes of Section 409A, the right to receive payment of Units at each Vesting Date shall be treated as a right to receive separate and distinct payments. No payment hereunder shall be made to you during the six (6)-month period following your &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">separation from service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (within the meaning of Section 409A) to the extent that the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determines that paying such amount at the time set forth herein would be a prohibited distribution under Section 409A(a)(2)(B)(i). If the payment of any such amounts is delayed as a result of the previous sentence, then within thirty (30) days following the end of such six (6)-month period (or, if earlier, your death), the Company shall pay to you (or to your estate) the cumulative amounts that would have otherwise been payable to you during such period, without interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electing to accept this Agreement, you acknowledge receipt of this Agreement and hereby confirm your understanding that the terms set forth in this Agreement constitute, subject to the terms of the Plan, which terms shall control in the event of any conflict between the Plan and this Agreement, the entire agreement and understanding of the parties with respect to the matters contained herein and supersede any and all prior agreements, arrangements and understandings, both oral and written, between the parties concerning the subject matter of this Agreement.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan (including this Agreement) by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Acknowledgement of Nature of Plan and Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting this Agreement, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future awards of Units, or benefits in lieu of Units even if Units have been awarded in the past&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;your participation in the Plan is voluntary&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the grant of Units, the Shares subject to the Units, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;neither the grant of Units nor any provision of this Agreement, the Plan or the policies adopted pursuant to the Plan confer upon you any right with respect to employment or continuation of current employment and shall not interfere with the ability of your Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;in the event that you are not an employee of the Company or any Affiliate, the Units shall not be interpreted to form an employment contract or relationship with the Company or any Affiliate&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;in consideration of the grant of Units hereunder, no claim or entitlement to compensation or damages arises from termination of Units, and no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from termination of your employment by the Company or an Affiliate (regardless of the reason for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and you irrevocably release the Company and your Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Units, the Shares subject to the Units, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k) &#160;&#160;&#160;&#160;except as otherwise provided in this Agreement or the Plan, the Units and the benefits evidenced by this Agreement do not create any entitlement to have the Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;the following provisions apply only if you are providing services outside the United States&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(i)  for employment law purposes outside the United States, the Units, Shares subject to the Units, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(ii)  neither the Company, your Employer nor any Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Units or of any amounts due to you pursuant to the settlement of the Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">No Advice Regarding Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying Shares.  You should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (which constitutes a part of this Agreement), are subject to the laws of any foreign jurisdiction, or relocate to one of the countries included in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Units granted hereunder shall be subject to any additional terms and conditions for your country set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and to the following additional terms and conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the terms and conditions of this Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are deemed modified to the extent necessary or advisable to comply with applicable foreign laws or facilitate the administration of the Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;if applicable, the effectiveness of your award of Units is conditioned upon its compliance with any applicable foreign laws, regulations, rules or local governmental </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulatory exemption and subject to receipt of any required foreign regulatory approvals&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;to the extent necessary to comply with applicable foreign laws, the payment of any earned Units shall be made in cash or Common Stock, at the Company&#8217;s election&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the Company may take any other action, before or after an award of Units is made, that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary contained herein, the Company shall not take any actions hereunder that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation, or the rules of any Securities Exchange.  Notwithstanding anything to the contrary contained herein, the Shares issuable upon vesting of the Unit shall not be issued unless such Shares are then registered under the Securities Act, or, if such Shares are not then so registered, the Company has determined that such vesting and issuance would be exempt from the registration requirements of the Securities Act, and that the issuance satisfied all other applicable legal requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:11.69pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.  In order for the Company to facilitate your participation in the Plan, the Company and your Employer must collect and use personal data about you.  In accordance with applicable laws, reasonable security measures will be implemented and maintained to protect the security of your personal data&#59; however, you understand that absolute security cannot be guaranteed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and your Employer may hold certain personal information about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor, for the purposes of implementing, administering and managing the Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Units may be deposited.  You understand that such authorized recipients of your personal data may be located in countries that do not provide the same level of data privacy laws and protections as the country in which your personal data originated.  Transfers of personal data among Company and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on Company&#8217;s BCRs, please visit http&#58;&#47;&#47;www.amgen.com&#47;bcr&#47;.  You acknowledge that the collection, use and transfer of your personal data is necessary to facilitate to your participation in the Plan, as well as to grant you Units or other equity awards and administer or maintain such awards.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You may correct or update your personal data previously provided to Company, by completing the form located at&#160;https&#58;&#47;&#47;preferences.amgen.com.  Subject to applicable law, you may have additional rights, including the right to object and&#47;or request destruction of your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">personal data.  To exercise these rights, where applicable, please contact your local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Agreement to be construed so as to foster the intent of this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electing to accept this Agreement, you acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement.  Further, if you have received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.7pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on your participation in the Plan, on the Units and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.71pt;text-decoration:underline">Compensation Subject to Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160; The Units subject to this Award and all compensation payable with respect to them shall be subject to recovery by the Company pursuant to&#160;any and all of the Company&#8217;s policies with respect to the recovery of compensation, as they shall be in effect and may be amended from time to time, to the maximum extent permitted by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement&#8217;s section headings are for convenience only and shall not constitute a part of this Agreement or affect this Agreement&#8217;s meaning.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">_____________________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Name&#58; </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><div id="i583914b2534b40c9ab170c1a518f0727_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDITIONAL TERMS AND CONDITIONS OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC. 2009 EQUITY INCENTIVE PLAN, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND&#47;OR RESTATED FROM TIME TO TIME</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GRANT OF RESTRICTED STOCK UNITS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(BY COUNTRY)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and&#47;or the Agreement to which this Appendix is attached.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix includes additional terms and conditions that govern any Units granted under the Plan if, under applicable law,&#160;you are a resident of, are deemed to be a resident of or are working in one of the countries listed below.&#160; Furthermore, the additional terms and conditions that govern any Units granted hereunder may apply to you if you transfer employment and&#47;or residency to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix also includes notifications relating to exchange control and other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of October 2022.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the Plan because the information may be outdated when you vest in the Units and acquire Shares under the Plan, or when you subsequently sell Shares acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the notifications are general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.  Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL NON-U.S. JURISDICTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding&#59; Issuance of Shares.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Company withholds or accounts for Tax Obligations by considering maximum applicable rates in your jurisdiction(s), in the event of over-withholding, you may receive a refund of any over-withheld amount in cash and will not be entitled to the equivalent amount in Shares, or if not refunded, you may seek a refund from the local tax authorities.  In the event of under-withholding, you may be required to pay any additional Tax Obligations directly to the applicable tax authority or to the Company and&#47;or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Insider Trading Restrictions&#47;Market Abuse Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker&#8217;s country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., Units) or rights linked to the value of Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Dividend Equivalents) during such times as you are considered to have &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">inside information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; regarding the Company (as defined by the laws in applicable jurisdictions).&#160; Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information.  Furthermore you could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees (other than on a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">need to know</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; basis) and (ii)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; You are responsible for ensuring your compliance with any applicable restrictions and you should speak with your personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account, Tax Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your country of residence may have certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any Dividends or Dividend Equivalents received, or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside of your country.  You may be required to report such accounts, assets or transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt.  You are responsible for ensuring your compliance with such regulations, and you should speak with your personal legal advisor on this matter. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) &#47; EUROPEAN UNION (&#8220;EU&#8221;) JURISDICTIONS, UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision replaces Section XIV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Please refer to the Fair Processing Notice previously provided by your local human resources representative, which notice governs the collection, use and transfer of your personal data necessary for the Company to facilitate your participation in the Plan.  If you have any questions or concerns regarding the Fair Processing Notice, including questions about your rights afforded thereunder, you should contact your local human resources representative or send an email to </font><font style="color:#0044cc;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">hrconnect&#64;amgen.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">For purposes of implementing, administering and managing the Plan, Company and your Employer may hold certain personal data about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Units may be deposited.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARGENTINA</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; The following provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Agreement, you acknowledge, understand and agree that the grant of the Units is made by the Company (not your Employer) in its sole discretion and that the value of the Units or any Shares acquired under the Plan shall not constitute salary or wages for any purpose under Argentine labor law including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, etc., or (ii) any termination or severance indemnities or similar payments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;Neither the Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; Exchange control regulations in Argentina are subject to frequent change.&#160; You should consult with your personal legal advisor regarding any exchange </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">control obligations that you may have prior to receiving proceeds from Dividend Equivalents, the sale of Shares or dividends.&#160; You must comply with any and all Argentine currency exchange restrictions, approvals and reporting requirements in connection with your participation in the Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;If you are an Argentine resident, you are required to report certain information regarding any Shares you hold as of December 31 each year to the Argentine tax authorities on your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Australia Offer Document.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This grant of Units is being made under Division 1A, Part 7.12 of the Corporations Act 2001 (Cth).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please note that if you offer Shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law.  You should obtain legal advice on your disclosure obligations prior to making any such offer.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the Units granted under the Plan, such that the Units are intended to be subject to deferred taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers.  If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.  If there is no Australian bank involved in the transfer, you will be required to file the report.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160; If you are an Austrian resident and you hold Shares acquired under the Plan outside of Austria, you may be subject to reporting obligations to the Austrian National Bank.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; A separate reporting requirement applies when you sell Shares acquired under the Plan, receive a cash Dividend paid on such Shares or Dividend Equivalents paid in cash.  In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria.  If the transaction volume of all cash accounts abroad meets or exceeds a specified threshold, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Meldungen SI-Forderungen und&#47;oder SI-Verpflichtungen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BELGIUM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Reporting&#59; Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;If you are a Belgian resident, you are required to report any taxable income attributable to the Units granted hereunder on your annual tax return.  You are also required to report any securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) held and bank accounts (including brokerage accounts) opened and maintained outside of Belgium on your annual tax return.  The first time you report the foreign security and&#47;or bank </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">account on your annual income tax return you will have to provide the National Bank of Belgium Central Contact Point with the account details of any such foreign accounts (including the account number, bank name and country in which such account was opened) in a separate form.  This report, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">www.nbb.be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Kredietcentrales &#47; Centrales des cr&#233;dits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> caption.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Exchange Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;A stock exchange tax applies to transactions executed by a Belgian resident through a non-Belgian financial intermediary, such as a U.S. broker.  The stock exchange tax likely will apply when Shares acquired under the Plan are sold.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is your responsibility to comply with this tax obligation and y</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ou should consult your personal tax advisor for additional details on your obligations with respect to the stock exchange tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Securities Accounts Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;An annual securities accounts tax may be payable if the total value of securities held in a Belgian or foreign securities account (e.g., Shares acquired under the Plan) exceeds a certain threshold on four reference dates within the relevant reporting period (i.e., December 31, March 31, June 30 and September 30).  In such case, the tax will be due on the value of the qualifying securities held in such account.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is your responsibility to comply with this obligation and y</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ou should consult with your personal tax or financial advisor for additional details.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the vesting of the Units, the sale of Shares acquired under the Plan, the payment of Dividends on such Shares and the receipt of any Dividend Equivalents paid in cash.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of Nature of Plan and Units.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Agreement, you acknowledge (i) that you are making an investment decision, (ii) that the Shares will be issued to you only if the vesting conditions are met and any necessary services are rendered by you during the vesting period set forth in the Vesting Schedule, and (iii) that the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights on December 31 of each year exceeds US$1,000,000.  If such amount exceeds US$100,000,000, the referenced declaration must be submitted quarterly, in the month following the end of each quarter.  Assets and rights that must be reported include the following&#58; (i) bank deposits&#59; (ii) loans&#59; (iii) financing transactions&#59; (iv) leases&#59; (v) direct investments&#59; (vi) portfolio investments, including Shares acquired under the Plan&#59; (vii) financial derivatives investments&#59; and (viii) other investments, such as real estate.  Please note that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement and must declare at least the assets held abroad that were acquired subsequent to the date of admittance as a resident of Brazil.  Individuals holding assets and rights outside of Brazil valued at less than US$1,000,000 are not required to submit a declaration. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BULGARIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be required to annually file statistical forms with the Bulgarian National Bank regarding your receivables in bank accounts abroad as well as your securities abroad (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) if the total sum of all such receivables and securities equals or exceeds BGN 50,000 as of the previous calendar year-end.&#160; The reports are due by March 31.  You should contact your bank in Bulgaria for additional information regarding this requirement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Section I(i) of the Agreement is amended to read as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your active employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date that you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of involuntary termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or unlawful, including for breaching employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive any Units and vest under the Plan, if any, will terminate effective as of the date that is the earlier of&#58; (1) the date you receive written notice of termination of employment from the Company or your Employer, or (2) the date you are no longer actively employed by the Company or your Employer regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law.  Your right, if any, to acquire Shares pursuant to the Units after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law.  You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting.  Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Units, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Settlement &#8211; Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Notwithstanding any discretion in Section&#160;9.5 of the Plan or anything to the contrary in the Agreement, the Units do not provide any right for you, as a resident of Canada, to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The following provision will apply to you if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">French Language Documents. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A French translation of this document and certain other documents related to this Award will be made available to Participant as soon as reasonably practicable.  Participant understands that, from time to time, additional information related to the Award may be provided in English and such information may not be immediately available in French.  However, upon request, the Company will provide a translation of such information into French as soon as reasonably practicable.  Notwithstanding anything to the contrary in the Agreement, and unless Participant indicates otherwise, the French translation of this document </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and certain other documents related to the Award will govern Participant&#8217;s participation in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XIV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration of the Plan.  You further authorize the Company, your Employer and Merrill Lynch Bank &#38; Trust Co., FSB (or any other stock plan service provider) to disclose and discuss your participation in the Plan with their advisors.  You also authorize the Company and your Employer to record such information and keep it in your file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Nasdaq Global Select Market). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified foreign property, including Shares, stock options and other rights to receive Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Units) of a non-Canadian company held by a Canadian resident employee generally must be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee&#8217;s specified foreign property exceeds C$100,000 at any time during the year.  Thus, such stock options and Units must be reported &#8211; generally at nil cost &#8211; if the C$100,000 cost threshold is exceeded because other specified foreign property is held by the employee.  When Shares are acquired, their cost generally is the adjusted cost base (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ACB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Shares.  The ACB ordinarily would equal the fair market value of the Shares at the time of acquisition, but if the employee owns other shares of the same company, this ACB may have to be averaged with the ACB of the other shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following terms apply only to individuals who are subject to exchange control restrictions in the People&#8217;s Republic of China (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221;), as determined by the Company in its sole discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting of the Units. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;Notwithstanding anything to the contrary in Section I(d) of the Agreement, if your employment with the Company or an Affiliate terminates due to your Voluntary Termination, as defined in Section I(d), then the vesting of Units granted under this Agreement shall be accelerated to vest as of the day immediately preceding such Voluntary Termination with respect to all Units granted hereunder.&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in the Agreement, due to exchange control laws in the PRC, you agree that the Company reserves the right to require the immediate sale of any Shares issued upon settlement of the Units.  You understand and agree that any such immediate sale of Shares will occur as soon as is practical following settlement of the Units.  Alternatively, if the Shares are not immediately sold upon settlement of the Units, the Company will require the sale of any Shares you may then hold within six (6) months (or such </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Paragraph (d) of Section I of the Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other period as may be required under applicable legal or exchange control requirements) following the termination of your employment with the Company including its Affiliates.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree that the Company is authorized to instruct Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company to assist with the sale of the Shares on your behalf pursuant to this authorization, and you expressly authorize such broker to complete the sale of such Shares.  You also agree to sign any agreements, forms and&#47;or consents that may be reasonably requested by the Company (or the Company&#8217;s designated broker) to effectuate the sale of the Shares (including, without limitation, as to the transfers of the proceeds and other exchange control matters noted below) and to otherwise cooperate with the Company with respect to such matters, provided that you shall not be permitted to exercise any influence over how, when or whether the sales occur.  Upon the sale of the Shares, you will receive the cash proceeds from the sale, less any applicable Tax Obligations, brokerage fees or commissions, in accordance with applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company is under no obligation to arrange for the sale of the Shares at any particular price.  Due to fluctuations in the Share price and&#47;or applicable exchange rates between the settlement date and (if later) the date on which the Shares are sold, the amount of proceeds ultimately distributed to you may be more or less than the market value of the Shares on the settlement date (which is the amount relevant to determining your liability for Tax Obligations).  You understand and agree that the Company is not responsible for the amount of any loss that you may incur and that the Company assumes no liability for any fluctuations in the Share price and&#47;or any applicable exchange rate.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Designated Broker Account.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Shares issued upon the settlement of the Units are not immediately sold, you acknowledge that you are required to maintain the Shares in an account with Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company until the Shares are sold through such Company-designated broker.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You understand and agree that, pursuant to local exchange control requirements, you will be required to repatriate the cash proceeds from the sale of the Shares issued to you upon settlement of the Units and from the receipt of any Dividends or Dividend Equivalents to China.  You further understand that, under applicable laws, such repatriation of your cash proceeds will need to be effectuated through a special exchange control account established by the Company or any Affiliate, including your Employer, and you hereby consent and agree that any proceeds may be transferred to such special account prior to being delivered to you.  You also understand that the Company will deliver the proceeds to you as soon as possible, but that there may be delays in distributing the funds to you due to exchange control requirements in China.  Proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account.  If the proceeds are paid to you in local currency, the Company is under no obligation to secure any particular currency conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COLOMBIA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; The following provision supplements Section XI of the Agreement&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that pursuant to Article 15 of Law 50&#47;1990 (Article 128 of the Colombian Labor Code), the Plan and related benefits do not constitute a component of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for any purpose.  Therefore, they are considered to be of an extraordinary nature and will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payroll taxes, social insurance contributions and&#47;or any other labor-related amounts, subject to the limitations provided in Law 1393&#47;2010.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Shares are not and will not be registered with the Colombian registry of publicly traded securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and therefore the Shares may not be offered to the public in Colombia.  Nothing in this document should be construed as the making of a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Investment in assets located abroad (such as Shares acquired under the Plan) does not require prior approval from the Central Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Banco de la Rep&#250;blica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  Nonetheless, such investments are subject to registration before the Central Bank as foreign investments held abroad, regardless of value.  In addition, you must file an annual informative return with the local tax authority detailing assets you hold abroad, which must include the Shares acquired at vesting (every year as long as you keep them).  This obligation is only applicable if the assets held abroad exceed the amount of 2,000 Tax Units (approx. US$22.000).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, local banks), which includes the obligation to correctly complete and file the appropriate foreign exchange form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">declaraci&#243;n de cambio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An annual information return may need to be filed with the Colombian Tax Office detailing any assets held abroad (including Shares acquired under the Plan).  If the individual value of any of these assets exceeds a certain threshold, each asset must be described (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, its nature and its value) and the jurisdiction in which it is located must be disclosed.  It is your responsibility to comply with this tax reporting requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CROATIA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Croatian residents may be required to report any foreign investments (including Shares acquired under the Plan) to the Croatian National Bank for statistical purposes.  You should be aware that exchange control regulations in Croatia are subject to frequent change and you are solely responsible for ensuring your continued compliance with current Croatian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A Czech resident may be required to notify the Czech National Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CNB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the acquisition of Shares under the Plan or maintenance of a foreign account if (i) he or she maintains foreign direct investments with a value of 2,500,000 K&#269; or more in the aggregate, (ii) he or she maintains other foreign financial assets with a value of 200,000,000 K&#269; or more, or (iii) the Czech resident is specifically requested to do so by the CNB.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DENMARK</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Danish Stock Option Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Units, you acknowledge that you have received an Employer Statement translated into Danish, which is being provided to comply with the Danish Stock Option Act.  To the extent more favorable to you and required to comply with the Stock Option Act, as amended with effect from January 1, 2019.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The requirement to report certain information to the Danish Tax Administration via Form V or K was eliminated effective January 1, 2019.  However, you still must report the foreign bank&#47;brokerage accounts and their deposits, and Shares held in a foreign bank or brokerage account in your tax return under the section on foreign affairs and income.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EGYPT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you transfer funds into Egypt in connection with the Units, you are required to transfer the funds through a registered bank in Egypt.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  There are no specific reporting requirements with respect to foreign assets&#47;accounts.  However, please note that you must check your pre-completed tax return to confirm that the ownership of Shares and other securities (foreign or domestic) are correctly reported.  If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By accepting the grant, you confirm having read and understood the Plan and Agreement which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">En acceptant l&#8217;attribution, vous confirmez avoir lu et compris le Plan et le Contrat, qui ont &#233;t&#233; communiqu&#233;s en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  French residents and non-residents must declare to the Customs Authorities the cash and securities they import or export without the use of a financial institution when the value of such cash or securities exceeds &#8364;10,000.  French residents also must report all foreign bank and brokerage accounts on an annual basis (including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accounts opened or closed during the tax year) on Form N&#176; 3916, together with the income tax return.  Failure to comply could trigger significant penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If your acquisition of Shares under the Plan leads to a qualified participation at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year.  A qualified participation is attained only in the unlikely event (i) you own at least 1% of the Company and the value of the Shares acquired exceeds &#8364;150,000 or (ii) you hold Shares exceeding 10% of the Company&#8217;s total Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  In case of payments in connection with securities (including proceeds realized upon the sale of Shares or the receipt of Dividends or Dividend Equivalents), the report must be made by the 5th day of the month following the month in which the payment was received and must be filed electronically.  The form of report (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Allgemeines Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) can be accessed via the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> website (www.bundesbank.de) and is available in both German and English. In addition, you may be required to report the acquisition or sale of Shares to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if the value of the Shares acquired or sold exceeds &#8364;12,500.  You are responsible for satisfying any applicable reporting obligation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The reporting of foreign assets (including Shares and other investments) is your own obligation and takes place through your annual tax return.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Settlement &#8211; Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Notwithstanding any discretion in Section&#160;9.5 of the Plan or anything to the contrary in the Agreement, the Units do not provide any right for you to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Shares received at vesting are accepted as a personal investment.  In the event that Shares are issued in respect of the Units within six (6) months of the Grant Date, you agree that you will not offer to the public or otherwise dispose of the Shares prior to the six (6)-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SECURITIES WARNING&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in doubt about any of the contents of the Agreement, including this Appendix, or the Plan, you should obtain independent professional advice.  The Units and any Shares issued in respect of the Units do not constitute a public offering of securities under Hong Kong law and are available only to members of the Board and Employees.  The Agreement, including this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Appendix, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong.  The Units and any documentation related thereto are intended solely for the personal use of each member of the Board and&#47;or Employee and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HUNGARY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ICELAND</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Approval by the Central Bank of Iceland is no longer required to participate in the Plan, regardless of the value of the Shares acquired under the Plan.  Despite the recent relaxation of the exchange control requirements, you should consult with your personal advisor to ensure compliance with applicable exchange control regulations in&#160;Iceland as such regulations are subject to frequent change.  You are responsible for ensuring compliance with all exchange control laws in&#160;Iceland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;You understand that you must repatriate any cash Dividends paid on Shares acquired under the Plan to India or any Dividend Equivalents paid in cash, as well as any proceeds from the sale of Shares acquired under the Plan within a prescribed period of time (currently, within one hundred and eighty (180) days of receipt of cash Dividends or Dividend Equivalents, and within ninety (90) days of receipt of sale proceeds), or such other period of time as may be required under applicable regulations.  You will receive a foreign inward remittance certificate (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FIRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from the bank where you deposit the foreign currency, and you must maintain the FIRC as proof of repatriation of funds in the event that the Reserve Bank of India or your Employer requests proof of repatriation.  It is your responsibility to comply with these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You are required to declare foreign bank accounts and any foreign financial assets (including Shares held outside of India) in your annual tax return.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor in this regard.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of Nature of Plan and Units.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Agreement, you understand and agree that the benefits received under the Plan will not be taken into account for any redundancy or unfair dismissal claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ITALY </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of Nature of Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In accepting this Agreement, you acknowledge that (1)&#160;you have received a copy of the Plan, the Agreement and this Appendix&#59; (2)&#160;you have reviewed the applicable documents in their entirety and fully understand the contents thereof&#59; and (3)&#160;you accept all provisions of the Plan, the Agreement and this Appendix.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For any Units granted, you further acknowledge that you have read and specifically and explicitly approve, without limitation, the following sections of the Agreement&#58; Section&#160;I&#59; Section&#160;II&#59; Section&#160;III&#59; Section VIII&#59; Section X&#59; Section XI&#59; Section XVI&#59; Section XVII&#59; and the Data Privacy Notice for All European Economic Area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) &#47; European Union (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Jurisdictions, United Kingdom and Switzerland in this Appendix.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Italian residents who, at any time during the fiscal year, hold foreign financial assets (including cash and Shares) which may generate income taxable in Italy are required to report these assets on their annual tax returns (UNICO Form, RW Schedule) for the year during which the assets are held, or on a special form if no tax return is due.  These reporting obligations will also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Financial Assets Tax.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The fair market value of any Shares held outside of Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is subject to a foreign assets tax at a flat rate.  The fair market value is considered to be the value of the Shares on the Nasdaq Global Select Market on December 31 of the applicable year in which you held the Shares (or when the Shares are acquired during the course of the year, the tax is levied in proportion to the actual days of holding over the calendar year).  No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does not exceed a certain threshold.  You should consult with your personal tax advisor about the foreign financial assets tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You will be required to report to the Japanese tax authorities details of any assets held outside of Japan as of December 31st (including any Shares acquired under the Plan) to the extent such assets have a total net fair market value exceeding &#165;50,000,000.  Such report will be due by March 15 each year.  You should consult with your personal tax advisor as to whether the reporting obligation applies to you and whether you will be required to include in the report details of any Shares or cash that you hold.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare all foreign financial accounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> non-Korean bank accounts, brokerage accounts holding Shares, etc.) to the Korean tax authority and file a report regarding such accounts if the monthly balance of such accounts exceeds a certain threshold.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor to ensure compliance with this requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LITHUANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you (i) hold certain job positions established by the law or (ii) donate to political parties or political campaigners, you must file an Annual Asset Return of the Individual (Family) in Form No. FR0001 with respect to assets held outside of Lithuania (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares).  If you open an account in a foreign financial institution and annual turnover in the account exceeds EUR 15,000, you must file a foreign account report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of the Agreement.&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Award granted hereunder, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.  You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section XI of the Agreement, in which the following is clearly described and established&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in the Plan are offered by Amgen Inc. on a wholly discretionary basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. and its Affiliates are not responsible for any decrease in the value of the Units granted and&#47;or Shares issued under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement and Policy Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;In accepting any Award granted hereunder, you expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Shares do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Amgen-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is as a result of a unilateral and discretionary decision of Amgen Inc.&#59; therefore, Amgen Inc. reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time without any liability to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen Inc., its Affiliates, stockholders, officers, agents or legal representatives with respect to any claim that may arise. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Spanish Translation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento del Otorgamiento.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Al aceptar cualquier Otorgamiento bajo el presente documento, usted reconoce que ha recibido una copia del Plan, que ha revisado el mismo en su totalidad, as&#237; como tambi&#233;n el Acuerdo de Opci&#243;n, el Acuerdo, incluyendo este Ap&#233;ndice, adem&#225;s que comprende y est&#225; de acuerdo con todas las disposiciones tanto del Plan y del Otorgamiento, incluyendo este Ap&#233;ndice.  Asimismo, usted reconoce que ha le&#237;do y manifiesta espec&#237;ficamente y expresamente la conformidad con los t&#233;rminos y condiciones establecidos en la Secci&#243;n XI del Acuerdo, en los que se establece y describe claramente que&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan de ninguna manera constituye un derecho adquirido. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan y su participaci&#243;n en el mismo son ofrecidos por Amgen Inc. de forma completamente discrecional. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. y sus Afiliados no son responsables de ninguna disminuci&#243;n en el valor de Unidades o de las Acciones Comunes emitidas mediante el Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento de la Ley Laboral y Declaraci&#243;n de Pol&#237;tica. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Al aceptar cualquier Otorgamiento de Acciones bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la &#250;nica responsable de la administraci&#243;n del Plan y que su participaci&#243;n en el mismo y la adquisici&#243;n de Acciones Comunes no constituyen de ninguna manera una relaci&#243;n laboral entre usted y Amgen Inc., debido a que su participaci&#243;n en el Plan es &#250;nicamente una relaci&#243;n comercial y que su &#250;nico empleador es Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-M&#233;xico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Derivado de lo anterior, usted reconoce expresamente que el Plan y los beneficios a su favor que pudieran derivar de la participaci&#243;n en el mismo, no establecen ning&#250;n derecho entre usted y su empleador, Amgen &#8211; M&#233;xico, y no forman parte de las condiciones laborales y&#47;o los beneficios otorgados por Amgen &#8211; M&#233;xico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n del mismo no constituir&#225; un cambio o desmejora de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Asimismo, usted entiende que su participaci&#243;n en el Plan es resultado de la decisi&#243;n unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y&#47;o descontinuar su participaci&#243;n en el Plan en cualquier momento y sin ninguna responsabilidad para usted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Amgen Inc., por cualquier compensaci&#243;n o da&#241;os y perjuicios, en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de toda responsabilidad, como as&#237; tambi&#233;n a sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Units and the Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Plan, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and your Employer and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of Amgen-Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="warninglabelb.jpg" src="warninglabelb.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NORWAY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Norwegian residents may be subject to foreign asset reporting as part of their ordinary tax return.  Norwegian banks, financial institutions, limited companies etc. must report certain information to the Tax Administration.  Such information may then be pre-completed in a Norwegian resident&#8217;s tax return.  However, if the resident has traded, or is the owner of, financial instruments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares) not pre-completed in the tax return, the Norwegian resident must enter this information in Form RF-1159, which is an appendix to the tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In general, Norwegian residents should not be subject to any foreign exchange requirements in connection with their acquisition or sale of Shares under the Plan, except normal reporting requirements to the Norwegian Currency Registry.  If any transfer of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must file reports with the National Bank of Poland if the aggregate value of Shares and cash held in such foreign accounts exceeds PLN 7,000,000.  If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National Bank of Poland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently &#8364;15,000 (or PLN 15,000 if such transfer of funds is associated with the business activity of a consultant)).  You must store all documents connected with any foreign exchange transactions you engage in for a period of five (5) years from the end of the year when such transactions were made.  Penalties may apply for failure to comply with exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PORTUGAL</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent to Receive Information in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Conhecimento da Lingua.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Certain transfers of funds may need to be reported to the National Office for Prevention and Control of Money Laundering on specific forms by the relevant bank or financial institution.  If you deposit proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income.  You should consult with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be required to repatriate certain cash amounts received with respect to the Units to Russia (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, cash Dividends, sale proceeds) as soon as you intend to use those cash amounts for any purpose, including reinvestment.  If the repatriation requirement applies, such funds must initially be credited to you through a foreign currency account at an authorized bank in Russia.  After the funds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.  Under the Directive N 5371-U of the Russian Central Bank (the &#8220;CBR&#8221;), the repatriation requirement may not apply in certain cases with respect to cash amounts received in an account that is considered by the CBR to be a foreign brokerage account.  Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The exchange control rules and regulations in Russia, including temporary restrictions imposed by the Russian government in March 2022, are subject to frequent change.  You should consult with your personal legal advisor to determine the applicability of any repatriation requirements applicable to any Shares or cash received in connection with the Plan and held in an account outside Russia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Any Units granted hereunder, the Agreement, including this Appendix, the Plan and all other materials you may receive regarding your participation in the Plan or any Units granted hereunder do not constitute advertising or an offering of securities in Russia.  The issuance of Shares under the Plan has not and will not be registered in Russia&#59; therefore, Shares may not be offered or placed in public circulation in Russia.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In no event will Shares acquired under the Plan be delivered to you in Russia&#59; all Shares will be maintained on your behalf in the United States.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are not permitted to sell any Shares acquired under the Plan directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge that if you continue to hold Shares acquired under the Plan after an involuntary termination of your employment, you will not be eligible to receive unemployment benefits in Russia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section XIV of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that you must complete and return a Consent to Processing of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) form to the Company.  Further, you understand and agree that if you do not complete and return a Consent form to the Company, the Company will not be able to administer or maintain the Units.  Therefore, you understand that refusing to complete a Consent form or withdrawing your consent may affect your ability to participate in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Russian residents are required to file the following reports or notifications with the Russian tax authorities, if applicable&#58; (i) annual cash flow reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; (ii) financial asset (including Shares) reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; and (ii) a one-time notification within one (1) month of opening, closing, or changing details of an offshore brokerage account.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are encouraged to contact your personal tax advisor before remitting your proceeds from participation in the Plan to Russia to ensure compliance with applicable requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Anti-Corruption Legislation Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Individuals holding public office in Russia, as well as their spouses and dependent children, may be prohibited from opening or maintaining a foreign brokerage or bank account and holding any securities, whether acquired directly or indirectly, in a foreign company (including Shares acquired under the Plan).  You should consult with your personal legal advisor to determine whether this restriction applies to your circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby agree that any Shares acquired pursuant to the Units will not be offered for sale in Singapore prior to the six (6)-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or pursuant to, and in accordance with the conditions of, any other applicable provisions of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The grant of the Units is being made pursuant to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made with a view to the Units being subsequently offered for sale to any other party.  The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Directors (including alternate, substitute, associate and shadow directors) of a Singapore Affiliate are subject to certain notification requirements under the Singapore Companies Act, regardless of whether they are resident or employed in Singapore.  Directors of a Singapore Affiliate must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Units, Shares, etc.) in the Company or any related company within two (2) business days of (i) its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> when the Shares are sold), or (iii) becoming a director.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVAK REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Slovak Republic residents who carry on business activities as an independent entrepreneur (in Slovakian, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">podnikatel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), must report foreign assets (including any Shares) to the National Bank of Slovakia (provided that the value of the foreign assets exceeds an amount of EUR&#160;2,000,000).  These reports must be submitted on a monthly basis by the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of the respective calendar month, as well as on a quarterly basis by the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of the calendar month following the respective calendar quarter, using notification form DEV (NBS) 1-12, which may be found at the National Bank of Slovakia&#8217;s website at </font><font style="color:#0044cc;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.nbs.sk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVENIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The following provision supplements Section XI of the Agreement&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Units granted hereunder, you consent to participation in the Plan and acknowledge that you have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to grant any Units under the Plan to individuals who may be members of the Board or Employees of the Company or its Affiliates throughout the world.  The decision is a limited decision, which is entered into upon the express assumption and condition that any Units granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the Agreement, including this Appendix.  Consequently, you understand that the Units granted hereunder are given on the assumption and condition that they shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary grant of Units since the future value of the Units and the underlying Shares is unknown and unpredictable.  In addition, you understand that any Units granted hereunder would not be made but for the assumptions and conditions referred to above&#59; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of Units or right to Units shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further, the vesting of the Units is expressly conditioned on your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Units may cease vesting immediately, in whole or in part, effective on the date of your termination of employment (unless otherwise specifically provided in Section I of the Agreement).  This will be the case, for example, even if (1) you are considered to be unfairly dismissed without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, subject to a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">despido improcedente</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (2) you are dismissed for disciplinary or objective reasons or due to a collective dismissal&#59; (3) you terminate service due to a change of work location, duties or any other employment or contractual condition&#59; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate&#59; or (5) your employment terminates for any other reason whatsoever.  Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Units that were not vested on the date of your termination of employment, as described in the Plan and the Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you have read and specifically accept the conditions referred to in Section I of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">offer of securities to the public</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; as defined under&#160;Spanish&#160;law,&#160;has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and does not constitute a public offering prospectus. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you acquire Shares under the Plan, you must declare the acquisition to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Direccion General de Comercio e Inversiones </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DGCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If you acquire the Shares through the use of a Spanish financial institution, that institution will automatically make the declaration to the DGCI for you&#59; otherwise, you will be required to make the declaration by filing a D-6 form.  You must declare ownership of any Shares with the DGCI each January while the Shares are owned and must also report, in January, any sale of Shares that occurred in the previous year for which the report is being made, unless the sale proceeds exceed the applicable threshold, in which case the report is due within one (1) month of the sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare electronically to&#160;the Bank of Spain any securities accounts (including brokerage accounts held abroad), as well as the Shares held in such accounts if the&#160;value of the transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax year exceed &#8364;1,000,000.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent that you hold Shares and&#47;or have bank accounts outside of Spain with a value in excess of &#8364;50,000 (for each type of asset) as of December 31 each year, you will be required to report information on such assets in your tax return (tax form 720) for such year.&#160;&#160;After such Shares and&#47;or accounts are initially reported, the reporting obligation will apply for subsequent years only if the value of any previously-reported Shares or accounts increases by more than &#8364;20,000 or if you sell or otherwise dispose of previously-reported Shares or accounts.  If the value of such Shares and&#47;or accounts as of December 31 does not exceed &#8364;50,000, a summarized form of declaration may be presented.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Authorization to Withhold.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax Obligations as set forth in the Agreement, in accepting the Units, you authorize the Company to withhold Shares or to sell Shares otherwise issuable to you upon vesting or settlement to satisfy Tax Obligations, regardless of whether the Company and&#47;or Employer have an obligation to withhold such Tax Obligations, provided that such withholding would not, in the Company&#8217;s determination, result in adverse accounting consequences to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Neither this document nor any other materials relating to the Awards (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Company or one of its Subsidiaries or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TAIWAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may acquire and remit foreign currency (including proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents) up to US$5,000,000 per year without justification.  If the transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.  If the transaction amount is US$500,000 or more in a single transaction, you must also provide supporting documentation to the satisfaction of the remitting bank.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">THAILAND</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If proceeds from the sale of Shares or the receipt of any Dividends or Dividend Equivalents exceed US$1,000,000, you must (i) immediately repatriate such funds to Thailand and (ii) report the inward remittance to the Bank of Thailand on a Foreign Exchange Transaction Form.  In addition, within three hundred and sixty (360) days of repatriation, you must either convert any funds repatriated to Thailand to Thai Baht or deposit the funds in a foreign exchange account with a Thai commercial bank.   Any such commercial bank must be duly authorized by the Bank of Thailand to engage in the purchase, exchange and withdrawal of foreign currency. The Employee is responsible for ensuring compliance with all exchange control laws in Thailand.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Units under the Plan are granted only to select Board members and Employees of the Company and its Affiliates and are for the purpose of providing equity incentives.  The Plan and the Agreement are intended for distribution only to such Board members and Employees and must not be delivered to, or relied on by, any other person.  You should conduct your own due diligence on the Units offered pursuant to this Agreement.  If you </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">do not understand the contents of the Plan and&#47;or the Agreement, you should consult an authorized financial adviser.  The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to Section III of the Agreement, you agree that you are liable for all Tax Obligations and hereby covenant to pay all such Tax Obligations as and when requested by the Company or your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and your Employer against any taxes that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you are an executive officer or director (as within the meaning of Section 13(k) of the Exchange Act, as amended from time to time), you understand that you may not be able to indemnify the Company or your Employer for the amount of income tax not collected from or paid by you, as it may be considered a loan.  In the event that you are an executive officer or director and income tax is not collected from you within ninety (90) days after the end of the tax year in which the Taxable Event occurs, the amount of any uncollected income tax may constitute an additional benefit to you on which additional income tax and national insurance contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may be payable.  You acknowledge that you are responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying your Employer for the amount of any NICs due on this additional benefit, which the Company or your Employer may obtain from you by any of the means set forth in Section III of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the maximum applicable withholding rate is used, any over-withheld amount may be credited to you by the Company or your Employer (with no entitlement to the Common Stock equivalent) or if not so credited, you may seek a refund from the local tax authorities.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are a resident of the United Kingdom between the Grant Date and the vesting of the Units, as a condition of the Units granted hereunder, you agree to accept any liability for secondary Class 1 National Insurance Contributions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which may be payable by the Company or your Employer with respect to the Units and&#47;or payment of the Units and issuance of Shares pursuant to the Units, the assignment or release of the Units for consideration, or the receipt of any other benefit in connection with the Units.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to the foregoing, you agree to make an election (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in the form specified and&#47;or approved for such election by HMRC, that the liability for your Employer NICs payments on any such gains shall be transferred to you to the fullest extent permitted by law. You further agree to execute such other elections as may be required between you and any successor to the Company and&#47;or your Employer. You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section III of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Units, without any liability to the Company or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED STATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provision replaces Section I(i) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your active employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date that you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of termination of your employment (whether or not in breach of local labor laws), your right to receive Units and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively employed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such right will be extended by any notice period mandated by law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Worker Adjustment and Retraining Notification Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that notwithstanding the effect of any such extension, in no event will the Units be paid later than the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day following your termination of employment&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>5
<FILENAME>exhibit107-formofperforman.htm
<DESCRIPTION>FORM OF PERFORMANCE UNIT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5b36df72f404474e830f10cf4e59a002_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.7</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Award Notice</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank &#38; Trust Co., FSB).  This Award Notice shall be replaced by the equivalent pages on such website.  References to Award Notice in this Agreement shall then refer to the equivalent pages on such website.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#93; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This notice of Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan.  The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement.  Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Type&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan&#58;&#160;&#160;&#160;&#160;Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Program&#160;&#160;&#160;&#160;Amgen Inc. 2009 Performance Award Program, as amended and&#47;or restated from time to time</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Shares&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Units&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Period&#58;&#160;&#160;&#160;&#160;The Performance Period beginning on                           and ending on                           .</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Resolutions&#58;&#160;&#160;&#160;&#160;The Resolutions of the Compensation and Management Development Committee of the Board of Directors of Amgen Inc. establishing the performance goals and Performance Period applicable to this Award.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Means the vesting date indicated in the Vesting Schedule</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;&#160;&#160;&#160;&#160;Means the schedule of vesting set forth under Vesting Details </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Details&#58;&#160;&#160;&#160;&#160;Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting.</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">IMPORTANT NOTICE REGARDING ACCEPTANCE OF THE AWARD AND THE REQUIREMENT TO OPEN A BROKERAGE ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RESIDENTS OF THE U.S. AND PUERTO RICO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Please read this Award Notice, the Plan and the Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) carefully.  If you, as a resident of the U.S. or Puerto Rico, do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> wish to receive this Award and&#47;or you do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> consent and agree to the terms and conditions on which this Award is offered, as set forth in the Grant Documents, then you must reject the Award by contacting the Merrill Lynch call center (800) 97AMGEN (800-972-6436) within the U.S., Puerto Rico and Canada or +1 (609) 818-8910 from all other countries (Merrill Lynch will accept the charges for your call) no later than the forty-fifth calendar day following the day on which this Award Notice is made available to you, in which case the Award will be cancelled.  For the purpose of determining the forty-five calendar days, Day 1 will be the day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> following the day on which this Award Notice is made </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> This provision is only for use on the form of grant used for the U.S. and Puerto Rico.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available to you. Your failure to notify the Company of your rejection of the Award within this specified period will constitute your acceptance of the Award and your agreement with all terms and conditions of the Award, as set forth in the Grant Documents.  If you agree to the terms and conditions of your grant and you desire to accept it, then no further action is needed on your part to accept the grant.  However, you must still open a brokerage account as directed by the Company, by 1&#58;00 pm Pacific Time on or before the date that is 11 months after the date of grant.  This step is necessary to process transactions related to your equity grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">If you do not open a brokerage account by this deadline, your grant will be cancelled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><div id="i5b36df72f404474e830f10cf4e59a002_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERFORMANCE UNIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SPECIFIC TERMS OF YOUR GRANT OF PERFORMANCE UNITS ARE FOUND IN THE PAGES RELATING TO THE GRANT OF PERFORMANCE UNITS FOUND ON MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK &#38; TRUST CO., FSB) (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AWARD NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;) WHICH ACCOMPANIES THIS DOCUMENT.  THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS PERFORMANCE UNIT AGREEMENT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;On the Grant Date specified in the Award Notice, Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), has granted to you, the grantee named in the Award Notice, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Number of Performance Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) specified in the Award Notice on the terms and conditions set forth in this Performance Unit Agreement (and any applicable additional terms and conditions for your country set forth in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (as described in greater detail in Section XIV below)) (collectively, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Plan, the Amgen Inc. 2009 Performance Award Program, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Resolutions (as defined in the Award Notice).  Capitalized terms not defined herein shall have the meanings assigned to such terms in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Performance Period shall have the meaning set forth in the Award Notice.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Value of Performance Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The value of each Performance Unit is equal to a share of Common Stock.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.03pt;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  An amount of the Performance Units up to the maximum amount specified in the Resolutions shall be earned, depending on the extent to which the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">achieves</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> objectively determinable performance goals established by the Committee pursuant to the Resolutions.  The Performance Units earned shall be calculated in accordance with the Resolutions and the Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Form and Timing of Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section XIII and subject to satisfaction of Tax Obligations or similar obligations as provided in Section V, and except as set forth in the Program, any Performance Units earned pursuant to Section III above shall be settled by the Company delivering to you a number of Shares equal to the number of Shares covered by the earned Performance Units or in a lump sum in cash with a value equal to the Fair Market Value of the number of Shares subject to the earned Performance Units as of the last day of the Performance Period (without interest thereon), or in a combination of Shares and cash, as determined by the Administrator at any time prior to settlement and in its discretion, as soon as practicable, and in any event within 90 days, after the last day of the Performance Period, in each case, subject to the terms of the Program (including Section 4.2 thereof).  Shares issued in respect of a Performance Unit shall be deemed to be issued in consideration of past services actually rendered by you to the Company or an Affiliate or for its benefit for which you have not previously been compensated or for future services to be rendered, as the case may be, which the Company deems to have a value at least equal to the aggregate par value thereof.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.02pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of the Performance Period by reason of your Voluntary Retirement and you are Retirement-Eligible on the date of such termination, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the full or prorated amount of your Award, if any, applicable to the Performance Period shall be paid in accordance with the provisions of Article VI of the Program.  For purposes of the foregoing, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company&#8217;s performance as compared to the Performance Goals for the Performance Period and (i) if the Award was granted with respect to a Performance Period commencing in a calendar year prior to the calendar year in which your Voluntary Retirement occurs, the full amount of the Award is payable, and (ii) if the Award was granted with respect to the Performance Period commencing in the calendar year in which your Voluntary Retirement occurs, the Award otherwise payable is multiplied by a fraction (rounded to two decimal places), the numerator of which is the number of complete months of employment during such calendar year, and the denominator of which is twelve (12).  Notwithstanding the foregoing, you shall not be entitled to such full or prorated amount of your Award pursuant to this paragraph (b) unless either you sign a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company) and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in no event shall payment of such full or prorated amount of your Award be made later than the specified payment date as set forth in Section 6.1 of the Program.  This paragraph (b) shall supersede Section 7.1(a) of the Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">Death and Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of the Performance Period by reason of your death or Permanent and Total Disability, the full or prorated amount of your Award, if any, applicable to such Performance Period shall be paid in accordance with the provisions of Article VI of the Program.  For purposes of the foregoing, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company&#8217;s performance as compared to the Performance Goals for the Performance Period and (i) if the Award was granted with respect to a Performance Period commencing in a calendar year prior to the calendar year in which such termination occurs, the full amount of the Award is payable, and (ii) if the Award was granted with respect to the Performance Period commencing in the calendar year in which such termination occurs, the Award otherwise payable is multiplied by a fraction (rounded to two decimal places), the numerator of which is the number of complete months of employment during such calendar year, and the denominator of which is twelve (12).  Notwithstanding the foregoing, if your employment is terminated due to your Permanent and Total Disability, you shall not be entitled to such full or prorated amount of your Award pursuant to this paragraph (c) unless either you sign a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company) and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in no event shall payment of such full or prorated amount of your Award be made later than the specified payment date as set forth in Section 6.1 of the Program.  This paragraph (c) shall supersede Section 7.1(b) of the Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.02pt;text-decoration:underline">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of the Performance Period for any reason other than as specified in paragraphs (b) and (c) above, all of your rights to an Award for the Performance Period shall be forfeited, unless, prior to the payment date described in Article VI of the Program, the Company, in its sole discretion, makes a written determination to otherwise pay the full or prorated amount of your Award, if any, applicable to the Performance Period, which full or prorated amount shall be paid in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance with the provisions of Article VI of the Program.  For purposes of the foregoing, if the payment of your Award is prorated, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company&#8217;s performance as compared to the Performance Goals for the Performance Period and (i) if the Award was granted with respect to a Performance Period commencing in a calendar year prior to the calendar year in which such termination occurs, the full amount of the Award is payable, and (ii) if the Award was granted with respect to the Performance Period commencing in the calendar year in which such termination occurs, the Award otherwise payable is multiplied by a fraction (rounded to two decimal places), the numerator of which is the number of complete months of employment during such calendar year, and the denominator of which is twelve (12).  Notwithstanding the foregoing, you shall not be entitled to such full or prorated amount of your Award pursuant to this paragraph (d) unless either you sign a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company) and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in no event shall payment of such full or prorated amount of your Award be made later than the specified payment date as set forth in Section 6.1 of the Program.  This paragraph (d) shall supersede Section 7.1(c) of the Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Issuance of Shares&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or your actual employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to your participation in the Plan and the Program and legally applicable to you (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you acknowledge that the ultimate liability for all Tax Obligations is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or your Employer.  You further acknowledge that the Company and&#47;or your Employer (i) make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Performance Units or the underlying Shares, including the grant of the Performance Units, the vesting of the Performance Units, the conversion of the Performance Units into shares or the receipt of an equivalent cash payment, the subsequent sale of any shares acquired at settlement and the receipt of any Dividends (as defined in Section VI, below) or Dividend Equivalents&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Performance Units to reduce or eliminate your liability for Tax Obligations or to achieve any particular tax result.  Furthermore, if you become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to any relevant taxable or tax withholding event, as applicable, you shall pay or make adequate arrangements satisfactory to the Company or to your Employer (in their sole discretion) to satisfy all Tax Obligations.  In this regard, you authorize the Company and&#47; or your Employer, or their respective agents, at their discretion, to satisfy all applicable Tax Obligations by one or a combination of the following&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a) &#160;&#160;&#160;&#160;withholding from your wages or other cash compensation paid to you by the Company and&#47;or your Employer&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;withholding from proceeds of the sale of Shares issued upon settlement of the Performance Units, either through your voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;&#160;withholding in Shares issuable, or cash payable, upon settlement of the Performance Units provided that, if such Shares are withheld, the Company and your Employer shall only withhold an amount of Shares with a fair market value not to exceed the Tax Obligations as determined in the discretion of the Company or your Employer, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Depending on the withholding method, the Company may withhold or account for Tax Obligations by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates.  If the Tax Obligations are satisfied by withholding in Shares, for tax purposes you are deemed to have been issued the full number of Shares subject to the earned Performance Units, notwithstanding that a number of Shares is held back and not actually issued to you solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan (any Shares withheld by the Company hereunder shall not be deemed to have been issued by the Company for any purpose under the Plan and shall remain available for issuance thereunder).</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan and the Program that cannot be or were not satisfied by the means previously described.  You agree to take any further actions and to execute any additional documents as may be necessary to effectuate the provisions of this Section V.  Notwithstanding Section IV above, the Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if you fail to comply with your obligations in connection with the Tax Obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Dividend Equivalents</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Crediting of Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to this Section VI, Dividend Equivalents shall be credited on each Performance Unit granted to you under this Agreement in the manner set forth in the remainder of this Section VI.  If the Company declares one or more dividends or distributions (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on its Common Stock with a record date which occurs during the period commencing on the Grant Date through and including the day immediately preceding the day the Shares subject to the Performance Units are issued to you, whether in the form of cash, Common Stock or other property, then, on the date such  Dividend is paid to the Company&#8217;s stockholders, you shall be credited with an amount equal to the amount or fair market value of such Dividend which would have been payable to you if you held a number of Shares equal to the number of Performance Units granted to you on the Grant Date (including any previously credited Dividends which have been deemed to have been reinvested in Common Stock as provided by the next succeeding sentence), as of each such record date for each such Dividend (not including on any Performance Units which were previously paid or forfeited) as if each such amount had been reinvested in Common Stock as of the date of the payment of such Dividend (such accumulated dividends, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Accumulated Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each such Dividend Equivalent shall be deemed to have been reinvested in Common Stock as of the Dividend payment date.  Dividend Equivalents shall be payable in full Shares, unless the Administrator determines, at any time prior to payment and in its discretion, that they shall be payable in cash.  Dividend Equivalents payable with respect to fractional Shares shall be paid in cash.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise expressly provided in this Section VI any Dividend Equivalents credited to you shall be subject to all of the provisions of this Agreement which apply to the Performance Units with respect to which they have been credited and shall be payable, if at all, at the time and to the extent that the underlying Performance Unit becomes payable.  Dividend Equivalents shall not be payable on any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Units that do not vest, or are forfeited, pursuant to the terms of this Agreement.  Dividend Equivalent rights and any amounts that may become distributable in respect thereof shall be treated separately from the Performance Units and the rights arising in connection therewith for purposes of the designation of time and form of payments required by Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Nontransferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No benefit payable under, or interest in, this Agreement or in the Shares that may become issuable to you hereunder shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge and any such attempted action shall be void and no such benefit or interest shall be, in any manner, liable for, or subject to, your or your beneficiary&#8217;s debts, contracts, liabilities or torts&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, nothing in this Section VII shall prevent transfer (i) by will or (ii) by applicable laws of descent and distribution. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt;text-decoration:underline">No Contract for Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is not an employment or service contract with the Company or an Affiliate and nothing in this Agreement shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment or service with the Company or an Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting the grant of Performance Units, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the Plan and the Program are established voluntarily by the Company, are discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan and in the Program&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the grant of the Performance Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future awards of Performance Units, or benefits in lieu of Performance Units, even if Performance Units have been awarded in the past&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;your participation in the Plan and the Program is voluntary&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the grant of Performance Units, the Shares subject to the Performance Units, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;neither the grant of Performance Units nor any provision of this Agreement, the Plan, the Program or the policies adopted pursuant to the Plan or Program confer upon you any right with respect to employment or continuation of current employment and shall not interfere with the ability of your Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) &#160;&#160;&#160;&#160;in the event that you are not an employee of the Company or any Affiliate, the Performance Units shall not be interpreted to form an employment contract or relationship with the Company or any Affiliate&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;the future value of the Shares that may be earned upon the end of the Performance Period is unknown, indeterminable, and cannot be predicted with certainty&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160; in consideration of the grant of Performance Units hereunder, no claim or entitlement to compensation or damages arises from termination of Performance Units, and no claim or entitlement to compensation or damages shall arise from forfeiture of the Performance Units resulting from termination of your employment by the Company or an Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any) and you irrevocably release the Company and your Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;in the event of termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive Performance Units and receive shares under the Plan and the Program, if any, will terminate effective as of the date that you are no longer actively employed and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, active employment would not include a period of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">garden leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Performance Units, the Shares subject to the Performance Units, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate of the Company&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;except as otherwise provided in this Agreement or the Plan, the Performance Units and the benefits evidenced by this Agreement do not create any entitlement to have the Performance Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;the following provisions apply only if you are providing services outside the United States&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;for employment law purposes outside the United States, the Performance Units, the Shares subject to the Performance Units, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;neither the Company, your Employer nor any Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Performance Units or of any amounts due to you pursuant to the settlement of the Performance Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan and the Program, or your acquisition or sale of the underlying Shares.  You should </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consult with your personal tax, legal and financial advisors regarding your participation in the Plan and the Program before taking any action related thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notices provided for in this Agreement, the Plan or the Program shall be given in writing or electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail or equivalent foreign postal service, postage prepaid, addressed to you at such address as is currently maintained in the Company&#8217;s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator.  Such notices may be given using any automated system for the documentation, granting or settlement of Awards, such as a system using an internet website or interactive voice response, as approved by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Resolutions, Plan and Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is subject to all of the provisions of the Resolutions, the Plan and the Program and their provisions are hereby made a part of this Agreement and incorporated herein by reference, including, without limitation, the provisions of Articles 5 and 9 of the Plan (relating to Performance-Based Compensation and Performance Awards, respectively) and Section 13.2 of the Plan (relating to adjustments upon changes in the Common Stock), and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of this Agreement and those of the Resolutions, the Plan and the Program, the provisions of the Plan shall control.  Notwithstanding any provision of this Agreement or the Program to the contrary, any earned Performance Units paid in cash rather than Shares shall not be deemed to have been issued by the Company for any purpose under the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The time and form of payment of the Performance Units is intended to comply with the requirements of Section 409A and this Agreement shall be interpreted in accordance with Section 409A. Accordingly, no acceleration or deferral of any payment shall be permitted if it would cause the payment of the Performance Units to violate Section 409A.  In addition, notwithstanding any provision herein to the contrary, in the event that following the Grant Date, the Committee determines that it may be necessary or appropriate to do so, the Committee may adopt such amendments to the Plan, Program and&#47;or this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Plan, Program and&#47;or the Performance Units from the application of Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to this Award, or (b) comply with the requirements of Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this paragraph shall not create an obligation on the part of the Committee to adopt any such amendment, policy or procedure or take any such other action.  No payment hereunder shall be made to you during the six (6)-month period following your &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">separation from service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (within the meaning of Section 409A) to the extent that the Company determines that paying such amount at the time set forth herein would be a prohibited distribution under Section 409A(a)(2)(B)(i). If the payment of any such amounts is delayed as a result of the previous sentence, then within thirty (30) days following the end of such six (6)-month period (or, if earlier, your death), the Company shall pay to you (or to your estate) the cumulative amounts that would have otherwise been payable to you during such period, without interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Provisions Applicable to Participants in Foreign Jurisdictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement or the Program to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (which constitutes a part of this Agreement), are subject to the laws of any foreign jurisdiction, or relocate to one of the countries included in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, your award of Performance Units shall be subject to any additional terms and conditions for such country set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and to the following additional terms and conditions&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the terms and conditions of this Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are deemed modified to the extent necessary or advisable to comply with applicable foreign laws or facilitate the administration of the Plan and the Program&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;if applicable, the effectiveness of your Award is conditioned upon its compliance with any applicable foreign laws, regulations, rules or local governmental regulatory exemption and subject to receipt of any required foreign regulatory approvals&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to the extent necessary to comply with applicable foreign laws, the payment of any earned Performance Units shall be made in cash or Common Stock, at the Company&#8217;s election&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;the Committee may take any other action, before or after an award of Performance Units is made, that it deems necessary or advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary contained herein, the Company shall not take any actions hereunder, and no Award of Performance Units shall be granted, and no Shares payable with respect to an Award shall be issued, that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation, or the rules of any Securities Exchange. Notwithstanding anything to the contrary contained herein, no Shares issuable with respect to an Award shall be issued unless such shares are then registered under the Securities Act, or, if such shares are not then so registered, the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act and that the issuance satisfied all other applicable legal requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:15.68pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">. In order for the Company to facilitate your participation in the Plan and the Program, the Company and your Employer must collect and use personal data about you.  In accordance with applicable laws, reasonable security measures will be implemented and maintained to protect the security of your personal data&#59; however, you understand that absolute security cannot be guaranteed.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and your Employer may hold certain personal information about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor, for the purposes of implementing, administering and managing the Plan and the Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;).  </font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan and the Program to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan and the Program, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Performance Units may be deposited.  You understand that such authorized recipients of your personal data may be located in countries that do not provide the same level of data privacy laws and protections as the country in which your personal data originated.  Transfers of personal data among Company and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company&#8217;s BCRs, please visit http&#58;&#47;&#47;www.amgen.com&#47;bcr&#47;.  You acknowledge that the collection, use and transfer of your personal data is necessary to facilitate to your participation in the Plan, as well as to grant you Performance Units or other equity awards and administer or maintain such awards.   </font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You may correct or update your personal data previously provided to Company, by completing the form located at&#160;https&#58;&#47;&#47;preferences.amgen.com.  Subject to applicable law, you may have additional rights, including the right to object and&#47;or request destruction of your personal data.  To exercise these rights, where applicable, please contact your local human resources representative.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electing to accept this Agreement, you acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement.  Furthermore, if you have received this Agreement or any other document related to the Plan and&#47;or the Program translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.7pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms of this Agreement shall be governed by the laws of the State of Delaware without giving effect to principles of conflicts of laws.  For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Agreement is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.71pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Agreement to be construed so as to foster the intent of this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide to&#160;deliver any documents related to current or future participation in the Plan and&#47;or the Program (including this Agreement) by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on your participation in the Plan and the Program, on the Performance Units and on any Shares acquired under the Plan and the Program, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XXI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XXII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.7pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement&#8217;s section headings are for convenience only and shall not constitute a part of this Agreement or affect this Agreement&#8217;s meaning.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;___________________________<br>Name&#58; </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><div id="i5b36df72f404474e830f10cf4e59a002_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDITIONAL TERMS AND CONDITIONS OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC. 2009 EQUITY INCENTIVE PLAN, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND&#47;OR RESTATED FROM TIME TO TIME</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AWARD OF PERFORMANCE UNITS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(BY COUNTRY)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and&#47;or the Agreement to which this Appendix is attached.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix includes additional terms and conditions that govern any Performance Units granted under the Plan if, under applicable law,&#160;you are a resident of, are deemed to be a resident of or are working in one of the countries listed below.&#160; Furthermore, the additional terms and conditions that govern the Performance Units granted hereunder may apply to you if you transfer employment and&#47;or residency to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix also includes notifications relating to exchange control and other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of October 2022.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the Plan because the information may be outdated when you acquire Shares under the Plan, or when you subsequently sell Shares acquired under the Plan and the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the notifications are general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.  Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL NON-U.S. JURISDICTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Issuance of Shares&#59; Tax Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section V. of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Company withholds or accounts for Tax Obligations by considering maximum applicable rates in your </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jurisdiction(s), in the event of over-withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, you may receive a refund of any over-withheld amount in cash and will not be entitled to the equivalent amount in Shares, or if not refunded, you may seek a refund from the local tax authorities.  In the event of under-withholding, you may be required to pay any additional Tax Obligations directly to the applicable tax authority or to the Company and&#47;or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Insider Trading Restrictions&#47;Market Abuse Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker&#8217;s country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., Performance Units) or rights linked to the value of Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Dividend Equivalents) during such times as you are considered to have &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">inside information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; regarding the Company (as defined by the laws in applicable jurisdictions).&#160; Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information.  Furthermore you could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees (other than on a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">need to know</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; basis) and (ii)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; You are responsible for ensuring your compliance with any applicable restrictions and you should speak with your personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account, Tax Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your country of residence may have certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any Dividends or Dividend Equivalents received, or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside of your country.  You may be required to report such accounts, assets or transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt.  You are responsible for ensuring your compliance with such regulations, and you should speak with your personal legal advisor on this matter.  </font></div><div style="margin-bottom:12pt;text-indent:31.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) &#47; EUROPEAN UNION (&#8220;EU&#8221;) JURISDICTIONS, UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision replaces Section XV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Please refer to the Fair Processing Notice previously provided by your local human resources representative, which notice governs the collection, use and transfer of your personal data necessary for the Company to facilitate your participation in the Plan and the Program.  If you have any questions or concerns regarding the Fair Processing Notice, including questions about your rights afforded thereunder, you should contact your local human resources representative or send an email to </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">hrconnect&#64;amgen.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">For purposes of implementing, administering and managing the Plan, Company and your Employer may hold certain personal data about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;).  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan and the Program to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan and the Program, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Performance Units may be deposited.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARGENTINA</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; The following provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the grant of Performance Units, you acknowledge, understand and agree that the grant of the Performance Units is made by the Company (not your Employer) in its sole discretion and that the value of the Performance Units or any Shares acquired under the Plan and the Program shall not constitute salary or wages for any purpose under Argentine labor law including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, etc., or (ii) any termination or severance indemnities or similar payments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;Neither the Performance Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; Exchange control regulations in Argentina are subject to frequent change.&#160; You should consult with your personal legal advisor regarding any exchange control obligations that you may have prior to receiving proceeds from Dividend Equivalents, the sale of Shares or dividends.&#160; You must comply with any and all Argentine currency exchange restrictions, approvals and reporting requirements in connection with your participation in the Plan and the Program. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Argentine resident, you are required to report certain information regarding any Shares you hold as of December 31 each year to the Argentine tax authorities on your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Australia Offer Document.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This grant of Units is being made under Division 1A, Part 7.12 of the Corporations Act 2001 (Cth).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please note that if you offer Shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law.  You should obtain legal advice on your disclosure obligations prior to making any such offer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the Performance Units granted under the Plan, such that the Performance Units are intended to be subject to deferred taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers.  If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.  If there is no Australian bank involved in the transfer, you will be required to file the report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; If you are an Austrian resident and you hold Shares acquired under the Plan and the Program outside of Austria, you may be subject to reporting obligations to the Austrian National Bank. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A separate reporting requirement applies when you sell Shares acquired under the Plan and the Program, receive a cash Dividend paid on such Shares or Dividend Equivalents paid in cash.  In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria.  If the transaction volume of all cash accounts abroad meets or exceeds a specified threshold, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Meldungen SI-Forderungen und&#47;oder SI-Verpflichtungen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BELGIUM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Reporting&#59; Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;If you are a Belgian resident, you are required to report any taxable income attributable to the Award granted hereunder on your annual tax return.  You are also required to report any securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under the Plan and the Program) held and bank accounts (including brokerage accounts) opened and maintained outside of Belgium on your annual tax return.  The first time you report the foreign security and&#47;or bank account on your annual income tax return you will have to provide the National Bank of Belgium Central Contact Point with the account details of any such foreign accounts (including the account number, bank name and country in which such account was opened) in a separate form.  This report, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Kredietcentrales &#47; Centrales des cr&#233;dits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> caption.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Exchange Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;A stock exchange tax applies to transactions executed by a Belgian resident through a non-Belgian financial intermediary, such as a U.S. broker.  The stock exchange tax likely will apply when Shares acquired under the Plan and the Program are sold.  It is your responsibility to comply with this tax obligation and you should consult your personal tax advisor for additional details on your obligations with respect to the stock exchange tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Securities Accounts Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;An annual securities accounts tax may be payable if the total value of securities held in a Belgian or foreign securities account (e.g., Shares acquired under the Plan and the Program) exceeds a certain threshold on four reference dates within the relevant reporting period (i.e., December 31, March 31, June 30 and September 30).  In such case, the tax will be due on the value of the qualifying securities held in such account.  It is your responsibility to comply with this obligation and you should consult with your personal tax or financial advisor for additional details.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By accepting the Performance Units, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the vesting of the Performance Units, the sale of Shares acquired under the Plan and the Program, the payment of Dividends on such Shares and the receipt of any Dividend Equivalents paid in cash.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the grant of Performance Units, you acknowledge (i) that you are making an investment decision, (ii) that the Shares will be issued to you only if the vesting conditions are met and any necessary services are rendered by you during the vesting period set forth in the Vesting Schedule, and (iii) that the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights on December 31 of each year exceeds US$1,000,000.  If such amount exceeds US$100,000,000, the referenced declaration must be submitted quarterly, in the month following the end of each quarter.  Assets and rights that must be reported include the following&#58; (i) bank deposits&#59; (ii) loans&#59; (iii) financing transactions&#59; (iv)&#160;leases&#59; (v) direct investments&#59; (vi) portfolio investments, including Shares acquired under the Plan and the Program&#59; (vii) financial derivatives investments&#59; and (viii) other investments, such as real estate.  Please note that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement and must declare at least the assets held abroad that were acquired subsequent to the date of admittance as a resident of Brazil.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Individuals holding assets and rights outside of Brazil valued at less than US$1,000,000 are not required to submit a declaration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BULGARIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be required to annually file statistical forms with the Bulgarian National Bank regarding your receivables in bank accounts abroad as well as your securities abroad (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) if the total sum of all such receivables and securities equals or exceeds BGN 50,000 as of the previous calendar year-end.&#160; The reports are due by March 31.  You should contact your bank in Bulgaria for additional information regarding this requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section IX(j) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the event of involuntary termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or unlawful, including for breaching employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive an Award and vest in such Award under the Plan and the Program, if any, will terminate effective as of the date that is the earlier of&#58; (1) the date you receive written notice of termination of employment from the Company or your Employer, or (2) the date you are no longer actively employed by the Company or your Employer regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law.  Your right, if any, to acquire Shares pursuant to an Award after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Performance Units, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Settlement - Performance Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Notwithstanding any discretion in Section 9.5 of the Plan or the Program or anything to the contrary in the Agreement, the Award does not provide any right for you, as a resident of Canada, to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The following provision will apply to you if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">French Language Documents. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A French translation of this document and certain other documents related to this Award will be made available to Participant as soon as reasonably practicable.  Participant understands that, from time to time, additional information related to the Award may be provided in English and such information may not be immediately available in French.  However, upon request, the Company will provide a translation of such information into French as soon as reasonably practicable.  Notwithstanding anything to the contrary in the Agreement, and unless Participant indicates otherwise, the French translation of this document and certain other documents related to the Award will govern Participant&#8217;s participation in the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration of the Plan and the Program.  You further authorize the Company, your Employer and Merrill Lynch Bank &#38; Trust Co., FSB (or any other stock plan service provider) to disclose and discuss your participation in the Plan with their advisors.  You also authorize the Company and your Employer to record such information and keep it in your file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Nasdaq Global Select Market).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified foreign property, including Shares, stock options and other rights to receive Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Performance Units) of a non-Canadian company held by a Canadian resident employee generally must be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee&#8217;s specified foreign property exceeds C$100,000 at any time during the year.  Thus, such stock options and Performance Units must be reported &#8211; generally at nil cost &#8211; if the C$100,000 cost threshold is exceeded because other specified foreign property is held by the employee.  When Shares are acquired, their cost generally is the adjusted cost base (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ACB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Shares.  The ACB ordinarily would equal the fair market value of the Shares at the time of acquisition, but if the employee owns other shares of the same company, this ACB may have to be averaged with the ACB of the other shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following terms apply only to individuals who are subject to exchange control restrictions in the People&#8217;s Republic of China (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221;), as determined by the Company in its sole discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting of the Performance Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding anything to the contrary in Article 7.1 of the Program, if your employment with the Company or an Affiliate terminates at any time during the Performance Period, you shall forfeit all Performance Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in the Agreement, due to exchange control laws in the PRC, you agree that the Company reserves the right to require the immediate sale of any Shares acquired upon settlement of the Performance Units.  You understand and agree that any such immediate sale of Shares will occur as soon as is practical following settlement of the Performance Units.  Alternatively, if the Shares are not immediately sold upon settlement of the Performance Units, the Company will require the sale of any Shares you may then hold within six (6) months (or such other period as may be required under applicable legal or exchange control requirements) following the termination of your employment with the Company, including its Affiliates.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree that the Company is authorized to instruct Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company to assist with the sale of the Shares on your behalf pursuant to this authorization, and you expressly authorize such broker to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">complete the sale of such Shares.  You also agree to sign any agreements, forms and&#47;or consents that may be reasonably requested by the Company (or the Company&#8217;s designated broker) to effectuate the sale of the Shares (including, without limitation, as to the transfers of the proceeds and other exchange control matters noted below) and to otherwise cooperate with the Company with respect to such matters, provided that you shall not be permitted to exercise any influence over how, when or whether the sales occur.  Upon the sale of the Shares, you will receive the cash proceeds from the sale, less any applicable Tax Obligations, brokerage fees or commissions, in accordance with applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company is under no obligation to arrange for the sale of the Shares at any particular price.  Due to fluctuations in the Share price and&#47;or applicable exchange rates between the settlement date and (if later) the date on which the Shares are sold, the amount of proceeds ultimately distributed to you may be more or less than the market value of the Shares on the settlement date (which is the amount relevant to determining your liability for Tax Obligations).  You understand and agree that the Company is not responsible for the amount of any loss that you may incur and that the Company assumes no liability for any fluctuations in the Share price and&#47;or any applicable exchange rate.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Designated Broker Account.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If Shares issued upon the settlement of the Performance Units are not immediately sold, you acknowledge that you are required to maintain the Shares in an account with Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company until the Shares are sold through such Company-designated broker.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You understand and agree that, pursuant to local exchange control requirements, you will be required to repatriate the cash proceeds from the sale of the Shares issued upon settlement of the Performance Units and from the receipt of any Dividends or Dividend Equivalents to China.  You further understand that, under applicable laws, such repatriation of your cash proceeds will need to be effectuated through a special exchange control account established by the Company or any Affiliate, including your Employer, and you hereby consent and agree that any proceeds may be transferred to such special account prior to being delivered to you.  You also understand that the Company will deliver the proceeds to you as soon as possible, but that there may be delays in distributing the funds to you due to exchange control requirements in China.  Proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account.  If the proceeds are paid to you in local currency, the Company is under no obligation to secure any particular currency conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The following provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that pursuant to Article 15 of Law 50&#47;1990 (Article 128 of the Colombian Labor Code), the Plan, the Program and related benefits do not constitute a component of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for any purpose. Therefore, they are considered to be of an extraordinary nature and will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amounts, subject to the limitations provided in Law 1393&#47;2010.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Shares are not and will not be registered with the Colombian registry of publicly traded securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and therefore the Shares may not be offered to the public in Colombia.  Nothing in this document should be construed as the making of a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investment in assets located abroad (such as Shares acquired under the Plan and the Program) does not require prior approval from the Central Bank (Banco de la Rep&#250;blica).  Nonetheless, such investments are subject to registration before the Central Bank as foreign investments held abroad, regardless of value.  In addition, you must file an annual informative return with the local tax authority detailing assets you hold abroad, which must include the Shares acquired at vesting (every year as long as you keep them).  This obligation is only applicable if the assets held abroad exceed the amount of 2,000 Tax Units (approx. US $22.000).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, local banks), which includes the obligation to correctly complete and file the appropriate foreign exchange form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">declaraci&#243;n de cambio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An annual information return may need to be filed with the Colombian Tax Office detailing any assets held abroad (including Shares acquired under the Plan).  If the individual value of any of these assets exceeds a certain threshold, each asset must be described (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, its nature and its value) and the jurisdiction in which it is located must be disclosed.  It is your responsibility to comply with this tax reporting requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CROATIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Croatian residents may be required to report any foreign investments (including Shares acquired under the Plan and the Program) to the Croatian National Bank for statistical purposes.  You should be aware that exchange control regulations in Croatia are subject to frequent change and you are solely responsible for ensuring your continued compliance with current Croatian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A Czech resident may be required to notify the Czech National Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CNB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the acquisition of Shares under the Plan or maintenance of a foreign account if (i) he or she maintains foreign direct investments with a value of 2,500,000 K&#269; or more in the aggregate, (ii) he or she maintains other foreign financial assets with a value of 200,000,000 K&#269; or more, or (iii) the Czech resident is specifically requested to do so by the CNB.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DENMARK</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Danish Stock Option Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Performance Units, you acknowledge that you have received an Employer Statement translated into Danish, which is being provided to comply with the Danish Stock Option Act.  To the extent more favorable to you and required to comply with the Stock Option Act, as amended with effect from January 1, 2019.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The requirement to report certain information to the Danish Tax Administration via Form V or K was eliminated effective January 1, 2019.  However, you still must report the foreign bank&#47;brokerage accounts and their deposits, and Shares held in a foreign bank or brokerage account in your tax return under the section on foreign affairs and income.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EGYPT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you transfer funds into Egypt in connection with the Performance Units, you are required to transfer the funds through a registered bank in Egypt.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no specific reporting requirements with respect to foreign assets&#47;accounts. However, please note that you must check your pre-completed tax return to confirm that the ownership of Shares and other securities (foreign or domestic) are correctly reported. If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By accepting the Award, you confirm having read and understood the Plan and Agreement which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement Relatif &#224; la Langue Utilis&#233;e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  En acceptant l&#8217;prix, vous confirmez avoir lu et compris le Plan et le Contrat, qui ont &#233;t&#233; communiqu&#233;s en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  French residents and non-residents must declare to the Customs Authorities the cash and securities they import or export without the use of a financial institution when the value of such cash or securities exceeds &#8364;10,000.  French residents also must report all foreign bank and brokerage accounts on an annual basis (including accounts opened or closed during the tax year) on Form N&#176; 3916, together with the income tax return.  Failure to comply could trigger significant penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If your acquisition of Shares under the Plan leads to a qualified participation at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year.  A qualified participation is attained </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">only in the unlikely event (i) you own at least 1% of the Company and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the value of the Shares acquired exceeds &#8364;150,000 or (ii) you hold Shares exceeding 10% of the Company&#8217;s total Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  In case of payments in connection with securities (including proceeds realized upon the sale of Shares or the receipt of Dividends or Dividend Equivalents), the report must be made by the 5th day of the month following the month in which the payment was received and must be filed electronically. The form of report (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Allgemeines Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) can be accessed via the Bundesbank&#8217;s website (www.bundesbank.de) and is available in both German and English. In addition, you may be required to report the acquisition or sale of Shares to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if the value of the Shares acquired or sold exceeds &#8364;12,500. You are responsible for satisfying any applicable reporting obligation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The reporting of foreign assets (including Shares and other investments) is your own obligation and takes place through your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Settlement - Performance Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Notwithstanding any discretion in Section 9.5 of the Plan or the Program or anything to the contrary in the Agreement, the Award does not provide any right for you, as a resident of Hong Kong, to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Shares received at vesting are accepted as a personal investment.  In the event that Shares are issued in respect of Performance Units within six (6) months of the Grant Date, you agree that you will not offer to the public or otherwise dispose of such Shares prior to the six (6)-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SECURITIES WARNING&#58;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in doubt about any of the contents of the Agreement, including this Appendix, or the Plan, you should obtain independent professional advice.  The Performance Units and any Shares issued in respect of the Performance Units do not constitute a public offering of securities under Hong Kong law and are available only to members of the Board and Employees.  The Agreement, including this Appendix, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221; for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a public offering of securities under the applicable securities legislation in Hong Kong.  The Performance Units and any documentation related thereto are intended solely for the personal use of each member of the Board and&#47;or Employee and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HUNGARY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ICELAND</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Approval by the Central Bank of Iceland is no longer required to participate in the Plan and the Program, regardless of the value of the Shares acquired under the Plan and the Program.  Despite the recent relaxation of the exchange control requirements, you should consult with your personal advisor to ensure compliance with applicable exchange control regulations in&#160;Iceland as such regulations are subject to frequent change.  You are responsible for ensuring compliance with all exchange control laws in&#160;Iceland.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;You understand that you must repatriate any cash Dividends paid on Shares acquired under the Plan and the Program to India or any Dividend Equivalents paid in cash, as well as any proceeds from the sale of Shares within a prescribed period of time (currently, within one hundred and eighty (180) days of receipt of cash Dividends or Dividend Equivalents, and within ninety (90) days of receipt of sale proceeds), or such other period of time as may be required under applicable regulations.  You will receive a foreign inward remittance certificate (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FIRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from the bank where you deposit the foreign currency, and you must maintain the FIRC as proof of repatriation of funds in the event that the Reserve Bank of India or your Employer requests proof of repatriation.  It is your responsibility to comply with these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You are required to declare foreign bank accounts and any foreign financial assets (including Shares held outside of India) in your annual tax return.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor in this regard.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the grant of Performance Units, you acknowledge that the benefits received under the Plan will not be taken into account for any redundancy or unfair dismissal claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ITALY </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In accepting the grant of Performance Units, you acknowledge that (1)&#160;you have received a copy of the Plan, the Program, the Agreement and this Appendix&#59; (2)&#160;you have reviewed the applicable documents in their entirety and fully understand the contents thereof&#59; and (3)&#160;you accept all provisions of the Plan, the Program, the Agreement and this Appendix.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further acknowledge that you have read and specifically and explicitly approve, without limitation, the following sections of the Agreement&#58; Section III, Section IV, Section V, Section IX, Section IV, Section XVI, Section XX and the Data Privacy Notice for All European Economic Area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) &#47; European Union (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Jurisdictions, United Kingdom and Switzerland in this Appendix.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Italian residents who, at any time during the fiscal year, hold foreign financial assets (including cash and Shares) which may generate income taxable in Italy are required to report these assets on their annual tax returns (UNICO Form, RW Schedule) for the year during which the assets are held, or on a special form if no tax return is due.  These reporting obligations will also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Financial Assets Tax.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The fair market value of any Shares held outside of Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is subject to a foreign assets tax at a flat rate.  The market value is considered to be the value of the Shares on the Nasdaq Global Select Market on December 31 of the applicable year in which you held the Shares (or when the Shares are acquired during the course of the year, the tax is levied in proportion to the actual days of holding over the calendar year).  No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does not exceed a certain threshold.  You should consult with your personal tax advisor about the foreign financial assets tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You will be required to report to the Japanese tax authorities details of any assets held outside of Japan as of December 31st (including any Shares acquired under the Plan and the Program) to the extent such assets have a total net fair market value exceeding &#165;50,000,000.  Such report will be due by March 15 each year.  You should consult with your personal tax advisor as to whether the reporting obligation applies to you and whether you will be required to include in the report details of any Shares or cash that you hold.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare all foreign financial accounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> non-Korean bank accounts, brokerage accounts holding Shares, etc.) to the Korean tax authority and file a report regarding such accounts if the monthly balance of such accounts exceeds a certain threshold.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor to ensure compliance with this requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LITHUANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you (i) hold certain job positions established by the law or (ii) donate to political parties or political campaigners, you must file an Annual Asset Return of the Individual (Family) in Form No. FR0001 with respect to assets held outside of Lithuania (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares). If you open an account in a foreign financial institution and annual turnover in the account exceeds EUR 15,000, you must file a foreign account report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of the Grant.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Award granted hereunder, you acknowledge that you have received a copy of the Plan and the Program, have reviewed the Plan and the Program and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan, the Program and the Agreement, including this Appendix.  You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section IX of the Agreement, in which the following is clearly described and established&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan and the Program do not constitute an acquired right. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in the Plan and the Program are offered by Amgen Inc. on a wholly discretionary basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan and the Program is voluntary. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. and its Affiliates are not responsible for any decrease in the value of any Shares issued with respect to the Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement and Policy Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;In accepting any Award granted hereunder, you expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Shares do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Based on the foregoing, you expressly recognize that the Plan and the Program and the benefits that you may derive from participation in the Plan and the Program do not establish any rights between you and your Employer, Amgen-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan and the Program is as a result of a unilateral and discretionary decision of Amgen Inc.&#59; therefore, Amgen Inc. reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time without any liability to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen&#160;Inc., its Affiliates, stockholders, officers, agents or legal representatives with respect to any claim that may arise. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Spanish Translation </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento del Otorgamiento.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Al aceptar cualquier Otorgamiento de Acciones bajo el presente documento, usted reconoce que ha recibido una copia del Plan y del Programa, que ha revisado el Plan y el Programa, as&#237; como tambi&#233;n el Ap&#233;ndice en su totalidad, adem&#225;s que comprende y est&#225; de acuerdo con todas las disposiciones tanto del Plan, del Programa y del Otorgamiento, incluyendo este Ap&#233;ndice.  Asimismo, usted reconoce que ha le&#237;do y manifiesta espec&#237;ficamente y expresamente la conformidad con los t&#233;rminos y condiciones establecidos en la Secci&#243;n IX del Acuerdo del Otorgamiento, en los que se establece y describe claramente que&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan y en el Programa de ninguna manera constituye un derecho adquirido. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Su participaci&#243;n en Plan y en el Programa son ofrecidos por Amgen Inc. de forma completamente discrecional. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan y en el Programa es voluntaria. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. y sus Afiliados no son responsables de ninguna disminuci&#243;n en el valor de las Acciones Comunes emitidas mediante el Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento de la Ley Laboral y Declaraci&#243;n de Pol&#237;tica. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Al aceptar cualquier Otorgamiento bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la &#250;nica responsable de la administraci&#243;n del Plan y que su participaci&#243;n en el mismo y la adquisici&#243;n de Acciones Comunes no constituyen de ninguna manera una relaci&#243;n laboral entre usted y Amgen Inc., debido a que su participaci&#243;n en el Plan es &#250;nicamente una relaci&#243;n comercial y que su &#250;nico empleador es Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Derivado de lo anterior, usted reconoce expresamente que el Plan y el Programa y los beneficios a su favor que pudieran derivar de la participaci&#243;n en el mismo, no establecen ning&#250;n derecho entre usted y su empleador, Amgen &#8211; M&#233;xico, y no forman parte de las condiciones laborales y&#47;o los beneficios otorgados por Amgen &#8211; M&#233;xico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n del mismo no constituir&#225; un cambio o desmejora de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Asimismo, usted entiende que su participaci&#243;n en el Plan y en el Programa es resultado de la decisi&#243;n unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y&#47;o descontinuar su participaci&#243;n en el Plan en cualquier momento y sin ninguna responsabilidad para usted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Amgen Inc., por cualquier compensaci&#243;n o da&#241;os y perjuicios, en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de toda responsabilidad, como as&#237; tambi&#233;n a sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Performance Units and the Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Performance Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">existing relationship with the Company and your Employer and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of Amgen-Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="warninglabelb.jpg" src="warninglabelb.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NORWAY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Norwegian residents may be subject to foreign asset reporting as part of their ordinary tax return. Norwegian banks, financial institutions, limited companies etc. must report certain information to the Tax Administration. Such information may then be pre-completed in a Norwegian resident&#8217;s tax return. However, if the resident has traded, or is the owner of, financial instruments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares) not pre-completed in the tax return, the Norwegian resident must enter this information in Form RF-1159, which is an appendix to the tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In general, Norwegian residents should not be subject to any foreign exchange requirements in connection with their acquisition or sale of Shares under the Plan, except normal reporting requirements to the Norwegian Currency Registry. If any transfer of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must file reports with the National Bank of Poland if the aggregate value of Shares and cash held in such foreign accounts exceeds PLN 7,000,000.  If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National Bank of Poland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently &#8364;15,000 (or PLN 15,000 if such transfer of funds is associated with the business activity of a consultant)).  You must store all documents connected with any foreign </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exchange transactions you engage in for a period of five (5) years from the end of the year when such transactions were made.  Penalties may apply for failure to comply with exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PORTUGAL</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent to Receive Information in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan, the Program and Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Conhecimento da Lingua.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano, no Programa e no Acordo.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Certain transfers of funds may need to be reported to the National Office for Prevention and Control of Money Laundering on specific forms by the relevant bank or financial institution.  If you deposit proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income.  You should consult with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be required to repatriate certain cash </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amounts received with respect to the Award to Russia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, cash Dividends, sale proceeds) as soon as you intend to use those cash amounts for any purpose, including reinvestment. If the repatriation requirement applies, such funds must initially be credited to you through a foreign currency account at an authorized bank in Russia. After the funds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.  Under the Directive N 5371-U of the Russian Central Bank (the &#8220;CBR&#8221;), the repatriation requirement may not apply in certain cases with respect to cash amounts received in an account that is considered by the CBR to be a foreign brokerage account. Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The exchange control rules and regulations in Russia, including temporary restrictions imposed by the Russian government in March 2022, are subject to frequent change.  You should consult with your personal legal advisor to determine the applicability of any repatriation requirements applicable to any Shares or cash received in connection with the Plan and held in an account outside Russia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The Award granted hereunder, the Agreement, including this Appendix, the Program, the Plan and all other materials you may receive regarding your participation in the Plan and the Program or the Award granted hereunder do not constitute </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">advertising or an offering of securities in Russia.  The issuance of Shares in respect of the Award has not and will not be registered in Russia&#59; therefore, such Shares may not be offered or placed in public circulation in Russia.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In no event will Shares acquired under the Plan and the Program be delivered to you in Russia&#59; all Shares will be maintained on your behalf in the United States.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are not permitted to sell any Shares acquired under the Plan and the Program directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge that if you continue to hold Shares acquired under the Plan and the Program after an involuntary termination of your employment, you will not be eligible to receive unemployment benefits in Russia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provision supplements Section XV of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that you must complete and return a Consent to Processing of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) form to the Company.  Further, you understand and agree that if you do not complete and return a Consent form to the Company, the Company will not be able to administer or maintain the Performance Units.  Therefore, you understand that refusing to complete a Consent form or withdrawing your consent may affect your ability to participate in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Russian residents are required to file the following reports or notifications with the Russian tax authorities, if applicable&#58; (i) annual cash flow reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; (ii) financial asset (including Shares) reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; and (ii) a one-time notification within one (1) month of opening, closing, or changing details of an offshore brokerage account.  You are encouraged to contact your personal tax advisor before remitting your proceeds from participation in the Plan to Russia to ensure compliance with applicable requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Anti-Corruption Legislation Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Individuals holding public office in Russia, as well as their spouses and dependent children, may be prohibited from opening or maintaining a foreign brokerage or bank account and holding any securities, whether acquired directly or indirectly, in a foreign company (including Shares acquired under the Plan and the Program).  You should consult with your personal legal advisor to determine whether this restriction applies to your circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby agree that any Shares acquired pursuant to the Performance Units will not be offered for sale in Singapore prior to the six (6)-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; ), or pursuant to, and in accordance with the conditions of, any other applicable provisions of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The grant of the Performance Units is being made pursuant to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made with a view to the Performance Units being subsequently offered for sale to any other party.  The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Directors (including alternate, substitute, associate and shadow directors) of a Singapore Affiliate are subject to certain notification requirements under the Singapore Companies Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, regardless of whether they are resident or employed in Singapore. Directors of a Singapore Affiliate must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Performance Units, Shares, etc.) in the Company or any related company within two (2) business days of (i) its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> when the Shares are sold), or (iii) becoming a director.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVAK REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Slovak Republic residents who carry on business activities as an independent entrepreneur (in Slovakian, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">podnikatel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), must report foreign assets (including any Shares) to the National Bank of Slovakia (provided that the value of the foreign assets exceeds an amount of EUR&#160;2,000,000).  These reports must be submitted on a monthly basis by the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of the respective calendar month, as well as on a quarterly basis by the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of the calendar month following the respective calendar quarter, using notification form DEV (NBS) 1-12, which may be found at the National Bank of Slovakia&#8217;s website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.nbs.sk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVENIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The following provision supplements Section IX of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Award granted hereunder, you consent to participation in the Plan and the Program and acknowledge that you have received a copy of the Plan and the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to grant the Award under the Plan and the Program to individuals who may be members of the Board or Employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that the Awards granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the applicable Agreement, including this Appendix.  Consequently, you understand that the Award granted hereunder is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from any gratuitous and discretionary grant of the Award since the future value of the Award and any Shares that may be issued in respect of such Award is unknown and unpredictable.  In addition, you understand that the Award granted hereunder would not be made but for the assumptions and conditions referred to above&#59; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then the grant of the Award or right to the Award shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further, the vesting of the Performance Units is expressly conditioned your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Performance Units may cease vesting immediately, in whole or in part, effective on the date of your termination of employment (unless otherwise specifically provided in Section I of the Agreement).  This will be the case, for example, even if (1) you are considered to be unfairly dismissed without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, subject to a &#8220;d</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">espido improcedente</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (2) you are dismissed for disciplinary or objective reasons or due to a collective dismissal&#59; (3) you terminate service due to a change of work location, duties or any other employment or contractual condition&#59; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate&#59; or (5) your employment terminates for any other reason whatsoever.  Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Performance Units that were not vested on the date of your termination of employment, as described in the Plan and the Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you have read and specifically accept the conditions referred to in Section I of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">offer of securities to the public</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; as defined under&#160;Spanish&#160;law,&#160;has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and does not constitute a public offering prospectus. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you acquire Shares under the Plan, you must declare the acquisition to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Direccion General de Comercio e Inversiones </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DGCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If you acquire the Shares through the use of a Spanish financial institution, that institution will automatically make the declaration to the DGCI for you&#59; otherwise, you will be required to make the declaration by filing a D-6 form.  You must declare ownership of any Shares with the DGCI each January while the Shares are owned and must also report, in January, any sale of Shares that occurred in the previous year for which the report is being made, unless the sale proceeds exceed the applicable threshold, in which case the report is due within one (1) month of the sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare electronically to&#160;the Bank of Spain any securities accounts (including brokerage accounts held abroad), as well as the Shares held in such accounts if the&#160;value of the transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax year exceed &#8364;1,000,000.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent that you hold Shares and&#47;or have bank accounts outside of Spain with a value in excess of &#8364;50,000 (for each type of asset) as of December 31 each year, you will be required to report information on such assets in your tax return (tax form 720) for such year.  After such Shares and&#47;or accounts are initially reported, the reporting obligation will apply for subsequent years only if the value of any previously-reported Shares or accounts increases by more than &#8364;20,000 or if you sell or otherwise dispose of previously-reported Shares or accounts.  If the value of such Shares and&#47;or accounts as of December 31 does not exceed &#8364;50,000, a summarized form of declaration may be presented.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Authorization to Withhold. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax Obligations as set forth in the Agreement, in accepting the Performance Units, you authorize the Company to withhold Shares or to sell Shares otherwise issuable to you upon vesting or settlement to satisfy Tax Obligations, regardless of whether the Company and&#47;or Employer have an obligation to withhold such Tax Obligations, provided that such withholding would not, in the Company&#8217;s determination, result in adverse accounting consequences to the Company</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160; Neither this document nor any other materials relating to the Performance Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available to any person other than an employee of the Company or one of its Subsidiaries in Switzerland or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may acquire and remit foreign currency (including proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents) up to US$5,000,000 per year without justification.  If the transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.  If the transaction amount is US$500,000 or more in a single transaction, you must also provide supporting documentation to the satisfaction of the remitting bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If proceeds from the sale of Shares or the receipt of any Dividends or Dividend Equivalents exceed US$1,000,000, you must (i) immediately repatriate such funds to Thailand and (ii) report the inward remittance to the Bank of Thailand on a Foreign Exchange Transaction Form.  In addition, within three hundred and sixty (360) days of repatriation, you must either convert any funds repatriated to Thailand to Thai Baht or deposit the funds in a foreign exchange account with a Thai commercial bank.  Any such commercial bank must be duly authorized by the Bank of Thailand to engage in the purchase, exchange and withdrawal of foreign currency.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Performance Units under the Plan are available only to Participants under the Program and are for the purpose of providing equity incentives.  The Plan, the Program and the Agreement are intended for distribution only to such Participants and must not be delivered to, or relied on by, any other person.  You should conduct your own due diligence on the Performance Units offered pursuant to this Agreement.  If you do not understand the contents of the Plan and&#47;or the Agreement, you should consult an authorized financial adviser.  The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section V of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to Section V of the Agreement, you agree that you are liable for all Tax Obligations and hereby covenant to pay all such Tax Obligations as and when requested by the Company or your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and your Employer against any taxes that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you are an executive officer or director (as within the meaning of Section 13(k) of the Exchange Act, as amended, from time to time), you understand that you may not be able to indemnify the Company or your Employer for the amount of income tax not collected from or paid by you, as it may be considered a loan.  In the event that you are an executive officer or director and income tax is not collected from you within ninety (90) days after the end of the tax year in which the Taxable Event occurs, the amount of any uncollected income tax may constitute an additional benefit to you on which additional income tax and national insurance contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may be payable.  You acknowledge that you are responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying your Employer for the amount of any NICs due on this additional benefit, which the Company or your Employer may obtain from you by any of the means set forth in Section V of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the maximum applicable withholding rate is used, any over-withheld amount may be credited to you by the Company or your Employer (with no entitlement to the Common Stock equivalent) or if not so credited, you may seek a refund from the local tax authorities.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are a resident of the United Kingdom between the Grant Date and the vesting of the Performance Units, as a condition of the Award, you agree to accept any liability for secondary Class 1 National Insurance Contributions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) which may be payable by the Company or your Employer with respect to the earning and&#47;or payment of the Performance Units and issuance of Shares in respect of the Performance Units, the assignment or release of the Performance Units for consideration or the receipt of any other benefit in connection with the Performance Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to the foregoing, you agree to make an election (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in the form specified and&#47;or approved for such election by HMRC, that the liability for your Employer NICs </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payments on any such gains shall be transferred to you to the fullest extent permitted by law.  You further agree to execute such other elections as may be required between you and any successor to the Company and&#47;or your Employer.  You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section V of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Performance Units, without any liability to the Company or your Employer.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED STATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provision replaces Section IX(j) of the Award Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;in the event of termination of your employment (whether or not in breach of local labor laws), your right to receive Performance Units and receive Shares under the Plan and the Program, if any, will terminate effective as of the date that you are no longer actively employed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such right will be extended by any notice period mandated by law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., the Worker Adjustment and Retraining Notification Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave.  In such event, payment of the Performance Units shall be made in accordance with Section IV&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that notwithstanding the effect of any such extension, subject to Section 4.2 of the Program, in no event will the Performance Units be paid later than the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day following the last day of the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-23</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11 4
<SEQUENCE>6
<FILENAME>exhibit10114-fourthamendme.htm
<DESCRIPTION>FOURTH AMENDMENT TO THE SUPPLEMENTAL RETIREMENT PLAN
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7b0f1a898e804aa095b242aa8b147572_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.11.4</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOURTH AMENDMENT TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Amgen Inc. Supplemental Retirement Plan, as Amended and Restated Effective October 16, 2013 (the &#8220;Plan&#8221;), is hereby amended, effective October 20, 2022, as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Section 2.27 is amended by adding the following at the end thereof&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you were employed by ChemoCentryx, Inc. or any affiliate of ChemoCentryx, Inc. (collectively &#8220;ChemoCentryx&#8221;) immediately preceding the Closing Date (as defined in the Agreement and Plan of Merger dated as of August 3, 2022, among ChemoCentryx, Inc., Amgen Inc. and Carnation Merger Sub, Inc.) and effective as of the Closing Date, your employment continues with ChemoCentryx or you transition to employment with the Company, then for purposes of calculating your Years of Service under the Plan, you will receive credit for your years of service with ChemoCentryx and with ChemoCentryx-recognized predecessors prior to the Closing Date.</font></div><div style="margin-bottom:24pt;margin-top:12pt;text-align:justify"><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To record this Fourth Amendment to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amgen Inc. Supplemental Retirement Plan, as Amended and Restated Effective October 16, 2013, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as set forth herein</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company has caused its authorized officer to execute this document this 19</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of December, 2022.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Derek Miller&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Derek Miller</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President, Human Resources</font></div><div style="padding-left:216pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16 1
<SEQUENCE>7
<FILENAME>exhibit10161-amendmentno1t.htm
<DESCRIPTION>AMENDMENT NO. 1 TO THE CREDIT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib6a58edfcca043b385670be29d25c61b_1"></div><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-right:16.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.16.1</font></div><div><font><br></font></div><div style="margin-top:10.7pt;padding-left:162.5pt;padding-right:162.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 1 TO THE CREDIT AGREEMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:333.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated as of December 29, 2022</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:89pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT&#160;&#160;&#160;&#160;NO.&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;TO&#160;&#160;&#160;&#160;THE&#160;&#160;&#160;&#160;CREDIT&#160;&#160;&#160;&#160;AGREEMENT&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(this</font></div><div style="margin-top:0.05pt;padding-left:17pt;padding-right:17.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) among Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), each financial institution whose name is set forth on the signature pages hereof as a Bank, Citibank, N.A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Citibank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as the Administrative Agent and an Issuing Bank.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:89pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PRELIMINARY STATEMENTS&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17pt;padding-right:17.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Company, the Banks and the Administrative Agent have entered into that certain Second Amended and Restated Credit Agreement, dated as of December 12, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Credit Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17pt;padding-right:17.35pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Pursuant to Section 3.8(e) of the Credit Agreement, the parties hereby agree to amend, consistent with the authority provided under such Section, the Credit Agreement and Exhibit E thereto as set forth in, and in accordance with the terms and conditions of, this Amendment (the Credit Agreement as so amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amended Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17pt;padding-right:17.35pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendments to Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In accordance with Section 3.8(e) of the Credit Agreement, the Administrative Agent has posted a copy of this Amendment on December 21, 2022 (the &#8220;Posting Date&#8221;). As of the Amendment Effective Date (as defined below), subject to the satisfaction of the conditions precedent set forth in Section 2 below, the Banks and the Company hereby agree to amend the Credit Agreement and Exhibit E thereto to delete the stricken text (indicated textually in the same manner as the following example&#58; </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">stricken text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and to add the double-underlined text (indicated textually in the same manner as the following example&#58; </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">double-underlined text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) as set forth in the pages of the Amended Credit Agreement attached as Annex A hereto and as set forth in the pages of the amended Exhibit E attached as Annex B hereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17pt;padding-right:17.45pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions of Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment shall become effective on and as of the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on which each of the following conditions precedent shall have been satisfied or waived&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:53pt;padding-right:17.45pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Administrative Agent shall have received counterparts of this Amendment executed by the Company and the Administrative Agent.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:53pt;padding-right:17.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Administrative Agent shall not have received, within five Business Days of the Posting Date, a written notice from the Majority Banks stating that such Majority Banks object to this Amendment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17pt;padding-right:17.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reference to and Effect on the Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (a) On and after the effectiveness of this Amendment, each reference in the Credit Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221; or words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to &#8220;the Credit Agreement&#8221;, &#8220;thereunder&#8221;,</font></div><div style="padding-right:17.15pt;text-align:justify"><font><br></font></div><div style="padding-right:17.15pt;text-align:justify"><font><br></font></div><div style="padding-right:17.15pt;text-align:justify"><font><br></font></div><div style="padding-right:17.15pt;text-align:justify"><font><br></font></div><div style="padding-right:17.15pt;text-align:justify"><font><br></font></div><div style="padding-right:17.15pt;text-align:justify"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amendment No. 1 to Amgen Credit Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">#96432517v8</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_4"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;thereof&#8221; or words of like import referring to the Credit Agreement, shall mean and be a reference to the Amended Credit Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17pt;padding-right:17.35pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Credit Agreement, as specifically amended by this Amendment, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17pt;padding-right:17.4pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Bank or the Administrative Agent under the Credit Agreement or any other Loan Document, nor constitute a waiver of any provision of the Credit Agreement or any other Loan Document.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17pt;padding-right:17.3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;This Amendment is subject to the provisions of Section 13.2 of the Amended Credit Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17pt;padding-right:17.25pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Costs and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company agrees to pay on demand all reasonable costs and expenses of the Administrative Agent (supported by invoices) in connection with the negotiation, preparation, execution and delivery of this Amendment (including, without limitation, the reasonable fees and expenses of Shearman &#38; Sterling LLP and Davis Polk &#38; Wardwell LLP) in accordance with the terms of Section 13.3 of the Amended Credit Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17pt;padding-right:17.25pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment may be executed in any number of counterparts and any party hereto may execute any counterpart, each of which when executed and delivered will be deemed to be an original and all of which counterparts of this Amendment when taken together will be deemed to be but one and the same instrument. Delivery of an executed counterpart of a signature page to this Amendment by telecopier shall be effective as delivery of a manually executed counterpart of this Amendment. The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in this Amendment shall be deemed to include electronic signatures or electronic records, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17pt;padding-right:17.3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK) WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;REMAINDER OF THIS PAGE IS LEFT BLANK INTENTIONALLY&#93;</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amendment No. 1 to Amgen Credit Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">#96432517v8</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_7"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:17pt;padding-right:17.05pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized, as of the date first above written.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:233pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE COMPANY&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:233pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN INC.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:233pt;padding-right:88.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Justin G. Claeys&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Name&#58; Justin G. Claeys</font></div><div style="padding-left:233pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Vice President, Finance and Treasurer</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.9pt;padding-left:233pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CITIBANK, N.A., as Administrative Agent</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:233pt;padding-right:88.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Richard Rivera&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Name&#58; Richard Rivera</font></div><div style="padding-left:233pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Vice President</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:0.05pt;padding-right:0.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Signature Page to Amendment No. 1 to Amgen Credit Agreement&#93;</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_10"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:162.5pt;padding-right:162.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNEX A</font></div><div><font><br></font></div><div style="padding-left:162.45pt;padding-right:162.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amended Credit Agreement</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:80%">#96432517v6</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_13"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.75pt;padding-right:19.95pt;text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EXECUTION COPY</font></div><div><font><br></font></div><div style="margin-top:10.55pt;padding-left:54.25pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ANNEX A TO AMENDMENT NO. 1 DATED AS OF DECEMBER 29, 2022</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:2.05pt;padding-right:2.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECOND AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div style="margin-top:5.95pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%">Dated as of December 12, 2019 among</font></div><div style="padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amgen Inc.,</font></div><div style="margin-top:5.9pt;padding-left:144.05pt;padding-right:144.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%">The Borrowing Subsidiaries Herein Named, The Banks Herein Named,</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Citibank, N.A.,</font></div><div style="margin-top:5.95pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">as Administrative Agent,</font></div><div><font><br></font></div><div style="margin-top:10.65pt;padding-left:176.52pt;padding-right:176.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%">JPMorgan Chase Bank, N.A., as Syndication Agent,</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:164.05pt;padding-right:164.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Citibank, N.A.</font></div><div style="margin-top:5.9pt;padding-left:196.85pt;padding-right:178.15pt;text-indent:-21.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%">JPMorgan Chase Bank, N.A. Barclays Bank PLC BofA Securities, Inc.</font></div><div style="padding-left:184.42pt;padding-right:184.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%">Goldman Sachs Bank USA and</font></div><div style="padding-left:1.7pt;padding-right:1.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Morgan Stanley Senior Funding, Inc.</font></div><div style="margin-top:5.85pt;padding-left:1.7pt;padding-right:1.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">as Joint Lead Arrangers and Joint Book Runners</font></div><div><font><br></font></div><div style="margin-top:10.7pt;padding-left:176.5pt;padding-right:176.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%">Bank of America, N.A. Barclays Bank PLC</font></div><div style="padding-left:184.42pt;padding-right:184.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%">Goldman Sachs Bank USA and</font></div><div style="padding-left:157.2pt;padding-right:157.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%">Morgan Stanley Senior Funding, Inc. as Co-Documentation Agents</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:80%">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_16"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:25.990%"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="margin-top:10.55pt;padding-left:16.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1</font></div></div><div style="display:inline-block;max-width:11.013%;min-width:10.513%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:25.990%"><div style="margin-top:3.6pt;padding-left:16.55pt"><font><br></font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Table of Contents</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:11.013%;min-width:10.513%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:25.994%"></div></div><div style="padding-left:36pt;text-align:right;text-indent:36pt"><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Page</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:25.990%"><div><font><br></font></div></div><div style="display:inline-block;max-width:11.013%;min-width:10.513%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:25.990%"></div><div style="display:inline-block;max-width:11.013%;min-width:10.513%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:25.994%"></div></div><div style="padding-left:87.84pt;text-align:right;text-indent:-35.85pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  </font></div><div id="ib6a58edfcca043b385670be29d25c61b_19"></div><div style="padding-right:24.25pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">DEFINITIONS AND ACCOUNTING TERMS</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DEFINITIONS AND</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ACCOUNTING TERMS</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div style="margin-top:4.8pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Defined Terms&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Defined Terms&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">21</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">22</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accounting Terms&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">21</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">22</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rounding                                                                                                         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">22</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">23</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibits and Schedules</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">22</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">23</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">References to &#8220;the Company and its Subsidiaries&#8221;&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">22</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">23</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous Terms</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">22</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">23</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Rates&#59; Alternative Currency Equivalents</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">22</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">23</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Divisions&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">22</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">23</font></div><div style="margin-top:5.65pt;padding-left:164.05pt;padding-right:164.05pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">ARTICLE 2</font></div><div style="padding-left:1.75pt;padding-right:1.75pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">LOANS AND LETTERS OF CREDIT</font></div><div style="margin-top:6.15pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rates</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24</font></div><div style="padding-left:87.85pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:3.95pt;padding-right:3.95pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 2 LOANS AND LETTERS OF CREDIT</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24</font></div><div style="padding-left:16.25pt"><font><br></font></div><div style="margin-top:4.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Advances - General&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">23</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">24</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Rate Advances</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">24</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">24</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Voluntary Reduction of Commitment&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">25</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Voluntary Conversion or Continuation of Advances&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">26</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">27</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Letters of Credit&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">26</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">28</font></div><div style="margin-top:5.7pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Agent&#8217;s Right to Assume Funds Available for</font></div><div style="margin-top:0.15pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Advances</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">31</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">33</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Increased Commitment&#59; Additional Banks&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">32</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">33</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extension of Maturity Date</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">33</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">34</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Defaulting Banks&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">34</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">35</font></div><div style="margin-top:5.65pt;padding-left:129.65pt;padding-right:129.65pt;text-align:center;text-indent:-0.1pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 3</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">PAYMENTS AND FEES</font></div><div style="margin-top:6.1pt;padding-left:3.82pt;padding-right:3.82pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 3 PAYMENTS AND FEES</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;38</font></div><div style="padding-left:16.25pt"><font><br></font></div><div style="margin-top:4.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Principal and Interest&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">36</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">38</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_22"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Facility Fee&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">38</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">39</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arranger Fees and Agency Fees&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">38</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">39</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LC Issuance Fee</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">39</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">40</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LC Reimbursement Fee</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">39</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">40</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LC Drawing Fee</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">39</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">40</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Capital Adequacy</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">39</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">40</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Increased Costs</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">40</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">41</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Default Rate</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">44</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Computation of Interest and Fees&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">44</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Banking Days&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">44</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manner and Treatment of Payments</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">44</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Funding Sources</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">47</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">48</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Failure to Charge Not Subsequent Waiver</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">47</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">48</font></div><div style="margin-top:5.65pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Agent&#8217;s Right to Assume Payments Will be Made by</font></div><div style="margin-top:0.2pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">47</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">48</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fee Determination Detail&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">48</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survivability</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">48</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dodd-Frank, Etc&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">48</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Replacement of Banks&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">48</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</font></div><div style="margin-top:5.65pt;padding-left:139.1pt;padding-right:72pt;text-indent:80.65pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 4</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-top:6.1pt;padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 4 REPRESENTATIONS AND WARRANTIES</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;50</font></div><div style="padding-left:16.25pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Existence and Qualification&#59; Power&#59; Compliance With Laws&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">49</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">50</font></div><div style="margin-top:5.7pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Authority&#59; Compliance With Other Agreements and Instruments and</font></div><div style="margin-top:0.15pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Government Regulations</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">49</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">50</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Governmental Approvals Required&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">50</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">51</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiaries&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">50</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">51</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Statements&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">50</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">51</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Other Liabilities&#59; No Material Adverse Effect&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">50</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">51</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental   Regulation&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Binding Obligations</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">51</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Default&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">51</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">2</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.85pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employee Benefit Plans</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">51</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulation U&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosure&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">52</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Liability</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">52</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental Matters</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">52</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sanctions</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">52</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Foreign Corrupt Practices Act&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">53</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">54</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA Financial Institution&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">53</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">54</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Certification&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">53</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">54</font></div><div style="margin-top:5.65pt;padding-left:72pt;padding-right:72pt;text-align:center;text-indent:47.8pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 5</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">AFFIRMATIVE COVENANTS</font></div><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">(OTHER THAN INFORMATION AND REPORTING REQUIREMENTS)</font></div><div style="margin-top:5.9pt;padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 5 AFFIRMATIVE COVENANTS</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(OTHER THAN INFORMATION</font></div><div style="margin-top:0.2pt;padding-left:106.05pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">AND REPORTING REQUIREMENTS)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;54</font></div><div style="padding-left:105.75pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment of Taxes and Other Potential Liens</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">53</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">54</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preservation of Existence</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">53</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">54</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Maintenance of Properties&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">54</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">55</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Maintenance of Insurance&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">54</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">55</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance With Laws</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">54</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">55</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Visitation&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">54</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">55</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Keeping of Records and Books of Account</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">54</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">55</font></div><div style="margin-top:0.2pt;padding-left:16.55pt;padding-right:24.25pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">5.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">Use of Proceeds&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">54</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">55</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">6</font></div><div style="margin-top:0.15pt;padding-left:106.05pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">NEGATIVE COVENANTS</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NEGATIVE COVENANTS</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;55</font></div><div style="padding-left:243.75pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Nature of Business</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">55</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">56</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mergers</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">55</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">56</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Liens&#59; Sales and Leasebacks&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">55</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">56</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transactions with Affiliates&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiary   Indebtedness</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">56</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">57</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Covenant&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">56</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">57</font></div><div style="margin-top:0.2pt;padding-left:16.55pt;padding-right:24.25pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">Use of Proceeds&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">56</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">57</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">7</font></div><div style="padding-left:106.05pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">INFORMATION AND REPORTING REQUIREMENTS</font></div><div style="margin-top:0.2pt;padding-left:106.05pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">INFORMATION AND REPORTING REQUIREMENTS</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;57</font></div><div style="padding-left:105.75pt"><font><br></font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">3</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.85pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial and Business Information</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">56</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">57</font></div><div style="margin-top:0.2pt;padding-left:16.55pt;padding-right:24.25pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">Compliance Certificates&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">58</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">59</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">8</font></div><div style="margin-top:0.15pt;padding-left:106.05pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">CONDITIONS</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CONDITIONS                                                                      </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div><div style="padding-left:181pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions to Effectiveness</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">58</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">59</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Any Advance and Any Letter of Credit</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">60</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</font></div><div style="margin-top:5.7pt;padding-left:164.05pt;padding-right:164.05pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">ARTICLE 9</font></div><div style="padding-left:1.67pt;padding-right:1.67pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EVENTS OF DEFAULT AND REMEDIES UPON EVENT OF DEFAULT</font></div><div style="padding-right:3.35pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">       </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 9 EVENTS OF DEFAULT AND REMEDIES UPON EVENT OF</font></div><div style="margin-top:6.15pt;padding-right:8.05pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                                  </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DEFAULT                                                                                                       </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div><div style="margin-top:4.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Events of Default</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">60</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies Upon Event of Default</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">63</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">64</font></div><div style="margin-top:5.7pt;padding-left:164.05pt;padding-right:164.05pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">ARTICLE 10</font></div><div style="padding-left:164.12pt;padding-right:164.12pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">THE ADMINISTRATIVE AGENT</font></div><div style="margin-top:6.15pt;padding-right:8.05pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">      </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 10 THE ADMINISTRATIVE AGENT                                                                     </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></div><div style="padding-left:16.25pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appointment and Authority</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">65</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">66</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rights as a Bank</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">65</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">66</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exculpatory Provisions&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reliance by Administrative Agent&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">67</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Delegation of Duties&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">67</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">68</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation of the Administrative Agent&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">67</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">68</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Reliance on Administrative Agent and Other Banks&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Right to Indemnity</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">69</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">70</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Other Duties, etc&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div><div style="margin-top:0.2pt;padding-left:16.55pt;padding-right:24.15pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">10.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">Bank ERISA Matters&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">70</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">11</font></div><div style="margin-top:0.15pt;padding-left:106.05pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">COMPANY GUARANTY</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COMPANY GUARANTY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">                                </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></div><div style="padding-left:238.15pt"><font><br></font></div><div style="margin-top:4.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">The Guaranty&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Guaranty Unconditional&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></div><div style="margin-top:5.65pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discharge Only Upon Payment in Full&#59; Reinstatement in Certain</font></div><div style="margin-top:0.2pt;padding-right:24.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Circumstances&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;padding-right:24pt;text-align:right;text-indent:-88.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waivers by the Company</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">73</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">74</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;padding-right:23.9pt;text-align:right;text-indent:-88.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subrogation, Etc</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">74</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">75</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">4</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_25"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.55pt;padding-left:82.9pt;padding-right:82.9pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">ARTICLE 12</font></div><div style="padding-left:34.07pt;padding-right:34.07pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">ADDITIONAL BORROWERS&#59; TERMINATION OF BORROWERS</font></div><div style="margin-top:6.15pt;padding-left:4.12pt;padding-right:4.12pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 12 ADDITIONAL BORROWERS&#59; TERMINATION OF BORROWERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">           </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">75 </font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement to Participate&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">75</font></div><div style="margin-top:0.2pt;padding-left:16.55pt;padding-right:24.15pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">Notice of Termination</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">76</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">77</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">ARTICLE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">13</font></div><div style="margin-top:0.15pt;padding-left:106.05pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">MISCELLANEOUS</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MISCELLANEOUS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">                                                    </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">77</font></div><div style="padding-left:207.4pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cumulative Remedies&#59; No Waiver&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendments&#59; Consents&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></div><div style="margin-top:6.3pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Costs, Expenses and Taxes&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">78</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Obligation to Make Payments in Dollars or Alternative Currency&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Banks&#8217; Obligations&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Other Communications&#59; Facsimile Copies&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">79</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">80</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Execution of Loan Documents&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Binding Effect&#59; Assignment&#59; Entire Agreement&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">81</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">82</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Setoff Rights&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">86</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">85</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sharing of Setoffs&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">86</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnity by the Company</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">87</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">86</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Third Parties Benefited&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">88</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">88</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">89</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">88</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Fiduciary Duties&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">89</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Integration&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">89</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability of Provisions&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">89</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Independent   Covenants&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">90</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">89</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">90</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">89</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Time of the Essence&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">90</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">89</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Law&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent to Jurisdiction and Service of Process&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Jury Trial&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">91</font></div><div style="margin-top:5.7pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgement and Consent to Bail-In of Certain Financial</font></div><div style="margin-top:0.15pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Institutions&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">92</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">91</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:80%">5</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_28"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Judgment Currency&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">94</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">93</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Forms&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">94</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.28&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation on Borrowing Subsidiary Obligations&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">96</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">95</font></div><div style="margin-top:5.9pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.29&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Damages&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">96</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">95</font></div><div style="margin-top:5.95pt;padding-left:88.15pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.30&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patriot Act Notice&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">96</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibits</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:344.6pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">A - Agreement to Participate</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">B - Note</font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">C - Compliance Certificate</font></div><div style="padding-left:16.55pt;padding-right:334.65pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">D -</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Request for Letter of Credit</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">E - Request for Loan</font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">F - Assignment Agreement</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedules</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">2.1</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Banks&#8217; Pro Rata Shares of the Commitment</font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">4.4</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Disclosure of Subsidiaries</font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">4.8</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Litigation</font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">4.11(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Employee Benefit Plans</font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">4.15</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Environmental</font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">6.3</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Liens</font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">13.7</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notices</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">6</font></div><div><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_31"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:2.05pt;padding-right:2.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SECOND AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:164.05pt;padding-right:164.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated as of December 12, 2019</font></div><div><font><br></font></div><div style="margin-top:9.15pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">SECOND AMENDED AND RESTATED CREDIT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> is</font></div><div style="padding-left:16.55pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dated as of December 12, 2019 and is entered into by and among Amgen Inc., a Delaware corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), each financial institution whose name is set forth on the signature pages hereof as a Bank, Citibank, N.A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Citibank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as the Administrative Agent and an Issuing Bank, and JPMorgan Chase Bank, N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">J PMorgan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as Syndication Agent.</font></div><div style="margin-top:11.55pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PRELIMINARY STATEMENT.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company, the lenders parties thereto and Citibank, as administrative agent, are parties to that certain Amended and Restated Credit Agreement dated as of July 30, 2014 (as amended to date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Subject to the satisfaction of the conditions set forth in Section 3.1, the Company, the parties hereto and Citibank, as Administrative Agent, desire to amend and restate the Existing Credit Agreement as herein set forth. In consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows&#58;</font></div><div style="margin-top:11.5pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 1 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 1</font></div><div style="margin-top:0.3pt;padding-left:36.85pt;padding-right:36.85pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:line-through">DEFINITIONS AND ACCOUNTING TERMS</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">DEFINITIONS AND ACCOUNTING</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">TERMS</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">1.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">As used in this Agreement, the following terms shall have the meanings set forth below&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Additional Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.8(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="margin-top:0.2pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Commitment Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.9(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="margin-top:0.2pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;Adjusted Term SOFR&#8221; means, for purposes of any calculation, the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">rate per</font></div><div style="padding-left:16.55pt;padding-right:33.85pt"><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">annum equal to</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a) Term SOFR for such calculation plus (b) 0.10%&#59; provided that if Adjusted</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term SOFR as so determined shall ever be</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">less than zero, such rate shall be deemed to be zero</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">for the purposes of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.2pt;padding-left:88.15pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Adjusted Term SOFR </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rate Advance&#8221; means an Advance that bears interest</font></div><div style="padding-left:16.55pt;padding-right:33.85pt;text-align:justify"><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">based on</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR. All Adjusted Term SOFR </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Advances shall be denominated in</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dollars.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:16.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means Citibank, when acting in its capacity as the administrative agent under any of the Loan Documents.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:34.3pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Administrative Agent&#8217;s Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means the Administrative Agent&#8217;s address as set forth on the signature pages of this Agreement, or such other address as the Administrative Agent hereafter may designate by written notice to the Company and the Banks.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_34"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Administrative Questionnaire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">means an Administrative Questionnaire in a form supplied by the Administrative Agent.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means any Advance made or to be made by any Bank to any Borrower as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">includes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> each Base Rate Advance and each </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advance.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.8pt;padding-left:16.55pt;padding-right:27.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, as to any Person, any other Person which directly or indirectly controls, or is under common control with, or is controlled by, such Person. As used in this definition, &#8220;control&#8221; (and the correlative terms, &#8220;contr olled by&#8221; and &#8220;under common control with&#8221;) shall mean possession, directly or indirectly, of power to direct or cause the direction of management or policies (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise).</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Agent Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.7(d)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means this Second Amended and Restated Credit Agreement,</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either as originally executed or as it may from time to time be supplemented, modified, amended, restated or extended in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Agreement to Participate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means an Agreement to Participate, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Alternative Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Euro.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Alternative Currency Equivalent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, with respect to any amount denominated in Dollars on any date of determination, the amount of the Alternative Currency that could be purchased with such amount of Dollars using the reciprocal of the foreign exchange rate(s) specified in the definition of &#8220;Dollar Equivalent,&#8221; as determined by the Administrative Agent.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:16.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Alternative Currency Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">means any Loan denominated in the Alternative Currency. Each Alternative Currency Loan must be composed of EURIBOR Rate Advances.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Alternative Currency Payment Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means such office of Citibank as shall be from time to time selected by the Administrative Agent and notified by the Administrative Agent to the Company and the Banks.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;Applicable </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Lending Office</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, as to each Bank, its office or branch so </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">designated by written notice to the Company and the Administrative Agent as its</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Lending Office. If no</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Applicable Lending</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Office is designated by a Bank, its</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Lending</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Office shall be its office at its address for purposes of notices hereunder.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Approved Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means any Fund that is administered or managed by (a) a Bank, (b) an Affiliate of a Bank or (c) an entity or an Affiliate of an entity that administers or manages a Bank.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Arranger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means each of Citibank, JPMorgan, BofA Securities, Inc., Barclays Bank PLC, Goldman Sachs Bank USA and Morgan Stanley Senior Funding, Inc. when acting in its capacity as an arranger and a bookrunner under any of the Loan Documents.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means an Assignment Agreement in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, executed by a Bank and an Eligible Assignee of all or part of that Bank&#8217;s interest hereunder.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Available Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">of any Letter of Credit means, at any time, the maximum amount available to be drawn under such Letter of Credit at such time (assuming compliance at such time with all conditions to drawing).</font></div><div><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Bail-In Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 13.25.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means the Persons identified as &#8220;Banks&#8221; and listed on the signature pages of this Agreement and each Eligible Assignee that shall become a party hereto pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.85pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Bank Insolvency Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means that (a) a Bank or its Parent Company is insolvent, or is generally unable to pay its debts as they become due, or admits in writing its inability to pay its debts as they become due, or makes a general assignment for the benefit of its creditors, or (b) such Bank or its Parent Company is the subject of (i) a Bail-In Action or (ii) a bankruptcy, insolvency, reorganization, liquidation or similar proceeding, or a receiver, trustee, conservator, intervenor or sequestrator or the like has been appointed for such Bank or its Parent Company, or such Bank or its Parent Company has taken any action in furtherance of or indicating its consent to or acquiescence in any such proceeding or appointment.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Banking Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">any Monday, Tuesday, Wednesday, Thursday or Friday, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">other than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> a day on which banks are authorized or required to be closed in California or New York and</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">if used in relation to a </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">EURIBOR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advance, </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">is also a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Eurocurrency Banking</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">a TARGET</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Day.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Base Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, for any day, means the highest of (i) the rate of interest in effect on such day as publicly announced by Citibank from time to time as its base commercial lending rate (such base rate is not intended to be the lowest rate of interest charged by Citibank) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Prime Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), (ii) the Federal Funds Effective Rate in effect on such day plus </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">1&#8260;2</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#189;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">of 1% and</font></div><div style="padding-left:16.55pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">the ICE Benchmark Administration Settlement Rate applicable to Dollars for a period of one</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">month (&#8220;One Month LIBOR&#8221;) plus 1.00% (for the avoidance of doubt, the One Month LIBOR</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">for any day shall be based on the rate appearing on the Bloomberg BBAM Screen (or any</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">successor thereto) that displays an average ICE Benchmark Administration Settlement Rate for</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">deposits in Dollars with a term equivalent to such Interest Period at approximately 11&#58;00 a.m.</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">London time on such day)&#59; provided that if One Month LIBOR shall </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">be less than zero, such rate</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">shall be deemed to be zero for the purposes of this Agreement</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR for a</font></div><div style="padding-left:16.55pt;padding-right:22.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">one-month tenor in effect on such day plus 1.00%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any change in the Base Rate due to a change in the Prime Rate, the Federal Funds Effective Rate or </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">One Month LIBOR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be effective on the effective day of such change in the Prime Rate, the Federal Funds Effective Rate or </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">One Month LIBOR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, respectively.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.05pt;padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Base Rate Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means an Advance made hereunder that bears interest as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Section 3.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> and designated as a Base Rate Advance in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Beneficial Ownership Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation.</font></div><div style="padding-right:22.55pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Beneficial Ownership Regulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means 31 C.F.R. &#167; 1010.230. &#8220;Benefit Plan&#8221; means any of (a) an &#8220;employee benefit plan&#8221; (as defined in ERISA) that is subject to Title I of ERISA, (b) a &#8220;plan&#8221; as defined in and subject to Section 4975 of the Code or (c) any Person whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such &#8220;employee benefit plan&#8221;or&#8220;plan&#8221;.</font></div><div><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means the Company and any Borrowing Subsidiary&#59; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means the Company and each other Borrower, collectively.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Borrowing Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means any Eligible Subsidiary that has executed an Agreement to Participate pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">.</font></div><div style="margin-top:0.45pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%;text-decoration:underline">Borrowing Subsidiary Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%;text-decoration:underline">Calculation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%"> means, in respect of a EURIBOR Rate Advance, (a) the date</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">falling two Banking Days (or such other period as is customary in the relevant foreign exchange market for delivery on the date of the relevant Advance) prior to the date of each Advance,</font></div><div style="padding-left:16.55pt;padding-right:27.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the date falling two Banking Days (or such other period as is customary in the relevant foreign exchange market for delivery on the date of the relevant conversion or continuation of a Loan) prior to the date of conversion or continuation of any Advance pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or</font></div><div style="padding-left:16.55pt;padding-right:36.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;such additional dates as the Administrative Agent or the Majority Banks shall specify or as any Borrower may reasonably request, in which case the Administrative Agent&#8217;s specification shall prevail.</font></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means, when used in connection with any Person, all monetary and</font></div><div style="padding-left:16.55pt;padding-right:25.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non-monetary items owned by that Person that are treated as cash in accordance with Generally Accepted Accounting Principles, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for amounts held by, or on deposit with, another Person as cash collateral or other security.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Cash Collateralize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, in respect of an obligation, provide and pledge (as a first priority perfected security interest) cash collateral in Dollars, at a location and pursuant to documentation in form and substance reasonably satisfactory to the Administrative Agent and each Issuing Bank (and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Collateralization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has a corresponding meaning).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:33.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Certificate of a Senior Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">means a certificate signed by a Senior Officer of the Person providing the certificate.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Citibank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in the introductory paragraph.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.05pt;padding-left:16.55pt;padding-right:25.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means the time and Banking Day on which the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> are satisfied.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means the Internal Revenue Code of 1986, as amended or replaced and as in effect from time to time.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means the aggregate commitment of the Banks (i) to make Advances pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> in an aggregate principal amount up to the Dollar Equivalent of $2,500,000,000 and (ii) to purchase an undivided interest in any Letters of Credit issued pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as the Commitment may be reduced in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or increased in accordance with</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"> Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The respective Pro Rata Shares of the Banks on the Closing Date with respect to the Commitment are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="padding-right:22.55pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.7(d)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the introductory paragraph. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a certificate in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, properly</font></div><div style="margin-top:0.05pt;padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">completed and signed by a Senior Officer of the Company.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:21.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Consolidated EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, for any period, Consolidated Net Income for such period plus, without duplication and to the extent deducted in determining Consolidated Net Income for such period, the sum of (a) interest expense, (b) provision for taxes based on income, (c) depreciation expense, (d) amortization expense, (e) unusual or non-recurring charges, expenses or losses and (f) other non-cash charges, expenses or losses (excluding any such non-cash charge to the extent it represents an accrual or reserve for potential cash charge in any future period or amortization of a prepaid cash charge that was paid in a prior period), minus, to the extent included in determining Consolidated Net Income for such period, the sum of (i) unusual or non-recurring gains and non-cash income, (ii) any other non-cash income or gains increasing Consolidated Net Income for such period (excluding any such non-cash gain to the extent it represents the reversal of an accrual or reserve for potential cash charge in any prior period) and (iii) any gains realized from the disposition of property outside of the ordinary course of business, all as determined on a consolidated basis&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the Consolidated EBITDA for any entity or business acquired by the Company or any Subsidiary pursuant to an acquisition the aggregate consideration for which equals or exceeds $1,000,000,000 during such period shall be included on a pro forma basis for such period (as determined in good faith by the Company, assuming the consummation of such acquisition and the incurrence or assumption of any indebtedness by the Company and its Subsidiaries in connection therewith incurred as of the first day of such period), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that the Consolidated EBITDA for any entity or business sold or otherwise disposed of for aggregate consideration of $1,000,000,000 or more by the Company or any Subsidiary shall be deducted on a pro forma basis for such period (as determined in good faith by the Company, assuming the consummation of such sale or other disposition occurred on the first day of such period).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Consolidated Interest Coverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, as of any date of determination, the ratio of (a) Consolidated EBITDA for the period of the four fiscal quarters most recently ended to (b) Consolidated Interest Expense for such period.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font><br></font></div><div style="padding-right:22.55pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Consolidated Interest Expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, for any period, total interest expense (including that attributable to leases recorded as Finance Leases in accordance with Generally Accepted Accounting Principles) of the Company and its Subsidiaries on a consolidated basis for such period with respect to all outstanding Indebtedness of the Company and its Subsidiaries.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Consolidated Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, for any period, the consolidated net income (or loss) of the Company and its Subsidiaries on a consolidated basis&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that there shall be excluded the income (or deficit) of any Person (other than a Subsidiary of the Company) in which the Company or any of its Subsidiaries has an ownership interest, except to the extent that any such income is actually received by the Company or such Subsidiary in the form of dividends or similar distributions.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Consolidated Net Worth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, as of any date of determination, the Shareholders&#8217; Equity of the Company and its Consolidated Subsidiaries on that date as set forth or reflected on the consolidated balance sheet of the Company and its Subsidiaries.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Consolidated Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, as of any date of determination and with respect to any Person, any Subsidiary of that Person whose financial data is, in accordance with Generally Accepted Accounting Principles, reflected in that Person&#8217;s consolidated financial statements.</font></div><div><font><br></font></div><div style="margin-top:4.9pt;padding-left:16.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Consolidated Total Debt to Capitalization Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means, as of any date of determination, the ratio of (a) Consolidated Total Debt to (b) Consolidated Capitalization.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:61.95pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Contractual Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, as to any Person, any provision of any outstanding Securities issued by that Person or of any material agreement, instrument or undertaking to which that Person is a party or by which it or any of its Property is bound.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:60.5pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Convert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Converted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> each refers to a conversion of Advances of one Type into Advances of another Type pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Section 2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">.</font></div><div style="padding-right:60.5pt;text-align:justify"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Current ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;, as applied to any Person, means (i) any corporation which is a member of a controlled group of corporations within the meaning of Section 414(b) of the Code of which that Person is a member&#59; (ii) any trade or business (whether or not incorporated) which is a member of a group of trades or businesses under common control within the meaning of Section 414(c) of the Code of which that Person is a member&#59; and (iii) any member of an affiliated service group within the meaning of Section 414(m) or (o) of the Code of which that Person, any corporation described in clause (i) above or any trade or business described in clause (ii) above is a member.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Daily Margin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means, for any date of determination, for the designated Level and the Type of Advance, the following interest rates per annum&#58;</font></div><div style="padding-right:25.7pt"><font><br></font></div><div style="padding-left:108pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.189%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#c0cafb;padding:2px 3.5pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#4c16ae;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Daily Margin</font></td></tr></table></div><div style="padding-left:122.15pt;padding-right:122.15pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%;text-decoration:line-through">Daily Margin</font></div><div style="padding-left:39.87pt;padding-right:39.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;TYPE OF ADVANCE&#160;&#160;&#160;&#160;</font></div><div style="margin-top:1.5pt;padding-left:229.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">   Base Rate  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline line-through">  </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font></div><div><font><br></font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.801%"><div style="margin-top:3.65pt;text-align:right"><font><br></font></div></div><div style="display:inline-block;max-width:0.397%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.802%"><div style="text-align:right"><font><br></font></div></div></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.801%"><div style="margin-top:3.65pt;padding-left:19.55pt;padding-right:141.55pt"><font><br></font></div><div id="ib6a58edfcca043b385670be29d25c61b_37"></div></div><div style="display:inline-block;max-width:0.397%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.802%"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;    </font></div><div style="padding-left:75.1pt;padding-right:75.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.115%"><tr><td style="width:1.0%"></td><td style="width:32.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.545%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 13.85pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advance</font></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate Advance</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 13.85pt 0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#c0cafb;padding:0 1pt"></td><td colspan="3" style="background-color:#c0cafb;padding:0 1pt"></td><td colspan="3" style="background-color:#c0cafb;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Level 1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:12.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">0.000%</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">0.700%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Level 2</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:12.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.000%</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.805%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Level 3</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:12.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.000%</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.910%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Level 4</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:12.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.025%</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1.025%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Level 5</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:12.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">0.125%</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">1.125%</font></div></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this definition, (a) if any change in the rating established by S&#38;P or Moody&#8217;s with respect to Long-Term Debt shall result in a change in the Level, the change in the Daily Margin shall be effective as of the date on which such rating change is publicly announced, and</font></div><div style="padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) if the ratings established by both of S&#38;P and Moody&#8217;s with respect to Long-Term Debt are unavailable for any reason for any day, then the applicable level for such day shall be deemed to be Level 5 (or, if the Majority Banks consent in writing, such other Level as may be reasonably determined by the Majority Banks from a rating with respect to Long-Term Debt for such day established by another rating agency reasonably acceptable to the Majority Banks).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Debtor Relief Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means the Bankruptcy Code of the United States of America, as amended from time to time, and all other applicable liquidation, conservatorship, bankruptcy, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws from time to time in effect affecting the rights of creditors generally.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means any Event of Default or any event that, with the giving of any applicable notice or passage of time specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, or both, would be an Event of Default.</font></div><div style="padding-right:17.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the interest rate described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Defaulting Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means at any time, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.10(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (i) any Bank that has failed for two or more Banking Days to comply with its obligations under this Agreement to make an Advance, make a payment to an Issuing Bank in respect of drawing under a Letter of Credit, or make any other payment due hereunder (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">funding obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), unless such Bank has notified the Administrative Agent and the Company in writing that such failure is the result of such Bank&#8217;s determination that one or more conditions precedent to funding has not been satisfied (which conditions precedent, together with the applicable default, if any, will be specifically identified in such writing), (ii) any Bank that has notified the Administrative Agent, the Company or an Issuing Bank in writing, or has stated publicly, that it does not intend to comply with its funding obligations hereunder, unless such writing or statement states that such position is based on such Bank&#8217;s determination that one or more conditions precedent to funding cannot be satisfied (which conditions precedent, together with the applicable default, if any, will be specifically identified in such writing or public statement), (iii) any Bank that has defaulted on its funding obligations under other loan agreements or credit agreements generally under which it has commitments to extend credit or that has notified, or whose Parent Company has notified, the Administrative Agent or the Company in writing, or has stated publicly, that it does not intend to comply with its funding obligations under loan agreements or credit agreements generally, (iv) any Bank that has, for two or more Banking Days after written request of the Administrative Agent or the Company, failed to confirm in writing to</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_40"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Administrative Agent and the Company that it will comply with its prospective funding obligations hereunder (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such Bank will cease to be a Defaulting Bank solely pursuant to this clause (iv) upon the Administrative Agent&#8217;s and the Company&#8217;s receipt of such written confirmation), or (v) any Bank with respect to which a Bank Insolvency Event has occurred and is continuing with respect to such Bank or its Parent Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that a Bank Insolvency Event shall not be deemed to occur with respect to a Bank or its Parent Company solely as a result of the acquisition or maintenance of an ownership interest in such Bank or Parent Company by a Governmental Agency or instrumentality thereof where such action does not result in or provide such Bank with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Bank (or such Governmental Agency or instrumentality) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Bank . Any determination by the Administrative Agent that a Bank is a Defaulting Bank under any of clauses</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%">(i) through (v) above will be conclusive and binding absent manifest error, and such Bank will be</font></div><div style="padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deemed to be a Defaulting Bank (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) upon notification of such determination by the Administrative Agent to the Company, the Issuing Banks, and the Banks.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Designated Deposit Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means a deposit account designated by a Borrower in its Request for Loan submitted with respect to each Loan.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Dollar Equivalent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means, as of any date of determination (a) with respect to any amount denominated in Dollars, such amount, and (b) with respect to any amount denominated in any currency other than Dollars, the amount of Dollars that would be required to purchase the amount of the Alternative Currency based on the spot rate for the purchase by Citibank of the Alternative Currency through its foreign exchange trading office prior to 11&#58;00</font></div><div style="margin-top:0.05pt;padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.M. (London time) on such date.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Dollar Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means any Loan denominated in Dollars. </font></div><div style="padding-right:25.7pt;text-indent:71.55pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means United States Dollars.</font></div><div style="padding-right:25.7pt"><font><br></font></div><div style="margin-top:0.15pt;padding-left:16.55pt;padding-right:52.35pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Eligible Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means any Person that meets the requirements to be an assignee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.9(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (subject to such consents, if any, as may be required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.9(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">).</font></div><div><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Eligible Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any of the wholly-owned Subsidiaries of the</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Company.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Employee Benefit Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any &#8220;employee benefit plan&#8221; as defined in</font></div><div style="padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3(3) of ERISA which is, or was at any time, maintained or contributed to by the Company or with respect to any such plan that is subject to Section 302 of ERISA or Title IV of ERISA or Section 412 of the Code, any of its ERISA Affiliates.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:32.15pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">EMU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the economic and monetary union in accordance with the Treaty of Rome 1957, as amended by the Single European Act 1986, the Maastrict Treaty of 1992 and the Amsterdam Treaty of 1998, as amended from time to time.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">EMU Legislation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means the legislative measures of the European Council for the introduction of, changeover to or operation of a single or unified European currency (whether known as the &#8220;euro&#8221; or otherwise).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means all plans, policies or decrees binding on the Company and its Subsidiaries in accordance with applicable statutes, ordinances, orders, rules or regulations and all statutes, ordinances, orders, rules or regulations and the like, in each case, relating to (i) environmental matters, including, without limitation, those relating to fines, injunctions, penalties, damages, contribution, cost recovery compensation, losses or injuries resulting from the release or threatened release of hazardous materials, (ii) the generation, use, storage, transportation or disposal of hazardous materials, or (iii) occupational safety and health, industrial hygiene, land use or the protection of human, plant or animal health or welfare, in any manner applicable to the Company or any of its Subsidiaries or any of their respective properties, including, without limitation, the Comprehensive Environmental Response, Compensation, and Liability Act (42 U.S.C. &#167; 9601 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.), the Hazardous Materials Transportation Act (49 U.S.C.&#167; 1801 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.), the Resource Conservation and Recovery Act (42 U.S.C. &#167; 6901 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.), the Federal Water Pollution Control Act (33 U.S.C. &#167; 1251 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.), the Clean Air Act (42 U.S.C. &#167; 7401 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.), the Toxic Substances Control Act (15 U.S.C. &#167; 2601 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.), the Federal Insecticide, Fungicide and Rodenticide Act (7 U.S.C. &#167;136 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.), the Occupational Safety and Health Act (29 U.S.C. &#167; 651 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.) and the Emergency Planning and Community Right-to-Know Act (42 U.S.C. &#167; 11001 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.), each as amended or supplemented, and any analogous future or present local, state and federal statutes and regulations promulgated pursuant thereto, each as in effect as of the date of determination.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">means the Employee Retirement Income Security Act of 1974, and any regulations issued pursuant thereto, as amended or replaced and as in effect from time to time.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as applied to any Person, means (i) any corporation which is, or was at any time, a member of a controlled group of corporations within the meaning of Section 414(b) of the Code of which that Person is, or was at any time, a member&#59; (ii) any trade or business (whether or not incorporated) which is, or was at any time, a member of a group of trades or businesses under common control within the meaning of Section 414(c) of the Code of which that Person is, or was at any time, a member&#59; and (iii) any member of an affiliated service group within the meaning of Section 414(m) or (o) of the Code of which that Person, any corporation described in clause (i) above or any trade or business described in clause (ii) above is, or was at any time, a member.</font></div><div><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">ERISA Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means (i) a &#8220;reportable event&#8221; within the meaning of Section 4043 of ERISA and the regulations issued thereunder with respect to any Pension Plan (excluding those for which the provision for 30-day notice to the PBGC, or the penalty for failure to provide such notice, has been waived by regulation or by PBGC technical update)&#59; (ii) the failure to meet the minimum funding standard of Sections 412 and 430 of the Code with respect to any Pension Plan (whether or not waived in accordance with Section 412(c) of the Code) or the failure to make by its due date a required installment under Section 430(j) of the Code with respect to any Pension Plan or the failure to make any required contribution to a Multiemployer Plan&#59; (iii) the provision by the administrator of any Pension Plan pursuant to Section 4041(a)(2) of ERISA of a notice of intent to terminate such plan in a distress termination described in</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4041(c) of ERISA&#59; (iv) the withdrawal by the Company or any of its ERISA Affiliates from any Pension Plan with two or more contributing sponsors or the termination of any such Pension Plan resulting in liability therefor pursuant to Sections 4063 or 4064 of ERISA&#59; (v) the institution by the PBGC of proceedings to terminate under Section 4042 of ERISA any Pension Plan, or the occurrence of any event or condition which might constitute grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan&#59; (vi) the imposition of liability on the Company or any of its ERISA Affiliates pursuant to Section 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA&#59;</font></div><div style="padding-left:16.55pt;padding-right:23.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii) the withdrawal by the Company or any of its ERISA Affiliates in a complete or partial withdrawal (within the meaning of Sections 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefor, or the receipt by the Company or any of its ERISA Affiliates of notice from any Multiemployer Plan that it is in reorganization or insolvency pursuant to Section 4241 or 4245 of ERISA, or that it intends to terminate or has terminated under Section 4041A or 4042 of ERISA&#59; (viii) the imposition on the Company or any of its ERISA Affiliates of fines, penalties, taxes or related charges under Chapter 43 of the Code or under Section 409 or 502(c), (i) or (l) or 4071 of ERISA in respect of any Pension Plan&#59; (ix) the assertion of a material claim (other than routine claims for benefits) against any Pension Plan or the assets thereof, or against the Company or any of its ERISA Affiliates in connection with any such Pension Plan&#59; (x) receipt from the Internal Revenue Service of notice of the failure of any Pension Plan (or any other Employee Benefit Plan intended to be qualified under Section 401(a) of the Code) to qualify under Section 401(a) of the Code, or the failure of any trust forming part of any Pension Plan to qualify for exemption from taxation under Section 501(a) of the Code&#59; or (xi) the conditions for imposition of a Lien under Section 303(k) of ERISA shall have been met with respect to any Pension Plan.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">EURIBOR Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means, for any Interest Period for each EURIBOR Rate Advance, an interest rate per annum equal to the offered quotation which appears on the page of the Bloomberg Screen which displays an average rate of the Banking Federation of the EMU for the Euro for such period at or about 10&#58;00 a.m. (London time) two </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Eurocurrency</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Banking Days before the first day of such Interest Period or, if such page or such service shall cease to be available, such other page or such other service for the purpose of displaying an average rate of the Banking Federation of the EMU as the Administrative Agent, after consultation with the Banks and the Company, shall reasonably select&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that if the EURIBOR Rate shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">EURIBOR Rate Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means an Advance in Euros which bears interest at a rate per annum determined on the basis of the EURIBOR Rate. All EURIBOR Rate Advances shall be denominated in Euros.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Euro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">&#8364;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means the lawful currency of the Participating Member States introduced in accordance with the EMU Legislation.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:24.25pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">&#8220;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline line-through">EURO </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Rate Advance</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means, as the context may require, </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">a Eurodollar </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">Rate Advance</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">or a EURIBOR Rate Advance.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:52.35pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">&#8220;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline line-through">Eurocurrency Banking Day</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">&#8221; means (a) if such day relates to any Eurodollar Rate</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">Advance, any Banking Day on which dealings in Dollar deposits are conducted by and</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:52.35pt;padding-right:23.55pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">among banks in the London interbank offer market for Dollar deposits or (b) if such day </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">relates to any EURIBOR Rate Advance, a TARGET Day.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:24.05pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">&#8220;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline line-through">Eurocurrency </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline line-through">Lending Office</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">&#8221; means, as to each Bank, its office or branch so</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> designated by written notice to the Company and the Administrative Agent as its </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Eurocurrency </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Lending Office. If no </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Eurocurrency Lending </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Office is designated by a</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Bank, its </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Eurocurrency Lending </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Office shall be its office at its address for purposes of</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">notices hereunder.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:25.7pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8220;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Eurocurrency </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Market</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means, with respect to </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">any EURO Rate Advance, the London </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">interbank offer market for </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">Dollar and Euro deposits.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:21.4pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Eurodollar Rate</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, for any Interest Period for each Eurodollar Rate Advance, an </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">interest </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">rate per annum equal to </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">the offered rate (if any) appearing on the Bloomberg</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> BBAM Screen (or any successor thereto) which displays ICE Benchmark Administration Settlement Rates for deposits of Dollars for a period equal to the Interest Period relating to that Advance at or about 11&#58;00 a.m. (London time) two Eurocurrency Banking Days </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">before </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">the first day of such Interest Period </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">with respect to each Eurodollar Rate Advance</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or, if such page or such service shall cease to be available, such other page or such other </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">service for the purpose of displaying an average rate for deposits of Dollars in the London</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> interbank market as the Administrative Agent, after consultation with the Banks and the </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Company, shall reasonably select&#59; </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline line-through">provided </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">that if the Eurodollar Rate shall be </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">less than</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">zero, such rate shall be deemed to be zero for the purposes of this Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:17.05pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">&#8220;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline line-through">Eurodollar </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Rate Advance</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means an Advance that bears interest based on </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">the </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">Eurodollar Rate. All Eurodollar Rate </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">Advances shall be denominated in Dollars.</font></div><div style="padding-right:17.05pt"><font><br></font></div><div style="margin-top:0.5pt;padding-left:88.15pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%"> shall have the meaning provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%;text-decoration:underline">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Section 3.12(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">. </font></div><div style="padding-left:88.15pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in the preliminary</font></div><div id="ib6a58edfcca043b385670be29d25c61b_43"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.572%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">statement.</font></div></div><div style="display:inline-block;max-width:0.855%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.573%"></div></div><div style="margin-top:5pt;padding-left:88.15pt;padding-right:63.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%;text-decoration:underline">Extending Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%;text-decoration:underline">Section 2.9(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">. </font></div><div style="margin-top:5pt;padding-left:88.15pt;padding-right:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%;text-decoration:underline">Extension Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%;text-decoration:underline">Section 2.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">.</font></div><div style="padding-left:16.55pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means Sections 1471 through 1474 of the Code, as of the date of this</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code, any published intergovernmental agreement entered into in connection with the implementation of such Sections of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to such published intergovernmental agreements.</font></div><div style="text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Federal Funds Effective Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means for any day, the rate per annum (expressed, as a decimal, rounded upwards, if necessary, to the next higher 1&#47;100 of 1%) equal to</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_46"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the rate on overnight federal funds transactions with members of the Federal Reserve System, as published by the Federal Reserve Bank of New York on the Banking Day next succeeding such day&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that (i) if such day is not a Banking Day, the Federal Funds Effective Rate for such day shall be such rate on such transactions on the next preceding Banking Day as so published on the next succeeding Banking Day, and (ii) if no such rate is so published on such next succeeding Banking Day, the Federal Funds Effective Rate for such day shall be the average rate charged to Administrative Agent, in its capacity as a Bank, on such day on such transactions as determined by the Administrative Agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if the Federal Funds Effective Rate shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Finance Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means, as to any Person, a lease of any Property by that Person as lessee that is, or should be recorded as a &#8220;finance lease&#8221; on the balance sheet of that Person prepared in accordance with Generally Accepted Accounting Principles.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Fiscal Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means the fiscal quarter of the Company consisting of a three month fiscal period ending on each March 31, June 30, September 30 and December 31.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means the fiscal year of the Company consisting of a twelve month fiscal period ending on each December 31.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:7.82pt;padding-right:7.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Foreign Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.27(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Fronting Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, at any time there is a Defaulting Bank with respect to any Issuing Bank, such Defaulting Bank&#8217;s Pro Rata Share of the LC Obligations with respect to Letters of Credit issued by such Issuing Bank, other than LC Obligations as to which such Defaulting Bank&#8217;s participation obligation has been reallocated to other Banks or Cash Collateralized in accordance with the terms hereof.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Generally Accepted Accounting Principles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means generally accepted accounting principles in the United States of America. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Generally Accepted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Accounting Principles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; shall be read in each instance as if the words &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">consistently applied</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; followed immediately thereafter, meaning that the accounting principles applied are consistent in all material respects (except for changes concurred in by the Company&#8217;s independent public accountants) to those applied at prior dates or for prior periods.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:66.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Governmental Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means (a) any foreign, federal, state, county or municipal government, or political subdivision thereof, (b) any governmental or</font></div><div style="padding-left:16.55pt;padding-right:26.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">quasi-governmental agency, authority, board, bureau, commission, department, instrumentality or public body, (c) any court or administrative tribunal or (d) with respect to any Person, any arbitration tribunal or other nongovernmental authority to whose jurisdiction that Person has consented.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:32.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Hostile Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means the acquisition of over 50% of the capital stock or other equity interests of a Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) through a tender offer or similar solicitation of the owners of such capital stock or other equity interests which has not been approved (prior to such acquisition) by resolutions of the Board of Directors or shareholders of the Target or by similar action if the Target is not a corporation and as to which such approval has not been withdrawn.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Increase Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="margin-top:0.2pt;padding-left:88.15pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%;text-decoration:underline">Increased Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Section 2.8(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:247%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%"> means, as to any Person, (a) all indebtedness of such Person for</font></div><div style="padding-left:16.55pt;padding-right:22.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">borrowed money, (b) that portion of the obligations of such Person under Finance Leases which is properly recorded as a liability on a balance sheet of that Person prepared in accordance with Generally Accepted Accounting Principles, (c) to the extent of the outstanding Indebtedness thereunder, any obligation of such Person that is evidenced by a promissory note or other similar instrument representing an extension of credit to such Person, whether or not for borrowed money, (d) any obligation of such Person for the deferred purchase price of Property or services (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">other than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> trade or other accounts payable in the ordinary course of business), (e) any obligation of such Person of the nature described in clauses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above that is secured by a Lien on assets of such Person, whether or not that Person has assumed such obligation or whether or not such obligation is non-recourse to the credit of such Person, but only to the extent of the lesser of the face amount of the obligation or the fair market value of the assets so subject to the Lien, (f) obligations of such Person arising under acceptance facilities or under facilities for the discount of accounts receivable of such Person, (g) any obligation of such Person to reimburse the issuer of any letter of credit issued for the account of such Person upon which and only to the extent a draw has been made and (h) in the case of the Company, the net obligations of the Company under Swap Agreements. Notwithstanding the provisions listed above, Indebtedness shall not include any intercompany loans made by the Company to a Subsidiary or by any Subsidiary to another Subsidiary or by any Subsidiary to the Company. As of any date of determination, the amount of the Company&#8217;s Indebtedness with respect to (1) Swap Agreements shall be equal to the net marked-to-market value (if negative) for the Company for all such Swap Agreements taken as a whole and (2) obligations under clause (d) shall be the stated balance sheet amount of such obligations, determined on a consolidated basis in accordance with Generally Accepted Accounting Principles, of the Company and its Consolidated Subsidiaries on that date.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:88.15pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%;text-decoration:underline">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%;text-decoration:underline">Section 3.12(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%;text-decoration:underline">Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%;text-decoration:underline">Section </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%;text-decoration:line-through">3.12</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%;text-decoration:underline">13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">.</font></div><div style="margin-top:0.25pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8220;Inter bank </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Market&#8221; means, with respect to </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">EURIBOR Rate Advances, the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> applicable </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">interbank offer market for </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Euro deposits.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Interest Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, as to each </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advance, the period commencing on the date specified by the Borrower of such Advance pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and ending 1, 3 or 6 months thereafter</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through"> (or (i) </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">in the case of </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO Rate Advances denominated</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">in Dollars, 2 months or (ii) if agreed to by all Banks, 12 months or a period of shorter than 1</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">month)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as specified by the applicable Borrower in the applicable Request for Loan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that&#58;</font></div><div style="margin-top:0.4pt;text-indent:71.55pt"><font><br></font></div><div id="ib6a58edfcca043b385670be29d25c61b_49"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.996%"><div><font><br></font></div></div><div style="display:inline-block;max-width:4.007%;min-width:3.007%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.997%"></div></div><div style="margin-top:4.45pt;padding-left:32.65pt;text-indent:-16.15pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The first day of any Interest Period shall be a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Banking Day&#59;</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.996%"><div style="margin-top:0.4pt"><font><br></font></div></div><div style="display:inline-block;max-width:4.007%;min-width:3.007%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.997%"></div></div><div style="padding-left:16.55pt;padding-right:24.25pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any Interest Period that would otherwise end on a day that is not a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Banking Day shall be extended to the next succeeding</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Banking Day unless such</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Banking Day falls in another calendar month, in which case such Interest Period shall end on the next preceding</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Banking Day&#59; and</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:56.3pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:218%;text-decoration:line-through">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:218%;text-decoration:underline">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:218%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:218%">No Interest Period shall extend beyond the final Maturity Date. </font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Issue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means the issuance or extension of, or amendment to, any Letter of </font></div><div style="padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Credit.</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.996%"><div style="margin-top:0.2pt"><font><br></font></div></div><div style="display:inline-block;max-width:4.007%;min-width:3.007%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.997%"></div></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Issuing Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means Citibank, JPMorgan, Bank of America, N.A., Barclays</font></div><div style="padding-left:16.55pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bank PLC, Goldman Sachs Bank USA, Morgan Stanley Bank, N.A. and any other Bank acceptable to the Company and the Administrative Agent that agrees in writing to perform the duties of an Issuing Bank under this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:10.37pt;padding-right:10.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">J PMorgan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in the introductory paragraph.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, collectively, all foreign, federal, state and local statutes, treaties, rules, regulations, ordinances, codes and administrative or controlling precedents of any Governmental Agency.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">LC Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, with respect to each Issuing Bank, the amount set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or such other amount as may be agreed by such Issuing Bank and the Company from time to time. Each Issuing Bank&#8217;s LC Commitment is part of, and not in addition to, its respective Pro Rata Share of the Commitment.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">LC Issuance Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means a fee payable to the applicable Issuing Bank as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">LC Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means, as of any date, the aggregate Available Amount of outstanding Letters of Credit and Advances made by an Issuing Bank in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Section</font></div><div style="padding-left:16.55pt;padding-right:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that have not been funded by the Banks and, in the case of any Letters of Credit denominated in Euro, shall be the Alternate Currency Equivalent in Dollars of such amount, determined as of the third Banking Day prior to such date.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">LC Reimbursement Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means a fee payable to the Administrative Agent, for the pro rata benefit of the Banks, as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_52"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:25.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Letters of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means any letters of credit issued by an Issuing Bank pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, either as originally executed or as the same may from time to time be supplemented, modified, reviewed, extended or supplanted.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Level</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means Level 1, Level 2, Level 3, Level 4 or Level 5, as the case may be, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that if, as of any date of determination, (a) there is a one Level difference between (x) the Level that would be applicable if such Level were determined solely by reference to the rating assigned by S&#38;P (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Hypothetical S&#38;P Level</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) and (y) the Level that would be applicable if such Level were determined solely by reference to the rating assigned by Moody&#8217;s (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Hypothetical Moody&#8217;s Level</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) then the &#8220;Level&#8221; for such date shall be deemed to be the higher of the Hypothetical S&#38;P Level and the Hypothetical Moody&#8217;s Level and (b) there is a two Level or more difference between the Hypothetical S&#38;P Level and the Hypothetical Moody&#8217;s Level, then the &#8220;Level&#8221; for such date shall be deemed to be the middle Level between the Hypothetical S&#38;P Level and the Hypothetical Moody&#8217;s Level, and if such middle Level does not exist, then the &#8220;Level&#8221; for such date shall be deemed to be the lower of the middle two Levels between the Hypothetical S&#38;P Level and the Hypothetical Moody&#8217;s Level (for these purposes Level 1 being higher than Level 2, etc.).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:33.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Level 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means that, as of any date of determination, the Long-Term Debt carries either of the following ratings&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:88.15pt;padding-right:269.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;A+&#8221; or higher from S&#38;P &#8220;A1&#8221; or higher from Moody&#8217;s.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Level 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means that, as of any date of determination, the criteria of Level 1 are not satisfied and the Long-Term Debt carries either of the following ratings&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;A&#8221; from S&#38;P</font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;A2&#8221; from Moody&#8217;s.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Level 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">means that, as of any date of determination, the criteria of neither Level 1 nor Level 2 are satisfied and the Long-Term Debt carries either of the following ratings&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:315.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;A-&#8221; from S&#38;P &#8220;A3&#8221; from Moody&#8217;s.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Level 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; means that, as of any date of determination, the criteria of none of Level 1, Level 2 or Leve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">l 3 are satisfied and the Long-Term Debt carries either of the following ratings&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:88.15pt;padding-right:305.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;BBB+&#8221; from S&#38;P &#8220;Baa1&#8221; from Moody&#8217;s.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:33.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Level 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means that, as of any date of determination, the criteria of none of Level 1, Level 2, Level 3 or Level 4 are satisfied.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, lien or charge of any kind, whether voluntarily incurred</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or arising by operation of Law or otherwise, affecting any Property, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> any agreement to grant any of the foregoing, any conditional sale or other title retention agreement, any lease in the nature of a security interest, and&#47;or the filing of or agreement to give any financing statement (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">other than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> a precautionary financing statement with respect to a lease that is not in the nature of a security interest) under the Uniform Commercial Code or comparable Law of any jurisdiction with respect to any Property.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means any group of Advances made at any one time by the Banks pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means, collectively, this Agreement, the Notes, any Request for Loan, any Agreement to Participate, any Letter of Credit, and any Request for Letter of Credit, in each case either as originally executed or as the same may from time to time be supplemented, modified, amended, restated, extended or supplanted.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Long-Term Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means senior, unsecured, long-term-debt securities of the</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Company.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Majority Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination, Banks to which more</font></div><div style="padding-left:16.55pt;padding-right:24.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than 50% of the aggregate Total Outstandings is owed or, if Total Outstandings at such time are zero, Banks whose aggregate Pro Rata Shares are greater than 50% of the Commitment then in effect&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if any Bank shall be a Defaulting Bank at such time, there shall be excluded from the determination of Majority Banks at such time the Total Outstandings owed to such Defaulting Bank at such time or, if the Total Outstandings at such time are zero, the Pro Rata Share of the Commitment of such Bank at such time, as applicable. For purposes of this definition, Total Outstandings in respect of the then undrawn portion of outstanding Letters of Credit and unreimbursed drawings under Letters of Credit shall be deemed to be owing to each Bank ratably in accordance with their respective Pro Rata Shares.</font></div><div style="margin-top:11.45pt;padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means a circumstance or set of circumstances or events affecting the business, financial condition or operations of the Company and its Subsidiaries, taken as a whole, that have a material adverse effect, individually or in the aggregate, upon the ability (i) of the Company and its Subsidiaries, taken as a whole, to perform under the Loan Documents or (ii) of the Banks to enforce, the Obligations under the Loan Documents.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means December 12, 2024, subject to the extension thereof pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Section 2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> that the Maturity Date for any Bank that is a</font></div><div style="padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Extending Bank to any requested extension pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be the Maturity Date in effect immediately prior to the applicable Extension Date for all purposes of this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means Moody&#8217;s Investors Service, Inc. or any successor thereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:20.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Multiemployer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means any employee benefit plan which is a &#8220;multiemployer plan&#8221; (as defined in Section 4001(a)(3) of ERISA) to which the Company or any of its ERISA Affiliates is contributing, or within the preceding six (6) years has contributed, or to</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which the Company or any of its ERISA Affiliates has, or within the preceding six (6) years has had, an obligation to contribute.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Non-Defaulting Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8221; means, at any time, a Bank that is not a Defaulting Bank or a Potential Defaulting Bank.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Extending Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means any of the promissory notes made by the Borrowers in favor of a Bank in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> to evidence revolving Advances made by that Bank under the Commitment, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as originally executed or as the same may from time to time be supplemented, modified, amended, renewed or extended.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notice Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notice of Conversion&#47;Continuation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%;text-decoration:underline">2.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means all present and future monetary obligations of every kind or</font></div><div style="padding-left:16.55pt;padding-right:25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature of the Borrowers at any time and from time to time owed to the Arrangers, the Administrative Agent, the Syndication Agent, any Issuing Bank or the Banks or any one or more of them under any one or more of the Loan Documents, whether due or to become due, matured or unmatured, liquidated or unliquidated, or contingent or noncontingent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> interest that accrues after the commencement of any proceeding under any Debtor Relief Law by or against the Company or any Subsidiary of the Company.</font></div><div style="margin-top:11.5pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Original Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.26(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to the Administrative Agent or any Bank, Taxes imposed as a result of a present or former connection between the Administrative Agent or such Bank and the jurisdiction imposing such Tax (other than connections arising from the Administrative Agent or such Bank having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:88.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%;text-decoration:underline">Other Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%;text-decoration:underline">Section 13.26(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%;text-decoration:underline">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:216%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%;text-decoration:underline">Section 3.12(d)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:216%">.</font></div><div style="margin-top:0.15pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Parent Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, with respect to a Bank, the bank holding company (as defined in Federal Reserve Board Regulation Y), if any, of such Bank, or if such Bank does not have a bank holding company, then any corporation, association, partnership or other business entity owning, beneficially or of record, directly or indirectly, a majority of the shares of such Bank.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:13.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.801%"><div style="margin-top:0.35pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.397%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.802%"></div></div><div style="padding-left:13.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Participating Member State</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each state so described in any EMU Legislation.</font></div><div style="margin-top:10.7pt;padding-left:13.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. thereto.)</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.801%"><div style="margin-top:0.35pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.397%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.802%"></div></div><div style="margin-top:0.05pt;padding-left:13.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PBGC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the Pension Benefit Guaranty Corporation (or any successor</font></div><div style="margin-top:10.65pt;padding-left:13.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Pension Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any Employee Benefit Plan other than a Multiemployer</font></div><div id="ib6a58edfcca043b385670be29d25c61b_55"></div><div style="padding-left:88.15pt;text-indent:-71.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:218%">Plan, that is subject to Section 412 of the Code or Section 302 of ERISA or Title IV of ERISA. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:218%;text-decoration:underline">Permitted Encumbrances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:218%">&#8221; means&#58;</font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inchoate Liens incident to construction or maintenance of real property, or Liens incident to construction or maintenance of real property, now or hereafter filed of record for sums not yet delinquent or being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by Generally Accepted Accounting Principles shall have been made therefor&#59;</font></div><div style="margin-top:10.85pt;padding-left:16.55pt;padding-right:32.35pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens for taxes and assessments on real property which are not yet past due, or Liens for taxes and assessments on real property for which adequate reserves have been set aside and are being contested in good faith by appropriate proceedings and have not proceeded to judgment, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, by reason of non-payment of the obligations secured by such Liens, no such material real property is subject to a material risk of loss or forfeiture&#59;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:21.65pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">easements, exceptions, reservations, or other agreements granted or entered into for the purpose of pipelines, conduits, cables, wire communication lines, power lines and substations, streets, trails, walkways, drainage, irrigation, water, and sewerage purposes, dikes, canals, ditches, the removal of oil, gas, coal, or other minerals, and other like purposes affecting real property which in the aggregate do not materially burden or impair the fair market value or use of such real property for the purposes for which it is or may reasonably be expected to be held&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:23.8pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(d)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights reserved to or vested in any Governmental Agency by Law to control or regulate, or obligations or duties under Law to any Governmental Agency with respect to, the use of any real property&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:23.8pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(e)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(e)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights reserved to or vested in any Governmental Agency by Law to control or regulate, or obligations or duties under Law to any Governmental Agency with respect to, any right, power, franchise, grant, license, or permit&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.5pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(f)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(f)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">present or future zoning laws and ordinances or other laws and ordinances restricting the occupancy, use, or enjoyment of real property&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:26.75pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(g)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(g)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statutory Liens, other than those described in clauses (a) or (b) above, arising in the ordinary course of business with respect to obligations which are not delinquent or</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_58"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by Generally Accepted Accounting Principles shall have been made therefor&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:48.35pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(h)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(h)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens consisting of pledges or deposits to secure obligations under workers&#8217; compensation laws or similar legislation, including Liens of judgments thereunder which are not currently dischargeable&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:28.05pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens consisting of pledges or deposits of Property to secure performance in connection with operating leases made in the ordinary course of business to which the Company or a Subsidiary is a party as lessee, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the aggregate value of all such pledges and deposits in connection with any such lease does not at any time exceed 16-2&#47;3% of the annual fixed rentals payable under such lease&#59;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:29.95pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(j)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(j)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens consisting of deposits of Property to secure statutory obligations of the Company or a Subsidiary of the Company in the ordinary course of its business&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:29.5pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(k)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(k)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens consisting of deposits of Property to secure (or in lieu of) surety, appeal or customs bonds in proceedings to which the Company or a Subsidiary of the Company is a party in the ordinary course of its business&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.1pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(l)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(l)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purchase money Liens or purchase money security interests upon or in any property acquired or held by the Company or any Subsidiary in the ordinary course of business to secure the purchase price of such property or to secure indebtedness incurred solely for the purpose of financing the acquisition of such property&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:28.45pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(m)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(m)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens on an asset to secure all or any part of the cost of development or construction of such asset or improvements thereon and which shall be released or satisfied within 120 days after completion of such development or construction&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:29.65pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(n)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(n)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens on an asset created in connection with the acquisition, construction or development of additions, extensions or improvements to such asset which shall be financed by obligations described in Sections 142, 144(a) or 144(c) of the Code, as amended, or by obligations entitled to substantially similar tax benefits under other legislation or regulations in effect from time to time&#59;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:23.9pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(o)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(o)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens on property subject to escrow or similar arrangements established in connection with litigation settlements&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.9pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(p)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(p)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens on an asset required in connection with any program, law, statute or regulation of any state or local authority which provides financial or tax benefits not available without such Lien, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that substantially all of the obligations secured by such Lien are obligations that are in lieu of, or reduce, a property tax or other payment obligation that itself would have been secured by a Lien permitted hereunder&#59; and</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:23.55pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(q)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(q)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens on Property securing any intercompany loans made by the Company to a Subsidiary or by any Subsidiary to another Subsidiary.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means any entity, whether an individual, trustee, corporation, general partnership, limited partnership, limited liability company, joint stock company, trust, estate, unincorporated organization, business association, tribe, firm, joint venture, Governmental Agency, or otherwise.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.7(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:20.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Potential Defaulting Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, at any time, (i) any Bank with respect to which an event of the kind referred to in the definition of &#8220;Bank Insolvency Event&#8221; has occurred and is continuing in respect of any financial institution affiliate of such Bank, (ii) any Bank that has notified, or whose Parent Company or a financial institution affiliate thereof has notified, the Administrative Agent, the Company or the Issuing Banks in writing, or has stated publicly, that it does not intend to comply with its funding obligations under any other loan agreement or credit agreement or other similar&#47;other financing agreement, unless such writing or statement states that such position is based on such Bank&#8217;s determination that one or more conditions precedent to funding cannot be satisfied (which conditions precedent, together with the applicable default, if any, will be specifically identified in such writing or public statement), or (iii) any Bank that has, or whose Parent Company has, a non-investment grade rating from Moody&#8217;s or S&#38;P or another nationally recognized rating agency. Any determination by the Administrative Agent that a Bank is a Potential Defaulting Bank under any of clauses (i) through (iii) above will be conclusive and binding absent manifest error, and such Bank will be deemed a Potential Defaulting Bank (subject to Section 2.10(c)) upon notification of such determination by the Administrative Agent to the Company, the Issuing Banks and the Banks.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, with respect to each Bank, with respect to the Commitment, and any Loan made under any portion of the Commitment, the percentage set forth opposite the name of that Bank and that portion of the Commitment on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> as modified from time to time. The Pro Rata Share of each Bank shall be deemed to have been modified at each time the Commitment is modified in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means any interest in any kind of property or asset, whether real, personal or mixed, or tangible or intangible.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">PTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:33.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Reference Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means (a) the </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Term SOFR Reference</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Rate, (b) the EURIBOR Rate or (c) </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">One Month LIBOR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Regulation D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means Regulation D, as at any time amended, of the Board of Governors of the Federal Reserve System, or any other regulation in substance substituted therefor.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Regulation U</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means Regulation U, as at any time amended, of the Board of Governors of the Federal Reserve System, or any other regulation in substance substituted therefor.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.8pt;padding-left:16.55pt;padding-right:27.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means, with respect to any Person, such Person&#8217;s Affiliates and the partners, directors, officers, employees, agents and advisors of such Person and of such Person&#8217;s Affiliates.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Request for Letter of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means a written request for a Letter of Credit substantially in the form of Exhibit D, together with the standard form of application for letter of credit used by the applicable Issuing Bank, signed by a Senior Officer of the applicable Borrower and properly completed to provide all information required to be provided therein.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Request for Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means a written request for a Loan substantially in the form of Exhibit E, signed by a Senior Officer of the applicable Borrower and properly completed to provide all information required to be included therein.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Requirement of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, as to any Person, the articles or certificate of incorporation and by-laws or other organizational or governing documents of such Person, and any Law, or judgment, award, decree, writ or determination of a Governmental Agency, in each case applicable to or binding upon such Person or any of its Property or to which such Person or any of its Property is subject.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means S&#38;P Global Ratings, or any successor thereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means any capital stock, share, voting trust certificate, bond, debenture, note or other evidence of indebtedness, limited partnership interest, or any warrant, option or other right to purchase or acquire any of the foregoing.</font></div><div><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Senior Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means the (a) chief executive officer, (b) chief operating officer,</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) chief financial officer, (d) chief accounting officer, (e) corporate controller, (f) treasurer, (g) assistant treasurer, (h) any senior vice president, or (i) any executive vice president, in each case whatever the title nomenclature may be, of the Person designated.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Shareholders&#8217; Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, as of any date of determination, shareholders&#8217; equity as of that date determined in accordance with Generally Accepted Accounting Principles&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that there shall be excluded from Shareholders&#8217; Equity any amount attributable to capital stock that is, directly or indirectly, required to be redeemed or repurchased by the issuer thereof at a specified date or upon the occurrence of specified events or at the election of the holder thereof.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:4.2pt;padding-right:4.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Significant Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">&#8220;SOFR&#8221;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline"> means a rate equal to the secured overnight financing rate as</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">administered by the SOFR Administrator.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">21</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.05pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">&#8220;SOFR Administrator&#8221;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline"> means the Federal Reserve Bank of New York (or a</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">successor administrator of the secured overnight financing rate).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, as of any date of determination and with respect to any Person, any corporation, limited liability company, partnership or joint venture, whether now existing or hereafter organized or acquired&#58; (a) in the case of a corporation or limited liability company, of which a majority of the securities or other ownership interests having ordinary voting power for the election of directors or other governing body (other than securities or other ownership interests having such power only by reason of the happening of a contingency) are at the time beneficially owned by such Person and&#47;or one or more Subsidiaries of such Person, or</font></div><div style="margin-top:0.2pt;padding-left:16.55pt;padding-right:32.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;in the case of a partnership or joint venture, of which such Person or a Subsidiary of such Person is a general partner or joint venturer or of which a majority of the partnership or other ownership interests are at the time beneficially owned by such Person and&#47;or one or more of its Subsidiaries, excluding any partnership or joint venture over which the Person or Subsidiary of such Person does not exercise actual control.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Successor Rate Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means, with respect to any proposed Successor Rate, any conforming changes to the definition of Base Rate, Interest Period, Daily Margin, timing and frequency of determining rates and making payments of interest and other administrative matters as may be appropriate, in the discretion of the Administrative Agent and the Company, to reflect the adoption of such Successor Rate and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent and the Company determine in good faith and in a commercially reasonable manner that adoption of any portion of such market practice is not administratively feasible or that no market practice for the administration of such Successor Rate exists, in such other manner of administration as determined in the good faith and commercially reasonable discretion of the Administrative Agent and the Company).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Swap Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means a written agreement between the Company and one or more financial institutions providing for &#8220;swap&#8221;, &#8220;collar &#8221; or other interest rate protection (other than &#8220;caps&#8221;) with respect to any Indebtedness.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:61.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Syndication Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means JPMorgan, when acting in its capacity as the syndication agent under any of the Loan Documents.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">TARGET Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means any day on which the </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Trans-European</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Trans-European</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Automated Real-time Gross Settlement Express Transfer (TARGET2) System (or, if such payment system ceases to be operative, such other payment system (if any) determined by the Administrative Agent to be a suitable replacement) is open for the settlement of payments in Euro.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;Term </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">Rate Advance&#8221;</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means, as the context may require, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">an Adjusted Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">SOFR </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Rate Advance or a EURIBOR Rate Advance.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#8220;Term SOFR&#8221;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> means,</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">22</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:22.8pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">for any calculation with respect to an Adjusted Term SOFR Advance, the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term SOFR Reference Rate for a tenor comparable to the applicable Interest Period on the day</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(such day, the </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#8220;Periodic Term SOFR Determination Day&#8221;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">) that is two (2) U.S. Government</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Business Days prior to</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">the first day of such Interest Period</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">, as such rate is published</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">by the Term SOFR Administrator&#59; provided, however, that if as of 5&#58;00 p.m. (</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New York City</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">time</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">applicable tenor has not been published by the Term SOFR Administrator and this Agreement</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">has not been amended to implement a Successor Rate, then Term SOFR will be the Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reference Rate for such tenor as published by the Term SOFR Administrator on the first</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">for such tenor was published by the Term SOFR Administrator so long as such first preceding</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business Days prior to such Periodic Term SOFR Determination Day, and</font></div><div style="margin-top:11.15pt;padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b) for any calculation with respect to a Base Rate Advance on any day, the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SOFR Reference Rate </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">for a tenor of one month on the day (such day, the &#8220;ABR Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SOFR Determination Day&#8221;) that is two (2) U.S. Government Securities Business Days prior to</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">such day, as such rate is published by the Term SOFR Administrator&#59; provided, however, that if</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">as of 5&#58;00 p.m. (New York City time) on any ABR Term SOFR Determination Day the Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administrator and this Agreement has not been amended to implement a Successor Rate, then</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SOFR Administrator on the first preceding U.S. Government Securities Business Day for which</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">so long as such first preceding U.S. Government Securities Business Day is not more than three</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(3) U.S. Government Securities Business Days prior to such ABR Term SOFR Determination</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Day&#59; provided that if Term SOFR determined as provided under this clause (b) shall ever</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">be less</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">than zero, such rate shall be deemed to be zero for the purposes of this Agreement</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:11.45pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">&#8220;Term SOFR Administrator&#8221;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"> means CME Group Benchmark Administration</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">by the</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Administrative Agent in</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">its reasonable discretion).</font></div><div><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#8220;Term SOFR Reference Rate&#8221; </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">means the forward-looking term rate based on</font></div><div style="padding-left:87.85pt"><font><br></font></div><div style="padding-left:16.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:104%;text-decoration:underline">SOFR.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Total Outstandings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, as of any date of determination, the sum on that</font></div><div style="padding-left:16.55pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date of (a) the aggregate Dollar Equivalent of the outstanding principal amount of the Advances, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) the aggregate then undrawn portion of Letters of Credit which are issued and outstanding, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (c) the aggregate unreimbursed drawings under Letters of Credit.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:33.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Type</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">when used with respect to any Loan or Advance, means the designation of whether such Loan or Advance is a Base Rate Advance or a </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Rate Advance.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Unused Portion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Commitment, less Total Outstandings as to the</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Commitment.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">23</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">&#8220;U.S. Government Securities Business Day&#8221;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"> means any day except for (a) a</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Association recommends that the fixed income departments of its members be closed for the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">entire day for purposes of trading in United States government securities.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Use of Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Any defined term used in the plural shall refer to all members of the relevant class, and any defined term used in the singular shall refer to any one or more of the members of the relevant class.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:28.5pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Accounting Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Unless otherwise specified herein, all accounting terms used herein shall be interpreted, all accounting determinations hereunder shall be made and all financial statements required to be delivered hereunder shall be prepared in accordance with Generally Accepted Accounting Principles as in effect from time to time, applied on a basis consistent (except for changes concurred in by the Company&#8217;s independent public accountants) with the audited consolidated financial statements of the Company and its Consolidated Subsidiaries most recently delivered to the Banks&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that, if the Company notifies the Administrative Agent that the Company wishes to amend any covenant in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> to eliminate the effect of any change in Generally Accepted Accounting Principles on the operation of such covenant (or if the Administrative Agent notifies the Company that the Majority Banks wish to amend </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> for such purpose), then the Company&#8217;s compliance with such covenant shall be determined on the basis of Generally Accepted Accounting Principles in effect immediately before the relevant change in Generally Accepted Accounting Principles became effective, until either such notice is withdrawn or such covenant is amended in a manner satisfactory to the Company and the Majority Banks.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Rounding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Any financial ratios required to be maintained by the Company pursuant to this Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed in this Agreement and rounding the result up or down to the nearest number (with a round-up if there is no nearest number) to the number of places by which such ratio is expressed in this Agreement.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Exhibits and Schedules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. All Exhibits and Schedules to this Agreement, either as originally existing or as the same may from time to time be supplemented, modified or amended, are incorporated herein by this reference. A matter disclosed on any Schedule shall be deemed disclosed on all Schedules.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:31.8pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">References to &#8220;the Company and its Subsidiaries&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Any reference herein to &#8220;the Company and its Subsidiaries&#8221; or the like shall refer solely to the Company during such times, if any, as the Company shall have no Subsidiaries.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:24.5pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Miscellaneous Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The term &#8220;or&#8221; is disjunctive&#59; the term &#8220;and&#8221; is conjunctive. The term &#8220;shall&#8221; is mandatory&#59; the term &#8220;may&#8221; is permissive. Masculine terms also apply to females&#59; feminine terms also apply to males. The term &#8220;including&#8221; is by way of example and not limitation.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">24</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:23.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Exchange Rates&#59; Alternative Currency Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On each Calculation Date, the Administrative Agent shall determine the exchange rate as of such Calculation Date to be used for calculating relevant Dollar Equivalent and Alternative Currency Equivalent amounts. The exchange rates so determined shall become effective on such Calculation Date and shall for all purposes of this Agreement (other than any provision expressly requiring the use of a current exchange rate) be the exchange rates employed in converting any amounts between the applicable currencies. Wherever in this Agreement in connection with an Advance, conversion or continuation of a Loan, an amount, such as a required minimum or multiple amount, is expressed in Dollars, but such Advance or Loan is denominated in the Alternative Currency, such amount shall be the Alternative Currency Equivalent of such Dollar amount (rounded to the nearest 1,000 units of the Alternative Currency), as determined by the Administrative Agent.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Divisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> For all purposes under this Agreement, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws)&#58; (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized and acquired on the first date of its existence by the holders of its equity interests at such time.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.10&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Rates.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"> The Administrative Agent does not warrant or accept</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">responsibility for, and shall not have any liability with respect to (a) the continuation of,</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">administration of, submission of, calculation of or any other matter related to the Base Rate, the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term SOFR Reference Rate, Adjusted Term SOFR, Term SOFR or EURIBOR Rate, or any</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">component definition thereof or rates</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">referred to in the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">definition thereof, or any alternative,</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">successor or replacement rate thereto (including any Successor Rate), including whether the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">composition or characteristics of any such alternative, successor or replacement rate (including</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">any Successor Rate) will be similar to, or produce the same value or economic equivalence of, or</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">have the same volume or liquidity as, the Base Rate, the Term SOFR Reference Rate, Adjusted</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term SOFR, Term SOFR, EURIBOR Rate or any other Successor Rate prior to its</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">discontinuance or unavailability, or (b) the effect, implementation or composition of any</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Successor Rate Conforming Changes. The Administrative Agent and its affiliates or other</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">related entities may engage in transactions that affect the calculation of the Base Rate, the Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">SOFR Reference Rate, Term SOFR, Adjusted Term SOFR, EURIBOR Rate any alternative,</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">successor or replacement rate (including any Successor Rate) or any relevant adjustments</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">thereto, in each case, in a manner adverse to the Company. The Administrative Agent may</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">select information sources or services in its reasonable discretion to ascertain the Base Rate, the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term SOFR Reference Rate, Term SOFR, Adjusted Term SOFR, EURIBOR Rate or any</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Successor Rate, in each case pursuant to the terms of this Agreement, and shall have no liability</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">to the Company, any Bank or any other person or entity for damages of any kind, including direct</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(whether in tort, contract or otherwise and whether</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">at law or in equity</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">), for any error or</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">calculation of any such rate (or component thereof) provided by any such information source or</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">service.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">25</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 2 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 2</font></div><div style="margin-top:0.3pt;padding-left:2.05pt;padding-right:2.05pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">LOANS AND LETTERS OF CREDIT</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LOANS AND LETTERS OF CREDIT</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Advances - General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:23.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Subject to the terms and conditions set forth in this Agreement, each Bank shall, at any time and from time to time from the Closing Date through the Maturity Date applicable to such Bank, according to its Pro Rata Share of the Commitment, make Advances to the Borrowers under the Commitment in such amounts in Dollars or in the Alternative Currency as the Borrowers may request that do not exceed in the aggregate at any one time outstanding the amount of that Bank&#8217;s Pro Rata Share of the Commitment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, giving effect to the Loan of which such Advance is a part, (i) the Total Outstandings shall not exceed the Commitment and (ii) the sum of all Advances then outstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the face amount of all Letters of Credit then outstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the sum of all unreimbursed drawings under Letters of Credit shall not exceed the Commitment. Subject to the limitations set forth herein, the Borrowers may borrow and repay under the Commitment without premium or penalty.</font></div><div style="margin-top:11.3pt;padding-left:16.55pt;padding-right:30pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Subject to the next sentence, each Loan under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be made pursuant to a Request for Loan which shall specify the requested (i) date of such Loan, (ii) type of Loan, (iii) amount of such Loan and (iv) Interest Period for such Loan. Unless the Administrative Agent has notified, in its sole and absolute discretion, the Borrowers to the contrary, a Loan may be requested by telephone by a Senior Officer of the applicable Borrower, in which case such Borrower shall promptly confirm such request by transmitting a telecopy or other electronic communication of, or at the Administrative Agent&#8217;s request by mailing, a Request for Loan executed by a Senior Officer of such Borrower conforming to the preceding sentence to the Administrative Agent.</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:20.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Promptly following receipt of a Request for Loan (or the receipt of a substitute request permitted under the second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), the Administrative Agent shall notify each Bank by telephone (so long as such notice by telephone is promptly followed by a notice in writing) or telecopier or other electronic communication (the method of notice shall be at the Administrative Agent&#8217;s option) of the date and type of the Loan, the applicable Interest Period and the amount of that Bank&#8217;s Pro Rata Share of the Loan. Not later than 2&#58;00 p.m., New York time, on the date specified for any Loan subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Bank shall make its Pro Rata Share of the Loan in immediately available funds available to the Administrative Agent at the Administrative Agent&#8217;s Office. Upon fulfillment of the applicable conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, all Advances shall be credited in immediately available funds to the Designated Deposit Account.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;Each Loan under the Commitment shall be in a minimum amount of</font></div><div style="padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$2,000,000 (or &#8364;2,000,000, if the applicable borrowing is in Euros) and multiples of $1,000,000 or &#8364;1,000,000, as applicable, in excess of that amount.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:26.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;If so requested by any Bank by written notice to the Company (with a copy to the Administrative Agent) at least two Banking Days prior to the Closing Date or at any time thereafter, each Borrower shall execute and deliver to such Bank (and&#47;or, if applicable and if so</font></div><div style="padding-right:26.9pt"><font><br></font></div><div style="padding-right:26.9pt"><font><br></font></div><div style="padding-right:26.9pt"><font><br></font></div><div style="padding-right:26.9pt"><font><br></font></div><div style="padding-right:26.9pt"><font><br></font></div><div style="padding-right:26.9pt"><font><br></font></div><div style="padding-right:26.9pt"><font><br></font></div><div style="padding-right:26.9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specified in such notice, to any Person who is an assignee of such Bank pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) on the Closing Date (or, if such notice is delivered after the Closing Date, promptly after the Company&#8217;s </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">26</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receipt of such notice) a promissory note or promissory notes to evidence such Bank&#8217;s Advances under its Pro Rata Share of the Commitment, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:24.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;A Request for Loan shall be irrevocable upon the Administrative Agent&#8217;s first notification thereof.</font></div><div style="padding-left:16.55pt;padding-right:30.45pt;text-indent:71.55pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">In connection with the use, administration, adoption or implementation of</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR, the Administrative Agent and the Borrower will have the right to make</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successor Rate Conforming Changes</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">from time to time</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and, notwithstanding anything to the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">contrary herein or in</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">any other Loan Document,</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">any amendments implementing such Successor</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rate Conforming Changes will become effective without any further action or consent of any</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">other party to this Agreement. The Administrative Agent will promptly notify the Banks of the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">effectiveness of any Successor Rate Conforming Changes</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">in connection with the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">use or</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">administration of Adjusted Term SOFR.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:30.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Base Rate Advances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each request by a Borrower for a Base Rate Advance shall be made pursuant to a Request for Loan (or telephonic request for Loan referred to in the second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, if applicable) received by the Administrative Agent, at the Administrative Agent&#8217;s Office, not later than 12&#58;00 noon, New York time, on the date of a proposed Base Rate Advance. All Advances denominated in Dollars shall constitute Base Rate Advances unless properly designated as</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:28.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Each request by a Borrower for</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">a Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">an Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance shall be made pursuant to a Request for Loan (or telephonic request for Loan referred to in the second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if applicable) received by the Administrative Agent, at the Administrative Agent&#8217;s Office, not later than 1&#58;00 p.m., New York time, at least three (3)</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency Banking</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Government Securities Business</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Days before the first day of the applicable Interest Period. Each request by a Borrower for a EURIBOR Rate Advance shall be made pursuant to a Request for Loan (or telephonic request for Loan referred to in the second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if applicable) received by the Administrative Agent, at the Administrative Agent&#8217;s Office, not later than 9&#58;30 a.m., London time, at least three (3)</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Banking Days before the first day of the applicable Interest Period.</font></div><div style="margin-top:11.35pt;padding-left:16.55pt;padding-right:22.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;On the second</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Government Securities Business Day before</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">the first day of the applicable Interest Period in the case of Adjusted Term SOFR Rate Advances,</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">the Administrative Agent shall determine the applicable Adjusted Term SOFR and on the second</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Banking Day before the first day of the applicable Interest Period in the case of</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurodollar Rate</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Advances and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EURIBOR Rate Advances, the Administrative Agent shall determine the applicable</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurodollar Rate or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EURIBOR Rate, as the case may be (which determination shall be conclusive in the absence of manifest error), and prior to 1&#58;00 p.m., New York time on that same day shall give notice of the same to the applicable Borrower and the Banks by telephone or</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">27</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">telecopier or other electronic communication (the method of notice shall be at the Administrative Agent&#8217;s option).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Unless all of the Banks otherwise consent, no</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance may be requested during the continuance of an Event of Default.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:32.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Prior to the submission of a Request for Loan with respect to a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance, any Borrower may request the Administrative Agent to provide a non-binding estimate of</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">the Eurodollar Rate</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or EURIBOR Rate that would then apply in the event such Borrower submitted a Request for Loan.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:20.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Voluntary Reduction of Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company shall have the right, at any time and from time to time, without penalty or charge, upon at least two (2) days&#8217; prior written notice to the Administrative Agent, to voluntarily reduce, permanently and irrevocably, in a minimum amount of $5,000,000 and multiples of $1,000,000 in excess thereof, or to terminate, all or a portion of the then Unused Portion of the Commitment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that any such reduction or termination shall be accompanied by payment of all accrued and unpaid facility fees with respect to the portion of the Commitment being reduced or terminated. Any such notice of reduction may be conditioned upon the successful closing of a new financing and the Administrative Agent will promptly notify each Bank thereof and of such Bank&#8217;s portion of the Commitments being reduced.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.2pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall have the right, at any time, upon at least three Banking Days&#8217; notice to a Defaulting Bank (with a copy to the Administrative Agent), to terminate in whole such Defaulting Bank&#8217;s Commitment under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.4(b</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">). The Borrowers will pay all principal of, and interest accrued to the date of such payment on, Advances owing to such Defaulting Bank and pay any accrued facility fee payable to such Defaulting Bank pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and all other amounts payable to such Defaulting Bank hereunder (including but not limited to any increased costs, additional interest or other amounts owing under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and</font></div><div style="padding-left:16.55pt;padding-right:20.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and any indemnification for Taxes under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and upon such payments, the obligations of such Defaulting Bank hereunder shall, by the provisions hereof, be released and discharged&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (i) such Defaulting Bank&#8217;s rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive such release and discharge as to matters occurring prior to such date and (ii) no claim that the Borrowers may have against such Defaulting Bank arising out of such Defaulting Bank&#8217;s default hereunder shall be released or impaired in any way. The aggregate amount of the Commitments of the Banks once reduced pursuant this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.4(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may not be reinstated&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Borrowers shall pay to a Defaulting Bank any principal of, or interest accrued on, the Advances owing to such Defaulting Bank, then the Borrowers shall either (x) confirm to the Administrative Agent that, except as disclosed by the Company and approved in writing by the Administrative Agent, acting at the direction of the Majority Banks, the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are true and correct in all material respects (except that to the extent any representation or warranty is qualified by materiality, it is true and correct in all respects) on and as of such date of payment as though made on that date (except to the extent such representations and warranties specifically relate to an earlier date in which case they are true and correct in all material respects (except that to the extent any representation or warranty is qualified by materiality, it is true and correct in all respects) as of such earlier date) and no Default has</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">28</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occurred and is continuing or (y) pay or cause to be paid a ratable payment of principal and interest to all Banks who are not Defaulting Banks.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Voluntary Conversion or Continuation of Advances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Each Borrower may on any Banking Day upon notice given to the Administrative Agent not later than 12&#58;00 noon (New York City time) on the third</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Government Securities Business Day (</font><font style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">in the case of</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">a notice relating to Advances in</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dollars) or on the third</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Banking Day</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(in the case of a notice relating to EURIBOR Rate</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Advances)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior to the date of the proposed Conversion or continuance (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of</font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Conversion&#47;Continuation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (1) Convert all or any portion of Advances of one Type into Advances made to such Borrower of another Type and (2) upon the expiration of any Interest Period applicable to Advances which are </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances, continue all (or, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, any portion of) such Advances as </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances and the succeeding Interest Period(s) of such continued Advances shall commence on the last day of the Interest Period of the Advances to be continued&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that any Conversion of any </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances into Base Rate Advances shall be made on, and only on, the last day of an Interest Period for such </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances. Each such Notice of Conversion&#47;Continuation shall, within the restrictions specified above, specify (i) the date of such continuation or Conversion, (ii) the Advances (or, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, any portion thereof) to be continued or Converted, (iii) if such continuation is of, or such Conversion is into, </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances, whether such </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advance is </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">an Adjusted Term SOFR Rate</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Advance or a EURIBOR Rate Advance and the duration of the Interest Period of each such Advance, and (iv) in the case of a continuation of or a Conversion into a </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advance, that no Event of Default has occurred and is continuing. Each Conversion or continuation shall be in a minimum amount of $2,000,000 or</font></div><div style="margin-top:0.9pt;padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8364;2,000,000, as applicable, and multiples of $1,000,000 or &#8364;1,000,000, as applicable.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;If upon the expiration of the then existing Interest Period applicable to any Advance which is a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance, the Borrower thereof shall not have delivered a Notice of Conversion&#47;Continuation in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, then such Advance if it is an Advance of Dollars shall upon such expiration automatically be continued as</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">an Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance with an Interest Period of one month&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in the case of a failure to timely request a continuation of Advances denominated in the Alternative Currency, such Advances shall be continued as EURIBOR Rate Advances in the Alternative Currency with an Interest Period of one month. No</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance may be converted into or continued as a EURIBOR Rate Advance, but instead must be prepaid in Dollars and reborrowed in the Alternative Currency, and no EURIBOR Rate Advance may be converted into or continued as</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">an Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance, but instead must be prepaid in the Alternative Currency and reborrowed in Dollars.</font></div><div style="margin-top:11.15pt;padding-left:16.55pt;padding-right:21pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;After the occurrence of and during the continuation of an Event of Default, the Borrowers may not elect to have an Advance be made or continued as, or Converted into, a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance after the expiration of any Interest Period then in effect for that Advance.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">29</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.85pt;padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Letters of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.6pt;padding-left:16.55pt;padding-right:22.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Subject to the terms and conditions hereof, at any time and from time to time from the Closing Date through the date that is thirty (30) days before the Maturity Date of the applicable Issuing Bank, each Issuing Bank shall issue such Letters of Credit denominated in Dollars as a Borrower may request by delivering a Request for Letter of Credit to such Issuing Bank and to the Administrative Agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, giving effect to such Letter of Credit (i) the aggregate effective face amounts of all outstanding Letters of Credit will not exceed</font></div><div style="padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$300,000,000, (ii) the sum of all Advances then outstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the face amount of all Letters of Credit then outstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the sum of all unreimbursed drawings under Letters of Credit shall not exceed the Commitment, (iii) Total Outstandings will not exceed the Commitment and</font></div><div style="padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) the aggregate effective face amounts of all outstanding Letters of Credit issued by any Issuing Bank will not exceed such Issuing Bank&#8217;s LC Commitment&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that none of Barclays Bank PLC, Goldman Sachs Bank USA or Morgan Stanley Bank, N.A. shall be required to issue trade or commercial Letters of Credit. Letters of Credit issued under the Commitment may be issued for terms up to five (5) years from the date of issuance but in no event shall the term of any such Letter of Credit extend beyond the Maturity Date applicable to the Issuing Bank of such Letter of Credit and no Letter of Credit may expire after the Maturity Date of any Non-Extending Bank if, after giving effect to such issuance, the aggregate Pro Rata Shares of the Commitment held by the Extending Banks (including any replacement Banks) for the period following such Maturity Date would be less than the face amounts of the Letters of Credit and Advances expiring after such Maturity Date. Each Letter of Credit shall be in a minimum amount of $500,000, unless otherwise consented to by the applicable Issuing Bank. The issuance of any Letter of Credit shall constitute usage of the Commitment. Subject to the limitations set forth herein, the Borrowers may request Letters of Credit, reimburse drawings under Letters of Credit and request further Letters of Credit without premium or penalty.</font></div><div style="margin-top:10.55pt;padding-left:16.55pt;padding-right:27.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;No Issuing Bank shall Issue any Letter of Credit if it has received written notice from the Majority Banks, the Administrative Agent or the Company on or prior to the Banking Day prior to the requested date of issuance of such Letter of Credit, that one or more of the applicable conditions contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is not then satisfied. Each Issuing Bank is under no obligation to Issue any Letter of Credit if&#58;</font></div><div style="margin-top:11.6pt;padding-left:52.35pt;padding-right:26.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any order, judgment or decree of any Governmental Agency or arbitrator shall by its terms purport to enjoin or restrain such Issuing Bank from issuing such Letter of Credit, or any Requirement of Law applicable to such Issuing Bank or any request or directive (whether or not having the force of law) from any Governmental Agency with jurisdiction over such Issuing Bank shall prohibit, or request that such Issuing Bank refrain from, the issuance of Letters of Credit generally or such Letter of Credit in particular&#59; or</font></div><div style="margin-top:11.55pt;padding-left:52.35pt;padding-right:24.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any requested Letter of Credit is not in form reasonably acceptable to such Issuing Bank, or the issuance of a Letter of Credit shall violate any generally applicable policies of such Issuing Bank.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:14.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Each Request for Letter of Credit shall be submitted to any Issuing Bank and the Administrative Agent at least three (3) Banking Days prior to the date when the issuance of a</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">30</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:37.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Letter of Credit is requested. Upon issuance of a Letter of Credit, the applicable Issuing Bank shall promptly notify the Banks of the amount and terms thereof. Any Letter of Credit issued shall conform with the applicable Issuing Bank&#8217;s generally applicable policies regarding form and substance.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:21.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Upon the issuance of a Letter of Credit, each Bank shall be deemed to have irrevocably purchased from the Issuing Bank of such Letter of Credit, without recourse to or warranty from such Issuing Bank, a pro rata undivided participation in the Letter of Credit, in an amount equal to that Bank&#8217;s Pro Rata Share. Without limiting the scope and nature of each Bank&#8217;s participation in any Letter of Credit, to the extent that any Issuing Bank has not been reimbursed by the applicable Borrower, in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for any payment made by such Issuing Bank under any Letter of Credit, each Bank shall reimburse such Issuing Bank promptly upon demand for the amount of such payment in accordance with its Pro Rata Share of the Commitment, as the case may be. The obligation of each Bank to so reimburse each Issuing Bank shall be absolute and unconditional and shall not be affected by the occurrence of an Event of Default or any other occurrence or event. Any such reimbursement shall not relieve or otherwise impair the obligation of the applicable Borrower to reimburse the applicable Issuing Bank for the amount of any payment made by such Issuing Bank under any Letter of Credit together with interest as hereinafter provided. The participation of the Bank in each Letter of Credit shall be automatically adjusted at each time the Pro Rata Shares are modified in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:11pt;padding-left:16.55pt;padding-right:28.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;After any drawing on a Letter of Credit, the applicable Issuing Bank shall notify the applicable Borrower and the Administrative Agent by telephone or telecopier or other electronic communication of such drawing by 2&#58;00 p.m., New York time, on the date such payment is to be made and such Borrower shall reimburse such Issuing Bank, in immediately available funds for any amount paid or to be paid by such Issuing Bank under such Letter of Credit by 4&#58;00 p.m., New York time on the date of such notice.</font></div><div style="margin-top:11.55pt;padding-left:16.55pt;padding-right:21.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;If the applicable Borrower fails to make the payment required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Administrative Agent shall notify the Banks by telephone (promptly followed in writing) or telecopier or other electronic communication (the method of notification shall be at the Administrative Agent&#8217;s option) of the unreimbursed amount of such payment. Each Bank irrevocably and unconditionally agrees (irrespective of the occurrence of an Event of Default or any other circumstance) that it shall make available to the Administrative Agent (for the account of the applicable Issuing Bank) an amount equal to its respective participation in same day funds, at the Administrative Agent&#8217;s Office, not later than the close of business (New York time) on the date notified by the Administrative Agent. In the event that any Bank fails to make available to the Administrative Agent the amount of such Bank&#8217;s participation in such Letter of Credit as provided above, the applicable Issuing Bank (through the Administrative Agent) shall be entitled to recover such amount on demand from such Bank together with interest thereon, for each day from the date of such payment until the date such amount is paid to such Issuing Bank, at the rate per annum equal to the average overnight federal funds rate. Any amount made available by a Bank to the Administrative Agent as such Bank&#8217;s participation in such Letter of Credit shall constitute a demand loan to the applicable Borrower bearing interest at a rate per annum equal to</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(i) from the date of any payment made by the applicable Issuing Bank through the date ten days</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">after such payment, the Base Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> the weighted average of the Daily Margin for each day</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">31</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during the applicable period, and (ii) thereafter, the Base Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the weighted average of the Daily Margin for each day during the applicable period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 2%&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if a Bank is prevented from making such demand loans by the provisions of the United States Bankruptcy Code or otherwise, the amount so paid to such Issuing Bank by such Bank shall constitute a funding and purchase by it of a participation in such Letter of Credit disbursement by such Issuing Bank and all obligations of the applicable Borrower with respect thereto, including interest thereon to the extent accruing from the date of such purchase. The Administrative Agent shall promptly pay to the applicable Issuing Bank all funds paid by the Banks to reimburse such Issuing Bank for the payment made by it under the Letter of Credit.</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:34.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;The issuance of any supplement, modification, amendment, renewal, or extension to or of any Letter of Credit shall be treated for the purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the same as the issuance of a new Letter of Credit.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Reserved.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.15pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The obligation of the Borrowers to reimburse each Issuing Bank for the amount of any payment made by such Issuing Bank under any Letter of Credit issued by it, and the obligations of the Banks under their respective participations under the Letters of Credit, shall be absolute, unconditional, and irrevocable and shall not be affected by any of the following circumstances&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:52.35pt;padding-right:38.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any lack of validity or enforceability of the Letter of Credit, this Agreement, or any other agreement or instrument relating thereto&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:29.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any amendment or waiver of or any consent to departure from the Letter of Credit, this Agreement, or any other agreement or instrument relating thereto&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:36.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the existence of any claim, setoff, defense, or other rights which any Borrower may have at any time against any Bank, any beneficiary of the Letter of Credit (or any persons or entities for whom any such beneficiary may be acting) or any other Person, whether in connection with the Letter of Credit, this Agreement, or any other agreement or instrument relating thereto, or any unrelated transactions&#59;</font></div><div style="margin-top:11.65pt;padding-left:52.35pt;padding-right:23.6pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;any demand, statement, or any other document presented under the Letter of Credit proving to be forged, fraudulent, invalid, or insufficient in any respect or any statement therein being untrue or inaccurate in any respect whatsoever so long as any such document appeared to comply with the terms of the Letter of Credit&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:40.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;the solvency or financial responsibility of any party issuing any documents in connection with a Letter of Credit&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:159.75pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;any failure or delay in notice of shipments or arrival of any</font></div><div style="padding-left:52.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">property&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:159.75pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;any error in the transmission of any message relating to a Letter of</font></div><div style="padding-left:52.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Credit not caused by such Issuing Bank, or any delay or interruption in any such message&#59;</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">32</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:52.35pt;padding-right:34.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;any error, neglect or default of any correspondent of any Bank in connection with a Letter of Credit&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:27.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;any consequence arising from acts of God, war, insurrection, disturbances, labor disputes, emergency conditions or other causes beyond the control of such Issuing Bank&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:52.35pt;padding-right:23.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)&#160;&#160;&#160;&#160;so long as such Issuing Bank in good faith determines that the draft, contract or document appears to comply with the terms of the Letter of Credit, the form, accuracy, genuineness or legal effect of any contract or document referred to in any document submitted to such Issuing Bank in connection with a Letter of Credit&#59; and</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:24.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xi)&#160;&#160;&#160;&#160;where such Issuing Bank has acted in good faith and without gross negligence or willful misconduct and observed general banking usage, any other circumstance whatsoever.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:73.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;each Issuing Bank shall be entitled to the protection accorded to the Administrative Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:23.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;As between any Borrower and each Issuing Bank, such Borrower assumes all risks of the acts and omissions of, or misuse of any Letter of Credit by, the respective beneficiaries of the Letters of Credit. In furtherance and not in limitation of the foregoing, no Issuing Bank shall be responsible&#58; (1) for the validity, genuineness or legal effect of any document submitted by any party in connection with the issuance of or any drawing under the Letters of Credit, even if it should in fact prove to be in any or all respects invalid, fraudulent or forged&#59; (2) for the validity or sufficiency of any instrument transferring or assigning or purporting to transfer or assign any Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, which may prove to be invalid or ineffective for any reason&#59; (3) for errors in interpretation of technical terms&#59; (4) for the misapplication by the beneficiary of any Letter of Credit of the proceeds of any drawing under such Letter of Credit&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that none of the events set forth in the foregoing clauses (1) through (4) shall have been caused by the gross negligence or willful misconduct of such Issuing Bank&#59; and (5) for any consequences arising from causes beyond the control of such Issuing Bank. None of the above shall affect, impair, or prevent the vesting of any of such Issuing Bank&#8217;s rights or powers hereunder. In furtherance and extension and not in limitation of the specific provisions hereinabove set forth, any action taken or omitted by an Issuing Bank under or in connection with the Letters of Credit, if taken or omitted in good faith, without gross negligence or willful misconduct, shall not put such Issuing Bank under any resulting liability to the Borrowers or the Banks.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:27.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;No Issuing Bank shall have any obligation whatsoever to make any factual or legal determinations as to the correctness of any demand or payment under any Letter of Credit strictly complying with the terms of such Letter of Credit before such Issuing Bank makes any payment under the Letter of Credit. The Borrowers and the Banks hereby waive (A) diligence, presentment, demand, protest or notice of any kind, (B) any requirement that the applicable Issuing Bank exhaust any right or remedy against the Borrowers, the Administrative Agent, any other participant in the credit, or any other Person, and (C) any claim or defense based on any</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">33</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time or other indulgence granted to any Borrower, the Administrative Agent or any other Person and any right of subrogation to any rights or remedies of such Issuing Bank in respect of any of the Letters of Credit or any defense that such Issuing Bank has impaired any such right of subrogation.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:25.15pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;In the event that any payment made by or on behalf of any Borrower pursuant to or in connection with any Letter of Credit is rescinded or must otherwise be restored or returned to such Borrower or other relevant party, as applicable, including as a result of any insolvency, bankruptcy or reorganization or similar proceedings in respect of such Borrower, the obligations of the Banks under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.6(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in respect of such rescinded, restored or returned payment shall be reinstated in full and the Banks shall be liable to indemnify the applicable Issuing Bank hereunder as fully as if such payment had never been made. The provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.6(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the payment of the obligations of the Borrowers under the Letters of Credit.</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:31.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;All amounts to be paid to any Issuing Bank by the Banks under this Agreement shall be paid by the Banks to the Administrative Agent for the account of such Issuing Bank, without any set-off or counterclaim whatsoever and free and clear of and without deduction for or on account of any taxes, duties or other charges whatsoever, and without any liability therefor.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:28.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Administrative Agent&#8217;s Right to Assume Funds Available for Advances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Unless the Administrative Agent shall have been notified by any Bank no later than the time of the funding by the Administrative Agent of any Loan that such Bank does not intend to make available to the Administrative Agent such Bank&#8217;s Pro Rata Share of the total amount of such Loan, the Administrative Agent may assume that such Bank has made such amount available to the Administrative Agent on the date of the Loan and the Administrative Agent may, in reliance upon such assumption, make available to the applicable Borrower a corresponding amount. If the Administrative Agent has made funds available to any Borrower based on such assumptions and such corresponding amount is not in fact made available to the Administrative Agent by such Bank, the Administrative Agent shall be entitled to recover such corresponding amount on demand from such Bank, which demand shall be made in a reasonably prompt manner. If such Bank does not pay such corresponding amount forthwith upon the Administrative Agent&#8217;s demand therefor, the Administrative Agent promptly shall notify the applicable Borrower and such Borrower shall pay such corresponding amount to the Administrative Agent. The Administrative Agent also shall be entitled to recover from such Bank interest on such corresponding amount in respect of each day from the date such corresponding amount was made available by the Administrative Agent to such Borrower to the date such corresponding amount is recovered by the Administrative Agent, at a rate per annum equal to the average overnight federal funds rate. Nothing herein shall be deemed to relieve any Bank from its obligation to fulfill its Pro Rata Share of the Commitment or to prejudice any rights that the Administrative Agent or any Borrower may have against any Bank as a result of any default by such Bank hereunder.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Increased Commitment&#59; Additional Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">34</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:25.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) On a single occasion during each year subsequent to the Closing Date, the Company may, upon at least thirty (30) days&#8217; notice to the Administrative Agent (which shall promptly provide a copy of such notice to such Banks and such Eligible Assignees identified by the Company), propose to increase the amount of the Commitment in an aggregate minimum amount of $10,000,000 and an aggregate maximum amount not to exceed $750,000,000 (the amount of any such increase, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Increased Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are satisfied. Each such Bank and each such Eligible Assignee shall have the right (but no obligation), for a period of fifteen (15) days following receipt of such notice, to elect by notice to the Company and the Administrative Agent to participate in the Increased Commitment.</font></div><div><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:25.4pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each such Bank and Eligible Assignee that agrees to participate in the Increased Commitment shall agree to (i) in the case of any such Bank that is an existing Bank, increase its Pro Rata Share of the Commitment and (ii) in the case of any such Eligible Assignee (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), become a party to this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Pro Rata Share of the Commitment of each Additional Bank equals or exceeds $10,000,000. The sum of the increases in the Pro Rata Shares of the Commitment of the existing Banks pursuant to this subsection (b) plus the Pro Rata Shares of the Commitment of the Additional Banks shall not in the aggregate exceed the Increased Commitments.</font></div><div style="margin-top:11.45pt;padding-left:16.55pt;padding-right:23.25pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An increase in the aggregate amount of the Commitment pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall become effective on the date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Increase Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on which the Administrative Agent receives an agreement in form and substance satisfactory to the Administrative Agent signed by the Company, by each Additional Bank and by each other Bank whose Pro Rata Share of the Commitment is to be increased, setting forth the new Pro Rata Shares of the Commitment of such Banks and setting forth the agreement of each Additional Bank to become a party to this Agreement and to be bound by all the terms and provisions hereof, together with (x) a certificate dated as of the Increase Date (i) certifying and attaching the resolutions adopted by the Company approving or consenting to such extension and (ii) certifying that, before and after giving effect to such extension, (A) the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are true and correct in all material respects (except that to the extent any representation or warranty is qualified by materiality, it shall be true and correct in all respects) on and as of the Increase Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects as of such earlier date, and except that for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 4.5, 4.6 and 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to refer to the most recent statements furnished pursuant to subsections (a) and (b), respectively, of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (B) no Default exists, and (y) such opinions of counsel for the Company with respect to the Increased Commitment as the Administrative Agent may reasonably request.</font></div><div style="margin-top:11.05pt;padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Extension of Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:22.15pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Requests for Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company may, by notice to the Administrative Agent (who shall promptly notify the Banks in writing) not earlier than 60 days and not later than 45 days prior to any anniversary of the Closing Date (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), request that each Bank extend such Bank&#8217;s Maturity Date for an additional one year from</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">35</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Maturity Date applicable to such Bank, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Company shall not request more than two extensions of the Maturity Date hereunder.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bank Elections to Extend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Bank, acting in its sole and individual discretion, shall, by notice to the Administrative Agent given not later than the date (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) that is 25 days prior to such Extension Date, advise the Administrative Agent whether or not such Bank agrees to such extension (and each Bank that determines not to so extend its Maturity Date (a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Extending Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) shall notify the Administrative Agent of such fact promptly after such determination (but in any event no later than the Notice Date) and any Bank that does not so advise the Administrative Agent on or before the Notice Date shall be deemed to be a Non-Extending Bank). The election of any Bank to agree to such extension shall not obligate any other Bank to so agree.</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:22.85pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notification by Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Administrative Agent shall notify the Company of each Bank&#8217;s determination under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> no later than the date 20 days prior to the applicable Extension Date (or, if such date is not a Banking Day, on the next preceding Banking Day).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:22.8pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(d)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Commitment Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall have the right to replace each Non-Extending Bank with another bank or other banks (which may be, but need not be, one or more of the existing Banks, but which shall be an Eligible Assignee) which at the time agree to (i) in the case of any such Bank that is an existing Bank, increase its Pro Rata Share of the Commitment and (ii) in the case of any other such Bank, become a party to this Agreement (each, an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Additional Commitment Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that each of such Additional Commitment Banks shall enter into an Assignment Agreement pursuant to which such Additional Commitment Bank shall, effective as of the applicable Extension Date, undertake a Pro Rata Share of the Commitment (and, if any such Additional Commitment Bank is already a Bank, its Pro Rata Share of the Commitment shall be in addition to such Bank&#8217;s Pro Rata Share of the Commitment hereunder on such date).</font></div><div style="margin-top:11.25pt;padding-left:16.55pt;padding-right:23.6pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(e)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Minimum Extension Requirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If (and only if) the total of the Pro Rata Shares of the Commitment of the Banks that have agreed so to extend their Maturity Date (each, an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Extending Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and the additional Pro Rata Shares of the Commitment of the Additional Commitment Banks shall be more than 50% of the Commitment in effect immediately prior to the Extension Date, then, effective as of the Extension Date, the Maturity Date of each Extending Bank and of each Additional Commitment Bank shall be extended to the date falling one year after the Maturity Date then applicable to such Bank (except that, if such date is not a Banking Day, such Maturity Date as so extended shall be the next preceding Banking Day) and each Additional Commitment Bank shall thereupon become a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for all purposes of this Agreement.</font></div><div style="margin-top:11.35pt;padding-left:16.55pt;padding-right:32.05pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(f)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions to Effectiveness of Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As a condition precedent to such extension, the Company shall deliver to the Administrative Agent a certificate dated as of the Extension Date (i) certifying and attaching the resolutions adopted by the Company approving or consenting to such extension and (ii) certifying that, before and after giving effect to such extension, (A) the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are true and correct in all material respects (except that to the extent any representation or warranty is</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">36</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">qualified by materiality, it shall be true and correct in all respects) on and as of the Extension Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects as of such earlier date, and except that for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 4.5, 4.6 and 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to refer to the most recent statements furnished pursuant to subsections (a) and (b), respectively, of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (B) no Default exists. In addition, on the Maturity Date of each Non-Extending Bank, the Company shall repay all Loans owing to such Non-Extending Bank and outstanding on such date (and pay any additional amounts required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) to the extent necessary to keep outstanding Loans ratable with any revised Pro Rata Shares of the respective Banks effective as of such date.</font></div><div style="margin-top:11.55pt;padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Defaulting Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Bank becomes, and during the period it remains, a Defaulting Bank, the following provisions shall apply&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:23.35pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Defaulting Bank&#8217;s Pro Rata Share of the LC Obligations will, subject to the limitation in the proviso below, automatically be reallocated (effective on the day such Bank becomes a Defaulting Bank) among the Non-Defaulting Banks pro rata in accordance with their respective Pro Rata Shares of the Commitment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that (A) the sum of each</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Defaulting Bank&#8217;s aggregate principal amount of Advances and Pro Rata Share of the LC Obligations may not in any event exceed the Pro Rata Share of the Commitment of such</font></div><div style="padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Defaulting Bank as in effect at the time of such reallocation and (B) subject to Section 13.25, neither such reallocation nor any payment by a Non-Defaulting Bank pursuant thereto will constitute a waiver or release of any claim the Company, any other Borrower, the Administrative Agent, any Issuing Bank, or any other Bank may have against such Defaulting Bank or cause such Defaulting Bank to be a Non-Defaulting Bank&#59;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:22.3pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(ii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">to the extent that any portion (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">unreallocated portion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) of the Defaulting Bank&#8217;s share of the LC Obligations cannot be so reallocated, whether by reason of the proviso in clause (i) above or otherwise, the Borrowers will, not later than three Banking Days after demand by the Administrative Agent (at the direction of an Issuing Bank), (A) Cash Collateralize the obligations of the Borrowers in respect of such LC Obligations in an amount equal to the aggregate amount of the unreallocated portion of such LC Obligations, or (B) make other arrangements satisfactory to the Administrative Agent and each Issuing Bank, as the case may be, in their sole discretion to protect them against the risk of non-payment by such Defaulting Bank&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.45pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any amount paid by the Borrowers or otherwise received by the Administrative Agent for the account of a Defaulting Bank under this Agreement (whether on account of principal, interest, fees, indemnity payments or other amounts) will not be paid or distributed to such Defaulting Bank, but will instead be retained by the Administrative Agent in a segregated non-interest bearing account until (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) the termination of the Commitment and payment in full of all obligations of the Borrowers hereunder and will be applied by the Administrative Agent, to the fullest extent permitted by law, to the making of payments from time to time in the following order of priority&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the payment of any amounts owing by such Defaulting Bank to the Administrative Agent under this Agreement,</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">37</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:22.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the payment of any amounts owing by such Defaulting Bank to an Issuing Bank (pro rata as to the respective amounts owing to each of them) under this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the payment of post-default interest and then current interest due and payable to the Banks hereunder other than Defaulting Banks, ratably among them in accordance with the amounts of such interest then due and payable to them, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the payment of fees then due and payable to the Non-Defaulting Banks hereunder, ratably among them in accordance with the amounts of such fees then due and payable to them, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">fifth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to pay principal then due and payable to the</font></div><div style="padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Defaulting Banks hereunder ratably in accordance with the amounts thereof then due and payable to them, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">sixth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the ratable payment of other amounts then due and payable to the</font></div><div style="padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Defaulting Banks, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">seventh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> after the termination of the Commitment and payment in full of all obligations of the Borrowers hereunder, to pay amounts owing under this Agreement to such Defaulting Bank or as a court of competent jurisdiction may otherwise direct. Any payments, prepayments or other amounts paid or payable to a Defaulting Bank that are applied (or held) to pay amounts owed by a Defaulting Bank or to post cash collateral pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed paid to and redirected by such Defaulting Bank, and each Bank irrevocably consents hereto&#59; and</font></div><div style="margin-top:10.95pt;padding-left:16.55pt;padding-right:22.65pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iv)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so long as such Bank is a Defaulting Bank or a Potential Defaulting Bank, the Issuing Banks shall not be required to issue, amend or increase any Letter of Credit, unless it is satisfied that the related exposure and such Defaulting Bank&#8217;s or such Potential Defaulting Bank&#8217;s Pro Rata Share of the then outstanding LC Obligations will be 100% covered by the Pro Rata Shares of the Commitment of the Non-Defaulting Banks and&#47;or cash collateral will be provided by the Borrowers in accordance with Section 2.10(a)(ii), and participating interests in any newly issued or increased Letter of Credit shall be allocated among Non-Defaulting Banks in a manner consistent with Section 2.10(a)(i) (and such Defaulting Bank or Potential Defaulting Bank shall not participate therein).</font></div><div style="margin-top:11.45pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In furtherance of the foregoing, if any Bank becomes, and during the period it remains, a Defaulting Bank or a Potential Defaulting Bank, each Issuing Bank is hereby authorized by each Borrower (which authorization is irrevocable and coupled with an interest) to give, in its discretion, through the Administrative Agent, a Request for Loan pursuant to Section</font></div><div style="padding-left:16.55pt;padding-right:24.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2 in such amounts and in such times as may be required to (i) reimburse an outstanding drawing under a Letter of Credit, and&#47;or (ii) Cash Collateralize the obligations of the Borrowers in respect of outstanding Letters of Credit in an amount at least equal to the aggregate amount of the obligations (contingent or otherwise) of such Defaulting Bank or Potential Defaulting Bank in respect of such Letter of Credit.</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:24.1pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Pro Rata Share of the Commitment of any Bank shall be increased or, except as otherwise expressly provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, otherwise affected, and performance by each Borrower of its obligations shall not be excused or otherwise modified as a result of the operation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The rights and remedies against a Defaulting Bank under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are in addition to any other rights and remedies which the Company, any other Borrower, the Administrative Agent, any Issuing Bank or any Bank may have against such Defaulting Bank.</font></div><div style="margin-top:11.5pt;padding-left:16.55pt;padding-right:22.8pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company and the Administrative Agent agree in writing in their reasonable determination that a Defaulting Bank or a Potential Defaulting Bank should no longer</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">38</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be deemed to be a Defaulting Bank or a Potential Defaulting Bank, as the case may be, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any cash collateral), that Bank will, to the extent applicable, purchase that portion of outstanding Advances of the other Banks or take such other actions as the Administrative Agent may determine to be necessary to cause the Advances to be funded and held on a pro rata basis by the Banks in accordance with their Pro Rata Share, whereupon such Bank will cease to be a Defaulting Bank or Potential Defaulting Bank&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrowers while that Bank was a Defaulting Bank&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Bank or Potential Defaulting Bank to Bank will constitute a waiver or release of any claim of any party hereunder arising from such Bank&#8217;s having been a Defaulting Bank or Potential Defaulting Bank.</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 3 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 3</font></div><div style="margin-top:0.3pt;padding-left:1.77pt;padding-right:1.77pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Payments and Fees</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PAYMENTS AND FEES</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Principal and Interest.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:28pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Interest shall be payable on the outstanding daily unpaid principal amount of each Loan from the date thereof until payment in full is made and shall accrue and be payable at the rates set forth herein before and after default, before and after maturity, before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law, with interest on overdue interest to bear interest at the Default Rate to the fullest extent permitted by applicable Laws.</font></div><div style="margin-top:11.6pt;padding-left:16.55pt;padding-right:23.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Interest accrued on each Base Rate Advance shall be payable quarterly in arrears on the last day of each March, June, September and December commencing on the first such date to occur after the Closing Date. Except as otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the unpaid principal amount of any Base Rate Advance shall bear interest at a fluctuating rate per annum equal to the Base Rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the weighted average of the Daily Margin for each day during the applicable period. Each change in the interest rate hereunder shall take effect simultaneously with the corresponding change in the Base Rate. Each change in the Base Rate shall be effective as of 12&#58;01 a.m., New York time, on the Banking Day on which the change in the Base Rate is announced, unless otherwise specified in such announcement, in which case the change shall be effective as so specified.</font></div><div style="margin-top:11.35pt;padding-left:16.55pt;padding-right:25.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Interest accrued on each</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance, the Interest Period for which is three months or less, shall be due and payable on the last day of the applicable Interest Period. Interest accrued on each other</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance shall be due and payable on every three month anniversary of the date which is three months after the date such</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance was made, converted or continued pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and on the last day of the Interest Period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) the unpaid principal amount of any</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance shall bear interest at a rate per annum</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">39</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equal to </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">the Eurodollar Rate</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for that </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the weighted average of the Daily Margin for each day during the applicable period and (ii) the unpaid principal amount of any EURIBOR Rate Advance shall bear interest at a rate per annum equal to the EURIBOR Rate for that EURIBOR Rate Advance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the weighted average of the Daily Margin for each day during the applicable period.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:32.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;If not sooner paid, the principal amount of each Advance shall be payable to each Bank on the Maturity Date applicable to such Bank.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;If the Administrative Agent notifies the Company at any time that the Dollar Equivalent of the Total Outstandings exceeds the Commitment, by reason of fluctuations in exchange rates or otherwise, the Borrowers shall, within two Banking Days after receipt of such notice, prepay Loans in an aggregate amount sufficient to reduce the Dollar Equivalent thereof as of the date of such payment to an amount not to exceed the Commitment then in effect.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:22.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;The Loans may, at any time and from time to time, voluntarily be paid or prepaid in whole or in part without premium or penalty, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that with respect to any voluntary prepayment under this subsection, (i) any partial prepayment shall be in minimum amount of</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$2,000,000 and &#8364;2,000,000 and multiples of $1,000,000 and &#8364;1,000,000, as applicable, in excess thereof, (ii) the Administrative Agent shall have received written notice of any prepayment by</font></div><div style="padding-left:16.55pt;padding-right:26.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x) 11&#58;00 a.m. (New York time) on the date of prepayment (which shall be a Banking Day), in the case of a Base Rate Advance, (y) by 1&#58;00 p.m. (New York time) three (3)</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Banking</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Government Securities Business</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Days before the date of prepayment, in the case of</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">a</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">an Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance, and (z) by 9&#58;30 a.m. (London time) three</font></div><div style="padding-left:16.55pt;padding-right:21.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Banking Days before the date of prepayment, in the case of a EURIBOR Rate Advance, which notice shall identify the date and amount of the prepayment and the Loan(s) being prepaid,</font></div><div style="padding-left:16.55pt;padding-right:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) each prepayment of principal shall be accompanied by payment of interest accrued through the date of payment on the amount of principal paid and (iv) in any event, any payment or prepayment of all or any part of any</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance on a day other than the last day of the applicable Interest Period shall be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any such notice of prepayment may be conditioned upon the successful closing of a new financing and the Administrative Agent will promptly notify each Bank thereof and of such Bank&#8217;s portion of the outstanding Loans being prepaid&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, to the extent such notice of prepayment is rescinded and&#47;or the prepayment is not made, the Borrowers shall pay any amounts required to be made under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:11.1pt;padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Facility Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company agrees to pay to the Administrative Agent for the account of each Bank (other than a Defaulting Bank for such time as such Bank is a Defaulting Bank solely in respect of its unused Pro Rata Share of the Commitment) a facility fee on such Bank&#8217;s daily average Pro Rata Share of the Commitment, whether used or unused, from the Closing Date in the case of each Bank and from the effective date specified in the Assignment Agreement pursuant to which it became a Bank in the case of each other Bank until the Maturity Date applicable to such Bank, payable quarterly in arrears on the last day of each March, June, September and December, commencing on December 31, 2019, in an amount equal to the product of (i) such Bank&#8217;s daily average Pro Rata Share of the Commitment, whether used or unused, in effect during the period for which such payment that is to be made </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">times</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (ii) the weighted average rate per annum that is derived from the following rates&#58; (a) a rate of 0.05% per</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">40</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:22.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">annum with respect to each day during such period that the ratings with respect to Long-Term Debt were at Level 1, (b) a rate of 0.07% per annum with respect to each day during such period that such ratings were at Level 2, (c) a rate of 0.09% per annum with respect to each day during such period that such ratings were at Level 3, (d) a rate of 0.10% per annum with respect to each day during such period that such ratings were at Level 4 and (e) a rate of 0.125% per annum with respect to each day during such period that such ratings were at Level 5. If any change in the rating established by S&#38;P or Moody&#8217;s with respect to Long-Term Debt shall result in a change in the Level, the change in the facility fee shall be effective as of the date on which such rating change is publicly announced. If the ratings established by S&#38;P or Moody&#8217;s with respect to Long-Term Debt are unavailable for any reason for any day, then the applicable Level for purposes of calculating the facility fee for such day shall be deemed to be Level 5 (or, if the Majority Banks consent in writing, such other Level as may be reasonably determined by the Majority Banks from a rating with respect to Long-Term Debt for such day established by another rating agency reasonably acceptable to the Majority Banks).</font></div><div style="margin-top:11.45pt;padding-left:16.55pt;padding-right:21.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Arranger Fees and Agency Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On the Closing Date, the Company shall pay to the Arrangers fees in the amounts agreed upon by letter agreements dated November 6, 2019 among the Company and the Arrangers. Such fees are for the sole account of the Arrangers and are fully earned upon receipt and non-refundable. The Company shall pay to the Administrative Agent agency fees in the amounts agreed upon by letter agreement dated November 6, 2019 between the Company and Citigroup Global Markets Inc. Such agency fees shall be payable annually in advance as set forth in such letter agreements. The agency fees are for the sole account of the Administrative Agent and are fully earned upon receipt and</font></div><div style="margin-top:0.25pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non-refundable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that in the event the facilities hereunder are terminated, the agency fees deemed earned shall be pro rated over the number of days from the last quarterly date on which the agency fees were paid to the termination date of the facilities.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">LC Issuance Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Company shall pay, on the last day of each Fiscal Quarter, a LC Issuance Fee to the Administrative Agent for the account of each Issuing Bank, in the amounts agreed upon in writing between the Company and such Issuing Bank. The LC Issuance Fees are for the sole account of the applicable Issuing Bank and are fully earned upon receipt and non-refundable.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">LC Reimbursement Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Company shall pay, on the last day of each Fiscal Quarter, a LC Reimbursement Fee to the Administrative Agent, for the pro rata benefit of the Banks in accordance with their respective Pro Rata Shares of the Commitment, in an amount equal to the average daily face amount of Letters of Credit outstanding during such Fiscal Quarter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">times</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> the weighted average of the Daily Margin for</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances for each day during such period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that (a) to the extent that all or a portion of the Fronting Exposure in respect of any Defaulting Bank is reallocated to the Non-Defaulting Banks pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, such fees that would have accrued for the benefit of such Defaulting Bank will instead accrue for the benefit of and be payable to such Non-Defaulting Banks, pro rata in accordance with their respective Pro Rata Shares of the Commitment, and (b) to the extent that all or any portion of such Fronting Exposure cannot be so reallocated, such fees will instead accrue for the benefit of and be payable to the respective Issuing Banks ratably according to the outstanding Letters of Credit issued by each Issuing Bank&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that, with respect to this subclause (b), to the extent that any portion of the Fronting Exposure in respect of any</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">41</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Defaulting Bank is Cash Collateralized pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or otherwise, no such fees shall be payable to the respective Issuing Banks with respect to such Cash Collateralized portion of such Fronting Exposure.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:22.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">LC Drawing Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company shall pay a drawing fee to each Issuing Bank in the amount of $250 for each drawing under any Letters of Credit issued by it, payable on the date of such drawing or promptly upon notice to the Company of the draw under any Letter of Credit.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.8pt;padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Capital Adequacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">If any Bank (including an Issuing Bank) determines in good faith that compliance with any Law or regulation or with any guideline or request (excluding any published as of the date hereof or currently scheduled to take effect) from any central bank or other Governmental Agency (whether or not having the force of Law), in each case adopted or effective after the date hereof has or would have the effect of reducing the rate of return on the capital of such Bank or any corporation controlling such Bank as a consequence of, or with reference to, such Bank&#8217;s Pro Rata Share of any portion of the Commitment or its making or maintaining of Advances, or its issuance of any Letter of Credit, below the rate which such Bank or such other corporation could have achieved but for such compliance (taking into account the policies of such Bank or corporation with regard to capital), then the Company shall from time to time, upon demand by such Bank (with a copy of such demand to the Administrative Agent), immediately pay to such Bank additional amounts sufficient to compensate such Bank or other corporation for such reduction. A certificate as to such amounts, setting forth in reasonable detail the basis for such calculations, submitted to the Company and the Administrative Agent by such Bank, shall be conclusive and binding for all purposes, absent manifest error. Each Bank agrees promptly to notify the Company and the Administrative Agent of any circumstances that would cause the Company to pay additional amounts pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Increased Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.6pt;padding-left:16.55pt;padding-right:32.5pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;If, after the date hereof, by reason of (i) the adoption of any Law by any Governmental Agency, central branch or comparable authority with respect to activities in the</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interbank</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market, or (ii) any change in the interpretation or administration of any existing Law by any Governmental Agency, central bank or comparable authority charged with the interpretation or administration thereof, or (iii) compliance by any Bank or its</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lending Office or any Issuing Bank with any request or directive (whether or not having the force of Law) of any such Governmental Agency, central bank or comparable authority, or (iv) the existence or occurrence of circumstances affecting the</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interbank</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market generally that are beyond the reasonable control of the Banks&#58;</font></div><div style="margin-top:11.45pt;padding-left:88.15pt;padding-right:25.9pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;any reserve (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, without limitation, any reserve imposed by the Board of Governors of the Federal Reserve System), liquidity, special deposit, compulsory loan, insurance charge or similar requirements shall be imposed, modified or deemed applicable against assets of, deposits with or for the account of, or credit extended by, any Bank or its</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lending Office or any Issuing Bank&#59; or</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">42</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:88.15pt;padding-right:26.15pt;text-indent:35.75pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;any Bank or its</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lending Office or the</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interbank</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market or any Issuing Bank shall have imposed on it any other condition, cost or expense affecting any Advance, any of its Notes, its obligation to make Advances or this Agreement, or its obligation to make or maintain Letters of Credit hereunder, or any of the same shall otherwise be adversely affected&#59;</font></div><div style="margin-top:11.55pt;padding-left:52.35pt;padding-right:22.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the result of any of the foregoing, as determined by such Bank, increases the cost to such Bank or its </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lending Office of making, converting to, continuing or maintaining any Advance or in respect of any Advance, any of its Notes or its obligation to make Advances or the issuance or maintenance of any Letter of Credit or reduces the amount of any sum received or receivable by such Bank or its </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lending Office with respect to any Advance, any of its Notes or its obligation to make Advances (assuming such Bank&#8217;s </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lending Office had funded 100% of its </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EURIBOR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance in the </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interbank</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market) or in respect of Letters of Credit or its participation therein, then, upon demand by such Bank or such Issuing Bank (with a copy to the Administrative Agent), the Company shall pay to such Bank or such Issuing Bank, as the case may be, such additional amount or amounts as will compensate such Bank or such Issuing Bank, as the case may be, for such increased cost or reduction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply to any increased cost resulting from Indemnified Taxes, which are covered by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or Excluded Taxes. A statement of any Bank or such Issuing Bank claiming compensation under this subsection and setting forth the additional amount or amounts to be paid to it hereunder shall be conclusive in the absence of manifest error. Each Bank and each Issuing Bank agree to endeavor promptly to notify the Company of any event of which it has actual knowledge (and, in any event, within 90 days from the date on which it obtained such knowledge), occurring after the Closing Date, which will entitle such Bank or such Issuing Bank to compensation pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and agrees to designate a different </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lending Office if such designation will avoid the need for or reduce the amount of such compensation and will not, in the judgment of such Bank or such Issuing Bank, otherwise be disadvantageous to such Bank or such Issuing Bank. If any Bank claims compensation under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company may at any time, upon at least four (4) Banking Days&#8217; prior notice to the Administrative Agent and Banks and upon payment in full of the amounts provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through the date of such payment plus any fee required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pay in full all Advances or request that all </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances be converted to Base Rate Advances or all Base Rate Advances be converted to </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances.</font></div><div style="margin-top:10.1pt;padding-left:88.15pt;padding-right:26.5pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any Bank shall have reasonably determined that it shall be unlawful for such Bank or its</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lending Office to make, maintain or fund its portion of any</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance, or the authority of such Bank to purchase or sell, or to take deposits of,</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Dollars or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Euros in the</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interbank</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market, or to determine or charge interest rates based upon</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">the Eurodollar Rate</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or EURIBOR Rate has become unlawful, then such Bank shall so notify the Administrative Agent and the other Banks, and such Bank&#8217;s obligation to make</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances shall be</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">43</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:88.15pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suspended for the duration of such illegality and the Administrative Agent forthwith shall give notice thereof to the Company and such Bank shall make a Base Rate Advance as part of any successive </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance. Upon receipt of such notice, the outstanding principal amount of all </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances made by such Bank</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">, together with accrued interest thereon,</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">automatically shall be converted to Base Rate Advances with Interest Periods corresponding to the </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances of which such </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances were a part and, if, on the date of any such conversion, any such </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance is an Alternative Currency Loan, it shall be redenominated into a Dollar Loan in a principal amount equal to the Dollar Equivalent of the amount of such Alternative Currency Loan on either (A) the last day of the Interest Period(s) applicable to such </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances if the affected Bank may lawfully continue to maintain and fund such </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances to such day(s) or (B) immediately if the affected Bank may not lawfully continue to fund and maintain such </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances to such day(s), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that in such event the conversion shall not be subject to payment of a fee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:10.9pt;padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">If</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">if</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with respect to any proposed</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:26.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the Majority Banks reasonably determine that, by reason of circumstances affecting the</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interbank</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market generally that are beyond the reasonable control of the Banks, deposits in</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Dollars or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Euros (in the applicable amounts) are not being offered to each of the Banks in the</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interbank</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market for the applicable Interest Period&#59; or</font></div><div style="margin-top:11.65pt;padding-left:52.35pt;padding-right:30.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Majority Banks advise the Administrative Agent that</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">the</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurodollar Rate</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or EURIBOR Rate, as the case may be, as determined by the Administrative Agent (1) does not represent the effective pricing to such Banks for deposits in</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Dollars or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Euros</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">, as the case may be,</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Eurocurrency</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interbank</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market in the relevant amount for the applicable Interest Period, or (2) will not adequately and fairly reflect the cost to such Banks of making the applicable</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances&#59;</font></div><div style="margin-top:11.5pt;padding-left:52.35pt;padding-right:22.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then the Administrative Agent forthwith shall give notice thereof to the Company and the Banks, whereupon until the Administrative Agent notifies the Company that the circumstances giving rise to such suspension no longer exist, the obligation of the Banks to make any future </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances shall be suspended. If at the time of such notice there is then pending a Request for Loan that specifies a </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance, such Request for Loan shall be deemed to specify a Base Rate Advance in Dollars.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> If at the time of such notice there are any Term Rate Advances outstanding, all</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">such Term Rate Advances automatically shall be converted to Base Rate Advances in</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dollars on the last day of the Interest Period(s) applicable to such Term Rate Advances.</font></div><div style="margin-top:11.45pt;padding-left:16.55pt;padding-right:21.75pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The Company shall compensate each Bank for any loss sustained by that Bank in connection with the liquidation or re-employment of funds, excluding any loss of margin, and, without duplication, all actual out-of-pocket expenses (excluding allocations of any expense </font></div><div style="padding-right:21.75pt;text-align:justify"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">44</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="padding-right:21.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">internal to such Bank) reasonably attributable thereto that such Bank may sustain&#58; (i) if for any reason (other than a default by that Bank) a borrowing of any </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance does not occur on a date or in the amount specified therefor in a Request for Loan or a telephonic request for loan or a Conversion to or continuation of any </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance does not occur on a date specified therefor in a Notice of Conversion&#47;Continuation or a telephone request for Conversion or continuation&#59; (ii) if any prepayment or other principal payment or any conversion (other than as a result of a conversion required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(a)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) or assignment in accordance with Section 3.19 of any of its </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances occurs on a date prior to the last day of an Interest Period applicable to that Loan, or (iii) if any prepayment of any of its </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances is not made on any date specified in a notice of prepayment given by the Company. Each Bank&#8217;s determination of any amount payable under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be conclusive in the absence of manifest error. Each Bank shall submit an invoice to the Administrative Agent of the amount payable by the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> setting forth in reasonable detail the basis for such amount and the Administrative Agent shall notify the Company of such amount. The Company shall pay such amount to the Administrative Agent for the account of the relevant Bank, and the Administrative Agent shall promptly pay each relevant Bank the portion of the amount owed to it.</font></div><div style="margin-top:10.9pt;padding-left:16.55pt;padding-right:24.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Anything in this Agreement to the contrary notwithstanding, to the extent any notice under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.7, 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is given by any Bank more than 180 days after such Bank has knowledge (or should have had knowledge) of the occurrence of the event (or, in the case of a claim under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, of the amount of such claim) giving rise to the additional cost, reduction in amounts, loss, Tax or other additional amounts described in such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.7, 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> , as the case may be, such Bank shall not be entitled to compensation under such Section for any such amounts incurred or accruing prior to the giving of such notice (except that, if such event giving rise to the cost, reduction in amounts, loss, Tax or other amounts described in such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.7, 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is retroactive, then the 180 day period referred to above shall be extended to include the period of retroactive effective thereof).</font></div><div style="margin-top:11.35pt;padding-left:16.55pt;padding-right:24.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement or any other Loan Documents, if the Administrative Agent determines (which determination shall be conclusive absent manifest error) that&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:30.2pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adequate and reasonable means do not exist for ascertaining the applicable Reference Rate for any requested Interest Period, including, without limitation, because the applicable Reference Rate is not available or published on a current basis and such circumstances are unlikely to be temporary&#59; or</font></div><div style="margin-top:11.7pt;padding-left:16.55pt;padding-right:23.6pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the supervisor for the administrator of the applicable Reference Rate or a governmental authority having jurisdiction over the Administrative Agent has made a public statement identifying a specific date after which the applicable Reference Rate shall no longer be used for determining the interest rate of loans (such specific date, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Scheduled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Unavailability Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;),</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then, after such determination by the Administrative Agent, the Administrative Agent and the Company may amend this Agreement (i) to replace the applicable Reference Rate with an alternate benchmark rate (including any mathematical or other adjustments to the benchmark (if any) incorporated therein) that gives due consideration to the then prevailing market convention for determining a rate of interest for syndicated loans in the United States at such time in lieu of the applicable Reference Rate (any such proposed rate, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successor Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if the Successor Rate shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement), and (ii) to make any Successor Rate Conforming Changes (as defined below) and, notwithstanding anything to the contrary in Section </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">3.2</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any such amendment shall become effective without any further action or consent of any other party to this Agreement at 5&#58;00 p.m. (New York time) on the fifth Business Day after the Administrative Agent shall have posted such proposed amendment to all Banks and the Company unless, prior to such time, Banks comprising the Majority Banks have delivered to the Administrative Agent notice that such Majority Banks do not accept such amendment.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">45</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.25pt;padding-left:16.55pt;padding-right:22.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If no Successor Rate has been determined and the circumstances under clause (i) above exist or the Scheduled Unavailability Date has occurred, the obligation of the Banks to make or maintain </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances shall be suspended (to the extent of the affected </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances or Interest Periods). Upon receipt of notice from the Administrative Agent regarding its determination, the Borrowers may revoke any pending request for a Borrowing of, conversion to, or continuation of, </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances (to the extent of the affected </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances or Interest Periods) or, failing that, will be deemed to have converted such request into a request for a Borrowing of Base Rate Advances in the amount specified therein (or, in the case of a </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advance denominated in an Alternative Currency, in an amount equal to the Dollar Equivalent thereof).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Upon the occurrence and during the continuation of any Event of Default under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the outstanding principal amount of all Advances and, to the extent permitted by applicable Law, any interest payments thereon not paid when due and any fees and other amounts then due and payable hereunder, shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to 2% in excess of the interest rate otherwise payable under this Agreement with respect to the applicable Advances (or, in the case of any such fees and other amounts, at a rate which is 2% per annum in excess of the interest rate otherwise payable under this Agreement for Base Rate Advances), to the fullest extent permitted by applicable Laws&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that, in the case of</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances, upon the expiration of the Interest Period in effect at the time any such increase in interest rate is effective such</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances shall thereupon become Base Rate Advances and shall thereafter bear interest payable upon demand at a rate which is 2% per annum in excess of the interest rate otherwise payable under this Agreement for Base Rate Advances. Accrued and unpaid interest on past due amounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, without limitation, interest on past due interest) shall be compounded daily and shall be payable on demand, to the fullest extent permitted by applicable Laws.</font></div><div><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Computation of Interest and Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Computation of interest on Base Rate Advances when the Base Rate is calculated by reference to Citibank&#8217;s base commercial lending rate shall be calculated on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed. Computation of all fees and other interest (including in the case of interest on Base Rate Advances determined by reference to</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">One-Month LIBOR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or the Federal Funds Effective Rate and</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">Eurodollar</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Adjusted Term SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rate Advances) shall be</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">46</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calculated on the basis of a year of 360 days and the actual number of days elapsed. Any Advance that is repaid on the same day on which it is made shall bear interest for one day.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:29.5pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Non-Banking Days</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. If any payment to be made by a Borrower or any other party under any Loan Document shall come due on a day other than a Banking Day, payment shall instead be considered due on the next succeeding Banking Day and the extension of time shall be reflected in computing the amount of such payment.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Manner and Treatment of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:21.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Except as set forth in the next sentence, each payment hereunder or on the Notes or under any other Loan Document in Dollars shall be made to the Administrative Agent, at the Administrative Agent&#8217;s Office, for the account of each of the appropriate Banks or the applicable Issuing Bank, as the case may be, in immediately available funds, without any set-off or counterclaim, not later than 2&#58;00 p.m., New York time, on the day of payment (which must be a Banking Day). Each Borrower shall make each payment hereunder with respect to amounts denominated in the Alternative Currency not later than 2&#58;00 p.m. (local time) (at the Alternative Currency Payment Office) on the day when due in such currency to the Administrative Agent in same day funds by deposit of such funds to the Administrative Agent&#8217;s account maintained at the Alternative Currency Payment Office. All payments received after 2&#58;00 p.m., New York time or local time (as the case may be), on any particular Banking Day, shall be deemed received on the next succeeding Banking Day. The amount of all payments received by the Administrative Agent for the account of each Bank or Issuing Bank shall be promptly paid by the Administrative Agent to the applicable Bank or the applicable Issuing Bank, as the case may be, in immediately available funds. All payments of principal and interest shall be made in the currency of the applicable Advance. All other payments shall be made in Dollars.</font></div><div style="margin-top:11pt;padding-left:16.55pt;padding-right:29.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Prior to the occurrence of any Event of Default, each payment or prepayment received by the Administrative Agent on account of any Loan shall be applied&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:32.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;To the Loans, pro rata in accordance with the aggregate principal amount thereof owed to each Bank,</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:22.15pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Any mandatory prepayment of Loans shall be applied first to Base Rate Advances to the full extent thereof before application to</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances as determined by Administrative Agent, in each case in a manner which minimizes the amount of any payments required to be made by Company pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:23.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Each Bank shall use its best efforts to keep a record of Advances made by it and payments received by it with respect to its Loans and, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such record shall be presumptive evidence of the amounts owing. Notwithstanding the foregoing sentence, no Bank shall be liable to any party for any failure to keep such a record.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:25.75pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any and all payments by any Borrower to or for the account of the Administrative Agent or any Bank under this Agreement or any other Loan Document and by the Company acting in its capacity as guarantor under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be made free and clear of and without deduction for any and all present or future taxes, duties, levies, imposts, deductions, assessments, fees, withholdings or similar charges imposed</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">47</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:52.35pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by any Governmental Agency, and all liabilities with respect thereto (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Taxes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">excluding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the case of the Administrative Agent and each Bank, (A) any Taxes imposed on or measured by its net income (however denominated), franchise taxes imposed on it (in lieu of net income Taxes) and branch profits Taxes, in each case, (1) imposed by the jurisdiction (or any political subdivision thereof) under the Laws of which the Administrative Agent or such Bank, as the case may be, is organized or maintains a lending office or (2) that are Other Connection Taxes, (B) any Taxes attributable to the Administrative Agent&#8217;s or such Bank&#8217;s failure or inability to provide the forms set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, other than as a result of a change in applicable Law after the date such Person became a party to this Agreement, (C) United States withholding Taxes imposed on amounts payable to or for the account of a Bank with respect to an applicable interest in a Loan or Commitment pursuant to a Law in effect on the date on which (1) such Bank acquires such interest in the Loan or Commitment or (2) such Bank changes its lending office,</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">&#59;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except in each case to the extent that, if at the date of the Assignment Agreement pursuant to which a Bank assignee becomes a party to this Agreement or at the date of such Bank changing its lending office, the assignor or such Bank was entitled to payments under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in respect of such United States withholding Tax paid at such date and (D) Taxes imposed under FATCA (all such</font></div><div style="padding-left:52.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%">non-excluded Taxes being hereinafter referred to as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%;text-decoration:underline">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:108%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%"> and all such</font></div><div style="margin-top:0.05pt;padding-left:52.35pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">excluded Taxes being hereinafter referred to as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">). If any Borrower, the Company acting in its capacity as guarantor under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or the Administrative Agent shall be required by any Laws to deduct any Taxes from or in respect of any sum payable under any Loan Document to the Administrative Agent or any Bank, as applicable, (i) if such Taxes are Indemnified Taxes, then the sum payable by any Borrower or the Company shall be increased as necessary so that after all such required deductions are made (including deductions applicable to additional sums payable under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">3.12(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), each of the Administrative Agent and such Bank receives an amount equal to the sum it would have received had no such deductions been made, (ii) such Borrower, the Company or the Administrative Agent, as applicable, shall make such deductions, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">such Borrower, the Company or the Administrative Agent, as applicable, shall pay the full amount deducted to the relevant Governmental Agency in accordance with applicable Laws, and (iv) as soon as practicable after the date of such payment, such Borrower or the Company shall furnish to the Administrative Agent (which shall forward the same to such Bank) the original or a certified copy of a receipt evidencing payment thereof (to the extent available).</font></div><div style="margin-top:11.6pt;padding-left:52.35pt;padding-right:25.95pt;text-indent:35.75pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, any Borrower or the Company acting in its capacity as guarantor under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> agrees to pay any and all present or future stamp, court or documentary Taxes and any other excise or property Taxes or charges or similar levies which arise from any payment made under any Loan Document or from the execution, delivery, performance, enforcement or registration of, or otherwise with respect to, any Loan Document, except any such Taxes imposed as a result of a grant of a participation, designation of a new lending office, transfer or assignment (other than an assignment pursuant to a request by a Borrower under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) (hereinafter referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">48</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:52.35pt;padding-right:21pt;text-indent:35.75pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Borrower and the Company acting in its capacity as guarantor under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> agrees to indemnify the Administrative Agent and each Bank for (A) the full amount of Indemnified Taxes and Other Taxes (including any Indemnified Taxes or Other Taxes imposed or asserted by any jurisdiction on amounts payable under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) paid by the Administrative Agent and such Bank and (B) any interest, penalties or additions to tax arising therefrom or with respect thereto, in each case whether or not such Indemnified Taxes or Other Taxes were correctly or legally imposed or asserted by the relevant Governmental Agency. Payment under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.12(d)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be made within 30 days after the date the Bank or the Administrative Agent makes a written demand therefor.</font></div><div style="margin-top:11.35pt;padding-left:52.35pt;padding-right:21.7pt;text-indent:35.75pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iv)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Borrower or the Company acting in its capacity as guarantor under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is required to pay additional amounts to or for the account of any Bank pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, then such Bank will change the jurisdiction of its applicable lending office if, in the judgment of such Bank, such change (A) will eliminate or reduce any such additional payment that may thereafter accrue and (B) is not otherwise disadvantageous to such Bank.</font></div><div style="margin-top:11.55pt;padding-left:52.35pt;padding-right:22pt;text-indent:35.75pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(v)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(v)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Administrative Agent, any Bank or any Issuing Bank determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified or reimbursed by any Borrower (or by the Company acting in its capacity as guarantor under Article 11) or with respect to which any Borrower (or the Company acting in its capacity as guarantor under Article 11) has paid an additional or indemnification amount hereunder, the Administrative Agent, such Bank or such Issuing Bank shall pay to the Borrowers or the Company as guarantor (within thirty (30) days after such Person became aware it received such refund) an amount equal to such refund. In the event such indemnified party is required by the relevant Governmental Agency to repay any portion of such refund, then such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party such portion of any refund previously paid over to such indemnifying party (plus any penalties, interest or other charges imposed by such Governmental Agency with respect to such portion of such refund). Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12(d)(v</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), in no event will the Administrative Agent or any Bank or Issuing Bank be required to pay any amount to any Borrower pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.12(d)(v</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) to the extent such payment would place the Administrative Agent or such Bank or Issuing Bank in a less favorable net after-Tax position than the Administrative Agent or such Bank or Issuing Bank would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.</font></div><div style="margin-top:10.65pt;padding-left:52.35pt;padding-right:49.7pt;text-indent:35.75pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(vi)&#160;&#160;&#160;&#160;    </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Section 3.12(d), the term &#8220;Law&#8221; includes FATCA.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.13&#160;&#160;&#160;&#160;Funding Sources.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Nothing in this Agreement shall be deemed to obligate any Bank to obtain the funds for any Loan or Advance in any particular place or manner or to constitute a representation by any Bank that it has obtained or will obtain the funds for any Loan</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">49</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or Advance in any particular place or manner. Each of the Borrowers agrees that, for the purposes of any determination to be made under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Bank shall be deemed to have funded its </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EURIBOR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances with </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Dollar or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Euro deposits</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">, as the case may be,</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">London interbank market</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interbank Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:28.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Failure to Charge Not  Subsequent Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any decision by any Bank not to require payment of any interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> interest arising under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), fee, cost or other amount payable under any Loan Document, or to calculate any amount payable by a particular method, on any occasion shall in no way limit or be deemed a waiver of such Bank&#8217;s right to require full payment of any interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> interest arising under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), fee, cost or other amount payable under any Loan Document, or to calculate an amount payable by another method, on any other or subsequent occasion.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Administrative Agent&#8217;s Right to Assume Payments Will be Made by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> .</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Unless the Administrative Agent shall have been notified by a Borrower prior to the date on which any payment to be made by that Borrower hereunder is due that such Borrower does not intend to remit such payment, the Administrative Agent may, in its discretion, assume that such Borrower has remitted such payment when so due and the Administrative Agent may, in its discretion and in reliance upon such assumption, make available to each Bank on such payment date an amount equal to such Bank&#8217;s share of such assumed payment. If a Borrower has not in fact remitted such payment to the Administrative Agent, each Bank shall forthwith on demand repay to the Administrative Agent the amount of such assumed payment made available to such Bank, together with interest thereon in respect of each day from and including the date such amount was made available by the Administrative Agent to such Bank to the date such amount is repaid to the Administrative Agent at a rate per annum equal to the average overnight federal funds rate.</font></div><div style="margin-top:11.55pt;padding-left:16.55pt;padding-right:23.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Fee Determination Detail</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Administrative Agent, any Issuing Bank and any Bank, shall provide reasonable detail to the Company regarding the manner in which the amount of any payment to the Banks, or that Bank, under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> has been determined.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">3.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Survivability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">. All of the Company&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> and</font></div><div style="padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive for thirty (30) days following the termination of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such obligations shall not, from and after the termination of this Agreement, be deemed Obligations for any purpose under the Loan Documents.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Dodd-Frank, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> For the avoidance of doubt and notwithstanding anything herein to the contrary, for the purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (a) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, regulations, guidelines, interpretations or directives thereunder or issued in connection therewith (whether or not having the force of law) and (b) all requests, rules, regulations, guidelines, interpretations or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority ) or the United States or foreign regulatory authorities (whether or not having the force of law), in case for this clause (b) pursuant to Basel III, shall in each case be deemed to be a change in Law regardless of the date enacted, adopted, issued, promulgated or implemented.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">50</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:21.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Replacement of Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> If (a) any Bank requests compensation under Sections 3.7 or 3.8, (b) any Borrower is required to pay additional amounts to any Bank or any Governmental Agency for the account of any Bank pursuant to Section 3.12, (c) any Bank is a Defaulting Bank or (d) any Bank fails to consent to a requested amendment, waiver or modification to any Loan Document in which the Majority Banks have already consented to such amendment, waiver or modification but the consent of each Bank (or each Bank directly affected thereby, as applicable) is required with respect thereto, then the Company may, at its sole expense and effort, upon notice to such Bank and the Administrative Agent, require such Bank to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), all of its interests, rights and obligations under this Agreement to an Eligible Assignee that shall assume such obligations (which assignee may be another Bank that is not a Defaulting Bank, if such Bank accepts such assignment)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:33.2pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(1)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(1)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Administrative Agent shall have received the assignment fee (if any) specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.95pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(2)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(2)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Bank shall have received payment of an amount equal to the outstanding principal of its Advances, accrued interest thereon, accrued fees and all other amounts payable to it hereunder (including any amounts under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrowers (in the case of all other amounts)&#59;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:38.2pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(3)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(3)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the case of any such assignment resulting from a claim for compensation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or payments required to be made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such assignment will result in a reduction in such compensation or payments thereafter&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:104.95pt;text-indent:-16.85pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(4)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(4)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such assignment does not conflict with applicable law&#59; and</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:88.15pt;padding-right:23.85pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(5)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(5)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the case of any assignment pursuant to clause (d) of this Section 3.19, the applicable assignee shall have consented to the applicable amendment, waiver or consent.</font></div><div style="margin-top:5.75pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Bank shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Bank or otherwise, the circumstances entitling the Company to require such assignment and delegation cease to apply.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 4 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 4</font></div><div style="margin-top:0.3pt;padding-left:1.7pt;padding-right:1.7pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">REPRESENTATIONS AND WARRANTIES</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company represents and warrants to the Banks and each other Borrower represents and warrants to the Banks (with respect to itself only) that&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Existence and Qualification&#59; Power&#59; Compliance With Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Each Borrower is an organization duly formed, validly existing and in good standing under the Laws of the jurisdiction of its incorporation. Each Borrower is duly qualified to transact business, and is in good standing, in any jurisdiction in which the conduct of its business or the ownership or leasing of its Properties makes such qualification or registration necessary, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> where the</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">51</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure so to qualify or register and to be in good standing would not constitute a Material Adverse Effect. Each Borrower has all requisite corporate power and authority to conduct its business and to own and lease its Properties. Each Borrower has all requisite corporate power and authority to execute and deliver each Loan Document to which it is a party and to perform its Obligations. Each Borrower has obtained all authorizations, consents, approvals, orders, licenses and permits from, and has accomplished all filings, registrations and qualifications with, or obtained exemptions from any of the foregoing from, any Governmental Agency that are necessary for the transaction of its business, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> where the failure so to comply, file, register, qualify or obtain exemptions does not constitute a Material Adverse Effect.</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:23.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Authority&#59; Compliance With Other Agreements and Instruments and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Government Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The execution, delivery and performance of the Loan Documents by such Borrower have been duly authorized by all necessary corporate action, and do not&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:55.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Require any consent or approval not heretofore obtained of any partner, director, stockholder, security holder or creditor of such Borrower&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:56.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Result in or require the creation or imposition of any Lien upon or with respect to any Property now owned or leased or hereafter acquired by such Borrower&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:40.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Violate, to the best knowledge of such Borrower, any Requirement of Law applicable to such Borrower&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.15pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Result (or, with the giving of notice or passage of time or both, would result) in a breach of or default under, or cause or permit the acceleration of any obligation owed under any Contractual Obligation to which such Borrower is a party or by which such Borrower or any of its Property is bound or affected&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except where failure to receive such consent or approval or creation of such Lien or violation of, or default under, any such Requirement of Law or Contractual Obligation would not constitute a Material Adverse Effect.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:37.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">No Governmental Approvals Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> No authorization, consent, approval, order, license or permit from, or filing, registration or qualification with, any Governmental Agency is required to authorize or permit under applicable Laws the execution, delivery and performance of the Loan Documents by such Borrower.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:25.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> hereto correctly sets forth as of December 31, 2018 the names of each Subsidiary of the Company that would constitute a Significant Subsidiary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Significant Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) under Rule 1-02(w) of Regulation S-X as adopted by the SEC under the provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934 as in force on the date of this Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Company has made available to the Banks the audited consolidated financial statements of the Company and its Consolidated Subsidiaries as of December 31, 2018. Such financial statements (including the footnotes thereto) fairly present in all material respects the consolidated financial condition and the consolidated results of operations of the Company as of such date and for such period in accordance with Generally</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">52</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted Accounting Principles. Also, the Company has made available the unaudited condensed consolidated financial statements of the Company and its Consolidated Subsidiaries as of September 30, 2019 and for the nine months then ended (the &#8220;interim financial statements&#8221;). The interim financial statements (including the footnotes thereto) were prepared in accordance with applicable Securities and Exchange Commission regulations and include all adjustments (consisting of normal recurring accruals, unless otherwise indicated) the Company considers necessary for the fair presentation, in all material respects, of the results of operations for those periods.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">No Other Liabilities&#59; No Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> As of the Closing Date, the Company and its Consolidated Subsidiaries do not have any material liability or material contingent liability not reflected or disclosed in the consolidated balance sheet or notes thereto described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, other than liabilities and contingent liabilities&#58; (i) arising in the ordinary course of business subsequent to December 31, 2018, (ii) described in materials filed with or furnished to the Securities and Exchange Commission and available to the public, or (iii) set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Except for matters described in documents filed with or furnished to Governmental Agencies and available to the public or in materials delivered to the Banks prior to the Closing Date, there has been no event or circumstance that constitutes a Material Adverse Effect with respect to the Company and its Subsidiaries taken as a whole since December 31, 2018.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:16.55pt;padding-right:33.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Governmental Regulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> No Borrower is subject to regulation under the Investment Company Act of 1940.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:23.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> for (a) any matter fully covered (subject to applicable deductibles and retentions) by insurance for which the insurance carrier has assumed full responsibility, (b) matters described in documents filed with or furnished to Governmental Agencies and available to the public or in materials delivered to the Banks prior to the Closing Date, and (c) matters disclosed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> hereto, there are no actions, suits, proceedings or investigations pending as to which the Company or any of its Subsidiaries have been served or have received written notice or, to the best knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries or any Property of any of them before any Governmental Agency which could reasonably be expected to constitute a Material Adverse Effect.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.8pt;padding-left:16.55pt;padding-right:26.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Binding Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each of the Loan Documents will, when executed and delivered by such Borrower, constitute the legal, valid and binding obligation of such Borrower, enforceable against such Borrower in accordance with its terms, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> as enforcement may be limited by Debtor Relief Laws or equitable principles relating to the granting of specific performance and other equitable remedies as a matter of judicial discretion.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:30.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">No Defaul</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">. No event has occurred and is continuing that is a Default or Event of Default.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">53</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.85pt;padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.6pt;padding-left:16.55pt;padding-right:23.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company and, to the knowledge of the Company, each of its ERISA Affiliates are in compliance with all applicable provisions and requirements of ERISA and the regulations and published interpretations thereunder with respect to each Employee Benefit Plan, and have performed all of their obligations under each Employee Benefit Plan, except where the failure to be in such compliance or to perform such obligation would not constitute a Material Adverse Effect.</font></div><div style="margin-top:11.6pt;padding-left:16.55pt;padding-right:65.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;No ERISA Event that would constitute a Material Adverse Effect has occurred or is reasonably expected to occur.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Except as set forth on Schedule 4.11(c) and to the extent required under Section 4980B of the Code, no Employee Benefit Plan maintained by the Company or any of its Current ERISA Affiliates provides health or welfare benefits (through the purchase of insurance or otherwise) for any retired or former employees of the Company or any of its Current ERISA Affiliates.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:24.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;As of the most recent valuation date for any Pension Plan with respect to which the Company or a Subsidiary has any financial liability (including potential joint and several liability) in the event any such Pension Plan were to terminate, the &#8220;amount of unfunded benefit liabilities&#8221; (as defined in Section 4001(a)(18) of ERISA), individually or in the aggregate for all Pension Plans (excluding for purposes of such computation any Pension Plans with respect to which assets exceed benefit liabilities), does not exceed $60,000,000.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Regulation U</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. No part of the proceeds of any Advance hereunder will be used to purchase or carry, or to extend credit to others for the purpose of purchasing or carrying, any &#8220;margin stock&#8221; (as such term is defined in Regulation U) in violation of Regulation U. Neither the Company nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying any such &#8220;margin stock.&#8221;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:20.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> All written information heretofore supplied by the Company to the Administrative Agent for the purposes of this Agreement (either directly or as documents filed with or furnished to Governmental Agencies and available to the public) is true and accurate in all material respects on the date as of which such information is stated. The Company has disclosed to the Administrative Agent (either directly or as documents filed with or furnished to Governmental Agencies and available to the public) all facts which could reasonably be expected to, in the good faith opinion of the Company, materially and adversely affect (to the extent the Company can reasonably foresee) the financial condition of the Company and its Subsidiaries, taken as a whole, or the ability of the Company to perform its obligations under this Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:35.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Tax Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each of the Company and its Subsidiaries has filed or caused to be filed all tax returns which are required to have been filed by it, and has paid or caused to be paid, or made provision for the payment of, all taxes with respect to the periods, Property or transactions covered by said returns, or pursuant to any assessment received by the</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">54</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company or any of its Subsidiaries, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) taxes for which the Company has been fully indemnified, (b) such taxes, if any, as are being contested in good faith by appropriate proceedings and as to which adequate reserves have been established and maintained or (c) where the failure to so file or pay would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.8pt;padding-left:16.55pt;padding-right:21.5pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Environmental Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. As of the Closing Date, except as set forth in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2018 to the Securities and Exchange Commission, or as disclosed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> annexed hereto, (a) the Company and each Subsidiary have complied with all Environmental Laws, except to the extent that the failure to so comply would not be reasonably expected to result in a Material Adverse Effect, (b) the Company&#8217;s and its Subsidiaries&#8217; facilities do not manage any hazardous wastes, hazardous substances, hazardous materials, toxic substances or toxic pollutants in any manner that would result in a violation of any Environmental Law, except for violations that would not be reasonably expected to result in a Material Adverse Effect and (c) the Company is aware of no events, conditions or circumstances involving environmental pollution or contamination or public or employee health or safety, in each case applicable to it or its Subsidiaries, that has resulted or would be reasonably expected to result in a Material Adverse Effect.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any director, officer, employee or agent of the Company or any of its Subsidiaries is (i) a Person whose name appears on the list of Specially Designated Nationals and Blocked Persons published by the Office of Foreign Assets Control of the U.S. Department of Treasury (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Consolidated List of Financial Sanctions Targets in the UK maintained by Her Majesty&#8217;s Treasury or the Consolidated List of Persons, Groups and Entities Subject to EU Financial Sanctions maintained by the European Union (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sanctioned Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="padding-left:16.55pt;padding-right:22.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) a Person who is engaged in a transaction with any Person who is a Sanctioned Person&#59; or (iii) a department, agency or instrumentality of, or is otherwise controlled by or acting on behalf of, directly or indirectly, (x) any Sanctioned Person, or (y) the government of a country that is the target of comprehensive economic sanctions administered by OFAC, the European Union or Her Majesty&#8217;s Treasury (as of the date of this Agreement, Iran, Cuba, Syria, the Crimea region of Ukraine and North Korea) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sanctioned Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:11.3pt;padding-left:16.55pt;padding-right:33.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Foreign Corrupt Practices Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Company has implemented and maintains in effect policies and procedures reasonably designed to promote reasonable compliance by the Company, its Subsidiaries and their respective directors, officers and employees with the Foreign Corrupt Practices Act of 1977 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and is in compliance with the FCPA in all material respects.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EEA Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> No Borrower is an EEA Financial</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Institution.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Beneficial Ownership Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In respect of each Borrower that is</font></div><div style="padding-left:16.55pt;padding-right:34.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a &#8220;legal entity customer&#8221; under the Beneficial Ownership Regulation, the information included in the Beneficial Ownership Certification delivered in respect of such Borrower, as of the date such Beneficial Ownership Certification is delivered, is true and correct in all respects.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">55</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_61"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 5 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 5</font></div><div style="margin-top:0.3pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Affirmative Covenants</font></div><div style="margin-top:0.3pt;padding-left:37.17pt;padding-right:37.17pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:line-through">(Other than Information and Reporting Requirements</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">AFFIRMATIVE COVENANTS</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">(OTHER THAN INFORMATION AND REPORTING REQUIREMENTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">)</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:21.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">So long as any Advance remains unpaid, or any other Obligation (other than indemnity obligations for which no claim has been made) remains unpaid or unperformed, or any portion of the Commitment remains in force, each Borrower shall, and shall cause each of its Subsidiaries to, unless the Administrative Agent (acting with the approval of the Majority Banks) otherwise consents in writing&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:25.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Payment of Taxes and Other Potential Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Pay and discharge promptly all taxes, assessments and governmental charges or levies imposed upon any of them, upon their respective Property or any part thereof, or upon their respective income or profits or any part thereof, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that the Company and its Subsidiaries shall not be required to pay or cause to be paid any tax, assessment, charge or levy (a) that is not yet past due, or is being contested in good faith by appropriate proceedings, so long as the relevant entity has established and maintains adequate reserves for the payment of the same and by reason of such nonpayment and contest no material item or portion of Property of the Company and its Subsidiaries, taken as a whole, is in jeopardy of being seized, levied upon or forfeited or (b) the nonpayment of which in the aggregate could not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Preservation of Existence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Preserve and maintain their respective existences in the jurisdiction of their formation and all authorizations, rights, franchises, privileges, consents, approvals, orders, licenses, permits, or registrations from any Governmental Agency that are necessary for the transaction of their respective business, and qualify and remain qualified to transact business in each jurisdiction in which such qualification is necessary in view of their respective business or the ownership or leasing of their respective Properties except where the failure to maintain such preservation or maintenance of existence, authorizations, rights, franchises, privileges, consents, approvals, orders, licenses, permits or registration or to do so qualify would not constitute a Material Adverse Effect and&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that a merger permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall not constitute a violation of this covenant. Nothing herein contained shall prevent the termination of the business or corporate existence of any Subsidiary (other than a Borrower) that, in the judgment of the Company, is no longer necessary or desirable, as long as immediately after giving effect to any such transaction, no Default shall have occurred and be continuing.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Maintenance of Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Maintain, preserve and protect all of their respective depreciable Properties in good order and condition, subject to wear and tear in the ordinary course of business, and not permit any waste of their respective Properties, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that any failure to so maintain, preserve or protect such Properties that does not constitute a Material Adverse Effect shall not constitute a violation of this covenant.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27.6pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Maintenance of Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Maintain liability, casualty and other insurance (subject to customary deductibles and retentions), with responsible insurance companies in such amounts and against such risks as is carried by responsible companies engaged in similar</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">56</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_64"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">businesses and owning similar assets in the general areas in which the Company and its Subsidiaries operate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, notwithstanding the foregoing, the Company may self-insure if reasonable and consistent with sound business practice.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:21.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Compliance With Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Comply with all Requirements of Law noncompliance with which constitutes a Material Adverse Effect, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that the Company and its Subsidiaries need not comply with a Requirement of Law then being contested by any of them in good faith by appropriate proceedings.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Visitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Upon reasonable notice permit the Administrative Agent or representatives of any Bank at the Administrative Agent&#8217;s or such Bank&#8217;s expense to visit any of its major properties, during normal business hours, to inspect and make abstracts from its financial and accounting records (other than materials protected by the attorney-client privilege and materials which are proprietary in nature or which may not be disclosed without violation of a binding confidentiality obligation), and to discuss its affairs and finances with its officers and independent public accountants, all at such reasonable times and as often as may reasonably be requested&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that so long as no Default or Event of Default has occurred and is continuing, visitation by representatives of the Banks shall be limited to not more than one visit in any calendar year for each Bank.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:43.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Keeping of Records and Books of Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Keep adequate records and books of account reflecting all financial transactions in conformity with Generally Accepted Accounting Principles, and in material conformity with all applicable requirements of any Governmental Agency having regulatory jurisdiction over the Company or any of its Subsidiaries.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.8pt;padding-left:16.55pt;padding-right:24.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Use the proceeds of Advances only for general corporate purposes of the Borrowers&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that proceeds of Advances shall not be used for any Hostile Acquisition. Use the Letters of Credit only for trade, commercial and standby letters of credit in the ordinary course of business.</font></div><div><font><br></font></div><div style="margin-top:4.45pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 6 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 6</font></div><div style="margin-top:0.3pt;padding-left:34.07pt;padding-right:34.07pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Negative Covenants</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NEGATIVE COVENANTS</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">So long as any Advance remains unpaid, or any other Obligation (other than indemnity obligations for which no claim has been made) remains unpaid or unperformed, or any portion of the Commitment remains in force, the Company shall not, and shall not permit any of its Subsidiaries to, unless the Administrative Agent (acting with the approval of the Majority Banks) otherwise consents in writing&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:35.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Change in Nature of Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Make any material change in the nature of the business of the Company and its Subsidiaries, taken as a whole, as at present conducted.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:49.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Mergers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Merge, consolidate or amalgamate with or into any Person, or convey substantially all of its Properties and assets to another Person, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">unless</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> each of the following conditions are met&#58;</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">57</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:36.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;no Default or Event of Default exists or would exist immediately following the consummation of such merger, consolidation, amalgamation or conveyance&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:45.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;in a merger, consolidation or amalgamation of the Company with another Person or Persons, the Company is the surviving entity&#59; and</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;in the case of a conveyance of Properties and assets, the Properties and assets conveyed do not consist of substantially all of the Properties and assets of the Company and its Subsidiaries taken as a whole.</font></div><div style="padding-right:27.85pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Liens&#59; Sales and Leasebacks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Create, incur, assume or suffer to exist any Lien of any nature upon or with respect to any of their respective Properties, whether now owned or hereafter acquired, or engage in any sale and leaseback transaction with respect to its Property, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div id="ib6a58edfcca043b385670be29d25c61b_67"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.801%"><div><font><br></font></div></div><div style="display:inline-block;max-width:0.397%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.802%"><div style="margin-top:0.15pt"><font><br></font></div></div></div><div style="padding-left:16.55pt;padding-right:21.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Permitted Encumbrances&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Liens in favor of the Administrative Agent or the Banks under the Loan Documents&#59;</font></div><div style="padding-left:16.55pt;padding-right:21.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Liens existing on the date hereof and listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and Liens on the same Property which secure Indebtedness or obligations which replaces or refinances the Indebtedness (or commitment) or obligations originally secured by those Liens&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that the Indebtedness or obligations secured thereby are not increased&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:79.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;pre-existing Liens on assets acquired by the Company or any of its Subsidiaries after the Closing Date&#59; and</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;additional Liens securing Indebtedness or obligations (including sale and leaseback transactions to which the Company or any Subsidiary is a party as vendor and lessee), the outstanding amount of which Indebtedness or obligation together with Indebtedness of the Company&#8217;s Subsidiaries permitted under Section 6.5, does not in the aggregate exceed 35% of Consolidated Net Worth (measured as of the last day of the most recently ended Fiscal Quarter).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Transactions with Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Enter into any transaction of any kind which is material to the Company and its Subsidiaries taken as a whole with any Affiliate of the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">other than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (a) transactions between or among the Company and its Subsidiaries or between or among its Subsidiaries&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that, for the purposes of this Section 6.4</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">the term &#8220;Subsidiary&#8221; shall include any partnership and joint venture that is excluded from the definition of the term &#8220;Subsidiary&#8221; but as to which the Company or Subsidiary owns 50% or more of the ownership interests, (b) transactions on terms at least as favorable to the Company or its Subsidiaries as would be the case in an arm&#8217;s-length transaction between unrelated parties of equal bargaining power, and (c) transactions approved by a majority of the disinterested members of the Board of Directors of Company or the applicable Subsidiary.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:48.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Subsidiary Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Permit Indebtedness of the Company&#8217;s Subsidiaries (other than under this Agreement) at any time that, when aggregated (without duplication) with Indebtedness permitted to be secured by Liens in accordance with Section</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">58</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_70"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3(e), exceeds 35% of Consolidated Net Worth (measured as of the last day of the most recently ended Fiscal Quarter).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:30.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Financial Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> Permit the Consolidated Interest Coverage Ratio as of the end of any Fiscal Quarter to be less than 3.50 to 1.00.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:25.1pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Use the proceeds of any Advance for the purpose of funding any activity or business in any Sanctioned Countries or for the purpose of funding any prohibited activity or business of any Person located, organized or residing in any Sanctioned Country or who is a Sanctioned Person or, to the Company&#8217;s knowledge, any person owned by or controlled by, or acting for or on behalf of a Sanctioned Person, in any case, absent valid and effective licenses and permits issued by the relevant government sanctioning authorities described in Section 4.16 (collectively, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sanctioning Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or otherwise in accordance with applicable laws, or in any other manner that will result in any violation by any Bank or the Agent of the sanctions administered or enforced by the Sanctioning Authorities&#59; nor</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:23.5pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Use the proceeds of any Advance for the purpose of funding an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person, in violation of the FCPA (as defined in Section 4.17).</font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 7 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 7</font></div><div style="margin-top:0.3pt;padding-left:3.95pt;padding-right:3.95pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:line-through">Information and Reporting Requirements</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">INFORMATION AND REPORTING</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">REQUIREMENTS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:31.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Financial and Business Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">So long as any Advance remains unpaid, or any other Obligation (other than indemnity obligations for which no claim has been made) remains unpaid or unperformed, or any portion of the Commitment remains in force, the Company shall, unless the Administrative Agent (with the approval of the Majority Banks) otherwise consents in writing, deliver to the Banks and the Administrative Agent, at the Company&#8217;s sole expense&#58;</font></div><div><font><br></font></div><div style="padding-left:16.55pt;padding-right:29.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;As soon as practicable, and in any event within 45 days after the end of each Fiscal Quarter (other than the fourth Fiscal Quarter in any Fiscal Year), (i) the consolidated balance sheets of the Company and its Subsidiaries as at the end of such Fiscal Quarter, (ii) consolidated statements of income and (iii) consolidated statements of cash flow, in each case described in clauses (ii) and (iii) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1(a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) of the Company and its Subsidiaries for such Fiscal Quarter and for the portion of the Fiscal Year ended with such Fiscal Quarter, all in reasonable detail. Such financial statements shall be certified by a Senior Officer of the Company as fairly presenting the financial condition, results of operations and changes in financial position of the Company and its Subsidiaries in accordance with Generally Accepted Accounting Principles (other than any requirement for footnote disclosures), as at such date and for such periods, subject only to normal year-end accruals and audit adjustments&#59;</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">59</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.15pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;As soon as practicable, and in any event within 90 days after the end of each Fiscal Year, (i) the consolidated balance sheets of the Company and its Subsidiaries as at the end of such Fiscal Year, (ii) consolidated statements of income of the Company and its Subsidiaries for such Fiscal Year and (iii) consolidated statements of cash flow of the Company and its Subsidiaries for such Fiscal Year, all in reasonable detail. Such financial statements shall be prepared in accordance with Generally Accepted Accounting Principles, and such consolidated balance sheet and consolidated statements shall be accompanied by a report and opinion of Ernst &#38; Young or other independent public accountants of recognized national standing selected by the Company, which report and opinion shall be prepared in accordance with generally accepted auditing standards as at such date&#59;</font></div><div style="margin-top:11.35pt;padding-left:16.55pt;padding-right:28.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the shareholders of the Company generally, and copies of all annual, regular, periodic, current and special reports and registration statements which the Company or a Subsidiary of the Company may file or be required to file under Sections 13 or 15(d) of the Securities Exchange Act of 1934&#59;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:21.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Promptly, and in any event within five (5) Banking Days after a Senior Officer of the Company obtains actual knowledge of the existence of any condition or event which constitutes a Default or Event of Default, written notice specifying the nature and period of existence thereof and specifying what action the Company or any of its Subsidiaries is taking or proposes to take with respect thereto&#59;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:21.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Promptly upon becoming aware of the occurrence of any ERISA Event defined in clauses (i) through (vii) or (xi) of the definition thereof involving Title IV of ERISA that could reasonably be expected to result in material liability to the Company or its Subsidiaries or any ERISA Event that could reasonably be expected to result in a Material Adverse Effect, a written notice specifying the nature thereof, what action the Company or any of its ERISA Affiliates has taken, is taking or proposes to take with respect thereto and, when known, any action taken or threatened by the Internal Revenue Service, the Department of Labor or the PBGC with respect thereto&#59;</font></div><div style="margin-top:11.45pt;padding-left:16.55pt;padding-right:27.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;With reasonable promptness, copies of (a) each Schedule SB (Actuarial Information) to the annual report, if any (Form 5500 Series), filed by the Company or any of its Current ERISA Affiliates with the Internal Revenue Service with respect to each Pension Plan following the Administrative Agent&#8217;s request&#59; (b) all notices received by the Company or any of its Current ERISA Affiliates from the sponsor of a Multiemployer Plan to which a Current ERISA Affiliate contributes concerning an ERISA Event defined in clauses (i) through (vii) or</font></div><div style="padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xi) of the definition thereof following the receipt thereof&#59; and (c) such other documents or governmental reports or filings relating to any Employee Benefit Plan as the Administrative Agent shall reasonably request&#59;</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:29.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;promptly following any reasonable request therefor, provide information and documentation reasonably requested by the Administrative Agent or any Bank for purposes of compliance with applicable &#8220;know your customer&#8221; and anti-money-laundering rules and</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">60</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulations, including, without limitation, the Patriot Act and the Beneficial Ownership Regulation&#59; and</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:32.7pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Such other material information related to any Borrower&#8217;s ability to meet its Obligations hereunder as from time to time may be reasonably requested by the Administrative Agent or the Majority Banks.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:21.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Documents required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (to the extent any such documents are included in materials otherwise filed with or furnished to the Securities and Exchange Commission and available to the public may be delivered electronically and if so delivered), shall be deemed to have been delivered for all purposes of this Agreement on the date</font></div><div style="padding-left:16.55pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;on which the Company posts such documents, or provides a link thereto on the Company&#8217;s website on the Internet at the website address listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; or (ii) on which such documents are posted on the Company&#8217;s behalf on IntraLinks&#47;IntraAgency or another relevant website (including, without limitation, the EDGAR System), if any, to which each Bank and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent). The Administrative Agent shall have no obligation to request the delivery or to maintain copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Company with any such request for delivery, and each Bank shall be solely responsible for requesting delivery to it or maintaining its copies of such documents.</font></div><div style="margin-top:11.45pt;padding-left:16.55pt;padding-right:26.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Compliance Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. So long as any Advance remains unpaid, or any other Obligation (other than indemnity obligations for which no claim has been made) remains unpaid or unperformed, or any portion of the Commitment remains outstanding, the Company shall, unless the Majority Banks otherwise consent, deliver to the Administrative Agent, at the Company&#8217;s sole expense, concurrently with the financial statements required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Sections 7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">7.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, a Compliance Certificate signed by a Senior Officer of the Company, including calculations as set forth therein.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE 8</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 8</font></div><div style="margin-top:0.3pt;padding-left:164.02pt;padding-right:164.02pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Conditions</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CONDITIONS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:36.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Conditions to Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The amendment and restatement of the Existing Credit Agreement as set forth in this Agreement and the Pro Rata Shares of the Commitment of the Banks hereunder shall be effective on the first date on which each of the following conditions precedent (unless the Administrative Agent, acting at the direction of the Banks, otherwise consents in writing) shall have been satisfied&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:38.45pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Administrative Agent shall have received all of the following, each of which shall be originals unless otherwise specified, each in form and substance satisfactory to the Administrative Agent, the Issuing Banks and the Banks&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:159.75pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;executed counterparts of this Agreement&#59;</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">61</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:88.15pt;padding-right:26.05pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;the Notes dated the Closing Date and executed by the Company in favor of each Bank, each in a principal amount equal to that Bank&#8217;s Pro Rata Share of the Commitment if requested in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:22pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;a certified copy of the Certificate of Incorporation of the Company, together with a good standing certificate from the Secretary of State of the State of incorporation of the Company and, to the extent generally available, a certificate or other evidence of good standing as to payment of any applicable franchise or similar taxes from the appropriate taxing authority of such state, each dated a recent date prior to the Closing Date&#59;</font></div><div style="margin-top:11.6pt;padding-left:88.15pt;padding-right:31.35pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;copies of the Company&#8217;s Bylaws, certified as of the Closing Date by the corporate secretary or an assistant secretary of the Company&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:30pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;resolutions of the Board of Directors of the Company approving and authorizing the execution, delivery and performance of this Agreement and the other Loan Documents to which the Company is a party, certified as of the Closing Date by the corporate secretary or an assistant secretary of the Company as being in full force and effect without modification or amendment&#59;</font></div><div style="margin-top:11.65pt;padding-left:88.15pt;padding-right:62.3pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;signature and incumbency certificates of the officers of the Company executing this Agreement and the other Loan Documents&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:21.05pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7)&#160;&#160;&#160;&#160;the favorable written opinion of Shearman &#38; Sterling LLP, counsel to the Administrative Agent&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:30.35pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8)&#160;&#160;&#160;&#160;the favorable written opinion of Latham &#38; Watkins LLP, counsel to the Borrowers&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:24.45pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(9)&#160;&#160;&#160;&#160;a Certificate of a Senior Officer of the Company certifying that the conditions specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 8.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> have been satisfied&#59; and</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:63.35pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10)&#160;&#160;&#160;&#160;such other assurances, certificates, documents, consents or opinions as the Administrative Agent reasonably may require.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:39.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The representations and warranties of the Borrowers contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be true and correct.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;No Default shall have occurred and be continuing.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:29.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;The Company shall have paid to the Arrangers and the Administrative Agent the fees payable on the date of this Agreement referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the fees, costs and expenses referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:34.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;The Company shall have repaid or prepaid all of the accrued obligations under the Existing Credit Agreement on the Closing Date.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">62</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(f)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon the reasonable request of any Bank made at least ten days prior to the Closing Date, (i) the Company shall have provided to such Bank the documentation and other information so requested in connection with applicable &#8220;know your customer&#8221; and</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">anti-money-laundering rules and regulations, including, without limitation, the Patriot Act and</font></div><div style="padding-left:16.55pt;padding-right:59.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;to the extent the Company qualifies as a &#8220;legal entity customer&#8221; under the Beneficial Ownership Regulation, it shall have delivered, to each Bank that so requests, a Beneficial Ownership Certification.</font></div><div><font><br></font></div><div style="padding-left:16.55pt;padding-right:35.25pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Any Advance and Any Letter of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The obligation of each Bank to make any Advance (including the initial Advance), and the obligation of each Issuing Bank to issue, amend or extend any Letter of Credit (including the initial Letter of Credit), is subject to the following conditions precedent (unless the Administrative Agent, acting at the direction of the Majority Banks, otherwise consents in writing)&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as disclosed by the Company and approved in writing by the Administrative Agent, acting at the direction of the Majority Banks, the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, shall be true and correct in all material respects (except that to the extent any representation or warranty is qualified by materiality, it shall be true and correct in all respects) on and as of the date of the Advance or the issuance, amendment or extension of the Letter of Credit, as the case may be, as though made on that date (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the extent such representations and warranties specifically relate to an earlier date in which case they shall be true and correct in all material respects (except that to the extent any representation or warranty is qualified by materiality, it shall be true and correct in all respects) as of such earlier date) and no Default shall have occurred and be continuing&#59; and</font></div><div style="margin-top:11.35pt;padding-left:16.55pt;padding-right:34.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the Administrative Agent shall have timely received a Request for Loan in compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (or telephonic request for Loan referred to in the second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if applicable) or Request for Letter of Credit in compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if applicable.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 9 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 9</font></div><div style="margin-top:0.3pt;padding-left:17.92pt;padding-right:17.92pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:line-through">Events of Default and Remedies upon Event of Default</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">EVENTS OF DEFAULT AND</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">REMEDIES UPON EVENT OF DEFAULT</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:37.9pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The existence or occurrence of any one or more of the following events, whatever the reason therefor and under any circumstances whatsoever, shall constitute an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;&#58;</font></div><div style="margin-top:11.55pt;padding-left:16.55pt;padding-right:38.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Any Borrower fails to pay any principal of any of the Loans, or any portion thereof, on the date when due&#59; or</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:29.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Any Borrower (i) fails to pay any interest on any of the Loans, or any portion thereof, or (ii) fails to pay any other fee or amount payable to the Administrative Agent, the Banks or the Issuing Banks under any Loan Document, or any portion thereof, in each case within five (5) Banking Days after demand therefor&#59; or</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Any failure to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; or</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">63</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Any Borrower fails to perform or observe any other covenant or agreement contained in any Loan Document on its part to be performed or observed within thirty (30) days after the giving of notice by the Administrative Agent or the Majority Banks of such Default&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any failure to observe any of the covenants contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (as it relates to the Borrower&#8217;s existence), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall constitute an immediate Event of Default hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any failure to observe any of the covenants contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall constitute an Event of Default upon notice from the Administrative Agent (acting on the direction of the Majority Banks) to the Company&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any failure to observe any of the covenants contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall constitute an Event of Default five (5) Banking Days after knowledge by the Company of such Default (other than as a result of the giving of notice by the Administrative Agent or the Majority Banks as hereinafter provided) or, if earlier, the giving of notice by the Administrative Agent or the Majority Banks of such Default&#59; or</font></div><div style="margin-top:11.15pt;padding-left:16.55pt;padding-right:23.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Any representation or warranty made in this Agreement, any Notes, any Request for Loan, any Agreement to Participate or any Request for Letter of Credit was incorrect in any material respect when made or reaffirmed&#59; or</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:23.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;The Company or any of its Subsidiaries (i) fails to pay the principal, or any principal installment, or any interest or fees or any other amount of any present or future Indebtedness (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">other than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> under the Loan Documents) in an amount in excess of $200,000,000, or any guaranty of present or future Indebtedness in an aggregate amount in excess of</font></div><div style="padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$200,000,000, on its part to be paid, when due (and after expiration of any stated grace or notice period), whether at the stated maturity, upon acceleration, by reason of required prepayment or otherwise or (ii) fails to perform or observe any other material term, covenant or agreement on its part to be performed or observed, or suffers any event to occur, and such failure or event continues after the applicable grace period, if any, and is not waived, in connection with any present or future Indebtedness in an amount in excess of $200,000,000, or of any guaranty of present or future Indebtedness in excess of $200,000,000, if as a result of such failure or sufferance any holder or holders thereof (or an agent or trustee on its or their behalf) has the right to declare such Indebtedness or guaranty due before the date on which it otherwise would become due&#59; or</font></div><div style="margin-top:11.15pt;padding-left:16.55pt;padding-right:23.1pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;Any Loan Document, at any time after its execution and delivery and for any reason other than the agreement of the Banks or satisfaction in full of all the Obligations, ceases to be in full force and effect or is declared by a court of competent jurisdiction to be null and void, invalid or unenforceable in any respect which, in any such event in the reasonable opinion of the Majority Banks, is materially adverse to the interests of the Banks&#59; or any Borrower denies that it has any or further liability or obligation under any Loan Document, or purports to revoke, terminate or rescind same&#59; or</font></div><div style="margin-top:11.5pt;padding-left:16.55pt;padding-right:26.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;A judgment against the Company or any of its Subsidiaries is entered for the payment of money in excess of $200,000,000 (to the extent not adequately covered by insurance as to which a solvent and unaffiliated insurance company has acknowledged coverage) and, absent procurement of a stay of execution, such judgment remains unstayed, unbonded or unsatisfied for sixty (60) calendar days after the date of entry of judgment&#59; or</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">64</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:22.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The Company, any Borrower or any other Subsidiary of the Company the Shareholders&#8217; Equity of which, as shown on the most recent consolidated balance sheet, equals or exceeds 10% of the Shareholders&#8217; Equity of the Company and its Consolidated Subsidiaries as shown on such consolidated balance sheet, institutes or consents to any proceeding under a Debtor Relief Law relating to it or to all or any substantial part of its Property, or is unable or admits in writing its inability to pay its debts as they mature, or makes an assignment for the benefit of creditors&#59; or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or for all or any substantial part of its Property&#59; or any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is appointed without the application or consent of that Person and the appointment continues undischarged or unstayed for sixty (60) calendar days&#59; or any proceeding under a Debtor Relief Law relating to any such Person or to all or any part of its Property is instituted without the consent of that Person and continues undismissed or unstayed for sixty (60) calendar days&#59; or any judgment, writ, warrant of attachment or execution or similar process is issued or levied against all or any material part of the Property of any such Person and is not released, vacated or fully bonded within sixty (60) calendar days after its issue or levy&#59; or any order for relief shall be entered in respect of the Company or any Borrower or any such Subsidiary&#59; or</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:25.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;(i) Any Person or two or more Persons acting in concert shall acquire beneficial ownership (within the meaning of Rule 13d-3 of the Securities and Exchange Commission under the Securities Exchange Act of 1934) directly or indirectly, of securities of the Company (or other securities convertible into such securities) representing 30% or more of the combined voting power of all securities of the Company entitled to vote in the election of directors, other than securities having such power only by reason of the happening of a contingency&#59; or (ii) during any period of up to 12 consecutive months, commencing before or after the date of this Agreement, individuals who at the beginning of such 12-month period were directors of the Company, or whose nomination for election to the Board of Directors of the Company was recommended or approved by a vote of at least a majority of the directors then still in office who were directors of the Company on the first day of such period, shall cease for any reason to constitute a majority of the Board of Directors of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that there shall not be an Event of Default pursuant to subsection (i) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.1(j</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) with respect to any Persons who on the date hereof meet the requirements set forth in said subsection (i) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.1(j</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#59; or</font></div><div style="margin-top:11pt;padding-left:16.55pt;padding-right:25.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;there shall occur one or more ERISA Events which individually or in the aggregate results in or might reasonably be expected to result in liability of the Company, a Subsidiary or any of their ERISA Affiliates in excess of $200,000,000 during the term of this Agreement&#59; or there shall exist an &#8220;amount of unfunded benefit liabilities&#8221; (as defined in Section 4001(a)(18) of ERISA), individually or in the aggregate for all Pension Plans with respect to which the Company or a Subsidiary has any financial liability, including potential joint and several liability in the event any such Pension Plan were to terminate (excluding for purposes of such computation any Pension Plans with respect to which assets exceed benefit liabilities), which exceeds $200,000,000 and Majority Banks determine that such event could reasonably be expected to have a Material Adverse Effect&#59; or</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">65</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:30pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;so long as any Subsidiary of the Company is a Borrowing Subsidiary, the Guaranty ceases to be in full force and effect or is declared to be null and void, or the Company denies that it has any further liability thereunder, or gives notice to such effect.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:27pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Remedies Upon Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Without limiting any other rights or remedies of the Administrative Agent, the Issuing Banks or the Banks provided for elsewhere in this Agreement, or the Loan Documents, or by applicable Law, or in equity, or otherwise&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:43.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Upon the occurrence, and during the continuance, of any Event of Default other than an Event of Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.1(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect to any Borrower&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:22.7pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;the commitment to make Advances, Issue Letters of Credit and all other obligations of the Administrative Agent, the Banks or the Issuing Banks and all rights of the Borrowers and any other parties under the Loan Documents shall be suspended without notice to or demand upon any Borrower, which are expressly waived by the Borrowers, except, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.2(a)(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Majority Banks (or all of the Banks to the extent required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) may waive the Event of Default or, without waiving, determine, upon terms and conditions satisfactory to the Majority Banks (or all of the Banks, as the case may be), to reinstate the Commitment and make further Advances and issue additional Letters of Credit, which waiver or determination shall apply equally to, and shall be binding upon, all the Banks and the Issuing Banks&#59; and</font></div><div style="margin-top:11.25pt;padding-left:88.15pt;padding-right:25.85pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;the Majority Banks may request any Issuing Bank to, and such Issuing Bank thereupon shall, demand immediate deposit by the Borrowers into an account designated by the applicable Issuing Bank of Cash in an amount equal to the aggregate effective face amount of all outstanding Letters of Credit issued by it&#59; and</font></div><div style="margin-top:11.65pt;padding-left:88.15pt;padding-right:21.5pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;the Majority Banks may request the Administrative Agent to, and the Administrative Agent thereupon shall, terminate the Commitment and declare, by notice to the Borrowers, all or any part of the unpaid principal of all Loans, all interest accrued and unpaid thereon and all other amounts payable under the Loan Documents to be forthwith due and payable, whereupon the same shall become and be forthwith due and payable, without protest, presentment, notice of dishonor, demand or further notice of any kind, all of which are expressly waived by the Borrowers.</font></div><div style="margin-top:11.5pt;padding-left:16.55pt;padding-right:28.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Upon the occurrence of any Event of Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.1(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect to any Borrower&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:26.9pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;the commitment to make Advances, issue Letters of Credit and all other obligations of the Administrative Agent or the Banks and all rights of the Borrowers and any other parties under the Loan Documents shall terminate without notice to or demand upon any Borrower, which are expressly waived by the Borrowers&#59; and</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">66</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:88.15pt;padding-right:22.45pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;an amount equal to the aggregate effective face amount of all outstanding Letters of Credit issued by an Issuing Bank shall be forthwith due and payable to such Issuing Bank, without protest, presentment, notice of dishonor, demand or further notice of any kind, all of which are waived by the Borrowers&#59; and</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:88.15pt;padding-right:35.7pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;the unpaid principal of all Loans, all interest accrued and unpaid thereon and all other amounts payable under the Loan Documents shall be forthwith due and payable, without protest, presentment, notice of dishonor, demand or further notice of any kind, all of which are expressly waived by the Borrowers.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:41.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Upon the occurrence of any Event of Default, subject to clause (d) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Banks and the Administrative Agent, or any of them, without notice to or demand upon any Borrower, which are expressly waived by the Borrowers, may proceed to protect, exercise and enforce their rights and remedies under the Loan Documents against the Borrowers and any other party and such other rights and remedies as are provided by Law or equity.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:25.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;The order and manner in which the Banks&#8217; rights and remedies are to be exercised shall be determined by the Majority Banks in their sole discretion, and all payments received by the Administrative Agent and the Banks, or any of them, shall be applied first to the costs and expenses (including attorneys&#8217; fees and disbursements covered by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) of the Administrative Agent, acting as Administrative Agent, and of the Banks (to the extent covered by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and thereafter paid pro rata to the Banks in the same proportions that the aggregate Obligations owed to each Bank under the Loan Documents bear to the aggregate Obligations owed under the Loan Documents to all the Banks, without priority or preference among the Banks. Regardless of how each Bank may treat payments for the purpose of its own accounting, for the purpose of computing the Borrowers&#8217; Obligations hereunder and under the Notes, payments shall be applied </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the costs and expenses of the Administrative Agent, acting as Administrative Agent, and the Banks, as set forth above, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the payment of accrued and unpaid interest due under any Loan Documents to and including the date of such application (ratably, and without duplication, according to the accrued and unpaid interest due under each of the Loan Documents), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the payment of all other amounts (including principal and fees) then owing to the Administrative Agent or the Banks under the Loan Documents. No application of payments will cure any Event of Default, or prevent acceleration, or continued acceleration, of amounts payable under the Loan Documents, or prevent the exercise, or continued exercise, of rights or remedies of the Banks hereunder or thereunder or at law or in equity.</font></div><div style="margin-top:10.75pt;padding-left:16.55pt;padding-right:21.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Upon the occurrence of an Event of Default resulting from or resulting in the default by the Company in the repayment of its</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURO</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate Advances when required by the terms of this Agreement, the Company shall compensate each Bank in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any amounts described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.2(a)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.2(b)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, when received by the applicable Issuing Bank, shall be held by such Issuing Bank in a collateral</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">67</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">account, which shall be established and maintained by such Issuing Bank and shall be under its sole dominion and control, as collateral security for the payment of all Obligations and applied as set forth below. If such collateral is provided pursuant hereto, the applicable Issuing Bank, for the benefit of the Banks, shall have a security interest in such collateral account and all amounts at any time held in or acquired in connection with such collateral account, together with all proceeds thereof. Upon any drawing under any outstanding Letter of Credit, the applicable Issuing Bank shall apply any amount in the collateral account to reimburse such Issuing Bank for the amount of such drawing. In the event of cancellation or expiration of any Letter of Credit, or in the event of any reduction in the maximum amount available under such Letter of Credit, the applicable Issuing Bank shall apply the excess of any amount then on deposit in the collateral account over the maximum available amount that may at any time be drawn under all Letters of Credit immediately after such cancellation, expiration or reduction as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:11.2pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 10 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 10</font></div><div style="margin-top:0.3pt;padding-left:2.05pt;padding-right:2.05pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">The Administrative Agent</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">THE ADMINISTRATIVE AGENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:22.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Appointment and Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Each of the Banks and the Issuing Banks hereby irrevocably appoints Citibank to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> are solely for the benefit of the Administrative Agent, the Issuing Banks and the Banks, and the Borrowers shall have no rights as a third party beneficiary of any of such provisions (except for the consents specifically required in Section 10.6). It is understood and agreed that the use of the term &#8220;agent&#8221; herein or in any other Loan Document (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Rights as a Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Bank as any other Bank and may exercise the same as though it were not the Administrative Agent and the term &#8220;Bank&#8221; or &#8220;Banks&#8221; shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Borrowers or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Banks.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exculpatory Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:26.6pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent&#58;</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">68</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:30.2pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing&#59;</font></div><div style="margin-top:5.85pt;padding-left:16.55pt;padding-right:25pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Majority Banks (or such other number or percentage of the Banks as shall be expressly provided for herein or in the other Loan Documents)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable Law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Bank in violation of any Debtor Relief Law&#59; and</font></div><div style="margin-top:5.35pt;padding-left:16.55pt;padding-right:23.9pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrowers or any of their Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.</font></div><div style="margin-top:5.7pt;padding-left:16.55pt;padding-right:22pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Majority Banks (or such other number or percentage of the Banks as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Administrative Agent shall be deemed not to have knowledge of any Default unless and until notice describing such Default is given to the Administrative Agent in writing by any Borrower or a Bank.</font></div><div style="margin-top:5.5pt;padding-left:16.55pt;padding-right:26.55pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document, or (v) the satisfaction of any condition set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.</font></div><div style="margin-top:5.7pt;padding-left:16.55pt;padding-right:27.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Reliance by Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, or the issuance, extension, renewal or increase of a Letter of Credit, that by its terms must</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">69</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be fulfilled to the satisfaction of a Bank or Issuing Bank, the Administrative Agent may presume that such condition is satisfactory to such Bank or Issuing Bank unless the Administrative Agent shall have received notice to the contrary from such Bank or Issuing Bank prior to the making of such Loan or the issuance of such Letter of Credit. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrowers), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Delegation of Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and each such sub-agent, and shall apply to their respective activities in connection with the syndication of the Loans as well as activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">sub-agents</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">sub-agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Resignation of the Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:23.9pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Agent may at any time give notice of its resignation to the Banks, the Issuing Banks and the Company. Upon receipt of any such notice of resignation, the Majority Banks shall have the right, with the written consent of the Company (such consent not to be unreasonably withheld and not to be required if an Event of Default has occurred and is continuing), to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States. If no such successor shall have been so appointed by the Majority Banks and shall have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of its resignation (or such earlier day as shall be agreed by the Majority Banks) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the retiring Administrative Agent may (but shall not be obligated to), on behalf of the Banks and the Issuing Banks, appoint a successor Administrative Agent meeting the qualifications set forth above.</font></div><div style="padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whether or not a successor has been appointed, such resignation shall become effective in accordance with such notice on the Resignation Effective Date.</font></div><div style="margin-top:5.2pt;padding-left:16.55pt;padding-right:27.6pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Person serving as Administrative Agent is a Defaulting Bank pursuant to clause (v) of the definition thereof, the Majority Banks may, to the extent permitted by applicable Law, by notice in writing to the Company and such Person remove such Person as Administrative Agent and, with the written consent of the Company (such consent not to be unreasonably withheld and not to be required if an Event of Default has occurred and is continuing), appoint a successor. If no such successor shall have been so appointed by the Majority Banks and shall have accepted such appointment within 30 days (or such earlier day as shall be agreed by the Majority Banks ) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Removal Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then such removal shall nonetheless become effective in accordance with such notice on the Removal Effective Date.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">70</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.3pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With effect from the Resignation Effective Date or the Removal Effective Date (as applicable) (1) the retiring or removed Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents and (2) except for any indemnity payments owed to the retiring or removed Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Bank and Issuing Bank directly, until such time, if any, as the Majority Banks appoint a successor Administrative Agent as provided for above. Upon the acceptance of a successor&#8217;s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring or removed Administrative Agent (other than any rights to indemnity payments owed to the retiring or removed Administrative Agent, as of the Resignation Effective Date or the Removal Effective Date, as applicable) and the retiring or removed Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">). The fees payable by the Company to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Company and such successor.</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">After the retiring or removed Administrative Agent&#8217;s resignation or removal hereunder and</font></div><div style="padding-left:16.55pt;padding-right:33.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under the other Loan Documents, the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall continue in effect for the benefit of such retiring or removed Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring or removed Administrative Agent was acting as Administrative Agent.</font></div><div style="margin-top:5.65pt;padding-left:16.55pt;padding-right:21.55pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(d)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any resignation by Citibank as Administrative Agent pursuant to this Section shall also constitute its resignation as Issuing Bank. If Citibank resigns as an Issuing Bank, it shall retain all the rights, powers, privileges and duties of an Issuing Bank hereunder with respect to all Letters of Credit outstanding as of the effective date of its resignation as an Issuing Bank and all LC Obligations with respect thereto, including the right to require the Banks to fund risk participations in unreimbursed amounts pursuant to Section 2.6(f). Upon the appointment by the Company of a successor Issuing Bank hereunder (which successor shall in all cases be a Bank other than a Defaulting Bank that agrees to serve as an Issuing Bank), (i) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring Issuing Bank, (ii) the retiring Issuing Bank shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents, and (iii) the successor Issuing Bank shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to Citibank to effectively assume the obligations of Citibank with respect to such Letters of Credit.</font></div><div style="margin-top:5.35pt;padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Reliance on Administrative Agent and Other Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:21.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Bank and Issuing Bank acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Banks or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Bank and Issuing Bank also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Bank or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">71</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.</font></div><div style="margin-top:6.2pt;padding-left:16.55pt;padding-right:25.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">10.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Right to Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> To the extent that the Company for any reason fails to indefeasibly pay any amount required under Section 13.12 to be paid by it to the Administrative Agent, its directors, officers, agents, employees, attorneys and Affiliates, each Bank shall, ratably in accordance with its Pro Rata Share of the Commitment, indemnify and hold the Administrative Agent, its directors, officers, agents, employees, attorneys and Affiliates harmless against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever (including, without limitation, reasonable attorneys&#8217; fees and disbursements) that may be imposed on, incurred by or asserted against them in any way relating to or arising out of the Loan Documents (other than losses incurred by reason of the failure of the Borrowers to pay the Obligations represented by the Loan Documents) or any action taken or not taken by it as Administrative Agent thereunder, except such as result from its own gross negligence or willful misconduct. Without limitation on the foregoing, each Bank shall reimburse the Administrative Agent upon demand for that Bank&#8217;s ratable share of any cost or expense incurred by the Administrative Agent in connection with the negotiation, preparation, execution, delivery, amendment, waiver, restructuring, reorganization (including a bankruptcy reorganization), enforcement or attempted enforcement of the Loan Documents, to the extent that the Company or any other party is required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> to pay that cost or expense but fails to do so upon demand. Nothing in this Section shall entitle the Administrative Agent to recover any amount from the Banks if and to the extent that such amount has theretofore been recovered from the Company or any of its Subsidiaries. The undertaking in this Section shall survive termination of the Commitment, the payment of all other Obligations and the resignation of the Administrative Agent.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:32.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">10.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">No Other Duties, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">. Anything herein to the contrary notwithstanding, none of the Persons acting as Arrangers, Joint Book Runners, Syndication Agent or</font></div><div style="padding-left:16.55pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Co-Documentation Agents listed on the cover page hereof shall have any powers, duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent, Issuing Bank or as a Bank hereunder.</font></div><div><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.15pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">10.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Bank ERISA Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. (a) Each Bank (x) represents and warrants, as of the date such Person became a Bank party hereto, to, and (y) covenants, from the date such Person became a Bank party hereto to the date such Person ceases being a Bank party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of doubt, to or for the benefit of the Company or any other Borrower, that at least one of the following is and will be true&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:30.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;such Bank is not using &#8220;plan assets&#8221; (within the meaning of Section 3(42) of ERISA or otherwise) of one or more Benefit Plans with respect to such Bank&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments or this Agreement,</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:52.35pt;padding-right:34.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">72</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:52.35pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Bank&#8217;s entrance into, participation in, administration of and performance of the Advances, the Letters of Credit, the Commitments and this Agreement,</font></div><div style="margin-top:11.65pt;padding-left:52.35pt;padding-right:29.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;(A) such Bank is an investment fund managed by a &#8220;Qualified Professional Asset Manager&#8221; (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Bank to enter into, participate in, administer and perform the Advances, the Letters of Credit, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Advances, the Letters of Credit, the Commitments and this Agreement satisfies the requirements of sub-sections (b) through</font></div><div style="padding-left:52.35pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) of Part I of PTE 84-14 and (D) to the best knowledge of such Bank, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Bank&#8217;s entrance into, participation in, administration of and performance of the Advances, the Letters of Credit, the Commitments and this Agreement, or</font></div><div style="margin-top:11.25pt;padding-left:52.35pt;padding-right:23.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Bank.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) In addition, unless either (1) sub-clause (i) in the immediately preceding clause (a) is true with respect to a Bank or (2) a Bank has provided another representation, warranty and covenant in accordance with sub-clause (iv) in the immediately preceding clause (a), such Bank further (x) represents and warrants, as of the date such Person became a Bank party hereto, to, and (y) covenants, from the date such Person became a Bank party hereto to the date such Person ceases being a Bank party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of doubt, to or for the benefit of the Company or any other Borrower, that the Administrative Agent is not a fiduciary with respect to the assets of such Bank involved in such Bank&#8217;s entrance into, participation in, administration of and performance of the Advances, the Letters of Credit, the Commitments and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any Loan Document or any documents related hereto or thereto).</font></div><div style="margin-top:11.2pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 11 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 11</font></div><div style="margin-top:0.3pt;padding-left:1.67pt;padding-right:1.67pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Company Guaranty</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COMPANY GUARANTY</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">The Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Company hereby unconditionally guaranties the due and punctual payment of all obligations (including, without limitation, the obligation to pay the principal amount of and interest on each Advance) of each Borrowing Subsidiary arising under this Agreement when due, whether by required prepayment, declaration, demand or otherwise (including amounts which would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, 11 U.S.C. &#167; 362(a)) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Borrowing Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and agrees to pay any and all costs and expenses (including reasonable fees and disbursements of counsel) incurred by the Administrative Agent and the Banks in enforcing any rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (to the extent covered by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The obligations of the</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">73</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">, as they may be amended, modified or supplemented from time to time, are sometimes referred to in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%"> as this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;text-decoration:underline">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">&#8221;.</font></div><div style="margin-top:11.55pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company agrees that this Guaranty constitutes a guaranty of payment when due and not of collection and waives any right to require that any resort be had by the Administrative Agent or any Bank to any security held for payment of the Borrowing Subsidiary Obligations or to any balance of any deposit account or credit on the books of the Administrative Agent or any Bank in favor of the Company or any Borrowing Subsidiary or any other Person.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:21.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company agrees, in furtherance of the foregoing and not in limitation of any other right which the Administrative Agent or any Bank may have at law or in equity against the Company by virtue hereof, upon the failure of any Borrowing Subsidiary to pay any of its Borrowing Subsidiary Obligations when and as the same shall become due, whether by required prepayment, declaration, demand or otherwise (including amounts which would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, 11 U.S.C. &#167; 362(a)), the Company will forthwith pay, or cause to be paid, in cash, to the Administrative Agent for the ratable benefit of the Banks an amount equal to the sum of the unpaid principal amount of such Borrowing Subsidiary Obligations then due as aforesaid, accrued and unpaid interest on such Borrowing Subsidiary Obligations (including, without limitation, interest which, but for the filing of a petition in bankruptcy with respect to such Borrowing Subsidiary (including without limitation, the Company), would accrue on such Borrowing Subsidiary Obligations).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.85pt;padding-left:16.55pt;padding-right:39.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Guaranty Unconditional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The obligations of the Company under this Guaranty shall be unconditional and absolute and, without limiting the generality of the foregoing, shall not be released, discharged or otherwise affected by&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:30.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;any extension, renewal, settlement, compromise, waiver or release in respect of any obligation of any Borrowing Subsidiary under this Agreement, by operation of law or otherwise&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;any modification or amendment of or supplement to this Agreement&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:33.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;any release, non-perfection or invalidity of any direct or indirect security for any obligation of any Borrowing Subsidiary under this Agreement&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:38.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;the failure of the Administrative Agent or any Bank to assert any claim or demand or to enforce any right or remedy against any Borrowing Subsidiary, the Company or any other Person under the provisions of this Agreement or any other agreement or otherwise&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;any change in the corporate existence, structure or ownership of any Borrowing Subsidiary or any insolvency, bankruptcy, reorganization or other similar proceeding affecting any Borrowing Subsidiary or its assets or any resulting release or discharge of any obligation of any Borrowing Subsidiary contained in this Agreement&#59;</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">74</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:36.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;the existence of any claim, set-off or other rights which the Company may have at any time against any other Borrower, the Administrative Agent, any Bank or any other Person, whether in connection herewith or any unrelated transactions&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:23.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;the invalidity or unenforceability relating to or against any Borrowing Subsidiary for any reason of this Agreement, or any provision of applicable law or regulation purporting to prohibit the payment by any Borrowing Subsidiary of the principal of or interest on any Advance or any other amount payable by any Borrowing Subsidiary under this Agreement, or the termination of any Borrowing Subsidiary&#8217;s status as a Borrowing Subsidiary hereunder&#59;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:26.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;the termination of a Borrowing Subsidiary&#8217;s status hereunder as a &#8220;Borrower&#8221; pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; or</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:30.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any other act or omission to act or delay of any kind by any Borrowing Subsidiary, the Administrative Agent, any Bank or any other Person or any other circumstance whatsoever which might, but for the provisions of this paragraph, constitute a legal or equitable discharge of the obligations of the Company hereunder.</font></div><div style="margin-top:11.7pt;padding-left:16.55pt;padding-right:20.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations of the Company under this Guaranty shall not be subject to any reduction, limitation, impairment or termination for any reason, including, without limitation, any claim of waiver, release, surrender, alteration or compromise of any of the Borrowing Subsidiary Obligations, and shall not be subject to any defense or set-off, counterclaim, recoupment or termination whatsoever by reason of the invalidity, illegality or unenforceability of any of the Borrowing Subsidiary Obligations, discharge of any Borrowing Subsidiary from any of the Borrowing Subsidiary Obligations in a bankruptcy or similar proceeding, or otherwise. Without limiting the generality of the foregoing, the obligations of the Company under this Guaranty shall not be discharged or impaired or otherwise affected by the failure of the Administrative Agent or any Bank to assert any claim or demand or to enforce any remedy under this Agreement or any document or instrument executed by any Borrowing Subsidiary in connection herewith, by any waiver or modification of any thereof, by any default, failure or delay, willful or otherwise, in the performance of the Borrowing Subsidiary Obligations, or by any other act or thing or omission or delay to do any other act or thing which may or might in any manner or to any extent vary the risk of the Company or which would otherwise operate as a discharge of the Company as a matter of law or equity.</font></div><div style="margin-top:10.95pt;padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Discharge Only Upon Payment in Full&#59; Reinstatement in Certain</font></div><div style="margin-top:0.3pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Circumstances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The obligations of the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall remain in full force and effect until the Commitment shall have terminated, all Letters of Credit have expired and the principal of and interest on the Advances and all other amounts payable by the Borrowers under this Agreement shall have been paid in full other than indemnity obligations for which no claim has been made. If at any time any payment of the principal of or interest on any Advance or any other amount payable by the Borrowers under this Agreement is rescinded or must be otherwise restored or returned upon the insolvency, bankruptcy or reorganization of any Borrower or otherwise, the obligations of the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall be reinstated as though such payment had been due but not made at such time.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">75</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.05pt;padding-left:16.55pt;padding-right:25.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Waivers by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> With respect to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">, the Company hereby waives for the benefit of the Administrative Agent and the Banks&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;any right to require the Administrative Agent or any Bank, as a condition of payment or performance by the Company under this Guaranty to (i) proceed against any Borrowing Subsidiary, any other guarantor of the obligations of any Borrowing Subsidiary under any other agreement or guaranty or any other Person, (ii) proceed against or exhaust any security held from any Borrowing Subsidiary, any other guarantor or any other Person, or (iii) pursue any other remedy in the power of the Administrative Agent or any Bank whatsoever&#59;</font></div><div style="margin-top:11.6pt;padding-left:16.55pt;padding-right:43.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;any defense arising by reason of the incapacity, lack of authority or any disability or other defense of any Borrowing Subsidiary including, without limitation, any defense based on or arising out of the lack of validity or unenforceability of the Borrowing Subsidiary Obligations or any agreement or instrument relating thereto or by reason of the cessation from any cause of the liability of any Borrowing Subsidiary other than indefeasible payment in full of the Borrowing Subsidiary Obligations&#59;</font></div><div style="margin-top:11.6pt;padding-left:16.55pt;padding-right:24.75pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;any defense based upon any statute or rule of law which provides that the obligation of a surety must be neither larger in amount nor in other respects more burdensome than that of the principal, or based upon the Administrative Agent&#8217;s or any Bank&#8217;s errors or omissions in the administration of the Borrowing Subsidiary Obligations, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> behavior which amounts to bad faith&#59;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:24.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;any (i) principles or provisions of law, statutory or otherwise, which are or might be in conflict with the terms of this Guaranty, any legal or equitable discharge of its obligations hereunder and the benefit of any statute of limitations affecting its liability hereunder or the enforcement thereof, (ii) rights to set-offs, recoupments and counterclaims, (iii) rights to deferral or modification of the Company&#8217;s obligations hereunder by reason of any bankruptcy, reorganization, arrangement, moratorium or other debtor relief proceeding, (iv) promptness, diligence and any requirement that the Administrative Agent or any Bank protect, secure, perfect or insure any security interest or lien or any property subject thereto or exhaust any right or take any action against any Borrowing Subsidiary or any other Person or any collateral&#59;</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:30.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;notice, demand, presentment, protests, notices of protest, notices of dishonor and notices of any action or inaction, including acceptance of this Guaranty, notices of default under this Agreement or any agreement or instrument related thereto, notice of any renewal, extension or modification of the Borrowing Subsidiary Obligations or any agreement related thereto, notice of any other extension of credit to any Borrowing Subsidiary&#59; and</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:25.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;any defenses or benefits that may be derived from or afforded by law which limit the liability of or exonerates guarantors or sureties, or which may conflict with the terms of this Guaranty including, without limitation, the provisions of California Civil Code Sections 2809, 2810, 2819, 2839, 2845, 2846, 2847, 2848, 2849, 2850, 2899 and 3433. In accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below, this Agreement shall be governed by, and shall be construed and enforced in accordance with, the internal laws of the State of New York, without regard to conflicts of laws principles. This clause (f) is included solely out of an abundance of caution,</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">76</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and shall not be construed to mean that any of the above-referenced provisions of California law are in any way applicable to this Agreement or to any of the Borrowing Subsidiary Obligations.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">11.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Subrogation, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Upon payment by the Company of any sum to the Administrative Agent for the ratable benefit of any Bank as provided above, so long as any of the Borrowing Subsidiary Obligations of a Borrowing Subsidiary shall remain outstanding hereunder, all rights of the Company against such Borrowing Subsidiary arising as a result thereof, by way of right of subrogation or otherwise, shall in all respects be subordinate and junior in right of payment to the prior indefeasible payment in full of all the Borrowing Subsidiary Obligations of that Borrowing Subsidiary to the Administrative Agent and the Banks. In furtherance of the foregoing, and not in limitation thereof, the Company agrees that until the Borrowing Subsidiary Obligations of a Borrowing Subsidiary shall have been paid in full, the Commitment has terminated and all Letters of Credit issued for the account of such Borrowing Subsidiary have expired, the Company shall withhold exercise of any right of subrogation, or any right to enforce any remedy which the Administrative Agent or any Bank may have against that Borrowing Subsidiary. If any amount shall be paid to the Company on account of such subrogation rights at any time prior to the date when the Borrowing Subsidiary Obligations of such Borrowing Subsidiary have been paid in full, the Commitment has terminated and all Letters of Credit issued for the account of such Borrowing Subsidiary have expired, such amount shall be held in trust for the benefit of the Banks and shall be paid to the Administrative Agent for the benefit of the Banks to be credited and applied upon the Borrowing Subsidiary Obligations of such Borrowing Subsidiary, whether matured or unmatured, in accordance with the terms of the Credit Agreement or to be held by the Administrative Agent for the benefit of the Banks as collateral security for any Obligations thereafter existing.</font></div><div><font><br></font></div><div style="padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 12 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">ARTICLE 12</font></div><div style="margin-top:0.3pt;padding-left:17.92pt;padding-right:17.92pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:line-through">Additional Borrowers&#59; Termination of Borrowers</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">ADDITIONAL BORROWERS&#59;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">TERMINATION OF BORROWERS</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:26.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Agreement to Participate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Any Eligible Subsidiary may become a party to this Agreement and become a &#8220;Borrower&#8221; for all purposes hereof on any date after the date hereof upon not less than 10 Banking Days notice to the Administrative Agent (which shall give prompt written notice thereof to each Bank) and upon the satisfaction of the following conditions&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:21.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;receipt by the Administrative Agent on or before such date of an Agreement to Participate executed by such Eligible Subsidiary and acknowledged and consented to by the Administrative Agent (which consent shall not be unreasonably withheld)&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:32.15pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;receipt by the Administrative Agent of a certificate dated such date from a Senior Officer of such Eligible Subsidiary to the effect that (i) no Default has occurred and is continuing on such date, (ii) the representations and warranties of such Eligible Subsidiary and its Subsidiaries contained in the Agreement to Participate executed by such Eligible Subsidiary are true, correct and complete in all material respects on and as of such date, and (iii) such Eligible Subsidiary is a wholly-owned Subsidiary&#59;</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">77</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.5pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;receipt by the Administrative Agent on or before such date of such additional documents it may reasonably request relating to the existence of such Eligible Subsidiary, the organizational power and authority of such Eligible Subsidiary, the validity of such Eligible Subsidiary&#8217;s obligations under the Agreement to Participate executed by such Eligible Subsidiary and under this Agreement, and other matters relevant thereto and hereto, all in form and substance satisfactory to the Administrative Agent&#59;</font></div><div style="margin-top:11.55pt;padding-left:16.55pt;padding-right:32.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;if requested in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, receipt by the Administrative Agent on or before such date of the Notes dated such date and executed by such Eligible Subsidiary, one Note in favor of each Bank in a principal amount equal to that Bank&#8217;s Pro Rata Share of the Commitment&#59; and</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:26.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;in the case of an Eligible Subsidiary that qualifies as a &#8220;legal entity customer&#8221; under the Beneficial Ownership Regulation, a duly executed and completed Beneficial Ownership Certification.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Following the giving of any notice pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if the designation of such Subsidiary as a Borrowing Subsidiary obligates the Administrative Agent or any Bank to comply with &#8220;know your customer&#8221; or similar identification procedures in circumstances where the necessary information is not already available to it, the Company shall, promptly upon the request of the Administrative Agent or any Bank, supply such documentation and other evidence as is reasonably requested by the Administrative Agent or any Bank in order for the Administrative Agent or such Bank to carry out and be satisfied it has complied with the results of all necessary &#8220;know your customer&#8221; or other similar checks under all applicable laws and regulations.</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company shall designate as a Borrowing Subsidiary hereunder any Subsidiary not organized under the laws of the United States or any State thereof, any Bank may, with notice to the Administrative Agent and the Company, fulfill its Pro Rata Share of the Commitment by causing an Affiliate or branch of such Bank to act as the Bank in respect of such Borrowing Subsidiary.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as practicable after receiving notice from the Company or the Administrative Agent of the Company&#8217;s intent to designate a Subsidiary as a Borrowing Subsidiary, and in any event no later than five Banking Days after the delivery of such notice, for a Borrowing Subsidiary that is organized under the laws of a jurisdiction other than of the United States or a political subdivision thereof, any Bank that may not legally lend to, establish credit for the account of and&#47;or do any business whatsoever with such Borrowing Subsidiary directly or through an Affiliate of such Bank as provided in the immediately preceding paragraph (a&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Protesting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) shall so notify the Company and the Administrative Agent in writing. With respect to each Protesting Lender, the Company shall, effective on or before the date that such Borrowing Subsidiary shall have the right to borrow hereunder, either (A) notify the Administrative Agent and such Protesting Lender that the Pro Rata Share of the Commitment of such Protesting Lender shall be terminated&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such Protesting Lender shall have received payment of an amount equal to the outstanding principal of its Advances and&#47;or Letter of Credit reimbursement obligations, accrued interest thereon, accrued fees and all other amounts payable to it hereunder, from the assignee (to the extent of such outstanding principal and</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">78</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:26.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accrued interest and fees) or the Company or the relevant Borrowing Subsidiary (in the case of all other amounts), or (B) cancel its request to designate such Subsidiary as a &#8220;Borrowing Subsidiary&#8221; hereunder.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Bank hereby authorizes the Administrative Agent to sign on such Bank&#8217;s behalf an Agreement to Participate delivered pursuant to clause (a) above, and the Company and each Bank hereby agree that, upon satisfaction by any Eligible Subsidiary of the conditions set forth in this Section 12.1, such Eligible Subsidiary shall become a &#8220;Borrower&#8221; hereunder for all purposes hereof. The Administrative Agent shall promptly notify the Banks of whenever an Eligible Subsidiary becomes a Borrower.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Any Borrower, other than the Company, that has no Advances outstanding to any Bank and is not the account party on any Letter of Credit, may cease to be a &#8220;Borrower&#8221; for the purposes of this Agreement (and all commitments as to such Borrower shall thereupon terminate) upon notice, in form and substance satisfactory to the Administrative Agent, by such Borrower to the Administrative Agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that such notice shall not affect any obligation of such Borrower theretofore incurred. The Administrative Agent shall send prompt written notice to each Bank of any Borrower ceasing, pursuant to this subsection, to be a Borrower.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">75</font></div><div style="padding-left:164.1pt;padding-right:164.1pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">ARTICLE 13 </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">ARTICLE 13</font></div><div style="margin-top:0.3pt;padding-left:164.02pt;padding-right:164.02pt;text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Miscellaneous</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cumulative Remedies&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"> No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> . The rights, powers, privileges and remedies of the Administrative Agent, the Issuing Banks and the Banks provided herein or in any Note or other Loan Document are cumulative and not exclusive of any right, power, privilege or remedy provided by Law or equity. No failure or delay on the part of the Administrative Agent, any Issuing Bank or any Bank in exercising any right, power, privilege or remedy may be, or may be deemed to be, a waiver thereof&#59; nor may any single or partial exercise of any right, power, privilege or remedy preclude any other or further exercise of the same or any other right, power, privilege or remedy. The terms and conditions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> hereof are inserted for the sole benefit of the Administrative Agent, the Issuing Banks and the Banks&#59; the same may be waived in whole or in part, with or without terms or conditions, in respect of any Loan or Letter of Credit without prejudicing the Administrative Agent&#8217;s, either Issuing Bank&#8217;s or the Banks&#8217; rights to assert them in whole or in part in respect of any other Loan or Letter of Credit.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:24.15pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendments&#59; Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No amendment, modification, supplement, extension, termination or waiver of any provision of this Agreement or any other Loan Document, no approval or consent thereunder, and no consent to any departure by any Borrower or any other party therefrom, may in any event be effective unless the same shall be in writing and signed by the Majority Banks (or signed by the Administrative Agent at the direction of the Majority Banks) (and, in the case of amendments, modifications or supplements of or to any Loan Document to which a Borrower is a party, the approval in writing of such Borrower), and then only in the specific instance and for the specific purpose given&#59; and, without the approval in writing of all the Banks directly and adversely affected by such amendment, modification,</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">79</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supplement, termination, waiver or consent, no amendment, modification, supplement, termination, waiver or consent may be effective&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27.5pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;To increase any Bank&#8217;s Pro Rata Share of the Commitment (other than expressly set forth in the definition of &#8220;Pro Rata Share&#8221;) extend scheduled payment dates of any Loan or Note beyond the Maturity Date, or reduce the rate of interest (other than any waiver of any increase in the interest rate applicable to any of the Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) or fees in respect of the Commitment, the Loans or the Letters of Credit, or extend the time of payment of principal, reimbursement obligations under Letters of Credit, interest or fees, or reduce the principal amount of the Obligations&#59;</font></div><div style="margin-top:11.55pt;padding-left:16.55pt;padding-right:50.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;To amend or modify the provisions of the definitions of &#8220;Maturity Date&#8221; (except to the extent permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), or &#8220;Majority Banks&#8221; or of this Section&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:106.05pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;To release the Company as guarantor&#59; or</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:31.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;To amend or modify any provision of this Agreement that expressly requires the consent or approval of all the Banks.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, no amendment, modification, supplement, termination, waiver or consent shall, unless in writing and signed by the Administrative Agent in addition to the Banks required above to take such action, affect the rights or duties of the Administrative Agent acting in such capacity under this Agreement or any Note. No amendment, modification, supplement, termination, waiver or consent shall, unless in writing and signed by each Issuing Bank, affect any provisions hereof relating to the Letters of Credit. Any amendment, modification, supplement, termination, waiver or consent pursuant to this Section shall apply equally to, and shall be binding upon, all the Banks, the Issuing Banks, the Administrative Agent and each Borrower. Copies of all amendments, modifications, supplements, terminations, waivers and consents shall be distributed to the Administrative Agent, each Bank, each Issuing Bank and each Borrower.</font></div><div style="margin-top:11.7pt;padding-left:16.55pt;padding-right:21.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Costs, Expenses and Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Company shall pay on demand the reasonable costs and expenses</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">of each Arranger, the Administrative Agent and the Syndication Agent in connection with the negotiation, preparation, execution and delivery of the Loan Documents (including, without limitation, the reasonable legal fees and out-of-pocket expenses of Shearman &#38; Sterling LLP), and, (b) if a Borrower requests the amendment, waiver, supplement or modification the Loan Documents, of the Administrative Agent and any Issuing Bank in connection with any such amendment, waiver, supplement or modification (including, without limitation, the reasonable legal fees and out-of-pocket expenses of counsel to the Administrative Agent and such Issuing Bank), and (c) if any Event of Default has occurred and is continuing, of the Administrative Agent, the Issuing Banks and the Banks in connection with any workout, restructuring, reorganization (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> a bankruptcy reorganization) and in any event enforcement or attempted enforcement of the Loan Documents, and any matter related thereto, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, without limitation, out-of-pocket expenses and the reasonable fees and out-of-pocket expenses of any legal counsel, independent public accountants and other outside experts retained by the Administrative Agent, any Issuing Bank or any Bank, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, without limitation, any costs, expenses or fees incurred or suffered by the Administrative Agent, any Issuing Bank or any Bank in connection with or during the course of any bankruptcy or insolvency</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">80</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceedings of the Company or any Subsidiary thereof. The Company shall pay any and all costs, expenses, fees and charges payable or determined to be payable in connection with the filing or recording of this Agreement, any other Loan Document or any other instrument or writing to be delivered hereunder or thereunder, or in connection with any transaction pursuant hereto or thereto, and shall reimburse, hold harmless and indemnify the Arrangers, the Administrative Agent, the Syndication Agent, the Issuing Banks and the Banks from and against any and all loss, liability or legal or other expense with respect to or resulting from any delay in paying or failure to pay any such tax, cost, expense, fee or charge or that any of them may suffer or incur by reason of the failure of any party (other than any Arranger, the Administrative Agent, the Syndication Agent, any Issuing Bank or any Bank) to perform any of its Obligations. This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply to the extent that any loss, liability or expense relates to any Taxes (including withholding Taxes and Other Taxes) for which there may be an indemnification, reimbursement or other payment obligation imposed on the Company pursuant to any other provision of this Agreement (including, without limitation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="margin-top:11.45pt;padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Obligation to Make Payments in Dollars or Alternative Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The obligation of the Borrowers to make payments in Dollars or the Alternative Currency of the principal and interest becoming due and payable on each Loan, and to pay all other Obligations hereunder in Dollars, (i) shall not be discharged or satisfied by any tender, or any recovery pursuant to any judgment, which is expressed in or converted into any currency other than Dollars or the Alternative Currency, as applicable, except to the extent that such tender or recovery shall result in the actual receipt by the Administrative Agent, the Banks and the Issuing Banks of the full amount of Dollars or the Alternative Currency, as applicable, expressed to be payable in respect of the principal and interest of each Loan and in respect of each other Obligation, (ii) shall be enforceable as an alternative or additional cause of action for the purpose of recovering in Dollars or the Alternative Currency, as applicable, the amount, if any, by which such actual receipt shall fall short of the full amount of Dollars or the Alternative Currency, as applicable, so expressed to be payable and (iii) shall not be affected by judgment being obtained for any other sum due under this Agreement.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:30.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Nature of Banks&#8217; Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The obligations of the Banks hereunder are several and not joint or joint and several. Nothing contained in this Agreement or any other Loan Document and no action taken by the Administrative Agent, the Issuing Banks or the Banks or any of them pursuant hereto or thereto may, or may be deemed to, make the Banks a partnership, an association, a joint venture or other entity, either among themselves or with the Company or any Affiliate of the Company. Each Bank&#8217;s obligation to make any Advance pursuant hereto is several and not joint or joint and several, and is not conditioned upon the performance by all other Banks of their obligations to make Advances.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:21.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> All representations and warranties contained herein or in any other Loan Document, or in any certificate or other writing delivered by or on behalf of any one or more of the parties to any Loan Document, will survive the making of the Advances hereunder and the execution and delivery of the Notes, and have been or will be relied upon by the Administrative Agent, each Issuing Bank and each Bank, notwithstanding any investigation made by the Administrative Agent, any Issuing Bank or any Bank or on their behalf. The obligations of the Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall survive for thirty (30) days following the termination of this Agreement and the repayment of the Notes. The obligations of</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">81</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of this Agreement and the repayment of the Notes, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such obligations shall not, from and after the termination of this Agreement, be deemed to be Obligations for any purpose under the Loan Documents.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notices and Other Communications&#59; Facsimile Copies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:21.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in paragraph (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by facsimile or other electronic communication as follows&#58;</font></div><div style="margin-top:11.65pt;padding-left:52.35pt;padding-right:22.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;if to any Borrower or the Company, the Administrative Agent or any Issuing Bank, to the address, facsimile number, electronic mail address or telephone number specified for such Person on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or to such other address, facsimile number, electronic mail address or telephone number as shall be designated by such party in a notice to the other parties&#59; and</font></div><div style="margin-top:11.6pt;padding-left:52.35pt;padding-right:33.9pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;if to any other Bank, to the address, facsimile number, electronic mail address or telephone number specified in its Administrative Questionnaire.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.2pt;text-indent:74.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received&#59; notices sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next business day for the recipient). Notices delivered through electronic communications, to the extent provided in paragraph (b) below, shall be effective as provided in said paragraph (b).</font></div><div style="margin-top:11.6pt;padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notices and other communications to the Banks and the Issuing Banks hereunder may be delivered or furnished by electronic communication (including e mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the foregoing shall not apply to notices to any Bank or Issuing Bank pursuant to Article 2 if such Bank or Issuing Bank, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Article 2 by electronic communication. The Administrative Agent or the Company may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that approval of such procedures may be limited to particular notices or communications.</font></div><div style="margin-top:11.35pt;padding-left:16.55pt;padding-right:23.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender&#8217;s receipt of an acknowledgement from the intended recipient (such as by the &#8220;return receipt requested&#8221; function, as available, return e-mail or other written acknowledgement), and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient, at its e-mail address as described in the foregoing clause (i) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, of notification that such notice or communication is available and identifying the website address</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">82</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therefor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, for both clauses (i) and (ii) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if such notice, email or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:30.1pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Address, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any party hereto may change its address or facsimile number for notices and other communications hereunder by notice to the other parties hereto.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:104.95pt;text-indent:-16.85pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.6pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of the Borrowers agrees that the Administrative Agent may, but shall not be obligated to, make the Communications available to the Issuing Banks and the Banks by posting the Communications on Debt Domain, Intralinks, Syndtrak or a substantially similar electronic transmission systems (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:29.4pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE PLATFORM IS PROVIDED &#8220;AS IS&#8221; AND &#8220;AS AVAILABLE&#8221;. THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OF THE PLATFORM AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS OR OMISSIONS IN THE COMMUNICATIONS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,</font></div><div style="padding-left:16.55pt;padding-right:23.4pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">NON-INFRINGEMENT</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NON-INFRINGEMENT</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY THE AGENT PARTIES IN CONNECTION WITH THE COMMUNICATIONS OR THE PLATFORM. IN NO EVENT SHALL THE ADMINISTRATIVE AGENT OR ANY OF ITS AFFILIATES OR ANY OF THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, ADVISORS OR REPRESENTATIVES (COLLECTIVELY, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGENT PARTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) HAVE ANY LIABILITY TO THE COMPANY, ANY OTHER BORROWER, ANY BANK OR ANY OTHER PERSON OR ENTITY FOR DAMAGES OF ANY KIND, INCLUDING, WITHOUT LIMITATION, DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES (WHETHER IN TORT, CONTRACT OR OTHERWISE) ARISING OUT OF ANY BORROWER&#8217;S OR THE ADMINISTRATIVE AGENT&#8217;S TRANSMISSION</font></div><div style="padding-left:16.55pt;padding-right:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OF COMMUNICATIONS THROUGH THE PLATFORM. &#8220;Communications&#8221; means, collectively, any notice, demand, communication, information, document or other material that any Borrower provides to the Administrative Agent pursuant to any Loan Document or the transactions contemplated therein which is distributed to the Administrative Agent, any Bank or any Issuing Bank by means of electronic communications pursuant to this Section, including through the Platform.</font></div><div style="margin-top:10.9pt;padding-left:16.55pt;padding-right:27.15pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Execution of Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Unless the Administrative Agent otherwise specifies with respect to any Loan Document, this Agreement and any other Loan Document may be executed in any number of counterparts and any party hereto or thereto may execute any counterpart, each of which when executed and delivered will be deemed to be an original and all of which counterparts of this Agreement or any other Loan Document, as the case may be, when taken together will be deemed to be but one and the same instrument. The execution of this Agreement or any other Loan Document by any party hereto or thereto will not</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">83</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become effective until counterparts hereof or thereof, as the case may be, have been executed by all the parties hereto or thereto.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Bi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">nding Effect&#59; Assignment&#59; Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:28.8pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement and the other Loan Documents shall be binding upon and shall inure to the benefit of the parties hereto and thereto and their respective successors and assigns, except that a Borrower, the Company and&#47;or their respective Affiliates may not assign their rights hereunder or thereunder or any interest herein or therein without the prior written consent of all the Banks.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:23.85pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Assignments by Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any Bank may at any time assign to one or more assignees all or a portion of its rights and obligations under this Agreement (including all or a portion of its Pro Rata Share of the Commitment and the Loans at the time owing to it or, in the case of an Issuing Bank, its unused LC Commitment)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that any such assignment shall be subject to the following conditions&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:102.35pt;text-indent:-14.25pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Minimum Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:21.05pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(A)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(A)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the case of an assignment of the entire remaining amount of the assigning Bank&#8217;s Pro Rata Share of the Commitment and&#47;or the Loans at the time owing to it or contemporaneous assignments to related Approved Funds that equal at least the amount specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in the aggregate or in the case of an assignment to a Bank, an Affiliate of a Bank or an Approved Fund, no minimum amount need be assigned&#59; and</font></div><div style="margin-top:11.6pt;padding-left:88.15pt;padding-right:21.15pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(B)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(B)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in any case not described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the aggregate amount of the Pro Rata Share of the Commitment (which for this purpose includes Loans outstanding thereunder) or, if the Commitment is not then in effect, the principal outstanding balance of the Advances of the assigning Bank subject to each such assignment (determined as of the date the Assignment Agreement with respect to such assignment is delivered to the Administrative Agent or, if &#8220;Trade Date&#8221; is specified in the Assignment Agreement, as of the Trade Date) or the amount of the unused LC Commitment assigned shall not be less than $5,000,000 and assigned amounts must be in increments of $1,000,000 unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Company otherwise consents in writing (each such consent not to be unreasonably withheld or delayed).</font></div><div style="margin-top:11.25pt;padding-left:16.55pt;padding-right:36.1pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Proportionate Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Bank&#8217;s rights and obligations under this Agreement with respect to the Loan or the Commitment assigned.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:61.8pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Required Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;No consent shall be required for any assignment except to the extent required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and, in addition&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:88.15pt;padding-right:59.05pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(A)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(A)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the written consent of the Company (such consent not to be unreasonably withheld or delayed) shall be required unless (x) an Event of</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">84</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:88.15pt;padding-right:26.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Default under Section 9.1(a), (b) or (i) has occurred and is continuing at the time of such assignment, or (y) such assignment is to a Bank, an Affiliate of a Bank or an Approved Fund&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:37.35pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(B)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(B)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the written consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required if such assignment is to a Person that is not a Bank, an Affiliate of such Bank or an Approved Fund&#59; and</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:88.15pt;padding-right:42.5pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(C)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(C)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the written consent of each Issuing Bank (such consent not to be unreasonably withheld or delayed) shall be required for any assignment (other than an assignment of unused LC Commitment).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iv)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assignment and Assumption. The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment Agreement, together with a processing and recordation fee of $3,500&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment. The assignee, if it is not a Bank, shall deliver to the Administrative Agent an Administrative Questionnaire.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:104.95pt;text-indent:-16.85pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(v)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(v)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">No Assignment to Certain Persons. No such assignment shall be made to</font></div><div style="padding-left:16.55pt;padding-right:28.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;the Borrowers or any Borrower&#8217;s Affiliates or Subsidiaries or (B) to any Defaulting Bank or Potential Defaulting Bank or any of their respective Subsidiaries, or any Person who, upon becoming a Bank hereunder, would constitute any of the foregoing Persons described in this clause (B).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:22.25pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(vi)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Assignment to Natural Persons. No such assignment shall be made to a natural Person.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:25.95pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(vii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(vii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Provision of Tax Forms. The documentation required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to such assignee shall have been provided to the Company and the Administrative Agent.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:16.55pt;padding-right:23.55pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(viii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(viii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In connection with any assignment of rights and obligations of any Defaulting Bank hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Company and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Bank, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Bank to the Administrative Agent, each Issuing Bank and each other Bank hereunder (and interest accrued thereon), and (y) acquire (and fund as appropriate) its full pro rata share of all Loans and participations in Letters of Credit in accordance with its Pro Rata Share. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Bank hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">85</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the assignee of such interest shall be deemed to be a Defaulting Bank for all purposes of this Agreement until such compliance occurs.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:10.85pt;padding-right:17.05pt;text-indent:77.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to acceptance and recording thereof by the Administrative Agent pursuant to Section 13.9(g), from and after the effective date specified in each Assignment Agreement, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment Agreement, have the rights and obligations of a Bank under this Agreement, and the assigning Bank thereunder shall, to the extent of the interest assigned by such Assignment Agreement, be released from its obligations under this Agreement (and, in the case of an Assignment Agreement covering all of the assigning Bank&#8217;s rights and obligations under this Agreement, such Bank shall cease to be a party hereto) but shall continue to be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.12(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to facts and circumstances occurring prior to the effective date of such assignment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting Bank will constitute a waiver or release of any claim of any party hereunder arising from that Bank&#8217;s having been a Defaulting Bank. Any assignment or transfer by a Bank of rights or obligations under this Agreement that does not comply with this paragraph shall be treated for purposes of this Agreement as a sale by such Bank of a participation in such rights and obligations in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:11.35pt;padding-left:16.55pt;padding-right:21.9pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Participations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Any Bank may at any time, without the consent of, or notice to, the Borrowers or the Administrative Agent, sell participations to any Person (other than a natural Person or the Borrowers or any Borrower&#8217;s Affiliates or Subsidiaries) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) in all or a portion of such Bank&#8217;s rights and&#47;or obligations under this Agreement (including all or a portion of its Pro Rata Share of the Commitment and&#47;or the Loans owing to it)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that (i) such Bank&#8217;s obligations under this Agreement shall remain unchanged, (ii) such Bank shall remain solely responsible to the other parties hereto for the performance of such obligations, and (iii) the Borrowers, the Administrative Agent, the Issuing Banks and Banks shall continue to deal solely and directly with such Bank in connection with such Bank&#8217;s rights and obligations under this Agreement. For the avoidance of doubt, each Bank shall be responsible for the indemnity under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> with respect to any payments made by such Bank to its Participant(s).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24.25pt;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any agreement or instrument pursuant to which a Bank sells such a participation shall provide that such Bank shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such agreement or instrument may provide that such Bank will not, without the consent of the Participant, agree to any amendment, modification or waiver described in clauses (a) and (b) (in the case of such clause (b), solely with respect to amendments or modifications of the provisions of the definition of &#8220;Maturity Date&#8221;) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that directly and adversely affects such Participant. The Borrowers agree that each Participant shall be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.12(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the same extent as if it were a Bank and had acquired its interest by assignment pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such Participant agrees to be subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as if it were an assignee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the extent permitted by Law, each Participant also shall be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">86</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">though it were a Bank&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such Participant agrees to be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as though it were a Bank.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:29.5pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(d)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(d)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Limitations upon Participant Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Unless the Company otherwise agrees in writing, a Participant shall not be entitled to receive any greater payment under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">3.12(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> than the applicable Bank would have been entitled to receive with respect to the participation sold to such Participant. A Participant shall not be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.12(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> with respect to United States withholding tax unless the Company is notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Borrowers, to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> as though it were a Bank.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:23.9pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(e)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(e)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each Bank that sells a participation, acting solely for this purpose as a non-fiduciary agent of the Borrowers (and such agency being solely for tax purposes), shall maintain a register for the recordation of the name and address of each Participant and the principal amounts (and stated interest) of each Participant&#8217;s interest in its rights and other obligations under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that no Bank shall have any obligation to disclose all or any portion of the Participation Register to any Person (including the identity of any participant or any information relating to a participant&#8217;s interest in any commitments, loans, letters of credit or its other obligations under this Agreement) except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Bank shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(f)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(f)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Certain Pledges. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Any Bank may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Bank, including any pledge or assignment to secure obligations to a Federal Reserve Bank or any central bank having jurisdiction over such Bank&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that no such pledge or assignment shall release such Bank from any of its obligations hereunder or substitute any such pledgee or assignee for such Bank as a party hereto.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:24pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(g)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(g)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">The Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Borrowers, shall maintain at one of its offices in the address referred to in Section 13.7 a copy of each Assignment Agreement delivered to it and a register for the recordation of the names and addresses of the Banks, and the Pro Rata Shares of the Commitment of, and principal amounts (and stated interest) of the Loans owing to, each Bank pursuant to the terms hereof from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). The entries in the Register shall be conclusive absent manifest error, and the Borrowers, the Administrative Agent and the Banks shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Bank hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Company and any Bank, at any reasonable time and from time to time upon reasonable prior notice.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:25.7pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">13.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Setoff Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">If an Event of Default has occurred and is continuing, the Administrative Agent, each Issuing Bank and each Bank and each of its Affiliates (but only with</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">87</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the consent of the Majority Banks) is hereby authorized to the fullest extent permitted by law to setoff and apply any funds in any deposit account maintained with it by any Borrower and&#47;or any Property of any Borrower in its possession against the Obligations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that no funds in any deposit account maintained by any Borrowing Subsidiary and&#47;or any Property of any Borrowing Subsidiary shall be setoff or applied against the Obligations of the Company or any other Borrower&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that in the event that any Defaulting Bank shall exercise any such right of setoff, (a) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.10 and, pending such payment, shall be segregated by such Defaulting Bank from its other funds and deemed held in trust for the benefit of the Administrative Agent, the Issuing Banks, and the Banks, and (b) the Defaulting Bank shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Bank as to which it exercised such right of setoff.</font></div><div style="margin-top:11.4pt;padding-left:16.55pt;padding-right:23.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sharing of Setoffs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Each Bank severally agrees that if it, through the exercise of any right of setoff, banker&#8217;s lien or counterclaim against any Borrower, or otherwise, receives payment, through any means, of the Obligations held by it that is in excess of that Bank&#8217;s proportionate share of the Total Outstandings as applied to such payment, then&#58; (a) the Bank exercising the right of setoff, banker&#8217;s lien or counterclaim or otherwise receiving such payment shall purchase, and shall be deemed to have simultaneously purchased, from the other Bank a participation in the Obligations held by the other Bank and shall pay to the other Bank a purchase price in an amount so that the share of the Obligations held by each Bank after the exercise of the right of setoff, banker&#8217;s lien or counterclaim or receipt of payment shall be in the same proportion that existed prior to the exercise of the right of setoff, banker&#8217;s lien or counterclaim or receipt of payment&#59; and (b) such other adjustments and purchases of participations shall be made from time to time as shall be equitable to ensure that all of the Banks share any payment obtained in respect of the Obligations ratably in accordance with each Bank&#8217;s share of the Obligations immediately prior to, and without taking into account, the payment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, if all or any portion of a disproportionate payment obtained as a result of the exercise of the right of setoff, banker&#8217;s lien, counterclaim or otherwise is thereafter recovered from the purchasing Bank by any Borrower or any Person claiming through or succeeding to the rights of any Borrower, the purchase of a participation shall be rescinded and the purchase price thereof shall be restored to the extent of the recovery, but without interest. Each Bank that purchases a participation in the Obligations pursuant to this Section shall from and after the purchase have the right to give all notices, requests, demands, directions and other communications under this Agreement with respect to the portion of the Obligations purchased to the same extent as though the purchasing Bank were the original owner of the Obligations purchased. Each Borrower expressly consents to the foregoing arrangements and agrees that any Bank holding a participation in an Obligation so purchased may exercise any and all rights of setoff, banker&#8217;s lien or counterclaim with respect to the participation as fully as if the Bank were the original owner of the Obligation purchased&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that each Bank agrees that it shall not exercise any right of setoff, banker&#8217;s lien or counterclaim without first obtaining the consent of the Majority Banks.</font></div><div style="margin-top:10.2pt;padding-left:16.55pt;padding-right:28.1pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Indemnity by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company agrees to indemnify, save and hold harmless each Arranger, each Issuing Bank, the Administrative Agent, the Syndication Agent and each Bank and their respective Related Parties (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">88</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and against&#58; (a) any and all claims, demands, actions or causes of action asserted by any third party or by the Company or any Borrower if the claim, demand, action or cause of action arises out of or relates to the Commitment, the use or contemplated use of proceeds of any Advance, any drawing under any Letter of Credit, any transaction contemplated by this Agreement, or any relationship or relationship alleged to exist by any Borrower, its Affiliates or any other third party of any Indemnitee to any Borrower related to this Agreement&#59; (b) any administrative or investigative proceeding by any Governmental Agency arising out of or related to a claim, demand, action or cause of action described in clause (a) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and (c) any and all liabilities, losses, costs or expenses (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> reasonable attorneys&#8217; fees and disbursements and other professional services) that any Indemnitee suffers or incurs as a result of the assertion of any foregoing claim, demand, action or cause of action&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that no Indemnitee shall be entitled to indemnification for any loss caused by its own gross negligence or willful misconduct as determined by final, nonappealable judgment of a court of competent jurisdiction. If any claim, demand, action or cause of action is asserted against any Indemnitee, such Indemnitee shall promptly notify the Company, but the failure to so promptly notify the Company shall not affect the Company&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> unless such failure materially prejudices the Company&#8217;s right to participate in the contest of such claim, demand, action or cause of action, as hereinafter provided. If requested by the Company in writing, such Indemnitee shall in good faith contest the validity, applicability and amount of such claim, demand, action or cause of action and shall permit the Company to participate in such contest. Any Indemnitee that proposes to settle or compromise any claim or proceeding for which the Company may be liable for payment of indemnity hereunder shall give the Company written notice of the terms of such proposed settlement or compromise reasonably in advance of settling or compromising such claim or proceeding and shall obtain the Company&#8217;s prior written consent. In connection with any claim, demand, action or cause of action covered by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> against more than one Indemnitee, all such Indemnitees shall be represented by the same legal counsel selected by the Indemnitees and reasonably acceptable to the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, if such legal counsel determines in good faith that representing all such Indemnitees would or could result in a conflict of interest under Laws or ethical principles applicable to such legal counsel or that a defense or counterclaim is available to an Indemnitee that is not available to all such Indemnitees, then to the extent reasonably necessary to avoid such a conflict of interest or to permit unqualified assertion of such a defense or counterclaim, each Indemnitee shall be entitled to separate representation by legal counsel selected by that Indemnitee and reasonably acceptable to the Company, with all such legal counsel using reasonable efforts to avoid unnecessary duplication of effort by counsel for all Indemnitees&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> further that the amount of the legal fees to be reimbursed by the Company shall be limited to an amount reasonably determined following consultation among the Company, the Administrative Agent, the Banks and their respective legal counsel, to be equal to the amount that would have been expended if the Indemnitees have been represented by one counsel. Any obligation or liability of the Company to any Indemnitee under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the expiration or termination of this Agreement and the repayment of all Advances and the payment and performance of all other Obligations owed to the Banks. In the case of an investigation, litigation or other proceeding to which the indemnity in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> applies, such indemnity shall be effective whether or not such investigation, litigation or proceeding is brought by the Company, its directors, equityholders or creditors or an Indemnitee or any other Person, whether or not any Indemnitee is otherwise a party thereto and whether or not the transactions</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:23.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contemplated hereby are consummated. This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply to the extent that the losses, claims, demands, actions, causes of action, damages, liabilities or expenses relate to any Taxes (including withholding Taxes and Other Taxes) for which there may be an indemnification, reimbursement or other payment obligation imposed on the Company or any other Borrower pursuant to any other provision of this Agreement (including, without limitation, Sections 3.8 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">). No party hereto or any Indemnitee shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby.</font></div><div style="margin-top:11.7pt;padding-left:16.55pt;padding-right:26.3pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">No Third Parties Benefited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> This Agreement is made for the purpose of defining and setting forth certain obligations, rights and duties of the Borrowers, the Administrative Agent, the Issuing Banks and the Banks in connection with the Loans, Advances and Letters of Credit, and is made for the sole benefit of the Borrowers, the Administrative Agent, the Issuing Banks and the Banks, and the Administrative Agent&#8217;s, the Issuing Banks&#8217; and the Banks&#8217; successors and assigns. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Sections 13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">13.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, no other Person shall have any rights of any nature hereunder or by reason hereof.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Each of the Administrative Agent, each Issuing Bank and each Bank agrees to hold any confidential information that it may receive from any Borrower pursuant to this Agreement in confidence&#58; except for disclosure&#58;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">to other Banks&#59;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">to legal counsel, accountants and other professional advisors to any Borrower or the Administrative Agent, any Issuing Bank or any Bank or agents involved in administration of this Agreement&#59;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">to regulatory officials having jurisdiction over the Administrative Agent, an Issuing Bank or a Bank or its Affiliates&#59;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(d)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(d)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">as required by Law or legal process or in connection with any legal proceeding to which the Administrative Agent, an Issuing Bank or a Bank and that Borrower are adverse parties&#59;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(e)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(e)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">to Affiliates of the Administrative Agent by the Administrative Agent,</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(f)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(f)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">to Affiliates of a Bank or to another financial institution, in each case, in connection with a disposition or proposed disposition to that financial institution of all or part of that Bank&#8217;s interests hereunder or a participation interest in its Advances or Letters of Credit&#59;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through">(g)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:line-through"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights and obligations under this Agreement, (ii) to any direct, indirect, actual or prospective counterparty (and its advisor) to any swap, derivative or securitization transaction related to the obligations under this Agreement or (iii) or to any credit insurance provider relating to a Borrower and its Obligations, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that such disclosure in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.14(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> is made subject to an appropriate confidentiality agreement on terms substantially similar to this Section&#59; (h) in connection with the exercise of any remedies hereunder or any other Loan Document or the enforcement of rights hereunder or thereunder&#59; or (i) with the consent of the Company. For purposes of the foregoing, &#8220;confidential information&#8221; shall mean any information respecting the Company or its Subsidiaries reasonably considered by the Company to be confidential, other than (i) information previously filed with or furnished to any Governmental Agency and available to the public, (ii) information previously published in any public medium from a source other than, directly or indirectly, that Bank, and (iii) information previously disclosed by a Borrower to any Person not associated with that Borrower without a written confidentiality agreement substantially similar to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 13.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall be</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">90</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">construed to create or give rise to any fiduciary duty on the part of the Administrative Agent, the Issuing Banks or the Banks to the Borrowers.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.25pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company and its Subsidiaries shall, at their expense and without expense to the Banks, the Issuing Banks or the Administrative Agent, do, execute and deliver such further acts and documents as any Bank, any Issuing Bank or the Administrative Agent from time to time reasonably requires for the assuring and confirming unto the Banks, the Issuing Banks or the Administrative Agent of the rights hereby created or intended now or hereafter so to be, or for carrying out the intention or facilitating the performance of the terms of any Loan Document.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:30.85pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">No Fiduciary Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Each Borrower agrees that in connection with all aspects of the transactions contemplated hereby and any communications in connection therewith, such Borrower and its Subsidiaries, on the one hand, and the Administrative Agent, Joint Lead Arrangers, Joint Book Runners, Co-Documentation Agents, Syndication Agents, Banks and Issuing Banks and their respective Affiliates, on the other hand, will have a business relationship that does not create, by implication or otherwise, any fiduciary duty on the part of the Administrative Agent, the Joint Lead Arrangers, the Joint Book Runners, the</font></div><div style="margin-top:0.2pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Co-Documentation Agents, the Syndication Agent, the Banks and the Issuing Banks or their respective Affiliates and no such duty will be deemed to have arisen in connection with any such transactions or communications. Accordingly, there may be situations where the Administrative Agent, a Joint Lead Arranger, a Joint Book Runner, a Co-Documentation Agent, the Syndication Agent, a Bank, an Issuing Bank or their Affiliates and&#47;or their clients either now have or may in the future have interests, or take actions, that may conflict with the Borrowers&#8217; and their Subsidiaries&#8217; interests.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:22.4pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This Agreement, together with the other Loan Documents, comprises the complete and integrated agreement of the parties on the subject matter hereof and supersedes all prior agreements, written or oral, on the subject matter hereof. In the event of any conflict between the provisions of this Agreement and those of any other Loan Document, the provisions of this Agreement shall control and govern&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that the inclusion of supplemental rights or remedies in favor of the Administrative Agent, the Issuing Banks or the Banks in any other Loan Document shall not be deemed a conflict with this Agreement. Each Loan Document was drafted with the joint participation of the respective parties thereto and shall be construed neither against nor in favor of any party, but rather in accordance with the fair meaning thereof.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Severability of Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Any provision in any Loan Document that is held to be inoperative, unenforceable or invalid as to any party or in any jurisdiction shall, as to that party or jurisdiction, be inoperative, unenforceable or invalid without affecting the remaining provisions or the operation, enforceability or validity of that provision as to any other party or in any other jurisdiction, and to this end the provisions of all Loan Documents are declared to be severable.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:34.8pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">13.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;text-decoration:underline">Independent Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> Each covenant in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Articles 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> is independent of the other covenants in those Articles&#59; the breach of any such covenant shall not</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">91</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be excused by the fact that the circumstances underlying such breach would be permitted by another such covenant.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:30.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Article and Section headings in this Agreement and the other Loan Documents are included for convenience of reference only and are not part of this Agreement or the other Loan Documents for any other purpose.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Time of the Essence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Time is of the essence of the Loan Documents.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:34pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK) WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.45pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Consent to Jurisdiction and Service of Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. (a) Each of the parties hereto hereby irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against any Borrower, the Administrative Agent, any Bank or any Related Party of the foregoing in any way relating to this Agreement or any other Loan Document or the transactions relating hereto, in any forum other than the courts of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State or, to the fullest extent permitted by applicable Law, in such federal court. Notwithstanding the foregoing sentence, each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:37pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By executing and delivering this agreement, each party hereto, for itself and in connection with its properties, irrevocably</font></div><div style="margin-top:5.85pt;padding-left:16.55pt;padding-right:23.85pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accepts generally and unconditionally the exclusive jurisdiction and venue of the courts of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof&#59;</font></div><div style="margin-top:5.8pt;padding-left:105.7pt;text-indent:-17.6pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waives any defense of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">forum non conveniens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-top:5.9pt;padding-left:16.55pt;padding-right:25.15pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees that service of all process in any such proceeding in any such court may be made by registered or certified mail, return receipt requested, to such party at its address as provided in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, with respect to each Borrower, service of process may be made to the Company at its address provided in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) or on the signature pages hereto&#59;</font></div><div style="margin-top:5.65pt;padding-left:16.55pt;padding-right:27.7pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iv)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees that service as provided in clause (iii) above is sufficient to confer personal jurisdiction over such party in any such proceeding in any such court, and otherwise constitutes effective and binding service in every respect&#59;</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:26.15pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(v)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(v)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees that each party hereto retains the right to serve process in any other manner permitted by law&#59; and</font></div><div style="margin-top:5.85pt;padding-left:16.55pt;padding-right:38.8pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(vi)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees that the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> relating to jurisdiction and venue shall be binding and enforceable to the fullest extent permissible under New York General Obligations Law section 5-1402 or otherwise.</font></div><div style="margin-top:5.8pt;padding-left:16.55pt;padding-right:25.15pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Borrowing Subsidiary hereby agrees that service of process may be made upon the Company and each Borrowing Subsidiary hereby irrevocably appoints the Company its authorized agent to accept such service of process, and agrees that the failure of the Company to give any notice of any such service shall not impair or affect the validity of such service or of any judgment rendered in any action or proceeding based thereon. To the extent that any Borrowing Subsidiary has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise) with respect to itself or its property, such Borrowing Subsidiary hereby irrevocably waives such immunity in respect of its obligations under this Agreement.</font></div><div style="margin-top:5.7pt;padding-left:16.55pt;padding-right:23.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY AGREES TO WAIVE ITS RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY OF THE OTHER LOAN DOCUMENTS OR ANY DEALINGS BETWEEN THEM RELATING TO THE SUBJECT MATTER OF THIS LOAN TRANSACTION OR THE LENDER&#47;BORROWER RELATIONSHIP THAT IS BEING ESTABLISHED. The scope of this waiver is intended to be all-encompassing of any and all disputes that may be filed in any court and that relate to the subject matter of this transaction, including contract claims, tort claims, breach of duty claims and all other common law and statutory claims. Each party hereto acknowledges that this waiver is a material inducement to enter into a business relationship, that each has already relied on this waiver in entering into this Agreement, and that each will continue to rely on this waiver in their related future dealings. Each party hereto further warrants and represents that it has reviewed this waiver with its legal counsel and that it knowingly and voluntarily waives its jury trial rights following consultation with legal counsel. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING (OTHER THAN BY A MUTUAL WRITTEN WAIVER SPECIFICALLY REFERRING TO THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">SECTION 13.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> AND EXECUTED BY EACH OF THE PARTIES HERETO), AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR ANY OF THE OTHER LOAN DOCUMENTS OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE LOANS MADE HEREUNDER. In the event of litigation, this Agreement may be filed as a written consent to a trial by the court.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:27.1pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Acknowledgement and Consent to Bail-In of Certain Financial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Institutions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges and accepts that, to the extent any Bank party to any Loan Document is subject to the Write-Down and Conversion Powers of a Resolution Authority, any liability of such Bank</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">93</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under or in connection with any Loan Document may be subject to Bail-In Action by the relevant Resolution Authority and acknowledges and accepts to be bound by the effect of&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:28.55pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the application of any Write-Down and Conversion Powers by a Resolution Authority to any such liabilities arising hereunder which may be payable to it by any Bank party hereto that is subject to the Write-Down and Conversion Powers of any Resolution Authority&#59; and</font></div><div id="ib6a58edfcca043b385670be29d25c61b_73"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.726%"><div style="margin-top:0.15pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.547%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.727%"></div></div><div style="padding-left:16.55pt;padding-right:28.55pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the effects of any Bail-In Action on any such liability, including, if applicable&#58;</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.726%"><div style="margin-top:0.15pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.547%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.727%"></div></div><div style="padding-left:16.55pt;padding-right:28.55pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">a reduction in full or in part or cancellation of any such liability&#59;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through">(ii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:line-through"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%;text-decoration:underline">(ii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:188%">a conversion of all, or a portion of, such liability into shares or other</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:101%">instruments of ownership that may be issued to it or otherwise conferred on it, and that such</font></div><div style="padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document&#59; or</font></div><div style="margin-top:5.8pt;padding-left:16.55pt;padding-right:35.45pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(iii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of any Resolution Authority.</font></div><div style="margin-top:5.85pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in this Section, the following terms shall have the meanings set forth</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">below&#58;</font></div><div style="margin-top:6.15pt;padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Article 55 BRRD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Article 55 of Directive 2014&#47;59&#47;EU establishing a</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">framework for the recovery and resolution of credit institutions and investment firms.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.3pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;Bail-In Action&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority with respect to any liability of any Bank party hereto that is subject to the Write-Down and Conversion Powers of such Resolution Authority.</font></div><div><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Bail-In Legislation&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means&#58;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:24.4pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect to an EEA Member Country which has implemented, or which at any time implements, Article 55 BRRD, the relevant implementing law or regulation as described in the EU Bail-In Legislation Schedule from time to time&#59; and</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:26.75pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect to any state other than such an EEA Member Country or (to the extent that the United Kingdom is not such an EEA Member Country) the United Kingdom, any analogous law or regulation from time to time which requires contractual recognition of any Write-Down and Conversion Powers contained in that law or regulation.</font></div><div><font><br></font></div><div style="padding-left:16.55pt;padding-right:22.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;EEA Financial Institution&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">94</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_76"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:16.55pt;padding-right:52.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;EEA Member Country&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:33.35pt;text-align:justify;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;EEA Resolution Authority&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;EU Bail-In Legislation Schedule&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.9pt;padding-left:16.55pt;padding-right:17.05pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">&#8220;Resolution Authority&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> means an EEA Resolution Authority or any other body which has authority to exercise any Write-down and Conversion Powers.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:21.2pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;UK Bail-In Legislation&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means (to the extent that the United Kingdom is not an EEA Member Country which has implemented, or implements, Article 55 BRRD) Part I of the United Kingdom Banking Act 2009 and any other law or regulation applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (otherwise than through liquidation, administration or other insolvency proceedings).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:88.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Write-Down and Conversion Powers&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means&#58;</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:33.1pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(a)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect to any Bail-In Legislation described in the EU Bail-In Legislation Schedule from time to time, the powers described as such in relation to that Bail-In Legislation in the EU Bail-In Legislation Schedule&#59; and</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:104.95pt;text-indent:-16.85pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in relation to any UK Bail-In Legislation or any other applicable Bail-In</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Legislation&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:138.15pt;text-indent:-14.25pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any powers under such Bail-In Legislation to cancel, transfer or</font></div><div style="padding-left:52.35pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dilute shares issued by a Person that is a bank or investment firm or other financial institution or affiliate of a bank, investment firm or other financial institution, to cancel, reduce, modify or change the form of a liability of such a Person or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that Person or any other Person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under such Bail-In Legislation that are related to or ancillary to any of those powers&#59; and</font></div><div style="margin-top:11.45pt;padding-left:105.7pt;text-indent:-17.6pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any similar or analogous powers under such Bail-In Legislation.</font></div><div style="margin-top:6.15pt;padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Judgment Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:29.35pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder in any currency (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Original Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) into another currency (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Other Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall be that at which in accordance with normal banking procedures the</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">95</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:24.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Administrative Agent or a Bank could purchase the Original Currency with such Other Currency in New York, New York on the Banking Day immediately preceding the day on which any such judgment, or any relevant part thereof, is given.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.65pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The obligations of each Borrower and the Company in respect of any sum due from it to any agent or Bank hereunder shall, notwithstanding any judgment in such Other Currency, be discharged only to the extent that on the Banking Day following receipt by such agent or Bank of any sum adjudged to be so due in such Other Currency such agent or Bank may in accordance with normal banking procedures purchase the Original Currency with such Other Currency&#59; if the Original Currency so purchased is less than the sum originally due such agent or Bank in the Original Currency, each of the Borrowers and the Company agrees, as a separate obligation and notwithstanding any such judgment, to indemnify such agent or Bank against such loss, and if the Original Currency so purchased exceeds the sum originally due to such agent or Bank in the Original Currency, such agent or Bank shall remit such excess to such Borrower or the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:123.95pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Tax Forms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11.65pt;padding-left:16.55pt;padding-right:26.15pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(i)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Bank that is not a &#8220;United States person&#8221; within the meaning of Section 7701(a)(30) of the Code (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Foreign Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall deliver to the Administrative Agent and the Company, prior to receipt of any payment (or upon accepting an assignment of an interest herein), two duly signed completed copies of either IRS Form W-8BEN or W-8BEN-E or any successor thereto (relating to such Foreign Bank and entitling it to an exemption from, or</font></div><div style="padding-left:16.55pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reduction of, withholding tax on all payments to be made to such Foreign Bank by any Borrower, the Company acting in its capacity as guarantor under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or the Administrative Agent, as applicable, pursuant to this Agreement) or IRS Form W-8ECI or any successor thereto (relating to all payments to be made to such Foreign Bank by such Borrower or the Company pursuant to this Agreement) or such other evidence satisfactory to such Borrower or the Company and the Administrative Agent that such Foreign Bank is entitled to an exemption from, or reduction of, United States withholding tax, including any exemption pursuant to Section 881(c) of the Code. Thereafter and from time to time, each such Foreign Bank shall (A) promptly submit to the Administrative Agent and the Company such additional duly completed and signed copies of one of such forms (or such successor forms as shall be adopted from time to time by the relevant United States taxing authorities) as may then be available under then current United States laws and regulations to avoid, or such evidence as is satisfactory to each Borrower, the Company and the Administrative Agent of any available exemption from or reduction of, United States withholding Taxes in respect of all payments to be made to such Foreign Bank by such Borrower or the Company pursuant to this Agreement, (B) promptly notify the Administrative Agent and the Company of any change in circumstances which would modify or render invalid any claimed exemption or reduction, and (C) take such steps as shall not be materially disadvantageous to it, in the reasonable judgment of such Bank, and as may be reasonably necessary (including the</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:106%">re-designation of its lending office) to avoid any requirement of applicable Laws that such</font></div><div style="padding-left:16.55pt;padding-right:26.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Borrower or the Company make any deduction or withholding for Taxes from amounts payable to such Foreign Bank under any Loan Document.</font></div><div style="margin-top:11.5pt;padding-left:16.55pt;padding-right:23.75pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Each Foreign Bank, to the extent it does not act or ceases to act for its own account with respect to any portion of any sums paid or payable to such Bank under any</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">96</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.6pt;padding-left:16.55pt;padding-right:23.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Loan Documents (for example, in the case of a typical participation by such Bank), shall deliver to the Administrative Agent and the Company on the date when such Foreign Bank ceases to act for its own account with respect to any portion of any such sums paid or payable, and at such other times as may be necessary in the determination of the Administrative Agent or the Company (in the reasonable exercise of their discretion), (A) two duly signed completed copies of the forms or statements required to be provided by such Bank as set forth above, to establish the portion of any such sums paid or payable with respect to which such Bank acts for its own account that is not subject to U.S. withholding Tax, and (B) two duly signed completed copies of IRS Form W-8IMY (or any successor thereto) accompanied by IRS Forms W-8BEN, W-8BEN-E, W-8ECI and&#47;or any other certificate or statement of exemption from each beneficial owner required under the Code, to establish that such Bank is not acting for its own account with respect to a portion of any such sums payable to such Bank.</font></div><div style="margin-top:11.2pt;padding-left:16.55pt;padding-right:24.4pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(b)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon the request of the Administrative Agent or the Company, each Bank that is a &#8220;United States person&#8221; within the meaning of Section 7701(a)(30) of the Code shall deliver to the Administrative Agent and the Company two duly signed completed copies of IRS Form W-9. If such Bank fails to deliver such forms, then the Administrative Agent or the Company, as applicable, may withhold from any interest payment to such Bank an amount equivalent to the applicable back-up withholding imposed by the Code. Upon the request of the Company, the Administrative Agent shall provide the Company two duly signed completed copies of IRS Form W-9.</font></div><div style="margin-top:11.5pt;padding-left:16.55pt;padding-right:21.6pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(c)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a payment made to a Bank under any Loan Document would be subject to withholding Tax imposed by FATCA if such Bank were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Bank shall deliver to the Administrative Agent and the Company, at the time or times prescribed by Law and at such time or times reasonably requested in writing by the Borrowers or the Administrative Agent, such documentation prescribed by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested in writing by the Borrowers or the Administrative Agent as may be necessary for each Borrower and the Administrative Agent to comply with their obligations under FATCA, to determine that such Bank has complied with such Bank&#8217;s obligations under FATCA or to determine the amount to deduct and withhold from such payment. For purposes of this clause (c), FATCA shall include any amendments made to FATCA after the date of this Agreement.</font></div><div style="margin-top:11.15pt;padding-left:16.55pt;padding-right:27.6pt;text-indent:71.55pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(d)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Bank agrees that if any form or certification it previously delivered becomes inaccurate in any respect, it shall update such form or certification or promptly notify the Company and the Administrative Agent in writing of its legal inability to do so. In addition, each Bank agrees that if any form or certification it previously delivered expires or becomes obsolete, upon written request by the Company or the Administrative Agent, the Bank shall update such form or certification or promptly notify the Company and the Administrative Agent in writing of its legal inability to do so.</font></div><div style="margin-top:11.5pt;padding-left:104.25pt;text-indent:-16.15pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">(e)&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(e)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Section 13.27, the term &#8220;Bank&#8221; includes any Issuing</font></div><div style="padding-left:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Bank.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.6pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">97</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_79"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:16.55pt;padding-right:40.95pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.28&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Limitation on Borrowing Subsidiary Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Notwithstanding anything herein to the contrary, no provision of this Agreement shall render any Borrowing Subsidiary liable for the Obligations of the Company or any other Borrower.</font></div><div style="padding-right:40.95pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:21.55pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.29&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Waiver of Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> To the extent permitted by applicable law, no party to this Agreement shall assert, and each party to this Agreement hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement or any agreement or instrument contemplated hereby, the transactions contemplated hereby, any Loan or Letter of Credit or the use of the proceeds thereof.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.55pt;padding-right:25.6pt;text-indent:71.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.30&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Patriot Act Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Each Bank and the Administrative Agent (for itself and not on behalf of any Bank) hereby notifies each Borrower that pursuant to the requirements of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Pub. L. 107-56, signed into law October 26, 2001 (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and the Beneficial Ownership Regulation, it is required to obtain, verify and record information that identifies each Borrower, which information includes the name and address of each Borrower and other information that will allow such Bank or the Administrative Agent, as applicable, to identify each Borrower in accordance with the Patriot Act and the Beneficial Ownership Regulation. Each Borrower shall provide such information and take such actions as are reasonably requested by the Administrative Agent or any Banks in order to assist the Administrative Agent and the Banks in maintaining compliance with the Patriot Act and the Beneficial Ownership Regulation.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Signature Pages </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Begin On Following Page</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intentionally Omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.65pt;padding-left:161.22pt;padding-right:161.22pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="ib6a58edfcca043b385670be29d25c61b_82"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SCHEDULE 2.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:6.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.047%"><tr><td style="width:1.0%"></td><td style="width:44.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bank</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commitment</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pro Rata Share</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Letter of <br>Credit Commitment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.5pt;padding-left:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Citibank, N.A.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 13.6pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$188,000,002</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5200%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$50,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JPMorgan Chase Bank, N.A.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 13.6pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$188,000,002</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5200%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$50,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bank of America, N.A.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 13.6pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$188,000,000</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5200%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$50,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Barclays Bank PLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 13.6pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$188,000,000</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5200%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$50,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Goldman Sachs Bank USA</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 13.6pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$188,000,000</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5200%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$50,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Morgan Stanley Bank, N.A.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 13.6pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$188,000,000</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5200%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$50,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BNP Paribas</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.5pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$152,444,444</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">6.0978%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.5pt;padding-left:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Credit Suisse AG, Cayman Islands Branch</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.5pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$152,444,444</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">6.0978%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.6pt;padding-left:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deutsche Bank AG, New York Branch</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.6pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$152,444,444</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.0978%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.15pt;padding-left:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HSBC Bank USA, National Association</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.15pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$152,444,444</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%">6.0978%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.25pt;padding-left:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mizuho Bank, Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.25pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$152,444,444</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%">6.0978%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.45pt;padding-left:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MUFG Bank, Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.45pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$152,444,444</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">6.0978%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.6pt;padding-left:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royal Bank of Canada</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.6pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$152,444,444</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.0978%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.05pt;padding-left:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sumitomo Mitsui Banking Corporation</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.05pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$152,444,444</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">6.0978%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.25pt;padding-left:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wells Fargo Bank, National Association</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.25pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$152,444,444</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%">6.0978%</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.4pt;padding-right:12.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$2,500,000,000</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.35pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100.0000%</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$300,000,00</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div id="ib6a58edfcca043b385670be29d25c61b_85"></div><div style="margin-top:3.6pt;padding-left:17.92pt;padding-right:17.92pt;text-align:center"><font><br></font></div><div style="padding-left:17.92pt;padding-right:17.92pt;text-align:center"><font><br></font></div><div style="padding-left:17.92pt;padding-right:17.92pt;text-align:center"><font><br></font></div><div style="padding-left:17.92pt;padding-right:17.92pt;text-align:center"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:line-through">-</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1-</font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:17.92pt;padding-right:17.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SCHEDULE 4.4</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:9.95pt;padding-right:9.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DISCLOSURE OF SUBSIDIARIES</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:18.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.929%"><tr><td style="width:1.0%"></td><td style="width:34.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Type of Entity</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:30.7pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Percentage of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Ownership</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.65pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alantos Pharmaceuticals Holdings</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Canada Inc.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen (Europe) GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">limited liability company</font></div></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Fremont Inc.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Global Finance B.V.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen GmbH Germany</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Holding No. 1 Limited</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">limited liability company</font></div></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Ilac Ticaret Limited Sirketi</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen K-A, Inc.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Manufacturing, Limited</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Research (Munich) GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">limited liability company</font></div></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Rockville, Inc.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen S.A.S.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.5pt;padding-left:2.5pt;padding-right:12.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Amgen Singapore Manufacturing Pte. Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">limited company</font></div></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.2pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen SF, LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.2pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">limited liability company</font></div></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.5pt;padding-left:2.5pt;padding-right:31.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Amgen Technology (Ireland) Unlimited Company</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">unlimited liability company</font></div></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.2pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Technology, Limited</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen USA Inc.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen Worldwide Holdings B.V.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ATL Holdings Limited</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ATL Holdings II Limited</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioVex, Inc.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Immunex Corporation</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.5pt;padding-left:2.5pt;padding-right:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Mustafa Nevzat Ilac Sanayii Anonim Sirketi</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.2pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Onyx Pharmaceuticals, Inc.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.4pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">Onyx Therapeutics, Inc.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 31.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr></table></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_88"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.45pt;padding-left:178.52pt;padding-right:178.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SCHEDULE 4.8</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:178.52pt;padding-right:178.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LITIGATION</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">None.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:line-through">-</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3-</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_91"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SCHEDULE 4.11(c)</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:186.65pt;padding-right:186.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ERISA</font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amgen Inc. Retiree Medical Savings Account Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:line-through">1-</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_94"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:132.65pt;padding-right:132.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SCHEDULE 4.15</font></div><div><font><br></font></div><div style="margin-top:0.55pt;padding-right:72pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:128.45pt;padding-right:128.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ENVIRONMENTAL</font></div><div><font><br></font></div><div style="margin-top:4.45pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">None.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">#96432516v4</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:line-through">1-</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_97"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:177.12pt;padding-right:177.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SCHEDULE 6.3</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:184.95pt;padding-right:184.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIENS</font></div><div><font><br></font></div><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">None.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_100"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:177.8pt;padding-right:177.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SCHEDULE 13.7</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:177.77pt;padding-right:177.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTICES</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.45pt;padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE COMPANY</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Amgen Inc.</font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">One Amgen Center Drive</font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Thousand Oaks, California 91320-1799</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Telecopier&#58; (805) 499-6751</font></div><div style="padding-left:5.65pt;padding-right:284.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Telephone&#58; (805) 447-1000 Email&#58; to.treasury&#64;amgen.com</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Website&#58; www.amgen.com</font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE ADMINISTRATIVE AGENT</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Citibank, N.A.</font></div><div style="padding-left:5.65pt;padding-right:286.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1615 Brett Road, Building #3 New Castle, Delaware 19720 Attention of Treasurer Facsimile No. (646) 274-5080</font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Telephone No. (302) 894-6160</font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">E-mail&#58; GLAgentOfficeOps&#64;CITIGROUP.COM</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ISSUING BANK</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Citibank, N.A.</font></div><div style="padding-left:5.65pt;padding-right:298.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1615 Brett Road, Building #3 New Castle, Delaware 19720</font></div><div style="padding-left:5.65pt;padding-right:261.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention of Bank Loan Syndications Facsimile No. (646) 274-5080</font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Telephone No. (302) 894-6160</font></div><div style="padding-left:5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">E-mail&#58; GLAgentOfficeOps&#64;CITIGROUP.COM</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">-3-</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_103"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:32.65pt;padding-right:32.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNEX B</font></div><div><font><br></font></div><div style="padding-left:32.75pt;padding-right:32.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amended Exhibit E</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.55pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#96432517v6</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib6a58edfcca043b385670be29d25c61b_106"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.2pt;padding-left:33.9pt;padding-right:33.9pt;text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:218%;text-decoration:underline">ANNEX B TO AMENDMENT NO. 1 DATED AS OF DECEMBER    , 2022</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:218%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:218%">EXHIBIT E</font></div><div style="margin-top:1.65pt;padding-left:33.87pt;padding-right:33.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;FORM OF REQUEST FOR LOAN&#93;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.85pt;padding-right:33.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">REQUEST FOR LOAN</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:59.45pt;text-align:justify;text-indent:-36.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;This Request for Loan is by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;Borrower&#8221;) to Citibank,</font></div><div style="margin-top:0.05pt;padding-left:59.45pt;padding-right:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">N.A. (the &#8220;Administrative Agent&#8221;) pursuant to that certain Second Amended and Restated Credit Agreement dated as of December 12, 2019 (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;Credit Agreement&#8221;) among Amgen Inc., the Banks from time to time party thereto, the Administrative Agent, and JPMorgan Chase Bank, N.A., as Syndication Agent. Capitalized terms used herein and not defined herein shall have the meanings defined in the Credit Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:59.45pt;padding-right:7.7pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Borrower hereby requests a Loan for the account of Borrower pursuant to the Credit Agreement as follows&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:95.6pt;text-indent:-36.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;DATE OF LOAN&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:95.6pt;text-indent:-36.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;TYPE OF LOAN (Check one box only)&#58;</font></div><div><font><br></font></div><div style="padding-left:131.25pt;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9679;&#160;&#160;&#160;&#160;BASE RATE ADVANCE</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:131.75pt;padding-right:8pt;text-indent:-36.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9679;&#160;&#160;&#160;&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">EURODOLLAR RATE</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADJUSTED TERM SOFR</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADVANCE WITH A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-MONTH INTEREST PERIOD</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:131.75pt;padding-right:6.2pt;text-indent:-36.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9679;&#160;&#160;&#160;&#160;EURIBOR RATE ADVANCE WITH A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-MONTH INTEREST PERIOD</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:95.6pt;text-indent:-36.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;AMOUNT OF REQUESTED LOAN&#58; &#91;$&#93; &#91;&#8364;&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:95.6pt;text-indent:-36.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;INTEREST PERIOD OF LOAN ENDS&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:23.3pt;padding-right:7.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In connection with the request pursuant to Section 2 above, Borrower certifies that&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:95.6pt;padding-right:7.95pt;text-align:justify;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Prior to giving effect to the Loans requested hereby, the aggregate outstanding balance of Advances is $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:95.6pt;padding-right:7.4pt;text-align:justify;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;As of the date of the requested Loan, (i) each representation and warranty made by Borrower in Article 4 of the Credit Agreement, other than Sections 4.4, 4.6 and 4.8, will be true and correct in all material respects (except that to the extent any representation or warranty is qualified by materiality, it shall be true and correct in all respects), both immediately before and after giving effect to such Loan, as though such representations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.65pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:line-through">96437907v1</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">96437907v2</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.2pt;padding-left:95.6pt;padding-right:5.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and warranties were made on and as of that date (except to the extent such representations and warranties specifically relate to an earlier date in which case they shall be true and correct in all material respects as of such earlier date), (ii) no Default has occurred and is continuing, and (iii) after giving effect to the requested Loan, the Total Outstandings will not exceed the Commitment.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:59.45pt;padding-right:5.7pt;text-align:justify;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;This Request for Loan is executed on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, by a Senior Officer of Borrower on behalf of Borrower. The undersigned, in such capacity, hereby certifies each and every matter contained herein to be true and correct </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as previously disclosed by Borrower in writing to the Banks and waived by the Majority Banks or all Banks, as applicable.</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:283.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;BORROWER&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:283.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-bottom:0.9pt;padding-left:283.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">                                         </font></div><div style="padding-left:295.65pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.65pt;padding-left:1pt"><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.55pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="margin-top:0.65pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:line-through">96437907v1</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">96437907v2</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>8
<FILENAME>amgn-ex21_20221231xq4.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i594755be245f4a27b2f768fdc824eba5_1"></div><div style="min-height:43.2pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 21</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">AMGEN INC.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The following is a list of subsidiaries of the Company as of December 31, 2022, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:49.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STATE OR OTHER JURISDICTION OF</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Name under which subsidiary does business)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INCORPORATION OR ORGANIZATION</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen (Europe) GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Canada Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Fremont Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Global Finance B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen GmbH Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Ila&#231; Ticaret Limited &#350;irketi</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen K-A, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Manufacturing, Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Research (Munich) GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen S.p.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen SF, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Singapore Manufacturing Pte. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Technology (Ireland) Unlimited Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Technology, Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen USA Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Worldwide Holdings B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioVex Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioVex, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ChemoCentryx, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunex Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunex Rhode Island Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onyx Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onyx Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saga Investments Co&#246;peratief U.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TeneoBio, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>9
<FILENAME>amgn-ex31_20221231xq4.htm
<DESCRIPTION>RULE 13A-14(A) CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i63c082a998ca4166a86544a6b43083a2_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President of Amgen Inc., certify that&#58;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Amgen Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this annual report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">February 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ROBERT A. BRADWAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i63c082a998ca4166a86544a6b43083a2_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter H. Griffith, Executive Vice President and Chief Financial Officer of Amgen Inc., certify that&#58;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Amgen Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this annual report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">February 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PETER H. GRIFFITH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>10
<FILENAME>amgn-ex32_20221231xq4.htm
<DESCRIPTION>SECTION 1350 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i997583282aec47649c9ff29dd39eaf0c_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the &#8220;Company&#8221;) hereby certifies that&#58;</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Annual Report on Form 10-K of the Company for the period ended December 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">February 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ROBERT A. BRADWAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 906&#8221;), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i997583282aec47649c9ff29dd39eaf0c_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the &#8220;Company&#8221;) hereby certifies that&#58;</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Annual Report on Form 10-K of the Company for the period ended December 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">February 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PETER H. GRIFFITH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 906&#8221;), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>amgn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4e826620-fc5c-4c14-9c2e-3ba20b6aa99d,g:1e6ee203-6cba-438e-aedd-ef42aa695ae1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amgen.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.amgen.com/role/Coverpage">
        <link:definition>0000001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.amgen.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome">
        <link:definition>0000003 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>0000010 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitionsanddivestitures" roleURI="http://www.amgen.com/role/Acquisitionsanddivestitures">
        <link:definition>0000011 - Disclosure - Acquisitions and divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.amgen.com/role/Revenues">
        <link:definition>0000012 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensation" roleURI="http://www.amgen.com/role/Stockbasedcompensation">
        <link:definition>0000013 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedcontributionplan" roleURI="http://www.amgen.com/role/Definedcontributionplan">
        <link:definition>0000014 - Disclosure - Defined contribution plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://www.amgen.com/role/Incometaxes">
        <link:definition>0000015 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningspershare" roleURI="http://www.amgen.com/role/Earningspershare">
        <link:definition>0000016 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborations" roleURI="http://www.amgen.com/role/Collaborations">
        <link:definition>0000017 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.amgen.com/role/Investments">
        <link:definition>0000018 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amgen.com/role/Inventories">
        <link:definition>0000019 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://www.amgen.com/role/Propertyplantandequipment">
        <link:definition>0000020 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwillandintangibleassets" roleURI="http://www.amgen.com/role/Goodwillandintangibleassets">
        <link:definition>0000021 - Disclosure - Goodwill and intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.amgen.com/role/Leases">
        <link:definition>0000022 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othercurrentassetsandaccruedliabilities" roleURI="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities">
        <link:definition>0000023 - Disclosure - Other current assets and accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financingarrangements" roleURI="http://www.amgen.com/role/Financingarrangements">
        <link:definition>0000024 - Disclosure - Financing arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockholdersequity" roleURI="http://www.amgen.com/role/Stockholdersequity">
        <link:definition>0000025 - Disclosure - Stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurement" roleURI="http://www.amgen.com/role/Fairvaluemeasurement">
        <link:definition>0000026 - Disclosure - Fair value measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Derivativeinstruments" roleURI="http://www.amgen.com/role/Derivativeinstruments">
        <link:definition>0000027 - Disclosure - Derivative instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingenciesandcommitments" roleURI="http://www.amgen.com/role/Contingenciesandcommitments">
        <link:definition>0000028 - Disclosure - Contingencies and commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS">
        <link:definition>0000029 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>0000030 - Disclosure - Summary of significant accounting policies - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresTables" roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresTables">
        <link:definition>0000031 - Disclosure - Acquisitions and divestitures - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.amgen.com/role/RevenuesTables">
        <link:definition>0000032 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationTables" roleURI="http://www.amgen.com/role/StockbasedcompensationTables">
        <link:definition>0000033 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTables" roleURI="http://www.amgen.com/role/IncometaxesTables">
        <link:definition>0000034 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareTables" roleURI="http://www.amgen.com/role/EarningspershareTables">
        <link:definition>0000035 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.amgen.com/role/InvestmentsTables">
        <link:definition>0000036 - Disclosure - Investments - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amgen.com/role/InventoriesTables">
        <link:definition>0000037 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://www.amgen.com/role/PropertyplantandequipmentTables">
        <link:definition>0000038 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsTables" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables">
        <link:definition>0000039 - Disclosure - Goodwill and other intangible assets - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.amgen.com/role/LeasesTables">
        <link:definition>0000040 - Disclosure - Leases - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsandaccruedliabilitiesTables" roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables">
        <link:definition>0000041 - Disclosure - Other current assets and accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsTables" roleURI="http://www.amgen.com/role/FinancingarrangementsTables">
        <link:definition>0000042 - Disclosure - Financing arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityTables" roleURI="http://www.amgen.com/role/StockholdersequityTables">
        <link:definition>0000043 - Disclosure - Stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementTables" roleURI="http://www.amgen.com/role/FairvaluemeasurementTables">
        <link:definition>0000044 - Disclosure - Fair value measurement - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsTables" roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables">
        <link:definition>0000045 - Disclosure - Derivative instruments - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsTables" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsTables">
        <link:definition>0000046 - Disclosure - Contingencies and commitments - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesNarrativeDetails" roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails">
        <link:definition>0000047 - Disclosure - Summary of significant accounting policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails" roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails">
        <link:definition>0000048 - Disclosure - Acquisitions and divestitures - Horizon Therapeutics PLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails" roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails">
        <link:definition>0000049 - Disclosure - Acquisitions and divestitures - ChemoCentryx Inc. Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails" roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails">
        <link:definition>0000050 - Disclosure - Acquisitions and divestitures - Summary of Total Consideration for ChemoCentryx Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresTeneobioIncDetails" roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails">
        <link:definition>0000051 - Disclosure - Acquisitions and divestitures - Teneobio Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails" roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails">
        <link:definition>0000052 - Disclosure - Acquisitions and divestitures - Summary of Total Consideration for Teneobio Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails" roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails">
        <link:definition>0000053 - Disclosure - Acquisitions and divestitures - Five Prime Therapeutics Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresDivestitureofGensentaDetails" roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails">
        <link:definition>0000054 - Disclosure - Acquisitions and divestitures - Divestiture of Gensenta (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails">
        <link:definition>0000055 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesCustomerConcentrationProductSalesDetails" roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails">
        <link:definition>0000056 - Disclosure - Revenues - Customer Concentration, Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationTextualDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails">
        <link:definition>0000057 - Disclosure - Stock-based compensation (Textual) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails">
        <link:definition>0000058 - Disclosure - Stock-based compensation (Components of Stock-based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationSummaryofRSUsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails">
        <link:definition>0000059 - Disclosure - Stock-based compensation (Summary of RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails">
        <link:definition>0000060 - Disclosure - Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationSummaryofStockOptionsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails">
        <link:definition>0000061 - Disclosure - Stock-based compensation (Summary of Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationWeightedaverageAssumptionsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails">
        <link:definition>0000062 - Disclosure - Stock-based compensation (Weighted-average Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedcontributionplanDetails" roleURI="http://www.amgen.com/role/DefinedcontributionplanDetails">
        <link:definition>0000063 - Disclosure - Defined contribution plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesIncomeBeforeIncomeTaxesDetails" roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails">
        <link:definition>0000064 - Disclosure - Income taxes (Income Before Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesProvisionforIncomeTaxesDetails" roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails">
        <link:definition>0000065 - Disclosure - Income taxes (Provision for Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000066 - Disclosure - Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTextualDetails" roleURI="http://www.amgen.com/role/IncometaxesTextualDetails">
        <link:definition>0000067 - Disclosure - Income taxes (Textual) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" roleURI="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails">
        <link:definition>0000068 - Disclosure - Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesReconciliationofFederalStatutoryTaxRateDetails" roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails">
        <link:definition>0000069 - Disclosure - Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareDetails" roleURI="http://www.amgen.com/role/EarningspershareDetails">
        <link:definition>0000070 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsBeiGeneDetails" roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails">
        <link:definition>0000071 - Disclosure - Collaborations - BeiGene (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsAstraZenecaPLCDetails" roleURI="http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails">
        <link:definition>0000072 - Disclosure - Collaborations - AstraZeneca PLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsUCBDetails" roleURI="http://www.amgen.com/role/CollaborationsUCBDetails">
        <link:definition>0000073 - Disclosure - Collaborations - UCB (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsNovartisAGDetails" roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails">
        <link:definition>0000074 - Disclosure - Collaborations - Novartis AG (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsKyowaKirinDetails" roleURI="http://www.amgen.com/role/CollaborationsKyowaKirinDetails">
        <link:definition>0000075 - Disclosure - Collaborations - Kyowa Kirin (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleDetails" roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails">
        <link:definition>0000076 - Disclosure - Investments - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValuesbyClassificationDetails" roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails">
        <link:definition>0000077 - Disclosure - Investments - Fair Values by Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforsaleDetails" roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails">
        <link:definition>0000078 - Disclosure - Investments - Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsEquitySecuritiesDetails" roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails">
        <link:definition>0000079 - Disclosure - Investments - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsLimitedPartnershipInvestmentsDetails" roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails">
        <link:definition>0000080 - Disclosure - Investments - Limited Partnership Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsBeiGeneDetails" roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails">
        <link:definition>0000081 - Disclosure - Investments - BeiGene (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNeumoraTherapeuticsIncDetails" roleURI="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails">
        <link:definition>0000082 - Disclosure - Investments - Neumora Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amgen.com/role/InventoriesDetails">
        <link:definition>0000083 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentScheduleDetails" roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails">
        <link:definition>0000084 - Disclosure - Property, plant and equipment (Schedule) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentGeographicInformationDetails" roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails">
        <link:definition>0000085 - Disclosure - Property, plant and equipment (Geographic Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsGoodwillRollForwardDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails">
        <link:definition>0000086 - Disclosure - Goodwill and other intangible assets - Goodwill Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails">
        <link:definition>0000087 - Disclosure - Goodwill and other intangible assets - Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsNarrativeDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails">
        <link:definition>0000088 - Disclosure - Goodwill and other intangible assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.amgen.com/role/LeasesNarrativeDetails">
        <link:definition>0000089 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofLeasesDetails" roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails">
        <link:definition>0000090 - Disclosure - Leases - Summary of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseCostsDetails" roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails">
        <link:definition>0000091 - Disclosure - Leases - Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>0000092 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>0000092 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedAverageRemainingLeaseTermsDiscountRatesDetails" roleURI="http://www.amgen.com/role/LeasesWeightedAverageRemainingLeaseTermsDiscountRatesDetails">
        <link:definition>0000093 - Disclosure - Leases - Weighted Average Remaining Lease Terms &amp; Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesCashandNoncashInformationofLeasesDetails" roleURI="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails">
        <link:definition>0000094 - Disclosure - Leases - Cash and Noncash Information of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails">
        <link:definition>0000095 - Disclosure - Other current assets and accrued liabilities - Schedule of Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails">
        <link:definition>0000096 - Disclosure - Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails">
        <link:definition>0000097 - Disclosure - Financing arrangements - Principal Amounts and Carrying Value of Long-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsDebtIssuancesDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails">
        <link:definition>0000098 - Disclosure - Financing arrangements - Debt Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsDebtRepaymentsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails">
        <link:definition>0000099 - Disclosure - Financing arrangements - Debt Repayments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails">
        <link:definition>0000100 - Disclosure - Financing arrangements - Interest Rate and Cross-currency Swaps (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails">
        <link:definition>0000101 - Disclosure - Financing arrangements - Shelf Registration Statements and Other Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails">
        <link:definition>0000102 - Disclosure - Financing arrangements - Contractual Maturities of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsInterestCostsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails">
        <link:definition>0000103 - Disclosure - Financing arrangements - Interest Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityStockRepurchaseProgramDetails" roleURI="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails">
        <link:definition>0000104 - Disclosure - Stockholders' equity - Stock Repurchase Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityDividendsDetails" roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails">
        <link:definition>0000105 - Disclosure - Stockholders' equity - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityComponentsofAOCIDetails" roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails">
        <link:definition>0000106 - Disclosure - Stockholders' equity - Components of AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" roleURI="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails">
        <link:definition>0000107 - Disclosure - Stockholders' equity - Accumulated Other Comprehensive Income (Loss), Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityReclassificationsoutofAOCIDetails" roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails">
        <link:definition>0000108 - Disclosure - Stockholders' equity - Reclassifications out of AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityOtherDetails" roleURI="http://www.amgen.com/role/StockholdersequityOtherDetails">
        <link:definition>0000109 - Disclosure - Stockholders' equity - Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>0000110 - Disclosure - Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementNarrativeDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails">
        <link:definition>0000111 - Disclosure - Fair value measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementContingentConsiderationObligationsDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails">
        <link:definition>0000112 - Disclosure - Fair value measurement - Contingent Consideration Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsNarrativeDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails">
        <link:definition>0000113 - Disclosure - Derivative instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsCrosscurrencySwapsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails">
        <link:definition>0000114 - Disclosure - Derivative instruments - (Cross-currency Swaps) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails">
        <link:definition>0000115 - Disclosure - Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails">
        <link:definition>0000116 - Disclosure - Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails">
        <link:definition>0000117 - Disclosure - Derivative instruments - (Summary of Income and Expense Line Items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsFairValueofDerivativesDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails">
        <link:definition>0000118 - Disclosure - Derivative instruments - Fair Value of Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsSandozPatentLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails">
        <link:definition>0000119 - Disclosure - Contingencies and commitments (Sandoz Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsRepathaPatentLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails">
        <link:definition>0000120 - Disclosure - Contingencies and commitments (Repatha Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails">
        <link:definition>0000121 - Disclosure - Contingencies and commitments (Janssen Biotech Inc v. Amgen Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsAdditionalInformationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails">
        <link:definition>0000122 - Disclosure - Contingencies and commitments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails">
        <link:definition>0000123 - Disclosure - Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails">
        <link:definition>0000124 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amgn_FivePointOneFivePercentNotesDue2041Member" abstract="true" name="FivePointOneFivePercentNotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" abstract="true" name="TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" abstract="false" name="IdentifiableIntangibleAssetsAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RepatriationTaxOnProposedAdditionalTax" abstract="false" name="RepatriationTaxOnProposedAdditionalTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" abstract="true" name="ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" abstract="true" name="TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointZeroPercent2032NotesMemberMember" abstract="true" name="TwoPointZeroPercent2032NotesMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" abstract="true" name="AccumulatedOtherAdjustmentAttributabletoParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AssetsByDescriptionAxis" abstract="true" name="AssetsByDescriptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" abstract="true" name="TwoPercentEuroNotesDueTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TermLoanCreditAgreementTotalAmount" abstract="false" name="TermLoanCreditAgreementTotalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" abstract="true" name="TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ChemoCentryxIncSecuritiesMattersMember" abstract="true" name="ChemoCentryxIncSecuritiesMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" abstract="false" name="DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPointThreeZeroPercentNotesDue2031Member" abstract="true" name="TwoPointThreeZeroPercentNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LossContingencyNumberOfLawsuitsFiled" abstract="false" name="LossContingencyNumberOfLawsuitsFiled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_OtezlaMember" abstract="true" name="OtezlaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" abstract="false" name="BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LossContingencyNumberOfPrimaryArguments" abstract="false" name="LossContingencyNumberOfPrimaryArguments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_LaboratoryEquipment" abstract="false" name="LaboratoryEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_BridgeCreditAgreementMaximumLength" abstract="false" name="BridgeCreditAgreementMaximumLength" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_FivePointSixFivePercentNotesDue2042Member" abstract="true" name="FivePointSixFivePercentNotesDue2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" abstract="false" name="PenaltiesOnProposedAdditionalIncomeTax20132105" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_SixPointNineZeroPercentNotesDue2038Member" abstract="true" name="SixPointNineZeroPercentNotesDue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SandozIncMember" abstract="true" name="SandozIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_MaximumBorrowingCapacityUnderCommercialPaper" abstract="false" name="MaximumBorrowingCapacityUnderCommercialPaper" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ApprovedProducts" abstract="false" name="ApprovedProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_MoleculeTypeAxis" abstract="true" name="MoleculeTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amgn_GainContingencyNumberOfChallenges" abstract="false" name="GainContingencyNumberOfChallenges" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" abstract="false" name="DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_IncreaseDecreaseInNoncurrentTaxLiability" abstract="false" name="IncreaseDecreaseInNoncurrentTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FixedEquipment" abstract="false" name="FixedEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RegeneronPharmaceuticalsIncAntitrustActionMember" abstract="true" name="RegeneronPharmaceuticalsIncAntitrustActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_StockRepurchaseProgramTableTextBlock" abstract="false" name="StockRepurchaseProgramTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" abstract="true" name="TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DerivativeNotionalAmountAmountTerminated" abstract="false" name="DerivativeNotionalAmountAmountTerminated" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_AMG340Member" abstract="true" name="AMG340Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ProfitAndLossShareOfExpenses" abstract="false" name="ProfitAndLossShareOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPointEightZeroPercent2041NotesMember" abstract="true" name="TwoPointEightZeroPercent2041NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPercentPoundSterlingNotesDue2029Member" abstract="true" name="FourPercentPoundSterlingNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_MoleculeTypeDomain" abstract="true" name="MoleculeTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AvailableForSalesInvestmentsMember" abstract="true" name="AvailableForSalesInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SalesReturnProvisionsAsPercentageOfProductSales" abstract="false" name="SalesReturnProvisionsAsPercentageOfProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_BeiGeneMember" abstract="true" name="BeiGeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" abstract="false" name="DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" abstract="true" name="OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TeneobioMember" abstract="true" name="TeneobioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" abstract="false" name="PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_DevelopmentCostsDueToCollaborationPartner" abstract="false" name="DevelopmentCostsDueToCollaborationPartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FloatingRateNotesDue2020Member" abstract="true" name="FloatingRateNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AssetsByDescriptionDomain" abstract="false" name="AssetsByDescriptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentChangeInCarryingValue" abstract="false" name="EquityMethodInvestmentChangeInCarryingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_CustomerTwoMember" abstract="false" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AlternativeInvestmentNetGainLoss" abstract="false" name="AlternativeInvestmentNetGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_InterestRateSwapDomain" abstract="true" name="InterestRateSwapDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointSixTwoFivePercentNotesDue2024Member" abstract="true" name="ThreePointSixTwoFivePercentNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A300NotesDue20293002029NotesMember" abstract="true" name="A300NotesDue20293002029NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointNineFivePercentNotesDue2041Member" abstract="true" name="FourPointNineFivePercentNotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NeumoraTherapeuticsIncMember" abstract="true" name="NeumoraTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A335NotesDue20323352032NotesMember" abstract="true" name="A335NotesDue20323352032NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SensiparAntitrustClassActionsMember" abstract="true" name="SensiparAntitrustClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LaboratoryEquipmentMember" abstract="false" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroNotesDue2020Member" abstract="true" name="TwoPointTwoZeroNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ProposedAdditionalIncomeTax20132015" abstract="false" name="ProposedAdditionalIncomeTax20132015" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" abstract="true" name="TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" abstract="true" name="FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" abstract="false" name="NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_EquitySecuritiesRealizedGainLossOnDisposal" abstract="false" name="EquitySecuritiesRealizedGainLossOnDisposal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ForeignCurrencyAndCrossCurrencySwapsMember" abstract="true" name="ForeignCurrencyAndCrossCurrencySwapsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NumberOfNoticesOnProposedAdditionalTax" abstract="false" name="NumberOfNoticesOnProposedAdditionalTax" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_A405NotesDue20294052029NotesMember" abstract="true" name="A405NotesDue20294052029NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries" abstract="false" name="DeferredTaxAssetEarningsOfForeignSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" abstract="true" name="FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_OtherCurrentNoncurrentAssetsMember" abstract="true" name="OtherCurrentNoncurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A165NotesDue20281652028NotesMember" abstract="true" name="A165NotesDue20281652028NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_RDTechnologyrightsMember" abstract="true" name="RDTechnologyrightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PerformanceUnitsMember" abstract="false" name="PerformanceUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" abstract="false" name="AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_AccruedLiabilitiesDisclosureTextBlock" abstract="false" name="AccruedLiabilitiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_TermLoanCreditAgreementNumberOfTraunches" abstract="false" name="TermLoanCreditAgreementNumberOfTraunches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RepathaevolocumabMember" abstract="true" name="RepathaevolocumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DerivativeAssetsFairValueDisclosureAbstract" abstract="true" name="DerivativeAssetsFairValueDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_ThreePointSixTwoFivePercentNotesDue2022Member" abstract="true" name="ThreePointSixTwoFivePercentNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_KyowaKirinCoLtdMember" abstract="true" name="KyowaKirinCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_Businessassetacquisitionconsiderationtransferred" abstract="false" name="Businessassetacquisitionconsiderationtransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_CommonStockFairValue" abstract="false" name="CommonStockFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="amgn_ChemoCentryxIncMember" abstract="true" name="ChemoCentryxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" abstract="true" name="TwoPointSixZeroNotesDueTwoZeroTwoSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DebtExchangeAdditionalCashConsideration" abstract="false" name="DebtExchangeAdditionalCashConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_A2.00SeniorNotesDue2026Member" abstract="true" name="A2.00SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RepatriationTaxOnProposedAdditionalTax20132015" abstract="false" name="RepatriationTaxOnProposedAdditionalTax20132015" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_SanofiRegeneronPatentLitigationMember" abstract="true" name="SanofiRegeneronPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A420NotesDue20334202033NotesMember" abstract="true" name="A420NotesDue20334202033NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_A200NotesDue20322002032NotesMember" abstract="true" name="A200NotesDue20322002032NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_SixPointThreeSevenFivePercentNotesDue2037Member" abstract="true" name="SixPointThreeSevenFivePercentNotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A300NotesDue20523002052NotesMember" abstract="true" name="A300NotesDue20523002052NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointSevenZeroPercentNotesDue2022Member" abstract="true" name="TwoPointSevenZeroPercentNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ForwardInterestRateContractMember" abstract="true" name="ForwardInterestRateContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_CrossCurrencySwapContractsMember" abstract="true" name="CrossCurrencySwapContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AranespMember" abstract="false" name="AranespMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_InterestRateSwapAxis" abstract="true" name="InterestRateSwapAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" abstract="false" name="ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_BridgeCreditReducedAmount" abstract="false" name="BridgeCreditReducedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" abstract="false" name="BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ThreePointFourFivePercentNotesDue2020Member" abstract="true" name="ThreePointFourFivePercentNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DevelopmentPrograms" abstract="false" name="DevelopmentPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_OtherGeneralExpenseMember" abstract="true" name="OtherGeneralExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" abstract="false" name="PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_LineofCreditFacilityNumberOfRenewalOptions" abstract="false" name="LineofCreditFacilityNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_BridgeCreditAgreementAmount" abstract="false" name="BridgeCreditAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" abstract="true" name="DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" abstract="false" name="NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_AstraZenecaPLCMember" abstract="true" name="AstraZenecaPLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" abstract="true" name="FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NplateMember" abstract="true" name="NplateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_IdentifiableIntangibleAssetsGross" abstract="false" name="IdentifiableIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ProposedAdditionalIncomeTax" abstract="false" name="ProposedAdditionalIncomeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_NatureOfOperationsPolicyTextBlock" abstract="false" name="NatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" abstract="true" name="OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_XgevaMember" abstract="false" name="XgevaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LineOfCreditFacilityInitialCommitmentTerm" abstract="false" name="LineOfCreditFacilityInitialCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_NumberOfPreclinicalOncologyPrograms" abstract="false" name="NumberOfPreclinicalOncologyPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" abstract="false" name="NumberOfCommonSharesToBeReducedForEachStockOptionGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_FixedEquipmentMember" abstract="true" name="FixedEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" abstract="false" name="AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_JanssenBiotechIncVsAmgenIncMember" abstract="true" name="JanssenBiotechIncVsAmgenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside" abstract="false" name="LossContingencyNumberOfStatesInWhichPlaintiffsReside" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_BusinessCombinationContingentConsiderationArrangementsPayments" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LossContingencyNumberOfClassActionSuits" abstract="false" name="LossContingencyNumberOfClassActionSuits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" abstract="false" name="NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices" abstract="false" name="BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_BridgeCreditAgreementInitialAmount" abstract="false" name="BridgeCreditAgreementInitialAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_InterestRateSwapOneMember" abstract="true" name="InterestRateSwapOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness" abstract="false" name="ForeignCurrencyTranslationLossOnDivestitureOfABusiness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" abstract="false" name="PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_ThreePointOneFivePercentNotesDue2040Member" abstract="true" name="ThreePointOneFivePercentNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" abstract="true" name="FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherNotesDue2097Member" abstract="true" name="OtherNotesDue2097Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LitigationSettlementLengthofTrial" abstract="false" name="LitigationSettlementLengthofTrial" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_NovartisPharmaAGMember" abstract="true" name="NovartisPharmaAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ProliaMember" abstract="false" name="ProliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FivePrimeTherapeuticsIncMember" abstract="true" name="FivePrimeTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointFiveZeroPercentNotesDue2020Member" abstract="true" name="FourPointFiveZeroPercentNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_UCBMember" abstract="true" name="UCBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_HedgedLiabilityDiscontinuedFairValueHedge" abstract="false" name="HedgedLiabilityDiscontinuedFairValueHedge" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_EquityInvestmentsPolicyPolicyTextBlock" abstract="false" name="EquityInvestmentsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" abstract="false" name="PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_EnbrelMember" abstract="false" name="EnbrelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" abstract="true" name="AcquiredResearchAndDevelopmentTechnologyRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherShortTermInterestBearingSecuritiesMember" abstract="true" name="OtherShortTermInterestBearingSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointEightSevenFivePercentNotesDue2021Member" abstract="true" name="ThreePointEightSevenFivePercentNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PercentageOfGrossRevenues" abstract="false" name="PercentageOfGrossRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_AccruedSalesDeductionsCurrent" abstract="false" name="AccruedSalesDeductionsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FivePointThreeSevenFivePercentNotesDue2043Member" abstract="true" name="FivePointThreeSevenFivePercentNotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" abstract="false" name="NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_A190NotesDue20251902025NotesMember" abstract="true" name="A190NotesDue20251902025NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A420NotesDue20524202052NotesMember" abstract="true" name="A420NotesDue20524202052NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" abstract="true" name="FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_CustomerThreeMember" abstract="false" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NumberOfNoticesConsolidated" abstract="false" name="NumberOfNoticesConsolidated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_AcceleratedStockRepurchaseAgreementMember" abstract="true" name="AcceleratedStockRepurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationContingentConsiderationRollForward" abstract="true" name="BusinessCombinationContingentConsiderationRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_AbandonedLeasesMember" abstract="true" name="AbandonedLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" abstract="false" name="LineOfCreditFacilityExtensionOfCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_HorizonTherapeuticsMember" abstract="true" name="HorizonTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentChangeInCarryingValueOther" abstract="false" name="EquityMethodInvestmentChangeInCarryingValueOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_A4875NotesDue205348752053NotesMember" abstract="true" name="A4875NotesDue205348752053NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ForwardInterestRateContractsMember" abstract="true" name="ForwardInterestRateContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TeneobioIncMember" abstract="true" name="TeneobioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_EvenityMember" abstract="true" name="EvenityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_GainContingencyNumberofLawsuitsFiled" abstract="false" name="GainContingencyNumberofLawsuitsFiled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" abstract="false" name="ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_BridgeCreditAgreementMember" abstract="true" name="BridgeCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" abstract="false" name="ComponentsOfStockBasedCompensationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" abstract="false" name="LongTermDebtMaturitiesRepaymentsOfPrincipalNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" abstract="true" name="FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_A280NotesDue2041Member" abstract="true" name="A280NotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_KyprolisMember" abstract="true" name="KyprolisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_CustomerOneMember" abstract="false" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_InterestRateSwapTwoMember" abstract="true" name="InterestRateSwapTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ManufacturingEquipmentMember" abstract="false" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OperatingLossesThatExpireBetween2022And2031Member" abstract="true" name="OperatingLossesThatExpireBetween2022And2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_NeulastaMember" abstract="false" name="NeulastaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SixPointFourZeroPercentNotesDue2039Member" abstract="true" name="SixPointFourZeroPercentNotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired" abstract="false" name="BusinessCombinationTurnoverPeriodOfInventoryAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" abstract="true" name="ThreePointThreeSevenFivePercentNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointOneZeroPercentNotesDue2021Member" abstract="true" name="FourPointOneZeroPercentNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" abstract="true" name="ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_StockBasedCompensationExpenseNetOfTax" abstract="false" name="StockBasedCompensationExpenseNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FivePointSevenFivePercentNotesDue2040Member" abstract="true" name="FivePointSevenFivePercentNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" abstract="false" name="ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" abstract="true" name="AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ExpirationInTaxYearsBetween2023And2043Member" abstract="true" name="ExpirationInTaxYearsBetween2023And2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" abstract="false" name="OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_A440NotesDue20624402062NotesMember" abstract="true" name="A440NotesDue20624402062NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LongTermDebtCurrentMaturitiesMember" abstract="true" name="LongTermDebtCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" abstract="true" name="OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" abstract="false" name="EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RevenuePaymentArrangementTerm" abstract="false" name="RevenuePaymentArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_ThreePointTwoZeroNotesDue2027Member" abstract="true" name="ThreePointTwoZeroNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointFourFivePercentNotesDue2030Member" abstract="true" name="TwoPointFourFivePercentNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" abstract="false" name="NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_SecuredOvernightFinancingRateMember" abstract="true" name="SecuredOvernightFinancingRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_UpFrontPayment" abstract="false" name="UpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AccruedSalesReturnReserveCurrent" abstract="false" name="AccruedSalesReturnReserveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BasicAndDilutedEarningPerShareAbstract" abstract="true" name="BasicAndDilutedEarningPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_ScheduleOfIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>amgn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4e826620-fc5c-4c14-9c2e-3ba20b6aa99d,g:1e6ee203-6cba-438e-aedd-ef42aa695ae1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_24c43691-258e-4585-817d-7c21cf6b8674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_67aef5e1-8e3e-4500-9202-c9fc3a65da85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_24c43691-258e-4585-817d-7c21cf6b8674" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_67aef5e1-8e3e-4500-9202-c9fc3a65da85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_885ac977-88c2-4984-bfed-a487d36e76cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_24c43691-258e-4585-817d-7c21cf6b8674" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_885ac977-88c2-4984-bfed-a487d36e76cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4b224b45-c328-4be1-991b-3a482a9ff54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65cbfd20-3228-449a-bbb0-c966d59a7ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4b224b45-c328-4be1-991b-3a482a9ff54f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65cbfd20-3228-449a-bbb0-c966d59a7ac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_322f1f30-7eee-4113-afd3-9a8754176a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4b224b45-c328-4be1-991b-3a482a9ff54f" xlink:to="loc_us-gaap_CostsAndExpenses_322f1f30-7eee-4113-afd3-9a8754176a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cf5e6e1c-c0ce-4865-bbbc-7815babdb320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9f6dce01-e03f-46d6-83ea-57bd35df2aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf5e6e1c-c0ce-4865-bbbc-7815babdb320" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9f6dce01-e03f-46d6-83ea-57bd35df2aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_87deb9c6-aaec-487a-9179-77e46e789b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf5e6e1c-c0ce-4865-bbbc-7815babdb320" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_87deb9c6-aaec-487a-9179-77e46e789b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_fb85a88f-4cec-486a-ab7d-2800252856f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf5e6e1c-c0ce-4865-bbbc-7815babdb320" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_fb85a88f-4cec-486a-ab7d-2800252856f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ac73200e-0fe9-4192-bd25-2030881ec92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf5e6e1c-c0ce-4865-bbbc-7815babdb320" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ac73200e-0fe9-4192-bd25-2030881ec92a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense_3c28ec07-fc20-4d6a-93d4-fe6d15f34c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf5e6e1c-c0ce-4865-bbbc-7815babdb320" xlink:to="loc_us-gaap_OtherGeneralExpense_3c28ec07-fc20-4d6a-93d4-fe6d15f34c77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_045f8254-ff78-4b41-a563-d73c397672bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d2d7c4dc-1f76-41db-be5c-232f75b529d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_045f8254-ff78-4b41-a563-d73c397672bb" xlink:to="loc_us-gaap_OperatingIncomeLoss_d2d7c4dc-1f76-41db-be5c-232f75b529d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1e3b0679-6b32-4a2b-aae9-69a061babff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_045f8254-ff78-4b41-a563-d73c397672bb" xlink:to="loc_us-gaap_InterestExpenseDebt_1e3b0679-6b32-4a2b-aae9-69a061babff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e4bda192-7c04-43e1-bee5-eeffc82eb073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_045f8254-ff78-4b41-a563-d73c397672bb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e4bda192-7c04-43e1-bee5-eeffc82eb073" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_828cdf09-25e0-4247-8eb7-a2148b353300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b8aad7aa-9731-4fc6-9583-db95e9650d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_828cdf09-25e0-4247-8eb7-a2148b353300" xlink:to="loc_us-gaap_NetIncomeLoss_b8aad7aa-9731-4fc6-9583-db95e9650d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9b0c6259-85c9-45b9-91da-7ba2715c374f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_828cdf09-25e0-4247-8eb7-a2148b353300" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9b0c6259-85c9-45b9-91da-7ba2715c374f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_17599e93-2ea8-4b8f-bacf-a5470784455d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_aba1c484-98f0-4065-a95b-6135dbf45485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_17599e93-2ea8-4b8f-bacf-a5470784455d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_aba1c484-98f0-4065-a95b-6135dbf45485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_7d20f34b-0410-4dc1-b786-dcedccb97919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_17599e93-2ea8-4b8f-bacf-a5470784455d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_7d20f34b-0410-4dc1-b786-dcedccb97919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_60ba51da-27c8-4a41-8cea-09549bc0e9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_17599e93-2ea8-4b8f-bacf-a5470784455d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_60ba51da-27c8-4a41-8cea-09549bc0e9f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_54935249-c30e-4b7a-bf3c-bf3a207d1e5b" xlink:href="amgn-20221231.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_17599e93-2ea8-4b8f-bacf-a5470784455d" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_54935249-c30e-4b7a-bf3c-bf3a207d1e5b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7a8bfe-dc09-4332-a559-eb244b5b58f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0eb18b0c-f6ce-4db9-af58-b43983038182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7a8bfe-dc09-4332-a559-eb244b5b58f5" xlink:to="loc_us-gaap_LiabilitiesCurrent_0eb18b0c-f6ce-4db9-af58-b43983038182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_87c1fde8-28b8-4eff-968b-3e480cc18754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7a8bfe-dc09-4332-a559-eb244b5b58f5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_87c1fde8-28b8-4eff-968b-3e480cc18754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_0eb9a8ba-2639-4e99-9872-956cfa29eb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7a8bfe-dc09-4332-a559-eb244b5b58f5" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_0eb9a8ba-2639-4e99-9872-956cfa29eb3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1979aaed-4460-4921-bd9a-f884b8277cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7a8bfe-dc09-4332-a559-eb244b5b58f5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1979aaed-4460-4921-bd9a-f884b8277cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d91c105f-9c96-42be-a4db-8114e3c984bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7a8bfe-dc09-4332-a559-eb244b5b58f5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d91c105f-9c96-42be-a4db-8114e3c984bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4efeaa0b-aa22-4e69-819a-89c64d760049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7a8bfe-dc09-4332-a559-eb244b5b58f5" xlink:to="loc_us-gaap_StockholdersEquity_4efeaa0b-aa22-4e69-819a-89c64d760049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b8ecfe7b-a559-4863-af3a-430ab96bc4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_35425d86-4352-42d2-a3ad-391330b7fa92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8ecfe7b-a559-4863-af3a-430ab96bc4c1" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_35425d86-4352-42d2-a3ad-391330b7fa92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_de99c3fc-2fac-4889-917d-5a7193253175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8ecfe7b-a559-4863-af3a-430ab96bc4c1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_de99c3fc-2fac-4889-917d-5a7193253175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8de2474b-1725-42c1-96cd-b2ffdefd4f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8ecfe7b-a559-4863-af3a-430ab96bc4c1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8de2474b-1725-42c1-96cd-b2ffdefd4f17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_937d0517-862b-48d4-b851-3958ee19a920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b32e8860-16ac-4246-bea8-4760e8209d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_937d0517-862b-48d4-b851-3958ee19a920" xlink:to="loc_us-gaap_AssetsCurrent_b32e8860-16ac-4246-bea8-4760e8209d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0eb1953f-0137-4faf-b3ad-91a848a8456a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_937d0517-862b-48d4-b851-3958ee19a920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0eb1953f-0137-4faf-b3ad-91a848a8456a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_54ab5683-04c1-4b14-8a03-b19fcbc372e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_937d0517-862b-48d4-b851-3958ee19a920" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_54ab5683-04c1-4b14-8a03-b19fcbc372e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1986503c-71b8-4c3d-859d-90effe707667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_937d0517-862b-48d4-b851-3958ee19a920" xlink:to="loc_us-gaap_Goodwill_1986503c-71b8-4c3d-859d-90effe707667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_95288dc3-4a2f-4cca-bdde-11c6530428ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_937d0517-862b-48d4-b851-3958ee19a920" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_95288dc3-4a2f-4cca-bdde-11c6530428ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ae0ff0e9-e2f8-440f-833c-f0e37771bc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_173f11f0-d217-4b77-89ba-d9a892fc3515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ae0ff0e9-e2f8-440f-833c-f0e37771bc84" xlink:to="loc_us-gaap_AccountsPayableCurrent_173f11f0-d217-4b77-89ba-d9a892fc3515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2c361f58-7d47-4e7d-a1c5-4dfd1ef590b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ae0ff0e9-e2f8-440f-833c-f0e37771bc84" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2c361f58-7d47-4e7d-a1c5-4dfd1ef590b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f15f955a-a965-4cf8-a537-a13392d54598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ae0ff0e9-e2f8-440f-833c-f0e37771bc84" xlink:to="loc_us-gaap_LongTermDebtCurrent_f15f955a-a965-4cf8-a537-a13392d54598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0829863a-dd62-4821-973a-e457eadb0f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_396651ec-6994-45ef-8856-30aad8852238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0829863a-dd62-4821-973a-e457eadb0f3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_396651ec-6994-45ef-8856-30aad8852238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0a0d0bc4-09e8-40e5-b537-493a578aa7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0829863a-dd62-4821-973a-e457eadb0f3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0a0d0bc4-09e8-40e5-b537-493a578aa7b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_85403686-0ee8-4dd6-846d-33a87707fc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0829863a-dd62-4821-973a-e457eadb0f3b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_85403686-0ee8-4dd6-846d-33a87707fc5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fdf8aa41-2e8d-4118-8957-5c9dfe05201b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0829863a-dd62-4821-973a-e457eadb0f3b" xlink:to="loc_us-gaap_InventoryNet_fdf8aa41-2e8d-4118-8957-5c9dfe05201b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b19b9772-f67f-48a7-a985-7b46a8767692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0829863a-dd62-4821-973a-e457eadb0f3b" xlink:to="loc_us-gaap_OtherAssetsCurrent_b19b9772-f67f-48a7-a985-7b46a8767692" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71493fee-f56d-401a-9239-bb9ae89e6599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_NetIncomeLoss_71493fee-f56d-401a-9239-bb9ae89e6599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_889ab31a-8537-4012-bb33-a346aef499fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_889ab31a-8537-4012-bb33-a346aef499fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dcd6823c-4770-48e0-80c4-1f2cfee1716f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_ShareBasedCompensation_dcd6823c-4770-48e0-80c4-1f2cfee1716f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_979202a9-2190-4938-a12b-def12990d57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_979202a9-2190-4938-a12b-def12990d57f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5aee4c3f-8edb-4d87-995d-b4b2b84321ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5aee4c3f-8edb-4d87-995d-b4b2b84321ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_45596981-ea0c-4bec-92a0-6bac0ad319dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_45596981-ea0c-4bec-92a0-6bac0ad319dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_730d545b-adfe-41b3-b4bb-a25bbc45bd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_730d545b-adfe-41b3-b4bb-a25bbc45bd33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_2e48b819-a907-4c73-bc21-16d0643c6d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_2e48b819-a907-4c73-bc21-16d0643c6d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_efb1e747-0870-4991-b399-8ee52ff486df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_efb1e747-0870-4991-b399-8ee52ff486df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_453a7fd8-17da-44c1-9e5a-290c48a17c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_453a7fd8-17da-44c1-9e5a-290c48a17c5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1b31561b-4b04-4f11-ab95-5aa749eb9af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1b31561b-4b04-4f11-ab95-5aa749eb9af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_41ed9d5e-55af-4890-b074-07ee2eed24b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_41ed9d5e-55af-4890-b074-07ee2eed24b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_93f4c816-05c6-447c-8d42-3b6562045a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_93f4c816-05c6-447c-8d42-3b6562045a8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_7966b7b4-c0f8-42e9-b34b-af7c207fc406" xlink:href="amgn-20221231.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_7966b7b4-c0f8-42e9-b34b-af7c207fc406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d5514a41-1e84-488d-953e-6e3b58e623b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a11461b-0af4-4b60-ac1b-681f1a52b8ad" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d5514a41-1e84-488d-953e-6e3b58e623b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b70df8e1-df89-4d0f-9601-9d57a150be98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_19a07e9e-01ad-41fd-b397-1845670c6069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b70df8e1-df89-4d0f-9601-9d57a150be98" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_19a07e9e-01ad-41fd-b397-1845670c6069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4682cbf9-59bb-400c-85d7-7c28d8700ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b70df8e1-df89-4d0f-9601-9d57a150be98" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4682cbf9-59bb-400c-85d7-7c28d8700ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_00c58e3e-d0f6-4cad-9df9-519f55eb239f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b70df8e1-df89-4d0f-9601-9d57a150be98" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_00c58e3e-d0f6-4cad-9df9-519f55eb239f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_da8b8f6b-e1fd-46f2-be47-6f06a7775ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b70df8e1-df89-4d0f-9601-9d57a150be98" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_da8b8f6b-e1fd-46f2-be47-6f06a7775ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_e8b0193e-ffe4-4146-b3e4-5b7bbe3fa5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b70df8e1-df89-4d0f-9601-9d57a150be98" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_e8b0193e-ffe4-4146-b3e4-5b7bbe3fa5a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_51e79289-ad9b-430c-a2aa-76cbb805b4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b70df8e1-df89-4d0f-9601-9d57a150be98" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_51e79289-ad9b-430c-a2aa-76cbb805b4d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4ad70ed1-16bf-49c7-9228-b8a1dd4d99cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77a24709-e990-4f26-9069-89349e735deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4ad70ed1-16bf-49c7-9228-b8a1dd4d99cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77a24709-e990-4f26-9069-89349e735deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ec8101c-5b8c-4ebd-a5cf-fbd346485bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4ad70ed1-16bf-49c7-9228-b8a1dd4d99cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ec8101c-5b8c-4ebd-a5cf-fbd346485bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cbdb274-07f2-40ae-af3f-cdb172f851d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4ad70ed1-16bf-49c7-9228-b8a1dd4d99cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cbdb274-07f2-40ae-af3f-cdb172f851d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b88d461e-09d5-4004-8577-85351d054a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_39060a56-1cd3-4f99-b9a8-0a2d3cdba3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b88d461e-09d5-4004-8577-85351d054a0d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_39060a56-1cd3-4f99-b9a8-0a2d3cdba3b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d13f1c46-2df2-47a9-8694-07c234e0c747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b88d461e-09d5-4004-8577-85351d054a0d" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d13f1c46-2df2-47a9-8694-07c234e0c747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7cf3aa87-3be5-4273-ac5b-605931fbe8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b88d461e-09d5-4004-8577-85351d054a0d" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7cf3aa87-3be5-4273-ac5b-605931fbe8fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77b88d43-73a8-43a5-8aab-7071169bb82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b88d461e-09d5-4004-8577-85351d054a0d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77b88d43-73a8-43a5-8aab-7071169bb82a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6d98e3c1-d9c1-4a9e-afd4-d7b5dcba8996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b88d461e-09d5-4004-8577-85351d054a0d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6d98e3c1-d9c1-4a9e-afd4-d7b5dcba8996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a17a8d0f-128f-46c1-b6d9-35a1a41984ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b88d461e-09d5-4004-8577-85351d054a0d" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a17a8d0f-128f-46c1-b6d9-35a1a41984ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_973c9c71-27b2-461c-84f8-2a3200fc6414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b88d461e-09d5-4004-8577-85351d054a0d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_973c9c71-27b2-461c-84f8-2a3200fc6414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3d452d2b-2969-41ea-8aa5-6b4b9e376de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b88d461e-09d5-4004-8577-85351d054a0d" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3d452d2b-2969-41ea-8aa5-6b4b9e376de4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_bf829621-20c7-42bd-b82c-f176806b5233" xlink:href="amgn-20221231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3256a931-c367-4c6d-8d11-f188ad7dea97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred_bf829621-20c7-42bd-b82c-f176806b5233" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3256a931-c367-4c6d-8d11-f188ad7dea97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_619965f0-49dc-4ff8-8dfa-965751e9dfdb" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred_bf829621-20c7-42bd-b82c-f176806b5233" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_619965f0-49dc-4ff8-8dfa-965751e9dfdb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax_3eda75ae-301f-47f1-96d1-e5ccbd03bde0" xlink:href="amgn-20221231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a5e517e4-c845-4541-9cce-cf63caed07f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_StockBasedCompensationExpenseNetOfTax_3eda75ae-301f-47f1-96d1-e5ccbd03bde0" xlink:to="loc_us-gaap_ShareBasedCompensation_a5e517e4-c845-4541-9cce-cf63caed07f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_46c7ee1a-0ae1-4b19-9d4b-03f866747ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_StockBasedCompensationExpenseNetOfTax_3eda75ae-301f-47f1-96d1-e5ccbd03bde0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_46c7ee1a-0ae1-4b19-9d4b-03f866747ce0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_988fae0b-8903-420a-be6c-a23d4ee2f0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_da7296ae-3e76-4bad-834b-850f771aad41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_988fae0b-8903-420a-be6c-a23d4ee2f0ef" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_da7296ae-3e76-4bad-834b-850f771aad41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5b89ac2c-aad3-4cdd-8ce4-401df232da32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_988fae0b-8903-420a-be6c-a23d4ee2f0ef" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5b89ac2c-aad3-4cdd-8ce4-401df232da32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e07aaaba-cf82-4124-b00e-8c02fd8c37cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_105cc8bb-15f8-4cfb-88be-674345f2c738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e07aaaba-cf82-4124-b00e-8c02fd8c37cb" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_105cc8bb-15f8-4cfb-88be-674345f2c738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_611bc957-26a5-495f-924a-2c100279f679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e07aaaba-cf82-4124-b00e-8c02fd8c37cb" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_611bc957-26a5-495f-924a-2c100279f679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f5732346-7e94-4183-b41b-a7b09d192863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e07aaaba-cf82-4124-b00e-8c02fd8c37cb" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f5732346-7e94-4183-b41b-a7b09d192863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1a4088d7-0945-425d-abd8-f3a865e61fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6d097974-3a5c-475f-8c9d-e941d2959173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1a4088d7-0945-425d-abd8-f3a865e61fd9" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6d097974-3a5c-475f-8c9d-e941d2959173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_96151a31-0047-460a-8f0b-46f6c17cd2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1a4088d7-0945-425d-abd8-f3a865e61fd9" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_96151a31-0047-460a-8f0b-46f6c17cd2ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ba5a9bae-2976-4238-9a8b-e9ac89c2ba2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1a4088d7-0945-425d-abd8-f3a865e61fd9" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ba5a9bae-2976-4238-9a8b-e9ac89c2ba2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3fd86bd7-4328-4b51-82e3-86eaf5f28dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_89384f62-ffa0-4219-afa1-77b067a32b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3fd86bd7-4328-4b51-82e3-86eaf5f28dbd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_89384f62-ffa0-4219-afa1-77b067a32b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_31b6b40b-47ad-4450-bcbf-1565c5a64632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3fd86bd7-4328-4b51-82e3-86eaf5f28dbd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_31b6b40b-47ad-4450-bcbf-1565c5a64632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_076b5c6f-e693-49a3-990f-6e7abd2cb8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_bb505b96-3ef9-4846-80a6-4663a551b5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_076b5c6f-e693-49a3-990f-6e7abd2cb8f3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_bb505b96-3ef9-4846-80a6-4663a551b5a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_16e9edb8-ab16-4c46-a29c-955a6a6a86e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_076b5c6f-e693-49a3-990f-6e7abd2cb8f3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_16e9edb8-ab16-4c46-a29c-955a6a6a86e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2b749607-ac42-4d42-b788-6e28533f01be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_076b5c6f-e693-49a3-990f-6e7abd2cb8f3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2b749607-ac42-4d42-b788-6e28533f01be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_931ff168-068c-4d3b-9e97-4cbfa4c87314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_076b5c6f-e693-49a3-990f-6e7abd2cb8f3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_931ff168-068c-4d3b-9e97-4cbfa4c87314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a1d97a27-3656-4e5b-a734-38611aa0bb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_114a3266-83f3-43ed-85c5-453b543b5f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a1d97a27-3656-4e5b-a734-38611aa0bb48" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_114a3266-83f3-43ed-85c5-453b543b5f3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3593e1c7-4b36-4afb-90ef-c3c7bf12fd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a1d97a27-3656-4e5b-a734-38611aa0bb48" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3593e1c7-4b36-4afb-90ef-c3c7bf12fd6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_90388fd4-2db0-4f8e-831c-c91c7540ffb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_bca46485-459d-43ea-96d6-4f62e9c78ecc" xlink:href="amgn-20221231.xsd#amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90388fd4-2db0-4f8e-831c-c91c7540ffb3" xlink:to="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_bca46485-459d-43ea-96d6-4f62e9c78ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2c431bf9-c13f-4304-bddd-28e892cdd785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90388fd4-2db0-4f8e-831c-c91c7540ffb3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2c431bf9-c13f-4304-bddd-28e892cdd785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_51b21f78-d584-46ef-87bb-b92750729a7d" xlink:href="amgn-20221231.xsd#amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90388fd4-2db0-4f8e-831c-c91c7540ffb3" xlink:to="loc_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_51b21f78-d584-46ef-87bb-b92750729a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_2b4339a0-082c-4743-882a-18525cd60d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90388fd4-2db0-4f8e-831c-c91c7540ffb3" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_2b4339a0-082c-4743-882a-18525cd60d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_9b0f3751-13d2-417e-a63c-ec6f7df1f982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90388fd4-2db0-4f8e-831c-c91c7540ffb3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_9b0f3751-13d2-417e-a63c-ec6f7df1f982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries_27ef834c-a68b-4978-b7d8-ff9e96b8fed7" xlink:href="amgn-20221231.xsd#amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90388fd4-2db0-4f8e-831c-c91c7540ffb3" xlink:to="loc_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries_27ef834c-a68b-4978-b7d8-ff9e96b8fed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2722ea04-67d7-4645-b6ac-0bfb83b32138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90388fd4-2db0-4f8e-831c-c91c7540ffb3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2722ea04-67d7-4645-b6ac-0bfb83b32138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_85303d09-e18c-4ab4-8524-1a39760963de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90388fd4-2db0-4f8e-831c-c91c7540ffb3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_85303d09-e18c-4ab4-8524-1a39760963de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesReconciliationofFederalStatutoryTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_988b42d5-c9d0-4ead-a962-8f4f728b649b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_988b42d5-c9d0-4ead-a962-8f4f728b649b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a252aab7-d981-494d-b2b1-7215f1ae1a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a252aab7-d981-494d-b2b1-7215f1ae1a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_f8023ae4-9b82-4d0e-a7fb-1f3e82e1665d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_f8023ae4-9b82-4d0e-a7fb-1f3e82e1665d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_e69df20f-b359-4eea-a35a-a67e3ce26313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_e69df20f-b359-4eea-a35a-a67e3ce26313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_269f10ba-4a4d-4657-a6dd-5e0429348caa" xlink:href="amgn-20221231.xsd#amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_269f10ba-4a4d-4657-a6dd-5e0429348caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f70f2783-9a2f-4fa4-a035-e0ec0fec9fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f70f2783-9a2f-4fa4-a035-e0ec0fec9fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_97e5d127-bb4f-4a90-8b6f-289dc0685908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_97e5d127-bb4f-4a90-8b6f-289dc0685908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_cd93b6af-7890-4794-9105-f587a27cb349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_cd93b6af-7890-4794-9105-f587a27cb349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_630d3ef2-e37c-4a50-b100-5dbe11dd1c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192d646-be7a-4230-845e-5af24a2685f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_630d3ef2-e37c-4a50-b100-5dbe11dd1c58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#EarningspershareDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/EarningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a6c26e3a-f174-45e0-98eb-ff4576a6e03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_86ca104e-17a9-4e63-871d-e4f2653a5b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a6c26e3a-f174-45e0-98eb-ff4576a6e03a" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_86ca104e-17a9-4e63-871d-e4f2653a5b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1fca63c7-9e5b-4817-b431-d33cb8746fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a6c26e3a-f174-45e0-98eb-ff4576a6e03a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1fca63c7-9e5b-4817-b431-d33cb8746fbe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c8a67b5e-8e36-49e1-9639-6086cbab4cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e0a4a8f0-dfa6-4c97-84a2-04b97996f607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c8a67b5e-8e36-49e1-9639-6086cbab4cc2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e0a4a8f0-dfa6-4c97-84a2-04b97996f607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0862b1ab-1665-479e-b205-961548201ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c8a67b5e-8e36-49e1-9639-6086cbab4cc2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0862b1ab-1665-479e-b205-961548201ed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1793b1a6-8d3e-44d3-96d4-55dbd136fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c8a67b5e-8e36-49e1-9639-6086cbab4cc2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1793b1a6-8d3e-44d3-96d4-55dbd136fe95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c370bab-12ed-4d88-a434-80eebb0eb12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3ec41b43-adf4-457c-9e45-ac4606c3fdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c370bab-12ed-4d88-a434-80eebb0eb12a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3ec41b43-adf4-457c-9e45-ac4606c3fdd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_46ed0e99-355c-4c5f-964c-d6414f0f1759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c370bab-12ed-4d88-a434-80eebb0eb12a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_46ed0e99-355c-4c5f-964c-d6414f0f1759" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f5829030-d65e-45f7-8a17-29f78d3d463d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1b648a8b-1e80-44f3-8d41-ff41e7e4bf20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5829030-d65e-45f7-8a17-29f78d3d463d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1b648a8b-1e80-44f3-8d41-ff41e7e4bf20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3cb67066-b5c1-45d2-a9aa-691e7a55bb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5829030-d65e-45f7-8a17-29f78d3d463d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3cb67066-b5c1-45d2-a9aa-691e7a55bb4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e4b04541-0af8-44f7-ab54-cbace005a8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5829030-d65e-45f7-8a17-29f78d3d463d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e4b04541-0af8-44f7-ab54-cbace005a8f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#PropertyplantandequipmentScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_552134b8-ca51-45ca-ab5b-94e7b1d06969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_f4a3d85b-e80c-4e7c-88e4-8dc13c4fb998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_552134b8-ca51-45ca-ab5b-94e7b1d06969" xlink:to="loc_us-gaap_Land_f4a3d85b-e80c-4e7c-88e4-8dc13c4fb998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_62be1515-43d5-4968-88d3-dbafee997d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_552134b8-ca51-45ca-ab5b-94e7b1d06969" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_62be1515-43d5-4968-88d3-dbafee997d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_bc026b59-f3af-4e75-ab73-3b0d981e125a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_552134b8-ca51-45ca-ab5b-94e7b1d06969" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_bc026b59-f3af-4e75-ab73-3b0d981e125a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment_d4e60e39-7710-4ad0-aa7a-586408cefd7e" xlink:href="amgn-20221231.xsd#amgn_LaboratoryEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_552134b8-ca51-45ca-ab5b-94e7b1d06969" xlink:to="loc_amgn_LaboratoryEquipment_d4e60e39-7710-4ad0-aa7a-586408cefd7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment_bfdc9fe6-c034-44da-96b8-6c3fe98910b3" xlink:href="amgn-20221231.xsd#amgn_FixedEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_552134b8-ca51-45ca-ab5b-94e7b1d06969" xlink:to="loc_amgn_FixedEquipment_bfdc9fe6-c034-44da-96b8-6c3fe98910b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_64136f2f-b651-4cbe-b80e-6f029720e98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_552134b8-ca51-45ca-ab5b-94e7b1d06969" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_64136f2f-b651-4cbe-b80e-6f029720e98c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_199615c0-1e76-4692-971d-1a935b70e494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_552134b8-ca51-45ca-ab5b-94e7b1d06969" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_199615c0-1e76-4692-971d-1a935b70e494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_32cf8be2-1146-4dab-b95e-94668d8b8957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_552134b8-ca51-45ca-ab5b-94e7b1d06969" xlink:to="loc_us-gaap_ConstructionInProgressGross_32cf8be2-1146-4dab-b95e-94668d8b8957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d9019c67-0451-4454-b771-06e9d2fc96a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78ca0d49-06f2-43e1-9cf5-f9aaf8a1a299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d9019c67-0451-4454-b771-06e9d2fc96a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78ca0d49-06f2-43e1-9cf5-f9aaf8a1a299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9c6ba9cd-8651-48d1-8c8d-c04b6456c51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d9019c67-0451-4454-b771-06e9d2fc96a7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9c6ba9cd-8651-48d1-8c8d-c04b6456c51e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b97f333e-7ce0-4633-9c51-19c50098be21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fa1c60a0-a91f-4fe4-a14c-5352cb50d1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b97f333e-7ce0-4633-9c51-19c50098be21" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fa1c60a0-a91f-4fe4-a14c-5352cb50d1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8db0bc44-8bde-4f76-886a-220d4933a457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b97f333e-7ce0-4633-9c51-19c50098be21" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8db0bc44-8bde-4f76-886a-220d4933a457" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a640b0a7-6b79-408f-ad22-c260776da54a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_08c4ae55-2325-4c20-a1b6-d1d51d4ffbe6" xlink:href="amgn-20221231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a640b0a7-6b79-408f-ad22-c260776da54a" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_08c4ae55-2325-4c20-a1b6-d1d51d4ffbe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_c94d5bac-91d2-4c7a-abbd-1858fede514e" xlink:href="amgn-20221231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a640b0a7-6b79-408f-ad22-c260776da54a" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_c94d5bac-91d2-4c7a-abbd-1858fede514e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_10ecc292-5fa0-4735-9d35-ef8de56b4de5" xlink:href="amgn-20221231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_007e40d2-6039-4d80-b752-839ab42d99bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross_10ecc292-5fa0-4735-9d35-ef8de56b4de5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_007e40d2-6039-4d80-b752-839ab42d99bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0b890cf9-b587-4258-a47a-2151d4cd99e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross_10ecc292-5fa0-4735-9d35-ef8de56b4de5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0b890cf9-b587-4258-a47a-2151d4cd99e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesSummaryofLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f0fded7b-e1ab-4619-a4a4-8bc245ed5a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8ca3f84c-bb53-48be-a861-4d3a76f22073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f0fded7b-e1ab-4619-a4a4-8bc245ed5a8f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8ca3f84c-bb53-48be-a861-4d3a76f22073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_577883ad-e286-4a7b-b290-680f884b4f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f0fded7b-e1ab-4619-a4a4-8bc245ed5a8f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_577883ad-e286-4a7b-b290-680f884b4f50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ac558026-850c-4a74-90f7-92d857ffd5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9ec8f551-4e22-409a-9ada-7e8eb7399c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac558026-850c-4a74-90f7-92d857ffd5e5" xlink:to="loc_us-gaap_OperatingLeaseCost_9ec8f551-4e22-409a-9ada-7e8eb7399c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_635311fb-eda1-4a2a-aaa0-d84752f401f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac558026-850c-4a74-90f7-92d857ffd5e5" xlink:to="loc_us-gaap_SubleaseIncome_635311fb-eda1-4a2a-aaa0-d84752f401f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0904e099-003a-442f-aabc-d40651c11313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f9ef27eb-c28e-47cf-9e2a-5cc7148ca69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0904e099-003a-442f-aabc-d40651c11313" xlink:to="loc_us-gaap_OperatingLeaseLiability_f9ef27eb-c28e-47cf-9e2a-5cc7148ca69e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c79a6a25-a7db-4e09-a6b8-e7690c9c7cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0904e099-003a-442f-aabc-d40651c11313" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c79a6a25-a7db-4e09-a6b8-e7690c9c7cbb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_66d0e3dd-ebfe-4e4b-a509-2f40c802a7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_84ca742a-0ff6-4332-bb7e-8252149dc257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_66d0e3dd-ebfe-4e4b-a509-2f40c802a7dc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_84ca742a-0ff6-4332-bb7e-8252149dc257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a5b10177-94cb-4e46-a87d-c896afedd26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_66d0e3dd-ebfe-4e4b-a509-2f40c802a7dc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a5b10177-94cb-4e46-a87d-c896afedd26f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3aa0231d-53ad-4227-b8c0-f5100f53bda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_66d0e3dd-ebfe-4e4b-a509-2f40c802a7dc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3aa0231d-53ad-4227-b8c0-f5100f53bda8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_63083189-4978-4ab3-842d-7571cc832a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_66d0e3dd-ebfe-4e4b-a509-2f40c802a7dc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_63083189-4978-4ab3-842d-7571cc832a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e8d5fbf7-687e-4bb4-8c3c-bd513561c4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_66d0e3dd-ebfe-4e4b-a509-2f40c802a7dc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e8d5fbf7-687e-4bb4-8c3c-bd513561c4c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2e819933-cc28-4d1e-958c-21c33c677483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_66d0e3dd-ebfe-4e4b-a509-2f40c802a7dc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2e819933-cc28-4d1e-958c-21c33c677483" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2e155ff0-476c-4c7b-8cc3-6d0b20a655e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_9fc9db2c-e7fe-42cf-bf1f-251965c5df04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_2e155ff0-476c-4c7b-8cc3-6d0b20a655e5" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_9fc9db2c-e7fe-42cf-bf1f-251965c5df04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_d05d28f2-9148-48aa-91bf-5c695f9d7c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_2e155ff0-476c-4c7b-8cc3-6d0b20a655e5" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_d05d28f2-9148-48aa-91bf-5c695f9d7c73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_0fb7b2d5-c445-4cf6-a1af-b288a982e7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_2e155ff0-476c-4c7b-8cc3-6d0b20a655e5" xlink:to="loc_us-gaap_InterestReceivableCurrent_0fb7b2d5-c445-4cf6-a1af-b288a982e7aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_1d6b8466-72bd-4ed4-b0b1-d6246a85c315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_2e155ff0-476c-4c7b-8cc3-6d0b20a655e5" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_1d6b8466-72bd-4ed4-b0b1-d6246a85c315" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_035e7bdb-70f2-4ffb-9298-ac7afa975183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesDeductionsCurrent_c75e6813-304d-467f-8ded-a207fa255d10" xlink:href="amgn-20221231.xsd#amgn_AccruedSalesDeductionsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_035e7bdb-70f2-4ffb-9298-ac7afa975183" xlink:to="loc_amgn_AccruedSalesDeductionsCurrent_c75e6813-304d-467f-8ded-a207fa255d10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_03b3bdb6-2ebb-41fc-b2ef-d8cdf82c3a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_035e7bdb-70f2-4ffb-9298-ac7afa975183" xlink:to="loc_us-gaap_DividendsPayableCurrent_03b3bdb6-2ebb-41fc-b2ef-d8cdf82c3a8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_701a4f01-4798-4f87-be36-84d8f083f2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_035e7bdb-70f2-4ffb-9298-ac7afa975183" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_701a4f01-4798-4f87-be36-84d8f083f2f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_406f4334-21be-4301-a48d-e385003f7a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_035e7bdb-70f2-4ffb-9298-ac7afa975183" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_406f4334-21be-4301-a48d-e385003f7a84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesReturnReserveCurrent_f7240414-3bbc-40a5-9777-fe8a47156aed" xlink:href="amgn-20221231.xsd#amgn_AccruedSalesReturnReserveCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_035e7bdb-70f2-4ffb-9298-ac7afa975183" xlink:to="loc_amgn_AccruedSalesReturnReserveCurrent_f7240414-3bbc-40a5-9777-fe8a47156aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_48024347-3b68-42c9-9a43-6d2894e537b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_035e7bdb-70f2-4ffb-9298-ac7afa975183" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_48024347-3b68-42c9-9a43-6d2894e537b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_65868fc7-151c-49e9-9382-6e75d9184a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ed6b5c65-2589-4b76-90d8-fa5674ae5dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_65868fc7-151c-49e9-9382-6e75d9184a7e" xlink:to="loc_us-gaap_LongTermDebtCurrent_ed6b5c65-2589-4b76-90d8-fa5674ae5dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_54a280cc-84a8-4b9c-bb8a-fad271d64ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_65868fc7-151c-49e9-9382-6e75d9184a7e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_54a280cc-84a8-4b9c-bb8a-fad271d64ef3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_73220137-1c4f-44ed-ab0f-fa80f69105e9" xlink:href="amgn-20221231.xsd#amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6ccecfa4-19a4-4a1f-bbd7-d316b8e46659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_73220137-1c4f-44ed-ab0f-fa80f69105e9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6ccecfa4-19a4-4a1f-bbd7-d316b8e46659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b7dcbb9f-bf02-4653-ada0-b09c9b2cffd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_73220137-1c4f-44ed-ab0f-fa80f69105e9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b7dcbb9f-bf02-4653-ada0-b09c9b2cffd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20eab228-35d8-44b2-b56f-80a1983afe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_73220137-1c4f-44ed-ab0f-fa80f69105e9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20eab228-35d8-44b2-b56f-80a1983afe2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7a7c7f8b-813e-44e1-bb73-13a46df636a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_73220137-1c4f-44ed-ab0f-fa80f69105e9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7a7c7f8b-813e-44e1-bb73-13a46df636a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_02fc5ff1-d968-4e34-b6e9-8e3db120b21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_73220137-1c4f-44ed-ab0f-fa80f69105e9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_02fc5ff1-d968-4e34-b6e9-8e3db120b21b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_86b42c31-6b3e-46e7-8b64-efed4332260a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_73220137-1c4f-44ed-ab0f-fa80f69105e9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_86b42c31-6b3e-46e7-8b64-efed4332260a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_18880624-66b5-433a-9481-24a9dd234901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fff3fd40-05b5-413b-872e-e95f99b34891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_18880624-66b5-433a-9481-24a9dd234901" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fff3fd40-05b5-413b-872e-e95f99b34891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_79051fca-33bf-46a7-bc29-5c3ff2ae8c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_18880624-66b5-433a-9481-24a9dd234901" xlink:to="loc_us-gaap_OtherInvestments_79051fca-33bf-46a7-bc29-5c3ff2ae8c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_890c2f77-c646-416e-ba16-cefafd7ff449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_18880624-66b5-433a-9481-24a9dd234901" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_890c2f77-c646-416e-ba16-cefafd7ff449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_d8865dce-4bd4-4660-9dbf-f4cbf06e9a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_18880624-66b5-433a-9481-24a9dd234901" xlink:to="loc_us-gaap_DerivativeAssets_d8865dce-4bd4-4660-9dbf-f4cbf06e9a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fc7f5a1d-4642-4ea1-82cf-8f0abffa27f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_53bfc2bc-43c2-41a3-8e64-276e9ca3f199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_fc7f5a1d-4642-4ea1-82cf-8f0abffa27f2" xlink:to="loc_us-gaap_DerivativeLiabilities_53bfc2bc-43c2-41a3-8e64-276e9ca3f199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9094573a-242c-430b-95e3-68a17043db4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_fc7f5a1d-4642-4ea1-82cf-8f0abffa27f2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9094573a-242c-430b-95e3-68a17043db4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_dfa85ed9-5da6-40e1-a259-cb49a1888d35" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_8a866eb9-bcc8-4202-905d-f95ee6d598fd" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_dfa85ed9-5da6-40e1-a259-cb49a1888d35" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_8a866eb9-bcc8-4202-905d-f95ee6d598fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_6357f45c-f3bb-4ba0-9467-9739670891a7" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_dfa85ed9-5da6-40e1-a259-cb49a1888d35" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_6357f45c-f3bb-4ba0-9467-9739670891a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_ecabb78a-a75e-49d9-aeef-8c6a96af67f4" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_dfa85ed9-5da6-40e1-a259-cb49a1888d35" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_ecabb78a-a75e-49d9-aeef-8c6a96af67f4" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>amgn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4e826620-fc5c-4c14-9c2e-3ba20b6aa99d,g:1e6ee203-6cba-438e-aedd-ef42aa695ae1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Coverpage" xlink:type="simple" xlink:href="amgn-20221231.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Coverpage" xlink:type="extended" id="if04028a5fcbe4cd7a9ed3eecde21fe1d_Coverpage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9106a000-87e5-4525-9fd1-447839e30c0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentType_9106a000-87e5-4525-9fd1-447839e30c0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ba6559e8-5548-4ab4-adf0-6aba33b995ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentAnnualReport_ba6559e8-5548-4ab4-adf0-6aba33b995ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b33bfc55-bbd9-496c-a113-cbbafeb96e30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentPeriodEndDate_b33bfc55-bbd9-496c-a113-cbbafeb96e30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_61c16320-3ab4-4e3c-834e-b94c07e226ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentTransitionReport_61c16320-3ab4-4e3c-834e-b94c07e226ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4c130044-d89c-475f-8f50-9c4ee2770040" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityFileNumber_4c130044-d89c-475f-8f50-9c4ee2770040" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_093acbb0-7e22-4f59-870c-c1444794ad0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityRegistrantName_093acbb0-7e22-4f59-870c-c1444794ad0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_142525e3-e107-48c7-a4cd-ce22d4368c81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_142525e3-e107-48c7-a4cd-ce22d4368c81" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d73d87dc-6428-46aa-8a3c-7eca79eb176a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityTaxIdentificationNumber_d73d87dc-6428-46aa-8a3c-7eca79eb176a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_dfb79f2d-8078-4161-b02b-986aeee53515" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityAddressAddressLine1_dfb79f2d-8078-4161-b02b-986aeee53515" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8c99b5c9-9f7d-492d-a829-325ed9365e86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityAddressCityOrTown_8c99b5c9-9f7d-492d-a829-325ed9365e86" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_07b9e04d-1b0f-4fdb-a2fb-bd7cf7ebb462" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityAddressStateOrProvince_07b9e04d-1b0f-4fdb-a2fb-bd7cf7ebb462" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b57c59d5-0349-4c5a-9b09-bf21731605db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityAddressPostalZipCode_b57c59d5-0349-4c5a-9b09-bf21731605db" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7b212a50-9582-41e7-9ca5-a3804b631bef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_CityAreaCode_7b212a50-9582-41e7-9ca5-a3804b631bef" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_72697f43-e613-4e4c-bfec-a93bc4d444f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_LocalPhoneNumber_72697f43-e613-4e4c-bfec-a93bc4d444f6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6f4a03bb-9cfe-4dc7-9abd-f955d13055d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_Security12bTitle_6f4a03bb-9cfe-4dc7-9abd-f955d13055d6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c6e75238-9155-4293-9155-d18b2ed2b415" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_TradingSymbol_c6e75238-9155-4293-9155-d18b2ed2b415" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_807f99ed-7e37-4a67-b270-25c78adadb35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_SecurityExchangeName_807f99ed-7e37-4a67-b270-25c78adadb35" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_eabd9234-40f7-4c1d-99ad-5d729eaa793c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_eabd9234-40f7-4c1d-99ad-5d729eaa793c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_e992e56c-3fdc-4970-bcf6-ff16a9638159" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityVoluntaryFilers_e992e56c-3fdc-4970-bcf6-ff16a9638159" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_932d26f7-f4b4-46b6-a3ed-8f8ae6176a34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityCurrentReportingStatus_932d26f7-f4b4-46b6-a3ed-8f8ae6176a34" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_878371b6-77cc-449c-abf9-9cdf5f1e7fbd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityInteractiveDataCurrent_878371b6-77cc-449c-abf9-9cdf5f1e7fbd" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d7dc18d3-c9aa-4965-a773-eb646be87891" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityFilerCategory_d7dc18d3-c9aa-4965-a773-eb646be87891" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_75cbdb30-c244-4c78-a793-fd8b82fc069f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntitySmallBusiness_75cbdb30-c244-4c78-a793-fd8b82fc069f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_df0369c5-6d61-4ab6-bfad-16995e152f54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityEmergingGrowthCompany_df0369c5-6d61-4ab6-bfad-16995e152f54" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_05e811ed-abcf-4a4e-8b92-e1c99ab62a35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_IcfrAuditorAttestationFlag_05e811ed-abcf-4a4e-8b92-e1c99ab62a35" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_25b7f567-622c-4552-b506-ae5fb90aa037" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityShellCompany_25b7f567-622c-4552-b506-ae5fb90aa037" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_975ae740-76ba-428a-b62a-544a15f2f413" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityPublicFloat_975ae740-76ba-428a-b62a-544a15f2f413" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_745a8d7a-73f6-41d8-91cc-70f7aae636ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_745a8d7a-73f6-41d8-91cc-70f7aae636ad" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_4323fc52-6a0e-4ae7-866a-42ca4b7da5e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_4323fc52-6a0e-4ae7-866a-42ca4b7da5e7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6070daa7-3f8a-4982-903a-a0f662dcfedf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityCentralIndexKey_6070daa7-3f8a-4982-903a-a0f662dcfedf" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fad49953-2034-4e21-b023-d0471876e019" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_AmendmentFlag_fad49953-2034-4e21-b023-d0471876e019" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_335f2265-e92f-49f8-a914-d97936c65e92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentFiscalYearFocus_335f2265-e92f-49f8-a914-d97936c65e92" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b088ffa0-cde2-4bc4-b18b-cb7e9d9c598a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b088ffa0-cde2-4bc4-b18b-cb7e9d9c598a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_287d6463-babe-4939-8def-bc59f2d9b33e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_CurrentFiscalYearEndDate_287d6463-babe-4939-8def-bc59f2d9b33e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_a340641d-f467-4385-8464-95e80618efe7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntitiesTable_a340641d-f467-4385-8464-95e80618efe7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_861803bf-167a-4ced-83d4-5751e6500282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_a340641d-f467-4385-8464-95e80618efe7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_861803bf-167a-4ced-83d4-5751e6500282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_861803bf-167a-4ced-83d4-5751e6500282_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_861803bf-167a-4ced-83d4-5751e6500282" xlink:to="loc_us-gaap_ClassOfStockDomain_861803bf-167a-4ced-83d4-5751e6500282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b2699e81-25b3-4d82-a9a1-c9385e753222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_861803bf-167a-4ced-83d4-5751e6500282" xlink:to="loc_us-gaap_ClassOfStockDomain_b2699e81-25b3-4d82-a9a1-c9385e753222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9384d7ba-614b-468b-be22-c7f4cb9ebf16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b2699e81-25b3-4d82-a9a1-c9385e753222" xlink:to="loc_us-gaap_CommonStockMember_9384d7ba-614b-468b-be22-c7f4cb9ebf16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_f5b47e38-bf34-4a1f-9f49-49f17b5e83d8" xlink:href="amgn-20221231.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b2699e81-25b3-4d82-a9a1-c9385e753222" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_f5b47e38-bf34-4a1f-9f49-49f17b5e83d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_3954baaf-d970-48dc-b02e-9f0c686a0a9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_a340641d-f467-4385-8464-95e80618efe7" xlink:to="loc_dei_EntityListingsExchangeAxis_3954baaf-d970-48dc-b02e-9f0c686a0a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_3954baaf-d970-48dc-b02e-9f0c686a0a9d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_3954baaf-d970-48dc-b02e-9f0c686a0a9d" xlink:to="loc_dei_ExchangeDomain_3954baaf-d970-48dc-b02e-9f0c686a0a9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_bb8d3d44-9cc6-4f39-b19e-d78ec8f8ae6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_3954baaf-d970-48dc-b02e-9f0c686a0a9d" xlink:to="loc_dei_ExchangeDomain_bb8d3d44-9cc6-4f39-b19e-d78ec8f8ae6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_5e641629-75e0-445c-a15c-d3b560b496d5" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNGS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_bb8d3d44-9cc6-4f39-b19e-d78ec8f8ae6a" xlink:to="loc_exch_XNGS_5e641629-75e0-445c-a15c-d3b560b496d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_c2600681-bdc8-4490-8816-29616077517f" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_bb8d3d44-9cc6-4f39-b19e-d78ec8f8ae6a" xlink:to="loc_exch_XNYS_c2600681-bdc8-4490-8816-29616077517f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="i3f0af17b77d043c48d875583dff3f222_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3fc6b85c-cfe8-4c73-aa1e-cf233f1ad2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_RevenuesAbstract_3fc6b85c-cfe8-4c73-aa1e-cf233f1ad2d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc9392f5-7ce9-4696-bb9a-10427ab17a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_3fc6b85c-cfe8-4c73-aa1e-cf233f1ad2d3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc9392f5-7ce9-4696-bb9a-10427ab17a07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_65f7579b-cfef-4564-8faf-e7c9259c4473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_65f7579b-cfef-4564-8faf-e7c9259c4473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6a4a7bc2-f86b-48d6-aa68-7e77abeb52b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6a4a7bc2-f86b-48d6-aa68-7e77abeb52b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_575528b6-acea-4d67-b04b-881e622fee10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_575528b6-acea-4d67-b04b-881e622fee10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_83b89b9f-cb9a-40f2-bf41-e06b7fb45469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_83b89b9f-cb9a-40f2-bf41-e06b7fb45469" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense_ead3123e-28a9-4d32-9575-cd355257a381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_OtherGeneralExpense_ead3123e-28a9-4d32-9575-cd355257a381" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6bc28b74-daa4-44d0-aecd-c384e3c10fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_CostsAndExpenses_6bc28b74-daa4-44d0-aecd-c384e3c10fa4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a5f4e767-9a12-40e0-8ca2-d1bd93d50a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_OperatingIncomeLoss_a5f4e767-9a12-40e0-8ca2-d1bd93d50a1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_92de95de-47a9-4c4c-827b-5d96024377dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_InterestExpenseDebt_92de95de-47a9-4c4c-827b-5d96024377dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_dba56d31-88a0-4a5b-aac6-5bee1dbfd73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_dba56d31-88a0-4a5b-aac6-5bee1dbfd73c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3430e662-7f62-42ee-9305-bd92a6f3552b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3430e662-7f62-42ee-9305-bd92a6f3552b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_508a2c48-b45c-44d0-9603-9f8efa90e722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_508a2c48-b45c-44d0-9603-9f8efa90e722" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_174b8ee3-13d6-4b47-96db-5548eee9761b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_NetIncomeLoss_174b8ee3-13d6-4b47-96db-5548eee9761b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fb6bd216-1344-418b-94a6-53272946c290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_EarningsPerShareAbstract_fb6bd216-1344-418b-94a6-53272946c290" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_673adf9f-1a73-4896-832d-8903cb8c9753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fb6bd216-1344-418b-94a6-53272946c290" xlink:to="loc_us-gaap_EarningsPerShareBasic_673adf9f-1a73-4896-832d-8903cb8c9753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d7c15ed9-b124-4711-b2fa-8c741c2e074f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fb6bd216-1344-418b-94a6-53272946c290" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d7c15ed9-b124-4711-b2fa-8c741c2e074f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0d43786c-4c11-45d8-baec-6e02e4d59eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0d43786c-4c11-45d8-baec-6e02e4d59eac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6284ffed-d07d-441a-afb5-a2ba891b357b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0d43786c-4c11-45d8-baec-6e02e4d59eac" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6284ffed-d07d-441a-afb5-a2ba891b357b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8eee17f6-51b1-4c9b-a1bb-44aef6a04088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0d43786c-4c11-45d8-baec-6e02e4d59eac" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8eee17f6-51b1-4c9b-a1bb-44aef6a04088" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_75a32ea7-c375-4ebc-ab41-aa0715176462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_StatementTable_75a32ea7-c375-4ebc-ab41-aa0715176462" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e38e3459-65af-446a-bdc2-a12feba2a3b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_75a32ea7-c375-4ebc-ab41-aa0715176462" xlink:to="loc_srt_ProductOrServiceAxis_e38e3459-65af-446a-bdc2-a12feba2a3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e38e3459-65af-446a-bdc2-a12feba2a3b7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e38e3459-65af-446a-bdc2-a12feba2a3b7" xlink:to="loc_srt_ProductsAndServicesDomain_e38e3459-65af-446a-bdc2-a12feba2a3b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a77e9aff-82cd-4639-b271-e3940186f0d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e38e3459-65af-446a-bdc2-a12feba2a3b7" xlink:to="loc_srt_ProductsAndServicesDomain_a77e9aff-82cd-4639-b271-e3940186f0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_31554eb8-9866-452d-bd84-65fa03fc6b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a77e9aff-82cd-4639-b271-e3940186f0d3" xlink:to="loc_us-gaap_ProductMember_31554eb8-9866-452d-bd84-65fa03fc6b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9fc3c413-646c-48f9-bf1e-b4761c3e05ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a77e9aff-82cd-4639-b271-e3940186f0d3" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9fc3c413-646c-48f9-bf1e-b4761c3e05ab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ied8720ed5a3147faa182c08616480f50_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_68c849a8-00ae-4ee6-9175-5b875caba786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_68c849a8-00ae-4ee6-9175-5b875caba786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0bf1bbb-c48f-4db0-9a3d-b4cbba0f90fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockholdersEquity_a0bf1bbb-c48f-4db0-9a3d-b4cbba0f90fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f3ccefed-4dd9-44b7-8e37-2cdf355f7da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_NetIncomeLoss_f3ccefed-4dd9-44b7-8e37-2cdf355f7da6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bd8d1eef-8728-462f-9d8f-14c0adca8e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bd8d1eef-8728-462f-9d8f-14c0adca8e92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_47c9c2a1-4f27-4f3a-8d34-a59ad2788a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_DividendsCommonStockCash_47c9c2a1-4f27-4f3a-8d34-a59ad2788a56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5a42b7d0-efd1-4d6c-ad94-df6a5c601e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5a42b7d0-efd1-4d6c-ad94-df6a5c601e2c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4fb4b968-54bc-48fb-897b-1702a1824c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4fb4b968-54bc-48fb-897b-1702a1824c92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_648ee284-4c21-45eb-8859-96ccc374b852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_648ee284-4c21-45eb-8859-96ccc374b852" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_30974e2c-4b41-45e4-881d-427a8564dc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_30974e2c-4b41-45e4-881d-427a8564dc09" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_07ed89ed-2f5a-4379-8c95-ee460a7eee46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_07ed89ed-2f5a-4379-8c95-ee460a7eee46" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ba60a4b0-a99d-41fb-9c09-db2ba6afc823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8acf4529-797f-4574-882c-8b9ca8cf0d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_45bc3b7f-4533-4f21-8778-aef4c8f4a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_45bc3b7f-4533-4f21-8778-aef4c8f4a4bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_cf64e2ed-63ea-40e7-9c10-4c4a47c194bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_cf64e2ed-63ea-40e7-9c10-4c4a47c194bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_17cdbb50-9d3a-49eb-a92b-1b187584dd85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:to="loc_us-gaap_StatementTable_17cdbb50-9d3a-49eb-a92b-1b187584dd85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_960469ed-f758-4eb1-9bff-e70ef11816e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_17cdbb50-9d3a-49eb-a92b-1b187584dd85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_960469ed-f758-4eb1-9bff-e70ef11816e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_960469ed-f758-4eb1-9bff-e70ef11816e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960469ed-f758-4eb1-9bff-e70ef11816e6" xlink:to="loc_us-gaap_EquityComponentDomain_960469ed-f758-4eb1-9bff-e70ef11816e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960469ed-f758-4eb1-9bff-e70ef11816e6" xlink:to="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1c4d9759-8186-4d6a-be0b-3852468e3ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:to="loc_us-gaap_CommonStockMember_1c4d9759-8186-4d6a-be0b-3852468e3ed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_685b12ee-c2e4-4d25-97c8-d0918876b0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_685b12ee-c2e4-4d25-97c8-d0918876b0bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c89fae0d-5ef4-4257-8b26-f0a5495df146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:to="loc_us-gaap_RetainedEarningsMember_c89fae0d-5ef4-4257-8b26-f0a5495df146" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1068a14c-a36f-4d40-9e83-4b64751fe75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1068a14c-a36f-4d40-9e83-4b64751fe75e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6a00bf91-4c0b-4bfc-9bb5-15af710e168e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_17cdbb50-9d3a-49eb-a92b-1b187584dd85" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6a00bf91-4c0b-4bfc-9bb5-15af710e168e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6a00bf91-4c0b-4bfc-9bb5-15af710e168e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6a00bf91-4c0b-4bfc-9bb5-15af710e168e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6a00bf91-4c0b-4bfc-9bb5-15af710e168e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_01abe208-74a3-402f-aebd-4a0f9d1b9d0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6a00bf91-4c0b-4bfc-9bb5-15af710e168e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_01abe208-74a3-402f-aebd-4a0f9d1b9d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fb6a0070-10d4-4fe3-943e-d18da3b98c91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_01abe208-74a3-402f-aebd-4a0f9d1b9d0e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fb6a0070-10d4-4fe3-943e-d18da3b98c91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended" id="i2272787cbb1f43ac9300aa5f996acb49_SummaryofsignificantaccountingpoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f178cef6-66a5-4ff9-b039-5fb6c4d80540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f178cef6-66a5-4ff9-b039-5fb6c4d80540" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_ba7f5905-80c8-4e6b-9891-8891f8eb8318" xlink:href="amgn-20221231.xsd#amgn_SalesReturnProvisionsAsPercentageOfProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_ba7f5905-80c8-4e6b-9891-8891f8eb8318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenuePaymentArrangementTerm_5e7f5753-02ba-4c40-a716-df667f4758c9" xlink:href="amgn-20221231.xsd#amgn_RevenuePaymentArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_amgn_RevenuePaymentArrangementTerm_5e7f5753-02ba-4c40-a716-df667f4758c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_351b2f0c-a7e7-4a30-baec-409b7d7b414d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_us-gaap_AdvertisingExpense_351b2f0c-a7e7-4a30-baec-409b7d7b414d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a717e350-4db6-4ebd-82e2-8d625b8943d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a717e350-4db6-4ebd-82e2-8d625b8943d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3dc97587-cea0-4ddf-a1e0-7370ff6f3c9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:to="loc_srt_RangeAxis_3dc97587-cea0-4ddf-a1e0-7370ff6f3c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3dc97587-cea0-4ddf-a1e0-7370ff6f3c9d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3dc97587-cea0-4ddf-a1e0-7370ff6f3c9d" xlink:to="loc_srt_RangeMember_3dc97587-cea0-4ddf-a1e0-7370ff6f3c9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4121c4ca-10cd-4e89-88cf-04e0771a21c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3dc97587-cea0-4ddf-a1e0-7370ff6f3c9d" xlink:to="loc_srt_RangeMember_4121c4ca-10cd-4e89-88cf-04e0771a21c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fcf88b14-6859-496c-96e2-12ac58d00882" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4121c4ca-10cd-4e89-88cf-04e0771a21c3" xlink:to="loc_srt_MinimumMember_fcf88b14-6859-496c-96e2-12ac58d00882" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3345e563-96fb-471f-8f04-e989d0d370ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4121c4ca-10cd-4e89-88cf-04e0771a21c3" xlink:to="loc_srt_MaximumMember_3345e563-96fb-471f-8f04-e989d0d370ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a962a71a-c780-46e3-993a-1ff6deeebd9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:to="loc_srt_ProductOrServiceAxis_a962a71a-c780-46e3-993a-1ff6deeebd9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a962a71a-c780-46e3-993a-1ff6deeebd9d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a962a71a-c780-46e3-993a-1ff6deeebd9d" xlink:to="loc_srt_ProductsAndServicesDomain_a962a71a-c780-46e3-993a-1ff6deeebd9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c98185a8-4839-4cc7-bcbb-f6cd217b0c9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a962a71a-c780-46e3-993a-1ff6deeebd9d" xlink:to="loc_srt_ProductsAndServicesDomain_c98185a8-4839-4cc7-bcbb-f6cd217b0c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember_0bca282d-8159-485d-9e51-e6348dd28429" xlink:href="amgn-20221231.xsd#amgn_NplateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c98185a8-4839-4cc7-bcbb-f6cd217b0c9f" xlink:to="loc_amgn_NplateMember_0bca282d-8159-485d-9e51-e6348dd28429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b226d25a-636c-41fc-a366-8bfa968213fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:to="loc_srt_StatementGeographicalAxis_b226d25a-636c-41fc-a366-8bfa968213fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b226d25a-636c-41fc-a366-8bfa968213fd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b226d25a-636c-41fc-a366-8bfa968213fd" xlink:to="loc_srt_SegmentGeographicalDomain_b226d25a-636c-41fc-a366-8bfa968213fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5b23035f-c98f-401a-b720-0474b99b4aed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b226d25a-636c-41fc-a366-8bfa968213fd" xlink:to="loc_srt_SegmentGeographicalDomain_5b23035f-c98f-401a-b720-0474b99b4aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4aadd13c-5cfb-449c-8a83-0bababb42d8f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5b23035f-c98f-401a-b720-0474b99b4aed" xlink:to="loc_country_US_4aadd13c-5cfb-449c-8a83-0bababb42d8f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails" xlink:type="extended" id="i5beb9683dd7e4a64ba39ac0b5b048c55_AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_ea580777-4ac8-4e6b-bf9f-3d4bda63c772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_ea580777-4ac8-4e6b-bf9f-3d4bda63c772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_46c52643-3984-43a5-b257-54847e4f8a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_46c52643-3984-43a5-b257-54847e4f8a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ApprovedProducts_f46913c5-50e8-4fc6-8e49-91e9ea379a25" xlink:href="amgn-20221231.xsd#amgn_ApprovedProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_ApprovedProducts_f46913c5-50e8-4fc6-8e49-91e9ea379a25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DevelopmentPrograms_9375f300-e3be-4f92-88a3-9f35215520e0" xlink:href="amgn-20221231.xsd#amgn_DevelopmentPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_DevelopmentPrograms_9375f300-e3be-4f92-88a3-9f35215520e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementMaximumLength_c27686dc-407a-4263-a2d7-03dd0d083f0f" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementMaximumLength"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_BridgeCreditAgreementMaximumLength_c27686dc-407a-4263-a2d7-03dd0d083f0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementInitialAmount_d8b09ddd-ccd0-4652-b961-08623e7c4b01" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementInitialAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_BridgeCreditAgreementInitialAmount_d8b09ddd-ccd0-4652-b961-08623e7c4b01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TermLoanCreditAgreementTotalAmount_2a0ae313-033b-41bb-a052-7ea6d9413c94" xlink:href="amgn-20221231.xsd#amgn_TermLoanCreditAgreementTotalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_TermLoanCreditAgreementTotalAmount_2a0ae313-033b-41bb-a052-7ea6d9413c94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TermLoanCreditAgreementNumberOfTraunches_313002d3-8688-4163-abae-a1d3d5881328" xlink:href="amgn-20221231.xsd#amgn_TermLoanCreditAgreementNumberOfTraunches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_TermLoanCreditAgreementNumberOfTraunches_313002d3-8688-4163-abae-a1d3d5881328" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditReducedAmount_80a1ad9f-e47a-4f29-9231-822e2a004b45" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditReducedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_BridgeCreditReducedAmount_80a1ad9f-e47a-4f29-9231-822e2a004b45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementAmount_927cfe8e-9638-419c-96ca-fa09244e0ca3" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_BridgeCreditAgreementAmount_927cfe8e-9638-419c-96ca-fa09244e0ca3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_8dc1c461-3544-499e-97c0-92180ecfd8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_8dc1c461-3544-499e-97c0-92180ecfd8df" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensatingBalanceAmount_010e2f12-3b44-430a-8cf2-925da6ff12ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatingBalanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_us-gaap_CompensatingBalanceAmount_010e2f12-3b44-430a-8cf2-925da6ff12ef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3f844dbb-12bc-4151-9c4d-25e02bd8f9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3f844dbb-12bc-4151-9c4d-25e02bd8f9cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7f99aa4c-b1b6-4ca5-99a2-e364b852fa83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3f844dbb-12bc-4151-9c4d-25e02bd8f9cf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7f99aa4c-b1b6-4ca5-99a2-e364b852fa83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7f99aa4c-b1b6-4ca5-99a2-e364b852fa83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7f99aa4c-b1b6-4ca5-99a2-e364b852fa83" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7f99aa4c-b1b6-4ca5-99a2-e364b852fa83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec623d3a-8983-410f-a6e8-f8c6ddae464b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7f99aa4c-b1b6-4ca5-99a2-e364b852fa83" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec623d3a-8983-410f-a6e8-f8c6ddae464b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HorizonTherapeuticsMember_7fab89bf-321c-4449-9d80-db2290fe3b5e" xlink:href="amgn-20221231.xsd#amgn_HorizonTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec623d3a-8983-410f-a6e8-f8c6ddae464b" xlink:to="loc_amgn_HorizonTherapeuticsMember_7fab89bf-321c-4449-9d80-db2290fe3b5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_119224f9-e843-4e85-ae1d-58d18a8fd932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3f844dbb-12bc-4151-9c4d-25e02bd8f9cf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_119224f9-e843-4e85-ae1d-58d18a8fd932" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_119224f9-e843-4e85-ae1d-58d18a8fd932_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_119224f9-e843-4e85-ae1d-58d18a8fd932" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_119224f9-e843-4e85-ae1d-58d18a8fd932_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6eeee6bf-087b-4d83-b1a8-55a52ef5d219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_119224f9-e843-4e85-ae1d-58d18a8fd932" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6eeee6bf-087b-4d83-b1a8-55a52ef5d219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementMember_84094c7c-391e-4a2d-b0f6-c7f3e43a47bc" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6eeee6bf-087b-4d83-b1a8-55a52ef5d219" xlink:to="loc_amgn_BridgeCreditAgreementMember_84094c7c-391e-4a2d-b0f6-c7f3e43a47bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails" xlink:type="extended" id="ic527b18b3e7e42949964353bc6762764_AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_f83fe2a6-cdbc-42ac-82b6-17793d8fe5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_f83fe2a6-cdbc-42ac-82b6-17793d8fe5a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_b91fc68c-c18c-4740-8d81-f2660dea8abe" xlink:href="amgn-20221231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_b91fc68c-c18c-4740-8d81-f2660dea8abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6f980b5e-c66b-4304-b1ca-29e22c12636d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6f980b5e-c66b-4304-b1ca-29e22c12636d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_874e241a-bc7b-4e08-b88e-17109b4bc526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_874e241a-bc7b-4e08-b88e-17109b4bc526" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices_a3287b3a-62fe-472f-ade9-f30a1718c7be" xlink:href="amgn-20221231.xsd#amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices_a3287b3a-62fe-472f-ade9-f30a1718c7be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_70bc40da-e1f8-40f4-86a7-4b485980ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_70bc40da-e1f8-40f4-86a7-4b485980ffe2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fe1d8297-f524-4304-8413-29f090e8b134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fe1d8297-f524-4304-8413-29f090e8b134" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d36c2ae1-2bac-4c89-b539-9c22a71ff08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d36c2ae1-2bac-4c89-b539-9c22a71ff08a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired_ed2d6088-9670-4c91-b2c0-f3e26f7d0d9a" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired_ed2d6088-9670-4c91-b2c0-f3e26f7d0d9a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_37c26af1-6ae3-4943-9053-a185d982be43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_37c26af1-6ae3-4943-9053-a185d982be43" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ade2e2e3-9276-4591-8956-e4e551d1ff94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_Goodwill_ade2e2e3-9276-4591-8956-e4e551d1ff94" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ec12849-043a-4abb-9b44-c8a40e874c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ec12849-043a-4abb-9b44-c8a40e874c36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_24d491a9-ddc9-4cdc-a347-2f7b4e201512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ec12849-043a-4abb-9b44-c8a40e874c36" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_24d491a9-ddc9-4cdc-a347-2f7b4e201512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24d491a9-ddc9-4cdc-a347-2f7b4e201512_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_24d491a9-ddc9-4cdc-a347-2f7b4e201512" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24d491a9-ddc9-4cdc-a347-2f7b4e201512_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96994789-4965-4e64-bb92-bb9ecc833f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_24d491a9-ddc9-4cdc-a347-2f7b4e201512" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96994789-4965-4e64-bb92-bb9ecc833f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ChemoCentryxIncMember_7e95c84b-3906-461b-84c1-d986647251e9" xlink:href="amgn-20221231.xsd#amgn_ChemoCentryxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96994789-4965-4e64-bb92-bb9ecc833f10" xlink:to="loc_amgn_ChemoCentryxIncMember_7e95c84b-3906-461b-84c1-d986647251e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a88ad51d-bf3e-47c7-b8c0-86c0189a87cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ec12849-043a-4abb-9b44-c8a40e874c36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a88ad51d-bf3e-47c7-b8c0-86c0189a87cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a88ad51d-bf3e-47c7-b8c0-86c0189a87cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a88ad51d-bf3e-47c7-b8c0-86c0189a87cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a88ad51d-bf3e-47c7-b8c0-86c0189a87cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70eb45c5-4b16-4206-afa6-65763eaf06ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a88ad51d-bf3e-47c7-b8c0-86c0189a87cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70eb45c5-4b16-4206-afa6-65763eaf06ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_85f5233b-ba74-4456-97ca-0caba169dea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70eb45c5-4b16-4206-afa6-65763eaf06ee" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_85f5233b-ba74-4456-97ca-0caba169dea4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails" xlink:type="extended" id="i4e16d10ac93f477fadee43136f5d7277_AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_dca9b3a3-8e92-45ab-96c0-f0e40787607f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_dca9b3a3-8e92-45ab-96c0-f0e40787607f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_61d4cf80-eeb7-481f-8ece-95df9de57c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_61d4cf80-eeb7-481f-8ece-95df9de57c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f851ff4f-102a-466f-bb74-42cf94324eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f851ff4f-102a-466f-bb74-42cf94324eaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85ee0bc9-deee-44e3-875f-90eb3ab346f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85ee0bc9-deee-44e3-875f-90eb3ab346f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c039f9ec-29e8-42da-a7b2-14b562d7935b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_Goodwill_c039f9ec-29e8-42da-a7b2-14b562d7935b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_cdfc5817-5068-4b00-8864-64a7dfcd58ae" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_cdfc5817-5068-4b00-8864-64a7dfcd58ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c19bb2a7-85ad-4643-b4ef-5e208ff8019d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c19bb2a7-85ad-4643-b4ef-5e208ff8019d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_68633570-8470-4183-bf8f-a985afb40827" xlink:href="amgn-20221231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_68633570-8470-4183-bf8f-a985afb40827" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5c3031-209b-4dfe-bb8c-626d8f07ef69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5c3031-209b-4dfe-bb8c-626d8f07ef69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59097fb9-3def-4e5e-85bf-6f3471383d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5c3031-209b-4dfe-bb8c-626d8f07ef69" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59097fb9-3def-4e5e-85bf-6f3471383d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59097fb9-3def-4e5e-85bf-6f3471383d5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59097fb9-3def-4e5e-85bf-6f3471383d5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59097fb9-3def-4e5e-85bf-6f3471383d5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c322ad23-4573-4ad3-87ec-6f302b613523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59097fb9-3def-4e5e-85bf-6f3471383d5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c322ad23-4573-4ad3-87ec-6f302b613523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ChemoCentryxIncMember_60dc3f1a-2b12-4f04-84f8-d5071ee0f716" xlink:href="amgn-20221231.xsd#amgn_ChemoCentryxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c322ad23-4573-4ad3-87ec-6f302b613523" xlink:to="loc_amgn_ChemoCentryxIncMember_60dc3f1a-2b12-4f04-84f8-d5071ee0f716" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_546ba6a8-cd05-4aef-99b6-4434ae134c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5c3031-209b-4dfe-bb8c-626d8f07ef69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_546ba6a8-cd05-4aef-99b6-4434ae134c14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_546ba6a8-cd05-4aef-99b6-4434ae134c14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_546ba6a8-cd05-4aef-99b6-4434ae134c14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_546ba6a8-cd05-4aef-99b6-4434ae134c14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_067e3572-b4ef-476f-93dc-3d8ce4abb34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_546ba6a8-cd05-4aef-99b6-4434ae134c14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_067e3572-b4ef-476f-93dc-3d8ce4abb34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e1547052-9679-4131-9c30-1e5de35feefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_067e3572-b4ef-476f-93dc-3d8ce4abb34f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e1547052-9679-4131-9c30-1e5de35feefc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresTeneobioIncDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails" xlink:type="extended" id="iccf9479967f04f2aa3b74bc469a42942_AcquisitionsanddivestituresTeneobioIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a3f5fe74-91d0-4137-a13a-7af566232f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a3f5fe74-91d0-4137-a13a-7af566232f28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_27c0d243-8895-4e54-8d72-7dd1df0dd0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_27c0d243-8895-4e54-8d72-7dd1df0dd0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4ee210c5-44d5-48a4-ab14-becfa5667e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4ee210c5-44d5-48a4-ab14-becfa5667e0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_c3e1bfba-557f-4a6c-87fa-4fed6e53bbfb" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_c3e1bfba-557f-4a6c-87fa-4fed6e53bbfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_132df20d-d61e-4fe4-b4c0-2089e488f989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_132df20d-d61e-4fe4-b4c0-2089e488f989" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfPreclinicalOncologyPrograms_550103a5-136a-47a0-bc50-68971ede2ef9" xlink:href="amgn-20221231.xsd#amgn_NumberOfPreclinicalOncologyPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_amgn_NumberOfPreclinicalOncologyPrograms_550103a5-136a-47a0-bc50-68971ede2ef9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_acbe829c-04b9-4d28-9f3d-f1e3fb7bbf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_acbe829c-04b9-4d28-9f3d-f1e3fb7bbf5c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0ab61084-ef0e-4828-82fa-090f09925f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0ab61084-ef0e-4828-82fa-090f09925f52" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7033fdd8-17ab-4c34-828e-2d132dfd2aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7033fdd8-17ab-4c34-828e-2d132dfd2aba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ba0867e7-a3d0-4633-bbdf-f582a6866e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_Goodwill_ba0867e7-a3d0-4633-bbdf-f582a6866e69" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b642a23b-afdd-459c-a8be-96bf0b1a614f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b642a23b-afdd-459c-a8be-96bf0b1a614f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b642a23b-afdd-459c-a8be-96bf0b1a614f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b642a23b-afdd-459c-a8be-96bf0b1a614f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b642a23b-afdd-459c-a8be-96bf0b1a614f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a91b2f6f-74dd-4e80-99b9-c919f1466849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b642a23b-afdd-459c-a8be-96bf0b1a614f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a91b2f6f-74dd-4e80-99b9-c919f1466849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_23151dcc-de55-42ca-aaf7-b6fd6d61f8a3" xlink:href="amgn-20221231.xsd#amgn_TeneobioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a91b2f6f-74dd-4e80-99b9-c919f1466849" xlink:to="loc_amgn_TeneobioMember_23151dcc-de55-42ca-aaf7-b6fd6d61f8a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6df28329-4b34-45fd-b3f2-4575104f38b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6df28329-4b34-45fd-b3f2-4575104f38b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6df28329-4b34-45fd-b3f2-4575104f38b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6df28329-4b34-45fd-b3f2-4575104f38b5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6df28329-4b34-45fd-b3f2-4575104f38b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a135f8f5-cd7d-46ff-b836-5e604c74dd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6df28329-4b34-45fd-b3f2-4575104f38b5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a135f8f5-cd7d-46ff-b836-5e604c74dd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b629da76-c306-4fcb-8e37-0d5fca1f928a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a135f8f5-cd7d-46ff-b836-5e604c74dd63" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b629da76-c306-4fcb-8e37-0d5fca1f928a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeAxis_c32b491b-19a5-4322-9a02-5f80e0fe941c" xlink:href="amgn-20221231.xsd#amgn_MoleculeTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:to="loc_amgn_MoleculeTypeAxis_c32b491b-19a5-4322-9a02-5f80e0fe941c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain_c32b491b-19a5-4322-9a02-5f80e0fe941c_default" xlink:href="amgn-20221231.xsd#amgn_MoleculeTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_MoleculeTypeAxis_c32b491b-19a5-4322-9a02-5f80e0fe941c" xlink:to="loc_amgn_MoleculeTypeDomain_c32b491b-19a5-4322-9a02-5f80e0fe941c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain_b5880889-b5a2-4705-a1a0-590f1e69aa7e" xlink:href="amgn-20221231.xsd#amgn_MoleculeTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_MoleculeTypeAxis_c32b491b-19a5-4322-9a02-5f80e0fe941c" xlink:to="loc_amgn_MoleculeTypeDomain_b5880889-b5a2-4705-a1a0-590f1e69aa7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AMG340Member_7795f792-c59b-4797-b300-275d869776af" xlink:href="amgn-20221231.xsd#amgn_AMG340Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_MoleculeTypeDomain_b5880889-b5a2-4705-a1a0-590f1e69aa7e" xlink:to="loc_amgn_AMG340Member_7795f792-c59b-4797-b300-275d869776af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5e5ad8f3-a5c7-43f4-9dbc-9fb643547499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5e5ad8f3-a5c7-43f4-9dbc-9fb643547499" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e5ad8f3-a5c7-43f4-9dbc-9fb643547499_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5e5ad8f3-a5c7-43f4-9dbc-9fb643547499" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e5ad8f3-a5c7-43f4-9dbc-9fb643547499_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2156c45-f85e-4a83-9bec-e296d147e947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5e5ad8f3-a5c7-43f4-9dbc-9fb643547499" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2156c45-f85e-4a83-9bec-e296d147e947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_823f0b84-aa5a-4f6a-abce-8f9e0c0d72f4" xlink:href="amgn-20221231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2156c45-f85e-4a83-9bec-e296d147e947" xlink:to="loc_amgn_RDTechnologyrightsMember_823f0b84-aa5a-4f6a-abce-8f9e0c0d72f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_1cd74235-71fe-417b-bc3b-5f68229bd5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2156c45-f85e-4a83-9bec-e296d147e947" xlink:to="loc_us-gaap_LicensingAgreementsMember_1cd74235-71fe-417b-bc3b-5f68229bd5ae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails" xlink:type="extended" id="i70a14c8c6e744ef78be5578d03953a51_AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_34158204-6309-4550-8ab1-5c4472531ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_34158204-6309-4550-8ab1-5c4472531ca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_f52aa5de-400d-4d98-a466-34d51e291395" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_f52aa5de-400d-4d98-a466-34d51e291395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_5ba10717-bd8e-49ab-98ef-1d5f028c9340" xlink:href="amgn-20221231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_5ba10717-bd8e-49ab-98ef-1d5f028c9340" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_05be1f4f-1683-4de3-ab5c-907ed46fa015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_05be1f4f-1683-4de3-ab5c-907ed46fa015" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc7ceb61-1cfc-4bbf-9836-cfed90428a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc7ceb61-1cfc-4bbf-9836-cfed90428a89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_24528adb-d4f8-4add-ad88-5b596913ac07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_24528adb-d4f8-4add-ad88-5b596913ac07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b7aac4d4-4a4b-4736-8b3a-4efbf69da993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_Goodwill_b7aac4d4-4a4b-4736-8b3a-4efbf69da993" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_79ebe9ab-ea93-4660-adca-977dfabb0f95" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_79ebe9ab-ea93-4660-adca-977dfabb0f95" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_63dd773e-e461-48ba-8f3a-4fbf951ec60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_63dd773e-e461-48ba-8f3a-4fbf951ec60f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_24c55a1d-c158-4697-98e7-d8da532a93e5" xlink:href="amgn-20221231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_24c55a1d-c158-4697-98e7-d8da532a93e5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e1f355ce-242b-404c-b3b9-5fae7598dfca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e1f355ce-242b-404c-b3b9-5fae7598dfca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1f355ce-242b-404c-b3b9-5fae7598dfca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1f355ce-242b-404c-b3b9-5fae7598dfca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1f355ce-242b-404c-b3b9-5fae7598dfca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66cc7bff-cf16-4dcb-94e8-d2fb8e7eb7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1f355ce-242b-404c-b3b9-5fae7598dfca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66cc7bff-cf16-4dcb-94e8-d2fb8e7eb7a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_d1b07a50-7ee2-44a9-a7c0-52eb16450a9c" xlink:href="amgn-20221231.xsd#amgn_TeneobioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66cc7bff-cf16-4dcb-94e8-d2fb8e7eb7a5" xlink:to="loc_amgn_TeneobioMember_d1b07a50-7ee2-44a9-a7c0-52eb16450a9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b69d26c3-8962-48c1-a86e-626edf636171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b69d26c3-8962-48c1-a86e-626edf636171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b69d26c3-8962-48c1-a86e-626edf636171_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b69d26c3-8962-48c1-a86e-626edf636171" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b69d26c3-8962-48c1-a86e-626edf636171_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5d44fc8b-2c2b-45d1-a097-894da3636612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b69d26c3-8962-48c1-a86e-626edf636171" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5d44fc8b-2c2b-45d1-a097-894da3636612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e3d44d0d-29c4-432e-b622-122683af1ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5d44fc8b-2c2b-45d1-a097-894da3636612" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e3d44d0d-29c4-432e-b622-122683af1ceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_799468ef-9e8e-4b39-84a4-765c5dab80f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_799468ef-9e8e-4b39-84a4-765c5dab80f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_799468ef-9e8e-4b39-84a4-765c5dab80f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_799468ef-9e8e-4b39-84a4-765c5dab80f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_799468ef-9e8e-4b39-84a4-765c5dab80f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0f392bd-f2f1-4ab6-b6b3-396ff92b2b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_799468ef-9e8e-4b39-84a4-765c5dab80f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0f392bd-f2f1-4ab6-b6b3-396ff92b2b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_0f3c6807-bf01-464e-b515-818fff78df99" xlink:href="amgn-20221231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0f392bd-f2f1-4ab6-b6b3-396ff92b2b87" xlink:to="loc_amgn_RDTechnologyrightsMember_0f3c6807-bf01-464e-b515-818fff78df99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e2c660a9-e724-4096-bcb1-b6a0cf885796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0f392bd-f2f1-4ab6-b6b3-396ff92b2b87" xlink:to="loc_us-gaap_LicensingAgreementsMember_e2c660a9-e724-4096-bcb1-b6a0cf885796" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails" xlink:type="extended" id="i3d96bf2b79ac42a18dfcb28e35e38816_AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6f7eb065-e3f1-4fd7-8288-b38897d687b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6f7eb065-e3f1-4fd7-8288-b38897d687b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_cb8ec8c0-bab6-44fb-bd32-88518e052a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_cb8ec8c0-bab6-44fb-bd32-88518e052a75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fc1cfafc-dcb5-46d7-834b-473a8fbaa906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fc1cfafc-dcb5-46d7-834b-473a8fbaa906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_46cf15ea-f52d-448c-b139-55f076b31b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_46cf15ea-f52d-448c-b139-55f076b31b59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_190e3d2f-4b33-4c59-8cd2-72559f6b8285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_190e3d2f-4b33-4c59-8cd2-72559f6b8285" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87f829f8-82e1-480c-804b-149954855c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_190e3d2f-4b33-4c59-8cd2-72559f6b8285" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87f829f8-82e1-480c-804b-149954855c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87f829f8-82e1-480c-804b-149954855c0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87f829f8-82e1-480c-804b-149954855c0f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87f829f8-82e1-480c-804b-149954855c0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c7a4a-4abf-4720-bd43-f376b5bbb262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87f829f8-82e1-480c-804b-149954855c0f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c7a4a-4abf-4720-bd43-f376b5bbb262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePrimeTherapeuticsIncMember_7414e3e6-9532-40f5-b450-06cf259fd607" xlink:href="amgn-20221231.xsd#amgn_FivePrimeTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c7a4a-4abf-4720-bd43-f376b5bbb262" xlink:to="loc_amgn_FivePrimeTherapeuticsIncMember_7414e3e6-9532-40f5-b450-06cf259fd607" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresDivestitureofGensentaDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails" xlink:type="extended" id="i1f5c1df723234c9480f27095340cf518_AcquisitionsanddivestituresDivestitureofGensentaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness_fd1407dd-458f-4fc8-b1fb-76df0e33a8da" xlink:href="amgn-20221231.xsd#amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:to="loc_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness_fd1407dd-458f-4fc8-b1fb-76df0e33a8da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9f16a0db-71d6-4c37-8890-59e15cf38a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9f16a0db-71d6-4c37-8890-59e15cf38a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ffa3a55b-f347-4445-b4d2-1a6c40af87e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ffa3a55b-f347-4445-b4d2-1a6c40af87e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_89d051ef-8991-4484-8741-faf34dedb56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_89d051ef-8991-4484-8741-faf34dedb56e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa2e4ea-f27b-4b10-bcd4-b4834223f210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa2e4ea-f27b-4b10-bcd4-b4834223f210" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6492499a-958b-4f8d-875c-accb465ab298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa2e4ea-f27b-4b10-bcd4-b4834223f210" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6492499a-958b-4f8d-875c-accb465ab298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6492499a-958b-4f8d-875c-accb465ab298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6492499a-958b-4f8d-875c-accb465ab298" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6492499a-958b-4f8d-875c-accb465ab298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88cbd7c2-d72b-45e4-a8fc-aa78d2a47944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6492499a-958b-4f8d-875c-accb465ab298" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88cbd7c2-d72b-45e4-a8fc-aa78d2a47944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherGeneralExpenseMember_d18c01c4-0cdc-489a-b68d-da8b2c62cc29" xlink:href="amgn-20221231.xsd#amgn_OtherGeneralExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88cbd7c2-d72b-45e4-a8fc-aa78d2a47944" xlink:to="loc_amgn_OtherGeneralExpenseMember_d18c01c4-0cdc-489a-b68d-da8b2c62cc29" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i22faa7960c1e44dda00f51c44af32fe9_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_14d3ac15-6de0-4fb2-a0ff-c1c58e649e8a" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_14d3ac15-6de0-4fb2-a0ff-c1c58e649e8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_b43a4228-7c2a-4e6d-9e89-42aa6f49d788" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_b43a4228-7c2a-4e6d-9e89-42aa6f49d788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_f89e1fb4-4414-4cf4-b0d6-80080402b5fb" xlink:href="amgn-20221231.xsd#amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_f89e1fb4-4414-4cf4-b0d6-80080402b5fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_c4b86440-a14f-44f9-b5bf-ab5acb27a67f" xlink:href="amgn-20221231.xsd#amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_c4b86440-a14f-44f9-b5bf-ab5acb27a67f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ec8a0375-c4f9-411f-8701-b5d08e26fc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ec8a0375-c4f9-411f-8701-b5d08e26fc7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_ce415763-7d36-4e6e-a939-3f67296d62bc" xlink:href="amgn-20221231.xsd#amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_ce415763-7d36-4e6e-a939-3f67296d62bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_054ef017-dd58-4ca1-b641-fdb76d82a5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_054ef017-dd58-4ca1-b641-fdb76d82a5cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a1197d11-e6ac-4136-a819-d963403032a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:to="loc_srt_MajorCustomersAxis_a1197d11-e6ac-4136-a819-d963403032a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a1197d11-e6ac-4136-a819-d963403032a7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a1197d11-e6ac-4136-a819-d963403032a7" xlink:to="loc_srt_NameOfMajorCustomerDomain_a1197d11-e6ac-4136-a819-d963403032a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a1197d11-e6ac-4136-a819-d963403032a7" xlink:to="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_c626279e-ec98-4a9b-8166-eb310afea13b" xlink:href="amgn-20221231.xsd#amgn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:to="loc_amgn_CustomerOneMember_c626279e-ec98-4a9b-8166-eb310afea13b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_bbbec83d-a671-42e1-acff-1163d844d6c8" xlink:href="amgn-20221231.xsd#amgn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:to="loc_amgn_CustomerTwoMember_bbbec83d-a671-42e1-acff-1163d844d6c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_78672897-7096-48d6-93be-a694aef23d4d" xlink:href="amgn-20221231.xsd#amgn_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:to="loc_amgn_CustomerThreeMember_78672897-7096-48d6-93be-a694aef23d4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8220b2b9-1754-41b1-876b-429c5f4295ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:to="loc_srt_ProductOrServiceAxis_8220b2b9-1754-41b1-876b-429c5f4295ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8220b2b9-1754-41b1-876b-429c5f4295ba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8220b2b9-1754-41b1-876b-429c5f4295ba" xlink:to="loc_srt_ProductsAndServicesDomain_8220b2b9-1754-41b1-876b-429c5f4295ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1c16cfa-4ad4-46e3-9490-fb1aed6fceb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8220b2b9-1754-41b1-876b-429c5f4295ba" xlink:to="loc_srt_ProductsAndServicesDomain_b1c16cfa-4ad4-46e3-9490-fb1aed6fceb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1c16cfa-4ad4-46e3-9490-fb1aed6fceb8" xlink:to="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember_3e399496-54f3-473d-ac10-de70d90c70e9" xlink:href="amgn-20221231.xsd#amgn_EnbrelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_EnbrelMember_3e399496-54f3-473d-ac10-de70d90c70e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember_7d1587f9-2c5d-459a-8aca-187a879961a4" xlink:href="amgn-20221231.xsd#amgn_ProliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_ProliaMember_7d1587f9-2c5d-459a-8aca-187a879961a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_5f30e428-e735-4743-bc3f-1fec6cb15409" xlink:href="amgn-20221231.xsd#amgn_OtezlaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_OtezlaMember_5f30e428-e735-4743-bc3f-1fec6cb15409" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember_137cbf0c-20d4-40b3-81e8-51e7d3386aaa" xlink:href="amgn-20221231.xsd#amgn_XgevaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_XgevaMember_137cbf0c-20d4-40b3-81e8-51e7d3386aaa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember_5fb9004e-34f0-4b54-9463-3a9a2bef9ea1" xlink:href="amgn-20221231.xsd#amgn_AranespMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_AranespMember_5fb9004e-34f0-4b54-9463-3a9a2bef9ea1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember_9056eb86-a02a-4e6d-b321-e31dfa096672" xlink:href="amgn-20221231.xsd#amgn_NplateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_NplateMember_9056eb86-a02a-4e6d-b321-e31dfa096672" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember_249bd083-06d8-410d-8e19-62669ee948d9" xlink:href="amgn-20221231.xsd#amgn_RepathaevolocumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_RepathaevolocumabMember_249bd083-06d8-410d-8e19-62669ee948d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_439b1840-0264-4b5f-9adf-4d4b4cad0933" xlink:href="amgn-20221231.xsd#amgn_KyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_KyprolisMember_439b1840-0264-4b5f-9adf-4d4b4cad0933" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember_b5d5ac34-da41-45f4-93d7-b6c42e48ea40" xlink:href="amgn-20221231.xsd#amgn_NeulastaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_NeulastaMember_b5d5ac34-da41-45f4-93d7-b6c42e48ea40" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EvenityMember_75956baf-5a81-4195-897f-18374e20c222" xlink:href="amgn-20221231.xsd#amgn_EvenityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_EvenityMember_75956baf-5a81-4195-897f-18374e20c222" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember_14a351f7-30ab-4f50-b15d-87876cf7c0a0" xlink:href="amgn-20221231.xsd#amgn_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_OtherProductsMember_14a351f7-30ab-4f50-b15d-87876cf7c0a0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ad571b37-2a6a-4158-904d-0b78e31683df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1c16cfa-4ad4-46e3-9490-fb1aed6fceb8" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ad571b37-2a6a-4158-904d-0b78e31683df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_65c1e1d4-1bbb-41ac-ae00-cf0f314bd65a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:to="loc_srt_StatementGeographicalAxis_65c1e1d4-1bbb-41ac-ae00-cf0f314bd65a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_65c1e1d4-1bbb-41ac-ae00-cf0f314bd65a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_65c1e1d4-1bbb-41ac-ae00-cf0f314bd65a" xlink:to="loc_srt_SegmentGeographicalDomain_65c1e1d4-1bbb-41ac-ae00-cf0f314bd65a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2597c69e-ce8c-4348-8b2c-724c4e3941ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_65c1e1d4-1bbb-41ac-ae00-cf0f314bd65a" xlink:to="loc_srt_SegmentGeographicalDomain_2597c69e-ce8c-4348-8b2c-724c4e3941ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_82423078-3176-469b-bd0f-a34f668416a9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2597c69e-ce8c-4348-8b2c-724c4e3941ab" xlink:to="loc_country_US_82423078-3176-469b-bd0f-a34f668416a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_26bf08d0-5205-42d0-9243-5e8a041ae389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2597c69e-ce8c-4348-8b2c-724c4e3941ab" xlink:to="loc_us-gaap_NonUsMember_26bf08d0-5205-42d0-9243-5e8a041ae389" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#RevenuesCustomerConcentrationProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="extended" id="ide76954e52c944c180506533217cbd4b_RevenuesCustomerConcentrationProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_44caf9b8-c6e4-47c0-9dce-d5775bd4411f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_44caf9b8-c6e4-47c0-9dce-d5775bd4411f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfGrossRevenues_2a542f80-bee1-401d-8277-8867b0501706" xlink:href="amgn-20221231.xsd#amgn_PercentageOfGrossRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:to="loc_amgn_PercentageOfGrossRevenues_2a542f80-bee1-401d-8277-8867b0501706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_816b8cc1-5d6e-444b-9e79-78be23bf6494" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_816b8cc1-5d6e-444b-9e79-78be23bf6494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_3ee51580-9a64-40b0-a46a-152c7fee0bc3" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_3ee51580-9a64-40b0-a46a-152c7fee0bc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_434c6f4d-7cc6-4546-a89d-3359daf2b7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_434c6f4d-7cc6-4546-a89d-3359daf2b7a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7df622b3-b3e1-4050-ac90-8a3d5deff471" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_434c6f4d-7cc6-4546-a89d-3359daf2b7a6" xlink:to="loc_srt_ProductOrServiceAxis_7df622b3-b3e1-4050-ac90-8a3d5deff471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7df622b3-b3e1-4050-ac90-8a3d5deff471_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7df622b3-b3e1-4050-ac90-8a3d5deff471" xlink:to="loc_srt_ProductsAndServicesDomain_7df622b3-b3e1-4050-ac90-8a3d5deff471_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ad8679e-1b52-40d6-901e-7e7b324b7a2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7df622b3-b3e1-4050-ac90-8a3d5deff471" xlink:to="loc_srt_ProductsAndServicesDomain_5ad8679e-1b52-40d6-901e-7e7b324b7a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7c06bbee-ef63-4346-8fb8-73f41bdfedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ad8679e-1b52-40d6-901e-7e7b324b7a2e" xlink:to="loc_us-gaap_ProductMember_7c06bbee-ef63-4346-8fb8-73f41bdfedbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2fe77a2c-3489-4bbf-9ef6-72b8edd1d100" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_434c6f4d-7cc6-4546-a89d-3359daf2b7a6" xlink:to="loc_srt_MajorCustomersAxis_2fe77a2c-3489-4bbf-9ef6-72b8edd1d100" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2fe77a2c-3489-4bbf-9ef6-72b8edd1d100_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2fe77a2c-3489-4bbf-9ef6-72b8edd1d100" xlink:to="loc_srt_NameOfMajorCustomerDomain_2fe77a2c-3489-4bbf-9ef6-72b8edd1d100_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2fe77a2c-3489-4bbf-9ef6-72b8edd1d100" xlink:to="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_fddc9c0d-3a85-4983-9333-a4aae4aa1475" xlink:href="amgn-20221231.xsd#amgn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:to="loc_amgn_CustomerOneMember_fddc9c0d-3a85-4983-9333-a4aae4aa1475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_44152feb-0d17-4488-a792-5685233f0bf2" xlink:href="amgn-20221231.xsd#amgn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:to="loc_amgn_CustomerTwoMember_44152feb-0d17-4488-a792-5685233f0bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_b7083a64-ed36-430d-8f1e-cfcaac24f693" xlink:href="amgn-20221231.xsd#amgn_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:to="loc_amgn_CustomerThreeMember_b7083a64-ed36-430d-8f1e-cfcaac24f693" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationTextualDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="extended" id="if4e10e4e8c2f4cff9c13facf59ee3d62_StockbasedcompensationTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_19fb8901-0172-4bfb-9050-475c57d9d4e0" xlink:href="amgn-20221231.xsd#amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_19fb8901-0172-4bfb-9050-475c57d9d4e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_2b0fe592-9c41-42bd-8f57-9f409ddc16f0" xlink:href="amgn-20221231.xsd#amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_2b0fe592-9c41-42bd-8f57-9f409ddc16f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_2d21cedd-bd7a-4fc4-ac47-92f61312ade0" xlink:href="amgn-20221231.xsd#amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_2d21cedd-bd7a-4fc4-ac47-92f61312ade0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_8a6aafe6-e831-4635-b0df-c0c8fc286561" xlink:href="amgn-20221231.xsd#amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_8a6aafe6-e831-4635-b0df-c0c8fc286561" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_db976134-be49-4832-a2b3-e7c71af71f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_db976134-be49-4832-a2b3-e7c71af71f97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53d6f91c-75f6-45d6-a619-2d867acaa92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53d6f91c-75f6-45d6-a619-2d867acaa92f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5c40a052-6e52-4693-bcfb-8ac7effd004b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5c40a052-6e52-4693-bcfb-8ac7effd004b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bce9c3d9-53cd-4c8c-b536-59aa9a828dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bce9c3d9-53cd-4c8c-b536-59aa9a828dbe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4976612b-5b76-466a-a725-8d02ee0eba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4976612b-5b76-466a-a725-8d02ee0eba6d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_91ac5962-4760-41e4-b429-c04e63ab3690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_91ac5962-4760-41e4-b429-c04e63ab3690" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c7db28c9-9e98-4446-ac6e-aa36ccd84b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c7db28c9-9e98-4446-ac6e-aa36ccd84b30" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_422e8868-1c16-4d12-aec4-2eaff0126235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_422e8868-1c16-4d12-aec4-2eaff0126235" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_095ada91-3881-40e0-88c8-a41993f39202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_095ada91-3881-40e0-88c8-a41993f39202" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_d8e455af-2b19-4b7e-9773-c069b714bfb6" xlink:href="amgn-20221231.xsd#amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_d8e455af-2b19-4b7e-9773-c069b714bfb6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_85c05877-fc81-4d4a-b6d5-bea287ab31b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_85c05877-fc81-4d4a-b6d5-bea287ab31b7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7f7f84df-b7b0-4a6d-8af1-73a683a5bd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7f7f84df-b7b0-4a6d-8af1-73a683a5bd17" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9df28876-82a9-4ce4-8084-5c6053d8c350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9df28876-82a9-4ce4-8084-5c6053d8c350" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f757f327-15a2-4524-aa58-3ff32880c179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f757f327-15a2-4524-aa58-3ff32880c179" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5f0080e8-2bec-4ef9-8575-42787433658a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5f0080e8-2bec-4ef9-8575-42787433658a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7babc472-eafe-433e-93d8-0bb16080e175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7babc472-eafe-433e-93d8-0bb16080e175" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_82d32400-6128-452d-a361-4708db1477ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7babc472-eafe-433e-93d8-0bb16080e175" xlink:to="loc_us-gaap_AwardTypeAxis_82d32400-6128-452d-a361-4708db1477ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82d32400-6128-452d-a361-4708db1477ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_82d32400-6128-452d-a361-4708db1477ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82d32400-6128-452d-a361-4708db1477ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_82d32400-6128-452d-a361-4708db1477ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f35c570c-37d1-4fdf-9cc5-ff4df9fbfaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f35c570c-37d1-4fdf-9cc5-ff4df9fbfaa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b83fd15c-3e59-4586-9c0f-59b30649cc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b83fd15c-3e59-4586-9c0f-59b30649cc9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_ce31f802-17f3-4ca3-b74b-c491a634b053" xlink:href="amgn-20221231.xsd#amgn_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:to="loc_amgn_PerformanceUnitsMember_ce31f802-17f3-4ca3-b74b-c491a634b053" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i52f5d3976eed4d4b9bc51da1d755c498_StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03e1d820-f110-4b98-b0c7-9032deafc241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03e1d820-f110-4b98-b0c7-9032deafc241" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bb9576a9-3ca3-4eb5-b058-56926cbd928d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:to="loc_us-gaap_ShareBasedCompensation_bb9576a9-3ca3-4eb5-b058-56926cbd928d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_af67eefa-0e17-4866-8c14-89e1a99885e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_af67eefa-0e17-4866-8c14-89e1a99885e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax_6591dec3-d9b5-4c2d-adaf-70459403cfe3" xlink:href="amgn-20221231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:to="loc_amgn_StockBasedCompensationExpenseNetOfTax_6591dec3-d9b5-4c2d-adaf-70459403cfe3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fd72825-159f-483d-aaf2-cf4efa478d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03e1d820-f110-4b98-b0c7-9032deafc241" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fd72825-159f-483d-aaf2-cf4efa478d92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9697809f-56d1-479e-a495-c238704601d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fd72825-159f-483d-aaf2-cf4efa478d92" xlink:to="loc_us-gaap_AwardTypeAxis_9697809f-56d1-479e-a495-c238704601d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697809f-56d1-479e-a495-c238704601d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9697809f-56d1-479e-a495-c238704601d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697809f-56d1-479e-a495-c238704601d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9697809f-56d1-479e-a495-c238704601d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d68a10ad-563c-4dcc-90b3-e577ea524e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d68a10ad-563c-4dcc-90b3-e577ea524e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_39f7699b-cdef-4684-8dfd-7e3715e94cad" xlink:href="amgn-20221231.xsd#amgn_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:to="loc_amgn_PerformanceUnitsMember_39f7699b-cdef-4684-8dfd-7e3715e94cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a4a254f3-92f7-446a-9931-e08e8adb918a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a4a254f3-92f7-446a-9931-e08e8adb918a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationSummaryofRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="extended" id="id5d409232c93499f8c6847eb687dda7a_StockbasedcompensationSummaryofRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9bb3ad1-6260-4651-854b-7c2199bdf990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9bb3ad1-6260-4651-854b-7c2199bdf990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_92ed56b6-a8d3-40cb-af28-531ee44248ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_92ed56b6-a8d3-40cb-af28-531ee44248ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d2fbf7e8-892a-4aba-b9d9-2875544b1ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d2fbf7e8-892a-4aba-b9d9-2875544b1ea7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_240aa4fd-46a9-41f0-84a9-e3c29ffd44f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_240aa4fd-46a9-41f0-84a9-e3c29ffd44f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_de856ca9-a47b-4483-963c-9d2d838c3bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_de856ca9-a47b-4483-963c-9d2d838c3bc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a261ae74-2819-4231-85c6-7f271bd13118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9bb3ad1-6260-4651-854b-7c2199bdf990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ff6c60b-7858-4bae-9389-03f9f43c8878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ff6c60b-7858-4bae-9389-03f9f43c8878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_118244b8-2a75-4893-af26-6a31b634742e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_118244b8-2a75-4893-af26-6a31b634742e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bd029f13-8496-4f5f-b306-278d83819719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bd029f13-8496-4f5f-b306-278d83819719" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0fdf2e8f-cbcf-44f1-8de8-370d538bd7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0fdf2e8f-cbcf-44f1-8de8-370d538bd7ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3286d4e0-f6d2-43b6-a0f9-0bc3b45a40e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05961f06-2272-4d91-bf1e-872d49ee4d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9bb3ad1-6260-4651-854b-7c2199bdf990" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05961f06-2272-4d91-bf1e-872d49ee4d8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9ebb93ed-8ff5-4d62-a8f5-5d03b5506cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05961f06-2272-4d91-bf1e-872d49ee4d8c" xlink:to="loc_us-gaap_AwardTypeAxis_9ebb93ed-8ff5-4d62-a8f5-5d03b5506cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ebb93ed-8ff5-4d62-a8f5-5d03b5506cf5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9ebb93ed-8ff5-4d62-a8f5-5d03b5506cf5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ebb93ed-8ff5-4d62-a8f5-5d03b5506cf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebfd4ab4-b901-4566-8eb7-89c81c3e3a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9ebb93ed-8ff5-4d62-a8f5-5d03b5506cf5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebfd4ab4-b901-4566-8eb7-89c81c3e3a13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_86cf7b88-e113-4de4-8029-0b9f74e651b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebfd4ab4-b901-4566-8eb7-89c81c3e3a13" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_86cf7b88-e113-4de4-8029-0b9f74e651b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended" id="i1a11f35fdd1646a0b19f58916dca96af_StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_fda79f74-59a8-4411-9a8f-41bc69310931" xlink:href="amgn-20221231.xsd#amgn_CommonStockFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_amgn_CommonStockFairValue_fda79f74-59a8-4411-9a8f-41bc69310931" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5bfc9fab-3217-4544-96e0-bc571dbf6160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5bfc9fab-3217-4544-96e0-bc571dbf6160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e310eac-77f8-4a99-8b14-4e46862999dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e310eac-77f8-4a99-8b14-4e46862999dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_22562f4a-1a9e-49fb-86bd-d6d1ec3c94ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_22562f4a-1a9e-49fb-86bd-d6d1ec3c94ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7cd5c7b5-dc47-4802-ab20-c411030c1b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7cd5c7b5-dc47-4802-ab20-c411030c1b47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b5411785-3636-4c20-adf7-92c5ff93d174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b5411785-3636-4c20-adf7-92c5ff93d174" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2b2800b-4c22-4b87-93e9-3be0778bb1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2b2800b-4c22-4b87-93e9-3be0778bb1ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46bd89ee-6dcf-42c5-bed0-0dbf7eacda59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2b2800b-4c22-4b87-93e9-3be0778bb1ed" xlink:to="loc_us-gaap_AwardTypeAxis_46bd89ee-6dcf-42c5-bed0-0dbf7eacda59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46bd89ee-6dcf-42c5-bed0-0dbf7eacda59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_46bd89ee-6dcf-42c5-bed0-0dbf7eacda59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46bd89ee-6dcf-42c5-bed0-0dbf7eacda59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_386ebcfd-b65a-4e55-bb5d-4e39346b8a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_46bd89ee-6dcf-42c5-bed0-0dbf7eacda59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_386ebcfd-b65a-4e55-bb5d-4e39346b8a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8fbf5bc8-1b3a-42b2-8087-f08f82fda335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_386ebcfd-b65a-4e55-bb5d-4e39346b8a9c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8fbf5bc8-1b3a-42b2-8087-f08f82fda335" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended" id="icba8110033ca42ffafa121cab1502672_StockbasedcompensationSummaryofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18e9de84-f9f4-407e-ada1-a3d4e1215fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18e9de84-f9f4-407e-ada1-a3d4e1215fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_cfca0852-8d40-4e83-ad18-1f2a4dd918e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_cfca0852-8d40-4e83-ad18-1f2a4dd918e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_913e3740-3b9a-4c6a-a0d3-13e711eccce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_913e3740-3b9a-4c6a-a0d3-13e711eccce6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_be6984fd-0a38-4ee4-a6b7-5dd80d5a29a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_be6984fd-0a38-4ee4-a6b7-5dd80d5a29a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd5cfd50-92fe-4a39-bb53-cab1131bcbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4cf0134f-bb0e-4b7c-83f6-43282a07821b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4cf0134f-bb0e-4b7c-83f6-43282a07821b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23b13dd6-1194-4120-ad8d-f4723863f18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23b13dd6-1194-4120-ad8d-f4723863f18e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c63503df-5596-4c94-9ba6-35b2d4230adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c63503df-5596-4c94-9ba6-35b2d4230adb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb6790dc-3ad0-4da8-a2fa-5fc0f10a0a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb6790dc-3ad0-4da8-a2fa-5fc0f10a0a94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f183829c-0c4b-484a-ae08-702edf60ebb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f183829c-0c4b-484a-ae08-702edf60ebb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5c12b8d2-db4e-48ca-bc7a-4abcdb9bae82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5c12b8d2-db4e-48ca-bc7a-4abcdb9bae82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e90b58a1-0a09-4607-a167-ec9d9cd8af86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a0b2dbe9-646e-47d3-bedf-c6b365fc435e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a0b2dbe9-646e-47d3-bedf-c6b365fc435e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_29ef4ba2-87ec-460b-bd1d-56f9551ba831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_29ef4ba2-87ec-460b-bd1d-56f9551ba831" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6ebf4e79-d5eb-4f0f-aa92-85773792135b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6ebf4e79-d5eb-4f0f-aa92-85773792135b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3f171152-fe08-468d-a59c-153773336778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3f171152-fe08-468d-a59c-153773336778" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a32af927-1f25-4ba8-b7c7-42b8a7704e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a32af927-1f25-4ba8-b7c7-42b8a7704e6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_eae8c323-3f1a-40f8-a2d0-1344bb20ffc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_eae8c323-3f1a-40f8-a2d0-1344bb20ffc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c03c50a3-5ef9-44d1-995a-7ffee2ae9b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c03c50a3-5ef9-44d1-995a-7ffee2ae9b79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6329cac5-3352-4107-9824-31dd25436edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6329cac5-3352-4107-9824-31dd25436edf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2eef23d-b146-40e9-831c-b409204cd8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2eef23d-b146-40e9-831c-b409204cd8d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c798bf61-6f2c-4321-be82-20f897e45b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2eef23d-b146-40e9-831c-b409204cd8d0" xlink:to="loc_us-gaap_AwardTypeAxis_c798bf61-6f2c-4321-be82-20f897e45b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c798bf61-6f2c-4321-be82-20f897e45b01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c798bf61-6f2c-4321-be82-20f897e45b01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c798bf61-6f2c-4321-be82-20f897e45b01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c0c08-7824-4c9b-bb43-e751a5469891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c798bf61-6f2c-4321-be82-20f897e45b01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c0c08-7824-4c9b-bb43-e751a5469891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80a35ddc-bb7d-4862-979c-15c26b27772c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c0c08-7824-4c9b-bb43-e751a5469891" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80a35ddc-bb7d-4862-979c-15c26b27772c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="extended" id="i9ddc96e6b51147429bf43feb16efea2f_StockbasedcompensationWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e59f14a-ab45-4f0d-90ba-6006b6f79505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e59f14a-ab45-4f0d-90ba-6006b6f79505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_654def05-2df8-4132-bd75-06eac8c34cfe" xlink:href="amgn-20221231.xsd#amgn_CommonStockFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:to="loc_amgn_CommonStockFairValue_654def05-2df8-4132-bd75-06eac8c34cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ce750290-5f64-48a5-b3ee-155f5d1d1529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ce750290-5f64-48a5-b3ee-155f5d1d1529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bebc4192-9b3c-47da-8597-2204bc0241e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bebc4192-9b3c-47da-8597-2204bc0241e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f761c47a-aeb5-43d9-a7b2-f9da48648abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f761c47a-aeb5-43d9-a7b2-f9da48648abc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b1756a55-332f-4d49-8bd5-133e9b91196a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e59f14a-ab45-4f0d-90ba-6006b6f79505" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b1756a55-332f-4d49-8bd5-133e9b91196a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16cd8c8f-33c3-4c7d-ba19-e21081b8de27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b1756a55-332f-4d49-8bd5-133e9b91196a" xlink:to="loc_us-gaap_AwardTypeAxis_16cd8c8f-33c3-4c7d-ba19-e21081b8de27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16cd8c8f-33c3-4c7d-ba19-e21081b8de27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_16cd8c8f-33c3-4c7d-ba19-e21081b8de27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16cd8c8f-33c3-4c7d-ba19-e21081b8de27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1ad2603-0fe0-4d40-af17-f67274da7374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_16cd8c8f-33c3-4c7d-ba19-e21081b8de27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1ad2603-0fe0-4d40-af17-f67274da7374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_5b6d1d82-9994-4ced-9818-dcfad3caf259" xlink:href="amgn-20221231.xsd#amgn_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1ad2603-0fe0-4d40-af17-f67274da7374" xlink:to="loc_amgn_PerformanceUnitsMember_5b6d1d82-9994-4ced-9818-dcfad3caf259" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesIncomeBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="extended" id="i75a4215c253a4f69a9442cfd91d72af5_IncometaxesIncomeBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_d175b902-02c1-4787-8af7-66e63bd44f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_578cbe10-9aa5-4e10-8f26-f1599d5fe00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d175b902-02c1-4787-8af7-66e63bd44f66" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_578cbe10-9aa5-4e10-8f26-f1599d5fe00d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_268cedd4-5487-4dd5-8a3c-e39559e23ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d175b902-02c1-4787-8af7-66e63bd44f66" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_268cedd4-5487-4dd5-8a3c-e39559e23ee8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_922bc1d3-a5b7-43d3-9f7c-81071888753a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_268cedd4-5487-4dd5-8a3c-e39559e23ee8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_922bc1d3-a5b7-43d3-9f7c-81071888753a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_922bc1d3-a5b7-43d3-9f7c-81071888753a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_922bc1d3-a5b7-43d3-9f7c-81071888753a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_922bc1d3-a5b7-43d3-9f7c-81071888753a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_99e5568c-b20b-4aa0-ac4e-73e77f03d1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_922bc1d3-a5b7-43d3-9f7c-81071888753a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_99e5568c-b20b-4aa0-ac4e-73e77f03d1be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_802a9983-f5b8-40be-9286-6da7bdf899e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_99e5568c-b20b-4aa0-ac4e-73e77f03d1be" xlink:to="loc_us-gaap_DomesticCountryMember_802a9983-f5b8-40be-9286-6da7bdf899e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_5b54b263-2e87-4360-aed4-4df0ae0ae5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_99e5568c-b20b-4aa0-ac4e-73e77f03d1be" xlink:to="loc_us-gaap_ForeignCountryMember_5b54b263-2e87-4360-aed4-4df0ae0ae5a6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="extended" id="i62a91294179646049bce4198b57c7517_IncometaxesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_c7a5e6cb-d9e2-4d09-9ab1-1aa70eb7d494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_c7a5e6cb-d9e2-4d09-9ab1-1aa70eb7d494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_6136832e-cf62-46fe-b924-fffcd0948a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_6136832e-cf62-46fe-b924-fffcd0948a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1bae5a23-08e9-4add-8ada-5fc21fe498af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1bae5a23-08e9-4add-8ada-5fc21fe498af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_f99dce77-1434-4f26-902e-59d13cb28c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_f99dce77-1434-4f26-902e-59d13cb28c6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_324745d0-4406-4185-99e3-60e329432fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_324745d0-4406-4185-99e3-60e329432fbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_88c7856d-f6f5-4ce0-9d71-acf1343e136e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_88c7856d-f6f5-4ce0-9d71-acf1343e136e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9e01bad0-89a4-4d27-9cc0-aeddcc0c226e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9e01bad0-89a4-4d27-9cc0-aeddcc0c226e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_84044a8b-6b0d-42f9-9110-4ca89d5ad5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_IncomeTaxesPaid_84044a8b-6b0d-42f9-9110-4ca89d5ad5fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax_6479a9dd-3a11-49cc-bfee-3ce176a94174" xlink:href="amgn-20221231.xsd#amgn_ProposedAdditionalIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_ProposedAdditionalIncomeTax_6479a9dd-3a11-49cc-bfee-3ce176a94174" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax_1e62def9-19a2-4f6b-88e0-4e12436c00f7" xlink:href="amgn-20221231.xsd#amgn_RepatriationTaxOnProposedAdditionalTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax_1e62def9-19a2-4f6b-88e0-4e12436c00f7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfNoticesOnProposedAdditionalTax_aca7edaa-ffee-4644-b074-a4ebb9868afc" xlink:href="amgn-20221231.xsd#amgn_NumberOfNoticesOnProposedAdditionalTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_NumberOfNoticesOnProposedAdditionalTax_aca7edaa-ffee-4644-b074-a4ebb9868afc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax20132015_2ad3edce-5dab-4ed1-bd86-0985bbdcd037" xlink:href="amgn-20221231.xsd#amgn_ProposedAdditionalIncomeTax20132015"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_ProposedAdditionalIncomeTax20132015_2ad3edce-5dab-4ed1-bd86-0985bbdcd037" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_6ec86f54-f910-425e-8421-cd4686845545" xlink:href="amgn-20221231.xsd#amgn_PenaltiesOnProposedAdditionalIncomeTax20132105"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_6ec86f54-f910-425e-8421-cd4686845545" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015_8118fd65-e382-4b2d-b8e1-0b982e7ffc81" xlink:href="amgn-20221231.xsd#amgn_RepatriationTaxOnProposedAdditionalTax20132015"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015_8118fd65-e382-4b2d-b8e1-0b982e7ffc81" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfNoticesConsolidated_e9db63ba-67c8-4b98-83ef-3d03337b6f39" xlink:href="amgn-20221231.xsd#amgn_NumberOfNoticesConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_NumberOfNoticesConsolidated_e9db63ba-67c8-4b98-83ef-3d03337b6f39" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_6b037c7d-b020-4b0e-ae31-7cf9d3515881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_6b037c7d-b020-4b0e-ae31-7cf9d3515881" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_80cf01ee-e514-4566-a268-e671db57e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b037c7d-b020-4b0e-ae31-7cf9d3515881" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_80cf01ee-e514-4566-a268-e671db57e66f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_80cf01ee-e514-4566-a268-e671db57e66f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_80cf01ee-e514-4566-a268-e671db57e66f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_80cf01ee-e514-4566-a268-e671db57e66f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_80cf01ee-e514-4566-a268-e671db57e66f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_376cfe09-8383-43c6-8f5f-c33ce1fde429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:to="loc_us-gaap_DomesticCountryMember_376cfe09-8383-43c6-8f5f-c33ce1fde429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_36676acf-75bc-4ba8-9004-de9400c91717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_36676acf-75bc-4ba8-9004-de9400c91717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_bced4afb-d8ba-4d0c-93d2-1f35ec63afee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:to="loc_us-gaap_ForeignCountryMember_bced4afb-d8ba-4d0c-93d2-1f35ec63afee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_fd85de47-6781-4f62-84f6-9ee8bd783917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b037c7d-b020-4b0e-ae31-7cf9d3515881" xlink:to="loc_us-gaap_TaxPeriodAxis_fd85de47-6781-4f62-84f6-9ee8bd783917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_fd85de47-6781-4f62-84f6-9ee8bd783917_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_fd85de47-6781-4f62-84f6-9ee8bd783917" xlink:to="loc_us-gaap_TaxPeriodDomain_fd85de47-6781-4f62-84f6-9ee8bd783917_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_85440b8a-95e8-4795-99a1-353fe4bd4173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_fd85de47-6781-4f62-84f6-9ee8bd783917" xlink:to="loc_us-gaap_TaxPeriodDomain_85440b8a-95e8-4795-99a1-353fe4bd4173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member_cce64fd6-c6fd-4a21-874c-7eeeaee4e1a9" xlink:href="amgn-20221231.xsd#amgn_OperatingLossesThatExpireBetween2022And2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_85440b8a-95e8-4795-99a1-353fe4bd4173" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member_cce64fd6-c6fd-4a21-874c-7eeeaee4e1a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ExpirationInTaxYearsBetween2023And2043Member_265763dc-cb8a-4be1-a279-6efb54fbaab8" xlink:href="amgn-20221231.xsd#amgn_ExpirationInTaxYearsBetween2023And2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_85440b8a-95e8-4795-99a1-353fe4bd4173" xlink:to="loc_amgn_ExpirationInTaxYearsBetween2023And2043Member_265763dc-cb8a-4be1-a279-6efb54fbaab8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsBeiGeneDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="extended" id="i5f25d79f46364a0e8a4dfd77cf8c0d42_CollaborationsBeiGeneDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_d9488fc5-8bd7-43cf-b740-8a4d7f0caa91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_d9488fc5-8bd7-43cf-b740-8a4d7f0caa91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_66cf712b-824b-405e-9f65-5eed4c4b5ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_66cf712b-824b-405e-9f65-5eed4c4b5ce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7ea2cf45-442b-4696-871c-8e1466655ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7ea2cf45-442b-4696-871c-8e1466655ee4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_ce6d969c-513c-4eeb-a2d1-9139ca7bf7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_ce6d969c-513c-4eeb-a2d1-9139ca7bf7eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c389ad70-15d7-418e-9098-c160f449ddc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c389ad70-15d7-418e-9098-c160f449ddc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses_99b7cc25-072d-4744-93d1-de5cb2bc4c75" xlink:href="amgn-20221231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_amgn_ProfitAndLossShareOfExpenses_99b7cc25-072d-4744-93d1-de5cb2bc4c75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_1d5c4fde-ad80-4bb0-a080-e47a05b1b848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_1d5c4fde-ad80-4bb0-a080-e47a05b1b848" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5be90bb3-cd87-493d-9d74-f471a9bf4f68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_srt_ProductOrServiceAxis_5be90bb3-cd87-493d-9d74-f471a9bf4f68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5be90bb3-cd87-493d-9d74-f471a9bf4f68_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5be90bb3-cd87-493d-9d74-f471a9bf4f68" xlink:to="loc_srt_ProductsAndServicesDomain_5be90bb3-cd87-493d-9d74-f471a9bf4f68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_692e7f48-8d62-48e0-a8ef-086ec5807279" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5be90bb3-cd87-493d-9d74-f471a9bf4f68" xlink:to="loc_srt_ProductsAndServicesDomain_692e7f48-8d62-48e0-a8ef-086ec5807279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_fcc3a532-98a5-4190-9ae3-5d600c2675d3" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_692e7f48-8d62-48e0-a8ef-086ec5807279" xlink:to="loc_amgn_BeiGeneMember_fcc3a532-98a5-4190-9ae3-5d600c2675d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5a77c5fe-8a80-4806-8d9e-eef33d07af07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5a77c5fe-8a80-4806-8d9e-eef33d07af07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5a77c5fe-8a80-4806-8d9e-eef33d07af07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5a77c5fe-8a80-4806-8d9e-eef33d07af07" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5a77c5fe-8a80-4806-8d9e-eef33d07af07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4f092d1f-7321-4454-b198-c766f8e3c363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5a77c5fe-8a80-4806-8d9e-eef33d07af07" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4f092d1f-7321-4454-b198-c766f8e3c363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53ed35f2-63ed-4416-9ffe-ce951e65087a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f092d1f-7321-4454-b198-c766f8e3c363" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53ed35f2-63ed-4416-9ffe-ce951e65087a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8d2a130-5120-4699-bda4-72bfff9c1659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f092d1f-7321-4454-b198-c766f8e3c363" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8d2a130-5120-4699-bda4-72bfff9c1659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c651bdc7-8c3f-4d94-8468-06787fc20e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c651bdc7-8c3f-4d94-8468-06787fc20e86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c651bdc7-8c3f-4d94-8468-06787fc20e86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c651bdc7-8c3f-4d94-8468-06787fc20e86" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c651bdc7-8c3f-4d94-8468-06787fc20e86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a920e8da-415b-4eb1-a3e7-e97de50ed71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c651bdc7-8c3f-4d94-8468-06787fc20e86" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a920e8da-415b-4eb1-a3e7-e97de50ed71d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_fa942b4b-6cbd-451d-a5d3-12cc6aab8571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a920e8da-415b-4eb1-a3e7-e97de50ed71d" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_fa942b4b-6cbd-451d-a5d3-12cc6aab8571" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_1e9d2cec-3f4f-464e-b00e-f042a8335e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a920e8da-415b-4eb1-a3e7-e97de50ed71d" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_1e9d2cec-3f4f-464e-b00e-f042a8335e66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00cb312b-ae6f-4c88-93c1-03d3500bf33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00cb312b-ae6f-4c88-93c1-03d3500bf33c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00cb312b-ae6f-4c88-93c1-03d3500bf33c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00cb312b-ae6f-4c88-93c1-03d3500bf33c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00cb312b-ae6f-4c88-93c1-03d3500bf33c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_721e5be9-275d-44dc-a387-1a385923fff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00cb312b-ae6f-4c88-93c1-03d3500bf33c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_721e5be9-275d-44dc-a387-1a385923fff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_a2377882-29c1-40d5-9df8-080754b49c88" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_721e5be9-275d-44dc-a387-1a385923fff7" xlink:to="loc_amgn_BeiGeneMember_a2377882-29c1-40d5-9df8-080754b49c88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_56de248e-9167-48c3-bcdb-629133ee2b3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_srt_CounterpartyNameAxis_56de248e-9167-48c3-bcdb-629133ee2b3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56de248e-9167-48c3-bcdb-629133ee2b3a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_56de248e-9167-48c3-bcdb-629133ee2b3a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56de248e-9167-48c3-bcdb-629133ee2b3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2afb93a7-38cd-493e-8db6-bb3c47436965" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_56de248e-9167-48c3-bcdb-629133ee2b3a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2afb93a7-38cd-493e-8db6-bb3c47436965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_14d7f46e-8368-494f-8cb4-e727602b59b5" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2afb93a7-38cd-493e-8db6-bb3c47436965" xlink:to="loc_amgn_BeiGeneMember_14d7f46e-8368-494f-8cb4-e727602b59b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsAstraZenecaPLCDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails" xlink:type="extended" id="iffa48463cf754de3a1907bda4573b40c_CollaborationsAstraZenecaPLCDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_27adf5a6-cb9a-4b42-b4d6-43feafe527c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_27adf5a6-cb9a-4b42-b4d6-43feafe527c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses_e53575a4-9b70-4ed8-a6cf-7046d9c86bd3" xlink:href="amgn-20221231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:to="loc_amgn_ProfitAndLossShareOfExpenses_e53575a4-9b70-4ed8-a6cf-7046d9c86bd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DevelopmentCostsDueToCollaborationPartner_c165666c-f7a3-45a5-8f6e-095df911cd20" xlink:href="amgn-20221231.xsd#amgn_DevelopmentCostsDueToCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:to="loc_amgn_DevelopmentCostsDueToCollaborationPartner_c165666c-f7a3-45a5-8f6e-095df911cd20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5d122eb-5314-46b0-915c-41b4c5611d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5d122eb-5314-46b0-915c-41b4c5611d93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e96d0b50-c93e-4c30-9660-06f358ca1f67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5d122eb-5314-46b0-915c-41b4c5611d93" xlink:to="loc_srt_CounterpartyNameAxis_e96d0b50-c93e-4c30-9660-06f358ca1f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e96d0b50-c93e-4c30-9660-06f358ca1f67_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e96d0b50-c93e-4c30-9660-06f358ca1f67" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e96d0b50-c93e-4c30-9660-06f358ca1f67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a67d876-b7f6-417d-abc8-417e92145e76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e96d0b50-c93e-4c30-9660-06f358ca1f67" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a67d876-b7f6-417d-abc8-417e92145e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AstraZenecaPLCMember_c1a95e40-6c65-4361-9970-03b59823649b" xlink:href="amgn-20221231.xsd#amgn_AstraZenecaPLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a67d876-b7f6-417d-abc8-417e92145e76" xlink:to="loc_amgn_AstraZenecaPLCMember_c1a95e40-6c65-4361-9970-03b59823649b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bcc0a7e7-dec0-4535-aa83-f785c585309f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5d122eb-5314-46b0-915c-41b4c5611d93" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bcc0a7e7-dec0-4535-aa83-f785c585309f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bcc0a7e7-dec0-4535-aa83-f785c585309f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bcc0a7e7-dec0-4535-aa83-f785c585309f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bcc0a7e7-dec0-4535-aa83-f785c585309f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bcc0a7e7-dec0-4535-aa83-f785c585309f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a674a14f-417e-4095-ab32-772f44812742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a674a14f-417e-4095-ab32-772f44812742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_802226dc-1758-43f3-83a6-ece9c7aa39b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_802226dc-1758-43f3-83a6-ece9c7aa39b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c143d5f2-cd95-4640-9969-18e7f4dcde82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:to="loc_us-gaap_CostOfSalesMember_c143d5f2-cd95-4640-9969-18e7f4dcde82" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsUCBDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsUCBDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsUCBDetails" xlink:type="extended" id="i269b6c93c9f84fe59dcffd81f4e87006_CollaborationsUCBDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5430c83c-5c1f-43d3-85fd-a9fd1e09b963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses_12956386-e393-41aa-9996-7a5364e78e66" xlink:href="amgn-20221231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5430c83c-5c1f-43d3-85fd-a9fd1e09b963" xlink:to="loc_amgn_ProfitAndLossShareOfExpenses_12956386-e393-41aa-9996-7a5364e78e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d8def7f-476d-4c38-a598-4ebcf74dea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5430c83c-5c1f-43d3-85fd-a9fd1e09b963" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d8def7f-476d-4c38-a598-4ebcf74dea5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_387afbac-9df7-4242-957d-fb86e60e5a09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d8def7f-476d-4c38-a598-4ebcf74dea5d" xlink:to="loc_srt_CounterpartyNameAxis_387afbac-9df7-4242-957d-fb86e60e5a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387afbac-9df7-4242-957d-fb86e60e5a09_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_387afbac-9df7-4242-957d-fb86e60e5a09" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387afbac-9df7-4242-957d-fb86e60e5a09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98aeb05c-9292-4bac-b38f-e7d969680996" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_387afbac-9df7-4242-957d-fb86e60e5a09" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98aeb05c-9292-4bac-b38f-e7d969680996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_UCBMember_78a70c67-0fcd-46b4-aa54-199f87ddce64" xlink:href="amgn-20221231.xsd#amgn_UCBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98aeb05c-9292-4bac-b38f-e7d969680996" xlink:to="loc_amgn_UCBMember_78a70c67-0fcd-46b4-aa54-199f87ddce64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8ec76e08-6126-42b4-b14f-964eb69ef0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d8def7f-476d-4c38-a598-4ebcf74dea5d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8ec76e08-6126-42b4-b14f-964eb69ef0ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8ec76e08-6126-42b4-b14f-964eb69ef0ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8ec76e08-6126-42b4-b14f-964eb69ef0ac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8ec76e08-6126-42b4-b14f-964eb69ef0ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c8e78b91-f4ef-4341-9a77-ba8d3f605b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8ec76e08-6126-42b4-b14f-964eb69ef0ac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c8e78b91-f4ef-4341-9a77-ba8d3f605b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bbb5f538-b54d-4b5a-9b14-71cf4258d1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c8e78b91-f4ef-4341-9a77-ba8d3f605b68" xlink:to="loc_us-gaap_CostOfSalesMember_bbb5f538-b54d-4b5a-9b14-71cf4258d1c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsNovartisAGDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="extended" id="ibc040ecdf0904549a8cb094e2dd68bc3_CollaborationsNovartisAGDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26b6e702-62d9-4e77-b817-4c86161c62ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_79f476e2-e15a-4a40-bbbe-d1743fadb174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26b6e702-62d9-4e77-b817-4c86161c62ac" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_79f476e2-e15a-4a40-bbbe-d1743fadb174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_3e1610d5-2c94-46f7-86f3-78e53e3a62b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26b6e702-62d9-4e77-b817-4c86161c62ac" xlink:to="loc_us-gaap_RoyaltyExpense_3e1610d5-2c94-46f7-86f3-78e53e3a62b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a2cb81-2bf8-424c-9ee8-755d4c2f540d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26b6e702-62d9-4e77-b817-4c86161c62ac" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a2cb81-2bf8-424c-9ee8-755d4c2f540d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7003c469-fa21-4de7-91e8-a8d662ee2c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a2cb81-2bf8-424c-9ee8-755d4c2f540d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7003c469-fa21-4de7-91e8-a8d662ee2c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7003c469-fa21-4de7-91e8-a8d662ee2c56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7003c469-fa21-4de7-91e8-a8d662ee2c56" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7003c469-fa21-4de7-91e8-a8d662ee2c56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7003c469-fa21-4de7-91e8-a8d662ee2c56" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5049d112-6c3d-4196-86a2-d713b35cd398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5049d112-6c3d-4196-86a2-d713b35cd398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d33b58f9-a15c-4b70-82f8-ee49b4e13ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:to="loc_us-gaap_CostOfSalesMember_d33b58f9-a15c-4b70-82f8-ee49b4e13ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d2741ad-cc8c-4078-b71e-ff71a665de63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d2741ad-cc8c-4078-b71e-ff71a665de63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4b1c06be-188f-49c9-a500-53a42fd03b7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a2cb81-2bf8-424c-9ee8-755d4c2f540d" xlink:to="loc_srt_CounterpartyNameAxis_4b1c06be-188f-49c9-a500-53a42fd03b7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b1c06be-188f-49c9-a500-53a42fd03b7e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4b1c06be-188f-49c9-a500-53a42fd03b7e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b1c06be-188f-49c9-a500-53a42fd03b7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ff80569-d0bc-4d4d-9490-0c591c0a7ccd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4b1c06be-188f-49c9-a500-53a42fd03b7e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ff80569-d0bc-4d4d-9490-0c591c0a7ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisPharmaAGMember_34c13b32-0ddc-4227-a3f3-d66797e1d6f4" xlink:href="amgn-20221231.xsd#amgn_NovartisPharmaAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ff80569-d0bc-4d4d-9490-0c591c0a7ccd" xlink:to="loc_amgn_NovartisPharmaAGMember_34c13b32-0ddc-4227-a3f3-d66797e1d6f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsKyowaKirinDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsKyowaKirinDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsKyowaKirinDetails" xlink:type="extended" id="ib8e91c77d83441f0bc7d9e3924f38a0c_CollaborationsKyowaKirinDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9594dce-db81-423d-9a09-dc20eb5d912e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_UpFrontPayment_b825a823-86c9-438f-9d94-cf9228d36ea8" xlink:href="amgn-20221231.xsd#amgn_UpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9594dce-db81-423d-9a09-dc20eb5d912e" xlink:to="loc_amgn_UpFrontPayment_b825a823-86c9-438f-9d94-cf9228d36ea8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_6bd59cf7-d16a-496e-b1d8-984e225925b1" xlink:href="amgn-20221231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9594dce-db81-423d-9a09-dc20eb5d912e" xlink:to="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_6bd59cf7-d16a-496e-b1d8-984e225925b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f821e2ee-5abb-4b60-9fcf-d3a2b3397812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9594dce-db81-423d-9a09-dc20eb5d912e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f821e2ee-5abb-4b60-9fcf-d3a2b3397812" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1409bcdd-b300-4f3e-ad81-d597d05e9ddb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f821e2ee-5abb-4b60-9fcf-d3a2b3397812" xlink:to="loc_srt_CounterpartyNameAxis_1409bcdd-b300-4f3e-ad81-d597d05e9ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1409bcdd-b300-4f3e-ad81-d597d05e9ddb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1409bcdd-b300-4f3e-ad81-d597d05e9ddb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1409bcdd-b300-4f3e-ad81-d597d05e9ddb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f656a5a-269f-4e55-a2b0-edac48a7f191" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1409bcdd-b300-4f3e-ad81-d597d05e9ddb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f656a5a-269f-4e55-a2b0-edac48a7f191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyowaKirinCoLtdMember_cfafa20e-3038-41da-b87b-76b5cc9352ba" xlink:href="amgn-20221231.xsd#amgn_KyowaKirinCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f656a5a-269f-4e55-a2b0-edac48a7f191" xlink:to="loc_amgn_KyowaKirinCoLtdMember_cfafa20e-3038-41da-b87b-76b5cc9352ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="extended" id="i80bba938fc8f4aa29b2075a244a23a98_InvestmentsScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_151fdb00-f232-4660-9c21-3ff8550c11a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_151fdb00-f232-4660-9c21-3ff8550c11a2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e7ae3989-63f4-44ad-89c7-33e1cbd3ba46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e7ae3989-63f4-44ad-89c7-33e1cbd3ba46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e541fb1a-bdfc-41e1-8f5d-127c5b5be07d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e541fb1a-bdfc-41e1-8f5d-127c5b5be07d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a58616b4-3731-4e82-9d02-8362f7c740c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a58616b4-3731-4e82-9d02-8362f7c740c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_042de559-a00f-4f46-947b-86ea6066d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_042de559-a00f-4f46-947b-86ea6066d0e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_40dd9a50-bf20-45d1-afcc-fe0ef647ac42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_151fdb00-f232-4660-9c21-3ff8550c11a2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_40dd9a50-bf20-45d1-afcc-fe0ef647ac42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_62f475e7-7b54-473f-90df-b78da9edf20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_40dd9a50-bf20-45d1-afcc-fe0ef647ac42" xlink:to="loc_us-gaap_FinancialInstrumentAxis_62f475e7-7b54-473f-90df-b78da9edf20f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62f475e7-7b54-473f-90df-b78da9edf20f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_62f475e7-7b54-473f-90df-b78da9edf20f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62f475e7-7b54-473f-90df-b78da9edf20f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_62f475e7-7b54-473f-90df-b78da9edf20f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c62b64da-512b-4e7b-b1ca-740a8efacafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c62b64da-512b-4e7b-b1ca-740a8efacafc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_adc0df1a-38f7-4232-870d-da1c4e4a6a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_adc0df1a-38f7-4232-870d-da1c4e4a6a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_72909f68-165f-4b51-9dc9-019c9a97a7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:to="loc_us-gaap_MoneyMarketFundsMember_72909f68-165f-4b51-9dc9-019c9a97a7b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_f2317580-a612-438a-afac-b1114db987ec" xlink:href="amgn-20221231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_f2317580-a612-438a-afac-b1114db987ec" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended" id="i747f18f462a8467fae752bba2916c512_InvestmentsFairValuesbyClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5745172c-de8d-43e4-8c27-84774d66f665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:href="amgn-20221231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5745172c-de8d-43e4-8c27-84774d66f665" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0a88c4ca-d514-495d-8dde-d9feb4aff904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0a88c4ca-d514-495d-8dde-d9feb4aff904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_34627770-6719-4db9-973b-067754e215f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_34627770-6719-4db9-973b-067754e215f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d3a67bee-52b6-4a88-93f2-9d1efaa3175b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d3a67bee-52b6-4a88-93f2-9d1efaa3175b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0520f679-bb3f-4104-981e-4ee4ceb355c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5745172c-de8d-43e4-8c27-84774d66f665" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0520f679-bb3f-4104-981e-4ee4ceb355c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0b983a41-1d36-4844-851a-8aa69db47e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0520f679-bb3f-4104-981e-4ee4ceb355c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0b983a41-1d36-4844-851a-8aa69db47e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b983a41-1d36-4844-851a-8aa69db47e36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0b983a41-1d36-4844-851a-8aa69db47e36" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b983a41-1d36-4844-851a-8aa69db47e36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d561330a-09c1-40d9-aec4-9948f67e01e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0b983a41-1d36-4844-851a-8aa69db47e36" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d561330a-09c1-40d9-aec4-9948f67e01e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember_c5c461e9-c1e9-452a-a58c-ee54a916c042" xlink:href="amgn-20221231.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d561330a-09c1-40d9-aec4-9948f67e01e2" xlink:to="loc_amgn_AvailableForSalesInvestmentsMember_c5c461e9-c1e9-452a-a58c-ee54a916c042" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended" id="i891b4915f3334d6091e95a1de6ccf829_InvestmentsEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a4e0d306-bcce-46ab-9273-244d69beca66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a4e0d306-bcce-46ab-9273-244d69beca66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a5fd1e12-aabd-40e2-8b3e-4539f4d93ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a5fd1e12-aabd-40e2-8b3e-4539f4d93ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9fa65f95-715c-4266-b326-3e8cd0a980d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9fa65f95-715c-4266-b326-3e8cd0a980d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_b66423b1-f510-46eb-bb63-c2cbac0a6a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_b66423b1-f510-46eb-bb63-c2cbac0a6a24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal_a3c2c4e5-929e-4b88-a293-bb621b99cc22" xlink:href="amgn-20221231.xsd#amgn_EquitySecuritiesRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal_a3c2c4e5-929e-4b88-a293-bb621b99cc22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_3d50b8b8-2081-4943-8bb9-3a9466faf118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_3d50b8b8-2081-4943-8bb9-3a9466faf118" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bc0f4d36-70b4-457c-b405-ab04c474d313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bc0f4d36-70b4-457c-b405-ab04c474d313" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_96a349c1-0edd-464b-a101-38817eab8dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bc0f4d36-70b4-457c-b405-ab04c474d313" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_96a349c1-0edd-464b-a101-38817eab8dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_96a349c1-0edd-464b-a101-38817eab8dcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_96a349c1-0edd-464b-a101-38817eab8dcd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_96a349c1-0edd-464b-a101-38817eab8dcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8387b7dd-49cc-44d3-8f11-fe211a6158a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_96a349c1-0edd-464b-a101-38817eab8dcd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8387b7dd-49cc-44d3-8f11-fe211a6158a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9e2e3245-1bf0-4327-9a7a-9f876123162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8387b7dd-49cc-44d3-8f11-fe211a6158a2" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9e2e3245-1bf0-4327-9a7a-9f876123162d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsLimitedPartnershipInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="extended" id="i0ed86a9b9b054026ac2fc08d16eeb44b_InvestmentsLimitedPartnershipInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_20db44c1-d833-4c32-a191-795554e74c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:to="loc_us-gaap_AlternativeInvestment_20db44c1-d833-4c32-a191-795554e74c66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss_9a7e62a6-a06a-4ff7-9b68-38e2b9c39064" xlink:href="amgn-20221231.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:to="loc_amgn_AlternativeInvestmentNetGainLoss_9a7e62a6-a06a-4ff7-9b68-38e2b9c39064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_16034e17-5b8f-435d-b06b-5d8ff79db4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:to="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_16034e17-5b8f-435d-b06b-5d8ff79db4e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5bde25cd-4e4e-4b2c-b856-7c557055fb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5bde25cd-4e4e-4b2c-b856-7c557055fb7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0025ad3b-5e98-4d97-a95f-e3918e10e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5bde25cd-4e4e-4b2c-b856-7c557055fb7b" xlink:to="loc_us-gaap_InvestmentTypeAxis_0025ad3b-5e98-4d97-a95f-e3918e10e54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0025ad3b-5e98-4d97-a95f-e3918e10e54f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0025ad3b-5e98-4d97-a95f-e3918e10e54f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0025ad3b-5e98-4d97-a95f-e3918e10e54f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7ec4c00e-f054-46be-96a3-afcde7f7ade3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0025ad3b-5e98-4d97-a95f-e3918e10e54f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7ec4c00e-f054-46be-96a3-afcde7f7ade3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_4daadc1d-7da4-41e9-8fe4-33dade98f19a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7ec4c00e-f054-46be-96a3-afcde7f7ade3" xlink:to="loc_srt_PartnershipInterestMember_4daadc1d-7da4-41e9-8fe4-33dade98f19a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94c7c1d3-b8bf-4c9b-bc27-eb0939a46d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5bde25cd-4e4e-4b2c-b856-7c557055fb7b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94c7c1d3-b8bf-4c9b-bc27-eb0939a46d7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94c7c1d3-b8bf-4c9b-bc27-eb0939a46d7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94c7c1d3-b8bf-4c9b-bc27-eb0939a46d7f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94c7c1d3-b8bf-4c9b-bc27-eb0939a46d7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a056c-786b-4bcd-8c9a-042ce706197e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94c7c1d3-b8bf-4c9b-bc27-eb0939a46d7f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a056c-786b-4bcd-8c9a-042ce706197e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_6331a470-063b-4351-8734-e7b96d7ad833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a056c-786b-4bcd-8c9a-042ce706197e" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_6331a470-063b-4351-8734-e7b96d7ad833" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsBeiGeneDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="extended" id="i6289bdd083d049d8a98ea1cc36451a05_InvestmentsBeiGeneDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e16c6c5-a312-4f74-9f8a-0a6d54365b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e16c6c5-a312-4f74-9f8a-0a6d54365b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_14030737-bf11-46ea-9359-8fd2abeeb0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_14030737-bf11-46ea-9359-8fd2abeeb0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_8d39be8d-9173-4f79-bc43-0dc1abd3a338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_8d39be8d-9173-4f79-bc43-0dc1abd3a338" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_37330a44-75b7-4c31-9c6c-a9cfbaacae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_37330a44-75b7-4c31-9c6c-a9cfbaacae7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_67c4237a-c622-4e4b-beb3-611bc1588652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_67c4237a-c622-4e4b-beb3-611bc1588652" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_1696342c-678b-4d94-bb2f-9c55b15d4cb6" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_1696342c-678b-4d94-bb2f-9c55b15d4cb6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_88431fd1-2c66-4794-bae9-88c6beb17522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_88431fd1-2c66-4794-bae9-88c6beb17522" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_3e9ee9d1-9015-455b-af59-716837659b6a" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_3e9ee9d1-9015-455b-af59-716837659b6a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e8a52532-159b-41ef-9b95-2892afc55c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e8a52532-159b-41ef-9b95-2892afc55c61" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_61ceea01-e8be-4f51-b482-6973a291ad2f" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_61ceea01-e8be-4f51-b482-6973a291ad2f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_696cdfdf-79f4-413c-b6bf-3de76b20d541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestments_696cdfdf-79f4-413c-b6bf-3de76b20d541" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_3ba504c5-798c-42da-8422-9f6202031496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_98a88004-fb65-43c4-bc27-2017450bdbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_98a88004-fb65-43c4-bc27-2017450bdbb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_98a88004-fb65-43c4-bc27-2017450bdbb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_98a88004-fb65-43c4-bc27-2017450bdbb7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_98a88004-fb65-43c4-bc27-2017450bdbb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d0689f-ab69-46fb-b759-c688c0622b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_98a88004-fb65-43c4-bc27-2017450bdbb7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d0689f-ab69-46fb-b759-c688c0622b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_edaa4783-ee59-4687-9647-cf4c47895782" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d0689f-ab69-46fb-b759-c688c0622b86" xlink:to="loc_amgn_BeiGeneMember_edaa4783-ee59-4687-9647-cf4c47895782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_784e925c-b519-4787-8efe-d9f5ec6bbd51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:to="loc_srt_RangeAxis_784e925c-b519-4787-8efe-d9f5ec6bbd51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_784e925c-b519-4787-8efe-d9f5ec6bbd51_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_784e925c-b519-4787-8efe-d9f5ec6bbd51" xlink:to="loc_srt_RangeMember_784e925c-b519-4787-8efe-d9f5ec6bbd51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a036ab03-8f6b-4866-a172-943a0eb757ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_784e925c-b519-4787-8efe-d9f5ec6bbd51" xlink:to="loc_srt_RangeMember_a036ab03-8f6b-4866-a172-943a0eb757ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4bdd30a2-1bdc-4994-a692-4d8354ec91d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a036ab03-8f6b-4866-a172-943a0eb757ec" xlink:to="loc_srt_MinimumMember_4bdd30a2-1bdc-4994-a692-4d8354ec91d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ec51f54-5b0d-4da1-b476-ed07eb49bc82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a036ab03-8f6b-4866-a172-943a0eb757ec" xlink:to="loc_srt_MaximumMember_4ec51f54-5b0d-4da1-b476-ed07eb49bc82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77d93c6e-9cce-48d6-a949-f700f5ed4d58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77d93c6e-9cce-48d6-a949-f700f5ed4d58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_77d93c6e-9cce-48d6-a949-f700f5ed4d58_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77d93c6e-9cce-48d6-a949-f700f5ed4d58" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_77d93c6e-9cce-48d6-a949-f700f5ed4d58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2edc7258-3a5e-4f39-8fe5-ef9315adb5c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77d93c6e-9cce-48d6-a949-f700f5ed4d58" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2edc7258-3a5e-4f39-8fe5-ef9315adb5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_d24a2c25-7dce-4614-80bb-78eda961acd5" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2edc7258-3a5e-4f39-8fe5-ef9315adb5c8" xlink:to="loc_amgn_BeiGeneMember_d24a2c25-7dce-4614-80bb-78eda961acd5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsNeumoraTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="extended" id="i7346e49ba6e841afb8a5cd4ad1110856_InvestmentsNeumoraTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f16ecb9c-24f2-4b4e-92ba-9f61758ae050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f16ecb9c-24f2-4b4e-92ba-9f61758ae050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_448f0d07-abfb-4367-926f-79fe154a533b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_448f0d07-abfb-4367-926f-79fe154a533b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a943ba7d-d9f4-457a-a8dc-931f3337ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a943ba7d-d9f4-457a-a8dc-931f3337ca61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_10d2ff8c-5e7a-42c7-b914-db07e6c1fc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_10d2ff8c-5e7a-42c7-b914-db07e6c1fc7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_f3aae7f7-50d3-44e6-aab2-bdf721fcdf28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_f3aae7f7-50d3-44e6-aab2-bdf721fcdf28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_e1245b2e-62df-408f-82a4-07acf2ca44b8" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_e1245b2e-62df-408f-82a4-07acf2ca44b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5fa6f2b2-23ef-4aa9-a439-04058f461769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5fa6f2b2-23ef-4aa9-a439-04058f461769" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c1695439-b04d-4647-98b0-b43891feac41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5fa6f2b2-23ef-4aa9-a439-04058f461769" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c1695439-b04d-4647-98b0-b43891feac41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1695439-b04d-4647-98b0-b43891feac41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c1695439-b04d-4647-98b0-b43891feac41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1695439-b04d-4647-98b0-b43891feac41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e89b60de-041f-4133-9c58-396832bf9866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c1695439-b04d-4647-98b0-b43891feac41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e89b60de-041f-4133-9c58-396832bf9866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_ec8d0697-a1b2-4597-9c50-5c69cc8a1279" xlink:href="amgn-20221231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e89b60de-041f-4133-9c58-396832bf9866" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_ec8d0697-a1b2-4597-9c50-5c69cc8a1279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ef17bd95-8fae-40ab-b652-23a9a267f0b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5fa6f2b2-23ef-4aa9-a439-04058f461769" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ef17bd95-8fae-40ab-b652-23a9a267f0b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ef17bd95-8fae-40ab-b652-23a9a267f0b3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ef17bd95-8fae-40ab-b652-23a9a267f0b3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ef17bd95-8fae-40ab-b652-23a9a267f0b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_81cf6c1b-49fc-4a15-8691-42384370ecdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ef17bd95-8fae-40ab-b652-23a9a267f0b3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_81cf6c1b-49fc-4a15-8691-42384370ecdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_b85a0836-8945-4933-96b9-ce30187fb83f" xlink:href="amgn-20221231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_81cf6c1b-49fc-4a15-8691-42384370ecdf" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_b85a0836-8945-4933-96b9-ce30187fb83f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#PropertyplantandequipmentScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="extended" id="ib827c415b65b4403aba57ef4b14aa5fe_PropertyplantandequipmentScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1f658e25-d245-42f6-b4bf-bfc8a2bc6b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1f658e25-d245-42f6-b4bf-bfc8a2bc6b7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_a72e6c06-dda7-4e42-98f7-655ea5b8ac36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_Land_a72e6c06-dda7-4e42-98f7-655ea5b8ac36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_bd0ff1e1-6dbf-46f1-af5b-6e773e1db18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_bd0ff1e1-6dbf-46f1-af5b-6e773e1db18f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_17b3ed33-f73a-48cb-88a1-57b515dcc3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_17b3ed33-f73a-48cb-88a1-57b515dcc3aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment_24440f74-c33b-4faa-be61-b52e818b5b21" xlink:href="amgn-20221231.xsd#amgn_LaboratoryEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_amgn_LaboratoryEquipment_24440f74-c33b-4faa-be61-b52e818b5b21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment_00b07198-7810-4bba-8ef1-9256d819df5a" xlink:href="amgn-20221231.xsd#amgn_FixedEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_amgn_FixedEquipment_00b07198-7810-4bba-8ef1-9256d819df5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_2539d8df-d82f-4819-b876-e5c04b1e4443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_2539d8df-d82f-4819-b876-e5c04b1e4443" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_eff2f7fb-4893-483a-9df6-294e60cc5b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_eff2f7fb-4893-483a-9df6-294e60cc5b63" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_d8ef02f5-f549-4913-9954-45dd0fc3adcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_ConstructionInProgressGross_d8ef02f5-f549-4913-9954-45dd0fc3adcf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5f24b340-84b8-44a8-9e6e-bd249ee3d005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5f24b340-84b8-44a8-9e6e-bd249ee3d005" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1517ddbe-d567-438a-b335-3f53ce5c664b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1517ddbe-d567-438a-b335-3f53ce5c664b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_288c1dcf-49bd-4d1b-92a9-4cb737aba8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_288c1dcf-49bd-4d1b-92a9-4cb737aba8d6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d6aeb812-53a5-4e9c-8a0f-93c031eaccb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_Depreciation_d6aeb812-53a5-4e9c-8a0f-93c031eaccb9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2701d936-12ca-4673-af6d-191a5f683cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2701d936-12ca-4673-af6d-191a5f683cdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_68ac2f28-d078-4388-a622-f8fe207b49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2701d936-12ca-4673-af6d-191a5f683cdc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_68ac2f28-d078-4388-a622-f8fe207b49b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ac2f28-d078-4388-a622-f8fe207b49b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_68ac2f28-d078-4388-a622-f8fe207b49b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ac2f28-d078-4388-a622-f8fe207b49b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_68ac2f28-d078-4388-a622-f8fe207b49b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_870714d6-d069-4a26-b9f9-40db8f9aeac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_870714d6-d069-4a26-b9f9-40db8f9aeac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ManufacturingEquipmentMember_3fea431d-cfb4-450e-b35c-ae64c75773a4" xlink:href="amgn-20221231.xsd#amgn_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_amgn_ManufacturingEquipmentMember_3fea431d-cfb4-450e-b35c-ae64c75773a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipmentMember_2a984796-89c4-4459-bb05-97794f113cc5" xlink:href="amgn-20221231.xsd#amgn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_amgn_LaboratoryEquipmentMember_2a984796-89c4-4459-bb05-97794f113cc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipmentMember_e54dfbbf-a707-44c6-bd2a-08827a8df3ac" xlink:href="amgn-20221231.xsd#amgn_FixedEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_amgn_FixedEquipmentMember_e54dfbbf-a707-44c6-bd2a-08827a8df3ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_524f1fa7-b238-45c5-ba14-0fb6ccc76216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_524f1fa7-b238-45c5-ba14-0fb6ccc76216" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_65d1356b-4921-48ef-a94e-252d50a26d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_65d1356b-4921-48ef-a94e-252d50a26d31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cd845ac-a092-4027-b281-eb146a09cc0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2701d936-12ca-4673-af6d-191a5f683cdc" xlink:to="loc_srt_RangeAxis_9cd845ac-a092-4027-b281-eb146a09cc0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9cd845ac-a092-4027-b281-eb146a09cc0b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9cd845ac-a092-4027-b281-eb146a09cc0b" xlink:to="loc_srt_RangeMember_9cd845ac-a092-4027-b281-eb146a09cc0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e05e5aab-287f-4c61-9267-f846a20e2d1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9cd845ac-a092-4027-b281-eb146a09cc0b" xlink:to="loc_srt_RangeMember_e05e5aab-287f-4c61-9267-f846a20e2d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_898df78b-bdb7-4802-958f-5f588a622e0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e05e5aab-287f-4c61-9267-f846a20e2d1c" xlink:to="loc_srt_MinimumMember_898df78b-bdb7-4802-958f-5f588a622e0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ac8f014-b87b-4dc4-a15a-21a7f2e263ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e05e5aab-287f-4c61-9267-f846a20e2d1c" xlink:to="loc_srt_MaximumMember_1ac8f014-b87b-4dc4-a15a-21a7f2e263ab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#PropertyplantandequipmentGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="extended" id="ie6e4b8eb6a274aa9a5be56e82c3bb9e2_PropertyplantandequipmentGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ccd55fdf-f585-4522-987a-ed82f7b19ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b53dafdf-921d-4de3-a77d-e6d0135fb093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ccd55fdf-f585-4522-987a-ed82f7b19ffd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b53dafdf-921d-4de3-a77d-e6d0135fb093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03e7d982-1d0d-436c-a08f-3e7229128453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ccd55fdf-f585-4522-987a-ed82f7b19ffd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03e7d982-1d0d-436c-a08f-3e7229128453" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4872fbd9-601d-48ae-ba93-edd1ecedca58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03e7d982-1d0d-436c-a08f-3e7229128453" xlink:to="loc_srt_StatementGeographicalAxis_4872fbd9-601d-48ae-ba93-edd1ecedca58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4872fbd9-601d-48ae-ba93-edd1ecedca58_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4872fbd9-601d-48ae-ba93-edd1ecedca58" xlink:to="loc_srt_SegmentGeographicalDomain_4872fbd9-601d-48ae-ba93-edd1ecedca58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4872fbd9-601d-48ae-ba93-edd1ecedca58" xlink:to="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_54ef6844-9bf7-468a-a554-de9136850a66" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:to="loc_country_US_54ef6844-9bf7-468a-a554-de9136850a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_bc27c292-d4c3-48d8-abb5-0943b4908f92" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:to="loc_country_PR_bc27c292-d4c3-48d8-abb5-0943b4908f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RestOfWorldMember_1906773e-71db-4013-ad9e-8796242efe4b" xlink:href="amgn-20221231.xsd#amgn_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:to="loc_amgn_RestOfWorldMember_1906773e-71db-4013-ad9e-8796242efe4b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended" id="i9f533466011645e5a8e67cf9bc1bb4da_GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d53a0284-9229-4387-acd4-1e7b0a82178a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d53a0284-9229-4387-acd4-1e7b0a82178a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_773a664a-b7f0-4212-8864-1e449f0c6cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_773a664a-b7f0-4212-8864-1e449f0c6cc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_44ec9559-f657-441f-9bd0-8ec15109d62f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_44ec9559-f657-441f-9bd0-8ec15109d62f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3783eee1-334e-49c5-a120-bb39c4f987d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3783eee1-334e-49c5-a120-bb39c4f987d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14e92199-3c11-4ac5-bdea-f52b44d03667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3783eee1-334e-49c5-a120-bb39c4f987d5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14e92199-3c11-4ac5-bdea-f52b44d03667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_e47fd641-94bb-40b2-8b25-3b7861725f1b" xlink:href="amgn-20221231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_e47fd641-94bb-40b2-8b25-3b7861725f1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_25102594-e27b-4df9-9443-d7763ecd5c9a" xlink:href="amgn-20221231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_25102594-e27b-4df9-9443-d7763ecd5c9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8230d9fe-177d-4d31-83e9-f6d3d1aea51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8230d9fe-177d-4d31-83e9-f6d3d1aea51d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2633530d-2714-4a51-951d-1b6e5c9ce844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2633530d-2714-4a51-951d-1b6e5c9ce844" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c10d380c-cbeb-416a-a199-c7f47da7a0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2633530d-2714-4a51-951d-1b6e5c9ce844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c10d380c-cbeb-416a-a199-c7f47da7a0ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c10d380c-cbeb-416a-a199-c7f47da7a0ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c10d380c-cbeb-416a-a199-c7f47da7a0ff" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c10d380c-cbeb-416a-a199-c7f47da7a0ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c10d380c-cbeb-416a-a199-c7f47da7a0ff" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3a53810e-be35-4d72-9ee0-ea2786a153e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3a53810e-be35-4d72-9ee0-ea2786a153e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_a04b8b4a-6653-4e5c-9edd-a3a15a1db869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:to="loc_us-gaap_LicensingAgreementsMember_a04b8b4a-6653-4e5c-9edd-a3a15a1db869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_765fd44f-bc69-4f39-95c1-56dda2481e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_765fd44f-bc69-4f39-95c1-56dda2481e22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_3ac11085-ce8d-4905-983b-bf06120ef892" xlink:href="amgn-20221231.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:to="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_3ac11085-ce8d-4905-983b-bf06120ef892" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e5f4f223-5388-4e64-b475-30b9f393ac63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2633530d-2714-4a51-951d-1b6e5c9ce844" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e5f4f223-5388-4e64-b475-30b9f393ac63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e5f4f223-5388-4e64-b475-30b9f393ac63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e5f4f223-5388-4e64-b475-30b9f393ac63" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e5f4f223-5388-4e64-b475-30b9f393ac63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5153f519-e517-4dab-b092-34f319ab3db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e5f4f223-5388-4e64-b475-30b9f393ac63" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5153f519-e517-4dab-b092-34f319ab3db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5f6273a4-b248-45a1-b2cb-0ec6c125c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5153f519-e517-4dab-b092-34f319ab3db6" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5f6273a4-b248-45a1-b2cb-0ec6c125c5b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i31c49ce93d154a539b47f8bae30e54af_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7d5f3dec-076f-47fd-9ed5-10f1e95df792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_77e9db77-170e-497f-9dd9-5b11e8d0dff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7d5f3dec-076f-47fd-9ed5-10f1e95df792" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_77e9db77-170e-497f-9dd9-5b11e8d0dff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ae3e612d-3cf5-4614-95ca-fef8c0a55cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7d5f3dec-076f-47fd-9ed5-10f1e95df792" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ae3e612d-3cf5-4614-95ca-fef8c0a55cca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f47535b3-2382-4ba8-b592-ad3f99298c49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ae3e612d-3cf5-4614-95ca-fef8c0a55cca" xlink:to="loc_srt_RangeAxis_f47535b3-2382-4ba8-b592-ad3f99298c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f47535b3-2382-4ba8-b592-ad3f99298c49_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f47535b3-2382-4ba8-b592-ad3f99298c49" xlink:to="loc_srt_RangeMember_f47535b3-2382-4ba8-b592-ad3f99298c49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb6a62e0-e96b-4825-9e79-5271329f26de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f47535b3-2382-4ba8-b592-ad3f99298c49" xlink:to="loc_srt_RangeMember_cb6a62e0-e96b-4825-9e79-5271329f26de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7bdd7281-1c21-4da5-a366-84aaed80c9ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb6a62e0-e96b-4825-9e79-5271329f26de" xlink:to="loc_srt_MinimumMember_7bdd7281-1c21-4da5-a366-84aaed80c9ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3eb70ae0-e989-4114-bfc8-b7343f09922f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb6a62e0-e96b-4825-9e79-5271329f26de" xlink:to="loc_srt_MaximumMember_3eb70ae0-e989-4114-bfc8-b7343f09922f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended" id="i62a403de750a4aa8a847957a4f5f1441_LeasesMaturitiesofLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9400c2f4-6c4f-4b4b-813d-2f03b8fb729e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9400c2f4-6c4f-4b4b-813d-2f03b8fb729e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f52e7c57-6428-4193-8c1a-11a5e6014414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f52e7c57-6428-4193-8c1a-11a5e6014414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5b554e48-bbe9-4451-859f-1f35f2937f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5b554e48-bbe9-4451-859f-1f35f2937f6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dddbd14d-22ae-44f0-b708-95bccb975c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dddbd14d-22ae-44f0-b708-95bccb975c96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fc66a615-d74e-467b-bb2c-9cb2bdc835e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fc66a615-d74e-467b-bb2c-9cb2bdc835e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4cb9b85b-d8ae-4f80-a93b-557cd39968dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4cb9b85b-d8ae-4f80-a93b-557cd39968dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c055ad4e-04c4-4cb9-ad1f-6df9d388b6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c055ad4e-04c4-4cb9-ad1f-6df9d388b6cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ca7e5404-bd46-460b-90a8-129ce0096444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ca7e5404-bd46-460b-90a8-129ce0096444" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b274118e-9e83-4ced-ac3d-d1dbc6eb4309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_OperatingLeaseLiability_b274118e-9e83-4ced-ac3d-d1dbc6eb4309" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_10e2bc0d-2f24-423d-9c36-8e35c784a61b" xlink:href="amgn-20221231.xsd#amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_10e2bc0d-2f24-423d-9c36-8e35c784a61b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_bab04b1b-2628-4a67-84de-0f9beb38168a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_bab04b1b-2628-4a67-84de-0f9beb38168a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c033cef9-9757-4c74-9129-010437122a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c033cef9-9757-4c74-9129-010437122a37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_720ccfbd-f1bd-49fb-bc05-03e1582296a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c033cef9-9757-4c74-9129-010437122a37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_720ccfbd-f1bd-49fb-bc05-03e1582296a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_720ccfbd-f1bd-49fb-bc05-03e1582296a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_720ccfbd-f1bd-49fb-bc05-03e1582296a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_720ccfbd-f1bd-49fb-bc05-03e1582296a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_815bb51e-40fb-432b-bcb5-e9f842154758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_720ccfbd-f1bd-49fb-bc05-03e1582296a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_815bb51e-40fb-432b-bcb5-e9f842154758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AbandonedLeasesMember_5457c214-4985-4bba-b6b4-faa07342c095" xlink:href="amgn-20221231.xsd#amgn_AbandonedLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_815bb51e-40fb-432b-bcb5-e9f842154758" xlink:to="loc_amgn_AbandonedLeasesMember_5457c214-4985-4bba-b6b4-faa07342c095" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended" id="i662ca7a58c3a49afa3f94068c14e2b2e_FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65f2a9c8-ee2f-4f64-8394-ad209cf5a4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65f2a9c8-ee2f-4f64-8394-ad209cf5a4a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_49f08c33-8b03-41e4-aee5-28c21dd2dfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_49f08c33-8b03-41e4-aee5-28c21dd2dfcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f0ec5b4d-048c-4dfa-a884-2a23f3e5b731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f0ec5b4d-048c-4dfa-a884-2a23f3e5b731" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_8e0a4e45-0762-4edf-81dc-95252c17af31" xlink:href="amgn-20221231.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_8e0a4e45-0762-4edf-81dc-95252c17af31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_e7070947-0145-4cb4-bb25-e7641a745df2" xlink:href="amgn-20221231.xsd#amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_e7070947-0145-4cb4-bb25-e7641a745df2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f9e95a87-c9d2-49ab-8cac-d0aa0738945f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f9e95a87-c9d2-49ab-8cac-d0aa0738945f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d7da89d1-68eb-4d8f-beb3-eac0a50181f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d7da89d1-68eb-4d8f-beb3-eac0a50181f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6cdc3c23-2732-4925-a72e-9e82d109533d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6cdc3c23-2732-4925-a72e-9e82d109533d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_be656336-0708-4c22-81c5-7d0f64ea292b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_OtherLongTermDebt_be656336-0708-4c22-81c5-7d0f64ea292b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a142a928-9a96-435a-b6f6-86ef18c416b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_LongTermDebt_a142a928-9a96-435a-b6f6-86ef18c416b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_08e5a47c-357b-4206-a77b-ff3425155851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_LongTermDebtCurrent_08e5a47c-357b-4206-a77b-ff3425155851" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d62026d4-19f7-4026-981f-d41b7a3e373f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d62026d4-19f7-4026-981f-d41b7a3e373f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ccaf1470-9cdf-4150-8e2f-813f85ce5660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ccaf1470-9cdf-4150-8e2f-813f85ce5660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ccaf1470-9cdf-4150-8e2f-813f85ce5660_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ccaf1470-9cdf-4150-8e2f-813f85ce5660" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ccaf1470-9cdf-4150-8e2f-813f85ce5660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e8c3c6cf-c7bd-4f10-8a22-359eb7ffc6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ccaf1470-9cdf-4150-8e2f-813f85ce5660" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e8c3c6cf-c7bd-4f10-8a22-359eb7ffc6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_4689b52d-5795-4420-811a-d9ac765ab321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e8c3c6cf-c7bd-4f10-8a22-359eb7ffc6c5" xlink:to="loc_us-gaap_NotesPayableToBanksMember_4689b52d-5795-4420-811a-d9ac765ab321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember_ada877ba-8ed3-4f0f-a97c-0d10831749a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e8c3c6cf-c7bd-4f10-8a22-359eb7ffc6c5" xlink:to="loc_us-gaap_DebtSecuritiesPayableMember_ada877ba-8ed3-4f0f-a97c-0d10831749a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_25b43e76-aa59-433c-9cbe-c85a99ea97eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:to="loc_us-gaap_DebtInstrumentAxis_25b43e76-aa59-433c-9cbe-c85a99ea97eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25b43e76-aa59-433c-9cbe-c85a99ea97eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_25b43e76-aa59-433c-9cbe-c85a99ea97eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25b43e76-aa59-433c-9cbe-c85a99ea97eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_25b43e76-aa59-433c-9cbe-c85a99ea97eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_c5d2f5ae-e180-43f6-b0cf-99cd718d393a" xlink:href="amgn-20221231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_c5d2f5ae-e180-43f6-b0cf-99cd718d393a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_abae1068-8b47-4bef-8620-bbb4bccd17f2" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_abae1068-8b47-4bef-8620-bbb4bccd17f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_68ac8ac9-f720-4e13-a583-06e4cbdc5018" xlink:href="amgn-20221231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_68ac8ac9-f720-4e13-a583-06e4cbdc5018" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_33be7f92-d8cb-4e3f-a244-db6d64d5f928" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_33be7f92-d8cb-4e3f-a244-db6d64d5f928" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_32b9a2d4-515a-4da4-b472-43ed43e6d498" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_32b9a2d4-515a-4da4-b472-43ed43e6d498" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember_dacd7531-887a-4b26-b2a0-6f9afeb17434" xlink:href="amgn-20221231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A190NotesDue20251902025NotesMember_dacd7531-887a-4b26-b2a0-6f9afeb17434" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_91bb59e8-572e-4b1a-893c-ab53f1c38251" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_91bb59e8-572e-4b1a-893c-ab53f1c38251" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_3ee3e9f9-0a64-428e-bf6d-6c3e05aad5bf" xlink:href="amgn-20221231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_3ee3e9f9-0a64-428e-bf6d-6c3e05aad5bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_aa05b90b-f4e7-4803-a18b-9edf3645c047" xlink:href="amgn-20221231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_aa05b90b-f4e7-4803-a18b-9edf3645c047" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_3dbc8703-0589-4d98-b2d4-b87452fa76d9" xlink:href="amgn-20221231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_3dbc8703-0589-4d98-b2d4-b87452fa76d9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_b97f4f7e-8480-4a5a-9d17-81503f643bc4" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_b97f4f7e-8480-4a5a-9d17-81503f643bc4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member_eea127d8-ad0d-4abe-b717-c7c5a6023c93" xlink:href="amgn-20221231.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointTwoZeroNotesDue2027Member_eea127d8-ad0d-4abe-b717-c7c5a6023c93" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember_6d060abe-61d9-445a-a940-b90923b45200" xlink:href="amgn-20221231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A165NotesDue20281652028NotesMember_6d060abe-61d9-445a-a940-b90923b45200" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20293002029NotesMember_fa0ce5c4-d454-4553-b9dc-e72214ce8f9f" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20293002029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A300NotesDue20293002029NotesMember_fa0ce5c4-d454-4553-b9dc-e72214ce8f9f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A405NotesDue20294052029NotesMember_c32de701-ddf7-4b32-b7e1-a0e7c69387ac" xlink:href="amgn-20221231.xsd#amgn_A405NotesDue20294052029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A405NotesDue20294052029NotesMember_c32de701-ddf7-4b32-b7e1-a0e7c69387ac" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_ed1fef55-7f67-445d-8194-7a73625bf625" xlink:href="amgn-20221231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_ed1fef55-7f67-445d-8194-7a73625bf625" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_3e9db160-05c8-43b7-9dba-876bd35ef4e1" xlink:href="amgn-20221231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_3e9db160-05c8-43b7-9dba-876bd35ef4e1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_2692019e-6961-45ed-a2fa-6ce5e2b0307d" xlink:href="amgn-20221231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_2692019e-6961-45ed-a2fa-6ce5e2b0307d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_d88bee42-7833-4573-b6b9-b45817a2d4fd" xlink:href="amgn-20221231.xsd#amgn_TwoPointZeroPercent2032NotesMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_d88bee42-7833-4573-b6b9-b45817a2d4fd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A335NotesDue20323352032NotesMember_568e2fe3-66aa-4496-97c0-c5f333b08629" xlink:href="amgn-20221231.xsd#amgn_A335NotesDue20323352032NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A335NotesDue20323352032NotesMember_568e2fe3-66aa-4496-97c0-c5f333b08629" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20334202033NotesMember_28eafc26-ce11-4c15-8921-ce31a8e4c973" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20334202033NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A420NotesDue20334202033NotesMember_28eafc26-ce11-4c15-8921-ce31a8e4c973" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_3a537b73-ef0f-4049-8261-18513585832e" xlink:href="amgn-20221231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_3a537b73-ef0f-4049-8261-18513585832e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_de65356e-090b-4a16-946d-c13cb174acb4" xlink:href="amgn-20221231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_de65356e-090b-4a16-946d-c13cb174acb4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_4f276b12-e095-46d5-8024-3a7f280296e1" xlink:href="amgn-20221231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_4f276b12-e095-46d5-8024-3a7f280296e1" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_0cc4c488-9441-4627-8f01-f0f2b685110f" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_0cc4c488-9441-4627-8f01-f0f2b685110f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_b3a9e8a8-3290-465a-8adc-f6daeb884777" xlink:href="amgn-20221231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_b3a9e8a8-3290-465a-8adc-f6daeb884777" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember_95004453-fd00-4136-b9ff-f22b25ef5e6a" xlink:href="amgn-20221231.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointEightZeroPercent2041NotesMember_95004453-fd00-4136-b9ff-f22b25ef5e6a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member_a1880d17-35cb-49f7-95e1-67290bb633c1" xlink:href="amgn-20221231.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointNineFivePercentNotesDue2041Member_a1880d17-35cb-49f7-95e1-67290bb633c1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_7d1ae5ca-675a-4996-beba-a86f98761327" xlink:href="amgn-20221231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_7d1ae5ca-675a-4996-beba-a86f98761327" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_0dd6a557-2514-4744-acd3-9e7b8558edf0" xlink:href="amgn-20221231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_0dd6a557-2514-4744-acd3-9e7b8558edf0" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_08719a43-2ecc-4868-85bd-96959f8037f8" xlink:href="amgn-20221231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_08719a43-2ecc-4868-85bd-96959f8037f8" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_7ef1ca33-c239-47ce-a05e-f426cd8e5981" xlink:href="amgn-20221231.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_7ef1ca33-c239-47ce-a05e-f426cd8e5981" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_6ba2a256-3d90-44f3-a3a6-ceb1a2a1dad2" xlink:href="amgn-20221231.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_6ba2a256-3d90-44f3-a3a6-ceb1a2a1dad2" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_9e37e09a-dda0-4db0-896a-8bc00c2d0523" xlink:href="amgn-20221231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_9e37e09a-dda0-4db0-896a-8bc00c2d0523" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_269cd128-b8da-450f-a919-5cc3b7e925f6" xlink:href="amgn-20221231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_269cd128-b8da-450f-a919-5cc3b7e925f6" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_bfb7d6b9-e91e-4878-a2ea-cab4c4e0b335" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_bfb7d6b9-e91e-4878-a2ea-cab4c4e0b335" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20524202052NotesMember_e14841d9-c6a7-43dd-add8-770a69abb9df" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20524202052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A420NotesDue20524202052NotesMember_e14841d9-c6a7-43dd-add8-770a69abb9df" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4875NotesDue205348752053NotesMember_663223be-f994-47f8-b930-e51e5d4444fb" xlink:href="amgn-20221231.xsd#amgn_A4875NotesDue205348752053NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A4875NotesDue205348752053NotesMember_663223be-f994-47f8-b930-e51e5d4444fb" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_603c5a65-4f01-4163-9c34-ef9b037a6c71" xlink:href="amgn-20221231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_603c5a65-4f01-4163-9c34-ef9b037a6c71" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A440NotesDue20624402062NotesMember_c0a65183-7d63-4c00-ad0e-3dfd94b99aa1" xlink:href="amgn-20221231.xsd#amgn_A440NotesDue20624402062NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A440NotesDue20624402062NotesMember_c0a65183-7d63-4c00-ad0e-3dfd94b99aa1" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member_762d09a8-9712-461e-82d2-b276781cb8b6" xlink:href="amgn-20221231.xsd#amgn_OtherNotesDue2097Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_OtherNotesDue2097Member_762d09a8-9712-461e-82d2-b276781cb8b6" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_d21ecd4f-341b-4692-a807-2d1d1f6463f6" xlink:href="amgn-20221231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_d21ecd4f-341b-4692-a807-2d1d1f6463f6" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_10dc7951-ae81-4307-a964-96d5027c275c" xlink:href="amgn-20221231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_10dc7951-ae81-4307-a964-96d5027c275c" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_a1218c48-ed96-439c-a22d-ff11e9fec2e3" xlink:href="amgn-20221231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_a1218c48-ed96-439c-a22d-ff11e9fec2e3" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_65da1bc0-7c99-4211-800c-68b3f8f0cdea" xlink:href="amgn-20221231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_65da1bc0-7c99-4211-800c-68b3f8f0cdea" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_128ce502-83b9-4337-8b94-075f2cd80f68" xlink:href="amgn-20221231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_128ce502-83b9-4337-8b94-075f2cd80f68" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_c7d644c0-eec5-43b4-824a-8fd723c8d2d0" xlink:href="amgn-20221231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_c7d644c0-eec5-43b4-824a-8fd723c8d2d0" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_4f771605-893a-444e-ae3c-6fa87137e292" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_4f771605-893a-444e-ae3c-6fa87137e292" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_23656c2c-6510-4616-a62b-d40dcdf0aa92" xlink:href="amgn-20221231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_23656c2c-6510-4616-a62b-d40dcdf0aa92" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A200NotesDue20322002032NotesMember_1f161baa-369b-4570-aea2-e4ed5844e86c" xlink:href="amgn-20221231.xsd#amgn_A200NotesDue20322002032NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A200NotesDue20322002032NotesMember_1f161baa-369b-4570-aea2-e4ed5844e86c" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A280NotesDue2041Member_2dfbe98b-2d1b-41fb-b4d2-49b15a658883" xlink:href="amgn-20221231.xsd#amgn_A280NotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A280NotesDue2041Member_2dfbe98b-2d1b-41fb-b4d2-49b15a658883" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b004a92-4032-4d35-8cd6-534bb2ca4f4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:to="loc_srt_RangeAxis_9b004a92-4032-4d35-8cd6-534bb2ca4f4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b004a92-4032-4d35-8cd6-534bb2ca4f4c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9b004a92-4032-4d35-8cd6-534bb2ca4f4c" xlink:to="loc_srt_RangeMember_9b004a92-4032-4d35-8cd6-534bb2ca4f4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_929c5cfb-e77d-4bc2-838c-2a32149bf530" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9b004a92-4032-4d35-8cd6-534bb2ca4f4c" xlink:to="loc_srt_RangeMember_929c5cfb-e77d-4bc2-838c-2a32149bf530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb1f9422-95d3-4755-be6a-069e8a599010" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_929c5cfb-e77d-4bc2-838c-2a32149bf530" xlink:to="loc_srt_MinimumMember_bb1f9422-95d3-4755-be6a-069e8a599010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_407f9d6c-8bb5-44c4-aea2-98e39cf8cd49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_929c5cfb-e77d-4bc2-838c-2a32149bf530" xlink:to="loc_srt_MaximumMember_407f9d6c-8bb5-44c4-aea2-98e39cf8cd49" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsDebtIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="extended" id="i3f67b87e303f4600945bdc021d76975f_FinancingarrangementsDebtIssuancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1eeae449-e999-487c-a1f0-e8c7e342f8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b1e149fd-a7a6-48c1-a2ff-64f056e955d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1eeae449-e999-487c-a1f0-e8c7e342f8a9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b1e149fd-a7a6-48c1-a2ff-64f056e955d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bf7aca4c-ef7d-4d93-96f1-011da69aa58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1eeae449-e999-487c-a1f0-e8c7e342f8a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bf7aca4c-ef7d-4d93-96f1-011da69aa58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1eeae449-e999-487c-a1f0-e8c7e342f8a9" xlink:to="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ade4077d-d187-4cb1-95b8-dc7e997d6c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ade4077d-d187-4cb1-95b8-dc7e997d6c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ade4077d-d187-4cb1-95b8-dc7e997d6c54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ade4077d-d187-4cb1-95b8-dc7e997d6c54" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ade4077d-d187-4cb1-95b8-dc7e997d6c54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aa248a59-f269-4111-8610-acea3a1a78d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ade4077d-d187-4cb1-95b8-dc7e997d6c54" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aa248a59-f269-4111-8610-acea3a1a78d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_6ab9c8ad-ad53-4905-94cb-34c2bb44ef66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_aa248a59-f269-4111-8610-acea3a1a78d8" xlink:to="loc_us-gaap_NotesPayableToBanksMember_6ab9c8ad-ad53-4905-94cb-34c2bb44ef66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_58f12321-e1c4-4d0b-9a31-225687f4c751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:to="loc_us-gaap_DebtInstrumentAxis_58f12321-e1c4-4d0b-9a31-225687f4c751" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_58f12321-e1c4-4d0b-9a31-225687f4c751_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_58f12321-e1c4-4d0b-9a31-225687f4c751" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_58f12321-e1c4-4d0b-9a31-225687f4c751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_58f12321-e1c4-4d0b-9a31-225687f4c751" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember_08779395-25fe-4452-a315-bfc0c70a1cca" xlink:href="amgn-20221231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A165NotesDue20281652028NotesMember_08779395-25fe-4452-a315-bfc0c70a1cca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A200NotesDue20322002032NotesMember_4bfe0072-3be0-4487-9533-58fcb65a5bd1" xlink:href="amgn-20221231.xsd#amgn_A200NotesDue20322002032NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A200NotesDue20322002032NotesMember_4bfe0072-3be0-4487-9533-58fcb65a5bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A280NotesDue2041Member_5728a37f-60a4-4bbd-95a3-cf0026b6a6a5" xlink:href="amgn-20221231.xsd#amgn_A280NotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A280NotesDue2041Member_5728a37f-60a4-4bbd-95a3-cf0026b6a6a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_98f9d60b-fbb1-4888-8409-6a36d140f99a" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_98f9d60b-fbb1-4888-8409-6a36d140f99a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember_3292ac7a-66e9-417f-bf28-1bad8d5ba3d3" xlink:href="amgn-20221231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A190NotesDue20251902025NotesMember_3292ac7a-66e9-417f-bf28-1bad8d5ba3d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_364c1f9e-d3a2-4576-accb-254dcd987be8" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_364c1f9e-d3a2-4576-accb-254dcd987be8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_627c487b-e2af-41fd-af33-80cdc0592ac5" xlink:href="amgn-20221231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_627c487b-e2af-41fd-af33-80cdc0592ac5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_99ddb374-a4cb-4092-b923-8d8a68bd661a" xlink:href="amgn-20221231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_99ddb374-a4cb-4092-b923-8d8a68bd661a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_1b4187bb-220f-4100-ad0b-5b7e1b4d9cb7" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_1b4187bb-220f-4100-ad0b-5b7e1b4d9cb7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_685292f5-ae03-4a11-82de-88541a7276da" xlink:href="amgn-20221231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_685292f5-ae03-4a11-82de-88541a7276da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20293002029NotesMember_94eae763-b122-4686-8ed3-9685302a192e" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20293002029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A300NotesDue20293002029NotesMember_94eae763-b122-4686-8ed3-9685302a192e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A405NotesDue20294052029NotesMember_23a31b41-e8e9-4bc5-8e03-41a569d59598" xlink:href="amgn-20221231.xsd#amgn_A405NotesDue20294052029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A405NotesDue20294052029NotesMember_23a31b41-e8e9-4bc5-8e03-41a569d59598" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A335NotesDue20323352032NotesMember_eef6dcce-0dde-4280-8308-1c6ed6c4d240" xlink:href="amgn-20221231.xsd#amgn_A335NotesDue20323352032NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A335NotesDue20323352032NotesMember_eef6dcce-0dde-4280-8308-1c6ed6c4d240" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20334202033NotesMember_2a18fded-3ee0-46e3-aa5a-b7432058de86" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20334202033NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A420NotesDue20334202033NotesMember_2a18fded-3ee0-46e3-aa5a-b7432058de86" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20524202052NotesMember_cf2e00ba-50ca-4c77-a9dc-d9bcbf436068" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20524202052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A420NotesDue20524202052NotesMember_cf2e00ba-50ca-4c77-a9dc-d9bcbf436068" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4875NotesDue205348752053NotesMember_cb1ba933-0d37-4ea9-a9b1-3506854f7060" xlink:href="amgn-20221231.xsd#amgn_A4875NotesDue205348752053NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A4875NotesDue205348752053NotesMember_cb1ba933-0d37-4ea9-a9b1-3506854f7060" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A440NotesDue20624402062NotesMember_56fb3c8f-fe45-48c3-a5f0-a70bdf692e36" xlink:href="amgn-20221231.xsd#amgn_A440NotesDue20624402062NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A440NotesDue20624402062NotesMember_56fb3c8f-fe45-48c3-a5f0-a70bdf692e36" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_939ab0fd-abe3-4763-ba8f-7e096f4beeeb" xlink:href="amgn-20221231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:to="loc_amgn_AssetsByDescriptionAxis_939ab0fd-abe3-4763-ba8f-7e096f4beeeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_939ab0fd-abe3-4763-ba8f-7e096f4beeeb_default" xlink:href="amgn-20221231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_AssetsByDescriptionAxis_939ab0fd-abe3-4763-ba8f-7e096f4beeeb" xlink:to="loc_amgn_AssetsByDescriptionDomain_939ab0fd-abe3-4763-ba8f-7e096f4beeeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_957fe5df-bfb8-4064-bf13-1461603efba9" xlink:href="amgn-20221231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_AssetsByDescriptionAxis_939ab0fd-abe3-4763-ba8f-7e096f4beeeb" xlink:to="loc_amgn_AssetsByDescriptionDomain_957fe5df-bfb8-4064-bf13-1461603efba9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsDebtRepaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="extended" id="i2665f2ac782d446caa80f32f96c94b98_FinancingarrangementsDebtRepaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4106931b-6dcf-4d7e-8f84-49ee07b81342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4106931b-6dcf-4d7e-8f84-49ee07b81342" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f571d127-5ecf-4b10-ab47-a7cd833edc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f571d127-5ecf-4b10-ab47-a7cd833edc47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a2f81464-2b76-4781-baff-dc317df2dc29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_InterestExpenseDebt_a2f81464-2b76-4781-baff-dc317df2dc29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_e1da8daf-b3ce-477e-a771-bb5ae3e0f2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_e1da8daf-b3ce-477e-a771-bb5ae3e0f2e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7b697a27-092d-4721-a843-500646d03342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7b697a27-092d-4721-a843-500646d03342" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b8823fa3-3cbb-4844-a181-512acf8294a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_DebtInstrumentTable_b8823fa3-3cbb-4844-a181-512acf8294a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_db565ea6-b84f-44ac-924a-bf1c3a7cfe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b8823fa3-3cbb-4844-a181-512acf8294a9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_db565ea6-b84f-44ac-924a-bf1c3a7cfe3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_db565ea6-b84f-44ac-924a-bf1c3a7cfe3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_db565ea6-b84f-44ac-924a-bf1c3a7cfe3c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_db565ea6-b84f-44ac-924a-bf1c3a7cfe3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_956317fa-21d4-40d8-8dc6-5a54fbad3f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_db565ea6-b84f-44ac-924a-bf1c3a7cfe3c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_956317fa-21d4-40d8-8dc6-5a54fbad3f41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_6812c6d4-f18a-4afe-9653-f746066b4185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_956317fa-21d4-40d8-8dc6-5a54fbad3f41" xlink:to="loc_us-gaap_NotesPayableToBanksMember_6812c6d4-f18a-4afe-9653-f746066b4185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_96d463cb-3b44-49b4-9482-8f65d694ccc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b8823fa3-3cbb-4844-a181-512acf8294a9" xlink:to="loc_us-gaap_DebtInstrumentAxis_96d463cb-3b44-49b4-9482-8f65d694ccc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_96d463cb-3b44-49b4-9482-8f65d694ccc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_96d463cb-3b44-49b4-9482-8f65d694ccc4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_96d463cb-3b44-49b4-9482-8f65d694ccc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_96d463cb-3b44-49b4-9482-8f65d694ccc4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_a6e93fd1-a6c9-4604-83cd-54da241978e1" xlink:href="amgn-20221231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_a6e93fd1-a6c9-4604-83cd-54da241978e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_787e3ce2-1b73-4cf3-8446-aeefce13a1e9" xlink:href="amgn-20221231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_787e3ce2-1b73-4cf3-8446-aeefce13a1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_93464093-610d-4c89-b89c-eab89bdf0096" xlink:href="amgn-20221231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_93464093-610d-4c89-b89c-eab89bdf0096" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_7b4160b2-3115-4c5e-bd5a-ad385dc6cc08" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_7b4160b2-3115-4c5e-bd5a-ad385dc6cc08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_81b99842-ca30-4362-9170-81eda9bbb6c2" xlink:href="amgn-20221231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_81b99842-ca30-4362-9170-81eda9bbb6c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_35848d38-acd9-428c-a025-0b49973f6361" xlink:href="amgn-20221231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_35848d38-acd9-428c-a025-0b49973f6361" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_5032979b-40b0-42da-842c-9e7caeb5b4bc" xlink:href="amgn-20221231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_5032979b-40b0-42da-842c-9e7caeb5b4bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_3fdbce7e-fa4b-46c9-a8ce-561422a77d6e" xlink:href="amgn-20221231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_3fdbce7e-fa4b-46c9-a8ce-561422a77d6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_9ee729e1-ebd3-474c-8f8a-136c707d0410" xlink:href="amgn-20221231.xsd#amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_9ee729e1-ebd3-474c-8f8a-136c707d0410" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member_fb68bf9b-088d-4c81-943a-d732fd5b7b71" xlink:href="amgn-20221231.xsd#amgn_TwoPointSevenZeroPercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member_fb68bf9b-088d-4c81-943a-d732fd5b7b71" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_f8096207-5f61-4952-a6a9-c0c4624e76a9" xlink:href="amgn-20221231.xsd#amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_f8096207-5f61-4952-a6a9-c0c4624e76a9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_a2471455-b67a-41f6-b5b4-457c5d847ac5" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_a2471455-b67a-41f6-b5b4-457c5d847ac5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_eb4aab6e-a55b-4876-8e0a-dd9e6f492dcd" xlink:href="amgn-20221231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_eb4aab6e-a55b-4876-8e0a-dd9e6f492dcd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_fc96ca4c-1c1a-4f4d-8d0d-39e1959f47a9" xlink:href="amgn-20221231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_fc96ca4c-1c1a-4f4d-8d0d-39e1959f47a9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember_ce3bd8e6-ee3d-4fbf-90b3-397c25b7c4d9" xlink:href="amgn-20221231.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointEightZeroPercent2041NotesMember_ce3bd8e6-ee3d-4fbf-90b3-397c25b7c4d9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_929515d1-8d4a-4d70-bf65-64ed3561255b" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_929515d1-8d4a-4d70-bf65-64ed3561255b" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="extended" id="i2ac4e9f0b30c44e5a46a2c103f747161_FinancingarrangementsInterestRateandCrosscurrencySwapsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5de1aff6-cd13-42d4-a5f4-a464a04aa52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5de1aff6-cd13-42d4-a5f4-a464a04aa52f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_f16ceb1e-54e0-42f4-87da-1b5735f12060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeBasisSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_f16ceb1e-54e0-42f4-87da-1b5735f12060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_39c1a7ef-91a0-4e5f-a911-ef5df20805c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DerivativeNotionalAmount_39c1a7ef-91a0-4e5f-a911-ef5df20805c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_fc196435-8fe5-41c0-828d-880f2e5f49d6" xlink:href="amgn-20221231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_fc196435-8fe5-41c0-828d-880f2e5f49d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_759cdaa5-01b4-4904-912c-8c7aad728c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_759cdaa5-01b4-4904-912c-8c7aad728c8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_948a6c00-d530-4bb1-b63f-91536bac3695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_948a6c00-d530-4bb1-b63f-91536bac3695" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_72bde99f-51ab-4076-ab5b-e53ee80e6093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_72bde99f-51ab-4076-ab5b-e53ee80e6093" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration_ccfbd2f9-0177-4c7d-a4fb-2586d69cefa9" xlink:href="amgn-20221231.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_amgn_DebtExchangeAdditionalCashConsideration_ccfbd2f9-0177-4c7d-a4fb-2586d69cefa9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2ada424e-cc0f-4ec6-b038-255cbdab670e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2ada424e-cc0f-4ec6-b038-255cbdab670e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bf524ce4-e5a5-4a35-a845-6c61379a2fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bf524ce4-e5a5-4a35-a845-6c61379a2fc9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cc680c2b-24cf-4ef5-a26a-57d9c6abcc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cc680c2b-24cf-4ef5-a26a-57d9c6abcc39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc680c2b-24cf-4ef5-a26a-57d9c6abcc39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc680c2b-24cf-4ef5-a26a-57d9c6abcc39" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc680c2b-24cf-4ef5-a26a-57d9c6abcc39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5d008a0d-cbbe-48e3-aa28-9a8a8add9270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc680c2b-24cf-4ef5-a26a-57d9c6abcc39" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5d008a0d-cbbe-48e3-aa28-9a8a8add9270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_2c81626d-70ac-46dc-a1bb-ed21c2f14cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5d008a0d-cbbe-48e3-aa28-9a8a8add9270" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_2c81626d-70ac-46dc-a1bb-ed21c2f14cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_461b2818-41de-4071-a73f-d1527262a7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5d008a0d-cbbe-48e3-aa28-9a8a8add9270" xlink:to="loc_us-gaap_NotesPayableToBanksMember_461b2818-41de-4071-a73f-d1527262a7f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1f7f164a-01b3-45bf-84f0-e30062d93dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_DebtInstrumentAxis_1f7f164a-01b3-45bf-84f0-e30062d93dc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1f7f164a-01b3-45bf-84f0-e30062d93dc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1f7f164a-01b3-45bf-84f0-e30062d93dc1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1f7f164a-01b3-45bf-84f0-e30062d93dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1f7f164a-01b3-45bf-84f0-e30062d93dc1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_42b1d33a-005b-4579-9157-cf08449bbd8b" xlink:href="amgn-20221231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_42b1d33a-005b-4579-9157-cf08449bbd8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_5ed69855-8672-4320-a8be-b75b834b36c5" xlink:href="amgn-20221231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_5ed69855-8672-4320-a8be-b75b834b36c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_ef0f2dd3-8818-42f8-9ea7-4aec14f05c44" xlink:href="amgn-20221231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_ef0f2dd3-8818-42f8-9ea7-4aec14f05c44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_2466957c-127c-4115-baa3-56aa115123ba" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_2466957c-127c-4115-baa3-56aa115123ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_33ff1097-42d0-43d0-92c3-c82f49d2b4b7" xlink:href="amgn-20221231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_33ff1097-42d0-43d0-92c3-c82f49d2b4b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_fc7f22a4-5447-4687-a259-6e2f7f1afbfa" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_fc7f22a4-5447-4687-a259-6e2f7f1afbfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_1a1fe5a6-6e71-44e1-a3cd-dc2afef0d77e" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_1a1fe5a6-6e71-44e1-a3cd-dc2afef0d77e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_22d7c25b-a98a-4632-be67-b3e54ff8c5d8" xlink:href="amgn-20221231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_22d7c25b-a98a-4632-be67-b3e54ff8c5d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_3b3fe925-bf20-4839-baaa-02634bd6cea2" xlink:href="amgn-20221231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_3b3fe925-bf20-4839-baaa-02634bd6cea2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_a6e9be9b-1a11-4cee-b370-fa88f652ce57" xlink:href="amgn-20221231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_a6e9be9b-1a11-4cee-b370-fa88f652ce57" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_8a2d74e6-7c73-4dc5-a874-e75e635e7a57" xlink:href="amgn-20221231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_8a2d74e6-7c73-4dc5-a874-e75e635e7a57" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_3f8b342b-9eae-4229-b1ce-bf63189684d9" xlink:href="amgn-20221231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_3f8b342b-9eae-4229-b1ce-bf63189684d9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_fca30b29-22cd-4196-b0c4-963b3ae0923d" xlink:href="amgn-20221231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_fca30b29-22cd-4196-b0c4-963b3ae0923d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_c3b41a94-59e5-42f7-b875-2b6f2ceae34d" xlink:href="amgn-20221231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_c3b41a94-59e5-42f7-b875-2b6f2ceae34d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_b543c4f6-76dc-4cde-8be7-adc1cf307841" xlink:href="amgn-20221231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_b543c4f6-76dc-4cde-8be7-adc1cf307841" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_4103c0a0-1479-415f-a9fb-df11f3f43f60" xlink:href="amgn-20221231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_4103c0a0-1479-415f-a9fb-df11f3f43f60" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_ba4b8ff2-03cb-4f2d-9d38-aaab571cd65e" xlink:href="amgn-20221231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_ba4b8ff2-03cb-4f2d-9d38-aaab571cd65e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_e25c3994-c3a4-4c88-83b8-a57873cef19c" xlink:href="amgn-20221231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_e25c3994-c3a4-4c88-83b8-a57873cef19c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_5e1b841e-9dff-4b98-a1aa-250765b55e14" xlink:href="amgn-20221231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_5e1b841e-9dff-4b98-a1aa-250765b55e14" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_32eb1f44-64c2-43c4-9108-c07612628f57" xlink:href="amgn-20221231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_32eb1f44-64c2-43c4-9108-c07612628f57" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_bcf6b0c2-fd83-45ae-9e4a-5da87954e844" xlink:href="amgn-20221231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_bcf6b0c2-fd83-45ae-9e4a-5da87954e844" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_c5da4881-b102-46cf-b56b-2d681440dd41" xlink:href="amgn-20221231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_c5da4881-b102-46cf-b56b-2d681440dd41" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_b3c50d22-025d-4dd1-9bb2-a9849a72a59a" xlink:href="amgn-20221231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_b3c50d22-025d-4dd1-9bb2-a9849a72a59a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_dc5d3ec6-1b56-4b6d-ae74-4e6ad2bd4846" xlink:href="amgn-20221231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_dc5d3ec6-1b56-4b6d-ae74-4e6ad2bd4846" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ed913850-50eb-467c-841b-b583a7e08f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_VariableRateAxis_ed913850-50eb-467c-841b-b583a7e08f6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ed913850-50eb-467c-841b-b583a7e08f6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_ed913850-50eb-467c-841b-b583a7e08f6a" xlink:to="loc_us-gaap_VariableRateDomain_ed913850-50eb-467c-841b-b583a7e08f6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b9bae7c1-4808-40d2-8a1f-6c4c027565d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_ed913850-50eb-467c-841b-b583a7e08f6a" xlink:to="loc_us-gaap_VariableRateDomain_b9bae7c1-4808-40d2-8a1f-6c4c027565d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_c2a1d827-a277-402b-94b5-b0f1ee609dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b9bae7c1-4808-40d2-8a1f-6c4c027565d3" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_c2a1d827-a277-402b-94b5-b0f1ee609dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_6b59c420-17ff-4ee8-9f8e-f9f42d28c559" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_amgn_InterestRateSwapAxis_6b59c420-17ff-4ee8-9f8e-f9f42d28c559" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_6b59c420-17ff-4ee8-9f8e-f9f42d28c559_default" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_InterestRateSwapAxis_6b59c420-17ff-4ee8-9f8e-f9f42d28c559" xlink:to="loc_amgn_InterestRateSwapDomain_6b59c420-17ff-4ee8-9f8e-f9f42d28c559_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_e7390204-e27b-41e2-b925-82ef54f13054" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_InterestRateSwapAxis_6b59c420-17ff-4ee8-9f8e-f9f42d28c559" xlink:to="loc_amgn_InterestRateSwapDomain_e7390204-e27b-41e2-b925-82ef54f13054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapOneMember_1d9face5-19d2-4fa9-8cba-eaaf1ae63758" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_InterestRateSwapDomain_e7390204-e27b-41e2-b925-82ef54f13054" xlink:to="loc_amgn_InterestRateSwapOneMember_1d9face5-19d2-4fa9-8cba-eaaf1ae63758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_ccd00634-61f9-4e9c-ba1d-8f98583d4979" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_InterestRateSwapDomain_e7390204-e27b-41e2-b925-82ef54f13054" xlink:to="loc_amgn_InterestRateSwapTwoMember_ccd00634-61f9-4e9c-ba1d-8f98583d4979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_13b74049-4fba-4d42-8cbe-6721eb80e986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_13b74049-4fba-4d42-8cbe-6721eb80e986" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_13b74049-4fba-4d42-8cbe-6721eb80e986_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_13b74049-4fba-4d42-8cbe-6721eb80e986" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_13b74049-4fba-4d42-8cbe-6721eb80e986_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a6a75709-e6c0-403a-9d2a-d413f658086f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_13b74049-4fba-4d42-8cbe-6721eb80e986" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a6a75709-e6c0-403a-9d2a-d413f658086f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5b3a038d-fccd-458e-92c1-c0ada77c76f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6a75709-e6c0-403a-9d2a-d413f658086f" xlink:to="loc_us-gaap_InterestRateSwapMember_5b3a038d-fccd-458e-92c1-c0ada77c76f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_e2885aeb-4eb4-40ff-b0fb-619bfd078226" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6a75709-e6c0-403a-9d2a-d413f658086f" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_e2885aeb-4eb4-40ff-b0fb-619bfd078226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6635e9d2-0528-4b30-a496-c74555b2d014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_HedgingDesignationAxis_6635e9d2-0528-4b30-a496-c74555b2d014" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6635e9d2-0528-4b30-a496-c74555b2d014_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6635e9d2-0528-4b30-a496-c74555b2d014" xlink:to="loc_us-gaap_HedgingDesignationDomain_6635e9d2-0528-4b30-a496-c74555b2d014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_96bbb884-dfc9-423e-b541-d920e88bff49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6635e9d2-0528-4b30-a496-c74555b2d014" xlink:to="loc_us-gaap_HedgingDesignationDomain_96bbb884-dfc9-423e-b541-d920e88bff49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e0511f67-a7d5-4f1e-830b-c120df484bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_96bbb884-dfc9-423e-b541-d920e88bff49" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e0511f67-a7d5-4f1e-830b-c120df484bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8f504b90-aec5-4272-a272-44c00d879da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8f504b90-aec5-4272-a272-44c00d879da5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8f504b90-aec5-4272-a272-44c00d879da5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8f504b90-aec5-4272-a272-44c00d879da5" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8f504b90-aec5-4272-a272-44c00d879da5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_463aa824-28a6-4d72-aa3f-9f1d001fd8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8f504b90-aec5-4272-a272-44c00d879da5" xlink:to="loc_us-gaap_HedgingRelationshipDomain_463aa824-28a6-4d72-aa3f-9f1d001fd8d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e8083e0b-1b9d-4b7e-95e6-6884adfe6eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_463aa824-28a6-4d72-aa3f-9f1d001fd8d3" xlink:to="loc_us-gaap_CashFlowHedgingMember_e8083e0b-1b9d-4b7e-95e6-6884adfe6eef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="extended" id="i1ab9f650b01b4796bef087f542e7a077_FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_5a45d20d-02c7-45c0-9f7b-0804c5528024" xlink:href="amgn-20221231.xsd#amgn_MaximumBorrowingCapacityUnderCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_5a45d20d-02c7-45c0-9f7b-0804c5528024" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_7ce86a9a-6130-419a-9b90-b886dbec3b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_CommercialPaper_7ce86a9a-6130-419a-9b90-b886dbec3b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e9b790de-73d5-44d4-9126-2ba728b2f81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e9b790de-73d5-44d4-9126-2ba728b2f81b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_e7ca9704-39e3-453a-8115-3139cc383ffe" xlink:href="amgn-20221231.xsd#amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_e7ca9704-39e3-453a-8115-3139cc383ffe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_25e6155c-e140-4350-9649-c83f22403540" xlink:href="amgn-20221231.xsd#amgn_LineOfCreditFacilityInitialCommitmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_25e6155c-e140-4350-9649-c83f22403540" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_8d1cf063-559e-4bf2-997a-99c7005abdd8" xlink:href="amgn-20221231.xsd#amgn_LineofCreditFacilityNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_8d1cf063-559e-4bf2-997a-99c7005abdd8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_d06a4b1b-24d9-45bd-8dc1-1eec94378d4d" xlink:href="amgn-20221231.xsd#amgn_LineOfCreditFacilityExtensionOfCommitmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_d06a4b1b-24d9-45bd-8dc1-1eec94378d4d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5a1b5177-46c8-4b0a-88c0-b635e8236b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5a1b5177-46c8-4b0a-88c0-b635e8236b27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_15ee37c5-a7c9-4a55-9e4c-fee0da8962d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_15ee37c5-a7c9-4a55-9e4c-fee0da8962d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_14f29e36-c213-4cdb-a6f6-74fd0931327f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_14f29e36-c213-4cdb-a6f6-74fd0931327f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_55f05b8c-d62d-4161-a5b3-0f5c91079092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_LineOfCredit_55f05b8c-d62d-4161-a5b3-0f5c91079092" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementInitialAmount_889c9e36-f4ef-4ed3-9ee2-6e81cad35005" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementInitialAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_BridgeCreditAgreementInitialAmount_889c9e36-f4ef-4ed3-9ee2-6e81cad35005" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementAmount_9f3cc100-1e08-43d3-878c-64ec08557fbf" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_BridgeCreditAgreementAmount_9f3cc100-1e08-43d3-878c-64ec08557fbf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ea7e87e8-80ec-4b55-b6c2-160bd0f5cca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ea7e87e8-80ec-4b55-b6c2-160bd0f5cca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ea7e87e8-80ec-4b55-b6c2-160bd0f5cca2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea7e87e8-80ec-4b55-b6c2-160bd0f5cca2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ea7e87e8-80ec-4b55-b6c2-160bd0f5cca2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3ef1696e-e5a5-42da-9ebf-89f2d0c0fcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea7e87e8-80ec-4b55-b6c2-160bd0f5cca2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3ef1696e-e5a5-42da-9ebf-89f2d0c0fcfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_813179c9-db6b-4294-80c4-2cee1da1f335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3ef1696e-e5a5-42da-9ebf-89f2d0c0fcfe" xlink:to="loc_us-gaap_LineOfCreditMember_813179c9-db6b-4294-80c4-2cee1da1f335" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementMember_e3ed3432-ae3e-4e20-9d14-d5fb9d9b2dea" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3ef1696e-e5a5-42da-9ebf-89f2d0c0fcfe" xlink:to="loc_amgn_BridgeCreditAgreementMember_e3ed3432-ae3e-4e20-9d14-d5fb9d9b2dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b9c2d924-cb02-4456-ae16-900822194a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:to="loc_us-gaap_VariableRateAxis_b9c2d924-cb02-4456-ae16-900822194a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b9c2d924-cb02-4456-ae16-900822194a4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_b9c2d924-cb02-4456-ae16-900822194a4b" xlink:to="loc_us-gaap_VariableRateDomain_b9c2d924-cb02-4456-ae16-900822194a4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1be79d4c-6764-4b30-8764-538e72bee4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_b9c2d924-cb02-4456-ae16-900822194a4b" xlink:to="loc_us-gaap_VariableRateDomain_1be79d4c-6764-4b30-8764-538e72bee4d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SecuredOvernightFinancingRateMember_fae7890b-1356-4252-ac46-0e9f86755032" xlink:href="amgn-20221231.xsd#amgn_SecuredOvernightFinancingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1be79d4c-6764-4b30-8764-538e72bee4d7" xlink:to="loc_amgn_SecuredOvernightFinancingRateMember_fae7890b-1356-4252-ac46-0e9f86755032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember_5690d5b0-74e0-45e5-b0cd-5ed010052d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1be79d4c-6764-4b30-8764-538e72bee4d7" xlink:to="loc_us-gaap_FederalFundsPurchasedMember_5690d5b0-74e0-45e5-b0cd-5ed010052d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8b25afd5-fb19-4d97-b678-3967790661eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8b25afd5-fb19-4d97-b678-3967790661eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b25afd5-fb19-4d97-b678-3967790661eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8b25afd5-fb19-4d97-b678-3967790661eb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b25afd5-fb19-4d97-b678-3967790661eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6737c073-95d3-4c64-8927-4274116d4323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8b25afd5-fb19-4d97-b678-3967790661eb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6737c073-95d3-4c64-8927-4274116d4323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HorizonTherapeuticsMember_d09025ca-6d5c-4a44-b39b-c518fed2aed0" xlink:href="amgn-20221231.xsd#amgn_HorizonTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6737c073-95d3-4c64-8927-4274116d4323" xlink:to="loc_amgn_HorizonTherapeuticsMember_d09025ca-6d5c-4a44-b39b-c518fed2aed0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityStockRepurchaseProgramDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="extended" id="id240534a23f14b1ca466172dfc9c8bcb_StockholdersequityStockRepurchaseProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2228f04a-eb2e-4a5a-83d1-fb8411d345d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_2228f04a-eb2e-4a5a-83d1-fb8411d345d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_480763e0-c00a-4e8e-9d74-f091d093a2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_480763e0-c00a-4e8e-9d74-f091d093a2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c1906400-f3b7-4cd2-a290-9d21921f5f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c1906400-f3b7-4cd2-a290-9d21921f5f61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_467bdf88-d743-448d-9a23-d5e903327d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_467bdf88-d743-448d-9a23-d5e903327d82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_cf42cfb0-ff2a-46ba-87ad-0e0b15f13ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_cf42cfb0-ff2a-46ba-87ad-0e0b15f13ff3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5665e915-374b-4a4c-ba8b-7639693e1639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5665e915-374b-4a4c-ba8b-7639693e1639" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e13b7457-0167-4c1e-8498-993ffd712870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5665e915-374b-4a4c-ba8b-7639693e1639" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e13b7457-0167-4c1e-8498-993ffd712870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_e13b7457-0167-4c1e-8498-993ffd712870_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e13b7457-0167-4c1e-8498-993ffd712870" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_e13b7457-0167-4c1e-8498-993ffd712870_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_84e2074b-357e-4822-a961-48a9194ded6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e13b7457-0167-4c1e-8498-993ffd712870" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_84e2074b-357e-4822-a961-48a9194ded6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcceleratedStockRepurchaseAgreementMember_69412be3-666c-4ba8-9c39-f9eee161aecb" xlink:href="amgn-20221231.xsd#amgn_AcceleratedStockRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_84e2074b-357e-4822-a961-48a9194ded6e" xlink:to="loc_amgn_AcceleratedStockRepurchaseAgreementMember_69412be3-666c-4ba8-9c39-f9eee161aecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4eec7580-7fae-4b15-b978-bb3c8a061fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5665e915-374b-4a4c-ba8b-7639693e1639" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4eec7580-7fae-4b15-b978-bb3c8a061fae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4eec7580-7fae-4b15-b978-bb3c8a061fae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4eec7580-7fae-4b15-b978-bb3c8a061fae" xlink:to="loc_us-gaap_EquityComponentDomain_4eec7580-7fae-4b15-b978-bb3c8a061fae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_da028243-851a-494d-abc1-3836a1d28b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4eec7580-7fae-4b15-b978-bb3c8a061fae" xlink:to="loc_us-gaap_EquityComponentDomain_da028243-851a-494d-abc1-3836a1d28b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_88107dbe-d206-4fba-b5cc-dfc6a2fdd340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_da028243-851a-494d-abc1-3836a1d28b16" xlink:to="loc_us-gaap_RetainedEarningsMember_88107dbe-d206-4fba-b5cc-dfc6a2fdd340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_62375a81-6919-4216-b9ef-2c7c50beea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_da028243-851a-494d-abc1-3836a1d28b16" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_62375a81-6919-4216-b9ef-2c7c50beea2a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="extended" id="idb9cc07936044ae59bf39a25de3b37ad_StockholdersequityDividendsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7a992170-64cb-40cf-9aa4-90315d82b22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_635c21fa-dda0-4434-9182-87c7ed9999a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7a992170-64cb-40cf-9aa4-90315d82b22a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_635c21fa-dda0-4434-9182-87c7ed9999a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_040cd69b-546b-40b9-8936-8e44dde13c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7a992170-64cb-40cf-9aa4-90315d82b22a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_040cd69b-546b-40b9-8936-8e44dde13c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_99d12b54-2c2b-4d48-a9ab-545a99a47a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7a992170-64cb-40cf-9aa4-90315d82b22a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_99d12b54-2c2b-4d48-a9ab-545a99a47a3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_965244cf-e37f-4e95-948c-ec71897bba7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_99d12b54-2c2b-4d48-a9ab-545a99a47a3e" xlink:to="loc_srt_StatementScenarioAxis_965244cf-e37f-4e95-948c-ec71897bba7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_965244cf-e37f-4e95-948c-ec71897bba7f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_965244cf-e37f-4e95-948c-ec71897bba7f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_965244cf-e37f-4e95-948c-ec71897bba7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_38834c45-8f08-45fe-906d-f663ff087f60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_965244cf-e37f-4e95-948c-ec71897bba7f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_38834c45-8f08-45fe-906d-f663ff087f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5b12b58e-740d-4fb5-bc4a-a2feb037cc86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_38834c45-8f08-45fe-906d-f663ff087f60" xlink:to="loc_srt_ScenarioForecastMember_5b12b58e-740d-4fb5-bc4a-a2feb037cc86" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityComponentsofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="extended" id="i04a155181937427b955a10ea4553f6c5_StockholdersequityComponentsofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ddcdfdfe-d877-4674-9e94-221984dd0906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ddcdfdfe-d877-4674-9e94-221984dd0906" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1f7d022b-bcbf-4c13-9aff-60598ec42983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_StockholdersEquity_1f7d022b-bcbf-4c13-9aff-60598ec42983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b28b2bcc-3ff0-400c-ae06-3dd6ff68b55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b28b2bcc-3ff0-400c-ae06-3dd6ff68b55e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_370c0e93-fe2a-40a4-b8de-8903a9c8b14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_370c0e93-fe2a-40a4-b8de-8903a9c8b14d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_189686d1-8ed8-4e41-b577-6eeefc44325e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_189686d1-8ed8-4e41-b577-6eeefc44325e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_c519f82a-eb75-4339-92c9-95b950db096d" xlink:href="amgn-20221231.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_c519f82a-eb75-4339-92c9-95b950db096d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_6ddaeabe-591c-4383-94ca-49710648812f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_6ddaeabe-591c-4383-94ca-49710648812f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_10a6010d-d2f2-424d-9eff-5e5f12cd98d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4271eded-c504-45df-b399-af426c1937f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ddcdfdfe-d877-4674-9e94-221984dd0906" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4271eded-c504-45df-b399-af426c1937f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_143d61de-52ea-4ff3-bd91-eb61f4a1916e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4271eded-c504-45df-b399-af426c1937f2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_143d61de-52ea-4ff3-bd91-eb61f4a1916e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_143d61de-52ea-4ff3-bd91-eb61f4a1916e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_143d61de-52ea-4ff3-bd91-eb61f4a1916e" xlink:to="loc_us-gaap_EquityComponentDomain_143d61de-52ea-4ff3-bd91-eb61f4a1916e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_143d61de-52ea-4ff3-bd91-eb61f4a1916e" xlink:to="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2f55df34-c72c-44cf-a0ad-933cea4e9d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2f55df34-c72c-44cf-a0ad-933cea4e9d37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_aebfdacb-8651-42f9-961f-da7b7e6e8178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_aebfdacb-8651-42f9-961f-da7b7e6e8178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_eae3b9db-0d19-4186-ae23-d0be609ddf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_eae3b9db-0d19-4186-ae23-d0be609ddf34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_7916d3ae-59eb-455e-ad05-82237f371c49" xlink:href="amgn-20221231.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_7916d3ae-59eb-455e-ad05-82237f371c49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c29a50ad-59cf-4079-b9d3-ac5deaac8ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c29a50ad-59cf-4079-b9d3-ac5deaac8ba4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_dd889087-4820-485c-8fd2-1e63c1dd121e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4271eded-c504-45df-b399-af426c1937f2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_dd889087-4820-485c-8fd2-1e63c1dd121e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dd889087-4820-485c-8fd2-1e63c1dd121e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_dd889087-4820-485c-8fd2-1e63c1dd121e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dd889087-4820-485c-8fd2-1e63c1dd121e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_285841a1-75a6-4270-af96-9eeb15516258" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_dd889087-4820-485c-8fd2-1e63c1dd121e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_285841a1-75a6-4270-af96-9eeb15516258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_af53d078-dea4-492d-a001-0ac6681d4481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_285841a1-75a6-4270-af96-9eeb15516258" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_af53d078-dea4-492d-a001-0ac6681d4481" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityReclassificationsoutofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="extended" id="ifde6f4ef55514022b19f7d90f140987a_StockholdersequityReclassificationsoutofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_fd3b06ec-d6cc-4f10-856a-1a45eee3121a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_fd3b06ec-d6cc-4f10-856a-1a45eee3121a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_af824650-a99e-4065-85a7-9fbc3ff83cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_af824650-a99e-4065-85a7-9fbc3ff83cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6021ff9f-de80-4c48-a4bb-24d45caa3a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_InterestExpenseDebt_6021ff9f-de80-4c48-a4bb-24d45caa3a54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c17fda00-ab8a-4490-ab4e-9d8d87b96406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c17fda00-ab8a-4490-ab4e-9d8d87b96406" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8dc7637a-4cbb-41c5-89ec-bd6a7c3ddb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8dc7637a-4cbb-41c5-89ec-bd6a7c3ddb0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8d38594-2205-463e-8ba1-b0a7071b02ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_NetIncomeLoss_c8d38594-2205-463e-8ba1-b0a7071b02ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3b8dbd0-7e57-48ad-aa0a-09f3d9a43ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3b8dbd0-7e57-48ad-aa0a-09f3d9a43ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3b8dbd0-7e57-48ad-aa0a-09f3d9a43ea8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3b8dbd0-7e57-48ad-aa0a-09f3d9a43ea8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3b8dbd0-7e57-48ad-aa0a-09f3d9a43ea8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_363484db-d284-47cc-afd4-013846ff4fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3b8dbd0-7e57-48ad-aa0a-09f3d9a43ea8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_363484db-d284-47cc-afd4-013846ff4fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b9df6c4a-1fb1-49ff-bcce-0b0ca17482bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_363484db-d284-47cc-afd4-013846ff4fa0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b9df6c4a-1fb1-49ff-bcce-0b0ca17482bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_39b53c9b-1add-4d69-bdc2-841a236df847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_39b53c9b-1add-4d69-bdc2-841a236df847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_39b53c9b-1add-4d69-bdc2-841a236df847_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_39b53c9b-1add-4d69-bdc2-841a236df847" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_39b53c9b-1add-4d69-bdc2-841a236df847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_20962906-ddca-4484-8bf5-cc34544ca0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_39b53c9b-1add-4d69-bdc2-841a236df847" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_20962906-ddca-4484-8bf5-cc34544ca0f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8d58c50c-19b9-4648-92c0-549dd0cb1370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20962906-ddca-4484-8bf5-cc34544ca0f8" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8d58c50c-19b9-4648-92c0-549dd0cb1370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_9b5f0f1d-0718-4173-9381-35b38a10442a" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20962906-ddca-4484-8bf5-cc34544ca0f8" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_9b5f0f1d-0718-4173-9381-35b38a10442a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_379e47fd-7462-43c5-8085-fa71db70083c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:to="loc_srt_ProductOrServiceAxis_379e47fd-7462-43c5-8085-fa71db70083c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_379e47fd-7462-43c5-8085-fa71db70083c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_379e47fd-7462-43c5-8085-fa71db70083c" xlink:to="loc_srt_ProductsAndServicesDomain_379e47fd-7462-43c5-8085-fa71db70083c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4b436ecf-48d4-402d-827c-1ee27a1da9cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_379e47fd-7462-43c5-8085-fa71db70083c" xlink:to="loc_srt_ProductsAndServicesDomain_4b436ecf-48d4-402d-827c-1ee27a1da9cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_26ee8ca9-aef1-409d-b152-cbd8b7ab2dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4b436ecf-48d4-402d-827c-1ee27a1da9cd" xlink:to="loc_us-gaap_ProductMember_26ee8ca9-aef1-409d-b152-cbd8b7ab2dd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1df0d766-c3fd-4e75-b840-43eef76b8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1df0d766-c3fd-4e75-b840-43eef76b8f7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1df0d766-c3fd-4e75-b840-43eef76b8f7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1df0d766-c3fd-4e75-b840-43eef76b8f7c" xlink:to="loc_us-gaap_EquityComponentDomain_1df0d766-c3fd-4e75-b840-43eef76b8f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9bd7bff1-46a2-4587-9cc7-8c10c322be64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1df0d766-c3fd-4e75-b840-43eef76b8f7c" xlink:to="loc_us-gaap_EquityComponentDomain_9bd7bff1-46a2-4587-9cc7-8c10c322be64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_32faeb30-3751-4cb9-ac40-dd55ddefc4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9bd7bff1-46a2-4587-9cc7-8c10c322be64" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_32faeb30-3751-4cb9-ac40-dd55ddefc4c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_53a4b396-4aad-469f-9188-d5d38f00d843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9bd7bff1-46a2-4587-9cc7-8c10c322be64" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_53a4b396-4aad-469f-9188-d5d38f00d843" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="iec7e628107dd450b886621a474dcb0eb_FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b55d2759-4dd2-43a7-a363-74bda51b633d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b55d2759-4dd2-43a7-a363-74bda51b633d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a986bf40-362a-40d1-a1aa-51813637fbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a986bf40-362a-40d1-a1aa-51813637fbe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_b1117e82-e7d3-461a-912f-0f5886e41ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_us-gaap_OtherInvestments_b1117e82-e7d3-461a-912f-0f5886e41ba3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d808eead-dcf3-45dd-be49-30cac98a42c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d808eead-dcf3-45dd-be49-30cac98a42c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_ee8d926e-e5c3-4a78-a6b8-4523bf24b8c3" xlink:href="amgn-20221231.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_ee8d926e-e5c3-4a78-a6b8-4523bf24b8c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_628187da-5064-47d1-be50-8c2eb37d916a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_ee8d926e-e5c3-4a78-a6b8-4523bf24b8c3" xlink:to="loc_us-gaap_DerivativeAssets_628187da-5064-47d1-be50-8c2eb37d916a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d2278f78-7864-40b0-b73e-9735ae134396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d2278f78-7864-40b0-b73e-9735ae134396" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b55d2759-4dd2-43a7-a363-74bda51b633d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_e95a3caa-ab55-40cb-aeaf-13fbe78598eb" xlink:href="amgn-20221231.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:to="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_e95a3caa-ab55-40cb-aeaf-13fbe78598eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_735a936c-722e-4f5d-99ea-f3f53cb18fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_e95a3caa-ab55-40cb-aeaf-13fbe78598eb" xlink:to="loc_us-gaap_DerivativeLiabilities_735a936c-722e-4f5d-99ea-f3f53cb18fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c66bbf45-c121-4b2a-b20e-e56199c75316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c66bbf45-c121-4b2a-b20e-e56199c75316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5caafb9f-8135-4ebf-bd57-034e0baf7e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5caafb9f-8135-4ebf-bd57-034e0baf7e42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b55d2759-4dd2-43a7-a363-74bda51b633d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_632ee99a-036d-4552-90fb-5df6299410ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_632ee99a-036d-4552-90fb-5df6299410ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632ee99a-036d-4552-90fb-5df6299410ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_632ee99a-036d-4552-90fb-5df6299410ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632ee99a-036d-4552-90fb-5df6299410ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_632ee99a-036d-4552-90fb-5df6299410ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7e7acf5-d365-42d9-aef1-4bde40c98f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7e7acf5-d365-42d9-aef1-4bde40c98f22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d81113fb-0093-402b-bae8-782fd6024928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d81113fb-0093-402b-bae8-782fd6024928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_779f0fc2-993a-44c8-bbb9-fc1c2504d60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_779f0fc2-993a-44c8-bbb9-fc1c2504d60e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b5d8f2d2-ede6-480d-a02b-675ec3418106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b5d8f2d2-ede6-480d-a02b-675ec3418106" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5d8f2d2-ede6-480d-a02b-675ec3418106_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b5d8f2d2-ede6-480d-a02b-675ec3418106" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5d8f2d2-ede6-480d-a02b-675ec3418106_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b5d8f2d2-ede6-480d-a02b-675ec3418106" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f492e15c-fd10-4e66-b1b9-ff594e8ab187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f492e15c-fd10-4e66-b1b9-ff594e8ab187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_fafa3446-1c89-48cc-a7df-e59100723c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_fafa3446-1c89-48cc-a7df-e59100723c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0eed6cd9-c25f-4f42-ad6b-e7f85e2ac169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0eed6cd9-c25f-4f42-ad6b-e7f85e2ac169" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_78bd293d-52aa-43ac-bd0e-77db47443b1c" xlink:href="amgn-20221231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_78bd293d-52aa-43ac-bd0e-77db47443b1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_11bdb513-7661-4348-8aaa-9230d7546e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_11bdb513-7661-4348-8aaa-9230d7546e98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_11bdb513-7661-4348-8aaa-9230d7546e98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_11bdb513-7661-4348-8aaa-9230d7546e98" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_11bdb513-7661-4348-8aaa-9230d7546e98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_11bdb513-7661-4348-8aaa-9230d7546e98" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c1614d5e-a56c-44da-bef1-ac29f2cfcd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c1614d5e-a56c-44da-bef1-ac29f2cfcd1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_b65f1330-0fb6-40c9-aa01-111245e23475" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_b65f1330-0fb6-40c9-aa01-111245e23475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_80cf62d3-4c9a-4938-8976-17bf0be49d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:to="loc_us-gaap_InterestRateSwapMember_80cf62d3-4c9a-4938-8976-17bf0be49d72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractsMember_fb9936cf-1bcf-48c0-93cf-9a9863a233de" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:to="loc_amgn_ForwardInterestRateContractsMember_fb9936cf-1bcf-48c0-93cf-9a9863a233de" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FairvaluemeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="extended" id="i2dc50784c6ba4ac681bed6885a3bf981_FairvaluemeasurementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_696c6bb0-255e-4118-8271-d6c0bed0989f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_696c6bb0-255e-4118-8271-d6c0bed0989f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_544ec4a5-45a9-4a7a-af50-a83e90030f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_544ec4a5-45a9-4a7a-af50-a83e90030f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_398c381d-96c0-41fb-85b3-1b0917d10e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_LongTermDebt_398c381d-96c0-41fb-85b3-1b0917d10e97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_0a68f513-5767-4e17-9fa8-2e6e2e4c88c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_0a68f513-5767-4e17-9fa8-2e6e2e4c88c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_5c8c4f36-ff87-451c-b08a-6efd6c124b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_EquityMethodInvestments_5c8c4f36-ff87-451c-b08a-6efd6c124b3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35cd7e91-e308-417f-bcb1-63ace19825de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35cd7e91-e308-417f-bcb1-63ace19825de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_74a8e485-82d1-4931-9130-56c8ced39151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35cd7e91-e308-417f-bcb1-63ace19825de" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_74a8e485-82d1-4931-9130-56c8ced39151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74a8e485-82d1-4931-9130-56c8ced39151_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_74a8e485-82d1-4931-9130-56c8ced39151" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74a8e485-82d1-4931-9130-56c8ced39151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4dcb01e7-73e1-499a-bc3f-e8236195a6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_74a8e485-82d1-4931-9130-56c8ced39151" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4dcb01e7-73e1-499a-bc3f-e8236195a6d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_920ff750-5d38-4d70-864a-f0c93d68fb67" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4dcb01e7-73e1-499a-bc3f-e8236195a6d1" xlink:to="loc_amgn_BeiGeneMember_920ff750-5d38-4d70-864a-f0c93d68fb67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_30345fff-24b1-4a81-a3b9-e348707ca235" xlink:href="amgn-20221231.xsd#amgn_TeneobioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4dcb01e7-73e1-499a-bc3f-e8236195a6d1" xlink:to="loc_amgn_TeneobioIncMember_30345fff-24b1-4a81-a3b9-e348707ca235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f04e0424-15c3-4143-9221-34c9094e9bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35cd7e91-e308-417f-bcb1-63ace19825de" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f04e0424-15c3-4143-9221-34c9094e9bec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f04e0424-15c3-4143-9221-34c9094e9bec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f04e0424-15c3-4143-9221-34c9094e9bec" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f04e0424-15c3-4143-9221-34c9094e9bec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c9868131-b551-496a-8cdc-9f1cafe4553e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f04e0424-15c3-4143-9221-34c9094e9bec" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c9868131-b551-496a-8cdc-9f1cafe4553e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c487331d-cecd-426c-ac57-d77414fc1061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c9868131-b551-496a-8cdc-9f1cafe4553e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c487331d-cecd-426c-ac57-d77414fc1061" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="extended" id="i519f99d65495438398064b313f86dc35_DerivativeinstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_5e6b886f-c564-418d-a9b3-82de6ca5a466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_5e6b886f-c564-418d-a9b3-82de6ca5a466" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2f320d51-a355-4ca3-a897-d78bb0e6a742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2f320d51-a355-4ca3-a897-d78bb0e6a742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_0526db52-6e88-41fe-b9ca-a31f88c54979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_0526db52-6e88-41fe-b9ca-a31f88c54979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ee55ab7-15d0-4e37-9a45-ca3b7fd6dd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ee55ab7-15d0-4e37-9a45-ca3b7fd6dd4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b317eb20-b6ff-436e-9a36-19913667c287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ee55ab7-15d0-4e37-9a45-ca3b7fd6dd4e" xlink:to="loc_us-gaap_HedgingDesignationAxis_b317eb20-b6ff-436e-9a36-19913667c287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b317eb20-b6ff-436e-9a36-19913667c287_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_b317eb20-b6ff-436e-9a36-19913667c287" xlink:to="loc_us-gaap_HedgingDesignationDomain_b317eb20-b6ff-436e-9a36-19913667c287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_85cb8692-1f21-45e0-aa60-1c60d05813d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_b317eb20-b6ff-436e-9a36-19913667c287" xlink:to="loc_us-gaap_HedgingDesignationDomain_85cb8692-1f21-45e0-aa60-1c60d05813d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aaf78329-c713-4936-a2e1-9cf3961f6649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_85cb8692-1f21-45e0-aa60-1c60d05813d7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aaf78329-c713-4936-a2e1-9cf3961f6649" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_533d12d1-bb9c-4a5a-96d3-2c0296a21b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_85cb8692-1f21-45e0-aa60-1c60d05813d7" xlink:to="loc_us-gaap_NondesignatedMember_533d12d1-bb9c-4a5a-96d3-2c0296a21b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_da8db032-885e-4ab2-9915-682eea431c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ee55ab7-15d0-4e37-9a45-ca3b7fd6dd4e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_da8db032-885e-4ab2-9915-682eea431c26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_da8db032-885e-4ab2-9915-682eea431c26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_da8db032-885e-4ab2-9915-682eea431c26" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_da8db032-885e-4ab2-9915-682eea431c26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_da8db032-885e-4ab2-9915-682eea431c26" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_8d98457a-7dd7-44bd-9f25-0deb5c47ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:to="loc_us-gaap_ForwardContractsMember_8d98457a-7dd7-44bd-9f25-0deb5c47ca95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_e646b90a-08a8-49f2-ae67-41ea20cb3810" xlink:href="amgn-20221231.xsd#amgn_ForeignCurrencyAndCrossCurrencySwapsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:to="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_e646b90a-08a8-49f2-ae67-41ea20cb3810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_bd835c4d-43c8-4306-958c-4f35909afe44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:to="loc_us-gaap_InterestRateSwapMember_bd835c4d-43c8-4306-958c-4f35909afe44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractsMember_86ef9bd8-d181-429a-a96f-f1cd17ede1cc" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:to="loc_amgn_ForwardInterestRateContractsMember_86ef9bd8-d181-429a-a96f-f1cd17ede1cc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsCrosscurrencySwapsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="extended" id="ic56f42fffa01445495b65bf96aacb185_DerivativeinstrumentsCrosscurrencySwapsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2d025e33-2e45-4174-8867-82ba17cac757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2d025e33-2e45-4174-8867-82ba17cac757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_c760ef44-5da7-4d96-bb01-8feadfda6fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_c760ef44-5da7-4d96-bb01-8feadfda6fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_06158f52-3e1f-4e8e-92fa-d6878657fc68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_06158f52-3e1f-4e8e-92fa-d6878657fc68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:to="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_516b32e4-1518-4d93-82f7-fbb5afae869e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_516b32e4-1518-4d93-82f7-fbb5afae869e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_516b32e4-1518-4d93-82f7-fbb5afae869e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_516b32e4-1518-4d93-82f7-fbb5afae869e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_516b32e4-1518-4d93-82f7-fbb5afae869e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_37f61bfb-9270-4bc1-937f-8b373bcd3bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_516b32e4-1518-4d93-82f7-fbb5afae869e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_37f61bfb-9270-4bc1-937f-8b373bcd3bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e98550ab-56bf-4ecc-8b69-29cb14ef9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_37f61bfb-9270-4bc1-937f-8b373bcd3bad" xlink:to="loc_us-gaap_CashFlowHedgingMember_e98550ab-56bf-4ecc-8b69-29cb14ef9ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_df8a8799-d06c-497b-b3f5-33f9e7cf4f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_df8a8799-d06c-497b-b3f5-33f9e7cf4f07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_df8a8799-d06c-497b-b3f5-33f9e7cf4f07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_df8a8799-d06c-497b-b3f5-33f9e7cf4f07" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_df8a8799-d06c-497b-b3f5-33f9e7cf4f07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_63381e14-02c6-4261-82ce-a6c3d282a39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_df8a8799-d06c-497b-b3f5-33f9e7cf4f07" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_63381e14-02c6-4261-82ce-a6c3d282a39a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_f812e203-68f0-4f7c-8157-a2a2f411f068" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63381e14-02c6-4261-82ce-a6c3d282a39a" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_f812e203-68f0-4f7c-8157-a2a2f411f068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_5194bc95-c2af-424e-967e-800c3b312765" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:to="loc_srt_CurrencyAxis_5194bc95-c2af-424e-967e-800c3b312765" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_5194bc95-c2af-424e-967e-800c3b312765_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_5194bc95-c2af-424e-967e-800c3b312765" xlink:to="loc_currency_AllCurrenciesDomain_5194bc95-c2af-424e-967e-800c3b312765_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_5194bc95-c2af-424e-967e-800c3b312765" xlink:to="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_9aee2a0a-e0e0-4a16-9847-afcdc6104020" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:to="loc_currency_EUR_9aee2a0a-e0e0-4a16-9847-afcdc6104020" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_ac976b6f-4fee-45bf-9e84-331627f2879d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:to="loc_currency_CHF_ac976b6f-4fee-45bf-9e84-331627f2879d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_491e36a0-339a-4dbf-9722-2dc3ce6d3589" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:to="loc_currency_GBP_491e36a0-339a-4dbf-9722-2dc3ce6d3589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_79ab4750-d3a4-4609-8083-f46f0598fdf5" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:to="loc_currency_USD_79ab4750-d3a4-4609-8083-f46f0598fdf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b247380f-0480-41c8-af4d-931fe1bbb4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:to="loc_us-gaap_DebtInstrumentAxis_b247380f-0480-41c8-af4d-931fe1bbb4aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b247380f-0480-41c8-af4d-931fe1bbb4aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b247380f-0480-41c8-af4d-931fe1bbb4aa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b247380f-0480-41c8-af4d-931fe1bbb4aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b247380f-0480-41c8-af4d-931fe1bbb4aa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_49a92cc3-df9d-4323-9480-5346d599b980" xlink:href="amgn-20221231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_49a92cc3-df9d-4323-9480-5346d599b980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_d92a9d5d-f154-467c-b61c-24aad587172b" xlink:href="amgn-20221231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_d92a9d5d-f154-467c-b61c-24aad587172b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_95c8ef89-a2a7-41fb-b774-2fc55fa4a797" xlink:href="amgn-20221231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_95c8ef89-a2a7-41fb-b774-2fc55fa4a797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_b569b640-b5d7-49f9-9c87-d5a449f95b29" xlink:href="amgn-20221231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_b569b640-b5d7-49f9-9c87-d5a449f95b29" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="extended" id="i654575c797dc4d5ba8eb4fcdbcc50fa7_DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ddd3165-117f-4889-b5e6-b87e8c35b6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_f8c1c0d9-936b-42ca-8352-fb22c87dbb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ddd3165-117f-4889-b5e6-b87e8c35b6e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_f8c1c0d9-936b-42ca-8352-fb22c87dbb75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2afbb6f2-00a6-4e6a-87ee-200691aa7ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ddd3165-117f-4889-b5e6-b87e8c35b6e9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2afbb6f2-00a6-4e6a-87ee-200691aa7ad5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_228ef113-c5cd-45ed-bf08-1323b3957566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2afbb6f2-00a6-4e6a-87ee-200691aa7ad5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_228ef113-c5cd-45ed-bf08-1323b3957566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_228ef113-c5cd-45ed-bf08-1323b3957566_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_228ef113-c5cd-45ed-bf08-1323b3957566" xlink:to="loc_us-gaap_HedgingRelationshipDomain_228ef113-c5cd-45ed-bf08-1323b3957566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_03a1a255-461c-4cd9-aad6-cdb59d842fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_228ef113-c5cd-45ed-bf08-1323b3957566" xlink:to="loc_us-gaap_HedgingRelationshipDomain_03a1a255-461c-4cd9-aad6-cdb59d842fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2c993674-f81b-4fd3-ac38-ec5f6d23a470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_03a1a255-461c-4cd9-aad6-cdb59d842fce" xlink:to="loc_us-gaap_CashFlowHedgingMember_2c993674-f81b-4fd3-ac38-ec5f6d23a470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6cfdf2-adb1-47d9-a2ac-dd1c3e5ef6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2afbb6f2-00a6-4e6a-87ee-200691aa7ad5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6cfdf2-adb1-47d9-a2ac-dd1c3e5ef6fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4f6cfdf2-adb1-47d9-a2ac-dd1c3e5ef6fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6cfdf2-adb1-47d9-a2ac-dd1c3e5ef6fa" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4f6cfdf2-adb1-47d9-a2ac-dd1c3e5ef6fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6cfdf2-adb1-47d9-a2ac-dd1c3e5ef6fa" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f163a844-ace1-4b8a-a8ab-4e5d9569613f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f163a844-ace1-4b8a-a8ab-4e5d9569613f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_67014822-1081-4f77-a465-15442c61de94" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_67014822-1081-4f77-a465-15442c61de94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember_f37d38e1-96b6-4f0d-8bec-038c6fdbc678" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:to="loc_amgn_ForwardInterestRateContractMember_f37d38e1-96b6-4f0d-8bec-038c6fdbc678" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="extended" id="i87883e64c1b247deb8c13f07958b5931_DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_c391a169-fbed-4830-b8ac-68392e8c8884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_c391a169-fbed-4830-b8ac-68392e8c8884" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_dcb1ae82-dfd4-440c-aac8-a3a555266112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_dcb1ae82-dfd4-440c-aac8-a3a555266112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_87669f1d-0b5b-4700-92e7-0430d4329e43" xlink:href="amgn-20221231.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:to="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_87669f1d-0b5b-4700-92e7-0430d4329e43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_7963a906-a6a8-4c33-84b2-ff6075043eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_7963a906-a6a8-4c33-84b2-ff6075043eb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1e12bcf6-8476-4232-af38-43d440bb3aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:to="loc_us-gaap_DerivativeTable_1e12bcf6-8476-4232-af38-43d440bb3aea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e1302051-7929-4489-a655-e4daf7941b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1e12bcf6-8476-4232-af38-43d440bb3aea" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e1302051-7929-4489-a655-e4daf7941b29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e1302051-7929-4489-a655-e4daf7941b29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e1302051-7929-4489-a655-e4daf7941b29" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e1302051-7929-4489-a655-e4daf7941b29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ffba6af6-5bc8-4db3-8ed4-7175723c5510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e1302051-7929-4489-a655-e4daf7941b29" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ffba6af6-5bc8-4db3-8ed4-7175723c5510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember_47256950-6cbd-458a-bb3a-6f26774761d3" xlink:href="amgn-20221231.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ffba6af6-5bc8-4db3-8ed4-7175723c5510" xlink:to="loc_amgn_LongTermDebtCurrentMaturitiesMember_47256950-6cbd-458a-bb3a-6f26774761d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_5ec19824-231c-4310-8c6a-a00531c280df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ffba6af6-5bc8-4db3-8ed4-7175723c5510" xlink:to="loc_us-gaap_LongTermDebtMember_5ec19824-231c-4310-8c6a-a00531c280df" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="extended" id="idd3c4f4618894c538905f43bda058694_DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d0d574c5-134a-4ad0-820c-67e30597d0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d0d574c5-134a-4ad0-820c-67e30597d0e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_17190df8-efb3-4011-a173-727d6fec5b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_17190df8-efb3-4011-a173-727d6fec5b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_61dfafee-9f97-4855-ac81-bcf606ce7815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_InterestExpenseDebt_61dfafee-9f97-4855-ac81-bcf606ce7815" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_eee4b57f-5443-442a-8ec6-8f2193f0fe09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_eee4b57f-5443-442a-8ec6-8f2193f0fe09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c15b91e8-e572-4c4e-9e1c-6a22735ad271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c15b91e8-e572-4c4e-9e1c-6a22735ad271" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7531c4d0-3691-4a27-9a12-bdb308accb5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:to="loc_srt_ProductOrServiceAxis_7531c4d0-3691-4a27-9a12-bdb308accb5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7531c4d0-3691-4a27-9a12-bdb308accb5c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7531c4d0-3691-4a27-9a12-bdb308accb5c" xlink:to="loc_srt_ProductsAndServicesDomain_7531c4d0-3691-4a27-9a12-bdb308accb5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf4cec0c-2ab6-423d-a2d4-1034e3f3be4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7531c4d0-3691-4a27-9a12-bdb308accb5c" xlink:to="loc_srt_ProductsAndServicesDomain_cf4cec0c-2ab6-423d-a2d4-1034e3f3be4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_eff88b08-cea9-4157-899d-715c707cc461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf4cec0c-2ab6-423d-a2d4-1034e3f3be4e" xlink:to="loc_us-gaap_ProductMember_eff88b08-cea9-4157-899d-715c707cc461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d591eec7-2b20-4c23-a82e-d0f33517ad37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d591eec7-2b20-4c23-a82e-d0f33517ad37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d591eec7-2b20-4c23-a82e-d0f33517ad37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d591eec7-2b20-4c23-a82e-d0f33517ad37" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d591eec7-2b20-4c23-a82e-d0f33517ad37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c9389abb-cdf2-4ab6-ac82-1986fe6543f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d591eec7-2b20-4c23-a82e-d0f33517ad37" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c9389abb-cdf2-4ab6-ac82-1986fe6543f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_587dad06-72b5-4c84-bd16-1560eddd0380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c9389abb-cdf2-4ab6-ac82-1986fe6543f9" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_587dad06-72b5-4c84-bd16-1560eddd0380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ac75db4a-acc0-4417-8a73-15de2e37fcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ac75db4a-acc0-4417-8a73-15de2e37fcbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ac75db4a-acc0-4417-8a73-15de2e37fcbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ac75db4a-acc0-4417-8a73-15de2e37fcbc" xlink:to="loc_us-gaap_EquityComponentDomain_ac75db4a-acc0-4417-8a73-15de2e37fcbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_59d27777-a680-4ef1-b5ed-6ed6fb1c40a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ac75db4a-acc0-4417-8a73-15de2e37fcbc" xlink:to="loc_us-gaap_EquityComponentDomain_59d27777-a680-4ef1-b5ed-6ed6fb1c40a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_127b692d-1be9-4712-954c-f52f3e800c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_59d27777-a680-4ef1-b5ed-6ed6fb1c40a4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_127b692d-1be9-4712-954c-f52f3e800c83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9dc76fe8-753b-4bea-bc46-881dee98ca3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9dc76fe8-753b-4bea-bc46-881dee98ca3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9dc76fe8-753b-4bea-bc46-881dee98ca3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9dc76fe8-753b-4bea-bc46-881dee98ca3d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9dc76fe8-753b-4bea-bc46-881dee98ca3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9dc76fe8-753b-4bea-bc46-881dee98ca3d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_547cdd28-be0a-42e0-80ac-f8755a6d1c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_547cdd28-be0a-42e0-80ac-f8755a6d1c01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_62987f32-3c08-4e55-b217-a38eb0e8c919" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_62987f32-3c08-4e55-b217-a38eb0e8c919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b3a4d7d4-96d2-4ea4-8f1a-c4537cbbb989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:to="loc_us-gaap_InterestRateSwapMember_b3a4d7d4-96d2-4ea4-8f1a-c4537cbbb989" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsFairValueofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="extended" id="i6828e7c65e4d464a9de6233ae7551060_DerivativeinstrumentsFairValueofDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_c4c85955-2dd8-4ca7-bd51-9827ef9e3744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_3cd6ad36-7151-4887-be50-4feabe65f9c0" xlink:href="amgn-20221231.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c4c85955-2dd8-4ca7-bd51-9827ef9e3744" xlink:to="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_3cd6ad36-7151-4887-be50-4feabe65f9c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4e394a6a-ef28-44ee-95a5-93fc7796916d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_3cd6ad36-7151-4887-be50-4feabe65f9c0" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4e394a6a-ef28-44ee-95a5-93fc7796916d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_636e2641-90b1-4bde-b09d-412997d74074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4e394a6a-ef28-44ee-95a5-93fc7796916d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_636e2641-90b1-4bde-b09d-412997d74074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_12564d18-fdb9-4420-a0ed-6d303c73b2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_3cd6ad36-7151-4887-be50-4feabe65f9c0" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_12564d18-fdb9-4420-a0ed-6d303c73b2d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fd7b2a5a-2678-4443-b93e-70b8790e0846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_12564d18-fdb9-4420-a0ed-6d303c73b2d6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fd7b2a5a-2678-4443-b93e-70b8790e0846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c4c85955-2dd8-4ca7-bd51-9827ef9e3744" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f87b503f-69ab-4ac0-9ba1-22cad18ac227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:to="loc_us-gaap_HedgingDesignationAxis_f87b503f-69ab-4ac0-9ba1-22cad18ac227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f87b503f-69ab-4ac0-9ba1-22cad18ac227_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_f87b503f-69ab-4ac0-9ba1-22cad18ac227" xlink:to="loc_us-gaap_HedgingDesignationDomain_f87b503f-69ab-4ac0-9ba1-22cad18ac227_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_945f9430-1cca-4983-8556-fa8a7aa12893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_f87b503f-69ab-4ac0-9ba1-22cad18ac227" xlink:to="loc_us-gaap_HedgingDesignationDomain_945f9430-1cca-4983-8556-fa8a7aa12893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8b63353c-237a-4edd-809c-3b64140a5dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_945f9430-1cca-4983-8556-fa8a7aa12893" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8b63353c-237a-4edd-809c-3b64140a5dc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bfd1f8b8-f70c-474e-80b8-a5ce2f94aec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bfd1f8b8-f70c-474e-80b8-a5ce2f94aec4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bfd1f8b8-f70c-474e-80b8-a5ce2f94aec4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bfd1f8b8-f70c-474e-80b8-a5ce2f94aec4" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bfd1f8b8-f70c-474e-80b8-a5ce2f94aec4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bfd1f8b8-f70c-474e-80b8-a5ce2f94aec4" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_501ca8a6-d62e-4145-9e47-19f8d14317df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_501ca8a6-d62e-4145-9e47-19f8d14317df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_a6c381d9-2d2a-4234-886b-c4a128b60fb3" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_a6c381d9-2d2a-4234-886b-c4a128b60fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_83fe61c0-7d40-4ac6-b7ed-b54b6d031b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:to="loc_us-gaap_InterestRateSwapMember_83fe61c0-7d40-4ac6-b7ed-b54b6d031b0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractsMember_0c80a72e-eda6-42f0-aa1d-825189a82917" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:to="loc_amgn_ForwardInterestRateContractsMember_0c80a72e-eda6-42f0-aa1d-825189a82917" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f2457ad0-6580-4471-a8e7-9a7942e89814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f2457ad0-6580-4471-a8e7-9a7942e89814" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f2457ad0-6580-4471-a8e7-9a7942e89814_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f2457ad0-6580-4471-a8e7-9a7942e89814" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f2457ad0-6580-4471-a8e7-9a7942e89814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_274fff88-7fea-4fb7-8ae5-de3963d085f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f2457ad0-6580-4471-a8e7-9a7942e89814" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_274fff88-7fea-4fb7-8ae5-de3963d085f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember_d5d69e0d-8ede-4bb7-8ad3-1559d92efb84" xlink:href="amgn-20221231.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_274fff88-7fea-4fb7-8ae5-de3963d085f7" xlink:to="loc_amgn_OtherCurrentNoncurrentAssetsMember_d5d69e0d-8ede-4bb7-8ad3-1559d92efb84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_a8ee9b60-6d79-4861-9a82-8bc4fb3c6380" xlink:href="amgn-20221231.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_274fff88-7fea-4fb7-8ae5-de3963d085f7" xlink:to="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_a8ee9b60-6d79-4861-9a82-8bc4fb3c6380" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsSandozPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="extended" id="i38576ceb07d946dea0f27fe67cc98b1c_ContingenciesandcommitmentsSandozPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_a15d319a-86c6-4157-bb6d-e690f800f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_8dce29eb-8423-4b22-874d-1da8f97f7bc6" xlink:href="amgn-20221231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_a15d319a-86c6-4157-bb6d-e690f800f2df" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_8dce29eb-8423-4b22-874d-1da8f97f7bc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_2307fb0f-ed71-403e-bab4-84914d37b920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_a15d319a-86c6-4157-bb6d-e690f800f2df" xlink:to="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_2307fb0f-ed71-403e-bab4-84914d37b920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_4ef06ad3-0da3-4fac-9277-3925675a5e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_a15d319a-86c6-4157-bb6d-e690f800f2df" xlink:to="loc_us-gaap_GainContingenciesTable_4ef06ad3-0da3-4fac-9277-3925675a5e20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2766b09d-0ca8-4fac-8cf1-83bda98e7c90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_4ef06ad3-0da3-4fac-9277-3925675a5e20" xlink:to="loc_srt_LitigationCaseAxis_2766b09d-0ca8-4fac-8cf1-83bda98e7c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2766b09d-0ca8-4fac-8cf1-83bda98e7c90_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2766b09d-0ca8-4fac-8cf1-83bda98e7c90" xlink:to="loc_srt_LitigationCaseTypeDomain_2766b09d-0ca8-4fac-8cf1-83bda98e7c90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_85945729-1d42-4a55-b7bf-35a7c0ae0860" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2766b09d-0ca8-4fac-8cf1-83bda98e7c90" xlink:to="loc_srt_LitigationCaseTypeDomain_85945729-1d42-4a55-b7bf-35a7c0ae0860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SandozIncMember_c8120823-0780-4c56-9274-80a58c88f5fe" xlink:href="amgn-20221231.xsd#amgn_SandozIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_85945729-1d42-4a55-b7bf-35a7c0ae0860" xlink:to="loc_amgn_SandozIncMember_c8120823-0780-4c56-9274-80a58c88f5fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember_bddbf32d-51dd-4095-8a54-f60ddad3a043" xlink:href="amgn-20221231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_85945729-1d42-4a55-b7bf-35a7c0ae0860" xlink:to="loc_amgn_SanofiRegeneronPatentLitigationMember_bddbf32d-51dd-4095-8a54-f60ddad3a043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d219556c-2a9c-48d6-badb-a70ddbe059dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_4ef06ad3-0da3-4fac-9277-3925675a5e20" xlink:to="loc_us-gaap_LitigationStatusAxis_d219556c-2a9c-48d6-badb-a70ddbe059dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_d219556c-2a9c-48d6-badb-a70ddbe059dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_d219556c-2a9c-48d6-badb-a70ddbe059dd" xlink:to="loc_us-gaap_LitigationStatusDomain_d219556c-2a9c-48d6-badb-a70ddbe059dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_89312d3b-73a4-4673-9545-e1914996d012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_d219556c-2a9c-48d6-badb-a70ddbe059dd" xlink:to="loc_us-gaap_LitigationStatusDomain_89312d3b-73a4-4673-9545-e1914996d012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_fb01a7da-9c1c-4673-b315-750799354741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_89312d3b-73a4-4673-9545-e1914996d012" xlink:to="loc_us-gaap_PendingLitigationMember_fb01a7da-9c1c-4673-b315-750799354741" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsRepathaPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="extended" id="ib42dd09d9fc74271b4f52f6116fb015f_ContingenciesandcommitmentsRepathaPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_fd982a67-240d-40aa-87a8-e6126acd77b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_fd982a67-240d-40aa-87a8-e6126acd77b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementLengthofTrial_164e20e2-2d16-44d7-814c-47484a52fccb" xlink:href="amgn-20221231.xsd#amgn_LitigationSettlementLengthofTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:to="loc_amgn_LitigationSettlementLengthofTrial_164e20e2-2d16-44d7-814c-47484a52fccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfChallenges_55e5285e-c6d4-4aa2-9d15-596b5cd4d929" xlink:href="amgn-20221231.xsd#amgn_GainContingencyNumberOfChallenges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:to="loc_amgn_GainContingencyNumberOfChallenges_55e5285e-c6d4-4aa2-9d15-596b5cd4d929" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_806f4f8e-5bff-42a0-b29f-1445827eed92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:to="loc_us-gaap_OtherCommitmentsTable_806f4f8e-5bff-42a0-b29f-1445827eed92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_341d7975-ad96-4a3b-aba1-2648826ba7a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_806f4f8e-5bff-42a0-b29f-1445827eed92" xlink:to="loc_srt_LitigationCaseAxis_341d7975-ad96-4a3b-aba1-2648826ba7a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_341d7975-ad96-4a3b-aba1-2648826ba7a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_341d7975-ad96-4a3b-aba1-2648826ba7a4" xlink:to="loc_srt_LitigationCaseTypeDomain_341d7975-ad96-4a3b-aba1-2648826ba7a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_adb3256d-3ddd-4779-be8a-3305213f33cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_341d7975-ad96-4a3b-aba1-2648826ba7a4" xlink:to="loc_srt_LitigationCaseTypeDomain_adb3256d-3ddd-4779-be8a-3305213f33cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember_c0cbf11f-769f-423f-8f33-006db9536cd1" xlink:href="amgn-20221231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_adb3256d-3ddd-4779-be8a-3305213f33cc" xlink:to="loc_amgn_SanofiRegeneronPatentLitigationMember_c0cbf11f-769f-423f-8f33-006db9536cd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_43c8bb3d-af57-4b60-9c0a-48b9f9e91e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_806f4f8e-5bff-42a0-b29f-1445827eed92" xlink:to="loc_us-gaap_LitigationStatusAxis_43c8bb3d-af57-4b60-9c0a-48b9f9e91e81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_43c8bb3d-af57-4b60-9c0a-48b9f9e91e81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_43c8bb3d-af57-4b60-9c0a-48b9f9e91e81" xlink:to="loc_us-gaap_LitigationStatusDomain_43c8bb3d-af57-4b60-9c0a-48b9f9e91e81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_25f37e35-f9dd-4d8f-842c-b17e1bb13dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_43c8bb3d-af57-4b60-9c0a-48b9f9e91e81" xlink:to="loc_us-gaap_LitigationStatusDomain_25f37e35-f9dd-4d8f-842c-b17e1bb13dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_45a907ba-c03a-4ff8-8f4c-db559f0c8a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_25f37e35-f9dd-4d8f-842c-b17e1bb13dac" xlink:to="loc_us-gaap_PendingLitigationMember_45a907ba-c03a-4ff8-8f4c-db559f0c8a23" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails" xlink:type="extended" id="i611ce5aaf4394be98e6770a3983b875d_ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_0e97feed-4470-441b-a8d3-472f018a5e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_6fe911ec-2330-4387-84ea-009507deb5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e97feed-4470-441b-a8d3-472f018a5e47" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_6fe911ec-2330-4387-84ea-009507deb5c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ab969268-bc89-41c9-89b5-baf5246b09e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e97feed-4470-441b-a8d3-472f018a5e47" xlink:to="loc_us-gaap_LossContingenciesTable_ab969268-bc89-41c9-89b5-baf5246b09e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e22c5d29-c01b-472c-99ea-4f2bf22eaabf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ab969268-bc89-41c9-89b5-baf5246b09e3" xlink:to="loc_srt_LitigationCaseAxis_e22c5d29-c01b-472c-99ea-4f2bf22eaabf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e22c5d29-c01b-472c-99ea-4f2bf22eaabf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_e22c5d29-c01b-472c-99ea-4f2bf22eaabf" xlink:to="loc_srt_LitigationCaseTypeDomain_e22c5d29-c01b-472c-99ea-4f2bf22eaabf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0bcde9a9-bb7e-4133-b740-aac69a4aad88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_e22c5d29-c01b-472c-99ea-4f2bf22eaabf" xlink:to="loc_srt_LitigationCaseTypeDomain_0bcde9a9-bb7e-4133-b740-aac69a4aad88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_JanssenBiotechIncVsAmgenIncMember_12e1698e-7b93-4b67-9fb9-86c78dcc15cd" xlink:href="amgn-20221231.xsd#amgn_JanssenBiotechIncVsAmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0bcde9a9-bb7e-4133-b740-aac69a4aad88" xlink:to="loc_amgn_JanssenBiotechIncVsAmgenIncMember_12e1698e-7b93-4b67-9fb9-86c78dcc15cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8f7e524f-e977-435b-8214-33a61c117a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ab969268-bc89-41c9-89b5-baf5246b09e3" xlink:to="loc_us-gaap_LitigationStatusAxis_8f7e524f-e977-435b-8214-33a61c117a02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_8f7e524f-e977-435b-8214-33a61c117a02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_8f7e524f-e977-435b-8214-33a61c117a02" xlink:to="loc_us-gaap_LitigationStatusDomain_8f7e524f-e977-435b-8214-33a61c117a02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b9af2a6d-ee73-4440-a906-e30e57b06b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_8f7e524f-e977-435b-8214-33a61c117a02" xlink:to="loc_us-gaap_LitigationStatusDomain_b9af2a6d-ee73-4440-a906-e30e57b06b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_4388cd11-b4b3-48ee-a1df-1b14616e7e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_b9af2a6d-ee73-4440-a906-e30e57b06b64" xlink:to="loc_us-gaap_PendingLitigationMember_4388cd11-b4b3-48ee-a1df-1b14616e7e9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="extended" id="ic5989cc5436b49569506f02d1cf31029_ContingenciesandcommitmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_49f888b1-db26-4510-ae15-141d3993fcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_49f888b1-db26-4510-ae15-141d3993fcdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_ec13b207-4b2f-4d37-adb9-999ade1d71a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_ec13b207-4b2f-4d37-adb9-999ade1d71a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuitsFiled_cfe8426f-ae63-4073-b726-4a7eb75e181c" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfLawsuitsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_LossContingencyNumberOfLawsuitsFiled_cfe8426f-ae63-4073-b726-4a7eb75e181c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfClassActionSuits_047f3694-8481-4475-b5d5-8e873669ebcb" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfClassActionSuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_LossContingencyNumberOfClassActionSuits_047f3694-8481-4475-b5d5-8e873669ebcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_8c7bdae4-09e0-486d-b909-88fda87c02a0" xlink:href="amgn-20221231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_8c7bdae4-09e0-486d-b909-88fda87c02a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside_82e9d4f8-3dec-40c8-8fa4-c0384621f041" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside_82e9d4f8-3dec-40c8-8fa4-c0384621f041" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfPrimaryArguments_db17b3c0-84f4-498c-93c1-a189132c7ea7" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfPrimaryArguments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_LossContingencyNumberOfPrimaryArguments_db17b3c0-84f4-498c-93c1-a189132c7ea7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_99801927-f90b-4eff-b2c3-5665cb17899b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_us-gaap_LossContingenciesTable_99801927-f90b-4eff-b2c3-5665cb17899b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_18fa7bcb-eddc-47a0-b3ed-354d486776c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_99801927-f90b-4eff-b2c3-5665cb17899b" xlink:to="loc_srt_LitigationCaseAxis_18fa7bcb-eddc-47a0-b3ed-354d486776c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_18fa7bcb-eddc-47a0-b3ed-354d486776c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_18fa7bcb-eddc-47a0-b3ed-354d486776c7" xlink:to="loc_srt_LitigationCaseTypeDomain_18fa7bcb-eddc-47a0-b3ed-354d486776c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_18fa7bcb-eddc-47a0-b3ed-354d486776c7" xlink:to="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember_ec5664a9-5576-4626-80ef-908d2ca23809" xlink:href="amgn-20221231.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:to="loc_amgn_SensiparAntitrustClassActionsMember_ec5664a9-5576-4626-80ef-908d2ca23809" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ChemoCentryxIncSecuritiesMattersMember_9c0b0065-5663-4083-9f85-ce346f2a921f" xlink:href="amgn-20221231.xsd#amgn_ChemoCentryxIncSecuritiesMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:to="loc_amgn_ChemoCentryxIncSecuritiesMattersMember_9c0b0065-5663-4083-9f85-ce346f2a921f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember_17e0c206-31e9-49a1-9315-d9030e9d2654" xlink:href="amgn-20221231.xsd#amgn_RegeneronPharmaceuticalsIncAntitrustActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:to="loc_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember_17e0c206-31e9-49a1-9315-d9030e9d2654" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_c1ddb49c-6d28-4aed-88b0-bc4584b02f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_99801927-f90b-4eff-b2c3-5665cb17899b" xlink:to="loc_us-gaap_LitigationStatusAxis_c1ddb49c-6d28-4aed-88b0-bc4584b02f79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_c1ddb49c-6d28-4aed-88b0-bc4584b02f79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_c1ddb49c-6d28-4aed-88b0-bc4584b02f79" xlink:to="loc_us-gaap_LitigationStatusDomain_c1ddb49c-6d28-4aed-88b0-bc4584b02f79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_9d8ac999-2d1a-4380-9f5e-ba263372f08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_c1ddb49c-6d28-4aed-88b0-bc4584b02f79" xlink:to="loc_us-gaap_LitigationStatusDomain_9d8ac999-2d1a-4380-9f5e-ba263372f08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_0c19531d-48b9-46f9-94eb-cebd9fc8ccce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_9d8ac999-2d1a-4380-9f5e-ba263372f08f" xlink:to="loc_us-gaap_PendingLitigationMember_0c19531d-48b9-46f9-94eb-cebd9fc8ccce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>amgn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4e826620-fc5c-4c14-9c2e-3ba20b6aa99d,g:1e6ee203-6cba-438e-aedd-ef42aa695ae1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_b160242e-ce72-439f-a7ef-1f442dd0b0c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal_3d7bf3ff-f7d8-43af-908e-6c75e479bfde_terseLabel_en-US" xlink:label="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Realized Gain (Loss) on Disposal</link:label>
    <link:label id="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Realized Gain (Loss) on Disposal</link:label>
    <link:label id="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal_documentation_en-US" xlink:label="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:href="amgn-20221231.xsd#amgn_EquitySecuritiesRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:to="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_993ec1ef-b924-4041-b5e1-024760f3a153_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4fbd2f10-d2f6-4aca-8e95-f5781c768c80_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_e61e25cd-8194-486c-935f-9644583f21a4_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds [Member]</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness_825d55f7-ef57-4aa8-8a2a-689cad5210f0_terseLabel_en-US" xlink:label="lab_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation, loss on divestiture of a business</link:label>
    <link:label id="lab_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness_label_en-US" xlink:label="lab_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation, loss on divestiture of a business</link:label>
    <link:label id="lab_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness_documentation_en-US" xlink:label="lab_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation, loss on divestiture of a business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness" xlink:href="amgn-20221231.xsd#amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness" xlink:to="lab_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2843000e-c12a-472a-9fd4-b38e0ff4c10f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_cb09dc8d-c260-4903-85e4-14011ce03a8d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e0d262ac-8e11-4ae7-b369-1265f20f2aef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e6507026-75c5-4543-b171-520b7a464c62_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred benefit:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_feac4c3b-c601-4373-aed2-266ef6bc2eaa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_68bbd1b3-0304-4e3e-bcb4-55cee7c07fe3_terseLabel_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_label_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities [Member]</link:label>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember" xlink:href="amgn-20221231.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LongTermDebtCurrentMaturitiesMember" xlink:to="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_432a11af-dae5-4709-85c0-e5999c4e556e_terseLabel_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% notes due 2050 (3.375% 2050 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_label_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Seven Five Percent Notes Due 2050 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_documentation_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Seven Five Percent Notes Due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:href="amgn-20221231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:to="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_146acb71-2769-468b-9897-cf1fb9ec3986_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f9dedd31-bf12-4b86-90c9-535bcbf4fe8c_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_fa7bfdfe-7d60-432d-8379-e133be03b3d1_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_a6bbbbb1-eabc-428d-90cc-0b884d31ad3a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TermLoanCreditAgreementTotalAmount_3d657fb7-3435-44a0-80b8-5f34d6b37410_terseLabel_en-US" xlink:label="lab_amgn_TermLoanCreditAgreementTotalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan credit agreement, total amount</link:label>
    <link:label id="lab_amgn_TermLoanCreditAgreementTotalAmount_label_en-US" xlink:label="lab_amgn_TermLoanCreditAgreementTotalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">term loan credit agreement, total amount</link:label>
    <link:label id="lab_amgn_TermLoanCreditAgreementTotalAmount_documentation_en-US" xlink:label="lab_amgn_TermLoanCreditAgreementTotalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">term loan credit agreement, total amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TermLoanCreditAgreementTotalAmount" xlink:href="amgn-20221231.xsd#amgn_TermLoanCreditAgreementTotalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TermLoanCreditAgreementTotalAmount" xlink:to="lab_amgn_TermLoanCreditAgreementTotalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_95fba938-ef0a-48f8-bb3a-1c6ec3ac37be_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_344b2fb9-7e55-492d-8c6f-d9ab6da78bf2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_56bcd30b-4096-42b2-ab75-c87f36bec245_terseLabel_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value with discontinued hedging relationships</link:label>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_label_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge</link:label>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_documentation_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:href="amgn-20221231.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:to="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_204d6cd2-ae07-4a9a-ae7d-cc150ae49af0_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_85b9acf7-ab52-47b5-97b5-004fcccf1aba_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0069f1a0-8263-447f-a332-0d9bc1783a28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A440NotesDue20624402062NotesMember_977855b8-75e0-451a-8a81-269a03fab224_terseLabel_en-US" xlink:label="lab_amgn_A440NotesDue20624402062NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% notes due 2062 (4.40% 2062 Notes)</link:label>
    <link:label id="lab_amgn_A440NotesDue20624402062NotesMember_label_en-US" xlink:label="lab_amgn_A440NotesDue20624402062NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% notes due 2062 (4.40% 2062 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A440NotesDue20624402062NotesMember_documentation_en-US" xlink:label="lab_amgn_A440NotesDue20624402062NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% notes due 2062 (4.40% 2062 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A440NotesDue20624402062NotesMember" xlink:href="amgn-20221231.xsd#amgn_A440NotesDue20624402062NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A440NotesDue20624402062NotesMember" xlink:to="lab_amgn_A440NotesDue20624402062NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_714dfaed-a6ee-43e2-934f-b7a5fb35c7c8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization charges associated with property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ba377ee7-97cc-4c59-aa0a-c25c959e4f20_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_6cf845de-69c3-49af-9897-cf3bfa4ea0e4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_fb672a6b-e518-4d4e-ac11-4eb9c4381da4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ac9ff700-7fb3-4e97-a7c6-0b07539a177f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_78df5dfd-d593-407b-bf01-0e5b9513bae6_totalLabel_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_label_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets Gross</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_documentation_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross" xlink:href="amgn-20221231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross" xlink:to="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_363e2823-97fe-41a2-9680-815516199fa7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e4cfad86-5237-4681-ba28-6590ad6f6087_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_202ffb08-0555-4083-b1ae-5a202b8d9ad1_terseLabel_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% notes due 2042 (5.65% 2042 Notes)</link:label>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_label_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Six Five Percent Notes Due 2042 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_documentation_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Six Five Percent Notes Due 2042 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:href="amgn-20221231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:to="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_a4062e5a-0d6b-4a57-905e-5aa727c867d6_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_11f9b19d-58ab-4784-8d79-dd741d25b38c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3a82e592-56b0-4753-8239-96636548db0b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_24a0f137-641f-40ad-a995-a9218cd36442_verboseLabel_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% notes due 2041 (4.95% 2041 Notes)</link:label>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_label_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Five Percent Notes Due 2041 [Member]</link:label>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Five Percent Notes Due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:href="amgn-20221231.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:to="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_b88dda1b-72b6-4330-9468-cc71e1638178_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_111c0631-3836-4312-a0bf-140dc5776560_terseLabel_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.45% notes due 2020 (3.45% 2020 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_label_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:href="amgn-20221231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:to="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_76635bde-b5ba-4546-9b02-68d48f58994a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesGrossCurrent_54bb99a4-758e-47dc-a826-dcaff7d20527_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate partner receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesGrossCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Gross, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesGrossCurrent" xlink:to="lab_us-gaap_OtherReceivablesGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0f1d732b-ecdb-4157-8803-582d08b6d007_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_41820fba-d22b-43a3-9792-6b40922eaea3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ad0771dd-4bc9-4973-a522-a8797a62dd43_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_f022a19e-0682-4147-9778-158fe1347d7c_terseLabel_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_dc4373b1-a7da-49ab-a896-94ac5d26498a_verboseLabel_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% 2026 pound sterling Notes [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_label_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:href="amgn-20221231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:to="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_be1ca82c-d050-4739-9733-4eb5c3d5f25a_terseLabel_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.90% notes due 2038 (6.90% 2038 Notes)</link:label>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_label_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Zero Percent Notes Due 2038 [Member]</link:label>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_documentation_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Zero Percent Notes Due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:href="amgn-20221231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:to="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_153da66f-9ca0-48ce-8e77-bfb7a9b2ed93_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3ef981f4-3ebe-481d-91a2-cad66548b22d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_XgevaMember_aabc3965-95a5-4ff9-abf8-a20199fb1aee_terseLabel_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA&#174; (denosumab) [Member]</link:label>
    <link:label id="lab_amgn_XgevaMember_label_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA [Member]</link:label>
    <link:label id="lab_amgn_XgevaMember_documentation_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember" xlink:href="amgn-20221231.xsd#amgn_XgevaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_XgevaMember" xlink:to="lab_amgn_XgevaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_89f4b8a8-8b0b-48c2-b19a-7aaa414ab1ad_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_173c4085-3409-4ee6-85f4-44c52b4904b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4da2c305-9deb-4826-b487-2c183454fa9e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69bb8193-4717-4047-9de6-f03bfcb0568b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b0f0269-264b-4796-af4f-d56857ac1dd6_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_2a7dd22c-3f86-42a3-9316-c193c0c4f3ce_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_edf00ff3-fac3-4505-abf6-7c3307267282_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_422a9fff-dcfa-4960-925f-821fd3bcc998_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_be6f6341-af63-4f1c-86f2-75acc3d23e75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_c0795b02-9022-4236-9cf3-9d0bfe96e7a4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under syndicated, unsecured, revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b9e1a9d6-6ff4-4b28-91d6-f00e0348e8d8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember_237edabe-20ce-4e7f-880d-51bc5ac0c74a_terseLabel_en-US" xlink:label="lab_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals Inc. Antitrust Action</link:label>
    <link:label id="lab_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember_label_en-US" xlink:label="lab_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals Inc. Antitrust Action [Member]</link:label>
    <link:label id="lab_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember_documentation_en-US" xlink:label="lab_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals Inc. Antitrust Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember" xlink:href="amgn-20221231.xsd#amgn_RegeneronPharmaceuticalsIncAntitrustActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember" xlink:to="lab_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40c208f0-a3c0-418f-a73b-0bea279b33cb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years), unexercised</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_b7a743e9-80bd-44d3-a4f3-dafbd2215858_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged</link:label>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:href="amgn-20221231.xsd#amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:to="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e7810c12-93bd-4685-9e47-848fee1a1bf6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0887c934-c891-45a5-87af-f577a1a8ccd4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_e7ae6c7b-0601-4cc7-a92b-06cb3482950b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding&#8212;534.0 shares in 2022 and 558.3 shares in 2021</link:label>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_76e55a53-48e8-4612-869f-93fe4b76bb41_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_0fe6f4bf-ed28-4a5b-9182-5c1e91174aaf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of businesses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_beaaa7a8-3978-4ce5-bd92-547bd4c02a55_verboseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SandozIncMember_d376436d-2fe4-4274-a889-4b9e2e890315_terseLabel_en-US" xlink:label="lab_amgn_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Inc.</link:label>
    <link:label id="lab_amgn_SandozIncMember_label_en-US" xlink:label="lab_amgn_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Inc. [Member]</link:label>
    <link:label id="lab_amgn_SandozIncMember_documentation_en-US" xlink:label="lab_amgn_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SandozIncMember" xlink:href="amgn-20221231.xsd#amgn_SandozIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SandozIncMember" xlink:to="lab_amgn_SandozIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_59bbe0e4-afd8-4610-a956-43a0f32e54ca_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_76cfd454-2b5e-44ff-8a8a-54477dfbb67e_terseLabel_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_label_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:href="amgn-20221231.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:to="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A4875NotesDue205348752053NotesMember_9bdb72c6-c34b-4eb2-a2b1-ff3e7625f63c_terseLabel_en-US" xlink:label="lab_amgn_A4875NotesDue205348752053NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% notes due 2053 (4.875% 2053 Notes)</link:label>
    <link:label id="lab_amgn_A4875NotesDue205348752053NotesMember_label_en-US" xlink:label="lab_amgn_A4875NotesDue205348752053NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% notes due 2053 (4.875% 2053 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A4875NotesDue205348752053NotesMember_documentation_en-US" xlink:label="lab_amgn_A4875NotesDue205348752053NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% notes due 2053 (4.875% 2053 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4875NotesDue205348752053NotesMember" xlink:href="amgn-20221231.xsd#amgn_A4875NotesDue205348752053NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A4875NotesDue205348752053NotesMember" xlink:to="lab_amgn_A4875NotesDue205348752053NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A190NotesDue20251902025NotesMember_a8404668-bcfe-494e-aada-6f7ab8d157fc_terseLabel_en-US" xlink:label="lab_amgn_A190NotesDue20251902025NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2025 (1.90% 2025 Notes)</link:label>
    <link:label id="lab_amgn_A190NotesDue20251902025NotesMember_label_en-US" xlink:label="lab_amgn_A190NotesDue20251902025NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2025 (1.90% 2025 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A190NotesDue20251902025NotesMember_documentation_en-US" xlink:label="lab_amgn_A190NotesDue20251902025NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2025 (1.90% 2025 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember" xlink:href="amgn-20221231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A190NotesDue20251902025NotesMember" xlink:to="lab_amgn_A190NotesDue20251902025NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_672398ef-0ac8-4db6-acd4-afed93d557eb_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_97454e45-6b76-41d7-bea3-626f1a5b2c39_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3abc1e18-089f-4ec7-99f3-dcdcca78e523_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3420e60-8445-4374-86b3-8fa061260830_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_9b92e9a1-5d04-4321-8555-2a3d16715401_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1822378-8cbd-4e94-af39-9a8c13dbe666_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A200NotesDue20322002032NotesMember_67b3c461-c9fd-47ed-8311-c601f961c348_terseLabel_en-US" xlink:label="lab_amgn_A200NotesDue20322002032NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% notes due 2032 (2.00% 2032 Notes)</link:label>
    <link:label id="lab_amgn_A200NotesDue20322002032NotesMember_label_en-US" xlink:label="lab_amgn_A200NotesDue20322002032NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% notes due 2032 (2.00% 2032 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A200NotesDue20322002032NotesMember_documentation_en-US" xlink:label="lab_amgn_A200NotesDue20322002032NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% notes due 2032 (2.00% 2032 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A200NotesDue20322002032NotesMember" xlink:href="amgn-20221231.xsd#amgn_A200NotesDue20322002032NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A200NotesDue20322002032NotesMember" xlink:to="lab_amgn_A200NotesDue20322002032NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_1332b9f6-ee57-427f-adf8-8f639edf1d33_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_03a4c493-8b07-4022-9502-cdd9ef53b1d2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8c7586b6-e29d-41b3-b04b-7c0fa06cc955_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointZeroPercent2032NotesMemberMember_f67a318e-5959-4940-a9e3-be624db96d56_terseLabel_en-US" xlink:label="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% notes due 2032 (2.00% 2032 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointZeroPercent2032NotesMemberMember_label_en-US" xlink:label="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point zero percent 2032 Notes Member [Member]</link:label>
    <link:label id="lab_amgn_TwoPointZeroPercent2032NotesMemberMember_documentation_en-US" xlink:label="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point zero percent 2032 Notes Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:href="amgn-20221231.xsd#amgn_TwoPointZeroPercent2032NotesMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:to="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RepathaevolocumabMember_5730fad4-dc2a-4428-9f41-e0d7bda22279_terseLabel_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:label id="lab_amgn_RepathaevolocumabMember_label_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:label id="lab_amgn_RepathaevolocumabMember_documentation_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember" xlink:href="amgn-20221231.xsd#amgn_RepathaevolocumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RepathaevolocumabMember" xlink:to="lab_amgn_RepathaevolocumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3a27c438-e1fb-4fc8-97fc-2185871ffc6f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and Arrangements with multiple performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8f7b6f51-af33-489b-97dc-f3e6d539bd62_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3420ff77-fd70-46b2-a61d-080e4328c397_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d677fc69-2b4b-4291-9d34-5eb01cf2ff34_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08e35c45-d791-4df7-9421-61ea4e87d683_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average exercise&#160;price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_892c2013-c24c-4e5b-9209-db98e27b52e0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful&#160;life&#160;(in&#160;years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c5cf4a9b-4218-438c-91e9-b991928c8511_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e076b568-7d99-46b1-8342-e80c317d19b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_12fadab2-61c5-4de4-9775-590f6bff5207_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A420NotesDue20524202052NotesMember_4958d6ca-fac5-4bc1-9fef-bdd769fe6077_terseLabel_en-US" xlink:label="lab_amgn_A420NotesDue20524202052NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% notes due 2052 (4.20% 2052 Notes)</link:label>
    <link:label id="lab_amgn_A420NotesDue20524202052NotesMember_label_en-US" xlink:label="lab_amgn_A420NotesDue20524202052NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% notes due 2052 (4.20% 2052 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A420NotesDue20524202052NotesMember_documentation_en-US" xlink:label="lab_amgn_A420NotesDue20524202052NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% notes due 2052 (4.20% 2052 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20524202052NotesMember" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20524202052NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A420NotesDue20524202052NotesMember" xlink:to="lab_amgn_A420NotesDue20524202052NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AstraZenecaPLCMember_c1df2888-9b10-4ecd-990f-1b3277f4458c_terseLabel_en-US" xlink:label="lab_amgn_AstraZenecaPLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca PLC</link:label>
    <link:label id="lab_amgn_AstraZenecaPLCMember_label_en-US" xlink:label="lab_amgn_AstraZenecaPLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca PLC [Member]</link:label>
    <link:label id="lab_amgn_AstraZenecaPLCMember_documentation_en-US" xlink:label="lab_amgn_AstraZenecaPLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca PLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AstraZenecaPLCMember" xlink:href="amgn-20221231.xsd#amgn_AstraZenecaPLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AstraZenecaPLCMember" xlink:to="lab_amgn_AstraZenecaPLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cb937dfb-6905-447e-ab60-f5d840ad8ec6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_118a4983-977c-4730-930b-c8c4d2fe0afe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8a59e307-2ed8-4f9f-8a25-a37c0ee0e31a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_88e7fcbb-9b2d-43a4-a5f6-72dc6f5c22f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_aada7b70-5c31-41aa-bb68-815c8ede2bec_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_7bfbcdb6-4d85-4f40-8a9f-b4a76f28ec17_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-related rights [Member]</link:label>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_cfb77500-7d1b-48a9-b019-768e292ffbdb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfNoticesConsolidated_b0d1d0ec-1079-4928-ad76-07f451379045_terseLabel_en-US" xlink:label="lab_amgn_NumberOfNoticesConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of notices consolidated in court</link:label>
    <link:label id="lab_amgn_NumberOfNoticesConsolidated_label_en-US" xlink:label="lab_amgn_NumberOfNoticesConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Notices Consolidated</link:label>
    <link:label id="lab_amgn_NumberOfNoticesConsolidated_documentation_en-US" xlink:label="lab_amgn_NumberOfNoticesConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Notices Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfNoticesConsolidated" xlink:href="amgn-20221231.xsd#amgn_NumberOfNoticesConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfNoticesConsolidated" xlink:to="lab_amgn_NumberOfNoticesConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_6fbdc422-65d6-40cf-9cf6-088c37dba52d_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_25554d05-2eca-4538-9e53-2810fab5e115_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_72f130c1-1f64-42e7-b52e-540f83b01ddc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_04760631-8218-4846-b50f-5ed220502ed9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AcceleratedStockRepurchaseAgreementMember_2732cbb7-d4b2-49b8-a369-1c4c24d19860_terseLabel_en-US" xlink:label="lab_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock repurchase agreement</link:label>
    <link:label id="lab_amgn_AcceleratedStockRepurchaseAgreementMember_label_en-US" xlink:label="lab_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock repurchase agreement [Member]</link:label>
    <link:label id="lab_amgn_AcceleratedStockRepurchaseAgreementMember_documentation_en-US" xlink:label="lab_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock repurchase agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:href="amgn-20221231.xsd#amgn_AcceleratedStockRepurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:to="lab_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_47c14579-c172-4b8b-8308-85cffe4e2e0a_verboseLabel_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments [Member]</link:label>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_label_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sales Investments [Member]</link:label>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_documentation_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sales investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember" xlink:href="amgn-20221231.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AvailableForSalesInvestmentsMember" xlink:to="lab_amgn_AvailableForSalesInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_fc06333c-868f-46db-9145-3e3128ac4cdf_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_f039e5c4-aaab-4bc7-a9ea-27025dac273c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d311baf5-fb14-4832-921a-45dd8821dac4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_982920ff-a55c-43a8-8eb3-5a022abe0534_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2e9f8ba7-45a2-4e7c-a33f-2053d40ccdb4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_fc92b1b1-a4fd-4182-8551-edc97da33539_verboseLabel_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business</link:label>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_label_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_documentation_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NatureOfOperationsPolicyTextBlock" xlink:href="amgn-20221231.xsd#amgn_NatureOfOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NatureOfOperationsPolicyTextBlock" xlink:to="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_493d4a86-e677-4924-99ea-d56b816b64b2_terseLabel_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone payments</link:label>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_label_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone payments</link:label>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_documentation_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:href="amgn-20221231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:to="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_0d8c516f-fc33-42f0-9b32-41a09678709b_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ForwardInterestRateContractMember_0e6fe782-290c-40d9-a2ad-35a442235e83_terseLabel_en-US" xlink:label="lab_amgn_ForwardInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward interest rate contracts</link:label>
    <link:label id="lab_amgn_ForwardInterestRateContractMember_label_en-US" xlink:label="lab_amgn_ForwardInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Interest Rate Contract [Member]</link:label>
    <link:label id="lab_amgn_ForwardInterestRateContractMember_documentation_en-US" xlink:label="lab_amgn_ForwardInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ForwardInterestRateContractMember" xlink:to="lab_amgn_ForwardInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5960f1f6-1b33-4951-8cab-c8d55a186756_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_eee01edf-8578-41b6-b1ad-286580926120_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_e72305d4-226c-4634-8100-17e576c51b9b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_223693a9-da77-4725-a226-ad689daf8926_terseLabel_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% notes due 2021 (3.875% 2021 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_label_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Notes Due 2021 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_documentation_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Notes Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:href="amgn-20221231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:to="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_f4566873-415d-4c48-ab9e-afb3f91382a8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_47b93d69-fec2-4847-a6f6-dfa3521bd68c_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_05164dfe-3e43-48ae-9a1c-ebacf446fb37_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb5684f0-db20-449b-a377-2a44df77b7cd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8cd6f86d-c252-482b-bb80-653c38d818a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapOneMember_12235aff-9c58-4798-bfba-b4e7d33721cd_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, One [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapOneMember_label_en-US" xlink:label="lab_amgn_InterestRateSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, One [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapOneMember_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapOneMember" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapOneMember" xlink:to="lab_amgn_InterestRateSwapOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_0191213f-fa27-41bc-8a65-f2f7eda71b56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_5eea73b5-c18f-42e4-84aa-d9ebedecb234_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Make-whole payments recognized in interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_2d8defd2-ffc4-4db8-9721-b1bb2a772720_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values of long-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, by Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_33a41a19-1d3f-4994-9428-1be509496cc7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_5688f87c-fe52-4ad3-83c6-b39b73064a3b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_132871d5-1abe-4c27-bad8-f0e7ac85a6fb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_49dc1eb3-8786-4030-8f8e-fdd51a6a6949_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_ecb9aac9-8496-4c86-9067-c0ffa52df99d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BridgeCreditAgreementInitialAmount_31386602-192b-4a2f-be59-8bfeaef2486a_terseLabel_en-US" xlink:label="lab_amgn_BridgeCreditAgreementInitialAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement, initial amount</link:label>
    <link:label id="lab_amgn_BridgeCreditAgreementInitialAmount_label_en-US" xlink:label="lab_amgn_BridgeCreditAgreementInitialAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement, initial amount</link:label>
    <link:label id="lab_amgn_BridgeCreditAgreementInitialAmount_documentation_en-US" xlink:label="lab_amgn_BridgeCreditAgreementInitialAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement, initial amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementInitialAmount" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementInitialAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BridgeCreditAgreementInitialAmount" xlink:to="lab_amgn_BridgeCreditAgreementInitialAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_3224ba48-7b58-48b0-bf0b-2fdef6ecf5bb_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales_6b1faf7e-55b3-4a75-8dee-2e02fb6847fc_terseLabel_en-US" xlink:label="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions as a percentage of gross product sales (less than)</link:label>
    <link:label id="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales_label_en-US" xlink:label="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return Provisions As Percentage Of Product Sales</link:label>
    <link:label id="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales_documentation_en-US" xlink:label="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return Provisions As Percentage Of Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:href="amgn-20221231.xsd#amgn_SalesReturnProvisionsAsPercentageOfProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:to="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_27371fe6-4b50-4bbb-b340-9aff43112ee7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_b0e3c133-94c3-4560-86fa-d1043e5d36a1_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_JanssenBiotechIncVsAmgenIncMember_899aad6b-50cf-4343-ba73-2f6a0a147af7_terseLabel_en-US" xlink:label="lab_amgn_JanssenBiotechIncVsAmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc. Vs, Amgen Inc</link:label>
    <link:label id="lab_amgn_JanssenBiotechIncVsAmgenIncMember_label_en-US" xlink:label="lab_amgn_JanssenBiotechIncVsAmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc. Vs, Amgen Inc [Member]</link:label>
    <link:label id="lab_amgn_JanssenBiotechIncVsAmgenIncMember_documentation_en-US" xlink:label="lab_amgn_JanssenBiotechIncVsAmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc. Vs, Amgen Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_JanssenBiotechIncVsAmgenIncMember" xlink:href="amgn-20221231.xsd#amgn_JanssenBiotechIncVsAmgenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_JanssenBiotechIncVsAmgenIncMember" xlink:to="lab_amgn_JanssenBiotechIncVsAmgenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_7c10650a-b6aa-4217-8104-618bc1f1ae0a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KyowaKirinCoLtdMember_df4d2dbf-7d76-4227-a48c-00c757cd433b_terseLabel_en-US" xlink:label="lab_amgn_KyowaKirinCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd.</link:label>
    <link:label id="lab_amgn_KyowaKirinCoLtdMember_label_en-US" xlink:label="lab_amgn_KyowaKirinCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd. [Member]</link:label>
    <link:label id="lab_amgn_KyowaKirinCoLtdMember_documentation_en-US" xlink:label="lab_amgn_KyowaKirinCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyowaKirinCoLtdMember" xlink:href="amgn-20221231.xsd#amgn_KyowaKirinCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KyowaKirinCoLtdMember" xlink:to="lab_amgn_KyowaKirinCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_132e7571-e38c-46f0-91c3-da234c5ccbb4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of derivatives included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_226912ee-866e-43ff-8aeb-dcd7c8c21430_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_d2fe6380-e462-4d98-967a-021d6a644371_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7644be7e-ec93-4ef3-9974-6cff16a5a73f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_92777dcd-6e62-41b3-940a-ca217f6a89cd_terseLabel_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% notes due 2045 (4.40% 2045 Notes)</link:label>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_label_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]</link:label>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_documentation_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:href="amgn-20221231.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:to="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b4998df3-188c-4b59-b87f-6b7ae48531c3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member_3709b009-5c51-491d-a004-74c3ced9f573_terseLabel_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2022 and 2031</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member_label_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2022 and 2031 [Member]</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member_documentation_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2022 and 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:href="amgn-20221231.xsd#amgn_OperatingLossesThatExpireBetween2022And2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:to="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_fe55beee-5760-426f-a8f7-09f922dd3e9d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash purchase price</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_8201c31d-adb5-436c-a94b-9e572deca221_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TeneobioMember_41b93ebe-74c8-4640-9004-563ec4ce1b90_terseLabel_en-US" xlink:label="lab_amgn_TeneobioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio</link:label>
    <link:label id="lab_amgn_TeneobioMember_label_en-US" xlink:label="lab_amgn_TeneobioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio [Member]</link:label>
    <link:label id="lab_amgn_TeneobioMember_documentation_en-US" xlink:label="lab_amgn_TeneobioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember" xlink:href="amgn-20221231.xsd#amgn_TeneobioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TeneobioMember" xlink:to="lab_amgn_TeneobioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_32b1e065-e442-4c34-a4df-e62f515d8810_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_e3006d63-81c9-4762-8c78-c978ca81deb7_totalLabel_en-US" xlink:label="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_label_en-US" xlink:label="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Maturities Repayments Of Principal Net</link:label>
    <link:label id="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_documentation_en-US" xlink:label="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:href="amgn-20221231.xsd#amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:to="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ManufacturingEquipmentMember_73cd0408-08fd-4bdc-95fc-e1a226b2c876_terseLabel_en-US" xlink:label="lab_amgn_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment [Member]</link:label>
    <link:label id="lab_amgn_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_amgn_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_amgn_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_amgn_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ManufacturingEquipmentMember" xlink:href="amgn-20221231.xsd#amgn_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ManufacturingEquipmentMember" xlink:to="lab_amgn_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5160b312-b5cd-4d4e-bf6e-c4a5aa80f02f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherGeneralExpenseMember_1f71c147-f7ef-49a4-9aff-00e3ec8b590f_terseLabel_en-US" xlink:label="lab_amgn_OtherGeneralExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other general expense</link:label>
    <link:label id="lab_amgn_OtherGeneralExpenseMember_label_en-US" xlink:label="lab_amgn_OtherGeneralExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other general expense [Member]</link:label>
    <link:label id="lab_amgn_OtherGeneralExpenseMember_documentation_en-US" xlink:label="lab_amgn_OtherGeneralExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other general expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherGeneralExpenseMember" xlink:href="amgn-20221231.xsd#amgn_OtherGeneralExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherGeneralExpenseMember" xlink:to="lab_amgn_OtherGeneralExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_e255f706-f128-46a7-8c39-5cf75820456e_terseLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:href="amgn-20221231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:to="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ef42b2a1-6c50-4a34-a7fb-74d95ee20101_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_31536a86-d74d-4e72-8a7a-2d9f9c9f335a_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a8466bbd-19b8-422e-8ff8-4926056c841a_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_StockBasedCompensationExpenseNetOfTax_3618bc42-954a-4cd5-a3c5-eb7b32a65979_totalLabel_en-US" xlink:label="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense, net of tax</link:label>
    <link:label id="lab_amgn_StockBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation Expense Net of Tax</link:label>
    <link:label id="lab_amgn_StockBasedCompensationExpenseNetOfTax_documentation_en-US" xlink:label="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense, net of tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax" xlink:href="amgn-20221231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_StockBasedCompensationExpenseNetOfTax" xlink:to="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_aadbb915-b4db-4608-aa61-db94a67d415d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_04c2e261-507f-4a3a-8373-fcde5b6d918c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_07de59df-b1a5-403c-900d-4bdcd1426b76_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_5535d52c-4582-47c6-a099-4ab79b055fa3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1311299d-daf3-4525-9d8f-4aa097d6ee43_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_348fb2a0-45b0-475e-bae5-0dc6fd2950b6_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4db55076-bb4c-4809-bfd8-b17ef04d80cc_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_aaa85fe5-c8bd-4e49-bab1-5eedc03ef3cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards, valuation allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4228737f-c0b9-411f-8e54-805ebc9e16f0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_53c96e91-5a4c-4239-8f6d-7d23943fc423_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_4556b397-5ce2-4f62-a1dc-9e87b7942d49_terseLabel_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.40% notes due 2039 (6.40% 2039 Notes)</link:label>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_label_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Zero Percent Notes Due 2039 [Member]</link:label>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_documentation_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Zero Percent Notes Due 2039 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:href="amgn-20221231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:to="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_89c186d3-45fc-4085-9f9d-2e6cf3d9f2b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits, primarily federal R&amp;D</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c68731d8-2f95-4d80-8f7c-5fc6df59bb59_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e5369515-c6fd-4358-88c0-bafd4175b338_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_b9333468-9f52-44a7-94b8-5b6ded515976_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_bc7e1f25-ba4e-4435-9212-d5093bcc470b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_beba2e58-b84a-482d-94c9-5dca772cd387_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_53c3888f-88b3-41a6-af99-098f2c13c3c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_274b974a-8049-43e4-bb24-f6d87d2ffbfc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses capitalized for tax</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_eda2eb6a-17e1-4bf3-8111-ce7e2bf36df3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82d618fc-7848-40f5-8e38-5a4f2e66d4cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4f67c7c9-3cd4-402f-b33f-e2f5238e54fc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1b2464d8-d7bd-4c61-b550-a5eeb1b63e3c_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_460171ab-d969-44c5-8a00-e557d58ef526_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.77% notes due 2053 (2.77% 2053 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_label_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Seven Percent Notes Due Two Zero Five Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:href="amgn-20221231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:to="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MoleculeTypeAxis_c5d0def2-7230-4798-9889-e1543750c2e9_terseLabel_en-US" xlink:label="lab_amgn_MoleculeTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Axis]</link:label>
    <link:label id="lab_amgn_MoleculeTypeAxis_label_en-US" xlink:label="lab_amgn_MoleculeTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Axis]</link:label>
    <link:label id="lab_amgn_MoleculeTypeAxis_documentation_en-US" xlink:label="lab_amgn_MoleculeTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeAxis" xlink:href="amgn-20221231.xsd#amgn_MoleculeTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MoleculeTypeAxis" xlink:to="lab_amgn_MoleculeTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_95e00386-dea0-4d0a-884b-1d85c4076bb7_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets locations</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:href="amgn-20221231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:to="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a77575f2-8aeb-4475-8a8e-e5dac08da729_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0d755262-1411-4d29-a7cb-99a66e6e3d0d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_a622f1cf-1a5f-47df-9308-03861a4775c6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProfitAndLossShareOfExpenses_b802357a-f790-4d5d-a873-c0e473188a88_terseLabel_en-US" xlink:label="lab_amgn_ProfitAndLossShareOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit and loss share of expenses</link:label>
    <link:label id="lab_amgn_ProfitAndLossShareOfExpenses_label_en-US" xlink:label="lab_amgn_ProfitAndLossShareOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit and loss share of expenses</link:label>
    <link:label id="lab_amgn_ProfitAndLossShareOfExpenses_documentation_en-US" xlink:label="lab_amgn_ProfitAndLossShareOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit and loss share of expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses" xlink:href="amgn-20221231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProfitAndLossShareOfExpenses" xlink:to="lab_amgn_ProfitAndLossShareOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ac5b9d4e-737b-4d84-af2d-7814ae0fbd12_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_96b72811-51a6-4c15-88c2-ccd5fbfa2835_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0e67d38b-a008-44e0-8a14-6bcf32668cff_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6d8f1a09-f43b-4130-b1da-3d5f602864ee_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SanofiRegeneronPatentLitigationMember_bacbe05b-50f3-454b-9c8e-935cd7838e21_terseLabel_en-US" xlink:label="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi/Regeneron Patent Litigation</link:label>
    <link:label id="lab_amgn_SanofiRegeneronPatentLitigationMember_label_en-US" xlink:label="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi/Regeneron Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_SanofiRegeneronPatentLitigationMember_documentation_en-US" xlink:label="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi/Regeneron Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember" xlink:href="amgn-20221231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SanofiRegeneronPatentLitigationMember" xlink:to="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_e53e52f1-0d58-4037-bf96-75e5a34eb203_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_4556d8ec-babc-4ea4-9d03-9dcba39c072f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which the grants of equity instruments vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_33a6a9ff-64b3-43bc-8d80-d5ad0194c993_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8b5cde85-60d3-42cd-a572-acdfbe8699e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_55bb9066-07f4-4778-8fc2-52c47a0c455f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_dcce04f5-f81e-41b0-8095-ce6f64bae736_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of units that vested during the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_70ee29f6-8c58-4271-b250-f1382c8cc782_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_ad4b7dda-f812-4818-89e3-e95b4229bf9e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_1b9c58aa-ad00-4772-93dc-8c3896feecd2_terseLabel_en-US" xlink:label="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL and credit carryforwards</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_label_en-US" xlink:label="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Tax Acquired Net Operating Loss And Credit Carry Forwards</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_documentation_en-US" xlink:label="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:href="amgn-20221231.xsd#amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:to="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DevelopmentCostsDueToCollaborationPartner_800a5e80-8308-4a5b-afc3-e4cfdcbac8c4_terseLabel_en-US" xlink:label="lab_amgn_DevelopmentCostsDueToCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development costs due to collaboration partner</link:label>
    <link:label id="lab_amgn_DevelopmentCostsDueToCollaborationPartner_label_en-US" xlink:label="lab_amgn_DevelopmentCostsDueToCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development costs due to collaboration partner</link:label>
    <link:label id="lab_amgn_DevelopmentCostsDueToCollaborationPartner_documentation_en-US" xlink:label="lab_amgn_DevelopmentCostsDueToCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development costs due to collaboration partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DevelopmentCostsDueToCollaborationPartner" xlink:href="amgn-20221231.xsd#amgn_DevelopmentCostsDueToCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DevelopmentCostsDueToCollaborationPartner" xlink:to="lab_amgn_DevelopmentCostsDueToCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePrimeTherapeuticsIncMember_256fa1d6-5d79-4966-ab05-5012c1107a16_terseLabel_en-US" xlink:label="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Prime Therapeutics, Inc.</link:label>
    <link:label id="lab_amgn_FivePrimeTherapeuticsIncMember_label_en-US" xlink:label="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Prime Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_amgn_FivePrimeTherapeuticsIncMember_documentation_en-US" xlink:label="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Prime Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePrimeTherapeuticsIncMember" xlink:href="amgn-20221231.xsd#amgn_FivePrimeTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePrimeTherapeuticsIncMember" xlink:to="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4093dd0a-7bc2-4a44-b861-f7debac7efd9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminated_1483651c-8e0f-4274-bf8f-3d24e76707a8_terseLabel_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminated_label_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminated_documentation_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated" xlink:href="amgn-20221231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeNotionalAmountAmountTerminated" xlink:to="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_f878bd6e-ea29-4124-a9da-ea5944f6571d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Gain Loss [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_407f9401-1bde-45a9-9749-daeb96979459_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_add04a37-ccb6-4945-83da-c7ee9d3c0959_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_b0bc827c-e5ea-46fe-be54-2d8b60560d14_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, number of annual installments</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d88d585d-5486-4273-a898-6cf1e4c1b5e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_05d31966-9717-4047-93e8-b1cb50e18e2f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_85504831-ca83-42ba-9a26-44e160815a18_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market mutual funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_f7d05fbe-bac7-431a-b5ff-6f97092e75ed_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PartnershipInterestMember_32667961-b6cb-475e-8c32-d1e29d439027_terseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Partnership [Member]</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_label_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_PartnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PartnershipInterestMember" xlink:to="lab_srt_PartnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5474fbba-5f08-431b-abef-8e61fec75ab2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e959b227-eacd-41da-9cf3-c0b58314cfa8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Company&#8217;s equity award programs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_c08f9f6a-d29e-450f-91b8-edc277c74798_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_e1a3af1b-4be2-4ceb-baa6-506fda165520_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_08acffef-f4c7-4a7f-8d55-ca4b08453216_terseLabel_en-US" xlink:label="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average assumptions used and the resulting weighted average grant date fair value of performance units</link:label>
    <link:label id="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_label_en-US" xlink:label="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Performance Units Fair Value Assumptions [Table Text Block]</link:label>
    <link:label id="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:href="amgn-20221231.xsd#amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:to="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_68768838-e7aa-452d-b7f1-6ea02bf7a816_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_653fe573-dbd4-4810-9d7a-d72dd84ed0a4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_bd23e0e8-45a4-4a87-bf42-674cf2f79090_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LitigationSettlementLengthofTrial_9fd26c4a-8e5f-4c07-a630-3b4eeff92046_terseLabel_en-US" xlink:label="lab_amgn_LitigationSettlementLengthofTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Length of trial</link:label>
    <link:label id="lab_amgn_LitigationSettlementLengthofTrial_label_en-US" xlink:label="lab_amgn_LitigationSettlementLengthofTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Length of Trial</link:label>
    <link:label id="lab_amgn_LitigationSettlementLengthofTrial_documentation_en-US" xlink:label="lab_amgn_LitigationSettlementLengthofTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Length of Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementLengthofTrial" xlink:href="amgn-20221231.xsd#amgn_LitigationSettlementLengthofTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LitigationSettlementLengthofTrial" xlink:to="lab_amgn_LitigationSettlementLengthofTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_05020e71-2bf7-42d1-954b-558ed5551bc7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_60293a1f-c86a-496d-97da-7921f45ca85d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d06ebfc0-33ad-4efc-8400-0d8fe8b3e12d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties related to unrecognized tax benefits recognized in income tax provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5e6d671b-ba3c-4623-a968-67aae223f4d7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3655903f-c3b3-4121-976e-43d3b427bc5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_c6f28ff4-9b38-49bb-86c5-55b053ce4819_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedLiabilitiesDisclosureTextBlock_9481f0ce-864e-4fce-bc55-386cd6392af2_terseLabel_en-US" xlink:label="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and accrued liabilities</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesDisclosureTextBlock_documentation_en-US" xlink:label="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:href="amgn-20221231.xsd#amgn_AccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices_7ae63264-cf88-45bf-9390-f313650b16f6_terseLabel_en-US" xlink:label="lab_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, cash consideration paid to equity holders for pre-acquisition services</link:label>
    <link:label id="lab_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices_label_en-US" xlink:label="lab_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, cash consideration paid to equity holders for pre-acquisition services</link:label>
    <link:label id="lab_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices_documentation_en-US" xlink:label="lab_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, cash consideration paid to equity holders for pre-acquisition services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices" xlink:href="amgn-20221231.xsd#amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices" xlink:to="lab_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_717e7517-acd5-409f-89be-3557a8982b85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_391b779b-a955-43f1-94de-200850c72417_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_73778d66-04b6-476f-8ef8-178d28fdf65a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0a76fcab-33c4-4cdb-8d96-1956fe072472_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_d8c1a79d-3a8a-4e97-a5e7-8836a3255151_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesTable_9b6bbf2f-ee55-4808-ba24-cf02e400785f_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable" xlink:to="lab_us-gaap_GainContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_86c07546-0160-4da8-970f-022d7e3e693e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax_741117fb-abc1-4c03-ba14-a6fcbb34fdfd_terseLabel_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax_label_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax_documentation_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:href="amgn-20221231.xsd#amgn_RepatriationTaxOnProposedAdditionalTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:to="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_2b51935f-27c4-4ed1-a88e-fc95e2fa6bdd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NovartisPharmaAGMember_bc4356eb-8f4b-46f9-a745-f18b96afae55_terseLabel_en-US" xlink:label="lab_amgn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:label id="lab_amgn_NovartisPharmaAGMember_label_en-US" xlink:label="lab_amgn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Pharma AG [Member]</link:label>
    <link:label id="lab_amgn_NovartisPharmaAGMember_documentation_en-US" xlink:label="lab_amgn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisPharmaAGMember" xlink:href="amgn-20221231.xsd#amgn_NovartisPharmaAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NovartisPharmaAGMember" xlink:to="lab_amgn_NovartisPharmaAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_f3dbf01f-c6b2-4dc3-b948-cc816043e56a_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_b5ca2fb9-e902-4370-b29e-eb01cb5a8277_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_68009156-6b27-450c-8e45-390163f3d294_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_736481e8-d2dc-4219-b60a-135194b8ffe0_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments to income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_358af258-2ecf-4910-ba89-aeef17d3592b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested or expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointEightZeroPercent2041NotesMember_ab305d7a-9437-42e5-8fa4-8e0471e0f4ad_terseLabel_en-US" xlink:label="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2041 (2.80% 2041 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointEightZeroPercent2041NotesMember_label_en-US" xlink:label="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point eight zero percent 2041 Notes [Member]</link:label>
    <link:label id="lab_amgn_TwoPointEightZeroPercent2041NotesMember_documentation_en-US" xlink:label="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point eight zero percent 2041 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:href="amgn-20221231.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:to="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_40f3c624-51d5-4846-bfd8-e1b595bd300d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e2213208-7663-4f48-8070-00f00c0d521b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_f0b0e82a-18e6-4702-9b70-c255a67229fc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_90c9ffcd-8a4a-472f-9729-daa7df633148_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_894d0d03-4f47-4482-b2e2-cef850e9a29f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RestOfWorldMember_f3c2e8bb-43dc-46ce-9050-a938fcebd263_terseLabel_en-US" xlink:label="lab_amgn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROW [Member]</link:label>
    <link:label id="lab_amgn_RestOfWorldMember_label_en-US" xlink:label="lab_amgn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_amgn_RestOfWorldMember_documentation_en-US" xlink:label="lab_amgn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RestOfWorldMember" xlink:href="amgn-20221231.xsd#amgn_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RestOfWorldMember" xlink:to="lab_amgn_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_09e661cd-f00d-44b7-97c1-5a0f5d11df67_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_06a13050-2408-4302-be63-6ab2746f36a1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_65b3943d-54c2-46c4-8244-f5001d4ef5c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4d7261b7-083d-4720-9511-f61f9c5fa66e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_14b2f0f0-6fd9-492b-987f-8cf944e2730a_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_ba69cebe-c503-4800-a8bf-2d57855b261f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_9a262739-a128-476e-834c-f210e26d445f_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_48bfb42f-6f69-4a52-82d9-727b3d73b30e_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberOfChallenges_c7b6fd71-8fe0-4bfa-9092-c8f2c7487e70_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberOfChallenges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of challenges</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfChallenges_label_en-US" xlink:label="lab_amgn_GainContingencyNumberOfChallenges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Challenges</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfChallenges_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberOfChallenges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Challenges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfChallenges" xlink:href="amgn-20221231.xsd#amgn_GainContingencyNumberOfChallenges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberOfChallenges" xlink:to="lab_amgn_GainContingencyNumberOfChallenges" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock_b4e32d3d-646f-40a8-85a3-a03ad2f04b6d_terseLabel_en-US" xlink:label="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments, policy</link:label>
    <link:label id="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments, policy [Policy Text Block]</link:label>
    <link:label id="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of the policy for investments in equity securities that are publicly traded and that do not have a readily determinable fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:href="amgn-20221231.xsd#amgn_EquityInvestmentsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:to="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a1dc30b1-b976-4454-b344-fa7092f8de30_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_9e9f7598-21c1-4822-8ff5-cd391b5bb5dd_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging adjustments on discontinued hedging relationships</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AranespMember_8266c799-9079-4b00-bf22-8b7a4b8c32d4_terseLabel_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp&#174; (darbepoetin alfa) [Member]</link:label>
    <link:label id="lab_amgn_AranespMember_label_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp [Member]</link:label>
    <link:label id="lab_amgn_AranespMember_documentation_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember" xlink:href="amgn-20221231.xsd#amgn_AranespMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AranespMember" xlink:to="lab_amgn_AranespMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1041b593-a8bc-4361-a05b-e3b2e2f641fb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f2e72312-fb41-42e3-8a59-b595c3c6a541_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2ddd890a-e855-46fe-9f36-c8e410543535_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ee271e69-05d1-4cdf-a3e1-61baddfb3767_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0c464c31-7ac3-4e77-b09d-31b1a443e8dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherNotesDue2097Member_cb5db3ae-4889-4a52-addb-e9321737b51f_terseLabel_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes due 2097</link:label>
    <link:label id="lab_amgn_OtherNotesDue2097Member_label_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Due 2097 [Member]</link:label>
    <link:label id="lab_amgn_OtherNotesDue2097Member_documentation_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Due 2097 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member" xlink:href="amgn-20221231.xsd#amgn_OtherNotesDue2097Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherNotesDue2097Member" xlink:to="lab_amgn_OtherNotesDue2097Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c3d7d743-b822-4ea4-80f1-eaebdd8f5cf5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_e06bfadb-3ccb-4e2a-9634-87748d9185e0_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_62ae0b73-cd4c-419e-9230-10beeb1161c7_verboseLabel_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of identifiable intangible assets</link:label>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:href="amgn-20221231.xsd#amgn_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_feba3378-dfcb-451a-8ebf-b220f228b0d7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_59e094a5-b53a-45f1-91db-7a6343414ee4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AssetsByDescriptionAxis_4eb2edb1-d241-482d-8633-5fa9438bf107_terseLabel_en-US" xlink:label="lab_amgn_AssetsByDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Axis]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionAxis_label_en-US" xlink:label="lab_amgn_AssetsByDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Axis]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionAxis_documentation_en-US" xlink:label="lab_amgn_AssetsByDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis" xlink:href="amgn-20221231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AssetsByDescriptionAxis" xlink:to="lab_amgn_AssetsByDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_6afcc0a2-f9d0-4050-aef4-d898774bc137_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_570a9175-eb07-4528-ac32-82aba447e381_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_15928a5a-e45f-4477-a2f8-9415283bd32f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_79d7bc74-782e-4246-8732-2b7fbdcf779e_terseLabel_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.375% notes due 2037 (6.375% 2037 Notes)</link:label>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_label_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Notes Due 2037 [Member]</link:label>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_documentation_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Notes Due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:href="amgn-20221231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:to="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_ee74a459-c928-49eb-a3f0-b95c8057ae60_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_57bfc41a-4e4f-4995-8303-e0b069ded924_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_8569b714-0363-47aa-a02f-08571696a7ea_terseLabel_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future rental commitments for abandoned leases</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_label_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_documentation_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:href="amgn-20221231.xsd#amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:to="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_7d7bf26e-0ca1-422e-8de0-642c06fe71bc_terseLabel_en-US" xlink:label="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares added back for tax withholding on full value awards</link:label>
    <link:label id="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_label_en-US" xlink:label="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Added Back for Tax Withholding on Full Value Awards</link:label>
    <link:label id="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_documentation_en-US" xlink:label="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Added Back for Tax Withholding on Full Value Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:href="amgn-20221231.xsd#amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:to="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_72c1a52a-15a4-49d6-973e-8ddaa02d6807_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_6643afa6-6a40-41da-8532-551ed624f8e1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_32fa61c3-2f6d-44df-8e9c-fdbd38a343ba_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_37938ba0-51c7-4fc5-b566-516dd00f630a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_70e8fcd2-55ee-4ac3-97f2-2f42dbdfbfe9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term tax liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_a3a7fefc-6b8e-4e2c-a002-823816198cfe_terseLabel_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.663% notes due 2051 (4.663% 2051 Notes)</link:label>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_label_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]</link:label>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_documentation_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:href="amgn-20221231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:to="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherProductsMember_5901c4db-665a-4aae-92a4-b0eacb6dcbc8_terseLabel_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products [Member]</link:label>
    <link:label id="lab_amgn_OtherProductsMember_label_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_amgn_OtherProductsMember_documentation_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember" xlink:href="amgn-20221231.xsd#amgn_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherProductsMember" xlink:to="lab_amgn_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_26e20e44-e5b4-4f02-a4b6-a3acff9f80b8_terseLabel_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% 2022 euro Notes</link:label>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:href="amgn-20221231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:to="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensatingBalanceAmount_914e3eee-80b3-4595-b346-19f3bf638177_terseLabel_en-US" xlink:label="lab_us-gaap_CompensatingBalanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensating balance, amount</link:label>
    <link:label id="lab_us-gaap_CompensatingBalanceAmount_label_en-US" xlink:label="lab_us-gaap_CompensatingBalanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensating Balance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensatingBalanceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatingBalanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensatingBalanceAmount" xlink:to="lab_us-gaap_CompensatingBalanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60f4a558-b36a-4e4d-96d2-0866f889b2c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1c9a75e8-dfb6-4098-a1db-3538219f2785_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProliaMember_2f87aea2-b442-4f76-a349-d89ba2473627_terseLabel_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia&#174; (denosumab) [Member]</link:label>
    <link:label id="lab_amgn_ProliaMember_label_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia [Member]</link:label>
    <link:label id="lab_amgn_ProliaMember_documentation_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember" xlink:href="amgn-20221231.xsd#amgn_ProliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProliaMember" xlink:to="lab_amgn_ProliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8ac09a57-69dc-4b50-bf54-52f7672117b1_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_06ef5a84-e0cb-4214-896f-f386482ff68a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years), vested or expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b3c57e76-94e9-4056-a603-1d874dfb4e77_verboseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of AOCI [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_be7e6a7b-fddd-493a-96e6-1569f63d9c97_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0f4cd3ff-547d-45e1-af78-25450ca7d895_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A300NotesDue20293002029NotesMember_cbbb159c-16e1-4bd1-999d-c02602e14ef0_terseLabel_en-US" xlink:label="lab_amgn_A300NotesDue20293002029NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2029 (3.00% 2029 Notes)</link:label>
    <link:label id="lab_amgn_A300NotesDue20293002029NotesMember_label_en-US" xlink:label="lab_amgn_A300NotesDue20293002029NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2029 (3.00% 2029 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A300NotesDue20293002029NotesMember_documentation_en-US" xlink:label="lab_amgn_A300NotesDue20293002029NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2029 (3.00% 2029 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20293002029NotesMember" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20293002029NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A300NotesDue20293002029NotesMember" xlink:to="lab_amgn_A300NotesDue20293002029NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ccae2338-1ceb-49e4-b7ae-df9d6ad7a057_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeBasisSpreadOnVariableRate_32771ed5-1f62-4f9d-be28-8653a49a123a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DerivativeBasisSpreadOnVariableRate_label_en-US" xlink:label="lab_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeBasisSpreadOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:to="lab_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_641260f2-45ca-4eae-a02b-d7cbb529a428_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7f9f9b52-65fd-49b7-aed6-feb8f784eb81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_ec3cb2b6-a509-4bd2-88e2-153d7883a43f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_bd87be95-699c-47d8-a9bb-30a713a97ed1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_173dbca4-7309-4e0a-8fc3-22bfed4d51ba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_db552308-d356-4eaa-9c9c-d4b774558517_terseLabel_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</link:label>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:href="amgn-20221231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:to="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_4be8751f-a747-4b5a-90e6-9617f50a9278_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes to goodwill resulting from acquisitions and divestitures, net(1)</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_94223906-4bd3-4f93-b8f0-304df22a5adb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_de8b2bfc-741a-478f-ad51-e2da3f0a9725_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9a6d270-1656-4c7d-87b8-53bf991b6903_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_78f283a2-1602-43a9-8832-3ef7dabd2d3d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2b25dfcc-db1c-4f4e-9c23-8a3ae22d430f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_46a5ab9c-3e3d-4d75-9d69-0f0c019ad8b7_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f608d49b-63cc-4227-a87e-41cbc5335aa6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member_5ffbf04c-3af6-4212-8499-8324d48317c6_terseLabel_en-US" xlink:label="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% notes due 2020 (4.50% 2020 Notes)</link:label>
    <link:label id="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member_label_en-US" xlink:label="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Zero Percent Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Zero Percent Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:href="amgn-20221231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:to="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_25c9235e-5a1d-40cc-ba5f-b86065be5507_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:href="amgn-20221231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_6ed51945-3881-47e0-a024-8f3bd3aacfb7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesPayableMember_1774a388-341f-41ff-a757-2adf2733244a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities payable</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesPayableMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesPayableMember" xlink:to="lab_us-gaap_DebtSecuritiesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8ab3d8ff-6cf7-4e6e-bc4b-e2ae49b53206_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options information [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_99cb5a9e-5f28-4fb0-a6c1-8aad0454c937_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e7fc84f3-0eab-4e76-9fa7-ab85887920e1_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7397d8b7-2933-4467-b9d8-ec5f2d0a1949_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fa2fa946-6045-46c9-8f23-12d9f67c4985_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_80b1182f-4f91-44fa-8754-4fce7815ccaa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized bond discounts, premiums and issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_99497145-73fa-4d8e-b976-c5f0216cdd3e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ef582adc-5b6e-49b8-9f8b-4453f0b270b1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets &#8211; developed-product-technology rights</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_45cf18bb-9476-48e0-91e1-002279a1135b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7c781e7c-b554-474f-935a-9613e0ed433b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_28cbbee6-766b-4046-8463-73f3960849d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest rate derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_0ae762dd-8303-4263-9bbb-eaa848262032_verboseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_69579dc9-6736-4a6d-8edc-9a34e9c6813b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_2994c875-6d70-45f2-be3b-389adb81cdc5_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_e8b35c25-9551-448c-9cde-8b5ed4bd51f5_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_73508a13-35b9-497e-b260-463654616256_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cb7b54c6-aa40-49b3-8787-8f485533bbb9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_09aea261-39e4-4e50-8842-abc2e96397fb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1d060102-1083-40d2-942c-9f0d8e8198fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b69bb9fe-3064-4f58-b9d5-d2e0e47fda3a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_88e0a551-0ec3-46e9-b977-160f96eec1df_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd555e3a-4e94-42e2-ad07-4e366dcf3b54_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_009ea4d7-c703-4c2a-af2b-5b2a6c3af59a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions_b157a81e-da05-4225-8afa-e2a2622b2f81_terseLabel_en-US" xlink:label="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional term extension options</link:label>
    <link:label id="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions_label_en-US" xlink:label="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number Of Renewal Options</link:label>
    <link:label id="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:href="amgn-20221231.xsd#amgn_LineofCreditFacilityNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:to="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1a591855-a026-49a7-87fa-db8f83f5dc30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedSalesReturnReserveCurrent_7dba7b7e-be7e-4ca7-a0d4-cb4e43be93e6_terseLabel_en-US" xlink:label="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns reserve</link:label>
    <link:label id="lab_amgn_AccruedSalesReturnReserveCurrent_label_en-US" xlink:label="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Return Reserve Current</link:label>
    <link:label id="lab_amgn_AccruedSalesReturnReserveCurrent_documentation_en-US" xlink:label="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesReturnReserveCurrent" xlink:href="amgn-20221231.xsd#amgn_AccruedSalesReturnReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedSalesReturnReserveCurrent" xlink:to="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_5703bb74-98a1-4149-b403-dc7c91332855_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_bdf35550-37e5-49e7-9e2b-8992e692127d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6054c3ca-938d-42e0-83c6-1ee945435dac_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_7fcbd7c1-b1b0-48cd-9d70-73b7b9f2fa5b_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_091a6a99-dcf3-401f-a871-9dcd909b5472_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2bd9dc3c-34eb-404e-b63d-94b9fa1965e5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_686b445d-a09b-490f-816d-b22500602da3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_d2a12ba8-9ebd-4324-b7be-94f4f83a038f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_e0d55bc6-515d-430a-8a77-265ff625933a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_32df32a6-9d80-4b00-8672-0105f43fb325_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_ec71d646-ed09-4d5d-a68b-aea210d11ae9_terseLabel_en-US" xlink:label="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional period for extension of commitment term</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_label_en-US" xlink:label="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Extension of Commitment Term</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_documentation_en-US" xlink:label="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Extension of Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:href="amgn-20221231.xsd#amgn_LineOfCreditFacilityExtensionOfCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:to="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_5b749bd0-b5cd-47c8-bee3-53934e82099b_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_label_en-US" xlink:label="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Combined Worldwide Gross Revenues From Major Customers</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_documentation_en-US" xlink:label="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:href="amgn-20221231.xsd#amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:to="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ee5da243-906c-4c5d-aaf2-96db678a5af0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7f6011e6-861e-479d-bd41-67846881abda_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside_81d0d1b3-c7ac-4de2-8ae5-0a70fd0cdb1e_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States In Which Plaintiffs Reside</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside_label_en-US" xlink:label="lab_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States In Which Plaintiffs Reside</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside_documentation_en-US" xlink:label="lab_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States In Which Plaintiffs Reside</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:to="lab_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_b2f71c62-a599-4e43-b71f-db1b033454e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebt_57071536-4ca5-4abd-84a3-721a74d2d683_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_27c24346-1921-4367-ad36-25b1868f5ec5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0e3e197c-9872-4aba-b257-c97196c9c963_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock, Shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f5641cdf-f131-4909-b00e-fa2a1e20a14c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1d076ed6-fa0e-4dac-8ee6-83790f0d279c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_6e3a43ec-f342-4c6d-b601-59e65a396e43_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther_9dfe4928-9f50-47de-809f-59e9c46c64d4_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Change In Carrying Value, Other</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Change In Carrying Value, Other</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Change In Carrying Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:to="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_2e47f85a-b811-4bcf-8a0c-37493afac889_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_8b2efc0a-8164-447e-a1f7-238dde5899d6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Member]</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_1b10c152-1cd8-478d-afbd-228ab2c7ba37_totalLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining U.S. repatriation tax commitments</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:to="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BridgeCreditAgreementAmount_39f79163-deca-430b-8fcc-d03edbda70af_terseLabel_en-US" xlink:label="lab_amgn_BridgeCreditAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement amount</link:label>
    <link:label id="lab_amgn_BridgeCreditAgreementAmount_label_en-US" xlink:label="lab_amgn_BridgeCreditAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement amount</link:label>
    <link:label id="lab_amgn_BridgeCreditAgreementAmount_documentation_en-US" xlink:label="lab_amgn_BridgeCreditAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementAmount" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BridgeCreditAgreementAmount" xlink:to="lab_amgn_BridgeCreditAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0fb1ba1e-dac2-4190-a9a3-eeead89bfc09_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46345e32-e522-4a13-9c62-a234b177808a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_67004448-56b8-44f3-bf6e-92a1972d6a19_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ac252ed3-0b2a-4ed1-b516-08ee5274ba89_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_a973d919-42fe-4e3c-b943-8d495d1a50b4_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_90b6a62a-c269-442e-9cab-d1f84daef09d_terseLabel_en-US" xlink:label="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties on proposed additional income tax 2013-2105</link:label>
    <link:label id="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_label_en-US" xlink:label="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties on proposed additional income tax 2013-2105</link:label>
    <link:label id="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_documentation_en-US" xlink:label="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties on proposed additional income tax 2013-2015</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:href="amgn-20221231.xsd#amgn_PenaltiesOnProposedAdditionalIncomeTax20132105"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:to="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c80bf21-eb40-4e65-915a-54127058f50e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MoleculeTypeDomain_9f8eb717-0ec0-499a-9abf-6f3ce2d5e42f_terseLabel_en-US" xlink:label="lab_amgn_MoleculeTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Domain]</link:label>
    <link:label id="lab_amgn_MoleculeTypeDomain_label_en-US" xlink:label="lab_amgn_MoleculeTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Domain]</link:label>
    <link:label id="lab_amgn_MoleculeTypeDomain_documentation_en-US" xlink:label="lab_amgn_MoleculeTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain" xlink:href="amgn-20221231.xsd#amgn_MoleculeTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MoleculeTypeDomain" xlink:to="lab_amgn_MoleculeTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_65dcf92b-4a82-4e77-a002-b4fcbbf9bcde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_779b82f3-36f2-4f63-a19c-0edd2a7e0c34_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in the calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_dc8befa9-d3df-44c7-b574-cb9c7caa1fa0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (Denominator):</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9df103d6-8949-4e35-b038-4889a9b1bbb4_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_2ae07a8c-7ea3-41ac-aeb9-800c77df05ae_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_13ad4040-6c61-49a3-a686-ad5db57a1daa_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2fbb437e-af73-48f6-8f97-e394cafa1810_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_93d1e26c-3b9a-427d-8b57-a26c28b08b15_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_73dcc151-94fe-4de4-b33a-8a6ab8d5bbce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested or expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RDTechnologyrightsMember_3c2f5334-fa05-42a2-8f33-3566c8c91ab0_terseLabel_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights</link:label>
    <link:label id="lab_amgn_RDTechnologyrightsMember_label_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights [Member]</link:label>
    <link:label id="lab_amgn_RDTechnologyrightsMember_documentation_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember" xlink:href="amgn-20221231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RDTechnologyrightsMember" xlink:to="lab_amgn_RDTechnologyrightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_956dd643-2869-49d0-a132-9eeef3b9a764_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c87c7eb-7777-4544-a830-77b3c42e4d3a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for basic EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_50300bf4-c575-4423-bd65-ce7844164b05_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_ef3b89d2-f3d1-4696-8977-9ac5e0daaacb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e272da29-5b09-462b-ae36-1b72988d15e5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_f52ec1b1-aaca-449f-b11d-03757c08f6fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of stock-based compensation expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7cff05e8-9a10-46b5-add9-e22974e01d11_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a6511ab5-ad51-4991-be9c-dc311ee40de1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_UCBMember_33100287-ffee-4212-9357-b6b6950a236a_terseLabel_en-US" xlink:label="lab_amgn_UCBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB</link:label>
    <link:label id="lab_amgn_UCBMember_label_en-US" xlink:label="lab_amgn_UCBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB [Member]</link:label>
    <link:label id="lab_amgn_UCBMember_documentation_en-US" xlink:label="lab_amgn_UCBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_UCBMember" xlink:href="amgn-20221231.xsd#amgn_UCBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_UCBMember" xlink:to="lab_amgn_UCBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_90f0e3b7-4021-4b5b-8d46-f8dea36f6db1_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6e0c754a-c131-40bf-8658-d409c2b4f579_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e93570ee-2d6e-4f2b-88bf-4b93ffbcc36e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9c61d17c-c084-4cca-8336-ed8eebbf36d5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_30fbd73d-d188-4748-903f-1e6fd47f1c65_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5be17765-e4f1-40f1-96b5-5764a66d523f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax_294d9428-987d-4302-b726-d61bcc30745d_terseLabel_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax_label_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax_documentation_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax" xlink:href="amgn-20221231.xsd#amgn_ProposedAdditionalIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProposedAdditionalIncomeTax" xlink:to="lab_amgn_ProposedAdditionalIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_6888df49-1ff4-4f16-99ff-ec1b094ae10f_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% notes due 2026 (2.60% 2026 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_7965f658-81a9-4023-9582-8431ab6b41d3_verboseLabel_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.600% notes due 2026 (2.60% 2026 notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_label_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Zero Notes Due Two Zero Two Six [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Zero Notes Due Two Zero Two Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:href="amgn-20221231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:to="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_de2aadad-6e2e-4e58-913e-03cbff089446_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_78ed124f-a26e-4b91-b5a3-dbfbadc1083e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_f40d9060-2ab1-4019-8f9f-edc129c4f7b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_6e939d7e-020c-4a14-a243-ddebc9557f22_terseLabel_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives:</link:label>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_documentation_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:href="amgn-20221231.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:to="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e524bcd1-3b6b-41fe-9ad4-9fccb5202d85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_8b621e1f-ccdc-418d-b29d-94e5fa9901df_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtezlaMember_d441a7a3-3a46-407c-b22d-b42673a3a60f_verboseLabel_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:label id="lab_amgn_OtezlaMember_label_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:label id="lab_amgn_OtezlaMember_documentation_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember" xlink:href="amgn-20221231.xsd#amgn_OtezlaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtezlaMember" xlink:to="lab_amgn_OtezlaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9c33c1e4-b7e0-449c-9057-1f3369c4cf85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ApprovedProducts_24c24b2c-3fd4-4bbb-8528-d3276d56dae5_terseLabel_en-US" xlink:label="lab_amgn_ApprovedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved products</link:label>
    <link:label id="lab_amgn_ApprovedProducts_label_en-US" xlink:label="lab_amgn_ApprovedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved products</link:label>
    <link:label id="lab_amgn_ApprovedProducts_documentation_en-US" xlink:label="lab_amgn_ApprovedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ApprovedProducts" xlink:href="amgn-20221231.xsd#amgn_ApprovedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ApprovedProducts" xlink:to="lab_amgn_ApprovedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_3d17a713-35cd-4f35-b748-30fa3515c766_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on fair value hedging relationships, Hedged Items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_83e9a25f-13ec-43cf-a87b-db1b559eff8e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_744debb2-8a96-43e3-8a73-384bee2975a4_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8967a31-d5ec-4f0e-8237-28fc7771f9b8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1db782f7-fb61-4a8a-95a5-2530f998118a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4b46caa5-7d31-4721-b6ff-a444aaa1e4b4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e13f6d8e-9fed-4667-b195-2124a0e9f0ae_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;other observable inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_22a8dbf0-29c5-4113-a485-0b96b072be64_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ForwardInterestRateContractsMember_49ec5988-b6ed-423b-b73a-f311af5513a3_terseLabel_en-US" xlink:label="lab_amgn_ForwardInterestRateContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward interest rate contracts</link:label>
    <link:label id="lab_amgn_ForwardInterestRateContractsMember_label_en-US" xlink:label="lab_amgn_ForwardInterestRateContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Interest Rate Contracts [Member]</link:label>
    <link:label id="lab_amgn_ForwardInterestRateContractsMember_documentation_en-US" xlink:label="lab_amgn_ForwardInterestRateContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Interest Rate Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractsMember" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ForwardInterestRateContractsMember" xlink:to="lab_amgn_ForwardInterestRateContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_151fea05-4d69-495d-8eab-f3e1de7730ec_terseLabel_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</link:label>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_label_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Percent Euro Notes Due Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Percent Euro Notes Due Two Thousand Twenty Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:href="amgn-20221231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:to="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_26467388-64f6-429b-96ab-247752229baa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8d7c3be2-90c8-465f-af2a-29e5afae462d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divested assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_65dc68ca-23b9-431c-9d65-2ae2b79b424f_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_64023ea0-d22b-4c08-b88c-c780fcf2f0f0_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5e371c4b-3b3b-49fe-ace6-6fc216cc2ba9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2b344f8e-b669-460b-8cf1-a995e25f7418_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A335NotesDue20323352032NotesMember_8703dce1-e7e4-48ec-aadf-d0f2586ae028_terseLabel_en-US" xlink:label="lab_amgn_A335NotesDue20323352032NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.35% notes due 2032 (3.35% 2032 Notes)</link:label>
    <link:label id="lab_amgn_A335NotesDue20323352032NotesMember_label_en-US" xlink:label="lab_amgn_A335NotesDue20323352032NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.35% notes due 2032 (3.35% 2032 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A335NotesDue20323352032NotesMember_documentation_en-US" xlink:label="lab_amgn_A335NotesDue20323352032NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.35% notes due 2032 (3.35% 2032 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A335NotesDue20323352032NotesMember" xlink:href="amgn-20221231.xsd#amgn_A335NotesDue20323352032NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A335NotesDue20323352032NotesMember" xlink:to="lab_amgn_A335NotesDue20323352032NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralExpense_276e2436-10a0-448a-9586-17cf1cb9fe33_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralExpense" xlink:to="lab_us-gaap_OtherGeneralExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e933ea26-c2c6-4321-9efc-2a8b939d5f1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_30ecee26-117d-4f25-ad50-45b428536b6c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period of stock options from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_faba9158-fc82-4c78-bc04-ba641cb314ad_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_1abe4530-3210-4602-a3d6-43ffd619c9f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5127a051-a613-44b2-9e70-a2bd36b87fb7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NeumoraTherapeuticsIncMember_2931b2ef-76ed-4dfe-bc85-0518af4c93a6_terseLabel_en-US" xlink:label="lab_amgn_NeumoraTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neumora Therapeutics, Inc.</link:label>
    <link:label id="lab_amgn_NeumoraTherapeuticsIncMember_label_en-US" xlink:label="lab_amgn_NeumoraTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neumora Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_amgn_NeumoraTherapeuticsIncMember_documentation_en-US" xlink:label="lab_amgn_NeumoraTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neumora Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember" xlink:href="amgn-20221231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NeumoraTherapeuticsIncMember" xlink:to="lab_amgn_NeumoraTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_79a54411-b643-4daa-939f-39e3f8ab1cae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_965e8df9-bcdb-499d-a6cb-0f9f1992763b_terseLabel_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost recoveries</link:label>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_label_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Direct Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e886b872-3ae3-4e18-9635-fc1bdbf5759f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_c7d6ccf5-b2cd-4ba9-b966-5948a0f7199e_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ChemoCentryxIncSecuritiesMattersMember_e5d353f3-0ccd-4a59-acaf-1f3edcd1b36d_terseLabel_en-US" xlink:label="lab_amgn_ChemoCentryxIncSecuritiesMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChemoCentryx, Inc. Securities Matters</link:label>
    <link:label id="lab_amgn_ChemoCentryxIncSecuritiesMattersMember_label_en-US" xlink:label="lab_amgn_ChemoCentryxIncSecuritiesMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChemoCentryx, Inc. Securities Matters [Member]</link:label>
    <link:label id="lab_amgn_ChemoCentryxIncSecuritiesMattersMember_documentation_en-US" xlink:label="lab_amgn_ChemoCentryxIncSecuritiesMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChemoCentryx, Inc. Securities Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ChemoCentryxIncSecuritiesMattersMember" xlink:href="amgn-20221231.xsd#amgn_ChemoCentryxIncSecuritiesMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ChemoCentryxIncSecuritiesMattersMember" xlink:to="lab_amgn_ChemoCentryxIncSecuritiesMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_8e6b5513-d88f-4835-a1ad-2b1130e51ded_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_6339afb7-c914-4832-b0f9-5a379feaa93f_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars [Member]</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b279143a-fd05-4449-b764-85d8d986e981_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7231fa22-3cfe-42e8-9a5d-b6f74b15a323_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f2c0b5e9-2360-4a36-aaf2-97aecc16d59f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_54123621-c82e-4c88-accd-f2e96cc63879_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_70ae0d50-b53a-49ef-92c2-ab586f899473_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment by geographic information</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_895adc7b-01e5-4fcc-9dc9-9ed5a3f1e425_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rates</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A420NotesDue20334202033NotesMember_197d9538-1e9c-4ab2-9144-1e98485b9dd8_terseLabel_en-US" xlink:label="lab_amgn_A420NotesDue20334202033NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% notes due 2033 (4.20% 2033 Notes)</link:label>
    <link:label id="lab_amgn_A420NotesDue20334202033NotesMember_label_en-US" xlink:label="lab_amgn_A420NotesDue20334202033NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% notes due 2033 (4.20% 2033 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A420NotesDue20334202033NotesMember_documentation_en-US" xlink:label="lab_amgn_A420NotesDue20334202033NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% notes due 2033 (4.20% 2033 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20334202033NotesMember" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20334202033NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A420NotesDue20334202033NotesMember" xlink:to="lab_amgn_A420NotesDue20334202033NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_6c1206a0-df76-4490-b7ca-348cd6523f06_terseLabel_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% notes due 2040 (3.15% 2040 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_label_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Five Percent Notes Due 2040 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_documentation_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Five Percent Notes Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:to="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ae928a23-7747-4f1c-a620-31c39e63b2cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_9753c28f-4652-4c8f-be72-49d48704d78f_terseLabel_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% notes due 2021 (1.85% 2021 Notes)</link:label>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_label_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Eight Five Percent Notes Due Two Zero Two One [Member]</link:label>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_documentation_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Eight Five Percent Notes Due Two Zero Two One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:href="amgn-20221231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:to="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_879db75a-147d-458a-9a80-566bde31bbd0_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NplateMember_65f3d9fa-b2ea-44c7-9be2-041b3f8c97f9_terseLabel_en-US" xlink:label="lab_amgn_NplateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nplate</link:label>
    <link:label id="lab_amgn_NplateMember_label_en-US" xlink:label="lab_amgn_NplateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nplate [Member]</link:label>
    <link:label id="lab_amgn_NplateMember_documentation_en-US" xlink:label="lab_amgn_NplateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nplate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember" xlink:href="amgn-20221231.xsd#amgn_NplateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NplateMember" xlink:to="lab_amgn_NplateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6bd21b0f-7471-4ae9-809d-d426384ed968_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5976902c-a970-477a-8f65-b2759f82285d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member_3ece7323-8f2e-4db8-946d-99a49406ed7c_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.70% notes due 2022 (2.70% 2022 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member_label_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Zero Percent Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Percent Notes Due Two Zero Two Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:href="amgn-20221231.xsd#amgn_TwoPointSevenZeroPercentNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:to="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_872b60b7-ff21-4f1e-8415-2533489ece47_negatedTerseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_label_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Payments</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationContingentConsiderationArrangementsPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:to="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A280NotesDue2041Member_70b5e842-5513-45a9-b836-8aa1b185148e_terseLabel_en-US" xlink:label="lab_amgn_A280NotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2041 (2.80% 2041 Notes)</link:label>
    <link:label id="lab_amgn_A280NotesDue2041Member_label_en-US" xlink:label="lab_amgn_A280NotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2041 [Member]</link:label>
    <link:label id="lab_amgn_A280NotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_A280NotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2041</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A280NotesDue2041Member" xlink:href="amgn-20221231.xsd#amgn_A280NotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A280NotesDue2041Member" xlink:to="lab_amgn_A280NotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_35bf3b1b-9806-41bd-a47e-1db0b9d6ea08_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BridgeCreditAgreementMaximumLength_cfa8aef3-af07-4c10-afd3-ecef5cebba31_terseLabel_en-US" xlink:label="lab_amgn_BridgeCreditAgreementMaximumLength" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement, maximum length</link:label>
    <link:label id="lab_amgn_BridgeCreditAgreementMaximumLength_label_en-US" xlink:label="lab_amgn_BridgeCreditAgreementMaximumLength" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement, maximum length</link:label>
    <link:label id="lab_amgn_BridgeCreditAgreementMaximumLength_documentation_en-US" xlink:label="lab_amgn_BridgeCreditAgreementMaximumLength" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement, maximum length</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementMaximumLength" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementMaximumLength"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BridgeCreditAgreementMaximumLength" xlink:to="lab_amgn_BridgeCreditAgreementMaximumLength" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_5a593889-4054-4a33-b23e-c5cdde2fe2f1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fa82cf23-a734-4333-99cb-e78d234d6f4e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_899fc8cf-a8f4-465a-a52c-1f1cda24e76c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f109f8fb-1e8b-4e6e-8eaa-0ff1aaa1d06d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5073fdcf-8abf-47d8-962e-1f00cc09c4c9_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_5e17d19b-68ec-4f12-925e-e8253ea072d6_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems" xlink:to="lab_us-gaap_GainContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_779cd340-6dd8-4ed1-ae40-279461381d24_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f201d95a-6f7f-44c4-b074-619a931e32d1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_7a305905-7f99-49f7-8d8d-adadae07173d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_c464be93-1b48-43a5-8f6b-6ee56e5e7a16_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative costs</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfGrossRevenues_baf557d8-3a17-4c07-b91b-490ed319a037_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfGrossRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product sales to major customer (as defined) as a percentage of total gross revenues</link:label>
    <link:label id="lab_amgn_PercentageOfGrossRevenues_label_en-US" xlink:label="lab_amgn_PercentageOfGrossRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Gross Revenues</link:label>
    <link:label id="lab_amgn_PercentageOfGrossRevenues_documentation_en-US" xlink:label="lab_amgn_PercentageOfGrossRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product sales to major customer (as defined) as a percentage of total gross revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfGrossRevenues" xlink:href="amgn-20221231.xsd#amgn_PercentageOfGrossRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfGrossRevenues" xlink:to="lab_amgn_PercentageOfGrossRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_7d55c97e-cc9e-4dd6-b37d-b1fceb42eb2d_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_39216b65-3d77-49e9-8f0b-189bb2ac3b06_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_ce5f4a32-139d-425f-af86-3e7c52c4beb1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_4d7542c5-0ff5-4817-bbb0-f208cab76524_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4debb2e9-7a53-49c7-b571-d48020570850_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_25f884ac-9b55-49f3-957a-a61eeaaeed37_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5babcf02-3a9b-4d7b-a770-c0b17fa4ce96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense, pretax</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_762e1502-f2d3-433a-a035-dcefcc34a1fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_05d3c2d6-22c5-40cd-b436-72fd9e82b553_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89a18fc1-e3c0-48bb-8257-16179c05f625_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_aac3dc90-a884-4ec4-af7d-32538acff53b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a0cc90ea-c345-4ce5-9984-c47ad763ecf8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_b6d890a3-4bdd-4474-a8ab-582f9aaddb97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_39f6a1e7-3016-4af8-83d8-4e4068a22c1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's share of profits (losses) of related party</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_be24f6bb-8478-4cc7-ba1a-0ad0e1502c22_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8215c731-1150-4216-afae-65dccde6a3f2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_b875b74d-27a1-486c-873d-f0c0b084c0f9_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_91c068a1-09aa-49a5-bc91-60ab7c9cfbf6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2af33465-c077-4029-8d18-7c808cc70e18_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation for basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_add80fa2-dade-43bc-a837-dc5dbabfa271_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_724d52c4-2b67-4125-801a-a222bcf88e7f_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01aa247f-6cda-4016-96ab-f52629262dea_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ec5fb742-75be-4f69-bf80-9846b94372de_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_063ce297-88cf-4563-8759-cd0fdbb6bc34_terseLabel_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other gains</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_label_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Adjustment, before Tax</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_documentation_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:href="amgn-20221231.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:to="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a63c77a6-07bb-420d-adfb-eb58be411fbd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LaboratoryEquipment_1ed555a8-b1d9-4f66-8faf-6a9efeac4421_terseLabel_en-US" xlink:label="lab_amgn_LaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_amgn_LaboratoryEquipment_label_en-US" xlink:label="lab_amgn_LaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_amgn_LaboratoryEquipment_documentation_en-US" xlink:label="lab_amgn_LaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of the balance sheet date of laboratory equipment, gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment" xlink:href="amgn-20221231.xsd#amgn_LaboratoryEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LaboratoryEquipment" xlink:to="lab_amgn_LaboratoryEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2c74db73-a342-40c0-91ba-dfa963205939_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7391c09e-db6e-4bf9-936d-e6b17eabcc4e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_9d117718-4921-42ad-841a-b04798ff7b9a_terseLabel_en-US" xlink:label="lab_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development expenses</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets. Deferred Expense, Capitalized Research And Development Costs</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets. Deferred Expense, Capitalized Research And Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="amgn-20221231.xsd#amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_8f8fad65-9145-4692-ac44-a219176eb20f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_f0001501-2de8-4543-b6c0-107d2d1a1ed5_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major customers (as defined) accounting for more than 10% of total revenue</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_label_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Customers Accounting for More Than Ten Percent of Revenue</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_documentation_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major customers (as defined) accounting for more than 10% of total revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:to="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_069f0782-2566-4f28-9f1b-c97723b91099_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_7dbe5fbd-781a-419f-859a-5df84360ef65_verboseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_label_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:to="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9d949ef7-4ed5-4878-8226-5c90e5664eca_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_0c329896-ffc0-47e5-a1e0-116e493aa306_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_d8894218-7dab-4480-9fec-e362f031bbc9_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:href="amgn-20221231.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:to="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PerformanceUnitsMember_0fda892e-9a40-4a48-9e03-577aaa14d94c_verboseLabel_en-US" xlink:label="lab_amgn_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units [Member]</link:label>
    <link:label id="lab_amgn_PerformanceUnitsMember_label_en-US" xlink:label="lab_amgn_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_amgn_PerformanceUnitsMember_documentation_en-US" xlink:label="lab_amgn_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember" xlink:href="amgn-20221231.xsd#amgn_PerformanceUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PerformanceUnitsMember" xlink:to="lab_amgn_PerformanceUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d6430ee4-8409-495b-8ccf-bee221bc421f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_7359c350-21f0-42f0-b705-4004f0d9f123_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ed7e2f32-c7f2-4792-bc39-3a8ece5d3190_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software [Member]</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNGS_1e2cc770-9b69-4b62-b399-99331bf27c2f_terseLabel_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The NASDAQ Global Select Market</link:label>
    <link:label id="lab_exch_XNGS_label_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNGS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNGS" xlink:to="lab_exch_XNGS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2f37b401-295d-4db6-8e9e-702fa54d8009_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9d49587c-0c04-4779-8646-079ebf70c4bd_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_8ac2a15c-9e8c-4ad6-8868-8a5561e8be4a_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net trade receivables due from customers located outside the United States, primarily in Europe</link:label>
    <link:label id="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_label_en-US" xlink:label="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Net Amount Due from Customers Located Outside Domestic Location</link:label>
    <link:label id="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_documentation_en-US" xlink:label="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:href="amgn-20221231.xsd#amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:to="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1bc4b48b-ca3f-4012-9c3c-691ba8662531_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_2ae084f5-7557-4907-ae5a-53fb27229845_terseLabel_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_label_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-Term Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_9f9a3ac5-7cf5-403e-9052-4a751097b50d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a8e1b45-e7cb-4ea1-9aac-157791a0591e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e7d64a6f-4748-4684-be2b-572d1f54b847_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for expiration of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BridgeCreditAgreementMember_fe70b65d-59de-4034-ba7f-26d6a860e15d_terseLabel_en-US" xlink:label="lab_amgn_BridgeCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bridge credit agreement</link:label>
    <link:label id="lab_amgn_BridgeCreditAgreementMember_label_en-US" xlink:label="lab_amgn_BridgeCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bridge credit agreement [Member]</link:label>
    <link:label id="lab_amgn_BridgeCreditAgreementMember_documentation_en-US" xlink:label="lab_amgn_BridgeCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bridge credit agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementMember" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BridgeCreditAgreementMember" xlink:to="lab_amgn_BridgeCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_be18b080-d237-4db0-9323-87d91cf990a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_89753090-883d-443f-a027-56b2c9f4d583_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_88389746-8969-4034-a8f4-ac5a58c65135_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_22183ab3-743e-4924-83d1-eb095ad6ea9f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_63655747-dbb4-4d23-b432-872bbe06e098_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a5d9199e-78a7-4e91-8d02-8ca80f725549_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income for basic and diluted EPS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_6e73a3ef-444f-4495-950e-3cbe1d18060c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_dd14ecb0-0a76-4424-88f3-5e06136bc56d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate contractual maturities of long-term debt obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_dc39995e-f703-4e7d-ae7c-e9fab3698e0c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_7ac6a67e-4fc0-4203-9d21-9a37139b68c9_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e9d4c149-83bf-4431-8412-e77592b4a56f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CustomerOneMember_76b9818c-5067-417f-9f22-c46e71c585bd_terseLabel_en-US" xlink:label="lab_amgn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:label id="lab_amgn_CustomerOneMember_label_en-US" xlink:label="lab_amgn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_amgn_CustomerOneMember_documentation_en-US" xlink:label="lab_amgn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember" xlink:href="amgn-20221231.xsd#amgn_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CustomerOneMember" xlink:to="lab_amgn_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7ec0c456-3f22-4eef-b5e3-5ef6604c1b2e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_c58bdf6e-124c-4a79-ba87-481df4ed366e_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_label_en-US" xlink:label="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Combined Net Trade Receivables from Major Customers</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_documentation_en-US" xlink:label="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:href="amgn-20221231.xsd#amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:to="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_48871d71-c4e7-452e-9700-e13217ac3355_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customers (as defined) accounting for more than 10% of gross trade receivables</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_label_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Customers Accounting for More Than Ten Percent of Gross Trade Receivables</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_documentation_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customers (as defined) accounting for more than 10% of gross trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:to="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_eee38ce9-7a8f-4bbc-8451-662ae3a76b14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit settlements</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_206bc34f-aac9-42b3-839c-f7e4a65fefd3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_2859f8c5-b554-4fee-bde9-f8f44af987dd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_6d81a25d-6d59-40f2-9047-5ee68abd6f7b_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e3f48a07-a062-472c-93d2-3fb16c303e27_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_7e2d9e96-deb6-424f-b8ae-86d3f2a72008_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares by which the pool of available shares will be reduced for other types of awards granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_label_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Common Shares to be Reduced For Other Types Of Awards Granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_documentation_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the pool of available shares will be reduced for other types of awards granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:href="amgn-20221231.xsd#amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:to="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_be25be59-f8d8-4f10-a089-905ab07d385c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b9b8e4f3-8210-41b7-963f-bcdd5088443e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015_d1f13d81-e404-4c87-9210-93f4044db29f_terseLabel_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax 2013-2015</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015_label_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax 2013-2015</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015_documentation_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax 2013-2015</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:href="amgn-20221231.xsd#amgn_RepatriationTaxOnProposedAdditionalTax20132015"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:to="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_60a20f5a-a7bb-45af-bbca-5d2543496f19_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_01162117-20fa-4521-bfc0-41cb9707b7b7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecc0c368-1afb-40e3-9eb2-e638f7e57068_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_154eca84-f9ca-49ec-a664-7b2482f2c19a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a2748398-b1c5-499e-97f4-d933104533b9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_2abe976a-b7c4-4259-8040-8e9d4489f823_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_8611b9f2-19b0-44a3-bf25-1b1a979edb6d_terseLabel_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap contract [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_5372e66e-05ad-4524-81d3-505e91e3dccf_verboseLabel_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap contracts</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_label_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Swap Contracts [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_documentation_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency swap contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CrossCurrencySwapContractsMember" xlink:to="lab_amgn_CrossCurrencySwapContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a0080d81-646b-47ca-9ea5-c6d773c30af0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberofLawsuitsFiled_6c06218b-6983-4902-aff2-3340a3b833a1_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits filed</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofLawsuitsFiled_label_en-US" xlink:label="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Lawsuits Filed</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofLawsuitsFiled_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Lawsuits Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled" xlink:href="amgn-20221231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberofLawsuitsFiled" xlink:to="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_1d92e5e8-d4ff-44a0-ba15-76e187233eaa_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_226e2dcc-4720-4c5f-9c06-676a23131693_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits, Puerto Rico excise tax</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d0a939ac-d1f7-44d7-80cb-fa9e361ecebf_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_02b59661-99fc-4301-a3bb-bd8c025bc259_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_867e48aa-bba7-4993-90a6-feb1cb6261ca_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A405NotesDue20294052029NotesMember_d332db61-2f92-41b4-8a54-b33b19ed1074_terseLabel_en-US" xlink:label="lab_amgn_A405NotesDue20294052029NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.05% notes due 2029 (4.05% 2029 Notes)</link:label>
    <link:label id="lab_amgn_A405NotesDue20294052029NotesMember_label_en-US" xlink:label="lab_amgn_A405NotesDue20294052029NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.05% notes due 2029 (4.05% 2029 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A405NotesDue20294052029NotesMember_documentation_en-US" xlink:label="lab_amgn_A405NotesDue20294052029NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.05% notes due 2029 (4.05% 2029 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A405NotesDue20294052029NotesMember" xlink:href="amgn-20221231.xsd#amgn_A405NotesDue20294052029NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A405NotesDue20294052029NotesMember" xlink:to="lab_amgn_A405NotesDue20294052029NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_11758529-c8ab-4aa8-9e1b-561a54e739bd_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4927979f-6c21-4296-ba85-98f69f23d8e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_d220a956-8546-46af-b906-d16e7a67ccb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of vesting of restricted stock units and stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_66b46939-cc53-457d-aaf4-1bb68f04680f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4abfa144-0245-4645-95b0-8f6c006d1295_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_be54f5e5-ccf6-489c-8d9a-bc385c399539_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_89377ddc-13fe-40ee-a6d2-1c70a9320bfe_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of notional amounts and interest rates for cross-currency swaps</link:label>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:href="amgn-20221231.xsd#amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:to="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1fdf7b8-c36e-4291-90f4-9acf72ddbe3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_6814ea13-18f6-4eb3-85a3-f6b88d3f2caa_terseLabel_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.30% notes due 2031 (2.30% 2031 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_label_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Zero Percent Notes Due 2031 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_documentation_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Zero Percent Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:href="amgn-20221231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:to="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a6cdf0c9-b5d4-4772-beef-7e0fc00de643_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_131f1869-3c15-4009-b4ec-c21a73835207_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a133e1a8-f51a-4bd3-914a-cd5aa3a39d8e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f286b8ef-e88a-44a1-9d83-7a01d960c111_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e259fd74-4032-438f-a874-016b209fbc47_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_fd279306-630c-4519-baf6-423b9ff7cf67_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e7634541-fed8-48bf-99f7-8aea1fc60ab5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f2c217ff-b0b5-4eb6-a268-7c542252d27c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestments_d2f4242f-1a88-4ddc-9035-51684d1e8eca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestments_label_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="lab_us-gaap_OtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_3f3b102a-782c-473d-9c2c-28362a4c477b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_b24f8384-e34f-436f-9f65-3034e0de06d7_verboseLabel_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity under our stock repurchase program</link:label>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_label_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program [Table Text Block]</link:label>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_documentation_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockRepurchaseProgramTableTextBlock" xlink:href="amgn-20221231.xsd#amgn_StockRepurchaseProgramTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_StockRepurchaseProgramTableTextBlock" xlink:to="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AuditInformationAbstract_label_en-US" xlink:label="lab_amgn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_amgn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_amgn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AuditInformationAbstract" xlink:href="amgn-20221231.xsd#amgn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AuditInformationAbstract" xlink:to="lab_amgn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8c45eddd-16ee-4e67-8ee8-b5cfca7168fc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SecuredOvernightFinancingRateMember_05fbdf73-cbe7-42d8-932b-80f9841ab9dc_terseLabel_en-US" xlink:label="lab_amgn_SecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured overnight financing rate</link:label>
    <link:label id="lab_amgn_SecuredOvernightFinancingRateMember_label_en-US" xlink:label="lab_amgn_SecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured overnight financing rate [Member]</link:label>
    <link:label id="lab_amgn_SecuredOvernightFinancingRateMember_documentation_en-US" xlink:label="lab_amgn_SecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured overnight financing rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SecuredOvernightFinancingRateMember" xlink:href="amgn-20221231.xsd#amgn_SecuredOvernightFinancingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SecuredOvernightFinancingRateMember" xlink:to="lab_amgn_SecuredOvernightFinancingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_aea4bb5c-923b-407d-a5e3-f9b91626ff86_terseLabel_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term tax liabilities</link:label>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_label_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Tax Liability</link:label>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_documentation_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:href="amgn-20221231.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:to="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_07375e2a-386e-461b-be37-6ab8ce857526_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9184960c-22c3-4c4f-a1ae-2d931927ddc7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_470364da-8c0a-43b6-81c8-186e79de4896_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ac0826bd-7e72-425c-a920-6caa9f47c886_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_022acc58-da71-475d-ae4b-8bce510564b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_3697c2d2-2882-4547-a6b8-43389d410b3f_terseLabel_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration</link:label>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_label_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration</link:label>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_documentation_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration" xlink:href="amgn-20221231.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DebtExchangeAdditionalCashConsideration" xlink:to="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_2bd9a35c-eccf-4be2-8dd9-5cc289e2e8bb_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_e324f2fc-1a15-476a-bdbb-a770854cdc7e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_bcc88365-af22-4a2c-9df3-faaff1d1dd96_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_bca4ec74-b45e-494a-ae22-1ad1d6d0e2ce_netLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap agreements [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ee344e8f-406d-44aa-a904-ad66e7217afa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_aa4a8543-b97f-419e-9867-6b00fe6af0f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_00c94800-a384-46fc-9295-f39e1a12fca4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, additional authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e852018f-4126-45ba-ae41-20b8b8c64e07_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_631c5dbd-46fe-4184-a13c-4b3ae74db165_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_711a3aa0-ff82-4159-ae6c-eb4980d6cf05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in fair value hedging relationships</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_aac2d801-2943-4cce-a99d-cc5a4949c167_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_41da903a-6718-4719-9692-e692e56f3c43_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_dffd9796-4c93-4cd9-ab0e-355f53021964_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, net of interest rate and cross currency swaps</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_b130687c-be1b-4334-b2d8-865deaefbfcb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_9831fb05-1fff-4829-b3c3-59f0351decf8_verboseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_cb24fef9-11ee-4edb-bb1d-952c5afac8cb_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the pool of available shares will be reduced for each stock option granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_label_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Shares To Be Reduced For Each Stock Option Granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_documentation_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the pool of available shares will be reduced for each stock option granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:href="amgn-20221231.xsd#amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:to="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfNoticesOnProposedAdditionalTax_171a2990-6283-4cde-81fe-fd0e90f96587_terseLabel_en-US" xlink:label="lab_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of notices on proposed additional tax</link:label>
    <link:label id="lab_amgn_NumberOfNoticesOnProposedAdditionalTax_label_en-US" xlink:label="lab_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of notices on proposed additional tax</link:label>
    <link:label id="lab_amgn_NumberOfNoticesOnProposedAdditionalTax_documentation_en-US" xlink:label="lab_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of notices on proposed additional tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:href="amgn-20221231.xsd#amgn_NumberOfNoticesOnProposedAdditionalTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:to="lab_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35f71225-9b52-4848-b6e2-1f5fb30cf418_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2b52af46-4afd-42c8-914f-c4e0acf71d49_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_defc319d-f88a-4e3c-bb7c-133ab8059c82_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_f00aca28-425d-4f10-88c6-59f4289102e2_terseLabel_en-US" xlink:label="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks</link:label>
    <link:label id="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_label_en-US" xlink:label="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks</link:label>
    <link:label id="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_documentation_en-US" xlink:label="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:href="amgn-20221231.xsd#amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:to="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_0ec0598a-21fa-4ee1-8423-f8476616d49c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of amounts of income and expense line items</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_905c5708-0ab5-4669-a4b8-61d4463a4182_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5550c4f9-f704-48ba-95f5-e80480da1729_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_051d23cf-e769-45e0-b5e0-f49fd7db6f10_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_c421af2a-d06d-4a34-8ba9-60c01a86d45b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_ba0cad82-eff7-4fb4-9d79-d6e13ec2f6cd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Financial Support to Investee Contractually Required, Amount</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Financial Support to Investee Contractually Required, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:to="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ExpirationInTaxYearsBetween2023And2043Member_58e67956-20b6-40db-9eda-7ef7915f8c10_terseLabel_en-US" xlink:label="lab_amgn_ExpirationInTaxYearsBetween2023And2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in tax years between 2023 and 2043</link:label>
    <link:label id="lab_amgn_ExpirationInTaxYearsBetween2023And2043Member_label_en-US" xlink:label="lab_amgn_ExpirationInTaxYearsBetween2023And2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in tax years between 2023 and 2043 [Member]</link:label>
    <link:label id="lab_amgn_ExpirationInTaxYearsBetween2023And2043Member_documentation_en-US" xlink:label="lab_amgn_ExpirationInTaxYearsBetween2023And2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in tax years between 2023 and 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ExpirationInTaxYearsBetween2023And2043Member" xlink:href="amgn-20221231.xsd#amgn_ExpirationInTaxYearsBetween2023And2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ExpirationInTaxYearsBetween2023And2043Member" xlink:to="lab_amgn_ExpirationInTaxYearsBetween2023And2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f8b6d9a2-acf6-4d63-b231-ef231d8dcb4e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_b229c277-ec0a-4281-b330-accf53fad622_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_1aa1623b-8d8b-4518-9320-d32e1af8051e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_73948dd9-9d6d-40f4-a278-255a26459b40_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2a79ea93-1e86-4b3d-a99b-7678ddc39a11_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash&#160;flow hedges [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries_5f71d871-df58-4609-b91a-3906381a4745_terseLabel_en-US" xlink:label="lab_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset, earnings of foreign subsidiaries</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset, earnings of foreign subsidiaries</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries_documentation_en-US" xlink:label="lab_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset, earnings of foreign subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries" xlink:href="amgn-20221231.xsd#amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries" xlink:to="lab_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_001a055a-cff1-4b34-adf3-c045ca9a503c_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:to="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_ef931f1a-d91f-4fc2-ba92-f275fc1891f1_terseLabel_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.10% notes due 2021 (4.10% 2021 Notes)</link:label>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_label_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Notes Due 2021 [Member]</link:label>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_documentation_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Notes Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:href="amgn-20221231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:to="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3f1a8a46-ec6a-4382-8c16-8edf4777100e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_35090b35-ace9-4278-bab4-6d079b720318_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_58a8d22e-78e0-48eb-acda-ff457309be50_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_e9996173-028f-48a0-8494-8ede7861864d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Investments Acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Investments Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapTwoMember_4aead758-2cba-48cd-8acc-b9834aa5100e_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Two [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapTwoMember_label_en-US" xlink:label="lab_amgn_InterestRateSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Two [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapTwoMember_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapTwoMember" xlink:to="lab_amgn_InterestRateSwapTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_ce413e0b-b6c3-49b0-b0b9-f9b54c1d51c5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards available to reduce income taxes</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_290f2116-19c3-42eb-901f-9b9daaabded6_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.65% notes due 2022 (2.65% 2022 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_label_en-US" xlink:label="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Percent Notes Due Two Zero Two Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:href="amgn-20221231.xsd#amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:to="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1b5cf4a3-2d3f-41a6-9480-c81396c66ea8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AssetsByDescriptionDomain_ca1e352e-c067-4bfc-9f6a-0c675fd9daab_terseLabel_en-US" xlink:label="lab_amgn_AssetsByDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Domain]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionDomain_label_en-US" xlink:label="lab_amgn_AssetsByDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Domain]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionDomain_documentation_en-US" xlink:label="lab_amgn_AssetsByDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain" xlink:href="amgn-20221231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AssetsByDescriptionDomain" xlink:to="lab_amgn_AssetsByDescriptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_5dec99b2-157d-4c80-b1e5-7ab6af7fc431_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_03176d5b-e01d-47a4-b771-9152ae74b94c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_00f608dd-d177-4cd5-b755-84f0d76e7c90_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_91e47f7e-2bc3-439d-98f7-a99364b30657_terseLabel_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_documentation_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:href="amgn-20221231.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:to="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_59c62ac7-c5d1-4fdf-ac9e-54a9ef3fa1dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_525fd8cf-4823-4223-ae63-c66fc9a100d7_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_67f3e5a1-c912-4878-9e51-ed48bf857dc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of reclassification adjustments and taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_4498b5a3-e069-4990-957d-ca93177cbe07_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR [Member]</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_a7f9074d-8e9c-454c-8c37-e10ddb299427_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_121426c2-fcfe-47aa-8574-f21e6e199ea3_verboseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FixedEquipmentMember_a0a55dec-60dc-4992-ba37-3d05f379f8a8_verboseLabel_en-US" xlink:label="lab_amgn_FixedEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment [Member]</link:label>
    <link:label id="lab_amgn_FixedEquipmentMember_label_en-US" xlink:label="lab_amgn_FixedEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment [Member]</link:label>
    <link:label id="lab_amgn_FixedEquipmentMember_documentation_en-US" xlink:label="lab_amgn_FixedEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipmentMember" xlink:href="amgn-20221231.xsd#amgn_FixedEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FixedEquipmentMember" xlink:to="lab_amgn_FixedEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_53017b14-e6f9-4fb8-87fb-62851cd9bb31_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_c3881891-ec6e-45ad-8f27-c70afcd0a551_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4a9daae7-8b4d-463f-b746-514286a2cc42_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_40861deb-5853-4564-9904-e1e3ddf59ff5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization charges associated with finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_b041c386-4d38-45f0-8a4e-56c602140bc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3b885928-064d-4831-8cb1-ac1882b903a8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyNumberOfPrimaryArguments_9ebb086a-e196-4117-8857-23825726f303_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyNumberOfPrimaryArguments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Primary Arguments</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfPrimaryArguments_label_en-US" xlink:label="lab_amgn_LossContingencyNumberOfPrimaryArguments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Primary Arguments</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfPrimaryArguments_documentation_en-US" xlink:label="lab_amgn_LossContingencyNumberOfPrimaryArguments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Primary Arguments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfPrimaryArguments" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfPrimaryArguments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyNumberOfPrimaryArguments" xlink:to="lab_amgn_LossContingencyNumberOfPrimaryArguments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_f2d90ab7-f4a4-4773-9b73-7298dc31f99f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0cd06ad2-e9c7-4ab1-95ab-99df4774869b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_53236409-8087-46f9-8c90-d6acc0d2fff9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9c46823a-e15d-4285-937b-79eeca678c47_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6e862588-d317-47d5-92da-6e2c82d94973_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_9d9350b3-2af1-4e90-9d0a-32c39f966461_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_9b61041c-e262-4bd0-9ee8-415e4dc429c0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards available to reduce income taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d7930854-4af3-4ba9-8bcc-55fe516a7c4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa53dd30-5217-42f2-908c-acb1d92a959b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_7b3c6b08-a7ee-44a8-a0e3-970d62ae74d4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5bcedfa2-32e6-41a9-8073-d76dc8496c1b_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm_3dd929e2-b07a-44e6-8fb0-622ddc07e0cc_terseLabel_en-US" xlink:label="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial commitment term of each bank which is a party to the agreement</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm_label_en-US" xlink:label="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Initial Commitment Term</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm_documentation_en-US" xlink:label="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Initial Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:href="amgn-20221231.xsd#amgn_LineOfCreditFacilityInitialCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:to="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1e7d800a-1584-4dd0-9b93-5f03d8446b33_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_2dae580a-b1c6-4344-976d-38b30358e69f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Numerator):</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_53fcddc1-88c4-4965-a76f-a53b1a1807ad_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Length of time hedged in foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_67107f84-a238-488a-9974-74ce2c85d40d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ec825467-77d8-432e-9a6c-78e9bff29976_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8e7a8883-f3e9-43d1-a6ef-70617a221799_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_0c54b560-1147-4a64-a378-dc1d5fbe7fd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_a06a39bf-5845-429e-acb4-2a263d2af0cc_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EnbrelMember_0efd6f0b-f338-41e3-88a5-10c3449c6ac0_terseLabel_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel&#174; (etanercept) [Member]</link:label>
    <link:label id="lab_amgn_EnbrelMember_label_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ENBREL [Member]</link:label>
    <link:label id="lab_amgn_EnbrelMember_documentation_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ENBREL.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember" xlink:href="amgn-20221231.xsd#amgn_EnbrelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EnbrelMember" xlink:to="lab_amgn_EnbrelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_01f838cf-1094-42ce-9cba-fbce0f7451b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_6216e0db-6068-4398-a8b1-d11cb4a1ed1a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_83f1c1fe-2b03-4b3e-8bb1-a84f83126fb6_terseLabel_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.15% notes due 2041 (5.15% 2041 Notes)</link:label>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_label_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Five Percent Notes Due 2041 [Member]</link:label>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Five Percent Notes Due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:href="amgn-20221231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:to="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8d15d379-69d0-4e14-8f54-52171cd49522_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary information, components of lease costs, cash and noncash information on leases and other lease information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_04a34515-3245-48d6-9a2c-6de2f19b2bee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ebbe73ee-f88e-4abb-96c4-1011be1e52a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_039c4212-0a2b-4a4a-8d4b-547d10b17aba_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_587f82f2-6a9b-4295-8888-209a4c2bbc47_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0f6e7470-8554-4faf-9938-987f6c68706d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate on note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ce04d5de-5b0c-4ef4-b1f4-b98c0bbb23bf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FloatingRateNotesDue2020Member_d660357e-6763-4a94-ba61-d749682af04c_terseLabel_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2020</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2020Member_label_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member" xlink:href="amgn-20221231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FloatingRateNotesDue2020Member" xlink:to="lab_amgn_FloatingRateNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7e497c15-3cbc-4203-9e0a-58dc5781f28e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedSalesDeductionsCurrent_d45e05e1-8785-4e65-ab61-ae1659f23be8_terseLabel_en-US" xlink:label="lab_amgn_AccruedSalesDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales deductions</link:label>
    <link:label id="lab_amgn_AccruedSalesDeductionsCurrent_label_en-US" xlink:label="lab_amgn_AccruedSalesDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Deductions Current</link:label>
    <link:label id="lab_amgn_AccruedSalesDeductionsCurrent_documentation_en-US" xlink:label="lab_amgn_AccruedSalesDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesDeductionsCurrent" xlink:href="amgn-20221231.xsd#amgn_AccruedSalesDeductionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedSalesDeductionsCurrent" xlink:to="lab_amgn_AccruedSalesDeductionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_65f5ef48-318a-4bbe-9acd-481ac890f20b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense attributed to Retirement and Savings Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_11aa07dd-6fbb-4d79-8e73-776794e5a464_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_bf06140f-7a00-45fb-aa7f-04423c1adb44_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d890550d-a27b-4d6c-8e8a-bc2601f1f95f_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_44892e95-4b27-44f9-bb23-710cc21dd3fd_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_29e4c7a0-f004-4b2e-b17c-c116c3dbaab2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_5791ff9e-e3e8-4a75-8355-2ed5c9e0e6f9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_032aeec5-59be-4bfd-9c18-5041ee02d5a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_9faaed0f-240d-4e1e-a695-7f2dbdd77070_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DevelopmentPrograms_f7d88803-384a-4ea9-a09c-0e3bdfa5ed53_terseLabel_en-US" xlink:label="lab_amgn_DevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development programs</link:label>
    <link:label id="lab_amgn_DevelopmentPrograms_label_en-US" xlink:label="lab_amgn_DevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development programs</link:label>
    <link:label id="lab_amgn_DevelopmentPrograms_documentation_en-US" xlink:label="lab_amgn_DevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DevelopmentPrograms" xlink:href="amgn-20221231.xsd#amgn_DevelopmentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DevelopmentPrograms" xlink:to="lab_amgn_DevelopmentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract_f8c7facc-0789-4f28-ac7a-392f100b6621_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_946ee832-34a6-4ba6-ad07-fd0c568e3e0c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_4402dae3-bf62-44f0-a586-5380130f1967_terseLabel_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.20% notes due 2027 (3.20% 2027 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_label_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Two Zero Notes Due 2027 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_documentation_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Two Zero Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:href="amgn-20221231.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:to="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BeiGeneMember_6b5c8769-deeb-4b6e-90ca-d5f1cb7ef96f_terseLabel_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene</link:label>
    <link:label id="lab_amgn_BeiGeneMember_label_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene [Member]</link:label>
    <link:label id="lab_amgn_BeiGeneMember_documentation_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BeiGeneMember" xlink:to="lab_amgn_BeiGeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f14fa5ab-7c1f-4d7f-bda1-0755d9b7127b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3c005c01-73f5-4431-939b-c330ae2ced29_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d8c5abb-3043-4810-8098-d11168304189_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_124458f7-74b3-409e-9235-8d86cfe1d6bc_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_e5c4845d-1b88-4bee-ae80-b148c17574fd_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_01544609-0a25-4fd2-bbe8-700dc8f8565d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6045f1be-1ee4-459c-a507-e44535d720eb_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amounts</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_d4ef150c-b055-4df5-b1c7-6338cccef647_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ca9c4c07-4d85-43c1-9a3f-b3390cc01db8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in valuations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7be56d1d-4332-4393-b2fe-f59b41d8f48b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4ea91cf3-dcad-43c9-91ee-124f7834e40a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_0ed91b21-b073-403a-9e6b-a3cdfc9abda7_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_892c7462-72b8-4d05-967d-a2bfcc5f75b8_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2027 (2.20% 2027 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:to="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_6da54e79-2b2e-4f40-89cd-a5054fecbebf_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1b30b100-3f28-4c76-909a-c696dce70506_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d817a1e6-f948-4fc4-9f89-520204d47602_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_6f8cca57-2755-4290-a307-6435e150a0c4_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_20bd6632-2be2-44e7-a77c-83702aa95b5f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_9bfdd36d-d587-4aa6-b48f-fef94641b5d6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4bad692a-b456-4ee5-9a73-9ab410a0357a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_a873ecbb-2e70-4828-8660-2bb484666e32_negatedLabel_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets Accumulated Amortization</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_documentation_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets accumulated amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:href="amgn-20221231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:to="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2a440703-e002-4300-b098-dd6c59e08f2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7834846e-60eb-49fa-8cd0-f7571c39da51_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2b72db94-b4b2-445a-a16e-2c449ea9d6a5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5722cb3f-5c80-4186-8244-b1d7751aa5f3_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_35131a18-ad9a-4197-91b4-0d7931ee5d21_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NeulastaMember_82a36992-0c8d-4441-96fa-391740b6ef3a_terseLabel_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta&#174; (pegfilgrastim) [Member]</link:label>
    <link:label id="lab_amgn_NeulastaMember_label_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta [Member]</link:label>
    <link:label id="lab_amgn_NeulastaMember_documentation_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember" xlink:href="amgn-20221231.xsd#amgn_NeulastaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NeulastaMember" xlink:to="lab_amgn_NeulastaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_19598d31-383e-459f-93ba-4757a12dc0d3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_c6364a2b-5c08-4758-9113-69453cb5e1dc_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchases, Shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b0fa9542-7820-4580-be54-809d00845681_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapDomain_71a72ecf-dcd0-43ed-9fc7-6ec09567c887_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Domain]</link:label>
    <link:label id="lab_amgn_InterestRateSwapDomain_label_en-US" xlink:label="lab_amgn_InterestRateSwapDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Domain]</link:label>
    <link:label id="lab_amgn_InterestRateSwapDomain_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapDomain" xlink:to="lab_amgn_InterestRateSwapDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29e6f3d2-c750-4a61-b662-c767eace62ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_424ddea5-389b-4b20-9d77-7238d9cdba6f_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23217b37-7946-4ad8-a191-27effb463521_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_de59957c-57e7-4af7-9c9d-9811f801f31b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_068b69b9-e043-471a-9e47-769ccb6f6feb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_696e3f49-92fd-46a4-970b-01a5f72e268a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_66b92038-2e0a-4148-b077-dc1c1c125dbb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_1e8c9bf8-6a59-4d9d-ae0c-94bf8628fb3a_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing rights</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_95b5d965-996e-49af-995c-f653cb2c765d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9f0b0733-6a93-4145-b8d7-80b2ad046355_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised during the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_c2324a4e-d132-4e98-bf3c-260abca026d8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a6cd33cc-fdc9-49e5-b691-5991c121bf9c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aaf69417-cf5a-481b-a4a0-0c83bcced5a3_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for diluted EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_39c8a8e4-730e-4e9e-8428-dc811234d710_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7576d496-36f9-45a8-bd94-bd6d095d0efe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_5724430e-4f69-4a42-a26c-6e28287094b9_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc0662-7a39-4679-8a09-2696b9058643_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_b0f0a9d5-0b56-4b77-ad78-58abca9e18a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends paid per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e0b73aa9-c89d-4ad4-ab2e-007ddd3af0d6_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_2e0ee480-acd3-448d-9159-17071cd46d2e_terseLabel_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% notes due 2020 (2.125% 2020 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_label_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_documentation_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:href="amgn-20221231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:to="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_85691010-c928-4afc-90d5-1c74bc198cab_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b81a9dcc-2753-4a25-92a3-149baa4be511_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e5d4afe3-591c-493e-b933-1e6fd1572af6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of unit (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a97e605d-fbb7-4c3e-af75-586aa1ed1a8f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_28d78c45-0f1b-4886-bd19-9c45d08439e8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b3955d7e-8a54-45ef-9eb3-416fe3a2e149_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6f57da56-3d1b-4e0e-9cba-6c35a1e00a7e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_1e419df4-57b6-4e39-9ffa-12dd4f900299_terseLabel_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_498c5f15-6008-41a7-8ebb-6d7379b7f069_totalLabel_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_label_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_documentation_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred" xlink:href="amgn-20221231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred" xlink:to="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_64c5b56d-880d-430d-a039-c53bcf81b5a4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6e573cac-28a3-496d-8aa3-888db9035e10_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_95b8dc96-b9b9-4a40-a3a3-ad0b5dc649f5_terseLabel_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on uncertain tax positions</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_label_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_documentation_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:href="amgn-20221231.xsd#amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:to="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_78ad7820-26f5-4797-b718-3c1cd685787b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate carrying value of the company's equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_257645e4-868b-4abf-96d2-27efe407f4f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in&#160;capital</link:label>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_194cd6ea-8fd3-4967-92be-fabf9e201205_terseLabel_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% notes due 2043 (5.375% 2043 Notes)</link:label>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_label_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Seven Five Percent Notes Due 2043 [Member]</link:label>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_documentation_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Seven Five Percent Notes Due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:href="amgn-20221231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:to="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_aa2bde9c-fda1-4ada-b127-41f20f061458_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Found Not Infringed upon, Number</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Found Not Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_0f30ba7a-a60c-4c2b-aaf7-a70255b6863e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_7d515ca5-f274-4fa4-9b2a-d07ad11795a0_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedge [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_615b5de7-f34c-4fef-ad58-b65defca05cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_93f93a6b-168a-4cfc-9acf-3a8092a11db5_terseLabel_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_8dd3fd4b-c0fe-4c48-a009-8c7338ea44eb_verboseLabel_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% 2029 pound sterling Notes [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_label_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Percent Pound Sterling Notes Due 2029 [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_documentation_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Percent Pound Sterling Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:href="amgn-20221231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:to="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_4040642c-b475-448d-8d57-b20a946cb066_terseLabel_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125% notes due 2025 (3.125% 2025 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_label_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_documentation_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:to="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a14298c-c315-4e0a-bf82-60a8d97a051d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_940d4217-595a-4ad5-8457-be34eb4f7c7a_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, net</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_51c42529-ff04-40d1-93c1-843967767a7d_verboseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, net</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_label_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:to="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_80315bcb-053c-463e-89b2-2353095ab0e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b9e1dbab-93ac-49e1-a506-30e430ca7040_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of notes issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_ca65104c-cf33-4dec-a5c9-e9fa597e3520_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_a98fb837-6b9c-4014-bec5-2780e8a39be6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_d7284206-d783-4f53-93ab-6ecfb7d116f6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-bearing securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_85528f52-b576-44c7-ab8b-4c8620bbd30a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_2576b74f-564a-4a83-96a3-be5e8160dc31_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_UpFrontPayment_51812c90-5ff8-40e5-b895-c5bd49c5521d_terseLabel_en-US" xlink:label="lab_amgn_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment</link:label>
    <link:label id="lab_amgn_UpFrontPayment_label_en-US" xlink:label="lab_amgn_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment</link:label>
    <link:label id="lab_amgn_UpFrontPayment_documentation_en-US" xlink:label="lab_amgn_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_UpFrontPayment" xlink:href="amgn-20221231.xsd#amgn_UpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_UpFrontPayment" xlink:to="lab_amgn_UpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_6cc24c67-b4ef-48cd-a2dc-38d8801435f0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on divestiture</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_be4b5259-c2e9-4ef8-8db5-810b834775fa_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_ffc78a54-c478-4ba7-ab9a-2dc479ccfd7c_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_6f9b7991-e16e-4360-a5ca-f6da3e98a569_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOLs with no valuation allowance and no expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_984658a6-6edb-4151-9221-5ad9498f2419_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2020 (2.20% 2020 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:to="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_09cedd87-9f0d-4b19-8dd7-ae316601fcea_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuitsFiled_e9b169e6-8499-4339-8fc3-f510552863c9_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of lawsuits filed</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuitsFiled_label_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Lawsuits Filed</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuitsFiled_documentation_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Lawsuits Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfLawsuitsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:to="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d327ec91-d2bb-4754-8a0e-aea094bd57ae_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions charged&#160;to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A300NotesDue20523002052NotesMember_285c8638-808a-453b-838f-45c2fd9680f9_terseLabel_en-US" xlink:label="lab_amgn_A300NotesDue20523002052NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2052 (3.00% 2052 Notes)</link:label>
    <link:label id="lab_amgn_A300NotesDue20523002052NotesMember_label_en-US" xlink:label="lab_amgn_A300NotesDue20523002052NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2052 (3.00% 2052 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A300NotesDue20523002052NotesMember_documentation_en-US" xlink:label="lab_amgn_A300NotesDue20523002052NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2052 (3.00% 2052 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A300NotesDue20523002052NotesMember" xlink:to="lab_amgn_A300NotesDue20523002052NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_bf8c9444-c607-4654-a12f-5a17edc04316_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cross-Currency Swaps [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_58c6cb37-eb9f-4665-8689-d51aa01ad89e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e995744a-6100-43dc-9f19-2273b357b3da_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_07f07caa-f301-44e3-bc30-00933e6dadc3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_e5fdb0ee-cfc4-4de1-97c8-fe0f6e345ce2_verboseLabel_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;current&#160;assets/ Other noncurrent assets</link:label>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_label_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Noncurrent Assets [Member]</link:label>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_documentation_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets/other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember" xlink:href="amgn-20221231.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherCurrentNoncurrentAssetsMember" xlink:to="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e7c27591-5539-4a4e-a558-1366538a5371_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6895a506-6caa-4cbe-980a-5fecb5e2a033_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7d5a3db7-095c-457e-857b-b13aff594a7a_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_b13c0dfa-cb3a-42d3-8edd-08bd6e219c7c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_844f376b-039c-438f-b476-14357d4b9f56_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_013162a5-f89b-487e-bb08-105bcd0e82d6_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_0669fee0-282d-482e-8aee-9eb0e84b43cc_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsPurchasedMember_e4729843-d6c0-4ea5-8a1a-4a1c7480d628_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Purchased</link:label>
    <link:label id="lab_us-gaap_FederalFundsPurchasedMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Purchased [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsPurchasedMember" xlink:to="lab_us-gaap_FederalFundsPurchasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BridgeCreditReducedAmount_7c3f6656-19fe-4e72-afe1-e60a663c447c_terseLabel_en-US" xlink:label="lab_amgn_BridgeCreditReducedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit reduced amount</link:label>
    <link:label id="lab_amgn_BridgeCreditReducedAmount_label_en-US" xlink:label="lab_amgn_BridgeCreditReducedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit, reduced amount</link:label>
    <link:label id="lab_amgn_BridgeCreditReducedAmount_documentation_en-US" xlink:label="lab_amgn_BridgeCreditReducedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge credit agreement, reduced amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditReducedAmount" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditReducedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BridgeCreditReducedAmount" xlink:to="lab_amgn_BridgeCreditReducedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_765c526b-a780-4443-b6d1-de1c6313663e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional consideration due contingent on certain milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_660c7fe0-5f47-463b-bbe6-c68d39b72e97_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_2f5a54de-443b-41c0-8782-0f19fde358d9_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable [Member]</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_a23edef1-947d-43c8-9a7d-ee796e3c4586_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% notes due 2023 (2.25% 2023 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_label_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Percent Notes Due Two Zero Two Three [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Percent Notes Due Two Zero Two Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:to="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c9d82c00-6650-4d34-9d10-2fecfa5ace38_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_5ee9203b-a8bd-4097-9e5b-bdfedf4ffc65_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4375231f-05fd-4c98-8d47-0c3f3ac3ee6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c2d2cbfc-7ed5-4cd3-9dee-ef4670f098ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_ff61c28a-25ca-4533-8919-ab0838c2291c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_508a7fb2-31a0-47cc-bcf7-e17712c27446_terseLabel_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions</link:label>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_label_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions [Member]</link:label>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_documentation_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember" xlink:href="amgn-20221231.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SensiparAntitrustClassActionsMember" xlink:to="lab_amgn_SensiparAntitrustClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_99001de3-cccb-451e-80bb-df85baddf95d_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs [Member]</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_28e5be26-46ab-4f96-b0d3-e1c65263dd78_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards, valuation allowance</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:to="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0bf36242-be9b-4960-aa0c-8f1abde0e5fc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_a53dd178-5885-42da-a295-fcb592f12f85_terseLabel_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_label_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_documentation_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss" xlink:href="amgn-20221231.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AlternativeInvestmentNetGainLoss" xlink:to="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f519818a-20e0-4399-b70c-e262fc7ee8b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_867b52a3-2ea0-43e3-a3a1-bfecc1322fe3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PR_ffa8917d-a400-4645-ad07-99ed817f2318_verboseLabel_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Puerto Rico [Member]</link:label>
    <link:label id="lab_country_PR_label_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PUERTO RICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PR" xlink:to="lab_country_PR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_03680718-b896-42d9-a92c-f61d607aa7b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ae51450b-fcb4-4b61-8325-e231200cab9e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_fb47b841-5a5d-462a-a026-28b7ebaa0785_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationRollForward_9aa7be3f-e8fa-43a3-89c9-71c14e8036f8_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration [Roll Forward]</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationRollForward_label_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration [Roll Forward]</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationRollForward_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationContingentConsiderationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:to="lab_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_cac9074f-a9be-4fb6-8324-fcdb1d7cc357_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_48d0d847-0e47-44c1-bdf6-a1c45bcf67e4_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b2289a3e-cbbe-49d6-a69e-23cba69e8f15_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_80dcf234-d48b-46b4-9676-037a4981d290_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7e48b600-2416-487c-a792-582dd7963426_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_c56e30b1-b4b2-4e45-9cf2-12f041cf96a2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual tax benefits realized from tax deductions from option exercises</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_423e6ce6-c882-407a-85c3-f2f3e1c7e3ea_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to nonvested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ea517d33-c8d2-4ff0-9b1e-4c06bebeaef8_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_92c5d272-2321-4229-8999-5c3658381cc3_terseLabel_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</link:label>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_label_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</link:label>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_documentation_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:href="amgn-20221231.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:to="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a1b2f37-f6e1-4f7d-9383-de3807c7882a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_69751c50-4445-4462-80d0-134354c590bb_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues earned from major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_15c991ec-ab30-4580-a938-4e38cda9fee1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_6716786b-ca93-46b2-bd21-87c413673081_terseLabel_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.563% notes due 2048 (4.563% 2048 Notes)</link:label>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_label_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_documentation_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:href="amgn-20221231.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:to="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_71fe307c-7f25-4475-b195-d8116244b1e7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a0c6b378-8fd4-4904-957b-89729c80afff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, unexercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b7a73b1c-136f-4617-ab93-de98c3490d69_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_f27e4b28-41ee-49df-8612-58be9a70b4ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6c13a554-738b-4363-a2cf-5591b4a63bfc_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_c9aeb500-df20-4645-abee-b582ed1f3518_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9dce74ae-08f7-4297-b40b-62c9f2fd0c2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_5ab5ba70-be24-4379-a293-5af1963a81f4_terseLabel_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2030 (2.45% 2030 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_label_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Four Five Percent Notes Due 2030 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_documentation_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Four Five Percent Notes Due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:href="amgn-20221231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:to="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_db813655-fb10-4bd7-9cd7-e585f4dd3f7e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_290c2aff-ca28-43da-a08d-bd44a772adcb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_ace12c5c-5334-4e6c-916b-3fc8f30dc26e_terseLabel_en-US" xlink:label="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of common stock available under the plan for future grants and/or issuances (in shares)</link:label>
    <link:label id="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_label_en-US" xlink:label="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Common Stock Available Under Plan For Future Grants And Or Issuances</link:label>
    <link:label id="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_documentation_en-US" xlink:label="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of common stock available under the plan for future grants and/or issuances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:href="amgn-20221231.xsd#amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:to="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5c89dd12-9c4f-4668-95d0-6994f822e76a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_be01db6c-3155-45cf-a79e-9c14a85ee1c0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_bd7f3ebb-05ee-4e73-8381-bd005f3172af_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_4d493135-f652-46a9-b337-eb121e044060_terseLabel_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% notes due 2040 (5.75% 2040 Notes)</link:label>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_label_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Notes Due 2040 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_documentation_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Notes Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:href="amgn-20221231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:to="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4e1d923c-b3ed-4436-832f-fb85832e9b17_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_5071eefe-55e5-43d7-9dfa-09d9dd4574f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_1cd88035-c78f-4c1a-b1fd-ce3f1d1518f2_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_20a4ff6b-96d0-4eb8-928e-5a2531056548_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KyprolisMember_7a2d62d0-ebd4-403d-9666-ab60635661eb_terseLabel_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:label id="lab_amgn_KyprolisMember_label_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:label id="lab_amgn_KyprolisMember_documentation_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember" xlink:href="amgn-20221231.xsd#amgn_KyprolisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KyprolisMember" xlink:to="lab_amgn_KyprolisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cecc5334-c201-42fe-9650-1647b093130d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6535bfa1-1865-470a-8e4a-e0f4e3473407_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e37235ae-66a4-452c-b990-b26dce1782d5_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected total future rental income to be received</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_8c10dc0d-7b7e-49da-baa1-b0fec57631e5_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Stock Exchange</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8fa01d85-a4de-42dd-88ed-8cbbefd0be6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d211873c-781c-4c98-9b30-e45daa8fa344_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_1107a817-5b56-429e-9343-a1fedf097882_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_f9f87494-d677-4981-b7f6-5e7ff4e468be_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_5be67fe4-329c-4fad-996e-9cabf59361ef_terseLabel_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption period without payment of make whole amount</link:label>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_label_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period without Payment of Make Whole Amount</link:label>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_documentation_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period without Payment of Make Whole Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:href="amgn-20221231.xsd#amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:to="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ff8d33f6-a9f4-468c-b49b-cd5a8be94c47_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c7f7bd5b-d02e-4dba-b87a-dd0f92878396_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_366684ca-de15-495f-bce5-84cce741c715_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_c6f3e4bd-bada-4b82-8e5f-eb5ee64ce550_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_748f2396-b6a8-4cc7-8fcc-99a3192f5251_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_951271ba-0097-4bea-bd9d-3f553c6087dd_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_f4eacf9d-f2d1-4eb9-94d9-611dc72aa6e8_terseLabel_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% notes due 2024 (3.625% 2024 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_label_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2024 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_documentation_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:to="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_662f8959-c5c8-452b-8fe7-3a98bfdf97c5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_3df3f539-a02b-49fa-bc14-804b780834bd_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US</link:label>
    <link:label id="lab_country_US_de2f9797-e548-4ae3-92b0-f8cfa18dfb27_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_882d95d9-c3cc-4da4-9398-b83c10f5ba36_terseLabel_en-US" xlink:label="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of stock-based compensation expense recognized in the Consolidated Statements of Income</link:label>
    <link:label id="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_label_en-US" xlink:label="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Stock based Compensation Expense [Table Text Block]</link:label>
    <link:label id="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:href="amgn-20221231.xsd#amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:to="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_45ebcb5a-ebfc-4b35-89da-ed8f155ab323_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestment_2bdd696e-45c8-46b8-9081-cd18ec4f49af_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestment_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestment" xlink:to="lab_us-gaap_AlternativeInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0f3b1890-e80b-45b4-8e0d-a48ba8d8c9bf_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c14d7924-8409-44a0-90d8-ce939486a3e5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ba9c62db-1418-4731-96ac-08725347dfac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0aa444f4-9a2f-4947-af65-6c705b03e2ce_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_82f5fa9c-1f48-4db4-8904-149230bd896b_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of amortization</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_027b86ca-c333-4ab2-bd49-92fcb1a815da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CustomerThreeMember_8546c43a-5c81-4422-8782-4d4d9982ae99_terseLabel_en-US" xlink:label="lab_amgn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_amgn_CustomerThreeMember_label_en-US" xlink:label="lab_amgn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_amgn_CustomerThreeMember_documentation_en-US" xlink:label="lab_amgn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember" xlink:href="amgn-20221231.xsd#amgn_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CustomerThreeMember" xlink:to="lab_amgn_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a5d1b4d9-22ff-4f90-813e-c8ec6a870c93_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_592cd1c4-e28a-4ab4-bc34-448c97428d17_terseLabel_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% notes due 2022 (1.25% 2022 Notes)</link:label>
    <link:label id="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_label_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_documentation_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Notes Due Two Zero Two Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:href="amgn-20221231.xsd#amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:to="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e5228b76-974d-4279-b4d5-9e9c96fb8025_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_142d5543-2e31-4b59-b88d-1e336547673b_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_e84415a5-f710-4294-9633-0ba491b0a7a4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_da39664a-c173-4d5a-9995-ab674b157be8_terseLabel_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_label_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Adjustment Attributable to Parent [Member]</link:label>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_documentation_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:href="amgn-20221231.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:to="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_ad8dd67e-4817-4e7c-b111-2eb2127656c7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_3ebca34b-ccdf-4d1e-bc00-dd4617ed0e03_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties due</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_f11bb448-d001-4903-8f9c-73f65cbf7c82_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ec8ad81e-9a8b-40e4-891a-8527db3d3cce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_50a55559-cf84-4707-838f-ccfbabe71e5e_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_89981a20-c38c-46e2-a52c-b973f6ff4677_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_9bd94667-a129-4351-a0d8-512a0c2cf2d9_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ca7c11e5-763c-452e-ae2a-ff14237571f4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_96ad4839-ac46-4268-8543-8c797cbc8d0e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for stock repurchases under a board approved stock repurchase plan</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_90267743-b359-4079-939d-0751017ef3a0_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_50bcacb2-8f97-400e-bf81-1d1258cacebc_verboseLabel_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives:</link:label>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_documentation_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments liabilities fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:href="amgn-20221231.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:to="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_d353a516-7832-4509-8a73-632ac5a1d6ef_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROW [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_bdd0a499-3760-405c-9546-5ff67d58ce4c_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_fc57c2e7-aeb7-4db6-84be-f7139539fdb3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d5a0f3e4-6fe7-4838-8786-cfa84fd8f110_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of income before income tax, domestic and foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f216d732-5f5c-41e5-8d45-36e06f89cddd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties associated with unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b4064ce8-00cd-49d0-8997-ab4f46e8d58d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_27d5c95e-01f1-4f17-ad4d-ce28c49ffacd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6e8b062b-3ee1-4d7c-9f0f-9332527e0081_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ChemoCentryxIncMember_3cb3dc44-37e2-4c91-970b-6435ab47c033_terseLabel_en-US" xlink:label="lab_amgn_ChemoCentryxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChemoCentryx, Inc.</link:label>
    <link:label id="lab_amgn_ChemoCentryxIncMember_label_en-US" xlink:label="lab_amgn_ChemoCentryxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChemoCentryx, Inc. [Member]</link:label>
    <link:label id="lab_amgn_ChemoCentryxIncMember_documentation_en-US" xlink:label="lab_amgn_ChemoCentryxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ChemoCentryx, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ChemoCentryxIncMember" xlink:href="amgn-20221231.xsd#amgn_ChemoCentryxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ChemoCentryxIncMember" xlink:to="lab_amgn_ChemoCentryxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A165NotesDue20281652028NotesMember_0ae911bf-534f-4579-953b-a4c3efdb000d_terseLabel_en-US" xlink:label="lab_amgn_A165NotesDue20281652028NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% notes due in 2028 (1.65% 2028 Notes)</link:label>
    <link:label id="lab_amgn_A165NotesDue20281652028NotesMember_label_en-US" xlink:label="lab_amgn_A165NotesDue20281652028NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% notes due 2028 (1.65% 2028 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A165NotesDue20281652028NotesMember_documentation_en-US" xlink:label="lab_amgn_A165NotesDue20281652028NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% notes due 2028 (1.65% 2028 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember" xlink:href="amgn-20221231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A165NotesDue20281652028NotesMember" xlink:to="lab_amgn_A165NotesDue20281652028NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_60e959e0-8eda-4401-b517-067ee3aca806_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ae59932a-1a2a-4512-926b-d6d15a29854a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6adcdf9c-8a82-4dd2-8a78-65c779bd169b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_5e72c680-351d-4aad-b079-ffc3fea3e370_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a390f35f-f0d3-4c64-97cc-29e1d0e0800c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_471ad0ee-d29e-4feb-a4e5-ca4ce9a9957c_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b621d3c1-ff06-4e48-8ebe-02238756e442_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_79d36073-1c29-4fda-aabe-0bc97e6aa05c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LaboratoryEquipmentMember_51f9801b-a67b-49b6-8c6b-faf2353d8828_terseLabel_en-US" xlink:label="lab_amgn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment [Member]</link:label>
    <link:label id="lab_amgn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_amgn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_amgn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_amgn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipmentMember" xlink:href="amgn-20221231.xsd#amgn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LaboratoryEquipmentMember" xlink:to="lab_amgn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f09b7c8b-bb35-4be8-b298-fb45b3e6513a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_d5ced1ae-23af-41b5-b3d6-df422bbf3894_terseLabel_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D technology rights [Member]</link:label>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_label_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Research And Development Technology Rights [Member]</link:label>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_documentation_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired research and development technology rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:href="amgn-20221231.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:to="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_979597fd-3c6d-4793-9662-e9a8ab716d25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4fedd649-8baa-4611-9728-0b59c85743fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_58f8dc8e-d3f6-4dcd-a2bf-8809af4c8c01_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual commitment fees for syndicated, unsecured, revolving credit agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_95c1badb-e300-4c67-91bd-85238a74644e_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of changes in accounting principles, net of taxes</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapAxis_51e84f9f-5fa5-4c01-8eaa-5ade4f935872_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Axis]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAxis_label_en-US" xlink:label="lab_amgn_InterestRateSwapAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Axis]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAxis_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapAxis" xlink:to="lab_amgn_InterestRateSwapAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AMG340Member_9ec1e31c-4129-4011-843a-140caca9091c_terseLabel_en-US" xlink:label="lab_amgn_AMG340Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG 340</link:label>
    <link:label id="lab_amgn_AMG340Member_label_en-US" xlink:label="lab_amgn_AMG340Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG 340 [Member]</link:label>
    <link:label id="lab_amgn_AMG340Member_documentation_en-US" xlink:label="lab_amgn_AMG340Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG 340</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AMG340Member" xlink:href="amgn-20221231.xsd#amgn_AMG340Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AMG340Member" xlink:to="lab_amgn_AMG340Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_167d1484-d6f7-4095-9758-7452b5a86472_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative assets, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6fba2407-d38a-4a2e-9112-c0c8ef478013_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CommonStockFairValue_9d7989d7-7b79-4149-85e3-9a640e46605b_terseLabel_en-US" xlink:label="lab_amgn_CommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of our common stock on grant date (in usd per share)</link:label>
    <link:label id="lab_amgn_CommonStockFairValue_label_en-US" xlink:label="lab_amgn_CommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Fair Value</link:label>
    <link:label id="lab_amgn_CommonStockFairValue_documentation_en-US" xlink:label="lab_amgn_CommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue" xlink:href="amgn-20221231.xsd#amgn_CommonStockFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CommonStockFairValue" xlink:to="lab_amgn_CommonStockFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_74709f22-98a5-4f0b-88e3-9f619edb5e62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_54a5af2f-3303-441d-bd02-5c373c2055a8_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments</link:label>
    <link:label id="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:href="amgn-20221231.xsd#amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:to="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e88861ab-4e35-4753-8d61-924fa7e61fcd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_7e4b76f2-14b2-4cf5-ab39-f16607769585_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_99fa2ece-ecb0-46ff-b289-dd2ab701087d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_7321d19c-da56-467f-a66b-e997391e727a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_bc73c2b6-213a-4319-8043-272a6cc9ac7a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AbandonedLeasesMember_47b9fdd3-e636-4f2e-988d-29a518cb6adb_terseLabel_en-US" xlink:label="lab_amgn_AbandonedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abandoned Leases [Member]</link:label>
    <link:label id="lab_amgn_AbandonedLeasesMember_label_en-US" xlink:label="lab_amgn_AbandonedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abandoned Leases [Member]</link:label>
    <link:label id="lab_amgn_AbandonedLeasesMember_documentation_en-US" xlink:label="lab_amgn_AbandonedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abandoned Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AbandonedLeasesMember" xlink:href="amgn-20221231.xsd#amgn_AbandonedLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AbandonedLeasesMember" xlink:to="lab_amgn_AbandonedLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TeneobioIncMember_3b94bc4d-4f18-459b-952e-cbf0cf9d9e7d_terseLabel_en-US" xlink:label="lab_amgn_TeneobioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio, Inc.</link:label>
    <link:label id="lab_amgn_TeneobioIncMember_label_en-US" xlink:label="lab_amgn_TeneobioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio, Inc. [Member]</link:label>
    <link:label id="lab_amgn_TeneobioIncMember_documentation_en-US" xlink:label="lab_amgn_TeneobioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember" xlink:href="amgn-20221231.xsd#amgn_TeneobioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TeneobioIncMember" xlink:to="lab_amgn_TeneobioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_a2c61bca-de71-47a5-b235-41d1bd8daf07_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_34b3d3d6-c7d0-4919-808a-c26679eed7be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7217c2dc-9f2e-42c5-97ec-ef6712a4f271_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_afa9dc91-dad1-4224-9e9d-bb4302809fe6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values and the fixed contractual coupon rates of long-term borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CustomerTwoMember_7c024ec5-d410-4dd0-8866-974bfcf1dd09_terseLabel_en-US" xlink:label="lab_amgn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_amgn_CustomerTwoMember_label_en-US" xlink:label="lab_amgn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_amgn_CustomerTwoMember_documentation_en-US" xlink:label="lab_amgn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember" xlink:href="amgn-20221231.xsd#amgn_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CustomerTwoMember" xlink:to="lab_amgn_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_6ef730a8-55c2-46f1-a6e9-637d9787a60f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_e8b4e762-4aa5-4e5a-9c24-fb86a257fb24_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyNumberOfClassActionSuits_5b33025d-96b5-47c9-88f7-d15ae46a5edb_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyNumberOfClassActionSuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Class Action Suits</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfClassActionSuits_label_en-US" xlink:label="lab_amgn_LossContingencyNumberOfClassActionSuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Class Action Suits</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfClassActionSuits_documentation_en-US" xlink:label="lab_amgn_LossContingencyNumberOfClassActionSuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Class Action Suits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfClassActionSuits" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfClassActionSuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyNumberOfClassActionSuits" xlink:to="lab_amgn_LossContingencyNumberOfClassActionSuits" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RevenuePaymentArrangementTerm_5f7ea031-0c0f-46ec-85a2-4253e736a86c_terseLabel_en-US" xlink:label="lab_amgn_RevenuePaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue payment term</link:label>
    <link:label id="lab_amgn_RevenuePaymentArrangementTerm_label_en-US" xlink:label="lab_amgn_RevenuePaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Payment Arrangement, Term</link:label>
    <link:label id="lab_amgn_RevenuePaymentArrangementTerm_documentation_en-US" xlink:label="lab_amgn_RevenuePaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Payment Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenuePaymentArrangementTerm" xlink:href="amgn-20221231.xsd#amgn_RevenuePaymentArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RevenuePaymentArrangementTerm" xlink:to="lab_amgn_RevenuePaymentArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_c10b17a3-1627-47d5-b557-4184d55c5ca4_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issued for each performance unit earned</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_label_en-US" xlink:label="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Common Shares Issued for Each Performance Unit Earned</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_documentation_en-US" xlink:label="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issued for each performance unit earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:href="amgn-20221231.xsd#amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:to="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_22fbecae-cec0-430d-9e33-a410913115b3_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amounts of hedged liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_71b39aed-cfa9-4e7c-b1a2-47797fb1fa5a_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising cost</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_94aad7a1-ea2f-402d-a9ee-0a043edbccff_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue by product and by geographic area</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper_cfa038d5-7e73-4772-925b-d5187fbdf437_terseLabel_en-US" xlink:label="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper, maximum borrowing capacity</link:label>
    <link:label id="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper_label_en-US" xlink:label="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Borrowing Capacity Under Commercial Paper</link:label>
    <link:label id="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper_documentation_en-US" xlink:label="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Borrowing Capacity Under Commercial Paper Program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:href="amgn-20221231.xsd#amgn_MaximumBorrowingCapacityUnderCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:to="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_0879b710-be59-4e7f-8388-c995acb837cc_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_84621b11-b8aa-47e7-bc21-8489586d9a50_terseLabel_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term interest-bearing securities</link:label>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_label_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short Term Interest Bearing Securities [Member]</link:label>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_documentation_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term interest bearing securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:href="amgn-20221231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:to="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_449eb886-0e7a-4bb0-ac54-71a1fd49f833_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FixedEquipment_d1b40f33-786e-405c-bf26-4e85cb8e02f0_terseLabel_en-US" xlink:label="lab_amgn_FixedEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:label id="lab_amgn_FixedEquipment_label_en-US" xlink:label="lab_amgn_FixedEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:label id="lab_amgn_FixedEquipment_documentation_en-US" xlink:label="lab_amgn_FixedEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment" xlink:href="amgn-20221231.xsd#amgn_FixedEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FixedEquipment" xlink:to="lab_amgn_FixedEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_a315bea8-be9c-423e-88d8-5a5ea37530aa_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_d09ba9d0-4d45-4caf-b825-dc47497079a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax20132015_aa8b5da4-2646-4eb1-83bf-7da2047812fb_terseLabel_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax20132015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax 2013-2015</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax20132015_label_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax20132015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax 2013-2015</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax20132015_documentation_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax20132015" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax 2013-2015</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax20132015" xlink:href="amgn-20221231.xsd#amgn_ProposedAdditionalIncomeTax20132015"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProposedAdditionalIncomeTax20132015" xlink:to="lab_amgn_ProposedAdditionalIncomeTax20132015" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bcffe107-fece-4d21-a13e-1bbd35949600_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_fd469bfe-0d5c-4260-99ab-8cde57a6615c_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4460d876-76f3-43f4-81d9-76e23ba7f531_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EvenityMember_3d38d1e7-9e9a-4824-aa44-0df3a27a54a3_terseLabel_en-US" xlink:label="lab_amgn_EvenityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evenity</link:label>
    <link:label id="lab_amgn_EvenityMember_label_en-US" xlink:label="lab_amgn_EvenityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evenity [Member]</link:label>
    <link:label id="lab_amgn_EvenityMember_documentation_en-US" xlink:label="lab_amgn_EvenityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evenity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EvenityMember" xlink:href="amgn-20221231.xsd#amgn_EvenityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EvenityMember" xlink:to="lab_amgn_EvenityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e2ccac71-b968-4cb5-b0e3-584fca346001_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5d1605de-96bc-4bea-a1ed-0e546382a2c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant&#160;date fair&#160;value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfPreclinicalOncologyPrograms_0185eddf-0b71-4845-a640-824abe60fefd_terseLabel_en-US" xlink:label="lab_amgn_NumberOfPreclinicalOncologyPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of oncology programs comprising remaining IPR&amp;D</link:label>
    <link:label id="lab_amgn_NumberOfPreclinicalOncologyPrograms_label_en-US" xlink:label="lab_amgn_NumberOfPreclinicalOncologyPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Preclinical Oncology Programs</link:label>
    <link:label id="lab_amgn_NumberOfPreclinicalOncologyPrograms_documentation_en-US" xlink:label="lab_amgn_NumberOfPreclinicalOncologyPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Preclinical Oncology Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfPreclinicalOncologyPrograms" xlink:href="amgn-20221231.xsd#amgn_NumberOfPreclinicalOncologyPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfPreclinicalOncologyPrograms" xlink:to="lab_amgn_NumberOfPreclinicalOncologyPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a2102f4b-d208-427c-8058-55e3e2795a61_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_6b6924e2-d58b-40b2-9bd8-a7f55b516e52_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_74bad5f7-74b2-4e62-97a8-34189c9fdc83_verboseLabel_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities/ Other&#160;noncurrent liabilities</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_label_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities Other Non Current Liabilities [Member]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities/other non-current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:href="amgn-20221231.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:to="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TermLoanCreditAgreementNumberOfTraunches_91a3d8df-e01e-4f0b-8cd0-4fac8bb207a9_terseLabel_en-US" xlink:label="lab_amgn_TermLoanCreditAgreementNumberOfTraunches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan credit agreement, number of traunches</link:label>
    <link:label id="lab_amgn_TermLoanCreditAgreementNumberOfTraunches_label_en-US" xlink:label="lab_amgn_TermLoanCreditAgreementNumberOfTraunches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan credit agreement, number of traunches</link:label>
    <link:label id="lab_amgn_TermLoanCreditAgreementNumberOfTraunches_documentation_en-US" xlink:label="lab_amgn_TermLoanCreditAgreementNumberOfTraunches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan credit agreement, number of traunches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TermLoanCreditAgreementNumberOfTraunches" xlink:href="amgn-20221231.xsd#amgn_TermLoanCreditAgreementNumberOfTraunches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TermLoanCreditAgreementNumberOfTraunches" xlink:to="lab_amgn_TermLoanCreditAgreementNumberOfTraunches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6cf89737-4d85-4ca8-864c-9af48d47fb0c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_49814064-6554-4182-9286-92bd36d6ddbe_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_HorizonTherapeuticsMember_d11a5519-f04a-47cf-b739-f1633d288062_terseLabel_en-US" xlink:label="lab_amgn_HorizonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics [Member]</link:label>
    <link:label id="lab_amgn_HorizonTherapeuticsMember_label_en-US" xlink:label="lab_amgn_HorizonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics [Member]</link:label>
    <link:label id="lab_amgn_HorizonTherapeuticsMember_documentation_en-US" xlink:label="lab_amgn_HorizonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HorizonTherapeuticsMember" xlink:href="amgn-20221231.xsd#amgn_HorizonTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_HorizonTherapeuticsMember" xlink:to="lab_amgn_HorizonTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_b2e5b2cd-9393-40f1-bdf7-b9d95956dc34_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_9097a448-5ca0-4999-8ed3-b3c6dd8b0b17_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro [Member]</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_19ed907a-3317-4598-b4af-ba718f149242_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_5a51bee2-d0ab-4ca3-947f-51e30ed041c2_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_84f56b7e-15a8-4ee7-beb3-8903851b9e61_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_aea83a39-bb51-42d0-a48b-fab6a4fca59a_terseLabel_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes Due 2022</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_label_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:to="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a6ce68b-5016-4db3-bb9b-98413a08c99f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_104bd043-f3d3-4cb0-aba5-0aa0ef92633b_verboseLabel_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_label_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earning Per Share [Abstract]</link:label>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_documentation_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earning per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:href="amgn-20221231.xsd#amgn_BasicAndDilutedEarningPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:to="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired_ec29bdf6-ec97-47c0-8bd0-b1c6fe440584_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, turnover period of inventory acquired</link:label>
    <link:label id="lab_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired_label_en-US" xlink:label="lab_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, turnover period of inventory acquired</link:label>
    <link:label id="lab_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, turnover period of inventory acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired" xlink:to="lab_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8560e75c-2ce0-44a4-bd2f-2dd75c48605e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_b66add14-507d-401b-8b62-009e00b49553_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_2cc1c2d5-cea3-47c0-9450-7ae07340023c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_2f3a0475-f787-4c79-a879-c52c2767df7f_verboseLabel_en-US" xlink:label="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross currency swap contracts [Member]</link:label>
    <link:label id="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_label_en-US" xlink:label="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency and Cross Currency Swaps [Member]</link:label>
    <link:label id="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_documentation_en-US" xlink:label="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross currency swaps.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:href="amgn-20221231.xsd#amgn_ForeignCurrencyAndCrossCurrencySwapsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:to="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_af367bb7-9a29-4cf0-b5a6-318f63c6fbf4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>amgn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:4e826620-fc5c-4c14-9c2e-3ba20b6aa99d,g:1e6ee203-6cba-438e-aedd-ef42aa695ae1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/Coverpage" xlink:type="simple" xlink:href="amgn-20221231.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a43b5800-6471-4ee9-b2cb-1e98bc8f081f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_a340641d-f467-4385-8464-95e80618efe7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a43b5800-6471-4ee9-b2cb-1e98bc8f081f" xlink:to="loc_dei_EntitiesTable_a340641d-f467-4385-8464-95e80618efe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_861803bf-167a-4ced-83d4-5751e6500282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_a340641d-f467-4385-8464-95e80618efe7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_861803bf-167a-4ced-83d4-5751e6500282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b2699e81-25b3-4d82-a9a1-c9385e753222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_861803bf-167a-4ced-83d4-5751e6500282" xlink:to="loc_us-gaap_ClassOfStockDomain_b2699e81-25b3-4d82-a9a1-c9385e753222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9384d7ba-614b-468b-be22-c7f4cb9ebf16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b2699e81-25b3-4d82-a9a1-c9385e753222" xlink:to="loc_us-gaap_CommonStockMember_9384d7ba-614b-468b-be22-c7f4cb9ebf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_f5b47e38-bf34-4a1f-9f49-49f17b5e83d8" xlink:href="amgn-20221231.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b2699e81-25b3-4d82-a9a1-c9385e753222" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_f5b47e38-bf34-4a1f-9f49-49f17b5e83d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_3954baaf-d970-48dc-b02e-9f0c686a0a9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_a340641d-f467-4385-8464-95e80618efe7" xlink:to="loc_dei_EntityListingsExchangeAxis_3954baaf-d970-48dc-b02e-9f0c686a0a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_bb8d3d44-9cc6-4f39-b19e-d78ec8f8ae6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_3954baaf-d970-48dc-b02e-9f0c686a0a9d" xlink:to="loc_dei_ExchangeDomain_bb8d3d44-9cc6-4f39-b19e-d78ec8f8ae6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_5e641629-75e0-445c-a15c-d3b560b496d5" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNGS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_bb8d3d44-9cc6-4f39-b19e-d78ec8f8ae6a" xlink:to="loc_exch_XNGS_5e641629-75e0-445c-a15c-d3b560b496d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_c2600681-bdc8-4490-8816-29616077517f" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_bb8d3d44-9cc6-4f39-b19e-d78ec8f8ae6a" xlink:to="loc_exch_XNYS_c2600681-bdc8-4490-8816-29616077517f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_a340641d-f467-4385-8464-95e80618efe7" xlink:to="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9106a000-87e5-4525-9fd1-447839e30c0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentType_9106a000-87e5-4525-9fd1-447839e30c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ba6559e8-5548-4ab4-adf0-6aba33b995ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentAnnualReport_ba6559e8-5548-4ab4-adf0-6aba33b995ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b33bfc55-bbd9-496c-a113-cbbafeb96e30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentPeriodEndDate_b33bfc55-bbd9-496c-a113-cbbafeb96e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_61c16320-3ab4-4e3c-834e-b94c07e226ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentTransitionReport_61c16320-3ab4-4e3c-834e-b94c07e226ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4c130044-d89c-475f-8f50-9c4ee2770040" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityFileNumber_4c130044-d89c-475f-8f50-9c4ee2770040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_093acbb0-7e22-4f59-870c-c1444794ad0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityRegistrantName_093acbb0-7e22-4f59-870c-c1444794ad0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_142525e3-e107-48c7-a4cd-ce22d4368c81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_142525e3-e107-48c7-a4cd-ce22d4368c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d73d87dc-6428-46aa-8a3c-7eca79eb176a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityTaxIdentificationNumber_d73d87dc-6428-46aa-8a3c-7eca79eb176a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_dfb79f2d-8078-4161-b02b-986aeee53515" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityAddressAddressLine1_dfb79f2d-8078-4161-b02b-986aeee53515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8c99b5c9-9f7d-492d-a829-325ed9365e86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityAddressCityOrTown_8c99b5c9-9f7d-492d-a829-325ed9365e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_07b9e04d-1b0f-4fdb-a2fb-bd7cf7ebb462" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityAddressStateOrProvince_07b9e04d-1b0f-4fdb-a2fb-bd7cf7ebb462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b57c59d5-0349-4c5a-9b09-bf21731605db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityAddressPostalZipCode_b57c59d5-0349-4c5a-9b09-bf21731605db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7b212a50-9582-41e7-9ca5-a3804b631bef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_CityAreaCode_7b212a50-9582-41e7-9ca5-a3804b631bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_72697f43-e613-4e4c-bfec-a93bc4d444f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_LocalPhoneNumber_72697f43-e613-4e4c-bfec-a93bc4d444f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6f4a03bb-9cfe-4dc7-9abd-f955d13055d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_Security12bTitle_6f4a03bb-9cfe-4dc7-9abd-f955d13055d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c6e75238-9155-4293-9155-d18b2ed2b415" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_TradingSymbol_c6e75238-9155-4293-9155-d18b2ed2b415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_807f99ed-7e37-4a67-b270-25c78adadb35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_SecurityExchangeName_807f99ed-7e37-4a67-b270-25c78adadb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_eabd9234-40f7-4c1d-99ad-5d729eaa793c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_eabd9234-40f7-4c1d-99ad-5d729eaa793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_e992e56c-3fdc-4970-bcf6-ff16a9638159" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityVoluntaryFilers_e992e56c-3fdc-4970-bcf6-ff16a9638159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_932d26f7-f4b4-46b6-a3ed-8f8ae6176a34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityCurrentReportingStatus_932d26f7-f4b4-46b6-a3ed-8f8ae6176a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_878371b6-77cc-449c-abf9-9cdf5f1e7fbd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityInteractiveDataCurrent_878371b6-77cc-449c-abf9-9cdf5f1e7fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d7dc18d3-c9aa-4965-a773-eb646be87891" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityFilerCategory_d7dc18d3-c9aa-4965-a773-eb646be87891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_75cbdb30-c244-4c78-a793-fd8b82fc069f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntitySmallBusiness_75cbdb30-c244-4c78-a793-fd8b82fc069f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_df0369c5-6d61-4ab6-bfad-16995e152f54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityEmergingGrowthCompany_df0369c5-6d61-4ab6-bfad-16995e152f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_05e811ed-abcf-4a4e-8b92-e1c99ab62a35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_IcfrAuditorAttestationFlag_05e811ed-abcf-4a4e-8b92-e1c99ab62a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_25b7f567-622c-4552-b506-ae5fb90aa037" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityShellCompany_25b7f567-622c-4552-b506-ae5fb90aa037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_975ae740-76ba-428a-b62a-544a15f2f413" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityPublicFloat_975ae740-76ba-428a-b62a-544a15f2f413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_745a8d7a-73f6-41d8-91cc-70f7aae636ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_745a8d7a-73f6-41d8-91cc-70f7aae636ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_4323fc52-6a0e-4ae7-866a-42ca4b7da5e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_4323fc52-6a0e-4ae7-866a-42ca4b7da5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6070daa7-3f8a-4982-903a-a0f662dcfedf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_EntityCentralIndexKey_6070daa7-3f8a-4982-903a-a0f662dcfedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fad49953-2034-4e21-b023-d0471876e019" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_AmendmentFlag_fad49953-2034-4e21-b023-d0471876e019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_335f2265-e92f-49f8-a914-d97936c65e92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentFiscalYearFocus_335f2265-e92f-49f8-a914-d97936c65e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b088ffa0-cde2-4bc4-b18b-cb7e9d9c598a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b088ffa0-cde2-4bc4-b18b-cb7e9d9c598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_287d6463-babe-4939-8def-bc59f2d9b33e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_144da6df-cc42-46c9-9725-6739da921fb7" xlink:to="loc_dei_CurrentFiscalYearEndDate_287d6463-babe-4939-8def-bc59f2d9b33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AuditInformation" xlink:type="simple" xlink:href="amgn-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AuditInformationAbstract_311afcfe-60cc-4f9d-8500-a9cd072d5d0c" xlink:href="amgn-20221231.xsd#amgn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_421f512e-abdb-4dc3-9782-e56205a9e11e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AuditInformationAbstract_311afcfe-60cc-4f9d-8500-a9cd072d5d0c" xlink:to="loc_dei_AuditorFirmId_421f512e-abdb-4dc3-9782-e56205a9e11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_6a748100-82fe-4ed4-b9e0-425660e041f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AuditInformationAbstract_311afcfe-60cc-4f9d-8500-a9cd072d5d0c" xlink:to="loc_dei_AuditorName_6a748100-82fe-4ed4-b9e0-425660e041f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6d3f2057-17e5-4d9c-b7d4-176715c91eb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AuditInformationAbstract_311afcfe-60cc-4f9d-8500-a9cd072d5d0c" xlink:to="loc_dei_AuditorLocation_6d3f2057-17e5-4d9c-b7d4-176715c91eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cabd1fc6-994e-4ac7-89d5-ce0c9248bff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_75a32ea7-c375-4ebc-ab41-aa0715176462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cabd1fc6-994e-4ac7-89d5-ce0c9248bff4" xlink:to="loc_us-gaap_StatementTable_75a32ea7-c375-4ebc-ab41-aa0715176462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e38e3459-65af-446a-bdc2-a12feba2a3b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_75a32ea7-c375-4ebc-ab41-aa0715176462" xlink:to="loc_srt_ProductOrServiceAxis_e38e3459-65af-446a-bdc2-a12feba2a3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a77e9aff-82cd-4639-b271-e3940186f0d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e38e3459-65af-446a-bdc2-a12feba2a3b7" xlink:to="loc_srt_ProductsAndServicesDomain_a77e9aff-82cd-4639-b271-e3940186f0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_31554eb8-9866-452d-bd84-65fa03fc6b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a77e9aff-82cd-4639-b271-e3940186f0d3" xlink:to="loc_us-gaap_ProductMember_31554eb8-9866-452d-bd84-65fa03fc6b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9fc3c413-646c-48f9-bf1e-b4761c3e05ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a77e9aff-82cd-4639-b271-e3940186f0d3" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9fc3c413-646c-48f9-bf1e-b4761c3e05ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_75a32ea7-c375-4ebc-ab41-aa0715176462" xlink:to="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3fc6b85c-cfe8-4c73-aa1e-cf233f1ad2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_RevenuesAbstract_3fc6b85c-cfe8-4c73-aa1e-cf233f1ad2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc9392f5-7ce9-4696-bb9a-10427ab17a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3fc6b85c-cfe8-4c73-aa1e-cf233f1ad2d3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc9392f5-7ce9-4696-bb9a-10427ab17a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_65f7579b-cfef-4564-8faf-e7c9259c4473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_65f7579b-cfef-4564-8faf-e7c9259c4473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6a4a7bc2-f86b-48d6-aa68-7e77abeb52b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6a4a7bc2-f86b-48d6-aa68-7e77abeb52b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_575528b6-acea-4d67-b04b-881e622fee10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_575528b6-acea-4d67-b04b-881e622fee10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_83b89b9f-cb9a-40f2-bf41-e06b7fb45469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_83b89b9f-cb9a-40f2-bf41-e06b7fb45469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense_ead3123e-28a9-4d32-9575-cd355257a381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_OtherGeneralExpense_ead3123e-28a9-4d32-9575-cd355257a381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6bc28b74-daa4-44d0-aecd-c384e3c10fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_146ed2fd-b836-48b5-83bf-7e9f068ef7c0" xlink:to="loc_us-gaap_CostsAndExpenses_6bc28b74-daa4-44d0-aecd-c384e3c10fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a5f4e767-9a12-40e0-8ca2-d1bd93d50a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_OperatingIncomeLoss_a5f4e767-9a12-40e0-8ca2-d1bd93d50a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_92de95de-47a9-4c4c-827b-5d96024377dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_InterestExpenseDebt_92de95de-47a9-4c4c-827b-5d96024377dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_dba56d31-88a0-4a5b-aac6-5bee1dbfd73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_dba56d31-88a0-4a5b-aac6-5bee1dbfd73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3430e662-7f62-42ee-9305-bd92a6f3552b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3430e662-7f62-42ee-9305-bd92a6f3552b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_508a2c48-b45c-44d0-9603-9f8efa90e722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_508a2c48-b45c-44d0-9603-9f8efa90e722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_174b8ee3-13d6-4b47-96db-5548eee9761b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_NetIncomeLoss_174b8ee3-13d6-4b47-96db-5548eee9761b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fb6bd216-1344-418b-94a6-53272946c290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_EarningsPerShareAbstract_fb6bd216-1344-418b-94a6-53272946c290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_673adf9f-1a73-4896-832d-8903cb8c9753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fb6bd216-1344-418b-94a6-53272946c290" xlink:to="loc_us-gaap_EarningsPerShareBasic_673adf9f-1a73-4896-832d-8903cb8c9753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d7c15ed9-b124-4711-b2fa-8c741c2e074f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fb6bd216-1344-418b-94a6-53272946c290" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d7c15ed9-b124-4711-b2fa-8c741c2e074f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0d43786c-4c11-45d8-baec-6e02e4d59eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd6ec97-862e-4e13-9046-1ddf483bbcd5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0d43786c-4c11-45d8-baec-6e02e4d59eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6284ffed-d07d-441a-afb5-a2ba891b357b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0d43786c-4c11-45d8-baec-6e02e4d59eac" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6284ffed-d07d-441a-afb5-a2ba891b357b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8eee17f6-51b1-4c9b-a1bb-44aef6a04088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0d43786c-4c11-45d8-baec-6e02e4d59eac" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8eee17f6-51b1-4c9b-a1bb-44aef6a04088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c6be46e8-4dbf-44cc-9e6c-d59d24165e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46e570f9-a95e-441f-94c6-f28b7392bb45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c6be46e8-4dbf-44cc-9e6c-d59d24165e70" xlink:to="loc_us-gaap_NetIncomeLoss_46e570f9-a95e-441f-94c6-f28b7392bb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_362fcd21-a20a-4ce9-813f-c3a04f6c661e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c6be46e8-4dbf-44cc-9e6c-d59d24165e70" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_362fcd21-a20a-4ce9-813f-c3a04f6c661e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_de216af8-e5de-41ff-b140-5b7fa6260100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_362fcd21-a20a-4ce9-813f-c3a04f6c661e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_de216af8-e5de-41ff-b140-5b7fa6260100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_51b6a236-a6ec-43d1-8aa6-26f0ae501e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_362fcd21-a20a-4ce9-813f-c3a04f6c661e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_51b6a236-a6ec-43d1-8aa6-26f0ae501e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d8f3191c-f69f-4cb2-87dc-8c56b4bc8324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_362fcd21-a20a-4ce9-813f-c3a04f6c661e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d8f3191c-f69f-4cb2-87dc-8c56b4bc8324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_34219be2-aede-490d-88c3-49612872d41a" xlink:href="amgn-20221231.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_362fcd21-a20a-4ce9-813f-c3a04f6c661e" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_34219be2-aede-490d-88c3-49612872d41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0e695d1c-b016-4104-a5da-c190a15a6c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_362fcd21-a20a-4ce9-813f-c3a04f6c661e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0e695d1c-b016-4104-a5da-c190a15a6c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5dac7f5b-a4dc-4782-8854-be941e4ff2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c6be46e8-4dbf-44cc-9e6c-d59d24165e70" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5dac7f5b-a4dc-4782-8854-be941e4ff2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_16de8b41-00c5-43c8-8784-e34492c1e126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_98632675-62cf-436e-b137-4a629f4b0847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_16de8b41-00c5-43c8-8784-e34492c1e126" xlink:to="loc_us-gaap_AssetsAbstract_98632675-62cf-436e-b137-4a629f4b0847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d5ee469a-5662-44c8-af61-187791f01827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98632675-62cf-436e-b137-4a629f4b0847" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d5ee469a-5662-44c8-af61-187791f01827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9f4437a-e560-4049-9a3c-e80400d499d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5ee469a-5662-44c8-af61-187791f01827" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9f4437a-e560-4049-9a3c-e80400d499d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c2b56dc0-3cd5-42d8-b633-0d3029fd616b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5ee469a-5662-44c8-af61-187791f01827" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c2b56dc0-3cd5-42d8-b633-0d3029fd616b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_95dcb318-224e-4f59-9c1c-9fcac0677e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5ee469a-5662-44c8-af61-187791f01827" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_95dcb318-224e-4f59-9c1c-9fcac0677e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f3a0dd65-c6b4-4343-b8d2-e281eda68940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5ee469a-5662-44c8-af61-187791f01827" xlink:to="loc_us-gaap_InventoryNet_f3a0dd65-c6b4-4343-b8d2-e281eda68940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c0784e6c-e5a7-4983-840b-b1a0e6f79f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5ee469a-5662-44c8-af61-187791f01827" xlink:to="loc_us-gaap_OtherAssetsCurrent_c0784e6c-e5a7-4983-840b-b1a0e6f79f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ebb5f1cc-f38c-4414-a72b-d86900670c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5ee469a-5662-44c8-af61-187791f01827" xlink:to="loc_us-gaap_AssetsCurrent_ebb5f1cc-f38c-4414-a72b-d86900670c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_323d62ef-dac7-4e1d-950d-a7144ba03f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98632675-62cf-436e-b137-4a629f4b0847" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_323d62ef-dac7-4e1d-950d-a7144ba03f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b484eb4e-049b-442e-b48d-f39682c6ff7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98632675-62cf-436e-b137-4a629f4b0847" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b484eb4e-049b-442e-b48d-f39682c6ff7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0063365b-5a41-4050-a22d-7357e91ab97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98632675-62cf-436e-b137-4a629f4b0847" xlink:to="loc_us-gaap_Goodwill_0063365b-5a41-4050-a22d-7357e91ab97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b375e762-b533-4d87-9241-c2e20b1629f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98632675-62cf-436e-b137-4a629f4b0847" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b375e762-b533-4d87-9241-c2e20b1629f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b7c5ec75-5e39-4b8a-9c45-7de8d1117bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98632675-62cf-436e-b137-4a629f4b0847" xlink:to="loc_us-gaap_Assets_b7c5ec75-5e39-4b8a-9c45-7de8d1117bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_729a9aaa-c0aa-4897-8d52-23147d7b3320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_16de8b41-00c5-43c8-8784-e34492c1e126" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_729a9aaa-c0aa-4897-8d52-23147d7b3320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0e0e861a-4466-4b5e-97cb-b611710b9b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_729a9aaa-c0aa-4897-8d52-23147d7b3320" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0e0e861a-4466-4b5e-97cb-b611710b9b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2662e0e8-b69d-4a23-9262-a8c32c470029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e0e861a-4466-4b5e-97cb-b611710b9b8c" xlink:to="loc_us-gaap_AccountsPayableCurrent_2662e0e8-b69d-4a23-9262-a8c32c470029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_608db9ac-5e35-42b5-b411-cece82728952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e0e861a-4466-4b5e-97cb-b611710b9b8c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_608db9ac-5e35-42b5-b411-cece82728952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9e28f5b0-9fb9-463e-b452-72442d0aabbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e0e861a-4466-4b5e-97cb-b611710b9b8c" xlink:to="loc_us-gaap_LongTermDebtCurrent_9e28f5b0-9fb9-463e-b452-72442d0aabbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_12c9236c-335f-42f3-9109-32570b225053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e0e861a-4466-4b5e-97cb-b611710b9b8c" xlink:to="loc_us-gaap_LiabilitiesCurrent_12c9236c-335f-42f3-9109-32570b225053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_39873937-e402-46bb-aa52-395650bc94d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_729a9aaa-c0aa-4897-8d52-23147d7b3320" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_39873937-e402-46bb-aa52-395650bc94d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_d5025034-706b-48fa-9bcc-7fba67a80115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_729a9aaa-c0aa-4897-8d52-23147d7b3320" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_d5025034-706b-48fa-9bcc-7fba67a80115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7e9b6589-7676-4f46-8d46-c5ba991063a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_729a9aaa-c0aa-4897-8d52-23147d7b3320" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7e9b6589-7676-4f46-8d46-c5ba991063a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87ab3586-ffae-444f-835e-ca0ff74bd928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_729a9aaa-c0aa-4897-8d52-23147d7b3320" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87ab3586-ffae-444f-835e-ca0ff74bd928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_71eec689-aa89-48b7-b7ce-6978073e8893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_729a9aaa-c0aa-4897-8d52-23147d7b3320" xlink:to="loc_us-gaap_StockholdersEquityAbstract_71eec689-aa89-48b7-b7ce-6978073e8893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_7585d642-ed82-463e-a44d-89f1befec1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71eec689-aa89-48b7-b7ce-6978073e8893" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_7585d642-ed82-463e-a44d-89f1befec1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6d402c68-7bd5-40ec-98ad-40e4d69da131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71eec689-aa89-48b7-b7ce-6978073e8893" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6d402c68-7bd5-40ec-98ad-40e4d69da131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0dea90cd-5d27-4aec-9ec1-78f9db091fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71eec689-aa89-48b7-b7ce-6978073e8893" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0dea90cd-5d27-4aec-9ec1-78f9db091fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bc4d5e28-3e10-4c88-acc0-044d2f066c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71eec689-aa89-48b7-b7ce-6978073e8893" xlink:to="loc_us-gaap_StockholdersEquity_bc4d5e28-3e10-4c88-acc0-044d2f066c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_779e1b06-f246-49bd-8511-b24df5efb6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_729a9aaa-c0aa-4897-8d52-23147d7b3320" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_779e1b06-f246-49bd-8511-b24df5efb6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0406a2d6-2928-4567-8c35-a94cc7305482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4ab67c65-fc7d-43f4-9d74-91ee3d96eb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0406a2d6-2928-4567-8c35-a94cc7305482" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4ab67c65-fc7d-43f4-9d74-91ee3d96eb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3ee1a801-4d18-48a8-af9a-a2c54451327a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0406a2d6-2928-4567-8c35-a94cc7305482" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3ee1a801-4d18-48a8-af9a-a2c54451327a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cbdc1f90-7502-4f88-afba-00fbf69b4e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0406a2d6-2928-4567-8c35-a94cc7305482" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cbdc1f90-7502-4f88-afba-00fbf69b4e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_03bfe058-9ff7-47e1-aab3-4306917b585d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_17cdbb50-9d3a-49eb-a92b-1b187584dd85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_03bfe058-9ff7-47e1-aab3-4306917b585d" xlink:to="loc_us-gaap_StatementTable_17cdbb50-9d3a-49eb-a92b-1b187584dd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_960469ed-f758-4eb1-9bff-e70ef11816e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17cdbb50-9d3a-49eb-a92b-1b187584dd85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_960469ed-f758-4eb1-9bff-e70ef11816e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960469ed-f758-4eb1-9bff-e70ef11816e6" xlink:to="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1c4d9759-8186-4d6a-be0b-3852468e3ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:to="loc_us-gaap_CommonStockMember_1c4d9759-8186-4d6a-be0b-3852468e3ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_685b12ee-c2e4-4d25-97c8-d0918876b0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_685b12ee-c2e4-4d25-97c8-d0918876b0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c89fae0d-5ef4-4257-8b26-f0a5495df146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:to="loc_us-gaap_RetainedEarningsMember_c89fae0d-5ef4-4257-8b26-f0a5495df146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1068a14c-a36f-4d40-9e83-4b64751fe75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_40902dea-4dd1-40a2-9e3e-74cb423fc4f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1068a14c-a36f-4d40-9e83-4b64751fe75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6a00bf91-4c0b-4bfc-9bb5-15af710e168e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17cdbb50-9d3a-49eb-a92b-1b187584dd85" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6a00bf91-4c0b-4bfc-9bb5-15af710e168e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_01abe208-74a3-402f-aebd-4a0f9d1b9d0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6a00bf91-4c0b-4bfc-9bb5-15af710e168e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_01abe208-74a3-402f-aebd-4a0f9d1b9d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fb6a0070-10d4-4fe3-943e-d18da3b98c91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_01abe208-74a3-402f-aebd-4a0f9d1b9d0e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fb6a0070-10d4-4fe3-943e-d18da3b98c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17cdbb50-9d3a-49eb-a92b-1b187584dd85" xlink:to="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_68c849a8-00ae-4ee6-9175-5b875caba786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_68c849a8-00ae-4ee6-9175-5b875caba786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0bf1bbb-c48f-4db0-9a3d-b4cbba0f90fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockholdersEquity_a0bf1bbb-c48f-4db0-9a3d-b4cbba0f90fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f3ccefed-4dd9-44b7-8e37-2cdf355f7da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_NetIncomeLoss_f3ccefed-4dd9-44b7-8e37-2cdf355f7da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bd8d1eef-8728-462f-9d8f-14c0adca8e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bd8d1eef-8728-462f-9d8f-14c0adca8e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_47c9c2a1-4f27-4f3a-8d34-a59ad2788a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_DividendsCommonStockCash_47c9c2a1-4f27-4f3a-8d34-a59ad2788a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5a42b7d0-efd1-4d6c-ad94-df6a5c601e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5a42b7d0-efd1-4d6c-ad94-df6a5c601e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4fb4b968-54bc-48fb-897b-1702a1824c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4fb4b968-54bc-48fb-897b-1702a1824c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_648ee284-4c21-45eb-8859-96ccc374b852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_648ee284-4c21-45eb-8859-96ccc374b852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_30974e2c-4b41-45e4-881d-427a8564dc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_30974e2c-4b41-45e4-881d-427a8564dc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_07ed89ed-2f5a-4379-8c95-ee460a7eee46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_07ed89ed-2f5a-4379-8c95-ee460a7eee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ba60a4b0-a99d-41fb-9c09-db2ba6afc823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ba60a4b0-a99d-41fb-9c09-db2ba6afc823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8acf4529-797f-4574-882c-8b9ca8cf0d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83e6e8ac-eaa4-423b-a71b-7ce87c6aa55c" xlink:to="loc_us-gaap_StockholdersEquity_8acf4529-797f-4574-882c-8b9ca8cf0d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_45bc3b7f-4533-4f21-8778-aef4c8f4a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_45bc3b7f-4533-4f21-8778-aef4c8f4a4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_cf64e2ed-63ea-40e7-9c10-4c4a47c194bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5dce99e8-2589-42d9-8ad2-8ae50a7f1d7a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_cf64e2ed-63ea-40e7-9c10-4c4a47c194bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_531b3fdf-7f9c-4830-bfd4-aead2f66268e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_4984c9b7-3e82-430f-b8cc-89eebffb4ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_531b3fdf-7f9c-4830-bfd4-aead2f66268e" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_4984c9b7-3e82-430f-b8cc-89eebffb4ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="amgn-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f809ab50-4b0f-4cd7-b2ec-7acba0247d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f809ab50-4b0f-4cd7-b2ec-7acba0247d6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c42e1a2-fa1a-4027-b2b5-6b8c6073abdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_NetIncomeLoss_5c42e1a2-fa1a-4027-b2b5-6b8c6073abdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7a35c7fb-a2e7-44dd-91e4-6294cad01cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7a35c7fb-a2e7-44dd-91e4-6294cad01cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_86f344c6-4b08-49f3-a54f-5496f67f016f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_ShareBasedCompensation_86f344c6-4b08-49f3-a54f-5496f67f016f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_40620c71-8a35-4bbb-a851-ae3ca0649604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_40620c71-8a35-4bbb-a851-ae3ca0649604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b102ddeb-a134-42ed-b7a9-d84804cfaa22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b102ddeb-a134-42ed-b7a9-d84804cfaa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a49ffb9e-c325-4a34-bf5c-0a2a4b0286e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a49ffb9e-c325-4a34-bf5c-0a2a4b0286e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_4ab2289b-7ab4-411e-bf83-6f8ea6eed6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_4ab2289b-7ab4-411e-bf83-6f8ea6eed6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b0eefe2c-2a69-4eea-8c3b-6ef249070835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b0eefe2c-2a69-4eea-8c3b-6ef249070835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21b29219-763b-4791-bf1d-2cd75ef2702a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21b29219-763b-4791-bf1d-2cd75ef2702a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e07af82f-e334-4025-a1f5-037ebae836e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21b29219-763b-4791-bf1d-2cd75ef2702a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e07af82f-e334-4025-a1f5-037ebae836e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6a068754-8d5a-49b5-87ba-f587eb49cf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21b29219-763b-4791-bf1d-2cd75ef2702a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6a068754-8d5a-49b5-87ba-f587eb49cf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_94b70c6d-6238-4678-aa3e-310a63c2889b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21b29219-763b-4791-bf1d-2cd75ef2702a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_94b70c6d-6238-4678-aa3e-310a63c2889b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c885df7c-7299-4ea5-bb10-48c3dbd4f420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21b29219-763b-4791-bf1d-2cd75ef2702a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c885df7c-7299-4ea5-bb10-48c3dbd4f420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8446ff90-521a-4816-8062-f2303ac4c947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21b29219-763b-4791-bf1d-2cd75ef2702a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8446ff90-521a-4816-8062-f2303ac4c947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_275bb6e3-e642-4b78-ba00-bb02dd79f04b" xlink:href="amgn-20221231.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21b29219-763b-4791-bf1d-2cd75ef2702a" xlink:to="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_275bb6e3-e642-4b78-ba00-bb02dd79f04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_081029f8-ef25-42f5-be89-0a432bae4743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21b29219-763b-4791-bf1d-2cd75ef2702a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_081029f8-ef25-42f5-be89-0a432bae4743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cf4f7e62-8854-426d-a005-7695e322f697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0420518e-67f5-4fdf-af49-bdd3f7914ba0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cf4f7e62-8854-426d-a005-7695e322f697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f809ab50-4b0f-4cd7-b2ec-7acba0247d6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_009c25d4-1d25-4793-b5fb-7d9efab56a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_009c25d4-1d25-4793-b5fb-7d9efab56a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_530c121b-73f6-41cc-84ac-bfac5dd6ce25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_530c121b-73f6-41cc-84ac-bfac5dd6ce25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_ec77639c-2679-4a36-8d4d-4488598ffd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_ec77639c-2679-4a36-8d4d-4488598ffd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e0f8ac16-3225-4041-9d6f-badfaed30de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e0f8ac16-3225-4041-9d6f-badfaed30de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_313bb05e-4844-4612-9751-4dbe3ad121a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_313bb05e-4844-4612-9751-4dbe3ad121a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7a0a95de-8bb3-40af-aae3-2934b04c8764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7a0a95de-8bb3-40af-aae3-2934b04c8764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_6b4a1f23-4a6b-4438-87b8-da1ef27c3f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_6b4a1f23-4a6b-4438-87b8-da1ef27c3f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ab38a025-c557-4a91-9c6b-37ff8c73e241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ab38a025-c557-4a91-9c6b-37ff8c73e241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d491727d-3a45-4618-9607-71db8ab5f73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1366c1fb-f441-4594-b2b5-11fcef1b3d79" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d491727d-3a45-4618-9607-71db8ab5f73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ef8f4ef-e0d8-4769-accc-3011f75ea0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f809ab50-4b0f-4cd7-b2ec-7acba0247d6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ef8f4ef-e0d8-4769-accc-3011f75ea0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c0eb0b42-d7fb-4a6a-a507-e96e3b57124d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ef8f4ef-e0d8-4769-accc-3011f75ea0ce" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c0eb0b42-d7fb-4a6a-a507-e96e3b57124d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7e3fbc52-5f1f-4554-a733-3a09d41f52aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ef8f4ef-e0d8-4769-accc-3011f75ea0ce" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7e3fbc52-5f1f-4554-a733-3a09d41f52aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e35d1224-0c5b-46f6-8726-c8397a14ba82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ef8f4ef-e0d8-4769-accc-3011f75ea0ce" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e35d1224-0c5b-46f6-8726-c8397a14ba82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1946bb67-f98f-4d16-97b0-3acd89614270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ef8f4ef-e0d8-4769-accc-3011f75ea0ce" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1946bb67-f98f-4d16-97b0-3acd89614270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_c99ce35d-b042-4743-845a-f5bd6e26e398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ef8f4ef-e0d8-4769-accc-3011f75ea0ce" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_c99ce35d-b042-4743-845a-f5bd6e26e398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b3792be1-a090-4bc5-9b5d-476a33b9fc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ef8f4ef-e0d8-4769-accc-3011f75ea0ce" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b3792be1-a090-4bc5-9b5d-476a33b9fc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_838e5aca-7bdd-449a-82ca-d9f8d1b0d4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ef8f4ef-e0d8-4769-accc-3011f75ea0ce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_838e5aca-7bdd-449a-82ca-d9f8d1b0d4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_31ae8fed-628d-4fd8-8b94-26c25daaa991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f809ab50-4b0f-4cd7-b2ec-7acba0247d6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_31ae8fed-628d-4fd8-8b94-26c25daaa991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f3dd4b7-4f9e-4928-84c3-ced540fd85c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f809ab50-4b0f-4cd7-b2ec-7acba0247d6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f3dd4b7-4f9e-4928-84c3-ced540fd85c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c912176b-f21d-49f5-998d-63ed40452cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f809ab50-4b0f-4cd7-b2ec-7acba0247d6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c912176b-f21d-49f5-998d-63ed40452cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="amgn-20221231.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0e7cb5cd-5765-4667-b70e-ff81c4b1255b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_dba48e03-c6da-4ffd-af0a-f72d4bfd6164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7cb5cd-5765-4667-b70e-ff81c4b1255b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_dba48e03-c6da-4ffd-af0a-f72d4bfd6164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Acquisitionsanddivestitures" xlink:type="simple" xlink:href="amgn-20221231.xsd#Acquisitionsanddivestitures"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Acquisitionsanddivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0c89b570-1aa5-4b52-9690-79c940d9acd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_bfd5ffc1-0d1d-4a8b-997b-7ea60d24ab1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0c89b570-1aa5-4b52-9690-79c940d9acd7" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_bfd5ffc1-0d1d-4a8b-997b-7ea60d24ab1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Revenues" xlink:type="simple" xlink:href="amgn-20221231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_688aaa2c-8ec4-4dd6-a71a-cea53937377d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_323c22d0-5a7e-46db-8ab4-4a2ef35405c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_688aaa2c-8ec4-4dd6-a71a-cea53937377d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_323c22d0-5a7e-46db-8ab4-4a2ef35405c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="amgn-20221231.xsd#Stockbasedcompensation"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_130a4642-cef0-479e-a7f3-da9459e7b383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d54892ef-664b-4ff2-81c5-8ed75993a6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_130a4642-cef0-479e-a7f3-da9459e7b383" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d54892ef-664b-4ff2-81c5-8ed75993a6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Definedcontributionplan" xlink:type="simple" xlink:href="amgn-20221231.xsd#Definedcontributionplan"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Definedcontributionplan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5962a5bb-9f94-45c2-a75f-caee235d91bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_977cf8a3-0192-403a-8c3d-f8211116e6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5962a5bb-9f94-45c2-a75f-caee235d91bf" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_977cf8a3-0192-403a-8c3d-f8211116e6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Incometaxes" xlink:type="simple" xlink:href="amgn-20221231.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fabd4990-4e5a-4141-a662-de259aa9fba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1c9e3e5f-ba55-4d50-b4c5-11cb40858d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fabd4990-4e5a-4141-a662-de259aa9fba6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1c9e3e5f-ba55-4d50-b4c5-11cb40858d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Earningspershare" xlink:type="simple" xlink:href="amgn-20221231.xsd#Earningspershare"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Earningspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_88763b69-4645-4056-a086-3089f85f264d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b707d0fc-b299-4c06-bcd8-0a09a0d383e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88763b69-4645-4056-a086-3089f85f264d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b707d0fc-b299-4c06-bcd8-0a09a0d383e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Collaborations" xlink:type="simple" xlink:href="amgn-20221231.xsd#Collaborations"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Collaborations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86636b43-8ef3-4b61-9a05-1f730a4bd5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_13f50233-583c-4ae0-9a5c-e746c8db2af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86636b43-8ef3-4b61-9a05-1f730a4bd5b5" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_13f50233-583c-4ae0-9a5c-e746c8db2af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Investments" xlink:type="simple" xlink:href="amgn-20221231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f0cb40f9-a24d-4ff0-bc3e-f0092475117b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_07ed48b1-c377-47c8-88a8-5f9bac333847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f0cb40f9-a24d-4ff0-bc3e-f0092475117b" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_07ed48b1-c377-47c8-88a8-5f9bac333847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Inventories" xlink:type="simple" xlink:href="amgn-20221231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e6ad5cb2-43c8-4183-a6bd-d3556485fb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_716ce138-21ec-48e0-8a42-a3e6bcec835e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e6ad5cb2-43c8-4183-a6bd-d3556485fb3e" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_716ce138-21ec-48e0-8a42-a3e6bcec835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="amgn-20221231.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_65d9990c-ce6f-40de-be2d-09bf12ea38ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_afc8e7a0-0f7e-4ee2-842f-12285c5e7c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_65d9990c-ce6f-40de-be2d-09bf12ea38ce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_afc8e7a0-0f7e-4ee2-842f-12285c5e7c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="simple" xlink:href="amgn-20221231.xsd#Goodwillandintangibleassets"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d8889dbf-e776-4f8a-b544-3a1350f5829e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d7db0910-1225-49bc-aa3e-2ac3881e6af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d8889dbf-e776-4f8a-b544-3a1350f5829e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d7db0910-1225-49bc-aa3e-2ac3881e6af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Leases" xlink:type="simple" xlink:href="amgn-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_22be2de4-5fcd-4e18-b5a7-498b516f42d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6214a38c-a1d9-46ea-8c25-2a6f0da0153e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22be2de4-5fcd-4e18-b5a7-498b516f42d4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6214a38c-a1d9-46ea-8c25-2a6f0da0153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="simple" xlink:href="amgn-20221231.xsd#Othercurrentassetsandaccruedliabilities"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_978b64b0-987e-4013-929d-06a851b6d81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesDisclosureTextBlock_f010fc2c-ac05-4919-8945-29b3b96c06e9" xlink:href="amgn-20221231.xsd#amgn_AccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_978b64b0-987e-4013-929d-06a851b6d81e" xlink:to="loc_amgn_AccruedLiabilitiesDisclosureTextBlock_f010fc2c-ac05-4919-8945-29b3b96c06e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Financingarrangements" xlink:type="simple" xlink:href="amgn-20221231.xsd#Financingarrangements"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Financingarrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e83c05b3-ae1e-4f50-9159-ef7f42a465f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_8ae55f95-a83f-4ade-bde6-d9188e24a2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e83c05b3-ae1e-4f50-9159-ef7f42a465f6" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_8ae55f95-a83f-4ade-bde6-d9188e24a2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockholdersequity" xlink:type="simple" xlink:href="amgn-20221231.xsd#Stockholdersequity"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Stockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8705787c-38a6-4dc0-9fda-fc1f9e700400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2e6faada-61dc-4079-9821-bb5a359dea02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8705787c-38a6-4dc0-9fda-fc1f9e700400" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2e6faada-61dc-4079-9821-bb5a359dea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="simple" xlink:href="amgn-20221231.xsd#Fairvaluemeasurement"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_75213064-a214-45a3-a76d-fee425572a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e6ded2ad-62c4-436b-b3ea-e4aa7fb94193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_75213064-a214-45a3-a76d-fee425572a41" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e6ded2ad-62c4-436b-b3ea-e4aa7fb94193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Derivativeinstruments" xlink:type="simple" xlink:href="amgn-20221231.xsd#Derivativeinstruments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Derivativeinstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e96ff6f5-db13-4cc0-a898-6bf1cd294833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_ad0d9400-d008-4946-ada9-d3930deb5d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e96ff6f5-db13-4cc0-a898-6bf1cd294833" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_ad0d9400-d008-4946-ada9-d3930deb5d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="simple" xlink:href="amgn-20221231.xsd#Contingenciesandcommitments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02f2eb66-f707-4c86-b028-a4bd81e2e76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69af7479-a96b-4e04-8908-0f2d343ae65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02f2eb66-f707-4c86-b028-a4bd81e2e76a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69af7479-a96b-4e04-8908-0f2d343ae65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="amgn-20221231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_2b817b2f-6e30-451c-9345-6fc77ba1eeb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_1294d203-f346-4efd-9edf-4fbdd100c0af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_2b817b2f-6e30-451c-9345-6fc77ba1eeb0" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_1294d203-f346-4efd-9edf-4fbdd100c0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="amgn-20221231.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NatureOfOperationsPolicyTextBlock_7f88f66d-796e-4621-9b83-952561233be7" xlink:href="amgn-20221231.xsd#amgn_NatureOfOperationsPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_amgn_NatureOfOperationsPolicyTextBlock_7f88f66d-796e-4621-9b83-952561233be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8c913603-d656-46ce-a07d-f68640d3e433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8c913603-d656-46ce-a07d-f68640d3e433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_55da8444-45d8-4885-8cfa-bd5ccd98cece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_UseOfEstimates_55da8444-45d8-4885-8cfa-bd5ccd98cece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3f79437a-a4d1-4362-9200-f97dcfa089ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3f79437a-a4d1-4362-9200-f97dcfa089ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e07f5a1b-bb44-4ceb-b8f9-1912fda7933e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e07f5a1b-bb44-4ceb-b8f9-1912fda7933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0fb9d667-2216-47ee-9a09-047147fccd82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0fb9d667-2216-47ee-9a09-047147fccd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_81316c09-be1a-4cd4-b3d0-0ac2ddf92749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_81316c09-be1a-4cd4-b3d0-0ac2ddf92749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ecff3582-236f-495e-8fdd-ca233b8e2707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ecff3582-236f-495e-8fdd-ca233b8e2707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_87e1db15-0a6d-4c32-932b-9059f6eb057c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_87e1db15-0a6d-4c32-932b-9059f6eb057c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_a6558230-f957-497b-aeb5-acb3c583eef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_a6558230-f957-497b-aeb5-acb3c583eef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_08d783b5-9004-42b6-a96f-ac144a12e3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_08d783b5-9004-42b6-a96f-ac144a12e3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_39c840cf-deab-4367-b51c-407f3b084a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_39c840cf-deab-4367-b51c-407f3b084a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_fdca1a04-5fe7-44b3-b0e3-615af00974e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_fdca1a04-5fe7-44b3-b0e3-615af00974e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_967be98b-e15f-43fa-ad2a-7118462fbe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_967be98b-e15f-43fa-ad2a-7118462fbe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_47f18806-e42b-4c41-a4c5-4dfb542a02b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_47f18806-e42b-4c41-a4c5-4dfb542a02b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_a68f205f-e37c-4e84-a04e-f409695b761e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_a68f205f-e37c-4e84-a04e-f409695b761e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_a43093da-a548-4570-98b8-d972f6e0142d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_a43093da-a548-4570-98b8-d972f6e0142d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8e931000-69e7-402b-abdd-60b84d7aa288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8e931000-69e7-402b-abdd-60b84d7aa288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityInvestmentsPolicyPolicyTextBlock_12dcc8a7-e85b-437e-aa6f-b43788feb663" xlink:href="amgn-20221231.xsd#amgn_EquityInvestmentsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_amgn_EquityInvestmentsPolicyPolicyTextBlock_12dcc8a7-e85b-437e-aa6f-b43788feb663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_8ab32553-6046-41fe-ab10-15e5107c45e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_8ab32553-6046-41fe-ab10-15e5107c45e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6fdcc1d7-7d44-4df4-a5d8-4d44a608fb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f1136db-179e-4e9d-9245-8438e7d4e276" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6fdcc1d7-7d44-4df4-a5d8-4d44a608fb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_203b92b4-bc1e-45d8-84e8-fa80ba670b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_87d0ddee-6fd5-4c9d-a1fc-680244cc9937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_203b92b4-bc1e-45d8-84e8-fa80ba670b1e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_87d0ddee-6fd5-4c9d-a1fc-680244cc9937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a7a60def-af44-4757-9c29-e1897e2abee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_5f2f3a26-b0cd-45d8-9c5d-12a2f8cdbf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a7a60def-af44-4757-9c29-e1897e2abee5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_5f2f3a26-b0cd-45d8-9c5d-12a2f8cdbf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_396c16af-d954-47d7-861d-e7f50579733d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a7a60def-af44-4757-9c29-e1897e2abee5" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_396c16af-d954-47d7-861d-e7f50579733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f8b8c1e-c5bf-44da-ad44-3292b7c34998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_3c12aec1-27e8-4298-88fe-58b46331156b" xlink:href="amgn-20221231.xsd#amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f8b8c1e-c5bf-44da-ad44-3292b7c34998" xlink:to="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_3c12aec1-27e8-4298-88fe-58b46331156b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4e8304e4-09dc-4072-84e5-d16eeac70354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f8b8c1e-c5bf-44da-ad44-3292b7c34998" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4e8304e4-09dc-4072-84e5-d16eeac70354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_66e477b3-d50d-4a2c-b761-2291996218f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f8b8c1e-c5bf-44da-ad44-3292b7c34998" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_66e477b3-d50d-4a2c-b761-2291996218f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0dd15364-b81a-4163-84a1-2d206dc0a479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f8b8c1e-c5bf-44da-ad44-3292b7c34998" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0dd15364-b81a-4163-84a1-2d206dc0a479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_08cbb078-f205-4d90-8c17-832a72b52820" xlink:href="amgn-20221231.xsd#amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f8b8c1e-c5bf-44da-ad44-3292b7c34998" xlink:to="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_08cbb078-f205-4d90-8c17-832a72b52820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_52acc212-fb2a-46fc-a9f2-60d37dab5177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_db129ed5-a482-4e81-a96e-79f27b151645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52acc212-fb2a-46fc-a9f2-60d37dab5177" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_db129ed5-a482-4e81-a96e-79f27b151645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a401235d-84ec-4387-bf44-8764c8cc1da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52acc212-fb2a-46fc-a9f2-60d37dab5177" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a401235d-84ec-4387-bf44-8764c8cc1da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cf6f4c70-75bc-41d4-976e-9b4616071090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52acc212-fb2a-46fc-a9f2-60d37dab5177" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cf6f4c70-75bc-41d4-976e-9b4616071090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_0ed175be-89cc-4fa3-9827-745c1519e54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52acc212-fb2a-46fc-a9f2-60d37dab5177" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_0ed175be-89cc-4fa3-9827-745c1519e54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7c3ad1bb-f11a-4d18-9a24-8a0a3fc62239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52acc212-fb2a-46fc-a9f2-60d37dab5177" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7c3ad1bb-f11a-4d18-9a24-8a0a3fc62239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#EarningspershareTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/EarningspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2452c3d1-3152-496e-9db5-55df400b7617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_05252593-8b76-4798-b343-a349b0d55a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2452c3d1-3152-496e-9db5-55df400b7617" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_05252593-8b76-4798-b343-a349b0d55a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7fd818f4-a120-4cc0-9801-ffe219960847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ab1bab60-aa99-4ca1-8e6f-519243a0eec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7fd818f4-a120-4cc0-9801-ffe219960847" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ab1bab60-aa99-4ca1-8e6f-519243a0eec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_2b4b7064-9450-41b1-be8d-d6c6628fede0" xlink:href="amgn-20221231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7fd818f4-a120-4cc0-9801-ffe219960847" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_2b4b7064-9450-41b1-be8d-d6c6628fede0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e9709c76-fd5d-4fba-abf6-4ca74c753fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82df34cb-505f-49a7-847b-31ef5243e41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e9709c76-fd5d-4fba-abf6-4ca74c753fe1" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82df34cb-505f-49a7-847b-31ef5243e41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_81414451-fa38-4ca2-a7b6-eb9741a520a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ad248a81-def3-4041-b293-27c2826f8dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_81414451-fa38-4ca2-a7b6-eb9741a520a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ad248a81-def3-4041-b293-27c2826f8dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_8ca56ae6-926f-4825-b7ee-e3b4ba4c5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_81414451-fa38-4ca2-a7b6-eb9741a520a8" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_8ca56ae6-926f-4825-b7ee-e3b4ba4c5cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#GoodwillandotherintangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4201705a-07be-48de-8f39-08829fe8c5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_221ac507-6fc6-425b-bdcd-3fb7cc44c570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4201705a-07be-48de-8f39-08829fe8c5fa" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_221ac507-6fc6-425b-bdcd-3fb7cc44c570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock_9c7f69ad-882e-46b7-acc8-e8706eb3689c" xlink:href="amgn-20221231.xsd#amgn_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4201705a-07be-48de-8f39-08829fe8c5fa" xlink:to="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock_9c7f69ad-882e-46b7-acc8-e8706eb3689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_307e63f3-4ef2-443f-b69a-ba8cc18702a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_9541a7d9-d64e-4aca-ac42-fd5c96ce377d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_307e63f3-4ef2-443f-b69a-ba8cc18702a6" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_9541a7d9-d64e-4aca-ac42-fd5c96ce377d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_19c8b5b5-6f72-4f16-bcdb-ef313498f30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_307e63f3-4ef2-443f-b69a-ba8cc18702a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_19c8b5b5-6f72-4f16-bcdb-ef313498f30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#OthercurrentassetsandaccruedliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3e0ff9c4-de8d-4998-bfe6-28c158c7934a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_bf45f097-892e-4c76-9b75-882d90a8ad45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3e0ff9c4-de8d-4998-bfe6-28c158c7934a" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_bf45f097-892e-4c76-9b75-882d90a8ad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b8972483-020d-4c16-9bfa-d2a984d4f156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3e0ff9c4-de8d-4998-bfe6-28c158c7934a" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b8972483-020d-4c16-9bfa-d2a984d4f156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6003d7ac-8768-47b8-8cb4-0f6ddd4feaad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e44fefaa-76b8-47ee-a40b-6d213f034fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6003d7ac-8768-47b8-8cb4-0f6ddd4feaad" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e44fefaa-76b8-47ee-a40b-6d213f034fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_773b1156-084d-4bfa-a4c7-054c1cd15689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6003d7ac-8768-47b8-8cb4-0f6ddd4feaad" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_773b1156-084d-4bfa-a4c7-054c1cd15689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_0879c743-4db1-4e48-9853-c35e086b1e96" xlink:href="amgn-20221231.xsd#amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6003d7ac-8768-47b8-8cb4-0f6ddd4feaad" xlink:to="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_0879c743-4db1-4e48-9853-c35e086b1e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7c3a3b1e-b9ae-4e4a-893e-0f657ded7bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6003d7ac-8768-47b8-8cb4-0f6ddd4feaad" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7c3a3b1e-b9ae-4e4a-893e-0f657ded7bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3bbb1ce6-858d-4b44-8695-fccffbbc44ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockRepurchaseProgramTableTextBlock_f648d085-6118-4075-9c5c-d0199eaec2ff" xlink:href="amgn-20221231.xsd#amgn_StockRepurchaseProgramTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3bbb1ce6-858d-4b44-8695-fccffbbc44ae" xlink:to="loc_amgn_StockRepurchaseProgramTableTextBlock_f648d085-6118-4075-9c5c-d0199eaec2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_547ee8a2-9418-4419-819a-2e9feb524c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3bbb1ce6-858d-4b44-8695-fccffbbc44ae" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_547ee8a2-9418-4419-819a-2e9feb524c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_de65f70c-24e4-4674-a9f7-1e4e4cb5ebba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3bbb1ce6-858d-4b44-8695-fccffbbc44ae" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_de65f70c-24e4-4674-a9f7-1e4e4cb5ebba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#FairvaluemeasurementTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c505a865-833c-461a-a816-c2b5b0cc6e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a0b1508e-a0d6-495a-9b0a-6e6669fe6e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c505a865-833c-461a-a816-c2b5b0cc6e0e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a0b1508e-a0d6-495a-9b0a-6e6669fe6e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_fcf2e50f-5948-4eb4-84b2-2d64745cf4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c505a865-833c-461a-a816-c2b5b0cc6e0e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_fcf2e50f-5948-4eb4-84b2-2d64745cf4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b6a45209-34f0-420a-bcc5-0cd233867217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_24446b51-578c-48d7-817e-ecf8b054e5bb" xlink:href="amgn-20221231.xsd#amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b6a45209-34f0-420a-bcc5-0cd233867217" xlink:to="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_24446b51-578c-48d7-817e-ecf8b054e5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_4e401a02-439e-44b2-ab85-5332f609bf99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b6a45209-34f0-420a-bcc5-0cd233867217" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_4e401a02-439e-44b2-ab85-5332f609bf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_0be5f52f-d523-43b0-a5f4-4444ee1908e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b6a45209-34f0-420a-bcc5-0cd233867217" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_0be5f52f-d523-43b0-a5f4-4444ee1908e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_019456d7-b206-49cb-8ce5-95cf5c6e13f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b6a45209-34f0-420a-bcc5-0cd233867217" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_019456d7-b206-49cb-8ce5-95cf5c6e13f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_11c62b5e-8c12-47ca-8bb1-835cd4c9fd01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b6a45209-34f0-420a-bcc5-0cd233867217" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_11c62b5e-8c12-47ca-8bb1-835cd4c9fd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65bbafd5-5f1e-4888-bea5-b7c119846454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_66f6e1d1-ab81-4786-95c3-68ddd402e079" xlink:href="amgn-20221231.xsd#amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65bbafd5-5f1e-4888-bea5-b7c119846454" xlink:to="loc_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_66f6e1d1-ab81-4786-95c3-68ddd402e079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_85bffe09-2711-4ec6-bbb5-04f811efbac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85bffe09-2711-4ec6-bbb5-04f811efbac7" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3dc97587-cea0-4ddf-a1e0-7370ff6f3c9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:to="loc_srt_RangeAxis_3dc97587-cea0-4ddf-a1e0-7370ff6f3c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4121c4ca-10cd-4e89-88cf-04e0771a21c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3dc97587-cea0-4ddf-a1e0-7370ff6f3c9d" xlink:to="loc_srt_RangeMember_4121c4ca-10cd-4e89-88cf-04e0771a21c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fcf88b14-6859-496c-96e2-12ac58d00882" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4121c4ca-10cd-4e89-88cf-04e0771a21c3" xlink:to="loc_srt_MinimumMember_fcf88b14-6859-496c-96e2-12ac58d00882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3345e563-96fb-471f-8f04-e989d0d370ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4121c4ca-10cd-4e89-88cf-04e0771a21c3" xlink:to="loc_srt_MaximumMember_3345e563-96fb-471f-8f04-e989d0d370ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a962a71a-c780-46e3-993a-1ff6deeebd9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:to="loc_srt_ProductOrServiceAxis_a962a71a-c780-46e3-993a-1ff6deeebd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c98185a8-4839-4cc7-bcbb-f6cd217b0c9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a962a71a-c780-46e3-993a-1ff6deeebd9d" xlink:to="loc_srt_ProductsAndServicesDomain_c98185a8-4839-4cc7-bcbb-f6cd217b0c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember_0bca282d-8159-485d-9e51-e6348dd28429" xlink:href="amgn-20221231.xsd#amgn_NplateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c98185a8-4839-4cc7-bcbb-f6cd217b0c9f" xlink:to="loc_amgn_NplateMember_0bca282d-8159-485d-9e51-e6348dd28429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b226d25a-636c-41fc-a366-8bfa968213fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:to="loc_srt_StatementGeographicalAxis_b226d25a-636c-41fc-a366-8bfa968213fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5b23035f-c98f-401a-b720-0474b99b4aed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b226d25a-636c-41fc-a366-8bfa968213fd" xlink:to="loc_srt_SegmentGeographicalDomain_5b23035f-c98f-401a-b720-0474b99b4aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4aadd13c-5cfb-449c-8a83-0bababb42d8f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5b23035f-c98f-401a-b720-0474b99b4aed" xlink:to="loc_country_US_4aadd13c-5cfb-449c-8a83-0bababb42d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_919cd184-d9b1-44a6-a685-4d6f5ccbdd92" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f178cef6-66a5-4ff9-b039-5fb6c4d80540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f178cef6-66a5-4ff9-b039-5fb6c4d80540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_ba7f5905-80c8-4e6b-9891-8891f8eb8318" xlink:href="amgn-20221231.xsd#amgn_SalesReturnProvisionsAsPercentageOfProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_ba7f5905-80c8-4e6b-9891-8891f8eb8318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenuePaymentArrangementTerm_5e7f5753-02ba-4c40-a716-df667f4758c9" xlink:href="amgn-20221231.xsd#amgn_RevenuePaymentArrangementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_amgn_RevenuePaymentArrangementTerm_5e7f5753-02ba-4c40-a716-df667f4758c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_351b2f0c-a7e7-4a30-baec-409b7d7b414d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_us-gaap_AdvertisingExpense_351b2f0c-a7e7-4a30-baec-409b7d7b414d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a717e350-4db6-4ebd-82e2-8d625b8943d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f096f52b-f640-435e-8d54-1af816b5feef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a717e350-4db6-4ebd-82e2-8d625b8943d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9adbfd50-f608-490c-adb9-7882053a9e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3f844dbb-12bc-4151-9c4d-25e02bd8f9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9adbfd50-f608-490c-adb9-7882053a9e58" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3f844dbb-12bc-4151-9c4d-25e02bd8f9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7f99aa4c-b1b6-4ca5-99a2-e364b852fa83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3f844dbb-12bc-4151-9c4d-25e02bd8f9cf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7f99aa4c-b1b6-4ca5-99a2-e364b852fa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec623d3a-8983-410f-a6e8-f8c6ddae464b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7f99aa4c-b1b6-4ca5-99a2-e364b852fa83" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec623d3a-8983-410f-a6e8-f8c6ddae464b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HorizonTherapeuticsMember_7fab89bf-321c-4449-9d80-db2290fe3b5e" xlink:href="amgn-20221231.xsd#amgn_HorizonTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec623d3a-8983-410f-a6e8-f8c6ddae464b" xlink:to="loc_amgn_HorizonTherapeuticsMember_7fab89bf-321c-4449-9d80-db2290fe3b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_119224f9-e843-4e85-ae1d-58d18a8fd932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3f844dbb-12bc-4151-9c4d-25e02bd8f9cf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_119224f9-e843-4e85-ae1d-58d18a8fd932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6eeee6bf-087b-4d83-b1a8-55a52ef5d219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_119224f9-e843-4e85-ae1d-58d18a8fd932" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6eeee6bf-087b-4d83-b1a8-55a52ef5d219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementMember_84094c7c-391e-4a2d-b0f6-c7f3e43a47bc" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6eeee6bf-087b-4d83-b1a8-55a52ef5d219" xlink:to="loc_amgn_BridgeCreditAgreementMember_84094c7c-391e-4a2d-b0f6-c7f3e43a47bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3f844dbb-12bc-4151-9c4d-25e02bd8f9cf" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_ea580777-4ac8-4e6b-bf9f-3d4bda63c772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_ea580777-4ac8-4e6b-bf9f-3d4bda63c772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_46c52643-3984-43a5-b257-54847e4f8a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_46c52643-3984-43a5-b257-54847e4f8a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ApprovedProducts_f46913c5-50e8-4fc6-8e49-91e9ea379a25" xlink:href="amgn-20221231.xsd#amgn_ApprovedProducts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_ApprovedProducts_f46913c5-50e8-4fc6-8e49-91e9ea379a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DevelopmentPrograms_9375f300-e3be-4f92-88a3-9f35215520e0" xlink:href="amgn-20221231.xsd#amgn_DevelopmentPrograms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_DevelopmentPrograms_9375f300-e3be-4f92-88a3-9f35215520e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementMaximumLength_c27686dc-407a-4263-a2d7-03dd0d083f0f" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementMaximumLength"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_BridgeCreditAgreementMaximumLength_c27686dc-407a-4263-a2d7-03dd0d083f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementInitialAmount_d8b09ddd-ccd0-4652-b961-08623e7c4b01" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementInitialAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_BridgeCreditAgreementInitialAmount_d8b09ddd-ccd0-4652-b961-08623e7c4b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TermLoanCreditAgreementTotalAmount_2a0ae313-033b-41bb-a052-7ea6d9413c94" xlink:href="amgn-20221231.xsd#amgn_TermLoanCreditAgreementTotalAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_TermLoanCreditAgreementTotalAmount_2a0ae313-033b-41bb-a052-7ea6d9413c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TermLoanCreditAgreementNumberOfTraunches_313002d3-8688-4163-abae-a1d3d5881328" xlink:href="amgn-20221231.xsd#amgn_TermLoanCreditAgreementNumberOfTraunches"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_TermLoanCreditAgreementNumberOfTraunches_313002d3-8688-4163-abae-a1d3d5881328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditReducedAmount_80a1ad9f-e47a-4f29-9231-822e2a004b45" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditReducedAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_BridgeCreditReducedAmount_80a1ad9f-e47a-4f29-9231-822e2a004b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementAmount_927cfe8e-9638-419c-96ca-fa09244e0ca3" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_amgn_BridgeCreditAgreementAmount_927cfe8e-9638-419c-96ca-fa09244e0ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_8dc1c461-3544-499e-97c0-92180ecfd8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_8dc1c461-3544-499e-97c0-92180ecfd8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensatingBalanceAmount_010e2f12-3b44-430a-8cf2-925da6ff12ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatingBalanceAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_33156628-3493-416d-9a28-8c9ee7fc28df" xlink:to="loc_us-gaap_CompensatingBalanceAmount_010e2f12-3b44-430a-8cf2-925da6ff12ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6769d1ae-3ee9-4edf-ace7-f53c1318b209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ec12849-043a-4abb-9b44-c8a40e874c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6769d1ae-3ee9-4edf-ace7-f53c1318b209" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ec12849-043a-4abb-9b44-c8a40e874c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_24d491a9-ddc9-4cdc-a347-2f7b4e201512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ec12849-043a-4abb-9b44-c8a40e874c36" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_24d491a9-ddc9-4cdc-a347-2f7b4e201512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96994789-4965-4e64-bb92-bb9ecc833f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_24d491a9-ddc9-4cdc-a347-2f7b4e201512" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96994789-4965-4e64-bb92-bb9ecc833f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ChemoCentryxIncMember_7e95c84b-3906-461b-84c1-d986647251e9" xlink:href="amgn-20221231.xsd#amgn_ChemoCentryxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96994789-4965-4e64-bb92-bb9ecc833f10" xlink:to="loc_amgn_ChemoCentryxIncMember_7e95c84b-3906-461b-84c1-d986647251e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a88ad51d-bf3e-47c7-b8c0-86c0189a87cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ec12849-043a-4abb-9b44-c8a40e874c36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a88ad51d-bf3e-47c7-b8c0-86c0189a87cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70eb45c5-4b16-4206-afa6-65763eaf06ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a88ad51d-bf3e-47c7-b8c0-86c0189a87cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70eb45c5-4b16-4206-afa6-65763eaf06ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_85f5233b-ba74-4456-97ca-0caba169dea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70eb45c5-4b16-4206-afa6-65763eaf06ee" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_85f5233b-ba74-4456-97ca-0caba169dea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ec12849-043a-4abb-9b44-c8a40e874c36" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_f83fe2a6-cdbc-42ac-82b6-17793d8fe5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_f83fe2a6-cdbc-42ac-82b6-17793d8fe5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_b91fc68c-c18c-4740-8d81-f2660dea8abe" xlink:href="amgn-20221231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_b91fc68c-c18c-4740-8d81-f2660dea8abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6f980b5e-c66b-4304-b1ca-29e22c12636d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6f980b5e-c66b-4304-b1ca-29e22c12636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_874e241a-bc7b-4e08-b88e-17109b4bc526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_874e241a-bc7b-4e08-b88e-17109b4bc526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices_a3287b3a-62fe-472f-ade9-f30a1718c7be" xlink:href="amgn-20221231.xsd#amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices_a3287b3a-62fe-472f-ade9-f30a1718c7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_70bc40da-e1f8-40f4-86a7-4b485980ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_70bc40da-e1f8-40f4-86a7-4b485980ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fe1d8297-f524-4304-8413-29f090e8b134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fe1d8297-f524-4304-8413-29f090e8b134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d36c2ae1-2bac-4c89-b539-9c22a71ff08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d36c2ae1-2bac-4c89-b539-9c22a71ff08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired_ed2d6088-9670-4c91-b2c0-f3e26f7d0d9a" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired_ed2d6088-9670-4c91-b2c0-f3e26f7d0d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_37c26af1-6ae3-4943-9053-a185d982be43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_37c26af1-6ae3-4943-9053-a185d982be43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ade2e2e3-9276-4591-8956-e4e551d1ff94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_807887a9-8b8e-45a5-80de-8a0c41b2a909" xlink:to="loc_us-gaap_Goodwill_ade2e2e3-9276-4591-8956-e4e551d1ff94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b3c06490-6d72-4382-8d8e-17ae4322ee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5c3031-209b-4dfe-bb8c-626d8f07ef69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b3c06490-6d72-4382-8d8e-17ae4322ee5c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5c3031-209b-4dfe-bb8c-626d8f07ef69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59097fb9-3def-4e5e-85bf-6f3471383d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5c3031-209b-4dfe-bb8c-626d8f07ef69" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59097fb9-3def-4e5e-85bf-6f3471383d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c322ad23-4573-4ad3-87ec-6f302b613523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59097fb9-3def-4e5e-85bf-6f3471383d5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c322ad23-4573-4ad3-87ec-6f302b613523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ChemoCentryxIncMember_60dc3f1a-2b12-4f04-84f8-d5071ee0f716" xlink:href="amgn-20221231.xsd#amgn_ChemoCentryxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c322ad23-4573-4ad3-87ec-6f302b613523" xlink:to="loc_amgn_ChemoCentryxIncMember_60dc3f1a-2b12-4f04-84f8-d5071ee0f716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_546ba6a8-cd05-4aef-99b6-4434ae134c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5c3031-209b-4dfe-bb8c-626d8f07ef69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_546ba6a8-cd05-4aef-99b6-4434ae134c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_067e3572-b4ef-476f-93dc-3d8ce4abb34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_546ba6a8-cd05-4aef-99b6-4434ae134c14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_067e3572-b4ef-476f-93dc-3d8ce4abb34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e1547052-9679-4131-9c30-1e5de35feefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_067e3572-b4ef-476f-93dc-3d8ce4abb34f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e1547052-9679-4131-9c30-1e5de35feefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5c3031-209b-4dfe-bb8c-626d8f07ef69" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_dca9b3a3-8e92-45ab-96c0-f0e40787607f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_dca9b3a3-8e92-45ab-96c0-f0e40787607f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_61d4cf80-eeb7-481f-8ece-95df9de57c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_61d4cf80-eeb7-481f-8ece-95df9de57c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f851ff4f-102a-466f-bb74-42cf94324eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f851ff4f-102a-466f-bb74-42cf94324eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85ee0bc9-deee-44e3-875f-90eb3ab346f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85ee0bc9-deee-44e3-875f-90eb3ab346f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c039f9ec-29e8-42da-a7b2-14b562d7935b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_Goodwill_c039f9ec-29e8-42da-a7b2-14b562d7935b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_cdfc5817-5068-4b00-8864-64a7dfcd58ae" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_cdfc5817-5068-4b00-8864-64a7dfcd58ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c19bb2a7-85ad-4643-b4ef-5e208ff8019d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c19bb2a7-85ad-4643-b4ef-5e208ff8019d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_68633570-8470-4183-bf8f-a985afb40827" xlink:href="amgn-20221231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ddc6337-5ef8-4e2a-bff6-8c9c7d4c0840" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_68633570-8470-4183-bf8f-a985afb40827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresTeneobioIncDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_457d8cdb-98c9-4178-8eea-a6f364e44596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_457d8cdb-98c9-4178-8eea-a6f364e44596" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b642a23b-afdd-459c-a8be-96bf0b1a614f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b642a23b-afdd-459c-a8be-96bf0b1a614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a91b2f6f-74dd-4e80-99b9-c919f1466849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b642a23b-afdd-459c-a8be-96bf0b1a614f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a91b2f6f-74dd-4e80-99b9-c919f1466849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_23151dcc-de55-42ca-aaf7-b6fd6d61f8a3" xlink:href="amgn-20221231.xsd#amgn_TeneobioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a91b2f6f-74dd-4e80-99b9-c919f1466849" xlink:to="loc_amgn_TeneobioMember_23151dcc-de55-42ca-aaf7-b6fd6d61f8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6df28329-4b34-45fd-b3f2-4575104f38b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6df28329-4b34-45fd-b3f2-4575104f38b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a135f8f5-cd7d-46ff-b836-5e604c74dd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6df28329-4b34-45fd-b3f2-4575104f38b5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a135f8f5-cd7d-46ff-b836-5e604c74dd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b629da76-c306-4fcb-8e37-0d5fca1f928a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a135f8f5-cd7d-46ff-b836-5e604c74dd63" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b629da76-c306-4fcb-8e37-0d5fca1f928a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeAxis_c32b491b-19a5-4322-9a02-5f80e0fe941c" xlink:href="amgn-20221231.xsd#amgn_MoleculeTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:to="loc_amgn_MoleculeTypeAxis_c32b491b-19a5-4322-9a02-5f80e0fe941c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain_b5880889-b5a2-4705-a1a0-590f1e69aa7e" xlink:href="amgn-20221231.xsd#amgn_MoleculeTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_MoleculeTypeAxis_c32b491b-19a5-4322-9a02-5f80e0fe941c" xlink:to="loc_amgn_MoleculeTypeDomain_b5880889-b5a2-4705-a1a0-590f1e69aa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AMG340Member_7795f792-c59b-4797-b300-275d869776af" xlink:href="amgn-20221231.xsd#amgn_AMG340Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_MoleculeTypeDomain_b5880889-b5a2-4705-a1a0-590f1e69aa7e" xlink:to="loc_amgn_AMG340Member_7795f792-c59b-4797-b300-275d869776af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5e5ad8f3-a5c7-43f4-9dbc-9fb643547499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5e5ad8f3-a5c7-43f4-9dbc-9fb643547499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2156c45-f85e-4a83-9bec-e296d147e947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5e5ad8f3-a5c7-43f4-9dbc-9fb643547499" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2156c45-f85e-4a83-9bec-e296d147e947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_823f0b84-aa5a-4f6a-abce-8f9e0c0d72f4" xlink:href="amgn-20221231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2156c45-f85e-4a83-9bec-e296d147e947" xlink:to="loc_amgn_RDTechnologyrightsMember_823f0b84-aa5a-4f6a-abce-8f9e0c0d72f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_1cd74235-71fe-417b-bc3b-5f68229bd5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2156c45-f85e-4a83-9bec-e296d147e947" xlink:to="loc_us-gaap_LicensingAgreementsMember_1cd74235-71fe-417b-bc3b-5f68229bd5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd54fe14-98cc-49a7-ae36-d98e53fe12d1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a3f5fe74-91d0-4137-a13a-7af566232f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a3f5fe74-91d0-4137-a13a-7af566232f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_27c0d243-8895-4e54-8d72-7dd1df0dd0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_27c0d243-8895-4e54-8d72-7dd1df0dd0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4ee210c5-44d5-48a4-ab14-becfa5667e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4ee210c5-44d5-48a4-ab14-becfa5667e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_c3e1bfba-557f-4a6c-87fa-4fed6e53bbfb" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_c3e1bfba-557f-4a6c-87fa-4fed6e53bbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_132df20d-d61e-4fe4-b4c0-2089e488f989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_132df20d-d61e-4fe4-b4c0-2089e488f989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfPreclinicalOncologyPrograms_550103a5-136a-47a0-bc50-68971ede2ef9" xlink:href="amgn-20221231.xsd#amgn_NumberOfPreclinicalOncologyPrograms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_amgn_NumberOfPreclinicalOncologyPrograms_550103a5-136a-47a0-bc50-68971ede2ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_acbe829c-04b9-4d28-9f3d-f1e3fb7bbf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_acbe829c-04b9-4d28-9f3d-f1e3fb7bbf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0ab61084-ef0e-4828-82fa-090f09925f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0ab61084-ef0e-4828-82fa-090f09925f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7033fdd8-17ab-4c34-828e-2d132dfd2aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7033fdd8-17ab-4c34-828e-2d132dfd2aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ba0867e7-a3d0-4633-bbdf-f582a6866e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e20a88e-308c-4437-9892-26ad7b9bdbcc" xlink:to="loc_us-gaap_Goodwill_ba0867e7-a3d0-4633-bbdf-f582a6866e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bbc33567-9d60-4567-8ab2-8b48930a3c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bbc33567-9d60-4567-8ab2-8b48930a3c7d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e1f355ce-242b-404c-b3b9-5fae7598dfca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e1f355ce-242b-404c-b3b9-5fae7598dfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66cc7bff-cf16-4dcb-94e8-d2fb8e7eb7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1f355ce-242b-404c-b3b9-5fae7598dfca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66cc7bff-cf16-4dcb-94e8-d2fb8e7eb7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_d1b07a50-7ee2-44a9-a7c0-52eb16450a9c" xlink:href="amgn-20221231.xsd#amgn_TeneobioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66cc7bff-cf16-4dcb-94e8-d2fb8e7eb7a5" xlink:to="loc_amgn_TeneobioMember_d1b07a50-7ee2-44a9-a7c0-52eb16450a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b69d26c3-8962-48c1-a86e-626edf636171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b69d26c3-8962-48c1-a86e-626edf636171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5d44fc8b-2c2b-45d1-a097-894da3636612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b69d26c3-8962-48c1-a86e-626edf636171" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5d44fc8b-2c2b-45d1-a097-894da3636612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e3d44d0d-29c4-432e-b622-122683af1ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5d44fc8b-2c2b-45d1-a097-894da3636612" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e3d44d0d-29c4-432e-b622-122683af1ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_799468ef-9e8e-4b39-84a4-765c5dab80f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_799468ef-9e8e-4b39-84a4-765c5dab80f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0f392bd-f2f1-4ab6-b6b3-396ff92b2b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_799468ef-9e8e-4b39-84a4-765c5dab80f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0f392bd-f2f1-4ab6-b6b3-396ff92b2b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_0f3c6807-bf01-464e-b515-818fff78df99" xlink:href="amgn-20221231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0f392bd-f2f1-4ab6-b6b3-396ff92b2b87" xlink:to="loc_amgn_RDTechnologyrightsMember_0f3c6807-bf01-464e-b515-818fff78df99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e2c660a9-e724-4096-bcb1-b6a0cf885796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0f392bd-f2f1-4ab6-b6b3-396ff92b2b87" xlink:to="loc_us-gaap_LicensingAgreementsMember_e2c660a9-e724-4096-bcb1-b6a0cf885796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ad1d133b-9c6f-4c4f-867c-77ddf346fe95" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_34158204-6309-4550-8ab1-5c4472531ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_34158204-6309-4550-8ab1-5c4472531ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_f52aa5de-400d-4d98-a466-34d51e291395" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_f52aa5de-400d-4d98-a466-34d51e291395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_5ba10717-bd8e-49ab-98ef-1d5f028c9340" xlink:href="amgn-20221231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_5ba10717-bd8e-49ab-98ef-1d5f028c9340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_05be1f4f-1683-4de3-ab5c-907ed46fa015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_05be1f4f-1683-4de3-ab5c-907ed46fa015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc7ceb61-1cfc-4bbf-9836-cfed90428a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc7ceb61-1cfc-4bbf-9836-cfed90428a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_24528adb-d4f8-4add-ad88-5b596913ac07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_24528adb-d4f8-4add-ad88-5b596913ac07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b7aac4d4-4a4b-4736-8b3a-4efbf69da993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_Goodwill_b7aac4d4-4a4b-4736-8b3a-4efbf69da993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_79ebe9ab-ea93-4660-adca-977dfabb0f95" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_79ebe9ab-ea93-4660-adca-977dfabb0f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_63dd773e-e461-48ba-8f3a-4fbf951ec60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_63dd773e-e461-48ba-8f3a-4fbf951ec60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_24c55a1d-c158-4697-98e7-d8da532a93e5" xlink:href="amgn-20221231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00fe702f-9de3-4588-be02-153fa9a07214" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_24c55a1d-c158-4697-98e7-d8da532a93e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_43161a69-524c-4a45-8fc2-9d595fba0a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_190e3d2f-4b33-4c59-8cd2-72559f6b8285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_43161a69-524c-4a45-8fc2-9d595fba0a21" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_190e3d2f-4b33-4c59-8cd2-72559f6b8285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87f829f8-82e1-480c-804b-149954855c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_190e3d2f-4b33-4c59-8cd2-72559f6b8285" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87f829f8-82e1-480c-804b-149954855c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c7a4a-4abf-4720-bd43-f376b5bbb262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87f829f8-82e1-480c-804b-149954855c0f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c7a4a-4abf-4720-bd43-f376b5bbb262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePrimeTherapeuticsIncMember_7414e3e6-9532-40f5-b450-06cf259fd607" xlink:href="amgn-20221231.xsd#amgn_FivePrimeTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c7a4a-4abf-4720-bd43-f376b5bbb262" xlink:to="loc_amgn_FivePrimeTherapeuticsIncMember_7414e3e6-9532-40f5-b450-06cf259fd607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_190e3d2f-4b33-4c59-8cd2-72559f6b8285" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6f7eb065-e3f1-4fd7-8288-b38897d687b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6f7eb065-e3f1-4fd7-8288-b38897d687b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_cb8ec8c0-bab6-44fb-bd32-88518e052a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_cb8ec8c0-bab6-44fb-bd32-88518e052a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fc1cfafc-dcb5-46d7-834b-473a8fbaa906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fc1cfafc-dcb5-46d7-834b-473a8fbaa906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_46cf15ea-f52d-448c-b139-55f076b31b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e526d9d6-3615-4301-ae39-aabc62166e00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_46cf15ea-f52d-448c-b139-55f076b31b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#AcquisitionsanddivestituresDivestitureofGensentaDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7f67b99c-f585-4395-b213-4da05f2cceac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa2e4ea-f27b-4b10-bcd4-b4834223f210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7f67b99c-f585-4395-b213-4da05f2cceac" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa2e4ea-f27b-4b10-bcd4-b4834223f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6492499a-958b-4f8d-875c-accb465ab298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa2e4ea-f27b-4b10-bcd4-b4834223f210" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6492499a-958b-4f8d-875c-accb465ab298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88cbd7c2-d72b-45e4-a8fc-aa78d2a47944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6492499a-958b-4f8d-875c-accb465ab298" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88cbd7c2-d72b-45e4-a8fc-aa78d2a47944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherGeneralExpenseMember_d18c01c4-0cdc-489a-b68d-da8b2c62cc29" xlink:href="amgn-20221231.xsd#amgn_OtherGeneralExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88cbd7c2-d72b-45e4-a8fc-aa78d2a47944" xlink:to="loc_amgn_OtherGeneralExpenseMember_d18c01c4-0cdc-489a-b68d-da8b2c62cc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa2e4ea-f27b-4b10-bcd4-b4834223f210" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness_fd1407dd-458f-4fc8-b1fb-76df0e33a8da" xlink:href="amgn-20221231.xsd#amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:to="loc_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness_fd1407dd-458f-4fc8-b1fb-76df0e33a8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9f16a0db-71d6-4c37-8890-59e15cf38a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9f16a0db-71d6-4c37-8890-59e15cf38a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ffa3a55b-f347-4445-b4d2-1a6c40af87e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ffa3a55b-f347-4445-b4d2-1a6c40af87e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_89d051ef-8991-4484-8741-faf34dedb56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_838faffb-540f-4600-925c-e6766350717d" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_89d051ef-8991-4484-8741-faf34dedb56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_250cac94-6c3f-47dc-abb0-5157eccdab5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b0e44c41-5bbe-4ce9-aafe-4ffd07153b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_250cac94-6c3f-47dc-abb0-5157eccdab5f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b0e44c41-5bbe-4ce9-aafe-4ffd07153b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_250cac94-6c3f-47dc-abb0-5157eccdab5f" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a1197d11-e6ac-4136-a819-d963403032a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:to="loc_srt_MajorCustomersAxis_a1197d11-e6ac-4136-a819-d963403032a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a1197d11-e6ac-4136-a819-d963403032a7" xlink:to="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_c626279e-ec98-4a9b-8166-eb310afea13b" xlink:href="amgn-20221231.xsd#amgn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:to="loc_amgn_CustomerOneMember_c626279e-ec98-4a9b-8166-eb310afea13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_bbbec83d-a671-42e1-acff-1163d844d6c8" xlink:href="amgn-20221231.xsd#amgn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:to="loc_amgn_CustomerTwoMember_bbbec83d-a671-42e1-acff-1163d844d6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_78672897-7096-48d6-93be-a694aef23d4d" xlink:href="amgn-20221231.xsd#amgn_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2f48e34b-1058-4e72-8656-8e636e485fd9" xlink:to="loc_amgn_CustomerThreeMember_78672897-7096-48d6-93be-a694aef23d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8220b2b9-1754-41b1-876b-429c5f4295ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:to="loc_srt_ProductOrServiceAxis_8220b2b9-1754-41b1-876b-429c5f4295ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1c16cfa-4ad4-46e3-9490-fb1aed6fceb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8220b2b9-1754-41b1-876b-429c5f4295ba" xlink:to="loc_srt_ProductsAndServicesDomain_b1c16cfa-4ad4-46e3-9490-fb1aed6fceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1c16cfa-4ad4-46e3-9490-fb1aed6fceb8" xlink:to="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember_3e399496-54f3-473d-ac10-de70d90c70e9" xlink:href="amgn-20221231.xsd#amgn_EnbrelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_EnbrelMember_3e399496-54f3-473d-ac10-de70d90c70e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember_7d1587f9-2c5d-459a-8aca-187a879961a4" xlink:href="amgn-20221231.xsd#amgn_ProliaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_ProliaMember_7d1587f9-2c5d-459a-8aca-187a879961a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_5f30e428-e735-4743-bc3f-1fec6cb15409" xlink:href="amgn-20221231.xsd#amgn_OtezlaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_OtezlaMember_5f30e428-e735-4743-bc3f-1fec6cb15409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember_137cbf0c-20d4-40b3-81e8-51e7d3386aaa" xlink:href="amgn-20221231.xsd#amgn_XgevaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_XgevaMember_137cbf0c-20d4-40b3-81e8-51e7d3386aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember_5fb9004e-34f0-4b54-9463-3a9a2bef9ea1" xlink:href="amgn-20221231.xsd#amgn_AranespMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_AranespMember_5fb9004e-34f0-4b54-9463-3a9a2bef9ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember_9056eb86-a02a-4e6d-b321-e31dfa096672" xlink:href="amgn-20221231.xsd#amgn_NplateMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_NplateMember_9056eb86-a02a-4e6d-b321-e31dfa096672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember_249bd083-06d8-410d-8e19-62669ee948d9" xlink:href="amgn-20221231.xsd#amgn_RepathaevolocumabMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_RepathaevolocumabMember_249bd083-06d8-410d-8e19-62669ee948d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_439b1840-0264-4b5f-9adf-4d4b4cad0933" xlink:href="amgn-20221231.xsd#amgn_KyprolisMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_KyprolisMember_439b1840-0264-4b5f-9adf-4d4b4cad0933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember_b5d5ac34-da41-45f4-93d7-b6c42e48ea40" xlink:href="amgn-20221231.xsd#amgn_NeulastaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_NeulastaMember_b5d5ac34-da41-45f4-93d7-b6c42e48ea40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EvenityMember_75956baf-5a81-4195-897f-18374e20c222" xlink:href="amgn-20221231.xsd#amgn_EvenityMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_EvenityMember_75956baf-5a81-4195-897f-18374e20c222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember_14a351f7-30ab-4f50-b15d-87876cf7c0a0" xlink:href="amgn-20221231.xsd#amgn_OtherProductsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_584c6859-e894-4734-8460-3a7dd9a29ad0" xlink:to="loc_amgn_OtherProductsMember_14a351f7-30ab-4f50-b15d-87876cf7c0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ad571b37-2a6a-4158-904d-0b78e31683df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1c16cfa-4ad4-46e3-9490-fb1aed6fceb8" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ad571b37-2a6a-4158-904d-0b78e31683df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_65c1e1d4-1bbb-41ac-ae00-cf0f314bd65a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:to="loc_srt_StatementGeographicalAxis_65c1e1d4-1bbb-41ac-ae00-cf0f314bd65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2597c69e-ce8c-4348-8b2c-724c4e3941ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_65c1e1d4-1bbb-41ac-ae00-cf0f314bd65a" xlink:to="loc_srt_SegmentGeographicalDomain_2597c69e-ce8c-4348-8b2c-724c4e3941ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_82423078-3176-469b-bd0f-a34f668416a9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2597c69e-ce8c-4348-8b2c-724c4e3941ab" xlink:to="loc_country_US_82423078-3176-469b-bd0f-a34f668416a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_26bf08d0-5205-42d0-9243-5e8a041ae389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2597c69e-ce8c-4348-8b2c-724c4e3941ab" xlink:to="loc_us-gaap_NonUsMember_26bf08d0-5205-42d0-9243-5e8a041ae389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b37c5f27-a9a0-4c3e-902e-6ba16986efb3" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_14d3ac15-6de0-4fb2-a0ff-c1c58e649e8a" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_14d3ac15-6de0-4fb2-a0ff-c1c58e649e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_b43a4228-7c2a-4e6d-9e89-42aa6f49d788" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_b43a4228-7c2a-4e6d-9e89-42aa6f49d788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_f89e1fb4-4414-4cf4-b0d6-80080402b5fb" xlink:href="amgn-20221231.xsd#amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_f89e1fb4-4414-4cf4-b0d6-80080402b5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_c4b86440-a14f-44f9-b5bf-ab5acb27a67f" xlink:href="amgn-20221231.xsd#amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_c4b86440-a14f-44f9-b5bf-ab5acb27a67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ec8a0375-c4f9-411f-8701-b5d08e26fc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ec8a0375-c4f9-411f-8701-b5d08e26fc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_ce415763-7d36-4e6e-a939-3f67296d62bc" xlink:href="amgn-20221231.xsd#amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_ce415763-7d36-4e6e-a939-3f67296d62bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_054ef017-dd58-4ca1-b641-fdb76d82a5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c69bc9e-2ee9-4b23-b238-d26660950d8f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_054ef017-dd58-4ca1-b641-fdb76d82a5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#RevenuesCustomerConcentrationProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_30e85987-3953-4c06-bec5-5f06e6b888a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_434c6f4d-7cc6-4546-a89d-3359daf2b7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_30e85987-3953-4c06-bec5-5f06e6b888a4" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_434c6f4d-7cc6-4546-a89d-3359daf2b7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7df622b3-b3e1-4050-ac90-8a3d5deff471" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_434c6f4d-7cc6-4546-a89d-3359daf2b7a6" xlink:to="loc_srt_ProductOrServiceAxis_7df622b3-b3e1-4050-ac90-8a3d5deff471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ad8679e-1b52-40d6-901e-7e7b324b7a2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7df622b3-b3e1-4050-ac90-8a3d5deff471" xlink:to="loc_srt_ProductsAndServicesDomain_5ad8679e-1b52-40d6-901e-7e7b324b7a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7c06bbee-ef63-4346-8fb8-73f41bdfedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ad8679e-1b52-40d6-901e-7e7b324b7a2e" xlink:to="loc_us-gaap_ProductMember_7c06bbee-ef63-4346-8fb8-73f41bdfedbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2fe77a2c-3489-4bbf-9ef6-72b8edd1d100" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_434c6f4d-7cc6-4546-a89d-3359daf2b7a6" xlink:to="loc_srt_MajorCustomersAxis_2fe77a2c-3489-4bbf-9ef6-72b8edd1d100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2fe77a2c-3489-4bbf-9ef6-72b8edd1d100" xlink:to="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_fddc9c0d-3a85-4983-9333-a4aae4aa1475" xlink:href="amgn-20221231.xsd#amgn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:to="loc_amgn_CustomerOneMember_fddc9c0d-3a85-4983-9333-a4aae4aa1475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_44152feb-0d17-4488-a792-5685233f0bf2" xlink:href="amgn-20221231.xsd#amgn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:to="loc_amgn_CustomerTwoMember_44152feb-0d17-4488-a792-5685233f0bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_b7083a64-ed36-430d-8f1e-cfcaac24f693" xlink:href="amgn-20221231.xsd#amgn_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ece99c27-8b8b-49f5-8b5e-34386f1d0117" xlink:to="loc_amgn_CustomerThreeMember_b7083a64-ed36-430d-8f1e-cfcaac24f693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_434c6f4d-7cc6-4546-a89d-3359daf2b7a6" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_44caf9b8-c6e4-47c0-9dce-d5775bd4411f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_44caf9b8-c6e4-47c0-9dce-d5775bd4411f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfGrossRevenues_2a542f80-bee1-401d-8277-8867b0501706" xlink:href="amgn-20221231.xsd#amgn_PercentageOfGrossRevenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:to="loc_amgn_PercentageOfGrossRevenues_2a542f80-bee1-401d-8277-8867b0501706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_816b8cc1-5d6e-444b-9e79-78be23bf6494" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_816b8cc1-5d6e-444b-9e79-78be23bf6494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_3ee51580-9a64-40b0-a46a-152c7fee0bc3" xlink:href="amgn-20221231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_be306f57-8655-4253-b810-963b5aa99381" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_3ee51580-9a64-40b0-a46a-152c7fee0bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d0ef4d2-63bd-4d25-ac7e-0ab95bd5189b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7babc472-eafe-433e-93d8-0bb16080e175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d0ef4d2-63bd-4d25-ac7e-0ab95bd5189b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7babc472-eafe-433e-93d8-0bb16080e175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_82d32400-6128-452d-a361-4708db1477ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7babc472-eafe-433e-93d8-0bb16080e175" xlink:to="loc_us-gaap_AwardTypeAxis_82d32400-6128-452d-a361-4708db1477ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_82d32400-6128-452d-a361-4708db1477ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f35c570c-37d1-4fdf-9cc5-ff4df9fbfaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f35c570c-37d1-4fdf-9cc5-ff4df9fbfaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b83fd15c-3e59-4586-9c0f-59b30649cc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b83fd15c-3e59-4586-9c0f-59b30649cc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_ce31f802-17f3-4ca3-b74b-c491a634b053" xlink:href="amgn-20221231.xsd#amgn_PerformanceUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14e4763b-9b6b-417c-b2e7-9efcc34adec3" xlink:to="loc_amgn_PerformanceUnitsMember_ce31f802-17f3-4ca3-b74b-c491a634b053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7babc472-eafe-433e-93d8-0bb16080e175" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_19fb8901-0172-4bfb-9050-475c57d9d4e0" xlink:href="amgn-20221231.xsd#amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_19fb8901-0172-4bfb-9050-475c57d9d4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_2b0fe592-9c41-42bd-8f57-9f409ddc16f0" xlink:href="amgn-20221231.xsd#amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_2b0fe592-9c41-42bd-8f57-9f409ddc16f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_2d21cedd-bd7a-4fc4-ac47-92f61312ade0" xlink:href="amgn-20221231.xsd#amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_2d21cedd-bd7a-4fc4-ac47-92f61312ade0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_8a6aafe6-e831-4635-b0df-c0c8fc286561" xlink:href="amgn-20221231.xsd#amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_8a6aafe6-e831-4635-b0df-c0c8fc286561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_db976134-be49-4832-a2b3-e7c71af71f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_db976134-be49-4832-a2b3-e7c71af71f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53d6f91c-75f6-45d6-a619-2d867acaa92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53d6f91c-75f6-45d6-a619-2d867acaa92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5c40a052-6e52-4693-bcfb-8ac7effd004b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5c40a052-6e52-4693-bcfb-8ac7effd004b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bce9c3d9-53cd-4c8c-b536-59aa9a828dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bce9c3d9-53cd-4c8c-b536-59aa9a828dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4976612b-5b76-466a-a725-8d02ee0eba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4976612b-5b76-466a-a725-8d02ee0eba6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_91ac5962-4760-41e4-b429-c04e63ab3690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_91ac5962-4760-41e4-b429-c04e63ab3690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c7db28c9-9e98-4446-ac6e-aa36ccd84b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c7db28c9-9e98-4446-ac6e-aa36ccd84b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_422e8868-1c16-4d12-aec4-2eaff0126235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_422e8868-1c16-4d12-aec4-2eaff0126235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_095ada91-3881-40e0-88c8-a41993f39202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_095ada91-3881-40e0-88c8-a41993f39202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_d8e455af-2b19-4b7e-9773-c069b714bfb6" xlink:href="amgn-20221231.xsd#amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_d8e455af-2b19-4b7e-9773-c069b714bfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_85c05877-fc81-4d4a-b6d5-bea287ab31b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_85c05877-fc81-4d4a-b6d5-bea287ab31b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7f7f84df-b7b0-4a6d-8af1-73a683a5bd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7f7f84df-b7b0-4a6d-8af1-73a683a5bd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9df28876-82a9-4ce4-8084-5c6053d8c350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9df28876-82a9-4ce4-8084-5c6053d8c350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f757f327-15a2-4524-aa58-3ff32880c179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f757f327-15a2-4524-aa58-3ff32880c179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5f0080e8-2bec-4ef9-8575-42787433658a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bcc7908-4f2a-4b30-a91c-42f67e9f9f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5f0080e8-2bec-4ef9-8575-42787433658a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98006942-a214-4c27-9f69-ef2df839a016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fd72825-159f-483d-aaf2-cf4efa478d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98006942-a214-4c27-9f69-ef2df839a016" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fd72825-159f-483d-aaf2-cf4efa478d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9697809f-56d1-479e-a495-c238704601d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fd72825-159f-483d-aaf2-cf4efa478d92" xlink:to="loc_us-gaap_AwardTypeAxis_9697809f-56d1-479e-a495-c238704601d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9697809f-56d1-479e-a495-c238704601d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d68a10ad-563c-4dcc-90b3-e577ea524e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d68a10ad-563c-4dcc-90b3-e577ea524e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_39f7699b-cdef-4684-8dfd-7e3715e94cad" xlink:href="amgn-20221231.xsd#amgn_PerformanceUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:to="loc_amgn_PerformanceUnitsMember_39f7699b-cdef-4684-8dfd-7e3715e94cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a4a254f3-92f7-446a-9931-e08e8adb918a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e59b9d74-b3fe-4278-9641-140b216d7f45" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a4a254f3-92f7-446a-9931-e08e8adb918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03e1d820-f110-4b98-b0c7-9032deafc241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3fd72825-159f-483d-aaf2-cf4efa478d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03e1d820-f110-4b98-b0c7-9032deafc241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03e1d820-f110-4b98-b0c7-9032deafc241" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bb9576a9-3ca3-4eb5-b058-56926cbd928d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:to="loc_us-gaap_ShareBasedCompensation_bb9576a9-3ca3-4eb5-b058-56926cbd928d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_af67eefa-0e17-4866-8c14-89e1a99885e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_af67eefa-0e17-4866-8c14-89e1a99885e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax_6591dec3-d9b5-4c2d-adaf-70459403cfe3" xlink:href="amgn-20221231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_df3c32ca-b91c-43d3-a357-b87958ef9a6e" xlink:to="loc_amgn_StockBasedCompensationExpenseNetOfTax_6591dec3-d9b5-4c2d-adaf-70459403cfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationSummaryofRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c3c2873-f2af-4342-877a-4a71914047a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05961f06-2272-4d91-bf1e-872d49ee4d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c3c2873-f2af-4342-877a-4a71914047a5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05961f06-2272-4d91-bf1e-872d49ee4d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9ebb93ed-8ff5-4d62-a8f5-5d03b5506cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05961f06-2272-4d91-bf1e-872d49ee4d8c" xlink:to="loc_us-gaap_AwardTypeAxis_9ebb93ed-8ff5-4d62-a8f5-5d03b5506cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebfd4ab4-b901-4566-8eb7-89c81c3e3a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9ebb93ed-8ff5-4d62-a8f5-5d03b5506cf5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebfd4ab4-b901-4566-8eb7-89c81c3e3a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_86cf7b88-e113-4de4-8029-0b9f74e651b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebfd4ab4-b901-4566-8eb7-89c81c3e3a13" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_86cf7b88-e113-4de4-8029-0b9f74e651b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9bb3ad1-6260-4651-854b-7c2199bdf990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05961f06-2272-4d91-bf1e-872d49ee4d8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9bb3ad1-6260-4651-854b-7c2199bdf990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9bb3ad1-6260-4651-854b-7c2199bdf990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_92ed56b6-a8d3-40cb-af28-531ee44248ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_92ed56b6-a8d3-40cb-af28-531ee44248ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d2fbf7e8-892a-4aba-b9d9-2875544b1ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d2fbf7e8-892a-4aba-b9d9-2875544b1ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_240aa4fd-46a9-41f0-84a9-e3c29ffd44f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_240aa4fd-46a9-41f0-84a9-e3c29ffd44f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_de856ca9-a47b-4483-963c-9d2d838c3bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_de856ca9-a47b-4483-963c-9d2d838c3bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a261ae74-2819-4231-85c6-7f271bd13118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aa41be1-1378-4936-986d-2a1083772817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a261ae74-2819-4231-85c6-7f271bd13118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9bb3ad1-6260-4651-854b-7c2199bdf990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ff6c60b-7858-4bae-9389-03f9f43c8878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ff6c60b-7858-4bae-9389-03f9f43c8878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_118244b8-2a75-4893-af26-6a31b634742e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_118244b8-2a75-4893-af26-6a31b634742e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bd029f13-8496-4f5f-b306-278d83819719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bd029f13-8496-4f5f-b306-278d83819719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0fdf2e8f-cbcf-44f1-8de8-370d538bd7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0fdf2e8f-cbcf-44f1-8de8-370d538bd7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3286d4e0-f6d2-43b6-a0f9-0bc3b45a40e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_307ee5de-7ede-4103-9178-c500fbd61a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3286d4e0-f6d2-43b6-a0f9-0bc3b45a40e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c3d41b-1060-4ba9-b094-58cd431f06f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2b2800b-4c22-4b87-93e9-3be0778bb1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c3d41b-1060-4ba9-b094-58cd431f06f0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2b2800b-4c22-4b87-93e9-3be0778bb1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46bd89ee-6dcf-42c5-bed0-0dbf7eacda59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2b2800b-4c22-4b87-93e9-3be0778bb1ed" xlink:to="loc_us-gaap_AwardTypeAxis_46bd89ee-6dcf-42c5-bed0-0dbf7eacda59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_386ebcfd-b65a-4e55-bb5d-4e39346b8a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_46bd89ee-6dcf-42c5-bed0-0dbf7eacda59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_386ebcfd-b65a-4e55-bb5d-4e39346b8a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8fbf5bc8-1b3a-42b2-8087-f08f82fda335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_386ebcfd-b65a-4e55-bb5d-4e39346b8a9c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8fbf5bc8-1b3a-42b2-8087-f08f82fda335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2b2800b-4c22-4b87-93e9-3be0778bb1ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_fda79f74-59a8-4411-9a8f-41bc69310931" xlink:href="amgn-20221231.xsd#amgn_CommonStockFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_amgn_CommonStockFairValue_fda79f74-59a8-4411-9a8f-41bc69310931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5bfc9fab-3217-4544-96e0-bc571dbf6160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5bfc9fab-3217-4544-96e0-bc571dbf6160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e310eac-77f8-4a99-8b14-4e46862999dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e310eac-77f8-4a99-8b14-4e46862999dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_22562f4a-1a9e-49fb-86bd-d6d1ec3c94ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_22562f4a-1a9e-49fb-86bd-d6d1ec3c94ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7cd5c7b5-dc47-4802-ab20-c411030c1b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7cd5c7b5-dc47-4802-ab20-c411030c1b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b5411785-3636-4c20-adf7-92c5ff93d174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fab6f96-9995-48bb-9efb-982d0468fda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b5411785-3636-4c20-adf7-92c5ff93d174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df5d1fb1-2fb7-42ed-a284-6081438d77ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2eef23d-b146-40e9-831c-b409204cd8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df5d1fb1-2fb7-42ed-a284-6081438d77ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2eef23d-b146-40e9-831c-b409204cd8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c798bf61-6f2c-4321-be82-20f897e45b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2eef23d-b146-40e9-831c-b409204cd8d0" xlink:to="loc_us-gaap_AwardTypeAxis_c798bf61-6f2c-4321-be82-20f897e45b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c0c08-7824-4c9b-bb43-e751a5469891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c798bf61-6f2c-4321-be82-20f897e45b01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c0c08-7824-4c9b-bb43-e751a5469891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80a35ddc-bb7d-4862-979c-15c26b27772c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c0c08-7824-4c9b-bb43-e751a5469891" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80a35ddc-bb7d-4862-979c-15c26b27772c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2eef23d-b146-40e9-831c-b409204cd8d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18e9de84-f9f4-407e-ada1-a3d4e1215fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18e9de84-f9f4-407e-ada1-a3d4e1215fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_cfca0852-8d40-4e83-ad18-1f2a4dd918e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_cfca0852-8d40-4e83-ad18-1f2a4dd918e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_913e3740-3b9a-4c6a-a0d3-13e711eccce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_913e3740-3b9a-4c6a-a0d3-13e711eccce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_be6984fd-0a38-4ee4-a6b7-5dd80d5a29a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_be6984fd-0a38-4ee4-a6b7-5dd80d5a29a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd5cfd50-92fe-4a39-bb53-cab1131bcbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5df8ea11-37b2-47ac-bccf-1df28ed94579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd5cfd50-92fe-4a39-bb53-cab1131bcbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4cf0134f-bb0e-4b7c-83f6-43282a07821b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4cf0134f-bb0e-4b7c-83f6-43282a07821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23b13dd6-1194-4120-ad8d-f4723863f18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23b13dd6-1194-4120-ad8d-f4723863f18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c63503df-5596-4c94-9ba6-35b2d4230adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c63503df-5596-4c94-9ba6-35b2d4230adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb6790dc-3ad0-4da8-a2fa-5fc0f10a0a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb6790dc-3ad0-4da8-a2fa-5fc0f10a0a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f183829c-0c4b-484a-ae08-702edf60ebb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f183829c-0c4b-484a-ae08-702edf60ebb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5c12b8d2-db4e-48ca-bc7a-4abcdb9bae82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5c12b8d2-db4e-48ca-bc7a-4abcdb9bae82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e90b58a1-0a09-4607-a167-ec9d9cd8af86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_893f552a-a320-4e8d-be0e-cf68bb019471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e90b58a1-0a09-4607-a167-ec9d9cd8af86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a0b2dbe9-646e-47d3-bedf-c6b365fc435e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a0b2dbe9-646e-47d3-bedf-c6b365fc435e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_29ef4ba2-87ec-460b-bd1d-56f9551ba831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_29ef4ba2-87ec-460b-bd1d-56f9551ba831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92784f5b-df2f-4320-936f-6ead8c38e09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6ebf4e79-d5eb-4f0f-aa92-85773792135b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6ebf4e79-d5eb-4f0f-aa92-85773792135b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3f171152-fe08-468d-a59c-153773336778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3f171152-fe08-468d-a59c-153773336778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a32af927-1f25-4ba8-b7c7-42b8a7704e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a32af927-1f25-4ba8-b7c7-42b8a7704e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_eae8c323-3f1a-40f8-a2d0-1344bb20ffc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_eae8c323-3f1a-40f8-a2d0-1344bb20ffc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c03c50a3-5ef9-44d1-995a-7ffee2ae9b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c03c50a3-5ef9-44d1-995a-7ffee2ae9b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6329cac5-3352-4107-9824-31dd25436edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_33499d70-e31f-43b6-9552-1078525449fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6329cac5-3352-4107-9824-31dd25436edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockbasedcompensationWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f9ebeab-9dea-44cf-9470-53751d3b133b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b1756a55-332f-4d49-8bd5-133e9b91196a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f9ebeab-9dea-44cf-9470-53751d3b133b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b1756a55-332f-4d49-8bd5-133e9b91196a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16cd8c8f-33c3-4c7d-ba19-e21081b8de27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b1756a55-332f-4d49-8bd5-133e9b91196a" xlink:to="loc_us-gaap_AwardTypeAxis_16cd8c8f-33c3-4c7d-ba19-e21081b8de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1ad2603-0fe0-4d40-af17-f67274da7374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_16cd8c8f-33c3-4c7d-ba19-e21081b8de27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1ad2603-0fe0-4d40-af17-f67274da7374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_5b6d1d82-9994-4ced-9818-dcfad3caf259" xlink:href="amgn-20221231.xsd#amgn_PerformanceUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1ad2603-0fe0-4d40-af17-f67274da7374" xlink:to="loc_amgn_PerformanceUnitsMember_5b6d1d82-9994-4ced-9818-dcfad3caf259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e59f14a-ab45-4f0d-90ba-6006b6f79505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b1756a55-332f-4d49-8bd5-133e9b91196a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e59f14a-ab45-4f0d-90ba-6006b6f79505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e59f14a-ab45-4f0d-90ba-6006b6f79505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_654def05-2df8-4132-bd75-06eac8c34cfe" xlink:href="amgn-20221231.xsd#amgn_CommonStockFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:to="loc_amgn_CommonStockFairValue_654def05-2df8-4132-bd75-06eac8c34cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ce750290-5f64-48a5-b3ee-155f5d1d1529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ce750290-5f64-48a5-b3ee-155f5d1d1529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bebc4192-9b3c-47da-8597-2204bc0241e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bebc4192-9b3c-47da-8597-2204bc0241e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f761c47a-aeb5-43d9-a7b2-f9da48648abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_191bdcdf-d7c7-4ecc-b916-2ec52ea1afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f761c47a-aeb5-43d9-a7b2-f9da48648abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DefinedcontributionplanDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8274baf-5837-46e1-a643-e662871fedf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_8f27ed82-6982-41df-8f77-191c086f323f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8274baf-5837-46e1-a643-e662871fedf2" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_8f27ed82-6982-41df-8f77-191c086f323f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesIncomeBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d82eff2c-3a61-4169-bb7e-17798d000153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_268cedd4-5487-4dd5-8a3c-e39559e23ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d82eff2c-3a61-4169-bb7e-17798d000153" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_268cedd4-5487-4dd5-8a3c-e39559e23ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_922bc1d3-a5b7-43d3-9f7c-81071888753a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_268cedd4-5487-4dd5-8a3c-e39559e23ee8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_922bc1d3-a5b7-43d3-9f7c-81071888753a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_99e5568c-b20b-4aa0-ac4e-73e77f03d1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_922bc1d3-a5b7-43d3-9f7c-81071888753a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_99e5568c-b20b-4aa0-ac4e-73e77f03d1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_802a9983-f5b8-40be-9286-6da7bdf899e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_99e5568c-b20b-4aa0-ac4e-73e77f03d1be" xlink:to="loc_us-gaap_DomesticCountryMember_802a9983-f5b8-40be-9286-6da7bdf899e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_5b54b263-2e87-4360-aed4-4df0ae0ae5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_99e5568c-b20b-4aa0-ac4e-73e77f03d1be" xlink:to="loc_us-gaap_ForeignCountryMember_5b54b263-2e87-4360-aed4-4df0ae0ae5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_d175b902-02c1-4787-8af7-66e63bd44f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_268cedd4-5487-4dd5-8a3c-e39559e23ee8" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_d175b902-02c1-4787-8af7-66e63bd44f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_578cbe10-9aa5-4e10-8f26-f1599d5fe00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d175b902-02c1-4787-8af7-66e63bd44f66" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_578cbe10-9aa5-4e10-8f26-f1599d5fe00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6e40dd48-43f3-4901-a062-7bf99ce58a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_19e1b1b1-e834-4956-92e1-6efdf5021737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6e40dd48-43f3-4901-a062-7bf99ce58a70" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_19e1b1b1-e834-4956-92e1-6efdf5021737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9da4f255-0553-477c-a08f-cf4ec595715e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_19e1b1b1-e834-4956-92e1-6efdf5021737" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9da4f255-0553-477c-a08f-cf4ec595715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e99ba05e-3199-4041-9960-400a8ef8880c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_19e1b1b1-e834-4956-92e1-6efdf5021737" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e99ba05e-3199-4041-9960-400a8ef8880c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_98e22b3f-9d4a-42dd-9fab-b3681a613bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_19e1b1b1-e834-4956-92e1-6efdf5021737" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_98e22b3f-9d4a-42dd-9fab-b3681a613bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_25ea8d15-1595-46a2-918f-54961febaab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_19e1b1b1-e834-4956-92e1-6efdf5021737" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_25ea8d15-1595-46a2-918f-54961febaab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e9da2213-983c-4973-af3d-32bbcaafa8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6e40dd48-43f3-4901-a062-7bf99ce58a70" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e9da2213-983c-4973-af3d-32bbcaafa8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_346ff91f-1df0-4046-a626-cc3dbe7df54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e9da2213-983c-4973-af3d-32bbcaafa8dc" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_346ff91f-1df0-4046-a626-cc3dbe7df54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0805b9dd-844f-486c-b314-1a3c28194fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e9da2213-983c-4973-af3d-32bbcaafa8dc" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0805b9dd-844f-486c-b314-1a3c28194fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3986d2cf-b961-4ac9-8012-deb30f439058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e9da2213-983c-4973-af3d-32bbcaafa8dc" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3986d2cf-b961-4ac9-8012-deb30f439058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e4a7dd02-6ca7-44cf-9330-7d0b8d99fd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e9da2213-983c-4973-af3d-32bbcaafa8dc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e4a7dd02-6ca7-44cf-9330-7d0b8d99fd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_36429ae3-717a-4e1e-b61f-86783baad615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6e40dd48-43f3-4901-a062-7bf99ce58a70" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_36429ae3-717a-4e1e-b61f-86783baad615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f4f9e033-bb86-4503-aec2-8a4d89667f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_14ebc88f-738c-4176-a016-d08abd4535db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f4f9e033-bb86-4503-aec2-8a4d89667f82" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_14ebc88f-738c-4176-a016-d08abd4535db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_14ebc88f-738c-4176-a016-d08abd4535db" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_0941cc6b-3533-431b-ba5c-2340fbadbb67" xlink:href="amgn-20221231.xsd#amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_0941cc6b-3533-431b-ba5c-2340fbadbb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d5b219f0-44c7-4735-81e1-9d61d00bcbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d5b219f0-44c7-4735-81e1-9d61d00bcbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_ddb7867b-63d7-4fe2-af43-6b103e099b5a" xlink:href="amgn-20221231.xsd#amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_ddb7867b-63d7-4fe2-af43-6b103e099b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_b3682b48-8704-4334-8008-32dbf7c479fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_b3682b48-8704-4334-8008-32dbf7c479fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_c82d43a8-924f-4956-b118-1af839b8038b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_c82d43a8-924f-4956-b118-1af839b8038b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries_52129b72-3e26-4270-aad3-7e8b3d772093" xlink:href="amgn-20221231.xsd#amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries_52129b72-3e26-4270-aad3-7e8b3d772093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e5cc26e9-d019-4e8b-8ffb-3c8089519341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e5cc26e9-d019-4e8b-8ffb-3c8089519341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_aacec320-d67f-4fad-9bb5-e26b3a524183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_aacec320-d67f-4fad-9bb5-e26b3a524183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2ec57b1b-7c0b-4378-b83f-259ec4d7d23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2ec57b1b-7c0b-4378-b83f-259ec4d7d23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_31bb6f40-58f5-431a-9aba-dd759de400e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_31bb6f40-58f5-431a-9aba-dd759de400e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9ea567d8-bfdf-4cdf-9865-68d74864bb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_88b10648-0447-429d-b02f-d491ec00a4aa" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9ea567d8-bfdf-4cdf-9865-68d74864bb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_bf8f6ae4-ef69-4dc0-a517-b303f67af1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_14ebc88f-738c-4176-a016-d08abd4535db" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_bf8f6ae4-ef69-4dc0-a517-b303f67af1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4094db76-6b94-4d31-88f2-97919de65103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_bf8f6ae4-ef69-4dc0-a517-b303f67af1af" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4094db76-6b94-4d31-88f2-97919de65103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_51700058-ab29-451a-b084-5116b047940c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_bf8f6ae4-ef69-4dc0-a517-b303f67af1af" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_51700058-ab29-451a-b084-5116b047940c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_56eb226f-04a1-4115-bb4a-179eec5a52eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_bf8f6ae4-ef69-4dc0-a517-b303f67af1af" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_56eb226f-04a1-4115-bb4a-179eec5a52eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_420f3fc4-5554-4211-98f3-13dbcb6c111f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_bf8f6ae4-ef69-4dc0-a517-b303f67af1af" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_420f3fc4-5554-4211-98f3-13dbcb6c111f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c968577f-d085-4880-a763-8c7c2893bb50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_bf8f6ae4-ef69-4dc0-a517-b303f67af1af" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_c968577f-d085-4880-a763-8c7c2893bb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ddbc8c8f-548f-4ba8-bd9d-31ba67fa161f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_bf8f6ae4-ef69-4dc0-a517-b303f67af1af" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ddbc8c8f-548f-4ba8-bd9d-31ba67fa161f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0736065f-f4c2-4d55-ac79-144fad24557e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_6b037c7d-b020-4b0e-ae31-7cf9d3515881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0736065f-f4c2-4d55-ac79-144fad24557e" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_6b037c7d-b020-4b0e-ae31-7cf9d3515881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_80cf01ee-e514-4566-a268-e671db57e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b037c7d-b020-4b0e-ae31-7cf9d3515881" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_80cf01ee-e514-4566-a268-e671db57e66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_80cf01ee-e514-4566-a268-e671db57e66f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_376cfe09-8383-43c6-8f5f-c33ce1fde429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:to="loc_us-gaap_DomesticCountryMember_376cfe09-8383-43c6-8f5f-c33ce1fde429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_36676acf-75bc-4ba8-9004-de9400c91717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_36676acf-75bc-4ba8-9004-de9400c91717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_bced4afb-d8ba-4d0c-93d2-1f35ec63afee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4990bc87-5fe4-4bb3-8cf2-07a1305ab59c" xlink:to="loc_us-gaap_ForeignCountryMember_bced4afb-d8ba-4d0c-93d2-1f35ec63afee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_fd85de47-6781-4f62-84f6-9ee8bd783917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b037c7d-b020-4b0e-ae31-7cf9d3515881" xlink:to="loc_us-gaap_TaxPeriodAxis_fd85de47-6781-4f62-84f6-9ee8bd783917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_85440b8a-95e8-4795-99a1-353fe4bd4173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_fd85de47-6781-4f62-84f6-9ee8bd783917" xlink:to="loc_us-gaap_TaxPeriodDomain_85440b8a-95e8-4795-99a1-353fe4bd4173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member_cce64fd6-c6fd-4a21-874c-7eeeaee4e1a9" xlink:href="amgn-20221231.xsd#amgn_OperatingLossesThatExpireBetween2022And2031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_85440b8a-95e8-4795-99a1-353fe4bd4173" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member_cce64fd6-c6fd-4a21-874c-7eeeaee4e1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ExpirationInTaxYearsBetween2023And2043Member_265763dc-cb8a-4be1-a279-6efb54fbaab8" xlink:href="amgn-20221231.xsd#amgn_ExpirationInTaxYearsBetween2023And2043Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_85440b8a-95e8-4795-99a1-353fe4bd4173" xlink:to="loc_amgn_ExpirationInTaxYearsBetween2023And2043Member_265763dc-cb8a-4be1-a279-6efb54fbaab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b037c7d-b020-4b0e-ae31-7cf9d3515881" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_c7a5e6cb-d9e2-4d09-9ab1-1aa70eb7d494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_c7a5e6cb-d9e2-4d09-9ab1-1aa70eb7d494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_6136832e-cf62-46fe-b924-fffcd0948a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_6136832e-cf62-46fe-b924-fffcd0948a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1bae5a23-08e9-4add-8ada-5fc21fe498af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1bae5a23-08e9-4add-8ada-5fc21fe498af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_f99dce77-1434-4f26-902e-59d13cb28c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_f99dce77-1434-4f26-902e-59d13cb28c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_324745d0-4406-4185-99e3-60e329432fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_324745d0-4406-4185-99e3-60e329432fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_88c7856d-f6f5-4ce0-9d71-acf1343e136e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_88c7856d-f6f5-4ce0-9d71-acf1343e136e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9e01bad0-89a4-4d27-9cc0-aeddcc0c226e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9e01bad0-89a4-4d27-9cc0-aeddcc0c226e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_84044a8b-6b0d-42f9-9110-4ca89d5ad5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_us-gaap_IncomeTaxesPaid_84044a8b-6b0d-42f9-9110-4ca89d5ad5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax_6479a9dd-3a11-49cc-bfee-3ce176a94174" xlink:href="amgn-20221231.xsd#amgn_ProposedAdditionalIncomeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_ProposedAdditionalIncomeTax_6479a9dd-3a11-49cc-bfee-3ce176a94174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax_1e62def9-19a2-4f6b-88e0-4e12436c00f7" xlink:href="amgn-20221231.xsd#amgn_RepatriationTaxOnProposedAdditionalTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax_1e62def9-19a2-4f6b-88e0-4e12436c00f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfNoticesOnProposedAdditionalTax_aca7edaa-ffee-4644-b074-a4ebb9868afc" xlink:href="amgn-20221231.xsd#amgn_NumberOfNoticesOnProposedAdditionalTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_NumberOfNoticesOnProposedAdditionalTax_aca7edaa-ffee-4644-b074-a4ebb9868afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax20132015_2ad3edce-5dab-4ed1-bd86-0985bbdcd037" xlink:href="amgn-20221231.xsd#amgn_ProposedAdditionalIncomeTax20132015"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_ProposedAdditionalIncomeTax20132015_2ad3edce-5dab-4ed1-bd86-0985bbdcd037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_6ec86f54-f910-425e-8421-cd4686845545" xlink:href="amgn-20221231.xsd#amgn_PenaltiesOnProposedAdditionalIncomeTax20132105"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_6ec86f54-f910-425e-8421-cd4686845545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015_8118fd65-e382-4b2d-b8e1-0b982e7ffc81" xlink:href="amgn-20221231.xsd#amgn_RepatriationTaxOnProposedAdditionalTax20132015"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015_8118fd65-e382-4b2d-b8e1-0b982e7ffc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfNoticesConsolidated_e9db63ba-67c8-4b98-83ef-3d03337b6f39" xlink:href="amgn-20221231.xsd#amgn_NumberOfNoticesConsolidated"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_4c94f032-cffb-455a-a55d-4ddf91050aa8" xlink:to="loc_amgn_NumberOfNoticesConsolidated_e9db63ba-67c8-4b98-83ef-3d03337b6f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4e981970-6a5e-4eb0-aaa9-c25fc2e71a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_89e81190-f8d8-4e80-92d7-2a9a930c768c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e981970-6a5e-4eb0-aaa9-c25fc2e71a61" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_89e81190-f8d8-4e80-92d7-2a9a930c768c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7ed174b0-a5a5-439b-ba73-fa6b4ec667e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_89e81190-f8d8-4e80-92d7-2a9a930c768c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7ed174b0-a5a5-439b-ba73-fa6b4ec667e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_77b406f9-1905-4fa7-bc59-e91a6935f23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_89e81190-f8d8-4e80-92d7-2a9a930c768c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_77b406f9-1905-4fa7-bc59-e91a6935f23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2e3fcfb8-5afc-45fd-aa67-7f784b140744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_89e81190-f8d8-4e80-92d7-2a9a930c768c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2e3fcfb8-5afc-45fd-aa67-7f784b140744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_babef996-0143-4cbc-947f-3210206c3c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_89e81190-f8d8-4e80-92d7-2a9a930c768c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_babef996-0143-4cbc-947f-3210206c3c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e51bd74d-ef84-4d8d-b124-33e726810a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_89e81190-f8d8-4e80-92d7-2a9a930c768c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e51bd74d-ef84-4d8d-b124-33e726810a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_dac55ccf-dfa9-462b-9c96-15b5abf10702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_89e81190-f8d8-4e80-92d7-2a9a930c768c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_dac55ccf-dfa9-462b-9c96-15b5abf10702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_356c4725-8ca2-4235-a056-0b95cd431d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_89e81190-f8d8-4e80-92d7-2a9a930c768c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_356c4725-8ca2-4235-a056-0b95cd431d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#IncometaxesReconciliationofFederalStatutoryTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_53365f43-a68b-4836-a5d0-88f53519f004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_53365f43-a68b-4836-a5d0-88f53519f004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0204a6e4-1d68-422d-9f0f-2d3280b4a6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0204a6e4-1d68-422d-9f0f-2d3280b4a6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_3fe498d9-3562-4087-90b8-c3de62d41e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_3fe498d9-3562-4087-90b8-c3de62d41e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_6c5a38d0-7b8c-4716-ac21-578e1cd80271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_6c5a38d0-7b8c-4716-ac21-578e1cd80271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_81be5332-a441-44d4-91d2-139bb6a144a5" xlink:href="amgn-20221231.xsd#amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_81be5332-a441-44d4-91d2-139bb6a144a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_420d26de-20b2-4fd8-9776-a04d788191be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_420d26de-20b2-4fd8-9776-a04d788191be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_fd4f450f-b9d1-4172-a042-e87691482236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_fd4f450f-b9d1-4172-a042-e87691482236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_b914518f-d586-458b-bc1e-a182e8b5dc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_b914518f-d586-458b-bc1e-a182e8b5dc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_39a81a5d-7f64-4649-84d7-172c30413a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_39a81a5d-7f64-4649-84d7-172c30413a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ee7330db-157f-4432-92d0-c6ebe1a306cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_123be3ae-a29e-4ddc-85ae-cde9c236354d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ee7330db-157f-4432-92d0-c6ebe1a306cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#EarningspershareDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/EarningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fa289c41-f78f-4c2e-9156-bab000c73173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasicAndDilutedEarningPerShareAbstract_efbf931a-80b4-4fe5-8645-580ef87ef0d7" xlink:href="amgn-20221231.xsd#amgn_BasicAndDilutedEarningPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fa289c41-f78f-4c2e-9156-bab000c73173" xlink:to="loc_amgn_BasicAndDilutedEarningPerShareAbstract_efbf931a-80b4-4fe5-8645-580ef87ef0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_b9d722e2-bc62-4268-8c57-356ab385e762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_efbf931a-80b4-4fe5-8645-580ef87ef0d7" xlink:to="loc_us-gaap_NetIncomeLossAbstract_b9d722e2-bc62-4268-8c57-356ab385e762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e5a457e-1325-4d87-b843-3ce0c9d48aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b9d722e2-bc62-4268-8c57-356ab385e762" xlink:to="loc_us-gaap_NetIncomeLoss_3e5a457e-1325-4d87-b843-3ce0c9d48aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2a61b6f1-c746-40e8-a2ab-b83d765fd356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_efbf931a-80b4-4fe5-8645-580ef87ef0d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2a61b6f1-c746-40e8-a2ab-b83d765fd356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f74e7b2a-5132-4ad2-9aca-c9f65d9107fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2a61b6f1-c746-40e8-a2ab-b83d765fd356" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f74e7b2a-5132-4ad2-9aca-c9f65d9107fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_966db21c-fe14-4006-9a35-9a9913c953dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2a61b6f1-c746-40e8-a2ab-b83d765fd356" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_966db21c-fe14-4006-9a35-9a9913c953dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_634d8175-a425-4df3-9c89-1d88088123ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2a61b6f1-c746-40e8-a2ab-b83d765fd356" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_634d8175-a425-4df3-9c89-1d88088123ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ee7d3ca6-3852-4c7b-9282-20353739167c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_efbf931a-80b4-4fe5-8645-580ef87ef0d7" xlink:to="loc_us-gaap_EarningsPerShareBasic_ee7d3ca6-3852-4c7b-9282-20353739167c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3155d562-2a36-4e17-9c8c-9a7db302a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_efbf931a-80b4-4fe5-8645-580ef87ef0d7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3155d562-2a36-4e17-9c8c-9a7db302a1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsBeiGeneDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68899752-aac1-4cfe-beed-70e119cba37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68899752-aac1-4cfe-beed-70e119cba37b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5be90bb3-cd87-493d-9d74-f471a9bf4f68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_srt_ProductOrServiceAxis_5be90bb3-cd87-493d-9d74-f471a9bf4f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_692e7f48-8d62-48e0-a8ef-086ec5807279" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5be90bb3-cd87-493d-9d74-f471a9bf4f68" xlink:to="loc_srt_ProductsAndServicesDomain_692e7f48-8d62-48e0-a8ef-086ec5807279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_fcc3a532-98a5-4190-9ae3-5d600c2675d3" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_692e7f48-8d62-48e0-a8ef-086ec5807279" xlink:to="loc_amgn_BeiGeneMember_fcc3a532-98a5-4190-9ae3-5d600c2675d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5a77c5fe-8a80-4806-8d9e-eef33d07af07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5a77c5fe-8a80-4806-8d9e-eef33d07af07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4f092d1f-7321-4454-b198-c766f8e3c363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5a77c5fe-8a80-4806-8d9e-eef33d07af07" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4f092d1f-7321-4454-b198-c766f8e3c363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53ed35f2-63ed-4416-9ffe-ce951e65087a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f092d1f-7321-4454-b198-c766f8e3c363" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53ed35f2-63ed-4416-9ffe-ce951e65087a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8d2a130-5120-4699-bda4-72bfff9c1659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f092d1f-7321-4454-b198-c766f8e3c363" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8d2a130-5120-4699-bda4-72bfff9c1659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c651bdc7-8c3f-4d94-8468-06787fc20e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c651bdc7-8c3f-4d94-8468-06787fc20e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a920e8da-415b-4eb1-a3e7-e97de50ed71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c651bdc7-8c3f-4d94-8468-06787fc20e86" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a920e8da-415b-4eb1-a3e7-e97de50ed71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_fa942b4b-6cbd-451d-a5d3-12cc6aab8571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a920e8da-415b-4eb1-a3e7-e97de50ed71d" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_fa942b4b-6cbd-451d-a5d3-12cc6aab8571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_1e9d2cec-3f4f-464e-b00e-f042a8335e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a920e8da-415b-4eb1-a3e7-e97de50ed71d" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_1e9d2cec-3f4f-464e-b00e-f042a8335e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00cb312b-ae6f-4c88-93c1-03d3500bf33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00cb312b-ae6f-4c88-93c1-03d3500bf33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_721e5be9-275d-44dc-a387-1a385923fff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00cb312b-ae6f-4c88-93c1-03d3500bf33c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_721e5be9-275d-44dc-a387-1a385923fff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_a2377882-29c1-40d5-9df8-080754b49c88" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_721e5be9-275d-44dc-a387-1a385923fff7" xlink:to="loc_amgn_BeiGeneMember_a2377882-29c1-40d5-9df8-080754b49c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_56de248e-9167-48c3-bcdb-629133ee2b3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_srt_CounterpartyNameAxis_56de248e-9167-48c3-bcdb-629133ee2b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2afb93a7-38cd-493e-8db6-bb3c47436965" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_56de248e-9167-48c3-bcdb-629133ee2b3a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2afb93a7-38cd-493e-8db6-bb3c47436965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_14d7f46e-8368-494f-8cb4-e727602b59b5" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2afb93a7-38cd-493e-8db6-bb3c47436965" xlink:to="loc_amgn_BeiGeneMember_14d7f46e-8368-494f-8cb4-e727602b59b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f09a49b8-975c-4aed-99fc-4ee6c116bd61" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_d9488fc5-8bd7-43cf-b740-8a4d7f0caa91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_d9488fc5-8bd7-43cf-b740-8a4d7f0caa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_66cf712b-824b-405e-9f65-5eed4c4b5ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_66cf712b-824b-405e-9f65-5eed4c4b5ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7ea2cf45-442b-4696-871c-8e1466655ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7ea2cf45-442b-4696-871c-8e1466655ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_ce6d969c-513c-4eeb-a2d1-9139ca7bf7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_ce6d969c-513c-4eeb-a2d1-9139ca7bf7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c389ad70-15d7-418e-9098-c160f449ddc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c389ad70-15d7-418e-9098-c160f449ddc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses_99b7cc25-072d-4744-93d1-de5cb2bc4c75" xlink:href="amgn-20221231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_amgn_ProfitAndLossShareOfExpenses_99b7cc25-072d-4744-93d1-de5cb2bc4c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_1d5c4fde-ad80-4bb0-a080-e47a05b1b848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73a1cb00-ec1b-411a-bc73-ed1ee9412268" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_1d5c4fde-ad80-4bb0-a080-e47a05b1b848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsAstraZenecaPLCDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed57f091-421b-49fd-976b-07b0115830fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5d122eb-5314-46b0-915c-41b4c5611d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed57f091-421b-49fd-976b-07b0115830fd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5d122eb-5314-46b0-915c-41b4c5611d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e96d0b50-c93e-4c30-9660-06f358ca1f67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5d122eb-5314-46b0-915c-41b4c5611d93" xlink:to="loc_srt_CounterpartyNameAxis_e96d0b50-c93e-4c30-9660-06f358ca1f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a67d876-b7f6-417d-abc8-417e92145e76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e96d0b50-c93e-4c30-9660-06f358ca1f67" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a67d876-b7f6-417d-abc8-417e92145e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AstraZenecaPLCMember_c1a95e40-6c65-4361-9970-03b59823649b" xlink:href="amgn-20221231.xsd#amgn_AstraZenecaPLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a67d876-b7f6-417d-abc8-417e92145e76" xlink:to="loc_amgn_AstraZenecaPLCMember_c1a95e40-6c65-4361-9970-03b59823649b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bcc0a7e7-dec0-4535-aa83-f785c585309f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5d122eb-5314-46b0-915c-41b4c5611d93" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bcc0a7e7-dec0-4535-aa83-f785c585309f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bcc0a7e7-dec0-4535-aa83-f785c585309f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a674a14f-417e-4095-ab32-772f44812742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a674a14f-417e-4095-ab32-772f44812742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_802226dc-1758-43f3-83a6-ece9c7aa39b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_802226dc-1758-43f3-83a6-ece9c7aa39b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c143d5f2-cd95-4640-9969-18e7f4dcde82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b649537-9a11-436b-84df-df9d89d347a4" xlink:to="loc_us-gaap_CostOfSalesMember_c143d5f2-cd95-4640-9969-18e7f4dcde82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5d122eb-5314-46b0-915c-41b4c5611d93" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_27adf5a6-cb9a-4b42-b4d6-43feafe527c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_27adf5a6-cb9a-4b42-b4d6-43feafe527c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses_e53575a4-9b70-4ed8-a6cf-7046d9c86bd3" xlink:href="amgn-20221231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:to="loc_amgn_ProfitAndLossShareOfExpenses_e53575a4-9b70-4ed8-a6cf-7046d9c86bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DevelopmentCostsDueToCollaborationPartner_c165666c-f7a3-45a5-8f6e-095df911cd20" xlink:href="amgn-20221231.xsd#amgn_DevelopmentCostsDueToCollaborationPartner"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47387985-ecb6-4eb2-9fb8-215d43021d5b" xlink:to="loc_amgn_DevelopmentCostsDueToCollaborationPartner_c165666c-f7a3-45a5-8f6e-095df911cd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsUCBDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsUCBDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsUCBDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_478896df-01ca-4675-b45b-706b8de531ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d8def7f-476d-4c38-a598-4ebcf74dea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_478896df-01ca-4675-b45b-706b8de531ea" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d8def7f-476d-4c38-a598-4ebcf74dea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_387afbac-9df7-4242-957d-fb86e60e5a09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d8def7f-476d-4c38-a598-4ebcf74dea5d" xlink:to="loc_srt_CounterpartyNameAxis_387afbac-9df7-4242-957d-fb86e60e5a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98aeb05c-9292-4bac-b38f-e7d969680996" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_387afbac-9df7-4242-957d-fb86e60e5a09" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98aeb05c-9292-4bac-b38f-e7d969680996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_UCBMember_78a70c67-0fcd-46b4-aa54-199f87ddce64" xlink:href="amgn-20221231.xsd#amgn_UCBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98aeb05c-9292-4bac-b38f-e7d969680996" xlink:to="loc_amgn_UCBMember_78a70c67-0fcd-46b4-aa54-199f87ddce64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8ec76e08-6126-42b4-b14f-964eb69ef0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d8def7f-476d-4c38-a598-4ebcf74dea5d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8ec76e08-6126-42b4-b14f-964eb69ef0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c8e78b91-f4ef-4341-9a77-ba8d3f605b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8ec76e08-6126-42b4-b14f-964eb69ef0ac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c8e78b91-f4ef-4341-9a77-ba8d3f605b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bbb5f538-b54d-4b5a-9b14-71cf4258d1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c8e78b91-f4ef-4341-9a77-ba8d3f605b68" xlink:to="loc_us-gaap_CostOfSalesMember_bbb5f538-b54d-4b5a-9b14-71cf4258d1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5430c83c-5c1f-43d3-85fd-a9fd1e09b963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d8def7f-476d-4c38-a598-4ebcf74dea5d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5430c83c-5c1f-43d3-85fd-a9fd1e09b963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses_12956386-e393-41aa-9996-7a5364e78e66" xlink:href="amgn-20221231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5430c83c-5c1f-43d3-85fd-a9fd1e09b963" xlink:to="loc_amgn_ProfitAndLossShareOfExpenses_12956386-e393-41aa-9996-7a5364e78e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsNovartisAGDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dd8d1914-af52-48b8-9dba-2ee1630f260c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a2cb81-2bf8-424c-9ee8-755d4c2f540d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dd8d1914-af52-48b8-9dba-2ee1630f260c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a2cb81-2bf8-424c-9ee8-755d4c2f540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7003c469-fa21-4de7-91e8-a8d662ee2c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a2cb81-2bf8-424c-9ee8-755d4c2f540d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7003c469-fa21-4de7-91e8-a8d662ee2c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7003c469-fa21-4de7-91e8-a8d662ee2c56" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5049d112-6c3d-4196-86a2-d713b35cd398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5049d112-6c3d-4196-86a2-d713b35cd398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d33b58f9-a15c-4b70-82f8-ee49b4e13ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:to="loc_us-gaap_CostOfSalesMember_d33b58f9-a15c-4b70-82f8-ee49b4e13ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d2741ad-cc8c-4078-b71e-ff71a665de63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9a1600a8-24c8-44d7-991a-afb482580c93" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d2741ad-cc8c-4078-b71e-ff71a665de63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4b1c06be-188f-49c9-a500-53a42fd03b7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a2cb81-2bf8-424c-9ee8-755d4c2f540d" xlink:to="loc_srt_CounterpartyNameAxis_4b1c06be-188f-49c9-a500-53a42fd03b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ff80569-d0bc-4d4d-9490-0c591c0a7ccd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4b1c06be-188f-49c9-a500-53a42fd03b7e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ff80569-d0bc-4d4d-9490-0c591c0a7ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisPharmaAGMember_34c13b32-0ddc-4227-a3f3-d66797e1d6f4" xlink:href="amgn-20221231.xsd#amgn_NovartisPharmaAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ff80569-d0bc-4d4d-9490-0c591c0a7ccd" xlink:to="loc_amgn_NovartisPharmaAGMember_34c13b32-0ddc-4227-a3f3-d66797e1d6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26b6e702-62d9-4e77-b817-4c86161c62ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a2cb81-2bf8-424c-9ee8-755d4c2f540d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26b6e702-62d9-4e77-b817-4c86161c62ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_79f476e2-e15a-4a40-bbbe-d1743fadb174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26b6e702-62d9-4e77-b817-4c86161c62ac" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_79f476e2-e15a-4a40-bbbe-d1743fadb174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_3e1610d5-2c94-46f7-86f3-78e53e3a62b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26b6e702-62d9-4e77-b817-4c86161c62ac" xlink:to="loc_us-gaap_RoyaltyExpense_3e1610d5-2c94-46f7-86f3-78e53e3a62b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsKyowaKirinDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#CollaborationsKyowaKirinDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsKyowaKirinDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2fdcbe0a-035a-479c-a29e-88c35d0bcbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f821e2ee-5abb-4b60-9fcf-d3a2b3397812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2fdcbe0a-035a-479c-a29e-88c35d0bcbfd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f821e2ee-5abb-4b60-9fcf-d3a2b3397812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1409bcdd-b300-4f3e-ad81-d597d05e9ddb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f821e2ee-5abb-4b60-9fcf-d3a2b3397812" xlink:to="loc_srt_CounterpartyNameAxis_1409bcdd-b300-4f3e-ad81-d597d05e9ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f656a5a-269f-4e55-a2b0-edac48a7f191" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1409bcdd-b300-4f3e-ad81-d597d05e9ddb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f656a5a-269f-4e55-a2b0-edac48a7f191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyowaKirinCoLtdMember_cfafa20e-3038-41da-b87b-76b5cc9352ba" xlink:href="amgn-20221231.xsd#amgn_KyowaKirinCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f656a5a-269f-4e55-a2b0-edac48a7f191" xlink:to="loc_amgn_KyowaKirinCoLtdMember_cfafa20e-3038-41da-b87b-76b5cc9352ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9594dce-db81-423d-9a09-dc20eb5d912e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f821e2ee-5abb-4b60-9fcf-d3a2b3397812" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9594dce-db81-423d-9a09-dc20eb5d912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_UpFrontPayment_b825a823-86c9-438f-9d94-cf9228d36ea8" xlink:href="amgn-20221231.xsd#amgn_UpFrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9594dce-db81-423d-9a09-dc20eb5d912e" xlink:to="loc_amgn_UpFrontPayment_b825a823-86c9-438f-9d94-cf9228d36ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_6bd59cf7-d16a-496e-b1d8-984e225925b1" xlink:href="amgn-20221231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9594dce-db81-423d-9a09-dc20eb5d912e" xlink:to="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_6bd59cf7-d16a-496e-b1d8-984e225925b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c03c87e5-9fa9-4394-a755-0b24cec84b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_40dd9a50-bf20-45d1-afcc-fe0ef647ac42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c03c87e5-9fa9-4394-a755-0b24cec84b86" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_40dd9a50-bf20-45d1-afcc-fe0ef647ac42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_62f475e7-7b54-473f-90df-b78da9edf20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_40dd9a50-bf20-45d1-afcc-fe0ef647ac42" xlink:to="loc_us-gaap_FinancialInstrumentAxis_62f475e7-7b54-473f-90df-b78da9edf20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_62f475e7-7b54-473f-90df-b78da9edf20f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c62b64da-512b-4e7b-b1ca-740a8efacafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c62b64da-512b-4e7b-b1ca-740a8efacafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_adc0df1a-38f7-4232-870d-da1c4e4a6a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_adc0df1a-38f7-4232-870d-da1c4e4a6a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_72909f68-165f-4b51-9dc9-019c9a97a7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:to="loc_us-gaap_MoneyMarketFundsMember_72909f68-165f-4b51-9dc9-019c9a97a7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_f2317580-a612-438a-afac-b1114db987ec" xlink:href="amgn-20221231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12b2776d-b4e3-4b00-9661-25a3bf53f619" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_f2317580-a612-438a-afac-b1114db987ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_151fdb00-f232-4660-9c21-3ff8550c11a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_40dd9a50-bf20-45d1-afcc-fe0ef647ac42" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_151fdb00-f232-4660-9c21-3ff8550c11a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_151fdb00-f232-4660-9c21-3ff8550c11a2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e7ae3989-63f4-44ad-89c7-33e1cbd3ba46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e7ae3989-63f4-44ad-89c7-33e1cbd3ba46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e541fb1a-bdfc-41e1-8f5d-127c5b5be07d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e541fb1a-bdfc-41e1-8f5d-127c5b5be07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a58616b4-3731-4e82-9d02-8362f7c740c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a58616b4-3731-4e82-9d02-8362f7c740c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_042de559-a00f-4f46-947b-86ea6066d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2edb8d41-9bf3-4647-b067-674a87c0a527" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_042de559-a00f-4f46-947b-86ea6066d0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da3f3f55-7055-4a4e-bbea-d0d93df95436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0520f679-bb3f-4104-981e-4ee4ceb355c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da3f3f55-7055-4a4e-bbea-d0d93df95436" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0520f679-bb3f-4104-981e-4ee4ceb355c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0b983a41-1d36-4844-851a-8aa69db47e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0520f679-bb3f-4104-981e-4ee4ceb355c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0b983a41-1d36-4844-851a-8aa69db47e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d561330a-09c1-40d9-aec4-9948f67e01e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0b983a41-1d36-4844-851a-8aa69db47e36" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d561330a-09c1-40d9-aec4-9948f67e01e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember_c5c461e9-c1e9-452a-a58c-ee54a916c042" xlink:href="amgn-20221231.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d561330a-09c1-40d9-aec4-9948f67e01e2" xlink:to="loc_amgn_AvailableForSalesInvestmentsMember_c5c461e9-c1e9-452a-a58c-ee54a916c042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5745172c-de8d-43e4-8c27-84774d66f665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0520f679-bb3f-4104-981e-4ee4ceb355c4" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5745172c-de8d-43e4-8c27-84774d66f665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:href="amgn-20221231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5745172c-de8d-43e4-8c27-84774d66f665" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0a88c4ca-d514-495d-8dde-d9feb4aff904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0a88c4ca-d514-495d-8dde-d9feb4aff904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_34627770-6719-4db9-973b-067754e215f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_34627770-6719-4db9-973b-067754e215f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d3a67bee-52b6-4a88-93f2-9d1efaa3175b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_e2810d07-406e-43fa-a5a0-9ea94787c2dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d3a67bee-52b6-4a88-93f2-9d1efaa3175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsAvailableforsaleDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4b78a06-85b6-4740-92fc-7571a855bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_2a4066d2-5f19-47a0-9089-621daeea503a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4b78a06-85b6-4740-92fc-7571a855bc26" xlink:to="loc_us-gaap_Cash_2a4066d2-5f19-47a0-9089-621daeea503a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4753400d-34dc-455c-ad5e-881b0fa81cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bc0f4d36-70b4-457c-b405-ab04c474d313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4753400d-34dc-455c-ad5e-881b0fa81cc8" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bc0f4d36-70b4-457c-b405-ab04c474d313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_96a349c1-0edd-464b-a101-38817eab8dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bc0f4d36-70b4-457c-b405-ab04c474d313" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_96a349c1-0edd-464b-a101-38817eab8dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8387b7dd-49cc-44d3-8f11-fe211a6158a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_96a349c1-0edd-464b-a101-38817eab8dcd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8387b7dd-49cc-44d3-8f11-fe211a6158a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9e2e3245-1bf0-4327-9a7a-9f876123162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8387b7dd-49cc-44d3-8f11-fe211a6158a2" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9e2e3245-1bf0-4327-9a7a-9f876123162d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bc0f4d36-70b4-457c-b405-ab04c474d313" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a4e0d306-bcce-46ab-9273-244d69beca66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a4e0d306-bcce-46ab-9273-244d69beca66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a5fd1e12-aabd-40e2-8b3e-4539f4d93ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a5fd1e12-aabd-40e2-8b3e-4539f4d93ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9fa65f95-715c-4266-b326-3e8cd0a980d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9fa65f95-715c-4266-b326-3e8cd0a980d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_b66423b1-f510-46eb-bb63-c2cbac0a6a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_b66423b1-f510-46eb-bb63-c2cbac0a6a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal_a3c2c4e5-929e-4b88-a293-bb621b99cc22" xlink:href="amgn-20221231.xsd#amgn_EquitySecuritiesRealizedGainLossOnDisposal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal_a3c2c4e5-929e-4b88-a293-bb621b99cc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_3d50b8b8-2081-4943-8bb9-3a9466faf118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_32b90846-2afd-43c3-ac27-17f3cbad6646" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_3d50b8b8-2081-4943-8bb9-3a9466faf118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsLimitedPartnershipInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1962cf51-8e27-42bf-a821-fc855a3feed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5bde25cd-4e4e-4b2c-b856-7c557055fb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1962cf51-8e27-42bf-a821-fc855a3feed7" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5bde25cd-4e4e-4b2c-b856-7c557055fb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0025ad3b-5e98-4d97-a95f-e3918e10e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5bde25cd-4e4e-4b2c-b856-7c557055fb7b" xlink:to="loc_us-gaap_InvestmentTypeAxis_0025ad3b-5e98-4d97-a95f-e3918e10e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7ec4c00e-f054-46be-96a3-afcde7f7ade3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0025ad3b-5e98-4d97-a95f-e3918e10e54f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7ec4c00e-f054-46be-96a3-afcde7f7ade3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_4daadc1d-7da4-41e9-8fe4-33dade98f19a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7ec4c00e-f054-46be-96a3-afcde7f7ade3" xlink:to="loc_srt_PartnershipInterestMember_4daadc1d-7da4-41e9-8fe4-33dade98f19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94c7c1d3-b8bf-4c9b-bc27-eb0939a46d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5bde25cd-4e4e-4b2c-b856-7c557055fb7b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94c7c1d3-b8bf-4c9b-bc27-eb0939a46d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a056c-786b-4bcd-8c9a-042ce706197e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94c7c1d3-b8bf-4c9b-bc27-eb0939a46d7f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a056c-786b-4bcd-8c9a-042ce706197e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_6331a470-063b-4351-8734-e7b96d7ad833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a056c-786b-4bcd-8c9a-042ce706197e" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_6331a470-063b-4351-8734-e7b96d7ad833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5bde25cd-4e4e-4b2c-b856-7c557055fb7b" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_20db44c1-d833-4c32-a191-795554e74c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:to="loc_us-gaap_AlternativeInvestment_20db44c1-d833-4c32-a191-795554e74c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss_9a7e62a6-a06a-4ff7-9b68-38e2b9c39064" xlink:href="amgn-20221231.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:to="loc_amgn_AlternativeInvestmentNetGainLoss_9a7e62a6-a06a-4ff7-9b68-38e2b9c39064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_16034e17-5b8f-435d-b06b-5d8ff79db4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3d24c64d-18b6-4626-9e81-17bac5596b90" xlink:to="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_16034e17-5b8f-435d-b06b-5d8ff79db4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsBeiGeneDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9a804523-e31c-4246-b84a-6d52ff1e432f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9a804523-e31c-4246-b84a-6d52ff1e432f" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_98a88004-fb65-43c4-bc27-2017450bdbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_98a88004-fb65-43c4-bc27-2017450bdbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d0689f-ab69-46fb-b759-c688c0622b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_98a88004-fb65-43c4-bc27-2017450bdbb7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d0689f-ab69-46fb-b759-c688c0622b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_edaa4783-ee59-4687-9647-cf4c47895782" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d0689f-ab69-46fb-b759-c688c0622b86" xlink:to="loc_amgn_BeiGeneMember_edaa4783-ee59-4687-9647-cf4c47895782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_784e925c-b519-4787-8efe-d9f5ec6bbd51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:to="loc_srt_RangeAxis_784e925c-b519-4787-8efe-d9f5ec6bbd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a036ab03-8f6b-4866-a172-943a0eb757ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_784e925c-b519-4787-8efe-d9f5ec6bbd51" xlink:to="loc_srt_RangeMember_a036ab03-8f6b-4866-a172-943a0eb757ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4bdd30a2-1bdc-4994-a692-4d8354ec91d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a036ab03-8f6b-4866-a172-943a0eb757ec" xlink:to="loc_srt_MinimumMember_4bdd30a2-1bdc-4994-a692-4d8354ec91d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ec51f54-5b0d-4da1-b476-ed07eb49bc82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a036ab03-8f6b-4866-a172-943a0eb757ec" xlink:to="loc_srt_MaximumMember_4ec51f54-5b0d-4da1-b476-ed07eb49bc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77d93c6e-9cce-48d6-a949-f700f5ed4d58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77d93c6e-9cce-48d6-a949-f700f5ed4d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2edc7258-3a5e-4f39-8fe5-ef9315adb5c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77d93c6e-9cce-48d6-a949-f700f5ed4d58" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2edc7258-3a5e-4f39-8fe5-ef9315adb5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_d24a2c25-7dce-4614-80bb-78eda961acd5" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2edc7258-3a5e-4f39-8fe5-ef9315adb5c8" xlink:to="loc_amgn_BeiGeneMember_d24a2c25-7dce-4614-80bb-78eda961acd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_03421f30-f240-441d-8282-780de247221a" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e16c6c5-a312-4f74-9f8a-0a6d54365b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e16c6c5-a312-4f74-9f8a-0a6d54365b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_14030737-bf11-46ea-9359-8fd2abeeb0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_14030737-bf11-46ea-9359-8fd2abeeb0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_8d39be8d-9173-4f79-bc43-0dc1abd3a338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_8d39be8d-9173-4f79-bc43-0dc1abd3a338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_37330a44-75b7-4c31-9c6c-a9cfbaacae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_37330a44-75b7-4c31-9c6c-a9cfbaacae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_67c4237a-c622-4e4b-beb3-611bc1588652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_67c4237a-c622-4e4b-beb3-611bc1588652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_1696342c-678b-4d94-bb2f-9c55b15d4cb6" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_1696342c-678b-4d94-bb2f-9c55b15d4cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_88431fd1-2c66-4794-bae9-88c6beb17522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_88431fd1-2c66-4794-bae9-88c6beb17522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_3e9ee9d1-9015-455b-af59-716837659b6a" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValueOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_3e9ee9d1-9015-455b-af59-716837659b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e8a52532-159b-41ef-9b95-2892afc55c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e8a52532-159b-41ef-9b95-2892afc55c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_61ceea01-e8be-4f51-b482-6973a291ad2f" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_61ceea01-e8be-4f51-b482-6973a291ad2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_696cdfdf-79f4-413c-b6bf-3de76b20d541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_561d2fcb-e749-46dc-9d00-fe7b1d128517" xlink:to="loc_us-gaap_EquityMethodInvestments_696cdfdf-79f4-413c-b6bf-3de76b20d541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_3ba504c5-798c-42da-8422-9f6202031496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InvestmentsNeumoraTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_57360e3c-5b36-4d9c-b314-4bc866a7c2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5fa6f2b2-23ef-4aa9-a439-04058f461769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_57360e3c-5b36-4d9c-b314-4bc866a7c2ca" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5fa6f2b2-23ef-4aa9-a439-04058f461769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c1695439-b04d-4647-98b0-b43891feac41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5fa6f2b2-23ef-4aa9-a439-04058f461769" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c1695439-b04d-4647-98b0-b43891feac41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e89b60de-041f-4133-9c58-396832bf9866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c1695439-b04d-4647-98b0-b43891feac41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e89b60de-041f-4133-9c58-396832bf9866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_ec8d0697-a1b2-4597-9c50-5c69cc8a1279" xlink:href="amgn-20221231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e89b60de-041f-4133-9c58-396832bf9866" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_ec8d0697-a1b2-4597-9c50-5c69cc8a1279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ef17bd95-8fae-40ab-b652-23a9a267f0b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5fa6f2b2-23ef-4aa9-a439-04058f461769" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ef17bd95-8fae-40ab-b652-23a9a267f0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_81cf6c1b-49fc-4a15-8691-42384370ecdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ef17bd95-8fae-40ab-b652-23a9a267f0b3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_81cf6c1b-49fc-4a15-8691-42384370ecdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_b85a0836-8945-4933-96b9-ce30187fb83f" xlink:href="amgn-20221231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_81cf6c1b-49fc-4a15-8691-42384370ecdf" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_b85a0836-8945-4933-96b9-ce30187fb83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5fa6f2b2-23ef-4aa9-a439-04058f461769" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f16ecb9c-24f2-4b4e-92ba-9f61758ae050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f16ecb9c-24f2-4b4e-92ba-9f61758ae050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_448f0d07-abfb-4367-926f-79fe154a533b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_448f0d07-abfb-4367-926f-79fe154a533b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a943ba7d-d9f4-457a-a8dc-931f3337ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a943ba7d-d9f4-457a-a8dc-931f3337ca61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_10d2ff8c-5e7a-42c7-b914-db07e6c1fc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_10d2ff8c-5e7a-42c7-b914-db07e6c1fc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_f3aae7f7-50d3-44e6-aab2-bdf721fcdf28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_f3aae7f7-50d3-44e6-aab2-bdf721fcdf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_e1245b2e-62df-408f-82a4-07acf2ca44b8" xlink:href="amgn-20221231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f1f0819-f33b-4a1c-a1b3-69e7a42410a5" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_e1245b2e-62df-408f-82a4-07acf2ca44b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0eaa20cd-c2d1-4c81-967b-0ad5cb84b332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9583f263-6b0c-4baa-9aa8-ee7d3b888432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0eaa20cd-c2d1-4c81-967b-0ad5cb84b332" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9583f263-6b0c-4baa-9aa8-ee7d3b888432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_757ac89c-e490-4ac3-8c5a-7d5535cc28a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0eaa20cd-c2d1-4c81-967b-0ad5cb84b332" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_757ac89c-e490-4ac3-8c5a-7d5535cc28a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3ecc01c6-4c19-47b2-847f-bfe6b1fe07e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0eaa20cd-c2d1-4c81-967b-0ad5cb84b332" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3ecc01c6-4c19-47b2-847f-bfe6b1fe07e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1d637a35-e74e-4a4e-b148-111d18b22720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0eaa20cd-c2d1-4c81-967b-0ad5cb84b332" xlink:to="loc_us-gaap_InventoryNet_1d637a35-e74e-4a4e-b148-111d18b22720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#PropertyplantandequipmentScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2da6fb2f-c31c-4c5f-b88f-fd4dc30ea185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2701d936-12ca-4673-af6d-191a5f683cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2da6fb2f-c31c-4c5f-b88f-fd4dc30ea185" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2701d936-12ca-4673-af6d-191a5f683cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_68ac2f28-d078-4388-a622-f8fe207b49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2701d936-12ca-4673-af6d-191a5f683cdc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_68ac2f28-d078-4388-a622-f8fe207b49b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_68ac2f28-d078-4388-a622-f8fe207b49b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_870714d6-d069-4a26-b9f9-40db8f9aeac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_870714d6-d069-4a26-b9f9-40db8f9aeac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ManufacturingEquipmentMember_3fea431d-cfb4-450e-b35c-ae64c75773a4" xlink:href="amgn-20221231.xsd#amgn_ManufacturingEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_amgn_ManufacturingEquipmentMember_3fea431d-cfb4-450e-b35c-ae64c75773a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipmentMember_2a984796-89c4-4459-bb05-97794f113cc5" xlink:href="amgn-20221231.xsd#amgn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_amgn_LaboratoryEquipmentMember_2a984796-89c4-4459-bb05-97794f113cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipmentMember_e54dfbbf-a707-44c6-bd2a-08827a8df3ac" xlink:href="amgn-20221231.xsd#amgn_FixedEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_amgn_FixedEquipmentMember_e54dfbbf-a707-44c6-bd2a-08827a8df3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_524f1fa7-b238-45c5-ba14-0fb6ccc76216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_524f1fa7-b238-45c5-ba14-0fb6ccc76216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_65d1356b-4921-48ef-a94e-252d50a26d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce063fd4-92e5-49a7-8bd3-8328eadda962" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_65d1356b-4921-48ef-a94e-252d50a26d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cd845ac-a092-4027-b281-eb146a09cc0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2701d936-12ca-4673-af6d-191a5f683cdc" xlink:to="loc_srt_RangeAxis_9cd845ac-a092-4027-b281-eb146a09cc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e05e5aab-287f-4c61-9267-f846a20e2d1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9cd845ac-a092-4027-b281-eb146a09cc0b" xlink:to="loc_srt_RangeMember_e05e5aab-287f-4c61-9267-f846a20e2d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_898df78b-bdb7-4802-958f-5f588a622e0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e05e5aab-287f-4c61-9267-f846a20e2d1c" xlink:to="loc_srt_MinimumMember_898df78b-bdb7-4802-958f-5f588a622e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ac8f014-b87b-4dc4-a15a-21a7f2e263ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e05e5aab-287f-4c61-9267-f846a20e2d1c" xlink:to="loc_srt_MaximumMember_1ac8f014-b87b-4dc4-a15a-21a7f2e263ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2701d936-12ca-4673-af6d-191a5f683cdc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1f658e25-d245-42f6-b4bf-bfc8a2bc6b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1f658e25-d245-42f6-b4bf-bfc8a2bc6b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_a72e6c06-dda7-4e42-98f7-655ea5b8ac36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_Land_a72e6c06-dda7-4e42-98f7-655ea5b8ac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_bd0ff1e1-6dbf-46f1-af5b-6e773e1db18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_bd0ff1e1-6dbf-46f1-af5b-6e773e1db18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_17b3ed33-f73a-48cb-88a1-57b515dcc3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_17b3ed33-f73a-48cb-88a1-57b515dcc3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment_24440f74-c33b-4faa-be61-b52e818b5b21" xlink:href="amgn-20221231.xsd#amgn_LaboratoryEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_amgn_LaboratoryEquipment_24440f74-c33b-4faa-be61-b52e818b5b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment_00b07198-7810-4bba-8ef1-9256d819df5a" xlink:href="amgn-20221231.xsd#amgn_FixedEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_amgn_FixedEquipment_00b07198-7810-4bba-8ef1-9256d819df5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_2539d8df-d82f-4819-b876-e5c04b1e4443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_2539d8df-d82f-4819-b876-e5c04b1e4443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_eff2f7fb-4893-483a-9df6-294e60cc5b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_eff2f7fb-4893-483a-9df6-294e60cc5b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_d8ef02f5-f549-4913-9954-45dd0fc3adcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_ConstructionInProgressGross_d8ef02f5-f549-4913-9954-45dd0fc3adcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5f24b340-84b8-44a8-9e6e-bd249ee3d005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5f24b340-84b8-44a8-9e6e-bd249ee3d005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1517ddbe-d567-438a-b335-3f53ce5c664b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1517ddbe-d567-438a-b335-3f53ce5c664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_288c1dcf-49bd-4d1b-92a9-4cb737aba8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_288c1dcf-49bd-4d1b-92a9-4cb737aba8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d6aeb812-53a5-4e9c-8a0f-93c031eaccb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5ddc35-c643-4d53-8203-a4d1fd983230" xlink:to="loc_us-gaap_Depreciation_d6aeb812-53a5-4e9c-8a0f-93c031eaccb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#PropertyplantandequipmentGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2d3d96e2-8c11-47c4-8095-0b75b460f4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03e7d982-1d0d-436c-a08f-3e7229128453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2d3d96e2-8c11-47c4-8095-0b75b460f4a3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03e7d982-1d0d-436c-a08f-3e7229128453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4872fbd9-601d-48ae-ba93-edd1ecedca58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03e7d982-1d0d-436c-a08f-3e7229128453" xlink:to="loc_srt_StatementGeographicalAxis_4872fbd9-601d-48ae-ba93-edd1ecedca58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4872fbd9-601d-48ae-ba93-edd1ecedca58" xlink:to="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_54ef6844-9bf7-468a-a554-de9136850a66" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:to="loc_country_US_54ef6844-9bf7-468a-a554-de9136850a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_bc27c292-d4c3-48d8-abb5-0943b4908f92" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:to="loc_country_PR_bc27c292-d4c3-48d8-abb5-0943b4908f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RestOfWorldMember_1906773e-71db-4013-ad9e-8796242efe4b" xlink:href="amgn-20221231.xsd#amgn_RestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_990a14a7-f76d-44cf-a71a-72523fcf0f24" xlink:to="loc_amgn_RestOfWorldMember_1906773e-71db-4013-ad9e-8796242efe4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ccd55fdf-f585-4522-987a-ed82f7b19ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_03e7d982-1d0d-436c-a08f-3e7229128453" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ccd55fdf-f585-4522-987a-ed82f7b19ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b53dafdf-921d-4de3-a77d-e6d0135fb093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ccd55fdf-f585-4522-987a-ed82f7b19ffd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b53dafdf-921d-4de3-a77d-e6d0135fb093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#GoodwillandotherintangibleassetsGoodwillRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_19d87391-b4e1-4be3-a3c5-5f1e067fbd01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_38feb561-4db2-4b7b-94cc-547856d0001a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_19d87391-b4e1-4be3-a3c5-5f1e067fbd01" xlink:to="loc_us-gaap_GoodwillRollForward_38feb561-4db2-4b7b-94cc-547856d0001a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_83ac9b72-5470-469a-b2d6-ba2528525aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_38feb561-4db2-4b7b-94cc-547856d0001a" xlink:to="loc_us-gaap_Goodwill_83ac9b72-5470-469a-b2d6-ba2528525aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_afd0ac8a-9f60-47e5-bfec-c163c60cba37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_38feb561-4db2-4b7b-94cc-547856d0001a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_afd0ac8a-9f60-47e5-bfec-c163c60cba37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_a8de0f4d-3af0-435e-9593-5c721a1edadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_38feb561-4db2-4b7b-94cc-547856d0001a" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_a8de0f4d-3af0-435e-9593-5c721a1edadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1acc652b-b5c1-4b60-a0dc-07f4ef5c6ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_38feb561-4db2-4b7b-94cc-547856d0001a" xlink:to="loc_us-gaap_Goodwill_1acc652b-b5c1-4b60-a0dc-07f4ef5c6ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8115350d-26ec-4943-989c-24c7734a11b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2633530d-2714-4a51-951d-1b6e5c9ce844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8115350d-26ec-4943-989c-24c7734a11b1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2633530d-2714-4a51-951d-1b6e5c9ce844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c10d380c-cbeb-416a-a199-c7f47da7a0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2633530d-2714-4a51-951d-1b6e5c9ce844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c10d380c-cbeb-416a-a199-c7f47da7a0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c10d380c-cbeb-416a-a199-c7f47da7a0ff" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3a53810e-be35-4d72-9ee0-ea2786a153e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3a53810e-be35-4d72-9ee0-ea2786a153e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_a04b8b4a-6653-4e5c-9edd-a3a15a1db869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:to="loc_us-gaap_LicensingAgreementsMember_a04b8b4a-6653-4e5c-9edd-a3a15a1db869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_765fd44f-bc69-4f39-95c1-56dda2481e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_765fd44f-bc69-4f39-95c1-56dda2481e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_3ac11085-ce8d-4905-983b-bf06120ef892" xlink:href="amgn-20221231.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67a31ae6-b9f9-4fe9-8d35-594e220c7175" xlink:to="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_3ac11085-ce8d-4905-983b-bf06120ef892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e5f4f223-5388-4e64-b475-30b9f393ac63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2633530d-2714-4a51-951d-1b6e5c9ce844" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e5f4f223-5388-4e64-b475-30b9f393ac63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5153f519-e517-4dab-b092-34f319ab3db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e5f4f223-5388-4e64-b475-30b9f393ac63" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5153f519-e517-4dab-b092-34f319ab3db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5f6273a4-b248-45a1-b2cb-0ec6c125c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5153f519-e517-4dab-b092-34f319ab3db6" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5f6273a4-b248-45a1-b2cb-0ec6c125c5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2633530d-2714-4a51-951d-1b6e5c9ce844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d53a0284-9229-4387-acd4-1e7b0a82178a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d53a0284-9229-4387-acd4-1e7b0a82178a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_773a664a-b7f0-4212-8864-1e449f0c6cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_773a664a-b7f0-4212-8864-1e449f0c6cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_44ec9559-f657-441f-9bd0-8ec15109d62f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e36f0e5-c1a4-4bfd-800e-04a6c1c458c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_44ec9559-f657-441f-9bd0-8ec15109d62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3783eee1-334e-49c5-a120-bb39c4f987d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3783eee1-334e-49c5-a120-bb39c4f987d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14e92199-3c11-4ac5-bdea-f52b44d03667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3783eee1-334e-49c5-a120-bb39c4f987d5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14e92199-3c11-4ac5-bdea-f52b44d03667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_e47fd641-94bb-40b2-8b25-3b7861725f1b" xlink:href="amgn-20221231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_e47fd641-94bb-40b2-8b25-3b7861725f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_25102594-e27b-4df9-9443-d7763ecd5c9a" xlink:href="amgn-20221231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_25102594-e27b-4df9-9443-d7763ecd5c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8230d9fe-177d-4d31-83e9-f6d3d1aea51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4d467750-a610-4bd7-96cb-2823a9b22e94" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8230d9fe-177d-4d31-83e9-f6d3d1aea51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#GoodwillandotherintangibleassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8786898-9f0a-47a6-b99a-28c25fb5d013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1ad2df04-91c8-414b-9d39-6eda5dd58d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8786898-9f0a-47a6-b99a-28c25fb5d013" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1ad2df04-91c8-414b-9d39-6eda5dd58d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8776f91c-1c75-4414-8267-3c76ea5b93eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8786898-9f0a-47a6-b99a-28c25fb5d013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8776f91c-1c75-4414-8267-3c76ea5b93eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9c16eab0-1032-4ee5-9d8a-641e475e0056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8786898-9f0a-47a6-b99a-28c25fb5d013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9c16eab0-1032-4ee5-9d8a-641e475e0056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d230f6e0-eefd-469a-998b-c59e5004aa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8786898-9f0a-47a6-b99a-28c25fb5d013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d230f6e0-eefd-469a-998b-c59e5004aa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0ae40645-d4c1-47cb-a990-2e5b4e7a804a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8786898-9f0a-47a6-b99a-28c25fb5d013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0ae40645-d4c1-47cb-a990-2e5b4e7a804a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81ac095d-7be9-49cb-bbc6-f9253710d915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8786898-9f0a-47a6-b99a-28c25fb5d013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_81ac095d-7be9-49cb-bbc6-f9253710d915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aa3c6eb7-fef7-4c6e-a51c-1e5092c16380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ae3e612d-3cf5-4614-95ca-fef8c0a55cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa3c6eb7-fef7-4c6e-a51c-1e5092c16380" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ae3e612d-3cf5-4614-95ca-fef8c0a55cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f47535b3-2382-4ba8-b592-ad3f99298c49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ae3e612d-3cf5-4614-95ca-fef8c0a55cca" xlink:to="loc_srt_RangeAxis_f47535b3-2382-4ba8-b592-ad3f99298c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb6a62e0-e96b-4825-9e79-5271329f26de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f47535b3-2382-4ba8-b592-ad3f99298c49" xlink:to="loc_srt_RangeMember_cb6a62e0-e96b-4825-9e79-5271329f26de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7bdd7281-1c21-4da5-a366-84aaed80c9ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb6a62e0-e96b-4825-9e79-5271329f26de" xlink:to="loc_srt_MinimumMember_7bdd7281-1c21-4da5-a366-84aaed80c9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3eb70ae0-e989-4114-bfc8-b7343f09922f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb6a62e0-e96b-4825-9e79-5271329f26de" xlink:to="loc_srt_MaximumMember_3eb70ae0-e989-4114-bfc8-b7343f09922f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7d5f3dec-076f-47fd-9ed5-10f1e95df792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ae3e612d-3cf5-4614-95ca-fef8c0a55cca" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_7d5f3dec-076f-47fd-9ed5-10f1e95df792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_77e9db77-170e-497f-9dd9-5b11e8d0dff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7d5f3dec-076f-47fd-9ed5-10f1e95df792" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_77e9db77-170e-497f-9dd9-5b11e8d0dff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesSummaryofLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_51ff9953-926a-473d-816d-de5751c426d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_98878603-c3e6-44c1-b58c-389b750e5707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_51ff9953-926a-473d-816d-de5751c426d0" xlink:to="loc_us-gaap_AssetsAbstract_98878603-c3e6-44c1-b58c-389b750e5707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b31d7721-d0fc-4a68-b00b-cbf00059e525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98878603-c3e6-44c1-b58c-389b750e5707" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b31d7721-d0fc-4a68-b00b-cbf00059e525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_521f5ffd-c6dc-4a48-aa70-b66e9aa0c677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98878603-c3e6-44c1-b58c-389b750e5707" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_521f5ffd-c6dc-4a48-aa70-b66e9aa0c677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_41c5f3b2-034c-4091-8714-c06eff39ca28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_51ff9953-926a-473d-816d-de5751c426d0" xlink:to="loc_us-gaap_LiabilitiesAbstract_41c5f3b2-034c-4091-8714-c06eff39ca28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_24635890-cec8-4d04-92a8-38989a157ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_41c5f3b2-034c-4091-8714-c06eff39ca28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_24635890-cec8-4d04-92a8-38989a157ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_42cbe48c-0a10-44c8-8dd1-930ef3dafe9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_41c5f3b2-034c-4091-8714-c06eff39ca28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_42cbe48c-0a10-44c8-8dd1-930ef3dafe9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_2a795bf1-2d03-4df8-8283-382a244a7132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_41c5f3b2-034c-4091-8714-c06eff39ca28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_2a795bf1-2d03-4df8-8283-382a244a7132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2c441f12-5197-4ac4-8be9-c16c5d001505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_41c5f3b2-034c-4091-8714-c06eff39ca28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2c441f12-5197-4ac4-8be9-c16c5d001505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_31e66c5a-a6c0-4f8a-bac1-5cbb6be9e2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_41c5f3b2-034c-4091-8714-c06eff39ca28" xlink:to="loc_us-gaap_OperatingLeaseLiability_31e66c5a-a6c0-4f8a-bac1-5cbb6be9e2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5ace5d9f-ee37-4191-9dd1-12b7d78b98db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1483563c-f904-426f-95aa-041f57f1326a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ace5d9f-ee37-4191-9dd1-12b7d78b98db" xlink:to="loc_us-gaap_OperatingLeaseCost_1483563c-f904-426f-95aa-041f57f1326a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9dc86b57-8c15-454f-9597-18a834e7c628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ace5d9f-ee37-4191-9dd1-12b7d78b98db" xlink:to="loc_us-gaap_SubleaseIncome_9dc86b57-8c15-454f-9597-18a834e7c628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_28ebce11-b1cf-4ed1-b697-7c0cfe41b6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ace5d9f-ee37-4191-9dd1-12b7d78b98db" xlink:to="loc_us-gaap_LeaseCost_28ebce11-b1cf-4ed1-b697-7c0cfe41b6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_87441821-1be9-4ca1-9f0e-d280b4cf56d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c033cef9-9757-4c74-9129-010437122a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87441821-1be9-4ca1-9f0e-d280b4cf56d1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c033cef9-9757-4c74-9129-010437122a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_720ccfbd-f1bd-49fb-bc05-03e1582296a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c033cef9-9757-4c74-9129-010437122a37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_720ccfbd-f1bd-49fb-bc05-03e1582296a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_815bb51e-40fb-432b-bcb5-e9f842154758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_720ccfbd-f1bd-49fb-bc05-03e1582296a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_815bb51e-40fb-432b-bcb5-e9f842154758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AbandonedLeasesMember_5457c214-4985-4bba-b6b4-faa07342c095" xlink:href="amgn-20221231.xsd#amgn_AbandonedLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_815bb51e-40fb-432b-bcb5-e9f842154758" xlink:to="loc_amgn_AbandonedLeasesMember_5457c214-4985-4bba-b6b4-faa07342c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c033cef9-9757-4c74-9129-010437122a37" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9400c2f4-6c4f-4b4b-813d-2f03b8fb729e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9400c2f4-6c4f-4b4b-813d-2f03b8fb729e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f52e7c57-6428-4193-8c1a-11a5e6014414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f52e7c57-6428-4193-8c1a-11a5e6014414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5b554e48-bbe9-4451-859f-1f35f2937f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5b554e48-bbe9-4451-859f-1f35f2937f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dddbd14d-22ae-44f0-b708-95bccb975c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dddbd14d-22ae-44f0-b708-95bccb975c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fc66a615-d74e-467b-bb2c-9cb2bdc835e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fc66a615-d74e-467b-bb2c-9cb2bdc835e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4cb9b85b-d8ae-4f80-a93b-557cd39968dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4cb9b85b-d8ae-4f80-a93b-557cd39968dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c055ad4e-04c4-4cb9-ad1f-6df9d388b6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c055ad4e-04c4-4cb9-ad1f-6df9d388b6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ca7e5404-bd46-460b-90a8-129ce0096444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ca7e5404-bd46-460b-90a8-129ce0096444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b274118e-9e83-4ced-ac3d-d1dbc6eb4309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_OperatingLeaseLiability_b274118e-9e83-4ced-ac3d-d1dbc6eb4309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_10e2bc0d-2f24-423d-9c36-8e35c784a61b" xlink:href="amgn-20221231.xsd#amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_10e2bc0d-2f24-423d-9c36-8e35c784a61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_bab04b1b-2628-4a67-84de-0f9beb38168a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a3f32278-ddc3-494d-9d6d-f0887bd0b321" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_bab04b1b-2628-4a67-84de-0f9beb38168a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesWeightedAverageRemainingLeaseTermsDiscountRatesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesWeightedAverageRemainingLeaseTermsDiscountRatesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesWeightedAverageRemainingLeaseTermsDiscountRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a5bc5851-a647-4887-8200-1d1bfd5a1802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d0680c05-8adf-48de-99ea-79eade36e297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a5bc5851-a647-4887-8200-1d1bfd5a1802" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d0680c05-8adf-48de-99ea-79eade36e297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9f058c4a-962d-4b00-9e1e-7fa62a68efd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a5bc5851-a647-4887-8200-1d1bfd5a1802" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9f058c4a-962d-4b00-9e1e-7fa62a68efd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#LeasesCashandNoncashInformationofLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c15d911b-ec69-436b-b39c-f639c82121d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5c469880-b472-4cb1-94ee-0513ddf2b397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c15d911b-ec69-436b-b39c-f639c82121d0" xlink:to="loc_us-gaap_OperatingLeasePayments_5c469880-b472-4cb1-94ee-0513ddf2b397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2953c6f3-015e-45a1-b547-4bb9f5c4ae6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c15d911b-ec69-436b-b39c-f639c82121d0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2953c6f3-015e-45a1-b547-4bb9f5c4ae6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_451477b1-9984-4a47-87a3-cc6f1da5d12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_1b36d057-0db2-4523-9d3d-3f2ca51572d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_451477b1-9984-4a47-87a3-cc6f1da5d12e" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_1b36d057-0db2-4523-9d3d-3f2ca51572d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_c16f2282-370d-4316-baac-fbc781f1640e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_451477b1-9984-4a47-87a3-cc6f1da5d12e" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_c16f2282-370d-4316-baac-fbc781f1640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_fc71d47a-a323-4274-b17c-a495f0fecf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_451477b1-9984-4a47-87a3-cc6f1da5d12e" xlink:to="loc_us-gaap_InterestReceivableCurrent_fc71d47a-a323-4274-b17c-a495f0fecf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_1870a429-e006-4abd-96ff-a46348fb0b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_451477b1-9984-4a47-87a3-cc6f1da5d12e" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_1870a429-e006-4abd-96ff-a46348fb0b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_fa97bd37-6955-475b-82e6-2eb896208e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_451477b1-9984-4a47-87a3-cc6f1da5d12e" xlink:to="loc_us-gaap_OtherAssetsCurrent_fa97bd37-6955-475b-82e6-2eb896208e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a5a467e6-8899-4ac1-aa1e-8742692126ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesDeductionsCurrent_94512742-a898-49b5-a6f8-53edf4bce9cb" xlink:href="amgn-20221231.xsd#amgn_AccruedSalesDeductionsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a5a467e6-8899-4ac1-aa1e-8742692126ea" xlink:to="loc_amgn_AccruedSalesDeductionsCurrent_94512742-a898-49b5-a6f8-53edf4bce9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_0e5e2b1f-13f6-4751-9594-32eee1bb571d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a5a467e6-8899-4ac1-aa1e-8742692126ea" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_0e5e2b1f-13f6-4751-9594-32eee1bb571d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_bd32c16f-abec-4e16-8dd4-a95ffd0877a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a5a467e6-8899-4ac1-aa1e-8742692126ea" xlink:to="loc_us-gaap_DividendsPayableCurrent_bd32c16f-abec-4e16-8dd4-a95ffd0877a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_85d6e285-a802-45e1-bdcb-6351db288cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a5a467e6-8899-4ac1-aa1e-8742692126ea" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_85d6e285-a802-45e1-bdcb-6351db288cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesReturnReserveCurrent_c2c42d3f-8351-4db9-91b9-ec461d7d5e08" xlink:href="amgn-20221231.xsd#amgn_AccruedSalesReturnReserveCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a5a467e6-8899-4ac1-aa1e-8742692126ea" xlink:to="loc_amgn_AccruedSalesReturnReserveCurrent_c2c42d3f-8351-4db9-91b9-ec461d7d5e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ba2ae572-21db-494c-b7b0-cb68681a93e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a5a467e6-8899-4ac1-aa1e-8742692126ea" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ba2ae572-21db-494c-b7b0-cb68681a93e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0e2f107b-239a-4131-8fbc-20d6d1d6b99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a5a467e6-8899-4ac1-aa1e-8742692126ea" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0e2f107b-239a-4131-8fbc-20d6d1d6b99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a3ef868d-2a39-4a30-a36e-e32e824c2ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a3ef868d-2a39-4a30-a36e-e32e824c2ebc" xlink:to="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ccaf1470-9cdf-4150-8e2f-813f85ce5660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ccaf1470-9cdf-4150-8e2f-813f85ce5660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e8c3c6cf-c7bd-4f10-8a22-359eb7ffc6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ccaf1470-9cdf-4150-8e2f-813f85ce5660" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e8c3c6cf-c7bd-4f10-8a22-359eb7ffc6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_4689b52d-5795-4420-811a-d9ac765ab321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e8c3c6cf-c7bd-4f10-8a22-359eb7ffc6c5" xlink:to="loc_us-gaap_NotesPayableToBanksMember_4689b52d-5795-4420-811a-d9ac765ab321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember_ada877ba-8ed3-4f0f-a97c-0d10831749a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e8c3c6cf-c7bd-4f10-8a22-359eb7ffc6c5" xlink:to="loc_us-gaap_DebtSecuritiesPayableMember_ada877ba-8ed3-4f0f-a97c-0d10831749a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_25b43e76-aa59-433c-9cbe-c85a99ea97eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:to="loc_us-gaap_DebtInstrumentAxis_25b43e76-aa59-433c-9cbe-c85a99ea97eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_25b43e76-aa59-433c-9cbe-c85a99ea97eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_c5d2f5ae-e180-43f6-b0cf-99cd718d393a" xlink:href="amgn-20221231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_c5d2f5ae-e180-43f6-b0cf-99cd718d393a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_abae1068-8b47-4bef-8620-bbb4bccd17f2" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_abae1068-8b47-4bef-8620-bbb4bccd17f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_68ac8ac9-f720-4e13-a583-06e4cbdc5018" xlink:href="amgn-20221231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_68ac8ac9-f720-4e13-a583-06e4cbdc5018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_33be7f92-d8cb-4e3f-a244-db6d64d5f928" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_33be7f92-d8cb-4e3f-a244-db6d64d5f928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_32b9a2d4-515a-4da4-b472-43ed43e6d498" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_32b9a2d4-515a-4da4-b472-43ed43e6d498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember_dacd7531-887a-4b26-b2a0-6f9afeb17434" xlink:href="amgn-20221231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A190NotesDue20251902025NotesMember_dacd7531-887a-4b26-b2a0-6f9afeb17434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_91bb59e8-572e-4b1a-893c-ab53f1c38251" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_91bb59e8-572e-4b1a-893c-ab53f1c38251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_3ee3e9f9-0a64-428e-bf6d-6c3e05aad5bf" xlink:href="amgn-20221231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_3ee3e9f9-0a64-428e-bf6d-6c3e05aad5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_aa05b90b-f4e7-4803-a18b-9edf3645c047" xlink:href="amgn-20221231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_aa05b90b-f4e7-4803-a18b-9edf3645c047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_3dbc8703-0589-4d98-b2d4-b87452fa76d9" xlink:href="amgn-20221231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_3dbc8703-0589-4d98-b2d4-b87452fa76d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_b97f4f7e-8480-4a5a-9d17-81503f643bc4" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_b97f4f7e-8480-4a5a-9d17-81503f643bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member_eea127d8-ad0d-4abe-b717-c7c5a6023c93" xlink:href="amgn-20221231.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointTwoZeroNotesDue2027Member_eea127d8-ad0d-4abe-b717-c7c5a6023c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember_6d060abe-61d9-445a-a940-b90923b45200" xlink:href="amgn-20221231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A165NotesDue20281652028NotesMember_6d060abe-61d9-445a-a940-b90923b45200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20293002029NotesMember_fa0ce5c4-d454-4553-b9dc-e72214ce8f9f" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20293002029NotesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A300NotesDue20293002029NotesMember_fa0ce5c4-d454-4553-b9dc-e72214ce8f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A405NotesDue20294052029NotesMember_c32de701-ddf7-4b32-b7e1-a0e7c69387ac" xlink:href="amgn-20221231.xsd#amgn_A405NotesDue20294052029NotesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A405NotesDue20294052029NotesMember_c32de701-ddf7-4b32-b7e1-a0e7c69387ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_ed1fef55-7f67-445d-8194-7a73625bf625" xlink:href="amgn-20221231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_ed1fef55-7f67-445d-8194-7a73625bf625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_3e9db160-05c8-43b7-9dba-876bd35ef4e1" xlink:href="amgn-20221231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_3e9db160-05c8-43b7-9dba-876bd35ef4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_2692019e-6961-45ed-a2fa-6ce5e2b0307d" xlink:href="amgn-20221231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_2692019e-6961-45ed-a2fa-6ce5e2b0307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_d88bee42-7833-4573-b6b9-b45817a2d4fd" xlink:href="amgn-20221231.xsd#amgn_TwoPointZeroPercent2032NotesMemberMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_d88bee42-7833-4573-b6b9-b45817a2d4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A335NotesDue20323352032NotesMember_568e2fe3-66aa-4496-97c0-c5f333b08629" xlink:href="amgn-20221231.xsd#amgn_A335NotesDue20323352032NotesMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A335NotesDue20323352032NotesMember_568e2fe3-66aa-4496-97c0-c5f333b08629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20334202033NotesMember_28eafc26-ce11-4c15-8921-ce31a8e4c973" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20334202033NotesMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A420NotesDue20334202033NotesMember_28eafc26-ce11-4c15-8921-ce31a8e4c973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_3a537b73-ef0f-4049-8261-18513585832e" xlink:href="amgn-20221231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_3a537b73-ef0f-4049-8261-18513585832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_de65356e-090b-4a16-946d-c13cb174acb4" xlink:href="amgn-20221231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_de65356e-090b-4a16-946d-c13cb174acb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_4f276b12-e095-46d5-8024-3a7f280296e1" xlink:href="amgn-20221231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_4f276b12-e095-46d5-8024-3a7f280296e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_0cc4c488-9441-4627-8f01-f0f2b685110f" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_0cc4c488-9441-4627-8f01-f0f2b685110f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_b3a9e8a8-3290-465a-8adc-f6daeb884777" xlink:href="amgn-20221231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_b3a9e8a8-3290-465a-8adc-f6daeb884777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember_95004453-fd00-4136-b9ff-f22b25ef5e6a" xlink:href="amgn-20221231.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointEightZeroPercent2041NotesMember_95004453-fd00-4136-b9ff-f22b25ef5e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member_a1880d17-35cb-49f7-95e1-67290bb633c1" xlink:href="amgn-20221231.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointNineFivePercentNotesDue2041Member_a1880d17-35cb-49f7-95e1-67290bb633c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_7d1ae5ca-675a-4996-beba-a86f98761327" xlink:href="amgn-20221231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_7d1ae5ca-675a-4996-beba-a86f98761327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_0dd6a557-2514-4744-acd3-9e7b8558edf0" xlink:href="amgn-20221231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_0dd6a557-2514-4744-acd3-9e7b8558edf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_08719a43-2ecc-4868-85bd-96959f8037f8" xlink:href="amgn-20221231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_08719a43-2ecc-4868-85bd-96959f8037f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_7ef1ca33-c239-47ce-a05e-f426cd8e5981" xlink:href="amgn-20221231.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_7ef1ca33-c239-47ce-a05e-f426cd8e5981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_6ba2a256-3d90-44f3-a3a6-ceb1a2a1dad2" xlink:href="amgn-20221231.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_6ba2a256-3d90-44f3-a3a6-ceb1a2a1dad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_9e37e09a-dda0-4db0-896a-8bc00c2d0523" xlink:href="amgn-20221231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_9e37e09a-dda0-4db0-896a-8bc00c2d0523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_269cd128-b8da-450f-a919-5cc3b7e925f6" xlink:href="amgn-20221231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_269cd128-b8da-450f-a919-5cc3b7e925f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_bfb7d6b9-e91e-4878-a2ea-cab4c4e0b335" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_bfb7d6b9-e91e-4878-a2ea-cab4c4e0b335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20524202052NotesMember_e14841d9-c6a7-43dd-add8-770a69abb9df" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20524202052NotesMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A420NotesDue20524202052NotesMember_e14841d9-c6a7-43dd-add8-770a69abb9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4875NotesDue205348752053NotesMember_663223be-f994-47f8-b930-e51e5d4444fb" xlink:href="amgn-20221231.xsd#amgn_A4875NotesDue205348752053NotesMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A4875NotesDue205348752053NotesMember_663223be-f994-47f8-b930-e51e5d4444fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_603c5a65-4f01-4163-9c34-ef9b037a6c71" xlink:href="amgn-20221231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_603c5a65-4f01-4163-9c34-ef9b037a6c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A440NotesDue20624402062NotesMember_c0a65183-7d63-4c00-ad0e-3dfd94b99aa1" xlink:href="amgn-20221231.xsd#amgn_A440NotesDue20624402062NotesMember"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A440NotesDue20624402062NotesMember_c0a65183-7d63-4c00-ad0e-3dfd94b99aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member_762d09a8-9712-461e-82d2-b276781cb8b6" xlink:href="amgn-20221231.xsd#amgn_OtherNotesDue2097Member"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_OtherNotesDue2097Member_762d09a8-9712-461e-82d2-b276781cb8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_d21ecd4f-341b-4692-a807-2d1d1f6463f6" xlink:href="amgn-20221231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_d21ecd4f-341b-4692-a807-2d1d1f6463f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_10dc7951-ae81-4307-a964-96d5027c275c" xlink:href="amgn-20221231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_10dc7951-ae81-4307-a964-96d5027c275c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_a1218c48-ed96-439c-a22d-ff11e9fec2e3" xlink:href="amgn-20221231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_a1218c48-ed96-439c-a22d-ff11e9fec2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_65da1bc0-7c99-4211-800c-68b3f8f0cdea" xlink:href="amgn-20221231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_65da1bc0-7c99-4211-800c-68b3f8f0cdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_128ce502-83b9-4337-8b94-075f2cd80f68" xlink:href="amgn-20221231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_128ce502-83b9-4337-8b94-075f2cd80f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_c7d644c0-eec5-43b4-824a-8fd723c8d2d0" xlink:href="amgn-20221231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_c7d644c0-eec5-43b4-824a-8fd723c8d2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_4f771605-893a-444e-ae3c-6fa87137e292" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_4f771605-893a-444e-ae3c-6fa87137e292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_23656c2c-6510-4616-a62b-d40dcdf0aa92" xlink:href="amgn-20221231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_23656c2c-6510-4616-a62b-d40dcdf0aa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A200NotesDue20322002032NotesMember_1f161baa-369b-4570-aea2-e4ed5844e86c" xlink:href="amgn-20221231.xsd#amgn_A200NotesDue20322002032NotesMember"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A200NotesDue20322002032NotesMember_1f161baa-369b-4570-aea2-e4ed5844e86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A280NotesDue2041Member_2dfbe98b-2d1b-41fb-b4d2-49b15a658883" xlink:href="amgn-20221231.xsd#amgn_A280NotesDue2041Member"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf4c56c3-9ee5-4429-9da0-a82705ecfb16" xlink:to="loc_amgn_A280NotesDue2041Member_2dfbe98b-2d1b-41fb-b4d2-49b15a658883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b004a92-4032-4d35-8cd6-534bb2ca4f4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:to="loc_srt_RangeAxis_9b004a92-4032-4d35-8cd6-534bb2ca4f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_929c5cfb-e77d-4bc2-838c-2a32149bf530" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9b004a92-4032-4d35-8cd6-534bb2ca4f4c" xlink:to="loc_srt_RangeMember_929c5cfb-e77d-4bc2-838c-2a32149bf530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb1f9422-95d3-4755-be6a-069e8a599010" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_929c5cfb-e77d-4bc2-838c-2a32149bf530" xlink:to="loc_srt_MinimumMember_bb1f9422-95d3-4755-be6a-069e8a599010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_407f9d6c-8bb5-44c4-aea2-98e39cf8cd49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_929c5cfb-e77d-4bc2-838c-2a32149bf530" xlink:to="loc_srt_MaximumMember_407f9d6c-8bb5-44c4-aea2-98e39cf8cd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c4c9869f-a499-482f-9af9-e088451869ed" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65f2a9c8-ee2f-4f64-8394-ad209cf5a4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65f2a9c8-ee2f-4f64-8394-ad209cf5a4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_49f08c33-8b03-41e4-aee5-28c21dd2dfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_49f08c33-8b03-41e4-aee5-28c21dd2dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f0ec5b4d-048c-4dfa-a884-2a23f3e5b731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f0ec5b4d-048c-4dfa-a884-2a23f3e5b731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_8e0a4e45-0762-4edf-81dc-95252c17af31" xlink:href="amgn-20221231.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_8e0a4e45-0762-4edf-81dc-95252c17af31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_e7070947-0145-4cb4-bb25-e7641a745df2" xlink:href="amgn-20221231.xsd#amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_e7070947-0145-4cb4-bb25-e7641a745df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1a1e0618-bdf1-4253-b0e0-44e849c2e8b2" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f9e95a87-c9d2-49ab-8cac-d0aa0738945f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f9e95a87-c9d2-49ab-8cac-d0aa0738945f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d7da89d1-68eb-4d8f-beb3-eac0a50181f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d7da89d1-68eb-4d8f-beb3-eac0a50181f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6cdc3c23-2732-4925-a72e-9e82d109533d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6cdc3c23-2732-4925-a72e-9e82d109533d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_be656336-0708-4c22-81c5-7d0f64ea292b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_OtherLongTermDebt_be656336-0708-4c22-81c5-7d0f64ea292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a142a928-9a96-435a-b6f6-86ef18c416b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_LongTermDebt_a142a928-9a96-435a-b6f6-86ef18c416b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_08e5a47c-357b-4206-a77b-ff3425155851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_LongTermDebtCurrent_08e5a47c-357b-4206-a77b-ff3425155851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d62026d4-19f7-4026-981f-d41b7a3e373f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_4e2bc924-69e3-4c9b-a7de-638957832f6a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d62026d4-19f7-4026-981f-d41b7a3e373f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsDebtIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_477f24b0-4280-4b19-b082-10446da5830b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_477f24b0-4280-4b19-b082-10446da5830b" xlink:to="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ade4077d-d187-4cb1-95b8-dc7e997d6c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ade4077d-d187-4cb1-95b8-dc7e997d6c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aa248a59-f269-4111-8610-acea3a1a78d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ade4077d-d187-4cb1-95b8-dc7e997d6c54" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aa248a59-f269-4111-8610-acea3a1a78d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_6ab9c8ad-ad53-4905-94cb-34c2bb44ef66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_aa248a59-f269-4111-8610-acea3a1a78d8" xlink:to="loc_us-gaap_NotesPayableToBanksMember_6ab9c8ad-ad53-4905-94cb-34c2bb44ef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_58f12321-e1c4-4d0b-9a31-225687f4c751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:to="loc_us-gaap_DebtInstrumentAxis_58f12321-e1c4-4d0b-9a31-225687f4c751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_58f12321-e1c4-4d0b-9a31-225687f4c751" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember_08779395-25fe-4452-a315-bfc0c70a1cca" xlink:href="amgn-20221231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A165NotesDue20281652028NotesMember_08779395-25fe-4452-a315-bfc0c70a1cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A200NotesDue20322002032NotesMember_4bfe0072-3be0-4487-9533-58fcb65a5bd1" xlink:href="amgn-20221231.xsd#amgn_A200NotesDue20322002032NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A200NotesDue20322002032NotesMember_4bfe0072-3be0-4487-9533-58fcb65a5bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A280NotesDue2041Member_5728a37f-60a4-4bbd-95a3-cf0026b6a6a5" xlink:href="amgn-20221231.xsd#amgn_A280NotesDue2041Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A280NotesDue2041Member_5728a37f-60a4-4bbd-95a3-cf0026b6a6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_98f9d60b-fbb1-4888-8409-6a36d140f99a" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_98f9d60b-fbb1-4888-8409-6a36d140f99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember_3292ac7a-66e9-417f-bf28-1bad8d5ba3d3" xlink:href="amgn-20221231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A190NotesDue20251902025NotesMember_3292ac7a-66e9-417f-bf28-1bad8d5ba3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_364c1f9e-d3a2-4576-accb-254dcd987be8" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_364c1f9e-d3a2-4576-accb-254dcd987be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_627c487b-e2af-41fd-af33-80cdc0592ac5" xlink:href="amgn-20221231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_627c487b-e2af-41fd-af33-80cdc0592ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_99ddb374-a4cb-4092-b923-8d8a68bd661a" xlink:href="amgn-20221231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_99ddb374-a4cb-4092-b923-8d8a68bd661a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_1b4187bb-220f-4100-ad0b-5b7e1b4d9cb7" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_1b4187bb-220f-4100-ad0b-5b7e1b4d9cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_685292f5-ae03-4a11-82de-88541a7276da" xlink:href="amgn-20221231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_685292f5-ae03-4a11-82de-88541a7276da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20293002029NotesMember_94eae763-b122-4686-8ed3-9685302a192e" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20293002029NotesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A300NotesDue20293002029NotesMember_94eae763-b122-4686-8ed3-9685302a192e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A405NotesDue20294052029NotesMember_23a31b41-e8e9-4bc5-8e03-41a569d59598" xlink:href="amgn-20221231.xsd#amgn_A405NotesDue20294052029NotesMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A405NotesDue20294052029NotesMember_23a31b41-e8e9-4bc5-8e03-41a569d59598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A335NotesDue20323352032NotesMember_eef6dcce-0dde-4280-8308-1c6ed6c4d240" xlink:href="amgn-20221231.xsd#amgn_A335NotesDue20323352032NotesMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A335NotesDue20323352032NotesMember_eef6dcce-0dde-4280-8308-1c6ed6c4d240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20334202033NotesMember_2a18fded-3ee0-46e3-aa5a-b7432058de86" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20334202033NotesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A420NotesDue20334202033NotesMember_2a18fded-3ee0-46e3-aa5a-b7432058de86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A420NotesDue20524202052NotesMember_cf2e00ba-50ca-4c77-a9dc-d9bcbf436068" xlink:href="amgn-20221231.xsd#amgn_A420NotesDue20524202052NotesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A420NotesDue20524202052NotesMember_cf2e00ba-50ca-4c77-a9dc-d9bcbf436068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4875NotesDue205348752053NotesMember_cb1ba933-0d37-4ea9-a9b1-3506854f7060" xlink:href="amgn-20221231.xsd#amgn_A4875NotesDue205348752053NotesMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A4875NotesDue205348752053NotesMember_cb1ba933-0d37-4ea9-a9b1-3506854f7060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A440NotesDue20624402062NotesMember_56fb3c8f-fe45-48c3-a5f0-a70bdf692e36" xlink:href="amgn-20221231.xsd#amgn_A440NotesDue20624402062NotesMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c781787-2321-41e8-92c9-61a41749b5b2" xlink:to="loc_amgn_A440NotesDue20624402062NotesMember_56fb3c8f-fe45-48c3-a5f0-a70bdf692e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_939ab0fd-abe3-4763-ba8f-7e096f4beeeb" xlink:href="amgn-20221231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:to="loc_amgn_AssetsByDescriptionAxis_939ab0fd-abe3-4763-ba8f-7e096f4beeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_957fe5df-bfb8-4064-bf13-1461603efba9" xlink:href="amgn-20221231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionAxis_939ab0fd-abe3-4763-ba8f-7e096f4beeeb" xlink:to="loc_amgn_AssetsByDescriptionDomain_957fe5df-bfb8-4064-bf13-1461603efba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1eeae449-e999-487c-a1f0-e8c7e342f8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e27e7a0-39d5-4e9c-91df-98d118b83c50" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1eeae449-e999-487c-a1f0-e8c7e342f8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b1e149fd-a7a6-48c1-a2ff-64f056e955d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1eeae449-e999-487c-a1f0-e8c7e342f8a9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b1e149fd-a7a6-48c1-a2ff-64f056e955d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bf7aca4c-ef7d-4d93-96f1-011da69aa58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1eeae449-e999-487c-a1f0-e8c7e342f8a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bf7aca4c-ef7d-4d93-96f1-011da69aa58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsDebtRepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_647b0240-d4a1-4d0c-bd5f-7b5579203f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b8823fa3-3cbb-4844-a181-512acf8294a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_647b0240-d4a1-4d0c-bd5f-7b5579203f69" xlink:to="loc_us-gaap_DebtInstrumentTable_b8823fa3-3cbb-4844-a181-512acf8294a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_db565ea6-b84f-44ac-924a-bf1c3a7cfe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b8823fa3-3cbb-4844-a181-512acf8294a9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_db565ea6-b84f-44ac-924a-bf1c3a7cfe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_956317fa-21d4-40d8-8dc6-5a54fbad3f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_db565ea6-b84f-44ac-924a-bf1c3a7cfe3c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_956317fa-21d4-40d8-8dc6-5a54fbad3f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_6812c6d4-f18a-4afe-9653-f746066b4185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_956317fa-21d4-40d8-8dc6-5a54fbad3f41" xlink:to="loc_us-gaap_NotesPayableToBanksMember_6812c6d4-f18a-4afe-9653-f746066b4185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_96d463cb-3b44-49b4-9482-8f65d694ccc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b8823fa3-3cbb-4844-a181-512acf8294a9" xlink:to="loc_us-gaap_DebtInstrumentAxis_96d463cb-3b44-49b4-9482-8f65d694ccc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_96d463cb-3b44-49b4-9482-8f65d694ccc4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_a6e93fd1-a6c9-4604-83cd-54da241978e1" xlink:href="amgn-20221231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_a6e93fd1-a6c9-4604-83cd-54da241978e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_787e3ce2-1b73-4cf3-8446-aeefce13a1e9" xlink:href="amgn-20221231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_787e3ce2-1b73-4cf3-8446-aeefce13a1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_93464093-610d-4c89-b89c-eab89bdf0096" xlink:href="amgn-20221231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_93464093-610d-4c89-b89c-eab89bdf0096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_7b4160b2-3115-4c5e-bd5a-ad385dc6cc08" xlink:href="amgn-20221231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_7b4160b2-3115-4c5e-bd5a-ad385dc6cc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_81b99842-ca30-4362-9170-81eda9bbb6c2" xlink:href="amgn-20221231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_81b99842-ca30-4362-9170-81eda9bbb6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_35848d38-acd9-428c-a025-0b49973f6361" xlink:href="amgn-20221231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_35848d38-acd9-428c-a025-0b49973f6361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_5032979b-40b0-42da-842c-9e7caeb5b4bc" xlink:href="amgn-20221231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_5032979b-40b0-42da-842c-9e7caeb5b4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_3fdbce7e-fa4b-46c9-a8ce-561422a77d6e" xlink:href="amgn-20221231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_3fdbce7e-fa4b-46c9-a8ce-561422a77d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_9ee729e1-ebd3-474c-8f8a-136c707d0410" xlink:href="amgn-20221231.xsd#amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_9ee729e1-ebd3-474c-8f8a-136c707d0410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member_fb68bf9b-088d-4c81-943a-d732fd5b7b71" xlink:href="amgn-20221231.xsd#amgn_TwoPointSevenZeroPercentNotesDue2022Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member_fb68bf9b-088d-4c81-943a-d732fd5b7b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_f8096207-5f61-4952-a6a9-c0c4624e76a9" xlink:href="amgn-20221231.xsd#amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_f8096207-5f61-4952-a6a9-c0c4624e76a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_a2471455-b67a-41f6-b5b4-457c5d847ac5" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_a2471455-b67a-41f6-b5b4-457c5d847ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_eb4aab6e-a55b-4876-8e0a-dd9e6f492dcd" xlink:href="amgn-20221231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_eb4aab6e-a55b-4876-8e0a-dd9e6f492dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_fc96ca4c-1c1a-4f4d-8d0d-39e1959f47a9" xlink:href="amgn-20221231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_fc96ca4c-1c1a-4f4d-8d0d-39e1959f47a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember_ce3bd8e6-ee3d-4fbf-90b3-397c25b7c4d9" xlink:href="amgn-20221231.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_TwoPointEightZeroPercent2041NotesMember_ce3bd8e6-ee3d-4fbf-90b3-397c25b7c4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_929515d1-8d4a-4d70-bf65-64ed3561255b" xlink:href="amgn-20221231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98161cb7-421b-437d-9be7-b85977bc05c8" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_929515d1-8d4a-4d70-bf65-64ed3561255b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b8823fa3-3cbb-4844-a181-512acf8294a9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4106931b-6dcf-4d7e-8f84-49ee07b81342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4106931b-6dcf-4d7e-8f84-49ee07b81342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f571d127-5ecf-4b10-ab47-a7cd833edc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f571d127-5ecf-4b10-ab47-a7cd833edc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a2f81464-2b76-4781-baff-dc317df2dc29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_InterestExpenseDebt_a2f81464-2b76-4781-baff-dc317df2dc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_e1da8daf-b3ce-477e-a771-bb5ae3e0f2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_e1da8daf-b3ce-477e-a771-bb5ae3e0f2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7b697a27-092d-4721-a843-500646d03342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c482c469-874d-4f15-82e5-e0ad2c9902f3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7b697a27-092d-4721-a843-500646d03342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_325ab3d3-af0e-4b1f-82cb-97690f1a1f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_325ab3d3-af0e-4b1f-82cb-97690f1a1f52" xlink:to="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cc680c2b-24cf-4ef5-a26a-57d9c6abcc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cc680c2b-24cf-4ef5-a26a-57d9c6abcc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5d008a0d-cbbe-48e3-aa28-9a8a8add9270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc680c2b-24cf-4ef5-a26a-57d9c6abcc39" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5d008a0d-cbbe-48e3-aa28-9a8a8add9270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_2c81626d-70ac-46dc-a1bb-ed21c2f14cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5d008a0d-cbbe-48e3-aa28-9a8a8add9270" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_2c81626d-70ac-46dc-a1bb-ed21c2f14cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_461b2818-41de-4071-a73f-d1527262a7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5d008a0d-cbbe-48e3-aa28-9a8a8add9270" xlink:to="loc_us-gaap_NotesPayableToBanksMember_461b2818-41de-4071-a73f-d1527262a7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1f7f164a-01b3-45bf-84f0-e30062d93dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_DebtInstrumentAxis_1f7f164a-01b3-45bf-84f0-e30062d93dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1f7f164a-01b3-45bf-84f0-e30062d93dc1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_42b1d33a-005b-4579-9157-cf08449bbd8b" xlink:href="amgn-20221231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_42b1d33a-005b-4579-9157-cf08449bbd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_5ed69855-8672-4320-a8be-b75b834b36c5" xlink:href="amgn-20221231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_5ed69855-8672-4320-a8be-b75b834b36c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_ef0f2dd3-8818-42f8-9ea7-4aec14f05c44" xlink:href="amgn-20221231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_ef0f2dd3-8818-42f8-9ea7-4aec14f05c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_2466957c-127c-4115-baa3-56aa115123ba" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_2466957c-127c-4115-baa3-56aa115123ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_33ff1097-42d0-43d0-92c3-c82f49d2b4b7" xlink:href="amgn-20221231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_33ff1097-42d0-43d0-92c3-c82f49d2b4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_fc7f22a4-5447-4687-a259-6e2f7f1afbfa" xlink:href="amgn-20221231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_fc7f22a4-5447-4687-a259-6e2f7f1afbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_1a1fe5a6-6e71-44e1-a3cd-dc2afef0d77e" xlink:href="amgn-20221231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_1a1fe5a6-6e71-44e1-a3cd-dc2afef0d77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_22d7c25b-a98a-4632-be67-b3e54ff8c5d8" xlink:href="amgn-20221231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_22d7c25b-a98a-4632-be67-b3e54ff8c5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_3b3fe925-bf20-4839-baaa-02634bd6cea2" xlink:href="amgn-20221231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_3b3fe925-bf20-4839-baaa-02634bd6cea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_a6e9be9b-1a11-4cee-b370-fa88f652ce57" xlink:href="amgn-20221231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_a6e9be9b-1a11-4cee-b370-fa88f652ce57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_8a2d74e6-7c73-4dc5-a874-e75e635e7a57" xlink:href="amgn-20221231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_8a2d74e6-7c73-4dc5-a874-e75e635e7a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_3f8b342b-9eae-4229-b1ce-bf63189684d9" xlink:href="amgn-20221231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_3f8b342b-9eae-4229-b1ce-bf63189684d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_fca30b29-22cd-4196-b0c4-963b3ae0923d" xlink:href="amgn-20221231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_fca30b29-22cd-4196-b0c4-963b3ae0923d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_c3b41a94-59e5-42f7-b875-2b6f2ceae34d" xlink:href="amgn-20221231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_c3b41a94-59e5-42f7-b875-2b6f2ceae34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_b543c4f6-76dc-4cde-8be7-adc1cf307841" xlink:href="amgn-20221231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_b543c4f6-76dc-4cde-8be7-adc1cf307841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_4103c0a0-1479-415f-a9fb-df11f3f43f60" xlink:href="amgn-20221231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_4103c0a0-1479-415f-a9fb-df11f3f43f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_ba4b8ff2-03cb-4f2d-9d38-aaab571cd65e" xlink:href="amgn-20221231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_ba4b8ff2-03cb-4f2d-9d38-aaab571cd65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_e25c3994-c3a4-4c88-83b8-a57873cef19c" xlink:href="amgn-20221231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_e25c3994-c3a4-4c88-83b8-a57873cef19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_5e1b841e-9dff-4b98-a1aa-250765b55e14" xlink:href="amgn-20221231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_5e1b841e-9dff-4b98-a1aa-250765b55e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_32eb1f44-64c2-43c4-9108-c07612628f57" xlink:href="amgn-20221231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_32eb1f44-64c2-43c4-9108-c07612628f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_bcf6b0c2-fd83-45ae-9e4a-5da87954e844" xlink:href="amgn-20221231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_bcf6b0c2-fd83-45ae-9e4a-5da87954e844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_c5da4881-b102-46cf-b56b-2d681440dd41" xlink:href="amgn-20221231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_c5da4881-b102-46cf-b56b-2d681440dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_b3c50d22-025d-4dd1-9bb2-a9849a72a59a" xlink:href="amgn-20221231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_b3c50d22-025d-4dd1-9bb2-a9849a72a59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_dc5d3ec6-1b56-4b6d-ae74-4e6ad2bd4846" xlink:href="amgn-20221231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89f4757b-6824-486e-9191-03d3266cfac0" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_dc5d3ec6-1b56-4b6d-ae74-4e6ad2bd4846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ed913850-50eb-467c-841b-b583a7e08f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_VariableRateAxis_ed913850-50eb-467c-841b-b583a7e08f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b9bae7c1-4808-40d2-8a1f-6c4c027565d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_ed913850-50eb-467c-841b-b583a7e08f6a" xlink:to="loc_us-gaap_VariableRateDomain_b9bae7c1-4808-40d2-8a1f-6c4c027565d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_c2a1d827-a277-402b-94b5-b0f1ee609dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b9bae7c1-4808-40d2-8a1f-6c4c027565d3" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_c2a1d827-a277-402b-94b5-b0f1ee609dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_6b59c420-17ff-4ee8-9f8e-f9f42d28c559" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_amgn_InterestRateSwapAxis_6b59c420-17ff-4ee8-9f8e-f9f42d28c559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_e7390204-e27b-41e2-b925-82ef54f13054" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapAxis_6b59c420-17ff-4ee8-9f8e-f9f42d28c559" xlink:to="loc_amgn_InterestRateSwapDomain_e7390204-e27b-41e2-b925-82ef54f13054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapOneMember_1d9face5-19d2-4fa9-8cba-eaaf1ae63758" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapDomain_e7390204-e27b-41e2-b925-82ef54f13054" xlink:to="loc_amgn_InterestRateSwapOneMember_1d9face5-19d2-4fa9-8cba-eaaf1ae63758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_ccd00634-61f9-4e9c-ba1d-8f98583d4979" xlink:href="amgn-20221231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapDomain_e7390204-e27b-41e2-b925-82ef54f13054" xlink:to="loc_amgn_InterestRateSwapTwoMember_ccd00634-61f9-4e9c-ba1d-8f98583d4979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_13b74049-4fba-4d42-8cbe-6721eb80e986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_13b74049-4fba-4d42-8cbe-6721eb80e986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a6a75709-e6c0-403a-9d2a-d413f658086f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_13b74049-4fba-4d42-8cbe-6721eb80e986" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a6a75709-e6c0-403a-9d2a-d413f658086f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5b3a038d-fccd-458e-92c1-c0ada77c76f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6a75709-e6c0-403a-9d2a-d413f658086f" xlink:to="loc_us-gaap_InterestRateSwapMember_5b3a038d-fccd-458e-92c1-c0ada77c76f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_e2885aeb-4eb4-40ff-b0fb-619bfd078226" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6a75709-e6c0-403a-9d2a-d413f658086f" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_e2885aeb-4eb4-40ff-b0fb-619bfd078226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6635e9d2-0528-4b30-a496-c74555b2d014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_HedgingDesignationAxis_6635e9d2-0528-4b30-a496-c74555b2d014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_96bbb884-dfc9-423e-b541-d920e88bff49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6635e9d2-0528-4b30-a496-c74555b2d014" xlink:to="loc_us-gaap_HedgingDesignationDomain_96bbb884-dfc9-423e-b541-d920e88bff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e0511f67-a7d5-4f1e-830b-c120df484bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_96bbb884-dfc9-423e-b541-d920e88bff49" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e0511f67-a7d5-4f1e-830b-c120df484bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8f504b90-aec5-4272-a272-44c00d879da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8f504b90-aec5-4272-a272-44c00d879da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_463aa824-28a6-4d72-aa3f-9f1d001fd8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8f504b90-aec5-4272-a272-44c00d879da5" xlink:to="loc_us-gaap_HedgingRelationshipDomain_463aa824-28a6-4d72-aa3f-9f1d001fd8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e8083e0b-1b9d-4b7e-95e6-6884adfe6eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_463aa824-28a6-4d72-aa3f-9f1d001fd8d3" xlink:to="loc_us-gaap_CashFlowHedgingMember_e8083e0b-1b9d-4b7e-95e6-6884adfe6eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8549d5bb-88f3-41b3-8782-edcba770f4df" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5de1aff6-cd13-42d4-a5f4-a464a04aa52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5de1aff6-cd13-42d4-a5f4-a464a04aa52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_f16ceb1e-54e0-42f4-87da-1b5735f12060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeBasisSpreadOnVariableRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_f16ceb1e-54e0-42f4-87da-1b5735f12060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_39c1a7ef-91a0-4e5f-a911-ef5df20805c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DerivativeNotionalAmount_39c1a7ef-91a0-4e5f-a911-ef5df20805c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_fc196435-8fe5-41c0-828d-880f2e5f49d6" xlink:href="amgn-20221231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_fc196435-8fe5-41c0-828d-880f2e5f49d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_759cdaa5-01b4-4904-912c-8c7aad728c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_759cdaa5-01b4-4904-912c-8c7aad728c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_948a6c00-d530-4bb1-b63f-91536bac3695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_948a6c00-d530-4bb1-b63f-91536bac3695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_72bde99f-51ab-4076-ab5b-e53ee80e6093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_72bde99f-51ab-4076-ab5b-e53ee80e6093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration_ccfbd2f9-0177-4c7d-a4fb-2586d69cefa9" xlink:href="amgn-20221231.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_amgn_DebtExchangeAdditionalCashConsideration_ccfbd2f9-0177-4c7d-a4fb-2586d69cefa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2ada424e-cc0f-4ec6-b038-255cbdab670e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2ada424e-cc0f-4ec6-b038-255cbdab670e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bf524ce4-e5a5-4a35-a845-6c61379a2fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d4b27b1c-4ebd-43da-900b-f99a70759690" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bf524ce4-e5a5-4a35-a845-6c61379a2fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e9f1225c-c0cd-42b9-b241-5f1be07acc52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e9f1225c-c0cd-42b9-b241-5f1be07acc52" xlink:to="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ea7e87e8-80ec-4b55-b6c2-160bd0f5cca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ea7e87e8-80ec-4b55-b6c2-160bd0f5cca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3ef1696e-e5a5-42da-9ebf-89f2d0c0fcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea7e87e8-80ec-4b55-b6c2-160bd0f5cca2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3ef1696e-e5a5-42da-9ebf-89f2d0c0fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_813179c9-db6b-4294-80c4-2cee1da1f335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3ef1696e-e5a5-42da-9ebf-89f2d0c0fcfe" xlink:to="loc_us-gaap_LineOfCreditMember_813179c9-db6b-4294-80c4-2cee1da1f335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementMember_e3ed3432-ae3e-4e20-9d14-d5fb9d9b2dea" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3ef1696e-e5a5-42da-9ebf-89f2d0c0fcfe" xlink:to="loc_amgn_BridgeCreditAgreementMember_e3ed3432-ae3e-4e20-9d14-d5fb9d9b2dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b9c2d924-cb02-4456-ae16-900822194a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:to="loc_us-gaap_VariableRateAxis_b9c2d924-cb02-4456-ae16-900822194a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1be79d4c-6764-4b30-8764-538e72bee4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_b9c2d924-cb02-4456-ae16-900822194a4b" xlink:to="loc_us-gaap_VariableRateDomain_1be79d4c-6764-4b30-8764-538e72bee4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SecuredOvernightFinancingRateMember_fae7890b-1356-4252-ac46-0e9f86755032" xlink:href="amgn-20221231.xsd#amgn_SecuredOvernightFinancingRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1be79d4c-6764-4b30-8764-538e72bee4d7" xlink:to="loc_amgn_SecuredOvernightFinancingRateMember_fae7890b-1356-4252-ac46-0e9f86755032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember_5690d5b0-74e0-45e5-b0cd-5ed010052d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1be79d4c-6764-4b30-8764-538e72bee4d7" xlink:to="loc_us-gaap_FederalFundsPurchasedMember_5690d5b0-74e0-45e5-b0cd-5ed010052d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8b25afd5-fb19-4d97-b678-3967790661eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8b25afd5-fb19-4d97-b678-3967790661eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6737c073-95d3-4c64-8927-4274116d4323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8b25afd5-fb19-4d97-b678-3967790661eb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6737c073-95d3-4c64-8927-4274116d4323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HorizonTherapeuticsMember_d09025ca-6d5c-4a44-b39b-c518fed2aed0" xlink:href="amgn-20221231.xsd#amgn_HorizonTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6737c073-95d3-4c64-8927-4274116d4323" xlink:to="loc_amgn_HorizonTherapeuticsMember_d09025ca-6d5c-4a44-b39b-c518fed2aed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59380e03-d2d6-4855-b96f-789518e14bc6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_5a45d20d-02c7-45c0-9f7b-0804c5528024" xlink:href="amgn-20221231.xsd#amgn_MaximumBorrowingCapacityUnderCommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_5a45d20d-02c7-45c0-9f7b-0804c5528024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_7ce86a9a-6130-419a-9b90-b886dbec3b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_CommercialPaper_7ce86a9a-6130-419a-9b90-b886dbec3b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e9b790de-73d5-44d4-9126-2ba728b2f81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e9b790de-73d5-44d4-9126-2ba728b2f81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_e7ca9704-39e3-453a-8115-3139cc383ffe" xlink:href="amgn-20221231.xsd#amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_e7ca9704-39e3-453a-8115-3139cc383ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_25e6155c-e140-4350-9649-c83f22403540" xlink:href="amgn-20221231.xsd#amgn_LineOfCreditFacilityInitialCommitmentTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_25e6155c-e140-4350-9649-c83f22403540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_8d1cf063-559e-4bf2-997a-99c7005abdd8" xlink:href="amgn-20221231.xsd#amgn_LineofCreditFacilityNumberOfRenewalOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_8d1cf063-559e-4bf2-997a-99c7005abdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_d06a4b1b-24d9-45bd-8dc1-1eec94378d4d" xlink:href="amgn-20221231.xsd#amgn_LineOfCreditFacilityExtensionOfCommitmentTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_d06a4b1b-24d9-45bd-8dc1-1eec94378d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5a1b5177-46c8-4b0a-88c0-b635e8236b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5a1b5177-46c8-4b0a-88c0-b635e8236b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_15ee37c5-a7c9-4a55-9e4c-fee0da8962d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_15ee37c5-a7c9-4a55-9e4c-fee0da8962d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_14f29e36-c213-4cdb-a6f6-74fd0931327f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_14f29e36-c213-4cdb-a6f6-74fd0931327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_55f05b8c-d62d-4161-a5b3-0f5c91079092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_us-gaap_LineOfCredit_55f05b8c-d62d-4161-a5b3-0f5c91079092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementInitialAmount_889c9e36-f4ef-4ed3-9ee2-6e81cad35005" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementInitialAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_BridgeCreditAgreementInitialAmount_889c9e36-f4ef-4ed3-9ee2-6e81cad35005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BridgeCreditAgreementAmount_9f3cc100-1e08-43d3-878c-64ec08557fbf" xlink:href="amgn-20221231.xsd#amgn_BridgeCreditAgreementAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dc38671b-7bea-4329-92ce-65b3e8ff7af8" xlink:to="loc_amgn_BridgeCreditAgreementAmount_9f3cc100-1e08-43d3-878c-64ec08557fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_24a51900-824c-447c-a0e1-48897422ea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_236995c2-1963-4950-be13-b0d41eff2a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_24a51900-824c-447c-a0e1-48897422ea6d" xlink:to="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_236995c2-1963-4950-be13-b0d41eff2a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_553b5a45-0e45-40b4-995f-ef2e6c353327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_236995c2-1963-4950-be13-b0d41eff2a09" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_553b5a45-0e45-40b4-995f-ef2e6c353327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_27e8bcaa-ae1b-4f41-9cb2-3d6bc8ab12c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_236995c2-1963-4950-be13-b0d41eff2a09" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_27e8bcaa-ae1b-4f41-9cb2-3d6bc8ab12c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_96de97a5-25ce-4b6a-9d11-c8f8815a1d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_236995c2-1963-4950-be13-b0d41eff2a09" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_96de97a5-25ce-4b6a-9d11-c8f8815a1d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_467f2aea-381a-465a-a70d-89b5a4bf6016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_236995c2-1963-4950-be13-b0d41eff2a09" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_467f2aea-381a-465a-a70d-89b5a4bf6016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2a036059-5338-496c-8a35-7a7c29df4435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_236995c2-1963-4950-be13-b0d41eff2a09" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2a036059-5338-496c-8a35-7a7c29df4435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_d6b3c77c-26d7-4dc4-8bd3-2e204e9a6051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_236995c2-1963-4950-be13-b0d41eff2a09" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_d6b3c77c-26d7-4dc4-8bd3-2e204e9a6051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_cdaf2954-16b4-48fc-8318-feff8e6242b6" xlink:href="amgn-20221231.xsd#amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_236995c2-1963-4950-be13-b0d41eff2a09" xlink:to="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_cdaf2954-16b4-48fc-8318-feff8e6242b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FinancingarrangementsInterestCostsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7bf39382-359a-4ad9-8e13-bc56a6df5147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_486b2bb1-5785-488f-bec1-bf167ff256a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7bf39382-359a-4ad9-8e13-bc56a6df5147" xlink:to="loc_us-gaap_InterestPaid_486b2bb1-5785-488f-bec1-bf167ff256a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityStockRepurchaseProgramDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_74879ec5-d953-411d-b07a-b42dc1e8800f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5665e915-374b-4a4c-ba8b-7639693e1639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_74879ec5-d953-411d-b07a-b42dc1e8800f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5665e915-374b-4a4c-ba8b-7639693e1639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e13b7457-0167-4c1e-8498-993ffd712870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5665e915-374b-4a4c-ba8b-7639693e1639" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e13b7457-0167-4c1e-8498-993ffd712870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_84e2074b-357e-4822-a961-48a9194ded6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e13b7457-0167-4c1e-8498-993ffd712870" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_84e2074b-357e-4822-a961-48a9194ded6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcceleratedStockRepurchaseAgreementMember_69412be3-666c-4ba8-9c39-f9eee161aecb" xlink:href="amgn-20221231.xsd#amgn_AcceleratedStockRepurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_84e2074b-357e-4822-a961-48a9194ded6e" xlink:to="loc_amgn_AcceleratedStockRepurchaseAgreementMember_69412be3-666c-4ba8-9c39-f9eee161aecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4eec7580-7fae-4b15-b978-bb3c8a061fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5665e915-374b-4a4c-ba8b-7639693e1639" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4eec7580-7fae-4b15-b978-bb3c8a061fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_da028243-851a-494d-abc1-3836a1d28b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4eec7580-7fae-4b15-b978-bb3c8a061fae" xlink:to="loc_us-gaap_EquityComponentDomain_da028243-851a-494d-abc1-3836a1d28b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_88107dbe-d206-4fba-b5cc-dfc6a2fdd340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_da028243-851a-494d-abc1-3836a1d28b16" xlink:to="loc_us-gaap_RetainedEarningsMember_88107dbe-d206-4fba-b5cc-dfc6a2fdd340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_62375a81-6919-4216-b9ef-2c7c50beea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_da028243-851a-494d-abc1-3836a1d28b16" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_62375a81-6919-4216-b9ef-2c7c50beea2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5665e915-374b-4a4c-ba8b-7639693e1639" xlink:to="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2228f04a-eb2e-4a5a-83d1-fb8411d345d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_2228f04a-eb2e-4a5a-83d1-fb8411d345d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_480763e0-c00a-4e8e-9d74-f091d093a2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_480763e0-c00a-4e8e-9d74-f091d093a2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c1906400-f3b7-4cd2-a290-9d21921f5f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c1906400-f3b7-4cd2-a290-9d21921f5f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_467bdf88-d743-448d-9a23-d5e903327d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_467bdf88-d743-448d-9a23-d5e903327d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_cf42cfb0-ff2a-46ba-87ad-0e0b15f13ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8d21e67-523f-469b-a196-c8ca7cac1d55" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_cf42cfb0-ff2a-46ba-87ad-0e0b15f13ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b72fc7fd-9e71-47a6-8ecb-1abcac8360cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_99d12b54-2c2b-4d48-a9ab-545a99a47a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b72fc7fd-9e71-47a6-8ecb-1abcac8360cb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_99d12b54-2c2b-4d48-a9ab-545a99a47a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_965244cf-e37f-4e95-948c-ec71897bba7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_99d12b54-2c2b-4d48-a9ab-545a99a47a3e" xlink:to="loc_srt_StatementScenarioAxis_965244cf-e37f-4e95-948c-ec71897bba7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_38834c45-8f08-45fe-906d-f663ff087f60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_965244cf-e37f-4e95-948c-ec71897bba7f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_38834c45-8f08-45fe-906d-f663ff087f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5b12b58e-740d-4fb5-bc4a-a2feb037cc86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_38834c45-8f08-45fe-906d-f663ff087f60" xlink:to="loc_srt_ScenarioForecastMember_5b12b58e-740d-4fb5-bc4a-a2feb037cc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7a992170-64cb-40cf-9aa4-90315d82b22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_99d12b54-2c2b-4d48-a9ab-545a99a47a3e" xlink:to="loc_us-gaap_ClassOfStockLineItems_7a992170-64cb-40cf-9aa4-90315d82b22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_635c21fa-dda0-4434-9182-87c7ed9999a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7a992170-64cb-40cf-9aa4-90315d82b22a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_635c21fa-dda0-4434-9182-87c7ed9999a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_040cd69b-546b-40b9-8936-8e44dde13c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7a992170-64cb-40cf-9aa4-90315d82b22a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_040cd69b-546b-40b9-8936-8e44dde13c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityComponentsofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_24529565-ee20-46e2-ad5a-ce5365446cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4271eded-c504-45df-b399-af426c1937f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24529565-ee20-46e2-ad5a-ce5365446cee" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4271eded-c504-45df-b399-af426c1937f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_143d61de-52ea-4ff3-bd91-eb61f4a1916e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4271eded-c504-45df-b399-af426c1937f2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_143d61de-52ea-4ff3-bd91-eb61f4a1916e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_143d61de-52ea-4ff3-bd91-eb61f4a1916e" xlink:to="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2f55df34-c72c-44cf-a0ad-933cea4e9d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2f55df34-c72c-44cf-a0ad-933cea4e9d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_aebfdacb-8651-42f9-961f-da7b7e6e8178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_aebfdacb-8651-42f9-961f-da7b7e6e8178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_eae3b9db-0d19-4186-ae23-d0be609ddf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_eae3b9db-0d19-4186-ae23-d0be609ddf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_7916d3ae-59eb-455e-ad05-82237f371c49" xlink:href="amgn-20221231.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_7916d3ae-59eb-455e-ad05-82237f371c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c29a50ad-59cf-4079-b9d3-ac5deaac8ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0a1123f-f656-464a-9a9d-f38ea2426215" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c29a50ad-59cf-4079-b9d3-ac5deaac8ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_dd889087-4820-485c-8fd2-1e63c1dd121e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4271eded-c504-45df-b399-af426c1937f2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_dd889087-4820-485c-8fd2-1e63c1dd121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_285841a1-75a6-4270-af96-9eeb15516258" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_dd889087-4820-485c-8fd2-1e63c1dd121e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_285841a1-75a6-4270-af96-9eeb15516258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_af53d078-dea4-492d-a001-0ac6681d4481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_285841a1-75a6-4270-af96-9eeb15516258" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_af53d078-dea4-492d-a001-0ac6681d4481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ddcdfdfe-d877-4674-9e94-221984dd0906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4271eded-c504-45df-b399-af426c1937f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ddcdfdfe-d877-4674-9e94-221984dd0906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ddcdfdfe-d877-4674-9e94-221984dd0906" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1f7d022b-bcbf-4c13-9aff-60598ec42983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_StockholdersEquity_1f7d022b-bcbf-4c13-9aff-60598ec42983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b28b2bcc-3ff0-400c-ae06-3dd6ff68b55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b28b2bcc-3ff0-400c-ae06-3dd6ff68b55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_370c0e93-fe2a-40a4-b8de-8903a9c8b14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_370c0e93-fe2a-40a4-b8de-8903a9c8b14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_189686d1-8ed8-4e41-b577-6eeefc44325e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_189686d1-8ed8-4e41-b577-6eeefc44325e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_c519f82a-eb75-4339-92c9-95b950db096d" xlink:href="amgn-20221231.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_c519f82a-eb75-4339-92c9-95b950db096d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_6ddaeabe-591c-4383-94ca-49710648812f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_6ddaeabe-591c-4383-94ca-49710648812f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_10a6010d-d2f2-424d-9eff-5e5f12cd98d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_827306f3-9da8-4690-bd93-703b59d3d19a" xlink:to="loc_us-gaap_StockholdersEquity_10a6010d-d2f2-424d-9eff-5e5f12cd98d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_168d4365-7f92-46aa-b107-35820d2260c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_95551d54-b089-4b85-b1f6-8b4ae207c552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_168d4365-7f92-46aa-b107-35820d2260c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_95551d54-b089-4b85-b1f6-8b4ae207c552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_2c9e182f-06d1-46af-b1eb-73332d9c9ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_168d4365-7f92-46aa-b107-35820d2260c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_2c9e182f-06d1-46af-b1eb-73332d9c9ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_309fb468-4cf5-496b-9390-63b0d48c37e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_168d4365-7f92-46aa-b107-35820d2260c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_309fb468-4cf5-496b-9390-63b0d48c37e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_7cf911d7-6b91-427c-9067-b519aa507049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_168d4365-7f92-46aa-b107-35820d2260c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_7cf911d7-6b91-427c-9067-b519aa507049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityReclassificationsoutofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_be9b1e0e-3a01-4e5f-8714-de4fde694415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_be9b1e0e-3a01-4e5f-8714-de4fde694415" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3b8dbd0-7e57-48ad-aa0a-09f3d9a43ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3b8dbd0-7e57-48ad-aa0a-09f3d9a43ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_363484db-d284-47cc-afd4-013846ff4fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3b8dbd0-7e57-48ad-aa0a-09f3d9a43ea8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_363484db-d284-47cc-afd4-013846ff4fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b9df6c4a-1fb1-49ff-bcce-0b0ca17482bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_363484db-d284-47cc-afd4-013846ff4fa0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b9df6c4a-1fb1-49ff-bcce-0b0ca17482bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_39b53c9b-1add-4d69-bdc2-841a236df847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_39b53c9b-1add-4d69-bdc2-841a236df847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_20962906-ddca-4484-8bf5-cc34544ca0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_39b53c9b-1add-4d69-bdc2-841a236df847" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_20962906-ddca-4484-8bf5-cc34544ca0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8d58c50c-19b9-4648-92c0-549dd0cb1370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20962906-ddca-4484-8bf5-cc34544ca0f8" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8d58c50c-19b9-4648-92c0-549dd0cb1370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_9b5f0f1d-0718-4173-9381-35b38a10442a" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20962906-ddca-4484-8bf5-cc34544ca0f8" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_9b5f0f1d-0718-4173-9381-35b38a10442a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_379e47fd-7462-43c5-8085-fa71db70083c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:to="loc_srt_ProductOrServiceAxis_379e47fd-7462-43c5-8085-fa71db70083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4b436ecf-48d4-402d-827c-1ee27a1da9cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_379e47fd-7462-43c5-8085-fa71db70083c" xlink:to="loc_srt_ProductsAndServicesDomain_4b436ecf-48d4-402d-827c-1ee27a1da9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_26ee8ca9-aef1-409d-b152-cbd8b7ab2dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4b436ecf-48d4-402d-827c-1ee27a1da9cd" xlink:to="loc_us-gaap_ProductMember_26ee8ca9-aef1-409d-b152-cbd8b7ab2dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1df0d766-c3fd-4e75-b840-43eef76b8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1df0d766-c3fd-4e75-b840-43eef76b8f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9bd7bff1-46a2-4587-9cc7-8c10c322be64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1df0d766-c3fd-4e75-b840-43eef76b8f7c" xlink:to="loc_us-gaap_EquityComponentDomain_9bd7bff1-46a2-4587-9cc7-8c10c322be64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_32faeb30-3751-4cb9-ac40-dd55ddefc4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9bd7bff1-46a2-4587-9cc7-8c10c322be64" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_32faeb30-3751-4cb9-ac40-dd55ddefc4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_53a4b396-4aad-469f-9188-d5d38f00d843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9bd7bff1-46a2-4587-9cc7-8c10c322be64" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_53a4b396-4aad-469f-9188-d5d38f00d843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_52b60819-78ef-4bb7-ace8-5b961c27ae1a" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_fd3b06ec-d6cc-4f10-856a-1a45eee3121a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_fd3b06ec-d6cc-4f10-856a-1a45eee3121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_af824650-a99e-4065-85a7-9fbc3ff83cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_af824650-a99e-4065-85a7-9fbc3ff83cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6021ff9f-de80-4c48-a4bb-24d45caa3a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_InterestExpenseDebt_6021ff9f-de80-4c48-a4bb-24d45caa3a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c17fda00-ab8a-4490-ab4e-9d8d87b96406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c17fda00-ab8a-4490-ab4e-9d8d87b96406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8dc7637a-4cbb-41c5-89ec-bd6a7c3ddb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8dc7637a-4cbb-41c5-89ec-bd6a7c3ddb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8d38594-2205-463e-8ba1-b0a7071b02ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7d92ec34-b363-4302-865b-8817bb8292c7" xlink:to="loc_us-gaap_NetIncomeLoss_c8d38594-2205-463e-8ba1-b0a7071b02ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#StockholdersequityOtherDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_12bcfc17-d7c9-4c10-8711-50a188edf243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fabd6f71-d503-4eb7-b129-1943cc3e01de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_12bcfc17-d7c9-4c10-8711-50a188edf243" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fabd6f71-d503-4eb7-b129-1943cc3e01de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0c281490-925f-41d1-8475-cdc5a8fc03e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_12bcfc17-d7c9-4c10-8711-50a188edf243" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0c281490-925f-41d1-8475-cdc5a8fc03e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6afede7a-28a4-4cd9-b439-8012512be601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_12bcfc17-d7c9-4c10-8711-50a188edf243" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6afede7a-28a4-4cd9-b439-8012512be601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a0930587-13e9-4c18-8a4f-a83be933ceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_12bcfc17-d7c9-4c10-8711-50a188edf243" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a0930587-13e9-4c18-8a4f-a83be933ceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_66605f12-66f6-44e5-a979-f86835163aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_66605f12-66f6-44e5-a979-f86835163aa6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_632ee99a-036d-4552-90fb-5df6299410ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_632ee99a-036d-4552-90fb-5df6299410ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_632ee99a-036d-4552-90fb-5df6299410ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7e7acf5-d365-42d9-aef1-4bde40c98f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7e7acf5-d365-42d9-aef1-4bde40c98f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d81113fb-0093-402b-bae8-782fd6024928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d81113fb-0093-402b-bae8-782fd6024928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_779f0fc2-993a-44c8-bbb9-fc1c2504d60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2f65f0-c130-4ed3-9318-f765fa5436c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_779f0fc2-993a-44c8-bbb9-fc1c2504d60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b5d8f2d2-ede6-480d-a02b-675ec3418106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b5d8f2d2-ede6-480d-a02b-675ec3418106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b5d8f2d2-ede6-480d-a02b-675ec3418106" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f492e15c-fd10-4e66-b1b9-ff594e8ab187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f492e15c-fd10-4e66-b1b9-ff594e8ab187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_fafa3446-1c89-48cc-a7df-e59100723c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_fafa3446-1c89-48cc-a7df-e59100723c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0eed6cd9-c25f-4f42-ad6b-e7f85e2ac169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0eed6cd9-c25f-4f42-ad6b-e7f85e2ac169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_78bd293d-52aa-43ac-bd0e-77db47443b1c" xlink:href="amgn-20221231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9bfa292-69de-448b-a0a5-7cc8dcbe2662" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_78bd293d-52aa-43ac-bd0e-77db47443b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_11bdb513-7661-4348-8aaa-9230d7546e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_11bdb513-7661-4348-8aaa-9230d7546e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_11bdb513-7661-4348-8aaa-9230d7546e98" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c1614d5e-a56c-44da-bef1-ac29f2cfcd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c1614d5e-a56c-44da-bef1-ac29f2cfcd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_b65f1330-0fb6-40c9-aa01-111245e23475" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_b65f1330-0fb6-40c9-aa01-111245e23475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_80cf62d3-4c9a-4938-8976-17bf0be49d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:to="loc_us-gaap_InterestRateSwapMember_80cf62d3-4c9a-4938-8976-17bf0be49d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractsMember_fb9936cf-1bcf-48c0-93cf-9a9863a233de" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7345c0d-098c-4d30-9f96-cfbd2cb8b2e9" xlink:to="loc_amgn_ForwardInterestRateContractsMember_fb9936cf-1bcf-48c0-93cf-9a9863a233de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b55d2759-4dd2-43a7-a363-74bda51b633d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5cef6980-96f0-4cdd-9a3a-086e84e3e44c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b55d2759-4dd2-43a7-a363-74bda51b633d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b55d2759-4dd2-43a7-a363-74bda51b633d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a986bf40-362a-40d1-a1aa-51813637fbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a986bf40-362a-40d1-a1aa-51813637fbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_b1117e82-e7d3-461a-912f-0f5886e41ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_us-gaap_OtherInvestments_b1117e82-e7d3-461a-912f-0f5886e41ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d808eead-dcf3-45dd-be49-30cac98a42c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d808eead-dcf3-45dd-be49-30cac98a42c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_ee8d926e-e5c3-4a78-a6b8-4523bf24b8c3" xlink:href="amgn-20221231.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_ee8d926e-e5c3-4a78-a6b8-4523bf24b8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_628187da-5064-47d1-be50-8c2eb37d916a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_ee8d926e-e5c3-4a78-a6b8-4523bf24b8c3" xlink:to="loc_us-gaap_DerivativeAssets_628187da-5064-47d1-be50-8c2eb37d916a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d2278f78-7864-40b0-b73e-9735ae134396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10fc4c0f-7611-4bca-b33f-3e7ec9a95a62" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d2278f78-7864-40b0-b73e-9735ae134396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b55d2759-4dd2-43a7-a363-74bda51b633d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_e95a3caa-ab55-40cb-aeaf-13fbe78598eb" xlink:href="amgn-20221231.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:to="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_e95a3caa-ab55-40cb-aeaf-13fbe78598eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_735a936c-722e-4f5d-99ea-f3f53cb18fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_e95a3caa-ab55-40cb-aeaf-13fbe78598eb" xlink:to="loc_us-gaap_DerivativeLiabilities_735a936c-722e-4f5d-99ea-f3f53cb18fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c66bbf45-c121-4b2a-b20e-e56199c75316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c66bbf45-c121-4b2a-b20e-e56199c75316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5caafb9f-8135-4ebf-bd57-034e0baf7e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b7301437-d271-42b0-9b09-8314479e09f0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5caafb9f-8135-4ebf-bd57-034e0baf7e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FairvaluemeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9681f0d1-dc3b-46ed-b54d-7354f4cd7f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35cd7e91-e308-417f-bcb1-63ace19825de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9681f0d1-dc3b-46ed-b54d-7354f4cd7f8e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35cd7e91-e308-417f-bcb1-63ace19825de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_74a8e485-82d1-4931-9130-56c8ced39151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35cd7e91-e308-417f-bcb1-63ace19825de" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_74a8e485-82d1-4931-9130-56c8ced39151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4dcb01e7-73e1-499a-bc3f-e8236195a6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_74a8e485-82d1-4931-9130-56c8ced39151" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4dcb01e7-73e1-499a-bc3f-e8236195a6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_920ff750-5d38-4d70-864a-f0c93d68fb67" xlink:href="amgn-20221231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4dcb01e7-73e1-499a-bc3f-e8236195a6d1" xlink:to="loc_amgn_BeiGeneMember_920ff750-5d38-4d70-864a-f0c93d68fb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_30345fff-24b1-4a81-a3b9-e348707ca235" xlink:href="amgn-20221231.xsd#amgn_TeneobioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4dcb01e7-73e1-499a-bc3f-e8236195a6d1" xlink:to="loc_amgn_TeneobioIncMember_30345fff-24b1-4a81-a3b9-e348707ca235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f04e0424-15c3-4143-9221-34c9094e9bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35cd7e91-e308-417f-bcb1-63ace19825de" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f04e0424-15c3-4143-9221-34c9094e9bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c9868131-b551-496a-8cdc-9f1cafe4553e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f04e0424-15c3-4143-9221-34c9094e9bec" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c9868131-b551-496a-8cdc-9f1cafe4553e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c487331d-cecd-426c-ac57-d77414fc1061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c9868131-b551-496a-8cdc-9f1cafe4553e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c487331d-cecd-426c-ac57-d77414fc1061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_35cd7e91-e308-417f-bcb1-63ace19825de" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_696c6bb0-255e-4118-8271-d6c0bed0989f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_696c6bb0-255e-4118-8271-d6c0bed0989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_544ec4a5-45a9-4a7a-af50-a83e90030f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_544ec4a5-45a9-4a7a-af50-a83e90030f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_398c381d-96c0-41fb-85b3-1b0917d10e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_LongTermDebt_398c381d-96c0-41fb-85b3-1b0917d10e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_0a68f513-5767-4e17-9fa8-2e6e2e4c88c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_0a68f513-5767-4e17-9fa8-2e6e2e4c88c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_5c8c4f36-ff87-451c-b08a-6efd6c124b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a56f2bd0-e483-4268-857b-da2123f79a56" xlink:to="loc_us-gaap_EquityMethodInvestments_5c8c4f36-ff87-451c-b08a-6efd6c124b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#FairvaluemeasurementContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2cecfcd7-4f82-496d-8890-c2228109c45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationRollForward_33ab618f-8336-4832-ae22-dc5570c2c97e" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationContingentConsiderationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2cecfcd7-4f82-496d-8890-c2228109c45d" xlink:to="loc_amgn_BusinessCombinationContingentConsiderationRollForward_33ab618f-8336-4832-ae22-dc5570c2c97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9d68aff7-95b4-4d87-8de1-a63b45a365bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward_33ab618f-8336-4832-ae22-dc5570c2c97e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9d68aff7-95b4-4d87-8de1-a63b45a365bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_ccd371c1-2d2d-49b0-ad4d-32619c0ab846" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward_33ab618f-8336-4832-ae22-dc5570c2c97e" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_ccd371c1-2d2d-49b0-ad4d-32619c0ab846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_42d59a6f-d044-4264-91d2-8153fe3d1284" xlink:href="amgn-20221231.xsd#amgn_BusinessCombinationContingentConsiderationArrangementsPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward_33ab618f-8336-4832-ae22-dc5570c2c97e" xlink:to="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_42d59a6f-d044-4264-91d2-8153fe3d1284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_97666fc3-3c02-4bef-8495-a9173078bd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward_33ab618f-8336-4832-ae22-dc5570c2c97e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_97666fc3-3c02-4bef-8495-a9173078bd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a6857333-3bdb-441f-b602-d04c56b9cb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward_33ab618f-8336-4832-ae22-dc5570c2c97e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a6857333-3bdb-441f-b602-d04c56b9cb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fe3be3b7-9533-459b-8e5c-9c44d73d61ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ee55ab7-15d0-4e37-9a45-ca3b7fd6dd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fe3be3b7-9533-459b-8e5c-9c44d73d61ba" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ee55ab7-15d0-4e37-9a45-ca3b7fd6dd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b317eb20-b6ff-436e-9a36-19913667c287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ee55ab7-15d0-4e37-9a45-ca3b7fd6dd4e" xlink:to="loc_us-gaap_HedgingDesignationAxis_b317eb20-b6ff-436e-9a36-19913667c287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_85cb8692-1f21-45e0-aa60-1c60d05813d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_b317eb20-b6ff-436e-9a36-19913667c287" xlink:to="loc_us-gaap_HedgingDesignationDomain_85cb8692-1f21-45e0-aa60-1c60d05813d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aaf78329-c713-4936-a2e1-9cf3961f6649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_85cb8692-1f21-45e0-aa60-1c60d05813d7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aaf78329-c713-4936-a2e1-9cf3961f6649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_533d12d1-bb9c-4a5a-96d3-2c0296a21b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_85cb8692-1f21-45e0-aa60-1c60d05813d7" xlink:to="loc_us-gaap_NondesignatedMember_533d12d1-bb9c-4a5a-96d3-2c0296a21b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_da8db032-885e-4ab2-9915-682eea431c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ee55ab7-15d0-4e37-9a45-ca3b7fd6dd4e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_da8db032-885e-4ab2-9915-682eea431c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_da8db032-885e-4ab2-9915-682eea431c26" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_8d98457a-7dd7-44bd-9f25-0deb5c47ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:to="loc_us-gaap_ForwardContractsMember_8d98457a-7dd7-44bd-9f25-0deb5c47ca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_e646b90a-08a8-49f2-ae67-41ea20cb3810" xlink:href="amgn-20221231.xsd#amgn_ForeignCurrencyAndCrossCurrencySwapsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:to="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_e646b90a-08a8-49f2-ae67-41ea20cb3810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_bd835c4d-43c8-4306-958c-4f35909afe44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:to="loc_us-gaap_InterestRateSwapMember_bd835c4d-43c8-4306-958c-4f35909afe44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractsMember_86ef9bd8-d181-429a-a96f-f1cd17ede1cc" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0f3ae9a4-2f46-4cdc-bfb6-65a08f8e92c6" xlink:to="loc_amgn_ForwardInterestRateContractsMember_86ef9bd8-d181-429a-a96f-f1cd17ede1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1ee55ab7-15d0-4e37-9a45-ca3b7fd6dd4e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_5e6b886f-c564-418d-a9b3-82de6ca5a466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_5e6b886f-c564-418d-a9b3-82de6ca5a466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2f320d51-a355-4ca3-a897-d78bb0e6a742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2f320d51-a355-4ca3-a897-d78bb0e6a742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_0526db52-6e88-41fe-b9ca-a31f88c54979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dd37eefc-f020-4ae0-bce6-5b212f9f9b61" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_0526db52-6e88-41fe-b9ca-a31f88c54979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsCrosscurrencySwapsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fb8823b0-275d-4a19-8f72-608254f97180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fb8823b0-275d-4a19-8f72-608254f97180" xlink:to="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_516b32e4-1518-4d93-82f7-fbb5afae869e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_516b32e4-1518-4d93-82f7-fbb5afae869e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_37f61bfb-9270-4bc1-937f-8b373bcd3bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_516b32e4-1518-4d93-82f7-fbb5afae869e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_37f61bfb-9270-4bc1-937f-8b373bcd3bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e98550ab-56bf-4ecc-8b69-29cb14ef9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_37f61bfb-9270-4bc1-937f-8b373bcd3bad" xlink:to="loc_us-gaap_CashFlowHedgingMember_e98550ab-56bf-4ecc-8b69-29cb14ef9ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_df8a8799-d06c-497b-b3f5-33f9e7cf4f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_df8a8799-d06c-497b-b3f5-33f9e7cf4f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_63381e14-02c6-4261-82ce-a6c3d282a39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_df8a8799-d06c-497b-b3f5-33f9e7cf4f07" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_63381e14-02c6-4261-82ce-a6c3d282a39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_f812e203-68f0-4f7c-8157-a2a2f411f068" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63381e14-02c6-4261-82ce-a6c3d282a39a" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_f812e203-68f0-4f7c-8157-a2a2f411f068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_5194bc95-c2af-424e-967e-800c3b312765" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:to="loc_srt_CurrencyAxis_5194bc95-c2af-424e-967e-800c3b312765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_5194bc95-c2af-424e-967e-800c3b312765" xlink:to="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_9aee2a0a-e0e0-4a16-9847-afcdc6104020" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:to="loc_currency_EUR_9aee2a0a-e0e0-4a16-9847-afcdc6104020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_ac976b6f-4fee-45bf-9e84-331627f2879d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:to="loc_currency_CHF_ac976b6f-4fee-45bf-9e84-331627f2879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_491e36a0-339a-4dbf-9722-2dc3ce6d3589" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:to="loc_currency_GBP_491e36a0-339a-4dbf-9722-2dc3ce6d3589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_79ab4750-d3a4-4609-8083-f46f0598fdf5" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8706187e-56f8-4bcd-8ae9-386026358e79" xlink:to="loc_currency_USD_79ab4750-d3a4-4609-8083-f46f0598fdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b247380f-0480-41c8-af4d-931fe1bbb4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:to="loc_us-gaap_DebtInstrumentAxis_b247380f-0480-41c8-af4d-931fe1bbb4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b247380f-0480-41c8-af4d-931fe1bbb4aa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_49a92cc3-df9d-4323-9480-5346d599b980" xlink:href="amgn-20221231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_49a92cc3-df9d-4323-9480-5346d599b980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_d92a9d5d-f154-467c-b61c-24aad587172b" xlink:href="amgn-20221231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_d92a9d5d-f154-467c-b61c-24aad587172b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_95c8ef89-a2a7-41fb-b774-2fc55fa4a797" xlink:href="amgn-20221231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_95c8ef89-a2a7-41fb-b774-2fc55fa4a797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_b569b640-b5d7-49f9-9c87-d5a449f95b29" xlink:href="amgn-20221231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1c252ba-f701-4bf2-a618-ca740be4bce8" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_b569b640-b5d7-49f9-9c87-d5a449f95b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4cbae8e8-4c37-439d-8017-60536b8db269" xlink:to="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2d025e33-2e45-4174-8867-82ba17cac757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2d025e33-2e45-4174-8867-82ba17cac757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_c760ef44-5da7-4d96-bb01-8feadfda6fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_c760ef44-5da7-4d96-bb01-8feadfda6fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_06158f52-3e1f-4e8e-92fa-d6878657fc68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d34d6253-9bb8-4247-a95f-490710870b63" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_06158f52-3e1f-4e8e-92fa-d6878657fc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_08c8fa75-1c9a-4311-a5ea-1c1b45f78ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2afbb6f2-00a6-4e6a-87ee-200691aa7ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_08c8fa75-1c9a-4311-a5ea-1c1b45f78ce0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2afbb6f2-00a6-4e6a-87ee-200691aa7ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_228ef113-c5cd-45ed-bf08-1323b3957566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2afbb6f2-00a6-4e6a-87ee-200691aa7ad5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_228ef113-c5cd-45ed-bf08-1323b3957566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_03a1a255-461c-4cd9-aad6-cdb59d842fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_228ef113-c5cd-45ed-bf08-1323b3957566" xlink:to="loc_us-gaap_HedgingRelationshipDomain_03a1a255-461c-4cd9-aad6-cdb59d842fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2c993674-f81b-4fd3-ac38-ec5f6d23a470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_03a1a255-461c-4cd9-aad6-cdb59d842fce" xlink:to="loc_us-gaap_CashFlowHedgingMember_2c993674-f81b-4fd3-ac38-ec5f6d23a470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6cfdf2-adb1-47d9-a2ac-dd1c3e5ef6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2afbb6f2-00a6-4e6a-87ee-200691aa7ad5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6cfdf2-adb1-47d9-a2ac-dd1c3e5ef6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6cfdf2-adb1-47d9-a2ac-dd1c3e5ef6fa" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f163a844-ace1-4b8a-a8ab-4e5d9569613f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f163a844-ace1-4b8a-a8ab-4e5d9569613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_67014822-1081-4f77-a465-15442c61de94" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_67014822-1081-4f77-a465-15442c61de94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember_f37d38e1-96b6-4f0d-8bec-038c6fdbc678" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8cd15fcd-77ae-4b9a-ad25-c266a9bd3c12" xlink:to="loc_amgn_ForwardInterestRateContractMember_f37d38e1-96b6-4f0d-8bec-038c6fdbc678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ddd3165-117f-4889-b5e6-b87e8c35b6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2afbb6f2-00a6-4e6a-87ee-200691aa7ad5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ddd3165-117f-4889-b5e6-b87e8c35b6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_f8c1c0d9-936b-42ca-8352-fb22c87dbb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ddd3165-117f-4889-b5e6-b87e8c35b6e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_f8c1c0d9-936b-42ca-8352-fb22c87dbb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c3739ed0-a251-4da2-a826-9996d29c05dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1e12bcf6-8476-4232-af38-43d440bb3aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c3739ed0-a251-4da2-a826-9996d29c05dc" xlink:to="loc_us-gaap_DerivativeTable_1e12bcf6-8476-4232-af38-43d440bb3aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e1302051-7929-4489-a655-e4daf7941b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1e12bcf6-8476-4232-af38-43d440bb3aea" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e1302051-7929-4489-a655-e4daf7941b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ffba6af6-5bc8-4db3-8ed4-7175723c5510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e1302051-7929-4489-a655-e4daf7941b29" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ffba6af6-5bc8-4db3-8ed4-7175723c5510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember_47256950-6cbd-458a-bb3a-6f26774761d3" xlink:href="amgn-20221231.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ffba6af6-5bc8-4db3-8ed4-7175723c5510" xlink:to="loc_amgn_LongTermDebtCurrentMaturitiesMember_47256950-6cbd-458a-bb3a-6f26774761d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_5ec19824-231c-4310-8c6a-a00531c280df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ffba6af6-5bc8-4db3-8ed4-7175723c5510" xlink:to="loc_us-gaap_LongTermDebtMember_5ec19824-231c-4310-8c6a-a00531c280df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1e12bcf6-8476-4232-af38-43d440bb3aea" xlink:to="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_c391a169-fbed-4830-b8ac-68392e8c8884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_c391a169-fbed-4830-b8ac-68392e8c8884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_dcb1ae82-dfd4-440c-aac8-a3a555266112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_dcb1ae82-dfd4-440c-aac8-a3a555266112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_87669f1d-0b5b-4700-92e7-0430d4329e43" xlink:href="amgn-20221231.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:to="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_87669f1d-0b5b-4700-92e7-0430d4329e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_7963a906-a6a8-4c33-84b2-ff6075043eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_42c2f06e-dda4-4228-93d7-d751f4aef40f" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_7963a906-a6a8-4c33-84b2-ff6075043eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3db0ec2e-1499-4361-b6e5-e431b8924ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3db0ec2e-1499-4361-b6e5-e431b8924ce1" xlink:to="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7531c4d0-3691-4a27-9a12-bdb308accb5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:to="loc_srt_ProductOrServiceAxis_7531c4d0-3691-4a27-9a12-bdb308accb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf4cec0c-2ab6-423d-a2d4-1034e3f3be4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7531c4d0-3691-4a27-9a12-bdb308accb5c" xlink:to="loc_srt_ProductsAndServicesDomain_cf4cec0c-2ab6-423d-a2d4-1034e3f3be4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_eff88b08-cea9-4157-899d-715c707cc461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf4cec0c-2ab6-423d-a2d4-1034e3f3be4e" xlink:to="loc_us-gaap_ProductMember_eff88b08-cea9-4157-899d-715c707cc461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d591eec7-2b20-4c23-a82e-d0f33517ad37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d591eec7-2b20-4c23-a82e-d0f33517ad37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c9389abb-cdf2-4ab6-ac82-1986fe6543f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d591eec7-2b20-4c23-a82e-d0f33517ad37" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c9389abb-cdf2-4ab6-ac82-1986fe6543f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_587dad06-72b5-4c84-bd16-1560eddd0380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c9389abb-cdf2-4ab6-ac82-1986fe6543f9" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_587dad06-72b5-4c84-bd16-1560eddd0380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ac75db4a-acc0-4417-8a73-15de2e37fcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ac75db4a-acc0-4417-8a73-15de2e37fcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_59d27777-a680-4ef1-b5ed-6ed6fb1c40a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ac75db4a-acc0-4417-8a73-15de2e37fcbc" xlink:to="loc_us-gaap_EquityComponentDomain_59d27777-a680-4ef1-b5ed-6ed6fb1c40a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_127b692d-1be9-4712-954c-f52f3e800c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_59d27777-a680-4ef1-b5ed-6ed6fb1c40a4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_127b692d-1be9-4712-954c-f52f3e800c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9dc76fe8-753b-4bea-bc46-881dee98ca3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9dc76fe8-753b-4bea-bc46-881dee98ca3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9dc76fe8-753b-4bea-bc46-881dee98ca3d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_547cdd28-be0a-42e0-80ac-f8755a6d1c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_547cdd28-be0a-42e0-80ac-f8755a6d1c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_62987f32-3c08-4e55-b217-a38eb0e8c919" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_62987f32-3c08-4e55-b217-a38eb0e8c919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b3a4d7d4-96d2-4ea4-8f1a-c4537cbbb989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd95c737-7df7-4c72-8fb2-bc8e5b4066bf" xlink:to="loc_us-gaap_InterestRateSwapMember_b3a4d7d4-96d2-4ea4-8f1a-c4537cbbb989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46f86d8e-d02f-4a8a-9d2f-0a4e678c638c" xlink:to="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d0d574c5-134a-4ad0-820c-67e30597d0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d0d574c5-134a-4ad0-820c-67e30597d0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_17190df8-efb3-4011-a173-727d6fec5b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_17190df8-efb3-4011-a173-727d6fec5b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_61dfafee-9f97-4855-ac81-bcf606ce7815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_InterestExpenseDebt_61dfafee-9f97-4855-ac81-bcf606ce7815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_eee4b57f-5443-442a-8ec6-8f2193f0fe09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_eee4b57f-5443-442a-8ec6-8f2193f0fe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c15b91e8-e572-4c4e-9e1c-6a22735ad271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7287cf34-a526-4670-88ab-2829eebb26e6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c15b91e8-e572-4c4e-9e1c-6a22735ad271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#DerivativeinstrumentsFairValueofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2bf68f91-2dcf-4b09-9b8e-154a2f079293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2bf68f91-2dcf-4b09-9b8e-154a2f079293" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f87b503f-69ab-4ac0-9ba1-22cad18ac227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:to="loc_us-gaap_HedgingDesignationAxis_f87b503f-69ab-4ac0-9ba1-22cad18ac227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_945f9430-1cca-4983-8556-fa8a7aa12893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_f87b503f-69ab-4ac0-9ba1-22cad18ac227" xlink:to="loc_us-gaap_HedgingDesignationDomain_945f9430-1cca-4983-8556-fa8a7aa12893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8b63353c-237a-4edd-809c-3b64140a5dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_945f9430-1cca-4983-8556-fa8a7aa12893" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8b63353c-237a-4edd-809c-3b64140a5dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bfd1f8b8-f70c-474e-80b8-a5ce2f94aec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bfd1f8b8-f70c-474e-80b8-a5ce2f94aec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bfd1f8b8-f70c-474e-80b8-a5ce2f94aec4" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_501ca8a6-d62e-4145-9e47-19f8d14317df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_501ca8a6-d62e-4145-9e47-19f8d14317df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_a6c381d9-2d2a-4234-886b-c4a128b60fb3" xlink:href="amgn-20221231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_a6c381d9-2d2a-4234-886b-c4a128b60fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_83fe61c0-7d40-4ac6-b7ed-b54b6d031b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:to="loc_us-gaap_InterestRateSwapMember_83fe61c0-7d40-4ac6-b7ed-b54b6d031b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractsMember_0c80a72e-eda6-42f0-aa1d-825189a82917" xlink:href="amgn-20221231.xsd#amgn_ForwardInterestRateContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05fbafcb-1ce9-447d-bb36-ffbe50fa4fbd" xlink:to="loc_amgn_ForwardInterestRateContractsMember_0c80a72e-eda6-42f0-aa1d-825189a82917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f2457ad0-6580-4471-a8e7-9a7942e89814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f2457ad0-6580-4471-a8e7-9a7942e89814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_274fff88-7fea-4fb7-8ae5-de3963d085f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f2457ad0-6580-4471-a8e7-9a7942e89814" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_274fff88-7fea-4fb7-8ae5-de3963d085f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember_d5d69e0d-8ede-4bb7-8ad3-1559d92efb84" xlink:href="amgn-20221231.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_274fff88-7fea-4fb7-8ae5-de3963d085f7" xlink:to="loc_amgn_OtherCurrentNoncurrentAssetsMember_d5d69e0d-8ede-4bb7-8ad3-1559d92efb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_a8ee9b60-6d79-4861-9a82-8bc4fb3c6380" xlink:href="amgn-20221231.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_274fff88-7fea-4fb7-8ae5-de3963d085f7" xlink:to="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_a8ee9b60-6d79-4861-9a82-8bc4fb3c6380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_c4c85955-2dd8-4ca7-bd51-9827ef9e3744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e2b4f122-401a-40d8-8a88-0c62dd7d2f2b" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_c4c85955-2dd8-4ca7-bd51-9827ef9e3744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_3cd6ad36-7151-4887-be50-4feabe65f9c0" xlink:href="amgn-20221231.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c4c85955-2dd8-4ca7-bd51-9827ef9e3744" xlink:to="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_3cd6ad36-7151-4887-be50-4feabe65f9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4e394a6a-ef28-44ee-95a5-93fc7796916d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_3cd6ad36-7151-4887-be50-4feabe65f9c0" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4e394a6a-ef28-44ee-95a5-93fc7796916d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_636e2641-90b1-4bde-b09d-412997d74074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4e394a6a-ef28-44ee-95a5-93fc7796916d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_636e2641-90b1-4bde-b09d-412997d74074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_12564d18-fdb9-4420-a0ed-6d303c73b2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_3cd6ad36-7151-4887-be50-4feabe65f9c0" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_12564d18-fdb9-4420-a0ed-6d303c73b2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fd7b2a5a-2678-4443-b93e-70b8790e0846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_12564d18-fdb9-4420-a0ed-6d303c73b2d6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fd7b2a5a-2678-4443-b93e-70b8790e0846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsSandozPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cce85455-f89b-425e-8c86-816125ccb541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_4ef06ad3-0da3-4fac-9277-3925675a5e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cce85455-f89b-425e-8c86-816125ccb541" xlink:to="loc_us-gaap_GainContingenciesTable_4ef06ad3-0da3-4fac-9277-3925675a5e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2766b09d-0ca8-4fac-8cf1-83bda98e7c90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_4ef06ad3-0da3-4fac-9277-3925675a5e20" xlink:to="loc_srt_LitigationCaseAxis_2766b09d-0ca8-4fac-8cf1-83bda98e7c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_85945729-1d42-4a55-b7bf-35a7c0ae0860" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2766b09d-0ca8-4fac-8cf1-83bda98e7c90" xlink:to="loc_srt_LitigationCaseTypeDomain_85945729-1d42-4a55-b7bf-35a7c0ae0860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SandozIncMember_c8120823-0780-4c56-9274-80a58c88f5fe" xlink:href="amgn-20221231.xsd#amgn_SandozIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_85945729-1d42-4a55-b7bf-35a7c0ae0860" xlink:to="loc_amgn_SandozIncMember_c8120823-0780-4c56-9274-80a58c88f5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember_bddbf32d-51dd-4095-8a54-f60ddad3a043" xlink:href="amgn-20221231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_85945729-1d42-4a55-b7bf-35a7c0ae0860" xlink:to="loc_amgn_SanofiRegeneronPatentLitigationMember_bddbf32d-51dd-4095-8a54-f60ddad3a043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d219556c-2a9c-48d6-badb-a70ddbe059dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_4ef06ad3-0da3-4fac-9277-3925675a5e20" xlink:to="loc_us-gaap_LitigationStatusAxis_d219556c-2a9c-48d6-badb-a70ddbe059dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_89312d3b-73a4-4673-9545-e1914996d012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_d219556c-2a9c-48d6-badb-a70ddbe059dd" xlink:to="loc_us-gaap_LitigationStatusDomain_89312d3b-73a4-4673-9545-e1914996d012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_fb01a7da-9c1c-4673-b315-750799354741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_89312d3b-73a4-4673-9545-e1914996d012" xlink:to="loc_us-gaap_PendingLitigationMember_fb01a7da-9c1c-4673-b315-750799354741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_a15d319a-86c6-4157-bb6d-e690f800f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_4ef06ad3-0da3-4fac-9277-3925675a5e20" xlink:to="loc_us-gaap_GainContingenciesLineItems_a15d319a-86c6-4157-bb6d-e690f800f2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_8dce29eb-8423-4b22-874d-1da8f97f7bc6" xlink:href="amgn-20221231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_a15d319a-86c6-4157-bb6d-e690f800f2df" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_8dce29eb-8423-4b22-874d-1da8f97f7bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_2307fb0f-ed71-403e-bab4-84914d37b920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_a15d319a-86c6-4157-bb6d-e690f800f2df" xlink:to="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_2307fb0f-ed71-403e-bab4-84914d37b920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsRepathaPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ca0cb310-cbd4-4296-8e01-301ddb8c0180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_806f4f8e-5bff-42a0-b29f-1445827eed92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ca0cb310-cbd4-4296-8e01-301ddb8c0180" xlink:to="loc_us-gaap_OtherCommitmentsTable_806f4f8e-5bff-42a0-b29f-1445827eed92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_341d7975-ad96-4a3b-aba1-2648826ba7a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_806f4f8e-5bff-42a0-b29f-1445827eed92" xlink:to="loc_srt_LitigationCaseAxis_341d7975-ad96-4a3b-aba1-2648826ba7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_adb3256d-3ddd-4779-be8a-3305213f33cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_341d7975-ad96-4a3b-aba1-2648826ba7a4" xlink:to="loc_srt_LitigationCaseTypeDomain_adb3256d-3ddd-4779-be8a-3305213f33cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember_c0cbf11f-769f-423f-8f33-006db9536cd1" xlink:href="amgn-20221231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_adb3256d-3ddd-4779-be8a-3305213f33cc" xlink:to="loc_amgn_SanofiRegeneronPatentLitigationMember_c0cbf11f-769f-423f-8f33-006db9536cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_43c8bb3d-af57-4b60-9c0a-48b9f9e91e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_806f4f8e-5bff-42a0-b29f-1445827eed92" xlink:to="loc_us-gaap_LitigationStatusAxis_43c8bb3d-af57-4b60-9c0a-48b9f9e91e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_25f37e35-f9dd-4d8f-842c-b17e1bb13dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_43c8bb3d-af57-4b60-9c0a-48b9f9e91e81" xlink:to="loc_us-gaap_LitigationStatusDomain_25f37e35-f9dd-4d8f-842c-b17e1bb13dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_45a907ba-c03a-4ff8-8f4c-db559f0c8a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_25f37e35-f9dd-4d8f-842c-b17e1bb13dac" xlink:to="loc_us-gaap_PendingLitigationMember_45a907ba-c03a-4ff8-8f4c-db559f0c8a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_806f4f8e-5bff-42a0-b29f-1445827eed92" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_fd982a67-240d-40aa-87a8-e6126acd77b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_fd982a67-240d-40aa-87a8-e6126acd77b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementLengthofTrial_164e20e2-2d16-44d7-814c-47484a52fccb" xlink:href="amgn-20221231.xsd#amgn_LitigationSettlementLengthofTrial"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:to="loc_amgn_LitigationSettlementLengthofTrial_164e20e2-2d16-44d7-814c-47484a52fccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfChallenges_55e5285e-c6d4-4aa2-9d15-596b5cd4d929" xlink:href="amgn-20221231.xsd#amgn_GainContingencyNumberOfChallenges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fdd8c6a5-2640-4ed0-b670-465a83e1f863" xlink:to="loc_amgn_GainContingencyNumberOfChallenges_55e5285e-c6d4-4aa2-9d15-596b5cd4d929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_42e9c471-8f7e-4e0e-81b5-c6fbf03b3114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ab969268-bc89-41c9-89b5-baf5246b09e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_42e9c471-8f7e-4e0e-81b5-c6fbf03b3114" xlink:to="loc_us-gaap_LossContingenciesTable_ab969268-bc89-41c9-89b5-baf5246b09e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e22c5d29-c01b-472c-99ea-4f2bf22eaabf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ab969268-bc89-41c9-89b5-baf5246b09e3" xlink:to="loc_srt_LitigationCaseAxis_e22c5d29-c01b-472c-99ea-4f2bf22eaabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0bcde9a9-bb7e-4133-b740-aac69a4aad88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_e22c5d29-c01b-472c-99ea-4f2bf22eaabf" xlink:to="loc_srt_LitigationCaseTypeDomain_0bcde9a9-bb7e-4133-b740-aac69a4aad88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_JanssenBiotechIncVsAmgenIncMember_12e1698e-7b93-4b67-9fb9-86c78dcc15cd" xlink:href="amgn-20221231.xsd#amgn_JanssenBiotechIncVsAmgenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0bcde9a9-bb7e-4133-b740-aac69a4aad88" xlink:to="loc_amgn_JanssenBiotechIncVsAmgenIncMember_12e1698e-7b93-4b67-9fb9-86c78dcc15cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8f7e524f-e977-435b-8214-33a61c117a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ab969268-bc89-41c9-89b5-baf5246b09e3" xlink:to="loc_us-gaap_LitigationStatusAxis_8f7e524f-e977-435b-8214-33a61c117a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b9af2a6d-ee73-4440-a906-e30e57b06b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_8f7e524f-e977-435b-8214-33a61c117a02" xlink:to="loc_us-gaap_LitigationStatusDomain_b9af2a6d-ee73-4440-a906-e30e57b06b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_4388cd11-b4b3-48ee-a1df-1b14616e7e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_b9af2a6d-ee73-4440-a906-e30e57b06b64" xlink:to="loc_us-gaap_PendingLitigationMember_4388cd11-b4b3-48ee-a1df-1b14616e7e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_0e97feed-4470-441b-a8d3-472f018a5e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ab969268-bc89-41c9-89b5-baf5246b09e3" xlink:to="loc_us-gaap_LossContingenciesLineItems_0e97feed-4470-441b-a8d3-472f018a5e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_6fe911ec-2330-4387-84ea-009507deb5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e97feed-4470-441b-a8d3-472f018a5e47" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_6fe911ec-2330-4387-84ea-009507deb5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_118587b9-b68e-474e-a517-181076dba5df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_99801927-f90b-4eff-b2c3-5665cb17899b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_118587b9-b68e-474e-a517-181076dba5df" xlink:to="loc_us-gaap_LossContingenciesTable_99801927-f90b-4eff-b2c3-5665cb17899b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_18fa7bcb-eddc-47a0-b3ed-354d486776c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_99801927-f90b-4eff-b2c3-5665cb17899b" xlink:to="loc_srt_LitigationCaseAxis_18fa7bcb-eddc-47a0-b3ed-354d486776c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_18fa7bcb-eddc-47a0-b3ed-354d486776c7" xlink:to="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember_ec5664a9-5576-4626-80ef-908d2ca23809" xlink:href="amgn-20221231.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:to="loc_amgn_SensiparAntitrustClassActionsMember_ec5664a9-5576-4626-80ef-908d2ca23809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ChemoCentryxIncSecuritiesMattersMember_9c0b0065-5663-4083-9f85-ce346f2a921f" xlink:href="amgn-20221231.xsd#amgn_ChemoCentryxIncSecuritiesMattersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:to="loc_amgn_ChemoCentryxIncSecuritiesMattersMember_9c0b0065-5663-4083-9f85-ce346f2a921f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember_17e0c206-31e9-49a1-9315-d9030e9d2654" xlink:href="amgn-20221231.xsd#amgn_RegeneronPharmaceuticalsIncAntitrustActionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d32052b2-a13f-42db-918f-23cabd9a48f1" xlink:to="loc_amgn_RegeneronPharmaceuticalsIncAntitrustActionMember_17e0c206-31e9-49a1-9315-d9030e9d2654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_c1ddb49c-6d28-4aed-88b0-bc4584b02f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_99801927-f90b-4eff-b2c3-5665cb17899b" xlink:to="loc_us-gaap_LitigationStatusAxis_c1ddb49c-6d28-4aed-88b0-bc4584b02f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_9d8ac999-2d1a-4380-9f5e-ba263372f08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_c1ddb49c-6d28-4aed-88b0-bc4584b02f79" xlink:to="loc_us-gaap_LitigationStatusDomain_9d8ac999-2d1a-4380-9f5e-ba263372f08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_0c19531d-48b9-46f9-94eb-cebd9fc8ccce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_9d8ac999-2d1a-4380-9f5e-ba263372f08f" xlink:to="loc_us-gaap_PendingLitigationMember_0c19531d-48b9-46f9-94eb-cebd9fc8ccce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_99801927-f90b-4eff-b2c3-5665cb17899b" xlink:to="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_49f888b1-db26-4510-ae15-141d3993fcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_49f888b1-db26-4510-ae15-141d3993fcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_ec13b207-4b2f-4d37-adb9-999ade1d71a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_ec13b207-4b2f-4d37-adb9-999ade1d71a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuitsFiled_cfe8426f-ae63-4073-b726-4a7eb75e181c" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfLawsuitsFiled"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_LossContingencyNumberOfLawsuitsFiled_cfe8426f-ae63-4073-b726-4a7eb75e181c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfClassActionSuits_047f3694-8481-4475-b5d5-8e873669ebcb" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfClassActionSuits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_LossContingencyNumberOfClassActionSuits_047f3694-8481-4475-b5d5-8e873669ebcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_8c7bdae4-09e0-486d-b909-88fda87c02a0" xlink:href="amgn-20221231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_8c7bdae4-09e0-486d-b909-88fda87c02a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside_82e9d4f8-3dec-40c8-8fa4-c0384621f041" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside_82e9d4f8-3dec-40c8-8fa4-c0384621f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfPrimaryArguments_db17b3c0-84f4-498c-93c1-a189132c7ea7" xlink:href="amgn-20221231.xsd#amgn_LossContingencyNumberOfPrimaryArguments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8ba96c5c-9e0f-4eba-8ecf-20bdff717540" xlink:to="loc_amgn_LossContingencyNumberOfPrimaryArguments_db17b3c0-84f4-498c-93c1-a189132c7ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_695385a0-5997-4357-8ad5-a0057eb5054f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_c023ade3-5a9a-4ab4-88d1-88946ef17afa" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_695385a0-5997-4357-8ad5-a0057eb5054f" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_c023ade3-5a9a-4ab4-88d1-88946ef17afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_10236f25-3802-41e1-beb0-d662331de05b" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_695385a0-5997-4357-8ad5-a0057eb5054f" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_10236f25-3802-41e1-beb0-d662331de05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_88cf0990-e155-4397-ab8d-f930c92959dc" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_695385a0-5997-4357-8ad5-a0057eb5054f" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_88cf0990-e155-4397-ab8d-f930c92959dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_6a0a04d9-efda-4bf3-a6f8-b6f01ff5752e" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_695385a0-5997-4357-8ad5-a0057eb5054f" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_6a0a04d9-efda-4bf3-a6f8-b6f01ff5752e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_2cec6805-9bec-4a80-8126-c610464c19ff" xlink:href="amgn-20221231.xsd#amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_695385a0-5997-4357-8ad5-a0057eb5054f" xlink:to="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_2cec6805-9bec-4a80-8126-c610464c19ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="amgn-20221231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_0671b9dc-13ef-4a56-b2fd-fa7d61264106" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_30210ba8-21bd-49fa-ad40-75d5eee013ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_0671b9dc-13ef-4a56-b2fd-fa7d61264106" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_30210ba8-21bd-49fa-ad40-75d5eee013ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1e685e06-9c79-460e-a7e9-8938bac4eefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_30210ba8-21bd-49fa-ad40-75d5eee013ee" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1e685e06-9c79-460e-a7e9-8938bac4eefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_7a050b59-2543-440c-97fc-e7ac109b51d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_30210ba8-21bd-49fa-ad40-75d5eee013ee" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_7a050b59-2543-440c-97fc-e7ac109b51d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b0ab30c4-5dac-41b7-9d4e-08ee423a58b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_30210ba8-21bd-49fa-ad40-75d5eee013ee" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b0ab30c4-5dac-41b7-9d4e-08ee423a58b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_482e5c29-8468-4a85-ac78-1da81eeb75b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_30210ba8-21bd-49fa-ad40-75d5eee013ee" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_482e5c29-8468-4a85-ac78-1da81eeb75b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_06ffb602-55c1-4555-81e5-d27373f047a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_30210ba8-21bd-49fa-ad40-75d5eee013ee" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_06ffb602-55c1-4555-81e5-d27373f047a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>amgn-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 amgn-20221231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHKP3]H?_ (*=_L-_LL?$.]^$OQF^.*VWB;2O#LFOZ[H6A>'-2UJYT;28]I>_
MODTVVG-C;*'0F:X\M &4[L$&O6_A5\5_AI\<_AWI'Q<^#OCK2_$WAC7K-;K1
MM=T6\2XMKN(DC<CH2#@@J1U5E((!!% '045YY\7?VK/@'\"?B7X!^#?Q/\>_
M8?%7Q/UB73/ N@6NEW5[=:I/%'YLS!+:*0Q0Q)AI)Y=D,8(+NN17H= !1110
M 445Y#^T;^WE^R=^R?XJT+X??&_XM1V/B?Q-%++X>\(:-H][K&M:C%$KO)+#
MIVG0SW4D:K'(6D$>P!&R?E. #UZBO*/V/OVY/V4/V^OAE+\8?V0_C3IOC7P_
M;WS6=Y=64,\$MK<!5;RIK>XCCFA;:RL Z+D$$9%<O\<O^"IW_!/?]FKXOS_
M'XY_M4^&O#GC2W@AFF\-7C3-=*DL8DC;9'&V=R$,,=J /?Z*^4HO^"XW_!)N
M?Q,?!<'[;_A%]8$QA.DHMR;GS!G*>5Y._<,'(QGBNT_9_P#^"GW[ G[5'Q6D
M^!O[/O[4/AOQ1XOBL9;R7P]8/*+E((]N^0HZ+@#>G7^\* />:*** "BFO/#'
M(D,DRJ\A(C4L 6P,G [\4Z@ HHKP#]HK_@J;_P $_/V1_B)_PJ;]IG]I_0?!
M'B)K=+B+3/$,5Q \\+_=EB)BVRH3D;T++N5ESE2  >_T45Y+^TW^W1^RG^QG
M9V^J_M1_%VW\$Z?=,B6VKZUIMVEC)(^_;$+I8C"9"$8^7OWX&<8(- 'K5%?*
M%G_P7._X)&WMM;7\?[>O@.*TN[@P6]_=7LL-LT@&2OG21K&"!URPQ7TK\//B
M3\._B[X-L?B)\*/'NC>)_#^IQ>;INN>']4BO;.Z3.-T<T+,CC((R">10!M44
M44 %%%% !17!_M#_ +3GP+_9/\!/\4_VAO'T/ACPW#($N=<O;.=[6V)( ,TD
M4;"$$D ,^T$D ')Q5+]E[]K_ /9F_;3\!WGQ/_96^,NC^.- T_5WTN]U71)6
M>*&\2**5H264'<(YHF^CB@#TFBBB@ HHHH **;Y\(F%L9E\PKN$>X;MN<9QZ
M4Z@ HKRS]IO]MC]EO]CFRTBY_:,^+]CX?N?$-V;;P[HT=K<7VIZO,,;DM+&T
MCEN;HC*Y\J-L;ESC(SQ_A'_@JG^P%XOU"3P^O[15CH>N1W5I;_\ "*^-='O_
M  _K4CW-PEO!Y>FZG!;W<BO,Z(&2(KEN2* /H.BBB@ HKQ']J'_@H]^Q%^Q5
MX@T_PQ^U;^T-H_@2\U:!IM*'B""XBCO44@.8I?+*2%=R[@K$KN7(&1GUSP;X
MO\,_$'PAI7C[P7K,.HZ-KFFP:AI.H6Y)CNK::-9(I5)_A9&5A[&@#2HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLW-U%:67EMNB=I;@*7CD6,RE&Q^-?_!%H$?\':'[2&1_S-_Q-_\ 3ZU?7O\
MP7HO?^";/@?_ (*#?L_?$GQO\*?%?Q(_:M&H:19_"3X?>&O%8TRQO2NJNVFR
MZO*Z.(+9;Z24H8P))"'5@8U)0 ^D/@'_ ,%T?@5\1?V^+[_@F=\?O@?XV^#W
MQ>A8#2]'\726%U9ZHS6XN8XX;NQN)H_,> ^8H.%;[H<R82ORP_X/;$0?M0_
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M]:SXE.BV'Q=N+32Y(Q()WMOM<FG17K7B6AFCDC$OEEBRA=FYE4_87B_]KO\
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MJ(J(O[ZU_.E_P9##'[17Q^!Z_P#"(:/_ .E=Q7]%M '\\/\ P4A_X*->._\
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M''^HE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''
M_'_2/C/XA^"OB?0/V=O%&CZ'XXOM'FM_#.MZ_;/-::==.NU;F2- 3)Y>2X3H
MS*H/!-<3^P)^Q=X#_8'_ &8]#_9[\%ZE/JUY TNH^+?%-_DWGB/6[EO,O=2N
M&)+-)-*2?F+%4")DA!7LU% 'PI^TY_P1ZU?7O^"GGA/_ (*Z_LC?$K1/#GQ.
MT?3)M.\4^'O%VES7.C^(XGT^6PCG=[>1)K>:."15R ZN((>$VL7Z/_@CC_P1
M^^'_ /P2<^&'BJTC^(DWC;X@?$36$U/Q[XRET\6D=U)&93#;P0!W\N&,SS,-
MS,SM*[$@;43[(HH *^#]-_X(M:O^SA^VWXZ_;D_X)Q?M*:;\*=7^*&GS0>//
M"'BCX?'Q%HES<2RB9KVUBBO[&6UF$H:4*9)(][N-@1M@^\** /D7_@EO_P $
M??@E_P $N?"_B[5_!/C*_P#&?Q*^(5\U[XW^)'B2R1)K^8N\BQQV\3!8+<22
M/(8U<L[.2TAP@3P[PW_P;W^)?#/_  5#;_@K7:_MPR2?$M]=N=3DTV7X;Q_V
M.?/L7L'MQ"+[S1%]FD9!^^WCAMY/-?I710 D8D$:B5@S8&YE7 )[X&3C\ZH^
M*;;Q1=^'[JV\%:Q8:?JKQXLKW5-->\MXGR.7ACFA:08SP)$^O:K]% 'Y3^%O
M^#9&_P#"7_!0;_AY?IW_  4#U>3XDMXZN/%4@G^'-L=/DNYW=I83"+H,("LC
MQ[0X8*>'##=7ZF>'H/$%MHEK;^*]3L[W4DA O;O3[%[6"63NR1/+*T:GLID<
MC^\:N44 ?!^D_P#!%K6/V;/VU_'G[;__  3@_:6TWX4ZK\4=/FA\=^#_ !1\
M/?\ A(M$GN)91,U[:Q17]C+:RB7=*%,DD>Z1QL"-L'=?\$K/^"0'P'_X):>&
M_%.I^$O%>I^-?B%X_P!1^W>//B)K]O'%<ZE)O>0110QY6V@#R2/L!9F=R6=M
MJ!/K:B@#\W?$G_!NSX;T3_@IGKG_  4D_9@_;:\;?"C4_&-U?7'C+0M T&QO
M)+I[[_C^^RW5T'6U$S%I,M#*T<C%XV0A K/^"E?_  ;=?!S_ (*"?M/^!/VI
M_#7[4?C7X8Z[X,T/3M)=]"B^V3S0V$C/:3P7,LJRVUTF[_7DRY*(VT,&9OTE
MHH _+OXN_P#!L%\*/&W[:_@7]MKX=?MR_%CP[XE\+-I\^M:IJ]VFO:SK-]:-
M\M]_:%ZS>3*R!5*F&2%0H"1H@"5U'_!6?_@WOTK_ (*U?%WPS\1OB;^U]J_A
M?3_!>A?V5X9T?2?"B7,D<3,'DEN+F>Y+W$SN =V$ 55&TMN=OT<HH R? NF^
M,='\(:?I7Q \4VFMZS;VRQZAJ]CI1LHKN0<>8(#++Y9(QD!R,Y(P"%'S9_P5
M7_X)Q>,?^"HGP#NOV6M7_:.C\#>!M2N[.[U:'3/!PO-1NYK:8RHIN9;I8TAW
MB)MBPA]T?^L*L5KZIHH ^/?^"2/_  2P\5?\$FOA+=_L]>#OVG%\;>![S7;G
M6/L.M>"UMK^VNIHHHV$5S%=[!$?*5BCPN<YPRYKZT\36OB*]\/7MGX1UBUT[
M5);5UT^_OK!KJ&WF((61X5DC,J@X)4.F<8W"KU% 'YQ?\$NO^#?<?\$MOVIM
M?_:?^''[9&H>*KGQ?ILUAXKTCQ!X(A1+J&6ZCN7:*2&Z4PRB2,88AU 9@4;C
M'VW^U9^RY\&/VT?V??$_[,?[0/A<:OX3\6:?]EU.V639)&0RO%/$_/ERQ2(D
MB/SAT4X(X/H5% 'YE:A_P;Y_%OQ+^Q1HW_!+[QE_P45N;O\ 9ZT3Q(NH0Z/:
M_#&*'Q1<62W;W::;+JQOWMS$D[^8KBQ#Y"C[BA*^N/B;_P $S?V0OBC^P++_
M ,$UM2^' L/A:/#D.D:=INFS;9].$+"2&ZBE<,?M*3*)O,<-ODW%PX9@WOM%
M 'Y3?"W_ (-L_C;X"_8U\9_\$]];_P""L7B[4_@YKB7LOAKP;:_#RULQIMY.
MWF++<W*W37%Y DO[\VD<EO#),N]P0SHWTC_P1Z_X(_>'O^"07PQU[X6>!?VG
M/%_C72O$6IG4[W2=9TRPMK&&_,<43W4*QQ&X5VC@B0JUPT>%SLW?-7V110!^
M6OP5_P"#:.X_9>_;0\<_M"_LJ_\ !13QS\.? ?Q%%Q!XG^'_ (;\-6POWL9Y
M_/DLH-5ED<VR!^(YH[<7$:'"R[LN>N_X)9?\&]/AC_@E%^U5KW[27P8_:KU/
M6[/Q/I-SI6L>%M;\)IY?V.2XCN$6*X6YWI)&\48#L'!7>"I+!E_1RB@#\P?^
M"EW_  ;,_"O]M;]K&']N;]FO]J/7_@3\3I+Z"^U?5]"T7[;!<WT(41W\*QW-
MM):W6%7=(DA5RH;8'+N_U[^PY^PSKO[*FG7/BOXT?M0^-?C7\1]3L(['4O'W
MCB94,-FC;A:6-I&3'90%\2.%+22N%:21]D83Z!HH _-']DS_ (-N_!/[$O[7
M/C#XX_LY?ML>//#/P\\<G9XC^%FF:5:HUW:?:/M"V!U-BTT=N'^3,*17'E%D
M\_YF8_I=110!\/WO_!'7Q?X4_;E^)W_!17]G?]N;QAX$^(WQ'U*T-UI7]@VF
MH^&9M.M[&VMDM+[3I"DEXV^!Y!.ES Z>;M3;\S/=^,7_  2M^*?[=?COP5J_
M_!3;]I/P[X^\&> =>37=&^%?P^^'<OA[1=1U2-62*YU)KO4=0N+L(DDBB%9(
MHR)&#!E9@WVG10!\"?\ !9O_ ((&_"3_ (+!^)O OC_7?CMK?P_\0>";6:Q2
M]TS2H[Z&\L9)%E\HQ/)'Y<BN"5D5L .P96^7;Y-^U=_P:Q_"?]I3Q?\ #/XI
M6W[>?Q>M_&W@2TM[?5_&_C+43XDU+7!!-YT$@>YE1;-XV+!1&IB ()C9][O^
MJE% 'P%_P5:_X(7)_P %6/"'PZ^&WQ(_;"U_1-!^&]K+]@D_X1N&^U+5;R6.
M*.:[O+IYD1V81*0L<4:J7?@@J$[GX_?\$=OA1^UW_P $U_#G_!.G]J;X@3^(
M(O!FEZ?:^$O'FC:.FGW^GS6-L+:UNO+:2:-I?)W1RCA)5D?"QDJ5^Q** /S+
M_8 _X-\?C!^R)H=O\%/C%_P5*\??$?X+6%\US:_!NU\/KI&EW>9/,-O=R&ZN
M9)+1W):2TC,44Q+>8&5W1OHKXI_L#?M&G]LSQ-^VO^R[^VV? NK>*/"NEZ'J
MO@O7_ ::WH%]'9&X,<]Q"MY;3&<&?"2131% &4^8KD#ZJHH ^4_^"87_  2J
M^'?_  3>3XC^.$^(,WC7XB_%_P 62^(/B)XRET6+38;NX:6:58+6SB=UM+='
MN9V6/>YS*V6("*OU9110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?&G[?W[5WQ]^"?QNM?"'PQ\>_V9ITGAZ"Y>W_
M ++M9LRM+,K-NEB9NB+QG''2OLNOSP_X*I?\G)V/_8IVO_H^XK]#\,<%@\?Q
M0J6*IQJ1Y).TDI*^FMFFC\Y\4L=C<OX5=;"U94Y\\5>,G%VUTNFF<G_P\-_;
M"_Z*_P#^6_I__P CT?\ #PW]L+_HK_\ Y;^G_P#R/7BU%?T9_JMPQ_T T?\
MP5#_ .1/YL_UKXI_Z#ZW_@V?_P D>T_\/#?VPO\ HK__ );^G_\ R/1_P\-_
M;"_Z*_\ ^6_I_P#\CUXM11_JMPQ_T T?_!4/_D0_UKXI_P"@^M_X-G_\D>T_
M\/#?VPO^BO\ _EOZ?_\ (]'_  \-_;"_Z*__ .6_I_\ \CUXM11_JMPQ_P!
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M_I__ ,CT?\/#?VPO^BO_ /EOZ?\ _(]>+44?ZK<,?] -'_P5#_Y$/]:^*?\
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M*_\ ^6_I_P#\CT?\/#?VPO\ HK__ );^G_\ R/7BU%'^JW#'_0#1_P#!4/\
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M?_\ (]>+44?ZK<,?] -'_P %0_\ D0_UKXI_Z#ZW_@V?_P D>T_\/#?VPO\
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MK_\ Y;^G_P#R/7BU%'^JW#'_ $ T?_!4/_D0_P!:^*?^@^M_X-G_ /)'M/\
MP\-_;"_Z*_\ ^6_I_P#\CT?\/#?VPO\ HK__ );^G_\ R/7BU%'^JW#'_0#1
M_P#!4/\ Y$/]:^*?^@^M_P"#9_\ R1[3_P /#?VPO^BO_P#EOZ?_ /(]'_#P
MW]L+_HK_ /Y;^G__ "/7BU%'^JW#'_0#1_\ !4/_ )$/]:^*?^@^M_X-G_\
M)'M/_#PW]L+_ **__P"6_I__ ,CT?\/#?VPO^BO_ /EOZ?\ _(]>+44?ZK<,
M?] -'_P5#_Y$/]:^*?\ H/K?^#9__)'M/_#PW]L+_HK_ /Y;^G__ "/1_P /
M#?VPO^BO_P#EOZ?_ /(]>+44?ZK<,?\ 0#1_\%0_^1#_ %KXI_Z#ZW_@V?\
M\D>T_P##PW]L+_HK_P#Y;^G_ /R/1_P\-_;"_P"BO_\ EOZ?_P#(]>+44?ZK
M<,?] -'_ ,%0_P#D0_UKXI_Z#ZW_ (-G_P#)'M/_  \-_;"_Z*__ .6_I_\
M\CU^C7PCUS5/$_PI\,>)=<NO/O=1\/65S>3[%7S)9($=VPH &6).  !V%?CY
M7Z\? 7_DAG@O_L4]._\ 26.OR+Q;RC*LMP.%EA,/"FW*5^2$8WT6]DKG[#X0
M9QFV9X_%1QF(G52C&RG.4K:O:[=CK****_#3]X"BBB@ HHHH **** "BBB@
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M %\A^I\U4445_4!_*X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?KQ\!?^2&>"_P#L4]._])8Z_(>OUX^ O_)#/!?_ &*>G?\ I+'7XMXT?\B_
M"?XY?DC]O\$O^1CC/\$?S9UE%%%?SX?T2%%%% !1110 4444 %%%% !1110
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M** "BBB@ KY9_P""LG_)#/#_ /V-D?\ Z2W%?4U?+/\ P5D_Y(9X?_[&R/\
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M5_/A_1(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC9'_ .DMQ7U-7RS_ ,%9/^2&>'_^QLC_ /26XKZ_@+_DL,'_ (_T9\=X@?\
M)&XW_!^J/@&BBBOZ]/XX"BBB@ HHHH **** "D8D*2%S@=!WI:* /B?XW_MX
M?M0^"_V_?A[^RG=>#?#_ (;T7Q!JFGSW4]K='4+J]LIIGCVM(Z(D!)C<,JHS
M CY9".:]'_X*9?MMZO\ L6?!S3]5\$:3:7GBGQ-J+66B+J"EH+957=+<.H(+
M[04 7(&Z0$Y (/SI^W'_ ,IJO@G_ -@_1?\ TX7M?0'_  5$_8<\2_MK?"'2
MK#X>ZQ:6OB;PQJ$EUID>HR%(+N.1 LL)< [&.V-E8@C*8. VY?S&.+XAK8#.
M882I*=:G4Y:=[72M&ZBK))V;M9;VZGZG+!\.4,PR6>,IQIT:E/FJ6O9N\K.3
M;;:NE>[VOT.4^+'[7/QE_8L_:^\"?"'XQ_$ ^,_!'C^QAC;5]0TJUM;O2;XS
M>2[(;6.-'@#M$Q5U+A7/S$K\V_\ '']J+XKZW_P4 \*?L0_##Q0WA>RN_#ES
MJFN^(;:PM[B[DE^S7$D,,0N8Y(E0&*,L2A9MQ *XR?E;]LVW^/\ ^TY^U]\!
M_P!G3XH?#S3M(\7Z=9P2:T-'UX7X,3SHT]T^V-1 !':R2A-SD*PR>1G[U^,'
M[('@SXG?&OP_^T?H?B74/#?C?PYI]Q86NLZ?'%(EQ:RQ2QF.:*12'VB:0HP(
M(+<[@  8#$9WFM7%T<).?LJ=>E;F<HSY+*56FI2M)-/NUNU>S09AALCRFE@Z
MV+A#VU6A53Y5&4.>[C2J.,;Q::[)[)VNF<1_P3$_;'\6?M>_LXW7CKXHVUI;
M:WX>UB73=6O;9!%!=*L4<JW&WI&=LF& XRA(P&"CL_V;?B;\1/C[XI\0_&I-
M8>U^'$S_ -F^ =(^QQ!M32%R)M8>0IYH65P4A3<%\I-Y4EP1Y'!^S[X%\"Z3
MIG_!,_\ 9LFOK;1[B/\ MGXO^(FN=UU'ILI"_9WD0*%N;WRQ$  -EO&[!<;:
MS/$W_!2:_P#"EM\6#\#OA/HTO@WX"2Z9I>H6ES.\,NI^9=M9M':^6-EM'%Y,
MFTLLFX(.%S@=^$S:KEN%P\,UKMNDFI.-W[2I&#E-::N-*";F_M3T^*-GYV+R
MBCF>*Q$\IH)*JTXJ5E[.G*:C!Z_#*K-I07V8:_#*Z^SZ*YSX0_$_PW\:OA=H
M'Q:\(&7^S?$6E0W]HDZ@21K(@;8X&0&4DJ<$C(.":Z.OO*56G6I1J4W>,DFG
MW3U3/@:M*I0JRIU%:46TUV:T:"BBBK,PHHHH **** "BBB@#O?V6?^3D_ G_
M &-EA_Z/2OUGK\F/V6?^3D_ G_8V6'_H]*_6>OYX\9O^1MA?\#_]*/Z.\%/^
M1/BO^OB_])04445^-'[4%%%% !1110 4444 %%%% !1110 5P7[4W_)MGCO_
M +%._P#_ $0]=[7!?M3?\FV>._\ L4[_ /\ 1#UZ.3_\C;#_ ..'_I2/-SG_
M )$^(_Z]S_\ 26?DQ1117]MG\,A1110 4444 %%%% !1110 45\>_MK_ !#_
M ."G$=MXC^(/[,&EZ+X;\&^$%G+C4+>*;6-:2WS]HN(X9XG18 5?8N5>14WK
MN#H*[?\ X)M?MB^+?VQOV:I_B+XO\.01^(M$U6;2]12Q'EPWTL<,<J2(&)$9
M995!&<!@3PI 'SU#B3!5LX>6N$XSLY1<HVC-+?D=[NWFE=:J^A]'7X9QU')5
MF:J4YPNHR497E!RU7.K65_)NST=FF?1=%?%6F_MV?M-ZK_P5$\/_ +''B[PM
MX?\ #F@QM=2:C;:7<&_EOX_[)GNH2US)&FT!A&VU(T(*E2S+U]!_X*=?M>>.
M?V2_@WH]U\+K>V'B+Q5KZ:587][ )8K!"C,\^P\.XPH56^7YB2#MP9CQ3E4L
MOQ6-]Y0P\W"5XV?-'ENDGKO))7MKY:E2X3S:.8X7 ^ZYXB$9QM*ZY9<UFVM-
MHMNU]//0^E**^6OV>OVIOBA'^WY\0_V'OB5XA?Q)::!I%OJOA[Q'<V5O!=A6
MM[262"86T<<3#_2OE8(I&P@[MPQZ%K7Q4\>_$S]IRT^#/P?U[[!H7@GR[_XE
MZU':Q2^=+(A-MHT9E5@KN#YTSJ R1A &5GKIP^>X+%4/:04K^T=+ELN;GBVI
M+>VEG)M.W*FSEQ.08W"XCV=1QM[-5>:[Y>223B]KZMJ*35^9I'L=%%%>T>(%
M%%% !1110 4444 %%%% !7Z\? 7_ )(9X+_[%/3O_26.OR'K]>/@+_R0SP7_
M -BGIW_I+'7XMXT?\B_"?XY?DC]O\$O^1CC/\$?S9UE%%%?SX?T2%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?GA_P %4O\ DY.Q_P"Q3M?_ $?<
M5^A]?GA_P52_Y.3L?^Q3M?\ T?<5^F>$W_)6K_!/]#\O\7O^2/?_ %\A^I\U
M4445_4!_*X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!]3?\$F_P#DN?B#_L4Y/_2JWK[^KX!_X)-_\ES\0?\ 8IR?
M^E5O7W]7\M^*O_)85/\ !#\C^K?"7_DC:?\ CG^84445^;GZ6%%%% !1110
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MI:M9W]ZMO_9/@;3[0NT6BZ7\K2M\ZC_2;B09D8 X5$0,0#GC/CW^QUKOB_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_C_ $9\=X@?\D;C?\'ZH^ :***_KT_C@**** "BBB@ HHHH **** "BBB@
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M\U4445_4!_*X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P <_P PHHHK\W/TL**** "BBB@ HHHH **** "BBB@ KY9_X*R?\D,\/_\
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MG^.7Y(_;_!+_ )&.,_P1_-G64445_/A_1(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5P/Q-_Y&)/^O5?_0FKOJX'XF_\C$G_ %ZK_P"A-7A\0_\
M(N?JCGQ/\(YVBBBO@SSPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#IOA;_P AJ?\ Z]3_ .A+7=5POPM_Y#4__7J?
M_0EKNJ^]X?\ ^1:O5_F>AAOX04445[9T!1110 4444 %%%% !1110 4444 %
M?+/_  5D_P"2&>'_ /L;(_\ TEN*^IJ^6?\ @K)_R0SP_P#]C9'_ .DMQ7U_
M 7_)88/_ !_HSX[Q _Y(W&_X/U1\ T445_7I_' 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!WO[+/_)R?@3_L;+#_
M -'I7ZSU^3'[+/\ R<GX$_[&RP_]'I7ZSU_/'C-_R-L+_@?_ *4?T=X*?\B?
M%?\ 7Q?^DH****_&C]J"BBB@ HHHH **** "BBB@ HHHH *X+]J;_DVSQW_V
M*=__ .B'KO:X+]J;_DVSQW_V*=__ .B'KT<G_P"1MA_\</\ TI'FYS_R)\1_
MU[G_ .DL_)BBBBO[;/X9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OUX^ O_ "0SP7_V*>G?^DL=?D/7Z\? 7_DA
MG@O_ +%/3O\ TECK\6\:/^1?A/\ '+\D?M_@E_R,<9_@C^;.LHHHK^?#^B0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@?B;_P C$G_7JO\ Z$U=
M]7 _$W_D8D_Z]5_]":O#XA_Y%S]4<^)_A'.T445\&>>%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =-\+?^0U/_P!>
MI_\ 0EKNJX7X6_\ (:G_ .O4_P#H2UW5?>\/_P#(M7J_S/0PW\(****]LZ H
MHHH **** "BBB@ HHHH **** "O&?VV_@7_POWX<:7X7_P"$I_LG[)K:W7G_
M &'S]^(94V[=Z8^_G.>W2O9JYGXI?\@6#_KZ'_H+5,LUQ^2+Z]@I\E6GK%V3
ML]MI)I_-,\_-<#A<RR^IA<3'FA-6:NU=>J:?W,^(_P#AVS_U6?\ \MW_ .Z*
M/^';/_59_P#RW?\ [HKZBHK+_B-'B7_T'_\ E*C_ /*S\_\ ^(;\%_\ 0+_Y
M/4_^3/EW_AVS_P!5G_\ +=_^Z*/^';/_ %6?_P MW_[HKZBHH_XC1XE_]!__
M )2H_P#RL/\ B&_!?_0+_P"3U/\ Y,^7?^';/_59_P#RW?\ [HH_X=L_]5G_
M /+=_P#NBOJ*BC_B-'B7_P!!_P#Y2H__ "L/^(;\%_\ 0+_Y/4_^3/EW_AVS
M_P!5G_\ +=_^Z*/^';/_ %6?_P MW_[HKZBHH_XC1XE_]!__ )2H_P#RL/\
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MH_XC1XE_]!__ )2H_P#RL/\ B&_!?_0+_P"3U/\ Y,^7?^';/_59_P#RW?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N!^)O_(Q)_P!>J_\
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M-O\ RL6?_P >H_X8O_:6_P"B;?\ E8L__CU?>=%'_$Q'&O\ T#X?_P  J?\
MRT/^(0\-?\_:W_@4/_E9\&?\,7_M+?\ 1-O_ "L6?_QZC_AB_P#:6_Z)M_Y6
M+/\ ^/5]YT4?\3$<:_\ 0/A__ *G_P M#_B$/#7_ #]K?^!0_P#E9\&?\,7_
M +2W_1-O_*Q9_P#QZC_AB_\ :6_Z)M_Y6+/_ ./5]YT4?\3$<:_] ^'_ / *
MG_RT/^(0\-?\_:W_ (%#_P"5GP9_PQ?^TM_T3;_RL6?_ ,>H_P"&+_VEO^B;
M?^5BS_\ CU?>=%'_ !,1QK_T#X?_ , J?_+0_P"(0\-?\_:W_@4/_E9\&?\
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MW@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\'^ Y=&TRWCUVS34+N:YN4N+W]U?1&W"R&WLDPS\_9020#BN&_X)!_L0?\%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_017E->K:'_R!;/_ *]8_P#T$5]/PQ_&J>B.K"?$RU1117V)W!1110 4444
M%%%% !1110 445\Q?\%'?VA_C#\!?^$-_P"%3^+_ .RO[5_M'[?_ ,2^WG\W
MROLVS_71OMQYC],9SSG KULCR;%<09I3P&':4YWLY72TBY.]DWLNVYY&?9UA
M>'LJJ9AB8R<(6NHI-^])15KM+=KKL?3M%?F)_P /#?VPO^BO_P#EOZ?_ /(]
M'_#PW]L+_HK_ /Y;^G__ "/7Z'_Q!SB?_G]1_P# I_\ RL_.?^(T<+?\^:W_
M (##_P"6'Z=T5^8G_#PW]L+_ **__P"6_I__ ,CT?\/#?VPO^BO_ /EOZ?\
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MJ5_^5S_[11_Q"GC[_H#_ /*E+_Y,/[*Q_P#)^*_S/H2BOGO_ (;O_P"J5_\
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M4K_\KG_VBC_B%/'W_0'_ .5*7_R8?V5C_P"3\5_F?0E%?/?_  W?_P!4K_\
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M_P#D_%?YGT)17SW_ ,-W_P#5*_\ RN?_ &BC_AN__JE?_E<_^T4?\0IX^_Z
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M%/'W_0'_ .5*7_R8?V5C_P"3\5_F?0E%?/?_  W?_P!4K_\ *Y_]HH_X;O\
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MD G.V(]A7/\ [7/Q<^#G[>'_  7+_98\5?\ !*#Q-IGBOQK\/=9FO?CY\2/
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M^+_P_P#B"FH>/OB/\/9%N[+PQX?$L!>'5-0M\Q;2!,1;.[-M,B;,W*K)V_\
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M7XO_ +0OPXD\.ZO\&]*L/$%O?^-+&)5@?2X4EW,TH\ME&3NX*,N>"* /.O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?"_P#P4C_Y+[9_]BS;_P#HZ>ONBOA?_@I'_P E]L_^Q9M__1T]?=>'
M?_)1K_!+]#MP'^\?(^?Z***_>CVPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#Z._X)G?\ECUO_L67_P#2B"OMJOB7
M_@F=_P ECUO_ +%E_P#TH@K[:K\"\0?^2DG_ (8_D>'CO]X?R"BBBOB#C"BB
MB@ HHHH **** "BBB@ HHHH *^<?^"F/_)'-$_[&9/\ TGGKZ.KYQ_X*8_\
M)'-$_P"QF3_TGGKZ3A#_ )*3#?XOT9T83_>(GQ+1117]('T 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!VG[.7_)?
M?!G_ &,UE_Z.6OTTK\R_V<O^2^^#/^QFLO\ T<M?II7XQXG?\C&A_@?YGDYC
M\<?0****_,CS0HHHH **** "BBB@ HHHH **** "N+_:-_Y(%XS_ .Q9O?\
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MUU]%?\)]XL_Z"W_D"/\ ^)H_X3[Q9_T%O_($?_Q->G_Q'#BC_H(E_P""Z/\
M\B?%?\0ZX"_Z W_X,J?_ "P^=?\ AT%_U<-_Y:7_ -UT?\.@O^KAO_+2_P#N
MNOHK_A/O%G_06_\ ($?_ ,31_P )]XL_Z"W_ ) C_P#B:/\ B.'%'_01+_P7
M1_\ D0_XAUP%_P! ;_\ !E3_ .6'/?L@_L@_\,I_\)#_ ,7#_M[^WOLG_,)^
MR^1Y'G?]-9-V[SO;&WOGCT[QO\,_AO\ $VT@T_XD?#[1/$$%M(9+:#7-)ANT
MB<C!91*K!3CC(JM\/M?U;7/M?]J7?F^5Y?E_NU7&=V>@'H*@^,/QT^#/[/?A
M&3Q_\=/BCH7A#0H3^_UGQ%J4=I:Q=/ORR$(O4=2.M>9B,\Q7$E9YCB9.4ZF[
M:2?NKE6D=-DMOS/M<HR[ 93E\,)@H<E*-[*[=KMMZMM[MO5F7_PR?^RS_P!&
MU?#_ /\ "-L?_C5:MU\"?@A?>$;;X?WOP;\*S:#97)N+/1)?#ULUI!,=V9$A
M*;%<[W^8 'YCZFO,_!/_  5$_P"";/Q(\167A'P'^WS\'-6U34I?*TW3['XC
MZ:\UW)D#9$@FS(V2!M7)]J]VK ](Q_!7P\\ ?#72Y-#^'/@;1] LIK@SRV>B
M:9%:Q/*553(4B506*JHW$9PH'85>DT319M8C\0RZ1:MJ$-J]M%?-;J9DA=D9
MX@^-P1FC0E<X)12>@JU10!P'_#)_[+/_ $;5\/\ _P (VQ_^-5TO@SX<?#SX
M<V<FG_#WP'HN@V\I!E@T;2X;5'(Z$K$J@]37!^)?VX?V3?"/[4'AO]BS6_CE
MHJ_%3Q;'<2:)X)MFDN+QT@M);R1IA$K+:@6\,D@,QC#@ +N+*#?UC]KC]G70
M/VI=)_8IU?XFVT'Q0UWPG+XFTGPHUG<&2XTJ.9X7N!*(_)'SQR (7#D1L0I"
MD@ U?$G[.O[/OC+6[CQ-XO\ @5X-U74KM@UUJ&I>&+2>>8@!07D>,LQ  ')Z
M 5MR_#_P'/X.'P[G\$Z0_A\6RVXT)]-B-F(1C$?D[=FP8&%QCBM>B@#@C^RK
M^R^T*V[?LW^ C&K%E0^#[+ )P"0/*ZG _(>E-_X9/_99_P"C:OA__P"$;8__
M !JN_HH Y37O@/\  [Q3I>FZ'XG^#7A34;+1H##I%G?^';::*QB.,I"CH1$I
MVKPH ^4>E9?_  R?^RS_ -&U?#__ ,(VQ_\ C5=_10!2\/>'/#WA'1;?PWX4
MT&RTS3K1-EI8:=:I!#"N2=J(@"J,DG '>KM%% !1110 4444 %%%% !1110
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M 'A_(****^(.,**** "BBB@ HHHH **** "BBB@ KYQ_X*8_\D<T3_L9D_\
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MNXVOY-J]K[7MK;I=7W1::;:04445J,**** "BBB@ HHHH **** "OU"^"O\
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M:%\.>/O'.CZ9$97;2K1Y"]T$7[ZQ%E#=E29W.%1B,[_@OU=_#K_@H9_P3S\
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MOA[QQH$&JZ9#J4(CN($D7F*55+*)$8,C;69<J<$C!/YD:S^WQ\)/VOH/VR/
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MQG_V+-[_ .B6KMRW_D8T?\<?S1=/^(O4_,NBBBOZG/I0HHHH **** "BBB@
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M:6(XZ5=\&^"/!?PY\.V_@_X>^$-+T+2+3=]ETO1M/CM;:'<Q9MD42JJY8DG
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MD>:%%%% !1110 4444 %%%% !1110 5Q?[1O_) O&?\ V+-[_P"B6KM*XO\
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M\3V?@W1=<LG*SZ9]IAN;B>>)ARDGV>TFC1Q@H\JNI#**]0_X)<_\SS_W#/\
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MB<PQ$*-/E:YJDXPC=VLN:32N^BN=V7IRQ%EV/E2BO0_^&4_CY_T(?_E4M?\
MX[1_PRG\?/\ H0__ "J6O_QVOUC_ (B+X??]#C"_^%%+_P"3/=]G4[,\\HKT
M/_AE/X^?]"'_ .52U_\ CM'_  RG\?/^A#_\JEK_ /':/^(B^'W_ $.,+_X4
M4O\ Y,/9U.S//**]#_X93^/G_0A_^52U_P#CM'_#*?Q\_P"A#_\ *I:__':/
M^(B^'W_0XPO_ (44O_DP]G4[,\\HKT/_ (93^/G_ $(?_E4M?_CM'_#*?Q\_
MZ$/_ ,JEK_\ ':/^(B^'W_0XPO\ X44O_DP]G4[,\\HKT/\ X93^/G_0A_\
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MX^?]"'_Y5+7_ ..T?\,I_'S_ *$/_P JEK_\=K]H_P"(B^'W_0XPO_A12_\
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MZ$/_ ,JEK_\ ':/^(B^'W_0XPO\ X44O_DP]G4[,\\HKT/\ X93^/G_0A_\
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M^A#_ /*I:_\ QVC_ (B+X??]#C"_^%%+_P"3#V=3LSSRBO0_^&4_CY_T(?\
MY5+7_P".T?\ #*?Q\_Z$/_RJ6O\ \=H_XB+X??\ 0XPO_A12_P#DP]G4[,\\
MHKT/_AE/X^?]"'_Y5+7_ ..T?\,I_'S_ *$/_P JEK_\=H_XB+X??]#C"_\
MA12_^3#V=3LSSROU"^"O_)'/"7_8LV'_ *3QU\ ?\,I_'S_H0_\ RJ6O_P =
MK]!OA3IM[HWPN\-Z/J4/EW-IH%G#<1[@VQU@16&02#@@\CBOA>.>)N&\^PU&
M&68VC7E%MR5.I";2:T;49.R?F>9F<91A&Z-^BBBOS<\<**** "BBB@ HHHH
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MRQOKJ,*,+MEGB9Q@=,'BN[T_3[#2;"'2]*L8;:UMHEBM[:WB"1Q(HPJJHX4
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M !1110!TOPQ_Y#,__7J?_0EKMZXCX8_\AF?_ *]3_P"A+7;U_3/A?_R25/\
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M]N;FS\3VL[+;7=R8DB4(Y9(5D95!:^F))\LM7[&1R1RQK+$X96 *LIR"#W%
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %<)\2O^1@3_KU7^;5W=<)\2O\ D8$_Z]5_
MFU?G'BG_ ,DJ_P#'']3U<G_WSY,YZBBBOYJ/JPHHHH **** "BBB@ HHHH *
M*_/#_@L1_P %8/B#^Q]^U#\$/V*_A;XDTKP9-\5-9M&\6?$[6[!+J/P[I4M\
MMJ7MXI3Y)FSYK,\P:.-47*G=N31T;]N/]I/]G#_@M3X6_P""8WQ-^(DOQ/\
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M;CHVM5?K9];;76CZ-K4WA+GBI!1116!04444 %%%% !1110 4444 =+\,?\
MD,S_ /7J?_0EKMZXCX8_\AF?_KU/_H2UV]?TSX7_ /))4_\ %/\ ,^3S?_?7
MZ(****_0SRPHHHH **** "BBB@ HHHH **** "N;^)W_ "!H/^OH?^@M725S
M?Q._Y T'_7T/_06KY/CG_DDL7_A_5';E_P#OL/4X>BBBOY//LPHHHH ****
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M?1<)Y'F/$F?T<NP,XQJU.;E<[J*Y82D[VC)[)I:/6WJ>]?\ "K/^H[_Y*_\
MV5'_  JS_J._^2O_ -E7YN_\/'_VS_\ HLO_ );NG?\ R/1_P\?_ &S_ /HL
MO_ENZ=_\CU^8?4/#?_H"G_X%+_Y:?LW_ ! [Q#_Z"\/_ .!3_P#E)^D7_"K/
M^H[_ .2O_P!E1_PJS_J._P#DK_\ 95^;O_#Q_P#;/_Z++_Y;NG?_ "/1_P /
M'_VS_P#HLO\ Y;NG?_(]'U#PW_Z I_\ @4O_ ):'_$#O$/\ Z"\/_P"!3_\
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MB@G7Q#?VSV:VR:3)%L$$1 ,VZ[65BWF B!=N#^K\44<,:PPQA$10J*HP !T
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MW!1110 4444 %%%% !1110 5ZGHO_(&M/^O6/_T$5Y97J>B_\@:T_P"O6/\
M]!%?L7@]_O\ BO\ #'\V>'GG\*'JRS1117[T?-A1110 4444 %%%% !1110
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MQLD3GR\M]X(I5V^5/VO/BC^RI^Q1_P %X/%'CK_@IQ\(O#6I?"/X\?##0X/
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MD@GNKB4)*.)#"Q!(P3^AU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PGQ*_Y&!/\
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M %%%% %[PU_R,%E_U])_,5Z=7F/AK_D8++_KZ3^8KTZOW[P@_P"15B?\:_\
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MO]F;]F_4+.TTZ_\ V?O!$]O81M'8P3>%+-DMT9V=EC4QX0%V9B!C)8GJ:L_
M;X[_  H_:<^$&@_'OX&>+5U[PEXGLOM>A:PEI- MU#N9=XCG1)%&5/WE!XST
M(KKJ .7\8_ _X*_$/P##\*OB!\(/"VN^%[=8U@\-ZQX?MKJPC6,80+;R(8P%
M' PO Z5<L?AC\-=+\#0_##3/A[H=OX:MX%AM_#L&DPI8Q1JVY46 +Y:J& (
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MI^LE%?DW11_JO_T^_P#)?_M@_P"(%_\ 4P_\I?\ W4_62BOR;HH_U7_Z??\
MDO\ ]L'_ ! O_J8?^4O_ +J?L3\,?^0S/_UZG_T):[>OSP_X)!_\E[\1?]BA
M)_Z56]?H?7[WX?X/ZCPW"ES7]Z6MK=?F?SSXB\.?ZJ\3SR_VOM+1B^;EY=U?
M:\MO4****^U/A0HHHH **** "BBB@ HHHH **** "N;^)W_(&@_Z^A_Z"U=)
M7R=_P5\_Y()X=_[&^/\ ]);BOG.+L/\ 6N&\32O:\=_FCZ;@[*/[>XGPN7\_
M)[25N:U[:-[75]NZ/5:*_)NBOYR_U7_Z??\ DO\ ]L?TU_Q O_J8?^4O_NI^
MLE%?DW11_JO_ -/O_)?_ +8/^(%_]3#_ ,I?_=3]9**_)NBC_5?_ *??^2__
M &P?\0+_ .IA_P"4O_NI^LE%?DW11_JO_P!/O_)?_M@_X@7_ -3#_P I?_=3
M]9**_)NBC_5?_I]_Y+_]L'_$"_\ J8?^4O\ [J?K)17Y-T4?ZK_]/O\ R7_[
M8/\ B!?_ %,/_*7_ -U/UDHK\FZ*/]5_^GW_ )+_ /;!_P 0+_ZF'_E+_P"Z
MGZR45^3=%'^J_P#T^_\ )?\ [8/^(%_]3#_RE_\ =3]9**_)NBC_ %7_ .GW
M_DO_ -L'_$"_^IA_Y2_^ZGZR45^3=%'^J_\ T^_\E_\ M@_X@7_U,/\ RE_]
MU/UDHK\FZ*/]5_\ I]_Y+_\ ;!_Q O\ ZF'_ )2_^ZGZR45^3=%'^J__ $^_
M\E_^V#_B!?\ U,/_ "E_]U/UDHK\FZ*/]5_^GW_DO_VP?\0+_P"IA_Y2_P#N
MI^N7AK_D8++_ *^D_F*].K\@/V3O^3G/ '_8WZ?_ .CTK]?Z_9?#/+O[.RZO
M'FYKS3VMT]6?B/BGP;_J;F6'H>W]KSP<K\O+:SM:W-*X4445^EGY:%%%% !1
M110 4444 %%%% !1110 52\2_P#(OWO_ %ZO_(U=KS[]K'_DV/Q__P!BAJ'_
M *(>N+,H>TRZM#O"2_!G=E>'^N9G0H7MSSC&^]KR2O8Q**_)NBOY<_U7_P"G
MW_DO_P!L?UE_Q O_ *F'_E+_ .ZGZR45^3=%'^J__3[_ ,E_^V#_ (@7_P!3
M#_RE_P#=3]9**_)NBC_5?_I]_P"2_P#VP?\ $"_^IA_Y2_\ NI^LE%?DW11_
MJO\ ]/O_ "7_ .V#_B!?_4P_\I?_ '4_62BOR;HH_P!5_P#I]_Y+_P#;!_Q
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M[]H33->TFVOK8_!7Q1+]GNX%D3S(]*N9(WVL"-RNJNIZAE!&"!6-_P $]O\
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M5_Q?H?R1](O_ )'V"_Z]/_TMA1117W!_.P4444 %%%% !1110 4444 %%%%
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M^9Z3_P .]O\ JKO_ )0/_NBC_AWM_P!5=_\ *!_]T5YM_P -=_M#_P#10O\
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M7QO;*G(Q)^QM^R"_[-5[XW\>^)_$4&I^*?B'XBDU779;*-EMK8&661+>+?\
M,P5IY27(4MN'RC;SI7JY;6RYU)?QFEW^+FU\N7DM;H<F7X3BW <4QPU-6P,6
MUT:]G[)6=_B=5U^9R;U:;;T:/<****\$_20HHHH **** "BBB@ HHHH *_9'
M]GS_ )()X(_[%#3?_26.OQNK]D?V?/\ D@G@C_L4--_])8Z^[X%_WFMZ+\S^
M</I&?\BG ?XY_P#I*.OHHHK])/Y."BBB@ HHHH **** "BBB@ KYM_X*$_\
M,H?]Q#_VVKZ2KYM_X*$_\RA_W$/_ &VH ^;:*** "BBB@#Z2_P"">W_,W_\
M</\ _;FM#_@K3!#<?\$K_P!I6.>)74? +Q@P##(RNBW9!^H(!_"L_P#X)[?\
MS?\ ]P__ -N:L?\ !7O7-&\/?\$I_P!I*^UW5;>SAE^!7BNVCEN9@BM--I%S
M%%&"3RSR.B*.I9@!R: /SM^'7[3?[!LW_!L)X3_9T^,_CCPIXN\6:]\$[C2O
M"_PQTR[AU+7[S7W2<6*VUA"7N%FCN&B?S0@\K&\D 5]J_P#!$7P%\??V5?\
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M:)MQY?OG/;%>DUX;^V?\8?B-\)_^$;_X5_XB_L_^T/MGVO\ T2&7S-GD;/\
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M_P"(;YY_S\I_?+_Y /\ B=;PK_Z \;_X+H?_ #2?3?[/?[/?_"A_[7_XJ_\
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MR\*^-X;"TM;F]N/"FN07\4$=P9A"7>%F52Q@E^4G<-AR!D9 .ZHHHH ****
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MHHH **** "BBB@ HJ*_O['2[&;4]3O(K>VMHFEN+B>0(D2*,LS,>%  ))/
MK\I/VI/VI/BO\<O^"N?[-WA^[BFTWX=2ZO8ZYX%TURR2:C!+=W%N-4G0@;3,
M+=FA4\K Z-A6ED6O?X?X?Q&?UJD8248TX2FV]?ABY62TNW;Y*[Z6.G#8:6)D
MTG9)-_<C]8**_/W_ (*7>*O&OB3_ (*8_LS?L\>+UDE^&.N:BU]J.DW"YL=9
MU".5AY5PA^6<1A8"$8$#SSQ\U0?\$4/B_P"+=#\*?M!:#\0O%$D7PS^''CZZ
M3PKJ.IW!-MIEHC73W,$<C'"PQ11V\FP':OFD@#=7?/A*M'A]9FJJ;<8SY+=)
MU)4TD[ZRO&[C;;K=6-'@I+#>UOT3MZMK[]#]":*^;?V0/#.O_M"?$:__ ."@
M7Q3T>XM3KE@VF_"/0;^,J^B^&RP87;(?N75\P69SR5B$,>[&X5])5\]C\)'
MXCV'-S227-V4NL4[Z\NS>BO>UU9OFJP5.7+>[Z^O;Y!1117$9A1110 4444
M%%%% !1110!U?P,_Y+-X6_[#]K_Z-6OOFO@;X&?\EF\+?]A^U_\ 1JU]\U_2
M7@A_R)\5_P!?%_Z2CZOA[^!/U_0****_;CZ$**** "BBB@ HHHH **** "BB
MB@ KE?CG_P D9\4_]@"Z_P#135U5<K\<_P#DC/BG_L 77_HIJ\S.O^1/B?\
MKW/_ -)9CB/X$_1_D? M%%%?PD?G(4444 %%%% !1110 4444 %%%?FI_P %
M^OVL_B39?LX:M\*O@K<&#PTOBBT\/?$+Q%#(5,UU/;372Z3 1][;'"'N2"-H
MEABYWRJOM</Y)B.(<UIX*E)1YFDY/:*O:_GY+J[(Z,-AY8JLJ<=+]3]*Z*^
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M*_H$_P ?PHHHH ^F/^"=?_,X?]P__P!N:T_^"M\4<W_!*S]I1)8U8#X"^+F
M89Y&C71!_ @&LS_@G7_S.'_</_\ ;FK7_!8/7-&\/_\ !*3]I&]US5+>SAE^
M!WBFVCEN9@BM--I5Q%%&">K/(Z(HZEF ')K^?N-_^2HQ'_;G_I$3_8#Z+?\
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M^O*^0_VZ_P#DLUK_ -@"#_T;-7Y9XP_\D<_^OD/U/&SW_</FCQ>BBBOY2/C
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MQ>\%L?AO?Z9HMQ>QZNTMS&L=G$T2-^^B$B*8CA@L!;&P!J^AOA'/^T!^R?\
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MK^LO"+_DBZ?^.?YGVN1_[@O5A1117Z<>N%%%% !1110 4444 %%%% !1110
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MN;\#91XDY?/AS-*2J4*]N:+E."?(U47O4VIJTH)Z/6UGHV>??\.Z_P#JL/\
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MG_/N7W/_ ""BBBC_ %3XJ_Z *W_@J?\ \B'U+&?\^Y?<_P#(****/]4^*O\
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MO^2->*?^P!=_^BFK*M1IXBC*E45XR337DU9BE%2BXO9GP+1117PG_$+>!/\
MH#_\J5?_ ),\W^Q\M_D_%_YA1111_P 0MX$_Z __ "I5_P#DP_L?+?Y/Q?\
MF%%%%'_$+>!/^@/_ ,J5?_DP_L?+?Y/Q?^84444?\0MX$_Z _P#RI5_^3#^Q
M\M_D_%_YA1111_Q"W@3_ * __*E7_P"3#^Q\M_D_%_YA117,_&+XQ_#/X ?#
M;5?B]\8?%UOH7AS1+<3:EJ=RKLL2E@J@*@9W9F955$4LS,  20*/^(6\"?\
M0'_Y4J__ "8?V/EO\GXO_,Z:BN8UGXS_  L\.?"7_A>WB3QO8Z;X1&D1ZHVN
MZBYMX4M)$5TD;S &7<&7"D!B6"XR<5SWP8_:X_9Z_: \07?A'X6?$(7FL66F
M6^I3Z/J&EW>GWGV*=%>&Z2"[BBDD@=70B55*?.O/(H_XA;P)_P! ?_E2K_\
M)A_8^6_R?B_\STBBN7^*OQG^&OP3TK3=8^)?B3^SXM9UNUT?2(H[.:YFO;ZX
M?9#;Q0P(\DCL<GY5.U59FPJDCJ*/^(6\"?\ 0'_Y4J__ "8?V/EO\GXO_,**
M**/^(6\"?] ?_E2K_P#)A_8^6_R?B_\ ,****/\ B%O G_0'_P"5*O\ \F']
MCY;_ "?B_P#,****/^(6\"?] ?\ Y4J__)A_8^6_R?B_\PHHHH_XA;P)_P!
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MXZ^(GP8\0?L="U\9^#/"&F:YH,6G>/(;C2/%'VZ:\ACBM[V:V@>$1O9L)3-
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M1^R-^TMX1_; _9T\+_M%^"-/GLK'Q)9/(UA<N&DM)XY7AGA+# ;9+&ZAL#<
M&P,XH ]'HHHH **** "BBB@ HHHH **** .J^!O_ "67PM_V'[3_ -&K7WU7
MP+\#?^2R^%O^P_:?^C5K[ZH **** "BBB@ HHHH **** "BBB@ HHHH *Y7X
MY?\ )&O%/_8 N_\ T4U=57*_'+_DC7BG_L 7?_HIJ /@6BBB@ HHHH ****
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M;59[>SU"QCU3XS:Y8RE6TOP^S$)IRNOW+F_96C SN6!9GP05- &3\%]>T/\
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M?L/>$OA+IWQ\\5?M<?#O3/ ^L7Z6.D>+]0\76D.FWUR\3RK%#<O((Y6,<;N
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MXWO[E LEW/+*\T\Q4$[=\LCL%R=H(7)QFO2** "BBB@ HHHH **** "BBB@
MHHHH ZKX&_\ )9?"W_8?M/\ T:M??5? OP-_Y++X6_[#]I_Z-6OOJ@ HHHH
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MZ_\ ,8_[=_\ VK7)_P#!4R**?_@F/^T9#-&KJWP(\7!E89!_XDUW76?LZ_\
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MS:ZK+96D(F6V< B:" /%!]H#L))4G XC#OUGB'QI_P &VOQ*\5_!?P%\6/\
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M_P"6^*_^4$U%0_:_^F?ZT?:_^F?ZT?ZD<4?] _\ Y/#_ .2#_B:3P)_Z&_\
MY;XK_P"4$U%0_:_^F?ZT?:_^F?ZT?ZD<4?\ 0/\ ^3P_^2#_ (FD\"?^AO\
M^6^*_P#E!-14/VO_ *9_K1]K_P"F?ZT?ZD<4?] __D\/_D@_XFD\"?\ H;_^
M6^*_^4$U%0_:_P#IG^M'VO\ Z9_K1_J1Q1_T#_\ D\/_ )(/^)I/ G_H;_\
MEOBO_E!-14/VO_IG^M'VO_IG^M'^I'%'_0/_ .3P_P#D@_XFD\"?^AO_ .6^
M*_\ E!-14/VO_IG^M'VO_IG^M'^I'%'_ $#_ /D\/_D@_P")I/ G_H;_ /EO
MBO\ Y0345#]K_P"F?ZT?:_\ IG^M'^I'%'_0/_Y/#_Y(/^)I/ G_ *&__EOB
MO_E!-14/VO\ Z9_K1]K_ .F?ZT?ZD<4?] __ )/#_P"2#_B:3P)_Z&__ );X
MK_Y0>\_L#_\ )4=6_P"P _\ Z/AKZQKY+_8"F\WXI:N-N,>'W[_]-X:^M*\'
M,,NQF5XET,5'EFK.UT]_--H_6>$>,N&^.\ECFV15_;8>3E%2Y9PUB[-<M2,9
M:/RMV"BBBN(^G"BBB@ HHHH **** "BBB@ HHHH *\(_;_=D^%FD%3C_ (J!
M/_1$U>[UX/\ \% O^25Z1_V,"?\ HB:O>X8HT<1G^'IU8J47+5-73T>Z9^3^
M.F99CE'A)F^,P-:=&M"E>,X2<)Q?-'6,HM-/S3/DK[1-_?\ TH^T3?W_ -*9
M17[S_8.1_P#0+3_\ C_D?Y+_ /$6?%3_ *'V-_\ "JO_ /+!_P!HF_O_ *4?
M:)O[_P"E,HH_L'(_^@6G_P" 1_R#_B+/BI_T/L;_ .%5?_Y8/^T3?W_TH^T3
M?W_TIE%']@Y'_P! M/\ \ C_ )!_Q%GQ4_Z'V-_\*J__ ,L'_:)O[_Z4?:)O
M[_Z4RBC^P<C_ .@6G_X!'_(/^(L^*G_0^QO_ (55_P#Y8/\ M$W]_P#2C[1-
M_?\ TIE%']@Y'_T"T_\ P"/^0?\ $6?%3_H?8W_PJK__ "P?]HF_O_I1]HF_
MO_I3**/[!R/_ *!:?_@$?\@_XBSXJ?\ 0^QO_A57_P#E@_[1-_?_ $H^T3?W
M_P!*911_8.1_] M/_P  C_D'_$6?%3_H?8W_ ,*J_P#\L'_:)O[_ .E'VB;^
M_P#I3**/[!R/_H%I_P#@$?\ (/\ B+/BI_T/L;_X55__ )8/^T3?W_TH^T3?
MW_TIE%']@Y'_ - M/_P"/^0?\19\5/\ H?8W_P *J_\ \L'_ &B;^_\ I1]H
MF_O_ *4RBC^P<C_Z!:?_ (!'_(/^(L^*G_0^QO\ X55__E@_[1-_?_2C[1-_
M?_2F44?V#D?_ $"T_P#P"/\ D'_$6?%3_H?8W_PJK_\ RP?]HF_O_I1]HF_O
M_I3**/[!R/\ Z!:?_@$?\@_XBSXJ?]#[&_\ A57_ /E@_P"T3?W_ -*/M$W]
M_P#2F44?V#D?_0+3_P# (_Y!_P 19\5/^A]C?_"JO_\ +#K_ ($S2M\:?"BE
MN#X@M.W_ $U6OT!K\^_@/_R6KPI_V,%I_P"C5K]!*_*/$'!8/!8ZC'#TXP3B
M[\J2OKY)'^@'T/>)N).)N%<RK9QC:N)G"M%1=:I.HXKV:=DYRDTKZV6EPHHH
MK\_/[ "BBB@ HHHH **** "BBB@ HHHH *Y/X\?\D5\5_P#8OW?_ **:NLKD
M_CQ_R17Q7_V+]W_Z*:NW+O\ D84?\<?S1\UQG_R1^8_]>*W_ *;D?GW1117]
M/G^$@4444 %%%% !1110 4444 %?&_\ P6(_X*-:U^Q#\$CH?P=</\0->>**
MRO3:)/#H4$GF;;J975D+OY,RPQN"':*5L,L+*?I3]HSXS:;^SM\!_%WQTU?2
M)M0M_"F@7.I/86[A7N#%&6$88\+N( SSC.<'&*_%G_@H7^WS^S)^T?\ L=VG
MP[\"ZWKVL?$O6?B):>)_'6NZEH?V:"Y=+*[@\F F1F6W@$T4,,1Z1IN)+L[-
M\IQ7G,<NP$Z5.HH57%M:Z]O=\WT[:O>U_P"@OH_^&E7C+BS"YAC,%+$X&G6A
M":4;PO;F;J]%3BK.2?QMQC9Q<W'](?VVOV[OB'^R=_P34\/?M(Z/:6VJ>,?$
M.CZ-:6=U?6X\A+Z[M1+)<R1IM! 5)6"#"[MHQMR*Y#]GW]MWX^>%?^"A7AC]
MBSXQ>-F\9Z9XZ^&-CK^G:S=:5:6MUIVH&P>YG3_1(HHVMV\B;"LI=2R#>0#G
MOO@GX3_9T_X*>_\ !,WPOX$\1Z?J=QX8OO#]KIKS%1;7=I?6"K T\+'<%998
MFVD@AE.&4JQ4XWC'X ?";]@S4Y?VR/$>K:U\1OB>WAW3O WPYTZ^2&)[N?RU
MM[2SMXHE \Z8J6FF).U/-90B[E.=;^TZE:EC*=;]Q:G)N^EES.=U]IR35M'K
MVZ].6_ZD87+LPX:QN77S1U,72C%TUS^TFZ4<-RU';V4:$XU'45X+E;OS)M1]
M-^-/QE^)/C7]H[P[^RA^SQXD_LR_L?(U_P"*'B>*SAN?[$T<,?)LD69'C%U>
MNI1=P+1PI)(%^Z:]VKX;U#XT:O\ \$^O$/PT_9O^Q6'BSXW_ +0/C!;_ ,<>
M*M09Q9VT\TL<4LY1</)#"K""WMU:,>7 260G#>M_L%?MW1_M>:G\1?AKXH\)
MPZ+XR^%GBJ71?$EO8SM):78$T\4=U 7 95=K>8&-MQ7:/F.X5Z6"S.A+%NC5
MF_:R?PZVC:/,H=N91?-+N[ZV22^*XGX'S6CP]3S++\/%X"A!-UERJ=7FJNE+
M$-?'[*59.E232Y8*+<5*<I2^B:***]T_*0HHHH **** "BBB@ HHHH *_1#X
M3?\ )*_#/_8OV7_HA*_.^OT0^$W_ "2OPS_V+]E_Z(2OS+Q,_P!SP_\ BE^2
M/[E^@]_R4><?]>J7_I<CH****_(#_1L**** "BBB@ HHHH **** "N9^(OPZ
M_P"$^^Q_\3C[)]D\S_EW\S?NV_[0QC;^M=-7Y[_\%W_VXOVH_P!C/_A5?_#-
MGQ/_ .$;_P"$D_MS^VO^)+97GVC[/_9_D_\ 'U#+LV^?+]W&=W.<#'!F>*P^
M"P,ZU=-Q5KI;ZM+NNK[GTO"&39GQ!Q%0P&73C"M/FY7._*K0E)WM&3V32]UZ
MVVW/KS_AG7_J</\ RG__ &RC_AG7_J</_*?_ /;*_#O_ (?A_P#!47_HY[_R
MRM$_^0J/^'X?_!47_HY[_P LK1/_ )"KY'_6GA__ )]3_#_Y,_;O^(.>)O\
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MMWXD\2ZQ:Z=IUA;/<7U_?7"PPVT**6>21W(5%5026)  !)KSW]ES]L;]F?\
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M2,LV%55&3P% Z"NDT#P_H'A31K?P[X7T.STW3[.,1VEA86R0PP)_=1$ 51[
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MV$*M#V]"G=I*7[I-SDM75YI2NY.3]THHHKZ(_&@HHHH **** "BBB@ HHHH
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M4T?_ ),/^(&>-G_1,9C_ .$6)_\ E1FT5I?\(CXA_P"@?_Y%3_&C_A$?$/\
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M_$3/#C_H=83_ ,*:/_R9\9_Q SQL_P"B8S'_ ,(L3_\ *C-HK2_X1'Q#_P!
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M*$SW-Q<B:6VA!<,D,44D\MQM9D3:CE=OX6_\%T_@G\8O^";_ (Q_X*'?#_\
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MC/PW^RS'_P %!='_ &*_$NK_  &-JNJ2^(;;Q# GB(:"6P-;71GC"M9F,B<
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MBN;A4:YF&L64GEQ@G+L$C=]HR=J,>@)KZ!_:W^+7P^\'?L6_$;XR:GK%I?\
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M5<ZG>^#?!>DZ1-K6H/?:Q+IFG16[7]T_WYYBB@RR-W=LL>YK6HH Y'2/V?\
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M (-Q/_S(<317;?\ "(^'O^@?_P"17_QH_P"$1\/?] __ ,BO_C1_Q-OX<?\
M0)B__!='_P"7A_Q3I\;/^AAEW_@W$_\ S(<317;?\(CX>_Z!_P#Y%?\ QH_X
M1'P]_P! _P#\BO\ XT?\3;^''_0)B_\ P71_^7A_Q3I\;/\ H89=_P"#<3_\
MR'$T5VW_  B/A[_H'_\ D5_\:/\ A$?#W_0/_P#(K_XT?\3;^''_ $"8O_P7
M1_\ EX?\4Z?&S_H89=_X-Q/_ ,R'$T5VW_"(^'O^@?\ ^17_ ,:/^$1\/?\
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M'_(_P_\ B_1GSE1117\5G[T%%%% !1110 4444 %%%% !1110 4444 %%%%
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MVE^9[;16%\0/B;\/?A5X!U#XI_$?QEIVB^'-*L_M6H:U?W2QV\,/&&+G@Y)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV>OV>OA_^S3X!D\ _#\WUPMYJUWJNL:OJ]R)[[5M0N93+/=W,H5?,E9B!G
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>._'O_ )'6+_L'Q_\
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M5I.%Y/T];6O\D4\!1A7<:2>J=_1N[BO\3W[*^VAQWP^_X*U?\$^M.B\/^#/
MOB.XTSP(_C#_ (5_X6\9P:+Y/AM]6MX(RNG03 Y5!&R*DQC6W8 [9"%)'UG7
MX,0_\$IOVX_%W[!GA#_@EM?? [6-,\5:/^TG=^(-7\9/:DZ#;Z"=.\A=2CON
M(Y0S2L5@4_:/W6&C4D5^\EM#]GMX[?S7?RT"[Y#EFP,9)[FIQ%.G"W*[[_\
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M\-?] W_R,_\ C1_PAGAK_H&_^1G_ ,:U**/]6>&_^@*C_P""X?\ R(?6*_\
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M?_(S_P"-'_"&>&O^@;_Y&?\ QK\=?^'L7[?_ /T7S_RU=*_^1:/^'L7[?_\
MT7S_ ,M72O\ Y%HMP;_T 0_\%4P_XA=Q5_T$4_\ P.?_ ,@?L5_PAGAK_H&_
M^1G_ ,:/^$,\-?\ 0-_\C/\ XU^.O_#V+]O_ /Z+Y_Y:NE?_ "+1_P /8OV_
M_P#HOG_EJZ5_\BT6X-_Z (?^"J8?\0NXJ_Z"*?\ X'/_ .0/V*_X0SPU_P!
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MKPEF_#>"PU3&5(R4Y22Y7)[);\T4=W1117W1^*A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7YU_\%6?^"H?_  QK^TK8_"C_ (4=_P )']H\)6NI
M?;_^$F^Q[?,GN4\O9]FDSCRL[MW.[IQS^BE?AS_P<<?\GZZ1_P!DUT__ -++
MZOG.*<37PF5.I2=GS+L_S/U;P:RG+\ZXS6&QD.>'LYNUVM5:VL6G^)M?\/\
M3_JT_P#\OO\ ^X:/^'^G_5I__E]__<-?G717YI_;F:?\_/PC_D?UK_Q#O@[_
M *!?_)ZG_P F?HI_P_T_ZM/_ /+[_P#N&C_A_I_U:?\ ^7W_ /<-?G711_;F
M:?\ /S\(_P"0?\0[X._Z!?\ R>I_\F?HI_P_T_ZM/_\ +[_^X:/^'^G_ %:?
M_P"7W_\ <-?G711_;F:?\_/PC_D'_$.^#O\ H%_\GJ?_ "9^BG_#_3_JT_\
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M_P#N&OSKHK\G_MS-/^?GX1_R/[6_XAWP=_T"_P#D]3_Y,_13_A_I_P!6G_\
ME]__ '#1_P /]/\ JT__ ,OO_P"X:_.NBC^W,T_Y^?A'_(/^(=\'?] O_D]3
M_P"3/T4_X?Z?]6G_ /E]_P#W#1_P_P!/^K3_ /R^_P#[AK\ZZ*/[<S3_ )^?
MA'_(/^(=\'?] O\ Y/4_^3/T4_X?Z?\ 5I__ )??_P!PT?\ #_3_ *M/_P#+
M[_\ N&OSKHH_MS-/^?GX1_R#_B'?!W_0+_Y/4_\ DS]%/^'^G_5I_P#Y??\
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M_P!PT?\ #_3_ *M/_P#+[_\ N&OSKHH_MS-/^?GX1_R#_B'?!W_0+_Y/4_\
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MO^2]7_7JI^A\"T445^3']L!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'Z+?\ !M5_R>#XV_[)K-_Z<+*OVJK\5?\
M@VJ_Y/!\;?\ 9-9O_3A95^U5?KG!_P#R)(^LOS/X@\=/^3@U?\%/_P!)"BBB
MOJ#\>"BBB@ HHHH **** "BBB@ HHHH *_.G_@Y5_P"3/O!/_92H?_3?>U^B
MU?G3_P '*O\ R9]X)_[*5#_Z;[VO%XB_Y$E?T_5'W_A9_P G!R__ !_^VL_%
M6BBBOQ4_T!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /9O^"=7_)^OP;_ .RE:-_Z61U_2U7\TO\ P3J_Y/U^#?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K\.?^#CC_D_72/\ LFNG_P#I9?5^XU?AS_P<<?\
M)^ND?]DUT_\ ]++ZOE.,O^1,_P#$OU/VCP&_Y+U?]>JGZ'P+1117Y,?VP%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?HM_P &U7_)X/C;_LFLW_IPLJ_:JOQ5_P"#:K_D\'QM_P!DUF_].%E7[55^
MN<'_ /(DCZR_,_B#QT_Y.#5_P4__ $D****^H/QX**** "BBB@ HHHH ****
M "BBB@ K\Z?^#E7_ ),^\$_]E*A_]-][7Z+5^=/_  <J_P#)GW@G_LI4/_IO
MO:\7B+_D25_3]4??^%G_ "<'+_\ '_[:S\5:***_%3_0$**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]F_X)U?\GZ_
M!O\ [*5HW_I9'7]+5?S2_P#!.K_D_7X-_P#92M&_]+(Z_I:K],X&_P!RJ_XO
MT/Y(^D7_ ,C[!?\ 7I_^EL****^X/YV"BBB@ HHHH **** "BBB@ HHHH *\
M9_X**_\ )A7QD_[)KK/_ *1R5[-7C/\ P45_Y,*^,G_9-=9_](Y*Y<;_ +G4
M_P ,OR9['#W_ "/\)_U]I_\ I:/YI:***_!3_2@**** "BBB@ HHHH ****
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M)KH7_IO@K[O@7_>:WHOS/YP^D9_R*<!_CG_Z2CTJBBBOTD_DX**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *_#G_@XX_Y/UTC_ +)KI_\ Z67U?N-7
MX<_\'''_ "?KI'_9-=/_ /2R^KY3C+_D3/\ Q+]3]H\!O^2]7_7JI^A\"T44
M5^3']L!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Z+?\ !M5_R>#XV_[)K-_Z<+*OVJK\5?\ @VJ_Y/!\;?\ 9-9O
M_3A95^U5?KG!_P#R)(^LOS/X@\=/^3@U?\%/_P!)"BBBOJ#\>"BBB@ HHHH
M**** "BBB@ HHHH *_.G_@Y5_P"3/O!/_92H?_3?>U^BU?G3_P '*O\ R9]X
M)_[*5#_Z;[VO%XB_Y$E?T_5'W_A9_P G!R__ !_^VL_%6BBBOQ4_T!"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /9
MO^"=7_)^OP;_ .RE:-_Z61U_2U7\TO\ P3J_Y/U^#?\ V4K1O_2R.OZ6J_3.
M!O\ <JO^+]#^2/I%_P#(^P7_ %Z?_I;"BBBON#^=@HHHH **** "BBB@ HHH
MH **** "O&?^"BO_ "85\9/^R:ZS_P"D<E>S5XS_ ,%%?^3"OC)_V376?_2.
M2N7&_P"YU/\ #+\F>QP]_P C_"?]?:?_ *6C^:6BBBOP4_TH"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OZ=OV,O
M^3/OA1_V370O_3?!7\Q-?T[?L9?\F??"C_LFNA?^F^"ON^!?]YK>B_,_G#Z1
MG_(IP'^.?_I*/2J***_23^3@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5?S2_P#!.K_D_7X-_P#92M&_]+(Z_I:K],X&_P!RJ_XOT/Y(^D7_ ,C[!?\
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M_D_72/\ LFNG_P#I9?5\IQE_R)G_ (E^I^T> W_)>K_KU4_0^!:***_)C^V
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MQ3E)N-.,79:1J35.,Y)N]ZU3LGRQ2ORMROZE1117D'W(4444 %%%% !1110
M4444 ?HM_P &U7_)X/C;_LFLW_IPLJ_:JOQ5_P"#:K_D\'QM_P!DUF_].%E7
M[55^N<'_ /(DCZR_,_B#QT_Y.#5_P4__ $D****^H/QX**** "BBB@ HHHH
M**** "BBB@ K\Z?^#E7_ ),^\$_]E*A_]-][7Z+5^=/_  <J_P#)GW@G_LI4
M/_IOO:\7B+_D25_3]4??^%G_ "<'+_\ '_[:S\5:***_%3_0$**** "BBB@
MHHHH **** //?%_P-E^)E_>:KXR\<Z[:L9732K32-2,$-G$.$?:!\\C8WL6S
MC<%'"\Y7[/>O?$W7?A7K>A:IK2WFKZ+KMWI&GZQ=+N\X1[5$SY_UFTLW?+!,
M$YR:[CQCXAU&-U\)>$G1M:O(B8W==R6,1.#<RCT'.U>KL,#@,RV/!7AG0/ V
M@VW@K0I/ELH0SB20-+(79BTK]R7?>2>YSZ5ZSQE3ZCR5$GJG%6V2O=^CT7GJ
MWJ?%PR/"_P"L:Q.$E*-HU(U9*3O4E/EY4];.4+.5U\'NQCHVEXY\;_A5JWPA
M\%S_ !C\#?%#Q(VM:3-%+=-J>J--%?*TBHR/'@+U8$*!C QCH1UOCW5]6UWX
MK> O!&KPRP:7JMI>WFI68D*K<310 K"Y&"RH6+%>A(&1Q6UJ=C#\7-9MH" _
MAO2;Y9Y7ZKJ=W&WRH/[T,;C<3T=U '"MG?UGPYX9\:6]M-J,"W M9S+9W5M<
MM')#)@J622-@RG!*G!&02#6TL>U&FJZO-*>ME=*4;1736+O)=KV5GMY]+AM3
MK8F66RY*$W0:@V^6HZ53FJRZVC5BXTVTO>Y7)J46F^'^ _C&6T\'>*O^$GU=
MSIOACQ7J5E9WUW*7(LX6#+ECDMM#%0>> !VKJ? EAJU]+<>._$D,L%YJ:J+6
MPD/_ !XV@R8XB.@D.2[G^\VW)"+6/I/AS1-:UB/P;X;TZ.W\,^&[K?=1QY*W
MM^&WB,DY+B-B)'))+2E03E'%<3J'QH\;P_#_ %GXW1ZPZV^E^+_L4>AB&/RG
ML5G2 JQV[_-.XONW<$ 8QD&I8>6-JS]BDG-QW_O?"M.LFKOHM%?<SHYI2R#!
MT%CY.<:,9M..J?LU^\GJTW"DGR0^U+67*_=:]QHHHKP3]("BBB@ HHHH ***
M* "BBB@#V;_@G5_R?K\&_P#LI6C?^ED=?TM5_-+_ ,$ZO^3]?@W_ -E*T;_T
MLCK^EJOTS@;_ '*K_B_0_DCZ1?\ R/L%_P!>G_Z6PHHHK[@_G8**** "BBB@
M HHHH **** "BBB@ KQG_@HK_P F%?&3_LFNL_\ I')7LU>,_P#!17_DPKXR
M?]DUUG_TCDKEQO\ N=3_  R_)GL</?\ (_PG_7VG_P"EH_FEHHHK\%/]* HH
MHH **** "BBB@ HHHH BO;VSTVSEU#4+J."""-I)II7"JB@9+$G@ #O7'?#_
M ,-7&L>.-4^,VLV;P2ZE:1V.C6TR%9(;!&+!G!Y5I7)?:>578#@Y%5_BYX(^
M+?C34[%?!OBS1[#3;-UFDM+^R>;[3,#E2X! *J<$+TW#)SA</\%^%?CK#XGM
M]1^(OQ(TV\TZW1V%CI6G& RRE=J[V/)4 L<>H4]J].E3IT\)*4:L5*2U6M[;
MV6EKMI=?+N?(XO%8G%9Y3I5,'5=.E).,O<Y')JW.[S4N6"D[+E;;UM=1+/QN
M\)?$;QIX)N]"^'OB>RT^6>!EFBNK(N;E3UB\S=B-6'!.QCSU%8/@%K/]I']G
MJ+3/%NE#3)9@UK<1V*!!;3V\F%>('.T!D4A>@Y7D5NV%A\?8[R]L]0\0>&)+
M26=S8WR64XG@C)^4-%NV.0/]H>^:WO!/@_2? 7ABU\*Z+YAAME8F68@O+(S%
MGD8C&69F9CVR>,"J==8?"*FI)SC)2BX[K1WN[*^O+:^JMVWRAEL\TSJ>*G3G
M&C4I3IU:=1^[)\T>3ECS2MHZG,XM1:DMWMR.I>'[WP5XGG^(=_J4.M>+-7LH
MM&T2".U-O"J F0C;O<[0VZ61L\*F  < MM/$]UX(UR3X6>#=)36-6M=(DUG7
M+Z^NC!Y\COCJJ-F21LX& J*% X %=/HOAO4)/%=[XQ\2-&T^&M=)@C8LMK:Y
M!)Y _>2, S'L%1>=I)P?$GP\\56/Q(O?B5X%-C-/JF@?V==VNH7#Q+'(K;HI
MPRH^X#)#)@< $'M50K4JLN2JT_=]%=6LM+625_67?0QQ. QN#IK$8*$H)U'>
MWO34)7<YVES-SJ34;WNXT[)*+3.D^'_C;2/B/X,T[QOH0<6NHVXDC20?,AR0
MR''=6!!^E;%<[\)?A_!\+?ASI7@*"\-Q_9UN5DGVX\R1F9W8#L"S-@>E=%7G
M8A45B)JC\%W;TOI^!]5E4L?/+*$L<DJSA'G2V4^5<R7ES7L%%%%8G>%%%% !
M1110 4444 %?T[?L9?\ )GWPH_[)KH7_ *;X*_F)K^G;]C+_ ),^^%'_ &37
M0O\ TWP5]WP+_O-;T7YG\X?2,_Y%. _QS_\ 24>E4445^DG\G!1110 4444
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MT?=:'1B,MP.*Q$*]6FG.%K/T=UZV>JO>SU5GJ%%%%8G<%%%% !1110 4444
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M# @D #J"..:OT5%?'8O$V]K-RMKKJ;9?P]DF4N3P6'C3<E9N*L[=KK4I>'=
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M<N-_W.I_AE^3/8X>_P"1_A/^OM/_ -+1_-+1117X*?Z4!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7].W[&7_)GW
MPH_[)KH7_IO@K^8FOZ=OV,O^3/OA1_V370O_ $WP5]WP+_O-;T7YG\X?2,_Y
M%. _QS_])1Z51117Z2?R<%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?AS_P<<?\ )^ND?]DUT_\ ]++ZOW&K\.?^#CC_ )/UTC_LFNG_ /I9?5\I
MQE_R)G_B7ZG[1X#?\EZO^O53]#X%HHHK\F/[8"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T6_P"#:K_D\'QM_P!D
MUF_].%E7[55^*O\ P;5?\G@^-O\ LFLW_IPLJ_:JOUS@_P#Y$D?67YG\0>.G
M_)P:O^"G_P"DA1117U!^/!1110 4444 %%%% !1110 4444 %?G3_P '*O\
MR9]X)_[*5#_Z;[VOT6K\Z?\ @Y5_Y,^\$_\ 92H?_3?>UXO$7_(DK^GZH^_\
M+/\ DX.7_P"/_P!M9^*M%%%?BI_H"%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 >S?\$ZO^3]?@W_V4K1O_2R.OZ6J
M_FE_X)U?\GZ_!O\ [*5HW_I9'7]+5?IG W^Y5?\ %^A_)'TB_P#D?8+_ *]/
M_P!+84445]P?SL%%%% !1110 4444 %%%% !1110 5XS_P %%?\ DPKXR?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?AS_P<<?\ )^ND?]DUT_\
M]++ZOW&K\.?^#CC_ )/UTC_LFNG_ /I9?5\IQE_R)G_B7ZG[1X#?\EZO^O53
M]#X%HHHK\F/[8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /T6_P"#:K_D\'QM_P!DUF_].%E7[55^*O\ P;5?\G@^
M-O\ LFLW_IPLJ_:JOUS@_P#Y$D?67YG\0>.G_)P:O^"G_P"DA1117U!^/!11
M10 4444 %%%% !1110 4444 %?G3_P '*O\ R9]X)_[*5#_Z;[VOT6K\Z?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7].W[&7_)GWPH_[)KH7_IO@K^8FOZ=OV,O^3/OA1_V370O_ $WP5]WP+_O-
M;T7YG\X?2,_Y%. _QS_])1Z51117Z2?R<%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?AS_P<<?\ )^ND?]DUT_\ ]++ZOW&K\.?^#CC_ )/UTC_L
MFNG_ /I9?5\IQE_R)G_B7ZG[1X#?\EZO^O53]#X%HHHK\F/[8"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T6_P"#
M:K_D\'QM_P!DUF_].%E7[55^*O\ P;5?\G@^-O\ LFLW_IPLJ_:JOUS@_P#Y
M$D?67YG\0>.G_)P:O^"G_P"DA1117U!^/!1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?AS_P<<?\
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M_P!M9^*M%%%?BI_H"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWH__ ,ET?\,1?M&_]"UH/_A=Z/\ _)=?F']D9M_T#S_\ E_D?U[_ *\<%_\
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MT#S_ / )?Y!_KQP7_P!#/#_^#J?_ ,D>3T5ZQ_PQ%^T;_P!"UH/_ (7>C_\
MR71_PQ%^T;_T+6@_^%WH_P#\ET?V1FW_ $#S_P# )?Y!_KQP7_T,\/\ ^#J?
M_P D>3T5ZQ_PQ%^T;_T+6@_^%WH__P ET?\ #$7[1O\ T+6@_P#A=Z/_ /)=
M']D9M_T#S_\  )?Y!_KQP7_T,\/_ .#J?_R1Y/17K'_#$7[1O_0M:#_X7>C_
M /R71_PQ%^T;_P!"UH/_ (7>C_\ R71_9&;?] \__ )?Y!_KQP7_ -#/#_\
M@ZG_ /)'D]%>L?\ #$7[1O\ T+6@_P#A=Z/_ /)='_#$7[1O_0M:#_X7>C__
M "71_9&;?] \_P#P"7^0?Z\<%_\ 0SP__@ZG_P#)'U]_P;5?\G@^-O\ LFLW
M_IPLJ_:JOQH_X(?^%+W]D#]I'Q1X^_:*UK0?#NDZCX'ET^SN_P#A)K&[\RY-
MY:R!-MK-(P^2-SD@#C&<D _J!_PW/^R/_P!%ZT'_ +_/_P#$U^H\*T*^'RB,
M*L7%W>C33W[,_COQES'+\TXYJXC!5HU:;A!<T)*4;J.NL6UH>KT5Y1_PW/\
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MS_LC_P#1>M!_[_/_ /$T >KU^=/_  <J_P#)GW@G_LI4/_IOO:^O_P#AN?\
M9'_Z+UH/_?Y__B:^+O\ @N!XT\#_ +7_ .S=X7\ _LZ^.]!\1:MIWCB+4+RT
M_MNWM/+MA9W49?==/&I^>1!@$GG., D>1GU*I6RBM"G%MM:)*[W70^W\-\7A
M<#QS@<1B:D84XSNY2:C%*SU;=DOF?C/17K'_  Q%^T;_ -"UH/\ X7>C_P#R
M71_PQ%^T;_T+6@_^%WH__P EU^1?V1FW_0//_P  E_D?W#_KQP7_ -#/#_\
M@ZG_ /)'D]%>L?\ #$7[1O\ T+6@_P#A=Z/_ /)='_#$7[1O_0M:#_X7>C__
M "71_9&;?] \_P#P"7^0?Z\<%_\ 0SP__@ZG_P#)'D]%>L?\,1?M&_\ 0M:#
M_P"%WH__ ,ET?\,1?M&_]"UH/_A=Z/\ _)=']D9M_P! \_\ P"7^0?Z\<%_]
M#/#_ /@ZG_\ )'D]%>L?\,1?M&_]"UH/_A=Z/_\ )='_  Q%^T;_ -"UH/\
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M=/,_E_QYSC*<XSK!SP&(A6C&FTW"<9I/F>C<6[,]7HKRC_AN?]D?_HO6@_\
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M_:E_9V^+/[(_Q+^&'P_^,>@ZAKGB#P/J>GZ18_;1%Y]S+;.D:;Y-J)EB!EF
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M'_\ DNC_ (8B_:-_Z%K0?_"[T?\ ^2Z/[(S;_H'G_P" 2_R#_7C@O_H9X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P 36[10!A?\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4
M87_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_
M]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\ \36[10!A?\*N^&?_ $3O0O\
MP40__$T?\*N^&?\ T3O0O_!1#_\ $UNT4 87_"KOAG_T3O0O_!1#_P#$T?\
M"KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1
M.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_
M /$UNT4 87_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &
M%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\ \36[10!A?\*N^&?_
M $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\ $UNT4 87_"KOAG_T3O0O_!1#
M_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\ 1.]"_P#!1#_\31_P
MJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]
M"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__
M !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\ \36[10!A
M?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\ $UNT4 87_"KOAG_T
M3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\ 1.]"_P#!
M1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_ ,31_P *
MN^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[
MT+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
M\36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\ $UNT4 87
M_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\
M1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_
M ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$/_Q-'_"K
MOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+
M_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\
M$UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_
MPJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.
M]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$
M/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[
MX9_]$[T+_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0
MO_!1#_\ $UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q
M-;M% &%_PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\
M*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$
M[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\
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M_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\
M!1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-;
MM% &?HWA+PIX<E>?P]X9T^P>1=LCV5E'$7'H2H&16A110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'4,=ORG]6J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9P & )K]FZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>amgn-20221231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 amgn-20221231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?FU_P<[_\ !4+Q_P#\$XOV%;/P_P# G7Y=)^(GQ6U2;1-
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M^"8W[+FJ_$E91XBNM7@EU\3+AQ>MHJF?<.Q\PMGWJ+_@OI;6T'_!K7^R+'#
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MZ\_;&^#/_!"OPA<V_@BS\!7T_P 9?C'\1-6EU.R6!+74OLVD^'K!#$THE(O
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M? /QIXA.D:!\6=1M=,GB#^9+&ES<:?;7LEY!;.T,H63RF+;1A/G3/2?\%O\
M]LJ?X;_\$F_'OQ#^ _A'QEXRLOB'\-M1AT7QO\.;:"ZL=%M+JQ)34[JX:>,P
MVK1R?+-$)&!((7O7PU_P4,MM(LO^#-GX:0PK'AO!7@9X< <3->6SOCWYDS^-
M:W['&L>/-9_X,S/%\OCJ2>00?#3Q?;Z)+<DEVL(]3NUB&3SM4AT7T1% X H
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MJ;1OVI?&NE_L6_LW_#'5OA9!K!7P3J6L7VD+=7%GL7#2";48W#;MWWD4\=*
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M]N,8%Y*Q/RU[S_P1E_:W\0?\%?\ 3?AC^V)XYTNX6W^"WP_;0]1DN;<I'?\
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M^*?[+/@;0O"&F:;9C2M9^'V@VL5M!X8U.)09[)8HU"K'EQ+&P4;XY4<@,S
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M&24EFD="&<LQ8DDU^(O[9<,,_P#P>D^#4GB5U'C+P@P#KD C0K4@_4$ CW%
M'Z7?LZ?\'$G[,'QO_;]'_!.OQ_\ L]_%CX4>.+^;R?#Z?$WP[%IYOIC!Y\44
MD(F:6V>:+#Q;UPX(!*LRJ?T"K^=+_@IFS0?\'A_P?DA.UF\7^ PQ'?(A!_3B
MOZ+: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!^*'
MPO\ AY\:OAYK/PF^+/@W3_$/AKQ#I\ECK6BZK;B6WO+>08:-U/4>_4$ @@@&
MMZB@#\S_ (*?\&^_Q+_X)_?%O7OB-_P2=_X**>(?A/H/B:99-=^''C?P9#XK
MT>X*D[ N^XMY8]@8A9"6FV_*92":^@]%_P"">'QH^,6NZ5K'_!1+]LF[^+FD
MZ)?0W]A\.O#O@R#PSX8FO(G$D4U]:QS7%QJ7ER*CI%/<&W#(&,)(&/JVB@#Y
M4_X*M_\ !)#]GS_@K'\)='\%_%;6=3\,^*/"5^]]X'\=Z"J&\T>=]OF+M?B6
M%S'&7C)4DQ(592H->7>/O^")/B3]L+]I[X:?M)?\%.?VJ-.^+<7PDL1'X1\&
M>&/AP/#FEW5WYB2/>:BLE_>M=/(\4+/%&8828479LW(_WY10!\1?\%D?^"-$
M'_!8?1O!W@CQS^TM>>"/#?@ZZFOK73]'\+1W=Q=7TJF-I9)Y)U&P1X58U0$$
MN2S94)R?[7O_  0IU_\ ;,_X)[_"?_@G1\2/VRIK+PK\*/[/%EK.E^ 8UOM3
M&GV,EA9"8O>,B[+>5P^Q1YC[6^7&#^A-% 'YZ?%7_@A3XC^+G_!+3PI_P2C\
M0_MG30^#/"U]$X\0VO@",:E>VD$OG6MM(3>&)?+E9RSJ@+JL2X4H[2XGQ8_8
M&OO^"9W_  ;Q_'G]C^S^-,GC;P]X<^$_BN;P[?7GA];&ZMH[J.ZNIHI2DSK,
M/.FD92%0J&(.[C'Z35YM^UM^RYX#_;-^!&M?LY?%/Q%XAL/#/B2$V^OP^&M3
M%G/?VI5@]J\NQF$3Y&X+M+;0"=I92 ?A;_P:\_LF?M2_'_\ X)Q?%J^_95_;
MQUCX.:CJOQ%O-"UF*7PA;:]I\]NVE6)2YAMY987M+U/.D N(I0&4H'1_+C*?
MJO\ \$G/^"+_ .SC_P $H?V>O$/P:\":Y?\ BS6O&[*WCSQAJD"VTVJ!(WCC
M@CBC8_9X(UEE*)O=@TTC%VR,=3_P3T_X)/?LR_\ !,'3]7\.?LH:_P"-+#0=
M>N_MFJ^'=9\0B]LYKORUC%P!)%O20(BKE' ( W X&/IN@#\I/V./^#4CX!_L
MF_$/QMJ _;:^+NJ>!_&5A+I]]X T/5WT*"_LF#B.#4Y[27=J"QB1B!MA1B2&
M5D9T;UC_ ()!?\$&]._X)"^(?'>M?#C]L;Q5XLL_%RH;/P]J>APVFG6TT2RK
M!<7*12&2\EC65U^62&,AV)3<(VC_ $#HH _-G]D'_@WPU+]C_P#X**:]_P %
M)_#/[:]WK?C#Q=K&KWWBO2=5^'\2V-Z-4N3<7B1B.[5X3O;,;!FV%5R'&5;[
M)_;L_9DU_P#;,_96\8?LMZ/\4D\'VOCG2)M(UW6AH8OYET^:-DFCA1IHU21@
M0/,;>%7=A,D,OKM% 'YV?L5_\$![3]BO]ASXW_L#^&?VM+S7?"/QHT#4[:6]
MU+P7''>:+J%Y8"Q^V1M'=!98UC5&,+*"S(I$B?,&L?M"_P#!$3XS_MF_"[P)
M^RQ^V;_P4&NO'_P@\">)+36(]/E^&\-IXIUHVT,L$4%[K*7C1LHBF=6ECLXY
MI-Q+.6^<_H710!\E?\%1?^"/'[-W_!4'X/>&? /C+4+[P7XC\ W(N/AWXT\,
MP1_:-";" PB)L++;MY41,65.84*LA'/G?C7_ ((F^(/VM_VKOAQ^U/\ \%,_
MVHM-^+3?">P6+P=X,\+_  Y'AS29KH2K*UY?I)?WKW3N\<3O&C0PDQ(NS9N1
M_OFB@#X8_P""R7_!%6U_X+%KX,T#Q_\ M-WO@KP]X(>ZN-/TS1O"D=U-<7=P
M$6266>6< J$C0*BHN"7)9L@+QG[<O_! ;5?V^/V2_@S^R!\6/VTKNPT'X-:3
M%:6%_H_@&);G5I(;<6D,]P7NV52MLB*50 ,YD?@,J)^C5% 'F'[&'[/FO_LG
M_LN^!_V9M;^)">+(O /ANST#2-;_ +&%C++86D"06RRQB616D6.-5+J5#8SM
M!SD_;)_9 ^!W[>'[./B7]EO]HCPX^H^%_$UJL=Q]FE$=S:3(P>&ZMY"#Y<T4
MBJZM@C(PRLI93Z?10!^9GB'_ (-]_BQ\3?V/_!?_  3;^-'_  4/GU?X!^"-
M?COK+1M)^&,=CXEO[6*25X+"XU5K^6 Q1&4[62R1CA,D[!7U-^U!_P $\_#W
MQC_8'N/^"=7P*\8V/PP\!WGA9/#4HLO#IU":VTI45?)M]]Q&$D8+AI9!*S;F
M/WSO'T;10!\<?\$>O^"35Y_P2%^%7B#X#^"_VC9/&WA#7O$4NOM:ZOX36TO+
M;49+>VMV9)X[EE,1BM8P8VC)W#(<<@_7NMPZU/H]U!X<U"UM-0>W<65S>V;7
M$,4N#M9XEDC:10<$J'0D<;AUJU10!^4WQ9_X-C[WXQ_\% S_ ,%+/$O_  4!
MU>W^)*>-M.\4VOV#X=6RV%M>6#0&UC6%[IB8D%M"NUG8LJ_,Q))K]1_"%IXO
ML?#=K:>/==T[4]71"+V^TG2I+&WF;<<%())YVC^7 (,KY()XS@:5% 'P+_P6
M0_X(9VG_  6/\4>"[SXF_M37W@[0_ ,%\OA_1]#\(QSR-+>?9_M$L\\MP/,)
M^RQ!0J(% /WB2:^Q_P!GGX;>*_@Y\$O#'PG\9^.[?Q-?>&]&M],_MV#1_L'V
MR*",11.\/FRA9"BKO*L%9LE50$*.SHH ^7?V'?\ @E3\"/V%/VG?CU^T[\,Y
M%EU+XX>*X=6>S-D(UT2 (9)K2)@QW+)>S74YP$ 5X8]I\D,VC_P5&_X)@_L_
M_P#!5S]FQ_V>?CK-?:;+9:@NI>%_%&D!/MFC7RHR"5 X*R1LCLDD3<.IX*LJ
M.OTC10!^;?\ P3V_X('_ !B_9#T72_A)\>/^"H/CWXJ_"3P[?+=Z'\(4T%=(
MTAY$E\V..[)NKF6>U$F)#9JT<#N/G5U+(WZ2444 %? ?_!7+_@B)XC_X+!77
MAG2_C3^U\?"_AWP9?7USX=T;PMX!7S";GRU+7,\]ZYFD5(E4%%B7ECLYX^_*
M* / /^"=?[&_Q#_8*_9T\-?LL:C\>;/QQX5\':4UCX>N;CP?_9^I)'YI=5FF
M2[>*55#,H A1L;26)!SD_P#!4W_@EQ^S]_P5A_9P_P"% _'*YOM*N-.U :EX
M5\5:0J&\T:]",F]0XVR1.C%9(FP'&""KJCK]*T4 ?G!_P3S_ ."#'QC_ &0]
M&T?X4_'[_@I]X]^+/PI\,7R7GA[X2#05TC1S+'+YL279-U<RW%LD@$OV0/'
M74;U=<HU?_@H#_P;?_##]N+_ (*$:;_P4+\/?M>^/?ACXEC&GOK">$8(_M3W
M%E&D,%S979=6L91%'&I.R490, "2#^D]% 'YAZI_P;(?"+3O^"C&A?\ !0;X
M4?MI_%#PSJ&G-!/K%E-=?VGJNI7:VGV2XG_M:\D>6-KB+?YA,;L&E<Q-$-@3
MI/\ @K-_P;]V/_!6?]H;P_\ ';XC?M>ZGX2B\(Z0FG>&-$T/P=#,+=!*9GDF
MEEN"9I&E).0J*%5%VY#,WZ,44 9?@JP\7Z9X5L=/\?>)++6-8A@"W^IZ=I36
M4-RX)^=8&EE,>1C(\QAG)& 0!J444 ?&?_!4O_@AI^QE_P %5CI_C/XJ6VK>
M$_B'HENL.B?$;PA,D.H1Q*Q=(9U=2ES$KDLH8!T).R1-S9J?"K]B+_@L'\.?
M"UK\-=5_X+*Z-KVD64 @M_$.K?L]VDWB P@ *&N'U(PR2@?\MIH968C+AB37
MVO10!Y1^RM^R!\./V4=(UJ?P_K^O^*/%?BV]COO''Q \8Z@+S6?$5TB%(WN)
M0J(D<:$I%;PI'!"I(CC7<Q/PKHO_  ;<ZC\'?^"BOC']N3]C[_@H?XR^$FE_
M$-[\>+_"GA[PG9W-Z]O?7"7-Y;6NH7$C);1O,BR1L;9Y("B[&) (_4&B@#\V
M?^">W_!NEX/_ .";?[=6K_MJ_ []K#6;X:ZFI6>H>$_$/AH7,;:;>7*7#6XN
MC=><94:*+;.^]B4RZON()^U3_P &]U[^U+_P4ITK_@IUJ_[:U]HWC#PUXATG
M4O"^BV7@*&2PLTTR5)+2&0/=[YQF,>8VY=Y9RHC!"K^DU% 'YN_\%&O^#?&?
M_@I!^V;X;_;5^(?[:%]X;UWP;I>FV'AC3-!\"0M;6L=E=2WD;.9KIFE8W$\K
M$D@8*KC"Y+O^"L'_  ;[3?\ !7?XF^%/B3\=_P!LBZ\/GP?X<73-,TWPMX#C
M2%I'VO<W#&>\D8F24$JN<1H$3+LK2/\ I!10!\M?\%&?^"8?AC_@I_\ L+K^
MR#^T?\4)4UFWNK74].\=:'HH@-MJUNDD:7@LWF=2K1RRH\7F %97VLAVE?CW
MQ'_P:\^(/C!^P_X5_8P_:2_X*>^/?%MCX"U&*3P(UKX3M;'3-"LU68/ EDLS
M-<RMYH N+B>5HXT\N)8U=PWZST4 ?$NG_P#!(CQEIO\ P2;?_@DW;_M9@^'7
MTV31?^$P;P(AU :,\IF:V\O[9Y7G;V*^?C'E?+Y>_P#>UR?[%G_! GP1^R7^
MP7\6?^"<.N_M*:KXO^''Q8-Y<WKOX<CL-3TR^N;:WMFGAG69T90EK"PC>(C>
MF22I93^@U% 'Y.?L]?\ !J%\%/A'^R_\0_V7?B!^W1\6O%&@^.4:6TT?3]0?
M2=$TV_&SRM1?3(IGCO;E/*B&9F*%4'R!EC=/IW_@DK_P2&T3_@EQ^S=KO[-E
M]^T?XC^)NC:[>7$K6.L:=%8:?91SKMF2&VC9V#2C&]Y)7^Z @CR^_P"QJ* /
MS;_X)Y_\&ZOAW_@F]\?_ !7XW^"'[<OC]/AKXKU2QOM2^%T>E6D!O38S2364
M-WJ0W3RPQ/*^5A6W,RDI*TB,Z-!\1_\ @WKUOXC?\%0X_P#@K)=_MO7%K\0[
M;Q%8ZK9Z3%\.XSI,8M+6*TAMVC-[YK1F"%4<^8'8EF#*2,?I710!R7QQ^"W@
MC]HOX(^*?@%\5].2_P! \9>'+O1M<@1=N^"XA:*0IG.Q@&+*>2K $'(S7FO_
M  33_81\"?\ !-G]C#P9^R%X#U@:LGANUE?5M>-D+=]6U">5IKBZ:/<^S<[D
M*I9BB*B;B%%>[T4 ?GK_ ,%CO^#>OX&?\%8/'.A?'K1OC#JGPM^*.@64=E'X
MNTG2EO8;ZVCD,D*W%OYL+&6)V;RYDE1E#8;>%0)[!^P5_P $YOBK^S->V?Q
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MH **** "BBB@ HKXP_X+7_\ !8[X9?\ !'O]GO3/'VK^$/\ A*_''B^\FLO
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M)Y(8(V<QQJ2 TC8"J"0-S#) R1^5_C'_ (+Z_MW^-_\ @EOK7_!83]G'P/\
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M5D#('7YJ^R_V?OC]\(OVI?@QX=_:#^ WC6U\0^$?%6G+>Z)J]ID+-&25*LK
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M\DL5\1PZW<W5M=:;#>J#:W@,1*M"SO'"P(#*\L>-P8[;?[%/_!4+XB?M;?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A-^SY=77B+2KU;S0'\3>([O4K?29U)*2P0S.4,B$Y220.Z'#*RMS0!\P_\
M!:__ ((J? /_ (*N^.V\-_LM_$-/"G[0OPG^&>C,NA^)=Z6WB+P].UTMBD[-
MF6.9)(+B/[1M.UB(Y5PT;QYO_!J+^V=^W#XVU'XR?\$[_P!LZ75]4N_@7/:V
MEA?Z[-Y][HLHN+BUGTF>?+><B/;DPDLQ58Y%5FC$83]$?C[_ ,$R?V6OVB?C
MZO[5?BFW\7Z'\3+?PW;Z#IGCGP3X[U+1=0L+"*6XE\F-K29$97:YDWK(KJX"
M9'R+CI/V0/V%OV:?V&/"^M^'?V>O!$]E<^*M:DUCQ?XAU?5;C4=5U_4)"6>Z
MO+RY=Y9W)9SRVT%W*@;FR ?A+_P9S:]H7@C]M+]I+5_&6MVFDV>F>!A<:C=Z
ME<K!%:PQ:DQEED=R B(.68D!1UQ5K_@Z495_X+Z?LSDL!CP?X3)R>G_%4ZE7
MZ]Z9_P $./\ @EYHW[6-W^VGI7[+EC;^.K[4CJ5Y)#K-ZNG37QE68W+:>)OL
MK/YJK)@QE/,42;=X#5/^U#_P1*_X)I?MH?&\?M'_ +37P%U?Q3XUCA@AM-<G
M^)OB.W:RBA=I(H[>.WU"..V1'=W"1*BAW9L;F)(!^/O_  >]$#]HKX!9(X\'
MZQG_ ,"[>O1?^#Y C_A!_P!FT9'.J^*L?]^M*K]/OVL/^")__!-?]N;Q?I7C
MS]K3X%ZUXXU71-&ATK2KK5_BAXD MK6-0 JI'J"IN;&YY,;Y7R\C.Q+&7]J#
M_@B[_P $YOVU+;PM:?M5?!KQ#XYC\%:6VG^&$USXK>)G%C"VW>1MU$;Y'\N/
M?,^Z1Q&@9F"+@ _*'_@ZV\">.M8_X)5_L?\ Q'TFUGE\.Z+8V]GK4D8)CCN;
MK1;1K5GQTRMM<@$]VQWKZ>^$7[&G_!('_@I#_P $Q_A_^UI^T]\8_B+XS\(:
M+X8M;O6++Q3\<M?U"+P]K*VZ0W5FEL]VYCN1+F%(8UWR[HQ&K"1,_H?J_P"P
M_P#LN^)OV4U_8B\:?"\>(_A@NCQZ6OAKQ3K-[JI%K&08D^U7<TESF(JOEOYN
M^+8FQEV+CYW_ &2?^#=G_@E'^Q=\:;7X_?"#]G^ZNO$FEW@NM G\3^(KK4H=
M)G7.R6"&9S'YB9RDKAY$/*LIYH _+G_@]JT[3]'\1_LQ:1I23+;6OACQ%#;)
M<EC(L:OI:J'W_-NP!G=SG.>:U/\ @]=93\//V1<,.=,\6$<_],= K]=?VT/^
M".G_  3L_P""AGCZQ^)G[8_P+U'QKJVEV7V32VN?B#KUI;V4)(++#;6E]%!$
M6*J694!<J"Q) K._:4_X(E?\$U_VP[/PEI_[3GP0U_QI#X%T3^R?"D>M?%7Q
M,XT^U^7<%QJ(WNVR,/*^Z1Q&@9F"+@ ^,?\ @YRAEG_X-\?"$L2%ECU;P>\C
M 9"K]E89/XD#\:^B_P#@VW\2^'(O^",'[/?AN77[)=1O?#FM36=@UT@FGB@U
MN[29T3.YEC:6)7(!"F1 <;AGZ;\4?L3?LR>._P!E-OV)/B#\-F\2?#-]&CTM
MO#WB;6[W4I#:QL'B4W=S-)=%HV5#')YN^,QIL9=BXY3]A?\ X)>_L2?\$X=(
MU#2OV2?@\= ?51LO;^_UJ[U&Y:+>7\E);N61H8MQW&./:K, S L,T 7/^"G?
MPQ\?_&C_ ()R_'3X3?"NVGN/$?B+X3:_8:+9VV?,N[B2PF5+=<=Y2?+'^_7Y
M2_\ !GGXBT7P[_P37_:.?4[A(9M)\83W>HI*=IB@_L=,,P/09BEZ_P!TU^YU
M?)GQ _X(I_L)>-/'/CKQYX:\.^+_  ++\4X&A^*&F?#GQYJ.B:?XLC;?O%[:
MVTJQ,6\V7<R*C-YLFXGS'W 'Y8?\&/GPN^(%O>?'_P"-$]C<P^%;J+0]%MKE
MU(BO+^(W<\BJ>C-#%+&6]!=)ZUR?_!FVRG_@HC^T. PY\'L1S_U%UK]Z/A#^
MR5^SU^S]^S];_LN? CX=1^"_!%I8R6MMI7A74;G3YHEDSYDBW<$JW(G8DL;@
M2>:6.XONYKQ7]EO_ ((A?\$S_P!BCQYJ7Q._96^!&M^"=>UC1;G2=3U'2/BG
MXEWW-I.N)$8/J+*2#AT?&^.15D1E=58 'Y _\&GK _\ !:O]I,!ASX/U\CGK
M_P 5'95_1=7RI^RG_P $3O\ @FI^Q!\9W_:%_9:^ FJ^$_&$UK-;7FKV_P 2
MO$5S]L@E=9)(KB*YU"2*X1G1'*RHPWHK8W*"/JF6-9HFA<L ZD$HY4X/H1R#
M[B@#^7?_ (.YW4?\%J/"Y+#Y?AMX=W<]/]/O:_>?_@M'^U;X!_8[_P""8_QA
M^*7C?7[:SN;[P1J&A>&+::4![[5KZVDMK6&->KG?)YC!<D1QR.>%)',?'[_@
MW^_X)/?M4?$R[^,O[1G[..M^,O%%[%'%<:WKWQ;\4SS&.-=J1J3J>$11T50%
M&3@<FNC7_@BO_P $U;_Q5I/C+Q[^SY>^.[W0E"Z,GQ2^(&O>+;>R48^6*WUF
M^NH4' X"8X'I0!^4W_!GM_P3A^,OA[PQ\4?^"@'BS1+O0+?Q=X+F\(?#*YO8
MFB:_265)[J^0$ ^2LMM:QI(,AF68 _)SX5_P:KZ+\))/VI?B[^Q)^TK\7_B-
M\.O&>J"T;P[I7A;XH:IX8:]O]/FNH;ZQF6RN(A<W*^<C(C[F589]O\5?TX6%
MA8Z58PZ7I=E%;6UM$L5O;V\82.*-0 J*HX50   . !7Q7^V)_P &]'_!*W]N
M'XU7'[0OQF^ =S:^+=1G6;7-3\+>(+G31JT@_CN(X7$;2''S2JJR-U9R<4 ?
M)'_!1[_@F9^QG^RS_P $;_VOO@1_P3 \-ZHNK6\?AS4?B9I\.O7VII'_ &?J
M$%]+ 99W=4FBLO-GEA1MZQM$9% D3-O_ (-)_P!K?]G_ ..W_!,&Y_8=\?ZK
MH%QKWP[UK5%U'PEKIA?[?HUY</?+=>3+D30B6>XC?@A#&N[&]2WZE? #]F7X
M!_LM?!?3?V>/@#\+=*\->#-*MWAM-!LH2T1#DF1I6D+/,[DDO)(6=R26))KX
MZUO_ (-@O^"+NO?&=_C1<_LIM"\MZ;R;PQ9^)[Z'1GF+;L_94E 1-W/DH5BP
M=NS;\M 'P7_P>2PZ/\5OV1_V<?C?\ K^RU/X9Z-XH\0Z*=0T!0=.6X>.VBME
MB* (8P-/O41E^0A<H2I!/TQX*_8L_P""/'_!1[_@G-X!_;%_:8^+_P 1_''A
M"P\.V]W<VWBGXY>(-3&AZN\,<5S81V[W;LMWYP\A8(U,DK>6L:OO3/Z-?&/]
ME#]F_P#: ^ %U^RQ\7O@SH.L?#R[TV'3V\)O9"&T@MX0HA2!8MIMS%L3RVB*
M-&44H5(%?,W['W_!O)_P2J_8A^,UM\??@S\ KJY\3Z;<_:-!O/$_B&ZU*/2)
M1G;);PS.8Q(N?EE=6D0\JRGF@#\MO^#WFW@L_B#^S=96QD,</AGQ"D?G,2^T
M2Z<!N+<YXYSS7=_\'J[*?V;OV9B"#G5=9(_\ ["OU,_;/_X(X_\ !.K_ (*%
M_$&R^)_[8WP*U'QKK&FV7V33'N?B%KUI;V4/!98;:TOHH(MQ +%$!<@%B2,U
M!^TQ_P $8?\ @G1^V1H'A#PO^T_\&O$'C33_  %I;:?X3M=9^*GB5EL86V[C
M\NH@RR,$0--)ND98T4L0B@ 'Y>?\'.#*?^#?_P#9-PPYU?PF1SU_XI6\KT[]
MMLY_X,OM%.<_\6:^'_\ Z>='K[S^-G_!%W_@G-^T?\&_!/[/OQR^#7B'Q-X,
M^'5J+?P;X?U/XK>)F@TZ-4\M.FHAI2D?[M&D+M''\BE4^6NFU3_@F!^QEJW[
M$\G_  3NNOAUJLGP@EELBWA2\\9:I>%8;6]M[V*V2YNKF2XC@\VVC'E)(JA=
MP7;N- 'YZ?\ !!SQ/X?\.?\ !KKXZ\0:Y>PI9:5X9^(,NHM(XVQHL5T[!O3Y
M2#CW'K7Q[_P;U_LH_'GQ+_P1._;Q^(7@_1+]H_B1X%DT'P?;11L'U2XT[3-2
M>Z2$?Q[Q?QP C@N&7.5('['^)O\ @AO_ ,$^];\.ZY\-_#7@_P 6^#_ /BJZ
MBN?%WPO\"^/]3T?PUK4J+&NZ;3[:98T++%$'\GR_,\M2^XC-?3?PC^$7PP^
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M;ZP\%76H!+R>%@2H4'Y3(RJ7$6[S"@+!2O-?C!_P<U?\$J/!?B?]O_\ 9O\
M''[&W@JWT7XE_&SQ?<Z3KNFZ!;B$7<]K):S#62D8 1HDFD:XGQC;&CL<AF;]
M.OVZO^"'7_!.W_@H?\5['X]?'_X6:I!XYL+>""+Q;X5\1W.FWDD<)S")/*;8
M[(?NR%/,4  -A0!ZM^SQ^P;^SM^S7XC'C_PGIOB+Q#XN_LH:9_PG'Q#\8ZCX
MCUE+('=]EBN]1GFDMX"0&,,)CC9@&*EN: .X^/<B1? OQI+(X55\)ZB68G@#
M[+)S7X(?\&.;H/B7^T9&6&XZ%X:(&>2!-J.?YC\Z_>3X]?L\_#+]I;P+=_#7
MXM+XAFT2_LY[34++0?&FJZ+]K@F79+%*^G7,#R(RY4JQ(PS#^(Y\'_94_P""
M(G_!-+]A_P >S?$S]D[X&Z_X&UFY@2"]N-&^*WB81WD2N)%CGA?46BG0, =L
MBL.O')H I_M_?\%P?^"?G_!-'XU>%?@'^U+\0=7L?$'BFR2_$>D:%)>1Z78O
M,\*7=VR'*1L\4H 022?NV.S&"?K/2-7TKQ!I-KKVA:C!>65];I<6=W;2AXYX
MG4,CHPX964@@C@@U^=__  78_P""9W[+7[?6GV.EP_LWW'C#]H;4_#QT'X?Z
M]:7=_;6OA^REG;=J>J30.L"VEH9+B>-)]S2R@Q1)(9&6OO/X-?#33/@O\'_"
MGP=T6^EN;/PGX:L=&M+F<8>6*UMT@5V]R$!/N: /"O\ @J]_P4W^#?\ P2R_
M99OOCG\2-4L9=>U&4Z=X$\.7,K@ZMJ3#Y=PC5I!;1 ^;/(JDK&N%#2/&C?G-
M^PA_P6"_X(P?L(_"WQC\1/#7[5][\=?VF?BQJ3:MXXU33_A[KEA/XKUZ8M]G
MTRUEO+&**SL8Y)!%$K, JDN5R0B_HS^VK_P1X_X)V_\ !1+Q_IOQ-_;)^ ][
MXTUC1],_L_2I)?'FN64%I;[RY6.WL[V*%"S'+.$W/A=Q.U<>9?#S_@VO_P""
M*7PJ\?Z%\4/ G[%:6>N>&]8M=5T:[D^(7B*=8+NWE6:%S%-J#1R!713L=65L
M88$$B@#\V?\ @\5^ 'B7PI^UQ^SO^W#=Z:QT&;3X?"VMW\0)ALKFRU![^%'8
M@8\Q+NZ*YZBV?@8K4_X/(/AEXQ_:%_:S_90_9^^%NG'4O$WBF+6-.TC3X<LT
MDUW>:=#$2!G"E@<MT 5CV-?M_P#M(?LT? G]KSX.ZO\  ']I'X9Z=XM\(ZY$
M$U'1]21MK%3E)$="KPRHV&62-E=",JP->6_ '_@EC^R5^S]\8K#]H:RTSQ1X
MQ\=Z)H2Z)X:\6?$GQC>Z_>:#IBA@+2Q:[D=;9,.X+(HD8.X9V#-D ]%\8>"M
M+^%G[(FJ?#K3)R;+PY\-Y]-MY7&,Q6]@T2D^GRH*_"O_ (,<W0?$O]HR,L-Q
MT+PT0,\D";4<_P Q^=?O)\>OV>?AE^TMX%N_AK\6E\0S:)?V<]IJ%EH/C35=
M%^UP3+LEBE?3KF!Y$9<J58D89A_$<^#_ +*G_!$3_@FE^P_X]F^)G[)WP-U_
MP-K-S D%[<:-\5O$PCO(E<2+'/"^HM%.@8 [9%8=>.30!]7U^9'_  28_P",
MV/\ @K?^UK_P4XO/]*\/^&M7@^#WPONOO1_9-.V2:C)$3_#),EM,I':Y<<=*
M_3#4['^T]-N--%Y/;_:('B^T6LFR6+<I&Y&YPPSD'L17EG[$G[$WP$_X)]_L
M_P"G_LU_LWZ'>V7AO3[^[O0VIW[75U<W%S,TLDLTS<R-E@H)Z*BCM0!ZU111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%>)>!=4U.7]O3QWI$NHSM:0^"-+
M>*U:9C&C&1LL%S@$]S0![;1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7A?@'_ )2">/\ _L1-*_\ 1C5[I7A?@'_E()X__P"Q$TK_ -&-0![I
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7SY_P5 _X*&?#;_@E_\ L<^(_P!K3XD:!<ZT-,DALM"\/6DX
MBDU;4IVVP6XD((B7AG=\-MCC<A7("M]!U\U_\%9_^"<_A/\ X*E?L3>(_P!E
M#Q%XI;0+Z[N(-3\,:^L'FKIVIVY)AD>/(WQL&>)P"#LE8J0P!H ^4_ ?[27_
M  68^.'QY\"2?#+]HKX)6M]XX_9GD^)>D?#Z?P!=S^'2SZA8QP64NH)?_:WE
M,5T ;Q,1 A@+4@AQ[;\-O^"H7QR\3_\ !-*+]JGQ/^Q]?1?&>[\3ZEX+TOX*
MZ3J?GRW_ (IM-2N=/-J)V51%"&M9KB5VR(8(9F+N$W-^#?P _:I_X*/_ /!L
M[^WAI/@[]L7X47/BO0K#PI>:!I.CWVM22V4WA^YOX;J6?1+OE(P9[=)/+9,*
M6D5XXG<LO]+7[#?[5_[.?[;_ .S7H/[3W[+E[%+X6\5-/=&(V2V]Q:WID874
M-U$N=EPLN\.<L&)WAG5E9@#\*?VS_P#@LK_P<Y?\$O?C?X<^(_[<?@CPCI_A
M+Q/=/+I?A"WT#2[G1+E$(,MFE]9-)=12JK# DN"V,-AU!S^]_P"R1^T?X2_:
M_P#V8O 7[4/@6QGM-*\>>%K/6;6RN6!EM//B5V@<@ ,T;ED)'!*$C@BOS'_X
M.@/!/B[_ (*"^.?V?_\ @D3^SEI\.J?$/Q1XS?QGKDVW='X9T2VMY[+[?>,.
M8H&-U.P[N;78H+LBM]Q_$SXC_![_ ()"?L#>#OAWX7L#J[^&M'TKP/\ #+PW
M->1V]QXEUCR1!:6[2.0D7F,C33S-\L4232MPAH ^7?\ @Y#_ ."X.J?\$Q/@
MQ9?!;]F;Q!;+\;/&2)-8WCV<-U'X7TW>P-]+%,KQO+*8Y(X(Y%*MLE<@B+:_
MTSKG[?FD_LQ?\$B=#_X*%_M(7\FKS:=\&]$\0ZYY"16\FKZI=V5MLA0(HCB:
MXNYTC&U0B&7A0!BOQ<_X.>/A)X/^%/[%?PDU76_C+X=\?_%CQO\ $W4O$'Q;
M\6Z+J$4WV[47T^-$AA569H;"UC5;:UB. D40)^=Y&;Z$_P""]?Q 6Y_X-?O@
M?:^"=?MKVTOHO .F:VUC=+(J"/16F,3E2<,LT,.5/((&10!OS_\ !4S_ (*A
MQ?\ !&V+_@N^OQQT(P/XSWO\#/\ A#;+^P%T'^W3HHA^U^7_ &C]J\X"3S_M
M.S!QY5?J3^PK^U]\//V]_P!DCP+^UU\+K:6VTCQMHHNQ83R!Y+"Y1VAN;5V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU5;NYA0E;73X$6+%M96T06.*!20 NYBS$M7ZM>%/V%K;_@O=_P $K?A9K_\
MP4YU+Q7X?UW7/$]]XX&E^"KB+3CI@EFO8+*R5;N"<B&.QFB&&&]G&XL23G](
M** /YA?^#A'_ (-]?V<O^"9_PB^'?C;]B^+XJ>*M2\3^)+NQUN#7+F'4E@@C
MMUD1E6TLXBA+$C+$@^E?HYHW_!#OP?XV_P"#<%_V(O@'<ZP?$_C?PSI?Q"TM
M?%EW%OA\3R6ME=O:JPBC$,+M$UN-X)C$S%F.*_5ZB@#^=2X^,VEWW_!L O\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
MX0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_
M )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC
M_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]
M_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F
M]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+
M:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ M
MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV*
M* ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/
M^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_
M .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](
M_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!]
M(_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GY
MO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_G
MYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\
M"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P
M+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:M
MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:
MC_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q
M_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?
M2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0
M?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y
M^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_
MY^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?
M_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_
M\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"V
MK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "
MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
M,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$
M'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^
M$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/
M^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2
M/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;
MW_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO
M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VK0TW3H-*M1:6[R,H8G,KE
MCS[FK%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?
M@'_E()X__P"Q$TK_ -&-7NE>%^ ?^4@GC_\ [$32O_1C4 >Z4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5X7X!_Y2">/_ /L1-*_]&-7NE>%^
M ?\ E()X_P#^Q$TK_P!&-0![I1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7A?@'_E()X__P"Q$TK_ -&-7NE>%^ ?^4@GC_\ [$32O_1C4 >Z
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5\^?\%0/^"AGPV_X)?\ ['/B/]K3XD:!<ZT-,DALM"\/6DXB
MDU;4IVVP6XD((B7AG=\-MCC<A7("M]!U\U_\%9_^"<_A/_@J5^Q-XC_90\1>
M*6T"^N[B#4_#&OK!YJZ=J=N289'CR-\;!GB< @[)6*D, : /E/P'^TE_P68^
M.'QY\"2?#+]HKX)6M]XX_9GD^)>D?#Z?P!=S^'2SZA8QP64NH)?_ &MY3%=
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M)TZ.&[MW)1W20AP,CJ-P_.@#Z:HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
MTJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\
M,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@
M#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$
MQ\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]
M!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
MTJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\
M,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@
M#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$
MQ\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]
M!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
MTJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\
M,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@
M#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$
MQ\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]
M!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
MTJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\
M,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@
M#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$
MQ\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]
M!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
MTJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\
M,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@
M#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$
MQ\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]
M!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
MTJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\
M,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@
M#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$
MQ\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]
M!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
MTJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\
M,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@
M#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$
MQ\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]
M!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
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M_P 7/B3:W/C#PYI$D#6MMI=U%JDMSIFG1B4[HHVLXXK8O(21Y[NQ))K]-J*
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MJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\
MGQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0
MH_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__
M )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ*
M (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQ
MA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_
ML[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y
M\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (
M?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_
M[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[
M3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8
M?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[
M.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]
M"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_
M /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^
M_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T
M_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"I
MJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\
MGQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0
MH_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__
M )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ*
M (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQ
MA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_
ML[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y
M\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (
M?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_
M[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[
M3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8
M?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[
M.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]
M"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_
M /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^
M_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T
M_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"I
MJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BF?:(!.+4S)YI3>(]PW;<XSCTSWI] !111
M0 4444 %%%% !1110 5X7X!_Y2">/_\ L1-*_P#1C5[I7A?@'_E()X__ .Q$
MTK_T8U 'NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
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M>37C/PQ\.^'])_;Y\>V&E:%9VT">!M+*0V]JB(I,C9( &!G _*OH&O"_ /\
MRD$\?_\ 8B:5_P"C&H ]N_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP_M3:0%;Q'_PCX\2_P!F7W_"/'5L9^P?VUY']F_:,?\ ++[1O]J^DP01D&@
MHHHH *\+\ _\I!/'_P#V(FE?^C&KW2O"_ /_ "D$\?\ _8B:5_Z,:@#W2BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4_P:U^6EF.99]+V>7?NZ/6JUJ_\  OU?X,^8?V7_ /@DC\2OC=XP_P"&C?\
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M$J<8;)(_W30!]345C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q2.Z1H9)'"JHRS,< #UKRS]H#]KOX6_LP^#3XW^,]P^E6S
M[EL[9I$:YO9 /]7#$#ND;D9QPN<L0.:_/SXA_M+?MR_\%9_$MY\+?V<O"%YX
M5^',4OE:K.LS)')&?^?VY4?.2#D6T>1@\A]N\?+Y[Q5@<FJ+#0BZV)E\-*&L
MGYO^5>;Z:I.QXN9YYALNFJ,4ZE:6T(ZM^O9>;_$]V_;5_P""QG@KX9:A+\'_
M -D^QA\;>,IY?LO]IVZ-/86<S':%C"<WDN> J?)DC+,04KSW]FO_ ()1_&3]
MI/QHO[2/_!1KQ?JEU<WS+-'X5ENR+N=,Y5+ATP+6( \0188 XS&05/T%^Q7_
M ,$_/@[^QKI\6M:7X"N_$/C%XMMWXKU.&/S$)&&6VCR1;IU'!+D'#.1@#Z)_
MX275_P#H4+W_ +Z6O'PW#&8Y[7CC.(Y*5M8T(_PX?XOYY=[Z;[K1>?1R7%YG
M56(S>5[:QI+X(^O\S_#U1+X.\&>$_A[X9L_!G@;PW9:1I.GPB*RT[3[98H84
M'954 #U/J22>:TZQ_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:^^A"-.*C%6
M2V2Z'U,8QC%)*R1L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2U0S8HK'_
M .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7
M_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=
M7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BO$OVK/^"??[-7[7MC)<_$7P<MEK_E
M[;;Q5HP6"^CP,*';!6=1_=D# #.W:>:]5_X275_^A0O?^^EH_P"$EU?_ *%"
M]_[Z6N3&X#!YEAW0Q5-3@]U)77_#]GNC#$X7#XRBZ5>"E%]&KGYDZM\ _P#@
MI-_P2FU.?Q7\"?$LOCOX=QRM-=V4-J]Q;JG4M<66XO;M@9,L#8P!N<?=KZ:_
M9$_X*_\ [-_[2'V7PIX\NT\">*I<(+#6+H?8[J3I^XNB N2>B2!&).%W]:^G
M/^$EU?\ Z%"]_P"^EKY=_:[_ ."87[/_ .U']J\4:3\/+SP9XLFRYUW0H8Q%
M<R'O<6V0DN3DEE*2$]7/2OAWP[GO#;]ID-;GI?\ /BJ[KTISWCY)Z=6V?-/*
M,TR=\V5U.:'_ #ZF[K_MV6Z]'IW9]= @C(.0>A%%?E1HWQ,_X*7_ /!**:+3
M?'_A^?QM\,X)!'"UT\EQ9Q1YP%BN #)8MV".#'G.%;K7V3^RW_P4Z_9[_:L6
M#1?!\TVF>)'3]YX8U>XCBN6;'/DDG;<#K]PEL#+*M>KE'&.79CB/J>)B\/B5
MO3J:-_X7M)=K:O>UCNP'$&$Q=7ZO63I5OY)Z/_MU[27:VK['T=16/_PDNK_]
M"A>_]]+1_P )+J__ $*%[_WTM?7'O&Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]
M"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q17.ZG\0%T
M2'[1K.C/:1_W[JZCC'YL17,:G^U#\.]+)225YF'\-JPDS^*\?K7FX[.<HRM7
MQF(A3_Q2C'\V=>'P&-Q;M0I2EZ)O\CTFBO%M4_;)T=3Y6@>![JX8\*;FZ6/G
MZ*&S5!_C#^TKXP'_ !2O@%K.)ON3)IKG_P ?E.P_E7R5;Q+X6]HZ>$E/$3_E
MI4Y2?WV2_$]F'"F<<O-64:4>\Y)?YO\  ]XK/UKQ;X6\.*6U_P 1V-E@=+FZ
M1"?H"<FO"KKX>_M-^+6_XJ;Q%?0QM]^(79 _[XBPIJ?1OV7K6-Q+XE?6;MB<
ML+6..+)^K%R?TK+_ %HXOQ__ "+\HE%?S5IQIV]8:R^YE_V1DF&_WG&IOM3B
MY?\ DVQWVN?M-_"+1LK#KDU\Z]4L;5F_\>;:I_.N2U/]L);J;['X0\ SW$C?
MZMKJ?D_\ 0'/_?5;VB?!OX<:'AX_A'<W3CJ]]/YN?^ D[?TKK=,NUT6'[/HW
MPY>TC_N6L4<8_)<4_P"S?$C,?]XQM'#)]*5-S?WU.OF@^M<+87^'AYU7_?ER
MK[HGE?\ PG7[5_C;C0O"ATR-^C"Q6'CUW7!/YBC_ (9_^.GC+YO'/Q)$<3_>
MA:\EFQ_P 83\C7KW_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2TO^(=X7%ZYIC<
M1B.ZE4<8?*,;6^\/]9ZU#_=*%.EYJ-Y?>[_D>=:)^Q[X)L\/KWB+4+UAU6$)
M"A_##']:[#0_@5\)O#^UK+P3:2,O\=X#.<^O[PD#\*U?^$EU?_H4+W_OI:/^
M$EU?_H4+W_OI:]W+^"^%,KM]7P=--=7'F?WRN_Q//Q.?9SB_XM>7HG9?<K(\
M%^(_P7^-'C7QA>:Y;> E@M6?996Z7UJJQ0KPHP),#CD^Y-8?_#-7QK_Z$O\
M\J-M_P#'*^EO^$EU?_H4+W_OI:T--O)[ZU$]Q826S%B/*E(S]>*^+Q?@UPUC
M<5/$5J]=RFVW[U/=N_\ S[/=H\=9KAZ,:4*=.T4DM)=/^WSD?@+IOC[0/!">
M&?'VC-:RV$FRSD-S')YD)Y ^1FP5.1SVQ7;445^EY5E\,IRZE@X3E.--**<F
MG*RVNTDM%IMLNY\IC,3+&8J=>45%R=VE>UWO:[?KN%%%%>@<P4444 %>(?\
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MKHGAGPQI,&F:%I%FI$=I:PH(XXUR23A5'))).2222:Z"B@ HHHH *\+\ _\
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M)RJ2^.I)WG-^<OT6GSU/8RS)\'E47[)7G+XI/64GYO\ 38****^@/5"BBB@
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MAJTJ56-I+1I]#[:A7HXFC&K2DI1DKIKJ%%%%9&H4444 %%%% !1110 4444
M%%%% !1110 4444 %>%^ ?\ E()X_P#^Q$TK_P!&-7NE>%^ ?^4@GC__ +$3
M2O\ T8U 'NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M<A\;?CU\)/V=/ \_Q$^,?C6TT73(<A'N&S)<28R(H8UR\KG^ZH)QD] 37YS?
M%/\ ;3_;+_X*@>-+OX#_ +&/@[4/#7@PMY>JZJ\WDRR0-QOO;I<BWC(S^XC)
M9QN&9/NCYK/>*<OR-QHM.I7G\-*&LY?+HO-_*YX^9YWA,M:IZSJR^&$=9/\
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M$UI5:LKR>K;ZGWU"A1PU&-*E%1C%6270****R-0HHHH **** "BBB@ HHHH
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MD:65PJJ"69C@ >IH 6BOFK6_^"QG_!+GPW\74^".N?MU_#:VUMK629II?$\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QKZ4]@V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &D^Q>-_^@W9?^ Q_QH V:"0H+,0 !R37E'Q!^/\
M:^!6>Q@\36>J7R\&VL8,JA_VWSM'T&2/2N1AMOV@_P!H.,?:;@Z7HDG=@889
M%^@^>7]5SZ5\1FO'6683$O!9?"6*Q/\ )2U2_P <_ABN^[75'T&#X=Q=:C]8
MQ,E1I?S3TO\ X8[OR[]SO_B)^TOX#\%^98:1+_;%^N1Y5I(/*0_[4G(_!<GU
MQ7"1Z%\?/VA76XURY.CZ'(<JC*T<3+ZK']Z7V+''H178^!?V<-/\#3)?PS65
M[>KRMS>VQ?8?55)POUY/O7<?8O&__0;LO_ 8_P"->9_JSQ)Q.^?B#$>SHO\
MYAZ+LK=JD]Y>:6G5-'7_ &ME64^[EE/FG_S\FKO_ +=CLO)O7NC!^'?P$\ ?
M#S9>6]A]NOUY^WWJAF4^J+T3\.?<UVU8_P!B\;_]!NR_\!C_ (T?8O&__0;L
MO_ 8_P"-?=Y;E679/AEA\%2C3@ND5;YOJWYN[/G<5C,5CJKJUYN4N[_K3T1L
M45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UWG,;%%8_V+QO_ -!NR_\
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M]FE:T/\ GW3TCZ2EN_-?<SY(_8J_X(3_ +"W['WV3Q-J/@S_ (6'XNM]K_\
M"1^,X$GCAD'\5O:8\F'!Y5F$DBGI)7V> % 50  . *Q_L7C?_H-V7_@,?\:/
ML7C?_H-V7_@,?\:^>Q>.Q>/J^TQ$W*7F_P NWR/HL'@<'E]+V6&IJ$?)?GU?
MJS8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QKE.LV**Q_L7C?\ Z#=E_P"
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M)N"#(X9E.Y48 FO"OA/_ ,'4W[*_]M0:1^U=^S-\7/A9IUS<;%\8:IX>BO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2_#5'$_ 7]G;X._LS^!XOA]\&?!5KI%@N&N)(QNGO) ,>;-*?FE?W8\#@
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M\0:QI<YBFD.<?9=/BQ<7!(Y!D,6".485YWX$_P"".?\ P4]_X*7>*K3XO_\
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MJ/\ M':OKNLWK++=>'=(U=[NZD'41W&H3;@JC[IC@4@#[DHK]3/A%\%/A%\
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M,_(+5O\ @TZ\,39_L/\ ;DO[;T^U_#Q)L<_[-\G;_/:J _X-?OCUX;X\$?\
M!0[R@/N_\4Q=6OL?]7>OV _E7[&45LN,>(DK.M?UC#_Y$Q?!G#E[JC;TE/\
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M.9O"?_(8_9*_M/9RW_%!QS;L<G_CUF&<]./PYK]C**/]8Z$OCP-'Y0:_4/\
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M&X;14Z3?:_-_[>E^9\6Q?M-?&O\ ;[OF@^.W_!2/X8^ _#5RV)-,U'X@V-A
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MAM\2?"]YHNO:+>/::KI6H0F.:VF4X*L#^8(X((()!!KZH_X)D_\ !(3]I_\
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M+UDW=WWMMV1\EF'$G'F:SO7P\++9>TM%>B2M^I]G77_!1W_@GQ:1>=+^W/\
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M[;CD^=?WTGY;ISBK\'_!''_@F);Q"&/]C/P@0O0R13,?S:0DT>TX/7V*S^<
M]GQD]YT%\IGB$_\ P<P_\$UX8FDC_P"%@2D=(X_"J GZ;IP/UK/N_P#@YY_X
M)SVR@P^%/BA<$GD1>&;08_[ZO!7TC!_P2;_X)KV\JS1_L4_#XE>@DT%&'XAL
M@U?M/^"7W_!.>R8M#^Q#\+V+#!\WP9:2#_QY#BCV_"*VHU7_ -O1#ZOQ@_\
ME_27_;LCY0NO^#I#_@GQ;R^7%\*OB_.,9WQ>'M, ^GS:B#^E9]Q_P=/?L.KO
M^R_ OXKOC/E^9INF+N],XOCC]<>]?9UK_P $XO\ @GQ:1>3%^PQ\(",YS+\-
M],<_FT!-:%O^P?\ L.VFS[+^QG\*(O*QY?E_#O3%V8Z8Q!QBCZWPHML-4?\
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M%M95GMO!6DQR+]UX]-B!'T(6C^T>&%M@6_\ N++_ "#^S>*'_P QZ7_<*/\
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M5[=>:SVOT5K]=!L,,5O$MO;Q*D:*%1$7 4#@  =!3J**_.#]*"BBB@ HHHH
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M%?CK\2+;XC>,?#UKHWQ!\"QZ,'D:U\-0V=J8K @P1$RV]C)=L5"ODJ '<G-
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
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M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q1
M6/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\
MC1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-
M &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P
M&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8
M_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&
M[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;L
MO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+Q
MO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&_
M_0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_
M &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?
M8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L
M45C_ &+QO_T&[+_P&/\ C6AIL>HQ6H35+B.67<<O$FT8[<4 6**** "BBB@
MHHHH *XWX^?L\? []J;X87_P7_:)^%FB^,?"VIE&O=$UVR6:%W1@R. >4=6
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M]B3]C7['XLU?PQ_PL3QG;[7_ .$E\76R216\H_BMK/F*'!P0S>9(IZ25]I
M# %%<>-XCQE>E]7PZ5&E_+#2_J]WY]^QV8+AO!8>M]8Q+=:K_-/6W^%;+RZK
MN'3I1117SY]$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45D>-
MO'_@7X:Z#+XI^(GC+2]"TV'_ %M_J]_';PK[;Y"!GVZU\B?'W_@N+^RM\,3-
MI/PFT[4_'VI1Y"R62&SL P[&>9=YY[I&ZGUKR,TS[)LEAS8ZO&'DWJ_2*O)_
M)'!C<TR_+8\V)JJ/DWK\EN_DC[2KAOC/^TQ\ OV>=-_M/XS_ !8T70 8]\5M
M>78-S,OK' F99/\ @*FOSY_X7Q_P6+_;X_<_"#P7/\/O"MW]S4;*(Z9&8CT?
M[9.3/+UY-OC_ '>*[GX,_P#!"'PO+J7_  F/[5WQLU/Q3J<[^;>6&B2-%%(_
M?S+F;=-,#ZA8F]Z^7_ULSG-],DP,I1?_ "\J_NX>J7Q27I9GB_V[F&/TRW#-
MK^>?NQ]4MY+TL.^-/_!=_P '#4?^$0_95^#&J>*M3G?RK2_UI&AAD?L8[:+=
M-,#Z$Q&N$_X4G_P6/_;Y_>_%;Q=/\//"MW]_3[R5M+B,1ZI]D@!N)>O N.#_
M 'N./T$^"W[,7[/_ .SOIPT[X+_"71M RFR2ZM;4-=3+Z27#[I9/^!,:[NC_
M %3SK-]<[QTI1?\ R[I?NX>C?Q27K9^8?V%F./US+%-K^2G[L?1O>2];'Q5\
M O\ @AO^RU\-/(U7XNZKJGCW4H\%XKMS96 8=Q!$V\\]GE93W6OKWP-\// 7
MPQT&/PM\.?!>E:#IL7^KL=(L([>('UVQ@#/OU-;%%?495D&39)#EP-",/-+W
MGZR=Y/YL]K Y7EV6QY<-24?-+7YO=_-A1534]?T+1$\S6=:M+1<9W75RL8_\
M>(KF-7_: ^$&C9$_C6WF8=%M$>;/XH"/UK;&YQE.7+_:\1"G_BG&/YM'LT,#
MC<5_!I2EZ)O\CLJ*\EU?]L#P#:932-"U.\8=&=$B0_B6)_2L1OVI?B/XC8IX
M'^%WF9.%RDUT?_(86OE<1XE<&T)^SAB?:2[4XRFWZ-*WXGL4N%<]J1YI4N5=
MY-1_-W_ ]UHKPK^TOVP/%O\ Q[6#:;$W7]U!!C_OO+_E2?\ #._QO\4?-XS^
M)^$;K&;V:?'_  $[5_(US_Z\YAB_^1?E.(J=G-*E%^CDWI\C7_5["T?]YQM*
M/E%N;^Y6/9-7\9^$= S_ &YXHT^T*]5N+Q$/Y$YKE]7_ &D?@_I.5_X2G[4X
M_@M+:1\_\"P%_6O.?$_P&^!7PBT;_A)/C9\<+/1;!,EKW5-0MM.AXZ_/.Q'Z
MUX#\4O\ @J#_ ,$C_@5YEMI?B74?'VHP9!MO#5E/=*3V_>S-%;,#ZJ[5R8G.
M_$"2O*CAL*O^GM1SE\E#1L]G*N%<%FDN7!4\1BGWIT[1^;EHEZL^G-7_ &R/
M"5OD:'X2U"Z(Z&YE2$'\M]9G_#17QL\4<>"_A> C=)!9S3X_X$-J_F*^!=1_
MX+K?&#XEZP_A#]@S]@&VFO@=L-Q/I\^JW)!Z,;:RCCV'ZR./7/2G_P#"C_\
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M;N^VV;RX=N?[ZN1ZFO>HOVK],TVSA\/?#WX6+%;P($M+9)%C2-1T58HDP![
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MX..K1]*LU^4CXHU__@W^_P""<FL;O[.\'>)])W9Q_9_BJ9MOT\_S/UKB=?\
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MUQX#K?[QP]!_X*]6'Y)GXU?MW_\ !<[X7_MD_L>>+OV=-.^ ^OZ!JOB(:?\
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MX9KEE3X:\'_V\O\ ,\3$<&\787^-E]>/K2G;[^6Q]!45YQX=_;$_9(\7;?\
MA%?VH_AWJ)?&U;+QK8RMSVPLI(/M7<Z)XH\->)8?M'ASQ%8ZA'C.^RNTE&/J
MI-=<*U*I\$D_1GBU\%C<*_WU*4?6+7YHO4445H<H4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>%^ ?^4@GC_P#[$32O_1C5[I7A?@'_ )2">/\ _L1-*_\ 1C4 >Z44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !102 ,DU\4_MQ?\
M!=[]B3]CC[9X3T#Q+_PL?QG;[D_X1SPE=(\%O*/X;F]YBAP0053S)%(YC%=>
M#P.,S"M[+#P<I>7ZO9>K.3&8_!Y?1]KB9J$?/]%NWY(^UB0!DG '4FOB;]N+
M_@O'^Q+^QW]L\)^&O$7_  LGQG;[D_X1[PE=(]O;RC^&YO?FBBP0053S9%(P
M4%?#[:M_P6T_X+CR&+2X3\*_@[J!P75IM-TRZMSZOS=:H2!T&8-R](Z^U_V'
M?^"!W[%'[(?V/Q;XUT+_ (6;XRM]K_VWXKM$-G;2C^*VL<M&F" 0TAE=2,JX
MZ5]#_96491KF57GG_P ^Z;_]*ET\TM>USYS^ULXSC3+*7)3?_+RHK?.,=WY-
MZ=['Q0;K_@MI_P %QY-MJA^%?P=U \D&;3=,NK<^IYNM4ROIF LO_+.OMK]A
MW_@@E^Q/^R#]C\6^,- _X67XRM]K_P!N^++1&M+:4?Q6UCEHH\$ AI#+(I&5
M<=*^WD1(U"(H55&  , "EKDQG$>,K4OJ^&2HTOY8:7_Q2W?GM?JCKP7#6#H5
MOK&*DZ]7^:>MO\,=DNV]NC$5510B*  ,  < 4M%%?/'T84444 %%%% !1110
M 4444 %%%% !116/XF^(/@GP<A;Q-XGL[1@,^5)*#(1[(,L?P%88G%8;!TG5
MKS4(K=R:27S>AI2I5:\U"G%R;Z)7?X&Q7R=^U%_P6<_X)X?LR>.[/X8^+_VQ
M/AW#X@AU01:]I*^)8)IM/C4D21S"-F\B7/\ #)M(QR.1GY/_ .#A3_@I?XUL
M/A]X(_85_94\7ZKX=UWXQ:C>1^)O%]D3#<:?X>LXU>[2W8'?'+.9$C$AQ\JR
MJ.6#+^:G@W]G;X(> _#T?AGP]\+]%6V1 KM<:='-+,<#+2.X+.QQU)-?FO%W
MB'E. P,*>#J2G*JKJ5-K2*E9M.2:=W%Q5D[V>JT/!S[B3#\(X^%#%T'.I:[@
M]+)K2_5=TO+4_IH^%7QB^$GQU\$VWQ)^"?Q/\/\ B[P]>9^RZYX9UB&^M)<8
MR%EA9D)&1D9R.]6]7^(G@/0<C6/&.F6[#K')>IO_ .^<Y_2OY=;2X^('[ WB
M6?\ :I_8UN9-&;3=MSXV\ V\[1Z1XFTZ/)E22 ?)'*B;F21!E2#@9)S^A7P;
M\:_\%#_^"B'A#2?''[-GPSN] \'^(+"*[LM;V"TA,$BA@3=SX+LN<$0#<",8
MKS\7XF9GBZ%*IDV!]JIW6K;E&2U:<(QVLTU)2LU?9II;9=Q/PSBLL6*FZLJC
M;C[*%-2E=)/67-RI:[_<G9H_3OXH?MV_LN_!^Q-_XW^)UM;J%)6,1L'D_P!Q
M6 +G_=S7RM\8_P#@OA\/;&5]"_9W^"^J>(KV0^7;7^N3?98-YZ%88P\DH_V2
M8S[U3^"W_!!K3KN^3Q9^U=\<;[7+Z5@]SIGAQF5';T>[G!DD![XC0^C5]G?!
M#]DG]F[]G*U2'X-?![1M&G1-AU)+;S;QQC!#7,I:5A[%L<]*]#!T_%#.8\V)
MJT\)%_RQ4I6]&Y+[Y)^2.2O6SW,W;#TEA:?>4O:5/P48+T:NN[/SDUBX_P""
MQ?[=P*ZN-:\(>&;S_ESLK272;4H>JE4!GE4CH)6*GUKLO@[_ ,$/I-,,6H_$
MPOJ]SPS1WE\MM;9Z\I"SR'\6Y[K7Z745G/PJP6/K>VS3&UJ\O5)?BI-+R31W
M9?DV3X*HJU:BL15_FK-SMZ0TA;R<96[GSEX _8'TWP;I$>A:;K&EZ-91D'['
MHVF?(3Z]4R?]H@DUW.D?LB_#:RP^IZAJ=ZW=6G6-#^"KG]:]4HKVL'X:\%8-
MIK"*;[S<I_A)M?@?7RXFSKV:ITZO)%;*"C%+TLD<GI'P+^$FB8-GX%LG([W:
MF?\ ]&%JZ6PTO3-*B\C2].@MD_N6\*H/R J>O./C+^V!^RW^SU')_P +H^/O
MA7P]/$,FPOM8C^UL/]FW4F5_^ J:^IP^7Y1E,+T*5.DO*,8K\$CAA_:N;UE2
MASU9OHN:;^[5GH]%? /QH_X.*_V*_ 7G67PG\->*O'=TN?)GMK$:?9OCUDN<
M2C_OR:\2;_@KA_P5I_:\8VG[&O[(']C:;<'$&L6VA3:D8L],WER$M!_P*,5R
M5N(\JIRY(3=27:"<G^&GXGVV!\*N-,51]OB**PU+K.O.--+U3?-_Y*?K62 ,
MDUXU\:?^"AG[$W[/GG0_%7]I7PM8W4&?-TRSU 7MXA'8V]L))1^*U^?(_P""
M5O\ P6'_ &P3]I_; _:U_P"$?TNY_P"/G1KKQ#)>;,]<65EML_RD'85[+\%_
M^#<O]CGP/Y5[\7_&_BKQS=)CS;<W*Z992?\ ;.#,P_[_ -9?VCG>*_W?"\J[
MU';_ ,E6IV_ZK>'V3ZYKG'MI+>&&@Y?=5E[GX&1\9_\ @Y(_9F\*F73_ ('?
M!WQ1XPNE)6.YU*2/2[1SV*D^;*1[&)37F'_#?W_!<W]LK]S^S1^S2_@[2+KB
MVU6U\-B)60_]/NJMY#''>-5(^M?H[\&/V*_V3?V>1%)\&OV>_"NA7,.-FHV^
MDI)><=,W,@:9OQ<UZ?1_9F<8K_><4XKM37+_ .3/4/\ 6[@7)],HR:-22VGB
M9NI?UIJT/N9^3%G_ ,$2O^"B_P"U+=QZS^VU^VD8+>1Q(=.?4[O6Y8>^T0LT
M5O%[>6S =<=J^@/@M_P;Y?L&?#7RKWX@VWB3QY>)AG&N:N;:VW#NL5H(CC_9
M=W'KD<5]ST5M0X=RFC+GE3YY=YMR?XZ?@>?F'BGQMCJ7L:6)]A3Z0HQ5)+T<
M4I?^3'%?"7]F_P" 'P&LQ8_!?X+^&/#"[-KR:+HL,$L@_P!N15#R'W8DUVM%
M%>S"$*<>6"27D?!8C$8C%575KS<Y/=R;;?S>H44459B%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% ')_''X'?"[]I'X7:I\%_C1X7_MGPSK/D?VEI
MOVV>W\[R9XYX_P!Y Z2+B2)&^5AG;@Y!(/SW_P .//\ @EU_T;#_ .7KK?\
M\FU]845RU\#@<5/GK4HR>UW%-V^:/9R[B/B'**#HX#&5:,&[N,*DX)NR5[1:
M5[)*^]DNQ\G_ /#CS_@EU_T;#_Y>NM__ ";7T)\#O@=\+OV;OA=I?P7^"_A?
M^QO#.C>?_9NF_;9[CR?.GDGD_>3N\C9DE=OF8XW8&  !UE%%# X'"SYZ-*,7
MM=12=OD@S'B/B'-Z"HX_&5:T$[J,ZDYI.S5[2;5[-J^]F^X4445U'C!1110
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M_@H&(=G^J_XFFJZ=]/\ 4O)BC_AWA_P7R^'O'A?]N ZRJ<1J/B7J,_';B]@
M]L?TK]8:*S_U9RZ/\.4X^DW_ ,$Z?^(N<55?]YIT*W^.A!_DD?D]_P (U_P<
MT?#T9TW7SK<"<O\ Z7X:NMW_ '_ D/X?XT?\-A?\'#_P\_Y&7]EPZYY?WO\
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M'[.MM\<8O!GCW]A;QYH'@B:Z55\57&OP/J<=NS86X?3/)5<8^8JMRQQG;N.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2V]MX=U+QWHWAW5=5N[P00Z6FH7*VPNY&(($<;NK/G "[F)&* /P"_X(\?\
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MB^#:YU/Q!;JEA;2#O!9 L@P<$-*TK C(*]*^B_LG*<H][,ZO//\ Y]TW=_\
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M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
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MK](T(C'X&NR\+?LN_"[P]MFU&RGU69>=]]+\F?9%P,>QS77?\(/I'_/S>_\
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M'F_V;Y?G1HQ:+=Y<FW<!G8V.AK\MZ^O_ /@J;_P3*\,_\$Y= ^&T.G_%2_\
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
M"#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\
M_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?
M\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO
M_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _
M-[_X%M6AING0:5:BTMWD90Q.97+'GW- %BBBB@ HHHH **** "N-^/G[/'P.
M_:F^&%_\%_VB?A9HOC'PMJ91KW1-=LEFA=T8,C@'E'5@"KJ0RGD$5V5% 'PY
M9_\ !OI_P3WLOC9IWCH^#M=O?!&G>!I?#T?PKUKQQKNH:0S-?07:2[+G4'7R
M%\G;]BV&W+%9"F]%-?8[?#CP;#X C^%VB:0=$T&"P2QLK#PU=2Z6+*W0!4BM
MWLVC>W554!?**X P,"MRB@#Y0N_^"'7_  2NO_B6WQHO_P!DG3Y_&+:J-4;Q
M9-XCU5M3-\'WBZ-T;KS?.#@-YF[=D9SFO6?C[^Q'^S)^U/\ !FQ_9]_:-^',
MOC3PAI]Y%=0Z3XAU^_N#+-$&$<DTS3^;<,N]B#*[\X/4 CU:B@#XP_XAXO\
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M\G2J*I4Z1B[Z^;6B2Z]3ZS_XB?O^,W?^2>?\6'_Y!O\ QZ_\3?[_ /R%NO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPOP#_P I!/'_
M /V(FE?^C&KW2O"_ /\ RD$\?_\ 8B:5_P"C&H ]THHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHKQWXV?\%!OV(_V=/.A^,O[4?@S1KJ
M#/FZ8=:CN+U<=?\ 18"\Q_!*UHT*V(GRTHN3[)-O\#*M7H8>'/5DHKNVDOQ/
M8J*_-[XV_P#!SM^PEX"\ZR^$'@WQGX]NESY-Q!IRZ;92?62Y83+_ -^#7A<G
M_!<;_@K?^UZ[6/[#_P"PB+#3[@D1:M!H%[K3P=@3=N(K1/J\>*]VCPKG56'/
M.FJ<>\VHK\=?P/ K\69'2GR4ZCJ2[03D_P -/Q/V5KSCXT?M@_LK?LZQ2-\<
MOVAO!WA>6-<_8]7U^"*Y?_<@W>:Y]E4FORO_ .'=/_!PM^VB/._:;_:O?P1I
M5US=Z5<^+A K(>WV/1D,#G'\+LN/8UZ/\%_^#6+]G?0Y8]4_:$_:0\6^++G=
MYDUMH%E!I4#L>2KM)]HD<=>0R$]>.E;?V/DF$_WO&IOM33E_Y-L8_P!LY[B_
M]TP+BN]22C_Y+N>F?&W_ (.4O^"='PS\ZS^'=UXL^(%VF5C.@:";:V+#^]+>
MM"P7_:5']LCFOG/4O^#AC_@H)^TY?R^'_P!A']@0S;G,8NWL+_Q#-'_MG[,D
M$41[_/O4=R>M??OP2_X)!_\ !-WX ^3/X'_9-\,7=W#@KJ'B:!]7GWC^,->M
M*$;_ ' N.V*^C--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A1_:'#6$_W
M?"RJ/O4E_P"VQT8?V=Q/C/\ >,7&FNU./_MTM4?C?_PRQ_P<J?MK_/\ %OXZ
MS_#71[OK;S>)8-'7RCU4P:.C3'TVS<GN>]=A\)_^#67P1>:A_P )+^U+^UUX
MB\17MP_F7MOX8TU+5F?OFZNFG:3/J8U/\Z_6>BIGQ7FBCR890HQ[0BE^+NRH
M<(Y5*7/B7.M+O.3?X*R/D_X)?\$0_P#@F3\#/)N=(_9BTKQ#>Q8W7_C2>75C
M(1W,-PS0#_@,8KZ'UKX'_!SQ!\+[_P"">J?##0G\(ZI9/:7WAN/3(X[.6%A@
MIY2 *.V" "" 000#74T5XE?'X[$S4ZU64FM;MMV].Q[M# 8'"P<*-*,4]TDE
M?U[GXY_\0P/_ !F[_P E#_XL/_R$O^/K_B;_ '_^03T_\F?^>?;?7ZY_#WX>
M^"/A/X(TOX;?#;PO9Z+H.BV:6FE:5I\(CAMH5& J@?F2>222222:V:*ZLRSK
M,<VC".)G=05E_F^[?<Y,LR3+<HE.6&A9S=W_ )+LET0445%>7MGI]NUY?W<4
M$2#+RS2!54>Y/ KR92C"+E)V2/72;=D2T5P/BG]I7X4^&=T4.M/J4R_\LM-C
M\P?]]G"?D37#W/[2?Q2\<SM8?"[P RC.//,37#K[D@!$_'(KXW,?$#A;+JGL
M57]K4Z0I)U)-]O=NK^3:/=PO#6<8J'.Z?)#^:;Y5^.OW(]U=TC0R2,%51DL3
M@ 5R'BKX\_"SPENCO?%,-S,O_+O8?OFSZ97Y0?J17FZ? OX[?$AA/\2O'!M(
M&.6MGG\TK](HR(Q^==?X6_99^&&@;9M4M[C5IASF\EPF?9$P,>S9KS?[>XYS
MC3+<O6'@_MXB5G_X+C[R?JVCJ_L[A[ _[UB74E_+26G_ ($]&<QJO[5WB+Q!
M='2OACX EGE;A'N%:5S[^7'T_P"^C5;_ (5[^TU\4?G\7>(VTJSDZP23B,%?
M3RH>OT?!KW#2M%T?0K46.B:5;6<(Z16T*QK^2@59H_U(S/-=<\S*I53WA3M2
MI^C4=9+ST8?ZP83!Z9?A80?\TO?EZIO1?B>4>%OV1_ 6D[9O$NHW>JRC[R;O
M)B/X*=W_ (]7HOA[P?X6\)P?9_#?A^TLEQAC;P!6;ZMU;\36E17T^4\+\/9$
ME]1PT(/O:\O_  )WD_O/(QN;YGF+_P!HJRDNU]/N6GX!1117O'G!15/Q!XC\
M/>$M'G\1>*M=LM,T^U3?=7VH720PPK_>9W(51[DU\G_M'?\ !:']DGX+PW&E
M?#G5)OB%K<>Y4M] ;98JXQC?>.-C*<\-")>G:O,S/.<KR:A[7&UHTX^;U?HM
MWZ),YL9C,-E^']OB)*,.[ZOLN[\EJ?7E?-/[4?\ P58_90_9E^TZ$?%7_"6^
M)(<K_8/AF19O*D'\,T^?*AP>",LX_N&OSI^*W[;?_!13_@HEJEUX)^%GA7Q%
M<Z-)(8I?#7P_TZ5+1%/\-Y=9Y!&,B:14SR$&<5T/P9_X(%?M>_%#RK_X[?$C
M0?ASILF#)IVG-_:NI =U;RV6%?3*RMC^Z>_P5;B_B'/G[/A_"-0?_+VHK+UC
M';T;?JAX# Y[GJ52ER8/#O7VV(NFUWIT8IU:E^DE'DOHVCA_VM_^"S/[1GQT
M-UX>@\9)X%\/2AA_87A>5_M,R?W9KD8D<D$C ,4;=UKQ+X&:]\1_B#XB.F?L
MR?LG7WQ"UU),?VAK.DS:E!;$G*RFTAQ!&><'[2\\9Z[1V_6O]G[_ ((7_L!_
M \PZGXA\!7GC[58R&:^\:7?GP[N^+6,) 5SVD1S[FOK;PSX5\+^"M%@\->#?
M#=AI.G6R[;;3],LT@@B'HJ( JCZ"LL'X?X[%XE8O-\1[6IY^];RBG[L?DG;H
M?9Y?@?"_AR:KRPM3-<4O^7F)?)13_N4(MWCY3;?H?DQH/_!([_@JC^V/;VI_
M;*_:0B\(^'E"^5X:-Z+I;51R!%IUB8[*( =@ZD8 QQ7U!^SY_P $$_V#?@QY
M&I^-O#FJ?$'5(L,9_%-[BU5^^VU@V(5_V9?-^M?:U%?<X;AW*\/+FE#GEWF^
M9_CI^!Z^9>)_%V.H?5J%58:CTIT(JE%>2<?>MY.5C)\%> O WPVT"'PI\._!
MFE:#I=N,0:;HVG16L$?^['&JJ/P%:U%%>VDHJRV/S^<YU9N<W=O=O5L****9
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7A?@'_E()X__ .Q$TK_T8U>Z5X7X!_Y2">/_ /L1-*_]
M&-0![I1110 4444 %%%% !1110 4444 %%5M8UK1O#NF3:UX@U:VL;.W3=/=
MWDZQ11KZLS$!1[DU\V_&W_@L?_P35^ GG6_B_P#:N\.:E>19']G^$W?6)2X_
M@)LUD1&_WV4#N171A\)BL7+EH4W)^2;_ ".;$8S"82/-7J1@O-I?F?3=%?E1
M\9/^#I[X&Z;<-H_[./[,7BKQ3=._EV]SXCOX=-C=R< K'"+AY!GHIV$^U>?_
M /#>O_!Q9^VH?)_9V_9@D\ Z3=<6^HV_A)+)7B/\7VO6G,;\?Q1!3Z#->[3X
M4S;EYZ_+2CWG)1_S?X'@U.+LHY^3#\U:7:G%R_'1?B?LK//#;0O<W,RQQQJ6
MDD=@%51R22>@KP+XV_\ !4W_ ()Z?L]>=#\3OVL_"$5U!D3:;H^H?VG=HP_A
M:"S$LBG_ 'E%?G5!_P $'_\ @JA^UK,FI?MS?MZ"VLYF#/IDNM7VNR0<Y(%N
M6AMH_81N17OGP2_X-D_V!/A[Y-[\6-?\9>/[I<>=!?ZL-/LWQZ1VBI*OXS&K
M_LWAS"?[SBW-]J<?_;I:$?VGQ)C/]VP:IKO4E_[;'4YKXV_\'27[)'@_SK+X
M&_!/QCXTN8\A+C4GATBSD]"KGSIL?6%:\E_X>Q?\%V/VR_\ 1_V0OV,CX8TN
MZ_X\];M?"4LX&>F;[4B+,_\ ?L>M?I[\$OV#OV,OV<O)F^"G[,G@S0;J#'EZ
MG;Z'%)>C'3-S(&F/XN:]:H_M;(<)_NN#YGWJ2<O_ "5:!_9'$&+_ -ZQO*NU
M**C_ .3/4_&C_AS]_P %NOVR3]H_;*_;7_X1_2KK_CZT2Z\57%]LSUQ8V(6S
M_*0=ATKV+X)?\&NG[&_@OR;WXV?%WQGXXNH\>9;VC1:392^N8XQ),/PF%?IK
M165;BO.9PY*4E3CVA%17^?XFM'A+)83YZL'5EWG)R?W;?@>$_!+_ ()C?L ?
ML\>3-\*?V3O!UI=08\G4]1TP:C>(1W6XNS+*I^C5[K'''%&L42!54 *JC  '
M84M!( R3@#J:\*MB,1B9<U:;D^[;?YGOT,-A\-#DHP45V227X!16;J'C'PCI
M.?[5\4Z=;8Z_:+Z-,?F:P]0^/'PATS/VGQW9MC_GWW3?^@ UX^)SG)\'_O&)
MIP_Q3BOS:/1I8#'5_P"'2E+TBW^2.NHKS74/VKOA+9Y^S7&H7>/^?>R(S_WV
M5K#U#]LKPU'G^RO!E]-Z?:+A(OY;J^?Q/B%P7A/CQT'_ (;S_P#24STJ7#.?
M5OAP\OG9?FT>S45X5_PU-\1M:_Y%;X6!\_=^6:X_] 5<TO\ PL']K/7_ /D'
M>"39;NG_ !+!'C_O^QKSO^(F</U?]TIUJ_\ U[HS=_OY3I_U3S.'\:5.G_BG
M%?E<]THKPO\ X1+]KW7_ /D(^)OL6[K_ *;#'C_OP#7*_%CX??$GP)H,6K>.
MOB6UY+=3>7!:)?SRE^,L27Q@ =?<@=ZY,?XB8_!X.>+64UU3@KMU.6G9?/F?
MRU9OAN&,-7KQHO&TW*6B4;S_ ,CJ9/VB$B^/K2R:ACP^JG3F);Y  W^O_P"^
M^_\ <KJ?%/[5?PST+=#HS7.K3#@?9HMD>?=WQ^8!KYCKZ'_9C\.?#'Q#X.75
M5\*6<FKV<QBOI+A?-;=U5U#Y"Y7T Y!K\XX)XRXPX@S&MEV&KTZ<JLI5>:HG
M)QO:\::V=EJE+2R9]3G^19'EF%IXJK3E)02A:+23[.3WUVNNMC';XU?'_P")
MC&+X<^"S96S\+<QP;\?667$?Z U)9_LR_$CQI<+J7Q1^(#9SGR5D:X=?;+$*
MGX9%>Z@!0%4  #@"BOU&/A[0Q\E/.\95Q;_E<N2G\H0M;[SY!\35,.N7+Z$*
M*[I<TO\ P*7^1PGA;]G#X4>&-LK:"=1F7_EMJ;^;G_@'"?\ CM=Q;6MM90+:
MV=O'%$@PD<2!54>P'2GT5]EEV3Y5E%+V>"H1IK^[%*_JUJ_F>%BL=C,=/FQ%
M1S?FV_N[!1117I'*%%8OCSXC_#WX6>'Y/%GQ,\=:/X>TN'_6ZCKFI16L"^Q>
M5E7/XU\=?M!_\%^OV%/@]Y^E_#W5-8^(>J1958_#ED8K,..S7-QL!7_:B645
MQXK,,%@8WKU%'U>OR6[/<R;AGB#B&IR9;A9U?.,7RKUE\*^;1]OUF^+?&?@_
MP!H4WBCQWXKTW1-,MAFXU'5[Z.V@B'JTDA"K^)K\E?$__!67_@JW^U]I=WJ/
M[*7P$M? GA2-29O%4ELDD5LF<'S=4U'R[./ZA$8<D'T^/_C'X?\ B%\3/%2:
MA\?/VF]5^(_B!I=BPZ=J%Q?11%N/*2YN %#!L86"*2)A]UZ^1S?CS+,LH\ZB
MVGLW[J?^%?%+Y(^HS#@S).$Z7M>+<VHX3_IU%^VKOR]G#:^U[M+KH?K?^T!_
MP7<_8*^"[S:3X0\7:C\0=6C)5;/P?9>9!O[9N92D3*?[T9D^AKX\^,O_  7H
M_;*^*IEL/@KX%T#X:Z9)D17D\?\ :NIX[$-,JPKGT,)(/<]\']D;_@B7^T3\
M8A;>(O%F@1?#S0)0K-?Z_;L^H3ICDQVI(<9Z_O#$O.1GI7Z6?LN_\$S/V4_V
M5Q;ZQX:\$C7?$4&&_P"$F\1A;FY1Q_%"N!'!@YP44-@X+-7@4<9Q_P 5:X>/
MU2@_MR5I-?W8_%\VTGW/B<=Q1@:O[KA?+G"'_03C+3J/SAAU^ZCY.HJEUV9^
M<WPC_P"">W_!0K]OK5[7Q[\<?%_B"WTB1Q)%XA^(=_,Y"GO:61((!!R-JQ1D
M'AJ^[/V>/^"-_P"QS\$X(-1\8>%I/'VM1[6DO?%(#VH;&&"6:_NMAZXE$I&.
M&KZOHKZ7*>!,ERZK]8Q">(K]9U?>=_)/1>6[7<^=I97&6,^NXRI*O7_GF[M>
M45M!+HDM-EH5=&T31O#FEP:'X>TBUL+*VC"6UG96ZQ11*.BJB@!1[ 5:HHK[
M1))61ZK;D[O<****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^&WP>G^&.C7?WI8O#]OH:K&>C"757>Z(Z',1R>H&*_1+X>_$W]E/X#Z6="^
M_P  =.\-VNT*T'A_P_9Z=&X]_)P6^I&<\UIS_MA:G?R&#P[\-FD;L7O&<_\
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M==['U7!^4<39SFLJ614^>M&+D]8*T;J+?[QI;R2TUU[7/I3_ (8M_P"JE?\
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MBBOJCVPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OFO_@K/_P3G\)_\%2OV)O$?[*'B+Q2V@7UW<0:
MGX8U]8/-73M3MR3#(\>1OC8,\3@$'9*Q4A@#7TI7SC_P5(_:B^+'[&G[--C^
MT7\*_AYXA\5)X?\ 'FAOXNT/POHK7]Y<: ]VL>H%(U5B"L#,X;Y0&5<LH)-
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M@[-WKY;F'_;TE_P3ZF_XB//V#?\ H2/B;_X3]E_\FT?\1'G[!O\ T)'Q-_\
M"?LO_DVOEO\ X7;X5\,<^/?^"./@*(+]_P#XHF:TX_[:0/CBIK+]MW]A"QF^
MQ^+?^"2G@B"5?OF"XM01_P  ?3QCG/\ %70O$'#)VJ8V,'_>HU5_[:S->(7@
M*OCPF*CZS_\ M3Z>_P"(CS]@W_H2/B;_ .$_9?\ R;5:7_@Y*_87CD*)\+_B
MM( >'30M-P?SU ']*\/TC]M?_@DS-C^W_P#@FAIMMZ_8]%TN?'_?21^U=CH?
M[9/_  1&NT2"^_88BL<<%KKX9Z-(!^*2,Q_*NREQKA*VV9T5ZQDOS2-X<>>
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M665__!__  #Y,/\ P<J?L;X.WX+_ !-)[9L-._\ DRJG_$2U^RE_T0?XA?\
M?%C_ /)%?7P_8!_8M4AE_9@\" CH1X2LO_C56O\ AAW]DC_HWCP=_P"$U:?_
M !JG]5XD?_,3#_P ?]L^%*VRJL_^X_\ P#XW_P"(EK]E+_H@_P 0O^^+'_Y(
MH_XB6OV4O^B#_$+_ +XL?_DBOLC_ (8=_9(_Z-X\'?\ A-6G_P :H_X8=_9(
M_P"C>/!W_A-6G_QJCZIQ'_T$Q_\  /\ @A_;?A5_T*:W_@]_Y'QK)_P<M?LK
MB-C#\!/B SX^56%B 3[GSSC\JK?\1,'[-_\ T;KXW_\  JS_ /CE?:L?[$/[
M)<,@EB_9[\'JRG*LOANT!!_[]U8_X8Y_9B_Z(?X8_P#!#;?_ !NCZGQ'_P!!
M,?\ P /[<\*UME%5_P#<P_\ (^(O^(F#]F__ *-U\;_^!5G_ /'*/^(F#]F_
M_HW7QO\ ^!5G_P#'*^W?^&.?V8O^B'^&/_!#;?\ QNC_ (8Y_9B_Z(?X8_\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M]OX4M86/XQHI[UZI17'5R[+ZW\2C"7K%/\T<\\)A*GQTXOU2/ ]7_P""77[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MA?@'_E()X_\ ^Q$TK_T8U>Z5X7X!_P"4@GC_ /[$32O_ $8U 'NE%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCP+^UU\+K:6VTCQMHHNQ83R!Y+"Y1VAN;5V  9H9XY8BP #;,@8- 'K-%%%
M!7A?@'_E()X__P"Q$TK_ -&-7NE>%^ ?^4@GC_\ [$32O_1C4 >Z4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"#%]%[&R@/XGXCH?YFOIW_ (,[->US6/\ @D(^GZM(YM]*^*NMVNF!\X6
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MJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !% '"_\-W?LA_\
M1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\17=?\*F^%?\ T33P_P#^":#_
M .(H_P"%3?"O_HFGA_\ \$T'_P 10!PO_#=W[(?_ $7C1/\ OJ3_ .(H_P"&
M[OV0_P#HO&B?]]2?_$5W7_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_
M /!-!_\ $4 <+_PW=^R'_P!%XT3_ +ZD_P#B*/\ AN[]D/\ Z+QHG_?4G_Q%
M=U_PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !% '"_\-W?L
MA_\ 1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\17=?\*F^%?\ T33P_P#^
M":#_ .(H_P"%3?"O_HFGA_\ \$T'_P 10!PO_#=W[(?_ $7C1/\ OJ3_ .(H
M_P"&[OV0_P#HO&B?]]2?_$5W7_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)
MIX?_ /!-!_\ $4 <+_PW=^R'_P!%XT3_ +ZD_P#B*/\ AN[]D/\ Z+QHG_?4
MG_Q%=U_PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !% '"_\
M-W?LA_\ 1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\17=?\*F^%?\ T33P
M_P#^":#_ .(H_P"%3?"O_HFGA_\ \$T'_P 10!PO_#=W[(?_ $7C1/\ OJ3_
M .(H_P"&[OV0_P#HO&B?]]2?_$5W7_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WP
MK_Z)IX?_ /!-!_\ $4 <+_PW=^R'_P!%XT3_ +ZD_P#B*/\ AN[]D/\ Z+QH
MG_?4G_Q%=U_PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%
M'"_\-W?LA_\ 1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\17=?\*F^%?\
MT33P_P#^":#_ .(H_P"%3?"O_HFGA_\ \$T'_P 10!PO_#=W[(?_ $7C1/\
MOJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$5W7_"IOA7_ -$T\/\ _@F@_P#B*/\
MA4WPK_Z)IX?_ /!-!_\ $4 <+_PW=^R'_P!%XT3_ +ZD_P#B*/\ AN[]D/\
MZ+QHG_?4G_Q%=U_PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_
M !% '"_\-W?LA_\ 1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\17=?\*F^
M%?\ T33P_P#^":#_ .(H_P"%3?"O_HFGA_\ \$T'_P 10!PO_#=W[(?_ $7C
M1/\ OJ3_ .(J.7]O7]D"%TC?X[:03(V%VI,P'U(3CZFN^_X5-\*_^B:>'_\
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M /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !% '"_\-W?LA_\ 1>-$_P"^I/\
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MO&B?]]2?_$5W7_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_ /!-!_\
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MJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !% '"_\-W?LA_\
M1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\17=?\*F^%?\ T33P_P#^":#_
M .(H_P"%3?"O_HFGA_\ \$T'_P 10!PO_#=W[(?_ $7C1/\ OJ3_ .(H_P"&
M[OV0_P#HO&B?]]2?_$5W7_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_
M /!-!_\ $4 <+_PW=^R'_P!%XT3_ +ZD_P#B*ZKX:?'[X-_&.[GL?AC\0+'6
M9K: 3SQVA;*1EB@8Y XW CZBM#_A4WPK_P"B:>'_ /P30?\ Q%>0_"O1M'T#
M]O;Q[IFA:5;65LG@;2REO:0+&BDR.20J@ 9- 'OU%%% !1110 4444 %%%%
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M_;6_9$^'_P"U=9^"W\.P^//#L.K1:'+?BZ:S60G$9E"('( Z[1UH ]7HHHH
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MG[?NG?#F?3[WP]+8^(_$&@0L9GT?2-:LHRWF$#YFBE%C'(0, L[<*M '#?\
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MA'BO6U8NP[;A:O*A[K)8KW&1^F] !1110 4444 %%%% !1110 4444 %%%%
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M67Q!OM,D>(7/E6Z26EA,Z_\ +*7-S(8R<.;49R%(KR3_ (.=?^"7?[%'@O\
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MLVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M''6]&^&FG7"7?[0.K^"-.DO+W53$Z/%X6MY(B!#O8![N;.45!"N7:55^HO\
M@F-_P6=_8A_;I^,NE?L:_P#!/'X=:M:^$? _P]GU'5KN_P! _LRST:TMYK2T
MLK"VBW$NS^>[<@*J6YY8M\H!\Q?\'L%G:'_@G3\,+TVT?G1_&NW1)=@W*K:1
MJ98 ]@2JD^NT>E?<'_!"+_E#S^SO_P!DTL?_ &:OB#_@]AGA7_@G-\,;9I%$
MC_&NV94SR0-(U,$_AN'YBOMW_@@Y-%/_ ,$=_P!GAX9 P'PVLU)4YY!<$?@0
M1^% 'UM1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)->G44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-O@[^R;)\4O$'Q:\-:A/X:T^RUU;*>35(I D,+O(ICAM@-\LT[?ZN.-C@XH
M^Z**_+/7_P#@M?\ \%(_V4?VG-*_8Z_;A_X)RZ!JGCWXEZ(UQ\$K;X1>,C-:
MZUJ F6(V-W-=\6R("9);DX$2)N\MPP(]"^!'_!4?]O?X=_\ !0KP'^P5_P %
M,_V1_!7@R7XP:1J5W\,_%OP[\52ZA:/<6,+3SV=RLPW%Q&H&\; &>(!6#ED
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M\4MX$_:E_:]\->'-?C16N/#]K%<ZGJ%LK %3-:V$4TL.X$$;U7(.1D5^:?\
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MK/P=\3WOA?7K>5HS9ZM8Q7=]9.S+\RH;BWB5F7YE5F*_,!0!^VE>.>#?V_\
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MKX=)=2%I(?"FM"2^L;0$\L(,M\WI<(   !7Z)4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?SW_P#!</\ Y2B_
M$_\ [@O_ *9+"OD^OA<7QI]5Q=2A["_))QOS;V=K_"?T9D?@!_;.2X;,/[2Y
M/;4X5.7V-^7GBI6O[57M>U[*_9']8%%?SW_\$//^4HOPP_[C7_IDOZ_H0KZ'
M(\V_MG"2K\G):3C:]^B=]EW/R_Q#X)_U"SJGE_UCVW/353FY.2UY3C:W-+^6
M][]=M K$^)7Q'\"_![X>:Y\6/B=XGM=%\.>&M)N-3UW5[U]L-G:01M)+*Y&3
MA44G@$\< FMNOS@_X.,?B%XI^)_PL^$W_!*WX2ZM);^+/VH?B19Z'?R6Q_>6
M7ARSEBN=2NCCD*O[C<.C1^<.<$5[)\&?<7[-?[4/P _;"^%5K\;_ -F?XI:;
MXP\*WMU-;6^LZ67\LS0N4DC*NJLK*PZ,!P01P03WM?EM_P $SK;2O^"9O_!9
M7XZ?\$JH+9=+^'WQ6L(?BK\$[+.V&&1T\G4[*%>GWHGVJ.%CT[/&X"O8?^"D
MG_!7#XM?L2?MH?"O]C;X._LFR?%+Q!\6O#6H3^&M/LM=6RGDU2*0)#"[R*8X
M;8#?+-.W^KCC8X.* /NBBORSU_\ X+7_ /!2/]E']IS2OV.OVX?^"<N@:IX]
M^)>B-<?!*V^$7C(S6NM:@)EB-C=S7?%LB F26Y.!$B;O+<,"/0O@1_P5'_;W
M^'?_  4*\!_L%?\ !3/]D?P5X,E^,&D:E=_#/Q;\._%4NH6CW%C"T\]G<K,-
MQ<1J!O&P!GB 5@Y9 #]"J*^#/CS_ ,%1OVLOB?\ MD>+OV$?^"5G[,'AKX@^
M)/AG:6\GQ2\?_$'Q')I_A[P_=7"%H;!1 K2W-PP!R$(VLCKM.QV3J/V%O^"F
M'QA^,G[1OC'_ ()^?MK?L^6/PJ^/7A+PXGB"QL=-UDZEH?BC1I'$2ZC83X5]
MBRLJ/"V6'/S;ED2( ^RZ*^ /@#_P71\%Z1HO[07A+_@HOX$L/@_\0_V<YGN_
M%7ANSU1KR'6=&?8MG?Z<\JQM<"XDDBC1,=;FVY!F"K[]_P $SOVFOVC?VQ_V
M5](_:7_:,^ 5C\-)O%TKWWA3PK#J4MU=)HS@&UN+IG1 DLJDR"-5P(V0D@L5
M4 ] _::_:K_9[_8V^%TGQJ_:<^*-AX/\+0WT-G+K.I)(T2SRDB-,1JS98@XX
M[5\[Z=_P<'?\$8]4OX=.MO\ @H)X)62>0(C7(NX8P3_>>2%50>[$ >M>#?\
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M^'FN?%CXG>)[71?#GAK2;C4]=U>]?;#9VD$;22RN1DX5%)X!/' )K;K\X/\
M@XQ^(7BGXG_"SX3?\$K?A+JTEOXL_:A^)%GH=_);']Y9>'+.6*YU*Z..0J_N
M-PZ-'YPYP10!]Q?LU_M0_ #]L+X56OQO_9G^*6F^,/"M[=36UOK.EE_+,T+E
M)(RKJK*RL.C <$$<$$][7Y;?\$SK;2O^"9O_  65^.G_  2J@METOX??%:PA
M^*OP3LL[889'3R=3LH5Z?>B?:HX6/3L\;@*]A_X*2?\ !7#XM?L2?MH?"O\
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M?QUX@\*3>(? ?C#X>:Y-J/A[Q!;P;OM$'[Y1+;31A';$A.0AR%S&9>#\$_\
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M.? /C#PYH=MJ$MW?LMR-4$0N#Y:_O'N%:1<LT4L !P:_:.N%_9__ &9/V?\
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M<M^SUX#O/AK8_#OX.?">_L+>RU"WTB*XANI[JYL[?"61>>!2(L!LR/G(422
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M^$;_ .$D^Q?\27_A!_MGV?[/906O^N^W1;]WD;_N#&['.,GR?_B&!_ZO@_\
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M#M/\0>&_$%A)9:UHNJ6XEM[RW<8:-T/!!_\ KUP_@O\ 8>_9'^'?B/P+XO\
M!'[/WAO3=4^&6CW.E?#^_MK'$N@V5PKK-;VS$_NXW61P5'&&(Z4R#XH_X*+(
MC_\ !Q'^P"'0$?V1\03R.XT60C]:D_X*J_\ *<S_ ()T?]A?X@_^FNRK[U\7
M_L[_  .\?_%[PG\??&GPOTC4_&G@6.[C\'^);NU#7>D+=1&*X$#_ , DC)5O
M4&CQW^SQ\#_B=\3_  ?\:?B!\,-(U?Q7\/Y+N3P5K][:A[G1FNHUCN# _P#
M9$1%;U"B@#\2_P!ES]D70/$/_!7;]L7]G/XX_P#!2GXX?L\>-M9^+5UXP\):
M/\/OB)#H%KXOT34)KBYAG7SH7%U+!'+&I"ME5<@+^[DV^_?L'?L^?L2>&?\
M@MNVC_#_ /;J_:5_:"^+GPS^&-R-;\5^-/%.FZ[X;T>PN7>(Z7/>HB3K<+)-
MYJP("@:0Y.Y953] _P!K/_@GC^Q'^W5:V,'[6W[-'A;QQ+ID;1Z;J&JV)6\M
M(V.6CBN8BDT:$G)17"D\XSS6A^SY^PU^R'^RC\+M3^#'[-_[/GAKP9X<UN-T
MUJQT&Q\E]0W(T9,\P/FS-L8J&=RR@X!% 'XJ_P#!4SX>_$+_ (+0_MJ>-_VO
M_P!A+X#>%?%_@[]CJPM[/4=4U2QDGC^+&JVE]%>W6B1^6P%U;00I/M49+ER
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M?X*WM[J7PS,_P\\0OXAT68:3XTT:V55L-1M)9%"7=O-9F!6(9F66*19 K<4
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M_!UNJK_P1$^)JJH &M^', #I_P 3FTJQ_P ',")'_P &_GQ:1%"JMAX2"@#
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MGQ:]IXDDLI& #/!,,20,P !,;*6  .14'[*?[#G[(O[#GA2\\%_LE_L_>&_
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MXO\ E#%XI_[';0/_ $K% 'L\7_!PQ_P1>FE6%/\ @H#X-!=@ 7M[U1D^I,&
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M=*;R/ W[5'PY7Q]IFG)Q#:^+M/\ ,@OVB7H&N+2W:XF8<LXC)Z< 'Z+T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^&M*C,>FZ#X=TN*SM+9223LBB554DDDG&222<DDUT$,,5O"EO!&%1%"HH'
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M<M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>warninglabela.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 warninglabela.jpg
M_]C_X  02D9)1@ ! @$ > !X  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\@^I8?\ Y]Q_'_,/^%EZ7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\
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M?_GW'\?\P_X67I?_ $#)?^_%Q1]=Q'_/Q_A_D'U+#_\ /N/X_P"8?\++TO\
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M\@^I8?\ Y]Q_'_,/^%EZ7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\
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M?_GW'\?\P_X67I?_ $#)?^_%Q1]=Q'_/Q_A_D'U+#_\ /N/X_P"8?\++TO\
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M\@^I8?\ Y]Q_'_,/^%EZ7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\
M"R]+_P"@9+_WXN*/KN(_Y^/\/\@^I8?_ )]Q_'_,/^%EZ7_T#)?^_%Q1]=Q'
M_/Q_A_D'U+#_ //N/X_YA_PLO2_^@9+_ -^+BCZ[B/\ GX_P_P @^I8?_GW'
M\?\ ,/\ A9>E_P#0,E_[\7%'UW$?\_'^'^0?4L/_ ,^X_C_F'_"R]+_Z!DO_
M 'XN*/KN(_Y^/\/\@^I8?_GW'\?\P_X67I?_ $#)?^_%Q1]=Q'_/Q_A_D'U+
M#_\ /N/X_P"8?\++TO\ Z!DO_?BXH^NXC_GX_P /\@^I8?\ Y]Q_'_,/^%EZ
M7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\ "R]+_P"@9+_WXN*/KN(_
MY^/\/\@^I8?_ )]Q_'_,/^%EZ7_T#)?^_%Q1]=Q'_/Q_A_D'U+#_ //N/X_Y
MA_PLO2_^@9+_ -^+BCZ[B/\ GX_P_P @^I8?_GW'\?\ ,/\ A9>E_P#0,E_[
M\7%'UW$?\_'^'^0?4L/_ ,^X_C_F'_"R]+_Z!DO_ 'XN*/KN(_Y^/\/\@^I8
M?_GW'\?\P_X67I?_ $#)?^_%Q1]=Q'_/Q_A_D'U+#_\ /N/X_P"8?\++TO\
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M\@^I8?\ Y]Q_'_,/^%EZ7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\
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M_"@ ^SQ?W%_[Y'^% !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\*
M#[/%_<7_ +Y'^% !]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@
M^SQ?W%_[Y'^% !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%
M_<7_ +Y'^% !]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?
MW%_[Y'^% !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_
M +Y'^% !]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[
MY'^% !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_ +Y'
M^% !]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[Y'^%
M !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_ +Y'^% !
M]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[Y'^% !]G
MB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_ +Y'^% !]GB_
MN+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[Y'^% !]GB_N+
M_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_ +Y'^% !]GB_N+_W
MR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[Y'^% !]GB_N+_P!\
MC_"@ ^SQ?W%_[Y'^% "-#"HR50 =R * &HEO)]P1MCTVG^5 #_L\7]Q?^^1_
MA0 ?9XO[B_\ ?(_PH /L\7]Q?^^1_A0 ?9XO[B_]\C_"@ ^SQ?W%_P"^1_A0
M ?9XO[B_]\C_  H /L\7]Q?^^1_A0 ?9XO[B_P#?(_PH /L\7]Q?^^1_A0 ?
M9XO[B_\ ?(_PH /L\7]Q?^^1_A0 ?9XO[B_]\C_"@ ^SQ?W%_P"^1_A0!Q'Q
M)@C7PSJ9"J"+.?L/^>;>U &AX?\ ^/EO^P=I_P#Z,OJ]"?\ NM+_ *_5_P#T
MC#GG0_WNK_UYP_\ Z7B3D_&/_'G?_P#85L__ $FL:,1_#PW_ %YE_P"I%<,/
M_$Q7_7Z/_J/0/6:\\]$* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M4YVGW_*@".#6K*YC>>&9'CA^^P/"X]?2@!EOKMA=R_9X)XWE_N*<G@9/'TH
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M[WLJR:19SH,\(9+9'./3DT <#IN@SWWB'2;M)9/.?0X[L<\[HXC&%^A*Y^M
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MP#>PCF<?(VU1NR/4]* *-AHNK>$+'PW?M 96@N96,?S'8LS$KG:,C"GOT[T
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M"X81QE$@0L0 79LX!..Q[4 ?=M 'D/QTN'M_!]\(LEI%6/@9.&//3Z4 <O\
MLW>&X=)\-+J&S;<7TCL[$8;:C%%7Z#:2/]XT ?0U !0 4 % !0 4 % !0 4
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M#'J0!F@!6AC9=I5=O7&!C\J #R4P5VK@]1@8- "I&L8VJ H] ,"@!514&%
M] ,"@!%B1>0H!'3  Q0 XH&P2 2.F1TH :(D'15&.1P.#ZT $D:RC:X##T(!
M_G0 AA0KY>T;?3 Q^72@#SSXF>%9?%&D+8V@"N+JWE. /NQL2?T- '>65JMM
M"D84 A%#8 &2% .: )E@CC!"JH!Z@ <_6@!Y12-I QZ8X_*@ **<<#Y>G X^
MGI0 P01AO,"KN]<#/YT .,2$%=HP>HP.?K0 BPHB[ JA?3 Q^5 "F-3R0.F.
M@Z>GTH > %&!P!0 4 ?-O[3/B7^R?#RZ;&V)-1E5"!U\M/G8_3*J/QH ^9O
M>L?\(+HKZX1E[^[BM0I_CMT;S+A?HP3:?K0!)J_PEN]7N1?>'0+G3[MMZ,"%
MV!N2N"<_+TH I^,;R'P;:VGA[2Y=\]K)]HNI5XS/V4_[@P/0XH ^^/AIXH'B
M_P /6>IDYDDB"R_]=$^1\_5E)H I_$WQ-I'AW3/^)R!(DYVI$?XV';CZT /^
M&OB72?$.F#^Q@(XX&*O$,_NV/S8YYYSF@#T2@ H * "@ H * "@ H * "@ H
M * "@#A_B5_R+&I_]><__HMJ +?A_P#X^6_[!VG_ /HR^KT)_P"ZTO\ K]7_
M /2,.>=#_>ZO_7G#_P#I>).3\8_\>=__ -A6S_\ 2:QHQ'\/#?\ 7F7_ *D5
MPP_\3%?]?H_^H] ]9KSST0H * "@ H * "@ H * "@ H * "@#C+WQM9V&O6
M_AR7Y;B[C:2-B1CY1G;CKDT 6="\5P:[>WMA"I5]-F\F0D@Y;U '3\: .JH
M* "@ H * "@ H * ,J\UFUL;J"RE=5GNR1$AZMM&21]* -6@ H * "@ H *
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M];MEO+1A)"Y8*PY!VD@X_$4 := !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MW\EU$C%<-E$\Q3N]VR* /H'X:>)[SQ5#>W=UM\J*\DA@VC'R1\'/J<T >F4
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M$MLMG>*'B61)0",C=&<J?PH Y_QC\.M*\:QPIJ$2LUKQ&Q&2%XRHYZ' S]*
M*OB/X8Z-X@L;:QG@3R]/'[D8SM7'S*.> V!F@#R;X:?#VR\2>&;C2M3AQ'#J
M<SQ!E/R[3M!4''521]#0!ZM:_"K1+*T>PAA1()9HIV4+QOA8,AZ]B* .ET[P
MI8Z;)>211K_Q,G+SC'WR1@Y]>* .=\*_"[1O"-Q/=6,**]R"IPN-J-U4<]*
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MC_O+^8H BB\B %8RB@G)P0.3WXH E\Z/^\OYB@ \Z/\ O+^8H /.C_O+^8H
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M"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\ P./^8?\ "M+3_H*K_P"!;?\
MQ='U:M_SZJ?^ 2_R#ZS0_P"?M/\ \#C_ )A_PK2T_P"@JO\ X%M_\71]6K?\
M^JG_ (!+_(/K-#_G[3_\#C_F'_"M+3_H*K_X%M_\71]6K?\ /JI_X!+_ "#Z
MS0_Y^T__  ./^8?\*TM/^@JO_@6W_P 71]6K?\^JG_@$O\@^LT/^?M/_ ,#C
M_F'_  K2T_Z"J_\ @6W_ ,71]6K?\^JG_@$O\@^LT/\ G[3_ / X_P"8?\*T
MM/\ H*K_ .!;?_%T?5JW_/JI_P" 2_R#ZS0_Y^T__ X_YA_PK2T_Z"J_^!;?
M_%T?5JW_ #ZJ?^ 2_P @^LT/^?M/_P #C_F'_"M+3_H*K_X%M_\ %T?5JW_/
MJI_X!+_(/K-#_G[3_P# X_YA_P *TM/^@JO_ (%M_P#%T?5JW_/JI_X!+_(/
MK-#_ )^T_P#P./\ F'_"M+3_ *"J_P#@6W_Q='U:M_SZJ?\ @$O\@^LT/^?M
M/_P./^8?\*TM/^@JO_@6W_Q='U:M_P ^JG_@$O\ (/K-#_G[3_\  X_YA_PK
M2T_Z"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\ P./^8?\ "M+3_H*K_P"!
M;?\ Q='U:M_SZJ?^ 2_R#ZS0_P"?M/\ \#C_ )A_PK2T_P"@JO\ X%M_\71]
M6K?\^JG_ (!+_(/K-#_G[3_\#C_F'_"M+3_H*K_X%M_\71]6K?\ /JI_X!+_
M "#ZS0_Y^T__  ./^8?\*TM/^@JO_@6W_P 71]6K?\^JG_@$O\@^LT/^?M/_
M ,#C_F'_  K2T_Z"J_\ @6W_ ,71]6K?\^JG_@$O\@^LT/\ G[3_ / X_P"8
M?\*TM/\ H*K_ .!;?_%T?5JW_/JI_P" 2_R#ZS0_Y^T__ X_YA_PK2T_Z"J_
M^!;?_%T?5JW_ #ZJ?^ 2_P @^LT/^?M/_P #C_F'_"M+3_H*K_X%M_\ %T?5
MJW_/JI_X!+_(/K-#_G[3_P# X_YA_P *TM/^@JO_ (%M_P#%T?5JW_/JI_X!
M+_(/K-#_ )^T_P#P./\ F'_"M+3_ *"J_P#@6W_Q='U:M_SZJ?\ @$O\@^LT
M/^?M/_P./^8?\*TM/^@JO_@6W_Q='U:M_P ^JG_@$O\ (/K-#_G[3_\  X_Y
MA_PK2T_Z"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\ P./^8?\ "M+3_H*K
M_P"!;?\ Q='U:M_SZJ?^ 2_R#ZS0_P"?M/\ \#C_ )A_PK2T_P"@JO\ X%M_
M\71]6K?\^JG_ (!+_(/K-#_G[3_\#C_F'_"M+3_H*K_X%M_\71]6K?\ /JI_
MX!+_ "#ZS0_Y^T__  ./^8?\*TM/^@JO_@6W_P 71]6K?\^JG_@$O\@^LT/^
M?M/_ ,#C_F'_  K2T_Z"J_\ @6W_ ,71]6K?\^JG_@$O\@^LT/\ G[3_ / X
M_P"8?\*TM/\ H*K_ .!;?_%T?5JW_/JI_P" 2_R#ZS0_Y^T__ X_YA_PK2T_
MZ"J_^!;?_%T?5JW_ #ZJ?^ 2_P @^LT/^?M/_P #C_F'_"M+3_H*K_X%M_\
M%T?5JW_/JI_X!+_(/K-#_G[3_P# X_YA_P *TM/^@JO_ (%M_P#%T?5JW_/J
MI_X!+_(/K-#_ )^T_P#P./\ F'_"M+3_ *"J_P#@6W_Q='U:M_SZJ?\ @$O\
M@^LT/^?M/_P./^8?\*TM/^@JO_@6W_Q='U:M_P ^JG_@$O\ (/K-#_G[3_\
M X_YA_PK2T_Z"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\ P./^8?\ "M+3
M_H*K_P"!;?\ Q='U:M_SZJ?^ 2_R#ZS0_P"?M/\ \#C_ )A_PK2T_P"@JO\
MX%M_\71]6K?\^JG_ (!+_(/K-#_G[3_\#C_F'_"M+3_H*K_X%M_\71]6K?\
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MW_/JI_X!+_(/K-#_ )^T_P#P./\ F'_"M+3_ *"J_P#@6W_Q='U:M_SZJ?\
M@$O\@^LT/^?M/_P./^8?\*TM/^@JO_@6W_Q='U:M_P ^JG_@$O\ (/K-#_G[
M3_\  X_YA_PK2T_Z"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\ P./^8?\
M"M+3_H*K_P"!;?\ Q='U:M_SZJ?^ 2_R#ZS0_P"?M/\ \#C_ )A_PK2T_P"@
MJO\ X%M_\71]6K?\^JG_ (!+_(/K-#_G[3_\#C_F'_"M+3_H*K_X%M_\71]6
MK?\ /JI_X!+_ "#ZS0_Y^T__  ./^8?\*TM/^@JO_@6W_P 71]6K?\^JG_@$
MO\@^LT/^?M/_ ,#C_F'_  K2T_Z"J_\ @6W_ ,71]6K?\^JG_@$O\@^LT/\
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MM_SZJ?\ @$O\@^LT/^?M/_P./^8?\*TM/^@JO_@6W_Q='U:M_P ^JG_@$O\
M(/K-#_G[3_\  X_YA_PK2T_Z"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\
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M$O\ (/K-#_G[3_\  X_YD-Q\+;&ZC:&74U:-P593='!!ZCEZ/JU;_GU4_P#
M)?Y!]9H?\_:?_@<?\SV31FA-_.ENZ2I%96*;D8,,K+?<9!/.,''7D5TU82IX
E:E&I%Q?MJ[M)-.W)A]=3EHSA4Q5:5.2DO8T%>+35^?$::=3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>warninglabelb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 warninglabelb.jpg
M_]C_X  02D9)1@ ! @$ > !X  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\@^I8?\ Y]Q_'_,/^%EZ7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\
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M?_GW'\?\P_X67I?_ $#)?^_%Q1]=Q'_/Q_A_D'U+#_\ /N/X_P"8?\++TO\
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M\@^I8?\ Y]Q_'_,/^%EZ7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\
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M?_GW'\?\P_X67I?_ $#)?^_%Q1]=Q'_/Q_A_D'U+#_\ /N/X_P"8?\++TO\
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M\@^I8?\ Y]Q_'_,/^%EZ7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\
M"R]+_P"@9+_WXN*/KN(_Y^/\/\@^I8?_ )]Q_'_,/^%EZ7_T#)?^_%Q1]=Q'
M_/Q_A_D'U+#_ //N/X_YA_PLO2_^@9+_ -^+BCZ[B/\ GX_P_P @^I8?_GW'
M\?\ ,/\ A9>E_P#0,E_[\7%'UW$?\_'^'^0?4L/_ ,^X_C_F'_"R]+_Z!DO_
M 'XN*/KN(_Y^/\/\@^I8?_GW'\?\P_X67I?_ $#)?^_%Q1]=Q'_/Q_A_D'U+
M#_\ /N/X_P"8?\++TO\ Z!DO_?BXH^NXC_GX_P /\@^I8?\ Y]Q_'_,/^%EZ
M7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\ "R]+_P"@9+_WXN*/KN(_
MY^/\/\@^I8?_ )]Q_'_,/^%EZ7_T#)?^_%Q1]=Q'_/Q_A_D'U+#_ //N/X_Y
MA_PLO2_^@9+_ -^+BCZ[B/\ GX_P_P @^I8?_GW'\?\ ,/\ A9>E_P#0,E_[
M\7%'UW$?\_'^'^0?4L/_ ,^X_C_F'_"R]+_Z!DO_ 'XN*/KN(_Y^/\/\@^I8
M?_GW'\?\P_X67I?_ $#)?^_%Q1]=Q'_/Q_A_D'U+#_\ /N/X_P"8?\++TO\
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M\@^I8?\ Y]Q_'_,/^%EZ7_T#)?\ OQ<4?7<1_P _'^'^0?4L/_S[C^/^8?\
M"R]+_P"@9+_WXN*/KN(_Y^/\/\@^I8?_ )]Q_'_,/^%EZ7_T#)?^_%Q1]=Q'
M_/Q_A_D'U+#_ //N/X_YA_PLO2_^@9+_ -^+BCZ[B/\ GX_P_P @^I8?_GW'
M\?\ ,/\ A9>E_P#0,E_[\7%'UW$?\_'^'^0?4L/_ ,^X_C_F'_"R]+_Z!DO_
M 'XN*/KN(_Y^/\/\@^I8?_GW'\?\P_X67I?_ $#)?^_%Q1]=Q'_/Q_A_D'U+
M#_\ /N/X_P"8?\++TO\ Z!DO_?BXH^NXC_GX_P /\@^I8?\ Y]Q_'_,CE^*&
MD6Z&2739$1!EF,,X  ZDD\4?7<1_S\?X?Y!]2P__ #[C^/\ F>Z:%%!#>S?9
M5\N*2SLI0HSC<\EZ"<$G!(50?H/2M:]2=;#TIU7>7M:ZN[7LH4&E][?WLQH4
MX4<36ITERQ]E0=E>UW/$)OU:2^Y')>,AFROP?^@K9_\ I-8UEB/X>&_Z\R_]
M2*YKA_XF*_Z_1_\ 4>@>I_9XO[B_]\C_  KSST0^SQ?W%_[Y'^% !]GB_N+_
M -\C_"@ ^SQ?W%_[Y'^% !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR
M/\* #[/%_<7_ +Y'^% !]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C
M_"@ ^SQ?W%_[Y'^% !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\*
M#[/%_<7_ +Y'^% !]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@
M^SQ?W%_[Y'^% !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%
M_<7_ +Y'^% !]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?
MW%_[Y'^% !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_
M +Y'^% !]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[
MY'^% !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_ +Y'
M^% !]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[Y'^%
M !]GB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_ +Y'^% !
M]GB_N+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[Y'^% !]G
MB_N+_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_ +Y'^% !]GB_
MN+_WR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[Y'^% !]GB_N+
M_P!\C_"@ ^SQ?W%_[Y'^% !]GB_N+_WR/\* #[/%_<7_ +Y'^% !]GB_N+_W
MR/\ "@ ^SQ?W%_[Y'^% !]GB_N+_ -\C_"@ ^SQ?W%_[Y'^% !]GB_N+_P!\
MC_"@ ^SQ?W%_[Y'^% "-#"HR50 =R * &HEO)]P1MCTVG^5 #_L\7]Q?^^1_
MA0 ?9XO[B_\ ?(_PH /L\7]Q?^^1_A0 ?9XO[B_]\C_"@ ^SQ?W%_P"^1_A0
M ?9XO[B_]\C_  H /L\7]Q?^^1_A0 ?9XO[B_P#?(_PH /L\7]Q?^^1_A0 ?
M9XO[B_\ ?(_PH /L\7]Q?^^1_A0 ?9XO[B_]\C_"@ ^SQ?W%_P"^1_A0!Q'Q
M)@C7PSJ9"J"+.?L/^>;>U &AX?\ ^/EO^P=I_P#Z,OJ]"?\ NM+_ *_5_P#T
MC#GG0_WNK_UYP_\ Z7B3D_&/_'G?_P#85L__ $FL:,1_#PW_ %YE_P"I%<,/
M_$Q7_7Z/_J/0/6:\\]$* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M4YVGW_*@".#6K*YC>>&9'CA^^P/"X]?2@!EOKMA=R_9X)XWE_N*<G@9/'TH
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M[WLJR:19SH,\(9+9'./3DT <#IN@SWWB'2;M)9/.?0X[L<\[HXC&%^A*Y^M
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MP#>PCF<?(VU1NR/4]* *-AHNK>$+'PW?M 96@N96,?S'8LS$KG:,C"GOT[T
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M"X81QE$@0L0 79LX!..Q[4 ?=M 'D/QTN'M_!]\(LEI%6/@9.&//3Z4 <O\
MLW>&X=)\-+J&S;<7TCL[$8;:C%%7Z#:2/]XT ?0U !0 4 % !0 4 % !0 4
M% !0 4 % '#_ !*_Y%C4_P#KSG_]%M0!;\/_ /'RW_8.T_\ ]&7U>A/_ '6E
M_P!?J_\ Z1ASSH?[W5_Z\X?_ -+Q)R?C'_CSO_\ L*V?_I-8T8C^'AO^O,O_
M %(KAA_XF*_Z_1_]1Z!ZS7GGHA0 4 % !0 4 % !0 4 % !0 4 % #0B@[@!
MD]\<_G0 UH4;.5!SUX'/UH 06\8((5<KP.!P/:@ 2".,DJJ@MUP ,_6@!WEH
M,#:/EZ<#CZ>E #1!&"3M7)Y/ Y(H 5H(W8,RJ6'0D#(H =L7).!DC!.!R/3Z
M4 ((T&"% QTX''T]* '$!A@C(/8T (8U( (&!T&!@4 (8D.25'/7@<_6@!K0
M1N0S*I*]"0.* )"H88(!'H>E #?+0<[1TQT'3T^E !Y:XVX&!T&!C\J $DA2
M48=0P'8@'^= "/!'( K*I Z @8%  T$;@ J"%Z# X^E #O*3&-HQG/0=?7ZT
M 'EKSP/FZ\#GZ^M #5@C1=BJH7TP,?E0 _RU)S@9QC.!T]/I0 B1K$-J */0
M# H :T$;KM*J5ZXP,9^E "B%!T5>N>@Z^OUH #"C J57!ZC YH <D:Q#:@"@
M=@,4 -:&-F#E5+#H2!G\Z !H4<[F4$CN0#0 &%#@E5^7IP./IZ4 (L$:,655
M#'J0!F@!6AC9=I5=O7&!C\J #R4P5VK@]1@8- "I&L8VJ H] ,"@!514&%
M] ,"@!%B1>0H!'3  Q0 XH&P2 2.F1TH :(D'15&.1P.#ZT $D:RC:X##T(!
M_G0 AA0KY>T;?3 Q^72@#SSXF>%9?%&D+8V@"N+JWE. /NQL2?T- '>65JMM
M"D84 A%#8 &2% .: )E@CC!"JH!Z@ <_6@!Y12-I QZ8X_*@ **<<#Y>G X^
MGI0 P01AO,"KN]<#/YT .,2$%=HP>HP.?K0 BPHB[ JA?3 Q^5 "F-3R0.F.
M@Z>GTH > %&!P!0 4 ?-O[3/B7^R?#RZ;&V)-1E5"!U\M/G8_3*J/QH ^9O
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M_AR7Y;B[C:2-B1CY1G;CKDT 6="\5P:[>WMA"I5]-F\F0D@Y;U '3\: .JH
M* "@ H * "@ H * ,J\UFUL;J"RE=5GNR1$AZMM&21]* -6@ H * "@ H *
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M];MEO+1A)"Y8*PY!VD@X_$4 := !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MW\EU$C%<-E$\Q3N]VR* /H'X:>)[SQ5#>W=UM\J*\DA@VC'R1\'/J<T >F4
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M$MLMG>*'B61)0",C=&<J?PH Y_QC\.M*\:QPIJ$2LUKQ&Q&2%XRHYZ' S]*
M*OB/X8Z-X@L;:QG@3R]/'[D8SM7'S*.> V!F@#R;X:?#VR\2>&;C2M3AQ'#J
M<SQ!E/R[3M!4''521]#0!ZM:_"K1+*T>PAA1()9HIV4+QOA8,AZ]B* .ET[P
MI8Z;)>211K_Q,G+SC'WR1@Y]>* .=\*_"[1O"-Q/=6,**]R"IPN-J-U4<]*
M*&C_  >T'1+U-1MH$6>*<SHP7!4GHHYZ"@#N-9\.6NN36L]TH9[&7S8B1G:Q
M &1Z=* .3UCX5:)K6KIKEQ C7"E6;*_?9<;6)SU  Q]* .HT_P +V>FZE<ZM
M @6XO5C61@.2(P0N3["@"CXM\$6'C VS7R!FLI1+&2,D$8) ^I _*@"@?AOI
M)L9=.\I?)N+A;EQC@R(P8'KUR!0 Z\^'.D7R7L<\*.-2V>=D=2GW">>2" 10
M!8\%> ]-\"P/!IT:H93EV P6QTS]* ,/7OA'H7B+4I-5O($>:9-K97.6Q@/G
M/44 /U[X3Z+XAFM;B[A1GLTCC!*YW)& %4\\  4 6]7^&>D:QJ":G-$OFQP?
M9^G5 -JC.>R\#VH O7/@+3+K3;72)(E:VL)$DA4CA60D@@9XY)H T+WPG8W]
M_'J<R*TT,#VZDC_EG)C<N?0XH ^<_BGH4/@_1_\ A%-'MO,_X2&Y#%E5OW;)
M+$V>,COC+=LT >]Z3X+L[22POF0?:=/M?(1L<@,@#@'\Z .WH * "@ H * "
M@ H * "@ H * "@ H * "@ - 'BU[\"O#E]/)<RP1EYG9V.WNQR>_K0!5_X9
M_P##/_/O'_WS_P#7H /^&?\ PS_S[Q_]\_\ UZ #_AG_ ,,_\^\?_?/_ ->@
M _X9_P##/_/O'_WQ_P#7H /^&?\ PS_S[Q_]\?\ UZ #_AG_ ,,_\^\?_?'_
M ->@ _X9_P##/_/O'_WQ_P#7H ]&\(>#;#P5;/9Z:BQQR/YC!1C+8 _D* .M
MH * "@ H * "@ H * "@ H * "@#B/B5_P BSJ?_ %YS_P#HMJ +7A__ (^6
M_P"P=I__ *,OJ]"?^ZTO^OU?_P!(PYYT/][J_P#7G#_^EXDY/QD<65__ -A6
MS_\ 2:QHQ'\/#?\ 7F7_ *D5PP_\3%?]?H_^H] ]5\Z/^\OYBO//1#SH_P"\
MOYB@ \Z/^\OYB@ \Z/\ O+^8H /.C_O+^8H /.C_ +R_F* #SH_[R_F* #SH
M_P"\OYB@ \Z/^\OYB@ \Z/\ O+^8H /.C_O+^8H /.C_ +R_F* #SH_[R_F*
M #SH_P"\OYB@ \Z/^\OYB@ \Z/\ O+^8H B'D!_-RF\C&[(SCTS0!+YT?]Y?
MS% !YT?]Y?S% !YT?]Y?S% $0\A7,H*!V&"<C)'UH E\Z/\ O+^8H /.C_O+
M^8H /.C_ +R_F* #SH_[R_F* #SH_P"\OYB@ \Z/^\OYB@ \Z/\ O+^8H /.
MC_O+^8H BB\B %8RB@G)P0.3WXH E\Z/^\OYB@ \Z/\ O+^8H /.C_O+^8H
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M"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\ P./^8?\ "M+3_H*K_P"!;?\
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MZ"J_^!;?_%T?5JW_ #ZJ?^ 2_P @^LT/^?M/_P #C_F'_"M+3_H*K_X%M_\
M%T?5JW_/JI_X!+_(/K-#_G[3_P# X_YA_P *TM/^@JO_ (%M_P#%T?5JW_/J
MI_X!+_(/K-#_ )^T_P#P./\ F'_"M+3_ *"J_P#@6W_Q='U:M_SZJ?\ @$O\
M@^LT/^?M/_P./^8?\*TM/^@JO_@6W_Q='U:M_P ^JG_@$O\ (/K-#_G[3_\
M X_YA_PK2T_Z"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\ P./^8?\ "M+3
M_H*K_P"!;?\ Q='U:M_SZJ?^ 2_R#ZS0_P"?M/\ \#C_ )A_PK2T_P"@JO\
MX%M_\71]6K?\^JG_ (!+_(/K-#_G[3_\#C_F'_"M+3_H*K_X%M_\71]6K?\
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MW_/JI_X!+_(/K-#_ )^T_P#P./\ F'_"M+3_ *"J_P#@6W_Q='U:M_SZJ?\
M@$O\@^LT/^?M/_P./^8?\*TM/^@JO_@6W_Q='U:M_P ^JG_@$O\ (/K-#_G[
M3_\  X_YA_PK2T_Z"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\ P./^8?\
M"M+3_H*K_P"!;?\ Q='U:M_SZJ?^ 2_R#ZS0_P"?M/\ \#C_ )A_PK2T_P"@
MJO\ X%M_\71]6K?\^JG_ (!+_(/K-#_G[3_\#C_F'_"M+3_H*K_X%M_\71]6
MK?\ /JI_X!+_ "#ZS0_Y^T__  ./^8?\*TM/^@JO_@6W_P 71]6K?\^JG_@$
MO\@^LT/^?M/_ ,#C_F'_  K2T_Z"J_\ @6W_ ,71]6K?\^JG_@$O\@^LT/\
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MM_SZJ?\ @$O\@^LT/^?M/_P./^8?\*TM/^@JO_@6W_Q='U:M_P ^JG_@$O\
M(/K-#_G[3_\  X_YA_PK2T_Z"J_^!;?_ !='U:M_SZJ?^ 2_R#ZS0_Y^T_\
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M$O\ (/K-#_G[3_\  X_YD-Q\+;&ZC:&74U:-P593='!!ZCEZ/JU;_GU4_P#
M)?Y!]9H?\_:?_@<?\SV31FA-_.ENZ2I%96*;D8,,K+?<9!/.,''7D5TU82IX
E:E&I%Q?MJ[M)-.W)A]=3EHSA4Q5:5.2DO8T%>+35^?$::=3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148593264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 06, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,940,091,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,976,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified portions of the registrant&#8217;s Proxy Statement with respect to the 2023 Annual Meeting of Stockholders to be held May 19, 2023, are incorporated by reference into Part&#160;III of this annual report.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | The NASDAQ Global Select Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member', window );">2.00% Senior Notes Due 2026 | New York Stock Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.00% Senior Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNGS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNGS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148335856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los Angeles, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969145105904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 26,323<span></span>
</td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">6,406<span></span>
</td>
<td class="nump">6,454<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="nump">4,819<span></span>
</td>
<td class="nump">4,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">5,414<span></span>
</td>
<td class="nump">5,368<span></span>
</td>
<td class="nump">5,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Other</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,757<span></span>
</td>
<td class="nump">18,340<span></span>
</td>
<td class="nump">16,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">9,566<span></span>
</td>
<td class="nump">7,639<span></span>
</td>
<td class="nump">9,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="num">(1,406)<span></span>
</td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(814)<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">7,346<span></span>
</td>
<td class="nump">6,701<span></span>
</td>
<td class="nump">8,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,552<span></span>
</td>
<td class="nump">$ 5,893<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 12.18<span></span>
</td>
<td class="nump">$ 10.34<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 12.11<span></span>
</td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="nump">$ 12.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in the calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 24,801<span></span>
</td>
<td class="nump">$ 24,297<span></span>
</td>
<td class="nump">$ 24,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,522<span></span>
</td>
<td class="nump">$ 1,682<span></span>
</td>
<td class="nump">$ 1,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144940576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,552<span></span>
</td>
<td class="nump">$ 5,893<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of reclassification adjustments and taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Gains (losses) on foreign currency translation</a></td>
<td class="nump">496<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Gains (losses) on cash flow hedges</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Losses on available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 7,117<span></span>
</td>
<td class="nump">$ 6,082<span></span>
</td>
<td class="nump">$ 6,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144708464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,629<span></span>
</td>
<td class="nump">$ 7,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">5,563<span></span>
</td>
<td class="nump">4,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">4,930<span></span>
</td>
<td class="nump">4,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,388<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">22,186<span></span>
</td>
<td class="nump">19,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,427<span></span>
</td>
<td class="nump">5,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">16,080<span></span>
</td>
<td class="nump">15,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">15,529<span></span>
</td>
<td class="nump">14,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">5,899<span></span>
</td>
<td class="nump">6,524<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">65,121<span></span>
</td>
<td class="nump">61,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,572<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">12,524<span></span>
</td>
<td class="nump">10,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,687<span></span>
</td>
<td class="nump">12,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">37,354<span></span>
</td>
<td class="nump">33,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Long-term tax liabilities</a></td>
<td class="nump">5,757<span></span>
</td>
<td class="nump">6,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">2,662<span></span>
</td>
<td class="nump">2,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies and commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding&#8212;534.0 shares in 2022 and 558.3 shares in 2021</a></td>
<td class="nump">32,514<span></span>
</td>
<td class="nump">32,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(28,622)<span></span>
</td>
<td class="num">(24,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(796)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 65,121<span></span>
</td>
<td class="nump">$ 61,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146839184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock and additional paid-in capital, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock and additional paid-in capital, shares authorized</a></td>
<td class="nump">2,750.0<span></span>
</td>
<td class="nump">2,750.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock and additional paid-in capital, shares outstanding</a></td>
<td class="nump">534.0<span></span>
</td>
<td class="nump">558.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141872768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect of changes in accounting principles, net of taxes</div></th>
<th class="th"><div>Number of shares of common stock</div></th>
<th class="th"><div>Common stock and additional paid-in&#160;capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Accumulated deficit </div>
<div>Cumulative effect of changes in accounting principles, net of taxes</div>
</th>
<th class="th"><div>Accumulated other comprehensive (loss) income</div></th>
<th class="th">
<div>Accumulated other comprehensive (loss) income </div>
<div>Cumulative effect of changes in accounting principles, net of taxes</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 9,673<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,531<span></span>
</td>
<td class="num">$ (21,330)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (528)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">7,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(3,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(3,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 9,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,802<span></span>
</td>
<td class="num">(21,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="nump">$ 6.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</a></td>
<td class="num">$ (169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">5,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(4,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">$ (4,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">558.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">558.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,096<span></span>
</td>
<td class="num">(24,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</a></td>
<td class="num">$ (149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">6,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(4,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">$ (6,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="nump">534.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 3,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,514<span></span>
</td>
<td class="num">$ (28,622)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="nump">$ 7.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</a></td>
<td class="num">$ (139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141800000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="12">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 7.95<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="nump">$ 6.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148183504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,552<span></span>
</td>
<td class="nump">$ 5,893<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and other</a></td>
<td class="nump">3,417<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">3,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(1,198)<span></span>
</td>
<td class="num">(453)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Adjustments for equity method investments</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on divestiture</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other items, net</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(262)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(746)<span></span>
</td>
<td class="num">(429)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(742)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">258<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">154<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Accrued income taxes, net</a></td>
<td class="num">(647)<span></span>
</td>
<td class="num">(854)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_IncreaseDecreaseInNoncurrentTaxLiability', window );">Long-term tax liabilities</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="num">(482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">9,721<span></span>
</td>
<td class="nump">9,261<span></span>
</td>
<td class="nump">10,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(2,587)<span></span>
</td>
<td class="num">(8,900)<span></span>
</td>
<td class="num">(8,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">8,831<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(936)<span></span>
</td>
<td class="num">(880)<span></span>
</td>
<td class="num">(608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired</a></td>
<td class="num">(3,839)<span></span>
</td>
<td class="num">(2,529)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchases of equity method investments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="num">(3,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from Divestiture of Businesses, Net of Cash Divested</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(6,044)<span></span>
</td>
<td class="nump">733<span></span>
</td>
<td class="num">(5,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of debt</a></td>
<td class="nump">6,919<span></span>
</td>
<td class="nump">4,945<span></span>
</td>
<td class="nump">8,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Extinguishment of debt</a></td>
<td class="num">(297)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,150)<span></span>
</td>
<td class="num">(6,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(6,360)<span></span>
</td>
<td class="num">(4,975)<span></span>
</td>
<td class="num">(3,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(4,196)<span></span>
</td>
<td class="num">(4,013)<span></span>
</td>
<td class="num">(3,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,037)<span></span>
</td>
<td class="num">(8,271)<span></span>
</td>
<td class="num">(4,867)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(360)<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">7,989<span></span>
</td>
<td class="nump">6,266<span></span>
</td>
<td class="nump">6,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">$ 7,629<span></span>
</td>
<td class="nump">$ 7,989<span></span>
</td>
<td class="nump">$ 6,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IncreaseDecreaseInNoncurrentTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Noncurrent Tax Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IncreaseDecreaseInNoncurrentTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146633712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#8217;s products, primarily in Europe, are excluded from revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;A expense in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with multiple-performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into arrangements for the R&amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#8217; costs; and amortization of acquired technology used in R&amp;D with alternative future uses. R&amp;D expenses also include costs and cost recoveries associated with third-party R&amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $841 million, $843 million and $962 million during the years ended December 31, 2022, 2021 and 2020, respectively. SG&amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#8217;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;D projects with no alternative future use are recorded in R&amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions and divestitures, and Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#8217; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#8217; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of IPR&amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#8217; earnings are translated into U.S. dollars by using average exchange rates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and nonmarketable equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other (expense) income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other (expense) income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#8217; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other (expense) income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other (expense) income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other (expense) income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. The provisions of these standards have not had and are not expected to have a material impact on our consolidated financial statements.</span></div>In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146910880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and divestitures</a></td>
<td class="text">Acquisitions and divestitures <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposed acquisition of Horizon Therapeutics plc</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2022, we announced that we entered into a transaction agreement under which Amgen will acquire all shares of Horizon for $116.50 per share in cash for a transaction equity value of approximately $27.8 billion. Horizon is a global biotechnology company headquartered in Dublin, Ireland and is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Horizon has 12 marketed medicines and a pipeline with more than 20 development programs. The closing of this transaction is contingent upon satisfaction of certain regulatory (including FTC review) and other customary closing conditions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the proposed acquisition of Horizon, Amgen entered into a 364-day bridge credit agreement with a syndicated group of banks for an aggregate amount of $28.5 billion on December 12, 2022. On December 22, 2022, we entered into a term loan credit agreement with an aggregate principal amount of $4.0 billion which provides for two equally sized tranches of term loans, one with an 18-month term and one with a three-year term. Accordingly, the bridge credit agreement was reduced by the amount of the term loan credit agreement to $24.5&#160;billion. As of December 31, 2022, no amounts have been drawn under the bridge credit agreement or the term loan credit agreement. In connection with these credit agreements, Amgen incurred approximately $97 million of financing costs, which was capitalized primarily in Other current assets in our Consolidated Balance Sheets and is being amortized to Interest expense, net, in our Consolidated Statements of Income over the terms of the agreements. Additionally, we have agreed to maintain a cash balance of $2.96 billion that, together with any borrowings under the bridge credit agreement and term loan credit agreement, represents sources of funds available to finance the acquisition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;30, 2023, the Company and Horizon each received a request for additional information and documentary materials (Second Request) from the FTC in connection with the FTC&#8217;s review of the Company&#8217;s proposed acquisition of Horizon. The effect of the Second Request is to extend the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, until 30 days after the Company and Horizon have substantially complied with the Second Request, unless that period is extended voluntarily by the Company and Horizon or terminated sooner by the FTC.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of ChemoCentryx, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2022, we acquired all the outstanding stock of ChemoCentryx, a publicly traded biotechnology company focused on orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52.00 per share in cash, representing a total consideration of $3.9&#160;billion. The acquisition, which was accounted for as a business combination, includes TAVNEOS, an orally administered selective complement 5a receptor inhibitor that was approved by the U.S. FDA in October 2021 as an adjunctive therapy for adults with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis). TAVNEOS is commercialized by us in the United States; for markets outside the United States, TAVNEOS is commercialized by a collaboration partner, and Amgen is entitled to royalties and milestones based off future sales of the product. Upon its acquisition, ChemoCentryx became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2022, the Company incurred approximately $106&#160;million of costs directly related to the acquisition of ChemoCentryx, consisting of share-based payments to settle non-vested equity awards attributable to post-combination services, severance and other transaction costs. These costs were included primarily in SG&amp;A expense in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; developed-product-technology rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $3.9&#160;billion total consideration consisted of (i) a $3.7&#160;billion cash payment to outstanding common stockholders of ChemoCentryx and (ii) a $181&#160;million cash payment to equity award holders of ChemoCentryx for services rendered prior to the acquisition date of October 20, 2022, under the ChemoCentryx equity award plans.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The developed-product-technology rights acquired relates to TAVNEOS, which is approved in the United States and EU for ANCA-associated vasculitis. The estimated fair values of $3.5&#160;billion were determined by using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The developed-product-technology rights are being amortized on a straight-line basis over a weighted-average period of approximately 11 years using the straight-line method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the acquired inventory of $41&#160;million was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer&#8217;s effort are applied. The inventory fair value adjustment is being amortized as inventory turns over, which we estimate to be approximately 13 months.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net deferred tax liability of $516&#160;million was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $667&#160;million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value is primarily attributable to the expected synergies from the TAVNEOS asset.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, liabilities assumed and tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Teneobio, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies, which complement Amgen&#8217;s existing antibody capabilities and bispecific T-cell engager BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen&#8217;s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustments for the year ended December 31, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $22&#160;million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen&#8217;s results of operations during the year ended December 31, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset &#8211; R&amp;D technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration for this transaction comprised of (i) an upfront cash payment of $993&#160;million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio&#8217;s former equity holders of up to $1.6&#160;billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $299&#160;million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 17, Fair value measurement, for information regarding the estimated fair value of these obligations as of December 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of acquired IPR&amp;D assets totaled $991&#160;million, of which $784&#160;million relates to AMG 340, that is in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to four separate preclinical oncology programs. The R&amp;D technology rights of $115&#160;million relate to Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over 10 years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41&#160;million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A deferred tax liability of $244&#160;million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $273 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Five Prime Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $1.6&#160;billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a Phase 3 first-in-class program for gastric cancer. Five Prime&#8217;s operations have been included in our consolidated financial statements commencing after the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Five Prime to the bemarituzumab IPR&amp;D program of $1.5&#160;billion, which was expensed immediately in Acquired IPR&amp;D expense in the Consolidated Statements of Income; deferred tax assets of $177&#160;million; and other net liabilities of $47&#160;million. The acquired IPR&amp;D expense was not tax deductible.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Gensenta &#304;la&#231; Sanayi ve Ticaret A.&#350;.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2022, we sold our shares in Gensenta, a subsidiary in Turkey, to Eczac&#305;ba&#351;&#305; for net cash proceeds of approximately $130&#160;million. The transaction was accounted for as a sale of a business and did not meet the criteria to be classified as discontinued operations. Upon closing of this transaction, net assets related to Gensenta of $86 million were divested, and during the year ended December 31, 2022, we recognized a loss on divestiture of $567&#160;million recorded in Other operating expenses in the Consolidated Statements of Income, primarily due to the reclassification of $615&#160;million of cumulative foreign currency translation losses from AOCI into earnings. See Note 16, Stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148329744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#8217; locations, are presented below. The majority of ROW revenues relates to products sold in Europe. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,743&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2022, 2021 and 2020. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had product sales to three customers that individually accounted for more than 10% of total revenues for each of the years ended December 31, 2022, 2021 and 2020. For the year ended December 31, 2022, on a combined basis, these customers accounted for 82% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 75% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2022 and 2021, 26% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2022 and 2021, was not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969228724688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text">Stock-based compensation<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2022, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 15 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units and stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee&#8217;s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date. RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2022, 2021 and 2020, were $234.47, $233.10 and $235.63, respectively. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our RSUs:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant&#160;date<br/>fair&#160;value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair values of RSUs that vested during the years ended December 31, 2022, 2021 and 2020, were $192 million, $166 million and $161 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire 10 years from the date of grant. We use the Black&#8211;Scholes option valuation model to estimate the grant date fair value of stock options. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (average of implied and historical volatility)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our stock options:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise&#160;price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value<br/>(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.47&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic values of options exercised during the years ended December 31, 2022, 2021 and 2020, were $67 million, $56 million and $98 million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2022, 2021 and 2020, were $14 million, $12 million and $21 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, $362 million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of 1.7 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally three years. The performance goals for the units granted during the years ended December 31, 2022, 2021 and 2020, which are accounted for as equity awards, are based on (i) Amgen&#8217;s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen&#8217;s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a payout simulation model to estimate the grant date fair value of performance units. The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of units granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both December 31, 2022 and 2021, 1.6 million performance units were outstanding, with weighted-average grant date fair values per unit of $250.27 and $229.39 per unit, respectively. During the year ended December 31, 2022, 0.6 million performance units with a weighted-average grant date fair value per unit of $247.48 were granted, and 0.1 million performance units with a weighted-average grant date fair value per unit of $250.94 were forfeited.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair values of performance units paid during the years ended December 31, 2022, 2021 and 2020, were $150 million, $149 million and $230 million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.</span></div>As of December 31, 2022, $132 million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of one year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969228602480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined contribution plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined contribution plan</a></td>
<td class="text">Defined contribution planThe Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $243&#160;million, $279 million and $231 million for the years ended December 31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969228602480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes included the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes included the following (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred benefit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of NOL carryforwards. As of December 31, 2022, we elected to establish deferred taxes with respect to the U.S. minimum tax on the earnings of our foreign subsidiaries for the reversal of temporary items in future years. Significant components of our deferred tax assets and liabilities were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses capitalized for tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,537&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,819&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,876)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased in 2022, primarily driven by the Company&#8217;s expectation that certain state R&amp;D credits will expire unused.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $170 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $6&#160;million of those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2042. We had $896 million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $813 million of those state tax credit carryforwards. We had $51&#160;million of tax credit carryforwards related to our foreign jurisdictions available to offset future foreign income taxes for which we have provided no valuation allowance. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $1.3 billion of federal NOL carryforwards available to reduce future federal income taxes and have provided no valuation allowance on those federal NOL carryforwards. Additionally, $1.0&#160;billion of those federal NOL carryforwards have no expiration; the remainder begin to expire between 2023 and 2037. We had $536 million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $415&#160;million of those state NOL carryforwards. We had $1.9 billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $186 million of those foreign NOL carryforwards. For the foreign NOLs with no valuation allowance provided, $640 million have no expiration; and the remainder will expire between 2023 and 2051.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the total gross amounts of UTBs were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for expiration of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,770&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the UTBs as of December 31, 2022, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2022, 2021 and 2020, we recognized $189 million, $98 million and $116 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The increase in interest expense for the year ended December 31, 2022, was primarily due to higher interest rates during 2022. As of December 31, 2022 and 2021, accrued interest and penalties associated with UTBs were $1.1 billion and $881 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, primarily federal R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the years ended December 31, 2022, 2021 and 2020, differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company&#8217;s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2050. Additionally, the Company&#8217;s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. territory of Puerto Rico imposes a 4% excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico effective through December 31, 2022. For 2022, we account for the excise tax as a manufacturing cost that is capitalized in Inventories and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid during the years ended December 31, 2022, 2021 and 2020, were $2.4 billion, $1.9 billion and $1.4 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#8211;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#8211;2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010&#8211;2012 by an amount that would result in additional federal tax of approximately $3.6&#160;billion plus interest. Any additional tax that could be imposed for the years 2010&#8211;2012 would be reduced by up to approximately $900&#160;million of repatriation tax previously accrued on our foreign earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#8211;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#8211;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#8211;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#8211;2015 by an amount that would result in additional federal tax of approximately $5.1&#160;billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0&#160;billion. Any additional tax that could be imposed for the years 2013&#8211;2015 would be reduced by up to approximately $2.2&#160;billion of repatriation tax previously accrued on our foreign earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010&#8211;2012 and 2013&#8211;2015 Notices are without merit. We are contesting the 2010&#8211;2012 and 2013&#8211;2015 Notices through the judicial process. The two cases were consolidated in U.S. Tax Court on December 19, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently under examination by the IRS for the years 2016&#8211;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969245750816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per share</a></td>
<td class="text">Earnings per share<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three years ended December 31, 2022, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146476176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text">Collaborations<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i)&#160;active participants in the activity and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalties and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized under these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we acquired an equity stake in BeiGene for approximately $2.8&#160;billion in cash as part of a collaboration to expand our oncology presence in China. For additional information regarding our equity investment in BeiGene, see Note 9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash and development services of up to $1.25&#160;billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, net costs recovered from BeiGene for oncology product candidates were $199&#160;million, $220&#160;million and $225&#160;million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2022 and 2021, product sales from Amgen to </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BeiGene under the collaboration were $64&#160;million and $72&#160;million, respectively, and were recorded in Product sales in the Consolidated Statements of Income. During the years ended December 31, 2022 and 2021, profit and loss share expenses related to the initial product-specific commercialization period were $53&#160;million and $64&#160;million, respectively, and were recorded in SG&amp;A expense in the Consolidated Statements of Income. Product sales from Amgen to BeiGene and profit and loss share expenses were not material during the year ended December 31, 2020. Amounts owed from BeiGene for product sales were $6&#160;million and $21&#160;million as of December 31, 2022 and 2021, respectively, which are included in Trade receivables, net, in the Consolidated Balance Sheets. Net amounts owed from BeiGene for cost recoveries and profit and loss share payments were $47&#160;million and $61&#160;million as of December 31, 2022 and 2021, respectively, which are included in Other current assets in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca plc</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with AstraZeneca for the development and commercialization of TEZSPIRE. Under our collaboration, both companies share global costs, profits and losses equally after payment by AstraZeneca of a mid-single-digit royalty to Amgen. AstraZeneca leads global development, and both Amgen and AstraZeneca jointly commercialize TEZSPIRE in North America. In North America, Amgen, as the principal, recognizes product sales of TEZSPIRE in the United States, and AstraZeneca, as the principal, recognizes product sales of TEZSPIRE in Canada. AstraZeneca leads commercialization for TEZSPIRE outside North America. Amgen manufactures and supplies TEZSPIRE worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, net costs due to AstraZeneca for global development were $74 million, $49&#160;million and $52&#160;million, respectively, and were recorded in R&amp;D Expense in the Consolidated Statements of Income. During the years ended December 31, 2022, 2021 and 2020, net costs due to AstraZeneca for global commercialization were $60&#160;million, $39&#160;million and $16&#160;million, respectively, and were recorded in SG&amp;A Expense in the Consolidated Statements of Income. During the year ended December 31, 2022, global profit and loss share expenses were $119 million and were recorded primarily in Cost of sales in the Consolidated Statements of Income. TEZSPIRE launched in the United States in January 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UCB</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with UCB for the development and commercialization of EVENITY. Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe and China (excluding Hong Kong). Amgen, as the principal, leads commercialization for EVENITY and recognizes product sales in all other territories, including the United States. Global development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, global profit and loss share expenses were $255&#160;million, $186 million and $115 million, respectively, and were recorded primarily in Cost of sales in the Consolidated Statements of Income. Net costs recovered from and due to UCB during the years ended December 31, 2022, 2021 and 2020, were not material.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, we modified the terms of the collaboration. Effective January 1, 2022, in the United States, Novartis no longer collaborates with Amgen, shares Aimovig commercialization costs or is required to pay milestones, and Amgen no longer pays royalties to Novartis on U.S. sales of Aimovig. Novartis continues to hold global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig. Amgen and Novartis share global development expenses, and Novartis pays Amgen double-digit royalties on net sales of the product outside the United States and Japan. Amgen manufactures and supplies Aimovig worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, net costs recovered from Novartis for migraine products were $53&#160;million and were recorded in R&amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2021 and 2020, net costs recovered from Novartis for migraine products were $160 million and $192 million, respectively, and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2021 and 2020, royalties due to Novartis for Aimovig were $116&#160;million and $139 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2022, 2021 and 2020, royalties due from Novartis for Aimovig were not material.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kyowa Kirin Co., Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, we closed our collaboration and licensing agreement with KKC to jointly develop and commercialize rocatinlimab, an anti-OX40 fully human monoclonal antibody, worldwide, except in Japan. Rocatinlimab is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we lead the global development, manufacture and commercialization of rocatinlimab, except in Japan. KKC will co-promote rocatinlimab with Amgen in the United States and have opt in rights to co-promote rocatinlimab in various other markets outside the United States, including in Europe and Asia.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made an upfront payment of $400&#160;million to KKC that was recognized in R&amp;D expense in the third quarter of 2021. Amgen and KKC share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by KKC will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850&#160;million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay KKC significant double-digit royalties on global sales, except in Japan. Net costs recovered from and due to KKC were not material during the years ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969245747840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents in the above table excludes bank account cash of $4,970 million and $733 million as of December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All interest-bearing securities as of December 31, 2022 and 2021, mature in one year or less.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values (publicly traded securities) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $480 million and $611 million as of December 31, 2022 and 2021, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. For the years ended December 31, 2022, 2021 and 2020, net unrealized gains and losses on publicly traded securities were a loss of $165&#160;million and gains of $161&#160;million and $174&#160;million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2022, 2021 and 2020, were not material. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments of $233 million and $262 million in equity securities without readily determinable fair values as of December 31, 2022 and 2021, respectively, which are included in Other noncurrent ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ets in the Consolidated Balance Sheets. For the years ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020, gains due to upward adjustments and gains realized upon dispositions of </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these securities were not material. For the year ended December 31, 2021, gains due to upward adjustments were $152&#160;million, and gains realized on the dispositions of these securities were $41&#160;million. For the year ended December 31, 2022, downward adjustments to the carrying values of these securities were $67&#160;million. For the years ended December 31, 2021 and 2020, downward adjustments were not material. Adjustments were based on observable price transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8&#160;billion, of which $2.6&#160;billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;D. Our equity investment in BeiGene is included in Other noncurrent assets in the Consolidated Balance Sheets.</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our equity investment is accounted for under the equity method of accounting due to our ability to exert significant influence over BeiGene. See Note 1, Summary of significant accounting policies, for factors in concluding our ability to exert significant influence over BeiGene. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sets of BeiGene by approximately $2.4&#160;billion. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity method of accounting requires us to identify and allocate amounts to items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Other (expense) income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from 8 to 15 years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, 2021 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the carrying value of the investment was reduced by our share of BeiGene&#8217;s net losses of $394&#160;million, $265 million and $229&#160;million, respectively, and amortization of the basis difference of $190&#160;million, $172&#160;million and $109&#160;million, respectively. During the years ended December 31, 2021 and 2020, we increased the carrying value by $50 million and $569&#160;million, respectively, as a result of our purchases of additional shares of BeiGene; we did not purchase additional shares of BeiGene during the year ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, during the years ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, 2021 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the carrying value increased by $11&#160;million, $265&#160;million and $34&#160;million, respectively, from the impact of other BeiGene ownership transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, our ownership interest in BeiGene was approximately 18.2% and 18.4%, respectively. As of December 31, 2022 and 2021, the carrying value of our investment in BeiGene was $2.2 billion and $2.8 billion, respectively. As of December 31, 2022 and 2021, the fair value of our investment in BeiGene was $4.2 billion and $5.1 billion, respectively. We believe that as of December 31, 2022, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 30, 2023, we relinquished our right to appoint a director to BeiGene&#8217;s Board of Directors. We no longer have the ability to exert significant influence over BeiGene and therefore will account for our equity investment at fair value, with changes in fair value recorded in earnings starting in the first quarter of 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neumora Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257&#160;million, which is included in Other noncurrent assets in the Consolidated Balance Sheets, in exchange for a $100&#160;million cash payment and $157&#160;million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. During the year ended December 31, 2022, we made an additional $10&#160;million cash investment via participation in Neumora&#8217;s subsequent financing round. As of December 31, 2022 and 2021, our ownership interest in Neumora was approximately 24.9% and 25.9%, respectively, and the fair value of our investment was $335&#160;million and $220&#160;million, respectively. During the years ended December 31, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized a net gain of $105&#160;million and a net loss of $37&#160;million, respectively, for the change in fair values in Other (expense) income, net, in the Consolidated Statements of Income. For information on determination of fair values, see Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limited partnerships</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held limited partnership investments of $249 million and $573 million as of December 31, 2022 and 2021, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. These investments, which are primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2022, unfunded additional commitments to be made for these investments during the next several years were $187&#160;million. For the years ended December 31, 2022, 2021 and 2020, net gains and losses recognized from our limited partnership investments were a net loss of $284&#160;million and net gains of $143&#160;million and $241 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969228891792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146450240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;life&#160;(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-40</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, we recognized depreciation and amortization expense associated with our property, plant and equipment of $661 million, $644 million and $640 million, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographic information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148471744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and other intangible assets</a></td>
<td class="text">Goodwill and other intangible assets<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes to goodwill resulting from acquisitions and divestitures, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For 2022, the changes to goodwill consist of goodwill resulting from the acquisition of ChemoCentryx, changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,045)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,596&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,525)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,525)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,080&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses. Developed-product-technology rights include assets acquired with the ChemoCentryx acquisition. IPR&amp;D, R&amp;D technology rights and licensing rights includes assets acquired with the Teneobio acquisition. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&amp;D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;D projects may vary from their estimated fair values. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.</span></div>During the years ended December 31, 2022, 2021 and 2020, we recognized amortization associated with our finite-lived intangible assets of $2.6 billion, $2.6 billion and $2.8 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $2.8 billion, $2.7 billion, $2.5 billion, $2.1 billion and $2.1 billion, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969228766128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain facilities and equipment related primarily to R&amp;D, administrative and commercial activities. Leases with terms of 12 months or less are expensed as incurred and are not recorded in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most leases include one or more options to renew, with renewal terms that may extend the lease term up to seven years. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&amp;D and administrative space.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_359201fb-5c99-405a-ab38-b09b1a0810df"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_e337db26-bca6-43a8-9a70-6927970d6b3a">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_8eb856b2-2130-4703-a4b4-acc8ce46190d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_cfef6f7b-b5d4-400a-8a9d-e47d21f5486b">Accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_8acdce6f-01bc-4f81-be80-17993b14c4ca"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_f528949b-9261-49f0-9348-a8f3a32624b2">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net lease costs were as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2022, were as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes future rental commitments for abandoned leases of $90&#160;million. We expect to receive total future rental income of $76&#160;million related to noncancelable subleases for abandoned facilities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and weighted-average discount rates were as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and noncash information related to our leases was as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total undiscounted future lease payments for leases that have not yet commenced were not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969245709024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets and accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_AccruedLiabilitiesDisclosureTextBlock', window );">Other current assets and accrued liabilities</a></td>
<td class="text">Other current assets and accrued liabilities<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate partner receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969228909104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financing arrangements</a></td>
<td class="text">Financing arrangements<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% notes due in 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2029 (3.00% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05% notes due 2029 (4.05% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35% notes due 2032 (3.35% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% notes due 2033 (4.20% 2033 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% notes due 2052 (4.20% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.875% notes due 2053 (4.875% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2062 (4.40% 2062 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(437)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to 101% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes&#8212;except our 0.41% 2023 Swiss franc Bonds and Other notes due 2097&#8212;may be redeemed at any time at our option&#8212;in whole or in part&#8212;at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt issuances</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021 and 2020, we issued debt securities in the following offerings:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2022, we issued $7.0&#160;billion of debt consisting of $750 million of the 3.00% 2029 Notes, $1.25&#160;billion of the 4.05% 2029 Notes, $1.0 billion of the 3.35% 2032 Notes, $750&#160;million of the 4.20% 2033 Notes, $1.0 billion of the 4.20% 2052 Notes, $1.0&#160;billion of the 4.875% 2053 Notes and $1.25 billion of the 4.40% 2062 Notes. The 3.00% 2029 Notes were issued to finance eligible projects that meet specified criteria to reduce our impact on the environment.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2021, we issued $5.0&#160;billion of debt consisting of $1.25&#160;billion of the 1.65% 2028 Notes, $1.25&#160;billion of the 2.00% 2032 Notes, $1.15&#160;billion of the 2.80% 2041 Notes and $1.35&#160;billion of the 3.00% 2052 Notes. </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we issued $9.0&#160;billion of debt consisting of $500&#160;million of the 1.90% 2025 Notes, $1.75&#160;billion of the 2.20% 2027 Notes, $1.25&#160;billion of the 2.45% 2030 Notes, $1.25&#160;billion of the 2.30% 2031 Notes, $2.0&#160;billion of the 3.15% 2040 Notes and $2.25&#160;billion of the 3.375% 2050 Notes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt extinguishment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we repurchased portions of the 2.20% 2027 Notes, the 1.65% 2028 Notes, the 2.00% 2032 Notes, the 2.80% 2041 Notes and the 3.00% 2052 Notes for an aggregate cost of $297&#160;million, which resulted in the recognition of a $78&#160;million gain on extinguishment of debt recorded in Other (expense) income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt repayments/redemptions</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made debt repayments/redemptions during the years ended December 31, 2022, 2021 and 2020, as follows:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2022, no debt was repaid/redeemed.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2021, we redeemed $4.2&#160;billion of debt, including the &#8364;1.25&#160;billion aggregate principal amount ($1.4&#160;billion upon settlement of the related cross-currency swap) of the 1.25% 2022 euro Notes, the $500&#160;million aggregate principal amount of the 2.70% 2022 Notes, the $1.5&#160;billion aggregate principal amount of the 2.65% 2022 Notes and the $750&#160;million aggregate principal amount of the 3.625% 2022 Notes. In connection with the redemption of these notes, we paid a total of $24&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we repaid/redeemed $6.5&#160;billion of debt, including the repayment at maturity of the $300&#160;million aggregate principal amount of the 4.50% 2020 Notes, the $750&#160;million aggregate principal amount of the 2.125% 2020 Notes, the $300&#160;million Floating Rate Notes due 2020 and the $700&#160;million aggregate principal amount of the 2.20% 2020 Notes. In connection with the redemption of the $900&#160;million aggregate principal amount of the 3.45% 2020 Notes, the $1.0&#160;billion aggregate principal balance of the 4.10% 2021 Notes, the $750&#160;million aggregate principal balance of the 1.85% 2021 Notes and the $1.75&#160;billion aggregate principal balance of the 3.875% 2021 Notes, we paid a total of $96&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $1.0&#160;billion with respect to the 2.45% 2030 Notes and an aggregate notional amount of $500&#160;million with respect to the 2.30% 2031 Notes. In connection with the redemption of the 3.625% 2022 Notes, discussed above, associated interest rate swap contracts with an aggregate notional amount of $750&#160;million were terminated.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of certain of the notes during the year ended December 31, 2020, discussed above, associated interest rate swap contracts with an aggregate notional value of $3.65&#160;billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2&#160;billion that hedged the 3.625% 2024 Notes, the 2.60% 2026 Notes, the 4.663% 2051 Notes and portions of the 3.625% 2022 Notes and the 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2024 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 3.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% 2025 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% 2026 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% 2030 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% 2031 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% 2051 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 4.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt exchange</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $940&#160;million principal amount of the newly issued 2.77% 2053 Notes (the Exchange Offer).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal amount exchanged</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% 2037 Notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% 2038 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% 2039 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% 2040 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% 2041 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% 2042 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% 2043 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2.77% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the 2.77% 2053 Notes. In connection with the Exchange Offer, $85 million was paid to holders of the Old Notes (the cash consideration).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $264 million discount associated with the 2.77% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cross-currency swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our 0.41% 2023 Swiss franc Bonds, 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of the 1.25% 2022 euro Notes, discussed above, associated cross-currency swap contracts with an aggregate notional amount of &#8364;1.25&#160;billion were terminated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf registration statement and other facilities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2022 and 2021, we had no amounts outstanding under our commercial paper program.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.1% of the unused portion of the facility based on our current credit rating. In December 2022, this revolving credit agreement was further amended to replace LIBOR with SOFR as the reference rate, pursuant to provisions contained therein related to determination of successor rates in case of phaseout or unavailability of existing designated reference rates. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) SOFR plus 1.125% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month SOFR plus 1.1%. As of December 31, 2022 and 2021, no amounts were outstanding under this facility.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depositary shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depositary shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023, and our Board has approved a new shelf registration statement to replace it.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, in connection with the proposed acquisition of Horizon, we entered into a bridge credit agreement and a term loan credit agreement which provide for borrowings aggregating $28.5&#160;billion. As of December 31, 2022, no amounts have been borrowed under either agreement. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement, bridge credit agreement and term loan agreement include a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements. We were in compliance with all applicable covenants under these arrangements as of December 31, 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual maturities of debt obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December 31, 2022, are as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest costs</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2022, 2021 and 2020, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during each of the years ended December 31, 2022, 2021 and 2020, were $1.2&#160;billion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146282048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text">Stockholders&#8217; equity<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, the Company entered into ASR agreements with third-party financial institutions (Dealers) whereby the Company made payments in an aggregate amount of $6.0 billion to the Dealers and received and retired an initial 23.3 million shares of the Company&#8217;s common stock from the Dealers. The payments were recorded as reductions to shareholders&#8217; equity, consisting of a $5.1 billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $0.9 billion decrease in additional paid-in capital, which reflects the value of the stock that remained to be delivered by the Dealers. During the third quarter of 2022, an additional 1.5 million shares of the Company&#8217;s common stock were received from the Dealers which constituted final settlement under the ASR agreements, and accordingly, the $0.9 billion decrease in additional paid-in capital recorded in the first quarter was reclassified to accumulated deficit. In total, we repurchased 26.1&#160;million shares of common stock during the year ended December 31, 2022, consisting primarily of the 24.8 million shares received under the ASR agreements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $2.4&#160;billion. As of December 31, 2022, $7.0 billion remained available under our stock repurchase program. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors declared quarterly dividends per share of $1.94, $1.76 and $1.60, which were paid in each of the four quarters of 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 12, 2022, the Board of Directors declared a quarterly cash dividend of $2.13 per share of common stock, which will be paid in March 2023, to all stockholders of record as of the close of business on February 15, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $19 million expense and a $0 million expense in 2022, a $33 million expense and a $55 million expense in 2021 and a $14 million benefit and a $110 million benefit in 2020, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $1 million expense and a $7 million benefit in 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2022 and 2021, no shares of preferred stock were issued or outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146589040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurement</a></td>
<td class="text">Fair value measurement<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations for which all significant inputs are observable either directly or indirectly&#8212;other than Level 1 inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2022, using:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing and equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. Other investments consist of interest-bearing deposits that are valued at amortized cost, which approximates fair value given their near term maturity. The fair value of equity securities for which the fair value option was elected are initially valued at the transaction price and subsequently valued based on a combination of observable price transactions, when available, market performance and publicly available market information for similar companies that have actively traded equity securities. See Note 9, Investments&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neumora Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency forward contracts, cross-currency swap contracts and interest rate swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs, as applicable, include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. Certain inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes to these inputs would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Teneobio in 2021, we are obligated to pay its former shareholders up to $1.6&#160;billion upon achieving separate development and regulatory milestones with regard to various R&amp;D programs. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of K-A in 2018, we are obligated to make single-digit royalty payments to Kirin Holdings Company, Limited contingent upon sales of brodalumab.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of BioVex Group Inc. in 2011, we were obligated to pay its former shareholders upon achieving separate sales-related milestones with regard to IMLYGIC if certain sales thresholds were met. During the year ended December 31, 2020, we determined that the likelihood of achieving these milestones was no longer probable, and accordingly, the obligations were written off.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of the fair values of other financial instruments</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2022 and 2021, the aggregate fair values of our borrowings were $35.0 billion and $37.9 billion, respectively, and the carrying values were $38.9 billion and $33.3 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in BeiGene</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2022 and 2021, the fair values were $4.2&#160;billion and $5.1&#160;billion, and the carrying values were $2.2&#160;billion and $2.8&#160;billion, respectively.</span></div>During the years ended December 31, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146562272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative instruments</a></td>
<td class="text">Derivative instruments<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We have designated certain of our derivatives as cash flow and fair value hedges; we also have derivatives not designated as hedges. We do not use derivatives for speculative trading purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. The foreign currency exchange rate fluctuation exposure associated with cash inflows from our international product sales are partially offset by corresponding cash outflows from our international operating expenses. To further reduce this exposure, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, 2021 and 2020, we had outstanding foreign currency forward contracts with aggregate notional amounts of $6.0 billion, $5.7 billion and $5.1 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The notional amounts and interest rates of our cross-currency swaps as of December 31, 2022, were as follows (notional amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. In December 2022, we entered into a forward interest rate contract with an aggregate notional amount of $700&#160;million. Amounts expected to be recognized during the subsequent 12 months on forward interest rate contracts are not material.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of both December 31, 2022 and 2021, we had interest rate swap contracts with aggregate notional amounts of $6.7&#160;billion that hedge certain portions of our long-term debt issuances. See Note 15, Financing arrangements, for information on our interest rate swaps.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt">Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $357 million and $440 million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt">Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $257 million and $340 million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of hedging transactions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2022, we expected to reclassify $159 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2022, 2021 and 2020, the total notional amounts of these foreign currency forward contracts were $517 million, $680 million and $1.0 billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair values of derivatives</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative contracts that were in liability positions as of December 31, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change-in-control and (ii)&#160;our or the surviving entity&#8217;s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change-in-control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146589040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and commitments</a></td>
<td class="text">Contingencies and commitments <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in June 2018, Celgene filed 19 separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC (Amneal); Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited (MSN); Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc. (Sandoz); Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc. (Zydus), each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the &#8217;940 Patent), 7,208,516 (the &#8217;516 Patent), 7,427,638 (the &#8217;638 Patent), 7,659,302 (the &#8217;302 Patent), 7,893,101 (the &#8217;101 Patent), 8,455,536 (the &#8217;536 Patent), 8,802,717 (the &#8217;717 Patent), 9,018,243 (the &#8217;243 Patent) and 9,872,854 (the &#8217;854 Patent), which are listed in the Orange Book for Otezla. Each of these lawsuits was based on each defendant&#8217;s submission of an ANDA seeking FDA approval to market a generic version of Otezla. The New Jersey District Court consolidated these 19 lawsuits for discovery and case management purposes into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, Celgene filed amended complaints against Alkem, Amneal, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz, Actavis, Unichem and Zydus additionally asserting U.S. Patent No. 9,724,330 (the &#8217;330 Patent), which is listed in the Orange Book for Otezla. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN, Pharmascience, Prinston, Sandoz, Actavis, Torrent, Unichem and Zydus additionally asserting U.S. Patent No. 10,092,541 (the &#8217;541 Patent), which is listed in the Orange Book for Otezla. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the &#8217;940, &#8217;302, &#8217;536, &#8217;243 and &#8217;330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the &#8217;283 Patent) and 8,629,173, which are not listed in the Orange Book for Otezla. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz, Shilpa, Actavis, Torrent, Unichem and Zydus filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Amgen&#8217;s acquisition of the patents-in-suit and the new drug application for Otezla, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;854 and &#8217;541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz with respect to the &#8217;717, &#8217;516 and &#8217;854 Patents, leaving the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents asserted by Amgen against Sandoz in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind&#8217;s apremilast product during the term of the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods&#8217; apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal&#8217;s apremilast product during the term of the &#8217;101, &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa&#8217;s apremilast product during the term of the &#8217;638, &#8217;101 and &#8217;854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis&#8217; apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;536, &#8217;717, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On March 24, 2021, based on a joint request by Amgen and Prinston, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Prinston&#8217;s apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 6, 2021, based on a joint request by Amgen and Aurobindo, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Aurobindo&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, based on a joint request by Amgen and Cipla, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Cipla&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 14, 2021, based on a joint request by Amgen and Torrent, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Torrent&#8217;s apremilast product during the term of the &#8217;101, &#8217;638, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 19, 2021, based on a joint request by Amgen and Alkem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Alkem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 25, 2021, based on a joint request by Amgen and MSN, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of MSN&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 11, 2021, based on a joint request by Amgen and Pharmascience, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience&#8217;s apremilast product during the term of the &#8217;243, &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;536 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the &#8217;638 Patent, claim 6 of the &#8217;536 Patent and claims 2 and 27 of the &#8217;283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the &#8217;101 Patent and claims 2, 19 and 21 of the &#8217;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus&#8217;s ANDA must be after expiration of the three infringed patents (the &#8217;638, &#8217;536 and &#8217;283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus&#8217;s generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the &#8217;638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the &#8217;638 Patent, claim 6 of the &#8217;536 Patent and claims 1 and 15 of the &#8217;101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the &#8217;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz&#8217;s ANDA must be after expiration of the three infringed patents (the &#8217;638, &#8217;536 and &#8217;101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz&#8217;s generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the &#8217;638 and &#8217;101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral argument for Amgen&#8217;s, Sandoz&#8217;s and Zydus&#8217; appeals was held on February 8, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Apotex Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 14, 2022, Amgen filed a lawsuit in the New Jersey District Court against Apotex Inc. (Apotex) for infringement of the &#8217;638 Patent, the &#8217;854 Patent and the &#8217;541 Patent. This lawsuit was based on Apotex&#8217;s submission of an ANDA seeking FDA approval to market a generic version of Otezla and seeks an order of the New Jersey District Court making any FDA approval of Apotex&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2022, Apotex filed its answer, disputing infringement and/or validity of the patents-in-suit. Along with its answer, Apotex also filed declaratory judgment counterclaims asserting that the patents-in-suit are not infringed and/or are invalid. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, based on a joint request by Amgen and Apotex, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Apotex&#8217;s apremilast product during the term of the &#8217;638, &#8217;854, and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Sanofi, et al. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, Amgen initiated a series of lawsuits that were consolidated by the U.S. District Court for the District of Delaware (Delaware District Court) in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing seven of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the &#8217;165 Patent); 8,859,741 (the &#8217;741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to PCSK9. By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron&#8217;s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen&#8217;s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron&#8217;s infringement of Amgen&#8217;s patents is willful.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT infringe certain of Amgen&#8217;s patents, including claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a five-day jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron&#8217;s posttrial motions seeking a new trial and for judgment as a matter of law, and granted Amgen&#8217;s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court&#8217;s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on two of Sanofi and Regeneron&#8217;s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#8217;s conclusion that the judgment affirming the validity of Amgen&#8217;s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen&#8217;s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron&#8217;s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen&#8217;s claim of willful infringement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2019, a jury of the Delaware District Court again unanimously upheld the validity of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. The jury also found that claims 7 and 15 of the &#8217;165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed posttrial motions seeking to reverse the jury verdict against them or for a new trial, and Amgen filed a motion for a permanent injunction. On August 28, 2019, the Delaware District Court ruled on the posttrial motions, denying Sanofi and Regeneron&#8217;s request for a new trial and their request to reverse the jury verdict that the &#8217;165 Patent and the &#8217;741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court and based on the subsequent hearing, on February 11, 2021 the Federal Circuit Court issued a decision affirming the Delaware District Court&#8217;s ruling. Amgen filed a petition for rehearing en banc which was denied on June 21, 2021. On November 18, 2021, Amgen filed a petition for writ of certiorari with the U.S. Supreme Court seeking review of the invalidation of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent as lacking an enabling disclosure of the invention. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2022, the U.S. Supreme Court granted review on Amgen&#8217;s petition for certiorari on the question of whether the appropriate standard was applied by the lower courts in invalidating claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent as lacking an enabling disclosure of the invention. Amgen filed its opening brief on December 27, 2022. On February 3, 2023, Sanofi and Regeneron filed a brief in response.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral argument before the U.S. Supreme Court is scheduled for March 27, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes in the International Region</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in Germany, Spain and Japan. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen&#8217;s patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen&#8217;s patent. In November 2018, the EPO confirmed the validity of Amgen&#8217;s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA&#8217;s decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA&#8217;s October 29, 2020 ruling.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, Amgen filed counterclaims alleging that PRALUENT infringes Amgen&#8217;s European Patent No. 2,641,917 (the &#8217;917 Patent). A EPO opposition to the &#8217;917 Patent, filed by Sanofi on February 5, 2021, is pending, and the hearing before the EPO&#8217;s Opposition Division is scheduled for February 21, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP&#8217;004 Patent), seeking infringement damages and injunctive relief. The EP&#8217;004 Patent is currently in opposition proceedings, initiated by Amgen and an anonymous third party, before the EPO. A hearing before the Opposition Division of the EPO was held on June 8 and 9, 2022, and on August 16, 2022, the Opposition Division issued a written decision upholding the validity of the EP&#8217;004 Patent claims at issue, with narrowing amendments. Proceedings before the TBA commenced on August 17, 2022. On November 22, 2022, Amgen filed Grounds of Appeal before the TBA, and on December 30, 2022, Regeneron filed Grounds of Appeal before the TBA. On January 23, 2023, the TBA invited Amgen to file any response to Regeneron&#8217;s Grounds of Appeal by May 23, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.&#8217;s appeals making final the Japanese High Court&#8217;s decisions that PRALUENT infringes Amgen&#8217;s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen&#8217;s Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. On April 15, 2021, the Japanese Patent Office dismissed Regeneron&#8217;s invalidity trials, and in August 2021 Regeneron appealed the decisions to the Japanese High Court. On January 26, 2023, the Japanese High Court found Amgen&#8217;s patent claims invalid for lacking adequate support. The decision is subject to appeal to the Japanese Supreme Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 654 (ustekinumab) Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Biotech, Inc. v. Amgen Inc. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 29, 2022, Janssen filed a lawsuit in the Delaware District Court alleging Amgen&#8217;s infringement of two patents by Amgen&#8217;s submission of an application for FDA licensure of ABP 654, Amgen&#8217;s biosimilar version of Janssen&#8217;s STELARA (ustekinumab) and also seeking declaratory judgment of infringement of the same two patents.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Class Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar Antitrust Class Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From February to April 2019, four plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceuticals USA, Inc. (Teva) alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. two of those actions were brought in the Delaware District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 21, 2019) (Local 1500) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cesar Castillo, Inc. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar and alleges that the plaintiffs have overpaid for Sensipar as a result of Amgen&#8217;s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lawsuits focus predominantly on the settlement among Amgen, Watson Laboratories, Inc. (Watson) and Teva of the parties&#8217; patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys&#8217; fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the four lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the four lawsuits, along with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cipla Ltd. v. Amgen Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consolidated and designated as an MDL in the Delaware District Court. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the four class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs&#8217; consolidated class action complaint and the indirect purchaser end payer plaintiffs&#8217; complaint. On December 6, 2019, the plaintiffs responded to Amgen&#8217;s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Delaware District Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge&#8217;s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs&#8217; objections. On November 30, 2020, the District Court adopted the Magistrate Judge&#8217;s recommendation in part and denied it in part, denying Amgen&#8217;s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen&#8217;s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs&#8217; offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court&#8217;s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the plaintiffs in the antitrust class action lawsuit brought on behalf of putative classes of direct or indirect purchasers of Sensipar filed their amended complaints. On March 4, 2021, a stipulation and order regarding the filing of a second amended complaint were filed to add another plaintiff: Teamsters Western Region &amp; Local 177 Health Care Fund. On March 17, 2021, a defendant, MSP Recovery Claims, Series LLC, filed its notice of voluntary dismissal. On March 30, 2021, the remaining defendants, including Amgen, filed their motions to dismiss the second amended complaint.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2021, plaintiffs filed their oppositions to defendants&#8217; (including Amgen&#8217;s) motion to dismiss, and defendants&#8217; reply was filed on May 25, 2021. A hearing on defendants&#8217; motion to dismiss was held in the Delaware District Court on July 13, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2022, the Delaware District Court granted defendants&#8217; (including Amgen&#8217;s) motion to dismiss except as to the reverse payment claim and various state law claims from ten of the states in which plaintiffs reside. On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal. The plaintiffs did not oppose Amgen&#8217;s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs&#8217; motion on June 10, 2022, and reply briefs were filed on June 24, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. Antitrust Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, Regeneron Pharmaceuticals, Inc. (Regeneron) filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen&#8217;s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payers and PBMs have harmed the sales of its product PRALUENT and focuses on two primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen&#8217;s initial responsive pleading, a motion to dismiss, was filed on August 1, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, Amgen moved to stay the case pending the ultimate decision on the merits of the ongoing patent litigation between Amgen and Regeneron in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Sanofi, et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2023, the Delaware District Court heard oral argument on the motion to stay and the motion to dismiss.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Litigation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. &amp; Subsidiaries v. Commissioner of Internal Revenue</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6, Income taxes, for discussion of the IRS tax dispute and the Company&#8217;s petitions in the U.S. Tax Court.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ChemoCentryx, Inc. Securities Matters</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5 and June 8 of 2021, ChemoCentryx and its Chief Executive Officer were named as defendants in two putative shareholder class actions filed in the U.S. District Court for the Northern District of California (Northern District Court of California). These cases were consolidated into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Homyk v. ChemoCentryx, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which the plaintiffs allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act in connection with statements regarding the New Drug Application for TAVNEOS and the underlying Phase 3 clinical trial, seeking an award of damages, interest and attorneys&#8217; fees. On March 28, 2022, the plaintiffs filed their consolidated amended complaint, and on May 19, 2022, ChemoCentryx moved to dismiss these claims.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2022, the Board of Directors and certain of ChemoCentryx&#8217;s officers were named as defendants in a putative shareholder derivative action filed in the Northern District Court of California, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Napoli v. Schall,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and on March 11, 2022, the Northern District Court of California stayed the action until judgment is entered in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Homyk v. ChemoCentryx, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action. On December 5, 2022 the plaintiffs in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Napoli</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> filed a Notice of Voluntary Dismissal, and on December 22, 2022, the Court ordered the dismissal of the case.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments &#8211; U.S. repatriation tax</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Tax Act, we elected to pay in eight annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2022 (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining U.S. repatriation tax commitments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144705264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2022, 2021 and 2020 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at beginning<br/>of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions<br/>charged&#160;to<br/>costs and<br/>expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at end<br/>of period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144709872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NatureOfOperationsPolicyTextBlock', window );">Business</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues and Arrangements with multiple performance obligations</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#8217;s products, primarily in Europe, are excluded from revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;A expense in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with multiple-performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into arrangements for the R&amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#8217; costs; and amortization of acquired technology used in R&amp;D with alternative future uses. R&amp;D expenses also include costs and cost recoveries associated with third-party R&amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, general and administrative costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $841 million, $843 million and $962 million during the years ended December 31, 2022, 2021 and 2020, respectively. SG&amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.</span></div>We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#8217;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;D projects with no alternative future use are recorded in R&amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions and divestitures, and Note 17, Fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash equivalents and restricted cash</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Interest-bearing securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#8217; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and other intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#8217; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of IPR&amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#8217; earnings are translated into U.S. dollars by using average exchange rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_EquityInvestmentsPolicyPolicyTextBlock', window );">Equity investments, policy</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and nonmarketable equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other (expense) income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other (expense) income, net, in the Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity method investments</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#8217; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other (expense) income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other (expense) income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other (expense) income, net, in the Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. The provisions of these standards have not had and are not expected to have a material impact on our consolidated financial statements.</span></div>In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityInvestmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the policy for investments in equity securities that are publicly traded and that do not have a readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityInvestmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969145842096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; developed-product-technology rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset &#8211; R&amp;D technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146263440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue by product and by geographic area</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,743&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.</span></div>(2)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2022, 2021 and 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenues earned from major customers</a></td>
<td class="text">Certain information with respect to these customers was as follows (dollar amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141807616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock', window );">Components of stock-based compensation expense recognized in the Consolidated Statements of Income</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSUs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our RSUs:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant&#160;date<br/>fair&#160;value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (average of implied and historical volatility)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock options</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our stock options:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise&#160;price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value<br/>(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.47&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock', window );">Weighted average assumptions used and the resulting weighted average grant date fair value of performance units</a></td>
<td class="text">The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of units granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148324976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of income before income tax, domestic and foreign</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes included the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes included the following (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred benefit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant components of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and liabilities were as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses capitalized for tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,537&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,819&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,876)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the total gross amounts of UTBs were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for expiration of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,770&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, primarily federal R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146316400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation for basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146633712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock', window );">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148444432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148436736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of property, plant and equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;life&#160;(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-40</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Property, plant and equipment by geographic information</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144653952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes to goodwill resulting from acquisitions and divestitures, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For 2022, the changes to goodwill consist of goodwill resulting from the acquisition of ChemoCentryx, changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ScheduleOfIntangibleAssetsTableTextBlock', window );">Schedule of identifiable intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,045)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,596&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,525)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,071&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,525)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,080&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146969328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary information, components of lease costs, cash and noncash information on leases and other lease information</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_359201fb-5c99-405a-ab38-b09b1a0810df"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_e337db26-bca6-43a8-9a70-6927970d6b3a">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_8eb856b2-2130-4703-a4b4-acc8ce46190d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_cfef6f7b-b5d4-400a-8a9d-e47d21f5486b">Accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_8acdce6f-01bc-4f81-be80-17993b14c4ca"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_f528949b-9261-49f0-9348-a8f3a32624b2">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net lease costs were as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and weighted-average discount rates were as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and noncash information related to our leases was as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of lease liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2022, were as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes future rental commitments for abandoned leases of $90&#160;million. We expect to receive total future rental income of $76&#160;million related to noncancelable subleases for abandoned facilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148445376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets and accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate partner receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969145649808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Carrying values and the fixed contractual coupon rates of long-term borrowings</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% notes due in 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2029 (3.00% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05% notes due 2029 (4.05% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35% notes due 2032 (3.35% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% notes due 2033 (4.20% 2033 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% notes due 2052 (4.20% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.875% notes due 2053 (4.875% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2062 (4.40% 2062 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(437)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Schedule of interest rate derivatives</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2024 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 3.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% 2025 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% 2026 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% 2030 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% 2031 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% 2051 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 4.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock', window );">Schedule of Long-term Debt Instruments Exchanged</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal amount exchanged</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% 2037 Notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% 2038 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% 2039 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% 2040 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% 2041 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% 2042 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% 2043 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate contractual maturities of long-term debt obligations</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December 31, 2022, are as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Long-term Debt Instruments Exchanged [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141031840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_StockRepurchaseProgramTableTextBlock', window );">Summary of activity under our stock repurchase program</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of accumulated other comprehensive income</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassifications out of accumulated other comprehensive income</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_StockRepurchaseProgramTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_StockRepurchaseProgramTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144559888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2022, using:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Changes in contingent consideration</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148293328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock', window );">Schedule of notional amounts and interest rates for cross-currency swaps</a></td>
<td class="text">The notional amounts and interest rates of our cross-currency swaps as of December 31, 2022, were as follows (notional amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock', window );">Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Derivatives in fair value hedging relationships</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt">Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $357 million and $440 million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt">Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $257 million and $340 million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Summary of amounts of income and expense line items</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div>(1)&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair values of derivatives included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note 17, Fair value measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148444432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock', window );">U.S. repatriation tax commitments</a></td>
<td class="text">The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2022 (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining U.S. repatriation tax commitments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148216688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_SalesReturnProvisionsAsPercentageOfProductSales', window );">Sales return provisions as a percentage of gross product sales (less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising cost</a></td>
<td class="nump">$ 841<span></span>
</td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">26,323<span></span>
</td>
<td class="nump">25,979<span></span>
</td>
<td class="nump">25,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 848<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_RevenuePaymentArrangementTerm', window );">Revenue payment term</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_RevenuePaymentArrangementTerm', window );">Revenue payment term</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RevenuePaymentArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Payment Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RevenuePaymentArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_SalesReturnProvisionsAsPercentageOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Return Provisions As Percentage Of Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_SalesReturnProvisionsAsPercentageOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_NplateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_NplateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141824320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - Horizon Therapeutics PLC (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 22, 2022 </div>
<div>USD ($) </div>
<div>traunche</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>USD ($) </div>
<div>product </div>
<div>program </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amgn_BridgeCreditAgreementMember', window );">bridge credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BridgeCreditAgreementAmount', window );">Bridge credit agreement amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember', window );">Horizon Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Acquisition price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ApprovedProducts', window );">Approved products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DevelopmentPrograms', window );">Development programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BridgeCreditAgreementMaximumLength', window );">Bridge credit agreement, maximum length</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BridgeCreditAgreementInitialAmount', window );">Bridge credit agreement, initial amount</a></td>
<td class="nump">$ 28,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,500,000,000<span></span>
</td>
<td class="nump">$ 28,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_TermLoanCreditAgreementTotalAmount', window );">Term loan credit agreement, total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_TermLoanCreditAgreementNumberOfTraunches', window );">Term loan credit agreement, number of traunches | traunche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BridgeCreditReducedAmount', window );">Bridge credit reduced amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensatingBalanceAmount', window );">Compensating balance, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,960,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember', window );">Horizon Therapeutics [Member] | bridge credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BridgeCreditAgreementAmount', window );">Bridge credit agreement amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ApprovedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Approved products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ApprovedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BridgeCreditAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bridge credit agreement amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BridgeCreditAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BridgeCreditAgreementInitialAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bridge credit agreement, initial amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BridgeCreditAgreementInitialAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BridgeCreditAgreementMaximumLength">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bridge credit agreement, maximum length</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BridgeCreditAgreementMaximumLength</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BridgeCreditReducedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bridge credit agreement, reduced amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BridgeCreditReducedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TermLoanCreditAgreementNumberOfTraunches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term loan credit agreement, number of traunches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TermLoanCreditAgreementNumberOfTraunches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TermLoanCreditAgreementTotalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>term loan credit agreement, total amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TermLoanCreditAgreementTotalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensatingBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensatingBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amgn_BridgeCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amgn_BridgeCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144524112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - ChemoCentryx Inc. Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 20, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,529<span></span>
</td>
<td class="nump">$ 14,890<span></span>
</td>
<td class="nump">$ 14,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_ChemoCentryxIncMember', window );">ChemoCentryx, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Acquisition price per share (in dollars per share)</a></td>
<td class="nump">$ 52.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_Businessassetacquisitionconsiderationtransferred', window );">Total consideration</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash purchase price</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices', window );">Business acquisition, cash consideration paid to equity holders for pre-acquisition services</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired', window );">Business combination, turnover period of inventory acquired</a></td>
<td class="text">13 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_ChemoCentryxIncMember', window );">ChemoCentryx, Inc. | Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets &#8211; developed-product-technology rights</a></td>
<td class="nump">$ 3,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, cash consideration paid to equity holders for pre-acquisition services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, turnover period of inventory acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_Businessassetacquisitionconsiderationtransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business asset acquisition, consideration transferred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_Businessassetacquisitionconsiderationtransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_ChemoCentryxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_ChemoCentryxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144580720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and divestitures - Summary of Total Consideration for ChemoCentryx Inc (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 20, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 15,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,890<span></span>
</td>
<td class="nump">$ 14,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_ChemoCentryxIncMember', window );">ChemoCentryx, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities', window );">Other liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet', window );">Total assets acquired, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_ChemoCentryxIncMember', window );">ChemoCentryx, Inc. | Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_ChemoCentryxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_ChemoCentryxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144962304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - Teneobio Inc. (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 15,529<span></span>
</td>
<td class="nump">15,529<span></span>
</td>
<td class="nump">$ 14,890<span></span>
</td>
<td class="nump">$ 14,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, Purchase Accounting Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash purchase price</a></td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum additional consideration due contingent on certain milestones</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Additions</a></td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | R &amp; D Technology rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired in-process research and development</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfPreclinicalOncologyPrograms', window );">Number of oncology programs comprising remaining IPR&amp;D | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | IPR&amp;D | AMG 340</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 784<span></span>
</td>
<td class="nump">$ 784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfPreclinicalOncologyPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Preclinical Oncology Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfPreclinicalOncologyPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_MoleculeTypeAxis=amgn_AMG340Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_MoleculeTypeAxis=amgn_AMG340Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144468384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - Summary of Total Consideration for Teneobio Inc (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 15,529<span></span>
</td>
<td class="nump">15,529<span></span>
</td>
<td class="nump">$ 14,890<span></span>
</td>
<td class="nump">$ 14,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash purchase price</a></td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Contingent consideration</a></td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_Businessassetacquisitionconsiderationtransferred', window );">Total consideration</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities', window );">Other assets, net</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet', window );">Total assets acquired, net</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | R &amp; D Technology rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="nump">$ 991<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_Businessassetacquisitionconsiderationtransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business asset acquisition, consideration transferred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_Businessassetacquisitionconsiderationtransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140481696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - Five Prime Therapeutics Inc. (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Total cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,839<span></span>
</td>
<td class="nump">$ 2,529<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_FivePrimeTherapeuticsIncMember', window );">Five Prime Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Total cash consideration</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_FivePrimeTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_FivePrimeTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969145115056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - Divestiture of Gensenta (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness', window );">Foreign currency translation, loss on divestiture of a business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of businesses</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Divested assets</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=amgn_OtherGeneralExpenseMember', window );">Other general expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (Loss) on Disposition of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (567)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation, loss on divestiture of a business</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=amgn_OtherGeneralExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=amgn_OtherGeneralExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969138567888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue', window );">Number of major customers (as defined) accounting for more than 10% of total revenue | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables', window );">Major customers (as defined) accounting for more than 10% of gross trade receivables | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers', window );">Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers', window );">Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,323<span></span>
</td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation', window );">Percentage of net trade receivables due from customers located outside the United States, primarily in Europe</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,323<span></span>
</td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">25,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,595<span></span>
</td>
<td class="nump">18,194<span></span>
</td>
<td class="nump">18,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,728<span></span>
</td>
<td class="nump">7,785<span></span>
</td>
<td class="nump">6,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,801<span></span>
</td>
<td class="nump">24,297<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,801<span></span>
</td>
<td class="nump">24,297<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,743<span></span>
</td>
<td class="nump">17,286<span></span>
</td>
<td class="nump">17,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
<td class="nump">7,011<span></span>
</td>
<td class="nump">6,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,117<span></span>
</td>
<td class="nump">4,465<span></span>
</td>
<td class="nump">4,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
<td class="nump">4,352<span></span>
</td>
<td class="nump">4,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,465<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="nump">445<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">943<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">Kyprolis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">Kyprolis [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="nump">736<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">Kyprolis [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">1,734<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EvenityMember', window );">Evenity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EvenityMember', window );">Evenity | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EvenityMember', window );">Evenity | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,570<span></span>
</td>
<td class="nump">5,321<span></span>
</td>
<td class="nump">5,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">3,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">1,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=amgn_CustomerOneMember', window );">AmerisourceBergen Corporation [Member] | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,443<span></span>
</td>
<td class="nump">14,783<span></span>
</td>
<td class="nump">14,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=amgn_CustomerTwoMember', window );">McKesson Corporation [Member] | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">15,187<span></span>
</td>
<td class="nump">13,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=amgn_CustomerThreeMember', window );">Cardinal Health, Inc. [Member] | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,319<span></span>
</td>
<td class="nump">$ 7,681<span></span>
</td>
<td class="nump">$ 7,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Major customers (as defined) accounting for more than 10% of gross trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers (as defined) accounting for more than 10% of total revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_ProliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_ProliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_OtezlaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_OtezlaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_XgevaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_XgevaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_AranespMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_AranespMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_NplateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_NplateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_KyprolisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_KyprolisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_EvenityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_EvenityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144571408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Customer Concentration, Product Sales (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 26,323<span></span>
</td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue', window );">Number of major customers (as defined) accounting for more than 10% of total revenue | customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables', window );">Major customers (as defined) accounting for more than 10% of gross trade receivables | customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 24,801<span></span>
</td>
<td class="nump">$ 24,297<span></span>
</td>
<td class="nump">$ 24,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | AmerisourceBergen Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 15,443<span></span>
</td>
<td class="nump">$ 14,783<span></span>
</td>
<td class="nump">$ 14,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageOfGrossRevenues', window );">Gross product sales to major customer (as defined) as a percentage of total gross revenues</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | McKesson Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 17,305<span></span>
</td>
<td class="nump">$ 15,187<span></span>
</td>
<td class="nump">$ 13,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageOfGrossRevenues', window );">Gross product sales to major customer (as defined) as a percentage of total gross revenues</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Cardinal Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 8,319<span></span>
</td>
<td class="nump">$ 7,681<span></span>
</td>
<td class="nump">$ 7,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageOfGrossRevenues', window );">Gross product sales to major customer (as defined) as a percentage of total gross revenues</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Major customers (as defined) accounting for more than 10% of gross trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers (as defined) accounting for more than 10% of total revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfGrossRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross product sales to major customer (as defined) as a percentage of total gross revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfGrossRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969138513392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Textual) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted', window );">Amount by which the pool of available shares will be reduced for each stock option granted</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances', window );">The amount of common stock available under the plan for future grants and/or issuances (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Description of vesting of restricted stock units and stock options</a></td>
<td class="text">RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to nonvested awards</a></td>
<td class="nump">$ 362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Period over which the grants of equity instruments vest</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned', window );">Number of common shares issued for each performance unit earned</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted', window );">The number of shares by which the pool of available shares will be reduced for other types of awards granted</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards', window );">Number of shares added back for tax withholding on full value awards</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">$ 234.47<span></span>
</td>
<td class="nump">$ 233.10<span></span>
</td>
<td class="nump">$ 235.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of units that vested during the year</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 228.71<span></span>
</td>
<td class="nump">$ 217.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Units, forfeited (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited (in usd per share)</a></td>
<td class="nump">$ 226.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of stock options from date of grant</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised during the year</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Actual tax benefits realized from tax deductions from option exercises</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember', window );">Performance units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted', window );">The number of shares by which the pool of available shares will be reduced for other types of awards granted</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards', window );">Number of shares added back for tax withholding on full value awards</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">$ 247.48<span></span>
</td>
<td class="nump">$ 254.68<span></span>
</td>
<td class="nump">$ 249.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of units that vested during the year</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to nonvested awards</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 250.27<span></span>
</td>
<td class="nump">$ 229.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Units, forfeited (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited (in usd per share)</a></td>
<td class="nump">$ 250.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock available under the plan for future grants and/or issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issued for each performance unit earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the pool of available shares will be reduced for each stock option granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the pool of available shares will be reduced for other types of awards granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Added Back for Tax Withholding on Full Value Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144398368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Components of Stock-based Compensation Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit from stock-based compensation expense</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_StockBasedCompensationExpenseNetOfTax', window );">Total stock-based compensation expense, net of tax</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember', window );">Performance units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_StockBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total stock-based compensation expense, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_StockBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147747616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Summary of RSUs) (Details) - RSUs [Member] - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance nonvested at beginning of period (in shares)</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance nonvested at end of period (in shares)</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant&#160;date fair&#160;value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance nonvested at beginning of period (in usd per share)</a></td>
<td class="nump">$ 217.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">234.47<span></span>
</td>
<td class="nump">$ 233.10<span></span>
</td>
<td class="nump">$ 235.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share)</a></td>
<td class="nump">201.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="nump">226.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance nonvested at end of period (in usd per share)</a></td>
<td class="nump">$ 228.71<span></span>
</td>
<td class="nump">$ 217.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144937680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_CommonStockFairValue', window );">Closing price of our common stock on grant date (in usd per share)</a></td>
<td class="nump">$ 230.92<span></span>
</td>
<td class="nump">$ 237.17<span></span>
</td>
<td class="nump">$ 236.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">24.50%<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
<td class="nump">28.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">$ 42.43<span></span>
</td>
<td class="nump">$ 40.43<span></span>
</td>
<td class="nump">$ 42.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_CommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_CommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148233552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Summary of Stock Options) (Details) - Stock options [Member]<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance unexercised at beginning of period (in shares) | shares</a></td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired/forfeited (in shares) | shares</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance unexercised at end of period (in shares) | shares</a></td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest (in shares) | shares</a></td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average exercise&#160;price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance unexercised at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 197.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">230.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">167.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">226.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance unexercised at end of period (in shares) | $ / shares</a></td>
<td class="nump">207.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested or expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">206.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 177.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock options information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years), unexercised</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (years), vested or expected to vest</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (years), exercisable</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, unexercised | $</a></td>
<td class="nump">$ 295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested or expected to vest | $</a></td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable | $</a></td>
<td class="nump">$ 187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969150988336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Weighted-average Assumptions) (Details) - Performance units [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_CommonStockFairValue', window );">Closing price of our common stock on grant date (in usd per share)</a></td>
<td class="nump">$ 230.92<span></span>
</td>
<td class="nump">$ 239.64<span></span>
</td>
<td class="nump">$ 236.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">28.10%<span></span>
</td>
<td class="nump">29.30%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of unit (in usd per share)</a></td>
<td class="nump">$ 247.48<span></span>
</td>
<td class="nump">$ 254.68<span></span>
</td>
<td class="nump">$ 249.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_CommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_CommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146305040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined contribution plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense attributed to Retirement and Savings Plan</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969151094400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Income Before Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">$ 7,346<span></span>
</td>
<td class="nump">$ 6,701<span></span>
</td>
<td class="nump">$ 8,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">3,026<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">4,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">$ 4,320<span></span>
</td>
<td class="nump">$ 4,851<span></span>
</td>
<td class="nump">$ 4,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969151103264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Provision for Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 1,721<span></span>
</td>
<td class="nump">$ 865<span></span>
</td>
<td class="nump">$ 921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,185)<span></span>
</td>
<td class="num">(308)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred benefit</a></td>
<td class="num">(1,275)<span></span>
</td>
<td class="num">(434)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969151045024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes (Components of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards', window );">NOL and credit carryforwards</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development expenses</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Deferred Tax Assets, Equity Method Investments</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Expenses capitalized for tax</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries', window );">Deferred tax asset, earnings of foreign subsidiaries</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">3,537<span></span>
</td>
<td class="nump">2,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(718)<span></span>
</td>
<td class="num">(663)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangible assets</a></td>
<td class="num">(1,238)<span></span>
</td>
<td class="num">(824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Debt</a></td>
<td class="num">(272)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(1,876)<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred income taxes, net</a></td>
<td class="nump">$ 943<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset, earnings of foreign subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets. Deferred Expense, Capitalized Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140720464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Textual) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 19, 2022 </div>
<div>Case</div>
</th>
<th class="th">
<div>Apr. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>numberOfNotices</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties related to unrecognized tax benefits recognized in income tax provision</a></td>
<td class="nump">$ 189,000,000<span></span>
</td>
<td class="nump">$ 98,000,000<span></span>
</td>
<td class="nump">$ 116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties associated with unrecognized tax benefits</a></td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="nump">881,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">2,400,000,000<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce income taxes</a></td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards available to reduce income taxes</a></td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs with no valuation allowance and no expiration</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ProposedAdditionalIncomeTax', window );">Proposed additional income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_RepatriationTaxOnProposedAdditionalTax', window );">Repatriation tax on proposed additional tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfNoticesOnProposedAdditionalTax', window );">Number of notices on proposed additional tax | numberOfNotices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ProposedAdditionalIncomeTax20132015', window );">Proposed additional income tax 2013-2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105', window );">Penalties on proposed additional income tax 2013-2105</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_RepatriationTaxOnProposedAdditionalTax20132015', window );">Repatriation tax on proposed additional tax 2013-2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_NumberOfNoticesConsolidated', window );">Number of notices consolidated in court | Case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Expiration in tax years between 2023 and 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforwards, valuation allowance</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce income taxes</a></td>
<td class="nump">896,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforwards, valuation allowance</a></td>
<td class="nump">813,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards available to reduce income taxes</a></td>
<td class="nump">536,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">415,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce income taxes</a></td>
<td class="nump">51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforwards, valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards available to reduce income taxes</a></td>
<td class="nump">1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">186,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs with no valuation allowance and no expiration</a></td>
<td class="nump">640,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member] | Operating Losses That Expire Between 2022 and 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfNoticesConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Notices Consolidated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfNoticesConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfNoticesOnProposedAdditionalTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of notices on proposed additional tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfNoticesOnProposedAdditionalTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Penalties on proposed additional income tax 2013-2015</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PenaltiesOnProposedAdditionalIncomeTax20132105</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ProposedAdditionalIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proposed additional income tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ProposedAdditionalIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ProposedAdditionalIncomeTax20132015">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proposed additional income tax 2013-2015</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ProposedAdditionalIncomeTax20132015</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RepatriationTaxOnProposedAdditionalTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repatriation tax on proposed additional tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RepatriationTaxOnProposedAdditionalTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RepatriationTaxOnProposedAdditionalTax20132015">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repatriation tax on proposed additional tax 2013-2015</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RepatriationTaxOnProposedAdditionalTax20132015</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amgn_ExpirationInTaxYearsBetween2023And2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amgn_ExpirationInTaxYearsBetween2023And2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2022And2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2022And2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147651184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 3,546<span></span>
</td>
<td class="nump">$ 3,352<span></span>
</td>
<td class="nump">$ 3,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior years</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions for expiration of statute of limitations</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 3,770<span></span>
</td>
<td class="nump">$ 3,546<span></span>
</td>
<td class="nump">$ 3,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144722256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings</a></td>
<td class="num">(5.60%)<span></span>
</td>
<td class="num">(7.80%)<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">Foreign-derived intangible income</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Credits, Puerto Rico excise tax</a></td>
<td class="num">(2.80%)<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent', window );">Interest on uncertain tax positions</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Credits, primarily federal R&amp;D</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Acquisition IPR&amp;D</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Audit settlements</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147639552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Income (Numerator):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">$ 6,552<span></span>
</td>
<td class="nump">$ 5,893<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares (Denominator):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares for basic EPS</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares for diluted EPS</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic EPS (in usd per share)</a></td>
<td class="nump">$ 12.18<span></span>
</td>
<td class="nump">$ 10.34<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted EPS (in usd per share)</a></td>
<td class="nump">$ 12.11<span></span>
</td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="nump">$ 12.31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140504912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - BeiGene (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,323,000,000<span></span>
</td>
<td class="nump">$ 25,979,000,000<span></span>
</td>
<td class="nump">$ 25,424,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets [Member] | BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Related Party Transaction, Due from (to) Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000,000<span></span>
</td>
<td class="nump">61,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Accounts Receivable | BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Related Party Transaction, Due from (to) Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cost recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,000,000<span></span>
</td>
<td class="nump">220,000,000<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative [Member] | BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ProfitAndLossShareOfExpenses', window );">Profit and loss share of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000,000<span></span>
</td>
<td class="nump">64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_BeiGeneMember', window );">BeiGene | BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000,000<span></span>
</td>
<td class="nump">$ 72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ProfitAndLossShareOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit and loss share of expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ProfitAndLossShareOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148395968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - AstraZeneca PLC (Details) - AstraZeneca PLC - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amgn_AstraZenecaPLCMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DevelopmentCostsDueToCollaborationPartner', window );">Development costs due to collaboration partner</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amgn_AstraZenecaPLCMember', window );">Selling, general and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cost recoveries</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amgn_AstraZenecaPLCMember', window );">Cost of sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ProfitAndLossShareOfExpenses', window );">Profit and loss share of expenses</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DevelopmentCostsDueToCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development costs due to collaboration partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DevelopmentCostsDueToCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ProfitAndLossShareOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit and loss share of expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ProfitAndLossShareOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amgn_AstraZenecaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amgn_AstraZenecaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969151335952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - UCB (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amgn_UCBMember', window );">UCB | Cost of sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_ProfitAndLossShareOfExpenses', window );">Profit and loss share of expenses</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ProfitAndLossShareOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit and loss share of expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ProfitAndLossShareOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amgn_UCBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amgn_UCBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969151047216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Novartis AG (Details) - Novartis Pharma AG - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cost recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cost recoveries</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amgn_NovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amgn_NovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146454480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Kyowa Kirin (Details) - Kyowa Kirin Co. Ltd. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_UpFrontPayment', window );">Up-front payment</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments', window );">Revenue Recognition, Milestone Method, Potential Future Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-front payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amgn_KyowaKirinCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amgn_KyowaKirinCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969145357280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 4,335<span></span>
</td>
<td class="nump">$ 7,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">4,335<span></span>
</td>
<td class="nump">7,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144494944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Fair Values by Classification (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets locations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 1,676<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale investments</a></td>
<td class="nump">4,335<span></span>
</td>
<td class="nump">7,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember', window );">Available-for-sale investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets locations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">7,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale investments</a></td>
<td class="nump">$ 4,335<span></span>
</td>
<td class="nump">$ 7,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146352144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 4,970<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144989824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Equity Securities, FV-NI, Unrealized Gain (Loss)</a></td>
<td class="num">(165)<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_EquitySecuritiesRealizedGainLossOnDisposal', window );">Equity Securities, Realized Gain (Loss) on Disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquitySecuritiesRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Realized Gain (Loss) on Disposal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquitySecuritiesRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144388928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Limited Partnership Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount', window );">Investment Company, Financial Support to Investee Contractually Required, Amount</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember', window );">Limited Partnership [Member] | Fair Value Measured at Net Asset Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Investments</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">$ 573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_AlternativeInvestmentNetGainLoss', window );">Alternative Investment, Net Gain (Loss)</a></td>
<td class="num">$ (284)<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AlternativeInvestmentNetGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Net Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AlternativeInvestmentNetGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL6742756-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 35<br> -Paragraph 54B<br> -URI https://asc.fasb.org/extlink&amp;oid=126972413&amp;loc=SL7495116-110257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financial support committed by investment company to investee that is contractually required.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 20<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=66023616&amp;loc=SL35737432-115832<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140496704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - BeiGene (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 3,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Company's share of profits (losses) of related party</a></td>
<td class="num">$ (891)<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">18.20%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity Method Investment, Quoted Market Value</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_EquityMethodInvestmentChangeInCarryingValueOther', window );">Equity Method Investment, Change In Carrying Value, Other</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Company's share of profits (losses) of related party</a></td>
<td class="num">(394)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Approximate carrying value of the company's equity method investment</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentChangeInCarryingValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Change In Carrying Value, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentChangeInCarryingValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969138430544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Neumora Therapeutics, Inc. (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 3,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_NeumoraTherapeuticsIncMember', window );">Neumora Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.90%<span></span>
</td>
<td class="nump">24.90%<span></span>
</td>
<td class="nump">25.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember', window );">Neumora Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1', window );">Noncash or Part Noncash Acquisition, Investments Acquired</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity Method Investments, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_EquityMethodInvestmentChangeInCarryingValue', window );">Equity method investment, change in carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentChangeInCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, change in carrying value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentChangeInCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126960272&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_NeumoraTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_NeumoraTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969151546528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 828<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 4,930<span></span>
</td>
<td class="nump">$ 4,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140949696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Schedule) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 292<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings and improvements</a></td>
<td class="nump">4,201<span></span>
</td>
<td class="nump">4,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Manufacturing equipment</a></td>
<td class="nump">3,105<span></span>
</td>
<td class="nump">3,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LaboratoryEquipment', window );">Laboratory equipment</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_FixedEquipment', window );">Fixed equipment</a></td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Capitalized software</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Other</a></td>
<td class="nump">929<span></span>
</td>
<td class="nump">862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">14,710<span></span>
</td>
<td class="nump">13,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(9,283)<span></span>
</td>
<td class="num">(8,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,427<span></span>
</td>
<td class="nump">5,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization charges associated with property, plant and equipment</a></td>
<td class="nump">$ 661<span></span>
</td>
<td class="nump">$ 644<span></span>
</td>
<td class="nump">$ 640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember', window );">Manufacturing equipment [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember', window );">Manufacturing equipment [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_FixedEquipmentMember', window );">Fixed equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Capitalized software [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Capitalized software [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Other [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Other [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FixedEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FixedEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LaboratoryEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of laboratory equipment, gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LaboratoryEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_FixedEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_FixedEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144929920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, plant and equipment (Geographic Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 5,427<span></span>
</td>
<td class="nump">$ 5,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,154<span></span>
</td>
<td class="nump">2,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PR', window );">Puerto Rico [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=amgn_RestOfWorldMember', window );">ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 1,072<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amgn_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amgn_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148721664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Goodwill Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 14,890<span></span>
</td>
<td class="nump">$ 14,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Changes to goodwill resulting from acquisitions and divestitures, net(1)</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 15,529<span></span>
</td>
<td class="nump">$ 14,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140624224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Identifiable Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">$ 35,596<span></span>
</td>
<td class="nump">$ 32,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(20,525)<span></span>
</td>
<td class="num">(17,987)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">15,071<span></span>
</td>
<td class="nump">14,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_IdentifiableIntangibleAssetsGross', window );">Identifiable intangible assets</a></td>
<td class="nump">36,605<span></span>
</td>
<td class="nump">33,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(20,525)<span></span>
</td>
<td class="num">(17,987)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets, net</a></td>
<td class="nump">16,080<span></span>
</td>
<td class="nump">15,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">29,028<span></span>
</td>
<td class="nump">25,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(15,045)<span></span>
</td>
<td class="num">(12,769)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">13,983<span></span>
</td>
<td class="nump">12,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">3,864<span></span>
</td>
<td class="nump">3,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(3,123)<span></span>
</td>
<td class="num">(2,973)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing-related rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,167)<span></span>
</td>
<td class="num">(1,112)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember', window );">R&amp;D technology rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,190)<span></span>
</td>
<td class="num">(1,133)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifiable intangible assets accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IdentifiableIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IdentifiableIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifiable intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IdentifiableIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147743664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization charges associated with finite-lived intangible assets</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Total estimated amortization of finite-lived intangible assets for 2023</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Total estimated amortization of finite-lived intangible assets for 2024</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Total estimated amortization of finite-lived intangible assets for 2025</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Total estimated amortization of finite-lived intangible assets for 2026</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Total estimated amortization of finite-lived intangible assets for 2027</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146455664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147800048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other assets</a></td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">$ 539<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 695<span></span>
</td>
<td class="nump">$ 670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141871008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total net lease costs</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969138483440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">$ 670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_AbandonedLeasesMember', window );">Abandoned Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases', window );">Future rental commitments for abandoned leases</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Expected total future rental income to be received</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_AbandonedLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_AbandonedLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147859104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted Average Remaining Lease Terms &amp; Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969228634656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Cash and Noncash Information of Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969145273712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets and accrued liabilities - Schedule of Other Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 1,204<span></span>
</td>
<td class="nump">$ 1,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Corporate partner receivables</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Tax receivables</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="nump">$ 2,388<span></span>
</td>
<td class="nump">$ 2,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144987120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_AccruedSalesDeductionsCurrent', window );">Sales deductions</a></td>
<td class="nump">$ 5,986<span></span>
</td>
<td class="nump">$ 5,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_AccruedSalesReturnReserveCurrent', window );">Sales returns reserve</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,559<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 12,524<span></span>
</td>
<td class="nump">$ 10,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AccruedSalesDeductionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AccruedSalesDeductionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AccruedSalesReturnReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AccruedSalesReturnReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969130842912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements - Principal Amounts and Carrying Value of Long-term Borrowings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized bond discounts, premiums and issuance costs, net</a></td>
<td class="num">$ (1,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Fair value adjustments</a></td>
<td class="num">(437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other Long-term Debt</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt</a></td>
<td class="nump">38,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="num">(1,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 37,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.625% Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.25% notes due 2023 (2.25% 2023 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.625% notes due 2024 (3.625% 2024 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 1.90% notes due 2025 (1.90% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.125% notes due 2025 (3.125% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.60% notes due 2026 (2.60% 2026 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.20% notes due 2027 (2.20% 2027 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.20% notes due 2027 (3.20% 2027 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 1.65% notes due in 2028 (1.65% 2028 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.00% notes due 2029 (3.00% 2029 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.05% notes due 2029 (4.05% 2029 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.00% notes due 2032 (2.00% 2032 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.35% notes due 2032 (3.35% 2032 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.20% notes due 2033 (4.20% 2033 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 6.375% notes due 2037 (6.375% 2037 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 6.90% notes due 2038 (6.90% 2038 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 6.40% notes due 2039 (6.40% 2039 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.15% notes due 2040 (3.15% 2040 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.75% notes due 2040 (5.75% 2040 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.80% notes due 2041 (2.80% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.95% notes due 2041 (4.95% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.15% notes due 2041 (5.15% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.65% notes due 2042 (5.65% 2042 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.375% notes due 2043 (5.375% 2043 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.40% notes due 2045 (4.40% 2045 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.563% notes due 2048 (4.563% 2048 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on note</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.375% notes due 2050 (3.375% 2050 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.663% notes due 2051 (4.663% 2051 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on note</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 3,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.00% notes due 2052 (3.00% 2052 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.20% notes due 2052 (4.20% 2052 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.875% notes due 2053 (4.875% 2053 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.77% notes due 2053 (2.77% 2053 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on note</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.40% notes due 2062 (4.40% 2062 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | Other notes due 2097</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.10% notes due 2021 (4.10% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.125% notes due 2020 (2.125% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.45% notes due 2020 (3.45% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 1.85% notes due 2021 (1.85% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.50% notes due 2020 (4.50% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.20% notes due 2020 (2.20% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.875% notes due 2021 (3.875% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.00% notes due 2032 (2.00% 2032 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.80% notes due 2041 (2.80% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember', window );">Debt securities payable | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount', window );">Redemption period without payment of make whole amount</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember', window );">Debt securities payable | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount', window );">Redemption period without payment of make whole amount</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Period without Payment of Make Whole Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A190NotesDue20251902025NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A190NotesDue20251902025NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointTwoZeroNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointTwoZeroNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A165NotesDue20281652028NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A165NotesDue20281652028NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20293002029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20293002029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A405NotesDue20294052029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A405NotesDue20294052029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointZeroPercent2032NotesMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointZeroPercent2032NotesMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A335NotesDue20323352032NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A335NotesDue20323352032NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A420NotesDue20334202033NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A420NotesDue20334202033NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointNineFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointNineFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A420NotesDue20524202052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A420NotesDue20524202052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A4875NotesDue205348752053NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A4875NotesDue205348752053NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A440NotesDue20624402062NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A440NotesDue20624402062NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OtherNotesDue2097Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OtherNotesDue2097Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A200NotesDue20322002032NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A200NotesDue20322002032NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A280NotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A280NotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140120144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing arrangements - Debt Issuances (Details) - Notes - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">1.65% notes due in 2028 (1.65% 2028 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">2.00% notes due 2032 (2.00% 2032 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">2.80% notes due 2041 (2.80% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">3.00% notes due 2052 (3.00% 2052 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">1.90% notes due 2025 (1.90% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">2.20% notes due 2027 (2.20% 2027 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">3.15% notes due 2040 (3.15% 2040 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">3.375% notes due 2050 (3.375% 2050 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">3.00% notes due 2029 (3.00% 2029 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">4.05% notes due 2029 (4.05% 2029 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">3.35% notes due 2032 (3.35% 2032 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">4.20% notes due 2033 (4.20% 2033 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">4.20% notes due 2052 (4.20% 2052 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">4.875% notes due 2053 (4.875% 2053 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">4.40% notes due 2062 (4.40% 2062 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A165NotesDue20281652028NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A165NotesDue20281652028NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A200NotesDue20322002032NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A200NotesDue20322002032NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A280NotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A280NotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A190NotesDue20251902025NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A190NotesDue20251902025NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20293002029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20293002029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A405NotesDue20294052029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A405NotesDue20294052029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A335NotesDue20323352032NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A335NotesDue20323352032NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A420NotesDue20334202033NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A420NotesDue20334202033NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A420NotesDue20524202052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A420NotesDue20524202052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A4875NotesDue205348752053NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A4875NotesDue205348752053NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A440NotesDue20624402062NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A440NotesDue20624402062NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141659248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements - Debt Repayments (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Make-whole payments recognized in interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Make-whole payments recognized in interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.50% notes due 2020 (4.50% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.125% notes due 2020 (2.125% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | Floating Rate Notes Due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.20% notes due 2020 (2.20% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.45% notes due 2020 (3.45% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.10% notes due 2021 (4.10% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 1.85% notes due 2021 (1.85% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.875% notes due 2021 (3.875% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 1.25% notes due 2022 (1.25% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">&#8364; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.70% notes due 2022 (2.70% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.65% notes due 2022 (2.65% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.625% Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.80% notes due 2041 (2.80% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.00% notes due 2052 (3.00% 2052 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenZeroPercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenZeroPercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969136763728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements - Interest Rate and Cross-currency Swaps (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="nump">$ 9,721<span></span>
</td>
<td class="nump">$ 9,261<span></span>
</td>
<td class="nump">$ 10,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">6,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminated', window );">Derivative, Notional Amount, Amount Terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapOneMember', window );">Interest Rate Swap, One [Member] | Interest rate swap contracts | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminated', window );">Derivative, Notional Amount, Amount Terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember', window );">Interest Rate Swap, Two [Member] | Interest rate swap contracts | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds) | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember', window );">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes) | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member', window );">5.50% 2026 pound sterling Notes [Member] | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member', window );">4.00% 2029 pound sterling Notes [Member] | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember', window );">1.25% 2022 euro Notes | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 6,650<span></span>
</td>
<td class="nump">$ 6,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2024 (3.625% 2024 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.125% notes due 2025 (3.125% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.45% notes due 2030 (2.45% 2030 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.30% notes due 2031 (2.30% 2031 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 4.663% notes due 2051 (4.663% 2051 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.45% notes due 2020 (3.45% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.10% notes due 2021 (4.10% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.875% notes due 2021 (3.875% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.625% Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.625% notes due 2024 (3.625% 2024 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 3.125% notes due 2025 (3.125% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.600% notes due 2026 (2.60% 2026 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 6.375% notes due 2037 (6.375% 2037 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 6.90% notes due 2038 (6.90% 2038 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 6.40% notes due 2039 (6.40% 2039 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.75% notes due 2040 (5.75% 2040 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.15% notes due 2041 (5.15% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.65% notes due 2042 (5.65% 2042 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 5.375% notes due 2043 (5.375% 2043 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 4.663% notes due 2051 (4.663% 2051 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.77% notes due 2053 (2.77% 2053 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DebtExchangeAdditionalCashConsideration', window );">Debt exchange additional cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 1.25% 2022 euro Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes | 2.125% notes due 2020 (2.125% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DebtExchangeAdditionalCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt exchange additional cash consideration paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DebtExchangeAdditionalCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeNotionalAmountAmountTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative, Notional Amount, Amount Terminated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeNotionalAmountAmountTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_InterestRateSwapAxis=amgn_InterestRateSwapOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147777264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements - Shelf Registration Statements and Other Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_MaximumBorrowingCapacityUnderCommercialPaper', window );">Commercial paper, maximum borrowing capacity</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial Paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Annual commitment fees for syndicated, unsecured, revolving credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember', window );">Horizon Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BridgeCreditAgreementInitialAmount', window );">Bridge credit agreement, initial amount</a></td>
<td class="nump">28,500,000,000<span></span>
</td>
<td class="nump">$ 28,500,000,000<span></span>
</td>
<td class="nump">$ 28,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement</a></td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks', window );">Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LineOfCreditFacilityInitialCommitmentTerm', window );">Initial commitment term of each bank which is a party to the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LineofCreditFacilityNumberOfRenewalOptions', window );">Number of additional term extension options | renewal_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm', window );">Additional period for extension of commitment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under syndicated, unsecured, revolving credit facility</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit [Member] | Secured overnight financing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">one-month SOFR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit [Member] | Federal Funds Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amgn_BridgeCreditAgreementMember', window );">bridge credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BridgeCreditAgreementAmount', window );">Bridge credit agreement amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amgn_BridgeCreditAgreementMember', window );">bridge credit agreement | Horizon Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BridgeCreditAgreementAmount', window );">Bridge credit agreement amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BridgeCreditAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bridge credit agreement amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BridgeCreditAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BridgeCreditAgreementInitialAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bridge credit agreement, initial amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BridgeCreditAgreementInitialAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Extension of Commitment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LineOfCreditFacilityExtensionOfCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LineOfCreditFacilityInitialCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Initial Commitment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LineOfCreditFacilityInitialCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LineofCreditFacilityNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LineofCreditFacilityNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_MaximumBorrowingCapacityUnderCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Borrowing Capacity Under Commercial Paper Program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_MaximumBorrowingCapacityUnderCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=amgn_SecuredOvernightFinancingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=amgn_SecuredOvernightFinancingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsPurchasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsPurchasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amgn_BridgeCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amgn_BridgeCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148665856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing arrangements - Contractual Maturities of Long-term Debt (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">2,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">2,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">30,868<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet', window );">Total</a></td>
<td class="nump">$ 40,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969151008768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements - Interest Costs (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid, net of interest rate and cross currency swaps</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140613392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Stock Repurchase Program (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchases, Shares</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,410<span></span>
</td>
<td class="nump">$ 1,461<span></span>
</td>
<td class="nump">$ 1,069<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 865<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 752<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">$ 933<span></span>
</td>
<td class="nump">$ 6,310<span></span>
</td>
<td class="nump">$ 4,987<span></span>
</td>
<td class="nump">$ 3,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, additional authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available for stock repurchases under a board approved stock repurchase plan</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock Repurchased and Retired During Period, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,310<span></span>
</td>
<td class="nump">4,987<span></span>
</td>
<td class="nump">3,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock Repurchased and Retired During Period, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,310<span></span>
</td>
<td class="nump">$ 4,987<span></span>
</td>
<td class="nump">$ 3,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember', window );">Common stock and additional paid-in&#160;capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock Repurchased and Retired During Period, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember', window );">Accelerated stock repurchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchases, Shares</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember', window );">Accelerated stock repurchase agreement | Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock Repurchased and Retired During Period, Value</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember', window );">Accelerated stock repurchase agreement | Common stock and additional paid-in&#160;capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock Repurchased and Retired During Period, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141674832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Dividends (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="13">1 Months Ended</th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.95<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="nump">$ 6.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends paid per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends paid per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141541840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Components of AOCI (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 9,409<span></span>
</td>
<td class="nump">$ 9,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">496<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">9,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative effect of changes in accounting principles, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
<td class="num">(718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">496<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(348)<span></span>
</td>
<td class="num">(844)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">61<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="num">(501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax', window );">Other gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(796)<span></span>
</td>
<td class="num">(985)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">496<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="num">(534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax', window );">Other gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">$ (231)<span></span>
</td>
<td class="num">$ (796)<span></span>
</td>
<td class="num">(985)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI [Member] | Cumulative effect of changes in accounting principles, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Other Adjustment, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147676320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Accumulated Other Comprehensive Income (Loss), Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="num">$ (110)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969145350560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Reclassifications out of AOCI (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 26,323<span></span>
</td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(814)<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="num">(1,406)<span></span>
</td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">7,346<span></span>
</td>
<td class="nump">6,701<span></span>
</td>
<td class="nump">8,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(794)<span></span>
</td>
<td class="num">(808)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">6,552<span></span>
</td>
<td class="nump">5,893<span></span>
</td>
<td class="nump">7,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">24,801<span></span>
</td>
<td class="nump">24,297<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Foreign currency contract [Member] | Product sales | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">231<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Cross-currency swap contract [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">$ (233)<span></span>
</td>
<td class="num">$ (245)<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140618864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' equity - Other (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969139672784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">$ 4,335<span></span>
</td>
<td class="nump">$ 7,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">5,621<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember', window );">Cross-currency swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractsMember', window );">Forward interest rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">4,815<span></span>
</td>
<td class="nump">7,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1) | Foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1) | Cross-currency swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1) | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1) | Forward interest rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1) | U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1) | Money market mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;prices&#160;in active markets&#160;for identical assets (Level 1) | Other short-term interest-bearing securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level 2) | Foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level 2) | Cross-currency swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level 2) | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level 2) | Forward interest rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level 2) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level 2) | U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level 2) | Money market mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level 2) | Other short-term interest-bearing securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) | Foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) | Cross-currency swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) | Forward interest rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) | U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) | Money market mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) | Other short-term interest-bearing securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeAssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeAssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instruments liabilities fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f,g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147832416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Aggregate fair value of long-term debt, including current portion</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 37,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of long-term debt, including current portion</a></td>
<td class="nump">38,945<span></span>
</td>
<td class="nump">33,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity Method Investment, Quoted Market Value</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Approximate carrying value of the company's equity method investment</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember', window );">Teneobio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144709344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - Contingent Consideration Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationContingentConsiderationRollForward', window );"><strong>Business Combination, Contingent Consideration [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_BusinessCombinationContingentConsiderationArrangementsPayments', window );">Payments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Net changes in valuations</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationContingentConsiderationArrangementsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationContingentConsiderationArrangementsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationContingentConsiderationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationContingentConsiderationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140955088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Length of time hedged in foreign currency contracts</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForeignCurrencyAndCrossCurrencySwapsMember', window );">Foreign currency and cross currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency forward contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Forward interest rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments [Member] | Foreign currency forward contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 517<span></span>
</td>
<td class="nump">$ 680<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForeignCurrencyAndCrossCurrencySwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_ForeignCurrencyAndCrossCurrencySwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141618704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments - (Cross-currency Swaps) (Details)<br> &#8364; in Millions, &#163; in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | Euro Member Countries, Euro [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | Switzerland, Francs [Member] | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | United Kingdom, Pounds [Member] | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | United Kingdom, Pounds [Member] | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | United States of America, Dollars [Member] | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | United States of America, Dollars [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | United States of America, Dollars [Member] | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts | United States of America, Dollars [Member] | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969148318960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cross-currency swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Forward interest rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969151356976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="num">$ (437)<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge', window );">Carrying value with discontinued hedging relationships</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Hedging adjustments on discontinued hedging relationships</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="nump">6,017<span></span>
</td>
<td class="nump">6,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="num">(519)<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge', window );">Carrying value with discontinued hedging relationships</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Hedging adjustments on discontinued hedging relationships</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hedged Liability, Discontinued Fair Value Hedge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_HedgedLiabilityDiscontinuedFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144445296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - (Summary of Income and Expense Line Items) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 26,323<span></span>
</td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(814)<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="num">(1,406)<span></span>
</td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Gains (losses) on fair value hedging relationships, Hedged Items</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments</a></td>
<td class="num">(636)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash&#160;flow hedges [Member] | Cross-currency swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">24,801<span></span>
</td>
<td class="nump">24,297<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash&#160;flow hedges [Member] | Foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969140508464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments - Fair Value of Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency forward contracts | Other&#160;current&#160;assets/ Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency forward contracts | Accrued liabilities/ Other&#160;noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Cross-currency swap contracts | Other&#160;current&#160;assets/ Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Cross-currency swap contracts | Accrued liabilities/ Other&#160;noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap contracts | Other&#160;current&#160;assets/ Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap contracts | Accrued liabilities/ Other&#160;noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Forward interest rate contracts | Other&#160;current&#160;assets/ Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Forward interest rate contracts | Accrued liabilities/ Other&#160;noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amgn_OtherCurrentNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amgn_OtherCurrentNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969151546528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Sandoz Patent Litigation) (Details) - Sandoz Inc.<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 12, 2021 </div>
<div>patent</div>
</th>
<th class="th">
<div>Sep. 28, 2021 </div>
<div>patent</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_GainContingencyNumberofLawsuitsFiled', window );">Number of lawsuits filed | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_SandozIncMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber', window );">Gain Contingency, Patents Found Not Infringed upon, Number | patent</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberofLawsuitsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Lawsuits Filed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberofLawsuitsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity was found not to have infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_SandozIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_SandozIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969147810960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Repatha Patent Litigation) (Details) - Sanofi/Regeneron Patent Litigation - Pending Litigation - patent<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2016</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LitigationSettlementLengthofTrial', window );">Length of trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_GainContingencyNumberOfChallenges', window );">Number of challenges</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberOfChallenges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Challenges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberOfChallenges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LitigationSettlementLengthofTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Length of Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LitigationSettlementLengthofTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_SanofiRegeneronPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_SanofiRegeneronPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969246249152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and commitments (Janssen Biotech Inc v. Amgen Inc (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 29, 2022 </div>
<div>patent</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_JanssenBiotechIncVsAmgenIncMember', window );">Janssen Biotech Inc. Vs, Amgen Inc | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_JanssenBiotechIncVsAmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_JanssenBiotechIncVsAmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969144479104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 08, 2021 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>lawsuit </div>
<div>numberOfPlaintiffs </div>
<div>numberOfClaims</div>
</th>
<th class="th">
<div>May 27, 2022 </div>
<div>argument</div>
</th>
<th class="th">
<div>Mar. 11, 2022 </div>
<div>States</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember', window );">Sensipar Antitrust Class Actions | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss contingency, number of plaintiffs | numberOfPlaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, number of lawsuits | numberOfClaims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LossContingencyNumberOfLawsuitsFiled', window );">Loss contingency, number of lawsuits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_GainContingencyNumberofLawsuitsFiled', window );">Number of lawsuits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside', window );">Loss Contingency, Number Of States In Which Plaintiffs Reside | States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_ChemoCentryxIncSecuritiesMattersMember', window );">ChemoCentryx, Inc. Securities Matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LossContingencyNumberOfClassActionSuits', window );">Loss Contingency, Number Of Class Action Suits</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_RegeneronPharmaceuticalsIncAntitrustActionMember', window );">Regeneron Pharmaceuticals Inc. Antitrust Action | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_LossContingencyNumberOfPrimaryArguments', window );">Loss Contingency, Number Of Primary Arguments | argument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberofLawsuitsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Lawsuits Filed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberofLawsuitsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LossContingencyNumberOfClassActionSuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Class Action Suits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LossContingencyNumberOfClassActionSuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LossContingencyNumberOfLawsuitsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Lawsuits Filed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LossContingencyNumberOfLawsuitsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LossContingencyNumberOfPrimaryArguments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Primary Arguments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LossContingencyNumberOfPrimaryArguments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of States In Which Plaintiffs Reside</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_ChemoCentryxIncSecuritiesMattersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_ChemoCentryxIncSecuritiesMattersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_RegeneronPharmaceuticalsIncAntitrustActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_RegeneronPharmaceuticalsIncAntitrustActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969146336896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments', window );">U.S. repatriation tax commitments, number of annual installments | installment</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears', window );">2024</a></td>
<td class="nump">1,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears', window );">2025</a></td>
<td class="nump">1,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1', window );">Total remaining U.S. repatriation tax commitments</a></td>
<td class="nump">$ 4,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139969141805264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Allowance for doubtful accounts [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions charged&#160;to costs and expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Other additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>amgn-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exch="http://xbrl.sec.gov/exch/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amgn-20221231.xsd" xlink:type="simple"/>
    <context id="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia583ee59c26e4591a6c760c2f5aa05d2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i580757a974aa4b85b143f5523fc7aa91_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa76a93f17df45cd9d66d36fd211676b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3dd260e9045c46d1bd6dbbdbd6942bb1_I20230206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2023-02-06</instant>
        </period>
    </context>
    <context id="i2f333186d8da4378bcf0c5a3e6baf0f9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6b25c75934844f82a32f7a76cdbe5042_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if8db07843e5b426fbe44e0590a500e74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id25b0832750a4204ac083f11c97f8288_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2457cd740816456db1f50da03ba631dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50cbcfb77ce746588d1956f2435637ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i129c92e214904c7e8aec016ec2d5e387_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2798874e9ac48be975005deb320dde9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0567102b4dbd4cabaf51e541f2a41652_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2edf981fef6d4fa4973e8992576dab4c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc5f2c87a3f74cd797cc6268b82470bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecb02e3f6128454a820a56e2cfbb6e3f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice20f9c10bef48889e1c07a014676f7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic10864dfaff048eca24b894294bae77d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaeb157cdc95045539f3bb40881b31817_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia56dda630a2e4ae3bbca72a1ff1cf2ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief1a47791c7f42599aacea53954586bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5998f096c32498584f7ddcb1b102049_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a339f1adc784aaa9ffccfd08a332107_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59da9a82507b4a00bb722da4afa5b3c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2470640538814b629fcb492196758669_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f7304b1f329421f82c9e6191840585b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e70878840254d839c51604f86fab42a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a40b865ed594f40bd48caac4049fc3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39f0e0839efe462786cfb45f06b6105b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b88900199d7479494b9b92a28082482_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46710aa460c94e759e4be58d5b0aa1cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9214e72c6081443dbdd4956e36759200_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5cc146400d04167a6eb49d6a45c2634_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0604e8ad2a44749afd263c7e0c52319_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib964505bb2264c0e858b211061796b49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee236cd90d724c118c6bd2bd1de4571e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida0d3563966d49f2afdae70577b5770d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if935497be7004087ab59197b95cf4c00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib6677b10603d44f784a36a5a29714649_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec4b231199d0442bb9d2420b71dfb984_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i349ee45aa1e94ce9adf98a1fa8b76e0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i74c70cd97a504fa799571d2da1e07298_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib368433c7847450cbea77bf019f238ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5514fe5c6f934d69accc89f4f6207683_I20221212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="i779f44ca9ddf42f9bd2fc86981e1cdd2_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic722736e5ec247d6afb3eb14a1913c36_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia18e6e75e0234bfb8fa9c069b0ac7278_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i547c2ec2000946a09fe9312e8ebfb63a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amgn:BridgeCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib6ad27c707bf4fc9a91323e63aadb826_D20221222-20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="i1304d3c33395494bb59cbeb2cb292045_I20221020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-20</instant>
        </period>
    </context>
    <context id="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-20</startDate>
            <endDate>2022-10-20</endDate>
        </period>
    </context>
    <context id="i5df31b4fae07412cbb1789e8d483f2f0_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife9b8122096240a5b48fd15f27ecd4ba_I20221020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-20</instant>
        </period>
    </context>
    <context id="ifd98af0751824e778fbc9d7d6daabf74_D20221020-20221020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:ChemoCentryxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-20</startDate>
            <endDate>2022-10-20</endDate>
        </period>
    </context>
    <context id="i8ad51334f6c74fc69c9126bdca69dd80_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i483da69e647945579f570280de6d2535_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c3e817eb2db4040b29557e7f0a8bdae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i878b1937a0c64c239da6ad0a2e1748ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96ea65e5beec49d492a8c189bb7ff681_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a560be5e64148d1b01ab70221c57257_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:MoleculeTypeAxis">amgn:AMG340Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4b93dbb92ca4fad905e8f7074369960_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic6c94a0244a24346bbce7f236220492d_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id61a508e81d74e23babeb5ae04b7c428_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2622610117f541b3981af6c597b45012_D20210416-20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="i7f833d40beb6488f852b2cd047fd2af3_I20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="ia1a449b4d91a4aa9837f80b68d94b3de_D20221102-20221102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-02</endDate>
        </period>
    </context>
    <context id="ifa290da793e84fbbbc403ed0500e088d_I20221102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2022-11-02</instant>
        </period>
    </context>
    <context id="ie2a81370a9864611897507a5c90c9308_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherGeneralExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i54d95ce0934d41258b8bb4e3c9ae99ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9fcbf93e9fd941c2b5eb2795960a999c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d8239300c734a85ac79f2e26ba5280f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf51567a953d41b99c4b4d59745e4ee4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4ef981e3c2740e0b2d606ba990e403a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08fe0ca98dba40f1916b2858ece00d3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d9b8bbe1fe042b38d3911eaa570829e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia96d969e20ba48c5865d66cf127544fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if847c1f2b53649958a0e412c568c260c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iabbccaadaa0e479bb555d47033b24d0d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28d0ac761b5e4c64a58d335767cf2473_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia9b224ccf76a440c8fff126d491a4b0b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81533ef907a44709b3be7b02daabe41e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0dfacc540ca4410bad949df3bf9e3989_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70dda4219ab244b7b55afbcb42b4096d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c3af95c457646d89f7ccabdfe96ed78_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e858062804243e7a95db1099336e60c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ea6afbe5b0948f38ad7891711ec6fdd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2eea70a9f89a460c81ea5589813c4763_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia1d0ac70f39f475ba99cef136b4e6db2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iad2d33f98f144869b7feb640d3176c4e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1e4a13b30ff4c109a876c1c9aaf2a6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1efdd0c80b64aa48ebe629be932cb59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2b509ea03164c7aa49578a912572c8f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i931aa36bec5b4419a4286d8ee93da365_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d05f99fee60403f9ca2a1f93a62cf48_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8e026f4c1ba44496a8bb17b973a51cba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie8037f0f06384716a6e33c023dafa910_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4ed14a4244f540049b8d29da49b4c3c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1effa3ff3a54202849eece7ac796687_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i14decb65256d4431b54b68596dcf53cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie55dd93e8acf407da56339a95d05c26d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id90e5f5a81c64fd8a2d5eca216f1ac96_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5d2433db185474e8f07acef38f88309_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife44f12d898a40c2b26d2899e1f87c7b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib72c4cccf0ed4d4e98361bdf264e1ab8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4672ebffc2642038eb7bc351335c563_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8989af1d9ee941ccbf1d38df278cc651_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ecec34e1ba548dfae54d6428a2be0ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i72818ade50a84197b7066c09d32fe4b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e998945c35c44b78153987bfb0988e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife184a05fefe4459858a75cd03edbb4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifa50e2701f6349c2976473694523273c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c662b22fd6d4f538341070c6658378a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id90e2b230dc243709b1d0eea15c4120d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i130d478f5c344266ad4bd4b7ab54798f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81d627f909504f5bb6aec2303812401b_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71b642d2cd344106b2a9b43195affb7d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e495b2d1a824af7811048f9f9bc9a17_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic905e297ec6e4217a0a0992727261a16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4824dabd1ef04421b159a085c221b393_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac4f0dce8ef748aeae685b9a10378f08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25bdbcb88c32403d8e379e2f8730b5ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie12cb06ca50647f08c8d0f02d992ddb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab84e501cf364e47a226c6765f0a1320_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34f569aa2b2b469081ca5099662ae431_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48d68f0d45e34ce3afe76b0c1819f0f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if1dd3fc9f8784e4c8374d245b0c7fb71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id28a9a6d2501418081e48da0d0dc78ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia79c2d0bccb749ce9727366fb1126ceb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i257e9c51364e4d82b08262ef2ac191a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic120030329c6425dad6cd6f3e198f509_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacf507146d984867ac54d44e61ad8dc6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c25cc3cd16f40dc875390afe7993316_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i04869452639e49c4889ecd6ea51662ad_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d869ac7f27a4395b24b5b634039d37e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iab122339be0b431f90bca45e37234133_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i260c1936cd204104b9c849ec4c5f1086_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib16b3709a01e464fbb530033aa9546a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i39749dabb5124d4da5d2ebbe0c7f9bab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1734816467749ce9071cf1a91e0ea7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1885db8f4e54fc68d9a604c36caefc1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e97be903941430ba5c15572221083c5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i862040fed4914d45b07c1986dde77ca1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iafe19cf36dad4281bb45cf16884ba782_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic31ee96f0c344214b71935816f6d82bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if976b4b2b7594c2d9f40e64ea67f3e83_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e2089ffa1cd467083ed4a1db7f715e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0b4597ba3cb4f84aa35b4d25bfb8261_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8eb3f737b3494a4cbc9bc33b832a55ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4bdc8fa194f44dfd99072ad9bcca3737_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f5bd2a8d54048c38e2e840cbd09500d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia5ab76d96eac4989a331ad1292e4f071_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2876569878e64fa28cfa8f94277c4955_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6814d750caec49fc9617453d49cd87de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f8b506414e4400f94126bb294f8de27_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab191a59b38e4a6aa145b09f8bd9d253_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifca7535ce0ea49c7b96444b2409cf8d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93535a2cb1d74743ba6ebf13264af448_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1164b97eced64b058786a55ff9fb37e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EvenityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02da5611affd4bb39c32bd0b8b1af6b4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia93f46843ff741beafe6a37517e53dd2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie830411e990944a58b257c504ac9bd03_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e7e76085a9842b38a2bd7b388f5d89a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2ea6966e44b490499ae329249bdde9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08293a2d22a847e882c434fc87376ede_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia1d34a61daa04c4abac9d3a4af47df32_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d2558e049e14f7fad9ba2b4954fbece_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47dc3c579513437d88fef139e4772cdb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8dddf5cfe0e94fa19b1688a79d7445ae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib65a6afa486142c9a0bed18deeea04c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c5766aba06f4d61bfab9fcffab156e5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic65873c515ce4f70aec863e02db39e0b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9e69273cff94b48bc90019f3c462804_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i419f6f8b71f643678f664afe333ad342_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9009ee1e369c449292e70d4d067b1184_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0cee17c29ea542229fc4893cb3183b4d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia4df96a522844448bf9e3616baca9df9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if37ac076bb994281907bc729c8f6d935_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d14a8530ad947f7b3fa2aefa3363fda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a6053e1fe314de1b2bb31df2e6ce976_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d4871c35ef74d7e8c872893b4cdaebc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf92b1997d60491abc1e2f5b65cf03a4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63498908586e409e90d8f39594556f93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie377953c909f44678464f43ddbf57467_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c5ae9adf5244a858af6f315eef250b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64d8fc93c0f84588aacc70e98160df80_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic492dbf72e134124ace0523e8918ae54_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3be857e2d3446f6a9576880dc95fdbf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3ced2b08bd74e91807733d80569e8f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ce35b441d394680be0e8bc1af6382e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i04ebce1b8e1b4437b11925ff3b848025_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i660bbb9450f640a2b53f5e591fae8ed1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if75d92c2783d458a8be680eb71b21a63_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4bf450c77c4449a8b3ecf57bc98e144a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd1681e5dde84590a71f0e996bf9146f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i821d0160b8fd46f592bae9bed6edeeca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11d0dbb92b9046b892ae095e67db26c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac17b1564825474f83ed71156fbe3405_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07973e812ee241aea2269d4041a67153_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i219ff676680c41029ce9c7eaf92b5b3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3eb195f7ff9c4f059c27b617ec488e62_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifeed4f08e59e4fb882fab3526d452c25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2088886061214180b8eaf2c7c870e341_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5361cc7c39a4e2aba0e4628230f4a9e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c95759e9f834fff8e2ab6b9325f2188_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i154b8bdaf9ab475f99a1f2846362c79c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6de81be8345e48fb922b906166ab900a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb430bb605c14773b903da59d06a7e70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8471d8b9c83641319a4f6ddfcd0f18c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ice4e89011fbe4e4cbcf5dd5272b78ecc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0a84fb02f834393b706d526a6e58884_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc64ba5f13184705bbcea61dca732af0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb268048ef47498c93e842c4884d3b1a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:ExpirationInTaxYearsBetween2023And2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c663e71979d4887b26c8be64eb736f1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b423717f36c40579ed83c7a713b6b0c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3470fa30c75149af83b41d392e448110_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2022And2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13c5612dc4a5450684e24434f6a3ec86_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ic981a166a2b44b269c7a5073481bc3dc_I20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="i94eb03241527483ebaf961e48ef6e18d_I20221219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="ia5ad848ccc9e43da99f1f90d2e7be305_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="i0b14ed1cf56b40588d947c7c195dba31_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i397d9bb426e14efc97584ac20babda5c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f6ac0af9e05484e9ff74b916399b3b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61880ef9cc974d208e701a854ba365f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48b5fe9d56b04cc0b750c143fe63a442_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id68f71c0e79f414eb9a0f7738f203cb6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i69081709322243d7bbce5ac32eca556d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1d993f3e9e94186b4be512af2ce0c7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i67856dd9461b467aa245cba68be2243c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e07e3056c344299b9420e74a38ebf5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24211ce70c914e6bbc5c138c04403948_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e2a1eff2f0448ba9a98ef6babf5bf8a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i550d1116353a45e988ecb42fddd2ea71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if22b1ca6b4224e409cb1dcbe7350db6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0717c9df57574deba2c7ff65d7c5e0b5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ief89781cb0e44c878c87fc5562d3ca89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ecf58c2e31f47edb3c517d8ed16b4ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3587bfdb4d8c43eca1da9c2f79b27ab9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:AstraZenecaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i356368409a2d4829afb562f99d59b84a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:UCBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2325b63848cb4d779d17a0fb7049c3ca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:UCBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iceb527e7ec734f6e818dc3d2674e17fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:UCBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i077a1aab04d044379338908da753b2fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iad6cab3b37664965858bb4a82cbba6fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if044214b0e1f473786d143875c57f645_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e19f3c8340e4982bd712b7b9ac5d3e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5d8484c53c2490ab0ee83876aa635bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2285c8c0ccac4adbb106cc9bee4bbb49_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:KyowaKirinCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i612eb99920494bc69ea0f16bc1bccb20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amgn:KyowaKirinCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i824e9eea42274a06994918fdb9b1899f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba24b9313e764100a95332b21228b55d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9bb5ac9be58f43fbb615c494dcccf380_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i213219e02daf455db4856867bb8edfc1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadf926a8c4ff481397c62e643795c0d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea6cee4c27ca4399a8a02d26694846a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95cead4d37bb4601864dc9667b4457bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i736ffca3dc1842b084f709c4fe9809b1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8c6fe835b2741e1b409f5f32f417ec2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e65698c0cb74a14bfeefadc59b77d5a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa1b51ec520940e1b313db6b89b5a604_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bb10a68da424589a4aa8d60cbb4b509_I20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="i6db31ce9c8264445a32e5e5e66606b87_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i55ba36de5fe841cbac0c77bb92159e4e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i742aa0979b534c78a1fbaaeec95b8732_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d78be49a55146f8aea0014dec6caca1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f9fd669564646ed90c1f923fcf22115_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd010ea395424e80984bb752c13cc1f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4568cf82cca34f0fa0f23589a150184f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i547718310bf54e6390c23b1af397545a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5225514442b04c37a257024814d81c9f_D20210930-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba147b39322644f2a1a03599c2a39483_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48de6ba3d9f0465e9462933890029a6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01ad554978334ac88cec9913e0cc5884_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia353ede4e8b345c0b2974e1070e1fe2e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89fb6287a84346aabe16f3d5d6175fe4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e93272860d242648586e251f19acc41_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0661190d8893467dbcd83a57c4222013_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0012e716a1434d35ac79af91c9e382bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c4b1eddbef0462d9ae3e1a3e2db2e8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i910730fc1f734dcb85a4bd843a18a53a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i68fa55908a0746a48abeb3eeff056228_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie659e94abdcd4ea3973f9174b5bd64ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bf57870a9f4462796cf71eb1204b562_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1cc1644aa9a14b298eb0dda7bc0c7d85_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e7adefe057e4125a56fb1a162b59975_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i13e514d61eb942da9c90cf58cce3e55c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b15e7cf27494cc1bd340423025d53ed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic6ca69fcdd8a42a6b7a9ac5979fa620c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b79fbf871a84da7a223e2f58e7878f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:FixedEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i604a564a01bb466c93664f563428196a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibea9550cddf5409f89486fce84d29e92_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibc07e2aaa249436e81ba3ffc71d13fb1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib9b7a507438942a2aaf4c1748fe959cd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iff279f49fa7b4713b3a0452ae164a793_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i92a78eea27ce4a75b4576bdbeb318deb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16e4fdfd9b274a029d3f820b2f8ec447_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i05b95da36271405f854a5fa63ee0cc73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i754ee2be39904612a8009537c4174025_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3acd696e90a462fa8d84de0529809d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07936c549f844514b26e4db0ad2a21fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e5aca0dc80d4c96b4e71d7909172c62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3d3bede71c84c74a83e0be4081f5b18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e0adc328161459b89b9bc11ba4f1e97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i417d0ad23573423c9d2dd34c69b3960f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b45a76886284dc78290674a5dee3ee5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ed7681dee014e09849b2353f1235d03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ided57f427b2f48c68511bb6a663847ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i509e8b79cd3447cdbd36db889a772260_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib88e57fb4e5e4aea802f1aeacd840bee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3d84b8dde9b4ef58d9a8a439a7b1fed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:AbandonedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib87a5903e27546d7be1b99e84a2bd998_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63458e59bdcd46bcbc8cde633cc0a217_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cbb8923ef5d4b82912c6157f84c6bef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i114486aa96344ee5b788b817b4b17d96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a39813c072d4e5eb904fe1d28cd03c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f1b495696b94d78b5dbd6696d16bd3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dae08b71e7d4ab88b6e9e253336b859_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9444cb9457a24d94834f8ec64291471e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i914ec06154d64420b43f2721a1ae01b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e4d0b0eb1fb4567ad07ac7b398eda3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6e2d495694d4d3cb2e097b25c5a10e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice6da97a847948f08a2ba11d9378169d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99921d01b0e541bf8d50ea58272c554b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i17b3e11f5be94ce49f2f3b9b0ecde667_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d9211ecea36437580bc7b0a70919e0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3f7dc76afa046759c07651d4147c51a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5597930bfb1b45bc98481de8f6393843_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab97f27b4cdb45eea26aa79814ee24f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i315cb82b31f04ff097bb4573859346f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i996fa0fbb28a4ae5a66025a540485a05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3d6933a21774133aab412e2e354668c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A165NotesDue20281652028NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42913198da614e1b811abab5b612e355_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A165NotesDue20281652028NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2abdf31bab164b7c95baa1ed9ef98248_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20293002029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A405NotesDue20294052029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i385a16395bf64c2bb403ca851a184d2a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0953d601cec9484fbc9df96f00426496_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf7b55ef9cb1473085781b63a83bbdac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i51217f4e8bed4990907c44f9d502ade2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11702be5618f4b6b84417ab7311bb910_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i343cbda319a14a27951c64ddae810439_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4de45cdb4364327a92140dc1f1c7cfb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i240a1929b4d74306bb09ea03fed64c41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21348edb6cd5466a9ef24edd6a2d0938_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A335NotesDue20323352032NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i51940b5cb1b241febc825ae180ec3de7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A420NotesDue20334202033NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc5f965633bd497bae6b284f87fd754a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i197c2b86499f4c749103e68bdb36f3f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4aff41f7e3e648c9be7ca6b79abca8e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f2e4ca4f8004d6c9bfebd3720cee531_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61c17dea73c8477a803ae09e22dccbbc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia00b4eabc3a7467ea3ebd7138b1b2a74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23363383d2174b2d8ab38bf2003a6ce8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b887f6d478f455aa05ed3a9d50ab8b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a2c9ab1d0d74042b5625c4d3863fc9a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6c2234b75d747f78a8f666e6a4bd7a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b1952961fcf4393b06b95f66a0599ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d652ba10ed148fcb905cf1d5cc7e9a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7ae3396aeb042e386de28c02ab1deee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0332f21f1314de4ae95621b6ac2c956_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i799db871194f4747ab9f6118c675a2f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2da62baf08ef4c5b91a5152a82a01c53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ceee26f1075435e9fdfdd7a75a72ab5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2e818249c4f49d79e8872325e9ce099_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieadcf920bf8f4c5f9aa97d54a77a11ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie22ac487559948448b70189d26074a44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c399705808348afac4fb0a614c63170_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idbe3e6b61a09400e97634eebf130e74a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9e2fac888b644c6bcecbe5803617340_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i459df9e4545545c5acca6667f316af22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61dde3927cd046c3ae459081902d8719_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a53c4efbbc3497fb791219ac49e571d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91a9673685984fa4a4d87c723a4b99b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3fbb4c180e604823bf8fe6193c622eaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4ea14090c5d46a68fa6c66a684d6252_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaec66496c6a840d998963fb080719768_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25202f83ea744eccb99587dd65d7f169_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A420NotesDue20524202052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4875NotesDue205348752053NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c0c22ebe78346a996c2daeeeab201b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f1ab566422f43e9ae7b52770249ed7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2a31746bf0d474c8f6cacbba8fbb650_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A440NotesDue20624402062NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18f3097471304363bf528a0d267e397a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A440NotesDue20624402062NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefc3b8cff79b4b5a9d37b0a3cfa13a59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5dcd01e084f04f7da2597aedeba26b9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ae65b7af0f742268bed15aafd3a152c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i015b4b460a304d11a76423022adf7fb4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i850e2cf58a7341ba9d67a7b5bb83feaa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i14ca5e3f8d5e4e19a9336ace84b8e4de_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibdf49fbaa3564bfeb07fa6eab5ff9453_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic1f60bbed45a476b84f32d5cd638fa27_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id071e59acfce43278b6718d99d9ada1d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if02f6daf07f04020881c0917e7205beb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc8d9408f58940f5aea794a5984b2b6d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i53bd2b17ef4e40b9ab31b350fb9bcca0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibeb1ef0f568a470293b1b4b19ff1eb25_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iafbc703b5ac5464b934f026814c76b10_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A405NotesDue20294052029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63aa0c69ac4d42fea8344496f99d3fb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A440NotesDue20624402062NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2c0f3163a47a477abfa471e4f31bc4ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i994c0f07cba345b594aa2dcc8f01ae2a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iae7d08a8c95844f89b4bc95827153edc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3ebe21c56f7b49eab0d1f2b569ab2d69_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7dedfbd2aadc42a4b92b844cb973cf5c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4875NotesDue205348752053NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6d2edc811fbf442281992e3f83c386d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i97e03c380118450bb96b17ea6c0975ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20293002029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id5abe004e1f64a0cb9c9056890639151_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4cbd26680ac94508aca54119b9a2b4f1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iabe3f9f94b8740cb8f007f2610521598_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibfa82e45553c4fe38c964335a7502e78_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7fd31a2352f045398f3a8eb8645c3d22_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife0fd2905ff54a6ea2da3ac299266202_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i66b14e567be349d2b9d238dd8fa3d12d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i093e46e46f254549afa8c5b85e22d6ec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iadf162d5956f4e0c8eeaf73fec25a6ee_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i64bd322d7bdc4336bdcaa7f9c771196d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A335NotesDue20323352032NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4bf447a9235a4172905a462133a6ffff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A200NotesDue20322002032NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic90390b22ae74a819b9f25f7e52c8cd4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A280NotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3b6372321cb54979aa35bc0ab3e56ae0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A165NotesDue20281652028NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic385067cc0a541f7acc94e65e1d25159_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i35ba09ad3416417584b285ae9e364e4d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A420NotesDue20334202033NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i304fcc0c170d49fab4f536fb9d368d1e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i198527cafdc44eeca16fc7290ab43d35_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ide32c761d0db4322ac4858a8059cfa8b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A420NotesDue20524202052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie30a691e9b49416cb63804f9bee95ad0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie930e646dcf5443abd63824803a610e3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie48acc0ed4094a3d91842dd5e715d92e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id185478a58284d89b9439c8843eb6f89_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc43e58b90c442fa9e2c3b2c14137433_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9924ee115de34d74a2b634b1cb90e492_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A200NotesDue20322002032NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if564b13b89634481901bd164eb63c59f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A280NotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e59b900a4ba40609f70a3f1ebf4fb65_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ecab054ef954f2bbe765d19ba69cf36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ec7e0e38fad401c881d41f4c40df8d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie507238fe5a046649c456d858ed9e23a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8bc2063ee0d4b268efa59bb040e751e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56bdffad54214969af59aa30ffe7fdc8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53fed3d90cd3422f8495f0171cae0423_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i83a71b99759f43bb8745b086512815bf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1ffa41fba39e4ab794adaacf3e2fa171_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaca4dae277dc4dd99ebb82e55a868dd1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1347de6bb8044d39a48f67625521dccc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6da1b9cbb0984b97a73d42d2db8533a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i847ad6943c6948fca81b24ff5d689fe3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i561a96f4dc354ad3a90b2b25b980a842_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if8e02d4a00804cc4a01eff072b7e2f66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i766094e09bca49dd9585d02df2f31831_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9de4610aa6c4469ea8f2b7e53baf43e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2efa7dc8599f4cbf803535c380f5c0a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93a2a77b537d4549980bc9ee3c342a33_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icbb916e5bc874443803468bda0e734e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffd7c6ea10ec4560aebf2e8cf2cdf029_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37fbc3aef92b4fe7a7795bdf6c1c7572_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9da66eabb244ebc99d3f74da210e1ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f0351400ea14a1a92d887dfc66b4eaa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iebdc2a05aee049ac9929bbe48b8b70e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida12280bfa6149bf8c7594c904e394c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3ec7f5fc463475eb5b87f53220a55e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80e1ce0caa3742e5b52a143ca346a03e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75d223f0739043aa95bb0cff432d8e57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic96413bd0bc84b608c7ceb7cbe2da49e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if86ae682dbc94b06a43ad27eff012f5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib98c19b2205645dc87dc300e20564cd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad19f1af440047f5bd2d2a7b58c2704c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i745dd63e9cdd4959af07252f017a9eaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ed264795f2f4426adc19343d029ad1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98780303768142868e91c1f5e2254492_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42e055314ebc4ed0b56423ed298d665f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95a65fbba5eb437390241efe7cc1bc36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97cf13585e1c40fb990546d925c79ac7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia87de4924b5449ffaf2a569727731d96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3596be95666d43788e785254aa341628_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9992852da66444809770265c95298e01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8bd0602a17242c7afbd9f2891132c95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c05fd05200c4fd89c9d750167797479_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e90624438bb44448c8bd5de6bd2ea2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie97d7b079fd244fc9390520981dfe82c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1572a102df9d4c8ea6c80c299b0c59c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1716ecbde7da4b99b7645064d92f04e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf0e44d0cbd340d5ba7c2e8a3f4793ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0783150b28c641c7902d993a142cb45c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id967fc79551b44ac97ef5042140ac816_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6d15fd3bd7a46d697fa1cb5eb430566_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff0e1c427c4f46afbcaa4a68bfb4d2e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7d6ca660c7746d3b61378810b89801d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b59b91df70443e68676c97eacce25d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40fd98a8110c4ff289fab753a7c5a2ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ee57e5a8a3245a6a3cb9a15be5df829_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic29bd0cf7cf0435990f458b78cd7e2dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8320821864644efe8f0edb105edca9e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0947ed7f05cf44148673b8fdbbb01f40_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a4586b2c0174806b7f34ea5bd75a188_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5fea782081e4895be4943c726463c8b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd293d73d43e4b46885dca2ec515d496_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i233084f1697843b28ef19302f4ca18c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i983918d489184fe48f8103d3daedddca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i525ba3ed8d5d45f998cd0b44ccdf96d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6df68bf77edd43e0967eb97c5820dae5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id934c9ad45d24abcaed4f914bd53414a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i93560032f3de4bcfb44d52d784c56eb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if925782f8a6e48fb9707082d9722b522_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iddb555093f204b73ad69194c448331d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f4b32aef48940438e79c7f4fdd934dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07692f763cdc46eb807c9eab3a20b027_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i626e02e818cb4ed494a4840a11c2d6c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8e42823293746a6bb668e39faa8573a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i230ad1456faf4cd5ae3a81c4e040d168_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6e784458a35492fbec6c0e6c982a3f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90e35bf522a340e79908048767761c5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f393109a944495bbe43538e525fdba7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if4039b3cb11c419c948393d621712209_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8ebc1d1a288841db9bff22881bf98a61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72e2726b4b0146ca9ec8b95c68183d50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2421a70ae11841d09f5ec2cee484630d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0717808e41b45288577472d48ad1319_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i400cdd89c79b4ce0a15e3ad45f90a859_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">amgn:SecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0e7270e76304c008e4095e3dcaa84f5_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib35744505c1e440c82abbaf57f20fe46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieafdc665523f4a6289df98ee45f3ca5b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:HorizonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic520f1877b1b468fb3b71c4ec23d7a05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amgn:BridgeCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f1639085198472380ac8baa83001db0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9bc00ec3fc9549debfc91c2a92aa5314_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9e695d739c9d4986a787a639a8e8a77b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie81249a29133467eabb1d34b6bdc5483_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i50725a0076ed4b89ba38bcbbbfecd2a2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2a53ed11f70c43369915dd0d29dbb42a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4136b215dbf24da08247954154d63658_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0d0caaabac894eaaaa6744f8d15302de_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8267ea8792a8481e880966120cbb1033_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa03d6422826451ab8c9411225c3e9c9_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i78ea81b8276943f0b89ca47f8b931e80_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79222ac692e1477aba781d2ff3a5f7c5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1cb79e8187a746398d43e3bd13cc6898_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i77bd16e1aee146a682056d066f6539d3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iae1609cedcdb41f08bdbbf907cf65e3c_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09775729f39c42a3a86f1013c58734d4_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2d9c119784043f18fc9dc9683bc2ff7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3de1e54db16b45a680ea17867c15ae9a_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="ib07ee9684f834ac189f302e8ce8f8377_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d05f148289f4f8ebcab61f83ce94ee7_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0375ffbe4dcf4bdaaf2abf150f3bca4e_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i1f2c6f9b7a7a46e09d3931f0d8199da3_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i1351e1c5d58d4b228b689baa94a08823_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="idcc68e5fe01f4338a8c7676f9e5e9152_D20201231-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd1a7ea27d4e4ea893aefca7f2ae9dd4_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iffab2bf10a0b4ec490ac20e7b6b5f6fb_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i4c44917d50b84030bdfa5f48afb2fd94_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i17bd2c1e1f6646129c19ffebbe131aa9_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2f99105a26404ad389de99b212cfe895_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i213496b5cf4a425b96468749b0447825_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i547af651cb9446b18cc108538306f5ab_D20230301-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib9817fa1cfe3409a975c7a8b3cdefd06_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e32313a221f41ad8ccd356225fd8eb0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i561b1b87095d42118b9170aa94c6c7ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1631e26b0d454c06bcc4b0fc4c38dcdc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if15d8369eda74b4090810b1af2596778_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9b691b97c86241478dd9d32f77155dd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe3a213cdc9d4969b1391eef5c1c503f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie255fb9441af4696b7b5537c9d7d9ffb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46d39b7cc594460ca05a08fe50fe2af5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8ce4697430147afaaf15b34b37a2893_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibad7d8f86bf24966a05f5ef686ce8c79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07bf0adb842e42abaf0c52d80659a7f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03d505608dcf4454bc0a6caf5d45ad79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6ba3418eed04a19b1d923ff8948405e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6baac2693814ca29a0d4ae5530452b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic696a300be6d4aa6a52c2fbcdfb34389_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia94576e55ab04deaaea5f1b0f981f32a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47cab96086794a69b3747cf784732a9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id21f25ed89f74791850385e82bcb5291_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a54ab8f414d41e9bfaf147b535c4239_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i074ac2af68414c0bbc7a1a601dca087a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97279c89cb3b4d598cc35eb7287e230f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i90308d5f52fe46da90947c1f214b73db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ica9d03894dc947b0b0664666c999e8d2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c7085eb7de24bdf9364ff05d2d06c22_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6cee74d142364011bb64569b6e7ff8a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5592ef4a3504edaab5252ca41492cdb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae23449150e54375b157ac5b160edbd9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idee57457aa704a5588746800b8bd3c58_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23ea2249a07045cea77ac843dd3ee186_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6bae6c3e9ff45c4bc483aa371e79620_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc245132cc174af6870e31cfd882e769_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icdafbb775bf94addace467b7558c90c5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6b34d2b5b6f4beba907bb845e7cc2b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic916478fec014452ac32d62171a7e5fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fec4c1d74cc4014b5be9b695eda82a9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i521f9300ea9e4c53a353c3a3895f2a5e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8a53f0a87704f59a5cb2cfabcd59979_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i562b0243b6ba47edb88a24870e0e2a7d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec76a0aa8be34cacb8193aae6cd1f062_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4567fe1b74d4ed5aa5d569e9dbeb8fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icbc2fff9b80c4cfd94f8bf10fa1a0426_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f0eab2c4927424ea7412f20ed53a84a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb3d055e549b4d20aa3bd79921592b07_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia228ad665d09441a9861fb9c7e5b0516_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia50199fde02748f9bf98f5cdedf79621_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d6aeb558db04b82be74458c91784748_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7fd7ca4767784bd68bc0e5d0a9794960_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8eac0bf72e7643508c5232330c7c0e0d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b0a668cee2e4193b99588a3b62eedff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22598ba91ebc4a90903405b80f9b2b90_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30ecd41cf6e44462b19bf11b5f28af8f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e803186d99e4d92800d0f91df12c1ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idaf69cca5e514b7aa23adb1152babe9a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44e12214117d468cadd851f609eafd23_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04cf9d5f14444094b92bcc0d9ae9c6c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id1185eef083e41a98369064a5c024e6a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffc1f370e2ad42c6b4c013b49ed46649_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69d9b4ff9d7f46de8ab75bad1566254f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i195a5331519a4c8ebc478f4e698c9bf0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c7ba0f3fb224e79ab0fe6a5fbf238e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i153762966e424fa9acf2972130ddc1c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib555b80a3d9d4e2e9c78009dab8a9f54_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96a24aee5c964365b0dc96473c06f9c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i681c12cca8b24893906caf0cabe34abd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8dcd8de791a54d38a00b14d46bd0e184_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ed68b118d34472994cc95aaa8e8a6c9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba7a6ebd1caa4564bcbb05dd9ae6251a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5402fe697c814ce7b466859cedc94d30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c0de5b5539746a0b7f92ee5f134419e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a10914bc11449188ce8ebe9ba6d1e7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac87a69358fc4fd589fb827383a29399_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8495c3e692f14eecb7e49b36322c3b37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id189833f84714d86b873bc1305ea1122_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i569bb5a225ac490892da958f5708abba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2668497e150b43a791a72f0c8455c08e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2d5b99ab33b4e739ed1626b9b36b488_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d74df6c17364a8aabc1122e2efe6f4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42fe4d733a7f4f13bb7813256bad4ea3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idabb4b707739487e85cf95efbce18ef9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i797ddf4c639f495e92b203d4350e1885_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i577871f373d34ff481985f5ec576c5a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i132049d557004a2b9c5a3e2500f496fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id70719b622e54833ae9798bf9ddc0a57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cba56b2736f4a09aa520371c0cb29ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4da8e4a0b6f4526bfb950095170ff2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifce18bab23fc49839c5ff35eebbc64f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if69c6f84cc55499992a9a2e32132005e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdb904ccb9024b858913d7acf42062d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccad64003d424270be4e3bf87201a726_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id946d775421d4962835fc013c2dd949a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia240f27fa9af4af381d9cd9b830cdc68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53e3c3e57bfa41579e675e5dacc3bd0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib665f9cde8cf48c5b5fc22d5eab5ff32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d24cfe7dee24743a1c19c57c666aad9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9866c2a563d74089bd190f1596f41fc2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c2ad38235c0444d8eb13ded4145682a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a7dfd23ab294cfdaa4374b169b9c14d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbbed003175d41bfa117df6296bf5c46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92535cf54c5042858d8b357cb40f0d14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied47fb81a807413c89dca88a7846b5c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92c83ac6e195467b945c631bdc59e85c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia46cd94f860647c4b3b4f6dd2d098fff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i944c4da8f51949d7bd4524a5221b53f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic575aff5abc14a04a5d1c46f2b053e12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a5af4745b754c7b874785b32bb24b00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a5962db8b8248e8a56de2423329a813_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2dddebd646fe4e9aae847684ea09146c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82707d8217c743548ff4520578c0f7cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18586610d42b4565923516e609315ed0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a279bb1582744739e5f9088fe666593_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb35b6ee6b4c481cbd643d0e1261cc8e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i141bfbb6d4734cb1906b822194473416_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i000c813b74c349b6be351b38fd528099_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36cf59fd6e684e63bd2fb4dcb7870271_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12701a294ac24a63ac70115c6686c71c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe0e2e65349e4185a303be08740aed7e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc93e8ad61544af5aef6ae040ba31401_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i893dec2695f241eea7e09febe91d6056_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4403c288e6734e15b800b88b0a641274_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d8039e3232a4ce3b5bcb3dfbf62c725_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia924eeb3bb7543ed8daaa1f3364c31e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72e3f19a1ae64901bda8ca62eb6abcfd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia013b3bfbdf74724934c7921f702d9ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1e86b4b83c1402e9dbc2c712ea987c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95699e6c8574452f9e3e864d40b1dc25_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0a18b2800d894d86bd5f131724792cfa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i224736ead83447e6a2b3bbfb08ecf30d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib60cabd0b1a14cb189936f2de2a378c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0921f2d8651244eab61f2a275f079822_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i916dce6d88664036bb8c4c3bcd21707a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61f2865a5c7548b6986efb37a72d32f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i35dca8996f6e45938deded2944b3efba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i10bea2bc73284b47b799ca78b75b4e06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7d1709057914d44afb932729cfecfcf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i235e4ed48f85437d8644836bbc43ca87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55a872aceca74648a5734c2e9893a09e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc2cebe6a0c248f594910077166c27c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie19c8a33e809469baa28577670a15fd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6c2d36bbe6a4d419b04a238a8121559_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForeignCurrencyAndCrossCurrencySwapsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0070fbcf9e5043e28c33ca586f2f12d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a3731a49f5b4c0ab1587258bbb6fa81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6300669025b46f7b380270aefda2eb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1b4d3bc8dd644d09c1cfa7a23a15d73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27ace983c9a64dc7b4239aea83dc7b02_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd95f2130b1849c0a6ac303164815eac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaef37d1d19a34b4abe782126c5137fe0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54e75f2069df4597912a649d3b21612f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f3b2c5c4c594281bf2350f890860495_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40227117f78447a9ad9ae92218498e28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2944af81b1f24f5e8934a081989872fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49d6cb8ea64d45f092c9ccbe06efae29_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i629346f484274f9ea377c96a9845eb29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id334802554e34a95a80f6c8df61e0238_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i378d88e1dff64d65904267fc06da9175_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09e8414ca5604a31a388ddd2badf96b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i824bdb4659bd41509979bb787b6de333_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6523296eb7b74ed7b7ff7acdfe444319_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdf6a2a3c143432ea3c1e2d1ca761a0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb8c2b20543e445bb5dea750ab9c396a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36b86d79154149259fd101e1fe5655b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2958a5f5fff1421995cfbfcd99f50244_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i2c106f85af6b497789bb2d2c5d8a09e5_D20210928-20210928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <context id="ia142d93a85b941c08264cf95a13ea31d_D20211012-20211012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-12</startDate>
            <endDate>2021-10-12</endDate>
        </period>
    </context>
    <context id="i726c606382b04686ab59e3bf5cf547f4_D20141001-20141031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="ice91453cc6994225aeb0216b9be20795_D20160201-20160228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-28</endDate>
        </period>
    </context>
    <context id="ifba99da398a24a8da5609feecbdda3b2_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ib5c422a12ee04646bd081c628e80d370_D20221129-20221129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:JanssenBiotechIncVsAmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="if7c1ec63c1ec45feb8a564cb6250b077_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="iee18063ebe5b4821977151cc6f74a5c1_I20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="ieb8da649b50d456aabccb1d09b37ed81_I20220527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:RegeneronPharmaceuticalsIncAntitrustActionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-27</instant>
        </period>
    </context>
    <context id="ib9fd3c9e12f348fda85ef0818a380f80_D20210505-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:ChemoCentryxIncSecuritiesMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>amgn:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="product">
        <measure>amgn:product</measure>
    </unit>
    <unit id="program">
        <measure>amgn:program</measure>
    </unit>
    <unit id="traunche">
        <measure>amgn:traunche</measure>
    </unit>
    <unit id="customer">
        <measure>amgn:customer</measure>
    </unit>
    <unit id="numberofnotices">
        <measure>amgn:numberOfNotices</measure>
    </unit>
    <unit id="case">
        <measure>amgn:Case</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="renewal_option">
        <measure>amgn:renewal_option</measure>
    </unit>
    <unit id="lawsuit">
        <measure>amgn:lawsuit</measure>
    </unit>
    <unit id="patent">
        <measure>amgn:patent</measure>
    </unit>
    <unit id="numberofplaintiffs">
        <measure>amgn:numberOfPlaintiffs</measure>
    </unit>
    <unit id="numberofclaims">
        <measure>amgn:numberOfClaims</measure>
    </unit>
    <unit id="states">
        <measure>amgn:States</measure>
    </unit>
    <unit id="argument">
        <measure>amgn:argument</measure>
    </unit>
    <unit id="installment">
        <measure>amgn:installment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF80L2ZyYWc6MmQxZWFiNzJiY2NlNDVhNDgwZDRmMjkxYWE1NGVhY2QvdGFibGU6ZjRlYzhkMjI2OTQzNGU3ZGI5OGU5MmRkOWI2YmUzMjQvdGFibGVyYW5nZTpmNGVjOGQyMjY5NDM0ZTdkYjk4ZTkyZGQ5YjZiZTMyNF8wLTEtMS0xLTE4ODk3NA_bece68e4-0a14-4c98-b3e5-285dd84e21be">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF80L2ZyYWc6MmQxZWFiNzJiY2NlNDVhNDgwZDRmMjkxYWE1NGVhY2QvdGFibGU6ZjRlYzhkMjI2OTQzNGU3ZGI5OGU5MmRkOWI2YmUzMjQvdGFibGVyYW5nZTpmNGVjOGQyMjY5NDM0ZTdkYjk4ZTkyZGQ5YjZiZTMyNF8xLTEtMS0xLTE4ODk3NA_710c3551-0f1c-4d48-83d0-050366542de6">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF80L2ZyYWc6MmQxZWFiNzJiY2NlNDVhNDgwZDRmMjkxYWE1NGVhY2QvdGFibGU6ZjRlYzhkMjI2OTQzNGU3ZGI5OGU5MmRkOWI2YmUzMjQvdGFibGVyYW5nZTpmNGVjOGQyMjY5NDM0ZTdkYjk4ZTkyZGQ5YjZiZTMyNF8yLTEtMS0xLTE4ODk3NA_34e3061b-2298-47dd-9668-a263063e36fb">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF80L2ZyYWc6MmQxZWFiNzJiY2NlNDVhNDgwZDRmMjkxYWE1NGVhY2QvdGFibGU6ZjRlYzhkMjI2OTQzNGU3ZGI5OGU5MmRkOWI2YmUzMjQvdGFibGVyYW5nZTpmNGVjOGQyMjY5NDM0ZTdkYjk4ZTkyZGQ5YjZiZTMyNF8zLTEtMS0xLTE4ODk3NA_7703955a-6a9c-4e47-a50c-d528e180f1a8">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_359201fb-5c99-405a-ab38-b09b1a0810df">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_e337db26-bca6-43a8-9a70-6927970d6b3a">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_8eb856b2-2130-4703-a4b4-acc8ce46190d">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_cfef6f7b-b5d4-400a-8a9d-e47d21f5486b">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_8acdce6f-01bc-4f81-be80-17993b14c4ca">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_f528949b-9261-49f0-9348-a8f3a32624b2">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDEw_08b7dff7-007b-49ab-8dfc-6f44d0f9fe52">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6YjkxOTZiYmYyNjQ3NDgwZWIxY2Y3ODAwMjFhMWIyNzUvdGFibGVyYW5nZTpiOTE5NmJiZjI2NDc0ODBlYjFjZjc4MDAyMWExYjI3NV8wLTAtMS0xLTE4ODk3NA_68e8b9fd-ab30-4ba1-bce3-90e98463289f">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV81NDk3NTU4MTc3MDk_661c9155-fdac-4274-afbe-601d5ce8d873">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV81NDk3NTU4MTc3MDk_27833414-9b5e-4056-936b-eb4e40c29a52">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6OGRhYWFjMWRhZDE3NGI2YTlkY2E2Zjg1YjFmODcwYzUvdGFibGVyYW5nZTo4ZGFhYWMxZGFkMTc0YjZhOWRjYTZmODViMWY4NzBjNV8wLTAtMS0xLTE4ODk3NA_a38e4830-5ff6-4139-aa12-e87663bb56b6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDEx_87d078f1-dd4f-49ee-91d2-5b7c937454b6">001-37702</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDEy_a42c4fd6-e4cd-458a-8451-165c71f5e3aa">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8wLTAtMS0xLTE4ODk3NA_b3188651-deb9-4952-8d3a-1bab63bf76aa">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8wLTItMS0xLTE4ODk3NA_87bce937-bc98-46dc-acf9-c40d38734207">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8yLTAtMS0xLTE4ODk3NA_e1c99252-4dba-401d-8059-e98c071ec9e5">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8yLTItMS0xLTE4ODk3NA_d9883055-6405-41ae-9711-45104b013598">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF8zLTAtMS0xLTE4ODk3NA_3e09113f-52b4-4d53-bc83-8a7efba124fe">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6ODg2OTM3NTZlNTAzNGQ0ZWEyYmYxNTNhOGQyNDkzMTgvdGFibGVyYW5nZTo4ODY5Mzc1NmU1MDM0ZDRlYTJiZjE1M2E4ZDI0OTMxOF80LTAtMS0xLTE4ODk3NA_983fa38d-8611-444e-a4bf-0e6866a8cde7">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA0_42dcaee8-88c7-49fd-93fc-a22f83fd89db">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA1_641c215e-9208-4af9-b8dc-ac2cf8661972">447-1000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia583ee59c26e4591a6c760c2f5aa05d2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18xLTAtMS0xLTE4ODk3NA_301fb877-fd52-480e-8a5d-a61a9f09c872">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia583ee59c26e4591a6c760c2f5aa05d2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18xLTEtMS0xLTE4ODk3NA_63f1340f-3d44-4a0a-ac61-8be92e1b4476">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia583ee59c26e4591a6c760c2f5aa05d2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18xLTItMS0xLTE4ODk3NA_2b0bf425-ee0b-4352-a58d-15147d8d9ae4">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i580757a974aa4b85b143f5523fc7aa91_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18yLTAtMS0xLTE4ODk3NA_e890454d-ad2e-4173-a937-04524572f79a">2.00% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i580757a974aa4b85b143f5523fc7aa91_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18yLTEtMS0xLTE4ODk3NA_afde0713-10c0-4e12-a13a-30500f88e72d">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i580757a974aa4b85b143f5523fc7aa91_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6NzQzNWJjZmVlMTZiNGEzNjkyMWM2ZTdkZTg2MDRjZDMvdGFibGVyYW5nZTo3NDM1YmNmZWUxNmI0YTM2OTIxYzZlN2RlODYwNGNkM18yLTItMS0xLTE4ODk3NA_30d578c9-faa2-4b77-b881-92ce0d40995a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDEz_fd3d7624-7adf-4e15-bd11-e84b1d521452">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA2_5c902bce-5783-43f5-ba2d-1ce0f5fc4873">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDE0_d3ff00f8-79a6-4650-9b10-7507e0709fa0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA3_4831ed18-aab3-4a36-957d-9a7a3098b2e7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6MTZhYmZhM2QxM2JjNDBjOGJhOTA1MTdhODYyZDZiNTMvdGFibGVyYW5nZToxNmFiZmEzZDEzYmM0MGM4YmE5MDUxN2E4NjJkNmI1M18wLTAtMS0xLTE4ODk3NA_0b10fb45-5603-42e2-8698-4e0df6e2d0bd">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6MTZhYmZhM2QxM2JjNDBjOGJhOTA1MTdhODYyZDZiNTMvdGFibGVyYW5nZToxNmFiZmEzZDEzYmM0MGM4YmE5MDUxN2E4NjJkNmI1M18xLTMtMS0xLTE4ODk3NA_f3438740-3263-48f5-90a5-15b775cbb8d1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGFibGU6MTZhYmZhM2QxM2JjNDBjOGJhOTA1MTdhODYyZDZiNTMvdGFibGVyYW5nZToxNmFiZmEzZDEzYmM0MGM4YmE5MDUxN2E4NjJkNmI1M18xLTQtMS0xLTE4ODk3NA_df42ca0b-1688-4f5f-af55-380f00c9d921">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDE1_5d35a10e-d75a-49cf-87ac-66c7066f9cee">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA4_22e82ac3-da7b-4293-8c5d-89be875ff43f">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ifa76a93f17df45cd9d66d36fd211676b_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8yNjAw_bd516064-efb0-4833-bab0-5cb4fc8865b1"
      unitRef="usd">129940091621</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3dd260e9045c46d1bd6dbbdbd6942bb1_I20230206"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zMTA2_7ca0e629-24bd-4104-8863-076d57af6c3d"
      unitRef="shares">533976238</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xL2ZyYWc6OGZjNmQwZjE5ZTc1NDYzNGE4NDVjODRiMDBkYjVlOWEvdGV4dHJlZ2lvbjo4ZmM2ZDBmMTllNzU0NjM0YTg0NWM4NGIwMGRiNWU5YV8zNDA5_317d3ad1-2a2b-44fd-8555-dad1ce446cad">&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specified portions of the registrant&#x2019;s Proxy Statement with respect to the 2023 Annual Meeting of Stockholders to be held May 19, 2023, are incorporated by reference into Part&#160;III of this annual report.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xMjEvZnJhZzpkMWI2OGVmZmQwZWM0MzcwYTQzYjQzMTUyM2MzMGRjZi90ZXh0cmVnaW9uOmQxYjY4ZWZmZDBlYzQzNzBhNDNiNDMxNTIzYzMwZGNmXzQxNjM_24bd42cc-dda8-4d05-b35e-eb18e4e93a4a">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xMjEvZnJhZzpkMWI2OGVmZmQwZWM0MzcwYTQzYjQzMTUyM2MzMGRjZi90ZXh0cmVnaW9uOmQxYjY4ZWZmZDBlYzQzNzBhNDNiNDMxNTIzYzMwZGNmXzQxNjQ_fc61861c-1121-4049-a9bd-7f18dbaac6de">Los Angeles, California</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNTcvZnJhZzo5ZTIzZTFmOGQwYWY0MjE2OTJlY2RhN2M1NDJiZDk3MC90YWJsZTpiZWRhOTk1NWU1OTM0Y2Y1YTc1ZWYzMGJlZGUyZGE5ZS90YWJsZXJhbmdlOmJlZGE5OTU1ZTU5MzRjZjVhNzVlZjMwYmVkZTJkYTllXzEtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246ZGE2NzdjNzVmOGJlNGY4NWI1MGEzZmViNzIxM2NkODZfNzE_b6612c4c-9e3a-458c-9346-334daac25957">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzIvZnJhZzozZTQwMDg2ODhiMTQ0ODkwYjkyNmNlZGI1MjY5ZTEwNS90YWJsZTo3ODQxZGIzZTk4YTE0MmMzYjY2YWU5NmYyNDgxNTkxOS90YWJsZXJhbmdlOjc4NDFkYjNlOThhMTQyYzNiNjZhZTk2ZjI0ODE1OTE5XzUtMi0xLTEtMTg4OTc0L3RleHRyZWdpb246Yjk5YWMyNGQ4ODM5NDZmNGI3NDdkODJmODJiNDU1NjlfOQ_11e9a07c-39fd-48c8-8e42-6b2314ec5548">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzIvZnJhZzozZTQwMDg2ODhiMTQ0ODkwYjkyNmNlZGI1MjY5ZTEwNS90ZXh0cmVnaW9uOjNlNDAwODY4OGIxNDQ4OTBiOTI2Y2VkYjUyNjllMTA1XzM1Nzk_3d3e955b-94a1-47e9-aff7-95bb73eb010a">Los Angeles, California</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f333186d8da4378bcf0c5a3e6baf0f9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzItMS0xLTEtMTg4OTc0_b88d2e08-8866-450a-8f6a-a2bba1d4ab51"
      unitRef="usd">24801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b25c75934844f82a32f7a76cdbe5042_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzItMy0xLTEtMTg4OTc0_76c0357b-eda9-42d8-946a-8286de91bfb3"
      unitRef="usd">24297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8db07843e5b426fbe44e0590a500e74_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzItNS0xLTEtMTg4OTc0_143d2a32-2cb2-4ecb-a3c3-f8547207b50c"
      unitRef="usd">24240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id25b0832750a4204ac083f11c97f8288_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMtMS0xLTEtMTg4OTc0_af9638ba-0c10-4afb-b80a-0f8fac22271b"
      unitRef="usd">1522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2457cd740816456db1f50da03ba631dc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMtMy0xLTEtMTg4OTc0_2028a9de-4f44-4fe9-a70b-3ba9af028f5e"
      unitRef="usd">1682000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50cbcfb77ce746588d1956f2435637ae_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMtNS0xLTEtMTg4OTc0_58fd98e4-aa96-45e2-9ce1-0ec6759c8f5d"
      unitRef="usd">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzQtMS0xLTEtMTg4OTc0_8defa462-223e-4760-a9ba-9338d83fb4e5"
      unitRef="usd">26323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzQtMy0xLTEtMTg4OTc0_afa8c79b-7aa1-4ac8-8d87-05a48544bb91"
      unitRef="usd">25979000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzQtNS0xLTEtMTg4OTc0_0115902a-8ad4-4a07-b449-2579c3bf814a"
      unitRef="usd">25424000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzctMS0xLTEtMTg4OTc0_148a0ab5-171b-4cd0-b6d0-0d9797c89739"
      unitRef="usd">6406000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzctMy0xLTEtMTg4OTc0_116bb8b7-b9de-469b-ac5f-9deeff97cee3"
      unitRef="usd">6454000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzctNS0xLTEtMTg4OTc0_6db25518-87de-40f8-a074-67562c9eb31f"
      unitRef="usd">6159000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzgtMS0xLTEtMTg4OTc0_6730120b-e778-4dd9-8303-6ede3bd5b2f3"
      unitRef="usd">4434000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzgtMy0xLTEtMTg4OTc0_6db62b91-7bf7-43e7-9f53-ac2609b15344"
      unitRef="usd">4819000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzgtNS0xLTEtMTg4OTc0_acc0de27-a5a0-4b9a-b0ed-f41adb13e765"
      unitRef="usd">4207000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzktMS0xLTEtMTg4OTc0_1cef4fca-3a17-48e0-810c-080fe515acc9"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzktMy0xLTEtMTg4OTc0_6081ce12-a859-4faa-a5c1-0fae1af8ed9d"
      unitRef="usd">1505000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzktNS0xLTEtMTg4OTc0_041e3fc4-7876-460e-91c3-60cff59c5a87"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEwLTEtMS0xLTE4ODk3NA_d4f37e9a-3361-4c7d-922c-72a86650a808"
      unitRef="usd">5414000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEwLTMtMS0xLTE4ODk3NA_906442a8-c4df-4e66-a2b5-7158a7e1f7fc"
      unitRef="usd">5368000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEwLTUtMS0xLTE4ODk3NA_2e5128de-68b0-4285-ab8d-68328ce9105b"
      unitRef="usd">5730000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzExLTEtMS0xLTE4ODk3NA_6c725a28-fe30-44c2-9083-f287057b0a73"
      unitRef="usd">503000000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzExLTMtMS0xLTE4ODk3NA_06c50921-2af9-42ee-b6d0-8e4d533539ec"
      unitRef="usd">194000000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzExLTUtMS0xLTE4ODk3NA_f45a35ee-4580-418a-8e73-b60c9bef2f5d"
      unitRef="usd">189000000</us-gaap:OtherGeneralExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEyLTEtMS0xLTE4ODk3NA_68a9b23b-ad1d-44da-b43b-d4a7d2c19aef"
      unitRef="usd">16757000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEyLTMtMS0xLTE4ODk3NA_26c79658-ee9e-4035-b898-2de0df5ed9d3"
      unitRef="usd">18340000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzEyLTUtMS0xLTE4ODk3NA_bc7c7bc7-f8e2-408d-b5b6-1de455463e7d"
      unitRef="usd">16285000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE0LTEtMS0xLTE4ODk3NA_3ea675a1-1811-4be7-a601-b9e6fe0dc9a3"
      unitRef="usd">9566000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE0LTMtMS0xLTE4ODk3NA_01f7351d-1e61-4205-aa91-a6e0dd9e7ea1"
      unitRef="usd">7639000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE0LTUtMS0xLTE4ODk3NA_8251dd2b-e344-47ca-8ebd-71503b73b7a9"
      unitRef="usd">9139000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseDebt
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE3LTEtMS0xLTE4ODk3NA_a4bb8425-3ca9-4565-8a6e-4d35ff5d3def"
      unitRef="usd">1406000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE3LTMtMS0xLTE4ODk3NA_5612fb69-4126-4a6d-80d6-95cc1381d441"
      unitRef="usd">1197000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE3LTUtMS0xLTE4ODk3NA_d3097df9-0473-48ea-9c24-5e2e1f4395ba"
      unitRef="usd">1262000000</us-gaap:InterestExpenseDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE4LTEtMS0xLTE4ODk3NA_0c98d736-2551-48c4-b9f8-822dfbdeb146"
      unitRef="usd">-814000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE4LTMtMS0xLTE4ODk3NA_96966e9d-e91d-4f65-925a-887d124523cb"
      unitRef="usd">259000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzE4LTUtMS0xLTE4ODk3NA_ad1ca72f-e394-48ee-80d5-c060cce55265"
      unitRef="usd">256000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIwLTEtMS0xLTE4ODk3NA_c8c71de5-1bf2-4252-9e7c-82c72f72eeaa"
      unitRef="usd">7346000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIwLTMtMS0xLTE4ODk3NA_5ef77341-bfbc-419e-b11f-fb3503c33003"
      unitRef="usd">6701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIwLTUtMS0xLTE4ODk3NA_1fae516a-6f7d-4432-9601-201b9d32cece"
      unitRef="usd">8133000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIyLTEtMS0xLTE4ODk3NA_988b3740-0a07-4e79-8a9f-0daa6863fbcd"
      unitRef="usd">794000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIyLTMtMS0xLTE4ODk3NA_2d24c6be-e5d7-4c02-ac64-10a053310081"
      unitRef="usd">808000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzIyLTUtMS0xLTE4ODk3NA_9c927bf6-0907-4318-bbb2-d16dcde6647a"
      unitRef="usd">869000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI0LTEtMS0xLTE4ODk3NA_213d2dc1-2f5e-426e-9ba6-061e388599f6"
      unitRef="usd">6552000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI0LTMtMS0xLTE4ODk3NA_61ce32e9-4638-4a30-87de-0b07151223be"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI0LTUtMS0xLTE4ODk3NA_d9ab75ce-0ee0-48c2-983e-69cb5ea51bfd"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI3LTEtMS0xLTE4ODk3NA_35feb22c-1204-4af8-9f5f-9503070621fe"
      unitRef="usdPerShare">12.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI3LTMtMS0xLTE4ODk3NA_1b6ba5f3-e813-402a-90aa-f9118a00c17a"
      unitRef="usdPerShare">10.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI3LTUtMS0xLTE4ODk3NA_b46a717a-10a4-4c64-a027-684fcb8763f4"
      unitRef="usdPerShare">12.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI4LTEtMS0xLTE4ODk3NA_3afd4988-050a-4898-a6d0-db788fd412fd"
      unitRef="usdPerShare">12.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI4LTMtMS0xLTE4ODk3NA_6af7e6ff-5f3b-42eb-85c9-92789cb3cc29"
      unitRef="usdPerShare">10.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzI4LTUtMS0xLTE4ODk3NA_17c769c7-0230-4321-bc01-edbbb07cdf92"
      unitRef="usdPerShare">12.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMxLTEtMS0xLTE4ODk3NA_34a28710-b20d-45e7-9e52-acdd7f58aa3c"
      unitRef="shares">538000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMxLTMtMS0xLTE4ODk3NA_294d1302-f7a3-4888-83a4-bfabc8e76d76"
      unitRef="shares">570000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMxLTUtMS0xLTE4ODk3NA_a7b23b0d-8aac-464a-9cae-7ac2d69963d2"
      unitRef="shares">586000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMyLTEtMS0xLTE4ODk3NA_22d96441-142e-4e2e-9dbc-daccd8b44e60"
      unitRef="shares">541000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMyLTMtMS0xLTE4ODk3NA_2f156750-e777-411b-b5b6-ae0aeb1da7b9"
      unitRef="shares">573000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzUvZnJhZzoyODNiMmEwYTA0NGM0YjM5ODdiYjllYmI2OTY3ZThiYS90YWJsZTpiYWFiMTYzODc0YzE0NGMzOGEwMGYwZWRhYzE2NDYzMy90YWJsZXJhbmdlOmJhYWIxNjM4NzRjMTQ0YzM4YTAwZjBlZGFjMTY0NjMzXzMyLTUtMS0xLTE4ODk3NA_5f0fff11-1bc1-407b-9090-8fe8c2f0f0d6"
      unitRef="shares">590000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzEtMS0xLTEtMTg4OTc0_14bc04c3-6a37-462c-b2ab-351b35e26065"
      unitRef="usd">6552000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzEtMy0xLTEtMTg4OTc0_63629072-852c-491d-b372-bf81b967eff6"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzEtNS0xLTEtMTg4OTc0_4ddcd2e2-53bb-43d9-82b5-2f3cd468fc19"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzMtMS0xLTEtMTg4OTc0_7488c5ea-b2ae-4238-9c05-b6a7477485a6"
      unitRef="usd">496000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzMtMy0xLTEtMTg4OTc0_cac4e98a-b3cb-4b11-b887-79605050e7d5"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzMtNS0xLTEtMTg4OTc0_c99c21cf-d920-46d2-bc73-eb2156574271"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzQtMS0xLTEtMTg4OTc0_504cf090-6ea6-49f9-9526-1aecbaa7695d"
      unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzQtMy0xLTEtMTg4OTc0_655ec8ba-f50a-496b-8f63-cdf779c02458"
      unitRef="usd">324000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzQtNS0xLTEtMTg4OTc0_f0877cbd-71bd-4e76-ae21-a578aec3f3b4"
      unitRef="usd">-438000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzUtMS0xLTEtMTg4OTc0_b1095882-9e60-412c-b0f0-c569580b160a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzUtMy0xLTEtMTg4OTc0_cf6db635-39e6-431a-a610-9463d23897e2"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzUtNS0xLTEtMTg4OTc0_f7ad989e-3380-450a-879a-d2ffa3717823"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzYtMS0xLTEtMTg4OTc0_d4ca1a3d-4f43-4a6a-ae7f-bc41befb497a"
      unitRef="usd">2000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzYtMy0xLTEtMTg4OTc0_7c92d8d3-9fa7-42d7-977f-e6d180e2e165"
      unitRef="usd">1000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzYtNS0xLTEtMTg4OTc0_0f005909-1a08-4dd4-81d8-10a8a9e84232"
      unitRef="usd">-7000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzctMS0xLTEtMTg4OTc0_f2018176-3a4c-4b90-b1f9-9530a26dca2c"
      unitRef="usd">565000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzctMy0xLTEtMTg4OTc0_1952c7f0-aaf1-472d-bce0-2910c1ffdfe7"
      unitRef="usd">189000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzctNS0xLTEtMTg4OTc0_23b5de90-9184-46e0-ac68-b285c139ad60"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzgtMS0xLTEtMTg4OTc0_e69207d7-78b2-4807-a5cd-5705ad527a9e"
      unitRef="usd">7117000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzgtMy0xLTEtMTg4OTc0_19a79603-13ab-432e-a762-bf02e631a7ff"
      unitRef="usd">6082000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xNzgvZnJhZzozMDNlNjRkNWRhNzA0NGViYTVmZjE0NDA2YTAzNmJmYy90YWJsZTo5MTYwOTZkM2U0YTI0NzZkYjllMWYxZTNiNzJmODhjZC90YWJsZXJhbmdlOjkxNjA5NmQzZTRhMjQ3NmRiOWUxZjFlM2I3MmY4OGNkXzgtNS0xLTEtMTg4OTc0_aa0dd0d2-8544-490f-b197-f3d3730c0df1"
      unitRef="usd">6807000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMtMS0xLTEtMTg4OTc0_cecfba4a-191b-4ba5-b642-e4e51d81b679"
      unitRef="usd">7629000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMtMy0xLTEtMTg4OTc0_5a510c90-74c3-4da9-bdcd-395bb7600fd5"
      unitRef="usd">7989000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzQtMS0xLTEtMTg4OTc0_ecd9ddb5-6bfc-4742-9df8-1e9cee3604cf"
      unitRef="usd">1676000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzQtMy0xLTEtMTg4OTc0_fd5049fc-5f6f-43b3-a4ce-357e2f42af62"
      unitRef="usd">48000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzUtMS0xLTEtMTg4OTc0_fe86a08a-ccfc-4f4c-b37e-1739252a3392"
      unitRef="usd">5563000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzUtMy0xLTEtMTg4OTc0_d3b87b84-850a-48b9-87bb-6e72218dc0ca"
      unitRef="usd">4895000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzYtMS0xLTEtMTg4OTc0_1341956a-c0ff-4e6a-9a32-2630c827d0e9"
      unitRef="usd">4930000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzYtMy0xLTEtMTg4OTc0_7f9e0516-d87d-497e-9ac7-c274ac5836b7"
      unitRef="usd">4086000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzctMS0xLTEtMTg4OTc0_67eb7cfc-3ae5-4c06-97ce-234f6ff0d969"
      unitRef="usd">2388000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzctMy0xLTEtMTg4OTc0_c4817cfa-0a6a-44da-879f-7094e71db6a6"
      unitRef="usd">2367000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzgtMS0xLTEtMTg4OTc0_3cd4f76d-1b51-4fc6-ba93-a05a3320bb74"
      unitRef="usd">22186000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzgtMy0xLTEtMTg4OTc0_98642183-1df4-4e18-aff7-6206010689e7"
      unitRef="usd">19385000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEwLTEtMS0xLTE4ODk3NA_18490382-bd9e-4b87-a325-968bf3bb5074"
      unitRef="usd">5427000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEwLTMtMS0xLTE4ODk3NA_be0dd8a4-30bc-4369-b323-9f468662dc83"
      unitRef="usd">5184000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzExLTEtMS0xLTE4ODk3NA_43c36c2b-eb23-4b61-aeac-a2bff5a5a1a3"
      unitRef="usd">16080000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzExLTMtMS0xLTE4ODk3NA_9f91b781-6307-4ede-823a-23ccac6b92b8"
      unitRef="usd">15182000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEyLTEtMS0xLTE4ODk3NA_4a0ceb39-f71d-4407-bfa7-4efd1867a9cd"
      unitRef="usd">15529000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEyLTMtMS0xLTE4ODk3NA_1fbd1dbd-e60b-49c1-8e83-4a48dcafb4d1"
      unitRef="usd">14890000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEzLTEtMS0xLTE4ODk3NA_af74b73f-ce57-4f06-8012-75ca03e91561"
      unitRef="usd">5899000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzEzLTMtMS0xLTE4ODk3NA_3b5b6144-963a-45ec-955e-e1f3a75acc5e"
      unitRef="usd">6524000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE0LTEtMS0xLTE4ODk3NA_39e422ff-a994-459e-85b2-34105802d8b8"
      unitRef="usd">65121000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE0LTMtMS0xLTE4ODk3NA_cffda9b5-aa35-4612-86a4-27ecdb8eda76"
      unitRef="usd">61165000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE4LTEtMS0xLTE4ODk3NA_8eb92059-33a5-461e-a05f-40fd69a84b61"
      unitRef="usd">1572000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE4LTMtMS0xLTE4ODk3NA_2d8eeb26-81cb-4437-848d-3e9c1757255d"
      unitRef="usd">1366000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE5LTEtMS0xLTE4ODk3NA_4da57fc8-51e9-458c-93fd-8ddba766caeb"
      unitRef="usd">12524000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzE5LTMtMS0xLTE4ODk3NA_f26216dc-64a0-4d04-a690-79d33f7acf80"
      unitRef="usd">10731000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIwLTEtMS0xLTE4ODk3NA_613f37dd-b465-4d06-8028-61679aa84b31"
      unitRef="usd">1591000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIwLTMtMS0xLTE4ODk3NA_58031cc3-4833-4725-bf6b-0e86a646924e"
      unitRef="usd">87000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIxLTEtMS0xLTE4ODk3NA_f10e0294-268b-414b-a5c0-95b7f9b7ebb3"
      unitRef="usd">15687000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIxLTMtMS0xLTE4ODk3NA_c2f36a9f-406f-4684-86e8-d9bf136a2740"
      unitRef="usd">12184000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIzLTEtMS0xLTE4ODk3NA_44b8140c-29e7-436f-b8f9-3d1ece700b15"
      unitRef="usd">37354000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzIzLTMtMS0xLTE4ODk3NA_adf646e9-d105-4765-84a1-4e552d8953fc"
      unitRef="usd">33222000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI1LTEtMS0xLTE4ODk3NA_8b7b902f-9b1a-4158-9502-88ca2118582b"
      unitRef="usd">5757000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI1LTMtMS0xLTE4ODk3NA_18c5f7b1-9b40-45cd-a978-cf073b83291f"
      unitRef="usd">6594000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI2LTEtMS0xLTE4ODk3NA_c51a0fc8-9802-4266-98f5-c71402091c1b"
      unitRef="usd">2662000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI2LTMtMS0xLTE4ODk3NA_8ce59234-9153-4251-b08a-fa09bb18243b"
      unitRef="usd">2465000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI4LTEtMS0xLTE4ODk3NA_efc3b42c-bfb8-4e9d-af6b-75f3e1227ac2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzI4LTMtMS0xLTE4ODk3NA_83777605-1c36-4920-bb77-bbec4dc1f140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzQ5_a9847645-e2f1-4c5b-8235-3cfb0652d5c3"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzQ5_efb011d4-7a9d-4952-a039-357975551069"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzcz_a80b8062-7ce4-4157-bf80-aacdc89909fa"
      unitRef="shares">2750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzcz_ae4697ea-151d-4eda-b100-e0a15822ad92"
      unitRef="shares">2750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzEwNw_a9ef3d00-8550-4225-bb70-5250100aeffe"
      unitRef="shares">534000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjYWUxYWZlMDdiODRhOTQ5NzZiZGFkNWUxYTJkYThlXzEyNw_fe91512e-c3c3-4bce-9ae0-018131a4c940"
      unitRef="shares">558300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTEtMS0xLTE4ODk3NA_9d06acba-5f87-4202-9cab-8cf93fdd9174"
      unitRef="usd">32514000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMxLTMtMS0xLTE4ODk3NA_4a43bf52-7227-4895-b0cb-655850e4c089"
      unitRef="usd">32096000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMyLTEtMS0xLTE4ODk3NA_2d871583-1549-4570-adb2-bfb8cc8537f5"
      unitRef="usd">-28622000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMyLTMtMS0xLTE4ODk3NA_62a75ae3-9d2b-4825-bdf7-5fda73d8fe9c"
      unitRef="usd">-24600000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMzLTEtMS0xLTE4ODk3NA_888cd757-8955-4e89-8e7f-ffd3d2850824"
      unitRef="usd">-231000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzMzLTMtMS0xLTE4ODk3NA_e35c7ab1-2c80-4089-a9e8-38bcdf452595"
      unitRef="usd">-796000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzM0LTEtMS0xLTE4ODk3NA_48a7d13e-497e-4239-b3aa-aee50c02771e"
      unitRef="usd">3661000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzM0LTMtMS0xLTE4ODk3NA_57cbbaea-22f4-42e8-bf45-42b6e073996a"
      unitRef="usd">6700000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzM1LTEtMS0xLTE4ODk3NA_86c2e035-0c8a-46ca-9d92-e6a087319bb7"
      unitRef="usd">65121000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODEvZnJhZzo4M2FmMjBkMTZhYjQ0NzZjYTAwMThhNDA2YzE3NDkwZC90YWJsZTphNjBmYzM2ODI0NGQ0ZDM4YjM3Mjk0ZWUzNDIwZjNlMC90YWJsZXJhbmdlOmE2MGZjMzY4MjQ0ZDRkMzhiMzcyOTRlZTM0MjBmM2UwXzM1LTMtMS0xLTE4ODk3NA_fa78e202-ee4f-4704-8b05-6f1b113fc01d"
      unitRef="usd">61165000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0567102b4dbd4cabaf51e541f2a41652_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtMS0xLTEtMTg4OTc0_2cedbbcc-a60a-44bb-9fea-b8a79c6a8e0b"
      unitRef="shares">591400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2edf981fef6d4fa4973e8992576dab4c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtMy0xLTEtMTg4OTc0_742de2c6-2727-477b-9f46-b3a02f38dbe6"
      unitRef="usd">31531000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc5f2c87a3f74cd797cc6268b82470bc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtNS0xLTEtMTg4OTc0_f229e73c-2b99-4d74-aeae-4d49903d3966"
      unitRef="usd">-21330000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecb02e3f6128454a820a56e2cfbb6e3f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtNy0xLTEtMTg4OTc0_08136141-dc30-4366-8b7e-ac4d1483fa03"
      unitRef="usd">-528000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEtOS0xLTEtMTg4OTc0_d6651a0f-07d7-4239-8f2c-d7cf294652ab"
      unitRef="usd">9673000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice20f9c10bef48889e1c07a014676f7b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzItNS0xLTEtMTg4OTc0_b43d0fb3-0746-462c-8d83-dd8c178471ac"
      unitRef="usd">-2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic10864dfaff048eca24b894294bae77d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzItNy0xLTEtMTg4OTc0_b0a9f1b1-5d00-4d0c-9bf0-5754d1afb92e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaeb157cdc95045539f3bb40881b31817_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzItOS0xLTEtMTg4OTc0_9195ebe3-fa6e-48bb-8874-55107f339c41"
      unitRef="usd">-2000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia56dda630a2e4ae3bbca72a1ff1cf2ef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzMtNS0xLTEtMTg4OTc0_18bb8a0f-95cf-4047-9822-1c906e0f57e4"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzMtOS0xLTEtMTg4OTc0_7198ade5-a4e8-4d1e-84c3-fca6ec725961"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzQtNy0xLTEtMTg4OTc0_da0a0454-0919-428e-8d12-8e762542be83"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzQtOS0xLTEtMTg4OTc0_987b366c-28fc-4010-a767-ac1359a004a3"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzUtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246NTE2ZDkyNWVkMzRiNDg5M2IzZGY4MTk5NjRhODY3OThfNDA_7819106c-1bda-4ee0-9f59-8b6a614901a4"
      unitRef="usdPerShare">6.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia56dda630a2e4ae3bbca72a1ff1cf2ef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzUtNS0xLTEtMTg4OTc0_0e60386e-d18d-4914-aeaf-a04bf104f053"
      unitRef="usd">3843000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzUtOS0xLTEtMTg4OTc0_6cbb7915-590f-4fa4-9b1e-207119ad4029"
      unitRef="usd">3843000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia5998f096c32498584f7ddcb1b102049_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzYtMS0xLTEtMTg4OTc0_f13d3f22-bd91-445c-adfa-d5da5c2841c2"
      unitRef="shares">2100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4a339f1adc784aaa9ffccfd08a332107_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzYtMy0xLTEtMTg4OTc0_ead76ca3-2bf9-4671-bae5-02465845855f"
      unitRef="usd">91000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzYtOS0xLTEtMTg4OTc0_894d2af9-5caa-4f88-af1f-01d56818d875"
      unitRef="usd">91000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4a339f1adc784aaa9ffccfd08a332107_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzctMy0xLTEtMTg4OTc0_42921a7f-4afb-494a-a922-9f3268640882"
      unitRef="usd">349000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzctOS0xLTEtMTg4OTc0_9a1ea7e7-2083-4ed7-a1a1-53bcfea4b9c6"
      unitRef="usd">349000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4a339f1adc784aaa9ffccfd08a332107_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzgtMy0xLTEtMTg4OTc0_e9be383a-cfc3-43e4-b5b4-465677283012"
      unitRef="usd">169000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzgtOS0xLTEtMTg4OTc0_889773a5-40af-4caa-8d4d-3708cc098a22"
      unitRef="usd">169000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ia5998f096c32498584f7ddcb1b102049_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzktMS0xLTEtMTg4OTc0_970a80a4-fafb-4531-8505-d422880ea66e"
      unitRef="shares">15200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ia56dda630a2e4ae3bbca72a1ff1cf2ef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzktNS0xLTEtMTg4OTc0_45091064-3b5f-4f2c-9800-5908e66c4957"
      unitRef="usd">3497000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzktOS0xLTEtMTg4OTc0_c39b5fde-6a76-4529-85cc-50337b4f5c32"
      unitRef="usd">3497000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i59da9a82507b4a00bb722da4afa5b3c1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTEtMS0xLTE4ODk3NA_dd8088a2-d903-4910-a68a-eb35b2977033"
      unitRef="shares">578300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2470640538814b629fcb492196758669_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTMtMS0xLTE4ODk3NA_2220702d-82c5-43ca-8ea2-20e8623d3863"
      unitRef="usd">31802000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f7304b1f329421f82c9e6191840585b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTUtMS0xLTE4ODk3NA_00a8ad1c-d43c-4174-a415-ce949d1de94e"
      unitRef="usd">-21408000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e70878840254d839c51604f86fab42a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTctMS0xLTE4ODk3NA_a5bb9666-3b2d-4c01-90a1-cca4062aeca8"
      unitRef="usd">-985000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEwLTktMS0xLTE4ODk3NA_c21d449d-09b3-4a0a-b505-5d61a7a206f0"
      unitRef="usd">9409000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i39f0e0839efe462786cfb45f06b6105b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEyLTUtMS0xLTE4ODk3NA_5e74b4f4-2292-44b7-9686-3f9bc4d8996d"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEyLTktMS0xLTE4ODk3NA_97660576-93a0-461b-803c-c260f315e2bb"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEzLTctMS0xLTE4ODk3NA_913bd6dd-e516-48ac-bfe4-49e0110808c0"
      unitRef="usd">189000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzEzLTktMS0xLTE4ODk3NA_8e17db96-982f-4233-bb9d-1d5b1be1dd0c"
      unitRef="usd">189000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE0LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjZkZWE0NWJlN2YxNzRjMGE5ZTE3MDU2M2M5Y2JhM2Q0XzQw_8242e7b6-9f33-4f03-9454-af39e41a2c71"
      unitRef="usdPerShare">7.22</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i39f0e0839efe462786cfb45f06b6105b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE0LTUtMS0xLTE4ODk3NA_36e9b521-cd63-4a68-b123-425b47684aea"
      unitRef="usd">4098000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE0LTktMS0xLTE4ODk3NA_7ec5c876-6477-4859-8459-e6a76d3d3ce3"
      unitRef="usd">4098000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5b88900199d7479494b9b92a28082482_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE1LTEtMS0xLTE4ODk3NA_22a83866-21b2-456c-a870-e687e2066a6a"
      unitRef="shares">1700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i46710aa460c94e759e4be58d5b0aa1cf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE1LTMtMS0xLTE4ODk3NA_07e8e77b-b47e-4014-b8d5-ec2ba1625378"
      unitRef="usd">82000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE1LTktMS0xLTE4ODk3NA_ee524a20-6bd9-41c4-8aa0-cb8626b250ee"
      unitRef="usd">82000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i46710aa460c94e759e4be58d5b0aa1cf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE2LTMtMS0xLTE4ODk3NA_242b88c4-2a40-45c5-912e-0a7d3ea43cfe"
      unitRef="usd">361000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE2LTktMS0xLTE4ODk3NA_9cd3dccb-21db-4d1d-aa2c-680865e82f57"
      unitRef="usd">361000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i46710aa460c94e759e4be58d5b0aa1cf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE3LTMtMS0xLTE4ODk3NA_00179a24-c69c-4760-b6cd-9f9fd7b44494"
      unitRef="usd">149000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE3LTktMS0xLTE4ODk3NA_77e3c574-aa9a-4aa4-a127-0d3adbb0516e"
      unitRef="usd">149000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i5b88900199d7479494b9b92a28082482_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE4LTEtMS0xLTE4ODk3NA_2672c628-4b76-45f5-9a9c-239cb9ccd9d0"
      unitRef="shares">21700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i39f0e0839efe462786cfb45f06b6105b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE4LTUtMS0xLTE4ODk3NA_29d1712d-6963-4cb3-a6b9-64aa068bc663"
      unitRef="usd">4987000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE4LTktMS0xLTE4ODk3NA_58fabdb9-f5cb-401c-b170-6d28757788f3"
      unitRef="usd">4987000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9214e72c6081443dbdd4956e36759200_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTEtMS0xLTE4ODk3NA_325bf93e-fc8f-40a1-9fd9-768bdcd4e6cb"
      unitRef="shares">558300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia5cc146400d04167a6eb49d6a45c2634_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTMtMS0xLTE4ODk3NA_11682dc6-1d81-49b9-bd0f-2d98c889564d"
      unitRef="usd">32096000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0604e8ad2a44749afd263c7e0c52319_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTUtMS0xLTE4ODk3NA_3997f653-4720-45e3-81cf-2ef27bc1c261"
      unitRef="usd">-24600000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib964505bb2264c0e858b211061796b49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTctMS0xLTE4ODk3NA_8a655154-2300-4dbe-9d43-97ece48d1cbf"
      unitRef="usd">-796000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzE5LTktMS0xLTE4ODk3NA_185dd1fb-fc94-4097-83e4-505011d936dc"
      unitRef="usd">6700000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iee236cd90d724c118c6bd2bd1de4571e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIxLTUtMS0xLTE5MDU1Mw_b02d48c0-842a-4446-a6c1-43856c8d70dc"
      unitRef="usd">6552000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIxLTktMS0xLTE4ODk3NA_a6fa37e8-1e70-4ad5-8957-cec2ab9dab8a"
      unitRef="usd">6552000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIyLTctMS0xLTE5MDU4MQ_6de218cc-dc10-498b-ae51-3ab877d5fe19"
      unitRef="usd">565000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIyLTktMS0xLTE4ODk3NA_5d9d04e4-35b7-4d9e-9fe3-78f6c00b3c06"
      unitRef="usd">565000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIzLTAtMS0xLTE5MDc0MC90ZXh0cmVnaW9uOjU3ODJlODZlNjhhYTQ3MWM4NDU3M2FhMjQwNjU2MDkyXzU0OTc1NTgxMzk0MQ_6f718bc1-5ae9-4317-a3f5-10b8762ba9eb"
      unitRef="usdPerShare">7.95</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="iee236cd90d724c118c6bd2bd1de4571e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIzLTUtMS0xLTE5MDU5NQ_934befa9-4502-43ce-9063-98499d8f3e2e"
      unitRef="usd">4264000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzIzLTktMS0xLTE4ODk3NA_ce0c1343-f496-448f-8925-cf8d2470032b"
      unitRef="usd">4264000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ida0d3563966d49f2afdae70577b5770d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI0LTEtMS0xLTE5MDQ3MA_8d7789e0-66bc-43d7-8aaf-79ac70e67beb"
      unitRef="shares">1800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI0LTMtMS0xLTE5MDYwOQ_2ce5432c-da86-4885-97dc-da0279b88bf7"
      unitRef="usd">138000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI0LTktMS0xLTE4ODk3NA_9351103c-5927-44c0-8216-a2f9debeab37"
      unitRef="usd">138000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI1LTMtMS0xLTE5MDYzMA_b11b6e0f-1cd1-4474-a90f-b61f4d31818c"
      unitRef="usd">419000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI1LTktMS0xLTE4ODk3NA_610d268e-bb8b-4cbe-8cb7-e20ce8cbbbea"
      unitRef="usd">419000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI2LTMtMS0xLTE5MDY1MQ_db4b1d27-2b0e-4255-a47f-88e7c42aa209"
      unitRef="usd">139000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI2LTktMS0xLTE4ODk3NA_3156f6f9-bd42-4cc0-81cc-14ecc88373ea"
      unitRef="usd">139000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ida0d3563966d49f2afdae70577b5770d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI3LTEtMS0xLTE5MDQ5Mg_2cd6794e-fc95-4e2e-a779-aa7acc2a66d3"
      unitRef="shares">26100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ib8082800babd4c81ba4d7c7a125cfbf2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI3LTMtMS0xLTE5MDY2OQ_a83940ac-a0d1-4d36-a679-bdc987ae20ed"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="iee236cd90d724c118c6bd2bd1de4571e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI3LTUtMS0xLTE5MDY3Nw_9c6651fe-78e4-4564-b25d-ebcf2d231d84"
      unitRef="usd">6310000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI3LTktMS0xLTE4ODk3NA_a22d0462-ad7f-46fa-85c5-762cfeb62aeb"
      unitRef="usd">6310000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if935497be7004087ab59197b95cf4c00_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTEtMS0xLTE4ODk3NA_3900bce9-dc98-4b06-84ea-7516a1d92ccd"
      unitRef="shares">534000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib6677b10603d44f784a36a5a29714649_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTMtMS0xLTE4ODk3NA_ba047496-7dfa-4f75-9f5b-946d493c403f"
      unitRef="usd">32514000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec4b231199d0442bb9d2420b71dfb984_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTUtMS0xLTE4ODk3NA_abf016dd-937c-43f4-9881-34535c617cfc"
      unitRef="usd">-28622000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i349ee45aa1e94ce9adf98a1fa8b76e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTctMS0xLTE4ODk3NA_3a7d3b59-feb8-463c-b09d-9b1ab276102c"
      unitRef="usd">-231000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODQvZnJhZzoxNTk1NjcyMTZiNDY0Yzc4OTAwODRjNjUzY2JlYzcwYS90YWJsZTphMTNmYmY5MzcxZjI0N2ZmYWJkYzliNTk0NDg3M2IyZC90YWJsZXJhbmdlOmExM2ZiZjkzNzFmMjQ3ZmZhYmRjOWI1OTQ0ODczYjJkXzI5LTktMS0xLTE4ODk3NA_51f0778c-55e2-40f5-9a41-5e4632083a03"
      unitRef="usd">3661000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzItMS0xLTEtMTg4OTc0_5a7f8116-936e-4179-863a-77f4bdebc8a9"
      unitRef="usd">6552000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzItMy0xLTEtMTg4OTc0_e0de8dee-c631-4d3c-b4eb-f08c706cc19b"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzItNS0xLTEtMTg4OTc0_a249a1dd-9e25-4cf6-b1df-538de3378bfd"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMtMS0xLTEtMTg4OTc0_c958b437-28ba-4a0b-9c0c-e47f02f3bddf"
      unitRef="usd">3417000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMtMy0xLTEtMTg4OTc0_b332c581-e06b-4489-8ea2-b329ccb01276"
      unitRef="usd">3398000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMtNS0xLTEtMTg4OTc0_2b36d93f-2fa4-45b3-bcc3-9625d5eeedfd"
      unitRef="usd">3601000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzQtMS0xLTEtMTg4OTc0_b16f2e89-c1e9-4ba8-b0c3-a21ed12c85d0"
      unitRef="usd">401000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzQtMy0xLTEtMTg4OTc0_143c054f-8707-4848-9e7b-f1face2a7939"
      unitRef="usd">341000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzQtNS0xLTEtMTg4OTc0_674e5b92-1837-4dd3-8982-9fdf87b27bca"
      unitRef="usd">330000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzUtMS0xLTEtMTg4OTc0_266ed60b-99d8-4832-9e01-71f405e32a2b"
      unitRef="usd">-1198000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzUtMy0xLTEtMTg4OTc0_5f34f8cb-ceec-4ae3-bf28-c11ca9658df4"
      unitRef="usd">-453000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzUtNS0xLTEtMTg4OTc0_31bb4434-9dd0-447b-98d3-67a4219b76f3"
      unitRef="usd">-287000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzYtMS0xLTEtMTg4OTc0_ad0e8935-524d-4a49-a4f5-321f4e2446be"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzYtMy0xLTEtMTg4OTc0_d0be7d49-b001-496c-9685-960670c3a387"
      unitRef="usd">1505000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzYtNS0xLTEtMTg4OTc0_f5892638-3eb7-44a5-86e4-c7f701e215a2"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctMS0xLTEtMTkyNTE5_3bd4b73d-b83f-462b-b9ef-32180ac36f4b"
      unitRef="usd">-891000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctMy0xLTEtMTk3ODIx_f43b75fa-3d5f-473a-85b5-e42eab64d8a8"
      unitRef="usd">-33000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctNS0xLTEtMTk3ODI0_b10d79d8-2a1b-46dd-afbf-376755ab86e9"
      unitRef="usd">-65000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzgtMS0xLTEtMTk3ODI3_8109adb8-69ca-47d6-afda-2ffee663399a"
      unitRef="usd">567000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzgtMy0xLTEtMTk3ODMw_d0ab8bbf-5bb3-43a5-b2af-fe2be0cb602d"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzgtNS0xLTEtMTk3ODMz_6a5b8fed-bca9-4120-8da5-0584a76fc0fa"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctMS0xLTEtMTg4OTc0_91e009ed-f24d-4840-8477-0fdb11aa6718"
      unitRef="usd">176000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctMy0xLTEtMTg4OTc0_9a20a2d1-f11e-448f-b5d4-863193943e5c"
      unitRef="usd">262000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzctNS0xLTEtMTg4OTc0_21d49397-d381-40ff-96ed-c25b7aee1fc8"
      unitRef="usd">260000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzktMS0xLTEtMTg4OTc0_cee09034-f1db-4913-8247-cc6787cd99d2"
      unitRef="usd">746000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzktMy0xLTEtMTg4OTc0_2012a595-5c98-4da2-a5af-d774e3e7f112"
      unitRef="usd">429000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzktNS0xLTEtMTg4OTc0_19409d25-66c7-4087-9f81-ea31ed12bd80"
      unitRef="usd">427000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEwLTEtMS0xLTE4ODk3NA_e0c57850-47ad-4749-a51b-e00e2a37efd3"
      unitRef="usd">742000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEwLTMtMS0xLTE4ODk3NA_680e1c7f-e2dc-49a8-b778-71012d78cb0b"
      unitRef="usd">165000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEwLTUtMS0xLTE4ODk3NA_9b33b88c-677e-4585-99d4-f325eab2e64a"
      unitRef="usd">215000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzExLTEtMS0xLTE4ODk3NA_522d6e54-6fb1-4fb7-b839-3476d5f9dea1"
      unitRef="usd">-258000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzExLTMtMS0xLTE4ODk3NA_8a4395d6-f7f2-43a3-ab11-f19d7d4140fa"
      unitRef="usd">237000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzExLTUtMS0xLTE4ODk3NA_5bbca096-fbf3-4b1c-9c09-ccc1af371b93"
      unitRef="usd">-129000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEyLTEtMS0xLTE4ODk3NA_775e4217-9e05-43a4-8852-49dce4371f6d"
      unitRef="usd">154000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEyLTMtMS0xLTE4ODk3NA_548d61cb-7b30-406d-bf02-a4b8a3df0876"
      unitRef="usd">-69000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEyLTUtMS0xLTE4ODk3NA_cbd2b8a5-78da-453c-888a-114bc8112c91"
      unitRef="usd">45000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEzLTEtMS0xLTE4ODk3NA_6cb3721b-9729-4392-ac75-210bfdb2bfdf"
      unitRef="usd">-647000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEzLTMtMS0xLTE4ODk3NA_ebe948d6-b651-4723-a827-c380c7a61609"
      unitRef="usd">-854000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzEzLTUtMS0xLTE4ODk3NA_6efb63bd-3294-4388-830d-74efd55b2cf8"
      unitRef="usd">-249000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE0LTEtMS0xLTE4ODk3NA_cd85d8c1-901b-4bad-869f-3313bcdda2e0"
      unitRef="usd">229000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE0LTMtMS0xLTE4ODk3NA_e0409fd8-a395-4e26-8adf-65255938cc4b"
      unitRef="usd">204000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE0LTUtMS0xLTE4ODk3NA_0bffb609-a44b-4748-ba60-ad5328a626f0"
      unitRef="usd">-482000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE1LTEtMS0xLTE4ODk3NA_e041c5cf-be9a-4c8e-967d-9092d6a3cb13"
      unitRef="usd">761000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE1LTMtMS0xLTE4ODk3NA_4f7d5a66-4f88-4ab6-90fc-834ea101eaf2"
      unitRef="usd">356000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE1LTUtMS0xLTE4ODk3NA_380d3035-4550-4108-b13d-c9379028ecb7"
      unitRef="usd">983000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE2LTEtMS0xLTE4ODk3NA_aa4c114e-7dee-453e-9452-713f1243a838"
      unitRef="usd">9721000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE2LTMtMS0xLTE4ODk3NA_9ec479f8-8a68-4a60-a027-1e0c35b893f1"
      unitRef="usd">9261000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE2LTUtMS0xLTE4ODk3NA_7048885b-2ab1-422f-997b-fbbb05982192"
      unitRef="usd">10497000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE4LTEtMS0xLTE4ODk3NA_be006b7e-e4fa-4a36-b38a-4da63b402b58"
      unitRef="usd">2587000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE4LTMtMS0xLTE4ODk3NA_74938be3-acd0-4a4a-b28e-8b923353aca9"
      unitRef="usd">8900000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE4LTUtMS0xLTE4ODk3NA_b8f4dbee-c844-4ec6-82fa-fde8357e3a3f"
      unitRef="usd">8477000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE5LTEtMS0xLTE4ODk3NA_8069b860-c52c-4932-96ec-a0b19103f2c7"
      unitRef="usd">98000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE5LTMtMS0xLTE4ODk3NA_79320623-5e84-4b2f-832e-fd0e23d5ac7e"
      unitRef="usd">4403000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzE5LTUtMS0xLTE4ODk3NA_a06ad226-d24f-4168-be68-45784e63d92e"
      unitRef="usd">2597000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIwLTEtMS0xLTE4ODk3NA_bedc9138-57ce-4e86-9902-af5e1d9adc03"
      unitRef="usd">1120000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIwLTMtMS0xLTE4ODk3NA_46d9b40f-0831-4ac1-8b60-2258e2a38e88"
      unitRef="usd">8831000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIwLTUtMS0xLTE4ODk3NA_ea8ea44c-e140-4a71-a075-770ef0ea6416"
      unitRef="usd">4381000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIxLTEtMS0xLTE4ODk3NA_fdea08f2-844a-4a93-b29a-ea898325263d"
      unitRef="usd">936000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIxLTMtMS0xLTE4ODk3NA_d26b415a-9ae1-4186-a168-f4bbb5e8e339"
      unitRef="usd">880000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIxLTUtMS0xLTE4ODk3NA_e7a07521-9972-4a31-9301-7032bb4dd9ea"
      unitRef="usd">608000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIyLTEtMS0xLTE4ODk3NA_e772af49-11f8-4e23-8b90-3b05b7734fbd"
      unitRef="usd">3839000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI0LTMtMS0xLTE5MjU0Mg_319d6e6a-d83c-4182-aa16-4a6fec621cbe"
      unitRef="usd">2529000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIyLTUtMS0xLTE4ODk3NA_ec1b749b-4f4f-43d5-90e1-291dd4d9103d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIzLTEtMS0xLTE4ODk3NA_a4f0fa56-6912-48e4-b002-f2b76265092a"
      unitRef="usd">18000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIzLTMtMS0xLTE4ODk3NA_a3eef4a4-3ad6-4bd7-bb14-59f29ad86d6b"
      unitRef="usd">157000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzIzLTUtMS0xLTE4ODk3NA_bd8597b6-aab2-450b-969c-0e7d731003e0"
      unitRef="usd">3219000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI2LTEtMS0xLTIwMDY3OQ_9f43d9c9-6be9-42ee-ad2f-c466a71502ca"
      unitRef="usd">130000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI2LTMtMS0xLTIwMDY4Ng_1b449f7a-c43d-4eb6-ad49-863fcde5fc9a"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI2LTUtMS0xLTIwMDY5Mw_4550d430-8348-4908-8a41-519b34f1c0c2"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI0LTEtMS0xLTE4ODk3NA_3b5ac558-9c74-4266-8bf8-de132f65889b"
      unitRef="usd">12000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI0LTMtMS0xLTE4ODk3NA_abddc3a6-03fe-4a13-831f-396b28f15ab1"
      unitRef="usd">35000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI2LTUtMS0xLTE5MjU2Mw_295ea152-e4fc-4a38-8501-55258e0e8f29"
      unitRef="usd">75000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI1LTEtMS0xLTE4ODk3NA_284451fa-1659-48ff-8de1-246c5bdde0f4"
      unitRef="usd">-6044000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI1LTMtMS0xLTE4ODk3NA_48e24ae1-819c-49e2-a7a6-4c92ac1c458a"
      unitRef="usd">733000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI1LTUtMS0xLTE4ODk3NA_e485bb12-c130-45ef-9370-c21fd4ffd4bb"
      unitRef="usd">-5401000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI3LTEtMS0xLTE4ODk3NA_82a38a24-f34e-4bc1-bff4-41881c113f6a"
      unitRef="usd">6919000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI3LTMtMS0xLTE4ODk3NA_e85ba3d1-e076-487a-8298-89856d8fa1fe"
      unitRef="usd">4945000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI3LTUtMS0xLTE4ODk3NA_f4d2c818-d33e-4d4e-8477-4e8ef0410c61"
      unitRef="usd">8914000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMxLTEtMS0xLTIwNzQyOA_a2ae790f-9cc1-4c93-b0ec-f08a64193781"
      unitRef="usd">297000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMxLTMtMS0xLTIwNzQzNw_5cf243f8-aaa1-463e-af70-0a86ed14f462"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMxLTUtMS0xLTIwNzQ0Nw_c0bcd46c-0404-4b57-a93e-36f86e9d07c3"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI4LTEtMS0xLTE4ODk3NA_b45037e9-f269-4b8e-a323-5c13e473f640"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI4LTMtMS0xLTE4ODk3NA_7e8cf7ce-1d8e-4cdc-93e0-0e0e03260e8f"
      unitRef="usd">4150000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI4LTUtMS0xLTE4ODk3NA_72b6057b-f3d9-4f7c-a6d3-bbe8b6201e6c"
      unitRef="usd">6450000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI5LTEtMS0xLTE4ODk3NA_abe50959-279f-4f80-b714-0e6295753095"
      unitRef="usd">6360000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI5LTMtMS0xLTE4ODk3NA_f637995d-0a73-45ab-a97d-522c4fa4d00e"
      unitRef="usd">4975000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzI5LTUtMS0xLTE4ODk3NA_e4ddaab3-d889-4e90-98f7-35724233104b"
      unitRef="usd">3486000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMwLTEtMS0xLTE4ODk3NA_654b16c1-1f8c-4aea-b450-9048ad90f887"
      unitRef="usd">4196000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMwLTMtMS0xLTE4ODk3NA_0b1a1f79-e0ae-4796-bedf-6206d11ff1cc"
      unitRef="usd">4013000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMwLTUtMS0xLTE4ODk3NA_7514a9fb-9640-4b23-be6b-9380e6754ea4"
      unitRef="usd">3755000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMyLTEtMS0xLTE4ODk3NA_e3f90a6e-1d4a-4c98-aa5e-652dc05ef092"
      unitRef="usd">-103000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMyLTMtMS0xLTE4ODk3NA_442787f6-a3d1-46e2-ac16-466f10e8f226"
      unitRef="usd">-78000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMyLTUtMS0xLTE4ODk3NA_865dc528-637d-4113-8fe8-4d9c04ed83a7"
      unitRef="usd">-90000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMzLTEtMS0xLTE4ODk3NA_cf216190-12ae-4360-869e-a2b881fd0812"
      unitRef="usd">-4037000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMzLTMtMS0xLTE4ODk3NA_181ec0ab-5b43-4c16-b2f0-948cac129c02"
      unitRef="usd">-8271000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzMzLTUtMS0xLTE4ODk3NA_304f2651-7e8f-4781-8534-59b70b7f1506"
      unitRef="usd">-4867000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM0LTEtMS0xLTE4ODk3NA_2990b2e2-6a65-4557-98d2-df5ca8a0d181"
      unitRef="usd">-360000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM0LTMtMS0xLTE4ODk3NA_b0dc24b6-c61f-4a12-bd60-9fa210f3c28f"
      unitRef="usd">1723000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM0LTUtMS0xLTE4ODk3NA_c103ef8c-915a-442e-b3e3-0988d08048e2"
      unitRef="usd">229000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM1LTEtMS0xLTE4ODk3NA_f73996dc-08ac-48b7-8633-2b439ed1eccb"
      unitRef="usd">7989000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM1LTMtMS0xLTE4ODk3NA_4957027f-9078-4398-82c4-72f76d79f7e8"
      unitRef="usd">6266000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM1LTUtMS0xLTE4ODk3NA_340ff7d5-25af-4883-b930-450b0bc8681b"
      unitRef="usd">6037000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM2LTEtMS0xLTE4ODk3NA_37e9b1ad-9fcf-45d3-8d8a-ea8c4d702e90"
      unitRef="usd">7629000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM2LTMtMS0xLTE4ODk3NA_7ec44cb3-f150-44ac-a4dd-a51c6f95114f"
      unitRef="usd">7989000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xODcvZnJhZzpiNTA0ZmVhMGEyZGU0NmUzODJkZTk4OGE1NjJkYzIwZi90YWJsZTo5NGRiZjljMzIwNmM0MWU2YjQ2MTJiN2JkMTRkMmY0Mi90YWJsZXJhbmdlOjk0ZGJmOWMzMjA2YzQxZTZiNDYxMmI3YmQxNGQyZjQyXzM2LTUtMS0xLTE4ODk3NA_409baa12-caa1-4047-9e2a-035c34256ddf"
      unitRef="usd">6266000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjIz_50405b20-4f41-497c-bc6a-0d7a852c882f">Summary of significant accounting policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc. (including its subsidiaries, referred to as &#x201c;Amgen,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#x2019;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product sales and sales deductions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#x2019;s products, primarily in Europe, are excluded from revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;amp;A expense in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements with multiple-performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into arrangements for the R&amp;amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#x2019; costs; and amortization of acquired technology used in R&amp;amp;D with alternative future uses. R&amp;amp;D expenses also include costs and cost recoveries associated with third-party R&amp;amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $841 million, $843 million and $962 million during the years ended December 31, 2022, 2021 and 2020, respectively. SG&amp;amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#x2019;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;amp;D projects with no alternative future use are recorded in R&amp;amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions and divestitures, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#x2019;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#x2019; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#x2019; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of IPR&amp;amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges may occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized IPR&amp;amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#x2019; products could result in partial or full impairment of the related intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#x2019; earnings are translated into U.S. dollars by using average exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable and nonmarketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other (expense) income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other (expense) income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#x2019; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other (expense) income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other (expense) income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other (expense) income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. The provisions of these standards have not had and are not expected to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <amgn:NatureOfOperationsPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjEx_ea28035f-e7dd-4ac5-8e50-b7afc3f2930c">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc. (including its subsidiaries, referred to as &#x201c;Amgen,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.&lt;/span&gt;&lt;/div&gt;</amgn:NatureOfOperationsPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI1Mg_5ad1c97c-fc5b-422e-a15e-d498e588091a"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjAz_863b5b7b-b957-4625-887d-3e1e23a79294">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#x2019;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTYy_939341b3-3f71-4fef-988b-f458abcf80ea">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTgx_a1fd94cd-c39b-4517-b296-edafe632078b">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product sales and sales deductions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#x2019;s products, primarily in Europe, are excluded from revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;amp;A expense in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements with multiple-performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into arrangements for the R&amp;amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <amgn:SalesReturnProvisionsAsPercentageOfProductSales
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI5MjA_35cc5f83-7cb6-4f65-834b-47deea1e4a34"
      unitRef="number">0.01</amgn:SalesReturnProvisionsAsPercentageOfProductSales>
    <amgn:RevenuePaymentArrangementTerm
      contextRef="i74c70cd97a504fa799571d2da1e07298_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzMyNDg_254c488c-4d66-46f0-80b9-7b6e2919d1c3">P30D</amgn:RevenuePaymentArrangementTerm>
    <amgn:RevenuePaymentArrangementTerm
      contextRef="ib368433c7847450cbea77bf019f238ce_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzMyNTQ_007a974b-0aae-465a-a635-1c8ebff8ad08">P120D</amgn:RevenuePaymentArrangementTerm>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjE4_072d1248-93e4-42fb-8a1a-78927e1fe5eb">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#x2019; costs; and amortization of acquired technology used in R&amp;amp;D with alternative future uses. R&amp;amp;D expenses also include costs and cost recoveries associated with third-party R&amp;amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTIx_fe921614-00c8-40d4-a2d5-cd8722fb33c5">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $841 million, $843 million and $962 million during the years ended December 31, 2022, 2021 and 2020, respectively. SG&amp;amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzc4NDM_31cf3cc4-5ed1-42e9-b898-c8c6b9c0907a"
      unitRef="usd">841000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzc4NDc_92fe5a3f-b5a9-4a23-a0e0-fada9b75764d"
      unitRef="usd">843000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzc4NTQ_df1da611-d388-4f16-8084-1ea9e27940d5"
      unitRef="usd">962000000</us-gaap:AdvertisingExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTYz_48a6478e-84df-45bd-a600-238da4490115">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTc2_0159afd4-ba79-4a3b-9c72-882f23efdd51">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTY0_cf3cb6ac-6bad-4a1d-9b50-90650e04dc49">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjA1_f1841258-fde5-40c2-baeb-2a49bc33b1bc">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#x2019;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;amp;D projects with no alternative future use are recorded in R&amp;amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions and divestitures, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTU4_1252e24a-e6c2-4cbf-8008-43c2233951ad">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MDk5_cc14a39d-6278-408e-bac2-64e92cb341f6">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#x2019;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTkx_6e285d9f-7da4-4c1b-85a8-3e40d32f1e09">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjQy_f6806e48-6128-402e-be6e-ce3252833528">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTQx_06c6e9ee-72e8-47fc-82f5-19b4c6a1a4ee">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#x2019; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjQ5_a5796338-3e8c-4561-8fde-160eb1658f70">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#x2019; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of IPR&amp;amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges may occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized IPR&amp;amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#x2019; products could result in partial or full impairment of the related intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjM4_6aa5d680-a754-436c-b721-6337068723e5">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjAx_ea4786fd-c152-460c-96ab-cd0088612f03">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#x2019; earnings are translated into U.S. dollars by using average exchange rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <amgn:EquityInvestmentsPolicyPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MTg4_37caa558-1891-4b36-b284-9139c20fc653">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable and nonmarketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other (expense) income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other (expense) income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</amgn:EquityInvestmentsPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjQz_71745e77-d2af-4f23-a1ee-98e3bd573706">&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#x2019; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other (expense) income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other (expense) income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other (expense) income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTMvZnJhZzo3NWFiMjdkODkwZWM0MDA1YmQwNzI1Y2Q3ZWU0NjQ0Mi90ZXh0cmVnaW9uOjc1YWIyN2Q4OTBlYzQwMDViZDA3MjVjZDdlZTQ2NDQyXzI0MjA5_89acd864-e516-4eaa-b2fe-ff3344b7fe6a">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. The provisions of these standards have not had and are not expected to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzEwOTk1MTE3MTY4MzY_2ce9bb1d-a8c7-4191-9aa8-19f20de69d1e">Acquisitions and divestitures &lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proposed acquisition of Horizon Therapeutics plc&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 12, 2022, we announced that we entered into a transaction agreement under which Amgen will acquire all shares of Horizon for $116.50 per share in cash for a transaction equity value of approximately $27.8 billion. Horizon is a global biotechnology company headquartered in Dublin, Ireland and is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Horizon has 12 marketed medicines and a pipeline with more than 20 development programs. The closing of this transaction is contingent upon satisfaction of certain regulatory (including FTC review) and other customary closing conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the proposed acquisition of Horizon, Amgen entered into a 364-day bridge credit agreement with a syndicated group of banks for an aggregate amount of $28.5 billion on December 12, 2022. On December 22, 2022, we entered into a term loan credit agreement with an aggregate principal amount of $4.0 billion which provides for two equally sized tranches of term loans, one with an 18-month term and one with a three-year term. Accordingly, the bridge credit agreement was reduced by the amount of the term loan credit agreement to $24.5&#160;billion. As of December 31, 2022, no amounts have been drawn under the bridge credit agreement or the term loan credit agreement. In connection with these credit agreements, Amgen incurred approximately $97 million of financing costs, which was capitalized primarily in Other current assets in our Consolidated Balance Sheets and is being amortized to Interest expense, net, in our Consolidated Statements of Income over the terms of the agreements. Additionally, we have agreed to maintain a cash balance of $2.96 billion that, together with any borrowings under the bridge credit agreement and term loan credit agreement, represents sources of funds available to finance the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;30, 2023, the Company and Horizon each received a request for additional information and documentary materials (Second Request) from the FTC in connection with the FTC&#x2019;s review of the Company&#x2019;s proposed acquisition of Horizon. The effect of the Second Request is to extend the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, until 30 days after the Company and Horizon have substantially complied with the Second Request, unless that period is extended voluntarily by the Company and Horizon or terminated sooner by the FTC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of ChemoCentryx, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 20, 2022, we acquired all the outstanding stock of ChemoCentryx, a publicly traded biotechnology company focused on orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52.00 per share in cash, representing a total consideration of $3.9&#160;billion. The acquisition, which was accounted for as a business combination, includes TAVNEOS, an orally administered selective complement 5a receptor inhibitor that was approved by the U.S. FDA in October 2021 as an adjunctive therapy for adults with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis). TAVNEOS is commercialized by us in the United States; for markets outside the United States, TAVNEOS is commercialized by a collaboration partner, and Amgen is entitled to royalties and milestones based off future sales of the product. Upon its acquisition, ChemoCentryx became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December 31, 2022, the Company incurred approximately $106&#160;million of costs directly related to the acquisition of ChemoCentryx, consisting of share-based payments to settle non-vested equity awards attributable to post-combination services, severance and other transaction costs. These costs were included primarily in SG&amp;amp;A expense in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &#x2013; developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $3.9&#160;billion total consideration consisted of (i) a $3.7&#160;billion cash payment to outstanding common stockholders of ChemoCentryx and (ii) a $181&#160;million cash payment to equity award holders of ChemoCentryx for services rendered prior to the acquisition date of October 20, 2022, under the ChemoCentryx equity award plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The developed-product-technology rights acquired relates to TAVNEOS, which is approved in the United States and EU for ANCA-associated vasculitis. The estimated fair values of $3.5&#160;billion were determined by using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The developed-product-technology rights are being amortized on a straight-line basis over a weighted-average period of approximately 11 years using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the acquired inventory of $41&#160;million was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer&#x2019;s effort are applied. The inventory fair value adjustment is being amortized as inventory turns over, which we estimate to be approximately 13 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A net deferred tax liability of $516&#160;million was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $667&#160;million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value is primarily attributable to the expected synergies from the TAVNEOS asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, liabilities assumed and tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Teneobio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio&#x2019;s proprietary bispecific and multispecific antibody technologies, which complement Amgen&#x2019;s existing antibody capabilities and bispecific T-cell engager BiTE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen&#x2019;s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurement period adjustments for the year ended December 31, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $22&#160;million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen&#x2019;s results of operations during the year ended December 31, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset &#x2013; R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &#x2013; licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration for this transaction comprised of (i) an upfront cash payment of $993&#160;million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio&#x2019;s former equity holders of up to $1.6&#160;billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $299&#160;million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 17, Fair value measurement, for information regarding the estimated fair value of these obligations as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of acquired IPR&amp;amp;D assets totaled $991&#160;million, of which $784&#160;million relates to AMG 340, that is in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to four separate preclinical oncology programs. The R&amp;amp;D technology rights of $115&#160;million relate to Teneobio&#x2019;s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over 10 years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41&#160;million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A deferred tax liability of $244&#160;million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $273 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Five Prime Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $1.6&#160;billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a Phase 3 first-in-class program for gastric cancer. Five Prime&#x2019;s operations have been included in our consolidated financial statements commencing after the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the consideration to acquire Five Prime to the bemarituzumab IPR&amp;amp;D program of $1.5&#160;billion, which was expensed immediately in Acquired IPR&amp;amp;D expense in the Consolidated Statements of Income; deferred tax assets of $177&#160;million; and other net liabilities of $47&#160;million. The acquired IPR&amp;amp;D expense was not tax deductible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Divestiture of Gensenta &#x130;la&#xe7; Sanayi ve Ticaret A.&#x15e;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 2, 2022, we sold our shares in Gensenta, a subsidiary in Turkey, to Eczac&#x131;ba&#x15f;&#x131; for net cash proceeds of approximately $130&#160;million. The transaction was accounted for as a sale of a business and did not meet the criteria to be classified as discontinued operations. Upon closing of this transaction, net assets related to Gensenta of $86 million were divested, and during the year ended December 31, 2022, we recognized a loss on divestiture of $567&#160;million recorded in Other operating expenses in the Consolidated Statements of Income, primarily due to the reclassification of $615&#160;million of cumulative foreign currency translation losses from AOCI into earnings. See Note 16, Stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTgwNTY_4edadcac-d4d8-4699-8262-358830acef7e"
      unitRef="usdPerShare">116.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i779f44ca9ddf42f9bd2fc86981e1cdd2_D20221201-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTY3NjU_bf737c4e-ca81-43e2-a029-2a327c5225e0"
      unitRef="usd">27800000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amgn:ApprovedProducts
      contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkxMDIyMzg_57a29867-3e13-4211-8919-449e8b0e1ccd"
      unitRef="product">12</amgn:ApprovedProducts>
    <amgn:DevelopmentPrograms
      contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkxMDIyNDI_9c72f506-9b62-4ce9-b1b9-988a9461f6fa"
      unitRef="program">20</amgn:DevelopmentPrograms>
    <amgn:DevelopmentPrograms
      contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkxMDIyNDI_b814ab8c-1b3f-408d-8363-e9e1f16102c1"
      unitRef="program">20</amgn:DevelopmentPrograms>
    <amgn:BridgeCreditAgreementMaximumLength
      contextRef="ic722736e5ec247d6afb3eb14a1913c36_D20221231-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTkwMjk2OA_d955cbbf-657c-4831-a0cb-556f06c4e91b">P364D</amgn:BridgeCreditAgreementMaximumLength>
    <amgn:BridgeCreditAgreementInitialAmount
      contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5MTAyOTE_e56cf7fd-06f9-4b64-9c6f-fd9fb6c446dc"
      unitRef="usd">28500000000</amgn:BridgeCreditAgreementInitialAmount>
    <amgn:TermLoanCreditAgreementTotalAmount
      contextRef="ia18e6e75e0234bfb8fa9c069b0ac7278_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5MTAyNzM_4786b60c-5af2-469d-b1e6-aa8524774b0d"
      unitRef="usd">4000000000</amgn:TermLoanCreditAgreementTotalAmount>
    <amgn:TermLoanCreditAgreementNumberOfTraunches
      contextRef="ia18e6e75e0234bfb8fa9c069b0ac7278_I20221222"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTkwMjk3Ng_7c76df90-1b85-420a-afd6-44f4b3cbb6c9"
      unitRef="traunche">2</amgn:TermLoanCreditAgreementNumberOfTraunches>
    <amgn:BridgeCreditReducedAmount
      contextRef="ia18e6e75e0234bfb8fa9c069b0ac7278_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5MTAzMTE_fd442c68-07c9-4048-ad21-2b3f26fd1c1c"
      unitRef="usd">24500000000</amgn:BridgeCreditReducedAmount>
    <amgn:BridgeCreditAgreementAmount
      contextRef="i547c2ec2000946a09fe9312e8ebfb63a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTkxMDA0Nw_6c1cf52c-7bbc-4960-a24e-b9db49fba2f3"
      unitRef="usd">0</amgn:BridgeCreditAgreementAmount>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="ib6ad27c707bf4fc9a91323e63aadb826_D20221222-20221222"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkxMDIyMTg_cb7120a2-b877-42f6-99c9-5a85370b4827"
      unitRef="usd">97000000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:CompensatingBalanceAmount
      contextRef="i5514fe5c6f934d69accc89f4f6207683_I20221212"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5MTY0MTc_a36cb837-f35f-4b22-932c-6120531428bf"
      unitRef="usd">2960000000</us-gaap:CompensatingBalanceAmount>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc3MDY_96c99eff-abf0-4f06-a905-8ec58ab36763"
      unitRef="usdPerShare">52.00</us-gaap:BusinessAcquisitionSharePrice>
    <amgn:Businessassetacquisitionconsiderationtransferred
      contextRef="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc1NzM_ab13e323-149c-4e9b-b2d2-a35da1a18b47"
      unitRef="usd">3900000000</amgn:Businessassetacquisitionconsiderationtransferred>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i5df31b4fae07412cbb1789e8d483f2f0_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc1ODc_a8e9979d-a263-473b-9184-120a2814a35e"
      unitRef="usd">106000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU5OTIzMzgzODA5OTE1_55b4ae2f-2132-4623-b11b-761e44618e34">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &#x2013; developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset &#x2013; R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &#x2013; licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzEtMi0xLTEtMjIzODk0_6c088ef1-76d8-4ca0-965f-cabfe02542de"
      unitRef="usd">86000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzItMi0xLTEtMjIzODk2_d8c19541-b6aa-4939-b295-2aec824b0262"
      unitRef="usd">235000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzMtMi0xLTEtMjIzODk4_4ae953c0-e436-4198-805d-f745823b0c4c"
      unitRef="usd">41000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ife9b8122096240a5b48fd15f27ecd4ba_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzQtMi0xLTEtMjIzOTAw_d0dfde78-9a45-46da-a884-ca1e05e7f4cf"
      unitRef="usd">3497000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzUtMi0xLTEtMjIzOTAy_cb9620ea-5f5e-4a24-8911-1af43e4d7073"
      unitRef="usd">667000000</us-gaap:Goodwill>
    <amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzYtMi0xLTEtMjIzOTA0_83c1ab9b-1b5a-403a-a904-48af75962d0d"
      unitRef="usd">-85000000</amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzctMi0xLTEtMjIzOTA2_b3c3ddd1-e310-4cd6-a3b2-f670beca812a"
      unitRef="usd">516000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZTo5YjAyNTUwMTZmYjE0ZTQwYTIxMTUzMTJhZTBhNjM4My90YWJsZXJhbmdlOjliMDI1NTAxNmZiMTRlNDBhMjExNTMxMmFlMGE2MzgzXzgtMi0xLTEtMjIzOTA4_8a7a4b37-cd7c-44a3-8f64-8e2734756570"
      unitRef="usd">3925000000</amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet>
    <amgn:Businessassetacquisitionconsiderationtransferred
      contextRef="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2MDE_3cf7ecc3-bbaa-45bf-82a0-21280524c9f6"
      unitRef="usd">3900000000</amgn:Businessassetacquisitionconsiderationtransferred>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2MTU_b5f97da4-49bf-4e6a-a374-f1ca62ccbaf7"
      unitRef="usd">3700000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amgn:BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2Mjk_4e9c938c-beec-4307-9d5c-ee6521375814"
      unitRef="usd">181000000</amgn:BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ife9b8122096240a5b48fd15f27ecd4ba_I20221020"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2NDM_0f2d720a-2ffa-4c0e-8af9-a220c95de31d"
      unitRef="usd">3500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ifd98af0751824e778fbc9d7d6daabf74_D20221020-20221020"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc3MDI_e8b73310-15c2-4c0e-a56e-d97d20e52c19">P11Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2NTc_4633c3e7-9f18-403f-b61c-a0cc0558a0a6"
      unitRef="usd">41000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <amgn:BusinessCombinationTurnoverPeriodOfInventoryAcquired
      contextRef="i3d5cdc0321034ea7ae3ae9573842560c_D20221020-20221020"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2OTg_80be080a-130e-480e-8e7e-0cd96a73a5b9">P13M</amgn:BusinessCombinationTurnoverPeriodOfInventoryAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2NzA_502fb546-fe18-493e-8086-4f1a20165001"
      unitRef="usd">516000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:Goodwill
      contextRef="i1304d3c33395494bb59cbeb2cb292045_I20221020"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyOTg1MzQ5NDc2ODQ_f3ea1cea-c386-45a5-805f-7bb7e3ad06f1"
      unitRef="usd">667000000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i8ad51334f6c74fc69c9126bdca69dd80_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTgzMzAwMg_f6271922-f222-4161-8bd1-2cf01ea112fd"
      unitRef="usd">22000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzEtMi0xLTEtMTg4OTc0_42a785fc-ef8c-45af-b3bd-78cc794bb156"
      unitRef="usd">993000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzItMi0xLTEtMTg4OTc0_edb46b8c-bcc9-40d1-834d-ef6096236bba"
      unitRef="usd">299000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <amgn:Businessassetacquisitionconsiderationtransferred
      contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzMtMi0xLTEtMTg4OTc0_e7612624-778e-4baf-bc62-e8a0bd24a8ea"
      unitRef="usd">1292000000</amgn:Businessassetacquisitionconsiderationtransferred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzUtMi0xLTEtMTg4OTc0_1d91d290-3274-4f72-a9b9-1ede86d1afa5"
      unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i3c3e817eb2db4040b29557e7f0a8bdae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzYtMi0xLTEtMTg4OTc0_2743f3a2-1874-4656-b286-4f337cd2f148"
      unitRef="usd">991000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i878b1937a0c64c239da6ad0a2e1748ac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzctMi0xLTEtMTg4OTc0_b9d60a7a-ad62-4e87-a35e-cd8525948150"
      unitRef="usd">115000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i96ea65e5beec49d492a8c189bb7ff681_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzgtMi0xLTEtMTg4OTc0_bc0c7620-0711-4c79-a155-67ebd92a3f6c"
      unitRef="usd">41000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzktMi0xLTEtMTg4OTc0_1fd2a6eb-dd52-45e8-8e05-ce02fc4b49fd"
      unitRef="usd">273000000</us-gaap:Goodwill>
    <amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities
      contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzEwLTItMS0xLTE4ODk3NA_13afd39e-9b6e-4e7d-85cf-8b11158e8e78"
      unitRef="usd">16000000</amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzExLTItMS0xLTE4ODk3NA_e1349b48-0219-43b0-9d98-e8ad75d8347b"
      unitRef="usd">244000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet
      contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90YWJsZToyYzMzMTg0N2ZlMGE0YmMwYTFhZWE0NDAwYmUxYmZjYi90YWJsZXJhbmdlOjJjMzMxODQ3ZmUwYTRiYzBhMWFlYTQ0MDBiZTFiZmNiXzEyLTItMS0xLTE4ODk3NA_f2f7f530-7639-410c-b934-67fe7e72a8ba"
      unitRef="usd">1292000000</amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzExMjA_bff04dda-a1b2-4324-aa6b-ba893de92c10"
      unitRef="usd">993000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzEyNTk_3975fff5-bfb0-4603-9e35-210e9adc12cf"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="i483da69e647945579f570280de6d2535_D20221231-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzE1NTE_77c1db94-c7f3-483e-b453-d9a293102904"
      unitRef="usd">299000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i3c3e817eb2db4040b29557e7f0a8bdae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzIwNDg_bab7ac02-f428-4f2c-8adb-f9cd8a1ad23d"
      unitRef="usd">991000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i4a560be5e64148d1b01ab70221c57257_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzIwNjE_aeab4fa0-58f3-4e79-8076-b5e64d2b65a5"
      unitRef="usd">784000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <amgn:NumberOfPreclinicalOncologyPrograms
      contextRef="ia4b93dbb92ca4fad905e8f7074369960_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzU0OTc1NTkwMjk3Nw_933de7ee-3674-4861-9365-2d31643be738"
      unitRef="program">4</amgn:NumberOfPreclinicalOncologyPrograms>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ic6c94a0244a24346bbce7f236220492d_D20221231-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzIyNDk_6bcfaa8c-395d-4990-ac00-d694138e17f7"
      unitRef="usd">115000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic6c94a0244a24346bbce7f236220492d_D20221231-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzIzNjM_3cd46b2a-19eb-4c7f-820e-df32aaf5ff0c">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="id61a508e81d74e23babeb5ae04b7c428_D20221231-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI1NDM_9b2d5618-d0f3-4f3c-bfae-6701b7a417fd"
      unitRef="usd">41000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzMyMDA_22586a09-66b7-4169-9c90-1d01215cc980"
      unitRef="usd">244000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:Goodwill
      contextRef="i18e4b428f51e44379bb74b2b0ee55a9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzM1MzM_d1e4e3f3-f035-48af-93fb-b4137b30df02"
      unitRef="usd">273000000</us-gaap:Goodwill>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i2622610117f541b3981af6c597b45012_D20210416-20210416"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwODY3OTA_95bff5b4-abfa-4cb4-a7d1-2c95dd969c0e"
      unitRef="usd">1600000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i2622610117f541b3981af6c597b45012_D20210416-20210416"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzQ3MTA_c65fb556-b33b-43ea-93ab-2f898b6e7e05"
      unitRef="usd">1500000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="i7f833d40beb6488f852b2cd047fd2af3_I20210416"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzQ4MzY_dc015225-a45e-4f29-a485-d8d36c219912"
      unitRef="usd">177000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i7f833d40beb6488f852b2cd047fd2af3_I20210416"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzQ4Njk_ca089ef5-1129-4676-93a0-7f0aa58b2ead"
      unitRef="usd">47000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ia1a449b4d91a4aa9837f80b68d94b3de_D20221102-20221102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTEwMTU_4264f405-4ed5-4109-b91b-fb9b3c59bfd0"
      unitRef="usd">130000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ifa290da793e84fbbbc403ed0500e088d_I20221102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTY1NTA_da70643b-21b7-4613-b302-8966579feb3e"
      unitRef="usd">86000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ie2a81370a9864611897507a5c90c9308_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTEwNDY_05ac0619-6b7a-4abc-b940-680a681a1135"
      unitRef="usd">-567000000</us-gaap:GainLossOnSaleOfBusiness>
    <amgn:ForeignCurrencyTranslationLossOnDivestitureOfABusiness
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTYvZnJhZzozNzZjOTdkMjc5YmQ0NTQ2OTNhMmJkYTNlZGMwZjExYy90ZXh0cmVnaW9uOjM3NmM5N2QyNzliZDQ1NDY5M2EyYmRhM2VkYzBmMTFjXzI3NDg3NzkwOTEwNjc_2b1701e0-c893-4cbb-a101-13e820af9846"
      unitRef="usd">615000000</amgn:ForeignCurrencyTranslationLossOnDivestitureOfABusiness>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE5NjE_2d1a5101-7fe2-4a29-a47e-c1cd038d757e">Revenues&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#x2019; locations, are presented below. The majority of ROW revenues relates to products sold in Europe. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ENBREL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nplate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EVENITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2022, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had product sales to three customers that individually accounted for more than 10% of total revenues for each of the years ended December 31, 2022, 2021 and 2020. For the year ended December 31, 2022, on a combined basis, these customers accounted for 82% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 75% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2022 and 2021, 26% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2022 and 2021, was not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzI2_6e5b0f96-04b7-45df-b34f-ba9d6b7358b3"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE5NjU_c82f81e5-a4a0-41cb-b5f7-93a479b5a492">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ENBREL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nplate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EVENITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2022, 2021 and 2020.</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54d95ce0934d41258b8bb4e3c9ae99ef_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMi0xLTEtMTg4OTc0_2a61b48d-e40a-42dd-b437-d66d91d46415"
      unitRef="usd">4044000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fcbf93e9fd941c2b5eb2795960a999c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItNC0xLTEtMTg4OTc0_f77b1431-cc46-4951-bf45-2ccd589ca389"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7d8239300c734a85ac79f2e26ba5280f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItNi0xLTEtMTg4OTc0_855db3ea-9da6-412f-956c-6c3f3b55023d"
      unitRef="usd">4117000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf51567a953d41b99c4b4d59745e4ee4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItOC0xLTEtMTg4OTc0_770520ac-6743-4f69-9257-4a363b7a0df7"
      unitRef="usd">4352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4ef981e3c2740e0b2d606ba990e403a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTAtMS0xLTE4ODk3NA_c3824708-4df5-4987-bfc4-c877ccc05f6c"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i08fe0ca98dba40f1916b2858ece00d3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTItMS0xLTE4ODk3NA_65e199be-5a0c-4784-bf86-27263d643b36"
      unitRef="usd">4465000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d9b8bbe1fe042b38d3911eaa570829e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTQtMS0xLTE4ODk3NA_e76de8ee-3301-4591-ab45-757c075b023a"
      unitRef="usd">4855000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia96d969e20ba48c5865d66cf127544fd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTYtMS0xLTE4ODk3NA_ead6580b-4575-45cb-8105-4624a23581bf"
      unitRef="usd">141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if847c1f2b53649958a0e412c568c260c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzItMTgtMS0xLTE4ODk3NA_a108bf0d-2c0d-4426-a1fd-7f921d30c637"
      unitRef="usd">4996000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabbccaadaa0e479bb555d47033b24d0d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMi0xLTEtMTg4OTc0_2164fd53-c94a-40d7-8d13-f03814450b17"
      unitRef="usd">2465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28d0ac761b5e4c64a58d335767cf2473_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtNC0xLTEtMTg4OTc0_d58fcd2d-566e-4fcb-9660-88d50dea47f7"
      unitRef="usd">1163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia9b224ccf76a440c8fff126d491a4b0b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtNi0xLTEtMTg4OTc0_5721f294-6620-4e07-a02b-17666f01bc1b"
      unitRef="usd">3628000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81533ef907a44709b3be7b02daabe41e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtOC0xLTEtMTg4OTc0_7671baf7-a498-4abe-be89-bb12a1b25e95"
      unitRef="usd">2150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dfacc540ca4410bad949df3bf9e3989_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTAtMS0xLTE4ODk3NA_e223820d-3f50-4972-940c-4df081e2246e"
      unitRef="usd">1098000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i70dda4219ab244b7b55afbcb42b4096d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTItMS0xLTE4ODk3NA_98af0fb2-5955-4398-b447-9475c7333179"
      unitRef="usd">3248000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c3af95c457646d89f7ccabdfe96ed78_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTQtMS0xLTE4ODk3NA_cb6969b0-c040-40dc-a73a-e273670ea4e7"
      unitRef="usd">1830000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e858062804243e7a95db1099336e60c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTYtMS0xLTE4ODk3NA_dc6595c7-b15e-4f46-84be-71774d98a6db"
      unitRef="usd">933000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6ea6afbe5b0948f38ad7891711ec6fdd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzMtMTgtMS0xLTE4ODk3NA_8c5ada24-3ae1-41d7-b27d-e1af97c1cb30"
      unitRef="usd">2763000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2eea70a9f89a460c81ea5589813c4763_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMi0xLTEtMTg4OTc0_b28da0aa-4b34-4ad7-9ae7-d17c7eb0dd7c"
      unitRef="usd">1886000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1d0ac70f39f475ba99cef136b4e6db2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtNC0xLTEtMTg4OTc0_1e7de747-4ff8-40e5-abb7-f43c37181f7e"
      unitRef="usd">402000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iad2d33f98f144869b7feb640d3176c4e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtNi0xLTEtMTg4OTc0_a47625e1-4a41-4a30-b323-b1bf3438b843"
      unitRef="usd">2288000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1e4a13b30ff4c109a876c1c9aaf2a6a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtOC0xLTEtMTg4OTc0_6fd2a9c1-3dc1-4870-8e3f-95bb178e0bce"
      unitRef="usd">1804000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1efdd0c80b64aa48ebe629be932cb59_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTAtMS0xLTE4ODk3NA_bcef37f7-a2eb-4c75-b6f9-74357bf3f724"
      unitRef="usd">445000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia2b509ea03164c7aa49578a912572c8f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTItMS0xLTE4ODk3NA_e865377d-bd95-4e5a-a9d2-df18f7de4353"
      unitRef="usd">2249000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i931aa36bec5b4419a4286d8ee93da365_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTQtMS0xLTE4ODk3NA_50b4bc80-c5bf-4ff0-8bbb-1d306a2eadda"
      unitRef="usd">1790000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d05f99fee60403f9ca2a1f93a62cf48_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTYtMS0xLTE4ODk3NA_468f049c-8b48-4873-b6c3-4dda33df3454"
      unitRef="usd">405000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8e026f4c1ba44496a8bb17b973a51cba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzQtMTgtMS0xLTE4ODk3NA_3a309d95-4111-40b8-8b2e-c048bb092465"
      unitRef="usd">2195000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8037f0f06384716a6e33c023dafa910_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMi0xLTEtMTg4OTc0_d07edc95-f4b2-4b5d-825d-87d2d04dee71"
      unitRef="usd">1480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ed14a4244f540049b8d29da49b4c3c4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtNC0xLTEtMTg4OTc0_d2f5ae01-a7ce-4552-a333-c5a1e055a77e"
      unitRef="usd">534000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id1effa3ff3a54202849eece7ac796687_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtNi0xLTEtMTg4OTc0_e662d50e-33ff-49fc-86ae-a439758931ce"
      unitRef="usd">2014000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14decb65256d4431b54b68596dcf53cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtOC0xLTEtMTg4OTc0_90e00bcd-519f-48ab-8dbd-28ffd8a3b283"
      unitRef="usd">1434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie55dd93e8acf407da56339a95d05c26d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTAtMS0xLTE4ODk3NA_9a9f82a5-8c69-4607-afb1-066435a61222"
      unitRef="usd">584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id90e5f5a81c64fd8a2d5eca216f1ac96_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTItMS0xLTE4ODk3NA_a19e9877-3144-4fe9-b570-eab78a9664ff"
      unitRef="usd">2018000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5d2433db185474e8f07acef38f88309_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTQtMS0xLTE4ODk3NA_f0146fe3-2fb7-44e1-acd3-469e6f9e0ece"
      unitRef="usd">1405000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife44f12d898a40c2b26d2899e1f87c7b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTYtMS0xLTE4ODk3NA_2e366b3a-e08c-415d-ac9c-1f2804360048"
      unitRef="usd">494000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib72c4cccf0ed4d4e98361bdf264e1ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzUtMTgtMS0xLTE4ODk3NA_a0b4f10e-ddd9-43f1-9dc0-4d7d0d4ddc04"
      unitRef="usd">1899000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4672ebffc2642038eb7bc351335c563_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMi0xLTEtMjA2MTg5_4acbf141-fa32-4914-b836-6fdc8d468b96"
      unitRef="usd">521000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8989af1d9ee941ccbf1d38df278cc651_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtNC0xLTEtMjA2MTg5_391acc2f-793b-43ff-94aa-70554b470620"
      unitRef="usd">900000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0ecec34e1ba548dfae54d6428a2be0ef_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtNi0xLTEtMjA2MTg5_62d870e0-c127-4f7f-9f5d-f1d21b9a9c9b"
      unitRef="usd">1421000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72818ade50a84197b7066c09d32fe4b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtOC0xLTEtMjA2MTg5_ced6de49-7b90-46ed-adfb-3ca27379d9b4"
      unitRef="usd">537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e998945c35c44b78153987bfb0988e0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTAtMS0xLTIwNjE4OQ_6088e5ce-fb76-467e-aa9e-79fa4f084f4b"
      unitRef="usd">943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ife184a05fefe4459858a75cd03edbb4e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTItMS0xLTIwNjE4OQ_dc73fce6-dc6a-46eb-9872-634c5ebe1a1b"
      unitRef="usd">1480000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa50e2701f6349c2976473694523273c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTQtMS0xLTIwNjE4OQ_56410f82-8d5a-4a64-bdb3-e2929a9c5d9b"
      unitRef="usd">629000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c662b22fd6d4f538341070c6658378a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTYtMS0xLTIwNjE4OQ_8c3de6fa-8f80-49b3-9b9f-2963a48b2f19"
      unitRef="usd">939000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id90e2b230dc243709b1d0eea15c4120d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTgtMS0xLTIwNjE4OQ_b0404e3b-45ae-42a4-89ff-1a97770937c0"
      unitRef="usd">1568000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i130d478f5c344266ad4bd4b7ab54798f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMi0xLTEtMjA2MjAx_59846407-2cb0-4fa1-bded-9a279f2c8f70"
      unitRef="usd">848000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81d627f909504f5bb6aec2303812401b_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctNC0xLTEtMjA2MjAx_ac8ddd72-a9e0-473d-aefd-ecb5592d6c91"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i71b642d2cd344106b2a9b43195affb7d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctNi0xLTEtMjA2MjAx_0d749272-ec73-4e86-91ae-5071a1ce539b"
      unitRef="usd">1307000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e495b2d1a824af7811048f9f9bc9a17_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctOC0xLTEtMjA2MjAx_d4891fba-440f-44e0-9c7c-b0debe2e807d"
      unitRef="usd">566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic905e297ec6e4217a0a0992727261a16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTAtMS0xLTIwNjIwMQ_f7a9ce6c-0f96-41a3-9db0-41924edc56cc"
      unitRef="usd">461000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4824dabd1ef04421b159a085c221b393_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTItMS0xLTIwNjIwMQ_e7c70047-7437-4411-9860-2fc25e0a12c9"
      unitRef="usd">1027000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac4f0dce8ef748aeae685b9a10378f08_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTQtMS0xLTIwNjIwMQ_3fbec480-c80d-44b2-aafc-2adf9f508846"
      unitRef="usd">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25bdbcb88c32403d8e379e2f8730b5ee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTYtMS0xLTIwNjIwMQ_5a996d69-38e0-407b-a033-c97d7b9aa404"
      unitRef="usd">365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie12cb06ca50647f08c8d0f02d992ddb8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzctMTgtMS0xLTIwNjIwMQ_360c3eee-d7b0-4227-9940-f10d91f7d29b"
      unitRef="usd">850000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab84e501cf364e47a226c6765f0a1320_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMi0xLTEtMjA2MjA2_dd1d7030-674d-4188-bc94-fe3c0a2bff4c"
      unitRef="usd">608000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34f569aa2b2b469081ca5099662ae431_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtNC0xLTEtMjA2MjA2_589032db-197e-4502-9ed8-d1d9b3364786"
      unitRef="usd">688000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i48d68f0d45e34ce3afe76b0c1819f0f5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtNi0xLTEtMjA2MjA2_a9d52039-6724-4052-b461-f117b00802bf"
      unitRef="usd">1296000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1dd3fc9f8784e4c8374d245b0c7fb71_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtOC0xLTEtMjA2MjA2_34cc0c5f-8e8e-49c4-9dcc-7c58afa41867"
      unitRef="usd">557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id28a9a6d2501418081e48da0d0dc78ce_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTAtMS0xLTIwNjIwNg_b7a0023d-e8e0-4fcf-8a40-7b30255e0b04"
      unitRef="usd">560000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia79c2d0bccb749ce9727366fb1126ceb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTItMS0xLTIwNjIwNg_8a4944f4-6020-4af6-8720-dff8a390bb2f"
      unitRef="usd">1117000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i257e9c51364e4d82b08262ef2ac191a3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTQtMS0xLTIwNjIwNg_2a739f3c-ef95-418d-8cf1-566c7f8b0108"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic120030329c6425dad6cd6f3e198f509_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTYtMS0xLTIwNjIwNg_db6b464b-9248-4727-936d-64b6ebce6663"
      unitRef="usd">428000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iacf507146d984867ac54d44e61ad8dc6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzgtMTgtMS0xLTIwNjIwNg_0ad15ba5-dd83-468d-943d-2d72f03f34df"
      unitRef="usd">887000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c25cc3cd16f40dc875390afe7993316_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMi0xLTEtMjA2MjA2_53357124-d1d2-4a0f-8163-65debd1f094b"
      unitRef="usd">850000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04869452639e49c4889ecd6ea51662ad_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktNC0xLTEtMjA2MjA2_02e9b228-b06f-4fe6-9f8b-3e14ef186eae"
      unitRef="usd">397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1d869ac7f27a4395b24b5b634039d37e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktNi0xLTEtMjA2MjA2_05333726-b52c-4a96-94a9-c7ceeeb0ef4e"
      unitRef="usd">1247000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab122339be0b431f90bca45e37234133_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktOC0xLTEtMjA2MjA2_73f7a517-6c9e-44f8-9228-e20148886507"
      unitRef="usd">736000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i260c1936cd204104b9c849ec4c5f1086_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTAtMS0xLTIwNjIwNg_bac3c57f-4168-4d54-b984-6c81d0ff1382"
      unitRef="usd">372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib16b3709a01e464fbb530033aa9546a9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTItMS0xLTIwNjIwNg_351fe121-6d09-4185-b784-750648727464"
      unitRef="usd">1108000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39749dabb5124d4da5d2ebbe0c7f9bab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTQtMS0xLTIwNjIwNg_143ee592-e6a4-48c4-ace7-a04db4d5a610"
      unitRef="usd">710000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1734816467749ce9071cf1a91e0ea7d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTYtMS0xLTIwNjIwNg_b4823258-71ce-407f-94a7-478d78e86611"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie1885db8f4e54fc68d9a604c36caefc1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzktMTgtMS0xLTIwNjIwNg_c2b8c1e8-8dee-4162-b4e4-845674814144"
      unitRef="usd">1065000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e97be903941430ba5c15572221083c5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMi0xLTEtMTg4OTc0_6522b1fc-02ff-4a22-861f-7336135dc566"
      unitRef="usd">959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i862040fed4914d45b07c1986dde77ca1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtNC0xLTEtMTg4OTc0_78bb9bc5-c3a6-4619-9859-69aa21741c66"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iafe19cf36dad4281bb45cf16884ba782_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtNi0xLTEtMTg4OTc0_171d6b8a-34ac-4ec5-bd58-d6e7234577c1"
      unitRef="usd">1126000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic31ee96f0c344214b71935816f6d82bf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtOC0xLTEtMTg4OTc0_185caec6-eb2d-4e98-9c2e-7cbde58d3933"
      unitRef="usd">1514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if976b4b2b7594c2d9f40e64ea67f3e83_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTAtMS0xLTE4ODk3NA_85663666-5fc4-4870-b79b-9e78c21e969f"
      unitRef="usd">220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1e2089ffa1cd467083ed4a1db7f715e7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTItMS0xLTE4ODk3NA_e878cc03-3503-41c2-ae51-362c0a66a295"
      unitRef="usd">1734000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0b4597ba3cb4f84aa35b4d25bfb8261_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTQtMS0xLTE4ODk3NA_32a47f56-9ef0-42f4-87f4-1e30803972ee"
      unitRef="usd">2001000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eb3f737b3494a4cbc9bc33b832a55ee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTYtMS0xLTE4ODk3NA_14ea657d-3834-43f1-a369-0b2e47d874eb"
      unitRef="usd">292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4bdc8fa194f44dfd99072ad9bcca3737_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzYtMTgtMS0xLTE4ODk3NA_5942795c-c911-4a78-98ee-bf4691e3df46"
      unitRef="usd">2293000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f5bd2a8d54048c38e2e840cbd09500d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTItMS0xLTIwODU1OA_94e2c266-6971-49e6-a7fb-adc191bb2f68"
      unitRef="usd">533000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5ab76d96eac4989a331ad1292e4f071_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTQtMS0xLTIwODU4NA_3cb853ca-7092-4854-80ed-3ab5b9d47b1a"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2876569878e64fa28cfa8f94277c4955_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTYtMS0xLTIwODYyNA_54c00367-e2fb-4208-96b3-4ae5ee6282d0"
      unitRef="usd">787000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6814d750caec49fc9617453d49cd87de_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTgtMS0xLTIwODU5OQ_0aff7f06-ffbd-4a7a-b046-1be2e889bd64"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f8b506414e4400f94126bb294f8de27_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTEwLTEtMS0yMDg2MDM_9a84fa2d-7208-40aa-897c-4651e47a92cd"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iab191a59b38e4a6aa145b09f8bd9d253_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTEyLTEtMS0yMjM4NDk_62c8d6b0-bd1b-430c-9df8-3b1b6934dce3"
      unitRef="usd">530000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca7535ce0ea49c7b96444b2409cf8d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE0LTEtMS0yMDg2MDg_4604c4f4-f7f1-4734-95c5-06de24fe5dd7"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93535a2cb1d74743ba6ebf13264af448_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE2LTEtMS0yMDg2MTk_55b42b9f-2db3-476c-bded-52215c5fba6e"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1164b97eced64b058786a55ff9fb37e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE4LTEtMS0yMjM4NTU_f01e934a-5a09-4995-85b4-a35d54d2a1cf"
      unitRef="usd">350000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02da5611affd4bb39c32bd0b8b1af6b4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTItMS0xLTE4ODk3NA_f7a09bfa-1c5d-406a-8530-f10c73b2ee9f"
      unitRef="usd">3549000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia93f46843ff741beafe6a37517e53dd2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTQtMS0xLTE4ODk3NA_84eb72e5-63ca-4762-945b-8922d385d34c"
      unitRef="usd">2021000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie830411e990944a58b257c504ac9bd03_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTYtMS0xLTE4ODk3NA_49ec2cbb-68fc-4e91-bb8a-0db54ba590bd"
      unitRef="usd">5570000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e7e76085a9842b38a2bd7b388f5d89a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTgtMS0xLTE4ODk3NA_79ca92b5-ea03-4984-8578-61c9c309ea5b"
      unitRef="usd">3305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2ea6966e44b490499ae329249bdde9b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTEwLTEtMS0xODg5NzQ_c93ef6ce-fd5d-490f-a197-f84f8972da26"
      unitRef="usd">2016000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i08293a2d22a847e882c434fc87376ede_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTEyLTEtMS0xODg5NzQ_09654626-2ddb-45cd-953e-befd49aa38c0"
      unitRef="usd">5321000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1d34a61daa04c4abac9d3a4af47df32_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE0LTEtMS0xODg5NzQ_d34be79d-c9f6-4e6b-955c-4a0b42560e0a"
      unitRef="usd">3630000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d2558e049e14f7fad9ba2b4954fbece_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE2LTEtMS0xODg5NzQ_30536263-d205-4491-9a3c-470789649c34"
      unitRef="usd">1744000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i47dc3c579513437d88fef139e4772cdb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzExLTE4LTEtMS0xODg5NzQ_f2765ecd-1ba7-4500-937e-172109cedffb"
      unitRef="usd">5374000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8dddf5cfe0e94fa19b1688a79d7445ae_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTItMS0xLTE4ODk3NA_6efd882e-f14b-4b42-b1c0-8300911e2db3"
      unitRef="usd">17743000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib65a6afa486142c9a0bed18deeea04c4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTQtMS0xLTE4ODk3NA_3d18ad00-30e2-4cde-b8bf-7950bc3c015e"
      unitRef="usd">7058000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2f333186d8da4378bcf0c5a3e6baf0f9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTYtMS0xLTE4ODk3NA_620e5923-7e34-4153-8ba3-0e4be1ac39cb"
      unitRef="usd">24801000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9c5766aba06f4d61bfab9fcffab156e5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTgtMS0xLTE4ODk3NA_e2dea178-c596-47b0-838f-dbbf18b04725"
      unitRef="usd">17286000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic65873c515ce4f70aec863e02db39e0b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTEwLTEtMS0xODg5NzQ_5e189da8-cfa9-4933-9109-13a1cb76c97a"
      unitRef="usd">7011000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6b25c75934844f82a32f7a76cdbe5042_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTEyLTEtMS0xODg5NzQ_fb956c23-8d08-4511-b8d8-266dca135f5a"
      unitRef="usd">24297000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib9e69273cff94b48bc90019f3c462804_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTE0LTEtMS0xODg5NzQ_dedf1a1c-ef04-47c8-a9b1-ef9ac6f78c68"
      unitRef="usd">17985000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i419f6f8b71f643678f664afe333ad342_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTE2LTEtMS0xODg5NzQ_386463d5-584b-4200-8dfe-13ba386f8b8e"
      unitRef="usd">6255000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if8db07843e5b426fbe44e0590a500e74_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEyLTE4LTEtMS0xODg5NzQ_6a0f5ae4-77d5-4039-819f-9d173addee1e"
      unitRef="usd">24240000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9009ee1e369c449292e70d4d067b1184_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTItMS0xLTE4ODk3NA_c745c926-a49f-4acc-80e5-755609a602e9"
      unitRef="usd">852000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0cee17c29ea542229fc4893cb3183b4d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTQtMS0xLTE4ODk3NA_125e8955-544c-4b0b-9d2e-2c6868595042"
      unitRef="usd">670000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id25b0832750a4204ac083f11c97f8288_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTYtMS0xLTE4ODk3NA_9f1ad583-f500-4b05-84e2-904fc046f299"
      unitRef="usd">1522000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia4df96a522844448bf9e3616baca9df9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTgtMS0xLTE4ODk3NA_be6127c3-095f-4d95-a052-a198f150db7e"
      unitRef="usd">908000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if37ac076bb994281907bc729c8f6d935_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTEwLTEtMS0xODg5NzQ_ddd4fe5b-886b-4024-a70e-bc61dfc7e484"
      unitRef="usd">774000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2457cd740816456db1f50da03ba631dc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTEyLTEtMS0xODg5NzQ_9b319c46-6eb7-4e88-acec-e55ade18d688"
      unitRef="usd">1682000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2d14a8530ad947f7b3fa2aefa3363fda_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTE0LTEtMS0xODg5NzQ_88844f14-4f7d-4eec-b065-93b2f6745b19"
      unitRef="usd">511000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6a6053e1fe314de1b2bb31df2e6ce976_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTE2LTEtMS0xODg5NzQ_1c1ad2c6-d908-4a8b-8231-0d5b495f626e"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i50cbcfb77ce746588d1956f2435637ae_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzEzLTE4LTEtMS0xODg5NzQ_3293af5c-b4c6-42e2-be3f-904b24b563db"
      unitRef="usd">1184000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7d4871c35ef74d7e8c872893b4cdaebc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTItMS0xLTE4ODk3NA_daebf730-5fad-4af2-ab11-660dda1e604d"
      unitRef="usd">18595000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icf92b1997d60491abc1e2f5b65cf03a4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTQtMS0xLTE4ODk3NA_37f1c889-176e-48d4-970e-b544555cc37e"
      unitRef="usd">7728000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTYtMS0xLTE4ODk3NA_5f09bccb-6759-4bf2-b31b-9a1585d9caf6"
      unitRef="usd">26323000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i63498908586e409e90d8f39594556f93_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTgtMS0xLTE4ODk3NA_088ebdb8-af23-4802-a227-489747343217"
      unitRef="usd">18194000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie377953c909f44678464f43ddbf57467_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTEwLTEtMS0xODg5NzQ_a848a664-d0a2-496c-b32e-795663867563"
      unitRef="usd">7785000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTEyLTEtMS0xODg5NzQ_79ef3947-0b5a-46bd-8717-1a9d87d3c383"
      unitRef="usd">25979000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5c5ae9adf5244a858af6f315eef250b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTE0LTEtMS0xODg5NzQ_22a61cb1-77d0-4aa1-8a70-7ece96483495"
      unitRef="usd">18496000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i64d8fc93c0f84588aacc70e98160df80_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTE2LTEtMS0xODg5NzQ_f8063990-68bf-4ea5-b986-64191bfae1ca"
      unitRef="usd">6928000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3ZTM1Njc1Nzg3YmI0MjE2YTY5YTNmNjI2ZTU4Zjc3My90YWJsZXJhbmdlOjdlMzU2NzU3ODdiYjQyMTZhNjlhM2Y2MjZlNThmNzczXzE0LTE4LTEtMS0xODg5NzQ_7a7a9733-bffb-4f31-95dc-75548e0d37a0"
      unitRef="usd">25424000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzExODE_0725b331-3a56-40ed-9fed-3a55349477e6"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzExODE_42b6e944-b279-4d08-b85a-cb2f320378bb"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzExODE_ddba0334-eaf3-4915-a313-1eeb126d4a90"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue>
    <amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzEzNzI_e639ba87-c8ce-4e38-8600-91cf4b395541"
      unitRef="number">0.82</amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE5NjA_3075ee93-4f5e-46e5-bd62-20fb73950840">Certain information with respect to these customers was as follows (dollar amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic492dbf72e134124ace0523e8918ae54_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzMtMS0xLTEtMTg4OTc0_adef51a0-468e-4cc3-9888-574b0783ea60"
      unitRef="usd">17305000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if3be857e2d3446f6a9576880dc95fdbf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzMtMy0xLTEtMTg4OTc0_a087388b-c346-466c-a58b-c44289fa8655"
      unitRef="usd">15187000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib3ced2b08bd74e91807733d80569e8f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzMtNS0xLTEtMTg4OTc0_88650fda-b87c-4780-8b2d-266ec9c459ed"
      unitRef="usd">13779000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:PercentageOfGrossRevenues
      contextRef="ic492dbf72e134124ace0523e8918ae54_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzQtMS0xLTEtMTg4OTc0_6c9e2c03-43cb-4205-9986-6534109a1647"
      unitRef="number">0.35</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="if3be857e2d3446f6a9576880dc95fdbf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzQtMy0xLTEtMTg4OTc0_9b5ae283-3e96-49de-841f-a3db4ca4bd5b"
      unitRef="number">0.33</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="ib3ced2b08bd74e91807733d80569e8f2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzQtNS0xLTEtMTg4OTc0_d667be95-47a0-47b1-a856-af1f53f347d2"
      unitRef="number">0.32</amgn:PercentageOfGrossRevenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1ce35b441d394680be0e8bc1af6382e6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzYtMS0xLTEtMTg4OTc0_6bba0a42-acea-4caf-8f77-dc2f27e45316"
      unitRef="usd">15443000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i04ebce1b8e1b4437b11925ff3b848025_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzYtMy0xLTEtMTg4OTc0_a0b20ffb-0d82-4587-8e70-e314afaba89f"
      unitRef="usd">14783000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i660bbb9450f640a2b53f5e591fae8ed1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzYtNS0xLTEtMTg4OTc0_718d5a07-ddc1-453b-be53-82f8920f399b"
      unitRef="usd">14743000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:PercentageOfGrossRevenues
      contextRef="i1ce35b441d394680be0e8bc1af6382e6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzctMS0xLTEtMTg4OTc0_e1fbed9e-5c66-4ff3-a6ba-e28ed28007e0"
      unitRef="number">0.31</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i04ebce1b8e1b4437b11925ff3b848025_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzctMy0xLTEtMTg4OTc0_c18fc0be-ec3d-495f-95e0-fd8e8f7e2a4b"
      unitRef="number">0.32</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i660bbb9450f640a2b53f5e591fae8ed1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzctNS0xLTEtMTg4OTc0_ae026990-b82a-4899-be04-c3708de4ded0"
      unitRef="number">0.34</amgn:PercentageOfGrossRevenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if75d92c2783d458a8be680eb71b21a63_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzktMS0xLTEtMTg4OTc0_47af6cdf-618c-4f15-b6b5-001f24e0dc20"
      unitRef="usd">8319000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4bf450c77c4449a8b3ecf57bc98e144a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzktMy0xLTEtMTg4OTc0_bcdb19fe-81ef-4444-bd22-9507076953a8"
      unitRef="usd">7681000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idd1681e5dde84590a71f0e996bf9146f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzktNS0xLTEtMTg4OTc0_023ab841-f9bf-4b93-a635-ea2babbc31c0"
      unitRef="usd">7332000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:PercentageOfGrossRevenues
      contextRef="if75d92c2783d458a8be680eb71b21a63_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzEwLTEtMS0xLTE4ODk3NA_c92647a8-3b69-4f35-867a-b0d09124c260"
      unitRef="number">0.16</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i4bf450c77c4449a8b3ecf57bc98e144a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzEwLTMtMS0xLTE4ODk3NA_5cca5bbb-788b-4355-b2b7-5fc2554170df"
      unitRef="number">0.17</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="idd1681e5dde84590a71f0e996bf9146f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90YWJsZTo3YTE4Nzk3NWM3YjA0MTUyYWFlY2FhY2I3ODIwNjZhMC90YWJsZXJhbmdlOjdhMTg3OTc1YzdiMDQxNTJhYWVjYWFjYjc4MjA2NmEwXzEwLTUtMS0xLTE4ODk3NA_f23a40e3-31ee-401e-bce9-a37058c2f288"
      unitRef="number">0.17</amgn:PercentageOfGrossRevenues>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE1NzE_28a9dd76-37e3-405f-91c7-608a12251bfc"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE1NzE_57f874ba-d643-4736-8494-642dad9d5c6b"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables>
    <amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE2NDc_126e3bf3-1ddb-409c-91f3-47e5e36574b3"
      unitRef="number">0.75</amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers>
    <amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE2NTQ_d12a10e5-4fd1-4f15-b781-1fbcb3bc6def"
      unitRef="number">0.73</amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers>
    <amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE3MzU_737a22bd-c7d9-43f8-8fae-16fa80cc2a12"
      unitRef="number">0.26</amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation>
    <amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8xOTkvZnJhZzphYzYzYTJiNWIwMTA0MjI1YWViOGU5NDFkN2QzOTNjMC90ZXh0cmVnaW9uOmFjNjNhMmI1YjAxMDQyMjVhZWI4ZTk0MWQ3ZDM5M2MwXzE3NDI_b19e5f94-6469-454d-9db1-9ea4b22dc4ed"
      unitRef="number">0.27</amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzcyOTY_b93f1b3c-9f86-45d9-8cde-821599eeea43">Stock-based compensation&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2022, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 15 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units and stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee&#x2019;s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date. RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2022, 2021 and 2020, were $234.47, $233.10 and $235.63, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;grant&#160;date&lt;br/&gt;fair&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total grant date fair values of RSUs that vested during the years ended December 31, 2022, 2021 and 2020, were $192 million, $166 million and $161 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire 10 years from the date of grant. We use the Black&#x2013;Scholes option valuation model to estimate the grant date fair value of stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (average of implied and historical volatility)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic values of options exercised during the years ended December 31, 2022, 2021 and 2020, were $67 million, $56 million and $98 million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2022, 2021 and 2020, were $14 million, $12 million and $21 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, $362 million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of 1.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally three years. The performance goals for the units granted during the years ended December 31, 2022, 2021 and 2020, which are accounted for as equity awards, are based on (i) Amgen&#x2019;s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen&#x2019;s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a payout simulation model to estimate the grant date fair value of performance units. The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of units granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of both December 31, 2022 and 2021, 1.6 million performance units were outstanding, with weighted-average grant date fair values per unit of $250.27 and $229.39 per unit, respectively. During the year ended December 31, 2022, 0.6 million performance units with a weighted-average grant date fair value per unit of $247.48 were granted, and 0.1 million performance units with a weighted-average grant date fair value per unit of $250.94 were forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair values of performance units paid during the years ended December 31, 2022, 2021 and 2020, were $150 million, $149 million and $230 million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.&lt;/span&gt;&lt;/div&gt;As of December 31, 2022, $132 million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of one year.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzMyNA_b2afb131-1632-492b-ac68-a0e695ed1633"
      unitRef="shares">1</amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted>
    <amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3MA_0670eef8-b528-472d-a0f1-b4fff73b0608"
      unitRef="shares">1.9</amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted>
    <amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3MA_2b613345-dca1-40a4-8e9b-32cf80e585f4"
      unitRef="shares">1.9</amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted>
    <amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzkxOA_c3eb6539-aa70-480c-85e1-8057570d8add"
      unitRef="shares">1.9</amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards>
    <amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzkxOA_f3706c69-aa57-441e-9b08-4f3e72502ba8"
      unitRef="shares">1.9</amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards>
    <amgn:AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzEwMjg_a8c594f2-9085-46d3-862f-c7d093087110"
      unitRef="shares">15000000</amgn:AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances>
    <amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMDI_cac20f5c-a1df-479e-9879-2a027d42b7ec">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzItMS0xLTEtMTg4OTc0_76236c25-a7aa-43f1-aac6-63979ec15a91"
      unitRef="usd">227000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i821d0160b8fd46f592bae9bed6edeeca_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzItMy0xLTEtMTg4OTc0_2a93dde2-c079-4baf-84f3-31c669e9ddff"
      unitRef="usd">183000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i11d0dbb92b9046b892ae095e67db26c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzItNS0xLTEtMTg4OTc0_5c992588-9a63-4c36-b4fa-f1678ec7842a"
      unitRef="usd">178000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzMtMS0xLTEtMTg4OTc0_f1a6e05d-1476-4cdc-b89a-6cf8164c72bc"
      unitRef="usd">132000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzMtMy0xLTEtMTg4OTc0_e540ee87-0336-4c84-8853-17be419af81f"
      unitRef="usd">121000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzMtNS0xLTEtMTg4OTc0_76911020-ba8c-491f-b54d-ca627d353bd5"
      unitRef="usd">118000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzQtMS0xLTEtMTg4OTc0_1439ccfe-e316-441f-abec-1de6e1be252a"
      unitRef="usd">42000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzQtMy0xLTEtMTg4OTc0_04990434-8d1f-4322-953b-39fb7eb7b081"
      unitRef="usd">37000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzQtNS0xLTEtMTg4OTc0_8aac31df-efb0-4ec1-be62-762ccceabac0"
      unitRef="usd">34000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzUtMS0xLTEtMTg4OTc0_b40f710f-7da9-4ce8-9ed1-a20000931299"
      unitRef="usd">401000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzUtMy0xLTEtMTg4OTc0_5c40bcbc-68cc-4bf1-8eb7-05b2b22d2b2d"
      unitRef="usd">341000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzUtNS0xLTEtMTg4OTc0_198a78cb-6ff3-4364-95c9-5d098f49d95a"
      unitRef="usd">330000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzYtMS0xLTEtMTg4OTc0_394c854b-f274-4f72-a595-dde2a64183e5"
      unitRef="usd">86000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzYtMy0xLTEtMTg4OTc0_85e46e73-289f-49ff-8a25-9cab55c7ca45"
      unitRef="usd">74000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzYtNS0xLTEtMTg4OTc0_cbeee7ac-9a1e-452b-9275-7d39d21e37a3"
      unitRef="usd">72000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <amgn:StockBasedCompensationExpenseNetOfTax
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzctMS0xLTEtMTg4OTc0_1af9b405-ec4f-4a7a-878b-c0b2151298b2"
      unitRef="usd">315000000</amgn:StockBasedCompensationExpenseNetOfTax>
    <amgn:StockBasedCompensationExpenseNetOfTax
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzctMy0xLTEtMTg4OTc0_78bcbe60-6cf0-4783-94e1-a72462c67488"
      unitRef="usd">267000000</amgn:StockBasedCompensationExpenseNetOfTax>
    <amgn:StockBasedCompensationExpenseNetOfTax
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZToyMjBlYzQxZGExMzA0Y2JlYmUyZTJjODJhZmJiYTIxOC90YWJsZXJhbmdlOjIyMGVjNDFkYTEzMDRjYmViZTJlMmM4MmFmYmJhMjE4XzctNS0xLTEtMTg4OTc0_70989f65-c465-47e5-bbda-e9d34acce114"
      unitRef="usd">258000000</amgn:StockBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMTg_f2885e4a-e43a-4d16-a368-8ca641c4424f">RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI3MDY_74e98047-d53a-47e2-bbdf-a8cf867a71c3"
      unitRef="usdPerShare">234.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i821d0160b8fd46f592bae9bed6edeeca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI3MTA_03470171-5c26-44b2-bed6-07490e4867ff"
      unitRef="usdPerShare">233.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i11d0dbb92b9046b892ae095e67db26c1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI3MTc_67591b36-4c1c-4f12-b471-a81f4dc5a8ac"
      unitRef="usdPerShare">235.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMTQ_b7cc32e6-ff97-4b3f-b119-42c390124ecb">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;grant&#160;date&lt;br/&gt;fair&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i219ff676680c41029ce9c7eaf92b5b3b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzItMS0xLTEtMTg4OTc0_c5f27914-64e5-4557-bc66-341f2e908f7e"
      unitRef="shares">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i219ff676680c41029ce9c7eaf92b5b3b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzItMy0xLTEtMTg4OTc0_440f4235-781d-4750-9b2c-f0a5f95c6e9a"
      unitRef="usdPerShare">217.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzMtMS0xLTEtMTg4OTc0_ce67e9fe-d29f-46d9-ad14-d2e65b96f5e4"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzMtMy0xLTEtMTg4OTc0_3d4486d6-578f-49e2-b9b5-8e8e69636dd8"
      unitRef="usdPerShare">234.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzQtMS0xLTEtMTg4OTc0_a5f2f3b9-d260-45fb-b34e-1c1f1855f1a5"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzQtMy0xLTEtMTg4OTc0_008dfe1b-3a4e-49af-9d22-59c2a00db5c6"
      unitRef="usdPerShare">201.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzUtMS0xLTEtMTg4OTc0_7189ad90-6005-42d2-8ffe-6dd471b8e057"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzUtMy0xLTEtMTg4OTc0_7203c48c-b52f-4506-b77f-80fcb5d7bf25"
      unitRef="usdPerShare">226.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3eb195f7ff9c4f059c27b617ec488e62_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzYtMS0xLTEtMTg4OTc0_b4d1e182-a1f1-49a9-a394-07ef91302550"
      unitRef="shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3eb195f7ff9c4f059c27b617ec488e62_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpjYTg3MWEwMDdkMjM0MzY3YjJjYWQwYTFhOGRmMWU2Ni90YWJsZXJhbmdlOmNhODcxYTAwN2QyMzQzNjdiMmNhZDBhMWE4ZGYxZTY2XzYtMy0xLTEtMTg4OTc0_4e32a8e9-7e3b-47d6-8d95-bed9e1c57834"
      unitRef="usdPerShare">228.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i834a25f0fac543d48b39035e1855c17f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI5MTA_8047756c-e615-420d-9d6a-4d86c899a9b1"
      unitRef="usd">192000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i821d0160b8fd46f592bae9bed6edeeca_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI5MTQ_4dbdf1ad-af38-4bee-b547-ae120f397d0d"
      unitRef="usd">166000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i11d0dbb92b9046b892ae095e67db26c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzI5MjE_e7de68bc-85bd-41c1-a31e-ab740bbca373"
      unitRef="usd">161000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzMxNDM_040da89d-60cd-40c2-a4ea-04551d34d828">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzcyOTk_5a796b47-bcc2-4d30-91a4-49dbad824d63">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (average of implied and historical volatility)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <amgn:CommonStockFairValue
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzItMS0xLTEtMTg4OTc0_73d0e737-61e6-49a6-b14a-980648b5407d"
      unitRef="usdPerShare">230.92</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzItMy0xLTEtMTg4OTc0_ed6d0a13-8b5b-47bb-ad8c-73acfa1aae28"
      unitRef="usdPerShare">237.17</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzItNS0xLTEtMTg4OTc0_0ceccaf3-43c7-41d6-9baa-4c0fd902af1f"
      unitRef="usdPerShare">236.36</amgn:CommonStockFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzMtMS0xLTEtMTg4OTc0_43f089b0-bd95-4d47-bc12-39160cf451f6"
      unitRef="number">0.245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzMtMy0xLTEtMTg4OTc0_fc1da60b-58d9-4acf-84b8-c614d27110d0"
      unitRef="number">0.256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzMtNS0xLTEtMTg4OTc0_845a8da4-808b-48ca-be65-13334cfae52f"
      unitRef="number">0.281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzQtMS0xLTEtMTg4OTc0_fbe56a39-bd75-46d9-ac54-584645d72f68">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzQtMy0xLTEtMTg4OTc0_79e55dec-3d9b-4d4d-b068-cec82a553ff7">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzQtNS0xLTEtMTg4OTc0_0522bf81-7492-4731-ba04-f224dad52dbe">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzUtMS0xLTEtMTg4OTc0_fa20a674-713a-4beb-8177-9b0e43758ca3"
      unitRef="number">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzUtMy0xLTEtMTg4OTc0_0a5a3d7c-31cf-44e6-a069-bcd21917656e"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzUtNS0xLTEtMTg4OTc0_a739b366-ad33-448c-a9b4-ff34f8526eec"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzYtMS0xLTEtMTg4OTc0_b41e77b0-a3fd-4b09-b590-bec910f4b50d"
      unitRef="number">0.033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzYtMy0xLTEtMTg4OTc0_816c8ff7-0e29-4591-8627-7ce444edb310"
      unitRef="number">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzYtNS0xLTEtMTg4OTc0_fbefc269-3cfc-4aa1-a12a-c722b80beaeb"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzctMS0xLTEtMTg4OTc0_876cbaca-b6a9-4b51-bf34-d98a5d9c4b69"
      unitRef="usdPerShare">42.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzctMy0xLTEtMTg4OTc0_da018e23-7c6f-4050-8701-076d2279c2f1"
      unitRef="usdPerShare">40.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTozYzJhNzA0NmRkYTc0NTEzYTg4NDNjMzBlMjk3Nzg5OC90YWJsZXJhbmdlOjNjMmE3MDQ2ZGRhNzQ1MTNhODg0M2MzMGUyOTc3ODk4XzctNS0xLTEtMTg4OTc0_01dce528-878e-4e30-ad39-b012311fb01c"
      unitRef="usdPerShare">42.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMTA_a09535f9-faef-4ea4-8326-b781f260c793">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifeed4f08e59e4fb882fab3526d452c25_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzItMS0xLTEtMTg4OTc0_557c7a6a-520a-4ad7-b422-1e9eb951e5d0"
      unitRef="shares">5100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifeed4f08e59e4fb882fab3526d452c25_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzItMy0xLTEtMTg4OTc0_6ace8647-e873-40c2-ba76-844de9742b4b"
      unitRef="usdPerShare">197.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzMtMS0xLTEtMTg4OTc0_8566bb32-25e0-45a0-a897-0aca180a9e9b"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzMtMy0xLTEtMTg4OTc0_7ef96be0-52f5-405a-a00b-e57efe8f54dc"
      unitRef="usdPerShare">230.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzQtMS0xLTEtMTg4OTc0_ea818779-ad96-4ae5-bcf1-7b4af606f2a3"
      unitRef="shares">700000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzQtMy0xLTEtMTg4OTc0_e541dadc-02ad-4cfc-ac33-dbbf32057a4a"
      unitRef="usdPerShare">167.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzUtMS0xLTEtMTg4OTc0_f1258aec-2e23-42b4-8625-3346472b8233"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzUtMy0xLTEtMTg4OTc0_9f6b47a2-9ceb-455f-99e0-e820127ae596"
      unitRef="usdPerShare">226.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2088886061214180b8eaf2c7c870e341_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzYtMS0xLTEtMTg4OTc0_68712bef-6f89-4655-85e7-5887e1cd5ae2"
      unitRef="shares">5300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2088886061214180b8eaf2c7c870e341_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzYtMy0xLTEtMTg4OTc0_d7cc21e6-a142-474e-b03b-d0b27a3cecff"
      unitRef="usdPerShare">207.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzYtNS0xLTEtMTg4OTc0_77302359-71fe-4f34-a5b9-3191c8c0f9a0">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2088886061214180b8eaf2c7c870e341_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzYtNy0xLTEtMTg4OTc0_650fcafa-5034-441a-9d0a-239006a7d163"
      unitRef="usd">295000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i2088886061214180b8eaf2c7c870e341_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzctMS0xLTEtMTg4OTc0_6eda6183-028b-4628-9fc6-840148d9e8ce"
      unitRef="shares">5200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i2088886061214180b8eaf2c7c870e341_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzctMy0xLTEtMTg4OTc0_cb16344e-d12d-4c7d-8a2d-13b2b801d3ac"
      unitRef="usdPerShare">206.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzctNS0xLTEtMTg4OTc0_27d3cf5d-b0b8-4c90-95a2-c442993f4fe7">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i2088886061214180b8eaf2c7c870e341_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzctNy0xLTEtMTg4OTc0_b1b6f16d-fe71-4832-b648-f8beb60bfa91"
      unitRef="usd">290000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2088886061214180b8eaf2c7c870e341_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzgtMS0xLTEtMTg4OTc0_e6b0380c-d4cb-49af-99c4-eb9fd7fc0517"
      unitRef="shares">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2088886061214180b8eaf2c7c870e341_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzgtMy0xLTEtMTg4OTc0_6cebd1dd-30f2-440a-8bb4-6e469412cba2"
      unitRef="usdPerShare">177.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzgtNS0xLTEtMTg4OTc0_8c4e9997-22cb-43de-895d-7f143895d760">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2088886061214180b8eaf2c7c870e341_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTpmNjVhOTA0NWI4ZDU0YTJmYTMwNDFjMWZiMmU4YWU0ZS90YWJsZXJhbmdlOmY2NWE5MDQ1YjhkNTRhMmZhMzA0MWMxZmIyZThhZTRlXzgtNy0xLTEtMTg4OTc0_b794789b-bd92-46ec-8aa3-80a5f32e451c"
      unitRef="usd">187000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM2MTA_cdbea7e8-2103-410f-95d0-97f17acd50b7"
      unitRef="usd">67000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM2MTQ_cf1d4313-3f8a-4239-b888-ec5cbe75bc0e"
      unitRef="usd">56000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM2MjE_70848fc6-88a6-472a-b9ba-45d20cb44235"
      unitRef="usd">98000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i07973e812ee241aea2269d4041a67153_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3NTc_bcc7cb67-9c0b-420f-b1db-20edb2824cd8"
      unitRef="usd">14000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ic4c1dc781173457ab97a69e2c67dbd86_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3NjE_363665df-97fa-4a30-a67a-ed5f9396524a"
      unitRef="usd">12000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="iebdbc28a9218438f8dddf1b1346348a5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3Njg_d76d244b-838d-4996-b400-6d7458188932"
      unitRef="usd">21000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM3OTY_add3bf95-18fd-4861-89fa-4baa0eeee845"
      unitRef="usd">362000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzM5NjA_3567477b-4673-4b06-af30-e1c774037e0d">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzQyNDk_6560ff2c-4f45-450d-b551-b66f91c40ced">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzUxMTQ_43a0f248-50fb-4b94-afc7-c40ab4e13a92"
      unitRef="shares">1</amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned>
    <amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzUxMTQ_584c1dfe-4b7a-4f08-b991-0b3c54b03c8e"
      unitRef="shares">1</amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned>
    <amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzUxMTQ_5c0ddc99-3e00-457d-a5e0-ecf9111d3ba5"
      unitRef="shares">1</amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned>
    <amgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzczMzQ_d3477492-8c3d-48e3-8c56-c981ae5365d8">The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of units granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock>
    <amgn:CommonStockFairValue
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzItMS0xLTEtMTg4OTc0_ee1d050d-2df8-47f0-a000-d6c7398a4949"
      unitRef="usdPerShare">230.92</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzItMy0xLTEtMTg4OTc0_fe0f12cb-9398-4d72-b349-26f120876b0e"
      unitRef="usdPerShare">239.64</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzItNS0xLTEtMTg4OTc0_dc0723a9-b19f-45af-a217-ac5e6190f091"
      unitRef="usdPerShare">236.36</amgn:CommonStockFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzMtMS0xLTEtMTg4OTc0_0364d3d0-9729-41e3-91fb-40ecd4d7809d"
      unitRef="number">0.281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzMtMy0xLTEtMTg4OTc0_d8841a9b-0db0-42c9-bcbe-aad60702d177"
      unitRef="number">0.293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzMtNS0xLTEtMTg4OTc0_586064e4-20f2-4357-a7dd-15f1e7a2658b"
      unitRef="number">0.275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzQtMS0xLTEtMTg4OTc0_3e638dfa-238a-4f59-9f86-cf47a7bac7fc"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzQtMy0xLTEtMTg4OTc0_d6ece1b7-88ab-48a6-b825-eb3c712498ac"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzQtNS0xLTEtMTg4OTc0_bec40350-cfb9-4b9c-80f6-843b2900a030"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzUtMS0xLTEtMTg4OTc0_76d9782c-5b83-4ef6-95f7-ca50e43377ba"
      unitRef="usdPerShare">247.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzUtMy0xLTEtMTg4OTc0_76829e00-7d7b-406b-b72a-17083b51b04e"
      unitRef="usdPerShare">254.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90YWJsZTplZDZlYzMzODU1N2Q0YTkzODFhNzQ3ZjU4N2VmYzNlYi90YWJsZXJhbmdlOmVkNmVjMzM4NTU3ZDRhOTM4MWE3NDdmNTg3ZWZjM2ViXzUtNS0xLTEtMTg4OTc0_58cbccbe-fec1-4dc6-9813-e9884a01a32a"
      unitRef="usdPerShare">249.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if5361cc7c39a4e2aba0e4628230f4a9e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY0Nzg_2aef6d5c-1cd6-463a-8c73-48bebde51bd8"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if5361cc7c39a4e2aba0e4628230f4a9e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY1ODE_7a7e4eaf-d7ee-4d22-bea3-645639da587c"
      unitRef="usdPerShare">250.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0c95759e9f834fff8e2ab6b9325f2188_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY1ODg_33038872-08f4-4394-90f0-29cf3601b176"
      unitRef="usdPerShare">229.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY2NDE_7a9be6b1-aa61-453a-91e1-1475b2c312ec"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY3MjA_a1870e58-6c58-448e-9a92-f7afd6b25027"
      unitRef="usdPerShare">247.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY3NDE_133d746d-50c9-4001-a193-f021ffcac15d"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY4MjA_1f6cdbad-c041-43c1-97d8-ae58168fa577"
      unitRef="usdPerShare">250.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY5NDM_ec7584e9-8b2f-464f-a62a-e9ad69a17cd0"
      unitRef="usd">150000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iac17b1564825474f83ed71156fbe3405_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY5NDc_f65706dc-77de-46c3-90e5-6db651350ac6"
      unitRef="usd">149000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i528df9c604e64825bd918ccdf8f661e3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzY5NTQ_abc706b2-aa21-4150-8756-d08e60d1e30a"
      unitRef="usd">230000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if5361cc7c39a4e2aba0e4628230f4a9e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzcxMzE_5335595b-fa0a-4fec-b0bd-a37de8ffeff5"
      unitRef="usd">132000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDIvZnJhZzo2YTE3OTJiMjUwM2Q0ZWU4OGUwYmEyOTVkOGFmM2M2MC90ZXh0cmVnaW9uOjZhMTc5MmIyNTAzZDRlZTg4ZTBiYTI5NWQ4YWYzYzYwXzcyODE_c02ae515-8f26-4cfa-871f-7ee4f0292ae2">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDUvZnJhZzpiMDc4MGExMzNlM2Q0MmJmYmMyMzI4MTlhNTc1ZWVkZi90ZXh0cmVnaW9uOmIwNzgwYTEzM2UzZDQyYmZiYzIzMjgxOWE1NzVlZWRmXzQxMQ_8da1fbb9-26c9-4c50-aec3-13e319adf018">Defined contribution planThe Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $243&#160;million, $279 million and $231 million for the years ended December 31, 2022, 2021 and 2020, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDUvZnJhZzpiMDc4MGExMzNlM2Q0MmJmYmMyMzI4MTlhNTc1ZWVkZi90ZXh0cmVnaW9uOmIwNzgwYTEzM2UzZDQyYmZiYzIzMjgxOWE1NzVlZWRmXzM1MA_a8129b8e-5131-497d-ba09-020342b0673a"
      unitRef="usd">243000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDUvZnJhZzpiMDc4MGExMzNlM2Q0MmJmYmMyMzI4MTlhNTc1ZWVkZi90ZXh0cmVnaW9uOmIwNzgwYTEzM2UzZDQyYmZiYzIzMjgxOWE1NzVlZWRmXzM1NA_3ea84675-880a-493f-959b-c010e80ad144"
      unitRef="usd">279000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDUvZnJhZzpiMDc4MGExMzNlM2Q0MmJmYmMyMzI4MTlhNTc1ZWVkZi90ZXh0cmVnaW9uOmIwNzgwYTEzM2UzZDQyYmZiYzIzMjgxOWE1NzVlZWRmXzM2MQ_26cc761e-ba68-4431-ad17-008f97669890"
      unitRef="usd">231000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc5MDU_42977328-7134-48e1-b498-60230cb03562">Income taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of NOL carryforwards. As of December 31, 2022, we elected to establish deferred taxes with respect to the U.S. minimum tax on the earnings of our foreign subsidiaries for the reversal of temporary items in future years. Significant components of our deferred tax assets and liabilities were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance increased in 2022, primarily driven by the Company&#x2019;s expectation that certain state R&amp;amp;D credits will expire unused.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we had $170 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $6&#160;million of those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2042. We had $896 million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $813 million of those state tax credit carryforwards. We had $51&#160;million of tax credit carryforwards related to our foreign jurisdictions available to offset future foreign income taxes for which we have provided no valuation allowance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we had $1.3 billion of federal NOL carryforwards available to reduce future federal income taxes and have provided no valuation allowance on those federal NOL carryforwards. Additionally, $1.0&#160;billion of those federal NOL carryforwards have no expiration; the remainder begin to expire between 2023 and 2037. We had $536 million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $415&#160;million of those state NOL carryforwards. We had $1.9 billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $186 million of those foreign NOL carryforwards. For the foreign NOLs with no valuation allowance provided, $640 million have no expiration; and the remainder will expire between 2023 and 2051.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the total gross amounts of UTBs were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for expiration of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the UTBs as of December 31, 2022, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2022, 2021 and 2020, we recognized $189 million, $98 million and $116 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The increase in interest expense for the year ended December 31, 2022, was primarily due to higher interest rates during 2022. As of December 31, 2022 and 2021, accrued interest and penalties associated with UTBs were $1.1 billion and $881 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, Puerto Rico excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, primarily federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Audit settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the years ended December 31, 2022, 2021 and 2020, differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company&#x2019;s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2050. Additionally, the Company&#x2019;s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. territory of Puerto Rico imposes a 4% excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico effective through December 31, 2022. For 2022, we account for the excise tax as a manufacturing cost that is capitalized in Inventories and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes paid during the years ended December 31, 2022, 2021 and 2020, were $2.4 billion, $1.9 billion and $1.4 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#x2013;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#x2013;2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010&#x2013;2012 by an amount that would result in additional federal tax of approximately $3.6&#160;billion plus interest. Any additional tax that could be imposed for the years 2010&#x2013;2012 would be reduced by up to approximately $900&#160;million of repatriation tax previously accrued on our foreign earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#x2013;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#x2013;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#x2013;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#x2013;2015 by an amount that would result in additional federal tax of approximately $5.1&#160;billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0&#160;billion. Any additional tax that could be imposed for the years 2013&#x2013;2015 would be reduced by up to approximately $2.2&#160;billion of repatriation tax previously accrued on our foreign earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We firmly believe that the IRS positions set forth in the 2010&#x2013;2012 and 2013&#x2013;2015 Notices are without merit. We are contesting the 2010&#x2013;2012 and 2013&#x2013;2015 Notices through the judicial process. The two cases were consolidated in U.S. Tax Court on December 19, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently under examination by the IRS for the years 2016&#x2013;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc5MTE_eaf0ec6b-cb47-4bb5-b061-4694f9132dfe">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i154b8bdaf9ab475f99a1f2846362c79c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzItMS0xLTEtMTg4OTc0_f91770e3-0cda-40ae-be94-ad499f211714"
      unitRef="usd">3026000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6de81be8345e48fb922b906166ab900a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzItMy0xLTEtMTg4OTc0_dcf6e148-f4e7-4cbb-aee0-0d08b4376034"
      unitRef="usd">1850000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ifb430bb605c14773b903da59d06a7e70_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzItNS0xLTEtMTg4OTc0_ee5b4ad8-08f0-4980-b573-457efd94b959"
      unitRef="usd">4087000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i8471d8b9c83641319a4f6ddfcd0f18c3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzMtMS0xLTEtMTg4OTc0_8dd2f89a-c123-48fa-b579-516bb0310838"
      unitRef="usd">4320000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ice4e89011fbe4e4cbcf5dd5272b78ecc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzMtMy0xLTEtMTg4OTc0_3c8811ce-a7ae-41dc-88c9-2804d89c9618"
      unitRef="usd">4851000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia0a84fb02f834393b706d526a6e58884_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzMtNS0xLTEtMTg4OTc0_dd941eb6-9312-4cd1-934c-15c91ec5b6fe"
      unitRef="usd">4046000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzQtMS0xLTEtMTg4OTc0_c758da96-803d-4b77-8cbb-f4e489aa4afc"
      unitRef="usd">7346000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzQtMy0xLTEtMTg4OTc0_aaf31f23-af39-4af6-b0fb-93853ca5077e"
      unitRef="usd">6701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTpiZDI0YTQ1ZmE0MGE0OGNhOWE3YzU4YjI0NjM5OWZmNC90YWJsZXJhbmdlOmJkMjRhNDVmYTQwYTQ4Y2E5YTdjNThiMjQ2Mzk5ZmY0XzQtNS0xLTEtMTg4OTc0_0f5b2dc0-38ba-41bc-b31a-8cff244f201f"
      unitRef="usd">8133000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc4OTc_1f9255fa-6116-4cdd-8c12-bec2c1a323f9">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzMtMS0xLTEtMTg4OTc0_9d23b9ab-274b-4850-aa46-fd7c89d884e4"
      unitRef="usd">1721000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzMtMy0xLTEtMTg4OTc0_d8a30ed4-7b0d-420a-a249-395a5cfc212c"
      unitRef="usd">865000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzMtNS0xLTEtMTg4OTc0_3fafb78e-a673-42fd-b04a-3ac5d77f1713"
      unitRef="usd">921000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzQtMS0xLTEtMTg4OTc0_9a5ed9ef-57f2-433b-8b02-08f209c3761e"
      unitRef="usd">44000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzQtMy0xLTEtMTg4OTc0_138b1869-aa79-4ac0-a89d-8b4f2f312eb0"
      unitRef="usd">18000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzQtNS0xLTEtMTg4OTc0_15ca0f56-3b68-405a-a1d0-800822a4a97f"
      unitRef="usd">34000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzUtMS0xLTEtMTg4OTc0_b80583b4-7e26-4681-980f-f3f1bdbdcbe9"
      unitRef="usd">304000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzUtMy0xLTEtMTg4OTc0_05e12d1e-132d-4032-8c4e-bc13b1a73c43"
      unitRef="usd">359000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzUtNS0xLTEtMTg4OTc0_2e6f0c0c-b98c-412e-a808-1d5ddbf619af"
      unitRef="usd">277000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzYtMS0xLTEtMTg4OTc0_5dbc03ac-2667-4c56-806c-bd7899f453c0"
      unitRef="usd">2069000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzYtMy0xLTEtMTg4OTc0_371ba370-7eab-49df-9eeb-486db8178cd7"
      unitRef="usd">1242000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzYtNS0xLTEtMTg4OTc0_e77f9249-7c65-43cb-8861-8fee2759402a"
      unitRef="usd">1232000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzgtMS0xLTEtMTg4OTc0_993ad3e1-ea9b-4632-99af-e104aa21ab21"
      unitRef="usd">-1185000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzgtMy0xLTEtMTg4OTc0_abb1be8a-13a8-47f5-9390-d09fc8dcdad0"
      unitRef="usd">-308000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzgtNS0xLTEtMTg4OTc0_3467282b-79a7-4db2-ad59-c12c1da8a382"
      unitRef="usd">-321000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzktMS0xLTEtMTg4OTc0_ff2603d2-c6fd-4e34-ab29-27271f27c267"
      unitRef="usd">-27000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzktMy0xLTEtMTg4OTc0_f0947523-d201-4c0f-8eac-dd48676852d1"
      unitRef="usd">-9000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzktNS0xLTEtMTg4OTc0_3bd5fc9f-2757-4dae-ae1e-15111aafc3f8"
      unitRef="usd">9000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEwLTEtMS0xLTE4ODk3NA_c364490c-a413-4cf3-a1bb-45c37da5d41b"
      unitRef="usd">-63000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEwLTMtMS0xLTE4ODk3NA_aba34f52-00e1-4f7e-b5a1-3e3899324471"
      unitRef="usd">-117000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEwLTUtMS0xLTE4ODk3NA_1e8c9fd0-291b-487d-9f52-3a0e4e20717d"
      unitRef="usd">-51000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzExLTEtMS0xLTE4ODk3NA_efc394eb-dc79-445a-bbfb-304653a17e91"
      unitRef="usd">-1275000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzExLTMtMS0xLTE4ODk3NA_f9fb7a42-a64d-47aa-a890-8daacbe63d56"
      unitRef="usd">-434000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzExLTUtMS0xLTE4ODk3NA_b75fc6e2-857a-4f38-81e6-b508a69be45f"
      unitRef="usd">-363000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEyLTEtMS0xLTE4ODk3NA_7572f4c4-b56b-4468-96fd-214baf6aeef9"
      unitRef="usd">794000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEyLTMtMS0xLTE4ODk3NA_42ae4fb0-8be2-41ac-aa34-f4a87f2d70a1"
      unitRef="usd">808000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTphYjM0YTJjYjg0Y2U0MDBiOGU2ZGMzYTU4NjU4ZGQxOC90YWJsZXJhbmdlOmFiMzRhMmNiODRjZTQwMGI4ZTZkYzNhNTg2NThkZDE4XzEyLTUtMS0xLTE4ODk3NA_24ad72e6-8309-4834-9e48-5b7ce39987fb"
      unitRef="usd">869000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc4ODU_590e3bce-bcca-4ab0-abc5-a3f63b93e15f">Significant components of our deferred tax assets and liabilities were as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzMtMS0xLTEtMTg4OTc0_99b37aaf-e893-46f9-a7c5-5481064f54b4"
      unitRef="usd">1344000000</amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards>
    <amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzMtMy0xLTEtMTg4OTc0_68ef2b0e-32e0-4edf-9585-5fc9ab0cb8c4"
      unitRef="usd">1065000000</amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzQtMS0xLTEtMTg4OTc0_a3610fa1-0048-4783-b2b8-74a5a9585bc2"
      unitRef="usd">584000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzQtMy0xLTEtMTg4OTc0_6c30fb45-7b7c-43e8-b91b-1a7e28ffab6c"
      unitRef="usd">600000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <amgn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzUtMS0xLTEtMjE0NjEz_29bf0063-6420-4850-a352-ff1ba799d30c"
      unitRef="usd">515000000</amgn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <amgn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzUtMy0xLTEtMjIzOTM1_9c194541-bca7-4405-8c02-682c5a461b5c"
      unitRef="usd">0</amgn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzYtMS0xLTEtMjEyMDgw_a09ff7fb-f82c-45b7-b041-63de0942444e"
      unitRef="usd">270000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzYtMy0xLTEtMjEyMDgw_d7dcca90-034b-4dfa-89f3-d1f32933c53b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzUtMS0xLTEtMTg4OTc0_a29254e7-9c5f-48c5-838f-9bfda7df001d"
      unitRef="usd">211000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzUtMy0xLTEtMTg4OTc0_dde062c7-c4d5-48ce-871a-8409142b89d6"
      unitRef="usd">244000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <amgn:DeferredTaxAssetEarningsOfForeignSubsidiaries
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzYtMS0xLTEtMTg4OTc0_15b6b61a-798b-43ef-aa7f-9ee05d7a3599"
      unitRef="usd">192000000</amgn:DeferredTaxAssetEarningsOfForeignSubsidiaries>
    <amgn:DeferredTaxAssetEarningsOfForeignSubsidiaries
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzYtMy0xLTEtMTg4OTc0_72fca3b0-f2b7-44fe-8685-db3111e4e7ab"
      unitRef="usd">0</amgn:DeferredTaxAssetEarningsOfForeignSubsidiaries>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzEwLTEtMS0xLTIxMjExMw_ff03510c-48b9-4710-b388-59143d2b26a1"
      unitRef="usd">104000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzEwLTMtMS0xLTIxMjExMw_2cb1069c-2b35-4b3f-afb2-29061d08dfaa"
      unitRef="usd">96000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzgtMS0xLTEtMTg4OTc0_4024510d-9647-40d7-8666-ad0228ba7c74"
      unitRef="usd">317000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzgtMy0xLTEtMTg4OTc0_83f44750-c281-4809-932a-132b8e6ecb72"
      unitRef="usd">326000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzktMS0xLTEtMTg4OTc0_eaae9d01-404c-4401-ac4b-e28f6abc4fe2"
      unitRef="usd">3537000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzktMy0xLTEtMTg4OTc0_0a8b2f1b-eb26-46f8-9bb0-b134ad263c13"
      unitRef="usd">2331000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzEwLTEtMS0xLTE4ODk3NA_685bb2f1-83f1-4106-836e-bd11d0dcd3c2"
      unitRef="usd">718000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzEwLTMtMS0xLTE4ODk3NA_59764c57-1eae-474e-bd78-9ec60f05a6bf"
      unitRef="usd">663000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzExLTEtMS0xLTE4ODk3NA_965d5768-9225-4fb6-9795-fe2ab86a0d81"
      unitRef="usd">2819000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzExLTMtMS0xLTE4ODk3NA_d910bd47-f169-4620-998e-008403b207f4"
      unitRef="usd">1668000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE0LTEtMS0xLTE4ODk3NA_276661a4-91ed-447f-8f20-cca9c28d98d7"
      unitRef="usd">1238000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE0LTMtMS0xLTE4ODk3NA_537de561-9f72-4f5c-b4fa-ef15b491c715"
      unitRef="usd">824000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE1LTEtMS0xLTE4ODk3NA_59975545-99fb-4cac-be41-6aae7eba4c3c"
      unitRef="usd">272000000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE1LTMtMS0xLTE4ODk3NA_b101c08a-0a7b-42f4-b0d2-b272030cd184"
      unitRef="usd">275000000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE2LTEtMS0xLTE4ODk3NA_973f0aa1-b5fb-4fc7-b50c-4fdb1c28bd93"
      unitRef="usd">112000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE2LTMtMS0xLTE4ODk3NA_a437355f-1a9e-4425-9eee-833525246fea"
      unitRef="usd">129000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE3LTEtMS0xLTE4ODk3NA_cdc8aa3d-1a99-4cea-be1d-05ba45237443"
      unitRef="usd">254000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE3LTMtMS0xLTE4ODk3NA_264d5559-7864-4cc0-9637-e37e4f19f7fb"
      unitRef="usd">221000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE4LTEtMS0xLTE4ODk3NA_dad88751-034a-4610-845e-d339d6bf1843"
      unitRef="usd">1876000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE4LTMtMS0xLTE4ODk3NA_b9819218-8438-4dbd-82da-5b39846311ee"
      unitRef="usd">1449000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE5LTEtMS0xLTE4ODk3NA_630061a5-ed06-4a81-8662-c5450a9a35d4"
      unitRef="usd">943000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZToyY2U1ZmJlODQ0ODc0NzNjOWZhY2ViOTJkMDBjNmE2ZC90YWJsZXJhbmdlOjJjZTVmYmU4NDQ4NzQ3M2M5ZmFjZWI5MmQwMGM2YTZkXzE5LTMtMS0xLTE4ODk3NA_c2cb388f-8be5-44b3-82b0-e7115e19d436"
      unitRef="usd">219000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ibc64ba5f13184705bbcea61dca732af0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzEwMzg_4cbb3463-fad5-4e6a-8061-fa1b53ad17e7"
      unitRef="usd">170000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="ibb268048ef47498c93e842c4884d3b1a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzQ1NjI5NzMyNTYzMjU3_2e289423-ce35-4d46-a3c6-cb2eee16838a"
      unitRef="usd">6000000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i0c663e71979d4887b26c8be64eb736f1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzEyODQ_15c8278a-3023-4f44-afb2-df2f2691d82c"
      unitRef="usd">896000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="i0c663e71979d4887b26c8be64eb736f1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE0MTE_0b81f397-766d-4f45-8850-68848f7b0981"
      unitRef="usd">813000000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgzMDAzNQ_bad8f65d-4754-4e0f-bca2-32180a0642c2"
      unitRef="usd">51000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgzMDA1NQ_4a607c58-3730-49d1-b1ac-6d62166ea3fe"
      unitRef="usd">0</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibc64ba5f13184705bbcea61dca732af0_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE0NzI_a02cbbe7-a4a7-4366-8004-becdfbd3ca0c"
      unitRef="usd">1300000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="ibc64ba5f13184705bbcea61dca732af0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgzMDA2Mw_6a0eafd4-abae-4458-8f3b-a7da238b0dff"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="ibc64ba5f13184705bbcea61dca732af0_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE3MjE_4f58884e-1871-4d27-b0a1-18241595b465"
      unitRef="usd">1000000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0c663e71979d4887b26c8be64eb736f1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE4MDQ_4cb632f0-0f29-4d8a-8fbc-b62ae887d991"
      unitRef="usd">536000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i0c663e71979d4887b26c8be64eb736f1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE5MjQ_a8c8c74c-8354-456f-ad69-b360e38e583f"
      unitRef="usd">415000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE5Njg_1d9f8466-65c8-484d-b90d-894e0e358ffe"
      unitRef="usd">1900000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzIwOTI_469f8626-e7c0-4498-b3b1-14ac8135b023"
      unitRef="usd">186000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i3470fa30c75149af83b41d392e448110_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzIxNTc_b0f23f3a-ed6c-4498-9f51-209757fc4cdd"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i7b423717f36c40579ed83c7a713b6b0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzIxOTA_556b4e76-a064-4e38-bb78-fa4d45692f93"
      unitRef="usd">640000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc5MDg_df0f86a6-467f-4e77-8622-a22e73bcfef2">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the total gross amounts of UTBs were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for expiration of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzItMS0xLTEtMTg4OTc0_22e6cc0f-859d-4644-87f0-61653a4454de"
      unitRef="usd">3546000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzItMy0xLTEtMTg4OTc0_400b894d-53c0-41f1-a076-549fd7bc1010"
      unitRef="usd">3352000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzItNS0xLTEtMTg4OTc0_81f4a0e0-02aa-4bcb-9f9d-4ba1b8b42116"
      unitRef="usd">3287000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzMtMS0xLTEtMTg4OTc0_afdacee6-370c-4e54-abf0-afc32f45900a"
      unitRef="usd">151000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzMtMy0xLTEtMTg4OTc0_537570b0-0630-4ba1-ab94-8fb375e11ce7"
      unitRef="usd">171000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzMtNS0xLTEtMTg4OTc0_bcfb3637-8425-4800-b1bc-2a0de2bbd119"
      unitRef="usd">165000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzQtMS0xLTEtMTg4OTc0_396bc76d-c98f-428a-b94b-420c052c6aa7"
      unitRef="usd">90000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzQtMy0xLTEtMTg4OTc0_18343b46-072d-4c42-b9fc-534ca4fe1792"
      unitRef="usd">35000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzQtNS0xLTEtMTg4OTc0_36e8b448-9101-4b37-a4af-49093ec622e9"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzUtMS0xLTEtMTg4OTc0_5696d294-01bd-4be8-9059-537cb972f12d"
      unitRef="usd">14000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzUtMy0xLTEtMTg4OTc0_15e56f14-d4ac-4422-9c4e-efffb55defd2"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzUtNS0xLTEtMTg4OTc0_1c72b5e0-8c54-4ca3-b613-c6fd980cba5d"
      unitRef="usd">35000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzYtMS0xLTEtMTg4OTc0_53dbff94-d872-48ab-9ba0-4bf8fec6b7e3"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzYtMy0xLTEtMTg4OTc0_513d2cbe-e303-42f5-ab11-7e366d949c5d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzYtNS0xLTEtMTg4OTc0_2e657b42-7b42-415c-931d-4f19e3d0e092"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzctMS0xLTEtMTg4OTc0_61087d32-96f6-4da9-9fe0-d441b5e5cff5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzctMy0xLTEtMTg4OTc0_427dd6ff-2344-44f9-8614-f6cfc5f8a77b"
      unitRef="usd">8000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzctNS0xLTEtMTg4OTc0_8af8f57a-d3ab-4b7c-b38a-79fc44a1a9ce"
      unitRef="usd">68000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzgtMS0xLTEtMTg4OTc0_5edb8904-fa81-46c5-9a26-de0f09e0d737"
      unitRef="usd">3770000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzgtMy0xLTEtMTg4OTc0_eb9b3887-9417-4a73-b5f3-adedd364f914"
      unitRef="usd">3546000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTplOTdkNjFlZDJmZjU0ZDFiOTBjODEyZGVmNGFjZDEwZC90YWJsZXJhbmdlOmU5N2Q2MWVkMmZmNTRkMWI5MGM4MTJkZWY0YWNkMTBkXzgtNS0xLTEtMTg4OTc0_f10258ad-a955-49a3-817b-aa7216a9fb25"
      unitRef="usd">3352000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzI3MzY_b365699c-8f03-4cee-9e1b-ebca9586d637"
      unitRef="usd">189000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzI3NDA_2c79e442-ee1c-483e-a996-d8a4ef053497"
      unitRef="usd">98000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzI3NDc_4649368d-bb55-4c91-8f77-c1c3c1a609a4"
      unitRef="usd">116000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzMxMDM_c5b51f9f-2be7-4b13-8e03-408b717ffc28"
      unitRef="usd">1100000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzMxMTA_ec56e64a-18dc-48e3-8065-01638b92de36"
      unitRef="usd">881000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc4ODE_6b84a09e-3e1e-475d-89e2-9bbda7071022">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, Puerto Rico excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, primarily federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Audit settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzItMS0xLTEtMTg4OTc0_b2b09d87-d31f-4b38-8eba-974950393747"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzItMy0xLTEtMTg4OTc0_e9b2888d-198c-4be6-9f1e-dc5e89a3d616"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzItNS0xLTEtMTg4OTc0_eb2adc16-57ef-4215-866a-34d1e2d8bc70"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzMtMS0xLTEtMTg4OTc0_86df5b3c-a660-451e-809d-1858d797b108"
      unitRef="number">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzMtMy0xLTEtMTg4OTc0_f26935ba-7627-4334-8bae-5d9508501819"
      unitRef="number">0.078</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzMtNS0xLTEtMTg4OTc0_a02452f9-659d-4cc4-8648-d70da24ca9bd"
      unitRef="number">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzQtMS0xLTEtMTg4OTc0_8f92dede-f103-47b4-8fe6-86c4ff9e4b16"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzQtMy0xLTEtMTg4OTc0_23fcd90b-8371-41b3-befd-3b7837b3137c"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzQtNS0xLTEtMTg4OTc0_3a0b3ef5-883c-4fba-8e41-6437df93e4c2"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzUtMS0xLTEtMTg4OTc0_d3663d6f-c244-47bf-8777-5550e07ff946"
      unitRef="number">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzUtMy0xLTEtMTg4OTc0_7c60332a-b161-4b5b-aaf6-870312a3e5b4"
      unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzUtNS0xLTEtMTg4OTc0_6bed2695-ee8b-49e3-b3fa-b27a72636cbf"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzctMS0xLTEtMTg4OTc0_89554488-2d9c-462d-9642-69cdb4812928"
      unitRef="number">0.019</amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzctMy0xLTEtMTg4OTc0_719a09a0-ce00-44fb-8503-b8a77945556f"
      unitRef="number">0.011</amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzctNS0xLTEtMTg4OTc0_339c1b51-8d45-4849-9e72-78553401b4cb"
      unitRef="number">0.011</amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzgtMS0xLTEtMTg4OTc0_e262754c-f12f-4d87-be3c-7a4214dcc337"
      unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzgtMy0xLTEtMTg4OTc0_d3141a01-c2f7-415c-90f0-4d4d852d64a1"
      unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzgtNS0xLTEtMTg4OTc0_826cc775-6e52-47f5-8a90-daa6e90f7eda"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzktMS0xLTEtMTg4OTc0_0a2ab19e-daba-4d97-a48c-2d22db70a7c7"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzktMy0xLTEtMTg4OTc0_a979e94f-603b-499c-8bc0-f5792a108859"
      unitRef="number">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzktNS0xLTEtMTg4OTc0_61d81d1a-da34-456b-9389-f921cf2300c4"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEwLTEtMS0xLTE4ODk3NA_e2c983df-4204-4ad4-8356-989c7b1d1cb7"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEwLTMtMS0xLTE4ODk3NA_2ed5dea8-f019-41c9-bacd-8856b4178375"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEwLTUtMS0xLTE4ODk3NA_a4e81baa-8045-4cb3-ad3a-a35fc858da6c"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzExLTEtMS0xLTE4ODk3NA_f2bb6937-c89d-4b69-88ff-6087f4dd61e1"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzExLTMtMS0xLTE4ODk3NA_63ae7668-579d-4e8e-9589-ca913cad28bc"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzExLTUtMS0xLTE4ODk3NA_4a9a413c-7732-4734-93ce-2366b3bef4d9"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEyLTEtMS0xLTE4ODk3NA_18af4cc2-ac41-4054-b95d-88001190da3e"
      unitRef="number">0.108</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEyLTMtMS0xLTE4ODk3NA_5a0fa111-bbd7-4c10-b0c8-bf3875619d31"
      unitRef="number">0.121</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90YWJsZTozZWZkZTZjMzdmYTM0YjRjYjk4ZDljZDhiMjhiMDY3My90YWJsZXJhbmdlOjNlZmRlNmMzN2ZhMzRiNGNiOThkOWNkOGIyOGIwNjczXzEyLTUtMS0xLTE4ODk3NA_822470a0-18bb-49c4-b584-894f2bb78600"
      unitRef="number">0.107</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzQ1NjE_e02017c6-21ae-4c96-a51a-0e6c4cad48e9"
      unitRef="usd">2400000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzQ1NjU_5e4fc14c-7f8e-4f0f-ae9f-c1b4dd9e63ab"
      unitRef="usd">1900000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzQ1NzI_a8767ee4-6e66-4860-bc52-396ed6efd9ff"
      unitRef="usd">1400000000</us-gaap:IncomeTaxesPaid>
    <amgn:NumberOfNoticesOnProposedAdditionalTax
      contextRef="i13c5612dc4a5450684e24434f6a3ec86_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzc5MDY_c0ccaad8-2eb0-4426-a777-0ddae895bad4"
      unitRef="numberofnotices">2</amgn:NumberOfNoticesOnProposedAdditionalTax>
    <amgn:ProposedAdditionalIncomeTax
      contextRef="i13c5612dc4a5450684e24434f6a3ec86_I20210531"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU5ODk_51f45a0d-798f-4c48-8ed7-dd1c745fd581"
      unitRef="usd">3600000000</amgn:ProposedAdditionalIncomeTax>
    <amgn:RepatriationTaxOnProposedAdditionalTax
      contextRef="i13c5612dc4a5450684e24434f6a3ec86_I20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzYwODg_d0b7a4c3-83ff-43fe-b5a7-84a2ed734454"
      unitRef="usd">900000000</amgn:RepatriationTaxOnProposedAdditionalTax>
    <amgn:ProposedAdditionalIncomeTax20132015
      contextRef="ic981a166a2b44b269c7a5073481bc3dc_I20220428"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgyOTk3NA_0c56e439-bf6a-4324-b71e-59c636deefec"
      unitRef="usd">5100000000</amgn:ProposedAdditionalIncomeTax20132015>
    <amgn:PenaltiesOnProposedAdditionalIncomeTax20132105
      contextRef="ic981a166a2b44b269c7a5073481bc3dc_I20220428"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgyOTk4OA_c939af78-6ab4-4bd6-bb98-6af4ca977fc3"
      unitRef="usd">2000000000</amgn:PenaltiesOnProposedAdditionalIncomeTax20132105>
    <amgn:RepatriationTaxOnProposedAdditionalTax20132015
      contextRef="ic981a166a2b44b269c7a5073481bc3dc_I20220428"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzU0OTc1NTgzMDAwMg_b4bdd015-ea9b-429d-bc68-1a2e20dee446"
      unitRef="usd">2200000000</amgn:RepatriationTaxOnProposedAdditionalTax20132015>
    <amgn:NumberOfNoticesConsolidated
      contextRef="i94eb03241527483ebaf961e48ef6e18d_I20221219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMDgvZnJhZzoxY2UyYTAwMzZiZDE0MWNmODgxN2IzMTViZGRiMTQ4My90ZXh0cmVnaW9uOjFjZTJhMDAzNmJkMTQxY2Y4ODE3YjMxNWJkZGIxNDgzXzE0MjkzNjUxMTc3MjI3_44c8e1f2-829f-43ee-b9c9-7f06e5ca3895"
      unitRef="case">2</amgn:NumberOfNoticesConsolidated>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90ZXh0cmVnaW9uOjM3YmVjZDVjMTZmZTRhN2M4ZTkyNTA1NmFmMDQ0MTg3XzczNA_8fa8954a-3dbf-4c58-9960-d49eba1d4d8a">Earnings per share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted EPS were as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (Numerator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (Denominator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each of the three years ended December 31, 2022, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90ZXh0cmVnaW9uOjM3YmVjZDVjMTZmZTRhN2M4ZTkyNTA1NmFmMDQ0MTg3XzczMw_557939d5-d26e-4727-8d17-82759d07378a">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted EPS were as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (Numerator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (Denominator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzMtMS0xLTEtMTg4OTc0_14bc04c3-6a37-462c-b2ab-351b35e26065"
      unitRef="usd">6552000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzMtMy0xLTEtMTg4OTc0_63629072-852c-491d-b372-bf81b967eff6"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzMtNS0xLTEtMTg4OTc0_4ddcd2e2-53bb-43d9-82b5-2f3cd468fc19"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzYtMS0xLTEtMTg4OTc0_34a28710-b20d-45e7-9e52-acdd7f58aa3c"
      unitRef="shares">538000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzYtMy0xLTEtMTg4OTc0_294d1302-f7a3-4888-83a4-bfabc8e76d76"
      unitRef="shares">570000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzYtNS0xLTEtMTg4OTc0_a7b23b0d-8aac-464a-9cae-7ac2d69963d2"
      unitRef="shares">586000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzctMS0xLTEtMTg4OTc0_8596bd1d-dd3c-4caf-984c-ae313a9fd5d6"
      unitRef="shares">3000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzctMy0xLTEtMTg4OTc0_38dc7f4b-395c-4799-b79f-21c5449178b8"
      unitRef="shares">3000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzctNS0xLTEtMTg4OTc0_8bccac63-644a-4092-b0e6-a482c043bd35"
      unitRef="shares">4000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzgtMS0xLTEtMTg4OTc0_6c665f2b-812b-4bc0-9f9c-25da653b16d7"
      unitRef="shares">541000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzgtMy0xLTEtMTg4OTc0_f11a24d8-91d2-4f8e-8ad3-ece0e8754282"
      unitRef="shares">573000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzgtNS0xLTEtMTg4OTc0_f155e408-3be3-4176-b1d8-aed0582de240"
      unitRef="shares">590000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzEwLTEtMS0xLTE4ODk3NA_46cc5025-da01-45b4-b269-822f44adbc6f"
      unitRef="usdPerShare">12.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzEwLTMtMS0xLTE4ODk3NA_9a731dbe-1917-4e26-ae17-5dc5174913ed"
      unitRef="usdPerShare">10.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzEwLTUtMS0xLTE4ODk3NA_3dd22796-56ce-483d-ae63-8ab75293c476"
      unitRef="usdPerShare">12.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzExLTEtMS0xLTE4ODk3NA_6a91dccf-63f0-429e-8320-581ef3f832cb"
      unitRef="usdPerShare">12.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzExLTMtMS0xLTE4ODk3NA_3d342c26-1202-427b-9d63-0fa123bcf106"
      unitRef="usdPerShare">10.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTEvZnJhZzozN2JlY2Q1YzE2ZmU0YTdjOGU5MjUwNTZhZjA0NDE4Ny90YWJsZTphOGQ0ZmY5ZWRmZjI0NzkwOGViMmU4YzQzYjAxZmU1MS90YWJsZXJhbmdlOmE4ZDRmZjllZGZmMjQ3OTA4ZWIyZThjNDNiMDFmZTUxXzExLTUtMS0xLTE4ODk3NA_78ee5e40-58f4-4f56-9039-246427d13d6e"
      unitRef="usdPerShare">12.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzgzMTY_58a9a7f0-d4ae-4636-adbe-79fda9913d74">Collaborations&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i)&#160;active participants in the activity and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into collaborative arrangements for the R&amp;amp;D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalties and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized under these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, we acquired an equity stake in BeiGene for approximately $2.8&#160;billion in cash as part of a collaboration to expand our oncology presence in China. For additional information regarding our equity investment in BeiGene, see Note 9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;amp;D costs by providing cash and development services of up to $1.25&#160;billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2022, 2021 and 2020, net costs recovered from BeiGene for oncology product candidates were $199&#160;million, $220&#160;million and $225&#160;million, respectively, and were recorded as an offset to R&amp;amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2022 and 2021, product sales from Amgen to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BeiGene under the collaboration were $64&#160;million and $72&#160;million, respectively, and were recorded in Product sales in the Consolidated Statements of Income. During the years ended December 31, 2022 and 2021, profit and loss share expenses related to the initial product-specific commercialization period were $53&#160;million and $64&#160;million, respectively, and were recorded in SG&amp;amp;A expense in the Consolidated Statements of Income. Product sales from Amgen to BeiGene and profit and loss share expenses were not material during the year ended December 31, 2020. Amounts owed from BeiGene for product sales were $6&#160;million and $21&#160;million as of December 31, 2022 and 2021, respectively, which are included in Trade receivables, net, in the Consolidated Balance Sheets. Net amounts owed from BeiGene for cost recoveries and profit and loss share payments were $47&#160;million and $61&#160;million as of December 31, 2022 and 2021, respectively, which are included in Other current assets in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AstraZeneca plc&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are in a collaboration with AstraZeneca for the development and commercialization of TEZSPIRE. Under our collaboration, both companies share global costs, profits and losses equally after payment by AstraZeneca of a mid-single-digit royalty to Amgen. AstraZeneca leads global development, and both Amgen and AstraZeneca jointly commercialize TEZSPIRE in North America. In North America, Amgen, as the principal, recognizes product sales of TEZSPIRE in the United States, and AstraZeneca, as the principal, recognizes product sales of TEZSPIRE in Canada. AstraZeneca leads commercialization for TEZSPIRE outside North America. Amgen manufactures and supplies TEZSPIRE worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2022, 2021 and 2020, net costs due to AstraZeneca for global development were $74 million, $49&#160;million and $52&#160;million, respectively, and were recorded in R&amp;amp;D Expense in the Consolidated Statements of Income. During the years ended December 31, 2022, 2021 and 2020, net costs due to AstraZeneca for global commercialization were $60&#160;million, $39&#160;million and $16&#160;million, respectively, and were recorded in SG&amp;amp;A Expense in the Consolidated Statements of Income. During the year ended December 31, 2022, global profit and loss share expenses were $119 million and were recorded primarily in Cost of sales in the Consolidated Statements of Income. TEZSPIRE launched in the United States in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are in a collaboration with UCB for the development and commercialization of EVENITY. Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe and China (excluding Hong Kong). Amgen, as the principal, leads commercialization for EVENITY and recognizes product sales in all other territories, including the United States. Global development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2022, 2021 and 2020, global profit and loss share expenses were $255&#160;million, $186 million and $115 million, respectively, and were recorded primarily in Cost of sales in the Consolidated Statements of Income. Net costs recovered from and due to UCB during the years ended December 31, 2022, 2021 and 2020, were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Novartis Pharma AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, we modified the terms of the collaboration. Effective January 1, 2022, in the United States, Novartis no longer collaborates with Amgen, shares Aimovig commercialization costs or is required to pay milestones, and Amgen no longer pays royalties to Novartis on U.S. sales of Aimovig. Novartis continues to hold global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig. Amgen and Novartis share global development expenses, and Novartis pays Amgen double-digit royalties on net sales of the product outside the United States and Japan. Amgen manufactures and supplies Aimovig worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, net costs recovered from Novartis for migraine products were $53&#160;million and were recorded in R&amp;amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2021 and 2020, net costs recovered from Novartis for migraine products were $160 million and $192 million, respectively, and were recorded primarily in SG&amp;amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2021 and 2020, royalties due to Novartis for Aimovig were $116&#160;million and $139 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2022, 2021 and 2020, royalties due from Novartis for Aimovig were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kyowa Kirin Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2021, we closed our collaboration and licensing agreement with KKC to jointly develop and commercialize rocatinlimab, an anti-OX40 fully human monoclonal antibody, worldwide, except in Japan. Rocatinlimab is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we lead the global development, manufacture and commercialization of rocatinlimab, except in Japan. KKC will co-promote rocatinlimab with Amgen in the United States and have opt in rights to co-promote rocatinlimab in various other markets outside the United States, including in Europe and Asia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We made an upfront payment of $400&#160;million to KKC that was recognized in R&amp;amp;D expense in the third quarter of 2021. Amgen and KKC share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by KKC will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850&#160;million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay KKC significant double-digit royalties on global sales, except in Japan. Net costs recovered from and due to KKC were not material during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzE0MTk_09481926-4457-4355-834d-23a5b94fe1f4"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="ia5ad848ccc9e43da99f1f90d2e7be305_D20200102-20200102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzIxMzM_e1e6899a-8538-4813-a12d-d192a33fbc32"
      unitRef="usd">1250000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i0b14ed1cf56b40588d947c7c195dba31_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI2Mzc_a3eca7b4-8ae8-4803-988d-5c1a7b0645dd"
      unitRef="usd">199000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i397d9bb426e14efc97584ac20babda5c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI2NDQ_32a265c7-bca2-477e-9483-38e4723ed307"
      unitRef="usd">220000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i5f6ac0af9e05484e9ff74b916399b3b1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwNzc4MjQ_45396b7b-a2a0-4804-ba27-917f8e4b6c2b"
      unitRef="usd">225000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i61880ef9cc974d208e701a854ba365f7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwNzc4NzY_0b5bb3cf-8c20-4876-8a27-a06b0902c71f"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i48b5fe9d56b04cc0b750c143fe63a442_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI4NDE_9cb367b6-f554-4fc6-be66-eae8777daa5c"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:ProfitAndLossShareOfExpenses
      contextRef="id68f71c0e79f414eb9a0f7738f203cb6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMwNDg_d91a0faf-6f69-46c6-b6b0-be027dd83510"
      unitRef="usd">53000000</amgn:ProfitAndLossShareOfExpenses>
    <amgn:ProfitAndLossShareOfExpenses
      contextRef="i69081709322243d7bbce5ac32eca556d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwNzc5Mjg_21ed5ef6-2a2c-4573-af09-98ccfc7ade2b"
      unitRef="usd">64000000</amgn:ProfitAndLossShareOfExpenses>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="ie1d993f3e9e94186b4be512af2ce0c7d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMzMTY_f5bd307a-be1e-43a7-9f85-bbed8df22ec5"
      unitRef="usd">6000000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="i67856dd9461b467aa245cba68be2243c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMzMjM_68b34d31-a491-45ce-bd41-b3b0a77a268a"
      unitRef="usd">21000000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="i2e07e3056c344299b9420e74a38ebf5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzM1Mjk_b2344063-4b7f-4791-b042-ad35c5784e5a"
      unitRef="usd">47000000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="i24211ce70c914e6bbc5c138c04403948_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzM1MzY_c86ca669-4fbf-4a38-8794-03a56a29d5f2"
      unitRef="usd">61000000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <amgn:DevelopmentCostsDueToCollaborationPartner
      contextRef="i9e2a1eff2f0448ba9a98ef6babf5bf8a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTcxMTY_a4226bc2-6679-4353-a28c-39366cc8fb83"
      unitRef="usd">74000000</amgn:DevelopmentCostsDueToCollaborationPartner>
    <amgn:DevelopmentCostsDueToCollaborationPartner
      contextRef="i550d1116353a45e988ecb42fddd2ea71_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMyOTg1MzQ5MTI4MjU_a83b1530-43d0-4189-9a4c-2e249d3fffc3"
      unitRef="usd">49000000</amgn:DevelopmentCostsDueToCollaborationPartner>
    <amgn:DevelopmentCostsDueToCollaborationPartner
      contextRef="if22b1ca6b4224e409cb1dcbe7350db6f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMyOTg1MzQ5MTI4Mzg_c93ab582-907d-4586-aeda-ab9933acda49"
      unitRef="usd">52000000</amgn:DevelopmentCostsDueToCollaborationPartner>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i0717c9df57574deba2c7ff65d7c5e0b5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTcxMzI_3a46d932-7e4b-4603-98a2-fdb1fa25df04"
      unitRef="usd">60000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="ief89781cb0e44c878c87fc5562d3ca89_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMyOTg1MzQ5MTI5MTI_4672f6c6-7f24-4ead-b8ba-23ffc7aa8e01"
      unitRef="usd">39000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i7ecf58c2e31f47edb3c517d8ed16b4ca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzMyOTg1MzQ5MTI5MjU_d6686812-cd15-480b-8b7b-7984704bdb02"
      unitRef="usd">16000000</us-gaap:RecoveryOfDirectCosts>
    <amgn:ProfitAndLossShareOfExpenses
      contextRef="i3587bfdb4d8c43eca1da9c2f79b27ab9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTcxNDg_66fbd1a3-adca-4e92-a2e2-69662bd74de1"
      unitRef="usd">119000000</amgn:ProfitAndLossShareOfExpenses>
    <amgn:ProfitAndLossShareOfExpenses
      contextRef="i356368409a2d4829afb562f99d59b84a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTc3OTU_8d96816c-8c21-42ce-aed4-b0ccb43fb870"
      unitRef="usd">255000000</amgn:ProfitAndLossShareOfExpenses>
    <amgn:ProfitAndLossShareOfExpenses
      contextRef="i2325b63848cb4d779d17a0fb7049c3ca_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTgxMzg_6c686010-ccd6-42a2-8f7b-63218ff8b5b1"
      unitRef="usd">186000000</amgn:ProfitAndLossShareOfExpenses>
    <amgn:ProfitAndLossShareOfExpenses
      contextRef="iceb527e7ec734f6e818dc3d2674e17fc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTgxNjE_b10ed742-b5cf-4cb8-8774-2bee6a70541c"
      unitRef="usd">115000000</amgn:ProfitAndLossShareOfExpenses>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i077a1aab04d044379338908da753b2fb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzI3NDg3NzkwOTg0OTk_018914f9-af3c-41c7-bfef-102491044b4c"
      unitRef="usd">53000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="iad6cab3b37664965858bb4a82cbba6fc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzU3Mzc_6188b91c-48d1-48e8-88bc-afa1d81947c3"
      unitRef="usd">160000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="if044214b0e1f473786d143875c57f645_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzU3NDQ_b421ede7-f2f7-452a-97c6-9010ef4075ad"
      unitRef="usd">192000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RoyaltyExpense
      contextRef="i0e19f3c8340e4982bd712b7b9ac5d3e7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzU5MzM_8e190470-dda5-4232-9e3b-ffec31e75544"
      unitRef="usd">116000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="id5d8484c53c2490ab0ee83876aa635bf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzU5NDA_74a0c793-215c-435a-b229-4031db19fd90"
      unitRef="usd">139000000</us-gaap:RoyaltyExpense>
    <amgn:UpFrontPayment
      contextRef="i2285c8c0ccac4adbb106cc9bee4bbb49_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzY4MTY_621285c0-2a78-4ca5-8422-90ffbd04c09a"
      unitRef="usd">400000000</amgn:UpFrontPayment>
    <amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments
      contextRef="i612eb99920494bc69ea0f16bc1bccb20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTQvZnJhZzphMDk4ZTMxYWMzNzU0MzMzYmI1ZGYwZmRmNWJhOGI0Yy90ZXh0cmVnaW9uOmEwOThlMzFhYzM3NTQzMzNiYjVkZjBmZGY1YmE4YjRjXzcxNzk_4812d6f0-b8ac-473b-8fe2-fefc351815fd"
      unitRef="usd">850000000</amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI0MTg5MjU1ODI0ODY0_4b804c80-1754-4b54-bf3f-e22505740a67">Investments&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents in the above table excludes bank account cash of $4,970 million and $733 million as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All interest-bearing securities as of December 31, 2022 and 2021, mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2022, 2021 and 2020, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held investments in equity securities with readily determinable fair values (publicly traded securities) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $480 million and $611 million as of December 31, 2022 and 2021, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. For the years ended December 31, 2022, 2021 and 2020, net unrealized gains and losses on publicly traded securities were a loss of $165&#160;million and gains of $161&#160;million and $174&#160;million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2022, 2021 and 2020, were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held investments of $233 million and $262 million in equity securities without readily determinable fair values as of December 31, 2022 and 2021, respectively, which are included in Other noncurrent ass&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ets in the Consolidated Balance Sheets. For the years ended December 31, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2020, gains due to upward adjustments and gains realized upon dispositions of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;these securities were not material. For the year ended December 31, 2021, gains due to upward adjustments were $152&#160;million, and gains realized on the dispositions of these securities were $41&#160;million. For the year ended December 31, 2022, downward adjustments to the carrying values of these securities were $67&#160;million. For the years ended December 31, 2021 and 2020, downward adjustments were not material. Adjustments were based on observable price transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8&#160;billion, of which $2.6&#160;billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;amp;D. Our equity investment in BeiGene is included in Other noncurrent assets in the Consolidated Balance Sheets.&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, our equity investment is accounted for under the equity method of accounting due to our ability to exert significant influence over BeiGene. See Note 1, Summary of significant accounting policies, for factors in concluding our ability to exert significant influence over BeiGene. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sets of BeiGene by approximately $2.4&#160;billion. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity method of accounting requires us to identify and allocate amounts to items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Other (expense) income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from 8 to 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022, 2021 and 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the carrying value of the investment was reduced by our share of BeiGene&#x2019;s net losses of $394&#160;million, $265 million and $229&#160;million, respectively, and amortization of the basis difference of $190&#160;million, $172&#160;million and $109&#160;million, respectively. During the years ended December 31, 2021 and 2020, we increased the carrying value by $50 million and $569&#160;million, respectively, as a result of our purchases of additional shares of BeiGene; we did not purchase additional shares of BeiGene during the year ended December 31, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, during the years ended December 31, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022, 2021 and 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the carrying value increased by $11&#160;million, $265&#160;million and $34&#160;million, respectively, from the impact of other BeiGene ownership transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, our ownership interest in BeiGene was approximately 18.2% and 18.4%, respectively. As of December 31, 2022 and 2021, the carrying value of our investment in BeiGene was $2.2 billion and $2.8 billion, respectively. As of December 31, 2022 and 2021, the fair value of our investment in BeiGene was $4.2 billion and $5.1 billion, respectively. We believe that as of December 31, 2022, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 30, 2023, we relinquished our right to appoint a director to BeiGene&#x2019;s Board of Directors. We no longer have the ability to exert significant influence over BeiGene and therefore will account for our equity investment at fair value, with changes in fair value recorded in earnings starting in the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neumora Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257&#160;million, which is included in Other noncurrent assets in the Consolidated Balance Sheets, in exchange for a $100&#160;million cash payment and $157&#160;million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. During the year ended December 31, 2022, we made an additional $10&#160;million cash investment via participation in Neumora&#x2019;s subsequent financing round. As of December 31, 2022 and 2021, our ownership interest in Neumora was approximately 24.9% and 25.9%, respectively, and the fair value of our investment was $335&#160;million and $220&#160;million, respectively. During the years ended December 31, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 and 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we recognized a net gain of $105&#160;million and a net loss of $37&#160;million, respectively, for the change in fair values in Other (expense) income, net, in the Consolidated Statements of Income. For information on determination of fair values, see Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Limited partnerships&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held limited partnership investments of $249 million and $573 million as of December 31, 2022 and 2021, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. These investments, which are primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2022, unfunded additional commitments to be made for these investments during the next several years were $187&#160;million. For the years ended December 31, 2022, 2021 and 2020, net gains and losses recognized from our limited partnership investments were a net loss of $284&#160;million and net gains of $143&#160;million and $241 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyNTk_9a750b4c-139a-47f9-94e7-70c4f97b742d">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEtMi0xLTEtMTg4OTc0_ff973d4e-7327-4c4c-b3f5-f433aacc6163"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEtNC0xLTEtMTg4OTc0_29d0aac1-0ae6-4e9c-b97c-b29024e3f7f7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEtNi0xLTEtMTg4OTc0_baa9a9a5-699b-4eb2-8cec-eeeca577d57a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEtOC0xLTEtMTg4OTc0_6f1734f5-a430-4da7-9f7c-66ea363a2093"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iba24b9313e764100a95332b21228b55d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzItMi0xLTEtMTg4OTc0_8a75894b-5c54-4e13-aea2-9d4df467b332"
      unitRef="usd">1676000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iba24b9313e764100a95332b21228b55d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzItNC0xLTEtMTg4OTc0_8f1e460f-b1bf-489a-b913-57ef992daeeb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iba24b9313e764100a95332b21228b55d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzItNi0xLTEtMTg4OTc0_02c72d3b-646a-4d30-a8db-c0157117e2e0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba24b9313e764100a95332b21228b55d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzItOC0xLTEtMTg4OTc0_783f6cb2-06aa-4583-8a49-cdd58cdc0737"
      unitRef="usd">1676000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzktMi0xLTEtMTg4OTc0_4104fcfe-c6bd-4b4f-bbdb-1146b7efb925"
      unitRef="usd">2659000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzktNC0xLTEtMTg4OTc0_f907486a-6802-42db-b2ac-0a3b5564ad3c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzktNi0xLTEtMTg4OTc0_ed668e44-4178-4ef3-b08c-6518e8c8b1aa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzktOC0xLTEtMTg4OTc0_6f18d04f-5a6e-4700-a612-4cd64e9688c7"
      unitRef="usd">2659000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i213219e02daf455db4856867bb8edfc1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEwLTItMS0xLTE4ODk3NA_a87f785a-5acf-4334-8af9-95c2281d5c3c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i213219e02daf455db4856867bb8edfc1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEwLTQtMS0xLTE4ODk3NA_0e374a12-c57d-45ed-adf0-edd2afd0ff7d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i213219e02daf455db4856867bb8edfc1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEwLTYtMS0xLTE4ODk3NA_6bc50a4b-4ad2-46fb-be24-c9f03835cc38"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i213219e02daf455db4856867bb8edfc1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzEwLTgtMS0xLTE4ODk3NA_e42560d3-a9a7-4213-a2d8-7ae3d83a17ab"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzExLTItMS0xLTE4ODk3NA_cccbd9a4-7ccb-4ece-adac-f6934b5a0d1a"
      unitRef="usd">4335000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzExLTQtMS0xLTE4ODk3NA_90e88772-993a-429e-b46d-91d1e5646464"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzExLTYtMS0xLTE4ODk3NA_eb26989d-8e6a-433c-b0c5-4a02919675eb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1ZGViZTlkMDlkYTY0NThjOTFiZTZlZjA2NWY3OTU5My90YWJsZXJhbmdlOjVkZWJlOWQwOWRhNjQ1OGM5MWJlNmVmMDY1Zjc5NTkzXzExLTgtMS0xLTE4ODk3NA_1e9ac942-05b2-434c-a75e-c9e932c16b04"
      unitRef="usd">4335000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEtMi0xLTEtMTg4OTc0_f8d41edc-fa40-4029-990a-083bf47e1c31"
      unitRef="usd">47000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEtNC0xLTEtMTg4OTc0_8185d6fc-3dd6-4423-8cbc-9a6ec995fd74"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEtNi0xLTEtMTg4OTc0_136616f1-04ba-4ef5-8002-0b584e0d935b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEtOC0xLTEtMTg4OTc0_bfad817a-7912-48ea-8d16-2d90cc1fb553"
      unitRef="usd">47000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzItMi0xLTEtMTg4OTc0_3e0260cd-2f95-44f9-8bc3-ff6cfac47864"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzItNC0xLTEtMTg4OTc0_f514c066-370a-4933-babe-b7289077e525"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzItNi0xLTEtMTg4OTc0_dd8d3482-8b44-4bd5-918f-d99f5d76d86f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzItOC0xLTEtMTg4OTc0_926fa423-be61-417a-bf5e-9c9417b32fb5"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzktMi0xLTEtMTg4OTc0_a76e83bf-d6da-4b48-982b-c58968f16328"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzktNC0xLTEtMTg4OTc0_73d8b5b3-87db-4f46-9b7c-f542c7b51158"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzktNi0xLTEtMTg4OTc0_bd02f8ad-a907-4c68-a13f-8020816f4bbc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzktOC0xLTEtMTg4OTc0_ca04ebbc-3915-4cd2-b2b7-95a3f51e069b"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEwLTItMS0xLTE4ODk3NA_4acc5cea-6826-405c-bd4f-39bdfb3952e4"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEwLTQtMS0xLTE4ODk3NA_2c0b0d39-120f-4994-844e-1b1d59611977"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEwLTYtMS0xLTE4ODk3NA_35952b3e-6e14-481d-be51-1d2bba6df07f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEwLTgtMS0xLTE4ODk3NA_6ef4eff1-0130-46cb-87d9-6cd4e1e34f36"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEzLTItMS0xLTE4ODk3NA_d2f94f61-d05b-4ba3-9096-1a314846710e"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEzLTQtMS0xLTE4ODk3NA_53849a56-3175-4db0-9979-d81886f91fae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEzLTYtMS0xLTE4ODk3NA_32ebdb3b-864f-470f-b00b-b53877cf2534"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo1YzU0ZjQxNDVlNTk0MWUzOTMxYjExZGZhNTVlNWI5Yy90YWJsZXJhbmdlOjVjNTRmNDE0NWU1OTQxZTM5MzFiMTFkZmE1NWU1YjljXzEzLTgtMS0xLTE4ODk3NA_4e650b67-d19d-499e-a8f7-4c62b6d9e4b9"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyODA_ecc17673-4e6a-4781-b3f7-e5d1bb59f356">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i736ffca3dc1842b084f709c4fe9809b1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzItMi0xLTEtMTg4OTc0_cdf0dd76-08b0-4a0b-9f34-efa8c25e2750"
      unitRef="usd">2659000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie8c6fe835b2741e1b409f5f32f417ec2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzItNC0xLTEtMTg4OTc0_a192722f-619c-4eb1-8849-1679c0ecc3ac"
      unitRef="usd">7256000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i736ffca3dc1842b084f709c4fe9809b1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzMtMi0xLTEtMTg4OTc0_7f8a98da-3519-4c82-a8dc-b779d0ddec02"
      unitRef="usd">1676000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie8c6fe835b2741e1b409f5f32f417ec2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzMtNC0xLTEtMTg4OTc0_d06fd4de-8ac5-4844-8ba7-c83d5265cdb2"
      unitRef="usd">48000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i736ffca3dc1842b084f709c4fe9809b1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzUtMi0xLTEtMTg4OTc0_138cbfc4-558a-4b1b-a6b8-ad18623b20db"
      unitRef="usd">4335000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie8c6fe835b2741e1b409f5f32f417ec2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90YWJsZTo5MWVhMzFlOGZmODQ0YWM3YTU0Njg3Y2VhYTBmYWYzNi90YWJsZXJhbmdlOjkxZWEzMWU4ZmY4NDRhYzdhNTQ2ODdjZWFhMGZhZjM2XzUtNC0xLTEtMTg4OTc0_ff8497e0-c2b4-41a5-a333-67681aa545f7"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:Cash
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ2Nw_22e1aa27-fbeb-413e-a038-37eaea0f6814"
      unitRef="usd">4970000000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ3NA_77950a1c-cd93-4312-bc4a-9332fbaf6357"
      unitRef="usd">733000000</us-gaap:Cash>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2e65698c0cb74a14bfeefadc59b77d5a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE1NjE_55960139-0507-4641-9a36-9e1a8c617792"
      unitRef="usd">480000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifa1b51ec520940e1b313db6b89b5a604_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE1Njg_727d8a5c-ff69-4295-a273-872c3b249905"
      unitRef="usd">611000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE3ODg_94817880-0c76-4680-abfe-a92c108870ad"
      unitRef="usd">-165000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE3OTI_64d9a9dc-0aab-4d31-ba70-e2dee2e444e2"
      unitRef="usd">161000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE3OTk_f6fae730-eb2b-4eea-9c37-28709a800bb7"
      unitRef="usd">174000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i2e65698c0cb74a14bfeefadc59b77d5a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE5NjQ_3487e0f3-8f5e-4fe8-8ca2-6e36f3065630"
      unitRef="usd">233000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ifa1b51ec520940e1b313db6b89b5a604_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE5NzE_8f9de7ce-e471-4e68-9dc2-9be20d4fae5e"
      unitRef="usd">262000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzczMzQ_cc1cee86-83b5-4130-9519-325f622e16b9"
      unitRef="usd">152000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <amgn:EquitySecuritiesRealizedGainLossOnDisposal
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc0MDE_0eea6c9e-aed0-4310-b964-b45b8250e26c"
      unitRef="usd">41000000</amgn:EquitySecuritiesRealizedGainLossOnDisposal>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE0MjkzNjUxMTcwMjAw_31b61470-9fcc-48f0-9a90-500b9b0818a5"
      unitRef="usd">67000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i7bb10a68da424589a4aa8d60cbb4b509_I20200102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3MjE_3e41040a-fe3f-4753-860c-96e4c34babf0"
      unitRef="number">0.205</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NTg_445eaad5-9eb6-447e-80ed-145f6398d90b"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NzE_18f1f147-d6ad-41e2-8db7-39dfe436d1ff"
      unitRef="usd">2600000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i7b1bfaf241854df193ee7bbd2de1cf72_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzM0MzM_b126fc9a-7c41-4a59-b263-146a85aaacf5"
      unitRef="usd">2400000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6db31ce9c8264445a32e5e5e66606b87_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQwODI_e648027d-6202-4e60-a4f8-e48e5a68500e">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i55ba36de5fe841cbac0c77bb92159e4e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQwODg_c278e404-d993-44e0-b199-8097789a9c32">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i742aa0979b534c78a1fbaaeec95b8732_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc0ODk_b9a68351-d90b-488c-a035-2cfed112f6f6"
      unitRef="usd">-394000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQyMzg_54029add-0879-4168-8a0a-720fb46ede6f"
      unitRef="usd">-265000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQyNDU_85115fc1-a3f3-4a34-8225-79d5c31979f2"
      unitRef="usd">-229000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i742aa0979b534c78a1fbaaeec95b8732_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc1MTc_36edad5d-5999-4e8f-a6c6-0606f77c41c5"
      unitRef="usd">190000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQzMDc_0ebce7a9-9d4e-4c36-b95c-1f542c281330"
      unitRef="usd">172000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQzMTQ_47b57c63-2592-42cf-a473-489dd9945332"
      unitRef="usd">109000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ0MTg_896a7182-87d2-4fa3-bd69-d7658a8165bb"
      unitRef="usd">50000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ0MjU_3eadc21e-ef9b-49c6-a38e-e1804e9e14f9"
      unitRef="usd">569000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <amgn:EquityMethodInvestmentChangeInCarryingValueOther
      contextRef="i742aa0979b534c78a1fbaaeec95b8732_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc5NDc_363c1102-9d59-4e96-bc3c-f26143041eaa"
      unitRef="usd">11000000</amgn:EquityMethodInvestmentChangeInCarryingValueOther>
    <amgn:EquityMethodInvestmentChangeInCarryingValueOther
      contextRef="iad5373051e904a50917f5c30bcb3c788_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ2MDA_0e151062-1f30-47f4-816a-77a56e20e902"
      unitRef="usd">265000000</amgn:EquityMethodInvestmentChangeInCarryingValueOther>
    <amgn:EquityMethodInvestmentChangeInCarryingValueOther
      contextRef="i3f14dccc56f4499a945d0c3d181ab54d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ2MDc_c8ef74fb-a150-4ca9-ab08-3297d60891c9"
      unitRef="usd">34000000</amgn:EquityMethodInvestmentChangeInCarryingValueOther>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0d78be49a55146f8aea0014dec6caca1_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ3NjU_0c728d88-d5bf-42a2-8b44-c6649a664d40"
      unitRef="number">0.182</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5f9fd669564646ed90c1f923fcf22115_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ3NzI_f6ef3e48-3a7b-4fbe-b721-5d4a36e76ab0"
      unitRef="number">0.184</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="idd010ea395424e80984bb752c13cc1f4_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ4NzI_d6e553a4-4bac-4b11-8439-2f3d7b671f00"
      unitRef="usd">2200000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ4Nzk_96dd050c-e78c-4663-bfd3-eeb0fb7c700d"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="idd010ea395424e80984bb752c13cc1f4_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ5NzU_0c8c53b9-100c-4ca4-9c8c-b8aaf9628e57"
      unitRef="usd">4200000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzQ5ODI_2d3b082b-9b2f-47a1-8d20-7784eb1f6d57"
      unitRef="usd">5100000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4568cf82cca34f0fa0f23589a150184f_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzUzMzU_f375b483-d6da-45a9-9792-d63efdcf3368"
      unitRef="number">0.259</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i547718310bf54e6390c23b1af397545a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzUzOTk_19c0cfad-b761-44f2-a1e8-3bc868644793"
      unitRef="usd">257000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i5225514442b04c37a257024814d81c9f_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzU1MDI_e558e1cc-a76f-4fff-ac39-fcb5b15b0487"
      unitRef="usd">100000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
      contextRef="i5225514442b04c37a257024814d81c9f_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzU1MjI_e2deb7c1-1d1d-4f77-b74e-a73d7f49ef8c"
      unitRef="usd">157000000</us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="iba147b39322644f2a1a03599c2a39483_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzE0MjkzNjUxMTcxNjE3_1b71cfe5-e738-43ef-afee-dc1074d30a2f"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i48de6ba3d9f0465e9462933890029a6f_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzYwNzU_bc9e9d9a-8ee7-402b-81c2-942292dafaf0"
      unitRef="number">0.249</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i01ad554978334ac88cec9913e0cc5884_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzc5OTc_127600e8-ab8e-42a6-8a5b-24231e3a1702"
      unitRef="number">0.259</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="ia353ede4e8b345c0b2974e1070e1fe2e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzgwNzY_8d92b862-e4b8-40a5-87b0-ed588f365d6c"
      unitRef="usd">335000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i89fb6287a84346aabe16f3d5d6175fe4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzYxMjA_6d715c91-839f-4f4a-942c-0f00b2e969a8"
      unitRef="usd">220000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <amgn:EquityMethodInvestmentChangeInCarryingValue
      contextRef="i4e93272860d242648586e251f19acc41_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzI3NDg3NzkwNzgyNjY_68194625-b552-4b93-aba2-9b58b2d2dd03"
      unitRef="usd">105000000</amgn:EquityMethodInvestmentChangeInCarryingValue>
    <amgn:EquityMethodInvestmentChangeInCarryingValue
      contextRef="i0661190d8893467dbcd83a57c4222013_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzYxOTY_15c79225-77ec-4adc-a5e9-9803ba714340"
      unitRef="usd">-37000000</amgn:EquityMethodInvestmentChangeInCarryingValue>
    <us-gaap:AlternativeInvestment
      contextRef="i0012e716a1434d35ac79af91c9e382bb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzY0NDk_d0a8a17f-62e3-4d11-bc08-86bc679fe33a"
      unitRef="usd">249000000</us-gaap:AlternativeInvestment>
    <us-gaap:AlternativeInvestment
      contextRef="i9c4b1eddbef0462d9ae3e1a3e2db2e8c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzY0NTY_64737de9-abbd-471d-9fcc-7c0d73e1ab73"
      unitRef="usd">573000000</us-gaap:AlternativeInvestment>
    <us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcxMTM_d91c2a6d-e157-4059-9827-b81aa6bcdd27"
      unitRef="usd">187000000</us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="i910730fc1f734dcb85a4bd843a18a53a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyMTk_89f54358-291a-4bfe-b788-7034bd92d61f"
      unitRef="usd">-284000000</amgn:AlternativeInvestmentNetGainLoss>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="i68fa55908a0746a48abeb3eeff056228_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyMjM_b0cc787e-31da-4f0f-b7ea-c0c9bc5ff03c"
      unitRef="usd">143000000</amgn:AlternativeInvestmentNetGainLoss>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="ie659e94abdcd4ea3973f9174b5bd64ce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMTcvZnJhZzo5Nzg1Njg3OGE3NDc0ZmQ0ODFhN2MzZjE3ZjViNDIzZi90ZXh0cmVnaW9uOjk3ODU2ODc4YTc0NzRmZDQ4MWE3YzNmMTdmNWI0MjNmXzcyMzA_9b640521-4669-407a-9742-9c996bf47db9"
      unitRef="usd">241000000</amgn:AlternativeInvestmentNetGainLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90ZXh0cmVnaW9uOjUzNjUyNWQ3MGY2NjQyN2RiYjdiNDQ5NGRhNGMxOWZlXzgx_9da5b293-e718-4fd7-8b68-19c4bc289121">Inventories&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90ZXh0cmVnaW9uOjUzNjUyNWQ3MGY2NjQyN2RiYjdiNDQ5NGRhNGMxOWZlXzc1_14d09584-dd53-48d2-99cf-a5aa81518b1d">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzItMS0xLTEtMTg4OTc0_bdba050b-022a-4206-af45-c2d4ffb5f34c"
      unitRef="usd">828000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzItMy0xLTEtMTg4OTc0_22c83960-03b1-4e54-9d34-9f85eeb57f74"
      unitRef="usd">647000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzMtMS0xLTEtMTg4OTc0_48767ecc-7f71-4bfd-9670-580441636746"
      unitRef="usd">3098000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzMtMy0xLTEtMTg4OTc0_d32b4045-3434-4e1c-af91-39868a7a98a4"
      unitRef="usd">2367000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzQtMS0xLTEtMTg4OTc0_21037099-3e35-4726-9fcb-9bcecffbc708"
      unitRef="usd">1004000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzQtMy0xLTEtMTg4OTc0_e73f82cb-8b37-4009-b1c9-cce19abded06"
      unitRef="usd">1072000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzUtMS0xLTEtMTg4OTc0_eadd1930-5163-4f49-af03-c961266462d8"
      unitRef="usd">4930000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjAvZnJhZzo1MzY1MjVkNzBmNjY0MjdkYmI3YjQ0OTRkYTRjMTlmZS90YWJsZTo0NWVjNTE2NjYyMTQ0ZTI5YjVhYzYwNTMwZjhlYmIxMi90YWJsZXJhbmdlOjQ1ZWM1MTY2NjIxNDRlMjliNWFjNjA1MzBmOGViYjEyXzUtMy0xLTEtMTg4OTc0_99400c1a-c8d3-4542-8626-e116d5b75457"
      unitRef="usd">4086000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzQ0Nw_2f653bbd-001c-449a-9cdb-c527bc3526cb">Property, plant and equipment&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consisted of the following (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful&#160;life&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2022, 2021 and 2020, we recognized depreciation and amortization expense associated with our property, plant and equipment of $661 million, $644 million and $640 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Geographic information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzQ0NQ_bd16e012-7f01-411b-ac70-cee1bd4750dd">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consisted of the following (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful&#160;life&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzItMy0xLTEtMTg4OTc0_14b63e5b-e3d2-41ce-a67e-e4fab6647290"
      unitRef="usd">292000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzItNS0xLTEtMTg4OTc0_c5d0c91d-676b-49de-9fd7-0653fbbb9466"
      unitRef="usd">279000000</us-gaap:Land>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3bf57870a9f4462796cf71eb1204b562_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzMtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YjM4NTE1YWVhMTQ5NDdhOWE5NGZmZmQ1MjEzYjk2YzNfNA_4dffc267-b5f2-44fa-ab26-cade8707d9b4">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1cc1644aa9a14b298eb0dda7bc0c7d85_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzMtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YjM4NTE1YWVhMTQ5NDdhOWE5NGZmZmQ1MjEzYjk2YzNfNw_648e637b-593c-458b-9b32-98c83ddc3cc0">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzMtMy0xLTEtMTg4OTc0_88c9d8c4-c875-4609-ad2c-5ea882506202"
      unitRef="usd">4201000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzMtNS0xLTEtMTg4OTc0_82ca5ae2-39fe-4a2c-8e44-c22fdf590fca"
      unitRef="usd">4028000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0e7adefe057e4125a56fb1a162b59975_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzQtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YjkwNTBhZmJlMzAyNDhkZDgyZjhkZDI2ODZhOTEyODBfNA_61bb1a76-4b62-4223-b514-90b07d2edd11">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i13e514d61eb942da9c90cf58cce3e55c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzQtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YjkwNTBhZmJlMzAyNDhkZDgyZjhkZDI2ODZhOTEyODBfNw_93fd6c65-de2f-4f92-968d-a97e169dc298">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzQtMy0xLTEtMTg4OTc0_8f481cfe-4738-42eb-811e-6e2ac0b4c17c"
      unitRef="usd">3105000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzQtNS0xLTEtMTg4OTc0_fca64b95-356f-4141-9d4e-85608f67b006"
      unitRef="usd">3080000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5b15e7cf27494cc1bd340423025d53ed_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzUtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246OWM4YTYyZGQzNTUwNDBjZGJlYmFkZjNkMmJjMWI2ZjJfNA_c2dbfd74-b874-40ca-a138-b5b6da868afb">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic6ca69fcdd8a42a6b7a9ac5979fa620c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzUtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246OWM4YTYyZGQzNTUwNDBjZGJlYmFkZjNkMmJjMWI2ZjJfNw_b2b51a1e-8157-4949-9bad-278724d26a1f">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <amgn:LaboratoryEquipment
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzUtMy0xLTEtMTg4OTc0_90cd3c45-e3cc-4cca-b967-f861482a764c"
      unitRef="usd">1277000000</amgn:LaboratoryEquipment>
    <amgn:LaboratoryEquipment
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzUtNS0xLTEtMTg4OTc0_07d159ad-6786-4fbf-86fb-4f9e7c8dd2e1"
      unitRef="usd">1193000000</amgn:LaboratoryEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5b79fbf871a84da7a223e2f58e7878f7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzYtMS0xLTEtMTg4OTc0_44fcbc47-50aa-44c0-88b3-cda61130ccc5">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <amgn:FixedEquipment
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzYtMy0xLTEtMTg4OTc0_4cf63e24-06ba-4e47-a421-6381cb917c5d"
      unitRef="usd">2478000000</amgn:FixedEquipment>
    <amgn:FixedEquipment
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzYtNS0xLTEtMTg4OTc0_4f0196bc-081f-40c2-8d00-f04eccf4a39e"
      unitRef="usd">2402000000</amgn:FixedEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i604a564a01bb466c93664f563428196a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzctMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YWIxMmM5OWQyNDA3NDdkNmI3NWNkNjUyZWRkYzM3ODZfNA_ea176e6b-9d4f-45f7-af5d-4f1c0c273cce">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibea9550cddf5409f89486fce84d29e92_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzctMS0xLTEtMTg4OTc0L3RleHRyZWdpb246YWIxMmM5OWQyNDA3NDdkNmI3NWNkNjUyZWRkYzM3ODZfNw_2aef6e1e-ff27-4ec5-9f6c-0d909cfc4518">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzctMy0xLTEtMTg4OTc0_1b691be8-9f37-4bc0-b8e0-2be59819fe16"
      unitRef="usd">1215000000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzctNS0xLTEtMTg4OTc0_6de18086-f5dd-4b43-b857-0c2775f13fa3"
      unitRef="usd">1151000000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibc07e2aaa249436e81ba3ffc71d13fb1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzgtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246ZTc3YjAyYzBjNzlmNDk4NGEyMjUxMjMxNzgzODMzYmFfNA_f6fab78c-30c5-4442-9870-d0059718f84b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib9b7a507438942a2aaf4c1748fe959cd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzgtMS0xLTEtMTg4OTc0L3RleHRyZWdpb246ZTc3YjAyYzBjNzlmNDk4NGEyMjUxMjMxNzgzODMzYmFfNw_da0056b0-7aee-48be-901d-34da9ef17799">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzgtMy0xLTEtMTg4OTc0_431d16b3-1392-4066-9a4f-ac007a1d11fa"
      unitRef="usd">929000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzgtNS0xLTEtMTg4OTc0_b10d32d4-d174-4e3c-a993-cbc4b65062be"
      unitRef="usd">862000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:ConstructionInProgressGross
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzktMy0xLTEtMTg4OTc0_90cff908-f55c-4289-981e-cfee4c36764d"
      unitRef="usd">1213000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzktNS0xLTEtMTg4OTc0_564fad86-d289-4a3f-9bf6-449519a06e89"
      unitRef="usd">987000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzEwLTMtMS0xLTE4ODk3NA_e2483b87-028a-4194-bf98-8fa47de43ed4"
      unitRef="usd">14710000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzEwLTUtMS0xLTE4ODk3NA_945132fd-7d34-4867-8a8a-8013c53043dd"
      unitRef="usd">13982000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzExLTMtMS0xLTE4ODk3NA_1c6768c0-20fe-4b01-8dea-55b13db0b623"
      unitRef="usd">9283000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzExLTUtMS0xLTE4ODk3NA_14c434f5-ac7e-4c86-9303-f199d04a5914"
      unitRef="usd">8798000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzEyLTMtMS0xLTE4ODk3NA_82c9152f-822d-4d31-8bd3-5f032d1eb893"
      unitRef="usd">5427000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTpjM2Y1NWUyY2RkODM0YjMyYTIzY2RjYjZlMjY5NGE4My90YWJsZXJhbmdlOmMzZjU1ZTJjZGQ4MzRiMzJhMjNjZGNiNmUyNjk0YTgzXzEyLTUtMS0xLTE4ODk3NA_7bf3b7e8-1597-4789-ad51-b4d00bfeed85"
      unitRef="usd">5184000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzI0NA_d20efd57-93d0-4ad4-a476-19a1382dcd0a"
      unitRef="usd">661000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzI0OA_da36e69a-14fe-4f12-8a97-95a254f6b4a8"
      unitRef="usd">644000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzI1NQ_e1e6e56a-1de0-4570-8506-8c6e61e4d7d3"
      unitRef="usd">640000000</us-gaap:Depreciation>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90ZXh0cmVnaW9uOjA5NzY0ZmUzNmYwYTQ4N2E5YTAzNzBjMDIyNjIwZWJhXzQzMQ_a8a19aad-c651-4ac8-84ff-62c7931ece79">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iff279f49fa7b4713b3a0452ae164a793_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzItMS0xLTEtMTg4OTc0_46c4091c-e424-49d2-bd26-e81c6ddd6a2d"
      unitRef="usd">3154000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i92a78eea27ce4a75b4576bdbeb318deb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzItMy0xLTEtMTg4OTc0_26617782-0977-4b61-81b3-4095de81f852"
      unitRef="usd">2801000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i16e4fdfd9b274a029d3f820b2f8ec447_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzMtMS0xLTEtMTg4OTc0_51a7686a-25b0-4a06-8bec-9c6e7099c632"
      unitRef="usd">1247000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i05b95da36271405f854a5fa63ee0cc73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzMtMy0xLTEtMTg4OTc0_a84b9c66-90f1-46e3-9ead-7edccf64604c"
      unitRef="usd">1311000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i754ee2be39904612a8009537c4174025_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzQtMS0xLTEtMTg4OTc0_fa3a90b7-76d2-4152-8d33-7a74d63c9497"
      unitRef="usd">1026000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if3acd696e90a462fa8d84de0529809d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzQtMy0xLTEtMTg4OTc0_87c256ff-8914-47c8-b06c-1dc00a52e437"
      unitRef="usd">1072000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzUtMS0xLTEtMTg4OTc0_3211b5a6-b741-419c-aee6-a777cdd573b4"
      unitRef="usd">5427000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjMvZnJhZzowOTc2NGZlMzZmMGE0ODdhOWEwMzcwYzAyMjYyMGViYS90YWJsZTphNmIxYzQzOTUyOTM0MjMzYjJjMmEyYjdkMGNlYjlmYy90YWJsZXJhbmdlOmE2YjFjNDM5NTI5MzQyMzNiMmMyYTJiN2QwY2ViOWZjXzUtMy0xLTEtMTg4OTc0_4ff2b4fa-6a58-490b-9327-f9e93214f1e8"
      unitRef="usd">5184000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5ODY_9f9e6a3a-f0bd-4ff3-a157-aeb886969658">Goodwill and other intangible assets&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes to goodwill resulting from acquisitions and divestitures, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For 2022, the changes to goodwill consist of goodwill resulting from the acquisition of ChemoCentryx, changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;amp;D technology rights pertains to technologies used in R&amp;amp;D that have alternative future uses. Developed-product-technology rights include assets acquired with the ChemoCentryx acquisition. IPR&amp;amp;D, R&amp;amp;D technology rights and licensing rights includes assets acquired with the Teneobio acquisition. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D consists of R&amp;amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&amp;amp;D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;amp;D projects may vary from their estimated fair values. We review IPR&amp;amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.&lt;/span&gt;&lt;/div&gt;During the years ended December 31, 2022, 2021 and 2020, we recognized amortization associated with our finite-lived intangible assets of $2.6 billion, $2.6 billion and $2.8 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $2.8 billion, $2.7 billion, $2.5 billion, $2.1 billion and $2.1 billion, respectively.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5Njc_52057781-fb92-4273-ab69-dc9d1d648b45">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes to goodwill resulting from acquisitions and divestitures, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For 2022, the changes to goodwill consist of goodwill resulting from the acquisition of ChemoCentryx, changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzItMS0xLTEtMTg4OTc0_ee9c29e4-94ff-48d6-ab1c-5f8d2c2d7b34"
      unitRef="usd">14890000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzItMy0xLTEtMTg4OTc0_64af3b90-004c-4e32-b272-1d3c7384fd93"
      unitRef="usd">14689000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzMtMS0xLTEtMTg4OTc0_f6fc4ca3-0c15-4611-89e9-c2a7533da6e3"
      unitRef="usd">651000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzMtMy0xLTEtMTg4OTc0_e7b26a28-7755-4e44-afca-c399a4c31259"
      unitRef="usd">251000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzQtMS0xLTEtMTg4OTc0_c60cdbae-b0f3-40e6-9c67-fc2a601c7da6"
      unitRef="usd">-12000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzQtMy0xLTEtMTg4OTc0_58bacae6-8350-41a5-80b1-8d3e9602d967"
      unitRef="usd">-50000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzUtMS0xLTEtMTg4OTc0_7d48e975-f157-4c4f-a7d5-68ec411c6f6c"
      unitRef="usd">15529000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo5MWQxOWExYWZkZWU0ZWU3YWE4NDk0MWQ4NTYxZmExNC90YWJsZXJhbmdlOjkxZDE5YTFhZmRlZTRlZTdhYTg0OTQxZDg1NjFmYTE0XzUtMy0xLTEtMTg4OTc0_374c68f1-8fd1-4a6b-9fe9-a267f8e4f7bb"
      unitRef="usd">14890000000</us-gaap:Goodwill>
    <amgn:ScheduleOfIntangibleAssetsTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5NzM_dfaf32c6-6084-4a83-9906-1012e192ce76">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i07936c549f844514b26e4db0ad2a21fc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtMS0xLTEtMTg4OTc0_59ecf769-a738-4570-9b21-4259dfb5366d"
      unitRef="usd">29028000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i07936c549f844514b26e4db0ad2a21fc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtMy0xLTEtMTg4OTc0_134a1180-7063-434d-a8eb-f284645fb11a"
      unitRef="usd">15045000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i07936c549f844514b26e4db0ad2a21fc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtNS0xLTEtMTg4OTc0_1b6d7f4a-fb9a-4195-bdf9-4379b5b7dffc"
      unitRef="usd">13983000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5e5aca0dc80d4c96b4e71d7909172c62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtNy0xLTEtMTg4OTc0_ce479969-f787-4375-a12c-b631754e3cdb"
      unitRef="usd">25561000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5e5aca0dc80d4c96b4e71d7909172c62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtOS0xLTEtMTg4OTc0_7357db1e-e53b-46dc-9cb5-617af4240731"
      unitRef="usd">12769000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5e5aca0dc80d4c96b4e71d7909172c62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzQtMTEtMS0xLTE4ODk3NA_b183c9d7-5f69-481f-b147-85c9ceba94d7"
      unitRef="usd">12792000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia3d3bede71c84c74a83e0be4081f5b18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtMS0xLTEtMTg4OTc0_3f3ee585-5c5e-4179-93c8-45c268c9f579"
      unitRef="usd">3864000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia3d3bede71c84c74a83e0be4081f5b18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtMy0xLTEtMTg4OTc0_957cd6e8-e7b3-4533-ac6e-e38e6bd99a24"
      unitRef="usd">3123000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia3d3bede71c84c74a83e0be4081f5b18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtNS0xLTEtMTg4OTc0_908e371b-4b68-4c82-97b5-519e623b8fb8"
      unitRef="usd">741000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4e0adc328161459b89b9bc11ba4f1e97_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtNy0xLTEtMTg4OTc0_72d1c112-7754-4c39-a13d-98121933a907"
      unitRef="usd">3807000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4e0adc328161459b89b9bc11ba4f1e97_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtOS0xLTEtMTg4OTc0_956d04ab-9245-43db-b06a-0bcc0e9ac1b4"
      unitRef="usd">2973000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4e0adc328161459b89b9bc11ba4f1e97_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzUtMTEtMS0xLTE4ODk3NA_1ba7aa82-fd2b-4eb7-ae4e-8e845cb56ad2"
      unitRef="usd">834000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i417d0ad23573423c9d2dd34c69b3960f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtMS0xLTEtMTg4OTc0_cd73d8b9-37f4-4264-8f0a-1c29b94ccf05"
      unitRef="usd">1326000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i417d0ad23573423c9d2dd34c69b3960f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtMy0xLTEtMTg4OTc0_f2f20405-68cb-42f4-8613-417bb7b96d4b"
      unitRef="usd">1167000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i417d0ad23573423c9d2dd34c69b3960f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtNS0xLTEtMTg4OTc0_5a511235-815c-482d-83cf-48415f80d938"
      unitRef="usd">159000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9b45a76886284dc78290674a5dee3ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtNy0xLTEtMTg4OTc0_7604da49-ac5d-40f0-bf69-040e82072d09"
      unitRef="usd">1354000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9b45a76886284dc78290674a5dee3ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtOS0xLTEtMTg4OTc0_6ca182c2-3284-42b9-bfda-aae67a1de769"
      unitRef="usd">1112000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9b45a76886284dc78290674a5dee3ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzYtMTEtMS0xLTE4ODk3NA_27a3b082-3cfe-4c2d-b88d-6d4bc3fe57ab"
      unitRef="usd">242000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0ed7681dee014e09849b2353f1235d03_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctMS0xLTEtMTg4OTc0_702b6a0f-de88-4a6e-8b01-8d35d91b19ae"
      unitRef="usd">1378000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0ed7681dee014e09849b2353f1235d03_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctMy0xLTEtMTg4OTc0_382bbadb-0493-4de6-877b-62120b1b10a4"
      unitRef="usd">1190000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0ed7681dee014e09849b2353f1235d03_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctNS0xLTEtMTg4OTc0_31f34cbd-eb59-4f6f-b1e6-137e88b98968"
      unitRef="usd">188000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ided57f427b2f48c68511bb6a663847ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctNy0xLTEtMTg4OTc0_009144aa-2cde-41af-b0af-18dd4b0c959d"
      unitRef="usd">1377000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ided57f427b2f48c68511bb6a663847ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctOS0xLTEtMTg4OTc0_7a316d65-2686-4d21-9f47-141f66e397f4"
      unitRef="usd">1133000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ided57f427b2f48c68511bb6a663847ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzctMTEtMS0xLTE4ODk3NA_1900574a-2678-4d4d-a8d5-c062401f4628"
      unitRef="usd">244000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtMS0xLTEtMTg4OTc0_684b4eb9-5217-432f-8b88-07c5222da88a"
      unitRef="usd">35596000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtMy0xLTEtMTg4OTc0_7decce0e-5669-4288-8e65-144fad97617e"
      unitRef="usd">20525000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtNS0xLTEtMTg4OTc0_285497b4-6332-4fb9-b4c9-fe0e788fcb11"
      unitRef="usd">15071000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtNy0xLTEtMTg4OTc0_beafc147-1fb8-401e-a86f-c5b3447a0e66"
      unitRef="usd">32099000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtOS0xLTEtMTg4OTc0_7735f19d-7343-4e45-b0c8-810c7e167584"
      unitRef="usd">17987000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzgtMTEtMS0xLTE4ODk3NA_fe3f5875-4684-475d-8f3d-3ee4433c08e3"
      unitRef="usd">14112000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i509e8b79cd3447cdbd36db889a772260_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzEwLTEtMS0xLTE4ODk3NA_13947819-b2e5-4e18-8963-52e6e3d5a38a"
      unitRef="usd">1009000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i509e8b79cd3447cdbd36db889a772260_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzEwLTUtMS0xLTE4ODk3NA_3e7760a5-6553-4f1d-a0b6-d35d21144c03"
      unitRef="usd">1009000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib88e57fb4e5e4aea802f1aeacd840bee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzEwLTctMS0xLTE4ODk3NA_ff91e167-1029-4cb8-9914-77b025f2a3ca"
      unitRef="usd">1070000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib88e57fb4e5e4aea802f1aeacd840bee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzEwLTExLTEtMS0xODg5NzQ_4b0af15b-adda-45a7-a7ff-d010dd7eedba"
      unitRef="usd">1070000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <amgn:IdentifiableIntangibleAssetsGross
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTEtMS0xLTE4ODk3NA_28cf6396-0348-448f-b774-6f81dc0926cc"
      unitRef="usd">36605000000</amgn:IdentifiableIntangibleAssetsGross>
    <amgn:IdentifiableIntangibleAssetsAccumulatedAmortization
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTMtMS0xLTE4ODk3NA_d475fa5c-148e-4698-84f2-bcc32df41eb2"
      unitRef="usd">20525000000</amgn:IdentifiableIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTUtMS0xLTE4ODk3NA_128fbde2-88c5-4b36-a758-27a917fdea14"
      unitRef="usd">16080000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <amgn:IdentifiableIntangibleAssetsGross
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTctMS0xLTE4ODk3NA_a91f6ba2-898e-4f3a-8413-800ade1e09ec"
      unitRef="usd">33169000000</amgn:IdentifiableIntangibleAssetsGross>
    <amgn:IdentifiableIntangibleAssetsAccumulatedAmortization
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTktMS0xLTE4ODk3NA_da33081c-149c-41a9-95c4-75c46c09aabc"
      unitRef="usd">17987000000</amgn:IdentifiableIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90YWJsZTo1ZDk4YTEwM2RkYWQ0YzUzYjg1MGIyMDA5ZWVlNjY2ZS90YWJsZXJhbmdlOjVkOThhMTAzZGRhZDRjNTNiODUwYjIwMDllZWU2NjZlXzExLTExLTEtMS0xODg5NzQ_a8ee4d21-faf7-4634-ba24-b8564cac0c78"
      unitRef="usd">15182000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI2NTI_ed6db2a0-32ad-49f0-b00f-afafb8495c7c"
      unitRef="usd">2600000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI2NTY_5a471cc2-6172-4414-87f8-56d2d69e31a0"
      unitRef="usd">2600000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI2NjM_3dbe6ff8-6ee9-49cf-a773-13292249b516"
      unitRef="usd">2800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5Mjk_5e0c1586-ecbf-4f27-8380-d188ceb0fa8e"
      unitRef="usd">2800000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5MzM_a372a51c-d41e-4ad3-9726-9099b6e3bfb4"
      unitRef="usd">2700000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5Mzc_8587acb3-d008-4c84-858c-cb4e9a675cfd"
      unitRef="usd">2500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5NDE_0ff9421e-49e8-4353-99a7-2121fd6c91eb"
      unitRef="usd">2100000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjYvZnJhZzo5MmU5YjAxNTMwZWY0OWM4YWI0NThhNGZmNWU4MjAzMC90ZXh0cmVnaW9uOjkyZTliMDE1MzBlZjQ5YzhhYjQ1OGE0ZmY1ZTgyMDMwXzI5NDg_3ab5c5f4-e15b-4165-9bb2-88f9de0e67b7"
      unitRef="usd">2100000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzE4MjE_470f8176-12da-4a4c-8292-983b85020121">Leases&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease certain facilities and equipment related primarily to R&amp;amp;D, administrative and commercial activities. Leases with terms of 12 months or less are expensed as incurred and are not recorded in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most leases include one or more options to renew, with renewal terms that may extend the lease term up to seven years. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&amp;amp;D and administrative space.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_359201fb-5c99-405a-ab38-b09b1a0810df"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_e337db26-bca6-43a8-9a70-6927970d6b3a"&gt;Other noncurrent assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_8eb856b2-2130-4703-a4b4-acc8ce46190d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_cfef6f7b-b5d4-400a-8a9d-e47d21f5486b"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_8acdce6f-01bc-4f81-be80-17993b14c4ca"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_f528949b-9261-49f0-9348-a8f3a32624b2"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net lease costs were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2022, were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes future rental commitments for abandoned leases of $90&#160;million. We expect to receive total future rental income of $76&#160;million related to noncancelable subleases for abandoned facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease terms and weighted-average discount rates were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and noncash information related to our leases was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the total undiscounted future lease payments for leases that have not yet commenced were not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzM4NQ_1e7688ad-b9f9-4e19-8087-1deb14b32c5e">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzE4MjM_face2242-80af-493a-b82d-8bfa9137388a">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_359201fb-5c99-405a-ab38-b09b1a0810df"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMC0xLTEtMTg4OTc0_e337db26-bca6-43a8-9a70-6927970d6b3a"&gt;Other noncurrent assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_8eb856b2-2130-4703-a4b4-acc8ce46190d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMC0xLTEtMTg4OTc0_cfef6f7b-b5d4-400a-8a9d-e47d21f5486b"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_8acdce6f-01bc-4f81-be80-17993b14c4ca"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMC0xLTEtMTg4OTc0_f528949b-9261-49f0-9348-a8f3a32624b2"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net lease costs were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease terms and weighted-average discount rates were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and noncash information related to our leases was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtMi0xLTEtMTg4OTc0_5688de39-a8c1-4fbf-8465-f23e50dc12a0"
      unitRef="usd">579000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzMtNC0xLTEtMTg4OTc0_78a07c84-9e97-440d-b88c-3d2d78c45153"
      unitRef="usd">566000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtMi0xLTEtMTg4OTc0_5169741c-d1c9-4465-bffe-cbc6de172863"
      unitRef="usd">156000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzUtNC0xLTEtMTg4OTc0_1d08aa3b-7ae8-4141-bf23-b6eb619f7a23"
      unitRef="usd">145000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtMi0xLTEtMTg4OTc0_c13257c6-4e6b-4735-9a91-bed927278a54"
      unitRef="usd">539000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzYtNC0xLTEtMTg4OTc0_b62c2106-d5b6-4f45-88d5-959d5463ce5b"
      unitRef="usd">525000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzctMi0xLTEtMTg4OTc0_d6b9479c-11f7-49b2-b264-eaec0a6754b4"
      unitRef="usd">695000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiY2FjYWIxMjkxZjE0ODFjYmI5NjcyN2Y0Nzg1MDM1Yy90YWJsZXJhbmdlOmJjYWNhYjEyOTFmMTQ4MWNiYjk2NzI3ZjQ3ODUwMzVjXzctNC0xLTEtMTg4OTc0_f18b4d80-0945-49d2-9834-8d1dee78ca77"
      unitRef="usd">670000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzItMi0xLTEtMTg4OTc0_dd3c7e65-4a4d-4813-af0f-6a0943589dc1"
      unitRef="usd">218000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzItNC0xLTEtMTg4OTc0_16f27dd6-2a1a-4843-ae2d-716991742b85"
      unitRef="usd">237000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzItNi0xLTEtMTg4OTc0_43f10eb1-c880-41fb-8cde-454b142dd280"
      unitRef="usd">223000000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzktMi0xLTEtMTg4OTc0_d0d2a840-974e-4a21-87c2-400415a99be6"
      unitRef="usd">32000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzktNC0xLTEtMTg4OTc0_b0b4ac00-16c5-4056-8aad-223c2b58f2ed"
      unitRef="usd">38000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzktNi0xLTEtMTg4OTc0_71b824a5-6d93-44d5-842f-2d21e7fa346f"
      unitRef="usd">34000000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzEwLTItMS0xLTE4ODk3NA_165a2da0-1168-4138-89da-8db8f05a34ba"
      unitRef="usd">186000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzEwLTQtMS0xLTE4ODk3NA_39b7c082-b807-41c3-bc11-90adf7252b44"
      unitRef="usd">199000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo4MDZkZjRjZTY1Yjk0MjcyYjE4MzU2ZWE5NTlmMjUyMS90YWJsZXJhbmdlOjgwNmRmNGNlNjViOTQyNzJiMTgzNTZlYTk1OWYyNTIxXzEwLTYtMS0xLTE4ODk3NA_37f65b16-c96c-4dec-ac6d-647c76cae491"
      unitRef="usd">189000000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzE4MjQ_32c5dd8c-2c3c-4a17-a3d4-83e8453734df">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2022, were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes future rental commitments for abandoned leases of $90&#160;million. We expect to receive total future rental income of $76&#160;million related to noncancelable subleases for abandoned facilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzEtMi0xLTEtMTg4OTc0_14b504e4-be65-4a94-a411-0baf339d9444"
      unitRef="usd">172000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzItMi0xLTEtMTg4OTc0_2c6d9d81-fe72-41cf-b62a-0c8e814aa131"
      unitRef="usd">109000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzMtMi0xLTEtMTg4OTc0_e652224a-86b5-466f-84de-f1f4d8ec5f66"
      unitRef="usd">80000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzQtMi0xLTEtMTg4OTc0_2ad77bd1-308a-4267-a462-07b17510818d"
      unitRef="usd">70000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzUtMi0xLTEtMTg4OTc0_7206a561-d874-47f0-85d1-270c3818f0df"
      unitRef="usd">64000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzYtMi0xLTEtMTg4OTc0_5499071f-8274-4443-a2d8-f32d2e0e101a"
      unitRef="usd">286000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzctMi0xLTEtMTg4OTc0_cc91e9db-fb9e-4353-9752-2a08d9c70a12"
      unitRef="usd">781000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzgtMi0xLTEtMTg4OTc0_0d1c4b72-ce59-4c5a-888e-0d331cfd6892"
      unitRef="usd">86000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTpiZTE2NzhkYzQ3YTM0ZjhlYjliZWU1NzI5ZjdmMjAxNi90YWJsZXJhbmdlOmJlMTY3OGRjNDdhMzRmOGViOWJlZTU3MjlmN2YyMDE2XzktMi0xLTEtMTg4OTc0_421924ac-1b83-45f3-afab-28ec0e393eeb"
      unitRef="usd">695000000</us-gaap:OperatingLeaseLiability>
    <amgn:LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases
      contextRef="ia3d84b8dde9b4ef58d9a8a439a7b1fed_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzEzMzI_98b2d9aa-4426-4cc1-a591-e8811fbe0256"
      unitRef="usd">90000000</amgn:LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="ia3d84b8dde9b4ef58d9a8a439a7b1fed_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90ZXh0cmVnaW9uOjI0NWMwMjllOTkzNjQwYmViNzY5YTMzOTZjNzhhYWQ0XzEzODc_f14b90a9-145a-4829-8007-3be3b5404d58"
      unitRef="usd">76000000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo2ZjM1NTc2NWRkODI0ZWYyYjQ2OGIyMDRlMjY4ZTUzNi90YWJsZXJhbmdlOjZmMzU1NzY1ZGQ4MjRlZjJiNDY4YjIwNGUyNjhlNTM2XzItNC0xLTEtMTg4OTc0_10c64acd-102d-4681-8813-409244e6ae28">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo2ZjM1NTc2NWRkODI0ZWYyYjQ2OGIyMDRlMjY4ZTUzNi90YWJsZXJhbmdlOjZmMzU1NzY1ZGQ4MjRlZjJiNDY4YjIwNGUyNjhlNTM2XzItNi0xLTEtMTg4OTc0_39ade86f-9724-4985-b804-0c530b24d97b">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo2ZjM1NTc2NWRkODI0ZWYyYjQ2OGIyMDRlMjY4ZTUzNi90YWJsZXJhbmdlOjZmMzU1NzY1ZGQ4MjRlZjJiNDY4YjIwNGUyNjhlNTM2XzMtNC0xLTEtMTg4OTc0_f480687d-2e3b-4deb-bae7-1cb3801382b8"
      unitRef="number">0.027</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTo2ZjM1NTc2NWRkODI0ZWYyYjQ2OGIyMDRlMjY4ZTUzNi90YWJsZXJhbmdlOjZmMzU1NzY1ZGQ4MjRlZjJiNDY4YjIwNGUyNjhlNTM2XzMtNi0xLTEtMTg4OTc0_6802306a-fbd6-4544-ba24-63076f63edd7"
      unitRef="number">0.025</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzMtNC0xLTEtMTg4OTc0_63120ca3-48ae-454d-8b39-72759e0e21c7"
      unitRef="usd">171000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzMtNi0xLTEtMTg4OTc0_5d3be5c3-43d2-45d5-8946-0520114e396f"
      unitRef="usd">190000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzMtOC0xLTEtMTg4OTc0_d7e83567-ec86-449a-8c76-5247054cd8b2"
      unitRef="usd">177000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzctNC0xLTEtMTg4OTc0_69be2a9d-8d69-4dc1-8425-7ada80fa5bc5"
      unitRef="usd">191000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzctNi0xLTEtMTg4OTc0_188ef07b-380d-4807-937c-6fac69fda926"
      unitRef="usd">340000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMjkvZnJhZzoyNDVjMDI5ZTk5MzY0MGJlYjc2OWEzMzk2Yzc4YWFkNC90YWJsZTplYmVlMDU3YzEwMGE0YzM3YTNmYjc2NDRjZGQ1NmQyNS90YWJsZXJhbmdlOmViZWUwNTdjMTAwYTRjMzdhM2ZiNzY0NGNkZDU2ZDI1XzctOC0xLTEtMTg4OTc0_8e6883d6-770b-4a7d-8589-5ac453170c8f"
      unitRef="usd">101000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <amgn:AccruedLiabilitiesDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90ZXh0cmVnaW9uOjY2MjhjYTAzNTg4ZjQ0YWJhOWM4N2IwYTA1YTA3NDc4XzE1NQ_d8463470-989d-4c36-ad97-8974285e9542">Other current assets and accrued liabilities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate partner receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:AccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90ZXh0cmVnaW9uOjY2MjhjYTAzNTg4ZjQ0YWJhOWM4N2IwYTA1YTA3NDc4XzE1MQ_c2fd68b8-6553-411a-bf3e-52aa691c1c11">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate partner receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzItMS0xLTEtMTg4OTc0_58e5a2ff-82e5-4cb1-a672-7fa263e9178d"
      unitRef="usd">1204000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzItMy0xLTEtMTg4OTc0_87772ff3-3fcc-48d1-95a8-9663c7ef0a7f"
      unitRef="usd">1223000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzMtMS0xLTEtMTg4OTc0_8926f157-7579-47d4-8143-47e948e4ce73"
      unitRef="usd">700000000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzMtMy0xLTEtMTg4OTc0_f42d6bd6-5331-476f-9ef9-3a6b39217fd2"
      unitRef="usd">780000000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzQtMS0xLTEtMTg4OTc0_6e775805-33e1-45d7-bb43-05c3bc8f7a7d"
      unitRef="usd">129000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzQtMy0xLTEtMTg4OTc0_581455d7-24ed-438f-892b-be9639308e4a"
      unitRef="usd">164000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzUtMS0xLTEtMTg4OTc0_7eabcc92-ac20-4163-9dd6-f394fc368b84"
      unitRef="usd">355000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzUtMy0xLTEtMTg4OTc0_5a337e77-af5e-4d04-b5e0-0e1c7d940d7c"
      unitRef="usd">200000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzYtMS0xLTEtMTg4OTc0_7b3f151e-e4ed-4e48-86da-6d64f6d8c3ae"
      unitRef="usd">2388000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTozNjMwNTY0OTQ0N2I0NGExODlmY2VmZGNiZjgyZDNhYS90YWJsZXJhbmdlOjM2MzA1NjQ5NDQ3YjQ0YTE4OWZjZWZkY2JmODJkM2FhXzYtMy0xLTEtMTg4OTc0_9e7bd6f2-9fea-49b2-87a4-61c278db2c4c"
      unitRef="usd">2367000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90ZXh0cmVnaW9uOjY2MjhjYTAzNTg4ZjQ0YWJhOWM4N2IwYTA1YTA3NDc4XzE0Ng_9946eced-7fe8-44cc-9a9d-565787cf7392">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <amgn:AccruedSalesDeductionsCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzItMS0xLTEtMTg4OTc0_ff35ff25-d437-426a-b3ec-f0478d565bcb"
      unitRef="usd">5986000000</amgn:AccruedSalesDeductionsCurrent>
    <amgn:AccruedSalesDeductionsCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzItMy0xLTEtMTg4OTc0_13b1354b-d6ab-41b7-8b31-a5d0de5641c3"
      unitRef="usd">5174000000</amgn:AccruedSalesDeductionsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzMtMS0xLTEtMjA3MTQz_f355e61c-c611-41d1-9db6-7c2cfcd73f56"
      unitRef="usd">1195000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzMtMy0xLTEtMjA3MTQz_5ec74d33-9ee8-4fe7-9be7-df359c19a5a3"
      unitRef="usd">701000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzMtMS0xLTEtMTg4OTc0_60f2f2de-1667-4b92-bb3b-849ea2a31e29"
      unitRef="usd">1137000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzMtMy0xLTEtMTg4OTc0_78f838e6-73fb-43fd-98a6-f31d652585ed"
      unitRef="usd">1083000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzQtMS0xLTEtMTg4OTc0_e6e8275c-1ad2-4d48-9f2a-4c65709638a5"
      unitRef="usd">1099000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzQtMy0xLTEtMTg4OTc0_35a3171b-f018-4410-8fab-61f8125c43a5"
      unitRef="usd">1081000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <amgn:AccruedSalesReturnReserveCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzYtMS0xLTEtMTg4OTc0_95aa7612-96dc-4504-8da0-d81241ed572c"
      unitRef="usd">548000000</amgn:AccruedSalesReturnReserveCurrent>
    <amgn:AccruedSalesReturnReserveCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzYtMy0xLTEtMTg4OTc0_3792b68d-c5c6-46dd-aa6b-0e6f91750d93"
      unitRef="usd">542000000</amgn:AccruedSalesReturnReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzctMS0xLTEtMTg4OTc0_0d17fb0f-ac47-4b00-88a2-17989724b213"
      unitRef="usd">2559000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzctMy0xLTEtMTg4OTc0_5ebc0a07-e90f-4833-92a1-e34236b6fe6c"
      unitRef="usd">2150000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzgtMS0xLTEtMTg4OTc0_2a8c8410-d37d-4be6-ba9d-3b4a1ca60e8d"
      unitRef="usd">12524000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzIvZnJhZzo2NjI4Y2EwMzU4OGY0NGFiYTljODdiMGEwNWEwNzQ3OC90YWJsZTo3OTY2OTZmOTM4Mzc0NzMyOThjMzVmM2M1MmUxMmQ1OC90YWJsZXJhbmdlOjc5NjY5NmY5MzgzNzQ3MzI5OGMzNWYzYzUyZTEyZDU4XzgtMy0xLTEtMTg4OTc0_ce07affe-2237-4d61-a876-48fb09e79a93"
      unitRef="usd">10731000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI0MTg5MjU1ODMyMjYw_62981de9-04b3-4f00-addd-72d06f07e147">Financing arrangements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our borrowings consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% notes due 2023 (2.25% 2023 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2024 (3.625% 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2025 (1.90% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% notes due 2025 (3.125% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% &#x20ac;750 million notes due 2026 (2.00% 2026 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% notes due 2026 (2.60% 2026 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% &#xa3;475 million notes due 2026 (5.50% 2026 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2027 (2.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20% notes due 2027 (3.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% notes due in 2028 (1.65% 2028 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2029 (3.00% 2029 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05% notes due 2029 (4.05% 2029 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% &#xa3;700 million notes due 2029 (4.00% 2029 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2030 (2.45% 2030 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% notes due 2031 (2.30% 2031 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% notes due 2032 (2.00% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35% notes due 2032 (3.35% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20% notes due 2033 (4.20% 2033 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% notes due 2037 (6.375% 2037 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% notes due 2038 (6.90% 2038 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% notes due 2039 (6.40% 2039 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15% notes due 2040 (3.15% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2040 (5.75% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2041 (2.80% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% notes due 2041 (4.95% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% notes due 2041 (5.15% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% notes due 2042 (5.65% 2042 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% notes due 2043 (5.375% 2043 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2045 (4.40% 2045 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.563% notes due 2048 (4.563% 2048 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% notes due 2050 (3.375% 2050 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% notes due 2051 (4.663% 2051 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2052 (3.00% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20% notes due 2052 (4.20% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.875% notes due 2053 (4.875% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77% notes due 2053 (2.77% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2062 (4.40% 2062 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes due 2097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized bond discounts, premiums and issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to 101% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes&#x2014;except our 0.41% 2023 Swiss franc Bonds and Other notes due 2097&#x2014;may be redeemed at any time at our option&#x2014;in whole or in part&#x2014;at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2022, 2021 and 2020, we issued debt securities in the following offerings:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2022, we issued $7.0&#160;billion of debt consisting of $750 million of the 3.00% 2029 Notes, $1.25&#160;billion of the 4.05% 2029 Notes, $1.0 billion of the 3.35% 2032 Notes, $750&#160;million of the 4.20% 2033 Notes, $1.0 billion of the 4.20% 2052 Notes, $1.0&#160;billion of the 4.875% 2053 Notes and $1.25 billion of the 4.40% 2062 Notes. The 3.00% 2029 Notes were issued to finance eligible projects that meet specified criteria to reduce our impact on the environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2021, we issued $5.0&#160;billion of debt consisting of $1.25&#160;billion of the 1.65% 2028 Notes, $1.25&#160;billion of the 2.00% 2032 Notes, $1.15&#160;billion of the 2.80% 2041 Notes and $1.35&#160;billion of the 3.00% 2052 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2020, we issued $9.0&#160;billion of debt consisting of $500&#160;million of the 1.90% 2025 Notes, $1.75&#160;billion of the 2.20% 2027 Notes, $1.25&#160;billion of the 2.45% 2030 Notes, $1.25&#160;billion of the 2.30% 2031 Notes, $2.0&#160;billion of the 3.15% 2040 Notes and $2.25&#160;billion of the 3.375% 2050 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt extinguishment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we repurchased portions of the 2.20% 2027 Notes, the 1.65% 2028 Notes, the 2.00% 2032 Notes, the 2.80% 2041 Notes and the 3.00% 2052 Notes for an aggregate cost of $297&#160;million, which resulted in the recognition of a $78&#160;million gain on extinguishment of debt recorded in Other (expense) income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt repayments/redemptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We made debt repayments/redemptions during the years ended December 31, 2022, 2021 and 2020, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2022, no debt was repaid/redeemed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2021, we redeemed $4.2&#160;billion of debt, including the &#x20ac;1.25&#160;billion aggregate principal amount ($1.4&#160;billion upon settlement of the related cross-currency swap) of the 1.25% 2022 euro Notes, the $500&#160;million aggregate principal amount of the 2.70% 2022 Notes, the $1.5&#160;billion aggregate principal amount of the 2.65% 2022 Notes and the $750&#160;million aggregate principal amount of the 3.625% 2022 Notes. In connection with the redemption of these notes, we paid a total of $24&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2020, we repaid/redeemed $6.5&#160;billion of debt, including the repayment at maturity of the $300&#160;million aggregate principal amount of the 4.50% 2020 Notes, the $750&#160;million aggregate principal amount of the 2.125% 2020 Notes, the $300&#160;million Floating Rate Notes due 2020 and the $700&#160;million aggregate principal amount of the 2.20% 2020 Notes. In connection with the redemption of the $900&#160;million aggregate principal amount of the 3.45% 2020 Notes, the $1.0&#160;billion aggregate principal balance of the 4.10% 2021 Notes, the $750&#160;million aggregate principal balance of the 1.85% 2021 Notes and the $1.75&#160;billion aggregate principal balance of the 3.875% 2021 Notes, we paid a total of $96&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $1.0&#160;billion with respect to the 2.45% 2030 Notes and an aggregate notional amount of $500&#160;million with respect to the 2.30% 2031 Notes. In connection with the redemption of the 3.625% 2022 Notes, discussed above, associated interest rate swap contracts with an aggregate notional amount of $750&#160;million were terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the redemption of certain of the notes during the year ended December 31, 2020, discussed above, associated interest rate swap contracts with an aggregate notional value of $3.65&#160;billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2&#160;billion that hedged the 3.625% 2024 Notes, the 2.60% 2026 Notes, the 4.663% 2051 Notes and portions of the 3.625% 2022 Notes and the 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% 2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% 2026 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% 2030 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% 2031 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% 2051 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 4.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt exchange&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $940&#160;million principal amount of the newly issued 2.77% 2053 Notes (the Exchange Offer).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal amount exchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% 2037 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% 2038 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% 2039 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% 2040 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% 2041 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% 2042 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% 2043 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2.77% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the 2.77% 2053 Notes. In connection with the Exchange Offer, $85 million was paid to holders of the Old Notes (the cash consideration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $264 million discount associated with the 2.77% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our 0.41% 2023 Swiss franc Bonds, 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the redemption of the 1.25% 2022 euro Notes, discussed above, associated cross-currency swap contracts with an aggregate notional amount of &#x20ac;1.25&#160;billion were terminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shelf registration statement and other facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2022 and 2021, we had no amounts outstanding under our commercial paper program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.1% of the unused portion of the facility based on our current credit rating. In December 2022, this revolving credit agreement was further amended to replace LIBOR with SOFR as the reference rate, pursuant to provisions contained therein related to determination of successor rates in case of phaseout or unavailability of existing designated reference rates. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) SOFR plus 1.125% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month SOFR plus 1.1%. As of December 31, 2022 and 2021, no amounts were outstanding under this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depositary shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depositary shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023, and our Board has approved a new shelf registration statement to replace it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, in connection with the proposed acquisition of Horizon, we entered into a bridge credit agreement and a term loan credit agreement which provide for borrowings aggregating $28.5&#160;billion. As of December 31, 2022, no amounts have been borrowed under either agreement. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement, bridge credit agreement and term loan agreement include a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements. We were in compliance with all applicable covenants under these arrangements as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contractual maturities of debt obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate contractual maturities of all borrowings due subsequent to December 31, 2022, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2022, 2021 and 2020, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during each of the years ended December 31, 2022, 2021 and 2020, were $1.2&#160;billion.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjE0_07cf0ce8-ee0d-4ce0-83db-d4bbe179d7a8">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our borrowings consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% notes due 2023 (2.25% 2023 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2024 (3.625% 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2025 (1.90% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% notes due 2025 (3.125% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% &#x20ac;750 million notes due 2026 (2.00% 2026 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% notes due 2026 (2.60% 2026 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% &#xa3;475 million notes due 2026 (5.50% 2026 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2027 (2.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20% notes due 2027 (3.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% notes due in 2028 (1.65% 2028 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2029 (3.00% 2029 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05% notes due 2029 (4.05% 2029 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% &#xa3;700 million notes due 2029 (4.00% 2029 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2030 (2.45% 2030 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% notes due 2031 (2.30% 2031 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% notes due 2032 (2.00% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35% notes due 2032 (3.35% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20% notes due 2033 (4.20% 2033 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% notes due 2037 (6.375% 2037 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% notes due 2038 (6.90% 2038 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% notes due 2039 (6.40% 2039 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15% notes due 2040 (3.15% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2040 (5.75% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2041 (2.80% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% notes due 2041 (4.95% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% notes due 2041 (5.15% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% notes due 2042 (5.65% 2042 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% notes due 2043 (5.375% 2043 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2045 (4.40% 2045 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.563% notes due 2048 (4.563% 2048 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% notes due 2050 (3.375% 2050 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% notes due 2051 (4.663% 2051 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2052 (3.00% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20% notes due 2052 (4.20% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.875% notes due 2053 (4.875% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77% notes due 2053 (2.77% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2062 (4.40% 2062 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes due 2097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized bond discounts, premiums and issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib87a5903e27546d7be1b99e84a2bd998_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzYtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246MGEyN2MwZGE5ZWRjNGVkMjgwMTU2NzIwNmExYzBkZjlfNA_c9509440-f78a-4374-ad69-93b7a380d446"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib87a5903e27546d7be1b99e84a2bd998_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzYtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246MGEyN2MwZGE5ZWRjNGVkMjgwMTU2NzIwNmExYzBkZjlfNw_787eb427-5526-4706-bcf8-d006bddc27be"
      unitRef="chf">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib87a5903e27546d7be1b99e84a2bd998_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzYtMS0xLTEtMTg4OTc0_04c8434f-db67-4f9a-a788-d9794d10a9ec"
      unitRef="usd">757000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i63458e59bdcd46bcbc8cde633cc0a217_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzYtMy0xLTEtMTg4OTc0_91c3dab6-77fb-43f4-9968-60f870240f16"
      unitRef="usd">767000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3cbb8923ef5d4b82912c6157f84c6bef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzctMC0xLTEtMTg4OTc0L3RleHRyZWdpb246MDhjMGE2MGY2OGU1NGFlMGJkNGU4ODVkODA1ZDBiOGJfNA_b89d2641-1264-4d65-9bcd-8628dcc93af4"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3cbb8923ef5d4b82912c6157f84c6bef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzctMS0xLTEtMTg4OTc0_b3ddabe5-02b3-45fb-9a4e-e98bd022eb8c"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i114486aa96344ee5b788b817b4b17d96_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzctMy0xLTEtMTg4OTc0_820eb1f7-3bf7-4eec-be83-0b5ff7005630"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1a39813c072d4e5eb904fe1d28cd03c2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzgtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246NzQ2NzlmYjhhYzc1NDlkOTk0N2YxMjYwOGE3NmUxNTBfNA_0bfebf87-8e9c-40f9-9c4a-0f440ce88e2f"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1a39813c072d4e5eb904fe1d28cd03c2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzgtMS0xLTEtMTg4OTc0_dc17ac99-d056-46b7-afba-1cf3ad9297fc"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2f1b495696b94d78b5dbd6696d16bd3d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzgtMy0xLTEtMTg4OTc0_efca9879-7caa-489b-875a-d1c6b9e844dc"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2dae08b71e7d4ab88b6e9e253336b859_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzktMC0xLTEtMTg4OTc0L3RleHRyZWdpb246ZTAyYWU1ODYzY2FmNDVmMzkzNGQ3MGJiM2VhMTE0MzBfNA_df8c5a1e-d906-43c8-9701-b1445c40caab"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2dae08b71e7d4ab88b6e9e253336b859_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzktMS0xLTEtMTg4OTc0_42b2fd71-671d-4ea1-996d-4e440d7acf61"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9444cb9457a24d94834f8ec64291471e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzktMy0xLTEtMTg4OTc0_83693f34-d0a9-443e-932a-e3f38b1c66b6"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i914ec06154d64420b43f2721a1ae01b6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEwLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmFmOGQwMTQ0N2I4OTQ2MjA5YzVkNTVkZWI3ZTg5ZjYwXzQ_75d0029b-0425-410a-b178-8ecaf38e6aaa"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i914ec06154d64420b43f2721a1ae01b6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEwLTEtMS0xLTE4ODk3NA_d7de417b-87f1-4a26-8c9e-3aa69866eed9"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6e4d0b0eb1fb4567ad07ac7b398eda3c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEwLTMtMS0xLTE4ODk3NA_8a0229e4-8dfe-4a24-8364-5a1fc9507390"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib6e2d495694d4d3cb2e097b25c5a10e6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzExLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmY5NzNlMzY1NjE4NjQ3ZWZiOTI5YmM4YzQ0YzZmMDE5XzQ_6e2a8881-868a-498d-807f-86f851146d38"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib6e2d495694d4d3cb2e097b25c5a10e6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzExLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmY5NzNlMzY1NjE4NjQ3ZWZiOTI5YmM4YzQ0YzZmMDE5Xzc_cb8da1f0-c7b8-4b47-8d63-66ac837bc2da"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib6e2d495694d4d3cb2e097b25c5a10e6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzExLTEtMS0xLTE4ODk3NA_e7c02910-e1ee-498d-89a7-4a514785ea8d"
      unitRef="usd">803000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ice6da97a847948f08a2ba11d9378169d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzExLTMtMS0xLTE4ODk3NA_ff78cf9b-c9c5-42a2-b62a-37aec01a6ae7"
      unitRef="usd">853000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i99921d01b0e541bf8d50ea58272c554b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEyLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjFmNDZlYWMxODRkNTRiZTNiZTFkYjQ0YjQ4NzNmMmRiXzQ_11c5441c-a1b7-4b46-a1c1-c4f9b879c54e"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i99921d01b0e541bf8d50ea58272c554b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEyLTEtMS0xLTE4ODk3NA_09db72ee-bd1f-4522-9fd4-779cd90df572"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i17b3e11f5be94ce49f2f3b9b0ecde667_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEyLTMtMS0xLTE4ODk3NA_c37e4095-06e1-4b6b-8d8e-937ffc6d155e"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d9211ecea36437580bc7b0a70919e0b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmRkMDgxZTczYTliMTQ2MzU5NGQyOWM3NWY2MWYzODM5XzQ_ab5efd91-18b5-46ff-95cb-3e1087821198"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0d9211ecea36437580bc7b0a70919e0b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmRkMDgxZTczYTliMTQ2MzU5NGQyOWM3NWY2MWYzODM5Xzc_b4e18eb2-f784-4ba7-8f9a-671a3339e7a6"
      unitRef="gbp">475000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0d9211ecea36437580bc7b0a70919e0b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTEtMS0xLTE4ODk3NA_d8737c30-5a12-4ddc-87e4-753d1bcbe12c"
      unitRef="usd">574000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic3f7dc76afa046759c07651d4147c51a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTMtMS0xLTE4ODk3NA_5dd06ee3-75bb-4bc2-9b34-4e66e3f741ca"
      unitRef="usd">643000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5597930bfb1b45bc98481de8f6393843_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjk3ZmNhY2Q5N2MzNDQ5Njk5MGJkMGVhNWM4YzY5OWVhXzQ_fd1113b1-a357-42fc-bbfc-5f98fbe86ded"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5597930bfb1b45bc98481de8f6393843_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTEtMS0xLTE4ODk3NA_525b8e6c-245c-411e-992f-986564e289cd"
      unitRef="usd">1724000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iab97f27b4cdb45eea26aa79814ee24f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTMtMS0xLTE4ODk3NA_67ea9e22-2c9c-495c-988b-f72bf1571867"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i315cb82b31f04ff097bb4573859346f2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE1LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmRlMWVhOGViNWI2ZTQ1MWI5OWU1YWViN2NhMDBjZjgyXzQ_5d2f4577-ada6-47a0-85ee-41baa56697a3"
      unitRef="number">0.0320</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i315cb82b31f04ff097bb4573859346f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE1LTEtMS0xLTE4ODk3NA_014b26a2-7b8d-4162-837b-f7c3c5eaa93d"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i996fa0fbb28a4ae5a66025a540485a05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE1LTMtMS0xLTE4ODk3NA_f6b4b582-caf4-43aa-90c2-6680ad49fd20"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie3d6933a21774133aab412e2e354668c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE2LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjdjMjRjZDJhNGM4YjQ2ZWE4YjMzODM4N2M2NjE4ZTRmXzQ_6ad57c91-c256-49b3-a10a-f86148b40bd6"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie3d6933a21774133aab412e2e354668c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE2LTEtMS0xLTE4ODk3NA_07014b9d-7f43-42fd-b6f2-74bda53e65ac"
      unitRef="usd">1234000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i42913198da614e1b811abab5b612e355_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE2LTMtMS0xLTE4ODk3NA_f873a85a-2086-49e3-ba57-2a716dca46d0"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTAtMS0xLTE5MjY1MS90ZXh0cmVnaW9uOmRjYjZlZThlYTc4MDRiNThhZDY4OGUxOWFjMGQyMDczXzEwOTk1MTE2Mjc4MjU_09cd083f-94e7-4c3b-b247-2515f31c301f"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzEzLTEtMS0xLTE5MjY1OA_5d2a7c2d-c827-4672-bf8d-17012033e875"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTAtMS0xLTE5MjY1MS90ZXh0cmVnaW9uOjRmYjVjMmE4ZjczMDQwNDdhYzUyOWEzZTkxNjI2NGUxXzEwOTk1MTE2Mjc4MjQ_4386f84a-5ffd-4c9a-a9eb-9f6087e00483"
      unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE0LTEtMS0xLTE5MjY1OA_3567b878-d2cf-41a2-8ba2-cd9d791901c4"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i385a16395bf64c2bb403ca851a184d2a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE3LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmYyMDdmYzhmOTFiZDQ1YWRiYmFhMGY1NjRmNjcwNjExXzQ_d69b5cee-cb8c-4ee3-a4d7-451b08af8a90"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i385a16395bf64c2bb403ca851a184d2a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE3LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmYyMDdmYzhmOTFiZDQ1YWRiYmFhMGY1NjRmNjcwNjExXzc_46152476-ca81-43ce-807e-1631f136efb1"
      unitRef="gbp">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i385a16395bf64c2bb403ca851a184d2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE3LTEtMS0xLTE4ODk3NA_b581bcbf-df47-45d9-98ba-76909534dfbd"
      unitRef="usd">846000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0953d601cec9484fbc9df96f00426496_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE3LTMtMS0xLTE4ODk3NA_8b58df8a-0c19-4055-804a-cc01729361b8"
      unitRef="usd">947000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaf7b55ef9cb1473085781b63a83bbdac_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE4LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmQ5ODkzN2EyMmViNzQyNjhiNThkMTY3MWMwOGRjODFmXzQ_56af8282-f181-47cd-b85a-19197ef60ab6"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaf7b55ef9cb1473085781b63a83bbdac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE4LTEtMS0xLTE4ODk3NA_4e95eb3d-3edd-456f-91ed-49229d69b57b"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i51217f4e8bed4990907c44f9d502ade2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE4LTMtMS0xLTE4ODk3NA_8db8095e-039c-4c16-ad40-b918731c2eaf"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i11702be5618f4b6b84417ab7311bb910_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmI4OWMzZDljNmE3MjQ2ZDFhOTUyOTRjMGRlODI3ZTJmXzQ_6a2df341-8edf-4280-abb9-1232a301630e"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i11702be5618f4b6b84417ab7311bb910_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTEtMS0xLTE4ODk3NA_8613ca19-f75d-4bb7-9989-ffa863190df0"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i343cbda319a14a27951c64ddae810439_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTMtMS0xLTE4ODk3NA_08c2dd26-f75c-4e07-88e3-59393914364b"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4de45cdb4364327a92140dc1f1c7cfb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmQ1MDIyNTE5MzkxNzRiODc5OWU2Y2U3Yjc1NmY1YjlkXzQ_79c3da43-f239-408c-a455-e955c92dd484"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia4de45cdb4364327a92140dc1f1c7cfb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTEtMS0xLTE4ODk3NA_2b99f6eb-9128-4769-96c7-f3c144e50ca1"
      unitRef="usd">1051000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i240a1929b4d74306bb09ea03fed64c41_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTMtMS0xLTE4ODk3NA_9f621340-c476-490f-8e75-d72a0438e966"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i21348edb6cd5466a9ef24edd6a2d0938_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTAtMS0xLTE5MjY5OS90ZXh0cmVnaW9uOjY3YzQxYzZiNTE1MDRkODZhNjk2Yjg4YTcyOGMyNzg5XzEwOTk1MTE2Mjc4MjQ_e13da757-f311-4784-89dc-e89a6b4ad715"
      unitRef="number">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i21348edb6cd5466a9ef24edd6a2d0938_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzE5LTEtMS0xLTE5MjcxMQ_7780c46d-ee56-4f7a-8aa5-3e2f4cafa6ed"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i51940b5cb1b241febc825ae180ec3de7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTAtMS0xLTE5MjY5OS90ZXh0cmVnaW9uOjVjMGQ0NWJlZWQxODQwNWE5ZjUwZDIwZjExODA4YTk0XzEwOTk1MTE2Mjc4MjQ_8f1edd98-8246-4739-b094-3c0e97842ea7"
      unitRef="number">0.0420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i51940b5cb1b241febc825ae180ec3de7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIwLTEtMS0xLTE5MjcxMQ_e5b44f95-4a67-43a3-a3f6-5677b6058d34"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idc5f965633bd497bae6b284f87fd754a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmY2YjFmYTkwMDQ2OTRjZGE4YzM4NGNhNjFiYjUxZjgwXzQ_55f5e763-5b92-4b15-8447-9ab7ca4707c8"
      unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idc5f965633bd497bae6b284f87fd754a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIxLTEtMS0xLTE4ODk3NA_36a2a324-c0c9-4e1c-8f42-f00fd324b92f"
      unitRef="usd">478000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i197c2b86499f4c749103e68bdb36f3f4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIxLTMtMS0xLTE4ODk3NA_76879f57-d811-4099-ba69-afe716134bb8"
      unitRef="usd">478000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4aff41f7e3e648c9be7ca6b79abca8e4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIyLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmE1NTA0MmM5YmM3YTQ4NmJhOTU0OTYzM2U3NzNkODRmXzQ_f89c090b-e959-4262-95ee-67f81a87b4b4"
      unitRef="number">0.0690</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4aff41f7e3e648c9be7ca6b79abca8e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIyLTEtMS0xLTE4ODk3NA_730575a2-96be-4d76-8f7a-77bae70b6e60"
      unitRef="usd">254000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9f2e4ca4f8004d6c9bfebd3720cee531_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIyLTMtMS0xLTE4ODk3NA_02caed66-8af2-4c34-a32b-24729480c22c"
      unitRef="usd">254000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i61c17dea73c8477a803ae09e22dccbbc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIzLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmI1NTAzMzJkNWE5ZDQ4YTQ5YzFhOTk0YzBiNWY1ZTJjXzQ_81b115e3-5bf9-45ef-b59e-80c6c6bc5e15"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i61c17dea73c8477a803ae09e22dccbbc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIzLTEtMS0xLTE4ODk3NA_0fd9a2c4-57b5-40cf-9505-2f0d5c78a38b"
      unitRef="usd">333000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia00b4eabc3a7467ea3ebd7138b1b2a74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzIzLTMtMS0xLTE4ODk3NA_3388e39d-76c9-4e2f-bc7f-5b56c77c0d3c"
      unitRef="usd">333000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23363383d2174b2d8ab38bf2003a6ce8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI0LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjM5NjBlZjljNWRmZjQ4ZjhiYmEyMmU3ZTZjNmM0M2MyXzQ_7e1e9965-6a08-4b45-834a-e0c155a8e99b"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i23363383d2174b2d8ab38bf2003a6ce8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI0LTEtMS0xLTE4ODk3NA_ba8112f1-35e1-42fe-afac-409ba91368d1"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1b887f6d478f455aa05ed3a9d50ab8b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI0LTMtMS0xLTE4ODk3NA_9d6a1832-76e1-48a9-b9d4-93a49d141f46"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a2c9ab1d0d74042b5625c4d3863fc9a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI1LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmIyOGUwNDgyNTk2YjRkODc4OWViNDk1ZjZjOTAwNWExXzQ_a82bcb58-6f1c-480f-bf1a-5890a1f0cfb8"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7a2c9ab1d0d74042b5625c4d3863fc9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI1LTEtMS0xLTE4ODk3NA_7f6297ea-f47f-417a-b4e4-5e345329b094"
      unitRef="usd">373000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if6c2234b75d747f78a8f666e6a4bd7a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI1LTMtMS0xLTE4ODk3NA_ad29b884-9495-4575-9e92-05556ae1f2f3"
      unitRef="usd">373000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1b1952961fcf4393b06b95f66a0599ae_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI2LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjRjNzM4YmU1MDRlMzRiOWVhOTUzYmNmYjlmNDI0YThkXzQ_ab4b91d5-07cc-4921-91fe-b644d2ddfbe4"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1b1952961fcf4393b06b95f66a0599ae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI2LTEtMS0xLTE4ODk3NA_cc52d900-d99a-4e60-999a-b623d9a8165a"
      unitRef="usd">1110000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9d652ba10ed148fcb905cf1d5cc7e9a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI2LTMtMS0xLTE4ODk3NA_0393c4ec-6391-44a3-b3fc-3259807968f5"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7ae3396aeb042e386de28c02ab1deee_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI3LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmYzYjEzZjQwY2VmZDQ2NDY5MDk2YjI3YjRhYTMxMTY2XzQ_cbfcce5c-72cb-46e2-9bc7-2a82b0493325"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id7ae3396aeb042e386de28c02ab1deee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI3LTEtMS0xLTE4ODk3NA_57f63538-d648-4ceb-8db1-32f99138eec6"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie0332f21f1314de4ae95621b6ac2c956_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI3LTMtMS0xLTE4ODk3NA_8a95907c-d2ed-4059-8cab-f85a5e73c7dd"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i799db871194f4747ab9f6118c675a2f7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI4LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjhiNzJlNjljMDY5ZTQxYzY4YjYzZDdjOWM4YWQwZTU5XzQ_54454e6e-60b4-49a0-bc18-cb462ab9beeb"
      unitRef="number">0.0515</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i799db871194f4747ab9f6118c675a2f7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI4LTEtMS0xLTE4ODk3NA_f0b756f3-1ebc-4cf0-a100-3b527c1c4b50"
      unitRef="usd">729000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2da62baf08ef4c5b91a5152a82a01c53_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI4LTMtMS0xLTE4ODk3NA_913fd52a-570b-4096-9c9d-e1b3ba6e4a44"
      unitRef="usd">729000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2ceee26f1075435e9fdfdd7a75a72ab5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI5LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjBmYTcyYzllNTc5YTQyZDliZTMwN2M3M2Q4NTZhMzIwXzQ_a53f4216-98f6-4106-865f-d3ebfffc8484"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2ceee26f1075435e9fdfdd7a75a72ab5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI5LTEtMS0xLTE4ODk3NA_0fc83a80-8141-4bde-a744-f1e50b2265b2"
      unitRef="usd">415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if2e818249c4f49d79e8872325e9ce099_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzI5LTMtMS0xLTE4ODk3NA_43b942fa-b204-4f73-a954-b58ac8f8e265"
      unitRef="usd">415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieadcf920bf8f4c5f9aa97d54a77a11ee_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMwLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOmZkMTgxMzFhODM5MTRjMWVhMjk5NWM3N2FkNjdlYWJiXzQ_add70b61-d666-4aa8-a1cc-546fb4be116c"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieadcf920bf8f4c5f9aa97d54a77a11ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMwLTEtMS0xLTE4ODk3NA_1210d367-b1c3-4ace-844d-7deadca570b9"
      unitRef="usd">185000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie22ac487559948448b70189d26074a44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMwLTMtMS0xLTE4ODk3NA_d29b12e6-3b4c-48f0-9e32-ec53d568f0a0"
      unitRef="usd">185000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6c399705808348afac4fb0a614c63170_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMxLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjVkYjdhOGUzNzRmNzQwMmE4ZTFkYjYzMDBiMmEzNjVkXzQ_29cab85e-a8b8-4d75-984c-5de402283cc4"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6c399705808348afac4fb0a614c63170_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMxLTEtMS0xLTE4ODk3NA_7bd192ac-06e9-4838-8303-b53c623f2440"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idbe3e6b61a09400e97634eebf130e74a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMxLTMtMS0xLTE4ODk3NA_099aebb4-ebb5-4459-adce-a6af5cc2f06d"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia9e2fac888b644c6bcecbe5803617340_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMyLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjQyNjFlMTFiNmJjZDQ5MzJiODkwNzExMzc5ZGQyMGRhXzQ_c04faa3c-cb9a-4c4d-b448-299836526956"
      unitRef="number">0.04563</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia9e2fac888b644c6bcecbe5803617340_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMyLTEtMS0xLTE4ODk3NA_74744156-4917-4e3d-aeb7-96d635d51c5f"
      unitRef="usd">1415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i459df9e4545545c5acca6667f316af22_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMyLTMtMS0xLTE4ODk3NA_fd4aa8e2-d479-44e9-85be-244f6a553827"
      unitRef="usd">1415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i61dde3927cd046c3ae459081902d8719_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMzLTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjE0OTBlZjBmZTYzNjQwZDdhYTJjM2UwMDQ2MTM4MGFlXzQ_15370a01-1e70-4bc9-bef9-ab868dfe65e2"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i61dde3927cd046c3ae459081902d8719_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMzLTEtMS0xLTE4ODk3NA_94dbc1df-5cf9-49d8-a5d8-4470736ddfe2"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4a53c4efbbc3497fb791219ac49e571d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzMzLTMtMS0xLTE4ODk3NA_7870364b-86f1-4e2c-aeb0-7359fedbd6b4"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i91a9673685984fa4a4d87c723a4b99b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM0LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjM2ODJkYjNmYzc5NTRhYWVhYTA5MjBlYzZmMmQ3ODUyXzQ_2cf47544-88f9-4e44-a59c-b2766fccc9c7"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i91a9673685984fa4a4d87c723a4b99b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM0LTEtMS0xLTE4ODk3NA_d8e00068-1032-46dc-b225-7a82c5bd10f5"
      unitRef="usd">3541000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3fbb4c180e604823bf8fe6193c622eaa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM0LTMtMS0xLTE4ODk3NA_d0966941-4c90-41e8-b563-494654da4af5"
      unitRef="usd">3541000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4ea14090c5d46a68fa6c66a684d6252_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM1LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjIzOTQ4NDdiYzk2MzQwMWJiMzYzNWZhNGEyODNkMmI5XzQ_abd3c3fb-2465-4451-8be6-0ed79b7ceb49"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia4ea14090c5d46a68fa6c66a684d6252_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM1LTEtMS0xLTE4ODk3NA_b6c31b38-8b35-458c-9b1e-0fab339b520c"
      unitRef="usd">1254000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaec66496c6a840d998963fb080719768_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM1LTMtMS0xLTE4ODk3NA_983ff15a-1400-4f42-8548-a776df50ede2"
      unitRef="usd">1350000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i25202f83ea744eccb99587dd65d7f169_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTAtMS0xLTE5MjcyMi90ZXh0cmVnaW9uOjBjODdlMjgxYTQ3NjQ1ZDA5YWY1N2RmZDVjMWVkYjhlXzEwOTk1MTE2Mjc4MjM_2b7e12bd-f9ba-44f1-a78b-0c7b933e741f"
      unitRef="number">0.0420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i25202f83ea744eccb99587dd65d7f169_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTEtMS0xLTE5MjczOA_3fd11d7b-2996-447b-a54c-bfa43adc641e"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM3LTAtMS0xLTE5MjcyMi90ZXh0cmVnaW9uOmU2Mjc0MTVkZTNhNzQwMjZiY2Y1ZjI4NDU3MWI5NTRhXzEwOTk1MTE2Mjc4Mjc_5a2c3a78-3c94-4dc0-9c55-f116591c4ffd"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM3LTEtMS0xLTE5MjczOA_c24d09fe-b320-4d95-a648-2b4f7491ab10"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTAtMS0xLTE4ODk3NC90ZXh0cmVnaW9uOjlhNDM3ZjZkZjIzNzQyYThhNmNhZTRjMGY0OGRmYTA1XzQ_ff5f999d-97d6-4a15-9cff-dd6a610f85f0"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTEtMS0xLTE4ODk3NA_6c5d333b-bee6-49d5-b81e-db7a2e76a1a7"
      unitRef="usd">940000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4f1ab566422f43e9ae7b52770249ed7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM2LTMtMS0xLTE4ODk3NA_1a085fa0-7e22-41f4-a506-8a93bdf9e48f"
      unitRef="usd">940000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if2a31746bf0d474c8f6cacbba8fbb650_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTAtMS0xLTE5Mjc0Ni90ZXh0cmVnaW9uOjMyMzJmYTVmZWNjNzQzMGJiYWU3YzVlYTE0MjJiZDNkXzEwOTk1MTE2Mjc4MjQ_c941998e-526f-4514-9f98-af9e31f9ea24"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if2a31746bf0d474c8f6cacbba8fbb650_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTEtMS0xLTE5Mjc2MQ_d6b37a02-20d4-4155-ad09-ca9fc8a33eb5"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i18f3097471304363bf528a0d267e397a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTMtMS0xLTE5Mjc2NQ_5305bd3a-36ec-41bb-901a-1086145c02ea"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iefc3b8cff79b4b5a9d37b0a3cfa13a59_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM3LTEtMS0xLTE4ODk3NA_00cb72f6-02ce-4bd8-822a-f7c9037bada5"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5dcd01e084f04f7da2597aedeba26b9f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM3LTMtMS0xLTE4ODk3NA_37f4ef63-875b-42a9-b568-0034c146291c"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM4LTEtMS0xLTE4ODk3NA_181cc8f2-af44-46e4-aeca-f2e04b0bd4a2"
      unitRef="usd">1246000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM4LTMtMS0xLTE4ODk3NA_83f2c743-edf2-4f28-870d-56f79a03a506"
      unitRef="usd">1213000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTEtMS0xLTE4ODk3NA_93952004-aae2-41d7-9266-a69aba3a14fd"
      unitRef="usd">-437000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzM5LTMtMS0xLTE4ODk3NA_674988cf-91a9-4ba3-938d-04b6ca79ec33"
      unitRef="usd">284000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:OtherLongTermDebt
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQwLTEtMS0xLTE4ODk3NA_ea126d76-50c2-46e9-bd11-05c1109065d3"
      unitRef="usd">12000000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQwLTMtMS0xLTE4ODk3NA_dc158c9d-5321-436b-b8e2-7081636850f4"
      unitRef="usd">15000000</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQxLTEtMS0xLTE4ODk3NA_045fdd2f-ad38-4111-adbc-9185448d4af7"
      unitRef="usd">38945000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQxLTMtMS0xLTE4ODk3NA_7d86e02a-1a9a-437f-9040-d33e95d91c51"
      unitRef="usd">33309000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQyLTEtMS0xLTE4ODk3NA_e15c6c91-c04c-42d0-bc79-18f0075988e6"
      unitRef="usd">1591000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQyLTMtMS0xLTE4ODk3NA_936557db-a8c3-4d16-baee-8382f4c5c053"
      unitRef="usd">87000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQzLTEtMS0xLTE4ODk3NA_52525914-e888-40d8-a52e-444f272f0058"
      unitRef="usd">37354000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTpmOGM4MWQyOGI1M2M0ZGEyODk5NGJjZWJjNmQ0MjI2ZS90YWJsZXJhbmdlOmY4YzgxZDI4YjUzYzRkYTI4OTk0YmNlYmM2ZDQyMjZlXzQzLTMtMS0xLTE4ODk3NA_2e062a80-a453-4776-90ce-5f73bc608592"
      unitRef="usd">33222000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia9e2fac888b644c6bcecbe5803617340_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIwNA_f91bfa03-1ca2-481c-9a7a-1dc4c0eadc5d"
      unitRef="number">0.04563</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i91a9673685984fa4a4d87c723a4b99b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIyMw_e39b5371-f116-4307-a7f7-4f449e3d28e3"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI0NQ_dea0965d-2d48-46ab-9736-46c1384aa9ac"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia9e2fac888b644c6bcecbe5803617340_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI5OQ_43904324-9443-43b4-a22f-b826b86a7ee5"
      unitRef="number">0.063</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i91a9673685984fa4a4d87c723a4b99b3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzMwMw_cc8405b7-255f-45e3-9b25-c81d9cec10f1"
      unitRef="number">0.056</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzMxMA_496912d8-cd5d-4bd3-a210-9dbc9dd789bf"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i4ae65b7af0f742268bed15aafd3a152c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_107ac993-9efe-4a54-93a4-72df5ab8791c"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i015b4b460a304d11a76423022adf7fb4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_16b1b076-b68b-4e86-8c43-b2bcbec9eb9d"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i850e2cf58a7341ba9d67a7b5bb83feaa_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_17cbdaf2-025c-4e78-99b2-78cb3276973c"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i14ca5e3f8d5e4e19a9336ace84b8e4de_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_19dcabf5-e9ab-4fed-b120-d952102009eb"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ibdf49fbaa3564bfeb07fa6eab5ff9453_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_2d0aa29f-7f94-4af4-aae5-e51d7bc8e59c"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ic1f60bbed45a476b84f32d5cd638fa27_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_31466459-e6f0-424b-8352-0802d1f06834"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="id071e59acfce43278b6718d99d9ada1d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_328eac04-d717-4758-936a-29c68b1c2069"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="if02f6daf07f04020881c0917e7205beb_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_370d5281-b95a-4ffb-8e0a-f0552446e74c"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="idc8d9408f58940f5aea794a5984b2b6d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_38071452-67c4-48c3-8088-6512a54c5d3a"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i53bd2b17ef4e40b9ab31b350fb9bcca0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_48310329-ef1d-470c-8f76-568b6af7d36e"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ibeb1ef0f568a470293b1b4b19ff1eb25_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_4d88b635-b15e-4c27-992b-d7bd2b617fd6"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iafbc703b5ac5464b934f026814c76b10_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_570ad544-608a-43cf-b5ab-8301db2de166"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i63aa0c69ac4d42fea8344496f99d3fb8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_593ec024-c0a6-49d0-bdfc-bcbc3c02dd37"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i2c0f3163a47a477abfa471e4f31bc4ab_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_6003789b-320b-4325-bc12-94bf1232460f"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i994c0f07cba345b594aa2dcc8f01ae2a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_61aec0a6-09da-4f6b-9d11-c548a9d0a9cd"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iae7d08a8c95844f89b4bc95827153edc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_750cf224-4123-4bdc-9067-7b13eb04f034"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i3ebe21c56f7b49eab0d1f2b569ab2d69_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_7554e0de-c319-4a5f-97c5-62312809d75b"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i7dedfbd2aadc42a4b92b844cb973cf5c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_755cb47b-5476-4e28-b3eb-fdd16e1ee476"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i6d2edc811fbf442281992e3f83c386d8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_7e60a1b6-f43b-4065-ba65-3bbf66c5b39e"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i97e03c380118450bb96b17ea6c0975ff_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_8abbcdf6-550f-43f6-9250-44031b043a13"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="id5abe004e1f64a0cb9c9056890639151_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_8fd77f7d-081d-4d20-96e6-73b9099a6b1a"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i4cbd26680ac94508aca54119b9a2b4f1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_901223c0-12f2-4a3a-a5e7-13c3009b719a"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iabe3f9f94b8740cb8f007f2610521598_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_95f0259d-01a5-42e2-93ff-76460d251dc8"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ibfa82e45553c4fe38c964335a7502e78_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_9edaaadb-d76f-4a48-9263-36cd8d286428"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i7fd31a2352f045398f3a8eb8645c3d22_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_b40c8d0f-79ae-4bec-a97a-f3f159f96517"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ife0fd2905ff54a6ea2da3ac299266202_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_bcd67532-c754-4e6f-a452-6c5e8d5ad58c"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i66b14e567be349d2b9d238dd8fa3d12d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_bd6cd962-cf32-4533-954e-65d86fc940d4"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i093e46e46f254549afa8c5b85e22d6ec_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_c3e2e67b-27af-4bef-b5a3-66996ce368e3"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iadf162d5956f4e0c8eeaf73fec25a6ee_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_c9046d03-fe68-4e1f-8f5c-f5e9d8c1ab3f"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i64bd322d7bdc4336bdcaa7f9c771196d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_cec1ea42-ee38-4fab-8b42-f52629a2e268"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i4bf447a9235a4172905a462133a6ffff_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_d179a3e5-ec8b-404c-9b6c-3bb77947b422"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ic90390b22ae74a819b9f25f7e52c8cd4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_d6c51a99-906a-4bba-a943-73571ebca168"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i3b6372321cb54979aa35bc0ab3e56ae0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_dd2526b9-ef56-4dcc-9d1c-2b0526f58dfe"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ic385067cc0a541f7acc94e65e1d25159_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_dfa96cf4-a561-4f9b-8699-1093802cc417"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i35ba09ad3416417584b285ae9e364e4d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_e400488e-4399-411f-b640-15912f4cc84a"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i304fcc0c170d49fab4f536fb9d368d1e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_e95acccb-209c-4e73-a334-c9cef640dc7f"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i198527cafdc44eeca16fc7290ab43d35_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_f1334941-4570-4ff4-a548-8e1cba9ede60"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ide32c761d0db4322ac4858a8059cfa8b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NQ_fd19d26b-91af-4107-b7a6-b66bcd6e0466"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie30a691e9b49416cb63804f9bee95ad0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY4Mw_6850545f-2524-4f0b-999d-1cce525c62b8"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount
      contextRef="ie930e646dcf5443abd63824803a610e3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzExNTU_c10e54bd-db4f-48ff-bc00-5f08b72e38c2">P1M</amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount>
    <amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount
      contextRef="ie48acc0ed4094a3d91842dd5e715d92e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzExNjE_4958ed6f-ed27-47cc-99b4-b8536eef884b">P6M</amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id185478a58284d89b9439c8843eb6f89_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM0MzM_5e70b591-c08e-460d-b487-0e2c9113994f"
      unitRef="usd">7000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzNzA_48707799-3369-4d7f-b7b2-857b389fecc4"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzNzY_7f2bbf32-1170-45fa-ae23-e57d37bfb2be"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NTA5_d5f1cbc9-f605-4039-abcd-63b8fbb2dd73"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic99a7fc4fd2c491bbdf73499bfc504eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NTMx_5c0a9f58-de94-4c60-95e5-4f0a5344cba3"
      unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i21348edb6cd5466a9ef24edd6a2d0938_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM0NzQ_22197061-7f4a-46e1-a405-925e5c10a25f"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i21348edb6cd5466a9ef24edd6a2d0938_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzODM_dfed069b-d8ee-49f7-9653-590bb05bc874"
      unitRef="number">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i51940b5cb1b241febc825ae180ec3de7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NTUy_87429013-0820-4ba9-bf49-111ca255c5ed"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i51940b5cb1b241febc825ae180ec3de7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NTcz_5ee59f83-cdcc-423f-8991-7fefdad8e835"
      unitRef="number">0.0420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i25202f83ea744eccb99587dd65d7f169_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM0OTE_82d415f8-f4c6-4aa9-a60e-68d97264b141"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i25202f83ea744eccb99587dd65d7f169_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzOTA_8345da7f-0ea4-4d0d-9be8-3b555f5393e5"
      unitRef="number">0.0420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NjIw_53a14575-27e1-4692-8882-569dbb063239"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f12c0e0a0f34ea2b40c556789e649dc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1NjQx_13182dc4-41fe-43af-9e60-17383ebd3ba5"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if2a31746bf0d474c8f6cacbba8fbb650_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM1MDg_1281b2af-6129-4ca4-89d1-fa82fff369d8"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if2a31746bf0d474c8f6cacbba8fbb650_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODMzOTc_9f3ac81c-8679-415e-ad4d-a79325f4b896"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2abdf31bab164b7c95baa1ed9ef98248_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODM0MjY_6a10f80e-9870-4f4b-b0e2-09827119bce1"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icc43e58b90c442fa9e2c3b2c14137433_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzMjI_44ff124b-467d-47ea-b8bf-7d901b80a22a"
      unitRef="usd">5000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i42913198da614e1b811abab5b612e355_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzNDc_be9f7b7e-9508-4e3f-8d80-1188ef9d4cf5"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i42913198da614e1b811abab5b612e355_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzNTc_df998893-b672-45ab-94c1-6a7f8221bdcb"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9924ee115de34d74a2b634b1cb90e492_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzNzI_230fcff1-d5a9-439c-8577-45d53b4c691a"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9924ee115de34d74a2b634b1cb90e492_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzODI_262f9215-3949-4ada-992d-b74636499b7c"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if564b13b89634481901bd164eb63c59f_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEzOTc_a1bb8015-6908-4c64-93e5-bc8660b5c65d"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if564b13b89634481901bd164eb63c59f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MDc_46c0aaf5-4bc0-4a51-93e7-d284d55885a6"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaec66496c6a840d998963fb080719768_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjU_b21ca0f8-a7a7-4f49-8e11-71f2d2946931"
      unitRef="usd">1350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaec66496c6a840d998963fb080719768_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MzU_63e50590-5372-441b-95e5-b84fd6a2c78b"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1e59b900a4ba40609f70a3f1ebf4fb65_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0NzA_fde6fb7b-0a43-4674-ac03-614533bdfd29"
      unitRef="usd">9000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1ecab054ef954f2bbe765d19ba69cf36_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0OTU_4346169b-1fa2-4c07-90bf-ee1765c6608e"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1ecab054ef954f2bbe765d19ba69cf36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1MDU_696af016-1343-4e9c-897f-e2548a09c96e"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1ec7e0e38fad401c881d41f4c40df8d8_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1MjA_bfe40c11-f253-429d-9c12-c6bab415586b"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1ec7e0e38fad401c881d41f4c40df8d8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1MzA_097bcdf3-b521-4369-959c-abff3068ffeb"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie507238fe5a046649c456d858ed9e23a_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1NDU_ac694fc1-aefc-4324-883f-e3c8ad6389f5"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie507238fe5a046649c456d858ed9e23a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1NTU_104191ec-f8f3-4468-b7fa-6d36f85aa39e"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if8bc2063ee0d4b268efa59bb040e751e_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1NzA_ec1f3f05-e2e0-469b-8879-ba8a1dd98944"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if8bc2063ee0d4b268efa59bb040e751e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1ODA_1ca65538-5e9a-4131-8ab9-d179579bfb07"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i56bdffad54214969af59aa30ffe7fdc8_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE1OTU_32f4ca23-1aed-41b3-85b6-f504de145df7"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i56bdffad54214969af59aa30ffe7fdc8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE2MDU_aebb5468-efe0-4070-8db2-9c2aceeb3147"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i53fed3d90cd3422f8495f0171cae0423_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE2MjM_a95ac867-5e2d-4d0f-b5ba-7a3bf9fe4c74"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53fed3d90cd3422f8495f0171cae0423_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE2MzM_86741b72-832f-4cdf-a038-02ba4a47b0a4"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5597930bfb1b45bc98481de8f6393843_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODIzNDQ_b2cdedf1-c476-4964-a164-1694ebf559ec"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie3d6933a21774133aab412e2e354668c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDg3NzkwODIzNTc_dd622ffa-b9a9-47ea-b088-57de54334f3a"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4de45cdb4364327a92140dc1f1c7cfb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTI5_58229b75-4305-4ad1-9396-5c5d8e5e7365"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1b1952961fcf4393b06b95f66a0599ae_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTM3_fb563140-890c-4321-a47f-23628034cd1f"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4ea14090c5d46a68fa6c66a684d6252_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTQ1_4b9723de-e12d-48eb-90c6-07866c3a678f"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTUz_ef2d565c-d231-44fe-ab35-7c7f1e77fb7c"
      unitRef="usd">297000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEyOTYx_73c64166-9584-4ca4-b247-0c76f2cb8f1c"
      unitRef="usd">78000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i83a71b99759f43bb8745b086512815bf_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjQw_327607e0-8871-449a-a703-b83e9607dde1"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1ffa41fba39e4ab794adaacf3e2fa171_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE4NzA_ae495450-9703-4f25-9537-886618c9492c"
      unitRef="usd">4200000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iaca4dae277dc4dd99ebb82e55a868dd1_D20210101-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE4OTY_cc9a7441-2ddb-41b6-bfcd-acff186e95bb"
      unitRef="eur">1250000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iaca4dae277dc4dd99ebb82e55a868dd1_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE5Mjc_de8ca1d6-0fb2-48a0-a45a-4e34f465c47c"
      unitRef="usd">1400000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1347de6bb8044d39a48f67625521dccc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE5ODk_9a57a82b-f187-4872-b18b-eadd22ba114d"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6da1b9cbb0984b97a73d42d2db8533a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIwMTM_43389f2c-cc1f-4548-8334-b3cf8585ff5e"
      unitRef="usd">500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i847ad6943c6948fca81b24ff5d689fe3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIwNTA_8de7a7a3-2a11-43ca-84bc-f413be733cd5"
      unitRef="number">0.0270</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i561a96f4dc354ad3a90b2b25b980a842_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIwNjk_6df437ee-dd41-4aa9-afb9-41d434f0de62"
      unitRef="usd">1500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if8e02d4a00804cc4a01eff072b7e2f66_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIxMDY_7b1b95e3-6779-4db3-bd34-df2cc8a6ac42"
      unitRef="number">0.0265</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i766094e09bca49dd9585d02df2f31831_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIxMjg_4fbf2e90-d973-430e-acbc-6849aa76402c"
      unitRef="usd">750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9de4610aa6c4469ea8f2b7e53baf43e4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIxNjU_343afbaf-3c21-4aeb-8e6e-9d3636d3adbd"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i1ffa41fba39e4ab794adaacf3e2fa171_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzIyNDk_4d036bde-c324-45de-b576-020cb992f164"
      unitRef="usd">24000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2efa7dc8599f4cbf803535c380f5c0a9_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI0NDM_7e9df007-c895-4b85-9a24-43895815155f"
      unitRef="usd">6500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i93a2a77b537d4549980bc9ee3c342a33_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI0OTg_187211f1-7071-4c12-a558-cdd1d4c5c69c"
      unitRef="usd">300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icbb916e5bc874443803468bda0e734e9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI1MzU_ea28f70d-e1c3-418c-b494-6108dd3ae6b5"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iffd7c6ea10ec4560aebf2e8cf2cdf029_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI1NTQ_faa5f834-328f-4379-ba11-fa7c6f6783d9"
      unitRef="usd">750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i37fbc3aef92b4fe7a7795bdf6c1c7572_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI1OTE_09cd5fb4-e83b-4ce3-b0b4-c8ea439fe64a"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id9da66eabb244ebc99d3f74da210e1ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI2MTA_d6a7b154-5940-45e2-8497-4e111dfe712f"
      unitRef="usd">300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4f0351400ea14a1a92d887dfc66b4eaa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI2NTA_378e9466-e266-4fc0-bf75-8b6eba721744"
      unitRef="usd">700000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iebdc2a05aee049ac9929bbe48b8b70e0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI2ODc_9647b409-7647-47b5-8a06-a108294b8c41"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ida12280bfa6149bf8c7594c904e394c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3NDM_65d7733c-7a28-4fb1-abe4-a1c3d9dc20e7"
      unitRef="usd">900000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic3ec7f5fc463475eb5b87f53220a55e9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3ODA_1bbba8b9-2522-49fc-a7f9-4af8df60b6d9"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i80e1ce0caa3742e5b52a143ca346a03e_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI3OTk_9eb4392d-fa3f-45ab-ba83-b26815349a1f"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i75d223f0739043aa95bb0cff432d8e57_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI4Mzc_83b2d39c-5d24-4a41-96ac-ec0e231c31d6"
      unitRef="number">0.0410</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic96413bd0bc84b608c7ceb7cbe2da49e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI4NTY_2c16ddcc-4cb9-40d8-9f5f-8787859e9f38"
      unitRef="usd">750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if86ae682dbc94b06a43ad27eff012f5f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI4OTQ_d22de948-a3d4-4889-ad1c-9e0fb9f6559c"
      unitRef="number">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib98c19b2205645dc87dc300e20564cd2_D20200101-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI5MTY_9a9b2bd8-4ac2-478a-8508-d2c95f1b6568"
      unitRef="usd">1750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iad19f1af440047f5bd2d2a7b58c2704c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI5NTQ_1c62913f-0873-4968-bd78-eade1616b653"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i2efa7dc8599f4cbf803535c380f5c0a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzI5ODg_647a4b22-0e39-4960-949c-7971d7ee5e9a"
      unitRef="usd">96000000</us-gaap:InterestExpenseDebt>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i51217f4e8bed4990907c44f9d502ade2_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQwMTk_bc980012-e5ac-49e4-b230-507ee387cd80"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i51217f4e8bed4990907c44f9d502ade2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQwNDI_cd9eb315-f784-401e-b287-93892f25bf72"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i343cbda319a14a27951c64ddae810439_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQwOTI_754e28fb-1f0c-40bf-be54-3f3e7b3fdbf9"
      unitRef="usd">500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i343cbda319a14a27951c64ddae810439_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQxMTU_2d06b708-3bde-4a5b-875d-7d93e0c1f7d9"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9de4610aa6c4469ea8f2b7e53baf43e4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQxNzE_f868b001-bc84-4dd8-bf35-4c3f3fb78742"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="i745dd63e9cdd4959af07252f017a9eaa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQyODA_bce66df3-f01a-47fd-ab39-fb041d9a33a2"
      unitRef="usd">750000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="i9ed264795f2f4426adc19343d029ad1b_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ0OTI_1dc06677-5d45-45eb-9a1c-2fa39756a67a"
      unitRef="usd">3650000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="i98780303768142868e91c1f5e2254492_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ2ODE_c1174c1b-f2a0-49ce-85c5-13859d333d8f"
      unitRef="usd">5200000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i42e055314ebc4ed0b56423ed298d665f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3MDA_4b3842c8-5030-46da-82f2-e1d62fd9610a"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i95a65fbba5eb437390241efe7cc1bc36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3MTk_5e2e6301-64f2-4bd4-97b9-c7ef91c83b17"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i97cf13585e1c40fb990546d925c79ac7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3Mzg_25c42408-6848-4be5-a36e-909f1facfad9"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia87de4924b5449ffaf2a569727731d96_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3NzI_c7428724-1129-4b13-a824-61812b3cb15d"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3596be95666d43788e785254aa341628_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ3OTQ_d26c6599-3839-4b54-b33b-12dcaaf8d60a"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9992852da66444809770265c95298e01_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzQ4NDI_f3f033e5-be66-40be-82b3-aa8ce38c83bb"
      unitRef="usd">576000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if8bd0602a17242c7afbd9f2891132c95_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzUwNDM_4d84ad0a-9680-43a1-a329-82f31ded03d5"
      unitRef="usd">5200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjEw_a57b7f5b-3b25-45e0-b97d-32e1b8ad776a">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% 2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% 2026 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% 2030 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% 2031 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% 2051 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 4.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7c05fd05200c4fd89c9d750167797479_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246MTMxYmU1MTk3NzlmNGQyYWEyODYzNTkwMjBiNzU3N2JfNA_8d88cea5-ab52-4a17-b2c7-3844ebe1de74"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1e90624438bb44448c8bd5de6bd2ea2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMi0xLTEtMTg4OTc0_5d58539b-8563-4b06-8345-9166088f9145"
      unitRef="usd">1400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7c05fd05200c4fd89c9d750167797479_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMi0xLTEtMTg4OTc0_f7901eb2-44bf-44e6-9a28-aa0bb197960b"
      unitRef="usd">1400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ie97d7b079fd244fc9390520981dfe82c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246YTliZDI3MTFjM2UyNDJlMGI0OWQ3YmEwZDIwODlhNDFfMTI_b6b805b9-97f0-4748-989c-a2af146bccfb"
      unitRef="number">0.032</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i1572a102df9d4c8ea6c80c299b0c59c3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzMtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246YTliZDI3MTFjM2UyNDJlMGI0OWQ3YmEwZDIwODlhNDFfMTI_ca8644c9-92fb-4bac-8fdf-3579951a6dc7"
      unitRef="number">0.032</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1716ecbde7da4b99b7645064d92f04e6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246OWRmMWJjYzI2YTZhNDFkMmE0YzcwZjEwY2ZmOGU4NDlfNA_7d3211e0-6c81-4c7f-88f8-aace8a900780"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaf0e44d0cbd340d5ba7c2e8a3f4793ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMi0xLTEtMTg4OTc0_101dc360-1fb8-4904-aaf2-c0655df90d7f"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1716ecbde7da4b99b7645064d92f04e6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMi0xLTEtMTg4OTc0_439d2ce4-7131-4e35-ae77-af289e722453"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i0783150b28c641c7902d993a142cb45c_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246YTk5OTFiN2I1YjI5NDY2OGJkMDc3MTZjOTcyYjhjMDBfMTI_5e780887-a377-4c90-9453-59baf1089366"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="id967fc79551b44ac97ef5042140ac816_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzQtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246YTk5OTFiN2I1YjI5NDY2OGJkMDc3MTZjOTcyYjhjMDBfMTI_ca2145b6-8eb9-492a-bb5e-b6890dfc76c7"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic6d15fd3bd7a46d697fa1cb5eb430566_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246OWVmZDAwYTdmMzc5NDNiZjgzMWM3MzMyYjYxYmVhMDNfNA_b666ebfa-5206-4bb1-8890-29cd7917e25c"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic6d15fd3bd7a46d697fa1cb5eb430566_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMi0xLTEtMTg4OTc0_47f7bf10-ddf5-432c-bee7-8ecdadb11b57"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iff0e1c427c4f46afbcaa4a68bfb4d2e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMi0xLTEtMTg4OTc0_635b0c47-6879-4527-8371-22335b873f85"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ia7d6ca660c7746d3b61378810b89801d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246NTJmMDkzYTA1YWJkNDhiYWFhNmJhZjA5MzA2NmVmYjZfMTI_13169e53-8417-4b9f-9ff5-57415894d5c2"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i9b59b91df70443e68676c97eacce25d3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzUtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246NTJmMDkzYTA1YWJkNDhiYWFhNmJhZjA5MzA2NmVmYjZfMTI_3c8577f0-e846-4ee1-8ed4-9647405422c9"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i40fd98a8110c4ff289fab753a7c5a2ca_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246YzdhMDRkNjk1ZjMyNDI5ZmEzODU0OGViMjk0NzZjNjNfNA_b03284d5-8452-4061-83d1-703d2e57c73a"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1ee57e5a8a3245a6a3cb9a15be5df829_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMi0xLTEtMTg4OTc0_067a1ae7-c168-4e8f-b859-ccdb75abf677"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i40fd98a8110c4ff289fab753a7c5a2ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMi0xLTEtMTg4OTc0_e82616e4-5528-4f44-a5e7-b0aa89388f0e"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ic29bd0cf7cf0435990f458b78cd7e2dd_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246MmZjMDNiOGZmNTFjNDI5MDg5N2I1NThjNGU1ZTE0ZjVfMTI_25c4e109-1648-442c-b5d3-e07667fbb807"
      unitRef="number">0.010</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i8320821864644efe8f0edb105edca9e4_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzYtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246MmZjMDNiOGZmNTFjNDI5MDg5N2I1NThjNGU1ZTE0ZjVfMTI_cf07c1d0-3805-4582-971f-ee57ea841808"
      unitRef="number">0.010</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0947ed7f05cf44148673b8fdbbb01f40_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMC0xLTEtMTg4OTc0L3RleHRyZWdpb246NWRiZmE4NmI5YjdjNDRkYzkxNDc1ZTkyNWI1ZTQ2MjVfNA_21390276-e6b3-4fff-82db-1c67c9416c46"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0947ed7f05cf44148673b8fdbbb01f40_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMi0xLTEtMTg4OTc0_08f6874a-bda8-4c57-a903-fc0bc0118611"
      unitRef="usd">500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1a4586b2c0174806b7f34ea5bd75a188_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMi0xLTEtMTg4OTc0_24a4379a-feb4-4fb8-aa3f-a63adf134440"
      unitRef="usd">500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ic5fea782081e4895be4943c726463c8b_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMy0xLTEtMTg4OTc0L3RleHRyZWdpb246ZDc5MWUxN2UzYmIzNDYyMWFlNDg5NGU0ZDI1MzNjNDZfMTI_73cb22d9-794c-4a2c-b226-59319954600f"
      unitRef="number">0.008</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ifd293d73d43e4b46885dca2ec515d496_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzctMy0xLTEtMTg4OTc0L3RleHRyZWdpb246ZDc5MWUxN2UzYmIzNDYyMWFlNDg5NGU0ZDI1MzNjNDZfMTI_a78b6f2b-8c04-42b8-8e20-41a7f3a0bcf0"
      unitRef="number">0.008</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i233084f1697843b28ef19302f4ca18c2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246OWM5ODA2ZmE2Y2MxNGJiMjg0MzJkZjQ0YzFkOTE3N2FfNA_9d661bcd-038d-406e-8b45-5cdda82d5809"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i983918d489184fe48f8103d3daedddca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMi0xLTEtMTg4OTc0_97bb58bf-453c-4020-9961-4ec1ba24a6d1"
      unitRef="usd">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i233084f1697843b28ef19302f4ca18c2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMi0xLTEtMTg4OTc0_cd242d73-6e82-43f4-a3a3-c013de7299f2"
      unitRef="usd">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i525ba3ed8d5d45f998cd0b44ccdf96d7_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246MzhiNWFjMzViYjIwNDBmMjhiN2E3ZWZkYmIyNWFiMzRfMTE_6403866c-d381-4936-ac76-c21e94d34348"
      unitRef="number">0.041</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i6df68bf77edd43e0967eb97c5820dae5_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzgtMy0xLTEtMTg4OTc0L3RleHRyZWdpb246MzhiNWFjMzViYjIwNDBmMjhiN2E3ZWZkYmIyNWFiMzRfMTE_d7d702a0-30a7-4562-8216-82b4f37d8844"
      unitRef="number">0.041</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id934c9ad45d24abcaed4f914bd53414a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzktMi0xLTEtMTg4OTc0_014eb2f6-9703-49a5-8147-003bcf27f263"
      unitRef="usd">6650000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i93560032f3de4bcfb44d52d784c56eb4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo5MWQ5OWRmNDkyODI0MGMyYTVkMTA2ZmYxMWI3MTIwZC90YWJsZXJhbmdlOjkxZDk5ZGY0OTI4MjQwYzJhNWQxMDZmZjExYjcxMjBkXzktMi0xLTEtMTg4OTc0_85619f11-5a1b-452f-b28e-30eaf776d7ad"
      unitRef="usd">6650000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if925782f8a6e48fb9707082d9722b522_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1MTM_73742113-0ea8-4150-a1d6-6ce2bb677136"
      unitRef="usd">940000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if925782f8a6e48fb9707082d9722b522_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU1NTM_4d6ab4cf-2e4f-40fd-80eb-43482b4e5b8a"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjE4_c3438209-5d75-41aa-88e8-5e59b8cae478">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal amount exchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% 2037 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% 2038 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% 2039 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% 2040 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% 2041 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% 2042 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% 2043 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idc5f965633bd497bae6b284f87fd754a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzEtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246M2I5MmJkNTZkMzM0NDExNmE4OWNlMTdlM2ZkYzc5ZGJfNA_aeb7c168-3eb0-45b7-a4d9-485c9b22514d"
      unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="iddb555093f204b73ad69194c448331d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzEtMS0xLTEtMTg4OTc0_4aa9b7c6-6222-42cd-bbe5-a5afe2d2d228"
      unitRef="usd">74000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4aff41f7e3e648c9be7ca6b79abca8e4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzItMC0xLTEtMTg4OTc0L3RleHRyZWdpb246YjViOTgwMDM0MjBiNDJiODkxOGEwNTEwMjExZGE5ZGRfNA_7ddecfb7-644a-45f1-8c73-f27edc39d044"
      unitRef="number">0.0690</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i0f4b32aef48940438e79c7f4fdd934dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzItMS0xLTEtMTg4OTc0_82b88177-4fec-40d6-a7c6-99668b6dca82"
      unitRef="usd">37000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i07692f763cdc46eb807c9eab3a20b027_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzMtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246N2YyMjAyMjE0MGQ3NDQ0MjljMDg5MmNkY2E2MThjOTBfNA_06bd6dfc-40c5-4bad-969b-b0d2ba0e8fb9"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i626e02e818cb4ed494a4840a11c2d6c4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzMtMS0xLTEtMTg4OTc0_54746616-d9e7-4344-a9fa-f68d1b937340"
      unitRef="usd">133000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a2c9ab1d0d74042b5625c4d3863fc9a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzQtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246NmJiYTlhY2NlYThhNGU4MjgzMDY2NGMzNWViYzI5MzRfNA_8b8b2b8e-c927-4a12-a654-5c57374b83ce"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="if8e42823293746a6bb668e39faa8573a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzQtMS0xLTEtMTg4OTc0_ea0cff8f-a2b8-4e9e-be4a-7be598dd6ed8"
      unitRef="usd">39000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i799db871194f4747ab9f6118c675a2f7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzUtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246N2YzNjhlODRhN2E2NDRjNTljMWNjOWM2NTE4YTA4YTNfNA_374caa35-2ef5-4f15-94f4-1a46626a4663"
      unitRef="number">0.0515</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i230ad1456faf4cd5ae3a81c4e040d168_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzUtMS0xLTEtMTg4OTc0_7e93260a-38dc-4dc7-8d14-c923c1eb7c4c"
      unitRef="usd">245000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2ceee26f1075435e9fdfdd7a75a72ab5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzYtMC0xLTEtMTg4OTc0L3RleHRyZWdpb246ODQwZGZkZmE0NDhmNDExMGFhZTAyNTY2ZjgzMTg2YjNfNA_81ea469d-1fbe-495b-8231-883e0c3118c0"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ia6e784458a35492fbec6c0e6c982a3f6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzYtMS0xLTEtMTg4OTc0_f91b9d3d-ce36-43f7-bdcc-787f91de7f2b"
      unitRef="usd">72000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieadcf920bf8f4c5f9aa97d54a77a11ee_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzctMC0xLTEtMTg4OTc0L3RleHRyZWdpb246ODQzN2E4OTI5MDE4NGY4NTliNWNiOTgyNjNhOWRlMTdfNA_09fec4c8-757c-4262-94f3-8a969bfd36ab"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i90e35bf522a340e79908048767761c5f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZTo0MGI5MmVmMGVmYmI0OWIxYjczOTdmMWJlNDAzYTM3Yi90YWJsZXJhbmdlOjQwYjkyZWYwZWZiYjQ5YjFiNzM5N2YxYmU0MDNhMzdiXzctMS0xLTEtMTg4OTc0_de6e9710-5f38-4404-aa76-79a5c39f446b"
      unitRef="usd">76000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU3NTc_b39bf9ad-5f8d-4478-845d-80be5f060642"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if925782f8a6e48fb9707082d9722b522_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzYwMjQ_39c14ba8-e579-4be7-abe4-2df73b990d9c"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:DebtExchangeAdditionalCashConsideration
      contextRef="if925782f8a6e48fb9707082d9722b522_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzYwNzg_ed833c9a-b812-4e35-90e8-0cee3c199d67"
      unitRef="usd">85000000</amgn:DebtExchangeAdditionalCashConsideration>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="if925782f8a6e48fb9707082d9722b522_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzYzMjM_1226ad1a-f3fe-434a-887d-9b8662e5afa3"
      unitRef="usd">264000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0c0c22ebe78346a996c2daeeeab201b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzYzNTU_d292945c-0af6-4d66-81f4-dfcc9f40d384"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3f393109a944495bbe43538e525fdba7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY4MjU_de3b3e13-a596-4a0a-b3ea-b331381f5c62"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if4039b3cb11c419c948393d621712209_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY4NTI_beb873d7-918c-4c1d-bab0-8157356cf7b6"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d9211ecea36437580bc7b0a70919e0b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY4NzI_d5fd4be4-c1ac-4c25-ba49-01bba0356ad3"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i385a16395bf64c2bb403ca851a184d2a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzY5MDU_ed44c33e-7368-45a4-b946-1ff2ee58780a"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8ebc1d1a288841db9bff22881bf98a61_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzcyMDg_540926ea-7dac-4215-a4fe-2024a6a58cc6"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i72e2726b4b0146ca9ec8b95c68183d50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc1ODM1_feceb19b-8bce-402c-a276-7e57b100b093"
      unitRef="eur">1250000000</us-gaap:DerivativeNotionalAmount>
    <amgn:MaximumBorrowingCapacityUnderCommercialPaper
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzc0Njk_052b2b1e-c7de-4b0e-b432-9225965e8c9f"
      unitRef="usd">2500000000</amgn:MaximumBorrowingCapacityUnderCommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU0OTc1NTgzNTAyOA_85a9def5-0242-4208-959a-8ebad48392d7"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU0OTc1NTgzNTAyOA_bd05617d-aba2-4f1a-95d3-f95a0c5014a2"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2421a70ae11841d09f5ec2cee484630d_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzc2NzA_f10ab0bf-dc65-45e5-a805-aa0a69fc33a5"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <amgn:AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks
      contextRef="id0717808e41b45288577472d48ad1319_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzc5MTM_c80efee5-5e02-421d-a50b-6d9f9d0516d7"
      unitRef="usd">750000000</amgn:AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks>
    <amgn:LineOfCreditFacilityInitialCommitmentTerm
      contextRef="id0717808e41b45288577472d48ad1319_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzgwMjY_09e35c5e-7fee-47bc-af33-edc2bc3c5a9e">P5Y</amgn:LineOfCreditFacilityInitialCommitmentTerm>
    <amgn:LineofCreditFacilityNumberOfRenewalOptions
      contextRef="id0717808e41b45288577472d48ad1319_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzgwNjY_1bb73270-997d-4fb4-a89f-43110dc3f483"
      unitRef="renewal_option">2</amgn:LineofCreditFacilityNumberOfRenewalOptions>
    <amgn:LineOfCreditFacilityExtensionOfCommitmentTerm
      contextRef="id0717808e41b45288577472d48ad1319_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjI3_c899f0a7-313e-4236-a608-c3882cdd3120">P1Y</amgn:LineOfCreditFacilityExtensionOfCommitmentTerm>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTc3NjQ5_07aee1e6-dc00-48fb-9f1c-5aaba40a4138"
      unitRef="number">0.001</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i400cdd89c79b4ce0a15e3ad45f90a859_D20221201-20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0ODQzNDA2OTkxNjU1_582b25a7-dc8f-4980-ab84-0be8f34b6e35"
      unitRef="number">0.01125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id0e7270e76304c008e4095e3dcaa84f5_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzg1MjE_6fd7a633-75d2-484a-a80f-262d4ef456a9"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i400cdd89c79b4ce0a15e3ad45f90a859_D20221201-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0ODQzNDA2OTkxNjQ3_93cbf1c2-48a7-463e-b3b9-4fd4804b2fce">one-month SOFR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i400cdd89c79b4ce0a15e3ad45f90a859_D20221201-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0ODQzNDA2OTkxNjQ5_7105bce0-6f61-4479-a119-ff2885bd4022"
      unitRef="number">0.011</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCredit
      contextRef="ib35744505c1e440c82abbaf57f20fe46_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzg3Mzk_7cfe718d-882d-4a39-a85e-f634fe42c7a9"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i2421a70ae11841d09f5ec2cee484630d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1Xzg3Mzk_bfffce29-0269-4b3d-b7f3-6726ee1a2ef8"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <amgn:BridgeCreditAgreementInitialAmount
      contextRef="ieafdc665523f4a6289df98ee45f3ca5b_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzU0OTc1NTgzNDI0Mg_795a1839-aef3-4304-ac85-4b26ff07e303"
      unitRef="usd">28500000000</amgn:BridgeCreditAgreementInitialAmount>
    <amgn:BridgeCreditAgreementAmount
      contextRef="ic520f1877b1b468fb3b71c4ec23d7a05_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjE1_3e7ef8d2-adcc-418e-a858-3904351d365f"
      unitRef="usd">0</amgn:BridgeCreditAgreementAmount>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzEwNjIx_467e392c-cb13-4217-9a9e-5b166ccf71bf">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate contractual maturities of all borrowings due subsequent to December 31, 2022, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzEtMi0xLTEtMTg4OTc0_f8ddd53d-09f2-404a-8f17-ed5976f4859d"
      unitRef="usd">1509000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzItMi0xLTEtMTg4OTc0_3d9a6c9b-04a4-4644-93f4-9e49639d74a4"
      unitRef="usd">1400000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzMtMi0xLTEtMTg4OTc0_71a99e30-766c-4429-9a4e-934563a3d2c8"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzQtMi0xLTEtMTg4OTc0_953d44cb-88d9-46e0-82fe-0d79bc5ae70b"
      unitRef="usd">2627000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzUtMi0xLTEtMTg4OTc0_d55f67a4-c074-4f78-9a92-dfaabc10439f"
      unitRef="usd">2724000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzYtMi0xLTEtMTg4OTc0_0a49fbc6-1489-4ede-a889-5e38ae84f8d0"
      unitRef="usd">30868000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <amgn:LongTermDebtMaturitiesRepaymentsOfPrincipalNet
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90YWJsZToxMDJlMDU2NDI0ZTI0ZjlkYTQ4OTdlMzhlMjAyNjA3My90YWJsZXJhbmdlOjEwMmUwNTY0MjRlMjRmOWRhNDg5N2UzOGUyMDI2MDczXzctMi0xLTEtMTg4OTc0_4b4a0bc0-9b1f-4800-bc85-219e022b4d79"
      unitRef="usd">40628000000</amgn:LongTermDebtMaturitiesRepaymentsOfPrincipalNet>
    <us-gaap:InterestPaid
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjYz_10fa6b2d-2671-4fa0-b322-c5384b07dbdc"
      unitRef="usd">1200000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjYz_44fcf620-64e1-424b-b3e8-998bb2f5d9aa"
      unitRef="usd">1200000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzUvZnJhZzo2MzgyNzZlNGZjODM0NjY2ODBmMTkxZmZkMjJmMzcwNS90ZXh0cmVnaW9uOjYzODI3NmU0ZmM4MzQ2NjY4MGYxOTFmZmQyMmYzNzA1XzE0MjkzNjUxMTgyMjYz_5d9a832d-3f35-4bab-947c-1321b39e8dfd"
      unitRef="usd">1200000000</us-gaap:InterestPaid>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzIwNDc_a4eac11b-adbb-4f15-983a-255152b9151f">Stockholders&#x2019; equity&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock repurchase program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2022, the Company entered into ASR agreements with third-party financial institutions (Dealers) whereby the Company made payments in an aggregate amount of $6.0 billion to the Dealers and received and retired an initial 23.3 million shares of the Company&#x2019;s common stock from the Dealers. The payments were recorded as reductions to shareholders&#x2019; equity, consisting of a $5.1 billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $0.9 billion decrease in additional paid-in capital, which reflects the value of the stock that remained to be delivered by the Dealers. During the third quarter of 2022, an additional 1.5 million shares of the Company&#x2019;s common stock were received from the Dealers which constituted final settlement under the ASR agreements, and accordingly, the $0.9 billion decrease in additional paid-in capital recorded in the first quarter was reclassified to accumulated deficit. In total, we repurchased 26.1&#160;million shares of common stock during the year ended December 31, 2022, consisting primarily of the 24.8 million shares received under the ASR agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $2.4&#160;billion. As of December 31, 2022, $7.0 billion remained available under our stock repurchase program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors declared quarterly dividends per share of $1.94, $1.76 and $1.60, which were paid in each of the four quarters of 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 12, 2022, the Board of Directors declared a quarterly cash dividend of $2.13 per share of common stock, which will be paid in March 2023, to all stockholders of record as of the close of business on February 15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of AOCI were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&#160;flow&lt;br/&gt;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Available-for-sale&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $19 million expense and a $0 million expense in 2022, a $33 million expense and a $55 million expense in 2021 and a $14 million benefit and a $110 million benefit in 2020, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $1 million expense and a $7 million benefit in 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of AOCI and into earnings were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2022 and 2021, no shares of preferred stock were issued or outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <amgn:StockRepurchaseProgramTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzIwMzg_7227f26b-c641-42f5-8763-7c1192787582">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:StockRepurchaseProgramTableTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i2f1639085198472380ac8baa83001db0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtMS0xLTEtMTg4OTc0_5befe1b1-641e-41d7-8bb8-8142ae1c1cd5"
      unitRef="shares">24600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2f1639085198472380ac8baa83001db0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtMy0xLTEtMTg4OTc0_f724855b-aacb-44bc-a5ed-b640c0bbce3b"
      unitRef="usd">5410000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i9bc00ec3fc9549debfc91c2a92aa5314_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtNS0xLTEtMTg4OTc0_367d7a59-6a8d-42b3-ac51-c2dd2cad8366"
      unitRef="shares">3700000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9bc00ec3fc9549debfc91c2a92aa5314_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtNy0xLTEtMTg4OTc0_66594f0c-cfc5-4bbb-a21d-ce11e9aaca9f"
      unitRef="usd">865000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i9e695d739c9d4986a787a639a8e8a77b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtOS0xLTEtMTg4OTc0_68263203-fafc-4eab-85b0-f4f55c746882"
      unitRef="shares">4300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9e695d739c9d4986a787a639a8e8a77b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzMtMTEtMS0xLTE4ODk3NA_f23c5d2e-36d7-4052-b538-ac1aa225214d"
      unitRef="usd">933000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ie81249a29133467eabb1d34b6bdc5483_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtMS0xLTEtMTg4OTc0_87d6621e-18ed-477b-a6a6-797d1acc8559"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie81249a29133467eabb1d34b6bdc5483_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtMy0xLTEtMTg4OTc0_f51469ae-2970-4acb-ad4e-40ab962e6a28"
      unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i50725a0076ed4b89ba38bcbbbfecd2a2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtNS0xLTEtMTg4OTc0_3abe5961-7cb4-4122-9767-ffed7df2a029"
      unitRef="shares">6500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i50725a0076ed4b89ba38bcbbbfecd2a2_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtNy0xLTEtMTg4OTc0_27c8a73f-0c57-493b-ab60-b44205f672c1"
      unitRef="usd">1592000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i2a53ed11f70c43369915dd0d29dbb42a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtOS0xLTEtMTg4OTc0_383b8058-1203-4f3b-a3e1-3f08a5a2e329"
      unitRef="shares">2600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2a53ed11f70c43369915dd0d29dbb42a_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzQtMTEtMS0xLTE4ODk3NA_103a246c-f1e6-4f35-bc64-c5b7e67f4b80"
      unitRef="usd">591000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i4136b215dbf24da08247954154d63658_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtMS0xLTEtMTg4OTc0_aa2e2129-7704-4f5e-80ac-b4ca4ccc0e3a"
      unitRef="shares">1500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i4136b215dbf24da08247954154d63658_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtMy0xLTEtMTg4OTc0_242fb390-2fe7-4a31-9e04-8725cecf0b22"
      unitRef="usd">900000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0d0caaabac894eaaaa6744f8d15302de_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtNS0xLTEtMTg4OTc0_15938095-3e74-402b-aaaa-11de3b417364"
      unitRef="shares">4600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0d0caaabac894eaaaa6744f8d15302de_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtNy0xLTEtMTg4OTc0_f38b32a9-ffc3-40a4-9232-b0388870aa36"
      unitRef="usd">1069000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8267ea8792a8481e880966120cbb1033_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtOS0xLTEtMTg4OTc0_a5e0c686-898f-4778-950e-8796d823e78c"
      unitRef="shares">3000000.0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8267ea8792a8481e880966120cbb1033_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzUtMTEtMS0xLTE4ODk3NA_eed042a3-8fe3-4ac4-b428-0c2579cc7ad6"
      unitRef="usd">752000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtMS0xLTEtMTg4OTc0_b791375c-219d-4c4b-b3a5-f169f9d02dbe"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtMy0xLTEtMTg4OTc0_7cb3b64e-d4e4-4603-b028-45fd6cdb37c9"
      unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iaa03d6422826451ab8c9411225c3e9c9_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtNS0xLTEtMTg4OTc0_29d22816-d0aa-439f-98f9-741f92853d99"
      unitRef="shares">6900000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iaa03d6422826451ab8c9411225c3e9c9_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtNy0xLTEtMTg4OTc0_249cdaf5-e27a-4ecd-8d0f-8b43706ebda8"
      unitRef="usd">1461000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i78ea81b8276943f0b89ca47f8b931e80_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtOS0xLTEtMTg4OTc0_9799947d-1d1e-4dc3-8819-a8f3fcdcbaed"
      unitRef="shares">5300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i78ea81b8276943f0b89ca47f8b931e80_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzYtMTEtMS0xLTE4ODk3NA_d6fff1ab-ee20-41ec-a765-3b79d8b150d9"
      unitRef="usd">1221000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctMS0xLTEtMTg4OTc0_45f8971a-a1d9-488d-9ce3-5debde598c2a"
      unitRef="shares">26100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctMy0xLTEtMTg4OTc0_d0b0de77-4e4b-4d53-ae5c-5b56e52c3ac0"
      unitRef="usd">6310000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctNS0xLTEtMTg4OTc0_0ad3ed23-b11c-4c67-a425-f2a91c5c869c"
      unitRef="shares">21700000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctNy0xLTEtMTg4OTc0_302a9f7e-cc93-45d4-b1b5-573a15c5e962"
      unitRef="usd">4987000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctOS0xLTEtMTg4OTc0_80dfc74e-6e0e-45c4-8c0a-56b138e2dd04"
      unitRef="shares">15200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTo1OGUxZjI4ZDg0OWU0YjJmYTAwNGJkMjdhZWJlODgwNy90YWJsZXJhbmdlOjU4ZTFmMjhkODQ5ZTRiMmZhMDA0YmQyN2FlYmU4ODA3XzctMTEtMS0xLTE4ODk3NA_a0be91ed-7019-43c3-8d90-2c4cea51f4da"
      unitRef="usd">3497000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i79222ac692e1477aba781d2ff3a5f7c5_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMxOTg_739a8a11-7763-4f37-9250-7d89f5a43664"
      unitRef="usd">6000000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i79222ac692e1477aba781d2ff3a5f7c5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyMTY_37a39082-e314-4d5c-9e8e-12a88dd2957a"
      unitRef="shares">23300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i1cb79e8187a746398d43e3bd13cc6898_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyMzY_05fefa9b-2fd5-48ba-943d-cc36174b1d75"
      unitRef="usd">5100000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i77bd16e1aee146a682056d066f6539d3_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyNTU_af7c73d6-ca03-4011-b5b1-cae19510d931"
      unitRef="usd">900000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iae1609cedcdb41f08bdbbf907cf65e3c_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyNzQ_69d6014a-c36a-4e6a-a0f9-6f5b1f4ce4c9"
      unitRef="shares">1500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i09775729f39c42a3a86f1013c58734d4_D20221001-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMyOTI_7999d8ce-b3fe-4563-a9b3-e34ff22cc15f"
      unitRef="usd">900000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0MjkzNjUxMTY1MDM1_e168981e-d826-4e43-8ff1-43002ffc4ccb"
      unitRef="shares">26100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ia2d9c119784043f18fc9dc9683bc2ff7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzMzMzk_d0e40df2-89f3-4447-a970-614a787071e3"
      unitRef="shares">24800000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i3de1e54db16b45a680ea17867c15ae9a_I20221031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE2Nzg_94cc2567-493c-4400-9b5c-834ea23df594"
      unitRef="usd">2400000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzM3Mw_89d01815-9d63-4048-9e0f-418fc97675b8"
      unitRef="usd">7000000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib07ee9684f834ac189f302e8ce8f8377_D20211201-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_1c6729dc-7443-43ca-acb6-796b6e36fc22"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9d05f148289f4f8ebcab61f83ce94ee7_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_42a4a9da-34e1-4284-839a-2fe0b2d70bf6"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i4136b215dbf24da08247954154d63658_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_43a2254a-e666-490d-97b7-595ca0ba9b2b"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i0375ffbe4dcf4bdaaf2abf150f3bca4e_D20220801-20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_49e437ad-c612-4b53-a994-fe804ba76ea7"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i2f1639085198472380ac8baa83001db0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_584fc2c7-1caf-4d91-9e8e-d88142773633"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i1f2c6f9b7a7a46e09d3931f0d8199da3_D20221001-20221031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_8662fd96-6777-4fb4-a05d-e572d5f23d3b"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ie81249a29133467eabb1d34b6bdc5483_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_e5fbd2c6-fd6b-4b14-b75a-5ed2d9347bc5"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzI3NDg3NzkwNzE3MzA_ee9114b3-6e19-4339-a1bf-c97e922b3f4c"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="iaa03d6422826451ab8c9411225c3e9c9_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_00b7ae48-f8f3-4fb6-b933-672ddd9d3858"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i1351e1c5d58d4b228b689baa94a08823_D20211001-20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_2f15d4cc-e6f9-458f-adfe-a05b438c697e"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i50725a0076ed4b89ba38bcbbbfecd2a2_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_3a407176-a8a1-42e8-9bb7-0adc236bcd99"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="idcc68e5fe01f4338a8c7676f9e5e9152_D20201231-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_532dc62b-bdf1-4122-bd92-09ac1bb4efbc"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i9bc00ec3fc9549debfc91c2a92aa5314_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_6f686a8e-e446-47a3-85be-d68b17e4ea0a"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="idd1a7ea27d4e4ea893aefca7f2ae9dd4_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_990d1d51-8771-4695-9ef4-3a2559077484"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iffab2bf10a0b4ec490ac20e7b6b5f6fb_D20210701-20210731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_e056550a-ec88-4b8f-81fb-11f15b581c9a"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i0d0caaabac894eaaaa6744f8d15302de_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUwNw_f0f1ceb6-05c9-42ef-8b00-4d2b64191b5a"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i78ea81b8276943f0b89ca47f8b931e80_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_37787581-606e-4ee5-8ada-9d5b001f86d8"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i8267ea8792a8481e880966120cbb1033_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_3f1300c1-ed37-4d0a-b027-6ec9fafd8191"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i2a53ed11f70c43369915dd0d29dbb42a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_7eb8bab9-3be5-4ebb-ad71-6c6ae0ab4e53"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4c44917d50b84030bdfa5f48afb2fd94_D20191201-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_ac410820-9e72-4ae4-9f65-a27976fd78ac"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i17bd2c1e1f6646129c19ffebbe131aa9_D20200301-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_bb4916c1-e510-4528-bbef-1fe73e181921"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2f99105a26404ad389de99b212cfe895_D20200701-20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_d1758898-f3e1-487a-8e1a-80615d00b41b"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i213496b5cf4a425b96468749b0447825_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_d3d67183-465a-4eec-9709-030e8af6a978"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i9e695d739c9d4986a787a639a8e8a77b_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzUxMQ_e782405d-4cb5-43d7-a828-dab847e67dd8"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i547af651cb9446b18cc108538306f5ab_D20230301-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0MjkzNjUxMTY1MzI1_1baf06ef-73d2-4bc2-94eb-2e29e7aa4f53"
      unitRef="usdPerShare">2.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib9817fa1cfe3409a975c7a8b3cdefd06_D20221201-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0MjkzNjUxMTY1MzI1_89314c70-5d2e-41ed-acae-8b2fe46e8d57"
      unitRef="usdPerShare">2.13</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzIwNDg_09f93e6e-bdbe-49e9-80e7-b0326256aec8">&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of AOCI were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&#160;flow&lt;br/&gt;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Available-for-sale&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i0e32313a221f41ad8ccd356225fd8eb0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtMS0xLTEtMTg4OTc0_0e5e5872-3bce-4233-a15a-d29bf79401c0"
      unitRef="usd">-718000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i561b1b87095d42118b9170aa94c6c7ea_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtMy0xLTEtMTg4OTc0_9a2a6ff2-24c8-4b44-90ab-f329ee0478d4"
      unitRef="usd">175000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1631e26b0d454c06bcc4b0fc4c38dcdc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtNS0xLTEtMTg4OTc0_78d8de84-6053-44d1-906d-1d403db71fde"
      unitRef="usd">22000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if15d8369eda74b4090810b1af2596778_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtNy0xLTEtMTg4OTc0_45ee791b-02af-44ac-bc1c-0aec4f93214e"
      unitRef="usd">-7000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecb02e3f6128454a820a56e2cfbb6e3f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEtOS0xLTEtMTg4OTc0_6d92d80c-3ccb-4047-aa99-c9708ed6ad28"
      unitRef="usd">-528000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9b691b97c86241478dd9d32f77155dd2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzItMS0xLTEtMTg4OTc0_a8a82d0a-b813-43f3-b06e-703e94a345c8"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzItOS0xLTEtMTg4OTc0_582aa17c-ef13-41e9-b65c-b405f9431cf9"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ibe3a213cdc9d4969b1391eef5c1c503f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzMtMy0xLTEtMTg4OTc0_d9c1ff5f-84cd-42b9-83c6-a98dc0ff4e90"
      unitRef="usd">-61000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ie255fb9441af4696b7b5537c9d7d9ffb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzMtNS0xLTEtMTg4OTc0_7bfaff0c-8dff-4fdc-811e-92cde33f00f1"
      unitRef="usd">6000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzMtOS0xLTEtMTg4OTc0_f6acdca6-2b42-4efe-9c1d-afd51369744d"
      unitRef="usd">-55000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ibe3a213cdc9d4969b1391eef5c1c503f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzQtMy0xLTEtMTg4OTc0_68d746c9-0a91-4abc-a6e3-e74fc53a59dd"
      unitRef="usd">501000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ie255fb9441af4696b7b5537c9d7d9ffb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzQtNS0xLTEtMTg4OTc0_f16a8502-c4f0-4b8a-babb-0b17e2d77529"
      unitRef="usd">33000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzQtOS0xLTEtMTg4OTc0_bc5d32a8-1058-41a2-bd88-66a6fa7cf96f"
      unitRef="usd">534000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="i46d39b7cc594460ca05a08fe50fe2af5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzUtNy0xLTEtMTg4OTc0_2ffb1c44-d539-4c10-8ffa-f611fe288698"
      unitRef="usd">-7000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzUtOS0xLTEtMTg4OTc0_9f06a140-ace5-49cd-a198-28fc67c379a2"
      unitRef="usd">-7000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i9b691b97c86241478dd9d32f77155dd2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzYtMS0xLTEtMTg4OTc0_c66624e9-5c3f-47dd-8358-84b31d4c025a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ibe3a213cdc9d4969b1391eef5c1c503f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzYtMy0xLTEtMTg4OTc0_0dabe21e-13cd-4a25-91cc-92f264f31746"
      unitRef="usd">-124000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ie255fb9441af4696b7b5537c9d7d9ffb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzYtNS0xLTEtMTg4OTc0_0707a102-6321-44f2-99ce-6c40e6e5d6df"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ief1a47791c7f42599aacea53954586bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzYtOS0xLTEtMTg4OTc0_d70aa805-498e-4401-9193-833429a1b2f3"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="id8ce4697430147afaaf15b34b37a2893_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctMS0xLTEtMTg4OTc0_1767e527-2bf6-4bcd-b232-89ee866aaa04"
      unitRef="usd">-709000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibad7d8f86bf24966a05f5ef686ce8c79_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctMy0xLTEtMTg4OTc0_8e0e20b7-0d14-4a18-ab8b-cb6f5d52477d"
      unitRef="usd">-263000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07bf0adb842e42abaf0c52d80659a7f7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctNS0xLTEtMTg4OTc0_d59f7eec-4413-47a9-8d59-706d020a6585"
      unitRef="usd">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i03d505608dcf4454bc0a6caf5d45ad79_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctNy0xLTEtMTg4OTc0_80a9b877-3994-4417-86be-b925c482b8fe"
      unitRef="usd">-14000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e70878840254d839c51604f86fab42a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzctOS0xLTEtMTg4OTc0_492f13f4-b10d-4ef6-9a61-d3b7c26c86a8"
      unitRef="usd">-985000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia6ba3418eed04a19b1d923ff8948405e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzktMS0xLTEtMTg4OTc0_426142c4-6b44-40df-ba8f-04b0388584ef"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzktOS0xLTEtMTg4OTc0_1f8b81bf-e21b-4764-869a-3c087f60c3aa"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ic6baac2693814ca29a0d4ae5530452b6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEwLTMtMS0xLTE4ODk3NA_a76c9129-c1e1-470a-9510-7b9b77433603"
      unitRef="usd">159000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ic696a300be6d4aa6a52c2fbcdfb34389_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEwLTUtMS0xLTE4ODk3NA_0f38a5a0-6caa-4a83-9193-e1b5b059587c"
      unitRef="usd">-1000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEwLTktMS0xLTE4ODk3NA_16802054-d435-472f-bd93-72762e292562"
      unitRef="usd">158000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ic6baac2693814ca29a0d4ae5530452b6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzExLTMtMS0xLTE4ODk3NA_c6a390b1-88e9-4e3a-84a1-2b1bfd703e97"
      unitRef="usd">-253000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ic696a300be6d4aa6a52c2fbcdfb34389_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzExLTUtMS0xLTE4ODk3NA_96588e13-9d64-4f35-8f90-5c756db1f725"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzExLTktMS0xLTE4ODk3NA_e4c4c133-11d9-4df0-89cc-e1786b00ff49"
      unitRef="usd">-253000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="ia94576e55ab04deaaea5f1b0f981f32a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEyLTctMS0xLTE4ODk3NA_fff06662-ab8d-4959-b705-78af0f73045d"
      unitRef="usd">1000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEyLTktMS0xLTE4ODk3NA_6e73d691-ae43-40b1-b78e-85e2c9993060"
      unitRef="usd">1000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ia6ba3418eed04a19b1d923ff8948405e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEzLTEtMS0xLTE4ODk3NA_b517ee54-e7ba-4e03-875b-82c4bf1a4a1e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ic6baac2693814ca29a0d4ae5530452b6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEzLTMtMS0xLTE4ODk3NA_53b45b90-7c20-4921-8753-22cc984a9cd8"
      unitRef="usd">88000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ic696a300be6d4aa6a52c2fbcdfb34389_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEzLTUtMS0xLTE4ODk3NA_c20cf829-0bbb-4be4-ba37-47e0695b98fb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i4a45d0665f9c47509a079c1747adaeda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzEzLTktMS0xLTE4ODk3NA_e1712ec4-f8e5-4640-880d-c1cbb935d0cf"
      unitRef="usd">88000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="i47cab96086794a69b3747cf784732a9b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTEtMS0xLTE4ODk3NA_000fdfaa-f852-44df-817b-4ab3c40667ac"
      unitRef="usd">-844000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id21f25ed89f74791850385e82bcb5291_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTMtMS0xLTE4ODk3NA_46a3cdc0-bc9f-4456-b848-672ea843d32e"
      unitRef="usd">61000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a54ab8f414d41e9bfaf147b535c4239_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTUtMS0xLTE4ODk3NA_8b98a14e-912e-421a-b05a-cc5c6fed1872"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i074ac2af68414c0bbc7a1a601dca087a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTctMS0xLTE4ODk3NA_e51cda16-5145-476e-ade1-2aca17be8c6d"
      unitRef="usd">-13000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib964505bb2264c0e858b211061796b49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE0LTktMS0xLTE4ODk3NA_19a64fea-b241-4024-a029-5b42e468634d"
      unitRef="usd">-796000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i97279c89cb3b4d598cc35eb7287e230f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE2LTEtMS0xLTE4ODk3NA_2aa917ab-2962-416a-8709-1f49066db56b"
      unitRef="usd">496000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE2LTktMS0xLTE4ODk3NA_47dc265d-4edc-4cff-a690-7155cad8b535"
      unitRef="usd">496000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i90308d5f52fe46da90947c1f214b73db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE3LTMtMS0xLTE4ODk3NA_b7b027b4-5e1f-4dd8-a562-f5af891030f8"
      unitRef="usd">84000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ica9d03894dc947b0b0664666c999e8d2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE3LTUtMS0xLTE4ODk3NA_06cf15af-4793-4eda-b791-7a8ac4fa2bb2"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE3LTktMS0xLTE4ODk3NA_360ec901-77fc-4750-a3aa-12b6c33806d5"
      unitRef="usd">84000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i90308d5f52fe46da90947c1f214b73db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE4LTMtMS0xLTE4ODk3NA_ef60abc3-8f21-4252-8fa1-c881b1d45c18"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ica9d03894dc947b0b0664666c999e8d2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE4LTUtMS0xLTE4ODk3NA_620070d4-e9fd-4354-a7c7-de758e19fd78"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE4LTktMS0xLTE4ODk3NA_1d949298-5d73-4d49-9246-55cca4a0042f"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="i9c7085eb7de24bdf9364ff05d2d06c22_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE5LTctMS0xLTE4ODk3NA_c852ab3c-aae7-4476-b324-7731d58eb91a"
      unitRef="usd">2000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzE5LTktMS0xLTE4ODk3NA_665238d4-b833-4e8e-ac2d-eb83b5e396f2"
      unitRef="usd">2000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i97279c89cb3b4d598cc35eb7287e230f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIwLTEtMS0xLTE4ODk3NA_1b884697-b127-4748-a28c-1abc94b97c55"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i90308d5f52fe46da90947c1f214b73db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIwLTMtMS0xLTE4ODk3NA_29cfbc2c-52eb-4ab0-87b9-aaeab3ccb666"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ica9d03894dc947b0b0664666c999e8d2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIwLTUtMS0xLTE4ODk3NA_7bf89d08-adfb-4ec5-ba8e-22cd8e948d9a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="id3e5029151b34513ad88c8784a6dbc01_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIwLTktMS0xLTE4ODk3NA_7ccb023d-e6c4-4b2d-933d-71510fefdf47"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="i6cee74d142364011bb64569b6e7ff8a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTEtMS0xLTE4ODk3NA_e1e2bee2-1c45-48c1-9586-8a459ae080eb"
      unitRef="usd">-348000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if5592ef4a3504edaab5252ca41492cdb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTMtMS0xLTE4ODk3NA_7808b792-4ff1-43f4-9a04-e94426e4a8f5"
      unitRef="usd">128000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae23449150e54375b157ac5b160edbd9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTUtMS0xLTE4ODk3NA_b8af49b7-a83a-46c3-9bc3-0596c80b6dde"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idee57457aa704a5588746800b8bd3c58_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTctMS0xLTE4ODk3NA_4b566872-41a5-4059-a9f5-a9f22aa08478"
      unitRef="usd">-11000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i349ee45aa1e94ce9adf98a1fa8b76e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplOTJlNDE0YzU4ZGY0YTY4YWI3OWQ3Nzc0ODk3MDI1NC90YWJsZXJhbmdlOmU5MmU0MTRjNThkZjRhNjhhYjc5ZDc3NzQ4OTcwMjU0XzIxLTktMS0xLTE4ODk3NA_c458622d-e9c8-4e08-b024-2ba06960581d"
      unitRef="usd">-231000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzEzNzU_423d3b74-7e99-40ba-bf84-4c91b9352fb2"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzEzOTI_051cc4a9-734b-439d-9150-9a60345894c2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0MTI_118d1ebb-6bf7-4c36-b566-6a6aec9a28d8"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0Mjk_99fc9319-cda7-45a8-b9b3-57e166dbf6e9"
      unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0NTI_25690518-bd1b-4bc8-8c1d-de1d711f6e26"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE0Njk_8ff36606-623b-412e-8093-64857afdcec4"
      unitRef="usd">-110000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE3MDE_45f77ff8-12a9-470a-a0fe-4991ee6f4d86"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE3MTg_a1667655-70d5-47ac-842b-1487bb3c15b6"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzIwNDQ_80de8e4d-9fad-4463-8eff-3441195b40a0">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of AOCI and into earnings were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i23ea2249a07045cea77ac843dd3ee186_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzMtMi0xLTEtMTg4OTc0_91b3ecab-edd2-4e84-86f7-b7a7270d694e"
      unitRef="usd">231000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie6bae6c3e9ff45c4bc483aa371e79620_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzMtNC0xLTEtMTg4OTc0_ed3cd2e2-fd06-43c3-9d71-78ce749cdfc0"
      unitRef="usd">-8000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibc245132cc174af6870e31cfd882e769_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzMtNi0xLTEtMTg4OTc0_9fe7442d-12bf-446c-bbb9-f1b3685ebe4b"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icdafbb775bf94addace467b7558c90c5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzQtMi0xLTEtMTg4OTc0_44ea5b76-0e9c-41b1-bffe-d0051cd25a79"
      unitRef="usd">-233000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if6b34d2b5b6f4beba907bb845e7cc2b9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzQtNC0xLTEtMTg4OTc0_3d1e4b81-8207-417f-bf75-2b74e646c482"
      unitRef="usd">-245000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic916478fec014452ac32d62171a7e5fd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzQtNi0xLTEtMTg4OTc0_3b3787a7-d680-4344-8e5c-4da1e9a43495"
      unitRef="usd">323000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7fec4c1d74cc4014b5be9b695eda82a9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzYtMi0xLTEtMTg4OTc0_ff4a9164-6007-4d78-af99-02dbe6fc82c8"
      unitRef="usd">-2000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i521f9300ea9e4c53a353c3a3895f2a5e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzYtNC0xLTEtMTg4OTc0_c2d9e344-efe7-4c44-a624-46f316e8bf11"
      unitRef="usd">-253000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic8a53f0a87704f59a5cb2cfabcd59979_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzYtNi0xLTEtMTg4OTc0_5e534776-3821-4d48-9d5e-7c35849ea63c"
      unitRef="usd">501000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7fec4c1d74cc4014b5be9b695eda82a9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzctMi0xLTEtMTg4OTc0_669bf7b9-fdef-4321-8a84-4982f8d59f3f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i521f9300ea9e4c53a353c3a3895f2a5e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzctNC0xLTEtMTg4OTc0_b97711c0-3857-4256-a7d5-062163d9c87d"
      unitRef="usd">-55000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic8a53f0a87704f59a5cb2cfabcd59979_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzctNi0xLTEtMTg4OTc0_234bab92-704c-41a6-ae92-53c1de91f882"
      unitRef="usd">110000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i7fec4c1d74cc4014b5be9b695eda82a9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzgtMi0xLTEtMTg4OTc0_df204872-b610-49af-b31c-e087df3e3537"
      unitRef="usd">-2000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i521f9300ea9e4c53a353c3a3895f2a5e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzgtNC0xLTEtMTg4OTc0_a7008316-468b-485d-83dc-176a7e4595a2"
      unitRef="usd">-198000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic8a53f0a87704f59a5cb2cfabcd59979_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzgtNi0xLTEtMTg4OTc0_debd6ca1-1e8c-4604-afda-abf7950ed40c"
      unitRef="usd">391000000</us-gaap:NetIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i562b0243b6ba47edb88a24870e0e2a7d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEwLTItMS0xLTE4ODk3NA_525a4049-84db-4c6b-9d11-90cf7ac1575e"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iec76a0aa8be34cacb8193aae6cd1f062_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEwLTQtMS0xLTE4ODk3NA_4ba63aad-cede-4736-863b-332c3f0e7e7f"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id4567fe1b74d4ed5aa5d569e9dbeb8fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEwLTYtMS0xLTE4ODk3NA_c44b80cf-4866-4a16-85ed-b67b3277e6cd"
      unitRef="usd">33000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i562b0243b6ba47edb88a24870e0e2a7d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzExLTItMS0xLTE4ODk3NA_5ffa0c81-f9e8-4b3a-8f00-734b088abe0f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iec76a0aa8be34cacb8193aae6cd1f062_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzExLTQtMS0xLTE4ODk3NA_e6ebd3fc-4a16-4dc2-bc05-52100e9487ed"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id4567fe1b74d4ed5aa5d569e9dbeb8fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzExLTYtMS0xLTE4ODk3NA_2a7c2658-6c90-4c33-ac14-7c99a8b409e9"
      unitRef="usd">7000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i562b0243b6ba47edb88a24870e0e2a7d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEyLTItMS0xLTE4ODk3NA_491ef811-7b44-40f9-89f2-f57e61eb86da"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iec76a0aa8be34cacb8193aae6cd1f062_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEyLTQtMS0xLTE4ODk3NA_a3d45d03-adcb-40de-9302-6fa0000e2044"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id4567fe1b74d4ed5aa5d569e9dbeb8fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90YWJsZTplYWMyNzE4NGY1NmU0NmMxOWExOGI0ZGU2Mjc0OWU5YS90YWJsZXJhbmdlOmVhYzI3MTg0ZjU2ZTQ2YzE5YTE4YjRkZTYyNzQ5ZTlhXzEyLTYtMS0xLTE4ODk3NA_000ff9e1-753f-4b0a-9b50-800efd548ef7"
      unitRef="usd">26000000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE4OTg_652627c2-d29e-4e14-8acf-9e6f52dd83ed"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5Mjg_aff4663d-25d7-41ff-b364-c5241bd6cc0a"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5NTk_0d397db3-e840-4cd8-ab84-3490aae2e1c2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5NTk_391cfe6d-5dba-4326-832e-aba66d9e9d95"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5NTk_4716f66a-5b44-441b-b839-e4b5bcac9bdd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yMzgvZnJhZzozMWMwYjMwMDA0MTE0NmNmOTdkYzgwNTJkNDdiM2M2NC90ZXh0cmVnaW9uOjMxYzBiMzAwMDQxMTQ2Y2Y5N2RjODA1MmQ0N2IzYzY0XzE5NTk_5543d2fb-3cfb-4e04-ad31-7abb047f86b0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzcxMjg_145e0a56-cf77-4cd1-843d-ca0363fefa13">Fair value measurement&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations for which all significant inputs are observable either directly or indirectly&#x2014;other than Level 1 inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each major class of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2022, using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. Other investments consist of interest-bearing deposits that are valued at amortized cost, which approximates fair value given their near term maturity. The fair value of equity securities for which the fair value option was elected are initially valued at the transaction price and subsequently valued based on a combination of observable price transactions, when available, market performance and publicly available market information for similar companies that have actively traded equity securities. See Note 9, Investments&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neumora Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our foreign currency forward contracts, cross-currency swap contracts and interest rate swap contracts are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by S&amp;amp;P, Moody&#x2019;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs, as applicable, include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. Certain inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes to these inputs would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net changes in valuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Teneobio in 2021, we are obligated to pay its former shareholders up to $1.6&#160;billion upon achieving separate development and regulatory milestones with regard to various R&amp;amp;D programs. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of K-A in 2018, we are obligated to make single-digit royalty payments to Kirin Holdings Company, Limited contingent upon sales of brodalumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of BioVex Group Inc. in 2011, we were obligated to pay its former shareholders upon achieving separate sales-related milestones with regard to IMLYGIC if certain sales thresholds were met. During the year ended December 31, 2020, we determined that the likelihood of achieving these milestones was no longer probable, and accordingly, the obligations were written off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of the fair values of other financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2022 and 2021, the aggregate fair values of our borrowings were $35.0 billion and $37.9 billion, respectively, and the carrying values were $38.9 billion and $33.3 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in BeiGene&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2022 and 2021, the fair values were $4.2&#160;billion and $5.1&#160;billion, and the carrying values were $2.2&#160;billion and $2.8&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;During the years ended December 31, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzcxMzg_98ae7513-a770-48cc-9fb4-907344440400">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each major class of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2022, using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbc2fff9b80c4cfd94f8bf10fa1a0426_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzMtMi0xLTEtMTg4OTc0_22a3d266-75b2-4788-9781-80a4da5da2e5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f0eab2c4927424ea7412f20ed53a84a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzMtNC0xLTEtMTg4OTc0_6e1066ea-0809-4504-b3dc-399968b62a85"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb3d055e549b4d20aa3bd79921592b07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzMtNi0xLTEtMTg4OTc0_6dbd0c31-821a-4051-8e2c-e018dcbd7e29"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i824e9eea42274a06994918fdb9b1899f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzMtOC0xLTEtMTg4OTc0_e3bdf258-598b-4402-96b9-7da372cbd278"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia228ad665d09441a9861fb9c7e5b0516_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzQtMi0xLTEtMTg4OTc0_ffde77eb-b226-41d3-856a-e46aaab0c113"
      unitRef="usd">1676000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia50199fde02748f9bf98f5cdedf79621_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzQtNC0xLTEtMTg4OTc0_1f34cd37-06f4-4034-b993-43a9469253e4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d6aeb558db04b82be74458c91784748_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzQtNi0xLTEtMTg4OTc0_da4fb870-bdb6-4562-85cf-a978fad5b870"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba24b9313e764100a95332b21228b55d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzQtOC0xLTEtMTg4OTc0_6edaae2d-34b1-40f8-954e-6bed22c3ee91"
      unitRef="usd">1676000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7fd7ca4767784bd68bc0e5d0a9794960_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzExLTItMS0xLTE4ODk3NA_88ed7248-8ecb-4f6f-a6b3-03ee72790267"
      unitRef="usd">2659000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8eac0bf72e7643508c5232330c7c0e0d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzExLTQtMS0xLTE4ODk3NA_777428c1-5943-4d47-825e-c203c4f74402"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b0a668cee2e4193b99588a3b62eedff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzExLTYtMS0xLTE4ODk3NA_a38bc9c5-b767-408f-8857-3e2a41d16efc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bb5ac9be58f43fbb615c494dcccf380_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzExLTgtMS0xLTE4ODk3NA_726530d0-f492-44fa-98a0-c3102ca0bc0f"
      unitRef="usd">2659000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22598ba91ebc4a90903405b80f9b2b90_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEyLTItMS0xLTE4ODk3NA_2c343acf-aca6-4c08-84b4-5755eeb685b7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i30ecd41cf6e44462b19bf11b5f28af8f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEyLTQtMS0xLTE4ODk3NA_af36a83b-bdd2-4b04-83ae-cfcb7cf7ec49"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e803186d99e4d92800d0f91df12c1ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEyLTYtMS0xLTE4ODk3NA_6a2679da-2118-4305-b978-69268f386c32"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i213219e02daf455db4856867bb8edfc1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEyLTgtMS0xLTE4ODk3NA_295d5f56-6559-41d4-b33d-b809b947cb03"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherInvestments
      contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTItMS0xLTE5MjQwNA_3af2b584-bc06-48fb-9772-ff029dfcc47a"
      unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments
      contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTQtMS0xLTE5MjQwOA_cbaa5dfd-42d0-4b0f-a318-606924b140fd"
      unitRef="usd">130000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments
      contextRef="i44e12214117d468cadd851f609eafd23_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTYtMS0xLTE5MjQxMg_07795d78-df9b-45d2-bc80-578309db34cc"
      unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTgtMS0xLTE5MjQxNg_7d29d456-d6aa-4b8c-ba52-b995a4aec86f"
      unitRef="usd">130000000</us-gaap:OtherInvestments>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTItMS0xLTE4ODk3NA_ebbe4e2d-ff97-42b1-ad26-94e86dd005f9"
      unitRef="usd">480000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTQtMS0xLTE4ODk3NA_308832db-4fda-47e5-87f5-a96d3949f938"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i44e12214117d468cadd851f609eafd23_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTYtMS0xLTE4ODk3NA_73e3a459-b2a3-405b-9b1b-85f52ae60d52"
      unitRef="usd">335000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzEzLTgtMS0xLTE4ODk3NA_4057ea23-261c-46b9-9490-fd7afdbbf64f"
      unitRef="usd">815000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="i04cf9d5f14444094b92bcc0d9ae9c6c2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE1LTItMS0xLTE4ODk3NA_86f2ae70-dea1-41fe-8ea5-81af81e781e0"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id1185eef083e41a98369064a5c024e6a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE1LTQtMS0xLTE4ODk3NA_65865377-dde2-4013-9e60-27c27cce3e07"
      unitRef="usd">287000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iffc1f370e2ad42c6b4c013b49ed46649_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE1LTYtMS0xLTE4ODk3NA_084e5897-45ac-4e92-b0a1-fcb10bf696ea"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i69d9b4ff9d7f46de8ab75bad1566254f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE1LTgtMS0xLTE4ODk3NA_7f6ac3ed-9d10-42f6-87c5-bee2e60955bd"
      unitRef="usd">287000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i195a5331519a4c8ebc478f4e698c9bf0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE2LTItMS0xLTE4ODk3NA_13408ada-81c5-4025-8fd2-fd9dab3439a6"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2c7ba0f3fb224e79ab0fe6a5fbf238e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE2LTQtMS0xLTE4ODk3NA_afa4e4b5-03f2-4ecb-96ce-bfedbd0db0d8"
      unitRef="usd">54000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i153762966e424fa9acf2972130ddc1c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE2LTYtMS0xLTE4ODk3NA_38fd5e85-5386-47a5-9939-893c552efe09"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib555b80a3d9d4e2e9c78009dab8a9f54_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE2LTgtMS0xLTE4ODk3NA_a223ffdb-33a3-4d0b-9892-f459682075ef"
      unitRef="usd">54000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i96a24aee5c964365b0dc96473c06f9c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE3LTItMS0xLTE4ODk3NA_8db7dd4c-4189-496b-9872-7424461734e2"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i681c12cca8b24893906caf0cabe34abd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE3LTQtMS0xLTE4ODk3NA_8e06ce21-505d-4276-89cf-a272bcf19383"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8dcd8de791a54d38a00b14d46bd0e184_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE3LTYtMS0xLTE4ODk3NA_2cf72ab5-a088-4db7-b0ea-226c0bfe2fb3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9ed68b118d34472994cc95aaa8e8a6c9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE3LTgtMS0xLTE4ODk3NA_17daabe7-78aa-4717-9e92-b21950310da1"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE4LTItMS0xLTE4ODk3NA_ecf44f4c-5d54-4633-92fd-b358f2920422"
      unitRef="usd">4815000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE4LTQtMS0xLTE4ODk3NA_a2ad289b-1d24-42e4-a7a0-62d1d459a5e8"
      unitRef="usd">471000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i44e12214117d468cadd851f609eafd23_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE4LTYtMS0xLTE4ODk3NA_741823c2-c646-44b9-a6cd-bfde064154b7"
      unitRef="usd">335000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzE4LTgtMS0xLTE4ODk3NA_ad67ce60-a132-4495-9905-33b1536a55bf"
      unitRef="usd">5621000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i04cf9d5f14444094b92bcc0d9ae9c6c2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIxLTItMS0xLTE4ODk3NA_eeddb609-1282-416f-88ee-fff7191ff07e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id1185eef083e41a98369064a5c024e6a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIxLTQtMS0xLTE4ODk3NA_7251a0de-961b-4253-b2a6-be4a43e2a379"
      unitRef="usd">76000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iffc1f370e2ad42c6b4c013b49ed46649_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIxLTYtMS0xLTE4ODk3NA_f96bdda7-8c1c-4afd-b977-04d8e1620e2b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i69d9b4ff9d7f46de8ab75bad1566254f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIxLTgtMS0xLTE4ODk3NA_07a9dd66-b66b-48a0-9ed4-f566dc752015"
      unitRef="usd">76000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i195a5331519a4c8ebc478f4e698c9bf0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIyLTItMS0xLTE4ODk3NA_66258a9c-356f-4da7-9452-0f7ef434fbf5"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2c7ba0f3fb224e79ab0fe6a5fbf238e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIyLTQtMS0xLTE4ODk3NA_68357b3e-bfc0-4bb8-9bc5-6999e1769097"
      unitRef="usd">541000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i153762966e424fa9acf2972130ddc1c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIyLTYtMS0xLTE4ODk3NA_ec013a74-7467-43be-9b28-e57170e755f9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib555b80a3d9d4e2e9c78009dab8a9f54_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIyLTgtMS0xLTE4ODk3NA_896d5ecc-6e3b-473a-9b6b-343f6d42d0d5"
      unitRef="usd">541000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i96a24aee5c964365b0dc96473c06f9c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIzLTItMS0xLTE4ODk3NA_bf3ae33f-ef26-40e2-adcc-1af9550e2b0c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i681c12cca8b24893906caf0cabe34abd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIzLTQtMS0xLTE4ODk3NA_b8eb492e-b758-4497-9662-ea4563990a68"
      unitRef="usd">776000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8dcd8de791a54d38a00b14d46bd0e184_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIzLTYtMS0xLTE4ODk3NA_1720c8a3-d27b-459e-8853-1389f7c6283c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9ed68b118d34472994cc95aaa8e8a6c9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzIzLTgtMS0xLTE4ODk3NA_33f52062-39fa-42de-b8a7-66e6898b917d"
      unitRef="usd">776000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iba7a6ebd1caa4564bcbb05dd9ae6251a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTItMS0xLTIxMDQ3OQ_c551bb2d-275a-4169-b819-57c9e58cd3d8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5402fe697c814ce7b466859cedc94d30_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTQtMS0xLTIxMDUwNw_3d755010-e3a1-42a7-908b-b888043dd525"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2c0de5b5539746a0b7f92ee5f134419e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTYtMS0xLTIxMDUxOA_17244a0b-0eee-481a-b373-d3ec383d591e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7a10914bc11449188ce8ebe9ba6d1e7a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTgtMS0xLTIxMDUyNQ_6b6564e3-a206-4be2-bf51-6d61831b0239"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI0LTItMS0xLTE4ODk3NA_11226ee3-7cff-4900-9f13-7e3a2ead470e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI0LTQtMS0xLTE4ODk3NA_239c2ad2-5419-4fe7-aa24-c573a1750dfc"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i44e12214117d468cadd851f609eafd23_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI0LTYtMS0xLTE4ODk3NA_4e38d4af-8135-4526-ad08-f64ed076c25a"
      unitRef="usd">270000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI0LTgtMS0xLTE4ODk3NA_ea50e8a9-9163-44fa-b6ec-649ee9fb1466"
      unitRef="usd">270000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib7e72a92e4a740deb3a2dfbba42d6acb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTItMS0xLTE4ODk3NA_400cf874-291f-419f-b0bc-b091a580021e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idaf69cca5e514b7aa23adb1152babe9a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTQtMS0xLTE4ODk3NA_b1e80614-e4dd-4861-bcfb-b3618c7f7f1e"
      unitRef="usd">1398000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i44e12214117d468cadd851f609eafd23_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTYtMS0xLTE4ODk3NA_8e6416ca-894f-48d9-a1fc-1f794e57713d"
      unitRef="usd">270000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1NmZlNmQ0YThjMmI0NmEyYmNmZDMwZGM0NjU3MmNmOC90YWJsZXJhbmdlOjU2ZmU2ZDRhOGMyYjQ2YTJiY2ZkMzBkYzQ2NTcyY2Y4XzI1LTgtMS0xLTE4ODk3NA_efbf5af4-4011-471f-af9b-b5ac30087040"
      unitRef="usd">1668000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac87a69358fc4fd589fb827383a29399_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzMtMi0xLTEtMTg4OTc0_dd86ce9b-6193-476d-af2b-7e0b3a2662f5"
      unitRef="usd">47000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8495c3e692f14eecb7e49b36322c3b37_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzMtNC0xLTEtMTg4OTc0_ffa4e1da-6b73-4904-81db-a69bebfd09dd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id189833f84714d86b873bc1305ea1122_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzMtNi0xLTEtMTg4OTc0_2965a2fa-fc41-433c-81d9-0878ebce38e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadf926a8c4ff481397c62e643795c0d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzMtOC0xLTEtMTg4OTc0_78b038f3-527e-49ba-9039-86704445669b"
      unitRef="usd">47000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i569bb5a225ac490892da958f5708abba_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzQtMi0xLTEtMTg4OTc0_a54a741a-3f18-48d5-8e87-38e3e6cda1ed"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2668497e150b43a791a72f0c8455c08e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzQtNC0xLTEtMTg4OTc0_5df9a695-5de9-4feb-bb19-d32815028be2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2d5b99ab33b4e739ed1626b9b36b488_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzQtNi0xLTEtMTg4OTc0_79c18015-1da4-4094-be61-a65c2cc83c69"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea6cee4c27ca4399a8a02d26694846a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzQtOC0xLTEtMTg4OTc0_098d6fd6-e9db-46e6-b3fe-7a8e4f08bd7b"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d74df6c17364a8aabc1122e2efe6f4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzExLTItMS0xLTE4ODk3NA_27adce58-87a9-4592-9fec-6b0fb9f899c3"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i42fe4d733a7f4f13bb7813256bad4ea3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzExLTQtMS0xLTE4ODk3NA_ee9de920-7ea3-450b-b32b-5d4b889cd7cd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idabb4b707739487e85cf95efbce18ef9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzExLTYtMS0xLTE4ODk3NA_97e3af27-cf9d-44c4-bd16-695e89bd0d95"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b8197b282c5479f91c7eb469b7b7ec2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzExLTgtMS0xLTE4ODk3NA_982e387a-ca37-4c77-929c-01e8efaa0f9f"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i797ddf4c639f495e92b203d4350e1885_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEyLTItMS0xLTE4ODk3NA_32cd64d7-37d0-486c-83c3-d287a3353f78"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i577871f373d34ff481985f5ec576c5a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEyLTQtMS0xLTE4ODk3NA_e4e63241-b7a2-4767-adb7-2d7b1efbc37c"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i132049d557004a2b9c5a3e2500f496fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEyLTYtMS0xLTE4ODk3NA_7048a63c-0703-4a0d-82ca-6ff426f375e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95cead4d37bb4601864dc9667b4457bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEyLTgtMS0xLTE4ODk3NA_50cfdfc4-bc61-4370-824e-98bc244511f8"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherInvestments
      contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTItMS0xLTE5MjM4MQ_0179398d-6919-4e16-b9e8-fdfada435214"
      unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments
      contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTQtMS0xLTE5MjM5NA_f2d1ed12-a681-448f-91d6-fea72fb68adc"
      unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments
      contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTYtMS0xLTE5MjM5MA_553a397f-807a-4812-be1f-1ae045946655"
      unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTgtMS0xLTE5MjM5OQ_3bc2e52a-fa0b-4cfc-9f5e-fe62f14b3319"
      unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTItMS0xLTE4ODk3NA_58474ea4-8d16-4bc2-a96a-c3403ac567ed"
      unitRef="usd">611000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTQtMS0xLTE4ODk3NA_ccf631a6-27b5-4cb4-a721-97e1cbafede5"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTYtMS0xLTE4ODk3NA_86c836b9-68b4-4873-af47-b4abdaf5a7e1"
      unitRef="usd">220000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzEzLTgtMS0xLTE4ODk3NA_21dc075c-a461-4477-bc03-ec0e5e6cee3b"
      unitRef="usd">831000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="ifce18bab23fc49839c5ff35eebbc64f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE1LTItMS0xLTE4ODk3NA_dc340727-2792-4c43-a0e8-1c73ba803670"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if69c6f84cc55499992a9a2e32132005e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE1LTQtMS0xLTE4ODk3NA_ffb70163-abd4-466f-88ab-f5fcd1ec52c2"
      unitRef="usd">183000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ifdb904ccb9024b858913d7acf42062d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE1LTYtMS0xLTE4ODk3NA_dbb1ff3f-3c72-4ee2-b583-02d9967df77b"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iccad64003d424270be4e3bf87201a726_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE1LTgtMS0xLTE4ODk3NA_04354853-f832-4593-b062-c3eaa1616b27"
      unitRef="usd">183000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id946d775421d4962835fc013c2dd949a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE2LTItMS0xLTE4ODk3NA_e0fcdce9-9842-458b-aa9d-02501880ec24"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia240f27fa9af4af381d9cd9b830cdc68_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE2LTQtMS0xLTE4ODk3NA_21f28e22-05e5-41a2-8cf9-d8229044cfee"
      unitRef="usd">66000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i53e3c3e57bfa41579e675e5dacc3bd0d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE2LTYtMS0xLTE4ODk3NA_d7394d5f-e075-4cc7-9b6a-50019bf5aa0e"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib665f9cde8cf48c5b5fc22d5eab5ff32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE2LTgtMS0xLTE4ODk3NA_634b4a9a-0fe6-4181-9108-12f11cff0bc7"
      unitRef="usd">66000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9d24cfe7dee24743a1c19c57c666aad9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE3LTItMS0xLTE4ODk3NA_8cacd4de-8960-4095-b2bb-b912c837336b"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9866c2a563d74089bd190f1596f41fc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE3LTQtMS0xLTE4ODk3NA_3c413c39-5162-4d25-bd21-04572f204663"
      unitRef="usd">16000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5c2ad38235c0444d8eb13ded4145682a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE3LTYtMS0xLTE4ODk3NA_1f41cd3b-5fa3-4bfc-bb88-50502483f04b"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2a7dfd23ab294cfdaa4374b169b9c14d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE3LTgtMS0xLTE4ODk3NA_48873f4b-0077-4b62-9a34-99915cf4cf11"
      unitRef="usd">16000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE4LTItMS0xLTE4ODk3NA_ce9cf546-d1ef-4eb4-ab3f-5f4c18467c71"
      unitRef="usd">7914000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE4LTQtMS0xLTE4ODk3NA_ece1135a-a5c3-4c3c-b949-59ed98c9e95b"
      unitRef="usd">266000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE4LTYtMS0xLTE4ODk3NA_78e3a768-0ce6-4ac5-8645-3f1d1a928346"
      unitRef="usd">220000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzE4LTgtMS0xLTE4ODk3NA_5ca837a0-80b4-407e-8da4-c6c4c0d0d500"
      unitRef="usd">8400000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ifce18bab23fc49839c5ff35eebbc64f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIxLTItMS0xLTE4ODk3NA_5ab5d891-25c7-4663-b8c8-9b12c990804a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if69c6f84cc55499992a9a2e32132005e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIxLTQtMS0xLTE4ODk3NA_435bfe03-c312-46af-854c-65d1b8902c5e"
      unitRef="usd">39000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ifdb904ccb9024b858913d7acf42062d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIxLTYtMS0xLTE4ODk3NA_cbfebfea-45ad-4f71-afa2-266724e62e6c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iccad64003d424270be4e3bf87201a726_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIxLTgtMS0xLTE4ODk3NA_9b19ddde-5704-465d-a5a4-3f2f91bba2e5"
      unitRef="usd">39000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id946d775421d4962835fc013c2dd949a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIyLTItMS0xLTE4ODk3NA_d9a018b0-1e17-4bee-bb4e-0c1c7233fd6d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia240f27fa9af4af381d9cd9b830cdc68_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIyLTQtMS0xLTE4ODk3NA_4b73ae1a-79d5-4804-bcdc-d5a3bc250963"
      unitRef="usd">339000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i53e3c3e57bfa41579e675e5dacc3bd0d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIyLTYtMS0xLTE4ODk3NA_b6fafbbe-d289-4d6d-99d4-2ac891417c55"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib665f9cde8cf48c5b5fc22d5eab5ff32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIyLTgtMS0xLTE4ODk3NA_1aca0ec7-e87c-4115-a061-276e07a2e446"
      unitRef="usd">339000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9d24cfe7dee24743a1c19c57c666aad9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIzLTItMS0xLTE4ODk3NA_21400288-aad5-47ad-943b-ba9268017306"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9866c2a563d74089bd190f1596f41fc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIzLTQtMS0xLTE4ODk3NA_abaf6ce3-c42e-4685-878b-95327023dd23"
      unitRef="usd">156000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5c2ad38235c0444d8eb13ded4145682a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIzLTYtMS0xLTE4ODk3NA_e2ba3d80-cca7-49f6-bebd-cc5127844cd9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2a7dfd23ab294cfdaa4374b169b9c14d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzIzLTgtMS0xLTE4ODk3NA_bcc2e2da-cb37-41d4-afdd-4a23ddc59ccd"
      unitRef="usd">156000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="icbbed003175d41bfa117df6296bf5c46_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTItMS0xLTIxMDU2MQ_61c48ce0-ed73-43e5-b309-05a3c31d2ff8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i92535cf54c5042858d8b357cb40f0d14_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTQtMS0xLTIxMDU2OQ_09d48f5c-8639-43b3-895c-4be1fafb5007"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ied47fb81a807413c89dca88a7846b5c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTYtMS0xLTIxMDU4MQ_70fbc2cc-1046-45a0-9824-5b33425da09f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i92c83ac6e195467b945c631bdc59e85c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTgtMS0xLTIxMDU4OA_f958d3f0-58ac-40e4-9fad-60869382c1c7"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI0LTItMS0xLTE4ODk3NA_41482491-168d-4617-baae-b3607790b263"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI0LTQtMS0xLTE4ODk3NA_cbe88e72-634d-464b-8026-a1c70c16ca34"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI0LTYtMS0xLTE4ODk3NA_35784297-8246-486d-bc97-aaaa7224bd85"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI0LTgtMS0xLTE4ODk3NA_e78e3db1-4459-43db-8765-391027a88f12"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id70719b622e54833ae9798bf9ddc0a57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTItMS0xLTE4ODk3NA_301658c5-77ab-481c-b7d2-f52b14f2063f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7cba56b2736f4a09aa520371c0cb29ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTQtMS0xLTE4ODk3NA_d72aeb1f-4318-43f0-9ff1-24c0618cf5e3"
      unitRef="usd">534000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if4da8e4a0b6f4526bfb950095170ff2f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTYtMS0xLTE4ODk3NA_fdb7f244-8f24-4f8a-8046-ed0812cc026a"
      unitRef="usd">342000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTozNmMxMTJlNWZiMDY0YjQ5ODZlOTAyMmRlNTEzYTIxNC90YWJsZXJhbmdlOjM2YzExMmU1ZmIwNjRiNDk4NmU5MDIyZGU1MTNhMjE0XzI1LTgtMS0xLTE4ODk3NA_8427767d-347d-4731-8c5f-7339e790d47a"
      unitRef="usd">876000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzcxMzQ_33c58279-f95b-4347-9b29-a996b554aec8">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net changes in valuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzItMi0xLTEtMTg4OTc0_77971dd2-788d-4684-9b96-f2cdf85e5c24"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzItNC0xLTEtMTg4OTc0_f4b8a436-7428-44fe-9b1e-b7d8c3312bae"
      unitRef="usd">33000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzItNi0xLTEtMTg4OTc0_35aad496-f614-4d2c-a1f6-85cd2d206e44"
      unitRef="usd">61000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzMtMi0xLTEtMTg4OTc0_0db950c6-3291-47c8-ad30-90969be3ef82"
      unitRef="usd">0</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzMtNC0xLTEtMTg4OTc0_3071ef8d-a383-4b4a-9ae1-0f3639a08be5"
      unitRef="usd">309000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzMtNi0xLTEtMTg4OTc0_26054794-aa14-43fa-b359-bdc6fd455588"
      unitRef="usd">0</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzQtMi0xLTEtMTg4OTc0_2d290e72-88d5-4b7e-beb5-89345310e66b"
      unitRef="usd">7000000</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzQtNC0xLTEtMTg4OTc0_6726cc50-f217-4188-9944-81890d0b6b0f"
      unitRef="usd">7000000</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzQtNi0xLTEtMTg4OTc0_732afd88-8edc-4f66-920d-832ff5cf6bf0"
      unitRef="usd">6000000</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzUtMi0xLTEtMTg4OTc0_296f7b02-ae3e-4c10-a539-61387a1b03a4"
      unitRef="usd">-65000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzUtNC0xLTEtMTg4OTc0_7eb98a21-30a7-4955-9308-6c101c0fb8ad"
      unitRef="usd">7000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzUtNi0xLTEtMTg4OTc0_b2d8baa2-4b11-42de-92d3-e86f802cbc1e"
      unitRef="usd">-22000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzYtMi0xLTEtMTg4OTc0_8d54d590-6189-4665-958d-ebb268370808"
      unitRef="usd">270000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzYtNC0xLTEtMTg4OTc0_2afae797-7f9b-4aad-881c-b4edef273c63"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90YWJsZTo1OTdhOGM3ZDE1MzQ0Y2M0ODUwNmU1YTUwNDE0YmIyNy90YWJsZXJhbmdlOjU5N2E4YzdkMTUzNDRjYzQ4NTA2ZTVhNTA0MTRiYjI3XzYtNi0xLTEtMTg4OTc0_9a9357c4-55d2-4e3c-bb93-679141fb15d3"
      unitRef="usd">33000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ia46cd94f860647c4b3b4f6dd2d098fff_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzU1NDY_f02c861e-b892-4d49-b9c4-ad997f5b6b0b"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY1Nzc_931eb32a-3c7d-46b1-a8bf-f1089e66c5ac"
      unitRef="usd">35000000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY1ODQ_36e6a429-b6db-4906-8127-38234b42d9ab"
      unitRef="usd">37900000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:LongTermDebt
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY2MzE_3c67ee9b-9563-4a68-aeaf-460a01386491"
      unitRef="usd">38900000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY2Mzg_b0277b32-185c-4e75-81b6-d0f928bc35b7"
      unitRef="usd">33300000000</us-gaap:LongTermDebt>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="idd010ea395424e80984bb752c13cc1f4_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY3OTg_6c506eb8-706f-4f05-881a-3b70778615ee"
      unitRef="usd">4200000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY4MDU_b8020be9-ba94-4971-85bf-576e4eab8de5"
      unitRef="usd">5100000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestments
      contextRef="idd010ea395424e80984bb752c13cc1f4_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY4Mzg_96628026-5978-46c9-9481-8e5364918a9b"
      unitRef="usd">2200000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8682e25ddb8343a685a3e4ceb16fe6b2_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDEvZnJhZzphZjU2MDUzNGRlYjY0NTIwYTQzYTdkYjgxMDA0NGVmOS90ZXh0cmVnaW9uOmFmNTYwNTM0ZGViNjQ1MjBhNDNhN2RiODEwMDQ0ZWY5XzY4NDU_0c264953-9cf4-4de3-8196-663b8288ba7d"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTMy_c7c12b07-3d37-4d74-b1fc-6548e2eb0b6b">Derivative instruments&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We have designated certain of our derivatives as cash flow and fair value hedges; we also have derivatives not designated as hedges. We do not use derivatives for speculative trading purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. The foreign currency exchange rate fluctuation exposure associated with cash inflows from our international product sales are partially offset by corresponding cash outflows from our international operating expenses. To further reduce this exposure, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, 2021 and 2020, we had outstanding foreign currency forward contracts with aggregate notional amounts of $6.0 billion, $5.7 billion and $5.1 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The notional amounts and interest rates of our cross-currency swaps as of December 31, 2022, were as follows (notional amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hedged notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% 2023 Swiss franc Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% 2026 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% 2026 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% 2029 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. In December 2022, we entered into a forward interest rate contract with an aggregate notional amount of $700&#160;million. Amounts expected to be recognized during the subsequent 12 months on forward interest rate contracts are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of both December 31, 2022 and 2021, we had interest rate swap contracts with aggregate notional amounts of $6.7&#160;billion that hedge certain portions of our long-term debt issuances. See Note 15, Financing arrangements, for information on our interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying amounts of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt"&gt;Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $357 million and $440 million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt"&gt;Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $257 million and $340 million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impact of hedging transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;__________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2022, we expected to reclassify $159 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2022, 2021 and 2020, the total notional amounts of these foreign currency forward contracts were $517 million, $680 million and $1.0 billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair values of derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative contracts that were in liability positions as of December 31, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change-in-control and (ii)&#160;our or the surviving entity&#x2019;s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change-in-control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEyNjI_4df61dd8-edfb-4e59-96b2-2eda54bfb60e">P3Y</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i944c4da8f51949d7bd4524a5221b53f5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzE1Mjc_eecf7058-6589-4c46-8c56-bf3ede58e46e"
      unitRef="usd">6000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic575aff5abc14a04a5d1c46f2b053e12_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzE1MzE_f15dc2f3-7008-4a9b-bdb7-093e5b426fa3"
      unitRef="usd">5700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5a5af4745b754c7b874785b32bb24b00_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzE1Mzg_b4729360-0524-4038-9926-f8564bc935a1"
      unitRef="usd">5100000000</us-gaap:DerivativeNotionalAmount>
    <amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTUw_011060ed-f98b-4407-b710-c080205e0ad9">The notional amounts and interest rates of our cross-currency swaps as of December 31, 2022, were as follows (notional amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hedged notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% 2023 Swiss franc Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% 2026 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% 2026 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% 2029 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i4a5962db8b8248e8a56de2423329a813_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzMtMi0xLTEtMTg4OTc0_16898639-a9b9-4a10-b742-766424081951"
      unitRef="chf">700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i2dddebd646fe4e9aae847684ea09146c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzMtNC0xLTEtMTg4OTc0_64dbdb8e-0cf9-4851-b6a9-ef4c2c1b2df2"
      unitRef="number">0.004</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i4a5962db8b8248e8a56de2423329a813_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzMtNi0xLTEtMTg4OTc0_51b1c0f6-2b61-45a3-ad32-f8f2cda80f4f"
      unitRef="usd">704000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i82707d8217c743548ff4520578c0f7cb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzMtOC0xLTEtMTg4OTc0_ac33aa50-b0ee-4fc6-8523-c6390b86bc9b"
      unitRef="number">0.034</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i18586610d42b4565923516e609315ed0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzQtMi0xLTEtMTg4OTc0_c227c0ee-08ab-4913-a5e4-5740fe698a27"
      unitRef="eur">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i2a279bb1582744739e5f9088fe666593_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzQtNC0xLTEtMTg4OTc0_0f772913-4671-4277-9e96-12ff20c8fb36"
      unitRef="number">0.020</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i18586610d42b4565923516e609315ed0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzQtNi0xLTEtMTg4OTc0_aa9d4d17-ccfe-4b33-8dff-eb0896e84b20"
      unitRef="usd">833000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ifb35b6ee6b4c481cbd643d0e1261cc8e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzQtOC0xLTEtMTg4OTc0_ecb369b6-a6b7-4357-bc0c-c0f2bc06da73"
      unitRef="number">0.039</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i141bfbb6d4734cb1906b822194473416_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzUtMi0xLTEtMTg4OTc0_371fcae1-9f38-4a7f-b15a-975daad2e9bb"
      unitRef="gbp">475000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i000c813b74c349b6be351b38fd528099_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzUtNC0xLTEtMTg4OTc0_5ae34d46-7e1e-4a33-a36e-91106f6a2d19"
      unitRef="number">0.055</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i141bfbb6d4734cb1906b822194473416_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzUtNi0xLTEtMTg4OTc0_0c95c8c6-cf39-4e4c-8793-665407e8fb20"
      unitRef="usd">747000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i36cf59fd6e684e63bd2fb4dcb7870271_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzUtOC0xLTEtMTg4OTc0_233f8fe2-6fe7-41ea-8829-1378d331b79b"
      unitRef="number">0.060</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i12701a294ac24a63ac70115c6686c71c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzYtMi0xLTEtMTg4OTc0_1eafe6b6-93c8-4833-8329-c282e477a10e"
      unitRef="gbp">700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ibe0e2e65349e4185a303be08740aed7e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzYtNC0xLTEtMTg4OTc0_eb6fa74f-51e4-4417-a336-7d51ec9071e9"
      unitRef="number">0.040</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i12701a294ac24a63ac70115c6686c71c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzYtNi0xLTEtMTg4OTc0_c5917341-ffd8-4483-826e-c0aae2fb96e8"
      unitRef="usd">1111000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ibc93e8ad61544af5aef6ae040ba31401_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyZmNkZTI5NDhmZDI0OWMyOGFhZDUwMmIyNDc4MzI5MC90YWJsZXJhbmdlOjJmY2RlMjk0OGZkMjQ5YzI4YWFkNTAyYjI0NzgzMjkwXzYtOC0xLTEtMTg4OTc0_36b2b9e9-4d6b-4c81-9f0f-c957ec30bb07"
      unitRef="number">0.046</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i893dec2695f241eea7e09febe91d6056_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzE0MjkzNjUxMTc2NDU0_8f42cdba-cef0-4ec3-a97d-98ced8306b16"
      unitRef="usd">700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTIw_1defcf3b-518d-461b-b36a-8da4e33c36df">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i4403c288e6734e15b800b88b0a641274_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzItNC0xLTEtMTg4OTc0_2f1d4445-5c9f-49e5-91cf-41c5cf1e8974"
      unitRef="usd">308000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i2d8039e3232a4ce3b5bcb3dfbf62c725_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzItNi0xLTEtMTg4OTc0_df291280-d024-4084-9f2f-bd7e96f1eba2"
      unitRef="usd">373000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ia924eeb3bb7543ed8daaa1f3364c31e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzItOC0xLTEtMTg4OTc0_d0617593-2b85-4c51-ab60-806a144d4de0"
      unitRef="usd">-251000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i72e3f19a1ae64901bda8ca62eb6abcfd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzMtNC0xLTEtMTg4OTc0_0f3a511a-c0d5-4a3a-a6cc-9353fe340ad5"
      unitRef="usd">-219000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ia013b3bfbdf74724934c7921f702d9ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzMtNi0xLTEtMTg4OTc0_25b3dbc8-2392-4f5b-98d3-caba845381dc"
      unitRef="usd">-214000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ib1e86b4b83c1402e9dbc2c712ea987c8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzMtOC0xLTEtMTg4OTc0_2660e211-c49d-4924-a3c7-079cfd506aa0"
      unitRef="usd">190000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i95699e6c8574452f9e3e864d40b1dc25_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzQtNC0xLTEtMTg4OTc0_1997d152-fe37-4ad6-ba0e-034b6c5c1ed0"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i0a18b2800d894d86bd5f131724792cfa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzQtNi0xLTEtMTg4OTc0_b3482146-8005-4e05-b359-85b85dd7babc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i224736ead83447e6a2b3bbfb08ecf30d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzQtOC0xLTEtMTg4OTc0_feb1c1cf-6495-4d08-8ec4-a7d42238034a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ib60cabd0b1a14cb189936f2de2a378c3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzUtNC0xLTEtMTg4OTc0_39cd8b4e-a16e-480d-befb-79f768569405"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i0921f2d8651244eab61f2a275f079822_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzUtNi0xLTEtMTg4OTc0_d1a734fa-f21f-4623-bb42-2694e26b5b57"
      unitRef="usd">159000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i916dce6d88664036bb8c4c3bcd21707a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjMzRlMjExMzgwNTk0YTlmYWI3NjUwZjU5YzdkNDcwYy90YWJsZXJhbmdlOmMzNGUyMTEzODA1OTRhOWZhYjc2NTBmNTljN2Q0NzBjXzUtOC0xLTEtMTg4OTc0_34f3e1f1-1d5e-4659-91de-f56571fd4f02"
      unitRef="usd">-61000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i61f2865a5c7548b6986efb37a72d32f6_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzQ5OTQ_de73349d-97e9-4b4c-876f-5fb0be352af2"
      unitRef="usd">6700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i745dd63e9cdd4959af07252f017a9eaa_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzQ5OTQ_e70dc189-c74c-4649-9111-43f508359d28"
      unitRef="usd">6700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTUx_7082fb96-13cc-48da-ab8b-444fcacde9df">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying amounts of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt"&gt;Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $357 million and $440 million of carrying value with discontinued hedging relationships as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.44pt"&gt;Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively. Long-term debt includes $257 million and $340 million of hedging adjustments on discontinued hedging relationships as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i35dca8996f6e45938deded2944b3efba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzMtMi0xLTEtMTg4OTc0_566c03e3-6e3d-4d0c-b13c-78d4fc859155"
      unitRef="usd">82000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i10bea2bc73284b47b799ca78b75b4e06_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzMtNC0xLTEtMTg4OTc0_6a731781-4973-434c-93bf-2ddac26b6dd3"
      unitRef="usd">85000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i35dca8996f6e45938deded2944b3efba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzMtNi0xLTEtMTg4OTc0_0d12dd6b-14b6-476e-ad78-7703c7c4686c"
      unitRef="usd">82000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i10bea2bc73284b47b799ca78b75b4e06_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzMtOC0xLTEtMTg4OTc0_c08918bb-dccc-4b3b-92de-9b4f81985f3b"
      unitRef="usd">85000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ib7d1709057914d44afb932729cfecfcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzQtMi0xLTEtMTg4OTc0_4117fa58-51a9-4d79-a477-bf1ab3144eb7"
      unitRef="usd">6017000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i235e4ed48f85437d8644836bbc43ca87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzQtNC0xLTEtMTg4OTc0_78fb2e87-d799-4fdb-90b9-a21cd0767455"
      unitRef="usd">6729000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ib7d1709057914d44afb932729cfecfcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzQtNi0xLTEtMTg4OTc0_7cf6b141-cc39-4b38-ba45-d59d0df17afd"
      unitRef="usd">-519000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i235e4ed48f85437d8644836bbc43ca87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToyN2ZmZmViYjY5ZmE0MGZhYjE2YjFkNWYyNTk3MzZkMC90YWJsZXJhbmdlOjI3ZmZmZWJiNjlmYTQwZmFiMTZiMWQ1ZjI1OTczNmQwXzQtOC0xLTEtMTg4OTc0_895998d3-9209-446e-8731-282624e29356"
      unitRef="usd">199000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i35dca8996f6e45938deded2944b3efba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc0MjY_5ffcb1e6-7eaa-49d5-9a40-b8eb32da3bc1"
      unitRef="usd">82000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i10bea2bc73284b47b799ca78b75b4e06_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc0MzM_6a17125e-8542-4bbb-a555-2fd0dcbebd9b"
      unitRef="usd">85000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="ib7d1709057914d44afb932729cfecfcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc1NDk_e84237a1-e8db-4160-8070-6c5ae03f28dd"
      unitRef="usd">357000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i235e4ed48f85437d8644836bbc43ca87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc1NTY_31246c40-2806-4f99-88e5-1d9bdcebb2be"
      unitRef="usd">440000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i35dca8996f6e45938deded2944b3efba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc2OTE_530f42cc-3620-4035-a399-252d34ba0891"
      unitRef="usd">82000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i10bea2bc73284b47b799ca78b75b4e06_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc2OTg_e3825ba1-14cb-46a5-ad91-9848d47575a4"
      unitRef="usd">85000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ib7d1709057914d44afb932729cfecfcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc4MTc_49ad99d1-481c-4b8f-ab9d-e5785c28db73"
      unitRef="usd">257000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i235e4ed48f85437d8644836bbc43ca87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzc4MjQ_efdf2612-3387-4ce5-a596-6101debea634"
      unitRef="usd">340000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTM3_69a0c7e4-e6b5-4028-8ebd-c39b04fc741f">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;__________&lt;/span&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f333186d8da4378bcf0c5a3e6baf0f9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzItMi0xLTEtMTg4OTc0_b88d2e08-8866-450a-8f6a-a2bba1d4ab51"
      unitRef="usd">24801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzItNC0xLTEtMTg4OTc0_0c98d736-2551-48c4-b9f8-822dfbdeb146"
      unitRef="usd">-814000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzItNi0xLTEtMTg4OTc0_a4bb8425-3ca9-4565-8a6e-4d35ff5d3def"
      unitRef="usd">1406000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i23ea2249a07045cea77ac843dd3ee186_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzUtMi0xLTEtMTg4OTc0_b2f29491-f312-43dd-8ef6-13e796679881"
      unitRef="usd">231000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icdafbb775bf94addace467b7558c90c5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzYtNC0xLTEtMTg4OTc0_de79d79c-fbdb-4df2-9c79-398fdfc01390"
      unitRef="usd">-233000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i55a872aceca74648a5734c2e9893a09e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzgtNi0xLTEtMTg4OTc0_e400639d-6a6d-493c-adca-2b26457bf820"
      unitRef="usd">716000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i55a872aceca74648a5734c2e9893a09e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTo3NDQzN2Q5OWU2N2I0YTQ4YWU5Njg4MjM0ZWRhMjY5Ny90YWJsZXJhbmdlOjc0NDM3ZDk5ZTY3YjRhNDhhZTk2ODgyMzRlZGEyNjk3XzktNi0xLTEtMTg4OTc0_bbb2cb74-6bb1-4369-a952-bfd26f3cb01a"
      unitRef="usd">-636000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6b25c75934844f82a32f7a76cdbe5042_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzItMi0xLTEtMTg4OTc0_82bd3165-eb96-4322-a499-ea71396decc5"
      unitRef="usd">24297000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzItNC0xLTEtMTg4OTc0_6359cbdf-e8e2-481d-a84e-4fa26663988e"
      unitRef="usd">259000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzItNi0xLTEtMTg4OTc0_25ad4589-43c0-470d-9c07-b5d103530d08"
      unitRef="usd">1197000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie6bae6c3e9ff45c4bc483aa371e79620_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzUtMi0xLTEtMTg4OTc0_4c8202f3-6f93-43e6-8b94-64ff5894750e"
      unitRef="usd">-8000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if6b34d2b5b6f4beba907bb845e7cc2b9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzYtNC0xLTEtMTg4OTc0_a8b1f90f-3e61-49cd-a59b-2211826840c4"
      unitRef="usd">-245000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="icc2cebe6a0c248f594910077166c27c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzgtNi0xLTEtMTg4OTc0_177e061a-4b5c-4a33-b265-2287d931d1a8"
      unitRef="usd">281000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="icc2cebe6a0c248f594910077166c27c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTpjOWRhOWI5MWE1M2Y0NzM1YjAwMzJiODY5MjUxZGQ3ZC90YWJsZXJhbmdlOmM5ZGE5YjkxYTUzZjQ3MzViMDAzMmI4NjkyNTFkZDdkXzktNi0xLTEtMTg4OTc0_de26e579-706c-4ea3-ba3f-c632bec5af45"
      unitRef="usd">-192000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if8db07843e5b426fbe44e0590a500e74_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzItMi0xLTEtMTg4OTc0_dae66def-b7d4-4d06-ad5c-5a7a4b5f9d82"
      unitRef="usd">24240000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzItNC0xLTEtMTg4OTc0_27ade040-9731-45e9-a9ca-8cce509fecff"
      unitRef="usd">256000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzItNi0xLTEtMTg4OTc0_371ede76-2fb5-4b38-b4da-64009437c9e5"
      unitRef="usd">1262000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibc245132cc174af6870e31cfd882e769_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzUtMi0xLTEtMTg4OTc0_92fafadf-df2f-4fe8-b345-60c502919cfa"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic916478fec014452ac32d62171a7e5fd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzYtNC0xLTEtMTg4OTc0_ff6a82c0-66ad-438f-8d33-2dbea5a00bcc"
      unitRef="usd">323000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ie19c8a33e809469baa28577670a15fd4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzktNi0xLTEtMTg4OTc0_a1ec7524-91ff-429c-882a-760b2fad2408"
      unitRef="usd">315000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ie19c8a33e809469baa28577670a15fd4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZTplNDgyYTYwZjQ4NjA0MzExOGRkZTM2MDg3YjVmODQ5NC90YWJsZXJhbmdlOmU0ODJhNjBmNDg2MDQzMTE4ZGRlMzYwODdiNWY4NDk0XzEwLTYtMS0xLTE4ODk3NA_d85bdec8-ea19-4147-a77d-34af75465328"
      unitRef="usd">-204000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="ib6c2d36bbe6a4d419b04a238a8121559_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1Xzg3MDM_b31f9009-59ac-4f65-a34c-3799f833d296"
      unitRef="usd">159000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0070fbcf9e5043e28c33ca586f2f12d1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzkyNTQ_0ccfa04f-97a3-4875-b8ad-047f36550785"
      unitRef="usd">517000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6a3731a49f5b4c0ab1587258bbb6fa81_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzkyNTg_7c3fc074-f144-4c72-9f12-d9353ac91dee"
      unitRef="usd">680000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id6300669025b46f7b380270aefda2eb5_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzkyNjU_37206cb6-9320-43dc-8159-e79b106f8d34"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90ZXh0cmVnaW9uOjFjMjM0Yzg4MmRjOTQ3MTM5MzEwYTIxYzgyMjA0YjU1XzEwOTIx_1b1916d3-6f4f-4943-957f-384c8ec0ee56">&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia1b4d3bc8dd644d09c1cfa7a23a15d73_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzMtNC0xLTEtMTg4OTc0_650ed824-c712-4418-b181-9130d0e9f3d4"
      unitRef="usd">287000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i27ace983c9a64dc7b4239aea83dc7b02_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzMtOC0xLTEtMTg4OTc0_673d37cb-6b6d-4261-bfe1-6f418f54c5be"
      unitRef="usd">76000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ibd95f2130b1849c0a6ac303164815eac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzQtNC0xLTEtMTg4OTc0_a0327358-86ac-4da7-b5f1-3c4a644aabd5"
      unitRef="usd">54000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iaef37d1d19a34b4abe782126c5137fe0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzQtOC0xLTEtMTg4OTc0_aecb9e48-9e26-40ec-8854-7585cb6422ba"
      unitRef="usd">541000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i54e75f2069df4597912a649d3b21612f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzUtNC0xLTEtMTg4OTc0_c38d3ca5-d436-4f40-9d44-1797348d715d"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2f3b2c5c4c594281bf2350f890860495_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzUtOC0xLTEtMTg4OTc0_197b77f3-4380-4309-8d9e-0ca7eca16fae"
      unitRef="usd">776000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i40227117f78447a9ad9ae92218498e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzYtNC0xLTEtMjA2OTA0_ffdf2d9d-bca6-4d6f-8407-13ce20e3ad43"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2944af81b1f24f5e8934a081989872fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzYtOC0xLTEtMjA2OTM1_8f87391e-7f91-4294-a890-154b04245ca2"
      unitRef="usd">5000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i49d6cb8ea64d45f092c9ccbe06efae29_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzYtNC0xLTEtMTg4OTc0_6483d215-e4c7-48d3-a0c0-51470f81b7d9"
      unitRef="usd">341000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i49d6cb8ea64d45f092c9ccbe06efae29_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzYtOC0xLTEtMTg4OTc0_555acd14-85b5-461f-9738-0b355fff30aa"
      unitRef="usd">1398000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzEwLTQtMS0xLTE4ODk3NA_dee0f245-d40a-4639-8a3e-8054245ef761"
      unitRef="usd">341000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzEwLTgtMS0xLTE4ODk3NA_e55ceb19-87c3-44b8-a7da-3ee1b58c0a3d"
      unitRef="usd">1398000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i629346f484274f9ea377c96a9845eb29_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE1LTQtMS0xLTE4ODk3NA_d353544e-6cbf-4c98-829c-f81c6572c8ae"
      unitRef="usd">183000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="id334802554e34a95a80f6c8df61e0238_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE1LTgtMS0xLTE4ODk3NA_452b9662-1c11-4c4e-8ec0-7355d9b976eb"
      unitRef="usd">39000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i378d88e1dff64d65904267fc06da9175_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE2LTQtMS0xLTE4ODk3NA_0dde4f87-471a-4b71-9226-ff47470b30ea"
      unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i09e8414ca5604a31a388ddd2badf96b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE2LTgtMS0xLTE4ODk3NA_c50c1595-6a1e-4e72-81ca-5eafd7a2f320"
      unitRef="usd">339000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i824bdb4659bd41509979bb787b6de333_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE3LTQtMS0xLTE4ODk3NA_f2956c0c-db69-4511-a470-6d39790a4083"
      unitRef="usd">16000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6523296eb7b74ed7b7ff7acdfe444319_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE3LTgtMS0xLTE4ODk3NA_948fe171-13a2-4882-a8c8-6fa194845df1"
      unitRef="usd">156000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ifdf6a2a3c143432ea3c1e2d1ca761a0d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE5LTQtMS0xLTIwNjkyNw_95fe94d6-3c90-4082-b4d1-3286507d91a7"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibb8c2b20543e445bb5dea750ab9c396a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE5LTgtMS0xLTIwNjk0Mw_885b00a6-a972-4cd4-a3cb-d84b1c2a614d"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i36b86d79154149259fd101e1fe5655b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE4LTQtMS0xLTE4ODk3NA_4c9d059a-7216-4140-ae5a-0235d70b0d78"
      unitRef="usd">265000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i36b86d79154149259fd101e1fe5655b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzE4LTgtMS0xLTE4ODk3NA_3a247e3d-35b7-43da-b1e1-4cc5fcb1d0ed"
      unitRef="usd">534000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzIyLTQtMS0xLTE4ODk3NA_1db66c98-ed39-40a7-a639-6e6513b4850b"
      unitRef="usd">265000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDQvZnJhZzoxYzIzNGM4ODJkYzk0NzEzOTMxMGEyMWM4MjIwNGI1NS90YWJsZToxMTdmYzIwOGZiMWY0NjYxYmY5YjY4M2JhNjdlZThmZC90YWJsZXJhbmdlOjExN2ZjMjA4ZmIxZjQ2NjFiZjliNjgzYmE2N2VlOGZkXzIyLTgtMS0xLTE4ODk3NA_4040854c-8afc-4d5d-ba45-fdbb4c3a9a7a"
      unitRef="usd">534000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzQ1MjE4_20fe6be8-2b4f-44b0-8f05-9204d4eba957">Contingencies and commitments &lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Our business may be affected by litigation and government investigations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain recent developments concerning our legal proceedings and other matters are discussed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ANDA Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Otezla ANDA Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Sandoz Inc., et al.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in June 2018, Celgene filed 19 separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC (Amneal); Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited (MSN); Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc. (Sandoz); Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc. (Zydus), each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the &#x2019;940 Patent), 7,208,516 (the &#x2019;516 Patent), 7,427,638 (the &#x2019;638 Patent), 7,659,302 (the &#x2019;302 Patent), 7,893,101 (the &#x2019;101 Patent), 8,455,536 (the &#x2019;536 Patent), 8,802,717 (the &#x2019;717 Patent), 9,018,243 (the &#x2019;243 Patent) and 9,872,854 (the &#x2019;854 Patent), which are listed in the Orange Book for Otezla. Each of these lawsuits was based on each defendant&#x2019;s submission of an ANDA seeking FDA approval to market a generic version of Otezla. The New Jersey District Court consolidated these 19 lawsuits for discovery and case management purposes into a single case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Celgene Corp. v. Sandoz Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant&#x2019;s ANDA effective no earlier than the expiration of the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, Celgene filed amended complaints against Alkem, Amneal, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz, Actavis, Unichem and Zydus additionally asserting U.S. Patent No. 9,724,330 (the &#x2019;330 Patent), which is listed in the Orange Book for Otezla. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN, Pharmascience, Prinston, Sandoz, Actavis, Torrent, Unichem and Zydus additionally asserting U.S. Patent No. 10,092,541 (the &#x2019;541 Patent), which is listed in the Orange Book for Otezla. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the &#x2019;940, &#x2019;302, &#x2019;536, &#x2019;243 and &#x2019;330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the &#x2019;283 Patent) and 8,629,173, which are not listed in the Orange Book for Otezla. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Celgene Corp. v. Sandoz Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz, Shilpa, Actavis, Torrent, Unichem and Zydus filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;243, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following Amgen&#x2019;s acquisition of the patents-in-suit and the new drug application for Otezla, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;243, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;516, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;717, &#x2019;243, &#x2019;330, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure&#x2019;s apremilast product during the term of the &#x2019;638, &#x2019;101, &#x2019;854 and &#x2019;541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz with respect to the &#x2019;717, &#x2019;516 and &#x2019;854 Patents, leaving the &#x2019;940, &#x2019;302, &#x2019;536, &#x2019;243, &#x2019;330, &#x2019;638, &#x2019;101 and &#x2019;541 Patents asserted by Amgen against Sandoz in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;302, &#x2019;536, &#x2019;243, &#x2019;330, &#x2019;638, &#x2019;101 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods&#x2019; apremilast product during the term of the &#x2019;638 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal&#x2019;s apremilast product during the term of the &#x2019;101, &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;243, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa&#x2019;s apremilast product during the term of the &#x2019;638, &#x2019;101 and &#x2019;854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis&#x2019; apremilast product during the term of the &#x2019;940, &#x2019;516, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;717, &#x2019;330, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On March 24, 2021, based on a joint request by Amgen and Prinston, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Prinston&#x2019;s apremilast product during the term of the &#x2019;638 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 6, 2021, based on a joint request by Amgen and Aurobindo, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Aurobindo&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;516, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;717, &#x2019;243, &#x2019;330, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2021, based on a joint request by Amgen and Cipla, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Cipla&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 14, 2021, based on a joint request by Amgen and Torrent, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Torrent&#x2019;s apremilast product during the term of the &#x2019;101, &#x2019;638, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 19, 2021, based on a joint request by Amgen and Alkem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Alkem&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 25, 2021, based on a joint request by Amgen and MSN, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of MSN&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 11, 2021, based on a joint request by Amgen and Pharmascience, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience&#x2019;s apremilast product during the term of the &#x2019;243, &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL&#x2019;s apremilast product during the term of the &#x2019;638, &#x2019;101, &#x2019;536 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the &#x2019;638 Patent, claim 6 of the &#x2019;536 Patent and claims 2 and 27 of the &#x2019;283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the &#x2019;101 Patent and claims 2, 19 and 21 of the &#x2019;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus&#x2019;s ANDA must be after expiration of the three infringed patents (the &#x2019;638, &#x2019;536 and &#x2019;283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus&#x2019;s generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the &#x2019;638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the &#x2019;638 Patent, claim 6 of the &#x2019;536 Patent and claims 1 and 15 of the &#x2019;101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the &#x2019;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz&#x2019;s ANDA must be after expiration of the three infringed patents (the &#x2019;638, &#x2019;536 and &#x2019;101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz&#x2019;s generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the &#x2019;638 and &#x2019;101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Oral argument for Amgen&#x2019;s, Sandoz&#x2019;s and Zydus&#x2019; appeals was held on February 8, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Apotex Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 14, 2022, Amgen filed a lawsuit in the New Jersey District Court against Apotex Inc. (Apotex) for infringement of the &#x2019;638 Patent, the &#x2019;854 Patent and the &#x2019;541 Patent. This lawsuit was based on Apotex&#x2019;s submission of an ANDA seeking FDA approval to market a generic version of Otezla and seeks an order of the New Jersey District Court making any FDA approval of Apotex&#x2019;s ANDA effective no earlier than the expiration of the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 14, 2022, Apotex filed its answer, disputing infringement and/or validity of the patents-in-suit. Along with its answer, Apotex also filed declaratory judgment counterclaims asserting that the patents-in-suit are not infringed and/or are invalid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2023, based on a joint request by Amgen and Apotex, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Apotex&#x2019;s apremilast product during the term of the &#x2019;638, &#x2019;854, and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Repatha Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc., et al. v. Sanofi, et al. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2014, Amgen initiated a series of lawsuits that were consolidated by the U.S. District Court for the District of Delaware (Delaware District Court) in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing seven of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the &#x2019;165 Patent); 8,859,741 (the &#x2019;741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to PCSK9. By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron&#x2019;s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen&#x2019;s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron&#x2019;s infringement of Amgen&#x2019;s patents is willful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT infringe certain of Amgen&#x2019;s patents, including claims 2, 7, 9, 15, 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a five-day jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron&#x2019;s posttrial motions seeking a new trial and for judgment as a matter of law, and granted Amgen&#x2019;s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court&#x2019;s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on two of Sanofi and Regeneron&#x2019;s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#x2019;s conclusion that the judgment affirming the validity of Amgen&#x2019;s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen&#x2019;s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron&#x2019;s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen&#x2019;s claim of willful infringement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2019, a jury of the Delaware District Court again unanimously upheld the validity of claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent. The jury also found that claims 7 and 15 of the &#x2019;165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed posttrial motions seeking to reverse the jury verdict against them or for a new trial, and Amgen filed a motion for a permanent injunction. On August 28, 2019, the Delaware District Court ruled on the posttrial motions, denying Sanofi and Regeneron&#x2019;s request for a new trial and their request to reverse the jury verdict that the &#x2019;165 Patent and the &#x2019;741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court and based on the subsequent hearing, on February 11, 2021 the Federal Circuit Court issued a decision affirming the Delaware District Court&#x2019;s ruling. Amgen filed a petition for rehearing en banc which was denied on June 21, 2021. On November 18, 2021, Amgen filed a petition for writ of certiorari with the U.S. Supreme Court seeking review of the invalidation of claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent as lacking an enabling disclosure of the invention. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 4, 2022, the U.S. Supreme Court granted review on Amgen&#x2019;s petition for certiorari on the question of whether the appropriate standard was applied by the lower courts in invalidating claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent as lacking an enabling disclosure of the invention. Amgen filed its opening brief on December 27, 2022. On February 3, 2023, Sanofi and Regeneron filed a brief in response.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Oral argument before the U.S. Supreme Court is scheduled for March 27, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Disputes in the International Region&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in Germany, Spain and Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen&#x2019;s patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen&#x2019;s patent. In November 2018, the EPO confirmed the validity of Amgen&#x2019;s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA&#x2019;s decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA&#x2019;s October 29, 2020 ruling.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2022, Amgen filed counterclaims alleging that PRALUENT infringes Amgen&#x2019;s European Patent No. 2,641,917 (the &#x2019;917 Patent). A EPO opposition to the &#x2019;917 Patent, filed by Sanofi on February 5, 2021, is pending, and the hearing before the EPO&#x2019;s Opposition Division is scheduled for February 21, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP&#x2019;004 Patent), seeking infringement damages and injunctive relief. The EP&#x2019;004 Patent is currently in opposition proceedings, initiated by Amgen and an anonymous third party, before the EPO. A hearing before the Opposition Division of the EPO was held on June 8 and 9, 2022, and on August 16, 2022, the Opposition Division issued a written decision upholding the validity of the EP&#x2019;004 Patent claims at issue, with narrowing amendments. Proceedings before the TBA commenced on August 17, 2022. On November 22, 2022, Amgen filed Grounds of Appeal before the TBA, and on December 30, 2022, Regeneron filed Grounds of Appeal before the TBA. On January 23, 2023, the TBA invited Amgen to file any response to Regeneron&#x2019;s Grounds of Appeal by May 23, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.&#x2019;s appeals making final the Japanese High Court&#x2019;s decisions that PRALUENT infringes Amgen&#x2019;s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen&#x2019;s Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. On April 15, 2021, the Japanese Patent Office dismissed Regeneron&#x2019;s invalidity trials, and in August 2021 Regeneron appealed the decisions to the Japanese High Court. On January 26, 2023, the Japanese High Court found Amgen&#x2019;s patent claims invalid for lacking adequate support. The decision is subject to appeal to the Japanese Supreme Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ABP 654 (ustekinumab) Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janssen Biotech, Inc. v. Amgen Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On November 29, 2022, Janssen filed a lawsuit in the Delaware District Court alleging Amgen&#x2019;s infringement of two patents by Amgen&#x2019;s submission of an application for FDA licensure of ABP 654, Amgen&#x2019;s biosimilar version of Janssen&#x2019;s STELARA (ustekinumab) and also seeking declaratory judgment of infringement of the same two patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sensipar Antitrust Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From February to April 2019, four plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceuticals USA, Inc. (Teva) alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. two of those actions were brought in the Delaware District Court, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UFCW Local 1500 Welfare Fund v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (February 21, 2019) (Local 1500) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cesar Castillo, Inc. v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar and alleges that the plaintiffs have overpaid for Sensipar as a result of Amgen&#x2019;s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lawsuits focus predominantly on the settlement among Amgen, Watson Laboratories, Inc. (Watson) and Teva of the parties&#x2019; patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys&#x2019; fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the four lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the four lawsuits, along with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cipla Ltd. v. Amgen Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, consolidated and designated as an MDL in the Delaware District Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the four class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs&#x2019; consolidated class action complaint and the indirect purchaser end payer plaintiffs&#x2019; complaint. On December 6, 2019, the plaintiffs responded to Amgen&#x2019;s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery Claims v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the Delaware District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge&#x2019;s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs&#x2019; objections. On November 30, 2020, the District Court adopted the Magistrate Judge&#x2019;s recommendation in part and denied it in part, denying Amgen&#x2019;s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen&#x2019;s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs&#x2019; offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court&#x2019;s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 16, 2021, the plaintiffs in the antitrust class action lawsuit brought on behalf of putative classes of direct or indirect purchasers of Sensipar filed their amended complaints. On March 4, 2021, a stipulation and order regarding the filing of a second amended complaint were filed to add another plaintiff: Teamsters Western Region &amp;amp; Local 177 Health Care Fund. On March 17, 2021, a defendant, MSP Recovery Claims, Series LLC, filed its notice of voluntary dismissal. On March 30, 2021, the remaining defendants, including Amgen, filed their motions to dismiss the second amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 27, 2021, plaintiffs filed their oppositions to defendants&#x2019; (including Amgen&#x2019;s) motion to dismiss, and defendants&#x2019; reply was filed on May 25, 2021. A hearing on defendants&#x2019; motion to dismiss was held in the Delaware District Court on July 13, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 11, 2022, the Delaware District Court granted defendants&#x2019; (including Amgen&#x2019;s) motion to dismiss except as to the reverse payment claim and various state law claims from ten of the states in which plaintiffs reside. On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal. The plaintiffs did not oppose Amgen&#x2019;s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs&#x2019; motion on June 10, 2022, and reply briefs were filed on June 24, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regeneron Pharmaceuticals, Inc. Antitrust Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2022, Regeneron Pharmaceuticals, Inc. (Regeneron) filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen&#x2019;s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payers and PBMs have harmed the sales of its product PRALUENT and focuses on two primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen&#x2019;s initial responsive pleading, a motion to dismiss, was filed on August 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 11, 2022, Amgen moved to stay the case pending the ultimate decision on the merits of the ongoing patent litigation between Amgen and Regeneron in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc., et al. v. Sanofi, et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 6, 2023, the Delaware District Court heard oral argument on the motion to stay and the motion to dismiss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Tax Litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. &amp;amp; Subsidiaries v. Commissioner of Internal Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6, Income taxes, for discussion of the IRS tax dispute and the Company&#x2019;s petitions in the U.S. Tax Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ChemoCentryx, Inc. Securities Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5 and June 8 of 2021, ChemoCentryx and its Chief Executive Officer were named as defendants in two putative shareholder class actions filed in the U.S. District Court for the Northern District of California (Northern District Court of California). These cases were consolidated into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Homyk v. ChemoCentryx, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in which the plaintiffs allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act in connection with statements regarding the New Drug Application for TAVNEOS and the underlying Phase 3 clinical trial, seeking an award of damages, interest and attorneys&#x2019; fees. On March 28, 2022, the plaintiffs filed their consolidated amended complaint, and on May 19, 2022, ChemoCentryx moved to dismiss these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2022, the Board of Directors and certain of ChemoCentryx&#x2019;s officers were named as defendants in a putative shareholder derivative action filed in the Northern District Court of California, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Napoli v. Schall,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and on March 11, 2022, the Northern District Court of California stayed the action until judgment is entered in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Homyk v. ChemoCentryx, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; action. On December 5, 2022 the plaintiffs in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Napoli&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; filed a Notice of Voluntary Dismissal, and on December 22, 2022, the Court ordered the dismissal of the case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments &#x2013; U.S. repatriation tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2017 Tax Act, we elected to pay in eight annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total remaining U.S. repatriation tax commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <amgn:GainContingencyNumberofLawsuitsFiled
      contextRef="i2958a5f5fff1421995cfbfcd99f50244_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjE5MA_7feff28d-10a5-4f46-b4ec-36c57e328f50"
      unitRef="lawsuit">19</amgn:GainContingencyNumberofLawsuitsFiled>
    <amgn:GainContingencyNumberofLawsuitsFiled
      contextRef="i2958a5f5fff1421995cfbfcd99f50244_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjIyNA_19f7670b-4d6e-4d86-87cc-3e7632fccdb1"
      unitRef="lawsuit">19</amgn:GainContingencyNumberofLawsuitsFiled>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="i2c106f85af6b497789bb2d2c5d8a09e5_D20210928-20210928"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0Mw_39071bc6-00cd-45a5-a668-f43e3632d728"
      unitRef="patent">3</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="i2c106f85af6b497789bb2d2c5d8a09e5_D20210928-20210928"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0NA_81049fd2-4d8e-4aa5-8f42-7e2ae06fcdc3"
      unitRef="patent">3</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="ia142d93a85b941c08264cf95a13ea31d_D20211012-20211012"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk2MQ_2e9f4b34-26dd-41b7-9f7c-e25921249fd5"
      unitRef="patent">3</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="ia142d93a85b941c08264cf95a13ea31d_D20211012-20211012"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk2Mg_9b9ca44f-4ed5-42b4-9326-c6e9254d891e"
      unitRef="patent">3</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i726c606382b04686ab59e3bf5cf547f4_D20141001-20141031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0NQ_91f082e6-c749-45e4-a269-9489c3969e1c"
      unitRef="patent">7</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <amgn:LitigationSettlementLengthofTrial
      contextRef="ice91453cc6994225aeb0216b9be20795_D20160201-20160228"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzI0MTg5MjU2MDU5NDgz_088ef9c0-4fe5-41eb-8868-c5d35582724b">P5D</amgn:LitigationSettlementLengthofTrial>
    <amgn:GainContingencyNumberOfChallenges
      contextRef="ice91453cc6994225aeb0216b9be20795_D20160201-20160228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0OA_f87ed247-e643-430a-9da4-641e1078199c"
      unitRef="patent">2</amgn:GainContingencyNumberOfChallenges>
    <amgn:GainContingencyNumberOfChallenges
      contextRef="ifba99da398a24a8da5609feecbdda3b2_D20180301-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk0OQ_22e2fe33-23ce-4df5-a4c1-efa65b0c1d14"
      unitRef="patent">2</amgn:GainContingencyNumberOfChallenges>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ib5c422a12ee04646bd081c628e80d370_D20221129-20221129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1MA_faa6d6b5-a589-44ed-a6ff-284b131b0d3a"
      unitRef="patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ib5c422a12ee04646bd081c628e80d370_D20221129-20221129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjE5Mw_71948553-5f95-4677-b49d-bbc80e2c5335"
      unitRef="patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjE4OA_c6229b8a-61ed-44f5-a252-ca7649e0a4ef"
      unitRef="numberofplaintiffs">4</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1MQ_441164a9-6651-4329-afc5-94afa9e0b502"
      unitRef="numberofclaims">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <amgn:LossContingencyNumberOfLawsuitsFiled
      contextRef="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1NA_dfd8736d-7dd0-4e1e-bd19-f023cb1824c9"
      unitRef="lawsuit">4</amgn:LossContingencyNumberOfLawsuitsFiled>
    <amgn:GainContingencyNumberofLawsuitsFiled
      contextRef="if7c1ec63c1ec45feb8a564cb6250b077_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA2MjE5NA_a6ab0462-10d6-4c63-b9c2-0b7ea167397f"
      unitRef="lawsuit">4</amgn:GainContingencyNumberofLawsuitsFiled>
    <amgn:LossContingencyNumberOfLawsuitsFiled
      contextRef="id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1NQ_4bbcdd95-3507-46f3-b8f4-f1651771b468"
      unitRef="lawsuit">4</amgn:LossContingencyNumberOfLawsuitsFiled>
    <amgn:LossContingencyNumberOfStatesInWhichPlaintiffsReside
      contextRef="iee18063ebe5b4821977151cc6f74a5c1_I20220311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1Ng_ed70d1f8-d076-40a7-8fc3-470194b8a908"
      unitRef="states">10</amgn:LossContingencyNumberOfStatesInWhichPlaintiffsReside>
    <amgn:LossContingencyNumberOfPrimaryArguments
      contextRef="ieb8da649b50d456aabccb1d09b37ed81_I20220527"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk1Nw_5bc2b144-0453-49b2-81b3-1ab377cc22fe"
      unitRef="argument">2</amgn:LossContingencyNumberOfPrimaryArguments>
    <amgn:LossContingencyNumberOfClassActionSuits
      contextRef="ib9fd3c9e12f348fda85ef0818a380f80_D20210505-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzU0OTc1NjA1OTk2MA_3eab8ab9-4203-4445-b4b4-861db911c3d7"
      unitRef="lawsuit">2</amgn:LossContingencyNumberOfClassActionSuits>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzQ0OTgy_da54da7f-d2ba-425f-92d5-7bfa630eca26"
      unitRef="installment">8</amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments>
    <amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90ZXh0cmVnaW9uOjQ1Y2I2YmM5NThlMjQ5ZjhhYjFlZTEyOTY5YmI0NGQxXzQ1MjI1_75e97d8a-6633-4b01-9869-3e38838af587">The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2022 (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total remaining U.S. repatriation tax commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90YWJsZTpjODUyZDhiZDYxNWU0MDZkODIzMjMzNDYyMGQ0NjZlZi90YWJsZXJhbmdlOmM4NTJkOGJkNjE1ZTQwNmQ4MjMyMzM0NjIwZDQ2NmVmXzEtMS0xLTEtMTg4OTc0_842dba9b-22f4-4c78-b6f7-66a0d0165318"
      unitRef="usd">1100000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90YWJsZTpjODUyZDhiZDYxNWU0MDZkODIzMjMzNDYyMGQ0NjZlZi90YWJsZXJhbmdlOmM4NTJkOGJkNjE1ZTQwNmQ4MjMyMzM0NjIwZDQ2NmVmXzItMS0xLTEtMTg4OTc0_134b8811-cb82-4b8e-ba0d-d5d13e633377"
      unitRef="usd">1467000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90YWJsZTpjODUyZDhiZDYxNWU0MDZkODIzMjMzNDYyMGQ0NjZlZi90YWJsZXJhbmdlOmM4NTJkOGJkNjE1ZTQwNmQ4MjMyMzM0NjIwZDQ2NmVmXzMtMS0xLTEtMTg4OTc0_1886529c-647d-4563-b94b-16dfb6bb3511"
      unitRef="usd">1834000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears>
    <amgn:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNDcvZnJhZzo0NWNiNmJjOTU4ZTI0OWY4YWIxZWUxMjk2OWJiNDRkMS90YWJsZTpjODUyZDhiZDYxNWU0MDZkODIzMjMzNDYyMGQ0NjZlZi90YWJsZXJhbmdlOmM4NTJkOGJkNjE1ZTQwNmQ4MjMyMzM0NjIwZDQ2NmVmXzUtMS0xLTEtMTg4OTc0_7e0d076f-7bc5-4832-be00-fcffd437b6d5"
      unitRef="usd">4401000000</amgn:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90ZXh0cmVnaW9uOmEyMzIxYjkzODVhNDQ3NTZhOTBhYjc1MDliYzllNjhjXzExMQ_d0757b4b-09e1-46eb-946b-5c0060f862f4">&lt;div style="margin-bottom:8pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;AMGEN INC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years ended December 31, 2022, 2021 and 2020 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at beginning&lt;br/&gt;of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;br/&gt;charged&#160;to&lt;br/&gt;costs and&lt;br/&gt;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at end&lt;br/&gt;of period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtMi0xLTEtMTg4OTc0_abeb6f61-5036-4a98-80e6-58828f8bda56"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtNC0xLTEtMTg4OTc0_1a014c76-7936-497b-96f6-152e2836a537"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtNi0xLTEtMTg4OTc0_5c40fe9a-4d37-4c57-a6e5-911921231b7c"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtOC0xLTEtMTg4OTc0_c23725b4-e3fe-463a-8caf-c6fcda0b761a"
      unitRef="usd">4000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i129c92e214904c7e8aec016ec2d5e387_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzEtMTAtMS0xLTE4ODk3NA_251294dc-e28a-4a59-80bb-e4344c2b040f"
      unitRef="usd">22000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItMi0xLTEtMTg4OTc0_666023ca-dbfd-4d6c-be22-b2bb74738765"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItNC0xLTEtMTg4OTc0_cefecfe9-7a12-4b3d-890c-86bdec0ea29f"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItNi0xLTEtMTg4OTc0_c20b904a-95f7-4c04-b8b8-f4ddc8fdd92b"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItOC0xLTEtMTg4OTc0_13a533be-ef24-428c-b781-a3e4b969e40e"
      unitRef="usd">6000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia2798874e9ac48be975005deb320dde9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzItMTAtMS0xLTE4ODk3NA_e47633e6-ddc1-497f-a557-787a5ed9254c"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1c1b6eb115494bd789be0adfdf7fdf82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtMi0xLTEtMTg4OTc0_e60d19a2-d988-4bda-a782-509355f4e61c"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtNC0xLTEtMTg4OTc0_599000b6-88b7-4fa4-892f-dfe910861787"
      unitRef="usd">8000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtNi0xLTEtMTg4OTc0_aa3d5fc4-ca0f-42b1-8963-5cbc17ec10a3"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtOC0xLTEtMTg4OTc0_149dd638-65c1-4f09-9e43-a76ed73b4cdf"
      unitRef="usd">2000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6a40b865ed594f40bd48caac4049fc3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4MDU1MDk5ZDE5OTRiYjQ5NDg3NWQ0MWMzNDFmMDBkL3NlYzpmODA1NTA5OWQxOTk0YmI0OTQ4NzVkNDFjMzQxZjAwZF8yNTMvZnJhZzphMjMyMWI5Mzg1YTQ0NzU2YTkwYWI3NTA5YmM5ZTY4Yy90YWJsZTpkZjU1MGRlODFhNzg0YzY3YTc2M2VlN2Q1NDVlNWUwZi90YWJsZXJhbmdlOmRmNTUwZGU4MWE3ODRjNjdhNzYzZWU3ZDU0NWU1ZTBmXzMtMTAtMS0xLTE4ODk3NA_241e5e04-f302-4ad3-b971-cd5c67c4d357"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>145
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M18$67-+INHSC==T;4L41L:^1J5\A0S,,P059\O )65\CK9N$FX+PD3S\GU$
M9]=$9R^TQCQ1-A,]LT1O''"7OZ%ID';4..'__0V.05-._/ _(N"I8%LL&(\&
MG\,]MLE= [I[2-@+:0Q^^4GO:E]$L%2*C12)%4"V3R#;,O7!B-H1C#H<K=[V
M1(1-'JYKS=]%?*11=?DH$BOPZ9SX="[C,PR""'MH0?:4<1$HN0YGD0BO)8VJ
M"TJ16 %4]P2J>QFH.6$N=>)Q"\$ *LRI"J7C2%4Z5$GCZT)3)%: UCM!ZUW8
M^QB&F3\9Q\HS3*ZUP5XH3#%I6%U:BL0*M&Y.M&ZD+<P&_8GK$32+_#5A(DIR
M#4W3FV:OIPGS2AI:EY0BL0*I_HE4_Q)2"[)U0PZIQ=$,^\*N*-<9^EL2P"QK
M7XMP26/KXE(D5L"E:WG1IET"#%I*&72_I**X0DL. QBB#%DT"CA[@[^.D&*%
M^F@LPB</JLM/E5H1X%G5JU\"<(5?T=2!$<W=N'9:EY7WU K)?J=I=MI:K]<5
MTI,&UZ:G2*U(S\CI&9?0&SH.J(=7QQ<H*6D? W'.R24A"J7=UX*? RS)B($?
M%)*4"M4FJ4BM2#+W!;JT6OX?DE;\#GKPBAX"(46YW&I'HQ!#*?.(GT,A/*5.
M0)5:$5[N!71Y-?\>WFG\FS/ZX@:V. _EFM90B$VI05"E5L266P1=7MN_QS:G
M(0>K\"]W7SYAR!7[NFEH3;W7[POA*34-JM2*\'+;H,NK_:2##AG!Y:SD C=:
M1PA)J4E0I5:$E-L$75[;?Z,V)-1\1P-9Y5LATF[WFKJF:4):2DV"*K4BK=PF
MZ!?YA#^)YS6? QCXT9+@$-@Y:!J&40D\N>83$0__2BV#*K4BM]PTZ!>YAA_4
M@VH7L]1I,5&[[RN49E0(2ZEA4*56O)N:.P;C(L=@18S%!CYU[6ZP32;-2 BM
M0K$DQ>11=:FI4BM2RVV"<9%-F,85:;I"$=\DPD>,0FIRQ3)J2NV!*K4BM=P>
M&!?9@Z0[(@MJLBUE;T)6<IUOF&W!%=@V 2&0<5))(3^EID"56I%?;@J,BTS!
MTL>>A^ZC$+X.Q3U4KE-ZBTT>5YO61[@ (W<!QD4N8.P3MHT'M*^@P'=0GOE[
M'(C33BY8CDVI"U"E5L26NP!#7K-/K<D"#2/'Y6"8AIP3, ')#9")A[=":O_?
MBH$\K#:TCZC^C;SZ-^3%^[%G[J!6DV:87*8\PY2Z %5J15BY"S#D!7P&:QZM
M/=>&M*)8/&&JK.4MI6JC3*V3J,5;*%X&NM'OMS6MKW<-_;;U(B*45_[&194_
M))(/'6_)J?U\!<F%X<K08\2A1P8.#&E":BHK>2M3ZYZULV.:_5[7,&].C<R0
M?$31;^1%OR$OU8]+4.'9S6\H#-;QZL&&0%$FONM3I?IH?7\8SU9+-)U9CXOY
MXV*X&H_0_1-:C"?CQ7AFC=%R3VQWX\+)DM*9!B&B&\1W!+'3NL4O/]T8>N]+
M&-^!>GU+;T@E"V8'%Z8DX $:''&:A,5;$X[KM ^$)-4X*"9IL*.> UXF/G1-
M$ PW#GK ;TCOISL:KA#D"'+?$6!' O -!,XQXV@ZG::7Z88(I^=B2>TO7"*1
M8ZK=>S["\IBYY3$OLSS GT&SIX%#7M'O1#A@5TAI\,_4;_1.6[B[0JGE4:56
MI)9;'E-N4(:0KTZ2LV6%0(5 Z>0FCZN-Z2,\CIE['%/N34Y+X1,WC&]V/1',
MT 0^%!;J%6)E&P?D8;6)?82K,<^V0,G=R'MBV<:+<F9RN<F3D)C:G4X?X6S,
MW-F8%6L1V<V:\Q23[5.ID&LV=:-IZD)L2IV-*K4BMMS9F'(G<EY.H?^B%4RU
ML^%R-/P#??7H&D NDUVG,*&R9R(L2>4GJ+WY3JD#4J56A)L[(#,U#2IW,JHT
M-992M9$JM2+-W"*9<HNT<KE'XOI,-WY=?X+$M",&>(44Y4I9TH>IA_A9NX:*
M14=[&#%>L"=VYG+%VB0_8A'%S*V4*;=2*X:=Y';VF[^FGA"@7&#X\'4FI*1T
MR4256I%2[IY,N<\Y)A@:O]H['&Q)Z4:K"J%T0!7R4FHA5*D5-QOG%J(MK_L-
MZ$;_@&X9N)2A&>7@RT=1XMRZ,+/,R $]4?:<335'IB*<\O/4'0.5JHU4J149
MYX:CK:N>4=HJG82E5&VD2JU(,_<E;;F5J#&C5"@)<M_)<E](4:E74:56I)A[
ME7;%/JK*V:1"()Y-2C@I=2BJU(J<SI[&D%N*R^>3"J'R^40>6)N74FO2.GON
M*EY^2IY?"Y$=;[]-'\$Z?7IZ1FZ8/!G6R@]/'[ #,[)U@Q!Y9 .AVG4/RGR6
M/K.6ON%TGSS%M::<4S]YN2/8(2P^ +[?4.BBV9OX!*<G!P=_ U!+ P04
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M(8VJ^VN],+)T+6HM#38\-\WQ20)E#?!\(Z4Y+&S7:Q^YY"]02P,$%     @
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M8-U"7:4^.^!!0_I0&H'2*(K&Z[;UE$RUI_2<2A!3_FHT2Y<6ZU K"4IS^^R
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M/&WEY]&0IU>PR[3=K@6\A L:Y;#L043B[(Y^YM]A#X"M$X"; ^YKH'T":.9
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M]\SM!: BP>R$&-&$N-%D:K!B<C#S-I<V=&!,S*TAH(IC:LU\6^73>.8X@HP
M0]P ,QFD*KNIG"9?/J!]R6K9 ;S>,L[N>PE +@DU&1-2Q;$U5 %5Z,4S!D?
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MQ0SU-E<4*J*"( WQHF\>H%]E!H10\.>)!(/4'2N+>]57#%*O+A-9IH&%'@2
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MJ\!/O/ZSBJPLX9I/PB.)<CM2B^'GFF2$';R1DQ 2>^@"X:?26(>)JO;*N$H
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MN$J5%BL](6(JPMI!P\4:GI8(<SHY[F21Z(7&'HK<R!Z:1TM1A_#=*%]\(52
MH4$P.(Z[Y?T(&S'=FM/+<47)1%Y@"W9/816(.-X8[?CQ1-UDF75D]Q*11#9[
M4NMP9'S79A(2]&J_$_KTC#J@KL/9::]X+,M;Z-0<,]5(U39,ZQ$Z#Q#'P$%R
MIQ_K@'+/R6C=5R1YRE/][F0^>B?LUCHR^Q;@75V 600_6J@%DB(,S''A:;#8
MD[26Z771$!AA#K@!@JC >,3?;R&R,#M!E_<&N\;WMG7(L[6W99&S?[_50,+,
MJ#LB+#XBXMS0<M"6:\0Y+'9''NH;93Z#?WJ 5FV:T=XY[QK\PQLE\3_40$W
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M]^RMCP84-_.<8&!PHBXHS%^.Q1N9B4<1W-@')9:%S[;GT\"=U#G+J=6XETJ
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M$(V&<^(M=BQB(3[(,D^-QASXY=?')C=T%*NJW)ZQ:Z;DQ)4UNE,_]2.P;J,
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M>VN&09=TBRSS)D9 \&S&3D/;>XU(IRRD"_;J85AT4%UY7#EU,#GM!\Q%J/*
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M@6\]W8M5M?N0DBAK5>D>$8"9T$2 _95"EVE?2,#NR]K=?P!02P,$%     @
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MK3^OZ7V@@26;@M%O?!NIN<L\O0/U/ VW8(]J>ODH<!\$)5'9T,\US2UI\U(
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M754:WH#UI=:N>6 %[>WW[#]02P,$%     @ 3H-)5@";_,T. P  -0<  !D
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M6@Z]"<O9D0FAGA 2WVHAXO)CVJ1O7]?5@=4X&JCA&]HJS0;F1(E*N6UJ^%;
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M!F!J)]J=9"D\!Y30 D;@@% D?EE"B7(!"\7S2_HWB"[9YU34["XM8)$T_Q?
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MP[^ES!#EFO73 LZ:98@[/;AF_Q1<:2;(-1@,*_(%^#3&I1^/?ESVDG  RYY
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M#=6R.E6[[J ^)TL)%N>=Q;PWKZ_?ON_Y+0Z/F,^I</2[%]XC1$/81;:<R%>
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MNTP@,F*K!=C_;[^ !R58$ )R)U ;2DNCC=4AQ/@PQ,$"6P$AMDI#1TKO2Y4
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M!V\0[!>(S\.Z9L4.27",>S(M4IQLMKD0["!XKBT;"*EU88#!QV0;W##T6QO
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M_(HLN$FV\;?@<_STCC,8I_EG"!K>BHF&E<EP)F]K<%';],/.4\"OD$#.BX4
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M5*#Z@;LH,<JT#F7=B,*P'$P+ZOZ*+$?U$RNSL2._:S!M1^G)T3 ].=AGI:6
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MN:5?IM1+P_P#!-8;6:I;XS%$))8HYPUWZVM3?C?;( .2GDNYJDW?V;%]'I'
M=A  EZ;"GL=@'-=+!HE>J<)NFU*M_JX2A8<.<B]-JDAFXDJ77'^R$AIW#[5+
M\:;?@CN6CCJ2+^9PR@/71OBF66[(X=F&]&$X;IL"UUW$#<L;P#?=;@'XC% /
M^%QB&1RNAU)=T*78A$H0#MKH.)'FSM86A'8CA7I2J+W(M7>BH')/[8UYRC6+
M3FYH+#:06LR<;E*3Z!(+SG28$=C:T11:+T!'@@87V_JRW:.S+3WU9*^XJPMA
M+.4<-X*P!4=^G>9@8:[HX)PVC5Y,;CYE24<9475!:;-.PHB\TGC2"4\C5GQH
MK].HF2X@5+B6;>LT:<;@N4,D!1T%N*P!F:IE\US'5VM03&[;R+QN$JL^F]A#
M_*AJ/71.(VQSHH-T=CMMM9+<5$VB(#,Z;W:FRBFVHK!6;]@E\XH8K^LLC6DI
M^99UX];)H9UQLP4BAG^3&>K9$OPA=NA6LW"K'0K<RIT,T=]K6QC:O]2X>%K^
M[<;%\.JOM"XM@C^P>7&=["XGMRC^"/O2S=08D,'^PQ@<_,[&4]0(%W7OK='5
M175^0P!7"8*\L$>/C>)HMW6P\72E:_F5/[IHG^M.PS8^MN7XUEYK9Q2"R;?Y
MP\YMO>2A50N^]CM$KD6QTX($G='1T1]>W='NH8_\$% />(ZF!>Z#G9H)G9KG
M,K.)V:RH-QL;I=-O:\:VK:11 W8XJUF.#-BWMCYWMJ[>J><YW!IDO1W=N:I'
M@#_&Q+8E+M^5VX*FI3\RH?T@@7$+L?'(M3NGQN</]$RY;]X$@=X^RC _!;DB
MK%F;HR)T6!90=&?JS.4@92N%-H'"7<]AG\L<+X20R;;[JWW^6@5;_PA?QQ&]
M,.@CS/C_3T[QK#_8+X(&3\F2S/&7S02_21&J)5TGDFEDI[]ZH[(C[W2HF5?D
MT.2#)*NV=C*X,F=WM]V G11/6N'U#+@V7@]1V#M ^D_!'J>'1Z/TZ.3X*1X?
MQ7,S1X?Q(53X;$[7T)##DW3<.J$U]B>T:,AXD)X,1O[/ _KS>)2>'(^>FB,Z
MQ\<GZ?'H@&*GRA^,<#?<N( X6>I"3W--$210<*(S<[G,Q=GE;R>[R<L;,E_^
MD(J5.6?O YWF.WR0%20]QA8I.L-0-'0A14E'&1B"2N32Q*C D)@?7IUS5>II
MLQ03O#!D'5P08@@;)!D# _.;T,KA3B6)<K?0)O,2)I)9Z[# 4EN$J-O=U)_L
M"3'\.C/>8H;W?'#HQX1YYU E^V5/JW-O$@ZPI_S3J!V?0QHS,WDP=R<,*_!&
M*K5CBA@;RW^%Q9X\GS5L2EQX=#N5O%T/^D79TT-HSK>U.$:Y((7.4%@CC-<7
M :[D4"&\N?AP^O:/5[]_=* G4W,;1A_XJ8GX<0:?6XWQV#4D=#[+.FGG=D['
M KEO%Z+&02#UQO5=W)DN&S)=?UI> *VNY)-,H*,'LM=\P0A='-04HE!+O&"(
M?H(8B^Y$L?[>*;'%G"[$R?/$'V8*1'Z\&6AP47B!ST:!6NFJ9OA8%2H7'PHZ
M'N-A1U_AG7S%=Z?4' +"^NQ.-VH9SB"2%7AF43 ->Z.$#28E)7MB @:^PX?L
MBXT6N(79R6A7BK?;29/@<!]G,D9RHLB&8K(N##:G/2TM'*>1N!CZ@*/N@BO=
MD-B%^BI\D-H%8! <X4TXLIC>!$&T7 \[QIL61O-?5GP.=(57N$64,O/V"2:B
M!\&;H'.1+!5>UNIK'0?;/@9W[>;;N9A^QE'7I:KQ1B?V>"MW!(DO.PIA(7TB
M>"F$ $G?"?O9^9*"/HB=)(<8MFWQ#[153O3JA2JS/KHDV]9&N_1A'6L.$#&%
MT!.Z$HUC6A"9BK,J=Z]@]1E\B-6?F:)<.TJ"=F(3>KQ)7NRI.%1G*FJ5$C2Z
ML!))(:-1H3ZI:0L**AW+RD8+-UV@ARWF_BZ],*<+XKH'DBIG+&< -%[;1%M!
MF?1Y:[<-9.-.FTM$R[@LL8+(QQE1]*!*EZ)4[N0OQZ27#29%TA#,6G*\^PZH
M9D#NY(^G%ETL6+EH)#: I"J69R$9N^,05YQ(K9G@&P.+1); (DGW[ 5'+^TE
M;^*ZAPM19CL.3Y5WH&_<7PNT;CK2Q&R2-OM4O)$W:TSI*Q3%!Y)!EZ0_A"QR
M3;77"H>%?&_86-]7N11\_Q@2JM-=VF368TE6#&'FX#.RD$1A[P,/+?,$!T*W
M>0S,)GWP!$K2K*CZUZ:E+?\_5(SXD>0?+QV@2HYN"E.G-PN->_89_#I+O-:9
MBE>>8UAY427]G4)^6X?5&[8=0N5X+P;6Y>SS79(03!3T$0_<!1,;XIS^R(_.
MZO)M>+5%WP:J-JVO\72_+MM&.0WR'VNZ;HW^PL,WP^-0J_O$H20-M*+:1@0O
M("UNS+Y OU+:\E?;KQA?JTHW8A-!G)7LEK!N=XXU4' )G2RMFA6%L;8V\TUJ
MS01:C](CV7VPX*1#>(T<W2K\>*-'& B$M(TW/$=6,+YC_X'P<286A^'I?.0R
MP+60@E/YZ-2_Z>VZ2VB3R:DBSQG[R=MB2N 5#-W=Y/!+:8 #.@+\Q=1>-2HJ
MZ^:TO9YQ$'2F^-V;GNWB:!641K*AWQ->&$%P#OVA9:TBS\A;"BQ5^'?F[PSW
M<+"ZQ(1P^P$]2-D$UB+5]G%]<9@1)[(7!O/KA:3XSV18I5Z56$#"3 U"8 CC
MD7L4_O@B+:2$%#$"*'3=CZ>F+X;\G:0,I0?+8OAB JK1EDKBC4U!79@;(X:Q
MWQ_9S8A-";B9C2Y,K5:XO]#>-YS(&=X*U<-#505A&O+)I"ACNSMH"'!..S_2
MW:OT!F,AOE86%@.PD)&?UF]2I_#K*^VESAJZ^=S\:BM#_JHNL[LDT=O,14G)
M&89[5,'T];K"W/ *UD]5:/K<Y>LE05&973^W%6ZO@C44"RY0MO')M>0K;@VO
MBN1G\KQ8%U\)@\2O8B6*OA+AJP8D5H)D&&J]QYN*(<=\=?%^QZE)>Q#>0#9,
MAY#Z#H8'.-9_VD'+3/)CD#%9K"U65V'[QN9R-8U<@G;A_:,HI*44M2O1&-%R
MU1R\\-K<!V-\@VLJ9$0OWH>ACU,Y21<LO0F,!Q.GM9-Q+IL:Q"W'I7]>3GY9
M&_!SJ9N53"YW3W=#^#ZI B]\7L$*68..P0RQ2L![= 'P41=**]?BN,M>^?06
MXF]@M%<L6K8NQ35(@+DBUF],^B4JQZ+6]&MD,+D^DHYVPUP!I3\I#&4A#?P7
MNVV96>9\E--%0;>VOM3F7O)3]NS;'U^>[L1!P4EX#0+\W)L6F)JSO<A@K<),
M.@,VND:M-KMW')IS*$6_3THML!1NGI$%;A4(WBER=6ZJK[B=V.!"<6M. 4Q'
M%!LRI(FS._Y"@=!H!&5THW3&++% \X7HN,)$LD^NR%P1X[SF;Y;<EC4.S(>]
MQ<>JB;T)'CP?(4^--P:0*T(($)%X(?G4I:CQ%I(59H<7&RWT26I&^RC4M-2F
M5YOQ+GCR9RA'77T=K7UVW')Q=;*U'8JJ+;F=1N[H '?EXEMB3_PML<!Z4H]U
MZ[,V-C5 ^OIO&(&ZEF3E;LQ/76IAP\+ (<*BGEQ^\7/%C%GWCM[V#ZR#?&\K
M40-+3 /82X4:LBATKN< [>EE4#2?KELI+U;\<9M)N9.\W/W7;@@T.UL,K?G:
MDEERCK>;YYDN9RUV<1,!]JIPY.+W%^VFN^=C-^?&AT?I_KZYEO?5A:$6?N-N
MR+2"'M5XG=0''0Y7].H,"%<X*>N8#0GN+Z%7D3^*WL+B=_>CA@RZ;% 7-[1I
M9.N_);Y,(&8Z"ER'.'2)@#%$*)YA&Q7E#]P-=F+Y3HWI_FJ,HS!\[I8NDPSY
MU-8D16"9=>[N$VOWU701SFJK2;%,4WXARM)LG."6[9)[?BZ"&_,#[-$EX)MT
M\"!+A$@8G7K'-NRR'>B_"PXTC".*%W!$:E^',$S78MO;YHI;=URT;%$!MZ+<
M]AK:$YS5]%URI(Q?KI<Z.I:]X5-EHT#E^3CT,+KG+HZLX7F*&:F9217LM%'H
MK'WX;?>WW:!#AUOU3 L8]W;BI#0'[G7^HN:+5C9LY:6ZHW'FLH.)Z$I\_Q?%
MTR:TM=U^'JF0LU9&S9V9UD ;YTU]JU@1JF+5C"J@OE P-!XI8"C3*HZ?NR/-
M&"=''YL@^,X>_R(;5EO?!P:0.6*A0#)AL+X2EI_;G@89YGD_<,XF8E.,@;D^
M2G;W)[1(EQIKZ>_@' ["P-0%?]A&X%FO^^2DZ]J+4=HWVA1LNT)::UW"PI5+
MAS/YI:%4G6MQ;-N=)5/46OFGZ:6-RTX.B$AQ=I-SXSNB-WM$+5+,"@SJ=#'7
M+2O^47^^T:T"$@;1*!+AXWA'K1=6K&DZ?L1[$*P&00)J%.;TY45RA%?6 [-0
M4'$/?:>CC0U8 ")0V( @];VVOO,V,JW.H]@G>QIN^\N:)@B(F;G69'NM_5[*
M36OP6D-L^]Y/[%"%+V1ARQ^&'&EKHHD"QX?-AV78)6LP<Z,N/[YZ>_KAM$5+
M\NF8?;E@NJLQM&-_F<J5X/-"'('>V#]?HFJ=Y9"*X/TI",XEOK,1XH2>WZOD
M-8;LSGJA1+#UIQ+KC+:D?,N2V3%H:K[V;4HSF8#/M1_&D1^;('Z7%O7XTXOM
M;!=5QK[\EC=J;./O.Y[U6 K E(MJ</3"M8):CN@%4$5A7C)),_NVS*[+Z8*>
MDI*\HNUYGH*/ B"FTC65[OJ&!(W];--@%WU"[VNZ3713>V\J8/W'Z[-/R5N-
MV>W@<'\_^23S&3[Q&LU4I#VN%W2[%9\/3G:2;3\%"]29K(#79Z*J(?777=K8
M-=^1F\\^N<.FCL-,PV#:Q8TQ[6T,#G']*,6RHBH50SL<C2-\P_[7+CC-7M9!
M"VF89L?E/RBHP.U^2#=UO;X2"%X1=;]>R**H;O(K42AA$@0S*OJEU1$;HOW;
MQ2_)+^ 1Z@6]0^92EE=@46RCJ=C[O">2WQ1(*]"N;.;5!F;A>0)RR_N.!C#[
M3O0>D.!]2QYY;":28.]GIMT@5ESX+E.EY%=Q8<<(_;UJ@-RB,@KA[ >;*U!
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M!6L_U'J%4V)B7^LE_0DF" B( ^#WF=:U_8 +7.OR,X'WXC]02P,$%     @
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M":$)* Q3XU'-J>9WH N, !N#E-1=XU%]YVH4F8%DNH'?>RWBV,E<DF%T939
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MF0$!%/PX@&" NB-E<2OZBD!RXC*!9?(D]$@ E&Z4Q\8 0$%X0*6LC?=1K>&
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MCIJ#K.GW\KC_U]OZH\31>#P@T<$^P\]<*E+-'QJP 2T9%!$3**27N4Z)J29
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MIQMLJ==3N)49"(T URPP\\AW+O+75,+%'X'.X'V:\!X!ZJ?F1H6N)HF_$7C
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M!?[SS8M?WI7I*.WFJOL8GK24.*TO^UOIKQZ0H73\ #*F0ZC%<?3W$,J!\C+
MF03!VW1"N1CDLSLH+/ZY)+ UBF_:>'XBDL-8>B%\.0#?=/Q@47S09&V;>$>:
M5Z NAL*I>B_OG[+4JV(.Y6P2ZO!<W1%D\,-#.K2,P%C*3$J5P&HO#W^$LH)
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;(U536_C-A#]*P-M$"2
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M=><H"M0\@;Y/E;*;%W;0_?]B\@]02P,$%     @ 3H-)5MN56Y&W!@  :!(
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M(!'^MFC_7<,OK-JX;PD+9:VJW.-:</ Q$L#[I5*V6Z" _N/2Q7\!4$L#!!0
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MI2QYLAM6] FB=@FT7BAEMX';8/A6T[]02P,$%     @ 3H-)5K#8O*S1 P
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MT_OO]&.8IS,8S(T/6ZU(+4K\&<%'L3]/&7QV2#S+FK*1W.4M1\IU)GCWF20
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MY8[^25"["_2^4,H^;YR!_B]G]2]02P,$%     @ 3H-)5I_@[E^)!   G@H
M !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULC59[;^)&$/\J(^X4@>0$
M>PW&3@ ICUX:J==&2=K^45758@^P/7N7VUV'Y-MW=FT(EQ":2#'[F,=OGCOC
MM=+?S!+1PE-52C/I+*U=G?;[)E]BQ<V)6J&DF[G2%;>TU8N^66GDA6>JRCX+
MPZ1?<2$[T[$_N]73L:IM*23>:C!U57']?(&E6D\Z46=S<"<62^L.^M/QBB_P
M'NWOJUM-N_Y62B$JE$8H"1KGD\YY='HQ=/2>X ^!:[.S!F?)3*EO;G-33#JA
M X0EYM9)X/3SB)=8EDX0P?C>RNQL53K&W?5&^A=O.]DRXP8O5?FG*.QRTDD[
M4."<UZ6]4^N?L;7' \Q5:?P7U@WM,.Y 7ANKJI:9$%1"-K_\J?7##D,:OL/
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M/@]TH:+Q!O1_I[4[3WR _HI>_0M02P,$%     @ 3H-)5HDDF99O!P  WA0
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MA,:;E/W,\.K*I1' ]:40NAT8!=UE>/8/4$L#!!0    ( $Z#259K#U_/\@0
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M63@@TEYIVQ<MMN8:^5IH+3+3W# *UN($&%\),*!\00'U_Q6<_0U02P,$%
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M<FMS:&5E=',O<VAE970T.2YX;6RMF5MOVS84Q[\*X19% R21*-];QT!BJ5N
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M]+:%\ 3P)2"E&_;%N!&'IP&E-^REP3Y(\_.$SI,(I\&H4UKDBM;V4AV/0GM
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M@!H@[Z\I%2\--4%[7A/\!U!+ P04    " !.@TE64 2421H#  !L"@  &0
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MD:9)?!IEY@6<-8QEH=E!;&%A%H]T$.5VC):[3S_^W?O'AZ(S//LY"E4Q*$U
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M@Z '-4,/W,RY"H7#_>P*@_DQS[.66=R#=DZ*UZ#=N*;=V$V[324<3I(E32]
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MG?Y]UND?O%J+?%EK@E^K"NQ6%=^[!F:FYZ[<N-?0&?%KB)2P%BGAI<\&_-;
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M:W-H965T<R]S:&5E=#4Y+GAM;*V8VV[C-A"&7X50BR(+-#K[E-H&UE&W[46
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MBR:S\< ='YO%)K/1P!^U9D?*AZWRX4GE/WB&&98Q=3 IJ+&NUSG4&7C!L*?
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M&&/Y$'5_6$\4+ZN.:<D5]E_5<(,M-0AM@/LKSM731!_0-NG17U!+ P04
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M2'9O@6ZB16-OQY70>-?:X1:?3R"- 7Y?"Z'?)F:#X4&6_0]02P,$%     @
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MG59ID:IVW1ZJ/3CD)K$*.+.=C_W[V8902"EJ)?J2V.:>8Y]C7[@>[AA_%"L
MB?9IDHF1M9)R?6';(EY!2L096T.FGBP83XE47;ZTQ9H#F1M0FM@NQH&=$II9
MX=",W?!PR#8RH1G<<"0V:4KXOS$D;#>R'.LP<$N7*ZD'['"X)DNX WF_ON&J
M9Y<L<YI")BC+$(?%R+IT+B(':X")^$5A)RIMI*7,&'O4G>OYR,)Z19! +#4%
M47];F$"2:":UCK\%J57.J8'5]H']FQ&OQ,R(@ E+?M.Y7(VL@87FL"";1-ZR
MW7<H!/4T7\P287[1+H_M!Q:*-T*RM "K%:0TR__)OC"B G!> K@%P#T&^"\
MO +@O1;@%P#?.)-+,3Y$1))PR-D.<1VMV'3#F&G02C[-]+[?2:Z>4H63X746
MLQ20)'L0Z+3HC4$=*$!%[Z=^]@F=1B )353K"[J_B]#IR2=T@FB&IC1)U!:*
MH2W5@C2M'1>3C_/)W1<F=UPT99E<"725S6%>)["5DE*.>Y S=EL9(XC/D.=\
M1BYVW88%35X/=QK@T>OAN$6-5VZ.9_B\]LU1&X"N]D3M/C&Y\O!#Q:%K":GX
MTV1Z3NHWD^H7R858DQA&EGI3".!;L,*/'YP ?VTRK$NRJ".RFIE^::;?QGXP
M<Y:?;5HY]TT>YEP]PZ7?G=NP[_G!T-Y6O7D>%/2Q4P^*G@<-',\K@VI:>J66
M7JN62*U=2!JCARFD,^"-QZ"5XJW'H$NRJ".RFG5!:5WP'CD5=&EFEV111V0U
M,_NEF?T.<RKG"BJ9X&'W.*>>!SF#'C[*J>=!/A[TFW-J4&H9M&I1980J$K+6
ME&IE>.LIZ)(LZHBLYMQYZ=SY>Z34>9=F=DD6=416,]/!3Q49[C"I"K+J]\7W
MW*.$F31%#7K'GZJF*%SYZN6"[$JUF0)?FJI=H)AM,IE7:N5H>3.X-/7PT?A8
MWQA,%?M$DU\WIH0O:290 @M%B<_Z:DD\K^#SCF1K4]/.F%05LFFNU*T'N Y0
MSQ>,R4-'3U#>H\+_4$L#!!0    ( $Z#258VZ_\B@@,  +H-   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;*U7T6ZC.!3]%8L=K3K23L&&0-)-D*9A
M1SL/E:KIS.ZS"S<)&L"L[22=OU\;" 7C1%65EP3;YQR?>XTO]O+(^$^Q Y#H
MI2PJL7)V4M9WKBO2'914W+(:*C6R8;RD4C7YUA4U!YHUI+)PB>>%;DGSRHF7
M3=\CCY=L+XN\@D>.Q+XL*?]U#P4[KASLG#J^Y=N=U!UNO*SI%IY _J@?N6JY
MO4J6EU")G%6(PV;E?,9W"?8UH4'\D\-1#)Z1#N69L9^Z\35;.9YV! 6D4DM0
M]7> -12%5E(^_NM$G7Y.31P^G]2_-,&K8)ZI@#4K_LTSN5LY<P=EL*'[0GYC
MQ[^A"VBF]5)6B.87'5ML%#HHW0O)RHZL')1YU?[3ERX1 P(^1R =@9B$X S!
M[PC^6PE!1PB:S+2A-'E(J*3QDK,CXAJMU/1#D\R&K<+/*[WN3Y*KT5SQ9/RU
M2ED)2-(7$.CFD;-#WBRI>J-0-_9=CWU$-PE(FA?JZ1/Z\92@FP\?T0>45^@A
M+PI%$4M7*D-:UDV[R>_;R<F9R3%!#ZR2.X'^JC+(Q@*NBJ0/AYS"N2<7%1-(
M;Y&/_T#$(\1B:/UV.K;0D[?3O0O1^/WB^(V>?T9OO><<*HGJT[+<V7+<:@1V
M#5TW[D1-4U@YJC (X =PXM]_PZ'WIRT_UQ1+KB0VREW0YRZXI!Y_@0PX+6P)
M:XFSAJCKXB'&D5[NPS 14] \G(TQR12S&.B,;,]ZV[.+MI\DE6 SW=+"P5Q!
M8%B>0O#<<#R%^('=<-@;#B_GF7%56RN;Y7 ZF6=ZMF!F"\/T%$.BR.XZZEU'
M%UU_9Y(6JKX:^\L6132=W0L-B^LI"). &''80#ZQ!S+O YE?+!$);$ %D:%G
MJ&"32VN%F%^S0EQ3++F2V"AUBSYUB_=6B,5DI3YA/#>V_]J"\CUSQ]E YXH$
M]EZ_VM[[RD3'&\U'(L.X#61N.@MF<<;UX*R!WULK.N;(4NB;OBT@C"/3N04U
M.Y=Q\NJ=O*%B9,9VLX9"+"Y)9+X]-EC@!V8P%I0_2,PXFM>#!;[X[>VBJ4?'
MO7QP%+3&Y4\^=]'"K.<6T'RR)VR@T'R[W,&AM@2^;2X' J5L7\GV0-CW]A>0
MS\VQV^B_UQ>3YK#\*M/>:AXHW^:50 5LE*1W&RE'O+THM W)ZN;H_,RD.H@W
MCSMUN0*N 6I\PY@\-?0$_74M_A]02P,$%     @ 3H-)5@T3)@%=!   LQ
M !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULK9C;;MLX$(9?A= 6BQ2(
M(Y&R93MK&TB=%AN@V09-V[VFI;%-1!)=DCYDGWY)69%LD5(3H#>Q#C.C;X;D
M_&0F>RZ>Y!I H4.6YG+JK97:7/N^C->047G%-Y#K-TLN,JKTK5CY<B. )H53
MEOHD""(_HRSW9I/BV8.83?A6I2R'!X'D-LNH>/X *=]//>R]//C*5FME'OBS
MR8:NX!'4]\V#T'=^%25A&>22\1P)6$Z]&WP])X%Q*"Q^,-C+DVMD4EEP_F1N
M[I*I%Q@B2"%6)@35/SN80YJ:2)KC9QG4J[YI'$^O7Z)_*I+7R2RHA#E/_V6)
M6D^]D8<26-)MJK[R_=]0)C0P\6*>RN(OVI>V@8?BK50\*YTU0<;RXR\]E(4X
M<<#]%@=2.I#7.H2E0U@D>B0KTKJEBLXF@N^1,-8ZFKDH:E-XZVQ8;H;Q40G]
MEFD_-;O+8YX!4O0 $EW,>;;A.>1*(KY$M[ $(2!!W^@!W4@)^C'-$_29T05+
MF6(@WZ.+6U"4I?JJA[X_WJ*+=^_1.\1R=,_25 ^4G/A*<YJO^7')].'(1%J8
M;B&^0B&^1"0@Q.$^?[T[/G?W=76J$I&J1*2(%[;&*\O JEHA6E3CVI7;,5C?
M'<RLRFNYH3%,/;WL)(@=>+,__\!1\)<KT]\4["SOL,H[[(H^^^?+YV*X8YT[
M4RBF0CSKOK&G(G$.ZC':H(AFNL=NAL-^?^+O3A-R& 71H#(Z ^U7H/U.T)LX
M%EL]/G#0S4V"$^X8(3KY[F#49+-MHB!PHPTJM$$GVIQNF*(I^T_CF1&B(EX7
M14U@IUOH1C=$U<D]L+GQH,%MV[101Q5UU$GM6/B7Z.//+5//Z![4FB?H+M^!
M5 ;?B1U92&08-+!MFQ;L884][,3^6-913]6ZZGK&FA7K@AS:D!@W(!TV)W/Z
M#'-488Y>5]VJD5PB/3%REJ^*MJN)M?CD6ED7DB6,"N:>&B,+#8]) ]^V::GQ
MN((?=\(_*AX_]8QPZL:@U4(7G!H]=@&.;<"@N>9LFW'D)L1!+6E!)^,7M0;A
ME)W ^EJ(APTBEQ%I8SJ16=S)](WK"6GV%RU2XL3%-LD@M'AM*Q*&N 6X%CW<
MJ2VS'S3=TN-.*]5[/9K'X&0DUM=[0SQJ,CJLHBAL8:P%"O]"H?0V]XTE#>UB
MC?"XB6M;X2@:M>#6,H7[;]Y(I/5>RKF;P)W2]];MQ.^*=EZ 6@QQMQK>Q%I#
MC@50-%^Q10I=8V7K6@^3T)I;#K,1:>G1N)9 _"L-7"@GE2U;/3)L]EVW5<L^
M!]<"A[L5[A,[Z.IUE,R6JQ[&%IS+BHQ;X&I9P]VZUMYV;17JD4%3"9Q6I*V/
MU7J%NP6KO?&>+#TGM2U-/3P:1DULEUF_WU)-4HL8Z1:Q5F[0>[$<G'.S#'FZ
MNQ[WPP:PPXC@)JY_<J(TQ_E[*E8LERB%I?8*KH;:71Q/R,<;Q3?%(7/!E3ZR
M%I=KH D(8Z#?+SE7+S?FW%K]GV+V/U!+ P04    " !.@TE6*@17#$4(  !-
M4P  &0   'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6RUG&MOVS@:A?\*X5TL
M.L!L+5&V8W<3 XTE<@OT$K2=W0^#_<#(3"R,+'DD.DX7\^.7NL0R(XF)=HZ+
M(K9D\B$E'O-R])J7AS3[+=](J<CC-D[RJ]%&J=V[\3@/-W(K\K?I3B;ZD[LT
MVPJE#[/[<;[+I%B7F;;QF#K.;+P543):7I;G;K+E9;I7<93(FXSD^^U69#^N
M99P>KD;NZ.G$U^A^HXH3X^7E3MS+;U+]LKO)]-'X2%E'6YGD49J03-Y=C=Z[
M[[@W+S*4*?X5R4-^\IX4EW*;IK\5!Q_65R.GJ)&,9:@*A- O#W(EX[@@Z7K\
M7D-'QS*+C*?OG^BLO'A],;<BEZLT_G>T5INKT7Q$UO).[&/U-3W\4]87-"UX
M81KGY5]RJ-,Z(Q+N<Y5NZ\RZ!MLHJ5[%8WTC3C)0VI.!UAGH:S-X=0;OM1DF
M=8;)LPSNHB?#M,XP?6T)LSK#[%D&[Z(GPT6=X:)LK.KNEDWC"R66EUEZ(%F1
M6M.*-V7[EKEUBT1)(<5O*M.?1CJ?6GY(PG0KB1*/,B=OOLM'M1?Q3^2-+Y6(
MXORGR['2I11IQV%-O*Z(M(?H4O(I3=0F)T&REFL3,-;5.]:1/M7QFEJ)O@S?
M$L_]F5"'4O++-Y^\^6M7Q5:OQ[@6C/]ZC&/!!*_ N(OZHE;ZV]3!8';&^UWV
MEM#YBS>&VS&?Q(_6?2')?GLKLR]WGU,5A3*W-*-WE)I7%N/U%/-=/))5)M>1
MTI>;93]T/WH0V9K\^E$G)!^4W.;_Z9);19UT4XNN^EV^$Z&\&NF^.)?9@QPM
M__87=^;\HTLB2)B/A 5(&$/". AFB&9R%,W$1M?]DY*:JHA(UD2/OR)6D>ZI
M,AD+)==$I62?9#),[Y/HO\6QUMBM3.1=I(I$Q_-1HO\_]71DEZ4/43&8=LFM
MJL^TK$\QD#\LW?G"*?]=CA].M=1.N9AW)?0[D/KV=*0,K#=CJ B0, Z"&2*8
M'D4PM8K@?1AF^[(5.\4@\CP-HU(/ATAM^A71U=Q5R3.C;1RGL[W;2>=SM[/!
MK9<SM&- PA@2QD$P0Q.SHR9F+W0,)Q.7G8C678T[:[48G?0T[JS]'5UT)_4[
MDO90 ^LU#&T[)(R#8$;;71S;[L+:=DRN929B\NLG64PR.D=]*V'HJ(^$^4A8
M@(0Q)(R#8(9 YD>!S,\R59PC18.$^4A8@(0Q)(R#8(9H%D?1+*R]2B&:L!)-
M>"(:/3]XT$M9<1O+8KJH$^Q#>3(;?+ZVJ92T:$\++KH'#FNEALH$"0N0,(:$
M<1#,D(GK-):'8Q7*YR\? 0JI"S$DXO5,+NP5&BH2*"V TAB4QE$T4R@GWI@[
M3"@_DP<1[T5EHL9Q>A!)V.7;7-?@4W&T-&$M>[ FD+0 2F-0&D?13$W01A/T
M)4WDU3(S2;O44*Y-]4?R<1=EY6>=^J#MSL/IZSRL%1HL%"0M@-(8E,91-%,H
MC=OI6GVQY4V6[M)<KHE8ZRF)UH%>\#1C2J<HH$XGE.9#:0&4QJ T7M-.E_?>
MK/75-$71N)FNW<[\*G="95'59Q36E'[9=0BE3R%(2V\%I?E06@"E,2B-NQW&
M[PL":9Q.UVYU?BX?NY#T3H\AY8,7BT+('_:G-+5FD);?"DKSH;0 2F-0&G?;
MYC'MT4KC@+IV"]0^PA#JN-[?]9]IIRJ09N(*2O.AM !*8V[;_)WV/"_@J))-
M>30FJVMW66^.#TAZNI"65ERG6RM0+Q9*\Z&T $IC-<WXSO=,\CFJ9%,KC=_J
M6IVY(?.2%_H5J 4+I?E06@"EL9IVVJ]0VJ>5<[BL;F.SNG:?M3U%"=,D3^-H
M73Z"C1)]O,^4GIWT1+5<VPL8+!*H PNE!6[;1Z9F:S)H@1Q%,P.U&FN5VJW5
MYT_VM B"HQ%22*/H0'Y(D>7D5JJ#E$D1=>25I@EU)EZ76NQ%#E4+E.9#:0&4
MQJ TCJ*9PFJL6.J>Y8D@17J/*RC-A]("*(U!:1Q%,\73>+;4[MGV/1E\M9U/
MVW9M9_S6REZ1P0*!>K50&H/2.(IF"J3Q:JG=J_VF]-3%&HYB!PSN1Z#>+)06
M0&D,2N,HFBF3QKVED_,,0E#;%DKSH;0 2F-0&D?13/$TSBZU.[O0\!3:$8NZ
MZ!F2H(XME!9 :0Q*XRB:*9?&W*5V<_?/SUG:P:_SIP"5YQ*!VK=06@"E,2B-
MHVBF1!J#E]H-7DP<$VV[E%.OIRN!6K=06@"E,2B-HVBF3AISE]K-W?\_C*D&
MGVICXDZ[M0&U:J&T $IC4!I'T4QM-&8NM9NY+,UD=)_8USY0NQ9*\Z&T $IC
M4!I'T<S?;C;.KN><9>WC0=U;*,V'T@(HC4%I'$4SQ=.XMYX]D!:Z]O':L;73
MSI_AK>RU&JP6J%T+I3$HC:-HIEH:N]8[LUWKM>W:EC2@1BV4%D!I#$KC*)HI
MC9,M!.Q&+6;)4Q=B1%_W_-AS9:_08*%@MPS [AF W33@'%:MUUBUGM7-^Q-K
MGAILB&/>O1ZVUV&P-J!.+)3&H#2.HIG::)Q8[X486\A/.+RV!3N;]/0A4 L6
M2@N@- :E<13-U$ECP7IV"_;YVIC\0;[L9*&(Y)Y\3/-<YN3[1J@JQ$62ZR:B
MA=81+9[;*1UH\"V4YD-I 93&H#2.HIGJ:MQ;[^(\"VIH-"Z4YD-I 93&H#2.
MHIGB:2Q=[UR6KM<.-&T-5U K%TH+H#0&I7$4K=+$^&13OZW,[LO]&HM8VWVB
MJKWSCF>/>T*^+W="?';^VGWG5SL[-IAJH\E/(KN/DIS$\DXCG;<76A59M7=C
M=:#27;EUX&VJ5+HMWVZD6,NL2* _OTM3]710%'#<07/Y/U!+ P04    " !.
M@TE6E$ADDKP#  !4#   &0   'AL+W=O<FMS:&5E=',O<VAE970V."YX;6RM
M5]MNXS80_15"710)D$0WWY+:!N*HV^Y#@"#9M,^,-+:)I4B7I&)OO[Y#2E9L
MF792("\V+V<.S^$PD_%X+=4/O00P9%-RH2?!TIC531CJ? DEU5=R!0)WYE*5
MU.!4+4*]4D +%U3R,(FB05A2)H+IV*T]J.E85H8S 0^*Z*HLJ?HY R[7DR .
MM@N/;+$T=B&<CE=T 4]@GE</"F=ARU*P$H1F4A %\TEP&]]D<60#'.(O!FN]
M,R;6RHN4/^SD6S$)(JL(..3&4E#\>H4[X-PRH8Y_&M*@/=,&[HZW[%^=>33S
M0C7<2?XW*\QR$HP"4L"<5MP\RO6?T!CJ6[Y<<NT^R;K!1@')*VUDV02C@I*)
M^IMNFHO8"8@'1P*2)B#I!O2.!*1-0/K1@%X3T',W4UMQ]Y!10Z=C)==$632R
MV8&[3!>-]IFP>7\R"G<9QIGI-Y'+$HBA&]#D[!%R*7+&&75)D7/R71K*R1]*
M:DUN2UD)H^WR\_>9/B=G&1C*.(XNR?-31LZ^G),OA ERSSA' CT.#6JT)X5Y
MHV=6ZTF.Z(D3<B^%66KRNRB@V"<(T5SK,-DZG"4G&3/(KT@:7Y D2A*/H+N/
MA\>>\.SCX=$)-VF;K]3QI4?X#C-D7(86+D/T+4.54 A="/8O%#:]Y 4$S!EN
MGL$FYU7!Q )394"!-A<$ZPCEAH&^(%A,\*]%N*!<06%CJ$"2)9 Y%*#PN!U"
M>Y@VU&P?D0*.$X3+XQK.?0^C-M[S&[?U[T:O: Z3  N<!O4*P?377^)!])LO
MJ9])EGT2V5[">VW">Z?8IS-8,"%LLEXHIR('W]75%'U'82O]ZS3M]P;C\'7W
M2CR@M)_L@S(/*!D-6]">A7YKH7_2PFV!;\B6 U>A"R+KM[62NEG>>3+VD>65
M4B ,^0E4^=S6IPUV-,;]N&/6@QEV,)D',^C[K0Y:JX-/L[I23"IGTELG!P?J
MKJ..R4-(VN]X]$#\#H>MP^%)AX]05'GM!0M%QQV6@G=<#0_T7,:]CBT/I@/)
M/)#T2.I&K;'1_S$&FQ53;9&U!:["$H=#SDIFW(;7X,BCK./O$-));'8*L6?N
MNC5W?=(<]F^& _9KQBOZ^CU%=X>(RU%'M <R&/EEQ]%;>Q*=%(Y=P#NUKR'8
M*UG#85>_#W50(C,?:K=&UB;"G7:K!+5P;:LFN?W?6_<E[6K;&M^ZAK"S/K,M
MLVOCWFCJ?ON>*BS[FG"8(V5T-41)JFYAZXF1*]?4O4B#+:(;+K'M!V4!N#^7
MTFPG]H#VA\3T/U!+ P04    " !.@TE6IRD17NT#   4#P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V.2YX;6RM5UUOXC@4_2M65COJ2%WR 07:@4@MF='V
M8;2([L?#:A],<@%K$CMC.X7^^[6=D)),XO P+Y /GV.?<^V;>Q='QK^) X!$
MIRRE8ND<I,P?7%?$!\BP&+$<J'JS8SS#4MWRO2MR#C@QH"QU \^;NADFU D7
MYMF:APM6R)106',DBBS#_.T)4G9<.KYS?K A^X/4#]QPD>,]O(#\*U]S=>?6
M+ G)@ K"*.*P6SJ/_D/DCS7 C/B;P%%<7",M9<O8-WWSG"P=3Z\(4HBEIL#J
M[Q56D*::2:WC>T7JU'-JX.7UF?V+$:_$;+& %4O_(8D\+)VY@Q+8X2*5&W;\
M'2I!=YHO9JDPO^A8CIUY#HH+(5E6@=4*,D++?WRJC+@ ^-,>0% !@C9@T@,8
M5X#QM8!)!9@89THIQH<(2QPN.#LBKD<K-GUAS#1H)9]0'?<7R=5;HG R?*8Q
MRP!)? *!;C80,QJ3E& 3%+9#7R !CE/T(K$L).-OZ$]\0ALLX2.ZB4!BDHJ/
M"U>JI6A"-ZZF?2JG#7JF]0/TE5%Y$.@S32!I$KA*0RTD. MY"JR,$<0C-/9O
M4> %0<>"5M?#_0YX=#W<LZ@9UV$9&[ZQ/2S:ZXB(.&6BX(#^?=P*R=51^:_+
M\9)QTLVH\\>#R'$,2T<E" '\%9SPPR_^U/O4Y=;/)(M^$EG#R4GMY,3&'IXW
ML*@WL-KKB*L-W.5AR>5[ADSGS-?0&^D-\7IISE6CHJ%1#3EWM9P[NQS&52JC
M"#"GA.Y%EP@[P\W=:.K]VG5F5P/ V6C>#8P&@)/1[ =@0_VT5C^]1OUO*J3J
M:Y$@0B6F>[)-05WJ$]-EAYWRQA^->^P8!'H]=@P O2$[9K4=,RO3BD-"I+A%
MZP*X9&A#8H;@%!-A,GJ7&7;"FZ OQ*L!X'@TZ3%C<,9[NQGSVHRYE>F92E#I
M0R+UX2IHK Q158\Y[#D31'_/.@]+2>H'C5/J^?>M(]\SK'WF!X<UI-W7TNZO
MBW/.B:K.2/J&=E5:VWS 6?XIZE)FYU3&]VS?U2#0[PGU -#OV",-/WSOO6KQ
MK%R/\?>"E%%%SVN+"15/,PNW8GL>TXK:I+4'(CM74\E%_>7;E10JM$B E"FH
M>EIV;M**PZYB>$PTL);.E-;4%;SK"JQ<?\@#\%M$078*LH-5BNQ))ZMA9,_7
M+1I&#J1E_[UZ\ZTE3?AYMP/3T%B+C8JDM>]\;]Z.;/>X'PJ./KY9:X^Z%^U"
M!GQOVBZ!8E9061;<]=.ZM7LT#4WK^9-N^4P;\DY3]HM?,=\3*E *.T6IG%45
M B];L/)&LMPT)5LF58MC+@^J;06N!ZCW.\;D^49/4#?"X?]02P,$%     @
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MEJ69U"BM@SDOA- ;PP9H9W_R%U!+ P04    " !.@TE6@YFF9F8#  #/#P
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M%^NV?:X$K>R@"(-=6+$+079?:230GL:9G5'8Z,\RI,V@\T,ZJGB-0%[/@_D
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M\,N<!A88YT#G:ZWQ8+B>:$=@^AM02P,$%     @ 3H-)5JL@GRWK P  ?1
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MER2\9Q(+KQ4QP.$Y]-T>>([G-01T^79SM\$\>+NYT\*F7RY)/\/KOX)WA8B
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M+W-H965T.#<N>&ULM5EM;]LV$/XKA%84+=!$(JG7U#:0QF@78,&"9-T^#/O
MR+0M1!(]BHZ;_?I1+Q$MB1)LC/MB2_+=X^>.=WI.XNS ^'.QI52 'UF:%W-K
M*\3NRK:+>$LS4ERR'<WE+VO&,R+D*=_8Q8Y3LJJ<LM1&CN/;&4ER:S&KKMWS
MQ8SM19KD])Z#8I]EA+]^H2D[S"UHO5UX2#9;45ZP%[,=V=!'*K[O[KD\LUN4
M59+1O$A8#CA=SZUK>'6#4>E06?R>T$-Q= S*4)X8>RY/;E=SRRD9T93&HH0@
M\NN%WM T+9$DC[\;4*O]S]+Q^/@-_6L5O SFB13TAJ5_)"NQG5NA!59T3?:I
M>&"'GVD3D%?BQ2PMJD]P:&P="\3[0K"L<98,LB2OO\F/)A%'#M =<4"- SK5
M 3<.N JT9E:%M22"+&:<'0 OK25:>5#EIO*6T21YN8R/@LM?$^DG%M\86QV2
M- 4D7P$FMI2#)!<DWR1/*06D**@HP 6X7=%<).N$E%=OE<%U;?!A205)TN*C
M-/W^N 0?WGT$[R00N)/0<K6*F2TDV?(O[;@A]J4FAD:(+6E\"3#\!)"#D,;]
MYG1WV'6W98K:/*$V3ZC"PR-X7Y,\$?0BE36W&F;H2A=?#>CJ <OVO"IV)*9S
M2_9?0?D+M1;O?X*^\UD7K2&P3NRXC1U/H2^^<584(":<OR;Y!I",[7.A7=(:
MQZMPRAO(RP)[7N3/[)?C6#16R(FBUJI#TFU)NI,DK^-XG^U3(N3Z2(9<)/^0
M\D:AHUDC^4<$+I#C(:_'4V,&@R@,]$2]EJ@W2?17?9-] CD5.K+>@ 7TG #V
MN&JL7 B1GJK?4O4GB_XVES?$\PO?-UGXAL Z\0=M_,'D4G7N>H/8=:$'@V7
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M1;%_+QJ*S_,=[80KO3_.+U-]Y %A!NC[4\[5NF$FJ Y1X5]02P,$%     @
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M4\-%-LIE"\5G=AH:<J5G*_LXU>,O"!.@OX\Y5ZN%&;"*@3K^!U!+ P04
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MN<3I#,HFX/>YE&:[L0>T\S[["U!+ P04    " !.@TE6_R]\MI8#  #E#@
M&0   'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6RU5]MNVS@0_15"+18MD$:B
M;,EVUA;0QBVV0 ($32\/Q3[0\C@F2HE:DK;3O]\AI<@7*4HKI"^V2'$.SQE2
M/)SI3JH?>@U@R'TF<CWSUL84%[ZOTS5D3)_+ G)\LY(J8P:;ZL[7A0*V=$&9
M\,,@B/V,\=Q+IJ[O1B53N3&"YW"CB-YD&5,_WX&0NYE'O8>.3_QN;6R'GTP+
M=@>W8+X4-PI;?HVRY!GDFLN<*%C-O+?TXI)&-L"-^,IAIP^>B96RD/*';7Q<
MSKS ,@(!J;$0#/^V< E"6"3D\5\%ZM5SVL##YP?T#TX\BEDP#9=2?.-+LYYY
M8X\L8<4VPGR2NW^@$N0(IE)H]TMVY=A1Y)%THXW,JF!DD/&\_&?W52(. NCP
MD8"P"@A_-6!0!0R<T)*9DS5GAB53)7=$V=&(9A]<;EPTJN&Y7<9;H_ MQSB3
M7 'F0),WY)J9C>*&8T.NB.LF5YPMN"@[7\W!,"[T:QS[Y79.7KU\35X2GI-K
M+@0NB)[Z!OE85#^MYGY7SAT^,O<<TG,RH&<D#,*P)?SRU\/I<;B/6:A3$=:I
M"!W>X-%4: UP5FH_(W/0J>*%VVS?KW L^6@@T_^VZ2R!A^W ]DN\T 5+8>;A
MIZ9!;<%+_GI!X^#O-M7/!':4@T&=@T$7>H*I'+0)+*,B%V5/AFU"1[ADVT/>
MG<@]>0]KWL.G> _;>)=1\2'O8'+"NQ.Y)^^HYAT]Q3MJXQTU>(^#$]J=P#UI
MQS7M^"G:<1OMN$%[=$J[$[@G[5%->_04[5$;[5&#=CP\H=T)W)/VN*8][J3]
M>0WHT"L#JHW\N$$^',<G[#OQ>[*?U.PGW>RE88((9R@%^XE7 -/J%9/FWAG3
M$QV=,_7408.]50:=2JQ!$)X5&P-+=#Y<#]"FU?:"AI8WC37IGJROF /?IYUB
M;BQH;LB6B0U8RR]72.PMOU49;7XJD^A4&6VX17QP#AP3WKLS[32^Y.V"Y4N9
M8^JK.\OW:\@6H%H-N1OK=QWYN=".E>\]F0[^U,6$/I,I5WGX$Q9/]QY/NTW^
MPP:OJ(#%0VY/E%1F&3?N."%8SA!6[P^WD]NW;_,^,#DUJ&X2?47N+P2T^T;P
M_K[ "@=5&'=NKHXT\QQ5 [XB"]N7 I9 RU:A4>,3'#4.H&>]0?@'-8@M *^9
MNN.YQL58(7QP;BLF5=949</(PI4E"VFPR'&/:ZQ#0=D!^'XEI7EHV$JGKFR3
M_P%02P,$%     @ 3H-)5M3\+#A< @  'P8  !D   !X;"]W;W)K<VAE971S
M+W-H965T.3,N>&ULK55=:]LP%/TK%P]*!VMLRTD;4L?0)HP-.BCIMCZ,/2CV
M32QJ29ZD),V_GR0[)@6G9+"76!_W'-USKG23[J1ZT26B@5=>"3T-2F/J21CJ
MO$1.]4#6*.S.2BI.C9VJ=:AKA;3P(%Z%)(JN0TZ9"++4KSVJ+)4;4S&!CPKT
MAG.J]O=8R=TTB(/#PH*M2^,6PBRMZ1J?T/RH'Y6=A1U+P3@*S:0 A:MI<!=/
M9D,7[P-^,MSIHS$X)4LI7]SD:S$-(I<05I@;QT#M9XLSK"I'9-/XTW(&W9$.
M>#P^L'_VVJV6)=4XD]4S*TPY#<8!%+BBF\HLY.X+MGI&CB^7E?:_L&MB;T8!
MY!MM)&_!-@/.1/.EKZT/1P!R"D!: #D7D+2 Q MM,O.RYM30+%5R!\I%6S8W
M\-YXM%7#A*OBDU%VEUF<R1[0>J#A"IZ]8"S@;HO*U@\6Z"X!$VOP,? =%==P
M07E]"W.F<[D1!A;46/3E' UEE?Z8AL;FY)C#O#W_OCF?G#A_COD DO@3D(B0
M'OCL?'C\%AY:)SH[2&<'\7S)^W;\NEMJH^P5^]VGJ*$8]E.X9S?1-<UQ&MAW
MI5%M,<@N/L37T6V?OO]$]D9MTJE-WF//#C6_HFW-55?SRM?<V)K#)1.P1ZKZ
MR_O^">,&"02X%*;4$!,HZ%[W.7$>4](QC7N8WM@P[&P8_IL-Q>%Z*WN]^T0W
M?'%S*UVCW&;1("(W:;@]5G0B;-2%->F&1\_7M<YO5*V9T+8&*XN+!J[9J*8=
M-1,C:_^BE]+8_N"'I>W@J%R W5]):0X3UR2Z_X3L+U!+ P04    " !.@TE6
MK/RI+\<"  "G!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6RM56UO
MTS 0_BM6F- FP?+2=(/11EH;$),83)L&'Q ?G.3:6'/L8#OM^/><G32T):OV
M85\2O]SS^)[S^6ZRENI!EP"&/%9<Z*E7&E-?^+[.2ZBH/I4U"-Q92%51@U.U
M]'6M@!8.5'$_"H(SOZ),>,G$K=VH9"(;PYF &T5T4U54_9D!E^NI%WJ;A5NV
M+(U=\)-)39=P!^:^OE$X\WN6@E4@-)."*%A,O<OP(AU;>V?PG<%:;XV)59))
M^6 G5\74"ZQ#P"$WEH'B;P5SX-P2H1N_.TZO/]("M\<;]D]..VK)J(:YY#]8
M8<JI]\XC!2QHP\VM7'^&3H]S,)=<NR]9=[:!1_)&&UEU8/2@8J+]T\<N#EN
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M$+PU(&P#0I-H0V;2FF*)LQ%G.\2U6KGI!U,;$ZVR(94>Q;GDZBM1<3+[+M?
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MC)4!;T[;IB%9;0ZL!9/J^#./:_6# EP+U/<E8_*EH<_ [I<G^P=02P,$%
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M;_+DL=I#_#;)\^10O7Q0X4ZE98'B[W=),?4V;\H&RNWDJVY?_0502P,$%
M  @ 3H-)5I,>GK?N'   W[<! !H   !X;"]W;W)K<VAE971S+W-H965T,3 P
M+GAM;,6=78_;1I:&_PKAG0P<P-,6/R5E' -QUU> R4[@3'8O%GLA=].V,-U2
MKR3'D\7\^"4EJEE5E$M%^>E97R22?/@4R_6"=?B>8O'5Y_7F[]N/=;U+_G%_
MM]I^_^SC;O?PW<N7VYN/]?UB>[5^J%?-W[Q?;^X7N^;KYL/+[<.F7MSN#[J_
M>YE-)M7+^\5R]>SUJ_UO/V]>OUI_VMTM5_7/FV3[Z?Y^L?G]37VW_OS]L_39
M\8>WRP\?=^T/+U^_>EA\J'^I=[\^_+QIOKU\I-PN[^O5=KE>)9OZ_??/?DB_
M,^FL:(_8A_S'LOZ\M3XG;5_>K==_;[_\>/O]LTE[2O5=?;-K&8OF?[_5U_7=
M78MJ3N1_.NJSQT;; ^W/1[K:][[IS;O%MKY>W_WG\G;W\?MGLV?);?U^\>EN
M]W;]V=1=C\J6=[.^V^[_FWSN8B?/DIM/V]WZOCNX.8/[Y>KP_\4_NG\)ZX L
M^\(!67= %GM WAV0QQY0= <4_@'%%PXHNP/*V!:J[H J]H!I=\ T]H!9=\!L
M/[J'X=B/I5CL%J]?;=:?DTT;W=#:#WM![(]NAG"Y:L7[RV[3_.VR.6[W6BU7
MB]7-<O4A66PVB]6'NA'F;IO\*?EQM:LW]7:7O%WLZF2QNDVN-^OM]D\WGS:;
M>G7S>_++Y\7#-GDNZMUB>;?]-OE#LEPE/RWO[AI);E^]W#4GUS;Q\J8[D3>'
M$\F^<")IEORT7NT^;A.YNJUO7<#+IE>/7<N.77N3!8FBOKE*\O1%DDVR+/GU
M%Y$\_\.W)T[L.AZ3!C B'C,)8.283ET;E3S_16U.@=08D/SU;?+\C_\VRZOB
MSZ=@>@Q,O_FYA:55?I)EQOQ[!T[,$47^J/=\3\^_2'^W:[2]W6T^M4I/_NLO
M34#RXZZ^W_[W*=$>:,5I6CNS?+=]6-S4WS]KIHYMO?FM?O:Z[?GDSZ>$1L($
M"9,D3)$P3<(,!'.45SPJKPC17_][DXE<+[8?DY\WZ]^6S24N>?=[\OS7;?-A
MN?HV^>M#O5GLV@OQ#^UTOMPMZY-7T4,CY;Z1-C/Y[?5\FJ6O7OYF"^U$4%9Y
M06(8E$Z*^=2-DL%.C54&"=,DS$ P1QGEHS+*H#+>U@^+WP_S[OI]DWB]VYT:
M^ .CLH9KXHWZ,*)(2R](#(.JP@^2P?,=.^@D3),P \&<0:\>![T*#OIC?K5I
M\ZMMDTPE-TW^LVF2^6WRST34V^6'5?-7M\EBFYCZ]D-[:; GKI_J^W?UYN2D
M%6QY[*1%P@0)DR1,D3!-P@P$<U0Z?53I%$V7IJ3R2)@@89*$*1*F29B!8([R
M9H_*FX73I77K;2SNDL7]^M/JY(PX&R0PU73B3XJSX7PW"!+!4QDK#A*F2)@F
M80:".>*8/XIC'A2'J#?+WQ:MZ_4B>13*#WNAO.C^G_RMWMPO]S/H*>T$^6,O
M5/.!$*>#O&L^T&%>#?(N\JP4"=,DS$ P1SKII'>\)O^*&[%P*V,EA-)$1[/5
M5DXK3VQHDPJE:91F*)HK.,MB3>-2_;V5VOJF+Y*_-FG4,85OTOVGO!L(G]UH
MH9(T@=(D2E,H3:,T0]%<16>]HC/TMJ##41(D:0*E292F4)I&:8:BN1+L??PT
M:-8"*6"X@=&B1,W]CN9,X)E_VR+1-A5*TRC-4#17;+UUGX:]^U,S^-\^K_]E
M,SAI=5^C-('2)$I3*$VC-$/17$7W)8>T9&=PTGB_1FD"I4F4IE":1FF&HKD2
M[ L@:;@"$N'PA0FC58>6,CK:N2D:+5*@-(W2#$5SU=07*M*@&_UZ<E6DWS13
M\W*[3=1FL;I)WJQ7M]M$?*K;E21Y\OP0L?]\"'O?AYU:I_(FW.)H]:'E#)0F
M49I":1JE&8KFJK0O:J0S=MHE+?MKE"90FD1I"J5IE&8HFBO!OG22AFLGSHW*
MBV2[V]^4/-2;FT:0BP_U21D>D&EFKSZYFDP*?^%1N.W1"B-I,K83*C90QP8:
MJB/N.MB^XI&%*QY?.3<VMZ_>VE_G]M:^"][75=[?-2?XL;G%K8-WM>&3'GMM
M0VD"I4F4IE":1FF&HKE"[RLM68I.KQE:&D%I J5)E*90FD9IAJ*Y$NQ+(UG0
M]XZYJ^T(SGJ!2>'-I.%F1HL)+7)TM-3M0??'FTS1EC5*,Q3-E4I?PLC")8RL
M216^2;J'&Z;E)+D_/#V3K-:[>IO<'F;G*GE^"-Q_KC]MUFV]HWZZ:1DMBZ T
M@=(D2E,H3:,T0]%<H??EDZQ@IV6TWH'2!$J3*$VA-(W2#$5S)=C7.[+P,Q8Q
MT_+PT8A9GOO3,EJY0&D2I:F.EMK_'LTD=6J2UVC+AJ*Y4NGK$EFX+E%>E<?9
M]J'1RFVRW=6;N[9<NY]WG7GU*>9?M.:!T@1*DRA-H32-T@Q%<Q7=UT8R]BF.
M#"U\H#2!TB1*4RA-HS1#T5P)]H6/[*L?Y\B&CVI,BZD__Z(E#)0F49I":;JC
MM>6OQW_=XCB=>VXUU;(KE;Y D84+%,7Q;G?^_S/_HH^&H#2!TB1*4RA-HS1#
MT=PM)_KZ2SY!Y]\<K8R@-('2)$I3*$VC-$/17 GVE9$\_ Q*Q/S;$>SY-VW^
M>!-PN)W1:D*+'"A-H33=T9P)^ N>N:%:=K72ES#R< DCO<K*;PY;^?1V\Q/-
MMN%3&7VI0XLF*$VB-(72-$HS%,V5K[7#$[S%$[O'$[O)$[O+$[O-$[O/$[O1
MTU,4//*^X)$'W>R+UEB%D:-E6)Q<FI1FI?=<.MJL1&D*I6F49B+^@5WQ]*6*
M_&RIHIEN'Q:_+][=G9D\T8<R4)I :1*E*92F49JA:*[X^N)'7K&3)UJM0&D"
MI4F4IE":1FF&HKD2[*L5>?A)CIA;U>E@!54UV$WE.BI*A,]FM$K0@@)*TRC-
M4#17)7U!(3];4#@Q2S9WGT_P(%#X5$9?Y- 2!DJ3*$VA-(W2#$5SY=L7.?(Y
M.\^B50F4)E":1&D*I6F49BB:NQUQ7Y4HPD^%7'*3VB'//P@4;GNLPE":C.V$
MB@W4L8&&ZH@[Y'T5H#A;!3@]:>975>OY.@N/B^1Y]_/^RV'1\4E1H$]1H#2!
MTB1*4RA-HS1#T5RA]B6(@MU@JD#+""A-H#2)TA1*TRC-4#17@GT9H0@_G7'1
M]'A IH4[#^25;[M>AQL?+3&T3!#="Q4=J:,C#=47=]BMMS2$K?L(]Z$C.&].
M* 8;#T=%B?#9C!XYU'Y':1JE&8KFJJ3WZ(M+//HQB503^Y<?W_SU;=#@#Y_%
MZ&D--?A1FD1I"J5IE&8HFJO<WN O6(._0 U^E"90FD1I"J5IE&8HFBO!WN O
MP@:_O75G_?Y]O7]]8;*T\ZV32IR>O,G.,W_BC8L3X;,<K9ZX5E5DG(Z,,^?C
MW%'J#?;B0H,]OTH'4US93G%I-\65(:\ M=)1FD!I$J4IE*91FJ%HKE![*[U@
MK?0"M=)1FD!I$J4IE*91FJ%H[OO;>BN]Y*WT#CFX(QXLT;H.-SY68BA-1O="
M14?JZ$A#]<4=]MY.+[]Z47U'<-^R./ *HJ)$^&Q&CQSJ9:,TC=(,17-5TGO9
MY=D=@;XRD8KR"L)G,79:0VD"I4F4IE":1FF&HKG*[2WPDEU)7Z(KZ5&:0&D2
MI2F4IE&:H6BN!'L[O@S;\1=Z!1UUL#I[YD^\<7$B?):CU1/7JHJ,TY%QYGR<
M.TK6"XPOM,.SJZI]F'NXH5EUW&)E=9CA@C,;ZH*C-('2)$I3*$VC-$/17,'V
M+GC)NN EZH*C-('2)$I3*$VC-$/17 GV+G@9=L$O\@Q.F[U9Y4]KZ)8[*$U&
M]D%%QNG(.$/UPAWNWDXOOWH#G'+X0N/F3G#@%<1$B?#9C!XSU,M&:1JE&8KF
MJJ3WLLOPWC=<(A7G&:!6.$H3*$VB-(72-$HS%,U1<-5;X16[UTV%[G6#T@1*
MDRA-H32-T@Q%<R78V_)5V):_T#/HJ&<]@\@X$3[+T>J):U5%QNG(.',^SAVE
MWA:O+K3%OW);])-#BWKC*$V@-(G2%$K3*,U0-%>^O3=>L=YXA7KC*$V@-(G2
M%$K3*,U0-%>"O3=>A;WQ2QR$#IE.O+ME?XXC_6Z!TF1<%U1<F(X+,U07W*'N
M#?;J8H.]\$K(^:2=&8M]!;GY')@445L=I0F4)E&:0FD:I1F*YLJTM]4KUE:O
M4%L=I0F4)E&:0FD:I1F*YDJPM]4KWE:OOF A%_Y*O'#;HQ6&^NJQG5"Q@3HV
MT% =<8>\M]:KK[;6JQ.F^7 97E24")_-Z&%#K764IE&:H6BN2GIKO;K86H]*
MH:(,]? YC)[04$,=I4F4IE":1FF&HCFZG?:&^I0UU*>HH8[2!$J3*$VA-(W2
M#$5S)=@;ZM,G,=0[JG]K[6\5%!<FPN<X6CM1C:JX,!T79LZ&N>/36^G3BZWT
MW"L:YVD[M>5[W[SY_&5W(-SDZ,L(:IFC-(G2%$K3*,U0-%>FO64^92WS*6J9
MHS2!TB1*4RA-HS1#T5P)]I;YE+?,.^3@-MA_-6BXZ=$"0SWSR#ZHR#@=&6>H
M7KC#W=OFTZ]^ZVM'L._YRX$Q$!,DPN<R>L10SQJE:91F*)JKD=ZSGH9?]_JU
MR5.4+Q ^A]%3&6ITHS2)TA1*TRC-4#17M[W1/65?ZCI%7^J*T@1*DRA-H32-
MT@Q%<R78&^_3L/%^J2\P.YD\3/R%=I%Q(GR6H]43UZJ*C-.1<>9\G#M*O?$]
MO=#X+JZJ*G=GN+*9X;J?]U\"_@#J=*,T@=(D2E,H3:,T0]$<H<YZIWO&.MTS
MU.E&:0*E292F4)I&:8:BN1+LG>Y9V.F^Q!_HD/YV-45S%?4FM'#CHR6&&N+1
MO5#1D3HZTE!]<8>]-]!G9PWT<SY!1W#6!@R-@J@H$3Z;T2.'^M<H3:,T0]%<
ME?3^]2R\(_C7)U)17D'X+$9/:ZCMC=(D2E,H3:,T0]%<Y?:V]ZQ@,RO2?+Y&
M:0*E292F4)I&:8:BN1+LK?A9V(J_T"OHJ/Y=\>!]0Y%Q(GR6H]43UZJ*C-.1
M<>9\G#M*O1D^BS##3XX#:F"C-('2)$I3*$VC-$/17*WU!O:,-;!GJ(&-T@1*
MDRA-H32-T@Q%<R78&]BSL(&M&G3HGF^X'GPZ7#5^(JH<KAKOHBHK:CZ(DN'S
M'3WRZ&IPE&8HFCORO2D^"YOB;^OF/JZ][&R3]?ODMKD4G13 ?#"T@]$?AA39
M</2'4=7 %Y#A<QX]^JC3C-(,17-&?]X[S?/P?MV'._EV!UY_Z7\V:3?@/2S]
MST)/3X9;&#L;H32!TB1*4RA-HS1#T5Q5]N;S/$43HCGZWDV4)E":1&D*I6F4
M9BB:*\'>")^'C?!+ZA]AY&@9HBO%.]K@[3C^(XP2;5:A-(W2#$5S%=:;Z/.P
MB1Z7>(4AHS6%>N =S<[EYH-4#FU2H32-T@Q%<_746]OSH&_YF,H55ZF_/^*^
M!),>MH@*+64)MS!:;*C;C=(D2E,H3:,T0]%<5?9N][QD4SET+Q:4)E":1&D*
MI6F49BB:*\'>RI^'K?R+4CG4Y4=IHJ.=JXU(M%6%TC1*,Q3-%5COW\_#.ZU$
M9G*H:X_21$<+[_<AT3852M,HS5 T5U"]&S^/>>-HZ\K-IKXME[:VW/[G<\D<
M^H)1E"90FD1I"J5IE&8HFJO+OE8P9U\P.D>7QJ,T@=(D2E,H3:,T0]$<"3:3
MS:,&V\]T.G>&.5:)+$X<<8/W?#:7>6\*9EM6+$ZS.(/A/*VEEM;"J^#C,KLS
ME/'J0@L01YR3W$W]]Z1(ME7%XC2+,QC.4U9F*2MFIYHVQ:O:=YP>OHI#BI>=
M%AE:76!Q@L5)%J=8G&9Q!L-Y8LPM,;+[T1QYF!;1L@2+DRQ.L3C-X@R&\[18
M6%H,ES$N2^_0PL41-\C'*O^]ZR(^5+(GJ5B<9G$FZM_%TTAI:22\A#XV+4-K
M"4><LPAR\+HYME')XA2+TRS.8#A/6)4EK)@M</Z93*Z*])ODE\_+[391F\7J
M)GFS7MT^)FAY\OP0L?]\"'O?AYVTX\XT/5Z-:$V!Q4D6IUB<9G$&PWFRG5JR
M91\@./(P+:+%"!8G69QB<9K%&0SG:7%F:3%<N[@L?_O"EB^#I]O.M#Y>:F@A
M(KH?*CI21T<:K#/>V,^ML0\_2V ]1=),HK^HS>G!1JL"+$ZP.'G$I?ZC,_L_
M U&@OC^+,QC.E5=J.?]I[,,*>\_,*8L6;5ET__/^RY?+HF<:&2T_%"=8G&1Q
MBL5I%F<PG"=0JUR0LL\M''F8%MG" 8J3+$ZQ.,WB#(;SM&@5&%+^ 88C\[R;
M=7VF^?%:BVU9QH>J^% ='VJPKGMC:_GU:<S^.^U$F XFPK*="--N(BR#$R%K
MXJ,XP>(DBU,L3K,X@^$\@5HF?EK $R%KX*,XP>(DBU,L3K,X@^$\+5K%@C1<
M++AL(BQ/SP;IB8D0?<8@OF49'ZKB0W5\J,&Z[HVMY=>G<7Y]=E5-_(>>JG:+
M^NKPT%-U^*MO@]O-G6EL_$6(=>A1G&1QBL5I%F<PG"=4RZ%/88<^91UZ%"=8
MG&1QBL5I%F<PG*=%RZ%/G\"A3T^[T%DUF Y9@SZR71D;J&(#=6R@P;KLC:CE
MNZ<Q&]NWTV ["_[QWV9Y5?QY6DZ2^^7=W7*].C$Q3HX38_UILP[>);)N/8H3
M+$ZR.,7B-(LS&,Z5;6;Y^1F[S?V11VD1Q0D6)UF<8G&:Q1D,YVG1LNXS?K_[
M(]-_C6GFSXGAML<+C?7EXWJA(N-T9)S!NN&-N6619V&+W"U7=]/FZ8%FU]ZC
M.,'B)(M31UQJ;_@X+4]6P#7;ML%PGL0LISZ+<^K+J_*8<#TT>KMM+C#UI@G^
MT#WY$?0EPFV,5Q]KU*,XR>(4B],LSF X3Y^649_!1GW&&O4H3K XR>(4B],L
MSF X3XN649\]@5&?G=X OAS8].'&QRN-7>8?V0T5&ZAC PW6$V_<+1,_"YOX
M?AJ65OD7LC#6GT=Q@L5)%J=8G#[B6B_S45W%,:L;*.Q)W/?,<M^S\ 8]QRRL
MNLK]_53R:?*\^WG_)>"$A1L9+S_6DD=QDL4I%J=9G,%PGD M2SZ;P6D8NKD/
MBQ,L3K(XQ>(TBS,8SM.B54S(PL6$R]*P^<E% U7N[V!R?:;Y\5IC*P#1'5'Q
MH3H^U&#]<<<_MUSY/+S*?G\MNEZO?JLWV^5Z]:+[W(J@OT*]2'[XXLM"SC0P
M^N*$XL01YSR04?C51+1-Q>(TBS,8SI.<9;[G8?.]W[JX*TO.+W#)PFV,5QWK
MV:,XR>(4B],LSF X3Y]6H2#/V/0L9^L%*$ZP.,GB%(O3+,Y@.$^+5D4A#U<4
M+DK/.J9?DBO\W"S<]GBAL:6!N%ZHR#@=&6>P;GAC;KGT>=![C7?(PISQUQW6
MG4=QDL4I%J>/.,<A^\*#OP9KVU.8Y;WG8>^]7T'FOP<LG[3+Q0[O <M#[P$[
MT\1X\;&&/8J3+$ZQ.,WB#(;SY&F5"/(*3L#84@&*$RQ.LCC%XC2+,QC.TZ)5
M3,C#Q83+$K#IR6I<YK]^ZSHZ4D1'RNA(%1VIHR--3*0W&)9QGI_=*7^Y7BWN
M N^N/8,8?RT8ON5V^*X$P;8J69QB<9K%&0SGR<KRP//HC6Q.2XI=%(_BQ!'G
M*#0;;OB,MJI8G&9Q!L.YDBHL6[V(V[PFN\J])Q7SM,VP\[WSF8?>Z'&FB=&R
M0W&"Q4D6IUB<9G$&PWGRM"SX MZZIF#M=A0G6)QD<8K%:19G,)RG1<MN+YY@
MZYKB] MNL]Q/L",#16R@C U4L8$Z-M!$!'JC8!G-Q=FEZV=3ZS!B_$5@^$+9
M<IA9HXU*%J=8G&9Q!L-YJK*L["+:RCZM*-;!1G'BB#N76:.M*A:G69S!<)ZD
M+.^ZB/.NJZNYGUG/VL6=\T-F/0MFUJQWC>($BY,L3K$XS>(,AO/D:7G7!>Q=
M%ZQWC>($BY,L3K$XS>(,AO.T:'G7Q1-XU\5I_[::3^P_@YVZPZ<R7G?L^O:+
M.J4N.TQ?=IC!^NSIQ;+7B["]_O5K0<,-C+^8L0O5BZ&7GT\'V1QKO:,XS>(,
MAO,D9UGO1=Q>-M55X6=S\S:;*P[9W#R8S;'V/(H3+$ZR.,7B-(LS&,Z59VG9
M^"6\9TW)>O8H3K XR>(4B],LSF X3XN69U\^P9XU'7.0B@S6@H8;'Z^TN'9E
M;*"*#=2Q@0;KLC>BEO-=AIWOK\^WP@V,O]RP*\\[G..?Y0,_'6U4L3C-X@R&
M\S1G^?QE[!8U_K/1Q21Y?OAU_SF0<(6;&*\Z=ADZBI,L3K$XS>(,AO/D:14,
MR@).N-@* HH3+$ZR.,7B-(LS&,[3HE5I*)]@AYKR"QNQ#)^,#K<^7FILU2"V
M'RHZ4D='&JPSWMA;-GX9WJ4&2,U87Q_%B2/.WJ4OGP\R,]:M1W&:Q1D,YTG.
M<NO+N&UKRJO4S\S2-C-+#YE9<,E@N(GQHF--?10G69QB<9K%&0SGR=,J#I3P
MIC4E6PM <8+%21:G6)QF<0;#>5JTJ@;E$VQ:TS$'V4<ZS,S8"@"*D]']4-&1
M.CK28)UQQ[ZR+/GJJ3>L"3<P^L*$XL019V=F)Y[Q0AM5+$ZS.(/A/,U9UGL5
MMV-->57YJ5G6IF;5(37+0JE9N(GQJF/]>A0G69QB<9K%&0SGR=.J(U3PAC45
M6S9 <8+%21:G6)QF<0;#>5JTZ@O5$VQ8TS$'Z4<U2,W"K8^7&ELKB.V'BH[4
MT9$&ZXPW]I9Y7P4M62(U8]U\%">...?5%MD@,V,]>A2G69S!<)[D+(^^BGL:
MH!SN]5SD;6K6[?7<? GE9NSS "A.L#C)XA2+TRS.8#A/H%8AH8*?!ZC8N@&*
M$RQ.LCC%XC2+,QC.TZ)58:B>X'F CNEO9ER>V.LYW/QXK;'E@NB.J/A0'1]J
ML/YXXV]9^-53K^\/-S#^XL1Z^M5P??]T\.98M$W%XC2+,QC.DYSEU%=QZ_N+
MJZK*W?RL3)/GW<_[+Z'\C%WAC^($BY,L3K$XS>(,AG,%.K7*"5-XA?^4K1Z@
M.,'B)(M3+$ZS.(/A/"U:98;I$ZSP[YA^ E(T%U8_/PLW/UYKL2W+^% 5'ZKC
M0PW6=6]L+8]^&E[KWV\(-IUZ\V#>;@C6_KK_')@&PTV,O_2PMCV*DRQ.L3C-
MX@R&\^1IV?;3')X&V6< 4)Q@<9+%*1:G69S!<)X6K3+"-%Q&N&P:+$Z62;+I
M=# +LD6!V(9E=*2*CM31D0;KMC>LEE4_#5OUY_:""A\^_HK"FO =SO86YL5@
M*RBT4<7B-(LS&,Y3E.6M3R,6Z=?_N/FX6'UHI'5[N^SVL+M9;#\F-^O5=GE;
M-Q>1YL?3BF.M=A0GCCB[VC@;K -#VU0L3K,X@^$\P5D&^C1LH'M9THODUU5S
M0=OLEO_;3%!BN;WY\L6-79B/XL019U_<LN&CVFBCBL5I%F<PG*<URZR?GMWK
M?G_#F%YE^PIVEB7UI\WZ<']X6F.L.8_B!(N3+$ZQ.,WB#(;SQ&C9^-,Y?'O(
M.O8H3K XR>(4B],LSF X5XLSR[&?G=U:W]ZI>/^*M%E>%:=.]\T9V&@AHCC!
MXB2+4RQ.LSASQ*5V@MQNS^N]<\W3F>7&S^(6_6=7:>8M+<OV;TE+NXDYN%=&
MN)'Q^F,M?!0G69QB<9K%&0SG"=0J*<S@9?\SMGZ X@2+DRQ.L3C-X@R&\[1H
MU0]F3[#L/\P<KT>VAM#A_.IBUESV_3MCM&7%XC2+,QC.TYI5'YB%ZP-OZX?%
M[^T5;YNLWR>WS57PM+I(G_^:Q8DCSEFK-GRU -JH8G&:Q1D,=Q#6R^W'NMZ)
MQ6[Q^M5]O?E07]=W=]MD;]&U<ZKU:[*IW[>Z^^Z'[-G+P>]OTN]$>N)WF7ZG
M][^_[/&O7STT%[N?%IL/R]4VN:O?-TU-KEJC?+/\\/'QRV[]T$C^6?)NO=NM
M[_<?/]:+VWK3!C1__W[=))3=E[:!S^O-W_?=>?U_4$L#!!0    ( $Z#25:/
MG;T;NP8  #@P   :    >&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6RU6UUO
MVS84_2N$-PP=D,86'>>C2PPTEH(&6-8@6;>'8AAHB;:)2J)+4G8S[,?O4E(L
M,Y%IJ[C+0V)9Y"%Y#LG+0S*7:ZF^Z 7GAGS+TEQ?]1;&+-_U^SI>\(SI8[GD
M.;R9294Q X]JWM=+Q5E29LK2/AT,3OL9$WEO?%E^=Z_&E[(PJ<CYO2*ZR#*F
MGJYY*M=7O:#W_,6#F"^,_:(_OERR.7_DYM/R7L%3?X.2B(SG6LB<*#Z[ZKT/
MWD7#@<U0IOA#\+7>^DQL4Z92?K$/M\E5;V!KQ%,>&PO!X,^*3WB:6B2HQ]<:
MM+<ITV;<_OR,?E,V'AHS99I/9/JG2,SBJG?>(PF?L2(U#W+]@=<-&EF\6*:Z
M_$W6==I!C\2%-C*K,T,-,I%7?]FWFHBM#)3NR$#K#/1%AN'9C@S#.L/PT!).
MZ@PGAV88U1G*IO>KMI?$A<RP\:62:Z)L:D"S'TKVR]S E\AM1WDT"MX*R&?&
M-R)G>2SR.6%*L7S.H1,83=Z2QP5/9^2!SX4VBI6B/AIFZO<L3\A'L^"*W+!8
MI,((KLF;D!LF4OWS9=] U6P!_;BNQG55#;JC&@&YD[E9:!+E"4]:\D_VY*<>
M@#YPLB&&/A-S3;V((8^/R3 X(G1 *?GT&)(W/[8U;/(=,##"<KYFZ=]R:8EM
M00T/0 WHWLI%AU<N:(=QN!MN.M6PQ!WNQ)T:<IM#QREL=R&??X4$Y!8ZC_ZK
MK6]4:"?M:':J?*>7+.97/9@+-5<KWAO_]$-P.OBE30],L! 3+$("<R0YV4AR
MXD,?3V26<14+EI(E6W)U9"<1D149F4H%6'8&B!D4+\Q3FT05^JA$M\%G-::C
M0?USV5]M"W!XTM!;YZ[T(H$Y](XV](X.I??>TMM&885PNL7+2^9&KYA[29BW
M%ET)\Q7GL'"Z8>'4R\+[/"^ @1C($*8<^3,.<0&6,T0_Y8F((7XD1Z3(-8\+
M93\JOI+IJNQ\\"P,87/%RQC3QJ"W]*[S1 46T.WF'P\&P0O&,<N,D, <<<XV
MXIQYQ?D@E?@'HOCO$+6ABQ9&Q)I\ON/9E*O66=D+UY5M3+ 0$RQ" G,T.=]H
M<HX:*,\Q)<$$"S'!(B0P1Y*+C207WF%RK40RYZ^FHR,B<ECEPNS&,EFT3T\7
MKR9X>KXK2%Z\#I*[TH8=TD;>QGTG=<&@,1,#+WEE]Y6S9_9\LXL?J6M?1D4+
M4=$B+#17DRV#%Z#.,34<EC"8:"$J6H2%Y@I#&V&H=[#<U0MP6 HI*\SKA3BL
ME!*PV QG]517QYF?=DU/'=*&_F9V%@4)S16E<:Z!UX6-WY>S.YD^D?5"Q(O#
M1&DT\4@"ANN)3#G$$7C#M,VUA.68+!1D^EIP#6D-282&U^5V"\RC4Y9_T:U:
MHEKF&FT[PIR-=HB-ZHBQT%RQ&T\<^$WQ;1W2MPR+X2JSS'-FQ0?ZZWX@-"B^
M9 KT-Y*8!=\SUC"=[61/,T;DB3/5UD]"U'I$6&BN7(W'#OPF^[?"KB:L.BR!
MH05C!+0K!>/?3+UW7>VH:?+O_CVV:W]QG45Z[>_IR\&#:M^QT%PU&J\?[#'[
MC09+KH1,2I^_I<3LY;AJU0#5T^^I<E .E-9Q@FKSL=!<91JC'_B=?AW#9&&T
M81"C(!A5,>O09<2LVM-OW0BLR_9L4DWV)PG]+>C,MZ] E\3&F0=>E[G+RL#$
M\EB'>KGB*K?G4&2V.4110&XK:ZC.'14M1$6+L-!<V1KW'ES@NATDPUP+@XD6
MHJ)%6&CN:5JS-4#]6P/73,,:JCK-)A >5DP)-DWYSB%3XP4G[@9M$-#1B_G&
M7W)7UE'1(BPTE_7&_%.OAX7A '9"+)_]A$.Z/6 7K>YB#ZC,^=O,GK:2QX\W
M#ZUGHJBN'Q4MPD)S%6E</_6[_MUQY89#C(;5U T$:TWN"Q4OK$UL%0C3<D]0
MT4)4M @+S56KV0Z@N"?9%-67HZ*%J&@1%IHK3&/=J=_S=@\G)^WG?:^"":9C
M#E'1(BPTE_/&?U.__YZV'XVTLHUJK5'10E2T" O-U:1QX?04=X)"]=NH:"$J
M6H2%Y@K3F'#J-^$[SA$]QX=TO[.NDWCND(3^:G4F\?\X':>-":=^$[YCQH'%
M4N?;#/Z2.G=\5 >.BA9AH;F:-0Z<XCIPBNK 4=%"5+0("\V]D]DX\.$>!]YY
M1JH!?3/2_B2AOUJ=+U&B&NK^ULWIC*MY>65=D]@R4EVBWGR[N1;_OKP,WF^2
M5W?J[YB:BUR3E,\@Z^#X##A1U37UZL'(97D/>RJ-D5GY<0&K5ZYL G@_D](\
M/]@"-O\L,/X/4$L#!!0    ( $Z#258"S\/D@@(  -(&   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$P,BYX;6R%E5UOFS 4AO^*Q:JID]9"G !)1Y#:1M4F
MK5+5KMO%M N'',"JL9GM)-V_GVTHRA8GN0G^.N_SGA-\R+9"OJ@:0*/7AG$U
M#VJMVZLP5$4-#5&7H@5N=DHA&Z+-5%:A:B60E0MJ6(BC* D;0GF09V[M0>:9
M6&M&.3Q(I-9-0^2?&V!B.P]&P=O"(ZUJ;1?"/&M)!4^@G]L':6;AH+*B#7!%
M!4<2RGEP/;JZF=GS[L!W"ENU,T8VDZ40+W;R934/(FL(&!3:*A#SV, M,&:%
MC(W?O68P(&W@[OA-_<[E;G)9$@6W@OV@*UW/@VF 5E"2-=./8OL9^GQBJU<(
MIMPOVO9GHP 5:Z5%TP<;!PWEW9.\]G78"<#X0 #N [#SW8&<RP71),^DV")I
M3QLU.W"INFACCG+[ISQI:7:IB=/Y'>6$%Y17B$A)> 6FX%JA"W0KN):F9FO"
MT#W1:TDU!85$B;X*7EUHD U:P%*C\P5H0IGZ@,X0Y>B>,F;*K;)0&WL6$A:]
ME9O."CY@90'%)1J//B(<88R>GQ;H_.S#OS*AR6Y($0\I8J<[/J![U/W/ZZ5R
M>?[R&>Z$)WYA>U^N5$L*F ?F0BB0&PCR]^]&2?3IB.WQ8'M\3#TW51C[/'51
ML8NR5VZ3C^)HEH4;#VLRL":G6!,?JXM*=EF3*/*SXH$5GV+%/E:\SXH/L9*!
ME9QB)3Y6LL?""4[]K'1@I:=8J8^5[K-26VT?:SJPID=9WVHP';@TK[&/.-TC
MCJ-I,O4C9P-R=API-&$^VFSO?9Q$"?Z?%NZT*-OM[XFL*%>(06GBHLO4",BN
M@W83+5K7M99"FQ[HAK7YZ("T!\Q^*81^F]A&.'S&\K]02P,$%     @ 3H-)
M5CL%H&*) @  O08  !H   !X;"]W;W)K<VAE971S+W-H965T,3 S+GAM;*U5
M74_;,!3]*U<9FD!BS4<+3*R-1)NA\8"$0&P/TQ[<Y#:U<.S,=AOX][MVTJQ#
M+>L#+XE]?<^Y'[:/QXW23V:):.&Y$M),@J6U]648FGR)%3,#5:.DE872%;,T
MU65H:HVL\*!*A$D4G8<5XS)(Q]YVI].Q6EG!)=YI,*NJ8OIEBD(UDR .-H9[
M7BZM,X3IN&8E/J!]K.\TS<*>I> 52L.5!(V+27 57V8CY^\=OG-LS-887"5S
MI9[<Y*:8!)%+" 7FUC$P^JUQAD(X(DKC=\<9]"$=<'N\8;_VM5,M<V9PIL0/
M7MCE)/@<0($+MA+V7C7?L*OGS/'E2AC_A:;UO1@%D*^,554'I@PJ+ML_>^[Z
ML 6(S_< D@Z0O ;LBS#L ,-# :,.X%L=MJ7X/F3,LG2L50/:>1.;&_AF>C25
MSZ7;]@>K:943SJ;77#*9<UD"TYK)$FE+K8%/<",M:C069LJ0X3A#R[@P)[3T
M^)#!\=$)' &7,.5"T ::<6@I'4<:YEWH:1LZV1,Z3N!62;LT\%466/Q+$%(=
M?3')IIAI\B9CAOD AO$I)%&2[$AH=C@\W@'/#H=';U0S[+=FZ/F&>_GF%C)N
M<J',2B/\O)H;J^FB_-K5ZY9KM)O+B<>EJ5F.DX#4P:!>8Y!^_!"?1U]V]>D]
MR;)W(ONGAZ.^AZ.WV-/^%->,%Z<@24?5@HYM9]7,(C!90*Z5,73?M$:9OX!I
M6+WS1+?1XG;+G*2NTWA 1VV]W;U#G++_.+75AEL7NT)=>H&D/-5*VO9:]-9>
M@Z^\]+RR3TF;6RG]2],*^RW3)9<&!"Z(,AI<G 6@6[%L)U;57C[FRI(8^>&2
MWA?4SH'6%TK9S<0%Z%^L] ]02P,$%     @ 3H-)5A52OKLH"0  ;7<  !H
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MS89J#E1S45J]?IY=1LE]@Y/F[D8N+JM(38!J(E23H)H,U12HID(U#:KI4,V
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MX]L!FHK;#(0O7T?T9CAX?S!?-%?4;&.IK[W-5:J<8FOQH.T,;V(_M\5A0(6
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M0EL+)PCPCS_8MA=M! W$3\.H_@M02P,$%     @ 3H-)5N&*3^\8!P  -S
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M;,+IGGC';0ZI2Z34);3407TD^%\P;B<AW4G?B@.E<2A-H&AZNJ5^)N&DTI]
M[1%*XU":0-'T1$A[3.C9TT&+/P\,JEZYFW"Z)]YQF\/X$FE\"3W+Z1S T*E.
M*(U#:0)%TQ,A%3*A%7+XJJS$5D1K%#N;<+H[WL&;PR$3Y8XX].0F^JKKO2>1
M[I_W:0*55"A-H&AZIJ6D)M-NXY- 9TVA- ZE"11-3X24WH2>-1UVP;6G0*U2
MY6S"Z9YXQVT.1TVDHR;3[NB30*= H30.I0D434^$--R$-ER/"ZY;<]U-.-T=
M[^#-H;FIU-STK]5<W]V-=/=\SQ(HC4-I D73$RT%-YTFN"E4<*$T#J4)%$U/
MA!3<%""XJ5MPW4TXW1/ON,TAN*D4W'2:X*90P872.)0F4#0]$5)P4Y3@IF[!
M=3?A='>\@S>'X*92<-._5G!';)2D>^A]HD 5%TH3*)J>:^5&M1/O5(N]52WV
M7K78F]7.H;BI5-QTL.*Z*I;;<]U-.-T=[^#-X;FI]-R4GHM%5ZR!&R_I7GF?
M'%!]AM($BJ;G5^IS.GH%<0I=00RE<2A-H&CZ[;2EA2_1*XB7[A7$/4VLC9=T
MOWRCB*+I492*N_P+EQ!;E>JK&SGI7OF>)5 :A]($BJ;G5YKS<O3"XB5T83&4
MQJ$T@:+I.9 6OD0_+&79=Q<F:R-G7ZN>QP% /1I%TT,I/7I)>S2Z7'EM#*7[
MYGW"(&D<2A,HFIYE*?Q+>E4T5;2@(@ZE<2A-H&AZ#J2(+^D%T2.*EKWXN6=C
M:$^KGHVA=.>\0SG+@U^4)[_0*HTN6E,WFM+=]3Z'H$NRH32!HNF)EU\#+.GI
M;JJ.054=2N-0FD#1]!Q(55_2,]TCZIA[QMO=A-/=\@[B'*Z=2=?.:-?^5-UO
MJKNN'FW:5^IV7X*VU[N7V@6W*T&/3[),1;V[2>D7\1WS4!J'T@2*IJ=+2GU&
MSUL3=2>#BC>4QJ$T@:+I.9#BG=%3UH-VDV;V?+3]=,>>1F:QH?OB';DY=#F3
MNIS1NCQH/VGFWH?K;L+IGGC';0XWSJ0;9VS2U%D&U5<HC4-I D73$R'U-:/G
MJUU[23/[UL1L:=[DOZ=19#VN@NZ(=]CF,,Y,&F<V;>HW@T[]0FD<2A,HFIX(
MZ:L9[:MC=Y)F[HE@=Q-.=\X[E+,\P%1Y@BD]$3QH)VEF;Z\-X]Q\D&1/JR0V
MMY;3W?$.WASJEDEURVAU\[>.T7M&Z9YXUQ;HK"V4)E T_7&RTB1S^I;%KB*?
M0QT12N-0FD#1]$1(1\SIB=]!2VIS^S[$]M,G>QK93Y^D>^,=NSG<+I=NET][
MZDT.G5F%TCB4)E T/1%2%?/!3[UQ7&-S6P:M^=2>-M9CM>@.>8=O#F/,I3'F
M]&SJJ NL]_90NA/>9P/4.Z$T@:+IZ93>F4^[F50.G3N%TCB4)E T/1'29'-Z
M[G38M;5G(M1\9&5/&^L[ +HOWI&;0SUSJ9[YM+M)Y="I2RB-0VD"1=,3(<4U
M1STG)^][]*KY;59/(_N1E727O ,XA[SF4E[S&>35=R<HW0?OTP&JK5":0-'T
M1^DNI+?N?IY2F8['@W*!Q7$L3L!P1CI")1T ?3U"J&\D^]I83[QT],8_?'/X
M:[B(E/!-,]CC\;#1#'58+$[ <$8Z8B4=*(\]DNB'7_:ULI]^Z>B5?QCGL-EP
MP90PSN"S(W:#.OKA?W9 G1:+$S"<D=9$2>LTKST>#TL'U&RQ. '#&>E(E70,
MMEMGL>IQ7*M4V6W,*4%'C_Q#.(?DAHNE$D)ZAG54H1JX"=3QVOYG U22L3@!
MPQFIS)14CE[C>SP4E@GH*E\L3L!P1B9R)1/HE;Y'(NT'[K6^CI[YAW(6V0T5
MV0W1ZWV';_UTO+;W60'%<2Q.P'!&*A51#D>O!3X>"LL$=#4P%B=@.",3BG.'
M](K@$?4I=-_2:D ;[NB9?RAG\>50\>60]N51]<EKKZ>C!_[G!O3>6%B<@.&,
MA"KF'K+Q50HKVU <Q^($#&=D0I'MD%Z\/*9*V4N5[2KE;,,=/?,/Y2RB'"JB
M'-*B/*I*3=W<Z>B4_^D"72>-Q0D8SLBQ8O(A/6%-%BZLB$-Q'(L3,)R1"47$
M0WK&>DSA<C_ZJ*^-^40Z1\_\0SF+28>*28>#YZZ#I\U7ZU7<N\O3 ?<?]M!9
M:2Q.P'!ZKB)%U2-Z7IHJ0!'6M*$XCL4)&,[(A&+:$3TE/6C'YQ%"UAQW&^[H
MC'_T9K'C2+'CB+;C0;L^CQ!]'9$UI=#3*HKL"&*E&(4S(JA(<33M9L_'XV'E
M *NT4)R X8QT*$H;T9/1KEV@Q^-=8]ENU3>6L1:*PAG!4RPTFCCE&V&G?*$X
MCL4)&,Y(AV*R$6VR8W>$'KG:Z%W:USN[5<PB:XQCU1&%,X*JJ&-$3P(/VAMZ
MA+@B:+?JBR!6^5 X(X**\D6T\@WVE-'[0AT]\*\SV"E<*$[ <$9"%?&,Z/LJ
MN\L^UBVA.([%"1A.3T>LN&5,3P,/6V0;NV^K/* -=W3&.WHHG!$]Q0?C:4\/
M.AZ/&LQ0',?B! QGI$,1S'CP,X1<U]QXP+2KNPUW],@_A+,89JP89CQXVM5Y
MO?7>)NIX<?_3 :NG4)R X8Q<*GH:TS.N[NJ$G7:%XC@6)V X(QV*\,;TM.O
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M9@&^WPC\:B@&IC<L_WDP_Q]02P,$%     @ 3H-)5FRF6,0/ P  L D  !H
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M-<"I>7Z^D=](MLZ^^#\Q*5F27:Z AL"5 #Y?,";W-VJ"\I1I^C=02P,$%
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M$;'RY+J\$717G.4^42'5*BXC("$P92"_WU J7F[4"^K?#U;_ 5!+ P04
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M8 9/&.AV'O1604KH9TI(B]7)&@)K,@3V4$7 ?T").2754J65."=I]!,H:7O
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ML**0&:CK*\;DTTGVHD7U8LWB?U!+ P04    " !.@TE67_89W_4"  "6"@
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MBW".NSSACX2)5-E?)VF2LY7VK7(>DVQ6DH6.S#:%370V\C<-&@UKC8:M&MV
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M28*+5-ZS_>^D;E!Y@1%+1?D7[:MS1RIC5 C)LCI8[6<TK_[CI[HCC@(\[T2
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !.@TE6U$BD]Y4(  !?40  #P
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M.Q?Y3AFQE??*_2CZEMFR_H&6R+SB,N\TG3"S9<7(QS,ME]J*659_F,YZ6#V
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MRW"O)[P; ?=V!.V@^VE>7;Q! ?<.!:V@]017  K-Q+UO 4[9/PE H9FX=S.
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 3H-)5@>?%R?M    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 3H-)
M5IE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !.@TE6H+8N )8(  !%.   &
M@($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 3H-)
M5E-G*IL] @  OP4  !@              ("!V!   'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( $Z#25;L4@Q:T 4  )<=   8
M      " @4L3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !.@TE6W?RD%Z\#  #U#   &               @(%1&0  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 3H-)5FN<:Z"#!0  U!8  !@
M             ("!-AT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( $Z#258]G<--G (  / &   8              " @>\B  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !.@TE6*7"W-<,*  "'
M=   &               @('!)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ 3H-)5@O(ELZM P  L1(  !@              ("!NC
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $Z#259A3A"J
M'@@  , F   8              " @9TT  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !.@TE6N"QN=A\?  !E80  &0
M@('Q/   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $Z#
M25:!:/;KA1,  /DY   9              " @4=<  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ 3H-)5E0RA,WK!P  ,!(  !D
M         ("! W   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !.@TE60YRI'L(,   $*   &0              @($E>   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $Z#25:QS?X)V0(  'X&
M   9              " @1Z%  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ 3H-)5E!2TW^O#P  3S   !D              ("!+H@
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !.@TE6MQGE
M^]$#  #;"   &0              @($4F   >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( $Z#259<1$2B30T  %0L   9
M  " @1R<  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M3H-)5J?OH[V]#   _"D  !D              ("!H*D  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !.@TE6F+.T[W "  !E!0  &0
M            @(&4M@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( $Z#25;"YE8*_0,  "L)   9              " @3NY  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 3H-)5E#Q"W>W!P
M91,  !D              ("!;[T  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !.@TE6>'?HNC@&   )#P  &0              @(%=
MQ0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $Z#258
MF_S-#@,  #4'   9              " @<S+  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ 3H-)5IJU8A0,%   FD   !D
M     ("!$<\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $Z#25;)!1]:S@(  '\&   9              "
M@=@K 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 3H-)
M5BA"IMBQ'P  /VD  !D              ("!W2X! 'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " !.@TE6(;0?@'X#  #R!P  &0
M        @('%3@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( $Z#258.K8R5704  *P+   9              " @7I2 0!X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 3H-)5M/+89!P!0  RQ
M !D              ("!#E@! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " !.@TE6VY5;D;<&  !H$@  &0              @(&U70$
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $Z#25;7A$-%
M[ (  ) &   9              " @:-D 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ 3H-)5GBY*W_! P  &@L  !D
M ("!QF<! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !.
M@TE6":_UQ78"  !B!0  &0              @(&^:P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $Z#25:PV+RLT0,  /$(   9
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M970T,BYX;6Q02P$"% ,4    " !.@TE6I7]W7E8%   8#P  &0
M    @(%UAP$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M $Z#259K#U_/\@0  +P/   9              " @0*- 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ 3H-)5O'W$<6#!P  8R   !D
M             ("!*Y(! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " !.@TE61;@L^HP"  "]!0  &0              @('EF0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $Z#259:,<X;-00
M $<5   9              " @:B< 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ 3H-)5@3@"_ F!0  5R$  !D              ("!
M%*$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !.@TE6
MH=Y[%#X%  !V'@  &0              @(%QI@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( $Z#259V!RSM0 0  ,08   9
M      " @>:K 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ 3H-)5N3NVTL%!@  >"D  !D              ("!7; ! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !.@TE6R$O+)D,%  ":(P
M&0              @(&9M@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( $Z#259.IR'$J@,  +L1   9              " @1.\ 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 3H-)5E $E$D:
M P  ; H  !D              ("!]+\! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " !.@TE6>@Q]($ 2   HU@  &0
M@(%%PP$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( $Z#
M258_R06G[ 0  .<:   9              " @;S5 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ 3H-)5L!:9--#"   KS(  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( $Z#259O"(,50P,  )P)   9
M  " @>SS 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M3H-)5LTECQ&# @  I08  !D              ("!9O<! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " !.@TE6,].T#1\#  !3#0  &0
M            @($@^@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( $Z#258VZ_\B@@,  +H-   9              " @7;] 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ 3H-)5@T3)@%=!
MLQ   !D              ("!+P$" 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " !.@TE6*@17#$4(  !-4P  &0              @('#
M!0( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( $Z#25:4
M2&22O ,  %0,   9              " @3\. @!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ 3H-)5J<I$5[M P  % \  !D
M     ("!,A(" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $Z#25:#F:9F9@,  ,\/   9              "
M@7(F @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ 3H-)
M5H WCG>P @  _ 8  !D              ("!#RH" 'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    " !.@TE6%<6"_4P$  !%&   &0
M        @('V+ ( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( $Z#25:V(1YMX0(  ,H)   9              " @7DQ @!X;"]W;W)K
M<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ 3H-)5H])<8@Q @  #@4
M !D              ("!D30" 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q0
M2P$"% ,4    " !.@TE6JR"?+>L#  !]$   &0              @('Y-@(
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( $Z#25;6P89$
M3@,  +8+   9              " @1L[ @!X;"]W;W)K<VAE971S+W-H965T
M.# N>&UL4$L! A0#%     @ 3H-)5JE=>:RV!0  GR0  !D
M ("!H#X" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " !.
M@TE6;SO7_48$   >&   &0              @(&-1 ( >&PO=V]R:W-H965T
M<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( $Z#25;5"GKM>P(  ,,&   9
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M970X-RYX;6Q02P$"% ,4    " !.@TE6=2BW&S<#  !0#0  &0
M    @(%^7@( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    (
M $Z#25984 N$[@$  !@$   9              " @>QA @!X;"]W;W)K<VAE
M971S+W-H965T.#DN>&UL4$L! A0#%     @ 3H-)5@RCU@X9 P  7 L  !D
M             ("!$60" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"
M% ,4    " !.@TE6&MV3DK0"  #[!P  &0              @(%A9P( >&PO
M=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( $Z#25;_+WRVE@,
M .4.   9              " @4QJ @!X;"]W;W)K<VAE971S+W-H965T.3(N
M>&UL4$L! A0#%     @ 3H-)5M3\+#A< @  'P8  !D              ("!
M&6X" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4    " !.@TE6
MK/RI+\<"  "G!P  &0              @(&L< ( >&PO=V]R:W-H965T<R]S
M:&5E=#DT+GAM;%!+ 0(4 Q0    ( $Z#259A&ZY]O (  *D'   9
M      " @:IS @!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%
M  @ 3H-)5O;)HPT# P  _@@  !D              ("!G78" 'AL+W=O<FMS
M:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " !.@TE6Q2D75.XH  #KB@(
M&0              @('7>0( >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+
M 0(4 Q0    ( $Z#258D.G<>F@@  #%9   9              " @?RB @!X
M;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ 3H-)5E3B*M:E
M"@  )7\  !D              ("!S:L" 'AL+W=O<FMS:&5E=',O<VAE970Y
M.2YX;6Q02P$"% ,4    " !.@TE6DQZ>M^X<  #?MP$ &@
M@(&IM@( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4    " !.
M@TE6CYV]&[L&   X,   &@              @('/TP( >&PO=V]R:W-H965T
M<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " !.@TE6 L_#Y(("  #2!@  &@
M            @('"V@( >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"
M% ,4    " !.@TE6.P6@8HD"  "]!@  &@              @(%\W0( >&PO
M=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " !.@TE6%5*^NR@)
M  !M=P  &@              @($]X ( >&PO=V]R:W-H965T<R]S:&5E=#$P
M-"YX;6Q02P$"% ,4    " !.@TE62*UBPCT&   90P  &@
M@(&=Z0( >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"% ,4    " !.
M@TE6X8I/[Q@'   W,   &@              @($2\ ( >&PO=V]R:W-H965T
M<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " !.@TE6V5V'%%\#  #'"@  &@
M            @(%B]P( >&PO=V]R:W-H965T<R]S:&5E=#$P-RYX;6Q02P$"
M% ,4    " !.@TE6?LU'@8X%  "_(   &@              @('Y^@( >&PO
M=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4    " !.@TE6_+V0#($"
M  !^!P  &@              @(&_  , >&PO=V]R:W-H965T<R]S:&5E=#$P
M.2YX;6Q02P$"% ,4    " !.@TE6;%+8J: 1  #MZ0  &@
M@(%X P, >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6Q02P$"% ,4    " !.
M@TE6)G3%<-8#  !($   &@              @(%0%0, >&PO=V]R:W-H965T
M<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    " !.@TE6;*98Q \#  "P"0  &@
M            @(%>&0, >&PO=V]R:W-H965T<R]S:&5E=#$Q,BYX;6Q02P$"
M% ,4    " !.@TE6PU SW'\$  !Q&@  &@              @(&E' , >&PO
M=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4    " !.@TE6XP.#; 0'
M  "60   &@              @(%<(0, >&PO=V]R:W-H965T<R]S:&5E=#$Q
M-"YX;6Q02P$"% ,4    " !.@TE6AG6]4:X#  !'$0  &@
M@(&8* , >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX;6Q02P$"% ,4    " !.
M@TE6<J':@XH#  #-#P  &@              @(%^+ , >&PO=V]R:W-H965T
M<R]S:&5E=#$Q-BYX;6Q02P$"% ,4    " !.@TE6S  Y;NT$  !+&   &@
M            @(% , , >&PO=V]R:W-H965T<R]S:&5E=#$Q-RYX;6Q02P$"
M% ,4    " !.@TE6F<@/Y?P$  !D(P  &@              @(%E-0, >&PO
M=V]R:W-H965T<R]S:&5E=#$Q."YX;6Q02P$"% ,4    " !.@TE67_89W_4"
M  "6"@  &@              @(&9.@, >&PO=V]R:W-H965T<R]S:&5E=#$Q
M.2YX;6Q02P$"% ,4    " !.@TE6[V?*JN0"   _"0  &@
M@('&/0, >&PO=V]R:W-H965T<R]S:&5E=#$R,"YX;6Q02P$"% ,4    " !.
M@TE6JB-J[$ "   -!0  &@              @('B0 , >&PO=V]R:W-H965T
M<R]S:&5E=#$R,2YX;6Q02P$"% ,4    " !.@TE6QUG?H*@$   V'@  &@
M            @(%:0P, >&PO=V]R:W-H965T<R]S:&5E=#$R,BYX;6Q02P$"
M% ,4    " !.@TE6_TB^59$"  !]!@  &@              @($Z2 , >&PO
M=V]R:W-H965T<R]S:&5E=#$R,RYX;6Q02P$"% ,4    " !.@TE62?[3RRP#
M  "\"0  &@              @($#2P, >&PO=V]R:W-H965T<R]S:&5E=#$R
M-"YX;6Q02P$"% ,4    " !.@TE6MR;!Q(H#  "I&   #0
M@ %G3@, >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $Z#25:7BKL<P    !,"
M   +              "  1Q2 P!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $Z#
M25;42*3WE0@  %]1   /              "  053 P!X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4    " !.@TE6&.HI468#  "_2   &@              @ ''
M6P, >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !.@TE6
M;A"HIZ4"  "S10  $P              @ %E7P, 6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08     A "$ &PD   [8@,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>738</ContextCount>
  <ElementCount>553</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>181</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>22</UnitCount>
  <MyReports>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Acquisitions and divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Acquisitionsanddivestitures</Role>
      <ShortName>Acquisitions and divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Stockbasedcompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Defined contribution plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Definedcontributionplan</Role>
      <ShortName>Defined contribution plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Earningspershare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Collaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Goodwill and intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Goodwillandintangibleassets</Role>
      <ShortName>Goodwill and intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Other current assets and accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities</Role>
      <ShortName>Other current assets and accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Financing arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Financingarrangements</Role>
      <ShortName>Financing arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Stockholdersequity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Fairvaluemeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Derivative instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Derivativeinstruments</Role>
      <ShortName>Derivative instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Contingencies and commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Contingenciesandcommitments</Role>
      <ShortName>Contingencies and commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of significant accounting policies - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Acquisitions and divestitures - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsanddivestituresTables</Role>
      <ShortName>Acquisitions and divestitures - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Acquisitionsanddivestitures</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Revenues</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Stockbasedcompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Incometaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/EarningspershareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Earningspershare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Investments - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsTables</Role>
      <ShortName>Investments - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Investments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Inventories</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Propertyplantandequipment</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Goodwill and other intangible assets - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsTables</Role>
      <ShortName>Goodwill and other intangible assets - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Leases - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesTables</Role>
      <ShortName>Leases - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Other current assets and accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables</Role>
      <ShortName>Other current assets and accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financing arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsTables</Role>
      <ShortName>Financing arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Financingarrangements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Stockholdersequity</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Fair value measurement - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementTables</Role>
      <ShortName>Fair value measurement - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Fairvaluemeasurement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Derivative instruments - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsTables</Role>
      <ShortName>Derivative instruments - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Derivativeinstruments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Contingencies and commitments - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsTables</Role>
      <ShortName>Contingencies and commitments - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Contingenciesandcommitments</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Summary of significant accounting policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails</Role>
      <ShortName>Summary of significant accounting policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Acquisitions and divestitures - Horizon Therapeutics PLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails</Role>
      <ShortName>Acquisitions and divestitures - Horizon Therapeutics PLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Acquisitions and divestitures - ChemoCentryx Inc. Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails</Role>
      <ShortName>Acquisitions and divestitures - ChemoCentryx Inc. Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Acquisitions and divestitures - Summary of Total Consideration for ChemoCentryx Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails</Role>
      <ShortName>Acquisitions and divestitures - Summary of Total Consideration for ChemoCentryx Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Acquisitions and divestitures - Teneobio Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails</Role>
      <ShortName>Acquisitions and divestitures - Teneobio Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Acquisitions and divestitures - Summary of Total Consideration for Teneobio Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails</Role>
      <ShortName>Acquisitions and divestitures - Summary of Total Consideration for Teneobio Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Acquisitions and divestitures - Five Prime Therapeutics Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails</Role>
      <ShortName>Acquisitions and divestitures - Five Prime Therapeutics Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Acquisitions and divestitures - Divestiture of Gensenta (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails</Role>
      <ShortName>Acquisitions and divestitures - Divestiture of Gensenta (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Revenues - Customer Concentration, Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails</Role>
      <ShortName>Revenues - Customer Concentration, Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Stock-based compensation (Textual) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationTextualDetails</Role>
      <ShortName>Stock-based compensation (Textual) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Stock-based compensation (Components of Stock-based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based compensation (Components of Stock-based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Stock-based compensation (Summary of RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails</Role>
      <ShortName>Stock-based compensation (Summary of RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails</Role>
      <ShortName>Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Stock-based compensation (Summary of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails</Role>
      <ShortName>Stock-based compensation (Summary of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Stock-based compensation (Weighted-average Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails</Role>
      <ShortName>Stock-based compensation (Weighted-average Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Defined contribution plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DefinedcontributionplanDetails</Role>
      <ShortName>Defined contribution plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Definedcontributionplan</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Income taxes (Income Before Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Income Before Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Income taxes (Provision for Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Provision for Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Income taxes (Textual) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesTextualDetails</Role>
      <ShortName>Income taxes (Textual) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails</Role>
      <ShortName>Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails</Role>
      <ShortName>Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/EarningspershareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/EarningspershareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Collaborations - BeiGene (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsBeiGeneDetails</Role>
      <ShortName>Collaborations - BeiGene (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Collaborations - AstraZeneca PLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails</Role>
      <ShortName>Collaborations - AstraZeneca PLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Collaborations - UCB (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsUCBDetails</Role>
      <ShortName>Collaborations - UCB (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Collaborations - Novartis AG (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsNovartisAGDetails</Role>
      <ShortName>Collaborations - Novartis AG (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Collaborations - Kyowa Kirin (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsKyowaKirinDetails</Role>
      <ShortName>Collaborations - Kyowa Kirin (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Investments - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsScheduleDetails</Role>
      <ShortName>Investments - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Investments - Fair Values by Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails</Role>
      <ShortName>Investments - Fair Values by Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Investments - Available-for-sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsAvailableforsaleDetails</Role>
      <ShortName>Investments - Available-for-sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Investments - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails</Role>
      <ShortName>Investments - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Investments - Limited Partnership Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails</Role>
      <ShortName>Investments - Limited Partnership Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Investments - BeiGene (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsBeiGeneDetails</Role>
      <ShortName>Investments - BeiGene (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Investments - Neumora Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails</Role>
      <ShortName>Investments - Neumora Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InventoriesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Property, plant and equipment (Schedule) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails</Role>
      <ShortName>Property, plant and equipment (Schedule) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/PropertyplantandequipmentTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Property, plant and equipment (Geographic Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails</Role>
      <ShortName>Property, plant and equipment (Geographic Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/PropertyplantandequipmentTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Goodwill and other intangible assets - Goodwill Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails</Role>
      <ShortName>Goodwill and other intangible assets - Goodwill Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Goodwill and other intangible assets - Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and other intangible assets - Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Goodwill and other intangible assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails</Role>
      <ShortName>Goodwill and other intangible assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Leases - Summary of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesSummaryofLeasesDetails</Role>
      <ShortName>Leases - Summary of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Leases - Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails</Role>
      <ShortName>Leases - Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Leases - Weighted Average Remaining Lease Terms &amp; Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesWeightedAverageRemainingLeaseTermsDiscountRatesDetails</Role>
      <ShortName>Leases - Weighted Average Remaining Lease Terms &amp; Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Leases - Cash and Noncash Information of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails</Role>
      <ShortName>Leases - Cash and Noncash Information of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Other current assets and accrued liabilities - Schedule of Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails</Role>
      <ShortName>Other current assets and accrued liabilities - Schedule of Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Financing arrangements - Principal Amounts and Carrying Value of Long-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails</Role>
      <ShortName>Financing arrangements - Principal Amounts and Carrying Value of Long-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Financing arrangements - Debt Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails</Role>
      <ShortName>Financing arrangements - Debt Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Financing arrangements - Debt Repayments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails</Role>
      <ShortName>Financing arrangements - Debt Repayments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Financing arrangements - Interest Rate and Cross-currency Swaps (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails</Role>
      <ShortName>Financing arrangements - Interest Rate and Cross-currency Swaps (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Financing arrangements - Shelf Registration Statements and Other Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails</Role>
      <ShortName>Financing arrangements - Shelf Registration Statements and Other Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Financing arrangements - Contractual Maturities of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails</Role>
      <ShortName>Financing arrangements - Contractual Maturities of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Financing arrangements - Interest Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails</Role>
      <ShortName>Financing arrangements - Interest Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Stockholders' equity - Stock Repurchase Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails</Role>
      <ShortName>Stockholders' equity - Stock Repurchase Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Stockholders' equity - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityDividendsDetails</Role>
      <ShortName>Stockholders' equity - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - Stockholders' equity - Components of AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails</Role>
      <ShortName>Stockholders' equity - Components of AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - Stockholders' equity - Accumulated Other Comprehensive Income (Loss), Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails</Role>
      <ShortName>Stockholders' equity - Accumulated Other Comprehensive Income (Loss), Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0000108 - Disclosure - Stockholders' equity - Reclassifications out of AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails</Role>
      <ShortName>Stockholders' equity - Reclassifications out of AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0000109 - Disclosure - Stockholders' equity - Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityOtherDetails</Role>
      <ShortName>Stockholders' equity - Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0000110 - Disclosure - Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FairvaluemeasurementTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>0000111 - Disclosure - Fair value measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails</Role>
      <ShortName>Fair value measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>0000112 - Disclosure - Fair value measurement - Contingent Consideration Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails</Role>
      <ShortName>Fair value measurement - Contingent Consideration Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>0000113 - Disclosure - Derivative instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails</Role>
      <ShortName>Derivative instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>0000114 - Disclosure - Derivative instruments - (Cross-currency Swaps) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails</Role>
      <ShortName>Derivative instruments - (Cross-currency Swaps) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>0000115 - Disclosure - Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails</Role>
      <ShortName>Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>0000116 - Disclosure - Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails</Role>
      <ShortName>Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>0000117 - Disclosure - Derivative instruments - (Summary of Income and Expense Line Items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails</Role>
      <ShortName>Derivative instruments - (Summary of Income and Expense Line Items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>0000118 - Disclosure - Derivative instruments - Fair Value of Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails</Role>
      <ShortName>Derivative instruments - Fair Value of Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>0000119 - Disclosure - Contingencies and commitments (Sandoz Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails</Role>
      <ShortName>Contingencies and commitments (Sandoz Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>0000120 - Disclosure - Contingencies and commitments (Repatha Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails</Role>
      <ShortName>Contingencies and commitments (Repatha Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>0000121 - Disclosure - Contingencies and commitments (Janssen Biotech Inc v. Amgen Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails</Role>
      <ShortName>Contingencies and commitments (Janssen Biotech Inc v. Amgen Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>0000122 - Disclosure - Contingencies and commitments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails</Role>
      <ShortName>Contingencies and commitments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>0000123 - Disclosure - Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails</Role>
      <ShortName>Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="amgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>0000124 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</ParentRole>
      <Position>124</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="amgn-20221231.htm">amgn-20221231.htm</File>
    <File>amgn-20221231.xsd</File>
    <File>amgn-20221231_cal.xml</File>
    <File>amgn-20221231_def.xml</File>
    <File>amgn-20221231_lab.xml</File>
    <File>amgn-20221231_pre.xml</File>
    <File>amgn-ex21_20221231xq4.htm</File>
    <File>amgn-ex31_20221231xq4.htm</File>
    <File>amgn-ex32_20221231xq4.htm</File>
    <File>exhibit10114-fourthamendme.htm</File>
    <File>exhibit10161-amendmentno1t.htm</File>
    <File>exhibit104-formofgrantofst.htm</File>
    <File>exhibit105-formofrestricte.htm</File>
    <File>exhibit107-formofperforman.htm</File>
    <File>exhibit434-descriptionofse.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amgn-20221231_g1.jpg</File>
    <File>amgn-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1802">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>150
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amgn-20221231.htm": {
   "axisCustom": 2,
   "axisStandard": 35,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 1802,
    "http://xbrl.sec.gov/dei/2022": 42
   },
   "contextCount": 738,
   "dts": {
    "calculationLink": {
     "local": [
      "amgn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amgn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "amgn-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd"
     ]
    }
   },
   "elementCount": 935,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 10
   },
   "keyCustom": 96,
   "keyStandard": 457,
   "memberCustom": 113,
   "memberStandard": 63,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.amgen.com/role/Coverpage",
     "shortName": "Cover page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of significant accounting policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Financing arrangements - Interest Rate and Cross-currency Swaps (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
     "shortName": "Financing arrangements - Interest Rate and Cross-currency Swaps (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i745dd63e9cdd4959af07252f017a9eaa_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "amgn:DerivativeNotionalAmountAmountTerminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:MaximumBorrowingCapacityUnderCommercialPaper",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Financing arrangements - Shelf Registration Statements and Other Facilities (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails",
     "shortName": "Financing arrangements - Shelf Registration Statements and Other Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommercialPaper",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ia2798874e9ac48be975005deb320dde9_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Financing arrangements - Contractual Maturities of Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails",
     "shortName": "Financing arrangements - Contractual Maturities of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InterestPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Financing arrangements - Interest Costs (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails",
     "shortName": "Financing arrangements - Interest Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InterestPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:StockRepurchaseProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Stockholders' equity - Stock Repurchase Program (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails",
     "shortName": "Stockholders' equity - Stock Repurchase Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:StockRepurchaseProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "idcc68e5fe01f4338a8c7676f9e5e9152_D20201231-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Stockholders' equity - Dividends (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.amgen.com/role/StockholdersequityDividendsDetails",
     "shortName": "Stockholders' equity - Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ia2798874e9ac48be975005deb320dde9_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - Stockholders' equity - Components of AOCI (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
     "shortName": "Stockholders' equity - Components of AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i0e32313a221f41ad8ccd356225fd8eb0_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - Stockholders' equity - Accumulated Other Comprehensive Income (Loss), Textual (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails",
     "shortName": "Stockholders' equity - Accumulated Other Comprehensive Income (Loss), Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i26907d1efb9747fa82cd882b98e046e6_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000108 - Disclosure - Stockholders' equity - Reclassifications out of AOCI (Details)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails",
     "shortName": "Stockholders' equity - Reclassifications out of AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i7fec4c1d74cc4014b5be9b695eda82a9_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000109 - Disclosure - Stockholders' equity - Other (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.amgen.com/role/StockholdersequityOtherDetails",
     "shortName": "Stockholders' equity - Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Acquisitions and divestitures",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.amgen.com/role/Acquisitionsanddivestitures",
     "shortName": "Acquisitions and divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000110 - Disclosure - Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000111 - Disclosure - Fair value measurement - Narrative (Details)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
     "shortName": "Fair value measurement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ia2798874e9ac48be975005deb320dde9_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000112 - Disclosure - Fair value measurement - Contingent Consideration Obligations (Details)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
     "shortName": "Fair value measurement - Contingent Consideration Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "amgn:BusinessCombinationContingentConsiderationArrangementsPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000113 - Disclosure - Derivative instruments - Narrative (Details)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
     "shortName": "Derivative instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie30a691e9b49416cb63804f9bee95ad0_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000114 - Disclosure - Derivative instruments - (Cross-currency Swaps) (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
     "shortName": "Derivative instruments - (Cross-currency Swaps) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ib60cabd0b1a14cb189936f2de2a378c3_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000115 - Disclosure - Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
     "shortName": "Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ib60cabd0b1a14cb189936f2de2a378c3_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000116 - Disclosure - Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
     "shortName": "Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i35dca8996f6e45938deded2944b3efba_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000117 - Disclosure - Derivative instruments - (Summary of Income and Expense Line Items) (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
     "shortName": "Derivative instruments - (Summary of Income and Expense Line Items) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i55a872aceca74648a5734c2e9893a09e_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000118 - Disclosure - Derivative instruments - Fair Value of Derivatives (Details)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
     "shortName": "Derivative instruments - Fair Value of Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i2958a5f5fff1421995cfbfcd99f50244_D20180601-20180630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofLawsuitsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000119 - Disclosure - Contingencies and commitments (Sandoz Patent Litigation) (Details)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails",
     "shortName": "Contingencies and commitments (Sandoz Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i2958a5f5fff1421995cfbfcd99f50244_D20180601-20180630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofLawsuitsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Revenues",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.amgen.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i726c606382b04686ab59e3bf5cf547f4_D20141001-20141031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000120 - Disclosure - Contingencies and commitments (Repatha Patent Litigation) (Details)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
     "shortName": "Contingencies and commitments (Repatha Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i726c606382b04686ab59e3bf5cf547f4_D20141001-20141031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ib5c422a12ee04646bd081c628e80d370_D20221129-20221129",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000121 - Disclosure - Contingencies and commitments (Janssen Biotech Inc v. Amgen Inc (Details)",
     "menuCat": "Details",
     "order": "121",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails",
     "shortName": "Contingencies and commitments (Janssen Biotech Inc v. Amgen Inc (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ib5c422a12ee04646bd081c628e80d370_D20221129-20221129",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "numberofplaintiffs",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000122 - Disclosure - Contingencies and commitments (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "122",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
     "shortName": "Contingencies and commitments (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "id075fa4f759e4ecb8d79ff90752525da_D20190201-20190430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "numberofplaintiffs",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000123 - Disclosure - Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)",
     "menuCat": "Details",
     "order": "123",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails",
     "shortName": "Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ia2798874e9ac48be975005deb320dde9_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000124 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "menuCat": "Details",
     "order": "124",
     "role": "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i1c1b6eb115494bd789be0adfdf7fdf82_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Stock-based compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.amgen.com/role/Stockbasedcompensation",
     "shortName": "Stock-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Defined contribution plan",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.amgen.com/role/Definedcontributionplan",
     "shortName": "Defined contribution plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Income taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.amgen.com/role/Incometaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Earnings per share",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.amgen.com/role/Earningspershare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Collaborations",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.amgen.com/role/Collaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.amgen.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.amgen.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.amgen.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Property, plant and equipment",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.amgen.com/role/Propertyplantandequipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Goodwill and intangible assets",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.amgen.com/role/Goodwillandintangibleassets",
     "shortName": "Goodwill and intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.amgen.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Other current assets and accrued liabilities",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities",
     "shortName": "Other current assets and accrued liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Financing arrangements",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.amgen.com/role/Financingarrangements",
     "shortName": "Financing arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stockholders' equity",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.amgen.com/role/Stockholdersequity",
     "shortName": "Stockholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair value measurement",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.amgen.com/role/Fairvaluemeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Derivative instruments",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.amgen.com/role/Derivativeinstruments",
     "shortName": "Derivative instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Contingencies and commitments",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.amgen.com/role/Contingenciesandcommitments",
     "shortName": "Contingencies and commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i0ca1995ffff3494d89144db4efeabcfe_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Statements of Income",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of significant accounting policies - (Policies)",
     "menuCat": "Policies",
     "order": "30",
     "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Summary of significant accounting policies - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Acquisitions and divestitures - (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.amgen.com/role/AcquisitionsanddivestituresTables",
     "shortName": "Acquisitions and divestitures - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenues (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.amgen.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Stock-based compensation (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.amgen.com/role/StockbasedcompensationTables",
     "shortName": "Stock-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Income taxes (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.amgen.com/role/IncometaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Earnings per share (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.amgen.com/role/EarningspershareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Investments - (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.amgen.com/role/InvestmentsTables",
     "shortName": "Investments - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.amgen.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Property, plant and equipment (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.amgen.com/role/PropertyplantandequipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Goodwill and other intangible assets - (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables",
     "shortName": "Goodwill and other intangible assets - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Leases - (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.amgen.com/role/LeasesTables",
     "shortName": "Leases - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Other current assets and accrued liabilities (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables",
     "shortName": "Other current assets and accrued liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Financing arrangements (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.amgen.com/role/FinancingarrangementsTables",
     "shortName": "Financing arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:StockRepurchaseProgramTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stockholders' equity (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.amgen.com/role/StockholdersequityTables",
     "shortName": "Stockholders' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:StockRepurchaseProgramTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Fair value measurement - (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.amgen.com/role/FairvaluemeasurementTables",
     "shortName": "Fair value measurement - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Derivative instruments - (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsTables",
     "shortName": "Derivative instruments - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Contingencies and commitments - (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsTables",
     "shortName": "Contingencies and commitments - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "amgn:NatureOfOperationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Summary of significant accounting policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails",
     "shortName": "Summary of significant accounting policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:SalesReturnProvisionsAsPercentageOfProductSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ic520f1877b1b468fb3b71c4ec23d7a05_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:BridgeCreditAgreementAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Acquisitions and divestitures - Horizon Therapeutics PLC (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
     "shortName": "Acquisitions and divestitures - Horizon Therapeutics PLC (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i5514fe5c6f934d69accc89f4f6207683_I20221212",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Acquisitions and divestitures - ChemoCentryx Inc. Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
     "shortName": "Acquisitions and divestitures - ChemoCentryx Inc. Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i1304d3c33395494bb59cbeb2cb292045_I20221020",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.amgen.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Acquisitions and divestitures - Summary of Total Consideration for ChemoCentryx Inc (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
     "shortName": "Acquisitions and divestitures - Summary of Total Consideration for ChemoCentryx Inc (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i1304d3c33395494bb59cbeb2cb292045_I20221020",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Acquisitions and divestitures - Teneobio Inc. (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
     "shortName": "Acquisitions and divestitures - Teneobio Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i8ad51334f6c74fc69c9126bdca69dd80_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillPurchaseAccountingAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Acquisitions and divestitures - Summary of Total Consideration for Teneobio Inc (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
     "shortName": "Acquisitions and divestitures - Summary of Total Consideration for Teneobio Inc (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i483da69e647945579f570280de6d2535_D20221231-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "amgn:Businessassetacquisitionconsiderationtransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Acquisitions and divestitures - Five Prime Therapeutics Inc. (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails",
     "shortName": "Acquisitions and divestitures - Five Prime Therapeutics Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i2622610117f541b3981af6c597b45012_D20210416-20210416",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:ForeignCurrencyTranslationLossOnDivestitureOfABusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Acquisitions and divestitures - Divestiture of Gensenta (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails",
     "shortName": "Acquisitions and divestitures - Divestiture of Gensenta (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:ForeignCurrencyTranslationLossOnDivestitureOfABusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "amgn:NatureOfOperationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Revenues - Narrative (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.amgen.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ia2798874e9ac48be975005deb320dde9_I20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Revenues - Customer Concentration, Product Sales (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
     "shortName": "Revenues - Customer Concentration, Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i1ce35b441d394680be0e8bc1af6382e6_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:PercentageOfGrossRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Stock-based compensation (Textual) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
     "shortName": "Stock-based compensation (Textual) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Stock-based compensation (Components of Stock-based Compensation Expense) (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based compensation (Components of Stock-based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i219ff676680c41029ce9c7eaf92b5b3b_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Stock-based compensation (Summary of RSUs) (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
     "shortName": "Stock-based compensation (Summary of RSUs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i834a25f0fac543d48b39035e1855c17f_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i07973e812ee241aea2269d4041a67153_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
     "shortName": "Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i07973e812ee241aea2269d4041a67153_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ifeed4f08e59e4fb882fab3526d452c25_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Stock-based compensation (Summary of Stock Options) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
     "shortName": "Stock-based compensation (Summary of Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ifeed4f08e59e4fb882fab3526d452c25_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Stock-based compensation (Weighted-average Assumptions) (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails",
     "shortName": "Stock-based compensation (Weighted-average Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i2e1c5d8f800248d29a975f52117b4019_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Defined contribution plan (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.amgen.com/role/DefinedcontributionplanDetails",
     "shortName": "Defined contribution plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Income taxes (Income Before Income Taxes) (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
     "shortName": "Income taxes (Income Before Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i154b8bdaf9ab475f99a1f2846362c79c_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Income taxes (Provision for Income Taxes) (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income taxes (Provision for Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Income taxes (Textual) (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.amgen.com/role/IncometaxesTextualDetails",
     "shortName": "Income taxes (Textual) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ia2798874e9ac48be975005deb320dde9_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails",
     "shortName": "Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i1c1b6eb115494bd789be0adfdf7fdf82_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails",
     "shortName": "Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i0567102b4dbd4cabaf51e541f2a41652_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i0567102b4dbd4cabaf51e541f2a41652_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Earnings per share (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.amgen.com/role/EarningspershareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Collaborations - BeiGene (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
     "shortName": "Collaborations - BeiGene (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ia5ad848ccc9e43da99f1f90d2e7be305_D20200102-20200102",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i9e2a1eff2f0448ba9a98ef6babf5bf8a_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:DevelopmentCostsDueToCollaborationPartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Collaborations - AstraZeneca PLC (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
     "shortName": "Collaborations - AstraZeneca PLC (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i9e2a1eff2f0448ba9a98ef6babf5bf8a_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:DevelopmentCostsDueToCollaborationPartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i356368409a2d4829afb562f99d59b84a_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:ProfitAndLossShareOfExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Collaborations - UCB (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.amgen.com/role/CollaborationsUCBDetails",
     "shortName": "Collaborations - UCB (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i356368409a2d4829afb562f99d59b84a_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:ProfitAndLossShareOfExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "iad6cab3b37664965858bb4a82cbba6fc_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RecoveryOfDirectCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Collaborations - Novartis AG (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
     "shortName": "Collaborations - Novartis AG (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "iad6cab3b37664965858bb4a82cbba6fc_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RecoveryOfDirectCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i2285c8c0ccac4adbb106cc9bee4bbb49_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:UpFrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Collaborations - Kyowa Kirin (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
     "shortName": "Collaborations - Kyowa Kirin (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i2285c8c0ccac4adbb106cc9bee4bbb49_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:UpFrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Investments - Schedule (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.amgen.com/role/InvestmentsScheduleDetails",
     "shortName": "Investments - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Investments - Fair Values by Classification (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
     "shortName": "Investments - Fair Values by Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i736ffca3dc1842b084f709c4fe9809b1_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Investments - Available-for-sale (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails",
     "shortName": "Investments - Available-for-sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Investments - Equity Securities (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails",
     "shortName": "Investments - Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "idcc68e5fe01f4338a8c7676f9e5e9152_D20201231-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Investments - Limited Partnership Investments (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails",
     "shortName": "Investments - Limited Partnership Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Investments - BeiGene (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
     "shortName": "Investments - BeiGene (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i0d78be49a55146f8aea0014dec6caca1_I20221231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Investments - Neumora Therapeutics, Inc. (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails",
     "shortName": "Investments - Neumora Therapeutics, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i4568cf82cca34f0fa0f23589a150184f_I20210930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.amgen.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Property, plant and equipment (Schedule) (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
     "shortName": "Property, plant and equipment (Schedule) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Property, plant and equipment (Geographic Information) (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
     "shortName": "Property, plant and equipment (Geographic Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "iff279f49fa7b4713b3a0452ae164a793_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ia2798874e9ac48be975005deb320dde9_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Goodwill and other intangible assets - Goodwill Roll Forward (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails",
     "shortName": "Goodwill and other intangible assets - Goodwill Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Goodwill and other intangible assets - Identifiable Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
     "shortName": "Goodwill and other intangible assets - Identifiable Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Goodwill and other intangible assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails",
     "shortName": "Goodwill and other intangible assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.amgen.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Leases - Summary of Leases (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.amgen.com/role/LeasesSummaryofLeasesDetails",
     "shortName": "Leases - Summary of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Leases - Components of Lease Costs (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails",
     "shortName": "Leases - Components of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Leases - Weighted Average Remaining Lease Terms & Discount Rates (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.amgen.com/role/LeasesWeightedAverageRemainingLeaseTermsDiscountRatesDetails",
     "shortName": "Leases - Weighted Average Remaining Lease Terms & Discount Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Leases - Cash and Noncash Information of Leases (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails",
     "shortName": "Leases - Cash and Noncash Information of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Other current assets and accrued liabilities - Schedule of Other Assets (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails",
     "shortName": "Other current assets and accrued liabilities - Schedule of Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedSalesDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails",
     "shortName": "Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedSalesDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Financing arrangements - Principal Amounts and Carrying Value of Long-term Borrowings (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
     "shortName": "Financing arrangements - Principal Amounts and Carrying Value of Long-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "i129c92e214904c7e8aec016ec2d5e387_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "id185478a58284d89b9439c8843eb6f89_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Financing arrangements - Debt Issuances (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
     "shortName": "Financing arrangements - Debt Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ie39aa1b66fa248e88c5ec1cf37877418_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Financing arrangements - Debt Repayments (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
     "shortName": "Financing arrangements - Debt Repayments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20221231.htm",
      "contextRef": "ib0d55d2aa64147189ba451ce692d2e1b_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ExtinguishmentOfDebtAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 181,
   "tag": {
    "amgn_A165NotesDue20281652028NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% notes due 2028 (1.65% 2028 Notes)",
        "label": "1.65% notes due 2028 (1.65% 2028 Notes) [Member]",
        "terseLabel": "1.65% notes due in 2028 (1.65% 2028 Notes)"
       }
      }
     },
     "localname": "A165NotesDue20281652028NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A190NotesDue20251902025NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.90% notes due 2025 (1.90% 2025 Notes)",
        "label": "1.90% notes due 2025 (1.90% 2025 Notes) [Member]",
        "terseLabel": "1.90% notes due 2025 (1.90% 2025 Notes)"
       }
      }
     },
     "localname": "A190NotesDue20251902025NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A2.00SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.00% Senior Notes Due 2026 [Member]",
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "terseLabel": "2.00% Senior Notes Due 2026"
       }
      }
     },
     "localname": "A2.00SeniorNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A200NotesDue20322002032NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.00% notes due 2032 (2.00% 2032 Notes)",
        "label": "2.00% notes due 2032 (2.00% 2032 Notes) [Member]",
        "terseLabel": "2.00% notes due 2032 (2.00% 2032 Notes)"
       }
      }
     },
     "localname": "A200NotesDue20322002032NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A280NotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% notes due 2041",
        "label": "2.80% notes due 2041 [Member]",
        "terseLabel": "2.80% notes due 2041 (2.80% 2041 Notes)"
       }
      }
     },
     "localname": "A280NotesDue2041Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A300NotesDue20293002029NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.00% notes due 2029 (3.00% 2029 Notes)",
        "label": "3.00% notes due 2029 (3.00% 2029 Notes) [Member]",
        "terseLabel": "3.00% notes due 2029 (3.00% 2029 Notes)"
       }
      }
     },
     "localname": "A300NotesDue20293002029NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A300NotesDue20523002052NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.00% notes due 2052 (3.00% 2052 Notes)",
        "label": "3.00% notes due 2052 (3.00% 2052 Notes) [Member]",
        "terseLabel": "3.00% notes due 2052 (3.00% 2052 Notes)"
       }
      }
     },
     "localname": "A300NotesDue20523002052NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A335NotesDue20323352032NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.35% notes due 2032 (3.35% 2032 Notes)",
        "label": "3.35% notes due 2032 (3.35% 2032 Notes) [Member]",
        "terseLabel": "3.35% notes due 2032 (3.35% 2032 Notes)"
       }
      }
     },
     "localname": "A335NotesDue20323352032NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A405NotesDue20294052029NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.05% notes due 2029 (4.05% 2029 Notes)",
        "label": "4.05% notes due 2029 (4.05% 2029 Notes) [Member]",
        "terseLabel": "4.05% notes due 2029 (4.05% 2029 Notes)"
       }
      }
     },
     "localname": "A405NotesDue20294052029NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A420NotesDue20334202033NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.20% notes due 2033 (4.20% 2033 Notes)",
        "label": "4.20% notes due 2033 (4.20% 2033 Notes) [Member]",
        "terseLabel": "4.20% notes due 2033 (4.20% 2033 Notes)"
       }
      }
     },
     "localname": "A420NotesDue20334202033NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A420NotesDue20524202052NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.20% notes due 2052 (4.20% 2052 Notes)",
        "label": "4.20% notes due 2052 (4.20% 2052 Notes) [Member]",
        "terseLabel": "4.20% notes due 2052 (4.20% 2052 Notes)"
       }
      }
     },
     "localname": "A420NotesDue20524202052NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A440NotesDue20624402062NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.40% notes due 2062 (4.40% 2062 Notes)",
        "label": "4.40% notes due 2062 (4.40% 2062 Notes) [Member]",
        "terseLabel": "4.40% notes due 2062 (4.40% 2062 Notes)"
       }
      }
     },
     "localname": "A440NotesDue20624402062NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A4875NotesDue205348752053NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.875% notes due 2053 (4.875% 2053 Notes)",
        "label": "4.875% notes due 2053 (4.875% 2053 Notes) [Member]",
        "terseLabel": "4.875% notes due 2053 (4.875% 2053 Notes)"
       }
      }
     },
     "localname": "A4875NotesDue205348752053NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AMG340Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMG 340",
        "label": "AMG 340 [Member]",
        "terseLabel": "AMG 340"
       }
      }
     },
     "localname": "AMG340Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AbandonedLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abandoned Leases [Member]",
        "label": "Abandoned Leases [Member]",
        "terseLabel": "Abandoned Leases [Member]"
       }
      }
     },
     "localname": "AbandonedLeasesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AcceleratedStockRepurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated stock repurchase agreement",
        "label": "Accelerated stock repurchase agreement [Member]",
        "terseLabel": "Accelerated stock repurchase agreement"
       }
      }
     },
     "localname": "AcceleratedStockRepurchaseAgreementMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Other current assets and accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities/other non-current liabilities.",
        "label": "Accrued Liabilities Other Non Current Liabilities [Member]",
        "verboseLabel": "Accrued liabilities/ Other\u00a0noncurrent liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesOtherNonCurrentLiabilitiesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AccruedSalesDeductionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.",
        "label": "Accrued Sales Deductions Current",
        "terseLabel": "Sales deductions"
       }
      }
     },
     "localname": "AccruedSalesDeductionsCurrent",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AccruedSalesReturnReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.",
        "label": "Accrued Sales Return Reserve Current",
        "terseLabel": "Sales returns reserve"
       }
      }
     },
     "localname": "AccruedSalesReturnReserveCurrent",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AccumulatedOtherAdjustmentAttributabletoParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Other Adjustment Attributable to Parent [Member]",
        "label": "Accumulated Other Adjustment Attributable to Parent [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherAdjustmentAttributabletoParentMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired research and development technology rights.",
        "label": "Acquired Research And Development Technology Rights [Member]",
        "terseLabel": "R&amp;D technology rights [Member]"
       }
      }
     },
     "localname": "AcquiredResearchAndDevelopmentTechnologyRightsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AlternativeInvestmentNetGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Investment, Net Gain (Loss)",
        "label": "Alternative Investment, Net Gain (Loss)",
        "terseLabel": "Alternative Investment, Net Gain (Loss)"
       }
      }
     },
     "localname": "AlternativeInvestmentNetGainLoss",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.",
        "label": "Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks",
        "terseLabel": "Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks"
       }
      }
     },
     "localname": "AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of common stock available under the plan for future grants and/or issuances.",
        "label": "Amount Of Common Stock Available Under Plan For Future Grants And Or Issuances",
        "terseLabel": "The amount of common stock available under the plan for future grants and/or issuances (in shares)"
       }
      }
     },
     "localname": "AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_ApprovedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Approved products",
        "label": "Approved products",
        "terseLabel": "Approved products"
       }
      }
     },
     "localname": "ApprovedProducts",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_AranespMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aranesp.",
        "label": "Aranesp [Member]",
        "terseLabel": "Aranesp\u00ae (darbepoetin alfa) [Member]"
       }
      }
     },
     "localname": "AranespMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AssetsByDescriptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets by description.",
        "label": "Assets By Description [Axis]",
        "terseLabel": "Assets By Description [Axis]"
       }
      }
     },
     "localname": "AssetsByDescriptionAxis",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_AssetsByDescriptionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets by description.",
        "label": "Assets By Description [Domain]",
        "terseLabel": "Assets By Description [Domain]"
       }
      }
     },
     "localname": "AssetsByDescriptionDomain",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AstraZenecaPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca PLC",
        "label": "AstraZeneca PLC [Member]",
        "terseLabel": "AstraZeneca PLC"
       }
      }
     },
     "localname": "AstraZenecaPLCMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.amgen.com/20221231",
     "xbrltype": "stringItemType"
    },
    "amgn_AvailableForSalesInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sales investments.",
        "label": "Available For Sales Investments [Member]",
        "verboseLabel": "Available-for-sale investments [Member]"
       }
      }
     },
     "localname": "AvailableForSalesInvestmentsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_BasicAndDilutedEarningPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earning per share.",
        "label": "Basic And Diluted Earning Per Share [Abstract]",
        "verboseLabel": "Computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningPerShareAbstract",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_BeiGeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BeiGene [Member]",
        "label": "BeiGene [Member]",
        "terseLabel": "BeiGene"
       }
      }
     },
     "localname": "BeiGeneMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_BridgeCreditAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge credit agreement amount",
        "label": "Bridge credit agreement amount",
        "terseLabel": "Bridge credit agreement amount"
       }
      }
     },
     "localname": "BridgeCreditAgreementAmount",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BridgeCreditAgreementInitialAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge credit agreement, initial amount",
        "label": "Bridge credit agreement, initial amount",
        "terseLabel": "Bridge credit agreement, initial amount"
       }
      }
     },
     "localname": "BridgeCreditAgreementInitialAmount",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BridgeCreditAgreementMaximumLength": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge credit agreement, maximum length",
        "label": "Bridge credit agreement, maximum length",
        "terseLabel": "Bridge credit agreement, maximum length"
       }
      }
     },
     "localname": "BridgeCreditAgreementMaximumLength",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_BridgeCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bridge credit agreement",
        "label": "bridge credit agreement [Member]",
        "terseLabel": "bridge credit agreement"
       }
      }
     },
     "localname": "BridgeCreditAgreementMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_BridgeCreditReducedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge credit agreement, reduced amount",
        "label": "Bridge credit, reduced amount",
        "terseLabel": "Bridge credit reduced amount"
       }
      }
     },
     "localname": "BridgeCreditReducedAmount",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, cash consideration paid to equity holders for pre-acquisition services",
        "label": "Business acquisition, cash consideration paid to equity holders for pre-acquisition services",
        "terseLabel": "Business acquisition, cash consideration paid to equity holders for pre-acquisition services"
       }
      }
     },
     "localname": "BusinessAcquisitionCashConsiderationPaidToEquityHoldersForPreAcquisitionServices",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationContingentConsiderationArrangementsPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Payments",
        "label": "Business Combination, Contingent Consideration Arrangements, Payments",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsPayments",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationContingentConsiderationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration",
        "label": "Business Combination, Contingent Consideration [Roll Forward]",
        "terseLabel": "Business Combination, Contingent Consideration [Roll Forward]"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationRollForward",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails": {
       "order": 2.0,
       "parentTag": "amgn_Businessassetacquisitionconsiderationtransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions",
        "label": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions",
        "terseLabel": "Additions",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)",
        "terseLabel": "Other liabilities, net",
        "verboseLabel": "Other assets, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination, turnover period of inventory acquired",
        "label": "Business combination, turnover period of inventory acquired",
        "terseLabel": "Business combination, turnover period of inventory acquired"
       }
      }
     },
     "localname": "BusinessCombinationTurnoverPeriodOfInventoryAcquired",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net",
        "label": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net",
        "terseLabel": "Total assets acquired, net"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_Businessassetacquisitionconsiderationtransferred": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business asset acquisition, consideration transferred",
        "label": "Business asset acquisition, consideration transferred",
        "terseLabel": "Total consideration",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "Businessassetacquisitionconsiderationtransferred",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ChemoCentryxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ChemoCentryx, Inc.",
        "label": "ChemoCentryx, Inc. [Member]",
        "terseLabel": "ChemoCentryx, Inc."
       }
      }
     },
     "localname": "ChemoCentryxIncMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ChemoCentryxIncSecuritiesMattersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ChemoCentryx, Inc. Securities Matters",
        "label": "ChemoCentryx, Inc. Securities Matters [Member]",
        "terseLabel": "ChemoCentryx, Inc. Securities Matters"
       }
      }
     },
     "localname": "ChemoCentryxIncSecuritiesMattersMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CommonStockFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.",
        "label": "Common Stock Fair Value",
        "terseLabel": "Closing price of our common stock on grant date (in usd per share)"
       }
      }
     },
     "localname": "CommonStockFairValue",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.",
        "label": "Components of Stock based Compensation Expense [Table Text Block]",
        "terseLabel": "Components of stock-based compensation expense recognized in the Consolidated Statements of Income"
       }
      }
     },
     "localname": "ComponentsOfStockBasedCompensationExpenseTableTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_CrossCurrencySwapContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cross currency swap contracts.",
        "label": "Cross Currency Swap Contracts [Member]",
        "terseLabel": "Cross-currency swap contract [Member]",
        "verboseLabel": "Cross-currency swap contracts"
       }
      }
     },
     "localname": "CrossCurrencySwapContractsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer one.",
        "label": "Customer One [Member]",
        "terseLabel": "AmerisourceBergen Corporation [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer three.",
        "label": "Customer Three [Member]",
        "terseLabel": "Cardinal Health, Inc. [Member]"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer two.",
        "label": "Customer Two [Member]",
        "terseLabel": "McKesson Corporation [Member]"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_DebtExchangeAdditionalCashConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt exchange additional cash consideration paid",
        "label": "Debt exchange additional cash consideration",
        "terseLabel": "Debt exchange additional cash consideration"
       }
      }
     },
     "localname": "DebtExchangeAdditionalCashConsideration",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Period without Payment of Make Whole Amount",
        "label": "Debt Instrument, Redemption Period without Payment of Make Whole Amount",
        "terseLabel": "Redemption period without payment of make whole amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_DeferredTaxAssetEarningsOfForeignSubsidiaries": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset, earnings of foreign subsidiaries",
        "label": "Deferred tax asset, earnings of foreign subsidiaries",
        "terseLabel": "Deferred tax asset, earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "DeferredTaxAssetEarningsOfForeignSubsidiaries",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets. Deferred Expense, Capitalized Research And Development Costs",
        "label": "Deferred Tax Assets. Deferred Expense, Capitalized Research And Development Costs",
        "terseLabel": "Capitalized research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.",
        "label": "Deferred Tax Assets Tax Acquired Net Operating Loss And Credit Carry Forwards",
        "terseLabel": "NOL and credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DerivativeAssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative assets.",
        "label": "Derivative Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Derivatives:"
       }
      }
     },
     "localname": "DerivativeAssetsFairValueDisclosureAbstract",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative financial instruments liabilities fair value disclosure.",
        "label": "Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]",
        "verboseLabel": "Derivatives:"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DerivativeNotionalAmountAmountTerminated": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Notional Amount, Amount Terminated",
        "label": "Derivative, Notional Amount, Amount Terminated",
        "terseLabel": "Derivative, Notional Amount, Amount Terminated"
       }
      }
     },
     "localname": "DerivativeNotionalAmountAmountTerminated",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DevelopmentCostsDueToCollaborationPartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development costs due to collaboration partner",
        "label": "Development costs due to collaboration partner",
        "terseLabel": "Development costs due to collaboration partner"
       }
      }
     },
     "localname": "DevelopmentCostsDueToCollaborationPartner",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DevelopmentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development programs",
        "label": "Development programs",
        "terseLabel": "Development programs"
       }
      }
     },
     "localname": "DevelopmentPrograms",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent",
        "terseLabel": "Interest on uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ENBREL.",
        "label": "ENBREL [Member]",
        "terseLabel": "Enbrel\u00ae (etanercept) [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_EquityInvestmentsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the policy for investments in equity securities that are publicly traded and that do not have a readily determinable fair value.",
        "label": "Equity investments, policy [Policy Text Block]",
        "terseLabel": "Equity investments, policy"
       }
      }
     },
     "localname": "EquityInvestmentsPolicyPolicyTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity",
        "label": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EquityMethodInvestmentChangeInCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, change in carrying value",
        "label": "Equity method investment, change in carrying value",
        "terseLabel": "Equity method investment, change in carrying value"
       }
      }
     },
     "localname": "EquityMethodInvestmentChangeInCarryingValue",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EquityMethodInvestmentChangeInCarryingValueOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Change In Carrying Value, Other",
        "label": "Equity Method Investment, Change In Carrying Value, Other",
        "terseLabel": "Equity Method Investment, Change In Carrying Value, Other"
       }
      }
     },
     "localname": "EquityMethodInvestmentChangeInCarryingValueOther",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EquitySecuritiesRealizedGainLossOnDisposal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Realized Gain (Loss) on Disposal",
        "label": "Equity Securities, Realized Gain (Loss) on Disposal",
        "terseLabel": "Equity Securities, Realized Gain (Loss) on Disposal"
       }
      }
     },
     "localname": "EquitySecuritiesRealizedGainLossOnDisposal",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EvenityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evenity",
        "label": "Evenity [Member]",
        "terseLabel": "Evenity"
       }
      }
     },
     "localname": "EvenityMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ExpirationInTaxYearsBetween2023And2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration in tax years between 2023 and 2043",
        "label": "Expiration in tax years between 2023 and 2043 [Member]",
        "terseLabel": "Expiration in tax years between 2023 and 2043"
       }
      }
     },
     "localname": "ExpirationInTaxYearsBetween2023And2043Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.",
        "label": "Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]",
        "verboseLabel": "Consolidated Balance Sheets locations"
       }
      }
     },
     "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.",
        "label": "Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]",
        "verboseLabel": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.",
        "label": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]",
        "verboseLabel": "Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]",
        "label": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]",
        "terseLabel": "5.50% \u00a3475 million notes due 2026 (5.50% 2026 pound sterling Notes)",
        "verboseLabel": "5.50% 2026 pound sterling Notes [Member]"
       }
      }
     },
     "localname": "FivePointFiveZeroPercentPoundSterlingNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointOneFivePercentNotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point One Five Percent Notes Due 2041 [Member]",
        "label": "Five Point One Five Percent Notes Due 2041 [Member]",
        "terseLabel": "5.15% notes due 2041 (5.15% 2041 Notes)"
       }
      }
     },
     "localname": "FivePointOneFivePercentNotesDue2041Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSevenFivePercentNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Seven Five Percent Notes Due 2040 [Member]",
        "label": "Five Point Seven Five Percent Notes Due 2040 [Member]",
        "terseLabel": "5.75% notes due 2040 (5.75% 2040 Notes)"
       }
      }
     },
     "localname": "FivePointSevenFivePercentNotesDue2040Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSixFivePercentNotesDue2042Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Six Five Percent Notes Due 2042 [Member]",
        "label": "Five Point Six Five Percent Notes Due 2042 [Member]",
        "terseLabel": "5.65% notes due 2042 (5.65% 2042 Notes)"
       }
      }
     },
     "localname": "FivePointSixFivePercentNotesDue2042Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointThreeSevenFivePercentNotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Three Seven Five Percent Notes Due 2043 [Member]",
        "label": "Five Point Three Seven Five Percent Notes Due 2043 [Member]",
        "terseLabel": "5.375% notes due 2043 (5.375% 2043 Notes)"
       }
      }
     },
     "localname": "FivePointThreeSevenFivePercentNotesDue2043Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePrimeTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Prime Therapeutics, Inc.",
        "label": "Five Prime Therapeutics, Inc. [Member]",
        "terseLabel": "Five Prime Therapeutics, Inc."
       }
      }
     },
     "localname": "FivePrimeTherapeuticsIncMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FixedEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed equipment",
        "label": "Fixed equipment",
        "terseLabel": "Fixed equipment"
       }
      }
     },
     "localname": "FixedEquipment",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_FixedEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed equipment",
        "label": "Fixed equipment [Member]",
        "verboseLabel": "Fixed equipment [Member]"
       }
      }
     },
     "localname": "FixedEquipmentMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FloatingRateNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Notes Due 2020 [Member]",
        "label": "Floating Rate Notes Due 2020 [Member]",
        "terseLabel": "Floating Rate Notes Due 2020"
       }
      }
     },
     "localname": "FloatingRateNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ForeignCurrencyAndCrossCurrencySwapsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency and cross currency swaps.",
        "label": "Foreign Currency and Cross Currency Swaps [Member]",
        "verboseLabel": "Foreign currency and cross currency swap contracts [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyAndCrossCurrencySwapsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ForeignCurrencyTranslationLossOnDivestitureOfABusiness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency translation, loss on divestiture of a business",
        "label": "Foreign currency translation, loss on divestiture of a business",
        "terseLabel": "Foreign currency translation, loss on divestiture of a business"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationLossOnDivestitureOfABusiness",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ForwardInterestRateContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward Interest Rate Contract [Member]",
        "label": "Forward Interest Rate Contract [Member]",
        "terseLabel": "Forward interest rate contracts"
       }
      }
     },
     "localname": "ForwardInterestRateContractMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ForwardInterestRateContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward Interest Rate Contracts",
        "label": "Forward Interest Rate Contracts [Member]",
        "terseLabel": "Forward interest rate contracts"
       }
      }
     },
     "localname": "ForwardInterestRateContractsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPercentPoundSterlingNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Percent Pound Sterling Notes Due 2029 [Member]",
        "label": "Four Percent Pound Sterling Notes Due 2029 [Member]",
        "terseLabel": "4.00% \u00a3700 million notes due 2029 (4.00% 2029 pound sterling Notes)",
        "verboseLabel": "4.00% 2029 pound sterling Notes [Member]"
       }
      }
     },
     "localname": "FourPercentPoundSterlingNotesDue2029Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]",
        "label": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]",
        "terseLabel": "4.563% notes due 2048 (4.563% 2048 Notes)"
       }
      }
     },
     "localname": "FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFiveZeroPercentNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Five Zero Percent Notes Due 2020 [Member]",
        "label": "Four Point Five Zero Percent Notes Due 2020 [Member]",
        "terseLabel": "4.50% notes due 2020 (4.50% 2020 Notes)"
       }
      }
     },
     "localname": "FourPointFiveZeroPercentNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]",
        "label": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]",
        "terseLabel": "4.40% notes due 2045 (4.40% 2045 Notes)"
       }
      }
     },
     "localname": "FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointNineFivePercentNotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Nine Five Percent Notes Due 2041 [Member]",
        "label": "Four Point Nine Five Percent Notes Due 2041 [Member]",
        "verboseLabel": "4.95% notes due 2041 (4.95% 2041 Notes)"
       }
      }
     },
     "localname": "FourPointNineFivePercentNotesDue2041Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointOneZeroPercentNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point One Zero Percent Notes Due 2021 [Member]",
        "label": "Four Point One Zero Percent Notes Due 2021 [Member]",
        "terseLabel": "4.10% notes due 2021 (4.10% 2021 Notes)"
       }
      }
     },
     "localname": "FourPointOneZeroPercentNotesDue2021Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]",
        "label": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]",
        "terseLabel": "4.663% notes due 2051 (4.663% 2051 Notes)"
       }
      }
     },
     "localname": "FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_GainContingencyNumberOfChallenges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Challenges",
        "label": "Gain Contingency, Number Of Challenges",
        "terseLabel": "Number of challenges"
       }
      }
     },
     "localname": "GainContingencyNumberOfChallenges",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_GainContingencyNumberofLawsuitsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number of Lawsuits Filed",
        "label": "Gain Contingency, Number of Lawsuits Filed",
        "terseLabel": "Number of lawsuits filed"
       }
      }
     },
     "localname": "GainContingencyNumberofLawsuitsFiled",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_HedgedLiabilityDiscontinuedFairValueHedge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Liability, Discontinued Fair Value Hedge",
        "label": "Hedged Liability, Discontinued Fair Value Hedge",
        "terseLabel": "Carrying value with discontinued hedging relationships"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedge",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_HorizonTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horizon Therapeutics",
        "label": "Horizon Therapeutics [Member]",
        "terseLabel": "Horizon Therapeutics [Member]"
       }
      }
     },
     "localname": "HorizonTherapeuticsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_IdentifiableIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible assets accumulated amortization.",
        "label": "Identifiable Intangible Assets Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "IdentifiableIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_IdentifiableIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible assets gross.",
        "label": "Identifiable Intangible Assets Gross",
        "totalLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "IdentifiableIntangibleAssetsGross",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_IncreaseDecreaseInNoncurrentTaxLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Noncurrent Tax Liability",
        "label": "Increase (Decrease) In Noncurrent Tax Liability",
        "terseLabel": "Long-term tax liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentTaxLiability",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_InterestRateSwapAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap [Axis]",
        "label": "Interest Rate Swap [Axis]",
        "terseLabel": "Interest Rate Swap [Axis]"
       }
      }
     },
     "localname": "InterestRateSwapAxis",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_InterestRateSwapDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap",
        "label": "Interest Rate Swap [Domain]",
        "terseLabel": "Interest Rate Swap [Domain]"
       }
      }
     },
     "localname": "InterestRateSwapDomain",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_InterestRateSwapOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap, One [Member]",
        "label": "Interest Rate Swap, One [Member]",
        "terseLabel": "Interest Rate Swap, One [Member]"
       }
      }
     },
     "localname": "InterestRateSwapOneMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_InterestRateSwapTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap, Two [Member]",
        "label": "Interest Rate Swap, Two [Member]",
        "terseLabel": "Interest Rate Swap, Two [Member]"
       }
      }
     },
     "localname": "InterestRateSwapTwoMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_JanssenBiotechIncVsAmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Biotech Inc. Vs, Amgen Inc",
        "label": "Janssen Biotech Inc. Vs, Amgen Inc [Member]",
        "terseLabel": "Janssen Biotech Inc. Vs, Amgen Inc"
       }
      }
     },
     "localname": "JanssenBiotechIncVsAmgenIncMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_KyowaKirinCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyowa Kirin Co. Ltd.",
        "label": "Kyowa Kirin Co. Ltd. [Member]",
        "terseLabel": "Kyowa Kirin Co. Ltd."
       }
      }
     },
     "localname": "KyowaKirinCoLtdMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_KyprolisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyprolis [Member]",
        "label": "Kyprolis [Member]",
        "terseLabel": "Kyprolis [Member]"
       }
      }
     },
     "localname": "KyprolisMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LaboratoryEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of laboratory equipment, gross.",
        "label": "Laboratory Equipment",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipment",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases",
        "terseLabel": "Future rental commitments for abandoned leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LineOfCreditFacilityExtensionOfCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Extension of Commitment Term",
        "label": "Line of Credit Facility, Extension of Commitment Term",
        "terseLabel": "Additional period for extension of commitment term"
       }
      }
     },
     "localname": "LineOfCreditFacilityExtensionOfCommitmentTerm",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LineOfCreditFacilityInitialCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Initial Commitment Term",
        "label": "Line of Credit Facility, Initial Commitment Term",
        "terseLabel": "Initial commitment term of each bank which is a party to the agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityInitialCommitmentTerm",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LineofCreditFacilityNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Number Of Renewal Options",
        "label": "Line of Credit Facility, Number Of Renewal Options",
        "terseLabel": "Number of additional term extension options"
       }
      }
     },
     "localname": "LineofCreditFacilityNumberOfRenewalOptions",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LitigationSettlementLengthofTrial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Length of Trial",
        "label": "Litigation Settlement, Length of Trial",
        "terseLabel": "Length of trial"
       }
      }
     },
     "localname": "LitigationSettlementLengthofTrial",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LongTermDebtCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Current Maturities [Member]",
        "label": "Long-Term Debt, Current Maturities [Member]",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.",
        "label": "Long Term Debt Maturities Repayments Of Principal Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LossContingencyNumberOfClassActionSuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Class Action Suits",
        "label": "Loss Contingency, Number Of Class Action Suits",
        "terseLabel": "Loss Contingency, Number Of Class Action Suits"
       }
      }
     },
     "localname": "LossContingencyNumberOfClassActionSuits",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LossContingencyNumberOfLawsuitsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Lawsuits Filed",
        "label": "Loss Contingency, Number of Lawsuits Filed",
        "terseLabel": "Loss contingency, number of lawsuits filed"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuitsFiled",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LossContingencyNumberOfPrimaryArguments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Primary Arguments",
        "label": "Loss Contingency, Number Of Primary Arguments",
        "terseLabel": "Loss Contingency, Number Of Primary Arguments"
       }
      }
     },
     "localname": "LossContingencyNumberOfPrimaryArguments",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of States In Which Plaintiffs Reside",
        "label": "Loss Contingency, Number Of States In Which Plaintiffs Reside",
        "terseLabel": "Loss Contingency, Number Of States In Which Plaintiffs Reside"
       }
      }
     },
     "localname": "LossContingencyNumberOfStatesInWhichPlaintiffsReside",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing equipment.",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment [Member]"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_MaximumBorrowingCapacityUnderCommercialPaper": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Borrowing Capacity Under Commercial Paper Program.",
        "label": "Maximum Borrowing Capacity Under Commercial Paper",
        "terseLabel": "Commercial paper, maximum borrowing capacity"
       }
      }
     },
     "localname": "MaximumBorrowingCapacityUnderCommercialPaper",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_MoleculeTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecule, Type",
        "label": "Molecule, Type [Axis]",
        "terseLabel": "Molecule, Type [Axis]"
       }
      }
     },
     "localname": "MoleculeTypeAxis",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_MoleculeTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecule, Type [Domain]",
        "label": "Molecule, Type [Domain]",
        "terseLabel": "Molecule, Type [Domain]"
       }
      }
     },
     "localname": "MoleculeTypeDomain",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as \"predominately\", \"about equally\", or \"major and other\". This element is also referred to as \"Business Description\".",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "Business"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_NeulastaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neulasta.",
        "label": "Neulasta [Member]",
        "terseLabel": "Neulasta\u00ae (pegfilgrastim) [Member]"
       }
      }
     },
     "localname": "NeulastaMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NeumoraTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neumora Therapeutics, Inc.",
        "label": "Neumora Therapeutics, Inc. [Member]",
        "terseLabel": "Neumora Therapeutics, Inc."
       }
      }
     },
     "localname": "NeumoraTherapeuticsIncMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NovartisPharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Pharma AG",
        "label": "Novartis Pharma AG [Member]",
        "terseLabel": "Novartis Pharma AG"
       }
      }
     },
     "localname": "NovartisPharmaAGMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NplateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nplate",
        "label": "Nplate [Member]",
        "terseLabel": "Nplate"
       }
      }
     },
     "localname": "NplateMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issued for each performance unit earned.",
        "label": "Number of Common Shares Issued for Each Performance Unit Earned",
        "terseLabel": "Number of common shares issued for each performance unit earned"
       }
      }
     },
     "localname": "NumberOfCommonSharesIssuedForEachPerformanceUnitEarned",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the pool of available shares will be reduced for each stock option granted.",
        "label": "Number Of Common Shares To Be Reduced For Each Stock Option Granted",
        "terseLabel": "Amount by which the pool of available shares will be reduced for each stock option granted"
       }
      }
     },
     "localname": "NumberOfCommonSharesToBeReducedForEachStockOptionGranted",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the pool of available shares will be reduced for other types of awards granted.",
        "label": "Number of Common Shares to be Reduced For Other Types Of Awards Granted",
        "terseLabel": "The number of shares by which the pool of available shares will be reduced for other types of awards granted"
       }
      }
     },
     "localname": "NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major customers (as defined) accounting for more than 10% of gross trade receivables.",
        "label": "Number of Customers Accounting for More Than Ten Percent of Gross Trade Receivables",
        "terseLabel": "Major customers (as defined) accounting for more than 10% of gross trade receivables"
       }
      }
     },
     "localname": "NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major customers (as defined) accounting for more than 10% of total revenue.",
        "label": "Number of Customers Accounting for More Than Ten Percent of Revenue",
        "terseLabel": "Number of major customers (as defined) accounting for more than 10% of total revenue"
       }
      }
     },
     "localname": "NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberOfNoticesConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Notices Consolidated",
        "label": "Number Of Notices Consolidated",
        "terseLabel": "Number of notices consolidated in court"
       }
      }
     },
     "localname": "NumberOfNoticesConsolidated",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberOfNoticesOnProposedAdditionalTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of notices on proposed additional tax",
        "label": "Number of notices on proposed additional tax",
        "terseLabel": "Number of notices on proposed additional tax"
       }
      }
     },
     "localname": "NumberOfNoticesOnProposedAdditionalTax",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberOfPreclinicalOncologyPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Preclinical Oncology Programs",
        "label": "Number Of Preclinical Oncology Programs",
        "terseLabel": "Number of oncology programs comprising remaining IPR&amp;D"
       }
      }
     },
     "localname": "NumberOfPreclinicalOncologyPrograms",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Shares Added Back for Tax Withholding on Full Value Awards",
        "label": "Number of Shares Added Back for Tax Withholding on Full Value Awards",
        "terseLabel": "Number of shares added back for tax withholding on full value awards"
       }
      }
     },
     "localname": "NumberofSharesAddedBackforTaxWithholdingonFullValueAwards",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]",
        "label": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]",
        "terseLabel": "1.85% notes due 2021 (1.85% 2021 Notes)"
       }
      }
     },
     "localname": "OnePointEightFivePercentNotesDueTwoZeroTwoOneMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]",
        "label": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]",
        "terseLabel": "1.25% 2022 euro Notes"
       }
      }
     },
     "localname": "OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Five Percent Notes Due Two Zero Two Two",
        "label": "One Point Two Five Percent Notes Due Two Zero Two Two [Member]",
        "terseLabel": "1.25% notes due 2022 (1.25% 2022 Notes)"
       }
      }
     },
     "localname": "OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OperatingLossesThatExpireBetween2022And2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Losses That Expire Between 2022 and 2031",
        "label": "Operating Losses That Expire Between 2022 and 2031 [Member]",
        "terseLabel": "Operating Losses That Expire Between 2022 and 2031"
       }
      }
     },
     "localname": "OperatingLossesThatExpireBetween2022And2031Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtezlaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otezla [Member]",
        "label": "Otezla [Member]",
        "verboseLabel": "Otezla [Member]"
       }
      }
     },
     "localname": "OtezlaMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Other Adjustment, before Tax",
        "label": "Other Comprehensive Income (Loss), Other Adjustment, before Tax",
        "terseLabel": "Other gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent",
        "label": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_OtherCurrentNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current assets/other non-current assets.",
        "label": "Other Current Noncurrent Assets [Member]",
        "verboseLabel": "Other\u00a0current\u00a0assets/ Other noncurrent assets"
       }
      }
     },
     "localname": "OtherCurrentNoncurrentAssetsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherGeneralExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other general expense",
        "label": "Other general expense [Member]",
        "terseLabel": "Other general expense"
       }
      }
     },
     "localname": "OtherGeneralExpenseMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherNotesDue2097Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Notes Due 2097 [Member]",
        "label": "Other Notes Due 2097 [Member]",
        "terseLabel": "Other notes due 2097"
       }
      }
     },
     "localname": "OtherNotesDue2097Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products [Member]",
        "label": "Other Products [Member]",
        "terseLabel": "Other products [Member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherShortTermInterestBearingSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term interest bearing securities.",
        "label": "Other Short Term Interest Bearing Securities [Member]",
        "terseLabel": "Other short-term interest-bearing securities"
       }
      }
     },
     "localname": "OtherShortTermInterestBearingSecuritiesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_PenaltiesOnProposedAdditionalIncomeTax20132105": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Penalties on proposed additional income tax 2013-2015",
        "label": "Penalties on proposed additional income tax 2013-2105",
        "terseLabel": "Penalties on proposed additional income tax 2013-2105"
       }
      }
     },
     "localname": "PenaltiesOnProposedAdditionalIncomeTax20132105",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.",
        "label": "Percentage of Combined Net Trade Receivables from Major Customers",
        "terseLabel": "Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables"
       }
      }
     },
     "localname": "PercentageOfCombinedNetTradeReceivablesFromMajorCustomers",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.",
        "label": "Percentage Of Combined Worldwide Gross Revenues From Major Customers",
        "terseLabel": "Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis"
       }
      }
     },
     "localname": "PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageOfGrossRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross product sales to major customer (as defined) as a percentage of total gross revenues.",
        "label": "Percentage of Gross Revenues",
        "terseLabel": "Gross product sales to major customer (as defined) as a percentage of total gross revenues"
       }
      }
     },
     "localname": "PercentageOfGrossRevenues",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.",
        "label": "Percentage of Net Amount Due from Customers Located Outside Domestic Location",
        "terseLabel": "Percentage of net trade receivables due from customers located outside the United States, primarily in Europe"
       }
      }
     },
     "localname": "PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event",
        "label": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event",
        "terseLabel": "Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event"
       }
      }
     },
     "localname": "PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PerformanceUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Units.",
        "label": "Performance Units [Member]",
        "verboseLabel": "Performance units [Member]"
       }
      }
     },
     "localname": "PerformanceUnitsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ProfitAndLossShareOfExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit and loss share of expenses",
        "label": "Profit and loss share of expenses",
        "terseLabel": "Profit and loss share of expenses"
       }
      }
     },
     "localname": "ProfitAndLossShareOfExpenses",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsUCBDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ProliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prolia.",
        "label": "Prolia [Member]",
        "terseLabel": "Prolia\u00ae (denosumab) [Member]"
       }
      }
     },
     "localname": "ProliaMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ProposedAdditionalIncomeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proposed additional income tax",
        "label": "Proposed additional income tax",
        "terseLabel": "Proposed additional income tax"
       }
      }
     },
     "localname": "ProposedAdditionalIncomeTax",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ProposedAdditionalIncomeTax20132015": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proposed additional income tax 2013-2015",
        "label": "Proposed additional income tax 2013-2015",
        "terseLabel": "Proposed additional income tax 2013-2015"
       }
      }
     },
     "localname": "ProposedAdditionalIncomeTax20132015",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_RDTechnologyrightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R &amp; D Technology rights [Member]",
        "label": "R &amp; D Technology rights [Member]",
        "terseLabel": "R &amp; D Technology rights"
       }
      }
     },
     "localname": "RDTechnologyrightsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RegeneronPharmaceuticalsIncAntitrustActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron Pharmaceuticals Inc. Antitrust Action",
        "label": "Regeneron Pharmaceuticals Inc. Antitrust Action [Member]",
        "terseLabel": "Regeneron Pharmaceuticals Inc. Antitrust Action"
       }
      }
     },
     "localname": "RegeneronPharmaceuticalsIncAntitrustActionMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RepathaevolocumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repatha (evolocumab) [Member]",
        "label": "Repatha (evolocumab) [Member]",
        "terseLabel": "Repatha (evolocumab) [Member]"
       }
      }
     },
     "localname": "RepathaevolocumabMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RepatriationTaxOnProposedAdditionalTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repatriation tax on proposed additional tax",
        "label": "Repatriation tax on proposed additional tax",
        "terseLabel": "Repatriation tax on proposed additional tax"
       }
      }
     },
     "localname": "RepatriationTaxOnProposedAdditionalTax",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_RepatriationTaxOnProposedAdditionalTax20132015": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repatriation tax on proposed additional tax 2013-2015",
        "label": "Repatriation tax on proposed additional tax 2013-2015",
        "terseLabel": "Repatriation tax on proposed additional tax 2013-2015"
       }
      }
     },
     "localname": "RepatriationTaxOnProposedAdditionalTax20132015",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest Of World [Member]",
        "label": "Rest Of World [Member]",
        "terseLabel": "ROW [Member]"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RevenuePaymentArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Payment Arrangement, Term",
        "label": "Revenue Payment Arrangement, Term",
        "terseLabel": "Revenue payment term"
       }
      }
     },
     "localname": "RevenuePaymentArrangementTerm",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Future Milestone Payments",
        "label": "Revenue Recognition, Milestone Method, Potential Future Milestone payments",
        "terseLabel": "Revenue Recognition, Milestone Method, Potential Future Milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_SalesReturnProvisionsAsPercentageOfProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Return Provisions As Percentage Of Product Sales",
        "label": "Sales Return Provisions As Percentage Of Product Sales",
        "terseLabel": "Sales return provisions as a percentage of gross product sales (less than)"
       }
      }
     },
     "localname": "SalesReturnProvisionsAsPercentageOfProductSales",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_SandozIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sandoz Inc.",
        "label": "Sandoz Inc. [Member]",
        "terseLabel": "Sandoz Inc."
       }
      }
     },
     "localname": "SandozIncMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SanofiRegeneronPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi/Regeneron Patent Litigation [Member]",
        "label": "Sanofi/Regeneron Patent Litigation [Member]",
        "terseLabel": "Sanofi/Regeneron Patent Litigation"
       }
      }
     },
     "localname": "SanofiRegeneronPatentLitigationMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ScheduleOfIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.",
        "label": "Schedule Of Intangible Assets [Table Text Block]",
        "verboseLabel": "Schedule of identifiable intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Long-term Debt Instruments Exchanged [Table]",
        "label": "Schedule of Long-term Debt Instruments Exchanged [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments Exchanged"
       }
      }
     },
     "localname": "ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps",
        "label": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]",
        "terseLabel": "Schedule of notional amounts and interest rates for cross-currency swaps"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]",
        "label": "Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]",
        "terseLabel": "U.S. repatriation tax commitments"
       }
      }
     },
     "localname": "ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_SecuredOvernightFinancingRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured overnight financing rate",
        "label": "Secured overnight financing rate [Member]",
        "terseLabel": "Secured overnight financing rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SensiparAntitrustClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensipar Antitrust Class Actions [Member]",
        "label": "Sensipar Antitrust Class Actions [Member]",
        "terseLabel": "Sensipar Antitrust Class Actions"
       }
      }
     },
     "localname": "SensiparAntitrustClassActionsMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Performance Units Fair Value Assumptions [Table Text Block]",
        "terseLabel": "Weighted average assumptions used and the resulting weighted average grant date fair value of performance units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_SixPointFourZeroPercentNotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Four Zero Percent Notes Due 2039 [Member]",
        "label": "Six Point Four Zero Percent Notes Due 2039 [Member]",
        "terseLabel": "6.40% notes due 2039 (6.40% 2039 Notes)"
       }
      }
     },
     "localname": "SixPointFourZeroPercentNotesDue2039Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointNineZeroPercentNotesDue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Nine Zero Percent Notes Due 2038 [Member]",
        "label": "Six Point Nine Zero Percent Notes Due 2038 [Member]",
        "terseLabel": "6.90% notes due 2038 (6.90% 2038 Notes)"
       }
      }
     },
     "localname": "SixPointNineZeroPercentNotesDue2038Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointThreeSevenFivePercentNotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Three Seven Five Percent Notes Due 2037 [Member]",
        "label": "Six Point Three Seven Five Percent Notes Due 2037 [Member]",
        "terseLabel": "6.375% notes due 2037 (6.375% 2037 Notes)"
       }
      }
     },
     "localname": "SixPointThreeSevenFivePercentNotesDue2037Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_StockBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total stock-based compensation expense, net of tax.",
        "label": "Stock Based Compensation Expense Net of Tax",
        "totalLabel": "Total stock-based compensation expense, net of tax"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseNetOfTax",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_StockRepurchaseProgramTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchase Program [Table Text Block]",
        "label": "Stock Repurchase Program [Table Text Block]",
        "verboseLabel": "Summary of activity under our stock repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramTableTextBlock",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability, Total",
        "label": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
        "totalLabel": "Total remaining U.S. repatriation tax commitments"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments",
        "terseLabel": "U.S. repatriation tax commitments, number of annual installments"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TeneobioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teneobio, Inc.",
        "label": "Teneobio, Inc. [Member]",
        "terseLabel": "Teneobio, Inc."
       }
      }
     },
     "localname": "TeneobioIncMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TeneobioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teneobio",
        "label": "Teneobio [Member]",
        "terseLabel": "Teneobio"
       }
      }
     },
     "localname": "TeneobioMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TermLoanCreditAgreementNumberOfTraunches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan credit agreement, number of traunches",
        "label": "Term loan credit agreement, number of traunches",
        "terseLabel": "Term loan credit agreement, number of traunches"
       }
      }
     },
     "localname": "TermLoanCreditAgreementNumberOfTraunches",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_TermLoanCreditAgreementTotalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "term loan credit agreement, total amount",
        "label": "term loan credit agreement, total amount",
        "terseLabel": "Term loan credit agreement, total amount"
       }
      }
     },
     "localname": "TermLoanCreditAgreementTotalAmount",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ThreePointEightSevenFivePercentNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]",
        "label": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]",
        "terseLabel": "3.875% notes due 2021 (3.875% 2021 Notes)"
       }
      }
     },
     "localname": "ThreePointEightSevenFivePercentNotesDue2021Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointFourFivePercentNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Four Five Percent Notes Due 2020 [Member]",
        "label": "Three Point Four Five Percent Notes Due 2020 [Member]",
        "terseLabel": "3.45% notes due 2020 (3.45% 2020 Notes)"
       }
      }
     },
     "localname": "ThreePointFourFivePercentNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointOneFivePercentNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Five Percent Notes Due 2040 [Member]",
        "label": "Three Point One Five Percent Notes Due 2040 [Member]",
        "terseLabel": "3.15% notes due 2040 (3.15% 2040 Notes)"
       }
      }
     },
     "localname": "ThreePointOneFivePercentNotesDue2040Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]",
        "label": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]",
        "terseLabel": "3.125% notes due 2025 (3.125% 2025 Notes)"
       }
      }
     },
     "localname": "ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointSixTwoFivePercentNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Two Five Percent Notes Due 2022 [Member]",
        "label": "Three Point Six Two Five Percent Notes Due 2022 [Member]",
        "terseLabel": "3.625% Notes Due 2022"
       }
      }
     },
     "localname": "ThreePointSixTwoFivePercentNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointSixTwoFivePercentNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Two Five Percent Notes Due 2024 [Member]",
        "label": "Three Point Six Two Five Percent Notes Due 2024 [Member]",
        "terseLabel": "3.625% notes due 2024 (3.625% 2024 Notes)"
       }
      }
     },
     "localname": "ThreePointSixTwoFivePercentNotesDue2024Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointThreeSevenFivePercentNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Seven Five Percent Notes Due 2050 [Member]",
        "label": "Three Point Three Seven Five Percent Notes Due 2050 [Member]",
        "terseLabel": "3.375% notes due 2050 (3.375% 2050 Notes)"
       }
      }
     },
     "localname": "ThreePointThreeSevenFivePercentNotesDue2050Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointTwoZeroNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Two Zero Notes Due 2027 [Member]",
        "label": "Three Point Two Zero Notes Due 2027 [Member]",
        "terseLabel": "3.20% notes due 2027 (3.20% 2027 Notes)"
       }
      }
     },
     "localname": "ThreePointTwoZeroNotesDue2027Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]",
        "label": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]",
        "terseLabel": "2.00% \u20ac750 million notes due 2026 (2.00% 2026 euro Notes)"
       }
      }
     },
     "localname": "TwoPercentEuroNotesDueTwoThousandTwentySixMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointEightZeroPercent2041NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two point eight zero percent 2041 Notes",
        "label": "Two point eight zero percent 2041 Notes [Member]",
        "terseLabel": "2.80% notes due 2041 (2.80% 2041 Notes)"
       }
      }
     },
     "localname": "TwoPointEightZeroPercent2041NotesMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointFourFivePercentNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Four Five Percent Notes Due 2030 [Member]",
        "label": "Two Point Four Five Percent Notes Due 2030 [Member]",
        "terseLabel": "2.45% notes due 2030 (2.45% 2030 Notes)"
       }
      }
     },
     "localname": "TwoPointFourFivePercentNotesDue2030Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]",
        "label": "Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]",
        "terseLabel": "2.125% notes due 2020 (2.125% 2020 Notes)"
       }
      }
     },
     "localname": "TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Seven Seven Percent Notes Due Two Zero Five Three",
        "label": "Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]",
        "terseLabel": "2.77% notes due 2053 (2.77% 2053 Notes)"
       }
      }
     },
     "localname": "TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSevenZeroPercentNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Seven Percent Notes Due Two Zero Two Two",
        "label": "Two Point Seven Zero Percent Notes Due 2022 [Member]",
        "terseLabel": "2.70% notes due 2022 (2.70% 2022 Notes)"
       }
      }
     },
     "localname": "TwoPointSevenZeroPercentNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Six Five Percent Notes Due Two Zero Two Two",
        "label": "Two Point Six Five Percent Notes Due Two Zero Two Two [Member]",
        "terseLabel": "2.65% notes due 2022 (2.65% 2022 Notes)"
       }
      }
     },
     "localname": "TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Six Zero Notes Due Two Zero Two Six [Member]",
        "label": "Two Point Six Zero Notes Due Two Zero Two Six [Member]",
        "terseLabel": "2.60% notes due 2026 (2.60% 2026 Notes)",
        "verboseLabel": "2.600% notes due 2026 (2.60% 2026 notes) [Member]"
       }
      }
     },
     "localname": "TwoPointSixZeroNotesDueTwoZeroTwoSixMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointThreeZeroPercentNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Three Zero Percent Notes Due 2031",
        "label": "Two Point Three Zero Percent Notes Due 2031 [Member]",
        "terseLabel": "2.30% notes due 2031 (2.30% 2031 Notes)"
       }
      }
     },
     "localname": "TwoPointThreeZeroPercentNotesDue2031Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]",
        "label": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]",
        "terseLabel": "2.25% notes due 2023 (2.25% 2023 Notes)"
       }
      }
     },
     "localname": "TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Notes Due 2020 [Member]",
        "label": "Two Point Two Zero Notes Due 2020 [Member]",
        "terseLabel": "2.20% notes due 2020 (2.20% 2020 Notes)"
       }
      }
     },
     "localname": "TwoPointTwoZeroNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]",
        "label": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]",
        "terseLabel": "2.20% notes due 2027 (2.20% 2027 Notes)"
       }
      }
     },
     "localname": "TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointZeroPercent2032NotesMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two point zero percent 2032 Notes Member",
        "label": "Two point zero percent 2032 Notes Member [Member]",
        "terseLabel": "2.00% notes due 2032 (2.00% 2032 Notes)"
       }
      }
     },
     "localname": "TwoPointZeroPercent2032NotesMemberMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_UCBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB",
        "label": "UCB [Member]",
        "terseLabel": "UCB"
       }
      }
     },
     "localname": "UCBMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsUCBDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_UpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-front payment",
        "label": "Up-front payment",
        "terseLabel": "Up-front payment"
       }
      }
     },
     "localname": "UpFrontPayment",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_XgevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XGEVA.",
        "label": "XGEVA [Member]",
        "terseLabel": "XGEVA\u00ae (denosumab) [Member]"
       }
      }
     },
     "localname": "XgevaMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]",
        "label": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]",
        "terseLabel": "0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)"
       }
      }
     },
     "localname": "ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember",
     "nsuri": "http://www.amgen.com/20221231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PUERTO RICO",
        "verboseLabel": "Puerto Rico [Member]"
       }
      }
     },
     "localname": "PR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US",
        "verboseLabel": "US"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "verboseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Switzerland, Francs [Member]"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro Member Countries, Euro [Member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "United Kingdom, Pounds [Member]"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "United States of America, Dollars [Member]"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r876",
      "r877",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r876",
      "r877",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r876",
      "r877",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r876",
      "r877",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r876",
      "r877",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_XNGS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]",
        "terseLabel": "The NASDAQ Global Select Market"
       }
      }
     },
     "localname": "XNGS",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "exch_XNYS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
        "terseLabel": "New York Stock Exchange"
       }
      }
     },
     "localname": "XNYS",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r330",
      "r331",
      "r462",
      "r493",
      "r829",
      "r836",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/CollaborationsUCBDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r273",
      "r343",
      "r350",
      "r356",
      "r414",
      "r587",
      "r588",
      "r589",
      "r617",
      "r618",
      "r655",
      "r658",
      "r660",
      "r661",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect of changes in accounting principles, net of taxes"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r273",
      "r343",
      "r350",
      "r356",
      "r414",
      "r587",
      "r588",
      "r589",
      "r617",
      "r618",
      "r655",
      "r658",
      "r660",
      "r661",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r273",
      "r343",
      "r350",
      "r356",
      "r414",
      "r587",
      "r588",
      "r589",
      "r617",
      "r618",
      "r655",
      "r658",
      "r660",
      "r661",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by currency.",
        "label": "Currency [Axis]",
        "verboseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r396",
      "r856",
      "r945",
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r545",
      "r749",
      "r769",
      "r814",
      "r815",
      "r853",
      "r862",
      "r871",
      "r942",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r545",
      "r749",
      "r769",
      "r814",
      "r815",
      "r853",
      "r862",
      "r871",
      "r942",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r396",
      "r856",
      "r945",
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PartnershipInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A general or limited ownership interest in a partnership or unincorporated joint venture.",
        "label": "Partnership Interest [Member]",
        "terseLabel": "Limited Partnership [Member]"
       }
      }
     },
     "localname": "PartnershipInterestMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r393",
      "r751",
      "r854",
      "r869",
      "r936",
      "r937",
      "r945",
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r393",
      "r751",
      "r854",
      "r869",
      "r936",
      "r937",
      "r945",
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r528",
      "r545",
      "r577",
      "r578",
      "r579",
      "r725",
      "r749",
      "r769",
      "r814",
      "r815",
      "r853",
      "r862",
      "r871",
      "r932",
      "r942",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r528",
      "r545",
      "r577",
      "r578",
      "r579",
      "r725",
      "r749",
      "r769",
      "r814",
      "r815",
      "r853",
      "r862",
      "r871",
      "r932",
      "r942",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r330",
      "r331",
      "r462",
      "r493",
      "r837",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/CollaborationsUCBDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r546",
      "r910",
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r356",
      "r546",
      "r883",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r339",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r394",
      "r395",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r818",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r855",
      "r870",
      "r945"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r394",
      "r395",
      "r799",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r818",
      "r819",
      "r855",
      "r870",
      "r945"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r356",
      "r546",
      "r883",
      "r884",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21",
      "r868"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r6",
      "r244",
      "r259"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r127",
      "r283"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r308",
      "r316",
      "r317",
      "r642",
      "r839",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Cash\u00a0flow hedges [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r308",
      "r316",
      "r317",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Available-for-sale securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r35",
      "r37",
      "r38",
      "r294",
      "r763",
      "r777",
      "r781"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r315",
      "r316",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r34",
      "r38",
      "r197",
      "r718",
      "r772",
      "r773",
      "r891",
      "r892",
      "r893",
      "r907",
      "r908",
      "r909"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "verboseLabel": "AOCI [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r33",
      "r38",
      "r197",
      "r316",
      "r317",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average period of amortization"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r160",
      "r161",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r592"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising cost"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestment": {
     "auth_ref": [
      "r664",
      "r669"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.",
        "label": "Alternative Investment",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AlternativeInvestment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r66",
      "r111",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization charges associated with finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r241",
      "r258",
      "r287",
      "r327",
      "r383",
      "r387",
      "r391",
      "r410",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r640",
      "r644",
      "r673",
      "r868",
      "r940",
      "r941",
      "r969"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets:",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r278",
      "r298",
      "r327",
      "r410",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r640",
      "r644",
      "r673",
      "r868",
      "r940",
      "r941",
      "r969"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r129",
      "r276",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Divested assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r402",
      "r422"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r90",
      "r401",
      "r422",
      "r758"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair values",
        "totalLabel": "Total available-for-sale investments",
        "verboseLabel": "Available-for-sale securities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r89",
      "r422"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r204",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r629",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r629",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Acquisition price per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r636",
      "r898"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Net changes in valuations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "verboseLabel": "Maximum additional consideration due contingent on certain milestones"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r189",
      "r190",
      "r635"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Acquisitions and divestitures"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Acquisitionsanddivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred tax liability",
        "negatedTerseLabel": "Deferred tax liability, net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Finite-lived intangible assets \u2013 developed-product-technology rights",
        "verboseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r981"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software, Gross",
        "terseLabel": "Capitalized software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r782",
      "r783",
      "r868",
      "r885"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r68",
      "r281",
      "r830"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r69",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r62",
      "r68",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r233"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedge [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Gains (losses) on fair value hedging relationships, Hedged Items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r327",
      "r359",
      "r360",
      "r362",
      "r364",
      "r372",
      "r373",
      "r410",
      "r448",
      "r451",
      "r452",
      "r453",
      "r457",
      "r458",
      "r491",
      "r492",
      "r495",
      "r499",
      "r506",
      "r673",
      "r816",
      "r882",
      "r901",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails",
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Collaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/CollaborationsUCBDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r4",
      "r242",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r249",
      "r264"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Contingencies and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r131",
      "r441",
      "r442",
      "r800",
      "r939"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Contingenciesandcommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, dividends paid per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "terseLabel": "Common stock and additional paid-in\u00a0capital"
       }
      }
     },
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r907",
      "r908",
      "r961"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Number of shares of common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock and additional paid-in capital, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock and additional paid-in capital, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "verboseLabel": "Common stock and additional paid-in capital, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r11",
      "r12",
      "r150"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.",
        "label": "Common Stocks, Including Additional Paid in Capital",
        "verboseLabel": "Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding\u2014534.0 shares in 2022 and 558.3 shares in 2021"
       }
      }
     },
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensatingBalanceAmount": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.",
        "label": "Compensating Balance, Amount",
        "terseLabel": "Compensating balance, amount"
       }
      }
     },
     "localname": "CompensatingBalanceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r39",
      "r311",
      "r313",
      "r319",
      "r760",
      "r765"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r195",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r44",
      "r751"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/CollaborationsUCBDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r904",
      "r953",
      "r955"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r904",
      "r953"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r178",
      "r612",
      "r622",
      "r904"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current provision:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r904",
      "r953",
      "r955"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt Conversion, Converted Instrument, Amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r139",
      "r325",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r475",
      "r482",
      "r483",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Financing arrangements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Financingarrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r243",
      "r246",
      "r257",
      "r333",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r692",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r7",
      "r246",
      "r257",
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reference rate used for variable rate of debt instrument.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r235",
      "r237",
      "r459",
      "r692",
      "r849",
      "r850"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Aggregate principal amount of notes issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r27",
      "r235",
      "r489",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate on note"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r27",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r28",
      "r333",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r692",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r28",
      "r144",
      "r147",
      "r148",
      "r149",
      "r234",
      "r235",
      "r237",
      "r255",
      "r333",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r692",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r234",
      "r237",
      "r943"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt Instrument, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r236",
      "r471",
      "r487",
      "r849",
      "r850"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized bond discounts, premiums and issuance costs, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "verboseLabel": "Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial obligations in a security form.",
        "label": "Debt Securities Payable [Member]",
        "terseLabel": "Debt securities payable"
       }
      }
     },
     "localname": "DebtSecuritiesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r904",
      "r954",
      "r955"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r178",
      "r904",
      "r954"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r66",
      "r178",
      "r613",
      "r621",
      "r622",
      "r904"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred benefit:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r8",
      "r9",
      "r245",
      "r256",
      "r607"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r904",
      "r954",
      "r955"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "auth_ref": [
      "r176",
      "r952"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Deferred Tax Assets, Equity Method Investments"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r951"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r951"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "NOLs with no valuation allowance and no expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r176",
      "r952"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r176",
      "r952"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r176",
      "r952"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Expenses capitalized for tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r176",
      "r952"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r176",
      "r952"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "negatedTerseLabel": "Debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r176",
      "r952"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Acquired intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r176",
      "r952"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r176",
      "r952"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense attributed to Retirement and Savings Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DefinedcontributionplanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization charges associated with property, plant and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r380"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and other"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r300",
      "r301",
      "r672",
      "r838"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeBasisSpreadOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.",
        "label": "Derivative, Basis Spread on Variable Rate",
        "terseLabel": "Derivative, effective interest rate"
       }
      }
     },
     "localname": "DerivativeBasisSpreadOnVariableRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r32",
      "r207",
      "r238",
      "r299",
      "r838"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total derivative assets, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r32",
      "r207",
      "r238",
      "r299",
      "r838"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total derivative liabilities, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Interest rates"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r205",
      "r208",
      "r213",
      "r214",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r223",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Derivativeinstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r202",
      "r205",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r202",
      "r205",
      "r213",
      "r214",
      "r218",
      "r220",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments Gain Loss [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r300",
      "r301",
      "r672",
      "r838"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r958",
      "r959"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r210",
      "r213",
      "r215",
      "r217",
      "r220",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]",
        "verboseLabel": "Schedule of Cross-Currency Swaps [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r199",
      "r202",
      "r203",
      "r216",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology Rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r945"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue by product and by geographic area"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r551",
      "r582",
      "r583",
      "r585",
      "r591",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Stockbasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Dividends declared on common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic [Member]",
        "verboseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r320",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r357",
      "r359",
      "r362",
      "r363",
      "r364",
      "r368",
      "r661",
      "r662",
      "r761",
      "r766",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in usd per share)",
        "verboseLabel": "Basic EPS (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r320",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r359",
      "r362",
      "r363",
      "r364",
      "r368",
      "r661",
      "r662",
      "r761",
      "r766",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in usd per share)",
        "verboseLabel": "Diluted EPS (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Earningspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r597"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r328",
      "r597",
      "r623"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r950",
      "r956"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedTerseLabel": "Foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r950",
      "r956"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Acquisition IPR&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r950",
      "r956"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r950",
      "r956"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "negatedTerseLabel": "Foreign-derived intangible income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r950",
      "r956"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "negatedTerseLabel": "Credits, Puerto Rico excise tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r950",
      "r956"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Credits, primarily federal R&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r950",
      "r956"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "negatedTerseLabel": "Audit settlements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to nonvested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails": {
       "order": 2.0,
       "parentTag": "amgn_StockBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "negatedTerseLabel": "Tax benefit from stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Actual tax benefits realized from tax deductions from option exercises"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r143",
      "r273",
      "r315",
      "r316",
      "r317",
      "r340",
      "r341",
      "r342",
      "r345",
      "r353",
      "r355",
      "r371",
      "r414",
      "r507",
      "r587",
      "r588",
      "r589",
      "r617",
      "r618",
      "r660",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r718",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity Method Investment, Aggregate Cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Equity Method Investment, Quoted Market Value"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r102",
      "r384",
      "r886"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Approximate carrying value of the company's equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Equity Method Investments, Fair Value Disclosure"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r61",
      "r104",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r288",
      "r671",
      "r832"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r767",
      "r918"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "terseLabel": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "terseLabel": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r665",
      "r666",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r224",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r473",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r666",
      "r722",
      "r723",
      "r724",
      "r849",
      "r850",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Fairvaluemeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r473",
      "r530",
      "r535",
      "r666",
      "r722",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r473",
      "r530",
      "r535",
      "r666",
      "r723",
      "r849",
      "r850",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant\u00a0other observable inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r473",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r666",
      "r724",
      "r849",
      "r850",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r530",
      "r664",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r473",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r722",
      "r723",
      "r724",
      "r849",
      "r850",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r204",
      "r210",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalFundsPurchasedMember": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term borrowing where a bank borrows, at the federal funds rate, from another bank.",
        "label": "Federal Funds Purchased [Member]",
        "terseLabel": "Federal Funds Purchased"
       }
      }
     },
     "localname": "FederalFundsPurchasedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r403",
      "r404",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r484",
      "r504",
      "r650",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r846",
      "r915",
      "r916",
      "r917",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r285",
      "r436"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r432",
      "r435",
      "r436",
      "r438",
      "r752",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r119",
      "r756"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "amgn_IdentifiableIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross carrying amounts"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r112",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r119",
      "r752"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "verboseLabel": "Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r838",
      "r857",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency forward contracts",
        "verboseLabel": "Foreign currency contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r960"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "verboseLabel": "Foreign currency forward contracts [Member]"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber": {
     "auth_ref": [
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity was found not to have infringed.",
        "label": "Gain Contingency, Patents Found Not Infringed upon, Number",
        "terseLabel": "Gain Contingency, Patents Found Not Infringed upon, Number"
       }
      }
     },
     "localname": "GainContingencyPatentsFoundNotInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r643",
      "r899"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Gain (Loss) on Disposition of Business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r66",
      "r137",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r284",
      "r429",
      "r757",
      "r847",
      "r868",
      "r921",
      "r928"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r430",
      "r847"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Changes to goodwill resulting from acquisitions and divestitures, net(1)"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and other intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Goodwillandintangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and other intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r180",
      "r927"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Goodwill, Purchase Accounting Adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r649"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Hedging adjustments on discontinued hedging relationships"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r647"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying amounts of hedged liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r648"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Fair value adjustments",
        "verboseLabel": "Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r202",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r66",
      "r124"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Loss on divestiture"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r383",
      "r386",
      "r390",
      "r392",
      "r845"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before income taxes",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r41",
      "r66",
      "r102",
      "r250",
      "r266",
      "r381"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Adjustments for equity method investments",
        "terseLabel": "Company's share of profits (losses) of related party"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails",
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/CollaborationsUCBDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails",
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/CollaborationsUCBDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r328",
      "r598",
      "r605",
      "r611",
      "r619",
      "r624",
      "r626",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Incometaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r329",
      "r354",
      "r355",
      "r382",
      "r596",
      "r620",
      "r625",
      "r768"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r314",
      "r594",
      "r595",
      "r605",
      "r606",
      "r610",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r63",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Accrued income taxes, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r434",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "amgn_IdentifiableIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r114",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r110",
      "r117"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Identifiable intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible assets:"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r51",
      "r479",
      "r490",
      "r851",
      "r852"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedTerseLabel": "Interest expense, net",
        "verboseLabel": "Make-whole payments recognized in interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r900"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid, net of interest rate and cross currency swaps"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "netLabel": "Interest rate swap agreements [Member]",
        "terseLabel": "Interest rate swap contracts",
        "verboseLabel": "Interest rate swap [Member]"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r889"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Tax receivables"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r108",
      "r833"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r296",
      "r831",
      "r868"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r280",
      "r295",
      "r370",
      "r426",
      "r427",
      "r428",
      "r750",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r108",
      "r835"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r108",
      "r834"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of financial support committed by investment company to investee that is contractually required.",
        "label": "Investment Company, Financial Support to Investee Contractually Required, Amount",
        "terseLabel": "Investment Company, Financial Support to Investee Contractually Required, Amount"
       }
      }
     },
     "localname": "InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r409",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Interest-bearing securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r239",
      "r254",
      "r270",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r888"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r709",
      "r867"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total net lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r966"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary information, components of lease costs, cash and noncash information on leases and other lease information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r965"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r712"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Expected total future rental income to be received"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r247",
      "r262",
      "r868",
      "r903",
      "r919",
      "r962"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r279",
      "r327",
      "r410",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r641",
      "r644",
      "r645",
      "r673",
      "r868",
      "r940",
      "r969",
      "r970"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Long-term tax liabilities"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing rights"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r7",
      "r246",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Amount outstanding under syndicated, unsecured, revolving credit facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Annual commitment fees for syndicated, unsecured, revolving credit agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Property, plant and equipment by geographic information"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r7",
      "r246",
      "r260",
      "r472",
      "r488",
      "r849",
      "r850"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Carrying value of long-term debt, including current portion",
        "totalLabel": "Total carrying value of debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, by Current and Noncurrent [Abstract]",
        "verboseLabel": "Carrying values of long-term borrowings"
       }
      }
     },
     "localname": "LongTermDebtByCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Less current portion",
        "verboseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r135",
      "r333",
      "r944"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 6.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r135",
      "r333",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r135",
      "r333",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 5.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r135",
      "r333",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 4.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r135",
      "r333",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 3.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r135",
      "r333",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Total long-term debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r28",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r132",
      "r133",
      "r443",
      "r444",
      "r445",
      "r934",
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r934",
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss contingency, number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r934",
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss contingency, number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.",
        "label": "Marketing-Related Intangible Assets [Member]",
        "terseLabel": "Marketing-related rights [Member]"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-Term Debt [Abstract]",
        "terseLabel": "Maturities of Long-term Debt [Abstract]"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Length of time hedged in foreign currency contracts"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market mutual funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "Allowance for doubtful accounts [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r42",
      "r67",
      "r251",
      "r267",
      "r277",
      "r309",
      "r312",
      "r317",
      "r327",
      "r344",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r361",
      "r383",
      "r386",
      "r390",
      "r392",
      "r410",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r662",
      "r673",
      "r845",
      "r940"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income for basic and diluted EPS"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/EarningspershareDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Income (Numerator):"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r76",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r356",
      "r368",
      "r399",
      "r400",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r587",
      "r588",
      "r589",
      "r615",
      "r616",
      "r617",
      "r618",
      "r631",
      "r632",
      "r633",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r690",
      "r691",
      "r693",
      "r694",
      "r695",
      "r696",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r753",
      "r754",
      "r755",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "ROW [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Investments Acquired",
        "terseLabel": "Noncash or Part Noncash Acquisition, Investments Acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives not designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net",
        "verboseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Aggregate fair value of long-term debt, including current portion"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes payable [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Notes"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "verboseLabel": "Number of business segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r383",
      "r386",
      "r390",
      "r392",
      "r845"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r703",
      "r867"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r698"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r698"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r698"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r700",
      "r705"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r708",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesWeightedAverageRemainingLeaseTermsDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r707",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesWeightedAverageRemainingLeaseTermsDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards available to reduce income taxes"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "NOL carryforwards, valuation allowance"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r297",
      "r868"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "totalLabel": "Total other current assets",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r193",
      "r194",
      "r196"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Losses on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r193",
      "r194",
      "r196"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Gains (losses) on foreign currency translation",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "terseLabel": "Gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r302",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "verboseLabel": "Total unrealized gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "terseLabel": "Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r40",
      "r143",
      "r310",
      "r313",
      "r318",
      "r682",
      "r687",
      "r688",
      "r759",
      "r764",
      "r891",
      "r892"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r193",
      "r194",
      "r196",
      "r310",
      "r313"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of reclassification adjustments and taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r36",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "terseLabel": "Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r193",
      "r194",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedTerseLabel": "Income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r36",
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r204",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherGeneralExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.",
        "label": "Other General Expense",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInvestments": {
     "auth_ref": [
      "r265",
      "r887"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments classified as other.",
        "label": "Other Investments",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "OtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r7",
      "r246",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-Term Debt",
        "terseLabel": "Other Long-term Debt"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r890",
      "r920"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Gross, Current",
        "terseLabel": "Corporate partner receivables"
       }
      }
     },
     "localname": "OtherReceivablesGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r894",
      "r895"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Extinguishment of debt"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for financing costs associated with business combinations.",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "terseLabel": "Financing costs"
       }
      }
     },
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r54",
      "r634"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails": {
       "order": 1.0,
       "parentTag": "amgn_Businessassetacquisitionconsiderationtransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash purchase price"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired",
        "terseLabel": "Total cash consideration"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchases of equity method investments",
        "terseLabel": "Payments to Acquire Equity Method Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsJanssenBiotechIncvAmgenIncDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r528",
      "r529",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r547",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined contribution plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Definedcontributionplan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r10",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestiture of businesses"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from Divestiture of Businesses, Net of Cash Divested"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "verboseLabel": "Net proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r88",
      "r321",
      "r322"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r896",
      "r897"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r52",
      "r88",
      "r321"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues",
        "verboseLabel": "Other revenues [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product [Member]",
        "verboseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r802",
      "r803",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Propertyplantandequipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r126",
      "r282"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r128",
      "r263",
      "r762",
      "r868"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Other, Gross",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful\u00a0life\u00a0(in\u00a0years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedLabel": "Reclassification adjustments to income"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "verboseLabel": "Reclassification out of AOCI [Member]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassifications out of accumulated other comprehensive income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecoveryOfDirectCosts": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.",
        "label": "Recovery of Direct Costs",
        "terseLabel": "Cost recoveries"
       }
      }
     },
     "localname": "RecoveryOfDirectCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": {
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r456",
      "r457",
      "r458",
      "r905",
      "r968"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Related Party Transaction, Due from (to) Related Party",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r150",
      "r261",
      "r776",
      "r781",
      "r868"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r273",
      "r340",
      "r341",
      "r342",
      "r345",
      "r353",
      "r355",
      "r414",
      "r587",
      "r588",
      "r589",
      "r617",
      "r618",
      "r660",
      "r772",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r378",
      "r379",
      "r385",
      "r388",
      "r389",
      "r393",
      "r394",
      "r396",
      "r524",
      "r525",
      "r751"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r378",
      "r379",
      "r385",
      "r388",
      "r389",
      "r393",
      "r394",
      "r396",
      "r524",
      "r525",
      "r751"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax",
        "verboseLabel": "Total product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues and Arrangements with multiple performance obligations"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r706",
      "r867"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalties due"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r38",
      "r963",
      "r964"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of accumulated other comprehensive income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Changes in contingent consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r182",
      "r183",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresChemoCentryxIncNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresDivestitureofGensentaDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresFivePrimeTherapeuticsIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresHorizonTherapeuticsPLCDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforChemoCentryxIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresSummaryofTotalConsiderationforTeneobioIncDetails",
      "http://www.amgen.com/role/AcquisitionsanddivestituresTeneobioIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsanddivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r957"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/CollaborationsUCBDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r28",
      "r144",
      "r147",
      "r148",
      "r149",
      "r234",
      "r235",
      "r237",
      "r255",
      "r849",
      "r851",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "verboseLabel": "Carrying values and the fixed contractual coupon rates of long-term borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.",
        "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Fair values of derivatives included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Summary of amounts of income and expense line items"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Computation for basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation between the federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r106",
      "r277",
      "r327",
      "r410",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Derivatives in fair value hedging relationships"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r112",
      "r118",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r847",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r904"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of income before income tax, domestic and foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Schedule of interest rate derivatives"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r3",
      "r17",
      "r18",
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Net Investment Income [Line Items]",
        "terseLabel": "Net Investment Income [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "auth_ref": [
      "r49",
      "r51",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table]",
        "terseLabel": "Investment Income [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Aggregate contractual maturities of long-term debt obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r548",
      "r550",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r290",
      "r291",
      "r292",
      "r372",
      "r491",
      "r492",
      "r493",
      "r495",
      "r499",
      "r504",
      "r506",
      "r853",
      "r882",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails",
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r80",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Revenues earned from major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsAstraZenecaPLCDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, general and administrative costs"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails": {
       "order": 1.0,
       "parentTag": "amgn_StockBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Total stock-based compensation expense, pretax",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Components of stock-based compensation expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Period over which the grants of equity instruments vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "terseLabel": "Description of vesting of restricted stock units and stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)",
        "terseLabel": "Units, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, forfeited (in usd per share)",
        "verboseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Units granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "netLabel": "Weighted average grant date fair value, granted (in usd per share)",
        "terseLabel": "Granted (in usd per share)",
        "verboseLabel": "Fair value of unit (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance nonvested at end of period (in shares)",
        "periodStartLabel": "Balance nonvested at beginning of period (in shares)",
        "terseLabel": "Units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance nonvested at end of period (in usd per share)",
        "periodStartLabel": "Balance nonvested at beginning of period (in usd per share)",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant\u00a0date fair\u00a0value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of units that vested during the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock options information [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised during the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r948"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r948"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired/forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, unexercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance unexercised at end of period (in shares)",
        "periodStartLabel": "Balance unexercised at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance unexercised at end of period (in shares)",
        "periodStartLabel": "Balance unexercised at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average exercise\u00a0price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested or expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r555",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period of stock options from date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years), unexercised"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years), vested or expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r75",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Capitalized software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r327",
      "r359",
      "r360",
      "r362",
      "r364",
      "r372",
      "r373",
      "r410",
      "r448",
      "r451",
      "r452",
      "r453",
      "r457",
      "r458",
      "r491",
      "r492",
      "r495",
      "r499",
      "r506",
      "r673",
      "r816",
      "r882",
      "r901",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r31",
      "r143",
      "r273",
      "r315",
      "r316",
      "r317",
      "r340",
      "r341",
      "r342",
      "r345",
      "r353",
      "r355",
      "r371",
      "r414",
      "r507",
      "r587",
      "r588",
      "r589",
      "r617",
      "r618",
      "r660",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r718",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r371",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r10",
      "r11",
      "r143",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r11",
      "r143",
      "r150",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r10",
      "r11",
      "r150",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, additional authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount available for stock repurchases under a board approved stock repurchase plan"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r10",
      "r11",
      "r143",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Repurchases of common stock, Shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r10",
      "r11",
      "r143",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchases of common stock",
        "terseLabel": "Stock Repurchased and Retired During Period, Value"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r10",
      "r11",
      "r143",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchases, Shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r10",
      "r11",
      "r143",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Stock repurchases"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r14",
      "r15",
      "r87",
      "r868",
      "r903",
      "r919",
      "r962"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r151",
      "r326",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Stockholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r704",
      "r867"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r167",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards available to reduce income taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardValuationAllowance": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Tax Credit Carryforward, Valuation Allowance",
        "terseLabel": "Tax credit carryforwards, valuation allowance"
       }
      }
     },
     "localname": "TaxCreditCarryforwardValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r403",
      "r404",
      "r484",
      "r504",
      "r650",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r915",
      "r916",
      "r917",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. Treasury bills"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r843",
      "r857",
      "r859",
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "verboseLabel": "U.S. Treasury notes"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r593",
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r601"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties associated with unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties related to unrecognized tax benefits recognized in income tax provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r601"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Reductions for expiration of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r334",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Additions charged\u00a0to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Other additions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r912"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "verboseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares for diluted EPS",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares (Denominator):",
        "verboseLabel": "Shares used in the calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r357",
      "r364"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares for basic EPS",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 22
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(3)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f,g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r872": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r873": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r874": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r875": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r876": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r877": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r878": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r879": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r881": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>151
<FILENAME>0000318154-23-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000318154-23-000017-xbrl.zip
M4$L#!!0    ( $Z#259?7(46PQH& /E(0P 1    86UG;BTR,#(R,3(S,2YH
M=&WLO6N;4T>N-OQ]_XJ\>;\^/:F#ZJ!<,WDN B&;V0$R@4R&?)E+4JG I-MF
MN[L)Y-<_JCYPR,  $W?;:W5#B _+7K;7?9=T2Z52_?G_OCC8_^RYK@\7J^5?
M/O=_<I]_]G^_^O/_M[?WCZ]_^.ZS6RLY/M#ET6<WUTI'VC[[=7'TY+.?FA[^
M\EE?KPX^^VFU_F7QG/;V3MYS<_7LY7KQ^,G19\&%^+N#ZR]!:\@YN+TN2?9
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MO;C_\!?WZ.".N__P;W#OM[__8J]]>O>WO[WX^>F-7W^^7=UWX>>7CWZ2?/?
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MP9GXPQ/R^&OR[!QY-,;2..0]%LH6OE/=0RIN+Z,A6ES+'&DJY/EN0;S8'X'
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ME37E@7LAY6*41#Q8M.R: Y\+9;58N9EH3!)RA#E"L]58>8/0.8N\M%(+!%
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MCS^*W91\P,E&UY>>4O"<(;0@+8Y&(ID#(4/TF*AW+C-H-3;?,>X4,'%HGFH
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M'J\7AVTA$TJ?%880BR\]9@&7"FJK40H5'SFSD^DC=-%^\4)@B>;?.D4G)7E
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MN 41HTJ&J^A$DVCNXB7ZMV"*'VX!TT9B)7*KP%A45EB(UGD'T@5K02:OLVW
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MLCB$2.6T3TYIK2,Y&VN3L8H(,F+9PTZL3)>WKQ6-EB];K'RMD[P3!(Y2.0H
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MN7&0]9Z+E'?.S)@T*F>?((8,/B)F@3YSQ3)9580T&S<['S=;RW&SMQ\WNZ"
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M\7WCK0%CE9?">P&>33N"L18CS<,(6]QR1U1.B^BMMP)*]T>E8Q(@I!0.+6_
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MIK5C@C"AL_'2,D&>.N6((GE5_Z;$+286W808N8<H?; Q4@ <F0L\9#3D[HG
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M@*FYV*Z(G"3X8/K]YW^77J7QDA[C/^4ICF8/L5L]0R,MUG>MSOOS]QQE-%I
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MF*V*H8.FF8"9J.9Y@RH]]>D9OUHE=7?;L]XNQOBBPYS*^9K/E#$*S5+I91-
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M>W5')&<$R5]?4%RW>TR6YK>=R@31!\_F[Z_DASN;CP]>''=F86&I^&O-TLJ
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MQH4<A9UZX&H%6<^^\(9/-0FKNUW 51W:W/YZH&856<OGB_.ZL%%8AB-C%<B
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MRHD3*HT?"5\-/=670:+E0U(1E@!-*ZBAG6N%5L,EF!$8GC[W>&VJY*D,F<T
M@/'I^Z&GQ@*F P7U"#N"!LV5J(MZE#7KX-2T;:K8@5WT3K_4)N%)"[S2!U@H
MWM)[P_&3&K @<3Q 6C;@%'6ZYF'(5S\R6&[#6!?W+"]ZM:D-37LY]8;8Y?]"
MA$HW#'5A#^OPY"UM__GR4QE=,P&V?I+GE?@R;3?*Z(YI,6QJ1!?U_"[.OM:%
MAVK\O*H&JTE=JD,JR$\NSOZH#>L4$5W8<ZNTURB9BWI*%Y=?:Y-RCQBII8,W
MGD:Q<JY9$LBX)A4A%60@E^18>MKEO%7<;@S*)=>NO=KL7"F=%2A_D@$/',F]
M[*XS=OR@DH0EP-P*,IK+PZ>5BU1PJW1#WZ5P$@U6$0R+!M+A=V?$@V']KC^O
M(M?Y7*^&)9'PX,MA*[T&W?0H<;',GHQY>5,3XZF"O":2%Z>U:==L:O#HLJ6!
MH/#HPS:_!*A90;9R>?:I-AGY).W!ACJ#107X?:J>(HXVJ?F+>W!7(/)47ZJZ
ML-!TOTT_DH4^)C(AKK3@4:)KTVITQLWFCP#!$B!J!?G)U\OSJ[.Z,$]"T',0
MYX"<:"-=:>X*GVOJVURW^Y:6YH+YKU<?G\-AEP8.2:"%HX8!O.*RF']/2_B6
M$:L7;\$-$!H@-$!H@-  H0%" X0&" T0&B#,"0CO8][W!/SKRIM?_QO^D[YA
MS86-;GM[$TR*4$424WX_8#4:1@GW;J4;CZPY47S1&D=K^2N\#U92$M_]2L%2
M<@1&?-[>*NK2[?129@80P:/XWY%.EQ/RH5CM:\&O5_D 5ON!>[=\'/WROK0I
M7P:K$T"<W+_9Y:__W=?PZHR)BZ-Q/80!+7!WPOCU0$0C?I Q'(CS *"=:X57
MI$?E#=RW]*)E_%<2Q7(P-E_)P(7C_]#MMC=?<X/W;N=J)%A?H\<GX#BL&C"5
M:!;:7;;H+U=X0 )ZC 5PE(V$SSO88D0&$V]@\U!7NCRV3\4PFV8\BI0C.:;B
M42!>.G8ZK@4;PM@!6.2>NFT_$*KK!"^BY9P.R5<!</-X&(D/Z8>]E!?(@'9/
M+^V5AT-DG7!7T &9GW,\;J\97+:LU,YL?V[33RE3*OW6W6EWUG?O_'FMW;GS
MM_N&W=IM;VW=_6IQV)]YPE[0T?,ZS1MV)K!Y^XX0D/8?XO!:DNT>B,C1,HPG
M,ZZ>Z?>,5;B00'EHL;G#0QYSG_=?P/>Y-+!@*P.E?:&],>N=?&:=K;5WS\.9
MIP4YY@L-Z:L;.7S#F$ZVW4S]F?.>7W0)6ZBX_'0-,Y1II*K5]?8,N=OGD< !
M?OGU7__H;&_LO<JZ'P@ZMB*T"!(@GE6NE'@WH;.^8<!^OE1S\OGPV]'56^:,
M+@#93&RZ2G2SL['3W6/SI)P5[L*R?"2=%Z&:*LJ:D]^?3C65%383FZX<U<Q7
MW.14L\KA*&LK<#0/1!362]Z4]UPEPIF_FN9RW1>A$K$,&/<&O+8R)XG5E4J<
M4;V$SN2NJTH\=6/SWR[/CFMF592V7%4\G0^3E\' D]\E*4??O_]=5Q[_\?CH
M=/_/-TU,GC_=3&ZZH9S'4$X?ON1QXJNGF>.5*&F9*TWN*^WQ0#WD)I#ED663
MFVYH\E'2[(;W-8<3?QFW<@4%V>& WW!/)-?6:)N'0%N$?4\$YC9WN\\,S%60
M@1[Z4BOW^4';JNYY @<VNMOU"\X>GGZ\.'Q:Y^:JJK6'01\$5R- GQ2:C7D@
M-+:_KJN;W! ,.Y&!K)7B.6/?526=NJE\YV>?#T_KQ>)+6ZXJGLZ)Q;]T2*>*
M3/[;X>G1U9_U8O#E/3=$\QBBT<I7D?IAD@C^_GM85_?"T<GQGY^/WK(QY_P)
M9V+/#>$\AG"P ,A76)["/#X2.N1:A#?"J:OD^=([_?WH].JH5J)G<M,-"3V*
MA#2/XL3*GB"(ZBI[OOQY?G%V?/2T:W.J*GPF-]V0SF-(Q^%Z(+T?RI<ODS%=
M08%S_/6D]^6B=_D>/OR)'VHE>=+=-^3S!/)YSR9QIDK@6X#,\TC%"H3W"S&?
M"HKLDV^]RZ>INE65UZ4=5XE<YLYM5OKBACO2ZKFWM[65V*<B\4#C?UKJ1E4%
M]>2F&])Y#.F$8@AZ[A -1>G75=B<'GZM7R1L<M,-W3R&;EZ8:*HH;$+O8;=-
M+)&H*6VY(9A'QL%DZ*DZBYDS+P233O.'7,>V7!N>R*?<V7UNLYL*\LNS(-1/
MN_NEJNRRM..J<LNZ\2CMBDA<RZ<F?E=[RQ-\:KNS44,^%8L?7KU<".4M5Y53
MS4>OXZ$6,#"80G55Z\ZYCGA?WM3*>S"YZ89H'E<L(3Q8FR-BZ=:VC]VY5IZL
MEZ I;[FAF4<U%1*!BNK<P>Y"A#P>S:4N=VX$,['GAF(>)65N8"KGQ4BF@B+F
MXJCW\;1>&;/E+3<$\R@?M8P3V]%(Z^^UE3/*@6,+/'*(U,4)5-KT1/7_9J=^
M7J +]4/V^2")PJ<W ZG^MB=[@6S7L$G_I0@B&7+]_D3Z\$^]],]T\XT\?3SL
M)A&F2K!;@!1@1P;<^(CJJKU?)EKL>]*YKI4"/[7K*M%-C2.G5UQ[S^B85>D=
M3\9--Y_;+ZN"W.JJ]^WT\*Q>15(3>ZXJIYI3Y/2&.PIF?E<]\+&Z\OC#_UR>
M'UT<ULH&FMQT==#44/E\;UZ*Q0\1"H]JD\3U=6TOD?DFG%CVY?=:R<?)35>-
M=.9<F\0#&2<O?FO9XM\V^T (_?OSX;=GW6?V*I"8&[&5P-%0VLOF5KRG>[K3
M[RM[O7IZ6SS38H"7B3K"93)@\4CB5Z'2,7SF,=V#'J@8?G.\Q$T?$HSWU8U@
MGHS,(['FK@ (7--%[>9N=2VB$-D^/*=N Z&C-KL:B3$]W[O!DK%@7DC:K2:2
MTLFUV+Z* '_&<Q.FU8;>0>_B/[WCPW\WT'L*] [_/#Z<FVRI-N@^)5XXDO-+
MKZ\V]'XS/=4;F?%$\'T].;IH"/=)L#L_.^D=_WEYU4#O\=![?W1R>O;MZ*"!
MW9,P[Z)W_/7PM,&\)T+O;/_BJ '>4X%WTMN?WXWI58;>^XO#;V?'O8.Y10J>
M [QY9OQ8W+L0/BS.G5N#D2KC'D#O\-OQT4DC<I\(O:/3;V?_V\#N2;##L@'>
M6&A/$1DGO'\U$O-+$JTR\%KL\GJLY8^Y7;M5<>"='1]=S*\_>L6!=W5XW&L\
M*T\#WA7WXA\-Z)X$.GBQKX)*ZLAD8K3F"3]VI84_&#?2]DFX]_7@\/3/_8;G
M/0EXWPZ/]ROJ&I@W\!@/7/9OX?W%@T9J/ %^[7)22R%YQ3ZVT6UOXQZF-W@K
MW7ADTV2*+]ITE[7\%=Z/E)?$=[]22(MQ1! +/:<4F$*C*I/C4_@O+E>Z__.+
M'.RL;6ZN[>ZZG=W=C7Y_8W=C9WO3W>@XZQN=P=J:^W^=]5_2ET8ZW4+(AV*U
MKP6_7N4#V.$'[MWR<?3+^W+&D Q6)P _"3,#F5__NZ_AU1FKO3/_:*.<?_1&
M@-Z>G6O4N[AB1].X]T  ;_WRT]VNPSKL-TB))JV*$K5R/*4,/]BRQ\-(?$@_
M[+DR"CT^_H E[[!P>FFO//H,JB;0FI_MF>WNMG<VU_'8;":FG=B>:)M.-,U-
M+/T&+^[<_>M:NW/G;_>-NK/=WNT^;-B?Y(\^,O\1#N#M\<S<,AD+'YCLUMI>
M)^=T=V>#5F9?'[]>'IT>7I8KJI8I&;'G#T7 C@*GS59,HB&<"Y-QQ**D'TE7
M<BU%U#*YBEJX+%:,1PP,B6YW;8_>;M$?G;WT2\Q1W%<^;&8\^=.MF/Q&)3K]
M1NGTRR2RW[UC,F*<]:6*A3,* ";#,> 3C8W_^C*.S9J2P%/.-:X=IP_A^2"6
MW,.42'B;WAO !"&(5/@%=S> #>'S ZU\AM!32<2DYP4BB@"^_3$#_N2H&WJJ
MQ5QQ(SP5TF> >C+@3IS0 *@9N:!HF">9# )U0Y*;C1)X$A>D>2@2P&C*P\0M
MA:%6W!FQO@!<H<F2B!:O@%B8)Z\%X^X-I]Q0,PI>0HHCF,UJ#JNAK2(T//$=
M% !!":"P: %Z#ZTJ 03348P?\=$!_,U]V#[WZ%$SL 7/W0I*%1%ZH)P$3U$%
MF//*S7;A*0")+V+F"Q?9"PL$P!?!X\'I:M <(D)]\3U$!@10!&!'L<:S1.PA
M[0H4K<@DZ$H?3A&/67 O'C&5Q' 8, 0AA.8^)Q[FC;,'0Z'@K!"W.]M[>,PW
M C"B-X'?(<P@A&XQLY41K'ZHU6V B^D+V)*PB;[L5FG/S8<3W! OG$(HZ"AF
M4@[1,XX*@'%&   X!8]V!<-F!,(I63^?AG8%J)O3 1!F*$/2L/%-@BE\CMBM
M!&B0"L9!]<J)\6X46WR$N@5X 7]4.E2:QR89>Q]6#&@12(Y_=79WU@A(?>$
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M?<S/L A*W]$I3RGO"H?F,54!4&XT>J>Z0-VS*12],["CSIIYX-Z]3/#..\^
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M=30AF(28$*]EK$S_B+S\Y7?@34&+[8^0J^7U+R"88XH=]R+)]]@Q*@JL!\L
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MY;"^IYQKH5MW]W':YP%W>=N.1$T-/9X$SL@T?^KL[NZDG8_H,G?3B1';RLJ
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MQOX)B1JZG\A%XQ/O)A">!T@-<_@2KW_E1"K8P-9:<=?2#<0XOZE^_\L!82O
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MO1-W+7^%]\$42N*[7YD"WDN#J;/V,SAUJ7'J!&X5_CO2.2<>BM4^D-#U*A_
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MV0A^\\845Z2-WB#YW4BM L/>>PPTQS[0)L@ D!I HOI:E)SP1EZDOGETR8/
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MO[=$X'R=[O8/;C,R$CJ)\ [I2X<N19[P(38:9Z-QSEOC_)1XX4AZ#\\M6$C
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M!6[M 'X(/2?.O#N1 5/X[TCGJMA0K/:UX->K? !K_<"]6SZ.?GE?%DD@CR9
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MG@_&4RIG8*K43HW0]&VS3XG&-Q")6\Q-=&:;<%CG /CI6' 4AF2LSEH01C
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MFAYT.2\>D55"/.6B1\HM:*61,+$1X"(W4BM#8<;K#SQ]' "C<UJ95[OG^C(
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MK%?H?<3@VVEM_FG_\3K-:G+=9O_,"GY?ONAU]W8+RBAY1>1K'?:K5YLOGKS
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M1P*T$JF3C$#L\^[]*KAW;07])?Q8TJ5(GH_K%$[BJ:O0!\62'TH2<2P!A3B
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M0C^#0R"D[K3UNCHM]"GB);0^6;).0MZ=26NM3+<R"O:2/[K%IUA5W?UT5GD
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MCRH)MDGP"S,QDM@U.I06'(IFY!E22WEPFN3F'+^1,U1LSJY9L7B6!H%YN8@
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M(=(/6YMVZ\5:7&1A:%AKQI],80V^P&Z_04' ,K.X8Z"I-=IW[IR-S':\A*>
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M%BR[;IE[T8@>[$19REK?1:HMC7=?N0ZS \((<HX8ROZ'W<?!IIH@ K'AW/&
M]S8T?0..92.EK\)<9["R+=!.CHVDR;@Z[Y.9>5,\.'&T>D2(+[%3&$U3-<R,
M&2ODK ,:7L(,X<YX'T,4>],L-8HT0L/ZY5Q3&0LJ5R6'V:]3-WFNZDC3JVK\
M=*- <T%<''Q;+P"G[[%3RTS/.HL?=]S3K( 28_GK:09-*'9,;PVW&L'FA4B"
M /G(:-2@KXB6173#U/.I9RL N)X!&2YV9P-YK(][IU'X,@,9E8NUZ),[Z+.@
MY-A^9BEP+K&A%U#KL66AO!3;3P;1:9G'U1\94,)[9355)F_,/HEJJI:M(-3Y
MM53E81A+LF/+;$;ZN(H%'L'L?8 >Y65MK8&LX>JMNF6XIUM99^70F@@&XQ*Z
M"B4[/$V8'5Q'JHAF / 7IW:3,C5B :'1IL9^W1NT4T%9X4TPTP&&B@]Y[J*E
ME@QTS&1&6RIUW7;B#KM&6-ANL+/M&>$'Z<F+8JYP2$M+<(UHK;5N#BS ]^@3
MHA8'1;+).V'1&@CYA\FG=0!@$F\8QTO%T6EHPT37M#?C' BE?35NBQ0SKN*:
MJ!B8  7'T]$UK..YZ(^HUQQU#>DZ7Q]ZK#M/UOGZ6T_:HJV#7>&"\9D-X*C%
M@XHTM78X2ZEB:8T=/1Q#_V!QNN):<P@WX?9JUL;7)TFM@52Z6$?PVM/81]^J
MU29,ZO@],&TM"1%4J36"8D$O^(JUFAT*Y&EM'-<7)2SH<<B<0BECE2H#0\[G
M ()C:1 :,9W/&15%IT4237,V^>74;2JNHU&L@TEB;A00=/;U&"TU=Z1JNOM8
MDB9 GK5 K=7XDH(X0N*301> _)-/8?O@I9@8"9 8'*VU,]CAQE8WP1X?M72.
MY, 3WK7DX*R<&#B-I C>(C)XOCT>W2%0.6Z4U9\DA%JH'<RI 19Q3D2R9<J'
M93*30&SGL.B:YZ&?^CA(\C%8P3HM=),\GB+"-ISYD-A@P4L&=_8?2FG( L-D
M@ROS4;AB8]&/ QXS3&3!YWJAT1/)]@7/X/P6@@OLS+D*B;*R #8Q(" XM#%5
M;C.I ++@T,<#V]H=06_X_=U6[P.+N1C37  E1P)H(1=6.B V<.I-2"S*$M;9
M0ZXX PP"$I<C9\07<8CDVN"G A71?5 ]5Z$7(W>=]_*B&!;DM6N\N47O.6YX
MQ-4"RUH;Y=0TB+8Q_38$]3BN7#'/PM14,!=R MAZ]G:!Y\&>9U;5^&T^"B".
M#OS<\SYX0E7]<^4*9R6*[HSZQ,/,-2GQI #.= ^'[W(8FM9UC[?D$ZZ*26U7
M5$FJZQ&4=+0=9\8)=5HFK6>)<.Z$JJP@X,?&GJW"#\?W"*=<Z.^RBG63[A26
M5[^EY1F 6:VG:7#'Q^P/V0 A:S0D7Z9PU.A9$GQDBUJ22!B8DH+0Z5<59F9+
ME'+GDOE4-',.U&;I*X:OQE5Z5DA8LLB6"-=9J]CLDC@HN2QS%QZ[C3!,-^SL
M;/FN)%F38M'&Z8B6M8OH^E&6-Y+:L&O(XPQT$\A#0HMG=P(\(7[U6+2K("*Z
M(W,6EG-+ L,*P4$GC<&T&-VKWOR1:/$2\Z?^<JMKF7_X;:RP;HTU!W\S"]W@
MJ I\,OO!4N<UK&$(XC "XTB%Z$)S-2&>J(-;P1[' 2VYRD7AD^TG?!N1/[*-
M[1CI@A2:O(-8#<Y> ::(P&6:3JF,'F&L3F0I"I.Q2 OF3:(NBNZ$1&Q&/Y,/
MR%5/[10(=X652$=/-9EX'F?RM&ZR@?<B*^C(E8QVG7W1G<9!6P=+Y#S8UH$,
MV]&[#$ @P&G/0[A:6OR9(1*I/;HY,JH2R#T+;*Y YI(#8*.>A&CBF0,]?G%O
M%=?[.OU][X_#L.<EDPUAFROI9!)(E/,RXSF=SX/]/_;>=;F-(]D6?A7$B?.=
MD"*:&DN>\<QL19P(FI)M[;$L!2G;L<^_!M @VP+0F.X&*<S3?Y4K+Y55W0!)
M>W0AA_O''ID ^E*7K+RL7,N5:Y,FTIC&(A,('P)H@;#=PS)"HPNR1\C%)Z(S
M<HJ[,G":CC$N"$SBH+0TW?:459;D?WX[*I=J]8>/O9BR*7*3L=CBG:B"W/$9
M19Y.7K&LC=5I:"=>A,6)8J+Z.-)@AT>IN+.)H.'N)78X';6ID0U\B>P_@0=1
M ];A6-;3EKH[.+D7NU427H[KY@?;0?R9/+Q/GXLJT?G1<UTY$*#/ ^=.M^?@
M2>\L)F#TF9,*\<<ZF.[)=G\1XEGHBCH@I<NP6L3>99RZ,4*+#8H(P(++MT*A
MN'$&.VOU%)?'=3GJY?@:L2#C<4KQ(KGV(%T%1X!H(RX(/:G+!Z%((0LDCXP,
MN^%*/^J8-5MN1#O0%J$7+&*)2:E&8Z01"T<Y43 !C%*MK-AH5L27S_!_,"C<
MV8U8,0*DV#-L?.PYEA$9K?W\G7T6=59XGD3_CGI@M.!0AHOMN#0TNM\B$:LK
M47@XO6]3V><2*=/@Y'C3UAQ:G%6;OE(4!E=1TF>-:PIK:!^&)EE1"C+"N.E'
M0'UM*FE'*MA9\D_JBMRQS.]\=2$=63<:2*1H"KFB.4+JICJDQC:VL0.-DYPN
M$D'0 I 14(ZY(5P#)00M'C"087"YAHH'@OGNFP29/;P%]1'96:]K?:SOW_&8
M)B@].O*8.0,T.=4\VV_NY_P %M7*DQ32)4^=R-0N@O'F@Q]?H&,/1P.Y*G1"
MX*3'H!G/%K>(^3#,:L6W\_H.'!!)-]>5ZS=(J]ZC-"^4PPOG2 TV$247H#:
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MMX<>=0P#2*\X 35WBRJF LA$TF;0<\E,_E[A'2L*?!8DS".9 HG??3])0MH
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M$V 58S<!R298AL22B8,+$N C\@(2TAL<TV2L@@=IM #1NF*#.UJ\-&,YS+F
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MIOQ@RW#*W9Y-A]2AW3RWY/3N3CR/..:V<I@[?H5!Y3A-)S9M$NHZ=^')Y.2
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M[7Z2T+RZJ&!+XZGCM0A*A2+.XX6O%*(IE8&(LV.F\CD'R_R'[+BU"6C:^AQ
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M66J<L'??0OJOR>O9/\)*" OH1,0'8'F/20Z)8Z]OJS980/\Q!O($N=QPAQ^
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M_.KV.SJ C[1C=7R[JC78:=#,1?[.VNQJ84GF6BU8.8FDGO'V#H.I0(V,YNV
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M0*%P@.94RLE1(H+AFH1_$A/FKY']J)PLPCZ\JBIB?39%0^+OA"K+5\F2(G7
M;(6S<@M"U3(\&[3'H.TA]Z%AHER,1;!^$[S49? 6/SDV97J'#R6 &R^Y!^Z&
M'+/PS5W&+'RF05N2QB($@:I_;EFD#1(OR/Z NND2K1'S:A:^DIRP+,B*;M,M
M]4^2(DE+->:XW;$GSJK@8HL:\+-GQ<#\(D$_-[GI>;DB/459X7P=LY0@_\*1
MLVA+3=-4V@XK.G+,&@K1NIK$ ]O*MJ$]*<E 0WA&' [.F$*$Y *E,K9Z@N(D
MU3TRDO,Z'&%D'_-4R;X424\$\:)[%!_+N\N28TR@_/1(->B;U\E@2K*1,+R]
MXTOKF9+>'2%:S^$L(+<T)ZQLTDI&_W06D NW6]8)74VJ#^& [231F3@6 J,@
MTT^Y06\4+6VN!P;C,X[0^!S/U*;5L74Y2FI9YC-MNZ:#!=3<E.@B*;\6,_<X
MRU4U8'R.47PZ$9F$L]/CIHCTY,TOKUX</?W[!,U7I#M%;HA#RH[.EB<E7>=K
M/1QG82'22<&G  LK-&T>_6&YS2<ON7@37N5-2]EEF3)-_2Z;V7OH8%-_M25]
M.=,9%1N2<!0ZATCW"K,N0K+UWK1L21XBG7D0(N\ !^^X/XR%<^F5=:!R^/E\
M:X_:;<G3H ?E(["4B1-L37!+*#)6+)+ BVN6M45#HL]!)\42.BQ-8YR2CF$_
M=PSUE@Z@5VL1#D*)YL=F?4[+A>HE9C>.!3=#%W_TZL?CQYKY]!--.KUM_=XZ
M);E7;A:,-VDKB$BOP://@K'^[VWX?V\)Y?#_B,X);D<%"=]@QG9AF9FMZ\33
MH3>"V>/UD?L4_-?APM3NQ?#H^I"\ VBQDI86^3\BI14^QT2OQPQHN21KN(O9
MZ_F$Y$:;5=CBWU;AE%JS]@OA^;_AIW%++5O%\VI1\N@)S!\H@V >__=?GTVF
M)(#'7B'5<B0 X$55Q(#A)$P78_$I%S\?.$5O5 &B"".H93#V#E_BP</HG)DU
M/)[U.K,5V<AEW5U0>L=5[:*DQ+0I6\XD)6[<,?P^AI.A)>B\Z6N?:I\VZ[F4
M@WP]@(@:5'Z@[@[<$>U(2#J%(ZNM>%V9JD!74C5 (+*LI$NB='&Y8]A>U%+$
M.PEVKC=DK_TYFZG8F6L6ZID[[+(@W#-](IT_DKDD4QF.1#3P401=</RV/XP8
M"2#(RB]K( SL_-(37L('8N; >@>P1':#VL4H$I4N\DH71JS1%'R@LVQ1T@9O
M;9;^RW:*2265>:*PP;( VN5,Y"C?DS/QT[$G&*.^B:K7\U^+5Y$2R5%@4.$K
M2B A(\J&B605&^U6U13,>VK4YL,REL-]H5(R*_Z9T^BF<.B#/YS221A@AXF_
MA^1G]UF;S.Y.*NSV)2[MAQGWMU%N2+L?2#10%SR0:G-5;=:69I;I7J/Q]^X,
MW4T':F]/^?BHW6JXPME*N1Y2UM(#+//8!VDL7" JRFD[RDF<-*[!W.XYH$C:
M-INVKGIZFEB?T^O=8!A@TR@<$58T&,A9[419<SJ!3N5LAE"XKIFH)MINLB+P
MG >B15MO%&Q=LZ3>5?  (/M%__*8L1S,AFL(E:B]A2JNT\^VX8#+)$M-<\':
M\( 'TE\/VX)T%1FW@CRA3O=9.-9.PG"\_R@&[QO0 5]/B#O(CO7-YK^.P!+\
MG$!8-)>R59'6"Q?X7__WL^IH>3Z<E*4]XU-:3$XKHO8*\08SY123XWI%B@GA
M'Z^_?_G+JW=,.GA,I"K=AIS"+ISV,[^ALNV4 %'3?K)T?XYNYH0'BI?#W(/8
M9@0':\7]^1,.U!8-N4JQMVS..<',2SSEYEFM2H(N37IVW()7&MYU38CH=KOB
M[I#MBN:+_WLY):#@?3';QZO&>E?*#O;%1'0CDE=H%MCIO9V=%([5![VEC_D(
MX]SZ9H%S$12!O^V!5&L@\T"1_\GG3.%S+A%@$H ,S69N*"U.<V&UE;@H)M;X
M;/5F;EJNWU/(,=L]S.JGGM7MVE#.\VJE4"27H@9YPV&K*JP1;%0?IO!33Z'C
ML0#4>1>!NJK(:32T29H8B7$3[72(-44(%A%90OTA*\TQB2?#"D@/$_[)+7$L
MU.DN+=(9*F1NXDREY9,^TB^J9QP]4< +V4>5S.#,%\(28_ P^9]Z\N=U-VLT
M&%)AU#!EV_7[-6IK+5@I>K;IU%G5+I0@Z?J$QH,I_ZR3.]M-*5O=E[/WV*>6
MQV!BJ>[Y;?J\'Z;DWS$EKNZOU+0CD+T+*XP6:?WSLEF&/S>\M18AT'F8PT\_
MATGMOO/>;:H:KK5P8P9<3"ZJ<AF<J0HMW1R#/E(JXG6PP\O)9=UN12E;*WJ=
ML16CXVU=*25\A*^2U]V2Y+2I@&N5_#%=:5!=!$ODP\+YQ OGG+1_%,1#E>ME
M?8]8P7+.PTU;-XH44"X+6Z?D#>JF05^@^(T'RQ^$T-XNQ24E_G(N[1*IR<4(
M-5=._N5KS%I5YLKME0>,C#^CZV*69#UYO'*0<K@3CMGR'!L041%A  2]-P)I
M2[._1!G010B;1E&^OAY[-!]PK1[7^M<'7.NM!\VE:1SIILO8C&S' 4XS[@UF
M3O444I165V*B^#T0=TIQ)*V9)(%"/!+'S ;K&KQ]\_W+GR;GR[+KPI$9+O'8
M6NCCER>J2Q)3B][FN.?E]Q)PEV+;B*-%-+<%HS!C$2BF*D[[:P394$1]7G,0
M)&I&V^]1L^V'O)#27!$?4YY;0*!2HJS.2]54'(>2@,)DEV3>ANV4G(#)>X-N
MW^F<(#)NHOERA\ZY+QS_<H=&\A;CIBDC!M6M*-^T:I95&,E*RI+]4)V"%19T
MQ OE.N%:9@VXI11^B#[XUU2GVXN5C/!X[FN[52*H ? [Z2C;#NCS1W6[B:D#
MMQ#TG8EV.V8P!N(52<M7*C N3DQZ]X]P1QK'L#LHD;]'U&5,,.<PX^CKE#OC
M1<Z=<1I.BM=Z4HS]AK5#G"'4=@V!X(D$UDUPFX_V3+EC;!MIK7S,,A]_I(?:
M]<PSFKF)/0C7KR+/C#.M/+#TH1C]R9-N90@$I/=D7V?\0RKTD\]*4G&:!FM0
MS]JF:<_+$#RR,(1D7EAW0PC3F+V :!4<\7L2N'%#YL.$WOU$ZL,4?IEYU"\U
MA?JP7CZY#3?FM1P9[&%?#Q/SR2<F:AS3P3DK.]ZJDESA?,3#M'SJ:0EQC])\
MBC;60%Z>G*%VNTY"W1J58M!+3UJ+ZW9UM9P_[*U//HG;C>A@YM&$-5(@M_0P
M,9\CHA!1BNC#&%0N;7P9C]H?YNPS6L1FV\]$0DKS/5IU"Q-)I8"'Z?G4T\,L
M))%04CA=$=YIY[-^^C [G]S@78<F>YB13SPC*&A3J[\1;!>*L25XMI+:L2!B
M2^A-L*TQ0\YR*0GH-LU&4R3%=(".>X:.M'J-BW$S?Y0I\1 (86([$I;G:JZ"
M$/:MIDUSVWMJ%$W&^9,KP#U^@+U]\M46.2-!@9\R+)&LJ<N;CC5;<=V)YH^X
M%"*ZAT7!D?*)XJL(6E25PF>#P(4G6!@H_G4F=RJB5V'5@01D4<VK)$/HJ%JZ
MBVT/C@R52WY835\&%NX.*4\=9AI=3*2XW*?0#I/%$ R'"[H)IK;&5\%%,JP,
MYL;S)H5!LOL+RG;.&S2YE[/9MN7:J.9J#@%&L-6A0;&?'3:5WAD@2T::;,/Q
MTXK(N-"N9<- )&QK*V.Z(5!A0'[D)Y-7"\T/2V5U7Y5W,7BUL<J^%/>Y9FO/
M[A!%(]@@IT8_QKH[!AV*4*!,\3S\*EBP0R@B[L09@1!]AP(5*,,:_&]4'JU)
MWX1E\>*O%>*U;,8 23F8\[^WX/A\^F<(2MOU2BJDA,7!=AP]0F24U]HP3U>/
M:ABQ)_[EST(@&@MLX%J-G2;$BJ !F3D1>)ZP3I?+YHJA-@XK@+T&@A]AP K7
M.-ZT]9*>^V_Y<V_H<?'#]-F# S.9EOWL@G,NO]"!-*T_Y"]Q%B+]?U6M8VV-
M4G^S-GA:>+R*JQ;\:M)I$P=A5?5@@@4 ;LV4K+HH@6G#\I9"!>G$!(.""8X;
M20_4<IW!#?8L>^C"]#4O7%G=RP;"F_Q73@1>[+JPG4K1B +[%-^MZL++35E2
MJ-(N7,7D=' L"?4WP*=\5GC9?R0L]F]W&1;[Y9SC;X90;:[X,VG:K0[C%-F3
M@=4/ACO,<0-YZ/.#RF^5(]J)PG[*Q3T77UNY\LAICQ1]_K)"KLQR=3@BA[)P
M"Z))8WA_N,=T6R_#B1F>!6>IP!<A:6@\.D/,NUKJ/;?H+]K*W0/GP6*77ALR
M4:,#CHIR-I1J4MFF0?:TBOX+V/W>5UYF;P2K;T,]K5@^#SR(5_OJD04^A''>
MD+B5Z1Q5'VHD&@>D%3H?8"D1PD21MO,TM>ECF0:XU^KZ)-Z*ZK1@ A)"2%?>
M?S(YVP*AECQSIA(%&G)R4,EGI>>S(=JWHUH[#=&I2FJ.0L LJ+^:7 :.^>C^
M,K.%DUZ[+Q&'1Z*.Q=^*_6X;DID,9W^S)D9.38C[Z/L:89<H6<86ASP<:L;I
M?I=%'%@[[-%Q:P0'D0AQA8;VBB.KF]UL2%]WV.C"4;FLFZ6XSN?2>Z3,U;1D
M*0HA<S=KVE8X1,N8POB32?1=E2VX8Y=5WVM<1GO(>NEIZW6$(&61M<OF?25^
M$'51N51(^,=%\$BQ*[:"2\NHI,9!_]A&F1(0+"1O&9[P]GW5>RI-ICGC848L
MJ#'9S<;[\  SOP3'J&$'42-7#SIM0@O#&'Q9/)?D# A@:!0D/A!4"8>:ZC4W
M2VY="9MO[ !_\ED)TV":I=G,#'%4-S<OPQ7+7-2L86;P.%9UCX"]:=/3D+R.
M@A=\+3*98_AQ4=LP(GG7=.>%L@M/,.#L4*^;+4$'=<3=+ ?US:W2K2Q%YF]Y
MWVHL(QKM&2E "SUW&$#V;^J;[2YV)@\ZC5$NO+PLZR4?DQ18R]DX+;LZ.0K%
M.;J52;UFB[.WTL:\2M)B8 ?]O^6%J0CB.'4=,84WA\J=S&S^'R_),TCA>$_J
MVG1.RB5_5;D$1,:Q3!F8E2NH#/M85.!<SI,593R2U F'JGB]'YMMW5T&-ZHJ
M)O\@"?+9^]B ^_,:A)UGO<&"PB^^#9YS60131%XK)428\_3EEHI-S-),^UVY
M$J%<P/^^:MKE/ K0J(.R:N)7PJ*MENJBQ [;/*^196=N>F][_$$+B>P0F=>D
MV>AW]7G8# ^D8:GGJ4/V1&:A&&R(^!5G<D0 :,\ >?DI>4,3XW7,HVZU&&FV
M]%>[DDO=BJ-6!G<#YT9A2R)/P>7I)JS)X"LW*]>G8H)6@Y[&2.0>PL"&[CY.
M]R\IY3V_'ZI4@3S<51Q$*WF'$+.\/TWX[RXHUQB;V3'*R^J<..![E?DNYROJ
MF2>:/?H3586;CMS!KJK>2_@4II_2F9<D+JS:">CM2GU-53=+#$-DZ^]Q?)\W
M[#N@ 'T)\!KO*R:X3W72_)6R/'188<?;<TJ%?%,X&1&E+0HV,[X7%1)81B1,
M0J8D$E;TB@7KITW#\>4\K,_.]15J,;SK)*D+:J/Z_V?O6YO;1G*U_PHK[^ZI
MS"E:T=62DMVI\CA.UCN)G6-G,F?.ERV*;$G<4*26%SN>7_\"Z&Y>=+%%^2)*
MQ%2-8TN\=*,!-(#& Q"00%<YHEJLX(W %B?+FY'=H!N/N?X<]7SLQAZ\B\[@
MFN\6!P)O.?,C2<JS]%V?LW=]5N\Z7?6N4_VN<_DN-$,^8R>9E;2D(;3>+>PL
M>.*4YP_-#* @TV"M=CE4 PK98D&@;M)]+[ZA6X;QXI,Q;,*A<DOF20C^-G5<
MT>84LI J:""95/I,\ZD5SBR;PLA$NPGVBZ!X2*'$/VZ=&.]>P2FR]]OM4_;I
M747&O&+<I+6?^>*->Y506%&DZBV2N9VN,6E]V0!)AXFTC9H=D$>&\"U;!:?0
M/9*6:_XA11-?.;UY(*)<7Y_AXYNXE87YYZR&^_<YJF"@,W_0%P*.%K(<=/KI
M&-9FZHH;[>,+_\8- UIERP.3-$@K4\OEE]E"Y,O D_:)[ \VF@VREI28I@3_
MWE(52T5O1:!T*? ,TB_2B_8LZM+CHC-%5A$1$".-OFH(AF+L8ZCY&@/:JA=.
M7F_(;*H;:@Z967*Y-D[JU)9BO5AL!BUPFRK)H&6F(_QI#8]<B!]_IVOI2GSL
MV?5'$#:43P)BGX^7/TT=)SI:EPD+46[LJG6,>F&AD[TJ!$HZ!^%4I%E&&YSO
MA0*V+&5JYIG?-+!RPHPR%.0$R&E"O\46A\*,EVH%@ @(*7=1SIT%+QVG?BM&
MD:L.4QQU]AJEZX=FE7:+:9.6K:)T.(8>J7P4O%S%=QQLJ>1()PL;HH6X*VE+
M'3.HL+2!\NW4'U&!C['(OR,30,,;<4><':-/+6Z+H9-Q:,T$=695G<K#>4#-
M<U(1HLT,?-V"@LJFILY%(CH3.D+S1XG-+#VJ'H6!Y:"O'80.HGN%H[?-K+23
MTJ'Y4QZ0+?3WLMHW\O0$(R$>-0@2^2]A"*IAA-886>S<5(N8AM'U>4-^.CGY
MRWMA.# M>KF\'&SU%46*]Y>E4#[0S2)(D0ZHZ<]4T9R;P+M1'BF>BQ1TA/PR
M9S4I:PP70G.';H$82-<@7BCJA7L]^?Q4>0(W>GFW<OEDF)1"8!(&EJVK'H@\
M.$0/6K.,W/VQRV:4#ZCY"=AJ:.&';O2]H$II'M),65T#/E/1"^HKK2->6"!S
ML:A.*.PP<6-3QW75$.5HP<&4N@VY''C<5KW;E""G&9*+:!"/H*_2CD(SVJ>Z
M'-1%"^A(6K@@">8B")8<9 *O8T_+X#:>ZM4J&!)93@HG1^23(X;[G!RQ(Z)9
M-DB57&EIF9/HYQIOJCV+Q"E+/#?3#:H@%%(.5#A.)Y.K',=4W9HI:MNVPA$Z
M+M1%D,3!B@L564A,%M/69G.+Y"7KPQ(XLF,T'G/ETP/!3465H\KU*<O:HKZ"
M.C<5M=]OWS&XJ\T<69UIE;RG_?INQ!2SVW+%S>2PW/2@+M]8$.4^"K)8;L'T
MQ/-!U#KZ!C7C$S_%Q*ST -('9WL1V G6++]=+/J#6QMO>VJKE?37OA9U\<0+
M1FA!>&2UJ@P#M4W(XZOE<.1]%=W6N()[1,^'BGZE@8^%=KN%7KVY^@^84Y!%
MXE8EY9C&U7^!U+][+TWE0HP]C:*8Y#51RJON,$9Z9.'T;D4KSFPP#IVDH!A3
MT1 3+68T-4")S6@R,CJ7KSL2A\%<QIRI(;0^^1E[0>"LR+1M-UO]7!=PV1A7
M*288-O;U#N93;(Y"K<!ER;,@(=P#W=YNHP);Z"-NZG/)!X)5M^3&/644;:&1
M*ODSMRIEY B4D4KXE<H8I  M= SCSJA-L)RB<BZ!63$6$J"%#$M$C01T&D@N
M7*FK)^;:4LA B2UR50F6EEFVO:8.Q7J'&H>$++%IOK?"PG$<K9?J]%@#5Y,.
M<E5Z6[365T=765\,RV:NUB8J>6K5&V^$8HXTYWFA#"=]:^8:Q^O&8;(PX8(<
MY@-X)3:$\M$\.G!+[6(3=DK?T=&0]/;4-J:S#%K ='&E)T"Q$/]NH=$LD, M
M:)=\YO&ZB*0R!:Q"6UF5I>;Z.<\M7S;PN[@K)$:%0FH7U?69.N\6%$A!VJ[A
M$VL>**C".7(61D!T5Q5Y1I=I/K)V\F (Y'WEW=XD'G:J5WGA1?9)67:I_7R.
M^5,IU<Z@@TX.GEVDRZ$8%Z6#"A:30XCMM:6S 0P"]I6M_%>5S2C)M/@^6CZ3
M5F[IJS0!)>,_8"]*"W6R-()<2^'TR"5=<!7 R-@POP<\$!3(]6A640'R L$4
MO%OTPJ+50BE]7A4KI*/Y'8A7];H$__Z41S,K#D0>W-U>_"3F78&9%BK!Y@X:
M,\2[CK[FA%RJKF+G<.E";-)*6J7FTG:S(G-EETEGM!S58M']*N3[[ 9\?R61
M/IY=G%V=?#*NSJ]_-3Z<G'Z]O+K>']^D)$=\E.:8 "$*,/<$<Y3<[&ANV8-+
M=&-Z##.@S-YEW9_19%$NQ[*[=RC^W>6R7Y>O0T"F!1K)9DJGHCUL%DXX)VOI
M+\WU] M$<X/<^KE2[FG)SN44(D3_N7,W5F! ]9:0,.FN/F.+@XF*;V,^"U:3
M5O6P,)7%'WMI]SI#@.DU2;/%U$%+OFA]KL-%*";2$B!*>-+TD!]::8<U-:"9
M98=!-O<4+;$4#RZ4_Y4(S!0,[R1R+:A8M<1;)F!!PQQM3"8$KJ1 NIR"M'CH
M8$+UHE 62<;A>N.ZT5[2*N%(D_ 6,QFS?I^()J1DELQ-R4/T4ULUGPDWM^Y4
M"6N"2%L3.O*2 HC)2S*F2,5>7?D8G3&#(Y*E(VU+V=NJUKZ(D5LJ:3*1CX0;
MA<HZE"E[0"(KC3"YLU$"RT-S)8;/D5 &6;,,OR5"FBI[W;7U\57Q@=D22==)
M"69V!.VYWY'T"TZMO,[4^]T8YJN/^G9I<)P42T>L5RVFC,*N8#SD5)D7#^Q9
MA+2KY@O2]2R2,1B!JM:&^3^#$4)N58%2R8/I&*9XNCAUYU&^^$JJ:W[*?",M
MBPJVJ\\&\T70QZ!SG0+/%^>OL63((S#+.VG5D&C3$70V:#/- "3Q G<4SP%N
MU(MR&*V''N/A[;D1N;Z*XV1<+8N(%"%PE"*,::Z"4 :$)$XU3:I&);>C.9;G
M1=V%),0A+;2E?7&(,FU9^F@T759,Q\Z%^O.HAVR-2-5-T*>7,S +1Q?YS//T
MP$7O#^D^N/Y X_7:<KN4Q@E+E(N7$IP]/>>6NYLZTA<ZS)B^1 \FUV&E[+',
M3[E\UHP@N;@5;E^PV?H:_KIH5.2LK>4[9"0J'SJ@/7"Q K$^K)+[I)D'%]!A
MKKF<V4WO(SY>#$P4W+LH7@*0*$KDN%PKW)$@3;VP)TM;J<!0J>IN&&=KC%>I
M2!:W]X7B/H6<]0"WC#2;.ULI5VW*P8A,'$K<=_^3N+2L^1#+*+FC% Y?NN<+
M[5^5U96&"508+],@$@(-LA *=;Q/IEFR(+ZK0YO%$)?*X%B:G]*DN6FFNC4_
M6_UA9LZDQ-4L#T//B("+"M^2 !<.>50<,W_LMQFYI;%'-0Q!1C"; ]'4+Z+%
M3@IQC5L8IO 5*F/]IJH&M<H &%GV]TF(9QA'RA88TW_O7LHRR+D#5'Y'40R%
M@H+S"I$@]R3RXG0V%FZPL-G[N[1K#L5SI.X\KJ]2:_(LAH'O<>"Y@;1;LA0P
M+*J"]4L<F2003:E\W0VPLMX(I2HE*TUA/MPL5P%WS4 6+  -:GEDBD13(51/
M+LW.$3"(+&N2NI)XUD,*5'EPN0,(?.T-HH8+H4E]L&,AGWEJ7-*TD:<X.@4*
M3,/B]H-3BN_R\S:S@TO8QFC^V:XQ]A*L2IO;L$GR3!EI5ED$PN&4H#SO]9J<
M$E2::!*_J,Q9?(:N4TU\F N8FKG##AF[)C:6,@;2FJ1[7UZX4QL%#TG76#RP
M" CJH[32/..;F35D4FQH$EJ.C +()")#FH%XH9=MTTI6%X0T%RW Z' 0YH[>
MLHG1!4=8M^0(DP&"D&"6 B/N&99DW61E(@_9VX$NKZ&W3!D:2=1!E(U>749$
MM)'#B09=H1FN;,CB"_(J-)0/ @[Z4Z2NJ*\"#44%NT=;RS:AE2Q;"<_HE<[>
MI\RE,E,T*5HC.5>?40B%^D76'+E!KJRKK .V@,IR$K1,*3TG1RYRH$)DV404
MLI8H+5=:D!115/(I%#J,SHN5O8^_H4^>;SB7>O]G4AIT,J"E0C#R8)B,UUS1
M!7.Q>D\A[9?Z<**VF-RE)3@L0^]L&$6DQH-J-K(AS9A:$:8QRLSDUY.3 \_F
M,Z)H17"[\O4PY'^K.BL@]%E(QE29=?>2D1Q_7*\D])?0$3K^FW,D\T947CVB
MNO$#S+M.BPZA*950]+M@?-RXELZ?1MRC1=3U!?J]6 T"M >%>709DWP!% S?
M%^*Y,,H;7'X=Q:5@PB:9<+) "#+?'18,R! B$J8F,QLL)R $=KIM9#4?\D1"
M@(QFQ"R%'3O\!*I&T*JY8%:0ZJ*!1WR8K-\PKF4N"H:U52. 0@9F9(U%UL0Y
M;0U0J$6@LEGRG^6:\RZTF-5<@(E0.I?%G=&R*)!("!N7LYC7DE<!"_,MAD12
M+J/4H<P'4CON'NG%\JD)^6(9*J1KR1XH>8- (GS)?M"V 57#QKR^U"0?6S=!
MFHF3;%9KJLK[R-?[";!0/$,G1.8\()63J:S!? Z,CLZF")!85W=++3(I/:AB
M@;VF\",,L4V +C^A4'0+>90"I5*E0S9U_B#%+==E9+A9-%*7S[#F(BP$)5$)
MP!?9$.B)V1F "G^-$U_638B!HT+,8U3'AA192#1N1V=Y91VUBTYO6NN-8-/6
MK:S:FH*HU"I(ZY*4R\CROT<%K43;>I!ZP<4SR14+Y6I>)BLP9UM'^867WC#.
M -^JJ>)@.H2N<$05[V#E9(YF8=PX'NGV2C6W1M+4B$T5O2[4M=6Y+NIT)5\G
M#FFO!HO1@ F&:\F[I\?DSJ5S1S:4H":$JEN"4!XZS9 #>9>.B +&,']=6=@1
MHS@M0E-H0";5/&7(4<%53$_$LAUZ:)@^3\AX(97SNYR#D4.?4K%:Q.!BO%)9
M+;@;>#+]CIZ=A" >A6(=>9A&VAB/,H6R;W!%_A&$[I]XIF2EU107$W?/I4S(
M6G]XJJP"B&N50>$,;57A9R4AQ476%A5&$/UT2\QI463)G!;=)LKY<%A35SW*
M':')9M+(LUDB84;=AG&:]3TK.I6Z](0L1:+.OLEW _'^4VBJ':E]-U>B#V>T
M%))?&-9#1-1'+OK(@IB@^/7Z3%C9XI2>*.TEY2IDP;/G,@-614/PX:[S]U?N
M>-#L]9K#H=,:#KNC47?8'?1[3K=E=[JM<;/I_*O7>[7)B. B%0S4(2NLPW%$
MD+QY)-[J7]YAT29P,MZZ/FV(=-.[XN,PL /D(^=(39(F)[]6,9_AL#'H=3#L
M$X?POZ-?K")"#8H(O8F=Y>_@QL'Z;YN-UMKO[GOJH-\8MC=[[!L:L1PUT 77
MY>^O.J^R8!@5]7_;GO\P6L6UQCK_2Z0)YB^?L$8!-^P[_E__KW7<?-?Z)6->
M-?M]GMAO%U=GUY>?OIV]-ZZ_GGSX8)Q>?OY\=O'UNC!)6L8WQ,!/(K-="FGN
MR!:]"/Q[XC.UC%RWUD>N2ZC/P:LJAKL[K+'KK;';!Z6POUQ=?CF[^GI^]KP:
M>I?!@A,RJ]\+6U 8M].B2FUM<@>"6U^&ZCR5TX1U97_H4%ZKUS1D@S+I?6#8
M(4-JJD1%JET)3EY6J+IP3IS>KC)J9G ]&=P:%Y>V#B%J1V\WM&5!#VE5 MQ#
M?ZX\A7M9305,U6A*)5M65;7ZC4Y[O3[:5E>UVHWN\)@?NV^/'>Y@>Y&L_-1J
M:K"9Y8PXL4]*N;Q]W!8CK;\JS:X 8SJTR9T4BI<>VNQ4&8-#F]8UY1;0W%1T
MZ0 Y\W>P.1 *>G!,^7ZY5OBR_;I^7UA.[[1M(<;C=\I 0HL*:&!0*IZ!LWE7
MB:WD88NW*8_'BO#?D__>8/T?HHGLE%DDRE;D>AIN^AV>[E!DN_U(#XAIP[1A
MVC!M#H,VH7S5H=.M] :O\!O[M(U?PRL_(!@1^[3B-KX5YZB)/TJJFDBK5W5Z
M\;[)0RT6Y7E?O*7F+ QJ6[]CG]12H1_3'SO;Z;=B!G[Q7KWX4+4P6W/UL^9.
MK=DH=!TL'OJ9+3FVY-B28TMNQRKIGXEO!Y&9KTC)@1L.:NT5;=@HKATWL%%\
M,$;Q[PCG^A@*X=^Z]M0TKLYW9@OM&WLP;:I!FP.UH9D;V+]X=!Z*-9M;IO'A
M4_VLPT.5D;U>E -]\4[4T1X:FY<$9Z=$:YMPPT^P2RAPQ&KB[VQ??X91':I"
MX^7DY=R3Y7PR/5\"V*<>HH;501C?0V"_(WG9CM!^::KSD[[\F";^T-M7P+MQ
M78XDV18%RXH$/N#5SQ)7NOQSEQ5\3]/J.%-A.?])K! ;B3$V<6_P<_Q8QB8^
M&03L\G>&)N[EY!B:N(?38FCB/D^,H8GWQ6!^":T_78\S*2H8EF7:5#!RS(O"
MM.%$F,,_FSBU?,NQZI?$L&^\R+1AVE2=-IQ<7PF-/G5]RV"+]5 DDQ>%%X63
M<YY-7;X7/L8Z#W33K*%H,FV8-H<IS&P!;Z;2/XH0GG%WH!M[#463:<.T.4QA
M9BM],Y5^;@O/\IT#W=AK*)I,FP-E6#:!*Z$OP^WU)5L43)O#M+9X49@VG.]2
MZWR7?UKPTOI99?O&BKPHO"CL1NQ<6UX(+%V GL1V-0O8^F#:L"O!B\*T85?B
MX%R):QBH-0_"39"$;$ R;:I#&_9X*K@HM:<-.V4;[CNW;ORG],K8N#X4*>%%
MX47A_*%GTYF_^6XL'.-7Y*=@QH;7H4@HTX9I<YC"S-9PF>+*-LPB#K<MK5S<
M;JM2O/791W6HPLV$8\(QX6I$N%T4J'Z@&'6[O<-:U&<_;"]QP-\9A\',@ W2
M</UQ$,ZHD*IAC8(;85BA,%Z[/QFP&.)&>,$<+L>0DH'_>\**X.]Y"!^'V+$
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MV$M,.Y4XG5EW51_MG8C!X366-\V]V152;[_JI%Z0\CW:"-JK-H*#SSNZM.,
M3<R6<63HWY_YD+_]A'GL36,%A:G(>J6BV*H2J-PJ%XG[9,3 ;XDHFQ.CTD"%
MI\AX8"ZL&1<^[Z)6KJG07YYM'4NLWRXF?FP.^T.S?=PQ!]U!15GZX).6+H(;
M>1: YD/Z1^=YTW;NT]PK"'C0RGDUPSRK_GV&5(1G?0:S2Y79Y=%+L\<[\JHI
M5IOK'K/I/B'O';Q7GIZQX[Z:.W#?M5]>&T6YFF'VQ;NNB@/-[%)9-_B0]]55
M4ZPVUSV!,UL%?W77=CP'[+8A!CN,S&C,:!L\XT7=CC3-_J5YX9^6CYT95(O.
MG/^A:](_R]GN,28^/SBZ=6>[G<:*G-S<V6YG\R2?ESA1RO(+#"=(,"M94RXG
M2RN^W4/-TCXV6]V^.6PV'Q6C?PJ*L47.%OGF?-MM-3KMO7<#63FQ<GJ1R%#9
M5I;J$S(:<;'40X]0R2D8U$-@J:-6YSG04AM8(NWM+9$LW?CE(5Y%(O<:PPY2
M3V7*ZQX^%ACO<Q$:E/:+\#XOP89?-$OA&.+'7/B1N*?Y^O):UV5MVY5;VW,_
M3>J32#WLF/9+8,GV:>_=4,"W(;:VMD-!B=V$>)V!U,>&E<33((01./E>;FLP
M?8A<A3GC()!REF?\I=WH&B/7\^!/YI;[?)+J<(L2=EQH=S:W;&IE=G)]95B3
M4*CNXY1<3'W.XT"#FMW0.4(L (*5=<-RUX>%BA.D3%0 ?%I&C( #?'2[:_8'
M71.&*/4-]4 KM"FCAH .T.R&7FK%Q&4%E86(Y$+'P+^TN^U&<YBIL0/!'[_7
M_>,.!'#\04'5$5P<K4,7$_P8&W80S)BVI_\DP&HBA)5..^HUC-\%[4W LL"6
M-KS;]1&A$, M=ZON,+&'W#1()M."SH.7Q>Y,X>T)?2_[W.5Z]V'7NV3T;_4J
M8KT;8&=0@*NU:\,XR;2BZU,9 4++A^(_B1M*U#]A[MU8S+ L0*$D /;%=/UB
M90!X[Q>8D7'^347N+H)8&*UCTR",NFJ6J>I'&?B:^,[$NV0% 9]B=/3T#ZF\
M7L?P 8GX/K;1S!=!R/8MH+5Q'D4)E6WXC730V0\WHFH-9T05JJ< %HU<D2\>
M#&H3B$7E9.D\QU?6*$AB(\HH8A4IXFJ*2*TL-$4DGZ#^S2@R1XHL\62!&<=A
M,%/L>'YN&M@7V6BU%6,^X;H\3HNO7ZI'=@COO-I04+A#>&T[A!\_LD-XM>9U
M=79]=O7M[/W63;M;#\J>NJV6M9RZ"V<5"X65-E1+QZE:JE(!J YKPGIKPOY!
M:<+/)Q<G'\\^GUU\5;;VM?'^_/KTM^OK\\L+X^3B/?Q_\NF/Z_-KX_*#\>'\
MXN3B]/SDDW%Z>?'^_*N^!O3I;Y^^TB677\ZN3O"+ZZV5:]6]OF)C^,_OJ=[M
MB30Q8^D$HEL516 /JN)0%AJ(X .1O9J6EZ)V?FF-W%$2P:LB\+;RCT3?S'5D
M>W4+W+;YW",?!UYADK,7@0OH.8@.Q]?@2\!W_'?BVV1W8GA#!LWLO-.4!3FB
MU&F2/=UM6Y9GP_'YX)/!<"[A[E!$B1=3=".8"UDL+0*?,K*3**)82C9J]"_G
M< /N07I :-M312P,MWP\.?G2D+-73Q-(.RJ_I:D UO\$A_76F":P8DC'T)I3
M8X&(VLB'5/]-SFWUZ"SR>O4(T:TH$F%DP0KMHZOX(0AOP4<_\H+@NRQ3IM?P
M0.(J7S&6$ IPUF1 (Z#2?TY@)Y)3;P65)"Q6),20B05<-%Y+'5GN =EB9"F6
M -\N1&F2D1?).*8A@!X8BH-?D<EL*U+B =*(81/)7N2D)I%D015ER559E)]K
M?E9_"<\58_DL_!LN!(L&!Y>J = ;R6Q.KV@8YUE &J-')I8[)&)$.'CYQ*GE
MC4TL8@'_?Q?W31^(@W))9R$8+(=!W8)K"SHK?Q6^@O3%;);XL$FIV<*(E3#1
MWT1ZU[\!4F'\G72';WEWD7P/+HJ/A/#@04D849 SE>UX&E+<:B8$>LPX#C$B
M*IO&?(IJ /9&3SX5E8?RT^G#AG&-=1EOP>BBXGI(N';SG5Q D_YJO=.?6C[H
M"W<.<UO\!M8.*;3XL8W*=/'#&(1'+#U;\<+BQW(/6+H8_/_%SX@9;I9&%@FQ
M-"S-D$O73E>-%WAAB1#(54)_B'1-)RP#C>E7*%V>A__>6*&K5A\6+\I1';<=
M%^0>2RK^()9*%6Y^"\1X(RH654ES+6.2/H]$82\*!=46G216"(LH9&!]6<AD
MO',J[I 7 ^\&F 1,*U0#H1M]C[!0H_I QI&033,!RQ2"XX['K@V;" 5<0^&X
M=DPA64=$=NB.A-YG=!71S1]/+&58XS'%6Z=481*$BTJ7KMZX8/0R&J5C42<-
MXPK>9WRP5#SV=ZQ7>9/J,=0_Z\5>:8H5NB:OCO+C3M5C/MAKW5BPXNCW (F*
M#\13#:JZ"9N .F0KK"06;:5!VQ8=IQAW0:)H;\<)GJ1(DLB1:**@2L-UH:JO
MLC"M=R>#=;=X+^P1BON$8^)Q#TS&0:IJG2WC?/=3!RB;E:N-9'E9U),6&N@)
M<CC,]A[BAF("W^"'H ^<!)8XLCS4K/ %W [+=:?K@;KXL0V['?5&BJE$KYHK
M7N[.1J@H\;%F>DIM&F=?KDW#<_^3N X:4*02K3G:"G@S3,[&J^)0'@F@GO&%
MDS\E6#SPQ$&@ASH*PIQN%\2?Q(FPX3MB1G;6V0];S&-4!FFH/SM)'0N'*NCF
MXK2>=1MID33"Q$M7E&BA58G:L>D\Q E(SHF;\;2"] ?Q".Y#([!/)/?!*B1S
MJN^K*W3)PXWU*Y,K"PR&.,BP9#U='EB:%UEA8;*OY7+@-3Y8,CGN-[7N 87M
MXWK)VL0DJWG)T?OSK1O=<VA7RZA0[TFB0L-*1H5>^MQUG4]/E+Z\$>&-"\\Z
M$&] .HHNRN=(=I;UX<T3><Z#2@!-531CR>A(? _TG:X#/0](G<C#>KB;[L/#
M&[ )75(348([#%Y/.PN.,4A KCT/357T?T\67CL'N1-X,N_BIM$:#IJF<F9!
MO1J3,+@E=84V@R^TO@/+R7/2C1?,;]HSD+QS031>.3?:,J:D?BU["A.<R704
MI:?5%"Q*<LM>HXNS.Z"LO&!.):EAU'-*W, [9VC?H"DNS7@2'0M$)B/7<QU5
MO33O8.QB#JN+3H"GMVAIE)Q=_')U]LDTOH2!YUJF<1F+/SWX]W\_GGT[@14%
MNQ/,/=.XF&/BF EV A!\"A?\^L>7J\M/Y[ M7PC8UF#+(8*??3N[./_Z!]DY
MEA<%8$N$WP5LGD9:!%<YLGH8ILI.HS#2MY-KL/>^H7DY<G^8QB^?SB].__AZ
MB1; Y<>S"QC19QC9^5<<FSL+;MR)B69B9(W<&QC4R<4_SR^^PB,^_?;YY->K
MD^LW\,L?^(MI?#W[O^LOYU=G,.*SW]33KL&^ **$;SYCHDPHY_#UY-O%V>5U
MP\#,!FOUH;_T>X,D/P_P60HFJ\)>-(Q?E,NG#E,_$TE@OJ;Q/K\IX[NOP2FU
M48CE1?#+%_7\0V)&F#1PT^0N2TQ$BV<B3Z4S0['@1T5HW4V =7SMF<^!B.2&
M:#M ^]PP39AU>$=<J&)KU,O _4%J4H04];,P6>XM+JMGS;2%$_@VZ9XW4P$?
MT:^F,4(=-A68:@)&#YJZP8T52<OX]>FWG]"XPEB""1;3'-QZ4EZXG+Y(PB"R
M7;2LI>T?^&0?8Q0A@"T*3^#A5C!*44)A)8'@<AI8NC\7[]MXM/1>W==!ZS@*
MHJ15_BWG!MU&Z3.YO@^3D714VM$$_0V++;\%4\*WE 1D<1PDOT?\:>G5A#'"
M+WYDV=I6M1**7BH_2?&S]A#0\!R#TJ$(KJHPF[[23Q]AD\5M_ -3#I2,:&_=
M47%AU!R)3R,-DSF^@R+$KG27Z>6IJI]XP8@\*!U]D7T2W% U1]#M.2Z_G;\_
M:@U3-T J-(H+>VXTE2F6&-"A#"(@7H1I<1YZ>2Y%X.1^DY%&AX[<.5+8D0E'
M%C9."%)7!@86V%:J"^0R41(3S.'L^B/Z)T"U@U$%>9[,%A5773*HU*\I4P)1
M8XS%H)M)2:N=!4<R(J,FO]6HM-;")K.T-<B[M$S0Y#$,ZL&Z8& #I,R;6Y$+
MO$U7GG[3XB[=.EHRWP/A'<DGQ6!MV&!WT%X1NY$6_&Q^:![=*U[9:(%%7'&#
MOWT7=P5_6F6LR4GKS4VKP+/?:'#_M&!9Y>$%+#J^*GN+MHQD[")3NO@X2ME3
MREEE$Z,@*C4+A#T%A1.<PIWA'6S3\J /1H?.%0B79X$XHY"HK50'2_+**U,
MF;&PE@G +-2QMK3["%EMZDWD@J*W*M6,.J_)[I+&C@R/RJ>GN87R"=(.S3]"
M:PC<YX$<G?RB($%^:X"%(&^F]-K/_R2[!)^BL)=TVZ'(JFHKH^255!TL@Y.0
M,H6%Q\TL]1^0/E+3I@J4V'%LV9+0.D\]W<6!'^C.PI+IC<RU,;A#V<:%^%+N
M0>V_FKD-U E!(U.RY4W@)3-! A=3]#4-C8Y GBE8A$$NFD4P'D=88AKN%ZA8
M-%=A$I[GR>B6:ZOL9O64S)CV,2HTMFZ"D,*#.C0B V= 27W,8M\!'ZJF3G3H
MU] FWM*D.G_5XOP;J#[X@)([HPUFNLVTY$EJ]O86O?WJ\O>MW[<=/>16>>]0
M&\97F7LNP\68]*A"A7BC&O_PKX8C<X=!Q*:9$L/XW?F7*SJG?4]G/^((QIQQ
M[@>TA;Z$&,;-:SW:D@T/WN]C@Z,CC:5)YG GJ-"Y=:?.I(U??SW%@<M\YU64
M@><$422/8WWP9%,SP4%3 A/NZ12!Q.U0-,BI%8$$8@\H2>IL\7*;#TDY$/4O
MPT9?PTY,A3A JP[V##I.1RH1M5V_<,*H5%,H@()D@VG;"CT(!!&HI.J"_:=7
M#N4:!YG+$L=#GL70L70,4\LEDQ@<2):C7G@4+GJK^5<<QE]:C6$W!\Y:P$J0
MJ9[FSZ=O08&P"#NQ\&"X_2_M1JNS_HFD]BA6[891K$=(P W:URP_G0-^B,.4
M=V#F!4:"'%.%<BAO'[,<R&&A[2W=NS,"@38^;K1TE"8'"=$GJNG G&Q3T9B0
MR00/$V(TF"):D;\<-SHI *G@QJ"Y >+BD(( 16P+X429&*?YT? 01XSTPX;Z
M83+B_P,Y,)$F_5^:V:OT7:N60V9S^"+++I%L% ;@B9('6["5E.]"8R[ ;BS8
MA%P'])Z-9VUQ!L]1N@8NG8&B +(L72 E0N7%T'*-@C"D9)STZ#FC)?'(H-&3
M$8DMT%Q5UBO%!**\7R7WL[RJD&DTBT='^4,\C!@2Y$/!E&)0S;8,ULP"4%.6
M_#T?5:2S'>WSH?J2FT!LV=\]>1((8N'!QQ,I!F'B2_?0E^P >UJ$:V@GZL!1
M'=?( (%9M-/)_]4A#/=/2S-9SHU/O5UI!>>! -@QTA=C-]:[;/9D[2K)DV 1
MP5I+2QFV:* 2 ;7R>1UP_0SA*N@4)^#R E?IHSG+F68(%]WIDGJ-*".#."D3
M'/*"1!2GYV+JGG11\YH;M&\28F"$Y$FE#ZAS5-H^0^68D;D>(4'P2!LWU#&H
M%$$X24FKI:TE(A6EIX);A@@Q+J)BS%+9H2/A3ZR)<AERFQ?M%B*F/6T2H&N&
MY_\SE%*A3F!AC7&%Y3@)SJ.&J?01S"?P\=%RDQG+J19"CY)!U"1E+%7%!99#
MD,9R]/$?) *G2@2N].DIG],5SNF.UY_35?_(K3JZ6:=HH+T+)G.:]&G-1JX.
M\8U0GFY<L*%1#RE_,IJ#5>R"XR 5!NWV&/I PPIM:)F-1 *6*E>#<JR\&^EE
M*+1I)D)2#F>9(%-D19EM^GG:5&HW6QT2F-8[V/.;R@Y*'5^9]1KB.3@I-64_
MY3(@<'*PSX##JY0B>"AJ\AINF")=@1$,4J(AQ2QO-$C;F@GU8G1XLI"%RF7!
MDQ@931*8&5*D(JBT"/<DI<S,A;A$B^+ :=S5HL@'$A8T,"T5V1[%)^9HKFB'
M5BT\K+\Z8&5;X2A ]RV!/50. LR8A$( MS1BS$1560/XJ"Y8GG(W3:\"A8U;
MH;2KX))^[Z^-9P%</W>]B-?MGXS=(<7!2DK/L3S)#&1TWTHS6:=/D7^ -J:/
M1QZ.]-8I2QID%.:$ JG3/U5B%V8O&I@0YHXQ\<A&=SIT$1PNEU%N?!J&+FV;
M'%L=BA&*AE8F-U%BVS+".I?I1V3LDYQ2'!:3FY00YXR-/-Q9FW^I];=D^8G"
MR4T^#*7/3##8E>8X"47\$#9^F+9*^96'37DS$'/%2%^F9^^D+&= \'0HJ"O2
M-^:T@=*'.MI&*5"!CGKH+S'P(2*=P29R(33XALQE%X/5TG9#R@2AO$[%"C,5
M*TU5'6MN&*<J)J<\S?2JL66+HH:&M2%[$,>0"T'FU=BZ0.1]I\+Y^Y<M-MP!
MW#!+ ,.$7%]M.9AEB@D7+W68K&[^(H<@]]AG?]MI1FF557H3D*,/.STFT8TH
M<*/L4>0<':/+IPZ.$!,MQ6N<9/'@/ LK][>82J+/A-'!FX+@>G=9VFH6Q%AD
ME=QY2V2',%?_CM* K;'0VSJFS%KVG0PRC@B/(:60,N\RYB8V/11U=^42>>21
MN(UBB.&:?"HP^-1V& A8W "C_WCN[2I@028DN!!"'0NE?!3*9VNG4 :%326$
MP3P =4E'?I@3[[E(VT*="%0B.7];G3QEN**38HJC3*14N 9T[T5N5D<JP*(\
M-[.079"^-E)6;*Z<! 6O%!:#>'(&#)6$VD>$-761;<CM=NV\4BK01P:VL#J*
MCH<WC,_ 8')G\,3$C13AA&_IDRVU[>;6AH+C#@65"X^GV47YA-3SJQ-36>R4
M"HLYQ<3,J&C=[VBL+FQ4\CIS@<A8CX(,C5OPV@6>:TAA\9VC!%@.KB1L%:A
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MGT_O(M=V+>QW%:IZW+).=_23B4TTO#OLH2&KO,%HIT%$79)5Z4S8[V:6387
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M7%/\0O8,"T64>#@UX%_='8^F@P-9IB9<A4_9(X0?2_!.)+CU9!+<, Z$V3X
M92S#<2,[B;1T!_XDP)EZL-@3$FB#%AP$$F10\:$)!%$JY/R;.LR^"&)AM(:F
M<1I@I\8)Z"]71*F"<6-4!I&I)1FNHKV<GOP!U(A/"N@ZA@_HRO42K>;0;<O
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M!;<B-$XOOYV_/VH-#<N/W5'@W!G1U*7JD!%AY6"TR=BRXR1$E]B&5T>F,;=
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M$F[F5OYSJU,QTR4UY)B=#!6B);4):27M9^;57411IY2HPK:;QOO@GUG@H3)
MX5AW$E#+0H#I63+8F322<S_T!WGL!@%S.3RBL>;N/DUNJUVK=QY& [N4S+51
ML[O-;6&>;=2:W1_#/-O=3N+9BFRV(IM]!K+9G2<"V7?3D8F>N!&E05^[H8H(
M<.8/WR(J-;JB4_U>\]_L,K^NZ=2;#RN[K[@H*U'>I(EWS/I#F\U7?)1/TX >
M Y/3U>^2BJ!M X]1JVE:]O,0(52L@#^MT%FFU5I7#ZF( =>P!T1"+Z;*"*]U
M&$>7>V"HC:G NN('W&;N+,ML=M?%[(JOK9*Y1^G;#U2V*WUZA<5]_S!PKI2;
M#3PH3MMTFNORMU8:=25TCQ(ZQ[1MN]*HO]L"GT_CP176Z/DB<:7]6C".5*KT
M-JLUCMEJ5:IT)7,_U/UAMNOU9]:FUV5W_$'IGFMFZSTX[KG=:4>GL\3HNZ$;
M#2B/=;#F*E!ZTJ_=FJ,**-UIK@^P*..^8,J7,19DQU3#CL7;HBI.8X)"+],P
MA@=A^OHTAI<&$67EIN[0YW1P>$R$;!(A5A7/< 6-$*OT*2DPS.6*N2#J$QYR
M]I$D2*]JQFGQO2 E=TP/EA52*4XI,>&['+D4UJ")G.'IW81KJ8AQD%8KCOP[
MR941('/.3%!2I51$1[P7Q*##J?%4J)'5&&;OV;M$3C)%XT#-UE.3\TEAW*$[
M(-XSY"L06?:P"6-WJC.7#>((4RN2K$8#PRW&((3_\I-P4(]DXMF@D\P9@EEE
MYHZ<5<P[#=*IKY,J9(<)ZS$F4Q#@;UPB,A#+@*(W0*(F*MOQ_$D8W\D:DMD8
M*SQ]CT^\P(&4^54RLB<8>.0G4I+2 (M^]"H?C8\AQ7*203CS2IC8@BB*KUW.
MZ805'_$QBR@5'I\-RRQ^-+67PS^B5!:0O,@>SG5+S%R"G#5,[I#A!Q?C(F$2
MSP=+-T5"?^).?#AV W7.7YI47WBG,YV:.EL&$=3XD<>G)44%'K\Q2P8C+%G;
ME1HFK#C"-8D\66!+M4>\CZ(\%E=9,I-@13]2N/H@7L2Y(64.OIUJ5DZN_$];
M5I*Z>]:6:BX2OX_U%$-,D<7WB(*'(7YQH+C-AC/B(Z.G#BE;5EPP:KQ23#P_
M#9*2(Q.G8EPT#5&8B+0X3%XLBG?A$^)5]XR=^46N\=)3Y5?ZP1ER]8)^9M0<
M>"$3O(43+:N\_&# ?7#M!J%&UB.RB'&M(OT>1,\@?)SN*9"2:ZP*UE\B6%ST
MV\;46:Y$01@]B@O!*%\_(Y3"W^2^D=N <>SY(5>34UTA4LGY.":M@)!((F,W
M\8B- @9&BR1*CN<DYA4M2G'AW41)11^+Q.5)3[DJ41--VE?^-)6=!:0*$;YJ
M<Z5YROK\?61NB^Y4'8-BJ4I+*J]+Q6=^P%@P1'0$?5]4=+"2@(LAZ8Q)A\FT
M-'X(Z P#+K'L@RYP185WM+2XRS/27A0-,\Y3J@J8:8Y4"6H0I.?@(UGL!>@O
M'"R++"QO2*/0CJM/5:$Q3 )%&V4OQ$H->&$ZXA%H^Z04RYP\[PJ@XD*6B++G
M@^J%U'__S-P$!!,NP()@P\=_M6K=AHG_:;=HG>!?K3INKEA'%(1X#(JFE 0W
MD RFMIGQGC)YAJ@!)@INU!XU-H.A8=7_14)68&;$A]%%K>@=\:$DXSF6)A;T
M9?-T\_.CZ=DURUDR&UF1/ P2.+]BH?!33"]6,@/%#\7R;W+-K%J68Q>$CKZ]
M*]*%A>((&7S_DA:W_/I%,"F>9M22P,08UXP#1@M%Q9%]!F2OI9EXA:W2KR_X
M7%U]CLO#>^=G&D)R$P!7:)Q@A4S#W.U6A!J4E%:M82@R"J:#L>9&N/"Y^(2F
M-JK"Z.43Z^L]T:DUES[Q%$[ O><CH\0C)AF^'D1U--(1\P(NVS6\(N D:>O3
M$R1.!1,<@*2M+0+<]F"WXB19;U <=3B0A2)2E5GK9=;M;2ZSWAP4 X%U9:UT
MJ;:!YS"[*-4=(HNJZ=QRC724LVD](C*;&F[YB= NM-."-2R_*9@:L& ;/4Y3
MIB_6"FZ%MB[U;K(G?"8BU(Z/0$DD>-5N^(1M3F&/@#I^272_1!-U.V$%4)I@
M7KZT5U@;28P&@RH7E$=HAZZW',^-(M@= E2EPDMYZ4="N21M-E9%P<*E(+XB
M:D6Y5)\=@RE9)YF=A$J(ZX$I),B]4GA..N3]B7S?XQOJ)DZN-$O75'<N44IZ
MS(B-K[C'PIJ$L#+$JYR3"OSFO.1D]/7*D HBV&MVN1"K%3R.KWUA'I)7A1F[
M]/M9(X7FEX&!XT<I_PF>)FAQ4;-00L^KCX/.O*N\( -X*6A88S_KVL*=782K
M5JRZ/@#:-$'&R@8.[UAN &#;N*&OL0T7O,[H/TJ2^(;XJN6;\0KV$SX)[H3]
M560<WL&V#-C+Q68MF-VBA-XL2 ,OLA>/T=\QR!'7T'[R:(1L<9,(\:N:L<5,
M!>_"N(\B#' 3CV'> UE\S:9>Y%^ZHGF/P+Z9M-QP_DB:=Z=<X>A>%\:Z!I12
M;I^3DV!'W-MO-<1*T,M"J+(CF'\1&R,_G "D^$7(R6.HO/-) R2*,#B^"#TQ
MR.:P=(G8KQ'%T2"?TJS<A%E>LP8O]VD/)O.5_>JT,RV<S77'J=F&8NC3#7 >
MR0 &=X>#O';#F7_/*!*?>BN0TS!(^"LYRD;F19KKDT5#F45@6\!<T:9 .@IB
MFL'PF3\.9F/A%D5_#2$T-@5;8D><4^.!#Z9Q',>>Y@2+D MC"B:VFR*19@:W
M(F8E?8%Z1[C4C]#9 $H6S__-FS?_8QIO7)==%_QCWG7!SBQ!1T>Q"-I]%<FC
M<%G-^*@UH="<D4SG(T>$^*4TQSE6':'<*6':&:]4SM O^(G@7(D()5UX[ >]
M!//]$D5*Q5X571':PIIA:>9M;3H'7?W/^6.PS.50/)T<6D6^3^FF_[6>.27T
M9Q7F@VIVX+T".4$?A)@8?KV1G4\>:2LSZHLCS?EU/?4J?H-_RR+FX9#:.;]
MGO]5EWT4>EIKCKG12L/7N_K7(_\&@\&\(7Q*>$=4*R3]P),^1XQ2(OY[AQ0B
M_JZ(+=P-[F!$]H K(C@>=2NA<,>M[^VI51B&,1UQ_@V'\VX*E\4\6)*YE1"?
M'1L<6M="^!-FPI O4WN9>@A@ZD2PTQ7VG-LFJGU& U*-S^3NB7L<'1+/4)[8
MD+1[P8"7B2,+ MTAJ;]\&I(Z7P8Y<-4NN<<#<LID-\G(]RY]A?KD]%U^Y9%G
M;.F["] !@V86JRP* N=-'98=$E):2VG'*QXO:4>P\C&X4Z#!BX=J\UPGSH(D
M99H!0P',-I8M.X*H^ 8R;XI"/TCB--U38\AOF;Q<2^2>1%!MM^*SHT">NA-R
M,?0RF64;W9_!($#[P)RT%/;'3T(9(3N_@8,"GX*C0B>%6%\]I"9*E, OG<(]
M$J]"PP\4^.7O7D'B'<U5NR,2OU!1%&OFSEOFTGG-5B(36\U2Q4\K6*%_M?,^
M]EE$'@ "RL(#\7S-1&Q?>&CVI&.&7!4%56->2? "NF#% )#.L?B2FG$2S[\9
M\]]R/8[O<S;NR*YSKY N4P&+[BWLO"+&2=Z*W YF?A@SVTI4LZ[CD+C7A;F@
M8D42CI#(5D4I\()EGU^H)1V UH@,Y.151;XTS6S$_-=T&D^D^;%(&(5-!G\-
MA$65!406CY%,B+[>W$B1FO_:;F:]'%2^5O9-@9%]-[H"\3Q$9GS\-Q\*G#/U
M!U(]P;(OCG"&D?  AMJ0*;F#M:%K00B-L\),2OR#&"JF6=%VX5+R4)%[6^.9
MC&&S*?XK$@GN'WTOBF;YH0Q]T6NIT,<+,1G9R^0#9M%,4_;E;X6'3DN;T7L+
MY>S*\G!TD"[;-#RTDIY1"B^U)Z!T2M;)>-+GIV_/4*)8"L!"IGPC]O"3=]7E
M;FN*GYC;Q'%LC1*7B%$VE+&#?+(+NDAGY'S$: #U@, T%!'3GJ =A/D<U#.M
MF."C7-O:#9<?(>S+.SXI9#?[&0$_*![)I:_I;]P4ZTY9=>QY4!%(6D^Y)^8*
MFV*BH?8B>,GK1\T)K)IE-_^%<WD1P!]P0:D=,)MR+WK\*PD29))=XG/I3. ;
M]9,;^HRVO!$OWO"7J:<48I1JGT"1 E:P:!#U6K/.8]A_26).5-OY4?YKH>]#
MTP>B6*T5N7_T*Z!DS78(]0M'K:3);[ZK2+X+Y>\8V18,\CG%U#7Z28!Z\]QA
MY1XOA&!@-44EIUEO\$:BK#G.1!)8II51ZDFGUBSVN%BDQ6@[3:ZB/K9U*9P/
MT?10#4D/!N089>%YO6($1FNEN@;%;!6+S\7B.U4L_DG.-VL>>KP[U^V033%Q
M01*LRLZ$DY%H[3B5,4R\2DD=HI0KTJYZ6N.^,W57G='%MT^ZP]0'/'<-+%B:
MB&*/:_CSGL@1S+42)=,TXG?@"-\*T#_S,>PJ$VYDTN;<7_%>@3?@RGT&DX'Z
MTV/HP8_(9'?EU3R<A9R;R"!&)NS\8A"$C6-,;XS[,W2)%+0%[#(^'E.05U<J
MYI^D9=,3+,$P1L++2%T\Z-N4VD;4U"";%)A#HG%>BY*UXN9/,5DXXC%T/PD/
M!$Z]0#*_+KG\7/C3V(K()V9^<*R98B!:]D"2Z[9)^A]%-K$:(,9K7@O%BPV+
M1?&"7@%AP/H@ ERJ0/'NJ )O_7Y"+3:5%2V[=Z5PDK!GTV762EG)2J8DG!_N
M+W8!1.@ZXK9N6JQ!9%7(1(#7N<2[UQC1@E.'2H7XQ0T% $4':YE547B(6<AF
M+#P$U47/ISL1YTK9JO!BT1!9?VXN?S5.YD>CU<UI7Q+NH_(_S\#*$PSU<X/
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M-6@,Y<&<\YHT68;XO;Q^S3D -R1F9-=E+Z)(CP@A?L4P!9Q?[8;,ZX2LP<A
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MN*<S6--KDA3FZ)$Q?RJ_HE0=$2;$\$:Y#.<7XD'2+#S4JO:9XI&*, I%0!,
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M4S9&J>_3[6/T]6;D$[WD0TX]1I U?]<B#6Q7-O14VT.!2KR^C( <0%!,BNO
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MG_F"-]2NU[O2%71$[4TQ7H1JB3PP3SK4%CJ$[AUK27 "=WO/J948[L@:@0\
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M@MN["$LPJ<Y.P])SX,Q)//6IQOS>O(SOE4)5@<3SG*=N?0=! B?57082#TN
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M[T;SE3N^C&!Z=OMO+&WN.O _M_\(/5,IF'3&J:T5Z&_'?G+I)Q+^N!=7FWL
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M*^#; N"KDNLKX,L#7Q=TEF;3?A3PJ91=JDRL=U<'O\8"\.MN ?@59UT!X!8
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M75"M7GA<70E<W2+^SLR:0NOXSDQL"Z25!G2[0_H3:?+.IJYUM@(RM*P?@IX
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MI$Z[XG2X6*A^D+V\X.*A>*WV*A9S4[T!2+D81&77#%'-DDR>YDT+,]/0..(
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M1S!EBVI-0+"F51Y,R_E8 9L*X!KA)B!1[IQ2G8LR1E%$7JQGM=S^!;LPO],
MVP.8J LC#8'/+J=\LK0GYO(?QL[40J18B=LOSK+XX'@<=X(3NVP_W&F;]J03
M?<)5W)P[[I%?]Y;P265XI%YL^*+MOEG,;5K/U(BU%IV4;*I1\,F*U&'DKW3
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MQJ!']=/P6[V1GXX\VA?YZ=>/^6']]/IH5^'3ZSW[O>NC3WN7AY].+[]]/6[
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M7'5(>"X%MCR%.63PH' _4%A45XQ2+6+&""*,&L0,_! Z54A+!?B>,F9B#*#
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M16&J,B-9*E1<-2GJH[2+&R3*GT'>NH#C";K&]98,^IW M"Z:G2MCBHCM76S
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MJD P],[S(%VJC2ZZ+N =K6^468QPCG )S_&8$UD9&2S77AHN')6,7T'H79/
M>Z?]-:\Z(5)1[R0B7A'$-<@FUN.(J-?**05PS?W.'J.[6,N.^)\-\5]'8S%8
M8AZ4\=1P7G%MH@>B=U7 3@#)ZZNIO^L"_D PL%X?3>LJ2L$0KVA*HP@,*>(
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MIQ2K6%+@MH8]/C/G6]?Q^SL[?M]-&&S7\?M.<(FMQ+^*@Y-CZKRL-$_MQ+1
M/-" 3%5I9$QEG*,&]I7M[%'Y@FQ'&D!G3MYVM^QWMS"-_4_!H\]A/.H(^]J$
MO:2/TS=OCXUBFF/C$" T0=RS5*JV2O*'TZHR@>+@YYK#%EF-.P+?^D3IKDGQ
M@Y%Y.W?Z3W9X<:R=E(+$@"H5..)"<F2I\"A8%ZF'K?2*IR*IC-RD%5A'WX_"
MHM-MTS;#\)V$4G<P_! PO%ZKFE*/N:3(^"HB#GN,E' "59*Z&*RD)J41;A$,
M=VV9'M&5]QU)\1!0^H,9Y#QVDRUP+X,+9S:,>XSL]A(<WJ1^>-WCK$SOGPPH
MQH]F=A#F?<ZN;(+V&'G2]0QX43/!=65#A3''H!A:H0G\K4'[YP[CW"SP&^QV
MK?H=Q3CW9C:=3,TPK5['8*['8$3+3K?H^8NQ=4&CI+XC;K%$B@>#*D&D(5Y3
MYT"=%XR_N.7.@#>EF@=V*=[=++\)'K8.9O_K_H[!V@(]4MS<8#.5LJHLP1(S
MSWE,9<N9-,)071$NZQ;*WRK!=QU6[Q!'#U9QU!J<VMY+5'F0T6'O!-)16*1Y
M<F QQS&+.WN,[@JR7OCHOH&TP](.2Q\EEE[++N*X!:0D.I4FY]1:[2FGV%;$
M1ZL5OQI,K]&/OD/5VT35W]?,'S9B(KU'FE6IBE+D2"M%$..""2=)Y:+;V:-J
M5]+U7EW?VZ^^ ]0.4#M 70=4QG4(7!A#@N:@,AH?M3(D&F4K&7"X%4#M,/.:
MF.G6-'I3>6:%1C%8T.@E<\AB#1!JB;&TD@33A)GL)H$W'6!V@/D\ ?,:>$FH
M=IH&2KC&W%5!F>! F@F.>A&8JCIM?ELP=+V?$8FXJI1#0@2*.(Z@S1M.D B
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M1,2TM%1%(HPEJ5EF1\-/DX;OS%O1T?!=ZP,Y6)&"/D"U"(8(FDK0NY11 ?J
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M0W!DCJ8J 62WHC=N$-0!S%,$F%L/[.NDDRW'D#4%SA',0@K6UT08Q#D-R++
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MRT4!&YA,X8.,?[W"L4*BS$8DS2M2N!KPJ8LP&*1_$T,[,^]'X_[T$HTNAO#
M-G][ 1P0,!A4R+-^CL:_. V)VN'^GAF7YY^/^UD2MF$80 KNUU*QZ7V$1R1;
M%XP&'A F*6QF"N_937>G.?1]>M+BB:<&^ [LPVEY[N@B<;$1\+!Q<--6-:ST
M^'1%>5QA=&<C>'Y+$A]<]OK :N&^Q96Y=W3UKTDOP-M'9P! P#@RIQBZD!EA
MNG9D8>>+,)YXNIV,QK8W&$U*9\7=Q([39=G>EZZ P87$,,O\83WC>'2VNS9
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M^'N^:QRFLS%<#*\%(;8_.847F\)A8!R9F:<;O]/'MW7'YX\DT)O!Y>=:1_/
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M@W0%-'/%,^><JGG$W_I_+Q[E1J4N3J$<Z-A$XX1,*2V%N1?Z^>8TR*0&%*?
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M$[CKXVC>SZQN;)J*TJ?XP% W!DG]3T=FG&?C^P"G^<GSS,I% 9MB+.K#:/(
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MNO2[KHE0;]0.:;2<)LUGTU/GM!0S?GC;+XNCZ!#%*Y'11N2DN;?V-LN7E:Z
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M(WPZ+*Q]TMQ7NR*OF?J=NC+OM3+?A2/NF:8L41*,%67;VA-7IH:A[>+496M
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M;AY\;E"1OKQ(CRR!8P+CSYPA,&J=082S8)W+W*DG4C"J2%\<TF<R?U2.W-G
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M&,TY."V%#$4O YUK[:T" ,^!VH#6F=8#^.5$,[UNFX^/H$@EE/YQZ&\S EH
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M<.?^K_;)ASM40U@P\C1;#>$B)^*R@[7V_OOXQ,]I\^AW>"<\[]V;'\VS;7Q
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M =$GMSX7C(B^K>9M!$W=[H9R-LLGU$'2^Z'ZO/+6A IMHT<TGXG,6V2Y<)!
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M2Z/D92EC@&,FOL;%6<M0%DIK#.&VDA7G.B:MBJRD8;LA_X)?-4YB/S;^[QW
M9-&"&TO?59@IJ;2?QVUZ ^&2V?2Z.^J@T!NB<:O6'GSNSX()]^]O'_K@HE51
M(THP0YS@A,#PP<B $:2L#P([M;$E9Z&C,>8%>G4G"5J0SKZ6H%63H ^'/I'
M&6&()6T1IYF\&4P.%+WP+BKA/,[9B/):"2H1Z2Y"M"!I>"U$*R9$1V\.%=9<
MESFLVDK$%;7(&0?B) +%WG$0*[&Q96;#/Q<PU(^#O+-<?(_MT\U&7D0KW[DQ
MM#\:+G9C*H8#^!:L^F>P/*9^KU->@K5RY*LUM?RL6F#/U]?!.J^O;SK'[=YI
MC'_%_O?"Q_EROF]__%X-SUOH_T26]]+E<JNU]%XCO6QWWQ\Z#PZ5DPH9CQU
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M =[6C\-1OUO:!G!7:)P40WC'^&\[A,?GO;'CK#WE9]TB#BXW!81^4,"#X%9
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M5:LK*B>P"-_ BG-IS?\$#7M3SN0L[L) G./NFJ=6WA^!/_W(>RN<69Q@;I#
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M\#6EFZ*$V$=64GJE8,CE.$.C'U,[^F%CV"H_:< \Y#][J3&,G>->W_9/&Z&
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MOC\"#R-6>TDSQN,S/_#XB-;6=(;P9=":?#;>T?L8H3O?8\:L<G[@2>-YNA2
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ML'M06:O![L9RAS=WWNYCITEB1B$E9<AR)Y#6 B,)2X].RF&34XUI,NMU;<R
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MH9+G/H2;FW\CF%G,K+LO-'DDL^X50@RTZ<V^$-+QJ"3*WG[$@>P@YY1&R?(
M/,C0E)- 2?Z3J(QYYEI>HRZ;;)/Q:G/,-4&FPM>JMVT-CF.WZ2^+5F3&6N*D
M3)9R#5:!%]$3GYC22G&B]S>R:&&"L\2/9.RR5'T>'!_;[MEV&I_Y^Z-$51W$
MMF_&W@Z\Z_=6QW][=5+A!;QS/R0,"X_-=5E5 JE0"L$Z1)&E-"KF?(J)KC0B
MZ,Y)#O#K#N)S#C/;*8(*(N:;K::M=J3*NID963[E=I#K 4\&ZW[9^1U6R-C-
M50P 7C)4]AK_;+9'.M'[UZ\WWWK(]5(*_1N'6)8 ;.A]RY[TXJ^C7WX+S=Y)
MRY[]VFR7/I2;?KO\N!R&.'U$, ]S]?4P0M&8-2%)#E(<GE0<OG@8O[A6XA>G
M@LFK[X1<D]A<^35>(U=^][/'$KK&;_G8GW\G&'^(Q@)H/J?&ZAL]]IJCJ]<>
M5B=BYMHYQXRJ".#'.52CI[1?S3U3LQMMM]>([6Q(36ZQ73I5<=?!F3@1ML 1
MY.4>N+RVWJ0ZSWT59GI) T?J@;O=P.%%U/+Y5US_/6]TM/-1'&=;\^JM/VQ^
MD&=\*'3A_M<G/Z=LI"_M3(H/VODT&1A(O\=V3,W740WJI+6]$[YM';UK[6W\
M>;QW] 7O;;QK;N_\?@16T]G>^[^/M]Z#5;7Q]G3F..CQ%[%%_Z*;7__^MGF\
M=[RU\^G;9CX&^GZ3;^Z I?5U%Z[? BOL]V]@@X^.@O8W=P[X]H['^V!A2>]Q
M0EJ8 /87YTBKA)$D4C#+N> !C"VV*OA5$>I+EQ3EGM(BU5!70]T4U$G+L=-2
MQ" ,3SS76-7> NQA;I)GKD =KJ%N.:#N; KJ8/J=-CP@P?+V!DD$6:PD$C!Y
M03E/,,$9ZIB834%?0UT-=:\*ZH@G3D9'"&@'=T%IXR*V(86DX)^F&>J(J:%N
M*:!N:YK5:9*XQ1$C3*U%W'F'3,K\SEGBM./ QV6&.JK5<X&ZUY33?Q3=VKO(
MJI$/O(QR(%PZY9*W#?R@V\W)-LZB?6VE !: M%OMX]T"VSX,DW+T/L7>H)5W
M^=YU.\=_5'/T$;K9R5=_'$UFC78+H=WFK UK4[" 0A(QE>L)19$#T<&&M<#)
M:>+"8)RKDUQYKJPN(/ "M!M[2XP1N:<,*$O0AG >'(\IVKR#7+2;C+3[]OZH
M6KL?6+NGS3;!E%#8 9>1^8P>,!C0;L-SG#9\$PGQ52*/6KM?L'93:; *)"9G
M%%?):NJ#UM09'3&741;MQB/MOKT+IM;NA]7N&4L%H-FQ7$!$YZ)B7&.,''$>
M48M#I,X%0@QHM[PJ%/ZY%Q5Y2:;(":A'MQ@AKZV$Z;.Q0C[F*:IQ[(XX]M>L
M#<*,=%Y)D&6C$^)46P0D)1=9QAX+ZJ6UP%+,5<<5ZPJG+T"UG]8$J57[GE1[
MV@ AFG'FN$18T8"XYQ14.WDD&/>6ITB4H2OK[,X,I5;MY57MI[4_:M6^']6>
ML3Z8C-IQKI'),\<=*WE28/TVV+#H):41K(\[UXNH2QO?2C\_5?F\LY61#Y=>
MMCMR8O$[VAO/UW.R2-FRQS(X-F(-70\%75]F#0XAC0S4<(2)RQN[$4 ,"P.L
M1'E8I&@B-*RLD[I>\@M5Z\<R-FJU?E"UGC$V1!0R$8X"M_DL-:7(>!X1\(?D
MA @Q!3 V:JU^H5K]6'9&K=4/J=4S=@;QBCH1,0+RE:NF6X:<) QYF8+1V#LK
MPEP7PK,OFO[,;(R+I *CO%Z#?LR_MIK'S:I:SFO;VUA&6^-BUB[AU[_SN?7M
M].;DI 6CYUKQ<S6!V^G?%]-7H]E":+8[Q_1@P:4$ID?0BB*NK4/&V1R;D72*
M7CH5V3ROR<+UDVM7Z!*Z0A_+\+B;CE^3JJG6_1OJ_DPT%F&!>@<&"<,,<9H$
MLHX0!"HO93#<^,QD2I4Y^ML2^4UK&'BF.R(U#"P!#,P8-#1*D5.NH?*#$^&1
M8227?R$FLH CSGNBRP<#KVG[Y'/L]ULQ5V'M-5[9_L@2FBSS/2X3<_2UV3^$
MZ^&+-X/^8:=;2E[7"'8O".9GC1A)L%:!461DDH@':Y!)$:/ .7$B"I^2N#<$
MJWVN2^RT>-J=E.L1H-;TQ31]YMP_52'(E!!EG"/.DT%:$HZ2],F+I*U2;F5=
M+X?OM5;OE[6E4JOW/:OW[%EWFW02RJ+ K$/<*8\<TQ8IDSSGEECCX\JZ7!+]
MOF%FQZ7/%/>V'6Z0)JY*"C!,%LM@R$)GD%//CMKW6A*+W-\X+#<N+Y)@A!IO
M:*2$&\R]BMI&CXF,G@81F58W3=A>)QAY<- ]F+,%%(/3,'$@1IH@+KU QE()
M XP3-A$'Q51.,*+4HB=>[DU5[I>!79<ZJ4:Z&NGJ!)DO .FFK<?H#-!)K9#A
M1"%N%4-.)(9LB"$P"=8DX;=+D%DC78UT+POIZOR8SPCI9@SI1# 5V@9DC1"(
M&\N0)LHA:Q4ETIKDJ+A=?LPG1[IB=?]2*IB,2J3\<JGBSS,N)_-YX'I]V^XW
M<RWD7$=K5$RF5(VQ5]5R;Z;&A9*M-DX[@U9HV)2B[S<Z@VXCEE^;WTL9P$;7
M]N-:8V/0S49_?G@^=36GBD5^."Z%XL?W0Z-ZQ0D&JPW,D6VV&\U>;Q"'-=_R
MPSY\^KS6> .-A29EWUEY0#<>1]L;='/2"6A/U1OO052@#:VSJ?I-SW;Z/N2J
M!['7+X6I3F+;MK);<#*M1M7S;JD6VQKD$8<AS$-2*J7U,B;GT-7)HHTS4S6O
MXLA0$#+Y'%;%&D[=A5PL5(+M$3-;5#6T/HY&ZTT[C(;Q[0\8PUY=Z/&J*FQL
M\WQWWS$II#$>Z92#N'R,R$3B4'0>L%_+(+/U3O2<$J/#BE.+%>=[Q,0(M63<
M6C*V-M[L4Z],Y)RB&(E'7+,(;,!(%+2%V<("IB^G,9EUIH_+\V4D640V'O%D
M?2T;=Y -O\\E-TSJ@)S+_- ; OBA% *,9YY8B8T%2YB0J\O#KN;U_61$"U8S
M,VG.7_[ZA]W.X*!B!Q<+V\2*!TM@_NZ/3KNPQ;)6YA# 8;P3/+F:\+7&3O6(
MLC>7;QN_,5:37ITM_SFE@67R%)C421<$H0L<H!$&I7SR(2SDL7OQR$R3>O!E
M67OS?876S"-@HQ47_@12TQV457WN4-A>K^.;I8.%,%T4 UQ$S6[I;I^IZGT;
M[7I3=; N^SU?NS9_;&YL[GOA!$DF(>JB0MP1L+YB7IVQ=KFN;?)4Y[+?LVDN
MQV6_%X7>!W9,WI],O#[$!9G8>;,?O8 5D%M$=,BK<029P%(@4%RFG:$A,KFR
MKO4<F9B+N(];\]8?QC!HQ>WT=F0*CB7B$\#9ITLE4'>R;?Z*Z^#FS_>ET]QB
M$Q&+)"*N1$#:1(J,<\$JK @,]<NN@SLJU5SJP\<0N[8U/(79Z9Z-/1$-F\/^
M*^MXR Y<S.7D+QG!!0_GNS*FB^DN>?E<+=BMRN>R-8T?H,@K6V/F=H^]KB(M
M??6-%?QFC:W+Y];E<^ORN77YW.4>N%=6/O?=E8SE+CDC[K:A_HPVE,'\ S2_
MWUV%#UOOI@V3FY@C;_K#N?P\FLI+%X\M4T2?J:E2[39WSO>^[GW;V]F#9X;C
MW9U-O'OTZ6CWZ!O?VV@=[6T<-C>/X-\&].AL:K?Y:*NU=_RIM74,[:=[AYOG
MGYI;[[>:VSN'W[:_;GW;?O_A#/Z=;AWY\[F%9QUUV 2M4& DY=2;&NGH+#**
M&X&988HKP!"@2\^@0ME3J-'_O<FB])#GVU\W+MUQ3ZO&I27!I9EX/^.HUCH@
M8K3/>34E,HE$%&#=T<:R('/IQ!J7:EQ:3ERZXWYJC4O+@4LST7G141L\D4BH
MF N,$(&TE!8Q#I--@W9>X1J7;HQ+]Y0(9(EMT4X7_FPWHNVVH<%UAO2'M#+9
M;3!S.$.7KMAHPHVYUEQS8ONS!LT;@>:<RK!:AB0<\\A*B1$7P.,T6)V(:*&#
M,LH1K%?6Q=ILR,IC'PY^>D2L,P\\ *[<T4JL<64Y<&7:2$S LIEP%BE)%>*,
M<:2=C4@$([ 6F.A<M5*M/7W2@1I77B2NW-'*JW%E*7!EQLBSF')!DT%2F%QJ
MS@.N2*Y14#@ ,?76N+"RSM=4C2NO8#>QTC<$5C@H9HD/MNV#9HX]JL*<ZD3T
MRV;2?8HGMM^M?M].PPE\.[3 :WQ<#!_G5-G5*0>]AH@2R:'1R@$^IB@!)#U/
MR43NLG.>K#U][OFGQ\<ZX_4+L>=J4+E?4)DVYBA+/ACLD&:*($X<0RZF@)A3
M\(ECA"F?0676L5Z#2@TJS]28JT'E7D%EMK*PQ8[%))#6S".>G$4Z<H(D9RHD
MPR+W=&4=W\F2>RF@\N+WXO[HQM#L]U8;'P?0I$[C4]-W&O&';_;*D91Z:V[9
M[#CX<#AG0V2L$7$Q1)Q3L#@P*5F0"7F:TW KEQ!,H$)""!RQR@7%<F!5[3.O
M?>8OQW:K@>3N0#)MKRDO,6/4(D<DV&M.Y!1E20*:8$:H95&XG)%Q[>F+)-=
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M_KMMOYK!]M&[H[V=/P\W-]Z<;QW_^0VN@6?M@JGQENT>;?[8^OKGM[WW'WY
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M80P%(Y6_Y"K('>E?9Q*N-;[&K&86! )NK73J, Z[D4=EHN4%%FS+7Y)(L'Q
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M6^CYT3#@>2P"]+87AQ'4(X)R">X2B%*[K(=%?\K+KU:395:*(92U.XU6IWT
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MD .RBBBL=UY9JR,F*^OLOA<]%7T2VM/(2.(J!L=RENB@8R"P$'I;1WT^HA@
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M$?=@86A.\U&+E%S W&.3S^;CZ[+.@OH49,]ER')EQHG"/%>[\?J'S6YH_.\
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M%:@&P!H GS\ >C\X'I0]R\(/OXRIX7N@R[]' ,,X4Q>S1L5;H^+6'U.H2$W
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M3#S7X1<H;U-+-/'SL'=9I^0@(@=+?8QL@N&^MZU3>]9_]]-5?0F4I:E5G%Z
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MK!,\W"'#I:*'QZ"'QN:W?2T($<D39%D"+<4RCC2E BD3@&<)8'P"+872Z_K
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M2$*ES$F/H)[Q-;AD2:;B\ACGF3U'%816$+KZ>G(%H<N&T&F%V!C8=4\L\CH
MA I.D99@YD9"9! NEW+/K7;6L):O!D(+=?JG(@YW,J_C2CC[O#R/FS,WWG21
M%(:O+Y*R2%H+NTAK>8;2*JN824,>/9/FCU[W!+CE[(^6[0PV.B$7FSK).6>K
MF%E3'Z/L*: 7;7S>:]7/]]KUSY_P]F8XW/[^Z;1^[D]WSS?@6D#2C'PSJ1$;
MHG&^B_?:W\X;[=W3W?PN^DGL[FR< V(?U3>WS@!)3_>^_W;X]_D7W#C=ITD*
ME@LY8$P\XMQ89'QPR NJG&>"2N^F<VLT[(H20K-D-)<,:\HT)H+KX(VR1$PG
M4XQW8:UVDO>AR$&,XYVX1[;-K>]_[&R;:\GJ31/3EWT7P*;$A"*58/4X(0Y9
MKS#R,1(7.&A,X15EVMQ(UC?FWH2</M.KV:)(0U&PY(94G$46Y]W+R=L1:IT1
MO?Q4&+8N^'US<YXE;^<E)1GQZ[]>9I+1XUQ:I2[==NF+6(]O_9B&K=(^:S53
M+'_[5[-3_E(48?GW'=*7WFJ&4I7:]9)2NV#IGLDW]COH,W<AE64$/3_7WM]Q
M*8J>*G3&&U1EDE29)"M\6)<9>(6<R/>S2$LG\LE1G>Z2QO=O9[OTZ_'V9AWO
M'M7/=G>VSN'OH]TC>-;1KFA\_L3K9U-.Y':NP_.-[.W\=K3W^0NOGW]MUL]_
M.ZP?->#O1K/1_@96+(Q]Y^!\;JX(X4ZR*!R*+%"P:7U$5JJ((D_62<D5-;EI
MCEE63,7*'+)5P%4!U_,<D57 =0_@:DP'$'@1L#<D(*FD0]R$B$PNG82E8,DY
M9[B4 %QJMBKSB@+7$R6Y/9_&_7'8;(6B<V5V)3;;N8-GV2GA7IKG W/\5NLL
M;A*+YKKUF4M":86M29Q+(&OIDR+1$8JY$Y(^Q*U?NAQ^;Z:K+4A@&OY]&/:R
MRZ%"J3N@U&R*V^_L:RO^OZ]G>]_#B:-<PGMY8^<3V?W^UV%])Z]/,79X]UY[
MK_V%U(\^G>\>'=/=\T9J;.SSD)*G4B$G$LW]P2VRCDKD<RDVA54PCD_VUQP?
M,J&;*(EX3R3GUAH+RA\U.CH07U8YC[T*6E24].HHZ71?<ATE4PX)PSSB0N=$
M"$:1T5ZS$#SS'M1\/D-)4V?M5?[C"AO$%_(5.')K0KI^[KV<TK,OA3NGS6BM
MO0G:<^2U$HA+;) -U",1K=948$ES.U*^!KBZ0IF/%2NOJ(E8L?*3L?*,8:FI
MM\)&BIA)$7$+7*PC!\ZF-(4D#$[>%F&5#R\+]?*2F)_/>JS;SC#E/B!%0Y.)
M^*J''UJ\<M,11P7V0HI8J,@)%5;(Y(@EDCIA *$JA?_Y<6@V@7E6X3\^;>Q\
M/-QK_P;CWSAK;!X>[VT>G.T=Y7^WZ/;FWN'VSJ>S[<V/V724Q,$>*XFXDV Z
M4LK B"0<&>S ;J0Q!$+>?="+68XLPB.")-$93H,%M17[)#2P$WPC?$5(KXZ0
M3O<-2T%Z*4#!H+E'M@&C4>J K%&12!,\-3F/GB[1<JR2VY_8<JQ;?PCCZ)U-
M<F2E:RZ?-6?,QL0U\5G-5$P#2D>'-"$1R4BMQXY[HGRN@'5]\^NJ2,4KX.-E
MF8T5'S\-'\_8C& 22NZ,0 QT:\0))\@$'I$6$NLDE<.XK&2G'YS-O'JU*5;7
M9OS=NF[/YFS4!QJ,;^NL43@BHO*)*FZX]\0%QC&G#%,1!(NATO.?'X1F2RI,
MZ_G;W^M\=V?W#)YUWMCY=MK8_ C/^:VUV_[U>.^H<5QO_W94_[Y%]XY^RP8C
MZ(PN!<61 T&$./8660)*B1-.!IOK]R6WJ,'H)>"B23X$;3FUTBD+$DX899*5
M%%<&X^LCI--]1YT@%I187?2=-=P@XVQ 5&E%>:#2YMZ>2S48J_.))S(8BRZ7
MEU+U@ADK]7*I##E3Z0'[P#P7*#+O$8ADBYR1"B4M"=?4*IG[5) UJE:IKFK%
MO2MF)E;<^Q3<.V,<8A6(,#9'JFJ)>'():9E<]J6"EJU#H)%D[B7FNN[&U8'B
MHY1$_A'#HQ\DKF"ZU\VF'^CF+FE%K.;!*DLIBS0)'4%[TTE5&OOS0\SNG$X*
M/'GGN4("6XLX]QAI[1CRP4I"&/;>BQMU[LJMNZK:=@%3E:A^'#Z:5K2Y3Q+P
MCB,L'?!1!(ZRG!(DF2;>&:*\"+F! 5?+:@E7G<>L(.,N1=&N&/?Q&'=&Q^8)
M$R.=1UB3E+V7%.F ,4J81^\3M\S$@G'Q*RP.OKHZ]B_VI#F 09R#IMWOIL&I
M[<7J .96+5QB;H7D%A/GN)3>,"EY$I)QJH',;:6%/S\(^=L#K;YO_:BWZWG.
M9XW-#=;8#,>-]A:L4>.X<?0-KOMZO'M>9]N;>_D )EJB9)0NGQP#A(D$ND<2
M ?%$/."98@ \[SZPA0Y@7+1&".Q#2()CD[3A6B8?P;:C)IHJ:_#U$=+I/K4Q
MR4@B2HDJ4&*]0"9)$(W!8..3YX+H=Q]$=?[R\BS",5-.R-5?NNV3(8BQ/T?B
MM0KW63Y_SA1-<=(0%S7P56Y%XSQ&3D>,J(O"@(1.D12M:"AY<-A>=1ZSNMR\
MK+"]BIN?DIMG;$<9(M%82P3:%JA;CC/@9J%05KJ42(0ERXKS&;%*N9NO_GQF
M>W 8>U5ZUZW&(D@?%:FUEG+#F8R:.,M2\HH$(%U'*AW_^5'GX%8=?V_'L]VC
MC;/=\X]'C?-6N[%YS.&],.9O/V"./QKG!^<POO/=]J_96$PR6:>T1PR#>L\Y
MSZ4<%$8!!)!11"?-W1P=_V9CT3AE!5:<@9E(+9!4R@D(7*=HA/%5V.?K(Z33
M_6"!8J3#2-D84=9BD,$D(,:#-3$1I8R95V*F2N]Z.=;BM5Q9B-A*@5R4 V=.
M#1F(6ND8(LQ0Q+&4R%B>D/48*PO?D63??3!T6:7HJC/#%63691F#%;,NE5EG
MK#U'<& T<!1(SG.(S"-K#$,Y?L;)7*G'Q7<?M*S."9_RG+#;Z0]ZPY+)FIW:
M2:][T(O]QRH,N8)!>0^IP5XY[)[:_3Y!KEN=/T;$6OGJEHS>QW,S(5(R6*,D
MA$><:@-V+XG(IQBY9U))'DK/^RK%4E>,O*+*UHV,7/'J0KPZHVD)R9,-6J*0
MV91;EI!Q2>8NC((8BV74!LPBO4HY2TORJA?O5F4KTY55NFYL\+=6.\A<\*@!
MXD]D=SZL5<.+QLE']R!5.L^2<?33Z>\[%]6?^?;F,<NA891KYK1"F&J+.#$<
MN60TTLER%2)G,>0ZX'Q-D675%WDI?5HJ(%@-[U0%!(\ !-^F@<!P01A- :G
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M+Z RV6:G=C"7-DOM:L1WM4'W9B6K<._6_M4"(D.M3&593P,R^S<H>;8/?P!
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M@U")4^5HXMI++0AQH*%)R317,54.^)7DY6FIB[$AG%N+J \YK]0"+V/X070
MJQ][(TPHU>HJ /ZE<?,B:O43L'.E5C\!@\\6VK&,R" %HE)+4*LI029QA0@G
M2<K(#.QZH5:S*@#^!?'V:K%VI5;?PP">$P!O,!:*@S"62@.O%J6/@T >2\HQ
M25Q2G1WPKS4 GI)UNNH>^)WNP+9JZ<;N/@^)AK]S/ZC7!U2$&F]HI(0;S#W8
MDC9Z3&3T-(C(M*H\]:N'8P>SGGJIN>/1&20HR;5(:4+::8VP\H)2&JS6]MT'
M)M:$65:L_")-U%Y*5,!K X)%K)$G0(+*&GD*;)B)]X.5]!%')&2NKD<!%G0$
MXX1PGFPP2A(5<U_B-4&7T-RA@H75AX750H6JPN:2$6#F\(!JP8UR'$G&*.(I
M!P1R;U "5%!:)^\(*=N[J&55*J]@X%7!@*7*:*UXKM[ M8M&"3";0W2,XA"B
MJ4X>5A((IE4!%VWRN;(N24XCCDE$5LN$O'",<V5QE!+,!+J&S;(R>2H@6'T@
M6*@8YN,C064F/ $VS!Y:*"82,0$IQAGBD0ODL =;@6#0^XA40N=#"[5F]!*R
M<2M86'U86"U4J,R$93L*9@]#4F1):"40ESES2(F =&(!L1@Y9\SG*IR  7QN
MZM"*Z@=+RE98Z0.2K4Z(-Q^/O+_V?.2)^L!7SZB>\2S/>&N'I5M_C!*6JOI@
MU[8-PB9JIXP/V>KUP04F@]/:6*4HE?BN3LU+V)VKL7SZX5O#O(R?N]UPVFRU
M*OUE>?K+I]/?YP1S,,.5)@8Y&D&)B03,%R,9$C3*R(*P+!^#DC6,JT(E+XV_
M_^__T\"2/U?;M-K;5,'PFX/A;],PS*)2$EN!I! ,\40"LMA)E--&*2&<>\PJ
M&'[U_ VL'(5*CD<1N8U68YH(_.N#YMC%>%>G4,7?S\O??L9-E S)'F%$,#6(
M>Z>1,80CI1RF(E'+?*EFJ=FTT8J_5YN_*S7K16Q3!<-O#H8__1A;O-N;!Z)Q
M_F6?Y[1!(AP"^K4HEWQ"5J6$ B8X!!5C<"N(PT_DD!]T3YXU7:$[.(R]V_,4
M;IOUZ'RD7,+W#-8\=(?Y<>-Y/.S4<>7<EW?O;+[\!7HUD/_0J$W;ALENA=@9
M-%/3PF)6P5J/#? _YK@SJ?9),B,19EPCSG5"3BF.9-(D>&RH]/[=!R;7))Z-
MW+Y?>MKRN.F9<U$K7*UP=?629&X%UBKV[4F@MCX-M8$KD:SPB' =$9=&(\T3
M1<Y[1D/B)#JZA"29"F4KE'V;*/L,.4=S(@@K)\4C ^O,61"A.KD0*=+:"\0=
MD\@JH1%5UA"50K0DAQ7+-:P?[*2HT+5"UPI='SE4N_(-/ >NSIS! 7HFZ2S@
MJLD*:V(6%%;"D,;8AD@B-C'[!M@:D0\^9*]PM<+5MXFK3YD95_D&5@-JCV=\
M Y8QK$GV#1B?ZW4:9(3G2,$/Z;&QUODE9,95*%NA[-M$V6=(-*Q\ \]POC43
MP&!UC$5YU&230EPRCD"EA1]:2.ZMQUX5;477B'YPON'*P&L1__#3($MX^#<T
M__DPGEICV 8&\A_^ Q^.)]*VO8-F9SQ>?17CCH9]4!;.RH^:G:P[O*=T710X
M_,2<3#,G;\9_8JM[$@,ZZ77#T _03->DS,_]9A]^Z:;Q1[U8:#6U0;<&\SV.
M^??1 _HUZ_\[;/:*I,;R]WXS[W]_O?9[TT=X5N=@YM$G/>#1'LPOOR0#2"::
MH6V-+[SNF7D$O>AC\Y]82\/!L!=KL$JQ/^AVXEJMUSVSK<%9S7:*X:4F+,XA
MO 8&<&+/VK#Z_9]KWIXT![ ]YWD.HT_S8P>'S5[^!"@#UAN0Y?+)5Q:@%P^R
MCM?MP7M.X"W_ (+ESWVW#=3AF\6C+U;GYV(PPQ.4>C#+RQ?:?K\+U^9GGC8'
MAQ=#[SH@'%O.M1C#]'*OU^K%1S I-![5C:L[NX6#PUCKVQSQ D,+<$>OZ88%
ML,/E<UYX;8.MV@GPD6V6VW+Q;5Z^8;_<NXM;#^V@=FAAUV"6L=>!&5[N(%P,
M;[D+:38[602,0W4NJ:18PCRM7PYCN_L+K'#O[,<DX:S7+M+NUFZ83UZ0UC31
MCE[:O_ZM.[$3NZ[9O?K&/V.L-;J#6*-KM8U)&BZ7_1^@K6:>?W_] B,+L'FQ
MX'*QQ%<@9/P9[.I1G,&+FAO"6L=^IMZV:W8*TB_)Q0)I=+J#_,5)"TBR!I_E
MU1[ F/.#)Q:[%H:QY,TVD&/>NTMJ] 6J](^+=?\)6*H%HJ=@C(PC(".*7T=#
MFL?<Z[6-5NN2?BXG4M!SVQ[!,R]> +J1+YFB@)%I-A^/OU6"5'\(4J_?3\/6
M>)8C+LS7A9(A,EX4%T\"C!U?..(50+5.: 9X47]M1+!Y%;K#7LVZ9JL)R%)
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M'(_YX:RQ^==1?7-+[.T<@SC;Q?7/O[5VCSS=_O[IO'Y^3'?//?#'K\>-&7X
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M[6Q8QU($A7QTUNSX82^?7.5'CT\SLT>[%\HS\1G?P4?;*D[A_CR,(-I>2[1
M/?M,6N4:CN,ZNIV8UPV$-_Q[,A'QTXFG:Z- F?Q[/GDM5KPX5,OG9\7Q:"C6
MKB2#_'UM>))OOPDW%]%%;H?+K^7@=N#=5]0,6"/_/@Q[I[#)_=AY<UA:YXTO
M^R0JJ;4-R)ED<O%?@S36"I$0'>&.41!9[S[T\YEJZ<B:1L327Q9_9%[L%R$@
MY5:/26),,<U^#A7);C/@H9@CG'POCJ* )L_9^]TRD"1?63[)'H#M6'KIQB0)
M#\_^N<O K9 Y*<,'C*F;SW9S$$-Q5-Q)+5N^9GO>$SNQ690<RO27 0K4I&;(
MY]S%873M8&A[%B@3V*%3'CQWX?X^\&XSAV@4P)5#M7PYR7SFW(6E@B_*<^Q^
MCI*<!,!\?%Z<&P_B3'Q;.<2+6TY 6TZ -]TKD3O=,6V/V;0X3\]D#;,8GY87
M*'85,P%-?%R?D5^/JKK ^+(3=B>?G+]MG:6^#Y(O4LI!:<<V@5W'+'*:!@3"
MWAK"%,O-AJ=4@Y24Y483:T#YYP$[D:.UHQ!&Z2BTG]997J[<R1@"M-[JGA;G
MST6H17_8SJK >2&*2MS.2M9$S.0%1N3PEE8KL\?I83.'"X&H\BW;[P.7E@+^
M@FW6+D\+@!WS$VX0Z[5_P37MTH3J__O]W84\+.-H$N,8C"(^&I:S94_Z\?WX
MEY\!!T]:]NQ]LU,L2G'3SU<?E^,4ILNTY7TKO[X,85C'91C#J$K<Z,VCK]>+
MKZ;BO<OOI%Q73%[[-5XG]_Q.L.M?>M.=-PV6\'4J[O?89QHLO]-C;ZGOMT"C
MCULO-3.7SDD$*L-^GB;A1=]F;.,R2O[RY.Q*_L(=E^Y9LYWN-L6;D A$9QF!
M?H>>1(NTA;DN<>.FRI&K1QQ9![E+LZ9;9_NFEHPLPD>W)0?=*?=GI7,--U:C
MZ=>=UO.YNT8MR$G+[">ERM#-5::D*R_-?@;4_($.FZ"]=]Z_.,NGS'D\:>[2
M7X]VOV_]@.? ,S_A;7@^O$\TCOQ9@^[BQOD!C+U._G_VWKRIS23+'OXJ!//K
MB9Z(2D\N-[>:"2)<!69PM$1#"]/2/XY<C00"ORR%T:=_;TK892.Y$"#0 V17
M&P1H>9[,/#?//7F7[M6-G,?A>WQ=^Z [V+C:[N#UX_6U]MMX;X>\/=H2O<&.
M*/F/K=&'P;]'K?/6[S>:K IIT=/,GLA@+0$J'7%>&.*I]<Q1PVC,=<P7.^9)
M"!T]5\0'IP@(9XAUFA)EN;::1N6%6UW;'FLGQR<3];2$X_]8KOG';PLL5/_@
MXO2-,QGS)[K/NL47DZJ^J#)V-R3@<C';>>]L<A+=H#3T9V(>^C?,@U3&Q"0L
M<28P MEG8D!)DKE(DL; > GTE?H%MBJJIN>%FIY%5<FHIF>1IJ=]DYEHXZ@N
MT7$69X@ T$B\,8&(R*,V 223 DV/FLXQ>/'=.Y:*M'_T)YFQ_=0H%WI&L9(&
M^M WKK(ZT=6)?HC9W)MVZ$PJ]8$\)YP)2D!301QX("X$4])!F:6QCOEBQSSD
ME%76GG@9@> J=\0X&TD"'3G+$HSRJVMO0SB]2*7&R3<#6AWHRF(;Y4!_W=RO
M?I\(/97&WM4V3'G03%D-)?>'!8LT%IUGGW,BP0<5$]/<J-+N5S:)QE;;4VW/
MTWO0U?8\T/9,N= L4N.<\$2[DE[$@*'MX8)XE3P2P:P=+[8''MP?K7DN='5^
M7OR"[\YP?ER((:E,*/.!0#:XX).AA&EKA6<0H/3>KF.^R#'/DAL+UA/+%9L4
M@K&E(Z,S63C!%8?2'&SJ!'&Q7M"\:LU?];N>84A>7K_K1W8;VM\FN.[>=P76
M3<\A,,&E#HI 4IZ %I)89XM%BY9KKHV3L+HFQ:(ZF#2H.G[%ZQ-1[8K7>^-U
MBFU[Q0-G5)$H/8(V@R3&1 2MM%&"$B%)CWB=T2)S>7A=Y%$#XV]XT^GVI/O\
M).]J%@-Y0O6C=OAXN@%Z,=O!(].WN@G<:1,(TZ0M*F]!VT 8*TT[K.?$<P4D
ME8DJU7V@E'I2=E&2R_([=C3>7%9;.?_HO!A#^<B\N1K*.QK**;:<F?$0#274
M(E$&&\=E78"8R&)*V@2G-1I*_>"^QXM%R +[&CWK).[2@^#D^&M)U>-T_K4
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M]>QLZDLK=/1/M+-(A%;^<$<7:6;:3:UZU-RHZYJ=_@C;V4MO$?XT&]:,FK'
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MRN;H+%>K:P*J"EHMU'.Q4 M70:N%>CH+-265FJ2,$5$1K:DGX#2R*6DLD2Z
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M92#,E8;S$0RQF3L"04E-K1+&R;%UL@].@Z]J1'/AO"B*4>'\M'"^23:$1*]
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M*]NC]E%KU&7MP0:T!SNBM]_K;W>V)+X7?M8.[8YZ.$X;LE!:G'-GC&'$J)(
M:DTDANJ,/V8C&0,5A2G1JS, _+>5__R/@O;_^>DR2Q=/M,9J$NAS6&WA8_ F
MXM9 "6[TAH 'C3N'$D0I%XS0/O#H9@>7?<L"_<&+4B5BFDY4?;6"R^VD2OOS
MY3[>"X=5+WQDM$TY2TD'RBVC)+&4KLVS=1JIEF2@C4RNU( U],%=2ZNXWURP
MAJ2BL]H9T!9,IL9Q[QB+5I2*:'9!D2@5K'<$ZY0WE+,V(5M/@@V2 '><>,4=
M$7I<>=LIES2"538)K%7>GRWO6\M9I,S3)('Y;**DR4G#-0]2@J^^T/(A>'4K
M.QV4 )/>47>_]65[??>PC>/4Z[3QW[M#'"^*__#^V\/6<+=??"'&@@1@@3CF
M2W\<4/@H,!( 06TT@AI2\874K=$F8UZJOO+2*N[/)>[?"W)5$%PF_J;X*K71
M:XY4U4>6"4C.B<T1B$;T1$MCEIH709 _/'^HBOO-Q3+37B3&LO3)0DA@,\_"
M6X1VJ4RA%E22HF)YD5B>HK-!Z 342D)58K@=*D],-"5D1><<5&12IN9AN8K[
M,PDMC;B[LA22$PJ$EH;ZH#UUFEIF$ZV$M@$@'-TNM^X>MM;Q_3IAU.T<]5LE
M7F6TA]>!U[;?PK'J\M9^*=#=&HO[SLN4HV6$&8\.J<J96!D\0=M,C3:X(*Q9
M79-O9@"XB/M,B9]K^Y_\YZ=98E7;?PZ++7STD)A)GI=2HH#;A=/$E&IM2C,G
MA+!).[6Z!GHZ-.JGVGY9F=<^U.=BLM'$IM.C4CF]JOSST+#[(;(*AX^,N^F0
M**.%#H*6N E.(,9 #'(OHJ6(S >?& ]HI_6#V[Q5E;^Y8 TBZQBT<ME14%K:
M0+62+ (#'21S5>5?"EBGW"(9(SI$22 ZO<=]+G!BO< =#QW;A',(++C5-;2W
M#0)K5?EG.D526FT%]=DS#](':Z#T1S)9"2L,B.H4+1^"]':5_U#TANV#+L>Q
MX65,\/O@4):2?:W-#P?M_1*'TL4Q^7!0G*(<&6/",^*$U 1X#L1[_"*S-=DG
MHV**XWI]MZK\>ERO;\)0=57YY]KE[@>YJ@PN$W]3?%5RZ4U2@7"0@0"Z&,1:
MGHDU2BI(W-A0.A/_HA?6F+BJ_ W$LO-69ZX]A(A83LEQY9RVAD%*'')5^1N(
MY2DZJW1R-G%.>"@%PRP"VAKC2=;<9R8U,TJ/L5Q5_D;!<7;]:2:#-]P+EBGD
M7$(Z$9E:&&D%J%PK_C4 A&P.X?6HA61U>_-#O[V/G]?98:W]+1R#/=;=Q]_Q
M]@&.T: W^'15"*V,/.,D:^*B*ZUU'"5&EFA1YIV32EGM1,E*G8O0B@42VE<A
MV]P/<G437";^IL-6&'@D+YQH;R("1W%2TA%P$PPBR.2<%7%!>6Q5@FTNEJU5
MV='L/3<.7)).*<JEDT#!2$=E);3-P_)T%+;RX*7A)+@,!(1SQ-+ B5*&N@@V
M1[ZHG-2JT#XVH4TB*BM$:6.D@>$#YX'QQ).0@!,:*J%=/@CY[0IM'+0&NX/>
M^ON#-EX3CA'O[6_@]U:)'H V;_&2/=CK[ ['.:DN2ATL(X&7 KS6"^)*K95L
M% /C@?JH2M4_]==55OK'A<>:4OA/3>JLF"K2SK4/W@]U=1]<)@2G.:TNK-9&
MHC.(<LX1B4=_A&CPT4F1E'3CXK=<5)'V!6.Y5  4S)KHT'@FY@UCSCLOO6(%
MSY73-A#+TYS6:.'0!2&<FK(C)D&\DYIPIYF*P8&*M(9B/Q-.RYV/63 $(5/@
MD>A([QQ+T:9L#8?[-D*OG/:1HF-E:]!EK7]-B;2#+CZWUSDXZG8"CMENO]TY
M..BM=V%[<^_+]C[>]R:^WWH8E>))^#FLU=G@K0$^=[#WD=H0J1&96$B:0!">
M> Z(:,DD+HX@*!OW:9E9=^4'T=86T?:Z!H:MHNU\E:WO!<$::_=4@;%CR&V7
M6#O<X0+'Q6DXHD1I3DIB*&'(;3D5(ADMF]:,K*JR\X#U/__#(+[^IPIN#2,G
MP5JG<X <>0#+/-I)+<!:GX.DD&J>6 ,L);V5G QVA]W!AT%KN &]01BUUG<N
MV^OQH#O:N]K>WQCU\![:>!UM)"K3Y&3G(XA2_@T<D3E')"?6$6>3)S8K:G2B
M%(Q878,W]-8RQTA.RM,614Y>A<=^/PA6C[T1(9)?F8N02GNC#<%)S 28X\1X
M_!*BC=HR2UF YGGL57U[/.Y2A95'CWXSTC$ET)G+"@+W'J@(SDCFF 'T)"IW
M6;ZM%'.4%+UJK<=A=W0PW.Z\Z^-K67<?QVKX[J"U6<J,[@[; [SVP<:7<E@8
ME?42H46"-Z'TJQ;$041G43)/C<O&E1+4\+,"MG?,<7^D)59SW)_#8@L?03')
M02N"<\Y*/[I4JB4G@DN"9294RIZMKND9:VUVCON$'G_5[FJ.^WWB+^^%R"KE
M/3+NIHZCO30EE3V3F*%8YVB)149,M++42@$Q^U+)%E25\EXN6,M,1X6^3PH6
M#&0?;,Q694J!*["JYK@O!:S3?3T0K1&I$Z&!60)42MSGP)$0*-/<"L6\65VS
MH!L$UBKHSG2*7-9>RI1M\ RTH$9J-,1*.".\CZY&4#8 @G [3]V1^/M1FV]<
MM88?^NW1SE5[<%!.G ];'1S1_=;E]N8NWM>[<02E5.CX<,-)9H6GZA")+^$C
MS#*K4U;4E4:3_ W<)N *6G+<82S@XN,JX,Z5%WLOR%4!=YGXF^*KD*Q,7D0B
M4HS(5U4FEB5\9#FW8]%!^RK@OG@L2\:9SI",3Q$LNBI4!X!LHZ3<Q<1K^&3S
ML#Q-9Z,WZ'HD0D7)<0],$1>!$F^9T8(%GEQN'I:KRC^3T#*F*?=)*F9R*4IL
M )AV'N>1>9Q06@GM\D$H;R>T^%H<B][Z$7[FAFB5E*#U=P?;G;TK'+-!:W/W
M:'N]=%]^?YT2Q&,6P(A),1/@AA*'LTUPFKD3E"E!QZT9Q&WADH(50BO&DBL^
MKAKK7.7<[P6YN@DN$W]3A-8H)H)CEF0MD<9ZKXFU!G_,SBC!2G.&1>405 FV
MN5@6( (ZH3CACH'CVDH6%,3HDF$4A*V$MGE8GB*TU 0>(U<%R^70FVIB3!)$
M6H'_,1 *%N6<5H7VT15:B EDJ:%6JG1S[2QG0&-@F04=<@VY73X(MR[G4&AQ
MC+:NVB4$<'3XI3W:[6^OAU*TB7?YGN@. FL/NZP[.#HLA%;;(*(#03(7Y83%
M!.) 2I*LE,$BN,' 3_LN_T!H^9\]</%Q56CG4FCO!;FZ"2X3?U.$EGMKLRIA
MZ8P; EI98E70)(O  )*DR';'A5XD:Y"J4Q7:1>?R 46OAEL/48.@RGMJDZ,B
MIZ@@ *N$MGE8GB*T"&3.!% 22G0=6)J)25J2J+E#K\0DJU15:)\)H2TS:5+T
M*L12+\;9E#FD&(N(1ZVH">[+!^$/"FW)69';4SED7='%^^J.>GTDM3A>NX?;
MZ[V#]N"0=P>?H-L)>(TMO+]/<E8.66+(;[4LVS$K(0@&B+$QD&2L4QY<U$R6
M!'=Q:P@"+PGN0BZ*X+X*E>=^$*R;8B,46\1C^-)"'U$;&D!%DE*I@Y:U(\8Y
M243B&8++3J5:E?298KGFOR_=:LYN"<0L4"^#9YX#R\D'PZ5+S- 41$RZ<I>E
MV\H?Q+B?<)</I?@.;>^_/^J5^R[Y[_L;LC?8N\3/N.P--O!W;Y'#'-)9W,5D
MAGNE-<1P*!75A27H5 (1@2:+3(8GITM.V:T5U84H"3Z3BNKXN(IS\X5<W0>"
M-4G@J?2WK_0D25\BX20!IW0IM"R($UD1J;3VBDH3!2RD.$]5WYX%.:G"RF.3
MDQADMDHJ(7P$J[U+RG,#V>@<M82:X-X 2_EECIQCWAV\&R+YN&RM[_ 2[H;7
M@I_1@O9F^Z ]>(?CMH?W_>ERG,LALTQ:"2*]Y00\D\0 :&*=U\&!ICJ8U37U
M1LSHK'V#C>B5OX^?][?)#U5*F8>.W ]TE8X\,LBFC@.%<MP)#B308 DD%HC)
MP$FF-$?\/:(GE_[SIFHE+Q>LS.K O5%@;8:@P3(JDC(^>J&RR% 3C)<"UJGS
M/JV,MEEJ$DTY': 6/6RG+'$Y:::8 %\2C)L%UJJ8S22EX')&-UTG!!J88'U"
M6J*\1GX2G$E02>GR(7AU.RG=*/=,6\.6Q->*;KG?X?N2CX'WCM24[XGVJ'VX
MO3YIT9*-#=127^+5<+/EBA-;>@XJG0US1GOP4$BIO54A,X63VHE"5ONSS-G3
MX5Z0J[O<(T-LBI)J0:66#K&A?"(0M4)*JAW1Q8O0U*NDZ.H:E[4!RPL&J\T\
M 3KJV5 *42%:<_)1:$[Q[J584'Q:!>L=P3J=4\&#2U$A1%WFI2,#$'0G/>&@
MN05# ^>A:6"M.NE,2JI88#HFIT4PH+4S5+A$2Y?S&(+WM>9- R XFB-%N-SS
MJ#5Z?S@^O%W? :2ELCLJ:<+XGJ/?^NW]+NMUW@\*)37,,R9+$I3/2$EERL1+
M6PHT!A64#S*5@#/U!FZEI+904IA0TMI19;Y=[GZ0J[O<(T-LNBM@CM;Q $1J
M+PG0D-%QHY+P3*,,VCAA_.J:$*)!PDM521>=_D2IAX3.HG :E$Y.("/5#*>>
M>8Z_JI1T*6"=HJ1"E*S>TL)3C8\T.&YI06?<X:0*6@<:16@:6*M*.CLG0@B%
MTRDB9QH\C\9YA%OF%/=)%5+-B6@ !.GMC:Q;LCWX[:@W.!JT]W>'O<$.] 8'
M_>ZPE&7<$[U.#Z^E1?$:K\9)OHDE:Y4DRE%#P(,D1H CB08FI3/XQ[+9OF&W
MG=P#+3D0;'QP#[4,XYPY$/>"7,V!6";^ILN&.X-$)#,BT'\K7:P3<=F%<F3H
MG65"F<A6U_@B<B"JB-I<+#-OC,XJ@C89T'0Z*E,4KI1A=!YI:TWR;1Z6IY-\
MHW+,"(YTMF#9.$N\C4"L<& C Y9!-0_+56.=26BUX\$ZSR*-&BAP=$FX#!"%
M42+C7RJA73X(V1P:*U[#WB6.RU6[4Q)[2Y)O@.W]#_WV^B'K#?">.F]+\LRX
MV9(SW <O#5&9X1YL*#JDF3DBC:6.91IR"=N1;VX-12V$MCQM483V5<@V]X-<
ME6T>&6+3Q_Y9<:N3(QETZ?VH'?&0@,@D0 IN2RX9NGVZ2;)-U5@7#-:L N<"
MO)8(5IVU<28KI9)RX*-V56-=#EBG2*F+"$ACD(5"26636A*;+"=42JE<8IEG
MT32P5HUU=F5PSZSD5K$<,@@K/%7>2D0=>HO6NE0IZ?(AR&_76'<'[5$+NL,R
M5KM'K5)(<?]#B40=X?L-NX.C87M]BW8[!^-"BLZ#MRQ*0G4(I3L'(Y;E1+P"
MB#S&[-.XD**Y[=@?QI7!S?C8'Q90&?R5Z#+W@5S599:)ORF^&H+DT5)*(DX9
M@:0HL>615UQ$ZPQ3TI4Z,XPU29>I&NNB U6CDMP[1E-D8'+PELJ0T;2&H)-U
MNFJLS</R=!0K&N$ *1 E+", 3A O<B""2VNHMLID.<9RH\HR5(UU=KZ_=DD(
MBVZ(I\"3,"HF;@+E101*J1+:!H!PGA[CH^Y@8]0;[%QV^8<AOI:WU[L2QXUW
M!UNB.]@]Z'9:7UJ=+B^$-OB,R)*!:!X\ 94XL3YHPHOX2L$*A'(I/F1OU5A9
M*3YDY:(([:N0;>X'N2K;/#+$ICBKU%D)*0R)"@R!D#PQT3/<Y[*U3)B4@EI=
M4[4RXDL&:Z)H##-GF0E6*OJ[9*7BS"L7>,"'56-="EBG^R\Z*TOC3!)YZ:!*
MI24F.$^RD4XF+8*.L6E@K1KK[&-_:Z,WFC$+&31HYVU6C)F@2J)KKO4Q&P#!
MV]N)E];AH_='[<'1H(54M-<I=;[Q,P;=46\]#K;W6]#=W[GL=?;DN 05@(2D
M$E'4 P'K*/&!&1(\*"1&UJ?DR['_[7&LK!S[LX51TE>AR]P/<G67>V2(35'2
M3+V6*@O"DB]=AC,E#B>;""^Y#BR EW1U37/;(.&EBJB+#CJ/3G'O,C4I0Y#>
M,B>9++Z[HRQ(42GI4L Z'8O*1(XX+T1JZDLTN2(VV$@2\\([A;X$0-/ 6E72
MV:E5.,*)J\RHEB!DLCGF&+7#W5$C.Y&5DBX?@K<W!!_\-BPM9;JCHZ-V)\AN
M9^>JMW[4[W5:EVW>$BV.]]_I';1&6^.JJ$Z*#)PA:DU6!!A5Q"B9213)XYH/
M9MP_4;Y1MU)27BBIFE#2VEYFSEWN7I"KN]PC0VQ&MG\PPAE*# -&P,=$G 8@
MF25)/>=*>KZZ!C/\MJJ2OABP9IX,,QQL0/_11FV3,9H+CK -B=H%=?RN8+TC
M6*<H*0AO@6='/.Y$I=V3(,Y*(%X:%TPV:'!ET\!:5=*9E#2Y&++EU&=3O,!L
MG;,Z2G!:.\;JP7T#(-B:HZ4W7E_GTY=6*3BUWI*MSNZ@M?_AH#7 :]EOB39_
M=]@>Q".\AOZ8DB(#HEXQ$I5"2NJ<(8Z%0"2H[,$GQE0HE/3V0OT@"B>]+M0/
MM6_0G*>!]P)=W><>&613I)1Q1J-0FG@6!.(DI-+0(I)2/BP&5P09N[K&S(/W
MN:J3-ABLG+L 1DMI+;KJ8+RFS-C(%=5%>ZND="E@G2*E)3N*\:2(\% R?C,E
M-@E.4I B2H4_.]HTL%:=='95U""LU50::@284D4%LJ=.,0A*,$TK*5T^!&_O
M'C7X<-@=Q(/MS;U1>[0[;(]V+EO##>AUWAV6XWL<GS[^/&KC\PHIY38X;V0B
MSGA32I!+8@TB6<8$.-M&A  EFO36JJ@@2S3II"HJ/JXZZ5Q54>\%N9I2L4S\
M3:?S^\@LLA5"5;*X!0I#C*"">"F"XB)S@%+%_Q?^\)2**J,V%\O1EW8;Z-\[
M:O'-DM5*0$H^,T&3ONX#5].C&H7EZ?2HDI3J/1#\(@F M 1]3MP=E<LR!)ZI
MBLW#<E599Q):9Q/'+=484Y*]2XWW%'S"S58HI@540ML $-[>>6JP<]4>O#MJ
M==[UVT/\[/4=V1J][^-S+]NCC2]XW;*WB>^WN7LP3H^BD)T3@01?DI4#1.(!
M#.'6&J$D5U:J0FBEFJ[8<8/1FL)H\7E_F_Q05=:Y:H??"W1U&UPF J<I+6@
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M3% 02O@LN7$T<J63L/H1TC=R_TN*9)1.3RJ,[PSCU@\P;N]\E()*'X4C0J6
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MH HBB;HRZ#DI0 %R)IT$[Z\,Q>)0# ;2$IL!PGF74]9TX820+'@TFB6:0.)
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MNL@4A0**(;RC@0>N@K/46\EKW/#T\M\_:.M4I# YDY0 5(Y& )2 ?6&3!.1
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M9I7 <YSC ?Q)DPN/CWC6JB.>?QZGF^]IO6:%FOLV76-+OJ<$7^J3M]TLDVL
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M&<F4=3*IR!<%Z2X B78L%4.E%%E;#60(N+ ' ^,JU<?!+TA_1+3*8"9!MA+
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MA@_S @Q!PE< ;DP*2(254>D<YN1SU?KP3/3!*LU<88PHSP(6LQ:"M!W">_:
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MI<]>.=!;:HN'"&.X#=SJ'-7B#:*>3>O(/P?]X9#$$XCAO7C6&)[ZH^%+ 3H
M\G("D-,_&:"Y]X<GX$D ^D'<AM\#JC!YZHO^D14%'G2&!S=BSD4WR5)]7;??
MVR65\QGWDLR]/FAK]?OP6U-7Z"#&.06B6SD?_ VXBWASY2NU0Q\XK)CPF-Y>
MN+>+=QL98-NX126^BOM8E?^ZX/ACCC[R?S/(.WQKKWJ0Q>*H*,()1IUW4N(I
M.Y TH83-BJN2@J]S(1\YCLKF/L31+(+(3!#P/A!'/04&)#+^)9B B*JBYCC[
M3MYL^H]QE(O&QU.(B8TR (#>>-/O)=#&!7=%)!4NB!@8BY*YZ*0%14B:,P-
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M^W34[VV=##[@$)SA\>MC3 H:9'R^K?+&]PZ&=7;0'#M2.(DM6II+!NM1F2*
M8!!]% U$)U<<Q".F$4"8&1O=E[E\DZVQ2R4<[XP%7/^UQ@:.-<*?1^0&S0=4
M?0"V,$X>OOS@'AI+#[07Z&!E4!/MO\@ON6V UU):>T5/9[GGS=&M_'EQ)SC7
MZYI.092*OZ>3 4#N-,R]7TZ1=D^;^SMMZK)0465B0)V(-"$27X0@.44>HH@
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M$-,M^^:?ZY*+P/EE/#IZ.HK#631X^B]ZI%%J:F5]:N5%WSLW+EDPT3..7C#
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M^N>G=;L[&UYZ?OQK+?Q:9?T#3H:3EW6Q/>HXX\?7K[S#;+50#*WE#%R,S)<
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MQ3SYSTS:2/\?L\J\ULIQM@'TX0*TE"B*LCQ+3""C"4".M K@<P)CP#?M>N?
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M!"7Y\R$!4!D50N)>,I,X:#]#'<4L<"8PF#5:%*MF/;'O?$[T@5$?)/B=B*F
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M<#"T[4:")=N?'*96YSL,X GTK@^_-TYAL;9\^[PQZ-D0P\3S&K87&\[VX4,
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M_2I%_9\P9M<SS3O#$Q2Z S1Z_R6HF&<**G>GZOQ"=C[L'R1,O9:9)$ ;P(3
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MD(+]==KK AX,ZOPH (AL?-V./ZD-UX]0?8P5,V^N.M;JU%VK.E3'9V]\=37
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M [BJW#MBL'0:T-]DWY436<RV1]4#7V8#2TR1Y&TDR"26R5-40HX(BXP2P=I
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MI>'!H@5XJ73;H+8XVBWK6FV0Q2JNW>F.30RX:NIQ<$6MV;(0UK R^\+IT[N
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M;LQ]Y<9>@&93E44A68L6?J/S\  =5#VR]LCZ&)"UMS7<$?0>S4.O"@*A4@*
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M7Q*104+\YB73+V-_D,3^'[:L7!PG@]AGV@I<-C6LZC9VM:O'.2U&A1B:=K=
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MC/WLY3&*#_!9V2L"UU $]K</LSA2DK+(52'S7>9[W$TD9VX($$J\*"9) HK
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MT481IQIJ>^:><\WYW\VV7W,)_N_=S;\];]V^9Z,FOE(DG95R+:*H&]Y6$CW
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MP8,YQT#[W[20%_#G>'HZ?/[_ 5!+ P04    " !.@TE6'FALG@8F  ",O@$
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MD__][/,)_H#QX/CT\(/WB [/3C_B0X1]_Q!/SP8(??CT'N$3P?0E^AQY<[Q
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MS&L@4W9^3;6M^FYPWUQS5XBP)Q0D,.80[Q'M,U,CH;+[:ZHN9^,(/H[$J$<
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M<(9RMS2=(OFEP_88C!V*L.(:4)[K34QS$6W5:#8X_4$O99PV&QO&2S4P^_U
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M5<B +O5;N_]+P\QZ[FQCRXZ*P1]MM?GQ"!H<0?46Z*<__2]02P,$%     @
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MO432K_CZYOC8)!*B: 4Y2K$R<Y$A,%=#S,X4[X0PO5-(#[GCMS/"_1$8<:0
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M676]1<4=AU8.??. \</?EJVUGU;6(<?&D+5K1_-=@5"DY)&%@,47PM@]2?<
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M#FYVV)K3.IZ%T2VB"_ACR,7]US+J1K ](YK=Y^V/A"OZZ[_\/U!+ P04
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MUL=\DE75NACDUP@;G#8J)]:\[,06\ITW$WM#JH>PSLUD72P 9C$[3]ZQ*#J
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MSI#3V;@)4Y[(-]Q$EA/V07M1=\,=9!/YELMB$PD;IA]O)M7^<Y';H[D%53I
MT3A1>4-)&:=_)IBCS3/0WL9$@8 Q@ZK!YYE'G]D^=I$#I3 ? U>V06#/'/ER
MG;]JP!ZK,BP#SC*9404E>$4G;^8N!QF]2WZC.XZN9\X=N?:;&-L'KMN<1EU
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M41BEFO:19L,/I S::%Q./"FR*J16Y-5[C[7:&2-.<L<PE=S^:G%+$<^ -/L
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M9BU\.YLNUU!^-LJ_T;>'E_.P&_K9]17]^F@61A?#6*NW6Q:38CD \N) L:+
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M'KC?1;D;5BZG'KAG9,O+H#CP+.EE<(HXIGD %X+Q.2J+LG4^[[,-W/>2>\?
M?1_^GWH8M,M>?@3N>\9#>P%DR'CH+M(]=<1F;;B4+ #SB9/2D3T$3/1:>^7H
M34?&L75JW.DC=<? _<D M8]06]=U/KQ"YG<4XIO0,-T2AJ.'5/]06E0=UR5
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MF0O?B;@I/^I 1I^;O8O$CU&PN0?S'XIO#\XU+K6[2TY@TH3(:G>LFOSLC('
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M%*2N^?6UWY37R,%8 FZ,1LK433_HON8YP& @#J]!PGX.P^]GUL;KZX9,FWE
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M$Q;NATV%&/S(LS*$IO+=8 :')2CO[74CG33!7%WW:N21#BE:?RX%5/2$D(<
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MP]9''.\D;2;]I[2YG^AZGYWW:9^4,F-&*C"\>#);GR#2&0^N>$=^9%;>[G>
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MA-)'YL%)KI3UR'QI?2D^#-FW'*MVT%W##6=ME[W+9=V7%2\&+@#IU9*)PJ1
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M;*;<<7O<?IKIR<NV>/#"/GR??MPPX.MA(N-N3-CJ#::?O;DD0Q%5X4+47O]
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MJX%/-[&00_04\H#)ECPN9SA47PA<3"0765NMAQ7"CW_V>9A$9YD?89S5F^4
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M=_LK/F&]T8 '1*.5C1J,!<-MX3()+$IP"?M8[[U&)R.\?0Q@T5"IDGEA.L?
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M^BP2F"[_M$@BW@+N7(Y/2G(CHZ1$I.K]J!09T'J95!AB@J!]:;HT=E .[Y/
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M:\>.?O?O^B=2S?K+3_\!4$L#!!0    ( $Z#25;5 QO?$9$! ,M" @ 4
M86UG;BTR,#(R,3(S,5]G,2YJ<&?LO LX5&_;-[R$;$OV29GL0DCV;60JV26$
M4(FI)+N0=G9C5E2$$$(14X1V3&67[60[(4EVH8QM]ID18S%KUGS+_7W/^[W_
MNX[W>_J.^WCN[WV^_^JX1G.--==YGM=Y_L[?>5W7PO["'@0V'#8Q-P$XUG
MI]%_ /L'L/[ .;^S;H ;@%X<['[ "%C#L7JMOJY9O;@X5U^YN;@XN=9RKUW[
MC\;#QXLVGK5K>05X^?A7+_1_@@+\@JMO5K_D_[QU#3<G)S<_SUH>_C^^V.\
M85ZN(]R!G!QRP!IA#DYA#G8]@$%EY/Z'>!S _W5QK.'DXE[+@XHA@/Y"\094
M?$Y.5&AN5&+TTU#T<X!+F%M$5O/ 6E&;,SQR_F):80F/>>4/OJX1MVVG*6B?
MO13.QR\AN5%JD^(V)665[3JZ>OJ[=N\Q.F1L8FIF?MCNF+V#X_$3)UW/N9UW
M]_#TNGSEZK6 P*#@&S=O143>CHI.3+J7G))Z_T%:5O:3G-R\I\^>ORDL*BXI
M?5M67EM7W]!(>=_4_+FCLZN[YTMOW]#PR.C8]_&)R2GZ_,^%1<82M+RRJA<'
MP,GQ']=O]1)&]5JS.@<\JWIQK E8_05A+FY9S;4B!VQXSOB+RFF%\8H=3'C\
MNH9/7MN6)G[V4CN_A(+.D")]5;5_:/:?4RS\_Y5F_T.Q_UNO/D"0DP.=/$YA
M  NPX*QH9>#O]M^\58HR(ME > 92![ZAU.^EWB1+5>_*+XTJ(JUO(DV72]P:
M:K4X6=9>=)^12JZVU.N[['KA\:<'!09%'/=^U*RM\AMR;  CB)N1+9,82</U
MT+0%73]"=UJWO+WXFP1]AWK!L$+L^PFS75N?;;&_%\[!=93G@''0> .UKW 0
M\XX81>" ].E8"OD,W;&>==99^UTY=T'JU9"KSZW%"!<^B/2I"!ZMO^^IE'I.
M,UR@?-3Q\2<.8[&C',;BH]@BO]DQIA*A"=G^J1J#]X.*M\1'P99B;Z"0VDUZ
M\2$OO4_>L5&M3*S+\_S4=E7!Z_7[DP=DW@F_(=A=%W+)JLQF&++*L&Y"_=-#
M]\@;P7/8V#U^L7BL'[X[(-7A:!M722F'?>6S_!_R<1Y.WJK 1!F7<,(I,D4#
MVAX BU(97A 9^PX3!Q9;1U3N'K$(E$WS6^>BTWKEF=I9L_YS_B4!LH*:?=?W
M(='+AS6@'?JPB"\HBN&N8?I!QHMAFC<GE4NWC7^0:@YRL6+5\<A+#5=8][(!
MA#^4N8;0A1%_ DDS#9%.0VFZ:<SPZY1YG-!Q@ZRQK?&^R_Q[=@ #&6"E,N>
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MLTN#AJ_O^;2QNQIS"F5ICAS'?(0COCR\Q:FDC5=GQ1*DX%VL?$-E0J^M9TE
MM184EV9_NW/@0U#?M5175T$^CSCSK08M.A\=/2[4;\2H6(9PBW' E; X&TAN
MG,/.#.NR 99P$*Y=Z0[HBHDP5&05X\69ER97?#(B[QAH#/DXU97'SD@<WM95
MQ&R3S8X[L58@2&3_"7WW-9[[&Z>0:P@_&V@>"2 R_#>AF?-V)6FRIZ%CNGM
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M7"W,=.VK:@[3!BE37.E/C)=]/MS)]BQ 8V5=)CH9IPD-Q%(L+'+3&RS&U66
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MGP4CA?[5$$,KN$7SJUL[/#:B9>&O/7FM1;Q2>,=)SXRWQVRFK,2TA5I)D*$
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MS3H'YQ*_MMUF T/]V$4T$.;1ZOI'-/8O[U:BHUL0>=,H< '%]'M/T>["GVP
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M1RBJQOY:>ZODN-;<0[!$NWRFFF%&^4!/C=-&;[8/Q!XW<_1FG1Q<';RYX8?
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M6&/VBKVB^Z&ZR%O4ISMS'UP7VGU"H/G;V#J/R5AV/)8KP&!=@K!,8SII9FL
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MRO2J#:.\GU<\4'Y>91W_^?/GPB=N;IX.D^6N\@IQ+W!(!Q6N,\$-W9]$]6Y
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M"XK@3TL>X*GZ.U"*>R8?Q2' @V(R70M6-4^L:(Y5P#3P%3'P'^</=W$%?'B
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M(J &I4J+"HB @(*(2HD-$1$0%) :%6D"(B!-0J+T(B(@(")$J2HETJ5&NH"
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M-FCLEJZ;M>(![/=80O9"-(%2!.KO1X%(9@DN=7OO5!;[_D\Y;;5L?1:;0 '
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M\9)H1C(BF@5;NMF+7+L\H*#*[(!PYZ;RX.3R)F(2N4B&6D6\VM8L+FSFGR]
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MAMD-LP K#)(F'%OXSFVQYNA;*&]PYO+#9PU'DB>TCRE*19P,K=^W&UBM4NG
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M.![9]&!OYAN?/4?"Z,,*IQK?C'R)8PS$FIXT,Q@\J2)D38J4%Q([\MKB_%Z
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M$=A@"I[YQ+J'6]DOYT:(-A_8;G26&TG6+Q_H('8%U:JTR,V?Y*O"-A-6CG&
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M#4[,IFV $4R[',^DIR69W<-*KWR\,[6<R=^5#>^,I93&6?4@1<G1(.DW,C)
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M\:BW O.LMUOJI$59D,\N9?F$(W(V#\M3_+_DG;YX4*<G!X-AQ;-EV-\=-:
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M#0Y9C6!N-DBF\X^U2^WHR"Z.DP"6SZ.9*&B2ZD?'4N,(.PUT,)=ZF7)O3G,
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M[[W#FMJVO>&EJ$A1E-ZC@B+25)K28@,$!%2D"[%L04!$!"2T+ 7I3?H6E*B
M@#3I4B.$(B =Z9 $1#HDE!!(^Q;W?M]SS]G;<[Y[WGO><Y_WOOZQG@=C,N:<
M8_[&&+\QUYQS-(:W60^^"^W?L&6+$IYN4R&/[BN;LW99+D;HT[PHIPBX81&"
M?"D1T23\H_!V&B5HT&JN\ZUMN%/H8CB+K+A=_XG8K%.UHZ=T;^WM<'K7I7'V
M#<4<VV_+31R/=KZ;,=OO.FSA0/[X/&A\;]>12V%G3$UWG!,%3MG*BRAME>UN
M;+V>LG'=>9AWK"+>YRQ-OK_$Q&K5 6?.MNC*EAYO5OO01F%*;'UL:-89Y(=X
MM'\Z:EA<@![L*PT%5(D:"C;+44OB&WC?*8_#C!A^4EAI^% O;:IWLJ1IL.SW
ME ?S4.(\/I5^9S=JT+J-',(-RO5Z[QDZA)77O: NO)D$I1C^EQA-5JPALE)%
MQ-K<<:$>7Q>%"*6"X#C'\R4RFLZ3E]N'SQ=_/23K%"*L\\RKX18W5V_I/.FA
M2XQ=?A+90]S@;/E2%K7(*5;8Y4O<0$?;I4??/\EB]V2N9Z_::#\<S]9R<*(-
M^]5M5Y!.G?GC/9'SZ,(!6O16$OT9E/GH-"-TS#O /WZRWAS !%:T39B *!-0
M)-FJ0O&:AL'"MLOAT<]M'OCI>Q1)>B'X'3V+(0LAZ'Q'O<>\I!:A=$22"1A"
M0;J5"<QDRTS0+D%444:$P?5-?(,3_,($N+;?%9[=MDDSU-J?%Q)K(>XHI XI
M/?F;!Y810U@>JB+,.9"#/V2&K!?6FIMT+1:>%]G16G9:5Y]ZY).Q/[HXN![W
M5#@ZP@,=['WOJV>M)LFY,U3#T,L'N=KFYG?2](Y09XOP\QT2-T]PXCF3UXN^
M.HOND[WTFIZ.)^QO>YD!)5&+'?>9P,BXKK@"E\:E686B]'3:HB<4")]9TB(1
MH4Q@CQ:OKT/O@Q)T&(YKK<9;[#1#?5%V3N7#BL78X59C%CKEGFU'H,5OJ^V^
M59/+06@NS'UX>!E(-(I^IL71J\05@..R*^M'*36^&<JHR:-C/Z9V8K&W=B3;
M[9Q;6+ER^^#O2DVU30G"EX>5$EX4O1!S3=@0VH6Z\REZ:)[L30&I2I0]Q@ -
MKCK X95C,U?95) S&KI<ZGSAAXGLAN?I0,1ILSM['@&FIL!NP-;F91N+SO7I
MN'@P6*36HF5\=;&=CSB+LLL GW2X6FB'9"4DH!NV2FH[T^:_YPT8=X!1N++R
MQ:,D=?)'>DXM#'EWXGTQ/H\5SUI'I>M^KC0/GN9_6ZI^S45J1/XDO.<BBL0O
M]?7"68'O8ZOH$@P^"5ZR'(5Y@!B\"#'<13:22I.@[_D\2YN+.9K5.\\LV956
MIW9GFHH>C_NRRAYQ_-_+KN,8;!E499H?)6$"%J[6ZC2\OWP2S@G6GYU,B>9T
M='J@H9NQ%%K;[EX@0@Y26KVS,C58I;HX49-"0&.-=_J*4,!T7UG*;4*XLPAV
M:]_S)]Y&+^W2=5W8.7<+218N6<1^U9.,U2MPT>AXS/E03Y<K\&V;Z1F;(9GC
MO5/)M2O3:,Q*U;<2KTT4ZRGL#YX<JPS\9F6-BTRST:O"#1 O$K]]&&_Y_]Q5
MHH.(08NYQ.NSE:_CS556FZ[[>$WNCY46/-&*/!35E-C?T]\T)+N0EQ8D&"_K
M>NF9*3 #B.ZX?LUHJ9]#9E0&KD]$![J+65\;*(%SSI+-AQM:Y M\''Z+:?,[
M<NB2U^MSIXO>L'-PGP/VRUP(XTV/TULZ%C?:3G()T(!-TO> [)3E^N2'Y1FC
MDXO"#PONBK57?SHKDO:"[X&X%Y]4$$V1@&&]_V1<B!@<O.">I]*AF9B,2KG_
MXOS.:?7K2CMNN'6QUVB;EZ"ECHZ5EQML?'S<G)(\# WOZLG_V>LX8I0-B*7D
M(LA<T4S@HC=E7 VRI/64PT@%IP7Z3-7*JK.?'))A_^V1ATO.](DGF$KH6]/)
M,GW'MRM034 ,I\^3 >6:2\'SL&'T* W$BR.TO0-YP08HK\]:IF5 W(V%:D)%
M1]-8VF8*KKZ+I@2 ZV),(!Y#?0,Z@FXD)O#4RX]O[M_J0+HPTC K24S G6O1
M> D%)W(IO*NY$ ;_BV:>T;/IG<V,'5-KYIK4^ZAA55A1?J#S>YHF'5UM3[)O
M%GY=DJ1F_JR:(U.I-_S^%RX/C^-FU@:/&@X]X>R8=I0@E%&F:=Q8!L=Y(D3"
MS2<5^'U%^E#L3HA]C$,4K;'\4CB'XT;]C'+1E8_Z;0H)'+(Q5[[$ZI .FQS!
ME[>7:^-+=5F5(WL9->#&Q<2;%P.##E]U&O>1P73T8Q*6_-BT?2>IYR ^5JU*
M')C -<&"$*Q:N_4FP\&GJ8+1%I24G/8)U_>YDNV\CZV&I(;>4V]TYT:U_U#:
MRRG_++0.?@W5@2L!ZW'# 604$;=XBHBUL"-B0DM<LX9O(HZ'+G;]9B"*E91H
MF)FAO1 2V15U/\E__;!(]4/T]FZ7ROU)!V[GW'#'YP^@[>U[K3653L]\0!="
M3E';@VJ+5+2D5+VAG8V[3#1 ;E_1J;;8\>ZWI$9A7ZDVYZOGIQ2&WL2:OKC
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M6B)^5N-[6V>[KNPWW?4@+$ZP?^RI^F^']6"6 _@&.%'?922Z$??1_CD<GSB
M8RF-5&RT@B]*>4[L0S09.QH%N+QYK?[%1E]]22)>4;_QE@DY>NQVVG5MU(KU
M1;(/<I$V ,KM7'XQE<(B)%61W6"2R?&X:ID)[*"UM9TZ4WTAJ2PP-\G <0-Q
M>.V:MEMJUA_1.X[JQ*THVX*#$&F<<;"ML-6EPL$OW[R8P*U5R"HRO*=\AD!J
MT;K]CU<0]"0<O!6V<^ E+>1/%Z4ZF("#G#S6C!@8+_Q<_(Y\>NZ>B;,KHT^T
MUF<2ZAA=\)430U (. ?.<-T\^YI=,'>WONF;#/Y2PV/H#]Z*_5\RCO]8LWKB
M2>?B8@+/%;&(-2CN?NED*('U0H2"+2BG^&[/!(3[WM4*T"T)F*V=:1#R((KX
M!9WO=P>SBJEY"1*#D$Z,9Q#?_;<W_Q<UE)G .1PM G+!5O'7&+E$''T'%.?K
M'D&B+LY#2>UK^D+;WV\K>MT>0N<,>S2#(WB[QKU% 6UYV0Y!.YPJS 3>N#!T
M0%(:XT#G/K!+%=(/G-*?P0OF:$!_G[L!$F_"-P]L-8+3H,]I)D#@) [06< 5
M1280"?O+CI8>3_OK\03WRS !=>H0%"I+$W"-X Y?B7A4&X8UK]ITDFY'UE3%
MJB3G]14Z))JH594NTCX,10T?G_0\@[T\<29^.<%I9;4.0[R*H)SH7)#;+G5#
ME%J F,KN8]'UXR>W=[?5F-5W&J=@O7VO87>9E\/OA?UH14H$Z:QDGHF5>6Y_
M(E-P- J\_S+A1O%)@#/66)^VUL782_%AL/- 0J3*MX^8^I[_5%Y(D2+"].,,
M*0Y9<]RY5Y%Q)F6)#@_7/R^=L^;PLGS^>/I!WH-8Z<&\J@_!^XCU$?$?>:W*
M:5N!RSW#XCKW-'P_F"0(]UZO[-:4(Z?8F%9MRK]/HO%>)#=2 HB3#/;=1!8&
MVS119X-Q,)B2XJU LY[<ZWRGHJJ\]WG1D9%AN1Z#G9<9ET92+W\?5G$6<X/3
M#@:0OY%PBPE<3;  .$PVKU2!UU>8U#M3A'S7@UO 6A9[Y:?Y6]X)/YB.'S:H
M:C.]('3RS7>T#SUG^XH:)L .4<$PW'[POGJ[YW4BK@$6Z/VYEI@4NI80VE%?
MEUY2$60JH\$5797@(;GH,5I7^_ ;QHZ+ ]62O%U:Q@'5D"K3+S(!-K\V6FY
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MMV,!1S0JV(0C D#R]1(7NFP4)N/#SW<G;-FS@!6FV[?T@9)^1YC =S]_)E
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M5\(8/,0,T[<O,+F*TOAIA/E9\M;M^#/W$=Z 6)$LF-U*6Z;)0B,.2&("T4S
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MT>Z+4YFA-S54-BK[+D;V+SG_-DP_ZI-M;!%U#FZ;]<\HHMK)!!R-AQ&$Z(4
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M?C]Z!-M8RY52;WN*TDC(TVU '20F)=Y-NM3S8&$Y7PG?]FRJ16*TZGF3F7+
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M&;Q\^,"7Q>=M?9*6$5JY)NC5W8]]4C'._99'XNX<R=Q2"U)'F63@X8-2DTR
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M^2T>L-J ][\!F^A?@-S<]<&7S:GN)E9R)@B>KU'/$%6J1$Y6!8E<27B#6@\
M-CI0$J@ ]*RU!?#I+DU* :/,MC:L(E+]%U171"WDZAU.W%,</7;N8\VS''V=
M7_NW3R$OC6'/E%[^^5>P(O2.5TQPGH1+;AWOH2(5NP^'=++WNUH>R.0Y,,)=
M\#\2IC9 "MB8LZ6C6>FZ_"@)W 1>4KU5LA0]]'5V[6];V?OZ@#OFOI:SNN$S
M^^./<L7>"(+3O2&W[[.[\8TX4A2%...RS,Y?'B@\Y=2@#*SD3 #3B<[>OU>%
MHV]<YV%$U?XZ<OHKS41^T2R:0-5B>.&&"#7#B<]I1*H^[?1BQU_%7\*1;0Z=
M7V<4<OF$OV4>SSSN^?Y(RYX9LO1/8PFF/:#?2X#]((D92P?95'Z_W"V/RZ^4
M.?E,4MO[[J%7_:_LEH],=^WA413RYWSV?^B+=\-I2"EC,28<D-N%]6AE$$0B
M4+R8T/-9N.>OP;2+J9_&YN7W_O#QL;,B[_N:#?N@]UOEWBZ,W+H(G$/+MLVS
M15B5?NWCP<K^Q%8+1->&$-[+[<W/U4#S]Z[/Y*+VF_2=[('%Q)A%?^M$SD[1
MO5C/6JTC*5IWD?)&&LN&<QJ"4Y>:=V'W7"ZEV26JJ>4K9_*>'Y'(^H91YHBZ
MOL/;>]3V^0B'F9C=_QHW%NNUJ"J !=T!#$?U;,Q*]KW!>'5)U"FZ%%"IKX9#
M C_=*'=)D3I;2CEC+!GF].D2IP7]&NLUR9<X9_%>$BV.\LE*OXS*8)[RJOI0
M]F5M5O$5S2Q:UOX<D/U1D")+TQ_M@=T^)69OPBTV:J1QS$W]H[?9/EJB3([5
M 1%#SOKE[S%J75@SJ&,T60FM2@SO:7P'RLB"8?[],T'RCR%FI0X(OG\E5-D2
M^WTIZ*[DS'+^4E>IUH&<R4<O[P_<1T3\SZ@_,1IU.[TM^O9BAK6A?"Q'=M"*
MA@J;/V\7QI4[M7[]CPT__2L00VVX9^[&2+.M_R!7RY&]J=-]6A7V]*F@*N?:
M7[45.22;_P%T?CY-(&&AZAENWEBHO6%\\C)[=?#*@-R;X/O>/O?N??K<&U98
M,=960O=DO<;[#L^A**SA'ML9OV7!!\MXP9FUL8"HRXUI"KKV"Q:R#JV*M?%O
M%4>UZ6$F\AG_B?;QDY2<A1/ESOY/@E-?\9J_/V&<Q(5\+E^_!E.M)&Y<'0_V
MG;A^+U$-<]F*ZVA]5H.I2N !]3[.!#NK[QQZ%#0GU)O(-RI4%5I!Z,PB&4]%
M41:%,*LSUS.&$T+.?[@#GTD1K>I3#+0O.9#H&,=S('T$WF9OAAVBA;+YD9!K
MGT!N""UDF!&L:EVMO6#BI/@O7938],*/[; 2OR"IBKM7#G=T] J>>(8H]R<^
M7H5Z[=,NK$-]BQ4XWL4^Q&IB"CS_@M;\:;IDO3TN8O9)GU=S3+?WSC?Q+7P2
MUH*R(>5_''<$R&WS>1EP.Z/V2L#?W,*(AW/SG<MJBC</'EDSY3H*=<L>ZO]=
M,1R>@-F;B?V7'"ZK4TS9#:B23]-V84S1-+IX'; +>U^(<U=94ND)<0@1-?D<
M,A<\:Y-N#V]O@UI^WT?B/LNN1T$/#AQX1AR[S+38A<7/H'PWY$ &_1IXBG$!
M$VI3]-,"C%P*<3Q/$[[+SW_IS\6ZS>M(9"17([_$<B\CN<]9C.,G'@CH6T<
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M(A#^SL7?'#__ZO3N"N+7V=NY^6G]P6N7\#T?$04!)."R5L(N#+$+\]_8PQY
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MOV $.OR]XMS\T'7F!_UO3LWO/ZJKEM-E)3H?^/2_:%MU%?S=IG^!)AAA?R0
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M$!B:M@L+1*<0&DA424KH'O;8PGY OUM+[/)L$%O!6 >\HTP*?]FJ/^7YX[Z
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M;N1^ZWY/R>U%;4[E6*,6%^B"#:S"9R-WL@_(P5!@^H($\K#<A]>:*<M9?)A
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M!<#C=>")N6C]3?J;# [,\X<HRHHK.S38,K_REV>VI-^*G.G-BRKG9Z UM>3
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MI>8/0RUJ84_,P\4_9+B]D!IU.OSE**]O4@=./A=6Q " MML $8NE6L-37?=
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M6UQQ&CN/ID?O!44BYJW=S$>051O%!VB+]>X\A2T_%]SJJIJ3)-5[U$EZ"*E
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MO;'CV?L;H7'![AXPYF%6%22M2CPU*(<IOC4/Q".4V5\Q?-0T+$E+8M:P ?5
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MC!,G-*^/9O,IUSF*9?FIDP]9B1_OC%E&O<[58XJNM[%U(?!M%'T_R!M4"I<
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M/="H($HJ:.\-)[SK=KNGMLML5?8@@7K63YDMH,'P .6NC&'VA0TR3"X/M2B
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M8Y6N0+1]@@PK$.?H=.(=T"CF'4_(+G$6_WX%'[^6;/*335QWY G\B4J#Y=.
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MJ?QH^WYY,/:E4X+&PY',>S^/?V05*2ZL"X.\88#$F-V;!!$V. R447V9;X1
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M_\:+UG?FJCB7]NS4F9B=<3K7"UHM2H<^!2=>XP"+T?L>S?^LF/%C1;106E*
M%&!AUJZF)G(8X7O:;]_SI%D.APG*_9S@7<=7+\!=,#"2%7"GJ*.;9W0TFS%/
M#M0/T#&5T['G;05M0G2>[OF)3GJH3/YX[1Z2O*V^Q5/['!21+4]FI7/?(:*9
M1OK/K36B37)+S%7W_41:^XZG<^",F?Y)E=HO?9+U"9O6EY#MAUV0CX.B9%A/
MOD#+TYD:JGLM&$.VK(33#$N\=V?I',Q2CDB1"JF\TW0VTB?4KVD.JIK[1Z#&
M>L1'3YN 7M>*3Z\."3FK$+UP[[#?K9E(-^MOG)1#^Z;\AP *!8QNOHN^-_WG
M'%H]AI>)RM!\.]$50%X>0O[&+RHK83S\["*3U#>%&^UGMJ\+:NB6SM3572+Q
M-#Q[6ER_R$,9:?MA1L8QI]A59@D%;,3Q67UZ 6'Z6;928SB+Z<"&TK%ZX@:F
M&&ZF-J;"JM)#EJG3O<C% :N)CH_8FE[/8PX5WQ,FGHK4 *3H'!S$XLX05:3I
MH)Z\WRPV]N#:^6%RM>;PP<MI+XIAO&!?IWCJ6$&;<^X%*8^9NSGB_K*!),IL
MYSJ3"QXY^^=2+::YZ/"Y1'$B@9NGX\\'9V8\4]HS#2SV)(_[W*U+J_NV5/?)
MOR%&INGGS[G/;N^XIYA-MC^,)KI<LX_S?$![KYL_F.ZGX$NYC+RTI?>= 0KK
M<I% U[>CHIC_*Y^N@L?]N3)26K9UW7N&N\J@H!106MEKL8_."3P;*FMVEG74
MC*_+M3)]E$TZ_8SI*IS%:^_7G[V-RD;$+]HUT5)/^C)F+D5"+\,=F<7E,NDK
M]2)QA'YL/A<1YU29(D"J2=(H"8&9VAX>CXEM=V"MT$@]MWN8IYG_T$'(O_H2
MQ,V#PG4S4GKKC=JR:EH<TB](C*_!?Z(]T*?:E?."?_K2A6\'(UQ$CAEX7(,S
MY3XPVZ:SV4QSOUCWIOG1(],"+UXCUV?2^?*\A<+W4Z"3ZH=V-0281;,I81F@
M2U&;M)U*=(L9$R#\R@EC@,(50?<M;S% Q)05!FCGC!,#-&UF3)6NP]'8A7![
M_;^.MO\M^[?LW[)_R_XM^[?L_QY9*]U\CWO)+47Q%2I?688;*LB/::5T0?IW
M RX#3:#WP8%UQ8:#KEORB07R!>A0ZW'=?%\C_Y9%A0L+.*C!*7K_=(TR50#3
M5H/A0+LK'W-"V!*^6^W;?UI5DPXP0B^2YXU_FF@+]LW=V8+XDK;V-P7N!'C%
M<1VK^_T:J9[S"?.&;KUPX)7Z>68A=$%4*3./?\4F_5=BR0'9R8^D/TX>8N*9
M#H0\(3U'N9F)-PTZ(**([E!4#ZW0-T$_ZNWWX*AX6<V4Q<<?M^[%5QRW:M@C
M>S,E+*GW:/E4#UQE$I7?N_V@8.C'MD(?8.-0KK1X;=Z*,/#7\$GP<<-HT*S*
MBYNT(Q0!)HJ &G#3.^J0]L,9>'G<<:!]9CQDIM%"F-HF[9P^II?LFV5\N):5
M<^X..!=-D&&V:NEZ(P/4E-Z U.1TTUY'S&HE7K495I>B:J'C]N>G#OSJ^D)W
M FX[N5O?50MU&NM( :16J;W$W2M-W$3WIW0)P*VW.?LH<3(].7^9^.Q3Y;K!
MZ-UH?O&TFR!]V$?I;&^+STSJ\$_U) &F0>@#?F7T9@&VZ:F4A9R*C=F].L@-
MX0X54WGI_VKXASA_Y_[[PMYQQ<I#Z+R.<'H4QS1EF4DYGF;8,D YE_;H!_:@
M_X8DEI=6#,5CT!6VZV$N,KUM<%;%=-S\>C7))EZ08XEX+F?\B+LE;90%I%;C
MN=!H^^\*FNO GPM-%__5?N/&DTE31W0K.2R/TT((')^[;!OY$FY4BKJW,@UB
M@/#YT\2K/A9H 2H;2:%)%P@1*]&8?'D>Z^_[<;"J/7V&O!Z1JL 5?ZBV<Q+[
M'G</!L@SP=\TQ20\HR5;KQ[V%Z+H]LFR8:68WQOYRY2XW+_FLI^?-)(FA.QB
M"Z'_W %-CK129FVOX!4,T+HQ&<OO"04KZXG,=)4O.O[*B3<,/+7I[_,B96XN
MW2J%;ZCW*A#26KO)A?-\,;Q8P  9R-5CKP9.&9@N#U4C![K5KF5MNP9IYS S
MWF_@UD=]&R6R1G=_G8Q_\N(1CR'JIL<TDXXQQ8A7S^8.(-&$?:H/\2?;X0=5
M UW^[ORA7V^5@E1OU=Q)Y S]*5 W,@HMGZ;RKY+#:,6"7$+-V^;O$<D#>]G"
M0QM2L?-OQ/:ELVI8L!,R9:K=52OS8BX9;EI)'V?N$H&T1IU,3;I098:WUUY5
MXAKK<6>5(!363L<:E_((2@E:EQD;:^KL&[2!_L><ZOMG=5*UV]GPW]-=MS<*
M28<>FJ#Z/BWU>D+V-DKSXE'W#0-/8-8O$S?-9*33%IRIYS])]\XTH*H69BO>
MYLG;=MP]!:-:Q://!Q&(PA,.5>Q6&;E^6_JG8TD^-\A=?8/[]JP1&Z7"Q/<+
MRRZ+2SD5-R&SX'7YV4,,$#_VL?W/TY34TYE,,@9YN09-0Z;Y\0(.8SH(4Q@/
M=+[ P@H=GD*%N8F=?1NP;6-9(+&= E]@@%BFY*'V)+^H!JV"*@:(Y_?HG8>U
M=5=DE]BZL.QU0!C%'*C"S;PG">RHU$P_<WP!W7Q6]KZP#^>Z>FO";,9VV/?W
MV[*J1*URU*?;F/YR!LA>Z\^I)TEJKB7\A[U_H=\M;^7:#%IRBC-NRO]CT^#,
M/ .4>C]D;'%=DQAGU-U::HY<'5+PL<.1%L8*MTO-;M#*TE?\/@.7OZI-F$RO
MC*V@8-1#AWIINPYCLLVXF!,2$M"G(9H6.HT[=%\T7GJ=)E\RH#1B&+-VH-F:
M49E$2?]L+$S-X&=29:3)=_242N6#KIT"\Q^T79W]=P<C',[HF)@L6]I^ +9.
M-HT!:@FBV +C"1PM,=<2#LY]OH78G7P 6SC# $6C@>59Y3>=4-XK_M"I**S,
M&PCQT%-JPJ.]?S-9*G$SX@3_1PNO)HRDZM*,A9%YH@Z;X-WL*O#>5?[ET ]3
M\##<7.CP<XH$<+H7C$7$76]T'G)F8X>T<J+MU]2A$7"V!FC5IP8^3REETA2+
M=B]VDXV%6 +_#[V4]Q^JQ'NR!U".4JT/A[.::PQUOJ9MU5-A4#Z,NQ9N9B0C
M-Q@>4*XG- -M1B=(:)"B%FI]\#*10QC7M#JX?5$[.S'OKVO<V@9SPQ"JFFT'
M[H"7 =K*\V& .N67_?ZCNA*N\UMAJY;Z[4_3O]]*DK-2VYUI4A;"CW"Y^-]H
ML\$Z=OO4;-Z8K&> >BLF\SKM2B7B/2]EZ1I*5V; *,@YU%_+30:_](YGBY#(
M\</EOTW+?UX.%,N^)_O"P.B^@+88N3UXT!)>,&^'5'U;E\[-]W+6_$SAZ;>?
MJNM-%07?W*_'G(UOZQ&)S0HU-.R:+ ASW/2N6?UB:2BP)-;\#Z)[BDGGV6C/
M=B# &?#:=" %N@H5H)KA0T<<!ZI*A-I1?.GJC0-!'*)17ZI?<WRDE$MFL]>P
M<.:[-3;%@JA#I&DJ[SB=/9SD1\XX/RT$Q;\[L,DAZ-OBN0OQ/N@9WPAB[H#Y
MB&QU_6"):^;72T$BSHD+MUR"*0$7>$"N/*RNR4P[G8YV48Z:+L.NE>2CNG'E
M1S&>A$GE5G)BG>-"K<?!$_,@J8STC37I,HVV%&TW'ZSPW)&QHB)]%+/Z.A*8
M*AH^ __C#3..H0K(4>CL'!\+V^9)MT]L2<.YUJ,SRR_S7A0O>SR9OG7X6!F^
MJP&KNX<<(H^L1U"XJ<I,'!"!ZM*I6<NB."KHM"?6^O T#"&UO<:0Z1F?SP-8
MA6$[V7,F\8<.95^XZ.K3_;UP;.D=^"<-2C_63+%C@%J/8JG,JIG:+/+EZ 3U
MA(-A_X\?-<TDH=CQ*[S[F%$72Q_+]2O.%^)-R9(4 Z<GF"(##G2SP9_;N2(@
MGY'0,M9(NI"#&?$KXM&B\:"ZONGW'Q]; R#K5K=-FT/=/,5'._I%FAQS;H(]
M<A]#U6WI7/,C.$(:C,IG#QLOO &M.$DJ)&\!9Y$<QTFRH_1A/V@%=Q49)[O&
M 'G2R)ME^_6X)#';I9 63!0&W,1*5?^%XJ:>(5:5/B=@.#W/>68*)KOE&WMZ
MLQ^;30@PU;(62S'5EDXQ+8W\OYS ?Q_5_Y/DGP.[%$.D..TU%:S<!HF?TJCN
M5["5]Q/-&I@R.8K\<!>BCEUC94FY<#B^>"0G*D^N*C]/N+AZ,L7)Y_50L46"
MIE5^2NQD(Z_NW0LBIYOD:-5_XE#3W"CVR5YB(=FGJH:$2W""58B^8LN E;W*
MRC&]_.9C8,1\QP/PD2UV""N00+F%&F,:3FN<\"15@/923S:4  >QZ94X7$\)
M% 0<$D9&3%_$]J22/6H$15A_L$BM8GZGTMF>$^7)NI5/VC;O9\N2:C(H#!"?
MU_E9P>]&[&-M 2>=\H*OQ<@J/JE$'KFVISWSL4Z$E_SP?+JD&6KEI=,FI1=F
M[(:LK-#KU$LM2%>ZZJ!3#C^XM,JTW%PBV\9K?S[Y50/L4QR 2:@G4VO@XJON
MU$3=>]*RU5M.1FS7NJ3Z"G9(H <[6+;00Q*PI<((/18\-EJ"OX*HV=K+<6MI
MS @CE.%>N$Q>Y;=,!%@^RJ; F--.>KA18.>U$)?KZR/GEV3E4H 5TZE 5 !-
M$*,/<U'H(H;>A)?;OFTZJ^\JRS2UYI&Q9[#O]*__B<'^VY1B*O6<L_R+M66Z
MFQ;(5KN$>@=P)DRV6I,ZLC_A'FFY;]]&?W7IHLFG"B5]Q9_J?5Y\PKLA/[>)
MW%<E=EZ*3\G^7 #*%/=MNK&\8O#^_, NATEA3?;Y1,3I>%63IW>*S^(CM4Z.
MM*.KL%0>.![;7KM(&EE;_2#;RNQKUNV4_DGAY1#>)R^05?LE%O[;AEM)^PLP
MC1VE6LIMJN; 5J9^=-X'+<JGLF>_Z$HAZ-FJ7NBZ+NER^[6[ )K8^4#V$/6C
M[[.]_;\B@)%%Y.7V;'&WETW%L9EM9KF%(A:F#%"PI3W45#[K2S9+ISN_MC_B
M8=Z4C]%4(K5G#NF"WQRO(5/^1*D0B2,$]/I'XO9UDGNT7N_I3KLO&.3:D\9&
M8O=M/'+J]G3#$H=Q?],&+0OG QNM)^<1^TC@EJ3G@@$]G!<W=Q(N&=8T,I%(
M:5GM3[6.W8FG.RZWX7%T450?3KQ!/Y"@_*S..FXI8[E\T6)(LN:X25-\A%T2
M5K()#O0P)XDZ*3V-CWJ9]IHNZ[!L3ZL('3[@S^#MY/'-OQBT-^/[5>MD:L])
M;':W6JG&5^N7 53Q1\!-K,"SV"C#>1''6J4Q31]>XQ\N 9RS47<*S 0X':5W
MWQ<\^@R?3"N1#PY>R[BQ^2-PMJ;%D25@"C'6;P/'5YP.Q, F(Z$ZLU6X<7#S
M^5!SUM;,J%7N!)5;U^G:+@>VBX7-N''C=G3Y=-LA8@R=79;(9Y<V<^=C<=L)
MT0\#6KS"0^GRWQB@Y?S[6JPT9VP_[+&$&K/URH"1LCBJ]R FILJ;Y?&(SD.S
MQ0MM]Z2+OIKQS0*W6:8%)E_ZLXJ07$VM\I[G1+UTL!!+2?,8;W"_1[</^;RC
M[83^^N7+V$NOP:*F,^9%/@;#MH^"O%:_S^(([PQT$)WSS%7A+ ;;<W/0=NND
M<A*@*L;4DY@J=$+M"-+FX;?I(M'YIRX#/E^@R=C@7";!V 4+)(RH_U 1J/_0
M9?5D-]YV)0RR*GX"LO'JZH-M[VPX$S%+M57V_MY5<J/ XQK"]=L2Z)]]?(@P
M*E=7+VW;T3>&HHJ4["OK7[H!U]D)6WWO1PT*_D@M_G4&:\9"8(!873<SL[EY
MPQ=#<?#P;W-M_DJASVW2@C,\*+@#\WB:: M*B+@2]4M/V\4U(GYL+)</B/CA
M86D8[GI"_<'.X%E#(_E<4^5:"?45BT^U[\=1C_YL:WGQG^X5[41*TG(,CE&1
M] D&*$J99&Q$4J9*V7_/M*FGI2+*:8GK!CM^27W1UF4/++A05NCF!W^N+D1O
M"=/BH2Y@(29.,H.* YO7,"OEM^Q,"E?*OQ<.':<M8'_X_0XASP"3%!:D;P70
M2X3?HJ_I;$0%2H6GVE5.IM>\-EXH-;CG:_P -:N$C_?55$B7]$OQNV6XRP )
M>>]01HFO,\3O/-#.?T!,TN.KG*M#QS36T;[12SRP8K08M*]R)+2FMUD4&L\$
M3+M)&ZVE2[:JRF,[WHVUWJ$O45ZS\T%S(2R_5V?E?Y5$E\A9NW@JG@@'5^<X
M)9Z.]^I/>7FO-'.%^?KWO/Z^<_6_2@$0490^4IJ6I0>&ML'B41J5?0^_!?!L
MB*K>-HU_EI,0L%5+7XGT3_W%!W\[S20G/M!Q93I[Q*P9[C&S?Y*>5(&Y$.=J
M,HI6L)JI"B\T13=],R2G5-4HS[K<1:/O4?(6*J;.]FQIGE#425LD]D=79/3D
M;J/ELPW<LPBJPQ]7=<H!9_%[#%!7*"ZM%TW[ L5C,>P,D/O'4I0(DC-ZO&-*
MB_..L]^I<*AYAM:X?,[W?I;.-)'5%]_S[P#8KW#@-'I=EN(#+"B/0>GLXK/F
M3OW=B[QV@*_Q%K8P1O>ITZU#]T\N;ISAA;QY*AMZ8$9F$KQ(.R28EGRJFI18
MP^\D3^K^X$8Z0ONR]0G^I?+9G'%BMO/WF+<"ATO"+SL)<)_XH15;Z8\T5/;7
M[00+;1A7O*$$4 TL.E^;R78L# D@1RG%M_KC]FP!S!@ZIN<RF-#9"@4A3Q'#
M,8\-A &CSBM]G_A\2C&%7WF$AI*"708K>+^'2F=.Y,92#AXN]T<^Y;6TEZXT
M#38Y>-5R+C;>.F6).2GM+O[S %G^ZR"^J9,EQ89ZB0%Z&M:B JC!,$*/FI"T
MPI<U-WII.P^:\!J(!L,L9R!,IN25S1C[<DAJO_S"&HX/I_#5^CMIA_AK"K;A
M".^2*/0.\@OS%E_/[Y&^821QEG].-?F%\6<!&81R,V;,K#7[.)$=$=9Q=\MN
M3?JLFV(.][VG6T=-04P6E/VJ.#-C/4)Q;=J%&-*Z7YC<-'N[-QU*/,P*W1M"
M5HNVT7FR'8QYX,?SM-LU#Q></1N4D(MQQ'IOA D@S'03Y1Y^[/=5\9ORD1XQ
M#AZY//X!R\9\E5YR!:F&&M&@^O +YDNYB=;!!"]:#DK(-C@/M"Z0IMO*DG%3
MSTOG,7Y4EOF+P GH2(.;YC6L/-:VXJ7U&:@I<ZV^0!=7GD$WSIYM[=+4#N^A
M]CJ,&$@C6%M#3TS'JZ^&.'W6Z,]@@)HN*A[80DI10SCVRL:>PA_A'\J6R0Z7
MBC&?HM#)GVA\9 .B8CKD]DB5Z(*XC6I9#A4DRP!)E+9> <2)F%;@O %K>;!3
M4G!T( 8^)=BN[#WCZT(<:"6XT!;E4N$ ^$MKZE-B?7>!^]Q+*8#2^?8V?1@E
M-^)V'L4"> V8]EV+W_[, #TVRML?1/O12JE^;8(^^5]IZ!"!IFG*IBK*>L-F
MN+KZ>ER8KL=, FK-_Z0UY/%')K&_H3810HW??M2_E9]G^"BLI@Z\OE8/IB]'
M1&YG,1&:J(0 9*V6!&GGEF4BQK;UN;=I8,4^B=& =[;&N:@N")?ZFD%)T(<5
M3H.M+JT$,/XQ#P,4;OO1TA$!X]:"<D ]]32K,'8W7[Z?+DKUIW)Z^UN$VN@5
M8:7##,_0F3W[_.<2F@UU A'(:DJTR(['!9LJMB5"\;#4@Y%+SY+?):JSO[MS
M1OBO]-@#JA+KD8B8TR=>.DOTQ<924HR?._ \:S/+_#2!>>.WS7XFMR[> C8+
M^8I["J\$/[U'U.R @9;'Z)G[9P76M!'"\7ZQ%V.B2%03Z\95O'(\AF@*&8.0
MG4D/,:),LY3%  D&7=9HN@V@PH:B]V]HJ^3'\#AV,D#7"D O0#2"QL$-0^1&
M2,N^4;CG2(SB+:K&R7UWB>&4]=')4 D+UY0[:F97/_EH5,[F9^0Q0+IYV[/D
M^TR5,/0CQYL)^@L9(%\&*"8C6V#D_KS@G@ZM](V"1]( 3:XOYC7;AOVYKZE[
MQP/AH8!:QQ0W$$>HAPL#'.V")WZFA4E0S(VOU9OFO Q3Y07GB"<=_0(;@Y%U
M:=D,D#<7"T5H5O.QSZ:OY+."Q"H?RAL*]&!1)^%WKZYH -^0.5)D5OFW&AE@
MMB,0D;(ZD[$&(_%=)\&CD;WG*88U,>&M1KJW;[TM^,G:LV!(:>[B@-CO;Y;Z
MNW-XQL=U.&>,1U;=PFX:>X[7C12'@V57139,WTM";^4V#=IN2C;,DAMMB]U7
M! 1(RFO,J7_D(Z!"<D+HL5&,/3\2F?.DF9K1D/5J.;";^]BVZ$*5=F^/<K<*
MO2Q;?MU!=%71XJ>BL7E#[,P48MA$-O+"LB3/B^[6R&-S/'"'E^ZO;<)BR+]/
M%'D7K33D9Q<O-()##KW&!^HX#7!IR(S4[3KDVI_);71I^+]W.6%5:>_1]S&C
M260](I8JPP!5AG3H0UK/Z;F6*"H5*H>&)N9R>+2:J_1")%_HSN!4Z3KHYA9(
MY<BZV:RI 9,;-\OAW$KNKEZOZS:<T8>9"HU%?Y_]F=BG>?G^X^T%BWXE\/>/
ML;M;:TFJWT<TSMASA)J98-_0E'HA*KT!WTNVK+,6R/%!J?O*P]]H%L \Y0J5
MDTDRA63;E),P NIP=D^>.<6ISX\^OW[%N?;<@-J;A(]7DVC!J3+9/1;0YFN#
M'_^S]X;=F,Z61C%8:5(:P>:?NX6(N=7O]GK!]TV)^A(Z3%8L^F6IRO85P[M(
M3@;H"1+MN3F6UY%,9<*+R")Z?UU[.^VG!)S;LZX,-QCL;G MPZ^.XQYKDM*1
MY <HFZLT==IKM ML-(ZLR^P>26A%4O,/2.OU!F>E3<4<52<GEYSLA4O]/WJE
MPH[K'G(J5.9FVDV^@Q_6?9[F4,?Y?;7NQ9G;BP2X=?X![E&>TQOC;6/\= <#
M!$A"J?P=B_B1YV@?:&PVJ,_HH_Y<9FD-?E*VR_'FY5.>I^L$T_WC'G)D=0B/
M(XXD?KT9N[]-%J?%H#11TU#13W1.I% ? U1_OKYTHF/Z7E^)IG/I:>=].?#K
M\8B)I)7A+YM/X173S9#'Z'$,L8 NY#%UXD^\P"[5>@1=?G]8N=H1-Y5,.CC3
M4FH!ZL+:Q$!FG:,^L@W<9H"<2WAW'7T&2'J9= F\>URAULT,V7&8K;+Z 1R+
M]\>5;:[I$HW)1P$I=Z(+OBF)-EHU&;R@07&J"*GA\E<#=UU'?FC@GJ.(\]NV
MV&(=^.RMO;JW'E4?8,(O18EI"/<7" BWV\G\8DZ];X/_U>Z[_W,=+_+I0#.I
MF.#W5?GP;:HAT#AKI@@VJ1+V?E-KX DY_&SV8GK:3VZ>0RY/VMUMJN3XLZZ6
M6\8.5:^E;(Q+!IVZRAT8;!:\8[+B/0<;3Z*S3Q*?D%V\<3%H]N'Q#I3.I;O>
MNIXUMY;+'S) )FG@GW@&J(=?]\NI3 .U[=X.\/@(N9ZY*EX@IA;)X;2H!I$B
M#R>1P/F5S)'7<Q,]++R<&9J@M(JG\?1UMI!F$>0:-I\Y7WH!&7"SWZBACU[0
MK/63=KK.!>D3C9.X Z4LV=OV;9/'H%M#Y8LBHJHV37]ACR]0S:T)7U!ZE>DI
M;:9AQ76%0B2H9N'[^'VOU]50[3=Y:?*7W6W,8!3_\,+%&GSO6SH;NED'YY4T
MOM=Y'-4'K]E+T/!1-LH %WIPZQ5WO9.5/$/H&#\&%K?]?I^O4I#7=JFSI??I
M-!>=#:$T0%AL23KZ>\E>(V6&0UZX.A+14ZOM*89W_9WN.S=B:!C.;=@JXGNI
M0"<DRY,:)/MICCIM.%>Y&?)Q9?ZU$EC>XGI#D=G,VZK4??(6$_S9]DE\^<_?
MT#,."O%V\=W+J%%IY?2N,W5]4)0WF/J5OT"&?SS8Q//\VG,Y4=JE3K/*%"9*
M:(R=.I:A:JX7(6#\43;"R8'$0BXB#L=)>1JP5.BT+_L4GS_V6+/:P%-[[1S8
MY?9D4@L\ 2JJ+#7<)+L:L%PM6F/H+4E@0ON[/(^S7_N]684?29K]KG'-K/G>
M0R?5NNG4J_[;6; H93-RG7L?X4O )T^Y_:=#[.@I  .XX*;WU$)FP.O..9[W
M#VQ;QUD^3@8<F2BR.6+0&HW^%99)3!($ZMLDM(;G2*S/@UC\ T]R?/EPZ.9#
M:Y;'K(6S@R.#= C 1^QMK>,_X*J.6"@9-'"<_-Y?@Y'+SGOTXJ8$X0&XX"8#
M%.T%G&6 +L'I-WW1P#P2RO= ^5F#K;">DU*&$OV'=@=/N**'V>L"<OYFL9DY
M_)>KWN66?;64O$LAXYE] =Z+,GZ&VP9N1*.*@B4)^<]#58URHJMG2EG'UGTE
MN;$BA"]ZO(>^[?W5U-FG4"EJ;J"MI^OBS57YN;B=;&+-\S(^\GQ$!U< E/@#
M?@2Z9,94$0F]#)!8*>[2KYU>KF7! \$$%D-O;XEO4IYV9&7G=.GD78.A'938
M [>0%HFQ;.W^M[+N0JRR,HJ9>SF0H.*@OI(J]XQV;3(\BZ+M/#B8EV=5;OYP
M#':36K<ON)0;2[L&$/\+CQO+5R:Z@ *RK&N]%$>''T4 KF7Z]]3IA[21V$KI
M6[YQ+DE:+JXM.Q M!5!+^2XV%HL20S>;H?$I>^6K4.Y=-])BZQD9U=L7Q7AO
MCQI+!-@[(/>K%2>Z1$-#.Q;]ZN%%ZL>/-0MLV>%874<3I59?>>H9R/A892<P
MP:"/S-1!(]:EN9-(YQ.R7>5W*'#8)^3MEQ0LAB-[TQF@/]%<Y;4!RG5:1LO!
M5+Z>P$Q7&>;WH_7N9[[W]$LV$*:J#_XJ,Y;-S:[:E4&^H?S9,WB2 7+;'#-;
M=Y(GZF<B^-H#YG_FY=EC?V_D[V8/'L]/?=O@*IR:KMC?Y-+?I(MN-F6"P9>9
M+R4$ 0*A5B^$N'+61M1LM/3>E^I;VX^K]^JOI?^(B(H-D@*MPV:P9_T%PUO]
M4@WR>LWHZ'Y;IZI3#<BQ@=QK!+MJS]2FV_T8=>CBFB"&O!/B5&S!1 >Y3<HD
M8ZI0*OD8$=Z,!APDI$:0QA+O#"[C*>%_F0:QG%<KTV* C-G#=*\6A2?UP 40
MA71V)C0]XL=4:<6(R$U"(96O&(_*P?NQB\0+94L.S!V=D=&_=O"I^535?>?(
M"X+.WVP>T8Q/?C60:E;PY<TWP#) 4+&4I )*:7%>W^^5-I+1#4-#JXRJM]7Q
M0FKHX&E]9-( 9FR6SBY%.8EJ.Z$+1_U""^_0="T]D#TPKE'-L2JSG,3S#L89
M[(]"DZJA-@+[Q21-.D<8LTU<S#8]0;2LXC%4WAZRW]##,&.#VW2I,)--C3.S
M+A'2Y;@#B;?Y]UQ[7CRPN>X]@+Z'!LYC"-5)GY3;8>/;,^U[;7Z\CN;D-^L<
M9HW9\JROWG[.7OY66R^]G3RW=_@<MA\;C69O$J$*$<.QK9M/48?Z]31R1I44
M*TOX8(ECAW=UI4""6O-)TENF&AMA*/$N)BZ"?!J">]G?@'7K]BP6N@6$<4O_
MA"8H%UNAW70&O7\Z&,]C'Z(<4-^9@-QG\3E*"E%,%T)3^<?)3X8:'+#P;[)-
M1')"L9G:]\G@22\U-U,M?/Y%_Z1T*_F= 3Q\;9FH3'8EWD:#48>0<GW(L_G&
MD<-U^BD=[G=4FFSG%Y!HL?CO89GK9[!2*C\#Q?K&&FA#E3;)3L\]#[(['%-<
M:ZV:)# ->ZG#L*%&-.QD;JQ\S[_R>IM*FR07I+441=J]PA]:\3CD@<VLP@$*
M[E3>Q5:TT U\8BTEB'J^>GALV#33$PD##<S>>^WL(4$)&;5ZL,;ZHI]-)^O+
MT::XOJ!&T;9,PYIG>KK%8]._G;Y6V$W;W58HZQ7E+,[[*-=M?#+RXCN.F[9I
M5$-:#7-989XRM4V#,D45V)O=BU%H.@5T[_OHZ>*_;")I5Q>,C)+-'%I$"/%%
MGWF[>=7B?7L%5EZ"+)W0E$OT(5P%?"V+\$H/3C%%/B".1*[YG=YZ2![9O85/
M.?"%!OGQ&+BVO4U*T7!;++A//0W4XZ<34,=AX@A!<7_U4=>S',"3EKKH)(7'
M<M6[T?1CKA[?[MA<*!!]J]+\E17V]YFN_\4DGP5\)/D1:IHA1R:1EP'LK+PX
MAU$%?-IIVJQ2</%8K&J_=N>Q=Q7!1W':3>>9RO$* ^2%&6> .OGH/W%E0I&[
M/O*&&2HK.@<8N2T/MN9TNXKJ%I:U*9<[7*,NXLB-L+9]WTMY[!E,M,&/QVI#
M9?I"&W4=ET)%LH.>=/?';\JE_/&ZT1T;1G?<U_]LL(<#RI0S)=,1>L?OD-")
M>4?5\L=@]+A"TP%-*ZP1*_W6^]NS7!6GBA>FGS! 9<;K04P1"5)CS3HK)0C1
M>_-7@^KB]P%UF')7;?I?%WG&'9*K?_*J4#J/3(,(-7[8'!P3N$EG_-DL]KS$
M0!)IY8T6 9:/I?GY.D^ZO.\:H4G(0M28!2N^]<4+W-KO'0G:'D2$:<YX%?.U
M@=-3AK40N*#@(.DFV?F:@C&]HE +J'9F26;]Y:"KRC!*.*UPOF8F$<Z$E\U^
M43@0E<>'N$H 1ZY5ZDL.NOJ42"T8?SUJ*C9?$!B1$7!KMB2(WQ*.OIH@QY^F
M8VD9:V,J+UTO76WP/DO+*O(IK^G]].='^"WM!?_#1VRRD7PJQ9B]2/7/"4][
M45-0Y>C[Z#'!+U]>NR3P5]27';JP8JHO_P,EB1J@'R-FO"X$[B>X[0>H^ (1
MX 9,^\YMFJ'_ T!MMK-S/YW2OK>>[['6G"(4W_'TT2?MB<6^MS0NY&G7SE?"
M=YTXSA8JN$GM>U*92T0<%BV_6='W^T!!F7M&QO2N2OG-LR'IFU2523JK(XF#
M_)X8$SVZT\O:2JL(R\J9O>_PD0$**Z8)/5F13ZT"_$F=LXW=7ICC0>[]E>7C
M>34IJE\@:Y>.,4!-;Q<G1@JI^@ $#XF1RSCA]IK\9EYL1>A5Z"$&R#U>%J^V
M8AZTVRK!UXM(+GIK^HPV36/I]SVW\[;I['[QJ'Y68LS;^5'[^>[EL.GMK4<]
M]$D'XX,Z;7@, W2T@94XHY%ZN?]*QAUG[$;9-B2G0VCIG:VUH<#>%TX<2QHA
M'<)FH8ZOMC15;L6&U!L$\CQON[M25_5^7G:H/HK?TC'Z_X7#>G0Q<IBUMO:U
M5**ZHG3*.?:BHZ;2.Z#K+!^PT5 ?.*#%PN2M+U$C!+]#WC](E]O+?"_F U>7
MN>)YN0>F7_2=^7F1A^T53V1NDXH?'[HY$(JOFFLEU!L#EL0,2ZWMO-#*+)V%
MB8.>)R$?_VHX_OCKK0 ^C1TM"]&.X8)UDJ)E 75@8,,!IXB=V)]PY\5[#)&%
M[ZU:TV]Y^]F6;T]-)C4Q0,PV*&:L*5.$F+8PLZ:-9Q8JY. + ZY03RP'*5AQ
MGY^ U7?5-'?,NZF" J2\ #Y'6@D3QU2BB?:V=43X6C.QCRZ*5,*YU30,KKN%
M.=B=DN6L.9%?)/U%2LMC_?@]2*;:<%,=+1:'GX+\+B:[4F3C#,Z-XMK]!"Y6
M_>A\KFBM_D5:?*;L2%HG+<0S_((]9:REI?/JYYAK_6LYU=4USUUJ:FKB):_$
MGBLJTKH. AWZ6IJ1]"V@H">R8+V0NBO$)&2^K=1=8PC9-_RM=U+QFB=N/\1\
M9<03MFUFA+J]Q#3(OB-QE; (S\(52"559S'IIF#&>J9F6H%) 7IV^H&B)BNT
MZ4X(]^?$2LQ1M.\F$Z^P902]1_UD@*HVORXK44_=B9PVJBNKBF5SKG$B5Q@=
M%O(X]+/C5#-4#7N5=NV3'X2J2Y1MAW'<!J1F8$_5:8$F#;=O>QYD%?W@>R1V
MCA!SO?6PQ,6C.,GO@*G>/=*^!KQH)+7^NMDH$PP^RJRT_6153;Y?2ZSBE$Z[
M7>J;<*5DV#+C96HC#16L#1V=)I<";)0;@#>=%Q:).^ZC 5-D<5K^A"SND0PS
M9W$>R-:\4^PR[S+<*(C3Q7F@ <F]YU26&3AP>YH(8R+>$#ID6.'M#Q_">(DE
M =&[Y^.G5ALX<*_M2>IKT$P%G17=[&R@2CU,NDOE8>*M&.K9P77E$I,$JJ'/
M^WTAC\;#J0[$U)S5A1:C"]]L936Z+L>KV%F[1L_(273 #&TTTT20>W%;&<6?
M;P*1U4=S\][<(/LLO:\J5,XF[:!U(?GJMAK$XEEPRV:B 4],)YI-+ZC0^^ F
M57$JZP'$Q457'+7CJYOWN/6+0/_(I%7QU48-J[<O<W?-==\W9!ID\T69G&V>
MU,\<^J/:^/^G$-C^GR"DJ3>FTB*" 3K\D+0^LK9]OO!XQLT! JGMX**S'@H2
M:E(W;^ L@C[EVBEA9E8_-PG/V?U.M62:YU8XBZ=.>$R[/.76?3W8IW'@T;#H
M>*"";8;MTW:!"J5^E5.Z!GXOTT&[[\!M?UQ1QE1^(;(,LX>BZ'T,$"?.'2Z$
M5"$N1KO\0M\SFX[1V7RL9WSDPX#&ZMQ09==5.Z-%H4L(Y_1 'KC&U9X7%&0'
MS906S5PQV09LM 2<BR>3IYKKMIUXV\1733)H#,QI2L)._9ZR]PS)K&I?KZH9
M6Y]+?)ARIL#D==]@]? BIR'J-+HY&(V/F&(GNJ^'EC"1)5L! 4&5#<RE"@TV
MG5VE'Z_&(?!_M=Z(9&. RA^+U+R0IC]J$75SEC]^R1*\7$,5/44)H ;1&G#X
M5X(2VK3<W9XL][8I;E+47I0,28;THZ/"S^_()^+$M>FM_@L9EP1?4'_>46BK
M5SD)2<F6 ,#$7K('$P"W/?1[ F7=\=QA@,">./[[I0J?-H+8-J8TZWZYU+]1
M_;DIM> Y)Q7(>XA%SW:'CVELA6A5>B+,T=FBQ2'#*4[ U#>G5H(XY/M 9852
MZX<5WF]E]O:+1<]E4V3<0.M6/YY4CA"@[9A]Q\0!>O?Y. ;H0U5).(TYS"@@
ML$-GD<HSQ@!9$MOX]+.32)#+#22V9V(RK]6^%GRF0CTS?P=.Q(( '/U8 @5%
M;T:=!!IG8("<,550BMQ)G-SK1 LC4AR5"<-9,Z+>;XK1K,O^(+-Q:4M3[C>-
M<XB!4".3W E1FJ01^A<.T-HD_\[ &U-YPCK@_"@6X&#,$R7]/HLPS87(N#0H
M>*N@:M#AX<!%]2O18%?Q;Z8\N/AS>K:M$*XF :0J,,DT*A;"&OJ"/\,V67^O
MV@]E]5QY[R!^=:0])& _]G=W_7B]$>R&6/NC$_N8UFPAH(\T0.?<']X5#UNO
MR?1KP8V=<UKB4%K<VK%Z<8$"7<Z<\LJ0GHUJW>D$02[" ?D+271.SSA+'R5(
M9>?#S)0?\PG3'G[/G(Q?8S9#%5QZ]Q!8Y@N<=R 7DT+6G9E=_Q0(+T%>'"X<
MK)H^,ND$F%T?5')5EEYV/4DY>S=4H3IE_)1T2CN;OC?>Q^E !(UO7YH28CU/
M;'OP2)5J<MUXR7L5!ZC#"=!G!B>82$6L$L;C/9QRJ>D\::&J='E9#O_F >E6
M\1VR6[F;Q+M(+<G'4(NE?^F:Q-PD*J\O*Q4&*B63IIN/CZEO^-S-:-E2DW9-
M')(-D>;\RSL:.))+]1O ^6#$[*C&I.J$#ZL<^$:]B2G/ ^_+?!VN!K>.P0YS
MC>IOG6%9\9*'K#EI,D#O)C/H+!!2WC\__&,W^=^Y?^?^G?MW[M^Y_]_/_:3\
M'')<L>DX0F=[AK5M\[F.4DS>K=.K)9>OFS]KBM7N45D2N.BF!X()",C=*&#5
MKLRM\EE*V1A5>^LL=%979BBK!%E/>8!NOM'$2O]6-@%H7DY7%D3,WRQ:$M1D
MZ?Z,ZMBP3);0V7=1E5#E/SZT+=3A!YS57+>E> -C?J,]Y&/$A8]<63]=ZDD"
M56616[<"*WL6^*I;P.0>-K!8CBZX@MX!(1IO'D/U[J7C^ R4O>S=XZ@>PM?>
M;TR^_SSP_F?(E:0DG0NAV_?$Q 2LI63Q\B0ESS;K@BC";\KSL5O/E0/T!X7&
M,PA;(0;VI?X)/XIT1*[NV:04RVQ@B=A*)HY*+WR&E&=2H_M8X.Q>@J*!'GU,
M0F503Q/?/^665B!M<*W\PF]=A?4W\GXBPC3JX_J$0MYPPH$*T0ROV0(?'?E*
M1.H"VOAB<Z%K,4?Z)P-EVEXUIWN**LIC-E5DWRV!2M"?$=/T)\%P@!/=D?1/
MOQLGXJ*VJ G=Y;X%H=0@]T_SVTL-&6D;CT+=3)_V.'S\M-+S)[+# ,G,X?CN
MQG92A!(8H"5-5P;H<2?5XS\]>2_#[OS._4QOGT4?<(VB\2H,T F#?WX _:_E
MPOZIE8_/>TB?46@#L4J/O$1>!!@@;[Q-F+">N7L17/GH6 =G$80\K6O\ZU[2
MU3GG:MH[!LA#JW/,ESLCUW0R(EI$:,D@%&W=6X T\NZT<^/C)=HA96*9>%Y&
MT8H!$J,+EU*JAB 7GQ F'+V@M]JZ_C#E?@:(D+C9@PO$ <\I9@"X&>4:G:Q,
M;C^8"[5) 9\%4ZP"H$>Z=ML?)"_!(5 /6X>$@+FE [$8N?@2L6M-Q9"IC-^?
M.W,$?@-"Y <#5"Y5>*M&VOK*5HUF=3L98FWU .<$:PR!W"7A:$?7<$1A!B@A
M%+/2R^NONSC#:5R1RP M2,25UWBE3CEY>@ZI!S%?V-4.5I]^8P%#I68RB6Z-
M2_F6G]-2,Q!"Y/L* 9]W<O@=7D<+I82O1+L:?&CD(RY.C/C<8O*+?ZKA/U47
M/N60YCIJ(.),O)EGP9%OW>17C/)=VY^P41-(+%H9>?.R'K<*N_*/4UC_MHR0
MMQWM DED95$&Z)=O#P-T* GH^T]/_SBH]7]4_C TD>H.:=EDGP069VS;-L$(
MM&%94OA&2<FU]&&B<K&IU!%XVT"\J^R]TO:S1BJ^%EWB4=8C&I-\K2?T>Y\A
M33_9+Y,%'U369(R,</"?,SIJ5E_+7L1J92&_M4VN95*O%-0)@-4ZE="[YDDH
M!+)FSKI2]*NQY[,4F])/RWKPR H)N8>(6KO8?).7LDUB<C6BQ32@@*,*]-ZH
M(76N_R!Y;1*F(Z73W"M_:7AP'N'3/LHER9MSZ^&V4JSIK_G5Y3,/AA!6UMML
M1?P,4",):N*W#U%[-G-?;Z5.!"DA6;B'$EC5S^A>',!48ZAB0923]-[U(/ST
MZ/!/>.R4;/RKX7 EM)11I 5&8]3*O?/P,8&A:.-7[YN<GN"%J$)@.H>IJA=.
M7 ^FW(*-RO@IKC[>$_IP_*RSK%3/P"#M/252Q&F^6HQ:SIVVU[OFPN0L?K27
MZ+MJ/EBJ'M$HJQ11-''TS_WH[>DMY'TQ-/^IQXF_=YN?"Y0]L"M>4?XG95%-
M'^W>PH8HY(4R0+W=F;A;G:YS]!T76ESFPA39T_X7 X1YN).47U"_#0\T,/GC
MCGK* )75K(6387Q>!IP,4%3,S&HXE@%B@\3C36>C+U)MR*^VG)OG[9ZFG%V6
M"<\&71>X .(&??IW.K4I3"BQ?7:%<NW*1,$" Z0T+;54AA"3@)N-.G_\8-R%
M"H<7GS_S;Z5K+2K^:T7KP7+W"S817H%M]ALS;O'!]R9 P9\T>O0T1Z=F]"O&
M/HLUJ"E)G-ZS4OLUY^^ ^[>KU]4IBM-<]FKES=P=S^+"E>SH($^K$O.6_!MQ
MDQH/Z<:+FNU^@ QZW8XBCJCV2T 38;"X$R4[*LAM#_"#Y.EGS;WI-R..''!;
M=%K[/I;*]JZFO4+CJW6X.LH,!%!C]&.89M2IJHRU/9T)0:N2LI?^<6^"CSJX
M[4H]FDL)9J<D_;/EQ\K0"J'.\"A(576*#TH9$6*>89FHF(XZ-;#>D'#I=S#'
M.<H*] LAM6EBI,6:H( RLYS1"L95-)7&;\I9[:P>I6#->;;5OOG;/9R\G5LH
M:VMA^^!_L/?>44T^7;MP%!&5)M*+1 5$I:F H)2(B( ($1&0&@61)J "$B0D
M*M)+% 04E"B"=$/O$.G21'HG"56I"27>D'9N?N_YSGK75YYGG>^O<]9Y_X"U
MLB:9>V;/GKVOZYZ]]Z _.C%A^X+DPU#F9+R$VX7ZTQ1,A&*9PWG:<;FTSUD.
MLK]^A@-O?B7>6^5UQ'?"!=!M"(HY!CCIB/>E<M/,J=T],:CC\^)EO&<Z1K]V
M\'U=@,NNSF O[;6'F#D+KR"* Q@B6F1LFV2$MB0U^DXQA2M2*J+)P_WCA7FS
M=R8O#>-]<4DW/SWB*/J63X@]NW:DT*9,([3Y*:Y!11-.QO19:S0^%H8^+!P!
M+@D'F9 QY*2>'5O<HUZ$X&Z=)@*I#%.BPA"L:4Z"<J-<IW4LVA"'M^QD:_M9
M1QD7>T5O#EB-MK4_?F1[-6KL)"E$)LQ%*U%LKV=C_>ZO!XC%!-J A.&* UT5
M90_89-E//$2(>:1)1[$AU\MO/>)MLOFQWM( ?2J_]B=E9W3FD5_>M9A% S.[
MDWT^O8[+?UTBFAK3LTYGRA=7UVP:+GH)1U*(T]9-:S&.^_KJ3Z%.4[\E3\/X
M/),\_;\LI2@MVMM.79F4OG@X\=[ (^2QN/3RI8R1_Q&8U PC?88528>P(9Q[
MF*FK&%>FZS0A$L5_::GZ:5DZ@&]\TII<[?W9^5&%2/]Q?]C3JQ8-5J1[;V.&
M*WHO0U/JM=B0EW:8!GB]$JMO?GQZ@2$$O3Z@+9_+V#/ X,4S3'_I"MFZ5\_2
MAI\EYI?<.6#V1?'<1">/-]';:.\QGO1CR\4JHYCBGF472@U-F)E8BAVUIEWN
M7]'6R@30O<,FM<-*T)ONWS*>K$].ODK:7QEOJ-A=-B/UO,;2TA //C]Y-]4Q
MQ*?69!H!G** 0\E$8!KT_-6 #_4*(8Y7H\EUA?U61DY&,N6')8NG+K\0D1+7
M2%Q KZ40].ME47R4BA5.BN =@(-^XX^$8;0:3L@M_D_:F;+R_HR2LKHX@^,Q
MC]7ZVO=(G7^C<.E\F-6^O5K/3G%LB#8@*#[\S2JAF.+P. +I XX'%*$&#5-"
MQ#*NJ>L8-NW@FK*_U9ID-=X/G2\N'0Q=O/RF>]:P+JWE1Y,PY,<LLX*21SO,
M3*KG1[<.$0LU7K%$QF"-OU&JNJ&^Y/&A\]%+-DW,S"RT^-S[C'C#UW>3GS1)
M.0___L3?+0Q.-M!_#7"Q  WO4 +MST#/\@]M=V9M_2'$WF9M8QJF++5GN:D@
M&-].AXUA@FN6=;W79MJ$=XY2LLBN3;L5''G5H"&$0]I*GNE(UR:)&Q(/0C-L
M<@3&;!M?:L[8QYL)&\K&FQG+QGM^^N^GB/_/(+6ZOO][W>5/_'[_,F?K?X>_
M8NW &5"H#!5*YD)<_0GDU[9KO9M ;6>WX<U*@1:QE?9%8]*IV7C(O@_6"]8K
M_.!NN0;0Z?:[;Q ?K 'RAB'^=RM"OU12K]Y\6)>FO>(NHQ1:%([;ZCO,B'/2
MAN)ZD,F*/TYG.E3=3FXP.[.1NHY=W-S^'6B3]CBD([WN2^T<I<'S-$QN9SE8
MA>X-;B==3G1;4@+@I/"6"HNM)4P@7<TJQ<J=-#USKEWE^#P><OQ'(VD5*HO2
M9"9@O## F>$8+UUUUI"N8BT%_UQ_N]H,)[7_!*5"ZZ&7W7'A9(Z5\ZN*9PU3
M]G/5HILQ%$-\.'3?ZB<@CVYD/XXDMO;(CQF4DCJSW#<$*POY5'V5GZ#:]ZO^
MN'S9E_8)PK,'H0$__K,RUZ,>Q?S(.Q,>32S)DZMA+?8&>F"EQ1V=TXPMNZ%R
M.H.G"$RE+;0)95 *_ATQ.DY:6^XA(>NA*'&*Y;<W=RL](V4DLVI?\P267$>[
M(R:Q',\A$+ZQ*(6UWS<_AWZ1N.WT12Q/-C'>T1AJ<3WQDMK@I<?7%>Z7&H$V
M:N#7_XBD_*8Z#6WS@:"T^#V#LIG%3*2(R%75$-;H;UQD3Q'^?#+(%Z0);J<E
MAINL7 U[[1/=S<<T.W;4*B?E*\VQY@CQ#X];+9*FT5EAMYJGG]W*J,(Q:X?>
MF!1LV8W\+=36B6VY1=NRS3397DC?5B(F&TYL8B)PI:+/=:';2:9!S"_9)PU'
M\M]=Z/^]UJO[ >>Q\71 5Y?U:]FY,)H.O?*:5*@D=*-^Y>_\#G^R3F@ E _4
M#/A>0*MS0'V -5)O?_3OZ8B;;$@)]!C3#A;Z[$IN^BL#R)[G$-*A=5BA9EY4
M\/(J8? W;/NQP>*P1^*E[>S?C/?CS,R$^SLNF\P" S9$Y60I@HR%G]S:TJ:3
MB<OC)!6.Y?J!8ZPA@CVTU/'8.HB9BJ#'@LW@E?@K8,>GTNN)9]J+\[$\A<"A
M<UG\<H34H(KY<=>>F7- 5R.^K-FT?9L5[;*^6SA4]?6_+RU>2Z=%,O-@KO!1
MC8:%-D0IO&5%M+$ZT.K"C'D5D]E[U.J X/F?Q.76_.#</WTYMAY"T^-!<GF8
M$V<LLZZE?C26$Z[Q;D?UZ'VSGN%OXP\AEJR]7  BJ373CK%DKR/$2/6CWLQC
MUQ[>/^%]\<U/30-.[&5>M WZ%X'RV+H5@T6?\WD!HYC 1PG60_Y!C;WC2*QU
MG\0ZM?612T5A])/T./[W6N>?H]V&BNM!N3?L(WA!Q^&MKU'^N\%2K+ZQVB/=
M&VQ(XT67'#G:UZ*$!/[W&[8C6<&O\[^4"PWW]9-;0E_FI5C>=F;4=.\8>"W2
M%K'O<IKQHAHF9S*6C'U4PE*V$HB]/KT?DU?,V1"N4W]VAB- \FD*/DI3E\O#
M48O*N_EU'$[=7Y3YTRE%_T-P,CQ:5'1?G-[KEI<7KPDOH/>!X[@(?AN.(65.
MG2D%"* !T61^]E?A_MT*O]3?E&"40+P:RSAK<]5JJ$DFYL,/_JF8%*8^$[2X
M]WQ&36A*E 6&#*@\N(8"!;UXHZL!U80DUP$50P31P;C:6GSAP<IS7.+EZ3KO
M7!N6H(K]>U-A+C8$)N=NNN.'3:\Z1UYV=!K8>/;3DQ7<2/U:]ZQS<(0"&UG;
M#3,71S==0GE1%,B\Z9Y.2LG22D-%@;D];\*8=.SD_J.W!"2@J\/UY@:H*1F!
MB!9+?P7C#GA>@&O_/<H(2D[.+$;(J5KNOI"Y@=/#_]?<MW4V9.7//X=*B?67
MD(+-"!&&#;F5LA:A]O'$DGDE52,\W6C^G;Z@T13*]>#CUW5V_"^>+R%N6D(%
MD0'7J9BP+?Z#2^4LK[@<9Z7,6;VB^M.'OWP+<KD31>XZ/['?,PR)<E'7U(U%
M*^2B/2U214,:9[*K[T2<-MC$#&&[H1T!RX;D!0)P!ZV)?!>-%T2NKCH86A%>
MKSZ&OFO?=PA^0C;6VF-3_#OI$,TDU=-SW%UQ3:G/S>5*?,N9_=:WSMX.:=CW
M.(JL?9"RU((KPC:O[98DT-;5"LD".LFM1;Z>F65C@2;3O,?G KW4)>VILD^N
M?B<_L19[>/:NEA*FV98K5.U]V9K@DE6*?V+U:MHJC>P4=V[1)F(O(5ZSA!O;
M1-4]D>A6IAS0D<^2I'^HMR\WKS#E;R@9$\NU&72[;<;X2203:GP4;&0650 -
MP1E<%,R5?[RDA4"!!YG:NNM* AL-?Z55*=ZQBBT)>H,K67%:/Y0&</'BTPG=
M9S1Y#Y%XBF"5ED T&[*?Q/K)TF*FPQX2#X-3N.Y=JQZ8Q5"E$$*\43*4I5N$
M,C=XQ-JJLOF:REV^\T-465.^50[M=URG3^!7!C$6CXJ[G)LJ7;"$LEG[86('
MZVG96L%:,'R\V"#&QE0XBE Z9UW/LMXHP\^#2QZTD/U_;C*D,!DD\S=[QI=(
MR0Q!'YKK(,P='KON8#_>X"N" ]OX_T1)T!T'3T[.WAD_O22S\D ^_816FJA0
MJK%#B+O,Q"F0+ IC&@+8$%(95' KB9K\4@T6 N55>R][WGU*H*Y7>2LHFZR=
MZS I;NEH%GA.UGE.BL\@6)A^$%S5]H1%XA&UGE%0L(?>4/"7 9>\);-[E+7F
M-6Z$B7QHF=;S@R(;BG.9_;,/46G.U57:VRAOREF49=/[,"5R(9!]W6-'OJZB
M9)21JIVO&_C6::E:+<^@W8\PU\OXAL8/_R26XQE"622-9:^LSG0/ZR_-NN>0
M%;9(BQN5TO?OQ^39M_^H, M_;?_RT&=QF7G$&)QUJ(*:3$NDYJ&[B10S!-=B
MLH9HUZ_VZ>P"HYJ/JF%!_BCN.V&!:?9GN31C8MM W^6$!V2R7J+%/ 10"&8>
M_C.U(F8^>04Q6L'7/V+3U?;8G7LC4#E0D0TY)DN^\WQK TB3[_(=6V^@S-XN
MR,CK!!Z!\MWH[#>ML$VS?+@D^GX B4K7*(_/91W8P:@R=,S)4_N9'S#>*H "
M-KI 5PG=RSI91<$V(><W_%*-2&XS;CV>D@]@%V5"0/S#S]FX#$W'E/0LMU/L
M:+:4*TA^4EO(L7ZE"(N@I^B@O#\@*+;1SII_4Z7)$OXI=&JZ9N!J[+['V9;F
MH3?/0C+QKB?(]GRFYM.N\G:"*E'Y6PGKB([:9%/)ISH\)3*-<WW^&9/7^Z:>
M#!+,.MO1QPV$K/O3?OV/4'S[-FS]6:0@N=G G^E@N^1]JW&<7_49BM"H,_+"
MT2*0JC\3T*:0W(>6_-WG_LS=J]B^E6X$7>EZC/UK@2M A06TCEZ (Q9?UZ'T
MQQ+ENK6VQXVV)Z?&,GI\]KQV+AI@EA:8Q4_Y]L&40411N\4? 9-@<%#FI'D1
MMP6G7JS_H;T+]&4-WV=#7@BLI*R/8Z51_L"VUA_6@7X[HS[Q\G;M)T+VF(H+
MYZ<60Q9Y_1'\!!?,(63P\&UJ60^M>S5 [)V =\'FDOQ@)6P2?ZNBHJ+TA9+7
M7:,OL5<R0/'<U()<.D2%%6LV1=4M#U4,GEUCV?<%9 ^[#_R9__+%+J-'?ZE*
M&OZ53WHLE^[KN,B&\&"L G%-/:,!#6B1T]E )J'<Y\5D9,+AXS3X]$ZYWJ;P
MGR(#J7/Y9UNS(R"WS9]S?1):5%A>1X7+_S@[U;3'P )KY\V&M,CGH0O2^+3.
MM<Y;!G\]Z0VG./YWW.,;\>]Q3SV&640@91&+,,NJSHH(*;3R&!OBG6%'HH2%
M1W=;/8S)7C_,FA7HG7<#E?A9>1.Y2"PW]Z/81>/-Z\M- I%-Y-.7$K]^$1ZL
MD?E]:!TZ5D*C,A-VM1WD$-ZL7HRX7QV?^_'S-FYYQW'F=4=K\^[\O?X]36/E
MP,'M=_[XSC4I3,-=&"D'2K'P$7+8Q0 O'[!ZQI)#U63D$P*FM?R,\4[Z# MB
ME\A0F\(/2R:))2XVG('NP%"\'H1G(T-8HOP,(=<9[\P9HH!CE[(_+X?1P,+Z
MR==;=$M&9665?'V/PKY@FO!F]+%&ET[<A?Q/;,C"A-=I@N.;;9RZ\K'6!Z9-
MI]+G"0NS:V(J9L6;5IK8: +%$3$>0)ND9K9][P'D#)?[\\9*"3+(N#4SDQ53
M&?F]M\(O)!T<J>T^MBINZK4;F47QQK3@XJ3/0H]B2-EL2.E3_+<EC?SB262
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M\;_HB)&_-*/BY)X29E*]5"/0"M0*W,V"FO,B2IGOV9 '=$Z7(B:N5N" <Y(
M\E:W[U:S7W!0:#*CH9T-F3!DZ6WQ*03-'".L@@!*=>,Z!K@T0RKNL!JG7:'J
M9U%*T^3*;V'VB+<MV(!NJF%$E_/.^P*"DY?-+$LXH<W\%.R6XD_8&:99""F\
M(>B.01V^$<K=)L$<P%XNAZ#W*%SGAP B0Y9IXPVVH%>:1&Z.O(!>$<&N2(O9
MW;5C0RJ+V9!CK.[I<#;DW!_,Q"DVY/WV\8#=*P;<LS^-L!KZ?_AN'$2?/ .!
M\:J7W,0T6SDJ#,#ZU'P ^=7?SUQ9(K+Q&\1Y!S7^)F$ZM_M7]W(>QS:SET>:
M>)Q";[\!#J5A5QPE[5R(VU:86>BH]O6_79CU&%@7XW$JB^\%L"VKX@N:A'U;
MEI%O2V_!(KT_<"X>/-%UWYD@3L-W^XS[T$C $CV(X58%=%.;[*Q?GPXQZ%6,
M5DIZX_DAXM@U>8Z:BW(?JYR0'#L5^#88H QE'-Y@Z4/+,<OWR/S;?P)G"'O=
M7P?;FM!/#03;WKG]K)J_MFP3I?J1PE#ELPR[[:(D5/6AWG8%- (G442A^_8&
MVC7OIQW<VJRE+:%I..$:5.^V*)D0X:A+\4[,_>UXF-J*S[RS-)3G]<WF3_7;
M0H/L[Y*/HORN[;W-^\-JGVL*<P540PM,@SCL'F$?0X#BNG)\!O8JA1B%LL.[
M#>TD)U-AIE=976^&M2S@^YH_/._H"\3'YHO[OB 1*?H]P/$%Q@L0]8'J"&N$
M;OS<^)ZV;X"THQ;PMZAP1^UFX68 U-^3=OY+C&:2NOS6#:&QDK]SHIZ;<_U!
M_D.3W*2?8A\O8>S;]+3P3\Y;5SAZZN![;9E^DCSG[)K+:=0SUZ*$!43W7"9!
MN/3,TJ,8).:I?Q\H\^__%,@X0!-'$P=F=O$3.'LG)([4MOQ'TA%9<GTH'Z5W
M[U/^M&I!00[F?)?JX9H.H_N7)]3>G)AUE5GU6(>-J]((0#!=$'7Q5[T2RBII
M:KRI.CENTX=OL;I@DO3RJ)(Z=V*YZ)-S^P[,!%BA2)P3S3$WN4BB#($9%C<5
M]ITX[MQ0S[\;#ZRT%A;^''W8 76FB*KZ6]70]U[L]0XDK(P,J]4_,J;&>^::
MW:JXX ECSQT1YKMZ808/8$W)\<*X&B^[4K"1ZG6&+9?\=EQF T1\=?,"E3\K
MEO= ?]QU]S[Z2_FV H0/@N]  )I0UL$B"C]MEIG/,,[WM"Y'BPS7*M"/>[*T
M^AF6SD+GE.9H[W-M\TW0=%_M_5/&3A-FSGSY&:%C4W4@>(A4:069\DL==QRE
MW. OS09XD0\%-YSW)';97H^%#V"4T /&J7&7II_#=.I/C8W;@/M\B?9KS"[#
M""WGMFJE#A'QX1Y7U3C:><1XU5B=>1CE 712QFF! 'R:/Y8HRC#?'[M[7U0\
M<4DBMM4H2E:\,;M3JZ@Q_93B:D<N]UFN[2F@),@-0]I:LFEI!%4L-#F]K29
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MQEZ&2.U!B'GHJH%DD]2:O;DU0!;=NZBCV7A?LG83>'5RG<I<DT-U80)2F =
M23BS(2X8$58'AF*D$KYCC=UT+UWQ:1U.KE>N+ZR,R7C=%G1,I.;%K$AIU.B/
M8X<17)D0]//=@$/K4("+=>L@N"?I FIXIMB@;@X),=[G8#;O(#-#>'F\U'UB
MK$4E=/:!4>?17+-5([%]N]>B&P#$+/2XKF8)@)WQDC0?$FUX%EA5V[\Y%"8?
MTX$J/)QV0+(X:/8FU\" %6RD%H3$>C4@RX+-&/[G#Y<EA?ZK];]:_P]J54R:
M4@V[D.3PK,523[';^S+$7W:^7IQ902"!AK_X[W+27_1ABFBLDJX\LI[WAQ_N
M4.*%"WU\PZ(3K947.9V.5,KPY W5G+W#\\#9>O3>_W6D-=,Z+_8?1UHW__N1
M%E.Q2$_05"TJ(LIF,F[OBX&$$>M&0H4H0XJ#+H)N)SRDA#<%6[-$L#%W)W"C
M:+%:Q#+=G<LS>EG-F>M8_A6K??=>;N%CE!@@I^.L LT4::6*^O0KD9MUF'BX
M4ZJW\ZM[Q4WII0/=/[/>_%"^H17.>S2XB+[+#0YB7%1&INS@(A-N-$<=:FC]
M,.((LOK[C:1U_NGR,MD6/O[C$8%"F_'_'&1UJ'=Y!%W?/<@*PD0Y:/<-#VP3
M5VXL7>Q7SES^0]@.-/=9$/-?]X'K3V>C>,&1E.Q&"]RHJ+\PD/K/R1K/:Q.A
ML:>IC[T#.8^U5PVT2X6]WI8+YX5>IU?\<[ FOGNPAAEA6 >0X< =:=7RW4OW
MWB*K)^5, @VIMF.^0F+:>4?7\>X*2_\Y-3WY/Z<]?]/V$7!^+%07=O2,&B%)
M(G@M8(%8-/Z"7"LB43%TCG<HC]$_-!7M,C<8\"^RQ>M1._^F+H<;QW^U;V_,
MK(&0F*[#ZF8%)S?#L"E28QGBO)_=DN9I&TC6?J-( >C.XLV@X?:I,^#J=J'[
M<5+JV]I[Z*(H2$U==4+$FG?IU_H:2QU9NO;%."E,X.3P-\]Y5<=SY.5T=$>!
MRYG44_K$U. "R=&=$>KC";VW)+GV2\FX];:IY,PDHA8TLSHIZ^OO(4&/ZM;/
MG)D%M2X+555O#:4\+I6H'H;\5=\0;2,"BES+]T#PW>^'E329<;!5?.%,/M72
MK%?C7>54.*/S5/4-<VP[O9-U<+=0MS2S&'^"JK*22K^L&WEW5=9!>O7ORI.K
MS^:4E*+&FMY,G+TWB6P)%J;(L YRT\\R^)#^%[7E7:>[K10%LI'5*F79/C0O
MRC&I33EN_C5K++.@]?W0.YX33188[YJ_];>'<MB0J-^D'39$X %LM518C U1
MAT?/<99L_=H>^LLZ= X<@0JS;$WN%\89^[P/Z6N4V(49HR6ES_47\0?[B8RI
MQC58AFO*"Y=0Z*P#[ZD),WSUN,,8$%N-V;)8M(?BRWYY[2K?HM*>2M:\MM+V
M&RNJWI%6V!3I-* ZIKH?#?N8[?Y+[]"^L ,/RT^<(IWB>,[U*0?]GTO#5*.X
M]<75K2\U#[28!!FO]\,[!'J#:>MGM%7A G+:K:5Y]=WK37/"+-<4!@<39#+W
MB:/Y^@&4-M)J2LH'31F'0<&5Y'%";7%G92L\(XBK+$C8F1G=RH9L2H(4]+LS
M2RWX/W]2I]VY(<*_Q^!6DT7,B6H#V?K98%Z>"U!N^&CORY@@V7C&OZQS].V+
M\_^L_GJ2X("RRDH1_2ZK5852#7L.%4G_-=Z\8"N1WD"F*Y0\\F(US/%O9KN,
M8W7A53&K"YIB,UWG!IY,2!6I6SR.Q7MMN?M[$GRGR&G2K53'0!.%QNOG<BQ2
M?GIETXO>3H[="C(8-RRH@R-VZUB"AE46<Q\W/MS*$@(2J _L</Q+8]XY/C[!
MN;\S95(=BO?A"F_ ?6-DORSH5?*\A.SXD->:B/M0\I1KR91Q<D7H\J8#ET&)
MB:G"]7ZR0)/7H1C.F[#S_]S0F8#X""MJ:\.-J\YH-'A"(S!E/BV2=78WZP9X
MYU^XG@QWO?OP+B)15L%KG\'['XK<"]R%,=X7^W^Q+J(G$#SJ!8AIZ(HP/5A/
M]%7^UD$[TR+X(;>DW*'QR!A[>YW76ATDH9B]1N3M%K2O1>MR;N:S2D5XJ5]V
M:4[&VP^I0&)5P9=>C\WEX!NUTLUWJ65UB<]TIVBICOU$]]%3ZJ85"_[":#KN
M,_HD-2"L5C+KHT7S3I?(H[@PZ[F>].PY;.&^X==('.T=U3I&79",#9$63S-&
MO A4E)R5H7=\R.6GI>J2+(-E:&Y4-B36NRT2?0;Y*37RK&G)C?L)T$E%74OI
M3EQCG5:3-,< 2CPK5J5QX49)./#*RM479^7TI&TBP0%*_?#8E6E"Z5EP-%G/
MPC .!GYI8D-B,"?9D.R4O#E3V$]$PKKV1B.F9'_5M!8; AC7GT?&!T7.:J7]
M/-U910ODUV-UL/99XY$!3=+2E+0/U=9AFTC%E6&6S?=W$\'&BVT3LX,^_U\^
M W>"? ,;[C1U)'D-VG++<7-N:OW9TJ""BLR/+M\/36I/"V#^7L(9UNF(@M$B
M@W^Y-39=D_YUC2#(?S7_5_-_-?]/-[NY%RV>LWTUJ"R3Y-"F<L1+;*4%<N<_
MA[!]TYA96*92M&A?@7L8"H(6"=BD VV-8^^OU?6JC\NEB/K=_4&2-A]\?F91
M__2L@$.BT![*'(XAN9LR_;<8&,U"_@:T'.HHUSZ2W%$ZT,8ZSS:)U<\9JNJ;
MHN[*G1_UAG\@Y'U&RB6?M-P_72<T/+)"F6DH!/;"0L=.OO8SW<^]KZBXD#(X
M4'VGN.*R\(F*H NQ*X.6EQ&GOD&^?R_H.,4QQTT C@\SCE2S(=-V*#<",]YO
MF^$TECTHV9* Q%IZW2!R32G']E9OH$@DC?<U3Z_YINR$-^D>+:2DO? DURE/
M[]@%:5Y]U)ZSF# U<3YN3:>IMKB";M85O+@EM&<65X9?/DZ704^F0?NT%>AV
M#+Z^VL=9OT7C'7[3JO,3SHQU_1:81&7IQW_B\W7$DG"<2&MRS\M2;+CNP5ZG
M_DU3+I.*?K_82T>NV]DV2+0(F53&7TG/C8E_I' K"K(=#"/%8"BF0M0WU$?,
M=P^[JZ@:#%D$):(BPE^5_";/&>HM(5#%ZMHH BUAR8/Z3Y!3ASY!N"#_R^4U
MR51?RYQ\"4[+#"),^?O/30D;S"C8?7@YTK!!8H&A2!2W6X4OPP]-?BXI?XOA
M;:%)J#7\4!!+'(@YKV*[U$ Z]SX4X1(6DK#.=.R<WTT6$7$P')OV.&78@T^?
MW)%9%?6+Y(G7_(\+LY\--R% %B@Z0SO-?,,:)4/W>"(H);4N^V=9K92",4F%
M_R"!GB\/*!Q.;!!S<2RC.NT6*+,#L8[V2R]'$D,!T,J6>N62:MJO[-63[NN?
M>S_ Z>Y$K=C2*GPD@'7 @'X$#0K<F?J@AHP'[DRI5NQRKC= ]: T-\BY[&PV
MA#2/'>Z9-\K*>%D?3E?YAP/2_^& F)W;U8&9>$^<%C/OHZN$2VG=Q_\(9F2
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M#,M#M9T*M++\VZ+IDF;=N"KT5#9OJ* R/^L7FLKB(LK)8=I@%@SW6/L78*_
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MNH8/0Q=IL@\Y4H02<S$@Y@88D]\4QB0?L O\[+E<-E3]U6^&-3<9E+KQD?2
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M/A+E';K*X:50Y-9ZX;)'C$#N8B\7<0I-?8VFT(@[?:A<Q/"U>=T@H,EIUW>
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MR^9H>1)UE4RWY")XO!C6$-_XL3VG%T*$"F_BM!,GI4\98T!MZ^^U$E_M5*.
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M/"0:$7M[F(L8KE4HQGRVNZ([,CB5):YU-/O,9]E3UMFA66*/2[2.W3R2M'A
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M([^H91:9[X$1T=)AM/FVUGG=D?&W\WCPF<"Z$\@7\H:Q0,76F3UU1)H)X%3
MD!00>YD@[:FIIJYRT6>N1 %!]&D/*3I:!BD*''_O>L9KKTI1!<9Y$96HLR
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MMCE][-QLG\M>RF4>3QH:NJ<N79NRK^R,S[KV/3>Q5RMU&M]Q#7,4WTQAV&!
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MB4\U8$%%E_FR3,,QRH +ZV(XC?#<H$8H_;E!L)<:QQ1U+X>O*/0X*BCP?LW
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MJWZ,.XW\65HM/)0.":!AQO83&I4R"R5[8IY)HE1^?34X$OC13>\4JUB^Q"(
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MTG</HC,^R+;9=\#!2DK3<-.ZR(]MA7#\>/)JVA8Y#X=>OC!PF$K8K?[);8R
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MZ#!(8I\#0QNUNW']VN7DYZ;SW4A68M_1J:5V>\9/6 !OM0>OZ9M\PAET%>]
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M$VDQ*_1_L_/XVO]EU_%R>-Z__-;H?UK^T_*?EO^T_*?E_W];_C\>?[%Q32J
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M:>WEI4)UCO>QKS>Y#4T+$AM?XH+<B.)*;BG+CF'K0AI8ODCG(9:OVC\DU9%
MY87YG%2@Y@1Y[(L45.A"??H+M9OCDY=/9MS-V!D2;MJ7X]6WL_VDL4-LL_P!
M>W7:)E'E7+\2BF3DO?<^T-?Q@Q&95U+N6['NOR(VR&)5'O@X#B7[^9R+).?G
MBV3KF(Q@-KO;97/*L#ZQN5*M-)<FY$ 2ZQ6CB7Z0?3"@:ZYVO2.FN +#'T#K
M-G/MVG^[;_V:C'E+@;"JJ5C:I99[+1?UPW8%^\4K1/SL.GRZ(CJN6K9L^3,W
M%A*8@V?&?&&XE$J9YS*N-!1CMX/"C4/8*$@-K.K5GEEW>/-Z%.>'NM>BU5#7
M-)$E^+*Y9L=!LR8.NNYN0+)\NJ#2\>CR#-I0D92[M0?V+P\1U-?7-,51,9*V
MTWGJZJ#DJYB;(U%<,3,QY>&.3^=LA8'CD$- @B,/\2R-[8.S)S-1^?X'$I<N
M=/ONP[1C3:('T<$:,B)[+XO4/[4>P0BB1'!'015J0*4D@UB=B E?_E8FD>B<
M4K\_/^:OT7'=OVTFLI/ERBKK&$7J^X2#T>MI\I]7D_JP?68.P:Z5A,'C\TGJ
M+?UL ]71Q:#F]5+2-!QL@ILR_O-3AO_UKO\@4S4X+0#S")@XD RK[WS12SQ$
M9\QIV9G_WBUM]A@8:@?[QUSH%HR*JZ *VY"CTHESHGI=%2YQ+:>_:A>Y]:%
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M3++,#3C6W^7J7<>]*V<43D!8-\ @]QKGS=9B=(/"R,-^W(;4ZJU\I4SK<S2
M]7.MC72E@:JWO^$U U]4?4-#G/$JNY(=[JQ^/C5=\\ #QY*/F ]TH)JOF-%X
M&!Y#H58YGT,U]E^9^6J4A=E4N/ F:19V8ALBR<))*)1^YRL7_\@A$6D(%.CF
MI,%$$QUV&QQI(X_N[4;4Z75-$.?"@TO0\JYJ+1HE!W=/=S8Y7/B9<-@QQ6C@
MS<R%9C*/^#2.- S;BU7BS!!IYPE1^,:U9[0?]TTV.S]/ .E=TKQJ/O=A%F.5
M1>H_]IGX)-EYR<;LY?XTHS+$)P2&I#T3G?Y@%B=Q>H9><'V[@C%./;4(IPI^
M.0\W_>N\M,[:%SSWJ95.Y.QATWAZVXXU121_H\FZ7<D5DVV)MLGQ,/9(_%9M
M==72*,O2&/EKG"-(GK."@;(FU>*J31Y2W[=-WJ_P0(NMW-4M^ICC?YB6^N<D
MR%]JU6I4]NG/M(?J;+%!O>#93^JW(1/K'/Y6FB_C%OU^8<,82X_BKC.^:L-J
M7M:*#@Z3B%@I\'<V9OR(A N#\"_&J6$,3@M9Z%6540U)D@K=AB2\WVM7[F@F
MW0QY+APIK(EH0]3YKM@Q]3AC'#4:*A'NKQ''D->JH:EW?Y]-I.+W376'ENBL
M+,E>7XOP%\GQOYZJZ-)X0W)55--^^@"<!TZ)U6L 0P3I"US6)XUZ(,C(G [K
MNSIC^<QUPFL\TF;(^<_#T[!'<-IM5/O@)/,B.[]-FM,)KR6LK-*V(:>!>*8Y
MQOFSD<*+90.]J)7 M3JV\7&%O%^KBFD'^Q+,ZH),8<W/?IT>P!:RM(!PJDT,
M0M@(3BMJSPN87,1*#:MK/Y,>N&?J'RC0N=>+_<4,%HN]#01SM/HYPIZC++-M
M"*Q@+SO-1/((/J!S(09-<'<ZWME #?A5N%;C0KB=N87Z1VE==C 9*\PZ25](
M:]&BJ_9@H?5?-@B[WX=JQ*ZMZYT:*7UKEN8ZG_(LRDOZD>CJ;*)B4N4+5QZL
M.(XT#J_!/F%>!Z5D#??!3>8S@FB!3W?,.NR%YS20]6-L)AP_Z;,L7MO4I#J8
MS=W]\MW=)=G R=.$2<(_=TE6$#L:1VDCTRP1T7A1#)*)P8X5&-'3DXA^J,1J
M7->OA0LTHQI7-.+"::'&^)#2[/%]YRJDPO.OO<T.:]M]E*<4=.A!3. KS%%V
M0AL$V]\D_/+.U*62N>3\_+(LFX)O_DXB[IT_8'/;D/2YKI"9YQO<[U# J?,]
M,C: +I2A&[L/>GB>NN*_,[QFC^<+S2WHAV8\8*! 3>\B3N=R]HS2'!CLD3;9
MP;)9X)X[3 2(/AV;,EBT)#WZZ$9+!]_'X0MJ7AD/(EVG8]U^XP$-7*(:!@6Z
MW0"G:\LF_@CS!J,JE&)3/3&5?M*U.+E#;Z@O(3GK8TU?^>F%8*XO0WS+SO_(
M$7<^9H8,] +]^Q+F3G5-HT5A/ )(R>B6CKUL5_%& +((F1=G)OY#UR,*$_\S
MM[#E6UQGR8F#7SP%S(.Q7X@=7==,F/S478_8#YJ8#/  <R*+ZTBU=V!QTMPI
MKG9DS"Y%,^7CHN>N-!^%IWE*@[%V"&/&;B92GLSNW^E<Q+K70B/';%@-BBU*
M[XKO04@LWW%?:I 6?]1A\=#6,?7KD41*0\Q%D_,I#P^E%%EL0XKQM'!R+V[*
MG.J[XD6;IRYTI*(N?VX1FT\7)[MB3-M&%-&Q@]E!66XN%W]N0]1*!C[&G;SU
MXXOO(0N"X@ZUQ%%R<=7F.]7?3W!@> Q,GR1W;,'BZHG\;@"NDS&>IZ;9*9GX
MQ[_JW-TYLXO\92EJ=Q1GJA,L*EUX)[B8ILS]G %Y27;J-L2;&(^O(4=CSNH2
MRM R'3EYEPU:.V(C?J1IME'*%34>?W]Z5/'H5:Z#/JUGVFQVAN"YLGQ!CD+)
M1$!6.'"E7T"VT:[=?[Y$\W_N'<B84(W[^T "X2-EE!(\</_:O^_>P41QCAC+
M")BG"&Y#8O'B+$WA>NI7YP\>#A9-8?MFS65?'DVR+0[/U#H<GUJ3=<@[U-O'
M8=A10P1([^1 :1O;D&2,:]64?YYGKJ_Z;$DY>4;-UFVZ)_9;COEU<1%'*PE%
M"->12/A).&5-B(?R"$<S3[7AB,&%_ ?G9' '_.[BA& K'X[4$Y'96N:H!]E?
MK\E-J+3L*TI_Y/7I#RH:=@!'R2;2_/E2C)3GLYL_MZ#":;\X]Z^_?V\9\D2'
M;7J5:6+0J^:T6?[:H+*0_KG%88Z/)=G)X3=G7L:1SAUB%^-NXN6 %TSJ)LG:
MR<*$!^"SIL6,.^5.14[_ $I9687?U0H#KQ[\>TRZC^1]O6AU4)8S5 ":6/0#
M(B4+5I?SC'D"K>R8W#G^QA/ 46>FOL!\F\<W5&4,K4V]-8,.2^71L[Z>#(,=
M>Q+Y:8B+#F7MN]LC OIL)6>BTA:[19XS2LV<01OT\8#$._U#\SIPTASTT#GX
MI,:\.4GNPM+WD1;-^7XY!YNTLYDB7]2F]$6"AX.O5J4]\3&V)&B#*I='9_7N
MC#% YJZ647'[K!A"9RU1L*G9R:_IQUV\\1TY=N=?5T55?EY+X?GT7:'J/C]X
M\0#L!\YQ0 =T, 8=M<HW;RR-E 2JYDU-8A[V7)[QOWOBK\B5O;_CWF;1A+MM
M3RB>> Y-Q5%^6+DC<<"I(HKVD/L+HRV^J(*[CI ^,BUC]O7\\MU7*5M'Y2HV
MR!SA0[3!+AS(%B1-3!;) JMK):/.'0WC6N8^Q>_>1-O6%VQ#'KQ'5/?>;F8_
M'?\&9\E.1_CM/.YK#Y>G<D\#P21LN#J'P%&1^;$P$@4=&O^3&AR("D<IE<SP
MJ]D76E[//*OZ4NI@-(GW=A*$);&SXY5E#MRF:W"$?-@O3400 7<)Y6B]3GDC
M@_KHOK:;_+H)XW<;E>[%^@J+I#LUWC)9#<'1O*%)K!L13$,,FF;-[AJ@LO5Z
M[IFMY8J)51]?4U>VRFJML9\:@9LZXBA$?#64)9K/N$HS7F@G3A0QU#^'PJ;R
MYZN^&*!B,8<H_?U_9WN&%T2O!/!=L!PH:5HU3SORRT'XQ[F_5S,(BWJL?=$<
M_LQ@4- $]H,05)3)R:PQG!PZWO9A%WQ?D+JBZ/F\%'I/U)@>+/Q@W-$7?8:N
M8^97^)Y#:_W^ 0U:P*JRE(%P>F^[Y#9$T$05N"Z'[&PB/&HJS0Q9.]22IF]O
MM[_0XO=A'S.HS W%,WW+?1_+?H=QA"E#)OP[&^'17[8A5"W:V%/.H49Z3KPO
M;9CS\072G?'.0?LN<,!C3.1K5 5)X-3?\W!KEOD<' K .\<YZG2?1O]2_WL>
M3QOOY13A;E6;(E'2DEFN<@F7S1S57#(@O'FL \ #,'J#4";*CC,*H]GMP?G#
MII5[L4?;@/LT!\<L:"2':P1S2&>TA/%<]V_;,:)B>;C547>7/287SM><<)4J
MAS!:92B]/0A "<62-IV'\@/?@_X09&8Q1D2\2\T=>X\CUCA;%Y/!M.I^\=9E
MU;2*HY@0PLZV.N&)#CAE%#\MG@0EN[/,,VL,T_E<(3CZ\%_GZ5E]=J$1:/M\
M/#B2(MQ?W1!4[J4*R7C"U5;P5CO?U9>;#(81EIUT[^9%]5V?.:>I,Z_4Y+UF
MXJ#%]:R(:@,<6@#3[DX[Y7?8*:PDG9=X]8MV#IU=M?ILXM?W.$O6L1O[ Y8G
M5 :.+[8;K=D;#/$Y@I\-AL>#X''"<+YQ)9J./VN-(TWYIFNW7K*68#C_4G;O
M,T7+J@K1:I?*/<4>?X,>;JKI6R9?P)%FI/E(1\%XGBZ-9QW!2H_@NW0Y)X=6
M.-+PR4?62.RXBD\:F4>UJ</PC2/ZD#GL:"^(G$B@A]4.;*Z,@JH=I2^L(NCA
M131&/EVP6S0 #&L5"8<\H!<;-9/'P]HM6&.M?]/[:PY.D@@2_Z6L'665@ +,
M@DFP3.=@DWKS<)+QF35+,,P* HS.RR/#TX<5RMVT[ZAL';\I7CVBUOM2AXE"
M9,!I/F4KA+GU: 3-!B7!&<)J#9=6XY)FM<46+8UN6/?D>D$SQ=L'3R$3-2 K
MCCS<9P78V']CUOM_/Z 20"/-D'$!T&3N WY2<2E86;\QG,!-#*SB*U![H2G]
M8UR$P]Y&R5RQEI(\UZ?KV3\R\\YGY*JYY[%V-E&IPKU0B3@H=A_&CEW'"BR=
MF? K@!?TGJ/==#AFT]AY_7?]Z 3?NOF/#QE%T+FXVU/-&L#Q1I:$ T..;K/*
M R),WCJ@F=[K/MPF[3_.'\8\O<S9,U+<TCIZ\5*Z9&S5MX0'P@RNM1^?[&S/
MO+N;[;RL 1S18TF$,0ZQF[ GEQ#5!)98+W6L"DF%\;",\7:CK]?_0%?ZC:4_
MSR*MK%0%_1I%5S@1C0=52MY]3\8\ASW>R69\W=;!C$C0.M8YGV'R+0XAOY=-
MCM&4$W4,$Q7U#\X N1=S_?[8GG@N#+'EX_Y75Q2L*I(HC*.L$*?XJ&L/0Y;*
M@/DY:%>KLFT#W[<;T8Y-Q-2$I6SD":YEGC=KR+>@6+ X7V,< ^0/T9EP?]@D
MKM<M) <*C0S]:W1R7. R8NDS,L]C].GPPCI??2A6*^HU5"6@D;7/EW&3SM>3
M#NB+,5ZR"94W/1'\&#@0/9^NX)8:O'<JK:QRIA,EH'?^R,37OEN7N%]C@>?0
M21 "X7B(WH1H6#4TK4T2Z*7VI/K22GM)6ZWD9.V*<E:?;_V)_MOAMPT_N)8\
M^?37T_] L3__G>YWA/=DX&0M0Q?(I6U2^;IATS8]4X$#<8GS?U=";'9WGWS$
MQ.AJ&'IX1&+_8&^^%#C!.>HK5U$#BNTGCG0#?HV\GS.D"XK3RB:9*!O:*D,M
M?78K%U<G3*"D&ECU?[W<M4A'N\U:).Q;ORJ_=O.[.*]JKK\C]L7.Y"0<R1=W
M'39=-G\\FPG"'9(15BY@K$V$!N^<W)!S6P/Y*>=C[7"5^H^ZNIHW#<FWCP\N
M--_A?N5>X-+X@>NW)$N>Y.N'HSR#[]6PKL.&X*17AY4F]%0:,E_F0!B\KQ[^
MK+OG/ .CG='X>W9P91U$NI][MR$^A 0XA7& B@"4]3IE?#+/I=-?3V9KO>>Q
M^$*"QU'_)C'#.'OTM1W VY';AOC&QYUNQ^C6VE]>R+@B NPSIYZ&N?^C_:U:
M5'(T<6^+*EVA"R&EK<$WU3F7+MZ+E&A]W;#P[EW<%/SX'KUW1T[9!ET3#;3^
M9<$,ZUOYJH,!B<FN:5!$72P]\+<W1NP-$%Z$.5,[8G*,=7X 'Z>$U&TQD:WQ
M^;6F,[DZ\B/SX*Z6\O2MI4<:,Y87(K'!V!YB]?E8.HB4)H R>C##AU9G@.A8
MCYH]_G848Q->W*%0%^]T7VNE9K(0D>V=ZQ#1J)E.B<,^?AW!$=BD.UP!GH#A
M,(C%#42\^FHX 0CVXH1#!G1G\)F\N8RMAV_D]"2;OVT<VG]7_ _H=V<Y@G:@
M_\:S\UE"%(T)&0[_?#'PN\?3!"3J==."K5[=\K)(_WHVPJXE3O4KTJ$I3"FI
MR/*8X]XS79GE GK0'2XUS_ET;QO23@#TO1C.[#<;<@86K$-TL=Y9@;3[_E\2
MKGVYJ>,>@4QP;3KFCJJQT/JBY;66!Z&"66L)FC2UW@X#3O$PP@ RU:HLVI9&
M[%P7"!@R\MV5!Q4+6+N\%><X94J),J6,_U'XY\H 3Z A4).U7;!&/I9L)],0
M^\F$OSKB-[QS':1='5:,4#)#R$ HV*FE)>_B_:&<YJ>^!]2B*P388N"R5D$K
MNH[=><ITTH1_ F,TW';(=0F_GZ/@,]@I6I_O"1-VU0H/DUYA+/VVR.">O6S.
M#OD@N:98<AJN3_1"3!2= 4"SY;N)<0#>,;70;G(:U# 22O)*0)MRR^=K(E-G
M*TR>,%QO#A$^U%B];)U^W$L["[_HO&X>O_.8A$;H2A?!7!UJ@2&A24;.<I5N
MC*;I@A\_9/Q8;P_.?GM,-7T78UFO]UYAE:Q0BS7;V>D I]3#:!:X26+[+#<;
MY!X%!C;I1C?FU^71/ZW?-(\9V5%[&O(1HQLR?==;Q^H-R^ZXO-+.RK;M4K.4
MCBRZM97+$6P$[381V GG?8#R-=KO\T"L;REX^ZGY\+T7Q@+1&'WO@>\SR-KI
MLH'#IP7#[6 ;(T<1;[.R(:P?[%3<]53!>2)+KIIN,[>P,D#U"R'&DG>U>-Q^
M!13\MHPQ]Q>NW/*=O%%[AJCR_GCI9I 7C+27K6D64?9_;(/<D7"?\O]HHD8O
M#HF;X&&8L)LK0SPT&&^!0]?FDVV$^[6;=$I?1MS)F+8\:ON+-^FR_;?#J1_Y
M>0[NXQ^LMCL-D\)U&2%H9H-;(/:-!F.C"G,;DJ7Z,Q&SBY*/Y\;'2;:)C:QA
M3FTY,[SSY$9?6"&5<G._RX0EDIQ3>G^)7S7U%$(.GX;I8$"F'V6*(QFV[4$S
M00(FTL+%-.:*H#!?KF'$O:K0%8ZCVH-[![36LZRU;%J;<D8NW:'H_D07'8PT
ME1)?Q\)INQ_0-3KO  Y=XP8M3L&G_(63YP0'3@:GT!<F^_<W7PKWF# F5;TZ
MRO-=(YY(.P<%E,HZ;&#3&!? D:GL@O;MU@VV5,<G8HSGK)WZ;:/,][Y>NBWT
MN:^2]%A41E&3[R7AU<W5Z]5U21\D,K.D1D5*GQ3?@;3/K%EI;BAFW<NRMC2#
MA/NNS#,E.9_P-;A$DX/H7DK8@Y(1'522B0:^:U;_2U ],O]]O?$%^^YB]=L*
MCX<D JN/3(P'!]KE;1C\^]#E7_!%CEVU#;D*G6 RUJJ'0XA3\Y38^#1U(T.U
MSXMC>26K'\X&*A:>[1,]9F>5D:1W0G%OY&EE$Z5MR#XZR"+A2S .% P_%>L<
M"T+MXO.]_T!1:&B'#: HR1)KIL2GM\#I,NVPVB')-FA3P0+)R6 \J=[#X2+M
MXXC)7\41;>;TRT#MA>,\08U))_?PBCQ 7!@^+=7V[ZF)D&\B#_KH/C@E!\]O
MA ND>U&=5YY=H^+W3PXH-F"5:)N).N[J9_AE3S:7=.E9':[=?=7B9D:7?&E;
MU8O(4^LI^-I-$F)*@6J\V3Z8M@T1JB-*H6WL&RQ0?VQ$2(RW9?Q1*3T7&Q\7
M[Q;U15^5.A&$[,1H@!YU#;3 V\ U(\VR09J& WUW)B6_\#9E4!!-GI-OG1,2
M.Y.Q=W?=B([JT@JE]]3TONFG>_<*;*4E02 "W.7M<O_3JY'_U?':?)[8CHO9
MAM0-=CQ#4'"]&GN.$*G6]Q2378=+F_*DUA6<77F#KH5<S\^VO$*MCMJCZ.QA
M!L%<^X^46(SS(4P&4_A6PFFOIRGI*X,TH@TM/C;P>.F[QN&ZCA\Z>;YDA1_G
M?93R"RQ7# 36RY]#\W9>])$.PBG/\ <X!X'X.>=TN&_&9H%F2]1Z3U/0P[DJ
M9^O/+5:W!=?3 JVL:YN2!FUO;4-T?R9X*R6J9R$7/;0ZL#)#+:I\#UCZ1:8E
M_A)Y]R8FEK;.L+,,K4)MU!5BSC:^=[3E7IFNXVJ4$B\$[_PE_2QG3S(HY+<
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MBHKQ/*GE]M,M\LEU7;U@#_K-!/XL]X</1(^LJW=R&PM2S%GB,,8F$+8-V25
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M"3=TNGVT/$;ZID3?E1??KOLJ21D\K#5$CL"];0!5'?*J#!/.NOD%>YC%]P[
MT?&,B-I6FT2\8+VQ79#][ ]5R]?JI5'+.MQ(JTR>E8R]J56I_37F$.;))-8;
M=@&10B#27!#3/QD^GXD!^ EG#G\^)9&E(8%79J3VIF'N,7ZCHSBB_:&HXC,/
M+-/T]W<H/XMZ?_@MY.;AMO?@';N#PC1M.00*0I^=BC%DNJ#=2<Z>!_!V;YM&
M-M:%/*_\'2Q9UOW\^$?\@$#;==KKJGI+2TF5JFP([*RS$"V,\0A09IY&SFK1
M%DADF=?-\,[U_9;408D!Y+5;#6/W*F\79TVI=_947[&4[HLR%23F]'JM7KV,
MWF1):#$^?2%>U0".$+M14Q&=#L7W..E4^@VJSU7A 7N&W\KJC2DLD.8Z=KUU
M[$@5&5!:6*GV8DIC0>ZR%\N=\*P>"=MK&C'7/_FX;GSJZP33J?"V0N/'E<V3
M'^YT912>1^_G^LRZRVZ">Z,F'\ZE1[4)8"* WX4 HALAHN$T0LH[7J*0&*J?
MYT=Q]'CER)7C,J25S?LPFM1;Z4R%K0HRCZ-S.8*%H"Z^LU\;28]+ZI+Y6' 4
M[2<CM*7NNNM&JL1W'?<E]:>WY)$)Y_P/__Z^C!X\0/@"LB3%QM5W9:!,S\(I
M!2")AP=HAHG]E.Z)R2E0CU.#*KC6'YG=N)O^5MIOZAP?Q[4OOG _US!G $^S
M0TSD,XA XIQ-#+$6L2I2"#1V%8@XH406M^Y]K'5Y]?&:S[7#QRF*,OQ7(BTV
M#FQ $V$B+5!:-'7M'1TQATJL"D$(HY&6;[]L?/7<2.KV]><-5*O5/V#H*)[8
MKIS&15C@X_!+&H^O7&/Z 3".P &AK@RT[QQLU74>%X4063CNI&@UL7+\3YS7
M$+3A@+>/L<3,??.?,);D(&*,HX*1^M?,K'&:?)F:_$%VF<G1)8Y4:X13UUB;
M;%TH<2QH_(LYKUV1\$_]_5P;\2M$IAOG$ZXAO5.!_I#A 525 ?V=//8Y[3^E
MKU^H9I<>++6@JZAZ\UV:^%O13T02 #5SEI@A0Y1NA19CE+ )&!WJ %;;Z2V-
M7>EL4%!XLY++0:<JQL%*F&(J,WI'^+P9UA\4\&&<_\]MR(081Z@*V(8PSP.[
M9T_5:^QBF=(O8J5<)>^9WM=R=9W44O6]5_S[3+?-K(#Y/:889P]H[[S# !_S
M%*>K@)]=A#T$*%C1S;O7D[!R#?3<=,YAX,6H1JCEZU"I6&K,E8L'YBT^.SH)
MG YSRJP9R(-LB3%.@4Z#Y[3C:;8\88',0]@1CAP]=2-%_OZ/5/Z\0;LXV0<_
MZI_-W+ZRY]=IC>^KO)&7+%X7S1%6JYDJ&"BP0%F?+)M;Z&%+=G+T@<C;%#(T
MX-+2\5?='Z]Y!3;K::4F5;;7[GLN>AJNCAW#TVQL)HCSA-5K-!SC"_LISF\]
MGKP'JXS1I1<;Q!'FX$)*R8U)(<]2:I?"[+IO[\GXH"GYM/M#MV)%?2.$> A'
MZL!5%U0QL:"P;N!\;29Q'1R#M[1/K94L.;KQ>NS&SW W+=\*E^ZP^]XK_;]5
M9)+1V4^P-YRN$T_LYV+Z>^I3R-/;$,8Y()5Y_">Q(;Z3F**)CJ;BXZK6?<=:
MK L7-QNC9@TU\TOWG16T4<[A4J_1;>?]PSL>CR.)XBA%L\?8[W"^ P[4L%69
MTH98^F_*;"E&@Y[<Z>Q7/<B8L#*7?RZ"GKS]7=\0:Z=R0?+;'O<>'&4$*:/N
MP-FS=*-TV>GV%?<K&%.ZK+/$[QXYI?-/=SLY='+S\\KOT>;:LJ(@9 'X7%A4
M77K"-@3:8NY?Z6? R-]=6!0P)L9_L*4^3U/1X7QGG--Y)[ZAL2KL75 &>XV0
MY2PH4,^TPI&.U#<O>=>P\29*@H1XR]!#_H=HI76*;=5UO+\Z]C8.+-V*A$#$
MMY3^>5]A<=8F>"F0_G\_2@0IPIK@-J342N"O29ND9 _>L?M+X8K&>V69WRA?
M)$OYCX\YA8_QR2KN([SNG7']J<O?&7K?%Y*R":N.JQ&>']B9[*MVB$$<:]]O
MCGTRK9,SC]CR)A(6S[3%*PP0&VYE$=Z_]S\UM;GXC.$QV,\Z2\%O"!J4Y;*]
MIH-''/7?Z:N'7])MU";F;!(]Z@2Z@&PZK)W(UR:/Q$N8**,+QLUH"W%U^:DV
M'J/KB)NZ=S/.?[92S7P8:Z8<:2/+C0PBGH)3YF$)GL< /*V6JL<2;:0>KU(B
M)L,#8(D2]^18.;V;.9ZRM3FJSRXLSF=4,%,[B\P7A&^912B3_@O6_&_ FF@3
MHYTM!$2D1N(VI,$\F7@-!BCYKI"HA 031<#7'Z7<K0$#@YML'BZ^!1YZ*[;P
MC1UW7:/>7JZ^,[HU!JN&<@_+V;%$2BE,"GL2.]P&@J0H+':*7/L]O8.0[BE*
MFT-']?1:CUTJ*02*SF=V695/V,3>3U95,5+/D65-YYQ+X%EI4J5 (^$T#]BN
M)6F-U5U4#> H\8&:"91UEOWT1P11'!TT>!G9%_KL $/]&>?IK\K 6\<5LXX.
M:X[]F,[P$6C;J;_^Q"XE^I&G80SGSW!_W)0613R]T[+%0Y6,=NAXLVS_U>-(
M"D7&/;DTY'36A^(^!<?VU(PL07%;Z&GPO #BY#JH/P_E'L)4\%QJ?#1+7>B/
M[IV?!ED6PVJ_LA0NGJ^<O"Y\:A5AN$2FW0ICB:1?)L9?:@ 7&H56\BXXG3!^
M>$V*!)\-/^1HNM;%]=-SIR@=)!8?9'50S*/W)#DI.7BZ,T<@>ANRNZZQL]43
M*O$3P5/_U<2=7W3!?,1D__W2N=4+^*\]B5[/%I[?+.?CNS-_D.>/\V5@GH:S
M -0CF.<'Z3"+_'90!4?&US#.U]"-3O#)S-,C[^]F=;ZUW)?HNGEDY4%/  J\
M@F2;#.8^<*V0Y0L8STW?C^C@*(Y\9IX=4Q>/<;Z[ONEM2]&%OMU-U"124DWD
M@=B=9HND9KPH1QF#!!"HUV@7/ZP>G?"@30;=!AH.2V4,>GMW+KK8HLV#E$3]
MN@>5L[)V)<=MPPQ</9&ER,[>J?<D\^ "-(0Y_3D92++XBO:  M6\'1]O*5?G
M;% RA%*V:9C<YZ(^+MO4=<OU\B%?QX.P0IWL.9PLH$JR]Q]&]W9/^3S:ZBF1
M>%9<6G1?=C?CU\6_=VGQ"A^SW]Q*SCEE= OY.W^NC"7NP!$@,7F!8"MV$9Q2
M@J/9#'*[8J2;OZP&8ARJ,$?I=5-I%93BMYD*:<@))?O<"XJW8MI)82>X:NQV
MIA-0WB'V$P-641P!7R84P%.4.[8A/.B'9W '/ (0>S94B9)6 D 2(\)*+\^P
MZLV;AL8]U_R^>WSOQ#_RRH!.+*O.0:=Y. +I])UZJ"Z-6.*;S14P^Q]?(H+,
MTG\]H6U?LL>8$4PR$3OX''UA5"QP=/7KSX.^C6+%PUW<11:'E54&I"VS:;X<
M@?O,:RQI$&R(,"5 T3MN0VYL0_@!27N@4CF9BNM"Q'&4<FV'0CW.B._=\GY_
MJT*G[MO)&!]%0X.CGF&V?+/9S^:A$D!PNXGHJ%'8O)"3H9""V4@9<52CE+>D
MM4ZS+JMO@I=JY_*4&TU(P/GC !7XJLW<X#2B"[:S=PI$LYW4]02L/DT^/;"<
M94TO2S<R.X*GD@7S'T%1?IP+3X)\0V\$EIMZGA:J<9 \MC-AR;S-"!,"7&/:
M<CIV=N:-!M*FYV&=ZU'W/H$N0$M;'BQ?]#P\O##RPZRU]MFCD]>^BK^XX_YC
M^8"W1;O).B!'[Z?"5X_1BLQ :];J&6M3H.$3 J?N2[K7.(MX]-1HWWAD4''5
MX,0WX>S1\3EGED@_ X3:46TS.)(R5AH$7&\T6&*_2;.':*C(.IE^RYU]$FU:
M2$.BI(=Y^&U%NK_3T'R @F:,E59LN$@[Y*7XU@YB; *_X@':G",0R#P (!DU
M-$+46HN.[DN=T;1WU(K^3*VE>[%U5?N'_CYP_G@E<GGZ\J/0#Q4W3O,-97^S
MW>FM=87##^33C\-3[A)I:1C9L: 0?,(6TW_\3+]%:V.JXMOH0<V;;_URSHF&
M[[913^OIY"X:Q%%JX0UQ+YF0G??E'!7.B+S$.Y<6LU(_JS+ KH^W]Y7GQYR[
MGV.-]![]YD\JJ!!T'H35;:Y4E6&[R;2;N'2X[]NKJ%5C98KU:&_2\>]*):UC
MK[TD#6*[4K ^ODTY7CF*#QX4'.49$^,([Y1%'.^C2G($>"@KU>U? ^_Q_0@$
M""]8>DQ7[(")-KM@?1L2L-/$&T7[\8XV?W$X:"/P;(_TD>+<'%LWMZ[/,WV#
MPFO7S]U92EV^'*75C74%;]D81WD!JC-HO), *,>3UG=CASVU@*-&B&*,VG E
MZX9_!>:49",>9265]?V(JO>J=G[G[H/57@7683!:D&0'F0]HMF=7FNAC)&@"
M_KA:R6Y\HI_)/@!N7W.YH6!6:JWPBZ^[<E_4U&WU%J18^=]#>R[S<D>:@" J
M(1Y'2<;_R8#R@:ZE#J(8A7$$39(C"$88WF9V&4=]D<R-Y<9.S$K3]9);3-4R
M%Z?D4ENG^D.&NWZ?LJ>]HLL&S61VY %XCO!+=A[<%Q8++N-BJE8740CNNS/6
M)\P.E9S'*U3NY[F_MNYI5\="R(VY5'?_]@\+?-S$2ZQ#3!5L/QF$<H'S.T_0
M9[F'=2*.^-2.:J?S3;I?:7>]4&WIE7 RJ_+#K?.F"JT0<R8<.XJK):\Z^,Y9
MGV5@@*)K<PF80W/(="@ZRXHWTRRN#.*@4_LWZ5VH\+L><V.DPOS"Z@#SR,Y$
M6R-E6OX\OF= XRS=.>TU)GT/VO=#WH+MJ/=L]0/QUB9+!>Z5_7+/)?IX,VX#
M3Y@"H%:\VW;A2 H[I?A3O5VS2OO0\7/P!#@2+D&(;.$1[U%JR[Q6OWN90A@0
M>NJ;BZT\W]4OZOP'9!L[[V"^Z3K?QI&<B3=124V(;G+Z-D2BSB_4$"?I>K%1
MVCGV3\7CZ,ZR):D/A_<\5;CP^*]EJHG]ZE&^R2EET%MMNN!U1YJ9*OYM>G9T
MGLX"^;KQ>KC05Y<KIH=&CGO,)ZWQY>BD+6MH2NNAI4UEJ(H373PSXPLV+$EB
MES.\NJ>")L,1Z*>,^NG P)0DIEX'EVWA@4V90,>T4+C X_"QP,RKZ&AOQ;0K
M0E]Q9H=SCLVY4C(]Y,XJ%/9=O;<O(@D2^N_-T@!5W7D&UW-Z&]*[R;+ ?9/9
M;+-IY1 YG##.=PP#US6)$KZ/^'FGL2$OZE?;+]S7M%RLWY]?,V62>1$VU]OV
MO(/_VKAO# UYD:2Z:'-"56S.N0O'S9('PE]C7(!G<Q$>DIT%TI^#=(S#G%OO
MOYF<,I6Q5'M]_I+X_@(NHUO\54TLRC8D.@5["%TVA^L8C"'3+I!CFNIR.&KL
M<JRBZV+8+W?8K"OZSB>7UZ&J16EG"&MZPJFPI_JD_5R;DBOC3%L6A/VF3=R-
MA6(_X1SS;SM!JUK],C:V]2D'T:]UYKMB2L6KFIHWB^VW3&7WV40@<LBTBS\#
M53G\^2#.RP:60!6_BIH,(<:3Q2L/ 16T2_V&U^+,;90=:F+OW5_$!Z1)&!L:
M!7&WQG,$+,$S;H$,1!0[!0/-R@L53:RYB=_?8DI'=KK%<*1'5NI':PJL[8]Q
MGQ5L2?**FQ#Z-6"(JTC3/77J.;3I**'?&,<11.QL*F8_POD/J#(,V&]QE*=-
MNU_.DQ/O*5S!B#8 9O,*.J_KR_ES%+S"=,@2?9%/E-Z=$CD<]&OFA,)0&R^.
M9+<-0>'B<31; A>'A* YP"=A),^]N?.[,U]ZL+3HJ$ZBN%6YFW%WBKH1(TSU
MQ,R5\\]1,A#?A%U7OV?P_%%) K3F!UGB,HP: ,_T1C<S=D:O.V$_RDL#T7,V
M<7=S?F'LP>S<!1-Y7P9$=&XZ[W&3V;5/U2KX5KMLC )2X?5(]:1!^H0[1^ :
M/7Y>>55F'@8H+ZQ6,4U<6"K !E5#6#E![6;(5^]E-UB2MK_LN:;4&,!YHJ:F
MJ&/RVN# .V^+2)/^%VT0@ >4PS#-,_,%9\ASIX(X&1#M! VA"S[YR;>9[ARW
MLG&^)=YU&']]DKPTJ-(SSCUG>3A53"XH\-WNJQ7KH!+7IY",5'8UF/GO*S!R
MV44F7"XL[?SNSZV;L4:JPB7JHY_]/G'5OVWR/<>O]NIBE,Z5/9/\!ZL=(7\T
MIMP9Q0 74XZE^A;XRKR(L7Y#2X\-/$YM>#M6OS_SA65)8'6A2(6NZUM9YT^:
M.%(GC&:V5.+BL),HACPB=ZVN7_;>>K@;LJDS#Z.%2;(*D[OA#$,_V):3ZN*N
M=^!2E%P!I>,89_A*K5R>?U(HWQ>9SNLG"ES(/U#S4I^"@2&^9C]B/7QE?@XW
MN<5D5-#P/03AGW#AD*_"ZRZM]+3$ETK?4YR<JEMR19\<5,>K>]WY</+#Y:B3
MFNZ(/28:&%W@+ZWW+#! PW7G;*W'LBS+2ACQE6ZJ>UZODM?Z"MMOPFX)8>5Q
M)/U"6C06A&PT)SDKAF/:#?93Y2&6U39$X.FYK.,%0>?C*]AO)W<O23ZZJ4GN
M9YY:]=RIE'C/;H13WHR!/F@3)Z_,3B12GK4)CYO(8XQI>^^BR@%F3SJR DVJ
M[*P:6<K)H)A)92JFZ3Y)?%3J&"YX&E9WV;G;Y  H@4F,#%V#)<H]S1$8]Z+E
M=^DY24I[J;#@(] IU+2S^U@U4CS389?)4/'?[[L/L:D76=GS"#F0"Y)I'OA)
M+\H-\FH9?9S#WTA+Q$HO-F@&%!RE85/I*DLLZV(738]5M53)R<EY)YD.A<RH
MNQ19"/;9,&(WCG262&G(0ZS<9I[ #N+K"1WD*,D"0]IZKX>7E96<DK)?J'AM
MVTC;-"1.9Z_\]UK9:_S3[[;HGC@ZGB.P %JC$3L!=UU#!CL..A<"-.IHHP-'
MTN?8W+T=6\<3YT>)>@UZORURSWOQ7!!%WA#QRA:M;1#G_A:)?3*,R$'405D2
M^1R!4*8B&M9);MA<!1D<[S2-'(_S50]VJVYLC8/*R*1+^35(INQJ_3XC8!23
M\=))MUWT]4\QB_B%,LXPCN:F 1P;7&FF#5JR6SD:.)*ND6$Q9\ MKN0:H^YA
M#\<W)>2K"N-RVA3GQU?S3$'B$Q'FB9F^7Y67EN]0>#94DOZJ<@0$P67( L^8
M!NAF*FJ%R3R('0AFN0$E]"SW7%I):D]IR"K,NKHQQEJ=O3&9VG#PC*N7E*_(
M^RB!5\24'?AB#X*'8GP-:C60ELO _NM161]"6)LHR JDNZ&]2!PCP'IN.O]M
MI4ZXJY,@LOSX> 0J7,&C\RK7DUQLCQN$+?NB38$-TG%*.4+>2('IY4^D6:\#
MRF$KDZ4L&Z!;(XXO@>5Z?^X^>FD*&J/=<"NS/_RPJJ5:FJNF:.!!*Y%=_:M[
MV>EP2BFNKIN\&E;):8?3[/&3M6< %'WW."EPCBP$$$A-*[D<:?KN;)E'S[(L
M'QE79C[*6,UX6FDO5AL0'@E##2/R84(XRBLB[3)\>GG\"D#^%P:*-=KUBB7]
M62>Y"M[)40>JY_7_3)-E=&KK[O2737<];DS_:)_T.ZLXBM_)511^!K@/BK+P
M\[]J1[3:3G*F[BF39 A0UAE W+_2E74.L)JS JT1V82Y\:TV?)@+[0[X[-&*
MDSFK .':5+>CZR6R="@$J"?0W.-YJ/ISR#/=R;50.1N'9@OUU6NFN5F6LK'G
M;/G5NB!\.M_($&) (&*G,<!"!ZSAV69,8"6*94V+Z^^Q7[3ST.KDK5U*O!?8
M%;-;Y4!#4,\MK206*.&H:LXLKLYWIT^2$ XQ-6T&'*"F*IP&8FQ99@E EH-N
MM#@^N6I5;6K@(F+)QW\UPT*JM#LSX6O*/NC8>BJ^/GYEB:D/(#IF=8 1NM?%
MH1"\-)#5?YI66GB[S:+>^ )=,6MJ5DNZX6*B6,W#V(Z-)<]XQ.-M2!UN-9;N
M2X&N"#)U@%K& CNF30Q=YD:']Z[SHQTZIW;-%NODJ\O+I)K<K1M_GC4WONE,
M3RB!J$1%G>]ZFL= 3/=S!![0XZEZJ^[4=$#9=^4 \]0DZS) GD,(PQ/JCX:V
M!C/AYVBE*352W:NL#Y4#[WJ&15=13_35%?TH,/]AA##V/6@3N*E?L&G/:0X_
M=><=$#N'!:?@Y-#1'0_1\>W8$R#TL"X'(KHD:$',<[ V._6ZX9B[73'?#O5=
MZ;E!V7GYO^L$*,$ZS@R.EL6R!O]$83O@4'6.U**)8O/P'QL15@ ]\'M<X5Q.
MP_T:FT!?WH# (N7O#JHB!64JR\]AS\DBG$. !A76.1 Q1^Q*WW>V& CKE%8?
MJR($-'*EW+WK-%0W\I%DJF2O[7.*EW)+R!$X2P^F]O82X@Q@/8@8>=7&<8SF
MG+6!X2K4I<Y)Q-/][0<+,'*++',1!LOAE.*\7M9^+\X>(M/K*^;"3B$]/H$L
MV 9#,TE$D1;9J;S9;M^74XNY[E,'1D^C)W*NR#L6W<ZU?3T+XG[>D]N01Z>Q
MG\@,JY!!MN1IF..5F6E7=\OP\%N99T4E<UROJ+QXD-55 .%Y.AZW#*,Y0">"
MS=G9@=N0P*^H^=7L^([\ >L5M1;_<G_G-VXS'QLU A_G6/!FG?_<LYSUZO$W
MGCM:Q_9B0>^(CN48 #\[\#4V,42O]1AI5I,OF$'\"8E3YIVJ0F<F$W(^=' \
M&D?2O:!K,D,>8CTGC7 <X2S BX*/PM-,XP%CVOC9Y(NTS5C0F@67#([@]W1,
M3[GW'4[D&]Z_=_,YM.@F&$>H&H""T,:7N[=PI-.L_0356 ?ML,SGRJ,%D%?&
M[[G;7H.!08\ZV&/#ZT\6,Q%%;YK3X?&A:*-5#8\AG:,$M;7Y]S)%>4>\;V>8
M\T7M6?4,(;Y!K>C/P?E[BWYN0ZH)'173[LWB5A41^/BF_];>FX=#]8;_XR-)
MUK&$$%/9*FMEJ<BDLB4IE36FLN^5/=,,R;Z%4,24B$BR)\P8:[9L91DQ,U2*
MD3.J<30SQ_=X__G[Y_?]_/W]N*[CXKJ<<<[]W,_K?KV>YW[NVZ^DXHJ[CDXP
MAD  SMOP.VTI4/@)6C#R)%HN56#U#0TT7" DY&XB)%H%Z 4I9?DGMZT/W9=/
MW#MGZ4"]U_XKS-GYOL.KFSQ_,1EX6BL>L,B(@XY/$.4BV*QOP,LG;\!PN^9Q
MO2K]*+\.5E[86OWELS/7E0[]Z+]E\6'9Q9P!/Q#?UFD9=V@"+19 E(2&J8UY
M]XU,YOW&S C/M9Y-3-JG\JA<3Z>['7V+*'SUCB:9RHO)IP)F5$H=)-#-1G-"
MN'7UJ)G+"ZB.81$_@TU$@U=2H&Y4$,IENM=HHGCIJK;8.]F#K3H+J;'7%CDR
MP0LV'$D_UN@8)/G?(4P8_#MD%S"4NXOSN4^":6GA]!TY*$K(8Z6YM>'@>WZ[
M301)6=\<AW,O#^VST_=%<#]--%2A.O--)Q.Q9RJ='1P<9MJZ5_XREG?I,_?G
M1BI,Q9E>W9Z[=2Z8J,$D</:$P[YY 4"E8=KE%E>8].GJA:==XS_^25>63P?R
MR\KDYF8YYVPBO"V;YEJM(*'1UQ&]K-JMG&./:E#)[,F"T(I2)UK.R'Q+512<
M>TK6@Y)*>UFQGJ]/:-R7;]K[E3]^!YEB>F^2/CR=PI+C/B&*4CAJHY @1Q](
MN&\K]3;E7,N8QK.Z=_VHK#,Z76M'*J6]-%;C/96_CO#[ ,X+>>1AB@'](X$9
M3M/NXB)[%'=_%FN(;Z:OG#.L]+$XYD&5W7NB2%94UF)OM)DZFF:SI>Y8>>-Z
M7'M:==JD T80K&!WXE2:LCKFQQ;.?PY >72_!J[U[JEYGU7B<2K4(U3C]6N<
M^Q;2X,G&Q.VX+DQ#4 ]>'M='K2^*U>[,2#XRO=2(WAXB%6^%$<%T).?)Y*ZI
M=/JGFX4IVG8D5]RP[KZ99EX$LKO6<!U4X!8U=N_H#*-(B%N#4W29]ILX\RT!
MDAC:=A*@\HP83K?J=XDZE@IWT:[S_G']OTGP)BD9[X?=G81J(J0:[UTF:H[A
M:<6HF_6?]0HJ!YS1C;ZQ'](='2?0N>>QSZ,7TM7_?DS^4\N8D<\Y9R,Z]KWA
M5_;,9T5/CT?7Z[R[;TIBFQH*G/_I37$$N>](M&A,4T*'S0,#PAXMG,$9IA\D
M_L/)BGN(8M6GO;+"/[C649?[6^IV<Z:%_QW>ZPN_[Y!JDL%%:$\D6QS?&0@+
M4R_8*_=M(FP(P/U( 6XFMYH4/L-IQ;>W/HW$>0UGT*O?];U;&2L]YO:98I^2
M?&X3,>OCW8;[30]^PY/F-%*$45==45&=);46?/YWK_=[ L,0=L-MW%9C3<Z^
M.I >P'R/>D "'G;4.OC8'W$UQ]_VQKGG>D17YU85]J=:N67)*!F/;R+$EF'X
MV43\5,9O&%9L(I@4;FIQJQS'I_!JQ?>GME%:#BV1+I5%7%&!O@.CJ7+9?N%#
M*N%S?=.[J:*MQ\LCT'16'%W3V98=,)?WPFEZUM6=8&Q1?,7'.!!WL^3WL!ZX
M7(9%@M_@Z?\"=I#/6!]N&8X/-WEBO<-&!!H<G>$<!Y"I1L>?S_A*S%)KOZ1=
M/*N%S"6U1L7YR&B,6B'X=Y"\E^.XA$V$I\WT)H)U%<A9CT%[H1_DJ\76I]DX
M%-A]\@\Q-)%PP9PKK[W6-_O5(UW'(<O"Y"?FH.HWU>F_-<FIMB[(7B2H7L80
M80=LG1/3,);'DV_J9<RP>S *H=1HU^/CI:WC1I;T%/4=L:=;GIX)2]&L'NQ3
M-[IX0F>ORF"J(&V12O+63ISC![>*I I!9,)N2'$I<\F)/XDH'%'G.*(]<ENO
MZF-&N(8M\GSO7@X34TJ5).[FG 1' ;8#>(F)(5/PB48&\T("&@U5,E>:)&;F
MG-]UFOV(V+N)^+N< & 8)]E*'$,F*@:+H65,LSOO!KX"!LR;QX@HZHS#O,N.
M?KJ+9U/C37RX_.MTP72=KI"2H_,9X(':K?3G+OS;G2';\>Y8$Z/T!=.'&1,E
ML)WA<>P/1M,*42P9,'83\;+E$'NR>Q-11VI?17%< 4(O50ZK/::'EHN0-GS'
M0<T[MUR<O'MZ]NS-=V)H0$!)Q?F3G%$XVP@>N4(FFKR)D,/MQ>J,Z>&E..BL
M7S9\?NN-SW^%>+Y/<WNG@P9DQ<6=/QUXAAP* I6#>J@/"&^'MRJHCG+3-Q%^
MJ,1_VO>Q-^8STO.H8JTJX?.S%]1W<\R+?4V_)5M%OO2PS->CN$@E[3!O-[Y6
M<!M&1#0EA498R8,M;8YUFH3'?57!P<_).(&M-$Q_R;1+.3+D$Q4EW?32J,[D
M$*=.(^#6_M^[<C1Y*!;DD_8KPPLH11\X-F!26V5@E].'3:&YC*H?[BA_4_P>
ME%V@QI($Z$S%RI>4$[D$&U):F42'W7D16L^;RRK7=#Q@![M_%NHCR'"V5D-X
MP$SXNR:3P+A#K9N,7C66F^(8@L>!(JAC;N!BT]C^=_%+494%AEB5S$B:[?YV
M_P\;'RXI1Z,D\60A](U-Q,X(V%_Q3 R#R52#!&?99SG\X'.@J?=$XY,%P@,B
M$JP)>CX]O>MQYCV^UR/2WE^_&CU//&+619,:'D&]->]$3C5^)@62DC81M<,K
M!LSE!?V6&\#\<J>K,?B":7-U_*\"RO5]K-6[PR+&__@<@Q1W+ZP]>1IP1:#I
M +,.%XO[1 #.:</L:N75@@6DC!NGUJ)B.?;SRNG'J*[OZJ*BID=UQ%6*9E]$
MYIQ":,1%[^%)5Q\CRD&#F+I><O7](?9QCAI, H=%(Z087O5Y'13]/(6VIS7G
M2SU%$Q'!>]W:"C2FE;.\>;]5@_JL \^W%@8XO!8O!)$)?W?L,SM^HN&G&E,Y
M_S<:U+NVU?70'\R\<AV9[GJP'?5W0H[+!QH"?G0OQ@8P?@ZVJ$U[?G@\5O-Y
M!]-'3CH;D4P9E3/+S-D5PC=;L-3S"BO(+83X<8-%(@7T10:L^4D60'K"[0J;
M\N'2'[G%NUU_W12NDT+U= D7@<^0L+?38+(AZ#<' ^O](^" \^AKRCQ*%&SJ
M_%=4MG-[?*/<@UM[8CC[%E,)IXY2VH8AP<_P,"-&2&XH4*4L ^V/W.''A&,U
M)N+",6/4-3/.\*LEBQJ'_EBP4=:4C/H2MSR']\%$&_-P*_!>J[+0T"9BUVM*
M$!*D=N;=-2Y7Z@$7BE1M](_<M7B08,;X4-: ?0*C\C+W22"D"W7)\3/,MQR3
MF[^)H.^#W=LK2%HK]J6OHL:(2H!ZE\[/'Y<M)T-^*F.TOHFDOA*_/OAS_[E:
M/K=DQ,8Z) #_^79E;@M\T_ 4F^RZ"\!PI&;F#3I^AKHHB@1U*0J,M(J_M!8M
MJ' ]F^URUH-PY-R/E;<M=\)N(1#"P^#^L(0%)*BBQI$R@,F1>,'\<)=?AM@/
M2'=<$U+!'F)*_<V"9;+O(/.0+\_>U$?F]U(%R_K1M=^49+>1,,O1S#)&#?L$
MQQ2<I6=0;'K@^1FB:=4[)]R4A12*>#\_*,\]<I W(?V@^6!%AR6/Z^-,4NL=
M'K".#6L:^TU$8SA'3(;5!5ZF1_G(=\MYK:C-KTI$:#G[)RU\_C,5,O!!6N*X
MH_):/B)*8/A"PQ\9C@22]; 5'L%>''6" %Q<">PY\XPC"HH4@U;GTBW.=6"]
M7I]JNKO2):MP\ZQTPK,#/TXMZOUS 8ZR;H-2[*,145< 0CLJ+A_]H'[6S_7=
M1(.?IO2G,PH3SX^9YG]K7U9*')&D>L,H63?):&$;0GU$L3: GS$.^'5".T=#
M%5Q=;-GG@>]%C2/#4?OW&S$JR7=JS)K_F"J4\ZZA( $%MHHOM<F&(Y_#-H'Z
MB^2+#OS%2W,LF>YW!0H[S"BI$HZS3NHU[/))L;.O9V/4&NYM%8&"&?_]M[A^
M_*Y-A)NV"*X+AJFFKGOR]+(>5+RB;$K[G#%XCRETV5KQ5[#'SCK),ZSXC(^_
M]Z<Y3APE&FCM%*HI6$5'4^LRVJNGH\C9'$-N$5':&Q(;^=5@^5<]3?M,@UBG
MRI<9['1RQD) 939U&VP\5L46X\:UHQI_E2F2V%=P?4119GSEKM/*D]KU5/6+
M:^T=O:QW@A<NAMF""G$(W'X\V0?OG@'N4^O "X%"M#R.Q$R'HNP$9+R,E_SS
MH'$4MR>BZ0I3960\YN''K$-?OIR1SUV[E99D\<ULI(?(X=;AOWE1IQ:A/G0J
M_D_LI>I:M <L@_D92FR)8;U-!*.*?0@T((>OB^]^HY>F;6E'RCTZH=^2%\(@
M,&1F5EQ(B;!G:\?@M,$9.I5B!1M(2#=J53'B7,?\0*>K^KL&D<B7,Q_3LTUW
M%5YU<;]E?JLG&GV"1*O%\Q%5X$ (DQ]?C C\0Q3:75O(!CN'BE= LK(!S_S#
MFP@![7B7K,/8*Z'YB)K[BX;82I^= MM;ZF&P&-T86X1V_BWYTEM8BSW+Y-6Z
M2_MRL'JL6B(B^!0S(R&(HS0_)#UI.];@?-#_[\D3__ARY2LC+Y9D6J3N#/&X
M66I!WA[K:N\&K-.\.)*5+#NF!#2$K@N9F$,!C87W7D]CC<';](U K0;#MKA!
MZ<81]=;L\_0KUQ6=U1 2"&,M>("PW6IPH*0MX&<(\T'Q-:I)ST$,V15%;,[X
M98GG%@0UVU3NJR]$OJ3>Y1ZISD334DDUU5T9TVXLC\^0$FZT\8/Q8:P_,VX]
M U*_OLBXF\9>S;"Y_%&"HIFYLKW\X4#]RGYBR__H..0VDB8V:DML<QN-[!>J
M_+KE,"O?6%8!5G;-[YOJV:XE1H^_YA1>3CK<OO=VK]2_'--;;FN#JN[%E2\W
MPNK\\&=^O@M*"7ZSJ]#RVUIRJ(1-OGC19$-S=N.JVT8>]QUQ6\0RZP:WG',)
M,)BW[T*!YT+;D Q,P&13/]7W]^MG[RYXJ$!7<BYG<_;<3EZ[RWVWQ;,?H(!I
M0@,J&>V#!GTS0#,8.Y79<)3&T_G97M/0L =?];_5)E-2>";IEW!@[[&^-3P8
MSP]5P\'@<-DF EOYVP@CN(AR?L7P<=TSG#>7/CD>B0G\1YB81J5^$:R]=J1W
MP;::05^1*+7KQU86:CEA&VU)G64!R&'\5#A-+9WDLTK)V,H&P,EQ3#81#YR=
M)XUG6)I1V$H61K4_*N'[?M1WBR?'T+W#LM4C&> MP@H<%2RW;2+ZVFPV$>GV
MKW&=). T$G1#__<Q]02.GCE'F0"D<9L@91(0R\U807G7%DURPV=*IYN&J>NB
M80NI7W$/[$>^8C7Y'N1-TCYM%%9IY6+Z5]HX6PE5S/36WQ5!\4RQ0J1G\]-7
MZK]_7UA>?VC;I*U%P?YR!X5.$8&RF!",T%)^ N57R*PJ96)^57ECS%SB!=IH
MS<3H]Q#NN ^5%SJ.)WMOI1AAY/ ^U!A,P\<V(+L37Z<;MHD0Q?(N($6]PR@/
MFL(934I7Q(5BOU6O*M*=3 =T;=MYR-64$W0\K%^FLUEX;@Y6Y1[-9GJ8KII$
M6U&Z/*'ZN4%>073D;)[]6(5&WI'P2%FW5&GE++&[]E]*BE]G+/IFYU@V#X3]
MPAW#DUW0UX-F@B !^@U@!A(2?XVCSAT!E]]PMC$_%FI^?S)O(^SHH"LG]65>
MOMXQ .=IZ3@?,QK#H^5^W9[?F,LVP9H!Z!XJ> S#$@9[@?4K&;8C1M: 6W?^
MQQA<;%)58$A4\\V'=SV/\R\F<[7 0J"7OMJ3D4#I[<A(AD3'.29TDIB#I4>5
M]_O2=[ES:[,]<@9GR/R;B.IKZ/N;B!NKTR@Z-9$C- ]/!]SPG/QXJ$V\T\F/
M.0 $47HE?NC;"R[KM=5)LM_-NM^Z<CM>J?0(,AE-*_Z0 8='<:A]WX@X-Y.Y
M?<TP3?HTVBD;$JS<1!P<A.=\"'X*,X^$\AF5JQ@9Z"/L6:UX9E0''H7U@>G-
M)XX/S>'7 H!/"EPYX_)3*%0\F08KM';EU)R@B]Y,*H,)H.?#87SDY_B ,4"G
MQ6>./0!9-1M)5<]1$II'\Y?TTFGM\ WN9TV#+A9'HR5@7CT\+7.*B80) ZN;
M^Q3:*DY\#G<,-ZRH/X'3=(GH['!"=ZXF/OPA3=0>U1-XHW6C$/OCFHO5]CL]
M)>H>5S\(L9OUV>L,!;8QKJMH:Q=DIC$#@"/,$K<4[ZV=0A"&=G])"^K&Z3(O
M%+P!@\S?-H<G_@R>*U9>OE5K_?WU3L$=#[_^<KR*AE_##PVJ93#,V:%.4V2V
M,VY(49K9]=X]0+&@W+=1)4A3R2TW7?UQLK6<Q)U+UPX:+1A-)# VV"*X#_C:
MC(X5&UHO@\HVCO C%^V96 B9>!TBCU+Y*_)A--NH?:-.O^>0[)?:V&A3!&YK
M;?NRL2+G]%:Q/8A29,"MAL=3.WI.BHF/);E5"D6=-+_R6<.]")TB5U7ZQ[[)
M21GGS!,:L/V@\6=9K6O1CH'%!]F&[&W0#&H'GO8<74N(0_MFQ.2]8"MU2>]U
M^1FT_\F?J!] D[1DS+I[TEH;PH.RG!.J]A848!MRA+FYD+P31Y%;B)/R+A(!
MNI^N#0<4>TNK!VVS4L_+9%7;>1Y7_OI' 5%!@$'"@S ]PW(SWH>J6R2O(,FC
M8+7C/><N'6_IFW/J,XL?E^/3<!<7CRGS/$3\>(% $?! .(GSO-,.%@8)S_$_
M^OR^<!R95I#(TCM@B&.L"7-71OCMEWJ5W/<"#=I"YVK-T\W:NYK>(K+N"D^.
MH^IE&-. /*L*#%?KL*&@Z1?2%M#" Y%2G_)5V[Q5FWQ>*/?NN\PY9TE>KQ:J
M@VVW!T_>RPA\T1H+TT^@JDA-N#A(J'N_Q,FK:Z]/)NZ/1NNA:7G!]ZHA 9CD
M\6FU@/+<"D)==N<"";SXUG?_C5UAA&FY)\ULG8)%L<=#Z3Q?];G4UM_JJ-Z\
M&JPD]SZ:]@C=I-TE!.LMNA,'YJ!/78T_9>W(U50]::*9*_0SQV3_L;3ZA#!C
MYE74T7+TNUJ.&&BH1EZNGOZ%BI>3:HH)"CG^QR]CY[3/;>>?O3;Y^LG.E[;?
MN'33/=RV M$I5U:*^XA"_ F*N04-AF'X6T_@%,@E(H?0?-=\+@V]Y"8*WWM*
MWNL.0^#TWF0$F >)"G$;T!XKAI" /%,&GA'=!)&(%X[@J^=GGF.-1K#HRC/X
MX#>SLS9B:2MN<8_[R\N&M$C:'YXI#,80L=PFK.%M]L&(7DA B8[)^,<MBE.+
M#JP*P4C[YG<OG0GR"M^14C+S0>7)!U-%?_\C%XXM8W#8[;"%81#6AF4N,OD2
MQP^484N"*!.F=>M<:'IMH\AMS0<$:J-D755EF(C8:9Z]H7H_J?7KC%CV88AB
MS)-"QZ]< LQ/,3_&!45HK6B$+N]3FWZSK3;IYNV$)%:=UM?K%C=/2!S@75-G
M<4!+VE 4)'I@A!/ #&8M@$D FHR6(VYSFL$>!NN IIZW/\5]PQ_:".D_6E_=
MD[G;_8IDW/8=6<[G)=POWD6F;")J>ADFP (DJ,#6QPJ#<%3E,^=602>QY_&)
M+)PRH/T T_L/DUBE*\M035Y8^9=E*:%7^LIA)KCWB=RQ;Q2=DLDEM:Z@*7/6
M";"-;>Q-K2WK1DWW=A#W@E'T ?DH-#("8S<N':'[KFI>_+3F@ ?-/=7?WDQ8
M1NF8:@W>G0JJ)C"DV$)+]I151B%;,^(R^6Y1*<_]=8=Q!L5Y^H;RX825HT?[
ME92WN0GORN'?([@UF@*%3"$8!6O#.=(#K%EN(=X[:-=4A!>,FY)&EXO!X79)
MOR8??^*^,2?U6M/Z++':Q\8CKVHLCSM&H]YCHU K,)?D,P"MV&<B7K#RN ]P
M.R/NX'>= =99X1.A&3(<L]&& UYCNNR-*BTEZWU/CA9D)0S2$^55;7G/=A"3
MN:])UY%3G:R?8_XA>,H,ZQ;0FVYO]45WH,IU0,;N!O%?9["L8['=7HD*F@3/
M7MI5:@QL8AE&!EN/(_N)Y%4=O:5-XCB:M%E/@>*)>DTU:X>%3[G>@[8%N=]^
MR;XP%+(8G+EU-)H/@?V[B=BQ:+H' YAJ1Q^4X./OE/$_G7HGU+#69MY2[QL!
M\"5P7A@X*Q+D.)<RV)L(*5PL%@7K[Q8:?V> &FV=',3K,R<'$.-XS[SXX71^
MFWJ4Q?1T?W%Z=%W-O^PK.#[<5G0B>:+Y!H!%%@[$E$28GRZX3+B8=VY4\ZQ.
MPZ<N6<]#Z*3$[?^);S2-@13Q>T_BB$]V$57'-/+GJ9V*QP!6945'<Z>ST-?8
MIV&_U3*,"Z/L&_!D/\Z9%V 3M+.%N=R-4R1:5:$O@^:1X6[!LOT#PIGJ+S)N
MOD8N8$QPXZ0Z:C3>#S6]T$.HL^^6M\L[Q>R-__7GGD4/_Q,):UD3W4B:I;Q4
M)M+3]&3E]ZU.=JA.?)+Q\2UN_05JQP,7\?>;FM[G=1Y%=PZ+D1)#'..S%ZSE
MIJ_ZZ\E;NE_,"_OM^%@JT=,C]Z#TJ:IN1$0&1U)H*\U0'Y[*#<#1\^#GA=5I
M3Y1D-Y!].J.+!1WXC-5O^AFAL5^R:NSCW/4\'&W>IN#XL-YW%'!V>1,1>[>:
M(Z/&*F_;6A O<.<^)M&%QG$SJ'BE@_0)YHVH\R?OIYI)^BY%K/5T'*U;QUV]
M5PN30_BQE?Z]O0'SC!70A;Q*[]+[HTVFQE!WH+TR>,G ,$V[ R\:H=TY\=%5
M1+*#HB$M7;XH3^B/NQJ^1[CQR.T^79X-F'/RW]Y$]*N'5+,UBA0A^ZO_XJZ9
M]\+H5D?37KE,<X!D<:-XP9 @V0B<IID\^"<M;,1ZVY?NEH%'!R&5+U/&WUON
M(CAN\!N$D&[@IVT6PMK8-SF!(!GPLF0:)(;B,XPU@)-#$W7(IZ^>]TM;KA1?
M[G+U:7YHL9S@(=B,N/Z' %S I/QG]_TX:C <@&7POMI2+G-8!3 .KU_%U@1_
MV^>I"^3;8L[DGUE+.-+8?JR+4:(U\X$%/>-(< N,>7%#C>__9K3CXTX8Q.UC
MFB>J36+/**9Y[Y>++]6YI/GI'7M,Y^I >/OK303E*.LT;%J_*B6+D:W:$3%S
M"LRJQIAR+NFL=92-8W['8N"XAO7ZBYN'GXH_/<C0X6&&<Q2<JYRV#I7)M$;1
MNF.'/[7:SV>(^)R0JDCMNQT6FN(<L^=ZJ)M":^M=7@R><VQ$FW,0^&T"$"N/
MY2Y;CP8$!'J(%*Z9"[[8L]ZW@WB86PLAL%;<-A*M%+\#Q[],$/V[C+Z/1P3>
M!#,71/!7QU53;)@&2;=&O2D!);7ESG7^1LLI\:=_2%^2S E#<(?__Y/7(G)?
ML8]RS(F??FE?!Y]_*QEO*<&Y4P]H6"CXS7A7\YZDOZY,I%\X]J.OW*7RW*6Y
M2=").&MCI354\^1:";"BY>?Z\V3;I=^H;DP<I /:%YM6^,+(I]P<]:2U7/-F
M[L7A'H>UNSR32R?]!I>7D"DD1 ,R17%OBGTSDSI%:XHV#?#4I>JHA07,7>]3
MFWG&VW '#W23_MJ2UM(V$3.5&\O)V*/SU\R"+WDX&/R-^*GH^S9@/:_-=FG5
MXV7N^[;A\2,XC7Z?ZVY_^Y<I;2[/50('+*9G?A_'QV&$.#>8E\_F71DS5K7T
M9XU'7J8,:)1FI[ZB_5$J&_EG?VD3(=S"/ HE5T-G"SA^KT%30.@B:#,O$!H5
MI,"M%4H4MM?WLE[K7+>;_;Y'[-Y["</)$OL?UP[3&S'.JB]_/S7Z.2_UJ<K)
MVC! I4\_9V*Y[4]#QI,AL%+21D&[_'/JJY/V[^I_-23?Q9V5<WG=>,*CX=':
M1H;P3EB"S^T[I4K:_6<51N(])%H]'G"J3D/7K[974Q9=04LZ:3K?$)]@S,-,
M2- U##CMW,)RSJS8&4=>FUS/N%6U_UO^P>L(VN2*PBT2S)L8?6PTU$^4( )J
MC$4@^RP0EOEJ6=*7DI:>X+W?JO+G56FK)X:MJ34]0A*6.T^JLW:>UJ45-SJA
MQ+=V+<"MC?\0;@PI@ 2JQ25T!H$:9C5L?,3 PIL60*CW1$A3OE>2T6&/ZR/>
M]L&)@:,>#1M/5+R2^<VV;V_.C+FVA[V^PL>4AT.?/)Y&QT\=74!USMJ>M#K%
M-"!G2/N=X/LGJMK0//KK6[+)S\=?447J?UKFPSM1"20Y8Y0?2M!8'32T8?+'
M<TQNJ.0V%"_ESCM'#83O]IY%;D=!;;<@(6X"R1V?@%,"M%,XXFQT1)#U9V-9
M[_43]IULMM\>JV?3U]1?3[ &;7XMA&:2+_7L3L\Y;7Q@*PMN/YJSQYR-2#AE
MSC+ODOSP2]=Q)]?7!CQ4S2D["@F,POP<GXC^YU=;W8;%P"Q:%*:RW:L"G'O,
ML@ZNTF5F68Q;2P894FEI$ DOT?QDIA[#NXE 9!VYVF;RHA=?M]7N)XDJR4$Q
MR^;Y.T64[)F8S@VMKX =*<I7<=',KWS",!:^@2=37*KM=#*"8\7-0[N[\':A
M ?N@&1E6\'^EO ^"=+91Q(PCV!"Z@!2 F2&2N/_,,R>0=/:3ZKOF^-#?SV^'
M:H@/R#VLRK'?J_WKZ\PJ]6TXK$\D(KP@H4 *NG-K;K!RN,^(6MBCH-L=/9(4
M.-Y](K"%WJ;8\6U.J73X;F)V54>?0?[;O0?DSF0W>USA\G)A/*,5H6M0*Y_]
MW/A7 MBZ$<Z]$C\SZ^\&/J^8RFFM3TMW.O;FYD%=;\L^TULEOU-_.\%:@:''
MW@?UHX4:T+&H.CQC@UZ](R+8.6W<J6;$'YOWR4#)[/QOWN^#,[O+O>[TB_+L
MX@%A]<EW'HQB"D%"9]B^$506B?N R!MAWPV)<M-?:S+^*ER^4I,5 6GX-N:-
MNLYZ9V[X\WVN%RMA7W%OOL/C\3ZQC+'*$&+[8[<$X .H'[>+6V&\PS6#D2'F
M$!->VIKL-;KZHN.+PP7^V2RU_C\\>7YOKGXJZJ2I,5:!HRQG,, /B&*%@E>+
M(PPZI8,'3C8F/7.H:A70>.-J3FES?/PU.WLD9%L%5HB;B_<*FDX%'^"&"?SU
M:'[S^3:/OT%BY&>.*1'5003#-W)Z&V>>TA[N.,5;G(K 2F[%/7S_[M;+FPBW
M1GCVEMYLB^I$ T$9'/&<D $1:YB)[; TF)Y_^*2T-=23@CPT_C"28::^A()E
M>EU>.XGR@@Z3PIUX;U)</CJU]7!PL%1W3\(;2E+5UUS56?F<DY^;I:8[A>V
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MOD$2D+IT>^?'YZ+C#2\L2IOYZIH,Q+*N\NJL:Z=3Y="T> )@!P.E)88BR4H
M+R\$)>2>*#'>U]@P8:PL(OMG^</*]R3W=Z;OF]XUA29_]SALW22_9K_/XM]B
M.UH8RP.TT"?R@(QVQ5WUXT9'BW\FE?DX*8M_GYL8E;QY*GFZR_?QQ;9MT?R\
M4K_1&6A:+!4PIR89ZV?/(Y-)- (5"5..[X\'#H_[*]<T9?;U>38U9AUSR.[K
MOV.I]NH9<C@(5$)U#D]9V?R7#:ZV3 #.404V2-LY:/9)8O:]ZA\)EUK&XIM5
M7Y59*ON%1WR\]KZK6^?;-1,E\^8K_R5\\.&2,8IXLB>:5KB)$,)JLE<\!WJ(
MAYA\2Z:%+)8T*]>VQ:#X_<Q']$IF]0CI 6H[) H-$W<T@&Z &MTKH56!/J-1
MX(+LE#/2UZ_)_OS@5L6;A=3<'LNO67Y?D=/J-+4N*@4-";Y@7H8$O9B3](EF
M>IM,AYPE?+_2&:9QCF;.I_<A$D]"-8,_/+DZJO7&<6SN-.])XKS9V(/H>T/_
MM\W"K_VM[AZ.,Y@[%+1M&GL!^$.A'#<?+9YXYE=ZXVFLV#T:$-'K]A.3C@8P
MZ!GV0E!O$&72%G;W&UA>L+ 2-&R'";S&*NZH'VY/JY\?]^;:OWUZC>G9VD,*
M[QK=LZS+UN/-S':?-U@<ASKPM04^*2_-@=RY_;%?WR=#WP*E6@P*O@?.9A99
M8U'B8%(F,(=>"GUQ?$CY6W]>R[VKOR:J_#Q&-K#4E#N#!*F_=Y-M\UROU).B
M&JHO_ZLO)L'8'4< +A$H2!IF)7+KF+H>R4<[1:XWG2/ Y#W?EDU')6$O102&
MGI2&/DH:O;\R*?+;.A!0?YR2=2E'R:0A$3-SZ-^7NB/DQ=V"$8,:S<_U0F!V
M3LB_BSXZ1W;3V8B7/I8LRLRE3F:/J/>@_9%;0'B)O>U'F-,F8N4>VRPBBBSP
MZM<)CZ+G&MFNKA4/99\WQ+@77;4]Y7EVGR4B,]-U& /'[<:\;N0#$G"! &I7
MIVXB JC@P57&1E4$@:Z61D3]H-B0AQ.7Z?B5*D/RNM@909>95G>#3/6/3;8>
M/(\%UBKL? 37"\U_V#.VCO0DPH;WQLT1-='(_Q(IJ9US*DS^1VO==':!<]L1
MB"XFL2+5P-&QTKG*][BX<>3(K>/5$2"!:4X?)MLD4$C=^)0B@W$C WK5CKXW
M?PN#'5NMHOR.V5>V-".$'_+?L>!5CL$\)4CA4'@RK$!I3<0#X&VF)$N<6\OA
MH=NDHD0X;E[S+KQ=D/AH<4*734! \]R8LRQEXKN%T,XO=:_$'P,(41H+9CK!
M>1UY8-56S77FF"G3\!2P  9=&6\]E3NG]MFMOF[2NF3NQKALB0=2^87J@;HG
M*NEZNS_2>%:H->L<:2%(H(X=Q3$A@I?8:M#GN]K)6*NR]M\#SXF%465?AB3<
ML ]5&&(%CZ[==]*D\6:=^MYFS\KEOC)&X'KQ@K^,#7#C*$E_(R6ZL]6[@#=Z
M5:;*WED^SO[>9WV'<@/YI3;TV")87Y@M$U' 1<ST.NL[*,Y&.V$/P<2OZ?DL
M)6+<(8I]*:IB:7WB</&/L(?MYPG3P(W4._WE57O&H\N'&MLZ(='Y3<2CPQ%E
M4&\ [R;B7#<BR@@#W.KEB-_UL=MJ]Q8-ZLI<YXF*^BQK7$*./CETSP:(74!W
MV%!XZ=R$;GP,2>(/6B;"Z\II"JZ%/F2K/N (W"*[)R7_LA6L73QDLGW;SNJG
M=HO0SAPOVJ-F)AP.:P?#?%X>_(2Z&"22V!'IAG]"2G4[/KR 4<*3:V^!)D0T
M1#F1QZC<,\ ^9L.\.PY)'4M2=C'Z$M?"OETK,J9]8,J-E,>Z38E&.QB9SVLB
M.Q0524ROI+\.&KI#6OW.;6;_OI_*G"'+R629NXU>O9(5Q8/1@N7R'SPM@_HG
M4SMN$P%>4@.OVH#:YCVKH-<JJ+3:NXHRC_QJ'4Z3_2/OPWOCP?N2S)\5]MQG
M@6N'QV57,(7XVM45&!6WW^4^0;L3'KP/7Y&!?W-DUA<)O@4\DU[ZD>J]DDF>
M0@+U)\]Q9KKW3*Z$GY!/>IX;P*CUU]KH>''[%*K>;A.A0!2^AI6*966@=X4<
M:.4-IO]HF,+>"'UE+OHTI&^_I,ITX0?3Q)Y^>A_O=CGF)F+Z!21(A__/%/<M
MI-('!+,"N35&J/F,7>4/.Y\[SUKR=4^=<AQZ_S&)];!"2%*:<T!S1!*S!P:.
MP 9T/%Z10;I!G4+257[EDG9 Q[%.8]\^:;2J]NTH? 4Z6R=/>#.>B=V0_KS0
MG)1YD>_RKK,\]7:+G#UQ[,-85= >_J_]>:PF4!Q8, 'P&9L(+Y(X&.4*WJZ.
M"+:(_QB@HU7IXSOQ8Z1B7B0[Z/"]CI'GO=NBT28X(]P(?CO: Y8>>519M#<^
M.1\5B]5^N2*3/T?"Y0+JASO,A%"%4T!YLZ<1POH6JM: LXO DN2V:NDIH%D6
MW#+LX07G6=5]6J6E/]>14@QQ::'O#?5+61M1B9BC@5\>'LU2IZ,H+QR!5<ZN
MRY!0+'L_[B-&ZL\!/9L$)YGVF8Q4^R(QHHEF#O0B3*VIWD"\:4 GAI;V2$=)
MF)96JW.""CAO(GA &98^]S7>;14\4$8.XO])W,,\BT:%#",BWJR;UEEY3H1H
MVLD^F)A4=-AV,=-$)^.6H7!)>BP"]4JJ$S>"J2>0T=-^Y# <&EQ>"!W5G;7"
MU(S\J<J5D<F3^9?SM4/>#T8A[Z_Y\XX*[RQ&$R\.WJH8-,SG_)C@7(#A<Q/!
MV6,: /@Y!-^F94Q+TBLB'ORL^FV*3FUXE.H\O)\[L>:OJBE^W/NKJ+U\.L)X
MB/L*[1\T'<XZ -XU/@A])NS!HFD!HI:M!7YM@;_=9@?2>@[LO^C^+EO64,G.
M?]OM&%=M]A'8 T)@(8!O1':E8!Z@$.@ ;=&E(A42X<-XR#W["Z0Q%>+CISMA
M/*O7I,F(1BE[/&GAQ<CCR?Z!?VRF8R%!)@#':1FV#_3Q/;6+,%W7B1;Y56]^
MS_"TB]UDAZMRUM*\S8I\@;VQJYQ!@^!JZN/PO3Y[34_F]6XBQ/!D(1AI27C>
MY[ >WP9]1HMR#)G25LN&U=O Y)G3+D>[*'I?+I>D-N9.GIZ(7"]N#9 [C'E\
MK._L=9[UZA4W=B"NG_2V-U:7FHAI(/2D:9/EM*I?P=[G\SZ^<L]@]FQDD/8C
MHY+@PLR6.X?7)N-@C0O<PG/$4RX34VRVRA?%@"KN^:<2)X7"!;?A6]=.2YFW
MB/%78;MAP7G(.VQN-WATJWK*_&)R0.@4'!XI;AT3<VH3?RLCYF,O.JQ\M2I(
M&DTZ:XD(#U4N%S91MO^,VK6*I\6R4$B]).B0-5M#+8%4]TVNFH*G*QX:R3%\
MQ+?Q))']W/CF[::G%_E;.!;<-R3/Z@?4ND^$AHPTW&'OGP!%_9C63,][_RI\
M64%DH5OZ;<V*#W*J7I>^"U</'O&K!'V8ZNV8W1#*FR1%E 9K!UR!Q<3ZJ5 1
M2<=Q3PF3R(!#_.E7;GR24OH2<DQO XZ:.YJP)VO!K?/A4V ##241X;EJ!^Z;
MQZ2ZJM2"'B_ 8OY,;:/#NI=,E9W=V2.&3W(2.'_99I&JK9*7N*](?C:@ 7\O
M\01L*A<026=5,M4["9+7J%!W7O@1#=*-3ZNK;DW9EN^U.N^<T6Q_5*X4DOSZ
MM%#'* +W(2*<U<HM:,6PS9=)M09QQAH^_PA=>&&?PTLX):#AP9TA_3S?^2,9
MMY;BCZ4(N.V3C15;.O6]&AI&;4T82A/] U@-2/8LO_D1>Z5U/%#%3RC%<D4[
MP--;2_.-YANW]*C(%YD[O;^9^E]?$"X!,1P)-"30MM5<Y3>7L,K?A9$@2&-O
M@BFO4.)83^;?@2=>$Z%/K S-:G6^!-"/G# 3Y=%4+KC2WQY1W3$LV<>6P),[
M(!WNDY"7:T8B["O8XQB43_Z=VR+5*?6;B"-"K*2[.][5-_DE/;[S44FM#($J
M_O,_J13__^@EM3&T8 ,J-:W<GK?9O32W?YSDOUH[0UT*_D(.8!5L(F:5/@R^
MZER(/K60KO[',QGX_49QX-A]G?3#^L^CG&S36:2.SRRC+[T'R9XUR5VJ&T%^
M^DU_O*&;T$'.-C"6K8 G6T &T$>\G)%9*$8,0\R</ZE^[6%?FM^%_%'[CZE]
MOX]TJ_YP*$I/W7';.8>M#A/(F[ ;H[&PWKS_-"+H##,T(3V0B.(X +9]FXB=
MYET!6D->$4K!>;4M#W)D[-+O8&O;7QR5.N8C83.D7@WN&^;(J)E/9,2N_%F-
M=NIRG$:F]";_%8JZV<JCW/A]9HB?7Z.\Q,.!=QR=>3LC_O@; [U_'QU]3I\[
M^.K<1Z.:2[._7F>WK4;]P"+% $]#R736E/JQ^IR".CO+P'4[U[)^JH2Q'#B^
M8+,B#FC3^<DN=U8O@$FPELO5)^XFO2V<L)(/&YX)_*(V]+4;H;T/03=9R><&
M;"(2M'!3A#]1A V]<CRSGT&"81PXL\++0C*[)U<LV6;82RGS7CU5YA?\=NN]
MT]U$U/UTE:W#_\U][Z^9R]=L_PYK6-TOQ6N!6JU@"[_H?/H^U^J,T..F$P^_
MAZ>6[FHNI-CY_HS\VU+;_&>WJ#AY?.#5Q>ZF@V;_7NDVA-<VU+OB@JR>% F-
M!AD9T%;4.M^GK5,"-70_:)8U]W&72WQ?<W[W;?\]K <DQ*%I-3@9 ,/9%;N
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M"(HH27V:Q"E-/1-RL99DIK0#:*<)6&UE-^,B^\'18ZE)(!^9OWJT>R7 KA8
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ML9OJ\?0[,=BAUCMQ,H>ETU5++R6XQSDS))%A<#5)Y'S )B*13E"UE755L;S
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MHD[V-VT8E*[Z3^*>M&^T*M<9[.10B@+Y5?VSF[\+95'*8HJAP(I7"/5A)KB
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MGH:DVBIZ>VKT$>9M8/&%.I*B_(Y56[)O1Q^U<=9JY([.'*#JB/#.D6122G0
MV2%INFC2PI?P30X=OR[E4OF]2EG[57E&/\C.K[E\VHO5YW+%ZW=K+H?*[[,D
M!6&<A3B##*O]ND05#Y:D"C&+TXQAD4I33-NW8-S]W'P-X>LTB7ZKMMUY#=B:
M R4J>-7]W'QIE-"LO&HY)AI>B%&1'MO#J60'C?"@D1XTX@,E/^@4:&$&[_HA
ML'!5F.-NX+H8%?^)7!FCC(.9?\,:QD%_AWFKT_D_K#7>\X?8MV)GJW\JBQMI
MKMZI0/-^G2E0%,=I$LK%>\0@HBB%F&0<8D%"D?EA&N#4S#-RI)?Y^40ZP<!]
M9\^5 BREW%#%60%F?'[[&+(H(5G(X@P*3@.5Z32!.!8Q9 *'4> 3.35OCL>/
MB^S^@F5D9#^IT#&Z#^_Y8.JM1<Y\]$:>,95T4(D'E'P;'PCX2<6"#3N/C-</
M T@X6A<<ZV%2>W] Q4,[?NA2RVQ*>9&O^%*2]9.BB9?T[^N\XLQ?>)$?(R8X
M##D*5?%"#C/L4\@)I@*A6%*L4;E5G4[G9HNW,L-&Z".E07NY#=,5Z:"O1QFN
M,1U[+["%\Y,MG.;)@PSP<94:2*?+:1/_&(#P)*V/R;UV9/29KU2VH.LV@I^]
M>?RY5IUMTVS05?[03# +2J(X1<*#C 0>1"@C$(=) @.,)%,E"4DH,]FPT>]Z
M;CLXJH8G57FZUG5;,5!L,LS@C=!FM&0P#GKD- ZZ(U.4 K9)@-:+K8XQO/JY
M1?GWNXE\3L-L3%?FB#DB+8..)Z4N<T ."<RB!>OM>Q66)9MLSD+(!C>'ZU/*
M8I'&#-(@4FNI@$!"4@_&44C#E*5^BHVJ1CS?U=SLIZVDH!?5.G/! ,#:V\T.
M8!M_O]D&,9L=YQ-@N-MR?JZCJ?><3RA\9-/YU!T6VR.[\4-??\7W5T4?0^RK
M,$HL5 G/*(4HR5)(!,&0()ZP,$P"GVH5\QSN9FX4L1_$ID2] %)8&V_[\]!J
M[&8X 6QD<I@$*X,="">83;338(V=V6["24@&=PV>OWNZW8&3&NSM IR^^KRJ
M?.^_W_.BYLKWM?#\S _\4$"!@T3%ZU&8XCB"(A )9SCQY?+0(N+F2%>SC:3I
MGF'>BGH!"F[HZS^&:\0Y3D(20>JKK.@!1S!%&$.6<<(9IR0(D=DNBBVDD^ZB
M_(3_QN&OM[+#S5E)E=]<'>#Z1[NHS@_P/A]J/4OU3/BFFH7>]T_A8,I@Z[*'
M1[1W7/!PMX<7*75X1,7GBAP>N_3\C=0WC]V.PF7!/DO9NR_]PBI@*>."!5 (
MBB!B)(69M$,A\0D)<)($2>#9[Z\.=SX_PGB+J^I1K<P>\'+-Z_UM5U)65?FK
MRK%AOU]X8C3,MQ'=(3SQ[B)YW&PPJA0@6]E'60R;0S;"-N2)CE]L=U(/D*%-
M2\T6+-DL+_B5>%MQEO?'O\(0(Q_[&?29-!91EB&8H2"%/N&1EZ$LIM1HY_)I
M%W-;1"L)%1W11D;#]>  DIJ,<Q8^8S-+!\U;36C,R>-9[5V1Q-,.IB6#9Q5\
M\M(_?Z7=R]VG);XJ5%6I*]%G=UI$<9J*-*%0<.52QRR$:4AC2,*,)*$7(QP:
M931XKJ.YO>B[R<++0N7RNB_KO \",TOK=Q)DO;??!70C<\"9J!E3PBE('!'#
ML]U,2@^GE#TDB9/7VU%%4P]4+N;E'?7[OZ_SU>/&;O;#($U\%D%?W@D1#1)(
M,$NA\'B":1KA6!"S5<SSG<UOU;(KZ^]^DP9^\D>5:D_*_ <SGAA 6(\IW* V
M,E?L"OF_02OF,P>F1EF+G ;)$7L,=#0I?YQ6^)!!-.ZPXY#W0G"ZVAR4^H:_
M*[>V2NI4T'R9-SL47:&SO2O>Y?+&JLWOM$ 9H[XJ2) F:0R1%WI0FBH<"L8B
M'\<XEBL0"R^U"]EFZM;N*Q#V24K-:,G)H.D1V&1C, W5;=3I#XNJNF7-]MB^
M2A>@'Z'#ZW85N^C/Z[CC0I=X.V)-)R)-RJ\N03QD8J=MFW%V7:T6;]=WZS83
M<2N(? #SDEV)2U8VB7_?E7?2V%QP2C*,:093E$E&II*6,R].(/6$P%' 1)9I
M!5;H=SFW9>-6:M"*W;RL4G"U_NE%![^TPFNZC0P&8)A=QX%U9.YTA*@V)9J#
M-$1XLK4=LI/?MD1GT-$D-&:N>$]2%G=:Q'.]J7)VPUN?U^5-Q9OTY!]5#E"\
M;(MH+T(_3./8"Z"?!00B' A(>"3IB B.N0A0&F/MP*[3_<V-?%J)>]\T[F56
M"?D;J0%NQ#8(7M+ ?)AR1D!R9+YY$1 -0L'<@CE13-BYH)J%ANE#-!@CIM',
M=,%B^CKM18T9W&9N%?ZD*D>\7=<K:6]6=5/&*@P"1#!*84)4:&U*/$B$1V @
M&!<QIR(B6ML%QYN?&^'VPAE5 WL&N=.FVWEXC&ZFZ4%A9(<]K_$9-M>11B>S
MKYY7:->6&KC*PFY2SO_Z"U^MJZ(YG%.K,B*7=>=#P#?\2ERW57^:*Q<Q\046
M"8=11$)I1"413!GG,.!>($B<HD10;2/*L/.YO>"-4*!JY&]+'S4*J (X&-QO
ME%!+D9M*5:+NZB>!NKGQU5)E.5!5C$QR")D.F(8%-N(PC+U+T #9B@ZVLH/+
M&FRE5[7#.OE!<\.(:!N8:B.B/I'=YAA],S/.$KY!F\ZTS>D,/$MM]ZP]VS8L
M-X+I+6=KM;/\]197_ VN.>NJ;%RJ!,[-[M%5L_JO_XR7Z[;H9%VO[]K?FM+5
MVXI\01(FON Q1"3RY/\(@21$'LRP$"CT_8!SHV RM^+-;6;Z"U>YH#B#^(%7
MZB7$6\G;L^I]03O9ZWK9G'/\]?">FPH7*\#4!H/ >=6&VZK)K%;8@-9S8[A+
MY/BIT-SP?K&Q'GOZZQ13@]*H!AO=^NI%H-'N C3Z@4[!"[!1$>SH"'YIM-2J
MJ&F^F3[* +C:@'<KW+2;]J, ^V2C?YQ>;)*:XN]OUZOZLF#_MR3U)5V5(O#\
MI-G4NE_R%=\>%OXFV:L-+I,W?2@K^9?6"<U9MQ7VOMOGWDR&>-EGMG[\6#1Y
M]?Z+XZI>$(^'U ]#F"$JUSQ1[,$T%A@RWT,ACU@88U\_,>I+J#"W^4F^A)%)
M_LX7&7:-E=/L!W/D"4A%("@ @$0 * A4/A8U&RD4+L 6![ %X@)LH6A"&*3Z
M8 >-391#C\<%V$%D4P'@434/VL2E#2RS?YY,<LK._;F:*B_M/\/S99CG]B6'
M=CA7[HM(-F&^W9=$?C]G[XM*8F%W_5\I1,V+-WFYXO16ROGG^O+NAJMHHNZ(
M4IIE&+.8P,BC J(0A9#@)(2!B+&'?91@H;4^U^MN;O9,)S#H)%;$]!K\63)+
M([;Z:C [G09;PS)Q"N'(5L1I]&Q2JYR&T6!"=@KG1)/G&0^EV92F#<[@]'.Z
ME>FF"FV-]FA=_RZW99)^+BJ.ERI;QK^72R;G@IVS/9QV::$O*SDY%#?OY-?B
MIHV_DC/*(J&^%T<>AB3&&*+ 3U3Y) 1C/R74%S[FGE90U(@RSHWL=PLI]2E)
MY#B"5X077.2KWP,AOZTW"H,;J6K=>%R74F%YD_H[?L#Y4CE&H/P&U8X@J#=
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MEDD;AB09\:)(8*-TXH.]S<U^V:LSN1$7_*($!HW$AKM#PUCK48XS!$<FFW/
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MG4/GO1"<JK)7FU@#E?SO"U<:YLN\>?[DCV\KSO)5_8777'9QNT@SZJ<Q4Z$
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M 2VA4TGPX^A9+ >78#(PSWN'PX&1+X%E)*H]A,<3>Y[2NY,67UPT'M^=DO>
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MJAL0SPU3QZO=N(J+8OYAN3(![>HUUSEDC^(]69%WZZI2 ZD==B9S%(0PI%Q
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M9WD:0IHR"I%ZX75QD CR4$0Y1W$>1)D- W2.,CT"N"\VQ:I;@1TSI;I![68
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M ]!*S$"KQM/FK$J+#+3,'@,B+T3-5\AD7S'&#:J\$*P789>7WJ]W)EIY+TS
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MF,XZR&E*J8PD%$*[X'" (261#E()(H&"(,.)=*&-X\-,C2ZTE.! S'[I'2=
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MJ%OV [OGS%=[]MENTO"WA>/:(G%M0;FYC#F5@2ZRF](((L[43C5'&#*&PS1
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MY759+%<?].W_CZA*96$P)5T4H/!+N1)UZQT@- X2GA&8HU@WFQ0)Q)(@B$6
MLE $$A'[F"O+0:>V>D:_XN!_Z*J>H@9\+8 6%[QI/C4_&]DMET4G]"T._ ;
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M)R2&)(@)5WL61%/[3&6[,:?&OJUSO=B)/0,/1F0'!K&$VX*(_8,XSN'$$?S
MGXW40(L-C-PN)\>6F#I0LW]L1^+G]T7-%F6]KDSW^=6=V""LF]+O(:_S=\2+
M<[O5'5D!HJY]6%-UU>()K"K"VR(CYH^\U)GZX(X\"D#.G>_]ZFD=<)N-SL7
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M=1[]5E9OJ0#=,'0G!9RX=L3T@&[I#Q,%SGSWTH._31:5[N^:$LE80"(H<QY
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M2;@!J!%P!G8B>@X2/86 SZC0%V.,'P9Z2LVC<9\GO]PCT/.C>B":V)?B49A
MF";V9:^>3]!&CR524AD@9782F>J.!!'$*%=;S#A"'.$XS%AJ'<QI/^[4MHCH
MU^1YF:D O&D^-3\[5T)SF(-N[A@0V8'91 N]B<K3,>A-E%X;E;=K\VSP[1$_
MZ8"P0XSD,$B/% ?I%7&W,$=WW#I#&1UN-UZXHKN.!R&)/2[O0_ZDJ'22DZB_
MRN>GW;N,S/KMT[N#$K^?EN_*95TN"JZWZ6V#W>]W0BU*-_H.-^+GZJU"XE_S
M*&%Y%"<")B3D$ 7*AJ0DD9#B-$@3*I(DL*Q8/XJ\TS-#M<;@T:BLCUW)001+
MK=0&Q4YOW6'D6;'N8@F4Q0#V]=^TI08- BXL.O3C8K.Z3>@1&'I-U'/_C^W<
M;[4%:NZ!UA?L*0S>/H%#E=5?N^8=_&D4!UIS8%1W6E"'?A1<EN$)/1(C+=Y*
MP/6"5(#OCA[5$R+]D 7;?VAH^]#4!AA?'2K'FK)NNV%H(4:T-D;"\]!&&6M0
M[^$EUVIT]K0CFU3P),Q1 F.,0X@R$>@2<@AB&5,>$\(D=6K28C_TU#:W!Z$.
MI7'Q%+N ASX^,(=IN#B*Y )P7S6$9 8:R<&?[;\VB[+/0)(3P T?1?)\X*F$
MD)P Q"%^Y-0=^A;CW8\]OB9/FBE;CT6898@HYH(Q"B54_]=I8DD&(\)EE,5Q
MA)!C$=Z38TV-KDR(?[V5%3PTPKH6W#V-K1TE>4)L8 YZE@\!6CD':-%D@8>W
M>KJG1QJYCNY9E5_6SSU_R05MC-^>;YCX]D3#Q"O.33(E6>RBX.J]?NDTYEBQ
M3,ID!I%(!:0,42@B(E!.DS@*K,X!1I%V:HSU?:46 U VDBO;2FW-[MO60CTC
M=8>=;#L"G,P4#DRA/OO\[G3>BR#V6_=KU.GQV89W,%G'[ZP[-.Q'F^4./NCK
MK$L??HJ*%;5>)[^LC7V6YXPF)!<PD1&&2%*U<T]9"#$A/$ )8GGLM'/W+N'4
MUI\] <&;8@EJK8WM:?5P\SC.,G/1[/R%EI8]/6>@T70ZB\G)29C( O)2OK_4
MHG$27M\+Q>F!^KHX'BK!BJ:CHWA8B+;RYM5]6:V*_VX/@C+),)(Q# 2A:N^A
MFZ%+DD%"<8)QED>!"-WB$6V&G=ZY\+[4,T#V9-UY;EV](!;PV[I#_$(ZN%]D
M'\NMP ;(?9%]^D?L ?+F*+$8<F2/B3T(+UTG#M>Z%Q!_IPO\BNJ!5*NG+^K)
M,07MLSC/=&8-C/(XA@BE&:0YQU P97OR@(0YRFW+A1\;8&J6XKZ,0 OIU!G@
M)(S=%.(#G('IPAD7IS+=7<I?4)3[Z&U'*\'=I=1^P>W.[_6L=W6^$[VNF6M.
MGN>21)+D*(6IVCM"E+(<8AG%,(QX+M.,H1P[54]Q&7QJK_]^8:2S5:+;8")'
MSZ73W-B9'D,A/C"G^ 7;O1I5#]1\%9UR&7K<VE(]0'E10JK//?J?$']:UJO*
MQ)_]L6SW!()K-Y[FU>M*W!?K>V4EF:_6]5H'WIC:+E_$:HX#&H8XDKJ:7ZC,
M&TD@SA*D?F4BPV'"&"$]$LHO%,OJ'1T_6WQ/#T!+4W"TT::>@8=&H:80:='J
MT]2?ZI%.?NFTVA]@#SU+(QYR[U29@?VIVF@#WK3Z_&(FJ;EF,U-M+:LO'3/5
MZT#< [X>#\TOD6;T@W4/T!T[?/=QVWYD_4T<AMY^7:^^2HO%HC&%<K73S$)E
MH6:Q8FG$L5 [T2R%:B,:1&'*.(^%BYEZD313LUN?*P/*M>E?8FEB]3)D+YM.
M.XH>;9(&)NB!Y\>9FKW@ZHF8+Y-E5%KV MMS4O9ST]<OS[6+!:WG0B8X(IS!
MA*9"=P?&,)>8*@L[B65 HTS9W:]5DVM/SJG1>-M_>V'Z;[\(00=_^S<<A>%_
M "X>Q:)\$!P^5"5?LQ5<"7:W+!?E[1.HBML[UW#UH1X#E# 98DIACM1*C; (
M8!Z*$ :* [*<A&&<4+>#JPD\""/E0'8^"M.87KLU? )3-O#J/E!IIO81,)W=
M]](G)EJ:Z<C43+ >T[Z4?]DB3$>@'K+RTK'AW,P-+HKY!S7DZDF;+M5#61F)
MOJ^4?6../ZJG=R47\XQE.!09@S313K@,29C'NNU/&L8B$!S%L56'#<OQIK;\
M-R*# YEGP$BM8 :MY$"+;K< V.+>3>0#H#DP(?L TII,'>$Y0HJU8+_>EH]_
M5W=J^%#]L*-!V_N/0F>.RFYHR?6RGI&V;</IK_*3/E$5]>J;NO][416/:KA'
M\:)0!V:4"I'"+$W5WB1 *<0HC;6'*<[3 *.<1TYQM&[C3XU^-N)KQT31*@ J
M_<[PG0J.,;..,V)G40Z(\\#$M _Q1G:@A0=[TKL4J7 /9.V'G:\P5<?1QPU"
M[0?-BQ#3GK?I$;%E*N&Q)Q-B%!"1I1'G$,=!#%&D>"RG:NLM",$(1VD4Q)'=
M7OOYK:>W.=Y(YQZ<M8]8-]E<@L+ +&*KOEL,UA%=+XF]VK_=>#%71Y0XB+4Z
M]O>>I6,?A#9BEK>?!:G%IHG,/,V3+.<LAVD6IQ"15+V0@C.8DQB)G*4XM-O"
M= \S-=/A':GOP ,IN"G31.Y-5( R(MABS8W_RM38N5<JK*LFJ4,M@ NM4?]^
M R<FP,Z$N!S6@=_QK8# 2#C;I+UX]/YT8^"KUNSQ0<8M-MNIZ(MJL]W?[GOV
M_;!M,_6Y7-[>B.I>'['/HSQ'#&<)3'D60)3("%(14QCCG'"*0\99XM;6X-10
M/:**!C^U;B75;,"5B*X'T"<P%9C&"8L2F">)CNK"BGX9%Q#31'!$>1)*IXC6
MBQ =-0I@(Z=G0&T/ZR^':?!S^'V$M)!02VF"H7R>KG<#X>W@_,0P(Y^)=RO[
M\KC[S/?[$>R'^X=%^22$*371).NUU6RR. DP"6,8)S2'*,\$I%&JN#:-TP2E
M81HECM7\3XXUO9W28>4-MR+2YZ%E-*,)8BDD! 7ZF#^&.,,9Q!+A)(ECM?^T
MR@[R"NPHKC*3CTP/\Y%W2:2;K&3O@-L1L1<8A_:$'<OH[H.@,SN?1<<3/9\>
M9U1^/JON<X(^?T$_AMXG^_9Q#G(B2)2&,,X%@D@D <0819!0%HD\C?-,.FV6
M7PXQ->(P)L=*FQSNYMD1 .WXX#)8!B:"0R-L@/?]M/:>7O0C XSZAI]6\/FK
MW?'-D6O;;,OHFAB#36V%!\'4KO,?Y4+=1O>ETX[S><B#- B#"(8!CB$*> 1S
M%*DMG0PX%CC,L21N]ML(4D_/$MS)-U+9&X<IMCSVF]:TC6@@]2R-LZNE#_8T
MUY5R&MW!3GES"#F!<CGN4_7:!70<)/YKE-1QGP)O179Z#-UOW5)RW>OP$V7A
M&DGJJ_7JKJQT<-R<IKG:MDH!XR#5F: )UB4O$L@C$0B424YBQ_6F8[3IK1.-
ML* VC@,=FTIV)1OU"0\LEH"1AV)%%K.VD!H@6WW<UI:N:;!;$SQ!._2!;8.I
M$7/6,'8-KLZ#YLR[%G!XXLNND4;E.0N5G_.3S26]"V]4:QTQVR3H_!3UN[;_
M)<8B(/HX(A!,6;&IR'7Z8J:;ULL\%8*%7#I6V3@^TM1VO&T*VTJ+V*]4^6E0
M[3C""U0#,T0KXR;AST@Y ^]\=Q<]"X6_ A<GQAF[FD6WND=*5YRYH.<^60>Z
M:C-'!X7I>U\M^9&4OFT!:LJ3)!$Q@4CDR@:)1 0)#W3=\3A-.9,Q39!39*K;
M^%/CD*WX^M3N>(9LWSKBCA-CN5,=#NZA=YT^D';?+O;#R]?6SW'T<;=Q_:!Y
ML27K>1OWH-3?R<_B?GV_\? 'N2"(9Y!E.BJ51002&5&8T(BD+"8RR:W:M+RX
M\]0HJA7./A3U$*=N7KE(^X$9HY7+H^/^I+87A*,>WF^T>-2C:NP'I![_0H^N
MMI^+I2CENTJHS?I'PHRCI*E0_%5^$TOQ@RS:$L9S&B89P:& G 2),BZB!&(B
MB6YE$J511".)K9+S'<>=VAO;2&EZ1NX\'.9H3OQ<:5+493H:T1UZA#K,0_<[
M/R"Z0Y_H*:&-^6#$!ANY-T79P5<)6MDWQ=N'P=>AF^HP.(_4%]4CWFX-3=U1
MZVQ-ZG"[\9J,NNMXT"ZTQ^67YCYN4K]-3G=MB*U^^[3W6U. *21)'N(DT4T_
M4XARDD&<J56 4RQQ+!/.XJ!?\J.= %-;#O93\[8%'?95F.G3MKT/^E7-<IXG
MRQWG@.@/O>7T#OP%29%NZ'G/BK0<_I72(MW .9T7Z7B?'M9PZ\?339GK;V*U
MKI;?1"VJ1['Q'&><DHSJ4&"A_H.8[J81< 0910+%5.2QL&KG9S7:Y*A."PHJ
M(ZG^U\CJ8(.=1=?"LO6)V4B^^0:V1EC02GO61=\#/0>[U2>*(UFK[TA5/>F\
MMD<3F$),)H;.#J1-4W10ZZ[H@)M:'1*4=%'<DB9\O5@RK1977Z_*]>V=^I>T
MW]0'U>WADDE!W+^L$DV!Q54)2#N5]=X;L'D!9H UH/WJR3RVG9Q.H_CL3<8S
MA6WU.3" K2_J>[!2LG]]$P_JZ;S3T2172ZY&T:6,WJ\K]91=BZHHN8DIF2=9
M$%.:(9AC$D(4HAQ2%,20LXSE81Q'RAKN4>S;002KUW'\PMX[X<W+R/8B0%Q/
M4^QG@W(9)TD2P#@3B=I_B SF(J(0YWDDTER]!AEW.^+R.PVCM\?=D]W062L]
M:,0'C?RS)IYON&FQ/> :!.S!#[>\X=SCB,L9,6_'6_8CCWRTY0S)RV,M]UOT
MC!@D]9T^,U/_?%#[%&6\Z!3&J]7&G&G>GC1($(L9@7F,N3ZW#R".60I#(7*4
MH#CAA#G&#MJ,Z_*.C11%J M"Z+>+Z1_$3G+' $$KU.TXRSN2 [/5%D+SPY[(
M,Z"LWJT9[9FGG%#R%4MH->:X484N,+R(+W2ZN&_GF[JX76H+\:K^3\%OU6UW
MG1TVF<^249ZQ$-*0!A!AQF&NJTQD,<UH+B-)$J?T.HLQIV9:[436.\U6Z+U6
M*3TS=&W0#_*0I"3/H8[7@B@()20X"]44,)X'.4U09EF0:R#\QVK:NBMLQP]F
MXZZ=C6*K0]\,=9OIL%LD/$,\\!)Q^=/=HZF/-4#>&O><'W'DYCS6$+QLP&-_
M:;]U85>LN:GL_$6L/OS49;C44+^5)?]1+!;;:,:(<L5&,8,Q$J8 JH TC=4J
M@=3R0,(\3813H1R7P:>V4GQ:<B$[B^[_NQLI.<V$'3L-A>_ -+43NRU^;QJ-
M@3=;V<%&^%\&"2_M YLG\G(:>E06ZP/*<SKK=0\?Y1:_Z28G7^4?=3/P7G3K
MQV))EJP@B^NR.4O\T 1S*1D_%_5JGN*4(I1P2)0)!E$>2(C#E$,:14D0I$'$
M2=R_/F-ON:;&AB_*#QK-8"FATJUYB]N"ZIM@\:V"8*,A^'.G(_BP5&M<4_7;
MT;CS-?-V%/L*\SDP^[[.5%Y8C?)BX <I7]E?JE>L=WDQE-T%,B^__66MR_;"
M1CZK#SZIT>LYCT@848)A+BB'*(X0I!D5RK"52.*8!#%VRK;L&FQJU'TLA@K\
MJ<4%1EY'^NW$V8Y3?:$W,%'V!ZYWXZ4N1#QW3SHZU*NT0.I2^E0?H\YK>EJ4
M';W)M>OVXZ+\H??HXC=2+/6'5U*]OL^[-5XM^0WY>4U,Y(X(>))0EL(D3#3M
M! 1BDF4P2A,ITRC)X]@JVVDX$:=&5EKP&KQ9*-E%_0LHE\V!D52*&?^@<U%P
M_Y-J:3>^ZE0-;4*>;DW[1NORRZPYI-)*&C>DLC*UGMN_$JTL>-$%5Y]N*7UU
M<7._>>[#S88ON]*_@..:F(,!_,+:'&ZD"T+.[LJ%NJ+6QWNKIR_E2N@.ZHK%
MUM5>-Z,XXC*.2 ISC@.(:!! G&81#,(@D2B6-(X2Q\IUMF-/[QQH7_3_QT0$
M.%>BLP;>CK(' 7-@)CY$L9$::+'!3F[PYS"=HUSA\AF_9#7N^-%++G <C5UR
MND'/M."OS_+//FS26]4?ROO[8J6WZ[HLZ%RP+.0I2J'@00X1UV[2%%.HJ_2&
M 0]#(JSJ>;L//36[]&JOZ)F)(3-1Y7N)P4V8;*. R1IVS&&UGY1N,AL6ZH'9
M[/.IS-4/^T#OQ <W0P+MF"\\"."OG3+<"WCWK&%G[,XF#MO?<=S<86=-7Z0/
MN]^AQSIQ+=23I1Z[6V'N2M6X_)]EM> _"BY^JY19_4T\BN5:U!^5CK^3_RJK
M=^MZI>SPJIXG-$,YY0&D">,090Q#*D0,DSB/D<!1D.=6<6872S*U562GBWZ=
M?FRT +=:#5"U>C3M585:8I1"X%YK!-A&)?"&Z"](#8/QCQ"]\!A4 "5UX5([
MX:))MEB&QIJZ@5>EO5G[:DBP07NK"3"J@(TN0"L#C#9@J\Y8L^*P9HTU.R,M
M86.\6[XR 7U W[D"7C3 > NB#QP.UD<O-[SL_+$9UCSLWP0K;Y>ZC.PGKJ0J
M9$&VH3'F *,R&2J?=QTO39UK76]R$WOV63^LS\-JYD(DG$0HAGF0,HB8WI<1
M&<$\Y33-,$F(=*K5,:+L4UN2-[J 8@D?JI*)NLF 5_/?9%MP]< LRH=[ZZ3N
MUW@@,ID&82A2B--0*(LKYY!R%$+U,* 4XY!0[EBC?**/Q#B^R4_7W_Y&[A_^
MX_UT9]SMI'UBLSC6P?V>VC.P4QSL:]Z&H((M$>B7?D][T*H_ WL1P08!\"*.
MU7] P(@3YSF^8 S)7R5<8<0I.17],*8(?9S,^BBN7.J0,-U<?5/?S(2"U9^6
M_[PKV-WU@A1:7*DLLEH99W,<\H"'-(8L(\JFX2*"F(@$!B0+) \8IZ&P]S7W
MD&!JEHG6 >PIL5^_KU%$$1 PJH"=+J!1QL4IVF>V;)S0 \_!T+[H*</OXIH>
M>!K&\E /,AV.GNH+H.QV6/>Y\8A^ZPOT/G1?7W*C"_M B^JQ8.)X*ZH;\O.M
M6*KE<*7= OM_T=VFEK68TTAF(4LC2)(\A[HF'*19*"'7J=1QC!(DLAZU@OQ(
M9_6ZCE]&2,D-:"-XXVXS%83:+LELOX6=:/3HV17YLIFUVTB-.%$3Z;?<BCS3
M 7F@56N ILM>\/3=H?DRH5ZGG;,7($_V?O9S]PL"L_=;U>K*;5F8Q*DNU)E
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M?['4@G[/RRJJY&-.63[7FGZ6/U>W/^3\N_Q4+%;WY2QC213*4$'.A=Y<A)F
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MP$,^GYNS@.=U_(.VCK]<MX707;LJ.,V3!9L/B?[ W%[5EJ]E!^_6SRK+MPJ
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MJC^M?G8VL_O,BH6]/3#6 ].F,?UJ(["2_Y09J*4'1HOJ!W--#R.\#_X.UOC
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M34_G=TI)7A?5;/I>F=@K4\)XP36AT9H']T*5]78K"EF@8(K3$&(J"<P"(J#
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M;8JU+&>,JC@V#F5$0Y.&$J20D9!IPR>0 FE#,4"I=1K*R6&FQG^5<.!Q69B
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M!N?W)N;N?;'C4#1>QM:K^#2C0F2!HA$45$B($>.09BB%@L>"4:;_DCH54KI
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M"4(AXZ:K'2(D1DYA>Z>'FAI;;22M-[E7;4_)O)(6O,H7S2>.':<ZP+8UI'Q
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M<48T9,3\%24%3Q'57&"O?=BE@HS-@C.O?!;&NYVGP(]KAP"V9WZM5;@"&R6
MT^)JDZ#_? 56<\ 5^,(J>07^PRQ^X&9VO$-",)5>"F(D^NPLQJ"4>2E8^S1Y
M\?,Z=@\XV)'J_WV:&T.OSJ!QU3@G6J8ES6R#@ P)B/.$0L[L462:<:IU*701
MQ(2>XXZ-^(YU8[L"M>B@EATXX0,[!'C.A!\A]H!OW[O@*-"&%_L/ RI6>7_/
M48<MZ!\&Q8L2_H&W=ZS[71\5L>DV4,-5-U-ED>$<)U K22 F7-O:WR4D3+%$
MBP(Q'I3]>&2<L1'21LQ6J%:W@M]'</6CFPAH]4PO78 *K_1]&H98-;Z/C#)L
M=>_3JKZHZWWF\HX;N_GL[E8M'NS9W.]LU:0I?E6/C;UTH\V&T@S[:,>U!K,[
MW)_H5*1)J37DB.<VFJJ +"T(+$6.TS1/C:TC@K9UG<08&Y68]RP/W-1U@]]S
M2]<[J'UOZ(P"T&H K I7H%'BN=FZ.7$C;MXN@BO6UJV;$,-NW"X"ZL6V[;*G
M=:,]%YC:ZA\\D:G&*4XU3!@QQH_-;:0HRV&>% 3+1!'EU\+@V !CHZHZ%+W:
M"AC&6R_P\V.D2U#IF6MJ0#YY !),+,>TCD09+QX_*!D<4V[_,S]Z7<</^+";
MY[,1NBZQL"G >Z,WEM/:&_[AYTK-EA6?*MLB89+IC"<H9; DJ6WGF$E(A?DI
M)5F1,BQP6?*@;S^>;*.CC1.NU:U^5V"CH3UJW&X<UDJ"/[=JNJ8@@5NMF+/O
MR5RO,Z=]DUX/T_EA9O8F"Q?_'7%?V /^L>@WHF3#,G=\2%^0?@]#=*E]80MI
M&(O2?#;W1HXO"UN2_6$O.YZG6).,8*@RK"'."@VI+G*8H0PK)!4J9.D7/.X]
M9@@3#!-&_NWIX8$MGNUGSFPS4>M/?II)FY7XM&BJQRXV2MFZA5:KD((&/E-Q
MFI)[@;=GHG7B@JV\H!'XPNH0/F"&5'V(#.I0U1PB@!M8L"$ J-.%&'P>-&"!
MA0"]=@LGA-S8I?78DZQ6GV9ZOGBHDU'Y<K4P#.75_.K(O2.B!R<B:,D(_EQ+
M&=3>ZAA*(4VM(J UT'?_ K583:O.0'"Z5=6QFP=L4'5&_MVV5.<N[MX9O(Y"
M^S"3[XV1-R$"YTI*"9-"*8A544*B%($\%UJP,BF(]CHR.#K"V/;*FR[83?BF
M$1-8.<.[@^\">9KRHL#3,]T%(].I0_A![2]J$;[[Q,%[A!]4Z%"3\,,7=MDX
MV<*E2MZ8S<?,EH;?9)G:(DA-RCG*-9>ZS*#@JH0XE032+.60($T)3ABGTNN[
M]AUP;)]Y(S*8KV4&>I.+N_#^W+WA]MD;Q06Q[ZW1&?RZ5$SP 3)D7Q07T*&V
M15U?S,"]D#\XI[="'L\9<"?DK]7N1BC@O@Z$_&E6Q_RO8_\_S;:^M%OV<^-A
MFS#%,#>F%:1IQB%&ML-&KC*H*:=)D19:$Z]&?D&CCHV:7?S RL8/V/2GZ;85
M5@"5>"/N0<Q]X-@S.Z]%!F_60O_%[+A:AP,N*VDC>1_ !A!U'P /Q-:Q@ XC
M[U# 3C*X]\.&H_%0_7:X//CFCI4^-T5'KX5YU9ZF-D74'9?;!-R%NK>G(-_-
MZ&+^H'Z;+_?+^J(R*W.5,I@16[JS2#CD*BMAP3@1BN1EG@;U;+U0GK$M KN=
MEMA6)3!W(1^BK12HG%:!I3LOG$"_$^@!IZ5OB[]5?;FE2U,><T<;4*L#WEB%
M_M)K(Z=(^,:J<GFA-,.6K8P#W8LZE)$>V[%YE&NE.J$)P;;  $Q3D4$LL(8L
M80JFDF8)36T7A'*RFJ_8U(]=Z\<&D>3FX?U]DK=V#,"<;($=GFJ8_#@L7/F^
M#UY.:QS>:6E'P5@-E.J'#ML7:4>1%^V.=O^U8^(D,UODV=WRBUJX<K*;TRI<
MHJS DD$B$(,XXP4DB2 P,?9-2:7"A!9A9?R.#36^ (RUI.#1+(6N7]'_"4R"
M/(8J$XBD!9>P5&4*<9H+R&B*8"$8HQJ7@OAY!&)B.DC"Z1I1(VA=6#OX</4L
MMG[L%P.QGOFP&UCA*:-GD(B5(WILF&&30L\H^R(+]-SU S>4^,BJA<L[=0WD
MZT+>US-9IZG.I_.[Y\UW8"; ;+!R B4K$XC+7$*F,(>$"Y4G*"\P#\IQ'T#F
ML='5WY1U&RL#G%EPV)VR1ME: U>R<+&I$/1C_]*[A>U]*^VAB38 @.\6@65G
MNAOBC?'<^X[K/>A[?WQY\PFK=YWG#Z[WWI^6[KUP^X!S]=H=)0(D_L=H(Q$^
M!=%Z1W08NL/YF4TR_/!3W%MIKJ6LZB9/[]CR_IT9KY)-XL(D*V@I4IG"E!!C
M+.>XA*S@Q&Q&,D(E3A#W:X<4,NC85B)7+ELU<@.V$1P((SD0;=$#CGU\9\#C
M.*T'7'MF]M>%-. @K0=H!SI'"X 8/+(J0FO;+H"=/$?S?=9PQVB!VNV<HH7>
M>TD5KFVC[8_?/U>3E$O*LEQ )82&F*L4$BDIS(5("56I(CPHL?/0(&-C[:8(
MU'(C9)<:6GLX>KHW+D2G;]=&#<Q6/F,E_SO\_.D*-$W98U?$.HQ$U/)7>T.\
M0JVKPTH>+FQUY-IN'WR[':?MOME$]:DLQ3K5 B;,]GTH"P:YY!RRLD0DQT**
MTJL._.EAQO;1?VIWD78=H^U*YZSEP.__"*Q<"$*R(H=,I\8>9JF 5.H,:L:T
M3F1B6#70)7\YL,,XY ] &Q:0>A99AI4H,>0X5Q!3S"!3!N.$&50+B50JU&2F
M5KVCNBE1OAH>47:W4'7'HKC@^BU<E[^*/2]=.]VH7>?I\S %+UJG48BT;!T9
M9-"%Z[2B^TO7F:O[+:=MRQU]K+ZKB5(9QHH8(Q85TO8_,"Q!$89,%H4JTZ1D
M.J@\4:@ 8UOPS(M5]E,^>P.Y'W?T"63/K-*I7+;58?AZV?OH#5PG>S/\*.MC
M[X/3M2[VB^?T=,ZX/.8";IH$?_BI%J):JN6G69W(MCX2NZZ/N=;__F51&=.(
M,<R,89]!3DM#CPE5D)*BA 5'2*N"::33J$>.4<4?&Z^NA9/@334#3TNYC4/Q
M[ G\2J]!I'/$5YO<$1PI+L^<*6Y:UF]  .8=J6&X FL@0(/$YBK@L!CP?+&7
M.1SJJ#&N\.,Z=>QE8H(/(/N1HN-:>;!LRO73ZGZ^L-U^KA_F3[-5,D%(4$P0
M@LP6J,*%MGE]-(<ZHRIA2:H%PT&+G-^X8UN=OAVI/W75/N=A&RT <VH$KEN>
M4^*YX,0'NN^5XD@QI2NPE1I<GP8VG-/#8(I%QIZC#LNB85"\H+_ VSN>MCT\
M3N?/2GU5+B?CMVUF;7.6,E$D3U%B'19)6D"<<^O6Q(F9!$XX$056?OV7O4<<
M&U>M!7;Y91MSRP9@\:9_6^#!W%G(/4_I8@+9]Y%=(RM<U,*"EK1]'-OY0A/K
M#._L>,,>Z/FJ_^)TS_O&;FSS52V5N>G^>B;?J^]J.G]T-MO6I'O7G'7=SHW%
M9BM9?9PO7)[8\MU\N3*&G$O:E;\NYLOEI,@2D4LNK1FE##T9@XHEF8"89TR5
M6/*D"&IS$U6ZL;'86CE'7"WUVOM&\R4V&EIW8:.C:SI;:VG_W>@)UHI> :=J
M&/W%?0?\J/+59K9G6GV-20TFXU[ CT3<<64;E.1[@75_0>AGD$NK*VPBC/^O
MDG?5[&[;1VFY*4.];->AKD4S?U%&D1?EJ7^SK[#Y[UXR?YDD+&,,0:UMY'"2
M4V/X%@(JCBE!LA :!2TO \L_M@7HO5I4WXV<WVMOXS:M!=S7* !G&UK'S7WU
M&+BH#/UN>/H,QCOC??L>6H4A6ADLC?:MMG/+5DN"Y5Y/@BT&;GU[V:W@"JR!
M&*B>Q*#3&+W^Q##2OU*]BD&GYGA]BV'%Z+:0OE=:V46Y+K=QRWXJFY]C_OO.
M_+):+2>,B502E,"48ELI0RC(*)50B)QABJE(PAH<GQMP?$M5+6]30\C6G N-
MOCZ+L=\*$A.YGBE_ UI3Z,<)ZXC;ECMKY(U'RK[(1&+1L\,-2GN^RN_SE/=]
M<>J ;.TEG$A&4<9@428$XC*AD!8TA<K\H?)"9P)GEQ4"&7$KEI>50"XK5A%J
MAD:!JF\'\8%R%;T8<V?!Z*EBQ2L92&?5/5>S(I;1L8Z^M1&($ZFUI"4MC&U!
MK8$AS=::(P6S/-=YAM*$%D&GX.V'C\V8V(1\/[K8RYERK=>JG=!YNTH*ZR(!
M=5%*\>RBZ3MF?#B(_:BA*W ]L\$&LSI>U2Q7TR=I-X[OV&.U8E-W=+V^J!WW
M:H&L6U/:OUW7C:].I<YU#JYO(Q8YI-X]^E4"Z=M*'0N?W[GFL@U(J_2JF2/G
M-ISP)$,%*07D*N$V2Q]#;CL1D"*7BBG-M>"3F;JSYU.WX5N0 T-ZO?>;G)J]
M@?O[!IQLW38=AW -VV]TA6G@K4:[D+([23X-6N=-Q@DX(N\O#HWT*EN+$RH?
MVU6<NJ4;47R<+VP\W_J08=DD@U&2)9JC'"9::XA)2B'/1 9SJE&6)U()3<)V
M$X<'&M]6PLBIJKO9UDS0M>#;)-&.:7='D/9CC<O1ZYDP&@$W)Z$>* 5SQ6D0
M(M'$D4$&98C3BNZ3PYFK.U3^^?QDGW"CW\T?'N8SMTE9WL[?JJ]*/@DES8 ?
MF+AWX7-U(/"OMIB:DA-A&\,J36&2N+YEDD/.$PEIGHJ<:2:(\"HB<9$48]N>
MU&&$-F'@QWTE[H%A;? XGT]=B?7OK)JZ<Q7GM5B"']5T:M/(%K62+HI &36;
M?K)SIVA=O$X=K\<2<4I/\]-@$]4S?=4J@!L-:B5J!\D2W,[!6P4:18#1!%A5
M0!WX6RL#?AUN,@*J$@TQ*4/UKNSM _HE4D6C2\$^6>*H\\.'JWETJ?X[19 N
M?M@%*][G^:H2QK*>?5G,'XVQ*;=5F(SM/4G*A*64(EBDQ'G5%"2)5E!+I"C2
MM,B)U[%=P)AC6\T:IC2?WJR6&]CB8(WD[=R2%?O9@1+/3$# :A0/UF'6GE="
MM,.2$@_9@1:0* AW6Q'\L/+B_S./&I[M_70[R.V>MPZ=5>_^N#6C7L_D%_,*
M?38OU?OY ZMFDRS799*F.:0\3R$FF$!>J!0F.M<\0T+CA R3.W]<R+&M%4Y2
M8$4%?]82QJZJW64F_3PNKST_/2\Z(5,S8-KY>>Q>/;G\A(C_("GDYT&.ERCN
M,58WDO_5/&)I&UG95>3#3WL:^50M[^W -]K649VDAJB9Q@7$3$N(4T$@3;"&
M BO$A&%SB6D(8Y\=<6ST:P5>=X,S!L^NR-8:LD*'$?)YU/W8-2J6/5/E93 &
MDZ<W-)&8\/QX@]*:M_K['.5_XZ7),=L\BU;L\0>ME5C=S )Z64JE1990"34A
M#&*5"<AY*6"298P3E%-!TK!#MN@RCN]\KM;!MKM\G"^<+\]\@=8C^#1;J"9N
MY<Y]L5/WQ2Z4F-_-W*_-+T^TS;2.0B,ED!ODS T;Z,ROE]7=S&56LV5=(%U/
MYS]<:DUHZ'+\5\G3IGW-UZ-GEF[GPVRUV\V#J16T)#Z6]JF1YR%Z0DLL^5XI
M924RO,>34F(/U,&%79^2O'W^FSTC>3M?+.8_S!+XCIGOI5H]_S$SC_GV/).5
ML!SVQ\P5O5?RJ_H^GWZW%[KX].MU<>'?V?-;M6[J+?]XG,]NGA9?U7\_J>7J
M>O6^6II_L>Q[H]^RV=^7$XV,3<U28ILE&F-;)P@2(@H;,()30A.4*J_2@J^O
MRMBL^/W3+[[&PRQ"-2!FZ3.(  :6&U#,KQI4S +8P *$PV5;0!H\L&=[5%:M
ML0%/CW8]-8O@HH8'L!60&X LM7(+48 7^G7?2H_C@G^8=ZUOA]#__YIU?LT"
MSE#^85ZW5SS;]WKUKK;OWM69E^_LNV<'W7W_G!@6LE@1 J.8]Y/'3*\KX7"G
M5Z.8B9U#L7%(%,\KLNRG(@12 N64,)@FVKI+5 ()3C.H"2Z+(BDDIJ);M9"^
M11^;2?GMZ>&!+9Y=_)1[]Y9UPI3;_]H$'_73.OD5,.,;[C0H1'!P]/16=/=\
MO/Y<OXI+9-GVB?PCE089:N9Z=*+T)/BK>U?ZG1 ?MTO/$G0MQOA=S9[41X/A
M.CK_;]7J_MW3<F68=K%)NKRVAQ9+E]XSH2@7>8D(1(SG$!<%A0QS HM$8EQD
M#">AAP(=I!B?V_]VOC+<\[B8RR>Q DLV#?6Y=YF+/,^1P)I"72(,,>$,TESG
M4!&$"9(L*=.@$^2>9V*8(I=.!6!Y85OV\(?1 JS5:&<3KS6Q>83]SQ?*$YEF
M0D-5FL\&YPI!;O_0F&I92E[H!/GWA^MKM@9K'M<H,,"'XF>$]?SZ]VQ-]?'F
M=ZCTV1G":/4\PR48N&IG9XA>UN;L_JAN%L.F4- [ME@\-ZFGOYE=V">["9L(
MG"9,IPQ*U]J.91B:18G" @F4,&*VP'E0D^;3PXUM[=E6N0)M><&?5F+@1 Z,
M+ST#MQ^MQ0.Q9P:["+]@JO*#)1(KG1EL4 +R4WR?:SSOZEH:R!9LJ:L)/SRR
MV?-F__/MZ='&T=S.ZTN46A/=$YM.GZW;L%JL.V%,.$."29)"I74)L>884EE2
M* N59$JDNA RK*A0#+'&1E-;K4"CUE7+?=)H9BN%KW4#.\J!M797YUK']#G5
M?M0W_ 3V3)&#S5V'JD@QH8Y63RF*4 -78HH)Y,L:3E&?WB$.Z,//QVKA?%F?
M9F91L9U*EV_5ZH=2,S-_V?5,I@AG3?61G*BBI'EA>PT5$"/)(562P5+IDB:Y
M)L+LF'W#=D)&'AMI;V6W8:(K8RD]6_$!K^4'5@'G"+<J! 0F!,V&1[A*7QCW
MS*M!\ 86V G'.2!>HR^\!PJOB/-:AX4Z=('L9&1"T .'"R3HHN?.N7^G!W3;
M +Q]6IJMQ')I%B5N%B0[YM=-8/PG:5[$2E?VZ,.Z,E;+:]&L1K-VARKS;^:=
ME7;]FIGY?YYHP@M)60J9T&;UD$4&N9DYLSTP?THB!<<J9#_0BY1C6VG6@IVJ
MF3G@'/H9^J\^,SVO3VO]0$O!*[!5$;1U!+628*VE(]"6GJ!1] IL5(VW#^AU
M)B)M"_J1<=!=0J\P[V\:^AVL8W[M?"YM+:6F'N*[IASB[8+-EG43(9MP9U,8
M)CQ-J4C+$BJ!&,0I22#/,F16!:'S3#-9I%ZQ_^%#CXW;UZ*"U596P.1_/=5;
MPD#"#Y@"/Q;O!]B>J7DM]!58E^;<H-P2'+2R="/FX@8#%BLIUW_@8;-S@P%Y
MD:8;_H1N!'8MS [KR759;3W\>O,Q-GO!A+&D2#,.B20<XCPAD&8I@C)+5<(T
M07D29,/Z#3LVXGI1];9-8-WJW7KB[\=<\5'MF;5: K_DK:W<X'JU6E3\:>7L
M2ML]E-DFP#T4SPU#,!*->0XZ*(6% ;%/7X%WAU&75-7D@S'V5L_74BZL06A^
MO%G<SG_,)F5&,9&20BKMT3_2&+*T)##-<Y86.*<<>WEJ3XPQ-E*JQ02-G%?
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MIG2U6JZ;@"V_JN73U"YCMI+YET4U7QB1JKF]=GU6NIPD/!<:LPRF,M,0)ZR
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MF[4N$=NY7XAFI'6NJQ2#KGP70K6_%E[ZN"[=0ZJ?2EK_SV.KVSA#++=9(K!
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MZ2Y+HS7&;)UJXF29E#P3!4<$LE(IB#$S/R&505HB6;ANP1)W29C='69LIEA
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M'IN.BV7"RE0)#:4-A<*9DI!JVVU*"43SHA2$>-4_/3'&V"AK+67=H='*&=C
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MTBQ-2IX9LJ*X,$:M)) E-(%IJ;3FN,CRL @^OV''9JANI*ZS2@UYL85KJ:K
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MJ$9FUY)EQIZ@F=W%Y) 364*">,HDLJ$!0543AQ!Z;'14)WQ7:QF;D(+]XM5
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M($7B3+\Q!Z6_(!CVF2SLYDNWZ-??636UYO7'^>(;FZIO2CPM7!WJ[6E&(;5
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M-=SK)LYTHP^H/75W-;JJ*DPT2IDSFO?G1ZM'%( GA+V%"UPJS\AQ!9[@.PQ
M\-5PGV1@/XJZ3%"=P64GTUC0)NK$*$TP36$J!8,H3$)(]$(-$RH((EA%*+1B
M8+ONID:OT:]1\"*_5P!^J7];_>R>WNLLXA;;(J\X#LR&)L-34T"L3?JTEVDP
MZ)67ZRR*+AFX?*(Y5JZMRU%U3*AE"U)WZJRSK8R8),M6H_UT6-9O]8S9L*BP
M?KWZ('6+=%Z=^.E!>]Y[>!80+H7 &20J$!"QD$ L1 :IC,,T#4+%I=7)O4>9
MID;LC;!@V4H+5MI8TPNJ:SR'A^&RLY!''H2AS[U:;5KW2F,K&QG!OD97@*Y
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MI18QS@=:!W^\UA,\3_SFVONH/-<3FI=\U[>9/M5DY]JV653)/#\NOLOEJLF
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M-?=+ 1&*4VTI1@HJAA/]@R0LS&9/]=Y@1<N5G;UHU;?+_'DIP8!W]K5P@*X
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MK1Q3C[0]-<9JI>MSB/4"-8O#P/Y8#$PM'F%P.*[K#\=()W+VL+B=MAU7O/-
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M(@X9(0%D42JX##,<B<3I4-RRXZDQYF8&5GZ1;>B%*7ZC_U4GB-9_ LS\KM;
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M,H)62/M9>0S!\S/S0EP&GIUND#A-T0[%>TW38^V--E4[E-F=KEV/];C)O]=
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M_P]*P@B2*&50I"),:$1P@JA3(AFW_J>V;.@)@3Q>L1T!W,/EVF4P3N!:;54
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MRMJ7W3'4T7Y$[)AC$)P')I33$-\Y0GQ!C( E7-ZC <[U^TI^_Y9PG/;PMVW
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M>- VQ H(<ZK1MP#,:<@M]IN7 CGT 7P-5R7?3D;82X%QJ?]P(4 C;4?OOTG
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MRAVJS<J',D:4$#&4::P-%64\,S$6,"(T"3%G*17V;DI'NY@:;6R$K'T!^R5
M/(JEQ>W6Q0@-3!##@>,2"G,I2&/%Q#B#Y1@ETX5#=[C,T3='C)OIDGP_@*;S
MR1XT=R\7LF!Y\7'!FR\O9@0QCH1FMQ!#E! &2:)YCC,5<$4$D78'+\>;GQJ]
MM0*:--G\M*.:#7 6?'81' -SV3X2?9CL$!('%KL(FK'<*.T^%C?:.JEX)V4=
MOC4>79V4>(^J3C_5;VMG+JZK1#1O:5D^ZQW^#UJ*I@QJQ-.0<0J%S$*(,II
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MS<NG,A3A J81V1I9XX-05I.<?>FS)#.Q AV)Z&G.1I99!K7K"W>0T^_ER$F
M54L9@T#6+ADQ@*AQEWB//T@;# DF M'.6&H$6.MJN^XM,^2=7;*<!%>55#$(
M6)4],ILV'"T^3&^''Z?4G.]^\MF/TX?IN;\>8RPQ,LJJI"4GD"Q?Q;E>RM+%
M/+. '$06:Z<U#Z&O[P=I=5"QQ8AUHJ!!P.\+%)<2TFWO\[,8;ZYN)N4QZ5O(
MXSA>CG3"T":6(=NA/#&@$(FS/I6?R:1=\DS4CC)?IJKO>\!.H%99&0/P\C<X
MV*=AP8@F\([&1%3BY2J^L(>;AAB;70K4L1QJ8^U $OM^WM\)\+I4TR#,W%.Y
MC4*420&W1 "C1$9KB8^1$HKVFF>J=12U'^(^I:+O>9V=H*FEL(>0;WW!BQT9
MXX %6GKT8C0L7< C7C5S063*"G+0OG;1[DLT]3M1[M2%"^W5\KJZCJRZ]ES"
M<AS1SW[ 0LL6) ^_W&$_DATLG+(Y"954>YXTX0[MD50: 1B%(M[)&(V@2MK:
M5_NG:$ZR$::@H#_-FS53\T[]=I[12/J@3=2*Y%C&=8@LB4L&?T!C+Y+3$'1M
M[VH/LOJ.&BMC9D?\6$4Q@_"G-IA:S=TXNUE>SN;C_X8T$@"L7#<0F1@*R_KR
M8LQYXGE44BHFN.F@'==SY/0=*)X.7:T4,4Q4;4YSB2%%EATE1I6;UEQ<R!P\
MH32'K%V0(&L_SMQ%3]]QX*EQ=:PJ7ME@G2U^=4MGZX6O=S=6YR56ZCM=.]Q^
M*D(&JBQQ.1LB#3",+(/ LXYJQTPH>=/NO*Y];TM:</^M5,*.F(DI!$7Q^!88
MW3@(N-MX("PP:Y25*=G:5]</*1B,,U4)"T]S"T?+>P#IT#OJ5Q(I:;;9M+D>
M_3%>C)RF4CM()"/I1$)@Q(6<"1@*F3'+-'36-G$;00/!TA&:?@XTK<4^  P]
MXN'M[,J/IR-)'>4)4#(IE9>KGA,' HB1,4@N<I2Y=FBWE9"!8*:]HA_/!FXM
M]0% 9\.I^PW*\,01BS(YHTK?::N1"^U) !J(L(I+;9&75/NEWQ,B>IY!WEZQ
MS[O.1TAY:('82U?>:Q:U58%Q@/+X62*+7)7Z;$L2=<Q:HP,-M0>3'TQDSR/+
MNP1:!UH:@+UZ?!^^YB):ESW01!1DY((KC&L#UR13KZ13*3-9VT_:3DF_.8#Z
M@*H@[P&@9H_+[%N[3+7U3$;BA<XH,(G>)5@,1(*61K$,1M7NG;(W<?W>#-?'
M5C=:Z1%NB_ER=+YB"3EXES/$Y6>8CV?I4SY+L^M&5<7MU)ZB675E C6>^3+D
MB&YG4(0IGPVCP- #V =EN. &PO!7]^C:EY:!),./C^@Z$?K 0;3>?)3A/^/4
MXF[SN!DHS\1#*.^L:7:)!9?H*6#49YC7C?8/@-81JA@XN.Y'OZVM;ZF1H-10
MPFC"PSZ#($ZBC4_,)B^"L]'ME4AH:ZT>T35<P!V#B4.L61L%#< ;NS/Z']&S
M_( _78Q4BN#P2">\O"R2/&%@[!/''T!1;S)+U2^(GU(QD/N[BLG-XP0\ (B@
M]S<'OX"WL/KOA^G3RX,OL\GD_6S^AY^GD16@P?I(P/L2CXA06H &8B)8$[7W
M2M5NKG @B0/)@AZ)B"<--+M3SP#0M_.F6]MHI?.64%I>J0%HXEAI^!9P7T8?
MO+&U4PVMBPXZPU6G0#BD_N 0K1R-L.OF(,:]-%]V58+NT4EE(002I2V1;FE@
MXD4B >/I4/P&FFL;LB/KACN+"4^)J98:& R2?H?E_9N,418Q(C6I)&70M,M@
MB 5A"(\I"Z6R2;ZVB7I 0+^.U"GQ<[S<!W#,[?6N)R2;&$ FUI2*,8U!C$NX
M,1C&T3Y%;\'5KHVN]N:JLUSH*2%674L#0-[;\?=Q@FE:;)SI9;#:2)KH(O<,
M@]CRBBQCZ&.3*'.('?JFQEJO:ENNYVCIMQG#*1%611N'H\JM4#6%BW(#\*UB
M>J'<?BX6-Y#>WLS1.5SE3U8^8_/C&Q1H,P(9]U.CT9'RD@>3*(%<KC&2CL0G
M)TG*VJNH*0/>B=MU&)G]]G$XN5_6H0X'45+Q#)/-.Y!G>)0YR."T)4J&6#HZ
M!6*="809BOO4<AFKG\:'4]GOL\,!P+26!@=P4M_GFA??9L]4DC2<AL><?@$4
M]6*\A*\P_SZ.L!+-%XBSBVGSE=7 5"TM +<H^<AQURH(92J\(T['&(61P=9O
MJ]LQ3WOAW_XCX']0Z!C ;FDD_06N;^;QLG!\-D66EN/YME-L)*@S$L\D(LMD
M .1-(F\,@T=NO%5:IDAK=^XYA+Z]4.S^$5#<F=8&YA._R.)JSU$#R9:::)Z5
M)U(81VQTBI2A?]0;*/_M!9<'C!6G___!Y>%*&PXL=Z;T@T?*9:#$NS([@*&G
MY'!SD10X_I'/T?+J@^U;7[3\X]^T'**6EOGQ=]/4U3T+2B9+Q1TQSF0TXZ:8
M<;3J-KCH;<PTB=J-/X^\9V'_J!<MAZA@($#:V!AW2;/;C@THQ0G^)XVD"E&$
MAJ4R RZCXVJ-L<1#EM%FB9NG=BYI'[H&4NA9IP"ANB(&$#QL!%-?H*F*_C;[
MYG_\;;R\+!L';2]NQ&>R"C%K=$KQ^->BU&)3,&B4F[9:R*6)S,E0N_E4"W('
M4FA5!XJG4EMMKZV?U@E5FU8=LM0IFRJ<M*W5CE?U2K @<LK$9%=RC8*2D)-$
M XC@SEKS/9\9'%-5V66'A?VLO[,RNF"(@-)W5]!,@HWH7CB D'.04'WB;;5C
MN.=N#(?@YKB3^0#=5#N93V'PRK7I^\GLCT5-TW;_T>Z,V#.$US=7=PO=H2U;
MZGRI=,:@$GVUF P)'"(Q/@9/N31)=]@'Y@D]%4JQRC<_SV<%_>G-S[_BJ?]A
M^@DC$5^&'9S%)>Z+IF'E?5<F3A6S0+3)"AU5W'D^2T="2B(;QR3*H7Z]UH%4
M#L9PM4/0E@JN+M4UB(OFAU5J*DH.S'.2?1F>1GF15E!$HPG6U @?4NWX]/#J
MP,Z U+6^=Q8('B+Z 42D;P%7CN-&-_CS"31*FJ:SJ]E\.?[O50QCO%#1Y$ \
MQ_!%RI1*CTI)-'<R^D19A-IM'O:AJ]]TQXE15EU1@S!;SP3-5F<A92PC'ZDE
MTF5!O)*9*.ET1N%1IFL#;HAIC!-#K((R!@&JM^N%5U;YF__1- ['_Y[C;XZ7
MBY&DFM-H&+&^#!LN+P&\50R#'Q$]U;*TC*INSW;3U&^Q\\EM644%#> 0_8+:
M0@(ND8FW\!TFL^OBQIXM%K \BQAWS]?=+[Y=^NFWR_GLYN+RS<UB/(5%J<<-
MXVFCZ+_-QTL,Q3[E/ J,\I3*>U FRC4,)!*,=R19::F,V7M>NV*J-@_]UE:?
M&-"] F  &^#>_WV/JEBEFGZ#Y>4,9?X=UJGSD<>S(P<') J.$O;(6<@J$NIY
MN6WF5D/M-JE[$=9OS?6)H5I?5<.I-?EP=>W'\U4*H4QN_CC^#JG9A8MOLS?P
M=KRX1A\C?<JE]3[GU@5B?,#]Q1@@?U80G2UX#9 TU"[,VYNX?FNK3PW'3E0V
M )/8V/LR4Q>%N=IS[WX4GQI&@0*2Q"/A7KORCMF7!NV!:,A<.FJH%9T,.MY&
M3+]US"?&6AV5M#5W'37/N!/:NB;[3F*<!>XX*\.<D2.),L)]PU)YL6H4\E<>
M)=0_=?>DKM\*Y-,?O5TH;1 Q]U/>SF*<W305$Q'&WYN&-T"-SY9G J)XM11=
M"\]0C%08"!ZLZ.#4W8.NH?77J(.*%\'74D$#M8/%BYWB/RK3QK6GVAHERZRY
MTF I*&)-\"0KB_Q(%W/UDW8G04-KNG$BH!VKDH$BK'$C[L^(QE<=.1D,C3H1
MS45YG5]J$+T (ACU6D1NT7/M_I3=0MG0&G6<"'.ME310\-T:[<_^9V.QH[4J
M91.)X:YXKEZ1$$IY(?JO*229):]=5_ B44-KW''B\_08U0S7AYO?/,C3WS)G
MI=2Y# -3O%QS6Z:)I9J3S 45/LKH9.TYR@>0-[3&'J=#8 5U]8K%4C*WA;,2
MM=_,YTWKS!^W X%_CKA1(6@0!+3D!*V[)1A_4=QG)7UN7*;RT:G[M"3OH!6'
MUIZC*K"ZD_T \G$ON0@;4Z9'U#+*7;8$!85!/L<(*(!UA'HI.,9!TLC:SQ(/
M(&]HO3=Z\>B.5=<@#MK]\TZCF&4V@)8:G8ER$8C.*VXRA2)U"@3G6;O:Y^S^
MU/7\4/OT=7Y=:*W:1/KJ>%Q="&X7)!-:Q_(P.,NF1X*3JS)'QG*$S(+ $^ T
MN-Q!Y4#>0YZHGKF6N@9A(M%QO>TYLRJ@^,W/_P[+XLQ^!71'UI:?NLA5DH25
MH59XP@@2%')IDH.,XM6^>B'77H0-LOZY&CYF7:MJ$+D7%%\$2$V9Q%<_@4_Y
M[+L?3PI;Y;6GW^3N+83RI(I&QLMC>9$UD:P\=I(^HL_CHTI)1^"UL\V'TCC(
MBNG.<-FE @<0T6SR]YM?KCGY/(?K]88\FZ9S/YDL=C$^@FC0/7>1<&U<J?31
MQ":9B)2E"Y?-.;G:3[.J$#[(RNQ30/DTJAZF$X!R0&][^?/SQ$^7R',I7VM*
M+4= L_61:8+>-1XO%$7LDLXD^)0])$$3=.X)/$O=((N[3^8.U%':,'R"Q[S=
M5O'"JD]WD?-MP>](,!$"54"DE1@$:L:),ZJTK0T@?,*3IGJ+_D/H&V2!]LE
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MDM1^TPC=0[0[O0T!GJL6U!N;[\%KC V?%A)#EH!8%Y&O[$69M6>(D2KB^>!
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M 5L&#H!5Q -+1-G$K+<Y.5'[J<DV.OI-XI[T!&NMA@%":;W'-.#_:-P0U)J
M 3%NM,"\)4IYQ2&KQ%GM3D7;*>EY"&]K#;\ F2/$W??1]&8^3A=PCJN.EV<7
M:)9+3F=M1ZVD3D83B7#EQ:KGB02:-8DF"Y#"2Q/V&^N^8Y%A(>(8!<XZD.8
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M:W,),;)R^!O%%!NSIVEL;?E8,:6$N["")VAW-#)G:R4"*G*0E(L!7*E&@&R
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MUO&:U)VO^Y "2F5*\;P SZ7Z%\I ,,) 2C)'M*3?:H12MSU.-O%(FE,!Y0&
M-I1:1UB\Y?4^1!MS3$=/OH=3JH!R)I$#PA7P()-PW*N2FB>%!YQO6L,X-2Z;
M2[ C=.[\X@=USCN312H0?2T?"\F#8UQ QBA94=(SW;K(;K^331O+3(W(AE+K
M"(L/D8,JV)R9 )."W<TZDY*!S2RZ['W)NG6=WA-'FC:JF1I]+>3405SSH/88
M)7Q "9;7);O($2+%9>",=9*"LVQXZR$S71JYL>*1%GQO!I^1$KVU;62YJ/GK
M9;E6FUJXM%[C9AW(E9B'6/NZYZV2OP=\8=.$\+$$GR!)7%3QR*2$&)T!I1F9
M/DP"7%#9>6-L:;[A?<PD\5>&O_J>X2]N,?S;FY;"F)PK8*4CX\\M15",&\C,
MA9B5ECJW'G1[P#'[30L/0=!W;X(CRZLC/^XK6;_CYBLMSD7.#-T83*FZ \9G
MB$P4R,IS3(P%U7Q6U6/GF;ZK<%0P/."Y'2V9J<=!?4=(_2']ZW).OT<T[1S>
MQ?M:5$9\_)%^FQSBL%I]^?EJU?QZQKSB*9D(4I,F*\DCQ* 3"*E8B2'':.Q3
M%V^CL_3QW'<\*);32:A'LU<OC]WO[5S<-R39U6>L!+](:749+M;;_\>;FC[+
M.@KNZ]NFJ@,6K-3@.'+PY/EFQF**I74M;*NS]_% V S)DXJV.QM[A^(?PZ<Y
M!5&U(;T23P?]0,3_A)_Q8OFIUNQN9]?/<HZ60K<(1F8BN:" 4)0$0^*0R+R/
M=U]M]K6S!YVGCP?#D6WM^)+JT=X^5#E>2SA$)+XZRQ3=(U*!8\R!%#D6FY3U
MI?E>CSW/UL<#XOCVLH5H>H3<]_? =B[1+#F1E0P.O*A9H%HU$CEWP$-QTD?'
MI!L=<@^<;=J5<5->T<-%T]L5_#*LZHI5BA9WF9^WEW$]S_.PJLZ%I@O31RM
MHC#$/LL@A"S!HHMDT:U@7AYTTS[ZM=-N1CO-A=J.[^=AQ.Y,.]J]S*_OG]Y6
MG8<9ZI2$00^9<0^** =7"H5NR3'G-?=2M9Z_.08=>X'9G@V8NQ%YC["_N@Y"
M2)BD8)"-I>N@A P^1@VDRE$&+11WK<<DW7^2O:#GSA]ZP]G>(WA^62W7=<)_
MTC;R"#;5@0/2.HA.%A#:8U+99B%'?ZG9GF0O\/CS!\]PMG=08/ =%74"Z95P
M+BZ6_ZX+?6:2QVB*8J!=J>-(>0 ?8H"<K?89%6/8NF%SCV/M]S#-SA]71TID
M.,C\%<@6VQ72^=VHN;>9QZ"-S:0E)9.QK;-[O3,:C,NVSKJ-T8]NIN@<^Z'I
M?/(<S7C>EXVZ\5Y]DT.QN&("*L!BR-W+B:(<S2U$R60Q-A0*H,<#T?V'FKB+
M<KKL;0,9]>55W2#HE^4R_WM^<;&=#+()B_?S>(%73+W[SS/%O,J1F&AB77Z7
M)0=BK@!O/2<C;31G(WKOAQVZFVQO"Q#M!=&Q)-KEM7N#[I_G"W(EYHOW-Y?K
MS8B7C#'M($1!_-7D6$3F%&C.363*>M6\)7W \;K)X)X,G<=+J7<<OEXM/^%J
M\Z5.$J\#EVHV9IOWFVF#40A3R.T)=2PPUQ"C"L"M1PJR*!#'$?,4^QRQFWSM
MR?#81EJ]8_+J&4@)5F1)I%9:D[47G).77"1PF6.*)G'.3^-4[O\$=XIL[,FP
M-EP*_>'J:Z7NS4*;Y(W3UI;J6%/T[ARQRAH)+MDDG)<QZM:3P!X[3S=)UQ&1
M=;0<CH;6>"]VM]E6*V72=I.\5O2+BH'"_.PS2!Z#L25P,Z;9NN](W61AQS5=
M1TNC]X:A=_CGYC)<M&D&NO-A31M]'COH"9IXF)6&&5V@J"0(3UI#2-8#5S67
M))36=K2Y^^V;>.A#;Q1 EZL"Z*MIQ!1L2)OL]CF2$;@90D *BFTJ/DO-M7.M
M$^L/GZ;?EIPA>+AK7QIQOX,'M0>6,#B6"N.(@)J3?Z>-@2", S26YTB<,:;U
M==7C@I-6<MYOP\D0IG<)G=U0?>4]H_O5@BYT?:L8J_-6!# ;N&0Z1.U;/U>=
MU8:307+>=\/)$*9W )[[%VY(:U)!YL%)5_MWD@%7R$0G*1/RDE$U7W]^3AM.
M!LEXKPTG0QC>QU[PFQ-U_I_+U7R=YZD*YIH@8ZP)J8#5,5UY]IXQ!1F]8BQY
M;GGKJH@GCM3):+B66&HIA YLT;V+7&+"K$*)D%T,Y!ZR!%YF ;Q(C<G(4+!U
MN'#PWISQ!WFT1,_1[.X ,L22J[71VPN]9*?)5%HPUG%0Q0AP]"MX1!>S==(W
M-SJW#C"MB1G)23Z<Q3WA8Z<O3BO%H@O@-3I0UFOP/O#:ITP*%+/BMG75P9TC
M3!Y('2K,AV!Q &>G;LZYU<*.ZW<?PN;EGY_F*_P!-_]&7%09TK4JF.0[LY@2
M&E6R@61*!A4$!V=5 HN( 5$A#W<<X@<:= 9_=2=X.43*RY.Q?&I ;4G9"N77
M.J#\?V-8K;\1)K>$*;DC3!AMC<P)4F6DBG7)N+"^SJ6.6I4Z/-KMA:4AWSKY
MU=0&1J,QNH^[ZOO[^[>OV[Y4\JHP*2#55AVE=8"@=:YK[HKG3+,06@_R?/Q$
MT[K$XWD[K830*Z1>?*P>_RS9H-$D\O0]UG=WYFN5/ <>@F48;59>G0)/5\>9
M_)IK)O5] '6 "'I%TSW]%X9+XZ1 8A=YE,H4A.B%@E)*(AJ5"ZKU^,T]CS;Y
M+7A2E!TIF@X0=\MKO$G:>L9CW>$K)#"'GMS#.K<[Y "Z),')B?"N>5/#PZ?I
M\"IL@ZM& N@:2O>H2?$^)[06N*JK8^JR4L](:[3/7*8H7#*MVZZ&G&_::L=)
MX':DD#H X/?MU \2^_MR\_8R_C>FS;OEMXAG)H6R2N<Z@HP94-S5J DE&(92
M>"5%B:,W PX]]+3EDR-"];3B[ "_?RQ6F);O%W46&1%]/6;B:VKB-2["Q;9C
M;MLKM%T1O9M0,7,N6:=-AF)J1VY"!CY;"L=3X5)))*^D=1+GB.-.6Y$Y(F9/
M)<(S1>MNZN/,(R/GAA33^5 ;V80%GVK9*^9,_Y^$Z *MN^-.._BF,[0>(L(.
MT'IC ?OK,,\SIYA2P44PD1&S1/'@.:>;(@7GLPY9-Y][>.<(T\ZT&1%5Q[!Z
MZC1#[2];KC&_R,0:$L6-758SHZP/=7N5#)R#(K1#+(A0ZX>L"5YQ>^<Y[X&L
MPB-?,NVLFA% T92K4Z/C#7X*F]5\*P\Z^ZO%]X15DC@:D9%@SGT0->D;P3FZ
MS15RH:1)C)7]IJ?O]WT3#Z(9"S0C,'MJ_/Q^6;-FKPJ%*_.$ZX=("BE8S"%
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MKN%- BDNU@9BB(RQ9&7[K2@/G>6HMYT?PGJ>JK,YO[BDNW;W'=^1BR46+WF
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M*@3VN#(068-1NBP>YM0^\7#X\EI?45;.*!!LIM/((E)SQKTO6&^L]"I#H5#
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M?XF60*5D02*T0N,$IN31/->,0<!CAM\H 2_]W?FAE/H<,$]]:M<#9A#IKW_
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M&4'>4K)&^B)D\SKJ6C82;QG[&3]>]\!T'K5$NF[P7BE"*-J"C8:4$ME+W[N
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M2? Q$_B/)",D$11(88PK:(,6O:W*QRGI&ZNX3(]QI#QY%*!CL6 H9HBR5-X
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MCJ%WIK'#^1 ]/;5DMQBPU4CR7:'HU6RZFLQ[:VA=,,%JRSR@28Q\91F [&2
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MX^;ZQH77*1KI%EYRPXRUOK"2R-![62L(DH,8(SG-B2>AF2*&6C]2/$#.N#G
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MFUW!D$L.I@PXZN8>.6/[VT/AYSRY=P&AVS?Z+\,.:A]RWMS-X0M>,,.U*UJ
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M4_O-NX^2U1ND3M'_O:>/MLKH(H7X8$E,+)D7%QT4RQ(H2[&:8_3;H!,*DF/
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MBZP($NU&%W_W]7%?'-H;:[WD8\_&[.Q?!D"=70@KS^FG1-_A\B=3BFY.%4P
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M)NL.\;+M(]5%6I0:BJ^'*KM2TQH)(K?(8^0RA];;VI_-:\=1&C[LM>,8<7<
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M"Y;YJSE#92121:S7N6Z4(@&->1I'81QX@?@PI]@9BZT8&S:[V#L\JKYUM3,
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M]V5'MH^Q-K+DD>00^NM7MO$V:9(&TDL:<!X(1K>C3]_Y="2!VJ_ZHY[UZ>P
M^2J@Z.Q\_V300X62:5[4>J;9M_KHV#H]076C7$&6P$P213C#U#0/A@54\)4*
MFZ8YF\V,6<W@8FI:8S.NJFY2SB48KG(+G7;\B7X%[';^:+\JE5"?.U$ 3"%'
M %;@HD@2-D47+LA+5"HM<O5X.!=DZBM4+5=KZ(*+2W*%TW1%%(5.5D_;3)_;
M9M)(V^;NO--VR14B[OL":>S5=QL-&ZKUAE?'U5V[ZNWNO/-<YUVU#C9N_%/1
M1IHZ>UI&JCF%]X6 L)(/<?O->LVHAJHU(Z[RFY5R^<_"K9P*KE4)4S)ES<1>
MG>IQW;M%LL,I%\VM<O+7BE-*'@X(G3??6"0 B88P0V,>8/:F*#7&)0F">&E&
M23Z#;E$WGCS.4GMV=3V4,,CLJ^Q4M$D'USZQB4:KTC;CW%F?[O3LAKV.1@_$
M,QG</3TZ&*+!L&?<-CAY23^P1>=.VCW=^#>2BGCSG]Z/^KW]L'Q 'J>4SV(6
M$XDPHD0JQ#TD(UL2EV!!='/Z6>FL/1Z$F,T13C[I@P.!#0+5*L68Z-4BX@%1
M*JY*\@!N5S'SB>,7D<.U*[H@M.L0EE2*IU,!4^U,133C$741XRK)ICTC4CH=
M20T4\8B#8X"R.N=WH7\4WOM'I=-6V*:0E;:YT/:5]!!0'$IH9F]:+I$AQ?,F
M80F02:%6@,54NYO-E>)!LZ%1OP*AM*UT84%B3)J\<,.]/6.O6HL]46EKE)LU
MO'!2(W%24[EWT^I[QFZY\6!RV:@\,6UO]VDEOVGLCNYF?:EJS00(D67(**K1
M+"0%]1!(3;SWA5HARQ-BU]5$:Y91)<F5M?$3LKX(ZQXK4PVOXU(H^6^4XTGA
MAIM0\.X2EX>_7EV3&6IROC\9] ?=\:?_??6'XO>BL+"ZU@$:C='(.CX8H[_.
MQX-)?]"S!J,A&AW>PF<-F; ]Q'H>B9@6Y'0"N:'_R.6Z(3L.P$#*MSE5=#@R
M&I^-QMV4')HRXZ/N</!W\GP?4[Y6M-HW%&TQ*^K>-6,\)*?$15F??H[<K=[D
M(QY@8^=R*KBF4VDQ)HX#X'FMWWNT[X1NR6AW@RDPM'T0"1["6W04V,=+N,"C
M$"PS+NL$XV1&U&<0%#-W?<3T6XSI889=C ;,,39),N^') 5CE8%?*_*GC#@4
M$,2-+TF)7$*^0K$/%,^P@,W0CR/*;4S1(6&8.8#VC8^YCG2&H/QT$I$;+B9Q
M'(*.0.CJYKF8K([B?="MK98,*'Z]5:U56LC25@E0Z(0$)-Y6?[U5:Y1;1%R"
M(KF\6)$&8B5.K)5/I&3Y4.H6\Q@ECU&6H,HI9I&''14);7\Q$Y5<1_;UY!)M
M_'IG#!*P<'RT?1HQXOCYYDD>K"Q!FXG1-2;Y6J=S*.*%WX9KR,0(-1URS5@=
MOX'"=%,4XU#''B>]7#*>$GVN%>D7?-!FXY +N!V@HC,%!CI1;JXG3SG R4#=
M#$VQP/&9;G$Z1]L# ?&6XUMTSNABWV3Q#:U<<A;8;+CB?&'+*JO@7&.^?]W\
M$KN9<N9\TLU/A_.PY0LA+KB@[HRX@(XYC?L@ESWURX7DQYP3OL2N)MPI)KLF
MN9),0DS8QLK(/N$?X3H/0)Z.X#E+HOL/VFZ7!^LN'2E?EC[L6W/MV/@HI.=#
MP'O E)@O3XI<0C;T!/B07 $Z$[I*9.E8"X<0:<-D+B:YF"3[0D$0,1V,]+@(
MN<#QCX)S-5D=Q@LL?6VSXBM%M2^QIQEAQC[7*^"!C!=O*[(GUY3U=H81FU^C
M,Q^+ #O);(.IS .5/%!9@C4W0Y1\P?-;Z4GZF_WGVC#"T_@W6E<@57Q-B-0S
MSNNM:GVG%4(\[8"'SE_T]T^>%=Q?O@O[K+VU@ '?)_SWDI=GA>1AA3&36STZ
MWWVGR(LJ=ONNH)"G=R4UXQ-TI5?3#]X>M+CTI/RE"+8EIY&Z6^1!,VZ]IK<?
M)?<P=?X#4$L#!!0    ( $Z#258*Y88CX0@  &1-   9    86UG;BUE>#,Q
M7S(P,C(Q,C,Q>'$T+FAT;>U<ZV_;.!+_?G\%U\5U4\!O.R_'#9"'LS5NKPV\
MWBOVTX&2*(L72M22E!W?7W\SI/R*[:YSW4T<0P6:1N)P.#/\S8/4H-T?;K_<
M#'^[[Y'(Q(+<_WK]<_^&E"JUVM?63:UV.[PEGX;__)FTJ_4&&2J::&ZX3*BH
MU7J?2Z04&9-V:K7)9%*=M*I2C6K#00U9M6M"2LVJ@0E*EUU\ S\9#2[_UOVA
M4B&WTL]BEACB*T8-"TBF>3(B7P.F'TBEDE/=R'2J^"@RI%EOMLA7J1[XF+IQ
MPXU@ES,^W9I[[M;L(EU/!M/+;L#'A <?2_RDY=?/FO3\_,RG[<;)"3T[.6ZW
MZ8G7;M7/6K3Y[P8(60-R-T>;J6 ?2S%/*A'#]3OM9O7T.#47$QZ8J-.HU_]>
M6B$U[-%4J."CI&,%AM%0@GKYL"^%5)UW=?OG D<J(8VYF'9^'/*8:?*93<A
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M5#2C?=MX:[T.+]]PM7<V^7^:/8KFJV^W&6QOOJJY_W_,_D]HE_\#4$L#!!0
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M(>:]%"/$U)^74]Q.A^"Y%T=KWO3+SU&94R]>O\Y3KSL3O==/[X>5;B;AB 7
MU,I(%2G=X+1U3V""YO2DT>P4^HE75]"O<(?- 16G)^Z%TSG<\_4[;H2O#<9U
MV[R\?MR!^GAF@$]IIEJO3ZJ+&PM:,/6F6(7K$I6HXHZM"C9I_W;HO=B9_0^.
M;7]"W*]2+WU47/>QSK<C9%;P!&OOWI$70>P\S2=1_7&V]P]02P,$%     @
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MYWS5=_S.??M) *3@CMWUN4Y9(N_41/Y"(M\WE<C[":8"'IRFH@5ETWJ&3"9
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M=[GS7<Q#S E.E.L+VA"?R(O&EQFFT$*EU,1:)=#F20M/8^$R3(UP'] ')<,
M;)$IMW!\H'96Y27%, (S6?PZ^P![KK SSXHHV: @611M1E*HB1=%NI<%J2'4
MLE\^M:PODLNC%MT>(V WHY&T-EE,;P^[\HAG?TX\JQ)'$V !7OIH2/$"6;U+
MED&#Q3X!C^9<IUZV,F,5<W>H>H=-^(S2C? C O/*GWP9AD#B+I5 QAE1.JF)
MDGSP;^J%LIIFMU%_5D*%U1:;Z'>ZIM5>=5<W=5I,B>@VV[76\5*MXW^P*QG<
MXG+IE\9 4]I'J:D2*7-Z-9!0#^'(-2? !W$L')@@P,E6<;_MJQJZO,@0@JB
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M'5-28[#*C7[%.RP.>Z.UJM]T.1.<)-?S-S''R'.DA35*.T]C08>@Y0'SGER
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M754L4KG\9N/G "P-\RXKZI3N_S_O:9">>)\4SBOGRE"@RRL).&-7<0-&7&X
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MV@DGH8O<"-2 B:[2</0QQ:>"GE@X)LP.C\-(8/C2)*+"GME7##$;%=@Q?VX
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M/\N81VS4:#WS.PO/^^.>"?(CQ2/;REMOZ3',;BJ&"=2AP,(56-(=A4G'./&
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MJSJ<U-"8N4Z BA4FU^#X9ZU-I,6LEO0DD3.OG"=8@8QVDB0<4EQ'-'9H21T
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MW01%XR$)S]LB_*ZU^W4+BN=NR$!-8$S/N-==W.,&_KG(V>ZV"#/;W3D(&LG
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M@IAW'^ =\!SE9M-9Z_"V]KLEFCA*Q*D@L:AB_%:\(.Z&P:[*S\3.>,F",.E
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MF1]J%!AXQQ27#WH (?PKU^ P^J\%8<HH0"X5.\L8:<W]OHDG<?SB@'%NXS'
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MMEO7/^YN=2$R&%;M?Q*J@HG$+5OY21H0*[H;3FTZB' -:6A9U1/?+W9P:+]
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MTI<:;UP/@R]B'*^5= IM9KS FRZ%H4ZNV5ZU]02['4P#91L"EBRV-?@VY"(
M7*ZP%'P*J1/H.2T,G-SJD/"LVI&9T[3#HFU:M>V+E0X*PM -8X3.HE&^3C%
MJ%JK*)7_6Y($>S.:R/7PK[^?O_CY Q<]\8SRX-*[([[Z-5C"V('#=Q%DS2Z]
M*WAH>3)4'+)IW:O4 '\,U3.WBF=W=:XMI F,A@IJZ[%!9!,SX#!Y?@1F^@TC
M.Z]"GFZQ(J@B$)KA&L;$ V&5: 11O;3,/0)<O$'GN\T:^#/.EJ<G,W\^YYI2
ME@&^27*I"JW>XY2X$F+1(!_PW?%7^JNO%?* 9LCI\SNVGO[@9DB:>!]%+KQ/
M&]BPD^U!MD?5PB!R1];6U4-J-X!SSXJ%<-M!-KQ'G47I#RLOP'O7VZYZ&95)
MRQ0#J(@:;-V=9$>*ATNS8[&5?#5(*]KPO-O@K]9[HYH:;DP['29_(X,"U!1(
MJ$%G'4R8;1*P!JS5DRV]ST@Q5MHF.,IF3=C2.B6@X4('.T/?&.:(+N%[EZ<H
M=%X *_Y]) VA7F1:;B.=/J-?7@PY>X,54!P8GK/ERVE8FH;E="AZ3][L8$>.
M<V20\7O(D>EIJW7SD7YOM\VXK+>+X:VWBT/6&Q5B#/=V@]MM%V6N1=U"ISOG
M* R$4"!.^QI5"=I,#\*V+M#Z0CX"*N#;(J3#@DOYXNL076GJQ=-_]=PJCXNQ
M,VV5NVV5SV^G74*[!/?")EQ1.A*\^S@3;,CY$6P,3WZ3VYT*=&6%-!VF?RX_
M+;TW$I.:NAOEO5A1M"*S0"KV:N3X )M8M88TV-5/7H-^?KZ\F/9+W_WR$4/G
M$GT0\'L&"PR,:^M@%Q3NA8Y7><QRVJ89*Y?3OBW2)$BB2*0'1NNQBE0/+*K/
M,MUZG_[XY:-GEM=P+SI<-2T]_",5=B (-BZIMW]^?/?JCX^TV2C [L_'N\S^
MB*7W&]QBX[W'EQ[G6KL*OA2$J6H6W9"S/174#%-0\Q&;2'-Y2!X^14'-H*TT
MQUU0\_(PR\)?K)IF7-[=Z--8'VWGWILIB86VJCLB[*,YH):V89_31:\2D5*8
MA M#D]0 ]/TB ZIP_<@PY-ZG/4C3[4)CD"0J@F*>114$U+ 'G@/]"VM29&#P
MPZ<FGNG8=.RACTU-/ _Q]+.3ED&?FGA:EMY]%^<Y(Q=/AM C&D)_3H90Q1#Z
M<]R&4*,0O[@7M_6+GF@!S^\(A/:C;ZZ(*IT_B!2)6D>POX9OGJN7Q.%VX.["
M!2>%^ ]3U'NEB]-ML:ANE5MX09C";1+\9P+G^?2CW.ZB9"\EEA!?$_01E=D%
M-V&F=JCS'&;Q7!]X=,_==SIY](/MM?\4F,='$-GW,D=L29C4UU3X/X*--P+%
M)JA,/Y<Q 1[IL1*UT:H@Z*@^&.PRQ'/>?J-<, 8)ZKT$>%F &E&?K9H+2,/A
MTR+S+-62460V9>QT(K@UXB 5P,_0 #F?9!S"C?[@S6ZX->REKY(T13YKVM=<
MQA'M-<XHEULJL"("!PIC(G*A-S1 4'#.2NK3E H.X[YE' ]*>SWUJ-]3!B1B
M#-WJ8][W6'+>:Z^_'6P+,MW9G;?@I(:'W((P?[;DYW;:A-R?FE5M7=HTX!CX
M$5..P5Y2O5;,@!$[T!'<!;;_27,#LOOHPCIP)>(UN:&H.8/$+QCVLVS;.BTG
MB&8(UVC^0#AR"[H;;&H)REDN2&PPJ+#;[H5:O1D0 E%VL67!1S8 1QP@ZW9J
M>MBHK<RUOQ/3'8<-GA_*O $*C?CPZ6&FD5#[RH@I=?ZPJ7/5>?FC9\Y9Z>HV
MU%^C9(51(&HVS4SX!Q:T+[.,.Z93F2=3QGCHU7VX?0E)5Z8PCH.!Y(M=B J
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MY,3;+;=+;S;.)6U:[EX?PI3Z0;<\/&:<:W3N4=?$WNNCOBO+N<$$G*SFQE2
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M1,GHV<C4PLOC4@MO0I8 /[!3_TM5<#K ITZ8O5'F<%9-2YI=)$C"F-_X3F_
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M!Z787'BST[G:C+GIU<5B#=OB:*LQUAZBKW[>[S ]XUI>E!_291K&C:062L[
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M+ZW3V $GX[9EJ;*N7.T=AA.1G5QB6$2"U1"41!IG$8F&/3H%8V "UJB/S[9
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MV!(*$",%+VY\ 59ZSBM0(Y_XAC5904&]=[8*:P/K0F;.XQ:E.U,3KPTBHJB
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M(V'=(C@O7QQ\UBC<ABI*KTK&>:-AAR3L/-B810XOGZO8P@I-*/A7XE->:=9
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M=]''[RCZH"N^RE2(#^<*03G9P.J(3/7DCG5V%TJ-@4#2_*##W7R\".T]JVM
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M-LBEZW9X >Y:G-[8T7% ^GH<')!Y=3B<Q.Q5I+!Y<U4Z^'!G,<\*?F)XV-0
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M3X'?XKCB\CS:WXQV6O1IRXYXRYX;)/I/NV??*8XB/F!HI7307LF5FDR)3H[
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M#B?<8?V9WB;&ZUGL],E&[_L_#>B?CPGL7+++>^!\>>%OMJCG6&;T<BA..[K
MXG.+]@B7N=2W ,N\U+Z9;A7FS?ECJ<7P.; ^A@?J!'R&7Z58PB56(=>Y*W;
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MY<UY9?;:N<2-[+&N-Q)&A @)A&5/?<.5P\@2M4:\A/"/(0 GJ"(;=L)/%@8
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M&P[O=/G>1H$[E,ED%(:&>)P#IPE9GQ\<#3IVUA6M+,=*[R$AL /)YB)%)KP
M^Q<W)F'D=),%7PMVX[5F#--,MDYJPS4-,##;E*C=S![5O8Y.&ZJ;A?%-XH.=
MW84U_N&EZTE:O"5ZP^2[PC6L]8*[(X8S0[@FU>VU=QMM4(X+GHFHT%"+ZS+B
MMD7>D$)JQ(P$UD 3I[56)N*!('>MHFBT4HZBT0!,M2_&QE1[>O#$2"A_JQXM
M]K@:U%\;T,;)D,#_%OH<5AHW7= !YNHQN AG!1\/(H)+.Z>^CDCID-61'C<5
M+UPQ[QND$B#H-/XA1@"^!-8F0R'A,F.6V*J/A':.SP?:Q-3>O<</F9(=>\Y=
M9$BO]/=OF@N"\TFT'ICVW$XX7<00>O?RB>Y^9O4SM4</&1J_(%1)$U0W*NO[
MQ/@@:];WK99K^'F#96U\K=+  FD0(-8H;AVU42MLX4JK,Z02[>4.9?6%98@D
MA?2X(JA.7I;8;=K9K%(@[$JN;BV$F%])XQ3W)>FP2Y;/7M=>S6G(S",8-S^;
M (_3>]-[$^!Q*,#C\Y\-\'@R-L#C$^&)U &'G*3I34+U(C[%M+J-IFE7"<D$
M^5CSL9G7O?5#=)[!-QXT,;AG.>K$(/GW0W;/8&*F0!<&B:A"5I(F/2-UF9*H
MBCO:J :?JWC]C%P<A5R33E>O1*,YI:H*]HMR<'="F]3:2O/M_82H[X=J68ZL
M=_[TX(GQ,;ZR7;[_P#E%2KN?-Z1X)?1\FN[O4TWB$T8'2]KUUF@M4*$#\GP7
M9=^44ODN_$B"HF><_W#FRITI/5%PJ:2!^D"<AT40]0:!].UM?\@LRNEPB-(N
MXS8V;KL]B_KO$42W0W;0CB!%_3O"<YR#'+8.,LE))K@3!DOE7,IA)@6];F3@
M$/;J^=U?-<1&R%))3:#P!?,B8GH2!GBA1$?A\NQM$%F+N\ZDG\,RP^V;((XA
MMI[&%::XB?X/?)6M)NK<^%]1,0>?!E6#"'D0D2R1YC<0127,TN!E,UPT85XI
MLADV4YVTM01J?E&D6:)NGP5QA$-DBN5R=_U%JVK"ID05 AE(_ (=*P.;1H]+
M@'"6SQ?M65H6-094;Q6))ER:K*.0P:950+:0=V#1'2Y6(L8!<U%K,&U"H,(#
MH?E3J&CO\JN@C=DJ,C2:>U0&RV<8 .)'=$;++JB"5JLPBJ?K@E%D^-NJ:"[$
M^I$-GFKZ?0Y"!W3H5%=A[;!.-"P*_5I% EKX6VRI=<'[C)<2)1T;NYKZP!',
M+M6%%7)7;B)!WA%!<$HX%-@?J&C(&U=X? ,_AC4#X1T17"-\AS'Z<+T?3PA[
M<FPK#R,Y,I\8E=9_*[45@-(G,8]$4)JF7VFMG+-%&')_''CXD"ZPUC[G2C^G
M6"YX<TU\=[B34%#.G 4522>&<B!<#FTJF<>_<7X";!?\9'"-83.<VZ/C(VM]
MQDJ*JY$].1I7(KMIF9FS6DS1!8Z[\J_YD"(RAQ2.D"K([[K&EMO-6?O0Z-A[
M22><-)EBAMZ:8^-JVK,U?\\U[H)D>7_>*!T'HBY0+.UM2+[,LHPFP6B!5E6)
M3V7@5/GDD?3Q2%J'N]+.08)\6H'^O]*\0 &8\P#L'5<9#\S4O5,D_(&7>L4J
MQV;>P#"'"N&GFXW*C-M.&4QP7V+[19%'WH]_^>Z$Y--G#G@^?N: 9I6I9ZO\
MR<%A2ZN\O#J"5OG]0_ >^V!::0-^_)K998O>7_RMHP_^QZ7%EB^X.C U6C]J
MH[7K61H;[[9:U^"$3Z[=^B%[P8Y/R2R-P[<]@27Y?'R]U2>[RU L= 4S^5Z2
M9&OO5SF^AWOB(7.W)P0O_JI$+$G'EF:<J+O2C%6UN^!^_9[X=^%)=HB@QR6F
M/Q^Z]'&O0N_)R['!]Y\_M7;+WZA%:&"M/7H([BT3Q1,ZG#9^?.GC(N=S@&0=
MI-G$$7" ;UVK6ZTO5K"FCF#L<8$[R&I.1Q/>A*[#9ZR^UC@C/3XJ!XWSE*/T
MOD[C.+V1FH.6-L.JQD85[>=LG]T_05:G]Z;W[GA*3I#5NT)67_PI(*M_)@7S
MX^?,I3:>N'WFS[L\N#T55^K8S:UL)OV[TCUK#T\\2M'=*3<;4\ZG$CJW;+N^
M$/7Y&5_(RH*"TX,9A=WB8_<2P>[C>9]2B6=$T[;JG#;2,&L=UXJ76<V!4(PD
M8F>NFXA?,2)\-0%8XNLILVOICB8>("XB@./9<XH>MN'N;&1[*]@U2;0G?$[2
M^\X*K[85.TX\3T"[?\]?5Z$6,Q:4,N^SEDBA^TH]XN9&V-P=';=.T8/-^-B
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M5&%I%+Q@++!R7%D*"\F*8N")U0VXRU>3!ZWF7(TYO5$KB*^4?IMS6UBO9OR
M?AL&*D.,^N ,_/NVK<X:+H\/7@RY<=D_P H!9;;T%+;L79Q)'M*V^=']VPE.
M3>:_@RG-_^/?3E[\0O_$LRF0M)\NY4H7MIZY60__Y^+UW\X_>9]OX4$V<YU
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MS%249:(2NA%M>_$(K2,(JVRA7^46/+(>48/SR5&U:.O\A^?6A@\5PT(8WMP
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M**(*9DI7@*V5W&2,^7VHE_5Z#\4I%)6W?C$N31$#>C7I"/9W<:'-L##8H1;
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M!28 WNTPTS$-ZPMGP$RKU>$M+/:"UB\1 16FFAGGK&8FRY"6R!FASF=U,/7
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MQ"3/E#%H2 I':462P39NID]8*_+MA2KS@F25;Z/5GJSD;S1^A^3#%7C ":4
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M1%^>9$N"J&?V^8+=HV"?$F22A@22]"#"XQ"'L;))] QP\<U'^(,:8;KZWA6
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MX6!W.XA1/G'F:2U[I$N-8*W%/#EUN&:1MDWF#?!D<VUS;0,\&2/P9*^CTS?
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M=@.8"YT-,,[K/L^@1"Y5C=8?MI3C#!?'1) CIH=SPK+4:[$CW"/Z+KY^:^\
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M2BH!71;T3R0&5!3>=WD =H)3GBR]-^2DM": BWZP71)RNK;11P;N1.2(GIW
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MG: CFJ(_G9@F&KM"F2%H>(F(F8>#L]=20V4$/]I%==L\D%B_5/AY)/MZW(K
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MX\R7$R8QWHM.3P2HO:G[>27B*$#AQ$TXPXR*2S"[P;;BS[+$DB*BDJ@[J81
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M62M),B_7 E0J!OU7OW<WH:+15 &"XF(R/*[(\M3PE8OBTN[M+8 >Q03P:>#
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M/+GEB>I!GPJ%Z!=A[N@0<T?=!V,)6*,*=E6C[&@FL.BM76&/N(65K/#%GFJ
M'!A!B0QNP,K>- JH!.U\PQL"3S%NR^(+720US&8.MN1*;8.GABVN/?7)0/4"
M^\M%8NF[5/QC+:K8^6KMJ2G]XW#5*#/-"-FJY#IJY7CBF!RV%AZ,5@VJ:Y6
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M?L?"^1W_,;5G*_CGP5N8__O_ 5!+ P04    " !.@TE6R)O\X9R?  #'* 0
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M#;^XTN@/;+&%JA]$#P4LY=8=1?FLU') 81;A4[C<=)&)6TT4'O%OYN7 2Y5
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M&XYF7W%(B1!BU)17N_?5'89>'5J1R(M#)O.NE>GY6 *%&*1J*U;J!LF#F-@
M9NC4!?N]&Z*6TFW=?_I*KPV&QH1Q_EED9NNUY,.5T;V?;S^A::@#=RT,.?5
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M- JJ>=%T:D;HVP;A7Y4AFFY% 07G\QZ3$QP+B.5YRU!8;ZDCN["M&G!B;"3
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M):F@GYCO&&4[^8:%<2OG "J)\#@-$_<W?"!6%/;)\T?I$U>; 871]8.K36$
M]&X)^QVTAIV#WD2I_[W/7K98U;(MN8Z1'8>$U!AMRINO):%^14,15D7_Q>H)
M R$=!P:I$#UH (AV44C5V(\24NQ*A 4H-:)31$'5"/-Z81[WM1XGSN?Q*3(+
MYUMOP WQ4L&UY1V%$5Z:<;Z>9(=S,)&!>8Q60+R@G4/8>(P[L"XL9;5$PKFB
M($-!JP+8RNK<<7(*- ?=<K0:9Y<.XX@[3&1,, ?^X6I-QE?1X9^@!2S^#[''
M%8L]/KX7L<>U4",6^G?>OWG=?\BY6,MQKR?;"FE*3)/"NJ-7O%P)5O1RIYNJ
MUU0+:^2HK%/9&TI5'%MH0"XSIE@AA88N/XP025J6-0:I8P[LWM[/D!OQR[(?
ME5DZ,WAQ)8YES-2501_[SE_U0&$>EE,FXT?:0G('#;4[GB7IX^XW.!$NEQL9
MU(B91;"G'&D+U5&QV9B/M383[Q$GQ(<.J\B:0Y02B+HF)B[BWL6>Y\XE^;*,
M+\-F1I#'#2'A$\PH09\*<>U4@62B#7I #?J-'ZWB)QZ0>W=$[E7"A3EB[3B/
M12I8N35!8>'-M_F3-.B.E!F1*"[312NK($$@6()@H**5N@7_N>WQ5;+1P*(,
MPW.#N8WT-9#$KGZ(I++:C58/C+43DHB58FV3^RIO%NE5!_V3_N$7TZI6176Z
M57!LC5801N234(Z%/G3I1+.!JT7U^\;+S8W=S4;\@5+:IY8E 6PD$N+LP<GO
M=W0"YT-J,JPF9UM1W54D2XW=6LL%P'"!8.:OG:+&ZJ5+<LDKNB2$]!*CED,J
M$Z7EBG4G*O<N<=P&_?$8G5<%!3/X%Z# F.02+'C:F(=2[\-Z:MM_SKXX<7::
M*W$Q$9L"7'L8UED\M\$&WT/D2;*F09@33B83RA&O!<&@T5CA>R+>Q80> :$R
M_PB\'K8]\7B621Q>C\O8=T5BP^BD&$[P+Z\O6AD;.^&7Q,8W9MY4\\Q2^Z0Q
M&-3R6L9F=7KB>X39V^QYM<&\JA0^Y Y'B([,!OT*-R%DY3HGT!LJW$H9R'8&
M:6=8FPE7)H2=3L4BQ%.\N^D>Y$0![@@FAQ4FT;IMV%YU_;SAV2*LWMZHD#HS
M?_!>[57L'03K#JQ=?^_IK-:XHNN-!M4-0WS-'&F3&*%?>*Y'V($&+S+G;<<$
M&%":8@J&A%,B@B966+5&Z5FG[?N&*B^1+?:S+2E\M+QNP9IDHF +YV68U)GV
M)?NM<\+5^  Q@ Q/=JK4Z]MVU"K2P'J>J24\/ .I9B3U_2@B*Q4 >5)!@HW"
MHFVLUAS"=F"#2:JVEO6Q!4=@MK8R:D(CHUPO!78GV7CB(L"4%2_1F\>DD/;J
MJ:'C84] WB-^7^H*[J^6+E1BK_CV.(46I#O;6-$/;31;3DC392Y3(N;&=72(
M$V\FZ0>P%W.DR8IR(?LVG_#9",O:R+[)24N/DM*; ]FL(=F+)=9SJDY\75+0
MF",?G)O?223X"?;4,E:DF8*5T_G^ 5?<NG&-F^M;B_[34H[A_O+S.R4(QL9K
M5Q?^TKK2U70/=*H.17C27M3  W-+(FODYR'Z@:#_*LW #.^+ZMGA8<*X+0+E
MDLL24^X.Q7N7+SD:WP^D9^0FC#U/*=S8ZF+D]![!$'.04[_*[?U%5PC\J(]U
MT]P5@547PJLPBC5C])W6F&)O1)[BA9.+L@4/H:#&RX*D',9*O>==X0>.2O?D
M[D>9C>^/L 9?IY_!ZZ>1;BI26R]2&-]1<AE'2$B"WA54^_Q&\'FYKOS*,6Z
MT !/J$^R385E4 :#0.A5E J:)ENYI;X(C=='"?1>%NPV<U>_4."5!2F;,@G$
M\!)RSI:?]?00!EWU,.B3>Q$&_>;D2\X0PN,-1AEJ[[Z$00#&D#(A2,Y=1YJG
M\$7%I/&E)->D]GMABT1UEY"^MQ?E&A6 ;X/\?KL:\"MSJ-#^0K\$FFV5JI]^
ME5WO;[N[:_7$A36XS',M+ &:^8#+8L:Q2T?R+T2Z_O%;SLU)3(S5/-.QH8IJ
MH &P;V:SP:NIE3"KL6&ISHXC&I<9.[+:AM2KN0*PJ[>L8!IL5&K/<J[?C$I#
M:0E=5@>R38]'F3.L=7INJ#*J<;XHT\2D7 DWD&RC>Y&J@V*W4)JUJ$'X\$=C
M9D%4N)JW46S66BP]P$'6B>Q<^6-<\6L$][51)6KJLCT?_@<CL$,O$[J9.4L9
M;59D3&CAG58OA\.'*(H?WB>9/%XJ3E"$']''%H?HZ'/HQ8,P"4=AI1?C<(@I
MBI'0-M4S@*W["9_U"D9)<:B'"'LMPLZ$#_DH_#-X':<#RB_&HLD8NOYHBGM+
M(+AN0)9SBTY0_/,,T5!9,6\BMGN.Z!WU KH\%9_NXA?GMF \$Q7064.@RU"N
M.4(R$\6!_<JZHFRDZM(D)B,D30/U;C$V> LB)=@TN-C=W7\<;.C4"^/][S@E
MD51-/$?<-X.J*NB.(;H)1??0MUOU*.^<'0OP.- < 01!$UL7>D*\'"6$=!#O
M0JE8=)W%QLCHO;LOO,%#FTDDG=1OI?ONQ?2MRRN/E(0=!:H9AB4B[5C3Z1Y.
ME-MU\6<".OZ'3_/@0<Y[HM_0VUV/)<H4CO 4FA%_/4!DX,9*QWW[!R]7(+AK
MP0(VE12=N] WT*+A)(:@WLZEEAQAC>3JBK#^!\K5:C*;KAK?D+0QB9*0"\=3
M3A]Z]J/J[L=B'[GN&'N8.5=V:O08]\35"%U#CYSR(PW0U4B49E[^+?5?((Y>
ML_?U#E@(+OKUH6C\O1Q^E[O"#\TP.H C,I0;"P=&RV'80_;.I+/874&@-%!-
M4E);)UAF<0.?^C:R]$ZC7;3MWYT=K%)7/7E+J@=%*L5\_^H]O:%?]SD$]]84
MDY2"O4=*TKLJE$*')=U?7.2J4KK5;8SN;%B$EE28)F89^I&TBKA<Q#YA\2+2
M5E*.D9*??.-H46^A@TT;]\LOA<[:MK3(I 1ZH3&*?=F>J2NP6C\ [>80$^0E
MCZ\^E!Z- _F@3CWJ+"(W)9O=RJNQ,82? 35A&I$+,.]Y4^8<!9CTSNJ-^K_0
M$YEA@B?9\XIVL*$YC[>9MA%UVO:R0HC-T)21N3)Q.EO_RN.?!X-=YLG"E:W2
MNE3+!D\Q_\=:&V2;!?V&/UCM.4V(ZNG)(9Q2(?%G/C,.==OP_KN*+=XAF"]$
M6M7@>]6#7_%WV28]TTY035^=PO(S+V,P$S'1?*F@!\V :"'N6+"2C B(/@4;
M3S8YGSYWT,-%T#>WE)HQ#F(Q<7R&LFX,K?5E9QS.<&UKKZSD\"]^WWT0/-VZ
M[6+1S<=<B&TEF%.Y6NF><'PPN8)!'!-,C1R*Y0#=R1X.SR(1_<NZ>^(?D!0K
MAJ1XNDY(BFF87<);9#O069&/BG3&?Z_,$6V07)!K;I!>&1=#SVLX092 ]?*?
M A^L1V.\S$-!87;\4$[E+&Q@V4%1^)RX_-)3LL\\=6;YI6(\5!ZS:3&Q'JE'
M/L <Q&);=4\WE&X+)S.S$*N)%:;%>K!WL,;@/.\C& $(=B8CI&)75,CX\!7D
MWJC%_KV!^=J>+_Q![/<T,U/ZZ%_%U9XR@ME8_#[CHTO&!5F"97*4(UM,?:Z4
M_A5I9 :(46Q-4L!_V;08/XY22XFPE0@9ND&U8T3)<2NHP/F;9UHN3YL8KVPK
MR ,O ]+^VY(R T.P[%K%&Q^K4%N!)G92?BP9K=)/.?@>0A*NS3P:H(F)/F=M
MRM6\@V:P[ ^(BA$: 5CAI)+9KTV.V%!?N(VQ%=U-[[1+EA(X\N42L6./0*$+
M,])'6)<8EAF"S>9!=<#6RD482&9<A:7*V"DFWOV6!9Q:H :7,Z7LYL>K!0MT
M7#"K;C5FM1$*Y1,A;102[)'SWMS;ZAQ4X;*1%A!/4I^YEWH_+#,VK1@84V+W
M[4S".L$N(=06U1RH09*H\V.,T[N-P#^QV\#?7+5EZMX43MO43:VDHP-D!*/4
M 6UE')<D"ZB/4?X1'BFNC="@CU3T=?&AVQ@++0R3*YJFRX2IHW!<O.CU#8=T
M2YZ;A%I%8G.&#"% P;(8;H(D*ZHK>5/3]FQY9_U#&S]K(EF$_A(E==EF=S'%
M#N$C%,CJ]*)UI//, J)M&3U9H\N24_D+A$.IU0<#9O8$+5/#9D-.)YV9T7CC
M"[Z[52:WGN(&\@3WD+T1&"-6YRB!WMBBU3UO5Y/TX/ 6C1!+K0<AI]_41KY=
MA;>ULN!:>%I%KOFCK3E1[ %-1&824RO"8+,1CTP@+CBR88T]^+;2]!X8LW>.
MV)V^.7W[\KNB6;IO0;N%@WT#]E!&R+J^DX'+IQ'H2NKZ:R3'*[HR"_"%]7O)
M-V?ZJ&7$6 D8AX]+^'B'+HC=Y\]W@@W[]=XSE_D>I],!0HYXV0_2D=GL.5PB
MW[Z<)C PB1E'!2874,(17CE%5)0%TS:!]$TD>TZ"L:"2A]E<T_3U&A2RJVU<
MT8R26NE]\SJ))-LCE,:,_NTL%,3''$/$K%A5DW6%_7-4OQ:EO3H!):@"J)$5
MDH1D&=1CF@@=K*/+I$@8M3O&J]MXCUR%#*HB5L^1F2:DEMSQN+Q,TX]!/RFB
M/\NP:Y\\NB7:<)DG=1;.X<*,F7X>IB^58CQYF=']2C<J63,2,=.U<E<\+<&6
M[CNF":*5J(0+XV@:%:)%^MERN.]W]Y_O4[M[.[L[:^UR?H" KQ,$_***AD;)
M5!=3&>;#%R22+"#,B6'^-B,]FX$NZ(7,0MS;JUM[](Q[G08GH%)+G9G@]Q"Z
M V^=!T=3S/BXLT3\LB7:U2;-')&"YR>2Q:'2RL[0%*@1ZONR0IS!.K$ &3_7
M3FC'!GR-%5G)=#'8D%02(!"PQ2^-B77$7U;_1??V\*XR$;PK\X 1-29\1J\!
MW4-"'J@*P4VD>:/4Y#[7LS@9PQE>5LB :#EB?*;W%3O9T*=ABJ<Y#A%Z]]./
M>X]W7N#^#9=ZF.D8)LAUA/B<GJ:#699S+K3G] 41J^S*\JA4*E-/G&-*>NZ:
M\IC&>S6&'4(7<PTQA>,(N *A[,1Y&=K2;#9;[<IH.55[ ;!GRO=KS:54E\<\
M3J[QU.L,9^#0NWSJ^X= [XT;:$4"O<_6*="[,G9P7?"&A0NB;2"]Q9RK6Z#1
MEM+QH:-#V:%P/J:;VUS9UW/7XU\(0/;B:%IHHUEN@+-)^%NF, 51L$>I)^C=
M?I^@D;Q!<O[3-M+_[^UMPY>;]^!&[SA-F.VL7&%C927S:B:!0+LD2!"K3:KC
MP"1)G" &JS<:U5E&K QVQ,^58)Z7KN@T:!7AUH4KF2 K=K$N/R71<8CGFWJ7
MR#7"2FLUG#5,,Z0]C.>NT#6N'EUR=!1PO\\X(MY8 [SY5FT%A(A]&(%2\VC_
M!<9E@F$(FRA=LFIS#^3$YZ>""K_&4NV ?E-G([8DTMG(6G2 B3$5B&JQY"G0
M.1Y'%,&UFAPZ&ILWRL9MBP%MNH"UJ\OCDMQ<@"ZW-]>"DKL]+K1$#UH)"Z=_
MF$6#AR3NIL3$>]US/N.?-/76MU"E1HTT1SXBLE&U(^U$"X_&YQ4#;RV==%^=
M!@OCD6>G_8OO*AQY\EWX>%?8370 0KNHEC?S$!<>0A!.*,GD-K?"[66^Y9G6
MUU9+9! 9M%=90X-<U6((F(A\'682-6S!-UR6<6@3O.15=3?*.).::O)K!>S1
M8VELB-=5Q)<@7PP&?BS6SY&]UA$7C,HIW" ;741@XW<IX/[[Z.#7X.SHW?N7
M;XX/UGD"'N3<6E6WZ@<'_S8$(Q8VDA8AAZS$8P%<T<-5V;3:'!<')RO%<>$1
M47@5V&N%UU.DMD RJ(1D)T64]'JQJ-@QP2TG1.:>4_@)?@'_[QS<S8JE@K-S
MQL1>[[$0JOP&%O*3YR_HW2F#Z*B_6H-62F&WO8\#^OI65[]4C)/&.UU]V?I;
MF3%?2E6;^M:,+#G-D&A7'/01&>M2Q <K+O#DY?=XBQP>G;SMG_VV\@BH!VA>
M]V /PP1IH,^)BDU@U_UAL63,PS$)'C,K;,$L[AI'PAJ -8IBA10#(X(LQ&LY
MAD=+2V5I;16VSX.WCLI<4C7\RHA50]D$W?-U4<F;)J$V#J_@V @C./6<L&_N
MJJNW7F^6\K^TCA&CB GMS('>?X1)B>"UW1X(N=WG31&T#D6S6C6RI>@F*R_'
M/E_G6QUJ8>/[ECR35AV)OG=4;%0Y<NC\K/$77$5"3O<[7N2_!==P6@QB^#CA
MP!7FJ)\4C[4>CR6L&Y9[0B>:=(?@_:)A8#B#/,N<P(!U#5Q]2';219DM L^9
M(Z)HD4,681^5QJBJ1[TMRS#+GCCR"SL]+1<8<NJ"4>$82<FX"Q&Q\=U;-_\B
M)>3H]8=W%U]ZW ^HAA5#-3Q_0#7<]]OV?HBJ57:^''-I(L4[2,XO:<*85U<2
MZ.3H<CXK)#,TD5O'ZJ<=B>62^T?:]ZQ0HBN;B]>S#EU?][7=\-*/;7:XAVC6
M*KO4L<_D,EB+K;/HEGMU?/(&+-)U'OF#I_8+,%DO.U\.P]1<4%)=8^U1XUP9
MR? QCO.HVDI>.AJJ:M';3AN?U=E4+/)U.#%@&G--B,QL*6!HY.O+9%$GXRB;
MNLS]]#HQ63Z)9I[_TW%K^_D/VD.L3 G:-(:^-B6#3&%*2B.]K;)T'!$=R#PP
M698RNT'J./ELYZ?A1T8T.=8E:92B8T3;GJ6).!I3HB?,A6O/3O0LG+'?<YK;
M?*4&QC?Z/CE_7YWU3PZ.UGG@#T[*1?G#4D_P@"D)ENR=?#FO>"<-4S'Q<5?Y
M,PFO6"2&(RG"110O:3JJ9L(ZWCUV0EZ;K%JH#Y_68GVQS(/R.5 G+$%>[G!:
MKB 7REA,<KV,YVLM%^YX/&2C\,R>D>$^5B?8WMZC%YA[0KO*!.^+""87/M[?
M?V&^_LZZ(T+M2#WAF(\="ZU&6-ATUUYPE9:Y;COS[R"\2J,LB,O %.1>SA F
M)AL./HK%+D&>)[BM QPDC[W@?Q&K;)E$?Y;\-]Q."6\\Q&9<QB$R"@?![_A6
M[AF\-$9X+VQ!DQ/BU>3>#C1L2L#O<@HO$B2V_/JTQ'?<,6MM53SHUE^B2LQ2
ME6NIO.C@7W@[8'$7#Q"&JB1#S(T%<,%G*8C^OM/_''D<4;DZ#9<H$9#2)L/T
M":R<C?^%BGI:\C52YAK^MU'U2!@9R \P$:(F&URGK IZ5UI1IA4A# )K_\FC
M%[L4?@>QT1PE\I_YGG?D2Z@XRQT!=L7S3O79%%,]"/.H G]SC\U,PE7E&1CK
MEXU!O1FS>C:Q,8HCG, =\?3)BV#_^>X39$*^-&0E6/\'^]D]DP.'%$9QF?GL
M0D-"QX&(OKQ$$P-&0A@"Y(0S21A_KSKZ:U!9^R<?UGGD#][6U=IN:^9 $:]!
M=CM85@RV [.^!EB'B*M*5>MA*G4EEO+S)=LPC$TR"C,2;QX9HB:9>%%.ORLD
MW]FM 7IB/1HYMFY>*5$J9;?ZG=U#4L0"P[HH@3$74NR9,HFCCXCL-5>HGR.P
M#-^:7M.(T 54!+O_VQ$*50NLMM9?4IQS_>)YS, OQGEMNGQG^1T_CM.VNU-_
MH>6PXRIF\.F4BIREPX_W57RO<O0"8=QYOC5@KCV;&QH1K%N2YW75"6?8+/Y&
MW/),P8SK_!HL%CAGK\S(K"Q7 LJ$'/6@97,C'">HY]&Y\^>^'B7R':I.';-\
ME)F!@?_;YRI6DEVM:=@()5%*&DBS7$C$1';IXDY#,"@%A_D8.C *+:$D+7>M
MD@!_%OFE1F4XA![Q &0NJXKS\:I.6JFK0DFH\#KIU(KMGGX<(\\>?)X';TT\
MHDYBG5!)[5CNIGH@E;C%"JX&_&)WYP%_\1E;'&P^2I(:$E7MB/!J/IO*:D@)
M=\>HQK/4>_[:#)!9.]BXOK[>'MB^;8\D)Q:5RBNPN9E1 R8X!8$N5SE^+\[R
M[18&G<Z$ND:J1%:_ET1E6-656^J*":W)0KT<9Q3U[KI^3IH:HCH^6(A(-=DO
MQZMJ/+>9[HY-Q06>':O$?57,%_I5SHZ.OJO8YX-;9>7<*DMGR/2$P;B&-6E+
MB[8 D HCD/(EH"/"8ZHAQT/X$7XWB[%Z@L+4V)7#'FC/)7QO-\7B]/GE)@PQ
M',?B$SUPH@,54IS"5?A$>W64A=<"/J24FM#"#5]G!FQ!5RL"VL%":_RL8"7E
MF8V(8Q%,W.5<2J%7#=X2I&QVZB)Y.<#WA,%UAJ4I;/DU/Q>"-*$OCX!L*;BU
M,DKT@J4%L_^:S7VOENO4%L!UI2ASCX+&E3]D0,#Q\<;>)CD'FT4MN:Z+MPQ5
MUEU9NX&A@#:BXGA[-&JQ5O;+YZ1IK(ZV\>OIR>O@-_C'.HNY![!5]V#/*X;/
MRA2/EIO;.>@\AD:T&P2+0O3((18]S8DRP-WO[,,D%/N55K;UB;6EB%J46-1J
M!>3.B%;XME:H5!YZC1"PX) RU^>NUHY"6*W<8(KF*A>T%K6YIB++44X5/:MV
ME"TF1BY3[L$6^S)! <'2/P0J;71FK961[Q75<L=QGQ\=O#\#H71T'OS1/SLY
M/GE=*4RR&JX*_RBCOHX,/!1#H"WK4YY3(C=?L0;/XE5DKKD$$U?!)5*A%#:[
MHS6&4_DKLK+^!O^H4A19$0$WM!*HL2/9Z51T)+<U.,NR(('^E(,""WF6A5^D
MJMKOBK+@K P:4']&U=(_]32FP04]YZYSZ4!27KFP.@Y^EJ5C0_!Q)+0871%O
M(44:M)2VX,VKE1^[A%9K716?+%X,)B]JPT%H.YU(D<0O11EK_6X4S87YFYKI
MP&1V-EZF8<:Q$\F^)\JHBUO.4P48J^;9D(!"6&.-<8FBB('5 ;T/X[RV7V98
MH#+C*6'LJ^.#TF'@PT1W8G/\O=D1=AE8")K/,J\4F[G5Y EUJ?JIO.]C3&N2
MW5?;M"UKK$="N2)C*:%IP-!,99_**(0I2T/T]OH30!=Q,O):-99*:Z7HBG'H
MR]4OJ)6S<R55^"5K?<-\K@[\_N1U_VRMD4PW.51<H@^Y?;+YELM#L66-O\N$
M\^.#HR^9BK<J6L0B&V<99LB:TW&\M5Z((U%!5L:2.N1"KE1\K%*]%:^DXR%<
M,\FHNX#N+)Q74X'!-!FZBJ2BE]3J:LG%IB7+4;SP58E:G7/=Y":.MQ  _( ,
MN'%%5P49L/N #/B,\^B\T(2@YR+DL/'E^.C!HY!I-)V:$7+@@X)'L"GG]Q!$
M9+7^NJ3?]P(Z4\VSVJ.#VBB:;&'V%O<X-@S(0LW;YK0V?)NVQ/"%A]6$09CL
M2G(1:)5(=G!>FPW+@_QA;VU><=>R.43:M1;*'IDK$Z<SBM/<(YZK];S;5A@C
MVM=*6,K,Z!=C@CTFUQM&^I*42KFX\L]RO2F V7)2LMU>K=)T(]ZABN6&TW$(
M]GDDY<W1B9D49-%]L@5*^* NJ!%=\1V@S5K&G+TC6?%J\Z';(&=O(3$E-TM1
M>\;I#:S-$B*160MS%E?^,XOIG+>[@1V6Q;G1.Q PK4S-]?Y\A4#8BIRQA?8'
MW/K?$S7]=Q5\65NS >[KL%<-=0S(#^6TA 66PU^R&K0T-!H/10KJ^!7K,.BT
M(Z5H5"+5+_]4ZMOQ-(=!4JI/S&I>'GMP7F*QE4B8"JGA5GW*I2>2RJ3^.T_,
MUK6M:R70)PVOJ=711-(S$O 2CRM='DB%[(%9:K.F[8QD_FZGF=%"L4/6SAG7
MMQ9TO+VA*HLG5^2X+&B.*YH;?N'I;=@"*W,@R]?;<_2]!J;64ROTA9C$>!C1
M4\'RD 2CHU!F,)#<J71%%^U90S#Y1&=598<S@_%@W$4!XY UJZ3P68;E@JP!
MQDBU2CVUD4$2!I@ S.0C'WVS,NP9GW^G$=.XH]QIP3;6[(:=V08MU;+Y- G+
M7 (2?F$^JJ&.+6.50DF_:Z0.CJ,<)0%E$-Z#$]&^\3XH_1/&I HN8X<BF,QU
MF]8$ZQMA>N0-)@0NB-RRH(9?PV5'2 ?,_E3#WZYQ#;O>U:( &D(,FBDZ"BZ"
MB!60 J8BV) :*O&\IX^GL+TFT%(F65(TXGFPL?ML9Q.SKW+.A[+Y6]71]J1X
M.34%MYC!GSYO_V6%1'"3XJAD?MCPD]_3L%DPAX=;08S[1^N#*BMZQ89>49UK
MC(ZQCX,L$^0GIBQ^S$Q8Z0H4KX[/#I8K;J4$A=V.!*F\II@2B@]A2JYP+/,V
M&\Y[5OL1WC0N^D#/XL!PF6%'P*)STAT?*[&@E<^R#O+I%GM:5]1RQ4N-AXZ7
MW*VJ&A(Q^?;[?1!T]R$)_T,+&:FRJE291WR6;[_F5J/F2!-A3LS?H%H@SXG=
M;YN6Y+N)&K]KP;ZV[!=[>&I.HJI_B.@"Q4=$AX5:0^_6?=VA"]TI9U\TG+L&
MYLAWY5 YX=J:!+X&Q7.%*B&PI<U("M!K0$L1YE1!IP?_/#YNH,PJR+Z'Z.C*
M1T?W[D5T=.7.^A>I&D2JJ4G,&(ON6EQYPT9RWDS, 4N8+UV+=BCL =0(^"$H
M!<3>6R98F@.1<Q@W1>QB'$;3[_)VO>B_^? ]^?J^J\MU;:,5L)KS)4.<'A @
M7Q(!<E].5%U=73)=W=TNU(W=33Y\+?7X8 O-;!(%(RHJBJWL9"\? %3=YR^"
MC;UFFY(14H/9.\9A]@!%"#$HX$P73!TW+I%;7WBX[;E))9V#4/7IF%^*WV[L
M>R\6IFT\GP[]?*?1W ^L0OM&>27>_:H(Y$TR+C,.1"RHV2@4Z95BJ^19_H2+
M&V'A!8YC2-(V1FPHRA#R9F1'HK)\G6M5A6JPIFI"62/KN.?^\W?WW]Y__K/G
M6V25/RI_^3_Y'4PWW6*'81$&[[+H*@3E\"0M]"KIPV8Z*K-T9K!8)6S$=!H-
M@SY,QXH[F(^.^BOA7R9'HYO"]PE._8I/W?N5F+E_E%F4CT0AZN',X37^&YR>
M$7(@8/U".&?_AEYS<<&:*%MG0?80NE][_SUJ[U&8>"3BUY.TIURX% STJ'"]
M2'./J5]OX\6W].FLCF\J;@@L@TN3F(SAH4H&KE1D9%<T8@N.8XRH*.A5J:HH
MC4  =./]R?'!*1&2]X*S/X+SX<2,RMALVC Z#D;'Z'@LI6E\/48?*%Z*,0&^
M6,.8R2JC,2)?/5I?S+TM)<LT;V?5$G.$N-I1XZ*(1.LRT-N=8X5>RQ68?%Z>
MQLRSI:0M3M/$S(,XI$]M06;..+OW9_"5G9L^SPV8:4LFUR&B4W1H3</LHRD<
M\-FSAAOQ+CP**Y$_MHP9BRKN@;!.2$41.&3Z&<?P+Q0F2B?;F.6(:KO@K(HT
M&9A.\+E@[D["?!3^&;R.TP%RO1)O;?"6&X5'#L$F(]#C_J[^WK.B2+18>EQ2
MTG%EO;=L,!HHJ<#>,^-0)CX/>5IF#C;%,KB0R@M4E^8JXE1M..$D=EQ6?C@L
M4# J+ 0E-PDEQ6!6*,Z1H/B$I9KB%4<E95R'&?H3A*%0&)JD.YW2")N!YA%R
M1>0]"1>EJ#]&$Q,.LA3LEU%J<G(3,_L3VKM2T-H2/U6)"1;@]_WX+/,/W-3;
M^RH5%ZG2_^B_ZY^L\[@?--&UI)@3,:>2C^0PL1%-4U)]0']!O]'C%_ KQ#X2
M_I%0=CE683-<]S8<>K2TB'2BB@LA>A"4*Z+O\=&R&N[JT+R-$F1E((<:*PR.
ME9#('03E](]PYG!^>SM6FC+YD.!<*Y?(??9350B!(UY.]/775V[_QH5S1!O>
M)*KG7HMHM##6-1?\G5Q7MUGAA[C_C4N\*G'__7L1]__6![1;A$DZY][.7Z[P
M@/4B1-N>98;.9T<%XRMD5*M$HA0$#X<?=;T*HEW?$?$K D<[JHRB-)+[H*IU
M'+VZ+/-S"CR.*Z0I8JK5A9<=KU%F4._MJ0+/E7A$C;=A!)3A%!8-$9R^11Z@
MNK 68:R;Q&-:$A'N83<=1WGM'B?C):G)<.*?;PAR@HS>,,)[L!7N@S_Q0P<,
M0/UV;(_2Z44'6:W:-B;=A%&<JS_$-PX]?PB+L9 >\RSPO*A4+73^E(Z<C4V7
MY8=Q2\8.Z"M#RF'@,Y* L=_T)CAN8M[;C^W6AN-VSJG=HH?P?(Q**J[S-H0S
M$NP^9B(QJ?OU&=8LU5%0*5I,VKV-[([@F@ND<6/"B)=^U+96/(<V'U%&45L:
M7 Z,_.+KA-2SY]4=(I^OBTVRR7Y/S^@BR_JWT[.C[RG!_/NPK._,Z+]48WM1
MCH9?(=;SAFFRQHK5X#+;E\N]W["&\&\P76$MJZ775E57W:PL%7N!*8;;]LZ1
M5OP+4* U;,N*U.5<$FR%;R=M._)T=E "!V%,5JU6$;;/J?K5[D-=1I9,-Y.*
MO,1:#=]HJ3M"'M_C;?7F^.+7]_V3[XH2Y>'&6CTK0MS#6,N64 8JN_Z5#@)U
ML(%L P5T@.7)F-$:Y2$2+&MYVA&(GH* R[,49!IBX3C]GS54]^$PG,Y"F!R0
M5@V?(LP8@PIHXF"R*,PO'A/,0[R*1OCUQBN:"4I*Y.KGZ7;PZ@PF:I>%FU)*
M8PBSW:IY X^581*%#[=N]?UJ5VPZ7G&L1$]E8F03DVNYJ<=$PD7MB* 9( )K
M2+%/L7"T%;TLC]Z?@7W&3HJZC]E&G^4WV;UV/RRZ+-X>_?/XX'2=!_Z0CM(]
MV+[#&/N411;YNS+)GS5<_8V$,@NPTPOP]4VTO"77;\-%+R#FOR6@GO[_)J2\
M??_-+Q8?TU^$D(,4SAV"G-W()IMRO@OH_J/(PL479=[VJB$%%W- A$YLPBR>
M>T6FZ-WNKE^<MKLR+OR[V \L9B-RZ?^R_V16+*G/-NFD^<\/9-!90D\INF W
MHL7L^/4?$N=YI3#:ER<JFV$,.KG<BLU80GHW3.[6,F=WKW-V+_P#/5\\U6$F
M9598[>U/+PUR!@ZW&:!Z#1HS'I\(CH^AM+#_U]Z7-K>-9%O^%43/Q(0407ML
MV:[J>HYY$;*LJE*WMR?)5?WF6Y)(22B# !L@);-__=QSE\P$N,AR>THDK8AN
MET2!0"*7N]]S&L0'VF(=P\!#TGO3DM[/=R+I?5=C9V,$X;.O%82DP:[I"%13
M.G;?N[Q[OG(2$Z'%73'D#A]>D(>%OMPV\ KU@?^8Q\>36$.1D$YZIW:W9_HE
MA#Q=BJ<>H/3.&O%OW)#>_8V[R?KF/&;]0TU^SSP[F]*D_XGQUB\ EKR;21_M
M4C+AZ\N*GBHV;=QE PO"7!;ME#5G#31:0:1\7WF]](A54O:Z*= >>7Y5SUI,
MU'OWJ1UD1[2BM L1H/GIZ;.#)X/LX^.SQX=T;U2H"V=4?\=R="$?2_U9!YT\
M,=_=]%:5S\Y K'F(!7)+.,FJS#,"V]A@T=DDORHFV=!/;[S67."6R2EL"X3A
M#7$S&0F,\F0DJ8F!1G84@@ A'O9%-%XP&SH*1%E:?=);_[D8U1DFC<YQ=O3X
MM\<;WF/(XWXDX]Z$;D/RXEZY5NKHK9#]LJ9%NN4D+#B, :LE.']HQT*+$+EU
M7%*TSM:7ZGQSR02T!:-M%[98!Q%PD*7S*?"$>C-NI\(C S9RW,.)7YE(]/ &
M"H,0C6&]?T":&]>YH$WVCQ\PVS %C/,J?VZOG&+4=(CLM) :7T"LN$E#(JL<
M8'[U^!J[H&56YY<MKM"!!+A=L$%HM)SMY*PADT_/J@*](F":X W2<61R5!GJ
M.D;Q)4@#TUCBEDBV#G:&^2<11,/1VG0L!3R/7KFH9OY6L9QT25HO/3X@,R:F
M48'FL;-+CVKJTN!?,/W#>2@M"))%C[@NA,Y)T_I2B[PD3D13'Q9EV%@%%X,]
M9>[2(92?+JO9@T@B^ZIU=H_<C<DI:I/$N<+Z7H=]DY[_CBP4\=<W#R.,:MA@
M8HD@&S K2\-Z<3D7L,(VI5=(;8^N>3N@1:I'GY#8XHR36"+XB0;.;*A-@-J!
M.!?2RFO#TT\326&">*XAP;E%:[L!X;\R'7$V<164T3F*5<7HV=%9^,M_GGI
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M@M9R3\8B/D1$JFYR^IFNS6K!N4'KM>PTW/WI2U18OGAIW=F>V[,=MQ1AP]&
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M6>K<C U&!K6"D7^A94EYRV6+ )SM8JHY>WDL(E#QJ6'#A:]P6FINF]?@5AN
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M-(M],-$7L:,QZ0D.-UW ]=9;)@VT20\O-W[RM[6#=%0T(Y4_G8'NP&%968V
MF#U"-C*W5AUC-%R]M1@"-::DO=1$ZZ8W^=8C[.+=+,Z0=&37E>S!H;]RY85M
MOH\5FTU,,+(3>>_U_.I<N@YU8199ZQD=?'[;,@@PA/0BNZ#M1!DA^@9ETX2R
MDEV8R.6R_K6;NNP#VKC)E'Y73P7&^#ZE_'F'G3"BR+<STNVJYHWH\.0?"SR'
M7TE5N''+M7K?]QDK\>8)IPA\*>OD4(N0J]]=EI0,?( GV+:J7#Z8,<:[(74M
M-A,135]D$W#0A$5%O14%>* #]+,XBQ+V7KU@Q47*UK!^U98\:-"!E4@U>["
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MFT9Q#()Z*U5C>-&3)]"5]HCYHR3#V^[G+7IJ19. U^G2"1A,KN"^.<E&V\$
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M)_ (JA<YO9QB :71 PR*@HP*<FM8O<;AIH%IN9%(0.&PSJ#H02W!ZR%B[>&
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M0>T$5[5]7_<0'"[\H8VSU]]*WPDUAA0 \&O'7)*VK/U%<!EZF&T*?*-'<K>
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M[SM,BB^CD=Y$W'F;+$6Y\\-2F@!]B,SCEQ*-#R8UYDJD9>[6%(OZK=3(]<:
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M&/=K7' T()W#;P8E2[0ZK1K\ I@"<Y4ZI*.EA?7@_5THX@ZG'_FKH\MH,S"
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MSU#WCY'Q-V%+ N<U5>B[0 5]6%(D4:J2PZ.J&FV3PH(H!L:14"JS4=Q+JO6
M/T(U;I*9VL@E]!^SSW1;:QU$?@3<=HS2*:2,(M\+D:\61H+R_E0EHG]I$9&)
M:LDZRAPEG8.'G=9#6%S4GPF@2M:D8&2%@INM7@.LA6.F94*TUIM[Z2*;JNB'
M.2>7N\N\^E6V5=MU\KN+Z7&72"HQ&)RU3@*7I' 7@6/=J!0=OS7:;'V[N$W,
M!GD,+-^ZB#T)+.\_!I8_X03J$Y<[F3J&(,& D:9%PEDY;.>*[LW8% +F=*%Z
MP@ZX#OL;!0[D'E>I=S[!?'.+AQ/*=:NV<6[XR#F@+E NY 1X>+]&_G9"HZ@&
M)T4;N%B(D0R+ T0/]FI8")Y;@)M;_6W!_SQQ: <R9X-H"H#0?-V![=*1")_%
MPY7_LELI)HBQ"V8J.8+=3^&"_=V *,CG*C(!4]N'1F*=J1@B"CQ^#09173P(
M8HU[>Y3>7UR>#]Z<W(GRLJ]C[X,IL2(VQAKKR:1)%)RABAT<276HE:=0)Z7U
M61A_Q5!QOF^L'0!X3Y'#:'<0!N^0S?W9]NZ>K>G!A8KI%AR BKFWL[,;;!Q6
MUTO#)&NP89=.GL _LKP2!Y!PNI 1I47A6"-SJ<H7*]%!+J&^N:5>075=[Q'6
M +B9=I*D9+W45D;S]2RN&MU(1D5+ E>ISX<DOJT"3]3]+&2=5EV=QF@P$ZI?
MI&,WU]R[3Q#$7S_5M$]]7$RWT!=E@0HRQ_JX_[0_V#K4Q_PD&R&H 'L[H-@7
MQ6KPO.\^?_Z,SSN'_)5!>"\C90PE7U![-H64JY#*E+%A770W/V*M2"N)/OJ3
MM<;BY1.\#ZN]-AI:I!4Y5HUL$?-9HR(IK7(YUHD27GH _!AL)'QV\/YH=R>$
MT9!A,J;X+MB?&A!"P'X3PRP9D>9WB;(:D/65 L?8)EDN)JP=C2R-&3U+C!+C
M)%5"]L5(%1&30W4=I6-^#T6NF9:L_<+L)D]OE(&$Z"ZR?DVO:,14&V]\&!?G
M)VFYCSKN.H[[09K+08>D<^6<2=%Q4\$6!>"<E"IIR..%\0KLZ4GQ_$MB,.M.
MG&HAB'";3Y(7JYS:+D!\'WJ^GJ& @<W?[?3>&;W,LIG>3F :.K1,=$D;=^4T
M2B@T1 J<=5%V)BG2LT+9I,F20..#/YGZNE#Z!+1T!G?W2P%DZH>3Y2BEZMMG
MR]S1[C4?P*T,=K<&9#*+E*; BH9%'L7!1$G&(FLAF"J(_,#)."'4.0P5#SLK
M#)/\1JPO% 3#*(TT>RU15NN6R4L[U$L#S4Q@@-=( QJ56KM.(W@FCN;Z;WJ$
M:N)2L)P(%/#SW0/07ISG+*S#_H)9-!&3E0Q9R9KTC<GD+:Q:#6N=!1<G6Z^(
M,8+_K'6J+NY$^.YW54S'T.9U1=^O\JQM/E1C8YE*]O+XS>N3]V_7>>2/*MD"
MIX-1OICA<5VU-%=)"UZJ],HW19=$- C4$WVD#(6$W1M1!;?'L*XT77';BV&+
M+2R.4-@D<$I:7_!JAQN^9^)Y]413RU633;[V^=:UM 6E2Z1@R0WTMYM89C<3
MYK=)E&C*:D=[H.U33Y8N+:$IDP)AZ)C^C_M+%K62RNUXBDRNC$,^07U]Q$;<
MNOP]P48\><1&?,+9-10B_A$2^6I/DG6%<;&G7*?&TC'RK%OW9!["CL7* FB)
M8:;GNQS.L77JZ;>[N5<Z:&%(83JDA?M;G7]&QQ7SZ:1&#9. &.9]E^LDF*$J
M3])%N%4LH1)<F+K ,LL)TOMG:(!%I1=-QT++6&4@E](=\.NDHL0O-!_&.3'C
MLGX_4T-*X! S8-%TA?=U%!_"%AH6R5_; K/9;#L;#K>':K67B+TT^G6]_@8W
M6J*J$6]E>!/S2QR:O['JS:CXX?N]_?T7,2@?*PT)C:+IPPZU7!"ZU?AX^A2/
M<_7<01.&2X@9)^#FQU! _ZB89J"M%:,C(Z^O0'P%69YMZ:_'219EDO>+8'?8
MI82Q9TF'KA J L":E6A"'7U*DP^* &FF;A>YG6[QCQ)(-4_C!<&M+ZB4W#'J
M56&PA\D(-+.3H05S,7B40T+<5L9_Q8[B56ZD-K;7A_727A)0+V6!6$IR<Y7*
MA>ZZY9H5M*K.'?%P1<> E1LG'V"@E8O>BI%,JV1N;3+=:]P'XH^=1G.VC,6/
MFL/U9O./G!_KY'<K9W@3N7:0\Y)@ \W+VTT\ZX U=&O:_8I[<<PGD2BU1XKX
M"TK-T.;5:;(><28% +5O6\'['5QB&+R-"I!Q^%__56<JV.>(\X6:5O+,SB9[
MKTD6&N^U\ =P/#>NE5;/O#2M?\)DPQ8EBN3VK+EJY,.0??V6>QTY#4)$:*^_
MY9+PH8JSI7[@\\'_G+Q9YX$_9B\O'NQA@XSR3;12*FD0@R_G7E:N.&%;";DV
MZT(R<7UQY##0O"RB?R4:&%EJGA<O8<*OK4(L]D2#0W4DM8,!"5<H-#]VN]61
ML[$PJDKA.4X-)7B\Y7GU(ZJZ J(PBVI7QEVBK ]VHS:2ZW%.3KF^)/R7K@C.
MB](';/5CJOTGI]I3OK@]W003$ PRPNO@%-(&@-N*)CCD-&V#)I4SI%4SJ@8<
MF_J36)96U%I]GIT2U/0RIHVF$V?Y\H1=JI2 4L9E+9C)3U?!<!L5A;-5N_YW
M^?X""]'7J0HU7;X[!$^';&?N2D'4<?+11#2HID%!L'3,&%/RW_!2:>M&!%&C
M?SKQWLNEEUK;Z[P9'R._ZX1E"ERXG2U*"QLYGR2C)&4X+=_CBX&T93V<))68
MN"DZO^ <I%%A>"B$DYPR'?'M90M"Q*\PY=0DX& \Z_RMB(_HZ@ISX"KGN(JW
MK/D6>+N;"0</VF0X;>J^O_BW780[X_\8P<2-<?DZ]RE^AOXG2H(8PK$W7@T]
MXEE!10:,T:)"46+J\Q%PR $2$:,?U^"C'LHOJ&!X<U!<!**);]*553R $M/(
MHE2GN(H0.I6,/2#AG>919O^&#\0@PSXYODW]Q,UF0"DX^H.;32'E<^X'\QVT
MAIV#WB2Y^[U+C;5<<3,MV8Z128A$OQBA+=NO):%^0T,1HD/WQ=JK"D(Z#12R
M$RJ8XU9:D7:D)!FE ->8IJO9"JU2"VI&5#;K+=FO]7'BC"27M;*R<:D6:! O
M%5Q;WE$(CJ 9Y^M)=C@'XAD[1_V=(:3/S*&MFJ[/DR::1#:SJB*;0Q/RFS+4
MW'%RN+0'W7&T6F>7#F/,'2YIFV;>X:*9XNJ/;='AGJ E2<R/\?J>Q>L/'D2\
M?BW4B*6NHO=O7@_6/(WCLZ8SK+QJ3J>B9#0D2CW"ZP<3I)"F%WM>6H_'RSJ]
MBMHI!T[NOSB&$2R.WA/BBO!Q67)!.+@'^HT;'. G'H%P]P3">=&9$J%KC#Z7
M>C)V3?"^=.9;_9,N50?H_O+U:7 @MZ/!I6OF>F1S Z40=%546+?@/UUR0=8?
M6/_ * A8Q#J@XN<@>_SLDBIG-EC3W=Y--"$*BU%3'BS-R#(9>S@X'1Q]-@G;
M%P-\F<]]%8+^TXHG]63[P'2Z?(5C(9JD([/B%'/Q?YZ@,=CT@%*R[L3D?X.B
M1M<&FY'E%_&/>F2\!T]NY^O>^K*$W4NG#^9L=:OWPINJO2?;3Y_C1/2[NJ=_
M"AB3.J+:'\J<B-6",[CV)S.T3E24N1EAE?*]X,+MB)$.=Q#*>(HUPRQ1N0:#
M\1@] !5YA/D7H/*I[ K,(*F$=R25#&YI@%T:XC-2-V*I4Z8[J'CH'>^::3O%
MP0;?X620RZO0/TU0CD+(()P64%^972L:+7Q/#+-116SIE/5/W!#P>CBFQ%A9
M9VDT&]>IZ]'!AM'6&UWC7TY?=)5D[(1;'AG?*+6':;)Y;JE]TK(4:L8=8XML
M'".A,-UFZ-2M<9CC*: @5!<P"G0'M0*$W$+(6KN>$N@,5:2D-LP$VOV1<#D@
M4,[2A/C<Q=^VNVD?Y%0%[L>L0']@IDL*87O^\CFC,U4DG:WA<1<S3^Y>XU7L
M8PG2/+M2[N;3D]J@1&XV&OC[A7B).5XAD1:W)E)(T=P6_R^7NDTIA*OI>,FE
M'$V(\)CH3W5%)GK6&DA#YRM>(E/%A)5:65V[8$Y]4%';IW51UI%U?LG*4\7(
MQ?.MS360!4C)8V9*N\[N)-+X "5"^CR4*BU2>8K"6E*;BN<4Q%@<58N&:AN"
M#28YJ;I>B:D) +.U55 ;.K[$)0U@=Y)9S+VEI!DGHY4'I4'U_J&AXV%.0!D2
MD2UU!?=71Q>\"!:^/<VA!>D.#.4TK]"N-852=,;.54X,U+B0%@3@S"7] #9C
MB?1)22FLUNHC/IM@Z0G9."59.$E6.Y,@NS4B&[O&2C7^U#<E!0U:9)/ "^XA
M$=Q$8FH7:T9,P"Y<^/8A5Q*Z=8G;R]L(H=)*CN$2,SO<1A+8W%_4A;^TK'0Q
M_27E;IVL0G(_D95_82MFH JQ"RH$BY=W MP\HS"W!E[W!H#:/(.XP [=/7:8
M#01^_/GV@=[;NK8R_**B&UVD*A$&1)R;XQD3H2-TXYPVMTXRHCHH=.3&?/&$
M[3#$891%<11ZU[=0$$16QK+>1H!9!N%H1@28_K4.GR\W+A?4E'!0_X*V2-S\
M7'=Z_[M60S5Z*)"7!8<5@[((J,NN:LQ%U<R/Y6J)XH-!(#VCR*JMTD#>M5@Z
MR7EO K[F"*;^JC1J%9U!A/)@G3*KNB![9'03):G.I'ZG>8*Q7:QR@3I^*28
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M,5K*AT$YN"3>W*V\8:JJQE3$["<"X5MCO/&.F!"M90AJK!V3-DM?4B"S[<G
M^X!JV]K5TFJ/HUWY!6P;:4G.,+19*74MU4<$ZI2I"_"A_DKWW$H5[IN=8+@'
M0-$<G265X4#PB9'TH=!...5RD,F(+@%FF=)'P&!>!5G;GI,-2==KXHY:\TM(
M&\ZBJ:/&&)S9LW5"0L.5ER9P:UDK7*P%4XO8\B?H6H4F:MDZH9,(KK^";GJ*
M!L$!W>2;.+=H6W@:HT#8R]:Q;)K5-/W2:A.U0,4?Z>85/+.'HU ?53%*2DZ/
M2+)Q6A.Y-A$'7N>SD)G\,5M',C/UC)5L'\!JOY\*!W9[(AW6-AVP)1/+*^IH
MM #\?<C\3;15K+!#:O4SRT(?.K6>QDI1@A]LRTE"6#"B^"(FDB*V#+=NFE>G
M_<8JS57-F.8'$099(M^:C+I?3WZ!\.'++,M=XG 4:T5!RS+.BT4'4ZQ71L3!
M4J%&B\#1(#ABVQPV,!UMUQ%/O^4'76G3M2,*\L,-5353XDMS#%%*=V/>SC&G
M)COYKXN0.Z4I'BJD?C @L_7KM$HF;/K&J,9C(3K+6BH3.<'$24R!,\1FV-J2
MR&+>W?,-[I\.!7-O#-82$8CB/3<,/W#7"^L[+DGC$&[>ZF=HK#JSKPF9?&J7
MV<X+/ICF96D%EU"<UH48*HU6X2*L\61@TK'75_SR/EO!%S?>=H!A/@AE9P$*
MVY[@EWR"!TLK$WPUYN!QE\>KL:U=S]!"?](R"O%&E4A=(M ]3'B59+;J%UXE
M7T]6PBN3M$NB&$PAO4 >WVJ]XB%<8G<DM74<S*O-?+U%*H:>+LY9]TM-N,7,
MMX6:1ECZNKI5JVI<$#XY]C)_*W7>-+6 F'YQ+7!X X6Z&TA[9W)X2MK6+6AD
MH:8TDU&Z-JL_5DYD5X;%P2KX]J!$Q@W6FFU]N)&2=8@I@9U4%?@O8P"[H,4&
M,88VI2110FR:+A^\Z;]( 6U+&'921*E)IW4?X>K*"QXF9>"K%)3JPBRF:WPU
M9KGM.9<?^V:+; K'[3^%&QDO;(8EZ:9L&7=H)IJ3H#0ZC&%:J#/;Y*+HB;O9
ML16]8]XUIH>RK76*<<:5R>(\!260-B ?)5 5T"<Y#_P!6XO0Q/YMP7BOO/R2
MMRSAH 9-K)[J<FG\N$>(:,8%LVI7H[D!A"*98KO&4#?7\1UZZ\^!'RQ9K'<3
M2:!J*M9F)F&=8)=0(E2A-6"W8>S\&)'O=B/P3\PV<#=78YD6;PH+J&GFZ706
M_C!Y-MYV<AT)R00YD+N0(;Q5J:H$)O05,7LZ!*N/8QXUZJ7<<1-_>7A'_Z!T
M9V_.WK[\%#+81UC<5]6@WD1#D)J8ZM.HL=(#WI# 1^A]YJHJCR&CGH6,?GH0
M(:/>G?M[N/]<FV2 *@#HX+M$PX,"XF"''"6[SY_O!!OFZ[V?+(%@FD^&F$+"
M0N4PCQ7CT6R))IT6/U29&COT/*@?5TE55T2U ]=LGHD1TNO$!+"JHF*EA0XU
MBZ1V=TF-!TY.*(ANC99@WBP2P382V7!($5=$DL0P#S*NK-7DD9/J'G$S5"/M
M-0M,@'XW(B^Z4#WI:FLI[0V]_K8<!D4RJ=TQINLHYY&;:*0]_LC$.LDH<S*\
MY[1_EA+G*_6&3:,Y*)DI5ZF#F<NE9G-9%Z23DA9*AI?D,KF.35:+:?:W]"ED
MGRLM@@&UXW&U0:[2X\I!*;"[_WR?VMW;V=U9:]7VZ^9_/R9R.VD7#?!?4]04
M2+98D5AQ@I[Z=N%O"Z(ZY&0*S-8H(MRD#M-]SY)!S[G7>7 *]J24E0U^CZ [
M"$\,CB?(VZ#*5:[,IC;J"TO3*2OE$&'EX[&^0,BJYW06-'9EA9B(BL"T9%6[
ME%!2#V#(5U%5U,Q&S*&L#X)6CP*3(S,F3EMW6=T7/5BK;&FQMM4F2YS8(HP8
M%.&B3.C.H0M%JGGH2_VV*A9QKG1$D.&[[-B,IGCK(+S8,!"[U=AZ=K*A3R,,
MF\+EBNE=/WR_=[#S O=OM-+#3,<P0[@&AHQ#3>IB*I$UL]E$K+(_T"'J]::>
M*/EU83+;E%,-+&SP-U-HFFNH:Z8^]J!2AC45H8E,:7K#.7.#EP"HH9;<1ER&
M6+-;0$G57"IS.]7!R.6>.YWA:#>]RRU/U]R8D:&5#3:0Q&_.!?I0+\VI=6J9
M*'#@YY--TJ_]FN<)4W^Z\0M=++!=,HV3P!N![SW*&,< .T==-N@<?-S&$F9[
M>]OPY>9#$'D+G!#D=Q:J[K$F!7=*OL**7Q%HD>\5?0G +(DG.DU@,>,FFZ+9
MI)LFI]^+L#BL+%;%T'O<.'@%9]$SR;-Z@@D^E!CC*#?U89-SQK>Z'V, &QJ+
M#J1SBQ^DT")* 3H+N.&G',QLK0&*AKZM@)0,'"4@]9_LO\CP&AA%L(GRU<K^
M!R F/IWO1F@$5ZHG#=IW&I'"TIU&VK0-5(^IR&V'I4-8J_$XH:B:N>D8\=2\
M43;N6M!TTP81;7Z[19"1KX"^+LW-I?E5(D-W:1A-0BX62P\: 0N'?U0DPT>J
MJK; Q'O=<;#AGS3UQO;RZY(D&D^84%*0UK/-1 M;8(QK2D](33[!US$4KA$D
M)8L,]:C.\J]K[=+YU&CE^=G@<DFP\M$K]0T8MH<@1BN_:'(S_8;15G!F&%G:
M80C=70J;.N/ZM7Z53:J-Y!3GU*YUOZXBINO/HD+"-QUP! -D)Y697]4T_,:%
M5&J67VOHDJ ,%:5<^(!=A3YG@WJRM4^:  D&>%1VD)V@^X>JK2P5.?]S?/AK
M<'[\[OW+-R>'ZSP!7U=@]6?<GR[G5HM+'02'_U*$J!2>OPXIAW5ZQ@*0HH=]
MX=1OMKC#TUZQQ3F4;@ZW@G\;('*18.<J(^%)3G!]OQCPX#C RIG7E 92DL><
M@>K6)Q=333_O1F)<G-7O]\(#H2;\#6S6I\]?T+MS!KUQ%O85>O 0W;J1+'@?
M!Q/U6\<)]IKPJ6POM-[);^QZ*Y>02_!%=K>9K9D8VL<1$1C:U#],5,D11JEQ
M?*<O'[/#[V"6]@/J\_P!0WWZIFD<'9^^'9S_=J^:QGU1%NX$Q5PKQ> HRK#:
MT 71SIX1[6PP&*T\SXIN&34U6&VAV5F8,T64HI+,BX@@6T7 </N:VD :R,Y#
M-U[B4I(7;)YRTTVA@L6S=<G6$Q6WK/C^&D<WL/V%+(5Z3H SJ]4T6V\VRZ7@
MI @U [PIA83#D/\5937"HW9#N,]VG[=OFW4X4,NU[[4Z2?=E/N]/51GE^ML<
MIX)VKKH>8_$2R$% A_# KV1RDPCO]N^H2?T6S& /*P1P<0:@K17:W+].P3(B
M!Z@0@$..1>D.Y4/()&.$A^;8IMR+6FK(@Y)"9ZZ4G/XDFBXYJ1$JX#5&A4:;
M;9G:(NR=)%^Y591+07KG-CX7C9%?F;N0$-'XM^A+.'[]Y[O+=1[WYQ!B*S&F
MUWG2U]5_<<)U17407[(+2<,XOII/*\D\RT1:F-O>56D:&=^F+2=;T22,.F!$
M$EQ8,Q+?\RU*FE<GIV] &U_GD3^Z*S^#+K5:"4"9#0(>-OZA[FAFV2)),JH#
MN:IHK%J3<56B::JP+@9R,SD\)*@=C:X56 U<DJU06QK($KM*"QD;V3@I)C;-
M-Y]EJBBODZGC!;3L4"YP67<QQX*2$X2EC38E?4/#9W19DFTC#\<)D0S, U44
M.>="YY8*R?1^$GU@J W(1U66J!!*JQ0E(@:*(L_$WX9*VASZQARY9JJGT93=
M?Q/#@-5&YR7?9A&)5^>#T\/C=1[X8[KLLG19*>A]R(0.*Y:$+^<-OPWQI/)Q
MUP+H.KIAH1C%4N69""'R//93\RS[+#MH9JKP*V7CT[I:=BKSH)DFJ!.!YI8L
M+8+(5L1E*C;H2CI?:[EPS^,A&X5G]IQB#F/MBMC;>_("4>.TJT!#!1,\@2MI
M;W__A?KR'L%[8J>.M8\0$T13H=*(*I-Q%@8W>5WJ;:?^%40W>5($:1VHBEQO
M!0*89,/!1ZD8%\C\ O=U@(/DL5?\+R+SJ[/DGS7_#;=3QAL/,0I7:91@GN/O
M^%+N&+P3&0EQ!V(9!;@O5>EL0,5V ?RLI" ;037K<KU=!H_J[-JKLZ^0 ^7:
M@1VA-,9J?0X0"54WQAHK QR"SW(0M0.K;UD"*&S"42DI 1B93XJ*R8+IOS2G
M*?Z*"M%1U-D$<Q-)R28KVA05T3%=@M?3NW)/>]5841 0^T^?O-BEJ.]VURB1
MG<CU-V)VL.<BQ$%T^!OSS,D8&49EXL&N'H/ MVZYG@2!=W<>1!3X:PL,>PZF
M"@L 81H^88#=0I=HB&$&TR:>%@H/G(+2\>SIBV#_^>[3$&3(%1/Y&O<8N\\=
M(Q;/;)2D=>&R+(T(=@AW_M45&JTP&X3-0$HRE47IMVKTO08;:'#ZYSJ/_-$'
MWZ_MMFY:S(EP,MX)[I:",4JNHRC 2JE<*X19YY(IQS4U.R+69G<EVPA))>.H
M(/'F</'I?!HG>.EVA108]I.!X=$,,FH28L.#+(6"!PN[AYQ\%49K40)CVJ<8
MR'66)A\0,JUNT.!#P!Z^-9_1B-"I6 6[_VXI<X3!6'(_.BO$:@!Y4[,Z8$ =
MX^<V;>JK_(X?QVG;W6F^T! A<MUE^'1"99GST8>'*KY['=,Z+/*RW.+24C8+
M-B&\O.11ZU4G_&:[/#75K^*JI;C.K\$&AG/V2L6JMVGS*!-*5/17G29_DJ$A
M0^?.G?MF$-%UT5M[P[!:@HJ:4D&0NED)01.R:QECZ'./;J/.%?HLD6EZT2=1
MK#3N]0 ZAC49Y7S3-FA4>^'/$I>97H9)8!$'Q643RS@ET8\&2,%K2L.%UTFG
M>K:K!FF*_(7P>1F\56E,G803<"&Y-*O=;+#/,EUCLT25'=$[N"#]FD1[-/5%
ML5+Q.%-#Y,,--F:SV?;0]&T[EJQ)O(MOP%1AS@68X!SVNTA _%Z<UML='!0+
M$[Q:R/VB>9Q%TO9UY5:Z8D)\L52=P1E%=:6IUM %I^,*!-3P<\]*/,CCN4F%
MMG0;-@)L60?N!]/LF<ZRU.0\/S[^IN*,CQ;GH\79A(&X1W[<@'9TY>(:N(7'
M"Z/3YM%(<_A*R"B+/L#OIBD2FVM(&)NY['YVW&4/5=#\>G;Z.O@-_K'.V_X1
MT[#TU$^X'JTI_D%JW^X+X:%Z%\WI?CT3/X=4^%L]03C_LZ.4MU/@@3K,9AP_
M_GS[0*LD.O7R'L6_;4T482X6A 2]E0MY"WD5*Y-<[BZ24B5B=E%T3I?!I>(-
M9E;)F?1P?3 7G@[=FRTD<V]-84L'ARJHP N(JC+"RHDEY4+;2X2=")201&X_
M OTY)*=2:B?)#!+1*Z_378M<'GF-D)[@B!)R&Q7EK?,SKX0LTV?E1!!@I2M)
MPIE "HF&/FY*R9#'@GNPQ2X#N..P,@R!!%N=6>L]^JVB)NXY[HOCP_?G</L=
M7P1_#,Y/3TY?>R45^F'RNN?X4H0WN?!HR[KDLY2TR"RV"D_B3:)FND;Y7).E
MY,7<(9B$4_DK$D#^!O_PJ5=,R=115.M[AM$$-FN+CJ2%Z$:<9!_G]1#N@"%"
M+RS;5J/?WJ5C%5D:T& Z143NQU"[%/$>DRPN[EP^E$2R6.&C.'BXI\:*X,"8
MIQ_?<+W,2Z_$%_;&+PZV2&)UT?:[I+VBD3LN4XX F<E$XA=^)\I7X[VA4 K6
MX%.3H5-.]V4>%>R@E#Q3(L*Y7#I+CT"06X].7X @NX] D,_C_#:"P4/V:I-W
M1,@KK+O%P$JNJH 5HZ$#45HV!.04:^X5+ 1:=93EY%*I391;)H';$0A?AR7F
M7G.TS- %"4F2KO[2WNY[7W!.B8\[25FA4M5^4>?[%)/9Y))JW&WMJT!?G)J[
M,I52B@HLJUQN,UEZX0G3<72C(@NLD#@B6::W1+HN4J$E.\>A+-]\HR2RK67!
M+UEK/?1373+O3U\/SM<:;G1;BKQ-\"('9#'?LME'N@[8-PDU.SD\_IPIF'TQ
M-9:;6&NT=KW&F0QT807-FN5R^X-@/AF!D.>(*A93AXO!EM(DZ6M!4(8OC(T/
MG_3_UN"?CP>#V^<(K(Q$2ABC&R:CHO311T/GSFPOMU9(%@,(]9 ZE4K=G*NI
MKR2T?4IV>1"-9;NL9U<-^&Y*3;8Z]:QAM5RN56R?6<ZUN23,:2@V6[U+.XH7
M(XUFLS_;#[9@_5+Y" ;-)Y0=[<^XOU7?U'K*5-?[U*CX[J>-.V7:486E>(#%
M?U$0(,]ND9,H04[ P(MT)?(NS)@)*. KB-)JIM*47-=NM?%69?A;7BT^Z@C-
M0LWN#C(UR6.2SC"GP8;0_:;S4#^>9RJXAI8*P9?1U,V#C=V?=C81MU8RDLP@
MXAK3L@ 6%TK%,'I%!FN"33[O;I&&IT>]22XS$M+&AG!'$+4YGUM%Z1WI+N*;
M7/ VU&-YH6=HXL#UE%05%^C#:MB8+X%@IEYSJ+XZ.3]<[;$2$E6S32DC;$:&
M 9619ZHICZ3*5CS7%-9"><"TI?0L#HS*V1<Y+#K#&/E<BIZAZ62:T1S\\US!
M<&"-C;JDSR)I&(8"3UA*%[SD?E3]F$/M:CD/U>19-_#)GQTT0CI!TT]B=&G2
M7-KX%FMN&Z]"U&EY76'*I-EOFX8EK8U!N6\5B"[$G#D\#57:UZ*)Z4,T:5WE
MCVV A[I#ERJ=YY_5*%\#M?.;0L@,+ 7J1,I2GW(-%_@OXV8GYVF/:":3TKK*
M0.<!#48HD00.$_S]I!5K].*[:[R.=Z*YQ5"J#1_.?>V=_F>A%J2"Z*+E!B?2
MTI%M#5M$#F9,2Z?9+76-;K@NX(<@_(E@J<Z0PQ+=W$C7A-&9-$HFGUV*/D8]
M^Q;UW'N,>G[>2_AR\.;/M79Y/=[!GW@'&S&^ZB3HVRZ8%IGZQNXFZPH=K.J@
M>D\-/(C=[-YE+6G##B((KN_G+X*-O7:;@G5J1(8M.1(;O GZG2NP9RK.21[7
MR +H^;0<H!)%@O,QOQ2_W=AW7BR<8.BNMA&[>XWF83BPN_?**]$%..).M&TJ
MYCTRK@OR32TCWA<N-Z\X"OG7/N+:)A77(89I5Z&A^4%2<([EA^(VT5FBI:9_
M[%0'??CT"2^W_UGWA_ZGP>^M3_[>^+/Y]>_M#T[L;F->]"H*WA7)303*%-?]
M)#5K +ONN"[RJ<+:!+!C\TDR"@8P<3UWO!T?#WKA=R,'C)U"V*8P_SV?NO>]
MF+G_<NIWEB$=<!"\O\$YB_,)$^/#B?P7])I9ZQLR;YTEWF/H:NW]FB>X>%X1
MS-EU'FHV%@J2.&0LXZ1$VE^F8B'RD;MX-PU#';LY-X68 ",O5V!B%PPNT'14
M.JL;>S9O^5QMNK8M5YQK7:;E((5NO#\].3PC2JPP./\CN!A=@S6>JDV#7</!
MZ#%:Q@1I&E^/7EF*(Z&OE*_@*&5:A&2,N F'6 ;AY[4 K<ON#.62W09$AX>J
M&7EJ.Y<AX$J?VA%!KV56:3?[L37S[*30+4[R3,V#-*)/3?V=!PVGLF?PE9F;
M <_-9?1QQ:67B%(#'4"3J/B@*K\0]Z(X !Z%K]/I[OE<Z8QA44"+J(F::;\4
MF:CP\Q3^A<)$$Y>T9CDANEJ<U<(48U\$71).E].HC*-_!J_3?(BL(L20$KSE
M1N&1(S#>".6ZOVOJ/UISBT2+(6(A=1Y7UGG+!H@5P[7I))"9J+S+A)77A4WG
M8AFLN?^(:O<F8? VG' 2.S8Q)1I5*!AUN!PE-PFE&_%F>B1;2)%SRE)-)S#&
M-:&)HP(38(3L(9K0I2;=62B-L!EH?E0SFAAE*/)^-A]S2]O'N2K)K<I4$5UE
MZ/W<G"7H+S=NQ2DXM_7VH4K%9:KT?PW>#4[7>=R/FNC::Z(&6;. H(<EV7]%
MTRA#U:I1>B*(%4B(M-0WJ2M6G)N4?HYX$&3CLK*[K%Q]U;F);ZOF+O4("6&D
M7QD1*HB9]C*X)MKWD*7J0]?)P8L#4RX7Y-H%0TJ%L9GG W1*A/#"O0/?[1YP
M?H5P%GZ"'"0R([AVR.UD"<>:N "\R)CX2%=7U+^9+U@KGD,#%991-);&TJ.1
M86!=72S7'^AQ7"9^?SL[/W[$L*[AN#^K^%VM7;(,X.0RM3LJDT8Z]8P24&U?
MK?8J0R[_WV"ZH@8D+.QBM]>Z.$O%,%#5:-M<+]**>]=)H 99;2,M8!F(19Y]
MNHATVXE#$IG.H3.IKC;O/Z<IV;H5[55 S!8G:\A+#$+R*RWU KOX,>O\]O/0
M%_S%_H/ 7ZS%Y;=,V7ES<OGK^\'I8]+..H[[ =F;0M*"C.T4R=!7WS_R8:"E
M+UR-914-D4V6B6/P.D4F$TW"'N=8=ILR)7.X$C$RSSF3;.#8#T?19!K!Y,!E
MYU1GY&L<9HP#%S1Q,%D42A#'&F+ ;Y(8O]YX13-!@'"N\9%O!Z_.8:)V6V4O
M%]B_;^"Q.LJ2Z%%I\]\?ZN"4I>_!>BM4><@6*X\ZU&"W;!(#23D(!6M(_E6Q
MA74K6M<Z?G\.ECS9_<W]8#W<\AO6J;Y%Q^3;X[^?')ZM\\ ?,7[WPOAY<"0/
M7+]2Z[@!](,^4JZ?X+@"!,;1KEV ^KL;V*\-W3.Y!G<E"+LCK(_^=QM>[QXO
M%C?D7T2R@?@M+9"-8UM4712_!YLQ3@QJ;4E*0^B7/K"H-XS^I2HJX!6Q26FE
M5]L[_A/S(;ZZ]G*/+K)X38@5[N?]I]-J17TVR-?V/_\D/X!?;\>23=AXH,LV
ME5G?/-E6VY_=<3S%V@'9U5:JQF+GW3*Y6ZN<W;V%LWOIGN?Y\JF."F$Q9'5W
M,+D"'>@D&VTS^&4&FG+JLNTB52B59/S\T]_CG;S_J3L91-!-GH)*!_/VK6_8
M)PLGT=EU!)D$.V8P!M48R11*0T/7)% A!C,%^Q)+^R2-ZJ66R5)?V0X3F4^!
MV:"J>;#*UYMH"&-_ \9L4PW#27\'ENMH3F5T5I]HX6X.3Q/#-5^JB5FM C2O
M_"J#E[)&8O=8J&WGJZ2L2/"! $RPE#0\=I8I>?20?*O!49$@QO[R.J]+G*>S
MZ ,8](=8-"XOT*Y^OKN_!R;=^^V+[0&TC> EYLIK[E<R"N-)DB'?G4=[Y"A?
M476KQ"95KJL&7P=G:Q8H(BV8:+XE4JBNDVDP5-5,2<D\J@YOSV"9H/-=$]HZ
M/4&=RNF)>T,@XR3RY9J*O>;NP=F07J!Q7,J;WJJ/R2@/<-*P4/?A]N_;/8>?
M4[^WN-]] **##OXR*AEBI3%.5SDLTBTGH:7NF[172V@3H6C%G<_\',M4-09N
M:8W:TN27K2WFD6B$@3N?S.@AC1'2%E]I:,'L'G:L D>@FQ$(6;_59:1]0\XP
MR6,F:&D>/Z0YJ+BV?)+QU\S@WZ)!%J(B_ &Z^ K7DEUDOM#0[3 >PB6S.*JL
MK<(.JJ1;="6BWX==B[%"*E9>9PG"")'"CC:(IX?",>7<=TP0-.*+\X<H=0U/
M1.A*MH+Y7;B.N@ZT254']*%.5.8I"O@^&'*2U>I6L>P Z'5"%GX 2HP-GD(;
M#W?I$7N=(C44XUX+-9S;DO9:LL@1EX60.2E*E0J*:Z2+L9E%&1;ZXJ>\^2"Z
MBM #ZRZKU@8Q=*RR,M)MQ-$DNE*E$RX7AJP;LV_<\^_)0A9_3>W0,@^9#<::
M"#IQZS35)>VCF$K-HF;Z_]J[UN:VK23[5U#9K2VQBO9:LA4GX]JM4BPET8PM
M>R4EWMIOE\25A!@$.  IF?/KMT]WWP< DK(]GA"46+6SD4D0N+B/?O<Y] JQ
M[=$T;H>T2.7X(_(1G"@02P1_T< 9*[X"I*\!_!3$N8#U8@=WXO]^@GBN(<&Y
M>O?;>QV[1'??$MTO'D2BNS])B(NI*6#+7-+)5C#M!R"UEWN%YQ;-L^-LDMF"
M*\#RY-VLK*Z-?- ;-_ (]6?D!9HJ&<]-3OX/B>5XI.1W_%$F-D]43H;F=[(N
M:8H1-Y1WM<G?29_?P-(89Z.,5-*\X/ \>7-X?Q'T_AI2%B;E.T^R>H(ZI:2>
M2[EOEIH4"(S_\6\'SU^^@OY!&\5DE.&#YZ\*_.AH/+=5BIE-WDW'^.8%?3.,
MOM(H^X*,CQ*6-'F@4[U!2MJ 'I#:"7UP</BJYF%!SU7 94\6N%Z^P@.,/FO,
MG2 IF5,Y_4]X@<AL*4&:2_:8KC/KO45GR>\9#EC3ZXRG8M6\YE8FA'Y/%C>=
MI:L,#D+"VDJ^@@T^X55:J*>B_\RQ$EPS@,GE-\E+&K6, ,8Y_6LAYK6^D3@?
MM)8I?46K0[>XL&,_U<@9I/%L6[DE!DOZV?W:)B%- $U:Z8#H,NF2?]S1N]7!
M_(MY,(O#I%O>_.(C6F!X7N.0T3C(F/?^U,+2T8.I9<?H?DP1WZ=5?.R1TM6A
M_1-_:NLULRYRJF8+M])S,05H0C"94^'Y-E)N:6>ZV<7!&C.)T"["_WG;VX88
M?V8>^];]K" _=B^\(#A!V)N%;%8-F$(:U['08.2T8MZ>_%N3P\?C.#^I"A1@
MX5_0>$=C50VOR\F<5<2$? [HPXE-,P2.W>K]&9N\+Y8=%.,;NT@X$8"N?G1$
M0=&%F:6+WI>YJ&C4L3W=:!%&<K_11P/VB]TV #OF2</0@/J/'?,QBTLZYH6I
M-3E0&3:ARC$MYS_X;[KZG\X0@*4'W$D'A\]>@:,IWO>Z2B%-$"^-E_ULN=PK
M_Q=R)\X4-%:X<SJ*,M+(R_0U_H2''VZ3ZQX"OX35>5XTYC.U;%J;>T?KA&B8
M$5F@[D.!&"$Y!C\'_D<EAU<MR9,*-]OR)(-8NSW*-!PC'&;$C<D1;0*E6%G=
M?\3"KH7-[8 M2@1Z:?FNS"VM%ZZ;SE,ZW&PMXDF5GH3U>WR(K>L->(:*O]8=
MX:W*Y@ZE9_I]XD+#C@PYFO5A GHJ,9$*'H1UNB7V//04T%\+"1FW7[)D6=6T
MOU8\+@@XEZ-8<O9+S(GF*)I?RYF/3G)6J5\X!U, ^:0EZ\=Z8O^@,<LZKO>K
M4CYA)(0@6!]NW+KMS:*2CIWKSQ5<DK!PA\-H7L)=&Z4P%@W[FD5Q)#"Q0_)2
M_/-&UH)Q91 O-WBJ]Y8D?,H/=3NF\OL0GJQD+DSU&2]1-+8?!TUP6(1]X5HD
ML2JIC*,>N*&1"7NX.X,S&I/8E(B"&=@=,%S#XKBI,E'LH?3KA>O+*KNFI[!J
M2RW=+#4\]R58FI;MA[ J+K?1N+7!W_NO^.1.;?7'G*4.1SC:FC->81\06B)?
M5"Y$,BQ5T5\'.0-Y)>,&]:!%7;P[/)^89H-;^))%R[LT+0\4(:KVQAI*%,W'
MU!KA-!,[#@99$C9ER%+"/]*,9IH$KG7I$W8)0N*$/^!LBF4Q[M(G,%*BR=%U
MB902/;6ZSJJMWNB[!J9E_->!.!-U4?UISFYR=<8H15JKV0(F;S-?^](FQS("
M+%W1.N?ZI595N_=W)"JA[8F-9[JW_R58422)FL:_)"\"P.:N'89^H@CI;JPE
M%P&ERFR:,^FV6.9/!5$WE4J)891F[2+'!EY0S_<M24?4II=1P5]$+>J?&'.,
M1D\7T+; C\N][VF*NAEIB.>V(%!6C^S8*->IU')\HCOBT8VB*C_;-"=3SF>W
MRU[<>C8>JUW2.F@(K#*=CV7FD)90BE[A%IGPL&5R67/(HDDM0N.V2\NH._RR
MNSSOUN1Y#W=YWJ^0I4T"99(!P(R[D<.CQZ)FVC.R<NB$3,EN\MU)T0^#7&BT
MLC (CNO8#"B.:G.XPD>6W,V*M(D1W)PV\S;3*W?Z<YPPCN2N@M*1XAIZ :F5
M=Z(=A ;-G?-0S39BM$OTIK*$F2'+31=5#\.4_])D_]G)Y:\GYV#WV6H[9V??
M?:U]]R]]ZVQ"]E(^^Z_O[DP%_S W(YN/GOXQO?XNJ:OQ\L\;^O?%X?33JXDA
M!Z1XHLKUD%[^%E2#)(+TB?QP^5J%^?<'+Z:?OGMPB[KV*+\[_W"TU:SINU/\
M#6 F^L+0=596=^1L-5">E7TT9HR.T6TC-"5P6(8:^(S\-92PHNZYP0<8'@+H
MJ7JX'*B /F=V")MR2,84$(E GO+<M8"5<H@869A,YUI=TC./&LTK#KDPOAAO
M-P.Z[8@MH"<:_E'_)>E.",?"7[ZJF^_T:WEG;]$BH'A6[FIR<VN8*ZD5?.Y,
M"KD9(IOFJ?WNE5*?[) OEB-?L#'862:',"RK(9YX=^%DWT@"E#O#XVW@X$K.
M?WZROW_XXU"[L[DK"-W>W$+N=E:T\@]6@JUEM^Z+N#HM%)T_'RY9\':4(D;H
MCDA//7%]S&G+9-5E46@/OW-S . ?-[)5;:KJ=NT]H%2F,QH!35T>B<K&LW1;
MA3=XK:S!&OE"(RX07[A;0UV?F!>8?@_H_[DP4-%=2*9EM;AKLYNJG%_?-$09
MQ*Z<$F$P!DKJQ'RT*KFN@\!\H-M[G47V_MTCHTW=663]0SI%:W-]$TDR!\'I
MA%84Y>EP- \XMN*BXVR8><)G:?0)0$XBD>HE07='*$Y#X0YW1=2_OD9KTBSJ
M6W<PU!Q(IT$SGE=62"RG!1,5<#S?OSE+7D:0TJ=7'M9U& $S2X ;V-+<NOOW
M.>H:JEP1'5S<_^ 9C3XUBPA)A9LP"S1*"Q*U_E*F!J\_LCP#W(L:$Z;0$V]-
MEG-ID[:IWMD1"7S?I+]BBAXN+O3V6 ,A+],Y06W@8*](18L&/1GCX6(?-P]
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M\XJTF8V!YBN;%;=DK+._QUI/,QBRNADW[OC-Z%@KAYHB$4V.2"PICEG&-;H
M=*%-DLU"47^(4+M([-BEB9WB8T0_1\/V#_1%0*-!'?(6 0[.U4SST_)8>-3A
MJ7Z_^9]P+F;A]JZ#2:P 3J!#<X/A6IYEU<%RHZ(;B<W-74U#^LVGS(^Y&PIA
MB;/D\/G+_2>_.<WI[H'^]<IE7O;PC;9&O_[IW+7^#M=/ONNUD,@Q3EPX>4M
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MX>'8,8#C._>/Y(2>>@M0@UD](-.;2_$N_OW0!;HAN202[BJ!92$5ZB!$!:/
MO ,9(0UY^>'X\)F/1G*@DG&W@)F0-WX4Y<4%;82N<MD6OWJ7T4-^EIS>VL?C
M3;[X\9R]4Q.?PQR.\$.U?2-G*>Z(/MAC>3@Z"034/\M(;P07ME^L_7ITNM9
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M?!5NF5*TRE.$'T5ZY@J%B,KD2ZF9GL' +ERBLI]F$QRV6%_JE:Y9D(W^,EZ
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M'@R:F] $ ^+<F$W(XJ@FW)*&=S)\YV<E&L/R+(_F#AS-:=_A/FT6@G+(2/J
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MR5K&A%@<59*;":^SNZ4I_#1OQRZ5IEH[Z>8MJ9H&D2W3&]6XAXBS$!YB)EB
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M&Z__A$/_\?C\],_-6RGKU5@6^U('%ZH982D1(<]@B0J39J:I9:3'KCE+3.2
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MA>-T@G?Q7V>*@0J"2LP]P!?:4&!O.-.!"ZU#[P5\)-B J\GA^0;:VHG]H;[
M%*7GWF-VYFZ>:+D']N\MT6*]!(H=>97\J;=-3%7]P'[= 6$R<?PZ)89_2F3/
M4D8-(_],^W$ 9X""[4]V ^+WGFMETX]N#(U:,MLS0$Q)_!K,]BI?TFYFO3?3
MTIC(Q[/ST^&[HQLQ2O;UW1_+U;J,F0H;2"2Q"D[0F P.I(7,R@NLX\(YX-;A
M'FDN!XZ,EXJ*C*(AN\,!M1X*7FSO[ADWVG17)S4Y!!V]M[.S&VSLEQ>WS#_T
M=4V[)T]P%N ,2S1#&%3(73!2<FRPJ=15E*T0ZO.#.;2Y(SI!>\?L$381^#;M
MDD&I^ZB<^&;]+?$$<Y,40PD"QQ2K*!N19'<6$#'FL_SU[NH;/=;$F5+#$I,G
MN>#1W5<9#0<#]%!_%/I9-8K,"?SER7!KWYR\HS3$!#J.=DBI'DI%X!'<??GR
M!1]!3F]K"SN^*4_A0 K:3.2LHT=/+JWC(DM*Z.]3Q!^1;:&^U'V.>[=;EGI:
MO;(%G71PQF#+ZW$.0EPX$W%L4/TU+#O\&/P=O';X\6!W9P!O0W[!F-*>X(8;
M4 2AT&WJKF!45GU(!,%'@E3*I^(]R0NQV5X5.GXONI:H$,9QHH4%B]$:(M%&
M^D(E8WX.)729KZO]P/0R2RY=-U8S1+:2Z1&-5&+CB?=U7U]KJ3[:J>OXWG?J
MZ/8@C-0AX7SY9NM(_'JEFR9VO#H@N7&-V,33=DYFUF)&XOZ:01T;88AHE'L<
M+^EMZ#% @F]3Z]D9"+/FDF/=O#W1YL"C]R&=:2.!,Q53^H!L*Q?]ZRQPHVN%
M^L>0[H Q!G\R47.NS49<&KB,A3(9Q^%5R$EKY_86MRK3U[H!*$GP6 U&D-F(
M#+>4&N69BH*IEFHW-@JPS P9;.-Q3$!H>%4\@ZR_I]FE^"TX=2.5*,.O2J3*
MYLX4 !V9I8+;3.$%+Y"N4MDN[8F":R)E.TG3)=1:DG*A5'R/G^\^ V/"N\YE
M^]TOF.T1D4'QB&V>:=]8,-[#JE6PUFEP=K3UAM@&^,_*E'GBSH3O/NE\-H9[
M7I3T_2J/W>9#M)%>'[Y[>_3Q_3J_^:.-M" V8*TAIDU</[.)_]>WG8+7.IG4
M/<,E:0+";(!CCZ#YF*,0J@3M,:I*0ZM+E@^"PCO: 2P.^[L"8BIX7O!HC[V\
M9^)Y]21%35/E$5+0 2EX^@@I^(K-M=SJW62+D@TZQZ90^/P.CG/!?+N)/8?3
M=G-[SS ER51-ETH-PF_&.>+PD94 19?(BU+Z9Z. MI5!'B=&G?FA_@@1;>Y)
M+BC$'8(R4SA)CZGY=_[(]V';(_D\^D-8]_<A@_=TX2WS=+\2QT3:+9='QVSZ
MOS752/0Z6%TE#4R8N\&2L_L4%<$56M$T^T*)X7AP0%>99KP\CV1R7Z$OI(I:
M=AB;\B(1?29]'>#7<4EE0&BYC[,JM3R%5WI$"'ZQP!=-UR"XNKK:3D>C[9&!
MC]+U_9+TOX-PC749\M+"D[@8?]_^C2U"PORG'_>>/'D5Q>5*&RMC0ZS['80_
M(S">C3PT,SA],;F&3=0@(2*\%$T]N@[RJN2B[+:!ACYU5DW@. =IEFZ9K\=Q
M"LXT5T4BK!9V*:%Y^>2C5TX\[RR)17)VC"F)/VN"'=DF1Q01N64$C:!;X/5C
M4*'$"#Q721MN&$LLY(.<B,"%V'%L%*/)!F, 7G5L%TVE(+L(;NU(AJUD%?GN
M!TB:W7;*S@FYOR=GR+K.0_(.C:[I[2E*C8;V^QB94>,^D,C83,W91Y&(5@;2
MW14!>#\VE;'NF/$F\LT&[R'!!AKZ;6/[.@O)A<8LB9()C.'>'//I(-+<4%.Q
M<V%XEVJ=7ESLDBN(P2K8UC >#X8U"-ZK'(X\_NOO5:J#)YR:.].S4J[9V>2X
M(HD&&U>48F-.?$65-MJ[5COQ3YA\V+)$?-J>1=_*N/71O_[8=^ ZA4W+";_E
M@N"^GN:E :G3X7\?O5OG%W^LKEO\LOL-1K5WZFK%J9;7\T;5V/7%8@YE+55B
M=?'@,36\SM6_8H-S*@P?0@T@76\<0+3,1!=![=>,ZX7$!)2V6U 2UHG7OG$:
MB/()7*I$(%E':EA/ 9D?"HV><0!ODA:ZMQOZF+NTP52\Q?AA'Z"2CV6A=U86
M2C6+[K13+E,@A@C)@5-)AP8T&4WX@$L%+1I-SHVQ4JBI9F2;N6%W1['XS/GV
M.KG2PY@7E4Z9XYT25I9"HMXI\[8S(Y:A>?=O*K97JS7T)_G^#/L\5XD>&#YH
M_Q5JYE2[!$VZ"X[C+S8V1J3=.:%.L6)$R[_AH7*O2Q%&C?&9XL]:/:>TK%WG
MS?F8GEHO[(67;G(='F$C9],XC!.&X+%>7PR^*ZK1-"[%^TLP+ +G(%&YK846
MTEVJ=&(RMB;.@1]A>P=):-;&(/E;$1]J,L'JE]([KA)':3X%GN[7P,"%K@S&
M>'T?S_[W+D(D\;\,L^";<:\F_RJ^AOXKAH'XA%'M?0T^@F<%#1OPR_(218EM
MA$7H!@_M0$Q8W'"*1BB_H+Z[S9=BEO,F",.T#JBA*)B.$:4Z1:"%[T3ZRI'P
M3C*5NK_A W'6<$Q>U,M<<2GD^02S-Y]>;@JCE:<D['=P2QPA#"G._.]]*IG;
M67#VSFZTY$,BB29FR8KV,$C27]+["6N8/Q 3A /)G00:J;XT3'RKE, $'N*4
MZ@(KK-TSU%_.\@5;1!7-+B/N:W/&N K!IX K75B_!7]"38,+SML,T[I8R2_\
M1K+M.<_#J!\:[Q6"D>R<NC[%YI 9UC9D!RI+,@L,#;5M],H#7V;1/N2$Y;/'
MA.576:CM\],ANENZ@81]Q'N_(#&8UH0W'3INI==63;Z$7FO[ZFOC3!_?O1VN
M.3K\'I4#_[G DK(F%-4SH"K"J@ODO\21%RY$\KI*)JJ-7_;*@B6RBY!7#+=0
M,7D= B#*PDLA<R=R+[#.5SS">:Z!\]0-ELUZ9J- E 1C:*6C@EL3%'C>?.M_
MDE3TX+JOWQX'ST2\672MH8A&RB&P&L&818MV"_ZY[3%GL2W!M@AF#,!E-LF'
M>@UBC?A8ZF_L!FO&ZKMKT,5XL2;+0Q2Q^\/CX<&="=B^..@WBM>OT0K"&_FT
M5N/@C.-+*W;#;Q3*W/AK\X%%,YM]HZDP$)07!@;+^CJ2].*.>>0T;;!T(EM1
M)@U#<Y30S:6.UKL#M7&^T.0=PO=$\*9*XEBE(DDJI87'PZP0ZU25)NIJ7"6^
M'XLW1DL_O,"_O+&8#H@X"+_U(3Y1^@JBE)9^?W1_TA\:=7['NRFS^M315:7S
MS8%'=>_QS5+Y%>%]\?W0Y[698/[XNF0)WW[ QHJ9+Q@IM:*B!]C9)7^2B^ZY
MW0#HI"0F2EB)0^QNN@L9#,B#O,HQ3I*:E@5XO_K:>J]NVT<9UL%F7VGFL-MK
M/(I]@R#)T@FRB]/8P<RR,]Z@,FS>-*AO)N(,Y#BN1*#]G@L#RGJUN/FXQUU"
MJ2Y#E4>A-C4E,D+B-S,='^A:9Q>.O*]XR2PK.NMR67JW8%YC,+%69E5>5(K]
M?[<MJ%/4XNDV1NH4CDZ5NXDRP8.N0\BS6]NOS1[I7Z1"?<3909D@F5*0&I$J
MN][4FLUX']A>4DY4Z[E.:Y-G6SG=PD3=F2,9]B;Y CQ8 J5ZQ4C\3@:463]/
M='3L_B\&Q%-'0\'=U3&$6EP?GYYD< <9SC:VKD!;WK*N&T#L)"-J2%Q%ERGU
M9I)^  M7(&5$7 C=I/Z"U\9(;2V[IB"K+DXK;PYDJRKR*RJDO:]/?%.&&'&Q
M( =["]'@EX/1,Y"/>@IV\<*1C+A%P;6KW5[I1HZ)%G4,QG=A]KH+M;*[LV@(
M_]8*4]SQ'JCEA<[VE&TGR[6]U4%&\4& 7B>4^S,XQ=X UIIG$!?5XZC% 8OI
M]7+[F04C2#/%6DDRL<B6I/4EN$I%GXI!WC5[;>#5X$29YH2BP:L3ISH=OS%K
MH$$[)+NO4A6I04W)2R&I<M*6Z6\);,?(!%/7"DMQ7YTS! 1T$T9[@%E)1\=^
ME94_O?]5Z9$.[XM5O>#X8M8*T4CII,*R#\-\5:R6'C88!C(R2CTY*F6*+D0R
M2"ZA$* F9W/,5X6UK^@4PH_XG%DC!MFSU*6*$U,/]\$0*>)]D:8:/8%"' 6X
M"$T)-&=(#V-2R+O>46AS3FX@MBE:%?C\&)OI+(R<>.,TXL# 8XVA!^]WF$Z2
M&,NZ\4BCU>[?!*\7@RJ>$J2\1)O6O2#<@"<41OY;=H7\S8.@FM'SJ5/6H&;T
MTC194=1<A-;CXQ1&+PMVD[GK$+<W%9GX^N!PH?7MKP!FXD*"X]HVU/Q&=[J-
MM+^+N)V:/PILZ[+[XE6QF)1SL;Q]R,FSY_<B>;8F$G^-VDQVA;Z^7Z?)WD2^
MT-7%X!!ZR+4F2W[?-^]O*X8:/0J%G; J"L-6;$D'T4*TQ0N^9.>&WZ@,",F?
MZ@2;)V5C;+M(JHP#9)LMGB[3:"CW9.["#I#XAN,J+[U6V_57'#1B,'B+&S:0
M"C9JW=&X<FB&X[!-WEC/Y9L>?R.79YKINH9IV:3BXMR4-11^5_#%BU9_*3;C
ML[Q#O^/%G[6>!7'INK+%B5YK^_T1'WB[A@TK-<B_S\.[YV3E^7F*Q]JVE(@E
MZ2*=,O6>5B[X'T3@6$Y2,B6YM!.=4"PS[V#V-.$T:_Y;4#(\3TH=_/*$4GW&
MH"ZV9/;!,AP>J(U"VO3&PN74K*.T$4\/PXWO+GTU^I;\7^6V^-:G\99SL6H8
M!/,%%)'Z9_ VR494KXI="A%G\%F7]X1I^C[@C<XLYYM!L8*8 >%6SMLXW($(
MB&PFI1EH,9(990#(+O(HXJ)O,F+E *%6+'R312]R I"$1N16*$8A(7>)3<!^
M92.2DJ#4P42G.B=H6 OZ;4%C:#,&%)L_W]U]\BS8,)M4.*D_X>N83LEGB'-&
M3ZH!5PHQBR&6NWFZ=2Z*A?O((I;V#5 >D9I$284!,:]0![%*1'%0&>QU>[]U
MM.QLOC6-:?>5-S'PO#26%S#?RJNY0=&WKKX[-G3)J*)UJ"JLXV&?8?&KQH5=
M,W^6X*7^\.D8//CU0#P%>KH;L23*582R3$?\]0AAY]^I[_*2;;R4:GC_]6J3
M.-Q)V6Q3R2LQ;0:,#?Q3D&<*',5Y<$40-P+6B3$4(X,_ZJ=ZM9=9-;:Y:-/B
MD0VYPRV5NV%2,JZ?C""[2@NS8VRG;RY/G6ISQ <2C8:AV4Y%G-57E\2\Y!6_
MTOCY%OYMU]KI^UI$W6_+>M&NP7L_\-KX6ZKM>O:.P4^<M*/BT3*KE=Y<763-
M)F0=K/FNY99#,F2SQ&DTL-:HIR#Y3A?8V6P#KUIQV_O;"N0/I_M]&JH3T93
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MY.39C71YI;5L:F=J4I$(TX&-N>S/*Q];E!\O;.,DX0J"%[);OTK >V3C-D)
M%#;A<&1H,I%3K#S"PA'+9X%W6Q*<SKI'OL'C,]D$'HU%=E'?3S8U+2\ F(U"
M]HI+TCB$F]=Z%8U59](-X9!-W#*[><$+DZPHG. 2YK0J%V18XZY@4U53JHYH
MC!6_O,U6J(N;VG: U[P7=O,"R*<[P:_Y!$N">O6$8Y9-CP@"JUE[6R_R_19Z
MC\M82QO=<DP_"_]@H5I)70L&5"O?3V["(^.D2[I8% \]0"[?:CWB/BBT&_+F
M>8&F5<<JETK(0<W%XPK6I:&!Q>1ZN9XI; %87FMA-92%?[QN=+2P1;"YWP+2
MV\6-$6&DE#YI 'N]&>)Y:8=.P$0;&&84>54_(%)_8:X'U;8JVEG\[K1(B\.N
M*3<G'%G>1EA9TUGZC?]G@RM^U*51:&[;F#).6YR<KA"<';^( N-<6)8J1$'(
MH,T8;9_WD:9"5IV E9U;(\+WQAJSW Z0R8_K?HP8(U[4#YQ^TN"<ZC:W<CTM
MX3;@(:.TM$:-+5ZN4G?+1:%4?\?C7<R.^="8'BI:-)5Z*??&B+($K$+:@'R>
MP'; ,I]Y4']AYR+:?)+KGEGKM;GD*4NX+L$TJV:F80=?7F]79-X+9M6M1G,#
M"!4C0>=M$,AQ\U\_VOH<U&.BBPUQXAK234O;SB2L$^P2*L/(C4GLWQ@'/T;
MJ=L(_!.[#?S-U5BFQ9O")6F;90&=A.,6UE_;3GYD(9XBK6)7MI&W*I%88]U7
M'G$432"R^,YA@[/]AIOXGNK@I?",DW<G[U^O-Z?< T=H+'W9=VH$PA8+$H;.
MKJZQ>ZW$\JK#1![IWZ\/ ?FVJ$F;[Q*C 2[NLQUREG=?OMP)-NS7>[^8F=N'
MH4]'B$KE#;&?17ISX%4N>*EWB;5Q]>Q(IWJ,EF64D<^&]E$9EU5)C 4@9K-4
M#-)>@QW!M%;YO =X1QO_$-K@;3P*.?'7T"+,F[3#;"*3"8^4.[D27.0\2+F/
M0Y.71TBDHV;H7N[7I"P&]1Y25%7(,TR3CX3VB5E^1[#\F*OJR%7]\IBK^HHC
M00EWVJ)CQ.=H;[==JM D$V(XQ=.42I^(E O,MX3[SL"FS*0?7U'E9.V1?4<N
MC:#0_1@B&YRTL;>,?./P)NUO"T%$6>CR246-S &%[>Z3ET_HOGL[NSMK;30^
M%G+>KI!SU:UR6@"<IO#/D5"L)$'OI26-[N=O<Z+P8L0L0G)SA7N[OYV_3WG4
M67 ,#I[TF@L^*1@.PH*"PRG6;>N5=H'=-%YV[ICH9*4\@I=L/#8JG=QLQBRC
M]RDKQ 0K!'4C-]>G.A&>WQ$;!V5.-.J%))L^"QY4!18(/2;21G]9_0?=V\.[
MM$O+:H_OD>N^A*D*9LO'^ KI(6'I-F;6;?M?6AHR Z/CR*.:H?)"^)^EW/3;
MLFS _X:86@2MB"CZGW[<>[;S"G>0VJ3-F"*L %.; T-M8'MN-('[(EPX3.4Q
M,M8>J JO!8>[E=?W8M"@Z:04*G?3-#Q,'-BC8C*B6%>V::EE7KC4IJ^X%8,<
MR:)6MHS#*N?2M-)K7D"1X,P;#&=EZ5E^=Y;F\BA+&AAL($73G/O3J(+82H66
MG8D@X.?33=,"W(OLQ4SLYH?53:^<=G,0KG=K)&CWJ#@.$\&<#-B@U?^R'7P\
M"_[WWMXV?+MY'T[^ G.<XJ%"R3HVY*]>RS-8\@DA-5F\&ED(TR2'*8EA-:,F
M69;=I9NV?K$6^?>*])VF-9O<!AX%$- SU;KZ(EL^E1A[+S;-:9.#QLJM'OL&
MWQZ;%"7,W$E -TIYH1B@PX [?L:9MM8:H&SHVPI(2Y,P!M'[],FK%&5QJ& 3
M92NU9^Z#F/CZFG\AUUJIM3!L*S7B_".E1D:E2Z".J<E;A\%/H*#Q.*9LCU5U
M#,UIJI2-F_;RVG3)+5?+YZ!.Y&G3UX5574NZ<P^X61I=: 4L'/X0W/@>,I>L
M7&"B8O<B?_@G3;UU0>KD]+$!OL5$Z6[,33O10IH5W;J9.!I2G9W.[JOH6)I%
M.ST9GC^H)-K#" 4M]R97FD';!Z%=UKL1-BN<&'@$)Y0!EQU^UXUE?MOA-%T^
MS3#J+:RH/8?7^<ID'.I-BY [X4KEDN'J2-);O#<9[/RHIM\YSJ4EHOS: 'H$
M@*>I,J&.:]48+[98($>RWX0-,.RA="_9B4U_D +OOP_W?PM.#S]\?/WN:'^=
M)^!1[JU5K^-AL/\O33!#(5?J$'K8 V(LJ"&ZN"Z;^DW+LW_<*UH>CSO'JS=N
M*(<L9T"V3DEV4B#:J!N+J!M3#^,+*I8H*&K-$&X7$6PW(!:PF',N]@;/A /J
M=W"8G[]\1<_.& E&XS5]I:6Q?=?S. ]HGNK:#XNSTGJFZQG=?"KW*9+V\[JY
M-6/+M1424Y0KD,-RC@RQA0;<=OSZSK1(WU3%P>'Q^^'I[[?J-]<7:7]GC?,>
M,CCBY3J (U9%Z9YB9X@SXLX[(>Z\8!BNFG_CB*2VGI5=I"E"W["P4H=XT:2<
M%#%(CB7;DA7:G@X&.<W38,._A:#E7:5L,_Z@@\4S=\Z.";4G*UDWC-4E""9I
M%T(C)X2;LQB:=V_>EEOX3+G?&2.*J6:!TVI_5VF%@*S= >B*W9=M2;X.HJ[3
ML%V)B?=5 K8WIO-M.67[T\%!^U$\+WA@0K9^'%J\?SF%&&8>UML&7,;"8OH)
M3:3?@RLX0!I!55STYAK,-0^/U^6&:N-+1+=0N%*&0^A_F63,&]$<NXISUQF;
M(Q9Q;NHT"B[V$1.60M^8AZ_=C+K3->]EB?LYYDD1>&<!%P)3SES63XV1H9*'
M$!-MZT.,$1R^_?/#^3J_]_V1H&LTZ6L:E\",&,HK PV06CHR;PXG\UDI=5:I
M2 MK:BRRK1H%S_:^7IV>+97T4'^F]3L]\R%*G3='Q^_ 85OG-W\,2=X%5_^*
MC2G,SW*_:A,#ZDZ7%BVZ(&M%4#B*7M48-=O..)HE&CG&D:3((^1 .RF\T."\
M<.>C7&\9H$SDFR_D\Z3C.)^Z\M;L*M5Y<1'/O$"?HTGR\<%FA-CX&HP;S/%L
M2MV*@><8BO=M(QC',178SP.=YQF7 &>.$L@.?JH^,Y('!*4N"K0,Y::4!B+V
MA3Q+):*&UMH<AL8\D7:B9VK& ;ZI98)JH__BA\G'_>9T>+Q_N,XO_ECNN:S<
M4]K![C./P8J-HM?S1B2)NG#R<3?RYT)=LDA4D?0()1Z$+(OJV6=;_"EAHBN=
MU_NLXM6FUVHB\V (%F@0= 53DEN DNL7RI1D,)0U;ZY\R^,A&X5G]I0BTEC+
MN;?W]!6"PFE#@64*;G@,NFCOR9-7NF<=E )8=5EAK(]-A#QBEL=?!L%E5A5F
MJ^E_!>HRB_,@J0)=4M O1TR4;#+X*!'/ DE.0$,'^'[\TB7_'Q'956G\SXK_
M!HV4\F9#X,$D43&6='["A_*(X)G(QH>[3A<$[M2%M^DT.P7PLX(\ $)_5L5Z
MQPL>[=<[L%]7*[BE^;+#%J$$QL9''MH(S36&+VN+!H+/,A"O0V=C.<(CZG_M
MK$@J=D:2C[QDTF7ZE^'SQ%]1'Q_*)=L4;2S5Y^1"7P@)H,W4$F*?GI75#%8#
M/P7)\.3YTU>[E,O=[GI+).+Q@XU""N_B@_@2'<'&+/6J4$:JB&O8*G?93&,#
M!:S()M2ESTR/MBD6C6SBS2AT>OS3C[LOGK\*GKS<?3Z *9XPQZ<-'7!HT3/K
M\954G%2YS[<2$M2JS./)!,UX>!-*2",YD4Y5\DWLX(><[MS=68=\9\_DXS*/
MY2T8\,/C/]=9,SQ&DONUW=9-'1\)C]Z-T%@)>%(4]U !=DSC_G?U'MB&T0[;
MV/HZ*$0BP$CEI(@\_C13:^*EX/RAD";F( ]8T,U4F6&2M62VTCQPN'!XR*-6
M8LX1ONF:^)$*/T]R6*UH2]9@3/]Y];U6A HUQ>6LTB3^C"AC?8DN%(+<<"JR
M*YIFC-*5P>[_<40\MHGX2K=4S6[JJFAMVDS/& #'>+=-5R@KO^/+<1_M[C1?
MUK+Y<7-*^'1*O2NS\/-:^SGKFJK:S[.BV!HQ<9XMF8T)WBY5UV;5"6_9[MM)
MO5:XG1NN\UN-":S@C8ZT*RWO5Y#@-0K) DWXU=954B%[J-BS\>>^F1OTX^W.
MD[#4C& Y)M0QI6KR^QN:<2-T+0?LP77\KT(()D+>+/I41=K@5)_!P")EZOMX
M&S3ZX?!GL<^W+J])&! /&>:JT+A^L1[;WQ:../"#X&DRIIYMJF&2()D>?%X$
M[W42T2"Q@[94OJQVK\$V2ZG$)L13#1.,F!Q<#W<6K&2^TB-D,@TVKJZNMD?V
M^^U(Z@I1(U^":\FT!'#;#!99CCU^+W'7[0Z:AH5%22UX>=[<PR)>^K7H_9 D
MAAMBJ0['&44=W=3E)-6W.3)..(-Z>52!NW<\M[7"CI#"93!=6?Y]5>%+7=+3
MP\,'E41[C-'V$6/@G\=Q S?05=MID_DU5A-3](T>B\>V0?A)]1E^-TN0+MK
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MY8/.0>X]YB#O0+.MN+KWWY;=&[N;K)8[&+C!DIU92 SC6FJ![)J2E!"+!^H
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MQ.5L7F'^W@*%NN23?HBFV?:)\C" M;H$JV1F)='696PZ"&*9?8X&WP_WV(\
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M?^D\O][_X3&Q=3<KUI2S?^Q]MW_854N 8:=LHIN;M1ZF2+M96LKSF30E6@0
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MWWG[?!/$9KP:/L8>BI_>MHJ=2(B#PI4L*.Z:<C+CN:^OQ3&(FSD<7J81VX8
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MOG(K4Z[FV*4EZC2?[&'S2UU3=(;=^%-A7*-=1K=[:+?B<'"Z'QA(["WUI;8
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M4?K;(!6T6?19V_=DJ;]=[6;UUYYTNOWE\G3[_R Y"?SGIIGF__I_4$L#!!0
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MZDG=J?HZ>9'2R4J3L\5,E\G;,CM,YJI)VE659(5J&DW7-SKK:CCX\*G6,],
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M L-4NX'WM3%$LERF$.KD5O$0ADD6 >M35<D%44')+^K&3IX!'UYB%J%J6W@
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M3J@3C:3,C=T8 I0L 8M*Y1NE.I?D'HRBZ!IBJ\'75H,7;<$6_/D1[+/BS[J
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M.!7;P%58I)<5R%)Q%N?X5],"OUST\C[EA7AL&I_MN0-G1K)97'I:.%':!>D
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MR'EZ2XJ[_KAD( OB;I(P&8S ,1$J^*.)<#61C(]L(&(-=^9++E,>#06#*^P
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MS_Y(,P]II<&HY%X96EC'@94 8[U9[Z95#K,'_276_?_IK=%N)S5QNK]:WN!
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M>0U.[!J #4:-27SJ\HU+L'Z\AJ=3U/?@E$E(&96@P0F04TS%%5-U53DPZ3%
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M&_PHBHY',RD0'0O$F"4DN+DJ9UI*A:CS.%;GJAP&VR RI7)-Q ,4MY'R$(K
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M6:8+7?<"K'R'A(5NCT"IV:S6,[2H-L6BUL(ZX_W1,#8F'CHW2YFT70OIDM;
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M^W?7[I!WFMJ+K2;5H-PK<[,6OH@UFCAU]PDV',Q;E'Q5>:6!B-L:7CW5!"V
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MSV,LH85&.C"P&Q!]OJ;)YC EZZ$GMS7R'N1.@45B2A<WZ:6Q[#7=Y#<1.C9
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M2P$"% ,4    " !.@TE67UR%%L,:!@#Y2$, $0              @ $
M86UG;BTR,#(R,3(S,2YH=&U02P$"% ,4    " !.@TE6'FALG@8F  ",O@$
M$0              @ 'R&@8 86UG;BTR,#(R,3(S,2YX<V102P$"% ,4
M" !.@TE6_NZ?Y\PO  "'X0$ %0              @ $G008 86UG;BTR,#(R
M,3(S,5]C86PN>&UL4$L! A0#%     @ 3H-)5IVWM%:V\   =\0* !4
M         ( !)G$& &%M9VXM,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M $Z#25;5 QO?$9$! ,M" @ 4              "  0]B!P!A;6=N+3(P,C(Q
M,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( $Z#258;?8&11P\" '^Z @ 4
M      "  5+S" !A;6=N+3(P,C(Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( $Z#
M25:]4_8<4]8! )X:$P 5              "  <L""P!A;6=N+3(P,C(Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    " !.@TE6=X_210U! 0#$LPX %0
M    @ %1V0P 86UG;BTR,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ 3H-)
M5N-;O.CQ!0  XDD  !D              ( !D1H. &%M9VXM97@R,5\R,#(R
M,3(S,7AQ-"YH=&U02P$"% ,4    " !.@TE6"N6&(^$(  !D30  &0
M        @ &Y( X 86UG;BUE>#,Q7S(P,C(Q,C,Q>'$T+FAT;5!+ 0(4 Q0
M   ( $Z#258[1Y)UU04  "TE   9              "  =$I#@!A;6=N+65X
M,S)?,C R,C$R,S%X<30N:'1M4$L! A0#%     @ 3H-)5L]7)$\A!0  ]Q4
M !X              ( !W2\. &5X:&EB:70Q,#$Q-"UF;W5R=&AA;65N9&UE
M+FAT;5!+ 0(4 Q0    ( $Z#25;3(%#F7@@" &*Q%  >              "
M 3HU#@!E>&AI8FET,3 Q-C$M86UE;F1M96YT;F\Q="YH=&U02P$"% ,4
M" !.@TE6R)O\X9R?  #'* 0 '@              @ '4/1  97AH:6)I=#$P
M-"UF;W)M;V9G<F%N=&]F<W0N:'1M4$L! A0#%     @ 3H-)5@T66Z)7G
MR38$ !X              ( !K-T0 &5X:&EB:70Q,#4M9F]R;6]F<F5S=')I
M8W1E+FAT;5!+ 0(4 Q0    ( $Z#259D5/#Q-)$  $CR P >
M  "  3]Z$0!E>&AI8FET,3 W+69O<FUO9G!E<F9O<FUA;BYH=&U02P$"% ,4
M    " !.@TE6V9O]''=@  !#D , '@              @ &O"Q( 97AH:6)I
M=#0S-"UD97-C<FEP=&EO;F]F<V4N:'1M4$L%!@     1 !$ JP0  &)L$@
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
